PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
1932512-8	1991	Interferon-gamma treatment caused an increase in serum concentrations of soluble HLA-DR molecules, whereas a decrease of circulating HLA-DR molecules was associated with an immunosuppressive with cyclosporine A.	Cyclosporine	196-210	interferon gamma	Homo sapiens	0-16
1954315-6	1991	CS may enhance immune responses by inactivating suppressor cells, by altering Th1/Th2 antagonism (e.g., CS promotes a protective Th1-type response in BALB/c mice infected with Leishmania major), or by promoting T cell activation through a CS-resistant IL-2-independent T cell activation/differentiation pathway.	Cyclosporine	0-2	negative elongation factor complex member C/D, Th1l	Mus musculus	78-81
1954315-6	1991	CS may enhance immune responses by inactivating suppressor cells, by altering Th1/Th2 antagonism (e.g., CS promotes a protective Th1-type response in BALB/c mice infected with Leishmania major), or by promoting T cell activation through a CS-resistant IL-2-independent T cell activation/differentiation pathway.	Cyclosporine	0-2	negative elongation factor complex member C/D, Th1l	Mus musculus	129-132
1954315-6	1991	CS may enhance immune responses by inactivating suppressor cells, by altering Th1/Th2 antagonism (e.g., CS promotes a protective Th1-type response in BALB/c mice infected with Leishmania major), or by promoting T cell activation through a CS-resistant IL-2-independent T cell activation/differentiation pathway.	Cyclosporine	104-106	negative elongation factor complex member C/D, Th1l	Mus musculus	78-81
1954315-6	1991	CS may enhance immune responses by inactivating suppressor cells, by altering Th1/Th2 antagonism (e.g., CS promotes a protective Th1-type response in BALB/c mice infected with Leishmania major), or by promoting T cell activation through a CS-resistant IL-2-independent T cell activation/differentiation pathway.	Cyclosporine	104-106	negative elongation factor complex member C/D, Th1l	Mus musculus	129-132
1954315-6	1991	CS may enhance immune responses by inactivating suppressor cells, by altering Th1/Th2 antagonism (e.g., CS promotes a protective Th1-type response in BALB/c mice infected with Leishmania major), or by promoting T cell activation through a CS-resistant IL-2-independent T cell activation/differentiation pathway.	Cyclosporine	104-106	negative elongation factor complex member C/D, Th1l	Mus musculus	78-81
1954315-6	1991	CS may enhance immune responses by inactivating suppressor cells, by altering Th1/Th2 antagonism (e.g., CS promotes a protective Th1-type response in BALB/c mice infected with Leishmania major), or by promoting T cell activation through a CS-resistant IL-2-independent T cell activation/differentiation pathway.	Cyclosporine	104-106	negative elongation factor complex member C/D, Th1l	Mus musculus	129-132
1989647-7	1991	The reduced CSA which was observed after treatment of fluids with both heparin and thrombin implicated coagulation factors in the manifestation of CSA.	Cyclosporine	12-15	coagulation factor II, thrombin	Homo sapiens	83-91
1989647-7	1991	The reduced CSA which was observed after treatment of fluids with both heparin and thrombin implicated coagulation factors in the manifestation of CSA.	Cyclosporine	147-150	coagulation factor II, thrombin	Homo sapiens	83-91
1906396-1	1991	A study was made of changes in the ratio of CD4+/CD8+ in patients who had received cadaverous kidneys and who were under treatment with a combination of cyclosporin A + azathioprine + cor ticosteroids.	Cyclosporine	153-166	CD4 molecule	Homo sapiens	44-47
1804642-1	1991	Pretreatment of rat vascular smooth muscle cells with cyclosporin A caused concentration- and time-dependent enhancement of both angiotensin II- and platelet-derived growth factor-stimulated cellular functions, which may be related to a rise in vascular tone.	Cyclosporine	54-67	angiotensinogen	Rattus norvegicus	129-143
1937931-3	1991	Immunosuppressive drugs such as ciclosporin, hydrocortisone and prednisolone inhibited the IL-4 mRNA expression dose dependently.	Cyclosporine	32-43	interleukin 4	Homo sapiens	91-95
1814853-4	1991	It was confirmed that cyclosporin A inhibited the release of IL-3 in the same experimental system.	Cyclosporine	22-35	interleukin 3	Mus musculus	61-65
1809790-5	1991	These intolerances were dose-related and reported predominantly in the TID group; QD and BID cyclosporine ophthalmic ointment were better tolerated than the placebo control.	Cyclosporine	93-105	BH3 interacting domain death agonist	Homo sapiens	89-92
1679456-4	1991	The binding of 3H-cyclosporine diazirine analogue to P-glycoprotein was competable by excess cyclosporine A and by the nonimmunosuppressive cyclosporine H.	Cyclosporine	93-107	ATP binding cassette subfamily B member 1	Homo sapiens	53-67
1679456-5	1991	These results suggest that cyclosporine reverses the MDR phenotype by binding directly to P-glycoprotein and that this binding is not dependent on the immunosuppressive potential of the cyclosporine derivative.	Cyclosporine	27-39	ATP binding cassette subfamily B member 1	Homo sapiens	90-104
1646408-3	1991	CS enhances contractions of mesangial cells elicited with angiotensin II.	Cyclosporine	0-2	angiotensinogen	Homo sapiens	58-72
1870754-0	1991	The effect of conversion from cyclosporin to azathioprine on renin-containing cells in renal allograft biopsies.	Cyclosporine	30-41	renin	Homo sapiens	61-66
1835259-3	1991	This effect is inhibited by cyclosporin A and by anti-IFN-gamma mAbs and is restored by adding exogenous recombinant IFN-gamma tb CsA treated cells.	Cyclosporine	28-41	interferon gamma	Homo sapiens	117-126
1835259-3	1991	This effect is inhibited by cyclosporin A and by anti-IFN-gamma mAbs and is restored by adding exogenous recombinant IFN-gamma tb CsA treated cells.	Cyclosporine	130-133	interferon gamma	Homo sapiens	54-63
1835259-3	1991	This effect is inhibited by cyclosporin A and by anti-IFN-gamma mAbs and is restored by adding exogenous recombinant IFN-gamma tb CsA treated cells.	Cyclosporine	130-133	interferon gamma	Homo sapiens	117-126
1851318-1	1991	The present investigation evaluates the circadian rhythm of renin-angiotensin-aldosterone system (RAAS) in subjects with kidney (KTS) or heart (HTS) transplantation undergoing conventional therapy with prednisone and cyclosporine.	Cyclosporine	217-229	renin	Homo sapiens	60-65
1789988-6	1991	In addition, ciclosporin blocked the interferon-gamma-induced increase in epidermal 12(S)-HETE binding.	Cyclosporine	13-24	interferon gamma	Homo sapiens	37-53
1676547-8	1991	The response via CD2 plus CD28 is IL-2-dependent, as demonstrated by the ability of mAb against the IL-2 receptor to block proliferation, and is almost completely inhibited by cyclosporine A (CsA).	Cyclosporine	176-190	interleukin 2	Homo sapiens	34-38
1676547-8	1991	The response via CD2 plus CD28 is IL-2-dependent, as demonstrated by the ability of mAb against the IL-2 receptor to block proliferation, and is almost completely inhibited by cyclosporine A (CsA).	Cyclosporine	176-190	interleukin 2	Homo sapiens	100-104
1676547-8	1991	The response via CD2 plus CD28 is IL-2-dependent, as demonstrated by the ability of mAb against the IL-2 receptor to block proliferation, and is almost completely inhibited by cyclosporine A (CsA).	Cyclosporine	192-195	interleukin 2	Homo sapiens	34-38
1676547-8	1991	The response via CD2 plus CD28 is IL-2-dependent, as demonstrated by the ability of mAb against the IL-2 receptor to block proliferation, and is almost completely inhibited by cyclosporine A (CsA).	Cyclosporine	192-195	interleukin 2	Homo sapiens	100-104
1898996-4	1991	Administration of CsA following syngeneic bone marrow transplantation leads to a developmental arrest of mature CD4+ and CD8+ T lymphocytes in the thymus and a marked reduction in cells expressing the alpha beta T cell receptor.	Cyclosporine	18-21	CD4 molecule	Homo sapiens	112-115
1987687-8	1991	Contrariwise, recipients afflicted with CsA-induced nephrotoxicity displayed reduced IL-6 levels (mean = 1.4 +/- 0.18 U/ml).	Cyclosporine	40-43	interleukin 6	Homo sapiens	85-89
1987692-4	1991	Similarly, cyclosporine potentiated the inhibitory effects of rapamycin upon proliferation of IL-2 (CTLL-2) and IL-6 (MH60.BSF-2) lymphokine-dependent cell lines.	Cyclosporine	11-23	interleukin 6	Mus musculus	112-116
2269327-3	1990	We have previously shown that CsA prevents the constitutive transcription of the IL2 gene in these cells.	Cyclosporine	30-33	interleukin 2	Homo sapiens	81-84
2269327-7	1990	Once IL2 induction was over, CsA exerted its full inhibition.	Cyclosporine	29-32	interleukin 2	Homo sapiens	5-8
2076903-2	1990	Increasing knowledge concerning the action of cytokines on the permeability of the vascular barrier, and the possibility to suppress their production with ciclosporin A (CsA), especially of the cytokine interleukin-2, made its therapeutic use for the treatment of NS reasonable.	Cyclosporine	170-173	interleukin 2	Homo sapiens	203-216
1965653-4	1990	Cs also significantly inhibited IL-1 beta and TNF alpha production.	Cyclosporine	0-2	interleukin 1 beta	Homo sapiens	32-41
1965653-4	1990	Cs also significantly inhibited IL-1 beta and TNF alpha production.	Cyclosporine	0-2	tumor necrosis factor	Homo sapiens	46-55
2277142-3	1990	Cyclophilin and calmodulin, two proteins that are present in both lymphocytes and keratinocytes, have been considered as possible intracellular targets for cyclosporine.	Cyclosporine	156-168	calmodulin 1	Homo sapiens	16-26
2277142-8	1990	Cyclosporine binds to calmodulin with low affinity, and such binding of cyclosporine isomers does not reflect their immunosuppressive activity.	Cyclosporine	0-12	calmodulin 1	Homo sapiens	22-32
2277142-9	1990	The physiologic importance of calmodulin-to-cyclosporine binding is controversial.	Cyclosporine	44-56	calmodulin 1	Homo sapiens	30-40
2147950-4	1990	Induced cell death is inhibited by cyclosporin A and by anti-interferon gamma (IFN-gamma), and is restored by adding exogenous recombinant IFN-gamma to cyclosporin A-treated cells.	Cyclosporine	152-165	interferon gamma	Homo sapiens	79-88
2147950-4	1990	Induced cell death is inhibited by cyclosporin A and by anti-interferon gamma (IFN-gamma), and is restored by adding exogenous recombinant IFN-gamma to cyclosporin A-treated cells.	Cyclosporine	152-165	interferon gamma	Homo sapiens	139-148
2096207-3	1990	Vascular nephropathy with plasma renin activity (PRA) elevation from cyclosporine (CsA) may also be major factor in the progress of hypertension.	Cyclosporine	69-81	renin	Homo sapiens	33-38
2096207-3	1990	Vascular nephropathy with plasma renin activity (PRA) elevation from cyclosporine (CsA) may also be major factor in the progress of hypertension.	Cyclosporine	83-86	renin	Homo sapiens	33-38
2246507-0	1990	Differential inhibition of T and B cell function in IL-4-dependent IgE production by cyclosporin A and methylprednisolone.	Cyclosporine	85-98	interleukin 4	Homo sapiens	52-56
2246507-1	1990	The present study examines the role of the immunosuppressive agents methylprednisolone (MPN) and cyclosporin (Cs)A on IL-4-dependent IgE and IgG production.	Cyclosporine	97-108	interleukin 4	Homo sapiens	118-122
2246507-5	1990	MPN (10(-7) M) and CsA (1 microgram/ml) markedly reduced IL4-induced IgE and IgG production as well as numbers of Ig-secreting cells in a dose-dependent fashion.	Cyclosporine	19-22	interleukin 4	Homo sapiens	57-60
2246507-7	1990	Delayed addition of CsA revealed that inhibition was maximal when the drug was added during the first 48 h after addition of IL-4 to the culture.	Cyclosporine	20-23	interleukin 4	Homo sapiens	125-129
2246507-8	1990	Addition of IL-2 (10 U/ml) partially overcame the inhibition induced by CsA.	Cyclosporine	72-75	interleukin 2	Homo sapiens	12-16
2246507-9	1990	In coculture experiments, in which separated T or B cells were precultured with the drugs and the cells were then combined and further incubated in the presence of IL-4, the suppressive effects of CsA on IgE production were related to pretreatment of the T but not B cells.	Cyclosporine	197-200	interleukin 4	Homo sapiens	164-168
2077348-4	1990	First, rats implanted with human growth hormone-secreting rat fibroblasts were treated with an immunosuppressant, cyclosporine A, at 20 mg/kg body weight per day.	Cyclosporine	114-128	growth hormone 1	Homo sapiens	33-47
1870754-4	1991	We demonstrated hyperplasia of renin-containing cells in patients treated with cyclosporin.	Cyclosporine	79-90	renin	Homo sapiens	31-36
1870754-6	1991	We suggest that local activation of the intrarenal renin-angiotensin system could mediate the effects of cyclosporin on renal haemodynamics.	Cyclosporine	105-116	renin	Homo sapiens	51-56
2125251-3	1990	Sequential measurements after transplantation and during CsA treatment revealed a transient significant increase of median values with highest amounts of vWF:Ag of 362% (2 p less than 0.0001), FVIII:Ag of 398% (2 p less than 0.001) and FVIII:C of 360% (2 p less than 0.0001) (Friedman test).	Cyclosporine	57-60	von Willebrand factor	Homo sapiens	154-157
2125251-0	1990	von Willebrand factor and factor VIII in renal transplant recipients under immunosuppression with cyclosporine and steroids.	Cyclosporine	98-110	von Willebrand factor	Homo sapiens	0-21
2125251-7	1990	However, multivariate statistics revealed to some extent a positive influence of CsA blood levels on vWF:Ag levels.	Cyclosporine	81-84	von Willebrand factor	Homo sapiens	101-104
2125251-2	1990	In 17 consecutive cadaver kidney transplant recipients treated with cyclosporine (CsA) and steroids, the median of antigenic and functional levels of von Willebrand factor (vWF) and factor VIII (FVIII) before transplantation were elevated (vWF:Ag: 206%, vWF:RCof: 202%; FVIII:Ag: 248%, FVIII:C: 224%; normal values 50-150%).	Cyclosporine	68-80	von Willebrand factor	Homo sapiens	150-171
2125251-8	1990	Patients with vascular rejection or chronic CsA nephrotoxicity showed significantly lower levels of vWF:Ag as compared with patients without endothelial cell damage in the kidney (2 p less than 0.05).	Cyclosporine	44-47	von Willebrand factor	Homo sapiens	100-103
2125251-2	1990	In 17 consecutive cadaver kidney transplant recipients treated with cyclosporine (CsA) and steroids, the median of antigenic and functional levels of von Willebrand factor (vWF) and factor VIII (FVIII) before transplantation were elevated (vWF:Ag: 206%, vWF:RCof: 202%; FVIII:Ag: 248%, FVIII:C: 224%; normal values 50-150%).	Cyclosporine	68-80	von Willebrand factor	Homo sapiens	240-243
2125251-2	1990	In 17 consecutive cadaver kidney transplant recipients treated with cyclosporine (CsA) and steroids, the median of antigenic and functional levels of von Willebrand factor (vWF) and factor VIII (FVIII) before transplantation were elevated (vWF:Ag: 206%, vWF:RCof: 202%; FVIII:Ag: 248%, FVIII:C: 224%; normal values 50-150%).	Cyclosporine	68-80	von Willebrand factor	Homo sapiens	240-243
2237060-1	1990	Cyclosporin is a potent immunosuppressive agent with a selective and reversible inhibitory effect on helper T lymphocytes functions mainly interleukin-2 production.	Cyclosporine	0-11	interleukin 2	Homo sapiens	139-152
2290026-0	1990	Circulating osteocalcin in primary biliary cirrhosis following liver transplantation and during treatment with ciclosporin.	Cyclosporine	111-122	bone gamma-carboxyglutamate protein	Homo sapiens	12-23
1978708-5	1990	Using (a) TH2 clones that varied in the amount of IL 5 secreted, (b) a neutralizing monoclonal antibody against IL 5 and (c) T cell clones pretreated with cyclosporin A to inhibit cytokine secretion, we found that IL 5 was essential for induction of IgG1 synthesis by TH2 but not TH1 T cells.	Cyclosporine	155-168	immunoglobulin heavy constant gamma 1 (G1m marker)	Mus musculus	250-254
2210078-1	1990	Preliminary data from our group indicated that cyclosporin A induced frequent remissions of insulin dependency in a group of 40 insulin-dependent (type I) diabetic children if given at the onset of clinical manifestations of diabetes.	Cyclosporine	47-60	insulin	Homo sapiens	92-99
1978708-5	1990	Using (a) TH2 clones that varied in the amount of IL 5 secreted, (b) a neutralizing monoclonal antibody against IL 5 and (c) T cell clones pretreated with cyclosporin A to inhibit cytokine secretion, we found that IL 5 was essential for induction of IgG1 synthesis by TH2 but not TH1 T cells.	Cyclosporine	155-168	negative elongation factor complex member C/D, Th1l	Mus musculus	280-283
2151903-1	1990	UNLABELLED: The present article aimed to study the intactness of the physiological mechanism of ANP secretion in 64 kidney transplant patients treated with cyclosporine A + prednisone (CyA group--35 patients) or azathioprine + prednisone + promethasine respectively (Aza group or--29 patients).	Cyclosporine	156-170	natriuretic peptide A	Homo sapiens	96-99
1981793-3	1990	In addition, SASP and CsA inhibited the production of interleukin 2 (IL-2) from splenocytes in these experiments.	Cyclosporine	22-25	interleukin 2	Homo sapiens	54-67
1981793-3	1990	In addition, SASP and CsA inhibited the production of interleukin 2 (IL-2) from splenocytes in these experiments.	Cyclosporine	22-25	interleukin 2	Homo sapiens	69-73
1981793-4	1990	The inhibitory effect of CsA on IL-2 production practically correlated with that on proliferative responses, whereas SASP showed a less marked inhibitory effect on IL-2 production than on proliferative responses.	Cyclosporine	25-28	interleukin 2	Homo sapiens	32-36
2151903-4	1990	Higher basal ANP levels were found in patients of the CyA and Aza group than in normals (significantly higher in patients of the CyA group).	Cyclosporine	54-57	natriuretic peptide A	Homo sapiens	13-16
2151903-4	1990	Higher basal ANP levels were found in patients of the CyA and Aza group than in normals (significantly higher in patients of the CyA group).	Cyclosporine	129-132	natriuretic peptide A	Homo sapiens	13-16
2219271-0	1990	Short-term effects of cyclosporine on secretagogue-induced insulin release by isolated islets.	Cyclosporine	22-34	insulin	Homo sapiens	59-66
2219321-0	1990	Inhibition of PHA lymphocyte responses by cyclosporine and methylprednisolone.	Cyclosporine	42-54	lamin B receptor	Homo sapiens	14-17
2219367-0	1990	Influence of cyclosporine on C-peptide levels in kidney allograft recipients.	Cyclosporine	13-25	insulin	Homo sapiens	29-38
2219271-1	1990	Brief exposure (30 min) of isolated islets to 0.5 microgram/ml cyclosporine leads to alterations in the insulin secretory response to selected stimuli.	Cyclosporine	63-75	insulin	Homo sapiens	104-111
2219271-2	1990	When glucose is used as the secretagogue, cyclosporine slightly stimulates insulin release at substimulatory concentrations of the hexose.	Cyclosporine	42-54	insulin	Homo sapiens	75-82
2219271-5	1990	Cyclosporine also inhibits by 66% the insulin secretory response to 100 nmol/L phorbol 12-myristate 13-acetate, suggesting that either cyclosporine interferes with phorbol ester action on beta cells or the action site is located beyond the protein kinase C activation.	Cyclosporine	0-12	insulin	Homo sapiens	38-45
2219271-6	1990	On the other hand ionomycin-stimulated insulin response is also blocked by cyclosporine, indicating that insulin release induced by transient changes in cytosolic Ca++ is also affected.	Cyclosporine	75-87	insulin	Homo sapiens	39-46
2219271-6	1990	On the other hand ionomycin-stimulated insulin response is also blocked by cyclosporine, indicating that insulin release induced by transient changes in cytosolic Ca++ is also affected.	Cyclosporine	75-87	insulin	Homo sapiens	105-112
2219271-7	1990	The evidence gathered here suggests that the inhibitory effect of cyclosporine on insulin release is apparent when glucose is used as a fuel stimulant and is reversed following removal of the stimulant.	Cyclosporine	66-78	insulin	Homo sapiens	82-89
2219271-8	1990	This effect is not reversed by using substances known to activate the protein kinase C or the Ca(++)-dependent branches of the stimulus-secretion coupling system in beta cells, indicating that the site of action of cyclosporine on pancreatic islets might be located in distal steps of the stimulus-secretion coupling of glucose-induced insulin release.	Cyclosporine	215-227	insulin	Homo sapiens	336-343
1724618-2	1990	The cyclic peptides cyclosporin A (CSA) and gramicidin-S (GRS) are shown to bind CaM and inhibit 3",5"-cyclic nucleotide phosphodiesterase (PDE) in a calcium-dependent manner.	Cyclosporine	20-33	calmodulin 1	Homo sapiens	81-84
2119587-4	1990	In addition, patients who responded clinically to CsA had a higher percentage of Leu-7+ natural killer cells in their peripheral blood prior to therapy.	Cyclosporine	50-53	beta-1,3-glucuronyltransferase 1	Homo sapiens	81-86
2119587-5	1990	All patients exhibited greater frequencies of cells that expressed interleukin-2 receptors, which decreased with CsA treatment.	Cyclosporine	113-116	interleukin 2	Homo sapiens	67-80
2224590-8	1990	Compared to controls, CsA resulted in significant elevation of BGP and a transient increase in 1,25(OH)2D with excess bone remodeling and loss of bone volume.	Cyclosporine	22-25	bone gamma-carboxyglutamate protein	Rattus norvegicus	63-66
2224590-12	1990	In conclusion, 1,25(OH)2D3 combined with CsA restores bone volume which is accompanied by increases in serum calcium and BGP.	Cyclosporine	41-44	bone gamma-carboxyglutamate protein	Rattus norvegicus	121-124
2402790-5	1990	Patients receiving either methotrexate or cyclosporine alone for GVHD prophylaxis had markedly lower IgA levels compared to those given a combination of these two drugs or patients transplanted with T-cell-depleted marrow (P less than 0.001).	Cyclosporine	42-54	CD79a molecule	Homo sapiens	101-104
2167005-3	1990	The high plasma ANF levels in heart-transplant recipients did not result from high atrial pressures but appeared to be related with elevated atrial dimensions and cyclosporine-induced renal failure.	Cyclosporine	163-175	natriuretic peptide A	Homo sapiens	16-19
2197329-3	1990	Cyclosporin A is thought to inhibit transcription that suggests that IL-2 and IL-3 are regulated primarily at the transcriptional level while GM-CSF is not.	Cyclosporine	0-13	interleukin 3	Mus musculus	78-82
2214606-3	1990	Cyclosporine A enhances contractions of mesangial cells elicited with angiotensin II.	Cyclosporine	0-14	angiotensinogen	Rattus norvegicus	70-84
2207449-5	1990	Patients given methotrexate and cyclosporine for prophylaxis against graft-versus-host disease (GVHD) had significantly lower EPO levels during the first 3 months post-BMT than patients transplanted with T cell-depleted marrow (p less than 0.05).	Cyclosporine	32-44	erythropoietin	Homo sapiens	126-129
2122226-7	1990	These studies demonstrated that combination therapy of CsA with steroid inhibits both gamma-IFN and IL-1 gene expression at the level of mRNA at physiological concentration.	Cyclosporine	55-58	interleukin 1 beta	Homo sapiens	100-104
2389448-0	1990	Cyclosporine suppresses IL-1 production by isolated human monocytes and by the human histiocytoma cell line, THP-1.	Cyclosporine	0-12	GLI family zinc finger 2	Homo sapiens	109-114
1972761-0	1990	Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine.	Cyclosporine	149-161	ATP binding cassette subfamily B member 1	Homo sapiens	14-18
2113443-0	1990	Interleukin-6 serum levels correlate with footpad swelling in adjuvant-induced arthritic Lewis rats treated with cyclosporin A or indomethacin.	Cyclosporine	113-126	interleukin 6	Rattus norvegicus	0-13
2113443-4	1990	Daily treatment with 5 mg cyclosporin A/kg prevented the increase in paw volume and held serum IL-6 activity to levels observed in untreated (normal) rats.	Cyclosporine	26-39	interleukin 6	Rattus norvegicus	95-99
2113443-6	1990	Linear regression analysis confirmed the positive correlation between mean paw volume and mean serum IL-6 activity (R2 = 0.783, P less than 0.01 on Day 17) in normal, arthritic, and cyclosporin A- or indomethacin-treated groups.	Cyclosporine	182-195	interleukin 6	Rattus norvegicus	101-105
1972761-4	1990	In vitro drug uptake studies by on-line flow cytometry showed that in leukemia cells expressing either mdr1 or mdr3, the steady-state accumulation of daunorubicin could be significantly increased by addition of cyclosporine and, to a lesser extent, by verapamil.	Cyclosporine	211-223	ATP binding cassette subfamily B member 1	Homo sapiens	103-107
2245532-6	1990	After the interesting experimental results obtained with thoracic duct drainage, a partially specific immunotherapy acting mainly on CD4+ T cells has been developed using cyclosporin A and total lymphoid irradiation.	Cyclosporine	171-184	CD4 molecule	Homo sapiens	133-136
1972761-5	1990	Because cyclosporine and verapamil are known as inhibitors of the mdr1-encoded P-glycoprotein drug-efflux pump, and because the mdr1 and mdr3 genes are highly homologous, our data suggest that the mdr3 gene encodes a functional drug pump in B-cell lymphocytic leukemias.	Cyclosporine	8-20	ATP binding cassette subfamily B member 1	Homo sapiens	66-70
1980302-0	1990	Cyclosporin A treatment enhances angiotensin converting enzyme activity in lung and serum of rats.	Cyclosporine	0-13	angiotensin I converting enzyme	Rattus norvegicus	33-62
2191883-11	1990	In contrast, in the CsA-treated group, the initial recovery in insulin secretory capacity was maintained over the 18-24 mo of the study.	Cyclosporine	20-23	insulin	Homo sapiens	63-70
1980302-6	1990	CSA treatment resulted in a decrease in creatinine clearance, urine flow and body weight and a significant increase in serum and lung ACE activities (436 +/- 9 vs 391 +/- 7 nmol mL-1 min-1, P less than 0.001; 184 +/- 8 vs 142 +/- 10 nmol mg-1 min-1 P less than 0.01, respectively).	Cyclosporine	0-3	angiotensin I converting enzyme	Rattus norvegicus	134-137
1980302-7	1990	In contrast, renal cortex ACE activity was reduced in the CSA-treated rats (0.35 +/- 0.02 vs 0.51 +/- 0.02 nmol mg-1 min-1, P less than 0.01).	Cyclosporine	58-61	angiotensin I converting enzyme	Rattus norvegicus	26-29
1980302-9	1990	In rats treated simultaneously with CSA and captopril (50 mg kg-1 day-1) ACE activity in the serum, lung and renal cortex was inhibited by 95, 93 and 92%, respectively.	Cyclosporine	36-39	angiotensin I converting enzyme	Rattus norvegicus	73-76
1980302-10	1990	These changes in ACE activity were associated with a decreased systolic blood pressure in the rats receiving CSA and captopril.	Cyclosporine	109-112	angiotensin I converting enzyme	Rattus norvegicus	17-20
1980302-11	1990	Therefore, ACE activity in the serum and lung of CSA-treated rats was increased, while its activity in the renal cortex was reduced.	Cyclosporine	49-52	angiotensin I converting enzyme	Rattus norvegicus	11-14
1971531-5	1990	Cyclosporine (CsA) prevented diC8 and ionomycin-induced expression of IL-2, IFN-gamma, and H-ras genes.	Cyclosporine	0-12	interleukin 2	Homo sapiens	70-74
1971531-5	1990	Cyclosporine (CsA) prevented diC8 and ionomycin-induced expression of IL-2, IFN-gamma, and H-ras genes.	Cyclosporine	0-12	interferon gamma	Homo sapiens	76-85
2142040-3	1990	During treatment for 12 to 18 months, cyclosporin A caused significant reductions in the glomerular filtration rate (before drug withdrawal, cyclosporin 97 +/- 18 vs placebo 125 +/- 16 ml min-1 1.73-m-2, p less than 0.05), renal plasma flow (454 +/- 83 vs 536 +/- 70 ml min-1 1.73-m-2, p less than 0.05), and lithium clearance (17 +/- 3 vs 28 +/- 5 ml min-1 1.73-m-2, p less than 0.05).	Cyclosporine	38-49	CD59 molecule (CD59 blood group)	Homo sapiens	188-193
2142040-3	1990	During treatment for 12 to 18 months, cyclosporin A caused significant reductions in the glomerular filtration rate (before drug withdrawal, cyclosporin 97 +/- 18 vs placebo 125 +/- 16 ml min-1 1.73-m-2, p less than 0.05), renal plasma flow (454 +/- 83 vs 536 +/- 70 ml min-1 1.73-m-2, p less than 0.05), and lithium clearance (17 +/- 3 vs 28 +/- 5 ml min-1 1.73-m-2, p less than 0.05).	Cyclosporine	38-51	CD59 molecule (CD59 blood group)	Homo sapiens	188-193
2142040-3	1990	During treatment for 12 to 18 months, cyclosporin A caused significant reductions in the glomerular filtration rate (before drug withdrawal, cyclosporin 97 +/- 18 vs placebo 125 +/- 16 ml min-1 1.73-m-2, p less than 0.05), renal plasma flow (454 +/- 83 vs 536 +/- 70 ml min-1 1.73-m-2, p less than 0.05), and lithium clearance (17 +/- 3 vs 28 +/- 5 ml min-1 1.73-m-2, p less than 0.05).	Cyclosporine	38-51	CD59 molecule (CD59 blood group)	Homo sapiens	270-275
2142040-3	1990	During treatment for 12 to 18 months, cyclosporin A caused significant reductions in the glomerular filtration rate (before drug withdrawal, cyclosporin 97 +/- 18 vs placebo 125 +/- 16 ml min-1 1.73-m-2, p less than 0.05), renal plasma flow (454 +/- 83 vs 536 +/- 70 ml min-1 1.73-m-2, p less than 0.05), and lithium clearance (17 +/- 3 vs 28 +/- 5 ml min-1 1.73-m-2, p less than 0.05).	Cyclosporine	38-51	CD59 molecule (CD59 blood group)	Homo sapiens	270-275
2142040-3	1990	During treatment for 12 to 18 months, cyclosporin A caused significant reductions in the glomerular filtration rate (before drug withdrawal, cyclosporin 97 +/- 18 vs placebo 125 +/- 16 ml min-1 1.73-m-2, p less than 0.05), renal plasma flow (454 +/- 83 vs 536 +/- 70 ml min-1 1.73-m-2, p less than 0.05), and lithium clearance (17 +/- 3 vs 28 +/- 5 ml min-1 1.73-m-2, p less than 0.05).	Cyclosporine	38-49	CD59 molecule (CD59 blood group)	Homo sapiens	270-275
2142040-3	1990	During treatment for 12 to 18 months, cyclosporin A caused significant reductions in the glomerular filtration rate (before drug withdrawal, cyclosporin 97 +/- 18 vs placebo 125 +/- 16 ml min-1 1.73-m-2, p less than 0.05), renal plasma flow (454 +/- 83 vs 536 +/- 70 ml min-1 1.73-m-2, p less than 0.05), and lithium clearance (17 +/- 3 vs 28 +/- 5 ml min-1 1.73-m-2, p less than 0.05).	Cyclosporine	38-49	CD59 molecule (CD59 blood group)	Homo sapiens	270-275
2115498-5	1990	An early IFN-gamma-independent decrease in CSA production was also detected 2-3 days post-infection.	Cyclosporine	43-46	interferon gamma	Mus musculus	9-18
1967044-0	1990	Treatment of end stage MRL-1pr/lpr mouse lupus disease by a cyclophosphazene derived drug and by cyclosporin A.	Cyclosporine	97-110	Fas (TNF receptor superfamily member 6)	Mus musculus	31-34
1967044-3	1990	MRL-lpr/lpr mice are treated from the age of 19 weeks, i.e. after the onset of renal disease and lymphoproliferation, with Cyclosporin A which acts at the T cell level, or with DIAM4 which can down modulate polyclonal activation of B lymphocytes.	Cyclosporine	123-136	Fas (TNF receptor superfamily member 6)	Mus musculus	4-7
1967044-3	1990	MRL-lpr/lpr mice are treated from the age of 19 weeks, i.e. after the onset of renal disease and lymphoproliferation, with Cyclosporin A which acts at the T cell level, or with DIAM4 which can down modulate polyclonal activation of B lymphocytes.	Cyclosporine	123-136	Fas (TNF receptor superfamily member 6)	Mus musculus	8-11
2140386-7	1990	In addition, lymphokine production by TH1 clones was more sensitive to inhibition by cholera toxin, 8-bromoadenosine 3":5"-cyclic monophosphate, and cyclosporin A than was lymphokine production by TH2 clones.	Cyclosporine	149-162	interleukin 2	Homo sapiens	13-23
2187900-5	1990	Although in some patients there appeared to be a sudden drop in serum IL-2 levels with the onset of cyclosporine A medication, no effect of this drug was noted on group analysis.	Cyclosporine	100-114	interleukin 2	Homo sapiens	70-74
2141571-5	1990	However, up-regulation of IL 4R by its own ligand or IL 2 and the growth-promoting effect of IL 4 on activated, IL 4R+ T cells were CsA resistant.	Cyclosporine	132-135	interleukin 4	Homo sapiens	26-30
2370014-9	1990	These results suggest that the IL-2 dependent pathway of immune activation is upregulated in vivo in CD and that cyclosporin may interfere with this process.	Cyclosporine	113-124	interleukin 2	Homo sapiens	31-35
2114169-8	1990	CYA 57, still sensitive to activation by high concentrations of calmodulin, exhibits less than 0.1% of the specific activity of CYA 62.	Cyclosporine	0-3	calmodulin	Bos taurus	64-74
2190313-10	1990	Some patients with recently diagnosed insulin dependent diabetes needed no further insulin therapy as long as cyclosporine was administered.	Cyclosporine	110-122	insulin	Homo sapiens	38-45
2159035-1	1990	We investigated, in vitro and in vivo, the cyclosporin A (CsA) regulation of LPS-induced TNF gene expression and subsequent pathophysiologic changes.	Cyclosporine	58-61	tumor necrosis factor	Mus musculus	89-92
2159035-2	1990	In vitro dose-response kinetics data showed that CsA inhibited TNF bioactivity in the supernatant without delaying its production, whereas Northern blot and in situ hybridization analysis demonstrated that CsA did not inhibit TNF mRNA expression.	Cyclosporine	49-52	tumor necrosis factor	Mus musculus	63-66
2159035-4	1990	CsA demonstrated suppression of local levels (ascites) of TNF as measured by either bioactivity or an anti-murine TNF ELISA.	Cyclosporine	0-3	tumor necrosis factor	Mus musculus	58-61
2159035-4	1990	CsA demonstrated suppression of local levels (ascites) of TNF as measured by either bioactivity or an anti-murine TNF ELISA.	Cyclosporine	0-3	tumor necrosis factor	Mus musculus	114-117
2159035-6	1990	In vivo kinetics studies were performed to show that CsA blocked both local (ascites) and systemic (plasma) LPS-induced TNF production without delaying these effects.	Cyclosporine	53-56	tumor necrosis factor	Mus musculus	120-123
2159035-8	1990	These observations are helpful in understanding the role of the macrophage in CsA immunosuppression, particularly with regard to the ability of CsA to block LPS-induced TNF secretion.	Cyclosporine	144-147	tumor necrosis factor	Mus musculus	169-172
2141571-1	1990	The effect of the immunosuppressant cyclosporin (CsA) on the expression of interleukin (IL) 4 membrane receptors on human peripheral blood mononuclear cells (PBMC) was investigated after cell activation by anti-CD3 antibody, IL 2 or IL 4.	Cyclosporine	36-47	interleukin 2	Homo sapiens	225-229
2141571-1	1990	The effect of the immunosuppressant cyclosporin (CsA) on the expression of interleukin (IL) 4 membrane receptors on human peripheral blood mononuclear cells (PBMC) was investigated after cell activation by anti-CD3 antibody, IL 2 or IL 4.	Cyclosporine	36-47	interleukin 4	Homo sapiens	233-237
2141571-1	1990	The effect of the immunosuppressant cyclosporin (CsA) on the expression of interleukin (IL) 4 membrane receptors on human peripheral blood mononuclear cells (PBMC) was investigated after cell activation by anti-CD3 antibody, IL 2 or IL 4.	Cyclosporine	49-52	interleukin 2	Homo sapiens	225-229
2141571-1	1990	The effect of the immunosuppressant cyclosporin (CsA) on the expression of interleukin (IL) 4 membrane receptors on human peripheral blood mononuclear cells (PBMC) was investigated after cell activation by anti-CD3 antibody, IL 2 or IL 4.	Cyclosporine	49-52	interleukin 4	Homo sapiens	233-237
2141571-6	1990	Since CsA inhibits the synthesis of IL 4, exogenous IL 4 was added to the cultures and it partially reversed the inhibitory effect of CsA on cell proliferation as well as on IL 4R expression.	Cyclosporine	6-9	interleukin 4	Homo sapiens	36-40
2141571-6	1990	Since CsA inhibits the synthesis of IL 4, exogenous IL 4 was added to the cultures and it partially reversed the inhibitory effect of CsA on cell proliferation as well as on IL 4R expression.	Cyclosporine	6-9	interleukin 4	Homo sapiens	52-56
2141571-6	1990	Since CsA inhibits the synthesis of IL 4, exogenous IL 4 was added to the cultures and it partially reversed the inhibitory effect of CsA on cell proliferation as well as on IL 4R expression.	Cyclosporine	134-137	interleukin 4	Homo sapiens	36-40
2141571-6	1990	Since CsA inhibits the synthesis of IL 4, exogenous IL 4 was added to the cultures and it partially reversed the inhibitory effect of CsA on cell proliferation as well as on IL 4R expression.	Cyclosporine	134-137	interleukin 4	Homo sapiens	52-56
1971791-2	1990	CsA specifically inhibited the generation of cells expressing high levels of alpha/beta TcR/CD3 complexes and a mature phenotype defined by CD4 and CD8 surface markers.	Cyclosporine	0-3	CD4 molecule	Homo sapiens	140-143
2139987-4	1990	Recombinant IL-4, when used at high concentrations, can support the generation of CTL in the presence of CsA during a secondary MLR response.	Cyclosporine	105-108	interleukin 4	Homo sapiens	12-16
2323839-9	1990	Since cyclosporin A is an inhibitor of the mdr1-encoded P-glycoprotein drug pump, these data suggest that in PLL cells mdr3 also codes for a drug efflux pump.	Cyclosporine	6-19	ATP binding cassette subfamily B member 1	Homo sapiens	43-47
1690080-7	1990	Suppressor activity persisted after depletion of Thy 1.2+ cells, but suppression was no longer antigen-specific, suggesting that culture of spleen cells with CsA and BP may generate suppressor macrophages which are antigen-nonspecific and Thy 1.2+ suppressor cells which are antigen-specific.	Cyclosporine	158-161	thymus cell antigen 1, theta	Mus musculus	239-246
1692302-2	1990	Previously, it was shown that in this system, cyclosporin A-sensitive precursors gave rise to allo-indifferent MHC-unrestricted CD4+ suppressive cells.	Cyclosporine	46-59	CD4 molecule	Homo sapiens	128-131
2108071-2	1990	We report the first type I diabetic patient with an established kidney transplant on basal cyclosporin immunosuppression who was able to eliminate the insulin requirement after human islet transplantation into the portal vein.	Cyclosporine	91-102	insulin	Homo sapiens	151-158
2187453-10	1990	After 3 months of treatment, whole blood CL responses to Con-A and FMLP returned to almost normal levels in patients treated with Cy-A (15 cases) but not in those receiving the placebo (17 cases); PMA-induced CL responses were also decreased, but this was found in both groups of patients.	Cyclosporine	130-134	formyl peptide receptor 1	Homo sapiens	67-71
2187453-11	1990	In purified phagocyte suspensions we detected no effect of Cy-A on PMN, whereas MN phagocytes from Cy-A-treated patients showed reduced CL responses to FMLP but not to other stimuli.	Cyclosporine	99-103	formyl peptide receptor 1	Homo sapiens	152-156
1686130-14	1991	In a double-blind, randomized, placebo-controlled, cross-over study of 10 AD patients, 10 days" treatment with cyclosporin A (CSA), 5 mg/kg/day, significantly reduced itch intensity, eczema score and the number of peripheral blood eosinophils.	Cyclosporine	111-124	itchy E3 ubiquitin protein ligase	Homo sapiens	167-171
1686130-14	1991	In a double-blind, randomized, placebo-controlled, cross-over study of 10 AD patients, 10 days" treatment with cyclosporin A (CSA), 5 mg/kg/day, significantly reduced itch intensity, eczema score and the number of peripheral blood eosinophils.	Cyclosporine	126-129	itchy E3 ubiquitin protein ligase	Homo sapiens	167-171
2338822-5	1990	Cholecystokinin is a comitogen for H-PBMC and activates H-PBMC in a cyclosporine-resistant fashion.	Cyclosporine	68-80	cholecystokinin	Homo sapiens	0-15
2183445-0	1990	Cyclosporine inhibition of insulin secretion: effect of tolbutamide and extracellular calcium concentration.	Cyclosporine	0-12	insulin	Homo sapiens	27-34
1968924-2	1990	T cell priming in vivo to alloantigen can be mediated by an IL-2-independent cyclosporine A-resistant pathway.	Cyclosporine	77-91	interleukin 2	Homo sapiens	60-64
1968924-3	1990	Cyclosporine A (CsA) inhibits T lymphocyte activation in vitro by blocking at a pretranslational level the production of IL-2 and other cytokines.	Cyclosporine	0-14	interleukin 2	Homo sapiens	121-125
2307938-6	1990	The induced cell surface expression of TNF could be blocked with cyclosporine and/or methylprednisolone, and Northern analysis for TNF-specific transcripts revealed that this inhibitory effect occurs pretranslationally.	Cyclosporine	65-77	tumor necrosis factor	Homo sapiens	39-42
2178559-2	1990	Cyclosporine (cyclosporin A) is an immunosuppressant that selectively acts on the CD4+ subset of T lymphocytes.	Cyclosporine	0-12	CD4 molecule	Homo sapiens	82-85
2178559-2	1990	Cyclosporine (cyclosporin A) is an immunosuppressant that selectively acts on the CD4+ subset of T lymphocytes.	Cyclosporine	14-27	CD4 molecule	Homo sapiens	82-85
2397185-3	1990	With cyclosporin A (CsA) treatment, the patient entered remission and serum IL-2 fell to undetectable levels.	Cyclosporine	20-23	interleukin 2	Homo sapiens	76-80
2397185-4	1990	After cessation of CsA, the patient relapsed and the serum IL-2 levels were elevated again.	Cyclosporine	19-22	interleukin 2	Homo sapiens	59-63
2397185-5	1990	Reinstitution of CsA therapy was followed by a partial remission and disappearance of detectable serum IL-2 levels.	Cyclosporine	17-20	interleukin 2	Homo sapiens	103-107
2320952-0	1990	Ciclosporin-dependent, nu-independent, mucosal interleukin 6 response to gram-negative bacteria.	Cyclosporine	0-11	interleukin 6	Mus musculus	47-60
1968051-0	1990	Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A.	Cyclosporine	172-185	ATP binding cassette subfamily B member 1	Homo sapiens	22-26
1969186-2	1990	However, the process is inhibited by cyclosporine, suggesting that lymphokine production is required for islet graft rejection.	Cyclosporine	37-49	interleukin 2	Homo sapiens	67-77
1968051-8	1990	The degree of Cy-A-induced increase in drug accumulation in the leukemic cells correlated approximately with the level of overexpression of the mdr1 gene.	Cyclosporine	14-18	ATP binding cassette subfamily B member 1	Homo sapiens	144-148
2110931-3	1990	Additionally, the effects of prostaglandin E2 (PGE2), dexamethasone (dex), and cyclosporine A (CsA) on TNF gene expression have been studied, although little is known of the effects these compounds have on TNF containing samples.	Cyclosporine	79-93	tumor necrosis factor	Homo sapiens	103-106
1689350-7	1990	In the whole blood culture, it was shown that expression of IL-6 mRNA by monocytes was inhibited by dexamethasone, but not by cyclosporin A.	Cyclosporine	126-139	interleukin 6	Homo sapiens	60-64
1689353-5	1990	RAP potentiated the effect of CsA on proliferation and IL-2R expression in T cells stimulated with ionomycin + PMA.	Cyclosporine	30-33	regulatory associated protein of MTOR, complex 1	Mus musculus	0-3
2110931-3	1990	Additionally, the effects of prostaglandin E2 (PGE2), dexamethasone (dex), and cyclosporine A (CsA) on TNF gene expression have been studied, although little is known of the effects these compounds have on TNF containing samples.	Cyclosporine	95-98	tumor necrosis factor	Homo sapiens	103-106
2136900-11	1990	Exposure of peCTL to IL-4 also generated CTL activity, to a somewhat lesser degree than IL-2, but the IL-4-induced activation was inhibited by CsA, suggesting that it depended on the induction of another CsA-sensitive lymphokine.	Cyclosporine	143-146	interleukin 4	Homo sapiens	102-106
2318512-9	1990	The results are consistent with CS preventing the release of cytokines which have anorectic and catabolic actions (IL-1, TNF), although there is also the possibility that CS has effects involving endocrine mechanisms.	Cyclosporine	32-34	tumor necrosis factor	Rattus norvegicus	121-124
2136900-11	1990	Exposure of peCTL to IL-4 also generated CTL activity, to a somewhat lesser degree than IL-2, but the IL-4-induced activation was inhibited by CsA, suggesting that it depended on the induction of another CsA-sensitive lymphokine.	Cyclosporine	204-207	interleukin 4	Homo sapiens	21-25
2136900-11	1990	Exposure of peCTL to IL-4 also generated CTL activity, to a somewhat lesser degree than IL-2, but the IL-4-induced activation was inhibited by CsA, suggesting that it depended on the induction of another CsA-sensitive lymphokine.	Cyclosporine	204-207	interleukin 4	Homo sapiens	102-106
2136900-13	1990	This study demonstrates that in the presence of CsA precursors for CTL can accumulate, and that these can be rapidly converted to cytotoxic effector cells by IL-2.	Cyclosporine	48-51	interleukin 2	Homo sapiens	158-162
2371836-0	1990	"In vitro" cyclosporin and methylprednisolone interaction with cytochrome P-450.	Cyclosporine	11-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-79
2297260-2	1990	Prolactin receptors have been described on the membrane of lymphocyte cells, and competitive binding to these receptors by cyclosporine and circulating prolactin has been demonstrated.	Cyclosporine	123-135	prolactin	Homo sapiens	0-9
2301592-5	1990	Cyclosporine augmented the decrease in renal blood flow and the increase in renal vascular resistance produced by intrarenal norepinephrine, angiotensin II, and arginine vasopressin.	Cyclosporine	0-12	angiotensinogen	Rattus norvegicus	141-155
2301592-5	1990	Cyclosporine augmented the decrease in renal blood flow and the increase in renal vascular resistance produced by intrarenal norepinephrine, angiotensin II, and arginine vasopressin.	Cyclosporine	0-12	arginine vasopressin	Rattus norvegicus	170-181
2301592-8	1990	Rather, cyclosporine caused enhanced baroreflex slowing of heart rate and a decrease in the pressor response to both norepinephrine and angiotensin II.	Cyclosporine	8-20	angiotensinogen	Rattus norvegicus	136-150
2301592-10	1990	Therefore, although cyclosporine augmented renal vasoconstriction in response to norepinephrine, angiotensin II, and arginine vasopressin, it did not acutely increase the systemic vascular response to these agents.	Cyclosporine	20-32	angiotensinogen	Rattus norvegicus	97-111
2301592-10	1990	Therefore, although cyclosporine augmented renal vasoconstriction in response to norepinephrine, angiotensin II, and arginine vasopressin, it did not acutely increase the systemic vascular response to these agents.	Cyclosporine	20-32	arginine vasopressin	Rattus norvegicus	126-137
2297260-10	1990	In conclusion, suppression of circulating prolactin by bromocriptine appears to improve the immunosuppressive effect of cyclosporine, at least during the early postoperative period when the risk of rejection and infection is higher, and could be a promising avenue to successful hormonal manipulations of the immune process after organ transplantation.	Cyclosporine	120-132	prolactin	Homo sapiens	42-51
2404598-13	1990	Diuretics and vasodilators have been the mainstay of our approach during the early phases of the hypertension but our recent data indicate that ACE inhibitors may become relatively specific in management during the later phases of the post-transplantation period as PRA levels rise in response to vascular damage by cyclosporine.	Cyclosporine	316-328	angiotensin I converting enzyme	Homo sapiens	144-147
2293908-2	1990	Decreased levels of autoantibodies against DNA, histones, cardiolipin, RNP, Sm, Ro (SS-A), and La (SS-B) were detected in the sera of patients with uveitis receiving cyclosporine A or cyclosporine A plus bromocriptine following 3 months of treatment.	Cyclosporine	166-180	tripartite motif containing 21	Homo sapiens	84-88
2303172-0	1990	Proinsulin and C-peptide at onset and during 12 months cyclosporin treatment of type 1 (insulin-dependent) diabetes mellitus.	Cyclosporine	55-66	insulin	Homo sapiens	15-24
2303172-10	1990	The effect of cyclosporin on the induction of non-insulin requiring remission was unrelated to fasting and glucagon stimulated C-peptide levels at entry, whereas 64% of the cyclosporin-treated against 28% of the placebo-treated subjects (p less than 0.01) went into remission if the proinsulin/C-peptide ratio at entry was above 0.024.	Cyclosporine	14-25	insulin	Homo sapiens	50-57
2297260-3	1990	Experimental evidence suggests a synergistic effect of cyclosporine and bromocriptine, an inhibitor of pituitary release of prolactin, on immunosuppression.	Cyclosporine	55-67	prolactin	Homo sapiens	124-133
2209678-5	1990	CYA and AZA did not influence CD4+/CD8+ ratio of circulating T cells but affected HNK-1+ cells.	Cyclosporine	0-3	beta-1,3-glucuronyltransferase 1	Homo sapiens	82-87
2312149-0	1990	Anti-CD3 antibody-induced expression of both p55 and p75 chains of the high affinity interleukin-2 receptor on human T lymphocytes is inhibited by cyclosporin A.	Cyclosporine	147-160	interleukin 2	Homo sapiens	85-98
2312149-3	1990	Exogenous recombinant interleukin-2 (rIL-2) partially reversed the inhibitory effect on antibody-stimulated cells only; however, at higher CsA concentrations (300 ng/ml) proliferation was again inhibited.	Cyclosporine	139-142	interleukin 2	Homo sapiens	22-35
2312149-6	1990	However, CsA inhibited both high and low affinity receptor expression as shown by [125I]IL-2 equilibrium binding studies on anti-CD3-stimulated cells.	Cyclosporine	9-12	interleukin 2	Homo sapiens	88-92
2312396-10	1990	Determination of steroidogenic enzyme activities indicated that the administration of CsA inhibited the activity of delta 5-3B-hydroxy steroid dehydrogenase-delta 5-4 isomerase (3 beta-HSD).	Cyclosporine	86-89	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1	Rattus norvegicus	178-188
1968970-7	1990	Treatment for 3 d with cyclosporine was associated with decreased rectal temperature, decreased magnesium concentrations in serum and CSF, increased serum creatinine and urea nitrogen concentrations, elevated serum aspartate aminotransferase activity and total bilirubin concentration, decreased serum total protein concentration, and increased hematocrit.	Cyclosporine	23-35	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	215-241
2329513-4	1990	The brain extraction of cyclosporine was related inversely to the lipoprotein concentration in the injected solution, allowing estimation of nKa in vivo: high-density lipoprotein, 2.25 +/- 0.59; low-density lipoprotein, 0.62 +/- 0.13; and very low-density lipoprotein, 0.57 +/- 0.14 liters/g.	Cyclosporine	24-36	tachykinin precursor 1	Homo sapiens	141-144
1967264-7	1990	Although pretreatment with AcD, CsA, or ChT strongly inhibits production of IL-2, TNF and IFN-gamma, only clones pretreated with AcD lose cytolytic activity against Ag-pulsed, Ia-bearing LK cells.	Cyclosporine	32-35	tumor necrosis factor	Mus musculus	82-85
1968970-11	1990	Pretreatment with a single 60-mg/kg im dose of cyclosporine 2 h before heptabarbital infusion caused no significant biochemical changes approximately 160 min later, except for elevated serum aspartate aminotransferase (which occurred also after injection of the surfactant-containing vehicle) and serum bilirubin.	Cyclosporine	47-59	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	191-217
1967264-7	1990	Although pretreatment with AcD, CsA, or ChT strongly inhibits production of IL-2, TNF and IFN-gamma, only clones pretreated with AcD lose cytolytic activity against Ag-pulsed, Ia-bearing LK cells.	Cyclosporine	32-35	interferon gamma	Mus musculus	90-99
1967264-13	1990	Only the TNF-independent cytolytic activity is resistant to CsA and ChT inhibition.	Cyclosporine	60-63	tumor necrosis factor	Mus musculus	9-12
2113642-6	1990	These results indicate that a physiological concentration of angiotensin II may potentialise but may not be the sole factor involved in the vasopressor effect of CsA.	Cyclosporine	162-165	angiotensinogen	Homo sapiens	61-75
1967265-1	1990	The immunosuppressive agent, cyclosporin A (CsA) blocks production of IL-2 by lymphocytes in vitro, and impairs immune responses in vivo.	Cyclosporine	44-47	interleukin 2	Homo sapiens	70-74
1967265-7	1990	In situ hybridization revealed a 50% reduction in the percentage of cells transcribing IL-2, suggesting that CsA blocked IL-2 production at the level of gene transcription.	Cyclosporine	109-112	interleukin 2	Homo sapiens	87-91
1967265-7	1990	In situ hybridization revealed a 50% reduction in the percentage of cells transcribing IL-2, suggesting that CsA blocked IL-2 production at the level of gene transcription.	Cyclosporine	109-112	interleukin 2	Homo sapiens	121-125
2137272-1	1990	Central to the immunosuppressive properties of cyclosporine is a drug imposed blockade of the interleukin-2 gene activation.	Cyclosporine	47-59	interleukin 2	Homo sapiens	94-107
1689083-3	1990	The present communication documents that inhibition of ADR activity reflects the in vitro immunosuppressive effects of Cyclosporine.	Cyclosporine	119-131	aldo-keto reductase family 1 member B	Homo sapiens	55-58
1689083-4	1990	CsA inhibition of both proliferation and generation of ADR was concentration-dependent and occurred only in the G0 phase of the cell cycle.	Cyclosporine	0-3	aldo-keto reductase family 1 member B	Homo sapiens	55-58
1689083-6	1990	ADR generation was inhibited both by CsA and by PGE2 alpha, possibly via effects on calcium-dependent activation pathways confined to G0/G1 transition.	Cyclosporine	37-40	aldo-keto reductase family 1 member B	Homo sapiens	0-3
1689083-12	1990	Thus, ADR and SPA may represent opposing components of a cytoplasmic signaling cascade the balance of which reflects the level of immunosuppression, and thus represents a focus for in vitro evaluation of the immunologic response of allografted patients to cyclosporine.	Cyclosporine	256-268	aldo-keto reductase family 1 member B	Homo sapiens	6-9
33822449-3	2021	The chiral information of CSA are effectively transferred to the microcrystals by hydrogen bonding to afford full-color CPL from deep-blue to red with g lum in the order of 10 -2 and Phi FL up to 80%.	Cyclosporine	26-29	lumican	Homo sapiens	153-156
33764520-9	2021	CSA re-stimulated LN cells from vaccinated mice after challenge infection secreted comparable IL-4 and IL-10 but reduced IFN-gamma, as compared to controls.	Cyclosporine	0-3	interleukin 10	Mus musculus	103-108
33764520-9	2021	CSA re-stimulated LN cells from vaccinated mice after challenge infection secreted comparable IL-4 and IL-10 but reduced IFN-gamma, as compared to controls.	Cyclosporine	0-3	interferon gamma	Mus musculus	121-130
33032826-9	2020	CsA was also found to promote the expression of titin, MMP9, EGFR, and PRR15.	Cyclosporine	0-3	epidermal growth factor receptor	Homo sapiens	61-65
33032826-10	2020	TRAIL may be a target gene for CsA-mediated regulation of EVTs.	Cyclosporine	31-34	TNF superfamily member 10	Homo sapiens	0-5
15812356-3	2005	Constant presence of cyclosporin A (CsA) as a P-glycoprotein (Pgp) blocker in some cell cultures simulated prophylactic inhibition of this protein activity for prevention of drug resistance development from the very beginning of treatment.	Cyclosporine	21-34	ATP binding cassette subfamily B member 1	Homo sapiens	46-60
15812356-3	2005	Constant presence of cyclosporin A (CsA) as a P-glycoprotein (Pgp) blocker in some cell cultures simulated prophylactic inhibition of this protein activity for prevention of drug resistance development from the very beginning of treatment.	Cyclosporine	21-34	ATP binding cassette subfamily B member 1	Homo sapiens	62-65
15812356-3	2005	Constant presence of cyclosporin A (CsA) as a P-glycoprotein (Pgp) blocker in some cell cultures simulated prophylactic inhibition of this protein activity for prevention of drug resistance development from the very beginning of treatment.	Cyclosporine	36-39	ATP binding cassette subfamily B member 1	Homo sapiens	46-60
15812356-3	2005	Constant presence of cyclosporin A (CsA) as a P-glycoprotein (Pgp) blocker in some cell cultures simulated prophylactic inhibition of this protein activity for prevention of drug resistance development from the very beginning of treatment.	Cyclosporine	36-39	ATP binding cassette subfamily B member 1	Homo sapiens	62-65
34953947-10	2022	Our data further demonstrated that PM2.5 caused reduction in nuclear expressions of PPARgamma and PGC-1alpha, which were reversed in the presence of CsA.	Cyclosporine	149-152	peroxisome proliferator activated receptor gamma	Homo sapiens	84-93
34953947-10	2022	Our data further demonstrated that PM2.5 caused reduction in nuclear expressions of PPARgamma and PGC-1alpha, which were reversed in the presence of CsA.	Cyclosporine	149-152	PPARG coactivator 1 alpha	Homo sapiens	98-108
34100277-3	2022	At group level, CSA increased from pre to post (DS: 7.8% vs. TRAD: 7.5%, P=0.02; CP: 7.5% vs. TRAD: 7.8%, P=0.02).	Cyclosporine	16-19	RAD51 paralog D	Homo sapiens	61-65
34100277-3	2022	At group level, CSA increased from pre to post (DS: 7.8% vs. TRAD: 7.5%, P=0.02; CP: 7.5% vs. TRAD: 7.8%, P=0.02).	Cyclosporine	16-19	RAD51 paralog D	Homo sapiens	94-98
1968392-6	1990	Similarly, pretreatment of a CD8 clone with actinomycin D or CsA inhibited lymphokine production without affecting cytolytic activity.	Cyclosporine	61-64	interleukin 2	Homo sapiens	75-85
33233866-5	2020	Conventional and recently developed agents for treating AD such as steroid, calcineurin inhibitors, cyclosporine, dupilumab, and JAK inhibitors inhibit the IL-13/IL-4-JAK-STAT6/STAT3 axis, while older remedies such as coal tar and glyteer are antioxidative AHR agonists.	Cyclosporine	100-112	interleukin 13	Homo sapiens	156-161
33233866-5	2020	Conventional and recently developed agents for treating AD such as steroid, calcineurin inhibitors, cyclosporine, dupilumab, and JAK inhibitors inhibit the IL-13/IL-4-JAK-STAT6/STAT3 axis, while older remedies such as coal tar and glyteer are antioxidative AHR agonists.	Cyclosporine	100-112	interleukin 4	Homo sapiens	162-166
33233866-5	2020	Conventional and recently developed agents for treating AD such as steroid, calcineurin inhibitors, cyclosporine, dupilumab, and JAK inhibitors inhibit the IL-13/IL-4-JAK-STAT6/STAT3 axis, while older remedies such as coal tar and glyteer are antioxidative AHR agonists.	Cyclosporine	100-112	signal transducer and activator of transcription 3	Homo sapiens	177-182
34953947-9	2022	The mPTP targeting compounds cyclosporin A (CsA; a potent inhibitor of cyclophilin D (CypD)) and VBIT-12 (a selective VDAC1 inhibitor) significantly inhibited PM2.5-induced mPTP opening and apoptosis, and preserved mitochondrial function by restoring mitochondrial membrane potential, reducing mitochondrial ROS generation and intracellular calcium content, and maintaining mitochondrial respiration function.	Cyclosporine	29-42	protein tyrosine phosphatase, receptor type, U	Mus musculus	4-8
34953947-9	2022	The mPTP targeting compounds cyclosporin A (CsA; a potent inhibitor of cyclophilin D (CypD)) and VBIT-12 (a selective VDAC1 inhibitor) significantly inhibited PM2.5-induced mPTP opening and apoptosis, and preserved mitochondrial function by restoring mitochondrial membrane potential, reducing mitochondrial ROS generation and intracellular calcium content, and maintaining mitochondrial respiration function.	Cyclosporine	29-42	peptidylprolyl isomerase F	Homo sapiens	71-84
34953947-9	2022	The mPTP targeting compounds cyclosporin A (CsA; a potent inhibitor of cyclophilin D (CypD)) and VBIT-12 (a selective VDAC1 inhibitor) significantly inhibited PM2.5-induced mPTP opening and apoptosis, and preserved mitochondrial function by restoring mitochondrial membrane potential, reducing mitochondrial ROS generation and intracellular calcium content, and maintaining mitochondrial respiration function.	Cyclosporine	29-42	peptidylprolyl isomerase F	Homo sapiens	86-90
34953947-9	2022	The mPTP targeting compounds cyclosporin A (CsA; a potent inhibitor of cyclophilin D (CypD)) and VBIT-12 (a selective VDAC1 inhibitor) significantly inhibited PM2.5-induced mPTP opening and apoptosis, and preserved mitochondrial function by restoring mitochondrial membrane potential, reducing mitochondrial ROS generation and intracellular calcium content, and maintaining mitochondrial respiration function.	Cyclosporine	29-42	protein tyrosine phosphatase, receptor type, U	Mus musculus	173-177
34953947-9	2022	The mPTP targeting compounds cyclosporin A (CsA; a potent inhibitor of cyclophilin D (CypD)) and VBIT-12 (a selective VDAC1 inhibitor) significantly inhibited PM2.5-induced mPTP opening and apoptosis, and preserved mitochondrial function by restoring mitochondrial membrane potential, reducing mitochondrial ROS generation and intracellular calcium content, and maintaining mitochondrial respiration function.	Cyclosporine	44-47	protein tyrosine phosphatase, receptor type, U	Mus musculus	4-8
34953947-9	2022	The mPTP targeting compounds cyclosporin A (CsA; a potent inhibitor of cyclophilin D (CypD)) and VBIT-12 (a selective VDAC1 inhibitor) significantly inhibited PM2.5-induced mPTP opening and apoptosis, and preserved mitochondrial function by restoring mitochondrial membrane potential, reducing mitochondrial ROS generation and intracellular calcium content, and maintaining mitochondrial respiration function.	Cyclosporine	44-47	peptidylprolyl isomerase F	Homo sapiens	71-84
34953947-9	2022	The mPTP targeting compounds cyclosporin A (CsA; a potent inhibitor of cyclophilin D (CypD)) and VBIT-12 (a selective VDAC1 inhibitor) significantly inhibited PM2.5-induced mPTP opening and apoptosis, and preserved mitochondrial function by restoring mitochondrial membrane potential, reducing mitochondrial ROS generation and intracellular calcium content, and maintaining mitochondrial respiration function.	Cyclosporine	44-47	peptidylprolyl isomerase F	Homo sapiens	86-90
34953947-9	2022	The mPTP targeting compounds cyclosporin A (CsA; a potent inhibitor of cyclophilin D (CypD)) and VBIT-12 (a selective VDAC1 inhibitor) significantly inhibited PM2.5-induced mPTP opening and apoptosis, and preserved mitochondrial function by restoring mitochondrial membrane potential, reducing mitochondrial ROS generation and intracellular calcium content, and maintaining mitochondrial respiration function.	Cyclosporine	44-47	protein tyrosine phosphatase, receptor type, U	Mus musculus	173-177
34927415-2	2022	Here, using human kidney-specific microvascular endothelial cells (HKMECs), we showed that CsA inhibited NFAT1 activation and impaired VEGF signaling in these ECs in a dose- and time-dependent manner.	Cyclosporine	91-94	vascular endothelial growth factor A	Homo sapiens	135-139
34927415-6	2022	Our results also suggest VEGF-related pathways as potential targets for therapy during CsA treatment and emphasize the importance of leveraging species and organ-specific cells to better reflect human pathophysiology and the response to injury.	Cyclosporine	87-90	vascular endothelial growth factor A	Homo sapiens	25-29
34637896-0	2022	Amorphous solid dispersions of cyclosporine A with improved bioavailability prepared via hot melt extrusion: formulation, physicochemical characterization, and in vivo evaluation.	Cyclosporine	31-45	alcohol dehydrogenase, iron containing, 1	Rattus norvegicus	89-92
34637896-1	2022	In this study, the amorphous solid dispersions of cyclosporine A (CsA-ASDs) were prepared by hot melt extrusion (HME) with PVP K12 as carrier to improve the oral bioavailability of CsA.	Cyclosporine	181-184	alcohol dehydrogenase, iron containing, 1	Rattus norvegicus	93-96
2137272-2	1990	As IL-6 stimulates antigen-activated T cells to release IL-2, we examined the influence of CsA on IL-6 gene expression and IL-6-supported T cell proliferation.	Cyclosporine	91-94	interleukin 6	Homo sapiens	98-102
2137272-2	1990	As IL-6 stimulates antigen-activated T cells to release IL-2, we examined the influence of CsA on IL-6 gene expression and IL-6-supported T cell proliferation.	Cyclosporine	91-94	interleukin 6	Homo sapiens	98-102
2137272-4	1990	In fact, increased IL-6 gene transcription and increased release of IL-6 bioactivity were detected using mitogen-activated PBMCs cultured with CsA doses (200-800 ng/ml) only slightly in excess of the minimal antiproliferative dose.	Cyclosporine	143-146	interleukin 6	Homo sapiens	19-23
2137272-4	1990	In fact, increased IL-6 gene transcription and increased release of IL-6 bioactivity were detected using mitogen-activated PBMCs cultured with CsA doses (200-800 ng/ml) only slightly in excess of the minimal antiproliferative dose.	Cyclosporine	143-146	interleukin 6	Homo sapiens	68-72
2137272-5	1990	CsA completely abrogated the IL-6-stimulated proliferative responses of macrophage-depleted T cells stimulated with polyvalent anti-CD3 monoclonal antibodies.	Cyclosporine	0-3	interleukin 6	Homo sapiens	29-33
2137272-7	1990	As IL-6 fosters B cell activation and growth of EBV-transformed B cells, excessive CsA doses may support development of EBV-transformed B cell lymphomas via superinduction of the IL-6 gene.	Cyclosporine	83-86	interleukin 6	Homo sapiens	179-183
34957889-4	2021	Kidney GSH levels decreased while MDA levels, CuZn-SOD, and CAT activities increased significantly in the CsA group compared to control indicating oxidative stress.	Cyclosporine	106-109	superoxide dismutase 1	Rattus norvegicus	46-54
34957889-4	2021	Kidney GSH levels decreased while MDA levels, CuZn-SOD, and CAT activities increased significantly in the CsA group compared to control indicating oxidative stress.	Cyclosporine	106-109	catalase	Rattus norvegicus	60-63
34957889-7	2021	PD98059 and CAPE applications in CsA given animals increased GSH and CAV1 gene expressions and decreased CuZn-SOD and CAT levels compared to the CsA group.	Cyclosporine	33-36	caveolin 1	Rattus norvegicus	69-73
34957889-7	2021	PD98059 and CAPE applications in CsA given animals increased GSH and CAV1 gene expressions and decreased CuZn-SOD and CAT levels compared to the CsA group.	Cyclosporine	33-36	catalase	Rattus norvegicus	118-121
34935100-8	2022	RESULTS: The data showed that drugs which are known P-gp inhibitors, including cyclosporin A, ketoconazole, and verapamil, caused great increases in rhodamine 123 retention, whereas noninhibitors did not affect the intracellular accumulation of the P-gp substrate.	Cyclosporine	79-92	ATP binding cassette subfamily B member 1	Homo sapiens	52-56
34992608-5	2021	Our data confirm that PIRCHE presented by HLA-DRB1 along with HLA-DRB3/4/5, -DQ, and -DP are significant predictors for the development of CSA.	Cyclosporine	139-142	major histocompatibility complex, class II, DR beta 1	Homo sapiens	42-50
34224738-8	2021	CsA suppressed activation of ITK in cultured CD4+ T cells and calcineurin-containing microclusters adjacent to the T cell receptor signaling complex.	Cyclosporine	0-3	IL2 inducible T cell kinase	Mus musculus	29-32
34788311-18	2021	MAGEH1 gene expression was not altered by CsA-induced cytotoxic injury, whereas GADD45G gene expression was increased significantly upon CsA treatment.	Cyclosporine	137-140	MAGE family member H1	Homo sapiens	0-6
34788311-20	2021	CsA-induced apoptosis was significantly reduced in MAGEH1 knockdown HRE stable cells which led to an increased survival of these cells.	Cyclosporine	0-3	MAGE family member H1	Homo sapiens	51-57
34788311-22	2021	Accordingly, CsA-induced apoptosis was significantly decreased in MAGEH1 siRNA and GADD45G siRNA transfected HK-2 cells.	Cyclosporine	13-16	MAGE family member H1	Homo sapiens	66-72
34788311-23	2021	CsA-induced activation of caspase-7 and caspase-9 was inhibited in MAGEH1 knockdown HRE stable cells, and similarly in GADD45G knockdown HRE stable cells.	Cyclosporine	0-3	MAGE family member H1	Homo sapiens	67-73
34779003-0	2022	Population pharmacokinetics of ciclosporin in allogeneic hematopoietic stem cell transplant recipients: C-reactive protein as a novel covariate for clearance.	Cyclosporine	31-42	C-reactive protein	Homo sapiens	104-122
34779003-7	2022	RESULTS AND DISCUSSION: The results showed that the daily CsA dose, haematocrit, total bile acid, C-reactive protein (CRP) and co-administration of triazole antifungal agent were identified as significant covariates for clearance (CL) of CsA.	Cyclosporine	238-241	C-reactive protein	Homo sapiens	98-116
34779003-7	2022	RESULTS AND DISCUSSION: The results showed that the daily CsA dose, haematocrit, total bile acid, C-reactive protein (CRP) and co-administration of triazole antifungal agent were identified as significant covariates for clearance (CL) of CsA.	Cyclosporine	238-241	C-reactive protein	Homo sapiens	118-121
34779003-12	2022	WHAT IS NEW AND CONCLUSION: CRP concentration was identified as a novel marker associated with CsA pharmacokinetics, which should be considered when determining the appropriate dosage of CsA in allo-HSCT recipients.	Cyclosporine	95-98	C-reactive protein	Homo sapiens	28-31
34779003-12	2022	WHAT IS NEW AND CONCLUSION: CRP concentration was identified as a novel marker associated with CsA pharmacokinetics, which should be considered when determining the appropriate dosage of CsA in allo-HSCT recipients.	Cyclosporine	187-190	C-reactive protein	Homo sapiens	28-31
34080717-4	2021	CSA/CPA history was associated with longer duration and earlier age of onset of condition(s), greater number of presenting problems and post-traumatic stress disorder co-occurrence, higher intensity treatment delivery, and lower recovery rates.	Cyclosporine	0-3	carboxypeptidase A1	Homo sapiens	4-7
34080717-6	2021	PRACTITIONER POINTS: A sizable minority of IAPT clients (14%) present with a history of CSA/CPA as recorded in clinical notes.	Cyclosporine	88-91	carboxypeptidase A1	Homo sapiens	92-95
34080717-7	2021	CSA/CPA history is associated with more complex and enduring presentations in IAPT clients.	Cyclosporine	0-3	carboxypeptidase A1	Homo sapiens	4-7
34119711-10	2021	Treatment of SMNKO mice with the Cyclophilin D inhibitor, Cyclosporine A, increased membrane integrity, decreased the number of centralized nuclei, and increased survival.	Cyclosporine	58-72	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	33-46
34350891-11	2022	The levels of autoantibodies against NGF are decreased by the immunomodulatory activity of cyclosporin A, which mainly controls pain and improves motor function and sensitivity.	Cyclosporine	91-104	nerve growth factor	Homo sapiens	37-40
34595834-0	2021	Targeting Extracellular Cyclophilin A via an Albumin-binding Cyclosporine A Analogue.	Cyclosporine	61-75	albumin	Homo sapiens	45-52
34595834-1	2021	An albumin-binding CsA analogue 4MCsA was achieved by attachment of a thiol-reactive maleimide group at the side-chain of P4 position of CsA derivative.	Cyclosporine	19-22	albumin	Homo sapiens	3-10
34595834-1	2021	An albumin-binding CsA analogue 4MCsA was achieved by attachment of a thiol-reactive maleimide group at the side-chain of P4 position of CsA derivative.	Cyclosporine	137-140	albumin	Homo sapiens	3-10
34224738-9	2021	Functionally, the capacity of CsA to suppress activity of experimental colitis was critically dependent on ITK.	Cyclosporine	30-33	IL2 inducible T cell kinase	Mus musculus	107-110
34224738-12	2021	CONCLUSION: ITK activation was detected in ulcerative colitis and could be downregulated in cultured T cells by CsA administration.	Cyclosporine	112-115	IL2 inducible T cell kinase	Mus musculus	12-15
34526721-6	2021	The resulting elongation complex, ECTCR, uses the CSA-stimulated translocase activity of CSB to pull on upstream DNA and push Pol II forward.	Cyclosporine	50-53	ERCC excision repair 6, chromatin remodeling factor	Homo sapiens	89-92
34561200-6	2021	There were also a significant (p<0.05) increase in the creatinine, BUN and glucose, but a decrease in the CRP value in the CsA-treated group.	Cyclosporine	123-126	C-reactive protein	Rattus norvegicus	106-109
34565275-7	2021	CsA decreased Bcl-2 levels, and administration of CsA + DAPA significantly increased Bcl-2 levels compared with only CsA administration (p < 0.001).	Cyclosporine	0-3	B cell leukemia/lymphoma 2	Mus musculus	14-19
34565275-7	2021	CsA decreased Bcl-2 levels, and administration of CsA + DAPA significantly increased Bcl-2 levels compared with only CsA administration (p < 0.001).	Cyclosporine	50-53	B cell leukemia/lymphoma 2	Mus musculus	85-90
34691416-6	2021	Clinical discussion: Cyclosporine is an immunosuppressive agent that interferes with T-cells activation by inhibiting transcription of cytokines, such as interleukin 2 and interferon-gamma.	Cyclosporine	21-33	interleukin 2	Homo sapiens	154-167
34638597-7	2021	Furthermore, chrysin co-treatment diminished CsA-induced TGF-beta1 signaling pathways, decreasing Smad 3 phosphorylation which lead to a subsequent reduction in Snail expression.	Cyclosporine	45-48	transforming growth factor, beta 1	Rattus norvegicus	57-66
34638597-7	2021	Furthermore, chrysin co-treatment diminished CsA-induced TGF-beta1 signaling pathways, decreasing Smad 3 phosphorylation which lead to a subsequent reduction in Snail expression.	Cyclosporine	45-48	SMAD family member 3	Rattus norvegicus	98-104
34638597-11	2021	Chrysin was shown to inhibit CsA-induced TGF-beta1-dependent EMT in proximal tubule cells by modulation of Smad-dependent and independent signaling pathways.	Cyclosporine	29-32	transforming growth factor, beta 1	Rattus norvegicus	41-50
34691416-6	2021	Clinical discussion: Cyclosporine is an immunosuppressive agent that interferes with T-cells activation by inhibiting transcription of cytokines, such as interleukin 2 and interferon-gamma.	Cyclosporine	21-33	interferon gamma	Homo sapiens	172-188
34552510-8	2021	Compared to the placebo group, the CsA group had dramatically lower endometrial CD56+ cell and CD57+ cell concentrations at the luteal phase of the second menstrual cycle (P < 0.05).	Cyclosporine	35-38	beta-1,3-glucuronyltransferase 1	Homo sapiens	95-99
34575860-4	2021	We hypothesized that CsA and Tac induce functional defects and activate an inflammatory cascade via NF-kappaB signaling in ECFCs.	Cyclosporine	21-24	nuclear factor kappa B subunit 1	Homo sapiens	100-109
34575860-12	2021	Pharmacological inhibition of NF-kappaB by parthenolide diminished CsA- and Tac-mediated proinflammatory effects.	Cyclosporine	67-70	nuclear factor kappa B subunit 1	Homo sapiens	30-39
34552880-9	2021	In conclusion, prior Rituximab before autologous HSCT and cyclosporine administration after allogeneic HSCT negatively affected the antibody response to Sars-COV2 vaccine, possibly due to their immunosuppressive action on CD20 +B cells and T cells, respectively.	Cyclosporine	58-70	keratin 20	Homo sapiens	222-226
34511871-13	2021	Conclusion: Cataract surgery patients with dry eye who are prescribed topical cyclosporine 0.09% BID for 28 days pre-surgery showed a statistically significant improvement in the prediction error of the spherical equivalent outcome of surgery.	Cyclosporine	78-90	BH3 interacting domain death agonist	Homo sapiens	97-100
34552938-5	2021	We conclude that CsA could have at least three major targets in COVID-19 patients: (i) an anti-inflammatory effect reducing the production of proinflammatory cytokines, (ii) an antiviral effect preventing the formation of the viral RNA synthesis complex, and (iii) an effect on tissue damage and thrombosis by acting against the deleterious action of angiotensin II.	Cyclosporine	17-20	angiotensinogen	Homo sapiens	351-365
34114691-0	2021	TRough vs. AUC Monitoring of cyclosporine: A randomized comparison of adverse drug reactions in adult allogeneic stem cell recipients (TRAM study).	Cyclosporine	29-41	translocation associated membrane protein 1	Homo sapiens	135-139
34109683-12	2021	CsA suppressed the TGF-beta-induced translocation of NFATc3 into the nuclei of hGF.	Cyclosporine	0-3	nuclear factor of activated T cells 3	Homo sapiens	53-59
34398134-17	2021	Both Parkin-si and CsA attenuated melatonin"s inhibitory effect on apoptosis and the NLRP3 inflammasome, indicating that the beneficial effects of melatonin in DRG cells are mediated through the Parkin-mediated mitophagy.	Cyclosporine	19-22	NLR family, pyrin domain containing 3	Rattus norvegicus	85-90
34483914-3	2021	Remdesivir and cyclosporine also separately reduced IL-6 production induced by HCoV-OC43 in human lung fibroblasts MRC-5 cells with EC50 values of 224 +- 53 nM and 1,292 +- 352 nM, respectively; and synergistically reduced it when combined.	Cyclosporine	15-27	interleukin 6	Homo sapiens	52-56
34439442-6	2021	The administration of CsA also significantly downregulated the renal expression of interferon-gamma, tumor necrosis factor-alpha, interleukin 1 beta, monocyte chemotactic protein 1, intercellular adhesion molecule-1, and vascular cell adhesion molecule 1 genes, and increased renal DNA damage.	Cyclosporine	22-25	tumor necrosis factor	Rattus norvegicus	101-128
34439442-6	2021	The administration of CsA also significantly downregulated the renal expression of interferon-gamma, tumor necrosis factor-alpha, interleukin 1 beta, monocyte chemotactic protein 1, intercellular adhesion molecule-1, and vascular cell adhesion molecule 1 genes, and increased renal DNA damage.	Cyclosporine	22-25	interleukin 1 beta	Rattus norvegicus	130-148
34269803-8	2021	This synonymous variant in P-glycoprotein may influence the risk of CMV reactivation by altering the efflux of cyclosporine and tacrolimus from donor lymphocytes.	Cyclosporine	111-123	ATP binding cassette subfamily B member 1	Homo sapiens	27-41
34474833-3	2021	This nanohybrid regulates the in vitro release of both bevacizumab and cyclosporine A in a sustainable way for up to four weeks to enhance CNV inhibition through the synergistic anti-VEGF and anti-inflammation.	Cyclosporine	71-85	vascular endothelial growth factor A	Homo sapiens	183-187
34445576-8	2021	Moreover, CD40-CD40L interaction induced a cytoskeleton reorganization and increased the expression of integrin beta1 on RCC cell lines, and this effect was reversed by cyclosporine A and NFAT inhibition.	Cyclosporine	169-183	CD40 ligand	Homo sapiens	15-20
34306041-9	2021	CYP3A4*22 was shown to significantly influence the pharmacokinetics of several drugs, with currently being most thoroughly investigated tacrolimus, cyclosporine, and statins.	Cyclosporine	148-160	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
34109683-14	2021	We confirmed that CsA, NIF, and PHT reduced cytosolic calcium levels increased by TGF-beta, while CaCl2 enhanced the TGF-beta-up-regulated NR4A1 expression.	Cyclosporine	18-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	139-144
34124083-15	2021	Compared to cyclosporin A monotherapy, additional stanozolol and danazol can both increase the level of regulatory T cells and upregulate interleukin-10, inhibiting the expression of tumor necrosis factor-alpha (P < 0.05).	Cyclosporine	12-25	interleukin 10	Mus musculus	138-152
34124083-15	2021	Compared to cyclosporin A monotherapy, additional stanozolol and danazol can both increase the level of regulatory T cells and upregulate interleukin-10, inhibiting the expression of tumor necrosis factor-alpha (P < 0.05).	Cyclosporine	12-25	tumor necrosis factor	Mus musculus	183-210
34122084-2	2021	We have previously shown that CsA increases the activity of the epithelial sodium channel (ENaC) in cultured distal nephron cells.	Cyclosporine	30-33	sodium channel epithelial 1 subunit gamma	Rattus norvegicus	91-95
34122084-4	2021	Our data show that the open probability of ENaC in principal cells of split-open cortical collecting ducts was significantly increased after treatment of rats with CsA; the increase was attenuated by lovastatin.	Cyclosporine	164-167	sodium channel epithelial 1 subunit gamma	Rattus norvegicus	43-47
34122084-6	2021	Lovastatin also abolished CsA-induced elevation of alpha-, ss-, and gamma-ENaC expressions.	Cyclosporine	26-29	sodium channel epithelial 1 subunit gamma	Rattus norvegicus	68-78
34122084-7	2021	CsA elevated systolic blood pressure in rats; the elevation was completely reversed by lovastatin (an inhibitor of cholesterol synthesis), NaHS (a donor of H2S which ameliorated CsA-induced elevation of reactive oxygen species), or amiloride (a potent ENaC blocker).	Cyclosporine	0-3	sodium channel epithelial 1 subunit gamma	Rattus norvegicus	252-256
34122084-8	2021	These results suggest that CsA elevates blood pressure by increasing ENaC activity via a signaling cascade associated with elevation of intracellular ROS, activation of Sgk1, and inactivation of Nedd4-2 in an intracellular cholesterol-dependent manner.	Cyclosporine	27-30	sodium channel epithelial 1 subunit gamma	Rattus norvegicus	69-73
34067576-0	2021	Camel Milk Mitigates Cyclosporine-Induced Renal Damage in Rats: Targeting p38/ERK/JNK MAPKs, NF-kappaB, and Matrix Metalloproteinases.	Cyclosporine	21-33	Eph receptor B1	Rattus norvegicus	78-81
34067576-9	2021	These findings propose that camel milk may be a promising agent that inhibits cyclosporine-triggered renal inflammation via curtailing the p38/ERK/JNK MAPK and NF-kappaB pathways, matrix metalloproteinases, and pro-inflammatory cytokines.	Cyclosporine	78-90	Eph receptor B1	Rattus norvegicus	143-146
34079822-9	2021	Troglitazone, BSP and erythrosine B were identified as pan-SLC10 inhibitors, whereas cyclosporine A, irbesartan, ginkgolic acid 17:1, and betulinic acid only inhibited NTCP and SOAT, but not ASBT.	Cyclosporine	85-99	solute carrier family 10 member 1	Homo sapiens	168-172
34427166-3	2020	CsA treatment significantly downregulated the expressions of miR-26-5p and PTEN and upregulated the expressions of PI3K and p-AKT in both rat gingival tissues and HGFs.	Cyclosporine	0-3	AKT serine/threonine kinase 1	Rattus norvegicus	126-129
34427166-6	2020	Our results revealed that miRNA-26-5p could repress CsA-induced overgrowth of human HGFs by regulating PTEN/PI3K/AKT pathway.	Cyclosporine	52-55	AKT serine/threonine kinase 1	Homo sapiens	113-116
34089287-8	2021	Through screening and molecular docking, PRKDC, CUL7, CUL1, HSPA8, HSPA4 and SIRT7 were the most likely multi-target mechanism of Cyclosporin A in the treatment of vitiligo.	Cyclosporine	130-143	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	41-46
34089287-9	2021	CONCLUSIONS: In our study, Cyclosporin A might not only affect the repair of DNA strands by targeting PRKDC, but also affected the innate and adaptive immune function of vitiligo patients by the targets of CUL1, CUL7 and HSP70.	Cyclosporine	27-40	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	102-107
35629245-6	2022	SNPs in CYP3A5*3 were significantly associated with greater dose-adjusted cyclosporine and tacrolimus concentrations.	Cyclosporine	74-86	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	8-14
35629245-7	2022	SNPs in POR*28 were observed with significantly lower dose-adjusted concentrations, particularly with cyclosporine and tacrolimus.	Cyclosporine	102-114	cytochrome p450 oxidoreductase	Homo sapiens	8-11
35629245-8	2022	ABCB1 homozygous polymorphisms were observed with significantly lower time spent in the therapeutic range with cyclosporine and everolimus/sirolimus.	Cyclosporine	111-123	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
35553638-10	2022	Cyclosporine A and prednisolone synergistically increased GCR expression and inhibited pro-inflammatory cytokine production by CD28null CD8- T and NKT-like cells.	Cyclosporine	0-14	nuclear receptor subfamily 3 group C member 1	Homo sapiens	58-61
34033431-3	2021	A pediatric case treated with cyclosporine and corticosteroids elevated C-reactive protein, and abnormal liver tests.	Cyclosporine	30-42	C-reactive protein	Homo sapiens	72-90
35272142-2	2022	Here, we show that CsA alone stimulates ICAM-1 overexpression in human pulmonary microvascular endothelial cells (HPMECs) through Toll-Like Receptor 4 (TLR4) and NF-kappaB activation.	Cyclosporine	19-22	nuclear factor kappa B subunit 1	Homo sapiens	162-171
35272142-5	2022	In addition, CsA triggered apoptosis as well as rearrangement of the actin cytoskeleton and adherens junctions (VE-Cadherin) in microvascular endothelial monolayers.	Cyclosporine	13-16	cadherin 5	Homo sapiens	112-123
35498740-7	2022	By 14 days post-transplantation, the CsA 25 and 50 mg/kg/day treatment groups had less (P < 0.05) CD3 and PAX5 positive areas in their allotransplants, compared to the unsuppressed group.	Cyclosporine	37-40	paired box protein Pax-5	Meleagris gallopavo	106-110
35498740-8	2022	At 35 days post-transplantation, the CsA 25 mg/kg/day allotransplant group also had less (P < 0.05) CD3 and PAX5 positive areas compared to the unsuppressed group.	Cyclosporine	37-40	paired box protein Pax-5	Meleagris gallopavo	108-112
35418571-3	2022	In this study, we show that the lipophilic cyclic peptide, cyclosporin A (CsA), interacted with, and likely induced aggregation, of polymeric, gel-forming mucins (MUC2, MUC5AC and MUC5B) which underpin the mucus gel-networks in the gastrointestinal tract.	Cyclosporine	74-77	mucin 2, oligomeric mucus/gel-forming	Homo sapiens	163-167
35418571-5	2022	Using rate-zonal centrifugation, purified MUC2, MUC5AC and MUC5B mucins sedimented faster in the presence of CsA, with a significant increase in mucins in the pellet fraction.	Cyclosporine	109-112	mucin 2, oligomeric mucus/gel-forming	Homo sapiens	42-46
35073210-0	2022	Role of (Pro)Renin Receptor in Cyclosporin A-Induced Nephropathy.	Cyclosporine	31-44	ATPase H+ transporting accessory protein 2	Rattus norvegicus	13-27
35383148-7	2022	Antioxidant N-acetylcysteine (NAC) or Cyclosporine A (mPTP inhibitor) blocked the mPTP opening, which significantly attenuated mitochondrial dysfunction and apoptosis induced by glucose oxidative stress.	Cyclosporine	38-52	protein tyrosine phosphatase, receptor type, U	Mus musculus	54-58
35383148-7	2022	Antioxidant N-acetylcysteine (NAC) or Cyclosporine A (mPTP inhibitor) blocked the mPTP opening, which significantly attenuated mitochondrial dysfunction and apoptosis induced by glucose oxidative stress.	Cyclosporine	38-52	protein tyrosine phosphatase, receptor type, U	Mus musculus	82-86
35073210-7	2022	Exposure of cultured human renal proximal tubular HK-2 cells to CsA induced expression of fibronectin and sPRR production, but the fibrotic response was attenuated by PRO20 and siRNA-mediated PRR knockdown.	Cyclosporine	64-67	fibronectin 1	Homo sapiens	90-101
35092471-8	2022	Moreover, we found that ferulic acid remarkably prevented cyclosporine-mediated nephrotoxicity by restoring the anti-oxidant system through activating the Nrf2/HO-1 axis.	Cyclosporine	58-70	NFE2 like bZIP transcription factor 2	Rattus norvegicus	155-159
35183993-8	2022	In aGVHD mice, C0127 enhanced the preventive effects of CSA including decreasing mortality, maintaining weight, reducing GVHD score and reducing the expression of IL-6 and TNF-alpha in serum.	Cyclosporine	56-59	interleukin 6	Mus musculus	163-167
35183993-8	2022	In aGVHD mice, C0127 enhanced the preventive effects of CSA including decreasing mortality, maintaining weight, reducing GVHD score and reducing the expression of IL-6 and TNF-alpha in serum.	Cyclosporine	56-59	tumor necrosis factor	Mus musculus	172-181
35074592-8	2022	The tissue levels of tumor necrosis factor-alpha, interleukin-1beta, and NFKB were also significantly higher with CsA treatment.	Cyclosporine	114-117	tumor necrosis factor	Mus musculus	21-48
35287416-12	2022	There was significant reduction in the number of episodes and cholinergic itch severity (mean NRS=7.8 to 0.3 at the end of second week after initiating cyclosporine therapy).	Cyclosporine	152-164	itchy E3 ubiquitin protein ligase	Homo sapiens	74-78
35287416-16	2022	Conclusion: Oral cyclosporine effectively controlled cholinergic itch in all included patients.	Cyclosporine	17-29	itchy E3 ubiquitin protein ligase	Homo sapiens	65-69
35293377-6	2022	Complete resolution of PG in TNF-alpha-associated cases occurred within an average of 2.2 months after switching to another TNF-alpha inhibitor (n = 1), an interleukin 12/23 inhibitor (n = 2), or treatment with systemic corticosteroids and cyclosporine (n = 3), systemic corticosteroids alone (n = 1), or cyclosporine alone (n = 1).	Cyclosporine	240-252	tumor necrosis factor	Homo sapiens	29-38
35293377-6	2022	Complete resolution of PG in TNF-alpha-associated cases occurred within an average of 2.2 months after switching to another TNF-alpha inhibitor (n = 1), an interleukin 12/23 inhibitor (n = 2), or treatment with systemic corticosteroids and cyclosporine (n = 3), systemic corticosteroids alone (n = 1), or cyclosporine alone (n = 1).	Cyclosporine	305-317	tumor necrosis factor	Homo sapiens	29-38
35244046-3	2022	We aimed to evaluate the efficacy of EPO on CSA-AKI and RBC transfusion according to the timing of administration.	Cyclosporine	44-47	erythropoietin	Homo sapiens	37-40
35074592-8	2022	The tissue levels of tumor necrosis factor-alpha, interleukin-1beta, and NFKB were also significantly higher with CsA treatment.	Cyclosporine	114-117	interleukin 1 beta	Mus musculus	50-67
35269813-0	2022	Prodrug-Based Targeting Approach for Inflammatory Bowel Diseases Therapy: Mechanistic Study of Phospholipid-Linker-Cyclosporine PLA2-Mediated Activation.	Cyclosporine	115-127	phospholipase A2 group IB	Homo sapiens	128-132
35033536-8	2022	Evaluation of pro-apoptotic (cleaved caspase-3 and Bax) and anti-apoptotic markers (BCL-2) suggested an enhanced apoptotic rate in CsA- compared to Tac-treated cells as well.	Cyclosporine	131-134	caspase 3	Homo sapiens	37-46
35033536-8	2022	Evaluation of pro-apoptotic (cleaved caspase-3 and Bax) and anti-apoptotic markers (BCL-2) suggested an enhanced apoptotic rate in CsA- compared to Tac-treated cells as well.	Cyclosporine	131-134	BCL2 associated X, apoptosis regulator	Homo sapiens	51-54
35033536-8	2022	Evaluation of pro-apoptotic (cleaved caspase-3 and Bax) and anti-apoptotic markers (BCL-2) suggested an enhanced apoptotic rate in CsA- compared to Tac-treated cells as well.	Cyclosporine	131-134	BCL2 apoptosis regulator	Homo sapiens	84-89
35269813-4	2022	Previously, we synthesized a series of a phospholipid-linker-cyclosporine (PLC) prodrugs designed to exploit the overexpression of phospholipase A2 (PLA2) in the inflamed intestinal tissues, as the prodrug-activating enzyme.	Cyclosporine	60-73	phospholipase A2 group IB	Homo sapiens	131-147
35269813-4	2022	Previously, we synthesized a series of a phospholipid-linker-cyclosporine (PLC) prodrugs designed to exploit the overexpression of phospholipase A2 (PLA2) in the inflamed intestinal tissues, as the prodrug-activating enzyme.	Cyclosporine	60-73	phospholipase A2 group IB	Homo sapiens	149-153
35269813-9	2022	This optimized length efficiently allows cyclosporine to be released from the prodrug to the active pocket of PLA2.	Cyclosporine	41-53	phospholipase A2 group IB	Homo sapiens	110-114
35202484-2	2022	Genetic variation within the CYP3A5 gene locus impacts the metabolism of several clinically important drugs, including the immunosuppressants tacrolimus, sirolimus, cyclosporine, and the benzodiazepine midazolam.	Cyclosporine	165-177	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	29-35
35484739-9	2022	Our present study demonstrated that the nucleartargeted nanoparticles could regulate the growth of bEnd.3 cells in CSA and promote autophagy of cells through blockage of the PI3K/Akt/mTOR signaling pathway.	Cyclosporine	115-118	thymoma viral proto-oncogene 1	Mus musculus	179-182
2479429-9	1989	Normalization of production of IFN-gamma and TNF-alpha accompanying a clinical response to cyclosporin-A may cautiously be taken as further evidence suggesting a pathogenetic role of cytokine overproduction in SAA.	Cyclosporine	91-104	interferon gamma	Homo sapiens	31-40
35089188-8	2022	Finally, the ROS level, cell proliferation, and apoptosis were measured again in both active HUVECs and HUVECs, in which the p38 proteins were inhibited.The combination of CyA and PROP reversed the effect of CyA on cell viability, reduced the ROS level and the cell apoptosis induced by PROP.	Cyclosporine	172-175	mitogen-activated protein kinase 14	Homo sapiens	125-128
34994326-0	2022	Cyclosporine Ameliorates Silica-Induced Autoimmune Hepatitis in Rat Model by Altering the Expression of Toll-Like Receptor-4, Interleukin-2 and Tumor Necrosis Factor-alpha.	Cyclosporine	0-12	toll-like receptor 4	Rattus norvegicus	104-124
34994326-0	2022	Cyclosporine Ameliorates Silica-Induced Autoimmune Hepatitis in Rat Model by Altering the Expression of Toll-Like Receptor-4, Interleukin-2 and Tumor Necrosis Factor-alpha.	Cyclosporine	0-12	tumor necrosis factor	Rattus norvegicus	144-171
34994326-9	2022	The relative quantity of TLR-4 mRNA was 1+-0, 13.57+-1.91, 4+-0.38, and 2+-0 in the control, AIH, cyclosporine, and prevention groups, respectively (p<0.001).	Cyclosporine	98-110	toll-like receptor 4	Rattus norvegicus	25-30
34994326-11	2022	Additionally, immuno-histochemical staining for TNF-alpha in liver sections was increased in the silica-AIH group but it was decreased in the cyclosporine-treated and prevention groups.	Cyclosporine	142-154	tumor necrosis factor	Rattus norvegicus	48-57
35221867-14	2022	The CSA in this regard proved to be a convenient and reproducible technique to detect and phenotypically characterise IFNy-secreting cells.	Cyclosporine	4-7	interferon gamma	Homo sapiens	118-122
2595372-2	1989	Cyclosporin A was found to specifically inhibit the appearance of DNA binding activity of NF-AT, AP-3, and to a lesser extent NF-kappa B, nuclear proteins that appear to be important in the transcriptional activation of the genes for interleukin-2 and its receptor, as well as several other lymphokines.	Cyclosporine	0-13	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	126-136
2479429-9	1989	Normalization of production of IFN-gamma and TNF-alpha accompanying a clinical response to cyclosporin-A may cautiously be taken as further evidence suggesting a pathogenetic role of cytokine overproduction in SAA.	Cyclosporine	91-104	tumor necrosis factor	Homo sapiens	45-54
2575078-0	1989	Cyclosporin A prevents the in vivo development of murine prothymocytes from uncommitted (Thy-1-) precursor cells.	Cyclosporine	0-13	thymus cell antigen 1, theta	Mus musculus	89-94
2575078-4	1989	However, if the marrow is depleted of either Thy-1+ or Lyt-1+ cells, thymic regeneration is severely inhibited by CsA.	Cyclosporine	114-117	thymus cell antigen 1, theta	Mus musculus	45-50
2584937-11	1989	The induction of all three mRNAs by either IL-2 or PMA/mitogen was partially blocked by the immunosuppressive drug cyclosporin A (CsA), but not by the biologically inactive analogue cyclosporin H.	Cyclosporine	115-128	interleukin 2	Homo sapiens	43-47
2584937-11	1989	The induction of all three mRNAs by either IL-2 or PMA/mitogen was partially blocked by the immunosuppressive drug cyclosporin A (CsA), but not by the biologically inactive analogue cyclosporin H.	Cyclosporine	130-133	interleukin 2	Homo sapiens	43-47
2809194-4	1989	Addition of CsA to organ culture resulted in a decreased cell yield and complete inhibition of the appearance of TCR-alpha beta-bearing, single positive thymocytes (both CD4+CD8- and CD4-CD8+).	Cyclosporine	12-15	CD4 molecule	Homo sapiens	170-173
2809194-4	1989	Addition of CsA to organ culture resulted in a decreased cell yield and complete inhibition of the appearance of TCR-alpha beta-bearing, single positive thymocytes (both CD4+CD8- and CD4-CD8+).	Cyclosporine	12-15	CD4 molecule	Homo sapiens	183-186
2809194-5	1989	Furthermore, the generation of CD4+CD8+ thymocytes was markedly inhibited by CsA treatment, whereas the development of CD3-, CD4-CD8+ thymocytes and TCR-gamma delta-bearing, CD4-CD8- thymocytes was not affected.	Cyclosporine	77-80	CD4 molecule	Homo sapiens	31-34
2573271-5	1989	Synergy between anti-CD4 monoclonal antibodies and other immunosuppressives, including anti-CD8 antibodies and cyclosporine, has also been demonstrated.	Cyclosporine	111-123	CD4 molecule	Homo sapiens	21-24
2688634-0	1989	Purification and characterization of an anticonvulsant-induced human cytochrome P-450 catalysing cyclosporin metabolism.	Cyclosporine	97-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
12412743-0	1989	Influence of systemic cyclosporin A on interleukin-2 and epidermal growth factor receptor expression in psoriatic skin lesions.	Cyclosporine	22-35	interleukin 2	Homo sapiens	39-52
2574207-13	1989	In addition, treatment of donor animals with cyclosporin, which inhibits the development of CD4+ cells, abrogated suppression.	Cyclosporine	45-56	CD4 molecule	Homo sapiens	92-95
12412743-0	1989	Influence of systemic cyclosporin A on interleukin-2 and epidermal growth factor receptor expression in psoriatic skin lesions.	Cyclosporine	22-35	epidermal growth factor receptor	Homo sapiens	57-89
2802644-0	1989	Cyclosporine inhibits basic fibroblast growth factor-driven proliferation of human endothelial cells and keratinocytes.	Cyclosporine	0-12	fibroblast growth factor 2	Homo sapiens	22-52
2802644-5	1989	Since b-FGF may be both a positive autocrine and paracrine signal involved in the proliferation of both keratinocytes and endothelial cells, we evaluated the effects of cyclosporine on the b-FGF-driven proliferation of these cell types in vitro.	Cyclosporine	169-181	fibroblast growth factor 2	Homo sapiens	189-194
2802644-6	1989	We have shown that normal human keratinocyte and endothelial cell proliferation driven by b-FGF alone can be inhibited by cyclosporine A.	Cyclosporine	122-136	fibroblast growth factor 2	Homo sapiens	90-95
2802644-7	1989	Concentrations of cyclosporine A achievable in skin after oral administration can significantly inhibit the b-FGF-driven proliferation of both of these cell types.	Cyclosporine	18-32	fibroblast growth factor 2	Homo sapiens	108-113
2802644-9	1989	The efficacy of cyclosporine A in treating these disease states may be due, at least in part, to the ability of cyclosporine A to interrupt b-FGF-mediated autocrine and paracrine feedback loops acting on and between endothelial cells and keratinocytes.	Cyclosporine	16-30	fibroblast growth factor 2	Homo sapiens	140-145
2802644-9	1989	The efficacy of cyclosporine A in treating these disease states may be due, at least in part, to the ability of cyclosporine A to interrupt b-FGF-mediated autocrine and paracrine feedback loops acting on and between endothelial cells and keratinocytes.	Cyclosporine	112-126	fibroblast growth factor 2	Homo sapiens	140-145
2478451-5	1989	In the majority of patients with PAN or CSA, there was a marked increase in serum IFN-alpha and IL-2 levels, while TNF-alpha and IL-beta levels were moderately elevated.	Cyclosporine	40-43	interferon alpha 1	Homo sapiens	82-91
2509009-3	1989	CsA as well as another potent immunosuppressive analog, CsG, inhibited parathyroid hormone (PTH) and interleukin-1 (IL-1)-stimulated resorption of fetal rat limb bones.	Cyclosporine	0-3	parathyroid hormone	Rattus norvegicus	71-90
2478451-5	1989	In the majority of patients with PAN or CSA, there was a marked increase in serum IFN-alpha and IL-2 levels, while TNF-alpha and IL-beta levels were moderately elevated.	Cyclosporine	40-43	interleukin 2	Homo sapiens	96-100
2478451-5	1989	In the majority of patients with PAN or CSA, there was a marked increase in serum IFN-alpha and IL-2 levels, while TNF-alpha and IL-beta levels were moderately elevated.	Cyclosporine	40-43	tumor necrosis factor	Homo sapiens	115-124
2678372-3	1989	The author summarizes recent experimental data showing that cyclosporin inhibits both the production of interleukin 2 and the formation of its membrane receptor.	Cyclosporine	60-71	interleukin 2	Homo sapiens	104-117
2789672-2	1989	Renal disease, symptoms of hyper IgE syndrome and level of serum IgE were improved by a long-term cyclosporine treatment (3/5 mg/kg/day) with a follow-up of 4 years.	Cyclosporine	98-110	immunoglobulin heavy constant epsilon	Homo sapiens	33-36
2547584-6	1989	The hypothesis is advanced that CSA exerts a dual effect on rat adrenal cortex: 1) a general inhibitory effect on the growth and steroidogenic capacity of adrenocortical cells, which manifests itself only after very prolonged treatment and may be caused by an impairment of protein synthesis; and 2) an acute effect involving the specific blockade of the angiotensin-II-induced stimulation of the secretory activity of ZG cells.	Cyclosporine	32-35	angiotensinogen	Rattus norvegicus	355-369
2570112-8	1989	Optimal doses of CsA inhibited TPA-induced ODC activity, TGase activity, arachidonic acid release, and interleukin-1 beta (IL-1 beta) mRNA to the same degree (approximately 80%), despite measurement at widely different times (30 min-12 h) required to obtain maximal induction by TPA.	Cyclosporine	17-20	interleukin 1 beta	Mus musculus	103-121
2570112-8	1989	Optimal doses of CsA inhibited TPA-induced ODC activity, TGase activity, arachidonic acid release, and interleukin-1 beta (IL-1 beta) mRNA to the same degree (approximately 80%), despite measurement at widely different times (30 min-12 h) required to obtain maximal induction by TPA.	Cyclosporine	17-20	interleukin 1 beta	Mus musculus	123-132
2593493-1	1989	DST and cyclosporine are two immunosuppressive strategies to improve first year graft survival in high MLC, one-haplotype matched, living-related donor kidney transplantation.	Cyclosporine	8-20	modulator of VRAC current 1	Homo sapiens	103-106
2668410-7	1989	Addition of 10 micrograms/ml cyclosporine A to the medium abolishes the effect of 2-ME and of all of the cytokines except IL-2 and IL-6.	Cyclosporine	29-43	interleukin 6	Mus musculus	131-135
2501389-10	1989	Cyclosporin A, which does not prevent PKC-induced CD69 expression, completely suppressed CD69-induced IL-2 and IFN-gamma gene expression.	Cyclosporine	0-13	interleukin 2	Homo sapiens	102-106
2501389-10	1989	Cyclosporin A, which does not prevent PKC-induced CD69 expression, completely suppressed CD69-induced IL-2 and IFN-gamma gene expression.	Cyclosporine	0-13	interferon gamma	Homo sapiens	111-120
2526685-5	1989	However, a major role for interleukin-2 (IL-2) in AKC was shown by the inhibition of AKC when anti-IL-2 antibody or cyclosporin was added to the induction cultures.	Cyclosporine	116-127	interleukin 2	Homo sapiens	26-39
2526685-5	1989	However, a major role for interleukin-2 (IL-2) in AKC was shown by the inhibition of AKC when anti-IL-2 antibody or cyclosporin was added to the induction cultures.	Cyclosporine	116-127	interleukin 2	Homo sapiens	41-45
2670519-14	1989	More recently, cyclosporin A, with its selective action on interleukin-2 release and/or synthesis, and inhibition of helper T cell function, has been shown to be helpful in Crohn"s disease.	Cyclosporine	15-28	interleukin 2	Homo sapiens	59-72
2682268-3	1989	The venoconstrictor response to bradykinin was attenuated after oral administration of both the thiazide-like diuretic clopamide (0.5 mg/kg) or cyclosporine-A (30 mg/kg), and by concomitant local infusion of cyclosporine-A (1-10 micrograms/min).	Cyclosporine	144-158	kininogen 1	Canis lupus familiaris	32-42
2682268-3	1989	The venoconstrictor response to bradykinin was attenuated after oral administration of both the thiazide-like diuretic clopamide (0.5 mg/kg) or cyclosporine-A (30 mg/kg), and by concomitant local infusion of cyclosporine-A (1-10 micrograms/min).	Cyclosporine	208-222	kininogen 1	Canis lupus familiaris	32-42
2682268-5	1989	infusion of the renin inhibitor H-77 (0.1 mg/kg/h) reversed the inhibition of bradykinin by both clopamide and cyclosporine-A.	Cyclosporine	111-125	kininogen 1	Canis lupus familiaris	78-88
2669194-7	1989	In experiment 1 cyclosporine did not alter IVGTTs; however, during sustained hyperglycemia, cyclosporine caused a 37% decrease in net glucose disposal (p less than 0.001) and a 39% decrease in plateau plasma insulin levels (p less than 0.05).	Cyclosporine	92-104	insulin	Homo sapiens	208-215
2669194-9	1989	Plateau insulin values in euglycemic clamp studies were lowered by 27% (p less than 0.05) after cyclosporine treatment.	Cyclosporine	96-108	insulin	Homo sapiens	8-15
2669194-12	1989	These experiments suggest that cyclosporine treatment results in impairment of sustained synthesis and secretion of insulin, increased insulin clearance, and unaltered insulin sensitivity.	Cyclosporine	31-43	insulin	Homo sapiens	116-123
2669194-12	1989	These experiments suggest that cyclosporine treatment results in impairment of sustained synthesis and secretion of insulin, increased insulin clearance, and unaltered insulin sensitivity.	Cyclosporine	31-43	insulin	Homo sapiens	135-142
2664510-1	1989	We measured serum erythropoietin levels serially in 31 renal-transplant recipients treated with cyclosporine, using the recently developed recombinant human erythropoietin-based radioimmunoassay.	Cyclosporine	96-108	erythropoietin	Homo sapiens	18-32
2502200-10	1989	Following treatment with anti-TNF antibodies, CSA was again detectable in the same supernatants.	Cyclosporine	46-49	tumor necrosis factor	Homo sapiens	30-33
2659163-2	1989	Our observations suggest that TNF-alpha interacts with IL-2 and with another factor(s) which is induced in the course of activation by concanavalin A, since the immunosuppressant drug cyclosporin A-, which inhibits thymocyte activation, prevents the effect of TNF-alpha on thymocytes activated with concanavalin A, whereas anti-Tac, which prevents the binding of IL-2 to its receptor without affecting the production of IL-2 or the expression of IL-2-specific mRNA, inhibits proliferation only partially.	Cyclosporine	184-197	tumor necrosis factor	Homo sapiens	30-39
2659163-2	1989	Our observations suggest that TNF-alpha interacts with IL-2 and with another factor(s) which is induced in the course of activation by concanavalin A, since the immunosuppressant drug cyclosporin A-, which inhibits thymocyte activation, prevents the effect of TNF-alpha on thymocytes activated with concanavalin A, whereas anti-Tac, which prevents the binding of IL-2 to its receptor without affecting the production of IL-2 or the expression of IL-2-specific mRNA, inhibits proliferation only partially.	Cyclosporine	184-197	interleukin 2	Homo sapiens	55-59
2659163-2	1989	Our observations suggest that TNF-alpha interacts with IL-2 and with another factor(s) which is induced in the course of activation by concanavalin A, since the immunosuppressant drug cyclosporin A-, which inhibits thymocyte activation, prevents the effect of TNF-alpha on thymocytes activated with concanavalin A, whereas anti-Tac, which prevents the binding of IL-2 to its receptor without affecting the production of IL-2 or the expression of IL-2-specific mRNA, inhibits proliferation only partially.	Cyclosporine	184-197	tumor necrosis factor	Homo sapiens	260-269
2659163-2	1989	Our observations suggest that TNF-alpha interacts with IL-2 and with another factor(s) which is induced in the course of activation by concanavalin A, since the immunosuppressant drug cyclosporin A-, which inhibits thymocyte activation, prevents the effect of TNF-alpha on thymocytes activated with concanavalin A, whereas anti-Tac, which prevents the binding of IL-2 to its receptor without affecting the production of IL-2 or the expression of IL-2-specific mRNA, inhibits proliferation only partially.	Cyclosporine	184-197	interleukin 2	Homo sapiens	363-367
2659163-2	1989	Our observations suggest that TNF-alpha interacts with IL-2 and with another factor(s) which is induced in the course of activation by concanavalin A, since the immunosuppressant drug cyclosporin A-, which inhibits thymocyte activation, prevents the effect of TNF-alpha on thymocytes activated with concanavalin A, whereas anti-Tac, which prevents the binding of IL-2 to its receptor without affecting the production of IL-2 or the expression of IL-2-specific mRNA, inhibits proliferation only partially.	Cyclosporine	184-197	interleukin 2	Homo sapiens	363-367
2659163-2	1989	Our observations suggest that TNF-alpha interacts with IL-2 and with another factor(s) which is induced in the course of activation by concanavalin A, since the immunosuppressant drug cyclosporin A-, which inhibits thymocyte activation, prevents the effect of TNF-alpha on thymocytes activated with concanavalin A, whereas anti-Tac, which prevents the binding of IL-2 to its receptor without affecting the production of IL-2 or the expression of IL-2-specific mRNA, inhibits proliferation only partially.	Cyclosporine	184-197	interleukin 2	Homo sapiens	363-367
2659163-5	1989	In addition, we show that activated human thymocytes express the TNF-alpha gene and that the expression of this gene is inhibited by cyclosporin A and dexamethasone.	Cyclosporine	133-146	tumor necrosis factor	Homo sapiens	65-74
2572668-4	1989	With several cloned CD4+ T cell lines, including an IL-4-producing clone that could not induce IgE synthesis, and cloned T cells pretreated with cyclosporin A to inhibit lymphokine synthesis, we showed that Th cell-B cell interactions are necessary for IgE synthesis, and that low molecular weight B cell growth factor (LMW-BCGF) and IL-4, in combination, are lymphokines of major importance in the induction of IgE synthesis.	Cyclosporine	145-158	interleukin 4	Homo sapiens	334-338
2682943-3	1989	Rifampin and perhaps nafcillin induce cytochrome P-450-dependent isoenzyme metabolism of cyclosporine.	Cyclosporine	89-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
2472451-2	1989	The activity of FK506, when compared to Cyclosporin A, another immunosuppressant, was 10 to 100x more potent in its ability to inhibit IL-2 mRNA synthesis.	Cyclosporine	40-53	interleukin 2	Homo sapiens	135-139
2733125-5	1989	Significant increases of 21% in total cholesterol, 31% in low-density lipoprotein cholesterol, and 12% in apolipoprotein B levels occurred only in the cyclosporine group.	Cyclosporine	151-163	apolipoprotein B	Homo sapiens	106-122
2504519-9	1989	CsA treatment with or without DFMO did reduce detectable levels of interleukin 2 (IL-2) activity.	Cyclosporine	0-3	interleukin 2	Homo sapiens	67-80
2504519-9	1989	CsA treatment with or without DFMO did reduce detectable levels of interleukin 2 (IL-2) activity.	Cyclosporine	0-3	interleukin 2	Homo sapiens	82-86
2504519-11	1989	These results indicate that CsA and DFMO may inhibit different processes required for CTL induction, IL-2 production and polyamine biosynthesis.	Cyclosporine	28-31	interleukin 2	Homo sapiens	101-105
2787338-5	1989	After 15 days of cyclosporine treatment, CD4+ cells were significantly fewer in the epidermis and dermis, and Langerhans cells were more regularly distributed in the epidermis.	Cyclosporine	17-29	CD4 molecule	Homo sapiens	41-44
2543699-5	1989	Stimulation of cells by optimal amounts of calcium ionophore and PMA induced IL-2 mRNA that was completely suppressed by cyclosporine.	Cyclosporine	121-133	interleukin 2	Homo sapiens	77-81
2593493-11	1989	Cyclosporine is equally efficacious for recipients of high MLC, one-haplotype matched kidney transplants, and may be preferred for transplants from more distant relatives and unrelated living donors.	Cyclosporine	0-12	modulator of VRAC current 1	Homo sapiens	59-62
2681969-7	1989	Higher incidence of diabetes mellitus requiring insulin therapy in cyclosporin treated transplant recipients has been reported.	Cyclosporine	67-78	insulin	Homo sapiens	48-55
2681969-8	1989	Cyclosporin may cause toxic effects on pancreatic beta-cells resulting in inhibition of insulin secretion.	Cyclosporine	0-11	insulin	Homo sapiens	88-95
2498428-8	1989	polyI:C increased renal class I MHC in nude mice and mice with severe combined immunodeficiency, and in mice treated with cyclosporine or mAb against IFN-gamma.	Cyclosporine	122-134	interferon gamma	Mus musculus	150-159
2498428-10	1989	However, a potent T cell stimulus, allogeneic ascites tumor cells, induced markedly different MHC changes, with massive and sustained increases in class I and II, presumably due to IFN-gamma release, which was inhibited by cyclosporine or by mAb against IFN-gamma.	Cyclosporine	223-235	interferon gamma	Mus musculus	181-190
2788051-5	1989	Ba2+-resistance of PHA responses was due to IL-2-dependent activation and growth of a Ba2+-resistant T cell subset since: (i) limiting dilution analysis demonstrated that this PHA response had a much lower precursor cell frequency than control PHA responses; (ii) proliferation was blocked by anti-IL2 agents, such as cyclosporin A and anti-IL-2 receptor light chain MoAbs, which were much less effective in blocking control PHA responses.	Cyclosporine	318-331	interleukin 2	Homo sapiens	44-48
2732228-12	1989	Clear differences were also detected in their catalytic activities toward the immunosuppressive drug cyclosporine, with two hydroxylated metabolites (M1 and M17) and one demethylated metabolite (M21) formed by hPCN1 but only one metabolite (M1) formed by hPCN3.	Cyclosporine	101-113	potassium voltage-gated channel subfamily A member 5	Homo sapiens	210-215
2735909-3	1989	We explored the mechanism of cyclosporine A (CsA) modulation of complete Freunds adjuvant macrophage (CFA-MO) TNF gene expression.	Cyclosporine	45-48	tumor necrosis factor	Homo sapiens	110-113
2735909-6	1989	Thus, CsA modulates TNF gene expression in a previously undescribed manner.	Cyclosporine	6-9	tumor necrosis factor	Homo sapiens	20-23
2743638-0	1989	Cyclosporine induced alterations in vasopressin signalling in the glomerular mesangial cell.	Cyclosporine	0-12	arginine vasopressin	Homo sapiens	36-47
2550020-3	1989	Stimulation of cells by CD3 MoAb induced only transiently expressed, small amounts of IL-2 mRNA that was completely suppressed by cyclosporine.	Cyclosporine	130-142	interleukin 2	Homo sapiens	86-90
2550020-6	1989	IL-2 gene expression and T-cell proliferation induced by CD3 MoAb plus PMA or calcium ionophore plus PMA were completely suppressible by cyclosporine.	Cyclosporine	137-149	interleukin 2	Homo sapiens	0-4
2550020-12	1989	These studies suggest the existence of two biochemical pathways for the induction of IL-2 production, one that occurs at the transcriptional level and is mediated by intracellular calcium release and protein kinase C and is cyclosporine-sensitive, and one that acts post-transcriptionally, is mediated by CD28 stimulation, and is cyclosporine-resistant.	Cyclosporine	224-236	interleukin 2	Homo sapiens	85-89
2550020-12	1989	These studies suggest the existence of two biochemical pathways for the induction of IL-2 production, one that occurs at the transcriptional level and is mediated by intracellular calcium release and protein kinase C and is cyclosporine-sensitive, and one that acts post-transcriptionally, is mediated by CD28 stimulation, and is cyclosporine-resistant.	Cyclosporine	330-342	interleukin 2	Homo sapiens	85-89
2788358-13	1989	In conclusion, CsA in the OX rat resulted in unexpected enhanced bone remodeling with high BGP levels and severe bone resorption.	Cyclosporine	15-18	bone gamma-carboxyglutamate protein	Rattus norvegicus	91-94
2785572-7	1989	The observation that both Ca2+ depletion and cyclosporine A prevented IL-2 secretion at all time points indicates that the pathways leading to lymphokine secretion and the G1/S block diverge early in the course of the cellular response, and establish the cell cycle block as a distinct activation event with unique characteristics.	Cyclosporine	45-59	interleukin 2	Homo sapiens	70-74
2796968-0	1989	[The inhibition of interleukin 2 (IL-2) receptor gene expression in kidney transplant recipients treated with ciclosporin: preliminary report].	Cyclosporine	110-121	interleukin 2	Homo sapiens	19-32
2660347-0	1989	Effects of cyclosporine on human renal allograft renin and prostaglandin production.	Cyclosporine	11-23	renin	Homo sapiens	49-54
2785025-6	1989	Bone histomorphometry was analyzed on days 14 and 28 in groups A and B and on day 28 in group C. CsA administration resulted in reversible hypomagnesemia and mild transient elevation in circulating 1,25-dihydroxyvitamin D levels with no change in Ca2+, PTH, blood urea nitrogen, or phosphorus.	Cyclosporine	97-100	parathyroid hormone	Rattus norvegicus	253-256
2650519-0	1989	Renin response to sympathetic stimulation in cyclosporin-treated heart-transplant patients.	Cyclosporine	45-56	renin	Homo sapiens	0-5
2655222-7	1989	The clones were also tested for inhibition of IL-2 production mediated by cyclosporine.	Cyclosporine	74-86	interleukin 2	Homo sapiens	46-50
2784875-1	1989	In order to understand the mechanism of immunosuppression by cyclosporine, its effects on macrophage-mediated antigen-specific T cell activation (IL-2 production) were studied in vitro.	Cyclosporine	61-73	interleukin 2	Homo sapiens	146-150
2732228-1	1989	cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine.	Cyclosporine	141-153	potassium voltage-gated channel subfamily A member 5	Homo sapiens	82-87
2465167-4	1989	Similar to IL-1, the double-stranded RNA polyriboinosinic-polyribocytidilic acid (poly[rI].poly[rC]) also stimulated release of CSA by endothelial cells in a dose-dependent manner.	Cyclosporine	128-131	interleukin 1 beta	Homo sapiens	11-15
2495007-0	1989	Differential effects of cyclosporin on hepatic and renal heme, cytochrome P-450 and drug metabolism.	Cyclosporine	24-35	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	63-79
2495007-11	1989	Therefore, the observed decrease in cytochrome P-450 concentration could reflect the direct inactivation of the hemoprotein or regulation of apoprotein production by cyclosporin and/or its metabolite(s).	Cyclosporine	166-177	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	36-52
2565211-3	1989	A cytochrome P-450 involved in the metabolism of cyclosporin A (CsA) was isolated and purified to electrophoretic homogeneity from human liver microsomes of renal transplant donors.	Cyclosporine	49-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	2-18
2565211-3	1989	A cytochrome P-450 involved in the metabolism of cyclosporin A (CsA) was isolated and purified to electrophoretic homogeneity from human liver microsomes of renal transplant donors.	Cyclosporine	64-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	2-18
2526799-6	1989	We further demonstrate that CsA inhibits preferentially IL-2 production and anti-IL2 RAb inhibits T cell proliferation by blocking an absorption of IL-2 by activated lymphocytes.	Cyclosporine	28-31	interleukin 2	Homo sapiens	56-60
2521882-3	1989	Similar to IL-2, both genes require the synergy of agents such as PHA and PMA for optimal expression, and, in addition, the induction of both is sensitive to the immunosuppressive drug cyclosporin A.	Cyclosporine	185-198	interleukin 2	Homo sapiens	11-15
2568442-5	1989	The addition of interleukin-2 (IL-2) increased the proliferative response, as well as resistance to inhibition induced by cyclosporin A and dexamethasone and partially abolished the selective actions of DPPAA and PHA.	Cyclosporine	122-135	interleukin 2	Homo sapiens	16-29
2568442-5	1989	The addition of interleukin-2 (IL-2) increased the proliferative response, as well as resistance to inhibition induced by cyclosporin A and dexamethasone and partially abolished the selective actions of DPPAA and PHA.	Cyclosporine	122-135	interleukin 2	Homo sapiens	31-35
2568442-6	1989	In IL-2 dependent cultures PHA induced stimulation was more sensitive to inhibition by cyclosporin than were the phorbol esters.	Cyclosporine	87-98	interleukin 2	Homo sapiens	3-7
2465167-5	1989	The kinetics of IL-1-induced CSA release as opposed to poly(rI).poly(rC)-induced release were found to be different, in that poly(rI).poly(rC)-induced CSA production occurred more slowly.	Cyclosporine	29-32	interleukin 1 beta	Homo sapiens	16-20
2465167-5	1989	The kinetics of IL-1-induced CSA release as opposed to poly(rI).poly(rC)-induced release were found to be different, in that poly(rI).poly(rC)-induced CSA production occurred more slowly.	Cyclosporine	151-154	interleukin 1 beta	Homo sapiens	16-20
2465167-6	1989	An anti-IL-1 beta antiserum was able to completely neutralize the IL-1-induced CSA release, but had no effect on poly(rI).poly(rC)-dependent CSA production, indicating that the latter effect was mediated by other mechanisms than intermediate production of IL-1 beta.	Cyclosporine	79-82	interleukin 1 beta	Homo sapiens	8-17
2465167-6	1989	An anti-IL-1 beta antiserum was able to completely neutralize the IL-1-induced CSA release, but had no effect on poly(rI).poly(rC)-dependent CSA production, indicating that the latter effect was mediated by other mechanisms than intermediate production of IL-1 beta.	Cyclosporine	79-82	interleukin 1 beta	Homo sapiens	8-12
2522254-6	1989	These preliminary results suggest that ANF may be useful in renal transplantation or in the management of patients given large doses of CsA (liver or heart transplant) since, despite nephrotoxic CsA levels (greater than 1500 ng/ml), ANF provides an improved GFR and tubular function after ischemia.	Cyclosporine	136-139	natriuretic peptide A	Homo sapiens	39-42
2784240-3	1989	Both lymph node and spleen cells from CsA-treated mice showed a significant increase in the percentage of Thy-1.2 negative, L3T4-Lyt-2- cells (perhaps B cells).	Cyclosporine	38-41	thymus cell antigen 1, theta	Mus musculus	106-113
2785816-2	1989	Cyclosporin A was used as a valuable tool to gain more insight into the quantitative aspects of interleukin 2 production, on the basis of the assumption that transcription of the interleukin 2 gene is completely inhibited shortly after administration of cyclosporin A.	Cyclosporine	0-13	interleukin 2	Homo sapiens	96-109
2785816-2	1989	Cyclosporin A was used as a valuable tool to gain more insight into the quantitative aspects of interleukin 2 production, on the basis of the assumption that transcription of the interleukin 2 gene is completely inhibited shortly after administration of cyclosporin A.	Cyclosporine	0-13	interleukin 2	Homo sapiens	179-192
2785816-2	1989	Cyclosporin A was used as a valuable tool to gain more insight into the quantitative aspects of interleukin 2 production, on the basis of the assumption that transcription of the interleukin 2 gene is completely inhibited shortly after administration of cyclosporin A.	Cyclosporine	254-267	interleukin 2	Homo sapiens	179-192
2785816-4	1989	This novel quantitative kinetic analysis revealed that, independent of the absence or presence of cyclosporin A, interleukin 2 protein is synthesized at a rate of approximately 1.3 molecules per molecule of interleukin 2 mRNA per second and secreted within 2 h after it is synthesized and that its half-life in the supernatant is approximately 10 h.	Cyclosporine	98-111	interleukin 2	Homo sapiens	113-126
2784322-4	1989	In the epidermis of the cyclosporin-injected plaques, total and HLA-DR+ CD4+ and CD8+ T cell numbers were significantly decreased compared to corresponding plaques treated with placebo (total CD4+, total CD8+, DR+ CD4+, P less than 0.01; DR+ CD8+, P less than 0.02).	Cyclosporine	24-35	CD4 molecule	Homo sapiens	72-75
2784322-4	1989	In the epidermis of the cyclosporin-injected plaques, total and HLA-DR+ CD4+ and CD8+ T cell numbers were significantly decreased compared to corresponding plaques treated with placebo (total CD4+, total CD8+, DR+ CD4+, P less than 0.01; DR+ CD8+, P less than 0.02).	Cyclosporine	24-35	CD4 molecule	Homo sapiens	192-195
2784322-4	1989	In the epidermis of the cyclosporin-injected plaques, total and HLA-DR+ CD4+ and CD8+ T cell numbers were significantly decreased compared to corresponding plaques treated with placebo (total CD4+, total CD8+, DR+ CD4+, P less than 0.01; DR+ CD8+, P less than 0.02).	Cyclosporine	24-35	CD4 molecule	Homo sapiens	192-195
2784322-5	1989	Similarly, T lymphocyte numbers in the dermis were decreased in the cyclosporin compared to placebo-treated plaques; the reduction in total CD4+ and DR+ CD8+ T cell numbers was statistically significant (P less than 0.05).	Cyclosporine	68-79	CD4 molecule	Homo sapiens	140-143
2650212-0	1989	Modulation of the HLA-A, -B, -DR matching effect by cyclosporin therapy.	Cyclosporine	52-63	major histocompatibility complex, class I, A	Homo sapiens	18-27
2650286-0	1989	A comparison of cyclosporine binding by cyclophilin and calmodulin.	Cyclosporine	16-28	calmodulin 1	Homo sapiens	56-66
2493179-4	1989	Both CsA and CsG showed very similar dose-dependent inhibition of IFN-G and LT/TNF activity (IC50 CsA for IFN-G = 8.0 ng/ml, for LT/TNF = 9.5 ng/ml; IC50 CsG for IFN-G = 13.0 ng/ml, for LT/TNF = 13.0 ng/ml).	Cyclosporine	5-8	interferon gamma	Homo sapiens	66-71
2493179-4	1989	Both CsA and CsG showed very similar dose-dependent inhibition of IFN-G and LT/TNF activity (IC50 CsA for IFN-G = 8.0 ng/ml, for LT/TNF = 9.5 ng/ml; IC50 CsG for IFN-G = 13.0 ng/ml, for LT/TNF = 13.0 ng/ml).	Cyclosporine	5-8	tumor necrosis factor	Homo sapiens	79-82
2493179-4	1989	Both CsA and CsG showed very similar dose-dependent inhibition of IFN-G and LT/TNF activity (IC50 CsA for IFN-G = 8.0 ng/ml, for LT/TNF = 9.5 ng/ml; IC50 CsG for IFN-G = 13.0 ng/ml, for LT/TNF = 13.0 ng/ml).	Cyclosporine	5-8	interferon gamma	Homo sapiens	106-111
2493179-4	1989	Both CsA and CsG showed very similar dose-dependent inhibition of IFN-G and LT/TNF activity (IC50 CsA for IFN-G = 8.0 ng/ml, for LT/TNF = 9.5 ng/ml; IC50 CsG for IFN-G = 13.0 ng/ml, for LT/TNF = 13.0 ng/ml).	Cyclosporine	5-8	tumor necrosis factor	Homo sapiens	132-135
2493179-4	1989	Both CsA and CsG showed very similar dose-dependent inhibition of IFN-G and LT/TNF activity (IC50 CsA for IFN-G = 8.0 ng/ml, for LT/TNF = 9.5 ng/ml; IC50 CsG for IFN-G = 13.0 ng/ml, for LT/TNF = 13.0 ng/ml).	Cyclosporine	5-8	interferon gamma	Homo sapiens	106-111
2783946-11	1989	Furthermore, IL-4 could augment proliferation and IL-2R expression of T cells stimulated with PHA in the presence of cyclosporin A, which blocks endogenous cytokine production or anti-Tac.	Cyclosporine	117-130	interleukin 4	Homo sapiens	13-17
2644144-0	1989	Effect of cyclosporin on interleukin 2-related T-lymphocyte parameters in IDDM patients.	Cyclosporine	10-21	interleukin 2	Homo sapiens	25-38
2522254-6	1989	These preliminary results suggest that ANF may be useful in renal transplantation or in the management of patients given large doses of CsA (liver or heart transplant) since, despite nephrotoxic CsA levels (greater than 1500 ng/ml), ANF provides an improved GFR and tubular function after ischemia.	Cyclosporine	195-198	natriuretic peptide A	Homo sapiens	39-42
2493179-4	1989	Both CsA and CsG showed very similar dose-dependent inhibition of IFN-G and LT/TNF activity (IC50 CsA for IFN-G = 8.0 ng/ml, for LT/TNF = 9.5 ng/ml; IC50 CsG for IFN-G = 13.0 ng/ml, for LT/TNF = 13.0 ng/ml).	Cyclosporine	5-8	tumor necrosis factor	Homo sapiens	132-135
2493179-4	1989	Both CsA and CsG showed very similar dose-dependent inhibition of IFN-G and LT/TNF activity (IC50 CsA for IFN-G = 8.0 ng/ml, for LT/TNF = 9.5 ng/ml; IC50 CsG for IFN-G = 13.0 ng/ml, for LT/TNF = 13.0 ng/ml).	Cyclosporine	98-101	interferon gamma	Homo sapiens	106-111
2645701-14	1989	Patients experiencing CsA toxicity (n = 12) showed mild creatinine elevations, normal or negative IL-2(P) and IL-2R(P) levels, and no IL-2(U).	Cyclosporine	22-25	interleukin 2	Homo sapiens	98-102
2493179-4	1989	Both CsA and CsG showed very similar dose-dependent inhibition of IFN-G and LT/TNF activity (IC50 CsA for IFN-G = 8.0 ng/ml, for LT/TNF = 9.5 ng/ml; IC50 CsG for IFN-G = 13.0 ng/ml, for LT/TNF = 13.0 ng/ml).	Cyclosporine	98-101	interferon gamma	Homo sapiens	106-111
2493179-7	1989	LT/TNF activity was suppressed by CsA and CsG in 2 degrees MLC, which was also dose- and time-dependent.	Cyclosporine	34-37	tumor necrosis factor	Homo sapiens	3-6
2521963-6	1989	Exogenous addition of Interleukin 2 to PHA-treated cells almost completely overcame the inhibitory effect of CsA on both nuclei and cytoplasm.	Cyclosporine	109-112	interleukin 2	Homo sapiens	22-35
2645701-14	1989	Patients experiencing CsA toxicity (n = 12) showed mild creatinine elevations, normal or negative IL-2(P) and IL-2R(P) levels, and no IL-2(U).	Cyclosporine	22-25	interleukin 2	Homo sapiens	110-114
2523586-0	1989	Cyclosporin A and prednisolone: an additive inhibitory effect of cell proliferation and interleukin-2 production.	Cyclosporine	0-13	interleukin 2	Homo sapiens	88-101
2645720-0	1989	Similar effects of cyclosporine and verapamil on lymphokine, interleukin 2 receptor, and proto-oncogene expression.	Cyclosporine	19-31	interleukin 2	Homo sapiens	61-74
2492047-10	1989	In addition we showed that cyclosporine A (CsA) profoundly inhibited IFN-gamma production as well as exocytosis induced by stimulation through the Ag receptor or by PMA + calcium ionophore.	Cyclosporine	27-41	interferon gamma	Mus musculus	69-78
2492047-10	1989	In addition we showed that cyclosporine A (CsA) profoundly inhibited IFN-gamma production as well as exocytosis induced by stimulation through the Ag receptor or by PMA + calcium ionophore.	Cyclosporine	43-46	interferon gamma	Mus musculus	69-78
2521453-5	1989	Thus, in the presence of the vitamin D3 metabolite, only one-hundredth the concentration of CsA was required to produce the same effect on IL-2 production as that produced by CsA alone.	Cyclosporine	92-95	interleukin 2	Homo sapiens	139-143
2623198-8	1989	CSA significantly inhibited AII stimulated PGE2 release in both experiments.	Cyclosporine	0-3	angiotensinogen	Rattus norvegicus	28-31
2623198-11	1989	This study demonstrated that CSA significantly inhibits AII-stimulated prostaglandin release.	Cyclosporine	29-32	angiotensinogen	Rattus norvegicus	56-59
2785298-0	1989	Cyclosporin A mediated immunosuppression in vitro: effect on high affinity interleukin-2 receptor expression and -turnover.	Cyclosporine	0-13	interleukin 2	Homo sapiens	75-88
2785298-1	1989	The effect of in vitro administration of Cyclosporin A (CsA) during mitogen, antigen and alloantigen activation of human T-lymphocytes on high affinity interleukin-2 (IL-2) receptor expression and -turnover and IL-2 production was investigated.	Cyclosporine	41-54	interleukin 2	Homo sapiens	152-165
2785298-1	1989	The effect of in vitro administration of Cyclosporin A (CsA) during mitogen, antigen and alloantigen activation of human T-lymphocytes on high affinity interleukin-2 (IL-2) receptor expression and -turnover and IL-2 production was investigated.	Cyclosporine	41-54	interleukin 2	Homo sapiens	167-171
2785298-1	1989	The effect of in vitro administration of Cyclosporin A (CsA) during mitogen, antigen and alloantigen activation of human T-lymphocytes on high affinity interleukin-2 (IL-2) receptor expression and -turnover and IL-2 production was investigated.	Cyclosporine	56-59	interleukin 2	Homo sapiens	152-165
2785298-1	1989	The effect of in vitro administration of Cyclosporin A (CsA) during mitogen, antigen and alloantigen activation of human T-lymphocytes on high affinity interleukin-2 (IL-2) receptor expression and -turnover and IL-2 production was investigated.	Cyclosporine	56-59	interleukin 2	Homo sapiens	167-171
2785298-2	1989	The presence of CsA reduced 3H-thymidine incorporation and binding of radiolabelled human recombinant (ala125) IL-2 to high-affinity receptors in a dose-dependent fashion, although a pronounced inter- and intra-individual variation in sensitivity to CsA mediated immunosuppression was observed.	Cyclosporine	16-19	interleukin 2	Homo sapiens	111-115
2785298-2	1989	The presence of CsA reduced 3H-thymidine incorporation and binding of radiolabelled human recombinant (ala125) IL-2 to high-affinity receptors in a dose-dependent fashion, although a pronounced inter- and intra-individual variation in sensitivity to CsA mediated immunosuppression was observed.	Cyclosporine	250-253	interleukin 2	Homo sapiens	111-115
2785298-5	1989	Although the number of IL-2 receptors was reduced, the turnover of the remaining high affinity IL-2 receptors on CsA treated cells was unaffected.	Cyclosporine	113-116	interleukin 2	Homo sapiens	95-99
2785298-7	1989	Finally, T cell activation in the presence of CsA reduced radioimmuno detectable IL-2 in cell culture supernatants to about 20%.	Cyclosporine	46-49	interleukin 2	Homo sapiens	81-85
3263432-5	1988	Addition of CsA (1 microgram/ml) to the cells in the initial, competence-inducing 30-min incubation with PDB/ionomycin abrogated their subsequent response to IL-2 or PDB.	Cyclosporine	12-15	interleukin 2	Homo sapiens	158-162
3263432-7	1988	Treatment with CsA during induction of competence prevented the expression of the 55-kDa IL-2R gene during competence induction and inhibited IL-2 gene expression and IL-2 production in response to PDB in the second phase.	Cyclosporine	15-18	interleukin 2	Homo sapiens	89-93
3263432-7	1988	Treatment with CsA during induction of competence prevented the expression of the 55-kDa IL-2R gene during competence induction and inhibited IL-2 gene expression and IL-2 production in response to PDB in the second phase.	Cyclosporine	15-18	interleukin 2	Homo sapiens	142-146
2854218-10	1988	Following oral administration of cyclosporine-A (10 and 30 mg/kg), venous responses to bradykinin were attenuated while those to enalaprilic acid remained unchanged.	Cyclosporine	33-47	kininogen 1	Canis lupus familiaris	87-97
2854218-11	1988	Concomitant local infusion of the angiotensin II receptor antagonist saralasin (1 microgram/min) reversed completely the cyclosporine-A-induced reduction of the venoconstrictor effects of bradykinin.	Cyclosporine	121-135	kininogen 1	Canis lupus familiaris	188-198
2784905-0	1989	Immunosuppressive activities of cyclosporine metabolites M17 and M21 within a bioassay based on inhibition of interleukin-2 production.	Cyclosporine	32-44	interleukin 2	Homo sapiens	110-123
2784911-0	1989	Role of kidney microsomal cytochrome P-450 in cyclosporin induced nephropathy.	Cyclosporine	46-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-42
2576219-7	1989	The data suggest that Ca2(+)-independent (CsA-resistant) T cell activation induces synthesis of GM-CSF and IFN-gamma but is a poor stimulus for IL-3 production.	Cyclosporine	42-45	interferon gamma	Mus musculus	107-116
2613398-3	1989	Lobenzarit, traxanox, mizoribine and cyclosporin A inhibited or tended to inhibit bone resorption stimulated by PTH, LPS, IL-1 beta or TNF-alpha in a dose-dependent manner.	Cyclosporine	37-50	toll-like receptor 4	Mus musculus	117-120
2613398-3	1989	Lobenzarit, traxanox, mizoribine and cyclosporin A inhibited or tended to inhibit bone resorption stimulated by PTH, LPS, IL-1 beta or TNF-alpha in a dose-dependent manner.	Cyclosporine	37-50	interleukin 1 beta	Mus musculus	122-131
2613398-3	1989	Lobenzarit, traxanox, mizoribine and cyclosporin A inhibited or tended to inhibit bone resorption stimulated by PTH, LPS, IL-1 beta or TNF-alpha in a dose-dependent manner.	Cyclosporine	37-50	tumor necrosis factor	Mus musculus	135-144
2649443-10	1989	The data indicate that this CsA-resistant pathway is both IL-2 and IL-4-independent.	Cyclosporine	28-31	interleukin 2	Homo sapiens	58-62
2649443-10	1989	The data indicate that this CsA-resistant pathway is both IL-2 and IL-4-independent.	Cyclosporine	28-31	interleukin 4	Homo sapiens	67-71
3069247-6	1988	Seventeen of 36 patients treated with Cyclosporine A and prednisone had at least 1 acute rejection; only 8 of these patients experienced a significant rise in the CRP (mean increase 27 micrograms/ml) and in only 5 of these did the increase occur prior to or on the day of rejection diagnosis.	Cyclosporine	38-52	C-reactive protein	Homo sapiens	163-166
2521453-8	1989	Exogenous IL-2 reversed a large part of the inhibitory effect induced by both CsA and 1,25(OH)2D3, indicating that the immunosuppressive properties of these agents are mediated by the inhibition of IL-2 secretion.	Cyclosporine	78-81	interleukin 2	Homo sapiens	10-14
2521453-8	1989	Exogenous IL-2 reversed a large part of the inhibitory effect induced by both CsA and 1,25(OH)2D3, indicating that the immunosuppressive properties of these agents are mediated by the inhibition of IL-2 secretion.	Cyclosporine	78-81	interleukin 2	Homo sapiens	198-202
3144073-0	1988	Lymphokine production in cyclosporine-treated renal transplant recipients.	Cyclosporine	25-37	interleukin 2	Homo sapiens	0-10
3264483-3	1988	This was confirmed in vitro: the addition of cyclosporine to T-cells recovered from the lungs of patients with active sarcoid suppressed the spontaneous release of interleukin-2 (IL-2) and monocyte chemotactic factor by these cells and inhibited their exaggerated spontaneous replication.	Cyclosporine	45-57	interleukin 2	Homo sapiens	164-177
3264483-3	1988	This was confirmed in vitro: the addition of cyclosporine to T-cells recovered from the lungs of patients with active sarcoid suppressed the spontaneous release of interleukin-2 (IL-2) and monocyte chemotactic factor by these cells and inhibited their exaggerated spontaneous replication.	Cyclosporine	45-57	interleukin 2	Homo sapiens	179-183
3266904-0	1988	[Action mechanism of cyclosporin A, immunomodulator in the treatment of MRL/lpr lupus mice].	Cyclosporine	21-34	Fas (TNF receptor superfamily member 6)	Mus musculus	76-79
3142484-1	1988	Pretreatment of rat renal mesangial cells with the immunosuppressive drug cyclosporin A caused a dose-dependent increase in the angiotensin II, [Arg8]vasopressin and noradrenalin-stimulated rise in intracellular free calcium as measured with quin 2.	Cyclosporine	74-87	angiotensinogen	Rattus norvegicus	128-142
3142484-5	1988	Cyclosporin A also augmented the angiotensin II, [Arg8]vasopressin and noradrenalin-stimulated efflux of 45Ca2+ from mesangial cells.	Cyclosporine	0-13	angiotensinogen	Rattus norvegicus	33-47
2903210-0	1988	In situ hybridization for interleukin 2 and interleukin 2 receptor mRNA in T cells activated in the presence or absence of cyclosporin A.	Cyclosporine	123-136	interleukin 2	Homo sapiens	44-57
3265333-2	1988	Cyclosporin A (CsA) has been used to suppress this response in patients treated with a radiolabelled antibody to carcinoembryonic antigen (CEA).	Cyclosporine	15-18	CEA cell adhesion molecule 3	Homo sapiens	113-137
3265333-2	1988	Cyclosporin A (CsA) has been used to suppress this response in patients treated with a radiolabelled antibody to carcinoembryonic antigen (CEA).	Cyclosporine	15-18	CEA cell adhesion molecule 3	Homo sapiens	139-142
3069390-2	1988	In the Canadian open study, the rate of clinical remissions (target control of glycemia maintained with less than or equal to 0.15 U.kg-1.day-1 insulin) was unexpectedly high among 81 subjects who had been treated with cyclosporin for at least 3 mo (mean serum trough levels approximately 125 ng/ml by radioimmunoassay).	Cyclosporine	219-230	insulin	Homo sapiens	144-151
3263462-16	1988	SAC-, PMA plus SAC-, and PMA plus anti-mu-stimulated, but not PMA-stimulated, increases in TNF mRNA accumulations in tonsillar B cells were inhibited by CsA.	Cyclosporine	153-156	tumor necrosis factor	Homo sapiens	91-94
2854218-0	1988	Changes in the venous compliance by bradykinin and angiotensin II and its significance for the vascular effects of cyclosporine-A.	Cyclosporine	115-129	kininogen 1	Canis lupus familiaris	36-46
2903210-3	1988	IL-2 transcripts peaked at 8-16 h, and IL-2-R at 24-40 h. Cyclosporin A (CSA) inhibited the synthesis of IL-2, but not IL-2-R mRNA, after stimulation by PHA or anti-CD3.	Cyclosporine	58-71	interleukin 2	Homo sapiens	0-4
2903210-3	1988	IL-2 transcripts peaked at 8-16 h, and IL-2-R at 24-40 h. Cyclosporin A (CSA) inhibited the synthesis of IL-2, but not IL-2-R mRNA, after stimulation by PHA or anti-CD3.	Cyclosporine	58-71	interleukin 2	Homo sapiens	39-43
2903210-3	1988	IL-2 transcripts peaked at 8-16 h, and IL-2-R at 24-40 h. Cyclosporin A (CSA) inhibited the synthesis of IL-2, but not IL-2-R mRNA, after stimulation by PHA or anti-CD3.	Cyclosporine	73-76	interleukin 2	Homo sapiens	39-43
3178833-0	1988	The effect of cyclosporin A on the growth and prolactin binding to Nb-2 rat lymphoma cells.	Cyclosporine	14-27	prolactin	Rattus norvegicus	46-55
3178833-1	1988	Cyclosporin A, an immunosuppressive agent, inhibited the prolactin stimulated growth of rat lymphoma Nb-2 cells.	Cyclosporine	0-13	prolactin	Rattus norvegicus	57-66
3178833-3	1988	The Kd of cyclosporin A binding to the Nb-2 cells was 10(-7) M and was independent of prolactin.	Cyclosporine	10-23	prolactin	Rattus norvegicus	86-95
3178833-4	1988	The Kd of prolactin binding to the Nb-2 cells was 2 x 10(-10) M. Cyclosporin A did not influence the binding of prolactin to the cells and vice versa.	Cyclosporine	65-78	prolactin	Rattus norvegicus	10-19
3063418-9	1988	In vitro addition of Cs (100 ng/ml) inhibited both beta 2m and VPF elevations observed in active INS.	Cyclosporine	21-23	vascular endothelial growth factor A	Homo sapiens	63-66
3140966-1	1988	In a consecutive series of 146 kidney transplant recipients treated with cyclosporin A a strong correlation between matching for the HLA-A, HLA-B, and HLA-DR loci specificities and outcome of the grafts was observed in male recipients with non-O blood groups.	Cyclosporine	73-86	major histocompatibility complex, class I, A	Homo sapiens	133-138
3049805-0	1988	Increased class I and class II MHC products and mRNA in kidneys of MRL-lpr/lpr mice during autoimmune nephritis and inhibition by cyclosporine.	Cyclosporine	130-142	Fas (TNF receptor superfamily member 6)	Mus musculus	71-74
3051564-11	1988	Cyclosporine significantly augmented the level of TPL activity in HUVEC stimulated with rIL-1 alpha, rIL-1 beta, and rTNF alpha and in MNC and M stimulated with rIL-1 alpha, rIL-1 beta, and rIL-2.	Cyclosporine	0-12	interleukin 1 alpha	Rattus norvegicus	88-99
3051564-11	1988	Cyclosporine significantly augmented the level of TPL activity in HUVEC stimulated with rIL-1 alpha, rIL-1 beta, and rTNF alpha and in MNC and M stimulated with rIL-1 alpha, rIL-1 beta, and rIL-2.	Cyclosporine	0-12	interleukin 1 beta	Rattus norvegicus	101-127
3051564-11	1988	Cyclosporine significantly augmented the level of TPL activity in HUVEC stimulated with rIL-1 alpha, rIL-1 beta, and rTNF alpha and in MNC and M stimulated with rIL-1 alpha, rIL-1 beta, and rIL-2.	Cyclosporine	0-12	interleukin 1 alpha	Rattus norvegicus	161-172
3051564-11	1988	Cyclosporine significantly augmented the level of TPL activity in HUVEC stimulated with rIL-1 alpha, rIL-1 beta, and rTNF alpha and in MNC and M stimulated with rIL-1 alpha, rIL-1 beta, and rIL-2.	Cyclosporine	0-12	interleukin 1 beta	Rattus norvegicus	101-111
3049805-0	1988	Increased class I and class II MHC products and mRNA in kidneys of MRL-lpr/lpr mice during autoimmune nephritis and inhibition by cyclosporine.	Cyclosporine	130-142	Fas (TNF receptor superfamily member 6)	Mus musculus	75-78
3141208-6	1988	During follow-up of individual patients, an inverse relationship was observed between the haematological response to CS and the levels of activated T-suppressor/cytotoxic cells, IFN-gamma+ lymphocytes (in PB and BM) and NK-like cells (in BM).	Cyclosporine	117-119	interferon gamma	Homo sapiens	178-187
3135859-1	1988	The effect of cyclosporin A (CsA), a potent immunosuppressive agent, on a human T-cell line, IARC 301, which constitutively secretes interleukin-2 (IL-2) and expresses high-affinity IL-2 receptors, was investigated.	Cyclosporine	29-32	interleukin 2	Homo sapiens	133-146
3042442-4	1988	CsA did not affect the kinetics of GM-CSF release, but inhibited the release of IL3 over a period of 40 h after the cells were stimulated and treated with CsA.	Cyclosporine	0-3	interleukin 3	Mus musculus	80-83
3042442-4	1988	CsA did not affect the kinetics of GM-CSF release, but inhibited the release of IL3 over a period of 40 h after the cells were stimulated and treated with CsA.	Cyclosporine	155-158	interleukin 3	Mus musculus	80-83
3042442-5	1988	In addition, CsA could be added up to 1 h after stimulation of the cells without affecting GM-CSF activity but inhibiting completely the IL3 activity.	Cyclosporine	13-16	interleukin 3	Mus musculus	137-140
3042442-8	1988	The data reveal that CsA can dissociate between the production of IL3 and GM-CSF, suggesting that these two CSFs are regulated by different mechanisms.	Cyclosporine	21-24	interleukin 3	Mus musculus	66-69
3135859-1	1988	The effect of cyclosporin A (CsA), a potent immunosuppressive agent, on a human T-cell line, IARC 301, which constitutively secretes interleukin-2 (IL-2) and expresses high-affinity IL-2 receptors, was investigated.	Cyclosporine	29-32	interleukin 2	Homo sapiens	148-152
3135859-3	1988	CsA also prevents the constitutive secretion of IL-2 in this T-cell line by blocking transcription of the IL-2 gene.	Cyclosporine	0-3	interleukin 2	Homo sapiens	48-52
3135859-3	1988	CsA also prevents the constitutive secretion of IL-2 in this T-cell line by blocking transcription of the IL-2 gene.	Cyclosporine	0-3	interleukin 2	Homo sapiens	106-110
3135859-5	1988	Thus, under such conditions, CsA inhibits IARC 301 growth by preventing its endogenous constitutive IL-2 synthesis.	Cyclosporine	29-32	interleukin 2	Homo sapiens	100-104
3135859-7	1988	We also show for the first time, that CsA not only can inhibit IL-2 production of T cells upon activation, but that it can also prevent ongoing constitutive IL-2 synthesis of a T-cell line.	Cyclosporine	38-41	interleukin 2	Homo sapiens	63-67
3135859-7	1988	We also show for the first time, that CsA not only can inhibit IL-2 production of T cells upon activation, but that it can also prevent ongoing constitutive IL-2 synthesis of a T-cell line.	Cyclosporine	38-41	interleukin 2	Homo sapiens	157-161
3135267-3	1988	The decrease in IFN-gamma production caused an increase in bacterial growth in the spleens and livers of CsA-treated mice.	Cyclosporine	105-108	interferon gamma	Mus musculus	16-25
3292324-1	1988	We report that cyclosporin A (CsA) suppresses the insulin autoantibodies that are present before insulin therapy in the sera of one-third of studied type I (insulin-dependent) diabetic children.	Cyclosporine	30-33	insulin	Homo sapiens	50-57
3292324-1	1988	We report that cyclosporin A (CsA) suppresses the insulin autoantibodies that are present before insulin therapy in the sera of one-third of studied type I (insulin-dependent) diabetic children.	Cyclosporine	30-33	insulin	Homo sapiens	97-104
3292324-1	1988	We report that cyclosporin A (CsA) suppresses the insulin autoantibodies that are present before insulin therapy in the sera of one-third of studied type I (insulin-dependent) diabetic children.	Cyclosporine	30-33	insulin	Homo sapiens	97-104
3292324-2	1988	CsA also reversibly blocks the production of antibodies after exogenous insulin injection, whereas high titers of heterologous insulin antibody are observed in all type I patients not receiving CsA.	Cyclosporine	0-3	insulin	Homo sapiens	72-79
3292324-2	1988	CsA also reversibly blocks the production of antibodies after exogenous insulin injection, whereas high titers of heterologous insulin antibody are observed in all type I patients not receiving CsA.	Cyclosporine	194-197	insulin	Homo sapiens	127-134
3261467-5	1988	Omission of the 6-hr interval between CsA treatment of APC and the addition of T hybridoma resulted in inhibition of interleukin 2 production, although the CsA concentrations required were 10-75-fold higher than the ones inhibiting T cells directly (IC50: 100-150 ng/ml vs. 2-10 ng/ml).	Cyclosporine	38-41	interleukin 2	Homo sapiens	117-130
2455447-4	1988	The incidence of diabetes mellitus (DM) requiring insulin therapy was higher in CsA-treated recipients (18/105, 17.1%) than in Az-treated recipients (23/180, 12.8%; P less than 0.05), although both the daily Pred and cumulative doses of methylprednisolone (MP) at the onset of DM were significantly smaller in the CsA group than in the Az group (26.1 +/- 2.2 mg v 41.4 +/- 3.4 mg, P less than 0.01 and 3,086 +/- 626 mg v 7,133 +/- 1,129 mg, P less than 0.01, respectively).	Cyclosporine	80-83	insulin	Homo sapiens	50-57
2455447-4	1988	The incidence of diabetes mellitus (DM) requiring insulin therapy was higher in CsA-treated recipients (18/105, 17.1%) than in Az-treated recipients (23/180, 12.8%; P less than 0.05), although both the daily Pred and cumulative doses of methylprednisolone (MP) at the onset of DM were significantly smaller in the CsA group than in the Az group (26.1 +/- 2.2 mg v 41.4 +/- 3.4 mg, P less than 0.01 and 3,086 +/- 626 mg v 7,133 +/- 1,129 mg, P less than 0.01, respectively).	Cyclosporine	314-317	insulin	Homo sapiens	50-57
2455447-7	1988	Insulin could be withdrawn within 3 months in six of eight patients who had been converted from CsA to Az.	Cyclosporine	96-99	insulin	Homo sapiens	0-7
3135313-6	1988	1) Decreased IL-2 secretion in vitro of PBL was found to correlate significantly with increased spontaneous IgG secretion of such cells; immunosuppressive treatment of 22 patients with steroids plus cyclosporin A led, to a large extent, to a correction of both abnormalities.	Cyclosporine	199-212	interleukin 2	Homo sapiens	13-17
3041644-10	1988	A sustained euglycemic, insulin-independent state can be established in nonuremic, nonkidney diabetic recipients of pancreas transplants alone, with a beneficial effect on neuropathy, lack of an immediate benefit on advanced retinopathy, and an effect on nephropathy compounded by the influence of CsA on renal function.	Cyclosporine	298-301	insulin	Homo sapiens	24-31
3043799-2	1988	The effects of cyclosporine were examined on gene expression induced in T lymphocytes by mitogenic lectins and interleukin 2 (IL-2).	Cyclosporine	15-27	interleukin 2	Homo sapiens	111-124
3043799-2	1988	The effects of cyclosporine were examined on gene expression induced in T lymphocytes by mitogenic lectins and interleukin 2 (IL-2).	Cyclosporine	15-27	interleukin 2	Homo sapiens	126-130
3136568-12	1988	The results indicate that there is a non T cell pathway for IFN-gamma release (and MHC induction) in vivo that is sensitive to CsA.	Cyclosporine	127-130	interferon gamma	Mus musculus	60-69
3136569-1	1988	The effect of CsA on antigen-induced IL-2 receptor expression was studied on a human T lymphocyte clone (4AS) obtained from cells infiltrating a rejected human kidney.	Cyclosporine	14-17	interleukin 2	Homo sapiens	37-41
3136569-3	1988	Addition of recombinant IL-2 only partially restored 4AS growth inhibition, suggesting that another antigen-induced activation signal such as IL-2-receptor expression could be impaired by CsA.	Cyclosporine	188-191	interleukin 2	Homo sapiens	24-28
3135267-5	1988	The administration of recombinant murine IFN-gamma on day 0 of L. monocytogenes infection prevented CsA-treated mice from developing fatal listeriosis and restored their ability to produce IFN-gamma in the bloodstream, in response to specific antigen in the late phase of infection.	Cyclosporine	100-103	interferon gamma	Mus musculus	41-50
3135267-5	1988	The administration of recombinant murine IFN-gamma on day 0 of L. monocytogenes infection prevented CsA-treated mice from developing fatal listeriosis and restored their ability to produce IFN-gamma in the bloodstream, in response to specific antigen in the late phase of infection.	Cyclosporine	100-103	interferon gamma	Mus musculus	189-198
3290005-0	1988	Inhibition of insulin release in vitro mediated by mononuclear cells from diabetic patients treated with cyclosporin A or placebo.	Cyclosporine	105-118	insulin	Homo sapiens	14-21
3260492-5	1988	Cyclosporin A completely blocked induction of lymphotoxin and partially inhibited induction of TNF and IL-6 mRNA.	Cyclosporine	0-13	tumor necrosis factor	Homo sapiens	95-98
3289771-4	1988	The cyclosporine level taken on the morning of surgery was 166 micrograms.L-1.	Cyclosporine	4-16	immunoglobulin kappa variable 1-16	Homo sapiens	74-77
2455682-3	1988	In order to investigate the effect of cyclosporin A (Cy A) on IFN systems in Behcet"s disease, 2-5AS activities of PBL from 2 patients under Cy A therapy (10 mg/kg/day) were examined.	Cyclosporine	53-57	interferon alpha 1	Homo sapiens	62-65
2455682-5	1988	The effect of Cy A on the production of IFN by PBL in vitro was also examined.	Cyclosporine	14-18	interferon alpha 1	Homo sapiens	40-43
2455682-6	1988	IFN synthesis was markedly suppressed by Cy A in patients and controls.	Cyclosporine	41-45	interferon alpha 1	Homo sapiens	0-3
3130699-5	1988	CsA, 0.1 microgram/ml, inhibited cytotoxic effector function by 11 +/- 12% and proliferation of cells that had been washed to remove lymphokines by 61 +/- 17% but only 17 +/- 8% in the presence of IL-2.	Cyclosporine	0-3	interleukin 2	Homo sapiens	197-201
3130699-9	1988	These results indicate that CsA has a greater inhibitory effect on gamma interferon production by activated lymphocytes in the presence of IL-2 than MPRED or AZA in vitro, which may explain their differential effects on renal tubular cell HLA DR expression in vivo.	Cyclosporine	28-31	interleukin 2	Homo sapiens	139-143
3130699-10	1988	Gamma interferon production was the only activated lymphocyte function tested that was inhibited by CsA in the presence of IL-2.	Cyclosporine	100-103	interleukin 2	Homo sapiens	123-127
3285537-0	1988	Serum C-reactive protein concentrations in cyclosporine-treated renal allograft recipients.	Cyclosporine	43-55	C-reactive protein	Homo sapiens	6-24
3285537-2	1988	To assess whether changes in serum CRP level might assist in differentiating nephrotoxicity from acute rejection in cyclosporine (CsA)-treated renal transplant recipients, we measured changes occurring in serum CRP concentrations in 74 CsA patients in response to transplant operation, acute rejection, cyclosporine nephrotoxicity, and serious infection, and compared these values with changes in AZA patients.	Cyclosporine	236-239	C-reactive protein	Homo sapiens	35-38
3285537-2	1988	To assess whether changes in serum CRP level might assist in differentiating nephrotoxicity from acute rejection in cyclosporine (CsA)-treated renal transplant recipients, we measured changes occurring in serum CRP concentrations in 74 CsA patients in response to transplant operation, acute rejection, cyclosporine nephrotoxicity, and serious infection, and compared these values with changes in AZA patients.	Cyclosporine	236-239	C-reactive protein	Homo sapiens	211-214
3172640-0	1988	Cyclosporine A enhances vasopressin-induced Ca2+ mobilization and contraction in mesangial cells.	Cyclosporine	0-14	arginine vasopressin	Homo sapiens	24-35
3378384-5	1988	The data suggest that this cytochrome P-450 is the major cyclosporine-metabolizing enzyme in human liver.	Cyclosporine	57-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-43
3378384-6	1988	The substrate specificity and the known inducers and inhibitors of this cytochrome P-450 explain several clinically observed drug interactions with cyclosporine.	Cyclosporine	148-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
3260048-4	1988	Administration of CsA did not affect the spontaneous decline in alloantibody titers against class I (RT1A) antigens, but it was associated with a significantly reduced response to class II (RT1B) antigens at the end of the study.	Cyclosporine	18-21	RT1 class II, locus B	Rattus norvegicus	190-194
3291292-0	1988	Renin-aldosterone system and renal function under cyclosporine A.	Cyclosporine	50-64	renin	Homo sapiens	0-5
3291322-0	1988	Interleukin 2 levels and urine cytology distinguish between cyclosporine toxicity and rejection in renal and liver allograft recipients.	Cyclosporine	60-72	interleukin 2	Homo sapiens	0-13
3291335-0	1988	Peripheral insulin resistance and decreased insulin secretion after cyclosporine A treatment.	Cyclosporine	68-82	insulin	Homo sapiens	11-18
2966195-0	1988	Cyclosporine blocks the activation of antigen-dependent cytotoxic T lymphocytes directly by an IL-2-independent mechanism.	Cyclosporine	0-12	interleukin 2	Homo sapiens	95-99
2966195-1	1988	The immunosuppressive drug Cyclosporin A (cyclosporine) inhibits the reactivation of quiescent Ag-dependent CTL in the presence of IL-2.	Cyclosporine	27-40	interleukin 2	Homo sapiens	131-135
2966195-1	1988	The immunosuppressive drug Cyclosporin A (cyclosporine) inhibits the reactivation of quiescent Ag-dependent CTL in the presence of IL-2.	Cyclosporine	42-54	interleukin 2	Homo sapiens	131-135
2966195-5	1988	The generation of primary CTL in mixed cultures was also blocked by cyclosporine in the presence of IL-2, in a time-dependent way that indicated that the sensitive time was early during the cultures.	Cyclosporine	68-80	interleukin 2	Homo sapiens	100-104
3285537-3	1988	Serum CRP concentration rose in response to operation in virtually all patients, regardless of immunosuppressive regimen, from mean baselines of 5.9 +/- 2.7 mcg/ml (AZA) and 6.8 +/- 6.5 mcg/ml (CsA) to mean peak levels of 43.8 +/- 33.4 mcg/ml and 65.1 +/- 39.5 mcg/ml, respectively.	Cyclosporine	194-197	C-reactive protein	Homo sapiens	6-9
3285537-5	1988	In contrast, in 80% of acute rejection episodes of CsA patients, CRP remained undetectable or failed to rise above a stable, minimally elevated baseline.	Cyclosporine	51-54	C-reactive protein	Homo sapiens	65-68
3285537-7	1988	In 14 CSA patients with serious infections (8 pulmonary, 3 intraabdominal, 3 genitourinary), CRP rose by a mean of 67.7 +/- 50.7 mcg/ml.	Cyclosporine	6-9	C-reactive protein	Homo sapiens	93-96
3260492-5	1988	Cyclosporin A completely blocked induction of lymphotoxin and partially inhibited induction of TNF and IL-6 mRNA.	Cyclosporine	0-13	interleukin 6	Homo sapiens	103-107
3165062-0	1988	Effect of cyclosporin A on rat mucosal mast cells and the associated protease RMCPII.	Cyclosporine	10-23	mast cell protease 2	Rattus norvegicus	78-84
3293865-0	1988	Effect of cyclosporine on insulin binding to erythrocytes in type 1 diabetes mellitus of recent onset.	Cyclosporine	10-22	insulin	Homo sapiens	26-33
3293865-1	1988	The effect of cyclosporine (Cyclosporin A) on insulin binding to erythrocytes was investigated in Type 1 diabetes mellitus of recent onset.	Cyclosporine	14-26	insulin	Homo sapiens	46-53
3293865-1	1988	The effect of cyclosporine (Cyclosporin A) on insulin binding to erythrocytes was investigated in Type 1 diabetes mellitus of recent onset.	Cyclosporine	28-41	insulin	Homo sapiens	46-53
3293865-6	1988	Insulin binding at tracer concentration, reflecting the number of insulin receptors, was initially normal but tended to decrease with duration of cyclosporine administration.	Cyclosporine	146-158	insulin	Homo sapiens	0-7
3293865-11	1988	After discontinuation of cyclosporine for one month or more, the mean daily insulin dosage increased and plasma C-peptide decreased.	Cyclosporine	25-37	insulin	Homo sapiens	76-83
3293865-12	1988	Insulin binding at tracer concentration was not affected but the apparent affinity was decreased after withdrawal of cyclosporine.	Cyclosporine	117-129	insulin	Homo sapiens	0-7
3293865-13	1988	These results suggest that insulin action at the receptor may be affected by the administration of cyclosporine.	Cyclosporine	99-111	insulin	Homo sapiens	27-34
3293865-16	1988	Thus immunosuppression with cyclosporine in newly diagnosed Type 1 diabetes mellitus may have a modest adverse effect on insulin receptors; whether the benefits of cyclosporine treatment outweigh this risk is difficult to assess.	Cyclosporine	28-40	insulin	Homo sapiens	121-128
2831399-0	1988	Phorbol diester-inducible, cyclosporine-suppressible transcription from a novel promoter within the mouse mammary tumor virus env gene.	Cyclosporine	27-39	gPr73	Mouse mammary tumor virus	126-129
3125434-10	1988	We conclude that early treatment with cyclosporine in children with recent-onset Type I diabetes can induce remission from insulin dependence, with half the patients not requiring insulin after a full year.	Cyclosporine	38-50	insulin	Homo sapiens	123-130
2966485-0	1988	Cyclosporine A acts as a potent co-stimulator in up-regulation of IgE antibody synthesis and expression of Fc receptor for IgE--a unifying hypothesis of the cellular mechanisms of cyclosporine A.	Cyclosporine	0-14	immunoglobulin heavy constant epsilon	Homo sapiens	66-69
2966485-0	1988	Cyclosporine A acts as a potent co-stimulator in up-regulation of IgE antibody synthesis and expression of Fc receptor for IgE--a unifying hypothesis of the cellular mechanisms of cyclosporine A.	Cyclosporine	0-14	immunoglobulin heavy constant epsilon	Homo sapiens	123-126
2966485-0	1988	Cyclosporine A acts as a potent co-stimulator in up-regulation of IgE antibody synthesis and expression of Fc receptor for IgE--a unifying hypothesis of the cellular mechanisms of cyclosporine A.	Cyclosporine	180-194	immunoglobulin heavy constant epsilon	Homo sapiens	66-69
2966485-0	1988	Cyclosporine A acts as a potent co-stimulator in up-regulation of IgE antibody synthesis and expression of Fc receptor for IgE--a unifying hypothesis of the cellular mechanisms of cyclosporine A.	Cyclosporine	180-194	immunoglobulin heavy constant epsilon	Homo sapiens	123-126
3128291-0	1988	Cyclosporin A inhibits proteolytic cleavage and degradation of membrane-bound protein kinase C in hepatocytes after stimulation by phorbol ester.	Cyclosporine	0-13	proline rich transmembrane protein 2	Homo sapiens	78-94
2896111-0	1988	Cyclosporin A does not inhibit the PHA-stimulated increase in intracellular Ca2+ concentration but inhibits the increase in E-rosette receptor (CD2) expression and appearance of interleukin-2 receptors (CD25).	Cyclosporine	0-13	interleukin 2	Homo sapiens	178-191
3179506-0	1988	Prolactin receptors on large granular lymphocytes: dual regulation by cyclosporin A.	Cyclosporine	70-83	prolactin	Homo sapiens	0-9
3179506-3	1988	The calculated receptor number was 660 per cell and the dissociation constant (Kd) was 3.0 X 10(-10) M. Since previous studies have reported that cyclosporin (CsA), an immunosuppressive agent used in organ transplant patients, affects the binding of PRL to T and B lymphocytes, but not to rabbit mammary gland cells, we investigated whether this compound could alter the binding of the hormone to LGL.	Cyclosporine	146-157	prolactin	Homo sapiens	250-253
3179506-3	1988	The calculated receptor number was 660 per cell and the dissociation constant (Kd) was 3.0 X 10(-10) M. Since previous studies have reported that cyclosporin (CsA), an immunosuppressive agent used in organ transplant patients, affects the binding of PRL to T and B lymphocytes, but not to rabbit mammary gland cells, we investigated whether this compound could alter the binding of the hormone to LGL.	Cyclosporine	159-162	prolactin	Homo sapiens	250-253
3179506-4	1988	At concentrations from 10(-7) to 10(-6), corresponding to the therapeutical range, CsA induced a complete inhibition of the PRL binding.	Cyclosporine	83-86	prolactin	Homo sapiens	124-127
3179506-5	1988	By contrast, concentrations of CsA ranging from 10(-11) to 10(-9) increased the PRL binding to more than 100% of control levels.	Cyclosporine	31-34	prolactin	Homo sapiens	80-83
3179506-7	1988	The finding that CsA can differently affect PRL-receptor expression on LGL points to an involvement of CsA--PRL interactions in determining the output of these immune responses.	Cyclosporine	17-20	prolactin	Homo sapiens	44-47
3179506-7	1988	The finding that CsA can differently affect PRL-receptor expression on LGL points to an involvement of CsA--PRL interactions in determining the output of these immune responses.	Cyclosporine	17-20	prolactin	Homo sapiens	108-111
3179506-7	1988	The finding that CsA can differently affect PRL-receptor expression on LGL points to an involvement of CsA--PRL interactions in determining the output of these immune responses.	Cyclosporine	103-106	prolactin	Homo sapiens	44-47
2967266-5	1988	Cyclosporin A and hydrocortisone allowed the selective activation of Ts in the presence of interleukin-2, while azathioprine inhibition was not reversed by interleukin-2.	Cyclosporine	0-13	interleukin 2	Homo sapiens	91-104
2830333-10	1988	Although IL-4 transcript levels were detectable in the presence of OKT3 alone or OKT3 + PMA, CsA at 0.05 microgram/ml allowed proliferation to occur in the absence of detectable IL-2 as well as IL-2 and IL-4 transcripts.	Cyclosporine	93-96	interleukin 4	Homo sapiens	203-207
3123493-7	1988	The immunosuppressive drug cyclosporin A inhibited IL 2 release without altering induction of IL 2 receptors or phosphorylation of the Mr 70,000 protein.	Cyclosporine	27-40	interleukin 2	Homo sapiens	51-55
3123074-6	1988	This model of lymphocyte activation was used to demonstrate that in vivo cyclosporin A inhibits both IL-2 receptor expression and the induction of spontaneous proliferation.	Cyclosporine	73-86	interleukin 2	Homo sapiens	101-105
3279221-0	1988	Enhanced allograft survival in H-2 compatible cyclosporine-treated mice.	Cyclosporine	46-58	histocompatibility-2, MHC	Mus musculus	31-34
3283402-4	1988	CsA therapy was also associated with significant elevation of renal vascular resistance (RVR), proteinuria, arterial hypertension, and impaired intrarenal conversion of inactive prorenin to active renin.	Cyclosporine	0-3	renin	Homo sapiens	181-186
3065205-4	1988	A significant reduction in insulin requirements was observed in the CsA-treated children, more marked in groups II and III (p less than 0.001 vs. control group).	Cyclosporine	68-71	insulin	Homo sapiens	27-34
3154466-20	1988	It is concluded that of the factors considered, graft number, CIT, transplant center, and, to a lesser extent, PRA influenced patient and graft survival and/or function in CsA-treated patients, while little or no effect was attributable to pretransplant blood transfusions and HLA-A,B matching.	Cyclosporine	172-175	major histocompatibility complex, class I, A	Homo sapiens	277-282
3154474-7	1988	HLA-A,B, and DR matching have independent and essentially equivalent benefits on graft survival in CsA-treated patients, whereas HLA-A,B matching has a greater benefit in non-CsA-treated patients.	Cyclosporine	99-102	major histocompatibility complex, class I, A	Homo sapiens	0-7
3154474-7	1988	HLA-A,B, and DR matching have independent and essentially equivalent benefits on graft survival in CsA-treated patients, whereas HLA-A,B matching has a greater benefit in non-CsA-treated patients.	Cyclosporine	175-178	major histocompatibility complex, class I, A	Homo sapiens	129-136
3154476-4	1988	Matching for HLA-DR, HLA-B + DR and HLA-A + B + DR improved kidney graft survival significantly in non-CsA-treated patients.	Cyclosporine	103-106	major histocompatibility complex, class I, A	Homo sapiens	36-45
3154476-6	1988	Matching for the HLA-A, -B, and -DR loci, apart and in combination, significantly improved kidney graft survival in CsA-treated patients.	Cyclosporine	116-119	major histocompatibility complex, class I, A	Homo sapiens	17-35
3154476-8	1988	The best kidney graft survival was observed in HLA-A + B + DR identical combinations treated with CsA (76% at 5 yrs).	Cyclosporine	98-101	major histocompatibility complex, class I, A	Homo sapiens	47-56
3065205-9	1988	This study demonstrates a dose-related effect of cyclosporin A (CsA) on the insulin requirements of newly diagnosed diabetic children (more frequent and prolonged remissions with the high CsA dosage).	Cyclosporine	49-62	insulin	Homo sapiens	76-83
3065205-9	1988	This study demonstrates a dose-related effect of cyclosporin A (CsA) on the insulin requirements of newly diagnosed diabetic children (more frequent and prolonged remissions with the high CsA dosage).	Cyclosporine	64-67	insulin	Homo sapiens	76-83
3065205-9	1988	This study demonstrates a dose-related effect of cyclosporin A (CsA) on the insulin requirements of newly diagnosed diabetic children (more frequent and prolonged remissions with the high CsA dosage).	Cyclosporine	188-191	insulin	Homo sapiens	76-83
3143680-9	1988	Since CS-A and MTX have been reported to be effective in the treatment of RA, their activity in the LAF, Fn, CRP, albumin and iron assays of the AA rat suggests that these immunological and serological parameters may be useful in identifying potential antirheumatic drugs and distinguishing them from standard NSAIDs.	Cyclosporine	6-10	C-reactive protein	Rattus norvegicus	109-112
3290834-4	1988	In the follow-up of bone marrow grafted patients plasma markers of endothelial function (von Willebrand"s factor, tissue type plasminogen activator, and plasma activity of angiotensin converting enzyme) were significantly altered at the time of overdose with cyclosporin A, probably due to a drug-induced in vivo lesion of the endothelium.	Cyclosporine	259-272	plasminogen activator, tissue type	Homo sapiens	114-201
3322045-3	1987	Influence of in vivo CSA treatment on in vitro angiotensin II (ANG II)-stimulated aldosterone secretion by isolated adrenal glomerulosa cells (AGC) was also measured.	Cyclosporine	21-24	angiotensinogen	Rattus norvegicus	47-61
3050579-4	1988	In animals potential mechanisms for CsA induced renal functional impairment are an increase in urinary thromboxane A2 excretion, plasma renin activity and renal sympathetic nervous system activity and an enhancement of vasopressin stimulated Ca++ mobilisation and cell contraction in vascular smooth muscle cells.	Cyclosporine	36-39	renin	Homo sapiens	136-141
3050579-4	1988	In animals potential mechanisms for CsA induced renal functional impairment are an increase in urinary thromboxane A2 excretion, plasma renin activity and renal sympathetic nervous system activity and an enhancement of vasopressin stimulated Ca++ mobilisation and cell contraction in vascular smooth muscle cells.	Cyclosporine	36-39	arginine vasopressin	Homo sapiens	219-230
3122387-2	1988	Several studies have shown a decrease in interleukin 2 (IL-2) and interferon-Gamma (IFN-G) production of renal Tx recipients on CsA treatment and have suggested that increases in lymphokine production can be correlated with rejection episodes.	Cyclosporine	128-131	interleukin 2	Homo sapiens	41-54
3122387-2	1988	Several studies have shown a decrease in interleukin 2 (IL-2) and interferon-Gamma (IFN-G) production of renal Tx recipients on CsA treatment and have suggested that increases in lymphokine production can be correlated with rejection episodes.	Cyclosporine	128-131	interleukin 2	Homo sapiens	56-60
3122387-2	1988	Several studies have shown a decrease in interleukin 2 (IL-2) and interferon-Gamma (IFN-G) production of renal Tx recipients on CsA treatment and have suggested that increases in lymphokine production can be correlated with rejection episodes.	Cyclosporine	128-131	interferon gamma	Homo sapiens	66-82
3122387-2	1988	Several studies have shown a decrease in interleukin 2 (IL-2) and interferon-Gamma (IFN-G) production of renal Tx recipients on CsA treatment and have suggested that increases in lymphokine production can be correlated with rejection episodes.	Cyclosporine	128-131	interferon gamma	Homo sapiens	84-89
3435490-0	1987	Cyclosporin A augments angiotensin II-stimulated rise in intracellular free calcium in vascular smooth muscle cells.	Cyclosporine	0-13	angiotensinogen	Rattus norvegicus	23-37
3435490-1	1987	Pretreatment of rat vascular smooth muscle cells with the immunosuppressive drug cyclosporin A caused concentration- and time-dependent increases in both the amplitude and duration of the angiotensin II-induced rise in cytosolic free calcium, as measured with quin 2.	Cyclosporine	81-94	angiotensinogen	Rattus norvegicus	188-202
3435490-5	1987	Cyclosporin A also augmented the angiotensin II-stimulated influx and efflux of 45Ca2+.	Cyclosporine	0-13	angiotensinogen	Rattus norvegicus	33-47
3435490-6	1987	These results demonstrate that cyclosporin A increases the permeability of the plasma membrane for Ca2+ and also augments the angiotensin II-induced increases in cytosolic free calcium.	Cyclosporine	31-44	angiotensinogen	Rattus norvegicus	126-140
3322045-3	1987	Influence of in vivo CSA treatment on in vitro angiotensin II (ANG II)-stimulated aldosterone secretion by isolated adrenal glomerulosa cells (AGC) was also measured.	Cyclosporine	21-24	angiotensinogen	Rattus norvegicus	63-69
3322045-8	1987	Despite the presence of hyperreninemia, plasma aldosterone was not elevated, suggesting that CSA may induce relative adrenal resistance to ANG II.	Cyclosporine	93-96	angiotensinogen	Rattus norvegicus	139-145
3322045-10	1987	ANG II-stimulated aldosterone secretion in AGC was diminished by low dose and aborted by high dose CSA-treatment.	Cyclosporine	99-102	angiotensinogen	Rattus norvegicus	0-6
3119712-3	1987	Although cyclosporin A (Cy A) has been widely used clinically as a potent suppressor of organ allograft rejection and has been shown to block T lymphocyte activation in vitro by inhibiting the generation of interleukin 2 (IL-2) and other lymphokines, little direct evidence is available to support the view that the immunosuppressive effects of Cy A in vivo are mediated by a similar inhibition of the autocrine lymphokine cascade.	Cyclosporine	9-22	interleukin 2	Homo sapiens	207-220
3121725-8	1987	Unlike IFN-gamma production induced by Con A, IFN-gamma production induced by IL-2 was not accompanied by an elevation of intracellular Ca2+ levels, did not require physiologic extracellular Ca2+ levels, and was not inhibited by the immunosuppressive agent cyclosporin A.	Cyclosporine	257-270	interferon gamma	Mus musculus	46-55
3316278-0	1987	Effect of cyclosporin A treatment on the production of antibody in insulin-dependent (type I) diabetic patients.	Cyclosporine	10-23	insulin	Homo sapiens	67-74
3316278-4	1987	Conversely, cyclosporin completely suppressed the synthesis of antibodies elicited by exogenous insulin irrespective of the insulin doses received, and decreased the autoantibody production against thyroid antigens, indicating that cyclosporin has variable effects on antibody production against various antigens.	Cyclosporine	12-23	insulin	Homo sapiens	96-103
3119712-3	1987	Although cyclosporin A (Cy A) has been widely used clinically as a potent suppressor of organ allograft rejection and has been shown to block T lymphocyte activation in vitro by inhibiting the generation of interleukin 2 (IL-2) and other lymphokines, little direct evidence is available to support the view that the immunosuppressive effects of Cy A in vivo are mediated by a similar inhibition of the autocrine lymphokine cascade.	Cyclosporine	9-22	interleukin 2	Homo sapiens	222-226
3119712-3	1987	Although cyclosporin A (Cy A) has been widely used clinically as a potent suppressor of organ allograft rejection and has been shown to block T lymphocyte activation in vitro by inhibiting the generation of interleukin 2 (IL-2) and other lymphokines, little direct evidence is available to support the view that the immunosuppressive effects of Cy A in vivo are mediated by a similar inhibition of the autocrine lymphokine cascade.	Cyclosporine	24-28	interleukin 2	Homo sapiens	207-220
3119712-3	1987	Although cyclosporin A (Cy A) has been widely used clinically as a potent suppressor of organ allograft rejection and has been shown to block T lymphocyte activation in vitro by inhibiting the generation of interleukin 2 (IL-2) and other lymphokines, little direct evidence is available to support the view that the immunosuppressive effects of Cy A in vivo are mediated by a similar inhibition of the autocrine lymphokine cascade.	Cyclosporine	24-28	interleukin 2	Homo sapiens	222-226
3119712-3	1987	Although cyclosporin A (Cy A) has been widely used clinically as a potent suppressor of organ allograft rejection and has been shown to block T lymphocyte activation in vitro by inhibiting the generation of interleukin 2 (IL-2) and other lymphokines, little direct evidence is available to support the view that the immunosuppressive effects of Cy A in vivo are mediated by a similar inhibition of the autocrine lymphokine cascade.	Cyclosporine	345-349	interleukin 2	Homo sapiens	207-220
3119712-3	1987	Although cyclosporin A (Cy A) has been widely used clinically as a potent suppressor of organ allograft rejection and has been shown to block T lymphocyte activation in vitro by inhibiting the generation of interleukin 2 (IL-2) and other lymphokines, little direct evidence is available to support the view that the immunosuppressive effects of Cy A in vivo are mediated by a similar inhibition of the autocrine lymphokine cascade.	Cyclosporine	345-349	interleukin 2	Homo sapiens	222-226
3316581-1	1987	Administration of cyclosporine resulted in reduced insulin requirements and improved glycemic control in patients with insulin-dependent diabetes mellitus of recent onset, but the drug was less effective in young children.	Cyclosporine	18-30	insulin	Homo sapiens	51-58
2960793-2	1987	Cyclosporine inhibited anti-CD3-mediated expression of IL-2 receptors and IL-2 factor production by peripheral blood mononuclear cells (PBM).	Cyclosporine	0-12	interleukin 2	Homo sapiens	55-59
2960793-2	1987	Cyclosporine inhibited anti-CD3-mediated expression of IL-2 receptors and IL-2 factor production by peripheral blood mononuclear cells (PBM).	Cyclosporine	0-12	interleukin 2	Homo sapiens	74-78
2830495-12	1987	These studies indicate that the CD28 molecule synergizes with protein kinase C activation to induce IL-2 gene expression and demonstrate that stimulation by the CD28 pathway can cause vigorous T-cell proliferation even in the presence of cyclosporine and that cyclosporine does not prevent transcription of 16-2 mRNA, as has been suggested previously.	Cyclosporine	260-272	interleukin 2	Homo sapiens	100-104
2830495-0	1987	T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression.	Cyclosporine	67-79	interleukin 2	Homo sapiens	90-103
3321590-6	1987	Inhibition of antigen-driven proliferation was reversed by pure recombinant IL-2 (rec-IL-2) only when low amounts of CsA (less than 25 ng/ml) were used, whereas this lymphokine was ineffective at higher but still pharmacological CsA concentrations (50-500 ng/ml).	Cyclosporine	117-120	interleukin 2	Homo sapiens	76-80
3321590-6	1987	Inhibition of antigen-driven proliferation was reversed by pure recombinant IL-2 (rec-IL-2) only when low amounts of CsA (less than 25 ng/ml) were used, whereas this lymphokine was ineffective at higher but still pharmacological CsA concentrations (50-500 ng/ml).	Cyclosporine	117-120	interleukin 2	Homo sapiens	86-90
3321590-6	1987	Inhibition of antigen-driven proliferation was reversed by pure recombinant IL-2 (rec-IL-2) only when low amounts of CsA (less than 25 ng/ml) were used, whereas this lymphokine was ineffective at higher but still pharmacological CsA concentrations (50-500 ng/ml).	Cyclosporine	229-232	interleukin 2	Homo sapiens	76-80
3321590-6	1987	Inhibition of antigen-driven proliferation was reversed by pure recombinant IL-2 (rec-IL-2) only when low amounts of CsA (less than 25 ng/ml) were used, whereas this lymphokine was ineffective at higher but still pharmacological CsA concentrations (50-500 ng/ml).	Cyclosporine	229-232	interleukin 2	Homo sapiens	86-90
3500299-2	1987	CsA, at concentrations of 10(-7) to 3 X 10(-5) M, inhibited bone resorption produced by 10(-8) M parathyroid hormone, 3 U/ml of mouse recombinant interleukin-1,5 X 10(-7) M prostaglandin E2, 14 U/ml of thrombin, 5 micrograms/ml of bacterial lipopolysaccharide or 10(-9) M 1 alpha,25-dihydroxyvitamin D3.	Cyclosporine	0-3	coagulation factor II	Mus musculus	202-210
3257444-10	1988	Similar increases in CSA and CFU-GM occurred following injection of rIL-1 alpha.	Cyclosporine	21-24	interleukin 1 alpha	Rattus norvegicus	68-79
15227289-3	1987	When stimulated in vitro, lymphocytes from cyclosporine-treated patients display an impaired ability to produce the critical lymphokine interleukin-2.	Cyclosporine	43-55	interleukin 2	Homo sapiens	136-149
3120928-1	1987	Cyclosporin"s known regulatory effects on the immune system suggest that it may be useful in treating patients with IgA nephropathy.	Cyclosporine	0-11	CD79a molecule	Homo sapiens	116-119
3120928-11	1987	Short term cyclosporin therapy may be beneficial in reducing proteinuria in some patients with IgA nephropathy.	Cyclosporine	11-22	CD79a molecule	Homo sapiens	95-98
3313982-0	1987	Cyclosporine A-related nephrotoxicity after cardiac transplantation: the role of plasma renin activity.	Cyclosporine	0-14	renin	Homo sapiens	88-93
3115263-3	1987	CyA attenuated both basal and PGE2 release evoked by angiotensin II (10(-10)-10(-6) M), arginine vasopressin (10(-10)-10(-6) M) and ionomycin (10(-9)-10(-6) M).	Cyclosporine	0-3	angiotensinogen	Rattus norvegicus	53-67
3115263-3	1987	CyA attenuated both basal and PGE2 release evoked by angiotensin II (10(-10)-10(-6) M), arginine vasopressin (10(-10)-10(-6) M) and ionomycin (10(-9)-10(-6) M).	Cyclosporine	0-3	arginine vasopressin	Rattus norvegicus	97-108
3118092-8	1987	Interferon gamma production was completely inhibited by CSA or MP and not inhibited by 6-MP.	Cyclosporine	56-59	interferon gamma	Mus musculus	0-16
3620471-4	1987	Cyclosporin A or neomycin sulfate reversibly blocked the mitogenic effect of prolactin on Nb-2 cells, but had little effect on constitutive levels of c-myc.	Cyclosporine	0-13	prolactin	Rattus norvegicus	77-86
3300293-5	1987	In 23 patients receiving CyA in whom the serum creatinine concentration was less than 2.0 mg/dL, the mean DTPA clearance was 49.5 +/- 2.83 mL/min/1.73 m2.	Cyclosporine	25-28	CD59 molecule (CD59 blood group)	Homo sapiens	142-147
3110354-1	1987	We investigated the ability of cyclosporin A (CsA) and transforming growth factor beta (TGF-beta) to modulate the production of TNF-alpha and TNF-beta and IFN-gamma by unseparated, nonadherent, and adherent PBMC.	Cyclosporine	31-44	tumor necrosis factor	Mus musculus	128-137
3110354-1	1987	We investigated the ability of cyclosporin A (CsA) and transforming growth factor beta (TGF-beta) to modulate the production of TNF-alpha and TNF-beta and IFN-gamma by unseparated, nonadherent, and adherent PBMC.	Cyclosporine	31-44	interferon gamma	Mus musculus	155-164
3117907-1	1987	Previous reports have documented that cyclosporin A (CsA) can inhibit the production of interferon-gamma (HuIFN-gamma) and interleukin-2 (IL-2).	Cyclosporine	53-56	interferon gamma	Homo sapiens	88-104
3117907-1	1987	Previous reports have documented that cyclosporin A (CsA) can inhibit the production of interferon-gamma (HuIFN-gamma) and interleukin-2 (IL-2).	Cyclosporine	53-56	interleukin 2	Homo sapiens	123-136
3117907-1	1987	Previous reports have documented that cyclosporin A (CsA) can inhibit the production of interferon-gamma (HuIFN-gamma) and interleukin-2 (IL-2).	Cyclosporine	53-56	interleukin 2	Homo sapiens	138-142
3117907-3	1987	In the presence of recombinant exogenous IL-2, the effect of CsA on the synthesis of HuIFN-gamma can be reversed depending on the concentrations of both the IL-2 and CsA.	Cyclosporine	61-64	interleukin 2	Homo sapiens	41-45
3117907-3	1987	In the presence of recombinant exogenous IL-2, the effect of CsA on the synthesis of HuIFN-gamma can be reversed depending on the concentrations of both the IL-2 and CsA.	Cyclosporine	61-64	interleukin 2	Homo sapiens	157-161
3303525-0	1987	The inhibition of interleukin 2 (IL-2) gene expression at the level of messenger RNA by in vivo cyclosporine treatment in kidney transplant recipients.	Cyclosporine	96-108	interleukin 2	Homo sapiens	18-31
3303525-0	1987	The inhibition of interleukin 2 (IL-2) gene expression at the level of messenger RNA by in vivo cyclosporine treatment in kidney transplant recipients.	Cyclosporine	96-108	interleukin 2	Homo sapiens	33-37
3300326-0	1987	Suppression of plasma renin activity by cyclosporine.	Cyclosporine	40-52	renin	Homo sapiens	22-27
3037548-3	1987	The tat-I protein also partially circumvents the pronounced inhibitory effects of cyclosporin A on the IL-2 promoter.	Cyclosporine	82-95	interleukin 2	Homo sapiens	103-107
3300326-1	1987	Cyclosporine treatment is associated with hypertension and suppression of plasma renin activity, the causes of which are unclear.	Cyclosporine	0-12	renin	Homo sapiens	81-86
3300326-4	1987	Upright plasma renin activity was suppressed in cyclosporine-treated patients (cyclosporine 2.9 +/- 0.9, azathioprine 4.7 +/- 0.9, renal insufficiency 5.2 +/- 1.9 ng/ml/hour) but could be stimulated by a four-day period of dietary sodium restriction and diuretic administration (cyclosporine 15.8 +/- 4.4 ng/ml/hour).	Cyclosporine	48-60	renin	Homo sapiens	15-20
3300326-4	1987	Upright plasma renin activity was suppressed in cyclosporine-treated patients (cyclosporine 2.9 +/- 0.9, azathioprine 4.7 +/- 0.9, renal insufficiency 5.2 +/- 1.9 ng/ml/hour) but could be stimulated by a four-day period of dietary sodium restriction and diuretic administration (cyclosporine 15.8 +/- 4.4 ng/ml/hour).	Cyclosporine	79-91	renin	Homo sapiens	15-20
3300326-4	1987	Upright plasma renin activity was suppressed in cyclosporine-treated patients (cyclosporine 2.9 +/- 0.9, azathioprine 4.7 +/- 0.9, renal insufficiency 5.2 +/- 1.9 ng/ml/hour) but could be stimulated by a four-day period of dietary sodium restriction and diuretic administration (cyclosporine 15.8 +/- 4.4 ng/ml/hour).	Cyclosporine	79-91	renin	Homo sapiens	15-20
3300326-7	1987	It is concluded that suppression of plasma renin activity by cyclosporine is physiologic and may reflect expansion of extracellular fluid volume, which can be reversed by sodium depletion.	Cyclosporine	61-73	renin	Homo sapiens	43-48
3110069-6	1987	CsA treatment inhibited the ability of BCG-vaccinated mice to produce gamma interferon (IFN-gamma) after a secondary stimulation with live BCG or with lipopolysaccharide.	Cyclosporine	0-3	interferon gamma	Mus musculus	70-97
3110069-7	1987	Spleen cells from BCG-infected mice which were exposed to daily treatment with CsA showed reduced IFN-gamma production in response to purified protein derivative or concanavalin A stimulation, suggesting that the immunosuppressive effect of CsA on BCG-infected mice was expressed by inhibiting the development of effector T cells responsible for the production of IFN-gamma.	Cyclosporine	79-82	interferon gamma	Mus musculus	98-107
3110069-7	1987	Spleen cells from BCG-infected mice which were exposed to daily treatment with CsA showed reduced IFN-gamma production in response to purified protein derivative or concanavalin A stimulation, suggesting that the immunosuppressive effect of CsA on BCG-infected mice was expressed by inhibiting the development of effector T cells responsible for the production of IFN-gamma.	Cyclosporine	79-82	interferon gamma	Mus musculus	364-373
3110069-7	1987	Spleen cells from BCG-infected mice which were exposed to daily treatment with CsA showed reduced IFN-gamma production in response to purified protein derivative or concanavalin A stimulation, suggesting that the immunosuppressive effect of CsA on BCG-infected mice was expressed by inhibiting the development of effector T cells responsible for the production of IFN-gamma.	Cyclosporine	241-244	interferon gamma	Mus musculus	98-107
2953808-3	1987	Thus, reagents which block the IL 2 pathway, e.g., cyclosporin A (CsA) or IL 2 receptor monoclonal antibodies (IL 2R Mab) enhanced Thc activation although T cell proliferation was blocked.	Cyclosporine	51-64	interleukin 2	Homo sapiens	31-35
2953808-3	1987	Thus, reagents which block the IL 2 pathway, e.g., cyclosporin A (CsA) or IL 2 receptor monoclonal antibodies (IL 2R Mab) enhanced Thc activation although T cell proliferation was blocked.	Cyclosporine	66-69	interleukin 2	Homo sapiens	31-35
2953808-5	1987	The regulatory role of IL 2 was reconfirmed by the addition of exogenous IL 2 into the cultures which reversed the enhancing or blocking effect of CsA.	Cyclosporine	147-150	interleukin 2	Homo sapiens	23-27
2953808-5	1987	The regulatory role of IL 2 was reconfirmed by the addition of exogenous IL 2 into the cultures which reversed the enhancing or blocking effect of CsA.	Cyclosporine	147-150	interleukin 2	Homo sapiens	73-77
2979004-0	1987	Interleukin-2 effect on the inhibition of mixed lymphocyte reaction induced by cyclosporin A.	Cyclosporine	79-92	interleukin 2	Homo sapiens	0-13
3306175-3	1987	TNF is a potent inducer of serum colony stimulating activity, CSA, in both mouse strains.	Cyclosporine	62-65	tumor necrosis factor	Mus musculus	0-3
3306175-8	1987	In vitro, TNF significantly increases the number of colonies in the presence of CSA in bone marrow cultures.	Cyclosporine	80-83	tumor necrosis factor	Mus musculus	10-13
2439348-3	1987	Human interferon-gamma abolished the depolarizing effect of cyclosporin on lymphocytes.	Cyclosporine	60-71	interferon gamma	Homo sapiens	6-22
3298044-4	1987	In vitro angiotensin II (ANG II)-stimulated aldosterone secretion by zona glomerulosa cells obtained from cyclosporin A-treated rats was also reduced (4.8 +/- 0.5, 1.5 +/- 0.2, and 0.2 +/- 0.2 ng/10(5) cells in control rats and rats receiving 5 mg and 20 mg of cyclosporin A, respectively).	Cyclosporine	106-119	angiotensinogen	Rattus norvegicus	9-23
3298044-4	1987	In vitro angiotensin II (ANG II)-stimulated aldosterone secretion by zona glomerulosa cells obtained from cyclosporin A-treated rats was also reduced (4.8 +/- 0.5, 1.5 +/- 0.2, and 0.2 +/- 0.2 ng/10(5) cells in control rats and rats receiving 5 mg and 20 mg of cyclosporin A, respectively).	Cyclosporine	106-119	angiotensinogen	Rattus norvegicus	25-31
3298044-4	1987	In vitro angiotensin II (ANG II)-stimulated aldosterone secretion by zona glomerulosa cells obtained from cyclosporin A-treated rats was also reduced (4.8 +/- 0.5, 1.5 +/- 0.2, and 0.2 +/- 0.2 ng/10(5) cells in control rats and rats receiving 5 mg and 20 mg of cyclosporin A, respectively).	Cyclosporine	261-274	angiotensinogen	Rattus norvegicus	9-23
3298044-4	1987	In vitro angiotensin II (ANG II)-stimulated aldosterone secretion by zona glomerulosa cells obtained from cyclosporin A-treated rats was also reduced (4.8 +/- 0.5, 1.5 +/- 0.2, and 0.2 +/- 0.2 ng/10(5) cells in control rats and rats receiving 5 mg and 20 mg of cyclosporin A, respectively).	Cyclosporine	261-274	angiotensinogen	Rattus norvegicus	25-31
3298044-6	1987	When added in vitro to zona glomerulosa cells from untreated rats, cyclosporin A also attenuated ANG II-stimulated aldosterone secretion, but did not affect potassium or ACTH-mediated aldosterone production.	Cyclosporine	67-80	angiotensinogen	Rattus norvegicus	97-103
3298044-7	1987	Thus, cyclosporin A-induced hyperreninemic hypoaldosteronism in the rat depends on opposing renal and adrenal effects, with a direct or feedback stimulation of renin secretion and a specific blockade of ANG II-mediated aldosterone production.	Cyclosporine	6-19	angiotensinogen	Rattus norvegicus	203-209
3496271-4	1987	Low concentrations of cyclosporine inhibited both proliferation and IL-2 production (ED50 = 12 and 9 ng/ml, respectively) and this inhibition was partially relieved in the presence of added IL-2 (ED50 = 110 ng/ml).	Cyclosporine	22-34	interleukin-2	Ovis aries	68-72
3496271-4	1987	Low concentrations of cyclosporine inhibited both proliferation and IL-2 production (ED50 = 12 and 9 ng/ml, respectively) and this inhibition was partially relieved in the presence of added IL-2 (ED50 = 110 ng/ml).	Cyclosporine	22-34	interleukin-2	Ovis aries	190-194
3036114-7	1987	PMA, bombesin, and thrombin act via kinase C. PDGF and vanadate cause additional stimulation of the Na+/H+ exchanger by a kinase C-independent pathway, inhibitable by cyclosporin A.	Cyclosporine	167-180	coagulation factor II, thrombin	Homo sapiens	19-27
2886317-9	1987	When highly purified forms of P-450, including P-450 2, 3b, 3c, and 4, were assayed in a reconstituted system, only P-450 3c exhibited type I binding spectrum upon CsA addition (Ks = 1.4 +/- 0.5 microM) and extensively metabolized the drug to all derivatives.	Cyclosporine	164-167	cytochrome P450 3A6	Oryctolagus cuniculus	116-124
3116404-4	1987	The induction of Interleukin-2, Interferon gamma and the Colony Stimulating Factor for granulocytes and macrophages was suppressed by Cyclosporin A at moderate concns.	Cyclosporine	134-147	interleukin 2	Homo sapiens	17-30
3116404-4	1987	The induction of Interleukin-2, Interferon gamma and the Colony Stimulating Factor for granulocytes and macrophages was suppressed by Cyclosporin A at moderate concns.	Cyclosporine	134-147	interferon gamma	Homo sapiens	32-48
3116404-7	1987	CsA interrupted ongoing transcription of IL2 by a mechanism not dependent on the induction of a new protein.	Cyclosporine	0-3	interleukin 2	Homo sapiens	41-44
3494996-1	1987	Although cyclosporin A (CsA), an immunosuppressive drug, has been shown to inhibit the production of certain lymphokines, including interleukin 2 (IL-2), interleukin 3 (IL-3), and gamma-interferon, its effect on the production of granulocyte/macrophage colony-stimulating factor (GM-CSF) has not been evaluated.	Cyclosporine	24-27	interleukin 3	Mus musculus	154-173
3494996-1	1987	Although cyclosporin A (CsA), an immunosuppressive drug, has been shown to inhibit the production of certain lymphokines, including interleukin 2 (IL-2), interleukin 3 (IL-3), and gamma-interferon, its effect on the production of granulocyte/macrophage colony-stimulating factor (GM-CSF) has not been evaluated.	Cyclosporine	24-27	interferon gamma	Mus musculus	180-196
3494996-3	1987	In contrast, significant activity was detected when the CsA-treated culture supernatants were assayed on a cell line that is dependent on GM-CSF and/or IL-3.	Cyclosporine	56-59	interleukin 3	Mus musculus	152-156
3494996-9	1987	The present data show that production of IL-2 and IL-3, but not that of GM-CSF, is inhibited by CsA and suggest a differential control mechanism for lymphokine synthesis in T lymphocytes.	Cyclosporine	96-99	interleukin 3	Mus musculus	50-54
2886317-10	1987	We conclude that the macrolide antibiotic-inducible form P-450 3c (or P-450 3c related from(s)) is responsible for the major part of CsA metabolism by rabbit liver microsomes.	Cyclosporine	133-136	cytochrome P450 3A6	Oryctolagus cuniculus	57-65
2886317-10	1987	We conclude that the macrolide antibiotic-inducible form P-450 3c (or P-450 3c related from(s)) is responsible for the major part of CsA metabolism by rabbit liver microsomes.	Cyclosporine	133-136	cytochrome P450 3A6	Oryctolagus cuniculus	70-78
3495054-1	1987	Cyclosporine (CsA) inhibits release of interleukin 2 (IL-2) and hemopoietic growth activities such as interleukin 3 (IL-3) from major histocompatibility complex (MHC)-antigen-activated T cells.	Cyclosporine	0-12	interleukin 2	Homo sapiens	39-52
3495054-1	1987	Cyclosporine (CsA) inhibits release of interleukin 2 (IL-2) and hemopoietic growth activities such as interleukin 3 (IL-3) from major histocompatibility complex (MHC)-antigen-activated T cells.	Cyclosporine	0-12	interleukin 2	Homo sapiens	54-58
2952974-4	1987	Because cyclosporin reduces excessive IgE levels in Brown Norway rats with mercuric chloride nephritis, we gave the patient this drug in daily doses of 3-4 mg/kg.	Cyclosporine	8-19	immunoglobulin heavy constant epsilon	Homo sapiens	38-41
3551631-0	1987	Cyclosporine nephrotoxicity: sodium excretion, autoregulation, and angiotensin II.	Cyclosporine	0-12	angiotensinogen	Rattus norvegicus	67-81
2436810-11	1987	Taken together, these data suggest that the inhibition by CsA of Ly-6A induction in Con A-treated T cells reflects the known inhibitory effects of the drug on IFN-gamma secretion.	Cyclosporine	58-61	interferon gamma	Mus musculus	159-168
3554640-4	1987	Clearance studies 6 weeks after Tx exhibited significantly lower rates in the CsA group: Cin = 47 +/- 16.5 versus 83 +/- 25 ml/min/1.73 sqm, CPAH = 271 +/- 110 versus 503 +/- 181 ml/min/1.73 sqm (P less than 0.001).	Cyclosporine	78-81	CD59 molecule (CD59 blood group)	Homo sapiens	127-132
3554640-4	1987	Clearance studies 6 weeks after Tx exhibited significantly lower rates in the CsA group: Cin = 47 +/- 16.5 versus 83 +/- 25 ml/min/1.73 sqm, CPAH = 271 +/- 110 versus 503 +/- 181 ml/min/1.73 sqm (P less than 0.001).	Cyclosporine	78-81	CD59 molecule (CD59 blood group)	Homo sapiens	182-187
3038453-0	1987	Different effect of two immunomodulating agents cyclosporin A and ciamexon on the insulin metabolism of cultured mouse islets.	Cyclosporine	48-61	insulin	Homo sapiens	82-89
3102542-3	1987	Cyclosporine A, known to inhibit lymphokine production, inhibited basal as well as lectin-mediated increases in levels of DR alpha-chain-specific mRNA and DR surface antigen expression on normal human thyrocytes.	Cyclosporine	0-14	solute carrier family 26 member 3	Homo sapiens	122-130
3319308-0	1987	Renin-angiotensin-aldosterone system and vasopressin in cyclosporine-treated renal allograft recipients.	Cyclosporine	56-68	renin	Homo sapiens	0-5
3319308-0	1987	Renin-angiotensin-aldosterone system and vasopressin in cyclosporine-treated renal allograft recipients.	Cyclosporine	56-68	arginine vasopressin	Homo sapiens	41-52
3100637-4	1987	The proliferative response is due to an autocrine IL 2-dependent mechanism and can be inhibited by antibodies against the IL 2 receptor or by Cyclosporin A.	Cyclosporine	142-155	interleukin 2	Homo sapiens	50-54
3554759-6	1987	Reported inductions, however, of insulin independence in patients with newly diagnosed type I diabetes using cyclosporine or other agents underscore the role of the immune system in the pathogenesis of the disease and highlight the need to develop safer, more specific immunomodulation designed to avoid complete beta-cell destruction.	Cyclosporine	109-121	insulin	Homo sapiens	33-40
2979210-2	1987	Seven of the eight patients responded to treatment with cyclosporin by symptomatic improvement, weight gain and a return of serum C-reactive protein concentration towards normal.	Cyclosporine	56-67	C-reactive protein	Homo sapiens	130-148
3152624-0	1987	Clinically used concentrations of cyclosporine A only partially inhibit interferon-gamma production by activated T lymphocytes.	Cyclosporine	34-48	interferon gamma	Homo sapiens	72-88
3494759-9	1987	These results show that protective immunity to larvae of B. pahangi in mice depends upon small numbers of Thy 1.2+ T cells which are CsA-resistant.	Cyclosporine	133-136	thymus cell antigen 1, theta	Mus musculus	106-113
3154418-9	1987	In recent transplants, zero HLA-A,B mismatched grafts appear to have an advantage in terms of long-term graft survival both with and without CsA immunosuppression.	Cyclosporine	141-144	major histocompatibility complex, class I, A	Homo sapiens	28-33
2856270-0	1987	Angiotensin-converting enzyme inhibition or aldosterone antagonism reduces cyclosporine nephrotoxicity in the rat.	Cyclosporine	75-87	angiotensin I converting enzyme	Rattus norvegicus	0-29
2950628-0	1987	Subcellular action of cyclosporine: interaction between CsA and calmodulin antagonists.	Cyclosporine	22-34	calmodulin 1	Homo sapiens	64-74
3097147-1	1987	Prolactin (PRL)-stimulated ornithine decarboxylase (ODC) activity and subsequent proliferation are inhibited by the cyclopeptides cyclosporine (CsA) and didemnin B (DB) in Nb 2 node lymphoma cells.	Cyclosporine	130-142	prolactin	Rattus norvegicus	0-9
3097147-1	1987	Prolactin (PRL)-stimulated ornithine decarboxylase (ODC) activity and subsequent proliferation are inhibited by the cyclopeptides cyclosporine (CsA) and didemnin B (DB) in Nb 2 node lymphoma cells.	Cyclosporine	130-142	prolactin	Rattus norvegicus	11-14
3097147-1	1987	Prolactin (PRL)-stimulated ornithine decarboxylase (ODC) activity and subsequent proliferation are inhibited by the cyclopeptides cyclosporine (CsA) and didemnin B (DB) in Nb 2 node lymphoma cells.	Cyclosporine	144-147	prolactin	Rattus norvegicus	0-9
3097147-1	1987	Prolactin (PRL)-stimulated ornithine decarboxylase (ODC) activity and subsequent proliferation are inhibited by the cyclopeptides cyclosporine (CsA) and didemnin B (DB) in Nb 2 node lymphoma cells.	Cyclosporine	144-147	prolactin	Rattus norvegicus	11-14
3509802-4	1987	The two lymphocyte populations also had different levels of interleukin-2 (IL-2) receptors and shifted plasma membrane potential differently upon treatment with cyclosporin and lymphokine IL-2.	Cyclosporine	161-172	interleukin 2	Homo sapiens	75-79
3509802-5	1987	The cell population that bound more dans-CsA contained the cells which possessed IL-2 receptors and responded to CsA and IL-2 with changes in membrane potential.	Cyclosporine	41-44	interleukin 2	Homo sapiens	81-85
3509802-5	1987	The cell population that bound more dans-CsA contained the cells which possessed IL-2 receptors and responded to CsA and IL-2 with changes in membrane potential.	Cyclosporine	41-44	interleukin 2	Homo sapiens	121-125
2881198-6	1986	NAG and AAP were more frequently elevated during treatment with cyclosporine A (21/29), than with azathioprine (10/23).	Cyclosporine	64-78	N-acetyl-alpha-glucosaminidase	Homo sapiens	0-3
2947365-0	1986	Mechanism of action of cyclosporine: role of calmodulin, cyclophilin, and other cyclosporine-binding proteins.	Cyclosporine	23-35	calmodulin 1	Homo sapiens	45-55
3501185-4	1987	Dexamethasone and Cyclosporin A (CsA) which inhibit early events of T cell activation and the expression of the interleukin-2 (IL-2) and gamma-interferon (gamma-IFN) genes also markedly suppress the expression of c-myc mRNA in Con A, and Con A + TPA-activated thymocytes.	Cyclosporine	18-31	interleukin 2	Homo sapiens	112-125
3501185-4	1987	Dexamethasone and Cyclosporin A (CsA) which inhibit early events of T cell activation and the expression of the interleukin-2 (IL-2) and gamma-interferon (gamma-IFN) genes also markedly suppress the expression of c-myc mRNA in Con A, and Con A + TPA-activated thymocytes.	Cyclosporine	18-31	interleukin 2	Homo sapiens	127-131
3501185-4	1987	Dexamethasone and Cyclosporin A (CsA) which inhibit early events of T cell activation and the expression of the interleukin-2 (IL-2) and gamma-interferon (gamma-IFN) genes also markedly suppress the expression of c-myc mRNA in Con A, and Con A + TPA-activated thymocytes.	Cyclosporine	33-36	interleukin 2	Homo sapiens	112-125
3501185-4	1987	Dexamethasone and Cyclosporin A (CsA) which inhibit early events of T cell activation and the expression of the interleukin-2 (IL-2) and gamma-interferon (gamma-IFN) genes also markedly suppress the expression of c-myc mRNA in Con A, and Con A + TPA-activated thymocytes.	Cyclosporine	33-36	interleukin 2	Homo sapiens	127-131
2948670-1	1986	We have analyzed the effect of cyclosporin-A (CsA) on the proliferative and cytotoxic responses induced by mixed-lymphocyte cultures (MLC-s) on low and high density T lymphocytes.	Cyclosporine	46-49	modulator of VRAC current 1	Homo sapiens	134-137
2948670-5	1986	In both subsets CsA inhibited the MLC-induced interleukin 2 (IL-2) production.	Cyclosporine	16-19	modulator of VRAC current 1	Homo sapiens	34-37
2948670-5	1986	In both subsets CsA inhibited the MLC-induced interleukin 2 (IL-2) production.	Cyclosporine	16-19	interleukin 2	Homo sapiens	46-59
2948670-5	1986	In both subsets CsA inhibited the MLC-induced interleukin 2 (IL-2) production.	Cyclosporine	16-19	interleukin 2	Homo sapiens	61-65
2948670-7	1986	Addition of exogenous IL-2 to the CsA-containing cultures fully restored the proliferation and the generation of nonspecific cytotoxicity.	Cyclosporine	34-37	interleukin 2	Homo sapiens	22-26
3100053-6	1986	This mechanism appears to be unique among immunosuppressive agents thus far studied; cyclosporin A and corticosteroids inhibit IL-2 production and are required at the initiation of activation for maximal effect.	Cyclosporine	85-98	interleukin 2	Homo sapiens	127-131
3749892-0	1986	Does the binding of cyclosporine to calmodulin result in immunosuppression?	Cyclosporine	20-32	calmodulin 1	Homo sapiens	36-46
2942329-9	1986	IL-2 production induced by PHA was strongly blocked by methylprednisolone and cyclosporin but not by 6-mercaptopurine, at least when a pharmacological concentration was used.	Cyclosporine	78-89	interleukin 2	Homo sapiens	0-4
3527825-8	1986	Glucose-stimulated insulin release from perifused islets was markedly depressed in CyA-treated islets.	Cyclosporine	83-86	insulin	Homo sapiens	19-26
3490431-0	1986	Exogenous IL2 partially reverts CML non-reactivity acquired during prophylactic immunosuppression with cyclosporin A of human allograft recipients.	Cyclosporine	103-116	interleukin 2	Homo sapiens	10-13
2871646-8	1986	We conclude that the urinary ABP assay provides information useful in the management of renal transplant patients with acute and chronic rejection and CsA toxicity.	Cyclosporine	151-154	sex hormone binding globulin	Homo sapiens	29-32
2939454-5	1986	Further, stimulation of prolactin secretion reversed the immunosuppression induced by cyclosporine.	Cyclosporine	86-98	prolactin	Rattus norvegicus	24-33
2939454-6	1986	We conclude that prolactin is involved in the maintenance of T-cell immunocompetence and that the immunosuppressive effects of cyclosporine may be mediated by the displacement of prolactin from binding sites on lymphocytes.	Cyclosporine	127-139	prolactin	Rattus norvegicus	179-188
3097893-5	1986	Exogenous interleukin-2 (IL-2) restored mitogenic responsiveness to cultures suppressed using W-7 and CsA, but not to lymphocytes suppressed with either CPZ or PB.	Cyclosporine	102-105	interleukin 2	Homo sapiens	10-23
3097893-5	1986	Exogenous interleukin-2 (IL-2) restored mitogenic responsiveness to cultures suppressed using W-7 and CsA, but not to lymphocytes suppressed with either CPZ or PB.	Cyclosporine	102-105	interleukin 2	Homo sapiens	25-29
3097893-8	1986	Thus, the mechanism of action of cyclosporine can be differentiated from those of anesthetic immunosuppressants at the level of responsiveness to interleukin-2.	Cyclosporine	33-45	interleukin 2	Homo sapiens	146-159
3097893-9	1986	The data support the hypothesis that cyclosporine may be an antagonist of calmodulin that selectively blocks early events in T lymphocyte activation leading to IL-2 synthesis, but does not inhibit the expression or function of the IL-2 receptor.	Cyclosporine	37-49	calmodulin 1	Homo sapiens	74-84
3097893-9	1986	The data support the hypothesis that cyclosporine may be an antagonist of calmodulin that selectively blocks early events in T lymphocyte activation leading to IL-2 synthesis, but does not inhibit the expression or function of the IL-2 receptor.	Cyclosporine	37-49	interleukin 2	Homo sapiens	160-164
3089830-2	1986	In these patients, bone marrow colony formation could be significantly enhanced by in vitro incubation of the bone marrow target with cyclosporin A (CyA; 0.5 microgram/ml) or with a monoclonal anti-gamma-(immune) interferon (IFN-gamma) antibody.	Cyclosporine	134-147	interferon gamma	Homo sapiens	225-234
3096881-0	1986	Cyclosporine inhibits the expression of receptors for interleukin 2 and transferrin on mitogen-activated human T lymphocytes.	Cyclosporine	0-12	interleukin 2	Homo sapiens	54-67
3096881-0	1986	Cyclosporine inhibits the expression of receptors for interleukin 2 and transferrin on mitogen-activated human T lymphocytes.	Cyclosporine	0-12	transferrin	Homo sapiens	72-83
3096881-1	1986	The effect of cyclosporine A (CsA) on the mitogen-induced expression of Interleukin 2 receptor (IL2R) and transferrin receptor (TR) was monitored using receptor-specific monoclonal antibodies and flow cytometry.	Cyclosporine	30-33	transferrin	Homo sapiens	106-117
3096881-4	1986	The addition of exogenous IL2 partially abrogated the CsA-mediated inhibition of all three activation parameters (IL2R, TR, DNA synthesis) in response to PHA, OKT3, and Leu 4.	Cyclosporine	54-57	interleukin 2	Homo sapiens	26-29
3096881-6	1986	These findings indicate that CsA inhibits mitogen-induced expression of IL2R and TR, and for some mitogen systems, this inhibition appears, at least in part, to be secondary to decreased IL2 production.	Cyclosporine	29-32	interleukin 2	Homo sapiens	72-75
2942563-4	1986	Cyclosporine A (CsA) treatment did not alter the defect in Con A-induced suppressor activity, but did markedly inhibit T8+ cell-mediated alloantigen directed cytolytic activity; this latter defect was reversible by in vitro addition of IL-2.	Cyclosporine	16-19	interleukin 2	Homo sapiens	236-240
3015982-8	1986	CsA inhibited mitogen-stimulation of interleukin-2 production in a separate cell line.	Cyclosporine	0-3	interleukin 2	Homo sapiens	37-50
3015982-9	1986	CsA also inhibited vasopressin stimulation of the antiporter in normal rat kidney fibroblasts, but had no effect on serum or 12-O-tetradecanoyl phorbol 13-acetate stimulation.	Cyclosporine	0-3	arginine vasopressin	Rattus norvegicus	19-30
3090550-7	1986	Increased IL-2R expression appears to be the direct effect of thymic hormones, since abrogation of interleukin 2 production by cyclosporin A did not affect TF5-mediated enhancement of PHA-induced IL-2R expression.	Cyclosporine	127-140	interleukin 2	Homo sapiens	99-112
3503544-2	1986	CsA inhibited parathyroid hormone (PTH), prostaglandin E2, 1,25-dihydroxy vitamin D3 (1,25(OH)2D3), and osteoclast-activating factor induced resorption of fetal rat limb bones in a dose-dependent manner.	Cyclosporine	0-3	parathyroid hormone	Rattus norvegicus	14-33
3503544-2	1986	CsA inhibited parathyroid hormone (PTH), prostaglandin E2, 1,25-dihydroxy vitamin D3 (1,25(OH)2D3), and osteoclast-activating factor induced resorption of fetal rat limb bones in a dose-dependent manner.	Cyclosporine	0-3	parathyroid hormone	Rattus norvegicus	35-38
3503544-4	1986	The CsA inhibition of bone resorption could be partially surmounted by higher concentrations of PTH and 1,25(OH)2D3.	Cyclosporine	4-7	parathyroid hormone	Rattus norvegicus	96-99
2939138-1	1986	The influence of cyclosporin A (CsA) on the interleukin 2 (IL 2)-driven proliferation of allo-activated human T lymphocytes has been studied.	Cyclosporine	32-35	interleukin 2	Homo sapiens	44-57
2939138-1	1986	The influence of cyclosporin A (CsA) on the interleukin 2 (IL 2)-driven proliferation of allo-activated human T lymphocytes has been studied.	Cyclosporine	32-35	interleukin 2	Homo sapiens	59-63
2939138-2	1986	CsA (50, 100, and 250 ng/ml) appeared to affect the IL 2-driven proliferation.	Cyclosporine	0-3	interleukin 2	Homo sapiens	52-56
3517164-3	1986	Simultaneous treatment of the mice with IL 2-containing murine lymphokine preparations or with recombinant human IL 2 reverses the effect of CsA on the induction of contact sensitivity.	Cyclosporine	141-144	interleukin 2	Homo sapiens	113-117
3527825-10	1986	We concluded that CyA has a direct inhibitory effect on insulin release from human pancreatic islets with a concomitant increase in the residual insulin content.	Cyclosporine	18-21	insulin	Homo sapiens	56-63
3527825-10	1986	We concluded that CyA has a direct inhibitory effect on insulin release from human pancreatic islets with a concomitant increase in the residual insulin content.	Cyclosporine	18-21	insulin	Homo sapiens	145-152
3456745-2	1986	Incubation for 20 min with cyclosporin A markedly suppressed, in a dose dependent manner, phospholipase A2 activity and the release of prostaglandin E2 in lymphocytes, and slightly those in neutrophils, while no inhibition of phosphatidylethanolamine (PE)-N methyltransferase activity was observed.	Cyclosporine	27-40	phospholipase A2 group IB	Homo sapiens	90-106
3456745-5	1986	These findings suggest that cyclosporin A acts upon early membrane events in the activation of cells involved in inflammatory reactions; they further suggest that suppression of immune response by cyclosporin A is at least partly due to inhibition of phospholipase A2 in the plasma membrane of inflammatory cells.	Cyclosporine	28-41	phospholipase A2 group IB	Homo sapiens	251-267
3456745-5	1986	These findings suggest that cyclosporin A acts upon early membrane events in the activation of cells involved in inflammatory reactions; they further suggest that suppression of immune response by cyclosporin A is at least partly due to inhibition of phospholipase A2 in the plasma membrane of inflammatory cells.	Cyclosporine	197-210	phospholipase A2 group IB	Homo sapiens	251-267
3487503-6	1986	Cys also inhibited the mitogen and LK dependent stimulation of purified T cells, but did not inhibit the LK dependent proliferation of T cell blasts.	Cyclosporine	0-3	interleukin 2	Homo sapiens	35-37
3486375-4	1986	Cyclosporine-treated recipients of grafts with minor histocompatibility differences had normal levels of thyroxine and prolactin, whereas untreated animals did not.	Cyclosporine	0-12	prolactin	Rattus norvegicus	119-128
3484763-2	1986	We used a human IL 2 cDNA clone to investigate the effect of antibody 9.6 and cyclosporin A (CsA) on the regulation of IL 2 mRNA levels in the cloned human leukemic T cell line Jurkat, J32.	Cyclosporine	78-91	interleukin 2	Homo sapiens	119-123
2939454-0	1986	Prolactin as a modulator of lymphocyte responsiveness provides a possible mechanism of action for cyclosporine.	Cyclosporine	98-110	prolactin	Rattus norvegicus	0-9
2939454-4	1986	Prolactin was shown to compete in a dose-dependent fashion with the immunosuppressant cyclosporine (cyclosporin A) for a common binding site on the surface of T lymphocytes.	Cyclosporine	86-98	prolactin	Rattus norvegicus	0-9
2939454-4	1986	Prolactin was shown to compete in a dose-dependent fashion with the immunosuppressant cyclosporine (cyclosporin A) for a common binding site on the surface of T lymphocytes.	Cyclosporine	100-113	prolactin	Rattus norvegicus	0-9
3003975-1	1986	Cyclosporine (CsA), a potent immunosuppressant for the prevention of transplant rejection, modulates T lymphocyte activation by blocking antigen stimulation and the production of interleukin-2.	Cyclosporine	0-12	interleukin 2	Homo sapiens	179-192
3511524-9	1986	Pilot studies using cyclosporin as immunosuppressive agent in newly diagnosed type 1 diabetics have demonstrated that after discontinuation of this treatment diabetics again became insulin-dependent.	Cyclosporine	20-31	insulin	Homo sapiens	181-188
3484763-9	1986	These findings indicate that signals induced by antibody 9.6 regulate IL 2 production at a pre-translational level, are operative for an extended period of time overlapping with the early phase of IL 2 mRNA accumulation, suppress IL 2 gene expression induced by PHA as well as TPA, and that antibody 9.6 and CsA exert their inhibitory effect by distinct mechanism(s).	Cyclosporine	308-311	interleukin 2	Homo sapiens	70-74
3484763-2	1986	We used a human IL 2 cDNA clone to investigate the effect of antibody 9.6 and cyclosporin A (CsA) on the regulation of IL 2 mRNA levels in the cloned human leukemic T cell line Jurkat, J32.	Cyclosporine	93-96	interleukin 2	Homo sapiens	119-123
3484763-6	1986	In contrast, the ability of CsA to suppress IL 2 mRNA accumulation appeared to be independent of PHA or TPA concentration and was minimal if CsA was added 4 hr after stimulation.	Cyclosporine	28-31	interleukin 2	Homo sapiens	44-48
3484763-6	1986	In contrast, the ability of CsA to suppress IL 2 mRNA accumulation appeared to be independent of PHA or TPA concentration and was minimal if CsA was added 4 hr after stimulation.	Cyclosporine	141-144	interleukin 2	Homo sapiens	44-48
3484439-0	1986	Cyclosporin-A inhibits IL-2 production by all human T-cell clones having this function, independent of the T4/T8 phenotype or the coexpression of cytolytic activity.	Cyclosporine	0-13	interleukin 2	Homo sapiens	23-27
3484439-1	1986	Cyclosporin A (CsA) is an immunosuppressive drug that acts, at least in part, by blocking IL-2 release.	Cyclosporine	0-13	interleukin 2	Homo sapiens	90-94
3484439-1	1986	Cyclosporin A (CsA) is an immunosuppressive drug that acts, at least in part, by blocking IL-2 release.	Cyclosporine	15-18	interleukin 2	Homo sapiens	90-94
3484439-3	1986	Preliminary dose/response experiments showed that 100 ng/ml CsA completely inhibited the PHA- or OKT3-induced IL-2 production by four representative T4+/T8- clones.	Cyclosporine	60-63	interleukin 2	Homo sapiens	110-114
3484439-8	1986	CsA (100 ng/ml) abrogated IL-2 production of all clones, including those displaying cytolytic activity and expressing the T4-/T8+ phenotype.	Cyclosporine	0-3	interleukin 2	Homo sapiens	26-30
3485481-1	1986	The in vitro lysis of varicella-zoster virus (VZV) infected human fibroblasts by blood mononuclear cells (MNC) is inhibited by cyclosporin A, whether or not the effector and target cells chare HLA A or B antigens.	Cyclosporine	127-140	major histocompatibility complex, class I, A	Homo sapiens	193-198
3485481-2	1986	Interleukin 2 (IL-2) reversed the inhibition by cyclosporin A (CyA) and also induced a further increase in target cell lysis by MNC in the absence of CyA.	Cyclosporine	48-61	interleukin 2	Homo sapiens	0-13
3485481-2	1986	Interleukin 2 (IL-2) reversed the inhibition by cyclosporin A (CyA) and also induced a further increase in target cell lysis by MNC in the absence of CyA.	Cyclosporine	48-61	interleukin 2	Homo sapiens	15-19
3940742-0	1986	Interstitial pneumonitis in autoimmune MRL/lpr mice and its treatment with cyclosporin A.	Cyclosporine	75-88	Fas (TNF receptor superfamily member 6)	Mus musculus	43-46
3940742-5	1986	Oral administration of cyclosporin A to 15-week-old MRL/lpr mice markedly prolonged their life span.	Cyclosporine	23-36	Fas (TNF receptor superfamily member 6)	Mus musculus	56-59
3940742-6	1986	The lungs of 44-week-old MRL/lpr mice given cyclosporin A showed few pathological findings except for minimal perivascular lymphocyte infiltration.	Cyclosporine	44-57	Fas (TNF receptor superfamily member 6)	Mus musculus	29-32
3154372-7	1986	The percentage of poor HLA-A,B matched recipients has increased for both CsA- and non-CsA-treated patients.	Cyclosporine	73-76	major histocompatibility complex, class I, A	Homo sapiens	23-28
3154372-7	1986	The percentage of poor HLA-A,B matched recipients has increased for both CsA- and non-CsA-treated patients.	Cyclosporine	86-89	major histocompatibility complex, class I, A	Homo sapiens	23-28
3154372-24	1986	By multivariate analysis, there is a significant relative risk of graft rejection associated with poor HLA-A,B matching in patients receiving CsA.	Cyclosporine	142-145	major histocompatibility complex, class I, A	Homo sapiens	103-108
3154457-5	1986	In centers where more than two-thirds of patients were treated with CsA at three months, a similar dichotomy between beneficially and nonbeneficially matched transplants was observed, confirming the view that CsA-treated patients benefit from good HLA-A,B and DR matching.	Cyclosporine	209-212	major histocompatibility complex, class I, A	Homo sapiens	248-255
2942335-5	1986	Cyclosporine was very effective at inhibiting the production of interleukin-2 (IL-2), a soluble lymphokine known to amplify cytotoxic T cell responses and was also capable of preventing IL-2 receptor expression on the precursor cytotoxic T lymphocyte.	Cyclosporine	0-12	interleukin 2	Homo sapiens	64-77
2942335-5	1986	Cyclosporine was very effective at inhibiting the production of interleukin-2 (IL-2), a soluble lymphokine known to amplify cytotoxic T cell responses and was also capable of preventing IL-2 receptor expression on the precursor cytotoxic T lymphocyte.	Cyclosporine	0-12	interleukin 2	Homo sapiens	79-83
3552407-0	1986	Renin-angiotensin system and glomerular prostaglandins in early nephrotoxicity of ciclosporin.	Cyclosporine	82-93	renin	Homo sapiens	0-5
2868869-2	1986	Difference spectroscopy studies indicated that CsA binds to cytochrome P-450 producing a type I spectral change.	Cyclosporine	47-50	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	60-76
3519028-13	1986	CSA administration was accompanied by a rise in plasma renin activity in animals treated with mannitol and without mannitol.	Cyclosporine	0-3	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	55-60
3484718-3	1986	In addition to blocking IL-2 release by specifically activated T-cell lines, CsA also affected the ability of irradiated spleen cells to present preprocessed antigen to T-cell lines.	Cyclosporine	77-80	interleukin 2	Homo sapiens	24-28
3484729-1	1986	Persistent anti-ovalbumin (OA) IgE antibody formation in the mouse was suppressed by oral administration of cyclosporin A (Cy A).	Cyclosporine	108-121	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	16-25
3484729-1	1986	Persistent anti-ovalbumin (OA) IgE antibody formation in the mouse was suppressed by oral administration of cyclosporin A (Cy A).	Cyclosporine	123-127	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	16-25
3090376-2	1986	In contrast, transplant patients treated with azathioprine or cyclosporine A have percentages of OKT 8 and Leu 7 positive PBL, similar to control persons (respectively 29 +/- 13, 33 +/- 10, 30 +/- 10 for the OKT 8+ cells and 8 +/- 7, 11 +/- 6 and 15 +/- 9 for the Leu 7+ cells).	Cyclosporine	62-76	beta-1,3-glucuronyltransferase 1	Homo sapiens	107-112
3484481-0	1986	Cyclosporine A, an in vitro calmodulin antagonist, induces nuclear lobulations in human T cell lymphocytes and monocytes.	Cyclosporine	0-14	calmodulin 1	Homo sapiens	28-38
3484481-2	1986	Cyclosporine A is an in vitro calmodulin antagonist.	Cyclosporine	0-14	calmodulin 1	Homo sapiens	30-40
3484481-3	1986	At the low concentrations required to inhibit calmodulin-dependent phosphodiesterase in vitro, cyclosporine A causes a dramatic alteration in the nuclear morphology of 23% of human peripheral blood mononuclear leukocytes in vitro without loss of viability.	Cyclosporine	95-109	calmodulin 1	Homo sapiens	46-56
3484481-10	1986	Cyclosporine A may be a useful noncytotoxic inhibitor of calmodulin-dependent systems that influence nuclear structure and function.	Cyclosporine	0-14	calmodulin 1	Homo sapiens	57-67
3090376-2	1986	In contrast, transplant patients treated with azathioprine or cyclosporine A have percentages of OKT 8 and Leu 7 positive PBL, similar to control persons (respectively 29 +/- 13, 33 +/- 10, 30 +/- 10 for the OKT 8+ cells and 8 +/- 7, 11 +/- 6 and 15 +/- 9 for the Leu 7+ cells).	Cyclosporine	62-76	beta-1,3-glucuronyltransferase 1	Homo sapiens	264-269
3939293-3	1985	Addition of cyclosporin A (CyA) to mixed lymphocyte cultures inhibits the development of allospecific cytotoxic activity and inhibits the development of IL-2 responsiveness.	Cyclosporine	12-25	interleukin 2	Homo sapiens	153-157
2948099-4	1986	Effective IFN-gamma production seems to require participation of plastic-adherent cells (presumably monocytes), while the addition of cyclosporin A (CyA) almost completely blocked generation of human IFN-gamma.	Cyclosporine	134-147	interferon gamma	Homo sapiens	200-209
3000160-0	1985	Systemic hypertension after cardiac transplantation: effect of cyclosporine on the renin-angiotensin-aldosterone system.	Cyclosporine	63-75	renin	Homo sapiens	83-88
2415587-5	1985	The fact that all the changes observed can be inhibited by low concentrations (I50 = 50 ng/ml) of cyclosporin A is further evidence that 1F5 is involved at an early stage of B cell activation.	Cyclosporine	98-111	CD59 molecule (CD59 blood group)	Homo sapiens	137-140
3833853-6	1985	Multiple doses of 60 mg/kg cyclosporin, given daily in the time interval between immunization and challenge, or on the last four days before challenge, inhibited the syn-DTH.	Cyclosporine	27-38	joined toes	Mus musculus	166-169
3833853-7	1985	Multiple injections of cyclosporin Before or close to the induction phase of the syn-DTH was ineffective, whereas single or multiple injections of cyclosporin close to the effector phase (the challenge time) markedly reduced the syn-DTH.	Cyclosporine	147-158	joined toes	Mus musculus	229-232
3833853-8	1985	Even a single injection of cyclosporin 24 h after the challenge efficiently reduced the 48-h syn-DTH.	Cyclosporine	27-38	joined toes	Mus musculus	93-96
3833853-10	1985	Similarly, the syn-DTH response of naive X-irradiated recipient mice injected with cyclosporin, failed to be reconstituted with primed T cells derived from X-irradiated mice immunized with concanavalin A-induced lymphoblasts.	Cyclosporine	83-94	joined toes	Mus musculus	15-18
3877052-2	1985	After treatment of Quin 2-loaded hepatocytes with cyclosporine, both the amplitude and duration of the vasopressin-induced rise in the cytosolic free Ca2+ are increased.	Cyclosporine	50-62	arginine vasopressin	Homo sapiens	103-114
3934806-0	1985	Pharmacodynamic assessment of the in vivo cyclosporine effect on interleukin-2 production by lymphocytes in kidney transplant recipients.	Cyclosporine	42-54	interleukin 2	Homo sapiens	65-78
3934806-2	1985	Experimental in vitro studies suggest that CsA causes reversible inhibition of T helper cell generation of interleukin-2 (IL-2).	Cyclosporine	43-46	interleukin 2	Homo sapiens	107-120
3934806-2	1985	Experimental in vitro studies suggest that CsA causes reversible inhibition of T helper cell generation of interleukin-2 (IL-2).	Cyclosporine	43-46	interleukin 2	Homo sapiens	122-126
3934806-3	1985	Therefore the present study examined the effect of CsA administered in vivo on the capacity of kidney transplant recipient lymphocytes to generate IL-2 after mitogen (phytohemagglutinin [PHA]) stimulation.	Cyclosporine	51-54	interleukin 2	Homo sapiens	147-151
3934806-5	1985	Peripheral blood lymphocytes (PBL) from CsA-Pred treated recipients displayed 40.6% inhibition (1.14 +/- 0.06 U/ml, n = 117, P less than 0.001) of IL-2 production compared with normal individuals (1.93 +/- 0.04 U/ml, n = 164).	Cyclosporine	40-43	interleukin 2	Homo sapiens	147-151
3934806-7	1985	The inhibition of IL-2 generation was observed in patients treated solely with CsA without supplemental corticosteroids (1.24 +/- 0.12 U/ml, n = 25; 35.8% inhibition, P less than 0.001).	Cyclosporine	79-82	interleukin 2	Homo sapiens	18-22
3934806-13	1985	These findings suggest not only that CsA treatment impairs the generation of IL-2 by patient lymphocytes, but also that failure to display this response is associated with a poor level of immunosuppression and allograft rejection.	Cyclosporine	37-40	interleukin 2	Homo sapiens	77-81
3934806-14	1985	These studies provide a foundation for serial analyses of IL-2 generation, in order to dissect its utility as a pharmacodynamic parameter to assess the level of CsA-induced immunosuppression.	Cyclosporine	161-164	interleukin 2	Homo sapiens	58-62
3877052-8	1985	The vasopressin-induced net efflux of Ca2+ from hepatocytes was 2-fold greater after treatment with 10 micrograms/ml cyclosporine for 10 min, but the lag time prior to the onset of Ca2+ efflux was not affected.	Cyclosporine	117-129	arginine vasopressin	Homo sapiens	4-15
2994206-3	1985	CsA inhibited dose-dependently the EBV-induced Hu IFN-gamma response, studied at the cellular level in human blood lymphocytes.	Cyclosporine	0-3	interferon gamma	Homo sapiens	50-59
4042335-1	1985	In this simple, precise, accurate, and specific isocratic liquid chromatographic procedure for determining cyclosporine, the cyclosporine is extracted from 1 mL of whole blood or from plasma, with 500 micrograms of cyclosporin D added per liter as internal standard, by elution from a Bond-ElutTM C18 extraction column with 300 microL of a mixture of ethanol and tetrahydrofuran.	Cyclosporine	125-137	Bardet-Biedl syndrome 9	Homo sapiens	297-300
3899932-4	1985	Interleukin 2, a primary target for the immunodepressive action of cyclosporine, appears to be of central importance in central nervous system defenses against cryptococci.	Cyclosporine	67-79	interleukin 2	Homo sapiens	0-13
2991164-0	1985	Prolactin-induced polyamine biosynthesis in spleen and thymus: specific inhibition by cyclosporine.	Cyclosporine	86-98	prolactin	Rattus norvegicus	0-9
3895641-0	1985	Effect of the immunosuppressive drugs cyclosporine and methylprednisolone on lymphokine responses in vitro.	Cyclosporine	38-50	interleukin 2	Homo sapiens	77-87
3899334-7	1985	Moreover, the immunosuppressive agent cyclosporin A specifically inhibits the induction of mRNA for IL2 and certain other lymphokines, without affecting the expression of the majority of other proteins.	Cyclosporine	38-51	interleukin 2	Homo sapiens	100-103
3892796-6	1985	In vitro, CsA caused a dose-dependent inhibition of accelerated (72-hr MLC) CTL generation following restimulation with donor spleen cells, which was quantitatively identical to that in parallel cultures using responder PBL from non-sensitized individuals.	Cyclosporine	10-13	modulator of VRAC current 1	Homo sapiens	71-74
2991164-1	1985	The induction of ornithine decarboxylase (ODC) in the rat spleen and thymus in response to prolactin shows a dose-dependent sensitivity to cyclosporine (CsA), a known immunosuppressive drug.	Cyclosporine	139-151	prolactin	Rattus norvegicus	91-100
2991164-1	1985	The induction of ornithine decarboxylase (ODC) in the rat spleen and thymus in response to prolactin shows a dose-dependent sensitivity to cyclosporine (CsA), a known immunosuppressive drug.	Cyclosporine	153-156	prolactin	Rattus norvegicus	91-100
2991164-2	1985	Marked inhibition of prolactin-stimulated ODC activity occurred at 0.12 mg CsA/kg body weight, and nearly total inhibition was detected at 1.2 mg CsA/kg, a dose comparable to that used to suppress organ rejection processes.	Cyclosporine	75-78	prolactin	Rattus norvegicus	21-30
2991164-3	1985	CsA blocked ODC induction in response to prolactin injection in both intact and hypophysectomized rats, suggestive of a direct effect of prolactin on spleen and thymus.	Cyclosporine	0-3	prolactin	Rattus norvegicus	41-50
2991164-3	1985	CsA blocked ODC induction in response to prolactin injection in both intact and hypophysectomized rats, suggestive of a direct effect of prolactin on spleen and thymus.	Cyclosporine	0-3	prolactin	Rattus norvegicus	137-146
2858508-11	1985	The addition of CsA at concentrations as low as 0.1 micrograms/ml inhibited not only IFN-gamma production by alloantigen-stimulated spleen cells, but also IFN-alpha/beta production by alloantigen-stimulated bone marrow cells.	Cyclosporine	16-19	interferon gamma	Mus musculus	85-94
3925762-2	1985	A trend towards increased allograft survival with better HLA-A,B, or DR matching in recipients of cadaver allografts treated with CsA was appreciated, but it fell short of statistical significance.	Cyclosporine	130-133	major histocompatibility complex, class I, A	Homo sapiens	57-64
2859508-4	1985	Haemostatic tests in cyclosporin-treated and azathioprine-treated patients and normal subjects (10 in each group) showed increased concentrations of factor VIII C, fibrinogen, antithrombin III, and protein C in the cyclosporin-treated patients.	Cyclosporine	21-32	fibrinogen beta chain	Homo sapiens	164-174
2984281-0	1985	Prolactin receptors on human T and B lymphocytes: antagonism of prolactin binding by cyclosporine.	Cyclosporine	85-97	prolactin	Homo sapiens	0-9
2984281-0	1985	Prolactin receptors on human T and B lymphocytes: antagonism of prolactin binding by cyclosporine.	Cyclosporine	85-97	prolactin	Homo sapiens	64-73
2984281-2	1985	Cyclosporine (CsA), an immunosuppressive cyclic endecapeptide utilized to prolong graft survival in human organ transplant patients, affects PRL binding to MNC.	Cyclosporine	0-12	prolactin	Homo sapiens	141-144
2984281-2	1985	Cyclosporine (CsA), an immunosuppressive cyclic endecapeptide utilized to prolong graft survival in human organ transplant patients, affects PRL binding to MNC.	Cyclosporine	14-17	prolactin	Homo sapiens	141-144
2984281-3	1985	At concentrations of CsA from 10(-10) through 10(-8) M, the amount of PRL bound to MNC markedly increased to ca.	Cyclosporine	21-24	prolactin	Homo sapiens	70-73
2984281-4	1985	400% of controls, whereas CsA concentrations of 10(-6) and 10(-5) M totally inhibited PRL binding to lymphocytes.	Cyclosporine	26-29	prolactin	Homo sapiens	86-89
2984281-5	1985	The ability of low concentrations of CsA to enhance PRL binding was temperature-dependent and did not occur when binding assays were conducted at 4 degrees C. PRL displaced [3H]CsA from lymphocytes with ca.	Cyclosporine	37-40	prolactin	Homo sapiens	52-55
2984281-5	1985	The ability of low concentrations of CsA to enhance PRL binding was temperature-dependent and did not occur when binding assays were conducted at 4 degrees C. PRL displaced [3H]CsA from lymphocytes with ca.	Cyclosporine	37-40	prolactin	Homo sapiens	159-162
2984281-5	1985	The ability of low concentrations of CsA to enhance PRL binding was temperature-dependent and did not occur when binding assays were conducted at 4 degrees C. PRL displaced [3H]CsA from lymphocytes with ca.	Cyclosporine	177-180	prolactin	Homo sapiens	159-162
3920317-8	1985	By the criteria tested, the immunosuppressive effect of L-ornithine is more selective than that of cyclosporine A, which was previously found to suppress not only the activation of cytotoxic activity but also proliferative responses and the production of the lymphokines IL 2 and IFN-gamma.	Cyclosporine	99-113	interleukin 2	Homo sapiens	271-275
3920317-8	1985	By the criteria tested, the immunosuppressive effect of L-ornithine is more selective than that of cyclosporine A, which was previously found to suppress not only the activation of cytotoxic activity but also proliferative responses and the production of the lymphokines IL 2 and IFN-gamma.	Cyclosporine	99-113	interferon gamma	Homo sapiens	280-289
3158107-0	1985	The differential inhibitory effects exerted by cyclosporine and hydrocortisone on the activation of human cytotoxic lymphocytes by recombinant interleukin-2 versus allospecific CTL.	Cyclosporine	47-59	interleukin 2	Homo sapiens	143-156
3885394-0	1985	Cyclosporin A binding to calmodulin: a possible site of action on T lymphocytes.	Cyclosporine	0-13	calmodulin 1	Homo sapiens	25-35
3885394-4	1985	Flow cytometry showed that the calmodulin inhibitors R24571 and W-7 competitively inhibited binding of cyclosporin A to cloned T lymphocytes.	Cyclosporine	103-116	calmodulin 1	Homo sapiens	31-41
3885394-5	1985	Cyclosporin A inhibited the calmodulin-dependent activation of phosphodiesterase in a dose-dependent manner.	Cyclosporine	0-13	calmodulin 1	Homo sapiens	28-38
3920796-0	1985	Mediation of the antiproliferative effect of cyclosporine on human lymphocytes by blockade of interleukin 2 biosynthesis.	Cyclosporine	45-57	interleukin 2	Homo sapiens	94-107
3920796-5	1985	In contrast, IL-2 receptor was expressed on the CsA-treated cells, and the antiproliferative influence of the drug was completely reversed by addition of highly purified human IL-2 to the CsA-treated cells.	Cyclosporine	48-51	interleukin 2	Homo sapiens	13-17
3920796-5	1985	In contrast, IL-2 receptor was expressed on the CsA-treated cells, and the antiproliferative influence of the drug was completely reversed by addition of highly purified human IL-2 to the CsA-treated cells.	Cyclosporine	188-191	interleukin 2	Homo sapiens	13-17
3920796-7	1985	This study suggests that CsA acts by inhibiting IL-2 production (via blockade of IL-2 gene expression) rather than by preventing the expression of the IL-2 receptor.	Cyclosporine	25-28	interleukin 2	Homo sapiens	48-52
3920796-7	1985	This study suggests that CsA acts by inhibiting IL-2 production (via blockade of IL-2 gene expression) rather than by preventing the expression of the IL-2 receptor.	Cyclosporine	25-28	interleukin 2	Homo sapiens	81-85
2857945-1	1985	In 68 newly diagnosed patients with insulin-dependent diabetes mellitus (IDDM) whose treatment included cyclosporin (CyA) the prevalence and mean titre of islet cell cytoplasmic antibodies (ICA) fell faster than they did in the 56 who received only insulin.	Cyclosporine	104-115	insulin	Homo sapiens	36-43
2857855-3	1985	In glomerulonephritis patients, but not in the other groups, cyclosporin was additive to the effect of transfusions and of HLA-A, B and HLA-Dr matching.	Cyclosporine	61-72	major histocompatibility complex, class I, A	Homo sapiens	123-128
3883934-2	1985	After stimulation by a low-sodium diet and furosemide, cyclosporine-treated patients demonstrated lower plasma renin activity when supine (1.9 +/- 0.3 v 7.8 +/- 1.4 ng/mL/hr) and after standing (3.0 +/- 0.7 v 12.2 +/- 1.5 ng/mL/hr).	Cyclosporine	55-67	renin	Homo sapiens	111-116
3883934-5	1985	These data suggest that cyclosporine causes suppression of plasma renin activity and a tubular insensitivity to aldosterone, both of which may impair potassium excretion.	Cyclosporine	24-36	renin	Homo sapiens	66-71
3918105-5	1985	These studies demonstrate that both signals are required for the appearance of IL 2 or IFN-gamma-specific transcripts and that the appearance of IL 2 and IFN-gamma RNA is coordinate with regard to a) the signals required for their production, b) the kinetics of their appearance, and c) the inhibition of their appearance by cyclosporin A.	Cyclosporine	325-338	interleukin 2	Homo sapiens	145-149
3918105-5	1985	These studies demonstrate that both signals are required for the appearance of IL 2 or IFN-gamma-specific transcripts and that the appearance of IL 2 and IFN-gamma RNA is coordinate with regard to a) the signals required for their production, b) the kinetics of their appearance, and c) the inhibition of their appearance by cyclosporin A.	Cyclosporine	325-338	interferon gamma	Homo sapiens	154-163
3970725-2	1985	From a consideration of the structures of those CsA metabolites identified so far, it seemed probable that the metabolism of CsA would occur at the hepatic cytochrome P-450 (cyt P-450) enzyme system.	Cyclosporine	48-51	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	156-172
3970725-2	1985	From a consideration of the structures of those CsA metabolites identified so far, it seemed probable that the metabolism of CsA would occur at the hepatic cytochrome P-450 (cyt P-450) enzyme system.	Cyclosporine	125-128	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	156-172
3928486-6	1985	Experiments with cyclosporin A suggest that lymphocytes contaminating the monocyte preparations can produce spontaneously sufficient amounts of IFN-gamma for maintenance of the DR antigens on monocytes.	Cyclosporine	17-30	interferon gamma	Homo sapiens	144-153
3974948-3	1985	In contrast, a large mass of grafted tissue was clearly detected in the third ventricle even 4 weeks after the transplantation in the cyclosporin A-treated group, and the grafted tissue was heavily stained with Thy-1.2 mouse monoclonal antibody.	Cyclosporine	134-147	thymus cell antigen 1, theta	Mus musculus	211-218
3920961-0	1985	Effects of treatment with azathioprine and cyclosporin A on interferon-gamma production by peripheral blood leukocytes of renal allograft recipients.	Cyclosporine	43-56	interferon gamma	Homo sapiens	60-76
3920961-2	1985	Both under immunosuppressive treatment with azathioprine and with cyclosporin A (CsA) the PBMC of these patients proved deficient for IFN-gamma production when compared to those of healthy controls.	Cyclosporine	66-79	interferon gamma	Homo sapiens	134-143
3920961-2	1985	Both under immunosuppressive treatment with azathioprine and with cyclosporin A (CsA) the PBMC of these patients proved deficient for IFN-gamma production when compared to those of healthy controls.	Cyclosporine	81-84	interferon gamma	Homo sapiens	134-143
3920961-3	1985	After conversion from conventional azathioprine to CsA medication the ConA-induced IFN-gamma production increased.	Cyclosporine	51-54	interferon gamma	Homo sapiens	83-92
3918874-1	1985	Cyclosporin A (CyA) strongly inhibited production of interleukin 3 (IL3) by normal mouse spleen cells and by the T lymphoma LBRM-33 clone 1A5 induced by alloantigens and by the lectins concanavalin A or phytohemagglutinin.	Cyclosporine	0-13	interleukin 3	Mus musculus	53-66
3918874-1	1985	Cyclosporin A (CyA) strongly inhibited production of interleukin 3 (IL3) by normal mouse spleen cells and by the T lymphoma LBRM-33 clone 1A5 induced by alloantigens and by the lectins concanavalin A or phytohemagglutinin.	Cyclosporine	0-13	interleukin 3	Mus musculus	68-71
2983414-4	1985	IL-2 significantly enhanced lymphoproliferation, cell-mediated cytotoxicity to CMV-infected fibroblasts (CMVF), natural killer cell activity, and the activity of cells capable of suppressing the response of fresh autologous cells to CMVFFx of cells derived from control and CSA-treated primary cultures.	Cyclosporine	274-277	interleukin 2	Homo sapiens	0-4
2857024-2	1985	Mean insulin dosage dropped from 46 +/- 5 U/day before cyclosporin treatment to 16 +/- 4 U/day by the 7th month.	Cyclosporine	55-66	insulin	Homo sapiens	5-12
3929574-7	1985	Close linkage between cytotoxicity and IL-2 secretion has been observed: induction of killing was consistently associated with IL-2 secretion and stimulation of both activities could be blocked by Cyclosporin A.	Cyclosporine	197-210	interleukin 2	Homo sapiens	39-43
18766902-6	1985	Interleukin 2 partially overcame the suppressive effect of CsA on the cell lines, and enhanced the stimulatory effects.	Cyclosporine	59-62	interleukin 2	Homo sapiens	0-13
3871829-1	1985	Erythroid-potentiating activity (EPA) was detected in culture medium conditioned by a human cancer cell line (KONT) that produces colony-stimulating activity (CSA), using erythroid colony formation in vitro.	Cyclosporine	159-162	TIMP metallopeptidase inhibitor 1	Homo sapiens	0-31
3155579-0	1985	Effect of interleukin 2 on the immunosuppressive action of cyclosporine.	Cyclosporine	59-71	interleukin 2	Homo sapiens	10-23
3881326-0	1985	Effect of cyclosporin-A on insulin secretion in vitro.	Cyclosporine	10-23	insulin	Homo sapiens	27-34
3155579-1	1985	The influence of exogenous interleukin 2 (IL-2) on the immunosuppressive effect of cyclosporine in the mixed lymphocyte response (MLR) was examined.	Cyclosporine	83-95	interleukin 2	Homo sapiens	42-46
3155579-2	1985	Results show that addition of exogenous IL-2 to a MLR containing graded doses of CsA (0.01-2.5 micrograms/ml) restored a normal proliferative response to alloantigens.	Cyclosporine	81-84	interleukin 2	Homo sapiens	40-44
3155579-3	1985	In contrast, the effect of exogenous IL-2 on the induction of cytotoxic lymphocytes in primary MLR in the presence of CsA was variable.	Cyclosporine	118-121	interleukin 2	Homo sapiens	37-41
3155579-5	1985	However, at a lower dose of CsA (0.1 microgram/ml) that routinely resulted in the total inhibition of cytotoxic T cell induction, addition of exogenous IL-2 resulted in significant levels of detectable cytotoxic T cell activity.	Cyclosporine	28-31	interleukin 2	Homo sapiens	152-156
3155579-11	1985	Thereafter addition of CsA-plus-IL-2 resulted in enhanced levels of cytotoxic T cell activity compared with cultures receiving CsA alone.	Cyclosporine	127-130	interleukin 2	Homo sapiens	32-36
3897885-0	1985	Renin-angiotensin-aldosterone system in cyclosporin A-treated renal allograft recipients.	Cyclosporine	40-53	renin	Homo sapiens	0-5
6603364-5	1983	Chicken IL2 binds specifically to thymocytes and activated T cells and its action upon T blast cells cannot be blocked by cyclosporin A.	Cyclosporine	122-135	interleukin 15	Gallus gallus	8-11
6334364-0	1984	Induction of interleukin 2 messenger RNA inhibited by cyclosporin A.	Cyclosporine	54-67	interleukin 2	Homo sapiens	13-26
6334364-1	1984	Cyclosporin A blocked production of the lymphokine interleukin 2 by activated T lymphocytes.	Cyclosporine	0-13	interleukin 2	Homo sapiens	51-64
6436374-3	1984	We have found that a pharmacologic level of CsA (10 ng/ml) blocks antigen- and lectin-driven interleukin 2 (IL 2) secretion without affecting cell proliferation.	Cyclosporine	44-47	interleukin 2	Homo sapiens	108-112
6436374-4	1984	In addition, one monoclonal hybridoma that is induced by concanavalin A to secrete colony stimulating factors (CSF) as well as IL 2 is concomitantly blocked by CsA for production of IL 2 and CSF.	Cyclosporine	160-163	interleukin 2	Homo sapiens	127-131
6436374-4	1984	In addition, one monoclonal hybridoma that is induced by concanavalin A to secrete colony stimulating factors (CSF) as well as IL 2 is concomitantly blocked by CsA for production of IL 2 and CSF.	Cyclosporine	160-163	interleukin 2	Homo sapiens	182-186
6436374-6	1984	We have shown that CsA blocks not only stimulation of lymphokine secretion but also ongoing IL 2 production, probably by interfering with the effective interaction of receptor and antigen.	Cyclosporine	19-22	interleukin 2	Homo sapiens	92-96
6436374-7	1984	Thus, blocking of IL 2 secretion from preactivated cells by CsA occurs by 1 to 2 hr, the time required to stop IL 2 production by removal of Ag/Lectin stimulator.	Cyclosporine	60-63	interleukin 2	Homo sapiens	18-22
6436374-7	1984	Thus, blocking of IL 2 secretion from preactivated cells by CsA occurs by 1 to 2 hr, the time required to stop IL 2 production by removal of Ag/Lectin stimulator.	Cyclosporine	60-63	interleukin 2	Homo sapiens	111-115
6239413-2	1984	In vitro CsA inhibits lymphoproliferation in response to allogeneic and mitogenic stimuli, presumably due to reversible suppression of T helper cell generation of interleukin-2.	Cyclosporine	9-12	interleukin 2	Homo sapiens	163-176
6334388-0	1984	Enhancement of natural killer cell activity by interferon and interleukin-2 in human large granular lymphocytes inhibited by cyclosporine.	Cyclosporine	125-137	interleukin 2	Homo sapiens	62-75
6732774-0	1984	Rapid elevation of rat serum prolactin concentration by cyclosporine, a novel immunosuppressive drug.	Cyclosporine	56-68	prolactin	Rattus norvegicus	29-38
6732774-1	1984	Within one hr of the administration of cyclosporine to rats, there was a 4-fold elevation in the serum prolactin concentration.	Cyclosporine	39-51	prolactin	Rattus norvegicus	103-112
6732774-2	1984	Doses of 0.12, 1.2, and 12 micrograms/100 g body weight cyclosporine significantly elevated the serum prolactin level.	Cyclosporine	56-68	prolactin	Rattus norvegicus	102-111
6732774-3	1984	Higher doses, 120 or 1200 micrograms/100 g body weight cyclosporine resulted in small but insignificant elevations of the serum prolactin concentration.	Cyclosporine	55-67	prolactin	Rattus norvegicus	128-137
6732774-4	1984	Bromocriptine, a dopamine agonist which inhibits prolactin release from the anterior pituitary, completely blocked the elevation in serum prolactin in response to cyclosporine alone.	Cyclosporine	163-175	prolactin	Rattus norvegicus	49-58
6732774-4	1984	Bromocriptine, a dopamine agonist which inhibits prolactin release from the anterior pituitary, completely blocked the elevation in serum prolactin in response to cyclosporine alone.	Cyclosporine	163-175	prolactin	Rattus norvegicus	138-147
6320765-5	1984	On the other hand, cyclosporine inhibited formyl-methionyl-leucyl-phenylalanine (FMLP)-directed chemotaxis by PAMs, and both FMLP and C5a stimulated chemotaxis by PMNs.	Cyclosporine	19-31	formyl peptide receptor 1	Homo sapiens	81-85
6320765-5	1984	On the other hand, cyclosporine inhibited formyl-methionyl-leucyl-phenylalanine (FMLP)-directed chemotaxis by PAMs, and both FMLP and C5a stimulated chemotaxis by PMNs.	Cyclosporine	19-31	complement C5a receptor 1	Homo sapiens	134-137
2984281-7	1985	CsA also did not alter the binding of a beta-receptor antagonist to MNC, again suggesting that CsA was specific in its antagonism of PRL binding.	Cyclosporine	95-98	prolactin	Homo sapiens	133-136
2984281-10	1985	Finally, PRL receptors were identified on purified populations of T and B lymphocytes isolated from human spleens, and CsA again inhibited PRL binding at concentrations of 10(-7) and 10(-6) M. The presence of PRL receptors on T and B lymphocytes suggests that PRL may be involved in the regulation of humoral and cell-mediated immunity, and that one effect of CsA on immune function may be its ability to inhibit the effects of PRL action on these lymphocytes.	Cyclosporine	119-122	prolactin	Homo sapiens	139-142
2984281-10	1985	Finally, PRL receptors were identified on purified populations of T and B lymphocytes isolated from human spleens, and CsA again inhibited PRL binding at concentrations of 10(-7) and 10(-6) M. The presence of PRL receptors on T and B lymphocytes suggests that PRL may be involved in the regulation of humoral and cell-mediated immunity, and that one effect of CsA on immune function may be its ability to inhibit the effects of PRL action on these lymphocytes.	Cyclosporine	119-122	prolactin	Homo sapiens	139-142
2984281-10	1985	Finally, PRL receptors were identified on purified populations of T and B lymphocytes isolated from human spleens, and CsA again inhibited PRL binding at concentrations of 10(-7) and 10(-6) M. The presence of PRL receptors on T and B lymphocytes suggests that PRL may be involved in the regulation of humoral and cell-mediated immunity, and that one effect of CsA on immune function may be its ability to inhibit the effects of PRL action on these lymphocytes.	Cyclosporine	119-122	prolactin	Homo sapiens	139-142
2984281-10	1985	Finally, PRL receptors were identified on purified populations of T and B lymphocytes isolated from human spleens, and CsA again inhibited PRL binding at concentrations of 10(-7) and 10(-6) M. The presence of PRL receptors on T and B lymphocytes suggests that PRL may be involved in the regulation of humoral and cell-mediated immunity, and that one effect of CsA on immune function may be its ability to inhibit the effects of PRL action on these lymphocytes.	Cyclosporine	119-122	prolactin	Homo sapiens	139-142
6237693-7	1984	The low levels of IL-2 production induced by PHA or PMA were more sensitive to CsA-mediated suppression than those induced by a combination of PHA and PMA (75% and 55% suppression, respectively).	Cyclosporine	79-82	interleukin 2	Homo sapiens	18-22
6237693-8	1984	CsA-mediated growth suppression could be overcome if the cultures were supplemented with appropriate amounts of exogenous IL-2.	Cyclosporine	0-3	interleukin 2	Homo sapiens	122-126
6237693-9	1984	We conclude from our data, that CsA in Sezary PBMs inhibits T cell growth indirectly as a consequence of suppression of IL-2 growth indirectly as a consequence of suppression of IL-2 production.	Cyclosporine	32-35	interleukin 2	Homo sapiens	120-124
6237693-9	1984	We conclude from our data, that CsA in Sezary PBMs inhibits T cell growth indirectly as a consequence of suppression of IL-2 growth indirectly as a consequence of suppression of IL-2 production.	Cyclosporine	32-35	interleukin 2	Homo sapiens	178-182
6435619-2	1984	The acquisition of tumoricidal properties by PEM challenged with macrophage activating factor (MAF) plus lipopolysaccharide (LPS) was inhibited in a dose-dependent fashion by CsA.	Cyclosporine	175-178	MAF bZIP transcription factor	Homo sapiens	95-98
6332315-0	1984	Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription.	Cyclosporine	0-13	interleukin 2	Homo sapiens	23-43
6610482-3	1984	With cyclosporin, concentrations of 1.0-100 micrograms/ml virtually abolished PHA-induced lymphocyte growth; as little as 0.01 microgram/ml decreased clonal growth by 48%.	Cyclosporine	5-16	lamin B receptor	Homo sapiens	78-81
6383922-3	1984	Islets cultured in the presence of the higher cyclosporin A concentration had impaired islet proinsulin biosynthesis and insulin release when challenged with high glucose concentration.	Cyclosporine	46-59	insulin	Homo sapiens	96-103
6331435-0	1984	Prolactin receptors on human lymphocytes and their modulation by cyclosporine.	Cyclosporine	65-77	prolactin	Homo sapiens	0-9
6331435-3	1984	The specific binding of [125I]prolactin to these cells can be selectively enhanced at certain concentrations and blocked by higher concentrations of cyclosporine , a known immunosuppressive agent which inhibits the mitogenesis of T-cells.	Cyclosporine	149-161	prolactin	Homo sapiens	30-39
6145646-0	1984	Cyclosporine inhibits prolactin induction of ornithine decarboxylase in rat tissues.	Cyclosporine	0-12	prolactin	Rattus norvegicus	22-31
6145646-1	1984	Cyclosporine (CyA), formerly cyclosporin A, significantly inhibited the ability of prolactin (PRL) to elevate ornithine decarboxylase (ODC) activity in a variety of rat tissues.	Cyclosporine	0-12	prolactin	Rattus norvegicus	83-92
6145646-1	1984	Cyclosporine (CyA), formerly cyclosporin A, significantly inhibited the ability of prolactin (PRL) to elevate ornithine decarboxylase (ODC) activity in a variety of rat tissues.	Cyclosporine	0-12	prolactin	Rattus norvegicus	94-97
6145646-1	1984	Cyclosporine (CyA), formerly cyclosporin A, significantly inhibited the ability of prolactin (PRL) to elevate ornithine decarboxylase (ODC) activity in a variety of rat tissues.	Cyclosporine	14-17	prolactin	Rattus norvegicus	83-92
6145646-1	1984	Cyclosporine (CyA), formerly cyclosporin A, significantly inhibited the ability of prolactin (PRL) to elevate ornithine decarboxylase (ODC) activity in a variety of rat tissues.	Cyclosporine	14-17	prolactin	Rattus norvegicus	94-97
6145646-1	1984	Cyclosporine (CyA), formerly cyclosporin A, significantly inhibited the ability of prolactin (PRL) to elevate ornithine decarboxylase (ODC) activity in a variety of rat tissues.	Cyclosporine	29-42	prolactin	Rattus norvegicus	83-92
6145646-1	1984	Cyclosporine (CyA), formerly cyclosporin A, significantly inhibited the ability of prolactin (PRL) to elevate ornithine decarboxylase (ODC) activity in a variety of rat tissues.	Cyclosporine	29-42	prolactin	Rattus norvegicus	94-97
6361123-4	1984	Cell fractionation studies demonstrated that cells expressing Mac-1 antigen produce CSA and are most likely to be mononuclear phagocytes.	Cyclosporine	84-87	integrin alpha M	Mus musculus	62-67
6361123-5	1984	The unusual proliferative capacity in vitro of splenic mononuclear phagocytes from motheaten mice probably results from the spontaneous production of CSA by Mac-1 antigen-positive cells.	Cyclosporine	150-153	integrin alpha M	Mus musculus	157-162
6349041-8	1983	There was a differential effect of cyclosporine treatment depending upon the genetic differences involved: a skin graft across an RT1.A (class I) difference was indefinitely prolonged, one across an RT1.B (class II) or RT1.AB difference was slightly prolonged (9 to 12 days and 12.5 to 16.5 days, respectively) and a graft across non-MHC differences was not affected.	Cyclosporine	35-47	RT1 class II, locus B	Rattus norvegicus	199-204
6406074-1	1983	The effect of cyclosporin A (CsA) on the production of gamma interferon (IFN gamma) versus IFN alpha/beta was studied using mouse and human lymphocytes and fibroblasts.	Cyclosporine	29-32	interferon gamma	Mus musculus	55-100
6406595-10	1983	In addition, T cells, even stimulated in the presence of CsA with these mitogens for 24 hr, were capable of responding to TCGF with the same grade of proliferation as did T cells stimulated with mitogen alone.	Cyclosporine	57-60	interleukin 2	Homo sapiens	122-126
6223754-5	1983	The effect of CsA on receptors for IL-2 was subsequently studied and it was found that the binding capacity of 125I-labeled IL-2 to lymphocytes was not altered by the presence of CsA.	Cyclosporine	14-17	interleukin 2	Homo sapiens	124-128
6406074-3	1983	The addition of CsA at concentrations as low as 0.1 microgram/ml completely inhibited (less than 10 U/ml) IFN gamma production in these cultures.	Cyclosporine	16-19	interferon gamma	Mus musculus	106-115
6406074-5	1983	The addition of CsA (0.1 microgram/ml) to these cultures also completely inhibited (less than 10 U/ml) IFN gamma production.	Cyclosporine	16-19	interferon gamma	Mus musculus	103-112
6406074-7	1983	IFN gamma production in SEA-stimulated mouse spleen cells was inhibited at 3 days of culture even when CsA was added at 24 or 48 hr postculture initiation.	Cyclosporine	103-106	interferon gamma	Mus musculus	0-9
6406074-8	1983	Thus, CsA inhibits IFN gamma production even when early events associated with lymphocyte activation have been allowed to take place.	Cyclosporine	6-9	interferon gamma	Mus musculus	19-28
6406074-11	1983	Thus, CsA inhibits the production of IFN gamma by T cells but appears to have no effect on the production of IFN alpha/beta by virus-infected cells or on the antiviral action of already produced IFN gamma and IFN alpha/beta.	Cyclosporine	6-9	interferon gamma	Mus musculus	37-46
6403360-6	1983	Finally, cyclosporin A, a potent and selective immunosuppressive drug for T cells, strongly inhibited the secretion of IFN-gamma as assayed at the cell level.	Cyclosporine	9-22	interferon gamma	Homo sapiens	119-128
6337088-3	1983	Addition of Cs A together with insoluble concanavalin A (iCon A) to LNC cultures resulted in suppressed lymphokine production, as assessed by measurement of migration inhibition factor (MIF), the generation of macrophage procoagulant activity (MPCA) and the release of lymphocyte-derived-macrophage chemotactic factor (LDCF).	Cyclosporine	12-16	macrophage migration inhibitory factor	Cavia porcellus	186-189
6337088-4	1983	Cs A also inhibited MIF and procoagulant production by sensitized peritoneal exudate cells in response to antigen, at the same concentrations which blocked lymphocyte transformation.	Cyclosporine	0-4	macrophage migration inhibitory factor	Cavia porcellus	20-23
6226616-7	1983	These data show that previously alloactivated continuously proliferating Interleukin 2-dependent human T-cell clones are fully susceptible to CsA-mediated inhibition of their function as well as their proliferation.	Cyclosporine	142-145	interleukin 2	Homo sapiens	73-86
6128567-0	1982	Effect of cyclosporin on renin-angiotensin-aldosterone system.	Cyclosporine	10-21	renin	Homo sapiens	25-30
6760389-8	1982	Nine out of 11 patients treated with CyA showed one or more increases in NAG excretion, but the number of such episodes did not differ between patients with CyA serum concentrations below 500 ng/ml and those with levels above 500 ng/ml.	Cyclosporine	37-40	N-acetyl-alpha-glucosaminidase	Homo sapiens	73-76
6978560-0	1982	Restoration of allogeneic responsiveness of lymphocytes from cyclosporin A-treated animals with interleukin 2.	Cyclosporine	61-74	interleukin 2	Homo sapiens	96-109
6459374-8	1982	Even at high doses of CsA (20 micrograms/ml), substantial levels of proliferation (50% of control response) and CML induction (60% of control response) were observed when the primed cells were exposed to secondary MLR supernatants containing TCGF activity.	Cyclosporine	22-25	interleukin 2	Homo sapiens	242-246
6459374-9	1982	It was concluded that inhibition of secondary mixed lymphocyte responses by CsA may be due in part to the inhibition of TCGF production rather than the inhibition of the effect of TCGF on mature cytotoxic T lymphocytes.	Cyclosporine	76-79	interleukin 2	Homo sapiens	120-124
6456149-0	1981	Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2.	Cyclosporine	0-13	interleukin 2	Homo sapiens	125-138
6173920-7	1981	Cyclosporin-A, a drug that abrogates activation of T cells by blocking their receptors for HLA-DR antigens, also rendered IL-2 producer T cells unresponsive to IL-1 and abrogated the production of IL-2 in AMLR and MLR.	Cyclosporine	0-13	interleukin 2	Homo sapiens	122-126
6173920-7	1981	Cyclosporin-A, a drug that abrogates activation of T cells by blocking their receptors for HLA-DR antigens, also rendered IL-2 producer T cells unresponsive to IL-1 and abrogated the production of IL-2 in AMLR and MLR.	Cyclosporine	0-13	interleukin 2	Homo sapiens	197-201
6456149-4	1981	While cyclosporin A did not interfere with the intracellular events required for the activation and subsequent clonal expansion of alloreactive T cells, the lack of interleukin 1 and interleukin 2 induced by cyclosporin A results in an inability of T responder cells to mount cytotoxic allograft responses in vitro.	Cyclosporine	208-221	interleukin 2	Homo sapiens	183-196
33949118-5	2021	In the present study, we observed that CsA suppressed the activation and expression of transcription factor EB (TFEB) by increasing the activation of mTOR, in turn promoting lysosomal dysfunction and autophagy flux blockade in tubular epithelial cells (TECs) in vivo and in vitro.	Cyclosporine	39-42	mechanistic target of rapamycin kinase	Homo sapiens	150-154
33974505-2	2021	In this study, we aimed to identify the association of CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms with CsA concentrations in patients with allogeneic hematopoietic cell transplantation (allo-HSCT) based on the route of administration.A total of 40 allo-HSCT recipients receiving CsA were genotyped for CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms.	Cyclosporine	123-126	nuclear receptor subfamily 1 group I member 2	Homo sapiens	100-103
33974505-2	2021	In this study, we aimed to identify the association of CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms with CsA concentrations in patients with allogeneic hematopoietic cell transplantation (allo-HSCT) based on the route of administration.A total of 40 allo-HSCT recipients receiving CsA were genotyped for CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms.	Cyclosporine	123-126	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	322-328
33974505-2	2021	In this study, we aimed to identify the association of CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms with CsA concentrations in patients with allogeneic hematopoietic cell transplantation (allo-HSCT) based on the route of administration.A total of 40 allo-HSCT recipients receiving CsA were genotyped for CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms.	Cyclosporine	123-126	ATP binding cassette subfamily B member 1	Homo sapiens	330-335
33974505-2	2021	In this study, we aimed to identify the association of CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms with CsA concentrations in patients with allogeneic hematopoietic cell transplantation (allo-HSCT) based on the route of administration.A total of 40 allo-HSCT recipients receiving CsA were genotyped for CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms.	Cyclosporine	123-126	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	344-349
33974505-2	2021	In this study, we aimed to identify the association of CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms with CsA concentrations in patients with allogeneic hematopoietic cell transplantation (allo-HSCT) based on the route of administration.A total of 40 allo-HSCT recipients receiving CsA were genotyped for CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms.	Cyclosporine	123-126	nuclear factor kappa B subunit 1	Homo sapiens	351-356
33974505-2	2021	In this study, we aimed to identify the association of CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms with CsA concentrations in patients with allogeneic hematopoietic cell transplantation (allo-HSCT) based on the route of administration.A total of 40 allo-HSCT recipients receiving CsA were genotyped for CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms.	Cyclosporine	123-126	cytochrome p450 oxidoreductase	Homo sapiens	358-361
33974505-2	2021	In this study, we aimed to identify the association of CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms with CsA concentrations in patients with allogeneic hematopoietic cell transplantation (allo-HSCT) based on the route of administration.A total of 40 allo-HSCT recipients receiving CsA were genotyped for CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms.	Cyclosporine	123-126	nuclear receptor subfamily 1 group I member 2	Homo sapiens	367-370
34021476-8	2021	Gene expression study of Cox-2 showed a drastically reduced expression with CsA treatment indicating Cox-2 involvement in the calcineurin-NFAT pathway.	Cyclosporine	76-79	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	25-30
34021476-8	2021	Gene expression study of Cox-2 showed a drastically reduced expression with CsA treatment indicating Cox-2 involvement in the calcineurin-NFAT pathway.	Cyclosporine	76-79	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	101-106
33991364-4	2021	Previous reports indicate increased systemic exposures of cyclosporine and sirolimus in patients receiving high-dose marine omega-3 FA supplements (3, 4) which could be related to reduced drug metabolism supported by the in vitro experimental observation of an inhibitory effect of omega-3 FAs on cytochrome P450 (CYP) 3A enzymes (5) expressed in the intestine and liver.	Cyclosporine	58-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	297-321
33993101-0	2021	Cyclosporin A impairs neurogenesis and cognitive abilities in brain development via the IFN-gamma-Shh-BDNF pathway.	Cyclosporine	0-13	interferon gamma	Homo sapiens	88-97
33993101-3	2021	Here, we found that the immunosuppressant cyclosporin A (CsA) decreased the number of BrdU+, BrdU+/DCX+, BrdU+/NeuN + cells in the hippocampus, impaired learning and memory and inhibited protein levels of the shh signaling pathway, including Shh, Smo and Gli1.	Cyclosporine	42-55	RNA binding fox-1 homolog 3	Homo sapiens	111-115
33993101-3	2021	Here, we found that the immunosuppressant cyclosporin A (CsA) decreased the number of BrdU+, BrdU+/DCX+, BrdU+/NeuN + cells in the hippocampus, impaired learning and memory and inhibited protein levels of the shh signaling pathway, including Shh, Smo and Gli1.	Cyclosporine	57-60	RNA binding fox-1 homolog 3	Homo sapiens	111-115
33975323-0	2021	Cyclosporine A Treatment of Proteinuria in a New Case of MAFB-Associated Glomerulopathy without Extrarenal Involvement: A Case Report.	Cyclosporine	0-14	MAF bZIP transcription factor B	Homo sapiens	57-61
7065147-3	1982	The present experiments were performed to determine whether CSA activated by epicardial bradykinin also mediate solely excitatory reflex responses in the dog.	Cyclosporine	60-63	kininogen 1	Canis lupus familiaris	88-98
7065147-5	1982	Activation of CSA with bradykinin (0.1--120 g/ml) elicited inhibitory responses in eight dogs, excitatory responses in four dogs, and biphasic responses in three dogs.	Cyclosporine	14-17	kininogen 1	Canis lupus familiaris	23-33
134044-4	1976	Further, we demonstrated that CSB is a hybrid consisting of approximately 40% CSA and 60% CSB and that CSC appears to be a polymer consisting essentially of glucuronic acid and N-acetylgalactosamine-6-sulfate.	Cyclosporine	78-81	ERCC excision repair 6, chromatin remodeling factor	Homo sapiens	30-33
33631201-6	2021	Although BLECs were still undergoing transcriptional changes over time, a targeted transcriptome analysis (TempO-Seq) indicated a time and concentration dependent activation of ATF4, XBP1, Nrf2 and p53 stress response pathways under CsA treatment.	Cyclosporine	233-236	NFE2 like bZIP transcription factor 2	Homo sapiens	189-193
33631201-6	2021	Although BLECs were still undergoing transcriptional changes over time, a targeted transcriptome analysis (TempO-Seq) indicated a time and concentration dependent activation of ATF4, XBP1, Nrf2 and p53 stress response pathways under CsA treatment.	Cyclosporine	233-236	tumor protein p53	Homo sapiens	198-201
34042216-6	2021	The cyclosporine actions appear to be a class rather than a drug effect because similar exacerbation of LPS nephrotoxicity was observed in rats treated with tacrolimus, another calcineurin inhibitor (CNI).	Cyclosporine	4-16	calcineurin binding protein 1	Rattus norvegicus	177-198
33974505-0	2021	Association of polymorphism of CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR with the concentration of cyclosporin a in allogeneic hematopoietic stem cell transplantation recipients.	Cyclosporine	106-119	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-37
33974505-0	2021	Association of polymorphism of CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR with the concentration of cyclosporin a in allogeneic hematopoietic stem cell transplantation recipients.	Cyclosporine	106-119	ATP binding cassette subfamily B member 1	Homo sapiens	39-44
33974505-0	2021	Association of polymorphism of CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR with the concentration of cyclosporin a in allogeneic hematopoietic stem cell transplantation recipients.	Cyclosporine	106-119	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	53-58
33974505-0	2021	Association of polymorphism of CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR with the concentration of cyclosporin a in allogeneic hematopoietic stem cell transplantation recipients.	Cyclosporine	106-119	nuclear factor kappa B subunit 1	Homo sapiens	60-65
33974505-0	2021	Association of polymorphism of CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR with the concentration of cyclosporin a in allogeneic hematopoietic stem cell transplantation recipients.	Cyclosporine	106-119	cytochrome p450 oxidoreductase	Homo sapiens	67-70
33974505-0	2021	Association of polymorphism of CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR with the concentration of cyclosporin a in allogeneic hematopoietic stem cell transplantation recipients.	Cyclosporine	106-119	nuclear receptor subfamily 1 group I member 2	Homo sapiens	76-79
33974505-2	2021	In this study, we aimed to identify the association of CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms with CsA concentrations in patients with allogeneic hematopoietic cell transplantation (allo-HSCT) based on the route of administration.A total of 40 allo-HSCT recipients receiving CsA were genotyped for CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms.	Cyclosporine	123-126	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	55-61
33974505-2	2021	In this study, we aimed to identify the association of CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms with CsA concentrations in patients with allogeneic hematopoietic cell transplantation (allo-HSCT) based on the route of administration.A total of 40 allo-HSCT recipients receiving CsA were genotyped for CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms.	Cyclosporine	123-126	ATP binding cassette subfamily B member 1	Homo sapiens	63-68
33974505-2	2021	In this study, we aimed to identify the association of CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms with CsA concentrations in patients with allogeneic hematopoietic cell transplantation (allo-HSCT) based on the route of administration.A total of 40 allo-HSCT recipients receiving CsA were genotyped for CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms.	Cyclosporine	123-126	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	77-82
33974505-2	2021	In this study, we aimed to identify the association of CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms with CsA concentrations in patients with allogeneic hematopoietic cell transplantation (allo-HSCT) based on the route of administration.A total of 40 allo-HSCT recipients receiving CsA were genotyped for CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms.	Cyclosporine	123-126	nuclear factor kappa B subunit 1	Homo sapiens	84-89
33974505-2	2021	In this study, we aimed to identify the association of CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms with CsA concentrations in patients with allogeneic hematopoietic cell transplantation (allo-HSCT) based on the route of administration.A total of 40 allo-HSCT recipients receiving CsA were genotyped for CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms.	Cyclosporine	123-126	cytochrome p450 oxidoreductase	Homo sapiens	91-94
33377278-12	2021	Angiotensin II antagonism alleviates CsA nephrotoxicity via the COX-2-dependent normalization of creatinine clearance and sodium excretion.	Cyclosporine	37-40	angiotensinogen	Rattus norvegicus	0-14
33716110-4	2021	In the first part of this study, we demonstrated in vitro that tacrolimus and cyclosporine were able to affect viability, inhibit leucocyte proliferation and suppress il2 expression in vitro.	Cyclosporine	78-90	interleukin 2	Oncorhynchus mykiss	167-170
33913796-8	2022	Methotrexate (aIRR 3.06 [2.31-4.4]; p = 0.000) and cyclosporine (aIRR 2.37 [1.05-5.35]; p = 0.0378) were associated with an increased risk for hypertransaminasemia when compared to anti-TNF-alpha agents.	Cyclosporine	51-63	tumor necrosis factor	Homo sapiens	186-195
33853687-7	2021	Notably, adding CsA to MSCs after IFNgamma pre-stimulation enhances MSC production of IDO.	Cyclosporine	16-19	interferon gamma	Homo sapiens	34-42
33853687-8	2021	Mechanistically, we identified that CsA reduces SOCS1 expression to facilitate enhanced IDO production in IFNgamma pre-stimulated MSCs.	Cyclosporine	36-39	interferon gamma	Homo sapiens	106-114
33853687-9	2021	Importantly, CsA exposure to IFNgamma pre-stimulated MSC before administration, significantly enhanced the potency of MSCs in a human relevant humanised mouse model of acute Graft versus Host Disease.	Cyclosporine	13-16	interferon gamma	Homo sapiens	29-37
33422553-12	2021	Further studies indicated that cyclosporine (10 muM), an inhibitor of calcineurin, could significantly diminish the effects of PF11 on TFEB nuclear translocation and ALP dysfunction in OGD-treated neurons.	Cyclosporine	31-43	transcription factor EB	Rattus norvegicus	135-139
33448057-6	2021	RESULTS: We found for the first time that ROS was responsible for the CsA-induced oxidative stress and TGF-beta1 expression in human primary gingival fibroblasts, as well as the GO of rats.	Cyclosporine	70-73	transforming growth factor beta 1	Homo sapiens	103-112
33448057-8	2021	CsA-induced oxidative stress, HO-1, TGF-beta1, and type II EMT were also rescued by antioxidants treatment.	Cyclosporine	0-3	transforming growth factor, beta 1	Rattus norvegicus	36-45
33540056-11	2021	These complexes were inhibited by CsA with Kn-93 or RIP3 siRNA pretreatment, which reduced brain edema and neurological deficits.	Cyclosporine	34-37	myosin phosphatase Rho interacting protein	Mus musculus	52-56
33349900-10	2021	RESULTS: Acute and subchronic treatment with the calcineurin inhibitor CsA disrupted PPI at a dose of 20 mg/kg.	Cyclosporine	71-74	calcineurin binding protein 1	Rattus norvegicus	49-70
34012969-10	2021	TIIA combined with CsA can alleviate lung apoptosis by regulating mitochondrial function through the PI3K/Akt/Bad pathway in obese rats.	Cyclosporine	19-22	AKT serine/threonine kinase 1	Rattus norvegicus	106-109
33716110-5	2021	In in vivo experiments, both doses of tacrolimus (0.5 and 1.5 mg/kg) and the lower dose of cyclosporine (20 mg/kg) significantly inhibited the expression of il2 in head kidney, three days post-injection.	Cyclosporine	91-103	interleukin 2	Oncorhynchus mykiss	157-160
33716110-6	2021	A higher dose of cyclosporine (40 mg/kg) was able to inhibit il2 expression for up to seven days post-injection.	Cyclosporine	17-29	interleukin 2	Oncorhynchus mykiss	61-64
33752661-14	2021	TIIA combined with CsA attenuated myocardial cell apoptosis by modulating mitochondrial function through the PI3K/Akt/Bad pathway in obese rats.	Cyclosporine	19-22	AKT serine/threonine kinase 1	Rattus norvegicus	114-117
33538721-1	2021	In an effort designed to discover superior inhibitors of cyclophilin D (CypD), we identified and screened members of a one-bead-one-compound (OBOC) library of cyclic peptoid analogues of cyclosporin A (CsA).	Cyclosporine	187-200	peptidylprolyl isomerase F	Homo sapiens	57-70
33538721-1	2021	In an effort designed to discover superior inhibitors of cyclophilin D (CypD), we identified and screened members of a one-bead-one-compound (OBOC) library of cyclic peptoid analogues of cyclosporin A (CsA).	Cyclosporine	187-200	peptidylprolyl isomerase F	Homo sapiens	72-76
33538721-1	2021	In an effort designed to discover superior inhibitors of cyclophilin D (CypD), we identified and screened members of a one-bead-one-compound (OBOC) library of cyclic peptoid analogues of cyclosporin A (CsA).	Cyclosporine	202-205	peptidylprolyl isomerase F	Homo sapiens	72-76
33606519-7	2021	This study, for the first time, reports the molecules like cyclosporine, calcitriol, and estradiol as candidate drugs with the binding ability to the host proteases, TMPRSS2, and cathepsin B/L.	Cyclosporine	59-71	transmembrane serine protease 2	Homo sapiens	166-173
33606519-11	2021	The molecular docking and MD simulation results showed strong and stable binding of cyclosporine A (CsA) with TMPRSS2 and CTSL genes.	Cyclosporine	84-98	transmembrane serine protease 2	Homo sapiens	110-117
33606519-11	2021	The molecular docking and MD simulation results showed strong and stable binding of cyclosporine A (CsA) with TMPRSS2 and CTSL genes.	Cyclosporine	84-98	cathepsin L	Homo sapiens	122-126
33606519-11	2021	The molecular docking and MD simulation results showed strong and stable binding of cyclosporine A (CsA) with TMPRSS2 and CTSL genes.	Cyclosporine	100-103	transmembrane serine protease 2	Homo sapiens	110-117
33606519-11	2021	The molecular docking and MD simulation results showed strong and stable binding of cyclosporine A (CsA) with TMPRSS2 and CTSL genes.	Cyclosporine	100-103	cathepsin L	Homo sapiens	122-126
33474856-8	2021	High total IgE may represent high disease activity, longer disease duration, high chance of responding to omalizumab treatment, quick relapse after stopping omalizumab, and lower chance of responding to cyclosporine.	Cyclosporine	203-215	immunoglobulin heavy constant epsilon	Homo sapiens	11-14
33474856-9	2021	Low IgE, in contrast, may suggest Type IIb autoimmune CSU, poor response to treatment with omalizumab and a better chance to benefits from cyclosporine treatment.	Cyclosporine	139-151	immunoglobulin heavy constant epsilon	Homo sapiens	4-7
33977232-11	2021	Treatment with cyclosporine A, an inhibitor of cyclophilin A, significantly attenuated apoptosis in macrophages.	Cyclosporine	15-29	peptidyl-prolyl cis-trans isomerase A	Oryctolagus cuniculus	47-60
33634990-0	2021	Cyclosporine modulates neutrophil functions via the SIRT6-HIF-1alpha-glycolysis axis to alleviate severe ulcerative colitis.	Cyclosporine	0-12	hypoxia inducible factor 1 subunit alpha	Homo sapiens	58-68
33634990-8	2021	We also observed that CsA-induced functional alternation of neutrophils was initiated through suppressing SIRT6 expression, which is responsible for expression of the downstream signaling molecules (e.g., HIF-1alpha, PFKFB3) and PDK4 ubiquitination, leading to fueling neutrophil glycolysis and TCA cycle.	Cyclosporine	22-25	hypoxia inducible factor 1 subunit alpha	Homo sapiens	205-215
33634990-8	2021	We also observed that CsA-induced functional alternation of neutrophils was initiated through suppressing SIRT6 expression, which is responsible for expression of the downstream signaling molecules (e.g., HIF-1alpha, PFKFB3) and PDK4 ubiquitination, leading to fueling neutrophil glycolysis and TCA cycle.	Cyclosporine	22-25	pyruvate dehydrogenase kinase 4	Homo sapiens	229-233
33634990-10	2021	CONCLUSIONS: The data reveal a novel mechanism of CsA in alleviating ASUC by promoting neutrophil HIF-1alpha expression and restricting excessive neutrophil activation in a SIRT6-HIF-1alpha-glycolysis axis, suggesting SIRT6 as a candidate target for maintaining mucosal homeostasis and treating intestinal inflammation.	Cyclosporine	50-53	hypoxia inducible factor 1 subunit alpha	Homo sapiens	98-108
33634990-10	2021	CONCLUSIONS: The data reveal a novel mechanism of CsA in alleviating ASUC by promoting neutrophil HIF-1alpha expression and restricting excessive neutrophil activation in a SIRT6-HIF-1alpha-glycolysis axis, suggesting SIRT6 as a candidate target for maintaining mucosal homeostasis and treating intestinal inflammation.	Cyclosporine	50-53	hypoxia inducible factor 1 subunit alpha	Homo sapiens	179-189
32794232-2	2021	The result revealed that CsA-stressed rats treated with captopril and extracts (ALE and ABE) had lowered ACE, arginase, AChE, PDE-5, ADA activities, and TBARS level, coupled with improved SOD and catalase activities compared with untreated CsA-stressed rats, which had reversed these biochemicals compared to normal rats.	Cyclosporine	25-28	angiotensin I converting enzyme	Rattus norvegicus	105-108
32794232-2	2021	The result revealed that CsA-stressed rats treated with captopril and extracts (ALE and ABE) had lowered ACE, arginase, AChE, PDE-5, ADA activities, and TBARS level, coupled with improved SOD and catalase activities compared with untreated CsA-stressed rats, which had reversed these biochemicals compared to normal rats.	Cyclosporine	25-28	catalase	Rattus norvegicus	196-204
33303698-2	2021	Inhibition of its modulator cyclophilin D (CypD) by cyclosporine A (CsA) reduces ischemia-reperfusion injury.	Cyclosporine	52-66	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	28-41
33303698-2	2021	Inhibition of its modulator cyclophilin D (CypD) by cyclosporine A (CsA) reduces ischemia-reperfusion injury.	Cyclosporine	52-66	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	43-47
33303698-2	2021	Inhibition of its modulator cyclophilin D (CypD) by cyclosporine A (CsA) reduces ischemia-reperfusion injury.	Cyclosporine	68-71	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	28-41
33303698-2	2021	Inhibition of its modulator cyclophilin D (CypD) by cyclosporine A (CsA) reduces ischemia-reperfusion injury.	Cyclosporine	68-71	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	43-47
33638630-0	2021	CD28 confers CD4+ T cells with resistance to cyclosporin A and tacrolimus but to different degrees.	Cyclosporine	45-58	CD4 molecule	Homo sapiens	13-16
33638630-7	2021	CSA or TAC was added at various concentrations, and the half-maximal inhibitory concentration on CD4+ T-cell proliferation was determined.	Cyclosporine	0-3	CD4 molecule	Homo sapiens	97-100
33638630-9	2021	RESULTS: Anti-CD28 mAb conferred CD4+ T cells with resistance to both CSA and TAC, and CD28"s effect on the latter was approximately twice that on the former.	Cyclosporine	70-73	CD4 molecule	Homo sapiens	33-36
33317956-9	2021	Treatment with prednisolone + theophylline + cyclosporin A inhibited IFN-gamma and TNF-alpha production by SA CD28null CD8+ T and NKT-like cells additively.	Cyclosporine	45-58	interferon gamma	Homo sapiens	69-78
33317956-9	2021	Treatment with prednisolone + theophylline + cyclosporin A inhibited IFN-gamma and TNF-alpha production by SA CD28null CD8+ T and NKT-like cells additively.	Cyclosporine	45-58	tumor necrosis factor	Homo sapiens	83-92
32810615-2	2021	As a substrate of cytochrome P450 3A enzyme (CYP3A) and P-glycoprotein (P-gp), the oral pharmacokinetics of CsA is susceptible to disease status and concomitant medications.	Cyclosporine	108-111	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	45-50
32810615-15	2021	CONCLUSIONS: DSS-induced colitis significantly altered oral CsA disposition through regulating intestinal and hepatic P-gp and CYP3A.	Cyclosporine	60-63	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	127-132
33501865-6	2021	Ovariectomy increased the Pcm myofiber CSA, which was exacerbated with the ATD administration.	Cyclosporine	39-42	protein-L-isoaspartate (D-aspartate) O-methyltransferase 1	Rattus norvegicus	26-29
33551621-0	2021	Transforming growth factor-beta profile in cyclosporine-A induced gingival enlargement in renal transplant patients.	Cyclosporine	43-57	tumor necrosis factor	Homo sapiens	0-31
33501865-10	2021	Estrogen actions, having a gonadal or extragonadal origin, influence importantly the CSA of the Pcm.	Cyclosporine	85-88	protein-L-isoaspartate (D-aspartate) O-methyltransferase 1	Rattus norvegicus	96-99
33569064-4	2020	We show that the combined treatment with high-dose intravenous cytomegalovirus-specific immunoglobulins (CMV-IVIG) after the switch to a mammalian target of rapamycin (mTOR)-inhibitor and cyclosporine A was a successful treatment alternative to direct antiviral treatment with high-dose ganciclovir and foscarnet.	Cyclosporine	188-202	mechanistic target of rapamycin kinase	Homo sapiens	168-172
33495413-16	2021	Additionally, from DrugBank database, cyclosporine may be effective for PPIF targeted therapy.	Cyclosporine	38-50	peptidylprolyl isomerase F	Homo sapiens	72-76
33492449-8	2021	RESULTS: FaDu cells pretreated with MRP1 inhibitors exhibited significantly higher radioactivity than those without inhibitor treatment (cyclosporine A: 6.91 +- 0.27, lapatinib: 10.03 +- 0.47, MK-571: 10.15 +- 0.44%dose/mg protein, p < 0.01).	Cyclosporine	137-151	ATP binding cassette subfamily C member 1	Homo sapiens	36-40
33505590-0	2021	Cyclosporine A Promotes Bone Remodeling in LPS-Related Inflammation via Inhibiting ROS/ERK Signaling: Studies In Vivo and In Vitro.	Cyclosporine	0-14	mitogen-activated protein kinase 1	Mus musculus	87-90
33498273-3	2021	CypD inhibitors, such as cyclosporin A (CsA) or NIM811, administered following TBI, are neuroprotective and quell neurological deficits.	Cyclosporine	25-38	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	0-4
33498273-3	2021	CypD inhibitors, such as cyclosporin A (CsA) or NIM811, administered following TBI, are neuroprotective and quell neurological deficits.	Cyclosporine	40-43	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	0-4
33498273-8	2021	The administration of CsA following experimental TBI in Ppif-/- mice improved cortical tissue sparing, highlighting the multiple cellular targets of CsA in the mitigation of TBI pathology.	Cyclosporine	22-25	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	56-60
33369415-0	2021	Potent and Specific Inhibition of NTCP-Mediated HBV/HDV Infection and Substrate Transporting by a Novel, Oral-Available Cyclosporine A Analogue.	Cyclosporine	120-134	solute carrier family 10 member 1	Homo sapiens	34-38
33505590-13	2021	CsA effectively enhanced bone remodeling and attenuated oxidative stress caused by LPS via inhibiting ROS/ERK signaling.	Cyclosporine	0-3	mitogen-activated protein kinase 1	Mus musculus	106-109
33390789-6	2021	Results: The ChSy-2 protein in the ChSy-2-/-group was below the detection threshold, which was accompanied a significant reduction in the pl-CSA level.	Cyclosporine	141-144	chondroitin sulfate synthase 3	Homo sapiens	13-19
33490716-1	2021	Purpose: To report long term results of two cases treated with topical cyclosporin A 1% for keratitis associated with autoimmune polyglandular syndrome (APS1).	Cyclosporine	71-84	autoimmune regulator	Homo sapiens	153-157
33490716-5	2021	Conclusions and Importance: Long-term topical CsA 1% offers a valuable option for treatment of APS1-related autoimmune keratitis.	Cyclosporine	46-49	autoimmune regulator	Homo sapiens	95-99
33052072-8	2021	Finally, these early events after 7 days of UBR5 knockdown culminated in significant reductions in muscle mass (-4.6%) and larger reductions in fiber CSA (-18.5%) after 30 days.	Cyclosporine	150-153	ubiquitin protein ligase E3 component n-recognin 5	Mus musculus	44-48
33220425-8	2021	In conclusion, we for the first time provided a physiological evidence of mPTP opening in lipid deposition, which could be directly induced by AA without Ca2+ and can be inhibited by cyclosporine A.	Cyclosporine	183-197	protein tyrosine phosphatase, receptor type, U	Mus musculus	74-78
33390789-6	2021	Results: The ChSy-2 protein in the ChSy-2-/-group was below the detection threshold, which was accompanied a significant reduction in the pl-CSA level.	Cyclosporine	141-144	chondroitin sulfate synthase 3	Homo sapiens	35-41
33240107-9	2020	Therefore, IFN-gamma and SCGF-beta might be novel predictive plasma biomarker, as well as potential therapeutic targets specific for adult CSA-AKI.	Cyclosporine	139-142	interferon gamma	Homo sapiens	11-20
32972988-6	2020	The patient had a difficult clinical course and was unable to tolerate standard AA therapy with cyclosporine A and eltrombopag, with complications attributed in part to the effect of cyclosporine A on NF-kappa B signaling.	Cyclosporine	183-197	nuclear factor kappa B subunit 1	Homo sapiens	201-211
32967779-2	2020	Typical CYP3A4-substrates including erythromycin, cyclosporin A (ca.1200 Da), ivermectin B1a and taxanes were applied successfully and regioselective metabolisms of these ligands were reconstituted faithfully on Template.	Cyclosporine	50-63	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	8-14
32666123-1	2020	PURPOSE: Drug-drug interaction (DDI) potentials of lusutrombopag, a thrombopoietin receptor agonist, on the activity of cytochrome P450 (CYP) 3A and of cyclosporine, which inhibits P-glycoprotein and breast cancer resistance protein, on lusutrombopag pharmacokinetics were assessed via clinical studies and physiologically based pharmacokinetic (PBPK) modeling.	Cyclosporine	152-164	MPL proto-oncogene, thrombopoietin receptor	Homo sapiens	68-91
32905741-3	2020	RESULTS: A significant increase was observed in CD2AP, ACTN4, podocin and also MMP9 and 2, cystatin C levels in the cyclosporine A group following treatment for four weeks, whereas a decrease was found in nephrin gene expression than the control group.	Cyclosporine	116-130	actinin alpha 4	Rattus norvegicus	55-60
32905741-3	2020	RESULTS: A significant increase was observed in CD2AP, ACTN4, podocin and also MMP9 and 2, cystatin C levels in the cyclosporine A group following treatment for four weeks, whereas a decrease was found in nephrin gene expression than the control group.	Cyclosporine	116-130	NPHS2 stomatin family member, podocin	Rattus norvegicus	62-69
31248333-3	2020	We present a case of a 41-year-old woman with a stable living-related kidney transplant maintained on an immunosuppressive regimen of cyclosporine, mycophenolate mofetil, and prednisone, who was subsequently diagnosed with a metastatic lobular breast carcinoma and papillary thyroid cancer and started palbociclib, a time-dependent CYP3A inhibitor.	Cyclosporine	134-146	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	332-337
32823017-0	2020	Corrigendum to "Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3" [Canc Lett 379 (2016) 124-133].	Cyclosporine	16-30	signal transducer and activator of transcription 3	Homo sapiens	116-122
32616594-9	2020	Importantly, CsA induced interferon regulatory factor 1 (IRF1), a pronounced type-III-interferon (IFNlambda) response and expression of antiviral genes.	Cyclosporine	13-16	interferon regulatory factor 1	Homo sapiens	25-55
32616594-9	2020	Importantly, CsA induced interferon regulatory factor 1 (IRF1), a pronounced type-III-interferon (IFNlambda) response and expression of antiviral genes.	Cyclosporine	13-16	interferon regulatory factor 1	Homo sapiens	57-61
32616594-10	2020	Down-regulation of IRF1 or IFNlambda increased MERS-CoV propagation in presence of CsA.	Cyclosporine	83-86	interferon regulatory factor 1	Homo sapiens	19-23
32090669-0	2020	PPAR gamma/TLR4/TGF-beta1 axis mediates the protection effect of erythropoietin on cyclosporin A-induced chronic nephropathy in rat.	Cyclosporine	83-96	toll-like receptor 4	Rattus norvegicus	11-15
32090669-0	2020	PPAR gamma/TLR4/TGF-beta1 axis mediates the protection effect of erythropoietin on cyclosporin A-induced chronic nephropathy in rat.	Cyclosporine	83-96	transforming growth factor, beta 1	Rattus norvegicus	16-25
33096599-8	2020	In contrast, CsA induced arteriolopathy, hypoperfusion, a reduction in the glomerular filtration rate, and downregulation of eNOS, angiotensinogen, and AT1R mRNA levels.	Cyclosporine	13-16	angiotensinogen	Rattus norvegicus	131-146
33102812-0	2020	Cyclosporine protects from intestinal epithelial injury by modulating butyrate uptake via upregulation of membrane monocarboxylate transporter 1 levels.	Cyclosporine	0-12	solute carrier family 16 member 1	Homo sapiens	115-144
33102812-4	2020	The present study was designed to elucidate the effects of cyclosporine on monocarboxylate transporter 1 (MCT1) regulation and butyrate uptake by IECs.	Cyclosporine	59-71	solute carrier family 16 member 1	Homo sapiens	75-104
33102812-4	2020	The present study was designed to elucidate the effects of cyclosporine on monocarboxylate transporter 1 (MCT1) regulation and butyrate uptake by IECs.	Cyclosporine	59-71	solute carrier family 16 member 1	Homo sapiens	106-110
33102812-9	2020	However, treatment with MCT1 inhibitor and the antibiotic cocktail negated the efficacy of cyclosporine, whereas TB supplementation restored its protective effect.	Cyclosporine	91-103	solute carrier family 16 member 1	Homo sapiens	24-28
33021322-0	2020	Itch Relief in Atopic Dermatitis: Comparison of Narrowband Ultraviolet B Radiation and Cyclosporine Treatment.	Cyclosporine	87-99	itchy E3 ubiquitin protein ligase	Homo sapiens	0-4
33102812-10	2020	Furthermore, cyclosporine upregulated MCT1 expression in the membrane and the AcH3 signal in IECs, while also inducing higher anti-inflammatory cytokine production compared to that in the vehicle-treated mice.	Cyclosporine	13-25	solute carrier family 16 member 1	Homo sapiens	38-42
33102812-11	2020	The transcription level of MCT1 mRNA in IECs and Caco-2 cells did not increase with cyclosporine treatment; however, cyclosporine treatment increased membrane MCT1 expression in these cells and uptake of butyrate derivative.	Cyclosporine	117-129	solute carrier family 16 member 1	Homo sapiens	27-31
33102812-11	2020	The transcription level of MCT1 mRNA in IECs and Caco-2 cells did not increase with cyclosporine treatment; however, cyclosporine treatment increased membrane MCT1 expression in these cells and uptake of butyrate derivative.	Cyclosporine	117-129	solute carrier family 16 member 1	Homo sapiens	159-163
33102812-12	2020	Conclusion: Cyclosporine treatment modulates butyrate uptake via the post-transcriptional upregulation of membrane MCT1 levels in IECs.	Cyclosporine	12-24	solute carrier family 16 member 1	Homo sapiens	115-119
33312408-6	2020	Incorporation of rifampicin, berberine, and monthly GCP into cyclosporine can enhance the immunosuppressive effect.	Cyclosporine	61-73	golgin B1	Homo sapiens	52-55
33046085-0	2020	Cyclosporin A protects JEG-3 cells against oxidative stress-induced apoptosis by inhibiting the p53 and JNK/p38 signaling pathways.	Cyclosporine	0-13	tumor protein p53	Homo sapiens	96-99
33076304-8	2020	Cell viability was significantly increased after adding vitamin C (VC) or cyclosporin A (CsA) individually to inhibit ROS and mPTP.	Cyclosporine	74-87	protein tyrosine phosphatase, receptor type, U	Mus musculus	126-130
33076304-8	2020	Cell viability was significantly increased after adding vitamin C (VC) or cyclosporin A (CsA) individually to inhibit ROS and mPTP.	Cyclosporine	89-92	protein tyrosine phosphatase, receptor type, U	Mus musculus	126-130
33046783-1	2020	Bisindolylpyrrole at 0.1 muM is cytoprotective in 2% FBS that is counteracted by cyclosporin-A (CsA), an inhibitor of cyclophilin-D (CypD).	Cyclosporine	81-94	peptidylprolyl isomerase F	Homo sapiens	118-131
33046783-1	2020	Bisindolylpyrrole at 0.1 muM is cytoprotective in 2% FBS that is counteracted by cyclosporin-A (CsA), an inhibitor of cyclophilin-D (CypD).	Cyclosporine	81-94	peptidylprolyl isomerase F	Homo sapiens	133-137
33046783-1	2020	Bisindolylpyrrole at 0.1 muM is cytoprotective in 2% FBS that is counteracted by cyclosporin-A (CsA), an inhibitor of cyclophilin-D (CypD).	Cyclosporine	96-99	peptidylprolyl isomerase F	Homo sapiens	118-131
33046783-1	2020	Bisindolylpyrrole at 0.1 muM is cytoprotective in 2% FBS that is counteracted by cyclosporin-A (CsA), an inhibitor of cyclophilin-D (CypD).	Cyclosporine	96-99	peptidylprolyl isomerase F	Homo sapiens	133-137
33046783-4	2020	Indeed, CsA-sensitive tPT-mediated apoptosis could be induced by bisindolylpyrrole at > 5 muM in HeLa cells cultured in 0.1% FBS, depending on CypD and VDAC1/2, as shown by siRNA knockdown experiments.	Cyclosporine	8-11	peptidylprolyl isomerase F	Homo sapiens	143-147
32739890-1	2020	This drug-drug interaction (DDI) study determined the effect of cyclosporine, an inhibitor of OATP1B3 and P-gp, on the pharmacokinetics (PK) of fevipiprant, an oral, highly selective, competitive antagonist of the prostaglandin D2 receptor 2 and a substrate of the two transporters.	Cyclosporine	64-76	solute carrier organic anion transporter family member 1B3	Homo sapiens	94-101
32682934-10	2020	The saturated binding of ciclosporin to erythrocytes, auto-inhibition induced by the inhibitory effects of ciclosporin on cytochrome P450 3A4/P-glycoprotein may have contributed to the nonlinearity.	Cyclosporine	25-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	122-141
32682934-10	2020	The saturated binding of ciclosporin to erythrocytes, auto-inhibition induced by the inhibitory effects of ciclosporin on cytochrome P450 3A4/P-glycoprotein may have contributed to the nonlinearity.	Cyclosporine	25-36	ATP binding cassette subfamily B member 1	Homo sapiens	142-156
32682934-10	2020	The saturated binding of ciclosporin to erythrocytes, auto-inhibition induced by the inhibitory effects of ciclosporin on cytochrome P450 3A4/P-glycoprotein may have contributed to the nonlinearity.	Cyclosporine	107-118	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	122-141
32682934-10	2020	The saturated binding of ciclosporin to erythrocytes, auto-inhibition induced by the inhibitory effects of ciclosporin on cytochrome P450 3A4/P-glycoprotein may have contributed to the nonlinearity.	Cyclosporine	107-118	ATP binding cassette subfamily B member 1	Homo sapiens	142-156
32449990-9	2020	Finally, silencing of galectin-8 in NIH3T3 cells abolished cyclosporine-induced fibronectin protein levels.	Cyclosporine	59-71	lectin, galactose binding, soluble 8	Mus musculus	22-32
32222391-13	2020	CONCLUSION: The study results suggest that in KTX metabolic transformations and transport, especially of cyclosporine, dependence on the genetic variability of CYP3A4, UGT1A9, and MDR1 may contribute to kidney damage.	Cyclosporine	105-117	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	160-166
32222391-13	2020	CONCLUSION: The study results suggest that in KTX metabolic transformations and transport, especially of cyclosporine, dependence on the genetic variability of CYP3A4, UGT1A9, and MDR1 may contribute to kidney damage.	Cyclosporine	105-117	ATP binding cassette subfamily B member 1	Homo sapiens	180-184
33061475-7	2020	Results: All tested CSAs exert substantial bactericidal activity against NDM-1-producing bacteria.	Cyclosporine	20-24	Beta-lactamase	Escherichia coli	73-78
33046085-15	2020	Promoting the activation of JNK and p38 impaired the protective effect of CsA on OS-induced trophoblast apoptosis.	Cyclosporine	74-77	mitogen-activated protein kinase 8	Homo sapiens	28-31
33046085-15	2020	Promoting the activation of JNK and p38 impaired the protective effect of CsA on OS-induced trophoblast apoptosis.	Cyclosporine	74-77	mitogen-activated protein kinase 1	Homo sapiens	36-39
33046085-16	2020	CONCLUSIONS: These results suggested that CsA protected trophoblast cells from OS-induced apoptosis via the inhibition of the p53 and JNK/p38 signaling pathways.	Cyclosporine	42-45	tumor protein p53	Homo sapiens	126-129
33046085-16	2020	CONCLUSIONS: These results suggested that CsA protected trophoblast cells from OS-induced apoptosis via the inhibition of the p53 and JNK/p38 signaling pathways.	Cyclosporine	42-45	mitogen-activated protein kinase 8	Homo sapiens	134-137
33046085-16	2020	CONCLUSIONS: These results suggested that CsA protected trophoblast cells from OS-induced apoptosis via the inhibition of the p53 and JNK/p38 signaling pathways.	Cyclosporine	42-45	mitogen-activated protein kinase 1	Homo sapiens	138-141
32866465-1	2020	The calcineurin inhibitor, cyclosporin A (CsA) is one of the most common immunosuppressive agents used in organ transplantation.	Cyclosporine	42-45	calcineurin binding protein 1	Mus musculus	4-25
33046085-0	2020	Cyclosporin A protects JEG-3 cells against oxidative stress-induced apoptosis by inhibiting the p53 and JNK/p38 signaling pathways.	Cyclosporine	0-13	mitogen-activated protein kinase 8	Homo sapiens	104-107
33046085-0	2020	Cyclosporin A protects JEG-3 cells against oxidative stress-induced apoptosis by inhibiting the p53 and JNK/p38 signaling pathways.	Cyclosporine	0-13	mitogen-activated protein kinase 1	Homo sapiens	108-111
33046085-13	2020	CsA also attenuated the activation of p53, decreased the expression of Bax and cleavage of PARP, and increased the expression of Bcl-2 and pro-caspase-3 in the JEG-3 treated with H2O2.	Cyclosporine	0-3	tumor protein p53	Homo sapiens	38-41
33046085-13	2020	CsA also attenuated the activation of p53, decreased the expression of Bax and cleavage of PARP, and increased the expression of Bcl-2 and pro-caspase-3 in the JEG-3 treated with H2O2.	Cyclosporine	0-3	BCL2 associated X, apoptosis regulator	Homo sapiens	71-74
33046085-13	2020	CsA also attenuated the activation of p53, decreased the expression of Bax and cleavage of PARP, and increased the expression of Bcl-2 and pro-caspase-3 in the JEG-3 treated with H2O2.	Cyclosporine	0-3	poly(ADP-ribose) polymerase 1	Homo sapiens	91-95
33046085-13	2020	CsA also attenuated the activation of p53, decreased the expression of Bax and cleavage of PARP, and increased the expression of Bcl-2 and pro-caspase-3 in the JEG-3 treated with H2O2.	Cyclosporine	0-3	BCL2 apoptosis regulator	Homo sapiens	129-134
33046085-13	2020	CsA also attenuated the activation of p53, decreased the expression of Bax and cleavage of PARP, and increased the expression of Bcl-2 and pro-caspase-3 in the JEG-3 treated with H2O2.	Cyclosporine	0-3	caspase 3	Homo sapiens	143-152
33046085-14	2020	Furthermore, CsA reduced the activation of JNK and P38 but had no significant effect on the activation of extracellular signal-regulated kinase 1/2 (ERK1/2) in the H2O2-treated JEG-3 cells.	Cyclosporine	13-16	mitogen-activated protein kinase 8	Homo sapiens	43-46
33046085-14	2020	Furthermore, CsA reduced the activation of JNK and P38 but had no significant effect on the activation of extracellular signal-regulated kinase 1/2 (ERK1/2) in the H2O2-treated JEG-3 cells.	Cyclosporine	13-16	mitogen-activated protein kinase 1	Homo sapiens	51-54
33041851-7	2020	ADP and cyclosporine A (CsA), which are known to increase Ca2+ buffering while maintaining a constant [mCa2+]ss, decreased the rate of Ca2+ efflux via the CHE, with a significantly greater decrease in the presence of ADP.	Cyclosporine	8-22	carbonic anhydrase 2	Mus musculus	58-61
32866465-3	2020	By using immunohistochemical and ELISA techniques, it was found that CsA administration causes a rapid activation of a disintegrin and metalloproteases-17 (ADAM-17), epidermal growth factor receptor (EGFR) and subsequent ERK1/2 phosphorylation in the liver and kidney of albino mice.	Cyclosporine	69-72	a disintegrin and metallopeptidase domain 17	Mus musculus	156-163
32866465-4	2020	Furthermore, this study presents mechanistic relevance of this signaling cascade involving reactive oxygen species (ROS)-mediated ADAM-17/EGFR/ERK1/2 activation as indicated by a clear reduction in ADAM-17 and EGFR activities as well as ERK1/2 phosphorylation when the animals pretreated with Polyethylene glycol-superoxide dismutase (PEG-SOD) before CsA administration.	Cyclosporine	351-354	a disintegrin and metallopeptidase domain 17	Mus musculus	130-137
32866465-5	2020	Collectively, our findings demonstrate that CsA has the ability to activate ADAM-17-mediated EGFR/ERK1/2 phosphorylation in the liver and kidney of albino mice in ROS-dependent manner.	Cyclosporine	44-47	a disintegrin and metallopeptidase domain 17	Mus musculus	76-83
33041851-7	2020	ADP and cyclosporine A (CsA), which are known to increase Ca2+ buffering while maintaining a constant [mCa2+]ss, decreased the rate of Ca2+ efflux via the CHE, with a significantly greater decrease in the presence of ADP.	Cyclosporine	8-22	carbonic anhydrase 2	Mus musculus	103-107
33041851-7	2020	ADP and cyclosporine A (CsA), which are known to increase Ca2+ buffering while maintaining a constant [mCa2+]ss, decreased the rate of Ca2+ efflux via the CHE, with a significantly greater decrease in the presence of ADP.	Cyclosporine	8-22	carbonic anhydrase 2	Mus musculus	104-107
33041851-7	2020	ADP and cyclosporine A (CsA), which are known to increase Ca2+ buffering while maintaining a constant [mCa2+]ss, decreased the rate of Ca2+ efflux via the CHE, with a significantly greater decrease in the presence of ADP.	Cyclosporine	24-27	carbonic anhydrase 2	Mus musculus	58-61
33041851-7	2020	ADP and cyclosporine A (CsA), which are known to increase Ca2+ buffering while maintaining a constant [mCa2+]ss, decreased the rate of Ca2+ efflux via the CHE, with a significantly greater decrease in the presence of ADP.	Cyclosporine	24-27	carbonic anhydrase 2	Mus musculus	103-107
32982390-7	2020	The effects of the adenylyl cyclase activator forskolin and the calcineurin inhibitor cyclosporin were determined.	Cyclosporine	86-97	calcineurin binding protein 1	Rattus norvegicus	64-85
32908164-6	2020	Focusing on human B cells (traditionally recognized as harder to assay than T cells), we show that single-capture CSA-Flow allows for isolation of highly-purified populations of both low-frequency (IL-10+; GM-CSF+) and high-frequency (TNF+) cytokine-defined B cells.	Cyclosporine	114-117	tumor necrosis factor	Homo sapiens	235-238
32618133-2	2020	Our approach relies on Phospholipase A 2 (PLA 2 ), which is overexpressed in the inflamed intestinal tissues, as the prodrug-activator to potentially release cyclosporine at the site of inflammation.	Cyclosporine	158-170	phospholipase A2 group IB	Homo sapiens	23-40
32618133-2	2020	Our approach relies on Phospholipase A 2 (PLA 2 ), which is overexpressed in the inflamed intestinal tissues, as the prodrug-activator to potentially release cyclosporine at the site of inflammation.	Cyclosporine	158-170	phospholipase A2 group IB	Homo sapiens	42-47
32280990-4	2020	The intensity of phospho-p130CAS was found to be dependent on LIUS stress level, and the p130CAS was phosphorylated after one-minute stimulation at CSA.	Cyclosporine	148-151	breast cancer anti-estrogen resistance 1	Mus musculus	25-32
32280990-4	2020	The intensity of phospho-p130CAS was found to be dependent on LIUS stress level, and the p130CAS was phosphorylated after one-minute stimulation at CSA.	Cyclosporine	148-151	breast cancer anti-estrogen resistance 1	Mus musculus	89-96
32529968-6	2020	The molecular mechanisms underlying the effects of CsA were explored, and it was found that CsA could inhibit the increase in CypA, p-Akt, NF-kappaB, and MMP-9 protein expression after middle cerebral artery occlusion, while Claudin-5 expression was decreased.	Cyclosporine	92-95	thymoma viral proto-oncogene 1	Mus musculus	134-137
32529968-6	2020	The molecular mechanisms underlying the effects of CsA were explored, and it was found that CsA could inhibit the increase in CypA, p-Akt, NF-kappaB, and MMP-9 protein expression after middle cerebral artery occlusion, while Claudin-5 expression was decreased.	Cyclosporine	92-95	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	139-148
32529968-7	2020	DISCUSSION: CsA showed potential as a neuroprotective drug for the treatment of ischemic stroke patients; besides interfering with the typical NF-kappaB signaling pathway, the Akt pathway may also be involved in the effects of CsA.	Cyclosporine	12-15	nuclear factor kappa B subunit 1	Homo sapiens	143-152
32529968-7	2020	DISCUSSION: CsA showed potential as a neuroprotective drug for the treatment of ischemic stroke patients; besides interfering with the typical NF-kappaB signaling pathway, the Akt pathway may also be involved in the effects of CsA.	Cyclosporine	12-15	AKT serine/threonine kinase 1	Homo sapiens	176-179
32529968-7	2020	DISCUSSION: CsA showed potential as a neuroprotective drug for the treatment of ischemic stroke patients; besides interfering with the typical NF-kappaB signaling pathway, the Akt pathway may also be involved in the effects of CsA.	Cyclosporine	227-230	AKT serine/threonine kinase 1	Homo sapiens	176-179
32189058-7	2020	PHDi and CsA differentially upregulated the expression of the lipid droplet-associated genes PLIN2, PLIN4 and HILPDA.	Cyclosporine	9-12	perilipin 2	Homo sapiens	93-98
32696520-6	2020	Cyclosporin A, a potent calcineurin inhibitor, suppresses nuclear retention of Nfatc1, abrogates hair follicle cycle delay, and promotes hair growth in Sirt7-/- mice.	Cyclosporine	0-13	calcineurin binding protein 1	Mus musculus	24-45
32696520-6	2020	Cyclosporin A, a potent calcineurin inhibitor, suppresses nuclear retention of Nfatc1, abrogates hair follicle cycle delay, and promotes hair growth in Sirt7-/- mice.	Cyclosporine	0-13	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	79-85
32439507-10	2020	CsA may inhibit T-helper 1 (Th1) cells and consequently IFNgamma production, causing a synergetic effect with Dex on virus reactivation.	Cyclosporine	0-3	interferon gamma	Homo sapiens	56-64
32187393-10	2020	Interestingly, cyclosporine A (CsA), a CypD inhibitor, significantly reversed the drop in MMP and the DNA damage, as well as ROS accumulation caused by T-2.	Cyclosporine	15-29	peptidylprolyl isomerase F	Homo sapiens	39-43
32187393-10	2020	Interestingly, cyclosporine A (CsA), a CypD inhibitor, significantly reversed the drop in MMP and the DNA damage, as well as ROS accumulation caused by T-2.	Cyclosporine	31-34	peptidylprolyl isomerase F	Homo sapiens	39-43
32331925-4	2020	We found that a total of 1697 differentially expressed genes (DEGs) and 21 differentially expressed proteins (DEPs) in CD4+ T cells between CsA & CS-resistant and -sensitive VKH patients.	Cyclosporine	140-143	CD4 molecule	Homo sapiens	119-122
32331925-5	2020	Ribosomal Protein S4, Y-Linked 1 (RPS4Y1) was verified to regulate the resistance of CD4+ T cells from male VKH patients to CsA & CS.	Cyclosporine	124-127	CD4 molecule	Homo sapiens	85-88
32471743-3	2020	METHODS: We first assessed the relative expression of microRNA-200a (miR-200a) in response to the CsA treatment using qRT-PCR.	Cyclosporine	98-101	microRNA 200a	Homo sapiens	54-67
32471743-3	2020	METHODS: We first assessed the relative expression of microRNA-200a (miR-200a) in response to the CsA treatment using qRT-PCR.	Cyclosporine	98-101	microRNA 200a	Homo sapiens	69-77
32471743-6	2020	RESULTS: The expression of miR-200a was dose-dependently downregulated following the CsA treatment.	Cyclosporine	85-88	microRNA 200a	Homo sapiens	27-35
32471743-7	2020	Luciferase reporter assay confirmed that ZEB2 was a direct downstream target regulated by miR-200a and ZEB2 was indeed increased after the administration of CsA.	Cyclosporine	157-160	microRNA 200a	Homo sapiens	90-98
32471743-9	2020	CONCLUSION: Our results showed that insufficient miR-200a in HGFs caused by CsA administration may lead to gingival enlargement mediated by the upregulation of ZEB2.	Cyclosporine	76-79	microRNA 200a	Homo sapiens	49-57
32471743-10	2020	This finding supported that CsA-induced EMT contributed to the adverse effect of using CsA and miR-200a may serve as an upstream target to prevent the overgrowth of the gingiva.	Cyclosporine	28-31	microRNA 200a	Homo sapiens	95-103
33089282-0	2020	[Effect of curcumin on TGF-beta1 /Smad3 pathway in rat gingival fibroblast treated with cyclosporine A].	Cyclosporine	88-102	transforming growth factor, beta 1	Rattus norvegicus	23-32
33089282-0	2020	[Effect of curcumin on TGF-beta1 /Smad3 pathway in rat gingival fibroblast treated with cyclosporine A].	Cyclosporine	88-102	SMAD family member 3	Rattus norvegicus	34-39
32278034-8	2020	When the ERK signaling inhibitor PD98095 was used, there was a similar result that mitophagy was reduced though in contrast with CsA the apoptosis rate was also decreased compared with NaAsO2 alone.	Cyclosporine	129-132	mitogen-activated protein kinase 1	Homo sapiens	9-12
32278034-10	2020	Thus the results with CsA indicate that the likely key biological event in NaAsO2 toxicity is at the level of the mitochondria leading to cytochrome c release and apoptosis.	Cyclosporine	22-25	cytochrome c, somatic	Homo sapiens	138-150
32278034-13	2020	When ERK signaling is inhibited by PD98095 both the levels of apoptosis and mitophagy are decreased compared with the response produced by NaAsO2 alone in comparison to the inhibition of mitophagy by CsA that reduced mitophagy but dramatically increased apoptosis in response.	Cyclosporine	200-203	mitogen-activated protein kinase 1	Homo sapiens	5-8
32774143-2	2020	Aim: This study aimed at investigating the effect of CsA and adalimumab on the profile of mRNAs and protein expression associated with transforming growth factor beta (TGFbeta) pathways in human keratinocyte (HaCaT) culture previously exposed to lipopolysaccharide (LPS).	Cyclosporine	53-56	tumor necrosis factor	Homo sapiens	135-166
32774143-12	2020	The anti-TNF drug seems to affect TGFbeta cascades to a greater extent than cyclosporin A.	Cyclosporine	76-89	tumor necrosis factor	Homo sapiens	9-12
33041851-7	2020	ADP and cyclosporine A (CsA), which are known to increase Ca2+ buffering while maintaining a constant [mCa2+]ss, decreased the rate of Ca2+ efflux via the CHE, with a significantly greater decrease in the presence of ADP.	Cyclosporine	24-27	carbonic anhydrase 2	Mus musculus	104-107
32569592-0	2020	Cyclosporine a induces testicular injury via mitochondrial apoptotic pathway by regulation of mir-34a and sirt-1 in male rats: The rescue effect of curcumin.	Cyclosporine	0-14	sirtuin 1	Rattus norvegicus	106-112
32569592-3	2020	The present study aimed to characterize the role of mir-34a/sirt-1 in CsA induced testicular injury alone or in combination with curcumin.	Cyclosporine	70-73	sirtuin 1	Rattus norvegicus	60-66
32569592-9	2020	In addition, exposure to CsA resulted in an increased expression of Bax, and a decreased expresion in that of Bcl-2, with a concomitant up-regulation of the Bax/Bcl-2, c-Caspase-3/p-Caspase-3 ratio and cytochrome c level.	Cyclosporine	25-28	BCL2, apoptosis regulator	Rattus norvegicus	110-115
32569592-9	2020	In addition, exposure to CsA resulted in an increased expression of Bax, and a decreased expresion in that of Bcl-2, with a concomitant up-regulation of the Bax/Bcl-2, c-Caspase-3/p-Caspase-3 ratio and cytochrome c level.	Cyclosporine	25-28	BCL2, apoptosis regulator	Rattus norvegicus	161-166
32569592-10	2020	Meanwhile, exposure to CsA increased the expression of mir-34a and decreased sirt-1 protein level in the testis tissue samples compared to the control group.	Cyclosporine	23-26	sirtuin 1	Rattus norvegicus	77-83
32339494-6	2020	The discoveries that cyclosporine blocks mitochondrial permeability transition via binding to cyclophilin D, and that cyclophilin D is an important component of F1FO ATP synthase, has heightened interest in the F1FO ATP synthase as a focal point for drug discovery, and we will discuss 2 plausible campaigns associated with disease indications.	Cyclosporine	21-33	peptidylprolyl isomerase F	Homo sapiens	94-107
32189058-7	2020	PHDi and CsA differentially upregulated the expression of the lipid droplet-associated genes PLIN2, PLIN4 and HILPDA.	Cyclosporine	9-12	hypoxia inducible lipid droplet associated	Homo sapiens	110-116
32454060-3	2020	The permeability transition strictly requires matrix Ca2+ and is favored by the matrix protein cyclophilin D, which mediates the inhibitory effects of cyclosporin A.	Cyclosporine	151-164	peptidylprolyl isomerase F	Homo sapiens	95-108
32162654-2	2020	Since the immunosuppressant cyclosporine-A produces pEMT in TECs and inhibits the peptidyl-prolyl isomerase (PPIase) activity of cyclophilin (Cyp) proteins, we hypothesized that cyclophilins could regulate TEC phenotype.	Cyclosporine	28-42	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	82-107
32162654-2	2020	Since the immunosuppressant cyclosporine-A produces pEMT in TECs and inhibits the peptidyl-prolyl isomerase (PPIase) activity of cyclophilin (Cyp) proteins, we hypothesized that cyclophilins could regulate TEC phenotype.	Cyclosporine	28-42	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	109-115
32676025-4	2020	After comprehensive assessment and stepwise exclusion of alternative causes, it was considered that inflammation resolution with etanercept administration has highly induced clearance of CsA, probably mediated by interleukin-2.	Cyclosporine	187-190	interleukin 2	Homo sapiens	213-226
32305124-7	2020	Baseline GLP-1 levels in cyclosporine-treated renal transplant patients were higher than in both tacrolimus-treated renal transplant patients (p = 0,016) and control groups (p < 0,001).	Cyclosporine	25-37	glucagon	Homo sapiens	9-14
32302594-10	2020	This effect was iNOS-dependent because pretreatment of a low dose of aminoguanidine (20 mg/kg) 15 min before the administration of a low dose of cyclosporine (1 mg/kg) reversed the proconvulsant action of sildenafil (40 mg/kg).	Cyclosporine	145-157	nitric oxide synthase 2, inducible	Mus musculus	16-20
32305124-8	2020	GLP-1 levels at the 30th minute were higher in tacrolimus-treated renal transplant patients when compared to the cyclosporine-treated renal transplant patients (p = 0,024).	Cyclosporine	113-125	glucagon	Homo sapiens	0-5
32305124-11	2020	GIP levels at 120th was lower in cyclosporine-treated renal transplant patients when compared to control group (p = 0,003).	Cyclosporine	33-45	gastric inhibitory polypeptide	Homo sapiens	0-3
31680236-7	2020	RESULTS: CsA suppressed the proliferation of hPDLSCs but enhanced osteogenic differentiation as determined by ALP and ARS staining and PCR of osteogenic transcripts.	Cyclosporine	9-12	alkaline phosphatase, placental	Homo sapiens	110-113
31680236-11	2020	CONCLUSION: CsA enhanced the osteogenic differentiation and reduced angiogenesis by blocking the ERK and p38/c-fos pathway in hPDLSCs.	Cyclosporine	12-15	mitogen-activated protein kinase 1	Homo sapiens	97-100
31680236-11	2020	CONCLUSION: CsA enhanced the osteogenic differentiation and reduced angiogenesis by blocking the ERK and p38/c-fos pathway in hPDLSCs.	Cyclosporine	12-15	mitogen-activated protein kinase 1	Homo sapiens	105-108
32708451-9	2020	We showed that the in-vitro inhibition of PPIA with ciclosporin A (CsA) resulted in downregulation of PPIA and fibronectin (FN1) expression and significantly reduced their secretion.	Cyclosporine	52-65	fibronectin 1	Homo sapiens	111-122
32708451-9	2020	We showed that the in-vitro inhibition of PPIA with ciclosporin A (CsA) resulted in downregulation of PPIA and fibronectin (FN1) expression and significantly reduced their secretion.	Cyclosporine	52-65	fibronectin 1	Homo sapiens	124-127
32708451-9	2020	We showed that the in-vitro inhibition of PPIA with ciclosporin A (CsA) resulted in downregulation of PPIA and fibronectin (FN1) expression and significantly reduced their secretion.	Cyclosporine	67-70	fibronectin 1	Homo sapiens	111-122
32708451-9	2020	We showed that the in-vitro inhibition of PPIA with ciclosporin A (CsA) resulted in downregulation of PPIA and fibronectin (FN1) expression and significantly reduced their secretion.	Cyclosporine	67-70	fibronectin 1	Homo sapiens	124-127
32305124-12	2020	CONCLUSION: These findings showed a temporally affected incretin hormones in renal transplant patients, a preserved GLP-1 response to an oral glucose load in renal transplant patients on cyclosporine and increased GLP -1 response to an oral glucose load in those on tacrolimus.	Cyclosporine	187-199	glucagon	Homo sapiens	116-121
32413063-5	2020	CSA demonstrated a significant negative correlation with IL-6 level (r = -0.28, p<0.	Cyclosporine	0-3	interleukin 6	Homo sapiens	57-61
32499781-7	2020	Cyclosporine A, tacrolimus and steroids dose-dependently inhibited IFN-gamma secretion, and reactivity was further reduced when calcineurin inhibitors were combined with steroids.	Cyclosporine	0-14	interferon gamma	Homo sapiens	67-76
32413063-7	2020	Sobel test and bootstrapping revealed a significant mediating role for trust between CSA and IL-6 level.	Cyclosporine	85-88	interleukin 6	Homo sapiens	93-97
32413063-10	2020	Trust played a mediating role between CSA and adulthood levels of IL-6.	Cyclosporine	38-41	interleukin 6	Homo sapiens	66-70
32040235-0	2020	Hydrogen-rich water alleviates cyclosporine A-induced nephrotoxicity via the Keap1/Nrf2 signaling pathway.	Cyclosporine	31-45	NFE2 like bZIP transcription factor 2	Rattus norvegicus	83-87
32083540-6	2020	POF was significantly associated with anti-Sm (p=0.0004), anti-RNP (p=0.02), anti-cardiolipin (p=0.0008), lupus anticoagulant (p=0.0002), treatment with cyclophosphamide (p=0.0001), azathioprine (p=0.0001), mycophenolate mofetil (p=0.0001), cyclosporine A (p=0.007).	Cyclosporine	241-255	POF1B actin binding protein	Homo sapiens	0-3
32440340-6	2020	The messenger RNA levels of clusterin, CysC, GSTpi and TIMP-1 also increased in RPTEC/TERT1 cells treated with cisplatin, cyclosporin, aristolochic acid I and gentamicin, indicating that drug-induced upregulation involves transcriptional activation.	Cyclosporine	122-133	TIMP metallopeptidase inhibitor 1	Homo sapiens	55-61
32821484-12	2020	In vitro CSA treatment of CD4+ cells inhibited MDR expression and proinflammatory cytokine production while increasing Foxp3.	Cyclosporine	9-12	CD4 molecule	Homo sapiens	26-29
31899361-7	2020	Mycophenolate mofetil and cyclosporin A inhibited re-epithelialization; AAT minimized the effect of cyclosporin A.	Cyclosporine	100-113	serpin family A member 1	Homo sapiens	72-75
32440340-5	2020	The protein levels of clusterin, CysC, GSTpi and TIMP-1 significantly increased in the conditioned media of RPTEC/TERT1 cells treated with cisplatin, cyclosporin, aristolochic acid I and gentamicin.	Cyclosporine	150-161	TIMP metallopeptidase inhibitor 1	Homo sapiens	49-55
30986119-4	2020	IL-6 and MMP-9 were significantly decreased in both groups at 12 weeks.Conclusions: Both nanoemulsion and conventional cyclosporin A improved ocular signs, symptoms, and conjunctival inflammation.	Cyclosporine	119-132	interleukin 6	Homo sapiens	0-4
31876430-5	2020	The cytokine profile in patient sera and the in vitro immunological studies indicate that MOC31PE induced an immunogenic response leading to T-cell activation; a response that was suppressed in patients treated with MOC31PE + CsA.Conclusions: The results reveal a promising clinical benefit of anti-EpCAM immunotoxin treatment in patients with advanced disease, an effect apparently explained by a previously unknown immunogenic effect of MOC31PE.	Cyclosporine	226-229	epithelial cell adhesion molecule	Homo sapiens	299-304
32094096-5	2020	There was also a significant association between the C/D cyclosporine ratio combined with voriconazole and the ABCB1 2677 G > T > A (rs2032582) genetic polymorphism (P = 0.05).	Cyclosporine	57-69	ATP binding cassette subfamily B member 1	Homo sapiens	111-116
32094096-9	2020	Results suggest that the ABCB1 2677 G > T > A genetic polymorphism plays a role in this interaction with cyclosporine related nephrotoxicity.	Cyclosporine	105-117	ATP binding cassette subfamily B member 1	Homo sapiens	25-30
31932642-10	2020	Meanwhile, CsA treatment significantly reduced serum IL-1beta, TNF-alpha, and IL-17 levels (P &lt; 0.01), decreased the seizure scores and prolonged the latency to seizure (P &lt; 0.01).	Cyclosporine	11-14	interleukin 1 beta	Rattus norvegicus	53-61
31932642-10	2020	Meanwhile, CsA treatment significantly reduced serum IL-1beta, TNF-alpha, and IL-17 levels (P &lt; 0.01), decreased the seizure scores and prolonged the latency to seizure (P &lt; 0.01).	Cyclosporine	11-14	tumor necrosis factor	Rattus norvegicus	63-72
31140111-7	2020	To study the drug-screening platform, NTCP-expressing cells were treated with cyclosporin A, an NTCP inhibitor, and ICG, and examined using a multimode detection platform.	Cyclosporine	78-91	solute carrier family 10 member 1	Homo sapiens	38-42
32183695-5	2020	Interestingly, the calcineurin inhibitor cyclosporine A is known to stimulate prolyl hydroxylase activity, resulting in HIF-1 alpha destabilization and may alter Bc responses directly.	Cyclosporine	41-55	hypoxia inducible factor 1 subunit alpha	Homo sapiens	120-131
32108135-0	2020	Nontoxic concentration of ochratoxin A decreases the dosage of cyclosporine A to induce chronic nephropathy model via autophagy mediated by toll-like receptor 4.	Cyclosporine	63-77	toll-like receptor 4	Mus musculus	140-160
32298299-0	2020	Apocynin and catalase prevent hypertension and kidney injury in Cyclosporine A-induced nephrotoxicity in rats.	Cyclosporine	64-78	catalase	Rattus norvegicus	0-21
32298299-3	2020	This study investigated the effect of apocynin, an NADPH oxidase inhibitor and catalase, an H2O2 scavenger on Cyclosporine A (CsA) nephrotoxicity in Wistar-Kyoto rats.	Cyclosporine	110-124	catalase	Rattus norvegicus	79-87
32298299-3	2020	This study investigated the effect of apocynin, an NADPH oxidase inhibitor and catalase, an H2O2 scavenger on Cyclosporine A (CsA) nephrotoxicity in Wistar-Kyoto rats.	Cyclosporine	126-129	catalase	Rattus norvegicus	79-87
32298299-11	2020	Treatment of CsA rats with apocynin, catalase, and their combination decreased blood pressure to near control values (all P<0.05).	Cyclosporine	13-16	catalase	Rattus norvegicus	37-45
32298299-13	2020	Treatment of CsA rats with apocynin, catalase, and their combination prevented hypertension and restored renal functional parameters and tissue Nox4 expression in this model.	Cyclosporine	13-16	catalase	Rattus norvegicus	37-45
32162881-8	2020	Moreover, frequent TDM monitoring as well as CYP3A4/CYP3A5/MDR1 genotyping were given so as to tailor the oral dosage of cyclosporine individually and prevent the adverse reaction between cyclosporine and posaconazole.	Cyclosporine	121-133	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-51
32162881-8	2020	Moreover, frequent TDM monitoring as well as CYP3A4/CYP3A5/MDR1 genotyping were given so as to tailor the oral dosage of cyclosporine individually and prevent the adverse reaction between cyclosporine and posaconazole.	Cyclosporine	121-133	ATP binding cassette subfamily B member 1	Homo sapiens	59-63
32162881-9	2020	RESULTS: The patient carried CYP3A5*3 GG genotype and the concentration of cyclosporine remained steady in the period of conversion and combination of cyclosporine and posaconazole.	Cyclosporine	75-87	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	29-35
32162881-9	2020	RESULTS: The patient carried CYP3A5*3 GG genotype and the concentration of cyclosporine remained steady in the period of conversion and combination of cyclosporine and posaconazole.	Cyclosporine	151-163	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	29-35
32108135-9	2020	These toxic effects induced by OTA and CsA could be reversed by knockdown of TLR4 and autophagy inhibitor 3-methyladenine in vitro.	Cyclosporine	39-42	toll-like receptor 4	Mus musculus	77-81
32108135-10	2020	Furthermore, the renal injury and autophagy induced by OTA and CsA could be attenuated in TLR4-/- mice.	Cyclosporine	63-66	toll-like receptor 4	Mus musculus	90-94
32108135-11	2020	It suggested that a chronic nephropathy model had been successfully developed by administration of nontoxic concentration of OTA and low dosage of CsA via TLR4-mediated autophagy.	Cyclosporine	147-150	toll-like receptor 4	Mus musculus	155-159
31916747-11	2020	Likewise, CaMKII inhibitor KN93 or calcineurin inhibitor cyclosporine A also inhibited SERT function; however, an additive effect with immepip was not seen.	Cyclosporine	57-71	solute carrier family 6 member 4	Rattus norvegicus	87-91
32148443-7	2020	In addition, the administration of cyclosporin A or shikonin decreased the expression of cytotoxic molecules and costimulatory CD80 and CD86 on CD8+ cells.	Cyclosporine	35-48	CD80 antigen	Mus musculus	127-131
32148443-7	2020	In addition, the administration of cyclosporin A or shikonin decreased the expression of cytotoxic molecules and costimulatory CD80 and CD86 on CD8+ cells.	Cyclosporine	35-48	CD86 antigen	Mus musculus	136-140
32049108-8	2020	At 15 days, less bone formation was observed in the CSDs filled with DBB, a smaller volume of mineralized tissue was observed in the CSDs filled with HA/TCP, and the expression levels of BMP2 and osteocalcin were lower in the CCP group compared to the CTR group.	Cyclosporine	226-229	bone gamma-carboxyglutamate protein	Rattus norvegicus	196-207
32049108-9	2020	The use of cyclosporine impaired bone repair in CSD, and this effect can be partially explained by the suppression of BMP2 and osteocalcin expression.	Cyclosporine	11-23	bone gamma-carboxyglutamate protein	Rattus norvegicus	127-138
31944097-3	2020	Topologically, the 4-c Na(I) ion directs in situ assembly of 4-c SDCA linker and 6-c Co(II) ion, resulting in the formation of 4,4,6-c net with a topology named as smm3.	Cyclosporine	61-69	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	85-91
31944097-3	2020	Topologically, the 4-c Na(I) ion directs in situ assembly of 4-c SDCA linker and 6-c Co(II) ion, resulting in the formation of 4,4,6-c net with a topology named as smm3.	Cyclosporine	127-134	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	85-91
31654209-5	2020	In the presence of Ca2+, AGM also activated the Bcl-2 family protein Bax, a key factor in inducing MOMP, which is inactivated by CsA.	Cyclosporine	129-132	BCL2, apoptosis regulator	Rattus norvegicus	48-53
31810121-6	2020	In fact, urinary transferrin pre-emptively correlates with the subsequent renal damage in animal models in which risk has been induced by drugs and toxins affecting the renal tubules (i.e. cisplatin, gentamicin and uranyl nitrate); whereas transferrin shows no relation with the risk posed by a drug affecting renal hemodynamics (i.e. cyclosporine A).	Cyclosporine	335-349	transferrin	Homo sapiens	17-28
31441337-6	2020	Data Synthesis: Studies demonstrate pharmacokinetic differences between cyclosporine and tacrolimus, particularly with regard to inhibition of 2 hepatic transporters: P-glycoprotein and organic anion transporting polypeptide (OATP).	Cyclosporine	72-84	ATP binding cassette subfamily B member 1	Homo sapiens	167-181
31820434-0	2020	PXR haplotype clusters will affect the pharmacokinetics of ciclosporin in Chinese renal transplant recipients.	Cyclosporine	59-70	nuclear receptor subfamily 1 group I member 2	Homo sapiens	0-3
31820434-2	2020	The aim of this study was to evaluate the influence of PXR haplotype clusters on ciclosporin concentration in Chinese renal transplant recipients during the early stage after transplantation.	Cyclosporine	81-92	nuclear receptor subfamily 1 group I member 2	Homo sapiens	55-58
31722821-3	2020	The accuracy and reliability of the proposed mass spectrometric NTCP activity assay have been validated with known HBV inhibitors including cyclosporine A (CsA) and pre-S1 peptide (PreS/2-48Myr or myrcludex B analog) that suppress the entry of HBV into hepatocytes by targeting NTCP.	Cyclosporine	140-154	solute carrier family 10 member 1	Homo sapiens	64-68
31722821-3	2020	The accuracy and reliability of the proposed mass spectrometric NTCP activity assay have been validated with known HBV inhibitors including cyclosporine A (CsA) and pre-S1 peptide (PreS/2-48Myr or myrcludex B analog) that suppress the entry of HBV into hepatocytes by targeting NTCP.	Cyclosporine	156-159	solute carrier family 10 member 1	Homo sapiens	64-68
31722821-4	2020	For the inhibitor screening assay, NTCP-overexpressing HepG2 or Huh-7 cells are treated with either a combination of TCA and an inhibitor (CsA or PreS/2-48Myr) or d4-TCA alone to serve as a reference.	Cyclosporine	139-142	solute carrier family 10 member 1	Homo sapiens	35-39
31963361-9	2020	The administration of cyclosporine A was followed by down-regulation of other genes: COL7A1, the transmembrane receptors ITGB2 and ITGB4, and the basement membrane constituents LAMA2 and LAMB1.	Cyclosporine	22-36	integrin subunit beta 2	Homo sapiens	121-126
32321312-0	2020	Cyclosporin A suppresses Porphyromonas gingivalis lipopolysaccharide induced matrix metalloproteinases activities in the co-culture of human gingival fibroblasts and monocyte cell line THP-1.	Cyclosporine	0-13	GLI family zinc finger 2	Homo sapiens	185-190
32321312-2	2020	In this study, we explore the pathway through which CsA suppressed the Porphyromonas gingivalis lipopolysaccharide (P.g-LPS)-induced increase in matrix metalloproteinase (MMP) activities in co-cultured human gingival fibroblasts (HGFs) and THP-1 monocytes.	Cyclosporine	52-55	GLI family zinc finger 2	Homo sapiens	240-245
32321312-5	2020	Taken together, CsA in the presence of P.g-LPS might suppress MMP activities by blocking the CyPA/CD147 interaction that results in the inhibition of ERK1/2 and NF-kappaB signaling by interfering with the phosphorylation of ERK1/2 and IkappaB.	Cyclosporine	16-19	mitogen-activated protein kinase 3	Homo sapiens	150-156
32321312-5	2020	Taken together, CsA in the presence of P.g-LPS might suppress MMP activities by blocking the CyPA/CD147 interaction that results in the inhibition of ERK1/2 and NF-kappaB signaling by interfering with the phosphorylation of ERK1/2 and IkappaB.	Cyclosporine	16-19	mitogen-activated protein kinase 3	Homo sapiens	224-230
31198949-5	2020	Results demonstrated that chlorpromazine, cyclosporin A and ANIT induced (miR-21-3p, -21-5p, -22-3p, -27a-5p, -1260b, -34a-5p and -98-5p) and repressed (-122-5p, -192-5p, -30c-5p, -424-5p and -16-5p) specific miRNAs in sandwich-cultured upcyte hepatocytes.	Cyclosporine	42-55	microRNA 181a-1	Homo sapiens	74-83
31601784-8	2019	Furthermore, cyclosporine A (CsA), which is a well-recognized modulator in regulating the opening of the mitochondrial permeability transition pore (mPTP) by interacting with Cyclophilin D (CypD), could significantly decrease cell apoptosis and partially restore VDAC expression in mutant yolk sac erythrocytes.	Cyclosporine	13-27	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	175-188
31884421-4	2019	In human macrophages MTB infection-induced programmed necrosis and apoptosis were largely attenuated by CypD inhibition (by cyclosporin A), silencing and knockout, but intensified with ectopic CypD overexpression.	Cyclosporine	124-137	peptidylprolyl isomerase F	Homo sapiens	104-108
31861674-5	2019	PEP correlated with cytosolic calcium and NFAT activity, together with transcriptional up-regulation of canonical targets PTGS2 and IL6 that was fully prevented by CsA pre-treatment.	Cyclosporine	164-167	prostaglandin-endoperoxide synthase 2	Homo sapiens	122-127
31861674-5	2019	PEP correlated with cytosolic calcium and NFAT activity, together with transcriptional up-regulation of canonical targets PTGS2 and IL6 that was fully prevented by CsA pre-treatment.	Cyclosporine	164-167	interleukin 6	Homo sapiens	132-135
31696965-11	2019	Notably, inactivation of the Cul3-Klhl18 ligase and calcineurin inhibitors FK506 and cyclosporine A that are known immunosuppressant drugs repressed light-induced photoreceptor damage, suggesting potential therapeutic targets.	Cyclosporine	85-99	kelch-like 18	Mus musculus	34-40
31613143-10	2019	Cyclosporine also caused upregulations of the vasoconstrictive renin-angiotensin system components in renal (angiotensin-converting enzyme) and aortic (angiotensin II type 1 receptor) tissues.	Cyclosporine	0-12	angiotensin I converting enzyme	Rattus norvegicus	109-138
31613143-10	2019	Cyclosporine also caused upregulations of the vasoconstrictive renin-angiotensin system components in renal (angiotensin-converting enzyme) and aortic (angiotensin II type 1 receptor) tissues.	Cyclosporine	0-12	angiotensin II receptor, type 1b	Rattus norvegicus	152-182
31090467-3	2019	To address these challenges, we developed a novel SNEDDS co-loaded with DTX and cyclosporine A (CsA) to achieve effective inhibition of P-gp efflux and P450 enzyme metabolization, improving oral bioavailability of DTX.	Cyclosporine	80-94	ATP binding cassette subfamily B member 1	Homo sapiens	136-140
31090467-3	2019	To address these challenges, we developed a novel SNEDDS co-loaded with DTX and cyclosporine A (CsA) to achieve effective inhibition of P-gp efflux and P450 enzyme metabolization, improving oral bioavailability of DTX.	Cyclosporine	96-99	ATP binding cassette subfamily B member 1	Homo sapiens	136-140
32084649-0	2019	The role of PPAR gamma agonists - rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 in experimental cyclosporine A hepatotoxicity.	Cyclosporine	105-119	peroxisome proliferator activated receptor gamma	Homo sapiens	12-22
32084649-3	2019	The aim of the study was to evaluate hepatoprotective activity of peroxisome-proliferator-activated receptors gamma (PPARgamma) ligands: rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 (PGDJ2) on CsA-induced hepatotoxicity in experimental animals.	Cyclosporine	203-206	peroxisome proliferator activated receptor gamma	Homo sapiens	117-126
32084649-7	2019	CsA induced liver injury was evidenced by increased serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin.	Cyclosporine	0-3	solute carrier family 17 member 5	Homo sapiens	68-94
32084649-7	2019	CsA induced liver injury was evidenced by increased serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin.	Cyclosporine	0-3	solute carrier family 17 member 5	Homo sapiens	96-99
32084649-10	2019	The biochemical and morphological changes induced by CsA were limited by administration of both PPARgamma agonist - rosiglitazone and PGDJ2.	Cyclosporine	53-56	peroxisome proliferator activated receptor gamma	Homo sapiens	96-105
32084649-11	2019	Our biochemical and liver histopathological examination indicate that both PPARgamma agonists may play an important role in protecting against CsA-induced hepatotoxicity.	Cyclosporine	143-146	peroxisome proliferator activated receptor gamma	Homo sapiens	75-84
31622690-11	2019	Overall, these results indicate that the IN-Z-CSA/CS0.2% nanocomposites can improve oral bioavailability of insulin and are a promising delivery system for insulin or other peptide/protein drugs.	Cyclosporine	46-49	insulin	Homo sapiens	108-115
31622690-11	2019	Overall, these results indicate that the IN-Z-CSA/CS0.2% nanocomposites can improve oral bioavailability of insulin and are a promising delivery system for insulin or other peptide/protein drugs.	Cyclosporine	46-49	insulin	Homo sapiens	156-163
31445706-0	2019	Cyclosporin A protects trophoblasts from H2O2-induced oxidative injury via FAK-Src pathway.	Cyclosporine	0-13	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	79-82
31445706-11	2019	CsA decreased ROS and MDA production, increased SOD and CAT activities, and restored the MMP of H2O2 treated JEG-3 cells.	Cyclosporine	0-3	catalase	Homo sapiens	56-59
31445706-12	2019	CsA administration suppressed H2O2-induced reduction of FAK and Src phosphorylation.	Cyclosporine	0-3	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	64-67
31445706-13	2019	Blocking the activation of FAK or Src attenuated the protective effect of CsA on JEG-3 cells in H2O2-induced oxidative injury.	Cyclosporine	74-77	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	34-37
31445706-14	2019	CsA protects JEG-3 cells from H2O2-induced oxidative injury, and the FAK/Src signaling pathway plays an important role in this process.	Cyclosporine	0-3	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	73-76
31619674-4	2019	Mechanistically, T cell receptor stimulation induces cyclosporine A-sensitive histone modifications and P300/CBP acetylase recruitment at these elements in activated CD4+ T cells.	Cyclosporine	53-67	CD4 molecule	Homo sapiens	166-169
31473379-4	2019	Ni(OH)2 NCs@MnO2 NSs CSA modified glassy carbon electrode (GCE) exhibited two satisfying sensitivities of 467.1 and 1249.9 muA mM-1 cm-2 within the two linear ranges of 0.02-16.30 muM and 18.30-118.58 muM, respectively.	Cyclosporine	21-24	latexin	Homo sapiens	180-183
31473379-4	2019	Ni(OH)2 NCs@MnO2 NSs CSA modified glassy carbon electrode (GCE) exhibited two satisfying sensitivities of 467.1 and 1249.9 muA mM-1 cm-2 within the two linear ranges of 0.02-16.30 muM and 18.30-118.58 muM, respectively.	Cyclosporine	21-24	latexin	Homo sapiens	201-204
31833229-6	2020	Additionally, an opener (atractyloside) or an inhibitor (cyclosporine A) of mPTP was used in the animal model before sevoflurane postconditioning.	Cyclosporine	57-71	protein tyrosine phosphatase, receptor type, U	Mus musculus	76-80
31070990-5	2020	Furthermore, we demonstrated that CsA with autoantigenic peptides modulates dendritic cells (DCs) to become immature IL-10hiCD40lo DCs.	Cyclosporine	34-37	interleukin 10	Mus musculus	117-122
30291799-3	2019	The investigation of the PTP took an unexpected turn after the discovery that cyclophilin D (the target of the PTP inhibitory effect of cyclosporin A) binds to FO F1 (F)-ATP synthase, thus inhibiting its catalytic activity by about 30%.	Cyclosporine	136-149	peptidylprolyl isomerase F	Homo sapiens	78-91
31631469-6	2019	The expression of TNF-alpha was downregulated during therapy, IL23A was upregulated during CsA treatment, while the expression of IFN-gamma and IL17 were higher after 42 days and lower after 84 days compared to 0 days of CsA treatment.	Cyclosporine	221-224	tumor necrosis factor	Homo sapiens	18-27
31631469-6	2019	The expression of TNF-alpha was downregulated during therapy, IL23A was upregulated during CsA treatment, while the expression of IFN-gamma and IL17 were higher after 42 days and lower after 84 days compared to 0 days of CsA treatment.	Cyclosporine	221-224	interferon gamma	Homo sapiens	130-139
31427432-0	2019	Enhanced and Persistent Inhibition of Organic Cation Transporter 1 (OCT1) Activity by Preincubation of Cyclosporine A.	Cyclosporine	103-117	solute carrier family 22 member 1	Homo sapiens	38-66
31427432-0	2019	Enhanced and Persistent Inhibition of Organic Cation Transporter 1 (OCT1) Activity by Preincubation of Cyclosporine A.	Cyclosporine	103-117	solute carrier family 22 member 1	Homo sapiens	68-72
31427432-3	2019	Following a 30 minute preincubation with an inhibitor, approximately 50-fold higher inhibition potency was observed for Cyclosporine (CsA) against OCT1-mediated uptake of metformin as compared to coincubation, with IC50 values of 0.43 +- 0.12 and 21.6 +- 4.5 muM, respectively.	Cyclosporine	120-132	solute carrier family 22 member 1	Homo sapiens	147-151
31495071-4	2019	5-ALA/SFC significantly inhibited apoptosis in CsA-treated mProx24 cells with increases in heme oxygenase (HO)-1, nuclear factor E2-related factor 2 (Nrf2), and p38, and Erk-1/2 phosphorylation.	Cyclosporine	47-50	nuclear factor, erythroid derived 2, like 2	Mus musculus	114-148
31495071-4	2019	5-ALA/SFC significantly inhibited apoptosis in CsA-treated mProx24 cells with increases in heme oxygenase (HO)-1, nuclear factor E2-related factor 2 (Nrf2), and p38, and Erk-1/2 phosphorylation.	Cyclosporine	47-50	nuclear factor, erythroid derived 2, like 2	Mus musculus	150-154
30943799-7	2019	Elovl-6 expression was increased in the liver, but decreased in the kidney in CsA group compared to control, which omega-3 FA treatment also reversed.	Cyclosporine	78-81	ELOVL fatty acid elongase 6	Rattus norvegicus	0-7
30943799-8	2019	CONCLUSIONS: Omega-3 FA supplementation decreased erythrocyte membrane oleic acid content by modulating SCD-1 and Elovl-6 expression in the kidney and liver of CsA-induced rats.	Cyclosporine	160-163	ELOVL fatty acid elongase 6	Rattus norvegicus	114-121
31601784-8	2019	Furthermore, cyclosporine A (CsA), which is a well-recognized modulator in regulating the opening of the mitochondrial permeability transition pore (mPTP) by interacting with Cyclophilin D (CypD), could significantly decrease cell apoptosis and partially restore VDAC expression in mutant yolk sac erythrocytes.	Cyclosporine	13-27	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	190-194
31601784-8	2019	Furthermore, cyclosporine A (CsA), which is a well-recognized modulator in regulating the opening of the mitochondrial permeability transition pore (mPTP) by interacting with Cyclophilin D (CypD), could significantly decrease cell apoptosis and partially restore VDAC expression in mutant yolk sac erythrocytes.	Cyclosporine	29-32	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	175-188
31601784-8	2019	Furthermore, cyclosporine A (CsA), which is a well-recognized modulator in regulating the opening of the mitochondrial permeability transition pore (mPTP) by interacting with Cyclophilin D (CypD), could significantly decrease cell apoptosis and partially restore VDAC expression in mutant yolk sac erythrocytes.	Cyclosporine	29-32	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	190-194
31518496-5	2019	OBJECTIVES: The present study examines this hypothesis by evaluating renal function and histology with regard to the potential role of U-II and its antagonist, palosuran, in the pathogenesis of CsA-induced nephrotoxicity in rats.	Cyclosporine	194-197	urotensin 2	Rattus norvegicus	135-139
31518496-10	2019	Plasma U-II levels decreased in the CsA-treated rats.	Cyclosporine	36-39	urotensin 2	Rattus norvegicus	7-11
31518496-11	2019	Cyclosporine-A treatment resulted in a marked deterioration in renal histology and an increase in the expression of U-II protein in the kidneys.	Cyclosporine	0-14	urotensin 2	Rattus norvegicus	116-120
31518496-14	2019	CONCLUSIONS: Cyclosporine-A-induced renal impairment was accompanied by an increase in U-II expression in kidneys and a contrary decrease in systemic U-II levels.	Cyclosporine	13-27	urotensin 2	Rattus norvegicus	87-91
31518496-14	2019	CONCLUSIONS: Cyclosporine-A-induced renal impairment was accompanied by an increase in U-II expression in kidneys and a contrary decrease in systemic U-II levels.	Cyclosporine	13-27	urotensin 2	Rattus norvegicus	150-154
31500337-3	2019	Opening of the pore can be delayed by cyclosporin A (CsA), possibly by inhibiting cyclophilin D (Cyp D), a key regulator of mPTP.	Cyclosporine	38-51	peptidylprolyl isomerase F	Homo sapiens	82-95
31779379-4	2019	The Cs ovens for ELISE (IPP Garching) and SPIDER (Consorzio RFX) are based on the evaporation of liquid Cs from a reservoir located at one end of the oven, which is controlled by the reservoir temperature.	Cyclosporine	4-6	regulatory factor X1	Homo sapiens	60-63
31568485-6	2019	Mechanistically, we show that down-regulation of CRT results in mitochondrial Ca2+ overload and induction of mitochondria permeability transition pore (mPTP)-dependent cell death, which can be significantly rescued by the mPTP inhibitor, Cyclosporin A (CsA).	Cyclosporine	238-251	calreticulin	Homo sapiens	49-52
31568485-6	2019	Mechanistically, we show that down-regulation of CRT results in mitochondrial Ca2+ overload and induction of mitochondria permeability transition pore (mPTP)-dependent cell death, which can be significantly rescued by the mPTP inhibitor, Cyclosporin A (CsA).	Cyclosporine	253-256	calreticulin	Homo sapiens	49-52
31500337-3	2019	Opening of the pore can be delayed by cyclosporin A (CsA), possibly by inhibiting cyclophilin D (Cyp D), a key regulator of mPTP.	Cyclosporine	38-51	peptidylprolyl isomerase F	Homo sapiens	97-102
31500337-3	2019	Opening of the pore can be delayed by cyclosporin A (CsA), possibly by inhibiting cyclophilin D (Cyp D), a key regulator of mPTP.	Cyclosporine	53-56	peptidylprolyl isomerase F	Homo sapiens	82-95
31500337-3	2019	Opening of the pore can be delayed by cyclosporin A (CsA), possibly by inhibiting cyclophilin D (Cyp D), a key regulator of mPTP.	Cyclosporine	53-56	peptidylprolyl isomerase F	Homo sapiens	97-102
31332983-6	2019	Decreased plasma D-dimer levels; and decreased serum IL-2, IL-5, and TNF-alpha levels were reported to be correlated with clinical improvement after CsA treatment.	Cyclosporine	149-152	interleukin 2	Homo sapiens	53-57
31332983-6	2019	Decreased plasma D-dimer levels; and decreased serum IL-2, IL-5, and TNF-alpha levels were reported to be correlated with clinical improvement after CsA treatment.	Cyclosporine	149-152	tumor necrosis factor	Homo sapiens	69-78
31188033-9	2019	In summary, CsA-mediated induction of oxidative stress is associated with CypD, with CypD deletion providing a protective effect, whereas the reduction of energy production observed upon CsA exposure did not depend on the animals" CypD status.	Cyclosporine	12-15	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	74-78
31188033-0	2019	Cyclophilin D knockout protects the mouse kidney against cyclosporin A-induced oxidative stress.	Cyclosporine	57-70	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	0-13
31188033-9	2019	In summary, CsA-mediated induction of oxidative stress is associated with CypD, with CypD deletion providing a protective effect, whereas the reduction of energy production observed upon CsA exposure did not depend on the animals" CypD status.	Cyclosporine	12-15	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	85-89
31188033-2	2019	CsA interacts with cyclophilin D (CypD), an essential component of the mitochondrial permeability transition pore and regulator of cell death processes.	Cyclosporine	0-3	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	19-32
31188033-9	2019	In summary, CsA-mediated induction of oxidative stress is associated with CypD, with CypD deletion providing a protective effect, whereas the reduction of energy production observed upon CsA exposure did not depend on the animals" CypD status.	Cyclosporine	12-15	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	85-89
31188033-2	2019	CsA interacts with cyclophilin D (CypD), an essential component of the mitochondrial permeability transition pore and regulator of cell death processes.	Cyclosporine	0-3	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	34-38
31598361-4	2019	In addition, hydrogen peroxide-induced p53 activation and BH3 interacting-domain death agonist (BID) expression were higher in CsA-treated cells than those in non-treated cells, whereas hydrogen peroxide-induced activation of mitogen-activated protein kinases including p38, c-Jun N-terminal kinase, and extracellular signal-regulated kinase and activation of protein kinase B were not significantly altered by treatment with CsA.	Cyclosporine	127-130	tumor protein p53	Homo sapiens	39-42
31188033-8	2019	However, a negative effect of CsA on the glycolysis and overall energy metabolism in Ppif-/- mice also indicated that additional, CypD-parallel pathways are involved in the toxic effects of CsA on the kidney.	Cyclosporine	190-193	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	130-134
31598361-4	2019	In addition, hydrogen peroxide-induced p53 activation and BH3 interacting-domain death agonist (BID) expression were higher in CsA-treated cells than those in non-treated cells, whereas hydrogen peroxide-induced activation of mitogen-activated protein kinases including p38, c-Jun N-terminal kinase, and extracellular signal-regulated kinase and activation of protein kinase B were not significantly altered by treatment with CsA.	Cyclosporine	127-130	BH3 interacting domain death agonist	Homo sapiens	96-99
31598361-4	2019	In addition, hydrogen peroxide-induced p53 activation and BH3 interacting-domain death agonist (BID) expression were higher in CsA-treated cells than those in non-treated cells, whereas hydrogen peroxide-induced activation of mitogen-activated protein kinases including p38, c-Jun N-terminal kinase, and extracellular signal-regulated kinase and activation of protein kinase B were not significantly altered by treatment with CsA.	Cyclosporine	127-130	mitogen-activated protein kinase 14	Homo sapiens	270-273
31598361-8	2019	Taken together, these data suggest that CsA can aggravate hydrogen peroxide-induced cell death through p53 activation, BID expression, and ROS production.	Cyclosporine	40-43	tumor protein p53	Homo sapiens	103-106
31598361-8	2019	Taken together, these data suggest that CsA can aggravate hydrogen peroxide-induced cell death through p53 activation, BID expression, and ROS production.	Cyclosporine	40-43	BH3 interacting domain death agonist	Homo sapiens	119-122
31232271-1	2019	BACKGROUND: A few clinical trials in IgA nephropathy (IgAN) have shown that cyclosporine A (CyA) had therapeutic efficacy in reducing proteinuria.	Cyclosporine	76-90	CD79a molecule	Homo sapiens	37-40
31232271-1	2019	BACKGROUND: A few clinical trials in IgA nephropathy (IgAN) have shown that cyclosporine A (CyA) had therapeutic efficacy in reducing proteinuria.	Cyclosporine	92-95	CD79a molecule	Homo sapiens	37-40
31240637-7	2019	CONCLUSION: Cyclosporine is a safe and effective treatment for PPP with few adverse effects, which might be related to the regulation of IL-23 and TNF-alpha.	Cyclosporine	12-24	tumor necrosis factor	Homo sapiens	147-156
31220549-8	2019	UVB irradiation induced Nrf2 degradation is inhibited by co-treatment of cells with W-7, cyclosporin A, SB-216763 or MG-132, which are inhibitors of calmodulin, calcineurin, GSK3beta and the proteasome, respectively.	Cyclosporine	89-102	calmodulin 1	Homo sapiens	149-159
30458698-9	2019	Placental growth factor increased in AZA (24 hours, 10 ng/mL) and CsA (125 ng/mL; P &lt; .05).	Cyclosporine	66-69	placental growth factor	Homo sapiens	0-23
31490380-1	2019	RATIONALE: Immunosuppressive agents such as tacrolimus (TAC) and cyclosporin might cause glycemic disorders by suppressing insulin production.	Cyclosporine	65-76	insulin	Homo sapiens	123-130
31085229-6	2019	Based on these findings, we treated Ts65Dn mice with CSA in the postnatal period P3-P15.	Cyclosporine	53-56	cyclin dependent kinase inhibitor 2B	Mus musculus	84-87
31402251-0	2019	Insulin Resistance in Nonobese Renal Allograft Recipients on Maintenance Doses of Cyclosporine or Tacrolimus.	Cyclosporine	82-94	insulin	Homo sapiens	0-7
31489369-5	2019	Moreover, liver mitochondria from mice with quadruple deletion of Ant1, Ant2, Ant4, and Ppif (cyclophilin D, target of CsA) lacked Ca2+-induced MPTP formation.	Cyclosporine	119-122	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	88-92
31489369-5	2019	Moreover, liver mitochondria from mice with quadruple deletion of Ant1, Ant2, Ant4, and Ppif (cyclophilin D, target of CsA) lacked Ca2+-induced MPTP formation.	Cyclosporine	119-122	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	94-107
31054961-5	2019	Suppression of ERK1/2, GSK3beta and CK2 activities attenuated CsA-induced down-regulation of HSP expression and up-regulation of HSF1 phosphorylation.	Cyclosporine	62-65	mitogen-activated protein kinase 3	Homo sapiens	15-21
31100416-3	2019	The IFNgamma-CSA fusion possessed potent anti-viral assay against vesicular stomatitis virus in cultured cells.	Cyclosporine	13-16	interferon gamma	Homo sapiens	4-12
31100416-4	2019	IFNgamma-CSA was also stable at 37  C up to 72 h compared with 8 h for IFNgamma alone.	Cyclosporine	9-12	interferon gamma	Homo sapiens	0-8
31100416-6	2019	These results indicate that IFNgamma-CSA expression in the baculovirus system was successful and provide a promising long-acting cytokine for veterinary clinical applications.	Cyclosporine	37-40	interferon gamma	Mus musculus	28-36
31054961-6	2019	CsA interfered with HSF1-SSBP1 complex formation and HSF1 nuclear translocation and recruitment to the HSP70 promoter.	Cyclosporine	0-3	heat shock protein family A (Hsp70) member 9	Homo sapiens	103-108
31085259-10	2019	In conclusion, etoposide transport across MDCKII MRP2 cells was modulated by cyclosporin A, an inhibitor of MRP2 and P-gp, but not by specific P-gp inhibitors (valspodar and zosuquidar), which suggests that etoposide transport is primarily influenced by MRP2.	Cyclosporine	77-90	ATP binding cassette subfamily C member 2	Canis lupus familiaris	49-53
31340913-0	2019	[Role of TGF-beta1/ILK/FSP1 signaling pathway in cyclosporin A-induced epithelialmesenchymal transition in cultured renal tubular epithelial cells].	Cyclosporine	49-62	transforming growth factor, beta 1	Rattus norvegicus	9-18
31340913-1	2019	OBJECTIVE: To explore the role of transforming growth factor-beta1/integrin-linked kinase/fibroblast-specific protein 1 (TGF- beta1/ILK/FSP1) signaling pathway in cyclosporine A (CsA)-induced renal tubular epithelial cell transdifferentiation.	Cyclosporine	163-177	transforming growth factor, beta 1	Rattus norvegicus	121-131
31340913-1	2019	OBJECTIVE: To explore the role of transforming growth factor-beta1/integrin-linked kinase/fibroblast-specific protein 1 (TGF- beta1/ILK/FSP1) signaling pathway in cyclosporine A (CsA)-induced renal tubular epithelial cell transdifferentiation.	Cyclosporine	179-182	transforming growth factor, beta 1	Rattus norvegicus	121-131
31340913-5	2019	RESULTS: Compared with the blank control cells, the cells treated with CsA showed significantly increased levels of TGF-beta1, ILK and FSP-1 mRNAs and proteins (P &amp;lt; 0.05).	Cyclosporine	71-74	transforming growth factor, beta 1	Rattus norvegicus	116-125
31340913-6	2019	The expressions of TGF-beta1, ILK and FSP-1 were significantly lower in TGF-beta1 inhibitor group than in CsA group (P &amp;lt; 0.05).	Cyclosporine	106-109	transforming growth factor, beta 1	Rattus norvegicus	19-28
31340913-9	2019	CONCLUSIONS: The activation of TGF-beta1/ILK/FSP-1 signaling pathway is an important mechanism for CsA-induced transdifferentiation in rat renal tubular epithelial cells.	Cyclosporine	99-102	transforming growth factor, beta 1	Rattus norvegicus	31-40
31238868-7	2019	Using immunohistochemical staining, we showed that resveratrol induced NFATc1 accumulation in the cell nuclei, and treatment with CsA inhibited resveratrol-mediated induction of NFATc1, suggesting that the calcineurin/NFATc1 signaling pathway plays an important role in the regulatory effect of resveratrol on osteoblasts.	Cyclosporine	130-133	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	178-184
31238868-7	2019	Using immunohistochemical staining, we showed that resveratrol induced NFATc1 accumulation in the cell nuclei, and treatment with CsA inhibited resveratrol-mediated induction of NFATc1, suggesting that the calcineurin/NFATc1 signaling pathway plays an important role in the regulatory effect of resveratrol on osteoblasts.	Cyclosporine	130-133	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	178-184
30725434-5	2019	CsA significantly increased the superoxide dismutase activity, glutathione production, and catalase activity but decreased the malonaldehyde level.	Cyclosporine	0-3	catalase	Rattus norvegicus	91-99
30725434-7	2019	CsA significantly decreased the Bax/Bcl-2 ratio, cl-casp-9/casp-9, and cl-casp-3/casp-3 in a concentration-dependent manner.	Cyclosporine	0-3	BCL2, apoptosis regulator	Rattus norvegicus	36-41
30725434-7	2019	CsA significantly decreased the Bax/Bcl-2 ratio, cl-casp-9/casp-9, and cl-casp-3/casp-3 in a concentration-dependent manner.	Cyclosporine	0-3	caspase 9	Rattus norvegicus	52-58
30725434-7	2019	CsA significantly decreased the Bax/Bcl-2 ratio, cl-casp-9/casp-9, and cl-casp-3/casp-3 in a concentration-dependent manner.	Cyclosporine	0-3	caspase 9	Rattus norvegicus	59-65
30725434-10	2019	CsA inhibited NF-kappaB activation, thereby preventing the upregulation of IL-1beta, TNF-alpha, iNOS, and intracellular NO release.	Cyclosporine	0-3	interleukin 1 alpha	Rattus norvegicus	75-83
30725434-10	2019	CsA inhibited NF-kappaB activation, thereby preventing the upregulation of IL-1beta, TNF-alpha, iNOS, and intracellular NO release.	Cyclosporine	0-3	tumor necrosis factor	Rattus norvegicus	85-94
30725434-10	2019	CsA inhibited NF-kappaB activation, thereby preventing the upregulation of IL-1beta, TNF-alpha, iNOS, and intracellular NO release.	Cyclosporine	0-3	nitric oxide synthase 2	Rattus norvegicus	96-100
30843027-15	2019	The co-administration of CsA ensured that cardioprotection was CypD-independent.	Cyclosporine	25-28	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	63-67
31261526-5	2019	The most commonly reported genotype was CYP3A53/3, which was strongly associated with cyclosporine A (CsA) and tacrolimus (FK506).	Cyclosporine	86-100	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	40-49
31261526-5	2019	The most commonly reported genotype was CYP3A53/3, which was strongly associated with cyclosporine A (CsA) and tacrolimus (FK506).	Cyclosporine	102-105	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	40-49
31261526-6	2019	MDR1 C3435T CC was also associated with CNI use, especially with CsA therapy.	Cyclosporine	65-68	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
30801551-8	2019	Hearts exposed to CsA for 45 minutes at reperfusion recovered poorly with no phospho-AMP-activated protein kinase alpha activation, decreased phospho-eNOSSer633, and decreased mitochondrial cytochrome c content with increased lactate dehydrogenase release.	Cyclosporine	18-21	cytochrome c, somatic	Homo sapiens	190-202
31489369-4	2019	Liver mitochondria from Ant1, Ant2, and Ant4 deficient mice were highly refractory to Ca2+-induced MPTP formation, and when also given cyclosporine A (CsA), the MPTP was completely inhibited.	Cyclosporine	135-149	solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 31	Mus musculus	40-44
31489369-4	2019	Liver mitochondria from Ant1, Ant2, and Ant4 deficient mice were highly refractory to Ca2+-induced MPTP formation, and when also given cyclosporine A (CsA), the MPTP was completely inhibited.	Cyclosporine	151-154	solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 31	Mus musculus	40-44
31947152-3	2019	Optimization of heart failure medication with Angiotensin receptor neprilysin inhibition (ARNi) can effect phenotypic traits of CSA-CSR indicating improvements of both, hemodynamic parameters and central chemosensitivity.	Cyclosporine	128-131	membrane metalloendopeptidase	Homo sapiens	67-77
31109455-2	2019	Here we show that CsA elevated systolic blood pressure in both wild-type and apolipoprotein E (ApoE) knockout (KO) mice to a similar level.	Cyclosporine	18-21	apolipoprotein E	Mus musculus	77-93
31109455-2	2019	Here we show that CsA elevated systolic blood pressure in both wild-type and apolipoprotein E (ApoE) knockout (KO) mice to a similar level.	Cyclosporine	18-21	apolipoprotein E	Mus musculus	95-99
30912163-0	2019	Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers.	Cyclosporine	23-34	ATP binding cassette subfamily B member 1	Homo sapiens	36-50
30912163-2	2019	The aim of the present study was to investigate the effects of the potent P-gp inhibitor ciclosporin and its combination with the moderate CYP3A inhibitor fluconazole on rivaroxaban pharmacokinetics and on CYP3A activity.	Cyclosporine	89-100	ATP binding cassette subfamily B member 1	Homo sapiens	74-78
30912163-2	2019	The aim of the present study was to investigate the effects of the potent P-gp inhibitor ciclosporin and its combination with the moderate CYP3A inhibitor fluconazole on rivaroxaban pharmacokinetics and on CYP3A activity.	Cyclosporine	89-100	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	206-211
30912163-6	2019	RESULTS: Compared to baseline, ciclosporin increased rivaroxaban average exposure by 47% (90% confidence interval 28-68%), maximum concentration by 104% (70-146%), and decreased CYP3A4 activity by 34% (25-42%).	Cyclosporine	31-42	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	178-184
30912163-7	2019	Ciclosporin combined with fluconazole increased rivaroxaban average exposure by 86% (58-119%) and maximum concentration by 115% (83-153%), which was considerably stronger than observed in historical controls receiving rivaroxaban with fluconazole alone, and decreased CYP3A4 activity by 79% (76-82%).	Cyclosporine	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	268-274
30927701-0	2019	Modulation of eNOS/iNOS by nebivolol protects against cyclosporine A-mediated nephrotoxicity through targeting inflammatory and apoptotic pathways.	Cyclosporine	54-68	nitric oxide synthase 2	Rattus norvegicus	19-23
30927701-6	2019	NEB also reversed CsA-induced effects on NO system; increasing renal NO level, with up-regulation of eNOS and down-regulation of iNOS expression.	Cyclosporine	18-21	nitric oxide synthase 2	Rattus norvegicus	129-133
31293389-11	2019	CsA attenuated IL-1beta and Iba1 expressions in BV-2 microglia exposed to OGD/R.	Cyclosporine	0-3	interleukin 1 beta	Mus musculus	15-23
31068389-8	2019	In this study, basophil-derived IL-6 that is resistant to suppression by CsA, was largely responsible for allograft fibrosis and limited transplant survival.	Cyclosporine	73-76	interleukin 6	Mus musculus	32-36
31085259-10	2019	In conclusion, etoposide transport across MDCKII MRP2 cells was modulated by cyclosporin A, an inhibitor of MRP2 and P-gp, but not by specific P-gp inhibitors (valspodar and zosuquidar), which suggests that etoposide transport is primarily influenced by MRP2.	Cyclosporine	77-90	ATP binding cassette subfamily C member 2	Canis lupus familiaris	108-112
31085259-10	2019	In conclusion, etoposide transport across MDCKII MRP2 cells was modulated by cyclosporin A, an inhibitor of MRP2 and P-gp, but not by specific P-gp inhibitors (valspodar and zosuquidar), which suggests that etoposide transport is primarily influenced by MRP2.	Cyclosporine	77-90	ATP binding cassette subfamily C member 2	Canis lupus familiaris	108-112
30690767-0	2019	Relationship between allograft cyclosporin concentrations and P-glycoprotein expression in the 1st month following renal transplantation.	Cyclosporine	31-42	ATP binding cassette subfamily B member 1	Homo sapiens	62-76
31005256-6	2019	Inhibition of calcineurin with cyclosporine A, FK506 down-regulates the levels of NFATc3 nuclear translocation and proinflammatory cytokines expression.	Cyclosporine	31-45	nuclear factor of activated T cells 3	Homo sapiens	82-88
30880061-1	2019	Cyclosporine A has long been known to suppress T cell responses by inhibiting the production of IL-2, which drives T cell proliferation, enabling its use as a therapeutic for transplantation or autoimmunity.	Cyclosporine	0-14	interleukin 2	Homo sapiens	96-100
31156436-2	2019	Metabolized mainly by CYP3A and being a substrate of P-glycoprotein (P-gp), CsA is susceptible to drug-drug interactions.	Cyclosporine	76-79	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	22-27
31156436-2	2019	Metabolized mainly by CYP3A and being a substrate of P-glycoprotein (P-gp), CsA is susceptible to drug-drug interactions.	Cyclosporine	76-79	ATP binding cassette subfamily B member 1	Homo sapiens	53-67
31156436-2	2019	Metabolized mainly by CYP3A and being a substrate of P-glycoprotein (P-gp), CsA is susceptible to drug-drug interactions.	Cyclosporine	76-79	ATP binding cassette subfamily B member 1	Homo sapiens	69-73
30690767-1	2019	The immunosuppressant cyclosporin is a P-glycoprotein (P-gp) substrate whose impaired function has been associated with an increased risk of cyclosporin-induced nephrotoxicity following renal transplantation.	Cyclosporine	22-33	ATP binding cassette subfamily B member 1	Homo sapiens	39-53
30690767-1	2019	The immunosuppressant cyclosporin is a P-glycoprotein (P-gp) substrate whose impaired function has been associated with an increased risk of cyclosporin-induced nephrotoxicity following renal transplantation.	Cyclosporine	22-33	ATP binding cassette subfamily B member 1	Homo sapiens	55-59
30690767-1	2019	The immunosuppressant cyclosporin is a P-glycoprotein (P-gp) substrate whose impaired function has been associated with an increased risk of cyclosporin-induced nephrotoxicity following renal transplantation.	Cyclosporine	141-152	ATP binding cassette subfamily B member 1	Homo sapiens	39-53
30690767-1	2019	The immunosuppressant cyclosporin is a P-glycoprotein (P-gp) substrate whose impaired function has been associated with an increased risk of cyclosporin-induced nephrotoxicity following renal transplantation.	Cyclosporine	141-152	ATP binding cassette subfamily B member 1	Homo sapiens	55-59
30689261-6	2019	RESULTS: We observed the frequency of CD4+ IFN-gamma+ T cells was higher in atopic individuals with SAR than with CSA.	Cyclosporine	114-117	CD4 molecule	Homo sapiens	38-41
30689261-6	2019	RESULTS: We observed the frequency of CD4+ IFN-gamma+ T cells was higher in atopic individuals with SAR than with CSA.	Cyclosporine	114-117	interferon gamma	Homo sapiens	43-52
30689261-7	2019	In addition, among the atopic and early-onset asthma (EOA), the frequency of CD4+ CTLA-4+ T cells was lower in the SAR group than the CSA group.	Cyclosporine	134-137	CD4 molecule	Homo sapiens	77-80
30689261-8	2019	In relation to non-atopic and late-onset asthma (LOA) phenotypes, we noted the frequency of CD4+ FoxP3+ T cells was lower in individuals with SAR than with CSA.	Cyclosporine	156-159	CD4 molecule	Homo sapiens	92-95
30689261-9	2019	We also observed among the LOA patients, the frequency of CD4+ TGF-beta+ T cells was decreased in SAR group than the in CSA group.	Cyclosporine	120-123	CD4 molecule	Homo sapiens	58-61
30689261-9	2019	We also observed among the LOA patients, the frequency of CD4+ TGF-beta+ T cells was decreased in SAR group than the in CSA group.	Cyclosporine	120-123	transforming growth factor beta 1	Homo sapiens	63-71
30580651-13	2019	The CsA-CLs group showed a lower level of IL-1beta than the BSS and soft CL groups (p < 0.01), and a lower level of IFN-gamma than the other groups (all p < 0.01).	Cyclosporine	4-7	interferon gamma	Oryctolagus cuniculus	116-125
30896878-4	2019	CsA treatment increased the phosphorylation of protein kinase B (Akt) and consequently the expression of Cyclin D1.	Cyclosporine	0-3	AKT serine/threonine kinase 1	Homo sapiens	65-68
30664361-12	2019	IL6RA was significantly upregulated by 0.05%CsA.	Cyclosporine	44-47	interleukin 6 receptor, alpha	Mus musculus	0-5
30664361-13	2019	CONCLUSIONS: This study indicates that the three CsA formulations effectively modulated TLR4, TGFbeta1, IL1, and IL6 pathways to reduce corneal epithelium lesions in a mouse model of severe dry eye.	Cyclosporine	49-52	toll-like receptor 4	Mus musculus	88-92
30664361-13	2019	CONCLUSIONS: This study indicates that the three CsA formulations effectively modulated TLR4, TGFbeta1, IL1, and IL6 pathways to reduce corneal epithelium lesions in a mouse model of severe dry eye.	Cyclosporine	49-52	interleukin 6	Mus musculus	113-116
30718919-5	2019	The peptidyl-prolyl isomerase inhibitor Cyclosporine A (CsA) selectively kills EGFR+ or HER2+ breast cancer cells in vitro by activating caspase-dependent apoptotic pathways.	Cyclosporine	40-54	epidermal growth factor receptor	Homo sapiens	79-83
30718919-5	2019	The peptidyl-prolyl isomerase inhibitor Cyclosporine A (CsA) selectively kills EGFR+ or HER2+ breast cancer cells in vitro by activating caspase-dependent apoptotic pathways.	Cyclosporine	40-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-92
30718919-5	2019	The peptidyl-prolyl isomerase inhibitor Cyclosporine A (CsA) selectively kills EGFR+ or HER2+ breast cancer cells in vitro by activating caspase-dependent apoptotic pathways.	Cyclosporine	56-59	epidermal growth factor receptor	Homo sapiens	79-83
30718919-5	2019	The peptidyl-prolyl isomerase inhibitor Cyclosporine A (CsA) selectively kills EGFR+ or HER2+ breast cancer cells in vitro by activating caspase-dependent apoptotic pathways.	Cyclosporine	56-59	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-92
30718919-6	2019	Further, CsA synergizes with the DDA tcyDTDO to kill HER2/EGFR overexpressing cells in vitro and the two agents cooperate to kill HER2+ tumors in vivo.	Cyclosporine	9-12	erb-b2 receptor tyrosine kinase 2	Homo sapiens	53-57
30718919-6	2019	Further, CsA synergizes with the DDA tcyDTDO to kill HER2/EGFR overexpressing cells in vitro and the two agents cooperate to kill HER2+ tumors in vivo.	Cyclosporine	9-12	epidermal growth factor receptor	Homo sapiens	58-62
30718919-8	2019	Drugs that target HER2/EGFR protein folding, including DDAs and CsA, have the potential to kill cancers that overexpress EGFR or HER2 through the induction of proteostatic synthetic lethality.	Cyclosporine	64-67	erb-b2 receptor tyrosine kinase 2	Homo sapiens	18-22
30718919-8	2019	Drugs that target HER2/EGFR protein folding, including DDAs and CsA, have the potential to kill cancers that overexpress EGFR or HER2 through the induction of proteostatic synthetic lethality.	Cyclosporine	64-67	epidermal growth factor receptor	Homo sapiens	121-125
30718919-8	2019	Drugs that target HER2/EGFR protein folding, including DDAs and CsA, have the potential to kill cancers that overexpress EGFR or HER2 through the induction of proteostatic synthetic lethality.	Cyclosporine	64-67	erb-b2 receptor tyrosine kinase 2	Homo sapiens	129-133
30896878-6	2019	Mechanistically, CsA treatment increased reactive oxygen species (ROS) generation, and the intracellular ROS scavenger N-acetyl-cysteine (NAC) attenuated CsA-induced cell proliferation as well as the activation of Akt/Cyclin D1 signaling.	Cyclosporine	154-157	AKT serine/threonine kinase 1	Homo sapiens	214-217
30896878-7	2019	However, notably, it was demonstrated that CsA treatment decreased cell proliferation and Akt phosphorylation under normal lipid loading.	Cyclosporine	43-46	AKT serine/threonine kinase 1	Homo sapiens	90-93
30995791-6	2019	The percentage of SOD1 immunopositive hepatocytes in rats treated with cyclosporine A, mycophenolate mofetil, everolimus, and glucocorticosteroid was significantly elevated above that of the control rats.	Cyclosporine	71-85	superoxide dismutase 1	Rattus norvegicus	18-22
30776644-4	2019	Treatment of the cells with CsA resulted in decreased expression of the mDC-specific markers (CD80, CD83 and CD88) induced by 27OHChol.	Cyclosporine	28-31	complement C5a receptor 1	Homo sapiens	109-113
30879923-0	2019	Cyclosporine A sensitizes lung cancer cells to crizotinib through inhibition of the Ca2+/calcineurin/Erk pathway.	Cyclosporine	0-14	mitogen-activated protein kinase 1	Homo sapiens	101-104
30879923-10	2019	CsA effectively blocked CaN-KSR2-Erk1/2 signaling, promoting crizotinib-induced apoptosis and G2/M arrest.	Cyclosporine	0-3	kinase suppressor of ras 2	Homo sapiens	28-32
30879923-10	2019	CsA effectively blocked CaN-KSR2-Erk1/2 signaling, promoting crizotinib-induced apoptosis and G2/M arrest.	Cyclosporine	0-3	mitogen-activated protein kinase 3	Homo sapiens	33-39
30879923-12	2019	Xenograft studies further confirmed that CsA or Erk1/2 inhibitor PD98059 enhanced the anti-cancer activity of crizotinib through inhibition of CaN-Erk1/2 axis.	Cyclosporine	41-44	mitogen-activated protein kinase 3	Homo sapiens	147-153
30785057-9	2019	CONCLUSIONS: Dasatinib significantly reduced cyclosporine exposure, which was most probably related to the induction of CYP3A-mediated cyclosporine metabolism.	Cyclosporine	45-57	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	120-125
30350412-9	2019	CONCLUSIONS: TGFb1 may be claimed as the supplementary molecular marker to evaluate the efficacy of CsA therapy.	Cyclosporine	100-103	transforming growth factor beta 1	Homo sapiens	13-18
30799725-11	2019	Conclusion: This study revealed the possible association of IL-17 G-197A with cyclosporine metabolism and transplant rejection after LT, which might be partly related to the upregulations of CYP3A4/5 dependent on PXR.	Cyclosporine	78-90	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	191-199
30799725-11	2019	Conclusion: This study revealed the possible association of IL-17 G-197A with cyclosporine metabolism and transplant rejection after LT, which might be partly related to the upregulations of CYP3A4/5 dependent on PXR.	Cyclosporine	78-90	nuclear receptor subfamily 1 group I member 2	Homo sapiens	213-216
30658157-5	2019	Celecoxib also reversed the CSA-evoked (i) reductions in the tubular and glomerular protein expression of CSE and levels of H2S, prostaglandin E2 (PGE2), and total antioxidant capacity (TAC), and (ii) increases in inflammatory (tumor necrosis factor-alpha, TNF-alpha), fibrotic (transforming growth factor-beta1, TGF-beta1) and apoptotic (caspase-3) cytokines.	Cyclosporine	28-31	tumor necrosis factor	Rattus norvegicus	228-255
30658157-5	2019	Celecoxib also reversed the CSA-evoked (i) reductions in the tubular and glomerular protein expression of CSE and levels of H2S, prostaglandin E2 (PGE2), and total antioxidant capacity (TAC), and (ii) increases in inflammatory (tumor necrosis factor-alpha, TNF-alpha), fibrotic (transforming growth factor-beta1, TGF-beta1) and apoptotic (caspase-3) cytokines.	Cyclosporine	28-31	tumor necrosis factor	Rattus norvegicus	257-266
30658157-5	2019	Celecoxib also reversed the CSA-evoked (i) reductions in the tubular and glomerular protein expression of CSE and levels of H2S, prostaglandin E2 (PGE2), and total antioxidant capacity (TAC), and (ii) increases in inflammatory (tumor necrosis factor-alpha, TNF-alpha), fibrotic (transforming growth factor-beta1, TGF-beta1) and apoptotic (caspase-3) cytokines.	Cyclosporine	28-31	transforming growth factor, beta 1	Rattus norvegicus	279-311
30658157-5	2019	Celecoxib also reversed the CSA-evoked (i) reductions in the tubular and glomerular protein expression of CSE and levels of H2S, prostaglandin E2 (PGE2), and total antioxidant capacity (TAC), and (ii) increases in inflammatory (tumor necrosis factor-alpha, TNF-alpha), fibrotic (transforming growth factor-beta1, TGF-beta1) and apoptotic (caspase-3) cytokines.	Cyclosporine	28-31	transforming growth factor, beta 1	Rattus norvegicus	313-322
30913036-8	2019	MMP-3 level decreased in adult group (p < 0.0001) but went up in fetal HGFs (p = 0.01) when treated with 150 ng/mL CsA.	Cyclosporine	115-118	matrix metallopeptidase 3	Homo sapiens	0-5
30547226-10	2019	In support of this, the calcineurin inhibitor, cyclosporin A, prevented the Ca2+-induced decrease in cell surface CFTR.	Cyclosporine	47-60	CF transmembrane conductance regulator	Homo sapiens	114-118
30785057-9	2019	CONCLUSIONS: Dasatinib significantly reduced cyclosporine exposure, which was most probably related to the induction of CYP3A-mediated cyclosporine metabolism.	Cyclosporine	135-147	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	120-125
30799432-0	2019	Effect of Multidrug-Resistant 1 (MDR1) and CYP3A4*1B Polymorphisms on Cyclosporine-Based Immunosuppressive Therapy in Renal Transplant Patients.	Cyclosporine	70-82	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-49
30799432-4	2019	The aim of this study was to determine the relationship between CYP3A4*1B and MDR1 polymorphisms and dose requirements to achieve the target therapeutic range for CsA.	Cyclosporine	163-166	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	64-70
30799432-4	2019	The aim of this study was to determine the relationship between CYP3A4*1B and MDR1 polymorphisms and dose requirements to achieve the target therapeutic range for CsA.	Cyclosporine	163-166	ATP binding cassette subfamily B member 1	Homo sapiens	78-82
30799432-7	2019	RESULTS Patients with the CYP3A4*1/*1 genotype received the lowest mean dose of CsA compared to CYP3A4*1/*1B, and had a higher average drug concentration in the blood.	Cyclosporine	80-83	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	26-32
30799432-8	2019	In the case of MDR1 3435C&gt;T polymorphism, we observed that patients with the CC genotype received lower doses of CsA than patients with the CT and TT genotypes.	Cyclosporine	116-119	ATP binding cassette subfamily B member 1	Homo sapiens	15-19
30679998-11	2019	However, the protective effects of Nrf2 overexpression on PQ-challenged A549 cells were abrogated following cyclosporine A treatment, a competitive inhibitor of P-gp, which also increased intracellular PQ levels.	Cyclosporine	108-122	nuclear factor, erythroid derived 2, like 2	Mus musculus	35-39
30794682-13	2019	The activation of caspase-3 and caspase-7 as well as caspase-9 induced by cisplatin or CsA was reduced by silencing of GADD45gamma, and was augmented by the overexpression of GADD45gamma, indicating that caspase activation is dependent on the expression of GADD45gamma.	Cyclosporine	87-90	caspase 3	Homo sapiens	18-27
30007073-0	2019	IgE levels are negatively correlated with clinical response to ciclosporin in chronic spontaneous urticaria.	Cyclosporine	63-74	immunoglobulin heavy constant epsilon	Homo sapiens	0-3
30610229-3	2019	Steroid therapy remains the first line therapy for moderate/severe and severe vision threatening TED The use of some traditional nonspecific immunosuppressant such as mycophenolate, cyclosporine and azathioprine seems useful in combination with steroid therapy to achieve stable results in the long term; methotrexate is useful as steroid-sparing medications and in steroid resistant or intolerant patients.	Cyclosporine	182-194	NALCN channel auxiliary factor 2	Homo sapiens	97-100
30520827-0	2019	Switching Immunosuppression From Cyclosporine to Tacrolimus in Kidney Transplant Recipients Based on CYP3A5 Genotyping.	Cyclosporine	33-45	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	101-107
30378503-14	2019	We also demonstrated that CsA could inhibit the expression of NFATc1 and its downstream genes COX-2, c-Myc, MMP-9, and MMP-2 in OSCC cells.	Cyclosporine	26-29	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	94-99
31385766-0	2019	Association Between CYP3A4 and CYP3A5 Genotypes and Cyclosporine"s Blood Levels and Doses among Jordanian Kidney Transplanted Patients BACKGROUND: Cyclosporine is used as an immunosuppressive agent in kidney transplantation.	Cyclosporine	52-64	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	20-26
30378493-12	2019	CYP3A families, especially CYP3A4 and CYP3A5, play an important role in the biotransformation of CsA.	Cyclosporine	97-100	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	27-33
30378493-12	2019	CYP3A families, especially CYP3A4 and CYP3A5, play an important role in the biotransformation of CsA.	Cyclosporine	97-100	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	38-44
31385766-0	2019	Association Between CYP3A4 and CYP3A5 Genotypes and Cyclosporine"s Blood Levels and Doses among Jordanian Kidney Transplanted Patients BACKGROUND: Cyclosporine is used as an immunosuppressive agent in kidney transplantation.	Cyclosporine	147-159	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	20-26
31385766-0	2019	Association Between CYP3A4 and CYP3A5 Genotypes and Cyclosporine"s Blood Levels and Doses among Jordanian Kidney Transplanted Patients BACKGROUND: Cyclosporine is used as an immunosuppressive agent in kidney transplantation.	Cyclosporine	147-159	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	31-37
31385766-2	2019	Cyclosporine is predominantly metabolized by CYP3A4 and CYP3A5.	Cyclosporine	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-51
31385766-2	2019	Cyclosporine is predominantly metabolized by CYP3A4 and CYP3A5.	Cyclosporine	0-12	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	56-62
31385766-3	2019	The most commonSingle Nucleotide Polymorphisms (SNPs) affecting cyclosporine metabolism (CYP3A4*1B, CYP3A4*1G,CYP3A4*22 and CYP3A5*3) were investigated among Jordanian kidney transplanted patients to find out the genotypesand allele frequencies of these SNPs.	Cyclosporine	64-76	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	89-95
31385766-3	2019	The most commonSingle Nucleotide Polymorphisms (SNPs) affecting cyclosporine metabolism (CYP3A4*1B, CYP3A4*1G,CYP3A4*22 and CYP3A5*3) were investigated among Jordanian kidney transplanted patients to find out the genotypesand allele frequencies of these SNPs.	Cyclosporine	64-76	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	100-106
31385766-3	2019	The most commonSingle Nucleotide Polymorphisms (SNPs) affecting cyclosporine metabolism (CYP3A4*1B, CYP3A4*1G,CYP3A4*22 and CYP3A5*3) were investigated among Jordanian kidney transplanted patients to find out the genotypesand allele frequencies of these SNPs.	Cyclosporine	64-76	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	100-106
31385766-3	2019	The most commonSingle Nucleotide Polymorphisms (SNPs) affecting cyclosporine metabolism (CYP3A4*1B, CYP3A4*1G,CYP3A4*22 and CYP3A5*3) were investigated among Jordanian kidney transplanted patients to find out the genotypesand allele frequencies of these SNPs.	Cyclosporine	64-76	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	124-130
30431066-12	2019	In addition, ethinyl targeted to TNF, whereas TNF and ERBB2 were targeted by cyclosporine, and tretinoin was a targeted chemical of ERBB2.	Cyclosporine	77-89	tumor necrosis factor	Homo sapiens	46-49
30431066-12	2019	In addition, ethinyl targeted to TNF, whereas TNF and ERBB2 were targeted by cyclosporine, and tretinoin was a targeted chemical of ERBB2.	Cyclosporine	77-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-59
30189151-6	2019	Topical CsA treatment induced a significant reduction in CD4 and IL-17 expressions (P &lt; 0.05); post-treatment levels were same as normals (P &gt; 0.05).	Cyclosporine	8-11	CD4 molecule	Homo sapiens	57-60
30548183-5	2019	AngII-induced CH in adult mice was reduced by treatment with cyclosporin A, without affecting the associated increase in blood pressure, and also by induction of calcineurin deletion in adult mouse cardiomyocytes, indicating that cardiomyocyte calcineurin is required for AngII-induced CH.	Cyclosporine	61-74	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	0-5
30548183-7	2019	Analysis of profibrotic genes revealed that AngII-induced expression of Tgfbeta family members and Lox was not inhibited by cyclosporin A but was markedly reduced by cardiac-specific calcineurin deletion.	Cyclosporine	124-137	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	44-49
30467953-12	2019	Moreover, the inactivation of calcineurin with cyclosporin A greatly offset the exacerbated hypertrophic response triggered by AB in TES knockdown mice.	Cyclosporine	47-60	testin LIM domain protein	Mus musculus	133-136
31257346-3	2019	In addition to MTX T-LPDs and MTX NK/T-LPDs, T-LPD and NK/T-LPDs have been reported in patients receiving other immunosuppressive agents such as thiopurines, TNF antagonists, and cyclosporine.	Cyclosporine	179-191	tumor necrosis factor	Homo sapiens	158-161
30648591-11	2019	KBrO3 increased the protein levels of these signals and the specific inhibitor, such as cyclosporine A and tacrolimus, attenuated the signaling in H9c2 cells at concentrations sufficient to inhibit calcineurin in addition to the reduction of mRNA levels of UBE3A, similar to ANP or BNP.	Cyclosporine	88-102	natriuretic peptide B	Rattus norvegicus	282-285
30726823-0	2019	[Successful treatment of pure red cell aplasia with cyclosporin in a patient with T-cell large granular lymphocytic leukemia harboring the STAT3 D661V mutation].	Cyclosporine	52-63	signal transducer and activator of transcription 3	Homo sapiens	139-144
29996743-4	2018	After treatment with HDIVIG + r-ATG + CSA, the percentage of CD20+ B cells in peripheral blood was decreased obviously, and the percentage of Tregs was significantly increased.	Cyclosporine	38-41	keratin 20	Homo sapiens	61-65
30419283-3	2018	Cyclosporin A and siRNA targeting Thrap1 (si-Thrap1) were used to inhibit NFATc1/MEF2C pathway and knockdown Thrap1, respectively.	Cyclosporine	0-13	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	74-80
30419283-3	2018	Cyclosporin A and siRNA targeting Thrap1 (si-Thrap1) were used to inhibit NFATc1/MEF2C pathway and knockdown Thrap1, respectively.	Cyclosporine	0-13	myocyte enhancer factor 2C	Mus musculus	81-86
30391882-3	2018	In the present study, it was found that administration of CsA causes a rapid activation of TGF-beta/Smad signaling cascade and subsequent expression of the profibrotic genes connective tissue growth factor (CTGF) and tissue inhibitors of matrix metallproteinases-1 (TIMP-1) in rat liver.	Cyclosporine	58-61	transforming growth factor, beta 1	Rattus norvegicus	91-99
30391882-0	2018	Vitamin E inhibits cyclosporin A-induced CTGF and TIMP-1 expression by repressing ROS-mediated activation of TGF-beta/Smad signaling pathway in rat liver.	Cyclosporine	19-32	transforming growth factor, beta 1	Rattus norvegicus	109-117
30171280-3	2018	Cyclosporine is a human breast cancer resistance protein (BCRP) inhibitor, and can potentially alter plasma exposure to eltrombopag, a BCRP substrate.	Cyclosporine	0-12	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	24-56
30171280-3	2018	Cyclosporine is a human breast cancer resistance protein (BCRP) inhibitor, and can potentially alter plasma exposure to eltrombopag, a BCRP substrate.	Cyclosporine	0-12	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	58-62
30171280-3	2018	Cyclosporine is a human breast cancer resistance protein (BCRP) inhibitor, and can potentially alter plasma exposure to eltrombopag, a BCRP substrate.	Cyclosporine	0-12	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	135-139
30044899-0	2018	Amenamevir: Studies of Potential CYP3A-Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers.	Cyclosporine	93-105	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	33-38
30442353-8	2018	The association of T/C and C/C genotypes in the SNP rs11706052 (IMPDH2) with the occurrence of rejection episodes considering only patients who received immunosuppressive drug MMF associated with cyclosporine or tacrolimus and corticoids, demonstrated association with a protection against rejection 15.6-fold.	Cyclosporine	196-208	inosine monophosphate dehydrogenase 2	Homo sapiens	64-70
30236524-7	2018	Remarkably, the SOD1G93A-induced mitoflash activity was attenuated by the application of cyclosporine A (CsA), an inhibitor of CypD.	Cyclosporine	89-103	superoxide dismutase 1, soluble	Mus musculus	16-20
30236524-7	2018	Remarkably, the SOD1G93A-induced mitoflash activity was attenuated by the application of cyclosporine A (CsA), an inhibitor of CypD.	Cyclosporine	89-103	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	127-131
30236524-7	2018	Remarkably, the SOD1G93A-induced mitoflash activity was attenuated by the application of cyclosporine A (CsA), an inhibitor of CypD.	Cyclosporine	105-108	superoxide dismutase 1, soluble	Mus musculus	16-20
30236524-7	2018	Remarkably, the SOD1G93A-induced mitoflash activity was attenuated by the application of cyclosporine A (CsA), an inhibitor of CypD.	Cyclosporine	105-108	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	127-131
30048737-6	2018	IL-2 production was reduced in response to treatment with well-known immunotoxicants cyclosporin A (CYA), dexamethasone (DEX), azathioprine (AZPR), methotrexate (MOT) and benzo(a)pyrene (BAP) but was not affected by treatment with cyclophosphamide (CYPH).	Cyclosporine	85-98	interleukin 2	Homo sapiens	0-4
30048737-6	2018	IL-2 production was reduced in response to treatment with well-known immunotoxicants cyclosporin A (CYA), dexamethasone (DEX), azathioprine (AZPR), methotrexate (MOT) and benzo(a)pyrene (BAP) but was not affected by treatment with cyclophosphamide (CYPH).	Cyclosporine	100-103	interleukin 2	Homo sapiens	0-4
30481230-0	2018	Kidney injury by cyclosporine A is aggravated in heme oxygenase-1 deficient mice and involves regulation of microRNAs.	Cyclosporine	17-31	heme oxygenase 1	Mus musculus	49-65
30464243-7	2018	Accordingly, addition of BAPTA-AM and cyclosporine-A, fully and partially inhibited IL-10 and TNF-alpha respectively.	Cyclosporine	38-52	tumor necrosis factor	Homo sapiens	94-103
30713473-0	2018	Cyclosporin A attenuating morphine tolerance through inhibiting NO/ERK signaling pathway in human glioblastoma cell line: the involvement of calcineurin.	Cyclosporine	0-13	mitogen-activated protein kinase 1	Homo sapiens	67-70
30391882-5	2018	Furthermore, CsA administration significantly increased the serum levels of the liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) as well as lipid peroxidation in hepatic tissues.	Cyclosporine	13-16	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	129-155
30391882-5	2018	Furthermore, CsA administration significantly increased the serum levels of the liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) as well as lipid peroxidation in hepatic tissues.	Cyclosporine	13-16	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	157-160
30391882-6	2018	Moreover, significant reduction in the hepatic content of reduced glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT) was observed in CsA-alone-treated animals.	Cyclosporine	148-151	catalase	Rattus norvegicus	117-125
30391882-9	2018	Furthermore, administration of PEG-SOD clearly attenuated TGF-beta/Smad signaling induced by CsA.	Cyclosporine	93-96	transforming growth factor, beta 1	Rattus norvegicus	58-66
30344674-8	2018	CsA treatment resulted in the decreased expression of insulin and PPIB; however, it also increased the phosphorylation of PERK, and upregulated the expression of PERK, BIP, CHOP and cleaved caspase-3.	Cyclosporine	0-3	heat shock protein 5	Mus musculus	168-171
30220530-0	2018	The mTOR-inhibitor Sirolimus decreases the cyclosporine-induced expression of the oncogene ATF3 in human keratinocytes.	Cyclosporine	43-55	mechanistic target of rapamycin kinase	Homo sapiens	4-8
30325678-7	2018	CsA mainly enhanced MUC5AC, with an increase in PAS-positive cells, whereas DQS chiefly increased membrane-associated mucins (MM).	Cyclosporine	0-3	mucin 5, subtypes A and C, tracheobronchial/gastric	Mus musculus	20-26
29717349-9	2018	The MPTP inhibitor cyclosporine A effectively suppressed cell death and cytochrome c release during wheat endosperm PCD.	Cyclosporine	19-33	cytochrome c, somatic	Homo sapiens	72-84
30221729-12	2018	Additionally, cyclosporine A attenuated the cardiac hypertrophy induced by KBrO3 in H9c2 cells at concentrations effective to inhibit calcineurin, in addition to reducing mRNA levels of BNP or beta-MHC.	Cyclosporine	14-28	natriuretic peptide B	Rattus norvegicus	186-189
30367813-7	2018	In addition, injection of CsA decreased total cells (P&lt;.05), neutrophils (P&lt;.05), and total protein (P&lt;.05) in BALF and inflammatory mediators, including tumor necrosis factor-a (TNF-a, P&lt;.05) and interleukin-6 (IL-6, P&lt;.05) in a dose-dependent manner.	Cyclosporine	26-29	tumor necrosis factor	Mus musculus	163-186
30367813-7	2018	In addition, injection of CsA decreased total cells (P&lt;.05), neutrophils (P&lt;.05), and total protein (P&lt;.05) in BALF and inflammatory mediators, including tumor necrosis factor-a (TNF-a, P&lt;.05) and interleukin-6 (IL-6, P&lt;.05) in a dose-dependent manner.	Cyclosporine	26-29	tumor necrosis factor	Mus musculus	188-193
30367813-7	2018	In addition, injection of CsA decreased total cells (P&lt;.05), neutrophils (P&lt;.05), and total protein (P&lt;.05) in BALF and inflammatory mediators, including tumor necrosis factor-a (TNF-a, P&lt;.05) and interleukin-6 (IL-6, P&lt;.05) in a dose-dependent manner.	Cyclosporine	26-29	interleukin 6	Mus musculus	209-222
30367813-7	2018	In addition, injection of CsA decreased total cells (P&lt;.05), neutrophils (P&lt;.05), and total protein (P&lt;.05) in BALF and inflammatory mediators, including tumor necrosis factor-a (TNF-a, P&lt;.05) and interleukin-6 (IL-6, P&lt;.05) in a dose-dependent manner.	Cyclosporine	26-29	interleukin 6	Mus musculus	224-228
30337298-7	2018	The STAT3-mutation-positive patients were younger (median age, 63 vs 73 years; P= .026) and less responsive to cyclosporine (46% [6 of 13] vs 100% [8 of 8]; P= .0092) in comparison with STAT3-mutation-negative patients.	Cyclosporine	111-123	signal transducer and activator of transcription 3	Homo sapiens	4-9
30056146-6	2018	However under the same conditions, 10 muL of chicken serum or 10 muL of buffer containing 216 mug of chicken serum albumin (CSA) (amount of albumin content in this serum volume) with 100 muM Cu2+ showed the same stereoselectivity and similar levels to the Cu2+-dependent R-(+)-HDCP hydrolysis.	Cyclosporine	124-127	albumin	Homo sapiens	115-122
30338826-8	2018	Cyclosporine treatment greatly reversed the cell damage on HK-2 cells induced by TGF-beta.	Cyclosporine	0-12	transforming growth factor beta 1	Homo sapiens	81-89
30338826-9	2018	Expression levels of mTOR pathway-related genes were downregulated after cyclosporine treatment.	Cyclosporine	73-85	mechanistic target of rapamycin kinase	Homo sapiens	21-25
30338826-10	2018	CONCLUSIONS: Cyclosporine protects HK-2 cells from inflammatory injury via regulating mTOR pathway.	Cyclosporine	13-25	mechanistic target of rapamycin kinase	Homo sapiens	86-90
30056146-6	2018	However under the same conditions, 10 muL of chicken serum or 10 muL of buffer containing 216 mug of chicken serum albumin (CSA) (amount of albumin content in this serum volume) with 100 muM Cu2+ showed the same stereoselectivity and similar levels to the Cu2+-dependent R-(+)-HDCP hydrolysis.	Cyclosporine	124-127	albumin	Homo sapiens	140-147
30429710-0	2018	Variances in the mRNA expression profile of TGF-beta1-3 isoforms and its TGF-betaRI-III receptors during cyclosporin a treatment of psoriatic patients.	Cyclosporine	105-118	transforming growth factor beta 1	Homo sapiens	44-53
30429710-3	2018	Aim: The aim of this study was to investigate the expression of genes encoding the transforming growth factor (TGF)-beta isoforms and receptors of the cytokine TGF-betaRs in psoriatic patients during an 84-day long observation of the effects of cyclosporin A therapy.	Cyclosporine	245-258	transforming growth factor beta 1	Homo sapiens	111-120
30429710-7	2018	Results: The expression of TGF-beta1-3 and TGF-betaRI-III were detected in the whole period of therapy with CsA.	Cyclosporine	108-111	transforming growth factor beta 1	Homo sapiens	27-36
30377135-8	2018	Pretreatment with cyclosporine A or 11R- VIVIT completely blocked nuclear accumulation of NFAT2.	Cyclosporine	18-32	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	90-95
30098482-2	2018	The neuroprotective effect of seventeen compounds against Abeta-induced mPTP opening was superior to that of the standard Cyclosporin A (CsA).	Cyclosporine	122-135	amyloid beta precursor protein	Homo sapiens	58-63
30121055-5	2018	Results: Our results showed that SC administration of CsA (30 mg/kg) to rats produced marked injury and apoptosis, elevation of Baxprotein expression, and inhibitionof Bcl-2protein expression in the kidneys, which were reversed significantly by oral administration of RG (0.2 or 0.4 mg/kg).	Cyclosporine	54-57	BCL2, apoptosis regulator	Rattus norvegicus	168-173
30185657-4	2018	Herein, we found that CSA drives SCC proliferation and tumor growth through IL-22 and JAK/STAT pathway induction.	Cyclosporine	22-25	Janus kinase 1	Homo sapiens	86-89
30185657-8	2018	JAK/STAT pathway genes were highly expressed in tumors from a cohort of CSA-exposed OTRs and in SCC with high risk for metastasis.	Cyclosporine	72-75	Janus kinase 1	Homo sapiens	0-3
30185657-10	2018	In nude mice engrafted with human A431 cells, IL-22 and CSA treatment increased tumor growth and upregulated IL-22 receptor, JAK1, and STAT1/3 expression.	Cyclosporine	56-59	Janus kinase 1	Homo sapiens	125-129
30111091-1	2018	In this work, we use antisolvent precipitation to prepare zein/carboxymethylated short-chain amylose (CSA) complex nanoparticles for insulin encapsulation, showing that insulin-loaded zein/CSA complex nanoparticles are homogeneous, generally exhibiting sizes of &lt;200 nm with a narrow distribution (polydispersity index &lt; 0.100), spherical shape, and strong negative charge (-40 mV).	Cyclosporine	102-105	insulin	Homo sapiens	133-140
30111091-1	2018	In this work, we use antisolvent precipitation to prepare zein/carboxymethylated short-chain amylose (CSA) complex nanoparticles for insulin encapsulation, showing that insulin-loaded zein/CSA complex nanoparticles are homogeneous, generally exhibiting sizes of &lt;200 nm with a narrow distribution (polydispersity index &lt; 0.100), spherical shape, and strong negative charge (-40 mV).	Cyclosporine	102-105	insulin	Homo sapiens	169-176
30111091-1	2018	In this work, we use antisolvent precipitation to prepare zein/carboxymethylated short-chain amylose (CSA) complex nanoparticles for insulin encapsulation, showing that insulin-loaded zein/CSA complex nanoparticles are homogeneous, generally exhibiting sizes of &lt;200 nm with a narrow distribution (polydispersity index &lt; 0.100), spherical shape, and strong negative charge (-40 mV).	Cyclosporine	189-192	insulin	Homo sapiens	169-176
29719087-8	2018	Telmisartan, cyclosporine-A, and 11R-VIVIT attenuated stretch-induced alterations in the levels of NFAT3 , mRNA and protein expression of Kir2.1, the density of Ik1 , and the APD.	Cyclosporine	13-27	potassium inwardly-rectifying channel, subfamily J, member 2	Rattus norvegicus	138-144
30098482-2	2018	The neuroprotective effect of seventeen compounds against Abeta-induced mPTP opening was superior to that of the standard Cyclosporin A (CsA).	Cyclosporine	137-140	amyloid beta precursor protein	Homo sapiens	58-63
29679227-7	2018	And the protective effects of knocking down CypD by siRNA interference or the addition of cyclosporin A (CsA), an inhibitor of CypD, were evidenced by rescued mitochondrial function and osteogenic function of osteoblast under tumor necrosis factor-alpha (TNF-alpha) treatment.	Cyclosporine	105-108	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	44-48
30109442-8	2018	The apparent permeability of the fluorescent P-gp substrate rhodamine 123 was decreased by 35% by co-incubation with cyclosporin A.	Cyclosporine	117-130	ATP binding cassette subfamily B member 1	Homo sapiens	45-49
29679227-7	2018	And the protective effects of knocking down CypD by siRNA interference or the addition of cyclosporin A (CsA), an inhibitor of CypD, were evidenced by rescued mitochondrial function and osteogenic function of osteoblast under tumor necrosis factor-alpha (TNF-alpha) treatment.	Cyclosporine	105-108	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	127-131
29679227-7	2018	And the protective effects of knocking down CypD by siRNA interference or the addition of cyclosporin A (CsA), an inhibitor of CypD, were evidenced by rescued mitochondrial function and osteogenic function of osteoblast under tumor necrosis factor-alpha (TNF-alpha) treatment.	Cyclosporine	105-108	tumor necrosis factor	Mus musculus	226-253
29679227-7	2018	And the protective effects of knocking down CypD by siRNA interference or the addition of cyclosporin A (CsA), an inhibitor of CypD, were evidenced by rescued mitochondrial function and osteogenic function of osteoblast under tumor necrosis factor-alpha (TNF-alpha) treatment.	Cyclosporine	105-108	tumor necrosis factor	Mus musculus	255-264
29752095-6	2018	To conform the above conclusion, cyclosporin A (CSA) was applied to inhibit NFATc signaling pathway.	Cyclosporine	33-46	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	76-81
29752095-6	2018	To conform the above conclusion, cyclosporin A (CSA) was applied to inhibit NFATc signaling pathway.	Cyclosporine	48-51	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	76-81
29380240-5	2018	Short- and long-term treatments with tacrolimus, cyclosporin A or another CNI deltamethrin (herbicide) decreased basal and insulin-dependent glucose uptake in adipocytes, without any additive effects observed when added together.	Cyclosporine	49-62	insulin	Homo sapiens	123-130
29992622-1	2018	BACKGROUND: Ace-1 canine prostate cancer cells grow orthotopically in cyclosporine immunosuppressed laboratory beagles.	Cyclosporine	70-82	angiotensin I converting enzyme	Homo sapiens	12-17
29678659-0	2018	Association of CYP3A4*1B genotype with Cyclosporin A pharmacokinetics in renal transplant recipients: A meta-analysis.	Cyclosporine	39-52	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	15-21
29678659-2	2018	CYP3A4*1B is reported to be associated with CsA pharmacokinetics parameters, but the relevance is still in dispute.	Cyclosporine	44-47	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
29678659-3	2018	Therefore, a meta-analysis was employed to evaluate the influence of CYP3A4*1B on CsA pharmacokinetics at different post-transplantation times in adult renal transplant recipients.	Cyclosporine	82-85	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-75
29678659-11	2018	CONCLUSIONS: CYP3A4*1B is associated with CsA C0/Dose ratio in renal transplant recipients which indicates patients with CYP3A4*1B allele require lower dose of CsA to reach target blood concentration compared with the CYP3A4*1 carriers.	Cyclosporine	42-45	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	13-19
29678659-11	2018	CONCLUSIONS: CYP3A4*1B is associated with CsA C0/Dose ratio in renal transplant recipients which indicates patients with CYP3A4*1B allele require lower dose of CsA to reach target blood concentration compared with the CYP3A4*1 carriers.	Cyclosporine	42-45	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	121-127
29678659-11	2018	CONCLUSIONS: CYP3A4*1B is associated with CsA C0/Dose ratio in renal transplant recipients which indicates patients with CYP3A4*1B allele require lower dose of CsA to reach target blood concentration compared with the CYP3A4*1 carriers.	Cyclosporine	42-45	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	121-127
29678659-11	2018	CONCLUSIONS: CYP3A4*1B is associated with CsA C0/Dose ratio in renal transplant recipients which indicates patients with CYP3A4*1B allele require lower dose of CsA to reach target blood concentration compared with the CYP3A4*1 carriers.	Cyclosporine	160-163	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	13-19
29678659-11	2018	CONCLUSIONS: CYP3A4*1B is associated with CsA C0/Dose ratio in renal transplant recipients which indicates patients with CYP3A4*1B allele require lower dose of CsA to reach target blood concentration compared with the CYP3A4*1 carriers.	Cyclosporine	160-163	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	121-127
29678659-11	2018	CONCLUSIONS: CYP3A4*1B is associated with CsA C0/Dose ratio in renal transplant recipients which indicates patients with CYP3A4*1B allele require lower dose of CsA to reach target blood concentration compared with the CYP3A4*1 carriers.	Cyclosporine	160-163	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	121-127
29266762-1	2018	Calcineurin inhibitor toxicity (CNT) is a frequent occurrence in transplanted renal grafts and autochthone kidneys from patients undergoing long-term treatment with calcineurin inhibitors, notably cyclosporin A (CsA) and tacrolimus.	Cyclosporine	197-210	calcineurin binding protein 1	Mus musculus	0-21
29976866-4	2018	Comparing the samples from fibroblasts cultured with CsA and those cultured without, up-regulated changes of CYP19A1, 1B1, 7A1, 7F1, 17A1 and down-regulated 2D6 gene expression were observed.	Cyclosporine	53-56	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	109-116
29266762-1	2018	Calcineurin inhibitor toxicity (CNT) is a frequent occurrence in transplanted renal grafts and autochthone kidneys from patients undergoing long-term treatment with calcineurin inhibitors, notably cyclosporin A (CsA) and tacrolimus.	Cyclosporine	212-215	calcineurin binding protein 1	Mus musculus	0-21
30304236-7	2018	ABCB1 activity was evaluated via the rhodamine-123 transport and inhibited by cyclosporin A in hydrocortisone-treated and control mice.	Cyclosporine	78-91	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-5
29712725-3	2018	CsA is an inhibitor of organic anion transporting polypeptide (OATP)1B1 and CYP3A4, and GEM and its glucuronide (GEM-glu) inhibit OATP1B1 and CYP2C8.	Cyclosporine	0-3	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	76-82
30364730-12	2018	Mitochondrial KATP channel opener diazoxide and mPTP inhibitor cyclosporin A also offset the effects of CRP in this process.	Cyclosporine	63-76	C-reactive protein	Rattus norvegicus	104-107
29663071-0	2018	Cyclosporine A responsive congenital nephrotic syndrome with single heterozygous variants in NPHS1, NPHS2, and PLCE1.	Cyclosporine	0-14	NPHS2 stomatin family member, podocin	Homo sapiens	100-105
29309904-9	2018	This increased response were diminished by etoricoxib, furegrelate, SQ 29548, cyclosporine A and parthenolide, inhibitors of COX-2, TXA2 synthase, TP receptors, calcineurin and NF-kappaB, respectively.	Cyclosporine	78-92	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	177-186
29605535-14	2018	Resveratrol also increases levels of osteocalcin and osteopontin in normal and CsA-treated rats.	Cyclosporine	79-82	bone gamma-carboxyglutamate protein	Rattus norvegicus	37-48
29942660-7	2018	Furthermore, in vivo results indicated that CsA formulated in NPs sensitized Gef-resistant cells and Gef-resistant tumors to Gef treatment by inactivating the STAT3/Bcl-2 signaling pathway.	Cyclosporine	44-47	signal transducer and activator of transcription 3	Homo sapiens	159-164
29942660-7	2018	Furthermore, in vivo results indicated that CsA formulated in NPs sensitized Gef-resistant cells and Gef-resistant tumors to Gef treatment by inactivating the STAT3/Bcl-2 signaling pathway.	Cyclosporine	44-47	BCL2 apoptosis regulator	Homo sapiens	165-170
29895783-8	2018	Immunoglobulin E (IgE) binding capacity of rCSA and nCSA was analysed by ELISA using sera from patients sensitised to CSA.	Cyclosporine	44-47	immunoglobulin heavy constant epsilon	Homo sapiens	18-21
29895783-2	2018	The objective of this study was to produce a recombinant version of CSA and compare its IgE reactivity to natural CSA (nCSA).	Cyclosporine	68-71	immunoglobulin heavy constant epsilon	Homo sapiens	88-91
29895783-8	2018	Immunoglobulin E (IgE) binding capacity of rCSA and nCSA was analysed by ELISA using sera from patients sensitised to CSA.	Cyclosporine	44-47	immunoglobulin heavy constant epsilon	Homo sapiens	0-16
29895783-9	2018	Levels of IgE-binding were similar for both the recombinant and the natural CSA, indicating the existence of similar epitopes.	Cyclosporine	76-79	immunoglobulin heavy constant epsilon	Homo sapiens	10-13
29681769-11	2018	Results: Our results showed that treatment with TGF-beta/CsA led to loss of epithelial characteristics and gain of mesenchymal phenotype in vitro.	Cyclosporine	57-60	transforming growth factor beta 1	Homo sapiens	48-56
29550215-5	2018	We also demonstrate that an estrogen receptor beta (ERbeta) antagonist inhibits MPT and knockout of ERbeta decreases the sensitivity of mitochondria to the CypD inhibitor, cyclosporine A.	Cyclosporine	172-186	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	156-160
29222397-9	2018	These findings suggest that increased activity of P-gp could be responsible for increased hepatic cyclosporin clearance.	Cyclosporine	98-109	ATP binding cassette subfamily B member 1	Homo sapiens	50-54
29426003-8	2018	Of note, the observed effects of necrostatin-1 (Nec-1, inhibitor of RIPK1) and cyclosporine A (CsA, inhibitor of CypD) on attenuating programmed necrosis and related cardiac injury further demonstrated the significant role of programmed necrosis in dictating cell demise and shed light on their further clinical application, along with other types of inhibitors targeting programmed necrosis.	Cyclosporine	79-93	peptidylprolyl isomerase F	Homo sapiens	113-117
29426003-8	2018	Of note, the observed effects of necrostatin-1 (Nec-1, inhibitor of RIPK1) and cyclosporine A (CsA, inhibitor of CypD) on attenuating programmed necrosis and related cardiac injury further demonstrated the significant role of programmed necrosis in dictating cell demise and shed light on their further clinical application, along with other types of inhibitors targeting programmed necrosis.	Cyclosporine	95-98	peptidylprolyl isomerase F	Homo sapiens	113-117
29571015-5	2018	CSA or indomethacin caused: (i) renal tubular atrophy and interstitial fibrosis, (ii) increases in serum creatinine, blood urea nitrogen (BUN), and renal LTD4, LTB4, TNF-alpha, TGF-beta1, and caspase-3, and (iii) decreases in renal PGE2 and total antioxidant capacity (TAC).	Cyclosporine	0-3	tumor necrosis factor	Rattus norvegicus	166-175
29571015-5	2018	CSA or indomethacin caused: (i) renal tubular atrophy and interstitial fibrosis, (ii) increases in serum creatinine, blood urea nitrogen (BUN), and renal LTD4, LTB4, TNF-alpha, TGF-beta1, and caspase-3, and (iii) decreases in renal PGE2 and total antioxidant capacity (TAC).	Cyclosporine	0-3	transforming growth factor, beta 1	Rattus norvegicus	177-186
29734357-10	2018	CsA DDS treatment also greatly reduced the CD4+ T cell density and the expression of interferon-gamma, interleukin-2 (IL-2), IL-6, CD80, and CD86 mRNA both in the corneal graft and iris-ciliary body (all p &lt; 0.01).	Cyclosporine	0-3	interferon gamma	Oryctolagus cuniculus	85-101
29734357-10	2018	CsA DDS treatment also greatly reduced the CD4+ T cell density and the expression of interferon-gamma, interleukin-2 (IL-2), IL-6, CD80, and CD86 mRNA both in the corneal graft and iris-ciliary body (all p &lt; 0.01).	Cyclosporine	0-3	interleukin-2	Oryctolagus cuniculus	103-116
29734357-10	2018	CsA DDS treatment also greatly reduced the CD4+ T cell density and the expression of interferon-gamma, interleukin-2 (IL-2), IL-6, CD80, and CD86 mRNA both in the corneal graft and iris-ciliary body (all p &lt; 0.01).	Cyclosporine	0-3	interleukin-2	Oryctolagus cuniculus	118-122
29734357-10	2018	CsA DDS treatment also greatly reduced the CD4+ T cell density and the expression of interferon-gamma, interleukin-2 (IL-2), IL-6, CD80, and CD86 mRNA both in the corneal graft and iris-ciliary body (all p &lt; 0.01).	Cyclosporine	0-3	interleukin-6	Oryctolagus cuniculus	125-129
29734357-11	2018	Moreover, CsA DDS significantly reduced the IL-2 level in aqueous humor (p &lt; 0.01).	Cyclosporine	10-13	interleukin-2	Oryctolagus cuniculus	44-48
29330945-1	2018	AIM: Cyclosporine A (CsA) induces renal vasoconstriction and hypoxia and enhances the expression of endothelin-1 (ET-1) pro-hormone (pre-pro-ET-1), plausibly leading to a feed-forward loop of renal vasoconstriction, hypoxia and enhanced synthesis of the potent vasoconstrictor ET-1.	Cyclosporine	5-19	endothelin 1	Rattus norvegicus	100-112
29330945-1	2018	AIM: Cyclosporine A (CsA) induces renal vasoconstriction and hypoxia and enhances the expression of endothelin-1 (ET-1) pro-hormone (pre-pro-ET-1), plausibly leading to a feed-forward loop of renal vasoconstriction, hypoxia and enhanced synthesis of the potent vasoconstrictor ET-1.	Cyclosporine	5-19	endothelin 1	Rattus norvegicus	114-118
29330945-1	2018	AIM: Cyclosporine A (CsA) induces renal vasoconstriction and hypoxia and enhances the expression of endothelin-1 (ET-1) pro-hormone (pre-pro-ET-1), plausibly leading to a feed-forward loop of renal vasoconstriction, hypoxia and enhanced synthesis of the potent vasoconstrictor ET-1.	Cyclosporine	5-19	endothelin 1	Rattus norvegicus	141-145
29330945-1	2018	AIM: Cyclosporine A (CsA) induces renal vasoconstriction and hypoxia and enhances the expression of endothelin-1 (ET-1) pro-hormone (pre-pro-ET-1), plausibly leading to a feed-forward loop of renal vasoconstriction, hypoxia and enhanced synthesis of the potent vasoconstrictor ET-1.	Cyclosporine	5-19	endothelin 1	Rattus norvegicus	141-145
29330945-1	2018	AIM: Cyclosporine A (CsA) induces renal vasoconstriction and hypoxia and enhances the expression of endothelin-1 (ET-1) pro-hormone (pre-pro-ET-1), plausibly leading to a feed-forward loop of renal vasoconstriction, hypoxia and enhanced synthesis of the potent vasoconstrictor ET-1.	Cyclosporine	21-24	endothelin 1	Rattus norvegicus	100-112
29330945-1	2018	AIM: Cyclosporine A (CsA) induces renal vasoconstriction and hypoxia and enhances the expression of endothelin-1 (ET-1) pro-hormone (pre-pro-ET-1), plausibly leading to a feed-forward loop of renal vasoconstriction, hypoxia and enhanced synthesis of the potent vasoconstrictor ET-1.	Cyclosporine	21-24	endothelin 1	Rattus norvegicus	114-118
29330945-1	2018	AIM: Cyclosporine A (CsA) induces renal vasoconstriction and hypoxia and enhances the expression of endothelin-1 (ET-1) pro-hormone (pre-pro-ET-1), plausibly leading to a feed-forward loop of renal vasoconstriction, hypoxia and enhanced synthesis of the potent vasoconstrictor ET-1.	Cyclosporine	21-24	endothelin 1	Rattus norvegicus	141-145
29330945-1	2018	AIM: Cyclosporine A (CsA) induces renal vasoconstriction and hypoxia and enhances the expression of endothelin-1 (ET-1) pro-hormone (pre-pro-ET-1), plausibly leading to a feed-forward loop of renal vasoconstriction, hypoxia and enhanced synthesis of the potent vasoconstrictor ET-1.	Cyclosporine	21-24	endothelin 1	Rattus norvegicus	141-145
29330945-3	2018	We hypothesized that in addition to the direct induction of ET-1 synthesis, CsA might also intensify renal ECE-1 expression, thus contributing to enhanced ET-1 synthesis following CsA.	Cyclosporine	76-79	endothelin converting enzyme 1	Rattus norvegicus	107-112
29330945-3	2018	We hypothesized that in addition to the direct induction of ET-1 synthesis, CsA might also intensify renal ECE-1 expression, thus contributing to enhanced ET-1 synthesis following CsA.	Cyclosporine	76-79	endothelin 1	Rattus norvegicus	155-159
29330945-3	2018	We hypothesized that in addition to the direct induction of ET-1 synthesis, CsA might also intensify renal ECE-1 expression, thus contributing to enhanced ET-1 synthesis following CsA.	Cyclosporine	180-183	endothelin 1	Rattus norvegicus	155-159
29330945-6	2018	RESULTS: Cyclosporine A intensified renal parenchymal ECE-1 expression in the rat kidney, particularly in distal nephron segments, along with renal hypoxia (detected by pimonidazole adducts) and HIF expression, in line with our recent observations showing episodic hypoxia in mice subjected to CsA.	Cyclosporine	9-23	endothelin converting enzyme 1	Rattus norvegicus	54-59
29330945-7	2018	Furthermore, in cultured normoxic HUVEC and HK-2 cells, CsA dose-dependently induced both pre-pro-ET-1 and ECE-1 mRNA and protein expression, with enhanced ET-1 generation.	Cyclosporine	56-59	endothelin 1	Rattus norvegicus	98-102
29330945-7	2018	Furthermore, in cultured normoxic HUVEC and HK-2 cells, CsA dose-dependently induced both pre-pro-ET-1 and ECE-1 mRNA and protein expression, with enhanced ET-1 generation.	Cyclosporine	56-59	endothelin converting enzyme 1	Rattus norvegicus	107-112
29330945-7	2018	Furthermore, in cultured normoxic HUVEC and HK-2 cells, CsA dose-dependently induced both pre-pro-ET-1 and ECE-1 mRNA and protein expression, with enhanced ET-1 generation.	Cyclosporine	56-59	endothelin 1	Rattus norvegicus	156-160
29330945-8	2018	CONCLUSION: CsA induces ECE-1 via both hypoxic and non-hypoxic pathways.	Cyclosporine	12-15	endothelin converting enzyme 1	Rattus norvegicus	24-29
29330945-9	2018	ECE-1 may contribute to increased renal ET-1 generation following CsA, participating in a feed-forward loop of renal parenchymal hypoxia and ET synthesis.	Cyclosporine	66-69	endothelin converting enzyme 1	Rattus norvegicus	0-5
29501733-9	2018	(2) CsA induced the formation of autophagosomes and up-regulated the expression of Beclin1, LC3B, and the ERK/MAPK pathway in cardiac fibroblasts.	Cyclosporine	4-7	mitogen-activated protein kinase 1	Homo sapiens	106-109
29501733-9	2018	(2) CsA induced the formation of autophagosomes and up-regulated the expression of Beclin1, LC3B, and the ERK/MAPK pathway in cardiac fibroblasts.	Cyclosporine	4-7	mitogen-activated protein kinase 1	Homo sapiens	110-114
29501733-10	2018	(3) CsA induced NRP-2 down-regulation and WDFY-1 up-regulation.	Cyclosporine	4-7	WD repeat and FYVE domain containing 1	Homo sapiens	42-48
29501733-11	2018	(4) Depletion of WDFY-1 inhibited CsA-induced autophagy, TNF-alpha and IFN-alpha up-regulation, and fibrosis.	Cyclosporine	34-37	WD repeat and FYVE domain containing 1	Homo sapiens	17-23
29501733-11	2018	(4) Depletion of WDFY-1 inhibited CsA-induced autophagy, TNF-alpha and IFN-alpha up-regulation, and fibrosis.	Cyclosporine	34-37	tumor necrosis factor	Homo sapiens	57-66
29501733-12	2018	(5) The autophagy inhibitor 3-MA inhibited CsA-induced TNF-alpha and IFN-alpha up-regulation and fibrosis.	Cyclosporine	43-46	tumor necrosis factor	Homo sapiens	55-64
29501733-12	2018	(5) The autophagy inhibitor 3-MA inhibited CsA-induced TNF-alpha and IFN-alpha up-regulation and fibrosis.	Cyclosporine	43-46	interferon alpha 1	Homo sapiens	69-78
29352737-7	2018	The addition of 2 5 ng/ml cyclosporin A and 1 microM prednisolone inhibit IFN-gamma/TNF-alpha production significantly by CD8+ Pgp+ T cells from BOS patients.	Cyclosporine	26-39	interferon gamma	Homo sapiens	74-83
29352737-7	2018	The addition of 2 5 ng/ml cyclosporin A and 1 microM prednisolone inhibit IFN-gamma/TNF-alpha production significantly by CD8+ Pgp+ T cells from BOS patients.	Cyclosporine	26-39	tumor necrosis factor	Homo sapiens	84-93
29352737-7	2018	The addition of 2 5 ng/ml cyclosporin A and 1 microM prednisolone inhibit IFN-gamma/TNF-alpha production significantly by CD8+ Pgp+ T cells from BOS patients.	Cyclosporine	26-39	ATP binding cassette subfamily B member 1	Homo sapiens	127-130
29863267-11	2018	Western blotting showed that the protein expressions of Caspase 3 and Caspase 9 were remarkably elevated in cells after the use of CsA, but were significantly reduced after administration of CST (p < 0.01).	Cyclosporine	131-134	caspase 9	Rattus norvegicus	70-79
28756540-8	2018	In the group treated with cyclosporine A, patients with C-reactive protein &gt;3 mg/L had a response rate significantly higher than those with C-reactive protein &lt;3 mg/L (P = 0.03); those with negative C-reactive protein and moderate Mayo score did not responded to therapy, while in the ones with elevated C-reactive protein and/or severe Mayo score, 15 versus 4 responded (P = 0.008).	Cyclosporine	26-40	C-reactive protein	Homo sapiens	56-74
28756540-8	2018	In the group treated with cyclosporine A, patients with C-reactive protein &gt;3 mg/L had a response rate significantly higher than those with C-reactive protein &lt;3 mg/L (P = 0.03); those with negative C-reactive protein and moderate Mayo score did not responded to therapy, while in the ones with elevated C-reactive protein and/or severe Mayo score, 15 versus 4 responded (P = 0.008).	Cyclosporine	26-40	C-reactive protein	Homo sapiens	143-161
28756540-8	2018	In the group treated with cyclosporine A, patients with C-reactive protein &gt;3 mg/L had a response rate significantly higher than those with C-reactive protein &lt;3 mg/L (P = 0.03); those with negative C-reactive protein and moderate Mayo score did not responded to therapy, while in the ones with elevated C-reactive protein and/or severe Mayo score, 15 versus 4 responded (P = 0.008).	Cyclosporine	26-40	C-reactive protein	Homo sapiens	143-161
28756540-8	2018	In the group treated with cyclosporine A, patients with C-reactive protein &gt;3 mg/L had a response rate significantly higher than those with C-reactive protein &lt;3 mg/L (P = 0.03); those with negative C-reactive protein and moderate Mayo score did not responded to therapy, while in the ones with elevated C-reactive protein and/or severe Mayo score, 15 versus 4 responded (P = 0.008).	Cyclosporine	26-40	C-reactive protein	Homo sapiens	143-161
29510137-7	2018	Our study also showed that CsA could inhibit interleukin-6 expression in BM-MSCs, while promoting programmed death-ligand 2 expression.	Cyclosporine	27-30	interleukin 6	Mus musculus	45-58
28925592-3	2018	Using photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP), we isolated RNAs associated with Argonaute 2 in the RNA-induced silencing complex (RISC) of cyclosporine A (CsA) treated and control human proximal tubule cells and identified mRNAs undergoing active targeting by miRNAs.	Cyclosporine	188-202	argonaute RISC catalytic component 2	Homo sapiens	129-140
28925592-3	2018	Using photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP), we isolated RNAs associated with Argonaute 2 in the RNA-induced silencing complex (RISC) of cyclosporine A (CsA) treated and control human proximal tubule cells and identified mRNAs undergoing active targeting by miRNAs.	Cyclosporine	204-207	argonaute RISC catalytic component 2	Homo sapiens	129-140
29623717-4	2018	The results show a multifactorial origin of thrombocytopenia and a possible effect on refractivity to cyclosporine A therapy caused by long-term smoking, MDR-1 gene polymorphism, genetic predisposition to autoimmune diseases, allergic reactions as a manifestation of hypersensitivity in the immune system, controversial compliance of the patient, overcome infections as well as impact of drugs taken.Key words: immune thrombocytopenia refractery form cyclosporine A therapy platelets.	Cyclosporine	102-116	ATP binding cassette subfamily B member 1	Homo sapiens	154-159
29720757-12	2018	Conclusion: Application of PEEP 10-15 cmH2O in Trendelenburg position significantly increased CSA and AP diameter of IJV and decreased CA overlap of IJV in anesthetised paralysed patients.	Cyclosporine	94-97	troponin T2, cardiac type	Homo sapiens	38-42
29393366-7	2018	Following the administration of D-pinitol, there were increased expression levels of heme oxygenase-1, NAD(P)H:quinone oxidoreductase 1, superoxide dismutase 1 and catalase in CsA-treated kidneys.	Cyclosporine	176-179	heme oxygenase 1	Mus musculus	85-135
29393366-7	2018	Following the administration of D-pinitol, there were increased expression levels of heme oxygenase-1, NAD(P)H:quinone oxidoreductase 1, superoxide dismutase 1 and catalase in CsA-treated kidneys.	Cyclosporine	176-179	catalase	Mus musculus	164-172
29393366-8	2018	In addition, D-pinitol increased the level of sirtuin 1 (Sirt1), and the total and nuclear expression levels of nuclear erythroid factor 2-related factor 2 (Nrf2), suggesting that activation of the Sirt1 and Nrf2 pathways may induce the cellular antioxidant system against CsA-induced nephropathy.	Cyclosporine	273-276	nuclear factor, erythroid derived 2, like 2	Mus musculus	112-155
29393366-8	2018	In addition, D-pinitol increased the level of sirtuin 1 (Sirt1), and the total and nuclear expression levels of nuclear erythroid factor 2-related factor 2 (Nrf2), suggesting that activation of the Sirt1 and Nrf2 pathways may induce the cellular antioxidant system against CsA-induced nephropathy.	Cyclosporine	273-276	nuclear factor, erythroid derived 2, like 2	Mus musculus	157-161
29393366-8	2018	In addition, D-pinitol increased the level of sirtuin 1 (Sirt1), and the total and nuclear expression levels of nuclear erythroid factor 2-related factor 2 (Nrf2), suggesting that activation of the Sirt1 and Nrf2 pathways may induce the cellular antioxidant system against CsA-induced nephropathy.	Cyclosporine	273-276	nuclear factor, erythroid derived 2, like 2	Mus musculus	208-212
29436671-8	2018	The results demonstrated that treatment of HK-2 cells with CsA significantly increased ROS and MDA levels, and decreased the activities of SOD, GSH-Px and CAT, compared with the control group.	Cyclosporine	59-62	catalase	Rattus norvegicus	155-158
29309803-8	2018	The gene expression as well as protein production of the cell cycle inhibitor p21 (CDKN1A) but not p16 (CDKN2A) was significantly induced by cyclosporine compared to the other two immunosuppressive agents when determined by western blotting an immuncytochemistry.	Cyclosporine	141-153	cyclin dependent kinase inhibitor 1A	Homo sapiens	78-81
29309803-8	2018	The gene expression as well as protein production of the cell cycle inhibitor p21 (CDKN1A) but not p16 (CDKN2A) was significantly induced by cyclosporine compared to the other two immunosuppressive agents when determined by western blotting an immuncytochemistry.	Cyclosporine	141-153	cyclin dependent kinase inhibitor 1A	Homo sapiens	83-89
29661427-10	2018	Cyclosporine A was the basis of immunosuppression in the majority [(n = 14); pretreatment and intra-treatment levels were 79.5 +- 23.0 and 91.8 +- 26.0 ng/mL, respectively (P = .08)]; tacrolimus (n = 8) and mammalian target of rapamycin (mTOR) levels (n = 5) were also similar.	Cyclosporine	0-14	mechanistic target of rapamycin kinase	Homo sapiens	207-236
29661427-10	2018	Cyclosporine A was the basis of immunosuppression in the majority [(n = 14); pretreatment and intra-treatment levels were 79.5 +- 23.0 and 91.8 +- 26.0 ng/mL, respectively (P = .08)]; tacrolimus (n = 8) and mammalian target of rapamycin (mTOR) levels (n = 5) were also similar.	Cyclosporine	0-14	mechanistic target of rapamycin kinase	Homo sapiens	238-242
29328412-9	2018	CsA significantly decreased the expression levels of IL-10, TNF-alpha, Cyp-D and AIF in the spinal cord of the SCI rats.	Cyclosporine	0-3	tumor necrosis factor	Rattus norvegicus	60-69
29434184-7	2018	ALP activity increased under HG with CsA or a calcifying medium compared to HG conditions alone.	Cyclosporine	37-40	alkaline phosphatase, placental	Homo sapiens	0-3
29434184-8	2018	CsA increased ALP activity under low glucose (LG, 5.5 mM) with a calcifying medium, but markedly increased under HG with a calcifying medium.	Cyclosporine	0-3	alkaline phosphatase, placental	Homo sapiens	14-17
29434184-9	2018	CsA significantly increased the mRNA expressions of the calcification markers (core binding factor-alpha 1, bone morphologic proteins 2) as well as those of the inflammatory marker (interleukin 6), under HG with a calcifying medium.	Cyclosporine	0-3	interleukin 6	Homo sapiens	182-195
29391135-4	2018	In this study, we found that CsA reduced the expression of PGC-1alpha at both the mRNA and protein levels in HepG2 cells.	Cyclosporine	29-32	PPARG coactivator 1 alpha	Homo sapiens	59-69
29391135-5	2018	Correspondingly, the expressions of its target genes NRF 1 and TFAM were reduced in response to CsA treatment.	Cyclosporine	96-99	transcription factor A, mitochondrial	Homo sapiens	63-67
29391135-7	2018	Over-expression of PGC-1alpha was found to rescue the negative effect of CsA administration on mitochondrial biogenesis.	Cyclosporine	73-76	PPARG coactivator 1 alpha	Homo sapiens	19-29
29225189-6	2018	Luteolin and cyclosporine A (CsA) which was a positive control also substantially reduced OVA-specific IgE levels, eotaxin 2 levels, and CCR3 expression in BAL Fluid.	Cyclosporine	13-27	chemokine (C-C motif) receptor 3	Mus musculus	137-141
29225189-6	2018	Luteolin and cyclosporine A (CsA) which was a positive control also substantially reduced OVA-specific IgE levels, eotaxin 2 levels, and CCR3 expression in BAL Fluid.	Cyclosporine	29-32	chemokine (C-C motif) receptor 3	Mus musculus	137-141
29568367-4	2018	Sensitivity was completely restored with specific inhibitors cyclosporine (ABCB1) and Ko143 (ABCG2): K562-Dox LD50asciminib+cyclosporine = 13 nM, K562-ABCG2 LD50asciminib+Ko143 = 15 nM (p &lt; 0.001).	Cyclosporine	61-73	ATP binding cassette subfamily B member 1	Homo sapiens	75-80
29136370-4	2017	Western blot showed that OTA induced cytochrome c (cyt-c) release and caspase-3 activation, which could be suppressed by inhibition of mPTP opening with cyclosporin A.	Cyclosporine	153-166	caspase 3	Sus scrofa	70-79
29411011-12	2018	CsA (10 muM) significantly inhibited the H2O2-induced expression of NFATc3 in normal and glaucoma LC cells.	Cyclosporine	0-3	latexin	Homo sapiens	8-11
29411011-12	2018	CsA (10 muM) significantly inhibited the H2O2-induced expression of NFATc3 in normal and glaucoma LC cells.	Cyclosporine	0-3	nuclear factor of activated T cells 3	Homo sapiens	68-74
29411011-13	2018	CsA also reduced the H2O2-induced NFATc3 dephosphorylation (and nuclear translocation), and also suppressed the H2O2-induced elevation in profibrotic ECM genes (TGFbeta1, Col1A1, and periostin), both in normal and in glaucoma LC cells.	Cyclosporine	0-3	nuclear factor of activated T cells 3	Homo sapiens	34-40
29411011-13	2018	CsA also reduced the H2O2-induced NFATc3 dephosphorylation (and nuclear translocation), and also suppressed the H2O2-induced elevation in profibrotic ECM genes (TGFbeta1, Col1A1, and periostin), both in normal and in glaucoma LC cells.	Cyclosporine	0-3	transforming growth factor beta 1	Homo sapiens	161-169
29411011-15	2018	CsA reduced the H2O2-induced enhancement in NFATc3 protein expression and nuclear translocation and the profibrotic gene expression both in normal and in glaucoma LC cells.	Cyclosporine	0-3	nuclear factor of activated T cells 3	Homo sapiens	44-50
29257277-9	2018	Furthermore, the effects of UII were substantially inhibited by treatment with the inhibitors PD98059, Y-27632, H-7, CSA and nicardipine.	Cyclosporine	117-120	urotensin 2	Rattus norvegicus	28-31
28472860-5	2018	RESULTS: There was a medium-effect size inverse relationship between CSA and CSF PGRN, but not between CSA and serum PGRN.	Cyclosporine	69-72	granulin precursor	Homo sapiens	81-85
29288949-3	2018	The inhibitory activity of twenty five compounds against Abeta-induced mPTP opening was superior to that of the standard cyclosporin A (CsA).	Cyclosporine	121-134	amyloid beta precursor protein	Homo sapiens	57-62
29288949-3	2018	The inhibitory activity of twenty five compounds against Abeta-induced mPTP opening was superior to that of the standard cyclosporin A (CsA).	Cyclosporine	136-139	amyloid beta precursor protein	Homo sapiens	57-62
29267497-10	2017	The results of this work suggested the direct participation of ET-1 in renal hemodynamics changes induced by cyclosporin in normotensive and hypertensive rats.	Cyclosporine	109-120	endothelin 1	Rattus norvegicus	63-67
29801578-4	2018	For calcineurin inhibitors like cyclosporine and in particular tacrolimus however, cytochrome P450 3A4 and 3A5 variants were found to significantly affect the pharmacokinetics.	Cyclosporine	32-44	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	83-102
29127010-8	2018	Kidney tumor necrosis factor alpha (TNF-alpha) levels were found to drop in female rats following CSA treatment, whereas no change was observed in male rats before and after treatment.	Cyclosporine	98-101	tumor necrosis factor	Rattus norvegicus	7-34
29127010-8	2018	Kidney tumor necrosis factor alpha (TNF-alpha) levels were found to drop in female rats following CSA treatment, whereas no change was observed in male rats before and after treatment.	Cyclosporine	98-101	tumor necrosis factor	Rattus norvegicus	36-45
30355923-15	2018	Following the addition of 500 muM Erinacine and MPTP opening inhibitor CsA, we found that the mitochondrial membrane potential level increased, while mitochondrial Ca2+ and Cyt-C decreased from the mitochondria.	Cyclosporine	71-74	cytochrome c, somatic	Homo sapiens	173-178
29069656-5	2018	Using an experimental model of ascending UTI, we showed that the pretreatment of mice with CsA prior to infection induced a marked fall in cytokine production by collecting duct cells, neutrophil recruitment, and a dramatic rise of bacterial load, but not in infected TLR4-defective mice kidneys.	Cyclosporine	91-94	toll-like receptor 4	Mus musculus	268-272
29031076-2	2017	The neuroprotective effect of seventeen compounds against Abeta-induced mPTP opening was superior to that of the standard Cyclosporin A (CsA).	Cyclosporine	122-135	amyloid beta precursor protein	Homo sapiens	58-63
29031076-2	2017	The neuroprotective effect of seventeen compounds against Abeta-induced mPTP opening was superior to that of the standard Cyclosporin A (CsA).	Cyclosporine	137-140	amyloid beta precursor protein	Homo sapiens	58-63
28777375-7	2017	Loss of mitochondrial inner membrane potential is also prevented by cyclosporine A, implicating the mitochondrial permeability transition pore in death aggravated by DeltaN-Bcl-xL.	Cyclosporine	68-82	BCL2 like 1	Homo sapiens	173-179
29135906-0	2017	Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia.	Cyclosporine	94-107	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	37-43
29135906-0	2017	Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia.	Cyclosporine	94-107	cytochrome p450 oxidoreductase	Homo sapiens	57-60
29135906-1	2017	BACKGROUND: The interindividual variability of cyclosporin A (CsA) pharmacokinetics might be explained by heterogeneity in the cytochrome P450 3A (CYP3A) subfamily.	Cyclosporine	47-60	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	127-145
29135906-1	2017	BACKGROUND: The interindividual variability of cyclosporin A (CsA) pharmacokinetics might be explained by heterogeneity in the cytochrome P450 3A (CYP3A) subfamily.	Cyclosporine	47-60	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	147-152
29135906-1	2017	BACKGROUND: The interindividual variability of cyclosporin A (CsA) pharmacokinetics might be explained by heterogeneity in the cytochrome P450 3A (CYP3A) subfamily.	Cyclosporine	62-65	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	127-145
29135906-1	2017	BACKGROUND: The interindividual variability of cyclosporin A (CsA) pharmacokinetics might be explained by heterogeneity in the cytochrome P450 3A (CYP3A) subfamily.	Cyclosporine	62-65	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	147-152
29135906-3	2017	The aim of this study was to assess the impact of age, CYP3A5*3, CYP3A4*22, and POR*28 alleles on CsA pharmacokinetics in pediatric renal transplant recipients.	Cyclosporine	98-101	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	55-61
29135906-3	2017	The aim of this study was to assess the impact of age, CYP3A5*3, CYP3A4*22, and POR*28 alleles on CsA pharmacokinetics in pediatric renal transplant recipients.	Cyclosporine	98-101	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	65-71
29135906-3	2017	The aim of this study was to assess the impact of age, CYP3A5*3, CYP3A4*22, and POR*28 alleles on CsA pharmacokinetics in pediatric renal transplant recipients.	Cyclosporine	98-101	cytochrome p450 oxidoreductase	Homo sapiens	80-83
29135906-8	2017	Carriers of CYP3A5*3 allele aged &lt;=6 years required higher dose of CsA and achieved lower C0/dose and C2/dose, at most time points, than older carriers of this allele.	Cyclosporine	70-73	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	12-18
29135906-9	2017	Carriers of POR*28 allele aged &lt;=6 years required higher doses of CsA, whereas they achieved lower C0/dose and C2/dose, at most time points, in comparison to older carriers of this allele.	Cyclosporine	69-72	cytochrome p450 oxidoreductase	Homo sapiens	12-15
29135906-12	2017	CONCLUSIONS: Younger age, POR*28 allele, and CYP3A5*3 allele were associated with higher CsA dosing requirements and lower concentration/dose ratio.	Cyclosporine	89-92	cytochrome p450 oxidoreductase	Homo sapiens	26-29
29135906-12	2017	CONCLUSIONS: Younger age, POR*28 allele, and CYP3A5*3 allele were associated with higher CsA dosing requirements and lower concentration/dose ratio.	Cyclosporine	89-92	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	45-51
28551242-5	2017	Cyclosporin A suppressed the MPTP opening, depolarization of the mitochondrial membrane potential, activities of caspase-9 and caspase-3, apoptosis rate, myofibril fragmentation index, reactive oxygen species generation, and Ca2+ levels.	Cyclosporine	0-13	caspase 3	Homo sapiens	127-136
28976551-6	2017	Importantly, in Nrf2-/- mice, CsA-induced renal damage, fibrosis, and EMT gene changes are restored by miR-181c mimics.	Cyclosporine	30-33	nuclear factor, erythroid derived 2, like 2	Mus musculus	16-20
29381954-0	2017	Effect of MDR1 C1236T polymorphism on cyclosporine pharmacokinetics: A systematic review and meta-analysis.	Cyclosporine	38-50	ATP binding cassette subfamily B member 1	Homo sapiens	10-14
29381954-2	2017	The published data reveal conflicting effects of the polymorphism of MDR1 exon 12 SNP C1236T on the pharmacokinetics of cyclosporine.This study aims to conduct a meta-analysis to investigate the effect of SNP C1236T on the pharmacokinetics of cyclosporine.	Cyclosporine	120-132	ATP binding cassette subfamily B member 1	Homo sapiens	69-73
29381954-2	2017	The published data reveal conflicting effects of the polymorphism of MDR1 exon 12 SNP C1236T on the pharmacokinetics of cyclosporine.This study aims to conduct a meta-analysis to investigate the effect of SNP C1236T on the pharmacokinetics of cyclosporine.	Cyclosporine	243-255	ATP binding cassette subfamily B member 1	Homo sapiens	69-73
29381954-9	2017	CONCLUSIONS: MDR1 C1236T polymorphism may have a minor effect on cyclosporine pharmacokinetics in transplantation patients.	Cyclosporine	65-77	ATP binding cassette subfamily B member 1	Homo sapiens	13-17
28952408-0	2017	Influence of CYP3A and ABCB1 polymorphisms on cyclosporine concentrations in renal transplant recipients.	Cyclosporine	46-58	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	13-18
28952408-0	2017	Influence of CYP3A and ABCB1 polymorphisms on cyclosporine concentrations in renal transplant recipients.	Cyclosporine	46-58	ATP binding cassette subfamily B member 1	Homo sapiens	23-28
28952408-1	2017	AIM: Cyclosporine is a substrate of CYP3A and ABCB1.	Cyclosporine	5-17	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	36-41
28952408-1	2017	AIM: Cyclosporine is a substrate of CYP3A and ABCB1.	Cyclosporine	5-17	ATP binding cassette subfamily B member 1	Homo sapiens	46-51
28952408-10	2017	The role of CYP3A7 in cyclosporine metabolism requires further study.	Cyclosporine	22-34	cytochrome P450 family 3 subfamily A member 7	Homo sapiens	12-18
28957350-12	2017	CyA pretreatment and/or RIP3(-/-) mice decreased Bax/Bcl2 expression; however, it did lead to an overall change in the levels of AST, ALT and LDH or necrotic injury.	Cyclosporine	0-3	B cell leukemia/lymphoma 2	Mus musculus	53-57
28875951-11	2017	The mRNA expression of WT-1, Pax2, and Pax8 was downregulated by CsA treatment.	Cyclosporine	65-68	paired box 2	Mus musculus	29-33
28927426-12	2017	Inhibition of the calcineurin/NFAT pathway by cyclosporine A (CsA) profoundly attenuated ASIC2-induced invasion under acidosis.	Cyclosporine	46-60	acid sensing ion channel subunit 2	Homo sapiens	89-94
28927426-12	2017	Inhibition of the calcineurin/NFAT pathway by cyclosporine A (CsA) profoundly attenuated ASIC2-induced invasion under acidosis.	Cyclosporine	62-65	acid sensing ion channel subunit 2	Homo sapiens	89-94
28446589-4	2017	Here, we describe the treatment of human lung fibroblasts (WI-38 and HFL-1 cells) with cyclosporine A (CsA), which reduces TGF-beta1-induced FMD via degradation of hypoxia-inducible factor-1alpha (HIF-1alpha).	Cyclosporine	103-106	transforming growth factor beta 1	Homo sapiens	123-132
28479356-5	2017	The time profiles of RPG and the inhibitors were analyzed by PBPK models, considering the inhibition of OATP1B1 and CYP3A4 by CsA or OATP1B1 inhibition by GEM and its glucuronide and the mechanism-based inhibition of CYP2C8 by GEM glucuronide.	Cyclosporine	126-129	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	116-122
28739698-12	2017	CONCLUSION: These results suggest that highly HAL-resistant cancer cells can be sensitized with cyclosporine A or elacridar, specific P-gp inhibitors that exert their effects at a low dose.	Cyclosporine	96-110	ATP binding cassette subfamily B member 1	Homo sapiens	134-138
28722255-3	2017	All of these agents are inhibitors of cytochrome P450 3A4, which plays a key role in metabolizing immunosuppressant drugs such as cyclosporine, tacrolimus, and sirolimus.	Cyclosporine	130-142	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-57
28703385-8	2017	A CsA-sensitive induction of p53 mRNA expression was also detected.	Cyclosporine	2-5	tumor protein p53	Homo sapiens	29-32
28472720-9	2017	RESULTS: The mRNA and protein levels of TGF-beta1, ZEB1, and ZEB2 in gingivae were significantly upregulated after 40 and 60days of CsA administration.	Cyclosporine	132-135	transforming growth factor, beta 1	Rattus norvegicus	40-49
28472720-9	2017	RESULTS: The mRNA and protein levels of TGF-beta1, ZEB1, and ZEB2 in gingivae were significantly upregulated after 40 and 60days of CsA administration.	Cyclosporine	132-135	zinc finger E-box binding homeobox 2	Rattus norvegicus	61-65
28472720-11	2017	Intense immunohistochemmical staining for TGF-beta1 were observed in the samples from CsA group at day 40 and 60.	Cyclosporine	86-89	transforming growth factor, beta 1	Rattus norvegicus	42-51
28472720-13	2017	Three members of miR-200s (miR-200a, miR-200b and miR-200c) were significantly downregulated in CsA-treated rats at 40 and 60days, while miR-9, miR-23a and miR-155 were significantly upregulated when compared with those of the control group.	Cyclosporine	96-99	microRNA 200a	Rattus norvegicus	27-35
28472720-13	2017	Three members of miR-200s (miR-200a, miR-200b and miR-200c) were significantly downregulated in CsA-treated rats at 40 and 60days, while miR-9, miR-23a and miR-155 were significantly upregulated when compared with those of the control group.	Cyclosporine	96-99	microRNA 200c	Rattus norvegicus	50-58
28472720-13	2017	Three members of miR-200s (miR-200a, miR-200b and miR-200c) were significantly downregulated in CsA-treated rats at 40 and 60days, while miR-9, miR-23a and miR-155 were significantly upregulated when compared with those of the control group.	Cyclosporine	96-99	microRNA 23a	Rattus norvegicus	144-151
28472720-14	2017	CONCLUSIONS: The process of EMT in CsA-induced rat gingival overgrowth is associated with increased expression of TGF-beta1, ZEB1, and ZEB2, and decreased expression of E-cadherin.	Cyclosporine	35-38	transforming growth factor, beta 1	Rattus norvegicus	114-123
28472720-14	2017	CONCLUSIONS: The process of EMT in CsA-induced rat gingival overgrowth is associated with increased expression of TGF-beta1, ZEB1, and ZEB2, and decreased expression of E-cadherin.	Cyclosporine	35-38	zinc finger E-box binding homeobox 2	Rattus norvegicus	135-139
28552691-4	2017	This study measured the accumulation of each BA in rat SCHs in the presence of 10 muM cyclosporine A (CsA), which only inhibits BSEP, and 50 muM CsA, which further inhibits basolateral BA efflux transporters.	Cyclosporine	102-105	ATP binding cassette subfamily B member 11	Rattus norvegicus	128-132
28214069-4	2017	Immunosuppressive agents, such as calcineurin inhibitors (tacrolimus, cyclosporine) are substrates of cytochromes P450 3A4 and P-gp.	Cyclosporine	70-82	ATP binding cassette subfamily B member 1	Homo sapiens	127-131
28903485-7	2017	T0901317 and cyclosporin A increased fatty acid uptake, decreased lipid efflux (inferred from apolipoprotein B100 levels), and increased fatty acid synthase protein levels.	Cyclosporine	13-26	apolipoprotein B	Homo sapiens	94-113
28784775-2	2017	Pore opening can be inhibited by cyclosporin A mediated via cyclophilin D.	Cyclosporine	33-46	peptidylprolyl isomerase F	Homo sapiens	60-73
28536123-1	2017	BACKGROUND AND OBJECTIVES: We showed that mineralocorticoid receptor blockade (MRB) prevented acute and chronic cyclosporine nephropathy (CsA-Nx) in the rat.	Cyclosporine	112-124	nuclear receptor subfamily 3, group C, member 2	Rattus norvegicus	42-68
28739760-4	2017	Its mechanism is not completely clear, but the hypothesis of CsA inhibiting P-glycoprotein mediated drug efflux is the most acceptable.	Cyclosporine	61-64	ATP binding cassette subfamily B member 1	Homo sapiens	76-90
28623111-6	2017	Among the well-known ABCB1 inhibitors, a similar effect was found for cyclosporin A (CsA) but not for zosuquidar.	Cyclosporine	85-88	ATP binding cassette subfamily B member 1	Homo sapiens	21-26
28556421-11	2017	There was a significant increase in the frequency of contractions after ciclosporin, tacrolimus, azathioprine and sirolimus treatment compared with control animals (4.6 +- 0.3 cycles min-1 ).	Cyclosporine	72-83	CD59 molecule (CD59 blood group)	Homo sapiens	183-188
28446589-4	2017	Here, we describe the treatment of human lung fibroblasts (WI-38 and HFL-1 cells) with cyclosporine A (CsA), which reduces TGF-beta1-induced FMD via degradation of hypoxia-inducible factor-1alpha (HIF-1alpha).	Cyclosporine	103-106	hypoxia inducible factor 1 subunit alpha	Homo sapiens	164-195
28446589-4	2017	Here, we describe the treatment of human lung fibroblasts (WI-38 and HFL-1 cells) with cyclosporine A (CsA), which reduces TGF-beta1-induced FMD via degradation of hypoxia-inducible factor-1alpha (HIF-1alpha).	Cyclosporine	103-106	hypoxia inducible factor 1 subunit alpha	Homo sapiens	197-207
28446589-5	2017	In addition, in primary myofibroblast-like cells that were obtained from a patient with pulmonary fibrosis, treatment with CsA and an HIF-1alpha inhibitor (HIFi) decreased the expression levels of alpha-smooth muscle actin and fibronectin, which indicated that CsA and HIFi promote dedifferentiation of myofibroblasts.	Cyclosporine	123-126	fibronectin 1	Homo sapiens	227-238
28446589-5	2017	In addition, in primary myofibroblast-like cells that were obtained from a patient with pulmonary fibrosis, treatment with CsA and an HIF-1alpha inhibitor (HIFi) decreased the expression levels of alpha-smooth muscle actin and fibronectin, which indicated that CsA and HIFi promote dedifferentiation of myofibroblasts.	Cyclosporine	261-264	hypoxia inducible factor 1 subunit alpha	Homo sapiens	134-144
28446589-5	2017	In addition, in primary myofibroblast-like cells that were obtained from a patient with pulmonary fibrosis, treatment with CsA and an HIF-1alpha inhibitor (HIFi) decreased the expression levels of alpha-smooth muscle actin and fibronectin, which indicated that CsA and HIFi promote dedifferentiation of myofibroblasts.	Cyclosporine	261-264	fibronectin 1	Homo sapiens	227-238
28969068-5	2017	Treatment with corticosteroids and cyclosporine (CsA) resulted in a decrease of the methylation level of GATA3 and TGF-beta in inactive BD patients.	Cyclosporine	35-47	transforming growth factor beta 1	Homo sapiens	115-123
28969068-5	2017	Treatment with corticosteroids and cyclosporine (CsA) resulted in a decrease of the methylation level of GATA3 and TGF-beta in inactive BD patients.	Cyclosporine	49-52	transforming growth factor beta 1	Homo sapiens	115-123
28257599-7	2017	Treatment with tacrolimus and cyclosporin render CD4+ CD25- cells more susceptible to Treg control.	Cyclosporine	30-41	CD4 molecule	Homo sapiens	49-52
28416371-4	2017	Here we investigated: (i) the interaction of CSA with NSAIDs possessing variable COX1/COX2 selectivities on hemodynamic, left ventricular (LV) and cardiac autonomic and histologic profiles, and (ii) role of NADPH-oxidase (NOX)/Rho-kinase (ROCK) pathway in the interaction.	Cyclosporine	45-48	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	81-85
28584011-2	2017	We and others have reported that cyclosporine A and tacrolimus decrease anti-inflammatory regulatory T cells and increase proinflammatory interleukin-17-producing T cells; therefore, we hypothesized that inhibition of these effects using noncellular therapies would prevent the hypertension, endothelial dysfunction, and renal glomerular injury induced by calcineurin inhibitor therapy.	Cyclosporine	33-47	calcineurin binding protein 1	Mus musculus	356-377
28527347-2	2017	Plumieride restores the suppressed cell mediated, humoral immune response and also enhances the release of TNF- alpha, IFN-gamma, and IL-2 (Th-1) in immune compromised cyclosporine and cyclophosphamide treated balb/c mice.	Cyclosporine	168-180	negative elongation factor complex member C/D, Th1l	Mus musculus	140-144
28363167-3	2017	Specifically, A mitochondrial matrix protein (cyclophilin D, CyPD) is involved in emodin-induced apoptosis, and the inhibitor of CyPD (cyclosporin A) could almost completely suppressing the apoptosis; Moreover, as the expression of CyPD could be effectively inhibited by antioxidant N-acetyl-l-cysteine and epidermal growth factor (the activator of ERK), reactive oxygen species and ERK might be involved in the relevant role of CyPD.	Cyclosporine	135-148	peptidylprolyl isomerase F	Homo sapiens	46-59
28190562-8	2017	A dual effect on thrombin generation was observed and suggested that CsA may interact with platelets in rat platelet rich plasma and speed up thrombin generation.	Cyclosporine	69-72	coagulation factor II	Rattus norvegicus	17-25
28190562-8	2017	A dual effect on thrombin generation was observed and suggested that CsA may interact with platelets in rat platelet rich plasma and speed up thrombin generation.	Cyclosporine	69-72	coagulation factor II	Rattus norvegicus	142-150
28054752-10	2017	By contrast, CSA effects are preserved or even exacerbated after COX-1 inhibition.	Cyclosporine	13-16	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	65-70
28363167-3	2017	Specifically, A mitochondrial matrix protein (cyclophilin D, CyPD) is involved in emodin-induced apoptosis, and the inhibitor of CyPD (cyclosporin A) could almost completely suppressing the apoptosis; Moreover, as the expression of CyPD could be effectively inhibited by antioxidant N-acetyl-l-cysteine and epidermal growth factor (the activator of ERK), reactive oxygen species and ERK might be involved in the relevant role of CyPD.	Cyclosporine	135-148	peptidylprolyl isomerase F	Homo sapiens	129-133
28363167-3	2017	Specifically, A mitochondrial matrix protein (cyclophilin D, CyPD) is involved in emodin-induced apoptosis, and the inhibitor of CyPD (cyclosporin A) could almost completely suppressing the apoptosis; Moreover, as the expression of CyPD could be effectively inhibited by antioxidant N-acetyl-l-cysteine and epidermal growth factor (the activator of ERK), reactive oxygen species and ERK might be involved in the relevant role of CyPD.	Cyclosporine	135-148	peptidylprolyl isomerase F	Homo sapiens	129-133
28363167-3	2017	Specifically, A mitochondrial matrix protein (cyclophilin D, CyPD) is involved in emodin-induced apoptosis, and the inhibitor of CyPD (cyclosporin A) could almost completely suppressing the apoptosis; Moreover, as the expression of CyPD could be effectively inhibited by antioxidant N-acetyl-l-cysteine and epidermal growth factor (the activator of ERK), reactive oxygen species and ERK might be involved in the relevant role of CyPD.	Cyclosporine	135-148	mitogen-activated protein kinase 1	Homo sapiens	349-352
28363167-3	2017	Specifically, A mitochondrial matrix protein (cyclophilin D, CyPD) is involved in emodin-induced apoptosis, and the inhibitor of CyPD (cyclosporin A) could almost completely suppressing the apoptosis; Moreover, as the expression of CyPD could be effectively inhibited by antioxidant N-acetyl-l-cysteine and epidermal growth factor (the activator of ERK), reactive oxygen species and ERK might be involved in the relevant role of CyPD.	Cyclosporine	135-148	mitogen-activated protein kinase 1	Homo sapiens	383-386
28363167-3	2017	Specifically, A mitochondrial matrix protein (cyclophilin D, CyPD) is involved in emodin-induced apoptosis, and the inhibitor of CyPD (cyclosporin A) could almost completely suppressing the apoptosis; Moreover, as the expression of CyPD could be effectively inhibited by antioxidant N-acetyl-l-cysteine and epidermal growth factor (the activator of ERK), reactive oxygen species and ERK might be involved in the relevant role of CyPD.	Cyclosporine	135-148	peptidylprolyl isomerase F	Homo sapiens	129-133
28315683-0	2017	Klotho ameliorates cyclosporine A-induced nephropathy via PDLIM2/NF-kB p65 signaling pathway.	Cyclosporine	19-33	PDZ and LIM domain 2	Homo sapiens	58-64
28141792-2	2017	Since neonatal cardiac myocytes remain relatively immature, we hypothesized that inducing PTP closure at this age, by inhibiting the PTP regulator, cyclophilin D (CyPD), genetically or with Cyclosporin A (CsA) and NIM811, would increase cardiac function by increasing mitochondrial maturation and myocyte differentiation.	Cyclosporine	205-208	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	163-167
29113387-3	2017	Meanwhile, the dose of FK506 and CsA was recorded, blood concentration of the drugs was measured, and graft outcome was monitored.These results indicate that CYP3A5*AA/AG carriers need higher FK506 dose than CYP3A5*GG homozygote to achieve the target blood concentration.	Cyclosporine	33-36	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	158-164
29113387-4	2017	For CYP3A5*GG carriers, taking FK506 or CsA are both advisable.	Cyclosporine	40-43	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	4-10
29113387-6	2017	CYP3A5 genotyping is a new approach to detecting FK506 dose requirement and a predictive index for the FK506 or CsA treatment selection in kidney recipients.	Cyclosporine	112-115	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	0-6
28373092-5	2017	In addition, Collagen IV, ZO-1, Occludin and Claudin 5 expressions in ipsilateral/left hemisphere were downregulated after SAH, but increased after CsA treatment.	Cyclosporine	148-151	tight junction protein 1	Mus musculus	26-30
28373092-5	2017	In addition, Collagen IV, ZO-1, Occludin and Claudin 5 expressions in ipsilateral/left hemisphere were downregulated after SAH, but increased after CsA treatment.	Cyclosporine	148-151	occludin	Mus musculus	32-40
28258057-5	2017	Additionally, cytokines such as TNF-alpha, IL-17A, and other immune pathways are the common links between the pathogenesis of psoriasis and atherosclerosis, and hence the approved treatments for psoriasis, which include selective cytokine inhibition (e.g., anti-TNF, anti-IL-17A, and anti-IL-12/23) and immune modulation (e.g., methotrexate or cyclosporine), provide an opportunity to examine the effect of modulating these pathways on atherogenesis.	Cyclosporine	344-356	tumor necrosis factor	Homo sapiens	32-35
26118469-5	2017	The numbers of graft-infiltrating macrophages and the production of nitric oxide (NO) were significantly decreased in recipients treated with MSCs and CsA, and this reduction correlated with impaired production of IFNgamma in the graft and DLNs.	Cyclosporine	151-154	interferon gamma	Mus musculus	214-222
26118469-8	2017	We suggest that the topical application of MSCs in combination with CsA induces a switch in macrophages to a population with an alternatively activated "healing" phenotype and producing elevated levels of IL-10.	Cyclosporine	68-71	interleukin 10	Mus musculus	205-210
28324237-2	2017	Cyclosporine"s anti-apoptotic activity in human gingival fibroblast is due to desensitization of mitochondrial permeability transition pore (MPTP) and augmentation of anti-apoptotic, Bcl2.	Cyclosporine	0-12	BCL2 apoptosis regulator	Homo sapiens	183-187
28315683-10	2017	These findings suggest that Klotho can modulate inflammation via PDLIM2/NF-kB p65 pathway in CsA-induced nephropathy.	Cyclosporine	93-96	PDZ and LIM domain 2	Homo sapiens	65-71
28395670-9	2017	The denervation-induced mitoflash activity was likely associated with an increased activity of mitochondrial permeability transition pore (mPTP), as the mitoflash activity was attenuated by application of cyclosporine A.	Cyclosporine	205-219	protein tyrosine phosphatase, receptor type, U	Mus musculus	139-143
28392640-9	2017	Cyclosporine significantly reduced the mean itch score and extent of erythema, and improved interference with daily activities and sleep.	Cyclosporine	0-12	itchy E3 ubiquitin protein ligase	Homo sapiens	44-48
27585667-0	2017	TLR4-mediated inflammation is a key pathogenic event leading to kidney damage and fibrosis in cyclosporine nephrotoxicity.	Cyclosporine	94-106	toll-like receptor 4	Mus musculus	0-4
27585667-4	2017	CsA-induced renal TLR4 expression in wild-type mice.	Cyclosporine	0-3	toll-like receptor 4	Mus musculus	18-22
27585667-8	2017	In vivo and in vitro CsA promoted secretion of the TLR ligand HMGB1 by tubular cells upstream of TLR4 activation, and prevention of HMGB1 secretion significantly reduced CsA-induced synthesis of MCP-1, suggesting that HMGB1 may be one of the mediators of CsA-induced TLR4 activation.	Cyclosporine	21-24	toll-like receptor 4	Mus musculus	97-101
27585667-8	2017	In vivo and in vitro CsA promoted secretion of the TLR ligand HMGB1 by tubular cells upstream of TLR4 activation, and prevention of HMGB1 secretion significantly reduced CsA-induced synthesis of MCP-1, suggesting that HMGB1 may be one of the mediators of CsA-induced TLR4 activation.	Cyclosporine	170-173	mast cell protease 1	Mus musculus	195-200
27585667-8	2017	In vivo and in vitro CsA promoted secretion of the TLR ligand HMGB1 by tubular cells upstream of TLR4 activation, and prevention of HMGB1 secretion significantly reduced CsA-induced synthesis of MCP-1, suggesting that HMGB1 may be one of the mediators of CsA-induced TLR4 activation.	Cyclosporine	170-173	toll-like receptor 4	Mus musculus	267-271
27585667-8	2017	In vivo and in vitro CsA promoted secretion of the TLR ligand HMGB1 by tubular cells upstream of TLR4 activation, and prevention of HMGB1 secretion significantly reduced CsA-induced synthesis of MCP-1, suggesting that HMGB1 may be one of the mediators of CsA-induced TLR4 activation.	Cyclosporine	170-173	mast cell protease 1	Mus musculus	195-200
27585667-8	2017	In vivo and in vitro CsA promoted secretion of the TLR ligand HMGB1 by tubular cells upstream of TLR4 activation, and prevention of HMGB1 secretion significantly reduced CsA-induced synthesis of MCP-1, suggesting that HMGB1 may be one of the mediators of CsA-induced TLR4 activation.	Cyclosporine	170-173	toll-like receptor 4	Mus musculus	267-271
27585667-9	2017	These results suggest that TLR4 is a potential pharmacological target in CsA nephrotoxicity.	Cyclosporine	73-76	toll-like receptor 4	Mus musculus	27-31
27890789-4	2017	METHODS: We characterized a series of cyclosporine (CsA) derivatives for their anti-HBV activity and NTCP binding specificity using HepG2 cells overexpressing NTCP and primary human hepatocytes.	Cyclosporine	38-50	solute carrier family 10 member 1	Homo sapiens	101-105
27890789-4	2017	METHODS: We characterized a series of cyclosporine (CsA) derivatives for their anti-HBV activity and NTCP binding specificity using HepG2 cells overexpressing NTCP and primary human hepatocytes.	Cyclosporine	52-55	solute carrier family 10 member 1	Homo sapiens	101-105
28616429-2	2017	It can increase blood concentrations of other medications including cyclosporine A (CsA) which are substrates for cytochrome P450 3A4.	Cyclosporine	68-82	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	114-133
28616429-2	2017	It can increase blood concentrations of other medications including cyclosporine A (CsA) which are substrates for cytochrome P450 3A4.	Cyclosporine	84-87	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	114-133
27993675-10	2017	The protective effect of CsA, or other molecules affecting the function of CypD hold promise as a potential novel therapeutic strategy for governing oxidative stress pathology via mitochondrial pathways.	Cyclosporine	25-28	peptidylprolyl isomerase F	Homo sapiens	75-79
28457398-13	2017	A significant difference on MgS levels between patients on tacrolimus and cyclosporine was found only when considering GFR &lt;45 mL/min/1.73 m2, in which patients on tacrolimus had significantly higher GFR than patients on cyclosporine, which may explain these results.	Cyclosporine	74-86	CD59 molecule (CD59 blood group)	Homo sapiens	133-138
28115173-4	2017	CSA (10mg/kg) reversed the LPS-evoked (i) hypotension and tachycardia, (ii) decreases in time and spectral measures of heart rate variability (HRV), and (iii) increases in serum TNFalpha and IL-6.	Cyclosporine	0-3	tumor necrosis factor	Rattus norvegicus	178-186
28115173-4	2017	CSA (10mg/kg) reversed the LPS-evoked (i) hypotension and tachycardia, (ii) decreases in time and spectral measures of heart rate variability (HRV), and (iii) increases in serum TNFalpha and IL-6.	Cyclosporine	0-3	interleukin 6	Rattus norvegicus	191-195
27916761-3	2017	In our previous study, a potent P-gp and MRP1 modulator, Cyclosporine A, potentiated MTX concentration in rat brain.	Cyclosporine	57-71	phosphoglycolate phosphatase	Rattus norvegicus	32-36
28013001-3	2017	In this study, we investigated the impact of three natural compounds, cyclosporine A (CsA), deoxynivalenol (DON) and cannabidiol (CBD) on mitochondrial functions in the THP-1 monocytic cell line.	Cyclosporine	86-89	GLI family zinc finger 2	Homo sapiens	169-174
28013001-7	2017	In THP-1 monocytes, the IC50 of CsA decreased basal and maximal respiration as well as ATP production with an impact on spare capacity indicating a mitochondrial dysfunction.	Cyclosporine	32-35	GLI family zinc finger 2	Homo sapiens	3-8
28219134-10	2017	The calcification level in CsA intervention group was lower than that in calcification group [(60.86+-7.95) vs (107.20+-11.07) mg/g, P&lt;0.05], and expression of Runx2 (mRNA and protein level) and ALP activity [(48.63+-3.02) vs (98.75+-3.46) U/g, P&lt;0.05] decreased as well.	Cyclosporine	27-30	RUNX family transcription factor 2	Rattus norvegicus	163-168
28165490-3	2017	Here, we uncover a novel class of cardiac lineage cells, PDGFRalpha+Flk1- cardioblasts (PCBs), from mouse and human pluripotent stem cells induced using CsAYTE, a combination of the small molecules Cyclosporin A, the rho-associated coiled-coil kinase inhibitor Y27632, the antioxidant Trolox, and the ALK5 inhibitor EW7197.	Cyclosporine	198-211	platelet derived growth factor receptor, alpha polypeptide	Mus musculus	57-72
27643869-4	2017	Here we show that exposure of vascular endothelial EA.hy926 cells to CsA induced phosphorylation of Src/vascular endothelial cadherin (VE-cadherin) and translocation of VE-cadherin from cell surface to cytoplasm, resulting in an increase in vascular permeability.	Cyclosporine	69-72	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	100-103
27643869-4	2017	Here we show that exposure of vascular endothelial EA.hy926 cells to CsA induced phosphorylation of Src/vascular endothelial cadherin (VE-cadherin) and translocation of VE-cadherin from cell surface to cytoplasm, resulting in an increase in vascular permeability.	Cyclosporine	69-72	cadherin 5	Homo sapiens	104-133
27643869-4	2017	Here we show that exposure of vascular endothelial EA.hy926 cells to CsA induced phosphorylation of Src/vascular endothelial cadherin (VE-cadherin) and translocation of VE-cadherin from cell surface to cytoplasm, resulting in an increase in vascular permeability.	Cyclosporine	69-72	cadherin 5	Homo sapiens	135-146
27643869-4	2017	Here we show that exposure of vascular endothelial EA.hy926 cells to CsA induced phosphorylation of Src/vascular endothelial cadherin (VE-cadherin) and translocation of VE-cadherin from cell surface to cytoplasm, resulting in an increase in vascular permeability.	Cyclosporine	69-72	cadherin 5	Homo sapiens	169-180
27643869-5	2017	In addition, CsA increased production of inflammatory cytokines, including interleukin (IL)-1beta and IL-6, associated with an increase in nuclear levels of nuclear factor-kappaB (NF-kappaB) which also enhanced vascular permeability.	Cyclosporine	13-16	interleukin 1 beta	Homo sapiens	75-97
27643869-5	2017	In addition, CsA increased production of inflammatory cytokines, including interleukin (IL)-1beta and IL-6, associated with an increase in nuclear levels of nuclear factor-kappaB (NF-kappaB) which also enhanced vascular permeability.	Cyclosporine	13-16	interleukin 6	Homo sapiens	102-106
27643869-6	2017	Importantly, the fourth and fifth regions of epidermal growth factor-like domain of TM (TME45) attenuated CsA-induced p-Src/VE-cadherin and vascular permeability in parallel with a decrease in nuclear levels of NF-kappaB and cytokine production in EA.hy926 cells.	Cyclosporine	106-109	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	120-123
27643869-6	2017	Importantly, the fourth and fifth regions of epidermal growth factor-like domain of TM (TME45) attenuated CsA-induced p-Src/VE-cadherin and vascular permeability in parallel with a decrease in nuclear levels of NF-kappaB and cytokine production in EA.hy926 cells.	Cyclosporine	106-109	cadherin 5	Homo sapiens	124-135
26961540-8	2017	From the further evaluation with the typical inhibitors of each transporter, it was confirmed that BPS is a substrate for P-gp, BCRP, OAT3, OATP1B1, OATP1B3 and MRP2, because the typical inhibitor, cyclosporine, had no effects on BPS transport by BSEP.	Cyclosporine	198-210	solute carrier organic anion transporter family member 1B3	Homo sapiens	149-156
27796696-7	2017	RESULTS: Administration of CsA for 28 days induced renal damage, decreased Klotho expression and activated the EMT response (demonstrated as increased TGF-beta1 and alpha-SMA expression accompanied by decreased in E-cadherin expression).	Cyclosporine	27-30	transforming growth factor, beta 1	Rattus norvegicus	151-160
27451286-3	2017	Using an mRNA microarray on microdissected tubules from a rat model of cyclosporin A toxicity to describe the related epithelial-specific transcriptional signature in vivo, we found that cyclosporin A induces pathways dependent on the transcription factor ATF4 and identified nuclear protein transcriptional regulator 1 (Nupr1), a stress response gene induced by ATF4, as the gene most strongly upregulated.	Cyclosporine	187-200	activating transcription factor 4	Rattus norvegicus	256-260
27451286-3	2017	Using an mRNA microarray on microdissected tubules from a rat model of cyclosporin A toxicity to describe the related epithelial-specific transcriptional signature in vivo, we found that cyclosporin A induces pathways dependent on the transcription factor ATF4 and identified nuclear protein transcriptional regulator 1 (Nupr1), a stress response gene induced by ATF4, as the gene most strongly upregulated.	Cyclosporine	187-200	activating transcription factor 4	Rattus norvegicus	363-367
27771871-6	2017	Administration of either IPostC or CsA alone in nondiabetic animals significantly reduced CK, TNF-alpha, IL-1beta, and IL-6 concentrations, increased the p-GSK3beta and Bcl-2, and decreased the level of apoptosis (P &lt; 0.05) but had no effect on diabetic hearts.	Cyclosporine	35-38	tumor necrosis factor	Rattus norvegicus	94-103
27771871-6	2017	Administration of either IPostC or CsA alone in nondiabetic animals significantly reduced CK, TNF-alpha, IL-1beta, and IL-6 concentrations, increased the p-GSK3beta and Bcl-2, and decreased the level of apoptosis (P &lt; 0.05) but had no effect on diabetic hearts.	Cyclosporine	35-38	interleukin 1 beta	Rattus norvegicus	105-113
27771871-6	2017	Administration of either IPostC or CsA alone in nondiabetic animals significantly reduced CK, TNF-alpha, IL-1beta, and IL-6 concentrations, increased the p-GSK3beta and Bcl-2, and decreased the level of apoptosis (P &lt; 0.05) but had no effect on diabetic hearts.	Cyclosporine	35-38	interleukin 6	Rattus norvegicus	119-123
27771871-6	2017	Administration of either IPostC or CsA alone in nondiabetic animals significantly reduced CK, TNF-alpha, IL-1beta, and IL-6 concentrations, increased the p-GSK3beta and Bcl-2, and decreased the level of apoptosis (P &lt; 0.05) but had no effect on diabetic hearts.	Cyclosporine	35-38	BCL2, apoptosis regulator	Rattus norvegicus	169-174
28102966-9	2017	Treatment with 10 mg/L theophylline + 1 micromol/L prednisolone or 2.5 ng/mL cyclosporine A synergistically upregulated HDAC2 and inhibited IFN-gamma and TNF-alpha production by CD8+ T and NKT-like lymphocytes.	Cyclosporine	77-91	histone deacetylase 2	Homo sapiens	120-125
28102966-9	2017	Treatment with 10 mg/L theophylline + 1 micromol/L prednisolone or 2.5 ng/mL cyclosporine A synergistically upregulated HDAC2 and inhibited IFN-gamma and TNF-alpha production by CD8+ T and NKT-like lymphocytes.	Cyclosporine	77-91	interferon gamma	Homo sapiens	140-149
28102966-9	2017	Treatment with 10 mg/L theophylline + 1 micromol/L prednisolone or 2.5 ng/mL cyclosporine A synergistically upregulated HDAC2 and inhibited IFN-gamma and TNF-alpha production by CD8+ T and NKT-like lymphocytes.	Cyclosporine	77-91	tumor necrosis factor	Homo sapiens	154-163
28167533-7	2017	Additionally, treatment with cyclosporin A improved WT-GAPDH aggregate-induced swelling and depolarization.	Cyclosporine	29-42	glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens	55-60
28152427-3	2017	The inhibitory activity of sixteen compounds against Abeta-induced mPTP opening was superior or almost similar to that of the standard Cyclosporin A (CsA).	Cyclosporine	135-148	amyloid beta precursor protein	Homo sapiens	53-58
28152427-3	2017	The inhibitory activity of sixteen compounds against Abeta-induced mPTP opening was superior or almost similar to that of the standard Cyclosporin A (CsA).	Cyclosporine	150-153	amyloid beta precursor protein	Homo sapiens	53-58
28003191-9	2017	Stimulation of cultured thick ascending limb cells with AVP agonist restored their responsiveness to CsA.	Cyclosporine	101-104	arginine vasopressin	Rattus norvegicus	56-59
28314264-2	2017	Cyclosporine A can promote oncogenesis in a cell-intrinsic manner by increasing the production of vascular endothelial growth factor (VEGF).	Cyclosporine	0-14	vascular endothelial growth factor A	Homo sapiens	98-132
28314264-2	2017	Cyclosporine A can promote oncogenesis in a cell-intrinsic manner by increasing the production of vascular endothelial growth factor (VEGF).	Cyclosporine	0-14	vascular endothelial growth factor A	Homo sapiens	134-138
28314264-4	2017	RESULTS: Cyclosporine A regulated the expression of VEGF at the post-transcriptional level.	Cyclosporine	9-23	vascular endothelial growth factor A	Homo sapiens	52-56
28314264-6	2017	Toyocamycin, an inhibitor of IRE1alpha, abolished the clonogenic growth of RCC cells and reduced induction of VEGF by cyclosporine A under hypoxia.	Cyclosporine	118-132	vascular endothelial growth factor A	Homo sapiens	110-114
28278322-6	2017	Treatment with systemic corticosteroid and cyclosporin A (CsA) decreased the methylation level of GATA3 and TGF-beta in association with an increased mRNA expression of molecules and reduced disease activity.	Cyclosporine	43-56	transforming growth factor beta 1	Homo sapiens	108-116
28278322-6	2017	Treatment with systemic corticosteroid and cyclosporin A (CsA) decreased the methylation level of GATA3 and TGF-beta in association with an increased mRNA expression of molecules and reduced disease activity.	Cyclosporine	58-61	transforming growth factor beta 1	Homo sapiens	108-116
27651429-8	2017	The antiproliferative effect of sirolimus (SRL) and cyclosporine A (CsA), which target the IL-2 signaling pathway, was diminished by DSCs in vitro.	Cyclosporine	68-71	interleukin 2	Homo sapiens	91-95
28057718-6	2017	Cyclosporin A blocked osmotic stress and DSS-induced ROS production, barrier dysfunction, TJ disruption and JNK activation.	Cyclosporine	0-13	mitogen-activated protein kinase 8	Homo sapiens	108-111
29296949-8	2017	This observation was highly concordant with clinical samples from allo-SCT recipients receiving CsA-based immune suppression where although the IFNgamma-negative-Th17 subset predominated, IFNgamma+-Th17 cells were also present.	Cyclosporine	96-99	interferon gamma	Homo sapiens	144-152
29296949-8	2017	This observation was highly concordant with clinical samples from allo-SCT recipients receiving CsA-based immune suppression where although the IFNgamma-negative-Th17 subset predominated, IFNgamma+-Th17 cells were also present.	Cyclosporine	96-99	interferon gamma	Homo sapiens	188-196
28068383-10	2017	Pretreatment with CsA prior to bevacizumab exposure markedly inhibited cell migration and the expression of both MMPs.	Cyclosporine	18-21	matrix metallopeptidase 3	Homo sapiens	113-117
28068383-11	2017	CsA enhanced the inhibitory effects of bevacizumab on pterygium fibroblast migration in vitro, possibly by inhibiting expression of both MMPs.	Cyclosporine	0-3	matrix metallopeptidase 3	Homo sapiens	137-141
28119815-6	2017	In particular, an inhibitor of the mitochondrial permeability transition pore (mPTP), cyclosporin A, attenuated mitochondrial damage and cell apoptosis, indicating that mPTP may be involved in the antiproliferative activity of MitoHCAs.	Cyclosporine	86-99	protein tyrosine phosphatase, receptor type, U	Mus musculus	79-83
28119815-6	2017	In particular, an inhibitor of the mitochondrial permeability transition pore (mPTP), cyclosporin A, attenuated mitochondrial damage and cell apoptosis, indicating that mPTP may be involved in the antiproliferative activity of MitoHCAs.	Cyclosporine	86-99	protein tyrosine phosphatase, receptor type, U	Mus musculus	169-173
27840960-7	2017	Moreover, MPTP blockage with cyclosporin A prevented the translocation of Bax, and inhibited oxidative stress-induced apoptotic killing in the HBx-expressing HL-7702 cells.	Cyclosporine	29-42	BCL2 associated X, apoptosis regulator	Homo sapiens	74-77
28848192-1	2017	OBJECTIVE: We examined the role of behavioral conditioning of immune responses with cyclosporine A (CsA) on the development of Th1/Th17-driven experimental autoimmune uveoretinitis (EAU).	Cyclosporine	100-103	negative elongation factor complex member C/D, Th1l	Mus musculus	127-130
28848192-7	2017	ELISA analysis of splenocytes revealed a reduced interferon (IFN)-gamma/IL-17 ratio in CsA-treated, conditioned but not reexposed, and conditioned animals.	Cyclosporine	87-90	interferon gamma	Mus musculus	49-71
28848192-11	2017	CONCLUSIONS: We conclude that CsA conditioning in the EAU model mitigates Th1 but enhances Th17 immune responses, and does not ameliorate disease.	Cyclosporine	30-33	negative elongation factor complex member C/D, Th1l	Mus musculus	74-77
28501872-8	2017	Besides, CsA attenuated I/R injury through suppressing the release of cytochrome-c (CytC), inhibiting cell apoptosis and decreasing the expression levels of cyclophilin-D (Cyp-D), adenine nucleotide translocase 1 (ANT1) and voltage-dependent anion channel 1 (VDAC1).	Cyclosporine	9-12	voltage-dependent anion-selective channel protein 1	Oryctolagus cuniculus	224-257
28501872-8	2017	Besides, CsA attenuated I/R injury through suppressing the release of cytochrome-c (CytC), inhibiting cell apoptosis and decreasing the expression levels of cyclophilin-D (Cyp-D), adenine nucleotide translocase 1 (ANT1) and voltage-dependent anion channel 1 (VDAC1).	Cyclosporine	9-12	voltage-dependent anion-selective channel protein 1	Oryctolagus cuniculus	259-264
28501872-10	2017	CONCLUSION: Our study found that the protective role of CsA on lung I/R injury depends on the inhibition of MPTP and CytC release, suppression of the activation of mitochondrial apoptosis pathway and the expressions of apoptotic-related proteins, as well as the decreased expression levels of ANT1 and VDAC1.	Cyclosporine	56-59	voltage-dependent anion-selective channel protein 1	Oryctolagus cuniculus	302-307
27664163-0	2017	Prevention of Cyclophilin D-Mediated mPTP Opening Using Cyclosporine-A Alleviates the Elevation of Necroptosis, Autophagy and Apoptosis-Related Markers Following Global Cerebral Ischemia-Reperfusion.	Cyclosporine	56-70	peptidylprolyl isomerase F	Homo sapiens	14-27
27664163-3	2017	We showed that while cerebral I/R injury is accompanied by loss of MMP, mitochondrial swelling and programmed cell death, pretreatment with cyclosporine-A (CsA) as a potent inhibitor of CypD, led to partial but significant reduction in necroptosis markers, RIP1 and RIP3 as well as activity of glutamate-ammonia ligase (GLUL) and glutamate dehydrogenase 1 (GLUD1), downstream enzymes of RIP3.	Cyclosporine	140-154	peptidylprolyl isomerase F	Homo sapiens	186-190
27664163-3	2017	We showed that while cerebral I/R injury is accompanied by loss of MMP, mitochondrial swelling and programmed cell death, pretreatment with cyclosporine-A (CsA) as a potent inhibitor of CypD, led to partial but significant reduction in necroptosis markers, RIP1 and RIP3 as well as activity of glutamate-ammonia ligase (GLUL) and glutamate dehydrogenase 1 (GLUD1), downstream enzymes of RIP3.	Cyclosporine	140-154	glutamate-ammonia ligase	Homo sapiens	294-318
27664163-3	2017	We showed that while cerebral I/R injury is accompanied by loss of MMP, mitochondrial swelling and programmed cell death, pretreatment with cyclosporine-A (CsA) as a potent inhibitor of CypD, led to partial but significant reduction in necroptosis markers, RIP1 and RIP3 as well as activity of glutamate-ammonia ligase (GLUL) and glutamate dehydrogenase 1 (GLUD1), downstream enzymes of RIP3.	Cyclosporine	140-154	glutamate-ammonia ligase	Homo sapiens	320-324
27664163-3	2017	We showed that while cerebral I/R injury is accompanied by loss of MMP, mitochondrial swelling and programmed cell death, pretreatment with cyclosporine-A (CsA) as a potent inhibitor of CypD, led to partial but significant reduction in necroptosis markers, RIP1 and RIP3 as well as activity of glutamate-ammonia ligase (GLUL) and glutamate dehydrogenase 1 (GLUD1), downstream enzymes of RIP3.	Cyclosporine	156-159	peptidylprolyl isomerase F	Homo sapiens	186-190
27664163-3	2017	We showed that while cerebral I/R injury is accompanied by loss of MMP, mitochondrial swelling and programmed cell death, pretreatment with cyclosporine-A (CsA) as a potent inhibitor of CypD, led to partial but significant reduction in necroptosis markers, RIP1 and RIP3 as well as activity of glutamate-ammonia ligase (GLUL) and glutamate dehydrogenase 1 (GLUD1), downstream enzymes of RIP3.	Cyclosporine	156-159	glutamate-ammonia ligase	Homo sapiens	294-318
27664163-3	2017	We showed that while cerebral I/R injury is accompanied by loss of MMP, mitochondrial swelling and programmed cell death, pretreatment with cyclosporine-A (CsA) as a potent inhibitor of CypD, led to partial but significant reduction in necroptosis markers, RIP1 and RIP3 as well as activity of glutamate-ammonia ligase (GLUL) and glutamate dehydrogenase 1 (GLUD1), downstream enzymes of RIP3.	Cyclosporine	156-159	glutamate-ammonia ligase	Homo sapiens	320-324
27664163-5	2017	Furthermore, we demonstrated that Bax/Bcl-2 ratio as well as caspase-3 activation, as the executioner of apoptosis, noticeably decreased by CsA pretreatment.	Cyclosporine	140-143	BCL2 associated X, apoptosis regulator	Homo sapiens	34-37
27664163-5	2017	Furthermore, we demonstrated that Bax/Bcl-2 ratio as well as caspase-3 activation, as the executioner of apoptosis, noticeably decreased by CsA pretreatment.	Cyclosporine	140-143	BCL2 apoptosis regulator	Homo sapiens	38-43
28439573-7	2017	Interleukin-1A, interleukin-10, transforming growth factor-beta1 and androgen receptor gene polymorphisms may have a significant effect on an individual susceptibility to cyclosporin A-induced gingival overgrowth in renal transplant patients.	Cyclosporine	171-184	androgen receptor	Homo sapiens	69-86
28736004-2	2017	However, the effect of TGF-beta1 and MDR1 gene polymorphisms on the pathogenesis of CsA-induced GO remains to be determined.	Cyclosporine	84-87	transforming growth factor beta 1	Homo sapiens	23-32
28736004-2	2017	However, the effect of TGF-beta1 and MDR1 gene polymorphisms on the pathogenesis of CsA-induced GO remains to be determined.	Cyclosporine	84-87	ATP binding cassette subfamily B member 1	Homo sapiens	37-41
27468796-0	2016	Gingival Crevicular Fluid and Plasma Levels of Transglutaminase-2 and Oxidative Stress Markers in Cyclosporin A-Induced Gingival Overgrowth.	Cyclosporine	98-111	transglutaminase 2	Homo sapiens	47-65
27924873-9	2016	Cyclosporine A (CsA), a mitochondrial permeability transition inhibitor, blocked translocation of Omi/HtrA2 from mitochondrial to cytoplasm, and protected transfected cells incompletely against H/R-induced caspase-3 activation.	Cyclosporine	0-14	HtrA serine peptidase 2	Rattus norvegicus	102-107
27924873-9	2016	Cyclosporine A (CsA), a mitochondrial permeability transition inhibitor, blocked translocation of Omi/HtrA2 from mitochondrial to cytoplasm, and protected transfected cells incompletely against H/R-induced caspase-3 activation.	Cyclosporine	16-19	HtrA serine peptidase 2	Rattus norvegicus	102-107
27836711-4	2016	In type I-like cells, rhodamine 123 (Rho123) accumulation was enhanced by various P-gp inhibitors such as verapamil and cyclosporine A.	Cyclosporine	120-134	ATP binding cassette subfamily B member 1	Homo sapiens	82-86
27468796-2	2016	The aim of this study is to investigate levels of gingival crevicular fluid (GCF) and plasma TGM-2 and oxidative stress markers (OSMs) in cyclosporin A (CsA)-induced gingival overgrowth (GO).	Cyclosporine	138-151	transglutaminase 2	Homo sapiens	93-98
27468796-2	2016	The aim of this study is to investigate levels of gingival crevicular fluid (GCF) and plasma TGM-2 and oxidative stress markers (OSMs) in cyclosporin A (CsA)-induced gingival overgrowth (GO).	Cyclosporine	153-156	transglutaminase 2	Homo sapiens	93-98
27468796-13	2016	CONCLUSIONS: CsA use significantly alters GCF and plasma levels of TGM-2 and OSMs.	Cyclosporine	13-16	transglutaminase 2	Homo sapiens	67-72
27468796-14	2016	TGM-2 may contribute to CsA-induced GO in CsA-treated patients by changing GCF and plasma levels of OSMs.	Cyclosporine	24-27	transglutaminase 2	Homo sapiens	0-5
27468796-14	2016	TGM-2 may contribute to CsA-induced GO in CsA-treated patients by changing GCF and plasma levels of OSMs.	Cyclosporine	42-45	transglutaminase 2	Homo sapiens	0-5
27881351-9	2016	CsA treatment significantly suppressed aorta restenosis and the alterations of CaN, NFATc3 and serum MCP-1 induced by ballon dilatation (P&lt;0.05).	Cyclosporine	0-3	nuclear factor of activated T-cells 3	Rattus norvegicus	84-90
27881351-9	2016	CsA treatment significantly suppressed aorta restenosis and the alterations of CaN, NFATc3 and serum MCP-1 induced by ballon dilatation (P&lt;0.05).	Cyclosporine	0-3	mast cell protease 1-like 1	Rattus norvegicus	101-106
27861627-3	2016	Cyclosporin A (CsA) prevented mitochondrial permeability transition pore opening and apoptosis; there was mitochondrial ultrastructural disruption, mitochondrial cytochrome c (cyt c) translocation to the cytoplasm, and subsequent caspase-9 and caspase-3 activation.	Cyclosporine	0-13	caspase 9	Rattus norvegicus	230-239
27861627-3	2016	Cyclosporin A (CsA) prevented mitochondrial permeability transition pore opening and apoptosis; there was mitochondrial ultrastructural disruption, mitochondrial cytochrome c (cyt c) translocation to the cytoplasm, and subsequent caspase-9 and caspase-3 activation.	Cyclosporine	15-18	caspase 9	Rattus norvegicus	230-239
27623348-5	2016	eGFR was higher in the MMF group (64.4+-21 vs 49.7+-14.7 mL/min/1.73 m2, P&lt;.001), although acute rejection (12 vs 4 in the CsA group, P=.03) and Class II DSA incidences were increased.	Cyclosporine	126-129	epidermal growth factor receptor	Homo sapiens	0-4
27882144-6	2016	Conversely, there were no significant differences in the expression levels of MMP-1 and IL-6 among the six groups, although a decreasing trend of IL-6 expression was observed following intervention with CSA.	Cyclosporine	203-206	interleukin-6	Oryctolagus cuniculus	146-150
27309728-10	2016	The levels of TNF, IL-4, IL-5, and IL-13 were significantly decreased after treatment with cyclosporine.	Cyclosporine	91-103	tumor necrosis factor	Mus musculus	14-17
27309728-10	2016	The levels of TNF, IL-4, IL-5, and IL-13 were significantly decreased after treatment with cyclosporine.	Cyclosporine	91-103	interleukin 13	Mus musculus	35-40
27580687-7	2016	Rescue treatment with ciclosporin or infliximab is indicated in patients who do not sufficiently respond to corticosteroids after 3-5 days, with close monitoring of the patients" symptoms, serum C-reactive protein and albumin levels.	Cyclosporine	22-33	C-reactive protein	Homo sapiens	195-213
27338269-2	2016	Treatment with the calcineurin inhibitor cyclosporine has shown benefits in patients with anti-EPO PRCA.	Cyclosporine	41-53	erythropoietin	Homo sapiens	95-98
26738448-0	2016	Cyclosporine A promotes cell proliferation, collagen and alpha-smooth muscle actin expressions in rat gingival fibroblasts by Smad3 activation and miR-29b suppression.	Cyclosporine	0-14	SMAD family member 3	Rattus norvegicus	126-131
26738448-1	2016	OBJECTIVES: Transforming growth factor (TGF)-beta/Smad3 signaling promotes tissue fibrosis, and miR-29b is a downstream inhibitor of TGF-beta/Smad3-mediated fibrosis, both of which may be involved in the pathogenesis of cyclosporine A-induced gingival overgrowth.	Cyclosporine	220-234	transforming growth factor, beta 1	Rattus norvegicus	133-141
26738448-2	2016	The aim of this study is to investigate the effect of miR-29b and TGF-beta/Smad3 signaling in cyclosporine A-stimulated rat gingival fibroblasts.	Cyclosporine	94-108	transforming growth factor, beta 1	Rattus norvegicus	66-74
26738448-2	2016	The aim of this study is to investigate the effect of miR-29b and TGF-beta/Smad3 signaling in cyclosporine A-stimulated rat gingival fibroblasts.	Cyclosporine	94-108	SMAD family member 3	Rattus norvegicus	75-80
26738448-5	2016	The effects of Smad3 and miR-29b on cyclosporine A-induced alterations were further determined by Smad3 knockdown and miR-29b overexpression using transient transfection experiments.	Cyclosporine	36-50	SMAD family member 3	Rattus norvegicus	15-20
26738448-5	2016	The effects of Smad3 and miR-29b on cyclosporine A-induced alterations were further determined by Smad3 knockdown and miR-29b overexpression using transient transfection experiments.	Cyclosporine	36-50	SMAD family member 3	Rattus norvegicus	98-103
26738448-7	2016	TGF-beta1 mRNA and protein expressions were upregulated and phosphorylated Smad3 was activated by cyclosporine A treatment, while miR-29b expression was significantly suppressed.	Cyclosporine	98-112	transforming growth factor, beta 1	Rattus norvegicus	0-9
26738448-7	2016	TGF-beta1 mRNA and protein expressions were upregulated and phosphorylated Smad3 was activated by cyclosporine A treatment, while miR-29b expression was significantly suppressed.	Cyclosporine	98-112	SMAD family member 3	Rattus norvegicus	75-80
26738448-8	2016	Moreover, Smad3 knockdown and miR-29b overexpression reversed cyclosporine A-enhanced cell proliferation, COL1 and alpha-SMA expressions in gingival fibroblasts.	Cyclosporine	62-76	SMAD family member 3	Rattus norvegicus	10-15
28164520-3	2016	METHODS: The genotype distribution of ABCB1 1236C&gt;T, 2677G&gt;T/A and 3435C&gt;T was investigated among 96 Austrian KTR who were converted from cyclosporin to TAC.	Cyclosporine	147-158	ATP binding cassette subfamily B member 1	Homo sapiens	38-43
26738448-9	2016	In addition, the suppression of miR-29b upon cyclosporine A exposure was significantly elevated by Smad3 knockdown, whereas cyclosporine A-induced Smad3 activation was not altered by miR-29b overexpression.	Cyclosporine	45-59	SMAD family member 3	Rattus norvegicus	99-104
26738448-9	2016	In addition, the suppression of miR-29b upon cyclosporine A exposure was significantly elevated by Smad3 knockdown, whereas cyclosporine A-induced Smad3 activation was not altered by miR-29b overexpression.	Cyclosporine	124-138	SMAD family member 3	Rattus norvegicus	147-152
26738448-10	2016	CONCLUSIONS: These results suggest that cyclosporine A promotes cell proliferation, collagen and alpha-SMA expressions in rat gingival fibroblasts by Smad3 activation and miR-29b suppression.	Cyclosporine	40-54	SMAD family member 3	Rattus norvegicus	150-155
27575704-7	2016	Moreover, CSA augmentation of Ang II contractions was abolished after cyclooxygenase inhibition (indomethacin) or endothelin ETA/ETB receptor blockade (atrasentan/BQ788).	Cyclosporine	10-13	angiotensinogen	Rattus norvegicus	30-36
27575704-10	2016	Further, endothelin receptors and vasoconstrictor prostanoids contribute to the CSA-evoked exaggeration of Ang II vascular responsiveness and hypertension.	Cyclosporine	80-83	angiotensinogen	Rattus norvegicus	107-113
27101736-5	2016	CsA treatment significantly decreased the percentages of CD4+ and CD8+ T lymphocytes in the thymus (P&lt;0.01).	Cyclosporine	0-3	CD4 molecule	Homo sapiens	57-60
27101736-7	2016	CsA treatment significantly depleted the peripheral blood CD3+, CD4+ and CD8+ T lymphocytes (P&lt;0.01).	Cyclosporine	0-3	CD4 molecule	Homo sapiens	64-67
27474449-4	2016	In mitochondria fed by NADH-generating substrates, the combination of Mn2+ and different respiratory chain inhibitors led to a dynamically increasing H2O2emission which was sensitive to the mPT inhibitor cyclosporine A (CsA) as well as Ru-360, an inhibitor of the mitochondrial calcium uniporter (MCU).	Cyclosporine	204-218	mitochondrial calcium uniporter	Homo sapiens	264-295
27474449-4	2016	In mitochondria fed by NADH-generating substrates, the combination of Mn2+ and different respiratory chain inhibitors led to a dynamically increasing H2O2emission which was sensitive to the mPT inhibitor cyclosporine A (CsA) as well as Ru-360, an inhibitor of the mitochondrial calcium uniporter (MCU).	Cyclosporine	220-223	mitochondrial calcium uniporter	Homo sapiens	264-295
27601896-4	2016	The results of a series of in vitro and in vivo investigations indicated that the TMLGNs were taken up by the resistant cancer cells by an endocytosis pathway that escaped the efflux induced by BCRP, and the simultaneous release of CsA with MTO further efficiently inhibited the efflux of the released MTO by BCRP; meanwhile GcNa induced the apoptosis process, and an associated synergistic antitumor activity and reversion of MDR were achieved because the reversal index was almost 1.0.	Cyclosporine	232-235	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	309-313
27443993-7	2016	The IC50 values of cyclosporine against the mitogen-activated PBMCs in the presence of 5 or 50 muunits/mL insulin were significantly higher than those of cyclosporine without insulin (p &lt; 0.05).	Cyclosporine	19-31	insulin	Homo sapiens	106-113
26547660-10	2016	In the cyclosporine A-treated rats, the expression of TGF-beta1 and TIMP-1 was significantly upregulated, whereas expression of the MMP-1 was downregulated, along with thicker and denser collagen fibers.	Cyclosporine	7-21	transforming growth factor, beta 1	Rattus norvegicus	54-63
26547660-12	2016	CONCLUSIONS: Cyclosporine A enhanced gingival fibrous overgrowth via upregulation of the TGF-beta1 and TIMP-1 expression, and downregulation of MMP-1 expression.	Cyclosporine	13-27	transforming growth factor, beta 1	Rattus norvegicus	89-98
26547660-13	2016	Tan IIA can effectively prevent cyclosporine A-induced gingival fibrous overgrowth in rats by downregulating TGF-beta1 and TIMP-1 expression, and upregulating MMP-1 expression.	Cyclosporine	32-46	transforming growth factor, beta 1	Rattus norvegicus	109-118
29441922-0	2016	The impact of CYP3A5 on the metabolism of cyclosporine A and tacrolimus in the evaluation of efficiency and safety of immunosuppressive treatment in patients after kidney transplantation.	Cyclosporine	42-56	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	14-20
29441922-1	2016	The aim of the study was to determine the impact of CYP3A5 mutation on the serum levels of immunosuppressive drugs (tacrolimus and cyclosporine A), and on the occurrence of acute rejection episodes among patients after kidney transplantation.	Cyclosporine	131-145	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	52-58
27147271-11	2016	RESULTS: CsA in MDSC-induction system significantly increased the number of CD11b(+)Gr1(+)MDSCs without detectable effects on the expressions of CD31, CD115 and CD274.	Cyclosporine	9-12	integrin alpha M	Mus musculus	76-81
27147271-12	2016	However, GM-CSF + CsA-induced MDSCs express higher iNOS than control MDSCs.	Cyclosporine	18-21	nitric oxide synthase 2, inducible	Mus musculus	51-55
27147271-13	2016	Blocking iNOS activity by inhibitor or gene deletion significantly reversed the inhibitory effects of GM-CSF + CsA-induced MDSCs on T cell proliferation.	Cyclosporine	111-114	nitric oxide synthase 2, inducible	Mus musculus	9-13
27147271-14	2016	Importantly, CsA treatment significantly increased the number and the immunosuppressive ability of CD11b(+)Gr1(+)MDSCs in allogeneic skin-grafted mice.	Cyclosporine	13-16	integrin alpha M	Mus musculus	99-104
27264264-0	2016	Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.	Cyclosporine	0-14	signal transducer and activator of transcription 3	Homo sapiens	100-105
27264264-3	2016	In this study, we found that CsA significantly augmented the anti-cancer effect of gefitinib in EGFR-TKI-sensitive and -resistant NSCLC cells.	Cyclosporine	29-32	epidermal growth factor receptor	Homo sapiens	96-100
27264264-4	2016	Mechanistically, CsA promoted gefitinib-induced apoptosis through inhibition of the STAT3 pathway.	Cyclosporine	17-20	signal transducer and activator of transcription 3	Homo sapiens	84-89
27264264-5	2016	Similar with the function of CsA, siRNAs against STAT3 also enhanced gefitinib-induced apoptosis in multiple lung cancer cells.	Cyclosporine	29-32	signal transducer and activator of transcription 3	Homo sapiens	49-54
27264264-6	2016	Xenograft studies further demonstrated that CsA promoted the anti-cancer activity of gefitinib on lung cancer cells through inhibition of STAT3.	Cyclosporine	44-47	signal transducer and activator of transcription 3	Homo sapiens	138-143
27264264-8	2016	This study provides preclinical evidence that the combination of CsA or a STAT3 inhibitor with EGFR-TKIs is a promising approach to improve the efficacy of EGFR-TKIs for the treatment of patients with advanced NSCLC.	Cyclosporine	65-68	epidermal growth factor receptor	Homo sapiens	156-160
27519420-10	2016	The pharmacological interaction between vinflunine and cyclosporine, both metabolized by CYP 3A4, may explain the excellent result and the concomitant severe toxicity.	Cyclosporine	55-67	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	89-96
27486749-9	2016	p38 MAPK (p38), c-Jun NH2-terminal kinase (JNK) and NFkB inhibitors, CsA and Dex induced a partial inhibition of HO-induced CCL2, while Dox and extracellular signal-regulated kinase (ERK) inhibitor did not.	Cyclosporine	69-72	mitogen-activated protein kinase 1	Homo sapiens	144-181
27486749-9	2016	p38 MAPK (p38), c-Jun NH2-terminal kinase (JNK) and NFkB inhibitors, CsA and Dex induced a partial inhibition of HO-induced CCL2, while Dox and extracellular signal-regulated kinase (ERK) inhibitor did not.	Cyclosporine	69-72	mitogen-activated protein kinase 1	Homo sapiens	183-186
27470424-8	2016	The levels of c-Fos, NF-kappaB, IL-6, and TNF-alpha were upregulated in LPS- and PGN-treated eyes and downregulated by CSA treatment.	Cyclosporine	119-122	interleukin 6	Homo sapiens	32-36
27470424-8	2016	The levels of c-Fos, NF-kappaB, IL-6, and TNF-alpha were upregulated in LPS- and PGN-treated eyes and downregulated by CSA treatment.	Cyclosporine	119-122	tumor necrosis factor	Homo sapiens	42-51
27279606-7	2016	Interestingly, the infectivity of wild-type or P90A virus could be rescued from the MX2-independent IFN-alpha-induced blocks in THP-1 cells by treatment with cyclosporine (Cs) or its nonimmunosuppressive analogue SDZ-NIM811, indicating that Cs-sensitive host cell cyclophilins other than CypA contribute to the activity of IFN-alpha-induced blocks.	Cyclosporine	158-170	interferon alpha 1	Homo sapiens	100-109
27279606-7	2016	Interestingly, the infectivity of wild-type or P90A virus could be rescued from the MX2-independent IFN-alpha-induced blocks in THP-1 cells by treatment with cyclosporine (Cs) or its nonimmunosuppressive analogue SDZ-NIM811, indicating that Cs-sensitive host cell cyclophilins other than CypA contribute to the activity of IFN-alpha-induced blocks.	Cyclosporine	158-170	interferon alpha 1	Homo sapiens	323-332
27279606-7	2016	Interestingly, the infectivity of wild-type or P90A virus could be rescued from the MX2-independent IFN-alpha-induced blocks in THP-1 cells by treatment with cyclosporine (Cs) or its nonimmunosuppressive analogue SDZ-NIM811, indicating that Cs-sensitive host cell cyclophilins other than CypA contribute to the activity of IFN-alpha-induced blocks.	Cyclosporine	172-174	interferon alpha 1	Homo sapiens	100-109
27279606-7	2016	Interestingly, the infectivity of wild-type or P90A virus could be rescued from the MX2-independent IFN-alpha-induced blocks in THP-1 cells by treatment with cyclosporine (Cs) or its nonimmunosuppressive analogue SDZ-NIM811, indicating that Cs-sensitive host cell cyclophilins other than CypA contribute to the activity of IFN-alpha-induced blocks.	Cyclosporine	241-243	interferon alpha 1	Homo sapiens	100-109
27279617-4	2016	In this study, the consequences of well-described CTL-associated p24 Gag sequence mutations for HIV-1 capsid stability were assessed using a cyclosporine (CsA) washout assay.	Cyclosporine	141-153	transmembrane p24 trafficking protein 2	Homo sapiens	65-68
27279617-4	2016	In this study, the consequences of well-described CTL-associated p24 Gag sequence mutations for HIV-1 capsid stability were assessed using a cyclosporine (CsA) washout assay.	Cyclosporine	155-158	transmembrane p24 trafficking protein 2	Homo sapiens	65-68
27489538-3	2016	Cyclosporine A provides protection against the mPTP opening through its interaction with cyclophilin-D (CypD).	Cyclosporine	0-14	protein tyrosine phosphatase, receptor type, U	Mus musculus	47-51
27489538-3	2016	Cyclosporine A provides protection against the mPTP opening through its interaction with cyclophilin-D (CypD).	Cyclosporine	0-14	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	89-102
27489538-3	2016	Cyclosporine A provides protection against the mPTP opening through its interaction with cyclophilin-D (CypD).	Cyclosporine	0-14	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	104-108
27367933-1	2016	The CD25-binding antibody daclizumab high-yield process (DAC HYP) is an interleukin (IL)-2 signal modulating antibody that shares primary amino acid sequence and CD25 binding affinity with Zenapax , a distinct form of daclizumab, which was approved for the prevention of acute organ rejection in patients receiving renal transplants as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids.	Cyclosporine	387-399	interleukin 2	Homo sapiens	72-90
27310200-8	2016	Cyclosporine predominantly inhibited CYP3A4 (half maximal inhibitory concentration = 0.71 microM) rather than CYP3A5 (&gt;5 microM), whereas tacrolimus showed similar inhibition for CYP3A4 (0.29 microM) and CYP3A5 (0.41 microM).	Cyclosporine	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	37-43
27310200-8	2016	Cyclosporine predominantly inhibited CYP3A4 (half maximal inhibitory concentration = 0.71 microM) rather than CYP3A5 (&gt;5 microM), whereas tacrolimus showed similar inhibition for CYP3A4 (0.29 microM) and CYP3A5 (0.41 microM).	Cyclosporine	0-12	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	207-213
27653228-4	2016	RESULTS: Expression of CYP3A5 by either or both the donor and the recipient was significantly associated with lower Tac, but not CsA, dose-normalized trough levels.	Cyclosporine	129-132	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	23-29
27283486-0	2016	Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates.	Cyclosporine	22-35	ATP binding cassette subfamily B member 1	Homo sapiens	72-77
27283486-1	2016	Cyclosporin A (CsA) and dipyridamole (DPy) are potent inhibitors of the P-glycoprotein (P-gp; ABCB1) in vitro.	Cyclosporine	0-13	ATP binding cassette subfamily B member 1	Homo sapiens	72-86
27283486-1	2016	Cyclosporin A (CsA) and dipyridamole (DPy) are potent inhibitors of the P-glycoprotein (P-gp; ABCB1) in vitro.	Cyclosporine	0-13	ATP binding cassette subfamily B member 1	Homo sapiens	88-92
27283486-1	2016	Cyclosporin A (CsA) and dipyridamole (DPy) are potent inhibitors of the P-glycoprotein (P-gp; ABCB1) in vitro.	Cyclosporine	0-13	ATP binding cassette subfamily B member 1	Homo sapiens	94-99
27357441-4	2016	In addition, CsA treatment blocked the CoCl2-induced increases in ROS production and mitochondrial dysfunction, including a decrease in membrane potential, cytochrome c (cyto-c) release, Bax/Bcl-2 imbalance, as well as the ratios of cl-casp-9/casp-9 and cl-casp-3/casp-3 ratios, via the inhibition of p38 and ERK MAPK signaling pathways.	Cyclosporine	13-16	BCL2, apoptosis regulator	Rattus norvegicus	191-196
27357441-4	2016	In addition, CsA treatment blocked the CoCl2-induced increases in ROS production and mitochondrial dysfunction, including a decrease in membrane potential, cytochrome c (cyto-c) release, Bax/Bcl-2 imbalance, as well as the ratios of cl-casp-9/casp-9 and cl-casp-3/casp-3 ratios, via the inhibition of p38 and ERK MAPK signaling pathways.	Cyclosporine	13-16	caspase 9	Rattus norvegicus	236-242
27357441-4	2016	In addition, CsA treatment blocked the CoCl2-induced increases in ROS production and mitochondrial dysfunction, including a decrease in membrane potential, cytochrome c (cyto-c) release, Bax/Bcl-2 imbalance, as well as the ratios of cl-casp-9/casp-9 and cl-casp-3/casp-3 ratios, via the inhibition of p38 and ERK MAPK signaling pathways.	Cyclosporine	13-16	caspase 9	Rattus norvegicus	243-249
27357441-4	2016	In addition, CsA treatment blocked the CoCl2-induced increases in ROS production and mitochondrial dysfunction, including a decrease in membrane potential, cytochrome c (cyto-c) release, Bax/Bcl-2 imbalance, as well as the ratios of cl-casp-9/casp-9 and cl-casp-3/casp-3 ratios, via the inhibition of p38 and ERK MAPK signaling pathways.	Cyclosporine	13-16	Eph receptor B1	Rattus norvegicus	309-312
27496439-8	2016	We found an association of Tac C0 with expression of TLR4 only and CsA dose per 1 kg body weight with TLR2 or up to 6 months after KT with TLR9.	Cyclosporine	67-70	toll like receptor 2	Homo sapiens	102-106
27635199-8	2016	In addition, CsA caused increases in the levels of malondialdehyde (MDA) and decreases in superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), glutathione reductase (GSR), glutathione-S-transferase (GST), and glutathione in kidney homogenate, which were reversed significantly by both doses of RG.	Cyclosporine	13-16	glutathione peroxidase 1	Rattus norvegicus	142-148
27430433-5	2016	The positive control animals taking CsA alone showed marked histopathological, ultrastructure, and genetic manifestations accompanied by an elevated content of lipid peroxidation and marked reduction of catalase (CAT), peroxidase (Px) activity, and glutathione concentration in the homogenate of testis tissues.	Cyclosporine	36-39	catalase	Rattus norvegicus	203-211
27430433-5	2016	The positive control animals taking CsA alone showed marked histopathological, ultrastructure, and genetic manifestations accompanied by an elevated content of lipid peroxidation and marked reduction of catalase (CAT), peroxidase (Px) activity, and glutathione concentration in the homogenate of testis tissues.	Cyclosporine	36-39	catalase	Rattus norvegicus	213-216
27247192-0	2016	Cyclosporine A Treatment Abrogates Ischemia-Induced Neuronal Cell Death by Preserving Mitochondrial Integrity through Upregulation of the Parkinson"s Disease-Associated Protein DJ-1.	Cyclosporine	0-14	Parkinsonism associated deglycase	Rattus norvegicus	169-181
27247192-10	2016	CsA prevented both mtDNA decrement and Deltapsim degradation after reperfusion, and enhanced secretion of DJ-1 in the mitochondria, coupled with reduced oxidative stress.	Cyclosporine	0-3	Parkinsonism associated deglycase	Rattus norvegicus	106-110
27247192-11	2016	CONCLUSION: These observations provided evidence that CsA maintained mitochondrial integrity likely via DJ-1 upregulation, supporting the concept that mitochondria-based treatments targeting the early phase of disease progression may prove beneficial in stroke.	Cyclosporine	54-57	Parkinsonism associated deglycase	Rattus norvegicus	104-108
27353300-10	2016	RESULTS: Our data showed that CsA administration resulted in a significant reduction of AhR expression.	Cyclosporine	30-33	aryl-hydrocarbon receptor	Mus musculus	88-91
27353300-12	2016	NFATc1 expression was also reduced in CsA-treated animals.	Cyclosporine	38-41	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	0-6
27353300-16	2016	Moreover, CsA can prevent B[alpha]P-induced lung tissue damage, and it remarkably decreases NFATc1 expression.	Cyclosporine	10-13	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	92-98
27295076-0	2016	Calcineurin inhibitors cyclosporine A and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling.	Cyclosporine	23-37	toll-like receptor 4	Mus musculus	117-121
27238624-9	2016	Strong immunosuppressive therapy (corticosteroid, intravenous immunoglobulin, and cyclosporine A) ameliorated the myositis, interstitial lung disease, and inflammation, with the decrease of MPO-ANCA levels, despite that severe lung complications are often associated with poor outcomes.	Cyclosporine	82-96	myeloperoxidase	Homo sapiens	190-193
27496457-10	2016	Significant correlation between SFA and eGFR was observed only in the CsA RTR group (P &lt; .05).	Cyclosporine	70-73	epidermal growth factor receptor	Homo sapiens	40-44
27016408-6	2016	Concentration-dependent uptake of DLM in 0.01% HSA was non-linear and was reduced at 4 C and by the P-gp inhibitor cyclosporine (CSA), indicative of a specific transport process.	Cyclosporine	115-127	ATP binding cassette subfamily B member 1	Homo sapiens	100-104
27016408-6	2016	Concentration-dependent uptake of DLM in 0.01% HSA was non-linear and was reduced at 4 C and by the P-gp inhibitor cyclosporine (CSA), indicative of a specific transport process.	Cyclosporine	129-132	ATP binding cassette subfamily B member 1	Homo sapiens	100-104
27016408-7	2016	Cellular accumulation of [(3)H]-paclitaxel, a P-glycoprotein (P-gp) substrate, was increased by CSA but not by DLM, suggesting that DLM is neither a substrate nor an inhibitor of P-gp.	Cyclosporine	96-99	ATP binding cassette subfamily B member 1	Homo sapiens	46-60
27016408-7	2016	Cellular accumulation of [(3)H]-paclitaxel, a P-glycoprotein (P-gp) substrate, was increased by CSA but not by DLM, suggesting that DLM is neither a substrate nor an inhibitor of P-gp.	Cyclosporine	96-99	ATP binding cassette subfamily B member 1	Homo sapiens	62-66
24777031-10	2016	In the CSA + MMF group, C4d excretion was 195.6 +- 200.3 ng/mL (5.0 +- 6.6 ng/mgCr).	Cyclosporine	7-10	MN1 proto-oncogene, transcriptional regulator	Homo sapiens	78-82
24777031-9	2016	At baseline, the greatest C4d urinary excretion was noticed in patients treated with CSA + AZA, 199.5 +- 175.9 ng/mL (5.3 +- 7.1 ng/mgCr) and the lowest in those in whom tacrolimus and mycophenolate mophetil was administered, 166.6 +- 186.3 ng/mL (3.9 +- 6.2 ng/mgCr).	Cyclosporine	85-88	MN1 proto-oncogene, transcriptional regulator	Homo sapiens	132-136
24777031-9	2016	At baseline, the greatest C4d urinary excretion was noticed in patients treated with CSA + AZA, 199.5 +- 175.9 ng/mL (5.3 +- 7.1 ng/mgCr) and the lowest in those in whom tacrolimus and mycophenolate mophetil was administered, 166.6 +- 186.3 ng/mL (3.9 +- 6.2 ng/mgCr).	Cyclosporine	85-88	MN1 proto-oncogene, transcriptional regulator	Homo sapiens	262-266
26950050-5	2016	The impact of phenotyping on the dose selection and pharmacokinetics of CYP3A substrates (docetaxel, irinotecan, tyrosine kinase inhibitors, ciclosporin, tacrolimus) are reviewed.	Cyclosporine	141-152	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	72-77
27173422-7	2016	Interestingly, ALP immediately decreased after termination of cyclosporine in two patients, whereas TH lasted 4 months in the one patient who continued cyclosporine.	Cyclosporine	62-74	alkaline phosphatase, placental	Homo sapiens	15-18
26585254-2	2016	To evaluate the brain expression of p-glycoprotein in patients with drug-resistant epilepsy, including neocortical epilepsy, we developed a noninvsive quantitative analysis including asymmetry indices based on (R)-[(11)C]-verapamil PET/MR imaging with cyclosporin A, a p-glycoprotein inhibitor.	Cyclosporine	252-265	ATP binding cassette subfamily B member 1	Homo sapiens	36-50
26894526-0	2016	Biological roles of KGF, CTGF and TGF-beta in cyclosporine-A- and phenytoin- induced gingival overgrowth: A comparative experimental animal study.	Cyclosporine	46-60	transforming growth factor, beta 1	Rattus norvegicus	34-42
26894526-1	2016	OBJECTIVE: To identify the possible biological roles of keratinocyte growth factor (KGF), connective tissue growth factor (CTGF) and transforming growth factor-beta (TGF-beta) in cyclosporine-A (CsA) and phenytoin (PNT)-induced gingival overgrowth (GO) and to correlate them with each other.	Cyclosporine	179-193	transforming growth factor, beta 1	Rattus norvegicus	166-174
26894526-1	2016	OBJECTIVE: To identify the possible biological roles of keratinocyte growth factor (KGF), connective tissue growth factor (CTGF) and transforming growth factor-beta (TGF-beta) in cyclosporine-A (CsA) and phenytoin (PNT)-induced gingival overgrowth (GO) and to correlate them with each other.	Cyclosporine	195-198	transforming growth factor, beta 1	Rattus norvegicus	166-174
26896299-8	2016	NMR analysis of the interactions of PTN with CS revealed that the C-terminal domain and hinge of PTN make up the major CS-binding site in PTN, and that removal of the C-terminal tail weakened the affinity of the site for CSA but not for other high sulfation density CS.	Cyclosporine	221-224	pleiotrophin	Homo sapiens	36-39
26826458-8	2016	More than 50% level of inflammatory factors including TNF-alpha, IFN-gamma, IL-2, IL-12, IL-22 and IL-23 in mouse serum was decreased by curcumin treatment as well as cyclosporine.	Cyclosporine	167-179	tumor necrosis factor	Mus musculus	54-63
26826458-8	2016	More than 50% level of inflammatory factors including TNF-alpha, IFN-gamma, IL-2, IL-12, IL-22 and IL-23 in mouse serum was decreased by curcumin treatment as well as cyclosporine.	Cyclosporine	167-179	interferon gamma	Mus musculus	65-74
27307657-7	2016	RESULTS: The data obtained from immunohistochemistry assessment shows that drug-induced gingival overgrowth (DIGO) samples express more IL-6 than control group and cyclosporin expresses more IL-6 followed by phenytoin and nifedipine.	Cyclosporine	164-175	interleukin 6	Homo sapiens	191-195
27307657-9	2016	Among the study group, cyclosporin expressed maximum IL-6 expression followed by phenytoin and nifedipine.	Cyclosporine	23-34	interleukin 6	Homo sapiens	53-57
26713664-7	2016	Moreover, CsA is highly metabolized by cytochrome P450 3A4 (CYP3A4), a polymorphic enzyme leading to variations of Cmax and AUC between 10-20% in patients using CsA.	Cyclosporine	10-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	39-58
26713664-7	2016	Moreover, CsA is highly metabolized by cytochrome P450 3A4 (CYP3A4), a polymorphic enzyme leading to variations of Cmax and AUC between 10-20% in patients using CsA.	Cyclosporine	10-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-66
26713664-7	2016	Moreover, CsA is highly metabolized by cytochrome P450 3A4 (CYP3A4), a polymorphic enzyme leading to variations of Cmax and AUC between 10-20% in patients using CsA.	Cyclosporine	161-164	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	39-58
26713664-7	2016	Moreover, CsA is highly metabolized by cytochrome P450 3A4 (CYP3A4), a polymorphic enzyme leading to variations of Cmax and AUC between 10-20% in patients using CsA.	Cyclosporine	161-164	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-66
26844915-5	2016	Moreover, cyclosporine A significantly reduced serum albumin, creatinine clearance, urinary total antioxidant, superoxide dismutase, glutathione and Bcl2 protein levels.	Cyclosporine	10-24	BCL2, apoptosis regulator	Rattus norvegicus	149-153
26896299-8	2016	NMR analysis of the interactions of PTN with CS revealed that the C-terminal domain and hinge of PTN make up the major CS-binding site in PTN, and that removal of the C-terminal tail weakened the affinity of the site for CSA but not for other high sulfation density CS.	Cyclosporine	221-224	pleiotrophin	Homo sapiens	97-100
26896299-8	2016	NMR analysis of the interactions of PTN with CS revealed that the C-terminal domain and hinge of PTN make up the major CS-binding site in PTN, and that removal of the C-terminal tail weakened the affinity of the site for CSA but not for other high sulfation density CS.	Cyclosporine	221-224	pleiotrophin	Homo sapiens	97-100
26952880-6	2016	CsA (10 muM) was cytotoxic toward HepaRG cells in the presence of BAs and also reduced the biliary efflux rate of [(3)H]taurocholic acid from 38.5% to 19.2%.	Cyclosporine	0-3	latexin	Homo sapiens	8-11
26936128-10	2016	However, CypD inhibitor, cyclosporin A (CsA), blocked HNK-induced necrosis.	Cyclosporine	25-38	peptidylprolyl isomerase F	Homo sapiens	9-13
26936128-10	2016	However, CypD inhibitor, cyclosporin A (CsA), blocked HNK-induced necrosis.	Cyclosporine	40-43	peptidylprolyl isomerase F	Homo sapiens	9-13
26936128-13	2016	Pretreatment with CsA, therefore, inhibits HNK-triggered regulated necrosis and reverses dephosphorylation of Akt, eIF4E-binding protein 1 and S6 kinase.	Cyclosporine	18-21	AKT serine/threonine kinase 1	Homo sapiens	110-113
27028319-5	2016	Intracellular and secreted IL-10 levels were determined by flow cytometry and Bioplex assay after treating PBMCs with PD98059, tipifarnib and cyclosporin A for blocking of ERK-, T-bet-and FoxP3-dependent pathways, respectively.	Cyclosporine	142-155	mitogen-activated protein kinase 1	Homo sapiens	172-175
26632647-6	2016	CsA-induced hepatotoxicity was evidenced by increase in serum levels of AST, ALT, and gammaGT; a decrease in serum albumin; and a significant alteration in hepatic architecture.	Cyclosporine	0-3	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	72-75
27627555-1	2016	BACKGROUND: Permeability glycoprotein (P-glycoprotein or P-gp) plays an important role in the intestinal absorption of the immunosuppressive agents: cyclosporine and tacrolimus.	Cyclosporine	149-161	phosphoglycolate phosphatase	Rattus norvegicus	57-61
27627555-2	2016	OBJECTIVES: The aim of this study was to determine how the intestinal absorption of cyclosporine and tacrolimus is affected when they are used with P-gp activating or inhibiting agents.	Cyclosporine	84-96	phosphoglycolate phosphatase	Rattus norvegicus	148-152
26385839-5	2016	It performed well in recovering the observed effect of the CYP3A4 inhibitors ketoconazole and cyclosporine, and the CYP3A4 inducer rifampicin, as well as in predicting interactions with S-warfarin and sildenafil.	Cyclosporine	94-106	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	59-65
26792730-7	2016	Our data suggest that the Gly(219)-Pro-Tyr motif in the human CrkII linker region serves as the recognition and isomerization site of PPIases, and raise the possibility that CsA and FK506 might interfere with selected effector T cell functions via a CrkII-, but not CrkI-dependent mechanisms.	Cyclosporine	174-177	CRK proto-oncogene, adaptor protein	Homo sapiens	62-67
26775841-9	2016	The in vivo activity by PF-543 was largely attenuated when combined with the Cyp-D inhibitor cyclosporin A.	Cyclosporine	93-106	peptidylprolyl isomerase F	Homo sapiens	77-82
26807900-10	2016	The levels of interferon gamma and TNF-alpha in the ocular surface and intraorbital gland were significantly repressed by TSG-6 and cyclosporine, and prednisolone treatment significantly reduced the level of interferon gamma.	Cyclosporine	132-144	interferon gamma	Mus musculus	14-44
26807900-10	2016	The levels of interferon gamma and TNF-alpha in the ocular surface and intraorbital gland were significantly repressed by TSG-6 and cyclosporine, and prednisolone treatment significantly reduced the level of interferon gamma.	Cyclosporine	132-144	interferon gamma	Mus musculus	14-30
26679998-4	2016	We therefore designed and synthesized a new mitochondrially targeted CypD inhibitor, JW47, using a quinolinium cation tethered to cyclosporine.	Cyclosporine	130-142	peptidylprolyl isomerase F	Homo sapiens	69-73
26792730-4	2016	Utilizing human Jurkat T cells, we demonstrate that CrkII-SH3N binding of C3G is inhibited by cyclosporin A (CsA) plus FK506 that inhibit the cyclophilin A (CypA) and FK506 binding protein (FKBP) peptidyl-prolyl cis-trans isomerases (PPIases; also termed immunophilins), respectively.	Cyclosporine	94-107	CRK proto-oncogene, adaptor protein	Homo sapiens	52-57
26792730-4	2016	Utilizing human Jurkat T cells, we demonstrate that CrkII-SH3N binding of C3G is inhibited by cyclosporin A (CsA) plus FK506 that inhibit the cyclophilin A (CypA) and FK506 binding protein (FKBP) peptidyl-prolyl cis-trans isomerases (PPIases; also termed immunophilins), respectively.	Cyclosporine	109-112	CRK proto-oncogene, adaptor protein	Homo sapiens	52-57
26792730-7	2016	Our data suggest that the Gly(219)-Pro-Tyr motif in the human CrkII linker region serves as the recognition and isomerization site of PPIases, and raise the possibility that CsA and FK506 might interfere with selected effector T cell functions via a CrkII-, but not CrkI-dependent mechanisms.	Cyclosporine	174-177	CRK proto-oncogene, adaptor protein	Homo sapiens	250-255
26259716-5	2016	The interplay between hepatic uptake and CYP3A4 metabolism was verified by simulations with rifampicin, a potent CYP3A4 inducer and OATP1B1/3 inhibitor, and maintenance doses of cyclosporine.	Cyclosporine	178-190	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-47
25594762-4	2016	In an immortalized normal urothelial cell line SVHUC, CsA and FK506 reduced NFATc1 expression, NFAT transcriptional activity, and the expression of c-myc, a downstream target of NFATc1 signals.	Cyclosporine	54-57	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	76-82
26353895-8	2016	Cyclosporine is an inhibitor of OATP1B1/3, BCRP and P-gp, and a mild inhibitor of CYP3A; cyclosporine causes a significant increase in simeprevir plasma concentrations, and coadministration is not recommended.	Cyclosporine	0-12	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	43-47
26353895-8	2016	Cyclosporine is an inhibitor of OATP1B1/3, BCRP and P-gp, and a mild inhibitor of CYP3A; cyclosporine causes a significant increase in simeprevir plasma concentrations, and coadministration is not recommended.	Cyclosporine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	52-56
26353895-8	2016	Cyclosporine is an inhibitor of OATP1B1/3, BCRP and P-gp, and a mild inhibitor of CYP3A; cyclosporine causes a significant increase in simeprevir plasma concentrations, and coadministration is not recommended.	Cyclosporine	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	82-87
26353895-8	2016	Cyclosporine is an inhibitor of OATP1B1/3, BCRP and P-gp, and a mild inhibitor of CYP3A; cyclosporine causes a significant increase in simeprevir plasma concentrations, and coadministration is not recommended.	Cyclosporine	89-101	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	43-47
26353895-8	2016	Cyclosporine is an inhibitor of OATP1B1/3, BCRP and P-gp, and a mild inhibitor of CYP3A; cyclosporine causes a significant increase in simeprevir plasma concentrations, and coadministration is not recommended.	Cyclosporine	89-101	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	82-87
23897745-9	2016	Investigations in vitro revealed that cyclosporine A inhibited extracellular-signal-regulated kinase (ERK) phosphorylation induced by Ac2-26 in neutrophils.	Cyclosporine	38-52	mitogen-activated protein kinase 1	Mus musculus	63-100
23897745-9	2016	Investigations in vitro revealed that cyclosporine A inhibited extracellular-signal-regulated kinase (ERK) phosphorylation induced by Ac2-26 in neutrophils.	Cyclosporine	38-52	mitogen-activated protein kinase 1	Mus musculus	102-105
25594762-4	2016	In an immortalized normal urothelial cell line SVHUC, CsA and FK506 reduced NFATc1 expression, NFAT transcriptional activity, and the expression of c-myc, a downstream target of NFATc1 signals.	Cyclosporine	54-57	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	178-184
26847727-9	2016	The most salient feature was a reduction in CRC in the presence of CsA, an effect reflecting PTP dysregulation.	Cyclosporine	67-70	protein tyrosine phosphatase, non-receptor type 1	Rattus norvegicus	93-96
26990469-1	2016	Cyclosporine-induced sebaceous hyperplasia (SH) is a well-documented entity, occurring in up to 30% of renal transplant patients treated with cyclosporine and has also been reported to occur following heart or hematopoetic stem cell transplantation (HCST).	Cyclosporine	0-12	hematopoietic cell signal transducer	Homo sapiens	250-254
26603313-2	2016	Immunological pathways, including TLR signaling, are also involved in chronic cyclosporine (CsA) nephrotoxicity.	Cyclosporine	78-90	toll-like receptor 4	Mus musculus	34-37
26603313-2	2016	Immunological pathways, including TLR signaling, are also involved in chronic cyclosporine (CsA) nephrotoxicity.	Cyclosporine	92-95	toll-like receptor 4	Mus musculus	34-37
26603313-11	2016	CONCLUSIONS: Neutralizing HMGB1 with an anti-HMGB1 antibody ameliorated chronic CsA nephrotoxicity via inhibition of the TLR4 signaling pathway.	Cyclosporine	80-83	toll-like receptor 4	Mus musculus	121-125
26472929-12	2016	Cyclosporin A, which inhibits calcineurin upstream of NFATc1, blocked BMP-2-induced NFATc1 mRNA and protein expression.	Cyclosporine	0-13	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	54-60
26234649-0	2016	IgE responses to exogenous and endogenous allergens in atopic dermatitis patients under long-term systemic cyclosporine A treatment.	Cyclosporine	107-121	immunoglobulin heavy constant epsilon	Homo sapiens	0-3
26472929-12	2016	Cyclosporin A, which inhibits calcineurin upstream of NFATc1, blocked BMP-2-induced NFATc1 mRNA and protein expression.	Cyclosporine	0-13	bone morphogenetic protein 2	Mus musculus	70-75
26472929-12	2016	Cyclosporin A, which inhibits calcineurin upstream of NFATc1, blocked BMP-2-induced NFATc1 mRNA and protein expression.	Cyclosporine	0-13	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	84-90
26735686-3	2016	The objective was to elucidate whether a conversion from tacrolimus to cyclosporine A affects fasting and/or dynamic insulin sensitivity, insulin secretion or all in HCV-positive renal transplant recipients.	Cyclosporine	71-85	insulin	Homo sapiens	117-124
26735686-11	2016	CONCLUSIONS: HCV-positive renal transplant recipients show significantly improved glucose-stimulated insulin sensitivity and overall glucose tolerance after conversion from tacrolimus to cyclosporine A.	Cyclosporine	187-201	insulin	Homo sapiens	101-108
26735686-12	2016	Considering the HCV-induced insulin resistance, HCV-positive renal transplant recipients may benefit from a cyclosporine A-based immunosuppressive regimen.	Cyclosporine	108-122	insulin	Homo sapiens	28-35
26563728-6	2016	Fluoromethyl compound [(18)F]-6 is classified as a non-transported P-gp substrate, because its efflux increases after cyclosporine A modulation.	Cyclosporine	118-132	ATP binding cassette subfamily B member 1	Homo sapiens	67-71
27166157-14	2016	CONCLUSIONS: ERS marker GRP78 in the glomeruli but not serum or kidney calcineurin expression could be a useful marker in PMN to negatively predict the response to cyclosporine treatment at the sixth month.	Cyclosporine	164-176	heat shock protein family A (Hsp70) member 5	Homo sapiens	24-29
26234649-2	2016	We analyzed serum samples from four AD patients who had received oral cyclosporine A (CyA) treatment for up to 17 months regarding IgE autoreactivity to nitrocellulose-blotted human epithelial cell extracts and IgE levels to environmental allergens by quantitative ImmunoCap measurements.	Cyclosporine	70-84	immunoglobulin heavy constant epsilon	Homo sapiens	131-134
26234649-2	2016	We analyzed serum samples from four AD patients who had received oral cyclosporine A (CyA) treatment for up to 17 months regarding IgE autoreactivity to nitrocellulose-blotted human epithelial cell extracts and IgE levels to environmental allergens by quantitative ImmunoCap measurements.	Cyclosporine	86-89	immunoglobulin heavy constant epsilon	Homo sapiens	131-134
26849622-7	2016	The insulin-induced elevation of TRPC6 transcripts was blocked in the presence of tacrolimus, cyclosporine A, and NFAT-inhibitor (each p &lt; 0.01 by ANOVA and Bonferroni"s multiple comparison test).	Cyclosporine	94-108	insulin	Homo sapiens	4-11
27374283-1	2016	Cyclosporine (CSA), which is one of the substrates of ATP binding cassette subfamily B member 1 (ABCB1), is widely used as an immunosuppressant in patients undergoing transplantation.	Cyclosporine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	54-95
27374283-1	2016	Cyclosporine (CSA), which is one of the substrates of ATP binding cassette subfamily B member 1 (ABCB1), is widely used as an immunosuppressant in patients undergoing transplantation.	Cyclosporine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	97-102
27725441-8	2016	Moreover, a calcineurin inhibitor, cyclosporine A, also decreased neprilysin activity, leading to increases in amyloid-beta peptide levels.	Cyclosporine	35-49	membrane metalloendopeptidase	Homo sapiens	66-76
26849622-10	2016	Insulin increased the activity of NFATc1 in nuclear extracts (p &lt; 0.001) whereas tacrolimus, cyclosporine A, and NFAT-inhibitor blocked that insulin effect (p &lt; 0.001; two way ANOVA).	Cyclosporine	96-110	insulin	Homo sapiens	144-151
26984091-0	2016	Thrombocytopenia and Anemia with Anti-c-Mpl antibodies Effectively Treated with Cyclosporine in a Patient with Rheumatoid Arthritis and Chronic Renal Failure.	Cyclosporine	80-92	MPL proto-oncogene, thrombopoietin receptor	Homo sapiens	38-43
26912097-6	2016	Cyclosporine disposition is less susceptible to these interactions compared with tacrolimus, possibly because cyclosporine is itself a moderately strong CYP3A4- and strong P-gp inhibitor, blunting the effect of additional inhibitors.	Cyclosporine	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	153-159
26912097-6	2016	Cyclosporine disposition is less susceptible to these interactions compared with tacrolimus, possibly because cyclosporine is itself a moderately strong CYP3A4- and strong P-gp inhibitor, blunting the effect of additional inhibitors.	Cyclosporine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	172-176
26912097-6	2016	Cyclosporine disposition is less susceptible to these interactions compared with tacrolimus, possibly because cyclosporine is itself a moderately strong CYP3A4- and strong P-gp inhibitor, blunting the effect of additional inhibitors.	Cyclosporine	110-122	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	153-159
26912097-6	2016	Cyclosporine disposition is less susceptible to these interactions compared with tacrolimus, possibly because cyclosporine is itself a moderately strong CYP3A4- and strong P-gp inhibitor, blunting the effect of additional inhibitors.	Cyclosporine	110-122	ATP binding cassette subfamily B member 1	Homo sapiens	172-176
26572087-9	2016	The inhibition of nuclear factor (NF)-kappaB by cyclosporine sensitized the MCF-7/del p53 cells to doxorubicin toxicity.	Cyclosporine	48-60	tumor protein p53	Homo sapiens	86-89
26386753-7	2016	In addition, for those who reported CSA, there was a cumulative increase in adult SV risk with each additional ACE experienced.	Cyclosporine	36-39	angiotensin I converting enzyme	Homo sapiens	111-114
26984091-3	2016	Cyclosporine treatment resulted in the improvement of her megakaryocyte and erythroblast levels, and a decrease in her serum level of anti-c-Mpl (thrombopoietin receptor) antibodies.	Cyclosporine	0-12	MPL proto-oncogene, thrombopoietin receptor	Homo sapiens	139-144
26984091-3	2016	Cyclosporine treatment resulted in the improvement of her megakaryocyte and erythroblast levels, and a decrease in her serum level of anti-c-Mpl (thrombopoietin receptor) antibodies.	Cyclosporine	0-12	MPL proto-oncogene, thrombopoietin receptor	Homo sapiens	146-169
26937363-1	2016	AIMS: This study was carried out to identify and outline the degree of relationship between immunophenotyped macrophages expressing CD163 and PDGF-B in cyclosporine-A, phenytoin, and nifedipine-induced gingival overgrowth.	Cyclosporine	152-166	CD163 molecule	Rattus norvegicus	132-137
25967121-6	2016	Short-term cyclosporine administration in mice augmented the abundance of phospho-NKCC2, and treatment of isolated TAL with cyclosporine increased the chloride affinity and transport activity of NKCC2.	Cyclosporine	11-23	solute carrier family 12, member 1	Mus musculus	82-87
25967121-6	2016	Short-term cyclosporine administration in mice augmented the abundance of phospho-NKCC2, and treatment of isolated TAL with cyclosporine increased the chloride affinity and transport activity of NKCC2.	Cyclosporine	124-136	solute carrier family 12, member 1	Mus musculus	195-200
25967121-10	2016	Cyclosporine administration rapidly normalized the abundance of phospho-NKCC2 in SORLA-deficient mice, and a functional interaction between calcineurin Abeta and SORLA was further corroborated by binding assays in rat kidney extracts.	Cyclosporine	0-12	solute carrier family 12, member 1	Mus musculus	72-77
26937363-13	2016	In addition, CD163 and PDGF-B upregulated in cyclosporine-A-induced GO compared to phenytoin and nifedipine medications.	Cyclosporine	45-59	CD163 molecule	Rattus norvegicus	13-18
26271661-6	2015	RESULTS: The recipients with grafts from normal CYP3A4 expresser donors carrying CYP3A5*3/*3 required CNI maintenance doses more or less similar to the bodyweight-controlled starting doses (9.1 mg kg(-1) of ciclosporin and 0.1 mg kg(-1) of tacrolimus).	Cyclosporine	207-218	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	81-87
26666562-6	2015	We demonstrated that delayed cyclosporin treatment afforded neurorestoration in three complementary models of PD including the Thy1-alpha-synuclein transgenic mouse, a novel AAV-alpha-synuclein mouse model, and the MPTP mouse model.	Cyclosporine	29-40	thymus cell antigen 1, theta	Mus musculus	127-131
26385159-4	2015	In previous studies mPT was inhibited by cyclosporine A which, beside CypD, inhibits cyclophilin A, B, C and calcineurin, regulating cell death and inflammatory pathways.	Cyclosporine	41-55	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	70-74
26634693-2	2015	The immunosuppressive drug cyclosporine A (CsA), which is a calcineurin inhibitor, is used to treat proteinuric kidney diseases.	Cyclosporine	27-41	calcineurin binding protein 1	Mus musculus	60-81
26634693-2	2015	The immunosuppressive drug cyclosporine A (CsA), which is a calcineurin inhibitor, is used to treat proteinuric kidney diseases.	Cyclosporine	43-46	calcineurin binding protein 1	Mus musculus	60-81
26833980-6	2015	Moreover, CsA treatment inhibited the activation of the signal transducer and activator of transcription 3 (STAT3) in MM U266 cells.	Cyclosporine	10-13	signal transducer and activator of transcription 3	Homo sapiens	56-106
26833980-6	2015	Moreover, CsA treatment inhibited the activation of the signal transducer and activator of transcription 3 (STAT3) in MM U266 cells.	Cyclosporine	10-13	signal transducer and activator of transcription 3	Homo sapiens	108-113
26817280-0	2015	A non-invasive CYP3A4 biomarker and body mass index predict cyclosporine dosage requirements in Chinese renal transplant recipients.	Cyclosporine	60-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	15-21
26374844-3	2015	In a mouse model of lethal mitochondrial myopathy, the muscle-specific Tfam knock-out (KO) mouse, we previously demonstrated an excessive mitochondrial Ca(2+) uptake in isolated muscle fibers that could be inhibited by the cyclophilin D (CypD) inhibitor, cyclosporine A (CsA).	Cyclosporine	271-274	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	223-236
26374844-3	2015	In a mouse model of lethal mitochondrial myopathy, the muscle-specific Tfam knock-out (KO) mouse, we previously demonstrated an excessive mitochondrial Ca(2+) uptake in isolated muscle fibers that could be inhibited by the cyclophilin D (CypD) inhibitor, cyclosporine A (CsA).	Cyclosporine	271-274	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	238-242
26817280-1	2015	An endogenous CYP3A4 biomarker for in vivo metabolism of cyclosporine should be useful for optimizing individual dosage.	Cyclosporine	57-69	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	14-20
26817280-7	2015	In summary, there is a significant relationship between endogenous CYP3A4 biomarker (assessed by urinary HOM) and in vivo metabolism of cyclosporine in renal transplant recipients.	Cyclosporine	136-148	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	67-73
26581448-10	2015	High-dose corticosteroid and cyclosporine therapy led to a drastic improvement of MAS with decreased IL-6 levels.	Cyclosporine	29-41	interleukin 6	Homo sapiens	101-105
26618109-6	2015	However, the use of biological agents that reduce P-gp expression as well as P-gp antagonists (e.g., cyclosporine) can successfully reduce the efflux of corticosteroids from lymphocytes in vitro, suggesting that both types of drugs can be used to overcome drug-resistance and improve clinical outcome.	Cyclosporine	101-113	ATP binding cassette subfamily B member 1	Homo sapiens	77-81
26301745-4	2015	These changes could be blocked by the duel CYP3A4/P-glycoprotein inhibitor cyclosporine A, consequently, Papp values for CLA enantiomers in both directions were significantly greater than those obtained by using verapamil or ketoconazole, and their ERs were similar to those following (-) or (+)-isomer treatment alone.	Cyclosporine	75-89	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-49
26543549-0	2015	Efficacy of oral glucocorticoid and cyclosporine in a case of rituximab-refractory type B insulin resistance syndrome.	Cyclosporine	36-48	insulin	Homo sapiens	90-97
26543549-1	2015	We describe a case of type B insulin resistance syndrome associated with systemic lupus erythematosus (SLE) that was refractory to rituximab and successfully treated with a combination of oral glucocorticoids and cyclosporine.	Cyclosporine	213-225	insulin	Homo sapiens	29-36
26543549-3	2015	The addition of cyclosporine to oral glucocorticoid therapy resulted in remission of insulin resistance.	Cyclosporine	16-28	insulin	Homo sapiens	85-92
26543549-4	2015	The combination of oral prednisolone and cyclosporine might be effective in treating type B insulin resistance syndrome, particularly in rituximab-resistant cases.	Cyclosporine	41-53	insulin	Homo sapiens	92-99
26170095-3	2015	The CypD ligand, Cyclosporin A (CsA), was identified as an inhibitor of this interaction.	Cyclosporine	17-30	peptidylprolyl isomerase F	Homo sapiens	4-8
26170095-3	2015	The CypD ligand, Cyclosporin A (CsA), was identified as an inhibitor of this interaction.	Cyclosporine	32-35	peptidylprolyl isomerase F	Homo sapiens	4-8
26170095-5	2015	It was observed that p53 binds at the CsA-binding site of CypD.	Cyclosporine	38-41	tumor protein p53	Homo sapiens	21-24
26170095-5	2015	It was observed that p53 binds at the CsA-binding site of CypD.	Cyclosporine	38-41	peptidylprolyl isomerase F	Homo sapiens	58-62
26283324-10	2015	However, Cyclosporine A, a CREB inhibitor, reduced the expression of p-CREB, Egr-3, VCAM-1, Ang1 and Tie2.	Cyclosporine	9-23	TEK receptor tyrosine kinase	Rattus norvegicus	101-105
26757533-6	2015	RESULTS: In the mitochondria plasma cultures, MDH and COX levels were increased with the time and peaked at about 3 h and 3.5 h; CsA can delay the appearance of peak to 4.5 h. Among different treated groups,there was no significant difference in TNF-alpha and IL-6 between group A and group B; there was significant difference in TNF-alpha and IL-6 other groups.	Cyclosporine	129-132	tumor necrosis factor	Rattus norvegicus	246-255
26757533-6	2015	RESULTS: In the mitochondria plasma cultures, MDH and COX levels were increased with the time and peaked at about 3 h and 3.5 h; CsA can delay the appearance of peak to 4.5 h. Among different treated groups,there was no significant difference in TNF-alpha and IL-6 between group A and group B; there was significant difference in TNF-alpha and IL-6 other groups.	Cyclosporine	129-132	interleukin 6	Rattus norvegicus	260-264
26757533-6	2015	RESULTS: In the mitochondria plasma cultures, MDH and COX levels were increased with the time and peaked at about 3 h and 3.5 h; CsA can delay the appearance of peak to 4.5 h. Among different treated groups,there was no significant difference in TNF-alpha and IL-6 between group A and group B; there was significant difference in TNF-alpha and IL-6 other groups.	Cyclosporine	129-132	tumor necrosis factor	Rattus norvegicus	330-339
26757533-6	2015	RESULTS: In the mitochondria plasma cultures, MDH and COX levels were increased with the time and peaked at about 3 h and 3.5 h; CsA can delay the appearance of peak to 4.5 h. Among different treated groups,there was no significant difference in TNF-alpha and IL-6 between group A and group B; there was significant difference in TNF-alpha and IL-6 other groups.	Cyclosporine	129-132	interleukin 6	Rattus norvegicus	344-348
26632468-12	2015	CONCLUSION: CsA combined with thalidomide regime could improve the anemia symptom in low/int-1 risk MDS patients without del(5q).	Cyclosporine	12-15	Wnt family member 1	Homo sapiens	89-94
26498345-8	2015	There was a synergistic upregulation of HDAC2 and associated decrease in pro-inflammatory cytokine production in CD28nullCD8+ T and NKT-like cells in the presence of 5 mg/L theophylline + 10(-6) M prednisolone or 2.5 ng/mL cyclosporine A (CsA).	Cyclosporine	223-237	histone deacetylase 2	Homo sapiens	40-45
26498345-8	2015	There was a synergistic upregulation of HDAC2 and associated decrease in pro-inflammatory cytokine production in CD28nullCD8+ T and NKT-like cells in the presence of 5 mg/L theophylline + 10(-6) M prednisolone or 2.5 ng/mL cyclosporine A (CsA).	Cyclosporine	239-242	histone deacetylase 2	Homo sapiens	40-45
27022464-2	2015	Specifically, acute administration of P-gp inhibitors, such as verapamil and cyclosporin A (CsA), has been shown to augment brain concentrations and functional activity of the antidepressant escitalopram in rodents.	Cyclosporine	77-90	ATP binding cassette subfamily B member 1	Homo sapiens	38-42
27022464-2	2015	Specifically, acute administration of P-gp inhibitors, such as verapamil and cyclosporin A (CsA), has been shown to augment brain concentrations and functional activity of the antidepressant escitalopram in rodents.	Cyclosporine	92-95	ATP binding cassette subfamily B member 1	Homo sapiens	38-42
26482353-13	2015	However, the more pronounced induction of pro-inflammatory genes and the downregulation of genes involved in mitochondrial functions only in FXRKO-PCLS suggest that FXR deficiency aggravates CsA-induced inflammation and impairs mitochondrial functions.	Cyclosporine	191-194	nuclear receptor subfamily 1, group H, member 4	Mus musculus	141-144
26527872-14	2015	Finally, the new CsA formulations showed in vitro dose-dependent immuno-suppressive effects caused by the inhibition of IL-2 levels secreted from stimulated Jurkat cells.	Cyclosporine	17-20	interleukin 2	Homo sapiens	120-124
26271661-2	2015	CYP3A5*3, CYP3A4*1B and CYP3A4*22 alleles of liver grafts may explain about one third of the inter-individual differences in pharmacokinetics of ciclosporin and tacrolimus in recipients.	Cyclosporine	145-156	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	0-6
26271661-2	2015	CYP3A5*3, CYP3A4*1B and CYP3A4*22 alleles of liver grafts may explain about one third of the inter-individual differences in pharmacokinetics of ciclosporin and tacrolimus in recipients.	Cyclosporine	145-156	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	10-16
26271661-2	2015	CYP3A5*3, CYP3A4*1B and CYP3A4*22 alleles of liver grafts may explain about one third of the inter-individual differences in pharmacokinetics of ciclosporin and tacrolimus in recipients.	Cyclosporine	145-156	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	24-30
26232180-6	2015	Inhibition of CypD-dependent mitochondrial permeability transition pore (mPTP) opening by cyclosporine A (CSA) attenuated ischemia-induced synaptic perturbation in CypD+ and non-transgenic (non-Tg) mice.	Cyclosporine	90-104	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	14-18
26408697-5	2015	We further observed that loss of mitochondrial membrane potential and increase in reactive oxygen species content, release of mitochondrial cytochrome c, caspase-9 activation, and apoptotic cell death induced by CHM-1, were suppressed by treatment with cyclosporine A, and by the overexpression of constitutively active AKT1 or GRP78.	Cyclosporine	253-267	cytochrome c, somatic	Homo sapiens	140-152
26408697-5	2015	We further observed that loss of mitochondrial membrane potential and increase in reactive oxygen species content, release of mitochondrial cytochrome c, caspase-9 activation, and apoptotic cell death induced by CHM-1, were suppressed by treatment with cyclosporine A, and by the overexpression of constitutively active AKT1 or GRP78.	Cyclosporine	253-267	AKT serine/threonine kinase 1	Homo sapiens	320-324
26408697-5	2015	We further observed that loss of mitochondrial membrane potential and increase in reactive oxygen species content, release of mitochondrial cytochrome c, caspase-9 activation, and apoptotic cell death induced by CHM-1, were suppressed by treatment with cyclosporine A, and by the overexpression of constitutively active AKT1 or GRP78.	Cyclosporine	253-267	heat shock protein family A (Hsp70) member 5	Homo sapiens	328-333
26232180-6	2015	Inhibition of CypD-dependent mitochondrial permeability transition pore (mPTP) opening by cyclosporine A (CSA) attenuated ischemia-induced synaptic perturbation in CypD+ and non-transgenic (non-Tg) mice.	Cyclosporine	90-104	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	164-168
26232180-6	2015	Inhibition of CypD-dependent mitochondrial permeability transition pore (mPTP) opening by cyclosporine A (CSA) attenuated ischemia-induced synaptic perturbation in CypD+ and non-transgenic (non-Tg) mice.	Cyclosporine	106-109	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	14-18
26232180-6	2015	Inhibition of CypD-dependent mitochondrial permeability transition pore (mPTP) opening by cyclosporine A (CSA) attenuated ischemia-induced synaptic perturbation in CypD+ and non-transgenic (non-Tg) mice.	Cyclosporine	106-109	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	164-168
26688934-9	2015	When the myoblasts were incubated with CsA, the apoptosis rate decreased, the mRNA expression of CnA and NFAT3 significantly decreased, and the NFAT3 protein expression levels became significantly lower than those of the groups without CsA.	Cyclosporine	39-42	nuclear factor of activated T cells 4	Homo sapiens	105-110
26153782-9	2015	The efflux was inhibited by treatment with a P-gp inhibitor, cyclosporine A (CsA).	Cyclosporine	61-75	ATP binding cassette subfamily B member 1	Homo sapiens	45-49
26153782-9	2015	The efflux was inhibited by treatment with a P-gp inhibitor, cyclosporine A (CsA).	Cyclosporine	77-80	ATP binding cassette subfamily B member 1	Homo sapiens	45-49
26153782-12	2015	Inhibition and knock down of P-gp by CsA and siRNA, respectively, enhanced etoposide- and doxorubicin-induced cell death in the EBV-positive T-cell lines.	Cyclosporine	37-40	ATP binding cassette subfamily B member 1	Homo sapiens	29-33
26688934-9	2015	When the myoblasts were incubated with CsA, the apoptosis rate decreased, the mRNA expression of CnA and NFAT3 significantly decreased, and the NFAT3 protein expression levels became significantly lower than those of the groups without CsA.	Cyclosporine	39-42	nuclear factor of activated T cells 4	Homo sapiens	144-149
26150050-7	2015	Regarding the biopharmaceutical characteristics, the endogenous CYP3A biomarker explains 74.5% of variability in oral cyclosporine clearance between individuals.	Cyclosporine	118-130	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	64-69
26598188-0	2015	[Effect of cyclosporine A on TGF-beta/Smad3 signaling in rat gingival fibroblasts].	Cyclosporine	11-25	transforming growth factor, beta 1	Rattus norvegicus	29-37
26099455-0	2015	Cyclosporin A-sensitive cytotoxicity of flurbiprofen non-stereoselectively mediated by cytochrome P450 metabolism in three-dimensional cultured rat hepatocytes.	Cyclosporine	0-13	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	87-102
26099455-13	2015	CYP metabolism of FLP non-stereoselectively participated in Cys A-sensitive cytotoxicity, suggesting mitochondrial injury.	Cyclosporine	60-65	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	0-3
26598188-0	2015	[Effect of cyclosporine A on TGF-beta/Smad3 signaling in rat gingival fibroblasts].	Cyclosporine	11-25	SMAD family member 3	Rattus norvegicus	38-43
26598188-1	2015	PURPOSE: The aim of the study was to investigate the effect of cyclosporine A (CsA) on TGF-beta/Smad3 signaling in rat gingival fibroblasts and to explore the mechanism of CsA induced gingival overgrowth.	Cyclosporine	63-77	transforming growth factor, beta 1	Rattus norvegicus	87-95
26598188-1	2015	PURPOSE: The aim of the study was to investigate the effect of cyclosporine A (CsA) on TGF-beta/Smad3 signaling in rat gingival fibroblasts and to explore the mechanism of CsA induced gingival overgrowth.	Cyclosporine	63-77	SMAD family member 3	Rattus norvegicus	96-101
26598188-1	2015	PURPOSE: The aim of the study was to investigate the effect of cyclosporine A (CsA) on TGF-beta/Smad3 signaling in rat gingival fibroblasts and to explore the mechanism of CsA induced gingival overgrowth.	Cyclosporine	79-82	transforming growth factor, beta 1	Rattus norvegicus	87-95
26598188-1	2015	PURPOSE: The aim of the study was to investigate the effect of cyclosporine A (CsA) on TGF-beta/Smad3 signaling in rat gingival fibroblasts and to explore the mechanism of CsA induced gingival overgrowth.	Cyclosporine	79-82	SMAD family member 3	Rattus norvegicus	96-101
26598188-8	2015	The mRNA levels of TGF-beta1 and collagen I were significantly promoted after CsA exposure.	Cyclosporine	78-81	transforming growth factor, beta 1	Rattus norvegicus	19-28
26598188-9	2015	The protein syntheses of TGF-beta1, p-Smad3 and Collagen I were also increased by CsA stimulation.	Cyclosporine	82-85	transforming growth factor, beta 1	Rattus norvegicus	25-34
26598188-9	2015	The protein syntheses of TGF-beta1, p-Smad3 and Collagen I were also increased by CsA stimulation.	Cyclosporine	82-85	SMAD family member 3	Rattus norvegicus	38-43
26598188-10	2015	CONCLUSIONS: CsA may activate TGF-beta/Smad3 signaling pathway, thus promoting the proliferation and migration of rat gingival fibroblasts as well as collagen accumulation, which eventually lead to gingival overgrowth.	Cyclosporine	13-16	transforming growth factor, beta 1	Rattus norvegicus	30-38
26598188-10	2015	CONCLUSIONS: CsA may activate TGF-beta/Smad3 signaling pathway, thus promoting the proliferation and migration of rat gingival fibroblasts as well as collagen accumulation, which eventually lead to gingival overgrowth.	Cyclosporine	13-16	SMAD family member 3	Rattus norvegicus	39-44
26164288-9	2015	Moreover, the release of cytochrome c from the mitochondria is dependent on cyclosporin A-sensitive mitochondrial permeability transition pore opening, but not formation of the Bax-voltage dependent anion channel complex or Bax oligomeric pores.	Cyclosporine	76-89	cytochrome c, somatic	Homo sapiens	25-37
26406246-4	2015	Hypoxia induced translocation of p53 was investigated by using mitochondrial membrane permeability transition pore blocker cyclosporin A (blocks entry of p53 to mitochondria) and confirmed by western blot and immunofluorescence.	Cyclosporine	123-136	tumor protein p53	Homo sapiens	33-36
26406246-4	2015	Hypoxia induced translocation of p53 was investigated by using mitochondrial membrane permeability transition pore blocker cyclosporin A (blocks entry of p53 to mitochondria) and confirmed by western blot and immunofluorescence.	Cyclosporine	123-136	tumor protein p53	Homo sapiens	154-157
26390404-10	2015	Cell viability was reduced by 46% and 41%, cleaved PARP was increased 2.6-fold and 2.2-fold, and cleaved caspase 3 increased 2.2-fold and 1.8-fold following treatment with Cyclosporine/MMF and Tacrolimus/MMF respectively.	Cyclosporine	172-184	poly(ADP-ribose) polymerase 1	Homo sapiens	51-55
26375467-11	2015	Cyclosporine A (CsA) inhibits mitochondrial permeability transition pore opening by inhibiting cyclophilin D (CypD).	Cyclosporine	16-19	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	95-108
26375467-11	2015	Cyclosporine A (CsA) inhibits mitochondrial permeability transition pore opening by inhibiting cyclophilin D (CypD).	Cyclosporine	16-19	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	110-114
26057330-0	2015	Cyclosporine A Downregulates MMP-3 and MMP-13 Expression in Cultured Pterygium Fibroblasts.	Cyclosporine	0-14	matrix metallopeptidase 3	Homo sapiens	29-34
26004138-6	2015	DAPE-induced mitochondrial damage was attenuated by cyclosporin A, an inhibitor of cyclophilin D (CypD).	Cyclosporine	52-65	peptidylprolyl isomerase F	Homo sapiens	83-96
26004138-6	2015	DAPE-induced mitochondrial damage was attenuated by cyclosporin A, an inhibitor of cyclophilin D (CypD).	Cyclosporine	52-65	peptidylprolyl isomerase F	Homo sapiens	98-102
26057330-0	2015	Cyclosporine A Downregulates MMP-3 and MMP-13 Expression in Cultured Pterygium Fibroblasts.	Cyclosporine	0-14	matrix metallopeptidase 13	Homo sapiens	39-45
25927423-2	2015	The current study determines gingival crevicular fluid (GCF) levels of fibrosis-related IL-6-type cytokines in cyclosporine A (CsA)-induced gingival overgrowth (GO).	Cyclosporine	127-130	interleukin 6	Homo sapiens	88-92
26013701-0	2015	Endothelin ETA receptor/lipid peroxides/COX-2/TGF-beta1 signalling underlies aggravated nephrotoxicity caused by cyclosporine plus indomethacin in rats.	Cyclosporine	113-125	transforming growth factor, beta 1	Rattus norvegicus	46-55
26013701-5	2015	KEY RESULTS: Oral treatment with CSA or indomethacin elevated serum urea and creatinine, caused renal tubular atrophy and interstitial fibrosis, increased renal TGF-beta1, and reduced immunohistochemical expressions of ETA receptors and COX-2.	Cyclosporine	33-36	transforming growth factor, beta 1	Rattus norvegicus	161-170
26013701-7	2015	Compared with individual treatments, simultaneous CSA/indomethacin exposure caused: (i) greater elevations in serum creatinine and renal MDA; (ii) loss of the compensatory increase in GSH; (iii) renal infiltration of inflammatory cells and worsening of fibrotic and necrotic profiles; and (iv) increased renal ET-1 and decreased ETA receptor and COX-2 expressions.	Cyclosporine	50-53	endothelin 1	Rattus norvegicus	310-341
26013701-10	2015	CONCLUSIONS AND IMPLICATIONS: The exaggerated oxidative insult and associated dysregulation of the ETA receptor/COX-2/TGF-beta1 signalling might account for the aggravated nephrotoxicity caused by the CSA/indomethacin regimen.	Cyclosporine	201-204	transforming growth factor, beta 1	Rattus norvegicus	118-127
26225924-8	2015	Also, a high protein expression of Bax with decreased Bcl-2 was revealed in the renal tissue of the CsA treated group.	Cyclosporine	100-103	BCL2, apoptosis regulator	Rattus norvegicus	54-59
26537083-10	2015	It was found that the expression levels of several miRs, in particular miR-195, was significantly decreased in CsA-treated U-87 MG cells.	Cyclosporine	111-114	microRNA 195	Homo sapiens	71-78
25927423-2	2015	The current study determines gingival crevicular fluid (GCF) levels of fibrosis-related IL-6-type cytokines in cyclosporine A (CsA)-induced gingival overgrowth (GO).	Cyclosporine	111-125	interleukin 6	Homo sapiens	88-92
25927423-12	2015	CONCLUSIONS: IL-6 and OSM increases in GCF as a result of CsA usage or an immunosuppressed state irrespective of the severity of inflammation and the presence of GO.	Cyclosporine	58-61	interleukin 6	Homo sapiens	13-17
26324318-6	2015	These cytokines and LPS can induce P-gp expression through the STAT3/Nf-kappab pathway, contributing to a decrease of cyclosporine A retention, which can be reversed by the application of a P-gp inhibitor.	Cyclosporine	118-132	signal transducer and activator of transcription 3	Mus musculus	63-68
26324318-6	2015	These cytokines and LPS can induce P-gp expression through the STAT3/Nf-kappab pathway, contributing to a decrease of cyclosporine A retention, which can be reversed by the application of a P-gp inhibitor.	Cyclosporine	118-132	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	69-78
26327754-9	2015	There are already some approved drugs available, including irbesartan, ezetimibe, and ritonavir and cyclosporin A, with documented inhibitory effects on NTCP"s metabolic function.	Cyclosporine	100-113	solute carrier family 10 member 1	Homo sapiens	153-157
25919767-5	2015	RESULTS: Compared to untreated animals, ixazomib alone or in combination with 1/2 dose CsA reduced donor-specific antibody, intragraft transcripts for chemokines CCL-21 and CXCL-13, and CD19 expression in both sensitized and naive transplants.	Cyclosporine	87-90	C-X-C motif chemokine ligand 13	Rattus norvegicus	173-180
25919767-5	2015	RESULTS: Compared to untreated animals, ixazomib alone or in combination with 1/2 dose CsA reduced donor-specific antibody, intragraft transcripts for chemokines CCL-21 and CXCL-13, and CD19 expression in both sensitized and naive transplants.	Cyclosporine	87-90	CD19 molecule	Rattus norvegicus	186-190
25976223-0	2015	CYP3A4*18B and CYP3A5*3 polymorphisms contribute to pharmacokinetic variability of cyclosporine among healthy Chinese subjects.	Cyclosporine	83-95	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
25976223-0	2015	CYP3A4*18B and CYP3A5*3 polymorphisms contribute to pharmacokinetic variability of cyclosporine among healthy Chinese subjects.	Cyclosporine	83-95	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	15-21
25976223-8	2015	The Cmax of cyclosporine in CYP3A4*1/*1 was significantly greater than that in CYP3A4*1/*18B in the male group (P=0.023), but not the female group.	Cyclosporine	12-24	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	28-34
25976223-10	2015	CONCLUSIONS: The results indicate that gender and polymorphism in CYP3A4*18B and CYP3A5*3 significantly affect cyclosporine pharmacokinetics in healthy subjects.	Cyclosporine	111-123	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	66-72
25976223-10	2015	CONCLUSIONS: The results indicate that gender and polymorphism in CYP3A4*18B and CYP3A5*3 significantly affect cyclosporine pharmacokinetics in healthy subjects.	Cyclosporine	111-123	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	81-87
26317213-5	2015	The present study reports the biochemical characterization of an Arabidopsis cyclophilin, AtCyp19-3, which demonstrated that this protein is enzymatically active and possesses peptidyl-prolyl cis-trans isomerase (PPIase) activity that is specifically inhibited by CsA with an inhibition constant (Ki) of 18.75 nM.	Cyclosporine	264-267	Cyclophilin	Arabidopsis thaliana	77-88
26317213-5	2015	The present study reports the biochemical characterization of an Arabidopsis cyclophilin, AtCyp19-3, which demonstrated that this protein is enzymatically active and possesses peptidyl-prolyl cis-trans isomerase (PPIase) activity that is specifically inhibited by CsA with an inhibition constant (Ki) of 18.75 nM.	Cyclosporine	264-267	peptidyl-prolyl cis-trans isomerase	Arabidopsis thaliana	176-211
26317213-5	2015	The present study reports the biochemical characterization of an Arabidopsis cyclophilin, AtCyp19-3, which demonstrated that this protein is enzymatically active and possesses peptidyl-prolyl cis-trans isomerase (PPIase) activity that is specifically inhibited by CsA with an inhibition constant (Ki) of 18.75 nM.	Cyclosporine	264-267	peptidyl-prolyl cis-trans isomerase	Arabidopsis thaliana	213-219
26270340-7	2015	In respect to long-term renal graft function, linear mixed models showed significantly improved eGFR trajectories (eGFRMDRD: p&lt;0.001, eGFRCKD-EPI: p&lt;0.001) in the TAC versus CSA group over 24 months of follow up.	Cyclosporine	180-183	epidermal growth factor receptor	Homo sapiens	96-100
26270340-12	2015	CONCLUSION: Conversion of CSA treated kidney transplant recipients with stable graft function to TAC (target 5-8 ng/ml) showed significantly improved long-term eGFR trajectories when compared to CSA maintenance (target 70-150 ng/ml).	Cyclosporine	26-29	epidermal growth factor receptor	Homo sapiens	160-164
25536375-0	2015	The Effect of ABCB1 C3435T Polymorphism on Cyclosporine Dose Requirements in Kidney Transplant Recipients: A Meta-Analysis.	Cyclosporine	43-55	ATP binding cassette subfamily B member 1	Homo sapiens	14-19
25944722-10	2015	In motor neurons it was also inhibited substantially by CGP37157 and cyclosporine-A, the blockers of Na(+)/Ca(2+) exchanger and mitochondrial permeability transition pore (MPTP) respectively, whereas no effect of these agents was observed in other spinal neurons.	Cyclosporine	69-83	solute carrier family 8 member A1	Homo sapiens	101-123
25536375-1	2015	Cyclosporine A (CsA) is a substrate of the multi-drug efflux pump P-glycoprotein (P-gp) encoded by ABCB1.	Cyclosporine	0-14	ATP binding cassette subfamily B member 1	Homo sapiens	66-80
25536375-1	2015	Cyclosporine A (CsA) is a substrate of the multi-drug efflux pump P-glycoprotein (P-gp) encoded by ABCB1.	Cyclosporine	0-14	ATP binding cassette subfamily B member 1	Homo sapiens	82-86
25536375-1	2015	Cyclosporine A (CsA) is a substrate of the multi-drug efflux pump P-glycoprotein (P-gp) encoded by ABCB1.	Cyclosporine	0-14	ATP binding cassette subfamily B member 1	Homo sapiens	99-104
25536375-1	2015	Cyclosporine A (CsA) is a substrate of the multi-drug efflux pump P-glycoprotein (P-gp) encoded by ABCB1.	Cyclosporine	16-19	ATP binding cassette subfamily B member 1	Homo sapiens	66-80
25536375-1	2015	Cyclosporine A (CsA) is a substrate of the multi-drug efflux pump P-glycoprotein (P-gp) encoded by ABCB1.	Cyclosporine	16-19	ATP binding cassette subfamily B member 1	Homo sapiens	82-86
25536375-1	2015	Cyclosporine A (CsA) is a substrate of the multi-drug efflux pump P-glycoprotein (P-gp) encoded by ABCB1.	Cyclosporine	16-19	ATP binding cassette subfamily B member 1	Homo sapiens	99-104
25536375-2	2015	Among the various single nucleotide polymorphisms (SNPs) of ABCB1, C3435T has been extensively investigated to determine the relationship with the pharmacokinetics of CsA.	Cyclosporine	167-170	ATP binding cassette subfamily B member 1	Homo sapiens	60-65
25536375-9	2015	Therefore, this meta-analysis showed a correlation between ABCB1 C3435T polymorphism and the dose-adjusted concentration of CsA.	Cyclosporine	124-127	ATP binding cassette subfamily B member 1	Homo sapiens	59-64
26267734-8	2015	Phototherapy, cyclosporine, and MTX were less effective in clearing psoriasis, although they were successful in improving S-MAPA &gt;= 50% from baseline 100%, 67%, and 36% of the time, respectively.	Cyclosporine	14-26	leucine rich repeat containing 25	Homo sapiens	124-128
26004871-10	2015	Cell surface Gb3 expression of resistant cells was annihilated by PPMP whereas cyclosporin A decreased Gb3 and MDR1 expression in H1299 cells.	Cyclosporine	79-92	ATP binding cassette subfamily B member 1	Homo sapiens	111-115
26052002-17	2015	CsA decreased the nuclear translocation of MEF-2 and NFAT induced by stress (Fig.	Cyclosporine	0-3	myocyte enhancer factor 2C	Mus musculus	43-48
25304169-6	2015	After treatment failure including corticosteroids, intravenous immunoglobulin, tetracycline, acyclovir, antituberculosis drugs, and anti-IL1R therapy, clinical improvement was obtained with intravenous cyclosporine.	Cyclosporine	202-214	interleukin 1 receptor type 1	Homo sapiens	137-141
25857708-9	2015	Pgp(+) cells exhibited very low R123 and (18)FRB accumulation (around 1-8% of the Pgp(-) cell lines) which was not sensitive to the mitochondrial proton gradient; rather it was increased by the Pgp inhibitor cyclosporine A (CsA).	Cyclosporine	208-222	ATP binding cassette subfamily B member 1	Homo sapiens	0-3
26017975-11	2015	The effects of TNF on NFATc1 and TRPC6 expression were blocked by cyclosporine A but were not blocked by the pan-TRP inhibitor SKF-96365.	Cyclosporine	66-80	tumor necrosis factor	Homo sapiens	15-18
25857708-9	2015	Pgp(+) cells exhibited very low R123 and (18)FRB accumulation (around 1-8% of the Pgp(-) cell lines) which was not sensitive to the mitochondrial proton gradient; rather it was increased by the Pgp inhibitor cyclosporine A (CsA).	Cyclosporine	224-227	ATP binding cassette subfamily B member 1	Homo sapiens	0-3
25891084-0	2015	Diltiazem augments the influence of MDR1 genotype status on cyclosporine concentration in Chinese patients with renal transplantation.	Cyclosporine	60-72	ATP binding cassette subfamily B member 1	Homo sapiens	36-40
25891084-2	2015	In this study, we investigated how diltiazem altered the relationship between MDR1 genetic polymorphisms and CsA concentration in Chinese patients with renal transplantation.	Cyclosporine	109-112	ATP binding cassette subfamily B member 1	Homo sapiens	78-82
25891084-8	2015	With regard to MDR1-3435, the adjusted CsA trough concentration was significantly higher in TT carriers than in CC and CT carriers when diltiazam was co-administered (58.83+-13.95 versus 46.14+-7.55 and 45.18+-12.35 ng/mL per mg/kg, P=0.011), and the differences were not observed in patients without diltiazam co-administered.	Cyclosporine	39-42	ATP binding cassette subfamily B member 1	Homo sapiens	15-19
25891084-9	2015	With regard to MDR1-2677, the adjusted CsA trough concentration was significantly higher in TT carriers than in GG and GT carriers when diltiazam was co-administered (61.31+-12.93 versus 52.25+-7.83 and 39.70+-7.26 ng/mL per mg/kg, P=0.0001).	Cyclosporine	39-42	ATP binding cassette subfamily B member 1	Homo sapiens	15-19
25891084-12	2015	CONCLUSION: MDR1 variants influence the adjusted CsA trough concentration in Chinese patients with renal transplant, and the influence more prominent when diltiazem is co-administered.	Cyclosporine	49-52	ATP binding cassette subfamily B member 1	Homo sapiens	12-16
25808405-11	2015	Administering IL-6 abrogated allograft tolerance induced by kaempferol and cyclosporine via diminishing CD4+FoxP3+ Tregs.	Cyclosporine	75-87	interleukin 6	Mus musculus	14-18
25731927-6	2015	Additionally, the CSA was increased in both groups: OC (1 x 50 % = 2.4 %; 3 x 50 % = 3.8 %; 1 x 20 % = 4.6 %; 3 x 20 % = 4.8 %) and NOC (1 x 50 % = 2.4 %; 3 x 50 % = 1.5 %; 1 x 20 % = 4.3 %; 3 x 20 % = 3.8 %) compared with the control group (-0.7 %).	Cyclosporine	18-21	nocturnin	Homo sapiens	132-135
25808405-1	2015	Calcineurin inhibitor cyclosporine is widely used as an immunosuppressant in clinic.	Cyclosporine	22-34	calcineurin binding protein 1	Mus musculus	0-21
26361868-10	2015	Inhibition of the calcineurin/NFATc1 pathway by cyclosporin A and FK506, attenuated Tbeta4-induced osteoblastic differentiation and activation of Wnt-related genes, as well as nuclear beta-catenin in hPDLCs.	Cyclosporine	48-61	thymosin beta 4 X-linked	Homo sapiens	84-90
25919187-5	2015	Uptake of [(3)H]16alpha-OH DHEAS by BM vesicles was significantly inhibited by OAT4 substrates such as dehydroepiandrosterone sulfate, estrone-3-sulfate, and bromosulfophthalein but not by cyclosporin A, tetraethylammonium, p-aminohippuric acid, or cimetidine.	Cyclosporine	189-202	solute carrier family 22 member 11	Homo sapiens	79-83
26311998-7	2015	The mRNA expression of VEGF was reduced in renal tissue after 5 weeks of CsA treatment.	Cyclosporine	73-76	vascular endothelial growth factor A	Homo sapiens	23-27
26311998-9	2015	In vivo administration of A2B adenosine receptor agonist increased renal VEGF which was inhibited by a selective A2B AR antagonist (MRS1754) in CsA-treated animals.	Cyclosporine	144-147	vascular endothelial growth factor A	Homo sapiens	73-77
25976987-4	2015	NFATc1 knockdown using inducible short hairpin RNA or pharmacological NFAT inhibition with cyclosporine A (CsA) or VIVIT significantly augmented sorafenib-induced apoptosis of FLT3-ITD+ cells.	Cyclosporine	91-105	fms related receptor tyrosine kinase 3	Homo sapiens	176-180
25976987-4	2015	NFATc1 knockdown using inducible short hairpin RNA or pharmacological NFAT inhibition with cyclosporine A (CsA) or VIVIT significantly augmented sorafenib-induced apoptosis of FLT3-ITD+ cells.	Cyclosporine	107-110	fms related receptor tyrosine kinase 3	Homo sapiens	176-180
25976987-5	2015	CsA also potently overcame sorafenib resistance in FLT3-ITD+ cell lines and primary AML.	Cyclosporine	0-3	fms related receptor tyrosine kinase 3	Homo sapiens	51-55
25976987-7	2015	Intriguingly, FLT3-ITD+ AML patients (n=26) who received CsA as part of their rescue chemotherapy displayed a superior outcome when compared with wild-type FLT3 (FLT3-WT) AML patients.	Cyclosporine	57-60	fms related receptor tyrosine kinase 3	Homo sapiens	14-18
25796200-5	2015	We found that combined treatment with Glu (300 mg/kg) and low-dose (10 or 20mg/kg) CsA strongly ameliorated the development of psoriasis-like skin lesions and reduced the levels of Th1 cytokine (TNF-alpha) and Th17 cytokines (IL-17, IL-22, and IL-23) in the serum and dorsal skin.	Cyclosporine	83-86	negative elongation factor complex member C/D, Th1l	Mus musculus	181-184
26049920-4	2015	In this study, we documented that TIRC7 levels in CsA group were higher than that in ATG + CsA (AC) group only in the follow-up phase (P &lt; 0.05; P &lt; 0.05); nevertheless, TIRC7 levels in SAA group were elevated than non severe aplastic anemia group not only in the treatment phase (P &lt; 0.05; P &lt; 0.05) but also in the follow-up phase (P &lt; 0.05; P &lt; 0.01).	Cyclosporine	50-53	T cell immune regulator 1, ATPase H+ transporting V0 subunit a3	Homo sapiens	34-39
26049920-4	2015	In this study, we documented that TIRC7 levels in CsA group were higher than that in ATG + CsA (AC) group only in the follow-up phase (P &lt; 0.05; P &lt; 0.05); nevertheless, TIRC7 levels in SAA group were elevated than non severe aplastic anemia group not only in the treatment phase (P &lt; 0.05; P &lt; 0.05) but also in the follow-up phase (P &lt; 0.05; P &lt; 0.01).	Cyclosporine	50-53	T cell immune regulator 1, ATPase H+ transporting V0 subunit a3	Homo sapiens	176-181
25796200-5	2015	We found that combined treatment with Glu (300 mg/kg) and low-dose (10 or 20mg/kg) CsA strongly ameliorated the development of psoriasis-like skin lesions and reduced the levels of Th1 cytokine (TNF-alpha) and Th17 cytokines (IL-17, IL-22, and IL-23) in the serum and dorsal skin.	Cyclosporine	83-86	tumor necrosis factor	Mus musculus	195-204
26082590-2	2015	Although usually idiopathic, IgA antibody is occasionally induced by drugs (e.g., vancomycin, carbamazepine, ceftriaxone, and cyclosporine), malignancies, infections, and other causes.	Cyclosporine	126-138	CD79a molecule	Homo sapiens	29-32
25854542-0	2015	MicroRNA-494 promotes cyclosporine-induced nephrotoxicity and epithelial to mesenchymal transition by inhibiting PTEN.	Cyclosporine	22-34	phosphatase and tensin homolog	Mus musculus	113-117
25854542-3	2015	Treatment of mice with CsA resulted in nephrotoxicity that was associated with an early increase in expression of microRNA mmu-miR-494 (miR-494).	Cyclosporine	23-26	microRNA 494	Mus musculus	123-134
25854542-3	2015	Treatment of mice with CsA resulted in nephrotoxicity that was associated with an early increase in expression of microRNA mmu-miR-494 (miR-494).	Cyclosporine	23-26	microRNA 494	Mus musculus	127-134
25854542-4	2015	Similarly, tubular epithelial cell epithelial-mesenchymal transition (EMT) induced by CsA toxicity resulted in the upregulation of microRNA-494 and a decrease in PTEN levels in vitro.	Cyclosporine	86-89	phosphatase and tensin homolog	Mus musculus	162-166
25854542-6	2015	Preventing Pten targeting by miR-494 was sufficient to prevent CsA induced EMT.	Cyclosporine	63-66	phosphatase and tensin homolog	Mus musculus	11-15
25854542-6	2015	Preventing Pten targeting by miR-494 was sufficient to prevent CsA induced EMT.	Cyclosporine	63-66	microRNA 494	Mus musculus	29-36
25854542-7	2015	Knockdown of miR-494 prevented the downregulation of PTEN in tubular epithelial cells following CsA treatment and also prevented CsA induced EMT.	Cyclosporine	96-99	microRNA 494	Mus musculus	13-20
25854542-7	2015	Knockdown of miR-494 prevented the downregulation of PTEN in tubular epithelial cells following CsA treatment and also prevented CsA induced EMT.	Cyclosporine	96-99	phosphatase and tensin homolog	Mus musculus	53-57
25854542-7	2015	Knockdown of miR-494 prevented the downregulation of PTEN in tubular epithelial cells following CsA treatment and also prevented CsA induced EMT.	Cyclosporine	129-132	microRNA 494	Mus musculus	13-20
25854542-8	2015	Thus, miR-494 plays a major role in promoting CsA induced nephrotoxicity through its ability to target Pten thereby contributing to EMT.	Cyclosporine	46-49	microRNA 494	Mus musculus	6-13
25854542-8	2015	Thus, miR-494 plays a major role in promoting CsA induced nephrotoxicity through its ability to target Pten thereby contributing to EMT.	Cyclosporine	46-49	phosphatase and tensin homolog	Mus musculus	103-107
25854542-9	2015	We suggest that manipulating miR-494 expression may represent a novel approach to preventing EMT associated with CsA induced nephrotoxicity.	Cyclosporine	113-116	microRNA 494	Mus musculus	29-36
25851535-7	2015	Pretreatment of wild-type CD8(+) CTLs with the NFATc1 inhibitor CsA could also downregulate PD-1 expression and enhance anti-tumor therapeutic efficacy.	Cyclosporine	64-67	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	47-53
25312097-10	2015	CONCLUSION: Different effects of oral cyclosporine therapy and oral antihistamine therapy to serum high-sensitivity CRP level, TARC level, and peripheral blood basophils in adult patients with AD were shown.	Cyclosporine	38-50	C-reactive protein	Homo sapiens	116-119
26250536-9	2015	In contrast, cyclosporine A, an immunosuppressive agent that blocks T cell function by inhibiting interleukin-2, yielded immediate improvements in systemic fluid retention and a gradual increase in platelet count, with complete resolution of disease symptoms.	Cyclosporine	13-27	interleukin 2	Homo sapiens	98-111
25817300-9	2015	Patients with TC genotype of TGF-beta at codon 10 had lower CsA blood concentrations than the TT and CC genotypes (P = 0.005) at 1 month in CsA treatment group.	Cyclosporine	60-63	transforming growth factor beta 1	Homo sapiens	29-37
25817300-9	2015	Patients with TC genotype of TGF-beta at codon 10 had lower CsA blood concentrations than the TT and CC genotypes (P = 0.005) at 1 month in CsA treatment group.	Cyclosporine	140-143	transforming growth factor beta 1	Homo sapiens	29-37
25817300-10	2015	The ratio of blood concentration/dose of CsA for patients with TGF-beta1-codon 10 TC genotype was lower than for patients with TT, CC genotypes, and the dose given to these patients was higher in the first month (P = 0.046).	Cyclosporine	41-44	transforming growth factor beta 1	Homo sapiens	63-72
25817300-11	2015	The ratio of blood concentration/dose of CsA for patients with IL-2-330 GG genotype was higher than for patients with GT, TT genotypes, and the dose given to these patients was lower at first month and sixth months (P = 0.043, P = 0.035 respectively).	Cyclosporine	41-44	interleukin 2	Homo sapiens	63-67
25817300-13	2015	Patients who had the TC genotype TGF-beta codon 10 had lower CsA blood concentrations and this group had higher acute rejection (P = 0.033).	Cyclosporine	61-64	transforming growth factor beta 1	Homo sapiens	33-41
25500744-10	2015	CsA reduced Ccr, induced urinary proteins and up-regulated COL-I, TGF-beta1, CTGF and PAI-1 gene expression with a significant development of TIF.	Cyclosporine	0-3	transforming growth factor, beta 1	Rattus norvegicus	66-75
25883698-6	2015	Calcineurin inhibitor, which includes cyclosporine, pimecrolimus and tacrolimus, impairs calcineurin-induced up-regulation of IL-2 expression, resulting in increased susceptibility to invasive fungal diseases.	Cyclosporine	38-50	interleukin 2	Homo sapiens	126-130
25646018-15	2015	The induction of mitofusin proteins and the reduction of podocin in ADR rat glomeruli were rescued by CsA or Mcy.	Cyclosporine	102-105	NPHS2 stomatin family member, podocin	Rattus norvegicus	57-64
25650527-0	2015	Association between endothelial and platelet function markers and adiponectin in renal transplanted recipients on cyclosporine and tacrolimus immunosuppression based therapy.	Cyclosporine	114-126	adiponectin, C1Q and collagen domain containing	Homo sapiens	66-77
25650527-12	2015	Since CsA induces higher adiponectin levels, platelet activation and endothelial dysfunction.	Cyclosporine	6-9	adiponectin, C1Q and collagen domain containing	Homo sapiens	25-36
25022552-8	2015	Akt and GSK-3beta was strongly phosphorylated after treatment with Ciclosporin A and PQS compared with the model group (P&lt;0.05, P&lt;0.01).	Cyclosporine	67-80	AKT serine/threonine kinase 1	Rattus norvegicus	0-3
26024660-7	2015	Blockade of Cyp-D by siRNA-mediated depletion or pharmacological inhibitors (cyclosporin A and sanglifehrin A) significantly suppressed salinomycin-induced glioma cell necrosis.	Cyclosporine	77-90	peptidylprolyl isomerase F	Homo sapiens	12-17
25772258-6	2015	Furthermore, CsA induced phosphorylation of extracellular regulated protein kinases 1 and 2 (ERK1/2), p38, and translocation of nuclear factor-kappaB (NF-kappaB) p65 in vasculature.	Cyclosporine	13-16	synaptotagmin 1	Rattus norvegicus	162-165
26177348-0	2015	Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.	Cyclosporine	29-42	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	46-52
25605636-9	2015	Moreover, the mPTP inhibitor, cyclosporine A, rescues VPA-induced apoptotic sensitivity in AHS iPSCs-Hep.	Cyclosporine	30-44	protein tyrosine phosphatase, receptor type, U	Mus musculus	14-18
26177348-1	2015	AIMS: To assess the efficacy and safety of tacrolimus and cyclosporin A (CsA)-based immunosuppressive regimens in Chinese de novo kidney transplant recipients who are CYP3A5 expressers.	Cyclosporine	73-76	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	167-173
26177348-15	2015	CONCLUSIONS: Cyclosporin A-based maintenance therapy is safe for Chinese de novo kidney transplant recipients who are CYP3A5 expressers.	Cyclosporine	13-26	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	118-124
25714796-6	2015	CsA reduced the proportion of CD4(+) T cells and the level of IFN-gamma.	Cyclosporine	0-3	interferon gamma	Mus musculus	62-71
25673014-2	2015	The donor ABCB1 polymorphisms have been related with chronic histological damage and long-term renal function among kidney transplanted patients who received cyclosporine A and tacrolimus (Tac).	Cyclosporine	158-172	ATP binding cassette subfamily B member 1	Homo sapiens	10-15
25809501-12	2015	In addition, treatment with cyclosporine A or CdCl2, other nephrotoxicants, increased Phlda3 mRNA and protein levels in NRK52E cells, as did cisplatin treatment.	Cyclosporine	28-42	pleckstrin homology-like domain, family A, member 3	Rattus norvegicus	86-92
25644970-8	2015	There was a non-significant trend of lower cyclosporine dose requirement in CYP3A4*22 carriers.	Cyclosporine	43-55	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	76-82
25673640-2	2015	In this study, we demonstrate that immune suppression with cyclosporin after SCT limits T-helper cell (Th) 1 differentiation and interferon-gamma secretion by donor T cells, which is critical for inhibiting interleukin (IL)-6 generation from lung parenchyma during an alloimmune response.	Cyclosporine	59-70	interferon gamma	Homo sapiens	129-145
25673640-2	2015	In this study, we demonstrate that immune suppression with cyclosporin after SCT limits T-helper cell (Th) 1 differentiation and interferon-gamma secretion by donor T cells, which is critical for inhibiting interleukin (IL)-6 generation from lung parenchyma during an alloimmune response.	Cyclosporine	59-70	interleukin 6	Homo sapiens	207-225
25420893-7	2015	The relative expressions of COX-1 and COX-2 genes to GAPDH revealed that the maximum increase was obtained in the group treated with CyA and vardenafil for both COX-1 and COX-2 genes.	Cyclosporine	133-136	cytochrome c oxidase I, mitochondrial	Mus musculus	28-33
25420893-7	2015	The relative expressions of COX-1 and COX-2 genes to GAPDH revealed that the maximum increase was obtained in the group treated with CyA and vardenafil for both COX-1 and COX-2 genes.	Cyclosporine	133-136	cytochrome c oxidase I, mitochondrial	Mus musculus	161-166
25948208-9	2015	CONCLUSIONS: The compound Zaofan pill combined with cyclosporine and androgen can obviously increase the levels of MVD and VEGF in bone marrow, and improve the efficacy of treatment in CAA patients.	Cyclosporine	52-64	mevalonate diphosphate decarboxylase	Homo sapiens	115-118
25512016-5	2015	WHAT IS NEW AND CONCLUSION: Cyclosporine is a moderate inhibitor of the cytochrome P450 CYP3A4 isoenzyme, which is known to increase the serum level of atorvastatin.	Cyclosporine	28-40	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	88-94
25948208-9	2015	CONCLUSIONS: The compound Zaofan pill combined with cyclosporine and androgen can obviously increase the levels of MVD and VEGF in bone marrow, and improve the efficacy of treatment in CAA patients.	Cyclosporine	52-64	vascular endothelial growth factor A	Homo sapiens	123-127
25775018-0	2015	Cyclosporin a disrupts notch signaling and vascular lumen maintenance.	Cyclosporine	0-13	notch receptor 1	Homo sapiens	23-28
25527778-12	2015	In summary, we show that CSA stimulation leads to an upregulation of hypothalamic alpha-ENaCs mediated via an increase in TNF-alpha and results in increased salt sensitivity.	Cyclosporine	25-28	tumor necrosis factor	Mus musculus	122-131
25354724-9	2015	Dexamethasone and cyclosporin A significantly reduced IL-17 and IFN-gamma production in PBMCs and dexamethasone up-regulated IL-10 production in activated PBMCs from healthy subjects.	Cyclosporine	18-31	interferon gamma	Homo sapiens	64-73
25555253-9	2015	CONCLUSION: Neutrophil infiltration due to extended inflammation might have increased GCF LL-37 levels at GO+ sites and contributed to the pathogenesis of CsA-induced GO.	Cyclosporine	155-158	cathelicidin antimicrobial peptide	Homo sapiens	90-95
25576381-3	2015	Further, cyclosporin A (CsA), the inhibitor of cyclophilin-D (Cyp-D, the key mPTP component), as well as Cyp-D RNA silencing also suppressed breast cancer cell death by the co-treatment, while cells overexpressing Cyp-D showed hypersensitivity to docetaxel.	Cyclosporine	9-22	peptidylprolyl isomerase F	Homo sapiens	47-60
25576381-3	2015	Further, cyclosporin A (CsA), the inhibitor of cyclophilin-D (Cyp-D, the key mPTP component), as well as Cyp-D RNA silencing also suppressed breast cancer cell death by the co-treatment, while cells overexpressing Cyp-D showed hypersensitivity to docetaxel.	Cyclosporine	9-22	peptidylprolyl isomerase F	Homo sapiens	62-67
25595785-9	2015	Amelioration of AD progression by cyclosporin A treatment was well correlated with downregulation of IL-31 expressions in CD4(+) T cells and total ear residual cells.	Cyclosporine	34-47	interleukin 31	Mus musculus	101-106
26269346-10	2015	(2) The [Ca2+]i was significantly higher in Ang II group of neonatal rat cardiomyocytes than that in control group (P&lt;0.01), which could be reduced by cotreatment with U50488H, CSA and Rp-cAMPS (P&lt;0.01).	Cyclosporine	180-183	angiotensinogen	Rattus norvegicus	44-50
26269346-12	2015	(3) The expression of CaN was significantly higher in Ang II group than that in control group (P&lt;0.01), which could be significantly reduced by cotreatment with U50488H, CSA and Rp-cAMPS (P&lt;0.01).	Cyclosporine	173-176	angiotensinogen	Rattus norvegicus	54-60
25581390-6	2015	In rats administered 10 and 30 mg/kg cyclosporin A, the plasma levels of bile acids were elevated and persisted for up to 24 hours after administration without an elevation of ALT and AST.	Cyclosporine	37-50	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	184-187
25648341-9	2015	Cyclosporine A treatment significantly reduced the mRNA expression levels of IL6 and TNFalpha in both short- and long-term treatments; however, it reduced MMP9 levels only in long-term treatment in cultured corneal epithelial cells.	Cyclosporine	0-14	interleukin 6	Homo sapiens	77-80
25485719-10	2015	CSA (calcineurin inhibitor) and KN93 (CaMKII inhibitor) inhibit A23187-induced the increase in myocardin expression.	Cyclosporine	0-3	calcineurin binding protein 1	Rattus norvegicus	5-26
25648341-9	2015	Cyclosporine A treatment significantly reduced the mRNA expression levels of IL6 and TNFalpha in both short- and long-term treatments; however, it reduced MMP9 levels only in long-term treatment in cultured corneal epithelial cells.	Cyclosporine	0-14	tumor necrosis factor	Homo sapiens	85-93
25452304-4	2015	In CsA-treated allograft recipient mice, CD11b(+) Gr1(+) myeloid-derived suppressor cells (MDSCs) were functional suppressive immune modulators that resulted in fewer gamma interferon (IFN-gamma)-producing CD8(+) T cells and CD4(+) T cells (T(H)1 T helper cells) and more interleukin 4 (IL-4)-producing CD4(+) T cells (T(H2)) and prolonged allogeneic skin graft survival.	Cyclosporine	3-6	integrin alpha M	Mus musculus	41-46
25155925-5	2015	Upon CsA treatment, analyses of cytokine levels revealed a significant reduction of IL-13 expression in PBMCs from patients with UC, whereas other cytokine expression levels remained unaffected.	Cyclosporine	5-8	interleukin 13	Homo sapiens	84-89
25407255-2	2015	Canagliflozin exposures may be affected by coadministration of drugs that induce (e.g., rifampin for UGT) or inhibit (e.g. probenecid for UGT; cyclosporine A for P-gp) these pathways.	Cyclosporine	143-157	ATP binding cassette subfamily B member 1	Homo sapiens	162-166
25757124-10	2015	Plasma interleukin-6 and thiobarbituric acid-reactive substances were significantly lower in the CsA50 group than in the control group and phosphorylation of Akt, GSK-3beta, and Bad were significantly increased in the CsA-treated groups compared with the control group.	Cyclosporine	97-100	interleukin 6	Rattus norvegicus	7-20
25757124-11	2015	Expressions of Bcl-2, cleaved caspase 3, and cytoplasmic cytochrome C were significantly decreased in the CsA-treated groups compared with the control group.	Cyclosporine	106-109	BCL2, apoptosis regulator	Rattus norvegicus	15-20
25803167-0	2015	Cyclosporine for the Treatment of HLTV-1-Induced HAM/TSP: An Experience from a Case Report: Erratum.	Cyclosporine	0-12	thrombospondin 1	Homo sapiens	53-56
25803167-1	2015	[In the article "Cyclosporine for the Treatment of HLTV-1-Induced HAM/TSP: An Experience from a Case Report", which appeared in Volume 94, Issue 1 of Medicine, a word in the title was misspelled.	Cyclosporine	17-29	thrombospondin 1	Homo sapiens	70-73
25803167-2	2015	The correct title is "Cyclosporine for the Treatment of HTLV-1-Induced HAM/TSP: An Experience from a Case Report".	Cyclosporine	22-34	thrombospondin 1	Homo sapiens	75-78
25452304-4	2015	In CsA-treated allograft recipient mice, CD11b(+) Gr1(+) myeloid-derived suppressor cells (MDSCs) were functional suppressive immune modulators that resulted in fewer gamma interferon (IFN-gamma)-producing CD8(+) T cells and CD4(+) T cells (T(H)1 T helper cells) and more interleukin 4 (IL-4)-producing CD4(+) T cells (T(H2)) and prolonged allogeneic skin graft survival.	Cyclosporine	3-6	interferon gamma	Mus musculus	167-194
25452304-5	2015	Importantly, the expression of NFATc1 is significantly diminished in the CsA-induced MDSCs.	Cyclosporine	73-76	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	31-37
25266172-0	2015	Cyclosporine-mediated allograft fibrosis is associated with micro-RNA-21 through AKT signaling.	Cyclosporine	0-12	AKT serine/threonine kinase 1	Homo sapiens	81-84
25270396-2	2015	Elevated fibroblast growth factor (FGF)-23 in cyclosporine A (CsA) users with SLE are associated with decreased active vitamin D and osteocalcin.	Cyclosporine	46-60	bone gamma-carboxyglutamate protein	Homo sapiens	133-144
25638160-4	2015	In bladder cancer cell lines, cyclosporine A (CsA) and tacrolimus (FK506), immunosuppressant drugs/non-selective NFAT inhibitors, attenuated NFATc1 expression and its nuclear translocation, NFAT transcriptional activity, and the expression of cyclooxygenase-2 and c-myc, downstream targets of NFATc1.	Cyclosporine	30-44	prostaglandin-endoperoxide synthase 2	Homo sapiens	243-259
25638160-4	2015	In bladder cancer cell lines, cyclosporine A (CsA) and tacrolimus (FK506), immunosuppressant drugs/non-selective NFAT inhibitors, attenuated NFATc1 expression and its nuclear translocation, NFAT transcriptional activity, and the expression of cyclooxygenase-2 and c-myc, downstream targets of NFATc1.	Cyclosporine	46-49	prostaglandin-endoperoxide synthase 2	Homo sapiens	243-259
25266172-7	2015	While CsA induces SMAD7 downregulation and TGF-beta1 upregulation in HPTECs, such changes were independent of miR-21.	Cyclosporine	6-9	SMAD family member 7	Homo sapiens	18-23
25266172-7	2015	While CsA induces SMAD7 downregulation and TGF-beta1 upregulation in HPTECs, such changes were independent of miR-21.	Cyclosporine	6-9	transforming growth factor beta 1	Homo sapiens	43-52
25266172-10	2015	Collectively, our results suggest that miR-21 mediates CsA nephrotoxicity via PTEN/AKT signaling pathway.	Cyclosporine	55-58	AKT serine/threonine kinase 1	Homo sapiens	83-86
25574099-7	2015	Factors considered to be possibly predictive of long-term efficacy of cyclosporine were sex, age, disease duration, clinical activity index score, C-reactive protein level, hemoglobin level, disease extent, endoscopic findings, and clinical course.	Cyclosporine	70-82	C-reactive protein	Homo sapiens	147-165
25653502-4	2015	The increased uptake of catalposide via the OAT3, OATP1B1, and OATP1B3 transporters was decreased to basal levels in the presence of representative inhibitors such as probenecid, furosemide, and cimetidine (for OAT3) and cyclosporin A, gemfibrozil, and rifampin (for OATP1B1 and OATP1B3).	Cyclosporine	221-234	solute carrier organic anion transporter family member 1B3	Homo sapiens	63-70
25450062-12	2015	These studies showed that the DEX induced increase in MYOC mRNA could be inhibited with either cyclosporin A or INCA-6 or by transfection with NFATc1 siRNA and that ionomycin was unable to increase MYOC mRNA.	Cyclosporine	95-108	myocilin	Homo sapiens	54-58
26027830-7	2015	Our study demonstrates CNED may suppress the NF-kappaB pathway to attenuate the immune response, which highlights the possible therapeutic applications of cyclosporine nanomicelle eye drops in corneal transplantation.	Cyclosporine	155-167	nuclear factor kappa B subunit 1	Homo sapiens	45-54
26356268-9	2015	In the case of CsA the mPTP blockade is due to the direct binding to Cyclophilin D (Cyp D), a mitochondrial matrix protein.	Cyclosporine	15-18	peptidylprolyl isomerase F	Homo sapiens	69-82
26356268-9	2015	In the case of CsA the mPTP blockade is due to the direct binding to Cyclophilin D (Cyp D), a mitochondrial matrix protein.	Cyclosporine	15-18	peptidylprolyl isomerase F	Homo sapiens	84-89
25975003-6	2015	Among CYP3A5 substrates are cyclosporine and tacrolimus prescribed after organ transplantations.	Cyclosporine	28-40	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	6-12
25986569-3	2015	Most Cyps and FKBP family members catalyse peptidyl-prolyl cis/trans isomerase (PPIase) mediated reactions and form binary complexes with their ligands cyclosporine A and FK506.	Cyclosporine	152-166	FKBP prolyl isomerase 5	Homo sapiens	43-78
25986569-3	2015	Most Cyps and FKBP family members catalyse peptidyl-prolyl cis/trans isomerase (PPIase) mediated reactions and form binary complexes with their ligands cyclosporine A and FK506.	Cyclosporine	152-166	FKBP prolyl isomerase 5	Homo sapiens	80-86
25385493-9	2015	CONCLUSIONS: Shh, regulated by TGF-beta, mediates CsA-altered gingival matrix homeostasis.	Cyclosporine	50-53	transforming growth factor beta 1	Homo sapiens	31-39
25193101-7	2015	Using isothermal titration calorimetry (ITC), we found that the RCAN1-1L/CN or CyP/CsA/CN interactions were exothermic with a dissociation constant of 0.46 muM or 0.17 muM, respectively.	Cyclosporine	83-86	latexin	Homo sapiens	156-159
25193101-7	2015	Using isothermal titration calorimetry (ITC), we found that the RCAN1-1L/CN or CyP/CsA/CN interactions were exothermic with a dissociation constant of 0.46 muM or 0.17 muM, respectively.	Cyclosporine	83-86	latexin	Homo sapiens	168-171
26448755-1	2015	Cyclosporine A (CSA) is an immunosuppressive agent that specifically targets T cells and also increases the percentage of pro-tolerogenic CD4+Foxp3+ regulatory T cells (Treg) through unknown mechanisms.	Cyclosporine	0-14	CD4 molecule	Homo sapiens	138-141
26448755-1	2015	Cyclosporine A (CSA) is an immunosuppressive agent that specifically targets T cells and also increases the percentage of pro-tolerogenic CD4+Foxp3+ regulatory T cells (Treg) through unknown mechanisms.	Cyclosporine	16-19	CD4 molecule	Homo sapiens	138-141
25385493-4	2015	The effect of Shh on CsA-induced alterations was further evaluated by the extra-supplement or inhibition of Shh or TGF-beta.	Cyclosporine	21-24	transforming growth factor beta 1	Homo sapiens	115-123
25385493-5	2015	RESULTS: Cyclosporine-A enhanced COL1, alpha-SMA, Shh and TGF-beta expressions in human gingival fibroblasts.	Cyclosporine	9-23	transforming growth factor beta 1	Homo sapiens	58-66
25179911-3	2015	Matrix cyclophilin D facilitates MPTP opening and is the target of its inhibition by cyclosporin A that is cardioprotective.	Cyclosporine	85-98	peptidylprolyl isomerase F	Homo sapiens	7-20
25385493-6	2015	The exogenous Shh/TGF-beta augmented the expression of COL1 and alpha-SMA, and the Shh/TGF-beta inhibition suppressed the CsA-enhanced COL1 and alpha-SMA expressions.	Cyclosporine	122-125	transforming growth factor beta 1	Homo sapiens	87-95
25061717-9	2015	IFN-beta mRNA expression was significantly increased in rotavirus-induced diarrhea mice treated with 5 mg   kg-1   day-1 of CsA, whereas the mRNA expression levels of inflammation-related cytokines (IL-8, IL-10, IFN-gamma, and tumor necrosis factor-alpha) and inflammatory signaling pathways (p38, c-Jun N-terminal kinase, activator protein-1, and nuclear factor-kappa B) were markedly decreased.	Cyclosporine	124-127	interferon gamma	Mus musculus	212-254
25618585-2	2015	The aim of this study was to compare HIF-1alpha expression in normal gingival tissues and CsA-induced gingival overgrowth specimens and further explore the potential mechanisms that may lead to induction of HIF-1alpha expression.	Cyclosporine	90-93	hypoxia inducible factor 1 subunit alpha	Homo sapiens	37-47
25618585-2	2015	The aim of this study was to compare HIF-1alpha expression in normal gingival tissues and CsA-induced gingival overgrowth specimens and further explore the potential mechanisms that may lead to induction of HIF-1alpha expression.	Cyclosporine	90-93	hypoxia inducible factor 1 subunit alpha	Homo sapiens	207-217
25618585-4	2015	Western blot was used to investigate the effects of CsA on the expression of HIF-1alpha in cultured human gingival fibroblasts.	Cyclosporine	52-55	hypoxia inducible factor 1 subunit alpha	Homo sapiens	77-87
25618585-6	2015	RESULTS: HIF-1alpha staining in gingival tissue was stronger in CsA-induced gingival overgrowth group than normal gingival group (p &lt; 0.05).	Cyclosporine	64-67	hypoxia inducible factor 1 subunit alpha	Homo sapiens	9-19
25618585-7	2015	The expression of HIF-1alpha was significantly higher in CsA-induced gingival overgrowth specimens with higher levels of inflammatory infiltrates (p = 0.041).	Cyclosporine	57-60	hypoxia inducible factor 1 subunit alpha	Homo sapiens	18-28
25618585-8	2015	CsA was found to upregulate HIF-1alpha protein in a dose-dependent manner (p &lt; 0.05).	Cyclosporine	0-3	hypoxia inducible factor 1 subunit alpha	Homo sapiens	28-38
25618585-10	2015	CONCLUSION: These results suggest that HIF-1alpha expression is significantly upregulated in CsA-induced gingival overgrowth specimens.	Cyclosporine	93-96	hypoxia inducible factor 1 subunit alpha	Homo sapiens	39-49
26336606-11	2015	LEARNING POINTS: The balance between intrathyroidal self-reactive T cell and natural CD4(+)CD25(+)Foxp3(+) Treg functions determine self-tolerance in the thyroid.CyA not only halts the expansion of self-reactive T cells but also impairs the function of Treg, which can provoke an unwanted immune response.A change in thyroid autoimmunity during treatment with CyA may result in the development of autoimmune thyroid diseases (AITD).Renal involvement in AITD frequently manifests as nephrotic syndrome, and thyrostatic treatment with thiamazole may be effective for excessive proteinuria.	Cyclosporine	162-165	CD4 molecule	Homo sapiens	85-88
25569667-0	2015	Cyclosporine for the treatment of HLTV-1-induced HAM/TSP: an experience from a case report.	Cyclosporine	0-12	thrombospondin 1	Homo sapiens	53-56
25569667-2	2015	Treatment options are scarce, and their safety and efficacy are currently a matter of concern.We present a case report describing our experience using cyclosporine in a patient with early HAM/TSP who started with a gait disturbance at Vall d"Hebron University Hospital (Barcelona) from August 2012 to October 2013.	Cyclosporine	151-163	thrombospondin 1	Homo sapiens	192-195
25569667-4	2015	No safety concerns were observed.Cyclosporine seems to be effective in new-onset HAM/TSP or in chronic HAM/TSP that develops a relapse.	Cyclosporine	33-45	thrombospondin 1	Homo sapiens	85-88
25569667-4	2015	No safety concerns were observed.Cyclosporine seems to be effective in new-onset HAM/TSP or in chronic HAM/TSP that develops a relapse.	Cyclosporine	33-45	thrombospondin 1	Homo sapiens	107-110
25240575-0	2015	Impact of CYP3A4 and MDR1 gene (G2677T) polymorphisms on dose requirement of the cyclosporine in renal transplant Egyptian recipients.	Cyclosporine	81-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	10-16
25119556-0	2015	Gelatinases and extracellular matrix metalloproteinase inducer are associated with cyclosporin-A-induced attenuation of periodontal degradation in rats.	Cyclosporine	83-96	basigin (Ok blood group)	Rattus norvegicus	16-62
25119556-9	2015	Consistent results were found for the expressions of gelatinases and EMMPRIN among the groups demonstrating that the Lig + CsA group had significantly less gingival protein expression of gelatinases and EMMPRIN than the Lig group.	Cyclosporine	123-126	basigin (Ok blood group)	Rattus norvegicus	69-76
25119556-9	2015	Consistent results were found for the expressions of gelatinases and EMMPRIN among the groups demonstrating that the Lig + CsA group had significantly less gingival protein expression of gelatinases and EMMPRIN than the Lig group.	Cyclosporine	123-126	basigin (Ok blood group)	Rattus norvegicus	203-210
25119556-10	2015	CONCLUSIONS: CsA inhibited the expressions of gelatinase MMPs and EMMPRIN and partially prevented the periodontal breakdown in ligature-induced experimental periodontitis.	Cyclosporine	13-16	basigin (Ok blood group)	Rattus norvegicus	66-73
25119556-11	2015	The CsA-induced attenuation of periodontal bone loss was strongly correlated positively with the expressions of MMP-2, MMP-9, and EMMPRIN in gingiva.	Cyclosporine	4-7	basigin (Ok blood group)	Rattus norvegicus	130-137
25272978-0	2015	Role of transforming growth factor-beta1 in cyclosporine-induced epithelial-to-mesenchymal transition in gingival epithelium.	Cyclosporine	44-56	transforming growth factor beta 1	Homo sapiens	8-40
25272978-2	2015	The aims of the present study are to confirm the notion that EMT occurs in human gingival epithelial (hGE) cells after CsA treatment and to investigate the role of transforming growth factor beta1 (TGF-beta1) on this CsA-induced EMT.	Cyclosporine	217-220	transforming growth factor beta 1	Homo sapiens	164-196
25272978-2	2015	The aims of the present study are to confirm the notion that EMT occurs in human gingival epithelial (hGE) cells after CsA treatment and to investigate the role of transforming growth factor beta1 (TGF-beta1) on this CsA-induced EMT.	Cyclosporine	217-220	transforming growth factor beta 1	Homo sapiens	198-207
25272978-7	2015	When CsA was given, the protein and mRNA expressions of E-cadherin and alpha-SMA were significantly altered, and these alterations were significantly reversed with pretreatment of TGF-beta1 inhibitor.	Cyclosporine	5-8	cadherin 1	Homo sapiens	56-66
25272978-7	2015	When CsA was given, the protein and mRNA expressions of E-cadherin and alpha-SMA were significantly altered, and these alterations were significantly reversed with pretreatment of TGF-beta1 inhibitor.	Cyclosporine	5-8	transforming growth factor beta 1	Homo sapiens	180-189
25272978-9	2015	The CsA-induced gingival EMT is dependent or at least partially dependent on TGF-beta1.	Cyclosporine	4-7	transforming growth factor beta 1	Homo sapiens	77-86
25858514-7	2015	), WGO (900 mg/kg/d by oral gavage), or CsA in combination with WGO daily for 21 d. RESULTS: CsA administration significantly increased serum levels of the liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST).	Cyclosporine	93-96	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	205-231
25858514-7	2015	), WGO (900 mg/kg/d by oral gavage), or CsA in combination with WGO daily for 21 d. RESULTS: CsA administration significantly increased serum levels of the liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST).	Cyclosporine	93-96	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	233-236
25858514-8	2015	In addition, an increase in lipid peroxidation, inducible NO-synthase (iNOS), and NF-kappaB expression were observed in hepatic tissues of CsA-alone-treated rats.	Cyclosporine	139-142	nitric oxide synthase 2	Rattus norvegicus	48-69
25858514-8	2015	In addition, an increase in lipid peroxidation, inducible NO-synthase (iNOS), and NF-kappaB expression were observed in hepatic tissues of CsA-alone-treated rats.	Cyclosporine	139-142	nitric oxide synthase 2	Rattus norvegicus	71-75
25858514-9	2015	Furthermore, significant reduction in the hepatic content of reduced glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT) was also observed in CsA-alone-treated animals.	Cyclosporine	156-159	catalase	Rattus norvegicus	120-128
25858514-9	2015	Furthermore, significant reduction in the hepatic content of reduced glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT) was also observed in CsA-alone-treated animals.	Cyclosporine	156-159	catalase	Rattus norvegicus	130-133
26107754-3	2015	RESULTS: The presence of serious infections was correlated to ABCB1 rs1128503 (p = 0.012), CC genotype reduced the probability of infections being also associated with lower blood cyclosporine concentrations.	Cyclosporine	180-192	ATP binding cassette subfamily B member 1	Homo sapiens	62-67
26329549-4	2015	The first finding is that the oral bioavailability of cyclosporine A (CsA), which is an immunosuppressant, was decreased by increased first-pass metabolism due to elevated CYP3A and P-glycoprotein (P-gp) specifically in the upper small intestine after liver I/R.	Cyclosporine	54-68	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	172-177
26329549-4	2015	The first finding is that the oral bioavailability of cyclosporine A (CsA), which is an immunosuppressant, was decreased by increased first-pass metabolism due to elevated CYP3A and P-glycoprotein (P-gp) specifically in the upper small intestine after liver I/R.	Cyclosporine	70-73	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	172-177
25240575-0	2015	Impact of CYP3A4 and MDR1 gene (G2677T) polymorphisms on dose requirement of the cyclosporine in renal transplant Egyptian recipients.	Cyclosporine	81-93	ATP binding cassette subfamily B member 1	Homo sapiens	21-25
25240575-6	2015	Interindividual heterogeneity in expression of ABCB1 and CYP3A4 has been suspected to be one of the factors resulting in cyclosporine (CsA) pharmacokinetic variation.	Cyclosporine	121-133	ATP binding cassette subfamily B member 1	Homo sapiens	47-52
25240575-6	2015	Interindividual heterogeneity in expression of ABCB1 and CYP3A4 has been suspected to be one of the factors resulting in cyclosporine (CsA) pharmacokinetic variation.	Cyclosporine	121-133	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	57-63
25240575-6	2015	Interindividual heterogeneity in expression of ABCB1 and CYP3A4 has been suspected to be one of the factors resulting in cyclosporine (CsA) pharmacokinetic variation.	Cyclosporine	135-138	ATP binding cassette subfamily B member 1	Homo sapiens	47-52
25240575-6	2015	Interindividual heterogeneity in expression of ABCB1 and CYP3A4 has been suspected to be one of the factors resulting in cyclosporine (CsA) pharmacokinetic variation.	Cyclosporine	135-138	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	57-63
25240575-7	2015	This study aimed to investigate the impact of inter-individual CYP3A4 rs4646437C&gt;T and MDR1 G2677T/A polymorphisms on cyclosporine dose requirements among a sample of renal transplant Egyptian recipients.	Cyclosporine	121-133	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	63-69
25240575-7	2015	This study aimed to investigate the impact of inter-individual CYP3A4 rs4646437C&gt;T and MDR1 G2677T/A polymorphisms on cyclosporine dose requirements among a sample of renal transplant Egyptian recipients.	Cyclosporine	121-133	ATP binding cassette subfamily B member 1	Homo sapiens	90-94
25240575-8	2015	Fifty adult Egyptian patients on CsA were genotyped for CYP3A4 rs4646437C&gt;T and MDR1 G2677T/A and correlated with CsA dose requirement and dose-adjusted CsA (C0) blood levels at 3, 6, and 9 months post transplantation.	Cyclosporine	117-120	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-62
25240575-8	2015	Fifty adult Egyptian patients on CsA were genotyped for CYP3A4 rs4646437C&gt;T and MDR1 G2677T/A and correlated with CsA dose requirement and dose-adjusted CsA (C0) blood levels at 3, 6, and 9 months post transplantation.	Cyclosporine	117-120	ATP binding cassette subfamily B member 1	Homo sapiens	83-87
25240575-8	2015	Fifty adult Egyptian patients on CsA were genotyped for CYP3A4 rs4646437C&gt;T and MDR1 G2677T/A and correlated with CsA dose requirement and dose-adjusted CsA (C0) blood levels at 3, 6, and 9 months post transplantation.	Cyclosporine	117-120	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-62
25240575-8	2015	Fifty adult Egyptian patients on CsA were genotyped for CYP3A4 rs4646437C&gt;T and MDR1 G2677T/A and correlated with CsA dose requirement and dose-adjusted CsA (C0) blood levels at 3, 6, and 9 months post transplantation.	Cyclosporine	117-120	ATP binding cassette subfamily B member 1	Homo sapiens	83-87
25240575-9	2015	CYP3A4 rs4646437C&gt;T influenced significantly cyclosporine kinetics, the T carriers requiring higher cyclosporine dose.	Cyclosporine	48-60	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
25240575-9	2015	CYP3A4 rs4646437C&gt;T influenced significantly cyclosporine kinetics, the T carriers requiring higher cyclosporine dose.	Cyclosporine	103-115	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
25240575-11	2015	Genotyping of both CYP3A4 and MDR1 SNPs may be helpful in providing pre-transplant pharmacogenetic information to individualize CsA dosing.	Cyclosporine	128-131	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	19-25
25240575-11	2015	Genotyping of both CYP3A4 and MDR1 SNPs may be helpful in providing pre-transplant pharmacogenetic information to individualize CsA dosing.	Cyclosporine	128-131	ATP binding cassette subfamily B member 1	Homo sapiens	30-34
25456855-10	2014	Tariquidar was also a more potent pharmacological chaperone than other P-gp substrates/modulators such as cyclosporine A.	Cyclosporine	106-120	ATP binding cassette subfamily B member 1	Homo sapiens	71-75
26858893-1	2015	The steroid receptor (SR) complex contains FKBP51 and FKBP52, which bind to tacrolimus (TAC) and cyclophilin 40, which, in turn, bind to cyclosporine (CYA); these influence the intranuclear mobility of steroid-SR complexes.	Cyclosporine	137-149	FKBP prolyl isomerase 4	Homo sapiens	54-60
26858893-1	2015	The steroid receptor (SR) complex contains FKBP51 and FKBP52, which bind to tacrolimus (TAC) and cyclophilin 40, which, in turn, bind to cyclosporine (CYA); these influence the intranuclear mobility of steroid-SR complexes.	Cyclosporine	151-154	FKBP prolyl isomerase 4	Homo sapiens	54-60
25554991-3	2014	Mechanisms of chronic CsA- induced renal damage include: activation of renin-angiotensin-aldosterone system, upregulation of transforming growth factor beta (TGF-beta), oxidative stress.	Cyclosporine	22-25	transforming growth factor, beta 1	Rattus norvegicus	158-166
25451590-9	2014	Indeed, shikonin inhibited the calcineurin activity to a similar extent as cyclosporin A that markedly suppressed the IgE/antigen-enhanced mRNA expression of TNF-alpha and the Nr4a family in mBMMCs.	Cyclosporine	75-88	tumor necrosis factor	Homo sapiens	158-167
25280976-2	2014	Calcium channel blockers (CCBs) are considered to be the best treatment for CsA-induced hypertension, but they may alter the exposure and the effect of CsA by inhibiting the CYP3A4 pathway of CsA metabolism or P-gp.	Cyclosporine	152-155	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	174-180
25280976-2	2014	Calcium channel blockers (CCBs) are considered to be the best treatment for CsA-induced hypertension, but they may alter the exposure and the effect of CsA by inhibiting the CYP3A4 pathway of CsA metabolism or P-gp.	Cyclosporine	152-155	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	174-180
25330904-5	2014	Pharmacological inhibitors of the catalytic subunit of protein phosphatase 2B (PP2B-A) such as cyclosporine A or tacrolimus (FK506) potentiated aggregation of human platelets.	Cyclosporine	95-109	protein phosphatase 3, catalytic subunit, beta isoform	Mus musculus	79-85
24889923-4	2014	The aim of the present study was to assess the ABCB1 T-129C, G1199A, C1236T, G2677T and C3435T single-nucleotide polymorphisms (SNPs) as candidate predictive markers of response to cyclosporine treatment in 84 psoriasis patients.	Cyclosporine	181-193	ATP binding cassette subfamily B member 1	Homo sapiens	47-52
25561870-9	2014	Therefore, using Ferula asafetida with CYP3A4 drug substrates should be cautioned especially those with narrow therapeutic index such as cyclosporine, tacrolimus and carbamazepine.	Cyclosporine	137-149	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	39-45
24739665-1	2014	BACKGROUND: Previous reports have suggested that imatinib may increase cyclosporine exposure by CYP3A4 inhibition.	Cyclosporine	71-83	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	96-102
24980806-9	2014	The results from a rat bioavailability study also showed that co-administrating CsA intravenously (20mg/kg) could significantly increase GA (C15:1) and GA (C17:1) AUC0-t by 1.46-fold and 1.53-fold and brain concentration levels of 1.43-fold and 1.51-fold, respectively, due to the inhibition of P-gp and BCRP efflux transporters by CsA.	Cyclosporine	80-83	phosphoglycolate phosphatase	Rattus norvegicus	295-299
25214539-6	2014	THP-1 macrophage-mediated HDL formation and inhibition of HDL formation by cyclosporine A could also be measured using apoA-I-POLARIC.	Cyclosporine	75-89	apolipoprotein A1	Homo sapiens	119-125
25225668-6	2014	Expression in Jurkat T cells of phosphorylation indicator of Crk chimeric unit plasmid, a plasmid encoding the human CrkII1-236 sandwiched between cyan fluorescent protein and yellow fluorescent protein, demonstrated a basal level of fluorescence resonance energy transfer, which increased in response to cell treatment with CsA and FK506, reflecting increased trans-to-cis conversion of CrkII.	Cyclosporine	325-328	CRK proto-oncogene, adaptor protein	Homo sapiens	61-64
24739669-3	2014	We thus assessed the role of genetic variation in CYP3A4, CYP3A5, POR, NR1I2, and ABCB1 acting jointly in immunosuppressive drug pathways in tacrolimus (TAC) and ciclosporin (CSA) dose requirement in HTx recipients.	Cyclosporine	162-173	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-56
24739669-3	2014	We thus assessed the role of genetic variation in CYP3A4, CYP3A5, POR, NR1I2, and ABCB1 acting jointly in immunosuppressive drug pathways in tacrolimus (TAC) and ciclosporin (CSA) dose requirement in HTx recipients.	Cyclosporine	162-173	cytochrome p450 oxidoreductase	Homo sapiens	66-69
24739669-3	2014	We thus assessed the role of genetic variation in CYP3A4, CYP3A5, POR, NR1I2, and ABCB1 acting jointly in immunosuppressive drug pathways in tacrolimus (TAC) and ciclosporin (CSA) dose requirement in HTx recipients.	Cyclosporine	162-173	nuclear receptor subfamily 1 group I member 2	Homo sapiens	71-76
24739669-3	2014	We thus assessed the role of genetic variation in CYP3A4, CYP3A5, POR, NR1I2, and ABCB1 acting jointly in immunosuppressive drug pathways in tacrolimus (TAC) and ciclosporin (CSA) dose requirement in HTx recipients.	Cyclosporine	162-173	ATP binding cassette subfamily B member 1	Homo sapiens	82-87
25295120-9	2014	CsA treatment also increased the expression levels of pERK1/2 without affecting the total ERK1/2 levels.	Cyclosporine	0-3	mitogen-activated protein kinase 3	Homo sapiens	55-61
25220683-4	2014	Treatment with CsA significantly reduced plasma concentrations of adrenocorticotropic hormone (ACTH), cortisol, and noradrenaline whereas adrenaline levels and state anxiety remained unaffected.	Cyclosporine	15-18	proopiomelanocortin	Homo sapiens	66-93
25220683-4	2014	Treatment with CsA significantly reduced plasma concentrations of adrenocorticotropic hormone (ACTH), cortisol, and noradrenaline whereas adrenaline levels and state anxiety remained unaffected.	Cyclosporine	15-18	proopiomelanocortin	Homo sapiens	95-99
25420853-6	2014	Factors that were found to correlate with erythropoietin levels were delayed graft function, cyclosporine use and prolonged cold ischemia time.	Cyclosporine	93-105	erythropoietin	Homo sapiens	42-56
25225668-5	2014	In addition, cyclophilin A increased Crk SH3 domain-binding guanine-nucleotide releasing factor (C3G) binding to CrkII, whereas inhibitors of immunophilins, such as cyclosporine A (CsA) and FK506, inhibited CrkII, but not CrkI association with C3G.	Cyclosporine	181-184	CRK proto-oncogene, adaptor protein	Homo sapiens	37-40
25299210-9	2014	In apoptotic or autophagic cells, p-ERK levels were highest at 1.0 microM CsA compared to control or other doses.	Cyclosporine	74-77	Eph receptor B1	Rattus norvegicus	36-39
25299210-12	2014	In conclusion, these results suggest that CsA induction of apoptotic or autophagic cell death in rat pituitary GH3 cells depends on the relative expression of factors and correlates with Bcl-2 and Mn-SOD levels.	Cyclosporine	42-45	BCL2, apoptosis regulator	Rattus norvegicus	187-192
24853271-6	2014	Under cyclosporin treatment, slanDCs displayed a normal pattern of maturation, and maintained an efficient chemotactic activity and capacity of releasing tumour necrosis factor (TNF)-alpha upon lipopolysaccharide (LPS) stimulation.	Cyclosporine	6-17	tumor necrosis factor	Homo sapiens	154-188
25219480-0	2014	Biliary strictures after liver transplantation: role of interleukin 28B genotypes in cyclosporine treated.	Cyclosporine	85-97	interferon lambda 3	Homo sapiens	56-71
25219480-9	2014	IL-28B rs12979860C/C genotype in association with cyclosporin was found to be an independent predictor of anastomotic strictures occurrence (p = 0.008).	Cyclosporine	50-61	interferon lambda 3	Homo sapiens	0-6
25219480-11	2014	CONCLUSIONS: In recipients carrying rs12979860 IL-28B C/C genotype the use of cyclosporine seems to contribute to enhance the probability of developing biliary complications which in hepatitis B and C positives appear to reduce patient survival.	Cyclosporine	78-90	interferon lambda 3	Homo sapiens	47-53
25125033-2	2014	This particular characteristic makes it advantageous when combined with drugs metabolized by CYP3A4, such as cyclosporine.	Cyclosporine	109-121	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	93-99
24969967-0	2014	Differential effects of mycophenolate mofetil and cyclosporine A on peripheral blood and cord blood natural killer cells activated with interleukin-2.	Cyclosporine	50-64	interleukin 2	Homo sapiens	136-149
24615518-5	2014	Dex-induced cell death requires mPTP composing protein CyPD, as CyPD inhibitor cyclosporin A (CsA) and CyPD siRNA knockdown inhibited Dex-induced MC3T3-E1 cell death, while CyPD overexpression aggravated Dex"s cytotoxic effect.	Cyclosporine	79-92	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	64-68
24615518-5	2014	Dex-induced cell death requires mPTP composing protein CyPD, as CyPD inhibitor cyclosporin A (CsA) and CyPD siRNA knockdown inhibited Dex-induced MC3T3-E1 cell death, while CyPD overexpression aggravated Dex"s cytotoxic effect.	Cyclosporine	79-92	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	64-68
24615518-5	2014	Dex-induced cell death requires mPTP composing protein CyPD, as CyPD inhibitor cyclosporin A (CsA) and CyPD siRNA knockdown inhibited Dex-induced MC3T3-E1 cell death, while CyPD overexpression aggravated Dex"s cytotoxic effect.	Cyclosporine	79-92	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	64-68
24615518-5	2014	Dex-induced cell death requires mPTP composing protein CyPD, as CyPD inhibitor cyclosporin A (CsA) and CyPD siRNA knockdown inhibited Dex-induced MC3T3-E1 cell death, while CyPD overexpression aggravated Dex"s cytotoxic effect.	Cyclosporine	94-97	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	55-59
25225668-6	2014	Expression in Jurkat T cells of phosphorylation indicator of Crk chimeric unit plasmid, a plasmid encoding the human CrkII1-236 sandwiched between cyan fluorescent protein and yellow fluorescent protein, demonstrated a basal level of fluorescence resonance energy transfer, which increased in response to cell treatment with CsA and FK506, reflecting increased trans-to-cis conversion of CrkII.	Cyclosporine	325-328	CRK proto-oncogene, adaptor protein	Homo sapiens	117-122
25225668-10	2014	The present data demonstrate that immunophilins regulate CrkII, but not CrkI activity in T cells and suggest that CsA and FK506 inhibit selected effector T cell functions via a CrkII-dependent mechanism.	Cyclosporine	114-117	CRK proto-oncogene, adaptor protein	Homo sapiens	177-182
24206119-0	2014	The role of androgen receptor gene in cyclosporine induced gingival overgrowth.	Cyclosporine	38-50	androgen receptor	Homo sapiens	12-29
24615518-5	2014	Dex-induced cell death requires mPTP composing protein CyPD, as CyPD inhibitor cyclosporin A (CsA) and CyPD siRNA knockdown inhibited Dex-induced MC3T3-E1 cell death, while CyPD overexpression aggravated Dex"s cytotoxic effect.	Cyclosporine	94-97	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	64-68
24615518-5	2014	Dex-induced cell death requires mPTP composing protein CyPD, as CyPD inhibitor cyclosporin A (CsA) and CyPD siRNA knockdown inhibited Dex-induced MC3T3-E1 cell death, while CyPD overexpression aggravated Dex"s cytotoxic effect.	Cyclosporine	94-97	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	64-68
24615518-5	2014	Dex-induced cell death requires mPTP composing protein CyPD, as CyPD inhibitor cyclosporin A (CsA) and CyPD siRNA knockdown inhibited Dex-induced MC3T3-E1 cell death, while CyPD overexpression aggravated Dex"s cytotoxic effect.	Cyclosporine	94-97	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	64-68
25143337-0	2014	Serum concentrations of interleukin-2 and tumour necrosis factor-alpha under cyclosporine versus acitretin treatment in plaque-type psoriasis.	Cyclosporine	77-89	interleukin 2	Homo sapiens	24-70
25143337-4	2014	RESULTS: PASI scores and serum IL-2 and TNF-alpha concentrations were significantly decreased after treatment with either cyclosporine (n = 21) or acitretin (n = 25).	Cyclosporine	122-134	interleukin 2	Homo sapiens	31-35
25143337-4	2014	RESULTS: PASI scores and serum IL-2 and TNF-alpha concentrations were significantly decreased after treatment with either cyclosporine (n = 21) or acitretin (n = 25).	Cyclosporine	122-134	tumor necrosis factor	Homo sapiens	40-49
24206119-5	2014	The present study was carried out to determine whether there is an association between CsA-induced gingival overgrowth and the length of the CAG repeats in the AR gene.	Cyclosporine	87-90	androgen receptor	Homo sapiens	160-162
25124319-0	2014	Elevated levels of cyclooxygenase 1 and 2 in human cyclosporine induced gingival overgrowth.	Cyclosporine	51-63	prostaglandin-endoperoxide synthase 1	Homo sapiens	19-41
25124319-1	2014	OBJECTIVE: This study was carried out to immuno-localize and estimate the levels of cyclooxygenase 1 and 2 in human gingival tissue samples from healthy individuals, chronic periodontitis patients and patients with cyclosporine induced gingival overgrowth.	Cyclosporine	215-227	prostaglandin-endoperoxide synthase 1	Homo sapiens	84-106
25124319-7	2014	COX-1 and COX-2 was localized to epithelium and connective tissue in human gingival tissue sections from cyclosporine induced gingival overgrowth.	Cyclosporine	105-117	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	10-15
25338569-7	2014	The expression level of calcineurin in S4C2 cells was higher than that in S9 cells.When CsA inhibited the calcineurin activity, the expression of DNA damage marker gamma-H2AX in S9 cells was significantly lower than that in S4C2 cells,while the expression level of gamma-H2AX between the two cell lines was no significantly different after treatment with imatinib, the expression level of gamma-H2AX in S9 cells was lower than that in S4C2 cells when the two drugs were combined.	Cyclosporine	88-91	H2A.X variant histone	Mus musculus	164-174
25338569-7	2014	The expression level of calcineurin in S4C2 cells was higher than that in S9 cells.When CsA inhibited the calcineurin activity, the expression of DNA damage marker gamma-H2AX in S9 cells was significantly lower than that in S4C2 cells,while the expression level of gamma-H2AX between the two cell lines was no significantly different after treatment with imatinib, the expression level of gamma-H2AX in S9 cells was lower than that in S4C2 cells when the two drugs were combined.	Cyclosporine	88-91	H2A.X variant histone	Mus musculus	265-275
25338569-7	2014	The expression level of calcineurin in S4C2 cells was higher than that in S9 cells.When CsA inhibited the calcineurin activity, the expression of DNA damage marker gamma-H2AX in S9 cells was significantly lower than that in S4C2 cells,while the expression level of gamma-H2AX between the two cell lines was no significantly different after treatment with imatinib, the expression level of gamma-H2AX in S9 cells was lower than that in S4C2 cells when the two drugs were combined.	Cyclosporine	88-91	H2A.X variant histone	Mus musculus	265-275
24929014-11	2014	Cyclosporine A dispersed in the various film formulations remained anti-inflammatorily active as significant suppression of interleukin-2 secretion in concanavalin A stimulated Jurkat T cells was measured.	Cyclosporine	0-14	interleukin 2	Homo sapiens	124-137
25238617-4	2014	The combined addition of UIC2 and 10 times lower concentrations of CsA than what is necessary for Pgp inhibition when the modulator is applied alone, decreased the EC50 of doxorubicin (DOX) in KB-V1 (Pgp+) cells in vitro almost to the level of KB-3-1 (Pgp-) cells.	Cyclosporine	67-70	ATP binding cassette subfamily B member 1	Homo sapiens	98-101
25238617-4	2014	The combined addition of UIC2 and 10 times lower concentrations of CsA than what is necessary for Pgp inhibition when the modulator is applied alone, decreased the EC50 of doxorubicin (DOX) in KB-V1 (Pgp+) cells in vitro almost to the level of KB-3-1 (Pgp-) cells.	Cyclosporine	67-70	ATP binding cassette subfamily B member 1	Homo sapiens	200-203
25238617-4	2014	The combined addition of UIC2 and 10 times lower concentrations of CsA than what is necessary for Pgp inhibition when the modulator is applied alone, decreased the EC50 of doxorubicin (DOX) in KB-V1 (Pgp+) cells in vitro almost to the level of KB-3-1 (Pgp-) cells.	Cyclosporine	67-70	ATP binding cassette subfamily B member 1	Homo sapiens	200-203
25226385-12	2014	On the other hand cyclosporin A (CSA) affected both NFATc1 activation and cell growth, definitively linking P2X7R stimulation to NFATc1 and cell proliferation.	Cyclosporine	18-31	purinergic receptor P2X 7	Homo sapiens	108-113
25226385-12	2014	On the other hand cyclosporin A (CSA) affected both NFATc1 activation and cell growth, definitively linking P2X7R stimulation to NFATc1 and cell proliferation.	Cyclosporine	33-36	purinergic receptor P2X 7	Homo sapiens	108-113
23994301-5	2014	Hence, [(18)F]FP was applied to Sprague Dawley rats, half of them being treated with the P-gp inhibitor cyclosporine A (CsA).	Cyclosporine	104-118	phosphoglycolate phosphatase	Rattus norvegicus	89-93
24946182-5	2014	We also found that cyclosporine A plus ADP, as well as ruthenium red, a Ca(2+) uptake blocker, prevented these effects, suggesting the involvement of the mitochondrial permeability transition pore (mPTP) and an important role for Ca(2+), respectively.	Cyclosporine	19-33	protein tyrosine phosphatase, receptor type, U	Mus musculus	198-202
24947867-7	2014	The OATP1A2-, OATP2B1-, and OCT1-mediated quercetin uptake was inhibited by known inhibitors such as naringin, cyclosporin A, and quinidine, respectively.	Cyclosporine	111-124	solute carrier family 22 member 1	Homo sapiens	28-32
24327206-4	2014	Ang II increased ~45 % cell surface area (CSA) and ~37 % [(3)H]-phenylalanine incorporation, effects that were blocked not only by losartan (Los) but also by BQ123 (AT1 and ETA receptor antagonists, respectively).	Cyclosporine	42-45	angiotensinogen	Homo sapiens	0-6
23994301-5	2014	Hence, [(18)F]FP was applied to Sprague Dawley rats, half of them being treated with the P-gp inhibitor cyclosporine A (CsA).	Cyclosporine	120-123	phosphoglycolate phosphatase	Rattus norvegicus	89-93
25065279-8	2014	RESULTS: We found that alpha2 and beta1 integrins were both markedly reduced following treatment with CsA, i.e., 25% and 13%, respectively, but were normal following subsequent consumption of the antioxidants vit.	Cyclosporine	102-105	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	34-39
24903378-9	2014	In addition, chloroform extract had the ability to inhibit human P-glycoprotein-mediated daunorubicin in K562/R7 leukaemic cells in a dose-dependent manner compared to the positive control, cyclosporin A.	Cyclosporine	190-203	ATP binding cassette subfamily B member 1	Homo sapiens	65-79
25242754-1	2014	BACKGROUND: The single-nucleotide polymorphisms (SNPs) of the Multidrug resistance 1 (MDR1) gene have been associated with changes in the pharmacokinetics of cyclosporine (CsA) and tacrolimus (FK506).	Cyclosporine	158-170	ATP binding cassette subfamily B member 1	Homo sapiens	62-84
25242754-1	2014	BACKGROUND: The single-nucleotide polymorphisms (SNPs) of the Multidrug resistance 1 (MDR1) gene have been associated with changes in the pharmacokinetics of cyclosporine (CsA) and tacrolimus (FK506).	Cyclosporine	158-170	ATP binding cassette subfamily B member 1	Homo sapiens	86-90
25242754-1	2014	BACKGROUND: The single-nucleotide polymorphisms (SNPs) of the Multidrug resistance 1 (MDR1) gene have been associated with changes in the pharmacokinetics of cyclosporine (CsA) and tacrolimus (FK506).	Cyclosporine	172-175	ATP binding cassette subfamily B member 1	Homo sapiens	62-84
25242754-1	2014	BACKGROUND: The single-nucleotide polymorphisms (SNPs) of the Multidrug resistance 1 (MDR1) gene have been associated with changes in the pharmacokinetics of cyclosporine (CsA) and tacrolimus (FK506).	Cyclosporine	172-175	ATP binding cassette subfamily B member 1	Homo sapiens	86-90
25242754-8	2014	CONCLUSIONS: Pretransplantation determination of MDR1 SNPs may be helpful to optimize the starting dose of CsA but can not predict long-term graft survival.	Cyclosporine	107-110	ATP binding cassette subfamily B member 1	Homo sapiens	49-53
24737737-8	2014	We found that CsA reduced proteinuria and repaired FP effacement of PAN-induced nephropathy, restored expression of nephrin, synaptopodin, cofilin-1, pho-cofilin-1 both in vivo and in vitro.	Cyclosporine	14-17	synaptopodin	Rattus norvegicus	125-137
24447269-8	2014	The high-sensitivity C-reactive protein was decreased (tacrolimus group, 1 mo) and increased (cyclosporine group, 6 and 12 mo) after the kidney transplant.	Cyclosporine	94-106	C-reactive protein	Homo sapiens	21-39
24732633-10	2014	Further, cyclosporin A (CsA), the Cyp-D inhibitor, prevented gemcitabine-induced MST1/Cyp-D mitochondrial complexation and cancer cell death.	Cyclosporine	24-27	peptidylprolyl isomerase F	Homo sapiens	34-39
24732633-10	2014	Further, cyclosporin A (CsA), the Cyp-D inhibitor, prevented gemcitabine-induced MST1/Cyp-D mitochondrial complexation and cancer cell death.	Cyclosporine	24-27	peptidylprolyl isomerase F	Homo sapiens	86-91
24737737-12	2014	The protective effect of CsA decreased significantly when cofilin-1 and synaptopodin were simultaneously knocked down compared to only cofilin-1 knock down.	Cyclosporine	25-28	synaptopodin	Rattus norvegicus	72-84
25132585-5	2014	Furthermore, microarray analysis revealed that cyclosporine down-regulated 57 genes whose expression levels were increased by TGF-beta, and up-regulated 73 genes, whose expression was decreased by TGF-beta.	Cyclosporine	47-59	transforming growth factor beta 1	Homo sapiens	126-134
23947915-0	2014	Effect of adjunctive roxithromycin therapy on interleukin-1beta, transforming growth factor-beta1 and vascular endothelial growth factor in gingival crevicular fluid of cyclosporine A-treated patients with gingival overgrowth.	Cyclosporine	169-183	vascular endothelial growth factor A	Homo sapiens	102-136
23947915-14	2014	The reduction of gingival crevicular fluid TGF-beta1 following ROX therapy suggests an anti-inflammatory/immunomodulatory effect of ROX on the treatment of cyclosporine A-induced gingival overgrowth.	Cyclosporine	156-170	transforming growth factor beta 1	Homo sapiens	43-52
24261911-7	2014	RESULTS: In CsA-treated rats, bcl-2 expression was significantly upregulated, whereas caspase-3 expression was downregulated, along with a reduced number of TUNEL-positive cells.	Cyclosporine	12-15	BCL2, apoptosis regulator	Rattus norvegicus	30-35
24261911-8	2014	The site-specific distribution of bcl-2 was consistent with the site-specific hyperplasia of the gingival epithelium in CsA-treated rats.	Cyclosporine	120-123	BCL2, apoptosis regulator	Rattus norvegicus	34-39
24261911-10	2014	The antiapoptotic protein bcl-2 might play a critical role in the pathogenesis of the site-specific hyperplasia of gingival epithelium induced by CsA.	Cyclosporine	146-149	BCL2, apoptosis regulator	Rattus norvegicus	26-31
25132585-5	2014	Furthermore, microarray analysis revealed that cyclosporine down-regulated 57 genes whose expression levels were increased by TGF-beta, and up-regulated 73 genes, whose expression was decreased by TGF-beta.	Cyclosporine	47-59	transforming growth factor beta 1	Homo sapiens	197-205
25132585-8	2014	Cyclosporine treatment decreased the expression levels of IGFBP2 and ID1, but increased PPARG expression.	Cyclosporine	0-12	peroxisome proliferator activated receptor gamma	Homo sapiens	88-93
24946211-7	2014	Inhibition of Cyp-D by its inhibitors cyclosporin A (CSA) or sanglifehrin A (SFA), and by Cyp-D shRNA depletion alleviated berberine-induced prostate cancer cell necrosis (but not apoptosis).	Cyclosporine	38-51	peptidylprolyl isomerase F	Homo sapiens	14-19
25072153-8	2014	Urinary TNF-alpha, KIM-1 and fibronectin increased in the early phase, and urinary TGF-beta and osteopontin increased in the late phase of CsA nephrotoxicity.	Cyclosporine	139-142	transforming growth factor, beta 1	Rattus norvegicus	83-91
25072153-10	2014	In conclusion, early increases in urinary KIM-1, TNF-alpha, and fibronectin and elevated microalbuminuria indicate acute CsA nephrotoxicity.	Cyclosporine	121-124	tumor necrosis factor	Rattus norvegicus	49-58
25072153-11	2014	Late increases in urinary osteopontin and TGF-beta indicate chronic CsA nephrotoxicity.	Cyclosporine	68-71	transforming growth factor, beta 1	Rattus norvegicus	42-50
24946211-7	2014	Inhibition of Cyp-D by its inhibitors cyclosporin A (CSA) or sanglifehrin A (SFA), and by Cyp-D shRNA depletion alleviated berberine-induced prostate cancer cell necrosis (but not apoptosis).	Cyclosporine	53-56	peptidylprolyl isomerase F	Homo sapiens	14-19
25268669-7	2014	Finally, in a pilot study of 7 patients with relapsing posterior uveitis refractory to azathioprine and/or cyclosporine, the anti-IL-1beta antibody Gevokizumab was beneficial.	Cyclosporine	107-119	interleukin 1 beta	Homo sapiens	130-138
24654232-4	2014	METHODS AND RESULTS: FGF-2 perfusion increased resistance to calcium-induced mPTP in SSM and IFM suspensions by 2.9- and 1.7-fold, respectively, compared with their counterparts from vehicle-perfused hearts, assessed spectrophotometrically as cyclosporine A-inhibitable swelling.	Cyclosporine	243-257	fibroblast growth factor 2	Homo sapiens	21-26
24641346-4	2014	Accumulation decreased in spheroids overexpressing Pgp (HEK-MDR) and was increased in the presence of Pgp inhibitors (verapamil, loperamide, cyclosporin A).	Cyclosporine	141-154	ATP binding cassette subfamily B member 1	Homo sapiens	51-54
24641346-4	2014	Accumulation decreased in spheroids overexpressing Pgp (HEK-MDR) and was increased in the presence of Pgp inhibitors (verapamil, loperamide, cyclosporin A).	Cyclosporine	141-154	ATP binding cassette subfamily B member 1	Homo sapiens	102-105
24711569-8	2014	CsA also significantly decreased the expression of CD154 by anti-Aspergillus TH1 cells.	Cyclosporine	0-3	CD40 ligand	Homo sapiens	51-56
24964791-0	2014	Systems biology modeling of omics data: effect of cyclosporine a on the Nrf2 pathway in human renal cells.	Cyclosporine	50-64	NFE2 like bZIP transcription factor 2	Homo sapiens	72-76
24964791-2	2014	We have recently shown that cyclosporine A (CsA) strongly activates the nuclear factor (erythroid-derived 2)-like 2 pathway (Nrf2) in renal proximal tubular epithelial cells (RPTECs) exposed in vitro.	Cyclosporine	28-42	NFE2 like bZIP transcription factor 2	Homo sapiens	125-129
24964791-2	2014	We have recently shown that cyclosporine A (CsA) strongly activates the nuclear factor (erythroid-derived 2)-like 2 pathway (Nrf2) in renal proximal tubular epithelial cells (RPTECs) exposed in vitro.	Cyclosporine	44-47	NFE2 like bZIP transcription factor 2	Homo sapiens	125-129
24658827-1	2014	PURPOSE: Tacrolimus (Tac) and cyclosporine (CsA) are mainly metabolized by CYP3A4 and CYP3A5.	Cyclosporine	30-42	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-81
24658827-1	2014	PURPOSE: Tacrolimus (Tac) and cyclosporine (CsA) are mainly metabolized by CYP3A4 and CYP3A5.	Cyclosporine	30-42	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	86-92
24658827-1	2014	PURPOSE: Tacrolimus (Tac) and cyclosporine (CsA) are mainly metabolized by CYP3A4 and CYP3A5.	Cyclosporine	44-47	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-81
24658827-1	2014	PURPOSE: Tacrolimus (Tac) and cyclosporine (CsA) are mainly metabolized by CYP3A4 and CYP3A5.	Cyclosporine	44-47	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	86-92
24658827-10	2014	CsA C2/D was 53 % higher among CYP3A4*22 carriers (P=0.03).	Cyclosporine	0-3	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-37
24658827-12	2014	Furthermore, initial CsA dosing may be improved by pre-transplant CYP3A4*22 determination.	Cyclosporine	21-24	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	66-72
24691060-0	2014	Association of CYP3A4*18B and CYP3A5*3 polymorphism with cyclosporine-related liver injury in Chinese renal transplant recipients.	Cyclosporine	57-69	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	15-21
24691060-0	2014	Association of CYP3A4*18B and CYP3A5*3 polymorphism with cyclosporine-related liver injury in Chinese renal transplant recipients.	Cyclosporine	57-69	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	30-36
24691060-1	2014	OBJECTIVE: The purpose of this study was to investigate the associations between CYP3A4*18B and CYP3A5*3 polymorphism and cyclosporine-related liver injuries in Chinese renal transplant recipients.	Cyclosporine	122-134	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	81-87
24691060-1	2014	OBJECTIVE: The purpose of this study was to investigate the associations between CYP3A4*18B and CYP3A5*3 polymorphism and cyclosporine-related liver injuries in Chinese renal transplant recipients.	Cyclosporine	122-134	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	96-102
24691060-4	2014	At 1 month after transplantation, the trough concentration of cyclosporine (C0) in the group with CYP3A4*1/*1(GG alleles) was significantly higher than in the group with CYP3A4*18B/*1 8B(AA alleles) (p &lt; 0.05).	Cyclosporine	62-74	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	98-104
24691060-4	2014	At 1 month after transplantation, the trough concentration of cyclosporine (C0) in the group with CYP3A4*1/*1(GG alleles) was significantly higher than in the group with CYP3A4*18B/*1 8B(AA alleles) (p &lt; 0.05).	Cyclosporine	62-74	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	170-176
24691060-10	2014	CONCLUSIONS: These results suggested that the wild type of CYP3A4*18B is a risk factor for the development of cyclosporine- related liver injuries in Chinese renal transplant recipients.	Cyclosporine	110-122	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	59-65
24797915-11	2014	Treatments with anti-IL-12/23p40 mAb and CsA prevented disease in PAC IL-10 k.o.	Cyclosporine	41-44	interleukin 10	Mus musculus	70-75
25484988-3	2014	Given that the actions of CsA are often attributed to inhibition of the calcineurin/NFAT axis, we hypothesized that CsA enhances gene expression in bone cells exposed to fluid flow, by inhibiting nuclear NFATc1 accumulation.	Cyclosporine	116-119	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	204-210
25484988-4	2014	When exposed to flow, MC3T3-E1 osteoblastic cells exhibited rapid nuclear accumulation of NFATc1 that was abolished by CsA treatment.	Cyclosporine	119-122	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	90-96
24975341-5	2014	In acquired PRCA, CD4/8 ratio in the bone marrow lymphocytes may correlate with the disease status and the outcome of CsA treatment.	Cyclosporine	118-121	CD4 molecule	Homo sapiens	18-21
24768635-8	2014	Moreover, when ATF3 knockdown cells were exposed to CsA, a prompt induction of CHOP was observed, which stimulated ROS production and induced cell death-related genes as compared to wild type.	Cyclosporine	52-55	DNA damage inducible transcript 3	Homo sapiens	79-83
24365983-0	2014	Severe decrease of cyclosporine levels in a heart transplant recipient receiving the direct thrombin inhibitor argatroban.	Cyclosporine	19-31	coagulation factor II, thrombin	Homo sapiens	92-100
24365983-1	2014	This case report is about a suspected interaction between argatroban, a direct thrombin inhibitor, and cyclosporine, which occurred in a 60-year-old patient after a second heart transplantation.	Cyclosporine	103-115	coagulation factor II, thrombin	Homo sapiens	79-87
24666466-10	2014	Analogous to CsA-treated CMV patients, the level of significance was reached for IFNgamma (61 +- 24 vs. 88 +- 29, P = 0.0154).	Cyclosporine	13-16	interferon gamma	Homo sapiens	81-89
24768635-9	2014	Taken together, our data demonstrate that ATF3 plays a pivotal role in the attenuation of CsA-induced nephrotoxicity by downregulating CHOP and ROS production mediated by ER stress.	Cyclosporine	90-93	DNA damage inducible transcript 3	Homo sapiens	135-139
24219005-1	2014	INTRODUCTION: Previously, we demonstrated that oral docetaxel plus the P-glycoprotein (Pgp; ABCB1) inhibitor cyclosporin A (CsA) is safe and results in adequate exposure to docetaxel.	Cyclosporine	124-127	ATP binding cassette subfamily B member 1	Homo sapiens	71-85
24735534-5	2014	The CyPD inhibitor cyclosporin A (CsA) or CyPD siRNA-depletion inhibited curcumin-induced WM-115 cell death and apoptosis, while WM-115 cells with CyPD over-expression were hyper-sensitive to curcumin.	Cyclosporine	19-32	peptidylprolyl isomerase F	Homo sapiens	4-8
24735534-5	2014	The CyPD inhibitor cyclosporin A (CsA) or CyPD siRNA-depletion inhibited curcumin-induced WM-115 cell death and apoptosis, while WM-115 cells with CyPD over-expression were hyper-sensitive to curcumin.	Cyclosporine	34-37	peptidylprolyl isomerase F	Homo sapiens	4-8
24853130-1	2014	Cyclosporin A (CsA), a calcineurin inhibitor, remain the cornerstone of immunosuppressive regimens, regardless of nephrotoxicity, which depends on the duration of drug exposure.	Cyclosporine	0-13	calcineurin binding protein 1	Rattus norvegicus	23-44
24853130-1	2014	Cyclosporin A (CsA), a calcineurin inhibitor, remain the cornerstone of immunosuppressive regimens, regardless of nephrotoxicity, which depends on the duration of drug exposure.	Cyclosporine	15-18	calcineurin binding protein 1	Rattus norvegicus	23-44
24853130-5	2014	In the short-term, creatinine and blood urea nitrogen (BUN) levels increased and clearances decreased, accompanied by glomerular filtration rate (GFR) reduction, but without kidney lesions; at that stage, CsA exposure induced proliferating cell nuclear antigen (PCNA), transforming growth factor beta 1 (TGF-beta1), factor nuclear kappa B (NF-kappabeta) and Tumor Protein P53 (TP53) kidney mRNA up-regulation.	Cyclosporine	205-208	transforming growth factor, beta 1	Rattus norvegicus	269-302
24853130-5	2014	In the short-term, creatinine and blood urea nitrogen (BUN) levels increased and clearances decreased, accompanied by glomerular filtration rate (GFR) reduction, but without kidney lesions; at that stage, CsA exposure induced proliferating cell nuclear antigen (PCNA), transforming growth factor beta 1 (TGF-beta1), factor nuclear kappa B (NF-kappabeta) and Tumor Protein P53 (TP53) kidney mRNA up-regulation.	Cyclosporine	205-208	transforming growth factor, beta 1	Rattus norvegicus	304-313
24819773-7	2014	Our data indicate that IL-8 induced NETosis is reduced by ascomycin and cyclosporine A, antagonists of the calcineurin pathway, but not following treatment with rapamycin, which utilizes the mTOR pathway.	Cyclosporine	72-86	C-X-C motif chemokine ligand 8	Homo sapiens	23-27
24819773-8	2014	The action of the G protein coupled receptor phospholipase C pathway appears to be essential for the induction of NETs by IL-8, as NETosis was diminished by treatment with either pertussis toxin, a G-protein inhibitor, the phospholipase C inhibitor, U73122, or staurosporine, an inhibitor of protein kinase C. The data regarding the calcineurin antagonists, ascomycin and cyclosporine A, open the possibility to therapeutically suppress or modulate NETosis.	Cyclosporine	372-386	C-X-C motif chemokine ligand 8	Homo sapiens	122-126
24219005-1	2014	INTRODUCTION: Previously, we demonstrated that oral docetaxel plus the P-glycoprotein (Pgp; ABCB1) inhibitor cyclosporin A (CsA) is safe and results in adequate exposure to docetaxel.	Cyclosporine	124-127	ATP binding cassette subfamily B member 1	Homo sapiens	87-90
24219005-1	2014	INTRODUCTION: Previously, we demonstrated that oral docetaxel plus the P-glycoprotein (Pgp; ABCB1) inhibitor cyclosporin A (CsA) is safe and results in adequate exposure to docetaxel.	Cyclosporine	124-127	ATP binding cassette subfamily B member 1	Homo sapiens	92-97
24486951-8	2014	RESULTS: NS2-5B replicons of genotype 2a (JFH1), but not genotype 1b, had increased sensitivity to cyclosporine.	Cyclosporine	99-111	NS2	Homo sapiens	9-12
24517287-14	2014	Based on other reported GPPP cases, TNF-alpha antagonists are used as rescue therapy in GPPP refractory to steroid and cyclosporine therapy, but careful consideration of the advantages and disadvantages is warranted before using them.	Cyclosporine	119-131	tumor necrosis factor	Homo sapiens	36-45
24486951-9	2014	This difference was lost with replication-attenuated NS3-5B JFH1 RNAs, showing that cyclosporine sensitivity is linked to reduced replication fitness of NS2-containing HCV RNAs.	Cyclosporine	84-96	NS2	Homo sapiens	153-156
24610957-1	2014	Clinically used calcineurin inhibitors, including tacrolimus (FK506) and cyclosporine A, can induce calcineurin inhibitor-induced pain syndrome (CIPS), which is characterized as severe pain and pain hypersensitivity.	Cyclosporine	73-87	calcineurin binding protein 1	Rattus norvegicus	16-37
24732379-2	2014	Here, we define genetic changes altered in hair follicle (HF) SCs in mice treated with a potent SC activator, cyclosporine A (CSA), which inhibits the phosphatase calcineurin (CN) and the activity of the transcription factor nuclear factor of activated T cells c1 (Nfatc1).	Cyclosporine	110-124	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	265-271
24732379-2	2014	Here, we define genetic changes altered in hair follicle (HF) SCs in mice treated with a potent SC activator, cyclosporine A (CSA), which inhibits the phosphatase calcineurin (CN) and the activity of the transcription factor nuclear factor of activated T cells c1 (Nfatc1).	Cyclosporine	126-129	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	265-271
23907422-7	2014	CsA suppressed TIMP in children, but PhT stimulated its expression.	Cyclosporine	0-3	TIMP metallopeptidase inhibitor 1	Homo sapiens	15-19
24375637-0	2014	Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP).	Cyclosporine	0-13	solute carrier family 10 member 1	Homo sapiens	178-182
24331739-5	2014	The GDNF plasma levels in the CSA+ group increased dramatically during 3 weeks of detoxification.	Cyclosporine	30-33	glial cell derived neurotrophic factor	Homo sapiens	4-8
24331739-6	2014	In contrast, those in the CSA- group showed lower and stable levels of GDNF under the same conditions.	Cyclosporine	26-29	glial cell derived neurotrophic factor	Homo sapiens	71-75
24331739-9	2014	However, within-group analyses showed that the CSA+ group exhibited higher levels of NT4/5 than the CSA- group at the end of detoxification.	Cyclosporine	47-50	neurotrophin 4	Homo sapiens	85-90
22903178-8	2014	The results indicate that CsA-induced aortic endothelial dysfunction was characterized by morphological and ultrastructural alterations in tissue architecture, changes in malondialdehyde and ferric reducing/antioxidant power levels, and increase in endothelial nitric oxide synthase and terminal-deoxynucleotidyl-transferase mediated dUTP nick end labeling (TUNEL) expression.	Cyclosporine	26-29	DNA nucleotidylexotransferase	Rattus norvegicus	287-324
24295872-0	2014	Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor.	Cyclosporine	0-13	solute carrier family 10 member 1	Homo sapiens	112-116
24680679-9	2014	However, inhibition of the relocation of Nur77 to mitochondria via Cyclosporin A reversed the changes in membrane potential mediated by H2O2 and reduced myocardial cell injury.	Cyclosporine	67-80	nuclear receptor subfamily 4 group A member 1	Homo sapiens	41-46
23943055-6	2014	Delphinidin increased the mRNA expression and production of IL-2 in Jurkat cells and was inhibited by BTP2 and cyclosporine A.	Cyclosporine	111-125	interleukin 2	Homo sapiens	60-64
24453045-0	2014	Requirement of miR-144 in CsA induced proliferation and invasion of human trophoblast cells by targeting titin.	Cyclosporine	26-29	microRNA 144	Homo sapiens	15-22
24453045-2	2014	In this study, with the treatment of CsA (Cyclosporin A), we showed that miR144 expression levels were decreased while titin mRNA expression levels were increased in human trophoblast (HT) cells, and identified titin as a novel direct target of miR-144.	Cyclosporine	37-40	microRNA 144	Homo sapiens	73-79
24453045-2	2014	In this study, with the treatment of CsA (Cyclosporin A), we showed that miR144 expression levels were decreased while titin mRNA expression levels were increased in human trophoblast (HT) cells, and identified titin as a novel direct target of miR-144.	Cyclosporine	37-40	microRNA 144	Homo sapiens	245-252
24941799-7	2014	The further study result implied that CsA could increase the expression of CRP on vascular endothelial cells and serum level of ROS (P&lt;0.	Cyclosporine	38-41	C-reactive protein	Rattus norvegicus	75-78
24941799-9	2014	CONCLUSION: CsA can significantly upregulate the expression of LOX-1 on vascular endothelium of hyperlipidemic rats through not only ox-LDL/LOX-1 pathway but also ROS/CRP pathway, which could cause the probability of occurrence of atherosclerosis.	Cyclosporine	12-15	C-reactive protein	Rattus norvegicus	167-170
24941805-8	2014	RESULTS: Compared with other groups, CsA+Talpha1 group had significant lower IL-1alpha, IL-2, IL-6, IL-17, and significant higher IL-10 at 1 d, 7 d, 14 d, 21 d after the treatments (P &lt; 0.05).	Cyclosporine	37-40	interleukin 6	Mus musculus	94-98
24941805-8	2014	RESULTS: Compared with other groups, CsA+Talpha1 group had significant lower IL-1alpha, IL-2, IL-6, IL-17, and significant higher IL-10 at 1 d, 7 d, 14 d, 21 d after the treatments (P &lt; 0.05).	Cyclosporine	37-40	interleukin 10	Mus musculus	130-135
24488610-7	2014	However, in higher-risk patients with longer cardiopulmonary bypass times, there was a significant reduction in PMI with CsA therapy (p=0.049), with a reduced postoperative cTnT rise by 0.03 ng/mL for every 10 min, when compared with control.	Cyclosporine	121-124	troponin T2, cardiac type	Homo sapiens	173-177
24295872-3	2014	NTCP is a bile salt transporter known to be inhibited by cyclosporin A.	Cyclosporine	57-70	solute carrier family 10 member 1	Homo sapiens	0-4
24295872-6	2014	The mode of action of cyclosporin A was studied by comparing the effect of different inhibitors, cyclophilin A/B/C-silenced cell lines as well as NTCP variants and mutants.	Cyclosporine	22-35	solute carrier family 10 member 1	Homo sapiens	146-150
24295872-9	2014	Binding of HBVpreS to NTCP was blocked by cyclosporin A concentrations at 8 muM.	Cyclosporine	42-55	solute carrier family 10 member 1	Homo sapiens	22-26
24295872-9	2014	Binding of HBVpreS to NTCP was blocked by cyclosporin A concentrations at 8 muM.	Cyclosporine	42-55	latexin	Homo sapiens	76-79
24295872-10	2014	An NTCP variant deficient in HBVpreS binding but competent for bile salt transport showed resistance to cyclosporin A.	Cyclosporine	104-117	solute carrier family 10 member 1	Homo sapiens	3-7
24658440-5	2014	Recently, different authors have demonstrated that P-gp inhibitors, such as cyclosporine A (CsA) and its analogue Tacrolimus, are able to reduce P-gp expression and or function in SLE, RA and PsA patients.	Cyclosporine	76-90	ATP binding cassette subfamily B member 1	Homo sapiens	145-149
24508908-8	2014	CsA markedly decreased expressions of Nur77, p-Nur77, Bcl-2 and cyto C, and inhibited apoptosis.Improvement of neurological deficit, alleviation of brain edema and amelioration of EBI were obtained after prophylactic use of CsA.	Cyclosporine	0-3	BCL2, apoptosis regulator	Rattus norvegicus	54-59
24772460-0	2014	Retraction: "Expression of angiotensin II and its receptors in cyclosporine-induced gingival overgrowth" by T. Subramani,K.	Cyclosporine	63-75	angiotensinogen	Homo sapiens	27-41
24658440-5	2014	Recently, different authors have demonstrated that P-gp inhibitors, such as cyclosporine A (CsA) and its analogue Tacrolimus, are able to reduce P-gp expression and or function in SLE, RA and PsA patients.	Cyclosporine	76-90	ATP binding cassette subfamily B member 1	Homo sapiens	51-55
24658440-5	2014	Recently, different authors have demonstrated that P-gp inhibitors, such as cyclosporine A (CsA) and its analogue Tacrolimus, are able to reduce P-gp expression and or function in SLE, RA and PsA patients.	Cyclosporine	92-95	ATP binding cassette subfamily B member 1	Homo sapiens	51-55
24658440-5	2014	Recently, different authors have demonstrated that P-gp inhibitors, such as cyclosporine A (CsA) and its analogue Tacrolimus, are able to reduce P-gp expression and or function in SLE, RA and PsA patients.	Cyclosporine	92-95	ATP binding cassette subfamily B member 1	Homo sapiens	145-149
24632797-5	2014	RESULTS: The levels of vascular endothelial growth factor, nitric oxide synthase 1 and 3, and Ki-67 were found to be significantly different among groups (P&gt;0.001), with patients treated with cyclosporin A showing higher levels of all the analyzed markers compared to control group.	Cyclosporine	195-208	vascular endothelial growth factor A	Homo sapiens	23-57
24621983-1	2014	OBJECTIVE: ATP-binding cassette, subfamily B, member 1 (ABCB1) transporter, or P-glycoprotein, is an efflux protein implicated in the absorption and the distribution of various compounds, including tacrolimus and cyclosporine A.	Cyclosporine	213-227	ATP binding cassette subfamily B member 1	Homo sapiens	11-54
24621983-1	2014	OBJECTIVE: ATP-binding cassette, subfamily B, member 1 (ABCB1) transporter, or P-glycoprotein, is an efflux protein implicated in the absorption and the distribution of various compounds, including tacrolimus and cyclosporine A.	Cyclosporine	213-227	ATP binding cassette subfamily B member 1	Homo sapiens	56-61
24621983-1	2014	OBJECTIVE: ATP-binding cassette, subfamily B, member 1 (ABCB1) transporter, or P-glycoprotein, is an efflux protein implicated in the absorption and the distribution of various compounds, including tacrolimus and cyclosporine A.	Cyclosporine	213-227	ATP binding cassette subfamily B member 1	Homo sapiens	79-93
24621983-5	2014	The impact of the 1199G&gt;A SNP on ABCB1 activity towards rhodamine (Rh123), doxorubicin, vinblastine, tacrolimus and cyclosporine A was assessed by accumulation, cytotoxicity and/or kinetic experiments.	Cyclosporine	119-133	ATP binding cassette subfamily B member 1	Homo sapiens	36-41
24621983-8	2014	Unlike tacrolimus, our results also indicate that cyclosporine A, Rh123 and doxorubicin are transported in a similar extent by the wild-type and variant ABCB1 proteins while the variant protein seems to be more efficient for the transport of vinblastine.	Cyclosporine	50-64	ATP binding cassette subfamily B member 1	Homo sapiens	153-158
24627421-3	2014	Here, we show that inhibition of the mitochondrial permeability transition pore (mPTP) by Cyclosporin A (CsA) promotes cardiomyocyte differentiation from PSCs.	Cyclosporine	90-103	protein tyrosine phosphatase, receptor type, U	Mus musculus	81-85
24627421-3	2014	Here, we show that inhibition of the mitochondrial permeability transition pore (mPTP) by Cyclosporin A (CsA) promotes cardiomyocyte differentiation from PSCs.	Cyclosporine	105-108	protein tyrosine phosphatase, receptor type, U	Mus musculus	81-85
24627421-5	2014	The cardiomyogenic effect of CsA mainly resulted from mPTP inhibition rather than from calcineurin inhibition.	Cyclosporine	29-32	protein tyrosine phosphatase, receptor type, U	Mus musculus	54-58
24627421-9	2014	CONCLUSIONS: Our data show that mPTP inhibition by CsA alters mitochondrial oxidative metabolism and redox signaling, which leads to differentiation of functional cardiomyocytes from PSCs.	Cyclosporine	51-54	protein tyrosine phosphatase, receptor type, U	Mus musculus	32-36
24603333-0	2014	Inhibition of cyclophilin D by cyclosporin A promotes retinal ganglion cell survival by preventing mitochondrial alteration in ischemic injury.	Cyclosporine	31-44	peptidylprolyl isomerase F	Homo sapiens	14-27
24603333-1	2014	Cyclosporin A (CsA) inhibits the opening of the mitochondrial permeability transition pore (MPTP) by interacting with cyclophilin D (CypD) and ameliorates neuronal cell death in the central nervous system against ischemic injury.	Cyclosporine	0-13	peptidylprolyl isomerase F	Homo sapiens	118-131
24603333-1	2014	Cyclosporin A (CsA) inhibits the opening of the mitochondrial permeability transition pore (MPTP) by interacting with cyclophilin D (CypD) and ameliorates neuronal cell death in the central nervous system against ischemic injury.	Cyclosporine	0-13	peptidylprolyl isomerase F	Homo sapiens	133-137
24603333-1	2014	Cyclosporin A (CsA) inhibits the opening of the mitochondrial permeability transition pore (MPTP) by interacting with cyclophilin D (CypD) and ameliorates neuronal cell death in the central nervous system against ischemic injury.	Cyclosporine	15-18	peptidylprolyl isomerase F	Homo sapiens	118-131
24603333-1	2014	Cyclosporin A (CsA) inhibits the opening of the mitochondrial permeability transition pore (MPTP) by interacting with cyclophilin D (CypD) and ameliorates neuronal cell death in the central nervous system against ischemic injury.	Cyclosporine	15-18	peptidylprolyl isomerase F	Homo sapiens	133-137
24603333-3	2014	We observed the first direct evidence that acute IOP elevation significantly upregulated CypD protein expression in ischemic retina at 12 h. However, CsA prevented the upregulation of CypD protein expression and promoted retinal ganglion cell (RGC) survival against ischemic injury.	Cyclosporine	150-153	peptidylprolyl isomerase F	Homo sapiens	184-188
24603333-4	2014	Moreover, CsA blocked apoptotic cell death by decreasing cleaved caspase-3 protein expression in ischemic retina.	Cyclosporine	10-13	caspase 3	Homo sapiens	65-74
24603333-6	2014	More importantly, CsA preserved Bcl-xL immunoreactivity in RGCs of ischemic retina.	Cyclosporine	18-21	BCL2 like 1	Homo sapiens	32-38
24603333-11	2014	On the basis of these observations, our findings suggest that CsA-mediated CypD inhibition may provide a promising therapeutic potential for protecting RGCs against ischemic injury-mediated mitochondrial dysfunction.	Cyclosporine	62-65	peptidylprolyl isomerase F	Homo sapiens	75-79
23624721-9	2014	Using cyclosporin A as an inhibitor, we revealed that NF-ATc1 directly regulates OC-STAMP and P2X7 receptor expression during LPA-stimulated osteoclast fusion.	Cyclosporine	6-19	purinergic receptor P2X 7	Homo sapiens	94-107
24559268-2	2014	This study investigated whether upregulation of Nrf2-dependent signaling by oleanolic acid (OA), which is known to activate Nrf2, could attenuate renal inflammation and fibrosis in cyclosporine (CsA)-induced kidney injury.	Cyclosporine	181-193	nuclear factor, erythroid derived 2, like 2	Mus musculus	48-52
24462674-0	2014	Celecoxib offsets the negative renal influences of cyclosporine via modulation of the TGF-beta1/IL-2/COX-2/endothelin ET(B) receptor cascade.	Cyclosporine	51-63	transforming growth factor, beta 1	Rattus norvegicus	86-95
24462674-3	2014	Ten-day treatment with CSA (20 mg/kg/day) significantly increased biochemical indices of renal function (serum urea, creatinine), inflammation (interleukin-2, IL-2) and fibrosis (transforming growth factor-beta1, TGF-beta1).	Cyclosporine	23-26	transforming growth factor, beta 1	Rattus norvegicus	179-211
24462674-3	2014	Ten-day treatment with CSA (20 mg/kg/day) significantly increased biochemical indices of renal function (serum urea, creatinine), inflammation (interleukin-2, IL-2) and fibrosis (transforming growth factor-beta1, TGF-beta1).	Cyclosporine	23-26	transforming growth factor, beta 1	Rattus norvegicus	213-222
24462674-8	2014	Together, the data suggest that the facilitation of the interplay between the TGF-beta1/IL-2/COX-2 pathway and the endothelin ET(B) receptors constitutes the cellular mechanism by which celecoxib ameliorates the nephrotoxic manifestations of CSA in rats.	Cyclosporine	242-245	transforming growth factor, beta 1	Rattus norvegicus	78-87
24415751-9	2014	The calcineurin-NFATc mediated up-regulation of the Itpr2 promoter was attenuated by cyclosporine-A.	Cyclosporine	85-99	inositol 1,4,5-trisphosphate receptor type 2	Homo sapiens	52-57
24559268-11	2014	Increased apoptotic cell death and a high ratio of B cell leukaemia/lymphoma 2 (Bcl-2)-associated X protein (Bax) to Bcl-2 in CsA-treated mice were also significantly ameliorated by OA treatment.	Cyclosporine	126-129	B cell leukemia/lymphoma 2	Mus musculus	117-122
24559268-12	2014	CONCLUSION: Our results suggest that OA activates Nrf2/HO-1 signaling in chronic CsA nephropathy, which may have beneficial effects on inflammation and oxidative stress.	Cyclosporine	81-84	nuclear factor, erythroid derived 2, like 2	Mus musculus	50-54
24559268-12	2014	CONCLUSION: Our results suggest that OA activates Nrf2/HO-1 signaling in chronic CsA nephropathy, which may have beneficial effects on inflammation and oxidative stress.	Cyclosporine	81-84	heme oxygenase 1	Mus musculus	55-59
24559268-2	2014	This study investigated whether upregulation of Nrf2-dependent signaling by oleanolic acid (OA), which is known to activate Nrf2, could attenuate renal inflammation and fibrosis in cyclosporine (CsA)-induced kidney injury.	Cyclosporine	195-198	nuclear factor, erythroid derived 2, like 2	Mus musculus	48-52
24559268-11	2014	Increased apoptotic cell death and a high ratio of B cell leukaemia/lymphoma 2 (Bcl-2)-associated X protein (Bax) to Bcl-2 in CsA-treated mice were also significantly ameliorated by OA treatment.	Cyclosporine	126-129	B cell leukemia/lymphoma 2	Mus musculus	51-78
24559268-11	2014	Increased apoptotic cell death and a high ratio of B cell leukaemia/lymphoma 2 (Bcl-2)-associated X protein (Bax) to Bcl-2 in CsA-treated mice were also significantly ameliorated by OA treatment.	Cyclosporine	126-129	B cell leukemia/lymphoma 2	Mus musculus	80-85
24342979-7	2014	RESULTS: Cyclosporine A and tacrolimus significantly reduced IFNgamma production in a dose-dependent manner (53%-83%), but showed minimal effect on degranulation (20%).	Cyclosporine	9-23	interferon gamma	Homo sapiens	61-69
24291639-6	2014	Furthermore, cyclosporin A (CsA) and knockdown of nuclear factor of activated T-cells c3 (NFATc3) inhibited the expression of COX-2 induced by ET-1, and NFATc3 could also bound to the -GGAAA- sequence in the promoter region of rat COX-2 gene, indicating that calcineurin/NFATc3 signaling participated in the transcriptional regulation of COX-2 following ET-1 treatment.	Cyclosporine	13-26	endothelin 1	Rattus norvegicus	143-147
24291639-6	2014	Furthermore, cyclosporin A (CsA) and knockdown of nuclear factor of activated T-cells c3 (NFATc3) inhibited the expression of COX-2 induced by ET-1, and NFATc3 could also bound to the -GGAAA- sequence in the promoter region of rat COX-2 gene, indicating that calcineurin/NFATc3 signaling participated in the transcriptional regulation of COX-2 following ET-1 treatment.	Cyclosporine	13-26	nuclear factor of activated T-cells 3	Rattus norvegicus	153-159
24291639-6	2014	Furthermore, cyclosporin A (CsA) and knockdown of nuclear factor of activated T-cells c3 (NFATc3) inhibited the expression of COX-2 induced by ET-1, and NFATc3 could also bound to the -GGAAA- sequence in the promoter region of rat COX-2 gene, indicating that calcineurin/NFATc3 signaling participated in the transcriptional regulation of COX-2 following ET-1 treatment.	Cyclosporine	13-26	nuclear factor of activated T-cells 3	Rattus norvegicus	153-159
24291639-6	2014	Furthermore, cyclosporin A (CsA) and knockdown of nuclear factor of activated T-cells c3 (NFATc3) inhibited the expression of COX-2 induced by ET-1, and NFATc3 could also bound to the -GGAAA- sequence in the promoter region of rat COX-2 gene, indicating that calcineurin/NFATc3 signaling participated in the transcriptional regulation of COX-2 following ET-1 treatment.	Cyclosporine	13-26	endothelin 1	Rattus norvegicus	354-358
24291639-6	2014	Furthermore, cyclosporin A (CsA) and knockdown of nuclear factor of activated T-cells c3 (NFATc3) inhibited the expression of COX-2 induced by ET-1, and NFATc3 could also bound to the -GGAAA- sequence in the promoter region of rat COX-2 gene, indicating that calcineurin/NFATc3 signaling participated in the transcriptional regulation of COX-2 following ET-1 treatment.	Cyclosporine	28-31	endothelin 1	Rattus norvegicus	143-147
24291639-6	2014	Furthermore, cyclosporin A (CsA) and knockdown of nuclear factor of activated T-cells c3 (NFATc3) inhibited the expression of COX-2 induced by ET-1, and NFATc3 could also bound to the -GGAAA- sequence in the promoter region of rat COX-2 gene, indicating that calcineurin/NFATc3 signaling participated in the transcriptional regulation of COX-2 following ET-1 treatment.	Cyclosporine	28-31	nuclear factor of activated T-cells 3	Rattus norvegicus	153-159
24291639-6	2014	Furthermore, cyclosporin A (CsA) and knockdown of nuclear factor of activated T-cells c3 (NFATc3) inhibited the expression of COX-2 induced by ET-1, and NFATc3 could also bound to the -GGAAA- sequence in the promoter region of rat COX-2 gene, indicating that calcineurin/NFATc3 signaling participated in the transcriptional regulation of COX-2 following ET-1 treatment.	Cyclosporine	28-31	nuclear factor of activated T-cells 3	Rattus norvegicus	153-159
24212378-4	2014	From a set of potential P-gp inhibitors, clarithromycin, cyclosporin A, itraconazole, ketoconazole, quinidine, and ritonavir inhibited P-gp-mediated transport of dabigatran etexilate over a concentration range that may hypothetically occur in the intestine.	Cyclosporine	57-70	ATP binding cassette subfamily B member 1	Homo sapiens	24-28
24551078-8	2014	Moreover, cyclosporine A treatment, which has been shown to prevent dephosphorylation and nuclear translocation of NFAT isoforms, resulted in enhanced C/EBPalpha binding.	Cyclosporine	10-24	CCAAT enhancer binding protein alpha	Homo sapiens	151-161
24522145-5	2014	CYP3A4*22 carriers showed a significant lower clearance for cyclosporine (-15%), and a trend was observed for everolimus (-7%) and tacrolimus (-16%).	Cyclosporine	60-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
24364805-1	2014	Using positron emission tomography (PET), (11)C-verapamil as the P-gp substrate, and cyclosporine A (CsA) as the P-gp inhibitor, we showed that the magnitude of P-gp-based drug interactions at the human blood-brain barrier (BBB) is modest.	Cyclosporine	101-104	ATP binding cassette subfamily B member 1	Homo sapiens	113-117
24364805-1	2014	Using positron emission tomography (PET), (11)C-verapamil as the P-gp substrate, and cyclosporine A (CsA) as the P-gp inhibitor, we showed that the magnitude of P-gp-based drug interactions at the human blood-brain barrier (BBB) is modest.	Cyclosporine	101-104	ATP binding cassette subfamily B member 1	Homo sapiens	113-117
24364805-2	2014	However, such interactions at clinically relevant CsA blood concentrations may be greater for substrates where P-gp plays an even larger role (fractional contribution of P-gp, ft &gt; 0.97) in preventing the CNS entry of the drug (e.g., nelfinavir).	Cyclosporine	50-53	ATP binding cassette subfamily B member 1	Homo sapiens	111-115
24364805-6	2014	Then, using these data, as well as in vitro data in LLCPK1 cells expressing the human P-gp, we predicted that CsA (at clinically relevant blood concentration of 1.5 muM) will increase the distribution of nelfinavir into the human brain by 236%.	Cyclosporine	110-113	ATP binding cassette subfamily B member 1	Homo sapiens	86-90
24291231-7	2014	Disruption of the interaction between cyclophilin-D and F1F0-ATP synthase by cyclosporin A attenuated the mitochondrial protection induced by hypoxic preconditioning in both NARP cybrids and wild-type 143B cells.	Cyclosporine	77-90	peptidylprolyl isomerase F	Homo sapiens	38-51
24333142-10	2014	Mice treated with CSA until day 60, but not mTOR inhibitors, developed severe chronic GVHD followed by adoptive transfer of the pathogenic CD4(+) T cells isolated from H2-Ab1 KO into C3H model.	Cyclosporine	18-21	histocompatibility 2, class II antigen A, beta 1	Mus musculus	168-174
24269672-1	2014	We previously demonstrated that a cellular factor, cyclosporin A (CsA) associated helicase-like protein (CAHL) that is identical to YTH domain containing 2 (YTHDC2), forms trimer complex with cyclophilin B and NS5B of hepatitis C virus (HCV) and facilitates HCV genome replication.	Cyclosporine	66-69	YTH domain containing 2	Homo sapiens	157-163
24212378-4	2014	From a set of potential P-gp inhibitors, clarithromycin, cyclosporin A, itraconazole, ketoconazole, quinidine, and ritonavir inhibited P-gp-mediated transport of dabigatran etexilate over a concentration range that may hypothetically occur in the intestine.	Cyclosporine	57-70	ATP binding cassette subfamily B member 1	Homo sapiens	135-139
24061445-3	2014	The aim of this study was to investigate the impact of the POR*28 allele on Tac and cyclosporine A (CsA) immunosuppressive therapies.	Cyclosporine	100-103	cytochrome p450 oxidoreductase	Homo sapiens	59-62
24270972-9	2014	Compared with the two CsA groups and the control group, the proportion of CD4+CD25+ regulatory T cells of rhIL-10 groups was significantly upregulated on the 4th and 7th days following surgery.	Cyclosporine	22-25	T-cell surface glycoprotein CD4	Oryctolagus cuniculus	74-77
24061445-7	2014	For CsA, POR*28/*28 patients not expressing CYP3A5 and not carrying the CYP3A4*22 decrease-of-function allele showed 15% lower CsA dose-adjusted predose concentrations (P = 0.01), indicating also increased CYP3A4 activity.	Cyclosporine	4-7	cytochrome p450 oxidoreductase	Homo sapiens	9-12
24061445-7	2014	For CsA, POR*28/*28 patients not expressing CYP3A5 and not carrying the CYP3A4*22 decrease-of-function allele showed 15% lower CsA dose-adjusted predose concentrations (P = 0.01), indicating also increased CYP3A4 activity.	Cyclosporine	127-130	cytochrome p450 oxidoreductase	Homo sapiens	9-12
24369269-3	2014	Before initiation of triple therapy, all patients switched from tacrolimus to cyclosporine, which has a lower inhibitory effect on CYP3A4 and CYP3A5 than tacrolimus.	Cyclosporine	78-90	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	131-137
24465763-12	2014	The forced expression of constitutively active NFATc1 rescued osteoclastogenesis in BMM cultures treated with CsA, but not that treated with arctigenin.	Cyclosporine	110-113	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	47-53
24369269-3	2014	Before initiation of triple therapy, all patients switched from tacrolimus to cyclosporine, which has a lower inhibitory effect on CYP3A4 and CYP3A5 than tacrolimus.	Cyclosporine	78-90	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	142-148
24596624-7	2014	[(3)H]Paclitaxel uptake was markedly inhibited by cyclosporine and verapamil, well-known substrates of P-glycoprotein (P-gp) transporter.	Cyclosporine	50-62	ATP binding cassette subfamily B member 1	Homo sapiens	103-117
24596624-7	2014	[(3)H]Paclitaxel uptake was markedly inhibited by cyclosporine and verapamil, well-known substrates of P-glycoprotein (P-gp) transporter.	Cyclosporine	50-62	ATP binding cassette subfamily B member 1	Homo sapiens	119-123
24824254-6	2014	Furthermore, the UII effects were significantly inhibited by treatment with its receptor antagonist SB710411, Rho kinase inhibitor Y27632, protein kinase C (PKC) inhibitor H7, mitogen-activated protein kinase inhibitor PD98059, calcineurin inhibitor cyclosporine A, and the Ca(2+)channel blocker nicardipine.	Cyclosporine	250-264	urotensin 2	Rattus norvegicus	17-20
24971338-8	2014	Prolonged CsA exposure aggravated renal damage, without clear changes on the traditional markers, but with changes in serums TGF- beta and IL-7, TBARs clearance, and kidney TGF-beta and mTOR.	Cyclosporine	10-13	transforming growth factor, beta 1	Rattus norvegicus	125-134
24971338-8	2014	Prolonged CsA exposure aggravated renal damage, without clear changes on the traditional markers, but with changes in serums TGF- beta and IL-7, TBARs clearance, and kidney TGF-beta and mTOR.	Cyclosporine	10-13	transforming growth factor, beta 1	Rattus norvegicus	173-181
25277512-10	2014	As a calcineurin-specific inhibitor, CsA inhibited (3)H-Leu incorporation, surface area, mRNA expressions of ANP, BNP, beta-MHC, CnAbeta and protein expression of CnAbeta of AngII-induced cardiomyocytes.	Cyclosporine	37-40	natriuretic peptide B	Rattus norvegicus	114-117
25277512-10	2014	As a calcineurin-specific inhibitor, CsA inhibited (3)H-Leu incorporation, surface area, mRNA expressions of ANP, BNP, beta-MHC, CnAbeta and protein expression of CnAbeta of AngII-induced cardiomyocytes.	Cyclosporine	37-40	angiotensinogen	Rattus norvegicus	174-179
23998925-0	2014	Comment on "Carbamylated erythropoietin ameliorates cyclosporine nephropathy without stimulating erythropoiesis".	Cyclosporine	52-64	erythropoietin	Homo sapiens	25-39
26155135-3	2014	The results showed that both DEX and CsA dose-dependently inhibited the production of eleven cytokines: interleukin (IL)-2, IL-4, IL-5, IL-6, IL-13, IL-17, interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF).	Cyclosporine	37-40	interleukin 4	Homo sapiens	124-128
26155135-3	2014	The results showed that both DEX and CsA dose-dependently inhibited the production of eleven cytokines: interleukin (IL)-2, IL-4, IL-5, IL-6, IL-13, IL-17, interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF).	Cyclosporine	37-40	interleukin 6	Homo sapiens	136-140
26155135-3	2014	The results showed that both DEX and CsA dose-dependently inhibited the production of eleven cytokines: interleukin (IL)-2, IL-4, IL-5, IL-6, IL-13, IL-17, interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF).	Cyclosporine	37-40	interleukin 13	Homo sapiens	142-147
26155135-3	2014	The results showed that both DEX and CsA dose-dependently inhibited the production of eleven cytokines: interleukin (IL)-2, IL-4, IL-5, IL-6, IL-13, IL-17, interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF).	Cyclosporine	37-40	interferon gamma	Homo sapiens	156-183
26155135-3	2014	The results showed that both DEX and CsA dose-dependently inhibited the production of eleven cytokines: interleukin (IL)-2, IL-4, IL-5, IL-6, IL-13, IL-17, interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF).	Cyclosporine	37-40	tumor necrosis factor	Homo sapiens	186-213
26155135-3	2014	The results showed that both DEX and CsA dose-dependently inhibited the production of eleven cytokines: interleukin (IL)-2, IL-4, IL-5, IL-6, IL-13, IL-17, interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF).	Cyclosporine	37-40	tumor necrosis factor	Homo sapiens	215-224
24335929-11	2014	Hubs of these networks were as follows: P38 mitogen-activated protein kinases (P38 MAPK), p42/p44 MAP kinase (ERK1/2) and glutathione for Network 1; protein kinase B (Akt), nuclear factor kappa B (NFkB) and ERK for Network 2; and dexamethasone, tretinoin, and cyclosporin A for Network 3.	Cyclosporine	260-273	mitogen-activated protein kinase 1	Homo sapiens	110-113
24990333-9	2014	CONCLUSION: Combining agents that are mainly metabolized by CYP3A4 such as LPZ elevates the blood concentrations of TAC and CSA, which could leading to adverse events.	Cyclosporine	124-127	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-66
24335929-11	2014	Hubs of these networks were as follows: P38 mitogen-activated protein kinases (P38 MAPK), p42/p44 MAP kinase (ERK1/2) and glutathione for Network 1; protein kinase B (Akt), nuclear factor kappa B (NFkB) and ERK for Network 2; and dexamethasone, tretinoin, and cyclosporin A for Network 3.	Cyclosporine	260-273	mitogen-activated protein kinase 3	Homo sapiens	110-116
23881596-10	2014	Subsequently, the validated model was used to investigate the impact of coadministration of cyclosporine (ciclosporin), an inhibitor of OATPs, BCRP and NTCP, on the exposure of rosuvastatin in healthy volunteers.	Cyclosporine	92-104	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	143-147
23881596-10	2014	Subsequently, the validated model was used to investigate the impact of coadministration of cyclosporine (ciclosporin), an inhibitor of OATPs, BCRP and NTCP, on the exposure of rosuvastatin in healthy volunteers.	Cyclosporine	92-104	solute carrier family 10 member 1	Homo sapiens	152-156
23881596-10	2014	Subsequently, the validated model was used to investigate the impact of coadministration of cyclosporine (ciclosporin), an inhibitor of OATPs, BCRP and NTCP, on the exposure of rosuvastatin in healthy volunteers.	Cyclosporine	106-117	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	143-147
23881596-10	2014	Subsequently, the validated model was used to investigate the impact of coadministration of cyclosporine (ciclosporin), an inhibitor of OATPs, BCRP and NTCP, on the exposure of rosuvastatin in healthy volunteers.	Cyclosporine	106-117	solute carrier family 10 member 1	Homo sapiens	152-156
24970700-3	2014	Selective inhibition of NFAT by cyclosporine A and a competitive peptide inhibitor 11R-VIVIT inhibited endotoxin-induced expression of iNOS and nitric oxide (NO) release.	Cyclosporine	32-46	nitric oxide synthase 2, inducible	Mus musculus	135-139
24527031-3	2014	Cytochrome P-450 isoenzymes CYP3A4 and CYP3A5 and protein P-glycoprotein (P-gp) are involved in CyA bioavailability.	Cyclosporine	96-99	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	28-34
24527031-3	2014	Cytochrome P-450 isoenzymes CYP3A4 and CYP3A5 and protein P-glycoprotein (P-gp) are involved in CyA bioavailability.	Cyclosporine	96-99	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	39-45
24527031-3	2014	Cytochrome P-450 isoenzymes CYP3A4 and CYP3A5 and protein P-glycoprotein (P-gp) are involved in CyA bioavailability.	Cyclosporine	96-99	ATP binding cassette subfamily B member 1	Homo sapiens	58-72
24527031-3	2014	Cytochrome P-450 isoenzymes CYP3A4 and CYP3A5 and protein P-glycoprotein (P-gp) are involved in CyA bioavailability.	Cyclosporine	96-99	ATP binding cassette subfamily B member 1	Homo sapiens	74-78
24041534-8	2013	Moreover, TNF-alpha significantly enhanced apoptotic cell death induced by cisplatin, cyclosporine A, tacrolimus and azidothymidine.	Cyclosporine	86-100	tumor necrosis factor	Mus musculus	10-19
24062016-8	2014	In addition, collapse of mitochondrial membrane potential, mitochondrial swelling, and release of cytochrome c following METH treatment were well inhibited by pretreatment of mitochondria with cyclosporin A and butylated hydroxytoluene.	Cyclosporine	193-206	cytochrome c, somatic	Homo sapiens	98-110
24391506-8	2014	In primary murine B cells, addition of cyclosporine (CsA) resulted in a significant decrease in M2-induced IL-10 levels as well as IRF4 expression, emphasizing the importance of the NFAT pathway in M2- -mediated induction of IL-10.	Cyclosporine	39-51	interleukin 10	Mus musculus	107-112
24391506-8	2014	In primary murine B cells, addition of cyclosporine (CsA) resulted in a significant decrease in M2-induced IL-10 levels as well as IRF4 expression, emphasizing the importance of the NFAT pathway in M2- -mediated induction of IL-10.	Cyclosporine	39-51	interleukin 10	Mus musculus	225-230
24391506-8	2014	In primary murine B cells, addition of cyclosporine (CsA) resulted in a significant decrease in M2-induced IL-10 levels as well as IRF4 expression, emphasizing the importance of the NFAT pathway in M2- -mediated induction of IL-10.	Cyclosporine	53-56	interleukin 10	Mus musculus	107-112
24391506-8	2014	In primary murine B cells, addition of cyclosporine (CsA) resulted in a significant decrease in M2-induced IL-10 levels as well as IRF4 expression, emphasizing the importance of the NFAT pathway in M2- -mediated induction of IL-10.	Cyclosporine	53-56	interleukin 10	Mus musculus	225-230
24120885-5	2013	Additionally, the P-gp inhibitors, verapamil and cyclosporin A, significantly decreased the efflux of AC.	Cyclosporine	49-62	ATP binding cassette subfamily B member 1	Homo sapiens	18-22
24244623-0	2013	Exposure to nerve growth factor worsens nephrotoxic effect induced by Cyclosporine A in HK-2 cells.	Cyclosporine	70-84	nerve growth factor	Homo sapiens	12-31
24282237-6	2013	Post-anoxia MEND is ablated in DHHC5-deficient hearts, inhibited by cyclosporine A (CsA) and adenosine, promoted by staurosporine (STS), reduced in hearts lacking PLM, and correlates with impaired post-anoxia contractile function.	Cyclosporine	68-82	zinc finger DHHC-type palmitoyltransferase 5	Homo sapiens	31-36
24282237-6	2013	Post-anoxia MEND is ablated in DHHC5-deficient hearts, inhibited by cyclosporine A (CsA) and adenosine, promoted by staurosporine (STS), reduced in hearts lacking PLM, and correlates with impaired post-anoxia contractile function.	Cyclosporine	84-87	zinc finger DHHC-type palmitoyltransferase 5	Homo sapiens	31-36
24064216-7	2013	The intracellularly trapped misprocessed protein associates more with chaperone Hsp70, and the treatment with cyclosporine A reduces the association of mutant P-gp, thus allowing it to be trafficked to the cell surface.	Cyclosporine	110-124	ATP binding cassette subfamily B member 1	Homo sapiens	159-163
24634818-7	2014	In all models, we observed that pharmacological inhibition of mPTP opening with the CypD inhibitor cyclosporin A was sufficient to prevent insulin resistance at the level of insulin-stimulated GLUT4 translocation to the plasma membrane.	Cyclosporine	99-112	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	84-88
24634818-7	2014	In all models, we observed that pharmacological inhibition of mPTP opening with the CypD inhibitor cyclosporin A was sufficient to prevent insulin resistance at the level of insulin-stimulated GLUT4 translocation to the plasma membrane.	Cyclosporine	99-112	solute carrier family 2 (facilitated glucose transporter), member 4	Mus musculus	193-198
24196705-7	2013	Finally, we show that we can pharmacologically induce wild-type HIV-1 infection to stimulate IFN secretion and an antiviral state using a non-immunosuppressive cyclosporine analogue.	Cyclosporine	160-172	interferon alpha 1	Homo sapiens	93-96
24064216-0	2013	Mutations in intracellular loops 1 and 3 lead to misfolding of human P-glycoprotein (ABCB1) that can be rescued by cyclosporine A, which reduces its association with chaperone Hsp70.	Cyclosporine	115-129	ATP binding cassette subfamily B member 1	Homo sapiens	69-83
24064216-0	2013	Mutations in intracellular loops 1 and 3 lead to misfolding of human P-glycoprotein (ABCB1) that can be rescued by cyclosporine A, which reduces its association with chaperone Hsp70.	Cyclosporine	115-129	ATP binding cassette subfamily B member 1	Homo sapiens	85-90
24244623-3	2013	Considering that nerve growth factor exerts beneficial effects in the treatment of major central and peripheral neurodegenerative diseases, skin and corneal ulcers, we asked whether nerve growth factor could also exert a role in Cyclosporine A-induced graft nephrotoxicity.	Cyclosporine	229-243	nerve growth factor	Homo sapiens	182-201
24244623-4	2013	Our hypothesis was raised from basic evidence indicating that Cyclosporine A-inhibition of calcineurin-NFAT pathway increases nerve growth factor expression levels.	Cyclosporine	62-76	nerve growth factor	Homo sapiens	126-145
24244623-5	2013	Therefore, we investigated the involvement of nerve growth factor and its receptors in the damage exerted by Cyclosporine A in tubular renal cells, HK-2.	Cyclosporine	109-123	nerve growth factor	Homo sapiens	46-65
24244623-6	2013	Our results showed that in HK-2 cells combined treatment with Cyclosporine A + nerve growth factor induced a significant reduction in cell vitality concomitant with a down-regulation of Cyclin D1 and up-regulation of p21 levels respect to cells treated with Cyclosporine A alone.	Cyclosporine	62-76	nerve growth factor	Homo sapiens	79-98
24244623-6	2013	Our results showed that in HK-2 cells combined treatment with Cyclosporine A + nerve growth factor induced a significant reduction in cell vitality concomitant with a down-regulation of Cyclin D1 and up-regulation of p21 levels respect to cells treated with Cyclosporine A alone.	Cyclosporine	62-76	cyclin dependent kinase inhibitor 1A	Homo sapiens	217-220
24244623-6	2013	Our results showed that in HK-2 cells combined treatment with Cyclosporine A + nerve growth factor induced a significant reduction in cell vitality concomitant with a down-regulation of Cyclin D1 and up-regulation of p21 levels respect to cells treated with Cyclosporine A alone.	Cyclosporine	258-272	nerve growth factor	Homo sapiens	79-98
24244623-8	2013	In addition we observed that the combined exposure to Cyclosporine A + nerve growth factor promoted an up-regulation of p75 (NTR) and its target genes, p53 and BAD leading to the activation of intrinsic apoptosis.	Cyclosporine	54-68	tumor protein p53	Homo sapiens	152-155
24244623-10	2013	We describe two new mechanisms by which nerve growth factor promotes growth arrest and apoptosis in tubular renal cells exposed to Cyclosporine A.	Cyclosporine	131-145	nerve growth factor	Homo sapiens	40-59
23851346-4	2013	METHODS: Fourteen healthy volunteers received morphine (0.1 mg/kg, 1-h IV infusion) in a crossover study without (control) or with the infusion of validated P-glycoprotein inhibitor cyclosporine (5 mg/kg, 2-h infusion).	Cyclosporine	182-194	ATP binding cassette subfamily B member 1	Homo sapiens	157-171
23965946-8	2013	CONCLUSION: Insulin resistance on glucose load (log post-glucose-IR), plasma high-density lipoprotein cholesterol levels, and smoking were significantly associated with CSA (r=0.225, P=0.004; r=-0.313, P&lt;0.001; and r=0.258, P=0.001, respectively).	Cyclosporine	169-172	insulin	Homo sapiens	12-19
22417245-0	2013	Downregulation of circulating CD4+ CD25(bright) Foxp3+ T cells by cyclosporine therapy and correlation with clinical response in psoriasis patients: report of three cases.	Cyclosporine	66-78	CD4 molecule	Homo sapiens	30-33
24112857-9	2013	Both CsA and CPZ down-regulated processes related to extracellular matrix (ECM) remodelling, BA homeostasis, Fxr signalling, and energy metabolism.	Cyclosporine	5-8	nuclear receptor subfamily 1, group H, member 4	Mus musculus	109-112
23853103-2	2013	The trials from decades ago using Cyclosporine A in significantly lower dosages than used for organ transplantation and in similar dosages that have increased T regulatory cell populations in conditions such as atopic dermatitis, demonstrated very high initial insulin-free remission rates when administered immediately after diagnosis.	Cyclosporine	34-48	insulin	Homo sapiens	261-268
23853103-3	2013	Over time, all newly diagnosed type 1 patients given Cyclosporine A required insulin.	Cyclosporine	53-67	insulin	Homo sapiens	77-84
23953030-3	2013	The canalicular transport of irinotecan and SN-38G is mediated by ABCC2 (MRP2) and ABCB1 (MDR1) which are both inhibited by ciclosporin.	Cyclosporine	124-135	ATP binding cassette subfamily B member 1	Homo sapiens	83-88
23953030-3	2013	The canalicular transport of irinotecan and SN-38G is mediated by ABCC2 (MRP2) and ABCB1 (MDR1) which are both inhibited by ciclosporin.	Cyclosporine	124-135	ATP binding cassette subfamily B member 1	Homo sapiens	90-94
24228106-6	2013	CsA pretreated JAR cells (red) were added to HUVEC monolayers (green) activated with either necrotic JAR cells or tumor necrosis factor alpha (TNFalpha).	Cyclosporine	0-3	tumor necrosis factor	Homo sapiens	114-141
24228106-11	2013	Moreover, CsA pretreatment up-regulated Titin expression, down-regulated E-cadherin expression, improved MMP2 and MMP9 activity, and increased the CXCL12 secretion in JAR cells.	Cyclosporine	10-13	cadherin 1	Homo sapiens	73-83
23908147-1	2013	Cyclosporine exhibits pharmacokinetic and pharmacodynamic variability in renal transplant recipients (RTR) attributed to P-glycoprotein (P-gp), an ABCB1 efflux transporter that influences bioavailability and intracellular distribution.	Cyclosporine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	121-135
23908147-1	2013	Cyclosporine exhibits pharmacokinetic and pharmacodynamic variability in renal transplant recipients (RTR) attributed to P-glycoprotein (P-gp), an ABCB1 efflux transporter that influences bioavailability and intracellular distribution.	Cyclosporine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	137-141
23908147-1	2013	Cyclosporine exhibits pharmacokinetic and pharmacodynamic variability in renal transplant recipients (RTR) attributed to P-glycoprotein (P-gp), an ABCB1 efflux transporter that influences bioavailability and intracellular distribution.	Cyclosporine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	147-152
23908147-5	2013	ABCB1 gene expression was assessed in PBMCs pre-dose and 4 hours after cyclosporine.	Cyclosporine	71-83	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
24157049-6	2013	RESULTS: CsA treatment caused diabetes, renal dysfunction, tubulointerstitial inflammation (ED-1-positive cells), and fibrosis, which were accompanied by an increase in 8-OHdG production and upregulation of TGF-beta1, caspase-3, and LC3-II.	Cyclosporine	9-12	transforming growth factor, beta 1	Rattus norvegicus	207-216
23173828-2	2013	Hence, the authors hypothesize that cyclosporin A (CsA) may regulate TGM-2 via ROS, and this regulation may have a role in the pathogenesis of CsA-induced gingival overgrowth.	Cyclosporine	51-54	transglutaminase 2	Homo sapiens	69-74
23173828-2	2013	Hence, the authors hypothesize that cyclosporin A (CsA) may regulate TGM-2 via ROS, and this regulation may have a role in the pathogenesis of CsA-induced gingival overgrowth.	Cyclosporine	143-146	transglutaminase 2	Homo sapiens	69-74
23670590-5	2013	Microdialysis-based pharmacokinetic studies demonstrated that administration of the P-gp inhibitor cyclosporin A resulted in increased brain levels of escitalopram without altering plasma escitalopram levels in the rat, thereby showing that P-gp restricts escitalopram transport across the blood-brain barrier (BBB) in vivo.	Cyclosporine	99-112	phosphoglycolate phosphatase	Rattus norvegicus	84-88
23670590-5	2013	Microdialysis-based pharmacokinetic studies demonstrated that administration of the P-gp inhibitor cyclosporin A resulted in increased brain levels of escitalopram without altering plasma escitalopram levels in the rat, thereby showing that P-gp restricts escitalopram transport across the blood-brain barrier (BBB) in vivo.	Cyclosporine	99-112	phosphoglycolate phosphatase	Rattus norvegicus	241-245
23173828-7	2013	TGM-2 protein induced by CsA was found in HGFs in a dose- and time-dependent manner (P &lt;0.05).	Cyclosporine	25-28	transglutaminase 2	Homo sapiens	0-5
23173828-8	2013	The addition of PD98059, LY294002, NAC, curcumin, EGCG, and SB203580 markedly inhibited TGM-2 expression induced by CsA (P &lt;0.05).	Cyclosporine	116-119	transglutaminase 2	Homo sapiens	88-93
23173828-9	2013	CONCLUSIONS: These results demonstrate that CsA significantly upregulates intracellular ROS generation and elevates TGM-2 expression in HGFs.	Cyclosporine	44-47	transglutaminase 2	Homo sapiens	116-121
23173828-10	2013	In addition, TGM-2 induced by CsA is downregulated by PD98059, LY294002, NAC, curcumin, EGCG, and SB203580.	Cyclosporine	30-33	transglutaminase 2	Homo sapiens	13-18
24088131-0	2013	Long-term effects of ABCB1 and SXR SNPs on the systemic exposure to cyclosporine in pediatric kidney transplant patients.	Cyclosporine	68-80	nuclear receptor subfamily 1 group I member 2	Homo sapiens	31-34
24088131-2	2013	The objective of this study was to evaluate the effects of ABCB1 and SXR SNPs on cyclosporine exposure in a group of kidney transplant patients followed up from childhood to adulthood.	Cyclosporine	81-93	nuclear receptor subfamily 1 group I member 2	Homo sapiens	69-72
24088131-7	2013	CONCLUSION: The presence of specific ABCB1 and SXR SNPs could significantly affect cyclosporine exposure during a kidney transplant patient"s development from childhood to adulthood in a time-dependent fashion.	Cyclosporine	83-95	ATP binding cassette subfamily B member 1	Homo sapiens	37-42
24088131-7	2013	CONCLUSION: The presence of specific ABCB1 and SXR SNPs could significantly affect cyclosporine exposure during a kidney transplant patient"s development from childhood to adulthood in a time-dependent fashion.	Cyclosporine	83-95	nuclear receptor subfamily 1 group I member 2	Homo sapiens	47-50
23855618-5	2013	Microarray analysis revealed enhanced intragraft expression of the B cell attracting chemokine CXCL13 early during CsA treatment.	Cyclosporine	115-118	C-X-C motif chemokine ligand 13	Rattus norvegicus	95-101
23752066-2	2013	The CNI cyclosporine A (CsA) can promote renal tumor growth through activation of the proto-oncogene ras and over-expression of the angiogenic cytokine VEGF; the ras activation also induces over-expression of the cytoprotective enzyme HO-1, which promotes survival of renal cancer cells.	Cyclosporine	24-27	vascular endothelial growth factor A	Homo sapiens	152-156
24133577-1	2013	Our previous studies have demonstrated that cyclosporin A (CsA) promotes the proliferation and migration of human trophoblasts via the mitgen-activated protein kinase-3/1 (MAPK3/1) pathway.	Cyclosporine	59-62	mitogen-activated protein kinase 3	Homo sapiens	172-179
24133577-7	2013	Blocking of the MAPK3/1 signal abrogated the enhanced PCNA expression and migration in trophoblasts by CsA.	Cyclosporine	103-106	mitogen-activated protein kinase 3	Homo sapiens	16-21
24133577-8	2013	In addition, CsA increased the phosphorylation of NF-kappaB p65 and the inhibitor I-kappaB in human trophoblasts in a time-related manner.	Cyclosporine	13-16	nuclear factor kappa B subunit 1	Homo sapiens	50-59
24133577-11	2013	This CsA-induced enhancement in the expression and migration of trophoblasts was abolished by pretreatment with pyrrolidine dithiocarbamate, a specific NF-kappaB inhibitor.	Cyclosporine	5-8	nuclear factor kappa B subunit 1	Homo sapiens	152-161
24133577-12	2013	Thus, our results suggest that CsA promotes PCNA expression and migration of human trophoblasts via MAPK-mediated NF-kappaB activation.	Cyclosporine	31-34	mitogen-activated protein kinase 3	Homo sapiens	100-104
24133577-12	2013	Thus, our results suggest that CsA promotes PCNA expression and migration of human trophoblasts via MAPK-mediated NF-kappaB activation.	Cyclosporine	31-34	nuclear factor kappa B subunit 1	Homo sapiens	114-123
23846495-11	2013	Finally, cyclosporine A and CyPA-peptidyl-prolyl cis-trans isomerase mutant, R55A, inhibited AngII-stimulated CyPA and p47phox association in VSMC, suggesting that peptidyl-prolyl cis-trans isomerase activity was required for their interaction.	Cyclosporine	9-23	angiotensinogen	Homo sapiens	93-98
23855618-6	2013	Increase in CXCL13 expression is accompanied by enhanced B cell infiltration with local and systemic IgG production and C3d deposition as early as 5 days upon CsA withdrawal.	Cyclosporine	159-162	C-X-C motif chemokine ligand 13	Rattus norvegicus	12-18
24218893-5	2013	RESULTS: The level of IL-2 in Jurkat T cells exposed to 100 microg/ml PM2.5 was significantly lower than parallel groups, but higher than PM2.5 + CSA group and PM2.5 + EGTA group (P &lt; 0.05).	Cyclosporine	146-149	interleukin 2	Homo sapiens	22-26
23470307-13	2013	Similarly, the CSA increase at 12 h was abolished by inhibitors of the PI3K/Akt pathway as well as by AR inhibition.	Cyclosporine	15-18	AKT serine/threonine kinase 1	Rattus norvegicus	76-79
23990993-7	2013	Additionally, CsA inhibited SOCS-1 expression (the key negative regulator of IFN-alpha/beta), but not SOCS-2 or SOCS-3.	Cyclosporine	14-17	interferon alpha 1	Homo sapiens	77-86
23990993-6	2013	Exploring the underlying mechanisms showed that CsA promoted Interferon Regulatory Factor-5 (IRF-5) expression (a key positive regulator of the type I IFN signaling pathway), but not IRF-1, IRF-3, or IRF-7.	Cyclosporine	48-51	interferon regulatory factor 7	Homo sapiens	200-205
23845906-6	2013	Inhibition of Cyp-D by its inhibitor cyclosporine A (CsA), or by shRNA-mediated knockdown suppressed cisplatin-induced pancreatic cancer cell death.	Cyclosporine	53-56	peptidylprolyl isomerase F	Homo sapiens	14-19
23845906-7	2013	Both CsA and Cyp-D knockdown also disrupted the Cyp-D/p53 complex formation in mitochondria.	Cyclosporine	5-8	peptidylprolyl isomerase F	Homo sapiens	48-53
23845906-7	2013	Both CsA and Cyp-D knockdown also disrupted the Cyp-D/p53 complex formation in mitochondria.	Cyclosporine	5-8	tumor protein p53	Homo sapiens	54-57
23588308-6	2013	In a different group of BMT patients treated with cyclosporine, the magnitude of interaction with IL-6 was underpredicted by threefold.	Cyclosporine	50-62	interleukin 6	Homo sapiens	98-102
23499874-8	2013	However, blocking the mitochondrial permeability transition pore (mPTP) opening with cyclosporin A completely abolished both apoptosis and autophagy due to nilotinib.	Cyclosporine	85-98	protein tyrosine phosphatase, receptor type, U	Mus musculus	66-70
23951193-6	2013	Gene expression analysis revealed that cyclosporine A inhibited the hepatic levels of cholesterol 7-alpha-hydroxylase, concomitantly with the increase in hepatic and intestinal expression of ATP Binding Cassette G5.	Cyclosporine	39-53	cytochrome P450, family 7, subfamily a, polypeptide 1	Mus musculus	86-117
23951193-8	2013	These results indicate that treatment of mice with cyclosporine A impaired the macrophage reverse cholesterol transport by reducing fecal sterol excretion, possibly through the inhibition of cholesterol 7-alpha-hydroxylase expression.	Cyclosporine	51-65	cytochrome P450, family 7, subfamily a, polypeptide 1	Mus musculus	191-222
23676782-10	2013	There was also statistically significant reduction from before 0.05% cyclosporine A treatment to after treatment in tear levels of IL-4, IL-5, IL-17A, TNFalpha, IFN-gamma, and eotaxin (P &lt; 0.05).	Cyclosporine	69-83	interleukin 4	Homo sapiens	131-135
23720091-0	2013	Functional G1199A ABCB1 polymorphism may have an effect on cyclosporine blood concentration in renal transplanted patients.	Cyclosporine	59-71	ATP binding cassette subfamily B member 1	Homo sapiens	18-23
23684917-6	2013	QGR, dexamethasone, cyclosporine A, Bay 11-7085 (an inhibitor of NF-kappaB activation) and cell signaling ERK inhibitor attenuated the TNF-alpha-induced formation of inflammatory mediators and activation of the NF-kappaB and ERK.	Cyclosporine	20-34	tumor necrosis factor	Homo sapiens	135-144
23720091-1	2013	Cyclosporine A (CsA) shows significant inter-individual variability in its pharmacokinetics, which may be due to polymorphisms in ABCB-1 genes coding for P-glycoprotein.	Cyclosporine	0-14	ATP binding cassette subfamily B member 1	Homo sapiens	130-136
23720091-1	2013	Cyclosporine A (CsA) shows significant inter-individual variability in its pharmacokinetics, which may be due to polymorphisms in ABCB-1 genes coding for P-glycoprotein.	Cyclosporine	0-14	ATP binding cassette subfamily B member 1	Homo sapiens	154-168
23720091-1	2013	Cyclosporine A (CsA) shows significant inter-individual variability in its pharmacokinetics, which may be due to polymorphisms in ABCB-1 genes coding for P-glycoprotein.	Cyclosporine	16-19	ATP binding cassette subfamily B member 1	Homo sapiens	130-136
23720091-1	2013	Cyclosporine A (CsA) shows significant inter-individual variability in its pharmacokinetics, which may be due to polymorphisms in ABCB-1 genes coding for P-glycoprotein.	Cyclosporine	16-19	ATP binding cassette subfamily B member 1	Homo sapiens	154-168
23720091-6	2013	Polymorphisms of ABCB-1 have only a minor effect on CsA blood concentrations.	Cyclosporine	52-55	ATP binding cassette subfamily B member 1	Homo sapiens	17-23
23822648-6	2013	The renal vasoconstriction in Cs or LCs to NA, PE and Ang II were lower than control by ~35-48% (all p &lt; 0.05).	Cyclosporine	30-32	angiotensinogen	Rattus norvegicus	54-60
22996305-2	2013	Cyclosporin A (CsA), a well-known immunosuppressant agent, is also a substrate of CYP3A and P-gp.	Cyclosporine	0-13	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	82-87
22996305-2	2013	Cyclosporin A (CsA), a well-known immunosuppressant agent, is also a substrate of CYP3A and P-gp.	Cyclosporine	0-13	phosphoglycolate phosphatase	Rattus norvegicus	92-96
22996305-2	2013	Cyclosporin A (CsA), a well-known immunosuppressant agent, is also a substrate of CYP3A and P-gp.	Cyclosporine	15-18	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	82-87
22996305-2	2013	Cyclosporin A (CsA), a well-known immunosuppressant agent, is also a substrate of CYP3A and P-gp.	Cyclosporine	15-18	phosphoglycolate phosphatase	Rattus norvegicus	92-96
23421623-6	2013	Pretreatment with cyclosporin A or L-carnitine, which might inhibit the transport of (13)C-enriched compounds into chloroplasts and mitochondria, caused a remarkable decline in yields of both [U-(13)C]Gluc and [3-(13)C]Ser in H(13)CHO-treated Arabidopsis.	Cyclosporine	18-31	beta glucosidase 25	Arabidopsis thaliana	201-205
23765110-6	2013	RESULTS: Concomitant administration of CsA and NAC significantly improved renal function and attenuated tubulointerstitial fibrosis, and these changes were accompanied by decreased urinary 8-OHdG level and increased MnSOD expression.	Cyclosporine	39-42	superoxide dismutase 2, mitochondrial	Mus musculus	216-221
23625833-4	2013	Mmp3 mRNA and protein expression was also induced by calcium ionophore (Io) and 2"(3")-O-(4-benzoylbenzoyl) adenosine 5"-triphosphate (Bz-ATP) and Mmp3 upregulation was prevented by the CN inhibitor cyclosporin A (CsA).	Cyclosporine	199-212	matrix metallopeptidase 3	Homo sapiens	0-4
23744057-10	2013	Similar results were obtained when NIM811, an analog of cyclosporine A, was used to pharmacologically (instead of genetically) inhibit cypD function.	Cyclosporine	56-70	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	135-139
23777496-0	2013	Ciclosporin A inhibits production of interleukin-12/23p40 and interleukin-23 by the human monocyte cell line, THP-1.	Cyclosporine	0-13	GLI family zinc finger 2	Homo sapiens	110-115
23777496-3	2013	We investigated how CsA affects production of IL-12/23p40 and IL-23 production by the human monocyte cell line, THP-1, which is able to differentiate into macrophage-like cells or normal human keratinocytes (NHKs).	Cyclosporine	20-23	GLI family zinc finger 2	Homo sapiens	112-117
23777496-4	2013	THP-1 cells were preincubated with CsA, then stimulated with lipopolysaccharide (LPS), polyinosinic:polycytidylic acid or adenosine triphosphate.	Cyclosporine	35-38	GLI family zinc finger 2	Homo sapiens	0-5
23694952-8	2013	Immunosuppressive effects of ICOS blockade were observed in MLR when anti-ICOS was combined with suboptimal concentrations of cytotoxic T-lymphocyte antigen 4-Ig or cyclosporine.	Cyclosporine	165-177	inducible T cell costimulator	Canis lupus familiaris	29-33
23777496-6	2013	CsA significantly reduced both IL-12/23p40 and IL-23 production by LPS-stimulated THP-1 cells, but not in LPS-stimulated macrophage-like differentiated THP-1 cells.	Cyclosporine	0-3	GLI family zinc finger 2	Homo sapiens	82-87
23625833-4	2013	Mmp3 mRNA and protein expression was also induced by calcium ionophore (Io) and 2"(3")-O-(4-benzoylbenzoyl) adenosine 5"-triphosphate (Bz-ATP) and Mmp3 upregulation was prevented by the CN inhibitor cyclosporin A (CsA).	Cyclosporine	214-217	matrix metallopeptidase 3	Homo sapiens	0-4
23756537-1	2013	OBJECTIVE: To investigate the occurrence of MDR1 C3435T gene polymorphisms in the Turkish renal transplant patients treated with cyclosporine (CsA), and correlate these findings with prevalence and degree of gingival hyperplasia (GH).	Cyclosporine	129-141	ATP binding cassette subfamily B member 1	Homo sapiens	44-48
23562926-8	2013	Cyclosporin A and verapamil, both inhibitors of P-glycoprotein (P-gp), significantly decreased the efflux of AC.	Cyclosporine	0-13	ATP binding cassette subfamily B member 1	Homo sapiens	48-62
23562926-8	2013	Cyclosporin A and verapamil, both inhibitors of P-glycoprotein (P-gp), significantly decreased the efflux of AC.	Cyclosporine	0-13	ATP binding cassette subfamily B member 1	Homo sapiens	64-68
23756537-1	2013	OBJECTIVE: To investigate the occurrence of MDR1 C3435T gene polymorphisms in the Turkish renal transplant patients treated with cyclosporine (CsA), and correlate these findings with prevalence and degree of gingival hyperplasia (GH).	Cyclosporine	143-146	ATP binding cassette subfamily B member 1	Homo sapiens	44-48
23557867-0	2013	CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients.	Cyclosporine	49-61	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
23727078-2	2013	It has also been shown that vascular endothelial growth factor (VEGF) treatment of endothelial cells produces a rapid S116 dephosphorylation, which is blocked by the calcineurin inhibitor, cyclosporin A (CsA).	Cyclosporine	189-202	vascular endothelial growth factor A	Homo sapiens	28-62
23840803-4	2013	Cytokine signaling analysis using an "active" kalata B1 mutant [T20K], and the reference drug cyclosporin A (CsA) demonstrated that treatment of activated T-lymphocytes with these compounds decreased the expression of the interleukin-2 (IL-2) surface receptor as well as IL-2 cytokine secretion and IL-2 gene expression, whereas the "inactive" kalata B1 mutant [V10K] did not cause any effects.	Cyclosporine	94-107	interleukin 2	Homo sapiens	222-235
23840803-4	2013	Cytokine signaling analysis using an "active" kalata B1 mutant [T20K], and the reference drug cyclosporin A (CsA) demonstrated that treatment of activated T-lymphocytes with these compounds decreased the expression of the interleukin-2 (IL-2) surface receptor as well as IL-2 cytokine secretion and IL-2 gene expression, whereas the "inactive" kalata B1 mutant [V10K] did not cause any effects.	Cyclosporine	109-112	interleukin 2	Homo sapiens	222-235
23216312-5	2013	Recent findings show that not only CSB, but also CSA is involved in the repair of oxidative DNA lesions, in the nucleus as well as in mitochondria.	Cyclosporine	49-52	ERCC excision repair 6, chromatin remodeling factor	Homo sapiens	35-38
23755172-8	2014	Peroxisome proliferator-activated receptor-gamma coactivator (PGC)-1alpha, the master regulator of MB, and mitochondrial transcription factor-A (Tfam), the transcription factor that regulates mtDNA replication and transcription, were 42% and 90% lower, respectively, in the kidneys of CsA-treated than in untreated rats.	Cyclosporine	285-288	PPARG coactivator 1 alpha	Rattus norvegicus	0-73
23416384-10	2013	Cyclosporine A restored the atorvastatin-induced cardioprotection abolished by TNF-alpha inhibitor (87 +- 6%) and AG490 (83 +- 9%).	Cyclosporine	0-14	tumor necrosis factor	Homo sapiens	79-88
23727078-2	2013	It has also been shown that vascular endothelial growth factor (VEGF) treatment of endothelial cells produces a rapid S116 dephosphorylation, which is blocked by the calcineurin inhibitor, cyclosporin A (CsA).	Cyclosporine	189-202	vascular endothelial growth factor A	Homo sapiens	64-68
23727078-2	2013	It has also been shown that vascular endothelial growth factor (VEGF) treatment of endothelial cells produces a rapid S116 dephosphorylation, which is blocked by the calcineurin inhibitor, cyclosporin A (CsA).	Cyclosporine	204-207	vascular endothelial growth factor A	Homo sapiens	28-62
23727078-2	2013	It has also been shown that vascular endothelial growth factor (VEGF) treatment of endothelial cells produces a rapid S116 dephosphorylation, which is blocked by the calcineurin inhibitor, cyclosporin A (CsA).	Cyclosporine	204-207	vascular endothelial growth factor A	Homo sapiens	64-68
23727078-3	2013	In this study, we show that activation of eNOS in response to a variety of other eNOS-activating agonists and the cytosolic calcium-elevating agent, thapsigargin also involves CsA-inhibitable S116 dephosphorylation.	Cyclosporine	176-179	nitric oxide synthase 3	Homo sapiens	42-46
23727078-3	2013	In this study, we show that activation of eNOS in response to a variety of other eNOS-activating agonists and the cytosolic calcium-elevating agent, thapsigargin also involves CsA-inhibitable S116 dephosphorylation.	Cyclosporine	176-179	nitric oxide synthase 3	Homo sapiens	81-85
23727078-6	2013	Agonist-stimulated eNOS-Src complex formation, as well as agonist-stimulated Y83 phosphorylation, are blocked by calcineurin inhibition by CsA and by a cell-permeable calcineurin inhibitory peptide.	Cyclosporine	139-142	nitric oxide synthase 3	Homo sapiens	19-23
23731729-5	2013	We further hypothesized that treatment with cyclosporine A, a Pgp1 inhibitor, would render cells more sensitive to treatment with corticosteroids.	Cyclosporine	44-58	ATP binding cassette subfamily B member 1	Homo sapiens	62-66
23432070-2	2013	Because cyclosporine is less diabetogenic than tacrolimus is, cyclosporine may be preferred in patients with pre-existing diabetes mellitus type 2, to prevent insulin treatment after a transplant.	Cyclosporine	62-74	insulin	Homo sapiens	159-166
23432070-5	2013	RESULTS: Of the 16 patients treated with cyclosporine, only 4 remained free of insulin treatment after a follow-up of least 1 year, compared with 2 of 12 patients who were treated with tacrolimus (25% vs 17%; P = .67).	Cyclosporine	41-53	insulin	Homo sapiens	79-86
23432070-8	2013	CONCLUSIONS: Cyclosporine cannot be preferred over tacrolimus to minimize either the chance of requiring insulin treatment posttransplant or the dosage of insulin in patients with pre-existing diabetes mellitus type 2.	Cyclosporine	13-25	insulin	Homo sapiens	105-112
23557867-2	2013	We approached the effect of the CYP3A4*18B and CYP3A5*3 polymorphisms and haplotypes on the whole blood cyclosporine or tacrolimus concentration in Chinese renal transplant patients during the first month after transplantation.	Cyclosporine	104-116	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	32-38
23557867-10	2013	CONCLUSIONS: Genetic polymorphisms of CYP3A5*3 and CYP3A4*18B may be partly responsible in large interindividual variability of cyclosporine and tacrolimus blood levels in Chinese renal transplant patients during the first month after transplantation.	Cyclosporine	128-140	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	38-44
23557867-10	2013	CONCLUSIONS: Genetic polymorphisms of CYP3A5*3 and CYP3A4*18B may be partly responsible in large interindividual variability of cyclosporine and tacrolimus blood levels in Chinese renal transplant patients during the first month after transplantation.	Cyclosporine	128-140	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	51-57
24113044-13	2013	CONCLUSIONS: These results suggest that CsA-NP and CsA could protect the oxidative stress-induced ASC apoptosis through decreasing the activation of caspase-3 and inhibiting the release of cytochrome C.	Cyclosporine	40-43	caspase 3	Sus scrofa	149-158
23011083-5	2013	RESULTS: The presence of an IL28B CC genotype with either low viral load (VL), young donor age, or cyclosporine A (CsA)-based immunosuppression identified individuals with 69-80 % probabilities of SVR.	Cyclosporine	99-113	interferon lambda 3	Homo sapiens	28-33
23011083-5	2013	RESULTS: The presence of an IL28B CC genotype with either low viral load (VL), young donor age, or cyclosporine A (CsA)-based immunosuppression identified individuals with 69-80 % probabilities of SVR.	Cyclosporine	115-118	interferon lambda 3	Homo sapiens	28-33
23106187-0	2013	Expression of angiotensin II and its receptors in cyclosporine-induced gingival overgrowth.	Cyclosporine	50-62	angiotensinogen	Homo sapiens	14-28
23106187-4	2013	This study was directed forward to the identification of the angiotensinogen, angiotensin II (Ang II) and its receptors AT1 /AT2 expression in DIGO tissues and cyclosporine-treated human gingival fibroblast cells.	Cyclosporine	160-172	angiotensinogen	Homo sapiens	94-100
23106187-8	2013	The expression of Ang II and its receptors were also examined in gingival fibroblast cells treated with cyclosporine.	Cyclosporine	104-116	angiotensinogen	Homo sapiens	18-24
23106187-11	2013	In gingival fibroblasts, Ang II and AT1 expressions were increased with cyclosporine incorporation compared to controls.	Cyclosporine	72-84	angiotensinogen	Homo sapiens	25-31
23106187-12	2013	CONCLUSION: These results suggest that cyclosporine can modulate local expression of RAS components such as angiotensinogen, Ang II and its receptors in gingival tissues and gingival fibroblast cells.	Cyclosporine	39-51	angiotensinogen	Homo sapiens	108-123
23106187-12	2013	CONCLUSION: These results suggest that cyclosporine can modulate local expression of RAS components such as angiotensinogen, Ang II and its receptors in gingival tissues and gingival fibroblast cells.	Cyclosporine	39-51	angiotensinogen	Homo sapiens	125-131
23595141-6	2013	Both diazoxide and cyclosporin A exerted significant protective effects on cell viability by ameliorating the decrease in Bcl-2 and the increase in cytochrome c and caspase-3 activity induced by A-beta1-42.	Cyclosporine	19-32	BCL2, apoptosis regulator	Rattus norvegicus	122-127
23683031-10	2013	CsA increased the protein expression of bax, cleaved caspase-9, caspase-3 and the activity of caspase-3; however, the anti-apoptotic bcl-2 protein was reduced.	Cyclosporine	0-3	BCL2, apoptosis regulator	Rattus norvegicus	133-138
24113044-11	2013	Pre-treatment with CsA or CsA-NP (0.1-10.0 mg/ml) significantly down -regulated caspase-3 activity.	Cyclosporine	19-22	caspase 3	Sus scrofa	80-89
23683031-7	2013	In CsA-treated rat kidneys, the protein expression of NOX4 and p22phox was reduced by BIL (P &lt; 0.05).	Cyclosporine	3-6	cytochrome b-245 alpha chain	Rattus norvegicus	63-70
24028719-9	2013	Compared with control group, the expression of TNF-beta was significantly higher in IL-2 group (73.36% +- 16.73% vs 66.61% +- 16.20%, P &lt; 0.05), significantly lower in FK506 and FK506 plus CsA groups (P &lt; 0.05).	Cyclosporine	192-195	interleukin 2	Homo sapiens	84-88
23577651-1	2013	The use of the mammal target of rapamycin (mTOR) inhibitors has been consolidated as the therapy of election for preventing graft rejection in kidney transplant patients, despite their immunosuppressive activity is less strong than anti-calcineurin agents like tacrolimus and cyclosporine A.	Cyclosporine	276-290	mechanistic target of rapamycin kinase	Homo sapiens	15-41
23499865-7	2013	The productions of pro-inflammatory cytokines (IL-1beta, IL-2, IL-12 and TNFalpha) and JNK activity were remarkably reduced in the CsA-treated obese animals.	Cyclosporine	131-134	interleukin 1 beta	Mus musculus	47-55
23499865-7	2013	The productions of pro-inflammatory cytokines (IL-1beta, IL-2, IL-12 and TNFalpha) and JNK activity were remarkably reduced in the CsA-treated obese animals.	Cyclosporine	131-134	tumor necrosis factor	Mus musculus	73-81
23454281-0	2013	Drosophila type XV/XVIII collagen mutants manifest integrin mediated mitochondrial dysfunction, which is improved by cyclosporin A and losartan.	Cyclosporine	117-130	anon-XVIII	Drosophila melanogaster	19-24
23454281-9	2013	Hence, our results provide new insights towards the roles of multiplexin collagens in mitochondrial homeostasis and may serve as pharmacological evidences for the potential use of cyclosporin A or losartan for the therapeutic strategies.	Cyclosporine	180-193	Multiplexin	Drosophila melanogaster	61-72
23436429-5	2013	In our study, we investigated RCAN1 and SOD1 expression in long-term CsA-treated mouse brain.	Cyclosporine	69-72	superoxide dismutase 1, soluble	Mus musculus	40-44
23436429-7	2013	At the same time, chronic CsA treatment also resulted in decreased expression of SOD1.	Cyclosporine	26-29	superoxide dismutase 1, soluble	Mus musculus	81-85
23436429-10	2013	In contrast, CsA treatment in SY5Y cells affected SOD1 expression and CN activity significantly, but had no obvious effects on RCAN1-1 mRNA expression.	Cyclosporine	13-16	superoxide dismutase 1	Homo sapiens	50-54
23683031-10	2013	CsA increased the protein expression of bax, cleaved caspase-9, caspase-3 and the activity of caspase-3; however, the anti-apoptotic bcl-2 protein was reduced.	Cyclosporine	0-3	caspase 9	Rattus norvegicus	53-62
23396419-7	2013	(-)-Epigallocatechin gallate, cyclosporin A, rifampicin, and telmisartan inhibited transport of dioscin in OATP1B3-HEK293 cells.	Cyclosporine	30-43	solute carrier organic anion transporter family member 1B3	Homo sapiens	107-114
23525116-7	2013	Cyclophilin D expression increased during cell death mode transition, and inhibition of cyclophilin D by cyclosporin A clearly blocked HNK-triggered programmed necrosis.	Cyclosporine	105-118	peptidylprolyl isomerase F	Homo sapiens	88-101
23525116-9	2013	Further results showed that blocked cyclophilin D by cyclosporin A inhibited HNK-induced necrosis, but did not affect HNK-induced RIP3 overexpression.	Cyclosporine	53-66	peptidylprolyl isomerase F	Homo sapiens	36-49
23577651-1	2013	The use of the mammal target of rapamycin (mTOR) inhibitors has been consolidated as the therapy of election for preventing graft rejection in kidney transplant patients, despite their immunosuppressive activity is less strong than anti-calcineurin agents like tacrolimus and cyclosporine A.	Cyclosporine	276-290	mechanistic target of rapamycin kinase	Homo sapiens	43-47
23262186-8	2013	Interestingly, CsA not only reversed the detrimental effects of doxorubicin, but also reduced p-Akt and p-Erk levels.	Cyclosporine	15-18	Eph receptor B1	Rattus norvegicus	106-109
22934840-10	2013	Importantly, fibroblast monolayers and 3D cultures treated with a combination of IL-1beta and CsA showed a decrease in the MMP-1/TIMP-1 ratio.	Cyclosporine	94-97	TIMP metallopeptidase inhibitor 1	Homo sapiens	129-135
22934840-11	2013	CONCLUSIONS: These data support the hypothesis that inflammation may alter the pathogenesis of CsA-induced gingival enlargement by promoting a synergistic decrease in the MMP-1/TIMP-1 ratio.	Cyclosporine	95-98	TIMP metallopeptidase inhibitor 1	Homo sapiens	177-183
23340267-12	2013	Pretreatment with cyclosporine A (500nM) or 11R-VIVIT (100nM) completely blocked NFAT2 nuclear accumulation.	Cyclosporine	18-32	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	81-86
23523711-3	2013	In the present study, we found that with CsA administration, the expression of TRAIL and FasL predominantly on NK cells from renal transplantation patients was increased at day 5 after operation and went down to normal level on day 13.	Cyclosporine	41-44	TNF superfamily member 10	Homo sapiens	79-84
23593196-6	2013	Validation of the assay was performed with known ABCB1 inhibitors, XR9576, verapamil, and cyclosporin A, all of which displayed dose-dependent inhibition of ABCB1-mediated calcein AM efflux in this assay.	Cyclosporine	90-103	ATP binding cassette subfamily B member 1	Homo sapiens	157-162
23593196-13	2013	Inhibition of ABCB1 with XR9576 and cyclosporin A enhanced the cytotoxicity of BI 2536 to ABCB1-overexpressing cancer cells, HCT-15-Pgp, and decreased the IC50 value of BI 2536 by several orders of magnitude.	Cyclosporine	36-49	ATP binding cassette subfamily B member 1	Homo sapiens	90-95
23593329-8	2013	Anti-OX40L or the NFATc1 inhibitor (CsA) markedly suppressed the cell proliferation induced by anti-OX40.	Cyclosporine	36-39	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	18-24
23385100-12	2013	Cyclosporine treatment also improved mitochondrial aconitase activity and attenuated the rise in cytosol cytochrome-c level (vs. controls, all p&lt;0.05).	Cyclosporine	0-12	aconitase 2	Homo sapiens	37-60
23353700-6	2013	The addition of either tamoxifen, VX-710, verapamil, or cyclosporin A, antagonists of P-gp, enhanced C6-ceramide cytotoxicity in all cell lines.	Cyclosporine	56-69	ATP binding cassette subfamily B member 1	Homo sapiens	86-90
23503472-2	2013	In this study, we investigated the associations of CYP3A4, CYP3A5, ABCB1, NFKB1, and NR1I2 polymorphisms with cyclosporine concentrations in Chinese renal transplant recipients in the early period after renal transplantation.	Cyclosporine	110-122	nuclear receptor subfamily 1 group I member 2	Homo sapiens	85-90
23503472-6	2013	RESULTS: The dose-adjusted trough concentration (C0) of cyclosporine in ABCB1 2677 TT carriers was significantly higher than that in GG carriers together with GT carriers [90.4+-24.5 vs 67.8+-26.8 (ng/mL)/(mg/kg), P=0.001].	Cyclosporine	56-68	ATP binding cassette subfamily B member 1	Homo sapiens	72-77
23503472-7	2013	ABCB1 3435 TT carriers had a significantly higher dose-adjusted C0 of cyclosporine than CC carriers together with CT carriers [92.0+-24.0 vs 68.4+-26.5 (ng/mL)/(mg/kg), P=0.002].	Cyclosporine	70-82	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
23503472-10	2013	CONCLUSION: These results illustrate that the ABCB1 and NFKB1 genotypes are closely correlated with cyclosporine trough concentrations, suggesting that these SNPs are useful for determining the appropriate dose of cyclosporine.	Cyclosporine	100-112	ATP binding cassette subfamily B member 1	Homo sapiens	46-51
23503472-10	2013	CONCLUSION: These results illustrate that the ABCB1 and NFKB1 genotypes are closely correlated with cyclosporine trough concentrations, suggesting that these SNPs are useful for determining the appropriate dose of cyclosporine.	Cyclosporine	100-112	nuclear factor kappa B subunit 1	Homo sapiens	56-61
23523711-7	2013	We conclude that CsA may inhibit the transplant rejection partially by down-regulating the expression of TRAIL and FasL on NK cells.	Cyclosporine	17-20	TNF superfamily member 10	Homo sapiens	105-110
22580614-11	2013	Our results demonstrate that CsA induces both apoptosis and autophagy in malignant glioma cells via induction of ER stress and inhibition of mTOR/p70S6K1 pathway, however autophagy is cytoprotective in this context.	Cyclosporine	29-32	mechanistic target of rapamycin kinase	Homo sapiens	141-145
23410723-5	2013	CsA-mediated induction of nuclear factor-kappa B (NF-kappaB) was evaluated by cotransfection with luciferase reporter constructs and luciferase activity assays.	Cyclosporine	0-3	nuclear factor kappa B subunit 1	Homo sapiens	26-48
23410723-5	2013	CsA-mediated induction of nuclear factor-kappa B (NF-kappaB) was evaluated by cotransfection with luciferase reporter constructs and luciferase activity assays.	Cyclosporine	0-3	nuclear factor kappa B subunit 1	Homo sapiens	50-59
23410723-7	2013	CsA also increased NF-kappaB-transcriptional activity in trophoblasts in time- and dose-dependent manners.	Cyclosporine	0-3	nuclear factor kappa B subunit 1	Homo sapiens	19-28
23410723-8	2013	Pharmacologically inhibiting mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) 1/2 signaling with U0126 attenuated the CsA-induced cell migration and NF-kappaB activity in trophoblasts.	Cyclosporine	153-156	mitogen-activated protein kinase 3	Homo sapiens	63-67
23410723-8	2013	Pharmacologically inhibiting mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) 1/2 signaling with U0126 attenuated the CsA-induced cell migration and NF-kappaB activity in trophoblasts.	Cyclosporine	153-156	mitogen-activated protein kinase 3	Homo sapiens	69-116
23410723-8	2013	Pharmacologically inhibiting mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) 1/2 signaling with U0126 attenuated the CsA-induced cell migration and NF-kappaB activity in trophoblasts.	Cyclosporine	153-156	nuclear factor kappa B subunit 1	Homo sapiens	184-193
23410723-9	2013	Furthermore, pretreatment with PDTC, a specific NF-kappaB inhibitor, inhibited the CsA-induced migration of trophoblasts in dose-dependent manners.	Cyclosporine	83-86	nuclear factor kappa B subunit 1	Homo sapiens	48-57
23410723-11	2013	Interestingly, ionomycin and CsA synergize to transactivate NF-kappaB.	Cyclosporine	29-32	nuclear factor kappa B subunit 1	Homo sapiens	60-69
23410723-14	2013	CONCLUSION: These observations indicate that both the MAPK/ERK/NF-kappaB pathway and Ca(2+)/calcineurin/NFAT pathways are involved in the CsA-promoted trophoblast migration.	Cyclosporine	138-141	mitogen-activated protein kinase 3	Homo sapiens	54-58
23410723-14	2013	CONCLUSION: These observations indicate that both the MAPK/ERK/NF-kappaB pathway and Ca(2+)/calcineurin/NFAT pathways are involved in the CsA-promoted trophoblast migration.	Cyclosporine	138-141	mitogen-activated protein kinase 1	Homo sapiens	59-62
23410723-14	2013	CONCLUSION: These observations indicate that both the MAPK/ERK/NF-kappaB pathway and Ca(2+)/calcineurin/NFAT pathways are involved in the CsA-promoted trophoblast migration.	Cyclosporine	138-141	nuclear factor kappa B subunit 1	Homo sapiens	63-72
23622648-11	2013	CsA-induced nephrotoxicity was accompanied by kidney overexpression of inflammatory and proliferative mRNA markers (IL-1beta, mTOR and PCNA), which were absent among SRL group.	Cyclosporine	0-3	interleukin 1 beta	Rattus norvegicus	116-124
23322110-5	2013	Disruption of this complex by Cyp-D inhibitor Cyclosporine A (CsA), or by Cyp-D or p53 deficiency, significantly inhibited OGD/re-oxygenation-induced apoptosis-independent cell death.	Cyclosporine	62-65	peptidylprolyl isomerase F	Homo sapiens	30-35
23347876-8	2013	Furthermore, CsA altered the mitochondrial dynamics, inducing an increase in mitochondrial fission; CsA increased the expression of dynamin related protein 1 (Drp1) that contributes to mitochondrial fission, and decreased the expression of mitofusin 2 (Mfn2) and optic atrophy protein 1 (Opa1), proteins involved in the fusion process.	Cyclosporine	13-16	mitofusin 2	Sus scrofa	240-251
23347876-8	2013	Furthermore, CsA altered the mitochondrial dynamics, inducing an increase in mitochondrial fission; CsA increased the expression of dynamin related protein 1 (Drp1) that contributes to mitochondrial fission, and decreased the expression of mitofusin 2 (Mfn2) and optic atrophy protein 1 (Opa1), proteins involved in the fusion process.	Cyclosporine	100-103	mitofusin 2	Sus scrofa	240-251
23347876-8	2013	Furthermore, CsA altered the mitochondrial dynamics, inducing an increase in mitochondrial fission; CsA increased the expression of dynamin related protein 1 (Drp1) that contributes to mitochondrial fission, and decreased the expression of mitofusin 2 (Mfn2) and optic atrophy protein 1 (Opa1), proteins involved in the fusion process.	Cyclosporine	100-103	mitofusin 2	Sus scrofa	253-257
22580614-5	2013	The induction of ER stress in glioma cells by CsA was evidenced by detection of unfolded protein response activation (phosphorylation of PERK, accumulation of IRE1alpha) and accumulation of ER stress-associated proteins (BIP and CHOP).	Cyclosporine	46-49	DNA damage inducible transcript 3	Homo sapiens	229-233
22580614-7	2013	Decrease of phosphorylation of 4E-BP1, p70S6K1 and its downstream target S6 ribosomal protein demonstrate inhibition of mTOR signaling by CsA.	Cyclosporine	138-141	mechanistic target of rapamycin kinase	Homo sapiens	120-124
22580614-10	2013	Surprisingly, silencing of autophagy effectors ULK1, Atg5 or Atg7 increased the level of active caspases 3, 7 and PARP degradation in CsA-treated cells.	Cyclosporine	134-137	autophagy related 5	Homo sapiens	53-57
23208368-0	2013	Synergistic Bcl-2 inhibition by ABT-737 and cyclosporine A.	Cyclosporine	44-58	B cell leukemia/lymphoma 2	Mus musculus	12-17
23331973-4	2013	We found that CsA prevented CD8(+)  T cell infiltration into the graft and downregulated the Th1 response but affected neither Th2 nor Th17 responses in vivo.	Cyclosporine	14-17	negative elongation factor complex member C/D, Th1l	Mus musculus	93-96
23331973-5	2013	In secondary mixed lymphocyte cultures, CsA dramatically decreased donor-specific IFN-gamma production, enhanced IL-17 production and did not affect IL-13.	Cyclosporine	40-43	interferon gamma	Homo sapiens	82-91
22886152-0	2013	ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients.	Cyclosporine	40-52	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
22886152-2	2013	We have investigated the effect of polymorphisms in the CYP3A and ABCB1 genes on CsA pharmacokinetics, acute rejection incidence and drug-related side effects in renal transplant recipients METHODS: The presence of CYP3A5*3, CYP3A4*1B and ABCB1 C1236T, G2677T/A and C3435T polymorphisms was assessed in 68 patients and retrospectively associated with pharmacokinetic and clinical parameters at 1 week and 1, 5 and 12 months after transplantation.	Cyclosporine	81-84	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-61
22886152-5	2013	In terms of CsA-induced adverse effects, the incidence of nephrotoxicity was higher in carriers of the ABCB1 3435TT genotype and in those patients carrying four to six variants in the three ABCB1 loci [odds ratio (OR) 4.2, 95 % confidence interval (CI) 1.3-13.9, p = 0.02 and OR 3.6, 95 % CI 1.1-11.8, p = 0.05, respectively].	Cyclosporine	12-15	ATP binding cassette subfamily B member 1	Homo sapiens	103-108
22886152-5	2013	In terms of CsA-induced adverse effects, the incidence of nephrotoxicity was higher in carriers of the ABCB1 3435TT genotype and in those patients carrying four to six variants in the three ABCB1 loci [odds ratio (OR) 4.2, 95 % confidence interval (CI) 1.3-13.9, p = 0.02 and OR 3.6, 95 % CI 1.1-11.8, p = 0.05, respectively].	Cyclosporine	12-15	ATP binding cassette subfamily B member 1	Homo sapiens	190-195
22886152-8	2013	CONCLUSIONS: ABCB1 polymorphisms may be helpful in predicting certain CsA-related side effects in renal transplant recipients.	Cyclosporine	70-73	ATP binding cassette subfamily B member 1	Homo sapiens	13-18
23359659-7	2013	The potency of CsA to inhibit P-gp was tissue-independent (maternal BBB half-maximal inhibitory concentration [IC50], 5.67 +- 1.07 muM, vs. BPB IC50, 7.63 +- 3.16 muM).	Cyclosporine	15-18	ATP binding cassette subfamily B member 1	Homo sapiens	30-34
23355260-1	2013	The standard therapy for anti-erythropoietin (EPO) antibody-mediated pure red cell aplasia (PRCA) is cyclosporine (CyA) or prednisolone (PSL) 0.5-1.0 mg/kg.	Cyclosporine	101-113	erythropoietin	Homo sapiens	30-44
23238221-4	2013	In this study we confirmed that preconditioning and postconditioning with CypD inhibitor cyclosporin-A (CsA) reduced cell death after hypoxia-reoxygenation (H/R) in wild-type (WT) cardiomyocytes and HL-1 mouse cardiac cell line as measured by nuclear staining with propidium iodide.	Cyclosporine	89-102	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	74-78
23238221-4	2013	In this study we confirmed that preconditioning and postconditioning with CypD inhibitor cyclosporin-A (CsA) reduced cell death after hypoxia-reoxygenation (H/R) in wild-type (WT) cardiomyocytes and HL-1 mouse cardiac cell line as measured by nuclear staining with propidium iodide.	Cyclosporine	104-107	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	74-78
23498817-0	2013	The role of protein kinase CK2 in cyclosporine-induced nephropathy in rats.	Cyclosporine	34-46	casein kinase 2 beta	Rattus norvegicus	27-30
23498817-7	2013	In addition, emodin prevented increased Bax/Bcl-2 ratio induced by CsA.	Cyclosporine	67-70	BCL2, apoptosis regulator	Rattus norvegicus	44-49
23450662-6	2013	Moreover, in patients, down-modulation of CD16 and CD6 on CD56(dim) NK cells was observed with significant differences between Cyclosporin A- and Tac-treated patients.	Cyclosporine	127-140	CD6 molecule	Homo sapiens	51-54
23425330-0	2013	The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity.	Cyclosporine	105-117	nuclear receptor subfamily 3, group C, member 2	Rattus norvegicus	4-30
23425330-0	2013	The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity.	Cyclosporine	149-161	nuclear receptor subfamily 3, group C, member 2	Rattus norvegicus	4-30
23448605-3	2013	The aim of our study was to detect the level of apoptosis, expression bcl-2 and p53, associated with the different doses of CsA.	Cyclosporine	124-127	BCL2 apoptosis regulator	Homo sapiens	70-75
23448605-3	2013	The aim of our study was to detect the level of apoptosis, expression bcl-2 and p53, associated with the different doses of CsA.	Cyclosporine	124-127	tumor protein p53	Homo sapiens	80-83
23261361-6	2013	RESULTS: Our present study has shown that lipopolysaccharide (LPS) and cyclosporin A (CsA) could increase or decrease the gene and protein expressions of TNF-alpha and IL-1beta respectively.	Cyclosporine	71-84	tumor necrosis factor	Mus musculus	154-163
23261361-6	2013	RESULTS: Our present study has shown that lipopolysaccharide (LPS) and cyclosporin A (CsA) could increase or decrease the gene and protein expressions of TNF-alpha and IL-1beta respectively.	Cyclosporine	71-84	interleukin 1 beta	Mus musculus	168-176
23261361-6	2013	RESULTS: Our present study has shown that lipopolysaccharide (LPS) and cyclosporin A (CsA) could increase or decrease the gene and protein expressions of TNF-alpha and IL-1beta respectively.	Cyclosporine	86-89	tumor necrosis factor	Mus musculus	154-163
23261361-6	2013	RESULTS: Our present study has shown that lipopolysaccharide (LPS) and cyclosporin A (CsA) could increase or decrease the gene and protein expressions of TNF-alpha and IL-1beta respectively.	Cyclosporine	86-89	interleukin 1 beta	Mus musculus	168-176
23238060-6	2013	CsA at 15muM induced mitochondrial disturbances and activation of the Nrf2-oxidative-damage and the unfolded protein-response pathways.	Cyclosporine	0-3	NFE2 like bZIP transcription factor 2	Homo sapiens	70-74
23425330-2	2013	We hypothesized that the mineralocorticoid receptor antagonist eplerenone (EPL) prevents chronic CsA-induced renal interstitial volume increase, tubule loss, and functional impairment in a rat model.	Cyclosporine	97-100	nuclear receptor subfamily 3, group C, member 2	Rattus norvegicus	25-51
23153588-0	2013	Cyclosporine A and PSC833 inhibit ABCA1 function via direct binding.	Cyclosporine	0-14	phospholipid-transporting ATPase ABCA1	Mesocricetus auratus	34-39
23153588-3	2013	Cyclosporine A inhibits ABCA1-mediated cholesterol efflux, but it is not clear whether this is mediated via inhibition of calcineurin.	Cyclosporine	0-14	phospholipid-transporting ATPase ABCA1	Mesocricetus auratus	24-29
23153588-4	2013	We analyzed the effects of cyclosporine A and related compounds on ABCA1 function in BHK/ABCA1 cells.	Cyclosporine	27-41	phospholipid-transporting ATPase ABCA1	Mesocricetus auratus	67-72
23153588-5	2013	Cyclosporine A, FK506, and pimecrolimus inhibited ABCA1-mediated cholesterol efflux in a concentration-dependent manner, with IC(50) of 7.6, 13.6, and 7.0muM, respectively.	Cyclosporine	0-14	phospholipid-transporting ATPase ABCA1	Mesocricetus auratus	50-55
23153588-9	2013	Furthermore, a non-immunosuppressive cyclosporine, PSC833, inhibited ABCA1-mediated cholesterol efflux with IC(50) of 1.9muM, and efficiently competed with [(3)H] cyclosporine A binding to ABCA1.	Cyclosporine	37-49	phospholipid-transporting ATPase ABCA1	Mesocricetus auratus	69-74
23153588-9	2013	Furthermore, a non-immunosuppressive cyclosporine, PSC833, inhibited ABCA1-mediated cholesterol efflux with IC(50) of 1.9muM, and efficiently competed with [(3)H] cyclosporine A binding to ABCA1.	Cyclosporine	37-49	phospholipid-transporting ATPase ABCA1	Mesocricetus auratus	189-194
23153588-9	2013	Furthermore, a non-immunosuppressive cyclosporine, PSC833, inhibited ABCA1-mediated cholesterol efflux with IC(50) of 1.9muM, and efficiently competed with [(3)H] cyclosporine A binding to ABCA1.	Cyclosporine	163-177	phospholipid-transporting ATPase ABCA1	Mesocricetus auratus	69-74
23153588-10	2013	These results indicate that cyclosporine A and PSC833 inhibit ABCA1 via direct binding, and that the ABCA1 inhibitor PSC833 is an excellent candidate for further investigations of the detailed mechanisms underlying formation of HDL.	Cyclosporine	28-42	phospholipid-transporting ATPase ABCA1	Mesocricetus auratus	62-67
23355260-1	2013	The standard therapy for anti-erythropoietin (EPO) antibody-mediated pure red cell aplasia (PRCA) is cyclosporine (CyA) or prednisolone (PSL) 0.5-1.0 mg/kg.	Cyclosporine	101-113	erythropoietin	Homo sapiens	46-49
23355260-1	2013	The standard therapy for anti-erythropoietin (EPO) antibody-mediated pure red cell aplasia (PRCA) is cyclosporine (CyA) or prednisolone (PSL) 0.5-1.0 mg/kg.	Cyclosporine	115-118	erythropoietin	Homo sapiens	30-44
23355260-1	2013	The standard therapy for anti-erythropoietin (EPO) antibody-mediated pure red cell aplasia (PRCA) is cyclosporine (CyA) or prednisolone (PSL) 0.5-1.0 mg/kg.	Cyclosporine	115-118	erythropoietin	Homo sapiens	46-49
23258196-13	2013	The expressions of ED-1, alpha-SMA, TGF-beta(1), Smad2/3, Smad4 and p-JNK were increased in CsA-treated rats, which were attenuated by RUS.	Cyclosporine	92-95	transforming growth factor, beta 1	Rattus norvegicus	36-47
23167600-10	2013	In cyclosporine-treated allografts VEGF-C/VEGFR-3 pathway was strongly upregulated leading to extensive lymphangiogenesis 60 days after transplantation.	Cyclosporine	3-15	vascular endothelial growth factor C	Rattus norvegicus	35-41
23190385-6	2013	CsA decreased whole-blood COX-2 activity by 39% (P = 0.05) and basal plasma 6-keto-PGF(1alpha)  levels by 31%, only nonsignificantly.	Cyclosporine	0-3	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	26-31
23190385-13	2013	CsA suppresses COX-2 activity, while Tac decreases platelet activity.	Cyclosporine	0-3	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	15-20
23216707-0	2013	Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients?	Cyclosporine	71-83	ATP binding cassette subfamily B member 1	Homo sapiens	21-26
23216707-8	2013	Pgp-high pumpers treated with cyclosporine showed lower values of Pgp function than macrolides.	Cyclosporine	30-42	ATP binding cassette subfamily B member 1	Homo sapiens	0-3
23216707-8	2013	Pgp-high pumpers treated with cyclosporine showed lower values of Pgp function than macrolides.	Cyclosporine	30-42	ATP binding cassette subfamily B member 1	Homo sapiens	66-69
23216707-12	2013	Pgp activity was influenced by cyclosporine but not macrolides exposure.	Cyclosporine	31-43	ATP binding cassette subfamily B member 1	Homo sapiens	0-3
23160140-1	2013	Cyclosporin A (CsA), tacrolimus and rapamycin are immunosuppressive agents (IAs) associated with insulin resistance and dyslipidemia, although their molecular effects on lipid metabolism in adipose tissue are unknown.	Cyclosporine	15-18	insulin	Homo sapiens	97-104
23160140-7	2013	These findings suggest that CsA, tacrolimus and rapamycin enhance lipolysis, inhibit lipid storage and expression of lipogenic genes in adipose tissue, which may contribute to the development of dyslipidemia and insulin resistance associated with immunosuppressive therapy.	Cyclosporine	28-31	insulin	Homo sapiens	212-219
23224887-2	2013	We have shown that cyclosporin A (CsA) treatment of NCX1-, NCX2-, or NCX3-transfected HEK 293 cells and non-transfected H9c2, L6, and aortic smooth muscle cells, which express NCX1 protein naturally, reduces NCX surface expression and transport activity but has no impact on total cell NCX protein.	Cyclosporine	34-37	solute carrier family 8 member A1	Homo sapiens	52-56
23224887-2	2013	We have shown that cyclosporin A (CsA) treatment of NCX1-, NCX2-, or NCX3-transfected HEK 293 cells and non-transfected H9c2, L6, and aortic smooth muscle cells, which express NCX1 protein naturally, reduces NCX surface expression and transport activity but has no impact on total cell NCX protein.	Cyclosporine	34-37	solute carrier family 8 member A3	Homo sapiens	69-73
23224887-2	2013	We have shown that cyclosporin A (CsA) treatment of NCX1-, NCX2-, or NCX3-transfected HEK 293 cells and non-transfected H9c2, L6, and aortic smooth muscle cells, which express NCX1 protein naturally, reduces NCX surface expression and transport activity but has no impact on total cell NCX protein.	Cyclosporine	34-37	solute carrier family 8 member A1	Rattus norvegicus	176-180
23224887-2	2013	We have shown that cyclosporin A (CsA) treatment of NCX1-, NCX2-, or NCX3-transfected HEK 293 cells and non-transfected H9c2, L6, and aortic smooth muscle cells, which express NCX1 protein naturally, reduces NCX surface expression and transport activity but has no impact on total cell NCX protein.	Cyclosporine	34-37	solute carrier family 8 member A1	Rattus norvegicus	52-55
23224887-2	2013	We have shown that cyclosporin A (CsA) treatment of NCX1-, NCX2-, or NCX3-transfected HEK 293 cells and non-transfected H9c2, L6, and aortic smooth muscle cells, which express NCX1 protein naturally, reduces NCX surface expression and transport activity but has no impact on total cell NCX protein.	Cyclosporine	34-37	solute carrier family 8 member A1	Rattus norvegicus	59-62
23224887-3	2013	Similar effect on functional expression of NCX1 protein can be obtained also without CsA treatment by knockdown of cell cyclophilin A (CypA), one of the cellular receptor of CsA.	Cyclosporine	174-177	solute carrier family 8 member A1	Homo sapiens	43-47
23224887-4	2013	This suggests that CypA has a role in acquisition of function competence of NCX1 protein.Unlike CsA treatment, which affects the functional expression of all three mammalian NCX proteins similarly, FK506 and rapamycin treatment modulates only the functional expression of NCX2 and NCX3 proteins.	Cyclosporine	96-99	solute carrier family 8 member A1	Homo sapiens	76-80
23160799-10	2013	Dvl-1 down-regulation decreased the apoptotic rate, caspase-3 activity, and the Bax/Bcl-2 ratio in H9c2 cells treated with CsA.	Cyclosporine	123-126	BCL2, apoptosis regulator	Rattus norvegicus	84-89
23160799-12	2013	Moreover, we further deleted the downstream member beta-catenin by specific siRNA, and found that CsA-induced the Bax/Bcl-2 ratio and the expression of c-Myc, which were attenuated.	Cyclosporine	98-101	BCL2, apoptosis regulator	Rattus norvegicus	118-123
23737767-5	2013	In particular, clinically relevant DDIs have been described during the treatment with MTX and NSAIDs, for example, diclofenac, indomethacin, or COX-2 inhibitors, and between MTX and prednisone or immunosuppressant drugs (e.g., leflunomide and cyclosporine).	Cyclosporine	243-255	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	144-149
23258196-12	2013	RUS decreased CsA-induced increased expression of Bax/Bcl-2 ratio.	Cyclosporine	14-17	BCL2, apoptosis regulator	Rattus norvegicus	54-59
23295863-6	2013	First, CsA could upregulate Fas/Fas ligand, downregulate Bcl-2/Bcl-XL, and increase caspase-1 and caspase-3.	Cyclosporine	7-10	BCL2 apoptosis regulator	Homo sapiens	57-62
23295863-6	2013	First, CsA could upregulate Fas/Fas ligand, downregulate Bcl-2/Bcl-XL, and increase caspase-1 and caspase-3.	Cyclosporine	7-10	BCL2 like 1	Homo sapiens	63-69
23295863-6	2013	First, CsA could upregulate Fas/Fas ligand, downregulate Bcl-2/Bcl-XL, and increase caspase-1 and caspase-3.	Cyclosporine	7-10	caspase 1	Homo sapiens	84-93
23295863-6	2013	First, CsA could upregulate Fas/Fas ligand, downregulate Bcl-2/Bcl-XL, and increase caspase-1 and caspase-3.	Cyclosporine	7-10	caspase 3	Homo sapiens	98-107
23295863-12	2013	CsA can induce renal cell apoptosis using five pathways in vivo and activated caspases might be the ultimate intersection of these pathways and the common intracellular pathway mediating apoptosis.	Cyclosporine	0-3	caspase 1	Homo sapiens	78-86
23353150-6	2013	Pretreatment of the cells with Cyclosporine blocked the effects of ET-1, and PDE5 inhibition by sildenafil pretreatment also abolished ET-1-induced reduction of cGMP level in the cells.	Cyclosporine	31-43	endothelin 1	Homo sapiens	67-71
23936793-3	2013	Flow cytometry showed that the number of CD4(+) and CD8(+) cells and the level of IFN- gamma decreased significantly in the groups treated with cyclosporin A.	Cyclosporine	144-157	CD4 molecule	Homo sapiens	41-44
23936793-3	2013	Flow cytometry showed that the number of CD4(+) and CD8(+) cells and the level of IFN- gamma decreased significantly in the groups treated with cyclosporin A.	Cyclosporine	144-157	interferon gamma	Homo sapiens	82-92
23037942-4	2013	Both secretion and mRNA expression of IL-6 were significantly up-regulated by EPS in a frequency-dependent manner in contracting myotubes during a 24-h period, and the response was blunted by cyclosporine A, a calcineurin inhibitor.	Cyclosporine	192-206	interleukin 6	Homo sapiens	38-42
23280075-0	2013	TGF-beta1 expression in kidney allograft protocol biopsies during cyclosporine A therapy.	Cyclosporine	66-80	transforming growth factor beta 1	Homo sapiens	0-9
23280075-1	2013	BACKGROUND: TGF-beta1 expression has been described to increase along with time from transplantation and has also been linked to allograft dysfunction and toxic effects of cyclosporine.	Cyclosporine	172-184	transforming growth factor beta 1	Homo sapiens	12-21
23280075-2	2013	Our aim was to correlate intragraft TGF-beta1 expression with cyclosporine exposure after kidney transplantation.	Cyclosporine	62-74	transforming growth factor beta 1	Homo sapiens	36-45
23280075-4	2013	TGF-beta1 expression in tubules, glomeruli, vessels, and inflammatory cells was semi-quantitatively scored and correlated with cyclosporine concentrations (C0 and C2), CADI, and graft function.	Cyclosporine	127-139	transforming growth factor beta 1	Homo sapiens	0-9
23280075-9	2013	Our findings suggest that the toxic effects of low-dose cyclosporine on TGF-beta expression may be milder than previously thought.	Cyclosporine	56-68	transforming growth factor beta 1	Homo sapiens	72-80
22902549-9	2013	Cyp inhibitors such as cyclosporine A (CsA) or non-immunosuppressive derivates such as alisporivir and SCY-635, prevent IRF9-CypA complex formation.	Cyclosporine	23-37	interferon regulatory factor 9	Homo sapiens	120-124
22902549-9	2013	Cyp inhibitors such as cyclosporine A (CsA) or non-immunosuppressive derivates such as alisporivir and SCY-635, prevent IRF9-CypA complex formation.	Cyclosporine	39-42	interferon regulatory factor 9	Homo sapiens	120-124
23353150-6	2013	Pretreatment of the cells with Cyclosporine blocked the effects of ET-1, and PDE5 inhibition by sildenafil pretreatment also abolished ET-1-induced reduction of cGMP level in the cells.	Cyclosporine	31-43	endothelin 1	Homo sapiens	135-139
23353150-7	2013	Both Cyclosporine and sildenafil suppressed ET-1-stimulated PASMC proliferation.	Cyclosporine	5-17	endothelin 1	Homo sapiens	44-48
23353150-9	2013	Both Cyclosporine and sildenafil can suppress ET-1-stimulated PASMC proliferation in vitro.	Cyclosporine	5-17	endothelin 1	Homo sapiens	46-50
23146841-2	2013	The effect of MPA treatment on CsA-induced signaling through the transforming growth factor-beta (TGF-beta)/Smad pathway was evaluated by immunoblot analysis in cultured primary rat mesangial cells.	Cyclosporine	31-34	SMAD family member 7	Rattus norvegicus	108-112
23841924-3	2013	The metabolism and bioavailability of cyclosporin can be significantly and persistently influenced through induction of CYP3A4 caused by the concomitant use of rifampicin.	Cyclosporine	38-49	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	120-126
23252948-5	2013	A new CYP3A4 allele (CYP3A4*22; rs35599367 C&gt;T in intron 6) with a frequency of 5-7% in the Caucasian population was recently discovered through its association with low hepatic CYP3A4 expression and CYP3A4 activity, and showing effects on statin, tacrolimus and cyclosporine metabolism.	Cyclosporine	266-278	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	6-12
23252948-5	2013	A new CYP3A4 allele (CYP3A4*22; rs35599367 C&gt;T in intron 6) with a frequency of 5-7% in the Caucasian population was recently discovered through its association with low hepatic CYP3A4 expression and CYP3A4 activity, and showing effects on statin, tacrolimus and cyclosporine metabolism.	Cyclosporine	266-278	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	21-27
23252948-5	2013	A new CYP3A4 allele (CYP3A4*22; rs35599367 C&gt;T in intron 6) with a frequency of 5-7% in the Caucasian population was recently discovered through its association with low hepatic CYP3A4 expression and CYP3A4 activity, and showing effects on statin, tacrolimus and cyclosporine metabolism.	Cyclosporine	266-278	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	21-27
23252948-5	2013	A new CYP3A4 allele (CYP3A4*22; rs35599367 C&gt;T in intron 6) with a frequency of 5-7% in the Caucasian population was recently discovered through its association with low hepatic CYP3A4 expression and CYP3A4 activity, and showing effects on statin, tacrolimus and cyclosporine metabolism.	Cyclosporine	266-278	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	21-27
23146841-4	2013	These results suggest that MPA may ameliorate CsA-induced FBN production by modulating the Smad signaling pathway.	Cyclosporine	46-49	SMAD family member 7	Rattus norvegicus	91-95
23085740-0	2012	Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China.	Cyclosporine	64-78	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	15-20
23382681-4	2013	We show that CsA-treated mice exhibit impaired production of the chemoattractant chemokines CXCL2 and CXCL1, decreased intrarenal recruitment of neutrophils, and greater susceptibility to UPEC than vehicle-treated mice.	Cyclosporine	13-16	chemokine (C-X-C motif) ligand 2	Mus musculus	92-97
23382681-4	2013	We show that CsA-treated mice exhibit impaired production of the chemoattractant chemokines CXCL2 and CXCL1, decreased intrarenal recruitment of neutrophils, and greater susceptibility to UPEC than vehicle-treated mice.	Cyclosporine	13-16	chemokine (C-X-C motif) ligand 1	Mus musculus	102-107
23382681-6	2013	CsA inhibited lipopolysaccharide (LPS)-induced, Tlr4-mediated production of CXCL2 by epithelial collecting duct cells.	Cyclosporine	0-3	toll-like receptor 4	Mus musculus	48-52
23382681-6	2013	CsA inhibited lipopolysaccharide (LPS)-induced, Tlr4-mediated production of CXCL2 by epithelial collecting duct cells.	Cyclosporine	0-3	chemokine (C-X-C motif) ligand 2	Mus musculus	76-81
23336303-13	2013	CsA treatment precluded CXCR1 expression in both glomeruli and tubulointerstitium only in the first 6 h. CXCR1 may contribute to inflammation in experimental mesangioproliferative glomerulonephritis.	Cyclosporine	0-3	C-X-C motif chemokine receptor 1	Rattus norvegicus	24-29
23336303-13	2013	CsA treatment precluded CXCR1 expression in both glomeruli and tubulointerstitium only in the first 6 h. CXCR1 may contribute to inflammation in experimental mesangioproliferative glomerulonephritis.	Cyclosporine	0-3	C-X-C motif chemokine receptor 1	Rattus norvegicus	105-110
23336303-14	2013	CsA may be beneficial by inhibiting CXCR1 expression and corresponding inflammation.	Cyclosporine	0-3	C-X-C motif chemokine receptor 1	Rattus norvegicus	36-41
23555904-7	2013	In comparison, addition of MPA and Cyclosporine A displayed reduced CD107a expression and IFN-gamma production following PMA/Ionomycin stimulation.	Cyclosporine	35-49	interferon gamma	Homo sapiens	90-99
23382681-12	2013	The findings suggest that such mechanism of NFATc1-dependent inhibition of Nod1-mediated innate immune response together with the decrease in Tlr4-mediated production of chemoattractant chemokines caused by CsA may contribute to sensitizing kidney grafts to APN.	Cyclosporine	207-210	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	44-50
23382681-12	2013	The findings suggest that such mechanism of NFATc1-dependent inhibition of Nod1-mediated innate immune response together with the decrease in Tlr4-mediated production of chemoattractant chemokines caused by CsA may contribute to sensitizing kidney grafts to APN.	Cyclosporine	207-210	toll-like receptor 4	Mus musculus	142-146
22875481-4	2013	METHODS: Calcineurin inhibitor cyclosporine A (CsA) and tacrolimus (FK506) were microinjected into the medial prefrontal cortex (mPFC) in rats, and the depressive-like behavior was measured in sucrose preference test and forced swim test.	Cyclosporine	31-45	calcineurin binding protein 1	Rattus norvegicus	9-30
22875481-6	2013	RESULTS: Chronic microinjection of CsA or FK506 into mPFC increased depressive-like behaviors and decreased mTOR activity, but acute CsA or FK506 had no effects on both behavioral phenotype and mTOR activity.	Cyclosporine	35-38	mechanistic target of rapamycin kinase	Homo sapiens	108-112
22875481-7	2013	Furthermore, activation of mTOR by NMDA reversed the depressive-like behavior induced by chronic CsA or FK506 administration.	Cyclosporine	97-100	mechanistic target of rapamycin kinase	Homo sapiens	27-31
22980806-0	2012	Liquorice reduced cyclosporine bioavailability by activating P-glycoprotein and CYP 3A.	Cyclosporine	18-30	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	80-86
23085740-1	2012	AIM: To evaluate retrospectively the association of cytochrome P450 3A (CYP3A) and ATP-binding cassette sub-family B member 1 (ABCB1) gene polymorphisms with the pharmacokinetics of cyclosporine A (CsA) in Chinese renal transplant patients.	Cyclosporine	182-196	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	52-70
23085740-1	2012	AIM: To evaluate retrospectively the association of cytochrome P450 3A (CYP3A) and ATP-binding cassette sub-family B member 1 (ABCB1) gene polymorphisms with the pharmacokinetics of cyclosporine A (CsA) in Chinese renal transplant patients.	Cyclosporine	182-196	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	72-77
23085740-1	2012	AIM: To evaluate retrospectively the association of cytochrome P450 3A (CYP3A) and ATP-binding cassette sub-family B member 1 (ABCB1) gene polymorphisms with the pharmacokinetics of cyclosporine A (CsA) in Chinese renal transplant patients.	Cyclosporine	182-196	ATP binding cassette subfamily B member 1	Homo sapiens	83-125
23085740-1	2012	AIM: To evaluate retrospectively the association of cytochrome P450 3A (CYP3A) and ATP-binding cassette sub-family B member 1 (ABCB1) gene polymorphisms with the pharmacokinetics of cyclosporine A (CsA) in Chinese renal transplant patients.	Cyclosporine	182-196	ATP binding cassette subfamily B member 1	Homo sapiens	127-132
23085740-1	2012	AIM: To evaluate retrospectively the association of cytochrome P450 3A (CYP3A) and ATP-binding cassette sub-family B member 1 (ABCB1) gene polymorphisms with the pharmacokinetics of cyclosporine A (CsA) in Chinese renal transplant patients.	Cyclosporine	198-201	ATP binding cassette subfamily B member 1	Homo sapiens	127-132
23085740-7	2012	RESULTS: The CYP3A5*3C polymorphism influenced the C(0) and C(0)/dose of CsA, which were significantly higher in patients with the GG genotype than in patients with the AA or GA genotypes.	Cyclosporine	73-76	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	13-19
23085740-10	2012	In the multiple regression model, CYP3A5*3C, age, hemoglobin and blood creatinine level were associated with the log-transformed CsA C(0)/dose.	Cyclosporine	129-132	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	34-40
23085740-11	2012	CONCLUSION: CYP3A5*3C correlates with the C(0)/dose of CsA on the seventh day after renal transplantation.	Cyclosporine	55-58	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	12-18
22869619-9	2012	These phosphorylation events might correlate with changes in endothelial permeability since CsA slows down the recovery from the thrombin-induced decrease of the transendothelial electrical resistance of the BPAEC monolayer.	Cyclosporine	92-95	coagulation factor II, thrombin	Homo sapiens	129-137
24175257-6	2012	Cyclosporine A (CsA) and tacrolimus (Tac) are T-cell-specific calcineurin inhibitors that prevent the activation of helper T cells, thereby inhibiting the transcription of the early activation genes of interleukin (IL)-2 and suppressing T cell-induced activation of tumor necrosis factor-alpha, IL-1beta and IL-6.	Cyclosporine	0-14	interleukin 2	Homo sapiens	202-220
24175257-6	2012	Cyclosporine A (CsA) and tacrolimus (Tac) are T-cell-specific calcineurin inhibitors that prevent the activation of helper T cells, thereby inhibiting the transcription of the early activation genes of interleukin (IL)-2 and suppressing T cell-induced activation of tumor necrosis factor-alpha, IL-1beta and IL-6.	Cyclosporine	0-14	interleukin 1 beta	Homo sapiens	295-303
24175257-6	2012	Cyclosporine A (CsA) and tacrolimus (Tac) are T-cell-specific calcineurin inhibitors that prevent the activation of helper T cells, thereby inhibiting the transcription of the early activation genes of interleukin (IL)-2 and suppressing T cell-induced activation of tumor necrosis factor-alpha, IL-1beta and IL-6.	Cyclosporine	0-14	interleukin 6	Homo sapiens	308-312
24175257-6	2012	Cyclosporine A (CsA) and tacrolimus (Tac) are T-cell-specific calcineurin inhibitors that prevent the activation of helper T cells, thereby inhibiting the transcription of the early activation genes of interleukin (IL)-2 and suppressing T cell-induced activation of tumor necrosis factor-alpha, IL-1beta and IL-6.	Cyclosporine	16-19	interleukin 2	Homo sapiens	202-220
24175257-6	2012	Cyclosporine A (CsA) and tacrolimus (Tac) are T-cell-specific calcineurin inhibitors that prevent the activation of helper T cells, thereby inhibiting the transcription of the early activation genes of interleukin (IL)-2 and suppressing T cell-induced activation of tumor necrosis factor-alpha, IL-1beta and IL-6.	Cyclosporine	16-19	interleukin 1 beta	Homo sapiens	295-303
24175257-6	2012	Cyclosporine A (CsA) and tacrolimus (Tac) are T-cell-specific calcineurin inhibitors that prevent the activation of helper T cells, thereby inhibiting the transcription of the early activation genes of interleukin (IL)-2 and suppressing T cell-induced activation of tumor necrosis factor-alpha, IL-1beta and IL-6.	Cyclosporine	16-19	interleukin 6	Homo sapiens	308-312
23015147-2	2012	Clinically, calcineurin inhibitors (e.g., cyclosporine A, CsA) are known to suppress T cells, yet are also being used to reduce proteinuria in FSGS, suggesting the possibility of signal cross talk between uPAR and calcineurin.	Cyclosporine	42-56	plasminogen activator, urokinase receptor	Rattus norvegicus	205-209
23217392-0	2012	CYP3A4 genetic polymorphisms predict cyclosporine-related clinical events in Chinese renal transplant recipients.	Cyclosporine	37-49	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
23003106-6	2012	RESULTS: Cyclosporine and tacrolimus decreased insulin sensitivity by 22% (P = 0.02) and 13% (P = 0.048), respectively.	Cyclosporine	9-21	insulin	Homo sapiens	47-54
23003106-8	2012	CONCLUSION: In conclusion, 8-10 days of treatment with cyclosporine and tacrolimus impairs insulin sensitivity to a similar degree in haemodialysis patients, while acute insulin responses and pulsatile insulin secretion remain unaffected.	Cyclosporine	55-67	insulin	Homo sapiens	91-98
23217392-1	2012	BACKGROUND: Cyclosporin A (CsA) is a substrate of both cytochrome P450 3A (CYP3A) and P-glycoprotein (P-gp), some of the single nucleotide polymorphisms (SNPs) in these genes are associated with interindividual variations in CsA pharmacokinetics.	Cyclosporine	27-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	55-73
23217392-1	2012	BACKGROUND: Cyclosporin A (CsA) is a substrate of both cytochrome P450 3A (CYP3A) and P-glycoprotein (P-gp), some of the single nucleotide polymorphisms (SNPs) in these genes are associated with interindividual variations in CsA pharmacokinetics.	Cyclosporine	27-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-80
23217392-1	2012	BACKGROUND: Cyclosporin A (CsA) is a substrate of both cytochrome P450 3A (CYP3A) and P-glycoprotein (P-gp), some of the single nucleotide polymorphisms (SNPs) in these genes are associated with interindividual variations in CsA pharmacokinetics.	Cyclosporine	27-30	ATP binding cassette subfamily B member 1	Homo sapiens	86-100
23217392-1	2012	BACKGROUND: Cyclosporin A (CsA) is a substrate of both cytochrome P450 3A (CYP3A) and P-glycoprotein (P-gp), some of the single nucleotide polymorphisms (SNPs) in these genes are associated with interindividual variations in CsA pharmacokinetics.	Cyclosporine	27-30	ATP binding cassette subfamily B member 1	Homo sapiens	102-106
23217392-1	2012	BACKGROUND: Cyclosporin A (CsA) is a substrate of both cytochrome P450 3A (CYP3A) and P-glycoprotein (P-gp), some of the single nucleotide polymorphisms (SNPs) in these genes are associated with interindividual variations in CsA pharmacokinetics.	Cyclosporine	225-228	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	55-73
23217392-1	2012	BACKGROUND: Cyclosporin A (CsA) is a substrate of both cytochrome P450 3A (CYP3A) and P-glycoprotein (P-gp), some of the single nucleotide polymorphisms (SNPs) in these genes are associated with interindividual variations in CsA pharmacokinetics.	Cyclosporine	225-228	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-80
23217392-1	2012	BACKGROUND: Cyclosporin A (CsA) is a substrate of both cytochrome P450 3A (CYP3A) and P-glycoprotein (P-gp), some of the single nucleotide polymorphisms (SNPs) in these genes are associated with interindividual variations in CsA pharmacokinetics.	Cyclosporine	225-228	ATP binding cassette subfamily B member 1	Homo sapiens	86-100
23217392-1	2012	BACKGROUND: Cyclosporin A (CsA) is a substrate of both cytochrome P450 3A (CYP3A) and P-glycoprotein (P-gp), some of the single nucleotide polymorphisms (SNPs) in these genes are associated with interindividual variations in CsA pharmacokinetics.	Cyclosporine	225-228	ATP binding cassette subfamily B member 1	Homo sapiens	102-106
23217392-4	2012	Retrospective case control study was utilized to identify the association between CYP3A4 1G, CYP3A5 3, ABCB1 genetic polymorphisms and CsA-related outcomes.	Cyclosporine	135-138	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	82-88
23217392-4	2012	Retrospective case control study was utilized to identify the association between CYP3A4 1G, CYP3A5 3, ABCB1 genetic polymorphisms and CsA-related outcomes.	Cyclosporine	135-138	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	93-99
23217392-4	2012	Retrospective case control study was utilized to identify the association between CYP3A4 1G, CYP3A5 3, ABCB1 genetic polymorphisms and CsA-related outcomes.	Cyclosporine	135-138	ATP binding cassette subfamily B member 1	Homo sapiens	103-108
22446981-4	2012	Hematocrit (HCT), plasma albumin (ALB) level, and coadministration of itraconazole (ITR) were found to significantly affect the clearance of CsA (CL, L/h).	Cyclosporine	141-144	albumin	Homo sapiens	25-32
22446981-4	2012	Hematocrit (HCT), plasma albumin (ALB) level, and coadministration of itraconazole (ITR) were found to significantly affect the clearance of CsA (CL, L/h).	Cyclosporine	141-144	albumin	Homo sapiens	34-37
23035695-3	2012	Incubation with 1,25(OH)(2)D(3) for 4 or 24 h increased P-gp transport activity (specific luminal accumulation of NBD-CSA, the fluorescent P-gp substrate) by 25-30%.	Cyclosporine	118-121	phosphoglycolate phosphatase	Rattus norvegicus	56-60
23015147-2	2012	Clinically, calcineurin inhibitors (e.g., cyclosporine A, CsA) are known to suppress T cells, yet are also being used to reduce proteinuria in FSGS, suggesting the possibility of signal cross talk between uPAR and calcineurin.	Cyclosporine	58-61	plasminogen activator, urokinase receptor	Rattus norvegicus	205-209
23015147-6	2012	Pathological uPAR signals in podocytes are independent of T cells and affect cell motility via activation, but not expression, changes of the beta3 integrin and can be blocked by CsA, NFAT-siRNA, or the cell-permeable NFAT inhibitor (11R-VIVIT) using rodent models of glomerular disease (LPS; 5/6 nephrectomized rats).	Cyclosporine	179-182	plasminogen activator, urokinase receptor	Rattus norvegicus	13-17
23086953-7	2012	SIRT6 increases the nuclear levels of the Ca(2+)-dependent transcription factor, nuclear factor of activated T cells (NFAT), and cyclosporin A, a calcineurin inhibitor that reduces NFAT activity, reduces TNF and IL8 expression in SIRT6-overexpressing cells.	Cyclosporine	129-142	tumor necrosis factor	Homo sapiens	204-207
23014881-10	2012	The efflux of Hoechst 33342, a substrate for MDR1, was blocked by MDR1 inhibitor cyclosporin A, suggesting the functional expression of this transporter.	Cyclosporine	81-94	ATP binding cassette subfamily B member 1	Homo sapiens	45-49
23014881-10	2012	The efflux of Hoechst 33342, a substrate for MDR1, was blocked by MDR1 inhibitor cyclosporin A, suggesting the functional expression of this transporter.	Cyclosporine	81-94	ATP binding cassette subfamily B member 1	Homo sapiens	66-70
23086953-7	2012	SIRT6 increases the nuclear levels of the Ca(2+)-dependent transcription factor, nuclear factor of activated T cells (NFAT), and cyclosporin A, a calcineurin inhibitor that reduces NFAT activity, reduces TNF and IL8 expression in SIRT6-overexpressing cells.	Cyclosporine	129-142	C-X-C motif chemokine ligand 8	Homo sapiens	212-215
22992618-11	2012	We conclude that CsA slows cell cycle progression and induces necroptosis of human carcinoma cell lines in a TGFbeta-, NFAT-, NFkappaB- and PI3K/mTOR-independent fashion.	Cyclosporine	17-20	mechanistic target of rapamycin kinase	Homo sapiens	145-149
23041290-4	2012	Further study indicates that ET-1 also dose-dependently stimulated calcineurin activation, specific calcineurin inhibitor cyclosporine A (CsA), abolished ET-1-induced HIF1alpha elevation, and reversed ET-1-induced RACK1 (receptor of activated protein kinase C 1) de-phosphorylation.	Cyclosporine	122-136	endothelin 1	Homo sapiens	29-33
23041290-4	2012	Further study indicates that ET-1 also dose-dependently stimulated calcineurin activation, specific calcineurin inhibitor cyclosporine A (CsA), abolished ET-1-induced HIF1alpha elevation, and reversed ET-1-induced RACK1 (receptor of activated protein kinase C 1) de-phosphorylation.	Cyclosporine	138-141	endothelin 1	Homo sapiens	29-33
23146536-3	2012	Moreover, we have previously described low doses of cyclosporine (CsA) to inhibit Treg activity by inducing interleukin-2 and interfron-gamma.	Cyclosporine	52-64	interleukin 2	Homo sapiens	108-121
23084335-7	2012	Although other confounding factors causing immunological modulation may exist, it is plausible that low serum and high intracellular cyclosporine concentrations, due to the inhibition of P-gp activity by voriconazole, also contribute to an immunosuppressive state.	Cyclosporine	133-145	ATP binding cassette subfamily B member 1	Homo sapiens	187-191
22903029-10	2012	In the present study, we found that Dexamethasone and Cyclosporine A negatively regulated NF-kappaB signaling pathway under LPS simulation in HaCaT cells by inhibiting TLR4 expression, on the other hand, Cyclosporine A could inhibit HaCaT cell proliferation by the induction of the apoptosis of HaCaT cells to protect OLP from the destruction of epidermal cells effectively.	Cyclosporine	54-68	nuclear factor kappa B subunit 1	Homo sapiens	90-99
22903029-10	2012	In the present study, we found that Dexamethasone and Cyclosporine A negatively regulated NF-kappaB signaling pathway under LPS simulation in HaCaT cells by inhibiting TLR4 expression, on the other hand, Cyclosporine A could inhibit HaCaT cell proliferation by the induction of the apoptosis of HaCaT cells to protect OLP from the destruction of epidermal cells effectively.	Cyclosporine	204-218	nuclear factor kappa B subunit 1	Homo sapiens	90-99
22576324-2	2012	Cyclosporine and tacrolimus are calcineurin inhibitor immunosuppressants used to prevent organ rejection after liver transplantation; both are substrates of CYP3A4.	Cyclosporine	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	157-163
22903029-0	2012	The molecular mechanisms of the effect of Dexamethasone and Cyclosporin A on TLR4 /NF-kappaB signaling pathway activation in oral lichen planus.	Cyclosporine	60-73	nuclear factor kappa B subunit 1	Homo sapiens	83-92
23146536-3	2012	Moreover, we have previously described low doses of cyclosporine (CsA) to inhibit Treg activity by inducing interleukin-2 and interfron-gamma.	Cyclosporine	66-69	interleukin 2	Homo sapiens	108-121
23146536-9	2012	CONCLUSION: We have previously shown CsA to significantly impair the function of CD4(+)CD25(+) Treg cells.	Cyclosporine	37-40	CD4 molecule	Homo sapiens	81-84
23146540-4	2012	CsA inhibits P-glycoprotein resulting in decreased hepatic metabolism and renal excretion of colchicine.	Cyclosporine	0-3	ATP binding cassette subfamily B member 1	Homo sapiens	13-27
22906739-4	2012	The binding affinity of compound 1a to CypA has been confirmed by Fortebio"s Octet RED system and the increased phosphorylation of ERK in H446 cells is observed by treatment with both compound 1a and CsA.	Cyclosporine	200-203	mitogen-activated protein kinase 1	Homo sapiens	131-134
22751334-12	2012	Anti-TNF use in the 4 weeks preceding IV cyclosporine was the only predictor of surgery in this setting (P=0.05).	Cyclosporine	41-53	tumor necrosis factor	Homo sapiens	5-8
22851699-8	2012	Importantly, activation of the RCAN1 promoter by ionomycin, in control and FHL2 knockdown cells, was abolished by the calcineurin inhibitor cyclosporine, confirming the calcineurin dependence of the response.	Cyclosporine	140-152	four and a half LIM domains 2	Mus musculus	75-79
22897149-0	2012	Insulin independence after conversion from tacrolimus to cyclosporine in islet transplantation.	Cyclosporine	57-69	insulin	Homo sapiens	0-7
22892127-6	2012	Further, cyclosporine A (Cs-A), a Cyp-D inhibitor, inhibited UVB- or H(2)O(2)-induced keratinocytes cell death.	Cyclosporine	9-23	peptidylprolyl isomerase F	Homo sapiens	34-39
22892127-6	2012	Further, cyclosporine A (Cs-A), a Cyp-D inhibitor, inhibited UVB- or H(2)O(2)-induced keratinocytes cell death.	Cyclosporine	25-29	peptidylprolyl isomerase F	Homo sapiens	34-39
22929409-6	2012	For the entire patient cohort, there was a statistically significant inverse correlation between the CsA sensitivity of IL-2 and chronological age (r = 0.142, P &lt; 0.0001).	Cyclosporine	101-104	interleukin 2	Homo sapiens	120-124
22929409-7	2012	Also, the CsA sensitivity of IFN-gamma (r = 0.131, P &lt; 0.0001) and GM-CSF (r = 0.036, P &lt; 0.01) were inversely correlated with chronological age.	Cyclosporine	10-13	interferon gamma	Homo sapiens	29-38
22929409-9	2012	CONCLUSIONS: An increased sensitivity of IL-2 to suppression by CsA was found in pediatric renal transplant recipients in vivo compared with adults.	Cyclosporine	64-67	interleukin 2	Homo sapiens	41-45
22935417-7	2012	Additionally, treatment with cyclosporin A, a potent inhibitor of cyclophilin D, which can block MPT, could significantly restore the attenuated SOCE in N2a APPwt cells.	Cyclosporine	29-42	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	66-79
22822477-6	2012	Immunosuppressive drugs, such as tacrolimus (FK506) and cyclosporine A (CsA), were used to inhibit T cell interactions under the physiologic model of T cell migration at a ratio of 5 : 4.3 : 3.9 (E-selectin : ICAM-1 : VCAM-1).	Cyclosporine	72-75	vascular cell adhesion molecule 1	Homo sapiens	218-224
22846842-10	2012	CsA-induced phosphoinositide 3-kinase(PI3K)/AKT activation was required for both XPC suppression and CypA upregulation.	Cyclosporine	0-3	AKT serine/threonine kinase 1	Homo sapiens	44-47
22846842-12	2012	Our findings identified deregulation of XPC and CypA as key targets of CsA, and UVB damage and PI3K/AKT activation as two principal drivers for CsA-sensitized skin tumorigenesis, further supporting an immunosuppression-independent mechanism of CsA action on skin tumorigenesis.	Cyclosporine	144-147	AKT serine/threonine kinase 1	Homo sapiens	100-103
22749977-2	2012	Although oral bioavailability of cyclosporine A (CsA) was decreased by increased first-pass metabolism through CYP3A and P-glycoprotein (P-gp) specifically in the upper small intestine after liver I/R, the mechanism responsible for them remained to be clarified.	Cyclosporine	33-47	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	111-116
22749977-2	2012	Although oral bioavailability of cyclosporine A (CsA) was decreased by increased first-pass metabolism through CYP3A and P-glycoprotein (P-gp) specifically in the upper small intestine after liver I/R, the mechanism responsible for them remained to be clarified.	Cyclosporine	49-52	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	111-116
22749977-3	2012	In the present study, the effect of Trolox (an alpha-tocopherol analogue) on the decreased oral absorption of CsA through elevated intestinal CYP3A and P-gp after liver I/R and their regulations were investigated.	Cyclosporine	110-113	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	142-147
22749977-9	2012	These results demonstrate that Trolox ameliorates the decreased oral absorption of CsA through elevated intestinal CYP3A and P-gp by preventing oxidative stress, where the biliary lithocholic acid may be responsible for the elevated transcription of CYP3A specifically in the upper small intestine after liver I/R.	Cyclosporine	83-86	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	115-120
22749977-9	2012	These results demonstrate that Trolox ameliorates the decreased oral absorption of CsA through elevated intestinal CYP3A and P-gp by preventing oxidative stress, where the biliary lithocholic acid may be responsible for the elevated transcription of CYP3A specifically in the upper small intestine after liver I/R.	Cyclosporine	83-86	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	250-255
22947591-0	2012	CYP3A5 polymorphism effect on cyclosporine pharmacokinetics in living donor renal transplant recipients: analysis by population pharmacokinetics.	Cyclosporine	30-42	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	0-6
22947591-6	2012	OBJECTIVE: To build a population pharmacokinetic model of cyclosporine in living donor renal transplant recipients and identify covariates including CYP3A5*3, ABCB1 genetic polymorphisms that affect cyclosporine pharmacokinetic parameters.	Cyclosporine	199-211	ATP binding cassette subfamily B member 1	Homo sapiens	159-164
22947591-13	2012	A population pharmacokinetic analysis showed that postoperative days, sex, and CYP3A5 genotype significantly affected the pharmacokinetics of cyclosporine.	Cyclosporine	142-154	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	79-85
22947591-15	2012	CONCLUSIONS: Using the present model to calculate the dose of cyclosporine with CYP3A5 genotyping can be possible for the patients whose cyclosporine concentration is not within the therapeutic range even with therapeutic drug monitoring.	Cyclosporine	62-74	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	80-86
22947591-15	2012	CONCLUSIONS: Using the present model to calculate the dose of cyclosporine with CYP3A5 genotyping can be possible for the patients whose cyclosporine concentration is not within the therapeutic range even with therapeutic drug monitoring.	Cyclosporine	137-149	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	80-86
22846842-12	2012	Our findings identified deregulation of XPC and CypA as key targets of CsA, and UVB damage and PI3K/AKT activation as two principal drivers for CsA-sensitized skin tumorigenesis, further supporting an immunosuppression-independent mechanism of CsA action on skin tumorigenesis.	Cyclosporine	144-147	AKT serine/threonine kinase 1	Homo sapiens	100-103
22846842-11	2012	Blocking UVB damage or inhibiting the PI3K/AKT pathway prevented CsA-sensitized skin tumorigenesis.	Cyclosporine	65-68	AKT serine/threonine kinase 1	Homo sapiens	43-46
22634404-6	2012	However, CsA also caused a Ca2+/calmodulin-dependent protein kinase kinase beta (CaMKKbeta)-dependent activation of AMPK, which inhibits mTORC1 signaling; this led to ineffective Akt signaling.	Cyclosporine	9-12	AKT serine/threonine kinase 1	Homo sapiens	179-182
22484354-6	2012	Analysis of T-cell phenotype by flow cytometry in 2 subjects showed a decrease in circulating activated CD8(+) and CD4(+) T effector memory cells after treatment with CSA.	Cyclosporine	167-170	CD4 molecule	Homo sapiens	115-118
22820192-0	2012	Combined inhibition of p38 and Akt signaling pathways abrogates cyclosporine A-mediated pathogenesis of aggressive skin SCCs.	Cyclosporine	64-78	mitogen-activated protein kinase 14	Homo sapiens	23-26
22820192-0	2012	Combined inhibition of p38 and Akt signaling pathways abrogates cyclosporine A-mediated pathogenesis of aggressive skin SCCs.	Cyclosporine	64-78	AKT serine/threonine kinase 1	Homo sapiens	31-34
22820192-3	2012	Previously, we have shown that immunosuppressive drug, cyclosporine A (CsA) directly alters tumor phenotype of cutaneous squamous cell carcinomas (SCCs) by activating TGF-beta and TAK1/TAB1 signaling pathways.	Cyclosporine	55-69	transforming growth factor beta 1	Homo sapiens	167-175
22820192-3	2012	Previously, we have shown that immunosuppressive drug, cyclosporine A (CsA) directly alters tumor phenotype of cutaneous squamous cell carcinomas (SCCs) by activating TGF-beta and TAK1/TAB1 signaling pathways.	Cyclosporine	71-74	transforming growth factor beta 1	Homo sapiens	167-175
22820192-5	2012	We observed that combined blockade of Akt and p38 kinases-dependent signaling pathways in CsA-promoted human epidermoid carcinoma A431 xenograft tumors abrogated their growth by more than 90%.	Cyclosporine	90-93	AKT serine/threonine kinase 1	Homo sapiens	38-41
22820192-5	2012	We observed that combined blockade of Akt and p38 kinases-dependent signaling pathways in CsA-promoted human epidermoid carcinoma A431 xenograft tumors abrogated their growth by more than 90%.	Cyclosporine	90-93	mitogen-activated protein kinase 14	Homo sapiens	46-49
22634404-7	2012	An EGFR or Akt inhibitor increased the growth suppressive activity of CsA, whereas the combination of an AMPK inhibitor and CsA markedly rescued cells from the G1 arrest and increased cell growth.	Cyclosporine	70-73	epidermal growth factor receptor	Homo sapiens	3-7
22634404-7	2012	An EGFR or Akt inhibitor increased the growth suppressive activity of CsA, whereas the combination of an AMPK inhibitor and CsA markedly rescued cells from the G1 arrest and increased cell growth.	Cyclosporine	70-73	AKT serine/threonine kinase 1	Homo sapiens	11-14
22592641-6	2012	Thapsigargin and cyclosporine A also increased cytosolic Ca(2+) concentration and T cell death-associated gene 51 (TDAG51) expression, whereas tunicamycin did not.	Cyclosporine	17-31	pleckstrin homology like domain family A member 1	Homo sapiens	82-113
22592641-6	2012	Thapsigargin and cyclosporine A also increased cytosolic Ca(2+) concentration and T cell death-associated gene 51 (TDAG51) expression, whereas tunicamycin did not.	Cyclosporine	17-31	pleckstrin homology like domain family A member 1	Homo sapiens	115-121
22696685-7	2012	Treatment with PMA/Io increased expression of the goblet cell differentiation marker MUC2; these changes were attenuated by pretreatment with CsA or knockdown of REDD1 or NFATc3.	Cyclosporine	142-145	mucin 2, oligomeric mucus/gel-forming	Homo sapiens	85-89
22584255-5	2012	To define the mechanisms responsible for this low bioavailability, two P-glycoprotein (P-gp) inhibitors, verapamil and cyclosporine A, were used, and their presence substantially decreased C-K"s efflux ratio in Caco-2 cells (from 26.6 to &lt;3) and significantly increased intracellular concentrations (by as much as 40-fold).	Cyclosporine	119-133	ATP binding cassette subfamily B member 1	Homo sapiens	87-91
22584255-5	2012	To define the mechanisms responsible for this low bioavailability, two P-glycoprotein (P-gp) inhibitors, verapamil and cyclosporine A, were used, and their presence substantially decreased C-K"s efflux ratio in Caco-2 cells (from 26.6 to &lt;3) and significantly increased intracellular concentrations (by as much as 40-fold).	Cyclosporine	119-133	ATP binding cassette subfamily B member 1	Homo sapiens	71-85
22678567-0	2012	Cyclosporin A induces apoptosis in H9c2 cardiomyoblast cells through calcium-sensing receptor-mediated activation of the ERK MAPK and p38 MAPK pathways.	Cyclosporine	0-13	Eph receptor B1	Rattus norvegicus	121-124
22678567-5	2012	H9c2 cells were treated with CsA in a dose-dependent manner, and decreased Bcl-2 expression, increased Bax expression, and caspase-3 activation were observed.	Cyclosporine	29-32	BCL2, apoptosis regulator	Rattus norvegicus	75-80
22678567-6	2012	In a time-dependent manner, CsA increased CaSR expression, activated the extracellularly regulated kinase (ERK) and p38 MAPK pathways, and inactivated the c-Jun N-terminal kinase (JNK) MAPK signaling pathway.	Cyclosporine	28-31	Eph receptor B1	Rattus norvegicus	73-105
22678567-6	2012	In a time-dependent manner, CsA increased CaSR expression, activated the extracellularly regulated kinase (ERK) and p38 MAPK pathways, and inactivated the c-Jun N-terminal kinase (JNK) MAPK signaling pathway.	Cyclosporine	28-31	Eph receptor B1	Rattus norvegicus	107-110
23117946-6	2012	Acetylcholinesterase inhibitors are often the first modality of therapy for MG. As an immune-mediated disorder, MG can respond to several immunosuppressive agents, such as corticosteroids, azathioprine, mycophenolate mofetil, and cyclosporin.	Cyclosporine	230-241	acetylcholinesterase (Cartwright blood group)	Homo sapiens	0-20
22294776-12	2012	Compared to sham treatment, one dose (1 and 5 mg/kg body weight) of CsA significantly reduced kidney tubular cell apoptosis, serum creatinine, blood urea, serum IL-6 and urinary NGAL 2 days after FA injection.	Cyclosporine	68-71	interleukin 6	Mus musculus	161-165
22290425-4	2012	Based on that, the present study aimed to evaluate the reversal of MDR phenotype through modulation of Pgp efflux pump activity in leukemia multidrug-resistant cells, using a low dose of cyclosporine A (CsA).	Cyclosporine	203-206	ATP binding cassette subfamily B member 1	Homo sapiens	103-106
22290425-5	2012	We showed that modulation of Pgp activity by using CsA did not induce cytotoxic effects in leukemia cells, independently of Pgp expression.	Cyclosporine	51-54	ATP binding cassette subfamily B member 1	Homo sapiens	29-32
22797101-8	2012	Also, GFR was 79.8 +- 22.3 mL/min/1.73 m2 in the sirolimus group and 70.3 +- 23.6 mL/min/1.73 m2 in the cyclosporine group B (P = .04).	Cyclosporine	104-116	CD59 molecule (CD59 blood group)	Homo sapiens	85-90
22743548-5	2012	RESULTS: Cyclosporine and tacrolimus both decreased Treg proliferation, but only low doses of cyclosporine reduced Treg activity, by inducing the production of interleukin 2 proinflammatory cytokines in these cells.	Cyclosporine	9-21	interleukin 2	Homo sapiens	160-173
22743548-5	2012	RESULTS: Cyclosporine and tacrolimus both decreased Treg proliferation, but only low doses of cyclosporine reduced Treg activity, by inducing the production of interleukin 2 proinflammatory cytokines in these cells.	Cyclosporine	94-106	interleukin 2	Homo sapiens	160-173
23018254-0	2012	Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.	Cyclosporine	74-86	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	10-16
23018254-0	2012	Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.	Cyclosporine	74-86	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	24-30
23018254-7	2012	The mean cyclosporine dose in CYP3A4*1/*1B subjects was 455.04+-128.68 mg/day vs. 261.68+-64.72 mg/day in CYP3A4*1/*1 subjects (p&lt;0.001).	Cyclosporine	9-21	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-36
23018254-8	2012	The mean cyclosporine dose-adjusted trough blood concentrations (ng/ml per mg/kg body weight) in CYP3A4*1/*1B subjects were lower than in the CYP3A4*1/*1 group (37.06+-10.38 vs. 44.63+-13.99; p&lt;0.218).	Cyclosporine	9-21	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-103
23018254-9	2012	The mean cyclosporine dose in CYP3A5*1/*3 subjects was 400.65+-164.97 mg/day vs. 263.52+-64.39 mg/day in CYP3A5*3/*3 subjects (p&lt;0.022).	Cyclosporine	9-21	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	30-36
23018254-11	2012	CONCLUSIONS: Genetic polymorphisms in CYP3A4 and CYP3A5 may underlie inter-individual differences in cyclosporine pharmacokinetics after renal transplantation.	Cyclosporine	101-113	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-44
23018254-11	2012	CONCLUSIONS: Genetic polymorphisms in CYP3A4 and CYP3A5 may underlie inter-individual differences in cyclosporine pharmacokinetics after renal transplantation.	Cyclosporine	101-113	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	49-55
23018254-12	2012	Patients with at least 1 functional CYP3A5*1 or CYP3A4*1B allele require significantly higher doses of cyclosporine to reach target drug levels compared to patients with the CYP3A4*1 or CYP3A5*3 alleles.	Cyclosporine	103-115	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	36-42
23018254-12	2012	Patients with at least 1 functional CYP3A5*1 or CYP3A4*1B allele require significantly higher doses of cyclosporine to reach target drug levels compared to patients with the CYP3A4*1 or CYP3A5*3 alleles.	Cyclosporine	103-115	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	48-54
23018254-12	2012	Patients with at least 1 functional CYP3A5*1 or CYP3A4*1B allele require significantly higher doses of cyclosporine to reach target drug levels compared to patients with the CYP3A4*1 or CYP3A5*3 alleles.	Cyclosporine	103-115	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	174-180
23018257-0	2012	Influence of conversion from cyclosporine A to tacrolimus on insulin sensitivity assessed by euglicaemic hyperinsulinemic clamp technique in patients after kidney transplantation.	Cyclosporine	29-43	insulin	Homo sapiens	61-68
22502817-3	2012	This study investigates the effects on a uterine transplant in the rat of the calcineurin inhibitor, cyclosporine A (CsA), on uterine morphology and expression patterns of some mediators involved in implantation/inflammation.	Cyclosporine	117-120	calcineurin binding protein 1	Rattus norvegicus	78-99
22502817-10	2012	The uterine mRNA levels of IL-1alpha were decreased after CsA in comparison to uteri of non-treated transplanted animals.	Cyclosporine	58-61	interleukin 1 alpha	Rattus norvegicus	27-36
22502817-11	2012	The mRNA levels of galectin-1 were decreased in the rejected uteri and were higher in the CsA-treated.	Cyclosporine	90-93	galectin 1	Rattus norvegicus	19-29
22502817-14	2012	CONCLUSION(S): Cyclosporine A suppresses rejection of an allogenic rat uterine transplant, with normalization of mRNA levels of the proinflammatory cytokine IL-1alpha and the glycan-binding protein galectin-1.	Cyclosporine	15-29	interleukin 1 alpha	Rattus norvegicus	157-166
22502817-14	2012	CONCLUSION(S): Cyclosporine A suppresses rejection of an allogenic rat uterine transplant, with normalization of mRNA levels of the proinflammatory cytokine IL-1alpha and the glycan-binding protein galectin-1.	Cyclosporine	15-29	galectin 1	Rattus norvegicus	198-208
22495096-9	2012	Blocking the mitogen-activated proteinkinase/extracellular signal-regulated kinase (MAPK/ERK1/2) signaling by U0126 abrogated the CsA-induced increase in CXCL12 and CXCR4 expression and neutralizing antibodies to CXCL12 or CXCR4 completely inhibited the CsA-induced increase in cell number, invasion and MMP-9 and MMP-2 activity of cytotrophoblast.	Cyclosporine	130-133	mitogen-activated protein kinase 3	Homo sapiens	84-88
22495096-9	2012	Blocking the mitogen-activated proteinkinase/extracellular signal-regulated kinase (MAPK/ERK1/2) signaling by U0126 abrogated the CsA-induced increase in CXCL12 and CXCR4 expression and neutralizing antibodies to CXCL12 or CXCR4 completely inhibited the CsA-induced increase in cell number, invasion and MMP-9 and MMP-2 activity of cytotrophoblast.	Cyclosporine	130-133	mitogen-activated protein kinase 3	Homo sapiens	89-95
22495096-9	2012	Blocking the mitogen-activated proteinkinase/extracellular signal-regulated kinase (MAPK/ERK1/2) signaling by U0126 abrogated the CsA-induced increase in CXCL12 and CXCR4 expression and neutralizing antibodies to CXCL12 or CXCR4 completely inhibited the CsA-induced increase in cell number, invasion and MMP-9 and MMP-2 activity of cytotrophoblast.	Cyclosporine	254-257	mitogen-activated protein kinase 3	Homo sapiens	84-88
22495096-9	2012	Blocking the mitogen-activated proteinkinase/extracellular signal-regulated kinase (MAPK/ERK1/2) signaling by U0126 abrogated the CsA-induced increase in CXCL12 and CXCR4 expression and neutralizing antibodies to CXCL12 or CXCR4 completely inhibited the CsA-induced increase in cell number, invasion and MMP-9 and MMP-2 activity of cytotrophoblast.	Cyclosporine	254-257	mitogen-activated protein kinase 3	Homo sapiens	89-95
22211698-0	2012	Interleukin-17- and protease-activated receptor 2-mediated production of CXCL1 and CXCL8 modulated by cyclosporine A, vitamin D3 and glucocorticoids in human keratinocytes.	Cyclosporine	102-116	C-X-C motif chemokine ligand 8	Homo sapiens	83-88
22211698-4	2012	The SLIGKV-NH(2) -induced production of both CXCL1 and CXCL8 was markedly reduced by cyclosporine A.	Cyclosporine	85-99	C-X-C motif chemokine ligand 8	Homo sapiens	55-60
22564366-8	2012	Cyclosporine A also attenuated the decline in mitochondrial membrane potential under TGFbeta(1) in WT cardiomyocytes.	Cyclosporine	0-14	transforming growth factor, beta 1	Rattus norvegicus	85-92
21940156-4	2012	The incidence of BK-related events may be reduced in patients receiving mTOR inhibitors (everolimus or sirolimus) with cyclosporine vs a calcineurin inhibitor with mycophenolic acid.	Cyclosporine	119-131	mechanistic target of rapamycin kinase	Homo sapiens	72-76
21940156-5	2012	De novo immunosuppression regimens that avoid rabbit antithymocyte globulin and tacrolimus, particularly tacrolimus with mycophenolic acid, may be advantageous, whereas low-exposure cyclosporine with an mTOR inhibitor appears a favorable option.	Cyclosporine	182-194	mechanistic target of rapamycin kinase	Homo sapiens	203-207
22416070-6	2012	Snail siRNA targeting prevented the downregulation of E-cadherin by CsA.	Cyclosporine	68-71	snail family transcriptional repressor 1	Homo sapiens	0-5
22841242-10	2012	Within the rejection group the frequency of patients with the GSTM1 null genotype was higher among subjects prescribed cyclosporine A versus tacrolimus (P = .029).	Cyclosporine	119-133	glutathione S-transferase mu 1	Homo sapiens	62-67
22841242-13	2012	This study suggested that GSTM1 genotype may be important for cyclosporine detoxification and for allograft outcomes due to drug nephrotoxicity.	Cyclosporine	62-74	glutathione S-transferase mu 1	Homo sapiens	26-31
22841259-9	2012	The lowest CAT mean levels were noted in the CsA and diltiazem groups with highest CAT content was in the CsA and cilostazol groups.	Cyclosporine	45-48	catalase	Rattus norvegicus	11-14
22841259-9	2012	The lowest CAT mean levels were noted in the CsA and diltiazem groups with highest CAT content was in the CsA and cilostazol groups.	Cyclosporine	45-48	catalase	Rattus norvegicus	83-86
22476221-6	2012	Both protease inhibitors can modify the levels of drugs metabolized by the CYP3A/4 pathway, and in posttransplant patients, the protease inhibitors increase the levels of cyclosporine and tacrolimus, with the magnitude of the drug-drug interactions varying with protease inhibitor and type of calcineurin inhibitor (CNI).	Cyclosporine	171-183	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-82
22416070-5	2012	CsA upregulated transcriptional repressors (Snail, Slug, and Twist) of the adherent and tight junction proteins were studied.	Cyclosporine	0-3	snail family transcriptional repressor 1	Homo sapiens	44-49
22416070-0	2012	GSK3, snail, and adhesion molecule regulation by cyclosporine A in renal tubular cells.	Cyclosporine	49-63	snail family transcriptional repressor 1	Homo sapiens	6-11
22416070-6	2012	Snail siRNA targeting prevented the downregulation of E-cadherin by CsA.	Cyclosporine	68-71	cadherin 1	Homo sapiens	54-64
22416070-4	2012	In renal tubular cells, cytotoxic concentrations of cyclosporine A (CsA) inhibited both gene and protein expression of adherent and tight junction proteins (E-cadherin, ZO-1, claudin-1, and beta-catenin) and increased vimentin expression, without involvement of transforming growth factor beta1 or caspase activity.	Cyclosporine	52-66	cadherin 1	Homo sapiens	157-167
22416070-4	2012	In renal tubular cells, cytotoxic concentrations of cyclosporine A (CsA) inhibited both gene and protein expression of adherent and tight junction proteins (E-cadherin, ZO-1, claudin-1, and beta-catenin) and increased vimentin expression, without involvement of transforming growth factor beta1 or caspase activity.	Cyclosporine	52-66	tight junction protein 1	Homo sapiens	169-173
22416070-7	2012	CsA promoted glycogen synthase kinase 3 (GSK3) phosphorylation and increased Snail half-life.	Cyclosporine	0-3	snail family transcriptional repressor 1	Homo sapiens	77-82
22416070-4	2012	In renal tubular cells, cytotoxic concentrations of cyclosporine A (CsA) inhibited both gene and protein expression of adherent and tight junction proteins (E-cadherin, ZO-1, claudin-1, and beta-catenin) and increased vimentin expression, without involvement of transforming growth factor beta1 or caspase activity.	Cyclosporine	68-71	cadherin 1	Homo sapiens	157-167
22416070-4	2012	In renal tubular cells, cytotoxic concentrations of cyclosporine A (CsA) inhibited both gene and protein expression of adherent and tight junction proteins (E-cadherin, ZO-1, claudin-1, and beta-catenin) and increased vimentin expression, without involvement of transforming growth factor beta1 or caspase activity.	Cyclosporine	68-71	tight junction protein 1	Homo sapiens	169-173
22416070-10	2012	Furthermore, GSK3 siRNA had a negative impact on CsA-induced upregulation of Snail.	Cyclosporine	49-52	snail family transcriptional repressor 1	Homo sapiens	77-82
22764569-6	2012	Although verapamil and cyclosporine A as MDR1 substrates completely inhibited the basolateral-to-apical transport, probenecid as MRP1 inhibitor did not show an effect.	Cyclosporine	23-37	ATP binding cassette subfamily B member 1	Homo sapiens	41-45
22616995-4	2012	Rotenone, cyclosporine A, and bongkrekic acid suppress TNF-alpha-induced VCAM-1 expression.	Cyclosporine	10-24	tumor necrosis factor	Homo sapiens	55-64
22616995-4	2012	Rotenone, cyclosporine A, and bongkrekic acid suppress TNF-alpha-induced VCAM-1 expression.	Cyclosporine	10-24	vascular cell adhesion molecule 1	Homo sapiens	73-79
22326661-4	2012	We used a rodent model of exhaustive running exercise, where rats were treated or not with cyclosporin A (CsA), a calcineurin inhibitor shown to blunt plasma Il-6 during exercise.	Cyclosporine	106-109	interleukin 6	Rattus norvegicus	158-162
22326661-5	2012	Despite similar running intensity and duration, animals treated with CsA had 50% lower plasma Il-6 concentrations at the end of exercise.	Cyclosporine	69-72	interleukin 6	Rattus norvegicus	94-98
22326661-6	2012	The concomitant rise in hepatic mRNA levels of two Il-6 responsive genes, suppressor of cytokine signaling (SOCS) 3 and Il-6 receptor alpha, was blunted in CsA-treated group.	Cyclosporine	156-159	interleukin 6	Rattus norvegicus	51-55
22326661-6	2012	The concomitant rise in hepatic mRNA levels of two Il-6 responsive genes, suppressor of cytokine signaling (SOCS) 3 and Il-6 receptor alpha, was blunted in CsA-treated group.	Cyclosporine	156-159	interleukin 6	Rattus norvegicus	120-124
22326661-7	2012	Finally, hepcidin mRNA levels increased in response to exercise, peaking 2h later, but peak values were significantly lower in CsA group compared to control group.	Cyclosporine	127-130	hepcidin antimicrobial peptide	Rattus norvegicus	9-17
22466612-2	2012	Cockayne syndrome is a related disorder with defective TCR and consists of two complementation groups, Cockayne syndrome (CS)-A and CS-B, which are caused by mutations in ERCC8 (CSA) and ERCC6 (CSB), respectively.	Cyclosporine	178-181	ERCC excision repair 6, chromatin remodeling factor	Homo sapiens	132-136
22388796-0	2012	The new CYP3A4 intron 6 C&gt;T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients.	Cyclosporine	147-159	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	8-14
22388796-0	2012	The new CYP3A4 intron 6 C&gt;T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients.	Cyclosporine	147-159	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-51
22521608-10	2012	Inhibition of c-Jun N-terminal kinase (JNK) attenuated palmitic acid and CsA induced toxicity, suggesting that JNK activation plays an important role in mediating the enhanced palmitic acid/CsA-induced toxicity.	Cyclosporine	73-76	mitogen-activated protein kinase 8	Homo sapiens	14-37
22521608-10	2012	Inhibition of c-Jun N-terminal kinase (JNK) attenuated palmitic acid and CsA induced toxicity, suggesting that JNK activation plays an important role in mediating the enhanced palmitic acid/CsA-induced toxicity.	Cyclosporine	73-76	mitogen-activated protein kinase 8	Homo sapiens	39-42
22521608-10	2012	Inhibition of c-Jun N-terminal kinase (JNK) attenuated palmitic acid and CsA induced toxicity, suggesting that JNK activation plays an important role in mediating the enhanced palmitic acid/CsA-induced toxicity.	Cyclosporine	73-76	mitogen-activated protein kinase 8	Homo sapiens	111-114
22521608-10	2012	Inhibition of c-Jun N-terminal kinase (JNK) attenuated palmitic acid and CsA induced toxicity, suggesting that JNK activation plays an important role in mediating the enhanced palmitic acid/CsA-induced toxicity.	Cyclosporine	190-193	mitogen-activated protein kinase 8	Homo sapiens	14-37
22521608-10	2012	Inhibition of c-Jun N-terminal kinase (JNK) attenuated palmitic acid and CsA induced toxicity, suggesting that JNK activation plays an important role in mediating the enhanced palmitic acid/CsA-induced toxicity.	Cyclosporine	190-193	mitogen-activated protein kinase 8	Homo sapiens	39-42
22521608-10	2012	Inhibition of c-Jun N-terminal kinase (JNK) attenuated palmitic acid and CsA induced toxicity, suggesting that JNK activation plays an important role in mediating the enhanced palmitic acid/CsA-induced toxicity.	Cyclosporine	190-193	mitogen-activated protein kinase 8	Homo sapiens	111-114
22368036-6	2012	Moreover, cyclosporine A, a blocker of mPTP opening, attenuates isoflurane-induced mPTP opening, caspase 3 activation, and impairment of learning and memory.	Cyclosporine	10-24	caspase 3	Homo sapiens	97-106
22494616-4	2012	Specially, compound 27 displayed 200-fold lower cytotoxicity (CC(50)=2174.39 muM) than cyclosporin A (CC(50)=10.10 muM) and showed SI value (SI=176.69) close to cyclosporin A (SI=154.13).	Cyclosporine	87-100	latexin	Homo sapiens	115-118
22471287-0	2012	Cyclosporin but not everolimus inhibits chemokine receptor expression on CD4+ T cell subsets circulating in the peripheral blood of renal transplant recipients.	Cyclosporine	0-11	CD4 molecule	Homo sapiens	73-76
22471287-9	2012	CsA, but not everolimus, inhibits both T(reg) development and expression of CXCR3 and CCR5 on CD4(+) T cell subsets.	Cyclosporine	0-3	CD4 molecule	Homo sapiens	94-97
22493070-7	2012	Ang II effects were blunted by an Ang II type 1 receptor antagonist (candesartan) and inhibitors of calcineurin (cyclosporine A and FK506) and nuclear factor of activated T-cells (VIVIT).	Cyclosporine	113-127	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	0-6
21976740-9	2012	After conversion from CsA to MMF, renal function improved significantly; the eGFR at last follow-up was 137 (range 106-198) mL/min x 1.73 m(2).	Cyclosporine	22-25	epidermal growth factor receptor	Homo sapiens	77-81
22743722-0	2012	Association of transforming growth factor beta1 (TGF- beta1) with gingival hyperplasia in heart transplant patients undergoing cyclosporine-A treatment.	Cyclosporine	127-141	transforming growth factor beta 1	Homo sapiens	15-47
22812226-7	2012	CsA inhibited the expression of VEGF and the complement inhibitor DAF and increased the expression of CRP of vascular endothelial cells.	Cyclosporine	0-3	CD55 molecule (Cromer blood group)	Rattus norvegicus	66-69
22812226-7	2012	CsA inhibited the expression of VEGF and the complement inhibitor DAF and increased the expression of CRP of vascular endothelial cells.	Cyclosporine	0-3	C-reactive protein	Rattus norvegicus	102-105
22812226-10	2012	CONCLUSION: CsA can damage vascular endothelium of hyperlipidemic rats by activating the complement system induced by VEGF/DAF and ROS/CRP pathway.	Cyclosporine	12-15	CD55 molecule (Cromer blood group)	Rattus norvegicus	123-126
22812226-10	2012	CONCLUSION: CsA can damage vascular endothelium of hyperlipidemic rats by activating the complement system induced by VEGF/DAF and ROS/CRP pathway.	Cyclosporine	12-15	C-reactive protein	Rattus norvegicus	135-138
22564602-12	2012	CsA treatment induced the degradation of 116-kDa PARP into an 89-kDa fragment.	Cyclosporine	0-3	poly(ADP-ribose) polymerase 1	Homo sapiens	49-53
22564603-8	2012	CsA induced p27 and p53, as well as degradation of 116-kd PARP into an 89-kd fragment.	Cyclosporine	0-3	tumor protein p53	Homo sapiens	20-23
22564605-7	2012	RESULTS: MMP-1, MMP-3, MMP-8, MMP-9, and MMP-13 activities were increased after CsA treatment; MMP-1 = 121; MMP-3 = 164; MMP-8 = 133; MMP-9 = 124; and MMP-13 = 121.	Cyclosporine	80-83	matrix metallopeptidase 3	Homo sapiens	16-21
22564605-7	2012	RESULTS: MMP-1, MMP-3, MMP-8, MMP-9, and MMP-13 activities were increased after CsA treatment; MMP-1 = 121; MMP-3 = 164; MMP-8 = 133; MMP-9 = 124; and MMP-13 = 121.	Cyclosporine	80-83	matrix metallopeptidase 13	Homo sapiens	41-47
22564605-7	2012	RESULTS: MMP-1, MMP-3, MMP-8, MMP-9, and MMP-13 activities were increased after CsA treatment; MMP-1 = 121; MMP-3 = 164; MMP-8 = 133; MMP-9 = 124; and MMP-13 = 121.	Cyclosporine	80-83	matrix metallopeptidase 3	Homo sapiens	95-113
22564605-7	2012	RESULTS: MMP-1, MMP-3, MMP-8, MMP-9, and MMP-13 activities were increased after CsA treatment; MMP-1 = 121; MMP-3 = 164; MMP-8 = 133; MMP-9 = 124; and MMP-13 = 121.	Cyclosporine	80-83	matrix metallopeptidase 13	Homo sapiens	151-157
22564630-5	2012	Nitric oxide production induces by CsA treatment was significantly suppressed by GTE and iNOS inhibitor.	Cyclosporine	35-38	nitric oxide synthase 2	Rattus norvegicus	89-93
22743722-3	2012	The aim of the study was to assess the impact of TGF- beta(1) and IL-2 on the development and maintenance of gingival hyperplasia in patients treated with CyA after orthotopic heart transplantation (OHT).	Cyclosporine	155-158	transforming growth factor beta 1	Homo sapiens	49-61
22743722-3	2012	The aim of the study was to assess the impact of TGF- beta(1) and IL-2 on the development and maintenance of gingival hyperplasia in patients treated with CyA after orthotopic heart transplantation (OHT).	Cyclosporine	155-158	interleukin 2	Homo sapiens	66-70
22743722-10	2012	CONCLUSIONS: TGF- beta(1) is associated with gingival hyperplasia in patients treated with CyA after OHT procedure.	Cyclosporine	91-94	transforming growth factor beta 1	Homo sapiens	13-25
22285391-10	2012	Mitochondrial collapse was demonstrated by transmission electron microscopy, and oxidative stress was evaluated by measuring Cu-Zn SOD, MDA, and 8-OHdG generated by EG administration, all of which were prevented by CsA.	Cyclosporine	215-218	superoxide dismutase 1	Rattus norvegicus	125-134
22205779-0	2012	Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.	Cyclosporine	0-14	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	54-60
22205779-0	2012	Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.	Cyclosporine	0-14	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	65-71
22205779-3	2012	For CsA, in particular, inhibition of CYP3A has been suggested as the main mechanism of interactions seen clinically with various drugs.	Cyclosporine	4-7	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-43
22205779-4	2012	The aim of this study was to investigate the inhibitory effect and inhibition characteristics of CsA and Tac on CYP3A4 and CYP3A5 in vitro and to evaluate its clinical relevance.	Cyclosporine	97-100	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	112-118
22205779-4	2012	The aim of this study was to investigate the inhibitory effect and inhibition characteristics of CsA and Tac on CYP3A4 and CYP3A5 in vitro and to evaluate its clinical relevance.	Cyclosporine	97-100	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	123-129
22205779-5	2012	Inhibition by CsA and Tac was studied using midazolam as the probe substrate in coincubation and preincubation investigations using human liver microsomes (HLMs) as well as specific CYP3A4- and CYP3A5-expressing insect microsomes (Supersomes).	Cyclosporine	14-17	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	182-188
22205779-5	2012	Inhibition by CsA and Tac was studied using midazolam as the probe substrate in coincubation and preincubation investigations using human liver microsomes (HLMs) as well as specific CYP3A4- and CYP3A5-expressing insect microsomes (Supersomes).	Cyclosporine	14-17	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	194-200
22205779-8	2012	Experiments in Supersomes revealed that Tac inhibited both CYP3A4 and CYP3A5, whereas CsA only inhibited CYP3A4.	Cyclosporine	86-89	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	105-111
22205779-10	2012	By application of HLM data, IVIVE estimated the area under the concentration versus time curve of midazolam to increase by 73 and 27% with CsA and Tac, respectively.	Cyclosporine	139-142	oxysterol binding protein 2	Homo sapiens	18-21
22696872-7	2012	RESULTS: The present study showed that cyclosporine induced the nephrotoxicity as appeared by elevation of serum and urinary levels of creatinine, urinary level of beta2 microglobulin, serum levels of ammonia, TGF-beta1 and TNF-alpha and the NAG level while decreased the creatinine clearance.	Cyclosporine	39-51	transforming growth factor, beta 1	Rattus norvegicus	210-219
22696872-7	2012	RESULTS: The present study showed that cyclosporine induced the nephrotoxicity as appeared by elevation of serum and urinary levels of creatinine, urinary level of beta2 microglobulin, serum levels of ammonia, TGF-beta1 and TNF-alpha and the NAG level while decreased the creatinine clearance.	Cyclosporine	39-51	tumor necrosis factor	Rattus norvegicus	224-233
21988494-4	2012	WHAT THIS STUDY ADDS: This is the first trial to investigate beta cell function and insulin sensitivity using gold standard methodology in healthy human volunteers treated with clinically relevant doses of ciclosporin and tacrolimus.	Cyclosporine	206-217	insulin	Homo sapiens	84-91
21988494-17	2012	CsA, and to a lesser degree Tac infusions, in healthy volunteers include increased insulin sensitivity, without any effect on first phase or pulsatile insulin secretion.	Cyclosporine	0-3	insulin	Homo sapiens	83-90
22437740-4	2012	It is shown that 2-AG causes a relevant decrease of calcium induced cyclosporine A sensitive cytochrome c release from mitochondria, a process representing an early event of the apoptotic program.	Cyclosporine	68-82	cytochrome c, somatic	Homo sapiens	93-105
22088485-8	2012	Inhibition of the multi-drug resistance pump ABCB1 with cyclosporine or knockdown with shRNA prior to treatment with YM155 demonstrated that cell lines with ABCB1 expression became 27-695 times more sensitive to YM155 treatment.	Cyclosporine	56-68	ATP binding cassette subfamily B member 1	Homo sapiens	45-50
22799027-6	2012	To assess the effect of known P-gp inhibitors on the efflux of Rh123, cyclosporine A (CyA), tariquidar (TQD) or quinidine (QND) (10, 50 and 100 micromol x L(-1)) was pre-incubated separately with SCRH for 30 min, then co-incubated with Rh123.	Cyclosporine	70-84	phosphoglycolate phosphatase	Rattus norvegicus	30-34
22334041-10	2012	In single-SNP adjusted analysis, nine SNPs in the XPC, CYP2C9, PAX4, MTRR, and GAN genes were associated with cyclosporine nephrotoxicity.	Cyclosporine	110-122	5-methyltetrahydrofolate-homocysteine methyltransferase reductase	Homo sapiens	69-73
22416178-3	2012	In the AGT group, all recipients were subcutaneously injected by Cyclosporin A after LT.	Cyclosporine	65-78	angiotensinogen	Rattus norvegicus	7-10
22198507-9	2012	During reoxygenation, coordinated redox changes also occurred across large regions and preceded mPTP opening on average by 122 +- 38 s. Fewer [Ca(2+)] waves led to mPTP opening in the presence of mPTP inhibitor cyclosporin A or mitochondrial-targeted scavenger of reactive oxygen species, MitoQ.	Cyclosporine	211-224	protein tyrosine phosphatase, receptor type, U	Mus musculus	164-168
22198507-9	2012	During reoxygenation, coordinated redox changes also occurred across large regions and preceded mPTP opening on average by 122 +- 38 s. Fewer [Ca(2+)] waves led to mPTP opening in the presence of mPTP inhibitor cyclosporin A or mitochondrial-targeted scavenger of reactive oxygen species, MitoQ.	Cyclosporine	211-224	protein tyrosine phosphatase, receptor type, U	Mus musculus	164-168
22420656-9	2012	However, repeated pretreatment (7 days) with oral ETP significantly decreased the oral morphine-induced analgesia, in a cyclosporine A (a P-gp inhibitor) reversible manner.	Cyclosporine	120-134	ATP binding cassette subfamily B member 1	Homo sapiens	138-142
22316009-2	2012	In addition, the potency (EC(50)) of CsA to inhibit rat BBB P-gp can be predicted from in vitro studies in MDRI-transfected cells.	Cyclosporine	37-40	phosphoglycolate phosphatase	Rattus norvegicus	60-64
22316009-5	2012	The potency (EC(50)) of CsA to inhibit P-gp at the rat BBB was independent of the substrate used (verapamil, Lop, or dLop).	Cyclosporine	24-27	phosphoglycolate phosphatase	Rattus norvegicus	39-43
22205628-7	2012	However, hPRL complexation was antagonized by cyclosporine A and anti-cyclophilins.	Cyclosporine	46-60	prolactin	Homo sapiens	9-13
22088485-8	2012	Inhibition of the multi-drug resistance pump ABCB1 with cyclosporine or knockdown with shRNA prior to treatment with YM155 demonstrated that cell lines with ABCB1 expression became 27-695 times more sensitive to YM155 treatment.	Cyclosporine	56-68	ATP binding cassette subfamily B member 1	Homo sapiens	157-162
22101490-0	2012	Annexin A1 protein attenuates cyclosporine-induced renal hemodynamics changes and macrophage infiltration in rats.	Cyclosporine	30-42	annexin A1	Rattus norvegicus	0-10
22345300-7	2012	Furthermore, cardiomyocyte hypertrophy induced by caffeine was inhibited by cyclosporin A (CsA) and KN93, whereas cardiomyocyte hypertrophy induced by Ang II was inhibited by KN93, but not CsA.	Cyclosporine	189-192	angiotensinogen	Rattus norvegicus	151-157
22101490-8	2012	RESULTS: CsA significantly impaired GFR and RBF, caused tubular dilation and macrophage infiltration and increased ANXA1 renal tissue expression.	Cyclosporine	9-12	annexin A1	Rattus norvegicus	115-120
22101490-9	2012	Treatment with ANXA1 attenuated CSA-induced hemodynamic changes, tubular injury and macrophage infiltration.	Cyclosporine	32-35	annexin A1	Rattus norvegicus	15-20
22101490-10	2012	CONCLUSION: ANXA1 treatment attenuated renal hemodynamic injury and inflammation in an acute CsA nephrotoxicity model.	Cyclosporine	93-96	annexin A1	Rattus norvegicus	12-17
22147139-0	2012	Cyclosporine A--induced oxidative stress in human renal mesangial cells: a role for ERK 1/2 MAPK signaling.	Cyclosporine	0-14	mitogen-activated protein kinase 3	Homo sapiens	84-91
22147139-0	2012	Cyclosporine A--induced oxidative stress in human renal mesangial cells: a role for ERK 1/2 MAPK signaling.	Cyclosporine	0-14	mitogen-activated protein kinase 3	Homo sapiens	92-96
22147139-8	2012	Bioinformatic analysis of these 282 genes indicated enriched apoptotic oxidative stress, mitogen-activated protein kinase (MAPK), and transforming growth factor-beta signaling in response to CsA treatment.	Cyclosporine	191-194	mitogen-activated protein kinase 3	Homo sapiens	123-127
22147139-9	2012	The focus of this study was directed on oxidative stress and MAPK signaling as potential novel mechanisms of CsA nephrotoxicity.	Cyclosporine	109-112	mitogen-activated protein kinase 3	Homo sapiens	61-65
22147139-11	2012	Inhibition of the MAPK pathway resulted in attenuation of the CsA-induced mesangial cell alterations.	Cyclosporine	62-65	mitogen-activated protein kinase 3	Homo sapiens	18-22
22343435-7	2012	The increased expression of HIF-1alpha ameliorated CsA-induced afferent arteriolopathy and tubulointerstitial injury in the kidney.	Cyclosporine	51-54	hypoxia inducible factor 1 subunit alpha	Homo sapiens	28-38
22343435-12	2012	HIF activation by cobalt decreased the CsA-induced apoptosis in HK-2 cells, as judged by the decreases in the number of apoptotic cells, pro-apoptotic caspase-3 activity, and the expression level of cleaved caspase-3, together with the increase in the expression of anti-apoptotic bcl-2.	Cyclosporine	39-42	BCL2 apoptosis regulator	Homo sapiens	281-286
22147139-12	2012	These findings suggest a major role for ROS, oxidative stress, and MAPK signaling in promoting CsA-induced glomerular dysfunction and subsequent nephrotoxicity.	Cyclosporine	95-98	mitogen-activated protein kinase 3	Homo sapiens	67-71
22737926-7	2012	RESULTS: (1) (CsA (0.2 micromol/L), a selective CaN inhibitor, significantly suppressed the increase of protein content, [3H]-leucine incorporation and cell size induced by TNF-alpha.	Cyclosporine	14-17	tumor necrosis factor	Rattus norvegicus	173-182
22737926-8	2012	(2) CsA (0.2 micromol/L) significantly suppressed the elevation of the amplitude of the spontaneous Ca2+ transients induced by TNF-alpha in cultured ventricular myocytes from the neonatal rat.	Cyclosporine	4-7	tumor necrosis factor	Rattus norvegicus	127-136
22205605-9	2012	The CsA group also exhibited lower expression of IL6 and TNF-alpha (P = 0.01).	Cyclosporine	4-7	interleukin 6	Mus musculus	49-52
22274409-5	2012	Both of the depressed bystander effect and NO generation in the CsA-treated cells were reversed when 5 muM cyt-c was added in the cell coculture medium.	Cyclosporine	64-67	cytochrome c, somatic	Homo sapiens	107-112
20641391-4	2004	Calcium channel blockers, cyclosporin A, and its non-immunosuppressive analog PSC 833 are MDR modulators that inhibit transport of P-gp substrates out of cells (6, 7).	Cyclosporine	26-39	ATP binding cassette subfamily B member 1	Homo sapiens	131-135
20641391-10	2004	Brain accumulation of [(11)C]CARV is reported to be highly sensitive to P-gp modulation by cyclosporin A (10).	Cyclosporine	91-104	ATP binding cassette subfamily B member 1	Homo sapiens	72-76
20641916-5	2004	Calcium channel blockers, cyclosporin A, and its non-immunosuppressive analog PSC 833 are MDR modulators that inhibit transport of P-gp substrates out of cells (6, 7).	Cyclosporine	26-39	ATP binding cassette subfamily B member 1	Homo sapiens	131-135
22205605-9	2012	The CsA group also exhibited lower expression of IL6 and TNF-alpha (P = 0.01).	Cyclosporine	4-7	tumor necrosis factor	Mus musculus	57-66
22205605-11	2012	CONCLUSIONS: Immunomodulation with CsA reduces the expression of cytokines (IL6) in the cornea and retards regenerative sprouting from transected corneal stromal nerve trunks.	Cyclosporine	35-38	interleukin 6	Mus musculus	76-79
20641759-5	2004	Calcium channel blockers, cyclosporin A, and its non-immunosuppressive analog PSC 833 are MDR modulators, inhibiting transport of P-gp substrates out of the cells (5, 6).	Cyclosporine	26-39	ATP binding cassette subfamily B member 1	Homo sapiens	130-134
22226864-10	2012	Anti-FCR3 anti-Id1-DBL2X antibodies also efficiently block the adhesion of erythrocytes infected by the HB3 parasite line to CSA.	Cyclosporine	125-128	Fc receptor, IgG, low affinity IIb	Mus musculus	5-9
22054202-7	2012	Gender-stratified tertiles of age-corrected EPO were positively associated with waist circumference (but not BMI), CVD history, time since transplantation, diuretics, azathioprine, CRP, mean corpuscular volume and triglyceride levels, and inversely with CrCl, RAAS-inhibition, cyclosporine, hemoglobin, total- and HDL-cholesterol.	Cyclosporine	277-289	erythropoietin	Homo sapiens	44-47
21381053-7	2012	Moreover, the increased IL-6 and TNF-alpha release by AMA was markedly reduced by BAPTA/AM and cyclosporin A.	Cyclosporine	95-108	interleukin 6	Mus musculus	24-28
22236010-7	2012	Senescent cells and CD4(+) /IL-17A(+) cells were increased among graft biopsies in subjects receiving cyclosporin A (CsA) compared to those under belatacept treatment.	Cyclosporine	102-115	CD4 molecule	Homo sapiens	20-26
22236010-7	2012	Senescent cells and CD4(+) /IL-17A(+) cells were increased among graft biopsies in subjects receiving cyclosporin A (CsA) compared to those under belatacept treatment.	Cyclosporine	117-120	CD4 molecule	Homo sapiens	20-26
21381053-7	2012	Moreover, the increased IL-6 and TNF-alpha release by AMA was markedly reduced by BAPTA/AM and cyclosporin A.	Cyclosporine	95-108	tumor necrosis factor	Mus musculus	33-42
22045333-7	2012	Addition of PP5 or cyclophilin-binding drug cyclosporine A prevented the association of endogenous CYP40 with HSP90-AGO1 complex and inhibited RISC assembly.	Cyclosporine	44-58	peptidyl-prolyl cis-trans isomerase CYP40-like	Nicotiana tabacum	99-104
22512090-6	2012	The inhibitory effects of U50,488H were reproduced by cyclosporine-A, an inhibitor of calcineurin, U0126, the inhibitor of ERK1/2 and verapamil, a L-type Ca2+ channel antagonist.	Cyclosporine	54-68	mitogen-activated protein kinase 3	Homo sapiens	123-129
22512090-7	2012	In addition, suppression of calcineurin activity by cyclosporine-A was associated with modest suppression of ERK1/2 phosphorylation.	Cyclosporine	52-66	mitogen-activated protein kinase 3	Homo sapiens	109-115
22184128-0	2012	Angiotensin II signalling and calcineurin in cardiac fibroblasts: differential effects of calcineurin inhibitors FK506 and cyclosporine A.	Cyclosporine	123-137	angiotensinogen	Rattus norvegicus	0-14
22045333-7	2012	Addition of PP5 or cyclophilin-binding drug cyclosporine A prevented the association of endogenous CYP40 with HSP90-AGO1 complex and inhibited RISC assembly.	Cyclosporine	44-58	heat shock cognate protein 80-like	Nicotiana tabacum	110-115
21896346-6	2012	The CYP3A5 +6986AA genotype was associated with a high cyclosporine blood level after transplantation.	Cyclosporine	55-67	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	4-10
22100870-1	2012	We previously demonstrated that the widely used immunosuppressive drugs cyclosporin A (CsA) and tacrolimus (FK506), independent of immunophilin binding, can activate profibrogenic transforming growth factor beta (TGFbeta)/Smad signaling cascades in rat renal mesangial cells (MC).	Cyclosporine	72-85	transforming growth factor, beta 1	Rattus norvegicus	213-220
22100870-1	2012	We previously demonstrated that the widely used immunosuppressive drugs cyclosporin A (CsA) and tacrolimus (FK506), independent of immunophilin binding, can activate profibrogenic transforming growth factor beta (TGFbeta)/Smad signaling cascades in rat renal mesangial cells (MC).	Cyclosporine	87-90	transforming growth factor, beta 1	Rattus norvegicus	213-220
22100870-8	2012	Our data suggest that CsA and FK506, via ROS-dependent and ADAM17-catalyzed HB-EGF shedding induce the mitogenic ERK1/2 signaling cascade in renal MC.	Cyclosporine	22-25	ADAM metallopeptidase domain 17	Rattus norvegicus	59-65
22100870-8	2012	Our data suggest that CsA and FK506, via ROS-dependent and ADAM17-catalyzed HB-EGF shedding induce the mitogenic ERK1/2 signaling cascade in renal MC.	Cyclosporine	22-25	heparin-binding EGF-like growth factor	Rattus norvegicus	76-82
22124337-13	2012	CONCLUSION: The dual blocking of CCR5/CXCR3 can be useful in decreasing rejection, with or without CsA.	Cyclosporine	99-102	C-C motif chemokine receptor 5	Rattus norvegicus	33-37
21896346-11	2012	Although the CYP3A5 +6986AA genotype was correlated with a high blood cyclosporine concentration, lack of the MDR1 +1236CC genotype in both the donor and recipient was correlated with less TRM and a longer OS in patients who received allogeneic HSCT.	Cyclosporine	70-82	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	13-19
22410315-0	2012	Carbamylated erythropoietin ameliorates cyclosporine nephropathy without stimulating erythropoiesis.	Cyclosporine	40-52	erythropoietin	Homo sapiens	13-27
22687422-5	2012	Moreover, THPB had an additive effect on the inhibition of IL-2 induction with CsA.	Cyclosporine	79-82	interleukin 2	Homo sapiens	59-63
21895605-4	2012	Pretreatment with cyclosporin A (10 mug/ml), a pharmacological inhibitor of CaN or 11R-VIVIT, a special inhibitor of NFAT, completely abrogated the aforementioned effects of VEGF treatment and increased apoptosis.	Cyclosporine	18-31	vascular endothelial growth factor A	Homo sapiens	174-178
22410315-7	2012	In parallel, morphological assessment revealed that EPO/CEPO significantly reduced CsA-induced interstitial  fibrosis and inhibited interstitial macrophage infiltration.	Cyclosporine	83-86	erythropoietin	Homo sapiens	52-55
22240838-0	2012	Long-lasting inhibitory effects of cyclosporin A, but not tacrolimus, on OATP1B1- and OATP1B3-mediated uptake.	Cyclosporine	35-48	solute carrier organic anion transporter family member 1B3	Homo sapiens	86-93
21889978-9	2012	Inhibition of calcineurin-NFAT signalling with cyclosporine-A or 11R-VIVIT abolished the HFES induced NGF down-regulation (NGF: 50 Hz+CsA=1.14, P&lt;0.05).	Cyclosporine	47-61	nerve growth factor	Homo sapiens	102-105
22240838-5	2012	The pretreatment of OATP1B1- and OATP1B3-expressing cells with 0.5-10 microM CsA, but not TCR, resulted in a reduction in their activity, even after washing out CsA from the incubation media.	Cyclosporine	161-164	solute carrier organic anion transporter family member 1B3	Homo sapiens	33-40
22240838-1	2012	Cyclosporin A (CsA) causes a number of clinically relevant drug-drug interactions (DDIs) by inhibiting OATP1B1 and OATP1B3.	Cyclosporine	0-13	solute carrier organic anion transporter family member 1B3	Homo sapiens	115-122
22240838-6	2012	Preincubating the cells with CsA significantly enhanced its inhibitory effects on OATP1B1 and OATP1B3 by coincubation at 0.1-1 microM.	Cyclosporine	29-32	solute carrier organic anion transporter family member 1B3	Homo sapiens	94-101
22240838-10	2012	Thus, CsA has a long-lasting inhibitory effect on OATP1B1 and OATP1B3.	Cyclosporine	6-9	solute carrier organic anion transporter family member 1B3	Homo sapiens	62-69
22240838-1	2012	Cyclosporin A (CsA) causes a number of clinically relevant drug-drug interactions (DDIs) by inhibiting OATP1B1 and OATP1B3.	Cyclosporine	15-18	solute carrier organic anion transporter family member 1B3	Homo sapiens	115-122
22240838-5	2012	The pretreatment of OATP1B1- and OATP1B3-expressing cells with 0.5-10 microM CsA, but not TCR, resulted in a reduction in their activity, even after washing out CsA from the incubation media.	Cyclosporine	77-80	solute carrier organic anion transporter family member 1B3	Homo sapiens	33-40
23428559-5	2012	Our results showed that CsA-induced ER stress and involved ER integrated stress response-related proteins (Bip/Grp78, ATF6, IRE1 and CHOP) but not cytoplasmic ER stress-related chaperones (HSP70, HSP40, HSP27, HSP90 and HSP60).	Cyclosporine	24-27	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	210-215
22124122-7	2012	Cyclosporine A inhibits the Wnt5a and calcium-induced activation of NF-kappaB and BCL-6 in Ramos cells, supporting a role of beta-catenin-independent Wnt/Ca(2+)/NFAT/NF-kappaB-BCL-6 signaling.	Cyclosporine	0-14	Wnt family member 5A	Homo sapiens	28-33
22124122-7	2012	Cyclosporine A inhibits the Wnt5a and calcium-induced activation of NF-kappaB and BCL-6 in Ramos cells, supporting a role of beta-catenin-independent Wnt/Ca(2+)/NFAT/NF-kappaB-BCL-6 signaling.	Cyclosporine	0-14	Wnt family member 5A	Homo sapiens	28-31
22315658-8	2012	CsA treatment increased profibrotic TGF-beta1 secretion in human mesangial cells whereas SRL did not, indicating a role for TGF-beta in CsA toxicity.	Cyclosporine	0-3	transforming growth factor beta 1	Homo sapiens	36-45
22315658-8	2012	CsA treatment increased profibrotic TGF-beta1 secretion in human mesangial cells whereas SRL did not, indicating a role for TGF-beta in CsA toxicity.	Cyclosporine	0-3	transforming growth factor beta 1	Homo sapiens	36-44
22315658-12	2012	Inhibition of the ERK 1/2 pathway, attenuated these CsA/SRL induced alterations indicating a potentially significant role for this pathway.	Cyclosporine	52-55	mitogen-activated protein kinase 3	Homo sapiens	18-25
22509094-14	2012	The 0.5% FTY720 increased TGF-beta1 mRNA expression and decreases infiltration of CD4+ T cells in corneal grafts, while topical 1% CsA down-regulated the expression of IL-2 and IFN-gamma.	Cyclosporine	131-134	interferon gamma	Mus musculus	177-186
22062948-0	2012	RhoA and Rho kinase mediate cyclosporine A and sirolimus-induced barrier tightening in renal proximal tubular cells.	Cyclosporine	28-42	ras homolog family member A	Homo sapiens	0-4
22062948-3	2012	We have previously shown that CsA and SRL elevate transepithelial resistance (TER) in kidney tubular cells partly through MEK/ERK1/2.	Cyclosporine	30-33	mitogen-activated protein kinase kinase 7	Homo sapiens	122-125
22062948-3	2012	We have previously shown that CsA and SRL elevate transepithelial resistance (TER) in kidney tubular cells partly through MEK/ERK1/2.	Cyclosporine	30-33	mitogen-activated protein kinase 3	Homo sapiens	126-132
22062948-4	2012	In this work we examined the hypothesis that the RhoA pathway may also be mediating effects of CsA and SRL.	Cyclosporine	95-98	ras homolog family member A	Homo sapiens	49-53
22062948-5	2012	We show that CsA and the CsA/SRL combination activated RhoA, induced cofilin phosphorylation and promoted stress fiber generation.	Cyclosporine	13-16	ras homolog family member A	Homo sapiens	55-59
22974789-8	2012	Pgp activity was also reduced in CsA and CsA+Rapa compared to the other immunosupressants but it was only significant in the CsA group for CD8+ subset.	Cyclosporine	33-36	ATP binding cassette subfamily B member 1	Homo sapiens	0-3
22974789-11	2012	CONCLUSIONS: Our data indicate that small molecules immunosuppressants, especially CsA, inhibit Pgp activity and T-cell function being the CD8+ T cells more susceptible to this effect.	Cyclosporine	83-86	ATP binding cassette subfamily B member 1	Homo sapiens	96-99
22028950-0	2012	c-Jun-N-Terminal Kinase Signaling Is Involved in Cyclosporine-Induced Epithelial Phenotypic Changes.	Cyclosporine	49-61	mitogen-activated protein kinase 8	Homo sapiens	0-23
22028950-2	2012	Previous toxicogenomic studies have demonstrated that cyclosporine- (CsA-) induced epithelial phenotypic changes (EPCs) are reminiscent of an incomplete epithelial to mesenchymal transition (EMT) in a TGF-beta-independent manner.	Cyclosporine	54-66	transforming growth factor beta 1	Homo sapiens	201-209
22028950-2	2012	Previous toxicogenomic studies have demonstrated that cyclosporine- (CsA-) induced epithelial phenotypic changes (EPCs) are reminiscent of an incomplete epithelial to mesenchymal transition (EMT) in a TGF-beta-independent manner.	Cyclosporine	69-72	transforming growth factor beta 1	Homo sapiens	201-209
22028950-4	2012	Because c-jun-N-terminal kinase (JNK), which is activated during ER stress, is implicated in kidney fibrogenesis, we undertook the current study to identify the role of JNK signaling in EPCs induced by CsA.	Cyclosporine	202-205	mitogen-activated protein kinase 8	Homo sapiens	8-31
22028950-4	2012	Because c-jun-N-terminal kinase (JNK), which is activated during ER stress, is implicated in kidney fibrogenesis, we undertook the current study to identify the role of JNK signaling in EPCs induced by CsA.	Cyclosporine	202-205	mitogen-activated protein kinase 8	Homo sapiens	33-36
22028950-4	2012	Because c-jun-N-terminal kinase (JNK), which is activated during ER stress, is implicated in kidney fibrogenesis, we undertook the current study to identify the role of JNK signaling in EPCs induced by CsA.	Cyclosporine	202-205	mitogen-activated protein kinase 8	Homo sapiens	169-172
22028950-5	2012	In primary cultures of human renal epithelial cells, CsA activates JNK signaling, and the treatment with a JNK inhibitor reduces the occurrence of cell shape changes, E-cadherin downregulation, cell migration, and Snail-1 expression.	Cyclosporine	53-56	mitogen-activated protein kinase 8	Homo sapiens	67-70
22028950-5	2012	In primary cultures of human renal epithelial cells, CsA activates JNK signaling, and the treatment with a JNK inhibitor reduces the occurrence of cell shape changes, E-cadherin downregulation, cell migration, and Snail-1 expression.	Cyclosporine	53-56	cadherin 1	Homo sapiens	167-177
22028950-5	2012	In primary cultures of human renal epithelial cells, CsA activates JNK signaling, and the treatment with a JNK inhibitor reduces the occurrence of cell shape changes, E-cadherin downregulation, cell migration, and Snail-1 expression.	Cyclosporine	53-56	snail family transcriptional repressor 1	Homo sapiens	214-221
22028950-6	2012	Our results suggest that CsA activates JNK signaling, which, in turn, may participate in the morphological alterations through the regulation of Snail-1 expression.	Cyclosporine	25-28	mitogen-activated protein kinase 8	Homo sapiens	39-42
22028950-6	2012	Our results suggest that CsA activates JNK signaling, which, in turn, may participate in the morphological alterations through the regulation of Snail-1 expression.	Cyclosporine	25-28	snail family transcriptional repressor 1	Homo sapiens	145-152
23028901-5	2012	Treatment with CsA completely blocked IFN-gamma production in DICs and inhibited TNF-alpha production in all examined cells.	Cyclosporine	15-18	interferon gamma	Homo sapiens	38-47
22720101-4	2012	We therefore tested the hypothesis that inhibition of T-cell activation with ciclosporin A would be safe and clinically beneficial in patients with early and/or clinically progressing HAM/TSP.	Cyclosporine	77-90	thrombospondin 1	Homo sapiens	188-191
22720101-13	2012	CONCLUSIONS: These data provide initial evidence that treatment with CsA is safe and may partially reverse the clinical deterioration seen in patients with early/progressive HAM/TSP.	Cyclosporine	69-72	thrombospondin 1	Homo sapiens	178-181
23028901-7	2012	These results suggest that CsA promotes Th2 bias at the maternal-fetal interface by increasing Th2-type cytokine production in trophoblasts with the aid of DSCs and DICs, while inhibiting Th1-type cytokine production in DICs and TNF-alpha production in all investigated cells.	Cyclosporine	27-30	tumor necrosis factor	Homo sapiens	229-238
23028901-5	2012	Treatment with CsA completely blocked IFN-gamma production in DICs and inhibited TNF-alpha production in all examined cells.	Cyclosporine	15-18	tumor necrosis factor	Homo sapiens	81-90
23028901-6	2012	CsA increased IL-10 and IL-4 production in trophoblasts co-cultured with DSCs and DICs although CsA treatment did not affect IL-10 or IL-4 production in any of the cells when cultured alone.	Cyclosporine	0-3	interleukin 4	Homo sapiens	24-28
22848341-10	2012	CONCLUSIONS: CsA may promote EGFR activation via CXCL12/CXCR4 axis, and EGFR downstream ERK signaling pathway may be involved in the CsA-induced proliferation of human trophoblast cells.	Cyclosporine	133-136	epidermal growth factor receptor	Homo sapiens	72-76
22911812-6	2012	The interactions of CsCyp with the CTD and PthA2 were inhibited by cyclosporin A (CsA), a cyclophilin inhibitor.	Cyclosporine	67-80	Peptidyl-prolyl cis-trans isomerase-like	Citrus sinensis	20-25
22911812-6	2012	The interactions of CsCyp with the CTD and PthA2 were inhibited by cyclosporin A (CsA), a cyclophilin inhibitor.	Cyclosporine	82-85	Peptidyl-prolyl cis-trans isomerase-like	Citrus sinensis	20-25
22911812-7	2012	Moreover, we present evidence that PthA2 inhibits the peptidyl-prolyl cis-trans isomerase (PPIase) activity of CsCyp in a similar fashion as CsA, and that silencing of CsCyp, as well as treatments with CsA, enhance canker lesions in X. citri-infected leaves.	Cyclosporine	202-205	Peptidyl-prolyl cis-trans isomerase-like	Citrus sinensis	111-116
22911812-7	2012	Moreover, we present evidence that PthA2 inhibits the peptidyl-prolyl cis-trans isomerase (PPIase) activity of CsCyp in a similar fashion as CsA, and that silencing of CsCyp, as well as treatments with CsA, enhance canker lesions in X. citri-infected leaves.	Cyclosporine	202-205	Peptidyl-prolyl cis-trans isomerase-like	Citrus sinensis	168-173
22848341-0	2012	CXCL12/CXCR4 axis triggers the activation of EGF receptor and ERK signaling pathway in CsA-induced proliferation of human trophoblast cells.	Cyclosporine	87-90	mitogen-activated protein kinase 1	Homo sapiens	62-65
22848341-5	2012	5-Bromo-2"-deoxyuridine (BrdU) cell proliferation assay was performed to analyze the involvement of EGFR and its downstream extracellular signal-regulated protein kinase (ERK) signaling pathway in the CsA-induced proliferation of human trophoblast cells.	Cyclosporine	201-204	epidermal growth factor receptor	Homo sapiens	100-104
22848341-10	2012	CONCLUSIONS: CsA may promote EGFR activation via CXCL12/CXCR4 axis, and EGFR downstream ERK signaling pathway may be involved in the CsA-induced proliferation of human trophoblast cells.	Cyclosporine	133-136	mitogen-activated protein kinase 1	Homo sapiens	88-91
22848341-5	2012	5-Bromo-2"-deoxyuridine (BrdU) cell proliferation assay was performed to analyze the involvement of EGFR and its downstream extracellular signal-regulated protein kinase (ERK) signaling pathway in the CsA-induced proliferation of human trophoblast cells.	Cyclosporine	201-204	mitogen-activated protein kinase 1	Homo sapiens	124-169
22848341-5	2012	5-Bromo-2"-deoxyuridine (BrdU) cell proliferation assay was performed to analyze the involvement of EGFR and its downstream extracellular signal-regulated protein kinase (ERK) signaling pathway in the CsA-induced proliferation of human trophoblast cells.	Cyclosporine	201-204	mitogen-activated protein kinase 1	Homo sapiens	171-174
22490220-14	2012	High-concentration CsA + TNF-alpha can enhance the fibroblast proliferation, which suggests that CsA in certain concentration have amplification effect on TNF-alpha to stimulate fibroblast proliferation.	Cyclosporine	19-22	tumor necrosis factor	Homo sapiens	155-164
22848341-7	2012	The inhibition of CXCL12 or CXCR4 by either neutralizing antibodies or small interfering RNA (siRNA) could completely block the CsA-induced EGFR phosphorylation.	Cyclosporine	128-131	epidermal growth factor receptor	Homo sapiens	140-144
22848341-8	2012	The CsA-induced proliferation of human trophoblast cells was effectively abrogated by the EGFR inhibitor AG1478 as well as the ERK inhibitor U0126, but not by the PI3K/PKB inhibitor LY294002.	Cyclosporine	4-7	epidermal growth factor receptor	Homo sapiens	90-94
22848341-8	2012	The CsA-induced proliferation of human trophoblast cells was effectively abrogated by the EGFR inhibitor AG1478 as well as the ERK inhibitor U0126, but not by the PI3K/PKB inhibitor LY294002.	Cyclosporine	4-7	mitogen-activated protein kinase 1	Homo sapiens	127-130
22848341-9	2012	CsA promoted the activation of ERK in JEG-3 cells, which was markedly abrogated in the presence of CXCL12 siRNA, or CXCR4 siRNA, or AG1478.	Cyclosporine	0-3	mitogen-activated protein kinase 1	Homo sapiens	31-34
22848341-10	2012	CONCLUSIONS: CsA may promote EGFR activation via CXCL12/CXCR4 axis, and EGFR downstream ERK signaling pathway may be involved in the CsA-induced proliferation of human trophoblast cells.	Cyclosporine	13-16	epidermal growth factor receptor	Homo sapiens	29-33
22558153-13	2012	The number of CD4+/CD25+ regulatory T-cells and IL-10 expressions in the circulating blood significantly increased in the MSC-CsA group compared to the other groups.	Cyclosporine	126-129	IL10	Sus scrofa	48-53
22490220-14	2012	High-concentration CsA + TNF-alpha can enhance the fibroblast proliferation, which suggests that CsA in certain concentration have amplification effect on TNF-alpha to stimulate fibroblast proliferation.	Cyclosporine	97-100	tumor necrosis factor	Homo sapiens	25-34
22490220-14	2012	High-concentration CsA + TNF-alpha can enhance the fibroblast proliferation, which suggests that CsA in certain concentration have amplification effect on TNF-alpha to stimulate fibroblast proliferation.	Cyclosporine	97-100	tumor necrosis factor	Homo sapiens	155-164
21802460-5	2011	The covering of skin allografts with CsA-loaded nanofibers significantly attenuated the local production of the proinflammatory cytokines IL-2, IFN-gamma and IL-17.	Cyclosporine	37-40	interferon gamma	Mus musculus	144-153
22144571-10	2011	The efficacy of cyclosporin A in cardiac Txnrd2 deficiency may indicate a role for Txnrd2 in reducing mitochondrial reactive oxygen species, thereby preventing opening of the mitochondrial permeability transition pore.	Cyclosporine	16-29	thioredoxin reductase 2	Homo sapiens	41-47
21880834-2	2011	We previously showed that not only CsA treatment but also its combination with SRL decreased paracellular permeability in renal proximal tubular cells by modification of the tight junction proteins, claudins, through ERK1/2 signaling pathway.	Cyclosporine	35-38	mitogen-activated protein kinase 3	Homo sapiens	217-223
21880834-3	2011	In this present study, evidence is presented that not only CsA but also the combination of CsA/SRL may have adverse effects on the barrier function of renal proximal cells, at least in part, through the expression of the cytokine transforming growth factor (TGF)-beta(1).	Cyclosporine	59-62	transforming growth factor beta 1	Homo sapiens	258-261
21880834-4	2011	CsA treatment upregulated TGF-beta(1) gene expression and this upregulation was enhanced when CsA and SRL were applied together.	Cyclosporine	0-3	transforming growth factor beta 1	Homo sapiens	26-37
21880834-4	2011	CsA treatment upregulated TGF-beta(1) gene expression and this upregulation was enhanced when CsA and SRL were applied together.	Cyclosporine	94-97	transforming growth factor beta 1	Homo sapiens	26-37
21880834-9	2011	It is most likely that the CsA- and CsA/SRL-induced increases in TGF-beta(1) expression may not be sufficient to trigger the Smad pathway but however may trigger other TGF-beta(1) receptor-mediated signaling including the ERK1/2 signaling pathway.	Cyclosporine	27-30	transforming growth factor beta 1	Homo sapiens	65-75
21880834-9	2011	It is most likely that the CsA- and CsA/SRL-induced increases in TGF-beta(1) expression may not be sufficient to trigger the Smad pathway but however may trigger other TGF-beta(1) receptor-mediated signaling including the ERK1/2 signaling pathway.	Cyclosporine	27-30	transforming growth factor beta 1	Homo sapiens	168-178
21880834-9	2011	It is most likely that the CsA- and CsA/SRL-induced increases in TGF-beta(1) expression may not be sufficient to trigger the Smad pathway but however may trigger other TGF-beta(1) receptor-mediated signaling including the ERK1/2 signaling pathway.	Cyclosporine	27-30	mitogen-activated protein kinase 3	Homo sapiens	222-228
21880834-9	2011	It is most likely that the CsA- and CsA/SRL-induced increases in TGF-beta(1) expression may not be sufficient to trigger the Smad pathway but however may trigger other TGF-beta(1) receptor-mediated signaling including the ERK1/2 signaling pathway.	Cyclosporine	36-39	transforming growth factor beta 1	Homo sapiens	65-75
21880834-9	2011	It is most likely that the CsA- and CsA/SRL-induced increases in TGF-beta(1) expression may not be sufficient to trigger the Smad pathway but however may trigger other TGF-beta(1) receptor-mediated signaling including the ERK1/2 signaling pathway.	Cyclosporine	36-39	transforming growth factor beta 1	Homo sapiens	168-178
21880834-9	2011	It is most likely that the CsA- and CsA/SRL-induced increases in TGF-beta(1) expression may not be sufficient to trigger the Smad pathway but however may trigger other TGF-beta(1) receptor-mediated signaling including the ERK1/2 signaling pathway.	Cyclosporine	36-39	mitogen-activated protein kinase 3	Homo sapiens	222-228
21918035-7	2011	However, vectorial transport across LLC-OCT1/MDR1 cells was identified, which was inhibited by the MDR1 inhibitor cyclosporine A, clearly indicating that YM155 is in fact a substrate of MDR1.	Cyclosporine	114-128	solute carrier family 22 member 1	Sus scrofa	40-44
21499692-6	2011	Interestingly, one patient with a pathological WT1 nucleotide variation responded fully to combined therapy with cyclosporine A and corticosteroids.	Cyclosporine	113-127	WT1 transcription factor	Homo sapiens	47-50
21885994-6	2011	MTP abrogated the oxidative (superoxide dismutase, catalase), lipid peroxidation (malondialdyde), and elevated the cytokine (TNF-alpha and TGF-beta) effects of CSA.	Cyclosporine	160-163	tumor necrosis factor	Rattus norvegicus	125-134
21885994-6	2011	MTP abrogated the oxidative (superoxide dismutase, catalase), lipid peroxidation (malondialdyde), and elevated the cytokine (TNF-alpha and TGF-beta) effects of CSA.	Cyclosporine	160-163	transforming growth factor, beta 1	Rattus norvegicus	139-147
22094768-9	2011	The in vivo study revealed that, compared with untreated control, rats administered adipose-derived stem cells along with transient antilymphocyte serum and cyclosporin A treatment had significantly prolonged allotransplant survival (p &lt; 0.001), decreased allotissue rejection, significantly elevated donor cell chimerism, and increased CD4/CD25/Foxp3 regulatory T cells in peripheral blood and alloskin tissue with up-regulation of transforming growth factor-beta and interleukin-10 levels.	Cyclosporine	157-170	CD4 molecule	Homo sapiens	340-343
22094768-9	2011	The in vivo study revealed that, compared with untreated control, rats administered adipose-derived stem cells along with transient antilymphocyte serum and cyclosporin A treatment had significantly prolonged allotransplant survival (p &lt; 0.001), decreased allotissue rejection, significantly elevated donor cell chimerism, and increased CD4/CD25/Foxp3 regulatory T cells in peripheral blood and alloskin tissue with up-regulation of transforming growth factor-beta and interleukin-10 levels.	Cyclosporine	157-170	transforming growth factor beta 1	Homo sapiens	436-467
22172253-1	2011	OBJECTIVE: To explore the expression diversification of CD4(+)CD25(+)CD127(low) regulatory T (Treg) cells and Foxp3 mRNA in the peripheral blood of children with aplastic anemia after the treatment with cyclosporine.	Cyclosporine	203-215	CD4 molecule	Homo sapiens	56-59
22172253-8	2011	Meanwhile, the cyclosporine group had significantly higher expressions of Foxp3 mRNA and CD4(+)CD25(+)CD127(low) Treg cells than the conventional group (P&lt;0.05).	Cyclosporine	15-27	CD4 molecule	Homo sapiens	89-92
22172253-9	2011	CONCLUSIONS: The expressions of CD4(+)CD25(+)CD127(low) Treg cells and Foxp3 mRNA in children with aplastic anemia increase after cyclosporine treatment.	Cyclosporine	130-142	CD4 molecule	Homo sapiens	32-35
22032989-5	2011	Tandem affinity purification and immunoprecipitations combined with mass spectrometry studies indicate that CSA and CSB associate within a Cullin Ring Ubiquitin Ligase complex responsible, under certain circumstances, for p53 ubiquitination.	Cyclosporine	108-111	tumor protein p53	Homo sapiens	222-225
21929645-8	2011	Our results demonstrate that a CsA-free regimen based on SRL reduces aortic stiffness, plasma endothelin-1 and oxidative stress in renal recipients suggesting a protective effect on the arterial wall that may be translated into cardiovascular risk reduction.	Cyclosporine	31-34	endothelin 1	Homo sapiens	94-106
21940781-8	2011	Calcineurin inhibitors (FK506, cyclosporin A, and a peptide calcineurin inhibitor [CAIN]) abolished glucose-induced IRS-2 mRNA and protein levels, whereas expression of a constitutively active calcineurin increased them.	Cyclosporine	31-44	insulin receptor substrate 2	Rattus norvegicus	116-121
22032989-6	2011	This study identifies CSA and CSB as the key elements of a regulatory mechanism that equilibrate beneficial and detrimental effects of p53 activity upon cellular stress.	Cyclosporine	22-25	tumor protein p53	Homo sapiens	135-138
21660974-6	2011	In co-treatment with beta-cyclodextrins, the apical to basolateral taxol flux was 4 to 6 times greater than in untreated monolayers and it was also higher than in cells treated with Pgp inhibitor cyclosporin A.	Cyclosporine	196-209	ATP binding cassette subfamily B member 1	Homo sapiens	182-185
21938677-0	2011	Transglutaminase 2 expression is significantly increased in cyclosporine-induced gingival overgrowth.	Cyclosporine	60-72	transglutaminase 2	Homo sapiens	0-18
21938677-6	2011	Transglutaminase 2 expression showed a significant increase (2.6-fold) in the stromal component of cyclosporine A-treated patients compared with controls (p&lt;0.001), which suggested that transglutaminase 2 had a role in the pathogenesis of the disease.	Cyclosporine	99-113	transglutaminase 2	Homo sapiens	0-18
21938677-6	2011	Transglutaminase 2 expression showed a significant increase (2.6-fold) in the stromal component of cyclosporine A-treated patients compared with controls (p&lt;0.001), which suggested that transglutaminase 2 had a role in the pathogenesis of the disease.	Cyclosporine	99-113	transglutaminase 2	Homo sapiens	189-207
22016125-8	2011	Calcineurin inhibitors (cyclosporine, tacrolimus) and mTOR inhibitors (sirolimus, everolimus) are particularly susceptible to the effects of substances that inhibit or induce cytochrome P450 (CYP) 3A4 and P-glycoprotein.	Cyclosporine	24-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	175-200
21865292-2	2011	In order to understand the mechanisms of the toxicity, we analyzed gene expression changes that underlie the development of CI immunosuppressant-mediated nephrotoxicity in male Sprague-Dawley rats dosed daily with cyclosporine (CsA; 2.5 or 25 mg/kg/day), FK506 (0.6 or 6 mg/kg/day), or rapamycin (1 or 10 mg/kg/day) for 1, 7, 14, or 28 days.	Cyclosporine	214-226	calcineurin binding protein 1	Rattus norvegicus	124-126
22016125-8	2011	Calcineurin inhibitors (cyclosporine, tacrolimus) and mTOR inhibitors (sirolimus, everolimus) are particularly susceptible to the effects of substances that inhibit or induce cytochrome P450 (CYP) 3A4 and P-glycoprotein.	Cyclosporine	24-36	ATP binding cassette subfamily B member 1	Homo sapiens	205-219
22016125-12	2011	Some immunosuppressive drugs also interact with one another: cyclosporine raises the level of mTOR inhibitors and lowers the level of mycophenolate.	Cyclosporine	61-73	mechanistic target of rapamycin kinase	Homo sapiens	94-98
21959050-0	2011	Cyclosporine, prednisone, and high-dose immunoglobulin treatment of angioimmunoblastic T-cell lymphoma refractory to prior CHOP or CHOP-like regimen.	Cyclosporine	0-12	DNA damage inducible transcript 3	Homo sapiens	123-127
21912224-8	2011	Transcriptional activities of NF-kappaB, AP-1, and NFAT1 were not stimulated by CsA; however, nuclear translocation of NFAT5 was markedly upregulated by CsA.	Cyclosporine	153-156	nuclear factor kappa B subunit 1	Homo sapiens	30-39
21912224-11	2011	These results suggest that CsA mediates NGF expression through activation of p38 and NFAT5.	Cyclosporine	27-30	mitogen-activated protein kinase 14	Homo sapiens	77-80
21707758-2	2011	We investigated the mechanisms of CsA-induced NER reduction by assessing all xeroderma pigmentosum (XP) genes (XPA-XPG).	Cyclosporine	34-37	XPA, DNA damage recognition and repair factor	Homo sapiens	111-114
21757611-4	2011	Two P-glycoprotein (P-gp) inhibitors, verapamil and cyclosporine A, substantially decreased the efflux ratio of Rh2s from 28.5 to 1.0 and 1.2, respectively, in Caco-2 cells.	Cyclosporine	52-66	ATP binding cassette subfamily B member 1	Homo sapiens	4-18
21757611-4	2011	Two P-glycoprotein (P-gp) inhibitors, verapamil and cyclosporine A, substantially decreased the efflux ratio of Rh2s from 28.5 to 1.0 and 1.2, respectively, in Caco-2 cells.	Cyclosporine	52-66	ATP binding cassette subfamily B member 1	Homo sapiens	20-24
21707758-3	2011	Western blot analyses revealed that XPA and XPG protein expression was reduced in normal human GM00637 fibroblasts exposed to 0.1 and 0.5 mum CsA.	Cyclosporine	142-145	XPA, DNA damage recognition and repair factor	Homo sapiens	36-39
21707758-6	2011	CsA-induced reduction in NER could be complemented by the overexpression of either XPA or XPG protein.	Cyclosporine	0-3	XPA, DNA damage recognition and repair factor	Homo sapiens	83-86
21707758-9	2011	Our data indicate that the CsA-induced inhibition of NER is a result of downregulation of XPA and XPG protein in a calcineurin-dependent manner.	Cyclosporine	27-30	XPA, DNA damage recognition and repair factor	Homo sapiens	90-93
21902502-1	2011	AIMS: CYP3A4 is involved in the oxidative metabolism of many drugs and xenobiotics including the immunosuppressants tacrolimus (Tac) and cyclosporine (CsA).	Cyclosporine	137-149	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	6-12
22128263-6	2011	Pretreatment of cyclosporine A blocked the increases of RCAN1.4 stimulated by IL-1beta or AGE-BSA, suggesting that activation of CaN is required for the RCAN1.4 induction.	Cyclosporine	16-30	interleukin 1 beta	Mus musculus	78-86
21587094-6	2011	Among a total of 28 patients of refractory KD treated with CyA, 18 (64.3%) responded promptly to be afebrile within 3 days and had decreased C-reactive protein levels, the other 4 became afebrile within 4 to 5 days.	Cyclosporine	59-62	C-reactive protein	Homo sapiens	141-159
21902502-1	2011	AIMS: CYP3A4 is involved in the oxidative metabolism of many drugs and xenobiotics including the immunosuppressants tacrolimus (Tac) and cyclosporine (CsA).	Cyclosporine	151-154	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	6-12
21902502-8	2011	CONCLUSION: The CYP3A4 intron 6 C&gt;T polymorphism is associated with altered Tac and CsA metabolism.	Cyclosporine	87-90	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	16-22
21538216-8	2011	This effect is prevented by Pgp inhibitors verapamil and cyclosporin A, as well as siRNA to ABCB1, with concomitant re-sensitization to silvestrol.	Cyclosporine	57-70	ATP binding cassette subfamily B member 1	Homo sapiens	28-31
21974705-12	2011	While cyclosporine A therapy gradually decreased MDR-1 expression, LDL adsorption therapy decreased expression sharply.	Cyclosporine	6-20	ATP binding cassette subfamily B member 1	Homo sapiens	49-54
21753749-5	2011	This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition.	Cyclosporine	112-124	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	49-54
21753749-0	2011	In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients.	Cyclosporine	49-61	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	8-13
21753749-5	2011	This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition.	Cyclosporine	112-124	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	284-289
21753749-1	2011	In vitro studies have identified cyclosporine and tacrolimus as CYP3A inhibitors.	Cyclosporine	33-45	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	64-69
21753749-5	2011	This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition.	Cyclosporine	228-240	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	49-54
21753749-5	2011	This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition.	Cyclosporine	228-240	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	284-289
21102498-5	2011	The CsA concentration was significantly higher when the genotype of CYP3A5 rs15524 was T/T (P=0.044) or rs776746 was G/G (P=0.027).	Cyclosporine	4-7	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	68-74
21341336-6	2011	Moreover, pretreatment of CsA, a cyclophilin D ligand that inhibits mitochondria potential uncoupling, prevented the activation of caspase-9 and caspase-3, but not caspase-8, and the apoptosis of MG-63 cells, triggered by corosolic acid.	Cyclosporine	26-29	caspase 3	Homo sapiens	145-154
21806386-1	2011	AIM: Polymorphisms in the CYP3A5 and ABCB1 genes have been investigated as modulators of the pharmacokinetics and clinical effects of cyclosporine (CSA) and tacrolimus (TAC) in European, North American and Asian populations, with controversial results.	Cyclosporine	134-146	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	26-32
21806386-1	2011	AIM: Polymorphisms in the CYP3A5 and ABCB1 genes have been investigated as modulators of the pharmacokinetics and clinical effects of cyclosporine (CSA) and tacrolimus (TAC) in European, North American and Asian populations, with controversial results.	Cyclosporine	134-146	ATP binding cassette subfamily B member 1	Homo sapiens	37-42
21806386-1	2011	AIM: Polymorphisms in the CYP3A5 and ABCB1 genes have been investigated as modulators of the pharmacokinetics and clinical effects of cyclosporine (CSA) and tacrolimus (TAC) in European, North American and Asian populations, with controversial results.	Cyclosporine	148-151	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	26-32
21806386-1	2011	AIM: Polymorphisms in the CYP3A5 and ABCB1 genes have been investigated as modulators of the pharmacokinetics and clinical effects of cyclosporine (CSA) and tacrolimus (TAC) in European, North American and Asian populations, with controversial results.	Cyclosporine	148-151	ATP binding cassette subfamily B member 1	Homo sapiens	37-42
21480191-2	2011	Seven separate drug-drug interaction (DDI) studies were performed to elucidate the in vivo effects of concomitant treatment with colchicine and known inhibitors of cytochrome P450 3A4 (CYP3A4)/P-glycoprotein (cyclosporine, ketoconazole, ritonavir, clarithromycin, azithromycin, verapamil ER [extended release]), and diltiazem ER) on the pharmacokinetics of colchicine.	Cyclosporine	209-221	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	185-191
21622902-8	2011	These findings suggest that CsA-stimulated HO-1 expression is mediated through the activation of ERK, and that Nrf-2 plays a protective role against CsA-induced gingival fibrosis by modulating collagen turnover-related genes.	Cyclosporine	28-31	mitogen-activated protein kinase 1	Homo sapiens	97-100
21622902-0	2011	Nrf-2 regulates cyclosporine-stimulated HO-1 expression in gingiva.	Cyclosporine	16-28	NFE2 like bZIP transcription factor 2	Homo sapiens	0-5
21622902-3	2011	The aim of this study was to examine the role of Nrf-2 in the regulation of CsA-stimulated HO-1 expression in human gingival fibroblasts.	Cyclosporine	76-79	NFE2 like bZIP transcription factor 2	Homo sapiens	49-54
21622902-8	2011	These findings suggest that CsA-stimulated HO-1 expression is mediated through the activation of ERK, and that Nrf-2 plays a protective role against CsA-induced gingival fibrosis by modulating collagen turnover-related genes.	Cyclosporine	149-152	NFE2 like bZIP transcription factor 2	Homo sapiens	111-116
21622902-6	2011	ERK inhibition significantly decreased CsA-stimulated Nrf-2 nuclear translocation and HO-1 mRNA expression.	Cyclosporine	39-42	mitogen-activated protein kinase 1	Homo sapiens	0-3
21168455-7	2011	CONCLUSIONS: mTOR inhibition by sirolimus and everolimus in experimental liver fibrosis associates with significantly less fibrosis progression and portal hypertension than treatment with calcineurin inhibitors tacrolimus and cyclosporine A.	Cyclosporine	226-240	mechanistic target of rapamycin kinase	Homo sapiens	13-17
21622902-6	2011	ERK inhibition significantly decreased CsA-stimulated Nrf-2 nuclear translocation and HO-1 mRNA expression.	Cyclosporine	39-42	NFE2 like bZIP transcription factor 2	Homo sapiens	54-59
21439998-1	2011	Based on our previous research, sulfated modification conditions of Tremella polysaccharide (TPS), the chlorosulfonic acid to pyridine (CSA-Pry) ratio, reaction temperature and time, were optimized by L(9) (3(4)) orthogonal design taking the yield and degree of sulfation (DS) of modifiers as indexes.	Cyclosporine	136-139	PTPN13 like Y-linked	Homo sapiens	140-143
21396934-8	2011	Further, whereas C6-ceramide and cyc A imparted 1.5- and 0-fold increases in caspase 3/7 activity, the combination produced a 3.5-fold increase.	Cyclosporine	33-38	caspase 3	Homo sapiens	77-86
21677130-6	2011	In this study, we show that pCD40L surface mobilization is resistant to cyclosporine or FK506 treatment, while de novo CD40L and cytokine expression are completely inhibited.	Cyclosporine	72-84	CD40 ligand	Homo sapiens	29-34
20804404-10	2011	Gene expressions of interleukin-1beta (IL-1beta), IL-6, and CXCL1 in the mice treated with CyA (0.2 mg/kg/day)-MS and CyA (2 mg/kg/day)-MS were downregulated compared with CyA (0)-MS. CyA-MS might be possible to treat ulcerative colitis effectively by decreasing the total dosage without the elevation of the serum level or the side effects of CyA.	Cyclosporine	91-94	chemokine (C-X-C motif) ligand 1	Mus musculus	60-65
20804404-10	2011	Gene expressions of interleukin-1beta (IL-1beta), IL-6, and CXCL1 in the mice treated with CyA (0.2 mg/kg/day)-MS and CyA (2 mg/kg/day)-MS were downregulated compared with CyA (0)-MS. CyA-MS might be possible to treat ulcerative colitis effectively by decreasing the total dosage without the elevation of the serum level or the side effects of CyA.	Cyclosporine	118-121	interleukin 1 beta	Mus musculus	20-37
20804404-10	2011	Gene expressions of interleukin-1beta (IL-1beta), IL-6, and CXCL1 in the mice treated with CyA (0.2 mg/kg/day)-MS and CyA (2 mg/kg/day)-MS were downregulated compared with CyA (0)-MS. CyA-MS might be possible to treat ulcerative colitis effectively by decreasing the total dosage without the elevation of the serum level or the side effects of CyA.	Cyclosporine	118-121	chemokine (C-X-C motif) ligand 1	Mus musculus	60-65
20804404-10	2011	Gene expressions of interleukin-1beta (IL-1beta), IL-6, and CXCL1 in the mice treated with CyA (0.2 mg/kg/day)-MS and CyA (2 mg/kg/day)-MS were downregulated compared with CyA (0)-MS. CyA-MS might be possible to treat ulcerative colitis effectively by decreasing the total dosage without the elevation of the serum level or the side effects of CyA.	Cyclosporine	118-121	interleukin 1 beta	Mus musculus	20-37
20804404-10	2011	Gene expressions of interleukin-1beta (IL-1beta), IL-6, and CXCL1 in the mice treated with CyA (0.2 mg/kg/day)-MS and CyA (2 mg/kg/day)-MS were downregulated compared with CyA (0)-MS. CyA-MS might be possible to treat ulcerative colitis effectively by decreasing the total dosage without the elevation of the serum level or the side effects of CyA.	Cyclosporine	118-121	chemokine (C-X-C motif) ligand 1	Mus musculus	60-65
21178983-6	2011	Cyclosporine A treatment during DS maintained the number of NK/NKT cells in the conjunctiva, increased IL-13 mRNA in NK+ cells, and decreased IFN-gamma and IL-17A mRNA transcripts in NK+ and NK- populations.	Cyclosporine	0-14	interleukin 13	Mus musculus	103-108
21606250-1	2011	The immunosuppressive calcineurin inhibitors (CNIs) cyclosporine A (CsA) and tacrolimus are widely used in transplant organ recipients, but in the kidney allograft, they may cause tubulointerstitial as well as mesangial fibrosis, with TGF-beta believed to be a central inductor.	Cyclosporine	52-66	transforming growth factor, beta 1	Rattus norvegicus	235-243
21606250-1	2011	The immunosuppressive calcineurin inhibitors (CNIs) cyclosporine A (CsA) and tacrolimus are widely used in transplant organ recipients, but in the kidney allograft, they may cause tubulointerstitial as well as mesangial fibrosis, with TGF-beta believed to be a central inductor.	Cyclosporine	68-71	transforming growth factor, beta 1	Rattus norvegicus	235-243
21606250-2	2011	In this study, we report that the cold-shock protein Y-box binding protein-1 (YB-1) is a TGF-beta independent downstream effector in CsA- as well as in tacrolimus- but not in rapamycin-mediated activation of rat mesangial cells (rMCs).	Cyclosporine	133-136	transforming growth factor, beta 1	Rattus norvegicus	89-97
21178983-6	2011	Cyclosporine A treatment during DS maintained the number of NK/NKT cells in the conjunctiva, increased IL-13 mRNA in NK+ cells, and decreased IFN-gamma and IL-17A mRNA transcripts in NK+ and NK- populations.	Cyclosporine	0-14	interferon gamma	Mus musculus	142-151
21294074-6	2011	To further evaluate this hypothesis, we assessed the effect of a specific mPTP inhibitor (cyclosporine A) on the toxic action of 7-xylosyl-10-deacetylpaclitaxel.	Cyclosporine	90-104	protein tyrosine phosphatase, receptor type, U	Mus musculus	74-78
21474569-6	2011	CsA decreased the expression of endothelial nitric-oxide synthase and increased inducible nitric-oxide synthase/3-nitrotyrosine in the kidney.	Cyclosporine	0-3	nitric oxide synthase 2	Rattus norvegicus	80-111
21294074-7	2011	The 7-xylosyl-10-deacetylpaclitaxel-induced decrease in mitochondrial inner transmembrane potential (DeltaPsim) was abolished by the addition of cyclosporine A (CsA) in PC-3 cells, indicating that 7-xylosyl-10-deacetylpaclitaxel may target mPTP.	Cyclosporine	145-159	protein tyrosine phosphatase, receptor type, U	Mus musculus	240-244
21294074-7	2011	The 7-xylosyl-10-deacetylpaclitaxel-induced decrease in mitochondrial inner transmembrane potential (DeltaPsim) was abolished by the addition of cyclosporine A (CsA) in PC-3 cells, indicating that 7-xylosyl-10-deacetylpaclitaxel may target mPTP.	Cyclosporine	161-164	protein tyrosine phosphatase, receptor type, U	Mus musculus	240-244
20559724-0	2011	Endothelial nitric oxide synthase gene intron 4 polymorphism predicts new onset diabetes mellitus after transplantation in kidney allograft recipients treated with cyclosporin A.	Cyclosporine	164-177	nitric oxide synthase 3	Homo sapiens	0-33
21839244-0	2011	Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels.	Cyclosporine	126-138	ATP binding cassette subfamily B member 1	Homo sapiens	25-30
21839244-0	2011	Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels.	Cyclosporine	126-138	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	35-41
21839244-3	2011	We evaluated the SNPs in ABCB1 (glycoprotein P) and CYP3A5 (metabolic enzyme) genes, seeking correlate them with tacrolimus or cyclosporine levels during the first year after heart transplantation.	Cyclosporine	127-139	ATP binding cassette subfamily B member 1	Homo sapiens	25-30
21839244-3	2011	We evaluated the SNPs in ABCB1 (glycoprotein P) and CYP3A5 (metabolic enzyme) genes, seeking correlate them with tacrolimus or cyclosporine levels during the first year after heart transplantation.	Cyclosporine	127-139	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	52-58
21839244-8	2011	To correlate ABCB1 SNPs, the variants described to cause higher blood levels in rs1045642, 1128503, 2032582 (in linkage disequilibrium) showed this effect only until 4 months posttransplantation among patients treated with cyclosporine (more than 100% higher than the other variant).	Cyclosporine	223-235	ATP binding cassette subfamily B member 1	Homo sapiens	13-18
21430235-5	2011	Finally, budesonide, cyclosporine, and rifampin were identified as inhibitors of OATP1B1-, OATP1B3-, and OATP2B1-meditated mesalazine uptake.	Cyclosporine	21-33	solute carrier organic anion transporter family member 1B3	Homo sapiens	91-98
21776863-0	2011	[Apoptosis and expression of Bcl-2 and caspase-3 in ciclosporin-induced gingival overgrowth of rats].	Cyclosporine	52-63	BCL2, apoptosis regulator	Rattus norvegicus	29-34
21776863-1	2011	OBJECTIVE: To observe the effect of Ciclosporin (CsP) on apoptosis and expression of the associated protein Bcl-2, Caspase-3 in gingival epithelium of rats in order to approach the mechanism of CsP-induced gingival epithelium overgrowth.	Cyclosporine	36-47	BCL2, apoptosis regulator	Rattus norvegicus	108-113
20351753-9	2011	These data suggest that the ZnT-8 W325 variant is protective against CsA-induced suppression of insulin secretion.	Cyclosporine	69-72	solute carrier family 30 member 8	Homo sapiens	28-33
20351753-0	2011	A low-risk ZnT-8 allele (W325) for post-transplantation diabetes mellitus is protective against cyclosporin A-induced impairment of insulin secretion.	Cyclosporine	96-109	solute carrier family 30 member 8	Homo sapiens	11-16
20368718-0	2011	The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis.	Cyclosporine	51-63	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	14-20
20351753-3	2011	We tested the hypothesis that the polymorphic residue at position 325 of ZnT-8 determines the susceptibility to cyclosporin A (CsA) suppression of insulin secretion.	Cyclosporine	112-125	solute carrier family 30 member 8	Homo sapiens	73-78
20351753-3	2011	We tested the hypothesis that the polymorphic residue at position 325 of ZnT-8 determines the susceptibility to cyclosporin A (CsA) suppression of insulin secretion.	Cyclosporine	127-130	solute carrier family 30 member 8	Homo sapiens	73-78
20351753-5	2011	A reduced number of insulin granule fusion events accompanied the decrease in insulin secretion in CsA-treated cells expressing ZnT-8 R325; however, ZnT-8 W325-expressing cells exhibited resistance to the dampening of insulin granule fusion by CsA, and transported zinc ions into secretory vesicles more efficiently.	Cyclosporine	99-102	insulin	Homo sapiens	20-27
20351753-5	2011	A reduced number of insulin granule fusion events accompanied the decrease in insulin secretion in CsA-treated cells expressing ZnT-8 R325; however, ZnT-8 W325-expressing cells exhibited resistance to the dampening of insulin granule fusion by CsA, and transported zinc ions into secretory vesicles more efficiently.	Cyclosporine	99-102	solute carrier family 30 member 8	Homo sapiens	128-133
20368718-1	2011	Cyclosporine (CsA) is a substrate of cytochrome P450 (CYP) 3A5 and has a narrow therapeutic range with large inter-individual variability.	Cyclosporine	0-12	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	37-62
20351753-5	2011	A reduced number of insulin granule fusion events accompanied the decrease in insulin secretion in CsA-treated cells expressing ZnT-8 R325; however, ZnT-8 W325-expressing cells exhibited resistance to the dampening of insulin granule fusion by CsA, and transported zinc ions into secretory vesicles more efficiently.	Cyclosporine	99-102	solute carrier family 30 member 8	Homo sapiens	149-154
20351753-5	2011	A reduced number of insulin granule fusion events accompanied the decrease in insulin secretion in CsA-treated cells expressing ZnT-8 R325; however, ZnT-8 W325-expressing cells exhibited resistance to the dampening of insulin granule fusion by CsA, and transported zinc ions into secretory vesicles more efficiently.	Cyclosporine	99-102	insulin	Homo sapiens	78-85
21779731-0	2011	[Expression of IL-6 in cyclosporin A-induced gingival overgrowth].	Cyclosporine	23-36	interleukin 6	Homo sapiens	15-19
20351753-5	2011	A reduced number of insulin granule fusion events accompanied the decrease in insulin secretion in CsA-treated cells expressing ZnT-8 R325; however, ZnT-8 W325-expressing cells exhibited resistance to the dampening of insulin granule fusion by CsA, and transported zinc ions into secretory vesicles more efficiently.	Cyclosporine	244-247	insulin	Homo sapiens	20-27
20351753-5	2011	A reduced number of insulin granule fusion events accompanied the decrease in insulin secretion in CsA-treated cells expressing ZnT-8 R325; however, ZnT-8 W325-expressing cells exhibited resistance to the dampening of insulin granule fusion by CsA, and transported zinc ions into secretory vesicles more efficiently.	Cyclosporine	244-247	solute carrier family 30 member 8	Homo sapiens	149-154
21779731-1	2011	PURPOSE: To estimate the role of IL-6 in cyclosporin A(CsA)-induced gingival overgrowth(GO) and collect the evidence of pathomechanism for CsA-induced GO.	Cyclosporine	41-54	interleukin 6	Homo sapiens	33-37
21779731-1	2011	PURPOSE: To estimate the role of IL-6 in cyclosporin A(CsA)-induced gingival overgrowth(GO) and collect the evidence of pathomechanism for CsA-induced GO.	Cyclosporine	55-58	interleukin 6	Homo sapiens	33-37
21779731-6	2011	The IL-6 expression of gingival epithelial cells and fibroblasts had no significance difference, but changed depending on the concentration and treated time with CsA.	Cyclosporine	162-165	interleukin 6	Homo sapiens	4-8
21779731-7	2011	During the first 24h, there was no significant difference between the experimental and control groups of gingival fibroblasts, while after stimulation of 1000ng/mL CsA for 24h or longer, the secretion of IL-6 in gingival fibroblasts was significantly higher than the control group (P&lt;0.05).	Cyclosporine	164-167	interleukin 6	Homo sapiens	204-208
21779731-8	2011	CONCLUSIONS: IL-6 is not the main cytokine of gingival epithelial cells, IL-6 in CsA-induced GO probably secreted by the gingival fibroblasts; the effect of CsA on the secretion of IL-6 in the gingival epithelial cells and gingival fibroblasts is associated with the time and concentrations of CsA.	Cyclosporine	81-84	interleukin 6	Homo sapiens	73-77
21779731-8	2011	CONCLUSIONS: IL-6 is not the main cytokine of gingival epithelial cells, IL-6 in CsA-induced GO probably secreted by the gingival fibroblasts; the effect of CsA on the secretion of IL-6 in the gingival epithelial cells and gingival fibroblasts is associated with the time and concentrations of CsA.	Cyclosporine	81-84	interleukin 6	Homo sapiens	73-77
21401729-3	2011	Tacr- compared with CsA-based immunosuppression was independently associated with increased IL-2 (P&lt;0.0001, CD4 cells; P=0.014, CD8 cells) and CD4 cell IL-4 responses (P=0.046; stepwise logistic regression) resulting in physiological responses in Tacr/Aza patients as compared with 25 healthy controls.	Cyclosporine	20-23	interleukin 2	Homo sapiens	92-96
21401729-3	2011	Tacr- compared with CsA-based immunosuppression was independently associated with increased IL-2 (P&lt;0.0001, CD4 cells; P=0.014, CD8 cells) and CD4 cell IL-4 responses (P=0.046; stepwise logistic regression) resulting in physiological responses in Tacr/Aza patients as compared with 25 healthy controls.	Cyclosporine	20-23	CD4 molecule	Homo sapiens	111-114
21401729-3	2011	Tacr- compared with CsA-based immunosuppression was independently associated with increased IL-2 (P&lt;0.0001, CD4 cells; P=0.014, CD8 cells) and CD4 cell IL-4 responses (P=0.046; stepwise logistic regression) resulting in physiological responses in Tacr/Aza patients as compared with 25 healthy controls.	Cyclosporine	20-23	CD4 molecule	Homo sapiens	146-149
21401729-3	2011	Tacr- compared with CsA-based immunosuppression was independently associated with increased IL-2 (P&lt;0.0001, CD4 cells; P=0.014, CD8 cells) and CD4 cell IL-4 responses (P=0.046; stepwise logistic regression) resulting in physiological responses in Tacr/Aza patients as compared with 25 healthy controls.	Cyclosporine	20-23	interleukin 4	Homo sapiens	155-159
21421030-4	2011	Co-administration of Danshen did not affect the plasma concentration profiles and pharmacokinetic parameters of docetaxel and clopidogrel, whereas cyclosporine A, a P-gp and CYP3A inhibitor, significantly influenced the pharmacokinetics of co-administered docetaxel and clopidogrel.	Cyclosporine	147-161	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	174-179
21693312-5	2011	RESULTS: The administration of tranilast decreased the expression of TGF-beta1 and Smad3 by CsA-treated rats, whereas it increased both mRNA and protein levels of Smad7.	Cyclosporine	92-95	transforming growth factor, beta 1	Rattus norvegicus	69-78
21693312-5	2011	RESULTS: The administration of tranilast decreased the expression of TGF-beta1 and Smad3 by CsA-treated rats, whereas it increased both mRNA and protein levels of Smad7.	Cyclosporine	92-95	SMAD family member 3	Rattus norvegicus	83-88
21693312-9	2011	CONCLUSION: Regulation of TGF-beta/Smad pathways is one of the mechanisims by which tranilast mitigates the progression of chronic CsA nephrotoxicity in rats.	Cyclosporine	131-134	transforming growth factor, beta 1	Rattus norvegicus	26-34
21466223-0	2011	Quercetin and rutin reduced the bioavailability of cyclosporine from Neoral, an immunosuppressant, through activating P-glycoprotein and CYP 3A4.	Cyclosporine	51-63	ATP binding cassette subfamily B member 1	Homo sapiens	118-132
21466223-0	2011	Quercetin and rutin reduced the bioavailability of cyclosporine from Neoral, an immunosuppressant, through activating P-glycoprotein and CYP 3A4.	Cyclosporine	51-63	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	137-144
21466223-2	2011	Cyclosporine (CSP), an immunosuppressant with a narrow therapeutic window, is a substrate of P-glycoprotein (P-gp) and cytochrome P-450 3A4 (CYP3A4).	Cyclosporine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	93-107
21466223-2	2011	Cyclosporine (CSP), an immunosuppressant with a narrow therapeutic window, is a substrate of P-glycoprotein (P-gp) and cytochrome P-450 3A4 (CYP3A4).	Cyclosporine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	109-113
21466223-2	2011	Cyclosporine (CSP), an immunosuppressant with a narrow therapeutic window, is a substrate of P-glycoprotein (P-gp) and cytochrome P-450 3A4 (CYP3A4).	Cyclosporine	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	119-139
21466223-2	2011	Cyclosporine (CSP), an immunosuppressant with a narrow therapeutic window, is a substrate of P-glycoprotein (P-gp) and cytochrome P-450 3A4 (CYP3A4).	Cyclosporine	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	141-147
21466223-2	2011	Cyclosporine (CSP), an immunosuppressant with a narrow therapeutic window, is a substrate of P-glycoprotein (P-gp) and cytochrome P-450 3A4 (CYP3A4).	Cyclosporine	14-17	ATP binding cassette subfamily B member 1	Homo sapiens	93-107
21466223-2	2011	Cyclosporine (CSP), an immunosuppressant with a narrow therapeutic window, is a substrate of P-glycoprotein (P-gp) and cytochrome P-450 3A4 (CYP3A4).	Cyclosporine	14-17	ATP binding cassette subfamily B member 1	Homo sapiens	109-113
21466223-2	2011	Cyclosporine (CSP), an immunosuppressant with a narrow therapeutic window, is a substrate of P-glycoprotein (P-gp) and cytochrome P-450 3A4 (CYP3A4).	Cyclosporine	14-17	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	119-139
21466223-2	2011	Cyclosporine (CSP), an immunosuppressant with a narrow therapeutic window, is a substrate of P-glycoprotein (P-gp) and cytochrome P-450 3A4 (CYP3A4).	Cyclosporine	14-17	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	141-147
21349923-5	2011	Three immunosuppressants (tacrolimus, sirolimus, and cyclosporine) were analyzed, because these CYP3A4 drug substrates are subject to long-term use and repeated concentration determinations.	Cyclosporine	53-65	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	96-102
21382357-3	2011	So we will discuss the effect of CIPC, pretreatment with nimodipine, MK801 and cyclosporine A on the expression of the CaN, cbl-b and p-AKT in the hippocampus neurons.	Cyclosporine	79-93	AKT serine/threonine kinase 1	Rattus norvegicus	136-139
21382357-14	2011	Nimodipine and cyclosporine A can reduce the expression of CaN and cbl-b, and increase the expression of p-AKT, via a moderate increase in the concentration of intracellular calcium and inhibition of the activity of CaN; MK801 counteracts the effect of CIPC.	Cyclosporine	15-29	AKT serine/threonine kinase 1	Rattus norvegicus	107-110
21306480-2	2011	We studied the determination of association between TGF-beta1 (TGFB1) gene polymorphism and gingival overgrowth in kidney transplant patients medicated with cyclosporin A.	Cyclosporine	157-170	transforming growth factor beta 1	Homo sapiens	52-61
21306480-2	2011	We studied the determination of association between TGF-beta1 (TGFB1) gene polymorphism and gingival overgrowth in kidney transplant patients medicated with cyclosporin A.	Cyclosporine	157-170	transforming growth factor beta 1	Homo sapiens	63-68
21490080-7	2011	RESULTS: Compared with the control group, acidic buffer or plus cyclosporine A post-conditioning significantly improved myocardial performance, decreased cytochrome C release into the cytosol, increased Bcl-2 expression and decreased Bax expression, decreased sensitivity of mPTP-opening to [Ca2+] and the rate of apoptosis after reperfusion.	Cyclosporine	64-78	BCL2, apoptosis regulator	Rattus norvegicus	203-208
21132005-5	2011	When HepG2 cells were treated with 20 muM pifithrin-alpha, an inhibitor of p53 function, or 5 muM cyclosporin A (CsA), an inhibitor of cytochrome-c release from mitochondria, the MN induction in bystander Chang liver cells was diminished.	Cyclosporine	98-111	cytochrome c, somatic	Homo sapiens	135-147
21251981-9	2011	On the contrary, hearts obtained from long-term surviving hosts treated with CD4(+) cells induced with high-dose CsA (CD4-CsA) had 50-70% of affected vessels.	Cyclosporine	113-116	CD4 molecule	Homo sapiens	77-80
21251981-9	2011	On the contrary, hearts obtained from long-term surviving hosts treated with CD4(+) cells induced with high-dose CsA (CD4-CsA) had 50-70% of affected vessels.	Cyclosporine	113-116	CD4 molecule	Homo sapiens	118-121
21132005-5	2011	When HepG2 cells were treated with 20 muM pifithrin-alpha, an inhibitor of p53 function, or 5 muM cyclosporin A (CsA), an inhibitor of cytochrome-c release from mitochondria, the MN induction in bystander Chang liver cells was diminished.	Cyclosporine	113-116	cytochrome c, somatic	Homo sapiens	135-147
21132005-8	2011	In addition, this exogenous cytochrome-c also partly recovered the RIBE induced by irradiated HepG2 cells even with CsA treatment.	Cyclosporine	116-119	cytochrome c, somatic	Homo sapiens	28-40
21354196-11	2011	Proteomic analysis of urine identified a number of differentially regulated proteins that may be involved in early CsA nephropathy including cadherin 1, superoxide dismutase and vinculin.	Cyclosporine	115-118	cadherin 1	Mus musculus	141-151
21453156-8	2011	RESULTS: Cyclosporine, dexamethasone, cyclosporine-dexamethasone combination, and CTLA4-Ig caused a significant decrease in IL-2, IFN-gamma, and GM-CSF production.	Cyclosporine	9-21	interferon gamma	Felis catus	130-139
21070202-2	2011	In mice engineered to overexpress the angiopoietin receptor Tie2 in KCs, skin spontaneously develops the characteristic clinical, histological and immune cell phenotypes of psoriasis which can be reversed with either transgene repression or ciclosporin administration, suggesting key roles for both KCs and T cells in mediating the skin disease in this murine model.	Cyclosporine	241-252	TEK receptor tyrosine kinase	Mus musculus	60-64
21453156-8	2011	RESULTS: Cyclosporine, dexamethasone, cyclosporine-dexamethasone combination, and CTLA4-Ig caused a significant decrease in IL-2, IFN-gamma, and GM-CSF production.	Cyclosporine	38-50	interferon gamma	Felis catus	130-139
21318225-5	2011	The cyclosporin derivative PSC833, a potent inhibitor of P-glycoprotein, sensitized DX5 but not GARF cells to the cytotoxic effects of daunorubicin.	Cyclosporine	4-15	ATP binding cassette subfamily B member 1	Homo sapiens	57-71
20571034-0	2011	Do drug transporter (ABCB1) SNPs influence cyclosporine and tacrolimus dose requirements and renal allograft outcome in the posttransplantation period?	Cyclosporine	43-55	ATP binding cassette subfamily B member 1	Homo sapiens	21-26
20571034-1	2011	Polymorphisms in the drug transporter gene (ABCB1) may play a significant role in individualizing cyclosporine (CsA) and tacrolimus (Tac) dosage and subsequently the allograft outcome in renal transplant recipients.	Cyclosporine	98-110	ATP binding cassette subfamily B member 1	Homo sapiens	44-49
20571034-1	2011	Polymorphisms in the drug transporter gene (ABCB1) may play a significant role in individualizing cyclosporine (CsA) and tacrolimus (Tac) dosage and subsequently the allograft outcome in renal transplant recipients.	Cyclosporine	112-115	ATP binding cassette subfamily B member 1	Homo sapiens	44-49
21566860-0	2011	[Expression of TGF-beta1 and PCNA in cyclosporin A-induced gingival overgrowth].	Cyclosporine	37-50	transforming growth factor, beta 1	Rattus norvegicus	15-24
21566860-1	2011	PURPOSE: To investigate the expression of transforming growth factor-beta1(TGF-beta1) and proliferating cell nuclear of antigen (PCNA) in cyclosporin A(CsA)-induced gingival overgrowth (GO) tissues.	Cyclosporine	138-151	transforming growth factor, beta 1	Rattus norvegicus	42-74
21566860-1	2011	PURPOSE: To investigate the expression of transforming growth factor-beta1(TGF-beta1) and proliferating cell nuclear of antigen (PCNA) in cyclosporin A(CsA)-induced gingival overgrowth (GO) tissues.	Cyclosporine	152-155	transforming growth factor, beta 1	Rattus norvegicus	42-74
21566860-1	2011	PURPOSE: To investigate the expression of transforming growth factor-beta1(TGF-beta1) and proliferating cell nuclear of antigen (PCNA) in cyclosporin A(CsA)-induced gingival overgrowth (GO) tissues.	Cyclosporine	152-155	transforming growth factor, beta 1	Rattus norvegicus	75-84
21393488-10	2011	Caution should be exercised when coadministering any statin with drugs that metabolize through cytochrome P-450 IIIA-4 in particular fibrates, cyclosporine, and azole antifungals.	Cyclosporine	143-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
21383650-1	2011	BACKGROUND: The association of CYP3A5, CYP3A4, and ABCB1 single nucleotide polymorphisms (SNPs) with cyclosporine (CsA) pharmacokinetics is controversial.	Cyclosporine	101-113	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	31-37
21383650-1	2011	BACKGROUND: The association of CYP3A5, CYP3A4, and ABCB1 single nucleotide polymorphisms (SNPs) with cyclosporine (CsA) pharmacokinetics is controversial.	Cyclosporine	101-113	ATP binding cassette subfamily B member 1	Homo sapiens	51-56
21383650-1	2011	BACKGROUND: The association of CYP3A5, CYP3A4, and ABCB1 single nucleotide polymorphisms (SNPs) with cyclosporine (CsA) pharmacokinetics is controversial.	Cyclosporine	115-118	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	31-37
21383650-1	2011	BACKGROUND: The association of CYP3A5, CYP3A4, and ABCB1 single nucleotide polymorphisms (SNPs) with cyclosporine (CsA) pharmacokinetics is controversial.	Cyclosporine	115-118	ATP binding cassette subfamily B member 1	Homo sapiens	51-56
21307294-5	2011	Furthermore, grafts from the MVC/CsA group had elevated numbers of alternatively activated macrophages (AAMs) and the expression of peroxisome proliferator-activated receptor gamma (PPARgamma).	Cyclosporine	33-36	peroxisome proliferator activated receptor gamma	Homo sapiens	132-180
21307294-5	2011	Furthermore, grafts from the MVC/CsA group had elevated numbers of alternatively activated macrophages (AAMs) and the expression of peroxisome proliferator-activated receptor gamma (PPARgamma).	Cyclosporine	33-36	peroxisome proliferator activated receptor gamma	Homo sapiens	182-191
21307294-6	2011	Blockade of PPARgamma abrogated the prolonged allograft survival (median survival time, 45 d) and the upregulated AAMs in MVC/CsA-treated recipients.	Cyclosporine	126-129	peroxisome proliferator activated receptor gamma	Homo sapiens	12-21
20848129-0	2011	Effect of cyclosporin A on proteinuria in the course of glomerulopathy associated with WT1 mutations.	Cyclosporine	10-23	WT1 transcription factor	Homo sapiens	87-90
21465949-6	2011	Substitution of tacrolimus with cyclosporine obviated the need for insulin or oral hypoglycaemics.	Cyclosporine	32-44	insulin	Homo sapiens	67-74
20813770-8	2011	RESULTS: CsA treatment decreased Klotho mRNA and protein in mouse kidney in a dose-dependent and time-dependent manner, but a concurrent treatment with losartan, an angiotensin II type 1 (AT1) receptor blocker, reversed the decrease in Klotho expression with histological improvement.	Cyclosporine	9-12	angiotensin II receptor, type 1a	Mus musculus	188-191
20813770-12	2011	AT1 receptor blocker may inhibit the ageing process by decreasing oxidative stress caused by CsA.	Cyclosporine	93-96	angiotensin II receptor, type 1a	Mus musculus	0-3
21343581-3	2011	Many younger patients who respond to immunosuppressive therapy with drugs such as antithymocyte globulin and cyclosporine have clonal expansions of cytotoxic CD8(+) T cells that suppress normal hematopoiesis, as well as expansion of CD4(+) helper T-cell subsets that promote and sustain autoimmunity.	Cyclosporine	109-121	CD4 molecule	Homo sapiens	233-236
21082355-9	2011	ROS scavenger-N-acetyl cysteine, mitochondrial stabilizer-cyclosporin-A, and broad spectrum caspase inhibitor Z-VAD-FMK inhibited the OA induced caspase-3 activation, DNA damage and cell death but caspase-8 inhibitor had no effect.	Cyclosporine	58-71	caspase 3	Homo sapiens	145-154
21310770-7	2011	RESULTS: Compared with the control group, acidic buffer or plus cyclosporine A post-conditioning significantly improved myocardial performance, decreased cytochrome C release into the cytosol, increased Bcl-2 expression and decreased Bax expression, decreased sensitivity of mPTP-opening to [Ca2+] and the rate of apoptosis after reperfusion.	Cyclosporine	64-78	BCL2, apoptosis regulator	Rattus norvegicus	203-208
20488842-6	2011	Results obtained showed that, CyA exert its toxic effect by increasing the free radicals and ROS that causes lipid peroxidation and cell damage, this is detected by elevation of hydroperoxides and thiobarbituric acid reactive substances, while the activities of antioxidant enzymes include (superoxide dismutase [SOD], catalase [CAT] and glutathione peroxidase [GPx]) were significantly decreased as compared with control rats.	Cyclosporine	30-33	catalase	Rattus norvegicus	319-327
21107704-4	2011	CsA significantly inhibited SSa-induced loss of mitochondrial transmembrane potential and moderately inhibited SSa-induced cell death.	Cyclosporine	0-3	tripartite motif containing 21	Homo sapiens	28-31
21107704-4	2011	CsA significantly inhibited SSa-induced loss of mitochondrial transmembrane potential and moderately inhibited SSa-induced cell death.	Cyclosporine	0-3	tripartite motif containing 21	Homo sapiens	111-114
21078360-0	2011	Human adipose tissue-derived mesenchymal stem cells facilitate the immunosuppressive effect of cyclosporin A on T lymphocytes through Jagged-1-mediated inhibition of NF-kappaB signaling.	Cyclosporine	95-108	nuclear factor kappa B subunit 1	Homo sapiens	166-175
21078360-8	2011	RESULTS: The combination of moderate-dose AMSCs and low-dose CsA was significantly more powerful than moderate-dose AMSCs or large-dose CsA alone in suppressing transcription and production of interleukin-2 and interferon-gamma, activation of NF-kappaB, and proliferation of T lymphocytes.	Cyclosporine	61-64	interleukin 2	Homo sapiens	193-206
21078360-8	2011	RESULTS: The combination of moderate-dose AMSCs and low-dose CsA was significantly more powerful than moderate-dose AMSCs or large-dose CsA alone in suppressing transcription and production of interleukin-2 and interferon-gamma, activation of NF-kappaB, and proliferation of T lymphocytes.	Cyclosporine	61-64	interferon gamma	Homo sapiens	211-227
21078360-8	2011	RESULTS: The combination of moderate-dose AMSCs and low-dose CsA was significantly more powerful than moderate-dose AMSCs or large-dose CsA alone in suppressing transcription and production of interleukin-2 and interferon-gamma, activation of NF-kappaB, and proliferation of T lymphocytes.	Cyclosporine	61-64	nuclear factor kappa B subunit 1	Homo sapiens	243-252
21078360-8	2011	RESULTS: The combination of moderate-dose AMSCs and low-dose CsA was significantly more powerful than moderate-dose AMSCs or large-dose CsA alone in suppressing transcription and production of interleukin-2 and interferon-gamma, activation of NF-kappaB, and proliferation of T lymphocytes.	Cyclosporine	136-139	interleukin 2	Homo sapiens	193-206
21078360-8	2011	RESULTS: The combination of moderate-dose AMSCs and low-dose CsA was significantly more powerful than moderate-dose AMSCs or large-dose CsA alone in suppressing transcription and production of interleukin-2 and interferon-gamma, activation of NF-kappaB, and proliferation of T lymphocytes.	Cyclosporine	136-139	interferon gamma	Homo sapiens	211-227
21078360-11	2011	CONCLUSIONS: Human AMSCs facilitate the immunosuppressive effect of CsA on T lymphocytes through Jagged-1/Notch-related inhibition of NF-kappaB signaling.	Cyclosporine	68-71	nuclear factor kappa B subunit 1	Homo sapiens	134-143
20621335-4	2011	Refractoriness to therapy with corticosteroids and cyclosporine A led to the use of humanized monoclonal anti-interleukin-6 receptor antibody "tocilizumab" with dramatic response.	Cyclosporine	51-65	interleukin 6	Homo sapiens	110-123
21148296-7	2011	In addition, pretreatment with CsA blocked NaBT-mediated induction of intestinal alkaline phosphatase (IAP) activity and villin and p27(kip1) expression; knockdown of either NFATc1 or NFATc4 attenuated NaBT-induced IAP activity.	Cyclosporine	31-34	alkaline phosphatase, intestinal	Homo sapiens	70-101
21148296-7	2011	In addition, pretreatment with CsA blocked NaBT-mediated induction of intestinal alkaline phosphatase (IAP) activity and villin and p27(kip1) expression; knockdown of either NFATc1 or NFATc4 attenuated NaBT-induced IAP activity.	Cyclosporine	31-34	alkaline phosphatase, intestinal	Homo sapiens	103-106
21148296-7	2011	In addition, pretreatment with CsA blocked NaBT-mediated induction of intestinal alkaline phosphatase (IAP) activity and villin and p27(kip1) expression; knockdown of either NFATc1 or NFATc4 attenuated NaBT-induced IAP activity.	Cyclosporine	31-34	nuclear factor of activated T cells 4	Homo sapiens	184-190
21148296-7	2011	In addition, pretreatment with CsA blocked NaBT-mediated induction of intestinal alkaline phosphatase (IAP) activity and villin and p27(kip1) expression; knockdown of either NFATc1 or NFATc4 attenuated NaBT-induced IAP activity.	Cyclosporine	31-34	alkaline phosphatase, intestinal	Homo sapiens	215-218
21276247-3	2011	In the present study, we examined the effects of prednisone, thalidomide, cyclosporine A, and amitriptyline, drugs used in a variety of clinical conditions, on the production of TNF-alpha, IL-10, and IL-12 by purified epidermal Langerhans cells and peritoneal macrophages in BALB/c mice.	Cyclosporine	74-88	tumor necrosis factor	Mus musculus	178-187
21148038-6	2011	After terminating TCR stimulation or adding cyclosporin A to the culture, Ccr9 gene transcription was induced, accompanied by inactivation of NFATc1 and sustained activation of NFATc2.	Cyclosporine	44-57	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2	Mus musculus	177-183
21560359-5	2011	RESULTS: In contrast to LPS group, the mitochondrial permeability transition pore inhibitor CsA induced a decrease in LDH activity in the BALF and TNF-alpha level in lung tissue, lung wet weight/dry weight ratio and the pulmonary capillary permeability index were declined.	Cyclosporine	92-95	tumor necrosis factor	Mus musculus	147-156
21298017-8	2011	Notably, cyclosporine represses HNF4alpha gene and protein expression and its DNA-binding activity at consensus sequences to AGT, AGTR1, ACE, and ACE2.	Cyclosporine	9-21	hepatocyte nuclear factor 4 alpha	Homo sapiens	32-41
21298017-8	2011	Notably, cyclosporine represses HNF4alpha gene and protein expression and its DNA-binding activity at consensus sequences to AGT, AGTR1, ACE, and ACE2.	Cyclosporine	9-21	angiotensinogen	Homo sapiens	125-128
21298017-8	2011	Notably, cyclosporine represses HNF4alpha gene and protein expression and its DNA-binding activity at consensus sequences to AGT, AGTR1, ACE, and ACE2.	Cyclosporine	9-21	angiotensin I converting enzyme	Homo sapiens	137-140
21298017-11	2011	Taken collectively we demonstrate cyclosporine to repress HNF4alpha activity through calcineurin inhibitor mediated inhibition of nuclear factor of activation of T-cells (NFAT) which in turn represses HNF4alpha that leads to a disturbed balance of RAS.	Cyclosporine	34-46	hepatocyte nuclear factor 4 alpha	Homo sapiens	58-67
21298017-11	2011	Taken collectively we demonstrate cyclosporine to repress HNF4alpha activity through calcineurin inhibitor mediated inhibition of nuclear factor of activation of T-cells (NFAT) which in turn represses HNF4alpha that leads to a disturbed balance of RAS.	Cyclosporine	34-46	hepatocyte nuclear factor 4 alpha	Homo sapiens	201-210
21148038-6	2011	After terminating TCR stimulation or adding cyclosporin A to the culture, Ccr9 gene transcription was induced, accompanied by inactivation of NFATc1 and sustained activation of NFATc2.	Cyclosporine	44-57	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	142-148
21358177-10	2011	Tacrolimus and cyclosporine increased fibronectin and TGF-beta expression and matrix deposition.	Cyclosporine	15-27	transforming growth factor, beta 1	Rattus norvegicus	54-62
22179001-8	2011	It is possible that a protein phosphatase is also involved in the WNK3 effects on its associated cotransporters because activation of KCCs and inhibition of NKCCs by inactive WNK3 can be prevented by known inhibitors of protein phosphatases, such as calyculin A and cyclosporine, suggesting that a protein phosphatase is also involved in the protein complex.	Cyclosporine	266-278	WNK lysine deficient protein kinase 3 S homeolog	Xenopus laevis	66-70
22179001-8	2011	It is possible that a protein phosphatase is also involved in the WNK3 effects on its associated cotransporters because activation of KCCs and inhibition of NKCCs by inactive WNK3 can be prevented by known inhibitors of protein phosphatases, such as calyculin A and cyclosporine, suggesting that a protein phosphatase is also involved in the protein complex.	Cyclosporine	266-278	WNK lysine deficient protein kinase 3 S homeolog	Xenopus laevis	175-179
21888018-7	2011	RESULTS: Cathepsin D, L, and vascular endothelial growth factor (VEGF)165 mRNA were markedly suppressed in CsA-treated HGFs, whereas cathepsin B, matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of metalloproteinase-1 (TIMP-1) mRNA were not reduced.	Cyclosporine	107-110	vascular endothelial growth factor A	Homo sapiens	29-63
21163525-1	2011	Immunophilins are receptors for immunosuppressive drugs such as the macrolides cyclosporin A (CsA) and FK506; correspondingly these immunophilins are referred to as cyclophilins and FK506-binding proteins (FKBPs).	Cyclosporine	79-92	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	165-177
21163525-1	2011	Immunophilins are receptors for immunosuppressive drugs such as the macrolides cyclosporin A (CsA) and FK506; correspondingly these immunophilins are referred to as cyclophilins and FK506-binding proteins (FKBPs).	Cyclosporine	94-97	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	165-177
21163525-2	2011	In particular, CsA targets cyclophilin D (CypD), which can modulate mitochondrial Ca(2+) dynamics.	Cyclosporine	15-18	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	27-40
21163525-2	2011	In particular, CsA targets cyclophilin D (CypD), which can modulate mitochondrial Ca(2+) dynamics.	Cyclosporine	15-18	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	42-46
21163525-5	2011	Furthermore, acute treatment with CsA to inhibit CypD modulation of mitochondrial Ca(2+) buffering, or with FK506 to inhibit FKBP12 interaction with inositol-trisphosphate receptor of the endoplasmic reticulum, led to similar reductive effects on astrocytic Ca(cyt)(2+) dynamics, but also to an enhanced Ca(2+)-dependent exocytotic release of glutamate in wild-type astrocytes.	Cyclosporine	34-37	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	49-53
21062675-0	2011	Reversion of resistance to immunosuppressive agents in three patients with psoriatic arthritis by cyclosporine A: modulation of P-glycoprotein function.	Cyclosporine	98-112	ATP binding cassette subfamily B member 1	Homo sapiens	128-142
21062675-3	2011	P-gp function can in vitro be inhibited by cyclosporine A (CSA) and verapamil; moreover, P-gp reduction by CSA in systemic lupus erythematosus and rheumatoid arthritis has been demonstrated.	Cyclosporine	43-57	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
21062675-3	2011	P-gp function can in vitro be inhibited by cyclosporine A (CSA) and verapamil; moreover, P-gp reduction by CSA in systemic lupus erythematosus and rheumatoid arthritis has been demonstrated.	Cyclosporine	59-62	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
21062675-3	2011	P-gp function can in vitro be inhibited by cyclosporine A (CSA) and verapamil; moreover, P-gp reduction by CSA in systemic lupus erythematosus and rheumatoid arthritis has been demonstrated.	Cyclosporine	107-110	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
21062675-3	2011	P-gp function can in vitro be inhibited by cyclosporine A (CSA) and verapamil; moreover, P-gp reduction by CSA in systemic lupus erythematosus and rheumatoid arthritis has been demonstrated.	Cyclosporine	107-110	ATP binding cassette subfamily B member 1	Homo sapiens	89-93
21062675-6	2011	CSA treatment resulted in good clinical outcome that was related with a significant P-gp function reduction at CD3+ and CD8+ levels.	Cyclosporine	0-3	ATP binding cassette subfamily B member 1	Homo sapiens	84-88
21062675-7	2011	In addition to its immunosuppressive activity, CSA results may also be related to MTX/SSA effect restoration through P-gp inhibition.	Cyclosporine	47-50	ATP binding cassette subfamily B member 1	Homo sapiens	117-121
21888018-7	2011	RESULTS: Cathepsin D, L, and vascular endothelial growth factor (VEGF)165 mRNA were markedly suppressed in CsA-treated HGFs, whereas cathepsin B, matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of metalloproteinase-1 (TIMP-1) mRNA were not reduced.	Cyclosporine	107-110	vascular endothelial growth factor A	Homo sapiens	65-69
21888018-7	2011	RESULTS: Cathepsin D, L, and vascular endothelial growth factor (VEGF)165 mRNA were markedly suppressed in CsA-treated HGFs, whereas cathepsin B, matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of metalloproteinase-1 (TIMP-1) mRNA were not reduced.	Cyclosporine	107-110	TIMP metallopeptidase inhibitor 1	Homo sapiens	185-224
21888018-7	2011	RESULTS: Cathepsin D, L, and vascular endothelial growth factor (VEGF)165 mRNA were markedly suppressed in CsA-treated HGFs, whereas cathepsin B, matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of metalloproteinase-1 (TIMP-1) mRNA were not reduced.	Cyclosporine	107-110	TIMP metallopeptidase inhibitor 1	Homo sapiens	226-232
19939655-7	2011	The results demonstrated that CsA treatment decreases blood levels of interleukins 1alpha (IL-1alpha), 1beta (IL-1beta) and interleukin 2 (IL-2), but does not alter interleukin 6 (IL-6) and IFN-gamma levels.	Cyclosporine	30-33	interleukin 1 alpha	Rattus norvegicus	91-100
19939655-7	2011	The results demonstrated that CsA treatment decreases blood levels of interleukins 1alpha (IL-1alpha), 1beta (IL-1beta) and interleukin 2 (IL-2), but does not alter interleukin 6 (IL-6) and IFN-gamma levels.	Cyclosporine	30-33	interleukin 1 beta	Rattus norvegicus	110-118
19939655-7	2011	The results demonstrated that CsA treatment decreases blood levels of interleukins 1alpha (IL-1alpha), 1beta (IL-1beta) and interleukin 2 (IL-2), but does not alter interleukin 6 (IL-6) and IFN-gamma levels.	Cyclosporine	30-33	interleukin 6	Rattus norvegicus	180-184
21304046-2	2011	We have established a protocol for tolerance induction under alpha/beta selective blocking antibody T-cell receptor combined with interleukin-2 blocker cyclosporin A therapy.	Cyclosporine	152-165	interleukin 2	Homo sapiens	130-143
21857093-0	2011	Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients.	Cyclosporine	61-75	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	35-41
20851640-0	2011	Endothelin-1 antagonism and nitric oxide augmentation prevents cyclosporine-induced vasomotor impairment.	Cyclosporine	63-75	endothelin 1	Rattus norvegicus	0-12
20851640-1	2011	BACKGROUND: We previously demonstrated that cyclosporine (CyA) impairs endothelial function as a result of alterations in nitric oxide (NO) and endothelin-1 (ET-1) regulation.	Cyclosporine	44-56	endothelin 1	Rattus norvegicus	144-156
20851640-1	2011	BACKGROUND: We previously demonstrated that cyclosporine (CyA) impairs endothelial function as a result of alterations in nitric oxide (NO) and endothelin-1 (ET-1) regulation.	Cyclosporine	44-56	endothelin 1	Rattus norvegicus	158-162
20851640-1	2011	BACKGROUND: We previously demonstrated that cyclosporine (CyA) impairs endothelial function as a result of alterations in nitric oxide (NO) and endothelin-1 (ET-1) regulation.	Cyclosporine	58-61	endothelin 1	Rattus norvegicus	144-156
20851640-1	2011	BACKGROUND: We previously demonstrated that cyclosporine (CyA) impairs endothelial function as a result of alterations in nitric oxide (NO) and endothelin-1 (ET-1) regulation.	Cyclosporine	58-61	endothelin 1	Rattus norvegicus	158-162
22470391-3	2011	RESULTS: CyA induced apoptosis at 24 h and nuclear translocation of phosphorylated (p)-Smad2/3 at 3 h, which was continued till 24 h. CyA enhanced the expression of p-ERK at 1 h, which was continued till 24 h, and of p-p38MAPK at 1-6 h, which returned to control level at 12 h. CyA did not affect JNK.	Cyclosporine	9-12	mitogen-activated protein kinase 1	Homo sapiens	167-170
22470391-3	2011	RESULTS: CyA induced apoptosis at 24 h and nuclear translocation of phosphorylated (p)-Smad2/3 at 3 h, which was continued till 24 h. CyA enhanced the expression of p-ERK at 1 h, which was continued till 24 h, and of p-p38MAPK at 1-6 h, which returned to control level at 12 h. CyA did not affect JNK.	Cyclosporine	9-12	mitogen-activated protein kinase 8	Homo sapiens	297-300
22470391-3	2011	RESULTS: CyA induced apoptosis at 24 h and nuclear translocation of phosphorylated (p)-Smad2/3 at 3 h, which was continued till 24 h. CyA enhanced the expression of p-ERK at 1 h, which was continued till 24 h, and of p-p38MAPK at 1-6 h, which returned to control level at 12 h. CyA did not affect JNK.	Cyclosporine	134-137	mitogen-activated protein kinase 1	Homo sapiens	167-170
22470391-3	2011	RESULTS: CyA induced apoptosis at 24 h and nuclear translocation of phosphorylated (p)-Smad2/3 at 3 h, which was continued till 24 h. CyA enhanced the expression of p-ERK at 1 h, which was continued till 24 h, and of p-p38MAPK at 1-6 h, which returned to control level at 12 h. CyA did not affect JNK.	Cyclosporine	134-137	mitogen-activated protein kinase 8	Homo sapiens	297-300
22470391-3	2011	RESULTS: CyA induced apoptosis at 24 h and nuclear translocation of phosphorylated (p)-Smad2/3 at 3 h, which was continued till 24 h. CyA enhanced the expression of p-ERK at 1 h, which was continued till 24 h, and of p-p38MAPK at 1-6 h, which returned to control level at 12 h. CyA did not affect JNK.	Cyclosporine	134-137	mitogen-activated protein kinase 1	Homo sapiens	167-170
22470391-3	2011	RESULTS: CyA induced apoptosis at 24 h and nuclear translocation of phosphorylated (p)-Smad2/3 at 3 h, which was continued till 24 h. CyA enhanced the expression of p-ERK at 1 h, which was continued till 24 h, and of p-p38MAPK at 1-6 h, which returned to control level at 12 h. CyA did not affect JNK.	Cyclosporine	134-137	mitogen-activated protein kinase 8	Homo sapiens	297-300
21857093-5	2011	Compared with CYP3A5*3/*3 individuals, CYP3A5*1/*1 subjects have a significantly lower dose-adjusted C0 and C2 at days 1-10 and a higher dose requirement for CsA at days 16-30 (p &lt; 0.05).	Cyclosporine	158-161	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	39-45
21857093-1	2011	The aim of this study was to retrospectively evaluate the effect of polymorphisms in the CYP3A4, CYP3A5 and ABCB1 genes on the dose-adjusted concentration and dose requirement of cyclosporine A(CsA) in Chinese recipients during the early period after bone marrow or hematopoietic stem cell transplantation.	Cyclosporine	179-193	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	89-95
21857093-1	2011	The aim of this study was to retrospectively evaluate the effect of polymorphisms in the CYP3A4, CYP3A5 and ABCB1 genes on the dose-adjusted concentration and dose requirement of cyclosporine A(CsA) in Chinese recipients during the early period after bone marrow or hematopoietic stem cell transplantation.	Cyclosporine	179-193	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	97-103
21857093-1	2011	The aim of this study was to retrospectively evaluate the effect of polymorphisms in the CYP3A4, CYP3A5 and ABCB1 genes on the dose-adjusted concentration and dose requirement of cyclosporine A(CsA) in Chinese recipients during the early period after bone marrow or hematopoietic stem cell transplantation.	Cyclosporine	179-193	ATP binding cassette subfamily B member 1	Homo sapiens	108-113
21857093-1	2011	The aim of this study was to retrospectively evaluate the effect of polymorphisms in the CYP3A4, CYP3A5 and ABCB1 genes on the dose-adjusted concentration and dose requirement of cyclosporine A(CsA) in Chinese recipients during the early period after bone marrow or hematopoietic stem cell transplantation.	Cyclosporine	194-197	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	89-95
22194945-3	2011	Cyclosporine A (CsA) promotes tissue accumulation and induces TGF -beta1 and, could thereby exert beneficial effects on AAA remodelling and expansion.	Cyclosporine	0-14	transforming growth factor, beta 1	Rattus norvegicus	62-72
22194945-3	2011	Cyclosporine A (CsA) promotes tissue accumulation and induces TGF -beta1 and, could thereby exert beneficial effects on AAA remodelling and expansion.	Cyclosporine	16-19	transforming growth factor, beta 1	Rattus norvegicus	62-72
22194945-4	2011	In this study, we assessed whether a short administration of CsA could durably stabilize AAAs through TGF-beta induction.	Cyclosporine	61-64	transforming growth factor, beta 1	Rattus norvegicus	102-110
22194945-5	2011	We showed that CsA induced TGF-beta1 and decreased MMP-9 expression dose-dependently in fragments of human AAAs in vitro, and in animal models of AAA in vivo.	Cyclosporine	15-18	transforming growth factor beta 1	Homo sapiens	27-36
22194945-8	2011	Co-administration of a blocking anti-TGF-beta antibody abrogated CsA impact on inflammation, alphaSMA-positive cell accumulation and diameter control in expanding AAAs.	Cyclosporine	65-68	transforming growth factor, beta 1	Rattus norvegicus	37-45
22194945-9	2011	Our study demonstrates that pharmacological induction of TGF-beta1 by a short course of CsA administration represents a new approach to induce aneurysm stabilization by shifting the degradation/repair balance towards healing.	Cyclosporine	88-91	transforming growth factor, beta 1	Rattus norvegicus	57-66
21980535-3	2011	Kidney androgen-regulated protein (KAP) is exclusively expressed in kidney proximal tubule cells, interacts with the CsA-binding protein cyclophilin B and its expression diminishes in kidneys of CsA-treated mice.	Cyclosporine	117-120	kidney androgen regulated protein	Mus musculus	0-33
21980535-3	2011	Kidney androgen-regulated protein (KAP) is exclusively expressed in kidney proximal tubule cells, interacts with the CsA-binding protein cyclophilin B and its expression diminishes in kidneys of CsA-treated mice.	Cyclosporine	117-120	kidney androgen regulated protein	Mus musculus	35-38
21980535-4	2011	Since we reported that KAP protects against CsA toxicity in cultured proximal tubule cells, we hypothesized that low KAP levels found in kidneys of CsA-treated mice might correlate with proximal tubule cell injury.	Cyclosporine	44-47	kidney androgen regulated protein	Mus musculus	23-26
21980535-4	2011	Since we reported that KAP protects against CsA toxicity in cultured proximal tubule cells, we hypothesized that low KAP levels found in kidneys of CsA-treated mice might correlate with proximal tubule cell injury.	Cyclosporine	148-151	kidney androgen regulated protein	Mus musculus	23-26
21980535-4	2011	Since we reported that KAP protects against CsA toxicity in cultured proximal tubule cells, we hypothesized that low KAP levels found in kidneys of CsA-treated mice might correlate with proximal tubule cell injury.	Cyclosporine	148-151	kidney androgen regulated protein	Mus musculus	117-120
21980535-5	2011	To test this hypothesis, we used KAP Tg mice developed in our laboratory and showed that these mice are more resistant to CsA-induced tubular injury than control littermates.	Cyclosporine	122-125	kidney androgen regulated protein	Mus musculus	33-36
21980535-6	2011	Furthermore, we found that calpain, which was activated by CsA in cell cultures and kidney, is involved in KAP degradation and observed that phosphorylation of serine and threonine residues found in KAP PEST sequences by protein kinase CK2 enhances KAP degradation by calpain.	Cyclosporine	59-62	kidney androgen regulated protein	Mus musculus	107-110
21980535-6	2011	Furthermore, we found that calpain, which was activated by CsA in cell cultures and kidney, is involved in KAP degradation and observed that phosphorylation of serine and threonine residues found in KAP PEST sequences by protein kinase CK2 enhances KAP degradation by calpain.	Cyclosporine	59-62	kidney androgen regulated protein	Mus musculus	199-202
21980535-6	2011	Furthermore, we found that calpain, which was activated by CsA in cell cultures and kidney, is involved in KAP degradation and observed that phosphorylation of serine and threonine residues found in KAP PEST sequences by protein kinase CK2 enhances KAP degradation by calpain.	Cyclosporine	59-62	kidney androgen regulated protein	Mus musculus	199-202
21603612-4	2011	Treatment with a combination of phorbol 12-myristate 13-acetate (PMA) plus the calcium ionophore A23187 (Io) increased NFAT activation and TRAIL expression; pretreatment with the calcineurin inhibitor cyclosporine A (CsA), an antagonist of NFAT signaling, diminished NFAT activation and TRAIL induction.	Cyclosporine	201-215	TNF superfamily member 10	Homo sapiens	139-144
20869436-2	2010	It has been shown earlier that the combined application of a class of Pgp modulators (e.g. cyclosporine A and SDZ PSC 833) used at low concentrations and UIC2 antibody is a novel, specific, and effective way of blocking Pgp function (Goda et al., 2007).	Cyclosporine	91-105	ATP binding cassette subfamily B member 1	Homo sapiens	70-73
20869436-2	2010	It has been shown earlier that the combined application of a class of Pgp modulators (e.g. cyclosporine A and SDZ PSC 833) used at low concentrations and UIC2 antibody is a novel, specific, and effective way of blocking Pgp function (Goda et al., 2007).	Cyclosporine	91-105	ATP binding cassette subfamily B member 1	Homo sapiens	220-223
20869436-4	2010	Co-incubation of cells with UIC2 and cyclosporine A (CSA, 2muM) increased the binding of UIC2 more than 3-fold and reverted the rhodamine 123 (R123), daunorubicin (DNR) and (99m)Tc-MIBI accumulation of the Pgp(+) 2780AD cells to approx.	Cyclosporine	37-51	ATP binding cassette subfamily B member 1	Homo sapiens	206-209
20869436-4	2010	Co-incubation of cells with UIC2 and cyclosporine A (CSA, 2muM) increased the binding of UIC2 more than 3-fold and reverted the rhodamine 123 (R123), daunorubicin (DNR) and (99m)Tc-MIBI accumulation of the Pgp(+) 2780AD cells to approx.	Cyclosporine	53-56	ATP binding cassette subfamily B member 1	Homo sapiens	206-209
21152118-5	2010	This study aimed to investigate the effects of selective opener (Atractyloside glycoside, ATR) and inhibitor (Cyclosporine A, CsA) of mitochondrial permeability transition pore (mPTP) on a CDDP-resistant HCC cell line (SK-Hep1 cells).	Cyclosporine	110-124	protein tyrosine phosphatase, receptor type, U	Mus musculus	178-182
21152118-5	2010	This study aimed to investigate the effects of selective opener (Atractyloside glycoside, ATR) and inhibitor (Cyclosporine A, CsA) of mitochondrial permeability transition pore (mPTP) on a CDDP-resistant HCC cell line (SK-Hep1 cells).	Cyclosporine	126-129	protein tyrosine phosphatase, receptor type, U	Mus musculus	178-182
21212461-3	2010	Here we report that the NAD+-dependent deacetylase SIRT3 deacetylates the regulatory component of the mPTP, cyclophilin D (CypD) on lysine 166, adjacent to the binding site of cyclosporine A, a CypD inhibitor.	Cyclosporine	176-190	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	108-121
21212461-3	2010	Here we report that the NAD+-dependent deacetylase SIRT3 deacetylates the regulatory component of the mPTP, cyclophilin D (CypD) on lysine 166, adjacent to the binding site of cyclosporine A, a CypD inhibitor.	Cyclosporine	176-190	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	123-127
21212461-3	2010	Here we report that the NAD+-dependent deacetylase SIRT3 deacetylates the regulatory component of the mPTP, cyclophilin D (CypD) on lysine 166, adjacent to the binding site of cyclosporine A, a CypD inhibitor.	Cyclosporine	176-190	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	194-198
20864690-6	2010	In an additional 33 patients, glomerular and tubular NEP protein levels from renal graft biopsies were significantly higher among the 13 patients receiving cyclosporine + EC-MPS than among the 12 patients receiving cyclosporine + azathioprine or 8 patients receiving cyclosporine alone.	Cyclosporine	156-168	membrane metalloendopeptidase	Homo sapiens	53-56
20384684-0	2010	Treatment of eosinophilic pustular folliculitis with ciclosporin: suppression of mRNA expression of IL-4 and IL-13.	Cyclosporine	53-64	interleukin 4	Homo sapiens	100-104
20384684-0	2010	Treatment of eosinophilic pustular folliculitis with ciclosporin: suppression of mRNA expression of IL-4 and IL-13.	Cyclosporine	53-64	interleukin 13	Homo sapiens	109-114
20951600-8	2010	Rp-8-Br-cGMPS, nicotinamide, RRed, BAPTA, CsA or FK506 paralled the cbl9 and atrbohD/F mutants to abolish the 8-Br-cGMP response.	Cyclosporine	42-45	calcineurin B-like protein 9	Arabidopsis thaliana	68-72
21168695-0	2010	Cyclosporine inhibits profibrotic effects of interleukin-4 and transforming growth factor beta on human intrahepatic fibroblasts cultured in vitro.	Cyclosporine	0-12	interleukin 4	Homo sapiens	45-58
21168695-0	2010	Cyclosporine inhibits profibrotic effects of interleukin-4 and transforming growth factor beta on human intrahepatic fibroblasts cultured in vitro.	Cyclosporine	0-12	transforming growth factor beta 1	Homo sapiens	63-94
21168695-12	2010	CONCLUSION: CsA inhibited the profibrotic effects of TGF-beta and IL-4 by decreasing the activation and production of collagen by HIF.	Cyclosporine	12-15	transforming growth factor beta 1	Homo sapiens	53-61
21168695-12	2010	CONCLUSION: CsA inhibited the profibrotic effects of TGF-beta and IL-4 by decreasing the activation and production of collagen by HIF.	Cyclosporine	12-15	interleukin 4	Homo sapiens	66-70
20852052-6	2010	In rabbit atrial myocytes, an overnight stimulation with endothelin-1, angiotensin II, and phenylephrine induced nuclear accumulation of NFATc1 that was sensitive to calcineurin inhibitors (cyclosporin A or inhibitor of NFAT-calcineurin association-6) and prevented by the IP(3) receptor inhibitor 2-aminoethoxydiphenyl borate.	Cyclosporine	190-203	nuclear factor of activated T-cells, cytoplasmic 1	Oryctolagus cuniculus	137-143
20826153-6	2010	This effect of TGF-beta(1) and IL-4/IL-13 was inhibited by glucocorticoids, but neither by cyclosporine nor by tacrolimus.	Cyclosporine	91-103	transforming growth factor beta 1	Homo sapiens	15-26
20960209-8	2010	STAT3 co-immunoprecipitated with cyclophilin D, the target of the cardioprotective agent and MPTP inhibitor cyclosporine A (CsA).	Cyclosporine	108-122	signal transducer and activator of transcription 3	Mus musculus	0-5
20960209-8	2010	STAT3 co-immunoprecipitated with cyclophilin D, the target of the cardioprotective agent and MPTP inhibitor cyclosporine A (CsA).	Cyclosporine	108-122	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	33-46
20960209-8	2010	STAT3 co-immunoprecipitated with cyclophilin D, the target of the cardioprotective agent and MPTP inhibitor cyclosporine A (CsA).	Cyclosporine	124-127	signal transducer and activator of transcription 3	Mus musculus	0-5
20960209-8	2010	STAT3 co-immunoprecipitated with cyclophilin D, the target of the cardioprotective agent and MPTP inhibitor cyclosporine A (CsA).	Cyclosporine	124-127	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	33-46
20960209-9	2010	However, CsA reduced infarct size to a similar extent in wildtype and STAT3-KO mice in vivo.	Cyclosporine	9-12	signal transducer and activator of transcription 3	Mus musculus	70-78
20826153-6	2010	This effect of TGF-beta(1) and IL-4/IL-13 was inhibited by glucocorticoids, but neither by cyclosporine nor by tacrolimus.	Cyclosporine	91-103	interleukin 4	Homo sapiens	31-35
20826153-6	2010	This effect of TGF-beta(1) and IL-4/IL-13 was inhibited by glucocorticoids, but neither by cyclosporine nor by tacrolimus.	Cyclosporine	91-103	interleukin 13	Homo sapiens	36-41
20599501-4	2010	Since Cyclosporin is metabolized by cytochrome P450 CYP3A4, we examined whether interaction between Orlistat and Cyclosporin involves induction of CYP3A4.	Cyclosporine	6-17	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	52-58
21273673-8	2010	None of the Tac pharmacokinetic parameters were associated with ABCB1 SNPs, but ABCB1 SNPs had early effects on the CsA exposure index and dose requirements.	Cyclosporine	116-119	ATP binding cassette subfamily B member 1	Homo sapiens	80-85
20540932-10	2010	Molecules known to interact with OATPs, including cyclosporin A, rifampicin, and glibenclamide, each demonstrated concentration-dependent inhibition of 8-FcA transport by OATP1B1 and OATP1B3.	Cyclosporine	50-63	solute carrier organic anion transporter family member 1B3	Homo sapiens	183-190
20400621-8	2010	HPC induced significant Akt phosphorylation in WT cardiomyocytes (two-fold increase; P &lt; 0.05), an effect which was abrogated by ciclosporin-A (a CYPD inhibitor) and N-2-mercaptopropionyl glycine (a ROS scavenger).	Cyclosporine	132-145	thymoma viral proto-oncogene 1	Mus musculus	24-27
20577812-8	2010	Cyclosporin A, which binds to cyclophilin D, had a similar necrotic effect.	Cyclosporine	0-13	peptidylprolyl isomerase F	Homo sapiens	30-43
20400621-8	2010	HPC induced significant Akt phosphorylation in WT cardiomyocytes (two-fold increase; P &lt; 0.05), an effect which was abrogated by ciclosporin-A (a CYPD inhibitor) and N-2-mercaptopropionyl glycine (a ROS scavenger).	Cyclosporine	132-145	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	149-153
21129263-8	2010	CsA lowers the abnormal activation of IFN-gamma/T-bet and IL-12/STAT4 pathways to correct Th1 hyperpolarization, which may reduce the abnormally activated cell-mediated immunity and relax hematopoietic depression of AA patients.	Cyclosporine	0-3	interferon gamma	Homo sapiens	38-47
21129276-1	2010	This study was purposed to detect the expression level of human endothelial cell tissue factor (hECTF) and concentration of IL-2, and to investigate the alterations of hECTF and IL-2 after using immunosuppressive agent (cyclosporin, CsA) and explore the significance of endothelial cell (EC) lesion and abnormal expression of tissue factor (TF) in GVHD.	Cyclosporine	220-231	interleukin 2	Homo sapiens	178-182
21129263-5	2010	After treating with CsA for 6 months of CsA treatment, expression of T-bet, STAT4, T-bet/GATA-3 ratio, Th1 proportion, IFN-gamma and IL-12 levels were lower than before, however, the expression of T-bet, STAT4, T-bet/GATA-3 ratio, Th1 proportion and IFN-gamma had not been reduced to normal state.	Cyclosporine	20-23	interferon gamma	Homo sapiens	119-128
21129263-5	2010	After treating with CsA for 6 months of CsA treatment, expression of T-bet, STAT4, T-bet/GATA-3 ratio, Th1 proportion, IFN-gamma and IL-12 levels were lower than before, however, the expression of T-bet, STAT4, T-bet/GATA-3 ratio, Th1 proportion and IFN-gamma had not been reduced to normal state.	Cyclosporine	20-23	interferon gamma	Homo sapiens	250-259
20862794-5	2004	Calcium channel blockers (such as verapamil), cyclosporine (CsA, P-gp inhibitor) and CsA"s non-immunosuppressive analog PSC 833 (other mechanism) are MDR modulators that inhibit the transport of P-gp substrates out of the cells (6, 7).	Cyclosporine	46-58	ATP binding cassette subfamily B member 1	Homo sapiens	65-69
20735140-8	2010	While 2-4 showed either no or very weak inhibition of cellular P-glycoprotein (P-gp) activity, they either activated or inhibited the actions of the first generation P-gp inhibitors verapamil or cyclosporin, respectively.	Cyclosporine	195-206	ATP binding cassette subfamily B member 1	Homo sapiens	166-170
20854672-9	2010	Interestingly, in addition to these cells, we found CsA-resistant IFN-gamma producing T cells (CD4+T = 26.9 +- 3.6% and CD8+T = 20.3 +- 2.1%) implying the existence of activated bystander T cells in response to dengue antigen in vitro.	Cyclosporine	52-55	interferon gamma	Homo sapiens	66-75
20862795-5	2004	Calcium channel blockers (such as verapamil), cyclosporine (CsA, P-gp inhibitor) and CsA"s non-immunosuppressive analog PSC 833 (other mechanism) are MDR modulators that inhibit the transport of P-gp substrates out of the cells (6, 7).	Cyclosporine	46-58	ATP binding cassette subfamily B member 1	Homo sapiens	65-69
20862795-5	2004	Calcium channel blockers (such as verapamil), cyclosporine (CsA, P-gp inhibitor) and CsA"s non-immunosuppressive analog PSC 833 (other mechanism) are MDR modulators that inhibit the transport of P-gp substrates out of the cells (6, 7).	Cyclosporine	46-58	ATP binding cassette subfamily B member 1	Homo sapiens	195-199
20862795-5	2004	Calcium channel blockers (such as verapamil), cyclosporine (CsA, P-gp inhibitor) and CsA"s non-immunosuppressive analog PSC 833 (other mechanism) are MDR modulators that inhibit the transport of P-gp substrates out of the cells (6, 7).	Cyclosporine	60-63	ATP binding cassette subfamily B member 1	Homo sapiens	195-199
20862794-5	2004	Calcium channel blockers (such as verapamil), cyclosporine (CsA, P-gp inhibitor) and CsA"s non-immunosuppressive analog PSC 833 (other mechanism) are MDR modulators that inhibit the transport of P-gp substrates out of the cells (6, 7).	Cyclosporine	46-58	ATP binding cassette subfamily B member 1	Homo sapiens	195-199
20862794-5	2004	Calcium channel blockers (such as verapamil), cyclosporine (CsA, P-gp inhibitor) and CsA"s non-immunosuppressive analog PSC 833 (other mechanism) are MDR modulators that inhibit the transport of P-gp substrates out of the cells (6, 7).	Cyclosporine	60-63	ATP binding cassette subfamily B member 1	Homo sapiens	195-199
20681522-6	2010	We have shown that treatment of transfected HEK 293 cells expressing the Na(+)-Ca(2+) exchanger NCX1 with CsA results in downregulation of surface expression and transport activity, without any reduction in the total level of cell NCX1 protein [Kimchi-Sarfaty, C., et al.	Cyclosporine	106-109	solute carrier family 8 member A1	Homo sapiens	96-100
20681522-6	2010	We have shown that treatment of transfected HEK 293 cells expressing the Na(+)-Ca(2+) exchanger NCX1 with CsA results in downregulation of surface expression and transport activity, without any reduction in the total level of cell NCX1 protein [Kimchi-Sarfaty, C., et al.	Cyclosporine	106-109	solute carrier family 8 member A1	Homo sapiens	231-235
20681522-13	2010	Overexpression of CypA or its R55A mutant, which exhibits a substantially reduced PPIase activity, alleviated the reduction of NCX1 surface expression caused by CsA treatment, suggesting that the PPIase domain was probably not mandatory for NCX1 functional expression.	Cyclosporine	161-164	solute carrier family 8 member A1	Homo sapiens	127-131
20945139-8	2010	Importantly, the synergistic effect of CsA or SFA with cisplatin was shown even in p53 defective Hep3B cells.	Cyclosporine	39-42	tumor protein p53	Homo sapiens	83-86
20440520-13	2010	Low-dose cyclo and mtx treatment of subjects with new onset T1D can safely induce remission of disease and decrease the amount of required insulin.	Cyclosporine	9-14	insulin	Homo sapiens	139-146
20945139-10	2010	In conclusion, CsA or SFA synergistically enhances cisplatin-induced apoptosis in HCC cells including the p53-defective Hep3B.	Cyclosporine	15-18	tumor protein p53	Homo sapiens	106-109
20588203-0	2010	Effects of the CYP3A5*3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: a meta-analysis.	Cyclosporine	35-47	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	15-21
20526589-8	2010	CsA administration resulted in significant alveolar bone resorption, as assessed by a lower bone volume and an increased number of osteoclasts, and increased serum bone-specific alkaline phosphatase, TRAP-5b, IL-1 beta, IL-6, and TNF-alpha concentrations.	Cyclosporine	0-3	interleukin 1 beta	Rattus norvegicus	209-218
20526589-8	2010	CsA administration resulted in significant alveolar bone resorption, as assessed by a lower bone volume and an increased number of osteoclasts, and increased serum bone-specific alkaline phosphatase, TRAP-5b, IL-1 beta, IL-6, and TNF-alpha concentrations.	Cyclosporine	0-3	interleukin 6	Rattus norvegicus	220-224
20526589-8	2010	CsA administration resulted in significant alveolar bone resorption, as assessed by a lower bone volume and an increased number of osteoclasts, and increased serum bone-specific alkaline phosphatase, TRAP-5b, IL-1 beta, IL-6, and TNF-alpha concentrations.	Cyclosporine	0-3	tumor necrosis factor	Rattus norvegicus	230-239
20588203-1	2010	BACKGROUND: Whether the loss-of-function allele CYP3A5*3 variant is associated with significantly impaired metabolism of cyclosporine A (CsA) in transplant patients is still controversial because of the lack of prospective, large-scale clinical studies performed among diversely ethnic populations.	Cyclosporine	121-135	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	48-54
20554520-4	2010	Here, we investigated whether the CNI cyclosporine (CsA) and the mTOR inhibitor rapamycin (RAPA) could alter the mRNA stability of VEGF in 786-0 and Caki-1 renal cancer cells.	Cyclosporine	38-50	vascular endothelial growth factor A	Homo sapiens	131-135
20718971-3	2010	Current therapies including cyclosporine A (CyA) and related compounds target IL-2 signaling.	Cyclosporine	28-42	interleukin 2	Homo sapiens	78-82
20554520-4	2010	Here, we investigated whether the CNI cyclosporine (CsA) and the mTOR inhibitor rapamycin (RAPA) could alter the mRNA stability of VEGF in 786-0 and Caki-1 renal cancer cells.	Cyclosporine	52-55	vascular endothelial growth factor A	Homo sapiens	131-135
20554520-9	2010	Finally, we found that the inhibition of PKC-delta using a dominant negative plasmid significantly decreased the CsA-induced cytoplasmic translocation of HuR and VEGF mRNA stability.	Cyclosporine	113-116	vascular endothelial growth factor A	Homo sapiens	162-166
20554534-4	2010	Molecular analysis showed that SrRan increased NFATc1 transactivation in osteoblasts, an effect that was fully abrogated by the calcineurin inhibitors cyclosporin A or FK506, confirming that SrRan activates NFATc1 signaling in osteoblasts.	Cyclosporine	151-164	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	207-213
20658967-8	2010	Inhibition may involve direct pharmacological targeting of the MPTP, such as with cyclosporin A that binds to CyP-D, or indirect inhibition of MPTP opening such as with preconditioning protocols.	Cyclosporine	82-95	peptidylprolyl isomerase F	Homo sapiens	110-115
20561905-10	2010	CsA treatment noticeably reduced both the serum levels and the pancreatic mRNA expression of TNF-alpha and IL-1beta and decreased brain water and MDA contents.	Cyclosporine	0-3	tumor necrosis factor	Rattus norvegicus	93-102
20663037-8	2010	Both PSP and ciclosporin blocked the reduction of the CD4/CD8 ratio in stimulated lymphocytes.	Cyclosporine	13-24	CD4 molecule	Homo sapiens	54-57
20566410-7	2010	Moreover, CsA can inhibit HIF-1alpha and MICB expression but upregulates MICA expression during H/R.	Cyclosporine	10-13	hypoxia inducible factor 1 subunit alpha	Homo sapiens	26-36
20566410-8	2010	SIGNIFICANCE: These findings suggest that proper control of HIF-1alpha expression via CsA dose may be a potential therapeutic approach for avoiding MIC expression, and improving the function and long-term survival of heart allografts.	Cyclosporine	86-89	hypoxia inducible factor 1 subunit alpha	Homo sapiens	60-70
20561905-10	2010	CsA treatment noticeably reduced both the serum levels and the pancreatic mRNA expression of TNF-alpha and IL-1beta and decreased brain water and MDA contents.	Cyclosporine	0-3	interleukin 1 beta	Rattus norvegicus	107-115
20489142-9	2010	Nifedipine- and cyclosporine A-induced gingival overgrowth tissues similarly contain diminished E-cadherin and elevated levels of FSP-1 and fibronectin, but normal levels of alphavbeta6 integrin.	Cyclosporine	16-30	cadherin 1	Homo sapiens	96-106
20489142-9	2010	Nifedipine- and cyclosporine A-induced gingival overgrowth tissues similarly contain diminished E-cadherin and elevated levels of FSP-1 and fibronectin, but normal levels of alphavbeta6 integrin.	Cyclosporine	16-30	fibronectin 1	Homo sapiens	140-151
20430366-2	2010	The present study was conducted to assess the association between IL-6 (-174 G/C) gene polymorphism and GO in renal transplant recipients under cyclosporine (CsA), tacrolimus (Tcr), or sirolimus (Sir)-based regimens.	Cyclosporine	144-156	interleukin 6	Homo sapiens	66-70
20430366-2	2010	The present study was conducted to assess the association between IL-6 (-174 G/C) gene polymorphism and GO in renal transplant recipients under cyclosporine (CsA), tacrolimus (Tcr), or sirolimus (Sir)-based regimens.	Cyclosporine	158-161	interleukin 6	Homo sapiens	66-70
20583270-7	2010	We found that added CsA inhibits both the expression of NFATc1 and IL-2 in T cells of stimulated whole blood samples with IC(50) values of 200 and 150 nM, respectively.	Cyclosporine	20-23	interleukin 2	Homo sapiens	67-71
20578209-6	2010	Adding high-dose cyclosporine to a low-therapeutic dose of sotrastaurin significantly enhanced the inhibition of cytokine production by 31% [95% confidence interval, 25-36%], of interleukin-2 messenger RNA levels by 13% [7-19%], and of thymidine uptake by 37% [32-42%] compared with sotrastaurin alone.	Cyclosporine	17-29	interleukin 2	Homo sapiens	178-191
20583270-9	2010	Further experiments have to demonstrate whether the parallel cytometric measurement of NFATc1 and IL-2 in whole blood is a good predictor of individual CsA efficacy and toxicity in CsA-treated patients.	Cyclosporine	181-184	interleukin 2	Homo sapiens	98-102
20943048-0	2010	Can Cyclosporine-A associated to methotrexate maintain remission induced by anti-TNF agents in rheumatoid arthritis patients?	Cyclosporine	4-18	tumor necrosis factor	Homo sapiens	81-84
20505666-1	2010	Cyclosporin A (CsA) is a substrate for cytochrome P450 3A and the efflux transporter P-glycoprotein (P-gp; ABCB1), both abundantly expressed in the kidney.	Cyclosporine	0-13	ATP binding cassette subfamily B member 1	Homo sapiens	107-112
20505666-1	2010	Cyclosporin A (CsA) is a substrate for cytochrome P450 3A and the efflux transporter P-glycoprotein (P-gp; ABCB1), both abundantly expressed in the kidney.	Cyclosporine	15-18	ATP binding cassette subfamily B member 1	Homo sapiens	107-112
20505666-6	2010	The study showed that the presence of ABCB1 polymorphisms in donors influences long-term graft outcome adversely with decrease in renal function and graft loss in transplant recipients receiving CsA.	Cyclosporine	195-198	ATP binding cassette subfamily B member 1	Homo sapiens	38-43
20943048-15	2010	Our data seem to suggest that more than half of the patients undergoing A-Cyclosporin and Methotrexate therapy seemed to maintain low disease activity parameters of rheumatoid arthritis, obtained after 6-8 months of anti-TNF therapy.	Cyclosporine	74-85	tumor necrosis factor	Homo sapiens	221-224
20943048-6	2010	In this study we investigated whether A-Cyclosporin and Methotrexate association may be effective in maintaining low disease activity obtained by anti-TNF therapies.	Cyclosporine	40-51	tumor necrosis factor	Homo sapiens	151-154
20413672-4	2010	First, CN inhibitors, cyclosporine A (CysA) and tacrolimus (FK506) inhibited the Ang II-induced elevation of CYP11B2 mRNA level.	Cyclosporine	22-36	angiotensinogen	Homo sapiens	81-87
20413672-4	2010	First, CN inhibitors, cyclosporine A (CysA) and tacrolimus (FK506) inhibited the Ang II-induced elevation of CYP11B2 mRNA level.	Cyclosporine	38-42	angiotensinogen	Homo sapiens	81-87
20540642-0	2010	Interaction of endothelin-1 and nitric oxide pathways in human tubular epithelial cells under the influence of cyclosporine-A.	Cyclosporine	111-125	endothelin 1	Homo sapiens	15-27
20361354-0	2010	Chronic administration of cyclosporine A changes expression of BDNF and TrkB in rat hippocampus and midbrain.	Cyclosporine	26-40	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	72-76
20540642-5	2010	RESULTS: A dose-dependent induction of synthesis of NO synthases eNOS and iNOS and ET receptors ETR-A and ETR-B was observed, even at therapeutic doses of CsA.	Cyclosporine	155-158	nitric oxide synthase 2	Homo sapiens	74-78
20540642-5	2010	RESULTS: A dose-dependent induction of synthesis of NO synthases eNOS and iNOS and ET receptors ETR-A and ETR-B was observed, even at therapeutic doses of CsA.	Cyclosporine	155-158	endothelin receptor type B	Homo sapiens	106-111
20871770-9	2010	CONCLUSION: The findings of the present study suggest that CsA can modify the expression of TNF-alpha and RANTES in drug-induced human gingival overgrowth.	Cyclosporine	59-62	tumor necrosis factor	Homo sapiens	92-101
20195644-1	2010	It has been reported (this issue Pediatric Nephrology) that cyclosporine A (CyA) therapy in combination with corticosteroids, angiotensin-converting enzyme inhibitor, and an angiotensin receptor blocker decreased proteinuria in three patients with nephrotic syndrome (NS) due to WT1 mutations.	Cyclosporine	60-74	WT1 transcription factor	Homo sapiens	279-282
20195644-1	2010	It has been reported (this issue Pediatric Nephrology) that cyclosporine A (CyA) therapy in combination with corticosteroids, angiotensin-converting enzyme inhibitor, and an angiotensin receptor blocker decreased proteinuria in three patients with nephrotic syndrome (NS) due to WT1 mutations.	Cyclosporine	76-79	WT1 transcription factor	Homo sapiens	279-282
20541997-6	2010	Together, our results indicate an essential role for protein ubiquitylation and CSB"s UBD in triggering damage incision during TC-NER and allow us to integrate the function of CSA and CSB in a model for the process.	Cyclosporine	176-179	ERCC excision repair 6, chromatin remodeling factor	Homo sapiens	80-83
20121715-8	2010	Inhibitors of P-gp, including cyclosporine A (CsA) and verapamil (Vpa), increased the intracellular level of IB-MECA and reversed the resistance of K562/HHT cells to this drug.	Cyclosporine	30-44	ATP binding cassette subfamily B member 1	Homo sapiens	14-18
20121715-8	2010	Inhibitors of P-gp, including cyclosporine A (CsA) and verapamil (Vpa), increased the intracellular level of IB-MECA and reversed the resistance of K562/HHT cells to this drug.	Cyclosporine	46-49	ATP binding cassette subfamily B member 1	Homo sapiens	14-18
20026006-1	2010	Cyclophilins are a family of peptidyl-prolyl cis-trans isomerases whose enzymatic activity can be inhibited by cyclosporin A.	Cyclosporine	111-124	peptidylprolyl isomerase F	Homo sapiens	0-12
20431509-4	2010	There are also genetic predictors of pharmacodynamics, including IMPDH1 for mycophenolate and ABCB1 for cyclosporine that may identify individuals at particular risk of efficacy failure or toxicity with a given drug.	Cyclosporine	104-116	ATP binding cassette subfamily B member 1	Homo sapiens	94-99
20051247-11	2010	Furthermore, CsA treatment prevented early Ca(2+) overload related to decreased NCX function.	Cyclosporine	13-16	solute carrier family 8 member A1	Rattus norvegicus	80-83
19909402-12	2010	The MEK inhibitor U0126 was found to inhibit cyclosporine A-induced Hsp47 expression (p &lt; 0.05).	Cyclosporine	45-59	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
19909402-13	2010	CONCLUSION: Expression of Hsp47 is significantly upregulated in cyclosporine A-induced gingival overgrowth specimens, and Hsp47 expression induced by cyclosporine A in fibroblasts may be mediated by the MEK signal transduction pathway.	Cyclosporine	64-78	mitogen-activated protein kinase kinase 7	Homo sapiens	203-206
19909402-13	2010	CONCLUSION: Expression of Hsp47 is significantly upregulated in cyclosporine A-induced gingival overgrowth specimens, and Hsp47 expression induced by cyclosporine A in fibroblasts may be mediated by the MEK signal transduction pathway.	Cyclosporine	150-164	mitogen-activated protein kinase kinase 7	Homo sapiens	203-206
20237458-6	2010	Paricalcitol effectively prevented TGF-beta1-induced epithelial-to-mesenchymal transitions and extracellular matrix accumulation as evidenced by attenuated collagen deposition and fibrosis in CsA-treated rats.	Cyclosporine	192-195	transforming growth factor, beta 1	Rattus norvegicus	35-44
20479245-4	2010	Preventing mitochondrial permeability transition pore opening with the cyclophilin D inhibitor cyclosporin A restored Deltapsi(m) and rescued cell viability.	Cyclosporine	95-108	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	71-84
20734536-7	2010	Cells treated with CsA activated NF-kappaB but cells in the CsA-induced damage of human kidney tubular epithelial cell.	Cyclosporine	19-22	nuclear factor kappa B subunit 1	Homo sapiens	33-42
19763573-0	2010	PSC833, cyclosporine analogue, downregulates MDR1 expression by activating JNK/c-Jun/AP-1 and suppressing NF-kappaB.	Cyclosporine	8-20	ATP binding cassette subfamily B member 1	Homo sapiens	45-49
20416375-2	2010	The aims of this study were to determine whether PXR activators could have an additional benefit of inhibiting inflammation in the liver, and determine whether cyclosporin A - which more effectively prevents PBC recurrence in transplanted patients than FK506 - is a PXR activator.	Cyclosporine	160-173	nuclear receptor subfamily 1 group I member 2	Homo sapiens	266-269
20416375-8	2010	Using a PXR reporter gene assay, cyclosporin A - but not FK506 - was shown to be a direct PXR activator, and also to induce expression of the classic PXR-regulated CYP3A4 gene in human hepatocytes and in a cell line null for the FXR, a nuclear receptor with similar properties to the PXR.	Cyclosporine	33-46	nuclear receptor subfamily 1 group I member 2	Homo sapiens	8-11
20416375-8	2010	Using a PXR reporter gene assay, cyclosporin A - but not FK506 - was shown to be a direct PXR activator, and also to induce expression of the classic PXR-regulated CYP3A4 gene in human hepatocytes and in a cell line null for the FXR, a nuclear receptor with similar properties to the PXR.	Cyclosporine	33-46	nuclear receptor subfamily 1 group I member 2	Homo sapiens	90-93
20416375-8	2010	Using a PXR reporter gene assay, cyclosporin A - but not FK506 - was shown to be a direct PXR activator, and also to induce expression of the classic PXR-regulated CYP3A4 gene in human hepatocytes and in a cell line null for the FXR, a nuclear receptor with similar properties to the PXR.	Cyclosporine	33-46	nuclear receptor subfamily 1 group I member 2	Homo sapiens	90-93
20416375-8	2010	Using a PXR reporter gene assay, cyclosporin A - but not FK506 - was shown to be a direct PXR activator, and also to induce expression of the classic PXR-regulated CYP3A4 gene in human hepatocytes and in a cell line null for the FXR, a nuclear receptor with similar properties to the PXR.	Cyclosporine	33-46	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	164-170
20416375-8	2010	Using a PXR reporter gene assay, cyclosporin A - but not FK506 - was shown to be a direct PXR activator, and also to induce expression of the classic PXR-regulated CYP3A4 gene in human hepatocytes and in a cell line null for the FXR, a nuclear receptor with similar properties to the PXR.	Cyclosporine	33-46	nuclear receptor subfamily 1 group I member 2	Homo sapiens	90-93
20508866-11	2010	In vitro, CsA significantly inhibited the production of IL-17 and IFN-gamma by PBMCs activated with anti-CD3 and anti-CD28 antibodies or phorbol 12-myristate,13-acetate and ionomycin in BD patients with active uveitis.	Cyclosporine	10-13	interferon gamma	Homo sapiens	66-75
20508866-13	2010	CONCLUSIONS: Our findings showed that CsA can significantly inhibit the intraocular inflammation of BD patients and the expression of IL-17 and IFN-gamma in vivo and in vitro.	Cyclosporine	38-41	interferon gamma	Homo sapiens	144-153
20508866-14	2010	The results suggested that the inhibitory effect of CsA on uveitis in BD patients may be partially mediated through inhibiting the production of IL-17 and IFN-gamma.	Cyclosporine	52-55	interferon gamma	Homo sapiens	155-164
19763573-0	2010	PSC833, cyclosporine analogue, downregulates MDR1 expression by activating JNK/c-Jun/AP-1 and suppressing NF-kappaB.	Cyclosporine	8-20	mitogen-activated protein kinase 8	Homo sapiens	75-78
19763573-2	2010	PSC833 is well known as a non-immunosuppressant cyclosporine analogue that functionally inhibits P-glycoprotein (Pgp), a product of the MDR1 gene.	Cyclosporine	48-60	ATP binding cassette subfamily B member 1	Homo sapiens	97-111
19763573-2	2010	PSC833 is well known as a non-immunosuppressant cyclosporine analogue that functionally inhibits P-glycoprotein (Pgp), a product of the MDR1 gene.	Cyclosporine	48-60	ATP binding cassette subfamily B member 1	Homo sapiens	113-116
19763573-2	2010	PSC833 is well known as a non-immunosuppressant cyclosporine analogue that functionally inhibits P-glycoprotein (Pgp), a product of the MDR1 gene.	Cyclosporine	48-60	ATP binding cassette subfamily B member 1	Homo sapiens	136-140
20043941-5	2010	CsA-treatment resulted in a significant reduction of absolute numbers of circulating CD4(+) and CD8alpha(+) T-lymphocytes by up to 82 and 65%, respectively (P&lt;0.05).	Cyclosporine	0-3	CD4 molecule	Homo sapiens	85-88
20336065-3	2010	Regional P-gp inhibition was expressed as cyclosporine A-induced percentage change in the distributional clearance of verapamil (K(1)) in the brain, normalized to the regional blood flow (rCBF).	Cyclosporine	42-56	ATP binding cassette subfamily B member 1	Homo sapiens	9-13
19965585-5	2010	We further demonstrate that calcineurin activity, the downstream target of Ca(2+) influx, was essential; inhibition of calcineurin activity by cyclosporine A or FK506 completely abolished apoA-I lipidation.	Cyclosporine	143-157	apolipoprotein A1	Homo sapiens	188-194
20534097-10	2010	CONCLUSION: Chronic idiopathic urticaria patients with elevated high sensitivity-CRP showed good response to oral cyclosporine therapy.	Cyclosporine	114-126	C-reactive protein	Homo sapiens	81-84
20447559-6	2010	RESULTS: Modulation of P-gp with CsA (50 mg/kg) as well as mdr1a gene depletion resulted in significant increase in cerebral uptake of [(123)I]-FMIP with only minor effect on blood activity.	Cyclosporine	33-36	THO complex 5	Mus musculus	144-148
20447559-9	2010	A dose-dependent sigmoidal increase in brain uptake of [(123)I]-FMIP with increasing doses of CsA was observed.	Cyclosporine	94-97	THO complex 5	Mus musculus	64-68
20447559-4	2010	The influence of increasing doses CsA on brain uptake of [(123)I]-FMIP was explored.	Cyclosporine	34-37	THO complex 5	Mus musculus	66-70
20091055-4	2010	After immunosuppressive therapy had been initiated with corticosteroids and cyclosporine, the EPO antibody levels decreased precipitously, associated with an increased level of endogenous EPO production.	Cyclosporine	76-88	erythropoietin	Homo sapiens	94-97
19938012-6	2010	Cytochrome c localization in treated and control cells was assessed +/- cyclosporine A (CsA).	Cyclosporine	72-86	cytochrome c, somatic	Homo sapiens	0-12
19938012-6	2010	Cytochrome c localization in treated and control cells was assessed +/- cyclosporine A (CsA).	Cyclosporine	88-91	cytochrome c, somatic	Homo sapiens	0-12
19938012-11	2010	Subsequently increased apoptosis and decreased proliferation mediated by cytochrome c was noted and this was reversed by CsA.	Cyclosporine	121-124	cytochrome c, somatic	Homo sapiens	73-85
20406686-6	2010	Reconstitution of the CD4(+) T-lymphocyte subset was significantly lower with sirolimus versus cyclosporine over year 1, but CD8(+) reconstitution did not differ significantly between groups.	Cyclosporine	95-107	CD4 molecule	Homo sapiens	22-25
20406686-7	2010	The proportion of naive CD4(+) T-lymphocytes showed an initial decrease with sirolimus versus cyclosporine.	Cyclosporine	94-106	CD4 molecule	Homo sapiens	24-27
20406686-9	2010	Memory CD4(+) T-lymphocytes occurred more frequently in sirolimus- versus cyclosporine-treated patients during year 1.	Cyclosporine	74-86	CD4 molecule	Homo sapiens	7-10
20096777-3	2010	In this study, the potential role of NRF2, which is the master regulator of genes associated with the cellular antioxidant defense system, in CsA-induced EMT renal fibrosis has been investigated.	Cyclosporine	142-145	nuclear factor, erythroid derived 2, like 2	Mus musculus	37-41
20096777-5	2010	Conversely, genetic inhibition of NRF2 in these cells aggravated changes in CsA-induced EMT markers.	Cyclosporine	76-79	nuclear factor, erythroid derived 2, like 2	Mus musculus	34-38
20096777-6	2010	These in vitro observations could be confirmed in vivo: CsA treatment resulted in severe renal damage and fibrosis with increased expression of alpha-SMA in NRF2-deficient mice compared to wild-type mice.	Cyclosporine	56-59	actin alpha 2, smooth muscle, aorta	Mus musculus	144-153
20096777-6	2010	These in vitro observations could be confirmed in vivo: CsA treatment resulted in severe renal damage and fibrosis with increased expression of alpha-SMA in NRF2-deficient mice compared to wild-type mice.	Cyclosporine	56-59	nuclear factor, erythroid derived 2, like 2	Mus musculus	157-161
20096777-7	2010	NRF2-mediated amelioration of CsA-caused EMT changes could be accounted for in part by the regulation of heme oxygenase-1 (HO-1).	Cyclosporine	30-33	nuclear factor, erythroid derived 2, like 2	Mus musculus	0-4
20096777-7	2010	NRF2-mediated amelioration of CsA-caused EMT changes could be accounted for in part by the regulation of heme oxygenase-1 (HO-1).	Cyclosporine	30-33	heme oxygenase 1	Mus musculus	105-121
20096777-7	2010	NRF2-mediated amelioration of CsA-caused EMT changes could be accounted for in part by the regulation of heme oxygenase-1 (HO-1).	Cyclosporine	30-33	heme oxygenase 1	Mus musculus	123-127
20096777-8	2010	CsA treatment increased HO-1 expression in an NRF2-dependent manner in NRK cells as well as in murine fibroblasts.	Cyclosporine	0-3	heme oxygenase 1	Mus musculus	24-28
20096777-8	2010	CsA treatment increased HO-1 expression in an NRF2-dependent manner in NRK cells as well as in murine fibroblasts.	Cyclosporine	0-3	nuclear factor, erythroid derived 2, like 2	Mus musculus	46-50
20096777-9	2010	Induction of HO-1 by CsA seems to be advantageous in that it counteracts EMT gene changes: specific increase in HO-1 expression caused by cobalt protoporphyrin prevented CsA-mediated alpha-SMA induction, whereas genetic inhibition of HO-1 by siRNA substantially enhanced alpha-SMA induction compared to control cells.	Cyclosporine	21-24	heme oxygenase 1	Mus musculus	13-17
20096777-9	2010	Induction of HO-1 by CsA seems to be advantageous in that it counteracts EMT gene changes: specific increase in HO-1 expression caused by cobalt protoporphyrin prevented CsA-mediated alpha-SMA induction, whereas genetic inhibition of HO-1 by siRNA substantially enhanced alpha-SMA induction compared to control cells.	Cyclosporine	21-24	heme oxygenase 1	Mus musculus	112-116
20096777-9	2010	Induction of HO-1 by CsA seems to be advantageous in that it counteracts EMT gene changes: specific increase in HO-1 expression caused by cobalt protoporphyrin prevented CsA-mediated alpha-SMA induction, whereas genetic inhibition of HO-1 by siRNA substantially enhanced alpha-SMA induction compared to control cells.	Cyclosporine	21-24	actin alpha 2, smooth muscle, aorta	Mus musculus	183-192
20096777-9	2010	Induction of HO-1 by CsA seems to be advantageous in that it counteracts EMT gene changes: specific increase in HO-1 expression caused by cobalt protoporphyrin prevented CsA-mediated alpha-SMA induction, whereas genetic inhibition of HO-1 by siRNA substantially enhanced alpha-SMA induction compared to control cells.	Cyclosporine	21-24	heme oxygenase 1	Mus musculus	112-116
20096777-9	2010	Induction of HO-1 by CsA seems to be advantageous in that it counteracts EMT gene changes: specific increase in HO-1 expression caused by cobalt protoporphyrin prevented CsA-mediated alpha-SMA induction, whereas genetic inhibition of HO-1 by siRNA substantially enhanced alpha-SMA induction compared to control cells.	Cyclosporine	21-24	actin alpha 2, smooth muscle, aorta	Mus musculus	271-280
20096777-9	2010	Induction of HO-1 by CsA seems to be advantageous in that it counteracts EMT gene changes: specific increase in HO-1 expression caused by cobalt protoporphyrin prevented CsA-mediated alpha-SMA induction, whereas genetic inhibition of HO-1 by siRNA substantially enhanced alpha-SMA induction compared to control cells.	Cyclosporine	170-173	heme oxygenase 1	Mus musculus	13-17
20096777-9	2010	Induction of HO-1 by CsA seems to be advantageous in that it counteracts EMT gene changes: specific increase in HO-1 expression caused by cobalt protoporphyrin prevented CsA-mediated alpha-SMA induction, whereas genetic inhibition of HO-1 by siRNA substantially enhanced alpha-SMA induction compared to control cells.	Cyclosporine	170-173	heme oxygenase 1	Mus musculus	112-116
20096777-9	2010	Induction of HO-1 by CsA seems to be advantageous in that it counteracts EMT gene changes: specific increase in HO-1 expression caused by cobalt protoporphyrin prevented CsA-mediated alpha-SMA induction, whereas genetic inhibition of HO-1 by siRNA substantially enhanced alpha-SMA induction compared to control cells.	Cyclosporine	170-173	actin alpha 2, smooth muscle, aorta	Mus musculus	183-192
20096777-9	2010	Induction of HO-1 by CsA seems to be advantageous in that it counteracts EMT gene changes: specific increase in HO-1 expression caused by cobalt protoporphyrin prevented CsA-mediated alpha-SMA induction, whereas genetic inhibition of HO-1 by siRNA substantially enhanced alpha-SMA induction compared to control cells.	Cyclosporine	170-173	heme oxygenase 1	Mus musculus	112-116
20096777-10	2010	Collectively, our results suggest that the NRF2-HO-1 system plays a protective role against CsA-induced renal fibrosis by modulating EMT gene changes.	Cyclosporine	92-95	nuclear factor, erythroid derived 2, like 2	Mus musculus	43-47
20096777-10	2010	Collectively, our results suggest that the NRF2-HO-1 system plays a protective role against CsA-induced renal fibrosis by modulating EMT gene changes.	Cyclosporine	92-95	heme oxygenase 1	Mus musculus	48-52
20658037-1	2010	Cyclosporin A (CyA) induces gingival overgrowth via its stimulatory effects on expression of transforming growth factor-beta1 (TGF-beta1) and collagen.	Cyclosporine	0-13	transforming growth factor, beta 1	Rattus norvegicus	93-125
20359571-3	2010	METHODS: Hyperpermeability was induced in microvascular endothelial cell monolayers using proapoptotic BAK or active caspase-3 after CsA or a specific calcineurin inhibitor, calcineurin autoinhibitory peptide (CIP), treatment.	Cyclosporine	133-136	caspase 3	Homo sapiens	117-126
20658037-1	2010	Cyclosporin A (CyA) induces gingival overgrowth via its stimulatory effects on expression of transforming growth factor-beta1 (TGF-beta1) and collagen.	Cyclosporine	0-13	transforming growth factor, beta 1	Rattus norvegicus	127-136
20214406-7	2010	For patients prescribed ciclosporin, the CYP3A5 6986A&gt;G SNP may influence long-term survival, possibly because of a different metabolite pattern over time.	Cyclosporine	24-35	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	41-47
20335656-0	2010	Preemptive CD20+ B cell depletion attenuates cardiac allograft vasculopathy in cyclosporine-treated monkeys.	Cyclosporine	79-91	keratin 20	Homo sapiens	11-15
20335656-4	2010	Furthermore, CD20+ B cell depletion therapy combined with the calcineurin inhibitor cyclosporine A (CsA) prolonged median primary graft survival relative to treatment with alphaCD20 or CsA alone.	Cyclosporine	185-188	keratin 20	Homo sapiens	13-17
20604838-1	2010	OBJECTIVES: There have been several previous studies showing that ciclosporin, a ligand for cyclophilin D (CypD), reduces mitochondrial permeability transition (mPT) and ameliorates delayed neuronal death.	Cyclosporine	66-77	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	92-105
20060322-6	2010	RESULTS: Compared with recipients treated with control Ab plus PBS, allografts treated with anti-CCR5 Ab and cyclosporine showed significantly prolonged survival (p &lt; 0.001), markedly decreased CD4+ and CD8+ T cells (p &lt; 0.005), and increased frequency of CD4+CD25+Foxp3+ regulatory cells (23.98% +/- 1.55% vs 6.30% +/- 0.57%, p &lt; 0.005).	Cyclosporine	109-121	chemokine (C-C motif) receptor 5	Mus musculus	97-101
20604838-1	2010	OBJECTIVES: There have been several previous studies showing that ciclosporin, a ligand for cyclophilin D (CypD), reduces mitochondrial permeability transition (mPT) and ameliorates delayed neuronal death.	Cyclosporine	66-77	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	107-111
20089655-7	2010	The inflammatory response and serum ALT/AST level were reduced when the chemotactic effect of CypA was inhibited by cyclosporine and anti-CD147 antibody.	Cyclosporine	116-128	solute carrier family 17 member 5	Homo sapiens	40-43
20089806-0	2010	Cyclosporine up-regulates Kruppel-like factor-4 (KLF4) in vascular smooth muscle cells and drives phenotypic modulation in vivo.	Cyclosporine	0-12	Kruppel like factor 4	Rattus norvegicus	26-47
20089806-0	2010	Cyclosporine up-regulates Kruppel-like factor-4 (KLF4) in vascular smooth muscle cells and drives phenotypic modulation in vivo.	Cyclosporine	0-12	Kruppel like factor 4	Rattus norvegicus	49-53
20089806-3	2010	Using real-time reverse transcription-polymerase chain reaction, Western blot analysis, and immunofluorescence microscopy, we show that CSA up-regulated the expression of Kruppel-like factor-4 (KLF4) in VSMCs.	Cyclosporine	136-139	Kruppel like factor 4	Rattus norvegicus	171-192
20089806-3	2010	Using real-time reverse transcription-polymerase chain reaction, Western blot analysis, and immunofluorescence microscopy, we show that CSA up-regulated the expression of Kruppel-like factor-4 (KLF4) in VSMCs.	Cyclosporine	136-139	Kruppel like factor 4	Rattus norvegicus	194-198
20089806-10	2010	CSA-treated arteries showed remarkable remodeling, including breakdown of the internal elastic lamina and reorientation of VSMCs, as well as increased KLF4 immunostaining in VSMCs and endothelial cells.	Cyclosporine	0-3	Kruppel like factor 4	Rattus norvegicus	151-155
20089806-11	2010	Altogether, these data show that cyclosporin up-regulates KLF4 expression and promotes phenotypic modulation of VSMCs.	Cyclosporine	33-44	Kruppel like factor 4	Rattus norvegicus	58-62
20023700-7	2010	Under knockdown conditions, the inhibitory effects of TPR ligands, cyclosporine A (CsA) and FK506, on AR activity were not observed, indicating that Cyp40 and FKBP51 are the targets of CsA and FK506, respectively.	Cyclosporine	83-86	androgen receptor	Homo sapiens	102-104
20023700-8	2010	Our findings show that FKBP51 and Cyp40 are positive regulators of AR that can be selectively targeted by CsA and FK506 to achieve inhibition of androgen-induced cell proliferation.	Cyclosporine	106-109	androgen receptor	Homo sapiens	67-69
20170205-8	2010	Influence of the CYP3A5 6986A&gt;G SNP on the pharmacokinetics of ciclosporin is also uncertain and likely to be small.	Cyclosporine	66-77	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	17-23
19955189-0	2010	Sirolimus and cyclosporine A alter barrier function in renal proximal tubular cells through stimulation of ERK1/2 signaling and claudin-1 expression.	Cyclosporine	14-28	mitogen-activated protein kinase 1	Canis lupus familiaris	107-113
19955189-8	2010	SRL and CsA treatment alone or in combination stimulated the phosphorylation of ERK1/2.	Cyclosporine	8-11	mitogen-activated protein kinase 1	Canis lupus familiaris	80-86
19955189-9	2010	The MEK-ERK1/2 pathway inhibitor, U0126, reduced the SRL, CsA, and CsA/SRL-induced increase in TER.	Cyclosporine	58-61	mitogen-activated protein kinase 1	Canis lupus familiaris	8-14
19955189-9	2010	The MEK-ERK1/2 pathway inhibitor, U0126, reduced the SRL, CsA, and CsA/SRL-induced increase in TER.	Cyclosporine	67-70	mitogen-activated protein kinase 1	Canis lupus familiaris	8-14
19955189-12	2010	However, the results suggest that the modulation in expression and localization of claudin-1 appears to be pivotal in the SRL- and CsA-induced modulation of the epithelial barrier function and that modulation is regulated by ERK1/2 signaling pathway.	Cyclosporine	131-134	mitogen-activated protein kinase 1	Canis lupus familiaris	225-231
20170205-9	2010	CYP3A4 may play a more dominant role than CYP3A5 in the metabolism of ciclosporin.	Cyclosporine	70-81	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
20170205-9	2010	CYP3A4 may play a more dominant role than CYP3A5 in the metabolism of ciclosporin.	Cyclosporine	70-81	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	42-48
20170205-13	2010	Influence of ABCB1 3435C&gt;T, 1236C&gt;T and 2677G&gt;T/A SNPs on the pharmacokinetics of ciclosporin and tacrolimus remains uncertain, with inconsistent results.	Cyclosporine	91-102	ATP binding cassette subfamily B member 1	Homo sapiens	13-18
19958325-0	2010	RGS4 controls renal blood flow and inhibits cyclosporine-mediated nephrotoxicity.	Cyclosporine	44-56	regulator of G-protein signaling 4	Mus musculus	0-4
20145903-6	2010	Beyond immunosuppression, cyclosporine A promotes carcinogenesis by TGF beta and VEGF, while mTOR inhibitors are antiproliferative.	Cyclosporine	26-40	transforming growth factor beta 1	Homo sapiens	68-76
20145903-6	2010	Beyond immunosuppression, cyclosporine A promotes carcinogenesis by TGF beta and VEGF, while mTOR inhibitors are antiproliferative.	Cyclosporine	26-40	vascular endothelial growth factor A	Homo sapiens	81-85
19903662-3	2010	The goal of this study was to compare the effects of cyclosporine A and rapamycin on the induction and suppressive functions of human CD4(+)CD25(+) Tregs in vitro.	Cyclosporine	53-67	CD4 molecule	Homo sapiens	134-137
19903662-4	2010	METHODS: CD4(+)CD25(+) Tregs were induced in two-way mixed lymphocyte reaction (MLR) in the presence of rapamycin (Treg-Rapa) or cyclosporine A (Treg-CsA).	Cyclosporine	129-143	CD4 molecule	Homo sapiens	9-12
19903662-8	2010	RESULTS: Although both rapamycin and cyclosporine A suppressed the induction of CD4(+)CD25(+) Tregs during MLRs, this effect was significantly more pronounced in cells cultured with cyclosporine.	Cyclosporine	37-51	CD4 molecule	Homo sapiens	80-83
19903662-8	2010	RESULTS: Although both rapamycin and cyclosporine A suppressed the induction of CD4(+)CD25(+) Tregs during MLRs, this effect was significantly more pronounced in cells cultured with cyclosporine.	Cyclosporine	37-49	CD4 molecule	Homo sapiens	80-83
20304212-1	2010	BACKGROUND: Mammalian target of rapamycin (mTOR) inhibitors behave as potent immunosuppressants, which have the advantages, with respect to calcineurin inhibitors (CNI; cyclosporine or tacrolimus), of no nephrotoxicity but inhibition of cell proliferation.	Cyclosporine	169-181	mechanistic target of rapamycin kinase	Homo sapiens	12-41
20304212-1	2010	BACKGROUND: Mammalian target of rapamycin (mTOR) inhibitors behave as potent immunosuppressants, which have the advantages, with respect to calcineurin inhibitors (CNI; cyclosporine or tacrolimus), of no nephrotoxicity but inhibition of cell proliferation.	Cyclosporine	169-181	mechanistic target of rapamycin kinase	Homo sapiens	43-47
19994912-5	2010	Cyclosporine affected the following groups of proteins: calcium homeostasis (regucalcin, calbindin), cytoskeleton (vimentin, caldesmon), response to hypoxia and mitochondrial function (prolyl 4-hydroxylase, proteasome, NADH dehydrogenase), and cell metabolism (kidney aminoacylase, pyruvate dehydrogenase, fructose-1,6-bis phosphate).	Cyclosporine	0-12	regucalcin	Rattus norvegicus	77-87
19994912-5	2010	Cyclosporine affected the following groups of proteins: calcium homeostasis (regucalcin, calbindin), cytoskeleton (vimentin, caldesmon), response to hypoxia and mitochondrial function (prolyl 4-hydroxylase, proteasome, NADH dehydrogenase), and cell metabolism (kidney aminoacylase, pyruvate dehydrogenase, fructose-1,6-bis phosphate).	Cyclosporine	0-12	calbindin 1	Rattus norvegicus	89-98
19958325-5	2010	Compared to congenic wild type control animals, rgs4(-/-) mice were intolerant of the CNI, cyclosporine (CyA), rapidly developing fatal renal failure.	Cyclosporine	91-103	regulator of G-protein signaling 4	Mus musculus	48-52
19958325-5	2010	Compared to congenic wild type control animals, rgs4(-/-) mice were intolerant of the CNI, cyclosporine (CyA), rapidly developing fatal renal failure.	Cyclosporine	105-108	regulator of G-protein signaling 4	Mus musculus	48-52
19958325-8	2010	The MAPK/ERK pathway was activated by cyclosporine administration and was inhibited by cotreatment with bosentan.	Cyclosporine	38-50	mitogen-activated protein kinase 1	Mus musculus	4-8
19958325-8	2010	The MAPK/ERK pathway was activated by cyclosporine administration and was inhibited by cotreatment with bosentan.	Cyclosporine	38-50	mitogen-activated protein kinase 1	Mus musculus	9-12
19823813-2	2010	It has been reported that, in humans, CyA is metabolized by cytochrome P450 (CYP) 3A or excreted by P-glycoprotein/multidrug resistant protein (MRP) 2.	Cyclosporine	38-41	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-84
20109345-15	2010	After the cells were exposed to 10 mug/mL DDP for 24 h, the cell apoptosis rate of SK-Hep1/DDP was decreased in comparison with SK-Hep1, but it was increased in those with pretreatment of MDR1 inhibitor CsA as compared with those without pretreatment.	Cyclosporine	203-206	ATP binding cassette subfamily B member 1	Homo sapiens	188-192
20023576-7	2010	The instillation of cyclosporine A, an inhibitor of cytokine production from T-cells, and betamethasone significantly inhibited the increase in corneal fluorescein score and EPO activity.	Cyclosporine	20-34	eosinophil peroxidase	Mus musculus	174-177
19879126-4	2010	An Immunoglobin A (IgA) immunosensor was constructed by the covalent bonding of IgA antibody molecules with the CSA aided by large numbers of carboxyl groups on the surface of carbon spheres.	Cyclosporine	112-115	CD79a molecule	Homo sapiens	3-17
19437409-4	2010	Hippocampal infusion of Cyclosporine A, which binds to Cyp D, replicated the defect in hippocampus-dependent cognition observed in Cyp D(-/-) mice.	Cyclosporine	24-38	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	55-60
19437409-4	2010	Hippocampal infusion of Cyclosporine A, which binds to Cyp D, replicated the defect in hippocampus-dependent cognition observed in Cyp D(-/-) mice.	Cyclosporine	24-38	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	131-136
19778329-4	2010	The aim of this study was to investigate whether an association exists between MMP-3 genotypes and gingival enlargement in kidney transplant patients medicated with cyclosporine A.	Cyclosporine	165-179	matrix metallopeptidase 3	Homo sapiens	79-84
19879126-4	2010	An Immunoglobin A (IgA) immunosensor was constructed by the covalent bonding of IgA antibody molecules with the CSA aided by large numbers of carboxyl groups on the surface of carbon spheres.	Cyclosporine	112-115	CD79a molecule	Homo sapiens	19-22
19879126-4	2010	An Immunoglobin A (IgA) immunosensor was constructed by the covalent bonding of IgA antibody molecules with the CSA aided by large numbers of carboxyl groups on the surface of carbon spheres.	Cyclosporine	112-115	CD79a molecule	Homo sapiens	80-83
20061922-1	2010	BACKGROUND: We hypothesized that genetic variation of ATP-binding cassette subfamily B member 1 (ABCB1) that encodes P-glycoprotein (involved in the uptake of cyclosporin A [CsA]) contributes to trough drug concentrations and thereby to CsA"s immunosuppressive and toxic effects.	Cyclosporine	159-172	ATP binding cassette subfamily B member 1	Homo sapiens	54-95
20061922-1	2010	BACKGROUND: We hypothesized that genetic variation of ATP-binding cassette subfamily B member 1 (ABCB1) that encodes P-glycoprotein (involved in the uptake of cyclosporin A [CsA]) contributes to trough drug concentrations and thereby to CsA"s immunosuppressive and toxic effects.	Cyclosporine	159-172	ATP binding cassette subfamily B member 1	Homo sapiens	97-102
20061922-1	2010	BACKGROUND: We hypothesized that genetic variation of ATP-binding cassette subfamily B member 1 (ABCB1) that encodes P-glycoprotein (involved in the uptake of cyclosporin A [CsA]) contributes to trough drug concentrations and thereby to CsA"s immunosuppressive and toxic effects.	Cyclosporine	174-177	ATP binding cassette subfamily B member 1	Homo sapiens	54-95
20061922-1	2010	BACKGROUND: We hypothesized that genetic variation of ATP-binding cassette subfamily B member 1 (ABCB1) that encodes P-glycoprotein (involved in the uptake of cyclosporin A [CsA]) contributes to trough drug concentrations and thereby to CsA"s immunosuppressive and toxic effects.	Cyclosporine	174-177	ATP binding cassette subfamily B member 1	Homo sapiens	97-102
20061922-1	2010	BACKGROUND: We hypothesized that genetic variation of ATP-binding cassette subfamily B member 1 (ABCB1) that encodes P-glycoprotein (involved in the uptake of cyclosporin A [CsA]) contributes to trough drug concentrations and thereby to CsA"s immunosuppressive and toxic effects.	Cyclosporine	237-240	ATP binding cassette subfamily B member 1	Homo sapiens	54-95
20061922-1	2010	BACKGROUND: We hypothesized that genetic variation of ATP-binding cassette subfamily B member 1 (ABCB1) that encodes P-glycoprotein (involved in the uptake of cyclosporin A [CsA]) contributes to trough drug concentrations and thereby to CsA"s immunosuppressive and toxic effects.	Cyclosporine	237-240	ATP binding cassette subfamily B member 1	Homo sapiens	97-102
20061922-7	2010	CONCLUSIONS: The association of ABCB1 12/1236, 21/2677, and 26/3435 CC/GG/CC haplotype with increased CsA dose- and weight-adjusted CsA trough concentrations in this group of adult white heart transplant recipients was not consistent over time and had no effect on the incidence of acute rejection or on the development of renal impairment.	Cyclosporine	102-105	ATP binding cassette subfamily B member 1	Homo sapiens	32-37
20061922-7	2010	CONCLUSIONS: The association of ABCB1 12/1236, 21/2677, and 26/3435 CC/GG/CC haplotype with increased CsA dose- and weight-adjusted CsA trough concentrations in this group of adult white heart transplant recipients was not consistent over time and had no effect on the incidence of acute rejection or on the development of renal impairment.	Cyclosporine	132-135	ATP binding cassette subfamily B member 1	Homo sapiens	32-37
21249305-4	2010	Our data indicate that DCs differentiated in the presence of CsA show an altered phenotype, with a lower expression of MHC-II and a lower activating capacity.	Cyclosporine	61-64	histocompatibility-2, MHC	Mus musculus	119-125
19914243-4	2010	Down Syndrome critical region 1 (DSCR1) and heparin-binding EGF-like growth factor (HB-EGF) are two genes identified by DNA microarray as being up-regulated by VEGF-A in a cyclosporine-A-sensitive manner.	Cyclosporine	172-186	vascular endothelial growth factor A	Homo sapiens	160-166
21171529-2	2010	Patients with NPHS2 gene mutations do not respond to corticoids and other immunosuppressive agents; partial remission can be rarely induced by cyclosporin A.	Cyclosporine	143-156	NPHS2 stomatin family member, podocin	Homo sapiens	14-19
19664589-8	2010	A combination of cyclosporin A and ADP, inhibitors of the mitochondrial permeability transition, attenuated Cyt c release, mitochondrial remodeling, and depolarization induced by BAX(oligo), but failed to influence the effects produced by t(c)BID plus BAX(mono).	Cyclosporine	17-30	cytochrome c, somatic	Homo sapiens	108-113
19664589-8	2010	A combination of cyclosporin A and ADP, inhibitors of the mitochondrial permeability transition, attenuated Cyt c release, mitochondrial remodeling, and depolarization induced by BAX(oligo), but failed to influence the effects produced by t(c)BID plus BAX(mono).	Cyclosporine	17-30	BCL2 associated X, apoptosis regulator	Homo sapiens	179-182
19664589-8	2010	A combination of cyclosporin A and ADP, inhibitors of the mitochondrial permeability transition, attenuated Cyt c release, mitochondrial remodeling, and depolarization induced by BAX(oligo), but failed to influence the effects produced by t(c)BID plus BAX(mono).	Cyclosporine	17-30	BH3 interacting domain death agonist	Homo sapiens	243-246
19664589-8	2010	A combination of cyclosporin A and ADP, inhibitors of the mitochondrial permeability transition, attenuated Cyt c release, mitochondrial remodeling, and depolarization induced by BAX(oligo), but failed to influence the effects produced by t(c)BID plus BAX(mono).	Cyclosporine	17-30	BCL2 associated X, apoptosis regulator	Homo sapiens	252-255
21249305-5	2010	Additionally, these CsA-treated DCs show decreased production of IL-2 and IL-12 and increased IL-10 secretion when stimulated with LPS, indicating an effect on the polarization of the immune response.	Cyclosporine	20-23	interleukin 10	Mus musculus	94-99
20708731-6	2010	Therefore we speculate CrmA can block down CsA-induced renal cell apoptosis through inhibiting the Caspase-3, -6, -8, -9 and -12 activated and further to eliminate CRD induced by CsA.	Cyclosporine	43-46	caspase 3	Homo sapiens	99-120
21220920-11	2010	This correlated with increased mRNA expression of genes associated with the death receptor pathway and detection of TNFalpha in culture medium of cells treated with CsA.	Cyclosporine	165-168	tumor necrosis factor	Rattus norvegicus	116-124
19890249-4	2010	The pharmacokinetics of both MPA and MPAG were significantly influenced by the OATP1B3 polymorphism 334T&gt;G/699G&gt;A in 70 renal transplant patients receiving combination treatment of MMF with either tacrolimus or sirolimus, but not in 115 patients receiving MMF and cyclosporine.	Cyclosporine	270-282	solute carrier organic anion transporter family member 1B3	Homo sapiens	79-86
19766721-0	2010	Antiapoptotic properties of recombinant human erythropoietin protects against tubular cyclosporine toxicity.	Cyclosporine	86-98	erythropoietin	Homo sapiens	46-60
20851384-2	2010	DTH paw swelling, along with the cytokines IL-2, IFNgamma, MCP-1 and TNFalpha, were inhibited in Balb/c mice by cyclosporine A (CsA).	Cyclosporine	112-126	interferon gamma	Mus musculus	49-57
20851384-2	2010	DTH paw swelling, along with the cytokines IL-2, IFNgamma, MCP-1 and TNFalpha, were inhibited in Balb/c mice by cyclosporine A (CsA).	Cyclosporine	112-126	mast cell protease 1	Mus musculus	59-64
20851384-2	2010	DTH paw swelling, along with the cytokines IL-2, IFNgamma, MCP-1 and TNFalpha, were inhibited in Balb/c mice by cyclosporine A (CsA).	Cyclosporine	112-126	tumor necrosis factor	Mus musculus	69-77
20851384-2	2010	DTH paw swelling, along with the cytokines IL-2, IFNgamma, MCP-1 and TNFalpha, were inhibited in Balb/c mice by cyclosporine A (CsA).	Cyclosporine	128-131	interferon gamma	Mus musculus	49-57
20851384-2	2010	DTH paw swelling, along with the cytokines IL-2, IFNgamma, MCP-1 and TNFalpha, were inhibited in Balb/c mice by cyclosporine A (CsA).	Cyclosporine	128-131	mast cell protease 1	Mus musculus	59-64
20851384-2	2010	DTH paw swelling, along with the cytokines IL-2, IFNgamma, MCP-1 and TNFalpha, were inhibited in Balb/c mice by cyclosporine A (CsA).	Cyclosporine	128-131	tumor necrosis factor	Mus musculus	69-77
19766721-2	2010	Taking into account the tissue protective effects of erythropoietin mediated through its antiapoptotic properties, we tested whether administration of recombinant human erythropoietin protects against acute cyclosporine nephrotoxicity.	Cyclosporine	207-219	erythropoietin	Homo sapiens	169-183
19766721-9	2010	Indeed, western blotting analysis of caspase 3 cleavage and Akt phosphorylation demonstrates that rhEPO activate Akt signaling and inhibits caspase 3 cleavage induced by CsA.	Cyclosporine	170-173	caspase 3	Homo sapiens	37-46
19766721-9	2010	Indeed, western blotting analysis of caspase 3 cleavage and Akt phosphorylation demonstrates that rhEPO activate Akt signaling and inhibits caspase 3 cleavage induced by CsA.	Cyclosporine	170-173	AKT serine/threonine kinase 1	Homo sapiens	60-63
19766721-9	2010	Indeed, western blotting analysis of caspase 3 cleavage and Akt phosphorylation demonstrates that rhEPO activate Akt signaling and inhibits caspase 3 cleavage induced by CsA.	Cyclosporine	170-173	caspase 3	Homo sapiens	140-149
20029328-6	2009	Although the expression of aquaporin-2, NaPi-2, and paracellin-1 mRNAs tended to increase in kidneys with a reduced nephron mass, NaPi-2 mRNA levels decreased in 1/2K rats exposed to CsA/SRL for 28 days (P&lt;0.05).	Cyclosporine	183-186	solute carrier family 34 member 1	Rattus norvegicus	40-46
20516727-8	2010	The rapid activation of NKT cells could be efficiently suppressed by low-dose CsA treatment, possibly in a CD1d-independent manner.	Cyclosporine	78-81	CD1d1 antigen	Mus musculus	107-111
20029328-6	2009	Although the expression of aquaporin-2, NaPi-2, and paracellin-1 mRNAs tended to increase in kidneys with a reduced nephron mass, NaPi-2 mRNA levels decreased in 1/2K rats exposed to CsA/SRL for 28 days (P&lt;0.05).	Cyclosporine	183-186	solute carrier family 34 member 1	Rattus norvegicus	130-136
19852929-4	2009	TRESK is highly activated by Ca(2+), calcineurin, acetylcholine, and histamine which induce hypertrophy, whereas TRESK is inhibited by immunosuppressants, such as cyclosporin A and FK506.	Cyclosporine	163-176	potassium two pore domain channel subfamily K member 18	Homo sapiens	0-5
19852929-4	2009	TRESK is highly activated by Ca(2+), calcineurin, acetylcholine, and histamine which induce hypertrophy, whereas TRESK is inhibited by immunosuppressants, such as cyclosporin A and FK506.	Cyclosporine	163-176	potassium two pore domain channel subfamily K member 18	Homo sapiens	113-118
19517226-5	2009	Pretreatment of the cells with GSL prior to CsA exposure could alleviate CsA-induced CN inhibition and tau hyperphosphorylation to some degree.	Cyclosporine	44-47	cathepsin A	Homo sapiens	31-34
20641310-5	2004	Calcium channel blockers, cyclosporin and its non-immunosuppressive analogue PSC 833 are MDR modulators inhibiting transport of P-gp substrates out of the cells (6, 7).	Cyclosporine	26-37	ATP binding cassette subfamily B member 1	Homo sapiens	128-132
19517226-5	2009	Pretreatment of the cells with GSL prior to CsA exposure could alleviate CsA-induced CN inhibition and tau hyperphosphorylation to some degree.	Cyclosporine	73-76	cathepsin A	Homo sapiens	31-34
19517226-7	2009	It is speculated that GSL weakens CsA-induced CN inhibition through the antioxidant mechanisms.	Cyclosporine	34-37	cathepsin A	Homo sapiens	22-25
19897783-5	2009	In human gingival fibroblasts, cyclosporin alone did not induce evident inflammatory responses, but augmented the expression of CD54 and the production of interleukin (IL)-6 and IL-8 induced by TLR ligands, whereas phenytoin attenuated those responses.	Cyclosporine	31-42	interleukin 6	Homo sapiens	155-173
19930311-4	2009	This complex of ciclosporin and cyclophilin inhibits calcineurin, which is responsible for activating the transcription of interleukin-2.	Cyclosporine	16-27	interleukin 2	Homo sapiens	123-136
19930321-1	2009	The inhibitory effect of Cyclosporine A (CsA) and Tacrolimus (Tacr) on interleukin 2 (IL-2) are well known, and the importance of Th1-type (IL-2, interferon gamma), and Th2-type (IL-4, IL-6, and IL-10) cytokine secretion in preventing allograft rejection is a controversial issue.	Cyclosporine	41-44	interleukin 2	Homo sapiens	71-84
19930321-1	2009	The inhibitory effect of Cyclosporine A (CsA) and Tacrolimus (Tacr) on interleukin 2 (IL-2) are well known, and the importance of Th1-type (IL-2, interferon gamma), and Th2-type (IL-4, IL-6, and IL-10) cytokine secretion in preventing allograft rejection is a controversial issue.	Cyclosporine	41-44	interleukin 2	Homo sapiens	86-90
19995330-2	2009	In addition, the efflux can be reversed by cyclosporine, indicating that S5 may be a human P-glycoprotein (P-gp) substrate.	Cyclosporine	43-55	ATP binding cassette subfamily B member 1	Homo sapiens	91-105
19995330-2	2009	In addition, the efflux can be reversed by cyclosporine, indicating that S5 may be a human P-glycoprotein (P-gp) substrate.	Cyclosporine	43-55	ATP binding cassette subfamily B member 1	Homo sapiens	107-111
20121928-3	2009	Although JNK may phosphorylate the cyclosporine A-sensitive transcription factor, nuclear factor of activated T cells c3, it was seemingly not involved because cyclosporine A did not reduce EGF-induced COX-2 expression.	Cyclosporine	35-49	mitogen-activated protein kinase 8	Homo sapiens	9-12
19917700-6	2009	Proliferation of OT-I cells was significantly inhibited in vitro and in vivo by anti-CD86 mAb but not by anti-CD80 mAb and could also be inhibited by cyclosporine A.	Cyclosporine	150-164	CD86 antigen	Mus musculus	85-89
19769983-7	2009	Treatment with a calcineurin activity inhibitor, cyclosporin A, reduced Ang-II-induced NFAT transcriptional activity and senescent VSMC.	Cyclosporine	49-62	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	72-78
19897783-5	2009	In human gingival fibroblasts, cyclosporin alone did not induce evident inflammatory responses, but augmented the expression of CD54 and the production of interleukin (IL)-6 and IL-8 induced by TLR ligands, whereas phenytoin attenuated those responses.	Cyclosporine	31-42	C-X-C motif chemokine ligand 8	Homo sapiens	178-182
20034899-6	2009	RESULTS: CsA can increase fibrin deposition and the expression of TGF-beta1 in the renal tissue, which were significantly reduced after uPA treatment (P&lt;0.05).	Cyclosporine	9-12	transforming growth factor, beta 1	Rattus norvegicus	66-75
20034917-4	2009	The first peak of MCP-1 was postponed by the application of CsA, which did not affect the peak level (P&gt;0.05).	Cyclosporine	60-63	mast cell protease 1-like 1	Rattus norvegicus	18-23
19925383-11	2009	MDR1 haplotypes and CYP3A5*3 genotypes can be related to C(2) and C(0) of CsA, respectively.	Cyclosporine	74-77	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
19729463-3	2009	Pharmacokinetic studies have demonstrated that cyclosporine increases statin drug levels, presumably via competitive inhibition of cytochrome P450 3A4.	Cyclosporine	47-59	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	131-150
19925383-0	2009	Influence of the MDR1 haplotype and CYP3A5 genotypes on cyclosporine blood level in Chinese renal transplant recipients.	Cyclosporine	56-68	ATP binding cassette subfamily B member 1	Homo sapiens	17-21
19925383-0	2009	Influence of the MDR1 haplotype and CYP3A5 genotypes on cyclosporine blood level in Chinese renal transplant recipients.	Cyclosporine	56-68	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	36-42
19925383-11	2009	MDR1 haplotypes and CYP3A5*3 genotypes can be related to C(2) and C(0) of CsA, respectively.	Cyclosporine	74-77	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	20-26
19925383-1	2009	The purpose of the study was to elucidate the influence of multidrug resistance gene (MDR1) haplotype and CYP3A5 genotype on cyclosporine (CsA) blood level in Chinese renal transplant recipients.	Cyclosporine	125-137	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	106-112
20137731-8	2009	The level of CD4(+)Foxp3(+)Treg cells between cyclosporin group and tacrolimus group was no significant difference (P &gt; 0.05).	Cyclosporine	46-57	CD4 molecule	Homo sapiens	13-16
19481339-0	2009	Cyclosporine A inhibits colorectal cancer proliferation probably by regulating expression levels of c-Myc, p21(WAF1/CIP1) and proliferating cell nuclear antigen.	Cyclosporine	0-14	cyclin dependent kinase inhibitor 1A	Homo sapiens	107-110
19481339-0	2009	Cyclosporine A inhibits colorectal cancer proliferation probably by regulating expression levels of c-Myc, p21(WAF1/CIP1) and proliferating cell nuclear antigen.	Cyclosporine	0-14	cyclin dependent kinase inhibitor 1A	Homo sapiens	111-115
19481339-0	2009	Cyclosporine A inhibits colorectal cancer proliferation probably by regulating expression levels of c-Myc, p21(WAF1/CIP1) and proliferating cell nuclear antigen.	Cyclosporine	0-14	cyclin dependent kinase inhibitor 1A	Homo sapiens	116-120
19481339-5	2009	CsA decreased the expressions of c-Myc and the proliferating cell nuclear antigen (PCNA) but also increased p21(WAF1/CIP1) expression.	Cyclosporine	0-3	cyclin dependent kinase inhibitor 1A	Homo sapiens	108-111
19481339-5	2009	CsA decreased the expressions of c-Myc and the proliferating cell nuclear antigen (PCNA) but also increased p21(WAF1/CIP1) expression.	Cyclosporine	0-3	cyclin dependent kinase inhibitor 1A	Homo sapiens	112-116
19481339-5	2009	CsA decreased the expressions of c-Myc and the proliferating cell nuclear antigen (PCNA) but also increased p21(WAF1/CIP1) expression.	Cyclosporine	0-3	cyclin dependent kinase inhibitor 1A	Homo sapiens	117-121
19168026-8	2009	Inhibition of mPTP opening can be achieved with inhibitors of each component, but targeting CyP-D with cyclosporin A (CsA) and its non-immunosuppressive analogues is the best described.	Cyclosporine	103-116	peptidylprolyl isomerase F	Homo sapiens	92-97
19692655-6	2009	Moreover, both IP3R-1 knockdown and blockade through 2-aminoethoxydiphenyle borate or CsA induced improved survival of dystrophin-deficient myotubes, demonstrating the cell death dependence on the IP3-dependent calcium signaling as well as the protective effect of CsA.	Cyclosporine	265-268	inositol 1,4,5-trisphosphate receptor type 1	Homo sapiens	15-21
19168026-8	2009	Inhibition of mPTP opening can be achieved with inhibitors of each component, but targeting CyP-D with cyclosporin A (CsA) and its non-immunosuppressive analogues is the best described.	Cyclosporine	118-121	peptidylprolyl isomerase F	Homo sapiens	92-97
20038391-1	2009	OBJECTIVE: To determine how single nucleotide polymorphisms located on genes MDR1, CYP3A4 and CYP3A5 affect the absorption kinetics of cyclosporine in cardiac transplant patients.	Cyclosporine	135-147	ATP binding cassette subfamily B member 1	Homo sapiens	77-81
19779705-0	2009	Oral cyclosporin A inhibits CD4 T cell P-glycoprotein  activity in HIV-infected adults initiating treatment  with nucleoside reverse transcriptase inhibitors.	Cyclosporine	5-18	CD4 molecule	Homo sapiens	28-31
19779705-4	2009	RESULTS: CD4 T cell P-glycoprotein activity decreased by a median of 8 percentage points with cyclosporin A/ART (difference between cyclosporin A/ART vs. ART only, P= 0.001).	Cyclosporine	94-107	CD4 molecule	Homo sapiens	9-12
19779705-4	2009	RESULTS: CD4 T cell P-glycoprotein activity decreased by a median of 8 percentage points with cyclosporin A/ART (difference between cyclosporin A/ART vs. ART only, P= 0.001).	Cyclosporine	132-145	CD4 molecule	Homo sapiens	9-12
19779705-6	2009	CONCLUSIONS: Oral cyclosporin A can inhibit peripheral blood CD4 T cell P-glycoprotein activity.	Cyclosporine	18-31	CD4 molecule	Homo sapiens	61-64
20038391-1	2009	OBJECTIVE: To determine how single nucleotide polymorphisms located on genes MDR1, CYP3A4 and CYP3A5 affect the absorption kinetics of cyclosporine in cardiac transplant patients.	Cyclosporine	135-147	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	83-89
20038391-1	2009	OBJECTIVE: To determine how single nucleotide polymorphisms located on genes MDR1, CYP3A4 and CYP3A5 affect the absorption kinetics of cyclosporine in cardiac transplant patients.	Cyclosporine	135-147	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	94-100
20038391-5	2009	DISCUSSION: Our results show that genotype differences in MDR1 3435C &gt; T can explain part of the variability in cyclosporine absorption among individuals in the population of Spanish cardiac transplant recipients.	Cyclosporine	115-127	ATP binding cassette subfamily B member 1	Homo sapiens	58-62
19577762-6	2009	RESULTS: Allografts treated with anti-CCR5 mAb plus CsA showed significantly prolonged survival (44.73 +/- 0.258 d, P &lt; 0.01) compared with PBS-treated group (11.067 +/- 0.707 d).	Cyclosporine	52-55	chemokine (C-C motif) receptor 5	Mus musculus	38-42
19744167-9	2009	Pretreatment with cyclosporine A prevented CoCl(2)-induced reduction of complex I- and II-dependent mitochondrial oxygen consumption and TNF-alpha-induced reduction of complex-I-dependent respiration, implicating the involvement of the mitochondrial permeability transition pore openings.	Cyclosporine	18-32	tumor necrosis factor	Homo sapiens	137-146
19577762-8	2009	CONCLUSIONS: Our findings demonstrated that anti-CCR5 mAb in combination with CsA can prolong the survival of allograft and alleviate both acute and chronic allograft rejection.	Cyclosporine	78-81	chemokine (C-C motif) receptor 5	Mus musculus	49-53
19370549-10	2009	In conclusion, berberine produced a dose-dependent increased bioavailability of digoxin and cyclosporine A by inhibition of intestinal P-gp.	Cyclosporine	92-106	phosphoglycolate phosphatase	Rattus norvegicus	135-139
18957484-6	2009	RESULTS: Treatment of PBL with leflunomide, cyclosporin A and FK-506 inhibited the IL-15-induced expression of both CD54 and CD69 by PBL, as well as TNF production in co-cultures of activated PBL and THP-1 cells.	Cyclosporine	44-57	tumor necrosis factor	Homo sapiens	149-152
19724275-8	2009	Regulation of COX-2 expression by NFAT was investigated using NFAT-targeted siRNA, calcineurin inhibitors cyclosporin A and FK506, in addition to COX-2 luciferase reporter vectors that selectively lacked NFAT binding sites.	Cyclosporine	106-119	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	14-19
18957484-6	2009	RESULTS: Treatment of PBL with leflunomide, cyclosporin A and FK-506 inhibited the IL-15-induced expression of both CD54 and CD69 by PBL, as well as TNF production in co-cultures of activated PBL and THP-1 cells.	Cyclosporine	44-57	GLI family zinc finger 2	Homo sapiens	200-205
19792854-17	2009	CONCLUSION: CsA differentially upregulated iNOS, but not eNOS, in overgrown gingiva, which may play a pivotal role in the pathogenesis of CsA-induced GO.	Cyclosporine	12-15	nitric oxide synthase 2	Homo sapiens	43-47
20009157-3	2009	In transplantation regimen, a 15 mg BID dose of cyclosporine was supposed to be given as part of the immunosuppressive therapy.	Cyclosporine	48-60	BH3 interacting domain death agonist	Homo sapiens	36-39
19767068-0	2009	Cyclosporin A reduces CD4(+)CD25(+) regulatory T-cell numbers in patients with atopic dermatitis.	Cyclosporine	0-13	CD4 molecule	Homo sapiens	22-25
19792854-1	2009	BACKGROUND: The contribution of nitric oxide (NO) to immune response and matrix degradation in the periodontal environment suggests a role for NO and NO-synthase (NOS) activity in the pathogenesis of cyclosporin A (CsA)-induced gingival overgrowth (GO).	Cyclosporine	215-218	nitric oxide synthase 2	Homo sapiens	150-161
19792854-17	2009	CONCLUSION: CsA differentially upregulated iNOS, but not eNOS, in overgrown gingiva, which may play a pivotal role in the pathogenesis of CsA-induced GO.	Cyclosporine	138-141	nitric oxide synthase 2	Homo sapiens	43-47
19495806-0	2009	Partial remission with cyclosporine A in a patient with nephrotic syndrome due to NPHS2 mutation.	Cyclosporine	23-37	NPHS2 stomatin family member, podocin	Homo sapiens	82-87
19857752-4	2009	We investigated the effects of cyclosporine (CsA), a widely used immunosuppressive agent, on human CD4+CD25+ Treg cells.	Cyclosporine	31-43	CD4 molecule	Homo sapiens	99-102
19857752-11	2009	CONCLUSION: CsA significantly impaired the function of CD4+CD25+ Treg cells by inducing interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) secretion.	Cyclosporine	12-15	interleukin 2	Homo sapiens	103-107
19857752-11	2009	CONCLUSION: CsA significantly impaired the function of CD4+CD25+ Treg cells by inducing interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) secretion.	Cyclosporine	12-15	interferon gamma	Homo sapiens	113-129
19857752-11	2009	CONCLUSION: CsA significantly impaired the function of CD4+CD25+ Treg cells by inducing interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) secretion.	Cyclosporine	12-15	interferon gamma	Homo sapiens	131-140
19857752-4	2009	We investigated the effects of cyclosporine (CsA), a widely used immunosuppressive agent, on human CD4+CD25+ Treg cells.	Cyclosporine	45-48	CD4 molecule	Homo sapiens	99-102
19857752-8	2009	RESULTS: CsA (40 or 400 ng/mL) inhibited the proliferative capacity of PBMC and CD4+CD25+ Treg in a dose-dependent manner.	Cyclosporine	9-12	CD4 molecule	Homo sapiens	80-83
19857752-9	2009	Interestingly, addition of 40 ng/mL CsA in MLR impaired the suppressive activity of CD4+CD25+ cells, whereas a higher dose of CsA had no effect on Treg function.	Cyclosporine	36-39	CD4 molecule	Homo sapiens	84-87
19857752-11	2009	CONCLUSION: CsA significantly impaired the function of CD4+CD25+ Treg cells by inducing interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) secretion.	Cyclosporine	12-15	CD4 molecule	Homo sapiens	55-58
19857752-11	2009	CONCLUSION: CsA significantly impaired the function of CD4+CD25+ Treg cells by inducing interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) secretion.	Cyclosporine	12-15	interleukin 2	Homo sapiens	88-101
19553348-7	2009	Inhibition of CypD using cyclosporin A in oxidant-injured cultured proximal tubular cells (PTC) prevented mitochondrial membrane depolarization, reduced LDH release, ATP depletion and necrotic cell death.	Cyclosporine	25-38	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	14-18
19608730-6	2009	Upregulation of cFLIP in the colonic epithelial cells, amelioration of body weight loss, and mucosal destruction by cyclosporine were attenuated by anti-TGF-beta antibody treatment.	Cyclosporine	116-128	transforming growth factor beta 1	Homo sapiens	153-161
19608730-0	2009	Cyclosporine regulates intestinal epithelial apoptosis via TGF-beta-related signaling.	Cyclosporine	0-12	transforming growth factor beta 1	Homo sapiens	59-67
19608730-7	2009	These results indicated that cyclosporine could have a protective role against epithelial apoptosis associated with upregulation of TGF-beta-related signaling.	Cyclosporine	29-41	transforming growth factor beta 1	Homo sapiens	132-140
19608730-2	2009	We analyzed the mechanism of the effects of cyclosporine on the regulation of epithelial apoptosis via TGF-beta-related signaling, because the balance between the apoptosis and regeneration of epithelial cells seems to be a key factor to maintain the intestinal homeostasis.	Cyclosporine	44-56	transforming growth factor beta 1	Homo sapiens	103-111
19608730-5	2009	Cyclosporine was shown to upregulate the expression of TGF-beta in the colonic tissue, enhance the expression of p-Smad2 and cFLIP in epithelial cells, and inhibit caspase-8 activity but not caspase-1 or -9.	Cyclosporine	0-12	transforming growth factor beta 1	Homo sapiens	55-63
19501648-8	2009	Measurements by blot analysis showed that NA-Gly caused a CsA-sensitive cytochrome c release.	Cyclosporine	58-61	cytochrome c, somatic	Homo sapiens	72-84
19608730-5	2009	Cyclosporine was shown to upregulate the expression of TGF-beta in the colonic tissue, enhance the expression of p-Smad2 and cFLIP in epithelial cells, and inhibit caspase-8 activity but not caspase-1 or -9.	Cyclosporine	0-12	CASP8 and FADD like apoptosis regulator	Homo sapiens	125-130
19463978-7	2009	In contrast, the inhibition of NFATc1 nuclear translocation either by cyclosporin or by using primary mouse osteoblasts with deleted calcineurin b1 prevents HDAC3 from associating with the proximal regulatory site of the osteocalcin promoter.	Cyclosporine	70-81	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	31-37
19467023-7	2009	Furthermore, we showed that fluvastatin or cyclosporine A in combination with IFN-alpha could prevent the relapse after therapy in the IFN-alpha-resistant HCV RNA-harboring cells.	Cyclosporine	43-57	interferon alpha 1	Homo sapiens	135-144
19553475-5	2009	32P-labeling demonstrated direct phosphorylation of TRPV1 or TRPV1t in anterior lingual epithelium by PMA, cyclosporin A, or FK-506.	Cyclosporine	107-120	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	52-57
19553475-5	2009	32P-labeling demonstrated direct phosphorylation of TRPV1 or TRPV1t in anterior lingual epithelium by PMA, cyclosporin A, or FK-506.	Cyclosporine	107-120	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	61-66
19215635-11	2009	In addition, BDNF Val66Met and 5-HTTLPR polymorphisms seemed to moderate the effect of CSA on adult depressive symptoms.	Cyclosporine	87-90	solute carrier family 6 member 4	Homo sapiens	31-39
19509316-10	2009	Inhibition of MPTP opening by reduction of CyP-D activity by nonimmunosuppressive analogs of cyclosporine A or sanglifehrin A, as well as attenuation of reactive oxygen species accumulation through mitochondria-targeted antioxidants, is the most promising.	Cyclosporine	93-107	peptidylprolyl isomerase F	Homo sapiens	43-48
19696629-6	2009	In our study, we use cyclosporin A, a calcineurin inhibitor.	Cyclosporine	21-34	calcineurin binding protein 1	Mus musculus	38-59
19718476-5	2009	As shown by real-time RT-PCR for selected genes, VEGF-induction was mostly mediated by VEGF receptor-2 and the capacity of VEGF-A to induce genes in common with IL-1 largely depended on activation of the calcineurin/NFAT pathway, since cyclosporin A inhibited this induction.	Cyclosporine	236-249	vascular endothelial growth factor A	Homo sapiens	49-53
19718476-5	2009	As shown by real-time RT-PCR for selected genes, VEGF-induction was mostly mediated by VEGF receptor-2 and the capacity of VEGF-A to induce genes in common with IL-1 largely depended on activation of the calcineurin/NFAT pathway, since cyclosporin A inhibited this induction.	Cyclosporine	236-249	vascular endothelial growth factor A	Homo sapiens	123-129
19667964-8	2009	Cyclosporine A and Tac are metabolized by CYP3A4 and CYP3A5, and several single nucleotide polymorphisms in the two genes have been associated with differences in drug clearance.	Cyclosporine	0-14	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	42-48
19667964-8	2009	Cyclosporine A and Tac are metabolized by CYP3A4 and CYP3A5, and several single nucleotide polymorphisms in the two genes have been associated with differences in drug clearance.	Cyclosporine	0-14	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	53-59
19464389-7	2009	Hirsutenone, dexamethasone, cyclosporin A and Bay 11-7085 inhibited the TNF-alpha-induced phosphorylation of inhibitory kappaB and the activation of nuclear factor (NF)-kappaB.	Cyclosporine	28-41	tumor necrosis factor	Homo sapiens	72-81
19666510-3	2009	Th2 cells that have upregulated T1ST2 produce IL-13, but not IL-4, in response to IL-33 plus a STAT5 activator in an antigen-independent, NF-kappaB-dependent, cyclosporin A (CsA)-resistant manner.	Cyclosporine	159-172	interleukin 13	Homo sapiens	46-51
19666510-3	2009	Th2 cells that have upregulated T1ST2 produce IL-13, but not IL-4, in response to IL-33 plus a STAT5 activator in an antigen-independent, NF-kappaB-dependent, cyclosporin A (CsA)-resistant manner.	Cyclosporine	174-177	interleukin 13	Homo sapiens	46-51
19503092-10	2009	Furthermore, Cyp depletion or treatment with CsA induced apoptosis in IL-6-dependent multiple myeloma cells, whereas an IL-6-independent line was not affected.	Cyclosporine	45-48	interleukin 6	Homo sapiens	70-74
19464389-5	2009	Immunosuppressants (dexamethasone and cyclosporin A) inhibited the TNF-alpha-elicited formation of IL-8, prostaglandin E(2) and CCL27, but did not affect formation of reactive species.	Cyclosporine	38-51	tumor necrosis factor	Homo sapiens	67-76
19464389-5	2009	Immunosuppressants (dexamethasone and cyclosporin A) inhibited the TNF-alpha-elicited formation of IL-8, prostaglandin E(2) and CCL27, but did not affect formation of reactive species.	Cyclosporine	38-51	C-X-C motif chemokine ligand 8	Homo sapiens	99-103
19464389-7	2009	Hirsutenone, dexamethasone, cyclosporin A and Bay 11-7085 inhibited the TNF-alpha-induced phosphorylation of inhibitory kappaB and the activation of nuclear factor (NF)-kappaB.	Cyclosporine	28-41	nuclear factor kappa B subunit 1	Homo sapiens	149-175
19391111-0	2009	S-allylcysteine attenuates renal injury by altering the expressions of iNOS and matrix metallo proteinase-2 during cyclosporine-induced nephrotoxicity in Wistar rats.	Cyclosporine	115-127	nitric oxide synthase 2	Rattus norvegicus	71-75
19391111-7	2009	Elevated expressions of inducible nitric oxide synthase (iNOS) and nuclear factor kappa B (NF-kappaB) due to CsA administration were reduced by SAC treatment.	Cyclosporine	109-112	nitric oxide synthase 2	Rattus norvegicus	24-55
19391111-7	2009	Elevated expressions of inducible nitric oxide synthase (iNOS) and nuclear factor kappa B (NF-kappaB) due to CsA administration were reduced by SAC treatment.	Cyclosporine	109-112	nitric oxide synthase 2	Rattus norvegicus	57-61
20187293-6	2009	Inhibitors of electron transport (rotenone and antimycin A) or inhibitor of mitochondrial permeability transition pore (cyclosporine A) reduced the effect of toxin- on ROS generation, loss of deltapsim and cytochrome c release.	Cyclosporine	120-134	cytochrome c, somatic	Homo sapiens	206-218
19076990-11	2009	CONCLUSION: This study shows that simvastatin therapy leads to a reversal of the cyclosporine A-induced bone loss, which may be mediated by downregulation of interleukin-1beta and prostaglandin E(2) production.	Cyclosporine	81-95	interleukin 1 beta	Rattus norvegicus	158-175
19617341-0	2009	Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans.	Cyclosporine	11-23	ATP binding cassette subfamily B member 1	Homo sapiens	38-52
19617341-3	2009	We have previously demonstrated P-gp activity at the human BBB using PET of (11)C-verapamil distribution into the brain in the absence and presence of the P-gp inhibitor cyclosporine-A (CsA).	Cyclosporine	170-184	ATP binding cassette subfamily B member 1	Homo sapiens	32-36
19505981-7	2009	As expected, cyclosporine treatment decreased nuclear translocation of calcineurin/NFAT in alpha(2A)/alpha(2C)ARKO mice, which was associated with improved ventricular function and a pronounced anti-remodelling effect.	Cyclosporine	13-25	adrenergic receptor, alpha 2a	Mus musculus	91-99
19477024-7	2009	The combination of N297A dosing with cyclosporine A (CSA) pretreatment showed a significant decrease of TNFalpha, IL-6 and IP-10 without effect on clinical efficacy.	Cyclosporine	37-51	tumor necrosis factor	Mus musculus	104-112
19661542-8	2009	The beneficial effects of CsA in angiogenesis-related diseases such as PsA and cutaneous psoriasis may also be mediated by its ability to block the angiogenic effects induced by vascular endothelial growth factor.	Cyclosporine	26-29	vascular endothelial growth factor A	Homo sapiens	178-212
19343327-3	2009	The dose-adjusted levels were significantly lower in CYP3A5 expressers for CsA (p = 0.037; 3 months) and Tac (p &lt; 0.001; 1 month and p &lt; 0.001; 3 months) compared to the non-expressers, suggesting that for a given dose their CsA/Tac blood concentration is lower.	Cyclosporine	75-78	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	53-59
19477024-7	2009	The combination of N297A dosing with cyclosporine A (CSA) pretreatment showed a significant decrease of TNFalpha, IL-6 and IP-10 without effect on clinical efficacy.	Cyclosporine	37-51	interleukin 6	Mus musculus	114-118
19719970-10	2009	Cyclosporine treatment markedly shortened the clotting time of RBCs ((305 +/- 10) seconds vs (366 +/- 15) seconds) and increased the generation of intrinsic factor Xase ((7.68 +/- 0.99) nmol/L vs (2.86 +/- 0.11) nmol/L) and thrombin ((15.83 +/- 1.37) nmol/L vs (4.88 +/- 0.13) nmol/L).	Cyclosporine	0-12	coagulation factor II, thrombin	Homo sapiens	224-232
19530699-8	2009	DVs of (11)C-7 and (11)C-verapamil were significantly increased by CsA (to 5.26 +/- 0.14 and 5.85 +/- 0.32, respectively).	Cyclosporine	67-70	complement C7	Rattus norvegicus	11-14
19564346-4	2009	We show that the immunosuppressant cyclosporine A, which has been linked to a thymus-dependent autoimmune syndrome in some patients, causes extensive loss of autoimmune regulator (Aire(+)) tolerance-inducing MHC class II(high) medullary TEC (mTEC(high)).	Cyclosporine	35-49	autoimmune regulator	Homo sapiens	158-178
19564346-4	2009	We show that the immunosuppressant cyclosporine A, which has been linked to a thymus-dependent autoimmune syndrome in some patients, causes extensive loss of autoimmune regulator (Aire(+)) tolerance-inducing MHC class II(high) medullary TEC (mTEC(high)).	Cyclosporine	35-49	autoimmune regulator	Homo sapiens	180-184
19564346-5	2009	Post-cyclosporine A, Aire expression was restored within 7 days.	Cyclosporine	5-19	autoimmune regulator	Homo sapiens	21-25
19447222-6	2009	The effect was reversed by the MDR1 inhibitor cyclosporine.	Cyclosporine	46-58	ATP binding cassette subfamily B member 1	Homo sapiens	31-35
19448042-5	2009	Body weight (WT), serum albumin level (ALB), and combination therapy with rifampicin were found to be the most significant covariates explaining the variability of the apparent clearance (CL/F) of CsA among patients.	Cyclosporine	197-200	albumin	Homo sapiens	24-31
19562680-6	2009	In the presence of cyclosporin A and verapamil, potent inhibitors of P-glycoprotein (P-gp), the P(ratio) decreased from 3.8 to 2.3 and 1.8, respectively, and permeation of apical to basolateral was enhanced.	Cyclosporine	19-32	ATP binding cassette subfamily B member 1	Homo sapiens	69-83
19562680-6	2009	In the presence of cyclosporin A and verapamil, potent inhibitors of P-glycoprotein (P-gp), the P(ratio) decreased from 3.8 to 2.3 and 1.8, respectively, and permeation of apical to basolateral was enhanced.	Cyclosporine	19-32	ATP binding cassette subfamily B member 1	Homo sapiens	85-89
19614980-10	2009	Cyclosporin A, a ligand of the permeability transition pore complex component cyclophilin D, prevented L-glutamine-triggered apoptosis.	Cyclosporine	0-13	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	78-91
19448042-5	2009	Body weight (WT), serum albumin level (ALB), and combination therapy with rifampicin were found to be the most significant covariates explaining the variability of the apparent clearance (CL/F) of CsA among patients.	Cyclosporine	197-200	albumin	Homo sapiens	39-42
19145636-5	2009	Moreover, the expression of Th1/Th2 mRNA cytokines (IL-2, IL-4, IL-5, IL-13) from mouse splenocytes was inhibited severely as was cyclosporine A.	Cyclosporine	130-144	negative elongation factor complex member C/D, Th1l	Mus musculus	28-31
19145636-5	2009	Moreover, the expression of Th1/Th2 mRNA cytokines (IL-2, IL-4, IL-5, IL-13) from mouse splenocytes was inhibited severely as was cyclosporine A.	Cyclosporine	130-144	interleukin 13	Mus musculus	70-75
19715866-1	2009	BACKGROUND: Mammalian target of rapamycin (mTOR) inhibitors behave as potent immunosuppressants which have the advantages, with respect to calcineurin inhibitors (CNI: cyclosporine or tacrolimus), of no nephrotoxicity and inhibition of cell proliferation.	Cyclosporine	168-180	mechanistic target of rapamycin kinase	Homo sapiens	43-47
19285518-0	2009	Dehydromonocrotaline induces cyclosporine A-insensitive mitochondrial permeability transition/cytochrome c release.	Cyclosporine	29-43	cytochrome c, somatic	Homo sapiens	94-106
19344364-4	2009	RESULTS: We show that inhibition of protein phosphatase 2B (PP2B) activity by cyclosporine A (CsA), tacrolimus or a cell-permeable PP2B autoinhibitory peptide promotes the secretion of ultralarge von Willebrand factor (ULVWF) from human umbilical vein endothelial cells (HUVECs) in the absence of any other endothelial cell-stimulating agent.	Cyclosporine	78-92	von Willebrand factor	Homo sapiens	196-217
19293339-3	2009	Treatment with cyclosporin (Cs) A, a drug that desensitizes the PTP by binding to cyclophilin (Cyp)-D, was shown to rescue myofiber alterations in Col6a1(-/-) mice and in UCMD patients, suggesting a correlation between PTP opening and pathogenesis of ColVI muscular dystrophies.	Cyclosporine	15-26	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	95-101
19293339-3	2009	Treatment with cyclosporin (Cs) A, a drug that desensitizes the PTP by binding to cyclophilin (Cyp)-D, was shown to rescue myofiber alterations in Col6a1(-/-) mice and in UCMD patients, suggesting a correlation between PTP opening and pathogenesis of ColVI muscular dystrophies.	Cyclosporine	28-30	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	95-101
19470683-0	2009	ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome.	Cyclosporine	24-36	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
19470683-1	2009	Cyclosporine A (CsA) is a substrate of P-glycoprotein, an efflux transporter encoded by the ABCB1 gene.	Cyclosporine	0-14	ATP binding cassette subfamily B member 1	Homo sapiens	39-53
19470683-1	2009	Cyclosporine A (CsA) is a substrate of P-glycoprotein, an efflux transporter encoded by the ABCB1 gene.	Cyclosporine	0-14	ATP binding cassette subfamily B member 1	Homo sapiens	92-97
19470683-1	2009	Cyclosporine A (CsA) is a substrate of P-glycoprotein, an efflux transporter encoded by the ABCB1 gene.	Cyclosporine	16-19	ATP binding cassette subfamily B member 1	Homo sapiens	39-53
19470683-1	2009	Cyclosporine A (CsA) is a substrate of P-glycoprotein, an efflux transporter encoded by the ABCB1 gene.	Cyclosporine	16-19	ATP binding cassette subfamily B member 1	Homo sapiens	92-97
19470683-2	2009	Compared with carriers of the wild-type gene, carriers of T allelic variants in exons 21 or 26 have reduced P-glycoprotein activity and, secondarily, increased intracellular concentration of CsA; therefore, carriers of T variants might be at increased risk for CsA-related adverse events.	Cyclosporine	191-194	ATP binding cassette subfamily B member 1	Homo sapiens	108-122
19470683-2	2009	Compared with carriers of the wild-type gene, carriers of T allelic variants in exons 21 or 26 have reduced P-glycoprotein activity and, secondarily, increased intracellular concentration of CsA; therefore, carriers of T variants might be at increased risk for CsA-related adverse events.	Cyclosporine	261-264	ATP binding cassette subfamily B member 1	Homo sapiens	108-122
19470683-3	2009	We evaluated the associations between ABCB1 genotypes (in exons 12, 21, and 26) and CsA-related outcomes in 147 renal transplant recipients who were receiving CsA-based immunosuppression and were included in the Mycophenolate Steroids Sparing study.	Cyclosporine	84-87	ATP binding cassette subfamily B member 1	Homo sapiens	38-43
19470683-7	2009	In conclusion, renal transplant recipients with T allelic variants in ABCB1 exons 21 or 26 are at increased risk for CsA-related adverse events.	Cyclosporine	117-120	ATP binding cassette subfamily B member 1	Homo sapiens	70-75
19454717-0	2009	Suppression of NF-kappaB by cyclosporin a and tacrolimus (FK506) via induction of the C/EBP family: implication for unfolded protein response.	Cyclosporine	28-41	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	15-24
19454717-3	2009	We found that, in renal tubular cells, induction of MCP-1 by inflammatory cytokines was blunted by CsA and FK506.	Cyclosporine	99-102	mast cell protease 1	Mus musculus	52-57
19454717-7	2009	In TNF-alpha-treated cells, suppression of MCP-1 by CsA or FK506 was associated with blunted responses of NF-kappaB, the crucial regulator of MCP-1.	Cyclosporine	52-55	tumor necrosis factor	Mus musculus	3-12
19454717-7	2009	In TNF-alpha-treated cells, suppression of MCP-1 by CsA or FK506 was associated with blunted responses of NF-kappaB, the crucial regulator of MCP-1.	Cyclosporine	52-55	mast cell protease 1	Mus musculus	43-48
19454717-7	2009	In TNF-alpha-treated cells, suppression of MCP-1 by CsA or FK506 was associated with blunted responses of NF-kappaB, the crucial regulator of MCP-1.	Cyclosporine	52-55	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	106-115
19454717-7	2009	In TNF-alpha-treated cells, suppression of MCP-1 by CsA or FK506 was associated with blunted responses of NF-kappaB, the crucial regulator of MCP-1.	Cyclosporine	52-55	mast cell protease 1	Mus musculus	142-147
19454717-9	2009	CsA and FK506, as well as other UPR inducers, caused up-regulation of C/EBP family members, especially C/EBPbeta and CHOP (C/EBP homologous protein), and overexpression of either C/EBPbeta or CHOP significantly attenuated TNF-alpha-triggered NF-kappaB activation.	Cyclosporine	0-3	tumor necrosis factor	Mus musculus	222-231
19454717-9	2009	CsA and FK506, as well as other UPR inducers, caused up-regulation of C/EBP family members, especially C/EBPbeta and CHOP (C/EBP homologous protein), and overexpression of either C/EBPbeta or CHOP significantly attenuated TNF-alpha-triggered NF-kappaB activation.	Cyclosporine	0-3	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	242-251
19454717-10	2009	Furthermore, down-regulation of C/EBPbeta by small interfering RNA substantially reversed the suppressive effect of CsA on TNF-alpha-induced MCP-1 expression.	Cyclosporine	116-119	tumor necrosis factor	Mus musculus	123-132
19454717-10	2009	Furthermore, down-regulation of C/EBPbeta by small interfering RNA substantially reversed the suppressive effect of CsA on TNF-alpha-induced MCP-1 expression.	Cyclosporine	116-119	mast cell protease 1	Mus musculus	141-146
19344364-9	2009	CONCLUSIONS: These observations suggest that CsA promotes VWF release, in part by inhibition of PP2B activity, and are compatible with the clinically observed association of CsA treatment and increased plasma VWF levels in humans.	Cyclosporine	45-48	von Willebrand factor	Homo sapiens	58-61
19344364-9	2009	CONCLUSIONS: These observations suggest that CsA promotes VWF release, in part by inhibition of PP2B activity, and are compatible with the clinically observed association of CsA treatment and increased plasma VWF levels in humans.	Cyclosporine	45-48	von Willebrand factor	Homo sapiens	209-212
19344364-9	2009	CONCLUSIONS: These observations suggest that CsA promotes VWF release, in part by inhibition of PP2B activity, and are compatible with the clinically observed association of CsA treatment and increased plasma VWF levels in humans.	Cyclosporine	174-177	von Willebrand factor	Homo sapiens	209-212
19806896-8	2009	Different P-gp inhibitors CyA or verapamil (VER) or digoxin (DGX) decreased the urinary GB excretion, the urinary excretion of GB in 0-8 h were about 34.8% (P &lt; 0.001), 59.4% (P &lt; 0.001) and 79.7% (P &lt; 0.05) of the control, separately.	Cyclosporine	26-29	phosphoglycolate phosphatase	Rattus norvegicus	10-14
19694312-8	2009	A high apoptotic index and TGF-beta intensity was observed in the Cyclosporine A group.	Cyclosporine	66-80	transforming growth factor, beta 1	Rattus norvegicus	27-35
19694312-11	2009	This study indicates that Cyclosporine A can enhance the TGF-beta expression in rat kidney, signifying accelerated apoptosis.	Cyclosporine	26-40	transforming growth factor, beta 1	Rattus norvegicus	57-65
19545743-8	2009	Allografts of As(2)O(3)-treated and As(2)O(3) plus CsA-treated mice showed a changing pattern of Th1/Th2 cytokine mRNA expression.	Cyclosporine	51-54	negative elongation factor complex member C/D, Th1l	Mus musculus	97-100
19346981-7	2009	African Americans who were carriers of the FST T(-5003) allele (n = 12) had greater baseline 1RM (11.9 +/- 0.7 vs 8.8 +/- 0.5 kg) and CSA (24.4 +/- 1.3 vs 19.1 +/- 1.2 cm(2)) than African Americans with the A-5003A genotype (n = 14; P &lt; 0.05).	Cyclosporine	134-137	follistatin	Homo sapiens	43-46
19429419-3	2009	The change in the mRNA expression of MDR1 was accompanied by a change in the CsA-dependent intracellular accumulation of rhodamine 123.	Cyclosporine	77-80	ATP binding cassette subfamily B member 1	Homo sapiens	37-41
19200788-7	2009	In vitro experiments showed that CsA and dexamethasone could decrease the frequencies of Th1 and Th17 cells and inhibit IL-17 and IFN-gamma production.	Cyclosporine	33-36	interferon gamma	Homo sapiens	130-139
18486150-3	2009	We have proposed that cyclosporin A (CsA), despite being a calcineurin inhibitor, will activate PKC in B cells, thus promoting Epstein-Barr virus (EBV)-induced transformation.	Cyclosporine	22-35	protein kinase C alpha	Homo sapiens	96-99
19233265-6	2009	Embryos treated in utero with the calcineurin inhibitor cyclosporine-A showed cytoplasmic NFATc1, diminished podoplanin and FGFR-3 expression by the lymphatics and irregular patterning of the LEC sprouts coming off the jugular lymph sac, which suggests a role for calcineurin-NFAT signaling in lymphatic patterning.	Cyclosporine	56-70	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	90-96
19530439-7	2009	After treatment of the MDR1-expressing HeLa cells with MDR1 substrate vinblastin or inhibitors cyclosporin A and verapamil, the amount of R-123 retained in the cells was increased to 2 to 2.3 times the level in untreated MDR1-expressing HeLa cells.	Cyclosporine	95-108	ATP binding cassette subfamily B member 1	Homo sapiens	23-27
19193738-7	2009	RESULTS: COX-2 in cultured vascular smooth muscle cells was suppressed by cyclosporine A (CsA); tacrolimus and rapamycin had no effect.	Cyclosporine	74-88	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	9-14
19193738-7	2009	RESULTS: COX-2 in cultured vascular smooth muscle cells was suppressed by cyclosporine A (CsA); tacrolimus and rapamycin had no effect.	Cyclosporine	90-93	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	9-14
19193738-13	2009	CONCLUSIONS: Although CsA suppressed COX-2 in cultured vascular smooth muscle cells, systemic prostacyclin was not suppressed by either CsA or tacrolimus in vivo.	Cyclosporine	22-25	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	37-42
19343062-1	2009	AIM: To evaluate the potential drug-drug interactions between bifendate and cyclosporine, a substrate of CYP3A4, in relation to different CYP3A4*18B genotype groups.	Cyclosporine	76-88	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	105-111
19418307-8	2009	With respect to these untreated allografts, CsA lowered mRNA levels of MMP-7, TIMP-1/-3 (TIMP-2/-4 remained relatively low) and ADAM17, but augmented mRNA levels of MMP-11/-16/-23 and of many ECM genes.	Cyclosporine	44-47	ADAM metallopeptidase domain 17	Rattus norvegicus	128-134
19228691-5	2009	A cyclophilin D inhibitor, cyclosporine A, disrupts the CypD-Bcl2 interaction.	Cyclosporine	27-41	BCL2 apoptosis regulator	Homo sapiens	61-65
19343062-1	2009	AIM: To evaluate the potential drug-drug interactions between bifendate and cyclosporine, a substrate of CYP3A4, in relation to different CYP3A4*18B genotype groups.	Cyclosporine	76-88	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	138-144
19343062-7	2009	The oral clearance of cyclosporine was altered in all the subjects, with substantial increases by 10.2%+/-4.4% (P=0.004) in CYP3A4*1/*1 subjects, 14.0%+/-12.0% (P=0.048) in CYP3A4*1/*18B subjects, and 32.4%+/-21.7% (P=0.013) in CYP3A4*18B/*18B subjects.	Cyclosporine	22-34	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	124-130
19343062-7	2009	The oral clearance of cyclosporine was altered in all the subjects, with substantial increases by 10.2%+/-4.4% (P=0.004) in CYP3A4*1/*1 subjects, 14.0%+/-12.0% (P=0.048) in CYP3A4*1/*18B subjects, and 32.4%+/-21.7% (P=0.013) in CYP3A4*18B/*18B subjects.	Cyclosporine	22-34	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	173-179
19343062-7	2009	The oral clearance of cyclosporine was altered in all the subjects, with substantial increases by 10.2%+/-4.4% (P=0.004) in CYP3A4*1/*1 subjects, 14.0%+/-12.0% (P=0.048) in CYP3A4*1/*18B subjects, and 32.4%+/-21.7% (P=0.013) in CYP3A4*18B/*18B subjects.	Cyclosporine	22-34	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	173-179
19343062-8	2009	CONCLUSION: These results suggest that bifendate decreases the plasma concentration of cyclosporine in a CYP3A4 genotype-dependent manner.	Cyclosporine	87-99	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	105-111
19336891-0	2009	Evaluation of interleukin-2 mRNA in whole blood as a parameter for monitoring cyclosporine pharmacodynamics.	Cyclosporine	78-90	interleukin 2	Homo sapiens	14-27
19336891-3	2009	We measured the suppression of IL-2 mRNA expression in whole blood following the addition of a range of CsA concentrations by a real-time reverse transcription-polymerase chain reaction (RT-PCR) method.	Cyclosporine	104-107	interleukin 2	Homo sapiens	31-35
19336891-4	2009	Individual CsA sensitivity on the IL-2 mRNA expression was assessed with healthy subjects both in vitro and ex vivo.	Cyclosporine	11-14	interleukin 2	Homo sapiens	34-38
19336891-6	2009	Sigmoid E(max) model was used to analyze the relationship between CsA concentration and IL-2 mRNA expression.	Cyclosporine	66-69	interleukin 2	Homo sapiens	88-92
19292871-4	2009	Activation of JNK by morphine led to reactive oxygen species (ROS) generation via the mitochondrial permeability transition pore, because the mPTP inhibitor cyclosporin A significantly inhibited ROS generation.	Cyclosporine	157-170	mitogen-activated protein kinase 8	Homo sapiens	14-17
19292871-5	2009	ROS in turn exerted feedback regulation on JNK activation, as shown by the observations that cyclosporin A and the antioxidant N-acetylcysteine significantly inhibited the phosphorylation of JNK induced by morphine.	Cyclosporine	93-106	mitogen-activated protein kinase 8	Homo sapiens	43-46
19292871-5	2009	ROS in turn exerted feedback regulation on JNK activation, as shown by the observations that cyclosporin A and the antioxidant N-acetylcysteine significantly inhibited the phosphorylation of JNK induced by morphine.	Cyclosporine	93-106	mitogen-activated protein kinase 8	Homo sapiens	191-194
19399405-0	2009	The effects of PDTC plus leflunomide and cyclosporine on the NF-kappaB signaling pathway in mouse-to-rat cardiac xenografts.	Cyclosporine	41-53	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	61-70
19287956-7	2009	CsA also elevated the expressions of both Bcl-2 and ERK1/2.	Cyclosporine	0-3	BCL2 apoptosis regulator	Homo sapiens	42-47
19287956-7	2009	CsA also elevated the expressions of both Bcl-2 and ERK1/2.	Cyclosporine	0-3	mitogen-activated protein kinase 3	Homo sapiens	52-58
19287956-8	2009	Fibronectin guided migration of HT168 cells was stimulated under the effect of CsA, while that of WM35 cells was reduced, moreover, HT168 cells switched from the expression of beta3 to beta1 integrin, but WM35 cells continued to express beta3.	Cyclosporine	79-82	fibronectin 1	Homo sapiens	0-11
19399405-1	2009	In this study, the effects of pirrolidine dithiocarbamate (PDTC) plus leflunomide (Lef) and cyclosporine (CsA) on the NF-kappaB signaling pathway in mouse-to-rat cardiac xeno-transplantation models were investigated.	Cyclosporine	92-104	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	118-127
19376366-0	2009	Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients.	Cyclosporine	107-119	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	25-31
19193795-9	2009	In BCG-immune mice the resistance to VV infection and VV-induced CD4 T-cell IFN-gamma production were ablated by cyclosporine A, which inhibits signaling through the T-cell receptor.	Cyclosporine	113-127	interferon gamma	Mus musculus	76-85
19376366-0	2009	Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients.	Cyclosporine	107-119	ATP binding cassette subfamily B member 1	Homo sapiens	36-40
19112104-6	2009	Cyclophilin A was produced and secreted into the media to a much greater extent than cyclophilins B and C. Our results also identified the direct CsA-sensitive interaction of cyclophilin A with hensin, suggesting that cyclophilin A is the PPIase that mediates the polymerization and matrix assembly of hensin.	Cyclosporine	146-149	peptidyl-prolyl cis-trans isomerase A	Oryctolagus cuniculus	0-13
19112104-6	2009	Cyclophilin A was produced and secreted into the media to a much greater extent than cyclophilins B and C. Our results also identified the direct CsA-sensitive interaction of cyclophilin A with hensin, suggesting that cyclophilin A is the PPIase that mediates the polymerization and matrix assembly of hensin.	Cyclosporine	146-149	peptidyl-prolyl cis-trans isomerase A	Oryctolagus cuniculus	175-188
19112104-6	2009	Cyclophilin A was produced and secreted into the media to a much greater extent than cyclophilins B and C. Our results also identified the direct CsA-sensitive interaction of cyclophilin A with hensin, suggesting that cyclophilin A is the PPIase that mediates the polymerization and matrix assembly of hensin.	Cyclosporine	146-149	peptidyl-prolyl cis-trans isomerase A	Oryctolagus cuniculus	218-231
19136475-3	2009	Here, we investigated the mechanism of the human non-genotoxic carcinogen cyclosporine A (CsA) in the Xpa/p53 mouse model.	Cyclosporine	90-93	XPA, DNA damage recognition and repair factor	Homo sapiens	102-105
19047468-5	2009	The effect of P-gp inhibition was investigated by administering cyclosporin A (CsA).	Cyclosporine	64-77	ATP binding cassette subfamily B member 1	Homo sapiens	14-18
19006121-3	2009	Cytochrome c release was ascribed to mitochondrial permeability transition (MPT) because the release was prevented by cyclosporine (CsA), a specific inhibitor of MPT.	Cyclosporine	118-130	cytochrome c, somatic	Homo sapiens	0-12
18936931-0	2009	Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem.	Cyclosporine	54-66	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	35-41
18936931-0	2009	Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem.	Cyclosporine	54-66	ATP binding cassette subfamily B member 1	Homo sapiens	46-50
18936931-8	2009	CONCLUSION: This study demonstrated that the G2677T/A single nucleotide polymorphisms in MDR1 and MDR1 haplotypes C-G-C, T-G-T and T-T-C are associated with the CsA concentration during the very early post-transplant period in Chinese renal transplant patients co-treated with diltiazem.	Cyclosporine	161-164	ATP binding cassette subfamily B member 1	Homo sapiens	89-93
18936931-8	2009	CONCLUSION: This study demonstrated that the G2677T/A single nucleotide polymorphisms in MDR1 and MDR1 haplotypes C-G-C, T-G-T and T-T-C are associated with the CsA concentration during the very early post-transplant period in Chinese renal transplant patients co-treated with diltiazem.	Cyclosporine	161-164	ATP binding cassette subfamily B member 1	Homo sapiens	98-102
19006121-3	2009	Cytochrome c release was ascribed to mitochondrial permeability transition (MPT) because the release was prevented by cyclosporine (CsA), a specific inhibitor of MPT.	Cyclosporine	132-135	cytochrome c, somatic	Homo sapiens	0-12
19006121-9	2009	In the presence of CsA, Bax was still activated at the end-stage of apoptotic process caused by HF-LPLI, suggesting that Bax was involved in an alternative-signaling pathway, which was independent of MPT.	Cyclosporine	19-22	BCL2 associated X, apoptosis regulator	Homo sapiens	24-27
19006121-9	2009	In the presence of CsA, Bax was still activated at the end-stage of apoptotic process caused by HF-LPLI, suggesting that Bax was involved in an alternative-signaling pathway, which was independent of MPT.	Cyclosporine	19-22	BCL2 associated X, apoptosis regulator	Homo sapiens	121-124
19247234-6	2009	In CyA-treated cultures, concentrations greater than 10 000 ng/mL were associated with decreased ALP activity after 8 days (P&lt;0.05).	Cyclosporine	3-6	alkaline phosphatase, placental	Homo sapiens	97-100
18692599-3	2009	The aim of the present study was to investigate the effects of immunosuppressive drugs cyclosporin A (CsA), tacrolimus (FK-506) and pimecrolimus on NO production through iNOS pathway in activated macrophages and fibroblasts.	Cyclosporine	87-100	nitric oxide synthase 2	Homo sapiens	170-174
19183931-7	2009	CYP3A4 inducers can lower levels of cyclosporine or tacrolimus so much that transplant rejection occurs, and CYP3A4 inhibitors can increase their levels, leading to nephrotoxicity.	Cyclosporine	36-48	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
20641209-5	2004	Calcium channel blockers, cyclosporin, and its non-immunosuppressive analog PSC 833 are MDR modulators that inhibit the transport of P-gp substrates out of the cells (6, 7).	Cyclosporine	26-37	ATP binding cassette subfamily B member 1	Homo sapiens	133-137
18793723-9	2009	PAC permeability was significantly increased in the presence of the pgp/CYP3A4 inhibitor cyclosporine A (CsA).	Cyclosporine	89-103	phosphoglycolate phosphatase	Rattus norvegicus	68-71
18793723-9	2009	PAC permeability was significantly increased in the presence of the pgp/CYP3A4 inhibitor cyclosporine A (CsA).	Cyclosporine	105-108	phosphoglycolate phosphatase	Rattus norvegicus	68-71
18692599-3	2009	The aim of the present study was to investigate the effects of immunosuppressive drugs cyclosporin A (CsA), tacrolimus (FK-506) and pimecrolimus on NO production through iNOS pathway in activated macrophages and fibroblasts.	Cyclosporine	102-105	nitric oxide synthase 2	Homo sapiens	170-174
18692599-4	2009	Calcineurin inhibitors (CsA, FK-506 and pimecrolimus) inhibited NO production and iNOS expression in a concentration-dependent manner, CsA being more potent than FK-506 and pimecrolimus.	Cyclosporine	24-27	nitric oxide synthase 2	Homo sapiens	82-86
18692599-4	2009	Calcineurin inhibitors (CsA, FK-506 and pimecrolimus) inhibited NO production and iNOS expression in a concentration-dependent manner, CsA being more potent than FK-506 and pimecrolimus.	Cyclosporine	135-138	nitric oxide synthase 2	Homo sapiens	82-86
19118153-4	2009	To attenuate NFATc1 activity further, we injected cyclosporin A daily.	Cyclosporine	50-63	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	13-19
19118153-5	2009	Cyclosporin A-treated Nfatc1(+/-) mice demonstrated rapid and severe injury after administration of mercuric chloride, with increased serum creatinine, increased apoptosis, decreased PTC proliferation, and increased mortality compared with similarly treated wild-type mice.	Cyclosporine	0-13	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	22-28
18973526-8	2009	CONCLUSION: Based on the present findings, we suggest that: (1) CsA upregulates the gingival expression of ET-1 and its receptors; and (2) ET(A) and ET(B) have different bioactivities, ET(A) being involved in cell proliferation and ET(B) being associated with iNOS expression.	Cyclosporine	64-67	nitric oxide synthase 2	Rattus norvegicus	260-264
18973526-0	2009	Expression and bioactivities of endothelin-1 in gingiva during cyclosporine A treatment.	Cyclosporine	63-77	endothelin 1	Rattus norvegicus	32-44
18973526-1	2009	BACKGROUND AND OBJECTIVE: This study aimed to evaluate the expression and bioactivities of endothelin-1 (ET-1) in gingiva during cyclosporine A (CsA) treatment.	Cyclosporine	129-143	endothelin 1	Rattus norvegicus	91-103
18962896-7	2009	Cyclosporine A treatment on wild type Th2 cells or Th2 cells derived from NFAT1 knockout (NFAT1(-/-)) mice showed significantly reduced trans-activity of CNS-9.	Cyclosporine	0-14	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2	Mus musculus	90-95
18973526-1	2009	BACKGROUND AND OBJECTIVE: This study aimed to evaluate the expression and bioactivities of endothelin-1 (ET-1) in gingiva during cyclosporine A (CsA) treatment.	Cyclosporine	129-143	endothelin 1	Rattus norvegicus	105-109
18973526-1	2009	BACKGROUND AND OBJECTIVE: This study aimed to evaluate the expression and bioactivities of endothelin-1 (ET-1) in gingiva during cyclosporine A (CsA) treatment.	Cyclosporine	145-148	endothelin 1	Rattus norvegicus	91-103
18973526-1	2009	BACKGROUND AND OBJECTIVE: This study aimed to evaluate the expression and bioactivities of endothelin-1 (ET-1) in gingiva during cyclosporine A (CsA) treatment.	Cyclosporine	145-148	endothelin 1	Rattus norvegicus	105-109
18973526-3	2009	The roles of the endothelin receptors A and B (ET(A) and ET(B)) in CsA-enhanced expression of PCNA and iNOS were examined in cultured human gingival fibroblasts pretreated with receptor antagonists, by immunocytochemistry and RT-PCR, respectively.	Cyclosporine	67-70	endothelin receptor type B	Homo sapiens	17-45
18973526-3	2009	The roles of the endothelin receptors A and B (ET(A) and ET(B)) in CsA-enhanced expression of PCNA and iNOS were examined in cultured human gingival fibroblasts pretreated with receptor antagonists, by immunocytochemistry and RT-PCR, respectively.	Cyclosporine	67-70	endothelin receptor type B	Homo sapiens	57-62
18973526-3	2009	The roles of the endothelin receptors A and B (ET(A) and ET(B)) in CsA-enhanced expression of PCNA and iNOS were examined in cultured human gingival fibroblasts pretreated with receptor antagonists, by immunocytochemistry and RT-PCR, respectively.	Cyclosporine	67-70	nitric oxide synthase 2	Homo sapiens	103-107
18973526-4	2009	RESULTS: The mRNA expression of ET-1, ET(A) and ET(B), as well as of PCNA and iNOS, was significantly greater in edentulous gingiva that received CsA compared with control gingiva.	Cyclosporine	146-149	endothelin 1	Rattus norvegicus	32-36
18973526-4	2009	RESULTS: The mRNA expression of ET-1, ET(A) and ET(B), as well as of PCNA and iNOS, was significantly greater in edentulous gingiva that received CsA compared with control gingiva.	Cyclosporine	146-149	nitric oxide synthase 2	Rattus norvegicus	78-82
18973526-5	2009	Immunohistochemistry revealed more cells positively stained for ET-1 and its receptors in the tissues of CsA-treated rats than in those of control rats.	Cyclosporine	105-108	endothelin 1	Rattus norvegicus	64-68
18973526-6	2009	In fibroblast cultures, enhanced mRNA expression of ET-1, ET(A) and ET(B) was observed after CsA treatment at the concentrations of 10 and 100 ng/mL.	Cyclosporine	93-96	endothelin 1	Rattus norvegicus	52-56
18973526-8	2009	CONCLUSION: Based on the present findings, we suggest that: (1) CsA upregulates the gingival expression of ET-1 and its receptors; and (2) ET(A) and ET(B) have different bioactivities, ET(A) being involved in cell proliferation and ET(B) being associated with iNOS expression.	Cyclosporine	64-67	endothelin 1	Rattus norvegicus	107-111
18962896-7	2009	Cyclosporine A treatment on wild type Th2 cells or Th2 cells derived from NFAT1 knockout (NFAT1(-/-)) mice showed significantly reduced trans-activity of CNS-9.	Cyclosporine	0-14	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2	Mus musculus	74-79
19070591-6	2009	In in vivo experiments using thoracic aortic endothelium from hyperlipidemic rats, CsA resulted in dose-dependent down-regulation of DAF, and accompanying endothelial damage.	Cyclosporine	83-86	CD55 molecule (Cromer blood group)	Rattus norvegicus	133-136
19017630-7	2009	The effects of erbB2 antibody on both cell death and ROS production were also reversed by cyclosporine A and diazoxide, chemicals that regulate the pro- and anti-apoptotic channels in the mitochondria, respectively.	Cyclosporine	90-104	erb-b2 receptor tyrosine kinase 2	Homo sapiens	15-20
19408691-8	2009	The P-glycoprotein inhibitor cyclosporine A significantly enhanced the transport amount of aripiprazole.	Cyclosporine	29-43	ATP binding cassette subfamily B member 1	Homo sapiens	4-18
18945718-7	2009	Mitochondrial [Ca(2+)] remained elevated long after the end of stimulation in muscle cells from terminally ill Tfam KO mice, and the increase was smaller in the presence of the cyclophilin D-binding inhibitor cyclosporin A.	Cyclosporine	209-222	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	177-190
19028555-6	2009	The effects were inhibited by cyclosporine A (CsA), suggesting that the activation of NFAT by AhR or HIF-1alpha signaling is calcineurin-dependent.	Cyclosporine	30-44	hypoxia inducible factor 1 subunit alpha	Homo sapiens	101-111
19028555-6	2009	The effects were inhibited by cyclosporine A (CsA), suggesting that the activation of NFAT by AhR or HIF-1alpha signaling is calcineurin-dependent.	Cyclosporine	46-49	hypoxia inducible factor 1 subunit alpha	Homo sapiens	101-111
19099400-1	2009	The clinical use of the immunosuppressant calcineurin inhibitor cyclosporine is limited by its nephrotoxicity.	Cyclosporine	64-76	calcineurin binding protein 1	Rattus norvegicus	42-63
19818214-2	2009	Anti-TNF agents were developed approximately one decade ago by rheumatologists and today represent one of the most effective classes of drugs in severe psoriasis resistant to 2 out of 3 "classic" systemic therapies (methotrexate, cyclosporine, and PUVA).	Cyclosporine	230-242	tumor necrosis factor	Homo sapiens	5-8
19728747-9	2009	Ciclosporin and tacrolimus have distinct pharmacokinetics, but both are metabolized by intestinal and hepatic CYP3A4/3A5 and transported across the cell membrane by P-glycoprotein.	Cyclosporine	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	110-116
19728747-9	2009	Ciclosporin and tacrolimus have distinct pharmacokinetics, but both are metabolized by intestinal and hepatic CYP3A4/3A5 and transported across the cell membrane by P-glycoprotein.	Cyclosporine	0-11	ATP binding cassette subfamily B member 1	Homo sapiens	165-179
19470292-10	2009	The effects produced by some of these components are found to be comparable to those of well-known P-gp inhibitors verapamil and cyclosporine.	Cyclosporine	129-141	ATP binding cassette subfamily B member 1	Homo sapiens	99-103
18842703-8	2009	Our study clearly demonstrates for the first time that liver I/R decreases the oral bioavailability of CsA and that this is attributable principally to increased first-pass metabolism mediated by CYP3A and P-gp in the upper small intestine.	Cyclosporine	103-106	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	196-201
19839837-0	2009	Cyclosporine induces endothelin-1 mRNA synthesis and nitric oxide production in human proximal tubular epithelial cell cultures.	Cyclosporine	0-12	endothelin 1	Homo sapiens	21-33
19096323-0	2009	Erlotinib combined with cyclosporine in a liver-transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer.	Cyclosporine	24-36	epidermal growth factor receptor	Homo sapiens	74-106
19960055-5	2009	After the control phase of each experiment, the P-glycoprotein inhibitor ciclosporin A was added at middle perfusion (45 minutes).	Cyclosporine	73-86	ATP binding cassette subfamily B member 1	Homo sapiens	48-62
19252740-0	2009	HNF4alpha and HNF1alpha dysfunction as a molecular rational for cyclosporine induced posttransplantation diabetes mellitus.	Cyclosporine	64-76	hepatocyte nuclear factor 4 alpha	Homo sapiens	0-9
19252740-4	2009	Furthermore, cyclosporine treatment of the insulinoma-1E cell line resulted in remarkable reduction in HNF4alpha protein and INS1 as well as INS2 gene expression, while transcript expression of HNF4alpha, apolipoprotein C2, glycerolkinase, pyruvatekinase and aldolase B was repressed in treated Caco-2 cells.	Cyclosporine	13-25	hepatocyte nuclear factor 4 alpha	Homo sapiens	103-112
19252740-4	2009	Furthermore, cyclosporine treatment of the insulinoma-1E cell line resulted in remarkable reduction in HNF4alpha protein and INS1 as well as INS2 gene expression, while transcript expression of HNF4alpha, apolipoprotein C2, glycerolkinase, pyruvatekinase and aldolase B was repressed in treated Caco-2 cells.	Cyclosporine	13-25	hepatocyte nuclear factor 4 alpha	Homo sapiens	194-203
19252740-6	2009	As cyclosporine inhibits the calcineurin dependent dephosphorylation of nuclear factor of activated T-cells (NFAT) we also searched for binding sites for NFAT in the pancreas specific P2 promoter of HNF4alpha.	Cyclosporine	3-15	hepatocyte nuclear factor 4 alpha	Homo sapiens	199-208
19252740-8	2009	Thus, cyclosporine caused inhibition of DNA binding of two important regulators for insulin signaling, i.e. NFAT and HNF4alpha.	Cyclosporine	6-18	hepatocyte nuclear factor 4 alpha	Homo sapiens	117-126
19252740-11	2009	We propose cyclosporine to repress HNF4alpha gene and protein expression, DNA-binding to targeted promoters and subsequent regulation of genes coding for glucose metabolism and of pancreatic beta-cell function.	Cyclosporine	11-23	hepatocyte nuclear factor 4 alpha	Homo sapiens	35-44
19925294-7	2009	RESULTS: The administration of CsA alone resulted in higher myeloperoxidase (MPO) activity, lipid peroxidation, superoxide dismutase (SOD), and catalase (CAT) than in the control.	Cyclosporine	31-34	catalase	Rattus norvegicus	144-152
19925294-7	2009	RESULTS: The administration of CsA alone resulted in higher myeloperoxidase (MPO) activity, lipid peroxidation, superoxide dismutase (SOD), and catalase (CAT) than in the control.	Cyclosporine	31-34	catalase	Rattus norvegicus	154-157
19839837-3	2009	The effect of CsA on the activation of tubular epithelial cells towards increased production of ET-1 and NO was investigated in this study.	Cyclosporine	14-17	endothelin 1	Homo sapiens	96-107
19839837-8	2009	A dose-dependent up-regulation of ET-1 mRNA production and NO accumulation was observed under the influence of CsA.	Cyclosporine	111-114	endothelin 1	Homo sapiens	34-38
19839837-9	2009	CONCLUSION: Increased synthesis of endothelin-1 mRNA and nitric oxide as well as a significant cytotoxic effect on tubular epithelial cells under the influence of CsA might be related to the development of CsA nephrotoxicity.	Cyclosporine	206-209	endothelin 1	Homo sapiens	35-47
19076452-4	2008	Consistently, the Col6a1(-/-) myopathic mice could be cured with cyclosporin A through inhibition of cyclophilin D, a matrix protein that sensitizes the pore to opening.	Cyclosporine	65-78	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	101-114
19249526-3	2009	We have reported herein the efficacy of divided administration of interferon (IFN) beta plus cyclosporine for chronic hepatitis C patients who failed pegylated (Peg)-IFN or IFN combined ribavirin treatment.	Cyclosporine	93-105	interferon alpha 1	Homo sapiens	166-176
18793755-1	2008	Artemisinin and Cyclosporin A were examined for their ability to inhibit the calmodulin-mediated activation of phosphodiesterase, which is based on the hydrolysis of cAMP to AMP by phosphodiesterase in the presence or absence of inhibitors, followed by quantitative analysis using spectrophotometer method.	Cyclosporine	16-29	calmodulin 1	Homo sapiens	77-87
18793755-3	2008	Our results indicates that Artemisinin and Cyclosporin A induced some conformational changes on calmodulin and increased the fluorescence emission, but Artemisinin increased fluorescence emission of calmodulin in higher amounts compared with the Cyclosporin A.	Cyclosporine	43-56	calmodulin 1	Homo sapiens	96-106
18793755-4	2008	Kinetic analysis of the Artemisinin-calmodulin and Cyclosporine A-calmodulin interaction showed that these agents competitively inhibited the activation of phosphodiesterase without affecting Vmax.	Cyclosporine	51-65	calmodulin 1	Homo sapiens	66-76
18793755-8	2008	However, the degree of decrease in DeltaG (H2O) value was as follows: Artemisinin&gt;Cyclosporin A, which means Artemisinin induced more instability in the calmodulin structure.In conclusion, our findings showed a good correlation between the ability of both Artemisinin and Cyclosporin A to block the activation of phosphodiesterase and their ability to bind to the activator and that Artemisinin is a more potent inhibitor of phosphodiesterase compared with Cyclosporin A.	Cyclosporine	85-98	calmodulin 1	Homo sapiens	156-166
18793755-8	2008	However, the degree of decrease in DeltaG (H2O) value was as follows: Artemisinin&gt;Cyclosporin A, which means Artemisinin induced more instability in the calmodulin structure.In conclusion, our findings showed a good correlation between the ability of both Artemisinin and Cyclosporin A to block the activation of phosphodiesterase and their ability to bind to the activator and that Artemisinin is a more potent inhibitor of phosphodiesterase compared with Cyclosporin A.	Cyclosporine	275-288	calmodulin 1	Homo sapiens	156-166
18793755-8	2008	However, the degree of decrease in DeltaG (H2O) value was as follows: Artemisinin&gt;Cyclosporin A, which means Artemisinin induced more instability in the calmodulin structure.In conclusion, our findings showed a good correlation between the ability of both Artemisinin and Cyclosporin A to block the activation of phosphodiesterase and their ability to bind to the activator and that Artemisinin is a more potent inhibitor of phosphodiesterase compared with Cyclosporin A.	Cyclosporine	275-288	calmodulin 1	Homo sapiens	156-166
18835257-4	2008	The efflux could be blocked by cyclosporine A, a specific P-glycoprotein (P-gp) inhibitor, suggesting that P-gp may be the responsible transporter.	Cyclosporine	31-45	ATP binding cassette subfamily B member 1	Homo sapiens	58-72
18835257-4	2008	The efflux could be blocked by cyclosporine A, a specific P-glycoprotein (P-gp) inhibitor, suggesting that P-gp may be the responsible transporter.	Cyclosporine	31-45	ATP binding cassette subfamily B member 1	Homo sapiens	74-78
18835257-4	2008	The efflux could be blocked by cyclosporine A, a specific P-glycoprotein (P-gp) inhibitor, suggesting that P-gp may be the responsible transporter.	Cyclosporine	31-45	ATP binding cassette subfamily B member 1	Homo sapiens	107-111
19053888-6	2008	N-4-methylpiperazine- (10a-d) and tetrahydroisoquinoline- (11a-d) derivatives were Cyclosporin A-like ABCB1 nontransported substrates.	Cyclosporine	83-96	ATP binding cassette subfamily B member 1	Homo sapiens	102-107
19707465-10	2008	Recipients with TT genotype of IL-2 and GC of TGF-beta codon 25 having low C2 levels may require higher cyclosporine dosage.	Cyclosporine	104-116	interleukin 2	Homo sapiens	31-35
19707465-10	2008	Recipients with TT genotype of IL-2 and GC of TGF-beta codon 25 having low C2 levels may require higher cyclosporine dosage.	Cyclosporine	104-116	transforming growth factor beta 1	Homo sapiens	46-54
18804502-9	2008	Inhibitor of caspase-3 (Z-DEVD-FMK, 100microM), and a mitochondrial permeability transition pore blocker, cyclosporine A (2microM) protected PC12 cells against alpha-synuclein or amyloid beta evoked cell death.	Cyclosporine	106-120	amyloid beta precursor protein	Homo sapiens	179-191
18982435-10	2008	TGF-beta1 levels in CsA-exposed groups were significantly higher than untreated groups, but ligation did not affect TGF-beta1 level.	Cyclosporine	20-23	transforming growth factor, beta 1	Rattus norvegicus	0-9
18384156-1	2008	This article describes the experimental set-up and pharmacokinetic modeling of P-glycoprotein function in the rat blood-brain barrier using [(11)C]verapamil as the substrate and cyclosporin A as an inhibitor of P-gp.	Cyclosporine	178-191	phosphoglycolate phosphatase	Rattus norvegicus	211-215
18384156-6	2008	Mixed effects modeling in NONMEM was used to build a pharmacokinetic model of CsA-induced P-gp inhibition.	Cyclosporine	78-81	phosphoglycolate phosphatase	Rattus norvegicus	90-94
18180803-0	2008	CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine.	Cyclosporine	117-129	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	0-6
18180803-1	2008	The CYP3A5*1 allele has been linked to high expression of CYP3A5 and metabolism of cyclosporine.	Cyclosporine	83-95	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	4-10
19100412-0	2008	Different effect of cyclosporine and tacrolimus on renal expression of P-glycoprotein in human kidney transplantation.	Cyclosporine	20-32	ATP binding cassette subfamily B member 1	Homo sapiens	71-85
19100412-1	2008	OBJECTIVE: To investigate the differential effects of cyclosporine (CsA) and tacrolimus (TAC) on renal expression of P-glycoprotein (P-gp) in a cohort of kidney transplant recipients.	Cyclosporine	54-66	ATP binding cassette subfamily B member 1	Homo sapiens	117-131
19100412-1	2008	OBJECTIVE: To investigate the differential effects of cyclosporine (CsA) and tacrolimus (TAC) on renal expression of P-glycoprotein (P-gp) in a cohort of kidney transplant recipients.	Cyclosporine	54-66	ATP binding cassette subfamily B member 1	Homo sapiens	133-137
19100412-1	2008	OBJECTIVE: To investigate the differential effects of cyclosporine (CsA) and tacrolimus (TAC) on renal expression of P-glycoprotein (P-gp) in a cohort of kidney transplant recipients.	Cyclosporine	68-71	ATP binding cassette subfamily B member 1	Homo sapiens	117-131
19100412-1	2008	OBJECTIVE: To investigate the differential effects of cyclosporine (CsA) and tacrolimus (TAC) on renal expression of P-glycoprotein (P-gp) in a cohort of kidney transplant recipients.	Cyclosporine	68-71	ATP binding cassette subfamily B member 1	Homo sapiens	133-137
19100412-8	2008	CONCLUSION: Less P-gp expression in the CsA group than the TAC group may be the molecular action pathway of the high incidence of CsA nephrotoxicity and CsA-induced CAN.	Cyclosporine	40-43	ATP binding cassette subfamily B member 1	Homo sapiens	17-21
19100412-8	2008	CONCLUSION: Less P-gp expression in the CsA group than the TAC group may be the molecular action pathway of the high incidence of CsA nephrotoxicity and CsA-induced CAN.	Cyclosporine	130-133	ATP binding cassette subfamily B member 1	Homo sapiens	17-21
19100412-8	2008	CONCLUSION: Less P-gp expression in the CsA group than the TAC group may be the molecular action pathway of the high incidence of CsA nephrotoxicity and CsA-induced CAN.	Cyclosporine	130-133	ATP binding cassette subfamily B member 1	Homo sapiens	17-21
18845086-0	2008	[Regulatory function of tacrolimus and CsA on CD4/CD8 T lymphocyte subgroups and costimulators on them in allo-liver recipients].	Cyclosporine	39-42	CD4 molecule	Homo sapiens	46-49
18845086-1	2008	AIM: To explore the regulatory function of FK506 and CsA on CD4/CD8 T lymphocyte subgroups and co-stimulators on them.	Cyclosporine	53-56	CD4 molecule	Homo sapiens	60-63
21298518-0	2011	The podocyte as a target: cyclosporin A in the management of the nephrotic syndrome caused by WT1 mutations.	Cyclosporine	26-39	WT1 transcription factor	Homo sapiens	94-97
18702631-0	2008	Role of MDR1 gene polymorphisms in gingival overgrowth induced by cyclosporine in transplant patients.	Cyclosporine	66-78	ATP binding cassette subfamily B member 1	Homo sapiens	8-12
18702631-1	2008	BACKGROUND AND OBJECTIVE: The aim of the present study was to determine the association between genotypes of the MDR1 gene, encoding P-glycoprotein, and gingival overgrowth in transplant patients treated with cyclosporine, and to evaluate the effect of periodontal treatment in these patients.	Cyclosporine	209-221	ATP binding cassette subfamily B member 1	Homo sapiens	113-117
18978522-1	2008	Cyclosporine is a substrate of cytochrome P450 (CYP) 3A and of the transporter ABCB1, for which polymorphisms have been described.	Cyclosporine	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-55
18978522-1	2008	Cyclosporine is a substrate of cytochrome P450 (CYP) 3A and of the transporter ABCB1, for which polymorphisms have been described.	Cyclosporine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	79-84
18978522-4	2008	CYP3A5 expressors (*1/*3 genotype; n = 8-10) presented significantly lower dose-adjusted cyclosporine trough concentrations (P &lt; 0.05) and required significantly higher daily doses per weight (P &lt; 0.01) than the nonexpressors (*3/*3 genotype; n = 55-59) 1, 3, 6, and 12 months after transplantation.	Cyclosporine	89-101	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	0-6
18978522-5	2008	In addition, 7 days after transplantation, more CYP3A5 expressors had uncorrected trough cyclosporine concentration below the target concentration of 200 ng/mL than the nonexpressors (odds ratio = 7.2; 95% confidence interval = 1.4-37.3; P = 0.009).	Cyclosporine	89-101	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	48-54
18978522-6	2008	CYP3A4 rs4646437C&gt;T influenced cyclosporine kinetics, the T carriers requiring higher cyclosporine dose.	Cyclosporine	34-46	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
18978522-6	2008	CYP3A4 rs4646437C&gt;T influenced cyclosporine kinetics, the T carriers requiring higher cyclosporine dose.	Cyclosporine	89-101	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
18978522-7	2008	CYP3A7*1C carriers required a 1.4-fold to 1.6-fold higher cyclosporine daily dose during the first year after transplantation (P &lt; 0.05).	Cyclosporine	58-70	cytochrome P450 family 3 subfamily A member 7	Homo sapiens	0-6
18978522-8	2008	In conclusion, CYP3A4, CYP3A5, and CYP3A7 polymorphisms affect cyclosporine metabolism, and therefore, their genotyping could be useful, in association with therapeutic drug monitoring, to prospectively optimize cyclosporine prescription in transplant recipients.	Cyclosporine	63-75	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	15-21
18978522-8	2008	In conclusion, CYP3A4, CYP3A5, and CYP3A7 polymorphisms affect cyclosporine metabolism, and therefore, their genotyping could be useful, in association with therapeutic drug monitoring, to prospectively optimize cyclosporine prescription in transplant recipients.	Cyclosporine	63-75	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	23-29
18978522-8	2008	In conclusion, CYP3A4, CYP3A5, and CYP3A7 polymorphisms affect cyclosporine metabolism, and therefore, their genotyping could be useful, in association with therapeutic drug monitoring, to prospectively optimize cyclosporine prescription in transplant recipients.	Cyclosporine	63-75	cytochrome P450 family 3 subfamily A member 7	Homo sapiens	35-41
18978522-8	2008	In conclusion, CYP3A4, CYP3A5, and CYP3A7 polymorphisms affect cyclosporine metabolism, and therefore, their genotyping could be useful, in association with therapeutic drug monitoring, to prospectively optimize cyclosporine prescription in transplant recipients.	Cyclosporine	212-224	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	15-21
18978522-8	2008	In conclusion, CYP3A4, CYP3A5, and CYP3A7 polymorphisms affect cyclosporine metabolism, and therefore, their genotyping could be useful, in association with therapeutic drug monitoring, to prospectively optimize cyclosporine prescription in transplant recipients.	Cyclosporine	212-224	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	23-29
18978522-8	2008	In conclusion, CYP3A4, CYP3A5, and CYP3A7 polymorphisms affect cyclosporine metabolism, and therefore, their genotyping could be useful, in association with therapeutic drug monitoring, to prospectively optimize cyclosporine prescription in transplant recipients.	Cyclosporine	212-224	cytochrome P450 family 3 subfamily A member 7	Homo sapiens	35-41
18978522-9	2008	The administration of a CYP3A genotype-dependent cyclosporine starting dose should therefore be tested prospectively in a randomized controlled clinical trial to assess whether it leads to an improvement of the patients outcome after transplantation, with adequate immunosuppression and decreased toxicity.	Cyclosporine	49-61	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	24-29
19005401-1	2008	BACKGROUND: Bioavailability of tacrolimus (Tac) and cyclosporine is determined by cytochrome P450IIIA and by P-glycoprotein encoded by the CYP3A4/CYP3A5 and ABCB1 genes.	Cyclosporine	52-64	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	139-145
19005401-1	2008	BACKGROUND: Bioavailability of tacrolimus (Tac) and cyclosporine is determined by cytochrome P450IIIA and by P-glycoprotein encoded by the CYP3A4/CYP3A5 and ABCB1 genes.	Cyclosporine	52-64	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	146-152
19005401-1	2008	BACKGROUND: Bioavailability of tacrolimus (Tac) and cyclosporine is determined by cytochrome P450IIIA and by P-glycoprotein encoded by the CYP3A4/CYP3A5 and ABCB1 genes.	Cyclosporine	52-64	ATP binding cassette subfamily B member 1	Homo sapiens	157-162
18948815-10	2008	Multivariate analysis, including all patients (tacrolimus + cyclosporine) characterized higher exposure to immunosuppression (P = 0.01), alpha-fetoprotein levels (P = 0.001), tumor grading (P = 0.009), and microvascular invasion (P = 0.04) as independent predictors of HCC recurrence.	Cyclosporine	60-72	alpha fetoprotein	Homo sapiens	137-154
18771651-6	2008	ATP or a combination of cyclosporin A and ADP, inhibitors of the mPT, suppressed BAX(oligo)-induced mitochondrial swelling and depolarization as well as cytochrome c release but did not influence BAX(oligo) insertion into the OMM.	Cyclosporine	24-37	BCL2 associated X, apoptosis regulator	Homo sapiens	81-84
18771651-6	2008	ATP or a combination of cyclosporin A and ADP, inhibitors of the mPT, suppressed BAX(oligo)-induced mitochondrial swelling and depolarization as well as cytochrome c release but did not influence BAX(oligo) insertion into the OMM.	Cyclosporine	24-37	cytochrome c, somatic	Homo sapiens	153-165
18801030-0	2008	Meta-analysis of the effect of MDR1 C3435T polymorphism on cyclosporine pharmacokinetics.	Cyclosporine	59-71	ATP binding cassette subfamily B member 1	Homo sapiens	31-35
18801030-1	2008	The published data revealed conflicting results of the polymorphism of MDR1 exon 26 SNP C3435T on the pharmacokinetics of cyclosporine; thus, the aim was to conduct a meta-analysis of significant magnitude to investigate the influence of SNP C3435T on the pharmacokinetics of cyclosporine.	Cyclosporine	122-134	ATP binding cassette subfamily B member 1	Homo sapiens	71-75
18801030-1	2008	The published data revealed conflicting results of the polymorphism of MDR1 exon 26 SNP C3435T on the pharmacokinetics of cyclosporine; thus, the aim was to conduct a meta-analysis of significant magnitude to investigate the influence of SNP C3435T on the pharmacokinetics of cyclosporine.	Cyclosporine	276-288	ATP binding cassette subfamily B member 1	Homo sapiens	71-75
18801030-7	2008	In conclusion, our meta-analysis of available studies has thus far failed to demonstrate a definitive correlation between the SNP C3435T in MDR1 gene and alterations in P-glycoprotein function that can result in altered pharmacokinetics of cyclosporine, although it was indicated in this meta-analysis that the carrier of CC genotype of the SNP C3435T of MDR1 had lower cyclosporine exposure presented as AUC(0-12) than those with at least one T allele.	Cyclosporine	240-252	ATP binding cassette subfamily B member 1	Homo sapiens	140-144
18801030-8	2008	There seems to be ethnic differences in the relationship between the SNP C3435T of MDR1 and cyclosporine pharmacokinetics.	Cyclosporine	92-104	ATP binding cassette subfamily B member 1	Homo sapiens	83-87
18608282-10	2008	Cyclosporine co-administration increases colchicine toxicity by a dual mechanism: cyclosporine inhibits P-glycoprotein resulting in increased intracellular colchicine concentrations and decreased hepatic and renal excretion of the drug and cyclosporine interacts with CYP3A4 to decreases the hepatic elimination of colchicine.	Cyclosporine	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	268-274
18608282-10	2008	Cyclosporine co-administration increases colchicine toxicity by a dual mechanism: cyclosporine inhibits P-glycoprotein resulting in increased intracellular colchicine concentrations and decreased hepatic and renal excretion of the drug and cyclosporine interacts with CYP3A4 to decreases the hepatic elimination of colchicine.	Cyclosporine	82-94	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	268-274
18636247-0	2008	Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients.	Cyclosporine	65-77	ATP binding cassette subfamily B member 1	Homo sapiens	15-19
18636247-0	2008	Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients.	Cyclosporine	65-77	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	37-43
18636247-1	2008	OBJECTIVE: The objective of this study was to retrospectively evaluate the effects of MDR1, CYP3A4*18B, and CYP3A5*3 genetic polymorphisms on cyclosporine A (CsA) pharmacokinetics in Chinese renal transplant patients during the first month after transplantation.	Cyclosporine	142-156	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	92-98
18636247-10	2008	Patients with CYP3A4*18B alleles may require higher doses of CsA to reach the target levels.	Cyclosporine	61-64	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	14-20
18636247-11	2008	Large prospective studies may be needed to further explore the impact of MDR1 and CYP3A5*3 polymorphisms on CsA pharmacokinetics in renal transplant recipients.	Cyclosporine	108-111	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	82-88
18765728-5	2008	Incubation of bovine lymphoblastoid cells (BL-3 cells) with the mitochondrial membrane-stabilizing agent cyclosporine (CSA) reduced LKT-mediated cytotoxicity, cytochrome c release, and collapse of the psi(m).	Cyclosporine	105-117	cytochrome c, somatic	Homo sapiens	159-171
18765728-5	2008	Incubation of bovine lymphoblastoid cells (BL-3 cells) with the mitochondrial membrane-stabilizing agent cyclosporine (CSA) reduced LKT-mediated cytotoxicity, cytochrome c release, and collapse of the psi(m).	Cyclosporine	119-122	cytochrome c, somatic	Homo sapiens	159-171
18546202-3	2008	Cyclosporin A (CyA) or bongkrekic acid (BK) inhibited the induction of the MPT, the release of cytochrome c and the cell death without affecting the perinuclear clustering of the mitochondria or the translocation of Bax.	Cyclosporine	0-13	cytochrome c, somatic	Homo sapiens	95-107
18546202-3	2008	Cyclosporin A (CyA) or bongkrekic acid (BK) inhibited the induction of the MPT, the release of cytochrome c and the cell death without affecting the perinuclear clustering of the mitochondria or the translocation of Bax.	Cyclosporine	0-13	BCL2 associated X, apoptosis regulator	Homo sapiens	216-219
18546202-3	2008	Cyclosporin A (CyA) or bongkrekic acid (BK) inhibited the induction of the MPT, the release of cytochrome c and the cell death without affecting the perinuclear clustering of the mitochondria or the translocation of Bax.	Cyclosporine	15-18	cytochrome c, somatic	Homo sapiens	95-107
18546202-3	2008	Cyclosporin A (CyA) or bongkrekic acid (BK) inhibited the induction of the MPT, the release of cytochrome c and the cell death without affecting the perinuclear clustering of the mitochondria or the translocation of Bax.	Cyclosporine	15-18	BCL2 associated X, apoptosis regulator	Homo sapiens	216-219
18789739-0	2008	Development of predictive in silico model for cyclosporine- and aureobasidin-based P-glycoprotein inhibitors employing receptor surface analysis.	Cyclosporine	46-58	ATP binding cassette subfamily B member 1	Homo sapiens	83-97
18789739-3	2008	Cyclosporine A (CsA), aureobasidin A (AbA) and related analogues were reported to possess potent inhibitory actions against Pgp.	Cyclosporine	0-14	ATP binding cassette subfamily B member 1	Homo sapiens	124-127
18789739-3	2008	Cyclosporine A (CsA), aureobasidin A (AbA) and related analogues were reported to possess potent inhibitory actions against Pgp.	Cyclosporine	16-19	ATP binding cassette subfamily B member 1	Homo sapiens	124-127
18789739-4	2008	In this work we employed receptor surface analysis (RSA) to construct two satisfactory receptor surface models (RSMs) for cyclosporine- and aureobasidin-based Pgp inhibitors.	Cyclosporine	122-134	ATP binding cassette subfamily B member 1	Homo sapiens	159-162
18789739-7	2008	The resulting 3D-QSAR was employed to probe the structural factors that control the inhibitory activities of cyclosporine and aureobasidin analogues against Pgp.	Cyclosporine	109-121	ATP binding cassette subfamily B member 1	Homo sapiens	157-160
18725544-0	2008	Contribution of down-regulation of intestinal and hepatic cytochrome P450 3A to increased absorption of cyclosporine A in a rat nephrosis model.	Cyclosporine	104-118	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	58-76
18725544-1	2008	This study examined the contribution of changes in regulation of intestinal and hepatic cytochrome P450 3A (CYP3A) and multidrug resistance transporter 1 (Mdr1) to absorption of cyclosporine A (CsA) in a rat nephrosis model.	Cyclosporine	178-192	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	88-106
18725544-1	2008	This study examined the contribution of changes in regulation of intestinal and hepatic cytochrome P450 3A (CYP3A) and multidrug resistance transporter 1 (Mdr1) to absorption of cyclosporine A (CsA) in a rat nephrosis model.	Cyclosporine	178-192	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	108-113
18725544-1	2008	This study examined the contribution of changes in regulation of intestinal and hepatic cytochrome P450 3A (CYP3A) and multidrug resistance transporter 1 (Mdr1) to absorption of cyclosporine A (CsA) in a rat nephrosis model.	Cyclosporine	194-197	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	88-106
18725544-12	2008	In conclusion, these findings suggest that the down-regulation of CYP3A in the upper intestine and liver predominantly contributes to the increase in CsA absorption, and Mdr1 showed less contribution in this rat nephrosis model.	Cyclosporine	150-153	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	66-71
18618151-1	2008	The aim of our study was to determine the effect of recombinant human erythropoietin (rhEPO) on cyclosporine (CsA) nephrotoxicity.	Cyclosporine	96-108	erythropoietin	Homo sapiens	70-84
18618151-1	2008	The aim of our study was to determine the effect of recombinant human erythropoietin (rhEPO) on cyclosporine (CsA) nephrotoxicity.	Cyclosporine	110-113	erythropoietin	Homo sapiens	70-84
19060372-11	2008	Compared with the normal-dose CsA group, the chronic rejection lesions of the anti-ICOS-Ab combined with low-dose CsA treatment group significantly were alleviated in the long-term survival grafts, and the proportion of CD4+CD25+ regulatory T cell increased in peripheral blood.	Cyclosporine	30-33	inducible T-cell co-stimulator	Rattus norvegicus	83-87
19060372-12	2008	CONCLUSION: The anti-ICOS-Ab combined with low-dose CsA can prolong the survival of cardiac allografts and alleviate the chronic rejection significantly.	Cyclosporine	52-55	inducible T-cell co-stimulator	Rattus norvegicus	21-25
19213345-8	2008	The P-gp expression was down-regulated after treated with CsA, Tet and both (75.32%, 76.86% and 48.61%); mdr1 mRNA was also down-regulated, and the effect of their combination was more obvious.	Cyclosporine	58-61	ATP binding cassette subfamily B member 1	Homo sapiens	4-8
19213345-8	2008	The P-gp expression was down-regulated after treated with CsA, Tet and both (75.32%, 76.86% and 48.61%); mdr1 mRNA was also down-regulated, and the effect of their combination was more obvious.	Cyclosporine	58-61	ATP binding cassette subfamily B member 1	Homo sapiens	105-109
18832697-6	2008	This was evidenced by our findings that agents suppressing NFAT activity (e.g., cyclosporin A and FK506) enhanced TCR-mediated GITR expression, whereas agents enhancing NFAT activity (e.g., lithium chloride) suppressed TCR-mediated GITR up-regulation.	Cyclosporine	80-93	TNF receptor superfamily member 18	Homo sapiens	127-131
18617642-8	2008	Cyclosporine A (100 ng/ml) inhibited proliferation of CD4(+)CD28(null) cells by 33 +/- 11% versus 68 +/- 12% inhibition of CD4(+)CD28(+) (P = 0.025).	Cyclosporine	0-14	CD4 molecule	Homo sapiens	54-57
18617642-8	2008	Cyclosporine A (100 ng/ml) inhibited proliferation of CD4(+)CD28(null) cells by 33 +/- 11% versus 68 +/- 12% inhibition of CD4(+)CD28(+) (P = 0.025).	Cyclosporine	0-14	CD4 molecule	Homo sapiens	123-126
18760199-0	2008	ABCB1 G2677 allele is associated with high dose requirement of cyclosporin A to prevent renal allograft rejection in North India.	Cyclosporine	63-76	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
18760199-1	2008	BACKGROUND: Interindividual heterogeneity in expression of ABCB1 gene has been suspected to be one of the factors resulting in cyclosporin (CsA) pharmacokinetic variation.	Cyclosporine	127-138	ATP binding cassette subfamily B member 1	Homo sapiens	59-64
18760199-1	2008	BACKGROUND: Interindividual heterogeneity in expression of ABCB1 gene has been suspected to be one of the factors resulting in cyclosporin (CsA) pharmacokinetic variation.	Cyclosporine	140-143	ATP binding cassette subfamily B member 1	Homo sapiens	59-64
18760199-2	2008	The present study explored the association of ABCB1 SNPs on CsA dose requirements and dose-adjusted C2 levels (CsA level/daily dose requirement) in renal allograft recipients.	Cyclosporine	60-63	ATP binding cassette subfamily B member 1	Homo sapiens	46-51
19262158-0	2008	Cyclosporin A inhibits CD11a/CD18 adhesion molecules due to inhibition of TNFalpha and IL-1 beta levels in the mouse model of pleurisy induced by carrageenan.	Cyclosporine	0-13	integrin beta 2	Mus musculus	29-33
19262158-0	2008	Cyclosporin A inhibits CD11a/CD18 adhesion molecules due to inhibition of TNFalpha and IL-1 beta levels in the mouse model of pleurisy induced by carrageenan.	Cyclosporine	0-13	tumor necrosis factor	Mus musculus	74-82
19262158-0	2008	Cyclosporin A inhibits CD11a/CD18 adhesion molecules due to inhibition of TNFalpha and IL-1 beta levels in the mouse model of pleurisy induced by carrageenan.	Cyclosporine	0-13	interleukin 1 beta	Mus musculus	87-96
19262158-4	2008	In the present work we evaluated whether CsA was able to downregulate CD11a/CD18 adhesion molecule in the lungs, as well as TNFalpha and IL-1 beta levels in the fluid leakage of the pleural cavity in this model.	Cyclosporine	41-44	integrin beta 2	Mus musculus	76-80
19262158-5	2008	Our results showed that CsA significantly decreased CD11a/CD18 in the lungs, as well as TNFalpha and IL-1 beta levels in the fluid leakage of the pleural cavity 4 h and 48 h after pleurisy induction.	Cyclosporine	24-27	integrin beta 2	Mus musculus	58-62
19262158-6	2008	It is our hypothesis that the inhibitory effect elicited by CsA upon these adhesion molecules may be also be attributed to the downregulation of TNFalpha and IL-1 beta cytokines.	Cyclosporine	60-63	tumor necrosis factor	Mus musculus	145-153
19262158-6	2008	It is our hypothesis that the inhibitory effect elicited by CsA upon these adhesion molecules may be also be attributed to the downregulation of TNFalpha and IL-1 beta cytokines.	Cyclosporine	60-63	interleukin 1 beta	Mus musculus	158-167
18802087-5	2008	Cell treatment with the calcineurin inhibitor cyclosporine A or a NFAT-specific inhibitor led to a sharp reduction in PD-1 expression in the constitutive and inducible systems.	Cyclosporine	46-60	MHC class I antigen 1	Sus scrofa	118-122
18694572-0	2008	Cyclosporine inhibition of angiogenesis involves the transcription factor HESR1.	Cyclosporine	0-12	hes related family bHLH transcription factor with YRPW motif 1	Homo sapiens	74-79
18694572-7	2008	RESULTS: At a 2 microg/mL dose, CyA treated HAEC revealed a 44-fold increase in the expression of hairy enhancer of split-related protein 1 (HESR1) and 1.73-fold down-regulation of transcripts encoding for the vascular endothelial growth factor (VEGF) receptor (VEGFR2).	Cyclosporine	32-35	hes related family bHLH transcription factor with YRPW motif 1	Homo sapiens	98-139
18694572-7	2008	RESULTS: At a 2 microg/mL dose, CyA treated HAEC revealed a 44-fold increase in the expression of hairy enhancer of split-related protein 1 (HESR1) and 1.73-fold down-regulation of transcripts encoding for the vascular endothelial growth factor (VEGF) receptor (VEGFR2).	Cyclosporine	32-35	hes related family bHLH transcription factor with YRPW motif 1	Homo sapiens	141-146
18981654-2	2008	CsA is known to suppress the expression of inflammatory cytokines, including IL-2, IL-4, IFN-gamma and TNF-alpha in humans, dogs and experimental mice.	Cyclosporine	0-3	interleukin 2	Homo sapiens	77-81
18981654-2	2008	CsA is known to suppress the expression of inflammatory cytokines, including IL-2, IL-4, IFN-gamma and TNF-alpha in humans, dogs and experimental mice.	Cyclosporine	0-3	interleukin 4	Homo sapiens	83-87
18981654-2	2008	CsA is known to suppress the expression of inflammatory cytokines, including IL-2, IL-4, IFN-gamma and TNF-alpha in humans, dogs and experimental mice.	Cyclosporine	0-3	interferon gamma	Homo sapiens	89-98
18981654-2	2008	CsA is known to suppress the expression of inflammatory cytokines, including IL-2, IL-4, IFN-gamma and TNF-alpha in humans, dogs and experimental mice.	Cyclosporine	0-3	tumor necrosis factor	Homo sapiens	103-112
18981654-5	2008	Real-time PCR analyses with Concanavalin A (ConA)-stimulated PBMC obtained from 5 cats revealed that the expression of mRNAs for IL-2, IL-4, IFN- gamma and TNF-alpha was inhibited by CsA in a dose-dependent manner.	Cyclosporine	183-186	interferon gamma	Felis catus	141-151
18929866-0	2008	Rapamycin and cyclosporine have different effects on expression of Ang-1 and Ang-2 and Tie2 in rat renal allograft with chronic allograft nephropathy.	Cyclosporine	14-26	TEK receptor tyrosine kinase	Rattus norvegicus	87-91
18929866-2	2008	This study of cardiac allografts investigated whether there is a difference between rapamycin and cyclosporine A (CsA) in the ability to affect expression of Ang1, Ang2, and Tie2 in rat renal allografts with chronic allograft nephropathy (CAN).	Cyclosporine	98-112	TEK receptor tyrosine kinase	Rattus norvegicus	174-178
18929866-2	2008	This study of cardiac allografts investigated whether there is a difference between rapamycin and cyclosporine A (CsA) in the ability to affect expression of Ang1, Ang2, and Tie2 in rat renal allografts with chronic allograft nephropathy (CAN).	Cyclosporine	114-117	TEK receptor tyrosine kinase	Rattus norvegicus	174-178
18929866-14	2008	CONCLUSIONS: Our results show that compared with CsA, rapamycin modulates the expression of Ang1, Ang2, and Tie2 in rat renal allografts with CAN, which suggests that rapamycin may improve the long-term survival of renal allografts through its vasculoprotective properties.	Cyclosporine	49-52	TEK receptor tyrosine kinase	Rattus norvegicus	108-112
18587562-0	2008	Administration of the calcineurin inhibitor cyclosporine modulates cocaine-induced locomotor activity in rats.	Cyclosporine	44-56	calcineurin binding protein 1	Rattus norvegicus	22-43
18463324-0	2008	Protective effect of COMP-angiopoietin-1 on cyclosporine-induced renal injury in mice.	Cyclosporine	44-56	angiopoietin 1	Mus musculus	26-40
18463324-5	2008	We investigated whether COMP-Ang1 ameliorates CsA-induced renal injury.	Cyclosporine	46-49	angiopoietin 1	Mus musculus	29-33
18463324-6	2008	METHODS: CsA-treated mice were injected with recombinant adenovirus expressing either COMP-Ang1 or LacZ.	Cyclosporine	9-12	angiopoietin 1	Mus musculus	91-95
18463324-8	2008	RESULTS: Histologic examination showed that COMP-Ang1 significantly decreased CsA-induced tubular damage and tubulointerstitial fibrosis.	Cyclosporine	78-81	angiopoietin 1	Mus musculus	49-53
18463324-9	2008	CsA-induced increases in macrophage infiltration and expression of MCP-1 and ICAM-1 after CsA treatment were significantly reduced by COMP-Ang1.	Cyclosporine	0-3	mast cell protease 1	Mus musculus	67-72
18463324-9	2008	CsA-induced increases in macrophage infiltration and expression of MCP-1 and ICAM-1 after CsA treatment were significantly reduced by COMP-Ang1.	Cyclosporine	0-3	angiopoietin 1	Mus musculus	139-143
18463324-9	2008	CsA-induced increases in macrophage infiltration and expression of MCP-1 and ICAM-1 after CsA treatment were significantly reduced by COMP-Ang1.	Cyclosporine	90-93	mast cell protease 1	Mus musculus	67-72
18463324-9	2008	CsA-induced increases in macrophage infiltration and expression of MCP-1 and ICAM-1 after CsA treatment were significantly reduced by COMP-Ang1.	Cyclosporine	90-93	angiopoietin 1	Mus musculus	139-143
18463324-10	2008	Treatment with COMP-Ang1 also decreased the CsA-induced increases in TGF-beta1 and Smad 2/3 levels while increasing Smad 7 levels.	Cyclosporine	44-47	angiopoietin 1	Mus musculus	20-24
18463324-10	2008	Treatment with COMP-Ang1 also decreased the CsA-induced increases in TGF-beta1 and Smad 2/3 levels while increasing Smad 7 levels.	Cyclosporine	44-47	SMAD family member 2	Mus musculus	83-91
18463324-11	2008	Laser-Doppler sonographic findings and endothelial factor VIII staining revealed that COMP-Ang1 preserved the integrity of peritubular vasculature and intrarenal haemodynamics from the CsA-induced renal injury.	Cyclosporine	185-188	angiopoietin 1	Mus musculus	91-95
18463324-12	2008	COMP-Ang1 inhibited tubular cell apoptosis while increasing tubular cell proliferation in CsA-induced renal injury.	Cyclosporine	90-93	angiopoietin 1	Mus musculus	5-9
18463324-13	2008	CONCLUSIONS: These results indicate that COMP-Ang1 exhibited a protective effect on damaged peritubular capillaries, haemodynamic alteration and inflammation in CsA-induced renal injury.	Cyclosporine	161-164	angiopoietin 1	Mus musculus	46-50
18478546-6	2008	In contrast, ketamine (Keta) and cyclosporine A (CsA), two chemicals that block calcium signal in ischemia, decrease ERK activity by blocking Raf dephosphorylation of Ser259.	Cyclosporine	33-47	Eph receptor B1	Rattus norvegicus	117-120
18478546-6	2008	In contrast, ketamine (Keta) and cyclosporine A (CsA), two chemicals that block calcium signal in ischemia, decrease ERK activity by blocking Raf dephosphorylation of Ser259.	Cyclosporine	49-52	Eph receptor B1	Rattus norvegicus	117-120
18424460-12	2008	CONCLUSIONS: MR blockade by EPL prevented short-term alterations in GFR, RBF and hypertension associated with CsA nephrotoxicity.	Cyclosporine	110-113	nuclear receptor subfamily 3, group C, member 2	Rattus norvegicus	13-15
18790238-3	2008	Previously, we demonstrated that activation of Akt/protein kinase B protects against cyclosporine nephrotoxicity and prevents apoptosis.	Cyclosporine	85-97	AKT serine/threonine kinase 1	Homo sapiens	47-50
18790238-6	2008	In theory, blockade of the Akt pathway through inhibition of m-TOR may increase cyclosporine-induced apoptosis.	Cyclosporine	80-92	AKT serine/threonine kinase 1	Homo sapiens	27-30
18790238-6	2008	In theory, blockade of the Akt pathway through inhibition of m-TOR may increase cyclosporine-induced apoptosis.	Cyclosporine	80-92	RAR related orphan receptor C	Homo sapiens	63-66
18342291-1	2008	BACKGROUND: Gingival crevicular fluid (GCF) levels of transforming growth factor-beta(1) (TGF-beta(1)) have been previously investigated in relation to the pathogenesis of cyclosporine-A (CsA)-induced gingival overgrowth (GO) but no clinical data are available regarding the GCF levels of TGF-beta(1) in patients treated with tacrolimus (Tac).	Cyclosporine	172-186	transforming growth factor beta 1	Homo sapiens	54-88
18684975-2	2008	Herein we demonstrate that the CNI cyclosporin A and tacrolimus (FK506), independent of TGFbeta synthesis, rapidly activate TGFbeta/Smad signaling in cultured mesangial cells and in whole kidney samples from CNI-treated rats.	Cyclosporine	35-48	transforming growth factor, beta 1	Rattus norvegicus	124-131
18342291-1	2008	BACKGROUND: Gingival crevicular fluid (GCF) levels of transforming growth factor-beta(1) (TGF-beta(1)) have been previously investigated in relation to the pathogenesis of cyclosporine-A (CsA)-induced gingival overgrowth (GO) but no clinical data are available regarding the GCF levels of TGF-beta(1) in patients treated with tacrolimus (Tac).	Cyclosporine	172-186	transforming growth factor beta 1	Homo sapiens	90-101
18342291-1	2008	BACKGROUND: Gingival crevicular fluid (GCF) levels of transforming growth factor-beta(1) (TGF-beta(1)) have been previously investigated in relation to the pathogenesis of cyclosporine-A (CsA)-induced gingival overgrowth (GO) but no clinical data are available regarding the GCF levels of TGF-beta(1) in patients treated with tacrolimus (Tac).	Cyclosporine	188-191	transforming growth factor beta 1	Homo sapiens	54-88
18342291-1	2008	BACKGROUND: Gingival crevicular fluid (GCF) levels of transforming growth factor-beta(1) (TGF-beta(1)) have been previously investigated in relation to the pathogenesis of cyclosporine-A (CsA)-induced gingival overgrowth (GO) but no clinical data are available regarding the GCF levels of TGF-beta(1) in patients treated with tacrolimus (Tac).	Cyclosporine	188-191	transforming growth factor beta 1	Homo sapiens	90-101
18342291-8	2008	GCF TGF-beta(1) total amount of CsA and Tac groups was similar (p&gt;0.008).	Cyclosporine	32-35	transforming growth factor beta 1	Homo sapiens	4-15
18673531-8	2008	MTT assay showed that Pgp inhibitors such as cyclosporine A, verapamil and PSC833 sensitized Colo320HSR (colon, highest MDR1 expression) but not SNU-668 (gastric, highest) and SNU-C5 (gastric, no expression) to paclitaxel.	Cyclosporine	45-59	ATP binding cassette subfamily B member 1	Homo sapiens	22-25
18816304-12	2008	While administration of cyclosporine A increased the MDA levels in kidney, liver and heart tissues, it decreased the GSH, GSH-Px and CAT in these samples when compared to the control group.	Cyclosporine	24-38	catalase	Rattus norvegicus	133-136
18717915-0	2008	ABCB1 polymorphisms may have a minor effect on ciclosporin blood concentrations in myasthenia gravis patients.	Cyclosporine	47-58	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
18673531-8	2008	MTT assay showed that Pgp inhibitors such as cyclosporine A, verapamil and PSC833 sensitized Colo320HSR (colon, highest MDR1 expression) but not SNU-668 (gastric, highest) and SNU-C5 (gastric, no expression) to paclitaxel.	Cyclosporine	45-59	ATP binding cassette subfamily B member 1	Homo sapiens	120-124
18717915-3	2008	The aim was to determine the role of genetic polymorphisms in MDR-1 with respect to interindividual variability of CsA blood concentrations in myasthenia gravis (MG) patients.	Cyclosporine	115-118	ATP binding cassette subfamily B member 1	Homo sapiens	62-67
19001679-6	2008	The enzyme activities of AST and GDH in cytosol released from mitochondrial matrix changed significantly at 24 and 72 h. CsA can inhibit the permeability of mitochondria partly at the same time.	Cyclosporine	121-124	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	25-28
18717915-7	2008	Furthermore, under the same CsA regimen, it was found that the trough concentrations of variant genotype (ABCB1 1236TT or ABCB1 2677TT) were significant greater than those of wild-type (ABCB1 1236CC or ABCB1 2677GG, respectively) (P = 0.0222 and 0.0081).	Cyclosporine	28-31	ATP binding cassette subfamily B member 1	Homo sapiens	106-111
18717915-7	2008	Furthermore, under the same CsA regimen, it was found that the trough concentrations of variant genotype (ABCB1 1236TT or ABCB1 2677TT) were significant greater than those of wild-type (ABCB1 1236CC or ABCB1 2677GG, respectively) (P = 0.0222 and 0.0081).	Cyclosporine	28-31	ATP binding cassette subfamily B member 1	Homo sapiens	122-127
18717915-7	2008	Furthermore, under the same CsA regimen, it was found that the trough concentrations of variant genotype (ABCB1 1236TT or ABCB1 2677TT) were significant greater than those of wild-type (ABCB1 1236CC or ABCB1 2677GG, respectively) (P = 0.0222 and 0.0081).	Cyclosporine	28-31	ATP binding cassette subfamily B member 1	Homo sapiens	122-127
18717915-7	2008	Furthermore, under the same CsA regimen, it was found that the trough concentrations of variant genotype (ABCB1 1236TT or ABCB1 2677TT) were significant greater than those of wild-type (ABCB1 1236CC or ABCB1 2677GG, respectively) (P = 0.0222 and 0.0081).	Cyclosporine	28-31	ATP binding cassette subfamily B member 1	Homo sapiens	122-127
18717915-9	2008	CONCLUSIONS: ABCB1 polymorphisms in both genotype and haplotype may have a minor effect on the CsA blood concentrations.	Cyclosporine	95-98	ATP binding cassette subfamily B member 1	Homo sapiens	13-18
18553108-0	2008	Interleukin-6 counteracts effects of cyclosporin A on extracellular matrix metabolism by human dermal fibroblasts.	Cyclosporine	37-50	interleukin 6	Homo sapiens	0-13
18550647-9	2008	PTHrP-(1-36) also decreased cyclosporine A- and/or osmotic stress-induced apoptosis in these cells and in renal fibroblastic NRK 49F cells.	Cyclosporine	28-42	parathyroid hormone-like peptide	Mus musculus	0-5
18312387-0	2008	Induction of synapse associated protein 102 expression in cyclosporin A-stimulated hair growth.	Cyclosporine	58-71	discs large MAGUK scaffold protein 3	Mus musculus	13-43
18312387-8	2008	The result showed that the expression of SAP102 was significantly induced by CsA treatment in the back skin of C57BL/6 mice.	Cyclosporine	77-80	discs large MAGUK scaffold protein 3	Mus musculus	41-47
18312387-11	2008	Immunohistochemistry analysis showed that CsA induced the expression of SAP102 in perifollicular region of mouse anagen hair.	Cyclosporine	42-45	discs large MAGUK scaffold protein 3	Mus musculus	72-78
18155508-3	2008	Pretreatment of HL60 cells with cyclosporine A, an inhibitor of the mitochondrial permeability transition pore (mPTP), inhibited allicin-treated cell death.	Cyclosporine	32-46	protein tyrosine phosphatase, receptor type, U	Mus musculus	112-116
18641302-5	2008	The ionomycin-mediated increase in HIF-1alpha protein levels was sensitive to the transcription inhibitor actinomycin D and to inhibitors of calcineurin, cyclosporin A (CsA), and FK506.	Cyclosporine	169-172	hypoxia inducible factor 1 subunit alpha	Homo sapiens	35-45
18641302-6	2008	The increased HIF-1alpha protein level was paralleled by a severalfold increase in HIF-1alpha mRNA that could be also inhibited with actinomycin D and CsA.	Cyclosporine	151-154	hypoxia inducible factor 1 subunit alpha	Homo sapiens	14-24
18641302-6	2008	The increased HIF-1alpha protein level was paralleled by a severalfold increase in HIF-1alpha mRNA that could be also inhibited with actinomycin D and CsA.	Cyclosporine	151-154	hypoxia inducible factor 1 subunit alpha	Homo sapiens	83-93
18641302-7	2008	The HIF1A promoter activity was significantly increased in ionomycin-activated mast cells, and the promoter activity could be inhibited by CsA and FK506.	Cyclosporine	139-142	hypoxia inducible factor 1 subunit alpha	Homo sapiens	4-9
18155508-6	2008	The effects of cyclosporine A and N-acetyl cysteine suggest the involvement of mPTP and intracellular GSH level in the cytotoxicity.	Cyclosporine	15-29	protein tyrosine phosphatase, receptor type, U	Mus musculus	79-83
18561950-0	2008	An interleukin-6-neutralizing antibody prevents cyclosporine-induced nephrotoxicity in mice.	Cyclosporine	48-60	interleukin 6	Mus musculus	3-16
18561950-24	2008	The current study identifies increased IL-6 expression as a mechanism by which CyA induces renal damage and that the use of an IL-6-neutralizing antibody may be useful in reducing CyA-induced renal damage.	Cyclosporine	79-82	interleukin 6	Mus musculus	39-43
18632814-11	2008	Furthermore, administration of cyclosporin A caused a significant reduction of lung, liver, and kidney washout along with a considerable variation in activity distribution in the intestinal tract in both male and female rats, thus indicating a possible implication of Pgp transporters in determining the biologic behavior of 99mTc(N)-DBODC5.	Cyclosporine	31-44	phosphoglycolate phosphatase	Rattus norvegicus	268-271
18561950-24	2008	The current study identifies increased IL-6 expression as a mechanism by which CyA induces renal damage and that the use of an IL-6-neutralizing antibody may be useful in reducing CyA-induced renal damage.	Cyclosporine	180-183	interleukin 6	Mus musculus	127-131
18582542-5	2008	Pretreatment with SB202190 (p38 MAPK inhibitor) and cyclosporine A (inhibitor of mitochondria permeability transition pore) rescued cell viability, DeltaPsim and cytochrome c release of PLA2-treated cells.	Cyclosporine	52-66	cytochrome c, somatic	Homo sapiens	162-174
18538359-2	2008	Chronic (&gt;or=3h) treatment of cultured bovine adrenal chromaffin cells with cyclosporin A or FK506 decreased IRS-2 protein level by approximately 50% (IC(50)=200 or 10nM), without changing IRS-2 mRNA level, and insulin receptor, insulin-like growth factor-I (IGF-I) receptor, IRS-1, PI3K/PDK-1/Akt/GSK-3beta and ERK1/ERK2 protein levels.	Cyclosporine	79-92	insulin receptor substrate 2	Bos taurus	112-117
18434587-6	2008	In isolated adult rat cardiomyocytes subjected to anoxia-reoxygenation, morphine (2 microM), SB (3 microM), and the direct mPTP inhibitor cyclosporine A (3 microM) delayed mPTP opening as assessed by the calcein loading Co(2+)-quenching technique.	Cyclosporine	138-152	protein tyrosine phosphatase, receptor type, U	Mus musculus	123-127
18434587-6	2008	In isolated adult rat cardiomyocytes subjected to anoxia-reoxygenation, morphine (2 microM), SB (3 microM), and the direct mPTP inhibitor cyclosporine A (3 microM) delayed mPTP opening as assessed by the calcein loading Co(2+)-quenching technique.	Cyclosporine	138-152	protein tyrosine phosphatase, receptor type, U	Mus musculus	172-176
18538359-2	2008	Chronic (&gt;or=3h) treatment of cultured bovine adrenal chromaffin cells with cyclosporin A or FK506 decreased IRS-2 protein level by approximately 50% (IC(50)=200 or 10nM), without changing IRS-2 mRNA level, and insulin receptor, insulin-like growth factor-I (IGF-I) receptor, IRS-1, PI3K/PDK-1/Akt/GSK-3beta and ERK1/ERK2 protein levels.	Cyclosporine	79-92	insulin like growth factor 1 receptor	Bos taurus	262-277
18538359-2	2008	Chronic (&gt;or=3h) treatment of cultured bovine adrenal chromaffin cells with cyclosporin A or FK506 decreased IRS-2 protein level by approximately 50% (IC(50)=200 or 10nM), without changing IRS-2 mRNA level, and insulin receptor, insulin-like growth factor-I (IGF-I) receptor, IRS-1, PI3K/PDK-1/Akt/GSK-3beta and ERK1/ERK2 protein levels.	Cyclosporine	79-92	mitogen-activated protein kinase 1	Bos taurus	320-324
18632621-4	2008	Here, we used 786-0 human renal cancer cells to investigate the effect of cyclosporine (CsA) on VEGF expression.	Cyclosporine	74-86	vascular endothelial growth factor A	Homo sapiens	96-100
18632621-4	2008	Here, we used 786-0 human renal cancer cells to investigate the effect of cyclosporine (CsA) on VEGF expression.	Cyclosporine	88-91	vascular endothelial growth factor A	Homo sapiens	96-100
18632621-9	2008	CsA also promoted the progression of human renal tumors in vivo, wherein VEGF is overexpressed.	Cyclosporine	0-3	vascular endothelial growth factor A	Homo sapiens	73-77
18594053-5	2008	DATA SYNTHESIS: Corticosteroids share common metabolic and transporter pathways, the cytochrome P450 and P-glycoprotein (P-gp/ABCB1) systems, respectively, with cyclosporine, tacrolimus, and sirolimus.	Cyclosporine	161-173	ATP binding cassette subfamily B member 1	Homo sapiens	105-119
18594053-5	2008	DATA SYNTHESIS: Corticosteroids share common metabolic and transporter pathways, the cytochrome P450 and P-glycoprotein (P-gp/ABCB1) systems, respectively, with cyclosporine, tacrolimus, and sirolimus.	Cyclosporine	161-173	ATP binding cassette subfamily B member 1	Homo sapiens	126-131
18538359-6	2008	Pulse-label followed by polyacrylamide gel electrophoresis revealed that cyclosporin A or FK506 accelerated IRS-2 degradation rate (t(1/2)) from &gt;24 to approximately 4.2h, without altering IRS-2 synthesis.	Cyclosporine	73-86	insulin receptor substrate 2	Bos taurus	108-113
18538359-7	2008	IRS-2 reduction by cyclosporin A or FK506 was prevented by lactacystin (proteasome inhibitor), but not by calpeptin (calpain inhibitor) or leupeptin (lysosome inhibitor).	Cyclosporine	19-32	insulin receptor substrate 2	Bos taurus	0-5
18538359-2	2008	Chronic (&gt;or=3h) treatment of cultured bovine adrenal chromaffin cells with cyclosporin A or FK506 decreased IRS-2 protein level by approximately 50% (IC(50)=200 or 10nM), without changing IRS-2 mRNA level, and insulin receptor, insulin-like growth factor-I (IGF-I) receptor, IRS-1, PI3K/PDK-1/Akt/GSK-3beta and ERK1/ERK2 protein levels.	Cyclosporine	79-92	insulin receptor substrate 2	Bos taurus	192-197
18706245-17	2008	CsA stimulates the secretion of ANGII and the expression of renin and ANGII in HUVEC and MC.	Cyclosporine	0-3	renin	Homo sapiens	60-65
18709005-0	2008	Clinical importance of insulin resistance after renal transplantation in patients on triple immunosuppressive therapy with cyclosporine, corticosteroids and mycophenolate mofetil.	Cyclosporine	123-135	insulin	Homo sapiens	23-30
18709005-15	2008	Higher CsA trough levels are assotiated with higher Insulin values and indexes of IR.	Cyclosporine	7-10	insulin	Homo sapiens	52-59
18448283-10	2008	CONCLUSIONS: The increase in CETP activity and suppression in LPL activity following CsA and RAPA treatment observed in the present study may be associated with elevated LDL cholesterol levels and hypertriglyceridemia seen in patients administered these drugs.	Cyclosporine	85-88	cholesteryl ester transfer protein	Homo sapiens	29-33
18706245-0	2008	Intrarenal activation of renin angiotensin system in the development of cyclosporine A induced chronic nephrotoxicity.	Cyclosporine	72-86	renin	Homo sapiens	25-30
18448283-7	2008	RESULTS: We found an increase in CETP activity in human normolipidemic plasma and rCETP treated with CsA and RAPA.	Cyclosporine	101-104	cholesteryl ester transfer protein	Homo sapiens	33-37
18369646-0	2008	Cyclosporin A modulates cellular localization of MEF2C protein and blocks fiber hypertrophy in the overloaded soleus muscle of mice.	Cyclosporine	0-13	myocyte enhancer factor 2C	Mus musculus	49-54
18369646-10	2008	Such a MEF2C-positive region emerged less often in the hypertrophied soleus muscle subjected to the treatment with CsA.	Cyclosporine	115-118	myocyte enhancer factor 2C	Mus musculus	7-12
18369646-11	2008	At 7 days, we observed many mononuclear cells possessing both MEF2C and myogenin protein in mice treated with CsA, but not the placebo.	Cyclosporine	110-113	myocyte enhancer factor 2C	Mus musculus	62-67
18369646-12	2008	Our results demonstrated that CsA treatment modulates the amount and cellular localization of MEF2C protein.	Cyclosporine	30-33	myocyte enhancer factor 2C	Mus musculus	94-99
18369646-13	2008	The modulation of MEF2C by CsA treatment may inhibit the hypertrophic process in the soleus muscle after mechanical overloading.	Cyclosporine	27-30	myocyte enhancer factor 2C	Mus musculus	18-23
18706245-1	2008	BACKGROUND: The relationship between cyclosporine-induced chronic nephrotoxicity (CAN) and renin-angiotensin II in humans is still contradictory.	Cyclosporine	37-49	renin	Homo sapiens	91-96
18706245-17	2008	CsA stimulates the secretion of ANGII and the expression of renin and ANGII in HUVEC and MC.	Cyclosporine	0-3	angiotensinogen	Homo sapiens	70-75
18706245-1	2008	BACKGROUND: The relationship between cyclosporine-induced chronic nephrotoxicity (CAN) and renin-angiotensin II in humans is still contradictory.	Cyclosporine	37-49	angiotensinogen	Homo sapiens	97-111
18706245-12	2008	In vitro, renin as well as ANGII expression increased significantly in both HUVEC and MC after the cells were incubated with CsA for 24 hours (P &lt; 0.05).	Cyclosporine	125-128	renin	Homo sapiens	10-15
18327972-6	2008	CsA or PBN inhibited iNOS expression and caspase 3 activity.	Cyclosporine	0-3	nitric oxide synthase 2	Homo sapiens	21-25
18706245-12	2008	In vitro, renin as well as ANGII expression increased significantly in both HUVEC and MC after the cells were incubated with CsA for 24 hours (P &lt; 0.05).	Cyclosporine	125-128	angiotensinogen	Homo sapiens	27-32
18706245-13	2008	CsA also stimulated the secretion of ANGII in HUVEC and MC in a dose-dependent manner.	Cyclosporine	0-3	angiotensinogen	Homo sapiens	37-42
18706245-15	2008	The intrarenal renin angiotensin system plays an important role in CsA-related chronic nephropathy.	Cyclosporine	67-70	renin	Homo sapiens	15-20
18706245-17	2008	CsA stimulates the secretion of ANGII and the expression of renin and ANGII in HUVEC and MC.	Cyclosporine	0-3	angiotensinogen	Homo sapiens	32-37
18327972-6	2008	CsA or PBN inhibited iNOS expression and caspase 3 activity.	Cyclosporine	0-3	caspase 3	Homo sapiens	41-50
24459518-7	2008	COMP-Ang1 administration also decreased increased macrophage infiltration, adhesion molecule expression, TGF-beta1, and Smad 2/3 levels in CsA-treated kidneys, while increasing Smad 7 levels.	Cyclosporine	139-142	SMAD family member 2	Mus musculus	120-128
18322274-4	2008	We showed that blocking mitogen-activated protein kinase 3 (MAPK3)/MAPK1 signaling by U0126 attenuated CsA-increased cell viability and invasiveness of trophoblasts.	Cyclosporine	103-106	mitogen-activated protein kinase 1	Homo sapiens	67-72
18568913-1	2008	Effects of concentration of Polyoxyethylene (40) stearate, Na(+) and P-gp inhibitor on cyclosporin A (CyA-SD) absorption were investigated by in situ circulation method.	Cyclosporine	87-100	phosphoglycolate phosphatase	Rattus norvegicus	69-73
18322274-0	2008	Cyclosporin A promotes growth and invasiveness in vitro of human first-trimester trophoblast cells via MAPK3/MAPK1-mediated AP1 and Ca2+/calcineurin/NFAT signaling pathways.	Cyclosporine	0-13	mitogen-activated protein kinase 3	Homo sapiens	103-108
18322274-0	2008	Cyclosporin A promotes growth and invasiveness in vitro of human first-trimester trophoblast cells via MAPK3/MAPK1-mediated AP1 and Ca2+/calcineurin/NFAT signaling pathways.	Cyclosporine	0-13	mitogen-activated protein kinase 1	Homo sapiens	109-114
18322274-0	2008	Cyclosporin A promotes growth and invasiveness in vitro of human first-trimester trophoblast cells via MAPK3/MAPK1-mediated AP1 and Ca2+/calcineurin/NFAT signaling pathways.	Cyclosporine	0-13	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	124-127
18322274-4	2008	We showed that blocking mitogen-activated protein kinase 3 (MAPK3)/MAPK1 signaling by U0126 attenuated CsA-increased cell viability and invasiveness of trophoblasts.	Cyclosporine	103-106	mitogen-activated protein kinase 3	Homo sapiens	24-58
18322274-4	2008	We showed that blocking mitogen-activated protein kinase 3 (MAPK3)/MAPK1 signaling by U0126 attenuated CsA-increased cell viability and invasiveness of trophoblasts.	Cyclosporine	103-106	mitogen-activated protein kinase 3	Homo sapiens	60-65
18410372-4	2008	Disease severity, daily dose of prednisolone, acetylcholine receptor-antibody titre levels and levels of interleukin-2 production by peripheral blood mononuclear cells were significantly reduced following treatment with CsA MEPC.	Cyclosporine	220-223	interleukin 2	Homo sapiens	105-118
18339970-9	2008	Oxidant-induced necrotic cell death was mediated by a CsA-insensitive loss of MMP that is regulated by the ERK pathway.	Cyclosporine	54-57	mitogen-activated protein kinase 1	Homo sapiens	107-110
18518855-3	2008	: Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1polymorphisms.	Cyclosporine	22-34	ATP binding cassette subfamily B member 1	Homo sapiens	86-91
18026717-0	2008	Down-regulation of TRPM6-mediated magnesium influx by cyclosporin A.	Cyclosporine	54-67	transient receptor potential cation channel subfamily M member 6	Canis lupus familiaris	19-24
18026717-2	2008	In this study, we show that TRPM6 expression is suppressed by cyclosporin A (CsA) via a down-regulation of c-Fos expression.	Cyclosporine	62-75	transient receptor potential cation channel subfamily M member 6	Canis lupus familiaris	28-33
18026717-2	2008	In this study, we show that TRPM6 expression is suppressed by cyclosporin A (CsA) via a down-regulation of c-Fos expression.	Cyclosporine	77-80	transient receptor potential cation channel subfamily M member 6	Canis lupus familiaris	28-33
18026717-13	2008	We suggest that CsA decreases TRPM6 expression mediated by inhibition of c-Fos transcription, resulting in a decrease of renal Mg2+ reabsorption.	Cyclosporine	16-19	transient receptor potential cation channel subfamily M member 6	Canis lupus familiaris	30-35
18518855-7	2008	In adults, genetic polymorphisms in the genes encoding the cyclosporine-metabolizing enzymes CYP3A4 and CYP3A5, as well as the ABCB1 gene, which encodes the efflux-pump P-glycoprotein, seem to have a limited effect, if any, on cyclosporine pharmacokinetics.	Cyclosporine	227-239	ATP binding cassette subfamily B member 1	Homo sapiens	169-183
18518855-8	2008	However, the authors have now reported for the first time an association between cyclosporine oral bioavailability and the ABCB1 c.1236C&gt;T and c.2677G&gt;T polymorphisms, as well as the related haplotype c.1199G-c.1236C-c.2677G-c.3435C, in children with end-stage renal disease older than 8 years of age.	Cyclosporine	81-93	ATP binding cassette subfamily B member 1	Homo sapiens	123-128
18518855-7	2008	In adults, genetic polymorphisms in the genes encoding the cyclosporine-metabolizing enzymes CYP3A4 and CYP3A5, as well as the ABCB1 gene, which encodes the efflux-pump P-glycoprotein, seem to have a limited effect, if any, on cyclosporine pharmacokinetics.	Cyclosporine	59-71	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	93-99
18518855-12	2008	These data suggest that the effect of ABCB1 polymorphisms on cyclosporine pharmacokinetics is related to age, and thus developmental stage.	Cyclosporine	61-73	ATP binding cassette subfamily B member 1	Homo sapiens	38-43
18518855-13	2008	Although further study is necessary to establish the predictive value of ABCB1 genotyping for individualization of cyclosporine therapy in children older than 8 years, an important step towards further personalized immunosuppressive drug therapy has been made.	Cyclosporine	115-127	ATP binding cassette subfamily B member 1	Homo sapiens	73-78
18518855-7	2008	In adults, genetic polymorphisms in the genes encoding the cyclosporine-metabolizing enzymes CYP3A4 and CYP3A5, as well as the ABCB1 gene, which encodes the efflux-pump P-glycoprotein, seem to have a limited effect, if any, on cyclosporine pharmacokinetics.	Cyclosporine	59-71	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	104-110
18589174-3	2008	Frequencies of CYP3A5*1 versus *3 and MDR1-C3435T were correlated with tacrolimus (TAC) and cyclosporine (CSA) concentration-to-dose (C/D) ratios.	Cyclosporine	92-104	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	15-21
18589174-3	2008	Frequencies of CYP3A5*1 versus *3 and MDR1-C3435T were correlated with tacrolimus (TAC) and cyclosporine (CSA) concentration-to-dose (C/D) ratios.	Cyclosporine	92-104	ATP binding cassette subfamily B member 1	Homo sapiens	38-42
18589174-3	2008	Frequencies of CYP3A5*1 versus *3 and MDR1-C3435T were correlated with tacrolimus (TAC) and cyclosporine (CSA) concentration-to-dose (C/D) ratios.	Cyclosporine	106-109	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	15-21
18589174-3	2008	Frequencies of CYP3A5*1 versus *3 and MDR1-C3435T were correlated with tacrolimus (TAC) and cyclosporine (CSA) concentration-to-dose (C/D) ratios.	Cyclosporine	106-109	ATP binding cassette subfamily B member 1	Homo sapiens	38-42
18451510-3	2008	P-gp function was estimated by the transporter activity of the cells based on the efflux of Rhodamine-123 (Rh123) from the cells in the presence or absence of a P-gp inhibitor, cyclosporine A.	Cyclosporine	177-191	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
18703392-3	2008	Cyclosporine A-induced nephrotoxicity is particularly due to the activation of pro-apoptotic genes leading to tubular atrophy with tubular cell apoptosis and to hemodynamic changes inducing interstitial fibrosis by the activation of factors stimulating the fibroblast proliferation (TGFbeta, Endothelin-A and Plasminogen activator inhibitor-1).	Cyclosporine	0-14	transforming growth factor beta 1	Homo sapiens	283-290
18953738-2	2008	It is well known that CsA inhibits calcium (Ca2+) induced mitochondrial permeability transition (mPT).	Cyclosporine	22-25	carbonic anhydrase 2	Rattus norvegicus	44-47
18953738-3	2008	The aim of this study was to investigate the influence of CsA on the alteration of Ca2+ homeostasis after experimental brain injury.	Cyclosporine	58-61	carbonic anhydrase 2	Rattus norvegicus	83-86
18285333-7	2008	The recruitment of the polycomb proteins Mel-18 and Ezh2 to the cytokine promoters was inhibited in the presence of cyclosporine A, suggesting the involvement of NFAT.	Cyclosporine	116-130	polycomb group ring finger 2	Homo sapiens	41-47
18285333-7	2008	The recruitment of the polycomb proteins Mel-18 and Ezh2 to the cytokine promoters was inhibited in the presence of cyclosporine A, suggesting the involvement of NFAT.	Cyclosporine	116-130	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	52-56
18358838-2	2008	Here we studied whether p53 mitochondrial translocation and subsequent apoptosis were affected by blocking mitochondrial permeability transition pore using cyclosporine A (CsA) and bongkrekic acid (BA) in skin epidermal JB6 cells and skin tissues.	Cyclosporine	156-170	tumor protein p53	Homo sapiens	24-27
18355347-1	2008	AIMS: The relationship between gingival overgrowth (GO) induced by cyclosporine A (CsA) and transforming growth factor-beta1 (TGF-beta1) remains unclear.	Cyclosporine	83-86	transforming growth factor beta 1	Homo sapiens	92-124
18355347-6	2008	RESULTS: The level of TGF-beta1 gene expression was insignificantly lower in the CsA-treated group compared with the tacrolimus group, and significantly lower in the group with GO compared with patients without GO.	Cyclosporine	81-84	transforming growth factor beta 1	Homo sapiens	22-31
18355347-7	2008	In tacrolimus- and CsA-treated patients, but not in patients with GO, the level of TGF-beta1 gene expression was associated with functional phenotypes of TGF-beta1.	Cyclosporine	19-22	transforming growth factor beta 1	Homo sapiens	83-92
18355347-7	2008	In tacrolimus- and CsA-treated patients, but not in patients with GO, the level of TGF-beta1 gene expression was associated with functional phenotypes of TGF-beta1.	Cyclosporine	19-22	transforming growth factor beta 1	Homo sapiens	154-163
18355347-9	2008	CONCLUSIONS: Lower level TGF-beta1 gene expression, not functional polymorphism, in patients treated with CsA may be considered to be a risk factor for GO.	Cyclosporine	106-109	transforming growth factor beta 1	Homo sapiens	25-34
18358838-2	2008	Here we studied whether p53 mitochondrial translocation and subsequent apoptosis were affected by blocking mitochondrial permeability transition pore using cyclosporine A (CsA) and bongkrekic acid (BA) in skin epidermal JB6 cells and skin tissues.	Cyclosporine	172-175	tumor protein p53	Homo sapiens	24-27
18358838-3	2008	Our results demonstrated that CsA and BA blocked TPA-induced p53 translocation, leading to protection against the loss of mitochondrial membrane potential and Complex I activity, and eventually suppression of apoptosis.	Cyclosporine	30-33	tumor protein p53	Homo sapiens	61-64
18180276-8	2008	As a result, cyclosporin A and rifampicin were found to have the potential to interact with OATP1B3-mediated uptake at clinical concentrations.	Cyclosporine	13-26	solute carrier organic anion transporter family member 1B3	Homo sapiens	92-99
19356075-0	2008	Influence of ABCB1 gene polymorphisms and P-glycoprotein activity on cyclosporine pharmacokinetics in peripheral blood mononuclear cells in healthy volunteers.	Cyclosporine	69-81	ATP binding cassette subfamily B member 1	Homo sapiens	13-18
19356075-0	2008	Influence of ABCB1 gene polymorphisms and P-glycoprotein activity on cyclosporine pharmacokinetics in peripheral blood mononuclear cells in healthy volunteers.	Cyclosporine	69-81	ATP binding cassette subfamily B member 1	Homo sapiens	42-56
19356075-1	2008	The calcineurin inhibitor cyclosporine is removed from lymphocytes by the drug efflux transporter P-glycoprotein (P-gp) encoded by the ABCB1 gene for which several single nucleotide polymorphisms (SNPs) have been identified.	Cyclosporine	26-38	ATP binding cassette subfamily B member 1	Homo sapiens	98-112
19356075-1	2008	The calcineurin inhibitor cyclosporine is removed from lymphocytes by the drug efflux transporter P-glycoprotein (P-gp) encoded by the ABCB1 gene for which several single nucleotide polymorphisms (SNPs) have been identified.	Cyclosporine	26-38	ATP binding cassette subfamily B member 1	Homo sapiens	135-140
18374784-7	2008	Cyclosporine A and hydrocortisone-treated rats demonstrated increased vasoreactivity to endothelin-1 compared with control, whereas cyclosporine A + hydrocortisone treatment resulted in a synergistic increase (P = .04).	Cyclosporine	0-14	endothelin 1	Rattus norvegicus	88-100
19356075-7	2008	Similarly, a negative correlation was detected in the GG-CC group between P-gp activity in CD4(+) and cyclosporine PBMC AUC(0-24) (r(S)=-0.69, p=0.03), as well as PBMC to whole blood AUC(0-24) ratio (r(S)=-0.60, p=0.07).	Cyclosporine	102-114	CD4 molecule	Homo sapiens	91-94
18337643-5	2008	MCSP-ETA" induced cell death synergistically with cyclosporin A, both in established human melanoma cell lines and cultured primary melanoma cells.	Cyclosporine	50-63	chondroitin sulfate proteoglycan 4	Homo sapiens	0-4
18331748-6	2008	Moreover we found that CsA exposure in vivo is associated with the upregulation of the ER stress marker BIP in kidney transplant biopsies.	Cyclosporine	23-26	growth differentiation factor 10	Homo sapiens	104-107
18182482-4	2008	We have shown previously (Kimchi-Sarfaty et al., 2002) that treatment of NCX1-transfected human embryonic kidney (HEK) 293 cells with the immunosuppressive cyclosporin A (CsA) and its nonimmunosuppressive analog PSC833 (valspodar) results in down-regulation of surface expression and transport activity of the protein without a decrease in expression of cell NCX1 protein.	Cyclosporine	156-169	solute carrier family 8 member A1	Homo sapiens	73-77
18182482-4	2008	We have shown previously (Kimchi-Sarfaty et al., 2002) that treatment of NCX1-transfected human embryonic kidney (HEK) 293 cells with the immunosuppressive cyclosporin A (CsA) and its nonimmunosuppressive analog PSC833 (valspodar) results in down-regulation of surface expression and transport activity of the protein without a decrease in expression of cell NCX1 protein.	Cyclosporine	156-169	solute carrier family 8 member A1	Homo sapiens	359-363
18182482-4	2008	We have shown previously (Kimchi-Sarfaty et al., 2002) that treatment of NCX1-transfected human embryonic kidney (HEK) 293 cells with the immunosuppressive cyclosporin A (CsA) and its nonimmunosuppressive analog PSC833 (valspodar) results in down-regulation of surface expression and transport activity of the protein without a decrease in expression of cell NCX1 protein.	Cyclosporine	171-174	solute carrier family 8 member A1	Homo sapiens	73-77
18182482-4	2008	We have shown previously (Kimchi-Sarfaty et al., 2002) that treatment of NCX1-transfected human embryonic kidney (HEK) 293 cells with the immunosuppressive cyclosporin A (CsA) and its nonimmunosuppressive analog PSC833 (valspodar) results in down-regulation of surface expression and transport activity of the protein without a decrease in expression of cell NCX1 protein.	Cyclosporine	171-174	solute carrier family 8 member A1	Homo sapiens	359-363
18182482-5	2008	In this study, we show that cyclosporin A and PSC833 treatment of NCX2- and NCX3-transfected HEK 293 cells also resulted in dose-dependent down-regulation of surface expression and transport activity of the two brain NCX proteins; however, whereas CsA had no effect on total cell NCX protein expression, PSC833 reduced mRNA and cell protein expression of NCX2 and NCX3.	Cyclosporine	28-41	solute carrier family 8 member A3	Homo sapiens	76-80
18182482-5	2008	In this study, we show that cyclosporin A and PSC833 treatment of NCX2- and NCX3-transfected HEK 293 cells also resulted in dose-dependent down-regulation of surface expression and transport activity of the two brain NCX proteins; however, whereas CsA had no effect on total cell NCX protein expression, PSC833 reduced mRNA and cell protein expression of NCX2 and NCX3.	Cyclosporine	28-41	solute carrier family 8 member A3	Homo sapiens	364-368
18182482-5	2008	In this study, we show that cyclosporin A and PSC833 treatment of NCX2- and NCX3-transfected HEK 293 cells also resulted in dose-dependent down-regulation of surface expression and transport activity of the two brain NCX proteins; however, whereas CsA had no effect on total cell NCX protein expression, PSC833 reduced mRNA and cell protein expression of NCX2 and NCX3.	Cyclosporine	248-251	solute carrier family 8 member A3	Homo sapiens	76-80
17934801-10	2008	Interestingly, cyclosporin A, a P-gp inhibitor, but not fumitremorgin C, a BCRP inhibitor, restored both imatinib-sensitivity and the intracellular imatinib level.	Cyclosporine	15-28	ATP binding cassette subfamily B member 1	Homo sapiens	32-36
18387391-7	2008	In the CyA group, post-treatment urinary EGF levels were significantly reduced (from 35 +/- 15.8 to 28.3 +/- 17.9 ng/mg creatinine; P &lt;0.034), whereas the urinary IL-6 levels were not affected by CyA or PPS treatment in the whole group.	Cyclosporine	7-10	interleukin 6	Homo sapiens	166-170
18334915-0	2008	Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients.	Cyclosporine	44-56	ATP binding cassette subfamily B member 1	Homo sapiens	13-18
18334915-1	2008	OBJECTIVE: The expression on lymphocytes of P-glycoprotein, an efflux transporter encoded by the ABCB1 gene, might influence cyclosporine intracellular concentration.	Cyclosporine	125-137	ATP binding cassette subfamily B member 1	Homo sapiens	44-58
18334915-1	2008	OBJECTIVE: The expression on lymphocytes of P-glycoprotein, an efflux transporter encoded by the ABCB1 gene, might influence cyclosporine intracellular concentration.	Cyclosporine	125-137	ATP binding cassette subfamily B member 1	Homo sapiens	97-102
18334915-4	2008	The ABCB1 1199A carriers presented a 1.8-fold decreased cyclosporine intracellular concentration (P=0.04), whereas the 3435T carriers presented a 1.7-fold increase (P=0.02) as well as a 1.2-fold increased blood concentration (P=0.04).	Cyclosporine	56-68	ATP binding cassette subfamily B member 1	Homo sapiens	4-9
18334915-6	2008	CONCLUSION: This is the first report demonstrating that ABCB1 polymorphisms influence cyclosporine intracellular concentration.	Cyclosporine	86-98	ATP binding cassette subfamily B member 1	Homo sapiens	56-61
18387391-0	2008	Urinary epidermal growth factor and interleukin-6 levels in patients with painful bladder syndrome/interstitial cystitis treated with cyclosporine or pentosan polysulfate sodium.	Cyclosporine	134-146	interleukin 6	Homo sapiens	36-49
18387391-10	2008	Interleukin-6 levels did not change significantly in all treated patients after either CyA or PPS treatment, but in older patients the levels were reduced after CyA treatment.	Cyclosporine	87-90	interleukin 6	Homo sapiens	0-13
18191430-5	2008	However, CyD gene silencing using siRNA left the cells susceptible to diclofenac toxicity, and CsA still protected the CyD-negative cells from lethal injury.	Cyclosporine	95-98	peptidylprolyl isomerase F	Homo sapiens	119-122
18191430-10	2008	In conclusion, we found that Bax/Bak-mediated MOMP is a key mechanism of diclofenac-induced lethal cell injury in human hepatocytes, and that CsA can prevent MOMP through inhibition of Bax activation.	Cyclosporine	142-145	BCL2 associated X, apoptosis regulator	Homo sapiens	29-32
18191430-4	2008	The CyD inhibitor, cyclosporin A (CsA, 2 microM) fully inhibited diclofenac-induced cell injury, suggesting that mPT was involved.	Cyclosporine	34-37	peptidylprolyl isomerase F	Homo sapiens	4-7
18191430-10	2008	In conclusion, we found that Bax/Bak-mediated MOMP is a key mechanism of diclofenac-induced lethal cell injury in human hepatocytes, and that CsA can prevent MOMP through inhibition of Bax activation.	Cyclosporine	142-145	BCL2 associated X, apoptosis regulator	Homo sapiens	185-188
18259766-7	2008	Cytokine expression analysis at the site of skin graft showed that CsA treatment significantly decreased pro-inflammatory cytokines IFN-gamma and IL-2 and reduced TNF-alpha gene expression; however, the level of TNF-alpha is high in MSC-treated and not immunosuppressed rats.	Cyclosporine	67-70	tumor necrosis factor	Rattus norvegicus	163-172
18081741-3	2008	BACE1 expression was stimulated by a calcium ionophore in primary cortical cultures, and by SH-SY5Y neuroblastoma cells, which was both blocked by pretreatment with either cyclosporin A, an inhibitor of calcineurin, or ethyleneglycotetraacetic acid, a calcium chelator.	Cyclosporine	172-185	beta-secretase 1	Homo sapiens	0-5
18081741-6	2008	In addition, primary cortical cultures from Tg2576 mouse brains generated more Abeta by ionophore stimulation, which was reversed by cyclosporin A treatment.	Cyclosporine	133-146	amyloid beta precursor protein	Homo sapiens	79-84
18184875-9	2008	Application of cyclosporin A or FK506, inhibitors of PP2B, significantly decreased ROMK channels, and the effect of PP2B inhibitors was abolished by blocking p38 mitogen-activated protein kinase (MAPK) and ERK.	Cyclosporine	15-28	mitogen-activated protein kinase 1	Mus musculus	196-200
18184875-9	2008	Application of cyclosporin A or FK506, inhibitors of PP2B, significantly decreased ROMK channels, and the effect of PP2B inhibitors was abolished by blocking p38 mitogen-activated protein kinase (MAPK) and ERK.	Cyclosporine	15-28	mitogen-activated protein kinase 1	Mus musculus	206-209
18184875-10	2008	Furthermore, Western blot demonstrated that inhibition of PP2B with cyclosporin A or small interfering RNA increased the phosphorylation of ERK and p38 MAPK.	Cyclosporine	68-81	mitogen-activated protein kinase 1	Mus musculus	140-143
18570909-7	2008	After binding to a specific immunophillin, cyclosporin and tacrolimus inhibit calcineurine, a serine/threonine phosphatase which plays a major role in cytokines transcription notably IL2 after T-cell activation.	Cyclosporine	43-54	interleukin 2	Homo sapiens	183-186
18337667-11	2008	When applied in combination with cyclosporine A, ciprofloxacin lowered the expression of transforming growth factor-beta and tumor necrosis factor-alpha and increased interferon-gamma expression.	Cyclosporine	33-47	transforming growth factor beta 1	Homo sapiens	89-152
18337667-11	2008	When applied in combination with cyclosporine A, ciprofloxacin lowered the expression of transforming growth factor-beta and tumor necrosis factor-alpha and increased interferon-gamma expression.	Cyclosporine	33-47	interferon gamma	Homo sapiens	167-183
18259766-7	2008	Cytokine expression analysis at the site of skin graft showed that CsA treatment significantly decreased pro-inflammatory cytokines IFN-gamma and IL-2 and reduced TNF-alpha gene expression; however, the level of TNF-alpha is high in MSC-treated and not immunosuppressed rats.	Cyclosporine	67-70	tumor necrosis factor	Rattus norvegicus	212-221
18057117-4	2008	Therefore, we developed a high throughput cell-based assay to determine the potential of putative P-gp inhibitors [including cyclosporine A (CsA)] to inhibit (EC(50)) the efflux of verapamil-bodipy, a model P-gp substrate.	Cyclosporine	125-139	ATP binding cassette subfamily B member 1	Homo sapiens	98-102
18057117-4	2008	Therefore, we developed a high throughput cell-based assay to determine the potential of putative P-gp inhibitors [including cyclosporine A (CsA)] to inhibit (EC(50)) the efflux of verapamil-bodipy, a model P-gp substrate.	Cyclosporine	125-139	ATP binding cassette subfamily B member 1	Homo sapiens	207-211
18057117-4	2008	Therefore, we developed a high throughput cell-based assay to determine the potential of putative P-gp inhibitors [including cyclosporine A (CsA)] to inhibit (EC(50)) the efflux of verapamil-bodipy, a model P-gp substrate.	Cyclosporine	141-144	ATP binding cassette subfamily B member 1	Homo sapiens	98-102
18057117-4	2008	Therefore, we developed a high throughput cell-based assay to determine the potential of putative P-gp inhibitors [including cyclosporine A (CsA)] to inhibit (EC(50)) the efflux of verapamil-bodipy, a model P-gp substrate.	Cyclosporine	141-144	ATP binding cassette subfamily B member 1	Homo sapiens	207-211
18057117-6	2008	Using this assay, quinine, quinidine, CsA, and amprenavir were predicted to be the most potent P-gp inhibitors in vivo at their respective therapeutic maximal unbound plasma concentrations.	Cyclosporine	38-41	ATP binding cassette subfamily B member 1	Homo sapiens	95-99
18057117-7	2008	The in vitro EC(50) of CsA (0.6 microM) for P-gp inhibition was virtually the same as our previously determined in vivo unbound EC(50) at the rat BBB (0.5 microM).	Cyclosporine	23-26	phosphoglycolate phosphatase	Rattus norvegicus	44-48
17986230-6	2008	Moreover, RU360, Ca2+-free medium, Na+-free medium, or cyclosporin A (CsA) largely prevented AA-induced opening of the mitochondrial permeability transition pore, cytochrome c release, and caspase 3-dependent neuronal apoptosis.	Cyclosporine	55-68	cytochrome c, somatic	Homo sapiens	163-175
18095305-13	2008	Liver mitochondria from PY plus LPS or PY plus TNF-alpha treated mice underwent calcium-dependent, cyclosporine A-sensitive swelling, which was prevented by SB203580 or SP600125.	Cyclosporine	99-113	tumor necrosis factor	Mus musculus	47-56
17986230-6	2008	Moreover, RU360, Ca2+-free medium, Na+-free medium, or cyclosporin A (CsA) largely prevented AA-induced opening of the mitochondrial permeability transition pore, cytochrome c release, and caspase 3-dependent neuronal apoptosis.	Cyclosporine	55-68	caspase 3	Homo sapiens	189-198
17986230-6	2008	Moreover, RU360, Ca2+-free medium, Na+-free medium, or cyclosporin A (CsA) largely prevented AA-induced opening of the mitochondrial permeability transition pore, cytochrome c release, and caspase 3-dependent neuronal apoptosis.	Cyclosporine	70-73	cytochrome c, somatic	Homo sapiens	163-175
17986230-6	2008	Moreover, RU360, Ca2+-free medium, Na+-free medium, or cyclosporin A (CsA) largely prevented AA-induced opening of the mitochondrial permeability transition pore, cytochrome c release, and caspase 3-dependent neuronal apoptosis.	Cyclosporine	70-73	caspase 3	Homo sapiens	189-198
17986230-7	2008	Importantly, Na+-ionophore/Ca2+-free medium, which induced [Na+](m) overload, but not [Ca2+](m) overload, also caused cyclosporin A-sensitive mitochondrial permeability transition pore opening, resulting in caspase 3-dependent apoptosis, indicating that [Na+](m) overload per se induced apoptosis.	Cyclosporine	118-131	caspase 3	Homo sapiens	207-216
18299432-4	2008	It was demonstrated that administration of CsA at the window of implantation significantly up-regulated the expression of CTLA-4, while down-regulating the levels of CD80, CD86, and CD28 at the materno-fetal interface in the CBA/J x DBA/2 abortion-prone matings, and the embryo resorption rate of the abortion-prone matings reduced significantly after CsA treatment, implying that modulation of costimulatory molecule expression by CsA might contribute to preventing the fetus from maternal immune attack.	Cyclosporine	43-46	CD80 antigen	Mus musculus	166-170
17933841-7	2008	Neutralizing TGF-beta1 antibody blocked CsA-induced EMT but had no effect on LC-exposed cells.	Cyclosporine	40-43	transforming growth factor beta 1	Homo sapiens	13-22
18003606-7	2008	Cell surface MDR1 was up-regulated 1 h after treatment with CsA or adaGb3, but at 72 h, cell surface expression was lost.	Cyclosporine	60-63	ATP binding cassette subfamily B member 1	Homo sapiens	13-17
18299432-4	2008	It was demonstrated that administration of CsA at the window of implantation significantly up-regulated the expression of CTLA-4, while down-regulating the levels of CD80, CD86, and CD28 at the materno-fetal interface in the CBA/J x DBA/2 abortion-prone matings, and the embryo resorption rate of the abortion-prone matings reduced significantly after CsA treatment, implying that modulation of costimulatory molecule expression by CsA might contribute to preventing the fetus from maternal immune attack.	Cyclosporine	43-46	CD86 antigen	Mus musculus	172-176
18223473-5	2008	A pharmacokinetic interaction between cyclosporine and everolimus has been described previously for healthy volunteers after single-dose application and presumably originates from a comparatively greater inhibition of hepatic CYP3A4 or P-glycoprotein efflux transporter with a low-dose cyclosporine regimen.	Cyclosporine	38-50	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	226-232
17906976-9	2008	Consistent with this, cell surface trapping of ABCA1 with cyclosporin A (CsA) results in increased apoA-I binding but reduced internalisation.	Cyclosporine	58-71	apolipoprotein A1	Homo sapiens	99-105
17906976-9	2008	Consistent with this, cell surface trapping of ABCA1 with cyclosporin A (CsA) results in increased apoA-I binding but reduced internalisation.	Cyclosporine	73-76	apolipoprotein A1	Homo sapiens	99-105
18271955-8	2008	In addition, P-gp inhibition by zosuquidar was found to be more potent than cyclosporine A in cells with highly active P-gp.	Cyclosporine	76-90	ATP binding cassette subfamily B member 1	Homo sapiens	119-123
18209060-8	2008	Using cyclosporin A to selectively block cytokine release, we found that CD4+ T cell cytotoxicity is the key effector of LCL outgrowth control.	Cyclosporine	6-19	CD4 molecule	Homo sapiens	73-76
18230104-11	2008	Thus, an up-regulation of p21 expression, via a p53-independent pathway, by cyclosporine A in gingival and oral epithelial cells was suggested.	Cyclosporine	76-90	tumor protein p53	Homo sapiens	48-51
18192894-0	2008	Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms.	Cyclosporine	20-32	ATP binding cassette subfamily B member 1	Homo sapiens	84-89
18192894-1	2008	OBJECTIVE: To evaluate whether variations in the ABCB1, ABCC2, SLCO1B1, CYP3A4, CYP3A5, or NR1I2 genes are associated with the pharmacokinetics of cyclosporine in pediatric renal transplant candidates, and whether the effects of these variants are related to age.	Cyclosporine	147-159	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	72-78
18192894-1	2008	OBJECTIVE: To evaluate whether variations in the ABCB1, ABCC2, SLCO1B1, CYP3A4, CYP3A5, or NR1I2 genes are associated with the pharmacokinetics of cyclosporine in pediatric renal transplant candidates, and whether the effects of these variants are related to age.	Cyclosporine	147-159	nuclear receptor subfamily 1 group I member 2	Homo sapiens	91-96
18192894-9	2008	CONCLUSIONS: Although these data suggest an age-related effect of ABCB1 polymorphism on oral bioavailability, further studies are required on the predictive value of genotyping for individualization of cyclosporine dosing in children.	Cyclosporine	202-214	ATP binding cassette subfamily B member 1	Homo sapiens	66-71
18197554-1	2008	The hypothesis tested was that ketoconazole can modulate P-glycoprotein, thereby altering cellular uptake and apparent permeability (P(app)) of multidrug-resistant substrates, such as cyclosporin A (CSA) and digoxin, across Caco-2, MDCKII-MDR1, and MDCKII wild-type cell transport models.	Cyclosporine	184-197	ATP binding cassette subfamily B member 1	Homo sapiens	57-71
19099959-7	2008	Treatment with SIN alone did not affect gene expressions of bFGF, VEGF, and ET-1 while expressions of bFGF, VEGF, and ET-1 were significantly reduced by combined treatment with SIN and CsA.	Cyclosporine	185-188	endothelin 1	Rattus norvegicus	118-122
18158868-8	2008	As a positive control, CsA has the same function as HPC, except for promoting ERK and Akt phosphorylation and upregulating VEGF.	Cyclosporine	23-26	mitogen-activated protein kinase 1	Homo sapiens	78-81
18158868-8	2008	As a positive control, CsA has the same function as HPC, except for promoting ERK and Akt phosphorylation and upregulating VEGF.	Cyclosporine	23-26	AKT serine/threonine kinase 1	Homo sapiens	86-89
18158868-8	2008	As a positive control, CsA has the same function as HPC, except for promoting ERK and Akt phosphorylation and upregulating VEGF.	Cyclosporine	23-26	vascular endothelial growth factor A	Homo sapiens	123-127
19036152-9	2008	Treatment with TNF antagonists (-0.28 (-0.5 to -0.05)) and with gold salts (-0.21 (-0.38 to -0.04)) was independently associated with a decrease in the DAS28-3 over time, whereas cyclosporin A treatment (0.45 (0.13 to 0.76)) was associated with an increase in disease activity.	Cyclosporine	179-192	tumor necrosis factor	Homo sapiens	15-18
18277615-4	2008	Moreover, the BL-AP transport in the Caco-2 cells was significantly reduced by the cis-presence of P-glycoprotein (P-gp) inhibitors such as cyclosporine A, verapamil, and digoxin.	Cyclosporine	140-154	ATP binding cassette subfamily B member 1	Homo sapiens	99-113
18277615-4	2008	Moreover, the BL-AP transport in the Caco-2 cells was significantly reduced by the cis-presence of P-glycoprotein (P-gp) inhibitors such as cyclosporine A, verapamil, and digoxin.	Cyclosporine	140-154	ATP binding cassette subfamily B member 1	Homo sapiens	115-119
19136727-3	2008	In this study, NALDI/SiNWs and ITO were tested as potentially useful DESI substrates for selected model analytes (cyclosporine, beauverolide, surfactin and nystatin).	Cyclosporine	114-126	desumoylating isopeptidase 2	Homo sapiens	69-73
18665658-8	2008	Several available statin medications are metabolized by cytochrome P450 (CYP) 3A4 and can therefore interact with commonly used medications such as amiodarone, macrolide antibacterials, calcium channel antagonists, fibric acid derivatives and ciclosporin.	Cyclosporine	243-254	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-81
18721002-3	2008	Cinacalcet, as well as some immunosuppressants such as ciclosporin, tacrolimus and sirolimus, is partially metabolized by the cytochrome P450 3A enzymes (CYP3A).	Cyclosporine	55-66	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	154-159
18076219-19	2008	Dosage adjustments may be required for drugs that are substrates of CYP3A4 (e.g. ciclosporin, triazolam) and CYP2C19 enzymes (e.g. diazepam, phenytoin) when administered with armodafinil.	Cyclosporine	81-92	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	68-74
18569092-0	2008	Cyclosporin a Up-regulates B7-DC expression on dendritic cells in an IL-4-dependent manner in vitro, which is associated with decreased allostimulatory capacity of dendritic cells.	Cyclosporine	0-13	interleukin 4	Homo sapiens	69-73
18440851-3	2008	Treatment of human proximal tubular epithelial cells with CsA resulted in increased fibronectin production which coincided with increased PKC activity.	Cyclosporine	58-61	fibronectin 1	Homo sapiens	84-95
18440851-6	2008	Inhibition of PKC-beta completely abrogated the CsA-induced increase in fibronectin secretion demonstrating a direct antifibrotic effect of PKC-beta inhibition.	Cyclosporine	48-51	fibronectin 1	Homo sapiens	72-83
18703855-1	2008	OBJECTIVE: To investigate the effects of the potent immunosuppressive agent cyclosporin A (CsA) on the proliferation of human endothelial progenitor cells (EPCs) and endothelial nitric oxide synthase (eNOS) expression in EPCs.	Cyclosporine	76-89	nitric oxide synthase 3	Homo sapiens	166-199
18703855-6	2008	The effects of CsA on EPC proliferation, apoptosis, and eNOS/NO production were dose dependent in the concentration ranging from 0.1 microg/mL to 10 microg/mL.	Cyclosporine	15-18	nitric oxide synthase 3	Homo sapiens	56-60
18703855-7	2008	Treatment with VEGF (50 ng/mL) significantly promoted EPC proliferation and eNOS/NO production, which were completely abrogated by pre-incubation with CsA (10 microg/mL).	Cyclosporine	151-154	vascular endothelial growth factor A	Homo sapiens	15-19
18703855-7	2008	Treatment with VEGF (50 ng/mL) significantly promoted EPC proliferation and eNOS/NO production, which were completely abrogated by pre-incubation with CsA (10 microg/mL).	Cyclosporine	151-154	nitric oxide synthase 3	Homo sapiens	76-80
18703855-9	2008	CONCLUSION: CsA significantly inhibited proliferation, eNOS mRNA expression and NO production of human EPCs, in a dose-dependent manner.	Cyclosporine	12-15	nitric oxide synthase 3	Homo sapiens	55-59
18306108-5	2008	Here, we first identified the cDNA and protein structures of miniature pig HIF-1alpha, and next investigated the effects of cyclosporine and FK506 on HIF-1alpha expression in endothelial cells of miniature pig.	Cyclosporine	124-136	hypoxia inducible factor 1 subunit alpha	Sus scrofa	150-160
17947497-6	2008	Pgp inhibitors verapamil, cyclosporine A, or PSC833 increased doxorubicin accumulation in the MDR cells up to 79%, and it reversed drug resistance in these cells.	Cyclosporine	26-40	ATP binding cassette subfamily B member 1	Homo sapiens	0-3
17461432-6	2008	A significant elevation in serum AST and ALT activities was observed in the CsA group, and when NAC and CsA were co-administered, the activities of AST and ALT were close to the control levels.	Cyclosporine	76-79	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	33-36
17461432-6	2008	A significant elevation in serum AST and ALT activities was observed in the CsA group, and when NAC and CsA were co-administered, the activities of AST and ALT were close to the control levels.	Cyclosporine	76-79	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	148-151
17461432-6	2008	A significant elevation in serum AST and ALT activities was observed in the CsA group, and when NAC and CsA were co-administered, the activities of AST and ALT were close to the control levels.	Cyclosporine	104-107	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	33-36
17461432-6	2008	A significant elevation in serum AST and ALT activities was observed in the CsA group, and when NAC and CsA were co-administered, the activities of AST and ALT were close to the control levels.	Cyclosporine	104-107	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	148-151
18179928-5	2008	RESULTS: Early apoptosis signaling events (Bax translocation to the mitochondria) were prominent in cold crystalloid cardioplegia and prevented in cold crystalloid cardioplegia + cyclosporine A myocardium.	Cyclosporine	179-193	BCL2 associated X, apoptosis regulator	Homo sapiens	43-46
18179928-6	2008	Mitochondrial release of cytochrome c, determined by Western blot of cytosolic fractions and confocal quantitative colocalization analysis, was also prominent in cold crystalloid cardioplegia but prevented in cold crystalloid cardioplegia + cyclosporine A myocardium.	Cyclosporine	241-255	cytochrome c, somatic	Homo sapiens	25-37
17949992-7	2008	Moreover, depolarization of cultured DRG neurons induced de novo synthesis of CCR2 mRNA, which was blocked by the calcineurin inhibitors cyclosporin A and FK506.	Cyclosporine	137-150	C-C motif chemokine receptor 2	Homo sapiens	78-82
17960138-5	2008	Cyclosporine decreased cell viability and induced ROS generation and ERK and phosphoinositide 3-kinase activation.	Cyclosporine	0-12	mitogen-activated protein kinase 1	Mus musculus	69-72
19378430-7	2008	CsA inhibited the H/R-induced translocation of cytochrome c, increased bcl-2 expression and restored mitochondrial membrane potential.	Cyclosporine	0-3	cytochrome c, somatic	Homo sapiens	47-59
17978097-5	2008	The effect of CCK was dependent on calcineurin, as these changes were blocked by immunosuppressants FK506 and CsA and by overexpression of the endogenous protein inhibitor CAIN.	Cyclosporine	110-113	cholecystokinin	Homo sapiens	14-17
18227030-6	2008	CsA treatment (at 20, 10, and 5 mg/kg, respectively) resulted in reduced serum IFN-gamma levels but produced virtually no effect on the tumor weight, and no obvious correlation was found between serum IFN-gamma level and the tumor weight.	Cyclosporine	0-3	interferon gamma	Mus musculus	79-88
19284090-3	2008	We report a case of a patient with recurrent staphylococcal cold abscesses, eczematous dermatitis and high serum IgE levels in which the treatment with Cyclosporine A seems to have a favorable effect.	Cyclosporine	152-166	immunoglobulin heavy constant epsilon	Homo sapiens	113-116
17693930-9	2008	Furthermore, overexpression of CRT or inhibition of CaN with cyclosporine A abolishes FGF-2-induced microvascular endothelial cells proliferation and CaN expression.	Cyclosporine	61-75	fibroblast growth factor 2	Homo sapiens	86-91
18261573-10	2008	Both CsA and FK506 caused mild osteoblastic proliferation and matrix mineralization activity, as reflected by increased osteocalcin and alkaline phosphatase levels in 22.6% and 12.5% of patients, respectively.	Cyclosporine	5-8	bone gamma-carboxyglutamate protein	Homo sapiens	120-131
19378430-7	2008	CsA inhibited the H/R-induced translocation of cytochrome c, increased bcl-2 expression and restored mitochondrial membrane potential.	Cyclosporine	0-3	BCL2 apoptosis regulator	Homo sapiens	71-76
23100926-2	2007	Response to various drugs like steroid, Intravenous Immunoglobin (IVIG), recombinant human erythropoietin and plasmapheresis vary in different cases.Cyclosporin A may be effective in cases even unresponsive to other modalities of therapy.	Cyclosporine	149-162	erythropoietin	Homo sapiens	91-105
17996694-2	2007	Using MACS-purified CD4 cells, we found that rapamycin and cyclosporine A (CsA) potently inhibited the TGFbeta and IL-6-induced generation of IL-17-producing cells.	Cyclosporine	59-73	CD4 molecule	Homo sapiens	20-23
17996694-2	2007	Using MACS-purified CD4 cells, we found that rapamycin and cyclosporine A (CsA) potently inhibited the TGFbeta and IL-6-induced generation of IL-17-producing cells.	Cyclosporine	59-73	interleukin 6	Homo sapiens	115-119
17996694-2	2007	Using MACS-purified CD4 cells, we found that rapamycin and cyclosporine A (CsA) potently inhibited the TGFbeta and IL-6-induced generation of IL-17-producing cells.	Cyclosporine	75-78	CD4 molecule	Homo sapiens	20-23
17996694-2	2007	Using MACS-purified CD4 cells, we found that rapamycin and cyclosporine A (CsA) potently inhibited the TGFbeta and IL-6-induced generation of IL-17-producing cells.	Cyclosporine	75-78	interleukin 6	Homo sapiens	115-119
18031601-7	2007	The inhibition of IK by CsA (100 micromol/L) persisted under the low Ca2+ conditions that blocked the basal activity of calcineurin.	Cyclosporine	24-27	carbonic anhydrase 2	Rattus norvegicus	69-72
18052710-0	2007	Apoptosis and expression of caspase-3 in cyclosporin-induced gingival overgrowth.	Cyclosporine	41-52	caspase 3	Homo sapiens	28-37
18052710-6	2007	RESULTS: Significant differences were found with regard to caspase-3 levels and the extent of apoptosis between the cyclosporin A group and the control group.	Cyclosporine	116-129	caspase 3	Homo sapiens	59-68
18052710-8	2007	CONCLUSION: The extent of keratinocyte apoptosis and decreased levels of caspase-3 may be an important factor affecting the gingiva of kidney transplant recipients with cyclosporin A-induced gingival overgrowth.	Cyclosporine	169-182	caspase 3	Homo sapiens	73-82
18089307-18	2007	Levels of TGF-beta1 were considerably reduced in FTY720-treated animals (compared with cyclosporine+IRI and IRI only), either alone (196+/-31 pg/mL vs 1105+/-59 pg/mL and 611+/-38; P&lt;.05) or in conjunction with cyclosporine (423+/-26 pg/mL vs 1105+/-59 pg/mL and 611+/-38; P&lt;.05).	Cyclosporine	214-226	transforming growth factor, beta 1	Rattus norvegicus	10-19
18089333-2	2007	Cyclosporine (CsA) has potent immunosuppressive properties, reflecting its ability to block the transcription of cytokine genes (mainly interleukin 2) in CD4+ T lymphocytes, markedly improving transplantation outcomes in the past 20 years.	Cyclosporine	0-12	interleukin 2	Homo sapiens	136-149
18089333-2	2007	Cyclosporine (CsA) has potent immunosuppressive properties, reflecting its ability to block the transcription of cytokine genes (mainly interleukin 2) in CD4+ T lymphocytes, markedly improving transplantation outcomes in the past 20 years.	Cyclosporine	14-17	interleukin 2	Homo sapiens	136-149
17998872-4	2007	RESULTS: A brief treatment of Serp-1 alone, or a subtherapeutic dose of CsA, resulted in a marked decrease in intragraft macrophage infiltration and downregulation of toll-like receptor (TLR)-2, TLR4 and MyD88 at 48 hours posttransplantation, which was associated with significantly reduced numbers of mature dendritic cells.	Cyclosporine	72-75	toll-like receptor 2	Rattus norvegicus	167-193
17761160-3	2007	FK506 and cyclosporine A, calcineurin inhibitors, partially inhibited UTP-induced IL-6 mRNA expression and protein production.	Cyclosporine	10-24	interleukin 6	Homo sapiens	82-86
17998872-4	2007	RESULTS: A brief treatment of Serp-1 alone, or a subtherapeutic dose of CsA, resulted in a marked decrease in intragraft macrophage infiltration and downregulation of toll-like receptor (TLR)-2, TLR4 and MyD88 at 48 hours posttransplantation, which was associated with significantly reduced numbers of mature dendritic cells.	Cyclosporine	72-75	toll-like receptor 4	Rattus norvegicus	195-199
17959987-1	2007	BACKGROUND: The calcineurin inhibitor, cyclosporine, is widely used for preventing allograft rejection in organ transplantation.	Cyclosporine	39-51	calcineurin binding protein 1	Mus musculus	16-37
17959987-2	2007	Systemically administered cyclosporine is prevented from entering into the brain by the action of P-glycoprotein, encoded by the multidrug resistant 1 (mdr1) gene.	Cyclosporine	26-38	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	152-156
17975262-6	2007	Furthermore, SB203580 and PD098059 act as inhibitors of p38MAPK and ERK1/2 respectively, wortmannin, an inhibitor of phosphatidylinositol-3-kinase, and cyclosporin A, a calcineurin inhibitor, hindered both translocation of Rac2 from the cytosol to the plasma membrane and enhancement of Rac2 GTP-binding elicited by Ang II.	Cyclosporine	152-165	Rac family small GTPase 2	Homo sapiens	223-227
17686907-4	2007	Considering that cyclosporin A and rifampicin inhibit multiple uptake/efflux transporters, the interactions of CP-671,305 with major human hepatic drug transporters, multidrug resistance protein 1 (MDR1), multidrug resistance-associated protein 2 (MRP2), breast cancer resistant protein (BCRP), and organic anion-transporting polypeptide (OATPs) were evaluated in vitro.	Cyclosporine	17-30	ATP binding cassette subfamily B member 1	Homo sapiens	166-196
17761346-2	2007	The importance of IL-2 down-regulation in preventing acute rejection in organ transplantation and the development of autoimmune diseases has been demonstrated by the therapeutic usefulness of the widely used immunosuppressants cyclosporine A and FK506.	Cyclosporine	227-241	interleukin 2	Homo sapiens	18-22
17761348-3	2007	However, there is evidence that high concentration of nitric oxide (NO) occurring as a result of iNOS induction and peroxynitrite formation, is capable of causing lipid peroxidation and protein oxidation in cyclosporine A (CsA) induced cellular damage.	Cyclosporine	207-221	nitric oxide synthase 2	Rattus norvegicus	97-101
17761348-3	2007	However, there is evidence that high concentration of nitric oxide (NO) occurring as a result of iNOS induction and peroxynitrite formation, is capable of causing lipid peroxidation and protein oxidation in cyclosporine A (CsA) induced cellular damage.	Cyclosporine	223-226	nitric oxide synthase 2	Rattus norvegicus	97-101
17975262-6	2007	Furthermore, SB203580 and PD098059 act as inhibitors of p38MAPK and ERK1/2 respectively, wortmannin, an inhibitor of phosphatidylinositol-3-kinase, and cyclosporin A, a calcineurin inhibitor, hindered both translocation of Rac2 from the cytosol to the plasma membrane and enhancement of Rac2 GTP-binding elicited by Ang II.	Cyclosporine	152-165	Rac family small GTPase 2	Homo sapiens	287-291
17991613-6	2007	COX-2 up-regulation was Ca(2+)-dependent and was partially blocked by cyclosporin A indicating that the 5-LO/COX-2 cross-talk involved signaling through a nuclear factor of activated T cells (NFAT) dependent pathway.	Cyclosporine	70-83	prostaglandin-endoperoxide synthase 2	Homo sapiens	0-5
17991613-6	2007	COX-2 up-regulation was Ca(2+)-dependent and was partially blocked by cyclosporin A indicating that the 5-LO/COX-2 cross-talk involved signaling through a nuclear factor of activated T cells (NFAT) dependent pathway.	Cyclosporine	70-83	prostaglandin-endoperoxide synthase 2	Homo sapiens	109-114
18021968-2	2007	In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients.	Cyclosporine	94-106	CD4 molecule	Homo sapiens	155-158
18005864-0	2007	Differential cyclosporin-A sensitivity on survival and activation of umbilical cord and adult peripheral blood CD4+ T cells.	Cyclosporine	13-26	CD4 molecule	Homo sapiens	111-114
18005864-1	2007	Enhanced cyclosporine-A (CsA) sensitivity of umbilical cord blood (CB) CD4(+) T cells may contribute to the lower incidence of graft-versus-host disease (GVHD) after mismatched CB transplantation.	Cyclosporine	9-23	CD4 molecule	Homo sapiens	71-74
18021968-2	2007	In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients.	Cyclosporine	94-106	CD4 molecule	Homo sapiens	170-173
18005864-1	2007	Enhanced cyclosporine-A (CsA) sensitivity of umbilical cord blood (CB) CD4(+) T cells may contribute to the lower incidence of graft-versus-host disease (GVHD) after mismatched CB transplantation.	Cyclosporine	25-28	CD4 molecule	Homo sapiens	71-74
18005864-3	2007	The present study examines CsA sensitivity of IL-15-driven CB CD4(+) T cell survival, activation and proliferation, comparing adult peripheral blood (APB) CD4(+) T cell responses.	Cyclosporine	27-30	CD4 molecule	Homo sapiens	62-65
18021968-2	2007	In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients.	Cyclosporine	94-106	CD4 molecule	Homo sapiens	170-173
18021968-2	2007	In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients.	Cyclosporine	108-111	CD4 molecule	Homo sapiens	155-158
18021968-2	2007	In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients.	Cyclosporine	108-111	CD4 molecule	Homo sapiens	170-173
18021968-2	2007	In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients.	Cyclosporine	108-111	CD4 molecule	Homo sapiens	170-173
18021968-8	2007	The percentage of CD4(+)CD25(+)Foxp3(+) T cells in rapamycin (sirolimus) treated patients did not differ from that observed in healthy individuals, but was significantly higher compared with CsA-treated patients.	Cyclosporine	191-194	CD4 molecule	Homo sapiens	18-21
18021968-9	2007	CsA therapy resulted in a reduction in the percentage of CD4(+)CD25(+)CTLA-4(+) and CD4(+)CD25(+)Foxp3(+) regulatory T cells after renal transplantation in both groups (RAR-S and RAR-CH) compared with patients treated with rapamycin or to healthy donors.	Cyclosporine	0-3	CD4 molecule	Homo sapiens	57-60
18021968-9	2007	CsA therapy resulted in a reduction in the percentage of CD4(+)CD25(+)CTLA-4(+) and CD4(+)CD25(+)Foxp3(+) regulatory T cells after renal transplantation in both groups (RAR-S and RAR-CH) compared with patients treated with rapamycin or to healthy donors.	Cyclosporine	0-3	CD4 molecule	Homo sapiens	84-87
18021968-9	2007	CsA therapy resulted in a reduction in the percentage of CD4(+)CD25(+)CTLA-4(+) and CD4(+)CD25(+)Foxp3(+) regulatory T cells after renal transplantation in both groups (RAR-S and RAR-CH) compared with patients treated with rapamycin or to healthy donors.	Cyclosporine	0-3	RAB40B, member RAS oncogene family	Homo sapiens	169-172
17689165-10	2007	The activities of superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) were higher in CsA plus erdosteine group than CsA group.	Cyclosporine	112-115	catalase	Rattus norvegicus	46-54
17880416-3	2007	RESULTS: Upon exposure to ciclosporin A (500 ng/mL) or tacrolimus (25 ng/mL) the number of cytokine expressing T cells was almost completely blocked in neonatal T cells while sirolimus (10 ng/mL) only inhibited intracytoplasmatic tumour necrosis factor alpha (TNF-alpha) expression (mean% positive cells; 4.0 +/- 2.1% vs. 1.09 +/- 0.6%, p = 0.003), but mildly stimulated the intracellular expression of interleukin (IL)-2 (24.4 +/- 6.5% vs. 28.1 +/- 7.1%, p = 0.041).	Cyclosporine	26-39	tumor necrosis factor	Homo sapiens	260-269
17880416-3	2007	RESULTS: Upon exposure to ciclosporin A (500 ng/mL) or tacrolimus (25 ng/mL) the number of cytokine expressing T cells was almost completely blocked in neonatal T cells while sirolimus (10 ng/mL) only inhibited intracytoplasmatic tumour necrosis factor alpha (TNF-alpha) expression (mean% positive cells; 4.0 +/- 2.1% vs. 1.09 +/- 0.6%, p = 0.003), but mildly stimulated the intracellular expression of interleukin (IL)-2 (24.4 +/- 6.5% vs. 28.1 +/- 7.1%, p = 0.041).	Cyclosporine	26-39	interleukin 2	Homo sapiens	403-421
17880416-4	2007	In cord blood lymphocytes, the inhibitory effect of ciclosporin A and tacrolimus was dose-dependent (e.g. IL-2: control, 12.3 +/- 5.33%, ciclosporin A 5 ng/mL, 10.1 +/- 5.5%; 50 ng/mL, 7.1 +/- 4.7%; 500 ng/mL, 1.2 +/- 0.3%; tacrolimus 0.25 ng/mL, 9.3 +/- 4.9%; 2.5 ng/mL, 6.1 +/- 3.3%; 25 ng/mL, 1.0 +/- 0.6%), while the function of adult lymphocytes was only impaired at high doses of both compounds.	Cyclosporine	52-65	interleukin 2	Homo sapiens	106-110
17666045-4	2007	Here we demonstrate that in mouse cortical neurons, inhibition of the Ca(2+)-dependent protein phosphatase calcineurin by FK506 or cyclosporine A blocks CREB-dependent gene expression induced by depolarization without inhibiting depolarization-induced Ca(2+) influx or CREB Ser-133 phosphorylation.	Cyclosporine	131-145	cAMP responsive element binding protein 1	Mus musculus	153-157
17651692-2	2007	CsA treatment reduced basal and TNFalpha-induced rates of lipolysis by 50%.	Cyclosporine	0-3	tumor necrosis factor	Homo sapiens	32-40
17651692-4	2007	CsA treatment dramatically reduced the mRNA levels of adipocyte-specific genes (aP2, HSL, PPARgamma, ACS and Adn), compared with control or TNFalpha-treatment, whereas Li(+) pretreatment blocked the inhibitory effects of CsA, and mRNA levels of aP2, HSL, PPARgamma, and ACS were found at or above control levels.	Cyclosporine	0-3	peroxisome proliferator activated receptor gamma	Homo sapiens	90-99
17651692-4	2007	CsA treatment dramatically reduced the mRNA levels of adipocyte-specific genes (aP2, HSL, PPARgamma, ACS and Adn), compared with control or TNFalpha-treatment, whereas Li(+) pretreatment blocked the inhibitory effects of CsA, and mRNA levels of aP2, HSL, PPARgamma, and ACS were found at or above control levels.	Cyclosporine	0-3	peroxisome proliferator activated receptor gamma	Homo sapiens	255-264
17615153-5	2007	We also tested the hypothesis that the AR interacts with another immunophilin, cyclophilin 40 (Cyp40), and is regulated by its cognate ligand cyclosporin A (CsA).	Cyclosporine	157-160	androgen receptor	Homo sapiens	39-41
17615153-7	2007	In the absence of androgen, CsA caused inhibition of cell growth in the AR-positive LNCaP and AR-negative PC-3 and DU145 cell lines.	Cyclosporine	28-31	androgen receptor	Homo sapiens	72-74
17615153-7	2007	In the absence of androgen, CsA caused inhibition of cell growth in the AR-positive LNCaP and AR-negative PC-3 and DU145 cell lines.	Cyclosporine	28-31	androgen receptor	Homo sapiens	94-96
17615153-11	2007	Further studies in LNCaP cells revealed that CsA and FK506 were able to block or attenuate several stages of AR signaling, including hormone binding, nuclear translocation, and activity at several AR-responsive reporter and endogenous genes.	Cyclosporine	45-48	androgen receptor	Homo sapiens	109-111
17760822-6	2007	RESULTS: In cultured human gingival fibroblasts and epithelial cells, the expression of cyclooxygenase-2 mRNA was measured after treatment with cyclosporine A.	Cyclosporine	144-158	prostaglandin-endoperoxide synthase 2	Homo sapiens	88-104
17760822-7	2007	Significantly lower expression of cyclooxygenase-2 and interleukin-1beta mRNA, but higher interleukin-6 expression, were observed in gingiva from cyclosporine A-treated rats than in those from the control rats.	Cyclosporine	146-160	interleukin 1 beta	Rattus norvegicus	55-72
17760822-7	2007	Significantly lower expression of cyclooxygenase-2 and interleukin-1beta mRNA, but higher interleukin-6 expression, were observed in gingiva from cyclosporine A-treated rats than in those from the control rats.	Cyclosporine	146-160	interleukin 6	Rattus norvegicus	90-103
17954189-5	2007	The next morning (D(0)) patients were given CsA (4 mg/kg bid).	Cyclosporine	44-47	BH3 interacting domain death agonist	Homo sapiens	57-60
17689165-10	2007	The activities of superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) were higher in CsA plus erdosteine group than CsA group.	Cyclosporine	112-115	catalase	Rattus norvegicus	56-59
17689165-11	2007	However, the CAT, GSH-Px and SOD activities were significantly lower in CsA group than in control group and erdosteine group.	Cyclosporine	72-75	catalase	Rattus norvegicus	13-16
17596534-7	2007	CsA caused an increase in p16(INK4a) (CDKN2A) expression after a 13-day exposure in primary proximal tubular cells but not in HK-2 cells.	Cyclosporine	0-3	cyclin dependent kinase inhibitor 2A	Homo sapiens	26-29
17557911-1	2007	Inhibition of mitochondrial permeability transition pore (mPTP) opening by cyclosporin A or ischemic postconditioning attenuates lethal reperfusion injury.	Cyclosporine	75-88	protein tyrosine phosphatase, receptor type, U	Mus musculus	58-62
17615162-0	2007	Cyclosporin inhibition of collagen remodeling is mediated by gelsolin.	Cyclosporine	0-11	gelsolin	Mus musculus	61-69
17596534-6	2007	Furthermore, CsA exposure lead to a reduction of telomere length, increased p53 serine 15 phosphorylation, and caused an upregulation of the cell cycle inhibitor p21(Kip1) (CDKN1A) mRNA levels.	Cyclosporine	13-16	tumor protein p53	Homo sapiens	76-79
17596534-7	2007	CsA caused an increase in p16(INK4a) (CDKN2A) expression after a 13-day exposure in primary proximal tubular cells but not in HK-2 cells.	Cyclosporine	0-3	cyclin dependent kinase inhibitor 2A	Homo sapiens	30-35
17596534-6	2007	Furthermore, CsA exposure lead to a reduction of telomere length, increased p53 serine 15 phosphorylation, and caused an upregulation of the cell cycle inhibitor p21(Kip1) (CDKN1A) mRNA levels.	Cyclosporine	13-16	cyclin dependent kinase inhibitor 1A	Homo sapiens	162-165
17615162-4	2007	Because gelsolin is a Ca(2+)-dependent actin-severing protein that mediates collagen phagocytosis, we determined whether gelsolin is a CsA target.	Cyclosporine	135-138	gelsolin	Mus musculus	121-129
17596534-7	2007	CsA caused an increase in p16(INK4a) (CDKN2A) expression after a 13-day exposure in primary proximal tubular cells but not in HK-2 cells.	Cyclosporine	0-3	cyclin dependent kinase inhibitor 2A	Homo sapiens	38-44
17596534-6	2007	Furthermore, CsA exposure lead to a reduction of telomere length, increased p53 serine 15 phosphorylation, and caused an upregulation of the cell cycle inhibitor p21(Kip1) (CDKN1A) mRNA levels.	Cyclosporine	13-16	cyclin dependent kinase inhibitor 1A	Homo sapiens	173-179
17645631-5	2007	In the present study, we investigated the angiogenic potential of recombinant human erythropoietin on cyclosporine A (CsA)-induced nephrotoxicity in the rat kidney and compared it with the effect of basic fibroblast growth factor (bFGF), a well-known angiogenic factor.	Cyclosporine	118-121	erythropoietin	Homo sapiens	84-98
17958337-6	2007	P-glycoprotein inhibitors such as cyclosporine, tariquidar and verapamil significantly increased the influx of udenafil and decreased the efflux of udenafil.	Cyclosporine	34-46	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
17615162-5	2007	Compared with vehicle controls, CsA treatment of wild-type mice increased collagen accumulation by 60% in periodontal tissues; equivalent increases were seen in vehicle-treated gelsolin-null mice.	Cyclosporine	32-35	gelsolin	Mus musculus	177-185
17615162-6	2007	Collagen degradation by phagocytosis in cultured gelsolin wild-type fibroblasts was blocked by CsA, comparable to levels of vehicle-treated gelsolin-null fibroblasts.	Cyclosporine	95-98	gelsolin	Mus musculus	49-57
17615162-8	2007	CsA blocked collagen-induced Ca(2+) fluxes subjacent to bound collagen beads, gelsolin recruitment, and actin assembly at bead sites.	Cyclosporine	0-3	gelsolin	Mus musculus	78-86
17615162-9	2007	CsA reduced gelsolin-dependent severing of actin in wild-type cells to levels similar to those in gelsolin-null fibroblasts.	Cyclosporine	0-3	gelsolin	Mus musculus	12-20
17615162-10	2007	We conclude that CsA-induced accumulation of collagen in the extracellular matrix involves disruption of the actin-severing properties of gelsolin, thereby inhibiting the binding step of collagen phagocytosis.	Cyclosporine	17-20	gelsolin	Mus musculus	138-146
19668484-0	2007	MDR1 polymorphisms effect cyclosporine AUC0-4 values in Behcet"s disease patients.	Cyclosporine	26-38	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
17636278-0	2007	Cyclosporine A induces titin expression via MAPK/ERK signalling and improves proliferative and invasive potential of human trophoblast cells.	Cyclosporine	0-14	mitogen-activated protein kinase 1	Homo sapiens	49-52
17684059-7	2007	Pretreatment of PC12 cells with inhibitors of calcineurin (protein phosphatase 2B), cyclosporin A and FK506, prevented depolarization-induced nuclear translocation and tyrosine phosphorylation of PYK2.	Cyclosporine	84-97	protein tyrosine kinase 2 beta	Rattus norvegicus	196-200
17917372-0	2007	Cyclosporine A inhibits the mRNA expressions of IL-2, IL-4 and IFN-gamma, but not TNF-alpha, in canine mononuclear cells.	Cyclosporine	0-14	interleukin 4	Canis lupus familiaris	54-58
17697052-7	2007	Cyclosporin A-mediated inhibition of Pgp enhanced the uptake of morphine in lambda-carrageenan and control animals.	Cyclosporine	0-13	ATP binding cassette subfamily B member 1	Homo sapiens	37-40
17581860-7	2007	CaN inhibitors (cypermethrin, cyclosporin A) discriminated between ORCC/CFTR by inhibiting the CFTR(inh172)-, but not the DIDS-sensitive currents, by &gt;70%.	Cyclosporine	30-43	CF transmembrane conductance regulator	Homo sapiens	72-76
17710652-5	2007	The inhibition profiles of cyclosporin A, verapamil, benzbromarone, and probenecid in erythrocyte membrane vesicles were typical for MRP1-mediated transport.	Cyclosporine	27-40	ATP binding cassette subfamily C member 1	Homo sapiens	133-137
17581860-7	2007	CaN inhibitors (cypermethrin, cyclosporin A) discriminated between ORCC/CFTR by inhibiting the CFTR(inh172)-, but not the DIDS-sensitive currents, by &gt;70%.	Cyclosporine	30-43	CF transmembrane conductance regulator	Homo sapiens	95-99
17764543-7	2007	For all cytokines except IFN gamma, the IC50 values for inhibition by cyclosporin A were similar in ABL and CBL.	Cyclosporine	70-83	interferon gamma	Homo sapiens	25-34
17889127-8	2007	At 3 months" posttransplant, patients treated with CyA showed significantly higher levels of IL-6 (P = .05), SAA (P = .03), and sIL-2R (P = .008) compared with patients treated with TC.	Cyclosporine	51-54	interleukin 6	Homo sapiens	93-97
17889127-12	2007	CONCLUSIONS: Patients treated with CyA displayed significantly higher levels of inflammatory markers (IL-6, SAA, sIL-2R) at 3 and 12 months" posttransplantation, independent of age, gender, time on dialysis, diabetes mellitus (preRT and de novo postRT), and renal function measured by serum creatinine.	Cyclosporine	35-38	interleukin 6	Homo sapiens	102-106
17617853-4	2007	We now test the hypothesis that the mechanism by which cyclosporine blocks tolerance induction is IL-2 dependent, and linked to a detrimental effect upon T(reg) function.	Cyclosporine	55-67	interleukin 2	Homo sapiens	98-102
17591771-4	2007	Given the well established interaction between cyclosporin A and the cyclophilin superfamily of peptidylprolyl cis-trans isomerases, we solved the structure of cyclophilin A from S. mansoni (SmCypA) by x-ray crystallography in the reduced and oxidized states at 1.5 and 1.8 A of resolution, respectively.	Cyclosporine	47-60	cyclophilin	Schistosoma mansoni	160-171
17687035-3	2007	Systemic cyclosporine administration decreased calcineurin activity in the brain, attenuated nicotine-mediated locomotor sensitization, and blocked the effects of nicotine on DARPP32 (dopamine- and cAMP-regulated phosphoprotein-32) activation in the striatum.	Cyclosporine	9-21	protein phosphatase 1, regulatory (inhibitor) subunit 1B	Rattus norvegicus	175-182
17687035-3	2007	Systemic cyclosporine administration decreased calcineurin activity in the brain, attenuated nicotine-mediated locomotor sensitization, and blocked the effects of nicotine on DARPP32 (dopamine- and cAMP-regulated phosphoprotein-32) activation in the striatum.	Cyclosporine	9-21	protein phosphatase 1, regulatory (inhibitor) subunit 1B	Rattus norvegicus	184-230
17617853-5	2007	Our study demonstrates that cyclosporine blocks IL-2 gene expression and activation induced cell death (AICD) of alloreactive T effector cells.	Cyclosporine	28-40	interleukin 2	Homo sapiens	48-52
17617853-6	2007	We also show that cyclosporine abolishes the beneficial effects of a donor specific transfusion (DST) plus anti-CD154 monoclonal antibody (alpha CD154) regimen on enhanced T(regs) function and allograft tolerance induction.	Cyclosporine	18-30	CD40 ligand	Homo sapiens	112-117
17617853-6	2007	We also show that cyclosporine abolishes the beneficial effects of a donor specific transfusion (DST) plus anti-CD154 monoclonal antibody (alpha CD154) regimen on enhanced T(regs) function and allograft tolerance induction.	Cyclosporine	18-30	CD40 ligand	Homo sapiens	145-150
17617853-7	2007	Interestingly, provision of IL-2/Fc, a long-lived form of IL-2, completely reverses the detrimental effects of this adjunctive cyclosporine treatment on AICD of alloreactive T effectors, T(regs) function and tolerance induction.	Cyclosporine	127-139	interleukin 2	Homo sapiens	28-32
17617853-7	2007	Interestingly, provision of IL-2/Fc, a long-lived form of IL-2, completely reverses the detrimental effects of this adjunctive cyclosporine treatment on AICD of alloreactive T effectors, T(regs) function and tolerance induction.	Cyclosporine	127-139	interleukin 2	Homo sapiens	58-62
17596340-10	2007	Inhibition of NFATc2 by VIVIT or cyclosporine restored Kv1.5 expression and current, decreased [Ca(2+)](i), [K(+)](i), bcl-2, and Delta Psi m, leading to decreased proliferation and increased apoptosis in vitro.	Cyclosporine	33-45	potassium voltage-gated channel subfamily A member 5	Homo sapiens	55-60
17559898-7	2007	While the DAS-mediated apoptosis and activation of caspase-9 and caspase-3 were slightly suppressed by the mitochondrial permeability transition pore inhibitor (CsA), both caspase-8 activation and Bid cleavage were not affected by CsA.	Cyclosporine	161-164	caspase 3	Homo sapiens	65-74
17612778-6	2007	Treatment with CsA for either 60 or 120 days was associated with bone resorption, represented by lower bone volume and increased number of osteoclasts; serum BALP, TRAP-5b, IL-1beta, IL-6, and TNF-alpha were also higher in these animals.	Cyclosporine	15-18	interleukin 1 beta	Rattus norvegicus	173-181
17612778-6	2007	Treatment with CsA for either 60 or 120 days was associated with bone resorption, represented by lower bone volume and increased number of osteoclasts; serum BALP, TRAP-5b, IL-1beta, IL-6, and TNF-alpha were also higher in these animals.	Cyclosporine	15-18	tumor necrosis factor	Rattus norvegicus	193-202
17612778-8	2007	This study shows that conversion from CsA to tacrolimus therapy leads to a reversal of the CsA-induced bone loss, which can probably be mediated by downregulation of IL-1beta, IL-6, and TNF-alpha production.	Cyclosporine	38-41	interleukin 1 beta	Rattus norvegicus	166-174
17612778-8	2007	This study shows that conversion from CsA to tacrolimus therapy leads to a reversal of the CsA-induced bone loss, which can probably be mediated by downregulation of IL-1beta, IL-6, and TNF-alpha production.	Cyclosporine	38-41	interleukin 6	Rattus norvegicus	176-180
17612778-8	2007	This study shows that conversion from CsA to tacrolimus therapy leads to a reversal of the CsA-induced bone loss, which can probably be mediated by downregulation of IL-1beta, IL-6, and TNF-alpha production.	Cyclosporine	38-41	tumor necrosis factor	Rattus norvegicus	186-195
17612778-8	2007	This study shows that conversion from CsA to tacrolimus therapy leads to a reversal of the CsA-induced bone loss, which can probably be mediated by downregulation of IL-1beta, IL-6, and TNF-alpha production.	Cyclosporine	91-94	interleukin 1 beta	Rattus norvegicus	166-174
17612778-8	2007	This study shows that conversion from CsA to tacrolimus therapy leads to a reversal of the CsA-induced bone loss, which can probably be mediated by downregulation of IL-1beta, IL-6, and TNF-alpha production.	Cyclosporine	91-94	interleukin 6	Rattus norvegicus	176-180
17612778-8	2007	This study shows that conversion from CsA to tacrolimus therapy leads to a reversal of the CsA-induced bone loss, which can probably be mediated by downregulation of IL-1beta, IL-6, and TNF-alpha production.	Cyclosporine	91-94	tumor necrosis factor	Rattus norvegicus	186-195
17606988-6	2007	In addition, specific chemical inhibitors of the NFAT pathway, such as cyclosporin A and VIVIT peptide, abolished antigen and anti-IgE-induced cyclooxygenase-2 (COX2) gene upregulation and prostaglandin (PGE(2)) release, suggesting that this process is through NFAT.	Cyclosporine	71-84	prostaglandin-endoperoxide synthase 2	Homo sapiens	143-159
17606988-6	2007	In addition, specific chemical inhibitors of the NFAT pathway, such as cyclosporin A and VIVIT peptide, abolished antigen and anti-IgE-induced cyclooxygenase-2 (COX2) gene upregulation and prostaglandin (PGE(2)) release, suggesting that this process is through NFAT.	Cyclosporine	71-84	prostaglandin-endoperoxide synthase 2	Homo sapiens	161-165
17591533-7	2007	A significant interaction of ACE inhibitors with cyclosporine in affecting LVMi change was shown by means of post hoc multiple regression analysis (P &lt; 0.01; differences between cyclosporine and tacrolimus group, 13.3 +/- 3.9 g/m(2.7); 95% CI, 5.3 to 21.2; P &lt; 0.01 in the ACE-inhibitor group; 3.7 +/- 4.2 g/m(2.7); 95% CI, -4.7 to 12.2; P = 0.4 in the control group).	Cyclosporine	49-61	angiotensin I converting enzyme	Homo sapiens	29-32
17591533-7	2007	A significant interaction of ACE inhibitors with cyclosporine in affecting LVMi change was shown by means of post hoc multiple regression analysis (P &lt; 0.01; differences between cyclosporine and tacrolimus group, 13.3 +/- 3.9 g/m(2.7); 95% CI, 5.3 to 21.2; P &lt; 0.01 in the ACE-inhibitor group; 3.7 +/- 4.2 g/m(2.7); 95% CI, -4.7 to 12.2; P = 0.4 in the control group).	Cyclosporine	49-61	angiotensin I converting enzyme	Homo sapiens	279-282
17591533-7	2007	A significant interaction of ACE inhibitors with cyclosporine in affecting LVMi change was shown by means of post hoc multiple regression analysis (P &lt; 0.01; differences between cyclosporine and tacrolimus group, 13.3 +/- 3.9 g/m(2.7); 95% CI, 5.3 to 21.2; P &lt; 0.01 in the ACE-inhibitor group; 3.7 +/- 4.2 g/m(2.7); 95% CI, -4.7 to 12.2; P = 0.4 in the control group).	Cyclosporine	181-193	angiotensin I converting enzyme	Homo sapiens	29-32
17591533-9	2007	Interaction of ACE inhibitors with cyclosporine treatment emerged from post hoc analysis.	Cyclosporine	35-47	angiotensin I converting enzyme	Homo sapiens	15-18
17591533-11	2007	This regression seems to be at least in part the effect of an interaction between ACE inhibitors and cyclosporine.	Cyclosporine	101-113	angiotensin I converting enzyme	Homo sapiens	82-85
17031644-1	2007	PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP).	Cyclosporine	86-89	ATP binding cassette subfamily B member 1	Homo sapiens	174-188
17580257-4	2007	The first cohort of 21 patients were given cyclosporine (CSP) and mycophenolate mofetil (MMF) as postgrafting immunosuppression, whereas the subsequent cohort was given additional methotrexate (MTX) and extended duration of CSP/MMF prophylaxis in an attempt to reduce graft-versus-host disease (GVHD).	Cyclosporine	43-55	DnaJ heat shock protein family (Hsp40) member C5	Homo sapiens	57-60
17031644-1	2007	PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP).	Cyclosporine	86-89	ATP binding cassette subfamily B member 1	Homo sapiens	190-193
17031644-5	2007	RESULTS: CsA increased cellular drug uptake in cells overexpressing Pgp, MRP-1 or BCRP and nuclear drug uptake in cells overexpressing LRP at the clinically achievable concentration of 2.5 microM.	Cyclosporine	9-12	ATP binding cassette subfamily B member 1	Homo sapiens	68-71
17031644-5	2007	RESULTS: CsA increased cellular drug uptake in cells overexpressing Pgp, MRP-1 or BCRP and nuclear drug uptake in cells overexpressing LRP at the clinically achievable concentration of 2.5 microM.	Cyclosporine	9-12	ATP binding cassette subfamily B member 1	Homo sapiens	73-78
17031644-1	2007	PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP).	Cyclosporine	86-89	ATP binding cassette subfamily B member 1	Homo sapiens	195-200
17031644-5	2007	RESULTS: CsA increased cellular drug uptake in cells overexpressing Pgp, MRP-1 or BCRP and nuclear drug uptake in cells overexpressing LRP at the clinically achievable concentration of 2.5 microM.	Cyclosporine	9-12	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	82-86
17031644-1	2007	PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP).	Cyclosporine	86-89	ATP binding cassette subfamily B member 1	Homo sapiens	203-233
17031644-9	2007	CONCLUSIONS: CsA, tacrolimus and sirolimus modulate drug transport by Pgp, MRP-1 and BCRP and CsA and sirolimus modulate drug transport by LRP at concentrations that differ from immunosuppressive concentrations and maximum tolerated concentrations.	Cyclosporine	13-16	ATP binding cassette subfamily B member 1	Homo sapiens	70-73
17031644-9	2007	CONCLUSIONS: CsA, tacrolimus and sirolimus modulate drug transport by Pgp, MRP-1 and BCRP and CsA and sirolimus modulate drug transport by LRP at concentrations that differ from immunosuppressive concentrations and maximum tolerated concentrations.	Cyclosporine	13-16	ATP binding cassette subfamily B member 1	Homo sapiens	75-80
17031644-1	2007	PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP).	Cyclosporine	86-89	ATP binding cassette subfamily B member 1	Homo sapiens	235-240
17031644-9	2007	CONCLUSIONS: CsA, tacrolimus and sirolimus modulate drug transport by Pgp, MRP-1 and BCRP and CsA and sirolimus modulate drug transport by LRP at concentrations that differ from immunosuppressive concentrations and maximum tolerated concentrations.	Cyclosporine	13-16	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	85-89
17031644-1	2007	PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP).	Cyclosporine	86-89	ATP binding cassette subfamily C member 1	Homo sapiens	242-247
17031644-1	2007	PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP).	Cyclosporine	86-89	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	253-285
17031644-1	2007	PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP).	Cyclosporine	86-89	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	287-291
17031644-1	2007	PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP).	Cyclosporine	86-89	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	293-298
17645716-1	2007	The mTOR (mammalian target of rapamycin) inhibitors sirolimus (SRL) and everolimus (EVL) are potent immunosuppressive agents, which allow reducing the dose of the nephrotoxic calcineurin inhibitors cyclosporin and tacrolimus (TAC) in solid organ transplant recipients.	Cyclosporine	198-209	mechanistic target of rapamycin kinase	Homo sapiens	4-8
17630850-12	2007	Furthermore, cyclosporin A, which inhibits mitochondrial pore opening and cytochrome c loss, did not alter NO-induced cell death.	Cyclosporine	13-26	cytochrome c, somatic	Homo sapiens	74-86
17645716-1	2007	The mTOR (mammalian target of rapamycin) inhibitors sirolimus (SRL) and everolimus (EVL) are potent immunosuppressive agents, which allow reducing the dose of the nephrotoxic calcineurin inhibitors cyclosporin and tacrolimus (TAC) in solid organ transplant recipients.	Cyclosporine	198-209	mechanistic target of rapamycin kinase	Homo sapiens	10-39
17584600-0	2007	Activation of PPARgamma enhances in vitro the immunosuppressive effect of cyclosporine on T lymphocytes.	Cyclosporine	74-86	peroxisome proliferator activated receptor gamma	Homo sapiens	14-23
18240909-5	2007	The association between the CYP3A4 and CYP3A5 polymorphisms and cyclosporine pharmacokinetics is more questionable.	Cyclosporine	64-76	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	28-34
18240909-5	2007	The association between the CYP3A4 and CYP3A5 polymorphisms and cyclosporine pharmacokinetics is more questionable.	Cyclosporine	64-76	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	39-45
17600343-4	2007	LT patients receiving cyclosporine (CsA) or tacrolimus (FK) had a similar fibrosis progression rate and alphaSMA and TGFbeta(1) expression.	Cyclosporine	22-34	transforming growth factor beta 1	Homo sapiens	117-127
17600343-4	2007	LT patients receiving cyclosporine (CsA) or tacrolimus (FK) had a similar fibrosis progression rate and alphaSMA and TGFbeta(1) expression.	Cyclosporine	36-39	transforming growth factor beta 1	Homo sapiens	117-127
17321721-4	2007	CsA induced p21WAF1/Cip1 expression de novo in human glioblastoma cells with p53 deficiency.	Cyclosporine	0-3	cyclin dependent kinase inhibitor 1A	Homo sapiens	20-24
17565322-5	2007	Interestingly, induction of IL-21 was highly dependent on IL-2 (as in the presence of anti-IL-2, anti-IL-2R alpha-chain, and the immunosuppressive drugs cyclosporine A, tacrolimus, and rapamycin) the transcription of IL-21 was almost completely inhibited, whereas in the presence of exogenous IL-2 the mRNA expression of IL-21 was even more upregulated.	Cyclosporine	153-167	interleukin 2	Homo sapiens	28-32
17565322-5	2007	Interestingly, induction of IL-21 was highly dependent on IL-2 (as in the presence of anti-IL-2, anti-IL-2R alpha-chain, and the immunosuppressive drugs cyclosporine A, tacrolimus, and rapamycin) the transcription of IL-21 was almost completely inhibited, whereas in the presence of exogenous IL-2 the mRNA expression of IL-21 was even more upregulated.	Cyclosporine	153-167	interleukin 2	Homo sapiens	58-62
17565322-5	2007	Interestingly, induction of IL-21 was highly dependent on IL-2 (as in the presence of anti-IL-2, anti-IL-2R alpha-chain, and the immunosuppressive drugs cyclosporine A, tacrolimus, and rapamycin) the transcription of IL-21 was almost completely inhibited, whereas in the presence of exogenous IL-2 the mRNA expression of IL-21 was even more upregulated.	Cyclosporine	153-167	interleukin 2	Homo sapiens	58-62
17303652-7	2007	PDGF also caused cyclosporin A-sensitive translocation of NFATc3, with no apparent effect on either CnAalpha or NFATc1 distribution.	Cyclosporine	17-30	nuclear factor of activated T-cells 3	Rattus norvegicus	58-64
17321721-4	2007	CsA induced p21WAF1/Cip1 expression de novo in human glioblastoma cells with p53 deficiency.	Cyclosporine	0-3	tumor protein p53	Homo sapiens	77-80
17321721-5	2007	We demonstrate that transcriptional activation of p21WAF1/Cip1 expression correlated with induction of ERK1/2 and c-Jun phosphorylation in CsA-treated glioblastoma cells.	Cyclosporine	139-142	cyclin dependent kinase inhibitor 1A	Homo sapiens	58-62
17321721-5	2007	We demonstrate that transcriptional activation of p21WAF1/Cip1 expression correlated with induction of ERK1/2 and c-Jun phosphorylation in CsA-treated glioblastoma cells.	Cyclosporine	139-142	mitogen-activated protein kinase 3	Homo sapiens	103-109
17321721-9	2007	It suggests that CsA activates p53-independent, transcriptional activation p21WAF1/Cip1 expression, mediated by ERK/c-Jun/AP-1 signaling pathway.	Cyclosporine	17-20	tumor protein p53	Homo sapiens	31-34
17321721-9	2007	It suggests that CsA activates p53-independent, transcriptional activation p21WAF1/Cip1 expression, mediated by ERK/c-Jun/AP-1 signaling pathway.	Cyclosporine	17-20	cyclin dependent kinase inhibitor 1A	Homo sapiens	83-87
17321721-9	2007	It suggests that CsA activates p53-independent, transcriptional activation p21WAF1/Cip1 expression, mediated by ERK/c-Jun/AP-1 signaling pathway.	Cyclosporine	17-20	mitogen-activated protein kinase 1	Homo sapiens	112-115
17545536-1	2007	PURPOSE: Increased clearance of drugs, such as oral cyclosporine, that are CYP3A and/or ABCB1 (P-gp/MDR1) substrates was reported in African-American compared with Caucasian patients.	Cyclosporine	52-64	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-80
17545536-1	2007	PURPOSE: Increased clearance of drugs, such as oral cyclosporine, that are CYP3A and/or ABCB1 (P-gp/MDR1) substrates was reported in African-American compared with Caucasian patients.	Cyclosporine	52-64	ATP binding cassette subfamily B member 1	Homo sapiens	88-93
17545536-1	2007	PURPOSE: Increased clearance of drugs, such as oral cyclosporine, that are CYP3A and/or ABCB1 (P-gp/MDR1) substrates was reported in African-American compared with Caucasian patients.	Cyclosporine	52-64	ATP binding cassette subfamily B member 1	Homo sapiens	100-104
17567463-4	2007	The combination of the mitochondrial permeability transition (MPT) inhibitors, cyclosporine A and trifluoperazine, protected AdIkappaBsr-infected hepatocytes from TNF-alpha- but not Fas-mediated apoptosis.	Cyclosporine	79-93	tumor necrosis factor	Homo sapiens	163-172
17258259-4	2007	Tax activates CD40L expression via a cyclosporin A insensitive pathway that is also independent of NF-kappaB.	Cyclosporine	37-50	CD40 ligand	Homo sapiens	14-19
17460148-2	2007	Activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinase (MAPK) cascade seems to be pivotal to the CsA-induced increase in transepithelial electrical resistance (TER).	Cyclosporine	144-147	mitogen-activated protein kinase 1	Canis lupus familiaris	61-67
17460148-2	2007	Activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinase (MAPK) cascade seems to be pivotal to the CsA-induced increase in transepithelial electrical resistance (TER).	Cyclosporine	144-147	mitogen-activated protein kinase 1	Canis lupus familiaris	103-107
17460148-3	2007	This study examined the role played by TGF-beta in mediating the CsA-induced activation of ERK1/2 and the resulting increase in TER in MDCK cells.	Cyclosporine	65-68	mitogen-activated protein kinase 1	Canis lupus familiaris	91-97
17299003-0	2007	The impact of short-term ciclosporin A treatment on insulin secretion and insulin sensitivity in man.	Cyclosporine	25-38	insulin	Homo sapiens	52-59
17308321-13	2007	CONCLUSIONS: These observations indicate that the thrombogenic properties of CsA may result from the alteration of lipid organization in platelet plasma membrane, leading to externalization of PS and accelerated thrombin generation.	Cyclosporine	77-80	coagulation factor II, thrombin	Homo sapiens	212-220
17369605-7	2007	Using HEK293-OATP1B3 cells, the cytotoxicity was attenuated by substrates and inhibitors of OATP1B3, including bromosulfophthalein, rifampicin, and cyclosporin A.	Cyclosporine	148-161	solute carrier organic anion transporter family member 1B3	Homo sapiens	13-20
17369605-7	2007	Using HEK293-OATP1B3 cells, the cytotoxicity was attenuated by substrates and inhibitors of OATP1B3, including bromosulfophthalein, rifampicin, and cyclosporin A.	Cyclosporine	148-161	solute carrier organic anion transporter family member 1B3	Homo sapiens	92-99
17549302-3	2007	Consistent with the importance of this pathway for tissue factor induction, treatment of endothelial cells with the Ca(++) chelator BAPTA-AM, as well as the calcineurin inhibitor cyclosporin A, partially inhibited VEGF-induced tissue factor upregulation.	Cyclosporine	179-192	vascular endothelial growth factor A	Homo sapiens	214-218
17376913-5	2007	This resistance is specific to CsA as the replicon cells most resistant to CsA were still sensitive to IFN-alpha and a polymerase inhibitor.	Cyclosporine	31-34	interferon alpha 1	Homo sapiens	103-112
17376913-5	2007	This resistance is specific to CsA as the replicon cells most resistant to CsA were still sensitive to IFN-alpha and a polymerase inhibitor.	Cyclosporine	75-78	interferon alpha 1	Homo sapiens	103-112
17493526-13	2007	The percentage of CD4+CD25+ T cells was higher in the CsA group.	Cyclosporine	54-57	CD4 molecule	Homo sapiens	18-21
17580145-14	2007	CONCLUSION: Cyclosporine, EC-MPS, and steroids with interleukin-2 antagonist induction offers effective and well-tolerated immunosuppression following renal transplantation.	Cyclosporine	12-24	interleukin 2	Homo sapiens	52-65
17519790-1	2007	BACKGROUND: Several single nucleotide polymorphisms (SNPs) in the multidrug resistance (MDR1) gene may play a role in the interindividual variation of cyclosporine A (CsA) absorption in renal transplant patients.	Cyclosporine	167-170	ATP binding cassette subfamily B member 1	Homo sapiens	88-92
17519790-10	2007	CONCLUSIONS: MDR1 polymorphisms are associated with differences in CsA exposure only in the first posttransplant week.	Cyclosporine	67-70	ATP binding cassette subfamily B member 1	Homo sapiens	13-17
17314201-7	2007	Cyclosporine A significantly inhibited Pgp-mediated transport of sitagliptin (IC50=1 microM).	Cyclosporine	0-14	ATP binding cassette subfamily B member 1	Homo sapiens	39-42
17347151-0	2007	Cyclosporin A and FK506 inhibit IL-12p40 production through the calmodulin/calmodulin-dependent protein kinase-activated phosphoinositide 3-kinase in lipopolysaccharide-stimulated human monocytic cells.	Cyclosporine	0-13	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	121-146
17019561-6	2007	Significant alterations in the lipid profile as well an increase in the activity of cholesterol ester synthase, coupled with a decrease in cholesterol ester hydrolase and lipoprotein lipase enzyme activities were noted in the plasma and kidneys of CsA-administered rats.	Cyclosporine	248-251	lipoprotein lipase	Rattus norvegicus	171-189
17229932-6	2007	CsA administration enhanced Th2 and reduced Th1 cytokine production at the materno-fetal interface, and it expanded peripheral CD4(+)CD25(+) FOXP3(+) regulatory T cells in abortion-prone matings, implying development of Th2 bias and regulatory T cells.	Cyclosporine	0-3	negative elongation factor complex member C/D, Th1l	Mus musculus	44-47
20477665-0	2007	The different effects of cyclosporin A and rapamycin on regulatory CD4+CD25+ T cells: potential relationship with transplant tolerance induction.	Cyclosporine	25-38	CD4 molecule	Homo sapiens	67-70
17516843-5	2007	Cyclosporin A abolished (p&lt;0.05) and KN-62 reduced (p&lt;0.1) the ionomycin-induced increase in PGC-1alpha mRNA.	Cyclosporine	0-13	PPARG coactivator 1 alpha	Rattus norvegicus	99-109
17024347-0	2007	Expression of multidrug resistance P-glycoprotein on lymphocytes from nephrotic children treated with cyclosporine A and ACE-inhibitor.	Cyclosporine	102-116	ATP binding cassette subfamily B member 1	Homo sapiens	35-49
17024347-1	2007	The aim of this work was to determine the expression of P-glycoprotein (P-gp) on peripheral lymphocytes (CD3) in children with steroid-dependent nephrotic syndrome (SDNS) during cyclosporine A (CyA) and ACE-inhibitor (ACE-I) treatment.	Cyclosporine	178-192	ATP binding cassette subfamily B member 1	Homo sapiens	56-70
17024347-1	2007	The aim of this work was to determine the expression of P-glycoprotein (P-gp) on peripheral lymphocytes (CD3) in children with steroid-dependent nephrotic syndrome (SDNS) during cyclosporine A (CyA) and ACE-inhibitor (ACE-I) treatment.	Cyclosporine	178-192	ATP binding cassette subfamily B member 1	Homo sapiens	72-76
17331500-6	2007	Induced VEGF production was strongly inhibited by anti-inflammatory agents, dexamethasone and cyclosporin A.	Cyclosporine	94-107	vascular endothelial growth factor A	Homo sapiens	8-12
17072346-5	2007	The protein mediates a cyclosporin A-inhibitable permeability transition, characterized by a loss of the inner transmembrane potential, matrix swelling, permeabilization of the inner mitochondrial membrane and the release of two pro-apoptotic proteins, cytochrome c and apoptosis-inducing factor (AIF).	Cyclosporine	23-36	cytochrome c, somatic	Homo sapiens	253-265
17452893-6	2007	A larger than 10 mL/min 1.73 m decrease in glomerular filtration rate was observed in more patients on CsA than on MMF (73% vs. 29%, P=0.019).	Cyclosporine	103-106	CD59 molecule (CD59 blood group)	Homo sapiens	20-25
17460566-0	2007	Influence of angiotensin II on expression of toll-like receptor 2 and maturation of dendritic cells in chronic cyclosporine nephropathy.	Cyclosporine	111-123	angiotensinogen	Rattus norvegicus	13-27
17578296-17	2007	CsA has immunosuppressive property in the condition of acute rejection in the rat orthotopic liver transplantation, which may be result from the decreased the level of Fkn.	Cyclosporine	0-3	C-X3-C motif chemokine ligand 1	Rattus norvegicus	168-171
17460566-0	2007	Influence of angiotensin II on expression of toll-like receptor 2 and maturation of dendritic cells in chronic cyclosporine nephropathy.	Cyclosporine	111-123	toll-like receptor 2	Rattus norvegicus	45-65
17460566-6	2007	RESULTS: AngII blockade with LSRT decreased toll-like receptor (TLR) 2 mRNA and protein expression, expression of tumor necrosis factor (TNF)-alpha mRNA, and expression of major histocompatibility complex class II antigen, which was upregulated in CsA-induced renal injury.	Cyclosporine	248-251	angiotensinogen	Rattus norvegicus	9-14
17291492-5	2007	Cyclosporin A (0.2 microM), a specific inhibitor of mitochondrial permeability transition, completely prevented the mitochondrial swelling induced by PK11195, and maintained the cytochrome c content and membrane potential.	Cyclosporine	0-13	cytochrome c, somatic	Homo sapiens	178-190
17460566-10	2007	CONCLUSION: AngII plays a pivotal role in activating the innate immune response in CsA-induced renal injury.	Cyclosporine	83-86	angiotensinogen	Rattus norvegicus	12-17
17374625-8	2007	DATA SYNTHESIS: Elevated plasma concentrations and toxicities have been reported for a number of CYP3A substrates including amiodarone, carbamazepine, quinidine, tacrolimus, and cyclosporine when administered with metronidazole.	Cyclosporine	178-190	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-102
17290357-6	2007	However, the addition of P-gp antagonists such as ciclosporin A and inhibitors of P-gp synthesis successfully reduce efflux of corticosteroids from lymphocytes in vitro and these results imply that P-gp antagonists and P-gp synthesis inhibitors could work in order to overcome drug-resistance in vivo.	Cyclosporine	50-63	ATP binding cassette subfamily B member 1	Homo sapiens	25-29
17320203-3	2007	The calpain inhibitor, calpeptin, and the calcineurin inhibitors, FK506 and cyclosporine A, inhibited acetylcholinesterase expression at both mRNA and protein levels and suppressed the activity of the human acetylcholinesterase promoter.	Cyclosporine	76-90	acetylcholinesterase (Cartwright blood group)	Homo sapiens	102-122
17320203-3	2007	The calpain inhibitor, calpeptin, and the calcineurin inhibitors, FK506 and cyclosporine A, inhibited acetylcholinesterase expression at both mRNA and protein levels and suppressed the activity of the human acetylcholinesterase promoter.	Cyclosporine	76-90	acetylcholinesterase (Cartwright blood group)	Homo sapiens	207-227
17425754-2	2007	Ciclosporin is a substrate for P-gp and is metabolized by cytochrome P450 (CYP) 3A enzymes.	Cyclosporine	0-11	ATP binding cassette subfamily B member 1	Homo sapiens	31-35
16947314-0	2007	Pure red cell aplasia caused by antibody to erythropoietin successfully treated by cyclosporine administration.	Cyclosporine	83-95	erythropoietin	Homo sapiens	44-58
17668351-6	2007	Treatment of CHO cells with cyclosporin A caused a reduction in the amount of full-length Cx43 and a concomitant increase in the amount of the 20-kDa band.	Cyclosporine	28-41	gap junction protein, alpha 1	Mus musculus	90-94
17425754-2	2007	Ciclosporin is a substrate for P-gp and is metabolized by cytochrome P450 (CYP) 3A enzymes.	Cyclosporine	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	58-82
17425754-4	2007	MDR-1 genotypes of SNPs C1236T, G2677T/A and C3435T, as well as haplotypes C-G-C and T-T-T and CYP3A5*1 genotype (predictive of CYP3A5 expression), were related to ciclosporin blood concentrations measured at both 0 and 2 h after drug dosing in 197 stable renal transplant patients.	Cyclosporine	164-175	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
17151193-8	2007	A deeper inhibitory effect of cyclosporine on the CL(int) of sirolimus depletion was found for rCYP 3A4 than for rCYP 3A5 (i.e., -44% versus -8% at 0.62 microM, 750 microg/l cyclosporine), and sirolimus metabolism was slightly less inhibited for HLMs expressing CYP 3A5 than not (-38% versus -56%).	Cyclosporine	30-42	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	114-121
17151193-10	2007	However, strong CYP 3A4 inhibition by cyclosporine could unveil the influence of this polymorphism.	Cyclosporine	38-50	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	16-23
17425754-5	2007	Significant differences (of a magnitude unlikely to be relevant clinically) in dose-normalized blood ciclosporin concentrations were found only between MDR-1 genotypes of the C1236T SNP and between haplotype groups C-G-C and T-T-T in patients that were expressers of CYP3A5.	Cyclosporine	101-112	ATP binding cassette subfamily B member 1	Homo sapiens	152-157
17425754-5	2007	Significant differences (of a magnitude unlikely to be relevant clinically) in dose-normalized blood ciclosporin concentrations were found only between MDR-1 genotypes of the C1236T SNP and between haplotype groups C-G-C and T-T-T in patients that were expressers of CYP3A5.	Cyclosporine	101-112	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	267-273
17000002-1	2007	Inhibition of the interleukin-2 (IL-2) pathway has potent immunosuppressive activity in humans as is evident from the broad therapeutic utility of cyclosporine, rapamycin, tacrolimus, and monoclonal antibodies blocking the high-affinity subunit of the IL-2 receptor (CD25).	Cyclosporine	147-159	interleukin 2	Homo sapiens	18-31
17362315-0	2007	Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial.	Cyclosporine	45-57	interferon alpha 1	Homo sapiens	63-79
17133350-7	2007	CsA administration totally inhibited the exercise-induced increase in MCIP-1 mRNA (P &lt; 0.01), blunted the IL-6 gene transcription related to muscle activity, and suppressed the changes in IL-6 protein in plasma.	Cyclosporine	0-3	interleukin 6	Rattus norvegicus	109-113
17133350-7	2007	CsA administration totally inhibited the exercise-induced increase in MCIP-1 mRNA (P &lt; 0.01), blunted the IL-6 gene transcription related to muscle activity, and suppressed the changes in IL-6 protein in plasma.	Cyclosporine	0-3	interleukin 6	Rattus norvegicus	191-195
17287424-6	2007	CD4(+)CD25(high) cells that expressed FOXP3 underwent homeostatic peripheral expansion during immune reconstitution, more intense in patients who received sirolimus than in those who were given CsA.	Cyclosporine	194-197	CD4 molecule	Homo sapiens	0-3
17027084-5	2007	IL-3 promoter region between -293 and -150bp was responsible for A23187-induced gene expression and PMA- or cyclosporin A (CsA)-mediated suppression.	Cyclosporine	108-121	interleukin 3	Mus musculus	0-4
17027084-5	2007	IL-3 promoter region between -293 and -150bp was responsible for A23187-induced gene expression and PMA- or cyclosporin A (CsA)-mediated suppression.	Cyclosporine	123-126	interleukin 3	Mus musculus	0-4
17000002-1	2007	Inhibition of the interleukin-2 (IL-2) pathway has potent immunosuppressive activity in humans as is evident from the broad therapeutic utility of cyclosporine, rapamycin, tacrolimus, and monoclonal antibodies blocking the high-affinity subunit of the IL-2 receptor (CD25).	Cyclosporine	147-159	interleukin 2	Homo sapiens	33-37
17123593-4	2007	While the daily administration of CsA at the dose 15 mg/kg for 21 days significantly decreased the seminal vesicles weight, epididymal sperm concentration, motility, testicular tissue glutathione (GSH), glutathione peroxidase (GSH-Px) and catalase (CAT), diameter of seminiferous tubules and germinal cell thickness, it increased malondialdehyde (MDA) level and abnormal sperm rates along with degeneration, necrosis, desquamative germ cells in testicular tissue.	Cyclosporine	34-37	catalase	Rattus norvegicus	239-247
17556798-0	2007	Polymorphism in the P-glycoprotein drug transporter MDR1 gene in renal transplant patients treated with cyclosporin A in a Polish population.	Cyclosporine	104-117	ATP binding cassette subfamily B member 1	Homo sapiens	20-34
17556798-0	2007	Polymorphism in the P-glycoprotein drug transporter MDR1 gene in renal transplant patients treated with cyclosporin A in a Polish population.	Cyclosporine	104-117	ATP binding cassette subfamily B member 1	Homo sapiens	52-56
17556798-1	2007	P-glycoprotein (P-gp), the product of MDR1 gene, is a protein which mediates transmembrane transport of a great number of xenobiotics including cyclosporin A used as an immunosuppressive drug in patients with allogenic kidney grafts.	Cyclosporine	144-157	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
17556798-1	2007	P-glycoprotein (P-gp), the product of MDR1 gene, is a protein which mediates transmembrane transport of a great number of xenobiotics including cyclosporin A used as an immunosuppressive drug in patients with allogenic kidney grafts.	Cyclosporine	144-157	ATP binding cassette subfamily B member 1	Homo sapiens	16-20
17556798-1	2007	P-glycoprotein (P-gp), the product of MDR1 gene, is a protein which mediates transmembrane transport of a great number of xenobiotics including cyclosporin A used as an immunosuppressive drug in patients with allogenic kidney grafts.	Cyclosporine	144-157	ATP binding cassette subfamily B member 1	Homo sapiens	38-42
17123593-4	2007	While the daily administration of CsA at the dose 15 mg/kg for 21 days significantly decreased the seminal vesicles weight, epididymal sperm concentration, motility, testicular tissue glutathione (GSH), glutathione peroxidase (GSH-Px) and catalase (CAT), diameter of seminiferous tubules and germinal cell thickness, it increased malondialdehyde (MDA) level and abnormal sperm rates along with degeneration, necrosis, desquamative germ cells in testicular tissue.	Cyclosporine	34-37	catalase	Rattus norvegicus	249-252
17624028-9	2007	The data suggest that the CYP3A4*18B genotype affects cyclosporine pharmacokinetics probably resulting from a higher enzymatic activity of this mutation in healthy subjects.	Cyclosporine	54-66	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	26-32
17624028-0	2007	Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects.	Cyclosporine	69-81	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	15-21
17268068-5	2007	P-gp function was estimated by transporter activity that was inferred from a decrease in fluorescent P-gp substrate Rhodamine 123 (Rh123) and its inhibition by cyclosporine A (CsA).	Cyclosporine	160-174	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
17624028-1	2007	The aim of this study is to evaluate the association of the CYP3A4*18B genotype with the cyclosporine metabolism in healthy subjects.	Cyclosporine	89-101	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-66
17115196-1	2007	The aim of this study was to assess the serum concentration of high-sensitivity C-reactive protein (hs-CRP) in children with nephrotic syndrome (NS) treated with prednisone and cyclosporine A (CyA).	Cyclosporine	177-191	C-reactive protein	Homo sapiens	80-98
17115196-1	2007	The aim of this study was to assess the serum concentration of high-sensitivity C-reactive protein (hs-CRP) in children with nephrotic syndrome (NS) treated with prednisone and cyclosporine A (CyA).	Cyclosporine	193-196	C-reactive protein	Homo sapiens	80-98
17227295-5	2007	RESULTS: In group I, at time points C0 and C2, increased CsA-PK significantly inhibited expression of IL-2, IFN-gamma, PCNA and CD25 (P &lt; 0.05).	Cyclosporine	57-60	interleukin 2	Homo sapiens	102-106
17227295-5	2007	RESULTS: In group I, at time points C0 and C2, increased CsA-PK significantly inhibited expression of IL-2, IFN-gamma, PCNA and CD25 (P &lt; 0.05).	Cyclosporine	57-60	interferon gamma	Homo sapiens	108-117
17268068-5	2007	P-gp function was estimated by transporter activity that was inferred from a decrease in fluorescent P-gp substrate Rhodamine 123 (Rh123) and its inhibition by cyclosporine A (CsA).	Cyclosporine	176-179	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
17202418-1	2007	The effects of the immunosuppressants cyclosporin A (CsA) and tacrolimus (FK506) on the IL-1beta-induced matrix metalloproteinase-9 (MMP-9) were investigated.	Cyclosporine	53-56	interleukin 1 beta	Homo sapiens	88-96
17357450-6	2007	These results above indicate that CsA can induce the expression of MMP-9 and MMP-2 through activating MAPK/ERK1/2, which contributes to the improved invasion of the first-trimester human trophoblast cells.	Cyclosporine	34-37	mitogen-activated protein kinase 3	Homo sapiens	102-106
17357450-6	2007	These results above indicate that CsA can induce the expression of MMP-9 and MMP-2 through activating MAPK/ERK1/2, which contributes to the improved invasion of the first-trimester human trophoblast cells.	Cyclosporine	34-37	mitogen-activated protein kinase 3	Homo sapiens	107-113
17105736-0	2007	Influence of the Plasmodium falciparum P-glycoprotein homologue 1 (pfmdr1 gene product) on the antimalarial action of cyclosporin.	Cyclosporine	118-129	ATP binding cassette subfamily B member 1	Homo sapiens	39-53
17105736-5	2007	We therefore investigated the possibility that the antimalarial target of cyclosporin might be a P-glycoprotein homologue.	Cyclosporine	74-85	ATP binding cassette subfamily B member 1	Homo sapiens	97-111
17202415-4	2007	It was reported recently that long-term CsA treatment was associated with decreased renal expression of TonEBP target genes, including aquaporin-2, urea transporter, and aldose reductase.	Cyclosporine	40-43	aldo-keto reductase family 1 member B	Homo sapiens	170-186
17202418-3	2007	It is demonstrated that CsA, in contrast to FK506, reduced the IL-1beta-induced MMP-9 content in conditioned media of mesangial cells, which coincides with a reduction in the cytokine-induced MMP-9 mRNA level.	Cyclosporine	24-27	interleukin 1 beta	Homo sapiens	63-71
17202418-5	2007	Moreover, CsA caused a dose-dependent inhibition on the IL-1beta-induced luciferase activity of a 1.3-kb MMP-9 promoter fragment.	Cyclosporine	10-13	interleukin 1 beta	Homo sapiens	56-64
17202418-10	2007	It is interesting that only the JNK inhibitor SP600125 impaired the cytokine-triggered MMP-9 level, suggesting that CsA, via inhibition of the JNK pathway, negatively interferes with the NF-kappaB-dependent transcriptional control of MMP-9.	Cyclosporine	116-119	mitogen-activated protein kinase 8	Homo sapiens	32-35
17202418-10	2007	It is interesting that only the JNK inhibitor SP600125 impaired the cytokine-triggered MMP-9 level, suggesting that CsA, via inhibition of the JNK pathway, negatively interferes with the NF-kappaB-dependent transcriptional control of MMP-9.	Cyclosporine	116-119	mitogen-activated protein kinase 8	Homo sapiens	143-146
17202418-10	2007	It is interesting that only the JNK inhibitor SP600125 impaired the cytokine-triggered MMP-9 level, suggesting that CsA, via inhibition of the JNK pathway, negatively interferes with the NF-kappaB-dependent transcriptional control of MMP-9.	Cyclosporine	116-119	nuclear factor kappa B subunit 1	Homo sapiens	187-196
29539178-1	2007	BACKGROUND: The purpose of this study was to study the expression of endothelin-1 (ET-1) and its receptors ETA and ETB in normal human gingiva and cyclosporin-induced gingival fibroblasts.	Cyclosporine	147-158	endothelin 1	Homo sapiens	69-81
17244767-3	2007	Cyclosporine was used as a probe P-glycoprotein inhibitor at a high dose to evaluate the potential effect of potent P-glycoprotein inhibition on single-dose sitagliptin pharmacokinetics in healthy male subjects.	Cyclosporine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	33-47
17244767-9	2007	These results rationalize the use of a single high-dose cyclosporine as a probe inhibitor of P-glycoprotein for compound candidates whose elimination is less dependent on CYP3A4-mediated metabolism.	Cyclosporine	56-68	ATP binding cassette subfamily B member 1	Homo sapiens	93-107
17244767-9	2007	These results rationalize the use of a single high-dose cyclosporine as a probe inhibitor of P-glycoprotein for compound candidates whose elimination is less dependent on CYP3A4-mediated metabolism.	Cyclosporine	56-68	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	171-177
29539178-1	2007	BACKGROUND: The purpose of this study was to study the expression of endothelin-1 (ET-1) and its receptors ETA and ETB in normal human gingiva and cyclosporin-induced gingival fibroblasts.	Cyclosporine	147-158	endothelin receptor type B	Homo sapiens	115-118
29539178-5	2007	The expression of ET-1 and its receptors was also examined in gingival fibroblast cells treated with CsA.	Cyclosporine	101-104	endothelin 1	Homo sapiens	18-22
29539178-6	2007	RESULTS: ET-1 mRNA expression was significantly higher in patients with CsA-induced gingival overgrowth (P &lt;0.001) than in patients with periodontitis and the controls.	Cyclosporine	72-75	endothelin 1	Homo sapiens	9-13
29539178-8	2007	In human gingival fibroblasts, ET-1 expression was increased with CsA incorporation compared to controls (P &lt;0.001).	Cyclosporine	66-69	endothelin 1	Homo sapiens	31-35
29539178-9	2007	CONCLUSION: These results suggest that CsA can modulate the expression of ET-1 in gingival fibroblasts and CsA-induced gingival overgrowth.	Cyclosporine	39-42	endothelin 1	Homo sapiens	74-78
17306744-7	2007	RESULTS: Western analyses showed that the mobility of apo-E was shifted at the latter tolerogenic phase after OLT in a natural tolerance model, and a similar phenomenon was confirmed in the serum of a drug-induced tolerance model (rejection model+cyclosporin A (CsA); 0 to 14 days) after cessation of CsA.	Cyclosporine	247-260	apolipoprotein E	Rattus norvegicus	54-59
17274718-1	2007	BACKGROUND: The purpose of this study was to study the expression of endothelin-1 (ET-1) and its receptors ETA and ETB in normal human gingiva and cyclosporin-induced gingival fibroblasts.	Cyclosporine	147-158	endothelin 1	Homo sapiens	69-81
17274718-1	2007	BACKGROUND: The purpose of this study was to study the expression of endothelin-1 (ET-1) and its receptors ETA and ETB in normal human gingiva and cyclosporin-induced gingival fibroblasts.	Cyclosporine	147-158	endothelin receptor type B	Homo sapiens	115-118
17274718-5	2007	The expression of ET-1 and its receptors was also examined in gingival fibroblast cells treated with CsA.	Cyclosporine	101-104	endothelin 1	Homo sapiens	18-22
17274718-6	2007	RESULTS: ET-1 mRNA expression was significantly higher in patients with CsA-induced gingival overgrowth (P &lt;0.001) than in patients with periodontitis and the controls.	Cyclosporine	72-75	endothelin 1	Homo sapiens	9-13
17274718-8	2007	In human gingival fibroblasts, ET-1 expression was increased with CsA incorporation compared to controls (P &lt;0.001).	Cyclosporine	66-69	endothelin 1	Homo sapiens	31-35
17274718-9	2007	CONCLUSION: These results suggest that CsA can modulate the expression of ET-1 in gingival fibroblasts and CsA-induced gingival overgrowth.	Cyclosporine	39-42	endothelin 1	Homo sapiens	74-78
17045309-8	2007	The AEDs phenytoin and levetiracetam were directionally transported by mouse but not human Pgp, whereas CsA was transported by both types of Pgp.	Cyclosporine	104-107	ATP binding cassette subfamily B member 1	Homo sapiens	141-144
16861707-4	2007	T-cell surface expression of CD40L was evaluated using two-colour flow cytometry in (i) the resting state and (ii) following stimulation with phorbol myristate acetate/ionomycin, with or without ciclosporin (CsA)-mediated inhibition.	Cyclosporine	195-206	CD40 ligand	Homo sapiens	29-34
16861707-4	2007	T-cell surface expression of CD40L was evaluated using two-colour flow cytometry in (i) the resting state and (ii) following stimulation with phorbol myristate acetate/ionomycin, with or without ciclosporin (CsA)-mediated inhibition.	Cyclosporine	208-211	CD40 ligand	Homo sapiens	29-34
16861707-6	2007	CsA-mediated inhibition of CD40L induction was equally effective in all study groups.	Cyclosporine	0-3	CD40 ligand	Homo sapiens	27-32
17490541-7	2007	After treatment with cyclosporine A, 9 out of 11 patients got good response, and CD3(+), CD8(+) cells in the responding patient decreased, the ratio of CD4(+)/CD8(+) returned to normal, and gammadelta T cells also decreased to normal range.	Cyclosporine	21-35	CD4 molecule	Homo sapiens	152-155
17306744-7	2007	RESULTS: Western analyses showed that the mobility of apo-E was shifted at the latter tolerogenic phase after OLT in a natural tolerance model, and a similar phenomenon was confirmed in the serum of a drug-induced tolerance model (rejection model+cyclosporin A (CsA); 0 to 14 days) after cessation of CsA.	Cyclosporine	262-265	apolipoprotein E	Rattus norvegicus	54-59
17306744-7	2007	RESULTS: Western analyses showed that the mobility of apo-E was shifted at the latter tolerogenic phase after OLT in a natural tolerance model, and a similar phenomenon was confirmed in the serum of a drug-induced tolerance model (rejection model+cyclosporin A (CsA); 0 to 14 days) after cessation of CsA.	Cyclosporine	301-304	apolipoprotein E	Rattus norvegicus	54-59
17141216-1	2007	Calcineurin, the Ca2+/calmodulin-dependant serine/threonine phosphatase is the target for the immunosuppressant drugs FK506 and cyclosporine-A.	Cyclosporine	128-142	calmodulin	Gossypium hirsutum	22-32
17477024-11	2007	CsA enhanced intrarenal RAS activity mainly through the activation of the AT1 receptor by increasing the receptor numbers.	Cyclosporine	0-3	angiotensin II receptor, type 1a	Mus musculus	74-77
17161467-0	2007	Cyclosporine A inhibits IL-15-induced IL-17 production in CD4+ T cells via down-regulation of PI3K/Akt and NF-kappaB.	Cyclosporine	0-14	AKT serine/threonine kinase 1	Homo sapiens	99-102
17161467-0	2007	Cyclosporine A inhibits IL-15-induced IL-17 production in CD4+ T cells via down-regulation of PI3K/Akt and NF-kappaB.	Cyclosporine	0-14	nuclear factor kappa B subunit 1	Homo sapiens	107-116
16636798-12	2007	As compared to cyclosporin A, these compounds showed reduced cellular toxicity and increased potency of BCRP and Pgp inhibition.	Cyclosporine	15-28	ATP binding cassette subfamily B member 1	Homo sapiens	113-116
17102134-7	2007	Treatment with the calcineurin inhibitors FK506 and cyclosporin A also blocked DREAM-mediated Kv4.2 channel trafficking and calcineurin de-phosphorylated GRK2-phosphorylated DREAM in vitro.	Cyclosporine	52-65	G protein-coupled receptor kinase 2	Homo sapiens	154-158
17596683-7	2007	RESULTS: Active caspase-7 was significantly increased in I/R and CsA-treated kidneys and decreased by Tac, Rap and MMF, while the caspase-7 precursor was enhanced by Rap.	Cyclosporine	65-68	caspase 7	Rattus norvegicus	16-25
17477024-12	2007	The results suggest the role of the AT1 receptor antagonist in treating CsA nephrotoxicity.	Cyclosporine	72-75	angiotensin II receptor, type 1a	Mus musculus	36-39
17727303-15	2007	Treatment with ciclosporin should be limited to patients with a relatively normal renal function (GFR &gt;60 mL/min/1.73m(2)) in view of its nephrotoxicity in patients with renal dysfunction.	Cyclosporine	15-26	CD59 molecule (CD59 blood group)	Homo sapiens	112-117
17299267-4	2007	This research showed that proliferation of cell lines with high-affinity IL-2 receptors derived from T cell malignancies were suppressed by the PMBN conjugated with IL-2 (PMBN-IL2 conjugate) incorporating paclitaxel (PTX) and cyclosporin A at lower concentrations than used conventionally.	Cyclosporine	226-239	interleukin 2	Homo sapiens	73-77
17299267-4	2007	This research showed that proliferation of cell lines with high-affinity IL-2 receptors derived from T cell malignancies were suppressed by the PMBN conjugated with IL-2 (PMBN-IL2 conjugate) incorporating paclitaxel (PTX) and cyclosporin A at lower concentrations than used conventionally.	Cyclosporine	226-239	interleukin 2	Homo sapiens	165-169
17198869-3	2007	MATERIALS AND METHODS: We investigated the relationships of the patients( *) HLA-DRB1 allele with both the presence of a small population of CD55(-)CD59(-) (PNH-type) blood cells and the response to antithymocyte globulin (ATG) plus cyclosporin (CsA) therapy in 140 Japanese AA patients.	Cyclosporine	233-244	major histocompatibility complex, class II, DR beta 1	Homo sapiens	77-85
17198869-3	2007	MATERIALS AND METHODS: We investigated the relationships of the patients( *) HLA-DRB1 allele with both the presence of a small population of CD55(-)CD59(-) (PNH-type) blood cells and the response to antithymocyte globulin (ATG) plus cyclosporin (CsA) therapy in 140 Japanese AA patients.	Cyclosporine	246-249	major histocompatibility complex, class II, DR beta 1	Homo sapiens	77-85
17038582-4	2007	Here, we show that treatment of T cells with cyclosporin A, FK506, and dexamethasone, which are known to inhibit calcineurin and NF-kappaB, respectively, but not rapamycin, the inhibitor of mammalian target of rapamycin, selectively prevented TCR/CD3 relocalization into the IS, while relocalization of adhesion and cytoskeletal proteins as well as T cell/APC conjugate formation remained unaltered.	Cyclosporine	45-58	nuclear factor kappa B subunit 1	Homo sapiens	129-138
17227616-5	2007	The bioactivity of ciclosporin MDI formulations was evaluated by determining the ciclosporin-mediated inhibition of interleukin-2 (IL-2) release from human Jurkat cells stimulated with phorbol 12-myristate 13-acetate (PMA).	Cyclosporine	19-30	interleukin 2	Homo sapiens	116-129
17227616-8	2007	HPLC analysis showed ciclosporin to be extremely stable in HFA 227 at room temperature and 40 degrees C. Stimulation of Jurkat cells with PMA released significant amounts of IL-2, which was inhibited by ciclosporin in a dose-dependent manner.	Cyclosporine	21-32	interleukin 2	Homo sapiens	174-178
17050779-4	2007	The rest of the Pgp molecules become recognized by this antibody only in the presence of certain substrates or modulators, including vinblastine, cyclosporine A (CsA), and SDZ PSC 833 (valspodar).	Cyclosporine	162-165	ATP binding cassette subfamily B member 1	Homo sapiens	16-19
17050779-6	2007	Remarkably, the inhibitory binding of the antibody is brought about by coincubation with concentrations of CsA or SDZ PSC 833 approximately 20 times lower than what is necessary for Pgp inhibition when the modulators are applied alone.	Cyclosporine	107-110	ATP binding cassette subfamily B member 1	Homo sapiens	182-185
17050779-7	2007	The feasibility of such a combinative treatment for in vivo multidrug resistance reversal was substantiated by the dramatic increase of daunorubicin accumulation in xenotransplanted Pgp+ tumors in response to a combined treatment with UIC2 and CsA, both administered at doses ineffective when applied alone.	Cyclosporine	244-247	ATP binding cassette subfamily B member 1	Homo sapiens	182-185
17227616-8	2007	HPLC analysis showed ciclosporin to be extremely stable in HFA 227 at room temperature and 40 degrees C. Stimulation of Jurkat cells with PMA released significant amounts of IL-2, which was inhibited by ciclosporin in a dose-dependent manner.	Cyclosporine	203-214	interleukin 2	Homo sapiens	174-178
17227616-5	2007	The bioactivity of ciclosporin MDI formulations was evaluated by determining the ciclosporin-mediated inhibition of interleukin-2 (IL-2) release from human Jurkat cells stimulated with phorbol 12-myristate 13-acetate (PMA).	Cyclosporine	19-30	interleukin 2	Homo sapiens	131-135
17164721-8	2006	More CD4CD25Treg cells expressing high levels of CD44 and CD45RB, and less CD4CD25Treg cells expressing CD62L were observed in CsA-treated mice, compared with the control mice.	Cyclosporine	127-130	selectin, lymphocyte	Mus musculus	104-109
17202802-3	2007	On the other hand, cyclosporine and tacrolimus competitively inhibited CYP3A4-mediated nifedipine oxidation activity, with inhibition constants (K(i)) of 1.42 and 0.36 muM, respectively.	Cyclosporine	19-31	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	71-77
17202802-4	2007	In addition, 20 muM cyclosporine inhibited CYP2C19 and CYP2D6 activities by 29% and 30%, respectively.	Cyclosporine	20-32	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	55-61
17109339-3	2006	RESULTS: Treatment with cyclosporin A provided only a marginal and transient enhancement in circulating T cell restoration that was largely restricted to cells expressing the CCR7 chemokine receptor and that did not persist beyond 2 weeks.	Cyclosporine	24-37	C-C motif chemokine receptor 7	Homo sapiens	175-179
17551263-8	2007	Furthermore, blocking calcineurin with deltamethrin, FK-506 or cyclosporin A blocked the inhibitory effect of GABA on [cAMP]i, supporting the involvement of AC9 in this effect.	Cyclosporine	63-76	adenylate cyclase 9	Mus musculus	157-160
17161347-10	2006	In CsA-treated animals (alone and with pioglitazone), TGF-beta1 and Smad3 increased significantly.	Cyclosporine	3-6	transforming growth factor, beta 1	Rattus norvegicus	54-63
17161347-10	2006	In CsA-treated animals (alone and with pioglitazone), TGF-beta1 and Smad3 increased significantly.	Cyclosporine	3-6	SMAD family member 3	Rattus norvegicus	68-73
17161347-11	2006	In animals treated with CsA and pioglitazone (5 mg/kg), PAI-1 was significantly lower than CsA alone (3.96+/-0.92 vs. 7.53+/-1.38, p&lt;0.05).	Cyclosporine	24-27	serpin family E member 1	Rattus norvegicus	56-61
17007989-5	2006	The spin-trap s-PBN, the ERK1/2 inhibitor U0126 and the antioxidant Vitamin E inhibited the 2-CPA-induced ROS formation completely, while the mitochondrial transition permeability pore blocker cyclosporine A inhibited the ROS formation partly.	Cyclosporine	193-207	carboxypeptidase A1	Homo sapiens	94-97
17199961-7	2006	RESULTS: Combined medication of 10(-9) mol/L calcitriol and 100 ng/ml CsA inhibited human peripheral mononuclear cells" proliferation to alloantigen and the production of IL-2 and IFN-gamma but promoted that of IL-4 and IL-10.	Cyclosporine	70-73	interleukin 2	Homo sapiens	171-175
17199961-7	2006	RESULTS: Combined medication of 10(-9) mol/L calcitriol and 100 ng/ml CsA inhibited human peripheral mononuclear cells" proliferation to alloantigen and the production of IL-2 and IFN-gamma but promoted that of IL-4 and IL-10.	Cyclosporine	70-73	interferon gamma	Homo sapiens	180-189
17199961-7	2006	RESULTS: Combined medication of 10(-9) mol/L calcitriol and 100 ng/ml CsA inhibited human peripheral mononuclear cells" proliferation to alloantigen and the production of IL-2 and IFN-gamma but promoted that of IL-4 and IL-10.	Cyclosporine	70-73	interleukin 4	Homo sapiens	211-215
17219692-5	2006	We investigated whether HO-1 played a role in cyclosporine-induced renal dysfunction in an established model of IRI.	Cyclosporine	46-58	heme oxygenase 1	Mus musculus	24-28
17219692-13	2006	HO-1 was markedly up-regulated after IRI, and its expression was decreased by cyclosporine (2.06 folds).	Cyclosporine	78-90	heme oxygenase 1	Mus musculus	0-4
17038319-8	2006	Cyclosporin A, a competitive P-glycoprotein inhibitor, restored intracellular dexamethasone levels in CD4+ T cells.	Cyclosporine	0-13	ATP binding cassette subfamily B member 1	Homo sapiens	29-43
17038319-8	2006	Cyclosporin A, a competitive P-glycoprotein inhibitor, restored intracellular dexamethasone levels in CD4+ T cells.	Cyclosporine	0-13	CD4 molecule	Homo sapiens	102-105
16892207-7	2006	On the other hand, the corrected V(max)/K(m) value of human P-gp for cyclosporin A transport was 3.8-fold higher than that of monkey P-gp.	Cyclosporine	69-82	ATP binding cassette subfamily B member 1	Homo sapiens	60-64
16790502-5	2006	Overexpression of mitochondrial calpain 10 resulted in mitochondrial swelling and autophagy that was blocked by the mitochondrial permeability transition (MPT) inhibitor cyclosporine A.	Cyclosporine	170-184	calpain 10	Mus musculus	32-42
17178259-9	2006	Cyclosporine (INN, ciclosporin) inhibits CYP3A4, P-glycoprotein (multidrug resistance protein 1), organic anion transporting polypeptide 1B1 (OATP1B1), and some other hepatic uptake transporters.	Cyclosporine	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-47
17178259-9	2006	Cyclosporine (INN, ciclosporin) inhibits CYP3A4, P-glycoprotein (multidrug resistance protein 1), organic anion transporting polypeptide 1B1 (OATP1B1), and some other hepatic uptake transporters.	Cyclosporine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	49-63
17178259-9	2006	Cyclosporine (INN, ciclosporin) inhibits CYP3A4, P-glycoprotein (multidrug resistance protein 1), organic anion transporting polypeptide 1B1 (OATP1B1), and some other hepatic uptake transporters.	Cyclosporine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	65-95
17178259-9	2006	Cyclosporine (INN, ciclosporin) inhibits CYP3A4, P-glycoprotein (multidrug resistance protein 1), organic anion transporting polypeptide 1B1 (OATP1B1), and some other hepatic uptake transporters.	Cyclosporine	19-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-47
17178259-9	2006	Cyclosporine (INN, ciclosporin) inhibits CYP3A4, P-glycoprotein (multidrug resistance protein 1), organic anion transporting polypeptide 1B1 (OATP1B1), and some other hepatic uptake transporters.	Cyclosporine	19-30	ATP binding cassette subfamily B member 1	Homo sapiens	49-63
17178259-9	2006	Cyclosporine (INN, ciclosporin) inhibits CYP3A4, P-glycoprotein (multidrug resistance protein 1), organic anion transporting polypeptide 1B1 (OATP1B1), and some other hepatic uptake transporters.	Cyclosporine	19-30	ATP binding cassette subfamily B member 1	Homo sapiens	65-95
17136718-1	2006	This work deals with the application of BSA and canine serum albumin (CSA) for enantioseparation of tryptophan derivatives with CE.	Cyclosporine	70-73	albumin	Homo sapiens	55-68
17106006-6	2006	Using genetic markers to adjust initial doses of cyclosporine or tacrolimus may prove difficult, considering the variety of polymorphism known to affect CYP3A4, CYP3A5, and the multidrug resistance-1 (MDR1) gene (the gene that codes for PGP).	Cyclosporine	49-61	ATP binding cassette subfamily B member 1	Homo sapiens	177-199
16892207-7	2006	On the other hand, the corrected V(max)/K(m) value of human P-gp for cyclosporin A transport was 3.8-fold higher than that of monkey P-gp.	Cyclosporine	69-82	ATP binding cassette subfamily B member 1	Homo sapiens	133-137
17081234-4	2006	Ciclosporin, at therapeutic concentrations, inhibits bile salt excretion pump (BSEP) function in rats and humans.	Cyclosporine	0-11	ATP binding cassette subfamily B member 11	Rattus norvegicus	79-83
17175314-1	2006	We previously confirmed that losartan (LOS), an angiotensin-II (A-II) receptor blocker, diminished plasminogen activator inhibitor-1 (PAI-1) in cyclosporine (CsA)-treated renal graft recipients.	Cyclosporine	158-161	angiotensinogen	Homo sapiens	48-62
17175267-10	2006	Interestingly, CsA treatment was associated with lower MCP-1 mRNA expression than that in the control group: mean MCP-1 mRNA expression 0.58 +/- 0.13 vs 1.02 +/- 0.12, respectively (P &lt; .05).	Cyclosporine	15-18	mast cell protease 1-like 1	Rattus norvegicus	55-60
16980307-7	2006	VEGF induction of the forkhead-dependent genes was down-regulated by the NF-kappaB inhibitor, constitutively active Ad-IkappaB, and in some cases by the nuclear factor of activated T-cells (NF-AT) inhibitor, cyclosporin.	Cyclosporine	208-219	vascular endothelial growth factor A	Homo sapiens	0-4
17175267-10	2006	Interestingly, CsA treatment was associated with lower MCP-1 mRNA expression than that in the control group: mean MCP-1 mRNA expression 0.58 +/- 0.13 vs 1.02 +/- 0.12, respectively (P &lt; .05).	Cyclosporine	15-18	mast cell protease 1-like 1	Rattus norvegicus	114-119
17122057-9	2006	Cyclosporin A, an inhibitor of CyP-D, mimicked the enhanced Ca2+ uptake in mutant mice.	Cyclosporine	0-13	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	31-36
17175234-13	2006	CsA-treated grafts showed intense posttransplant expression of TGF-beta and TGF-betaR1 after 90 days.	Cyclosporine	0-3	transforming growth factor, beta 1	Rattus norvegicus	63-71
17175234-17	2006	When combined with CsA or Tac, it decreased posttransplant TGF-beta ligand and receptor expression.	Cyclosporine	19-22	transforming growth factor, beta 1	Rattus norvegicus	59-67
17053191-8	2006	Trapping ABCA1 on the cell surface with cyclosporin A enhanced apoA-I binding but decreased its internalization and transcytosis.	Cyclosporine	40-53	apolipoprotein A1	Homo sapiens	63-69
17067582-3	2006	We have evaluated the effect of the immunophilin ligands FK506 and cyclosporin A on HIF1alpha levels in different tumor cell lines.	Cyclosporine	67-80	hypoxia inducible factor 1 subunit alpha	Homo sapiens	84-93
17042920-0	2006	Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.	Cyclosporine	63-75	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	36-42
16873536-7	2006	Inhibition of P-gp-mediated glucocorticoid efflux by cyclosporin A in BeWoMDR cells returned GR activation to levels similar to those in BeWo cells.	Cyclosporine	53-66	ATP binding cassette subfamily B member 1	Homo sapiens	14-18
16873536-7	2006	Inhibition of P-gp-mediated glucocorticoid efflux by cyclosporin A in BeWoMDR cells returned GR activation to levels similar to those in BeWo cells.	Cyclosporine	53-66	nuclear receptor subfamily 3 group C member 1	Homo sapiens	93-95
17049128-1	2006	AIM: To investigate whether the CYP3A5*3 polymorphism would affect cyclosporine A (CsA) metabolism in Chinese renal transplant patients.	Cyclosporine	83-86	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	32-38
17042920-0	2006	Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.	Cyclosporine	63-75	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	44-50
17042920-0	2006	Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.	Cyclosporine	63-75	ATP binding cassette subfamily B member 1	Homo sapiens	55-59
17042920-4	2006	Interindividual differences in the activity and expression of the metabolising enzymes cytochrome P450 (CYP) 3A4 and 3A5 and the multidrug efflux pump P-glycoprotein (P-gp) contribute considerably to cyclosporine pharmacokinetics.	Cyclosporine	200-212	ATP binding cassette subfamily B member 1	Homo sapiens	151-165
17042920-4	2006	Interindividual differences in the activity and expression of the metabolising enzymes cytochrome P450 (CYP) 3A4 and 3A5 and the multidrug efflux pump P-glycoprotein (P-gp) contribute considerably to cyclosporine pharmacokinetics.	Cyclosporine	200-212	ATP binding cassette subfamily B member 1	Homo sapiens	167-171
17042920-7	2006	The aim of the present study was to evaluate retrospectively the effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine dose adjusted trough blood concentration during the early period after renal transplantation in Chinese patients.	Cyclosporine	128-140	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	101-107
17042920-7	2006	The aim of the present study was to evaluate retrospectively the effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine dose adjusted trough blood concentration during the early period after renal transplantation in Chinese patients.	Cyclosporine	128-140	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	109-115
17042920-7	2006	The aim of the present study was to evaluate retrospectively the effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine dose adjusted trough blood concentration during the early period after renal transplantation in Chinese patients.	Cyclosporine	128-140	ATP binding cassette subfamily B member 1	Homo sapiens	120-124
17042920-14	2006	The median cyclosporine dose-adjusted C(0) in CYP3A5*1/*1 genotype subjects (n = 6) was 14.8 ng/mL per mg per kg (range 11.1-26.8 ng/mL per mg per kg), in CYP3A5*1/*3 patients (n = 34) it was 23.7 ng/mL per mg per kg (range 9.0-61.0 ng/mL per mg per kg) and for CYP3A5*3/*3 patients (n = 66) it was 26.4 ng/mL per mg per kg (range 9.8-85.8 ng/mL per mg per kg; P = 0.012, Kruskal-Wallis test).	Cyclosporine	11-23	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	46-52
17042920-15	2006	Accordingly, cyclosporine dose-adjusted C0 was larger in CYP3A5 non-expressors than expressors in the first week after renal transplantation.	Cyclosporine	13-25	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	57-63
17042920-18	2006	In conclusion, the present study shows that genetic polymorphisms in CYP3A5 may be responsible, in part, for the large interindividual variability of cyclosporine pharmacokinetics during the early phase after renal transplantation in Chinese patients.	Cyclosporine	150-162	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	69-75
17042920-19	2006	Patients with the CYP3A5*3 variant genotype require a low dose of cyclosporine to reach target levels compared with those with the CYP3A5*1 allele.	Cyclosporine	66-78	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	18-24
17058250-2	2006	Because cyclosporine inhibits erythropoietin (Epo) production in experimental models, we investigated whether Epo production was impaired in liver transplant recipients receiving a cyclosporine- or tacrolimus-based immunosuppressive regimen.	Cyclosporine	8-20	erythropoietin	Homo sapiens	30-44
16965524-8	2006	IL-1alpha, IL-1beta and IL-8, but not IL-6, were detected in GCF of CsA-treated patients, but none of them was significantly associated with gingival overgrowth.	Cyclosporine	68-71	interleukin 1 beta	Homo sapiens	11-19
16965524-8	2006	IL-1alpha, IL-1beta and IL-8, but not IL-6, were detected in GCF of CsA-treated patients, but none of them was significantly associated with gingival overgrowth.	Cyclosporine	68-71	C-X-C motif chemokine ligand 8	Homo sapiens	24-28
16904696-3	2006	The purpose of this study was to determine if cyclosporine A (CSA) that inhibits both NF-kappaB and iNOS would prevent the vasodilatory response to endotoxin.	Cyclosporine	46-60	nitric oxide synthase 2	Rattus norvegicus	100-104
16904696-3	2006	The purpose of this study was to determine if cyclosporine A (CSA) that inhibits both NF-kappaB and iNOS would prevent the vasodilatory response to endotoxin.	Cyclosporine	62-65	nitric oxide synthase 2	Rattus norvegicus	100-104
17058250-2	2006	Because cyclosporine inhibits erythropoietin (Epo) production in experimental models, we investigated whether Epo production was impaired in liver transplant recipients receiving a cyclosporine- or tacrolimus-based immunosuppressive regimen.	Cyclosporine	8-20	erythropoietin	Homo sapiens	46-49
17058250-6	2006	Serum Epo levels were significantly lower after than before liver transplantation, especially in cyclosporine-treated patients.	Cyclosporine	97-109	erythropoietin	Homo sapiens	6-9
17058250-8	2006	Using multiple linear regression models, the polynomial relationship between hematocrit and serum Epo values was similar to the control group in patients under tacrolimus, whereas Epo production was significantly reduced in patients under cyclosporine-based immunosuppression.	Cyclosporine	239-251	erythropoietin	Homo sapiens	180-183
17058250-10	2006	In conclusion, cyclosporine, but not tacrolimus, inhibits Epo production at the doses used in clinical practice.	Cyclosporine	15-27	erythropoietin	Homo sapiens	58-61
17127624-1	2006	Mitochondria isolated from engineered mice lacking Cyclophilin D (CypD), a component of the Permeability Transition Pore (PTP) complex, can still undergo a Ca2+ -dependent but Cyclosporin A-insensitive permeabilization of the inner membrane.	Cyclosporine	176-189	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	66-70
17021852-4	2006	After 21 days of in vitro culture, astrocytes were subjected to OGD (for 8 h) and CsA (0.25-10 microM); 0.25 microM CsA distinctly stimulated the Erk1/2 pathway in astrocytes exposed to OGD.	Cyclosporine	116-119	mitogen-activated protein kinase 3	Homo sapiens	146-152
17138058-6	2006	RESULTS: sCD30 and caspase-1 concentrations were non-significantly up-regulated in all analysed groups--with or without rejection signs or immunosuppressed with cyclosporine or especially tacrolimus.	Cyclosporine	161-173	caspase 1	Homo sapiens	19-28
17021852-5	2006	This protective effect of CsA was strongly associated with CaN inhibition, increased expression of anti-apoptotic factors such as Bcl-X(L) and NF-kappaB, as well as suppression of caspase-3 activity.	Cyclosporine	26-29	BCL2 like 1	Homo sapiens	130-138
17021852-5	2006	This protective effect of CsA was strongly associated with CaN inhibition, increased expression of anti-apoptotic factors such as Bcl-X(L) and NF-kappaB, as well as suppression of caspase-3 activity.	Cyclosporine	26-29	nuclear factor kappa B subunit 1	Homo sapiens	143-152
17021852-5	2006	This protective effect of CsA was strongly associated with CaN inhibition, increased expression of anti-apoptotic factors such as Bcl-X(L) and NF-kappaB, as well as suppression of caspase-3 activity.	Cyclosporine	26-29	caspase 3	Homo sapiens	180-189
17021852-8	2006	The results obtained suggest that, depending on the concentration used, CsA might act as a protective agent towards ischemia-injured astroglial cells through alternative intracellular pathways associated with increased p-Erk1/2 and p-Akt expression or CaN inactivation.	Cyclosporine	72-75	mitogen-activated protein kinase 3	Homo sapiens	221-227
17112845-0	2006	MDR1 C3435T polymorphisms correlate with cyclosporine levels in de novo renal recipients.	Cyclosporine	41-53	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
17112845-2	2006	PGP serves as a hydrophobic export pump that extrudes cyclosporine (CsA) across the luminal membrane thus preventing CsA absorption.	Cyclosporine	54-66	ATP binding cassette subfamily B member 1	Homo sapiens	0-3
17112845-2	2006	PGP serves as a hydrophobic export pump that extrudes cyclosporine (CsA) across the luminal membrane thus preventing CsA absorption.	Cyclosporine	68-71	ATP binding cassette subfamily B member 1	Homo sapiens	0-3
17112845-2	2006	PGP serves as a hydrophobic export pump that extrudes cyclosporine (CsA) across the luminal membrane thus preventing CsA absorption.	Cyclosporine	117-120	ATP binding cassette subfamily B member 1	Homo sapiens	0-3
16969354-3	2006	Previously, we demonstrated that oral paclitaxel plus the P-gp inhibitor cyclosporin (CsA) is safe and results in adequate exposure to paclitaxel.	Cyclosporine	73-84	ATP binding cassette subfamily B member 1	Homo sapiens	58-62
17112845-10	2006	CONCLUSIONS: MDR1 SNPs are correlated with CsA exposure in the early post-transplant period.	Cyclosporine	43-46	ATP binding cassette subfamily B member 1	Homo sapiens	13-17
17262945-0	2006	Inhibitory effect of cyclosporin A on growth and collagen synthesis of rat cardiac fibroblasts induced by arginine vasopressin.	Cyclosporine	21-34	arginine vasopressin	Rattus norvegicus	115-126
17262945-1	2006	AIM: To investigate the effects of cyclosporin A (CsA) on growth and collagen synthesis of cardiac fibroblasts (CFs) induced by arginine vasopressin (AVP).	Cyclosporine	35-48	arginine vasopressin	Rattus norvegicus	137-148
17262945-1	2006	AIM: To investigate the effects of cyclosporin A (CsA) on growth and collagen synthesis of cardiac fibroblasts (CFs) induced by arginine vasopressin (AVP).	Cyclosporine	50-53	arginine vasopressin	Rattus norvegicus	137-148
16716285-10	2006	CsA administration induced significant elevation in lipid peroxidation along with abnormal levels of enzymic (superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, glutathione-S-transferase and glucose-6-phosphate dehydrogenase) and non-enzymic antioxidants (glutathione, vitamins C and E) in the rat kidney.	Cyclosporine	0-3	catalase	Rattus norvegicus	132-140
16935404-15	2006	Finally, while the CaM antagonist W-13 and the calcineurin inhibitor cyclosporin A attenuated SM-induced caspase-3 activation, inhibitors for CaM-dependent protein kinase II (KN62 and KN93) did not.	Cyclosporine	69-82	caspase 3	Homo sapiens	105-114
16716285-9	2006	An apparent rise in the activities of N-acetyl-beta-D-glucosaminidase, beta-glucuronidase and cathepsin D were seen in the renal tissue of CsA given rats, which were reversed upon treatment with LA.	Cyclosporine	139-142	cathepsin D	Rattus norvegicus	94-105
17032751-0	2006	Cyclosporin A inhibits apolipoprotein AI gene expression.	Cyclosporine	0-13	apolipoprotein A1	Homo sapiens	23-40
17075191-6	2006	However, the addition of P-gp antagonists such as ciclosporin A and inhibitors of P-gp synthesis successfully reduce efflux of corticosteroids from lymphocytes in vitro and these results imply that P-gp antagonists and P-gp synthesis inhibitors could work in order to overcome drug-resistance in vivo.	Cyclosporine	50-63	ATP binding cassette subfamily B member 1	Homo sapiens	25-29
16721582-4	2006	We report on a pediatric kidney transplant recipient with NPHS2-associated nephrotic syndrome and FSGS, who developed biopsy-proven recurrence of FSGS 10 years post-transplant in temporal association with conversion from cyclosporin A (CsA)- to sirolimus (SRL)-based immunosuppression, due to histological evidence of severe CsA-induced nephrotoxicity.	Cyclosporine	236-239	NPHS2 stomatin family member, podocin	Homo sapiens	58-63
16721582-4	2006	We report on a pediatric kidney transplant recipient with NPHS2-associated nephrotic syndrome and FSGS, who developed biopsy-proven recurrence of FSGS 10 years post-transplant in temporal association with conversion from cyclosporin A (CsA)- to sirolimus (SRL)-based immunosuppression, due to histological evidence of severe CsA-induced nephrotoxicity.	Cyclosporine	325-328	NPHS2 stomatin family member, podocin	Homo sapiens	58-63
17045162-8	2006	CsA restored sensitivity to DOX and CIS, and enhanced the accumulation and efflux half-life of radiotracers in MDR1-expressing cell lines.	Cyclosporine	0-3	ATP binding cassette subfamily B member 1	Homo sapiens	111-115
17096884-6	2006	Cyclosporine A and raloxifene (alone or combination) elevated the intracellular DNR concentration in K562/A02, down regulated P-gp and mdr-1 mRNA expressions.	Cyclosporine	0-14	ATP binding cassette subfamily B member 1	Homo sapiens	126-130
16759707-5	2006	Both tacrolimus and cyclosporine are substrates of Pgp, CYP3A4 and CYP3A5, and therefore, these molecules are potential pharmacokinetic factors with which to establish personalized dosage regimens for these drugs.	Cyclosporine	20-32	ATP binding cassette subfamily B member 1	Homo sapiens	51-54
16759707-5	2006	Both tacrolimus and cyclosporine are substrates of Pgp, CYP3A4 and CYP3A5, and therefore, these molecules are potential pharmacokinetic factors with which to establish personalized dosage regimens for these drugs.	Cyclosporine	20-32	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-62
16759707-5	2006	Both tacrolimus and cyclosporine are substrates of Pgp, CYP3A4 and CYP3A5, and therefore, these molecules are potential pharmacokinetic factors with which to establish personalized dosage regimens for these drugs.	Cyclosporine	20-32	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	67-73
17096884-6	2006	Cyclosporine A and raloxifene (alone or combination) elevated the intracellular DNR concentration in K562/A02, down regulated P-gp and mdr-1 mRNA expressions.	Cyclosporine	0-14	ATP binding cassette subfamily B member 1	Homo sapiens	135-140
17006323-8	2006	The conversion from CsA to tacrolimus resulted in a significant decrease in uric acid, total- and LDL-cholesterol, apolipoprotein B, creatinine, and homocysteine levels (all P&lt;0.05).	Cyclosporine	20-23	apolipoprotein B	Homo sapiens	115-131
16880206-3	2006	Here, we report that Fyn, NFAT, and ERK signaling influence ICOS expression as various chemical inhibitors, such as PP2 that targets Src kinases, U0126 that targets MEK1/2, and cyclosporin A or FK506 that targets calcineurin and thereby affects NFAT, attenuate T cell receptor-mediated ICOS induction.	Cyclosporine	177-190	mitogen-activated protein kinase 1	Mus musculus	36-39
16404634-6	2006	The EC(50) values of cyclosporin A, tacrolimus and sirolimus for inhibition of BCRP-mediated pheophorbide A efflux were 4.3 +/- 1.9 microM, 3.6 +/- 1.8 microM and 1.9 +/- 0.4 microM, respectively.	Cyclosporine	21-34	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	79-83
16799071-5	2006	MEASUREMENTS: Transcript levels of genes encoding the serotonin transporter or four HIF-1 target genes, in rats exposed for 6 h to ambient hypoxia, treated or not by CsA, were measured.	Cyclosporine	166-169	solute carrier family 6 member 4	Rattus norvegicus	54-75
16799071-8	2006	MAIN RESULTS: Acute exposure to hypoxia led to a marked increase in mRNA levels of serotonin transporter, modulatory calcineurin-interacting protein-1, and HIF-1 target genes, which was blunted by CsA treatment.	Cyclosporine	197-200	solute carrier family 6 member 4	Rattus norvegicus	83-104
16404634-0	2006	Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.	Cyclosporine	0-13	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	75-107
16404634-7	2006	Cyclosporin A, tacrolimus and sirolimus also effectively reversed resistance of HEK cells to topotecan and mitoxantrone conferred by BCRP.	Cyclosporine	0-13	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	133-137
16404634-0	2006	Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.	Cyclosporine	0-13	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	109-114
16760228-7	2006	The well known cholestatic drugs, rifampicin, rifamycin SV, glibenclamide, and cyclosporin A, reduced the basal-to-apical transport and the apical efflux clearance of taurocholate across NTCP- and BSEP-coexpressing cell monolayers.	Cyclosporine	79-92	solute carrier family 10 member 1	Homo sapiens	187-191
16404634-1	2006	PURPOSE: Several studies have demonstrated significant interactions between immunosuppressants (e.g., cyclosporin A) and chemotherapeutic drugs that are BCRP substrates (e.g., irinotecan), resulting in increased bioavailability and reduced clearance of these agents.	Cyclosporine	102-115	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	153-157
16404634-3	2006	Therefore, the aim of this study was to determine whether the immunosuppressants cyclosporin A, tacrolimus and sirolimus are inhibitors and/or substrates of BCRP.	Cyclosporine	81-94	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	157-161
16404634-5	2006	RESULTS: Cyclosporin A, tacrolimus and sirolimus significantly inhibited BCRP-mediated efflux of pheophorbide A, mitoxantrone and BODIPY-prazosin.	Cyclosporine	9-22	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	73-77
16670920-0	2006	Elevated gene expression of MMP-1, MMP-10, and TIMP-1 reveal changes of molecules involved in turn-over of extracellular matrix in cyclosporine-induced gingival overgrowth.	Cyclosporine	131-143	TIMP metallopeptidase inhibitor 1	Homo sapiens	47-53
16762474-2	2006	Our previous study reported that quercetin significantly decreased the bioavailability of cyclosporin, a substrate for CYP3A4 and Pgp, in rats and pigs.	Cyclosporine	90-101	phosphoglycolate phosphatase	Rattus norvegicus	130-133
16837925-0	2006	Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction.	Cyclosporine	26-38	ATP binding cassette subfamily B member 1	Homo sapiens	8-22
16915037-0	2006	Nitric oxide/cytochrome P450 interactions in cyclosporin A-induced effects in the rat.	Cyclosporine	45-58	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	13-28
16915037-2	2006	METHODS AND RESULTS: The treatment of rats with cyclosporin A (25 mg/kg) for 7 days increased the renal microsomal conversion of arachidonic acid (AA) to 20-HETE (93 +/- 6%, P &lt; 0.05), increased systolic blood pressure (SBP), reduced the urinary excretion of nitrite (53 +/- 8%, P &lt; 0.05), induced renal damage as indicated by a marked increase in protein excretion (163 +/- 14%, P &lt; 0.05), increased renal vasoconstrictor responses to AA (82 +/- 5%, P &lt; 0.05) but not endothelin-1 or phenylephrine, and decreased vasodilator responses to bradykinin (42 +/- 10%, P &lt; 0.05) and sodium nitroprusside (SNP; 56 +/- 13%, P &lt; 0.05) in the renal preglomerular vessel treated with indomethacin and NO synthase inhibitor.	Cyclosporine	48-61	endothelin 1	Rattus norvegicus	481-493
16915037-3	2006	The pretreatment of rats with HET0016 (10 mg/kg) or 1-aminobenzotriazole (50 mg/kg), inhibitors of cytochrome P450 (CYP450) activity, attenuated or prevented cyclosporin A-induced increases in 20-HETE production, SBP, and protein excretion, as did L-arginine (4 g/l), a substrate for NO synthase.	Cyclosporine	158-171	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	116-122
16915037-8	2006	The cyclosporin A-induced nephrotoxicity is thus an ideal model for evaluating NO/CYP450 interactions.	Cyclosporine	4-17	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	82-88
16837925-3	2006	We hypothesized that the Pgp activity level may affect cyclosporine cytotoxicity by interfering with the ability of Pgp to remove cyclosporine from within tubular cells, and that an interaction between cyclosporine and sirolimus on Pgp function may explain the enhancement of cyclosporine nephrotoxicity by sirolimus.	Cyclosporine	130-142	ATP binding cassette subfamily B member 1	Homo sapiens	25-28
16837925-3	2006	We hypothesized that the Pgp activity level may affect cyclosporine cytotoxicity by interfering with the ability of Pgp to remove cyclosporine from within tubular cells, and that an interaction between cyclosporine and sirolimus on Pgp function may explain the enhancement of cyclosporine nephrotoxicity by sirolimus.	Cyclosporine	130-142	ATP binding cassette subfamily B member 1	Homo sapiens	116-119
16837925-3	2006	We hypothesized that the Pgp activity level may affect cyclosporine cytotoxicity by interfering with the ability of Pgp to remove cyclosporine from within tubular cells, and that an interaction between cyclosporine and sirolimus on Pgp function may explain the enhancement of cyclosporine nephrotoxicity by sirolimus.	Cyclosporine	130-142	ATP binding cassette subfamily B member 1	Homo sapiens	116-119
23105616-11	2006	Serum antiproteinase activities of serum alpha 2 macroglobulin (AMG), alpha 1-antitrypsin (AT) and alpha 1-antichymotrypsin (ACT) were found to be altered in renal transplant patients receiving cyclosporine.	Cyclosporine	194-206	serpin family A member 1	Homo sapiens	70-89
16837925-3	2006	We hypothesized that the Pgp activity level may affect cyclosporine cytotoxicity by interfering with the ability of Pgp to remove cyclosporine from within tubular cells, and that an interaction between cyclosporine and sirolimus on Pgp function may explain the enhancement of cyclosporine nephrotoxicity by sirolimus.	Cyclosporine	130-142	ATP binding cassette subfamily B member 1	Homo sapiens	25-28
16837925-0	2006	Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction.	Cyclosporine	59-71	ATP binding cassette subfamily B member 1	Homo sapiens	8-22
16837925-3	2006	We hypothesized that the Pgp activity level may affect cyclosporine cytotoxicity by interfering with the ability of Pgp to remove cyclosporine from within tubular cells, and that an interaction between cyclosporine and sirolimus on Pgp function may explain the enhancement of cyclosporine nephrotoxicity by sirolimus.	Cyclosporine	130-142	ATP binding cassette subfamily B member 1	Homo sapiens	116-119
16837925-3	2006	We hypothesized that the Pgp activity level may affect cyclosporine cytotoxicity by interfering with the ability of Pgp to remove cyclosporine from within tubular cells, and that an interaction between cyclosporine and sirolimus on Pgp function may explain the enhancement of cyclosporine nephrotoxicity by sirolimus.	Cyclosporine	130-142	ATP binding cassette subfamily B member 1	Homo sapiens	116-119
16837925-8	2006	Pgp expression and function were confirmed in HRECs and cyclosporine and sirolimus were shown to be Pgp inhibitors in this model.	Cyclosporine	56-68	ATP binding cassette subfamily B member 1	Homo sapiens	100-103
16837925-9	2006	Verapamil-induced inhibition of Pgp led to a significant increase in cellular concentration of cyclosporine (P&lt;0.05).	Cyclosporine	95-107	ATP binding cassette subfamily B member 1	Homo sapiens	32-35
16837925-10	2006	Cyclosporine exerted a concentration-dependent cytotoxic effect on HRECs that was significantly increased by inhibition of Pgp activity.	Cyclosporine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	123-126
16837925-12	2006	These data demonstrate that Pgp plays a critical role in protecting renal epithelial cells from cyclosporine toxicity.	Cyclosporine	96-108	ATP binding cassette subfamily B member 1	Homo sapiens	28-31
16837925-13	2006	The inhibitory effect of sirolimus on Pgp-mediated efflux and the cellular concentration of cyclosporine could explain the exacerbation of cyclosporine nephrotoxicity observed clinically.	Cyclosporine	139-151	ATP binding cassette subfamily B member 1	Homo sapiens	38-41
16837925-2	2006	Cyclosporine and sirolimus are P-glycoprotein (Pgp) substrates.	Cyclosporine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	31-45
16837925-2	2006	Cyclosporine and sirolimus are P-glycoprotein (Pgp) substrates.	Cyclosporine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	47-50
16837925-3	2006	We hypothesized that the Pgp activity level may affect cyclosporine cytotoxicity by interfering with the ability of Pgp to remove cyclosporine from within tubular cells, and that an interaction between cyclosporine and sirolimus on Pgp function may explain the enhancement of cyclosporine nephrotoxicity by sirolimus.	Cyclosporine	55-67	ATP binding cassette subfamily B member 1	Homo sapiens	25-28
16837925-3	2006	We hypothesized that the Pgp activity level may affect cyclosporine cytotoxicity by interfering with the ability of Pgp to remove cyclosporine from within tubular cells, and that an interaction between cyclosporine and sirolimus on Pgp function may explain the enhancement of cyclosporine nephrotoxicity by sirolimus.	Cyclosporine	55-67	ATP binding cassette subfamily B member 1	Homo sapiens	116-119
16837925-3	2006	We hypothesized that the Pgp activity level may affect cyclosporine cytotoxicity by interfering with the ability of Pgp to remove cyclosporine from within tubular cells, and that an interaction between cyclosporine and sirolimus on Pgp function may explain the enhancement of cyclosporine nephrotoxicity by sirolimus.	Cyclosporine	55-67	ATP binding cassette subfamily B member 1	Homo sapiens	116-119
16837925-3	2006	We hypothesized that the Pgp activity level may affect cyclosporine cytotoxicity by interfering with the ability of Pgp to remove cyclosporine from within tubular cells, and that an interaction between cyclosporine and sirolimus on Pgp function may explain the enhancement of cyclosporine nephrotoxicity by sirolimus.	Cyclosporine	130-142	ATP binding cassette subfamily B member 1	Homo sapiens	25-28
16837925-3	2006	We hypothesized that the Pgp activity level may affect cyclosporine cytotoxicity by interfering with the ability of Pgp to remove cyclosporine from within tubular cells, and that an interaction between cyclosporine and sirolimus on Pgp function may explain the enhancement of cyclosporine nephrotoxicity by sirolimus.	Cyclosporine	130-142	ATP binding cassette subfamily B member 1	Homo sapiens	116-119
16837925-3	2006	We hypothesized that the Pgp activity level may affect cyclosporine cytotoxicity by interfering with the ability of Pgp to remove cyclosporine from within tubular cells, and that an interaction between cyclosporine and sirolimus on Pgp function may explain the enhancement of cyclosporine nephrotoxicity by sirolimus.	Cyclosporine	130-142	ATP binding cassette subfamily B member 1	Homo sapiens	116-119
16980029-14	2006	RESULTS: CsA and FK506 stimulated gene expression and protein production of TGF-beta1, smad2, and smad3, but inhibited expression of smad7 both in VSMC and in the transplanted kidney.	Cyclosporine	9-12	transforming growth factor, beta 1	Rattus norvegicus	76-85
16980029-14	2006	RESULTS: CsA and FK506 stimulated gene expression and protein production of TGF-beta1, smad2, and smad3, but inhibited expression of smad7 both in VSMC and in the transplanted kidney.	Cyclosporine	9-12	SMAD family member 3	Rattus norvegicus	98-103
16980029-14	2006	RESULTS: CsA and FK506 stimulated gene expression and protein production of TGF-beta1, smad2, and smad3, but inhibited expression of smad7 both in VSMC and in the transplanted kidney.	Cyclosporine	9-12	SMAD family member 7	Rattus norvegicus	133-138
16980036-0	2006	Comparison of expression of TGF-beta1, its receptors TGFbeta1R-I and TGFbeta1R-II in rat kidneys during chronic nephropathy induced by cyclosporine and tacrolimus.	Cyclosporine	135-147	transforming growth factor, beta 1	Rattus norvegicus	28-37
16980037-0	2006	Impact of Lotensin and Salviae on the changes of TGF-beta1 and its receptors in a rat model of chronic cyclosporine-induced nephropathy.	Cyclosporine	103-115	transforming growth factor, beta 1	Rattus norvegicus	49-58
16980029-19	2006	CsA and FK506 can cause CAN, owing to up-regulated expression of smad2 and smad3, and down-regulation of smad7 expression.	Cyclosporine	0-3	SMAD family member 3	Rattus norvegicus	75-80
16980037-1	2006	OBJECTIVES: Transforming growth factor-beta(1) (TGF-beta(1)) and its receptors, type 1 (TR-1) and type 2 (TR-2) play important roles in chronic cyclosporine (CsA)-induced nephropathy.	Cyclosporine	144-156	transforming growth factor, beta 1	Rattus norvegicus	12-46
16980052-8	2006	Pro-caspase-3 and Bcl-2 proteins were decreased by CsA.	Cyclosporine	51-54	BCL2, apoptosis regulator	Rattus norvegicus	18-23
16980029-19	2006	CsA and FK506 can cause CAN, owing to up-regulated expression of smad2 and smad3, and down-regulation of smad7 expression.	Cyclosporine	0-3	SMAD family member 7	Rattus norvegicus	105-110
16980037-1	2006	OBJECTIVES: Transforming growth factor-beta(1) (TGF-beta(1)) and its receptors, type 1 (TR-1) and type 2 (TR-2) play important roles in chronic cyclosporine (CsA)-induced nephropathy.	Cyclosporine	144-156	transforming growth factor, beta 1	Rattus norvegicus	48-59
16980037-1	2006	OBJECTIVES: Transforming growth factor-beta(1) (TGF-beta(1)) and its receptors, type 1 (TR-1) and type 2 (TR-2) play important roles in chronic cyclosporine (CsA)-induced nephropathy.	Cyclosporine	158-161	transforming growth factor, beta 1	Rattus norvegicus	12-46
16980035-1	2006	OBJECTIVE: We sought to detect expression of transforming growth factor-beta 1 (TGF-beta1) as well as its receptors type I (TRI) and type II (TRII) in rat kidneys during chronic cyclosporine (CsA)-induced nephropathy.	Cyclosporine	178-190	transforming growth factor, beta 1	Rattus norvegicus	45-78
16980037-1	2006	OBJECTIVES: Transforming growth factor-beta(1) (TGF-beta(1)) and its receptors, type 1 (TR-1) and type 2 (TR-2) play important roles in chronic cyclosporine (CsA)-induced nephropathy.	Cyclosporine	158-161	transforming growth factor, beta 1	Rattus norvegicus	48-59
16980037-4	2006	Therefore, in this study we assessed the effects of Lotensin or Salviae on the chronic CsA-induced upregulation of TGF-beta(1), TR-1, and TR-2 in a rat model.	Cyclosporine	87-90	transforming growth factor, beta 1	Rattus norvegicus	115-126
16980055-10	2006	CsA produced dose-dependent induction of p53, caspase-6, and Bax protein expression.	Cyclosporine	0-3	caspase 6	Rattus norvegicus	46-55
16980055-12	2006	RMCs with CsA reduced Bcl-2 and cIAP expression.	Cyclosporine	10-13	BCL2, apoptosis regulator	Rattus norvegicus	22-27
16980055-13	2006	CONCLUSIONS: In this study, CsA induced apoptosis by up-regulating proapoptotic factors, caspase-3 and -6, p53, Bax, cleaving PARP, and down-regulating antiapoptotic factor, Bcl-2, and cIAP.	Cyclosporine	28-31	BCL2, apoptosis regulator	Rattus norvegicus	174-179
16980051-0	2006	Comparison of cyclosporine versus mycophenolate mofetil on expression of Fractalkine and CX3CR1 in chronic allograft nephropathy.	Cyclosporine	14-26	C-X3-C motif chemokine ligand 1	Rattus norvegicus	73-84
16980051-1	2006	INTRODUCTION: We sought to investigate whether there was a difference between cyclosporine (CsA) and mycophenolate mofetil (MMF) to affect the expression of Fractalkine/CX3CR1 in chronic allograft nephropathy (CAN).	Cyclosporine	78-90	C-X3-C motif chemokine ligand 1	Rattus norvegicus	157-168
16980051-1	2006	INTRODUCTION: We sought to investigate whether there was a difference between cyclosporine (CsA) and mycophenolate mofetil (MMF) to affect the expression of Fractalkine/CX3CR1 in chronic allograft nephropathy (CAN).	Cyclosporine	92-95	C-X3-C motif chemokine ligand 1	Rattus norvegicus	157-168
16980051-11	2006	The expression of Fractalkine/CX3CR1 in grafted kidneys at all the time points was significantly less in the MMF than in the CsA group or the control group (P &lt; .05).	Cyclosporine	125-128	C-X3-C motif chemokine ligand 1	Rattus norvegicus	18-29
16980076-7	2006	RESULTS: The CsA group exhibited higher TC (P = .001), LDL-C (P = .004), non-HDL-C (P = .009), HDL-C (P = .03), apoB (P = .008), and apoCIII (P = .002) levels than the FK group.	Cyclosporine	13-16	component of oligomeric golgi complex 2	Homo sapiens	55-60
16980076-7	2006	RESULTS: The CsA group exhibited higher TC (P = .001), LDL-C (P = .004), non-HDL-C (P = .009), HDL-C (P = .03), apoB (P = .008), and apoCIII (P = .002) levels than the FK group.	Cyclosporine	13-16	apolipoprotein B	Homo sapiens	112-116
16980035-1	2006	OBJECTIVE: We sought to detect expression of transforming growth factor-beta 1 (TGF-beta1) as well as its receptors type I (TRI) and type II (TRII) in rat kidneys during chronic cyclosporine (CsA)-induced nephropathy.	Cyclosporine	178-190	transforming growth factor, beta 1	Rattus norvegicus	80-89
16782708-6	2006	Apop-1-induced apoptosis is not blocked by Bcl-2 or Bcl-xL, inhibitors of Bax/Bak-dependent channels, whereas it is completely blocked by cyclosporin A, an inhibitor of permeability transition pore.	Cyclosporine	138-151	cytochrome c oxidase assembly factor 8	Mus musculus	0-6
16806187-5	2006	Mutant SOD1-dependent cell death could be induced by heat shock, and by treating the cells with cyclosporine A or lactacystin.	Cyclosporine	96-110	superoxide dismutase 1, soluble	Mus musculus	7-11
16825605-8	2006	Caspase 8 activities induced by ANG II were attenuated by U-0126, SP-600125, and CsA.	Cyclosporine	81-84	angiotensinogen	Rattus norvegicus	32-38
16783494-4	2006	Since P-glycoprotein transports a wide range of drugs (e.g. antidepressants, antiepileptics, HIV protease inhibitors, cyclosporine, digoxin), its location in these tissues limits bioavailability of orally administered drugs and prevents entry of xenobiotics into the brain, testis and the fetus.	Cyclosporine	118-130	ATP binding cassette subfamily B member 1	Homo sapiens	6-20
16825605-9	2006	DNA fragmentation induced by ANG II was totally blocked by SP-600125, and CsA and was attenuated by U-0126.	Cyclosporine	74-77	angiotensinogen	Rattus norvegicus	29-35
16911928-6	2006	RESULTS: The SNPs of CYP3A and P-gp are closely correlated to the large variations of cyclosporine and tacrolimus dosage between different patients, although conflicting results were obtained by some authors.	Cyclosporine	86-98	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	21-26
16911928-6	2006	RESULTS: The SNPs of CYP3A and P-gp are closely correlated to the large variations of cyclosporine and tacrolimus dosage between different patients, although conflicting results were obtained by some authors.	Cyclosporine	86-98	ATP binding cassette subfamily B member 1	Homo sapiens	31-35
16882103-5	2006	However, in the group treated by phototherapy a significant increase in IGFBP-3 secretion was observed, whereas in the group treated with cyclosporin A - a significant increase in IGF-I secretion was observed in remission.	Cyclosporine	138-151	insulin like growth factor 1	Homo sapiens	180-185
16707627-8	2006	This Ca(2+)-sensitive pathway probably includes calcineurin and nuclear factor of activated T cells, because A(2B) receptor-dependent IL-4 secretion was blocked with cyclosporin A or 11R-VIVIT peptide.	Cyclosporine	166-179	interleukin 4	Homo sapiens	134-138
16542695-6	2006	Blocking NFAT activity using a number of reagents, such as Cyclosporin A, FK-506, or the NFAT-specific inhibitor known as VIVIT peptide, all markedly reduced IL-7-mediated induction of HIV replication in naive T cells.	Cyclosporine	59-72	interleukin 7	Homo sapiens	158-162
16803872-4	2006	Moreover, TNF-alpha-induced anchorage-independent cell growth was significantly inhibited by NFAT3 siRNA and cyclosporine A, a chemical inhibitor for the calcineurin/NFAT pathway, which suggests the importance of NFAT3 in regulating TNF-alpha-induced anchorage-independent cell growth.	Cyclosporine	109-123	tumor necrosis factor	Mus musculus	10-19
16803872-4	2006	Moreover, TNF-alpha-induced anchorage-independent cell growth was significantly inhibited by NFAT3 siRNA and cyclosporine A, a chemical inhibitor for the calcineurin/NFAT pathway, which suggests the importance of NFAT3 in regulating TNF-alpha-induced anchorage-independent cell growth.	Cyclosporine	109-123	tumor necrosis factor	Mus musculus	233-242
16618940-9	2006	Pups that were exposed antenatally to CsA presented several pathologic findings in all immature parenchyma and an increase in iNOS and MMP2 expression.	Cyclosporine	38-41	nitric oxide synthase 2	Rattus norvegicus	126-130
17051976-9	2006	IFN-gamma production is inhibited by IL-4, IL-10, TGFbeta, glucocorticoids, cyclosporin A and FK506.	Cyclosporine	76-89	interferon gamma	Homo sapiens	0-9
16522809-6	2006	The functional defect of Treg cells after CSA exposure could be reversed by exogenous IL-2.	Cyclosporine	42-45	interleukin 2	Homo sapiens	86-90
16801165-12	2006	CONCLUSION: Our data, together with a similar, published observation, suggest that the TNF inhibitor etanercept is potentially useful for obtaining remission in children not responding to steroids and cyclosporin A.	Cyclosporine	201-214	tumor necrosis factor	Homo sapiens	87-90
16801185-12	2006	Serum interleukin -8 may be useful in assessing the therapeutic effects of cyclosporine A in hyperzincaemia and hypercalprotectinaemia.	Cyclosporine	75-89	C-X-C motif chemokine ligand 8	Homo sapiens	6-20
16641133-3	2006	Here, we show that calcineurin antagonists such as cyclosporin A (CsA) or tacrolimus can markedly enhance the production of interferon-gamma (IFN-gamma) by human T cells.	Cyclosporine	51-64	interferon gamma	Homo sapiens	124-140
17077659-7	2006	Cyclosporine provided statistically significant improvements in Schirmer basal secretion scores (P = 0.003), tear breakup time (P = 0.002), and tear lysozyme levels (P = 0.033) after 3 months of treatment.	Cyclosporine	0-12	lysozyme	Homo sapiens	149-157
16547931-4	2006	Pronounced swelling of mitochondria was evident ultrastructurally, and the MPT inhibitor cyclosporin A prevented the release of cytochrome c.	Cyclosporine	89-102	cytochrome c, somatic	Homo sapiens	128-140
16818126-7	2006	RESULTS: Continuous CsA treatment attenuated intimal hyperplasia and cell infiltration (2.9 +/- 0.3% and 0.4 +/- 0.1; p &lt; 0.01 vs vehicle), but increased Cr and hyalinosis (0.43 +/- 0.03 mg/dl and 57.2 +/- 0.4%; p &lt; 0.01) with upregulated TGF-beta1.	Cyclosporine	20-23	transforming growth factor, beta 1	Rattus norvegicus	245-254
16641133-3	2006	Here, we show that calcineurin antagonists such as cyclosporin A (CsA) or tacrolimus can markedly enhance the production of interferon-gamma (IFN-gamma) by human T cells.	Cyclosporine	51-64	interferon gamma	Homo sapiens	142-151
16641133-3	2006	Here, we show that calcineurin antagonists such as cyclosporin A (CsA) or tacrolimus can markedly enhance the production of interferon-gamma (IFN-gamma) by human T cells.	Cyclosporine	66-69	interferon gamma	Homo sapiens	124-140
16641133-3	2006	Here, we show that calcineurin antagonists such as cyclosporin A (CsA) or tacrolimus can markedly enhance the production of interferon-gamma (IFN-gamma) by human T cells.	Cyclosporine	66-69	interferon gamma	Homo sapiens	142-151
16641133-5	2006	IL-27, which could mimic the effect of IL-12, was however less potent in inducing IFN-gamma production in the presence of CsA and TCR stimulation.	Cyclosporine	122-125	interferon gamma	Homo sapiens	82-91
16641133-7	2006	CsA-dependent IFN-gamma production is observable in therapeutic concentrations.	Cyclosporine	0-3	interferon gamma	Homo sapiens	14-23
16730577-11	2006	Expression of iNOS was decreased 50% by alpha-TPGS equipotent to CsA, but apparently via an NF-kappaB- and AP-1-independent pathway.	Cyclosporine	65-68	nitric oxide synthase 2	Rattus norvegicus	14-18
16763183-7	2006	Furthermore, the increases in CSA and ETH relative to wild-type mice were significantly greater (P&lt;0.05) in CuZnSOD-/- mice than in CuZnSOD+/- mice (CSA=108 versus 214 microm2; ETH=12 versus 28%).	Cyclosporine	30-33	superoxide dismutase 1, soluble	Mus musculus	111-118
16770245-9	2006	Use of CsA was able to facilitate TGF-beta1 expression and the subsequent TGF-beta-mediated random migration was blocked by the use of the specific signaling inhibitor SB431542 in vitro.	Cyclosporine	7-10	transforming growth factor, beta 1	Rattus norvegicus	34-43
16770245-9	2006	Use of CsA was able to facilitate TGF-beta1 expression and the subsequent TGF-beta-mediated random migration was blocked by the use of the specific signaling inhibitor SB431542 in vitro.	Cyclosporine	7-10	transforming growth factor, beta 1	Rattus norvegicus	34-42
16770245-10	2006	CONCLUSIONS: Whereas the chemokine receptor expression by cancer cells is implicated with early organotropic dissemination even under CsA-mediated immune suppression, rather, CsA enhances the late-phase progression after tumor adhesion through TGF-beta1 expression.	Cyclosporine	175-178	transforming growth factor, beta 1	Rattus norvegicus	244-253
16858127-3	2006	The present objectives are to elucidate the dysfunction of P-glycoprotein (P-gp) in addition to the opening of TJ by t-BuOOH at a high concentration condition using rhodamine123 (Rho123) as a P-gp substrate and cyclosporine A (CyA) as a P-gp inhibitor.	Cyclosporine	211-225	ATP binding cassette subfamily B member 1	Homo sapiens	59-73
16858127-3	2006	The present objectives are to elucidate the dysfunction of P-glycoprotein (P-gp) in addition to the opening of TJ by t-BuOOH at a high concentration condition using rhodamine123 (Rho123) as a P-gp substrate and cyclosporine A (CyA) as a P-gp inhibitor.	Cyclosporine	211-225	ATP binding cassette subfamily B member 1	Homo sapiens	75-79
16858127-3	2006	The present objectives are to elucidate the dysfunction of P-glycoprotein (P-gp) in addition to the opening of TJ by t-BuOOH at a high concentration condition using rhodamine123 (Rho123) as a P-gp substrate and cyclosporine A (CyA) as a P-gp inhibitor.	Cyclosporine	227-230	ATP binding cassette subfamily B member 1	Homo sapiens	59-73
16858127-3	2006	The present objectives are to elucidate the dysfunction of P-glycoprotein (P-gp) in addition to the opening of TJ by t-BuOOH at a high concentration condition using rhodamine123 (Rho123) as a P-gp substrate and cyclosporine A (CyA) as a P-gp inhibitor.	Cyclosporine	227-230	ATP binding cassette subfamily B member 1	Homo sapiens	75-79
16940704-7	2006	The frequencies of the PON1 genotype in the CSA group did not differ significantly from those in the non-CSA group.	Cyclosporine	44-47	paraoxonase 1	Homo sapiens	23-27
16763183-6	2006	RESULTS: CSA and ETH were significantly increased (P&lt;0.05) in both CuZnSOD+/- and CuZnSOD-/- mice (CSA=435+/-24 and 541+/-48 microm2; ETH=18+/-1 and 34+/-2%) compared with wild-type mice (CSA=327+/-28 microm2; ETH=6%).	Cyclosporine	9-12	superoxide dismutase 1, soluble	Mus musculus	70-77
16763183-6	2006	RESULTS: CSA and ETH were significantly increased (P&lt;0.05) in both CuZnSOD+/- and CuZnSOD-/- mice (CSA=435+/-24 and 541+/-48 microm2; ETH=18+/-1 and 34+/-2%) compared with wild-type mice (CSA=327+/-28 microm2; ETH=6%).	Cyclosporine	9-12	superoxide dismutase 1, soluble	Mus musculus	85-92
16827636-0	2006	Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation.	Cyclosporine	20-32	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	76-82
16827636-0	2006	Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation.	Cyclosporine	20-32	ATP binding cassette subfamily B member 1	Homo sapiens	87-91
16647797-6	2006	Treatment with quinidine or cyclosporine A, which are P-gp inhibitors, decreased the P(app) of Rho-123 to the same degree in both monolayers.	Cyclosporine	28-42	ATP binding cassette subfamily B member 1	Homo sapiens	54-58
16735732-10	2006	The strain carrying the hog1(F315S) allele was highly resistant to the calcineurin inhibitor cyclosporin A, which suggests the existence of links between the two pathways.	Cyclosporine	93-106	mitogen-activated protein kinase HOG1	Saccharomyces cerevisiae S288C	24-28
16775548-10	2006	In UT, 1RM (11%) and CSA (2%) increases were greater for ACE DD/ID than ACE II (1RM, 7%; CSA, -0.1%) (P&lt;0.05).	Cyclosporine	21-24	angiotensin I converting enzyme	Homo sapiens	57-60
16775548-10	2006	In UT, 1RM (11%) and CSA (2%) increases were greater for ACE DD/ID than ACE II (1RM, 7%; CSA, -0.1%) (P&lt;0.05).	Cyclosporine	21-24	angiotensin I converting enzyme	Homo sapiens	72-75
16775548-10	2006	In UT, 1RM (11%) and CSA (2%) increases were greater for ACE DD/ID than ACE II (1RM, 7%; CSA, -0.1%) (P&lt;0.05).	Cyclosporine	89-92	angiotensin I converting enzyme	Homo sapiens	57-60
16775548-10	2006	In UT, 1RM (11%) and CSA (2%) increases were greater for ACE DD/ID than ACE II (1RM, 7%; CSA, -0.1%) (P&lt;0.05).	Cyclosporine	89-92	angiotensin I converting enzyme	Homo sapiens	72-75
16775548-11	2006	ACE ID genotype explained approximately 1% of the MVC response to RT in T and approximately 2% of MVC, 2% of 1RM, and 4% of CSA response in UT (P&lt;0.05).	Cyclosporine	124-127	angiotensin I converting enzyme	Homo sapiens	0-3
16797290-1	2006	Transforming growth factor (TGF)-beta is involved in the pathogenesis of chronic cyclosporine nephrotoxicity (CyAN).	Cyclosporine	81-93	transforming growth factor beta 1	Homo sapiens	0-37
16859130-1	2006	OBJECTIVE: To investigate the effects of inflammation cytokines, (FK506) and cyclosporine (CSA) on albumin secretion, and the effects of FK506 and CSA on the IL-6 induced suppression of albumin synthesis in cultured human hepatocytes.	Cyclosporine	147-150	interleukin 6	Homo sapiens	158-162
16380462-8	2006	This mechanism likely regulates TNF gene transcription as U-73122, CsA, and VIVIT blocked CaR-dependent activity of a TNF promoter construct.	Cyclosporine	67-70	tumor necrosis factor	Homo sapiens	32-35
16380462-4	2006	Increases in calcineurin activity in cells challenged with Ca(2+) were inhibited after pretreatment with U-73122 and CsA, suggesting that CaR activation increases calcineurin activity in a PI-PLC-dependent manner.	Cyclosporine	117-120	calcium sensing receptor	Homo sapiens	138-141
16756642-1	2006	AIM AND METHODS: P-glycoprotein (gp-170, P-gp) is a transmembrane transporter involved in drug, for example cyclosporine A, efflux from the cells thus limiting their intracellular concentration.	Cyclosporine	108-122	ATP binding cassette subfamily B member 1	Homo sapiens	17-31
16756642-1	2006	AIM AND METHODS: P-glycoprotein (gp-170, P-gp) is a transmembrane transporter involved in drug, for example cyclosporine A, efflux from the cells thus limiting their intracellular concentration.	Cyclosporine	108-122	ATP binding cassette subfamily B member 1	Homo sapiens	33-39
16756642-1	2006	AIM AND METHODS: P-glycoprotein (gp-170, P-gp) is a transmembrane transporter involved in drug, for example cyclosporine A, efflux from the cells thus limiting their intracellular concentration.	Cyclosporine	108-122	ATP binding cassette subfamily B member 1	Homo sapiens	41-45
16756642-3	2006	The aim of the present study was to evaluate P-gp expression on the surface of CD4(+), CD8(+), CD19(+) and CD56(+) cells in kidney transplant patients treated with cyclosporine A as a main immunosuppressant, using flow cytometry.	Cyclosporine	164-178	ATP binding cassette subfamily B member 1	Homo sapiens	45-49
16756642-3	2006	The aim of the present study was to evaluate P-gp expression on the surface of CD4(+), CD8(+), CD19(+) and CD56(+) cells in kidney transplant patients treated with cyclosporine A as a main immunosuppressant, using flow cytometry.	Cyclosporine	164-178	CD4 molecule	Homo sapiens	79-82
16926769-5	2006	There is conflicting evidence regarding the effect of specific immunosuppressant medications (eg, tacrolimus vs cyclosporine) on the risk of recurrent PBC.	Cyclosporine	112-124	dihydrolipoamide S-acetyltransferase	Homo sapiens	151-154
16380462-4	2006	Increases in calcineurin activity in cells challenged with Ca(2+) were inhibited after pretreatment with U-73122 and CsA, suggesting that CaR activation increases calcineurin activity in a PI-PLC-dependent manner.	Cyclosporine	117-120	phospholipase C gamma 1	Homo sapiens	189-195
16380462-5	2006	Moreover, U-73122, CsA, and VIVIT inhibited CaR-dependent activity of an NFAT construct that drives expression of firefly luciferase in transiently transfected mTAL cells.	Cyclosporine	19-22	calcium sensing receptor	Homo sapiens	44-47
16380462-7	2006	Activation of the CaR also increased the binding of NFAT to a consensus oligonucleotide, an effect that was blocked by U-73122 and CsA, suggesting that a calcineurin- and NFAT-dependent pathway increases TNF production in mTAL cells.	Cyclosporine	131-134	calcium sensing receptor	Homo sapiens	18-21
16380462-7	2006	Activation of the CaR also increased the binding of NFAT to a consensus oligonucleotide, an effect that was blocked by U-73122 and CsA, suggesting that a calcineurin- and NFAT-dependent pathway increases TNF production in mTAL cells.	Cyclosporine	131-134	tumor necrosis factor	Homo sapiens	204-207
16380462-8	2006	This mechanism likely regulates TNF gene transcription as U-73122, CsA, and VIVIT blocked CaR-dependent activity of a TNF promoter construct.	Cyclosporine	67-70	calcium sensing receptor	Homo sapiens	90-93
16380462-8	2006	This mechanism likely regulates TNF gene transcription as U-73122, CsA, and VIVIT blocked CaR-dependent activity of a TNF promoter construct.	Cyclosporine	67-70	tumor necrosis factor	Homo sapiens	118-121
16730326-7	2006	Clustering of Bax into distinct regions on mitochondria could be prevented by CsA, an inhibitor of the mitochondrial permeability transition pore, and also by SB203580, an inhibitor of p38 MAPK.	Cyclosporine	78-81	BCL2 associated X, apoptosis regulator	Homo sapiens	14-17
16724420-3	2006	Here we show that the MDR1 inhibitor, cyclosporin A (CsA) can deplete Gaucher lymphoid cell lines of accumulated glucosyl ceramide and Fabry cell lines of globotriaosyl ceramide (Gb3), by preventing de novo synthesis.	Cyclosporine	38-51	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	22-26
16513166-5	2006	PTP inhibition by cyclosporine A (CsA) or its non-immunosuppressive derivative NIM811 caused an amplification of the secondary [Ca(2+)](i) peak and induced a hyperpolarization of psi(m).	Cyclosporine	18-32	protein tyrosine phosphatase, receptor type, U	Mus musculus	0-3
16513166-5	2006	PTP inhibition by cyclosporine A (CsA) or its non-immunosuppressive derivative NIM811 caused an amplification of the secondary [Ca(2+)](i) peak and induced a hyperpolarization of psi(m).	Cyclosporine	34-37	protein tyrosine phosphatase, receptor type, U	Mus musculus	0-3
16513166-9	2006	So, simultaneous inhibition of PTP and activation of the mtK-ATP channel prevents the increased slope of the secondary [Ca(2+)](i) peak induced by CsA (or NIM811) and also the depolarization after diazoxide application.	Cyclosporine	147-150	protein tyrosine phosphatase, receptor type, U	Mus musculus	31-34
16568474-7	2006	Even in a small population of viable cells, P-gp positive cells emitting low red fluorescence, gained on red fluorescence after P-gp inhibition with CsA permitting an evaluation of P-gp activity.	Cyclosporine	149-152	ATP binding cassette subfamily B member 1	Homo sapiens	44-48
16568474-7	2006	Even in a small population of viable cells, P-gp positive cells emitting low red fluorescence, gained on red fluorescence after P-gp inhibition with CsA permitting an evaluation of P-gp activity.	Cyclosporine	149-152	ATP binding cassette subfamily B member 1	Homo sapiens	128-132
16568474-7	2006	Even in a small population of viable cells, P-gp positive cells emitting low red fluorescence, gained on red fluorescence after P-gp inhibition with CsA permitting an evaluation of P-gp activity.	Cyclosporine	149-152	ATP binding cassette subfamily B member 1	Homo sapiens	128-132
16568474-9	2006	Most importantly, the apoptotic cells could be distinguished by the loss of red fluorescence and the increase of green fluorescence without any change after P-gp inhibition with CsA.	Cyclosporine	178-181	ATP binding cassette subfamily B member 1	Homo sapiens	157-161
16724420-3	2006	Here we show that the MDR1 inhibitor, cyclosporin A (CsA) can deplete Gaucher lymphoid cell lines of accumulated glucosyl ceramide and Fabry cell lines of globotriaosyl ceramide (Gb3), by preventing de novo synthesis.	Cyclosporine	53-56	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	22-26
16724577-9	2006	The CYP system seems to be involved in the pro-oxidant influence of CSA.	Cyclosporine	68-71	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	4-7
16612258-10	2006	The detrimental effects of CsA were associated with upregulation of myocardial atrial natriuretic peptide (ANP) mRNA expression, paradoxical activation of the renin-angiotensin system (RAS), induction of renal reduced nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase, and overexpression of oxidative stress-induced transcription factor NRF2.	Cyclosporine	27-30	NFE2 like bZIP transcription factor 2	Rattus norvegicus	347-351
16612258-13	2006	CsA-induced myocardial ANP and connective tissue growth factor (CTGF) mRNA overexpression, RAS activation, NADPH oxidase induction, and NRF2 overexpression were prevented by LA.	Cyclosporine	0-3	NFE2 like bZIP transcription factor 2	Rattus norvegicus	136-140
16671876-8	2006	By contrast, significantly stronger beta-catenin and Cyclin D1 mRNA expressions and protein levels were found in CsA-treated rats than controls by RT-PCR and immunohistochemistry at week 4, whereas PCNA production was stronger at both times.	Cyclosporine	113-116	cyclin D1	Rattus norvegicus	53-62
29539165-4	2006	The aims of this study were to investigate transforming growth factor-beta1 (TGF-beta1) gene polymorphisms in renal transplant recipients treated with CsA or tacrolimus and to establish an association between these polymorphisms and TGF-beta1 plasma concentration and the incidence of GO.	Cyclosporine	151-154	transforming growth factor beta 1	Homo sapiens	43-75
29539165-4	2006	The aims of this study were to investigate transforming growth factor-beta1 (TGF-beta1) gene polymorphisms in renal transplant recipients treated with CsA or tacrolimus and to establish an association between these polymorphisms and TGF-beta1 plasma concentration and the incidence of GO.	Cyclosporine	151-154	transforming growth factor beta 1	Homo sapiens	77-86
29539165-12	2006	TGF-beta1 levels in the CsA group showed correlation with the phenotypes.	Cyclosporine	24-27	transforming growth factor beta 1	Homo sapiens	0-9
16612332-8	2006	TGF-beta1 expression was heightened in borderline changes (P &lt; 0.01), recurrence of glomerulonephritis, and cyclosporine toxicity (P &lt; 0.05).	Cyclosporine	111-123	transforming growth factor beta 1	Homo sapiens	0-9
16612333-0	2006	The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients.	Cyclosporine	45-57	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	17-22
16612333-1	2006	Cyclosporine is a substrate of cytochrome P-450 3A (CYP3A) subfamily of enzymes and characterized by a narrow therapeutic range with wide interindividual variation in pharmacokinetics.	Cyclosporine	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-50
16612333-1	2006	Cyclosporine is a substrate of cytochrome P-450 3A (CYP3A) subfamily of enzymes and characterized by a narrow therapeutic range with wide interindividual variation in pharmacokinetics.	Cyclosporine	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	52-57
16612333-4	2006	The objective of our study is to determine correlation if any between single-nucleotide polymorphisms of CYP3A5 and CYP3AP1 on cyclosporine dose requirement and concentration-to-dose ratio in renal allograft recipients.	Cyclosporine	127-139	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	105-111
16612333-4	2006	The objective of our study is to determine correlation if any between single-nucleotide polymorphisms of CYP3A5 and CYP3AP1 on cyclosporine dose requirement and concentration-to-dose ratio in renal allograft recipients.	Cyclosporine	127-139	cytochrome P450 family 3 subfamily A member 51, pseudogene	Homo sapiens	116-123
16612333-5	2006	Cyclosporine-dependent renal allograft recipients were genotyped for CYP3A5 A6986G and CYP3AP1 G-44A.	Cyclosporine	0-12	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	69-75
16612333-5	2006	Cyclosporine-dependent renal allograft recipients were genotyped for CYP3A5 A6986G and CYP3AP1 G-44A.	Cyclosporine	0-12	cytochrome P450 family 3 subfamily A member 51, pseudogene	Homo sapiens	87-94
16612333-9	2006	Patients with *1*1*1*1 (n=5) CYP3A5- and CYP3AP1-linked genotypes needed higher dose of cyclosporine compared to patients with *1*3*1*3 (n = 27) and *3*3*3*3 (n = 33) linked genotypes in months 3 and 6 post-transplantation (P &lt; 0.016).	Cyclosporine	88-100	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	29-35
16612333-9	2006	Patients with *1*1*1*1 (n=5) CYP3A5- and CYP3AP1-linked genotypes needed higher dose of cyclosporine compared to patients with *1*3*1*3 (n = 27) and *3*3*3*3 (n = 33) linked genotypes in months 3 and 6 post-transplantation (P &lt; 0.016).	Cyclosporine	88-100	cytochrome P450 family 3 subfamily A member 51, pseudogene	Homo sapiens	41-48
16612333-10	2006	The identification of patients with *1*1*1*1 by CYP3A5 and CYP3AP1 genotyping may have a clinically significant and positive impact on patient outcome with reduced rejection rate by providing pretransplant pharmacogenetic information for optimization of cyclosporine A dosing.	Cyclosporine	254-268	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	48-54
16612333-10	2006	The identification of patients with *1*1*1*1 by CYP3A5 and CYP3AP1 genotyping may have a clinically significant and positive impact on patient outcome with reduced rejection rate by providing pretransplant pharmacogenetic information for optimization of cyclosporine A dosing.	Cyclosporine	254-268	cytochrome P450 family 3 subfamily A member 51, pseudogene	Homo sapiens	59-66
16408277-7	2006	Pharmacological inhibition of calcineurin by cyclosporin A blocks IGF-1-induced cyclin D1 and p21Cip1expression significantly (P &lt; 0.05).	Cyclosporine	45-58	cyclin D1	Rattus norvegicus	80-89
16671880-4	2006	The aims of this study were to investigate transforming growth factor-beta1 (TGF-beta1) gene polymorphisms in renal transplant recipients treated with CsA or tacrolimus and to establish an association between these polymorphisms and TGF-beta1 plasma concentration and the incidence of GO.	Cyclosporine	151-154	transforming growth factor beta 1	Homo sapiens	43-75
16671880-4	2006	The aims of this study were to investigate transforming growth factor-beta1 (TGF-beta1) gene polymorphisms in renal transplant recipients treated with CsA or tacrolimus and to establish an association between these polymorphisms and TGF-beta1 plasma concentration and the incidence of GO.	Cyclosporine	151-154	transforming growth factor beta 1	Homo sapiens	77-86
16671880-12	2006	TGF-beta1 levels in the CsA group showed correlation with the phenotypes.	Cyclosporine	24-27	transforming growth factor beta 1	Homo sapiens	0-9
16671876-9	2006	CONCLUSIONS: CsA treatment reduced the production of E-cadherin but increased the production of beta-catenin, Cyclin D1, and PCNA.	Cyclosporine	13-16	cyclin D1	Rattus norvegicus	110-119
16443926-5	2006	In addition, brucine caused depolarization of the mitochondrial membrane of HepG2 cells, the inhibition of which by cyclosporine A completely abrogated the activation of casapses and release of cytochrome c in brucine-treated HepG2 cells.	Cyclosporine	116-130	cytochrome c, somatic	Homo sapiens	194-206
16449275-18	2006	Expression of ET-RB was markedly increased in CSA toxicity in glomeruli, tubuli and vessels.	Cyclosporine	46-49	endothelin receptor type B	Homo sapiens	14-19
16689978-5	2006	Administration of cyclosporine A in addition to prednisone enabled the patient to become transfusion and EPO independent.	Cyclosporine	18-32	erythropoietin	Homo sapiens	105-108
16611021-0	2006	Evaluation of microsomal incubation conditions on CYP3A4-mediated metabolism of cyclosporine A by a statistical experimental design.	Cyclosporine	80-94	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-56
16643797-0	2006	[Effect of cyclosporin A on the production of IFN-gamma by murine splenocytes].	Cyclosporine	11-24	interferon gamma	Mus musculus	46-55
16643797-1	2006	AIM: To explore the effect of cyclosporine A (CsA) on the production of IFN-gamma by murine splenocytes after stimulation with different reagents.	Cyclosporine	46-49	interferon gamma	Mus musculus	72-81
16643797-5	2006	RESULTS: The mouse splenocytes stimulated with anti-CD3 mAb, anti-CD3 mAb + anti-CD28 mAb or anti-CD3 mAb + IL-12 could produce high level of IFN-gamma, but CsA inhibited INF-gamma production in a dose-dependent manner.	Cyclosporine	157-160	interferon gamma	Mus musculus	142-151
16631000-8	2006	Circulating ET-1 concentration increased in the CyA group but significantly decreased over time in the Tac group (CyA +17% vs. Tac -25%; p &lt; 0.05).	Cyclosporine	48-51	endothelin 1	Homo sapiens	12-16
16631000-8	2006	Circulating ET-1 concentration increased in the CyA group but significantly decreased over time in the Tac group (CyA +17% vs. Tac -25%; p &lt; 0.05).	Cyclosporine	114-117	endothelin 1	Homo sapiens	12-16
16631000-11	2006	Microvascular endothelial function deteriorates more in CyA-treated patients, a finding that correlates with enhanced ET-1 concentration and an increased intimal area during follow-up.	Cyclosporine	56-59	endothelin 1	Homo sapiens	118-122
16611021-7	2006	The present study showed that relatively small changes in the incubation matrix had a significant influence on the microsomal CYP3A4-mediated metabolism of CsA.	Cyclosporine	156-159	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	126-132
16705489-9	2006	Biochemical experiments provided evidence that cyclosporin-A influenced calmodulin binding and activation of calcineurin consistent with overlapping binding regions.	Cyclosporine	47-60	calmodulin 1	Homo sapiens	72-82
16584346-1	2006	BACKGROUND: To understand the roles of epidermal growth factor (EGF) and EGF receptor (EGF-R) in cyclosporin A (CsA)-induced gingival overgrowth, expression of EGF and EGF-R upon CsA treatment was examined in an oral epidermoid carcinoma cell line of humans (OECM-1) and in edentulous gingiva of rats.	Cyclosporine	112-115	epidermal growth factor receptor	Homo sapiens	39-92
16584346-1	2006	BACKGROUND: To understand the roles of epidermal growth factor (EGF) and EGF receptor (EGF-R) in cyclosporin A (CsA)-induced gingival overgrowth, expression of EGF and EGF-R upon CsA treatment was examined in an oral epidermoid carcinoma cell line of humans (OECM-1) and in edentulous gingiva of rats.	Cyclosporine	112-115	epidermal growth factor receptor	Homo sapiens	87-92
16584346-1	2006	BACKGROUND: To understand the roles of epidermal growth factor (EGF) and EGF receptor (EGF-R) in cyclosporin A (CsA)-induced gingival overgrowth, expression of EGF and EGF-R upon CsA treatment was examined in an oral epidermoid carcinoma cell line of humans (OECM-1) and in edentulous gingiva of rats.	Cyclosporine	179-182	epidermal growth factor receptor	Homo sapiens	39-92
16584346-7	2006	RESULTS: In vitro: dose-dependently increased mRNA expression of EGF and EGF-R in OECM-1 cells was noted after CsA treatment.	Cyclosporine	111-114	epidermal growth factor receptor	Homo sapiens	73-78
16584346-8	2006	Protein expressions of EGF and EGF-R were higher in OECM-1 with CsA treatment than without CsA.	Cyclosporine	64-67	epidermal growth factor receptor	Homo sapiens	31-36
16584346-8	2006	Protein expressions of EGF and EGF-R were higher in OECM-1 with CsA treatment than without CsA.	Cyclosporine	91-94	epidermal growth factor receptor	Homo sapiens	31-36
16584346-11	2006	CONCLUSIONS: Higher expression of EGF and EGF-R upon CsA therapy was observed in OECM-1 epithelial cells of humans and in edentulous gingiva of rats.	Cyclosporine	53-56	epidermal growth factor receptor	Homo sapiens	42-47
16584346-12	2006	We suggest that CsA could upregulate gene and protein expression of EGF and EGF-R, and the upregulation may play a role in gingival overgrowth.	Cyclosporine	16-19	epidermal growth factor receptor	Homo sapiens	76-81
16507844-2	2006	The immunosuppressant cyclosporin A has been shown to inhibit tumour growth factor (TGF)-beta-induced collagen deposition in vitro, and is widely used in Japan as a potent antifibrotic agent.	Cyclosporine	22-35	transforming growth factor beta 1	Homo sapiens	84-87
16476567-2	2006	CsA is reported to competitively inhibit the transport of the substrates of the bile salt export pump (Bsep), multidrug resistance protein 2 (Mrp2) and P-glycoprotein (P-gp) in the canalicular membrane vesicles.	Cyclosporine	0-3	ATP binding cassette subfamily B member 11	Rattus norvegicus	80-101
16497638-0	2006	Vascular endothelial growth factor in children with nephrotic syndrome treated with cyclosporine A.	Cyclosporine	84-98	vascular endothelial growth factor A	Homo sapiens	0-34
16497638-1	2006	AIM: To assess the effect of cyclosporine A (CyA) on the level of vascular endothelial growth factor (VEGF) in the plasma and urine of nephrotic syndrome children.	Cyclosporine	29-43	vascular endothelial growth factor A	Homo sapiens	66-100
16497638-1	2006	AIM: To assess the effect of cyclosporine A (CyA) on the level of vascular endothelial growth factor (VEGF) in the plasma and urine of nephrotic syndrome children.	Cyclosporine	29-43	vascular endothelial growth factor A	Homo sapiens	102-106
16497638-1	2006	AIM: To assess the effect of cyclosporine A (CyA) on the level of vascular endothelial growth factor (VEGF) in the plasma and urine of nephrotic syndrome children.	Cyclosporine	45-48	vascular endothelial growth factor A	Homo sapiens	66-100
16497638-1	2006	AIM: To assess the effect of cyclosporine A (CyA) on the level of vascular endothelial growth factor (VEGF) in the plasma and urine of nephrotic syndrome children.	Cyclosporine	45-48	vascular endothelial growth factor A	Homo sapiens	102-106
16476567-2	2006	CsA is reported to competitively inhibit the transport of the substrates of the bile salt export pump (Bsep), multidrug resistance protein 2 (Mrp2) and P-glycoprotein (P-gp) in the canalicular membrane vesicles.	Cyclosporine	0-3	ATP binding cassette subfamily B member 11	Rattus norvegicus	103-107
16476567-4	2006	Therefore, in the present study, the acute effect of CsA on the biliary excretion of the substrates of Bsep, Mrp2 and P-gp was examined under the same condition.	Cyclosporine	53-56	ATP binding cassette subfamily B member 11	Rattus norvegicus	103-107
16476567-8	2006	In conclusion, CsA may competitively inhibit biliary excretion of substrates of Bsep, Mrp2 and P-gp also in vivo, and CsA is considered to inhibit bile acid-dependent bile flow by the competitive inhibition of the canalicular transport of bile acids by Bsep.	Cyclosporine	15-18	ATP binding cassette subfamily B member 11	Rattus norvegicus	80-84
16476567-8	2006	In conclusion, CsA may competitively inhibit biliary excretion of substrates of Bsep, Mrp2 and P-gp also in vivo, and CsA is considered to inhibit bile acid-dependent bile flow by the competitive inhibition of the canalicular transport of bile acids by Bsep.	Cyclosporine	15-18	ATP binding cassette subfamily B member 11	Rattus norvegicus	253-257
16476567-8	2006	In conclusion, CsA may competitively inhibit biliary excretion of substrates of Bsep, Mrp2 and P-gp also in vivo, and CsA is considered to inhibit bile acid-dependent bile flow by the competitive inhibition of the canalicular transport of bile acids by Bsep.	Cyclosporine	118-121	ATP binding cassette subfamily B member 11	Rattus norvegicus	253-257
16511917-1	2006	OBJECTIVE: This study assessed the efficacy and safety of combination (COMB) of cyclosporine (CSA) and leflunomide (LEF) versus each drug alone, in the treatment of severe rheumatoid arthritis (RA).	Cyclosporine	80-92	heat shock protein family A (Hsp70) member 9	Homo sapiens	94-97
16634729-2	2006	Possible causes, such as the inhibition of CYP3A4 induced by cyclosporine causing elevations of serum fentanyl, are discussed.	Cyclosporine	61-73	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-49
16549165-1	2006	BACKGROUND: Insulin resistance, a frequent prediabetic metabolic complication after renal transplantation, is generally linked to immunosuppressive drugs including corticosteroids, cyclosporine (CsA) or tacrolimus, as well as to age, cadaveric donors and ethnic factors.	Cyclosporine	195-198	insulin	Homo sapiens	12-19
16549165-1	2006	BACKGROUND: Insulin resistance, a frequent prediabetic metabolic complication after renal transplantation, is generally linked to immunosuppressive drugs including corticosteroids, cyclosporine (CsA) or tacrolimus, as well as to age, cadaveric donors and ethnic factors.	Cyclosporine	181-193	insulin	Homo sapiens	12-19
16458014-8	2006	CsA treatment also increased activity of the cysteine protease caspase-3, decreased the mitochondrial membrane potential and induced the release of cytochrome c into the cytosol.	Cyclosporine	0-3	caspase 3	Homo sapiens	63-72
16458014-8	2006	CsA treatment also increased activity of the cysteine protease caspase-3, decreased the mitochondrial membrane potential and induced the release of cytochrome c into the cytosol.	Cyclosporine	0-3	cytochrome c, somatic	Homo sapiens	148-160
16221533-6	2006	The efflux rate significantly decreased in the presence of metabolic inhibitors sodium azide and 2-deoxy-d-glucose, P-gp inhibitors cyclosporin A and valspodar, but not in the presence of MRPs inhibitor MK571.	Cyclosporine	132-145	ATP binding cassette subfamily B member 1	Homo sapiens	116-120
16495804-10	2006	Circulating interferon-gamma was reduced by CsA, but inhibition was dramatic with SRL alone or combined with CsA.	Cyclosporine	44-47	interferon gamma	Homo sapiens	12-28
16495804-12	2006	CONCLUSIONS: SRL plus CsA prevented allograft arteriopathy, correlating with suppression of intragraft interferon-gamma, suggesting that SRL effects may result from anti-inflammatory consequences from inhibiting interferon-gamma.	Cyclosporine	22-25	interferon gamma	Homo sapiens	103-119
16495808-8	2006	Splenocytes from mice treated with CsA after skin transplants had no response to third-party alloantigen, but showed an effector/memory pattern of IFN-gamma elaboration with donor cell stimulation (immunosuppression), although the IFN-gamma levels were not as high as those mice with unmodified graft rejection.	Cyclosporine	35-38	interferon gamma	Mus musculus	147-156
16495808-8	2006	Splenocytes from mice treated with CsA after skin transplants had no response to third-party alloantigen, but showed an effector/memory pattern of IFN-gamma elaboration with donor cell stimulation (immunosuppression), although the IFN-gamma levels were not as high as those mice with unmodified graft rejection.	Cyclosporine	35-38	interferon gamma	Homo sapiens	231-240
16451059-7	2006	P-gp inhibition by CsA confirmed that these new analogues are no longer P-gp substrates.	Cyclosporine	19-22	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
16254147-0	2006	Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421.	Cyclosporine	33-36	ATP binding cassette subfamily B member 1	Homo sapiens	50-64
16399625-7	2006	Cyclosporine A, verapamil and trifluoperazine inhibited the activity of thymic ABCB1.	Cyclosporine	0-14	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	79-84
16299163-8	2006	Moreover, basal-to-apical transport of [3H]CsA in the Caco-2 cell monolayer was not affected by DHA but was decreased by valspodar (PSC 833), a P-gp inhibitor.	Cyclosporine	43-46	ATP binding cassette subfamily B member 1	Homo sapiens	144-148
16522547-4	2006	This study was planned to study the expression of P-glycoprotein/170 in patients with acute leukemia and the effect of Cyclosporin A (CSA) as a modulator of P-glycoprotein functional activity.	Cyclosporine	119-132	ATP binding cassette subfamily B member 1	Homo sapiens	157-171
16522547-4	2006	This study was planned to study the expression of P-glycoprotein/170 in patients with acute leukemia and the effect of Cyclosporin A (CSA) as a modulator of P-glycoprotein functional activity.	Cyclosporine	134-137	ATP binding cassette subfamily B member 1	Homo sapiens	157-171
16458528-3	2006	Recently, we demonstrated that CsA up-regulates the expression of transforming growth factor-beta1 (TGF-beta1), its receptors type I (TbetaR-I) and type II (TbetaR-II), as well as related matrix protein synthesis in mesangial cells (MCs).	Cyclosporine	31-34	transforming growth factor beta 1	Homo sapiens	66-98
16246479-8	2006	CsA blocked the release both of Endo G and cytochrome c significantly.	Cyclosporine	0-3	endonuclease G	Rattus norvegicus	32-38
16267833-7	2006	Survival of PLAP SCs was enhanced by immunosuppression with cyclosporin; delayed transplantation in conjunction with immunosuppression resulted in the best survival.	Cyclosporine	60-71	alkaline phosphatase, placental	Homo sapiens	12-16
16436964-0	2006	Dietary phytosterols reduce cyclosporine-induced hypercholesterolemia in apolipoprotein E-knockout mice.	Cyclosporine	28-40	apolipoprotein E	Mus musculus	73-89
16458528-3	2006	Recently, we demonstrated that CsA up-regulates the expression of transforming growth factor-beta1 (TGF-beta1), its receptors type I (TbetaR-I) and type II (TbetaR-II), as well as related matrix protein synthesis in mesangial cells (MCs).	Cyclosporine	31-34	transforming growth factor beta 1	Homo sapiens	100-109
16620716-8	2006	After the treatment of CsA at the concentration of 1.3, 2.5, and 5.0 microg/ml, in comparison to the control group, the suppression rates of HBsAg expression in the HepG2.2.15 cells were 16.5% +/- 9.4%, 21.5% +/- 8.9%, and 33.1% +/- 5.3% respectively (all P &lt; 0.05); the suppression rates of HBeAg expression in the HepG2.2.15 cells were 7.8% +/- 2.2%, 11.0% +/- 2.3%, and 20.8% +/- 1.5% respectively (all P &lt; 0.05); and the HBV DNA replication levels were 56 +/- 16, 42 +/- 11, and 40 +/- 10 respectively (P &gt; 0.05, P &lt; 0.05, and P &gt; 0.05).	Cyclosporine	23-26	capsid protein;pre-capsid protein	Hepatitis B virus	295-300
16455045-6	2006	Finally, we observed competitive and non-competitive interactions between one of such dihydro-beta-agarofurans (Mama12) and classical Pgp modulators such as cyclosporin A, verapamil, progesterone, vinblastine and GF120918.	Cyclosporine	157-170	ATP binding cassette subfamily B member 1	Homo sapiens	134-137
16926534-10	2006	The results were different for TGF-beta1, which was increased by both CsA and SRL and to a greater extent by the drug combination.	Cyclosporine	70-73	transforming growth factor, beta 1	Rattus norvegicus	31-40
16433894-7	2006	Animals receiving cyclosporine and antioxidants showed significantly increased (P&lt;0.05) catalase activity compared to both groups not receiving cyclosporine.	Cyclosporine	18-30	catalase	Rattus norvegicus	91-99
16377671-5	2006	Hepatobiliary excretion experiments revealed that cyclosporine almost completely inhibited the biliary clearance of telithromycin, suggesting that telithromycin is a substrate of P glycoprotein and a potential substrate of Mrp2.	Cyclosporine	50-62	ATP binding cassette subfamily B member 1	Homo sapiens	179-193
16394527-2	2006	The values of total clearance (CL(tot)) of cyclosporin A, doxorubicin, tacrolimus and zonisamide in the CCl4-treated rats were decreased to about 1/2-1/3 of those in control rats.	Cyclosporine	43-56	C-C motif chemokine ligand 4	Rattus norvegicus	104-108
16398502-8	2006	bFGF and IPM adsorption on top of the (PLL/CSA)(10)/PLL polyelectrolyte films increased the number of photoreceptor cells attached and maintained the differentiation of rod and cone cells.	Cyclosporine	43-46	fibroblast growth factor 2	Homo sapiens	0-4
17170517-5	2006	The cardiomyogenic effect of Cyclosporin and Verapamil correlated with an expression of early cardiac markers Nkx2.5 and GATA4.	Cyclosporine	29-40	GATA binding protein 4	Mus musculus	121-126
15584088-0	2006	Cyclosporin-A inhibits stretch-induced changes in myosin heavy chain expression in C2C12 skeletal muscle cells.	Cyclosporine	0-13	myosin heavy chain, cardiac muscle complex	Mus musculus	50-68
16430309-10	2006	In the case of midazolam, ciclosporin, nifedipine and docetaxel, clearance by individuals with a CYP3A5-expressing genotype did not differ from that for nonexpressors, but in the case of tacrolimus, eight independent studies have demonstrated faster clearance by those carrying one or two CYP3A5*1 alleles.	Cyclosporine	26-37	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	97-103
16841511-5	2006	inhibition of P-gp with cyclosporine A (CsA, 200 mg/kg, i.p.)	Cyclosporine	24-38	phosphoglycolate phosphatase	Rattus norvegicus	14-18
16841511-5	2006	inhibition of P-gp with cyclosporine A (CsA, 200 mg/kg, i.p.)	Cyclosporine	40-43	phosphoglycolate phosphatase	Rattus norvegicus	14-18
17190738-3	2006	Immunosuppressive agents should be used for preventing graft rejection, but of these, rapamycin and cyclosporine A have been reported to inhibit HIF-1.	Cyclosporine	100-114	hypoxia inducible factor 1 subunit alpha	Homo sapiens	145-150
16431291-4	2006	RESULTS: Cyclosporine increased caspase-3 activation in MLC, which corresponded with a decrease in lymphocyte apoptosis in MLC.	Cyclosporine	9-21	caspase 3	Homo sapiens	32-41
16622732-9	2006	Plasma PTH and OCN levels in CsA-treated rats were significantly higher than those in control animals on day 8.	Cyclosporine	29-32	bone gamma-carboxyglutamate protein	Rattus norvegicus	15-18
16622732-10	2006	Northern blot analysis revealed that the CsA-treated group showed an increase in the expression of OCN, OPN, and cathepsin K mRNAs on day 8 compared with the controls.	Cyclosporine	41-44	bone gamma-carboxyglutamate protein	Rattus norvegicus	99-102
16355273-2	2006	The upstream regulatory region of CCR1 showed RANKL-dependent and CsA-suppressible promoter activity.	Cyclosporine	66-69	chemokine (C-C motif) receptor 1	Mus musculus	34-38
16355273-13	2006	RESULTS AND CONCLUSIONS: We identified the chemokine receptor gene CCR1 as a gene showing significant differential expression profiles in osteoclastogenesis in the presence versus the absence of CsA, an inhibitor of NFAT.	Cyclosporine	195-198	chemokine (C-C motif) receptor 1	Mus musculus	67-71
16355273-13	2006	RESULTS AND CONCLUSIONS: We identified the chemokine receptor gene CCR1 as a gene showing significant differential expression profiles in osteoclastogenesis in the presence versus the absence of CsA, an inhibitor of NFAT.	Cyclosporine	195-198	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	216-220
16355273-16	2006	The functional significance of CCR1 was assessed by monitoring the migration of cells in a transwell migration assay, and this activity was abolished when either CsA- or CCR1 siRNA-treated cells were used.	Cyclosporine	162-165	chemokine (C-C motif) receptor 1	Mus musculus	31-35
16405612-2	2006	We report the case of a patient with PNP associated with a CD20+ non-Hodgkin follicular lymphoma who was treated with Rituximab plus corticosteroids and short courses of cyclosporin.	Cyclosporine	170-181	keratin 20	Homo sapiens	59-63
16568834-9	2006	An immunosuppressant cyclosporine A taken at antiproliferative concentration decreased phosphorylation of both STAT5 and STAT3 by 1.5-2.0 times at early stages, as well as at late stages of activation.	Cyclosporine	21-35	signal transducer and activator of transcription 3	Homo sapiens	121-126
16431291-7	2006	CONCLUSIONS: In humans, blockade of IL-2 receptor signal with rapamycin allows apoptosis of allospecifically activated CD4+ lymphocytes to occur, while blockade of IL-2 production with cyclosporine results in decreased apoptosis in this T cell subset.	Cyclosporine	185-197	interleukin 2	Homo sapiens	164-168
16517475-9	2006	The increased staining intensity of tumor necrosis factor-alpha and intercellular adhesion molecule-1 on epidermal keratinocytes and endothelial cells was reduced after cyclosporin A therapy.	Cyclosporine	169-182	tumor necrosis factor	Homo sapiens	36-63
16517475-10	2006	Cyclosporin A treatment results in total normalization of the electron microscopic picture of psoriasis and its beneficial effect depends on the direct inhibition of tumor necrosis factor-alpha and consequently intercellular adhesion molecule-1.	Cyclosporine	0-13	tumor necrosis factor	Homo sapiens	166-193
16438909-0	2005	Relationship between MDR1 polymorphism and blood concentration of cyclosporine A.	Cyclosporine	66-80	ATP binding cassette subfamily B member 1	Homo sapiens	21-25
16378061-5	2005	RESULTS: A significant differences was seen between rejected kidneys and acute CsA toxicity in regards of tubular TGF-beta1 expression that patients with CsA toxicity exhibited significantly higher grade of tubular TGF-beta1 expression than patients with AR (P&lt;0.05) and CAN (P&lt;0.05).	Cyclosporine	79-82	transforming growth factor beta 1	Homo sapiens	114-123
16378061-5	2005	RESULTS: A significant differences was seen between rejected kidneys and acute CsA toxicity in regards of tubular TGF-beta1 expression that patients with CsA toxicity exhibited significantly higher grade of tubular TGF-beta1 expression than patients with AR (P&lt;0.05) and CAN (P&lt;0.05).	Cyclosporine	79-82	transforming growth factor beta 1	Homo sapiens	215-224
16378061-5	2005	RESULTS: A significant differences was seen between rejected kidneys and acute CsA toxicity in regards of tubular TGF-beta1 expression that patients with CsA toxicity exhibited significantly higher grade of tubular TGF-beta1 expression than patients with AR (P&lt;0.05) and CAN (P&lt;0.05).	Cyclosporine	154-157	transforming growth factor beta 1	Homo sapiens	114-123
16378061-5	2005	RESULTS: A significant differences was seen between rejected kidneys and acute CsA toxicity in regards of tubular TGF-beta1 expression that patients with CsA toxicity exhibited significantly higher grade of tubular TGF-beta1 expression than patients with AR (P&lt;0.05) and CAN (P&lt;0.05).	Cyclosporine	154-157	transforming growth factor beta 1	Homo sapiens	215-224
16378061-6	2005	A significant difference was found between the grades of tubular TGF-beta1 expression in regards to graft function of cases with AR and CsA toxicity (P&lt;0.05).	Cyclosporine	136-139	transforming growth factor beta 1	Homo sapiens	65-74
16378110-9	2005	(3) CsA 10(-6) mol/L and H(7) 50 micromol/L, an inhibitor of PKC, inhibited UII-stimulated CaN activity by 45% (P&lt;0.01) and 21% (P&lt;0.05), respectively, while PD(98059) 50 micromol/L, an inhibitor of MAPK, had no effect on CaN activity (P&gt;0.05).	Cyclosporine	4-7	urotensin 2	Rattus norvegicus	76-79
16378110-10	2005	(4) CsA 10(-6) mol/L inhibited UII-stimulated PKC activity by 14% (P&lt;0.05), while having no effect on MAPK activity (P&gt;0.05).	Cyclosporine	4-7	urotensin 2	Rattus norvegicus	31-34
16332238-0	2005	Effect of cyclosporin A on the expression of inducible nitric oxide synthase in the gingiva of rats.	Cyclosporine	10-23	nitric oxide synthase 2	Rattus norvegicus	45-76
16260145-7	2005	Pretreatment with 0.2 micromol/L cyclosporin A for the last 5 min of ischemia and first 15 min of reperfusion showed similar effects to those of TNF-alpha, and they were not attenuated by paxilline.	Cyclosporine	33-46	tumor necrosis factor	Rattus norvegicus	145-154
16303967-14	2005	Furthermore, ketoconazole, all-trans retinoic acid, and cyclosporine inhibited CYP3A6 mediated [3H]testosterone 6beta hydroxylation in a concentration-dependent manner, with IC50 ranging from 3.73 to 435 microM.	Cyclosporine	56-68	cytochrome P450 3A6	Oryctolagus cuniculus	79-85
16364863-3	2005	However, recent reports have suggested that carvedilol, but not metoprolol, modulates P-glycoprotein (P-gp), a membrane protein that regulates CsA absorption.	Cyclosporine	143-146	ATP binding cassette subfamily B member 1	Homo sapiens	86-100
16364863-3	2005	However, recent reports have suggested that carvedilol, but not metoprolol, modulates P-glycoprotein (P-gp), a membrane protein that regulates CsA absorption.	Cyclosporine	143-146	ATP binding cassette subfamily B member 1	Homo sapiens	102-106
16364863-16	2005	Although carvedilol and CsA do not interact at the level of cytochrome P450 system, it appears that carvedilol influences CsA levels through its effects on P-gp.	Cyclosporine	122-125	ATP binding cassette subfamily B member 1	Homo sapiens	156-160
16332239-7	2005	The mRNA expressions of TGF-beta1, IGF-1, and VEGF were higher in the gingivae of the CsA group than in the control group.	Cyclosporine	86-89	transforming growth factor, beta 1	Rattus norvegicus	24-33
16332239-10	2005	CONCLUSIONS: Greater mRNA expression and positive staining for TGF-beta1 and VEGF were observed in the edentulous gingivae of rats that received CsA.	Cyclosporine	145-148	transforming growth factor, beta 1	Rattus norvegicus	63-72
16332238-8	2005	Significantly greater iNOS enzyme activities were detected in lung and gingival tissues obtained from CsA-treated animals than from control animals.	Cyclosporine	102-105	nitric oxide synthase 2	Rattus norvegicus	22-26
16332239-11	2005	Therefore, CsA may upregulate TGF-beta1 and VEGF gene expression and protein secretion in CsA-induced gingival overgrowth.	Cyclosporine	11-14	transforming growth factor, beta 1	Rattus norvegicus	30-39
16332238-9	2005	In addition, cells positively staining for iNOS were clearly observed in both gingival and lung tissues obtained from the CsA-treated animals by immunohistochemistry, whereas a few stained cells were found in those from the control group.	Cyclosporine	122-125	nitric oxide synthase 2	Rattus norvegicus	43-47
16332238-11	2005	CONCLUSIONS: The effect of CsA on gingival iNOS expression was evaluated in rats for 4 weeks.	Cyclosporine	27-30	nitric oxide synthase 2	Rattus norvegicus	43-47
16332238-12	2005	A greater iNOS expression in the gingiva was observed after CsA therapy by both enzyme activities and immunohistochemica staining.	Cyclosporine	60-63	nitric oxide synthase 2	Rattus norvegicus	10-14
16332238-13	2005	Therefore, we suggest that CsA can increase gingival iNOS expression, which may play an important role in cyclosporin-induced gingival overgrowth.	Cyclosporine	27-30	nitric oxide synthase 2	Rattus norvegicus	53-57
16332238-13	2005	Therefore, we suggest that CsA can increase gingival iNOS expression, which may play an important role in cyclosporin-induced gingival overgrowth.	Cyclosporine	106-117	nitric oxide synthase 2	Rattus norvegicus	53-57
16332239-0	2005	Upregulation of transforming growth factor-beta1 and vascular endothelial growth factor gene and protein expression in cyclosporin-induced overgrown edentulous gingiva in rats.	Cyclosporine	119-130	transforming growth factor, beta 1	Rattus norvegicus	16-48
16316327-3	2005	We evaluated the effect of CsA and the antioxidant N-acetylcysteine (NAC) on inducible nitric oxide synthase (iNOS) mRNA expression and nitric oxide synthesis, in rat renal artery vascular smooth muscle cells (rVSMCs) primary culture.	Cyclosporine	27-30	nitric oxide synthase 2	Rattus norvegicus	110-114
16316327-5	2005	RESULTS: In rVSMCs, LPS increased nitric oxide and iNOS expression; CsA decreased basal and LPS-induced nitric oxide and iNOS expression; NAC increased nitric oxide and blunted the nitric oxide reduction caused by CsA, with no effect on iNOS.	Cyclosporine	68-71	nitric oxide synthase 2	Rattus norvegicus	121-125
16051742-1	2005	The peripheral benzodiazepine receptor (pBR) ligand, PK11195, promotes mitochondrial apoptosis and blocks P-glycoprotein (Pgp)-mediated drug efflux to chemosensitize cancer cells at least as well or better than the Pgp modulator, cyclosporine A (CSA).	Cyclosporine	230-244	ATP binding cassette subfamily B member 1	Homo sapiens	122-125
16316327-5	2005	RESULTS: In rVSMCs, LPS increased nitric oxide and iNOS expression; CsA decreased basal and LPS-induced nitric oxide and iNOS expression; NAC increased nitric oxide and blunted the nitric oxide reduction caused by CsA, with no effect on iNOS.	Cyclosporine	68-71	nitric oxide synthase 2	Rattus norvegicus	121-125
16316327-7	2005	CONCLUSION: In this study, CsA reduced nitric oxide synthesis in rVSMCs, both through iNOS down-regulation and reduction of cell viability, which could be responsible for the vasoconstrictive effect of the CsA.	Cyclosporine	27-30	nitric oxide synthase 2	Rattus norvegicus	86-90
15956028-0	2005	Provinol prevents CsA-induced nephrotoxicity by reducing reactive oxygen species, iNOS, and NF-kB expression.	Cyclosporine	18-21	nitric oxide synthase 2	Rattus norvegicus	82-86
15956028-7	2005	However, PV prevented these negative effects through a protective mechanism that involved reduction of both oxidative stress and increased iNOS and NF-kB expression induced by CsA.	Cyclosporine	176-179	nitric oxide synthase 2	Rattus norvegicus	139-143
16387179-7	2005	Treatment with cyclosporine reduced type I collagen and TIMP-1 expression and enhanced MMP-1 expression.	Cyclosporine	15-27	TIMP metallopeptidase inhibitor 1	Homo sapiens	56-62
16387179-8	2005	Cyclosporine also inhibited phosphorylation strongly for JNK and p38, and weakly inhibited for Erk1/2.	Cyclosporine	0-12	mitogen-activated protein kinase 8	Homo sapiens	57-60
16387179-8	2005	Cyclosporine also inhibited phosphorylation strongly for JNK and p38, and weakly inhibited for Erk1/2.	Cyclosporine	0-12	mitogen-activated protein kinase 1	Homo sapiens	65-68
16387179-8	2005	Cyclosporine also inhibited phosphorylation strongly for JNK and p38, and weakly inhibited for Erk1/2.	Cyclosporine	0-12	mitogen-activated protein kinase 3	Homo sapiens	95-101
16051742-1	2005	The peripheral benzodiazepine receptor (pBR) ligand, PK11195, promotes mitochondrial apoptosis and blocks P-glycoprotein (Pgp)-mediated drug efflux to chemosensitize cancer cells at least as well or better than the Pgp modulator, cyclosporine A (CSA).	Cyclosporine	246-249	ATP binding cassette subfamily B member 1	Homo sapiens	122-125
16051742-5	2005	PK11195 and CSA bind noncompetitively in Pgp-expressing cells, indicating that PK11195 interacts with Pgp at sites that are distinct from CSA-binding sites.	Cyclosporine	12-15	ATP binding cassette subfamily B member 1	Homo sapiens	41-44
16051742-5	2005	PK11195 and CSA bind noncompetitively in Pgp-expressing cells, indicating that PK11195 interacts with Pgp at sites that are distinct from CSA-binding sites.	Cyclosporine	12-15	ATP binding cassette subfamily B member 1	Homo sapiens	102-105
15998842-9	2005	In chronic model, CsA produced pro-renin and ET upregulation, altered adenosine receptors expression, and reduced Ang, AT(1A), AT(1B), ET(B), and COX-2 mRNA levels.	Cyclosporine	18-21	renin	Homo sapiens	35-40
16314802-7	2005	Increased osteopontin, TGF-beta1, betaig-h3, and angiotensin II expression in CsA-treated rat kidneys were decreased with FTY720 treatment.	Cyclosporine	78-81	transforming growth factor, beta 1	Rattus norvegicus	23-32
16314802-7	2005	Increased osteopontin, TGF-beta1, betaig-h3, and angiotensin II expression in CsA-treated rat kidneys were decreased with FTY720 treatment.	Cyclosporine	78-81	angiotensinogen	Rattus norvegicus	49-63
15998842-9	2005	In chronic model, CsA produced pro-renin and ET upregulation, altered adenosine receptors expression, and reduced Ang, AT(1A), AT(1B), ET(B), and COX-2 mRNA levels.	Cyclosporine	18-21	angiotensinogen	Homo sapiens	114-117
15998842-9	2005	In chronic model, CsA produced pro-renin and ET upregulation, altered adenosine receptors expression, and reduced Ang, AT(1A), AT(1B), ET(B), and COX-2 mRNA levels.	Cyclosporine	18-21	endothelin receptor type B	Homo sapiens	135-139
15998842-9	2005	In chronic model, CsA produced pro-renin and ET upregulation, altered adenosine receptors expression, and reduced Ang, AT(1A), AT(1B), ET(B), and COX-2 mRNA levels.	Cyclosporine	18-21	prostaglandin-endoperoxide synthase 2	Homo sapiens	146-151
16308546-0	2005	Inhibitory effect of pravastatin on transforming growth factor beta1-inducible gene h3 expression in a rat model of chronic cyclosporine nephropathy.	Cyclosporine	124-136	transforming growth factor, beta 1	Rattus norvegicus	36-68
16212625-7	2005	IL1-beta stimulated IL-8 production was significantly increased in rapidly growing hTBEC cultures (n = 8) treated with cyclosporin (p = 0.049).	Cyclosporine	119-130	interleukin 1 beta	Homo sapiens	0-8
16212625-7	2005	IL1-beta stimulated IL-8 production was significantly increased in rapidly growing hTBEC cultures (n = 8) treated with cyclosporin (p = 0.049).	Cyclosporine	119-130	C-X-C motif chemokine ligand 8	Homo sapiens	20-24
16212625-9	2005	Inhibition of hTBEC growth, stimulation of IL-8 production and long-term effects on mucociliary phenotype and intact multi-layered epithelium suggest that cyclosporin may have a direct toxic effect on airway epithelium after transplantation.	Cyclosporine	155-166	C-X-C motif chemokine ligand 8	Homo sapiens	43-47
16308546-6	2005	RESULTS: Co-administration of pravastatin significantly inhibited betaig-h3 mRNA production and gene expression within the tubulointerstitium of the CsA-treated kidneys, and this paralleled an attenuation of TIF (12.7 +/- 2.2 vs. 35.9 +/- 5.4%, p &lt; 0.01 vs. CsA) and the expression of TGF-beta1 mRNA (279 +/- 40 vs. 719 +/- 85%, p &lt; 0.01 vs. CsA).	Cyclosporine	149-152	transforming growth factor, beta 1	Rattus norvegicus	288-297
16132116-6	2005	However, the NF-kappaB inhibitors, such as aspirin, cyclosporin A and dexamethasone, inhibited both the acetaldehyde-induced NF-kappaB activity and the induced cytokine production.	Cyclosporine	52-65	nuclear factor kappa B subunit 1	Homo sapiens	13-22
19641681-11	2005	Angiotensin II-mediated apoptosis, as assessed by cytochrome c release and terminal deoxynucleotidyl transferase-mediated 2"-deoxyuridine-5"-triphosphate-biotin nick end labelling, was largely blocked by the mitochondrial permeability transition pore antagonist, cyclosporin A.	Cyclosporine	263-276	angiotensinogen	Homo sapiens	0-14
16259758-5	2005	In the presence of ciclosporin and verapamil, potent inhibitors of P-glycoprotein (P-gp)/MRP2, the absorptive transport was enhanced and secretory efflux was diminished.	Cyclosporine	19-30	ATP binding cassette subfamily B member 1	Homo sapiens	67-81
16259758-5	2005	In the presence of ciclosporin and verapamil, potent inhibitors of P-glycoprotein (P-gp)/MRP2, the absorptive transport was enhanced and secretory efflux was diminished.	Cyclosporine	19-30	ATP binding cassette subfamily B member 1	Homo sapiens	83-87
16006549-6	2005	CsA significantly reduced infarct size in control and lpr hearts.	Cyclosporine	0-3	Fas (TNF receptor superfamily member 6)	Mus musculus	54-57
16006549-8	2005	CsA treatment significantly reduced caspase 3 activity in control and lpr hearts.	Cyclosporine	0-3	Fas (TNF receptor superfamily member 6)	Mus musculus	70-73
16321613-10	2005	CD40L expression was reduced in tacrolimus-treated patients (median, 34 [interquartile range, 28-41] to 21 [interquartile range, 12-26] mean fluorescence intensity; P &lt; .002) and cyclosporine-treated patients (median, 33 [interquartile range, 30-37] to 26 [interquartile range, 19-26] mean fluorescence intensity; P &lt; .02).	Cyclosporine	182-194	CD40 ligand	Homo sapiens	0-5
16237086-4	2005	TCR stimulation rapidly induced IFN-gamma expression in CD8+ T lymphocytes in a cyclosporin A-sensitive manner.	Cyclosporine	80-93	interferon gamma	Mus musculus	32-41
16087277-4	2005	In studied glioma cells, an accumulation of p21Cip1/Waf1 protein, a cell cycle inhibitor, was observed following CsA treatment, even in the absence of functional p53 tumour suppressor.	Cyclosporine	113-116	cyclin dependent kinase inhibitor 1A	Homo sapiens	44-51
16087277-4	2005	In studied glioma cells, an accumulation of p21Cip1/Waf1 protein, a cell cycle inhibitor, was observed following CsA treatment, even in the absence of functional p53 tumour suppressor.	Cyclosporine	113-116	cyclin dependent kinase inhibitor 1A	Homo sapiens	52-56
16087277-5	2005	CsA induced a senescence-associated growth arrest, in U87-MG glioma cells with functional p53, while in U373 and T98G glioma cells with mutated p53, CsA treatment triggered cell death associated with alterations of cell morphology, cytoplasm vacuolation, and condensation of chromatin.	Cyclosporine	0-3	tumor protein p53	Homo sapiens	90-93
16087277-5	2005	CsA induced a senescence-associated growth arrest, in U87-MG glioma cells with functional p53, while in U373 and T98G glioma cells with mutated p53, CsA treatment triggered cell death associated with alterations of cell morphology, cytoplasm vacuolation, and condensation of chromatin.	Cyclosporine	149-152	tumor protein p53	Homo sapiens	144-147
16087277-7	2005	Moreover, CsA-induced cell death was accompanied by activation of executory caspases followed by PARP cleavage.	Cyclosporine	10-13	poly(ADP-ribose) polymerase 1	Homo sapiens	97-101
15930144-5	2005	Pharmacological inhibition of calcineurin in mice with either cyclosporin A or FK506 resulted in a marked decrease in utrophin A expression at synaptic sites, whereas constitutive activation of calcineurin had the opposite effect.	Cyclosporine	62-75	utrophin	Mus musculus	118-126
16198658-15	2005	CONCLUSIONS: Cyclosporine raised the plasma concentrations of repaglinide, probably by inhibiting its CYP3A4-catalyzed biotransformation and OATP1B1-mediated hepatic uptake.	Cyclosporine	13-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	102-108
16118767-6	2005	When P-gp was inhibited with cyclosporine A (CsA) in Wistar rats, the effect was an order of magnitude less than that observed for the knock-out mice experiments (1-1.5 times the controls), and co-administration of NT had no effect.	Cyclosporine	29-43	phosphoglycolate phosphatase	Rattus norvegicus	5-9
16118767-6	2005	When P-gp was inhibited with cyclosporine A (CsA) in Wistar rats, the effect was an order of magnitude less than that observed for the knock-out mice experiments (1-1.5 times the controls), and co-administration of NT had no effect.	Cyclosporine	45-48	phosphoglycolate phosphatase	Rattus norvegicus	5-9
16132116-6	2005	However, the NF-kappaB inhibitors, such as aspirin, cyclosporin A and dexamethasone, inhibited both the acetaldehyde-induced NF-kappaB activity and the induced cytokine production.	Cyclosporine	52-65	nuclear factor kappa B subunit 1	Homo sapiens	125-134
16030052-13	2005	CsA-induced EMT was also associated with increased expression of connective tissue growth factor (CTGF) suggesting that this molecule may serve as downstream mediator of TGF-beta1 pro-fibrotic activity in this setting.	Cyclosporine	0-3	transforming growth factor beta 1	Homo sapiens	170-179
16205037-4	2005	In in vivo pharmacokinetic studies, it is well known that itraconazole is a potent clinically important inhibitor of the clearance of CYP3A4 substrates, and fluconazole and voriconazole are reported to increase the blood or plasma concentrations of not only midazolam and cyclosporine (CYP3A4 substrates) but also of phenytoin (CYP2C9 substrate) and/or omeprazole (CYP2C19/CYP3A4 substrate).	Cyclosporine	272-284	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	134-140
16030052-11	2005	RESULTS: CsA induced striking morphological changes in epithelial cells, including changes in cellular morphology, F-actin stress fibre formation, delocalization of the adherens junction protein beta-catenin and increased levels of collagen IV and fibronectin.	Cyclosporine	9-12	fibronectin 1	Homo sapiens	248-259
16030052-12	2005	In addition, CsA-induced EMT was associated with increased TGF-beta1 protein levels and EMT was markedly attenuated in the presence of anti-TGF-beta1 antibody.	Cyclosporine	13-16	transforming growth factor beta 1	Homo sapiens	59-68
16030052-12	2005	In addition, CsA-induced EMT was associated with increased TGF-beta1 protein levels and EMT was markedly attenuated in the presence of anti-TGF-beta1 antibody.	Cyclosporine	13-16	transforming growth factor beta 1	Homo sapiens	140-149
15986223-10	2005	The amount of myostatin, TGF-beta2 and Smad3 mRNA and proteins was increased more markedly in the mice treated with CsA.	Cyclosporine	116-119	transforming growth factor, beta 2	Mus musculus	25-34
16298597-1	2005	Cytochrome-P450 enzymes metabolize cyclosporine both in the liver and in the intestinal wall.	Cyclosporine	35-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
16298597-3	2005	Some evidence points to a higher activity of some specific enzymes in women, such as CYP3A, that may influence differences in cyclosporine pharmacokinetics.	Cyclosporine	126-138	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	85-90
16159384-4	2005	Observations that cyclosporin A, and certain other substances, inhibit both the proteasome and P-glycoprotein led us to investigate whether anthracyclines, well known substrates of P-gp, also inhibit the function of the proteasome.	Cyclosporine	18-31	ATP binding cassette subfamily B member 1	Homo sapiens	95-109
16174287-2	2005	The protective effects of PPARgamma agonists are observed in diabetic nephropathy and non-diabetic renal diseases such as 5/6 ablation model of renal failure, experimental glomerulonephritis, ischemia-reperfusion injury, hypertensive nephropathy and cyclosporin-induced renal injury.	Cyclosporine	250-261	peroxisome proliferator activated receptor gamma	Homo sapiens	26-35
16177646-5	2005	RESULTS: Long-term CsA treatment upregulated TLR2 and TLR4 mRNA and protein expression on renal tubular cells, and these were accompanied by increased MYD88, NF-kappaB and AP-1 expression.	Cyclosporine	19-22	toll-like receptor 2	Rattus norvegicus	45-49
16177646-5	2005	RESULTS: Long-term CsA treatment upregulated TLR2 and TLR4 mRNA and protein expression on renal tubular cells, and these were accompanied by increased MYD88, NF-kappaB and AP-1 expression.	Cyclosporine	19-22	toll-like receptor 4	Rattus norvegicus	54-58
16177646-7	2005	CsA-treatment increased expression of TNF-alpha mRNA, the number of dendritic cells, and expression of MHC class II antigen.	Cyclosporine	0-3	tumor necrosis factor	Rattus norvegicus	38-47
16127204-3	2005	The plasma log-adiponectin levels were significantly lower in patients with CSA than with CPS (0.61+/-0.28 vs 0.80+/-0.21 microg/ml, p &lt; 0.0001).	Cyclosporine	76-79	adiponectin, C1Q and collagen domain containing	Homo sapiens	15-26
16095503-8	2005	Concomitantly, a profound decrease of hepatic and intestinal PGP and an increase of intestinal CYP3A4 were noted with CsA, whereas no effect was seen after atorvastatin therapy with or without Tac.	Cyclosporine	118-121	ATP binding cassette subfamily B member 1	Homo sapiens	61-64
16095503-8	2005	Concomitantly, a profound decrease of hepatic and intestinal PGP and an increase of intestinal CYP3A4 were noted with CsA, whereas no effect was seen after atorvastatin therapy with or without Tac.	Cyclosporine	118-121	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-101
16307158-8	2005	Moreover, in favour of non-endotoxin-mediated white cell activation, the calcineurin inhibitor, cyclosporin-A, which did not alter endotoxin-induced TNF-alpha production, decreased TNF-alpha produced by unstimulated cultured cells in patients to values not significantly greater than those in controls.	Cyclosporine	96-109	tumor necrosis factor	Homo sapiens	181-190
16030077-9	2005	An objective causality assessment in this case revealed that this supratherapeutic LDL-C reduction was probably related to coadministration of ezetimibe and cyclosporine.	Cyclosporine	157-169	component of oligomeric golgi complex 2	Homo sapiens	83-88
16116327-10	2005	VCAM-1 blockade on ECs partially reversed cyclosporine-induced DC adhesion (P&lt;0.001), whereas DC adhesion under tacrolimus exposure was significantly decreased by ICAM-1 (P&lt;0.01) and PECAM-1 (P&lt;0.001) blockade.	Cyclosporine	42-54	vascular cell adhesion molecule 1	Homo sapiens	0-6
16128906-8	2005	Cyclosporine A administration for 7 days resulted in a significant increase (P&lt;0.05) in plasma malondialdehyde, methaemoglobin, and superoxide dismutase and catalase activities.	Cyclosporine	0-14	catalase	Rattus norvegicus	160-168
16143140-7	2005	Furthermore, cyclosporin A treatment of Huh7 cells induced an unfolded protein response exemplified by expression of cellular BiP/GRP78.	Cyclosporine	13-26	heat shock protein family A (Hsp70) member 5	Homo sapiens	126-129
16143140-7	2005	Furthermore, cyclosporin A treatment of Huh7 cells induced an unfolded protein response exemplified by expression of cellular BiP/GRP78.	Cyclosporine	13-26	heat shock protein family A (Hsp70) member 5	Homo sapiens	130-135
16171442-9	2005	After 60 days of treatment with CsA, gingival overgrowth and significant increase in salivary TGF-beta1, EGF, and IL-6 concentrations were observed; no statistically significant changes were induced by FK-506.	Cyclosporine	32-35	transforming growth factor, beta 1	Rattus norvegicus	94-103
16171442-9	2005	After 60 days of treatment with CsA, gingival overgrowth and significant increase in salivary TGF-beta1, EGF, and IL-6 concentrations were observed; no statistically significant changes were induced by FK-506.	Cyclosporine	32-35	interleukin 6	Rattus norvegicus	114-118
16171442-10	2005	CONCLUSION: Within the limits of this experimental study, it can be concluded that CsA, but not FK-506, induced gingival overgrowth associated with an increase of the salivary levels of the cytokines TGF-beta1, EGF, and IL-6.	Cyclosporine	83-86	transforming growth factor, beta 1	Rattus norvegicus	200-209
16171442-10	2005	CONCLUSION: Within the limits of this experimental study, it can be concluded that CsA, but not FK-506, induced gingival overgrowth associated with an increase of the salivary levels of the cytokines TGF-beta1, EGF, and IL-6.	Cyclosporine	83-86	interleukin 6	Rattus norvegicus	220-224
16027407-1	2005	Cyclosporine is a marketed immunosuppressive agent and a known substrate for CYP3A.	Cyclosporine	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	77-82
16002416-8	2005	ACE genotype and responsiveness to CsA were strictly associated, because homozygosis for ACE B clade was able to influence CsA sensitivity.	Cyclosporine	123-126	angiotensin I converting enzyme	Homo sapiens	0-3
16002416-8	2005	ACE genotype and responsiveness to CsA were strictly associated, because homozygosis for ACE B clade was able to influence CsA sensitivity.	Cyclosporine	123-126	angiotensin I converting enzyme	Homo sapiens	89-92
15914462-4	2005	Both proline oxidase- and p53-induced activation of NFAT were sensitive to the calcineurin inhibitors cyclosporin A and FK-506, to scavengers of ROS, and to inhibitors of calcium mobilization.	Cyclosporine	102-115	tumor protein p53	Homo sapiens	26-29
16008590-0	2005	Endothelin-1 plasma levels and hypertension in cyclosporine-treated renal transplant patients.	Cyclosporine	47-59	endothelin 1	Homo sapiens	0-12
16008590-1	2005	Experimental models suggest that endothelin-1 (ET-1) has a significant role in the pathogenesis of cyclosporin A (CyA)-induced hypertension.	Cyclosporine	99-112	endothelin 1	Homo sapiens	33-45
16008590-1	2005	Experimental models suggest that endothelin-1 (ET-1) has a significant role in the pathogenesis of cyclosporin A (CyA)-induced hypertension.	Cyclosporine	99-112	endothelin 1	Homo sapiens	47-51
16008590-1	2005	Experimental models suggest that endothelin-1 (ET-1) has a significant role in the pathogenesis of cyclosporin A (CyA)-induced hypertension.	Cyclosporine	114-117	endothelin 1	Homo sapiens	33-45
16008590-1	2005	Experimental models suggest that endothelin-1 (ET-1) has a significant role in the pathogenesis of cyclosporin A (CyA)-induced hypertension.	Cyclosporine	114-117	endothelin 1	Homo sapiens	47-51
16008590-6	2005	Blood pressure was significantly higher in the CyA group (mean blood pressure: 101.2 +/- 9.5 vs. 91.1 +/- 10.7 mmHg; p &lt; 0.001), who also presented higher serum creatinine (1.2 +/- 0.28 vs. 0.97 +/- 0.13 mg/dL; p &lt; 0.001) and ET-1 levels.	Cyclosporine	47-50	endothelin 1	Homo sapiens	232-236
16008590-9	2005	In conclusion, in the present study chronic CyA ingestion was associated with higher blood pressure and plasma ET-1 levels.	Cyclosporine	44-47	endothelin 1	Homo sapiens	111-115
16140768-5	2005	Cyclosporine A, an inhibitor of NFAT activation, abrogated the induction of IL-2 mRNA in HTLV-2-immortalized T-cell lines and concomitantly inhibited cell growth.	Cyclosporine	0-14	interleukin 2	Homo sapiens	76-80
16043202-12	2005	Inhibitors such as calcium-channel blockers (verapamil), cyclosporin A, ONT-093, and XR9576 can modulate the P-gp functionality.	Cyclosporine	57-70	ATP binding cassette subfamily B member 1	Homo sapiens	109-113
16101723-5	2005	Urinary excretion of N-telopeptides and the concentrations of serum osteocalcin were consistently higher in the CsA-treated patients and significantly different at week 24 for N-telopeptides and at weeks 12, 24, and 52 for osteocalcin.	Cyclosporine	112-115	bone gamma-carboxyglutamate protein	Homo sapiens	68-79
16101723-5	2005	Urinary excretion of N-telopeptides and the concentrations of serum osteocalcin were consistently higher in the CsA-treated patients and significantly different at week 24 for N-telopeptides and at weeks 12, 24, and 52 for osteocalcin.	Cyclosporine	112-115	bone gamma-carboxyglutamate protein	Homo sapiens	223-234
15963461-5	2005	Superposition of the structure of the C domain of hCyP33 with the structure of CypA suggests that the C domain contains PPIase active site which binds to CsA.	Cyclosporine	154-157	peptidylprolyl isomerase E	Homo sapiens	50-56
15885675-8	2005	The presence of 0.5 microM cyclosporin A did not prevent hypercontracture but increased the percentage of cells recovering Ca2+ homeostasis to 56.2+/-3.6% and contractile function to 52+/-4.3%.	Cyclosporine	27-40	carbonic anhydrase 2	Rattus norvegicus	123-126
15778808-3	2005	The purpose of this study was to examine the Glu298Asp variant of the endothelial nitric oxide synthase (eNOS) gene to determine whether this polymorphism was associated with susceptibility to CSA in patients with HCM.	Cyclosporine	193-196	nitric oxide synthase 3	Homo sapiens	70-103
15778808-3	2005	The purpose of this study was to examine the Glu298Asp variant of the endothelial nitric oxide synthase (eNOS) gene to determine whether this polymorphism was associated with susceptibility to CSA in patients with HCM.	Cyclosporine	193-196	nitric oxide synthase 3	Homo sapiens	105-109
15778808-11	2005	In conclusion, the Asp298 variant of the eNOS gene may be associated with CSA in HCM patients.	Cyclosporine	74-77	nitric oxide synthase 3	Homo sapiens	41-45
16024800-8	2005	CnA(beta)-LacZ mice showed expression in the heart that was cyclosporine sensitive, as well as expression in the central nervous system and skeletal muscle from early embryonic stages through adulthood.	Cyclosporine	60-72	protein phosphatase 3, catalytic subunit, beta isoform	Mus musculus	0-9
16056106-7	2005	GCDC stimulated reactive oxygen species generation and release of cytochrome c and apoptosis-inducing factor, which were significantly inhibited by the antioxidants, cyclosporin A, and TUDC.	Cyclosporine	166-179	cytochrome c, somatic	Homo sapiens	66-78
15980236-0	2005	Down-regulation of IFN-gamma-producing CD56+ T cells after combined low-dose cyclosporine/prednisone treatment in patients with Behcet"s uveitis.	Cyclosporine	77-89	interferon gamma	Homo sapiens	19-28
15963994-2	2005	Isolated human colon tumor (HCT116) Bax- mitochondria exposed to recombinant Bax exhibited a slow, cyclosporin A-sensitive swelling, but only at [Bax]&gt;200 nM.	Cyclosporine	99-112	BCL2 associated X, apoptosis regulator	Homo sapiens	36-39
15963994-2	2005	Isolated human colon tumor (HCT116) Bax- mitochondria exposed to recombinant Bax exhibited a slow, cyclosporin A-sensitive swelling, but only at [Bax]&gt;200 nM.	Cyclosporine	99-112	BCL2 associated X, apoptosis regulator	Homo sapiens	77-80
15963994-2	2005	Isolated human colon tumor (HCT116) Bax- mitochondria exposed to recombinant Bax exhibited a slow, cyclosporin A-sensitive swelling, but only at [Bax]&gt;200 nM.	Cyclosporine	99-112	BCL2 associated X, apoptosis regulator	Homo sapiens	77-80
15845749-0	2005	Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4.	Cyclosporine	14-27	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	98-104
15845749-8	2005	Similarly, following intravenous administration of cyclosporin A (20 mg/kg), CYP3A4 transgenic mice displayed a reduced plasma AUC compared with wild-type (24.3 +/- 0.66 versus 35.8 +/- 0.53 microg .	Cyclosporine	51-64	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	77-83
15845749-10	2005	Thus, midazolam and cyclosporin A, compounds with markedly different clearance rates and half-lives, both demonstrated clearly accelerated kinetics in the CYP3A4 transgenic mice.	Cyclosporine	20-33	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	155-161
15784653-13	2005	In general, WW85 had no direct action on expression of the proapoptotic gene, Fas ligand; however, WW85 given alone or with cyclosporine enhanced expression of antiapoptotic genes Bcl-2 and Bcl-xL.	Cyclosporine	124-136	BCL2, apoptosis regulator	Rattus norvegicus	180-185
15788440-7	2005	It is surprising that the increased proliferation of CD4(+) T cells with a suppressive dose of Con A on blocking CTLA4-CD80/CD86 interactions is largely interleukin (IL)-2-independent but is cyclosporine A-sensitive.	Cyclosporine	191-205	CD86 antigen	Mus musculus	124-128
15982605-7	2005	There were no changes in high-density lipoprotein cholesterol and triglyceride levels, but apolipoprotein B therapy was reduced in tacrolimus-converted vs cyclosporine-maintained patients (p=0.0003).	Cyclosporine	155-167	apolipoprotein B	Homo sapiens	91-107
15982605-10	2005	CONCLUSIONS: Conversion from cyclosporine microemulsion- to tacrolimus-based immunoprophylaxis resulted in decreased cholesterol, apolipoprotein B, urea, creatinine, and uric acid without any clinically evident perturbation of glucose metabolism in stable heart transplant recipients with treated but persistent mild dyslipidemia.	Cyclosporine	29-41	apolipoprotein B	Homo sapiens	130-146
15876424-7	2005	In the Be-Wo cell line, methadone and paclitaxel uptake was also increased in the presence of the P-gp inhibitor cyclosporin A.	Cyclosporine	113-126	ATP binding cassette subfamily B member 1	Homo sapiens	98-102
16020127-4	2005	The aim of this study was to analyze the P-gP-modulating effects of PSC 833, a cyclosporine derivate, and verapamil on the chemotherapy of HB in vivo.	Cyclosporine	79-91	ATP binding cassette subfamily B member 1	Homo sapiens	41-45
15948868-12	2005	The mRNA expression of COX1 is not affected and COX-2 is decreased in CsA-treated TAL cells.	Cyclosporine	70-73	cytochrome c oxidase I, mitochondrial	Mus musculus	23-27
16182762-1	2005	BACKGROUND: Basiliximab, a chimeric monoclonal antibody (mAb) directed against the alpha chain of the interleukin-2 (IL-2) receptor (CD25), has been extensively evaluated as induction therapy for kidney transplant recipients, more frequently in combination with a cyclosporine-based regimen.	Cyclosporine	264-276	interleukin 2	Homo sapiens	102-115
15899924-2	2005	Immunosuppressive drugs, such as FK506 and cyclosporin A, block the priming of alloreactive CD4 T(h) cells and the subsequent induction of allospecific CD8 cytotoxic effector T cells and inhibit allograft rejection.	Cyclosporine	43-56	CD4 molecule	Homo sapiens	92-95
15940041-6	2005	Increased levels of angiotensin II, intrarenal CRP, osteopontin, and TGF-beta1 in CsA-treated rat kidney were reduced by treatment with either LSRT or PRVT and were further decreased by the combination of the two drugs.	Cyclosporine	82-85	angiotensinogen	Rattus norvegicus	20-34
15940041-6	2005	Increased levels of angiotensin II, intrarenal CRP, osteopontin, and TGF-beta1 in CsA-treated rat kidney were reduced by treatment with either LSRT or PRVT and were further decreased by the combination of the two drugs.	Cyclosporine	82-85	C-reactive protein	Rattus norvegicus	47-50
15940041-6	2005	Increased levels of angiotensin II, intrarenal CRP, osteopontin, and TGF-beta1 in CsA-treated rat kidney were reduced by treatment with either LSRT or PRVT and were further decreased by the combination of the two drugs.	Cyclosporine	82-85	transforming growth factor, beta 1	Rattus norvegicus	69-78
15961982-11	2005	The modest inhibition of human BBB P-gp by cyclosporine has implications for P-gp-based drug interactions at the human BBB.	Cyclosporine	43-55	ATP binding cassette subfamily B member 1	Homo sapiens	35-39
15961982-11	2005	The modest inhibition of human BBB P-gp by cyclosporine has implications for P-gp-based drug interactions at the human BBB.	Cyclosporine	43-55	ATP binding cassette subfamily B member 1	Homo sapiens	77-81
16167169-3	2005	Studies on mitochondria lacking cyclophilin D (CyP-D) have proved that this protein is the target for PTP inhibition by CsA; yet they have also unequivocally demonstrated that the PTP can form and open in the absence of CyP-D.	Cyclosporine	120-123	peptidylprolyl isomerase F	Homo sapiens	32-45
16167169-3	2005	Studies on mitochondria lacking cyclophilin D (CyP-D) have proved that this protein is the target for PTP inhibition by CsA; yet they have also unequivocally demonstrated that the PTP can form and open in the absence of CyP-D.	Cyclosporine	120-123	peptidylprolyl isomerase F	Homo sapiens	47-52
15949725-2	2005	Endothelin-1 (ET-1) has been suggested to mediate cyclosporine-induced vasoconstriction when binding to ET-A receptors.	Cyclosporine	50-62	endothelin 1	Homo sapiens	0-12
15949725-2	2005	Endothelin-1 (ET-1) has been suggested to mediate cyclosporine-induced vasoconstriction when binding to ET-A receptors.	Cyclosporine	50-62	endothelin 1	Homo sapiens	14-18
15949725-11	2005	CONCLUSIONS: The results demonstrate that cyclosporine-treated lung transplant recipients have increased plasma levels of ET-1 and a blunted response to ET-A receptor blockade compared with healthy subjects.	Cyclosporine	42-54	endothelin 1	Homo sapiens	122-126
15853967-7	2005	A dose-dependent increase in the number of mineralized nodules occurred in cultures of cementoblastoma-derived cells treated with cyclosporin A, and RT-PCR analyses showed significantly higher levels of expression of alkaline phosphatase, bone sialoprotein, type I collagen, matrix metalloproteinase-1, osteocalcin, osteopontin, and Cbfa1.	Cyclosporine	130-143	bone gamma-carboxyglutamate protein	Homo sapiens	303-314
15774549-7	2005	Time-of-addition studies revealed that 2-AG treatment up to 12 h post-cellular activation resulted in suppression of IFN-gamma, which was consistent with a time course conducted with cyclosporin A, an inhibitor of NFAT activity.	Cyclosporine	183-196	interferon gamma	Mus musculus	117-126
15853967-7	2005	A dose-dependent increase in the number of mineralized nodules occurred in cultures of cementoblastoma-derived cells treated with cyclosporin A, and RT-PCR analyses showed significantly higher levels of expression of alkaline phosphatase, bone sialoprotein, type I collagen, matrix metalloproteinase-1, osteocalcin, osteopontin, and Cbfa1.	Cyclosporine	130-143	RUNX family transcription factor 2	Homo sapiens	333-338
15910291-8	2005	TGF-beta1 expression within graft tissue was significantly higher in patients treated with CyA when compared with TAC (9.94 +/- 4.2 vs. 5.0 +/- 3.2; P &lt; 0.001).	Cyclosporine	91-94	transforming growth factor beta 1	Homo sapiens	0-9
15910387-1	2005	We encountered two cases of pediatric living-related liver transplant recipients who showed increases in blood concentration of cyclosporine or tacrolimus, a dual substrate for cytochrome P450 (CYP) 3A and P-glycoprotein (P-gp), during a diarrheal episode.	Cyclosporine	128-140	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	177-201
15910387-8	2005	These findings suggest that the suppression of CYP3A and P-gp activities may be involved in the mechanism of elevated blood concentrations of cyclosporine and tacrolimus during enteritis-induced diarrhea.	Cyclosporine	142-154	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	47-52
16044913-0	2005	[Cyclosporin a induces titin expression in human trophoblast cells through the MEK/ERK1/2 signal pathway].	Cyclosporine	1-14	mitogen-activated protein kinase kinase 7	Homo sapiens	79-82
16044913-0	2005	[Cyclosporin a induces titin expression in human trophoblast cells through the MEK/ERK1/2 signal pathway].	Cyclosporine	1-14	mitogen-activated protein kinase 3	Homo sapiens	83-89
16044913-1	2005	To investigate the role of MEK/ERK1/2 signal pathway in the regulation of cyclosporin A(CsA) -induced titin expression in human trophoblast cells.	Cyclosporine	74-87	mitogen-activated protein kinase kinase 7	Homo sapiens	27-30
16044913-1	2005	To investigate the role of MEK/ERK1/2 signal pathway in the regulation of cyclosporin A(CsA) -induced titin expression in human trophoblast cells.	Cyclosporine	74-87	mitogen-activated protein kinase 3	Homo sapiens	31-37
16044913-1	2005	To investigate the role of MEK/ERK1/2 signal pathway in the regulation of cyclosporin A(CsA) -induced titin expression in human trophoblast cells.	Cyclosporine	88-91	mitogen-activated protein kinase kinase 7	Homo sapiens	27-30
16044913-1	2005	To investigate the role of MEK/ERK1/2 signal pathway in the regulation of cyclosporin A(CsA) -induced titin expression in human trophoblast cells.	Cyclosporine	88-91	mitogen-activated protein kinase 3	Homo sapiens	31-37
16044913-5	2005	These results indicated that MEK/ERK1/2 signal pathway may play an important role in the expression of titin in human trophoblast induced by cyclosporin A.	Cyclosporine	141-154	mitogen-activated protein kinase kinase 7	Homo sapiens	29-32
16044913-5	2005	These results indicated that MEK/ERK1/2 signal pathway may play an important role in the expression of titin in human trophoblast induced by cyclosporin A.	Cyclosporine	141-154	mitogen-activated protein kinase 3	Homo sapiens	33-39
15964419-0	2005	Peritransplant and long-term secretion of interleukin-1beta in cyclosporine treated syngeneic rats allografted with islets of langerhans.	Cyclosporine	63-75	interleukin 1 beta	Rattus norvegicus	42-59
15964419-14	2005	Our results suggest that IL-1beta secretion, which is detrimental for islet engraftment, decreases at peritransplant day +2, but is upregulated during long-term graft survival both in controls and in CyA-treated recipients.	Cyclosporine	200-203	interleukin 1 beta	Rattus norvegicus	25-33
15792954-5	2005	These experiments demonstrate that (i) the PTP can form and open in the absence of CyP-D, (ii) that CyP-D represents the target for PTP inhibition by CsA, and (iii) that CyP-D modulates the sensitivity of the PTP to Ca2+ but not its regulation by the proton electrochemical gradient, adenine nucleotides, and oxidative stress.	Cyclosporine	150-153	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	100-105
15792954-5	2005	These experiments demonstrate that (i) the PTP can form and open in the absence of CyP-D, (ii) that CyP-D represents the target for PTP inhibition by CsA, and (iii) that CyP-D modulates the sensitivity of the PTP to Ca2+ but not its regulation by the proton electrochemical gradient, adenine nucleotides, and oxidative stress.	Cyclosporine	150-153	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	100-105
15879096-9	2005	Rag2(-/-) mice reconstituted with Ppia(-/-) splenocytes were also cyclosporine resistant, indicating that this property is intrinsic to Ppia(-/-) immune cells.	Cyclosporine	66-78	recombination activating gene 2	Mus musculus	0-4
15716327-0	2005	Concentrations of cyclosporin A and FK506 that inhibit IL-2 induction in human T cells do not affect TGF-beta1 biosynthesis, whereas higher doses of cyclosporin A trigger apoptosis and release of preformed TGF-beta1.	Cyclosporine	18-31	interleukin 2	Homo sapiens	55-59
15898974-6	2005	RESULTS: Pre-incubating cells with ciclosporin and ascomycin produced dose-dependent inhibition of histamine release when cells were stimulated by sera of urticaria patients, by purified IgG from these sera, but not by C5a.	Cyclosporine	35-46	complement C5a receptor 1	Homo sapiens	219-222
15716327-0	2005	Concentrations of cyclosporin A and FK506 that inhibit IL-2 induction in human T cells do not affect TGF-beta1 biosynthesis, whereas higher doses of cyclosporin A trigger apoptosis and release of preformed TGF-beta1.	Cyclosporine	149-162	transforming growth factor beta 1	Homo sapiens	206-215
15716327-2	2005	It was reported that CsA up-regulated the transcription of transforming growth factor-beta1 (TGF-beta1) in lymphocytes and other cells and activated its promoter in A549 lung carcinoma cells, but the mechanisms involved are poorly understood, and it is unclear whether calcineurin plays any role.	Cyclosporine	21-24	transforming growth factor beta 1	Homo sapiens	59-91
15716327-2	2005	It was reported that CsA up-regulated the transcription of transforming growth factor-beta1 (TGF-beta1) in lymphocytes and other cells and activated its promoter in A549 lung carcinoma cells, but the mechanisms involved are poorly understood, and it is unclear whether calcineurin plays any role.	Cyclosporine	21-24	transforming growth factor beta 1	Homo sapiens	93-102
15716327-4	2005	In Jurkat T cells, the TGF-beta1 promoter was activated by calcineurin and NFATc and inhibited by CsA and FK506.	Cyclosporine	98-101	transforming growth factor beta 1	Homo sapiens	23-32
15716327-7	2005	However, pretreatment of fresh lymphocytes with CsA or FK506 during primary TCR stimulation reduced their production of TGF-beta1 during secondary TCR activation.	Cyclosporine	48-51	transforming growth factor beta 1	Homo sapiens	120-129
15716327-8	2005	Finally, high concentrations of CsA (10 microM), in the range attained in vivo in experiments in rodents, caused apoptosis in human T cells and the release of preformed, bioactive TGF-beta1.	Cyclosporine	32-35	transforming growth factor beta 1	Homo sapiens	180-189
15716327-10	2005	Our results indicate that CsA and FK506 are not general inducers of TGF-beta1 biosynthesis but can cause different effects on TGF-beta1 depending on the cell type and concentrations used.	Cyclosporine	26-29	transforming growth factor beta 1	Homo sapiens	68-77
15716327-10	2005	Our results indicate that CsA and FK506 are not general inducers of TGF-beta1 biosynthesis but can cause different effects on TGF-beta1 depending on the cell type and concentrations used.	Cyclosporine	26-29	transforming growth factor beta 1	Homo sapiens	126-135
15898928-10	2005	There was a significant positive correlation between serum CsA level and level of bcl-2 expression, but serum CsA was not significantly correlated with level of apoptosis or level of p53 expression.	Cyclosporine	59-62	BCL2 apoptosis regulator	Homo sapiens	82-87
15898928-11	2005	CONCLUSION: The results indicate that the pathogenesis of CsA-induced GO might involve inhibition of apoptosis, and overexpression of bcl-2 in the setting of high serum CsA.	Cyclosporine	58-61	BCL2 apoptosis regulator	Homo sapiens	134-139
15898928-11	2005	CONCLUSION: The results indicate that the pathogenesis of CsA-induced GO might involve inhibition of apoptosis, and overexpression of bcl-2 in the setting of high serum CsA.	Cyclosporine	169-172	BCL2 apoptosis regulator	Homo sapiens	134-139
15777344-3	2005	CsA induced the apoptosis of ECFCs in the presence of EPO or IFN-gamma, but at different magnitudes.	Cyclosporine	0-3	erythropoietin	Homo sapiens	54-57
15919474-6	2005	injection of various doses of CsA/tacrolimus decreased the percentage of PerC CD5+ B-1a cells and increased B-2 cells in a dose-dependent fashion.	Cyclosporine	30-33	peroxisome proliferative activated receptor, gamma, coactivator 1 beta	Mus musculus	73-77
16292443-4	2005	The purpose of the present study was to investigate the level of TGF-beta1 in saliva and describe the densities of fibroblasts and collagen fibers in the gingival tissue of rats treated with CsA for long periods.	Cyclosporine	191-194	transforming growth factor, beta 1	Rattus norvegicus	65-74
16292443-8	2005	After 60 and 120 days of CsA treatment, there was a significant increase in Vf and Vcf as well as a significant increase in TGF-beta1 levels.	Cyclosporine	25-28	transforming growth factor, beta 1	Rattus norvegicus	124-133
15772250-0	2005	ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation.	Cyclosporine	80-92	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
15772250-2	2005	Animal models and in vivo studies indicate that the transmembrane efflux pump P-glycoprotein contributes substantially to CsA nephrotoxicity.	Cyclosporine	122-125	ATP binding cassette subfamily B member 1	Homo sapiens	78-92
15772250-3	2005	It was hypothesized that the TT genotype at the ABCB1 3435C--&gt;T polymorphism, which is associated with decreased expression of P-glycoprotein in renal tissue, is a risk factor for developing CsA nephrotoxicity.	Cyclosporine	194-197	ATP binding cassette subfamily B member 1	Homo sapiens	48-53
15772250-3	2005	It was hypothesized that the TT genotype at the ABCB1 3435C--&gt;T polymorphism, which is associated with decreased expression of P-glycoprotein in renal tissue, is a risk factor for developing CsA nephrotoxicity.	Cyclosporine	194-197	ATP binding cassette subfamily B member 1	Homo sapiens	130-144
15772250-7	2005	The P-glycoprotein low expressor genotype 3435TT only of renal organ donors but not of the recipients was overrepresented in patients with CsA nephrotoxicity as compared with patients without toxicity (chi2 = 10.5; P = 0.005).	Cyclosporine	139-142	ATP binding cassette subfamily B member 1	Homo sapiens	4-18
15772250-9	2005	In a multivariate model that included several other nongenetic covariates, only the donor"s ABCB1 3435TT genotype was strongly associated with CsA nephrotoxicity (odds ratio, 13.4; 95% confidence interval, 1.2 to 148; P = 0.034).	Cyclosporine	143-146	ATP binding cassette subfamily B member 1	Homo sapiens	92-97
15772250-10	2005	A dominant role of the donor"s ABCB1 genotype was identified for development of CsA nephrotoxicity.	Cyclosporine	80-83	ATP binding cassette subfamily B member 1	Homo sapiens	31-36
15772250-11	2005	This suggests that P-glycoprotein is an important factor in CsA nephrotoxicity.	Cyclosporine	60-63	ATP binding cassette subfamily B member 1	Homo sapiens	19-33
15919519-8	2005	CsA, MMF, and AS-ODNs inhibited MD-1 expression and lymphocyte proliferation, as well as decreased serum level of IL-2 and increased that of IL-10; FK506, treatment showed all the effects mentioned above but up-regulated the IL-10 level; SRL had no significant influence on either MD-1 expression or IL-2 and IL-10 level, although it equally suppressed the proliferation (P &lt; .05 vs controls).	Cyclosporine	0-3	interleukin 10	Mus musculus	141-146
15919519-8	2005	CsA, MMF, and AS-ODNs inhibited MD-1 expression and lymphocyte proliferation, as well as decreased serum level of IL-2 and increased that of IL-10; FK506, treatment showed all the effects mentioned above but up-regulated the IL-10 level; SRL had no significant influence on either MD-1 expression or IL-2 and IL-10 level, although it equally suppressed the proliferation (P &lt; .05 vs controls).	Cyclosporine	0-3	interleukin 10	Mus musculus	225-230
15919519-8	2005	CsA, MMF, and AS-ODNs inhibited MD-1 expression and lymphocyte proliferation, as well as decreased serum level of IL-2 and increased that of IL-10; FK506, treatment showed all the effects mentioned above but up-regulated the IL-10 level; SRL had no significant influence on either MD-1 expression or IL-2 and IL-10 level, although it equally suppressed the proliferation (P &lt; .05 vs controls).	Cyclosporine	0-3	interleukin 10	Mus musculus	225-230
15760400-4	2005	A significant difference in tubular and interstitial VEGF expressions was found between patients with AR, BC, CAN and CsA toxicity (p &lt; 0.001).	Cyclosporine	118-121	vascular endothelial growth factor A	Homo sapiens	53-57
15777344-3	2005	CsA induced the apoptosis of ECFCs in the presence of EPO or IFN-gamma, but at different magnitudes.	Cyclosporine	0-3	interferon gamma	Homo sapiens	61-70
15777344-4	2005	In the presence of a relatively low concentration of CsA (10 microm), apoptosis was induced only in cultures with EPO.	Cyclosporine	53-56	erythropoietin	Homo sapiens	114-117
15777344-6	2005	In the presence of EPO, NF-kappaB was abundant both in the cytoplasm and in the nucleus, and nuclear expression was diminished after adding CsA.	Cyclosporine	140-143	erythropoietin	Homo sapiens	19-22
15777344-9	2005	CsA disturbed the transmembrane potential in the presence of either EPO or IFN-gamma, although the viability of the cells was maintained in the presence of IFN-gamma plus CsA.	Cyclosporine	0-3	erythropoietin	Homo sapiens	68-71
15777344-9	2005	CsA disturbed the transmembrane potential in the presence of either EPO or IFN-gamma, although the viability of the cells was maintained in the presence of IFN-gamma plus CsA.	Cyclosporine	0-3	interferon gamma	Homo sapiens	75-84
15791000-5	2005	Inhibition of calcineurin by cyclosporin A blocked the effects of vasopressin on ALC-1 promoter activity to approximately 50%.	Cyclosporine	29-42	arginine vasopressin	Homo sapiens	66-77
15749732-6	2005	IFN-gamma further significantly up-regulated its expression, which, however, was inhibited by CsA.	Cyclosporine	94-97	interferon gamma	Homo sapiens	0-9
15711594-8	2005	Using GAL4-CBP fusion proteins, cyclosporin A inhibited depolarization-induced CBP activity, with cyclosporin A-sensitive domains mapped to both the N- (aa 1-451) and C-terminal (aa 2040-2305) ends of CBP.	Cyclosporine	32-45	CREB binding protein	Homo sapiens	11-14
15711594-8	2005	Using GAL4-CBP fusion proteins, cyclosporin A inhibited depolarization-induced CBP activity, with cyclosporin A-sensitive domains mapped to both the N- (aa 1-451) and C-terminal (aa 2040-2305) ends of CBP.	Cyclosporine	32-45	CREB binding protein	Homo sapiens	79-82
15711594-8	2005	Using GAL4-CBP fusion proteins, cyclosporin A inhibited depolarization-induced CBP activity, with cyclosporin A-sensitive domains mapped to both the N- (aa 1-451) and C-terminal (aa 2040-2305) ends of CBP.	Cyclosporine	32-45	CREB binding protein	Homo sapiens	79-82
15711594-9	2005	The depolarization-induced transcriptional activity of the CBP C-terminus was enhanced by overexpression of calcineurin and was inhibited by cyclosporin A and tacrolimus in a concentration-dependent manner with IC50 values (10 and 1 nM, respectively) consistent with their known IC50 values for inhibition of calcineurin.	Cyclosporine	141-154	CREB binding protein	Homo sapiens	59-62
15710339-2	2005	We demonstrated that 10 ng/ml CsA, which reduced the proliferation of HPTC costimulated with anti-CD3 and anti-CD28 by half, prevented NF-AT and NF-kappaB from migrating into the nucleus.	Cyclosporine	30-33	nuclear factor kappa B subunit 1	Homo sapiens	145-154
15710339-4	2005	CsA, which was added to HPTC simultaneously with the engagement of both CD3 and CD28 or the 1-h-delayed engagement of CD28 after prior TCR/CD3-triggering, inhibited NF-kappaB p65/RelA from binding to the target DNA fragment, followed by reduction of HPTC proliferation in response to the costimulation.	Cyclosporine	0-3	nuclear factor kappa B subunit 1	Homo sapiens	165-174
15710339-6	2005	Antisense NF-kappaB p65/RelA oligonucleotides inhibited p65/RelA mRNA expression, diminished IL-2 mRNA expression in the costimulated HPTC and reduced HPTC proliferation to the same extent as CsA added simultaneously with the costimulation.	Cyclosporine	192-195	nuclear factor kappa B subunit 1	Homo sapiens	10-19
15710339-7	2005	The CsA- or antisense p65/RelA oligonucleotide-induced reduction in the proliferation of costimulated HPTC was overcome by the addition of exogenous IL-2.	Cyclosporine	4-7	interleukin 2	Homo sapiens	149-153
15710339-8	2005	These findings indicate that the major effects of CsA on the early phase of CD28-mediated costimulation in the presence of TCR/CD3 signaling are to inhibit NF-kappaB/RelA from translocating into the nucleus and binding to the target DNA sequence in the IL-2 gene promoter region, which induces IL-2 expression leading to HPTC proliferation.	Cyclosporine	50-53	nuclear factor kappa B subunit 1	Homo sapiens	156-165
15632146-5	2005	COX-2 expression and prostaglandin E2 (PGE2) production were induced upon pharmacological stimuli leading to NFAT activation and blunted by inhibition of calcineurin phosphatase with cyclosporin A or tacrolimus (FK506).	Cyclosporine	183-196	prostaglandin-endoperoxide synthase 2	Homo sapiens	0-5
15710339-8	2005	These findings indicate that the major effects of CsA on the early phase of CD28-mediated costimulation in the presence of TCR/CD3 signaling are to inhibit NF-kappaB/RelA from translocating into the nucleus and binding to the target DNA sequence in the IL-2 gene promoter region, which induces IL-2 expression leading to HPTC proliferation.	Cyclosporine	50-53	interleukin 2	Homo sapiens	253-257
15710339-8	2005	These findings indicate that the major effects of CsA on the early phase of CD28-mediated costimulation in the presence of TCR/CD3 signaling are to inhibit NF-kappaB/RelA from translocating into the nucleus and binding to the target DNA sequence in the IL-2 gene promoter region, which induces IL-2 expression leading to HPTC proliferation.	Cyclosporine	50-53	interleukin 2	Homo sapiens	294-298
15813744-7	2005	The protein phosphatase calcineurin is required for azole tolerance, and we find that the calcineurin inhibitor cyclosporin reverses fluconazole resistance of cka2 mutants.	Cyclosporine	112-123	casein kinase 2 catalytic subunit CKA2	Saccharomyces cerevisiae S288C	159-163
16019806-8	2005	CsA inhibits P-gp in a different way from its metabolites, whereas roquefortine C activates P-gp and also inhibits P450-3A and other haemoproteins.	Cyclosporine	0-3	ATP binding cassette subfamily B member 1	Homo sapiens	13-17
15660259-9	2005	Inhibition of the calcium binding proteins calmodulin or calcineurin by W-7 or cyclosporin A, respectively, also prevented the calcium-dependent rapid run-down.	Cyclosporine	79-92	calmodulin 1	Homo sapiens	43-53
15788683-2	2005	The Pgp modulator cyclosporin A has shown clinical efficacy in AML, whereas its analogue PSC-833 has not.	Cyclosporine	18-31	ATP binding cassette subfamily B member 1	Homo sapiens	4-7
15788683-3	2005	Cyclosporin A is known to also modulate MRP-1, and we hypothesized that broad-spectrum multidrug resistance modulation might contribute to its clinical efficacy.	Cyclosporine	0-13	ATP binding cassette subfamily C member 1	Homo sapiens	40-45
15788683-6	2005	RESULTS: Cyclosporin A enhanced retention of the substrate drug mitoxantrone in cells overexpressing Pgp (HL60/VCR), MRP-1 (HL60/ADR), and BCRP (8226/MR20, HEK-293 482R) and increased cytotoxicity 6-, 4-, 4-, and 3-fold, respectively.	Cyclosporine	9-22	ATP binding cassette subfamily B member 1	Homo sapiens	101-104
15788683-6	2005	RESULTS: Cyclosporin A enhanced retention of the substrate drug mitoxantrone in cells overexpressing Pgp (HL60/VCR), MRP-1 (HL60/ADR), and BCRP (8226/MR20, HEK-293 482R) and increased cytotoxicity 6-, 4-, 4-, and 3-fold, respectively.	Cyclosporine	9-22	ATP binding cassette subfamily C member 1	Homo sapiens	117-122
15788683-6	2005	RESULTS: Cyclosporin A enhanced retention of the substrate drug mitoxantrone in cells overexpressing Pgp (HL60/VCR), MRP-1 (HL60/ADR), and BCRP (8226/MR20, HEK-293 482R) and increased cytotoxicity 6-, 4-, 4-, and 3-fold, respectively.	Cyclosporine	9-22	aldo-keto reductase family 1 member B	Homo sapiens	129-132
15788683-6	2005	RESULTS: Cyclosporin A enhanced retention of the substrate drug mitoxantrone in cells overexpressing Pgp (HL60/VCR), MRP-1 (HL60/ADR), and BCRP (8226/MR20, HEK-293 482R) and increased cytotoxicity 6-, 4-, 4-, and 3-fold, respectively.	Cyclosporine	9-22	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	139-143
15788683-7	2005	Moreover, cyclosporin A enhanced nuclear distribution of doxorubicin in 8226/MR20 cells, which also express LRP, and increased doxorubicin cytotoxicity 12-fold without an effect on cellular doxorubicin content, consistent with expression of wild-type BCRP, which does not efflux doxorubicin.	Cyclosporine	10-23	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	251-255
15788683-10	2005	CONCLUSIONS: Cyclosporin A modulates Pgp, MRP-1, BCRP, and LRP, and this broad-spectrum activity may contribute to its clinical efficacy.	Cyclosporine	13-26	ATP binding cassette subfamily B member 1	Homo sapiens	37-40
15788683-10	2005	CONCLUSIONS: Cyclosporin A modulates Pgp, MRP-1, BCRP, and LRP, and this broad-spectrum activity may contribute to its clinical efficacy.	Cyclosporine	13-26	ATP binding cassette subfamily C member 1	Homo sapiens	42-47
15788683-10	2005	CONCLUSIONS: Cyclosporin A modulates Pgp, MRP-1, BCRP, and LRP, and this broad-spectrum activity may contribute to its clinical efficacy.	Cyclosporine	13-26	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	49-53
15483225-6	2005	Using SB-203580 and cyclosporine A drugs to inhibit both p38- or/and calcineurin-dependent signals, respectively, we have shown that MEF2A phosphorylation and subsequent nuclear translocation are regulated by p38 and calcineurin in a biphasic, time-dependent manner.	Cyclosporine	20-34	mitogen-activated protein kinase 14	Homo sapiens	57-60
15483225-6	2005	Using SB-203580 and cyclosporine A drugs to inhibit both p38- or/and calcineurin-dependent signals, respectively, we have shown that MEF2A phosphorylation and subsequent nuclear translocation are regulated by p38 and calcineurin in a biphasic, time-dependent manner.	Cyclosporine	20-34	mitogen-activated protein kinase 14	Homo sapiens	209-212
15486347-3	2005	IFN-gamma reduced cellular uptake of cyclosporin A (CysA) but not methotrexate (MTX) in a time- and concentration-dependent manner.	Cyclosporine	37-50	interferon gamma	Homo sapiens	0-9
15486347-3	2005	IFN-gamma reduced cellular uptake of cyclosporin A (CysA) but not methotrexate (MTX) in a time- and concentration-dependent manner.	Cyclosporine	52-56	interferon gamma	Homo sapiens	0-9
15618541-6	2005	Cyclosporin-A inhibited cytochrome C release, possibly by inhibiting the opening of the mitochondrial permeability transition pore (mPTP).	Cyclosporine	0-13	cytochrome c, somatic	Homo sapiens	24-36
15734424-13	2005	Cyclosporine selectively reduces proinflammatory mediator secretion, likely by transcriptional regulation through NFkappaB and EGR-1.	Cyclosporine	0-12	early growth response 1	Rattus norvegicus	127-132
15618541-6	2005	Cyclosporin-A inhibited cytochrome C release, possibly by inhibiting the opening of the mitochondrial permeability transition pore (mPTP).	Cyclosporine	0-13	protein tyrosine phosphatase, receptor type, U	Mus musculus	132-136
15744065-3	2005	Since cyclosporin A (MDR1 P-gp inhibitor) but not MK571 (MRP1 inhibitor) inhibited SAL-induced PS externalization, it was suggested that MDR1 P-gp is involved in this phenomenon.	Cyclosporine	6-19	ATP binding cassette subfamily B member 1	Homo sapiens	21-25
15743796-0	2005	A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice.	Cyclosporine	2-14	TEK receptor tyrosine kinase	Mus musculus	60-64
15744065-3	2005	Since cyclosporin A (MDR1 P-gp inhibitor) but not MK571 (MRP1 inhibitor) inhibited SAL-induced PS externalization, it was suggested that MDR1 P-gp is involved in this phenomenon.	Cyclosporine	6-19	ATP binding cassette subfamily B member 1	Homo sapiens	137-141
15895894-5	2005	RESULTS: PBL of patients with MPO-ANCA-associated vasculitis produced MPO-ANCA following Con-A stimulation, and this effect was inhibited by treatment with cyclosporin A (CyA) or elimination of CD4 cells.	Cyclosporine	156-169	myeloperoxidase	Homo sapiens	30-33
15726428-7	2005	Calpain-3 gene expression decreased at 1 day after cryolesion and also following CsA treatment combined with cryolesion.	Cyclosporine	81-84	calpain 3	Rattus norvegicus	0-9
15726428-9	2005	CsA treatment blocked calpain-3 gene expression rise induced by 10 days of cryolesion.	Cyclosporine	0-3	calpain 3	Rattus norvegicus	22-31
15726428-10	2005	Atrogin-1 gene expression was decreased at 1 day after cryolesion and following cryolesion combined with CsA treatment, returning to control levels at day 10.	Cyclosporine	105-108	F-box protein 32	Rattus norvegicus	0-9
15895894-5	2005	RESULTS: PBL of patients with MPO-ANCA-associated vasculitis produced MPO-ANCA following Con-A stimulation, and this effect was inhibited by treatment with cyclosporin A (CyA) or elimination of CD4 cells.	Cyclosporine	156-169	myeloperoxidase	Homo sapiens	70-73
15749687-3	2005	Forward logistic regression analysis confirmed the role of IFN-gamma 3/3 genotype as one of the risk factors for manifestation of chronic GvHD (OR=3.180, p=0.018) together with previous acute GvHD (OR=2.752, p=0.024), cyclosporine A monotherapy (OR=2.607, p=0.029) and malignant disorders (OR=4.371, p=0.032).	Cyclosporine	218-232	interferon gamma	Homo sapiens	59-68
15728480-5	2005	Cyclosporin A and FK506, which target calcineurin and thereby inhibit TCR-mediated Ca(2+) signal pathways, block IL-6-mediated c-Maf expression.	Cyclosporine	0-13	interleukin 6	Homo sapiens	113-117
15728480-5	2005	Cyclosporin A and FK506, which target calcineurin and thereby inhibit TCR-mediated Ca(2+) signal pathways, block IL-6-mediated c-Maf expression.	Cyclosporine	0-13	MAF bZIP transcription factor	Homo sapiens	127-132
15598974-7	2005	We also demonstrated, for the first time, that [125I]iodoarylazidoprazosin, a photoaffinity analog of the substrate prazosin, labels multiple variants of ABCG2 specifically and that this labeling, although competed by some ABCG2 substrates, is unaffected by cyclosporin A.	Cyclosporine	258-271	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	154-159
15709044-0	2005	Chimeric human immunodeficiency virus type 1 virions that contain the simian immunodeficiency virus nef gene are cyclosporin A resistant.	Cyclosporine	113-126	nef protein	Simian immunodeficiency virus	100-103
15709044-1	2005	We have previously shown that human immunodeficiency virus type 1 (HIV-1) virions which have their own nef gene deleted and are trans complemented to contain HIV-2 or simian immunodeficiency virus (SIV) Nef become resistant to treatment with cyclosporin A.	Cyclosporine	242-255	nef protein	Simian immunodeficiency virus	203-206
15598974-3	2005	In this study, we demonstrate that human ABCG2 and P-glycoprotein, despite overlapping substrate specificities, differ in sensitivity to the immunomodulator cyclosporin A.	Cyclosporine	157-170	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	41-46
15598974-3	2005	In this study, we demonstrate that human ABCG2 and P-glycoprotein, despite overlapping substrate specificities, differ in sensitivity to the immunomodulator cyclosporin A.	Cyclosporine	157-170	ATP binding cassette subfamily B member 1	Homo sapiens	51-65
16895664-4	2005	Calcineurin inhibitors, cyclosporine and tacrolimus, are involved in tumor development through various mechanisms: they promote B-cell proliferation by increasing T lymphocyte IL6 secretion, decrease DNA repair ability and may be able to promote metastasis spreading by a direct cellular effect that is independent of their effect on the host"s immune cells.	Cyclosporine	24-36	interleukin 6	Homo sapiens	176-179
15886424-4	2005	Cyclosporine A which is used as an immunosuppressive drug in patients with allogenic kidney grafts is a substrate for P-gp.	Cyclosporine	0-14	ATP binding cassette subfamily B member 1	Homo sapiens	118-122
15598974-5	2005	By flow cytometric analysis using the fluorescent substrates rhodamine 123 and mitoxantrone, we showed that cyclosporin A inhibits P-gp function at low micromolar concentrations, whereas ABCG2 function was unaffected.	Cyclosporine	108-121	ATP binding cassette subfamily B member 1	Homo sapiens	131-135
15882134-5	2005	This review describes polymorphisms of the genes coding for P-gp and CYPs, and focuses on the compounds cyclosporin and tacrolimus.	Cyclosporine	104-115	ATP binding cassette subfamily B member 1	Homo sapiens	60-64
15886424-6	2005	It was assumed that polymorphism of MDR1 gene which is associated with change in P-gp activity plays a role in induction of tremor in some patients with allogenic kidney graft treated with cyclosporine A.	Cyclosporine	189-203	ATP binding cassette subfamily B member 1	Homo sapiens	36-40
15886424-6	2005	It was assumed that polymorphism of MDR1 gene which is associated with change in P-gp activity plays a role in induction of tremor in some patients with allogenic kidney graft treated with cyclosporine A.	Cyclosporine	189-203	ATP binding cassette subfamily B member 1	Homo sapiens	81-85
15848603-7	2005	After conversion to CSA, among the 3 patients started on insulin, 1 has come completely off antidiabetic medications, whereas 1 required decreased doses of insulin, and the third has been converted to oral medications.	Cyclosporine	20-23	insulin	Homo sapiens	57-64
15848523-11	2005	Weakly increased (P &lt; .05) expressions of TGF-beta1 were found during CsA toxicity.	Cyclosporine	73-76	transforming growth factor beta 1	Homo sapiens	45-54
15738623-8	2005	The inhibitory effects of QPA on P-gp were more effective than those of the typical P-gp inhibitors cyclosporin A and verapamil.	Cyclosporine	100-113	ATP binding cassette subfamily B member 1	Homo sapiens	84-88
15848605-7	2005	Whole blood CsA levels causing 50% inhibition of IL-2 mRNA (IC50) were 256, 310, 175, and 55 ng/mL for Ht 50%, 40%, 30%, and 20%, respectively.	Cyclosporine	12-15	interleukin 2	Homo sapiens	49-53
15848605-10	2005	A pharmacodynamic study, such as the IL-2 mRNA inhibition test, is preferable for CsA monitoring.	Cyclosporine	82-85	interleukin 2	Homo sapiens	37-41
15684491-0	2005	In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats.	Cyclosporine	19-32	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	126-150
15582708-5	2005	The enhancement of 3H-leucine incorporation and c-Jun mRNA expression in cardiomyocytes treated with NPY were markedly inhibited by cyclosporine A (CsA), a selective inhibitor of CaN.	Cyclosporine	132-146	neuropeptide Y	Rattus norvegicus	101-104
15582708-5	2005	The enhancement of 3H-leucine incorporation and c-Jun mRNA expression in cardiomyocytes treated with NPY were markedly inhibited by cyclosporine A (CsA), a selective inhibitor of CaN.	Cyclosporine	148-151	neuropeptide Y	Rattus norvegicus	101-104
15652240-9	2005	The protective effect of the previous heat treatment (corroborated by the irreversible catalase inhibitor 3-aminotriazole) against the CsA cytotoxicity was due to an increased expression and activity of catalase that was significantly reduced by the effect of CsA.	Cyclosporine	135-138	catalase	Homo sapiens	87-95
15652240-9	2005	The protective effect of the previous heat treatment (corroborated by the irreversible catalase inhibitor 3-aminotriazole) against the CsA cytotoxicity was due to an increased expression and activity of catalase that was significantly reduced by the effect of CsA.	Cyclosporine	135-138	catalase	Homo sapiens	203-211
15652240-9	2005	The protective effect of the previous heat treatment (corroborated by the irreversible catalase inhibitor 3-aminotriazole) against the CsA cytotoxicity was due to an increased expression and activity of catalase that was significantly reduced by the effect of CsA.	Cyclosporine	260-263	catalase	Homo sapiens	203-211
15697228-8	2005	In contrast, CsA only affected the GR through upregulation of hormone retention.	Cyclosporine	13-16	nuclear receptor subfamily 3 group C member 1	Homo sapiens	35-37
15697228-11	2005	Interestingly, no GR-associated Cyp40 was found in these cells, consistent with the ability of CsA ligand to only affect GR through the hormone export mechanism.	Cyclosporine	95-98	nuclear receptor subfamily 3 group C member 1	Homo sapiens	121-123
15681831-8	2005	By electrophysiological recordings ex vivo, we found that CsA counteracted the decrease in chloride conductance (gCl), a functional index of degeneration in diaphragm and extensor digitorum longus muscle fibers.	Cyclosporine	58-61	germ cell-less, spermatogenesis associated 1	Mus musculus	113-116
15684491-1	2005	In this study, the in vivo effects of cyclosporin A (CsA) and ketoconazole (KCZ), which are used as inhibitors of P-glycoprotein (Pgp) and cytochrome P450 (CYP) 3A, respectively, on the pharmacokinetics of rhodamine 123 (Rho123), nelfinavir (NFV) and erythromycin (EM) were evaluated in rats.	Cyclosporine	38-51	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	139-163
15684491-1	2005	In this study, the in vivo effects of cyclosporin A (CsA) and ketoconazole (KCZ), which are used as inhibitors of P-glycoprotein (Pgp) and cytochrome P450 (CYP) 3A, respectively, on the pharmacokinetics of rhodamine 123 (Rho123), nelfinavir (NFV) and erythromycin (EM) were evaluated in rats.	Cyclosporine	53-56	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	139-163
15613074-6	2005	RESULTS: Cyclosporin A induced 23-25% (p &lt; 0.001) increases in the proliferation of rat gingival cells and approximately 130% (p &lt; 0.05) and 60% (p &lt; 0.05) elevations in the mRNA expression levels for TGF-beta1 and FGF-2, respectively.	Cyclosporine	9-22	transforming growth factor, beta 1	Rattus norvegicus	210-219
15613074-7	2005	On the other hand, exogenous IGF-I induced 8-11% (p &lt; 0.05) increases in the proliferation, but cyclosporin A induced 30-80% (p &lt; 0.05-0.01) reductions in the mRNA expression levels for endogenous IGF-I, IGFR1, IGFBP2, IGFBP3, IGFBP5, and IGFBP6.	Cyclosporine	99-112	insulin-like growth factor binding protein 2	Rattus norvegicus	217-223
15613074-7	2005	On the other hand, exogenous IGF-I induced 8-11% (p &lt; 0.05) increases in the proliferation, but cyclosporin A induced 30-80% (p &lt; 0.05-0.01) reductions in the mRNA expression levels for endogenous IGF-I, IGFR1, IGFBP2, IGFBP3, IGFBP5, and IGFBP6.	Cyclosporine	99-112	insulin-like growth factor binding protein 6	Rattus norvegicus	245-251
15542593-11	2005	Mutant L1260A P-gp exhibited drug-stimulated ATPase activities similar to that of wild-type enzyme after rescue with cyclosporin A.	Cyclosporine	117-130	ATP binding cassette subfamily B member 1	Homo sapiens	14-18
15514034-6	2005	Cyclosporine A, the calcineurin inhibitor, regulated AUF1 posttranslationally, and this correlated with an increase in the stability of GH-PTH 63-nt mRNA but not of the control GH mRNA.	Cyclosporine	0-14	parathyroid hormone	Homo sapiens	139-142
15681425-5	2005	The perturbations of MAP kinase phosphorylation could be eliminated by cyclosporine A-mediated inhibition of nuclear factor of activated T cells, suggesting that the inactivation of JNK signaling and hyporesponsiveness to IL-2 induction were downstream consequences of C-induced Ca(2+) flux in a manner that mimics the induction of clonal anergy.	Cyclosporine	71-85	mitogen-activated protein kinase 8	Homo sapiens	182-185
15681425-5	2005	The perturbations of MAP kinase phosphorylation could be eliminated by cyclosporine A-mediated inhibition of nuclear factor of activated T cells, suggesting that the inactivation of JNK signaling and hyporesponsiveness to IL-2 induction were downstream consequences of C-induced Ca(2+) flux in a manner that mimics the induction of clonal anergy.	Cyclosporine	71-85	interleukin 2	Homo sapiens	222-226
15746540-0	2005	Attenuation of interstitial inflammation and fibrosis by recombinant human erythropoietin in chronic cyclosporine nephropathy.	Cyclosporine	101-113	erythropoietin	Homo sapiens	75-89
15353404-10	2005	However, [AD-Ser](8) CsA, a CsA derivative, which does not inhibit calcineurin but inhibits PPIase activity of cyclophilin A, completely blocked the effect of acid incubation on apical Cl(-):HCO(3)(-) exchange.	Cyclosporine	21-24	peptidyl-prolyl cis-trans isomerase A	Oryctolagus cuniculus	111-124
15353404-10	2005	However, [AD-Ser](8) CsA, a CsA derivative, which does not inhibit calcineurin but inhibits PPIase activity of cyclophilin A, completely blocked the effect of acid incubation on apical Cl(-):HCO(3)(-) exchange.	Cyclosporine	28-31	peptidyl-prolyl cis-trans isomerase A	Oryctolagus cuniculus	111-124
15522880-3	2005	In this report, we demonstrate that the IL-12-induced CsA-resistant pathway of IFN-gamma production is sensitive to rapamycin.	Cyclosporine	54-57	interferon gamma	Homo sapiens	79-88
15746540-7	2005	Increased apoptotic cell death in CsA-treated rat kidneys was significantly decreased with rHuEPO cotreatment, and apoptosis-related genes were regulated in favor of cell survival (increased Bcl-2 and suppressed caspase-3).	Cyclosporine	34-37	BCL2, apoptosis regulator	Rattus norvegicus	191-196
15779861-4	2005	Cyclosporine A at 3 mg/kg/day in two divided doses was given on days 4-21, alpha-interferon 1 million units/m2 subcutaneously every other day on days 4-21 and interleukin-2 1 million units/m2 BID subcutaneously days 21-28 were also given.	Cyclosporine	0-14	interleukin 2	Homo sapiens	159-172
15642162-12	2005	Both 1A and 2B protein phosphatases participated in dephosphorylation of ERKs, as demonstrated by efficient reversal of ERK1/2 inactivation with okadaic acid and cyclosporin A.	Cyclosporine	162-175	mitogen-activated protein kinase 3	Homo sapiens	73-77
15642162-12	2005	Both 1A and 2B protein phosphatases participated in dephosphorylation of ERKs, as demonstrated by efficient reversal of ERK1/2 inactivation with okadaic acid and cyclosporin A.	Cyclosporine	162-175	mitogen-activated protein kinase 3	Homo sapiens	120-126
17192032-6	2005	Cyclosporin A treatment caused injury to the thick ascending limb (TAL) of the nephron and was associated with a down-regulation of calbindin protein expression in cortical distal tubules (mean score 75% reduction) and TALs (21% reduction).	Cyclosporine	0-13	calbindin 1	Rattus norvegicus	132-141
16218035-10	2005	CsA should be converted to mofetil mycophenolate or mTOR-inhibitors.	Cyclosporine	0-3	mechanistic target of rapamycin kinase	Homo sapiens	52-56
15637343-8	2005	No HO-1 expression and increased expression of endothelin-1 (ET-1) were observed in CsA-treated rats compared with controls.	Cyclosporine	84-87	endothelin 1	Rattus norvegicus	47-59
15647646-7	2005	CsA was started on the basis of their C-reactive protein (CRP) and/or stool frequency after 3 days or after 5-7 days of i.v.	Cyclosporine	0-3	C-reactive protein	Homo sapiens	38-56
15647646-7	2005	CsA was started on the basis of their C-reactive protein (CRP) and/or stool frequency after 3 days or after 5-7 days of i.v.	Cyclosporine	0-3	C-reactive protein	Homo sapiens	58-61
15661399-11	2005	P-gp inhibitors GF120918 and cyclosporin A enhanced ceramide-induced apoptosis in the p-gp expressing cells.	Cyclosporine	29-42	ATP binding cassette subfamily B member 1	Homo sapiens	86-90
16696343-8	2005	It was concluded that CsA eye drop exerts marked therapeutic effect on KCS by inhibiting T lymph cells, increasing the goblet cells and AQP3 expression in conjunctiva.	Cyclosporine	22-25	aquaporin 3	Mus musculus	136-140
16463674-9	2005	It was concluded that CsA can suppress the Ang II-induced c-fos protein expression and [Ca2+]i elevation in single cardiomyocyte, which might play a role in the prevention of Ang II-induced cardiomyocyte hypertrophy by CsA.	Cyclosporine	219-222	angiotensinogen	Rattus norvegicus	175-181
16463674-0	2005	Effects of cyclosporine A on angiotensin II-induced cardiomyocyte hypertrophy in neonatal rats.	Cyclosporine	11-25	angiotensinogen	Rattus norvegicus	29-43
16463674-5	2005	The results revealed that as compared with control, the total protein contents were increased in cardiomyocytes treated with Ang II (10(-7) mol/ L), which could be inhibited by CsA in a dose-dependent manner.	Cyclosporine	177-180	angiotensinogen	Rattus norvegicus	125-131
16463674-6	2005	It was found that Ang II could increase the c-fos protein expression, which could be inhibited by CsA in a dose-dependent manner.	Cyclosporine	98-101	angiotensinogen	Rattus norvegicus	18-24
15573402-9	2005	Cyclosporin A (CsA), a potent immunosuppressive drug, inhibits mitochondrial permeability transition (mPT) by binding to matrix cyclophilin D and blocking its binding to the adenine nucleotide translocator.	Cyclosporine	15-18	peptidylprolyl isomerase F	Homo sapiens	128-141
16463674-8	2005	CsA did not influence the resting intracellular Ca2+, but inhibited significantly the Ang II-induced [Ca2+]i elevation.	Cyclosporine	0-3	angiotensinogen	Rattus norvegicus	86-92
16463674-9	2005	It was concluded that CsA can suppress the Ang II-induced c-fos protein expression and [Ca2+]i elevation in single cardiomyocyte, which might play a role in the prevention of Ang II-induced cardiomyocyte hypertrophy by CsA.	Cyclosporine	22-25	angiotensinogen	Rattus norvegicus	43-49
16463674-9	2005	It was concluded that CsA can suppress the Ang II-induced c-fos protein expression and [Ca2+]i elevation in single cardiomyocyte, which might play a role in the prevention of Ang II-induced cardiomyocyte hypertrophy by CsA.	Cyclosporine	22-25	angiotensinogen	Rattus norvegicus	175-181
16463674-9	2005	It was concluded that CsA can suppress the Ang II-induced c-fos protein expression and [Ca2+]i elevation in single cardiomyocyte, which might play a role in the prevention of Ang II-induced cardiomyocyte hypertrophy by CsA.	Cyclosporine	219-222	angiotensinogen	Rattus norvegicus	43-49
15637465-0	2005	Blockade of angiotensin II with losartan attenuates transforming growth factor-beta1 inducible gene-h3 (betaig-h3) expression in a model of chronic cyclosporine nephrotoxicity.	Cyclosporine	148-160	angiotensinogen	Rattus norvegicus	12-26
15825831-1	2005	Cyclosporine A (CsA), a common immunosuppressive agent, produces hyperlipidemia and apolipoprotein profile alterations in plasma as well as neurological and psychiatric complications.	Cyclosporine	0-14	apolipoprotein E	Rattus norvegicus	84-98
15825831-1	2005	Cyclosporine A (CsA), a common immunosuppressive agent, produces hyperlipidemia and apolipoprotein profile alterations in plasma as well as neurological and psychiatric complications.	Cyclosporine	16-19	apolipoprotein E	Rattus norvegicus	84-98
15808546-9	2005	CsA suppressed the upregulation of OX40 expression after allo-Ag in a dose-dependent manner.	Cyclosporine	0-3	TNF receptor superfamily member 4	Homo sapiens	35-39
15723604-5	2005	The association between the CYP3A4 and CYP3A5 polymorphisms and cyclosporine pharmacokinetics is more questionable.	Cyclosporine	64-76	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	28-34
15723604-5	2005	The association between the CYP3A4 and CYP3A5 polymorphisms and cyclosporine pharmacokinetics is more questionable.	Cyclosporine	64-76	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	39-45
15829105-9	2005	Erythrocyte CAT was significantly (P &lt; 0.05) increased in CsA treated rats compared to controls.	Cyclosporine	61-64	catalase	Rattus norvegicus	12-15
16541750-3	2005	Since cyclosporine is a substrate and inhibitor of CYP3A4, researchers suspect that the immunosuppressant inhibits CYP3A4-mediated metabolism of statins, leading to an increase in statin plasma concentration and infrequently resulting in rhabdomyolysis.	Cyclosporine	6-18	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	51-57
16541750-3	2005	Since cyclosporine is a substrate and inhibitor of CYP3A4, researchers suspect that the immunosuppressant inhibits CYP3A4-mediated metabolism of statins, leading to an increase in statin plasma concentration and infrequently resulting in rhabdomyolysis.	Cyclosporine	6-18	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	115-121
16541750-8	2005	Furthermore, in the Japanese package inserts, it is either stated that cyclosporine inhibits CYP3A4-mediated metabolism or no comment is made on the mechanism.	Cyclosporine	71-83	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	93-99
16044165-5	2005	Computational dissection of these transcriptional profiles in activated T cells uncovers a novel regulatory synergy between IGF-1 and CD28 costimulation that modulates NF-kappaB and AP1 pathways through signaling cascades sensitive to cyclosporin A and wortmannin.	Cyclosporine	235-248	insulin like growth factor 1	Homo sapiens	124-129
16044165-5	2005	Computational dissection of these transcriptional profiles in activated T cells uncovers a novel regulatory synergy between IGF-1 and CD28 costimulation that modulates NF-kappaB and AP1 pathways through signaling cascades sensitive to cyclosporin A and wortmannin.	Cyclosporine	235-248	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	182-185
15702787-1	2005	OBJECTIVE: To investigate the effect of cyclosporine A (CsA) on the trophoblast cell secretion of interleukin-10 (IL-10) and interferon-gamma (IFN-gamma) in early pregnancy.	Cyclosporine	56-59	interferon gamma	Homo sapiens	125-141
15702787-7	2005	IFN-gamma protein expressed in the trophoblast membrane of cell in the CsA at 4 concentrations were almost the same; there was no significant difference among the 4 CsA concentrations (P&gt;0.05).	Cyclosporine	71-74	interferon gamma	Homo sapiens	0-9
15808547-8	2005	At day 63 under CsA monotherapy a low level of chimerism for RT1(n)/CD4 was induced after intraosseous (1.9%) and intravenous (0.8%) transplantation of (70 x 10(6)) BMC.	Cyclosporine	16-19	CD4 molecule	Homo sapiens	68-71
15808547-9	2005	Under alphabetaTCR/CsA protocol chimerism for RT1(n)/CD4 revealed 6.5% and 0.9% in intraosseous and intravenous (70 x 10(6)) BMC transplantation, respectively.	Cyclosporine	19-22	CD4 molecule	Homo sapiens	53-56
15808586-0	2005	Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.	Cyclosporine	63-75	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	25-31
15808586-2	2005	Our objective was to determine the relationship between genetic polymorphisms of CYP3A5 with respect to interindividual variability in CsA and tacrolimus pharmacokinetics.	Cyclosporine	135-138	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	81-87
15466861-5	2004	PC1-mediated activation of NFAT was completely inhibited by the calcineurin inhibitor, cyclosporin A.	Cyclosporine	87-100	calcineurin binding protein 1	Mus musculus	64-85
15583082-3	2004	Transforming growth factor-beta (TGF-beta) is one of the most potent mediators of the fibrogenic effects of cyclosporine.	Cyclosporine	108-120	transforming growth factor, beta 1	Rattus norvegicus	33-41
15614148-5	2004	RESULTS: CsA-induced tubular cell apoptosis; cellular infiltration; and increase of Fas, Bax, TGF-beta protein expression with significant tubulointerstitial fibrosis, and reduced Bcl2 protein expression.	Cyclosporine	9-12	transforming growth factor, beta 1	Rattus norvegicus	94-102
15614148-5	2004	RESULTS: CsA-induced tubular cell apoptosis; cellular infiltration; and increase of Fas, Bax, TGF-beta protein expression with significant tubulointerstitial fibrosis, and reduced Bcl2 protein expression.	Cyclosporine	9-12	BCL2, apoptosis regulator	Rattus norvegicus	180-184
15614148-7	2004	CONCLUSIONS: These findings suggest that chronic CsA nephrotoxicity is related to Bax and Bcl2-related apoptosis pathways, and that alpha-MSH can attenuate the CsA-induced tubulointerstitial fibrosis as well as tubular cell apoptosis.	Cyclosporine	49-52	BCL2, apoptosis regulator	Rattus norvegicus	90-94
15583082-8	2004	Cyclosporine-induced graft survival (immunosuppressive effect) was abrogated with a higher concentration (2.5 mg/kg) of anti-TGF-beta antibody, whereas a lower concentration (1 mg/kg) inhibited both cyclosporine-induced expression of fibrogenic molecules and renal toxicity.	Cyclosporine	0-12	transforming growth factor, beta 1	Rattus norvegicus	125-133
15583082-10	2004	Furthermore, these findings support a potentially significant therapeutic use of optimal concentration of anti-TGF-beta antibody to ameliorate cyclosporine-associated nephrotoxicity in cardiac transplant recipients.	Cyclosporine	143-155	transforming growth factor, beta 1	Rattus norvegicus	111-119
15494300-8	2004	In clinical trials in MDS, first-generation Pgp blockers, such as cyclosporin-A and verapamil, were minimally effective, non-specific, and toxic.	Cyclosporine	66-79	ATP binding cassette subfamily B member 1	Homo sapiens	44-47
15548389-7	2004	30-40%) of caspase-3 activation by 5 microM FK506 and CsA was observed.	Cyclosporine	54-57	caspase 3	Homo sapiens	11-20
15601549-9	2004	CONCLUSIONS: CsA may induce apoptosis of HR20, and HT9 cells in a Caspase-3 independent manner, which is different from apoptosis of sensitive cells.	Cyclosporine	13-16	caspase 3	Homo sapiens	66-75
15592326-10	2004	CONCLUSION: Patients carrying a CYP3A4*1B variant allele have a significantly higher oral cyclosporine clearance compared with patients homozygous for CYP3A4*1 .	Cyclosporine	90-102	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	32-38
15517563-8	2004	ABCG2-mediated transport was inhibited by fumitremorgin C, cyclosporine A, and PSC-833, but not by verapamil or probenecid.	Cyclosporine	59-73	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	0-5
16602240-5	2005	An immunosuppressant cyclosporin A decreases both IL-2-dependent T-lymphocyte progression and alfa1-subunit abundance by 48 h of PHA-induced lymphocyte activation.	Cyclosporine	21-34	interleukin 2	Homo sapiens	50-54
15530432-8	2004	By contrast, all misprocessed P-gp mutants were rescued by the chemical chaperone/drug substrate cyclosporin A in a dose-dependent manner.	Cyclosporine	97-110	ATP binding cassette subfamily B member 1	Homo sapiens	30-34
15592326-1	2004	OBJECTIVE: Our objective was to determine the relationship between single nucleotide polymorphisms (SNPs) in the multidrug resistance 1 (MDR-1) gene and the cytochrome P450 (CYP) genes CYP3A4 and CYP3A5 and the pharmacokinetics of cyclosporine (INN, ciclosporin).	Cyclosporine	231-243	ATP binding cassette subfamily B member 1	Homo sapiens	113-135
15592326-1	2004	OBJECTIVE: Our objective was to determine the relationship between single nucleotide polymorphisms (SNPs) in the multidrug resistance 1 (MDR-1) gene and the cytochrome P450 (CYP) genes CYP3A4 and CYP3A5 and the pharmacokinetics of cyclosporine (INN, ciclosporin).	Cyclosporine	231-243	ATP binding cassette subfamily B member 1	Homo sapiens	137-142
15592326-1	2004	OBJECTIVE: Our objective was to determine the relationship between single nucleotide polymorphisms (SNPs) in the multidrug resistance 1 (MDR-1) gene and the cytochrome P450 (CYP) genes CYP3A4 and CYP3A5 and the pharmacokinetics of cyclosporine (INN, ciclosporin).	Cyclosporine	231-243	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	185-191
15592326-1	2004	OBJECTIVE: Our objective was to determine the relationship between single nucleotide polymorphisms (SNPs) in the multidrug resistance 1 (MDR-1) gene and the cytochrome P450 (CYP) genes CYP3A4 and CYP3A5 and the pharmacokinetics of cyclosporine (INN, ciclosporin).	Cyclosporine	250-261	ATP binding cassette subfamily B member 1	Homo sapiens	113-135
15592326-1	2004	OBJECTIVE: Our objective was to determine the relationship between single nucleotide polymorphisms (SNPs) in the multidrug resistance 1 (MDR-1) gene and the cytochrome P450 (CYP) genes CYP3A4 and CYP3A5 and the pharmacokinetics of cyclosporine (INN, ciclosporin).	Cyclosporine	250-261	ATP binding cassette subfamily B member 1	Homo sapiens	137-142
15592326-1	2004	OBJECTIVE: Our objective was to determine the relationship between single nucleotide polymorphisms (SNPs) in the multidrug resistance 1 (MDR-1) gene and the cytochrome P450 (CYP) genes CYP3A4 and CYP3A5 and the pharmacokinetics of cyclosporine (INN, ciclosporin).	Cyclosporine	250-261	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	185-191
15569157-7	2004	Cyclosporin A, a competitive inhibitor of P-glycoprotein, recovered intracellular dexamethasone levels in lymphocytes.	Cyclosporine	0-13	ATP binding cassette subfamily B member 1	Homo sapiens	42-56
15621770-5	2004	After rapid tapering of cyclosporin, serum levels of AST and ALP normalized in parallel with recovery of complete chimerism on day 134.	Cyclosporine	24-35	solute carrier family 17 member 5	Homo sapiens	53-56
15681897-9	2004	However, ketoconazole and cyclosporin A, which are specific CYP3A inhibitors, inhibited the metabolic extraction of diltiazem (0.05 mM) by only about 20% at the concentration (40 microM) at which they inhibited CYP3A almost completely, suggesting that the contribution of CYP3A to intestinal diltiazem metabolism is not marked.	Cyclosporine	26-39	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	60-65
15681897-9	2004	However, ketoconazole and cyclosporin A, which are specific CYP3A inhibitors, inhibited the metabolic extraction of diltiazem (0.05 mM) by only about 20% at the concentration (40 microM) at which they inhibited CYP3A almost completely, suggesting that the contribution of CYP3A to intestinal diltiazem metabolism is not marked.	Cyclosporine	26-39	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	211-216
15681897-9	2004	However, ketoconazole and cyclosporin A, which are specific CYP3A inhibitors, inhibited the metabolic extraction of diltiazem (0.05 mM) by only about 20% at the concentration (40 microM) at which they inhibited CYP3A almost completely, suggesting that the contribution of CYP3A to intestinal diltiazem metabolism is not marked.	Cyclosporine	26-39	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	211-216
15490252-0	2004	Transforming growth factor-beta1 in nephrotic syndrome treated with cyclosporine and ACE inhibitors.	Cyclosporine	68-80	transforming growth factor beta 1	Homo sapiens	0-32
15575024-9	2004	A comparison of the effects of tacrolimus and ciclosporin on glucose metabolism revealed reduced insulin release with tacrolimus at week 3 post-transplant, but for the remainder of the 3 year follow-up there were no significant differences between the two treatment arms.	Cyclosporine	46-57	insulin	Homo sapiens	97-104
15490252-1	2004	The aim of the study was to assess urinary transforming growth factor (TGF)-beta1 in children with steroid-dependent nephrotic syndrome (SDNS) treated with cyclosporine A (CyA) and ACE inhibitors (ACEI).	Cyclosporine	156-170	transforming growth factor beta 1	Homo sapiens	43-81
15490252-1	2004	The aim of the study was to assess urinary transforming growth factor (TGF)-beta1 in children with steroid-dependent nephrotic syndrome (SDNS) treated with cyclosporine A (CyA) and ACE inhibitors (ACEI).	Cyclosporine	172-175	transforming growth factor beta 1	Homo sapiens	43-81
15490252-8	2004	Prior to CyA treatment, the urinary TGF-beta1 level was the highest (135.61+/-38.31 pg/mg creatinine).	Cyclosporine	9-12	transforming growth factor beta 1	Homo sapiens	36-45
15490252-12	2004	Treatment with CyA and ACEI also influences urinary TGF-beta1, which is still higher after 12 months of treatment than in healthy children.	Cyclosporine	15-18	transforming growth factor beta 1	Homo sapiens	52-61
15813023-0	2004	[Effect of MDR1 polymorphic expression on oral disposition of cyclosporine A].	Cyclosporine	62-76	ATP binding cassette subfamily B member 1	Homo sapiens	11-15
15686683-0	2004	Impact of kidney transplantation on glycemic control and cardiovascular risk factors in insulin-treated diabetic patients receiving cyclosporine: a longitudinal study.	Cyclosporine	132-144	insulin	Homo sapiens	88-95
15686683-2	2004	In 10 selected insulin-treated diabetic patients with normally functioning kidney transplants, receiving cyclosporine for immunosuppression, we evaluated the fasting blood glucose, HbA1c, lipid levels, blood pressure, and insulin-requirement from 1 year before to 1 year after KTP.	Cyclosporine	105-117	insulin	Homo sapiens	15-22
15533818-3	2004	X-CypA belongs to the superfamily of the immunophilin/PPIase proteins that can bind the immunosuppressant drug Cyclosporin A.	Cyclosporine	111-124	FKBP prolyl isomerase 1A L homeolog	Xenopus laevis	54-60
15450954-1	2004	The objectives of this study were to characterize and compare the metabolic profile of cyclosporine A (CsA) catalyzed by CYP3A4, CYP3A5 and human kidney and liver microsomes, and to evaluate the impact of the CYP3A5 polymorphism on product formation from parent drug and its primary metabolites.	Cyclosporine	103-106	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	121-127
15450954-1	2004	The objectives of this study were to characterize and compare the metabolic profile of cyclosporine A (CsA) catalyzed by CYP3A4, CYP3A5 and human kidney and liver microsomes, and to evaluate the impact of the CYP3A5 polymorphism on product formation from parent drug and its primary metabolites.	Cyclosporine	103-106	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	129-135
15450954-2	2004	Three primary CsA metabolites (AM1, AM9 and AM4N) were produced by heterologously expressed CYP3A4.	Cyclosporine	14-17	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	92-98
15450954-5	2004	Microsomes isolated from human kidney produced only AM9 and the rate of product formation (2 and 20 microM CsA) was positively associated with the detection of CYP3A5 protein and presence of the CYP3A5*1 allele in 4 of the 20 kidneys tested.	Cyclosporine	107-110	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	160-166
15450954-5	2004	Microsomes isolated from human kidney produced only AM9 and the rate of product formation (2 and 20 microM CsA) was positively associated with the detection of CYP3A5 protein and presence of the CYP3A5*1 allele in 4 of the 20 kidneys tested.	Cyclosporine	107-110	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	195-201
15450954-9	2004	AM19 and AM1c9, two of the major secondary metabolites of CsA, were produced by CsA, AM1 and AM1c when incubated with CYP3A4, CYP3A5, kidney microsomes from CYP3A5*1/*3 donors and all liver microsomes.	Cyclosporine	58-61	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	118-124
15450954-9	2004	AM19 and AM1c9, two of the major secondary metabolites of CsA, were produced by CsA, AM1 and AM1c when incubated with CYP3A4, CYP3A5, kidney microsomes from CYP3A5*1/*3 donors and all liver microsomes.	Cyclosporine	58-61	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	126-132
15450954-9	2004	AM19 and AM1c9, two of the major secondary metabolites of CsA, were produced by CsA, AM1 and AM1c when incubated with CYP3A4, CYP3A5, kidney microsomes from CYP3A5*1/*3 donors and all liver microsomes.	Cyclosporine	58-61	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	157-163
15450954-9	2004	AM19 and AM1c9, two of the major secondary metabolites of CsA, were produced by CsA, AM1 and AM1c when incubated with CYP3A4, CYP3A5, kidney microsomes from CYP3A5*1/*3 donors and all liver microsomes.	Cyclosporine	80-83	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	118-124
15450954-9	2004	AM19 and AM1c9, two of the major secondary metabolites of CsA, were produced by CsA, AM1 and AM1c when incubated with CYP3A4, CYP3A5, kidney microsomes from CYP3A5*1/*3 donors and all liver microsomes.	Cyclosporine	80-83	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	126-132
15450954-9	2004	AM19 and AM1c9, two of the major secondary metabolites of CsA, were produced by CsA, AM1 and AM1c when incubated with CYP3A4, CYP3A5, kidney microsomes from CYP3A5*1/*3 donors and all liver microsomes.	Cyclosporine	80-83	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	157-163
15450954-11	2004	Together, the data demonstrate that CYP3A5 may contribute to the formation of primary and secondary metabolites of CsA, particularly in kidneys carrying the wild-type CYP3A5*1 allele.	Cyclosporine	115-118	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	36-42
15450954-11	2004	Together, the data demonstrate that CYP3A5 may contribute to the formation of primary and secondary metabolites of CsA, particularly in kidneys carrying the wild-type CYP3A5*1 allele.	Cyclosporine	115-118	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	167-173
15383526-0	2004	Cyclosporin A inhibits flow-mediated activation of endothelial nitric-oxide synthase by altering cholesterol content in caveolae.	Cyclosporine	0-13	nitric oxide synthase 3	Bos taurus	51-84
15548982-6	2004	Moreover, addition of MMF to a low CsA dose regime improved the correlation between CsA-C2h and both CN activity and IL-2 production.	Cyclosporine	35-38	interleukin 2	Homo sapiens	117-121
15308617-6	2004	Concurrent with mitochondrial swelling, external release of matrix proteins from mitochondria, such as aspartate aminotransferase and malate dehydrogenase, is shown to be CsA insensitive 24 h after PH and CsA sensitive 96 h after PH.	Cyclosporine	171-174	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	103-129
15496177-9	2004	The increase of laminin beta2 and TGF-beta mRNA levels was significantly higher in the CsA toxicity group than in the chronic rejection group (P &lt; 0.001 and P= 0.004, respectively).	Cyclosporine	87-90	transforming growth factor beta 1	Homo sapiens	34-42
15326467-13	2004	Fasting insulin was negatively correlated with CSA output on levels of adjustment.	Cyclosporine	47-50	insulin	Homo sapiens	8-15
15626898-7	2004	Microscopic damage score, myeloperoxidase activity, tumor necrosis factor alpha (TNF-alpha), and interleukin-6 in colonic tissue were significantly diminished by CsA.	Cyclosporine	162-165	tumor necrosis factor	Mus musculus	52-79
15626898-7	2004	Microscopic damage score, myeloperoxidase activity, tumor necrosis factor alpha (TNF-alpha), and interleukin-6 in colonic tissue were significantly diminished by CsA.	Cyclosporine	162-165	tumor necrosis factor	Mus musculus	81-90
15626898-7	2004	Microscopic damage score, myeloperoxidase activity, tumor necrosis factor alpha (TNF-alpha), and interleukin-6 in colonic tissue were significantly diminished by CsA.	Cyclosporine	162-165	interleukin 6	Mus musculus	97-110
15626898-9	2004	TNF-alpha-induced ICAM-1 and VCAM-1 expression in primary cultures of human umbilical vein endothelial cells was reduced by co-incubation with CsA.	Cyclosporine	143-146	tumor necrosis factor	Homo sapiens	0-9
15626898-9	2004	TNF-alpha-induced ICAM-1 and VCAM-1 expression in primary cultures of human umbilical vein endothelial cells was reduced by co-incubation with CsA.	Cyclosporine	143-146	vascular cell adhesion molecule 1	Homo sapiens	29-35
15496177-11	2004	CONCLUSION: Renal laminin beta2 and TGF-beta mRNA levels can be used to differentiate between chronic rejection and chronic CsA toxicity in renal transplants.	Cyclosporine	124-127	transforming growth factor beta 1	Homo sapiens	36-44
15315778-3	2004	The cyano column showed comparable retention for all three compounds, whereas the C18 column showed stronger retention, especially for cyclosporin A.	Cyclosporine	135-148	Bardet-Biedl syndrome 9	Homo sapiens	82-85
15381200-9	2004	Recipients treated with DL and delayed CsA had a reduced level of intra-graft interleukin (IL)-2, interferon (IFN)-gamma, IL-4, and IL-4R mRNA expression and reduced infiltrate compared to DL alone.	Cyclosporine	39-42	interleukin 4	Homo sapiens	122-126
15299003-3	2004	Our results show that upon activation of the ryanodine receptor (RYR), myotubes release interleukin-6 (IL-6); this was dependent on de novo protein synthesis and could be blocked by dantrolene and cyclosporine.	Cyclosporine	197-209	ryanodine receptor 1	Homo sapiens	45-63
15299003-3	2004	Our results show that upon activation of the ryanodine receptor (RYR), myotubes release interleukin-6 (IL-6); this was dependent on de novo protein synthesis and could be blocked by dantrolene and cyclosporine.	Cyclosporine	197-209	ryanodine receptor 1	Homo sapiens	65-68
15299003-3	2004	Our results show that upon activation of the ryanodine receptor (RYR), myotubes release interleukin-6 (IL-6); this was dependent on de novo protein synthesis and could be blocked by dantrolene and cyclosporine.	Cyclosporine	197-209	interleukin 6	Homo sapiens	88-101
15299003-3	2004	Our results show that upon activation of the ryanodine receptor (RYR), myotubes release interleukin-6 (IL-6); this was dependent on de novo protein synthesis and could be blocked by dantrolene and cyclosporine.	Cyclosporine	197-209	interleukin 6	Homo sapiens	103-107
15369802-2	2004	We found a significant inhibition of human CYP3A4-dependent transformation of cyclosporine by resveratrol, with IC50 = 4.5 microM.	Cyclosporine	78-90	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-49
15483743-9	2004	(2) Combined with cyclosporine A (CsA), fluvastatin would further repress CD69 expression, cells proliferation and activity of killer cells, meanwhile significantly induced the secretion of IL-4 and IL-10.	Cyclosporine	18-32	interleukin 4	Homo sapiens	190-194
15483743-9	2004	(2) Combined with cyclosporine A (CsA), fluvastatin would further repress CD69 expression, cells proliferation and activity of killer cells, meanwhile significantly induced the secretion of IL-4 and IL-10.	Cyclosporine	34-37	interleukin 4	Homo sapiens	190-194
15284224-0	2004	Decay-accelerating factor induction on vascular endothelium by vascular endothelial growth factor (VEGF) is mediated via a VEGF receptor-2 (VEGF-R2)- and protein kinase C-alpha/epsilon (PKCalpha/epsilon)-dependent cytoprotective signaling pathway and is inhibited by cyclosporin A.	Cyclosporine	267-280	vascular endothelial growth factor A	Homo sapiens	99-103
15382121-5	2004	DCA activated the ERK1/2 pathway in HuH7 human hepatoma cells that was blocked by the incubation of cells with an ERBB1 inhibitor, NAC, TX, CsA, or BKA.	Cyclosporine	140-143	mitogen-activated protein kinase 3	Homo sapiens	18-24
15284224-10	2004	The widely used immunosuppressive drug cyclosporin A (CsA) inhibited DAF induction by VEGF in a dose-dependent manner.	Cyclosporine	39-52	vascular endothelial growth factor A	Homo sapiens	86-90
15284224-10	2004	The widely used immunosuppressive drug cyclosporin A (CsA) inhibited DAF induction by VEGF in a dose-dependent manner.	Cyclosporine	54-57	vascular endothelial growth factor A	Homo sapiens	86-90
15284224-0	2004	Decay-accelerating factor induction on vascular endothelium by vascular endothelial growth factor (VEGF) is mediated via a VEGF receptor-2 (VEGF-R2)- and protein kinase C-alpha/epsilon (PKCalpha/epsilon)-dependent cytoprotective signaling pathway and is inhibited by cyclosporin A.	Cyclosporine	267-280	vascular endothelial growth factor A	Homo sapiens	123-127
15284224-11	2004	The VEGF-induced DAF expression was functionally effective, significantly reducing complement-mediated EC lysis, and this cytoprotective effect was reversed by CsA.	Cyclosporine	160-163	vascular endothelial growth factor A	Homo sapiens	4-8
15284224-0	2004	Decay-accelerating factor induction on vascular endothelium by vascular endothelial growth factor (VEGF) is mediated via a VEGF receptor-2 (VEGF-R2)- and protein kinase C-alpha/epsilon (PKCalpha/epsilon)-dependent cytoprotective signaling pathway and is inhibited by cyclosporin A.	Cyclosporine	267-280	vascular endothelial growth factor A	Homo sapiens	123-127
15324353-2	2004	We reported previously that lysosomal protease cathepsin-L activity, but not cathepsin-B, was significantly suppressed by short-term cyclosporin A exposure in human gingival fibroblasts.	Cyclosporine	133-146	cathepsin L	Homo sapiens	47-58
15324353-13	2004	CONCLUSION: The decreased ability of protein degradation by not only cathepsin-L but also cathepsin-B is, at least, one of the several factors developing the cyclosporin A-induced gingival overgrowth.	Cyclosporine	158-171	cathepsin L	Homo sapiens	69-80
15690711-9	2004	Many researches indicate the possible role of ET-1 in pathogenesis of many renal disorders such as: glomerulonephritis, acute and chronic renal failure and rejection of transplanted kidney Nephrotoxicity induced by cyclosporine maybe also partially provoked by ET-1.	Cyclosporine	215-227	endothelin 1	Homo sapiens	46-50
15454731-0	2004	The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients.	Cyclosporine	44-56	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	23-29
15454731-1	2004	OBJECTIVE: Cyclosporine is extensively metabolized by cytochrome-P450 3A (CYP3A) enzymes in the liver and intestine including the CYP3A5 isoenzyme.	Cyclosporine	11-23	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	54-72
15454731-1	2004	OBJECTIVE: Cyclosporine is extensively metabolized by cytochrome-P450 3A (CYP3A) enzymes in the liver and intestine including the CYP3A5 isoenzyme.	Cyclosporine	11-23	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	74-79
15454731-1	2004	OBJECTIVE: Cyclosporine is extensively metabolized by cytochrome-P450 3A (CYP3A) enzymes in the liver and intestine including the CYP3A5 isoenzyme.	Cyclosporine	11-23	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	130-136
15454731-4	2004	We tested whether the presence of the CYP3A5*1 allele in renal transplant recipients and in donor kidneys influences cyclosporine dose requirements, blood pressure and long-term graft survival in renal transplant patients during chronic treatment with a cyclosporine-based immunosuppressive regimen.	Cyclosporine	117-129	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	38-44
15454731-4	2004	We tested whether the presence of the CYP3A5*1 allele in renal transplant recipients and in donor kidneys influences cyclosporine dose requirements, blood pressure and long-term graft survival in renal transplant patients during chronic treatment with a cyclosporine-based immunosuppressive regimen.	Cyclosporine	254-266	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	38-44
15385832-11	2004	Cyclosporine dosing began on average at 274 +/- 78 mg bid, was down-titrated in months 2-3 from 181 +/- 80 mg to 81 +/- 33 mg bid, and stabilized at 70 +/- 26 mg bid thereafter.	Cyclosporine	0-12	BH3 interacting domain death agonist	Homo sapiens	54-57
15385832-11	2004	Cyclosporine dosing began on average at 274 +/- 78 mg bid, was down-titrated in months 2-3 from 181 +/- 80 mg to 81 +/- 33 mg bid, and stabilized at 70 +/- 26 mg bid thereafter.	Cyclosporine	0-12	BH3 interacting domain death agonist	Homo sapiens	126-129
15385832-11	2004	Cyclosporine dosing began on average at 274 +/- 78 mg bid, was down-titrated in months 2-3 from 181 +/- 80 mg to 81 +/- 33 mg bid, and stabilized at 70 +/- 26 mg bid thereafter.	Cyclosporine	0-12	BH3 interacting domain death agonist	Homo sapiens	126-129
15562764-7	2004	Cyclosporin A (CsA) specific inhibitor of the mitochondrial permeability transition pore could partially prevent the decrease of delta psi m and the release of cyt C.	Cyclosporine	0-13	cytochrome c, somatic	Homo sapiens	160-165
15690711-9	2004	Many researches indicate the possible role of ET-1 in pathogenesis of many renal disorders such as: glomerulonephritis, acute and chronic renal failure and rejection of transplanted kidney Nephrotoxicity induced by cyclosporine maybe also partially provoked by ET-1.	Cyclosporine	215-227	endothelin 1	Homo sapiens	261-265
15562764-7	2004	Cyclosporin A (CsA) specific inhibitor of the mitochondrial permeability transition pore could partially prevent the decrease of delta psi m and the release of cyt C.	Cyclosporine	15-18	cytochrome c, somatic	Homo sapiens	160-165
15239129-5	2004	Furthermore, using rhodamine-123 efflux assays, we observed a significant decrease in P-glycoprotein activity in caveolin-1 overexpressing cells, similar to that observed with 5 microM cyclosporine A or 10 microM verapamil, 2 inhibitors of P-glycoprotein activity.	Cyclosporine	185-199	ATP binding cassette subfamily B member 1	Homo sapiens	86-100
15239129-5	2004	Furthermore, using rhodamine-123 efflux assays, we observed a significant decrease in P-glycoprotein activity in caveolin-1 overexpressing cells, similar to that observed with 5 microM cyclosporine A or 10 microM verapamil, 2 inhibitors of P-glycoprotein activity.	Cyclosporine	185-199	caveolin 1	Homo sapiens	113-123
15307840-0	2004	CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus.	Cyclosporine	82-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
15498318-0	2004	[Ciclosporin down-regulates interferon-gamma gene transcription via its inhibition of nuclear factor kappaB activity after liver transplantation].	Cyclosporine	1-12	interferon gamma	Homo sapiens	28-44
15498318-1	2004	OBJECTIVE: To investigate the relation between the activity of nuclear factor kappaB (NF-kappaB) and the expression of interferon (IFN)-gamma gene transcription with or without ciclosporin treatment after liver transplantation.	Cyclosporine	177-188	nuclear factor kappa B subunit 1	Homo sapiens	86-95
15498318-8	2004	The activity of NF-kappaB and IFN-gammamRNA expression were significantly inhibited in SD-to-Wistar + ciclosporin group which was significantly lower than that of SD-to-Wistar group (P &lt; 0.001).	Cyclosporine	102-113	nuclear factor kappa B subunit 1	Homo sapiens	16-25
15498318-8	2004	The activity of NF-kappaB and IFN-gammamRNA expression were significantly inhibited in SD-to-Wistar + ciclosporin group which was significantly lower than that of SD-to-Wistar group (P &lt; 0.001).	Cyclosporine	102-113	interferon alpha 1	Homo sapiens	30-33
15498318-11	2004	CsA down-regulates NF-kappaB activity and further inhibit IFN-gamma gene transcription.	Cyclosporine	0-3	nuclear factor kappa B subunit 1	Homo sapiens	19-28
15498318-11	2004	CsA down-regulates NF-kappaB activity and further inhibit IFN-gamma gene transcription.	Cyclosporine	0-3	interferon gamma	Homo sapiens	58-67
15307840-1	2004	This study aimed to determine the impact of maintenance immunosuppressive therapy with cyclosporin A (CsA), tacrolimus (FK506) and sirolimus (Rapa) on the in vivo activity of both intestinal and hepatic cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (PGP) in renal transplant patients.	Cyclosporine	87-100	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	203-222
15307840-1	2004	This study aimed to determine the impact of maintenance immunosuppressive therapy with cyclosporin A (CsA), tacrolimus (FK506) and sirolimus (Rapa) on the in vivo activity of both intestinal and hepatic cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (PGP) in renal transplant patients.	Cyclosporine	102-105	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	203-222
15307840-0	2004	CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus.	Cyclosporine	82-93	ATP binding cassette subfamily B member 1	Homo sapiens	11-25
15307840-1	2004	This study aimed to determine the impact of maintenance immunosuppressive therapy with cyclosporin A (CsA), tacrolimus (FK506) and sirolimus (Rapa) on the in vivo activity of both intestinal and hepatic cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (PGP) in renal transplant patients.	Cyclosporine	102-105	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	224-230
15307840-1	2004	This study aimed to determine the impact of maintenance immunosuppressive therapy with cyclosporin A (CsA), tacrolimus (FK506) and sirolimus (Rapa) on the in vivo activity of both intestinal and hepatic cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (PGP) in renal transplant patients.	Cyclosporine	102-105	ATP binding cassette subfamily B member 1	Homo sapiens	236-250
15358289-8	2004	The Pgp modulators verapamil and CsA increased the uptake of CAM into CR1R12.	Cyclosporine	33-36	glycerol-3-phosphate phosphatase	Cricetulus griseus	4-7
15307840-1	2004	This study aimed to determine the impact of maintenance immunosuppressive therapy with cyclosporin A (CsA), tacrolimus (FK506) and sirolimus (Rapa) on the in vivo activity of both intestinal and hepatic cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (PGP) in renal transplant patients.	Cyclosporine	102-105	ATP binding cassette subfamily B member 1	Homo sapiens	252-255
15307840-5	2004	A significant increase in intestinal CYP3A4 activity and a significant decrease in hepatic and intestinal PGP activity was seen in patients on CsA in comparison with those on FK506 or Rapa (p &lt; 0.01).	Cyclosporine	143-146	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	37-43
15307840-5	2004	A significant increase in intestinal CYP3A4 activity and a significant decrease in hepatic and intestinal PGP activity was seen in patients on CsA in comparison with those on FK506 or Rapa (p &lt; 0.01).	Cyclosporine	143-146	ATP binding cassette subfamily B member 1	Homo sapiens	106-109
15472471-3	2004	In both cells, the accumulation increased with the addition of PCB-126 and cyclosporine A (CYA), which are P-glycoprotein modulators, though the magnitudes were different in these two cell groups as well as for these two chemicals.	Cyclosporine	75-89	ATP binding cassette subfamily B member 1	Homo sapiens	107-121
15461875-3	2004	Cyclosporine (CsA) inhibits the proliferation and the IL-2 dependent expansion of T-lymphocytes.	Cyclosporine	0-12	interleukin 2	Homo sapiens	54-58
15322229-3	2004	Luminal NBDL-CSA accumulation was rapidly and reversibly reduced in a concentration-dependent manner by 0.1 to 100 nM endothelin-1 (ET-1).	Cyclosporine	13-16	endothelin 1	Homo sapiens	132-136
15322232-4	2004	Moreover, exposing isolated capillaries to the PXR ligands pregnenolone-16alpha-carbonitrile (PCN) and dexamethasone increased p-glycoprotein expression and p-glycoprotein-specific transport of a fluorescent cyclosporine A derivative into capillary lumens.	Cyclosporine	208-222	nuclear receptor subfamily 1 group I member 2	Homo sapiens	47-50
15322232-4	2004	Moreover, exposing isolated capillaries to the PXR ligands pregnenolone-16alpha-carbonitrile (PCN) and dexamethasone increased p-glycoprotein expression and p-glycoprotein-specific transport of a fluorescent cyclosporine A derivative into capillary lumens.	Cyclosporine	208-222	ATP binding cassette subfamily B member 1	Homo sapiens	157-171
15526904-3	2004	The molecular mechanisms of CsA nephrotoxicity are not well characterized, but more recent studies suggest an involvement of angiotensin II (ANG II) and reactive oxygen species in the development of cyclosporine nephrotoxicity.	Cyclosporine	199-211	angiotensinogen	Rattus norvegicus	125-139
15526904-3	2004	The molecular mechanisms of CsA nephrotoxicity are not well characterized, but more recent studies suggest an involvement of angiotensin II (ANG II) and reactive oxygen species in the development of cyclosporine nephrotoxicity.	Cyclosporine	199-211	angiotensinogen	Rattus norvegicus	141-147
15526904-7	2004	This study was thus designed to investigate the role of Angiotensin II type I (AT1) receptor antagonist, irbesartan, on CsA-induced nephrotoxicity.	Cyclosporine	120-123	angiotensinogen	Rattus norvegicus	56-70
15526904-16	2004	These results clearly demonstrate the pivotal role of ANG II-induced oxidative stress and therapeutic potential of AT, receptor antagonist in ameliorating CsA-induced nephrotoxicity.	Cyclosporine	155-158	angiotensinogen	Rattus norvegicus	54-60
15178703-6	2004	Moreover, an inhibitory effect of cyclosporin A, an immunosuppressor that inhibits calcineurin activity, on IL-8 release and IL-8 mRNA expression was observed.	Cyclosporine	34-47	C-X-C motif chemokine ligand 8	Homo sapiens	108-112
15178703-6	2004	Moreover, an inhibitory effect of cyclosporin A, an immunosuppressor that inhibits calcineurin activity, on IL-8 release and IL-8 mRNA expression was observed.	Cyclosporine	34-47	C-X-C motif chemokine ligand 8	Homo sapiens	125-129
15322229-3	2004	Luminal NBDL-CSA accumulation was rapidly and reversibly reduced in a concentration-dependent manner by 0.1 to 100 nM endothelin-1 (ET-1).	Cyclosporine	13-16	endothelin 1	Homo sapiens	118-130
15340056-10	2004	This difference in the DNA damage response between CSA- and CSB-deficient cells is unexpected, since until now no consistent differences between CSA and CSB patients have been reported.	Cyclosporine	145-148	ERCC excision repair 6, chromatin remodeling factor	Homo sapiens	60-63
15472471-3	2004	In both cells, the accumulation increased with the addition of PCB-126 and cyclosporine A (CYA), which are P-glycoprotein modulators, though the magnitudes were different in these two cell groups as well as for these two chemicals.	Cyclosporine	91-94	ATP binding cassette subfamily B member 1	Homo sapiens	107-121
15569226-7	2004	Five had AST elevations at least possibly related to caspofungin/CsA, but none were &gt;3.6 times the normal upper limit.	Cyclosporine	65-68	solute carrier family 17 member 5	Homo sapiens	9-12
15197524-1	2004	OBJECTIVE: The aim of this study was to (a) quantify the gene expression of some cytochromes P(450) (CYP), especially CYP3A4, in serial biopsies from liver grafts the first year after orthoptic liver transplantation (OLT) and (b) study the relationship between hepatic CYP3A4 gene expression and plasma levels of cyclosporine and tacrolimus.	Cyclosporine	313-325	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	118-124
15201276-0	2004	Desensitization of the permeability transition pore by cyclosporin a prevents activation of the mitochondrial apoptotic pathway and liver damage by tumor necrosis factor-alpha.	Cyclosporine	55-68	tumor necrosis factor	Rattus norvegicus	148-175
15201276-3	2004	Treatment with CsA before or within 5 h of the administration of LPS plus D-GalN protected rats from hepatotoxicity despite the normal increase of serum TNF-alpha and BID cleavage.	Cyclosporine	15-18	tumor necrosis factor	Rattus norvegicus	153-162
15201276-4	2004	These results indicate that CsA prevents the hepatotoxic effects of TNF-alpha by blocking the mitochondrial proapoptotic pathway through inhibition of the PTP and provides a viable strategy for the treatment of liver diseases that depend on increased production and/or liver sensitization to TNF-alpha.	Cyclosporine	28-31	tumor necrosis factor	Rattus norvegicus	68-77
15201276-4	2004	These results indicate that CsA prevents the hepatotoxic effects of TNF-alpha by blocking the mitochondrial proapoptotic pathway through inhibition of the PTP and provides a viable strategy for the treatment of liver diseases that depend on increased production and/or liver sensitization to TNF-alpha.	Cyclosporine	28-31	tumor necrosis factor	Rattus norvegicus	292-301
15173172-3	2004	An NFAT-dependent enhancer modulated by NFATs or calcineurin and sensitive to cyclosporin was identified in the Sftpd promoter.	Cyclosporine	78-89	surfactant associated protein D	Mus musculus	112-117
15197524-7	2004	The gene expression of CYP3A4 was related to the plasma concentration of cyclosporine and tacrolimus, i.e. low mRNA concentrations corresponded to high serum concentration levels and vice versa.	Cyclosporine	73-85	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	23-29
15197524-11	2004	Low CYP3A4 gene expression was related to high plasma levels of cyclosporine and tacrolimus and vice versa.	Cyclosporine	64-76	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	4-10
15183458-6	2004	CsA treatment increased lipid peroxidation measured as thiobarbituric acid reactive substances (TBARS) concentration and decreased reduced glutathione (GSH) content and activities of catalase and glutathione peroxidase (GSH-Px) in the rat liver.	Cyclosporine	0-3	catalase	Rattus norvegicus	183-191
15325564-8	2004	hBD1 mRNA expression was not changed by dexamethasone but was down-regulated by cyclosporin A.	Cyclosporine	80-93	defensin beta 1	Homo sapiens	0-4
15325564-9	2004	hBD2 mRNA expression was up-regulated by dexamethasone and down-regulated by cyclosporin A.	Cyclosporine	77-90	defensin beta 4A	Homo sapiens	0-4
15250830-0	2004	Regulation of keratinocyte growth factor and scatter factor in cyclosporin-induced gingival overgrowth.	Cyclosporine	63-74	fibroblast growth factor 7	Homo sapiens	14-40
15250830-3	2004	The aims of this study were to investigate: (i) the effects of cyclosporin on KGF and SF expression by gingival fibroblasts; and (ii) the expression levels of KGF and SF mRNA in normal and overgrown gingival tissue.	Cyclosporine	63-74	fibroblast growth factor 7	Homo sapiens	78-81
15250830-7	2004	RESULTS: In overgrown fibroblasts, 500 ng/ml cyclosporin significantly inhibited KGF and SF mRNA and protein while 2000 ng/ml cyclosporin induced a stimulatory effect.	Cyclosporine	45-56	fibroblast growth factor 7	Homo sapiens	81-84
15250830-8	2004	In normal cells cyclosporin significantly increased both KGF and SF.	Cyclosporine	16-27	fibroblast growth factor 7	Homo sapiens	57-60
15250830-10	2004	CONCLUSION: These results suggest that KGF and SF may have an important role in cyclosporin-induced gingival overgrowth.	Cyclosporine	80-91	fibroblast growth factor 7	Homo sapiens	39-42
15157537-2	2004	Simple three- or five-pulse CSA-recoupling sequences with "gamma-integral" cleanly suppress the signals of all sp2- and sp-hybridized carbons.	Cyclosporine	28-31	Sp2 transcription factor	Homo sapiens	111-114
15240127-3	2004	ABCG1 had a high basal ATPase activity, further stimulated by lipophilic cations and significantly inhibited by cyclosporin A, thyroxine or benzamil.	Cyclosporine	112-125	ATP binding cassette subfamily G member 1	Homo sapiens	0-5
14871880-8	2004	Plasma vasopressin levels were not significantly different between two groups, but infusion of vasopressin restored CsA-induced impairment of urine concentration.	Cyclosporine	116-119	arginine vasopressin	Rattus norvegicus	95-106
15200483-1	2004	BACKGROUND: It has been demonstrated that cyclosporin A (CyA) blocks the immune system, acts on cytoskeleton and stimulates the production of extracellular matrix (ECM) and transforming growth factor-beta1 (TGF-beta1).	Cyclosporine	42-55	transforming growth factor beta 1	Homo sapiens	173-205
15001429-2	2004	CsA transforms the fully regenerative, self-limited form of Cr pancreatitis into a chroniclike disease in conjunction with increased transforming growth factor (TGF)-beta and myofibroblast proliferation.	Cyclosporine	0-3	transforming growth factor, beta 1	Rattus norvegicus	161-170
15491507-3	2004	Cyclosporine A represents a macrolide immune modulator with primary inhibitory effects on T helper lymphocyte production of interleukin-2, and other cytokines leading to altered T-lymphocyte and B-lymphocyte function.	Cyclosporine	0-14	interleukin 2	Homo sapiens	124-137
15163892-5	2004	Cyclosporin A treatment reduced the frequencies of IL4-producing CD4(pos) T cells, without significantly affecting the T helper 1 to T helper 2 (Th1/Th2) balance but in conjunction with the decreasing number of peripheral blood eosinophil counts.	Cyclosporine	0-13	interleukin 4	Homo sapiens	51-54
15191592-10	2004	CONCLUSIONS: The findings of the present study indicate alterations in GCF t-PA and PAI-2 levels in CsA-induced gingival overgrowth and might suggest involvement of the plasminogen activating system in the pathogenesis of this side-effect of CsA therapy.	Cyclosporine	100-103	plasminogen activator, tissue type	Homo sapiens	75-79
15191592-10	2004	CONCLUSIONS: The findings of the present study indicate alterations in GCF t-PA and PAI-2 levels in CsA-induced gingival overgrowth and might suggest involvement of the plasminogen activating system in the pathogenesis of this side-effect of CsA therapy.	Cyclosporine	242-245	plasminogen activator, tissue type	Homo sapiens	75-79
15200483-1	2004	BACKGROUND: It has been demonstrated that cyclosporin A (CyA) blocks the immune system, acts on cytoskeleton and stimulates the production of extracellular matrix (ECM) and transforming growth factor-beta1 (TGF-beta1).	Cyclosporine	42-55	transforming growth factor beta 1	Homo sapiens	207-216
15263820-5	2004	Moreover, VEGF-stimulated induction of DSCR1 was blocked by anti-VEGF receptor-2 monoclonal antibody (mAb), or the specific calcineurin inhibitors cyclosporin A and FK506.	Cyclosporine	147-160	vascular endothelial growth factor A	Homo sapiens	10-14
15229940-10	2004	The upregulation of synoviocyte COX-2 expression by supernatants from stimulated T cells was partially inhibited by addition of neutralizing antibodies against IL-17 or TNF-a or by treatment of T cells with cyclosporin A prior to stimulation.	Cyclosporine	207-220	prostaglandin-endoperoxide synthase 2	Homo sapiens	32-37
15615187-8	2004	Standard immunosuppressive therapy with cyclosporine A and prednisolone significantly suppresses the acute phase CRP reaction both in operation itself and acute rejection, but not in infection.	Cyclosporine	40-54	C-reactive protein	Homo sapiens	113-116
15615187-10	2004	Different reaction of SAA and CRP in transplant patients to cyclosporine A therapy helps in differentiation between the infection and rejection.	Cyclosporine	60-74	C-reactive protein	Homo sapiens	30-33
15350444-5	2004	TGF-beta tended to increase in supernatants from patients under Rapa + CsA + P at 6 months posttransplant and at 1 month after CsA withdrawal without correlation to Rapa blood levels.	Cyclosporine	71-74	transforming growth factor beta 1	Homo sapiens	0-8
15221123-3	2004	Withdrawal of CsA from an mTOR-based regimen reduces renal toxicity, but this may be achieved at the price of increased late rejection and sirolimus-related adverse events.	Cyclosporine	14-17	mechanistic target of rapamycin kinase	Homo sapiens	26-30
15221123-4	2004	Use of a concentration-controlled mTOR inhibitor with low-exposure CsA seems to be effective in preventing rejection with good renal function.	Cyclosporine	67-70	mechanistic target of rapamycin kinase	Homo sapiens	34-38
15493833-6	2004	RESULTS: Inhalation of CsA significantly reduced the number of eosinophils in BALF and peripheral blood, inflammatory infiltration and tissue edema of lung tissue, decreased the content of TNF-alpha in BALF.	Cyclosporine	23-26	tumor necrosis factor	Rattus norvegicus	189-198
15493833-7	2004	CONCLUSION: Inhalation of CsA inhibited airway inflammation in rats, and the mechanism is related to inhibition of TNF-alpha release.	Cyclosporine	26-29	tumor necrosis factor	Rattus norvegicus	115-124
15341350-10	2004	Chymase-positive mast cells may play a role in formation of gingival overgrowth, especially in patients receiving cyclosporin A (CsA) medication with no concomitant nifedipine.	Cyclosporine	114-127	chymase 1	Homo sapiens	0-7
15341350-10	2004	Chymase-positive mast cells may play a role in formation of gingival overgrowth, especially in patients receiving cyclosporin A (CsA) medication with no concomitant nifedipine.	Cyclosporine	129-132	chymase 1	Homo sapiens	0-7
15350444-5	2004	TGF-beta tended to increase in supernatants from patients under Rapa + CsA + P at 6 months posttransplant and at 1 month after CsA withdrawal without correlation to Rapa blood levels.	Cyclosporine	127-130	transforming growth factor beta 1	Homo sapiens	0-8
15350444-6	2004	TGF-beta remained stable throughout the study period for patients included in the CsA + Aza + P group.	Cyclosporine	82-85	transforming growth factor beta 1	Homo sapiens	0-8
15120939-1	2004	MRP1 activity was evaluated and compared in 11 cell lines with different levels of MRP1 expression using functional assays of calcein acetoxymethyl ester (calcein-AM), carboxyfluorescein diacetate (CFDA) and Rhodamine 123 (Rh123) in combination with the modulators cyclosporin A (CsA), probenecid and MK571.	Cyclosporine	265-278	ATP binding cassette subfamily C member 1	Homo sapiens	0-4
14962898-3	2004	We also previously reported that inhibition of drug transport by the Pgp modulator, cyclosporine A (CSA), can increase GO sensitivity in Pgp(+) AML cells and that the peripheral benzodiazepine receptor ligand, PK11195, sensitizes AML cells to standard chemotherapeutics both by inhibiting Pgp-mediated efflux and by promoting mitochondrial apoptosis.	Cyclosporine	84-98	ATP binding cassette subfamily B member 1	Homo sapiens	69-72
14962898-3	2004	We also previously reported that inhibition of drug transport by the Pgp modulator, cyclosporine A (CSA), can increase GO sensitivity in Pgp(+) AML cells and that the peripheral benzodiazepine receptor ligand, PK11195, sensitizes AML cells to standard chemotherapeutics both by inhibiting Pgp-mediated efflux and by promoting mitochondrial apoptosis.	Cyclosporine	84-98	ATP binding cassette subfamily B member 1	Homo sapiens	137-140
14962898-3	2004	We also previously reported that inhibition of drug transport by the Pgp modulator, cyclosporine A (CSA), can increase GO sensitivity in Pgp(+) AML cells and that the peripheral benzodiazepine receptor ligand, PK11195, sensitizes AML cells to standard chemotherapeutics both by inhibiting Pgp-mediated efflux and by promoting mitochondrial apoptosis.	Cyclosporine	84-98	ATP binding cassette subfamily B member 1	Homo sapiens	137-140
14962898-3	2004	We also previously reported that inhibition of drug transport by the Pgp modulator, cyclosporine A (CSA), can increase GO sensitivity in Pgp(+) AML cells and that the peripheral benzodiazepine receptor ligand, PK11195, sensitizes AML cells to standard chemotherapeutics both by inhibiting Pgp-mediated efflux and by promoting mitochondrial apoptosis.	Cyclosporine	100-103	ATP binding cassette subfamily B member 1	Homo sapiens	69-72
14962898-3	2004	We also previously reported that inhibition of drug transport by the Pgp modulator, cyclosporine A (CSA), can increase GO sensitivity in Pgp(+) AML cells and that the peripheral benzodiazepine receptor ligand, PK11195, sensitizes AML cells to standard chemotherapeutics both by inhibiting Pgp-mediated efflux and by promoting mitochondrial apoptosis.	Cyclosporine	100-103	ATP binding cassette subfamily B member 1	Homo sapiens	137-140
14962898-3	2004	We also previously reported that inhibition of drug transport by the Pgp modulator, cyclosporine A (CSA), can increase GO sensitivity in Pgp(+) AML cells and that the peripheral benzodiazepine receptor ligand, PK11195, sensitizes AML cells to standard chemotherapeutics both by inhibiting Pgp-mediated efflux and by promoting mitochondrial apoptosis.	Cyclosporine	100-103	ATP binding cassette subfamily B member 1	Homo sapiens	137-140
15194553-5	2004	Additional treatment with erythropoietin enhanced the effects of cyclosporin A and restored the patient"s hemoglobin to normal levels.	Cyclosporine	65-78	erythropoietin	Homo sapiens	26-40
15149314-10	2004	Glomerular and tubulointerstitial repair in thrombotic microangiopathy and cyclosporin nephrotoxicity may also be VEGF-dependent.	Cyclosporine	75-86	vascular endothelial growth factor A	Homo sapiens	114-118
15120939-1	2004	MRP1 activity was evaluated and compared in 11 cell lines with different levels of MRP1 expression using functional assays of calcein acetoxymethyl ester (calcein-AM), carboxyfluorescein diacetate (CFDA) and Rhodamine 123 (Rh123) in combination with the modulators cyclosporin A (CsA), probenecid and MK571.	Cyclosporine	280-283	ATP binding cassette subfamily C member 1	Homo sapiens	0-4
15239612-11	2004	CONCLUSIONS: Both CYP3A1/2 and Pgp participate in the disposition of CsA and SRL in rats.	Cyclosporine	69-72	phosphoglycolate phosphatase	Rattus norvegicus	31-34
15251335-16	2004	CONCLUSION: While cyclosporine caused increased TGF-beta expression and apoptotic cell death in the renal tissue of rats colchicine prevented the increase in MDA serum levels, TGF-beta expression, and apoptosis in renal tissue.	Cyclosporine	18-30	transforming growth factor, beta 1	Rattus norvegicus	48-56
15251335-16	2004	CONCLUSION: While cyclosporine caused increased TGF-beta expression and apoptotic cell death in the renal tissue of rats colchicine prevented the increase in MDA serum levels, TGF-beta expression, and apoptosis in renal tissue.	Cyclosporine	18-30	transforming growth factor, beta 1	Rattus norvegicus	176-184
15251423-5	2004	Treatment with cyclosporin A at higher concentrations resulted in superior histologic preservation of lymphoid tissue structures and seemed to further prevent the expression of CD95 by CD3(+) cells and the activation in tissue culture of CD21(+) cells.	Cyclosporine	15-28	complement C3d receptor 2	Homo sapiens	238-242
15239612-12	2004	Changes in the individual activities of CYP3A1/2 and Pgp may contribute to an interaction between CsA and SRL resulting in unanticipated effects during chronic therapy.	Cyclosporine	98-101	phosphoglycolate phosphatase	Rattus norvegicus	53-56
15183848-7	2004	Our results evidenced an up-regulation of COL-I and TGF-beta1 gene expression 72 h after CsA treatment.	Cyclosporine	89-92	transforming growth factor beta 1	Homo sapiens	52-61
15258465-6	2004	In addition, inhibition of the mitochondrial permeability transition pores by cyclosporine A significantly reduced the Delta Psi m loss and the sub-G1 DNA content in p53 positive cells.	Cyclosporine	78-92	tumor protein p53	Homo sapiens	166-169
15066204-5	2004	Upregulation of TGF-beta and Fas expression in CsA-treated rat kidneys was decreased significantly after withdrawal of CsA.	Cyclosporine	47-50	transforming growth factor, beta 1	Rattus norvegicus	16-24
15116055-0	2004	CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation.	Cyclosporine	42-54	ATP binding cassette subfamily B member 1	Homo sapiens	11-15
15116055-1	2004	BACKGROUND: The immunosuppressive drug cyclosporine (INN, ciclosporin), whose pharmacokinetic characteristics vary greatly among individuals, is a substrate for cytochrome P450 (CYP) 3A and P-glycoprotein, the product of the multidrug resistance 1 (MDR1) gene.	Cyclosporine	39-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	161-185
15116055-1	2004	BACKGROUND: The immunosuppressive drug cyclosporine (INN, ciclosporin), whose pharmacokinetic characteristics vary greatly among individuals, is a substrate for cytochrome P450 (CYP) 3A and P-glycoprotein, the product of the multidrug resistance 1 (MDR1) gene.	Cyclosporine	39-51	ATP binding cassette subfamily B member 1	Homo sapiens	190-204
15116055-1	2004	BACKGROUND: The immunosuppressive drug cyclosporine (INN, ciclosporin), whose pharmacokinetic characteristics vary greatly among individuals, is a substrate for cytochrome P450 (CYP) 3A and P-glycoprotein, the product of the multidrug resistance 1 (MDR1) gene.	Cyclosporine	39-51	ATP binding cassette subfamily B member 1	Homo sapiens	225-247
15116055-1	2004	BACKGROUND: The immunosuppressive drug cyclosporine (INN, ciclosporin), whose pharmacokinetic characteristics vary greatly among individuals, is a substrate for cytochrome P450 (CYP) 3A and P-glycoprotein, the product of the multidrug resistance 1 (MDR1) gene.	Cyclosporine	39-51	ATP binding cassette subfamily B member 1	Homo sapiens	249-253
15116055-1	2004	BACKGROUND: The immunosuppressive drug cyclosporine (INN, ciclosporin), whose pharmacokinetic characteristics vary greatly among individuals, is a substrate for cytochrome P450 (CYP) 3A and P-glycoprotein, the product of the multidrug resistance 1 (MDR1) gene.	Cyclosporine	58-69	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	161-185
15116055-1	2004	BACKGROUND: The immunosuppressive drug cyclosporine (INN, ciclosporin), whose pharmacokinetic characteristics vary greatly among individuals, is a substrate for cytochrome P450 (CYP) 3A and P-glycoprotein, the product of the multidrug resistance 1 (MDR1) gene.	Cyclosporine	58-69	ATP binding cassette subfamily B member 1	Homo sapiens	190-204
15116055-1	2004	BACKGROUND: The immunosuppressive drug cyclosporine (INN, ciclosporin), whose pharmacokinetic characteristics vary greatly among individuals, is a substrate for cytochrome P450 (CYP) 3A and P-glycoprotein, the product of the multidrug resistance 1 (MDR1) gene.	Cyclosporine	58-69	ATP binding cassette subfamily B member 1	Homo sapiens	225-247
15116055-1	2004	BACKGROUND: The immunosuppressive drug cyclosporine (INN, ciclosporin), whose pharmacokinetic characteristics vary greatly among individuals, is a substrate for cytochrome P450 (CYP) 3A and P-glycoprotein, the product of the multidrug resistance 1 (MDR1) gene.	Cyclosporine	58-69	ATP binding cassette subfamily B member 1	Homo sapiens	249-253
15607500-6	2004	At inhibitory doses, CsA inhibited ERK kinase activation by PDGF, although cytotoxicity was also apparent.	Cyclosporine	21-24	mitogen-activated protein kinase 1	Homo sapiens	35-38
15043540-7	2004	Both betamethasone and CsA significantly suppressed IL-1alpha and IL-8 at day 4.	Cyclosporine	23-26	interleukin 1 alpha	Rattus norvegicus	52-61
15194301-0	2004	Cyclosporine increases endothelin-1 plasma levels in renal transplant recipients.	Cyclosporine	0-12	endothelin 1	Homo sapiens	23-35
15194301-1	2004	Endothelin-1 (ET-1) has been associated with the development of hypertension in cyclosporine-treated renal transplant recipients.	Cyclosporine	80-92	endothelin 1	Homo sapiens	0-12
15194301-1	2004	Endothelin-1 (ET-1) has been associated with the development of hypertension in cyclosporine-treated renal transplant recipients.	Cyclosporine	80-92	endothelin 1	Homo sapiens	14-18
15194301-2	2004	To clarify this association, this observational study compared ET-1 levels in 33 patients taking cyclosporine therapy versus 10 controls.	Cyclosporine	97-109	endothelin 1	Homo sapiens	63-67
15194301-3	2004	Three hours after cyclosporine administration, ET-1 levels were higher than in the controls, namely 1.81 + 0.99 versus 1.17 + 0.46 pg/mL (P &lt;.04).	Cyclosporine	18-30	endothelin 1	Homo sapiens	47-51
15194301-4	2004	These results suggest a role of ET-1 in the pathogenesis of post-renal transplantation hypertension in cyclosporine-treated recipients.	Cyclosporine	103-115	endothelin 1	Homo sapiens	32-36
15042551-1	2004	Mutations of NPHS2, ie, the gene coding for podocin, are associated with nephrotic syndrome (NS) in children, with a clinical phenotype characterized by variable age at onset (from 1 to 10 years) and steroid/cyclosporine resistance.	Cyclosporine	208-220	NPHS2 stomatin family member, podocin	Homo sapiens	13-18
15042551-1	2004	Mutations of NPHS2, ie, the gene coding for podocin, are associated with nephrotic syndrome (NS) in children, with a clinical phenotype characterized by variable age at onset (from 1 to 10 years) and steroid/cyclosporine resistance.	Cyclosporine	208-220	NPHS2 stomatin family member, podocin	Homo sapiens	44-51
15066204-5	2004	Upregulation of TGF-beta and Fas expression in CsA-treated rat kidneys was decreased significantly after withdrawal of CsA.	Cyclosporine	119-122	transforming growth factor, beta 1	Rattus norvegicus	16-24
15110634-11	2004	TGF-beta was markedly increased by cyclosporine.	Cyclosporine	35-47	transforming growth factor beta 1	Homo sapiens	0-8
14684598-7	2004	IGF-I increased calcineurin activity, which was inhibited by cyclosporine A.	Cyclosporine	61-75	insulin like growth factor 1	Homo sapiens	0-5
14684598-8	2004	Further, cyclosporine A inhibited K(+)+IGF-I-induced activation of the skeletal alpha-actin promoter.	Cyclosporine	9-23	insulin like growth factor 1	Homo sapiens	39-44
15099443-8	2004	Although there is a general consideration that MP cannot act as an enzyme inducer at maintenance doses, the present results strongly suggest that high-dose MP is likely to interact pharmacokinetically with CsA by inducing hepatic CYP3A.	Cyclosporine	206-209	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	230-235
15056263-4	2004	Furthermore, chronic CsA exposure causes a further increase in c-fos and c-jun mRNA and increases the renal expression of transforming growth factor-beta (TGF-beta) mRNA.	Cyclosporine	21-24	transforming growth factor, beta 1	Rattus norvegicus	155-163
14981234-8	2004	We find that silencing of mutant SOD1 protects these cells against cyclosporin A-induced cell death.	Cyclosporine	67-80	superoxide dismutase 1	Homo sapiens	33-37
14985103-4	2004	Here we have extended these observations to 44 Pgp interacting agents, and found that only 8 fall into the cyclosporin-like category, inducing a conformational state characterized by the complete UIC2 dominance.	Cyclosporine	107-118	ATP binding cassette subfamily B member 1	Homo sapiens	47-50
15006554-10	2004	By contrast, annexin 1 secretion is not blocked by other inhibitors of MRP1 (indomethacin, MK571), MRP2 (ochratoxin A1 or MK571), MRP5 (trequinsin or sulfinpyrazone) or by verapamil, cyclosporin A or glyburide.	Cyclosporine	183-196	annexin A1	Rattus norvegicus	13-22
15021830-7	2004	However, in CsA-treated rats, RWI produced a marked increase in tubulointerstitial fibrosis, as shown by the potentiation of collagen III and TGF-beta1 determined by immunochemistry and mRNA analysis.	Cyclosporine	12-15	transforming growth factor, beta 1	Rattus norvegicus	142-151
15249910-4	2004	Cyclosporin has been found to be effective in a variety of inflammatory skin disorders since it reduces the number of activated T-cells expressing interleukin 2 (IL-2) receptors.	Cyclosporine	0-11	interleukin 2	Homo sapiens	147-160
15249910-4	2004	Cyclosporin has been found to be effective in a variety of inflammatory skin disorders since it reduces the number of activated T-cells expressing interleukin 2 (IL-2) receptors.	Cyclosporine	0-11	interleukin 2	Homo sapiens	162-166
14985103-3	2004	In the case of cyclosporin A, vinblastine or valinomycin, this up-shift was found to be concomitant with the near-complete suppression of labeling with other mAbs specific for Pgp epitopes overlapping with UIC2, while pre-treatment with verapamil or Tween 80 brings about a modest suppression.	Cyclosporine	15-28	ATP binding cassette subfamily B member 1	Homo sapiens	176-179
15110230-3	2004	In contrast, many other compounds such as calcium channel blockers (verapamil) and immunosupressors (cyclosporine-A) are able to inhibit P-gp function.	Cyclosporine	101-115	ATP binding cassette subfamily B member 1	Homo sapiens	137-141
14993807-5	2004	The AUC of CsA mono-oxidative metabolite via CYP3A (M-OH) in ARF rats after oral or intravenous administration increased significantly by 84% or 241%, respectively, while there was no difference in the portal M-OH between control and ARF rats, suggesting that the elimination of M-OH was prolonged because of nephrotoxicity.	Cyclosporine	11-14	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	45-50
14617681-10	2004	It is, however, clear that inhibition of CYP3A4-mediated metabolism by cyclosporin A alone is insufficient to explain the increased bosentan concentrations and that inhibition of hepatocellular uptake offers an attractive mechanistic alternative also in human.	Cyclosporine	71-84	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-47
15007308-8	2004	Quantitative analysis revealed that CsA induced a significant (twofold) increase in betaig-h3 mRNA and protein, and this increase was correlated with up-regulation of TGF-beta1 expression (r =.943, P &lt;.001) and the tubulointerstitial fibrosis score (r =.746, P =.05).	Cyclosporine	36-39	transforming growth factor, beta 1	Rattus norvegicus	167-176
15007308-1	2004	Up-regulation of transforming growth factor-beta (TGF-beta) is known to play an important role in the tubulointerstitial injury of chronic cyclosporin A (CsA) nephropathy, but the expression of the TGF-beta-inducible gene-h3 (betaig-h3) is undetermined.	Cyclosporine	139-152	transforming growth factor, beta 1	Rattus norvegicus	50-58
15007308-1	2004	Up-regulation of transforming growth factor-beta (TGF-beta) is known to play an important role in the tubulointerstitial injury of chronic cyclosporin A (CsA) nephropathy, but the expression of the TGF-beta-inducible gene-h3 (betaig-h3) is undetermined.	Cyclosporine	154-157	transforming growth factor, beta 1	Rattus norvegicus	50-58
15167702-0	2004	The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.	Cyclosporine	55-67	ATP binding cassette subfamily B member 1	Homo sapiens	31-36
14724652-6	2004	The modulation of Pgp by cyclosporin A (CSA) readily restored imatinib cytotoxicity in these cells.	Cyclosporine	25-38	ATP binding cassette subfamily B member 1	Homo sapiens	18-21
14724652-6	2004	The modulation of Pgp by cyclosporin A (CSA) readily restored imatinib cytotoxicity in these cells.	Cyclosporine	40-43	ATP binding cassette subfamily B member 1	Homo sapiens	18-21
15167702-4	2004	The objective of this study was to investigate the effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood concentrations in stable transplant patients.	Cyclosporine	102-114	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	61-67
15167702-4	2004	The objective of this study was to investigate the effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood concentrations in stable transplant patients.	Cyclosporine	102-114	ATP binding cassette subfamily B member 1	Homo sapiens	72-76
15167702-4	2004	The objective of this study was to investigate the effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood concentrations in stable transplant patients.	Cyclosporine	102-114	ATP binding cassette subfamily B member 1	Homo sapiens	78-83
14662772-5	2004	We now show that MDR1 inhibitors, cyclosporin A or ketoconazole, inhibit neutral glycosphingolipid biosynthesis in 11 of 12 cell lines tested.	Cyclosporine	34-47	ATP binding cassette subfamily B member 1	Homo sapiens	17-21
15041358-8	2004	Unfortunately, the TOR inhibitors also potentiate the nephrotoxicity of cyclosporine.	Cyclosporine	72-84	RAR related orphan receptor C	Homo sapiens	19-22
15041358-9	2004	Both mycophenolate and the TOR inhibitors are subject to pharmacokinetic interactions with cyclosporine.	Cyclosporine	91-103	RAR related orphan receptor C	Homo sapiens	27-30
15041361-2	2004	CsA is a calcineurin inhibitor that binds to cyclophilins and inhibits transcription of interleukin 2 in T cells, thereby preventing proliferation of activated T cells.	Cyclosporine	0-3	interleukin 2	Homo sapiens	88-101
15041382-7	2004	In vitro production of IL-2 was significantly lower in the CsA+MMF group than in the CsA group (median IL-2 2h: 280.52 ng/L, 169.48 ng/L, P&lt;.001).	Cyclosporine	59-62	interleukin 2	Homo sapiens	23-27
15041382-7	2004	In vitro production of IL-2 was significantly lower in the CsA+MMF group than in the CsA group (median IL-2 2h: 280.52 ng/L, 169.48 ng/L, P&lt;.001).	Cyclosporine	59-62	interleukin 2	Homo sapiens	103-107
15041382-7	2004	In vitro production of IL-2 was significantly lower in the CsA+MMF group than in the CsA group (median IL-2 2h: 280.52 ng/L, 169.48 ng/L, P&lt;.001).	Cyclosporine	85-88	interleukin 2	Homo sapiens	23-27
15041382-10	2004	CNa and IL-2 production may be good biological markers of CsA immunosuppression.	Cyclosporine	58-61	interleukin 2	Homo sapiens	8-12
15041382-11	2004	The measurement of CNa depends mainly on CsA concentration, whereas in vitro IL-2 production reflects the effect of both CsA and MMF.	Cyclosporine	121-124	interleukin 2	Homo sapiens	77-81
14662772-7	2004	Microsomal lactosyl ceramide and globotriaosyl ceramide synthesis from endogenous or exogenously added liposomal glucosyl ceramide was inhibited by cyclosporin A, consistent with a direct role for MDR1/glucosyl ceramide translocase activity in their synthesis.	Cyclosporine	148-161	ATP binding cassette subfamily B member 1	Homo sapiens	197-201
15036611-2	2004	Cyclosporin-A (CsA), an immunosupressive agent, may be used to inhibit the activity of iNOS and perhaps to protect against neural tissue destruction.	Cyclosporine	0-13	nitric oxide synthase 2	Rattus norvegicus	87-91
15036611-2	2004	Cyclosporin-A (CsA), an immunosupressive agent, may be used to inhibit the activity of iNOS and perhaps to protect against neural tissue destruction.	Cyclosporine	15-18	nitric oxide synthase 2	Rattus norvegicus	87-91
15084935-0	2004	Whole-blood cultures from renal-transplant patients stimulated ex vivo show that the effects of cyclosporine on lymphocyte proliferation are related to P-glycoprotein expression.	Cyclosporine	96-108	ATP binding cassette subfamily B member 1	Homo sapiens	152-166
15036611-4	2004	Results showed an increase in the activity of iNOS at 72 h after the SCI, inhibited by CsA (2.5 mg/kg) administered 12 h after trauma.	Cyclosporine	87-90	nitric oxide synthase 2	Rattus norvegicus	46-50
15084935-1	2004	BACKGROUND: Cyclosporine (CsA) is a substrate for the MDR-1 gene product P-glycoprotein (P-gp).	Cyclosporine	12-24	ATP binding cassette subfamily B member 1	Homo sapiens	54-59
15036611-5	2004	iNOS Western blot assay showed an increase in the expression of iNOS after trauma, also antagonized by CsA administration.	Cyclosporine	103-106	nitric oxide synthase 2	Rattus norvegicus	0-4
15084935-1	2004	BACKGROUND: Cyclosporine (CsA) is a substrate for the MDR-1 gene product P-glycoprotein (P-gp).	Cyclosporine	12-24	ATP binding cassette subfamily B member 1	Homo sapiens	73-87
15084935-1	2004	BACKGROUND: Cyclosporine (CsA) is a substrate for the MDR-1 gene product P-glycoprotein (P-gp).	Cyclosporine	12-24	ATP binding cassette subfamily B member 1	Homo sapiens	89-93
15036611-5	2004	iNOS Western blot assay showed an increase in the expression of iNOS after trauma, also antagonized by CsA administration.	Cyclosporine	103-106	nitric oxide synthase 2	Rattus norvegicus	64-68
14757168-10	2004	Concomitantly with MPT, gold(I) compounds determined the release of cytochrome c that, however, occurred also in the presence of cyclosporin A and, partially, of EGTA, indicating its independence of MPT.	Cyclosporine	129-142	cytochrome c, somatic	Homo sapiens	68-80
14966405-4	2004	METHODS: Expression of NFAT (nuclear factor of activated T cells)-regulated genes (interleukin 2, interferon-gamma, and granulocyte-macrophage colony-stimulating factor) in phorbol myristate acetate/ionomycin-stimulated peripheral blood from healthy volunteers (n=34) and from stable renal (n=25), cardiac (n=26), and liver (n=14) transplant recipients receiving CsA therapy was measured by quantitative real-time reverse transcriptase-polymerase chain reaction before and 2 hr after drug intake.	Cyclosporine	363-366	interleukin 2	Homo sapiens	83-96
14741691-3	2004	iNOS expression and NO secretion in response to LPS were suppressed by Ca(2+) antagonists (TMB-8, BAPTA/AM, and nifedipine) and CN inhibitor (cyclosporin A).	Cyclosporine	142-155	nitric oxide synthase 2, inducible	Mus musculus	0-4
14966405-6	2004	RESULTS: Two hours after oral CsA ingestion, the mean suppression of induced interleukin 2, interferon-gamma, and granulocyte-macrophage colony-stimulating factor gene expression was 85%.	Cyclosporine	30-33	interleukin 2	Homo sapiens	77-90
14966405-6	2004	RESULTS: Two hours after oral CsA ingestion, the mean suppression of induced interleukin 2, interferon-gamma, and granulocyte-macrophage colony-stimulating factor gene expression was 85%.	Cyclosporine	30-33	interferon gamma	Homo sapiens	92-162
14976124-5	2004	Flavopiridol, an inhibitor of cyclin-dependent kinases (CDKs), prevented the neurotoxic effects of colchicine plus CsA.	Cyclosporine	115-118	cyclin-dependent kinase 1	Rattus norvegicus	56-60
14976124-8	2004	Roscovitine (25-50 microM), a selective cdk1, 2 and 5 inhibitor, showed an antiapoptotic effect against colchicine- and colchicine plus CsA-induced apoptosis.	Cyclosporine	136-139	cyclin-dependent kinase 1	Rattus norvegicus	40-53
15108766-0	2004	Activation of nuclear factor-kappa B and macrophage invasion in cyclosporin A-and tacrolimus-treated renal transplants.	Cyclosporine	64-77	nuclear factor kappa B subunit 1	Homo sapiens	14-36
15108766-1	2004	This retrospective study was designed to compare the efficacy of cyclosporin A (CyA) and tacrolimus (FK506) on chronic rejection (CR) associated with nuclear factor-kappa B (NF-kappaB) activation and macrophage invasion.	Cyclosporine	65-78	nuclear factor kappa B subunit 1	Homo sapiens	150-172
15108766-1	2004	This retrospective study was designed to compare the efficacy of cyclosporin A (CyA) and tacrolimus (FK506) on chronic rejection (CR) associated with nuclear factor-kappa B (NF-kappaB) activation and macrophage invasion.	Cyclosporine	65-78	nuclear factor kappa B subunit 1	Homo sapiens	174-183
15108766-4	2004	Compared with specimens from FK506-treated patients (n = 20), specimens from CyA-treated patients (n = 43) showed a significant increase in tubulointerstitial CD68-positive cells (1.5 +/- 0.9 vs. 0.9 +/- 0.8, p &lt; 0.01), although no significant differences were observed in NF-kappaB activation.	Cyclosporine	77-80	nuclear factor kappa B subunit 1	Homo sapiens	276-285
14736946-0	2004	Cyclosporin A toxicity, and more: vascular endothelial growth factor (VEGF) steps forward.	Cyclosporine	0-13	vascular endothelial growth factor A	Homo sapiens	34-68
14719107-5	2004	Besides, cytochrome c release from mitochondria happened simultaneously to apoptotic phenotypes, shrinkage of mitochondria but being independent of the mitochondrial permeability transition, since cyclosporine A and bongkrekic acid were inefficient on induced apoptosis.	Cyclosporine	197-211	cytochrome c, somatic	Homo sapiens	9-21
14743390-8	2004	The mononuclear cells resulting from high cyclosporin treatment (1,000 ng/ml) were cathepsin K (CTSK) and tartrate-resistant acid phosphatase (TRAP) positive but expression of calcitonin receptor (CTR) was downregulated by more than 30-fold.	Cyclosporine	42-53	calcitonin receptor	Homo sapiens	176-195
14743390-8	2004	The mononuclear cells resulting from high cyclosporin treatment (1,000 ng/ml) were cathepsin K (CTSK) and tartrate-resistant acid phosphatase (TRAP) positive but expression of calcitonin receptor (CTR) was downregulated by more than 30-fold.	Cyclosporine	42-53	calcitonin receptor	Homo sapiens	197-200
14736979-0	2004	Low-dose cyclosporin therapy for recombinant erythropoietin-induced pure red-cell aplasia.	Cyclosporine	9-20	erythropoietin	Homo sapiens	45-59
14736946-0	2004	Cyclosporin A toxicity, and more: vascular endothelial growth factor (VEGF) steps forward.	Cyclosporine	0-13	vascular endothelial growth factor A	Homo sapiens	70-74
14704129-0	2004	Inhibitory effect of tea polyphenols on transforming growth factor-beta1 expression in rat with cyclosporine A-induced chronic nephrotoxicity.	Cyclosporine	96-110	transforming growth factor, beta 1	Rattus norvegicus	40-72
14565991-8	2004	CsA inhibited the pacing-induced BNP gene expression, whereas pacing alone had no effect on the expression of c-fos.	Cyclosporine	0-3	natriuretic peptide B	Rattus norvegicus	33-36
14634722-4	2004	The present study evaluated the effect of cyclosporin A (CyA) on big ET-1 levels (a precursor of ET-1) in patients 1 year after successful OHTx.	Cyclosporine	42-55	endothelin 1	Homo sapiens	69-73
14634722-4	2004	The present study evaluated the effect of cyclosporin A (CyA) on big ET-1 levels (a precursor of ET-1) in patients 1 year after successful OHTx.	Cyclosporine	42-55	endothelin 1	Homo sapiens	97-101
14634722-4	2004	The present study evaluated the effect of cyclosporin A (CyA) on big ET-1 levels (a precursor of ET-1) in patients 1 year after successful OHTx.	Cyclosporine	57-60	endothelin 1	Homo sapiens	69-73
14634722-4	2004	The present study evaluated the effect of cyclosporin A (CyA) on big ET-1 levels (a precursor of ET-1) in patients 1 year after successful OHTx.	Cyclosporine	57-60	endothelin 1	Homo sapiens	97-101
14634722-11	2004	The plasma levels of big ET-1 are dependent on CyA plasma levels 1 year after successful OHTx in patients treated with the immunosuppressive combination of cyclosporine, azathioprine, and prednisone.	Cyclosporine	156-168	endothelin 1	Homo sapiens	25-29
15147634-6	2004	Bcl-2 expression increased significantly in neurons after 14 and even more after 21 days of treatment with 7 mg/kg cyclosporine-A, mainly in type B and C neurons.	Cyclosporine	115-129	BCL2, apoptosis regulator	Rattus norvegicus	0-5
15147634-7	2004	With 15 mg/kg cyclosporine-A, Bcl-2 increased moderately in type A and B neurons and strongly in type C neurons only after 7 days.	Cyclosporine	14-28	BCL2, apoptosis regulator	Rattus norvegicus	30-35
15147634-10	2004	We conclude that (1) in normal conditions, Bax and Bcl-2 were differently expressed in neurons and satellite cells; (2) cyclosporine-A treatment rapidly enhanced Bax expression in satellite cells only, whereas Bcl-2 expression increased moderately in type A neurons and was strongly expressed in type B and C neurons; (3) cyclosporine-A has a protective role in neurons but not in satellite cells; and (4) the neuroprotective role of cyclosporine-A is dose dependent.	Cyclosporine	120-134	BCL2, apoptosis regulator	Rattus norvegicus	51-56
15147634-10	2004	We conclude that (1) in normal conditions, Bax and Bcl-2 were differently expressed in neurons and satellite cells; (2) cyclosporine-A treatment rapidly enhanced Bax expression in satellite cells only, whereas Bcl-2 expression increased moderately in type A neurons and was strongly expressed in type B and C neurons; (3) cyclosporine-A has a protective role in neurons but not in satellite cells; and (4) the neuroprotective role of cyclosporine-A is dose dependent.	Cyclosporine	120-134	BCL2, apoptosis regulator	Rattus norvegicus	210-215
14704129-1	2004	AIM: To investigate the inhibitory effect of tea polyphenols (TP) on the transforming growth factor-beta1 (TGF-beta1) expression in rat model of cyclosporine A (CsA)-induced chronic nephrotoxicity.	Cyclosporine	145-159	transforming growth factor, beta 1	Rattus norvegicus	73-105
14704129-1	2004	AIM: To investigate the inhibitory effect of tea polyphenols (TP) on the transforming growth factor-beta1 (TGF-beta1) expression in rat model of cyclosporine A (CsA)-induced chronic nephrotoxicity.	Cyclosporine	145-159	transforming growth factor, beta 1	Rattus norvegicus	107-116
14704129-1	2004	AIM: To investigate the inhibitory effect of tea polyphenols (TP) on the transforming growth factor-beta1 (TGF-beta1) expression in rat model of cyclosporine A (CsA)-induced chronic nephrotoxicity.	Cyclosporine	161-164	transforming growth factor, beta 1	Rattus norvegicus	73-105
14704129-1	2004	AIM: To investigate the inhibitory effect of tea polyphenols (TP) on the transforming growth factor-beta1 (TGF-beta1) expression in rat model of cyclosporine A (CsA)-induced chronic nephrotoxicity.	Cyclosporine	161-164	transforming growth factor, beta 1	Rattus norvegicus	107-116
14704129-5	2004	RESULTS: CsA-treated rats had increased renal expression of TGF-beta1 mRNA and its protein, compared with the vehicle- or TP-treated controls.	Cyclosporine	9-12	transforming growth factor, beta 1	Rattus norvegicus	60-69
14704129-6	2004	The renal function and interstitial fibrosis were ameliorated and renal expression of TGF-beta1 mRNA and its protein was decreased in animals treated with CsA plus TP, compared with animals treated with CsA alone (P&lt;0.05).	Cyclosporine	155-158	transforming growth factor, beta 1	Rattus norvegicus	86-95
14704129-6	2004	The renal function and interstitial fibrosis were ameliorated and renal expression of TGF-beta1 mRNA and its protein was decreased in animals treated with CsA plus TP, compared with animals treated with CsA alone (P&lt;0.05).	Cyclosporine	203-206	transforming growth factor, beta 1	Rattus norvegicus	86-95
14704129-7	2004	CONCLUSION: TP significantly inhibits renal expression of TGF-beta1 in rat model of cyclosporine-induced chronic nephrotoxicity, suggesting that the decreased renal expression of TGF-beta1 exerted by TP is one of mechanisms to protect renal function and tissue structure.	Cyclosporine	84-96	transforming growth factor, beta 1	Rattus norvegicus	58-67
14733770-13	2004	CsA 10(-6) mol/L inhibited UII-stimulated PKC activity by 14% (P &lt; 0.05), while having no effect on MAPK activity (P &gt; 0.05).	Cyclosporine	0-3	proline rich transmembrane protein 2	Homo sapiens	42-45
15191166-7	2004	Immunologic response via FACS analysis revealed a decreased presence of cytotoxic cells, characterized by near complete absence of CD8+ cells, and lack of activation depicted by low CD69 expression in CsA-treated transplanted animals.	Cyclosporine	201-204	Cd69 molecule	Rattus norvegicus	182-186
15350151-5	2004	Drugs most prominently affected and contraindicated for concomitant use with St John"s wort are metabolised via both CYP3A4 and P-glycoprotein pathways, including HIV protease inhibitors, HIV non-nucleoside reverse transcriptase inhibitors (only CYP3A4), the immunosuppressants ciclosporin and tacrolimus, and the antineoplastic agents irinotecan and imatinib mesylate.	Cyclosporine	278-289	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	117-123
14709642-9	2004	When CsA was added to whole-blood cultures, the influence on IL-2 mRNA expression was comparable to that of tacrolimus in 9 of 11 individuals.	Cyclosporine	5-8	interleukin 2	Homo sapiens	61-65
14709642-11	2004	Kinetic profiles of IL-2 mRNA expression also revealed individually distinct degrees of calcineurin inhibitor sensitivity in patients undergoing tacrolimus or CsA monotherapy before living-donor kidney transplantation.	Cyclosporine	159-162	interleukin 2	Homo sapiens	20-24
15217301-6	2004	With regard to the variability, polymorphisms of the MDR1 gene have recently been reported to be associated with alterations in disposition kinetics and interaction profiles of clinically useful drugs, including digoxin, fexofenadine, ciclosporin and talinolol.	Cyclosporine	235-246	ATP binding cassette subfamily B member 1	Homo sapiens	53-57
14967314-5	2004	The plasma eotaxin concentration was, in turn, most closely associated with the cyclosporin dose (P&lt;0.001) and plasma prednisolone concentration (P=0.022).	Cyclosporine	80-91	C-C motif chemokine ligand 11	Homo sapiens	11-18
15325009-4	2004	Here, we review different molecular effects induced by cyclosporine A (inhibition of DNA repair, synthesis of TGF Beta, induction of apoptosis of activated T cells, inhibition of apoptosis through the inhibition of the opening of the mitochondrial Permeability Transition Pore) and propose that cyclosporine A can promote the genesis and the spread of cancer not only because of immunosuppression but also because of its ability to facilitate DNA mutations accumulation, to diminish the clearance of altered cells and to transform cancer cells into aggressive cancer cells.	Cyclosporine	55-69	transforming growth factor beta 1	Homo sapiens	110-118
16268121-1	2004	We previously showed that Ca2+-induced cyclosporin A-sensitive membrane permeability transition (MPT) of mitochondria occurred with concomitant generation of reactive oxygen species (ROS) and release of cytochrome c (Free Rad.	Cyclosporine	39-52	cytochrome c, somatic	Homo sapiens	203-215
15013322-2	2004	Cyclosporine displays deleterious effects due to direct toxicity to the nephrons and vasoconstriction of afferent arterioles, effects that may be due to increased angiotensin II and decreased nitric oxide activity.	Cyclosporine	0-12	angiotensinogen	Homo sapiens	163-177
15013322-9	2004	In recent studies angiotensin II and nitric oxide have been suggested to be related to cyclosporine toxicity; however, our results failed to reveal an association between cyclosporine toxicity and angiotensin II or nitric oxide-related gene polymorphisms.	Cyclosporine	87-99	angiotensinogen	Homo sapiens	18-32
15013323-9	2004	In a rat model histologic changes characteristic of CsA-induced nephrotoxicity are associated with decreased expression of BMP-7, which seems to be at least partially restored by ACE inhibition.	Cyclosporine	52-55	angiotensin I converting enzyme	Rattus norvegicus	179-182
15047987-4	2004	CsA (at concentrations of 10-50 microM), FK506 (at all used concentrations) and rapamycin (in dose-dependent manner) significantly attenuated IL-1beta release after 24 h exposure to ischemic conditions.	Cyclosporine	0-3	interleukin 1 beta	Rattus norvegicus	142-150
14967314-9	2004	Cyclosporin may also indirectly influence these changes by inhibiting eotaxin production.	Cyclosporine	0-11	C-C motif chemokine ligand 11	Homo sapiens	70-77
14629285-0	2003	Mycophenolate mofetil ameliorates arteriolopathy and decreases transforming growth factor-beta1 in chronic cyclosporine nephrotoxicity.	Cyclosporine	107-119	transforming growth factor, beta 1	Rattus norvegicus	63-95
14653942-4	2003	The effects of a P-glycoprotein (P-gp) inhibitor-cyclosporin A, some surfactants, and lower pH on the transepithelial transport of CPU-86017 were also observed.	Cyclosporine	49-62	ATP binding cassette subfamily B member 1	Homo sapiens	33-37
14612935-6	2003	Simultaneous exposure of cells to cyclosporin A prevented the release of cytochrome c to cytosol and reduced the loss of viability.	Cyclosporine	34-47	cytochrome c, somatic	Homo sapiens	73-85
14627919-0	2003	C-jun N-terminal kinase (JNK) inhibitor, SP600125, blocks interleukin (IL)-6-induced vascular endothelial growth factor (VEGF) production: cyclosporine A partially mimics this inhibitory effect.	Cyclosporine	139-153	mitogen-activated protein kinase 8	Homo sapiens	0-23
14500711-4	2003	Noxa-induced cytochrome c release is inhibited by permeability transition pore inhibitors such as CsA or MgCl2, and Noxa induces an ultra-structural change of mitochondria yielding "swollen" mitochondria that are unlike changes induced by tBid.	Cyclosporine	98-101	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	0-4
14500711-4	2003	Noxa-induced cytochrome c release is inhibited by permeability transition pore inhibitors such as CsA or MgCl2, and Noxa induces an ultra-structural change of mitochondria yielding "swollen" mitochondria that are unlike changes induced by tBid.	Cyclosporine	98-101	cytochrome c, somatic	Homo sapiens	13-25
14638906-10	2003	CsA promoted a caspase-independent release of cytochrome c and Smac/Diablo from mitochondria.	Cyclosporine	0-3	diablo, IAP-binding mitochondrial protein	Mus musculus	63-67
14638906-10	2003	CsA promoted a caspase-independent release of cytochrome c and Smac/Diablo from mitochondria.	Cyclosporine	0-3	diablo, IAP-binding mitochondrial protein	Mus musculus	68-74
14645681-2	2003	Proenkephalin (PEnk) gene activation after depolarization of chromaffin cells with 40 mM KCl was blocked by the voltage-sensitive calcium-channel blocker methoxyverapamil (D600) (30 microM) and by calcineurin inhibition with 100 nM cyclosporin A or ascomycin but not by inhibiting new protein synthesis with 0.5 microg/ml cycloheximide.	Cyclosporine	232-245	proenkephalin	Homo sapiens	0-13
14645681-2	2003	Proenkephalin (PEnk) gene activation after depolarization of chromaffin cells with 40 mM KCl was blocked by the voltage-sensitive calcium-channel blocker methoxyverapamil (D600) (30 microM) and by calcineurin inhibition with 100 nM cyclosporin A or ascomycin but not by inhibiting new protein synthesis with 0.5 microg/ml cycloheximide.	Cyclosporine	232-245	proenkephalin	Homo sapiens	15-19
14645681-3	2003	KCl-induced elevation of PEnk mRNA was distinct from activation of the PEnk gene by either cAMP or protein kinase C. Twenty-five micromolar forskolin- and 100 nM phorbol 12-myristate 13-acetate-induced elevations of PEnk mRNA were cycloheximide-sensitive and were not blocked by cyclosporin A or ascomycin.	Cyclosporine	279-292	proenkephalin	Homo sapiens	25-29
14627919-0	2003	C-jun N-terminal kinase (JNK) inhibitor, SP600125, blocks interleukin (IL)-6-induced vascular endothelial growth factor (VEGF) production: cyclosporine A partially mimics this inhibitory effect.	Cyclosporine	139-153	mitogen-activated protein kinase 8	Homo sapiens	25-28
14627919-0	2003	C-jun N-terminal kinase (JNK) inhibitor, SP600125, blocks interleukin (IL)-6-induced vascular endothelial growth factor (VEGF) production: cyclosporine A partially mimics this inhibitory effect.	Cyclosporine	139-153	interleukin 6	Homo sapiens	58-76
14627919-0	2003	C-jun N-terminal kinase (JNK) inhibitor, SP600125, blocks interleukin (IL)-6-induced vascular endothelial growth factor (VEGF) production: cyclosporine A partially mimics this inhibitory effect.	Cyclosporine	139-153	vascular endothelial growth factor A	Homo sapiens	85-119
14627919-0	2003	C-jun N-terminal kinase (JNK) inhibitor, SP600125, blocks interleukin (IL)-6-induced vascular endothelial growth factor (VEGF) production: cyclosporine A partially mimics this inhibitory effect.	Cyclosporine	139-153	vascular endothelial growth factor A	Homo sapiens	121-125
14627919-8	2003	In fact, CsA suppressed IL-6-induced phosphorylation of JNK.	Cyclosporine	9-12	interleukin 6	Homo sapiens	24-28
14627919-8	2003	In fact, CsA suppressed IL-6-induced phosphorylation of JNK.	Cyclosporine	9-12	mitogen-activated protein kinase 8	Homo sapiens	56-59
14627919-9	2003	The results indicate that although both SP600125 and CsA are anti-angiogenic by inhibiting VEGF production by way of a JNK-dependent pathway, the inhibitory effect was much stronger with the novel inhibitor of JNK than with CsA.	Cyclosporine	53-56	vascular endothelial growth factor A	Homo sapiens	91-95
14627919-9	2003	The results indicate that although both SP600125 and CsA are anti-angiogenic by inhibiting VEGF production by way of a JNK-dependent pathway, the inhibitory effect was much stronger with the novel inhibitor of JNK than with CsA.	Cyclosporine	53-56	mitogen-activated protein kinase 8	Homo sapiens	119-122
14627919-9	2003	The results indicate that although both SP600125 and CsA are anti-angiogenic by inhibiting VEGF production by way of a JNK-dependent pathway, the inhibitory effect was much stronger with the novel inhibitor of JNK than with CsA.	Cyclosporine	53-56	mitogen-activated protein kinase 8	Homo sapiens	210-213
14614027-0	2003	Cyclosporin-A enhances docetaxel-induced apoptosis through inhibition of nuclear factor-kappaB activation in human gastric carcinoma cells.	Cyclosporine	0-13	nuclear factor kappa B subunit 1	Homo sapiens	73-94
14561585-9	2003	Finally, pharmacological studies have shown that the expression of Pept-1 can be upregulated by agents such as 5 fluorouracil and downregulated by agents such as cyclosporine.	Cyclosporine	162-174	solute carrier family 15 member 1	Homo sapiens	67-73
14705863-4	2003	Increased expression of MDR1 reduces the bioavailability of MDR1 substrates such as digoxin, cyclosporin, and taxol.	Cyclosporine	93-104	ATP binding cassette subfamily B member 1	Homo sapiens	24-28
14564197-9	2003	Two polymorphisms (C3435T and G2677[A/T]) of the MDR-1 gene have been shown to influence the bioavailability and toxicity of tacrolimus and cyclosporin.	Cyclosporine	140-151	ATP binding cassette subfamily B member 1	Homo sapiens	49-54
14705863-4	2003	Increased expression of MDR1 reduces the bioavailability of MDR1 substrates such as digoxin, cyclosporin, and taxol.	Cyclosporine	93-104	ATP binding cassette subfamily B member 1	Homo sapiens	60-64
14579273-6	2003	Cyclosporin A, but not concanamycin A, an H+-ATPase vacuolar inhibitor which affects perforin and granzyme release, strongly reduced the sHLA-I-mediated CD8-dependent IFN-gamma production but did not affect cytolytic activity of NK cells, suggesting that different biochemical pathways are involved.	Cyclosporine	0-13	interferon gamma	Homo sapiens	167-176
14579273-7	2003	Altogether, these findings indicate that CD8 engagement by sHLA-I activates a cyclosporin A-dependent pathway leading to production and secretion of IFN-gamma which may play a role in the regulation of innate immune responses in humans.	Cyclosporine	78-91	interferon gamma	Homo sapiens	149-158
12975485-4	2003	A P-gp modulator, cyclosporin A, inhibited the basal-to-apical transport in L-MDR1 cells.	Cyclosporine	18-31	ATP binding cassette subfamily B member 1	Homo sapiens	2-6
14570757-13	2003	For the exclusive CYP3A substrate, felodipine, AUC was unchanged from control by GG918 but increased by troleandomycin and cyclosporine.	Cyclosporine	123-135	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	18-23
12975485-7	2003	The Ki values for the inhibition of P-gp function by cyclosporin A and imatinib mesilate were estimated to be 6.1 and 18.3 muM, respectively, using a calcein-AM efflux assay.	Cyclosporine	53-66	ATP binding cassette subfamily B member 1	Homo sapiens	36-40
14551352-0	2003	Cyclosporin A tubular effects contribute to nephrotoxicity: role for Ca2+ and Mg2+ ions.	Cyclosporine	0-13	carbonic anhydrase 2	Rattus norvegicus	69-72
14682659-2	2003	The pathogenesis of this condition is not fully understood; however, recent studies show that CsA regulates the transcription of several cytokines including transforming growth factor-beta 1 (TGF-beta1).	Cyclosporine	94-97	transforming growth factor beta 1	Homo sapiens	157-190
14682659-2	2003	The pathogenesis of this condition is not fully understood; however, recent studies show that CsA regulates the transcription of several cytokines including transforming growth factor-beta 1 (TGF-beta1).	Cyclosporine	94-97	transforming growth factor beta 1	Homo sapiens	192-201
14682659-7	2003	Furthermore, neutralization of TGF-beta1 production in CsA-treated NG fibroblasts inhibited CsA"s effect on NG fibroblast proliferation, demonstrating an autocrine stimulatory effect of TGF-beta1 in CsA-treated NG fibroblast proliferation.	Cyclosporine	55-58	transforming growth factor beta 1	Homo sapiens	31-40
14682659-7	2003	Furthermore, neutralization of TGF-beta1 production in CsA-treated NG fibroblasts inhibited CsA"s effect on NG fibroblast proliferation, demonstrating an autocrine stimulatory effect of TGF-beta1 in CsA-treated NG fibroblast proliferation.	Cyclosporine	55-58	transforming growth factor beta 1	Homo sapiens	186-195
14682659-8	2003	CONCLUSION: The results presented here suggest that CsA stimulatory induction of NG fibroblast proliferation is mediated via TGF-beta1 in an autocrine fashion.	Cyclosporine	52-55	transforming growth factor beta 1	Homo sapiens	125-134
14713364-12	2003	The current study suggests that TET enhances the cytotoxicity of anticancer drugs in the P-gp expressing MDR cell line by modulating P-gp in a different manner to the well-known P-gp inhibitor CsA.	Cyclosporine	193-196	ATP binding cassette subfamily B member 1	Homo sapiens	89-93
14765557-9	2003	(4) CYP3A mRNA was suppressed to a greater degree in the LDL- and HDL-CSA treated groups as compared with the suppression caused by CSA alone.	Cyclosporine	132-135	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	4-9
14765557-9	2003	(4) CYP3A mRNA was suppressed to a greater degree in the LDL- and HDL-CSA treated groups as compared with the suppression caused by CSA alone.	Cyclosporine	70-73	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	4-9
14765557-13	2003	Furthermore, LDL-R is one regulatory factor responsible for altering CSA metabolism as a result of an increase in uptake of CSA into hepatocytes.	Cyclosporine	69-72	low density lipoprotein receptor	Rattus norvegicus	13-18
12967592-11	2003	In the mdr2 knock-out mice, CsA treatment decreased the BF and the secretion of BS but after the injection of TCA+CsA, the BF and the biliary secretion of BS were increased and the phospholipid secretion was slightly stimulated as compared to the mdr2 knock-out mice treated with CsA alone.	Cyclosporine	28-31	ATP-binding cassette, sub-family B (MDR/TAP), member 4	Mus musculus	7-11
12967592-11	2003	In the mdr2 knock-out mice, CsA treatment decreased the BF and the secretion of BS but after the injection of TCA+CsA, the BF and the biliary secretion of BS were increased and the phospholipid secretion was slightly stimulated as compared to the mdr2 knock-out mice treated with CsA alone.	Cyclosporine	28-31	ATP-binding cassette, sub-family B (MDR/TAP), member 4	Mus musculus	247-251
14765557-13	2003	Furthermore, LDL-R is one regulatory factor responsible for altering CSA metabolism as a result of an increase in uptake of CSA into hepatocytes.	Cyclosporine	124-127	low density lipoprotein receptor	Rattus norvegicus	13-18
12967592-11	2003	In the mdr2 knock-out mice, CsA treatment decreased the BF and the secretion of BS but after the injection of TCA+CsA, the BF and the biliary secretion of BS were increased and the phospholipid secretion was slightly stimulated as compared to the mdr2 knock-out mice treated with CsA alone.	Cyclosporine	114-117	ATP-binding cassette, sub-family B (MDR/TAP), member 4	Mus musculus	247-251
12967592-11	2003	In the mdr2 knock-out mice, CsA treatment decreased the BF and the secretion of BS but after the injection of TCA+CsA, the BF and the biliary secretion of BS were increased and the phospholipid secretion was slightly stimulated as compared to the mdr2 knock-out mice treated with CsA alone.	Cyclosporine	114-117	ATP-binding cassette, sub-family B (MDR/TAP), member 4	Mus musculus	247-251
14500684-7	2003	The disruption of the IL-12 or IFN-gamma genes in C57BL/6 mice shifted ACR to AVR, and resulted in concomitant recipient resistance to CsA therapy.	Cyclosporine	135-138	interferon gamma	Mus musculus	31-40
12801884-6	2003	Supporting this, CRHSP-24 dephosphorylation in response to the Ca2+-mobilizing hormone cholecystokinin was differentially inhibited by calyculin A and the PP2B-selective inhibitor cyclosporin A.	Cyclosporine	180-193	calcium regulated heat stable protein 1	Homo sapiens	17-25
14555277-9	2003	Although CsA did not affect RANKL-induced osteoclast generation in the culture of monocytes alone, it completely rescued the T-cell-induced inhibition of osteoclast formation and strongly inhibited the production of GM-CSF and IFN-gamma.	Cyclosporine	9-12	interferon gamma	Homo sapiens	227-236
12874088-0	2003	Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension.	Cyclosporine	54-68	angiotensinogen	Rattus norvegicus	8-22
14609717-4	2003	The mechanism of action of CsA involves initial binding to cyclophilin to form a complex that then inhibits calcineurin (CN), leading to reduced interleukin (IL)-2 production as part of the signal transduction pathway for the activation of B-lymphocytes and T-lymphocytes.	Cyclosporine	27-30	interleukin 2	Homo sapiens	145-163
12923165-5	2003	Using cell-permeable forms of superoxide dismutase and catalase, we finally show that superoxide mediates the CsA-induced effects on vasopressin type 1A receptor.	Cyclosporine	110-113	catalase	Rattus norvegicus	55-63
14576824-3	2003	In the present paper, we investigated an involvement of Akt signalling in the regulation of FasL expression in CsA-induced apoptosis.	Cyclosporine	111-114	AKT serine/threonine kinase 1	Homo sapiens	56-59
14576824-4	2003	We demonstrated that the level of active Akt decreases significantly after CsA treatment, which results in the decrease of Forkhead phosphorylation and its translocation to the nucleus.	Cyclosporine	75-78	AKT serine/threonine kinase 1	Homo sapiens	41-44
14521916-7	2003	Inhibition of CsA- but not lactacytin-induced apoptosis by overexpression of Bcl-2 in Jurkat T cells revealed that CsA and proteasome inhibitors activate different apoptotic pathways, while both CsA- and lactacystin-induced apoptosis were found to be dependent on caspase activation and independent of the FasL/Fas system.	Cyclosporine	14-17	BCL2 apoptosis regulator	Homo sapiens	77-82
14521916-7	2003	Inhibition of CsA- but not lactacytin-induced apoptosis by overexpression of Bcl-2 in Jurkat T cells revealed that CsA and proteasome inhibitors activate different apoptotic pathways, while both CsA- and lactacystin-induced apoptosis were found to be dependent on caspase activation and independent of the FasL/Fas system.	Cyclosporine	115-118	BCL2 apoptosis regulator	Homo sapiens	77-82
14521916-7	2003	Inhibition of CsA- but not lactacytin-induced apoptosis by overexpression of Bcl-2 in Jurkat T cells revealed that CsA and proteasome inhibitors activate different apoptotic pathways, while both CsA- and lactacystin-induced apoptosis were found to be dependent on caspase activation and independent of the FasL/Fas system.	Cyclosporine	115-118	BCL2 apoptosis regulator	Homo sapiens	77-82
14520422-9	2003	Transplantation of the CD34-selected stem cell graft that does not accompany transfusion of regulatory cells may potentiate the inducibility of autologous GVHD by the administration of CsA and IFN-gamma.	Cyclosporine	185-188	CD34 molecule	Homo sapiens	23-27
14550820-7	2003	RESULTS: CsA and FK 506 reduced the presence graft-infiltrating leukocytes (CD4, CD8, CD11a, CD18) in the PVS of intra- and epicardial arteries when compared with control animals.	Cyclosporine	9-12	integrin subunit beta 2	Rattus norvegicus	93-97
12821677-6	2003	Co-incubation with rotenone and antimycin A, inhibitors of mitochondrial electron transport chain complexes I and III, or with cyclosporine A, an inhibitor of mitochondrial permeability transition pore, resulted in inhibition of bortezomib-induced ROS generation, increase in Delta psi m, and cytochrome c release.	Cyclosporine	127-141	cytochrome c, somatic	Homo sapiens	293-305
14527673-0	2003	Changes in Hsp90 expression determine the effects of cyclosporine A on the NO pathway in rat myocardium.	Cyclosporine	53-67	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	11-16
14527673-3	2003	CsA treatment rapidly led to an increase in myocardial Hsp90 expression promoting the recruitment of Akt and calcineurin, thereby promoting eNOS activation through Ser1177 phosphorylation and Thr495 dephosphorylation, respectively.	Cyclosporine	0-3	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	55-60
14527673-3	2003	CsA treatment rapidly led to an increase in myocardial Hsp90 expression promoting the recruitment of Akt and calcineurin, thereby promoting eNOS activation through Ser1177 phosphorylation and Thr495 dephosphorylation, respectively.	Cyclosporine	0-3	AKT serine/threonine kinase 1	Rattus norvegicus	101-104
14527673-5	2003	Upon longer CsA exposure, cardiac toxicity developed, as documented by the infiltration of connective tissue and the increase in iNOS expression.	Cyclosporine	12-15	nitric oxide synthase 2	Rattus norvegicus	129-133
14527673-6	2003	These later effects were associated with a dramatic decrease in the abundance and scaffold function of Hsp90, thereby unraveling the key role of Hsp90 in governing CsA effects.	Cyclosporine	164-167	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	103-108
14527673-6	2003	These later effects were associated with a dramatic decrease in the abundance and scaffold function of Hsp90, thereby unraveling the key role of Hsp90 in governing CsA effects.	Cyclosporine	164-167	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	145-150
12796489-0	2003	Cloning and characterization of N4WBP5A, an inducible, cyclosporine-sensitive, Nedd4-binding protein in human T lymphocytes.	Cyclosporine	55-67	Nedd4 family interacting protein 2	Homo sapiens	32-39
12796489-2	2003	We originally identified N4WBP5A as an unknown expressed sequence tag (AA770150) represented in a cDNA microarray analysis that was up-regulated upon activation of T cells and inhibited by cell treatment with the calcineurin phosphatase inhibitors, cyclosporine (CsA) and tacrolimus (FK506).	Cyclosporine	249-261	Nedd4 family interacting protein 2	Homo sapiens	25-32
14526408-0	2003	Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation.	Cyclosporine	59-71	ATP binding cassette subfamily B member 1	Homo sapiens	34-48
14500383-5	2003	Although the initial release of cytochrome c from the mitochondria could be inhibited by cyclosporin A or by bongkrekic acid, the later release continued even in its presence.	Cyclosporine	89-102	cytochrome c, somatic	Homo sapiens	32-44
12934071-4	2003	In vivo application of inhibitors of the mitochondrial permeability transition pore, Bongkrekic acid and cyclosporin A prevented cytochrome c release as well as caspase-3 activation and attenuated motoneuron apoptosis.	Cyclosporine	105-118	cytochrome c, somatic	Homo sapiens	129-141
12934071-4	2003	In vivo application of inhibitors of the mitochondrial permeability transition pore, Bongkrekic acid and cyclosporin A prevented cytochrome c release as well as caspase-3 activation and attenuated motoneuron apoptosis.	Cyclosporine	105-118	caspase 3	Homo sapiens	161-170
12871122-6	2003	CsA is cytoprotective in many cellular and animal models, but protection may result from either inhibition of the MPT through an interaction with CYP D or inhibition of calcineurin-mediated dephosphorylation of BAD through an interaction with CYP A.	Cyclosporine	0-3	peptidylprolyl isomerase F	Homo sapiens	146-151
12966368-0	2003	Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.	Cyclosporine	112-124	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	29-35
12966368-0	2003	Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.	Cyclosporine	112-124	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	37-43
12966368-0	2003	Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.	Cyclosporine	112-124	ATP binding cassette subfamily B member 1	Homo sapiens	49-54
12966368-3	2003	OBJECTIVE: Our objective was to determine the role of genetic polymorphisms in CYP3A4, CYP3A5, and MDR-1 with respect to interindividual variability in cyclosporine and tacrolimus pharmacokinetics.	Cyclosporine	152-164	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	79-85
12966368-3	2003	OBJECTIVE: Our objective was to determine the role of genetic polymorphisms in CYP3A4, CYP3A5, and MDR-1 with respect to interindividual variability in cyclosporine and tacrolimus pharmacokinetics.	Cyclosporine	152-164	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	87-93
12966368-3	2003	OBJECTIVE: Our objective was to determine the role of genetic polymorphisms in CYP3A4, CYP3A5, and MDR-1 with respect to interindividual variability in cyclosporine and tacrolimus pharmacokinetics.	Cyclosporine	152-164	ATP binding cassette subfamily B member 1	Homo sapiens	99-104
14677627-7	2003	CYP3A and CYP2C11 protein expression was suppressed by 27% and 39%, respectively, in the HDL-CSA treatment group and by 38% and 40% in the Plasma-CSA treated group as compared with CSA controls.	Cyclosporine	93-96	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	0-5
14677627-7	2003	CYP3A and CYP2C11 protein expression was suppressed by 27% and 39%, respectively, in the HDL-CSA treatment group and by 38% and 40% in the Plasma-CSA treated group as compared with CSA controls.	Cyclosporine	146-149	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	0-5
14677627-8	2003	In addition, 6beta-hydroxytestosterone, a marker of CYP3A activity, was reduced by 33% and 34% in the HDL-CSA and the Plasma-CSA treatment groups, respectively, as compared with the CSA control group.	Cyclosporine	125-128	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	52-57
14677627-8	2003	In addition, 6beta-hydroxytestosterone, a marker of CYP3A activity, was reduced by 33% and 34% in the HDL-CSA and the Plasma-CSA treatment groups, respectively, as compared with the CSA control group.	Cyclosporine	125-128	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	52-57
14677627-11	2003	In summary, Plasma-CSA treatment resulted in renal dysfunction and suppressed CYP3A and CPY2C11 protein expression.	Cyclosporine	19-22	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	78-83
12878392-7	2003	The energy inhibitor and P-gp inhibitor influenced the accumulated absorption of CsA significantly (P&lt;0.05).	Cyclosporine	81-84	phosphoglycolate phosphatase	Rattus norvegicus	25-29
12783880-4	2003	In particular, calmodulin antagonists, FK506, and cyclosporin, immunosuppressants that inhibit the calcium-dependent phosphatase calcineurin, suppress ERK1/2 activation by both glucose and GLP-1.	Cyclosporine	50-61	mitogen-activated protein kinase 3	Homo sapiens	151-157
12952249-2	2003	Cyclosporin A (CsA) is known to inhibit T-cell proliferation, induce apoptosis of CD4-positive T-cells and downregulate cytokine gene expression.	Cyclosporine	15-18	CD4 molecule	Homo sapiens	82-85
12952249-3	2003	It was assessed whether CsA-induced inhibition of the late asthmatic reaction was associated with apoptosis of BALF T-lymphocytes and other cell types, as well as expression of the antiapoptotic protein B-cell leukaemia/lymphoma 2 gene product (Bcl-2).	Cyclosporine	24-27	BCL2 apoptosis regulator	Homo sapiens	245-250
12952249-6	2003	The numbers of Bcl-2-positive cells were significantly reduced in the CsA but not the placebo group.	Cyclosporine	70-73	BCL2 apoptosis regulator	Homo sapiens	15-20
12819040-9	2003	Blockade of calcineurin activity by cyclosporine A completely normalized Ang II-induced CTGF overexpression in heart and kidney, suppressed the inflammatory response, and mitigated Ang II-induced cell proliferation and apoptosis.	Cyclosporine	36-50	angiotensinogen	Rattus norvegicus	73-79
12897082-0	2003	Cyclosporin increases the density of angiotensin II subtype 1 (AT1) receptors in mouse medullary thick ascending limb cells.	Cyclosporine	0-11	angiotensin II receptor, type 1a	Mus musculus	37-61
12897082-0	2003	Cyclosporin increases the density of angiotensin II subtype 1 (AT1) receptors in mouse medullary thick ascending limb cells.	Cyclosporine	0-11	angiotensin II receptor, type 1a	Mus musculus	63-66
12876275-6	2003	Third, permeability transition pore inhibition by cyclosporin A attenuates NGF deprivation-induced loss of mitochondrial proteins, suggesting that permeability transition pore opening may have a function in regulating the degradation of mitochondria after cytochrome c release.	Cyclosporine	50-63	cytochrome c, somatic	Homo sapiens	256-268
12948013-5	2003	RESULTS: In situ experimental results revealed that the extent to which the intestinal absorption is affected by P-gp was in the following order: quinidine &gt; ritonavir &gt; loperamide, verapamil, daunomycin &gt; digoxin, cyclosporin A &gt; dexamethasone, and vinblastine.	Cyclosporine	224-237	ATP binding cassette subfamily B member 1	Homo sapiens	113-117
12821286-5	2003	Furthermore, CsA modified the expression and activity of several renal enzymes (ciclooxygenase, superoxide-dismutase, catalase and glutathione-peroxidase).	Cyclosporine	13-16	catalase	Homo sapiens	118-126
12821286-7	2003	Thus, Vit E inhibited the synthesis of ROS and TX and the lipid peroxidation process induced by CsA in kidney structures.	Cyclosporine	96-99	vitrin	Homo sapiens	6-9
12819040-9	2003	Blockade of calcineurin activity by cyclosporine A completely normalized Ang II-induced CTGF overexpression in heart and kidney, suppressed the inflammatory response, and mitigated Ang II-induced cell proliferation and apoptosis.	Cyclosporine	36-50	angiotensinogen	Rattus norvegicus	181-187
12848778-1	2003	AIMS: To investigate the frequency of the single nucleotide polymorphism C3435T in exon 26 of the MDR1 gene in Asians and to determine the functional significance of this SNP with the clinical pharmacokinetics of oral cyclosporin (Neoral) in 10 stable heart transplant patients.	Cyclosporine	218-229	ATP binding cassette subfamily B member 1	Homo sapiens	98-102
12810356-11	2003	The results demonstrated a significant inhibition of calcineurin activity and IL-2 and IFN-gamma production in patients receiving cyclosporine monotherapy compared to healthy controls.	Cyclosporine	130-142	interleukin 2	Homo sapiens	78-82
12890213-8	2003	In this case, the anti-TNF-alpha agent may have played a role in association with ciclosporin in the development of the lymphoproliferative disorder.	Cyclosporine	82-93	tumor necrosis factor	Homo sapiens	23-32
12890213-10	2003	Psoriatic patients who may require anti-TNF-alpha treatment have often been or will be treated with ciclosporin.	Cyclosporine	100-111	tumor necrosis factor	Homo sapiens	40-49
12810356-11	2003	The results demonstrated a significant inhibition of calcineurin activity and IL-2 and IFN-gamma production in patients receiving cyclosporine monotherapy compared to healthy controls.	Cyclosporine	130-142	interferon gamma	Homo sapiens	87-96
12821042-8	2003	The MPT inhibitors, cyclosporine A (5 microM) plus trifluoperazine (12.5 microM), blocked depolarization of the mitochondrial membrane and release of cytochrome c, but did not block apoptosis in HSCs.	Cyclosporine	20-34	cytochrome c, somatic	Homo sapiens	150-162
12819249-15	2003	In conclusion, conversion from cyclosporine to tacrolimus in stable renal transplant patients has a beneficial effect on renal function, BP, serum concentration and atherogenic properties of serum lipids, and fibrinogen.	Cyclosporine	31-43	fibrinogen beta chain	Homo sapiens	209-219
12880286-3	2003	Our hypothesis is that CSA will bind to the neutral lipid-binding site of LTP I because of its high solubility/interaction with cholesterol and triglycerides.	Cyclosporine	23-26	cholesteryl ester transfer protein	Homo sapiens	74-79
12835079-13	2003	Cyclosporine and Tacrolimus, collectively known as calcineurin inhibitors, seems to act on the IL-2 by inhibiting its production thus leading to a decrease in the proliferation of the activated lymphocyte.	Cyclosporine	0-12	interleukin 2	Homo sapiens	95-99
12880286-0	2003	Cyclosporine binds to the neutral lipid and potentially other binding sites of lipid transfer protein I.	Cyclosporine	0-12	cholesteryl ester transfer protein	Homo sapiens	79-103
12880286-1	2003	PURPOSE: The objective of this study was to determine if cyclosporine (CSA) binds directly to the neutral lipid-binding site of lipid transfer protein I (LTP I).	Cyclosporine	57-69	cholesteryl ester transfer protein	Homo sapiens	128-152
12880286-5	2003	Coincubation of LTP I with 3H-CSA liposomes resulted in a significant decrease in the LTP I peak reported at fraction 10 and fraction 30 compared to control.	Cyclosporine	30-33	cholesteryl ester transfer protein	Homo sapiens	16-21
12880286-1	2003	PURPOSE: The objective of this study was to determine if cyclosporine (CSA) binds directly to the neutral lipid-binding site of lipid transfer protein I (LTP I).	Cyclosporine	57-69	cholesteryl ester transfer protein	Homo sapiens	154-159
12880286-1	2003	PURPOSE: The objective of this study was to determine if cyclosporine (CSA) binds directly to the neutral lipid-binding site of lipid transfer protein I (LTP I).	Cyclosporine	71-74	cholesteryl ester transfer protein	Homo sapiens	128-152
12880286-5	2003	Coincubation of LTP I with 3H-CSA liposomes resulted in a significant decrease in the LTP I peak reported at fraction 10 and fraction 30 compared to control.	Cyclosporine	30-33	cholesteryl ester transfer protein	Homo sapiens	86-91
12880286-1	2003	PURPOSE: The objective of this study was to determine if cyclosporine (CSA) binds directly to the neutral lipid-binding site of lipid transfer protein I (LTP I).	Cyclosporine	71-74	cholesteryl ester transfer protein	Homo sapiens	154-159
12880286-6	2003	In addition, 30% of the original radioactivity associated with 3H-CSA liposomes was found coeluted with the unbound LTP I peak at fraction 10.	Cyclosporine	66-69	cholesteryl ester transfer protein	Homo sapiens	116-121
12880286-7	2003	Taken together, these findings suggest that CSA does bind to the neutral lipid-binding site of LTP I but may also bind to other regions along the LTP I molecule.	Cyclosporine	44-47	cholesteryl ester transfer protein	Homo sapiens	95-100
12880286-7	2003	Taken together, these findings suggest that CSA does bind to the neutral lipid-binding site of LTP I but may also bind to other regions along the LTP I molecule.	Cyclosporine	44-47	cholesteryl ester transfer protein	Homo sapiens	146-151
12880286-8	2003	CONCLUSIONS: We have determined that LTP I mediated transfer of CSA between lipoproteins may be a result of the direct binding of CSA to LTP I at both its neutral binding site and potentially other binding sites along the molecule.	Cyclosporine	64-67	cholesteryl ester transfer protein	Homo sapiens	37-42
12880286-8	2003	CONCLUSIONS: We have determined that LTP I mediated transfer of CSA between lipoproteins may be a result of the direct binding of CSA to LTP I at both its neutral binding site and potentially other binding sites along the molecule.	Cyclosporine	64-67	cholesteryl ester transfer protein	Homo sapiens	137-142
12880286-8	2003	CONCLUSIONS: We have determined that LTP I mediated transfer of CSA between lipoproteins may be a result of the direct binding of CSA to LTP I at both its neutral binding site and potentially other binding sites along the molecule.	Cyclosporine	130-133	cholesteryl ester transfer protein	Homo sapiens	37-42
12880286-8	2003	CONCLUSIONS: We have determined that LTP I mediated transfer of CSA between lipoproteins may be a result of the direct binding of CSA to LTP I at both its neutral binding site and potentially other binding sites along the molecule.	Cyclosporine	130-133	cholesteryl ester transfer protein	Homo sapiens	137-142
12890451-0	2003	Impact of PGE1 on cyclosporine A induced up-regulation of TGF-beta1, its receptors, and related matrix production in cultured mesangial cells.	Cyclosporine	18-32	transforming growth factor, beta 1	Rattus norvegicus	58-67
12890451-1	2003	Transforming growth factor-beta1 (TGF-beta1) plays a major role in cyclosporine A (CsA) induced glomerulosclerosis.	Cyclosporine	67-81	transforming growth factor, beta 1	Rattus norvegicus	0-32
12890451-1	2003	Transforming growth factor-beta1 (TGF-beta1) plays a major role in cyclosporine A (CsA) induced glomerulosclerosis.	Cyclosporine	67-81	transforming growth factor, beta 1	Rattus norvegicus	34-43
12890451-1	2003	Transforming growth factor-beta1 (TGF-beta1) plays a major role in cyclosporine A (CsA) induced glomerulosclerosis.	Cyclosporine	83-86	transforming growth factor, beta 1	Rattus norvegicus	0-32
12890451-1	2003	Transforming growth factor-beta1 (TGF-beta1) plays a major role in cyclosporine A (CsA) induced glomerulosclerosis.	Cyclosporine	83-86	transforming growth factor, beta 1	Rattus norvegicus	34-43
12890451-2	2003	We have recently shown that CsA up-regulates the expression of TGF-beta1 and its receptors type I (TbetaR-I) and type II (TbetaR-II) in rat mesangial cells (MCs).	Cyclosporine	28-31	transforming growth factor, beta 1	Rattus norvegicus	63-72
12890451-4	2003	Here, we assessed the effect of PGE1 on CsA induced up-regulation of TGF-beta1, TbetaR-I, TbetaR-II and related matrix production in MCs.	Cyclosporine	40-43	transforming growth factor, beta 1	Rattus norvegicus	69-78
12890451-5	2003	Co-incubation with PGE1 reduced CsA induced up-regulation of TGF-beta1 and TbetaR-II at the mRNA and protein level.	Cyclosporine	32-35	transforming growth factor, beta 1	Rattus norvegicus	61-70
12942158-3	2003	The inhibition of calcineurin activation by cyclosporin A and FK-506 blocks T-cell receptor-mediated production of interleukin-2 (IL-2), a growth factor critical for T-cell proliferation.	Cyclosporine	44-57	interleukin 2	Homo sapiens	115-128
12734112-3	2003	Treatment of nude or C57BL/6 depilated normal mice with CsA inhibited the expression of keratinocyte terminal differentiation markers associated with catagen, along with the inhibition of calcineurin and NFAT1 nuclear translocation.	Cyclosporine	56-59	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2	Mus musculus	204-209
12814453-1	2003	AIMS: Nafcillin (Wyeth Laboratories, Philadelphia, PA, USA) has been reported to induce the metabolism of cyclosporin and warfarin, which are known substrates of cytochrome P-450 (CYP).	Cyclosporine	106-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-178
12814453-1	2003	AIMS: Nafcillin (Wyeth Laboratories, Philadelphia, PA, USA) has been reported to induce the metabolism of cyclosporin and warfarin, which are known substrates of cytochrome P-450 (CYP).	Cyclosporine	106-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-183
12877795-6	2003	CsA (10(-8) - 10(-6) mol/L) inhibited lung fibroblast (3)H-TdR incorporation induced by bFGF in a dose-dependent manner, with the inhibitory rates by 20%, 46% and 66% (P &lt; 0.01).	Cyclosporine	0-3	fibroblast growth factor 2	Homo sapiens	88-92
12877795-7	2003	CsA (10(-7) - 10(-6) mol/L) inhibited (3)H-proline incorporation in lung fibroblasts stimulated by bFGF, with the inhibitory rates by 21% and 37% (P &lt; 0.01).	Cyclosporine	0-3	fibroblast growth factor 2	Homo sapiens	99-103
12877795-8	2003	In a culture medium, CsA (10(-8) - 10(-6) mol/L) inhibited (3)H-proline secretion induced by bFGF in a dose-dependent manner, with the inhibitory rates by 19%, 29% (P &lt; 0.05) and 56% (P &lt; 0.01).	Cyclosporine	21-24	fibroblast growth factor 2	Homo sapiens	93-97
12818611-5	2003	In comparison with persons who were not exposed to CSA, the likelihood of experiencing each category of ACE increased 2- to 3.4-fold for women and 1.6- to 2.5-fold for men (p &lt; 0.05).	Cyclosporine	51-54	angiotensin I converting enzyme	Homo sapiens	104-107
12818611-6	2003	The adjusted mean ACE score showed a significant positive graded relationship to the severity, duration, and frequency of CSA and an inverse relationship to age at first occurrence of CSA (p &lt; 0.01).	Cyclosporine	122-125	angiotensin I converting enzyme	Homo sapiens	18-21
12818611-6	2003	The adjusted mean ACE score showed a significant positive graded relationship to the severity, duration, and frequency of CSA and an inverse relationship to age at first occurrence of CSA (p &lt; 0.01).	Cyclosporine	184-187	angiotensin I converting enzyme	Homo sapiens	18-21
12942158-3	2003	The inhibition of calcineurin activation by cyclosporin A and FK-506 blocks T-cell receptor-mediated production of interleukin-2 (IL-2), a growth factor critical for T-cell proliferation.	Cyclosporine	44-57	interleukin 2	Homo sapiens	130-134
12753284-13	2003	Patients under treatment with cyclosporine (CsA) showed increased concentrations of osteocalcin and D-pyr and higher lumbar bone mineral density (BMD), but bone histomorphometry was not influenced by CsA.	Cyclosporine	30-42	bone gamma-carboxyglutamate protein	Homo sapiens	84-95
12910207-5	2003	Cyclosporin has a specific effect, because it inhibits interleukin-2 transcription and, consequently, the specific activation of T lymphocytes.	Cyclosporine	0-11	interleukin 2	Homo sapiens	55-68
12817518-0	2003	The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients.	Cyclosporine	56-68	ATP binding cassette subfamily B member 1	Homo sapiens	25-29
12817518-1	2003	Variability in CYP3A (CYP3A4/5) and P-glycoprotein (human MDR1 gene product) activity underlies interindividual differences in oral cyclosporine (CsA) bioavailability.	Cyclosporine	132-144	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	15-20
12817518-1	2003	Variability in CYP3A (CYP3A4/5) and P-glycoprotein (human MDR1 gene product) activity underlies interindividual differences in oral cyclosporine (CsA) bioavailability.	Cyclosporine	132-144	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	22-30
12817518-1	2003	Variability in CYP3A (CYP3A4/5) and P-glycoprotein (human MDR1 gene product) activity underlies interindividual differences in oral cyclosporine (CsA) bioavailability.	Cyclosporine	132-144	ATP binding cassette subfamily B member 1	Homo sapiens	36-50
12817518-1	2003	Variability in CYP3A (CYP3A4/5) and P-glycoprotein (human MDR1 gene product) activity underlies interindividual differences in oral cyclosporine (CsA) bioavailability.	Cyclosporine	132-144	ATP binding cassette subfamily B member 1	Homo sapiens	58-62
12817518-1	2003	Variability in CYP3A (CYP3A4/5) and P-glycoprotein (human MDR1 gene product) activity underlies interindividual differences in oral cyclosporine (CsA) bioavailability.	Cyclosporine	146-149	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	15-20
12817518-1	2003	Variability in CYP3A (CYP3A4/5) and P-glycoprotein (human MDR1 gene product) activity underlies interindividual differences in oral cyclosporine (CsA) bioavailability.	Cyclosporine	146-149	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	22-30
12817518-1	2003	Variability in CYP3A (CYP3A4/5) and P-glycoprotein (human MDR1 gene product) activity underlies interindividual differences in oral cyclosporine (CsA) bioavailability.	Cyclosporine	146-149	ATP binding cassette subfamily B member 1	Homo sapiens	36-50
12817518-1	2003	Variability in CYP3A (CYP3A4/5) and P-glycoprotein (human MDR1 gene product) activity underlies interindividual differences in oral cyclosporine (CsA) bioavailability.	Cyclosporine	146-149	ATP binding cassette subfamily B member 1	Homo sapiens	58-62
12817518-3	2003	Our objective was to evaluate the effect of CYP3A5 and MDR1 polymorphic expression on CsA oral disposition.	Cyclosporine	86-89	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	44-50
12817518-3	2003	Our objective was to evaluate the effect of CYP3A5 and MDR1 polymorphic expression on CsA oral disposition.	Cyclosporine	86-89	ATP binding cassette subfamily B member 1	Homo sapiens	55-59
12817518-8	2003	MDR1 C3435T genotype was identified as the best predictor of CsA systemic exposure.	Cyclosporine	61-64	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
12817518-14	2003	Thus, the MDR1 C3435T genotype offers a potential mechanistic basis to explain interracial differences in CsA oral bioavailability.	Cyclosporine	106-109	ATP binding cassette subfamily B member 1	Homo sapiens	10-14
12753284-13	2003	Patients under treatment with cyclosporine (CsA) showed increased concentrations of osteocalcin and D-pyr and higher lumbar bone mineral density (BMD), but bone histomorphometry was not influenced by CsA.	Cyclosporine	44-47	bone gamma-carboxyglutamate protein	Homo sapiens	84-95
12826225-0	2003	Additive effects of oxidized low-density lipoproteins and cyclosporine on endothelin-1 production of renal arterial endothelial cells.	Cyclosporine	58-70	endothelin 1	Homo sapiens	74-86
12761338-0	2003	Inhibition of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus in primary, mature islets of transgenic mice.	Cyclosporine	78-91	insulin	Homo sapiens	20-27
12761338-8	2003	After stimulation with glucose, human insulin promoter-mediated gene expression was inhibited in normal, mature islet cells by both tacrolimus and cyclosporin A to a large extent (approximately 70%) and with high potency at concentrations that are known to inhibit calcineurin phosphatase activity (IC50 values of 1 and 35 nM, respectively).	Cyclosporine	147-160	insulin	Homo sapiens	38-45
12761338-10	2003	The high potency of cyclosporin A and tacrolimus in normal islets suggests that inhibition of insulin gene transcription by cyclosporin A and tacrolimus is clinically important and is one mechanism of the diabetogenic effect of these immunosuppressive drugs.	Cyclosporine	20-33	insulin	Homo sapiens	94-101
12761338-10	2003	The high potency of cyclosporin A and tacrolimus in normal islets suggests that inhibition of insulin gene transcription by cyclosporin A and tacrolimus is clinically important and is one mechanism of the diabetogenic effect of these immunosuppressive drugs.	Cyclosporine	124-137	insulin	Homo sapiens	94-101
12817895-4	2003	Cyclosporin A (CsA) was used as a model compound for P-gp mediated efflux.	Cyclosporine	15-18	ATP binding cassette subfamily B member 1	Homo sapiens	53-57
12766558-0	2003	Association of the CYP3A4*1B 5"-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects.	Cyclosporine	66-78	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	19-25
12730091-6	2003	VLDL-induced NFAT translocation and proliferation were blocked by cyclosporin A and LY294002 involving calcineurin and phosphatidylinositol 3-kinase (PI3K) pathways.	Cyclosporine	66-79	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta	Rattus norvegicus	119-148
12704789-7	2003	Here we show that CWSV-1 cells treated with cyclosporine A, which prevents opening of mitochondrial membrane pores required for ROS generation, inhibits TGFbeta1-induced apoptosis.	Cyclosporine	44-58	transforming growth factor, beta 1	Rattus norvegicus	153-161
12642584-6	2003	cis-(Z)-Flupentixol-induced complex formation requires involvement of the Pgp substrate site, because agents that either physically compete (cyclosporin A) for or indirectly occlude (vanadate) the substrate-binding site prevent formation of the complex.	Cyclosporine	141-154	ATP binding cassette subfamily B member 1	Homo sapiens	74-77
12777847-6	2003	Basiliximab and cyclosporine had little effect on apoptosis, but did alter Bcl-2 and Fas expression.	Cyclosporine	16-28	BCL2 apoptosis regulator	Homo sapiens	75-80
12798218-4	2003	RESULTS: The cyclosporine dose correlated with the MEGX test (r=0.38, P=0.01) and with the ICG (r=0.38, P=0.0001) and BSP (r=0.37, P=0.0002) clearances; it had an inverse correlation with transaminases (AST: r=0.38, P=0.0001) and histological lesions (r=-0.29, P=0.005).	Cyclosporine	13-25	solute carrier family 17 member 5	Homo sapiens	203-206
12611882-8	2003	Both the early release of proteins like cytochrome c and Hsp60 from the mitochondria as well as the later translocation of the active caspase-9/-3 are partially inhibited by cyclosporin A, an inhibitor of mitochondrial membrane permeabilization.	Cyclosporine	174-187	cytochrome c, somatic	Homo sapiens	40-52
12695292-8	2003	UA and CSA were associated with a significant increase in the frequency of CD4+ T cells that produced IFN-gamma, whereas these conditions caused no significant difference in the frequency of CD4+ T cells that produced IL-4.	Cyclosporine	7-10	interferon gamma	Homo sapiens	102-111
12798218-6	2003	In the longitudinal study, the percent variation of AST correlated inversely with that of cyclosporine dose (r=-0.62, P=0.0002).	Cyclosporine	90-102	solute carrier family 17 member 5	Homo sapiens	52-55
12697421-9	2003	These results suggest that activation of DEX-sensitive, CSA-resistant MEK/ERK and p38 pathways, and activation of NF-kappaB, PKC, and PTK are essential for IL-8 and MCP-1 expression by hRPE cells.	Cyclosporine	56-59	mitogen-activated protein kinase 1	Mus musculus	74-77
12697421-8	2003	In addition, anti-inflammatory drugs dexamethasone (DEX) and cyclosporin A (CSA) both blocked activation of JNKS/SAPK and the cell-cell contact induced production of hRPE IL-8 and MCP-1, while activation of p38 and ERK was only inhibited by DEX, but not by CSA.	Cyclosporine	61-74	mitogen-activated protein kinase 9	Homo sapiens	113-117
12697421-8	2003	In addition, anti-inflammatory drugs dexamethasone (DEX) and cyclosporin A (CSA) both blocked activation of JNKS/SAPK and the cell-cell contact induced production of hRPE IL-8 and MCP-1, while activation of p38 and ERK was only inhibited by DEX, but not by CSA.	Cyclosporine	61-74	mitogen-activated protein kinase 1	Homo sapiens	207-210
12697421-8	2003	In addition, anti-inflammatory drugs dexamethasone (DEX) and cyclosporin A (CSA) both blocked activation of JNKS/SAPK and the cell-cell contact induced production of hRPE IL-8 and MCP-1, while activation of p38 and ERK was only inhibited by DEX, but not by CSA.	Cyclosporine	61-74	mitogen-activated protein kinase 1	Homo sapiens	215-218
12697421-8	2003	In addition, anti-inflammatory drugs dexamethasone (DEX) and cyclosporin A (CSA) both blocked activation of JNKS/SAPK and the cell-cell contact induced production of hRPE IL-8 and MCP-1, while activation of p38 and ERK was only inhibited by DEX, but not by CSA.	Cyclosporine	76-79	mitogen-activated protein kinase 9	Homo sapiens	113-117
12697421-8	2003	In addition, anti-inflammatory drugs dexamethasone (DEX) and cyclosporin A (CSA) both blocked activation of JNKS/SAPK and the cell-cell contact induced production of hRPE IL-8 and MCP-1, while activation of p38 and ERK was only inhibited by DEX, but not by CSA.	Cyclosporine	76-79	mitogen-activated protein kinase 1	Homo sapiens	207-210
12697421-8	2003	In addition, anti-inflammatory drugs dexamethasone (DEX) and cyclosporin A (CSA) both blocked activation of JNKS/SAPK and the cell-cell contact induced production of hRPE IL-8 and MCP-1, while activation of p38 and ERK was only inhibited by DEX, but not by CSA.	Cyclosporine	76-79	mitogen-activated protein kinase 1	Homo sapiens	215-218
12684049-7	2003	The increase of astrocytic GDNF mRNA by ET-1 was inhibited by BAPTA/AM (30 microM) and PD98059 (50 microM), but not by calphostin C, staurosporine, and cyclosporine A.	Cyclosporine	152-166	endothelin 1	Rattus norvegicus	40-44
12831511-6	2003	The uptake and efflux of Rhodamine123, an MDR1 substrate, in Caco/DX cells were significantly less and greater, respectively, than those in Caco-2 cells, and these transports were affected by the addition of ciclosporin.	Cyclosporine	208-219	ATP binding cassette subfamily B member 1	Homo sapiens	42-46
12751630-7	2003	CONCLUSIONS: The results suggest that the effects of surfactants via micellar solubilization and inhibition of P-gp efflux on CsA transport in Caco-2 cells are significant.	Cyclosporine	126-129	ATP binding cassette subfamily B member 1	Homo sapiens	111-115
12706476-1	2003	Immunophilin ligands, cyclosporine A and FK506 (tacrolimus), besides their immunosuppressive action, have several effects on different neural functions, such as modulation of the release of many neurotransmitters, the reduction of nitric oxide (NO) production by the inhibition of dephosphorylation of neuronal nitric oxide synthase (nNOS) and the alteration of the expression of certain genes.	Cyclosporine	22-36	nitric oxide synthase, brain	Cavia porcellus	302-332
12706476-1	2003	Immunophilin ligands, cyclosporine A and FK506 (tacrolimus), besides their immunosuppressive action, have several effects on different neural functions, such as modulation of the release of many neurotransmitters, the reduction of nitric oxide (NO) production by the inhibition of dephosphorylation of neuronal nitric oxide synthase (nNOS) and the alteration of the expression of certain genes.	Cyclosporine	22-36	nitric oxide synthase, brain	Cavia porcellus	334-338
12639710-3	2003	NF-kappaB activation by CnA was associated with elevated phospho-IkappaBalpha, and could be repressed by specific genetic (porZAKI-4 and porDSCR1) and chemical (cyclosporin A) inhibitors of CnA, but tumour necrosis factor-alpha (TNF-alpha) appeared not to be a key component in the cross-talk.	Cyclosporine	161-174	tumor necrosis factor	Mus musculus	229-238
12759722-3	2003	The use of angiotensin-converting enzyme (ACE) inhibitors in the anti-hypertensive treatment of renal transplant recipients who receive immunosuppression with cyclosporine has long been discussed controversially.	Cyclosporine	159-171	angiotensin I converting enzyme	Homo sapiens	11-40
12759722-3	2003	The use of angiotensin-converting enzyme (ACE) inhibitors in the anti-hypertensive treatment of renal transplant recipients who receive immunosuppression with cyclosporine has long been discussed controversially.	Cyclosporine	159-171	angiotensin I converting enzyme	Homo sapiens	42-45
12586829-9	2003	CsA stimulated the enzymatic activity in the presence of a peptide that mimicked the 557-576 sequence of HIF-1alpha.	Cyclosporine	0-3	hypoxia inducible factor 1 subunit alpha	Homo sapiens	105-115
12586829-12	2003	CsA effects were not observed when the proline residue corresponding to Pro-564 in the HIF-1alpha sequence was replaced by a hydroxyproline or an alanine residue.	Cyclosporine	0-3	hypoxia inducible factor 1 subunit alpha	Homo sapiens	87-97
12586829-14	2003	We conclude that CsA destabilizes HIF-1alpha by promoting hydroxylation of Pro-564 in the ODD domain.	Cyclosporine	17-20	hypoxia inducible factor 1 subunit alpha	Homo sapiens	34-44
12683694-12	2003	The elevated levels of vWF antigen are consistent with diffuse endothelial injury likely because of multiple interacting factors such as extensive prior therapy, GVHD, cyclosporine, and reactivation of cytomegalovirus.	Cyclosporine	168-180	von Willebrand factor	Homo sapiens	23-26
12698077-12	2003	SN in combination with CsA, however, markedly reduced expression of bFGF, vascular endothelial growth factor, and endothelin 1.	Cyclosporine	23-26	endothelin 1	Rattus norvegicus	114-126
14570377-4	2003	The cytochrome c release is shown to be equal to 27 +/- 4%, 40 +/- 12%, 70 +/- 5% at pH 7.4, 7.0, 6.5, respectively, the last value being reduced by cyclosporin A to 10 +/- 3%.	Cyclosporine	149-162	cytochrome c, somatic	Homo sapiens	4-16
14570377-6	2003	It is concluded that acidification of the high phosphate medium induces release of a large part of the cytochrome c pool from liver mitochondria due to opening the Ca(2+)-dependent cyclosporin A-sensitive permeability transition pore and subsequent high amplitude swelling.	Cyclosporine	181-194	cytochrome c, somatic	Homo sapiens	103-115
12691936-0	2003	Role of endothelin-1 in microvascular dysfunction caused by cyclosporin A.	Cyclosporine	60-73	endothelin 1	Homo sapiens	8-20
12689974-4	2003	SELECTION OF STUDIES: Randomised controlled trials comparing interleukin-2 receptor antibodies with placebo or no additional treatment in patients with renal transplants receiving ciclosporin based immunosuppression.	Cyclosporine	180-191	interleukin 2	Homo sapiens	61-74
12689974-10	2003	CONCLUSIONS: Adding interleukin-2 receptor antibodies to ciclosporin based immunosuppression reduces episodes of acute rejection at six months by 49%.	Cyclosporine	57-68	interleukin 2	Homo sapiens	20-33
12673034-3	2003	In this study, we demonstrated the inductive effects of phenobarbital, rifampicin, carbamazepine, phenytoin, prednisolone, ciclosporin and clotrimazole on CYP3A4, CYP3A5 and CYP3A7 mRNA expression, and established the relationship between the expression of human glucocorticoid receptor alpha (hGR) mRNA and the induction of CYP3A4 mRNA in cultured HepG2 cells by reverse transcription polymerase chain reaction (RT-PCR).	Cyclosporine	123-134	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	155-161
12673034-3	2003	In this study, we demonstrated the inductive effects of phenobarbital, rifampicin, carbamazepine, phenytoin, prednisolone, ciclosporin and clotrimazole on CYP3A4, CYP3A5 and CYP3A7 mRNA expression, and established the relationship between the expression of human glucocorticoid receptor alpha (hGR) mRNA and the induction of CYP3A4 mRNA in cultured HepG2 cells by reverse transcription polymerase chain reaction (RT-PCR).	Cyclosporine	123-134	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	163-169
12673034-3	2003	In this study, we demonstrated the inductive effects of phenobarbital, rifampicin, carbamazepine, phenytoin, prednisolone, ciclosporin and clotrimazole on CYP3A4, CYP3A5 and CYP3A7 mRNA expression, and established the relationship between the expression of human glucocorticoid receptor alpha (hGR) mRNA and the induction of CYP3A4 mRNA in cultured HepG2 cells by reverse transcription polymerase chain reaction (RT-PCR).	Cyclosporine	123-134	cytochrome P450 family 3 subfamily A member 7	Homo sapiens	174-180
12673034-3	2003	In this study, we demonstrated the inductive effects of phenobarbital, rifampicin, carbamazepine, phenytoin, prednisolone, ciclosporin and clotrimazole on CYP3A4, CYP3A5 and CYP3A7 mRNA expression, and established the relationship between the expression of human glucocorticoid receptor alpha (hGR) mRNA and the induction of CYP3A4 mRNA in cultured HepG2 cells by reverse transcription polymerase chain reaction (RT-PCR).	Cyclosporine	123-134	nuclear receptor subfamily 3 group C member 1	Homo sapiens	263-286
12673034-3	2003	In this study, we demonstrated the inductive effects of phenobarbital, rifampicin, carbamazepine, phenytoin, prednisolone, ciclosporin and clotrimazole on CYP3A4, CYP3A5 and CYP3A7 mRNA expression, and established the relationship between the expression of human glucocorticoid receptor alpha (hGR) mRNA and the induction of CYP3A4 mRNA in cultured HepG2 cells by reverse transcription polymerase chain reaction (RT-PCR).	Cyclosporine	123-134	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	325-331
12673034-6	2003	The induction of CYP3A4 mRNA expression by clotrimazole and ciclosporin was negligible.	Cyclosporine	60-71	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	17-23
12673034-7	2003	Treatment with phenytoin, rifampicin, carbamazepine and ciclosporin induced approximately 2-fold increases in the expression of CYP3A5 mRNA, although prednisolone, phenytoin and clotrimazole had no effect.	Cyclosporine	56-67	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	128-134
12673034-8	2003	Treatment with rifampicin, phenytoin, clotrimazole and ciclosporin resulted in approximately a 2-fold induction of the CYP3A7 mRNA level.	Cyclosporine	55-66	cytochrome P450 family 3 subfamily A member 7	Homo sapiens	119-125
12673034-12	2003	Furthermore, we studied the associations between the expression of hGRalpha mRNA and the induced level of CYP3A4 mRNA by prednisolone and ciclosporin.	Cyclosporine	138-149	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-112
12673034-13	2003	Treatment with both prednisolone and ciclosporin showed synergistic effects on induction of CYP3A4 mRNA and, following treatment with both drugs, the expression level of CYP3A4 mRNA was 2-fold greater compared with prednisolone alone after the fifth day.	Cyclosporine	37-48	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	92-98
12673034-13	2003	Treatment with both prednisolone and ciclosporin showed synergistic effects on induction of CYP3A4 mRNA and, following treatment with both drugs, the expression level of CYP3A4 mRNA was 2-fold greater compared with prednisolone alone after the fifth day.	Cyclosporine	37-48	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	170-176
12747447-3	2003	The aim of this study was to investigate the effect of cyclosporin on matrix metalloproteinases (MMP)-1 and tissue inhibitors of MMP (TIMP)-1 expression at the mRNA, protein, and enzyme activity levels.	Cyclosporine	55-66	TIMP metallopeptidase inhibitor 1	Homo sapiens	108-141
12531223-1	2003	The cyclosporine analog Valspodar (PSC 833, Novartis Pharma) is a strong inhibitor of the mdr1 gene product p-glycoprotein (pgp).	Cyclosporine	4-16	ATP binding cassette subfamily B member 1	Homo sapiens	90-94
12531223-1	2003	The cyclosporine analog Valspodar (PSC 833, Novartis Pharma) is a strong inhibitor of the mdr1 gene product p-glycoprotein (pgp).	Cyclosporine	4-16	ATP binding cassette subfamily B member 1	Homo sapiens	108-122
12531223-1	2003	The cyclosporine analog Valspodar (PSC 833, Novartis Pharma) is a strong inhibitor of the mdr1 gene product p-glycoprotein (pgp).	Cyclosporine	4-16	ATP binding cassette subfamily B member 1	Homo sapiens	124-127
12868191-0	2003	[Concentration of tissue plasminogen activator and its inhibitor 1 in cyclosporine A-treated children with idiopathic nephrotic syndrome].	Cyclosporine	70-84	protein phosphatase 1 regulatory inhibitor subunit 1A	Homo sapiens	55-66
12700632-5	2003	Exogenous ROS also induced mitochondrial permeability transition (PT) pore opening and cytochrome c release in isolated mitochondria, which could be blocked by inhibition of PT with cyclosporin A.	Cyclosporine	182-195	cytochrome c, somatic	Homo sapiens	87-99
12657888-0	2003	Effects of cyclosporine-A on brain lipids and apolipoprotein E, J gene expression in rats.	Cyclosporine	11-25	apolipoprotein E	Rattus norvegicus	46-62
12624190-9	2003	Treatment with cyclosporine blocked the (i) elevation of plasma nitrate + nitrite, (ii) up-regulation of iNOS protein, (iii) decrease in Fe-S cluster EPR signal, (iv) formation of dinitrosyl-iron complexes, and (v) loss of aconitase enzyme activity.	Cyclosporine	15-27	nitric oxide synthase 2	Homo sapiens	105-109
12612995-0	2003	Cyclosporine treatment for patients with CRF who developed pure red blood cell aplasia following EPO therapy.	Cyclosporine	0-12	erythropoietin	Homo sapiens	97-100
12799206-11	2003	The cytolytic response was inhibited maximally only when CsA was added to the combination of anti-CD80/86.	Cyclosporine	57-60	CD80 molecule	Macaca mulatta	98-102
12644839-5	2003	Cyclosporin A interfered with Taxol (0.1 microM)-induced AKT activation and BAD phosphorylation.	Cyclosporine	0-13	AKT serine/threonine kinase 1	Homo sapiens	57-60
12644839-9	2003	Our results indicate that the combination of cyclosporin A and Taxol is effective in the reversal of Taxol resistance through the inhibition of PI3 kinase-AKT1 pathway.	Cyclosporine	45-58	AKT serine/threonine kinase 1	Homo sapiens	155-159
12514115-6	2003	We found that CsA-induced cell death is independent of caspase activation, p53 induction, and calcineurin inhibition.	Cyclosporine	14-17	tumor protein p53	Homo sapiens	75-78
12614449-10	2003	In immunoblotting studies, ascomycin and cyclosporin A reduced IgE-dependent p38 MAPK activation but were less potent at reducing ERK phosphorylation in basophils.	Cyclosporine	41-54	mitogen-activated protein kinase 1	Homo sapiens	77-80
12614449-10	2003	In immunoblotting studies, ascomycin and cyclosporin A reduced IgE-dependent p38 MAPK activation but were less potent at reducing ERK phosphorylation in basophils.	Cyclosporine	41-54	mitogen-activated protein kinase 3	Homo sapiens	81-85
12612910-11	2003	Finally, the mGSH depletion induced by acetaldehyde sensitized HepG2 cells to tumor necrosis factor (TNF)-alpha-induced apoptosis that was prevented by cyclosporin A, GSH ethyl ester, and lovastatin.	Cyclosporine	152-165	tumor necrosis factor	Homo sapiens	78-111
12619929-2	2003	Cyclosporine, complexed with the appropriate immunophilin, inhibits calcineurin (the calcium/calmodulin dependent serine/threonine phosphatase) activity.	Cyclosporine	0-12	calmodulin 1	Homo sapiens	93-103
16120330-4	2003	Carvedilol and cyclosporine A (CyA) reduced both cytochrome c release and alterations in membrane fluidity induced by CDCA.	Cyclosporine	15-29	cytochrome c, somatic	Homo sapiens	49-61
12631071-2	2003	In this study, we examine the effect of the extracellular signal-regulated protein kinase (ERK) 1/2 and p38 mitogen-activated protein kinase (MAPK) pathways on the basal transepithelial resistance (TER) and on the CsA-induced increase in TER across MDCK monolayers.	Cyclosporine	214-217	mitogen-activated protein kinase 1	Canis lupus familiaris	44-99
12631071-2	2003	In this study, we examine the effect of the extracellular signal-regulated protein kinase (ERK) 1/2 and p38 mitogen-activated protein kinase (MAPK) pathways on the basal transepithelial resistance (TER) and on the CsA-induced increase in TER across MDCK monolayers.	Cyclosporine	214-217	mitogen-activated protein kinase 14	Canis lupus familiaris	104-140
12631071-3	2003	Here we present evidence that CsA may be mediating some of its effects through activation of the ERK 1/2 MAPK pathway.	Cyclosporine	30-33	mitogen-activated protein kinase 1	Canis lupus familiaris	97-104
12631071-3	2003	Here we present evidence that CsA may be mediating some of its effects through activation of the ERK 1/2 MAPK pathway.	Cyclosporine	30-33	mitogen-activated protein kinase 1	Canis lupus familiaris	105-109
12631071-8	2003	The ERK 1/2 inhibitor PD98059 decreased basal TER and also ameliorated the CsA-induced increase in TER.	Cyclosporine	75-78	mitogen-activated protein kinase 1	Canis lupus familiaris	4-11
12631071-11	2003	CsA was shown to significantly activate ERK 1/2 and this activation by CsA was prevented by PD98059.	Cyclosporine	0-3	mitogen-activated protein kinase 1	Canis lupus familiaris	40-47
12631071-11	2003	CsA was shown to significantly activate ERK 1/2 and this activation by CsA was prevented by PD98059.	Cyclosporine	71-74	mitogen-activated protein kinase 1	Canis lupus familiaris	40-47
12631071-12	2003	Inhibition of the p38 pathway by SB203580 also resulted in activation of ERK 1/2 and this activation of ERK 1/2 was further enhanced by CsA.	Cyclosporine	136-139	mitogen-activated protein kinase 1	Canis lupus familiaris	73-80
12631071-12	2003	Inhibition of the p38 pathway by SB203580 also resulted in activation of ERK 1/2 and this activation of ERK 1/2 was further enhanced by CsA.	Cyclosporine	136-139	mitogen-activated protein kinase 1	Canis lupus familiaris	104-111
16120330-4	2003	Carvedilol and cyclosporine A (CyA) reduced both cytochrome c release and alterations in membrane fluidity induced by CDCA.	Cyclosporine	31-34	cytochrome c, somatic	Homo sapiens	49-61
12589150-8	2003	At a molecular level, increased expression of angiotensin II protein, osteopontin, and TGF-beta1 mRNAs in the CsA group were significantly decreased with MMF, and further decrease was observed with the combined treatment using MMF and LSRT.	Cyclosporine	110-113	angiotensinogen	Rattus norvegicus	46-60
12573279-3	2003	In cyclosporin-sensitive and calcium-induced mitochondrial permeability transition (MPT) a release of cyto-c can also be observed.	Cyclosporine	3-14	cytochrome c, somatic	Homo sapiens	102-108
12574351-9	2003	Cyclosporin A, but not cyclosporin H, inhibited protein L-induced release of IL-4 and IL-13 from basophils.	Cyclosporine	0-13	interleukin 4	Homo sapiens	77-81
12574351-9	2003	Cyclosporin A, but not cyclosporin H, inhibited protein L-induced release of IL-4 and IL-13 from basophils.	Cyclosporine	0-13	interleukin 13	Homo sapiens	86-91
12589150-8	2003	At a molecular level, increased expression of angiotensin II protein, osteopontin, and TGF-beta1 mRNAs in the CsA group were significantly decreased with MMF, and further decrease was observed with the combined treatment using MMF and LSRT.	Cyclosporine	110-113	transforming growth factor, beta 1	Rattus norvegicus	87-96
12591057-2	2003	Because cyclosporine acts by inhibiting interleukin-2 (IL-2) production, we studied the efficacy and safety of humanized anti-IL2 receptor (CD25) antibodies daclizumab for refractory UC in an open label pilot study.	Cyclosporine	8-20	interleukin 2	Homo sapiens	40-53
12591057-2	2003	Because cyclosporine acts by inhibiting interleukin-2 (IL-2) production, we studied the efficacy and safety of humanized anti-IL2 receptor (CD25) antibodies daclizumab for refractory UC in an open label pilot study.	Cyclosporine	8-20	interleukin 2	Homo sapiens	55-59
12562644-1	2003	BACKGROUND: Pharmacokinetic study has shown that co-administration of cyclosporin A (CsA), which acts as a P-glycoprotein (P-gp) and CYP-3A blocker, resulted in an 8-fold increase in the systemic exposure of oral paclitaxel.	Cyclosporine	70-83	ATP binding cassette subfamily B member 1	Homo sapiens	107-121
12562644-1	2003	BACKGROUND: Pharmacokinetic study has shown that co-administration of cyclosporin A (CsA), which acts as a P-glycoprotein (P-gp) and CYP-3A blocker, resulted in an 8-fold increase in the systemic exposure of oral paclitaxel.	Cyclosporine	85-88	ATP binding cassette subfamily B member 1	Homo sapiens	107-121
12562644-1	2003	BACKGROUND: Pharmacokinetic study has shown that co-administration of cyclosporin A (CsA), which acts as a P-glycoprotein (P-gp) and CYP-3A blocker, resulted in an 8-fold increase in the systemic exposure of oral paclitaxel.	Cyclosporine	70-83	ATP binding cassette subfamily B member 1	Homo sapiens	123-127
12562644-1	2003	BACKGROUND: Pharmacokinetic study has shown that co-administration of cyclosporin A (CsA), which acts as a P-glycoprotein (P-gp) and CYP-3A blocker, resulted in an 8-fold increase in the systemic exposure of oral paclitaxel.	Cyclosporine	85-88	ATP binding cassette subfamily B member 1	Homo sapiens	123-127
12562644-1	2003	BACKGROUND: Pharmacokinetic study has shown that co-administration of cyclosporin A (CsA), which acts as a P-glycoprotein (P-gp) and CYP-3A blocker, resulted in an 8-fold increase in the systemic exposure of oral paclitaxel.	Cyclosporine	85-88	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	133-139
12562644-1	2003	BACKGROUND: Pharmacokinetic study has shown that co-administration of cyclosporin A (CsA), which acts as a P-glycoprotein (P-gp) and CYP-3A blocker, resulted in an 8-fold increase in the systemic exposure of oral paclitaxel.	Cyclosporine	70-83	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	133-139
12588317-1	2003	Induction of transforming growth factor beta (TGF-beta) by the immunosuppressive drug cyclosporin A (CsA) in activated lymphocytes has been claimed to add to the renal pro-fibrotic effects of CsA.	Cyclosporine	101-104	transforming growth factor beta 1	Homo sapiens	13-44
12588317-1	2003	Induction of transforming growth factor beta (TGF-beta) by the immunosuppressive drug cyclosporin A (CsA) in activated lymphocytes has been claimed to add to the renal pro-fibrotic effects of CsA.	Cyclosporine	101-104	transforming growth factor beta 1	Homo sapiens	46-54
12588317-9	2003	Furthermore, up-regulation of Cox-2 mRNA was inhibited by CsA.	Cyclosporine	58-61	prostaglandin-endoperoxide synthase 2	Homo sapiens	30-35
12490546-8	2003	Stimulation of transfected cells with AngII or specific AT2-receptor agonists resulted in a significant increase in eNOS promoter activity, which was blocked by CsA, MCIP1, and mutation of an upstream NF-AT site.	Cyclosporine	161-164	angiotensinogen	Rattus norvegicus	38-43
12744774-8	2003	In patients undergoing CsA monotherapy (ex vivo study, n = 9), we found a significant suppression of IL-2 mRNA levels in 4 of 9 patients ex vivo.	Cyclosporine	23-26	interleukin 2	Homo sapiens	101-105
12538738-12	2003	eNOS was significantly reduced in the endothelium of arterioles in the kidneys of mice treated with CsA, whereas iNOS was induced in the cortical tubules.	Cyclosporine	100-103	nitric oxide synthase 2, inducible	Mus musculus	113-117
12586544-6	2003	Interestingly, the rapid degradation of NF-kappaB inhibitor IkappaBalpha induced by Pa- and beta-endorphin was reversed by a pretreatment with H-89 and cyclosporin A, inhibitors of protein kinase A (PKA) and protein phosphatase 2B (PP2B), respectively.	Cyclosporine	152-165	NFKB inhibitor alpha	Homo sapiens	60-72
12538746-3	2003	This study was designed to determine P(alb) activity before, during, and after 24 wk of treatment with cyclosporine or placebo given as part of a randomized controlled trial in steroid-resistant FSGS patients with nephrotic range proteinuria.	Cyclosporine	103-115	albumin	Homo sapiens	39-42
12586544-6	2003	Interestingly, the rapid degradation of NF-kappaB inhibitor IkappaBalpha induced by Pa- and beta-endorphin was reversed by a pretreatment with H-89 and cyclosporin A, inhibitors of protein kinase A (PKA) and protein phosphatase 2B (PP2B), respectively.	Cyclosporine	152-165	proopiomelanocortin	Homo sapiens	92-106
12563178-0	2003	Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients.	Cyclosporine	97-108	ATP binding cassette subfamily B member 1	Homo sapiens	78-82
12541065-0	2003	Cyclosporin A-mediated killing of Leishmania major by macrophages is independent of reactive nitrogen and endogenous TNF-alpha and is not inhibited by IL-10 and 13.	Cyclosporine	0-13	tumor necrosis factor	Mus musculus	117-120
12563178-1	2003	Intestinal cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) both play a vital role in the metabolism of oral cyclosporine (CsA).	Cyclosporine	115-127	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	32-38
12563178-1	2003	Intestinal cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) both play a vital role in the metabolism of oral cyclosporine (CsA).	Cyclosporine	129-132	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	32-38
12591359-0	2003	Apoptosis and expression of BCL-2 and BAX in cyclosporine-induced experimental renal fibrosis.	Cyclosporine	45-57	BCL2 apoptosis regulator	Homo sapiens	28-33
12728666-0	2003	[Increased thrombin-genesis in cyclosporine A-treated idiopathic nephrotic syndrome in children].	Cyclosporine	31-45	coagulation factor II, thrombin	Homo sapiens	11-19
12563113-0	2003	Cyclosporin A induced internalization of the bile salt export pump in isolated rat hepatocyte couplets.	Cyclosporine	0-13	ATP binding cassette subfamily B member 11	Rattus norvegicus	45-66
12563113-3	2003	Compared to controls (DMSO-treated cells), CsA, in the approximate range of concentrations used therapeutically, caused inhibition of CVA of CLF, disorganization of the bile salt export pump (Bsep) localization at canalicular level resulting in its relocation into the cell, and disruption of the pericanalicular F-actin cytoskeleton.	Cyclosporine	43-46	ATP binding cassette subfamily B member 11	Rattus norvegicus	169-190
12563113-3	2003	Compared to controls (DMSO-treated cells), CsA, in the approximate range of concentrations used therapeutically, caused inhibition of CVA of CLF, disorganization of the bile salt export pump (Bsep) localization at canalicular level resulting in its relocation into the cell, and disruption of the pericanalicular F-actin cytoskeleton.	Cyclosporine	43-46	ATP binding cassette subfamily B member 11	Rattus norvegicus	192-196
12591359-0	2003	Apoptosis and expression of BCL-2 and BAX in cyclosporine-induced experimental renal fibrosis.	Cyclosporine	45-57	BCL2 associated X, apoptosis regulator	Homo sapiens	38-41
12427739-4	2003	VEGF-induced NFATc1 nuclear translocation was inhibited by either cyclosporin A or a calcineurin-specific peptide inhibitor; these findings suggest that VEGF stimulates NFATc1 nuclear import in human pulmonary valve endothelial cells by a calcineurin-dependent mechanism.	Cyclosporine	66-79	vascular endothelial growth factor A	Homo sapiens	0-4
12783679-6	2003	The peak of FKN mRNA expression (0.8 +/- 0.26) appeared on the seventh day after transplantation, which could be down-regulated by CsA significantly (t = 2.390, P &lt; 0.05).	Cyclosporine	131-134	C-X3-C motif chemokine ligand 1	Rattus norvegicus	12-15
12427739-4	2003	VEGF-induced NFATc1 nuclear translocation was inhibited by either cyclosporin A or a calcineurin-specific peptide inhibitor; these findings suggest that VEGF stimulates NFATc1 nuclear import in human pulmonary valve endothelial cells by a calcineurin-dependent mechanism.	Cyclosporine	66-79	vascular endothelial growth factor A	Homo sapiens	153-157
12427739-5	2003	Importantly, both cyclosporin A and the calcineurin-specific peptide inhibitor reduced VEGF-induced human pulmonary valve endothelial cell proliferation, indicating a functional role for NFATc1 in endothelial growth.	Cyclosporine	18-31	vascular endothelial growth factor A	Homo sapiens	87-91
12666991-7	2003	After 2 days of cyclosporine-A treatment, we observed by immunohistochemistry and immunoblotting a distinct decrease in all mGluRs and their expression had almost completely disappeared after 21 days of treatment.	Cyclosporine	16-30	glutamyl-tRNA synthetase 2, mitochondrial	Mus musculus	124-130
12666991-8	2003	The results clearly indicate that: 1) mGluR2/3, 4 and 5 are widely expressed in thymic cells; 2) the mGluR5 subtype is expressed most strongly in medullary cells; and 3) cyclosporine-A rapidly inhibits expression of all mGluR subtypes after 2 days of treatment and their complete disappearance after prolonged treatment.	Cyclosporine	170-184	glutamate receptor, metabotropic 2	Mus musculus	38-55
12508271-0	2003	Cyclosporin A induces erythroid differentiation of K562 cells through p38 MAPK and ERK pathways.	Cyclosporine	0-13	mitogen-activated protein kinase 14	Homo sapiens	70-73
12508271-0	2003	Cyclosporin A induces erythroid differentiation of K562 cells through p38 MAPK and ERK pathways.	Cyclosporine	0-13	mitogen-activated protein kinase 1	Homo sapiens	83-86
12508271-4	2003	p38 inhibitor (SB203580) prevented CsA-induced hemoglobin synthesis in K562 cells, although MEK/ERK inhibitor (U0126) enhanced it by 3.3 times in K562 cells.	Cyclosporine	35-38	mitogen-activated protein kinase 14	Homo sapiens	0-3
12508271-5	2003	These results indicate activation of p38 and inactivation of ERK are involved in CsA-induced erythroid differentiation of K562 cells.	Cyclosporine	81-84	mitogen-activated protein kinase 14	Homo sapiens	37-40
12508271-5	2003	These results indicate activation of p38 and inactivation of ERK are involved in CsA-induced erythroid differentiation of K562 cells.	Cyclosporine	81-84	mitogen-activated protein kinase 1	Homo sapiens	61-64
12848377-0	2003	Influence of long term cyclosporine therapy on insulin and its precursors secretion in patients after heart transplantation.	Cyclosporine	23-35	insulin	Homo sapiens	47-54
12848377-7	2003	We observed a statistically significant negative correlation between CyA concentration and insulin in both groups, a statistically significant negative correlation between CyA concentration and proinsulin, C-peptide blood level in group 1 and statistically significant positive correlation between CyA and glucose blood level in both groups.	Cyclosporine	69-72	insulin	Homo sapiens	91-98
12848377-7	2003	We observed a statistically significant negative correlation between CyA concentration and insulin in both groups, a statistically significant negative correlation between CyA concentration and proinsulin, C-peptide blood level in group 1 and statistically significant positive correlation between CyA and glucose blood level in both groups.	Cyclosporine	172-175	insulin	Homo sapiens	194-204
12848377-7	2003	We observed a statistically significant negative correlation between CyA concentration and insulin in both groups, a statistically significant negative correlation between CyA concentration and proinsulin, C-peptide blood level in group 1 and statistically significant positive correlation between CyA and glucose blood level in both groups.	Cyclosporine	172-175	insulin	Homo sapiens	194-204
12393716-7	2003	By contrast, the induction of interleukin-8 was delayed and was found to be cyclosporine insensitive.	Cyclosporine	76-88	C-X-C motif chemokine ligand 8	Homo sapiens	30-43
12871167-4	2003	However, recent studies indicate that both CsA and FK506 can block activation of JNK and p38 signaling pathways during T cell activation.	Cyclosporine	43-46	mitogen-activated protein kinase 14	Homo sapiens	89-92
15618715-4	2003	However, cloxacillin, cyclosporin A and midecamycin inhibited BSEP, and cyclosporin A and midecamycin inhibited MRP2 with an inhibition constant close to the clinical concentration.	Cyclosporine	22-35	ATP binding cassette subfamily B member 11	Rattus norvegicus	62-66
12558459-7	2003	Cyclosporin-treated patients on the other hand show several-fold higher systemic exposure of all statins, both those that are metabolised by CYP3A4 and fluvastatin (metabolised by CYP2C9).	Cyclosporine	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	141-147
12871167-5	2003	CsA and FK506, thus, have two distinct mechanisms of action; one is the inhibition of the protein phosphatase activity of calcineurin, leading to the blockade of the nuclear translocation of NFAT transcription factors, and the other is the suppression of JNK and p38 activation pathways.	Cyclosporine	0-3	mitogen-activated protein kinase 14	Homo sapiens	263-266
12445856-8	2002	This review examines the current understanding of the relationship between CETP activity and the lipoprotein distribution of a number of compounds (e.g. amphotericin B and cyclosporine A).	Cyclosporine	172-186	cholesteryl ester transfer protein	Homo sapiens	75-79
14677764-2	2003	Little is known about molecular mechanisms of constitutive expression of CD40L on some non-Hodgkin"s lymphomas, especially about involvement of two signal pathways regulating its expression in normal cells; one involving calcineurin, and the other protein kinase C. We analyzed by flow cytometry the effects of 6-hour stimulation of both pathways (stimuli: PMA and ionomycin) and their inhibitors: cyclosporin A and chelerythrine, on CD40L expression.	Cyclosporine	398-411	CD40 ligand	Homo sapiens	73-78
12644037-6	2003	Hydrophilic bile salts significantly inhibited cholestasis after CsA injection by increasing CM fluidity and by increasing the expression of Mrp2 and Bsep, whereas Mdr1 and Mdr2 were unaltered.	Cyclosporine	65-68	ATP binding cassette subfamily B member 11	Rattus norvegicus	150-154
12531875-3	2003	Cyclosporin A treatment rescued mGSH-depleted hepatocytes from TNF-alpha-induced cell death.	Cyclosporine	0-13	tumor necrosis factor	Mus musculus	63-72
14622914-8	2003	Treatments of neuronal cultures with the permeability transitory pore blockers cyclosporin A and bongkrekic acid prevented veratridine-induced p53 immunoreactivity and neuronal death, placing mitochondria upstream of veratridine-induced p53 immunoreactivity.	Cyclosporine	79-92	tumor protein p53	Homo sapiens	143-146
14622914-8	2003	Treatments of neuronal cultures with the permeability transitory pore blockers cyclosporin A and bongkrekic acid prevented veratridine-induced p53 immunoreactivity and neuronal death, placing mitochondria upstream of veratridine-induced p53 immunoreactivity.	Cyclosporine	79-92	tumor protein p53	Homo sapiens	237-240
14552591-9	2003	Animals treated with a combination of a known MDR modulator, cyclosporin A, and a cytotoxic drug, doxorubicin, exhibited significantly reduced tumor growth compared with untreated controls or animals treated with either cyclosporin A or doxorubicin alone.	Cyclosporine	220-233	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	46-49
12608534-9	2003	In the presence of a Pgp inhibitor such as verapamil, cyclosporine A, or progesterone, the ATP-dependent uptakes of [3H]digoxin and [3H]vinblastine into BBMVs were significantly reduced.	Cyclosporine	54-68	ATP binding cassette subfamily B member 1	Homo sapiens	21-24
12499886-5	2002	RESULTS: In 20 kidney transplant recipients chronically treated with cyclosporine (CsA), 1-month treatment with captopril increased TGF-beta mRNA by 120% and TGF-beta1 protein release by 140% upon stimulation of PBMC with phytohemagglutinin (PHA) and phorbol myristate acetate (PMA) ( P&lt;0.01).	Cyclosporine	69-81	transforming growth factor beta 1	Homo sapiens	132-140
12499886-5	2002	RESULTS: In 20 kidney transplant recipients chronically treated with cyclosporine (CsA), 1-month treatment with captopril increased TGF-beta mRNA by 120% and TGF-beta1 protein release by 140% upon stimulation of PBMC with phytohemagglutinin (PHA) and phorbol myristate acetate (PMA) ( P&lt;0.01).	Cyclosporine	69-81	transforming growth factor beta 1	Homo sapiens	158-167
12499886-5	2002	RESULTS: In 20 kidney transplant recipients chronically treated with cyclosporine (CsA), 1-month treatment with captopril increased TGF-beta mRNA by 120% and TGF-beta1 protein release by 140% upon stimulation of PBMC with phytohemagglutinin (PHA) and phorbol myristate acetate (PMA) ( P&lt;0.01).	Cyclosporine	83-86	transforming growth factor beta 1	Homo sapiens	132-140
12499886-5	2002	RESULTS: In 20 kidney transplant recipients chronically treated with cyclosporine (CsA), 1-month treatment with captopril increased TGF-beta mRNA by 120% and TGF-beta1 protein release by 140% upon stimulation of PBMC with phytohemagglutinin (PHA) and phorbol myristate acetate (PMA) ( P&lt;0.01).	Cyclosporine	83-86	transforming growth factor beta 1	Homo sapiens	158-167
12499886-7	2002	Ang II (100 pM) strongly inhibited TGF-beta1 synthesis by PBMC, and such effect was completely abolished by the addition of 200 ng/mL CsA, as well as by 1 micrpM losartan.	Cyclosporine	134-137	transforming growth factor beta 1	Homo sapiens	35-44
12499886-8	2002	Thus, captopril enhances TGF-beta1 gene and protein expression by PBMC by way of a mechanism independent, at least in part, from ACE inhibition, while CsA abrogates the inhibition of TGF-beta1 expression induced by Ang II.	Cyclosporine	151-154	transforming growth factor beta 1	Homo sapiens	183-192
12486498-7	2002	Insulin gene expression was significantly reduced only in islets exposed to CsA.	Cyclosporine	76-79	insulin	Homo sapiens	0-7
12486498-8	2002	FK506 was, among those tested, the immunosuppressive drug that most profoundly altered the normal insulin secretory pattern of human beta-cells, whereas CsA was the only inhibiting insulin gene expression.	Cyclosporine	153-156	insulin	Homo sapiens	181-188
12446480-1	2002	BACKGROUND: Because cyclosporin A (CsA) and glucocorticoids inhibit the production of interleukin-2 (IL-2) and other cytokines, quantitative analysis of cytokine mRNA might constitute a pharmacodynamic measure for immunosuppressive drug effects.	Cyclosporine	35-38	interleukin 2	Homo sapiens	86-99
12446480-1	2002	BACKGROUND: Because cyclosporin A (CsA) and glucocorticoids inhibit the production of interleukin-2 (IL-2) and other cytokines, quantitative analysis of cytokine mRNA might constitute a pharmacodynamic measure for immunosuppressive drug effects.	Cyclosporine	35-38	interleukin 2	Homo sapiens	101-105
12446480-4	2002	The effect of CsA on IL-2 mRNA expression kinetics was also determined ex vivo in patients undergoing CsA monotherapy (ex vivo study II) and after in vitro addition of CsA.	Cyclosporine	14-17	interleukin 2	Homo sapiens	21-25
12434394-6	2002	p-Glycoprotein (p-gp)inhibitors, such as verapamil (100 microM) and cyclosporin A (CsA, 20 microM) significantly (p &lt; 0.05) inhibited P(BA) but significantly (p &lt; 0.05) enhanced P(AB).	Cyclosporine	68-81	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
12446480-7	2002	In patients undergoing CsA monotherapy (ex vivo study II), the inhibitory effect of CsA was detectable as an individually delayed increase in IL-2 mRNA during costimulation.	Cyclosporine	84-87	interleukin 2	Homo sapiens	142-146
12446480-8	2002	In vitro addition of CsA also induced a dose-independent displacement of IL-2 mRNA expression kinetics (i.e., a delay).	Cyclosporine	21-24	interleukin 2	Homo sapiens	73-77
14561179-4	2002	Cyclosporine and tacrolimus are calcineurin inhibitors that impair the transcription of interleukin 2, reduce the expression of cytokines, and diminish T lymphocyte proliferation.	Cyclosporine	0-12	interleukin 2	Homo sapiens	88-101
12427154-0	2002	Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity.	Cyclosporine	89-101	transforming growth factor beta 1	Homo sapiens	14-22
12427154-3	2002	A comparison of intrarenal expression of TGF-beta and other fibrogenic genes in biopsies from patients with either CsA or Tac nephrotoxicity have not been documented.	Cyclosporine	115-118	transforming growth factor beta 1	Homo sapiens	41-49
12427154-7	2002	RESULTS: Intrarenal expression of TGF-beta, collagen, fibronectin, MMP-2, TIMP-2, and osteopontin were significantly increased in patients treated with Tac nephrotoxicity compared with CsA nephrotoxicity.	Cyclosporine	185-188	transforming growth factor beta 1	Homo sapiens	34-42
12427154-9	2002	CONCLUSIONS: This study compares the intrarenal expression of TGF-beta and profibrogenic genes in renal transplant recipients treated with Tac and CsA.	Cyclosporine	147-150	transforming growth factor beta 1	Homo sapiens	62-70
12434394-6	2002	p-Glycoprotein (p-gp)inhibitors, such as verapamil (100 microM) and cyclosporin A (CsA, 20 microM) significantly (p &lt; 0.05) inhibited P(BA) but significantly (p &lt; 0.05) enhanced P(AB).	Cyclosporine	83-86	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
12510360-1	2002	Cyclosporin is a non-cytotoxic immunomodulating drug which inhibits NF-AT-dependent IL-2 transcription in lymphocytes.	Cyclosporine	0-11	interleukin 2	Homo sapiens	84-88
12421236-2	2002	Although CsA is known to inhibit the proliferation and function of CD4+ T cells, it is not clear what type of IP is responsive to CsA administration.	Cyclosporine	9-12	CD4 molecule	Homo sapiens	67-70
12553571-6	2002	A variety of modulators known to interfere with mammalian P-glycoprotein function perturbed resorufin excretion from male adult schistosomes, including cyclosporin A, Ro11-2933, verapamil, or nifedipine.	Cyclosporine	152-165	ATP binding cassette subfamily B member 1	Homo sapiens	58-72
12421236-4	2002	RESULTS: Cell densities of CD4+ T cells were significantly decreased in the alveolar tissues obtained from CsA responders (n = 3) compared to non-responders (n = 3) (120 +/- 86/mm2 vs 503 +/- 172/mm2, P=0.0495).	Cyclosporine	107-110	CD4 molecule	Homo sapiens	27-30
12421236-7	2002	CONCLUSIONS: The present observations, contrary to expectation, reveal that lower cell densities of CD4+ T cells and lower CD4/CD8 ratios are associated with responsiveness to CsA in combination therapy, suggesting that pharmacological actions other than suppression of CD4+ T cells explain the efficacy of CsA in patients with chronic IP.	Cyclosporine	176-179	CD4 molecule	Homo sapiens	100-103
12421236-7	2002	CONCLUSIONS: The present observations, contrary to expectation, reveal that lower cell densities of CD4+ T cells and lower CD4/CD8 ratios are associated with responsiveness to CsA in combination therapy, suggesting that pharmacological actions other than suppression of CD4+ T cells explain the efficacy of CsA in patients with chronic IP.	Cyclosporine	176-179	CD4 molecule	Homo sapiens	123-126
12421236-7	2002	CONCLUSIONS: The present observations, contrary to expectation, reveal that lower cell densities of CD4+ T cells and lower CD4/CD8 ratios are associated with responsiveness to CsA in combination therapy, suggesting that pharmacological actions other than suppression of CD4+ T cells explain the efficacy of CsA in patients with chronic IP.	Cyclosporine	176-179	CD4 molecule	Homo sapiens	123-126
12421236-5	2002	CD4/CD8 ratios of CsA responders were also significantly lower than those of non-responders (0.315 +/- 0.070 vs 1.975 +/- 0.965, P=0.0463).	Cyclosporine	18-21	CD4 molecule	Homo sapiens	0-3
12444550-2	2002	In the present study, it is shown that release of cytochrome c and apoptosis induced by tumor necrosis factor alpha (TNF) in HeLa cells can be inhibited by (i) overexpression of an oncoprotein Bcl-2, (ii) Cyclosporin A, an inhibitor of the mitochondrial permeability transition pore (PTP) or (iii) oligomycin, an inhibitor of H+- ATP-synthase.	Cyclosporine	205-218	cytochrome c, somatic	Homo sapiens	50-62
12228224-5	2002	Caspase-3 activation induced by thapsigargin was blocked by increasing the phosphorylation of Ser-9-GSK3beta with insulin-like growth factor-1 or with the phosphatase inhibitors okadaic acid and calyculin A, but the calcineurin inhibitors FK506 and cyclosporin A were ineffective.	Cyclosporine	249-262	caspase 3	Homo sapiens	0-9
12444550-2	2002	In the present study, it is shown that release of cytochrome c and apoptosis induced by tumor necrosis factor alpha (TNF) in HeLa cells can be inhibited by (i) overexpression of an oncoprotein Bcl-2, (ii) Cyclosporin A, an inhibitor of the mitochondrial permeability transition pore (PTP) or (iii) oligomycin, an inhibitor of H+- ATP-synthase.	Cyclosporine	205-218	tumor necrosis factor	Homo sapiens	88-115
12444550-2	2002	In the present study, it is shown that release of cytochrome c and apoptosis induced by tumor necrosis factor alpha (TNF) in HeLa cells can be inhibited by (i) overexpression of an oncoprotein Bcl-2, (ii) Cyclosporin A, an inhibitor of the mitochondrial permeability transition pore (PTP) or (iii) oligomycin, an inhibitor of H+- ATP-synthase.	Cyclosporine	205-218	tumor necrosis factor	Homo sapiens	117-120
12444550-2	2002	In the present study, it is shown that release of cytochrome c and apoptosis induced by tumor necrosis factor alpha (TNF) in HeLa cells can be inhibited by (i) overexpression of an oncoprotein Bcl-2, (ii) Cyclosporin A, an inhibitor of the mitochondrial permeability transition pore (PTP) or (iii) oligomycin, an inhibitor of H+- ATP-synthase.	Cyclosporine	205-218	BCL2 apoptosis regulator	Homo sapiens	193-198
12215435-0	2002	Cyclosporine inhibits growth through the activating transcription factor/cAMP-responsive element-binding protein binding site in the cyclin D1 promoter.	Cyclosporine	0-12	cyclin D1	Rattus norvegicus	133-142
12215435-6	2002	This element overlaps the described cAMP-responsive element (CRE) and confers cyclosporine sensitivity to the cyclin D1 promoter.	Cyclosporine	78-90	cyclin D1	Rattus norvegicus	110-119
12215435-8	2002	These results demonstrate that cyclosporine can inhibit proliferation of acinar cells by targeting the cyclin D1 promoter at the proximal CRE via a reduction of CREB protein abundance.	Cyclosporine	31-43	cyclin D1	Rattus norvegicus	103-112
12384443-6	2002	At 1 week after transplantation, CsA decreased thymic numbers more profoundly than sirolimus or tacrolimus in anti-CD40L mAb-treated recipients.	Cyclosporine	33-36	CD40 ligand	Homo sapiens	115-120
12188924-4	2002	Cyclosporin A (CsA), a potent and specific inhibitor of calcineurin, a calcium/calmodulin-dependent serine phosphatase involved in the dephosphorylation and activation of NFATs, blocked NFAT-DNA binding activity and NFAT-dependent reporter gene expression induced by PDGF-BB and thrombin.	Cyclosporine	15-18	coagulation factor II, thrombin	Homo sapiens	279-287
12188924-5	2002	CsA also completely inhibited PDGF-BB- and thrombin-induced VSMC growth, as measured by DNA synthesis and cell number.	Cyclosporine	0-3	coagulation factor II, thrombin	Homo sapiens	43-51
12502559-6	2002	Reduced surface expression of the Na(+)/Ca(2+) exchanger NCX1 is also observed when HEK293 cells expressing the transporter are treated with cyclosporin A (CsA) or with PSC833.	Cyclosporine	141-154	solute carrier family 8 member A1	Homo sapiens	57-61
12502559-6	2002	Reduced surface expression of the Na(+)/Ca(2+) exchanger NCX1 is also observed when HEK293 cells expressing the transporter are treated with cyclosporin A (CsA) or with PSC833.	Cyclosporine	156-159	solute carrier family 8 member A1	Homo sapiens	57-61
12411407-0	2002	Cyclosporine A regulate oxidative stress-induced apoptosis in cardiomyocytes: mechanisms via ROS generation, iNOS and Hsp70.	Cyclosporine	0-14	nitric oxide synthase 2	Rattus norvegicus	109-113
12411407-13	2002	Pre-treatment with CsA at concentration of 0.01-1.0 micro M for 24 h produced up-regulation of heat shock protein 70 (Hsp 70), inducible nitric oxide synthase (iNOS) and also induced NO production, indicating that these factors might be associated with the cell protective effects of CsA.	Cyclosporine	19-22	nitric oxide synthase 2	Rattus norvegicus	127-158
12411407-13	2002	Pre-treatment with CsA at concentration of 0.01-1.0 micro M for 24 h produced up-regulation of heat shock protein 70 (Hsp 70), inducible nitric oxide synthase (iNOS) and also induced NO production, indicating that these factors might be associated with the cell protective effects of CsA.	Cyclosporine	19-22	nitric oxide synthase 2	Rattus norvegicus	160-164
12404285-10	2002	CsA added in vitro to patient"s lymphocytes significantly decreased the number of IFN-gamma-expressing CD4(+) cells, but not Fas-L production.	Cyclosporine	0-3	interferon gamma	Homo sapiens	82-91
12411407-15	2002	These results suggest that CsA could protect the oxidative stress-induced cardiomyocyte apoptosis not only by preventing the loss of DeltaPsim in mitochondria, but also through ROS generation, Hsp70, and iNOS up-regulation.	Cyclosporine	27-30	nitric oxide synthase 2	Rattus norvegicus	204-208
12404285-15	2002	The ability of CsA to decrease in vitro IFN-gamma production may improve hematopoietic function, explaining the beneficial effect of this agent in HMDS patients.	Cyclosporine	15-18	interferon gamma	Homo sapiens	40-49
12404285-10	2002	CsA added in vitro to patient"s lymphocytes significantly decreased the number of IFN-gamma-expressing CD4(+) cells, but not Fas-L production.	Cyclosporine	0-3	CD4 molecule	Homo sapiens	103-106
12270545-4	2002	Here we show that Nef-induced IL-10 production and mRNA expression are strongly blocked by rapamycin, but are not blocked by cyclosporin (CsA) or FK506.	Cyclosporine	138-141	S100 calcium binding protein B	Homo sapiens	18-21
12698985-3	2002	MATERIALS AND METHODS: We chose 3 model drugs that are metabolized by distinct cytochrome P450 (CYP) isoforms (theophylline, phenytoin and cyclosporine for CYPIA2, CYP2C9/2C19 and CYP3A4, respectively).	Cyclosporine	139-151	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	180-186
12429717-5	2002	However, TNF-alpha-induced DC maturation was affected, as CsA-treated DC expressed lower levels of human leukocyte antigen and costimulatory molecules but sustained levels of CD1a, and less DC expressed DC-lysosomal-associated-membrane-protein (LAMP) and CD83.	Cyclosporine	58-61	tumor necrosis factor	Homo sapiens	9-18
12479636-0	2002	Expression of matrix metalloproteinases in cyclosporin-treated gingival fibroblasts is regulated by transforming growth factor (TGF)-beta1 autocrine stimulation.	Cyclosporine	43-54	transforming growth factor beta 1	Homo sapiens	100-138
12388638-2	2002	Both drugs exhibited greater permeability in the basolateral (BL) to apical (AP) direction than in the AP to BL direction, indicating apically directed secretion; BL to AP transport was inhibited by P-glycoprotein (P-gp) inhibitors verapamil and cyclosporin A.	Cyclosporine	246-259	ATP binding cassette subfamily B member 1	Homo sapiens	199-213
12388638-2	2002	Both drugs exhibited greater permeability in the basolateral (BL) to apical (AP) direction than in the AP to BL direction, indicating apically directed secretion; BL to AP transport was inhibited by P-glycoprotein (P-gp) inhibitors verapamil and cyclosporin A.	Cyclosporine	246-259	ATP binding cassette subfamily B member 1	Homo sapiens	215-219
12479636-2	2002	The pathogenesis of this condition is not fully understood; however, recent studies show that CsA regulates the transcription of several cytokines including transforming growth factor-beta1 (TGF-beta1).	Cyclosporine	94-97	transforming growth factor beta 1	Homo sapiens	157-189
12479636-3	2002	The aim of this study was to investigate the potential role of TGF-beta1 in the pathogenesis of CsA-induced gingival overgrowth, exploring a possible autocrine stimulation of TGF-beta1 as a cellular regulator of synthesis of matrix metalloproteinases (MMPs) and its tissue inhibitors (TIMPs).	Cyclosporine	96-99	transforming growth factor beta 1	Homo sapiens	63-72
12479636-2	2002	The pathogenesis of this condition is not fully understood; however, recent studies show that CsA regulates the transcription of several cytokines including transforming growth factor-beta1 (TGF-beta1).	Cyclosporine	94-97	transforming growth factor beta 1	Homo sapiens	191-200
12479636-7	2002	RESULTS: CsA simultaneously stimulated TGF-beta1 expression and production and inhibited expression of MMP-1 and MMP-2 by human gingival fibroblasts, whereas CsA has a slight effect on TIMP-1 and TIMP-2 expression.	Cyclosporine	9-12	transforming growth factor beta 1	Homo sapiens	39-48
12381413-9	2002	Stills others such as the immunosuppressants cyclosporine A and FK506/tacrolimus or erythropoietin have inconsistent effects on eNOS.	Cyclosporine	45-59	nitric oxide synthase 3	Homo sapiens	128-132
12479636-7	2002	RESULTS: CsA simultaneously stimulated TGF-beta1 expression and production and inhibited expression of MMP-1 and MMP-2 by human gingival fibroblasts, whereas CsA has a slight effect on TIMP-1 and TIMP-2 expression.	Cyclosporine	158-161	TIMP metallopeptidase inhibitor 1	Homo sapiens	185-191
12479636-9	2002	The inhibition of TGF-beta1 production by AON modulated MMP expression, demonstrating the autocrine inhibitory effect of TGF-beta1 in CsA-treated human gingival fibroblasts.	Cyclosporine	134-137	transforming growth factor beta 1	Homo sapiens	18-27
12479636-9	2002	The inhibition of TGF-beta1 production by AON modulated MMP expression, demonstrating the autocrine inhibitory effect of TGF-beta1 in CsA-treated human gingival fibroblasts.	Cyclosporine	134-137	transforming growth factor beta 1	Homo sapiens	121-130
12135706-4	2002	Coincidentally, the inducible binding of NIL-2 to a negative-regulatory element in the IL-2 promoter becomes less sensitive to CsA in the cells with increasing Ras activity.	Cyclosporine	127-130	interleukin 2	Homo sapiens	42-46
12171919-5	2002	Moreover, cyclosporin A significantly suppressed the multinucleated cell formation accompanying the reduction of the nuclear localization of NFAT2.	Cyclosporine	10-23	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	141-146
12135706-5	2002	The dose of CsA required for inhibition of IL-2 induction in the cells with increased Ras activity remains similar to the concentration of CsA needed for the suppression of NFAT activation in control cells.	Cyclosporine	12-15	interleukin 2	Homo sapiens	43-47
12352326-7	2002	At baseline, in cyclosporine-and tacrolimus-treated patients, p22 and TGF-beta mRNA were similarly increased in comparison with normotensive healthy controls (0.90 +/- 0.05 d.u.	Cyclosporine	16-28	transforming growth factor beta 1	Homo sapiens	70-78
12239231-4	2002	Furthermore, CsA blunted the increase of renocortical COX-2 expression in response to low salt intake or a combination of low-salt diet with the ACE inhibitor ramipril (10 mg/kg per day), which strongly stimulates renocortical COX-2 expression.	Cyclosporine	13-16	angiotensin I converting enzyme	Rattus norvegicus	145-148
12352326-9	2002	Endothelial NOS mRNA was increased in cyclosporine-and tacrolimus-treated patients in comparison with controls (0.92 +/- 0.09, 0.96 +/- 0.04, and 0.37 +/- 0.05 respectively; p &lt; 0.001), whereas no difference was found between patients and controls in HO-1 mRNA.	Cyclosporine	38-50	nitric oxide synthase 3	Homo sapiens	0-15
12244165-6	2002	Wnt-5a promotes T cell NFAT nuclear accumulation in the presence of CsA, an effect mimicked by Li(+), a potent inhibitor of GSK-3beta.	Cyclosporine	68-71	Wnt family member 5A	Homo sapiens	0-6
12244165-9	2002	Thus, EC promote CsA-resistant nuclear localization of NFAT and subsequent IL-2 synthesis through a noncanonical wnt-dependent pathway.	Cyclosporine	17-20	interleukin 2	Homo sapiens	75-79
12235233-8	2002	CsA also mediated a significant increase in cellular Ca(2+) mobilization by phenylephrine, vasopressin, and epidermal growth factor (EGF) in the presence of extracellular Ca(2+) concentration.	Cyclosporine	0-3	arginine vasopressin	Rattus norvegicus	91-102
12389075-7	2002	Unsurprisingly, both cyclosporin A and tacrolimus significantly inhibited IL-2 and IL-2Rbeta at both time points.	Cyclosporine	21-34	interleukin 2 receptor subunit beta	Rattus norvegicus	83-92
12377946-7	2002	Furthermore, AG treatment reduced the production of IL-12 and IFN-gamma mRNA in the colons of CsA-treated mice.	Cyclosporine	94-97	interferon gamma	Mus musculus	62-71
12110686-0	2002	Cyclosporine A enhances leukocyte binding by human intestinal microvascular endothelial cells through inhibition of p38 MAPK and iNOS.	Cyclosporine	0-14	mitogen-activated protein kinase 14	Homo sapiens	116-119
12118012-8	2002	Finally, prevention of the TNF-alpha-stimulated neosynthesis of GD3, cyclosporin A, and latrunculin A or filipin protected sensitized hepatocytes from TNF-alpha-mediated cell death.	Cyclosporine	69-82	tumor necrosis factor	Rattus norvegicus	27-36
12095984-1	2002	Cyclosporin A (CsA) inhibits opening of the mitochondrial permeability transition pore (MPTP), a critical event in some forms of necrotic and apoptotic cell death, by binding to cyclophilin D (CyP-D) and inhibiting its peptidyl-prolyl cis-trans isomerase (PPIase) activity.	Cyclosporine	0-13	peptidylprolyl isomerase like 3	Rattus norvegicus	219-254
12095984-1	2002	Cyclosporin A (CsA) inhibits opening of the mitochondrial permeability transition pore (MPTP), a critical event in some forms of necrotic and apoptotic cell death, by binding to cyclophilin D (CyP-D) and inhibiting its peptidyl-prolyl cis-trans isomerase (PPIase) activity.	Cyclosporine	0-13	peptidylprolyl isomerase like 3	Rattus norvegicus	256-262
12095984-1	2002	Cyclosporin A (CsA) inhibits opening of the mitochondrial permeability transition pore (MPTP), a critical event in some forms of necrotic and apoptotic cell death, by binding to cyclophilin D (CyP-D) and inhibiting its peptidyl-prolyl cis-trans isomerase (PPIase) activity.	Cyclosporine	15-18	peptidylprolyl isomerase like 3	Rattus norvegicus	219-254
12095984-1	2002	Cyclosporin A (CsA) inhibits opening of the mitochondrial permeability transition pore (MPTP), a critical event in some forms of necrotic and apoptotic cell death, by binding to cyclophilin D (CyP-D) and inhibiting its peptidyl-prolyl cis-trans isomerase (PPIase) activity.	Cyclosporine	15-18	peptidylprolyl isomerase like 3	Rattus norvegicus	256-262
12110686-7	2002	CsA blocked p38 MAPK phosphorylation in activated HIMEC, a key pathway in iNOS expression, but failed to inhibit NFkappaB activation.	Cyclosporine	0-3	mitogen-activated protein kinase 14	Homo sapiens	12-15
12110686-7	2002	CsA blocked p38 MAPK phosphorylation in activated HIMEC, a key pathway in iNOS expression, but failed to inhibit NFkappaB activation.	Cyclosporine	0-3	nitric oxide synthase 2	Homo sapiens	74-78
12110686-8	2002	These studies demonstrate that CsA exerts a proinflammatory effect on HIMEC by blocking iNOS expression.	Cyclosporine	31-34	nitric oxide synthase 2	Homo sapiens	88-92
12110686-0	2002	Cyclosporine A enhances leukocyte binding by human intestinal microvascular endothelial cells through inhibition of p38 MAPK and iNOS.	Cyclosporine	0-14	nitric oxide synthase 2	Homo sapiens	129-133
12110686-3	2002	We hypothesized that CsA would promote a proinflammatory phenotype in human intestinal microvascular endothelial cells (HIMEC), by inhibiting inducible nitric-oxide synthase (iNOS, NOS2)-derived NO, normally an important mechanism in limiting endothelial activation and leukocyte adhesion.	Cyclosporine	21-24	nitric oxide synthase 2	Homo sapiens	142-173
12110686-3	2002	We hypothesized that CsA would promote a proinflammatory phenotype in human intestinal microvascular endothelial cells (HIMEC), by inhibiting inducible nitric-oxide synthase (iNOS, NOS2)-derived NO, normally an important mechanism in limiting endothelial activation and leukocyte adhesion.	Cyclosporine	21-24	nitric oxide synthase 2	Homo sapiens	175-179
12110686-3	2002	We hypothesized that CsA would promote a proinflammatory phenotype in human intestinal microvascular endothelial cells (HIMEC), by inhibiting inducible nitric-oxide synthase (iNOS, NOS2)-derived NO, normally an important mechanism in limiting endothelial activation and leukocyte adhesion.	Cyclosporine	21-24	nitric oxide synthase 2	Homo sapiens	181-185
12110686-5	2002	CsA significantly increased leukocyte binding to activated HIMEC, but paradoxically decreased endothelial expression of cell adhesion molecules (E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule-1).	Cyclosporine	0-3	vascular cell adhesion molecule 1	Homo sapiens	196-229
12110686-6	2002	In contrast, CsA completely inhibited the expression of iNOS in tumor necrosis factor-alpha/lipopolysaccharide-activated HIMEC.	Cyclosporine	13-16	nitric oxide synthase 2	Homo sapiens	56-60
12110686-6	2002	In contrast, CsA completely inhibited the expression of iNOS in tumor necrosis factor-alpha/lipopolysaccharide-activated HIMEC.	Cyclosporine	13-16	tumor necrosis factor	Homo sapiens	64-91
12393172-7	2002	In addition, we observed that Cyclosporin A, a mitochondrial permeability transition (MPT) inhibitor, protected L929 cells against TNF-alpha, underlining the importance of mitochondria in the cytotoxic process induced by TNF-alpha in L929 cells.	Cyclosporine	30-43	tumor necrosis factor	Mus musculus	131-140
12082098-4	2002	The promotion of leakage by tBid is also inhibited by several substances that promote positive membrane curvature, including lysophosphatidylcholine, tritrpticin, a potent antimicrobial peptide, and cyclosporin A, a known inhibitor of cytochrome c release from mitochondria.	Cyclosporine	199-212	cytochrome c, somatic	Homo sapiens	235-247
12393172-7	2002	In addition, we observed that Cyclosporin A, a mitochondrial permeability transition (MPT) inhibitor, protected L929 cells against TNF-alpha, underlining the importance of mitochondria in the cytotoxic process induced by TNF-alpha in L929 cells.	Cyclosporine	30-43	tumor necrosis factor	Mus musculus	221-230
12176916-6	2002	We conclude that Pgp has prognostic relevance in CML-BP but that the modulation of Pgp function with CsA as applied in this trial is ineffective.	Cyclosporine	101-104	ATP binding cassette subfamily B member 1	Homo sapiens	83-86
12231370-6	2002	RESULTS: Exposure to cyclosporine and mycophenolate mofetil was associated with a dose-dependent decrease in endothelium-dependent relaxations to serotonin (an agonist that binds to 5-HT1D receptors coupled to Gi-protein) but no impairment of relaxations to bradykinin (an agonist that binds to B2 receptors coupled to Gq-proteins).	Cyclosporine	21-33	kininogen 1	Homo sapiens	258-268
12176916-0	2002	Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase.	Cyclosporine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	27-41
12198207-0	2002	Cyclosporine A up-regulates the expression of TGF-beta1 and its receptors type I and type II in rat mesangial cells.	Cyclosporine	0-14	transforming growth factor, beta 1	Rattus norvegicus	46-55
12198207-4	2002	We investigated whether CsA up-regulates the expression of TGF-beta1 and its receptors type I (TbetaR-I) and type II (TbetaR-II) in cultured rat MCs, and whether this effect translates into enhanced matrix protein accumulation.	Cyclosporine	24-27	transforming growth factor, beta 1	Rattus norvegicus	59-68
12198207-8	2002	RESULTS: Compared with untreated controls, CsA stimulated mRNA production of TGF-beta1 (maximum at 72 h, 500 ng/ml CsA: 2.1+/-0.5-fold, P&lt;0.001) and TbetaR-II (maximum at 72 h, 1000 ng/ml CsA: 2.4+/-0.4-fold, P&lt;0.005) time- and dose-dependently.	Cyclosporine	43-46	transforming growth factor, beta 1	Rattus norvegicus	77-86
12198207-12	2002	Co-incubation with neutralizing anti-TGF-beta1 antibodies reduced (P&lt;0.05) CsA-induced expression of TbetaR-I (1.0+/-0.1-fold), TbetaR-II (1.3+/-0.1-fold) and PAI-1 (1.3-fold), but not FN production (1.6-fold).	Cyclosporine	78-81	transforming growth factor, beta 1	Rattus norvegicus	37-46
12198207-13	2002	CONCLUSIONS: Pharmacologically relevant concentrations of CsA time- and dose-dependently up-regulate the expression of TGF-beta1 and, via autocrine mechanisms, its receptors type I and II in rat MCs.	Cyclosporine	58-61	transforming growth factor, beta 1	Rattus norvegicus	119-128
12387747-8	2002	Both MDR-1 Pgp and MDR-1 mRNA were significantly increased in cells cultured in the presence of cyclosporin A (CsA), 1,25(OH)(2)D(3), platelet activating factor, dexamethasone (Dex), or aldosterone.	Cyclosporine	111-114	ATP binding cassette subfamily B member 1	Homo sapiens	5-10
12387747-11	2002	Vp, CsA, 1,25(OH)(2)D(3) and Dex significantly increased R-123 intracellular retention, indicating the inhibition of Pgp-mediated transport.	Cyclosporine	4-7	ATP binding cassette subfamily B member 1	Homo sapiens	117-120
12387747-12	2002	Drug-pretreated, Pgp-overexpressing cells showed increased Pgp activity and were less susceptible to toxic concentrations of CsA.	Cyclosporine	125-128	ATP binding cassette subfamily B member 1	Homo sapiens	17-20
12387747-8	2002	Both MDR-1 Pgp and MDR-1 mRNA were significantly increased in cells cultured in the presence of cyclosporin A (CsA), 1,25(OH)(2)D(3), platelet activating factor, dexamethasone (Dex), or aldosterone.	Cyclosporine	111-114	ATP binding cassette subfamily B member 1	Homo sapiens	11-14
12387747-8	2002	Both MDR-1 Pgp and MDR-1 mRNA were significantly increased in cells cultured in the presence of cyclosporin A (CsA), 1,25(OH)(2)D(3), platelet activating factor, dexamethasone (Dex), or aldosterone.	Cyclosporine	111-114	ATP binding cassette subfamily B member 1	Homo sapiens	19-24
12022919-6	2002	Ivermectin, cyclosporin A and rapamycin all inhibited the skeletal muscle sarcoplasmic reticulum Ca(2+)-ATPase (SERCA1).	Cyclosporine	12-25	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1	Homo sapiens	112-118
12050171-6	2002	Cyclosporin A, an inhibitor of calcineurin, completely blocks VEGF-induced eNOS dephosphorylation; under identical conditions, cyclosporin A also inhibits VEGF-induced eNOS activation.	Cyclosporine	0-13	vascular endothelial growth factor A	Homo sapiens	62-66
12050171-6	2002	Cyclosporin A, an inhibitor of calcineurin, completely blocks VEGF-induced eNOS dephosphorylation; under identical conditions, cyclosporin A also inhibits VEGF-induced eNOS activation.	Cyclosporine	0-13	vascular endothelial growth factor A	Homo sapiens	155-159
12050171-6	2002	Cyclosporin A, an inhibitor of calcineurin, completely blocks VEGF-induced eNOS dephosphorylation; under identical conditions, cyclosporin A also inhibits VEGF-induced eNOS activation.	Cyclosporine	127-140	vascular endothelial growth factor A	Homo sapiens	155-159
12227681-0	2002	Oxidative stress and TGFbeta in kidney-transplanted patients with cyclosporin-induced hypertension.	Cyclosporine	66-77	transforming growth factor beta 1	Homo sapiens	21-28
12193059-1	2002	Several studies have demonstrated that endothelin-1 (ET-1) plays an important pathophysiological role in ischaemic renal failure and drug-induced renal injury, such as cyclosporine A (CsA)- and tacrolimus-associated nephrotoxicity.	Cyclosporine	168-182	endothelin 1	Homo sapiens	39-51
12193059-1	2002	Several studies have demonstrated that endothelin-1 (ET-1) plays an important pathophysiological role in ischaemic renal failure and drug-induced renal injury, such as cyclosporine A (CsA)- and tacrolimus-associated nephrotoxicity.	Cyclosporine	168-182	endothelin 1	Homo sapiens	53-57
12193059-1	2002	Several studies have demonstrated that endothelin-1 (ET-1) plays an important pathophysiological role in ischaemic renal failure and drug-induced renal injury, such as cyclosporine A (CsA)- and tacrolimus-associated nephrotoxicity.	Cyclosporine	184-187	endothelin 1	Homo sapiens	39-51
12193059-1	2002	Several studies have demonstrated that endothelin-1 (ET-1) plays an important pathophysiological role in ischaemic renal failure and drug-induced renal injury, such as cyclosporine A (CsA)- and tacrolimus-associated nephrotoxicity.	Cyclosporine	184-187	endothelin 1	Homo sapiens	53-57
12193060-0	2002	HMG-CoA reductase inhibition and PPAR- alpha activation both inhibit cyclosporin A induced endothelin-1 secretion in cultured endothelial cells.	Cyclosporine	69-82	peroxisome proliferator activated receptor alpha	Bos taurus	33-44
12227681-2	2002	Cyclosporin is a powerful stimulator of oxidative stress signaling, leading to TGFbeta production, NO degradation, endothelial dysfunction, hypertension and post-transplant nephropathy.	Cyclosporine	0-11	transforming growth factor beta 1	Homo sapiens	79-86
12112526-6	2002	MDR1 gene amplification precedes the emergence of a mutant allele in cells that were coselected with doxorubicin and a cyclosporin inhibitor of P-glycoprotein (P-gp).	Cyclosporine	119-130	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
12112526-6	2002	MDR1 gene amplification precedes the emergence of a mutant allele in cells that were coselected with doxorubicin and a cyclosporin inhibitor of P-glycoprotein (P-gp).	Cyclosporine	119-130	ATP binding cassette subfamily B member 1	Homo sapiens	144-158
12112526-6	2002	MDR1 gene amplification precedes the emergence of a mutant allele in cells that were coselected with doxorubicin and a cyclosporin inhibitor of P-glycoprotein (P-gp).	Cyclosporine	119-130	ATP binding cassette subfamily B member 1	Homo sapiens	160-164
12228764-0	2002	Cyclosporin A and FK506 decrease adenosine kinase activity and adenosine uptake in T-lymphocytes.	Cyclosporine	0-13	adenosine kinase	Homo sapiens	33-49
12228764-4	2002	The immunosuppressive drugs cyclosporin A (CsA) and FK506 inhibited both adenosine uptake and AK activity in a concentration-dependent manner.	Cyclosporine	28-41	adenosine kinase	Homo sapiens	94-96
12228764-4	2002	The immunosuppressive drugs cyclosporin A (CsA) and FK506 inhibited both adenosine uptake and AK activity in a concentration-dependent manner.	Cyclosporine	43-46	adenosine kinase	Homo sapiens	94-96
12228764-8	2002	These data demonstrate that CsA and FK506 enhance adenosine concentrations in T-lymphocytes by way of a mechanism that involves AK inhibition.	Cyclosporine	28-31	adenosine kinase	Homo sapiens	128-130
12130727-5	2002	We therefore investigated the influence of piperine on P-glycoprotein-mediated, polarized transport of digoxin and cyclosporine in monolayers of Caco-2 cells.	Cyclosporine	115-127	ATP binding cassette subfamily B member 1	Homo sapiens	55-69
12195825-3	2002	Its transport was completely inhibited by two specific P-gp inhibitors, ciclosporin A and GG918, in our experiments.	Cyclosporine	72-85	ATP binding cassette subfamily B member 1	Homo sapiens	55-59
12144947-0	2002	Calcineurin inhibitors, cyclosporin A and tacrolimus inhibit expression of inducible nitric oxide synthase in colon epithelial and macrophage cell lines.	Cyclosporine	24-37	nitric oxide synthase 2	Homo sapiens	75-106
12110003-0	2002	Angiotensin II regulation of vascular endothelial growth factor and receptors Flt-1 and KDR/Flk-1 in cyclosporine nephrotoxicity.	Cyclosporine	101-113	angiotensinogen	Rattus norvegicus	0-14
12127970-8	2002	Azidopine-binding assay showed that cyclosporin A or verapamil inhibited azidopine binding on Pgp partially but sinensetin did not.	Cyclosporine	36-49	ATP binding cassette subfamily B member 1	Homo sapiens	94-97
12144947-4	2002	Cyclosporin A and FK-506 inhibited iNOS expression, and subsequent NO production, in a dose-dependent manner at therapeutically achievable drug concentrations in both cell lines.	Cyclosporine	0-13	nitric oxide synthase 2	Homo sapiens	35-39
12144947-9	2002	Two inhibitors of phosphatase calcineurin, cyclosporin A and FK-506, inhibited iNOS expression and NO production in human T84 colon epithelial cells and in murine J774 macrophages by an NF-kappaB independent manner.	Cyclosporine	43-56	nitric oxide synthase 2	Homo sapiens	79-83
12123747-5	2002	In cells incubated in the presence of CsA, there was an increase in the expression and activity of MnSOD and CuZnSOD but not in that of catalase and GPx.	Cyclosporine	38-41	superoxide dismutase 1	Rattus norvegicus	109-116
12123747-5	2002	In cells incubated in the presence of CsA, there was an increase in the expression and activity of MnSOD and CuZnSOD but not in that of catalase and GPx.	Cyclosporine	38-41	catalase	Rattus norvegicus	136-144
12123747-6	2002	However, when hepatocytes were coincubated with CsA and VitE, an increase in the expression and activity in all antioxidant enzymes (MnSOD, CuZnSOD, catalase and GPx) was observed.	Cyclosporine	48-51	superoxide dismutase 1	Rattus norvegicus	140-147
12123747-6	2002	However, when hepatocytes were coincubated with CsA and VitE, an increase in the expression and activity in all antioxidant enzymes (MnSOD, CuZnSOD, catalase and GPx) was observed.	Cyclosporine	48-51	catalase	Rattus norvegicus	149-157
12123747-7	2002	In conclusion, we suggest (a) that the imbalance between SOD and catalase/GPx by the effect of CsA is the main mechanism responsible for peroxide accumulation and cell death in hepatocytes, and (b) that the presence of VitE in culture media reduces the oxidative stress through the inhibition of lipid peroxidation, but also through the increase of the expression and activity of catalase and GPx which allows the restoration of SOD and catalase/GPx coordination, indispensable for the correct cell defense against ROS.	Cyclosporine	95-98	catalase	Rattus norvegicus	65-73
12140175-4	2002	The mitochondrial potential transition (MPT), including the reduction of the mitochondrial transmembrane potential and the release of mitochondrial cytochrome c, occurred in beta-lapachone-treated cells; cotreatment of these cells with cyclosporin A, an inhibitor of MPT pore, failed to prevent necrotic cell death.	Cyclosporine	236-249	cytochrome c, somatic	Homo sapiens	148-160
12218287-5	2002	All-trans-retinoic acid, dithranol and the p38 mitogen-activated protein (MAP) kinase inhibitor SB220025 displayed a strong inhibitory effect on SKALP expression while cyclosporin A, dexamethasone, the vitamin D(3) derivative calcipotriol and the p38 MAP kinase inhibitor SB203580 showed only moderate inhibition.	Cyclosporine	168-181	mitogen-activated protein kinase 14	Homo sapiens	43-46
12111807-10	2002	Pretreatment with cyclosporin A or ADP plus oligomycin prevented the deleterious effects promoted by A beta and/or Ca(2+).	Cyclosporine	18-31	amyloid beta precursor protein	Homo sapiens	101-107
12402553-3	2002	CsA decreased deposits of type IV collagen but increased accumulation of fibronectin in both models.	Cyclosporine	0-3	fibronectin 1	Homo sapiens	73-84
12402553-7	2002	In experimental models of inflammatory RNN and non-inflammatory CPAN nephropathy CsA raised fibronectin production, MP increased deposition of laminine.	Cyclosporine	81-84	fibronectin 1	Homo sapiens	92-103
12071854-3	2002	The increased transport of C6-NBD-PS is mediated by MDR1 Pgp, shown by transport reduction nearly to the level of controls in the presence of MDR1 Pgp inhibitors [PSC 833, cyclosporin A and dexniguldipine hydrochloride (Dex)].	Cyclosporine	172-185	ATP binding cassette subfamily B member 1	Homo sapiens	52-56
12071854-3	2002	The increased transport of C6-NBD-PS is mediated by MDR1 Pgp, shown by transport reduction nearly to the level of controls in the presence of MDR1 Pgp inhibitors [PSC 833, cyclosporin A and dexniguldipine hydrochloride (Dex)].	Cyclosporine	172-185	ATP binding cassette subfamily B member 1	Homo sapiens	142-146
12087018-0	2002	IA-2 antibody-negative status predicts remission and recovery of C-peptide levels in type 1 diabetic patients treated with cyclosporin.	Cyclosporine	123-134	insulin	Homo sapiens	65-74
12087018-8	2002	Cyclosporin caused significant reduction in insulin requirements and significant increases in C-peptide secretion mainly in patients negative for IA-2 antibodies.	Cyclosporine	0-11	insulin	Homo sapiens	94-103
12183111-6	2002	To circumvent this resistant phenotype, several P-gp modulators such as cyclosporin A (CsA) are available.	Cyclosporine	72-85	ATP binding cassette subfamily B member 1	Homo sapiens	48-52
12183111-6	2002	To circumvent this resistant phenotype, several P-gp modulators such as cyclosporin A (CsA) are available.	Cyclosporine	87-90	ATP binding cassette subfamily B member 1	Homo sapiens	48-52
12523495-2	2002	The CYPs activities were assessed by measuring the rate of acetanilide 4-hydroxylation (CYP1A2) and cyclosporine A oxidation (CYP3A4) after treatment with TCDD (a CYP1A subfamily inducer) or rifampicin (mainly a CYP3A4 inducer).	Cyclosporine	100-114	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	126-132
12123558-8	2002	As for BK injection, binding of Tau-1 to Tau was decreased after CSA injection.	Cyclosporine	65-68	synaptotagmin 17	Rattus norvegicus	7-9
12067705-5	2002	A plausible candidate for Ca(2+)-dependent PLD regulation by S1P was represented by calcineurin, in view of the observed reduction of the stimulatory effect by cyclosporin A.	Cyclosporine	160-173	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	43-46
12084995-12	2002	In the acute rejection model cyclosporine acts synergistically with anti-CD154 therapy to prolong allograft survival and induce tolerance.	Cyclosporine	29-41	CD40 ligand	Homo sapiens	73-78
12066135-8	2002	The decreased expression of Bcl-2 and the ratio of Bcl-2 to Bax protein seen in cyclosporine-treated rat kidneys were significantly increased after colchicine treatment, accompanying a suppression of caspase-3 activity (P &lt;.05).	Cyclosporine	80-92	BCL2, apoptosis regulator	Rattus norvegicus	28-33
12029627-0	2002	Cyclosporine A protects against arachidonic acid toxicity in rat hepatocytes: role of CYP2E1 and mitochondria.	Cyclosporine	0-14	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	86-92
12066135-8	2002	The decreased expression of Bcl-2 and the ratio of Bcl-2 to Bax protein seen in cyclosporine-treated rat kidneys were significantly increased after colchicine treatment, accompanying a suppression of caspase-3 activity (P &lt;.05).	Cyclosporine	80-92	BCL2, apoptosis regulator	Rattus norvegicus	51-56
12134947-6	2002	The substrate activity of AD for MRP2 was determined by using cyclosporin A, a known MRP2 and P-gp inhibitor.	Cyclosporine	62-75	ATP binding cassette subfamily C member 2	Canis lupus familiaris	33-37
12059038-6	2002	Using enzyme-linked immunosorbentassay (ELISA) it was found that LVV-H4 neutralized the inhibitory effect of cyclosporin A (CsA) and TFP on interleukin-2 (IL-2) synthesis by activated blood lymphocytes.	Cyclosporine	109-122	interleukin 2	Homo sapiens	140-153
12059038-6	2002	Using enzyme-linked immunosorbentassay (ELISA) it was found that LVV-H4 neutralized the inhibitory effect of cyclosporin A (CsA) and TFP on interleukin-2 (IL-2) synthesis by activated blood lymphocytes.	Cyclosporine	109-122	interleukin 2	Homo sapiens	155-159
12059038-6	2002	Using enzyme-linked immunosorbentassay (ELISA) it was found that LVV-H4 neutralized the inhibitory effect of cyclosporin A (CsA) and TFP on interleukin-2 (IL-2) synthesis by activated blood lymphocytes.	Cyclosporine	124-127	interleukin 2	Homo sapiens	140-153
12152989-2	2002	There are several potential agents for modulating Pgp-mediated multi-drug resistance, such as cyclosporin A and PSC833, which are currently being evaluated in clinical trials.	Cyclosporine	94-107	ATP binding cassette subfamily B member 1	Homo sapiens	50-53
12053071-10	2002	However, after termination of CsA treatment, the SMemb expression increased.	Cyclosporine	30-33	myosin heavy chain 10	Rattus norvegicus	49-54
12053071-11	2002	The expression of SMemb was higher in the allograft model than in either isograft or CsA-treated models.	Cyclosporine	85-88	myosin heavy chain 10	Rattus norvegicus	18-23
12134949-8	2002	The efflux of the modified prodrug could be inhibited by GF120918 (an inhibitor for P-gp) and cyclosporin A (an inhibitor for P-gp and MRP2).	Cyclosporine	94-107	ATP binding cassette subfamily C member 2	Canis lupus familiaris	135-139
12134947-6	2002	The substrate activity of AD for MRP2 was determined by using cyclosporin A, a known MRP2 and P-gp inhibitor.	Cyclosporine	62-75	ATP binding cassette subfamily C member 2	Canis lupus familiaris	85-89
12134947-11	2002	A mixture of GF120918 (2 microM) and cyclosporin A (25 microM) decreased the Papp BL-to-AP/Papp AP-to-BL ratios of AD in MDCK-WT, MDCK-MDR1, and MDCK-MRP2 cells to 1.2,1.8, and 2.3, respectively.	Cyclosporine	37-50	ATP binding cassette subfamily C member 2	Canis lupus familiaris	145-154
12134948-8	2002	The substrate activity of CD for MRP2 was determined by using cyclosporin A (CsA), a known MRP2 and P-gp inhibitor.	Cyclosporine	62-75	ATP binding cassette subfamily C member 2	Canis lupus familiaris	33-37
12134948-8	2002	The substrate activity of CD for MRP2 was determined by using cyclosporin A (CsA), a known MRP2 and P-gp inhibitor.	Cyclosporine	62-75	ATP binding cassette subfamily C member 2	Canis lupus familiaris	91-95
12134948-8	2002	The substrate activity of CD for MRP2 was determined by using cyclosporin A (CsA), a known MRP2 and P-gp inhibitor.	Cyclosporine	77-80	ATP binding cassette subfamily C member 2	Canis lupus familiaris	33-37
12134948-8	2002	The substrate activity of CD for MRP2 was determined by using cyclosporin A (CsA), a known MRP2 and P-gp inhibitor.	Cyclosporine	77-80	ATP binding cassette subfamily C member 2	Canis lupus familiaris	91-95
12134948-17	2002	A mixture of GF120918 (2 microM) and CsA (25 microM) decreased the Papp BL-to-AP/Papp AP-to-BL ratios of CD in MDCK-WT, MDCK-MDR1, and MDCK-MRP2 cells to 1.4, 2.7, and 5.4. respectively.	Cyclosporine	37-40	ATP binding cassette subfamily C member 2	Canis lupus familiaris	135-144
12072296-0	2002	Differential modulation of synthesis of human IL-1 beta and IL-1 receptor antagonist by cyclosporin A.	Cyclosporine	88-101	interleukin 1 beta	Homo sapiens	46-55
12021632-1	2002	To determine the relationship between C3435T mutation in exon 26 of the human multidrug resistant 1 (MDR1) gene and cyclosporine pharmacokinetic parameters among healthy volunteers, the oral cyclosporine pharmacokinetic study was performed for 14 healthy subjects.	Cyclosporine	116-128	ATP binding cassette subfamily B member 1	Homo sapiens	78-99
12021632-1	2002	To determine the relationship between C3435T mutation in exon 26 of the human multidrug resistant 1 (MDR1) gene and cyclosporine pharmacokinetic parameters among healthy volunteers, the oral cyclosporine pharmacokinetic study was performed for 14 healthy subjects.	Cyclosporine	116-128	ATP binding cassette subfamily B member 1	Homo sapiens	101-105
12021632-1	2002	To determine the relationship between C3435T mutation in exon 26 of the human multidrug resistant 1 (MDR1) gene and cyclosporine pharmacokinetic parameters among healthy volunteers, the oral cyclosporine pharmacokinetic study was performed for 14 healthy subjects.	Cyclosporine	191-203	ATP binding cassette subfamily B member 1	Homo sapiens	78-99
12021632-1	2002	To determine the relationship between C3435T mutation in exon 26 of the human multidrug resistant 1 (MDR1) gene and cyclosporine pharmacokinetic parameters among healthy volunteers, the oral cyclosporine pharmacokinetic study was performed for 14 healthy subjects.	Cyclosporine	191-203	ATP binding cassette subfamily B member 1	Homo sapiens	101-105
12042638-8	2002	RESULTS: Intrarenal expression of TGF-beta, collagen, fibronectin, MMP-2, MMP-9, and tissue inhibitor of MMP-2 was significantly increased in rats treated with CsA for 180 days compared with untreated rats and those treated for 30 days.	Cyclosporine	160-163	transforming growth factor, beta 1	Rattus norvegicus	34-42
12042638-10	2002	CONCLUSION: Posttransplantation nephrotoxicity in cardiac transplant recipients treated with CsA for a long term is related to increased expression of TGF-beta and other fibrogenic genes.	Cyclosporine	93-96	transforming growth factor, beta 1	Rattus norvegicus	151-159
12042638-11	2002	Therapies designed to inhibit expression of TGF-beta could ameliorate CsA-associated nephrotoxicity in cardiac transplant recipients.	Cyclosporine	70-73	transforming growth factor, beta 1	Rattus norvegicus	44-52
12004198-3	2002	The estrogen receptor ligands tamoxifen, nafoxidine and clomiphene were identified as agents which affect mitochondrial membrane potential in a cyclosporin A-like manner.	Cyclosporine	144-157	estrogen receptor 1	Homo sapiens	4-21
12004198-6	2002	These studies indicate that estrogen receptor ligands appear to affect mitochondria in a cyclosporin A-like manner in human neuroblastoma cells.	Cyclosporine	89-102	estrogen receptor 1	Homo sapiens	28-45
12160480-8	2002	The combined up-regulation in intestinal P-glycoprotein and hepatic and intestinal CYP3A4 impairs the absorption and stimulates the metabolism of cyclosporine, leading to subtherapeutic plasma levels.	Cyclosporine	146-158	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	83-89
12013470-10	2002	However, there was a significant decrease in number of CD8+ lymphocytes with reversal of the CD4+:CD8+ in both eyes after CsA treatment for 30 days, compared with the control group.	Cyclosporine	122-125	T-cell surface glycoprotein CD4	Canis lupus familiaris	93-96
12044791-0	2002	Cyclosporin A inhibits angiotensin II-induced c-Jun NH(2)-terminal kinase activation but not protein synthesis in vascular smooth muscle cells.	Cyclosporine	0-13	angiotensinogen	Homo sapiens	23-37
12044791-0	2002	Cyclosporin A inhibits angiotensin II-induced c-Jun NH(2)-terminal kinase activation but not protein synthesis in vascular smooth muscle cells.	Cyclosporine	0-13	mitogen-activated protein kinase 8	Homo sapiens	46-73
12044791-3	2002	Here, an immunosuppressant, cyclosporin A but not FK506, selectively inhibited angiotensin II-induced JNK activation in vascular smooth muscle cells.	Cyclosporine	28-41	angiotensinogen	Homo sapiens	79-93
12044791-3	2002	Here, an immunosuppressant, cyclosporin A but not FK506, selectively inhibited angiotensin II-induced JNK activation in vascular smooth muscle cells.	Cyclosporine	28-41	mitogen-activated protein kinase 8	Homo sapiens	102-105
12044791-5	2002	Thus, angiotensin II-induced JNK activation but not protein synthesis is mediated by a mechanism sensitive to cyclosporin A, which is independent from calcineurin in vascular smooth muscle cells.	Cyclosporine	110-123	angiotensinogen	Homo sapiens	6-20
12044791-5	2002	Thus, angiotensin II-induced JNK activation but not protein synthesis is mediated by a mechanism sensitive to cyclosporin A, which is independent from calcineurin in vascular smooth muscle cells.	Cyclosporine	110-123	mitogen-activated protein kinase 8	Homo sapiens	29-32
11864976-2	2002	Simultaneous treatment of the cells with wortmannin, cycloheximide, furosemide, cyclosporin A, or decylubiquinone prevented the release of cytochrome c and significantly reduced the loss of viability.	Cyclosporine	80-93	cytochrome c, somatic	Homo sapiens	139-151
11864976-9	2002	Cyclosporin A and decylubiquinone, inhibitors of MPT, prevented the release of cytochrome c without affecting Bax translocation.	Cyclosporine	0-13	cytochrome c, somatic	Homo sapiens	79-91
11978159-5	2002	Since the interaction between cyclosporine and HMG-CoA reductase inhibitors involves the CYP3A4 enzyme system, the possibility of amplifying this interaction exists when other drugs affecting the same enzyme system are coprescribed.	Cyclosporine	30-42	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	89-95
12123203-9	2002	The ratio between bax and bcl-2 protein increased significantly in the CsA group (5.3-fold), compared with the VH group.	Cyclosporine	71-74	B cell leukemia/lymphoma 2	Mus musculus	26-31
12115224-0	2002	Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts.	Cyclosporine	0-12	vascular endothelial growth factor A	Homo sapiens	27-61
11976833-7	2002	The highest MDR was expressed in MOLT-4/DNR cells, which was overcome by the P-gp modulator, cyclosporin A (CsA).	Cyclosporine	93-106	ATP binding cassette subfamily B member 1	Homo sapiens	77-81
11976833-7	2002	The highest MDR was expressed in MOLT-4/DNR cells, which was overcome by the P-gp modulator, cyclosporin A (CsA).	Cyclosporine	108-111	ATP binding cassette subfamily B member 1	Homo sapiens	77-81
12182113-6	2002	However, when combined with CsA, IL-2 abrogated or reversed effects of CsA on both allograft rejection and forelimb regeneration, in a dose-dependent manner.	Cyclosporine	71-74	interleukin 2	Homo sapiens	33-37
12102473-0	2002	Combination therapy with cyclosporine and methotrexate in patients with early rheumatoid arthritis soon inhibits TNFalpha production without decreasing TNFalpha mRNA levels.	Cyclosporine	25-37	tumor necrosis factor	Homo sapiens	113-121
12102473-2	2002	OBJECTIVE: To evaluate the ability of two different combination therapies with prednisone (PDN), methotrexate (MTX) and cyclosporine (CSA) to modulate both TNFalpha transcription and production in early rheumatoid arthritis (RA).	Cyclosporine	120-132	tumor necrosis factor	Homo sapiens	156-164
12123630-0	2002	Selective angiotensin II type 1 receptor blockade ameliorates cyclosporine nephrotoxicity.	Cyclosporine	62-74	angiotensinogen	Rattus norvegicus	10-24
12123630-2	2002	The molecular mechanisms of CsA nephrotoxicity are not well characterized, but previous studies have demonstrated that angiotensin II (Ang II), the primary mediator of renin-angiotensin system (RAS) cascade plays a role in its pathogenesis.	Cyclosporine	28-31	angiotensinogen	Rattus norvegicus	119-133
12123630-5	2002	The aims of this study were to investigate the role of Ang II-induced oxidative stress in CsA nephrotoxicity, and to examine the effects of the insurmountable Ang II type 1 (AT (1)) receptor antagonist, candesartan on CsA-induced nephrotoxicity in rats.	Cyclosporine	90-93	angiotensinogen	Rattus norvegicus	55-61
12123630-2	2002	The molecular mechanisms of CsA nephrotoxicity are not well characterized, but previous studies have demonstrated that angiotensin II (Ang II), the primary mediator of renin-angiotensin system (RAS) cascade plays a role in its pathogenesis.	Cyclosporine	28-31	angiotensinogen	Rattus norvegicus	135-141
11965031-0	2002	Inhibition of endothelin-1 improves survival and vasculopathy in rat cardiac transplants treated with cyclosporine.	Cyclosporine	102-114	endothelin 1	Rattus norvegicus	14-26
12180829-9	2002	Thus, the combination of an IMPDH inhibitor (MPS, MMF) and a calcineurin inhibitor (cyclosporine A) enables fine-tuning in achieving optimal immunosuppression avoiding drug side effects.	Cyclosporine	84-98	calcineurin binding protein 1	Rattus norvegicus	61-82
11956130-7	2002	Treatment with either cyclosporin A or verapamil prevented increases in heart weight to body weight ratios, interstitial fibrosis, impaired contractility, PKC activation, and changes in the expression patterns of beta-MHC and SERCA2a.	Cyclosporine	22-35	protein kinase C, alpha	Mus musculus	155-158
11965031-1	2002	BACKGROUND: In animal models, endothelin-1 (ET-1) blockade attenuates transplant vasculopathy and chronic allograft dysfunction even in the absence of cyclosporine (CsA).	Cyclosporine	151-163	endothelin 1	Rattus norvegicus	30-42
11920342-1	2002	We previously reported that the percentage of change in inverse serum creatinine (Delta1/Cr) was the best of several time-dependent serum creatinine-derived predictors of renal allograft failure in patients not administered cyclosporine (CsA).	Cyclosporine	238-241	delta like non-canonical Notch ligand 1	Homo sapiens	82-91
11920342-4	2002	A time-dependent covariate determined by the date of first chronic decline (excluding creatinine levels from periods of acute rejection) in Delta1/Cr to less than -30% of baseline similarly was predictive of graft failure in 101 patients treated without CsA (relative risk, 5.04; 95% confidence interval, 2.18 to 11.6; P = 0.0002) and 100 patients treated with CsA (relative risk, 5.02; 95% confidence interval, 2.50 to 10.1; P &lt; 0.0001).	Cyclosporine	254-257	delta like non-canonical Notch ligand 1	Homo sapiens	140-149
11920342-4	2002	A time-dependent covariate determined by the date of first chronic decline (excluding creatinine levels from periods of acute rejection) in Delta1/Cr to less than -30% of baseline similarly was predictive of graft failure in 101 patients treated without CsA (relative risk, 5.04; 95% confidence interval, 2.18 to 11.6; P = 0.0002) and 100 patients treated with CsA (relative risk, 5.02; 95% confidence interval, 2.50 to 10.1; P &lt; 0.0001).	Cyclosporine	361-364	delta like non-canonical Notch ligand 1	Homo sapiens	140-149
11920342-8	2002	Thus, Delta1/Cr less than -30% is an excellent predictor of graft failure that is similarly predictive in patients treated with and without CsA.	Cyclosporine	140-143	delta like non-canonical Notch ligand 1	Homo sapiens	6-15
11920344-2	2002	Cyclosporine A (CsA) has been shown to strongly modulate ET-1 and NO synthesis and thus has the potential to affect fetal growth and maternal state.	Cyclosporine	16-19	endothelin 1	Homo sapiens	57-61
11920344-11	2002	CsA potently affected the placental ET-1/ecNOS vasoactive balance.	Cyclosporine	0-3	endothelin 1	Homo sapiens	36-40
11920344-11	2002	CsA potently affected the placental ET-1/ecNOS vasoactive balance.	Cyclosporine	0-3	nitric oxide synthase 3	Homo sapiens	41-46
12055538-2	2002	Ciclosporin interferes with nuclear factors of activated T-cells, specifically by preventing cytokine gene transcription, particularly interleukin-2, which induces maturation and proliferation of helper T-cells.	Cyclosporine	0-11	interleukin 2	Homo sapiens	135-148
11914905-7	2002	The inhibitory concentrations of paclitaxel, tamoxifen and cyclosporine on MMDx metabolism were in the range of those observed in patients upon administration of these drugs, which are known to be CYP3A4 substrates.	Cyclosporine	59-71	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	197-203
11903043-5	2002	The activation of all four caspases was inhibited by cyclosporin A, with the order of susceptibility caspase-8=caspase-9=caspase-6&gt;caspase-3.	Cyclosporine	53-66	caspase 6	Rattus norvegicus	27-35
11903043-5	2002	The activation of all four caspases was inhibited by cyclosporin A, with the order of susceptibility caspase-8=caspase-9=caspase-6&gt;caspase-3.	Cyclosporine	53-66	caspase 9	Rattus norvegicus	111-120
11903043-5	2002	The activation of all four caspases was inhibited by cyclosporin A, with the order of susceptibility caspase-8=caspase-9=caspase-6&gt;caspase-3.	Cyclosporine	53-66	caspase 6	Rattus norvegicus	121-130
11959794-7	2002	Cyclosporine (CsA) and FK-506 inhibited IL-13 synthesis, when cells were stimulated by TPA/ionomycin.	Cyclosporine	0-12	interleukin 13	Homo sapiens	40-45
11959794-7	2002	Cyclosporine (CsA) and FK-506 inhibited IL-13 synthesis, when cells were stimulated by TPA/ionomycin.	Cyclosporine	14-17	interleukin 13	Homo sapiens	40-45
11959794-18	2002	In difference to PBMCs alpha-CD3/alpha-CD28 stimulated IL-13 synthesis was effectively inhibited by CsA, FK-506 and U0126.	Cyclosporine	100-103	interleukin 13	Homo sapiens	55-60
12020442-8	2002	A significant increase in CSA in sera was observed in the presence of a suboptimal concentration of IL-3, implying that they comprise the co-stimulatory activity (CoSA).	Cyclosporine	26-29	interleukin 3	Mus musculus	100-104
11956505-2	2002	This study investigated the effect of voriconazole on the pharmacokinetics of cyclosporine (INN, ciclosporin).	Cyclosporine	78-90	growth hormone releasing hormone	Homo sapiens	92-95
11999357-0	2002	Successful immunosuppressive therapy with cyclosporine A for posthepatitis B-cell deficiency with activated cytoplasmic interferon--gamma-positive T-lymphocytes.	Cyclosporine	42-56	interferon gamma	Homo sapiens	120-137
12033380-6	2002	P-gp inhibitors (i.e., GG918, cyclosporine, ketoconazole, vinblastine) decreased the B--&gt;A transport of dicloxacillin and trimethoprim and increased the A--&gt;B transport of trimethoprim while non-P-gp inhibitors (e.g., PAH) had no effect.	Cyclosporine	30-42	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
11930095-5	2002	Anti-CD20 therapy was associated with withdrawal of tacrolimus or ciclosporine therapy in all patients.	Cyclosporine	66-78	keratin 20	Homo sapiens	5-9
12033380-6	2002	P-gp inhibitors (i.e., GG918, cyclosporine, ketoconazole, vinblastine) decreased the B--&gt;A transport of dicloxacillin and trimethoprim and increased the A--&gt;B transport of trimethoprim while non-P-gp inhibitors (e.g., PAH) had no effect.	Cyclosporine	30-42	ATP binding cassette subfamily B member 1	Homo sapiens	201-205
11923685-8	2002	The CsA-treated mothers and their pups (15 and 25 mg/kg/day dose) had a significant increase in the percentage of CD4+CD8+ thymocytes and a significant decrease in the percentages of CD4+, CD3hi, and T-cell receptor (TCR)hi thymocyte phenotype subsets and CD4/CD8 ratios.	Cyclosporine	4-7	CD4 molecule	Homo sapiens	114-117
11923685-8	2002	The CsA-treated mothers and their pups (15 and 25 mg/kg/day dose) had a significant increase in the percentage of CD4+CD8+ thymocytes and a significant decrease in the percentages of CD4+, CD3hi, and T-cell receptor (TCR)hi thymocyte phenotype subsets and CD4/CD8 ratios.	Cyclosporine	4-7	CD4 molecule	Homo sapiens	183-186
11923685-8	2002	The CsA-treated mothers and their pups (15 and 25 mg/kg/day dose) had a significant increase in the percentage of CD4+CD8+ thymocytes and a significant decrease in the percentages of CD4+, CD3hi, and T-cell receptor (TCR)hi thymocyte phenotype subsets and CD4/CD8 ratios.	Cyclosporine	4-7	CD4 molecule	Homo sapiens	183-186
11923685-9	2002	Thymocyte proliferative responses to concanavalin A + interleukin-2 were also significantly decreased in the mother and pup after both doses of CsA.	Cyclosporine	144-147	interleukin 2	Homo sapiens	54-67
11786533-7	2002	This promoter segment was cyclosporin A-sensitive, and mutation of the NFAT site abrogated inducible promoter activity and inhibited formation of an inducible DNA x protein complex containing NFATc2 in primary T cells.	Cyclosporine	26-39	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2	Mus musculus	192-198
11960369-3	2002	When added to isolated mitochondria, BaxBH3 and Bcl2BH3 induced MMP, which was inhibited by CsA.	Cyclosporine	92-95	BCL2 apoptosis regulator	Homo sapiens	48-55
11790791-6	2002	The induction of the mitochondrial permeability transition (MPT) was documented by the cyclosporin A (CyA) sensitivity of the release of cytochrome c, the release of malate dehydrogenase from the mitochondrial matrix, the loss of the mitochondrial membrane potential, and the pronounced swelling of these organelles, as assessed by electron microscopy.	Cyclosporine	87-100	cytochrome c, somatic	Homo sapiens	137-149
11790791-6	2002	The induction of the mitochondrial permeability transition (MPT) was documented by the cyclosporin A (CyA) sensitivity of the release of cytochrome c, the release of malate dehydrogenase from the mitochondrial matrix, the loss of the mitochondrial membrane potential, and the pronounced swelling of these organelles, as assessed by electron microscopy.	Cyclosporine	102-105	cytochrome c, somatic	Homo sapiens	137-149
11901205-7	2002	Molecular analyzes showed that the beneficial effects of targeting of LIGHT in CsA-treated recipients were accompanied by decreased intragraft expression of interferon (IFN)-gamma, plus IFN-gamma-induced chemokine, inducible protein-10, and its receptor, CXCR3.	Cyclosporine	79-82	interferon gamma	Mus musculus	157-179
11907418-8	2002	During cyclosporine, glomerular filtration rate decreased from 98+/-9 ml/min/1.732 to 85+/-10 ml/min/1.732 (P&lt;0.05), and ERPF decreased from 597+/-108 ml/min/1.732 to 438+/-84 ml/min/1.732 (P&lt;0.01).	Cyclosporine	7-19	CD59 molecule (CD59 blood group)	Homo sapiens	73-78
11907418-8	2002	During cyclosporine, glomerular filtration rate decreased from 98+/-9 ml/min/1.732 to 85+/-10 ml/min/1.732 (P&lt;0.05), and ERPF decreased from 597+/-108 ml/min/1.732 to 438+/-84 ml/min/1.732 (P&lt;0.01).	Cyclosporine	7-19	CD59 molecule (CD59 blood group)	Homo sapiens	97-102
11907418-8	2002	During cyclosporine, glomerular filtration rate decreased from 98+/-9 ml/min/1.732 to 85+/-10 ml/min/1.732 (P&lt;0.05), and ERPF decreased from 597+/-108 ml/min/1.732 to 438+/-84 ml/min/1.732 (P&lt;0.01).	Cyclosporine	7-19	CD59 molecule (CD59 blood group)	Homo sapiens	97-102
11907418-8	2002	During cyclosporine, glomerular filtration rate decreased from 98+/-9 ml/min/1.732 to 85+/-10 ml/min/1.732 (P&lt;0.05), and ERPF decreased from 597+/-108 ml/min/1.732 to 438+/-84 ml/min/1.732 (P&lt;0.01).	Cyclosporine	7-19	CD59 molecule (CD59 blood group)	Homo sapiens	97-102
11809535-4	2002	These inhibitory potencies for P-gp were more potent than typical P-gp inhibitors, cyclosporine A and verapamil.	Cyclosporine	83-97	ATP binding cassette subfamily B member 1	Homo sapiens	31-35
11866578-15	2002	The pair of analytical expressions are used to calculate ring current contributions to the CSA (Deltasigma) of 1H(N) backbone amide resonances in a structure of the second type 2 module from the protein fibronectin.	Cyclosporine	91-94	fibronectin 1	Homo sapiens	203-214
11888457-8	2002	The mechanism of interaction between St John"s wort and cyclosporine has been recently elucidated and involves both P-glycoprotein and cytochrome P 450 3A4 expression.	Cyclosporine	56-68	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	135-155
11932959-1	2002	The current work evaluated the effect of the CYP3A inhibitor ketoconazole on the oral absorption and first-pass metabolism of cyclosporine administered as the SangCyA formulation.	Cyclosporine	126-138	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	45-50
11966773-10	2002	Pharmacological drugs used in therapy of RA, such as cyclosporin and methotrexate, induced a fourfold increase of IL-17R mRNA expression and augmented the IL-17-stimulated IL-8 expression.	Cyclosporine	53-64	C-X-C motif chemokine ligand 8	Homo sapiens	172-176
11926202-14	2002	The explanation remains speculative but probably relates to the known cyclosporine-induced upregulation of ecNOS gene and enzyme activity.	Cyclosporine	70-82	nitric oxide synthase 3	Homo sapiens	107-112
11877340-7	2002	The accumulation of NBD-octreotide in capillary lumens was inhibited in a concentration-dependent manner by unlabelled octreotide, by verapamil, PSC-833 and cyclosporin A, potent inhibitors of p-glycoprotein, and by leucotriene C(4), a strong modulator of Mrp2.	Cyclosporine	157-170	ATP binding cassette subfamily B member 1	Homo sapiens	193-207
11877476-6	2002	CsA restored normal CD4(+) T cell levels, both in terms of percentage and absolute numbers.	Cyclosporine	0-3	CD4 molecule	Homo sapiens	20-23
11865967-1	2002	Cyclosporine and tacrolimus are substrates and potent inhibitors of the multidrug transporter, P-glycoprotein, in vitro.	Cyclosporine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	95-109
11865967-6	2002	However, patients who were started on tacrolimus or cyclosporine had an initial decline in expression of P-gp on CD4 T cells.	Cyclosporine	52-64	CD4 molecule	Homo sapiens	113-116
11891440-3	2002	However, the same cyclosporin A concentration (500 microg/L) was found to be the most efficient concentration to inhibit the hypoxia-induced mitochondrial release of Ca2+ in primary rat hippocampal cells with cytosolic Ca2+ concentrations not significantly different from normoxic controls.	Cyclosporine	18-31	carbonic anhydrase 2	Rattus norvegicus	166-169
11891440-3	2002	However, the same cyclosporin A concentration (500 microg/L) was found to be the most efficient concentration to inhibit the hypoxia-induced mitochondrial release of Ca2+ in primary rat hippocampal cells with cytosolic Ca2+ concentrations not significantly different from normoxic controls.	Cyclosporine	18-31	carbonic anhydrase 2	Rattus norvegicus	219-222
11987039-4	2002	The mode of action of Fk506 is similar to that of cyclosporin A, i.e. it exerts an inhibitory effect on transcription of interleukin 2 in T lymphocytes.	Cyclosporine	50-63	interleukin 2	Homo sapiens	121-134
12009599-0	2002	Endothelin-1 plasma levels in cyclosporine-treated stable renal transplant patients.	Cyclosporine	30-42	endothelin 1	Homo sapiens	0-12
11831844-5	2002	In this report, we demonstrate that recombinant BNip3 (rBNip3) induces mitochondrial permeability transition (MPT) and cytochrome c release from isolated mitochondria, which are inhibited by the PT inhibitor cyclosporin A (CsA).	Cyclosporine	208-221	BCL2 interacting protein 3	Homo sapiens	48-53
11861326-4	2002	The aim of this study was to investigate whether cytochrome P-450 (CYP) dependent metabolism of CsA could be responsible for ROS generation since it has been suggested that CsA may influence the CYP system to produce ROS.	Cyclosporine	96-99	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	49-65
11831844-5	2002	In this report, we demonstrate that recombinant BNip3 (rBNip3) induces mitochondrial permeability transition (MPT) and cytochrome c release from isolated mitochondria, which are inhibited by the PT inhibitor cyclosporin A (CsA).	Cyclosporine	208-221	cytochrome c, somatic	Homo sapiens	119-131
11831844-5	2002	In this report, we demonstrate that recombinant BNip3 (rBNip3) induces mitochondrial permeability transition (MPT) and cytochrome c release from isolated mitochondria, which are inhibited by the PT inhibitor cyclosporin A (CsA).	Cyclosporine	223-226	BCL2 interacting protein 3	Homo sapiens	48-53
11992648-0	2002	Modulation of mdr1a and CYP3A gene expression in the intestine and liver as possible cause of changes in the cyclosporin A disposition kinetics by dexamethasone.	Cyclosporine	109-122	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	24-29
11992648-15	2002	Our results indicate that the drug interaction between CyA and DEX is a consequence of modulation of P-gp and CYP3A2 gene expression by DEX, with differential dose-dependence.	Cyclosporine	55-58	phosphoglycolate phosphatase	Rattus norvegicus	101-105
12022946-5	2002	Pore opening is inhibited by cyclosporin A analogues with the same affinity as they inhibit the peptidyl-prolyl cis-trans isomerase activity of mitochondrial cyclophilin (CyP-D).	Cyclosporine	29-42	peptidylprolyl isomerase F	Homo sapiens	144-169
12022946-5	2002	Pore opening is inhibited by cyclosporin A analogues with the same affinity as they inhibit the peptidyl-prolyl cis-trans isomerase activity of mitochondrial cyclophilin (CyP-D).	Cyclosporine	29-42	peptidylprolyl isomerase F	Homo sapiens	171-176
11861326-4	2002	The aim of this study was to investigate whether cytochrome P-450 (CYP) dependent metabolism of CsA could be responsible for ROS generation since it has been suggested that CsA may influence the CYP system to produce ROS.	Cyclosporine	173-176	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	49-65
11861326-4	2002	The aim of this study was to investigate whether cytochrome P-450 (CYP) dependent metabolism of CsA could be responsible for ROS generation since it has been suggested that CsA may influence the CYP system to produce ROS.	Cyclosporine	173-176	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	67-70
11861326-4	2002	The aim of this study was to investigate whether cytochrome P-450 (CYP) dependent metabolism of CsA could be responsible for ROS generation since it has been suggested that CsA may influence the CYP system to produce ROS.	Cyclosporine	173-176	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	195-198
11861326-4	2002	The aim of this study was to investigate whether cytochrome P-450 (CYP) dependent metabolism of CsA could be responsible for ROS generation since it has been suggested that CsA may influence the CYP system to produce ROS.	Cyclosporine	96-99	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	67-70
11861326-4	2002	The aim of this study was to investigate whether cytochrome P-450 (CYP) dependent metabolism of CsA could be responsible for ROS generation since it has been suggested that CsA may influence the CYP system to produce ROS.	Cyclosporine	96-99	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	195-198
12064514-7	2002	Recombinant calcineurin introduced into cells that have previously been treated with okadaic acid and cyclosporin A, which are inhibitors of phosphatases (PP1/PP2A and PP2B), has a direct effect on the phosphorylation status on all phosphorylation sites studied.	Cyclosporine	102-115	inorganic pyrophosphatase 1	Homo sapiens	155-158
11805199-1	2002	The adrenochrome reaction (oxidation of epinephrine to adrenochrome) has been widely employed as a standard assay for reactive oxygen species, produced under a variety of conditions, including those produced during cytochrome P450 (CYP)-mediated oxidation of substrates such as cyclosporine.	Cyclosporine	278-290	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	215-230
11876576-9	2002	CsA antagonised the harmful effects of RAS over-expression on renal damage in double transgenic rats harbouring human renin and angiotensinogen genes.	Cyclosporine	0-3	renin	Homo sapiens	118-123
11876576-10	2002	The protection was due to anti-inflammatory properties of CsA by inhibition of interleukin-6 and inducible nitric oxide synthase (iNOS) expression.	Cyclosporine	58-61	interleukin 6	Rattus norvegicus	79-92
11876576-10	2002	The protection was due to anti-inflammatory properties of CsA by inhibition of interleukin-6 and inducible nitric oxide synthase (iNOS) expression.	Cyclosporine	58-61	nitric oxide synthase 2	Rattus norvegicus	97-128
11876576-10	2002	The protection was due to anti-inflammatory properties of CsA by inhibition of interleukin-6 and inducible nitric oxide synthase (iNOS) expression.	Cyclosporine	58-61	nitric oxide synthase 2	Rattus norvegicus	130-134
11876576-11	2002	Other studies have confirmed the inhibitory effect of CsA on iNOS.	Cyclosporine	54-57	nitric oxide synthase 2	Rattus norvegicus	61-65
11876576-13	2002	However, because angiotensin II plays a major role in the development of CsA-induced structural renal damage, pharmacological inhibition of RAS in CsA-treatment may have some beneficial effects beyond blood pressure control.	Cyclosporine	73-76	angiotensinogen	Rattus norvegicus	17-31
11823439-4	2002	The cyclophilin inhibitor cyclosporin A slows pre-mRNA splicing in vitro, and we show that its inhibition of the second step of splicing is caused by blocking the action of USA-CyP within its complex with hPrp18.	Cyclosporine	26-39	peptidylprolyl isomerase H	Homo sapiens	173-180
11823439-5	2002	Cyclosporin A also slows splicing in vivo, and we show that this slowing results specifically from inhibition of USA-CyP.	Cyclosporine	0-13	peptidylprolyl isomerase H	Homo sapiens	113-120
11805199-1	2002	The adrenochrome reaction (oxidation of epinephrine to adrenochrome) has been widely employed as a standard assay for reactive oxygen species, produced under a variety of conditions, including those produced during cytochrome P450 (CYP)-mediated oxidation of substrates such as cyclosporine.	Cyclosporine	278-290	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	232-235
11842822-0	2002	Patients chosen for treatment with cyclosporine because of severe rheumatoid arthritis are more likely to carry HLA-DRB1 shared epitope alleles, and have earlier disease onset.	Cyclosporine	35-47	major histocompatibility complex, class II, DR beta 1	Homo sapiens	112-120
11842822-1	2002	OBJECTIVE: To determine whether patients with rheumatoid arthritis (RA) selected for treatment with cyclosporin A (CSA) because of severe disease are more likely to carry HLA-DRB1 alleles encoding the conserved "shared epitope" (SE) sequence.	Cyclosporine	100-113	major histocompatibility complex, class II, DR beta 1	Homo sapiens	171-179
11842822-1	2002	OBJECTIVE: To determine whether patients with rheumatoid arthritis (RA) selected for treatment with cyclosporin A (CSA) because of severe disease are more likely to carry HLA-DRB1 alleles encoding the conserved "shared epitope" (SE) sequence.	Cyclosporine	115-118	major histocompatibility complex, class II, DR beta 1	Homo sapiens	171-179
11700317-0	2002	Transport activity and surface expression of the Na+-Ca2+ exchanger NCX1 are inhibited by the immunosuppressive agent cyclosporin A and by the nonimmunosuppressive agent PSC833.	Cyclosporine	118-131	solute carrier family 8 member A1	Homo sapiens	68-72
11849412-16	2002	In particular, the use of cyclosporine compared to tacrolimus was associated with a tenfold increase in TGF-beta mRNA (TGF-beta mRNA at 6 months, CsA vs. Tac, 3 +/- 0.3 vs. 2 +/- 0.3 log copies, P &lt; 0.05), interstitial fibrosis (Vvi at 6 months, CsA vs. Tac, 33 +/- 4% vs. 24 +/- 2%, P &lt; 0.05).	Cyclosporine	26-38	transforming growth factor beta 1	Homo sapiens	104-112
11849412-16	2002	In particular, the use of cyclosporine compared to tacrolimus was associated with a tenfold increase in TGF-beta mRNA (TGF-beta mRNA at 6 months, CsA vs. Tac, 3 +/- 0.3 vs. 2 +/- 0.3 log copies, P &lt; 0.05), interstitial fibrosis (Vvi at 6 months, CsA vs. Tac, 33 +/- 4% vs. 24 +/- 2%, P &lt; 0.05).	Cyclosporine	26-38	transforming growth factor beta 1	Homo sapiens	119-127
11805719-1	2002	The intracellular class of proteins that bind the interleukin-2 suppressing drugs (cyclosporin, tacrolimus, and sirolimus) are called immunophilins.	Cyclosporine	83-94	interleukin 2	Homo sapiens	50-63
11700317-1	2002	Cyclosporin A (CsA) treatment of HEK 293 cells expressing the rat heart RHE-1 (NCX1.1, EMBL accession number ) or the rat brain RBE-2 (NCX1.5, GenBank(TM) accession number ) Na(+)-Ca(2+) exchanger inhibited their transport activity in a concentration-dependent manner.	Cyclosporine	0-13	solute carrier family 8 member A1	Homo sapiens	79-83
11700317-1	2002	Cyclosporin A (CsA) treatment of HEK 293 cells expressing the rat heart RHE-1 (NCX1.1, EMBL accession number ) or the rat brain RBE-2 (NCX1.5, GenBank(TM) accession number ) Na(+)-Ca(2+) exchanger inhibited their transport activity in a concentration-dependent manner.	Cyclosporine	0-13	calcium voltage-gated channel subunit alpha1 E	Rattus norvegicus	128-133
11700317-1	2002	Cyclosporin A (CsA) treatment of HEK 293 cells expressing the rat heart RHE-1 (NCX1.1, EMBL accession number ) or the rat brain RBE-2 (NCX1.5, GenBank(TM) accession number ) Na(+)-Ca(2+) exchanger inhibited their transport activity in a concentration-dependent manner.	Cyclosporine	0-13	solute carrier family 8 member A1	Rattus norvegicus	135-139
11784143-9	2002	Compound 5 has greater potency than verapamil and is equipotent with cyclosporin A, for inhibiting P-glycoprotein function.	Cyclosporine	69-82	ATP binding cassette subfamily B member 1	Homo sapiens	99-113
11755532-4	2002	Moreover, caspase-3 stimulated the rate of mitochondrial state 4 respiration, superoxide production and NAD(P)H oxidation in a Bcl-xL- and cyclosporin A-inhibitable manner.	Cyclosporine	139-152	caspase 3	Homo sapiens	10-19
11890524-6	2002	Tx-CsA-treatment abrogated the IBDV-induced inflammatory response and significantly (P &lt; 0.05) reduced the incidence of apoptotic bursa cells and the expression of cytokines such as interleukin 2 (IL-2) and interferon-gamma (IFN-gamma) in comparison to T cell-intact birds.	Cyclosporine	3-6	interleukin 2	Homo sapiens	200-204
12221903-12	2002	In recipients with stable graft function we found a correlation between CsA concentration and tPA activity (p = 0.04), as well as an association between the dose of CsA and uPA-Ant concentration in plasma (p = 0.049).	Cyclosporine	72-75	plasminogen activator, tissue type	Homo sapiens	94-97
12221903-12	2002	In recipients with stable graft function we found a correlation between CsA concentration and tPA activity (p = 0.04), as well as an association between the dose of CsA and uPA-Ant concentration in plasma (p = 0.049).	Cyclosporine	165-168	proline rich acidic protein 1	Homo sapiens	173-176
12221903-18	2002	The results of our study suggest a stimulatory effect of CsA on tPA and PAI-I plasma activities as well as on uPA-Ant concentration, while prednisone in turn seems to enhance PAI-I activity in plasma and decrease uPA expression.	Cyclosporine	57-60	plasminogen activator, tissue type	Homo sapiens	64-67
11817583-6	2002	The expression of ADAM-TS4, ADAM-TS5, and MMP-13 was abrogated by the inclusion of 10 microM CSA in the culture medium.	Cyclosporine	93-96	matrix metallopeptidase 13	Homo sapiens	42-48
11817607-0	2002	Cyclosporine differentially regulates interleukin-10, interleukin-15, and tumor necrosis factor a production by rheumatoid synoviocytes.	Cyclosporine	0-12	tumor necrosis factor	Homo sapiens	74-95
11890524-6	2002	Tx-CsA-treatment abrogated the IBDV-induced inflammatory response and significantly (P &lt; 0.05) reduced the incidence of apoptotic bursa cells and the expression of cytokines such as interleukin 2 (IL-2) and interferon-gamma (IFN-gamma) in comparison to T cell-intact birds.	Cyclosporine	3-6	interferon gamma	Homo sapiens	228-237
12014835-5	2002	Reduced IGF-I signalling is involved in muscle atrophy and results from decreased muscle exercise, reduced growth hormone and insulin levels, reduced vitamin D, and treatment with drugs like corticosteroids, dexamethasone, and cyclosporin.	Cyclosporine	227-238	insulin like growth factor 1	Homo sapiens	8-13
15618710-6	2002	A similar result was obtained for cyclosporin A (40 microM), another specific CYP3A inhibitor.	Cyclosporine	34-47	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	78-83
11849198-5	2002	As indinavir and cyclosporin are substrates for both CYP3A4 and the multi drug transporter P-glycoprotein we hypothesized that modulation of P-glycoprotein expression and function by SJW may contribute to the development of potentially harmful drug-drug interactions.	Cyclosporine	17-28	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	53-59
11849198-5	2002	As indinavir and cyclosporin are substrates for both CYP3A4 and the multi drug transporter P-glycoprotein we hypothesized that modulation of P-glycoprotein expression and function by SJW may contribute to the development of potentially harmful drug-drug interactions.	Cyclosporine	17-28	ATP binding cassette subfamily B member 1	Homo sapiens	91-105
11849198-5	2002	As indinavir and cyclosporin are substrates for both CYP3A4 and the multi drug transporter P-glycoprotein we hypothesized that modulation of P-glycoprotein expression and function by SJW may contribute to the development of potentially harmful drug-drug interactions.	Cyclosporine	17-28	ATP binding cassette subfamily B member 1	Homo sapiens	141-155
12036392-14	2002	Thus, rhabdomyolysis has occurred following the coadministration of cyclosporin, a potent CYP3A4 and P-glycoprotein inhibitor, and lovastatin.	Cyclosporine	68-79	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	90-96
12036392-14	2002	Thus, rhabdomyolysis has occurred following the coadministration of cyclosporin, a potent CYP3A4 and P-glycoprotein inhibitor, and lovastatin.	Cyclosporine	68-79	ATP binding cassette subfamily B member 1	Homo sapiens	101-115
11789662-10	2002	LPS or CM increased iNOS expression while CsA pretreatment reduced iNOS expression.	Cyclosporine	42-45	nitric oxide synthase 2	Rattus norvegicus	67-71
11789662-12	2002	This study demonstrates that NO produced during endotoxemia and under the present conditions is protective to the liver and may function as an adaptive mechanism and that the inhibition of iNOS by compounds like CsA produce unfavorable effects.	Cyclosporine	212-215	nitric oxide synthase 2	Rattus norvegicus	189-193
11990773-4	2002	Drug levels in Pgp-expressing organs may be increased by modulation of this Pgp-facilitated transport with several compounds, such as cyclosporin A.	Cyclosporine	134-147	ATP binding cassette subfamily B member 1	Homo sapiens	15-18
11752040-10	2002	The only significant difference between patients who received tacrolimus and those who received cyclosporine was in pancreatic secretion capacity at week 3 after transplantation, when the increment of C-peptide secretion was 57% lower and the increment of insulin secretion was 48% lower for patients receiving tacrolimus.	Cyclosporine	96-108	insulin	Homo sapiens	201-210
12497749-1	2002	AIM: Hepatic metabolism of sildenafil uses the same metabolic pathway as the calcineurin inhibitors (cyclosporine/tacrolimus), through the CYP3A4 isoenzyme.	Cyclosporine	101-113	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	139-145
11990773-4	2002	Drug levels in Pgp-expressing organs may be increased by modulation of this Pgp-facilitated transport with several compounds, such as cyclosporin A.	Cyclosporine	134-147	ATP binding cassette subfamily B member 1	Homo sapiens	76-79
11740395-0	2001	Transforming growth factor-beta1 and tumor growth factor-beta-inducible gene-H3 in nonrenal transplant cyclosporine nephropathy.	Cyclosporine	103-115	transforming growth factor beta 1	Homo sapiens	0-32
11840795-7	2002	The aim of this study was to investigate the effect of complementary immune suppression with the IL-2 synthesis inhibitor cyclosporin and the IL-2 receptor antagonist basiliximab on the incidence of transplant rejection after high-risk keratoplasty.	Cyclosporine	122-133	interleukin 2	Homo sapiens	97-101
11719356-1	2001	Cyclosporine A (CsA) inhibits P-glycoprotein (Pgp)-mediated cellular export of anthracyclines at clinically achievable concentrations.	Cyclosporine	0-14	ATP binding cassette subfamily B member 1	Homo sapiens	30-44
11831486-0	2001	Immunohistochemical analysis of epidermal growth factor receptor in cyclosporin A-induced gingival overgrowth.	Cyclosporine	68-81	epidermal growth factor receptor	Homo sapiens	32-64
11831486-2	2001	The purpose of this study was to evaluate the expression of EGF-receptor (EGF-r) in frozen sections of CsA-induced overgrown gingival tissue using immunohistochemical and semiquantitative techniques.	Cyclosporine	103-106	epidermal growth factor receptor	Homo sapiens	60-79
11831486-5	2001	The expression of EGF-r was more pronounced in the oral gingival epithelium of CsA-induced overgrown gingiva as compared to those of the clinically healthy gingival specimens.	Cyclosporine	79-82	epidermal growth factor receptor	Homo sapiens	18-23
11831486-7	2001	In conclusion, the results of the present study may suggest that CsA affects EGF-r metabolism in gingival keratinocytes resulting in an increased number of cell surface receptors, which may eventually play a role in the pathogenesis of gingival tissue alterations.	Cyclosporine	65-68	epidermal growth factor receptor	Homo sapiens	77-82
12644894-0	2003	Regulation of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus at concentrations that inhibit calcineurin activity and involving the transcription factor CREB.	Cyclosporine	78-91	insulin	Homo sapiens	20-27
12644894-5	2003	However, after stimulation by the major second messengers in the regulation of the insulin gene, cAMP and depolarization-induced calcium influx, both tacrolimus and cyclosporin A inhibited human insulin gene transcription in a concentration-dependent manner with IC(50) values of 1 nM and 30 nM, respectively.	Cyclosporine	165-178	insulin	Homo sapiens	83-90
12644894-5	2003	However, after stimulation by the major second messengers in the regulation of the insulin gene, cAMP and depolarization-induced calcium influx, both tacrolimus and cyclosporin A inhibited human insulin gene transcription in a concentration-dependent manner with IC(50) values of 1 nM and 30 nM, respectively.	Cyclosporine	165-178	insulin	Homo sapiens	195-202
12644894-7	2003	These data demonstrate for the first time that cAMP- and calcium-induced activity of the human insulin gene is mediated by CREB and blocked by both tacrolimus and cyclosporin A at concentrations that inhibit calcineurin phosphatase activity.	Cyclosporine	163-176	insulin	Homo sapiens	95-102
12644894-8	2003	Since also the immunosuppressive effects of cyclosporin A and tacrolimus are thought to be secondary to inhibition of calcineurin, the present study suggests that inhibition of human insulin gene transcription by the immunosuppressants is clinically important and may contribute to their diabetogenic effect.	Cyclosporine	44-57	insulin	Homo sapiens	183-190
11719356-1	2001	Cyclosporine A (CsA) inhibits P-glycoprotein (Pgp)-mediated cellular export of anthracyclines at clinically achievable concentrations.	Cyclosporine	0-14	ATP binding cassette subfamily B member 1	Homo sapiens	46-49
11719356-1	2001	Cyclosporine A (CsA) inhibits P-glycoprotein (Pgp)-mediated cellular export of anthracyclines at clinically achievable concentrations.	Cyclosporine	16-19	ATP binding cassette subfamily B member 1	Homo sapiens	30-44
11719356-1	2001	Cyclosporine A (CsA) inhibits P-glycoprotein (Pgp)-mediated cellular export of anthracyclines at clinically achievable concentrations.	Cyclosporine	16-19	ATP binding cassette subfamily B member 1	Homo sapiens	46-49
11719356-7	2001	The effect of CsA on survival was greatest in patients with moderate or bright Pgp expression (median 12 months with CsA versus 4 months for controls) compared to patients with absent or low Pgp expression (median 6 months in both arms).	Cyclosporine	14-17	ATP binding cassette subfamily B member 1	Homo sapiens	79-82
12903763-14	2001	Cyclosporin A, inhibitor of CaN, inhibited 3H-TdR incorporation of the airway smooth muscle cells induced by U-II in a dose-dependent manner.	Cyclosporine	0-13	urotensin 2	Rattus norvegicus	109-113
12152879-3	2001	Specific inhibitors of mitochondrial channels ADP and cyclosporine A prevented beta-amyloid peptide-induced swelling of mitochondria.	Cyclosporine	54-68	amyloid beta precursor protein	Homo sapiens	79-99
11733621-1	2001	BACKGROUND: Endothelin-1 (ET-1) is a potent vasoconstrictive peptide which plays an important pathophysiological role in ischaemic renal failure and drug-induced renal injury such as cyclosporin A (CsA)- and tacrolimus-associated nephrotoxicity.	Cyclosporine	183-196	endothelin 1	Homo sapiens	12-24
11762554-1	2001	Immunosuppressive agents such as cyclosporine, tacrolimus, sirolimus, and corticosteroids are substrates for the transmembrane multidrug resistance pump P-glycoprotein (P-gp).	Cyclosporine	33-45	ATP binding cassette subfamily B member 1	Homo sapiens	153-167
11762554-1	2001	Immunosuppressive agents such as cyclosporine, tacrolimus, sirolimus, and corticosteroids are substrates for the transmembrane multidrug resistance pump P-glycoprotein (P-gp).	Cyclosporine	33-45	ATP binding cassette subfamily B member 1	Homo sapiens	169-173
11886532-3	2001	Here, we show that cyclosporine A (28 mg per kg), at a dose that results in systemic immunosuppression, potentiates tributyltin-induced skin irritation through increased tumor necrosis factor alpha production, associated with increased tributyltin-induced activation of transcription factor nuclear factor kappa B in cyclosporine-A-treated mice.	Cyclosporine	19-33	tumor necrosis factor	Mus musculus	170-197
11886532-10	2001	Cyclophilin D suppression prevented cyclosporine A potentiation of tributyltin-induced cellular oxidative activity, indicating the key role of the binding of cyclosporine A to mitochondrial cyclophilin D in mediating this effect.	Cyclosporine	36-50	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	0-13
11886532-10	2001	Cyclophilin D suppression prevented cyclosporine A potentiation of tributyltin-induced cellular oxidative activity, indicating the key role of the binding of cyclosporine A to mitochondrial cyclophilin D in mediating this effect.	Cyclosporine	36-50	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	176-203
11886532-10	2001	Cyclophilin D suppression prevented cyclosporine A potentiation of tributyltin-induced cellular oxidative activity, indicating the key role of the binding of cyclosporine A to mitochondrial cyclophilin D in mediating this effect.	Cyclosporine	158-172	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	0-13
11886532-10	2001	Cyclophilin D suppression prevented cyclosporine A potentiation of tributyltin-induced cellular oxidative activity, indicating the key role of the binding of cyclosporine A to mitochondrial cyclophilin D in mediating this effect.	Cyclosporine	158-172	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	176-203
11767997-3	2001	The changes in dilatation of the left coronary artery in response to bradykinin at doses of 0.2, 0.6 and 2.0 microg/min in the CSA group were significantly greater than those in the other 2 groups.	Cyclosporine	127-130	kininogen 1	Homo sapiens	69-79
11767997-5	2001	Bradykinin caused a similar increase in coronary blood flow in the control group and CSA group, but had less of an effect in the CSA+CAD group.	Cyclosporine	85-88	kininogen 1	Homo sapiens	0-10
11733621-1	2001	BACKGROUND: Endothelin-1 (ET-1) is a potent vasoconstrictive peptide which plays an important pathophysiological role in ischaemic renal failure and drug-induced renal injury such as cyclosporin A (CsA)- and tacrolimus-associated nephrotoxicity.	Cyclosporine	183-196	endothelin 1	Homo sapiens	26-30
11733621-1	2001	BACKGROUND: Endothelin-1 (ET-1) is a potent vasoconstrictive peptide which plays an important pathophysiological role in ischaemic renal failure and drug-induced renal injury such as cyclosporin A (CsA)- and tacrolimus-associated nephrotoxicity.	Cyclosporine	198-201	endothelin 1	Homo sapiens	12-24
11733621-1	2001	BACKGROUND: Endothelin-1 (ET-1) is a potent vasoconstrictive peptide which plays an important pathophysiological role in ischaemic renal failure and drug-induced renal injury such as cyclosporin A (CsA)- and tacrolimus-associated nephrotoxicity.	Cyclosporine	198-201	endothelin 1	Homo sapiens	26-30
11844153-5	2001	Finally, potential therapeutic strategies are discussed to modify NF-kappaB activity with certain immunosuppression medications, including cyclosporine, tacrolimus, and glucocorticoids.	Cyclosporine	139-151	nuclear factor kappa B subunit 1	Homo sapiens	66-75
11691790-10	2001	Additionally, in drug-selected MCF7/Adr cells, which constitutively express high levels of Pgp, inhibition of Pgp by cyclosporin A resulted in significantly increased accumulation of TMA-DPH in intracellular membranes but no difference in its accumulation in the extracellular leaflet of the plasma membrane.	Cyclosporine	117-130	ATP binding cassette subfamily B member 1	Homo sapiens	91-94
12901109-6	2001	RESULTS: Both lovastatin and CsA inhibited PBMC proliferation, expression of IL-2 and IFN-gamma, and NK cell cytotoxicity in a dose-dependent manner.	Cyclosporine	29-32	interleukin 2	Homo sapiens	77-81
12901109-6	2001	RESULTS: Both lovastatin and CsA inhibited PBMC proliferation, expression of IL-2 and IFN-gamma, and NK cell cytotoxicity in a dose-dependent manner.	Cyclosporine	29-32	interferon gamma	Homo sapiens	86-95
11707743-12	2001	A decrease of insulin release by PBMCs was reproduced with plastic-adherent cells and was abolished by depletion of MHC class II+ cells or by addition of 100 microg/ml gadolinium (which inhibits macrophages), but not by cyclosporine.	Cyclosporine	220-232	insulin	Homo sapiens	14-21
11606756-3	2001	Here, we report that the up-regulation of slow myosin heavy chain (MyHC) and a MyHC-slow promoter induced by slow motor neurons in regenerating rat soleus muscle is prevented by the calcineurin inhibitors cyclosporin A (CsA), FK506, and the calcineurin inhibitory protein domain from cain/cabin-1.	Cyclosporine	205-218	myosin heavy chain 13	Rattus norvegicus	67-71
11606756-3	2001	Here, we report that the up-regulation of slow myosin heavy chain (MyHC) and a MyHC-slow promoter induced by slow motor neurons in regenerating rat soleus muscle is prevented by the calcineurin inhibitors cyclosporin A (CsA), FK506, and the calcineurin inhibitory protein domain from cain/cabin-1.	Cyclosporine	205-218	myosin heavy chain 13	Rattus norvegicus	79-83
11606756-3	2001	Here, we report that the up-regulation of slow myosin heavy chain (MyHC) and a MyHC-slow promoter induced by slow motor neurons in regenerating rat soleus muscle is prevented by the calcineurin inhibitors cyclosporin A (CsA), FK506, and the calcineurin inhibitory protein domain from cain/cabin-1.	Cyclosporine	205-218	calcineurin binding protein 1	Rattus norvegicus	284-288
11606756-3	2001	Here, we report that the up-regulation of slow myosin heavy chain (MyHC) and a MyHC-slow promoter induced by slow motor neurons in regenerating rat soleus muscle is prevented by the calcineurin inhibitors cyclosporin A (CsA), FK506, and the calcineurin inhibitory protein domain from cain/cabin-1.	Cyclosporine	205-218	calcineurin binding protein 1	Rattus norvegicus	289-296
11606756-3	2001	Here, we report that the up-regulation of slow myosin heavy chain (MyHC) and a MyHC-slow promoter induced by slow motor neurons in regenerating rat soleus muscle is prevented by the calcineurin inhibitors cyclosporin A (CsA), FK506, and the calcineurin inhibitory protein domain from cain/cabin-1.	Cyclosporine	220-223	myosin heavy chain 13	Rattus norvegicus	67-71
11606756-3	2001	Here, we report that the up-regulation of slow myosin heavy chain (MyHC) and a MyHC-slow promoter induced by slow motor neurons in regenerating rat soleus muscle is prevented by the calcineurin inhibitors cyclosporin A (CsA), FK506, and the calcineurin inhibitory protein domain from cain/cabin-1.	Cyclosporine	220-223	myosin heavy chain 13	Rattus norvegicus	79-83
11606756-3	2001	Here, we report that the up-regulation of slow myosin heavy chain (MyHC) and a MyHC-slow promoter induced by slow motor neurons in regenerating rat soleus muscle is prevented by the calcineurin inhibitors cyclosporin A (CsA), FK506, and the calcineurin inhibitory protein domain from cain/cabin-1.	Cyclosporine	220-223	calcineurin binding protein 1	Rattus norvegicus	284-288
11606756-3	2001	Here, we report that the up-regulation of slow myosin heavy chain (MyHC) and a MyHC-slow promoter induced by slow motor neurons in regenerating rat soleus muscle is prevented by the calcineurin inhibitors cyclosporin A (CsA), FK506, and the calcineurin inhibitory protein domain from cain/cabin-1.	Cyclosporine	220-223	calcineurin binding protein 1	Rattus norvegicus	289-296
11606756-5	2001	The activation of MyHC-slow induced by direct electrostimulation of denervated regenerating muscle with a continuous low frequency impulse pattern is blocked by CsA, showing that calcineurin function in muscle fibers and not in motor neurons is responsible for nerve-dependent specification of slow muscle fibers.	Cyclosporine	161-164	myosin heavy chain 13	Rattus norvegicus	18-22
11606756-6	2001	Calcineurin is also involved in the maintenance of the slow muscle fiber gene program because in the adult soleus muscle, cain causes a switch from MyHC-slow to fast-type MyHC-2X and MyHC-2B gene expression, and the activity of the MyHC-slow promoter is inhibited by CsA and FK506.	Cyclosporine	267-270	calcineurin binding protein 1	Rattus norvegicus	122-126
11708797-5	2001	Subsequent treatment with cyclosporin A significantly retarded growth, which suggests that ESS1 and cyclophilin A are functionally linked in yeast cells and play important roles at the G(1) phase of the cell cycle.	Cyclosporine	26-39	peptidylprolyl isomerase ESS1	Saccharomyces cerevisiae S288C	91-95
11509557-8	2001	Cyclosporin A, an inhibitor of calcineurin, blocked both IGF-I-mediated hypertrophy and up-regulation of ECM.	Cyclosporine	0-13	insulin like growth factor 1	Homo sapiens	57-62
11813632-0	2001	[Quantitative changes in CD4+ and CD8+ T-lymphocytes in the skin of patients with psoriasis treated with cyclosporin A].	Cyclosporine	105-118	CD4 molecule	Homo sapiens	25-28
11691790-10	2001	Additionally, in drug-selected MCF7/Adr cells, which constitutively express high levels of Pgp, inhibition of Pgp by cyclosporin A resulted in significantly increased accumulation of TMA-DPH in intracellular membranes but no difference in its accumulation in the extracellular leaflet of the plasma membrane.	Cyclosporine	117-130	ATP binding cassette subfamily B member 1	Homo sapiens	110-113
11719731-1	2001	BACKGROUND: Interindividual variation in the pharmacokinetics of the immunosuppressive agents cyclosporine (INN, ciclosporin) and tacrolimus may result from differences in the activity of cytochrome P4503A (CYP3A).	Cyclosporine	94-106	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	188-194
11719731-1	2001	BACKGROUND: Interindividual variation in the pharmacokinetics of the immunosuppressive agents cyclosporine (INN, ciclosporin) and tacrolimus may result from differences in the activity of cytochrome P4503A (CYP3A).	Cyclosporine	94-106	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	207-212
11719731-1	2001	BACKGROUND: Interindividual variation in the pharmacokinetics of the immunosuppressive agents cyclosporine (INN, ciclosporin) and tacrolimus may result from differences in the activity of cytochrome P4503A (CYP3A).	Cyclosporine	113-124	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	188-194
11719731-1	2001	BACKGROUND: Interindividual variation in the pharmacokinetics of the immunosuppressive agents cyclosporine (INN, ciclosporin) and tacrolimus may result from differences in the activity of cytochrome P4503A (CYP3A).	Cyclosporine	113-124	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	207-212
11750417-0	2001	CD4 and CD8 cytokine-producing T cells are transiently reduced following cyclosporine intake: maximal inhibition occurs at 2 hours coincidental with drug C(max).	Cyclosporine	73-85	CD4 molecule	Homo sapiens	0-3
11722644-0	2001	Multiple cytokines sharing the common receptor gamma chain can induce CD154/CD40 ligand expression by human CD4+ T lymphocytes via a cyclosporin A-resistant pathway.	Cyclosporine	133-146	CD40 ligand	Homo sapiens	70-75
11722644-0	2001	Multiple cytokines sharing the common receptor gamma chain can induce CD154/CD40 ligand expression by human CD4+ T lymphocytes via a cyclosporin A-resistant pathway.	Cyclosporine	133-146	CD40 ligand	Homo sapiens	76-87
11722644-0	2001	Multiple cytokines sharing the common receptor gamma chain can induce CD154/CD40 ligand expression by human CD4+ T lymphocytes via a cyclosporin A-resistant pathway.	Cyclosporine	133-146	CD4 molecule	Homo sapiens	76-79
11722644-3	2001	Cyclosporin A (CsA), which interferes with NFAT1 activation, has been shown to be an effective inhibitor of TCR-triggered CD154/CD40L expression by resting T cells.	Cyclosporine	0-13	CD40 ligand	Homo sapiens	122-127
11722644-3	2001	Cyclosporin A (CsA), which interferes with NFAT1 activation, has been shown to be an effective inhibitor of TCR-triggered CD154/CD40L expression by resting T cells.	Cyclosporine	0-13	CD40 ligand	Homo sapiens	128-133
11722644-3	2001	Cyclosporin A (CsA), which interferes with NFAT1 activation, has been shown to be an effective inhibitor of TCR-triggered CD154/CD40L expression by resting T cells.	Cyclosporine	15-18	CD40 ligand	Homo sapiens	122-127
11722644-3	2001	Cyclosporin A (CsA), which interferes with NFAT1 activation, has been shown to be an effective inhibitor of TCR-triggered CD154/CD40L expression by resting T cells.	Cyclosporine	15-18	CD40 ligand	Homo sapiens	128-133
11722644-5	2001	Recombinant IL-2-mediated CD154/CD40L expression, in contrast to that triggered by CD3/TCR stimulation, is only partially inhibited by CsA.	Cyclosporine	135-138	interleukin 2	Homo sapiens	12-16
11722644-5	2001	Recombinant IL-2-mediated CD154/CD40L expression, in contrast to that triggered by CD3/TCR stimulation, is only partially inhibited by CsA.	Cyclosporine	135-138	CD40 ligand	Homo sapiens	26-31
11722644-7	2001	A similar CsA-resistant CD154/CD40L induction pathway can be triggered in primary T cells by the combination of anti-CD3 stimulation and recombinant lymphokines.	Cyclosporine	10-13	CD40 ligand	Homo sapiens	24-29
11722644-7	2001	A similar CsA-resistant CD154/CD40L induction pathway can be triggered in primary T cells by the combination of anti-CD3 stimulation and recombinant lymphokines.	Cyclosporine	10-13	CD40 ligand	Homo sapiens	30-35
11722644-8	2001	In contrast to T lymphoblasts, the CsA-resistant CD154/CD40L induction in primary lymphocytes can be efficiently triggered by multiple cytokines which bind the common gamma chain receptor family.	Cyclosporine	35-38	CD40 ligand	Homo sapiens	49-54
11722644-8	2001	In contrast to T lymphoblasts, the CsA-resistant CD154/CD40L induction in primary lymphocytes can be efficiently triggered by multiple cytokines which bind the common gamma chain receptor family.	Cyclosporine	35-38	CD40 ligand	Homo sapiens	55-60
11836874-6	2001	The concomitant use of statins with drugs that inhibit CYP3A4 (cyclosporin, erythromycin, clarithromycin, itraconazole, and ketoconazole), may result in increased plasma concentrations of HMG-CoA reductase inhibitors leading occasionally to myotoxicity.	Cyclosporine	63-74	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	55-61
11714218-9	2001	Administration of azithromycin may have caused the increased cyclosporine concentrations in this patient through p-glycoprotein inhibition and/or competition for biliary excretion.	Cyclosporine	61-73	ATP binding cassette subfamily B member 1	Homo sapiens	113-127
11750429-0	2001	Prostaglandin E(1) inhibits cyclosporine A-induced upregulation of transforming growth factor-beta 1 in rat mesangial cells.	Cyclosporine	28-42	transforming growth factor, beta 1	Rattus norvegicus	67-100
11597611-8	2001	Furthermore, inhibition of mPTP opening by cyclosporin A partially prevented Cyto C release, caspase activation and neuronal death.	Cyclosporine	43-56	cytochrome c, somatic	Homo sapiens	77-83
11594953-7	2001	Interleukin 6 and IL-8 were increased by 10 microg/mL of CsA, whereas transforming growth factor beta, PIIIP, and total protein were unaffected.	Cyclosporine	57-60	interleukin 6	Homo sapiens	0-13
11602842-5	2001	Third we assessed whether a subtherapeutic course of cyclosporine would potentiate enhance survival in CCR5-deficient recipients.	Cyclosporine	53-65	chemokine (C-C motif) receptor 5	Mus musculus	103-107
11557129-5	2001	In hepatocytes cultured for 4 days and expressing high levels of P-gp, intracellular Rh123 accumulation was enhanced in the presence of mdr1 inhibitors (cyclosporin A, 8 and 80 microM, verapamil, 8 and 80 microM, or triton X-100, 8 microM).	Cyclosporine	153-166	phosphoglycolate phosphatase	Rattus norvegicus	65-69
11557129-6	2001	Surprisingly, in hepatocytes expressing low levels of P-gp (after 1 day of culture), time-dependent Rh123 accumulation was not enhanced, but delayed by cyclosporin A, verapamil or triton X-100.	Cyclosporine	152-165	phosphoglycolate phosphatase	Rattus norvegicus	54-58
11583938-0	2001	Cyclosporine elimination in the presence of TOR inhibitors: effects on renal function, acute rejection, and safety.	Cyclosporine	0-12	RAR related orphan receptor C	Homo sapiens	44-47
11594953-7	2001	Interleukin 6 and IL-8 were increased by 10 microg/mL of CsA, whereas transforming growth factor beta, PIIIP, and total protein were unaffected.	Cyclosporine	57-60	C-X-C motif chemokine ligand 8	Homo sapiens	18-22
11594953-9	2001	Long-term exposure to CsA reduced IL-6 but did not modify PIIIP production.	Cyclosporine	22-25	interleukin 6	Homo sapiens	34-38
11820454-5	2001	Prostaglandins and cytokines (interleukin 1, 2, 6, 8, and tumor necrosis factor alpha) accounted for the hyperalgesia induced by MnS, as it was reduced (40 to 90%) by synthesis inhibitors such as indomethacin, dexamethasone, rolipram, and cyclosporin added to the cultures at a microgram dose-range.	Cyclosporine	239-250	tumor necrosis factor	Rattus norvegicus	30-85
11557243-14	2001	Furthermore, cyclosporin increased survival time (118+/-7 min; P&lt;0.01) and survival rate (vehicle=0% and cyclosporin=80%, at 120 min after the end of bleeding), reverted the marked hypotension, decreased liver mRNA for TNF-alpha, reduced plasma TNF-alpha (28+/-7 pg ml(-1)), and restored to control values the hypo-reactivity to PE.	Cyclosporine	13-24	tumor necrosis factor	Rattus norvegicus	222-231
11557243-14	2001	Furthermore, cyclosporin increased survival time (118+/-7 min; P&lt;0.01) and survival rate (vehicle=0% and cyclosporin=80%, at 120 min after the end of bleeding), reverted the marked hypotension, decreased liver mRNA for TNF-alpha, reduced plasma TNF-alpha (28+/-7 pg ml(-1)), and restored to control values the hypo-reactivity to PE.	Cyclosporine	13-24	tumor necrosis factor	Rattus norvegicus	248-257
11707530-9	2001	Deletion of pin1(+) (pin1 Delta) did not affect cell cycle progression or cell growth, but increased sensitivity to the cyclophilin inhibitor, cyclosporin A, suggesting that cyclophilin family PPIases have overlapping functions with the Pin1p PPIase.	Cyclosporine	143-156	peptidylprolyl isomerase ESS1	Saccharomyces cerevisiae S288C	12-16
11581284-5	2001	Electrical stimulation using activity patterns typical of slow-twitch muscle, either continuously at 10 Hz or in 5-s trains at 10 Hz every 50 s, caused cyclosporin A-sensitive appearance of fluorescent foci of NFATc-GFP in all nuclei.	Cyclosporine	152-165	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	210-215
11707530-9	2001	Deletion of pin1(+) (pin1 Delta) did not affect cell cycle progression or cell growth, but increased sensitivity to the cyclophilin inhibitor, cyclosporin A, suggesting that cyclophilin family PPIases have overlapping functions with the Pin1p PPIase.	Cyclosporine	143-156	peptidylprolyl isomerase ESS1	Saccharomyces cerevisiae S288C	21-25
11907637-6	2001	We investigated 10 patients receiving immunosuppressive therapy consisting of cyclosporine A, prednisone, and azathioprine who had increased concentrations of LDL-cholesterol (LDL-C), and 10 age-matched healthy controls.	Cyclosporine	78-92	component of oligomeric golgi complex 2	Homo sapiens	176-181
11676863-1	2001	P-Glycoprotein, which mediates multidrug resistance (MDR) in cancer chemotherapy, is a principal target of cyclosporin A and [3"-keto-Bmt(1)]-[Val(2)]-cyclosporin (valspodar; PSC 833).	Cyclosporine	107-120	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
11641530-0	2001	alpha-Melanocyte stimulating hormone (MSH) decreases cyclosporine a induced apoptosis in cultured human proximal tubular cells.	Cyclosporine	53-67	proopiomelanocortin	Homo sapiens	0-36
11641530-0	2001	alpha-Melanocyte stimulating hormone (MSH) decreases cyclosporine a induced apoptosis in cultured human proximal tubular cells.	Cyclosporine	53-67	proopiomelanocortin	Homo sapiens	38-41
11641530-8	2001	In conclusion, these data suggest that tubular cell apoptosis mediated by Fas system may play a role in tubular atrophy in chronic CsA nephrotoxicity and pretreatment of alpha-MSH may have a some inhibitory effect on CsA induced tubular cell apoptosis.	Cyclosporine	217-220	proopiomelanocortin	Homo sapiens	170-179
11768242-0	2001	Angiotensin II induced cardiac hypertrophy in vivo is inhibited by cyclosporin A in adult rats.	Cyclosporine	67-80	angiotensinogen	Rattus norvegicus	0-14
11768242-2	2001	The purpose of this study was to determine if cardiac hypertrophy in animals chronically treated with angiotensin II (AngII), could be prevented by blocking this pathway with cyclosporin A (CsA).	Cyclosporine	175-188	angiotensinogen	Rattus norvegicus	102-116
11768242-2	2001	The purpose of this study was to determine if cardiac hypertrophy in animals chronically treated with angiotensin II (AngII), could be prevented by blocking this pathway with cyclosporin A (CsA).	Cyclosporine	175-188	angiotensinogen	Rattus norvegicus	118-123
11768242-2	2001	The purpose of this study was to determine if cardiac hypertrophy in animals chronically treated with angiotensin II (AngII), could be prevented by blocking this pathway with cyclosporin A (CsA).	Cyclosporine	190-193	angiotensinogen	Rattus norvegicus	102-116
11768242-2	2001	The purpose of this study was to determine if cardiac hypertrophy in animals chronically treated with angiotensin II (AngII), could be prevented by blocking this pathway with cyclosporin A (CsA).	Cyclosporine	190-193	angiotensinogen	Rattus norvegicus	118-123
11768242-6	2001	Substantial increases in ANF and betaMHC gene expression were detected in the AngII treated animals, which were either attenuated or blocked with CsA treatment.	Cyclosporine	146-149	angiotensinogen	Rattus norvegicus	78-83
11768242-7	2001	Thus, this study demonstrates that CsA does prevent the development of cardiac hypertrophy in AngII treated rats, suggesting that the calcium-calmodulin-dependent calcineurin pathway is associated with angiotensin II induced hypertrophy in vivo.	Cyclosporine	35-38	angiotensinogen	Rattus norvegicus	94-99
11768242-7	2001	Thus, this study demonstrates that CsA does prevent the development of cardiac hypertrophy in AngII treated rats, suggesting that the calcium-calmodulin-dependent calcineurin pathway is associated with angiotensin II induced hypertrophy in vivo.	Cyclosporine	35-38	angiotensinogen	Rattus norvegicus	202-216
11562436-7	2001	Damage to mitochondria plays a role in the CYP2E1-dependent toxicity of Fe + AA, because the mitochondrial transmembrane potential decreased early in the process, and cyclosporin A prevented the toxicity.	Cyclosporine	167-180	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	43-49
11516757-5	2001	Immunosuppressants acting via inhibition of interleukin-2 synthesis, such as CSA or FK506, inhibited the production of GFP in a dose-dependent manner.	Cyclosporine	77-80	interleukin 2	Homo sapiens	44-57
11562451-2	2001	In the present article we show that 2 to 5 microM CsA diminishes glucose-induced insulin secretion of isolated mouse pancreatic islets in vitro by inhibiting glucose-stimulated oscillations of the cytoplasmic free-Ca(2+) concentration [Ca(2+)](c).	Cyclosporine	50-53	insulin	Homo sapiens	81-88
11676863-1	2001	P-Glycoprotein, which mediates multidrug resistance (MDR) in cancer chemotherapy, is a principal target of cyclosporin A and [3"-keto-Bmt(1)]-[Val(2)]-cyclosporin (valspodar; PSC 833).	Cyclosporine	107-118	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
11676863-6	2001	In addition, the intracellular accumulation of valspodar was found to be 3 - 6 fold higher than that of cyclosporin A in four sublines and verapamil, an inhibitor of P-glycoprotein-mediated transport, enhanced the accumulation of cyclosporin A, but not valspodar.	Cyclosporine	230-243	ATP binding cassette subfamily B member 1	Homo sapiens	166-180
11513333-4	2001	However, it has been recently observed that drugs like cyclosporin A, FK506, leflunomide, mycophenolate mofetil, pentoxifylline, and linomide can directly modulate cytokine and/or LPS-induced NO production in various cell types in vitro, probably by interfering with iNOS gene transcription or catalytic activity of iNOS enzyme.	Cyclosporine	55-68	nitric oxide synthase 2	Homo sapiens	267-271
11579312-0	2001	Coadministration of either cyclosporine or steroids with humanized monoclonal antibodies against CD80 and CD86 successfully prolong allograft survival after life supporting renal transplantation in cynomolgus monkeys.	Cyclosporine	27-39	T-lymphocyte activation antigen CD86	Macaca fascicularis	106-110
11579312-16	2001	In addition, combining CsA with mAbs directed against the CD80 and CD86 receptors significantly prolongs graft survival when compared to CsA monotherapy.	Cyclosporine	23-26	T-lymphocyte activation antigen CD86	Macaca fascicularis	67-71
11514315-6	2001	Cardiomyocytes isolated from neonatal Sod2(-/+) and Sod2(-/-) mice were more sensitive to cell death than cardiomyocytes from Sod2(+/+) mice after t-butylhydroperoxide treatment, and this increased sensitivity was prevented by inhibiting the permeability transition with cyclosporin A.	Cyclosporine	271-284	superoxide dismutase 2, mitochondrial	Mus musculus	52-56
11514315-6	2001	Cardiomyocytes isolated from neonatal Sod2(-/+) and Sod2(-/-) mice were more sensitive to cell death than cardiomyocytes from Sod2(+/+) mice after t-butylhydroperoxide treatment, and this increased sensitivity was prevented by inhibiting the permeability transition with cyclosporin A.	Cyclosporine	271-284	superoxide dismutase 2, mitochondrial	Mus musculus	52-56
11570623-0	2001	IgE-mediated anaphylaxis after first intravenous infusion of cyclosporine.	Cyclosporine	61-73	immunoglobulin heavy constant epsilon	Homo sapiens	0-3
11513333-4	2001	However, it has been recently observed that drugs like cyclosporin A, FK506, leflunomide, mycophenolate mofetil, pentoxifylline, and linomide can directly modulate cytokine and/or LPS-induced NO production in various cell types in vitro, probably by interfering with iNOS gene transcription or catalytic activity of iNOS enzyme.	Cyclosporine	55-68	nitric oxide synthase 2	Homo sapiens	316-320
11523700-10	2001	Decreased production of IL-12 and tumor necrosis factor alpha, but not of IL-10, is likely to contribute to the impaired accessory-cell function of tacrolimus- and CsA-treated DCs.	Cyclosporine	164-167	tumor necrosis factor	Homo sapiens	34-61
11573696-17	2001	The decreases in mRNA levels of Kv4.2 and Kv4.3 and I(to) density in the LV of the post-MI + cyclosporin A group were significantly less compared with the post-MI group.	Cyclosporine	93-106	potassium voltage-gated channel subfamily D member 3	Rattus norvegicus	42-47
11532080-11	2001	CONCLUSIONS: These results suggest that angiotensin II blockade with LSRT decreases EGF expression in normal rats on the LSD, but it protects EGF expression in CsA-induced nephrotoxicity.	Cyclosporine	160-163	angiotensinogen	Rattus norvegicus	40-54
11517250-9	2001	Decreased psi(m) was associated with a cyclosporin A-sensitive loss of cytochrome c but not with activation of caspase-3 or caspase-9.	Cyclosporine	39-52	cytochrome c, somatic	Homo sapiens	71-83
11564166-8	2001	On the other hand, we found that cyclosporin A reduces the overall expression of protein kinase C alpha, betaI, and betaII in cultured murine hair epithelial cells, and reduces the levels of protein kinase C alpha, betaI, betaII, and eta in the particulate fraction from cultured murine hair epithelial cells.	Cyclosporine	33-46	protein kinase C, alpha	Mus musculus	81-103
11564166-8	2001	On the other hand, we found that cyclosporin A reduces the overall expression of protein kinase C alpha, betaI, and betaII in cultured murine hair epithelial cells, and reduces the levels of protein kinase C alpha, betaI, betaII, and eta in the particulate fraction from cultured murine hair epithelial cells.	Cyclosporine	33-46	protein kinase C, alpha	Mus musculus	191-213
11504821-4	2001	An increase in the rate of accumulation of the MRP1 substrate calcein was observed following treatment with the organic anion/MRP1 inhibitor indomethacin, the Pgp inhibitors cyclosporin A (CsA) and vinblastine, as well as conditions of energy depletion.	Cyclosporine	189-192	ATP binding cassette subfamily C member 1	Homo sapiens	47-51
11504821-4	2001	An increase in the rate of accumulation of the MRP1 substrate calcein was observed following treatment with the organic anion/MRP1 inhibitor indomethacin, the Pgp inhibitors cyclosporin A (CsA) and vinblastine, as well as conditions of energy depletion.	Cyclosporine	189-192	ATP binding cassette subfamily B member 1	Homo sapiens	159-162
11532080-12	2001	This finding provides a new perspective on the renoprotection of angiotensin II blockade in chronic CsA nephrotoxicity.	Cyclosporine	100-103	angiotensinogen	Rattus norvegicus	65-79
11778653-8	2001	In addition, cFLIP mRNA expression was found only in naive gammadelta T cells and activated T cells treated with cyclosporin A (CsA), which inhibited AICD in the activated T cells.	Cyclosporine	113-126	CASP8 and FADD like apoptosis regulator	Homo sapiens	13-18
11548882-6	2001	IGF-1-mediated ARVM hypertrophy was also attenuated by cyclosporine A (calcineurin inhibitor), and staurosporine and chelerythrine (protein kinase C inhibitors).	Cyclosporine	55-69	calcineurin binding protein 1	Rattus norvegicus	71-92
11778653-8	2001	In addition, cFLIP mRNA expression was found only in naive gammadelta T cells and activated T cells treated with cyclosporin A (CsA), which inhibited AICD in the activated T cells.	Cyclosporine	128-131	CASP8 and FADD like apoptosis regulator	Homo sapiens	13-18
11390385-10	2001	Prx II was reduced by hCyP-A without help from any other reductant, and the reduction was cyclosporin A-independent.	Cyclosporine	90-103	peroxiredoxin 2	Homo sapiens	0-6
11493443-2	2001	The MDR phenotype often correlates with expression of P-glycoprotein (Pgp), and Pgp antagonists such as cyclosporine (CSA) have been used as chemosensitizing agents in AML.	Cyclosporine	104-116	ATP binding cassette subfamily B member 1	Homo sapiens	80-83
11745783-1	2001	The objectives of this study were to determine if lipid transfer protein I (LTP I)-facilitated phospholipid (PC) transfer activity regulates the plasma lipoprotein distribution of cyclosporine (CSA) and if the association of CSA with high-density lipoproteins (HDL) is due to the high protein and/or alterations in coat lipid content of HDL.	Cyclosporine	180-192	cholesteryl ester transfer protein	Homo sapiens	50-74
11745783-1	2001	The objectives of this study were to determine if lipid transfer protein I (LTP I)-facilitated phospholipid (PC) transfer activity regulates the plasma lipoprotein distribution of cyclosporine (CSA) and if the association of CSA with high-density lipoproteins (HDL) is due to the high protein and/or alterations in coat lipid content of HDL.	Cyclosporine	180-192	cholesteryl ester transfer protein	Homo sapiens	76-81
11502962-13	2001	CONCLUSIONS: Treatment of allograft recipients with SERP-1 in combination with CsA early after transplantation significantly decreases the incidence of GVD when compared to grafts treated with only CsA.	Cyclosporine	198-201	stress associated endoplasmic reticulum protein 1	Homo sapiens	52-58
11448138-8	2001	Immunoblotting demonstrated a decrease in the phosphorylation of Akt and Bad, and also Bcl-2 levels were reduced in aortic banded cyclosporine treated animals at 7 days compared with aortic banded vehicle treated animals.	Cyclosporine	130-142	thymoma viral proto-oncogene 1	Mus musculus	65-68
11406149-5	2001	The expression of CD8alpha in mitogen-stimulated CD4(+) cells was blocked completely by calcineurin inhibitors (cyclosporine A and FK-506), and partially by rapamycin and SDZ-RAD.	Cyclosporine	112-126	CD8a molecule	Rattus norvegicus	18-26
11502320-5	2001	These findings could affect use of drugs that are P-glycoprotein substrates (such as HIV-1 protease inhibitors and ciclosporin) in African populations.	Cyclosporine	115-126	ATP binding cassette subfamily B member 1	Homo sapiens	50-64
11448138-8	2001	Immunoblotting demonstrated a decrease in the phosphorylation of Akt and Bad, and also Bcl-2 levels were reduced in aortic banded cyclosporine treated animals at 7 days compared with aortic banded vehicle treated animals.	Cyclosporine	130-142	B cell leukemia/lymphoma 2	Mus musculus	87-92
11547546-6	2001	In contrast, in PC60R1R2/Bcl-2 cells cytochrome c release and apoptosis were suppressed by addition of zVAD-fmk or cyclosporin A.	Cyclosporine	115-128	BCL2 apoptosis regulator	Homo sapiens	25-30
11474225-6	2001	CONCLUSION: The present study of Japanese children with FSGS showed that the D allele of the ACE gene is associated with the development of FSGS, but not associated with the progression of FSGS which was greatly ameliorated with ciclosporin, irrespective of ACE genotypes.	Cyclosporine	229-240	angiotensin I converting enzyme	Homo sapiens	93-96
11474225-6	2001	CONCLUSION: The present study of Japanese children with FSGS showed that the D allele of the ACE gene is associated with the development of FSGS, but not associated with the progression of FSGS which was greatly ameliorated with ciclosporin, irrespective of ACE genotypes.	Cyclosporine	229-240	angiotensin I converting enzyme	Homo sapiens	258-261
11516264-5	2001	Pre-treatment by cyclosporine A simultaneously with PHA dose-dependently lowered the IL-2 production and susceptibility of the cells to astilbin, while the treatment after 120 h of PHA-activation did not.	Cyclosporine	17-31	interleukin 2	Homo sapiens	85-89
11547546-6	2001	In contrast, in PC60R1R2/Bcl-2 cells cytochrome c release and apoptosis were suppressed by addition of zVAD-fmk or cyclosporin A.	Cyclosporine	115-128	cytochrome c, somatic	Homo sapiens	37-49
11555319-13	2001	After CsA treatment there was a significant reduction in interferon-gamma (IFN-gamma), IL-2, IL-4, IL-13, and HLA-DR-positive CD3(+) cells.	Cyclosporine	6-9	interferon gamma	Homo sapiens	57-73
11555319-13	2001	After CsA treatment there was a significant reduction in interferon-gamma (IFN-gamma), IL-2, IL-4, IL-13, and HLA-DR-positive CD3(+) cells.	Cyclosporine	6-9	interferon gamma	Homo sapiens	75-84
11555319-13	2001	After CsA treatment there was a significant reduction in interferon-gamma (IFN-gamma), IL-2, IL-4, IL-13, and HLA-DR-positive CD3(+) cells.	Cyclosporine	6-9	interleukin 2	Homo sapiens	87-91
11555319-13	2001	After CsA treatment there was a significant reduction in interferon-gamma (IFN-gamma), IL-2, IL-4, IL-13, and HLA-DR-positive CD3(+) cells.	Cyclosporine	6-9	interleukin 4	Homo sapiens	93-97
11555319-13	2001	After CsA treatment there was a significant reduction in interferon-gamma (IFN-gamma), IL-2, IL-4, IL-13, and HLA-DR-positive CD3(+) cells.	Cyclosporine	6-9	interleukin 13	Homo sapiens	99-104
12575579-6	2001	RESULTS: Chronic CsA-induced nephropathy might be correlated to TGF-beta 1 and renin mRNA up-regulation as well as matric proteins accumulation in interstitium.	Cyclosporine	17-20	transforming growth factor, beta 1	Rattus norvegicus	64-74
12575579-8	2001	CONCLUSION: Decreased CsA-related TGF-beta 1 and renin upregulation expression and accumulation of matrix proteins in the kidney might be related to the protective mechanism of CSI on CsA-induced chronic nephrotoxicity.	Cyclosporine	22-25	transforming growth factor, beta 1	Rattus norvegicus	34-44
11437380-4	2001	ABCG2-ATPase was inhibited by low concentrations of Na-orthovanadate, N-ethylmaleimide and cyclosporin A.	Cyclosporine	91-104	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	0-5
11414742-4	2001	Furthermore, azodicarbonamide synergizes with cyclosporin A to inhibit CD4+ T cell proliferation.	Cyclosporine	46-59	CD4 molecule	Homo sapiens	71-74
11549208-7	2001	In addition, the higher levels of CsA with docetaxel than with paclitaxel co-administration may be explained by the fact that docetaxel is almost exclusively metabolised by CYP 3A4, whereas paclitaxel is predominantly metabolised by CYP 2C8 and to a lesser extent by CYP 3A4.	Cyclosporine	34-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	173-180
11549208-7	2001	In addition, the higher levels of CsA with docetaxel than with paclitaxel co-administration may be explained by the fact that docetaxel is almost exclusively metabolised by CYP 3A4, whereas paclitaxel is predominantly metabolised by CYP 2C8 and to a lesser extent by CYP 3A4.	Cyclosporine	34-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	267-274
11772258-9	2001	In addition, CD4+ T-cells from tresperimus-treated animals can transfer donor specific tolerance to naive animals, an effect not seen with cyclosporin or other traditional immunosuppressive drugs.	Cyclosporine	139-150	CD4 molecule	Homo sapiens	13-16
11422747-1	2001	BACKGROUND: The multidrug resistance (MDR) gene product P-glycoprotein (P-gp) is a transmembrane efflux pump for hydrophobic, potentially toxic compounds, including the immunosuppressant cyclosporine A (CsA).	Cyclosporine	203-206	ATP binding cassette subfamily B member 1	Homo sapiens	56-70
11423565-6	2001	Stimulation of mesangial cells with endothelin-1 caused translocation of NFAT2 into the nucleus with a concomitant increase in NFAT2 DNA-binding activity, both of which were inhibited by CsA.	Cyclosporine	187-190	endothelin 1	Rattus norvegicus	36-48
11423565-7	2001	Furthermore, CsA inhibited endothelin-1-induced cyclooxygenase-2 (COX-2) expression in mesangial cells.	Cyclosporine	13-16	endothelin 1	Rattus norvegicus	27-39
11408558-8	2001	Incubation of Caco-2 cells with UIC2 in the presence of 1 microM CsA resulted in 50 to 80% inhibition of Pgp-mediated vinblastine efflux, with no significant inhibition observed by UIC2 or CsA alone.	Cyclosporine	65-68	ATP binding cassette subfamily B member 1	Homo sapiens	105-108
11408558-9	2001	Inhibition of Pgp in CYP3A4-expressing Caco-2 cells by UIC2 and 1 microM CsA resulted in a significant decrease in the apical secretion of M6, M5, and OH-indinavir and an increase in the amount of the metabolites secreted in the basolateral compartment and retained in the cytosol.	Cyclosporine	73-76	ATP binding cassette subfamily B member 1	Homo sapiens	14-17
11408558-9	2001	Inhibition of Pgp in CYP3A4-expressing Caco-2 cells by UIC2 and 1 microM CsA resulted in a significant decrease in the apical secretion of M6, M5, and OH-indinavir and an increase in the amount of the metabolites secreted in the basolateral compartment and retained in the cytosol.	Cyclosporine	73-76	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	21-27
11422747-13	2001	Increased expression of P-gp in infiltrating leukocytes correlated with the severity of allograft rejection, suggesting that P-gp may decrease the immunosuppressive efficacy of CsA.	Cyclosporine	177-180	ATP binding cassette subfamily B member 1	Homo sapiens	125-129
11422747-1	2001	BACKGROUND: The multidrug resistance (MDR) gene product P-glycoprotein (P-gp) is a transmembrane efflux pump for hydrophobic, potentially toxic compounds, including the immunosuppressant cyclosporine A (CsA).	Cyclosporine	203-206	ATP binding cassette subfamily B member 1	Homo sapiens	72-76
11422747-14	2001	Thus, individual differences in the P-gp induction response of CsA-exposed renal parenchymal cells and/or infiltrating leukocytes may predispose to either CsA nephrotoxicity or rejection, respectively.	Cyclosporine	63-66	ATP binding cassette subfamily B member 1	Homo sapiens	36-40
11422747-14	2001	Thus, individual differences in the P-gp induction response of CsA-exposed renal parenchymal cells and/or infiltrating leukocytes may predispose to either CsA nephrotoxicity or rejection, respectively.	Cyclosporine	155-158	ATP binding cassette subfamily B member 1	Homo sapiens	36-40
11422747-2	2001	We have previously shown that CsA increases P-gp expression in proximal tubule and endothelial cells in vitro.	Cyclosporine	30-33	ATP binding cassette subfamily B member 1	Homo sapiens	44-48
11422747-7	2001	RESULTS: P-gp expression in biopsies with acute tubular necrosis (ATN; N = 10) after CsA treatment was significantly higher in arterial endothelia, proximal tubules, and epithelial cells of Bowman"s capsule (BC), whereas P-gp was sparsely induced in CsA nephrotoxicity (N = 19) compared with controls.	Cyclosporine	85-88	ATP binding cassette subfamily B member 1	Homo sapiens	9-13
11422747-7	2001	RESULTS: P-gp expression in biopsies with acute tubular necrosis (ATN; N = 10) after CsA treatment was significantly higher in arterial endothelia, proximal tubules, and epithelial cells of Bowman"s capsule (BC), whereas P-gp was sparsely induced in CsA nephrotoxicity (N = 19) compared with controls.	Cyclosporine	85-88	ATP binding cassette subfamily B member 1	Homo sapiens	221-225
11422747-7	2001	RESULTS: P-gp expression in biopsies with acute tubular necrosis (ATN; N = 10) after CsA treatment was significantly higher in arterial endothelia, proximal tubules, and epithelial cells of Bowman"s capsule (BC), whereas P-gp was sparsely induced in CsA nephrotoxicity (N = 19) compared with controls.	Cyclosporine	250-253	ATP binding cassette subfamily B member 1	Homo sapiens	9-13
11422747-8	2001	Acute cellular (N = 30) and vascular rejection (N = 10) or chronic allograft nephropathy (N = 10) after CsA was associated with strong P-gp expression in infiltrating leukocytes and increased P-gp expression in arterial endothelia, proximal tubules, and BC.	Cyclosporine	104-107	ATP binding cassette subfamily B member 1	Homo sapiens	135-139
11422747-10	2001	Zero biopsies showed a weak, homogeneous, nonpolarized expression of P-gp in tubules and an increased expression of P-gp after CsA therapy in the brush border, arterial endothelia, and BC.	Cyclosporine	127-130	ATP binding cassette subfamily B member 1	Homo sapiens	116-120
11422747-11	2001	CONCLUSIONS: CsA treatment was associated with increased P-gp expression in parenchymal cells of kidney transplants with ATN, acute or chronic transplant rejection, but P-gp was not increased in patients with CsA nephrotoxicity.	Cyclosporine	13-16	ATP binding cassette subfamily B member 1	Homo sapiens	57-61
11422747-12	2001	This indicates that CsA induces its own detoxification by P-gp and that inadequate up-regulation of P-gp in renal parenchymal cells contributes to CsA nephrotoxicity.	Cyclosporine	20-23	ATP binding cassette subfamily B member 1	Homo sapiens	58-62
11422747-12	2001	This indicates that CsA induces its own detoxification by P-gp and that inadequate up-regulation of P-gp in renal parenchymal cells contributes to CsA nephrotoxicity.	Cyclosporine	147-150	ATP binding cassette subfamily B member 1	Homo sapiens	100-104
11422747-13	2001	Increased expression of P-gp in infiltrating leukocytes correlated with the severity of allograft rejection, suggesting that P-gp may decrease the immunosuppressive efficacy of CsA.	Cyclosporine	177-180	ATP binding cassette subfamily B member 1	Homo sapiens	24-28
11399937-7	2001	RESULTS: Significant reductions were observed with respect to the percentages of CD4+ and CD23+ cells in the conjunctival impression cytology specimens and clinical and symptom scores following treatment with topical CsA, while no change occurred in the percentages of CD8+ and CD45RA+ cells.	Cyclosporine	217-220	CD4 molecule	Homo sapiens	81-84
11399937-9	2001	CONCLUSION: Topical CsA treatment is a very effective alternative in severe VKC cases in clinical ground and clinical efficacy of topical CsA treatment in severe, resistant VKC cases can be (at least partly) related to reduction of the CD23+ and CD4+ cell populations on the conjunctival surface.	Cyclosporine	20-23	CD4 molecule	Homo sapiens	246-249
11399937-9	2001	CONCLUSION: Topical CsA treatment is a very effective alternative in severe VKC cases in clinical ground and clinical efficacy of topical CsA treatment in severe, resistant VKC cases can be (at least partly) related to reduction of the CD23+ and CD4+ cell populations on the conjunctival surface.	Cyclosporine	138-141	CD4 molecule	Homo sapiens	246-249
11425645-0	2001	Transforming growth factor-beta administration modifies cyclosporine A-induced bone loss.	Cyclosporine	56-70	transforming growth factor beta 1	Homo sapiens	0-31
11458978-1	2001	The objective of the present study was to investigate the regulation of P-glycoprotein by cyclosporine, a known inhibitor of CYP3A, at different dosage levels and lengths of treatment.	Cyclosporine	90-102	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	125-130
11458978-12	2001	Therefore this induction of hepatic P-glycoprotein and suppression of hepatic CYP3A may have a coordinate effect on the metabolism of cyclosporine.	Cyclosporine	134-146	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	78-83
11368793-4	2001	We found that moderately low doses of tributyltin decrease mitochondrial membrane potential and induce cytochrome c release by a mechanism inhibited by cyclosporine A and bongkrekic acid.	Cyclosporine	152-166	cytochrome c, somatic	Homo sapiens	103-115
11425645-4	2001	CsA stimulates secretion of TGF-beta1 in humans, which, while improving immunosuppression, may also contribute to renal toxicity.	Cyclosporine	0-3	transforming growth factor beta 1	Homo sapiens	28-37
11425645-5	2001	This study was performed determine whether exogenously administered TGF-beta would modify the bone effects of CsA.	Cyclosporine	110-113	transforming growth factor beta 1	Homo sapiens	68-76
11425645-9	2001	CsA increased osteocalcin (BGP), but TGF-beta negated this effect.	Cyclosporine	0-3	bone gamma-carboxyglutamate protein	Homo sapiens	14-25
11425645-9	2001	CsA increased osteocalcin (BGP), but TGF-beta negated this effect.	Cyclosporine	0-3	bone gamma-carboxyglutamate protein	Homo sapiens	27-30
11425645-11	2001	However, in combination, TGF-beta blocked CsA"s effect and increased osteoblast recruitment and activity, as reflected by increased percent mineralizing surface, percent osteoid perimeter, bone formation rate (bone volume referent), and activation frequency.	Cyclosporine	42-45	transforming growth factor beta 1	Homo sapiens	25-33
11425645-12	2001	Thus, it appears as if TGF-beta administration may have potential in modulating the deleterious bone effects of CsA.	Cyclosporine	112-115	transforming growth factor beta 1	Homo sapiens	23-31
11375290-1	2001	BACKGROUND: A substantial proportion of the variability in the absorption and clearance of cyclosporin A (CsA) after oral administration has been attributed to variability in liver cytochrome P-450 3A4 (CYP3A4) activity and intestinal P-glycoprotein (P-gp) concentration.	Cyclosporine	106-109	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	181-201
11385620-4	2001	The expression of Nur77 in response to TG treatment is sensitive to cyclosporin A, implicating that activation of calcineurin is necessary for Nur77 expression.	Cyclosporine	68-81	nuclear receptor subfamily 4 group A member 1	Homo sapiens	18-23
11442496-5	2001	To overcome this drug resistance, we added cyclosporine A (CsA) and these agents to culture media as a P-gp antagonist.	Cyclosporine	59-62	ATP binding cassette subfamily B member 1	Homo sapiens	103-107
11390035-9	2001	Additionally, alteration of insulin release from PIC cultured with PBMC or plastic-adherent cells was abolished dose-dependently (p &lt; 0.0001 and p &lt; 0.04, respectively) by gadolinium chloride (which inhibits macrophages), but not modified by cyclosporin A or mycophenolate mofetil which did not alter insulin release from PIC but blocked the proliferation of PBMC against PIC.	Cyclosporine	248-261	insulin	Homo sapiens	28-35
11375290-1	2001	BACKGROUND: A substantial proportion of the variability in the absorption and clearance of cyclosporin A (CsA) after oral administration has been attributed to variability in liver cytochrome P-450 3A4 (CYP3A4) activity and intestinal P-glycoprotein (P-gp) concentration.	Cyclosporine	106-109	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	203-209
11375290-1	2001	BACKGROUND: A substantial proportion of the variability in the absorption and clearance of cyclosporin A (CsA) after oral administration has been attributed to variability in liver cytochrome P-450 3A4 (CYP3A4) activity and intestinal P-glycoprotein (P-gp) concentration.	Cyclosporine	106-109	ATP binding cassette subfamily B member 1	Homo sapiens	235-249
11375290-1	2001	BACKGROUND: A substantial proportion of the variability in the absorption and clearance of cyclosporin A (CsA) after oral administration has been attributed to variability in liver cytochrome P-450 3A4 (CYP3A4) activity and intestinal P-glycoprotein (P-gp) concentration.	Cyclosporine	106-109	ATP binding cassette subfamily B member 1	Homo sapiens	251-255
11278965-9	2001	The calcineurin blockers CsA and FK506 also prevented the PDGF-induced NFAT4 nuclear localization.	Cyclosporine	25-28	nuclear factor of activated T cells 3	Homo sapiens	71-76
11453236-0	2001	Upregulation of keratinocyte growth factor in cyclosporin A-induced gingival overgrowth.	Cyclosporine	46-59	fibroblast growth factor 7	Homo sapiens	16-42
11453244-0	2001	The influence of transforming growth factor-beta1 gene polymorphisms on the severity of gingival overgrowth associated with concomitant use of cyclosporin A and a calcium channel blocker.	Cyclosporine	143-156	transforming growth factor beta 1	Homo sapiens	17-49
11453244-1	2001	BACKGROUND: The purpose of this study was to determine whether the prevalence and severity of gingival overgrowth in renal transplant recipients concomitantly treated with cyclosporin and a calcium channel blocker was associated with functional polymorphisms within the signal sequence of the transforming growth factor-(TGF)beta1 gene.	Cyclosporine	172-183	transforming growth factor beta 1	Homo sapiens	293-330
11453244-7	2001	CONCLUSIONS: Polymorphisms in the TGF-beta1 gene influence the expression of gingival overgrowth in renal transplant recipients concomitantly treated with cyclosporin and a calcium channel blocker.	Cyclosporine	155-166	transforming growth factor beta 1	Homo sapiens	34-43
11356940-11	2001	For example, the administration of SDZ RAD or FTY720 with CsA resulted in a more than additive increase in potency, compared with the sum of the drugs as single agents.	Cyclosporine	58-61	Ras-related associated with diabetes	Mus musculus	39-42
11871046-6	2001	St John"s wort may induce cytochrome P-450 3A4 activity and/or P-glycoprotein expression, which are both involved in the metabolism and absorption of cyclosporine.	Cyclosporine	150-162	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	26-46
11871046-6	2001	St John"s wort may induce cytochrome P-450 3A4 activity and/or P-glycoprotein expression, which are both involved in the metabolism and absorption of cyclosporine.	Cyclosporine	150-162	ATP binding cassette subfamily B member 1	Homo sapiens	63-77
11302876-6	2001	CSA treatment significantly reduced the tender joints score, swollen joints score, visual analogue pain scale, patient"s or doctor"s global assessment, patient"s self assessed disability, and C reactive protein.	Cyclosporine	0-3	C-reactive protein	Homo sapiens	192-210
11446745-3	2001	Although A23187 and ionomycin stimulated low levels of GM-CSF production, the IL-1beta pathway was cyclosporin A insensitive and did not interact with the calcium pathway.	Cyclosporine	99-112	interleukin 1 beta	Homo sapiens	78-86
11393381-12	2001	The two MCNS specimens showing positive CRP immunoreactivity were both from patients who had undergone cyclosporin therapy.	Cyclosporine	103-114	C-reactive protein	Homo sapiens	40-43
11343252-7	2001	Cyclosporin A, glibenclamide and rifamycin SV, all competitive inhibitors of Bsep transport, also reduced the bile salt-stimulated ATPase activity.	Cyclosporine	0-13	ATP-binding cassette, sub-family B (MDR/TAP), member 11	Mus musculus	77-81
11288109-3	2001	In Calu-3 cells, accumulation of the Pgp substrates rhodamine 123 (Rh123) and calcein acetoxymethyl ester (calcein-AM) was increased in the presence of the specific Pgp inhibitors cyclosporin A (CsA), vinblastine, and taxol.	Cyclosporine	195-198	ATP binding cassette subfamily B member 1	Homo sapiens	37-40
11288109-3	2001	In Calu-3 cells, accumulation of the Pgp substrates rhodamine 123 (Rh123) and calcein acetoxymethyl ester (calcein-AM) was increased in the presence of the specific Pgp inhibitors cyclosporin A (CsA), vinblastine, and taxol.	Cyclosporine	195-198	ATP binding cassette subfamily B member 1	Homo sapiens	165-168
11288109-10	2001	These results support an energy-dependent Pgp efflux pump pathway that is sensitive to inhibition with CsA in Calu-3 cells.	Cyclosporine	103-106	ATP binding cassette subfamily B member 1	Homo sapiens	42-45
11465431-0	2001	Effects of tacrolimus and cyclosporin A on peptide transporter PEPT1 in Caco-2 cells.	Cyclosporine	26-39	solute carrier family 15 member 1	Homo sapiens	63-68
11499549-13	2001	PGP immunoblottable amount was increased when cells were cultured in the presence of either cyclosporin A or dexamethasone.	Cyclosporine	92-105	ATP binding cassette subfamily B member 1	Homo sapiens	0-3
11311876-0	2001	Cyclosporin A, but not FK506, prevents the downregulation of phosphorylated Akt after transient focal ischemia in the rat.	Cyclosporine	0-13	AKT serine/threonine kinase 1	Rattus norvegicus	76-79
11278367-7	2001	Transfection of a NFAT/luciferase reporter in the neuronal cell line PC12, which also expresses NFAT1-D, showed that these cells expressed a constitutive NFAT activity that was enhanced after nerve growth factor-induced differentiation but was resistant to the immunosuppressant cyclosporin A.	Cyclosporine	279-292	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2	Mus musculus	96-103
11278367-8	2001	NFAT1-D was, however, inducibly activated in a cyclosporin A-sensitive manner when expressed in T-cells, suggesting that the activity of NFAT proteins might be controlled by their specific cellular context.	Cyclosporine	47-60	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2	Mus musculus	0-7
11311876-13	2001	Since this down regulation of Akt was prevented by CsA, the results suggested a link between dephosphorylaltion of Bad, and cell death.	Cyclosporine	51-54	AKT serine/threonine kinase 1	Rattus norvegicus	30-33
11374423-8	2001	Significant increase of TGF-beta mRNA expression was revealed after sequential RPM and adjunctive CsA treatment.	Cyclosporine	98-101	transforming growth factor, beta 1	Rattus norvegicus	24-32
11318416-1	2001	The Micromass Platform LCZ mass detector parameters were optimized for simultaneous recording of the protonated (CsA-H+), sodium adduct (CsA-Na+) and potassium adduct (CsA-K+) of cyclosporin A eluted from a Symmetry Shield RP8 column.	Cyclosporine	179-192	programmed cell death 2	Homo sapiens	223-226
11360196-10	2001	Treatment of Jurkat cells with cyclosporin A delayed TRAIL-induced Deltapsi(m), caspase-3 activation and apoptosis.	Cyclosporine	31-44	TNF superfamily member 10	Homo sapiens	53-58
11360196-10	2001	Treatment of Jurkat cells with cyclosporin A delayed TRAIL-induced Deltapsi(m), caspase-3 activation and apoptosis.	Cyclosporine	31-44	caspase 3	Homo sapiens	80-89
11329505-11	2001	Damage to mitochondria appears to play a role in the CYP2E1- and BSO-dependent toxicity, because mitochondrial membrane potential was decreased and cyclosporin A, an inhibitor of the mitochondrial membrane permeability transition, prevented the apoptosis and the necrosis.	Cyclosporine	148-161	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	53-59
11134037-7	2001	In contrast, tumor necrosis factor alpha caused phospholipid hydrolysis, induction of the PT, cytochrome c release, and cell death that could be inhibited by both cyclosporin A and aristolochic acid.	Cyclosporine	163-176	tumor necrosis factor	Rattus norvegicus	13-40
11357886-4	2001	Cyclosporin A (CsA) also inhibited the anti-CD3/CD28 induced IL-6 production but was about 100 times less potent than FK506.	Cyclosporine	0-13	interleukin 6	Homo sapiens	61-65
11290556-9	2001	The results show that cyclosporine, but not tacrolimus, stimulates BEC TGF-beta1 production, which in turn, causes BEC mito-inhibition and up-regulation of nuclear p21(WAF1/Cip1).	Cyclosporine	22-34	transforming growth factor beta 1	Homo sapiens	71-80
11290556-9	2001	The results show that cyclosporine, but not tacrolimus, stimulates BEC TGF-beta1 production, which in turn, causes BEC mito-inhibition and up-regulation of nuclear p21(WAF1/Cip1).	Cyclosporine	22-34	cyclin dependent kinase inhibitor 1A	Homo sapiens	164-167
11290556-9	2001	The results show that cyclosporine, but not tacrolimus, stimulates BEC TGF-beta1 production, which in turn, causes BEC mito-inhibition and up-regulation of nuclear p21(WAF1/Cip1).	Cyclosporine	22-34	cyclin dependent kinase inhibitor 1A	Homo sapiens	168-172
11290556-9	2001	The results show that cyclosporine, but not tacrolimus, stimulates BEC TGF-beta1 production, which in turn, causes BEC mito-inhibition and up-regulation of nuclear p21(WAF1/Cip1).	Cyclosporine	22-34	cyclin dependent kinase inhibitor 1A	Homo sapiens	173-177
11357881-5	2001	Cyclosporine A, herbimycin A, LY294002, calphostin C and PD98059 all inhibited anti-Thy-1-induced T lymphocyte proliferation, indicating the involvement of calcineurin, protein tyrosine kinases, phosphatidylinositol 3-kinase, protein kinase C, and MEK1 (MAPK kinase 1), respectively, in Thy-1 signaling.	Cyclosporine	0-14	thymus cell antigen 1, theta	Mus musculus	84-89
11357881-5	2001	Cyclosporine A, herbimycin A, LY294002, calphostin C and PD98059 all inhibited anti-Thy-1-induced T lymphocyte proliferation, indicating the involvement of calcineurin, protein tyrosine kinases, phosphatidylinositol 3-kinase, protein kinase C, and MEK1 (MAPK kinase 1), respectively, in Thy-1 signaling.	Cyclosporine	0-14	thymus cell antigen 1, theta	Mus musculus	287-292
11254887-5	2001	The expression of Bcl-2 and Bax proteins were high in LBC cells and following CsA treatment the expression of these proteins as well as Bcl-XL decreased.	Cyclosporine	78-81	B cell leukemia/lymphoma 2	Mus musculus	18-23
11357886-4	2001	Cyclosporin A (CsA) also inhibited the anti-CD3/CD28 induced IL-6 production but was about 100 times less potent than FK506.	Cyclosporine	15-18	interleukin 6	Homo sapiens	61-65
11418017-0	2001	Role of prostanoids and endothelins in the prevention of cyclosporine-induced nephrotoxicity.	Cyclosporine	57-69	endothelin 1	Rattus norvegicus	24-35
11279262-8	2001	The dephosphorylation of IRS-1 by NMDA was calcium-dependent and was inhibited by the calcineurin inhibitor cyclosporine.	Cyclosporine	108-120	insulin receptor substrate 1	Rattus norvegicus	25-30
11338306-1	2001	BACKGROUND: The aim of the present study was to investigate the level of transforming growth factor-beta 1 (TGF-beta 1) in gingival crevicular fluid (GCF) samples of cyclosporin A (CsA)-treated patients and to compare the results with control groups.	Cyclosporine	181-184	transforming growth factor beta 1	Homo sapiens	73-106
11338306-1	2001	BACKGROUND: The aim of the present study was to investigate the level of transforming growth factor-beta 1 (TGF-beta 1) in gingival crevicular fluid (GCF) samples of cyclosporin A (CsA)-treated patients and to compare the results with control groups.	Cyclosporine	181-184	transforming growth factor beta 1	Homo sapiens	108-118
11338306-9	2001	CONCLUSIONS: The results of the present study support the theory that CsA increases the synthesis of TGF-beta 1 in GCF.	Cyclosporine	70-73	transforming growth factor beta 1	Homo sapiens	101-111
11260423-7	2001	Urinary excretion of 11-dehydro-TXB2 and plasma levels of vWF were significantly increased in RTRs who received CsA compared with those who did not.	Cyclosporine	112-115	von Willebrand factor	Homo sapiens	58-61
11418017-2	2001	Several vasoactive agents have been found to be implicated in cyclosporine induced nephrotoxicity, among which prostanoids and endothelins are the most important.	Cyclosporine	62-74	endothelin 1	Rattus norvegicus	127-138
11418017-5	2001	Nifedipine averted the cyclosporine induced increase of urinary endothelin-1 release.	Cyclosporine	23-35	endothelin 1	Rattus norvegicus	64-76
11278005-0	2001	Cyclosporin A increases basal intracellular calcium and calcium responses to endothelin and vasopressin in human coronary myocytes.	Cyclosporine	0-13	arginine vasopressin	Homo sapiens	92-103
11102441-10	2001	CsA blocked the TNF-alpha-induced release of pro-caspase 8 but not cytochrome c.	Cyclosporine	0-3	tumor necrosis factor	Homo sapiens	16-25
11238613-9	2001	Thus, inhibition of Jak3 prolongs allograft survival and also potentiates the immunosuppressive effects of cyclosporin A, but not rapamycin.	Cyclosporine	107-120	Janus kinase 3	Rattus norvegicus	20-24
11292301-11	2001	In the cyclosporine monotherapy subgroup, patients with high IFN-gamma genotype had a 61% incidence of rejection compared with only 20% in the low IFN-gamma genotype patients (OR=3.06).	Cyclosporine	7-19	interferon gamma	Homo sapiens	61-70
11248096-4	2001	Prevention of anti-IgM-induced cell death in B104 cells by the calcineurin phosphatase inhibitor, cyclosporin A, abrogated both intracellular acidification and cell shrinkage and was associated with an increase in the phosphorylation level of NHE1 within the first 60 min of stimulation.	Cyclosporine	98-111	solute carrier family 9 member A1	Homo sapiens	243-247
11292301-15	2001	CONCLUSION: In this study we have shown that high producer genotype for IFN-gamma may have an influence on acute rejection of kidney transplants, particularly in patients on cyclosporine monotherapy.	Cyclosporine	174-186	interferon gamma	Homo sapiens	72-81
12899339-6	2001	Cyclosporin A(CsA), a specific inhibitor of calcineurin, markedly inhibited the calcineurin activity and decreased the 3H-leucine incorporation in AngII-treated cardiomyocytes in a dose-dependent manner.	Cyclosporine	0-13	angiotensinogen	Rattus norvegicus	147-152
12899339-6	2001	Cyclosporin A(CsA), a specific inhibitor of calcineurin, markedly inhibited the calcineurin activity and decreased the 3H-leucine incorporation in AngII-treated cardiomyocytes in a dose-dependent manner.	Cyclosporine	14-17	angiotensinogen	Rattus norvegicus	147-152
12899339-7	2001	It was also found that CsA slightly reduced the mRNA level of ANF gene in AngII-stimulated cardiomyocytes.	Cyclosporine	23-26	angiotensinogen	Rattus norvegicus	74-79
11179286-5	2001	Mice pretreated with cyclosporine (Cs) or neutralizing antibodies against gamma interferon (IFN-gamma) did not develop lethal LPS hypersensitivity when injected with TSST-1, and these agents reduced the enhancement effect of TSST-1 on LPS-induced serum TNF-alpha by 99 and 85%, respectively.	Cyclosporine	21-33	tumor necrosis factor	Mus musculus	253-262
11259398-0	2001	Molecular mechanisms of TGF-(beta) antagonism by interferon (gamma) and cyclosporine A in lung fibroblasts.	Cyclosporine	72-86	transforming growth factor beta 1	Homo sapiens	24-34
11179286-6	2001	Cs pretreatment also completely inhibited the known capacity of TSST-1 to amplify LPS-induced levels of IFN-gamma in serum.	Cyclosporine	0-2	interferon gamma	Mus musculus	104-113
11179286-8	2001	Cs given after TSST-1 also did not inhibit enhancement of LPS-induced serum TNF-alpha by TSST-1 but inhibited the enhancement effect of TSST-1 on LPS-induced serum IFN-gamma by 50%.	Cyclosporine	0-2	interferon gamma	Mus musculus	164-173
11207322-7	2001	The increase in eIF-6 gene expression in murine mast cells was blocked by therapeutic agents such as dexamethasone and cyclosporin A.	Cyclosporine	119-132	eukaryotic translation initiation factor 6	Mus musculus	16-21
11262086-4	2001	Inhibition of membrane Pgp within leukemic cells, characterized by intracellular drug accumulation, was specifically produced by isoprenylated derivatives, with 8-(3,3-dimethylallyl)chrysin being even more efficient than the commonly used cyclosporin A.	Cyclosporine	239-252	ATP binding cassette subfamily B member 1	Homo sapiens	23-26
11226376-5	2001	We conclude that the increases in cyclin D1, PCNA, and cyclin E, together with the invariable level of p27, clearly show that CsA induces hepatocytes to proliferate.	Cyclosporine	126-129	cyclin D1	Rattus norvegicus	34-43
12171683-1	2001	Two cases of Dogger Bank Itch responding to oral cyclosporin (Neoral) are reported.	Cyclosporine	49-60	itchy E3 ubiquitin protein ligase	Homo sapiens	25-29
28095248-5	2001	Experimental studies have demonstrated that angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin II receptor blockers (ARBs) can attenuate cyclosporine-mediated increases in TGF-beta production in renal tissue.	Cyclosporine	151-163	angiotensinogen	Homo sapiens	97-111
28095248-5	2001	Experimental studies have demonstrated that angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin II receptor blockers (ARBs) can attenuate cyclosporine-mediated increases in TGF-beta production in renal tissue.	Cyclosporine	151-163	transforming growth factor beta 1	Homo sapiens	186-194
28095248-7	2001	Moreover, other studies have demonstrated that a chronic reduction in the dose of cyclosporine in transplant patients can reduce serum TGF-beta levels.	Cyclosporine	82-94	transforming growth factor beta 1	Homo sapiens	135-143
28095248-8	2001	Treatment with an ARB can normalise the plasma levels of TGF-beta in renal transplant patients receiving cyclosporine.	Cyclosporine	105-117	transforming growth factor beta 1	Homo sapiens	57-65
28095248-9	2001	All these observations suggest that there may be a role of cyclosporine, and possibly tacrolimus, in worsening chronic allograft nephropathy through their effects on the renin-angiotensin-aldosterone system (RAAS) and TGF-beta production.	Cyclosporine	59-71	transforming growth factor beta 1	Homo sapiens	218-226
11284449-6	2001	Inhibition of P-glycoprotein-mediated transport of these compounds in Caco-2 cells was determined using the cyclosporine analogue PSC-833 (valspodar) as inhibitor of P-glycoprotein.	Cyclosporine	108-120	ATP binding cassette subfamily B member 1	Homo sapiens	14-28
11181682-3	2001	The purpose of this study was to enhance the systemic exposure to oral docetaxel on coadministration of cyclosporine (CsA), an efficacious inhibitor of P-gp and substrate for CYP 3A4.	Cyclosporine	104-116	ATP binding cassette subfamily B member 1	Homo sapiens	152-156
11181682-3	2001	The purpose of this study was to enhance the systemic exposure to oral docetaxel on coadministration of cyclosporine (CsA), an efficacious inhibitor of P-gp and substrate for CYP 3A4.	Cyclosporine	104-116	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	175-182
11181682-3	2001	The purpose of this study was to enhance the systemic exposure to oral docetaxel on coadministration of cyclosporine (CsA), an efficacious inhibitor of P-gp and substrate for CYP 3A4.	Cyclosporine	118-121	ATP binding cassette subfamily B member 1	Homo sapiens	152-156
11181682-3	2001	The purpose of this study was to enhance the systemic exposure to oral docetaxel on coadministration of cyclosporine (CsA), an efficacious inhibitor of P-gp and substrate for CYP 3A4.	Cyclosporine	118-121	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	175-182
11181432-5	2001	We have shown previously that 20 h treatment of rat vascular smooth muscle cells (VSMC) with therapeutically relevant CsA concentrations increased the cellular response to [Arg8]vasopressin (AVP) by increasing about 2 fold the number of vasopressin receptors.	Cyclosporine	118-121	arginine vasopressin	Rattus norvegicus	178-189
11226376-4	2001	We also examined in nucleus the levels of nuclear factor kappaB (a nuclear factor involved in the transcription of the cyclin D1 gene) and found that this transcription factor increased in the presence of CsA.	Cyclosporine	205-208	cyclin D1	Rattus norvegicus	119-128
11226376-5	2001	We conclude that the increases in cyclin D1, PCNA, and cyclin E, together with the invariable level of p27, clearly show that CsA induces hepatocytes to proliferate.	Cyclosporine	126-129	cyclin E1	Rattus norvegicus	55-63
11159725-12	2001	In addition, lumenal but not cellular fluorescence intensity was significantly decreased when capillaries were incubated with PSC-833, Cyclosporin A or Verapamil, all inhibitors of p-glycoprotein.	Cyclosporine	135-148	ATP binding cassette subfamily B member 1	Homo sapiens	181-195
11181432-5	2001	We have shown previously that 20 h treatment of rat vascular smooth muscle cells (VSMC) with therapeutically relevant CsA concentrations increased the cellular response to [Arg8]vasopressin (AVP) by increasing about 2 fold the number of vasopressin receptors.	Cyclosporine	118-121	arginine vasopressin	Rattus norvegicus	237-248
11322650-1	2001	The modulatory effect of FK 506 and cyclosporin A (CsA) on the expression of inducible nitric oxide synthase (iNOS) in macrophages and mechanisms of their action were analysed.	Cyclosporine	36-49	nitric oxide synthase 2	Rattus norvegicus	77-108
11310347-3	2001	Endothelin-1 (ET), a vasoconstrictive peptide, has been implicated in CsA-induced nephrotoxicity and hypertension.	Cyclosporine	70-73	endothelin 1	Rattus norvegicus	0-12
11310347-10	2001	Both CsA-treated rats and CsA/ETRA-treated rats demonstrated trabecular osteopenia with raised serum osteocalcin, and 1,25(OH)2D levels when compared to control animals (P &lt; 0.05).	Cyclosporine	5-8	bone gamma-carboxyglutamate protein	Rattus norvegicus	101-112
11310347-10	2001	Both CsA-treated rats and CsA/ETRA-treated rats demonstrated trabecular osteopenia with raised serum osteocalcin, and 1,25(OH)2D levels when compared to control animals (P &lt; 0.05).	Cyclosporine	26-29	bone gamma-carboxyglutamate protein	Rattus norvegicus	101-112
11239516-1	2001	OBJECTIVES: Little is known about the effect of ischemia/reperfusion with xenogenic blood on function and gene expression of CYP3A4, the enzyme largely responsible for the metabolism of the immunosuppressants Cyclosporin A (CsA) and Tacrolimus.	Cyclosporine	209-222	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	125-131
11239516-1	2001	OBJECTIVES: Little is known about the effect of ischemia/reperfusion with xenogenic blood on function and gene expression of CYP3A4, the enzyme largely responsible for the metabolism of the immunosuppressants Cyclosporin A (CsA) and Tacrolimus.	Cyclosporine	224-227	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	125-131
11322650-1	2001	The modulatory effect of FK 506 and cyclosporin A (CsA) on the expression of inducible nitric oxide synthase (iNOS) in macrophages and mechanisms of their action were analysed.	Cyclosporine	36-49	nitric oxide synthase 2	Rattus norvegicus	110-114
11322650-1	2001	The modulatory effect of FK 506 and cyclosporin A (CsA) on the expression of inducible nitric oxide synthase (iNOS) in macrophages and mechanisms of their action were analysed.	Cyclosporine	51-54	nitric oxide synthase 2	Rattus norvegicus	77-108
11322650-1	2001	The modulatory effect of FK 506 and cyclosporin A (CsA) on the expression of inducible nitric oxide synthase (iNOS) in macrophages and mechanisms of their action were analysed.	Cyclosporine	51-54	nitric oxide synthase 2	Rattus norvegicus	110-114
11322650-9	2001	iNOS expression down-regulation by CsA is occurred post-transcriptionally.	Cyclosporine	35-38	nitric oxide synthase 2	Rattus norvegicus	0-4
11160247-13	2001	TRAIL induction is not inhibited by cyclosporin A, but highly sensitive to dexamethasone.	Cyclosporine	36-49	TNF superfamily member 10	Homo sapiens	0-5
11168932-1	2001	BACKGROUND: Several experimental and clinical studies have implicated a role for transforming growth factor-beta (TGF-beta) in mediating the nephrotoxic effects of cyclosporine (CsA).	Cyclosporine	164-176	transforming growth factor, beta 1	Rattus norvegicus	114-122
11168932-1	2001	BACKGROUND: Several experimental and clinical studies have implicated a role for transforming growth factor-beta (TGF-beta) in mediating the nephrotoxic effects of cyclosporine (CsA).	Cyclosporine	178-181	transforming growth factor, beta 1	Rattus norvegicus	114-122
11168932-10	2001	RESULTS: CsA-treated rats had significantly lower creatinine clearance as compared with normal controls (0.43 +/- 0.07 vs. 0.67 +/- 0.14 mL/min, P = 0.0002), increased interstitial damage and afferent arteriolar hyalinosis (P = 0.0001), and increased alpha1(I) collagen (4-fold) and TGF-beta 1 (2.5-fold) mRNA expression.	Cyclosporine	9-12	transforming growth factor, beta 1	Rattus norvegicus	283-293
11168932-11	2001	CsA-treated rats also had significantly increased TIMP-1 (7.4-fold, P &lt; 0.001), MMP-2, and PAI-1 (all approximately 2-fold, P &lt; 0.02) and decreased MMP-9 (85% reduction, P &lt; 0.001) as compared with controls.	Cyclosporine	0-3	serpin family E member 1	Rattus norvegicus	94-99
11168932-12	2001	Treatment with alpha-TGF-beta in CsA-treated rats significantly prevented the reduction in creatinine clearance (0.58 +/- 0.03 mL/min, P = 0.009 vs. CsA alone), the increase in afferent arteriolar hyalinosis (P &lt; 0.05 vs. CsA alone), normalized alpha 1(I) collagen mRNA levels, and attenuated CsA effects on TGF-beta1, TIMP-1, and MMP-9.	Cyclosporine	33-36	transforming growth factor, beta 1	Rattus norvegicus	21-29
11168932-12	2001	Treatment with alpha-TGF-beta in CsA-treated rats significantly prevented the reduction in creatinine clearance (0.58 +/- 0.03 mL/min, P = 0.009 vs. CsA alone), the increase in afferent arteriolar hyalinosis (P &lt; 0.05 vs. CsA alone), normalized alpha 1(I) collagen mRNA levels, and attenuated CsA effects on TGF-beta1, TIMP-1, and MMP-9.	Cyclosporine	33-36	transforming growth factor, beta 1	Rattus norvegicus	311-320
11168932-12	2001	Treatment with alpha-TGF-beta in CsA-treated rats significantly prevented the reduction in creatinine clearance (0.58 +/- 0.03 mL/min, P = 0.009 vs. CsA alone), the increase in afferent arteriolar hyalinosis (P &lt; 0.05 vs. CsA alone), normalized alpha 1(I) collagen mRNA levels, and attenuated CsA effects on TGF-beta1, TIMP-1, and MMP-9.	Cyclosporine	149-152	transforming growth factor, beta 1	Rattus norvegicus	21-29
11168932-12	2001	Treatment with alpha-TGF-beta in CsA-treated rats significantly prevented the reduction in creatinine clearance (0.58 +/- 0.03 mL/min, P = 0.009 vs. CsA alone), the increase in afferent arteriolar hyalinosis (P &lt; 0.05 vs. CsA alone), normalized alpha 1(I) collagen mRNA levels, and attenuated CsA effects on TGF-beta1, TIMP-1, and MMP-9.	Cyclosporine	149-152	transforming growth factor, beta 1	Rattus norvegicus	21-29
11168932-12	2001	Treatment with alpha-TGF-beta in CsA-treated rats significantly prevented the reduction in creatinine clearance (0.58 +/- 0.03 mL/min, P = 0.009 vs. CsA alone), the increase in afferent arteriolar hyalinosis (P &lt; 0.05 vs. CsA alone), normalized alpha 1(I) collagen mRNA levels, and attenuated CsA effects on TGF-beta1, TIMP-1, and MMP-9.	Cyclosporine	149-152	transforming growth factor, beta 1	Rattus norvegicus	21-29
11168932-14	2001	Based on our results with alpha-TGF-beta antibodies, many but not all of these nephrotoxic effects of CsA are mediated by TGF-beta.	Cyclosporine	102-105	transforming growth factor, beta 1	Rattus norvegicus	122-130
11360881-1	2001	BACKGROUND: The aim of the study was to investigate the behaviour of plasma levels of endothelin-1 (ET-1), an endothelial peptide with vasoconstrictive and proliferative actions, in patients with cardiac transplantation and in chronic treatment with cyclosporine A, some of whom became hypertensive after cardiac transplantation.	Cyclosporine	250-264	endothelin 1	Homo sapiens	100-104
11360881-0	2001	Endothelin-1 circulating levels increase in patients with orthotopic heart transplantation and in chronic therapy with cyclosporine.	Cyclosporine	119-131	endothelin 1	Homo sapiens	0-12
11175814-1	2001	Interleukin-12 (IL-12) and IL-18 induce synergistic transcription of interferon gamma (IFN-gamma) that is T cell receptor (TCR)-independent, not inhibited by cyclosporin A and requires new protein synthesis.	Cyclosporine	158-171	interferon gamma	Homo sapiens	69-96
11360881-1	2001	BACKGROUND: The aim of the study was to investigate the behaviour of plasma levels of endothelin-1 (ET-1), an endothelial peptide with vasoconstrictive and proliferative actions, in patients with cardiac transplantation and in chronic treatment with cyclosporine A, some of whom became hypertensive after cardiac transplantation.	Cyclosporine	250-264	endothelin 1	Homo sapiens	86-98
11158413-10	2001	Among 52 allograft recipients there was a significantly higher mean TGF beta(1) level in plasma from patients on cyclosporine therapy compared with patients on tacrolimus (28,090+/-26,860 pg/ml vs 7173+/-10 610 pg/ml, respectively; P&lt;0.002).	Cyclosporine	113-125	transforming growth factor beta 1	Homo sapiens	68-79
11169223-6	2001	In contrast, cyclosporine A and tacrolimus inhibited the tumour necrosis factor (TNF)-alpha production in response to LPS, but not to PepG and LTA.	Cyclosporine	13-27	tumor necrosis factor	Homo sapiens	57-91
11267336-0	2001	TGF-beta expression in protocol transplant liver biopsies: a comparative study between cyclosporine-A (CyA) and tacrolimus (FK 506) immunosuppression.	Cyclosporine	87-101	transforming growth factor beta 1	Homo sapiens	0-8
11266817-0	2001	Cyclosporin induces apoptosis of renal cells by enhancing nitric oxide synthesis: modulating effect of angiotensin II inhibitors.	Cyclosporine	0-11	angiotensinogen	Homo sapiens	103-117
11267336-0	2001	TGF-beta expression in protocol transplant liver biopsies: a comparative study between cyclosporine-A (CyA) and tacrolimus (FK 506) immunosuppression.	Cyclosporine	103-106	transforming growth factor beta 1	Homo sapiens	0-8
11228102-6	2001	Serum endothelin-1 (Et) concentration in the CsA-treated group was higher than that in the vehicle-treated group.	Cyclosporine	45-48	endothelin 1	Rattus norvegicus	6-18
11213066-7	2001	CONCLUSIONS: Patients taking SJW concomitantly with CSA or other medications whose absorption and metabolism are mediated by cytochrome P-450 and/or P-glycoprotein should require close monitoring.	Cyclosporine	52-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-141
11213066-7	2001	CONCLUSIONS: Patients taking SJW concomitantly with CSA or other medications whose absorption and metabolism are mediated by cytochrome P-450 and/or P-glycoprotein should require close monitoring.	Cyclosporine	52-55	ATP binding cassette subfamily B member 1	Homo sapiens	149-163
11167679-9	2001	In one patient examined before and 8 days after cyclosporin therapy, 50% or greater reductions were observed in percentages of peripheral blood CD8+/IL-5+, CD8+/IL-13+, CD4+/IL-4+ and CD4+/IL-5+ T lymphocytes following cyclosporin therapy.	Cyclosporine	48-59	interleukin 13	Homo sapiens	161-166
11139311-2	2001	We have recently demonstrated that the oral bioavailability of paclitaxel can be increased at least 7-fold by co-administration of the P-gp blocker cyclosporin A (CsA).	Cyclosporine	163-166	ATP binding cassette subfamily B member 1	Homo sapiens	135-139
11141501-1	2001	Cyclosporin A (CsA) nephropathy is associated with altered expression of apoptosis regulatory genes such as Fas-ligand and Bcl-2 family members in the glomerular, tubulointerstitial, and vascular compartments.	Cyclosporine	15-18	B cell leukemia/lymphoma 2	Mus musculus	123-128
11167679-9	2001	In one patient examined before and 8 days after cyclosporin therapy, 50% or greater reductions were observed in percentages of peripheral blood CD8+/IL-5+, CD8+/IL-13+, CD4+/IL-4+ and CD4+/IL-5+ T lymphocytes following cyclosporin therapy.	Cyclosporine	48-59	interleukin 4	Homo sapiens	174-178
11167679-10	2001	A smaller reduction of 15% after cyclosporin therapy was found in percentages of CD4+/IL-13+ T cells.	Cyclosporine	33-44	interleukin 13	Homo sapiens	86-91
11455576-3	2001	In fact, during treatment and after withdrawal, CY-treated animals remained euglycemic, showed good islet cell preservation and had low levels of Th1 and Th2 cytokines; ICAM-1 positivity within the islets was also found to be relatively low.	Cyclosporine	48-50	negative elongation factor complex member C/D, Th1l	Mus musculus	146-149
11134891-6	2001	Moreover, pretreatment with cyclosporin A plus trifluoperazine, two mitochondrial permeability transition (MPT) inhibitors, was capable of attenuating O(2)(*)(-)-mediated cytochrome c release and mitochondrial depolarization, and subsequently inhibiting apoptosis.	Cyclosporine	28-41	cytochrome c, somatic	Homo sapiens	171-183
11149492-10	2001	Osteocalcin was raised on days 28 and 56 in the high dose CsA group.	Cyclosporine	58-61	bone gamma-carboxyglutamate protein	Rattus norvegicus	0-11
21336903-6	2001	CD28 ligation provides cyclosporin A-resistant biochemical signals to T cells, which are an absolute requirement to drive proliferation and IL-2 production from CD3-stimulated T cells, as well as enhance cell survival (5,6).	Cyclosporine	23-36	interleukin 2	Homo sapiens	140-144
11344963-0	2001	[Cyclosporin A inhibits the response of osmotic water permeability to antidiuretic hormone in toad"s bladder and to angiotensin II and antidiuretic hormone in toad"s skin].	Cyclosporine	1-14	angiotensinogen	Homo sapiens	116-130
11125025-2	2001	The resulting Pgp-stationary phase was used in frontal and zonal chromatographic studies to investigate the binding of vinblastine (VBL), doxorubicin (DOX), verapamil (VER), and cyclosporin A (CsA) to the immobilized Pgp.	Cyclosporine	178-191	ATP binding cassette subfamily B member 1	Homo sapiens	14-17
11125025-2	2001	The resulting Pgp-stationary phase was used in frontal and zonal chromatographic studies to investigate the binding of vinblastine (VBL), doxorubicin (DOX), verapamil (VER), and cyclosporin A (CsA) to the immobilized Pgp.	Cyclosporine	193-196	ATP binding cassette subfamily B member 1	Homo sapiens	14-17
11369837-3	2001	Production of TGF-beta1 in these circumstances may be modulated by the intrarenal renin-angiotensin system (angiotensin II induces TGF-beta1 production and secretion by the mesangial cells) and by a direct effect of cyclosporin A, which stimulates the synthesis and expression of TGF-beta1.	Cyclosporine	216-229	transforming growth factor beta 1	Homo sapiens	14-23
11369812-1	2001	BACKGROUND: We have reported previously that exposure of endothelial cells to cyclosporin A (CsA) may result in the regulation of specific genes, such as the endothelial nitric oxide synthase.	Cyclosporine	78-91	nitric oxide synthase 3	Bos taurus	158-191
11369837-3	2001	Production of TGF-beta1 in these circumstances may be modulated by the intrarenal renin-angiotensin system (angiotensin II induces TGF-beta1 production and secretion by the mesangial cells) and by a direct effect of cyclosporin A, which stimulates the synthesis and expression of TGF-beta1.	Cyclosporine	216-229	angiotensinogen	Homo sapiens	108-122
11369812-1	2001	BACKGROUND: We have reported previously that exposure of endothelial cells to cyclosporin A (CsA) may result in the regulation of specific genes, such as the endothelial nitric oxide synthase.	Cyclosporine	93-96	nitric oxide synthase 3	Bos taurus	158-191
11516824-5	2001	Based on these observations, we attempted to investigate how cyclosporin A treatment would affect the changes of phosphorylated CREB (pCREB), BDNF and its receptor tyrosine kinase B (TrkB) after forebrain ischemia in rats.	Cyclosporine	61-74	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	164-181
11516824-5	2001	Based on these observations, we attempted to investigate how cyclosporin A treatment would affect the changes of phosphorylated CREB (pCREB), BDNF and its receptor tyrosine kinase B (TrkB) after forebrain ischemia in rats.	Cyclosporine	61-74	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	183-187
11516824-0	2001	Involvement of the brain-derived neurotrophic factor/TrkB pathway in neuroprotecive effect of cyclosporin A in forebrain ischemia.	Cyclosporine	94-107	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	53-57
11516824-8	2001	The protein expression of BDNF and TrkB appeared to be up-regulated in cyclosporin A-treated animals, whereas it was transiently up-regulated but decreased to the marginal level of expression without cyclosporin A.From these results we suggest that cyclosporin A induces pCREB by an inhibition of calcineurin, resulting in the induction of BDNF.	Cyclosporine	71-84	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	35-39
11516824-8	2001	The protein expression of BDNF and TrkB appeared to be up-regulated in cyclosporin A-treated animals, whereas it was transiently up-regulated but decreased to the marginal level of expression without cyclosporin A.From these results we suggest that cyclosporin A induces pCREB by an inhibition of calcineurin, resulting in the induction of BDNF.	Cyclosporine	200-213	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	35-39
11516824-8	2001	The protein expression of BDNF and TrkB appeared to be up-regulated in cyclosporin A-treated animals, whereas it was transiently up-regulated but decreased to the marginal level of expression without cyclosporin A.From these results we suggest that cyclosporin A induces pCREB by an inhibition of calcineurin, resulting in the induction of BDNF.	Cyclosporine	200-213	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	35-39
11516824-9	2001	The mechanisms by which cyclosporin A protects the CA1 region from neuronal cell death in forebrain ischemia may involve the interaction of pCREB, BDNF and TrkB.	Cyclosporine	24-37	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	156-160
11336351-6	2001	The potency of inhibition of P-gp was cyclosporine &gt; tacrolimus &gt; quinidine &gt; verapamil &gt; vinblastine.	Cyclosporine	38-50	ATP binding cassette subfamily B member 1	Homo sapiens	29-33
11104682-7	2000	Furthermore, mobilization of calcium by A23187 and thapsigargin blocked the TNFalpha-mediated induction of RGS16, which was reversed by EGTA and by the immunosuppressants FK506 and cyclosporin A, suggesting that the calcineurin/NF-AT (nuclear factor of activated T cells) pathway may repress the up-regulation process.	Cyclosporine	181-194	tumor necrosis factor	Homo sapiens	76-84
11256528-17	2001	However, CsA may also be exerting direct effects on NO synthesis through its interactions with both iNOS and cNOS.	Cyclosporine	9-12	nitric oxide synthase 2	Sus scrofa	100-104
11120854-7	2000	The fMLP-induced chemokine production was blocked by pertussis toxin, PD98059, and cyclosporin A, which respectively inhibit G(i)alpha activation, mitgen-activated protein kinase kinase-mediated ERK phosphorylation, and calcineurin-mediated activation of NFAT.	Cyclosporine	83-96	formyl peptide receptor 1	Homo sapiens	4-8
11120854-7	2000	The fMLP-induced chemokine production was blocked by pertussis toxin, PD98059, and cyclosporin A, which respectively inhibit G(i)alpha activation, mitgen-activated protein kinase kinase-mediated ERK phosphorylation, and calcineurin-mediated activation of NFAT.	Cyclosporine	83-96	mitogen-activated protein kinase 1	Homo sapiens	195-198
11175349-3	2000	Here we show that Bid-induced MMP can be inhibited, both in cells and in the cell-free system, by three pharmacological inhibitors of the permeability transition pore complex (PTPC), namely cyclosporin A, N-methyl-4-Val-cyclosporin A, and bongkrekic acid (a ligand of the adenine nucleotide translocase, ANT, one of the PTPC components).	Cyclosporine	190-203	BH3 interacting domain death agonist	Homo sapiens	18-21
11139374-10	2000	Experiments have shown that P-gp can be inhibited by different non-chemotherapeutic substrates such as cyclosporin A.	Cyclosporine	103-116	ATP binding cassette subfamily B member 1	Homo sapiens	28-32
11117236-11	2000	Hepatic gamma-glutamylcysteine synthetase activity was increased after long-term treatment with both doses of CsA, whereas the activity of GSH hepatic peroxidase and GSH transferase was not significantly modified in any of the experimental groups.	Cyclosporine	110-113	glutamate-cysteine ligase, catalytic subunit	Rattus norvegicus	8-41
11180020-2	2000	Previous reports have described reductions in concentrations of CYP3A4 substrates indinavir and cyclosporine (INN, ciclosporin) associated with St John"s Wort.	Cyclosporine	115-126	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	64-70
11498403-6	2000	A wealth of recent experimental data shows that many of the previously tested P-glycoprotein inhibitors, including verapamil, cyclosporin A, and valspodar (SDZ PSC 833), are substrates and/or potent inhibitors of cytochrome P450 3A4 (CYP3A4).	Cyclosporine	126-139	ATP binding cassette subfamily B member 1	Homo sapiens	78-92
11498403-6	2000	A wealth of recent experimental data shows that many of the previously tested P-glycoprotein inhibitors, including verapamil, cyclosporin A, and valspodar (SDZ PSC 833), are substrates and/or potent inhibitors of cytochrome P450 3A4 (CYP3A4).	Cyclosporine	126-139	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	213-232
11498403-6	2000	A wealth of recent experimental data shows that many of the previously tested P-glycoprotein inhibitors, including verapamil, cyclosporin A, and valspodar (SDZ PSC 833), are substrates and/or potent inhibitors of cytochrome P450 3A4 (CYP3A4).	Cyclosporine	126-139	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	234-240
11121130-0	2000	Suppressive effects of cyclosporin A and FK-506 on superoxide generation in human polymorphonuclear leukocytes primed by tumor necrosis factor alpha.	Cyclosporine	23-36	tumor necrosis factor	Homo sapiens	121-148
11095649-0	2000	Immunohistochemical analysis of renin activity in chronic cyclosporine nephropathy in childhood nephrotic syndrome.	Cyclosporine	58-70	renin	Homo sapiens	32-37
11095649-1	2000	Although the pivotal role of activation of the intrarenal renin-angiotensin system (RAS) has been demonstrated in the rat model of chronic cyclosporine (CyA) nephropathy, it is still unclear whether intrarenal RAS activation is responsible for chronic CyA nephropathy in humans.	Cyclosporine	139-151	renin	Homo sapiens	58-63
11095649-1	2000	Although the pivotal role of activation of the intrarenal renin-angiotensin system (RAS) has been demonstrated in the rat model of chronic cyclosporine (CyA) nephropathy, it is still unclear whether intrarenal RAS activation is responsible for chronic CyA nephropathy in humans.	Cyclosporine	153-156	renin	Homo sapiens	58-63
11095649-8	2000	Moreover, the ratio of the number of renin-positive cells to the number of glomeruli (histologic renin index) increased significantly with long-term CyA treatment (from 1.26+/-0.24 to 4.30+/-0.40, P&lt;0.0001).	Cyclosporine	149-152	renin	Homo sapiens	37-42
11095649-8	2000	Moreover, the ratio of the number of renin-positive cells to the number of glomeruli (histologic renin index) increased significantly with long-term CyA treatment (from 1.26+/-0.24 to 4.30+/-0.40, P&lt;0.0001).	Cyclosporine	149-152	renin	Homo sapiens	97-102
11086108-5	2000	Cyclosporin A could block CD40L expression by lupus T cells when added early during the anti-CD3 stimulation period, but only partially when added later, indicating that another mechanism regulates the prolonged hyperexpression of CD40L besides the Ca(2+) --&gt; calcineurin-dependent NF-AT pathway.	Cyclosporine	0-13	CD40 ligand	Homo sapiens	26-31
11086108-5	2000	Cyclosporin A could block CD40L expression by lupus T cells when added early during the anti-CD3 stimulation period, but only partially when added later, indicating that another mechanism regulates the prolonged hyperexpression of CD40L besides the Ca(2+) --&gt; calcineurin-dependent NF-AT pathway.	Cyclosporine	0-13	CD40 ligand	Homo sapiens	231-236
11124597-1	2000	BACKGROUND/AIMS: Several recent studies have suggested that angiotensin-converting enzyme (ACE) inhibitors ameliorate chronic cyclosporin A (CyA) tubulo-interstitial disease by mechanisms independent of their antihypertensive effects.	Cyclosporine	126-139	angiotensin I converting enzyme	Homo sapiens	60-89
11124597-1	2000	BACKGROUND/AIMS: Several recent studies have suggested that angiotensin-converting enzyme (ACE) inhibitors ameliorate chronic cyclosporin A (CyA) tubulo-interstitial disease by mechanisms independent of their antihypertensive effects.	Cyclosporine	126-139	angiotensin I converting enzyme	Homo sapiens	91-94
11124597-6	2000	Enalaprilat completely reversed the stimulatory effects of CyA on CF collagen synthesis (CyA + enalaprilat 6.40 +/- 0.50% vs. CyA alone 8.33 +/- 0.56% vs. control 6.57 +/- 0.62% vs. enalaprilat alone 5.55 +/- 0.93%, p &lt; 0.05) and PTC secretion of TGFbeta1 (0.71 +/- 0.11, 1.13 +/- 0.09, 0.89 +/- 0.07, and 0.67 +/- 0.09 ng/mg protein/day, respectively, p &lt; 0.05).	Cyclosporine	59-62	transforming growth factor beta 1	Homo sapiens	250-258
11134812-0	2000	Changes in cyclosporine A levels in pediatric renal allograft recipients receiving recombinant human growth hormone therapy.	Cyclosporine	11-25	growth hormone 1	Homo sapiens	101-115
11236632-9	2000	(3) Cyclosporin A (10(-8)-10(-6) mol/L), inhibitor of CaN, an inhibited the airway smooth muscle cell 3H-TdR incorporation induced by Urotensin II (10(-7) mol/L) in a dose-dependent manner, with the inhibitory rate of 76% at 10(-6) mol/L (P &lt; 0.01).	Cyclosporine	4-17	urotensin 2	Rattus norvegicus	134-146
11067738-5	2000	The inhibitory effects of ketoconazole, cyclosporin A, and cimetidine toward the 2-hydroxylation of E2 catalyzed by CYP3A4 were obtained, and their IC(50) values were 7 nM, 64 nM, and 290 microM, respectively.	Cyclosporine	40-53	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	116-122
11074805-5	2000	RESULTS: In cyclosporine-treated eyes, biopsy results of conjunctivae showed decreases in the number of cells positive for CD3, CD4, and CD8, while in vehicle-treated eyes, results showed increases in these markers, although these differences were not statistically significant.	Cyclosporine	12-24	CD4 molecule	Homo sapiens	128-131
11205313-1	2000	BACKGROUND: The non-immunosuppressive cyclosporine analog PSC 833 has been shown to reverse multidrug-resistance of neoplastic cells including the MDR-1 gene coded P-glycoprotein (P-gp)-mediated cells resistant to paclitaxel.	Cyclosporine	38-50	ATP binding cassette subfamily B member 1	Homo sapiens	147-152
11205313-1	2000	BACKGROUND: The non-immunosuppressive cyclosporine analog PSC 833 has been shown to reverse multidrug-resistance of neoplastic cells including the MDR-1 gene coded P-glycoprotein (P-gp)-mediated cells resistant to paclitaxel.	Cyclosporine	38-50	ATP binding cassette subfamily B member 1	Homo sapiens	164-178
11205313-1	2000	BACKGROUND: The non-immunosuppressive cyclosporine analog PSC 833 has been shown to reverse multidrug-resistance of neoplastic cells including the MDR-1 gene coded P-glycoprotein (P-gp)-mediated cells resistant to paclitaxel.	Cyclosporine	38-50	ATP binding cassette subfamily B member 1	Homo sapiens	180-184
11091247-6	2000	RESULTS: The expression of messenger RNA (mRNA) for collagen III and TIMP-1 was significantly higher in patients receiving cyclosporin therapy than in those having tacrolimus (P &lt; 0.01); this finding was accounted for by differences in the biopsy material at 1 week.	Cyclosporine	123-134	TIMP metallopeptidase inhibitor 1	Homo sapiens	69-75
11122104-9	2000	However, P-gp function, measured using cyclosporin modulation of rhodamine 123 (R123) uptake, was not associated with the CDR, demonstrating that there are other properties of P-gp, besides its role in drug efflux, that modulate the responsiveness of AML blasts to chemotherapy.	Cyclosporine	39-50	ATP binding cassette subfamily B member 1	Homo sapiens	9-13
11103756-10	2000	The 50% lymphocyte-mitosis inhibition of cyclosporine on interleukin-2 production in culture medium was correlated with 50% lymphocyte-mitosis inhibition of the drug on peripheral blood mononuclear cell blastogenesis (r = 0.806, P &lt; .02).	Cyclosporine	41-53	interleukin 2	Homo sapiens	57-70
11103756-11	2000	Decreasing rates of interleukin-2R-positive cells by cyclosporine treatment in vitro were negatively correlated with peripheral blood mononuclear cells blastogenesis in the presence of the drug (r = -0.694, P &lt; .02).	Cyclosporine	53-65	interleukin 2	Homo sapiens	20-33
11103756-13	2000	Peripheral blood mononuclear cell resistance to cyclosporine was correlated with ability of the cells to express interleukin 2 and interleukin 2R.	Cyclosporine	48-60	interleukin 2	Homo sapiens	113-126
11038163-11	2000	All three K11777 metabolites were formed by isolated CYP3A and their formation by human liver microsomes was inhibited by the CYP3A inhibitor cyclosporine (50 microM, 54-62% inhibition) and antibodies against human CYP3A4/5 (100 microg of antibodies/100 microg microsomal protein, 55-68% inhibition).	Cyclosporine	142-154	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	53-58
11038163-11	2000	All three K11777 metabolites were formed by isolated CYP3A and their formation by human liver microsomes was inhibited by the CYP3A inhibitor cyclosporine (50 microM, 54-62% inhibition) and antibodies against human CYP3A4/5 (100 microg of antibodies/100 microg microsomal protein, 55-68% inhibition).	Cyclosporine	142-154	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	126-131
11038163-11	2000	All three K11777 metabolites were formed by isolated CYP3A and their formation by human liver microsomes was inhibited by the CYP3A inhibitor cyclosporine (50 microM, 54-62% inhibition) and antibodies against human CYP3A4/5 (100 microg of antibodies/100 microg microsomal protein, 55-68% inhibition).	Cyclosporine	142-154	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	215-223
11121733-2	2000	Because cytochrome P450 (CYP) 3A-mediated first-pass metabolism contributes to this unpredictable bioavailability, an in vivo oral CYP3A phenotyping probe could be a valuable tool in optimizing cyclosporine therapy.	Cyclosporine	194-206	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	131-136
11129282-0	2000	Increase in proliferation rate and normalization of TNF-alpha secretion by blockage of gene transfer-induced apoptosis in lymphocytes using low-dose cyclosporine A.	Cyclosporine	149-163	tumor necrosis factor	Homo sapiens	52-61
11129282-5	2000	In this study, we show that blockage of apoptosis by addition of low-dose cyclosporine A can lead to normalization of elevated TNF-alpha secretion and to a significant increase in the proliferation rate of transfected lymphocytes.	Cyclosporine	74-88	tumor necrosis factor	Homo sapiens	127-136
11258483-5	2000	We further demonstrate that co-expression of a constitutively active NFAT and a constitutively active MEKK1 renders the interleukin-2 promoter in Jurkat T lymphocytes resistant to CsA and FK506, whereas Jurkat cells expressing a constitutively active NFAT alone are still sensitive to CsA or FK506.	Cyclosporine	180-183	interleukin 2	Homo sapiens	120-133
11258483-5	2000	We further demonstrate that co-expression of a constitutively active NFAT and a constitutively active MEKK1 renders the interleukin-2 promoter in Jurkat T lymphocytes resistant to CsA and FK506, whereas Jurkat cells expressing a constitutively active NFAT alone are still sensitive to CsA or FK506.	Cyclosporine	285-288	interleukin 2	Homo sapiens	120-133
11258483-6	2000	Therefore, CsA and FK506 exert their immunosuppressive effects through targeting both the calcineurin-dependent NFAT pathway and calcineurin-independent activation pathway for JNK and p38.	Cyclosporine	11-14	mitogen-activated protein kinase 14	Homo sapiens	184-187
11121733-5	2000	Differing extents of intestinal first-pass metabolic extraction between the two drugs, inhibition of midazolam metabolism by cyclosporine at the level of the intestine, and/or P-glycoprotein-mediated intestinal efflux of cyclosporine (but not midazolam) may account for this poor correlation.	Cyclosporine	221-233	ATP binding cassette subfamily B member 1	Homo sapiens	176-190
11058574-6	2000	Using different reporter gene constructs, we establish that Tec in transfected T cells dramatically induced NF-AT-dependent gene transcription, which was prevented by a dominant-negative mutant of NF-AT or by the immunosuppressive drug cyclosporin A.	Cyclosporine	236-249	tec protein tyrosine kinase	Homo sapiens	60-63
11151744-1	2000	OBJECTIVE: Case reports have described elevated concentrations of CYP3A4 substrates (e.g. cyclosporin) during metronidazole treatment.	Cyclosporine	90-101	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	66-72
11040041-5	2000	IL-6 mRNA induction by UTP is more rapid and transient then that caused by IL-1beta stimulation and is partially blocked by cyclosporin A or by expression of a trans-dominant NFAT inhibitor.	Cyclosporine	124-137	interleukin 6	Rattus norvegicus	0-4
11058832-2	2000	Although recent experimental studies show that CsA prevents severe hepatic injury associated with tumor necrosis factor-alpha (TNF-alpha), the efficacy of CsA has not been confirmed.	Cyclosporine	47-50	tumor necrosis factor	Rattus norvegicus	98-125
11058832-2	2000	Although recent experimental studies show that CsA prevents severe hepatic injury associated with tumor necrosis factor-alpha (TNF-alpha), the efficacy of CsA has not been confirmed.	Cyclosporine	47-50	tumor necrosis factor	Rattus norvegicus	127-136
11079467-4	2000	In rats receiving CsA, the mRNA expression of pre-pro-endothelin-1 increased, whereas that of endothelial nitric oxide (NO) synthase decreased, both in the aorta and in the renal cortex (increases in pre-pro-endothelin-1 mRNA in aorta and renal cortex, respectively: 275%+/-18%, 300%+/-27%; decreases in endothelial NO synthase mRNA in aorta and renal cortex respectively: 40%+/-8%, 42%+/-6%).	Cyclosporine	18-21	endothelin 1	Rattus norvegicus	54-66
11079467-4	2000	In rats receiving CsA, the mRNA expression of pre-pro-endothelin-1 increased, whereas that of endothelial nitric oxide (NO) synthase decreased, both in the aorta and in the renal cortex (increases in pre-pro-endothelin-1 mRNA in aorta and renal cortex, respectively: 275%+/-18%, 300%+/-27%; decreases in endothelial NO synthase mRNA in aorta and renal cortex respectively: 40%+/-8%, 42%+/-6%).	Cyclosporine	18-21	endothelin 1	Rattus norvegicus	208-220
11079467-5	2000	Moreover, long-term CsA treatment also induced an up-regulation of the endothelin-converting enzyme 1 mRNA expression (156% vs. control rats) in the renal cortex, with a significantly increased protein content and enzyme activity.	Cyclosporine	20-23	endothelin converting enzyme 1	Rattus norvegicus	71-101
11079467-7	2000	This imbalance between endothelin-1 and NO systems could explain the hypertension and the deranged kidney function observed after long-term CsA treatment in rats.	Cyclosporine	140-143	endothelin 1	Rattus norvegicus	23-35
11119931-0	2000	Existence of serum p53 antibodies in cyclosporine A-treated transplant patients: possible detection of p53 protein over-expression.	Cyclosporine	37-51	tumor protein p53	Homo sapiens	19-22
11096286-8	2000	We investigated a possible role of cyclosporin (CsA) on human monocytic (THP-1) and lymphoid (Jurkat) cell lines.	Cyclosporine	48-51	GLI family zinc finger 2	Homo sapiens	73-78
11096286-9	2000	CsA decreases CD43 expression in monocytic and not in lymphoid cell lines and could be responsible for the specific dys-sialylation of KTR monocytes.	Cyclosporine	0-3	sialophorin	Homo sapiens	14-18
11096287-4	2000	In the present study, we examined the effect of the NEP inhibitor thiorphan on the acute fall in GFR induced by CyA.	Cyclosporine	112-115	membrane metalloendopeptidase	Homo sapiens	52-55
11119931-0	2000	Existence of serum p53 antibodies in cyclosporine A-treated transplant patients: possible detection of p53 protein over-expression.	Cyclosporine	37-51	tumor protein p53	Homo sapiens	103-106
11032765-9	2000	Pretreatment with cyclosporin A (500 nM, 30 h) significantly decreased caspase-3 activation during extended incubations with paraoxon, parathion, and TPPi (p &lt; 0.05).	Cyclosporine	18-31	caspase 3	Homo sapiens	71-80
11032765-12	2000	Alteration of OP compound-induced nuclear fragmentation or caspase-3 activation by pretreatment with cyclosporin A, Ac-IETD-CHO, or PMSF suggested that OP compound-induced cytotoxicity may be modulated through multiple sites, including mitochondrial permeability pores, receptor-mediated caspase pathways, or serine proteases.	Cyclosporine	101-114	caspase 3	Homo sapiens	59-68
10906142-7	2000	Finally, we also found that Grb3-3 potentiates HIV-1 long terminal (LTR) repeat promoter activity following T-cell receptor stimulation, an effect that can be largely suppressed by cyclosporin A.	Cyclosporine	181-194	growth factor receptor bound protein 2	Homo sapiens	28-34
11073027-0	2000	Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients.	Cyclosporine	55-66	interleukin 2	Homo sapiens	0-13
11073027-3	2000	We suggest that an interleukin-2 receptor-mediated alteration of the cytochrome P450 system causes this systemic drug interaction and propose that the initial ciclosporin dose should be limited to 400 mg/m2 if used in combination with basiliximab.	Cyclosporine	159-170	interleukin 2	Homo sapiens	19-32
10908570-3	2000	This response was partially inhibited by cyclosporin A and staurosporine, suggesting the participation of both the Ca(2+) and the protein kinase C pathways in CD43 signaling.	Cyclosporine	41-54	sialophorin	Homo sapiens	159-163
10975874-8	2000	In the first experiment, CsA treated 3NP-lesioned rats displayed significantly more dopamine-and adenosine-3;, 5;-monophosphate-regulated phosphoprotein (DARPP32-ir) neurons ipsilateral to BBB disruption compared to the contralateral intact striatum, indicating that disruption of the BBB maybe necessary for CsA"s neuroprotective effects.	Cyclosporine	25-28	protein phosphatase 1, regulatory (inhibitor) subunit 1B	Rattus norvegicus	154-161
10975874-9	2000	In the second experiment, stereological counts of DARPP32-ir neurons revealed that CsA protected striatal neurons in a dose-dependent manner following bilateral disruption of the striatal BBB.	Cyclosporine	83-86	protein phosphatase 1, regulatory (inhibitor) subunit 1B	Rattus norvegicus	50-57
11041251-11	2000	Treatment with cyclosporin A markedly decreased the PMA/A23187-induced IL-2 promoter activity.	Cyclosporine	15-28	interleukin 2	Homo sapiens	71-75
11029348-3	2000	For these reasons, we determined whether CsA inhibited the allergen-induced increases in bronchial eosinophils, basophils, eotaxin, interleukin-5 (IL-5), and granulocyte macrophage colony-stimulating factor (GM-CSF).	Cyclosporine	41-44	C-C motif chemokine ligand 11	Homo sapiens	123-130
11202156-8	2000	Furthermore, drug uptake and efflux studies, performed by flow cytometry on isolated nuclei in the presence of the P-glycoprotein inhibitor cyclosporin A, suggested the presence of a functional P-glycoprotein in the nuclear membrane, but not in the nuclear matrix, of drug resistant cells.	Cyclosporine	140-153	ATP binding cassette subfamily B member 1	Homo sapiens	115-129
11202156-8	2000	Furthermore, drug uptake and efflux studies, performed by flow cytometry on isolated nuclei in the presence of the P-glycoprotein inhibitor cyclosporin A, suggested the presence of a functional P-glycoprotein in the nuclear membrane, but not in the nuclear matrix, of drug resistant cells.	Cyclosporine	140-153	ATP binding cassette subfamily B member 1	Homo sapiens	194-208
11073292-3	2000	A kidney transplantation patient treated with 75 mg bid doses of cyclosporin for many years experienced a sudden drop in her cyclosporin trough concentrations.	Cyclosporine	65-76	BH3 interacting domain death agonist	Homo sapiens	52-55
10999939-4	2000	CsA significantly suppresses strong COX-2 mRNA induction caused by the Ca(2+)-mobilizing mitogens UTP, angiotensin II, and platelet-derived growth factor-BB, and the synergistic induction caused by costimulation with ionomycin and a phorbol ester.	Cyclosporine	0-3	angiotensinogen	Rattus norvegicus	103-117
11073292-3	2000	A kidney transplantation patient treated with 75 mg bid doses of cyclosporin for many years experienced a sudden drop in her cyclosporin trough concentrations.	Cyclosporine	125-136	BH3 interacting domain death agonist	Homo sapiens	52-55
11004222-2	2000	The addition of humanized IL-2 receptor antibody daclizumab (DZB) to CsA-based immunosuppression decreases the rate of acute renal transplant rejection.	Cyclosporine	69-72	interleukin 2	Homo sapiens	26-30
11034368-5	2000	In this report we also demonstrate and offer an explanation for two observed forms of the RelB protein and show that RelB can be induced in myeloid cells, either directly or indirectly, through a calcium-dependent and cyclosporin A-sensitive pathway.	Cyclosporine	218-231	RELB proto-oncogene, NF-kB subunit	Homo sapiens	90-94
11034368-5	2000	In this report we also demonstrate and offer an explanation for two observed forms of the RelB protein and show that RelB can be induced in myeloid cells, either directly or indirectly, through a calcium-dependent and cyclosporin A-sensitive pathway.	Cyclosporine	218-231	RELB proto-oncogene, NF-kB subunit	Homo sapiens	117-121
11012914-13	2000	The mean trough level of cyclosporine for the first six months was positively correlated to osteocalcin and total alkaline phosphatase increase at six months, and both bone formation and resorption marker increases were significantly correlated to the lumbar QCT Z score increase at 24 months.	Cyclosporine	25-37	bone gamma-carboxyglutamate protein	Homo sapiens	92-103
11071287-1	2000	In order to explain the schistosomicidal effect of cyclosporin A, the hypothesis was advanced that the drug, complexed with cyclophilin, inhibits the phosphatase activity of parasite calcineurin (CN), with mechanisms similar to those operating in its immunosuppressive action.	Cyclosporine	51-64	cyclophilin	Schistosoma mansoni	124-135
10999939-6	2000	CsA strongly inhibits UTP-, angiotensin II-, and platelet-derived growth factor-BB-stimulated COX-2 gene transcription as measured by nuclear run-on or promoter-reporter studies, but has no effect on mRNA induction caused by post-transcriptional stabilization of a distal COX-2 mRNA 3"-untranslated region regulatory element.	Cyclosporine	0-3	angiotensinogen	Rattus norvegicus	28-42
10942734-3	2000	The resting DeltaPsi of Bcl-2 nonexpressing PC12 and wild-type SY5Y cells was increased significantly by the presence of the PTP inhibitor cyclosporin A (CsA) or by intracellular Ca(2+) chelation through exposure to the acetoxymethyl ester of 1, 2-bis(2-aminophenoxy)ethane-N,N,N",N"-tetraacetic acid (BAPTA-AM).	Cyclosporine	154-157	BCL2, apoptosis regulator	Rattus norvegicus	24-29
10973631-6	2000	FK506 and cyclosporin A suppressed the chemotactic activity of the supernatant in parallel to the suppression of interleukin-8 production by peripheral blood mononuclear cells.	Cyclosporine	10-23	C-X-C motif chemokine ligand 8	Homo sapiens	113-126
10981246-6	2000	DISCUSSION: St. John"s wort is suspected to be a significant inducer of CYP3A4 isoenzyme activity and of P-glycoprotein (P-gp) expression, both of which are important in the metabolism and absorption of cyclosporine.	Cyclosporine	203-215	ATP binding cassette subfamily B member 1	Homo sapiens	105-119
10981246-6	2000	DISCUSSION: St. John"s wort is suspected to be a significant inducer of CYP3A4 isoenzyme activity and of P-glycoprotein (P-gp) expression, both of which are important in the metabolism and absorption of cyclosporine.	Cyclosporine	203-215	ATP binding cassette subfamily B member 1	Homo sapiens	121-125
10981246-7	2000	Cyclosporine exhibits a relatively small therapeutic window and is sensitive to medications that can modulate the CYP3A4 isoenzyme and P-gp in both the liver and small intestines.	Cyclosporine	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	114-120
10981246-7	2000	Cyclosporine exhibits a relatively small therapeutic window and is sensitive to medications that can modulate the CYP3A4 isoenzyme and P-gp in both the liver and small intestines.	Cyclosporine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	135-139
11131636-10	2000	A positive correlation was found between the IFN-gamma level and CsA-induced apoptosis.	Cyclosporine	65-68	interferon gamma	Homo sapiens	45-54
11131636-11	2000	The CsA-induced apoptosis was also blocked by a specific antibody against human IFN-gamma.	Cyclosporine	4-7	interferon gamma	Homo sapiens	80-89
11131636-12	2000	These results indicated that both recombinant and endogenous IFN-gamma can induce potent tumor-apoptosis when combined with CsA.	Cyclosporine	124-127	interferon gamma	Homo sapiens	61-70
11053632-8	2000	Our data show that switching of immunosuppressive therapy from CsA to tacrolimus results in suppression of costimulatory ligands, adhesion molecules, Th1 responses and CD4 helper activity.	Cyclosporine	63-66	CD4 molecule	Homo sapiens	168-171
11042226-4	2000	Polarised transport of doxorubicin in the Caco-2 and the LLC-PK1:MDR1 cell lines could be inhibited by the P-gp inhibitors SDZ-PSC 833 (PSC 833), cyclosporin A (CsA), verapamil and quinine, but not by the inhibitors for the organic cation carrier systems cimetidine and tetraethylammonium (TEA).	Cyclosporine	146-159	ATP binding cassette subfamily B member 1	Homo sapiens	107-111
11042226-4	2000	Polarised transport of doxorubicin in the Caco-2 and the LLC-PK1:MDR1 cell lines could be inhibited by the P-gp inhibitors SDZ-PSC 833 (PSC 833), cyclosporin A (CsA), verapamil and quinine, but not by the inhibitors for the organic cation carrier systems cimetidine and tetraethylammonium (TEA).	Cyclosporine	161-164	ATP binding cassette subfamily B member 1	Homo sapiens	107-111
10938401-3	2000	Derivatives of cyclosporin interact with and reverse the ability of P-gp to act as a drug efflux pump.	Cyclosporine	15-26	ATP binding cassette subfamily B member 1	Homo sapiens	68-72
10925353-7	2000	Modulation of P-gp function by cyclosporin A was found to alter DOX accumulation and efflux in LoVo 7 cells, indicating that intracellular P-gp plays a functional role in drug trafficking and suggesting possible implications in determining the intrinsic resistance displayed by this clone.	Cyclosporine	31-44	ATP binding cassette subfamily B member 1	Homo sapiens	14-18
10925353-7	2000	Modulation of P-gp function by cyclosporin A was found to alter DOX accumulation and efflux in LoVo 7 cells, indicating that intracellular P-gp plays a functional role in drug trafficking and suggesting possible implications in determining the intrinsic resistance displayed by this clone.	Cyclosporine	31-44	ATP binding cassette subfamily B member 1	Homo sapiens	139-143
10938401-4	2000	To determine if the Gly185 residue of human P-gp is also important for the interaction of P-gp with closely related cyclosporin derivatives, we examined the effect of PSC-833 and CsA on P-gp in KB3-1 cells transfected with human wild-type P-gp (GSV-2) or with the mutant P-gp (VSV-1) that habored the Gly185--&gt;Val substitution.	Cyclosporine	116-127	ATP binding cassette subfamily B member 1	Homo sapiens	44-48
10938401-7	2000	Furthermore, the intracellular accumulation of CsA was low in GSV-2 P-gp-expressing cells, compared with its accumulation in VSV-1 cells and it was found to be as high as in non-P-gp expressing KB3-1 cells.	Cyclosporine	47-50	ATP binding cassette subfamily B member 1	Homo sapiens	68-72
10938401-7	2000	Furthermore, the intracellular accumulation of CsA was low in GSV-2 P-gp-expressing cells, compared with its accumulation in VSV-1 cells and it was found to be as high as in non-P-gp expressing KB3-1 cells.	Cyclosporine	47-50	ATP binding cassette subfamily B member 1	Homo sapiens	178-182
10938401-8	2000	These results indicated an enhanced sensitivity of Val185-P-gp expressing cells to CsA that correlated with increased intracellular accumulation in these cells.	Cyclosporine	83-86	ATP binding cassette subfamily B member 1	Homo sapiens	58-62
11045663-9	2000	The optimal doses of CsA and tacrolimus had similar inhibitory effects on Th1 type cytokine IL-2 and interferon [INF]-gamma), inflammatory cytokine (IL-1beta and tumor necrosis factor [TNF]-alpha), and cytotoxic factor (granzyme B and perforin) mRNA expression.	Cyclosporine	21-24	interleukin 1 beta	Rattus norvegicus	149-157
11045663-9	2000	The optimal doses of CsA and tacrolimus had similar inhibitory effects on Th1 type cytokine IL-2 and interferon [INF]-gamma), inflammatory cytokine (IL-1beta and tumor necrosis factor [TNF]-alpha), and cytotoxic factor (granzyme B and perforin) mRNA expression.	Cyclosporine	21-24	tumor necrosis factor	Rattus norvegicus	185-195
10972680-0	2000	Effect of nitric oxide modulation on TGF-beta1 and matrix proteins in chronic cyclosporine nephrotoxicity.	Cyclosporine	78-90	transforming growth factor, beta 1	Rattus norvegicus	37-46
11008076-1	2000	BACKGROUND: To determine whether genetic factors are involved in the development of renal dysfunction due to cyclosporine nephrotoxicity, we analyzed 2 polymorphisms in the signal sequence of the transforming growth factor (TGF)-beta 1 gene; codon 10 (Leu(10) --&gt; Pro) and codon 25 (Arg(25) --&gt; Pro).	Cyclosporine	109-121	transforming growth factor beta 1	Homo sapiens	196-235
11008076-10	2000	CONCLUSION: Our data support the hypothesis that TGF-beta 1 is involved in the process leading to renal insufficiency in cyclosporine-treated cardiac allograft recipients.	Cyclosporine	121-133	transforming growth factor beta 1	Homo sapiens	49-59
10972680-4	2000	Thus, we examined the effect of NO modulation on fibrosis and the expression of transforming growth factor-beta1 (TGF-beta1) and matrix proteins in chronic CsA nephrotoxicity.	Cyclosporine	156-159	transforming growth factor, beta 1	Rattus norvegicus	114-123
10972680-8	2000	In addition, the CsA-induced up-regulated expression of TGF-beta1, PAI-1, and the matrix proteins biglycan, fibronectin, and collagen I was significantly increased with L-NAME and strikingly improved with L-Arg.	Cyclosporine	17-20	transforming growth factor, beta 1	Rattus norvegicus	56-65
10972680-8	2000	In addition, the CsA-induced up-regulated expression of TGF-beta1, PAI-1, and the matrix proteins biglycan, fibronectin, and collagen I was significantly increased with L-NAME and strikingly improved with L-Arg.	Cyclosporine	17-20	serpin family E member 1	Rattus norvegicus	67-72
10972680-8	2000	In addition, the CsA-induced up-regulated expression of TGF-beta1, PAI-1, and the matrix proteins biglycan, fibronectin, and collagen I was significantly increased with L-NAME and strikingly improved with L-Arg.	Cyclosporine	17-20	biglycan	Rattus norvegicus	98-106
10956206-2	2000	Identified initially as inhibitors of IL-2 synthesis, the BTPs have been optimized in this regard and even inhibit IL-2 production with a 10-fold enhancement over cyclosporine in an ex vivo assay.	Cyclosporine	163-175	interleukin 2	Homo sapiens	115-119
10972232-2	2000	The mechanism of action of cyclosporine and tacrolimus has been explained on the basis of their inhibition of interleukin-2 (IL-2), and induction of transforming growth factor-beta (TGF-beta).	Cyclosporine	27-39	interleukin 2	Homo sapiens	110-123
10972232-2	2000	The mechanism of action of cyclosporine and tacrolimus has been explained on the basis of their inhibition of interleukin-2 (IL-2), and induction of transforming growth factor-beta (TGF-beta).	Cyclosporine	27-39	transforming growth factor beta 1	Homo sapiens	149-180
10972232-2	2000	The mechanism of action of cyclosporine and tacrolimus has been explained on the basis of their inhibition of interleukin-2 (IL-2), and induction of transforming growth factor-beta (TGF-beta).	Cyclosporine	27-39	transforming growth factor beta 1	Homo sapiens	182-190
10972232-5	2000	RESULTS: In this study, we report that rapamycin in combination with either tacrolimus or cyclosporine significantly inhibited the lymphocyte proliferation, IL-2 expression, and induced TGF-beta, compared with these drugs alone.	Cyclosporine	90-102	transforming growth factor beta 1	Homo sapiens	186-194
10900260-10	2000	In conclusion, CsA administration for 3 weeks resulted in a significant reduction of hepatic cholesterol 7alpha-hydroxylase and marked down-regulation of skeletal muscle and adipose tissue lipoprotein lipase abundance in rats.	Cyclosporine	15-18	cytochrome P450 family 7 subfamily A member 1	Rattus norvegicus	93-123
10949194-6	2000	The modifying effect of cyclosporine (CsA) and FK506 on CD40L gene expression was further tested in vitro in CD4+ T lymphocytes separated from pokeweed mitogen- (PWM) activated peripheral blood lymphocytes (PBL) preparations.	Cyclosporine	24-36	CD40 ligand	Homo sapiens	56-61
10949194-9	2000	After in vitro activation, CD40L gene expression increased by approximately 4-fold and the addition of CsA or FK506 diminished CD40L gene expression to a base level.	Cyclosporine	103-106	CD40 ligand	Homo sapiens	127-132
10949194-10	2000	CONCLUSION: Peripheral CD4+ T cell CD40L gene expression increases significantly in acute rejection and CAN and may serve as a non-invasive method to monitor allograft function and determine the biological response to CsA and FK506.	Cyclosporine	218-221	CD40 ligand	Homo sapiens	35-40
11009048-8	2000	The median cyclosporin pseudo-clearance of transplant patients with wild-type CYP3A4 was 0.90 l/h/kg (range: 0.35-3.8 l/h/kg; n = 86), whereas the corresponding value for the five patients heterozygotic for the CYP3A4-G variant was 0.71 l/h/kg (range 0.35-0.91 l/h/kg).	Cyclosporine	11-22	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	78-84
10900260-10	2000	In conclusion, CsA administration for 3 weeks resulted in a significant reduction of hepatic cholesterol 7alpha-hydroxylase and marked down-regulation of skeletal muscle and adipose tissue lipoprotein lipase abundance in rats.	Cyclosporine	15-18	lipoprotein lipase	Rattus norvegicus	189-207
10908312-6	2000	Pretreatment with cyclosporin A, an agent that stabilizes mitochondrial permeability transition pore, inhibited BHA-induced loss of Deltapsi(m), cytochrome c release, caspase activation, and apoptosis.	Cyclosporine	18-31	cytochrome c, somatic	Homo sapiens	145-157
11951112-4	2000	(3)H-TdR incorporation of Ang II stimulated fibroblasts was 72% higher than control (P&lt;0.01), which was inhibited by CsA (0.1 10 micromol/L) in a dose dependent manner.	Cyclosporine	120-123	angiotensinogen	Rattus norvegicus	26-32
10928765-0	2000	Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion.	Cyclosporine	98-110	interleukin 6	Homo sapiens	0-13
11021666-8	2000	However, two out of six IFN-gamma receptor-deficient mice given post-transplant treatment with CsA and MDL 201,449A exhibited intact ICC xenografts with ICCs arranged in chords and duct-like structures on day 7 after transplantation.	Cyclosporine	95-98	interferon gamma	Mus musculus	24-33
10933163-4	2000	METHODS: The effect of CsA on MHC antigen expression during tumor necrosis factor (TNF)-alpha- or lymphocyte-mediated PAEC activation was evaluated in vitro by flow cytometry and correlated to the ability of porcine ECs to promote human T lymphocyte proliferation.	Cyclosporine	23-26	tumor necrosis factor	Homo sapiens	60-93
10933163-6	2000	RESULTS: Flow cytometry analysis showed that TNF-alpha-mediated induction of class II MHC antigen expression on PAECs was completely inhibited by CsA, whereas expression of class I MHC was reduced by 50%.	Cyclosporine	146-149	tumor necrosis factor	Homo sapiens	45-54
10933163-11	2000	Semiquantitative reverse transcriptase-polymerase chain reaction experiments showed that CsA markedly reduced the steady-state level of porcine class II (SLA-DRA and SLA-DQA) mRNA at 16 hr, compared with PAECs stimulated with TNF-alpha alone.	Cyclosporine	89-92	tumor necrosis factor	Homo sapiens	226-235
10886243-5	2000	However, differences between IL-4 on the one hand and IL-5 and IL-13 on the other hand were observed when sensitivity to cyclosporin A (CsA) was studied.	Cyclosporine	121-134	interleukin 4	Homo sapiens	29-33
10886243-5	2000	However, differences between IL-4 on the one hand and IL-5 and IL-13 on the other hand were observed when sensitivity to cyclosporin A (CsA) was studied.	Cyclosporine	121-134	interleukin 13	Homo sapiens	63-68
10886243-5	2000	However, differences between IL-4 on the one hand and IL-5 and IL-13 on the other hand were observed when sensitivity to cyclosporin A (CsA) was studied.	Cyclosporine	136-139	interleukin 4	Homo sapiens	29-33
10886243-5	2000	However, differences between IL-4 on the one hand and IL-5 and IL-13 on the other hand were observed when sensitivity to cyclosporin A (CsA) was studied.	Cyclosporine	136-139	interleukin 13	Homo sapiens	63-68
10886243-6	2000	CsA (an inhibitor of calcineurin phosphatase activity) strongly inhibited IL-4 production, but it did either not affect or even increased IL-5 and IL-13 production.	Cyclosporine	0-3	interleukin 4	Homo sapiens	74-78
10928765-7	2000	IL-6 normalized for G3PDH (IL-6/G3PDH ratio) was not different from baseline at 3 months but showed a significant decrease from baseline in the group treated with 0.05% CsA (p = 0.048) at 6 months.	Cyclosporine	169-172	interleukin 6	Homo sapiens	0-4
10928765-7	2000	IL-6 normalized for G3PDH (IL-6/G3PDH ratio) was not different from baseline at 3 months but showed a significant decrease from baseline in the group treated with 0.05% CsA (p = 0.048) at 6 months.	Cyclosporine	169-172	interleukin 6	Homo sapiens	27-31
10928765-9	2000	CONCLUSIONS: This preliminary, small-cohort study showed a decrease in IL-6 in the conjunctival epithelium of moderate to severe dry eye patients treated with 0.05% CsA for 6 months.	Cyclosporine	165-168	interleukin 6	Homo sapiens	71-75
11030448-6	2000	Likewise, luciferase assays demonstrate stronger ET-1 promoter-dependent stimulation of the reporter gene by CsA than by FK506.	Cyclosporine	109-112	endothelin 1	Rattus norvegicus	49-53
11030448-9	2000	These observations demonstrate that calcineurin antagonists FK506 and CsA differ in quality to induce transcription of prepro ET-1 in HUVEC via calcium-dependent nuclear signalling events.	Cyclosporine	70-73	endothelin 1	Rattus norvegicus	126-130
10979207-7	2000	The positive rate for HLA-DRB1*1501 was 60% (3/5) among 5 CyA-dependent patients, which tended to be higher than the 20% (1/5) among 5 CyA-independent patients.	Cyclosporine	58-61	major histocompatibility complex, class II, DR beta 1	Homo sapiens	22-30
11030448-0	2000	Differential transcriptional regulation of endothelin-1 by immunosuppressants FK506 and cyclosporin A.	Cyclosporine	88-101	endothelin 1	Rattus norvegicus	43-55
11030448-1	2000	Calcineurin antagonists FK506 and CsA, administered to treat organ allograft rejection, exert specific effects on renal vasoconstriction and nephrotoxicity, possibly due to endogenous vasoconstrictor release such as ET-1.	Cyclosporine	34-37	endothelin 1	Rattus norvegicus	216-220
11030448-2	2000	We investigated contribution of FK506 and CsA on regulation of prepro ET-1 gene transcription in HUVEC.	Cyclosporine	42-45	endothelin 1	Rattus norvegicus	70-74
11030448-5	2000	Northern blot analysis shows differential induction of prepro ET-1 mRNA in favour of CsA over FK506.	Cyclosporine	85-88	endothelin 1	Rattus norvegicus	62-66
10923914-7	2000	Very few of nonsomatotroph adenomas were immunopositive for GHRH using the CSA system.	Cyclosporine	75-78	growth hormone releasing hormone	Homo sapiens	60-64
10887328-8	2000	This DNA-binding activity was inhibited by cyclosporin A, which indicated that NFATx nuclear translocation in CD4(+)CD8(+) thymocytes was regulated by calcineurin phosphatase.	Cyclosporine	43-56	nuclear factor of activated T cells 3	Homo sapiens	79-84
10887328-8	2000	This DNA-binding activity was inhibited by cyclosporin A, which indicated that NFATx nuclear translocation in CD4(+)CD8(+) thymocytes was regulated by calcineurin phosphatase.	Cyclosporine	43-56	CD4 molecule	Homo sapiens	110-113
10979207-7	2000	The positive rate for HLA-DRB1*1501 was 60% (3/5) among 5 CyA-dependent patients, which tended to be higher than the 20% (1/5) among 5 CyA-independent patients.	Cyclosporine	135-138	major histocompatibility complex, class II, DR beta 1	Homo sapiens	22-30
10887335-5	2000	RESULTS: Dexamethasone, FK506, and cyclosporin A suppressed the production of IL-2, IL-4, and IL-5 by human helper T cells, which shows a similar concentration-response relationship in each case.	Cyclosporine	35-48	interleukin 2	Homo sapiens	78-82
10887335-5	2000	RESULTS: Dexamethasone, FK506, and cyclosporin A suppressed the production of IL-2, IL-4, and IL-5 by human helper T cells, which shows a similar concentration-response relationship in each case.	Cyclosporine	35-48	interleukin 4	Homo sapiens	84-88
10892661-7	2000	CsA at both "attack" and "maintenance" doses increased basal, 5-HT, and thrombin-evoked [Ca2+]i after 2 and 7 weeks versus the control group.	Cyclosporine	0-3	coagulation factor II	Rattus norvegicus	72-80
11003717-1	2000	BACKGROUND: Contact hypersensitivity (CHS) is a Th1-mediated immune response that can be down-regulated by immunosuppressive agents such as cyclosporine and environmental stimuli such as ultraviolet light.	Cyclosporine	140-152	negative elongation factor complex member C/D, Th1l	Mus musculus	48-51
10886556-12	2000	TIMP-1 mRNA was up-regulated by cyclosporine in fibroblasts.	Cyclosporine	32-44	TIMP metallopeptidase inhibitor 1	Homo sapiens	0-6
10914494-9	2000	It is interesting that cyclosporin A (CsA) blocked RT-induced apoptosis with an inhibition of cytochrome c release from mitochondria.	Cyclosporine	23-36	cytochrome c, somatic	Homo sapiens	94-106
10914494-9	2000	It is interesting that cyclosporin A (CsA) blocked RT-induced apoptosis with an inhibition of cytochrome c release from mitochondria.	Cyclosporine	38-41	cytochrome c, somatic	Homo sapiens	94-106
10886556-15	2000	Cyclosporine treatment induces ECM accumulation by increasing collagen synthesis in endothelial and epithelial cells and reducing its degradation by up-regulating TIMP-1 expression in fibroblasts.	Cyclosporine	0-12	TIMP metallopeptidase inhibitor 1	Homo sapiens	163-169
12659178-5	2000	With the use of cyclosporin A to inhibit the delta psi m dissipation, the cytotoxicity mediated by hyperthermia or TNF-alpha was suppressed.	Cyclosporine	16-29	tumor necrosis factor	Mus musculus	115-124
10898107-10	2000	The point estimates of rGC for composite (hepatic + intestinal) CYP3A4 activity measured after oral administration of cyclosporine, ethinylestradiol, ethylmorphine, nifedipine and nitrendipine, ranged from 0.66-0.98 (median: 0.83) (P &lt; 0.05).	Cyclosporine	118-130	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	64-70
10898107-11	2000	Cyclosporine data suggested a higher genetic control of CYP3A4 at night than during the day.	Cyclosporine	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-62
20950543-21	2000	The reverse effect of CsA for expression of MDR1 requires further clinical study.	Cyclosporine	22-25	ATP binding cassette subfamily B member 1	Homo sapiens	44-48
10849438-10	2000	In contrast to NF-AT-dependent transcription, Vav1-mediated transcriptional induction of the CD28RE/AP element in the interleukin-2 promoter could only partially be inhibited by cyclosporin A, suggesting a dual role of Vav1 for controlling Ca(2+)-dependent and -independent events.	Cyclosporine	178-191	interleukin 2	Homo sapiens	118-131
10854232-1	2000	The killing of L929 mouse fibroblasts by tumor necrosis factor-alpha (TNF-alpha) in the presence of 0.5 microg/ml actinomycin D (Act D) is prevented by inhibition of the mitochondrial permeability transition (MPT) with cyclosporin A (CyA) in combination with the phospholipase A(2) inhibitor aristolochic acid (ArA).	Cyclosporine	219-232	tumor necrosis factor	Mus musculus	41-68
10837354-2	2000	Aldosterone secretion is significantly decreased by the PGP inhibitors verapamil, cyclosporin A (CSA), PSC-833, and vinblastine.	Cyclosporine	82-95	ATP binding cassette subfamily B member 1	Homo sapiens	56-59
10837354-2	2000	Aldosterone secretion is significantly decreased by the PGP inhibitors verapamil, cyclosporin A (CSA), PSC-833, and vinblastine.	Cyclosporine	97-100	ATP binding cassette subfamily B member 1	Homo sapiens	56-59
10854232-1	2000	The killing of L929 mouse fibroblasts by tumor necrosis factor-alpha (TNF-alpha) in the presence of 0.5 microg/ml actinomycin D (Act D) is prevented by inhibition of the mitochondrial permeability transition (MPT) with cyclosporin A (CyA) in combination with the phospholipase A(2) inhibitor aristolochic acid (ArA).	Cyclosporine	219-232	tumor necrosis factor	Mus musculus	70-79
10854232-1	2000	The killing of L929 mouse fibroblasts by tumor necrosis factor-alpha (TNF-alpha) in the presence of 0.5 microg/ml actinomycin D (Act D) is prevented by inhibition of the mitochondrial permeability transition (MPT) with cyclosporin A (CyA) in combination with the phospholipase A(2) inhibitor aristolochic acid (ArA).	Cyclosporine	234-237	tumor necrosis factor	Mus musculus	41-68
10854232-1	2000	The killing of L929 mouse fibroblasts by tumor necrosis factor-alpha (TNF-alpha) in the presence of 0.5 microg/ml actinomycin D (Act D) is prevented by inhibition of the mitochondrial permeability transition (MPT) with cyclosporin A (CyA) in combination with the phospholipase A(2) inhibitor aristolochic acid (ArA).	Cyclosporine	234-237	tumor necrosis factor	Mus musculus	70-79
10820137-6	2000	Less potent P-glycoprotein inhibitors like valspodar (PSC-833), cyclosporin A, and ketoconazole, as well as quinidine and verapamil, had modest or little effect on brain/plasma ratios but increased plasma nelfinavir concentrations due to inhibition of CYP3A-mediated metabolism.	Cyclosporine	64-77	ATP binding cassette subfamily B member 1	Homo sapiens	12-26
10841236-9	2000	CONCLUSIONS: Vitamin C improves both endothelial function and insulin sensitivity in patients with CSA.	Cyclosporine	99-102	insulin	Homo sapiens	62-69
10736526-8	2000	The number of CD4(+), CD8(+), T cell receptor (TCR) alpha ss-bearing cells and TCRgamma delta-bearing cells decreased markedly in the peripheral blood of CsA-treated chickens compared to those of untreated chickens.	Cyclosporine	154-157	T-cell surface glycoprotein CD4	Gallus gallus	14-17
10894164-1	2000	By DNase I hypersensitivity analysis, we have identified an inducible, cyclosporin A-sensitive enhancer located 3" of the interleukin-4 (IL-4) gene.	Cyclosporine	71-84	interleukin 4	Homo sapiens	122-135
10894164-1	2000	By DNase I hypersensitivity analysis, we have identified an inducible, cyclosporin A-sensitive enhancer located 3" of the interleukin-4 (IL-4) gene.	Cyclosporine	71-84	interleukin 4	Homo sapiens	137-141
10914799-0	2000	Phenytoin and cyclosporin A suppress the expression of MMP-1, TIMP-1, and cathepsin L, but not cathepsin B in cultured gingival fibroblasts.	Cyclosporine	14-27	TIMP metallopeptidase inhibitor 1	Homo sapiens	62-68
10914799-0	2000	Phenytoin and cyclosporin A suppress the expression of MMP-1, TIMP-1, and cathepsin L, but not cathepsin B in cultured gingival fibroblasts.	Cyclosporine	14-27	cathepsin L	Homo sapiens	74-85
10914799-10	2000	CONCLUSIONS: The results indicate that, besides suggested effects of these drugs on gingival fibroblasts and/or on accumulated cells in the gingival tissues, extracellular matrix-degrading ability, particularly that by cathepsin L, is also suppressed by cyclosporin A and phenytoin in gingival fibroblasts, and that lysosomal enzyme plays an important role in the pathogenesis of drug-induced gingival hyperplasia.	Cyclosporine	254-267	cathepsin L	Homo sapiens	219-230
11014613-6	2000	CyA treatment reduced but did not normalize (p&lt;0.05) this parameter in hyperprolactinemic rats and did not modify circulating prolactin in control animals.	Cyclosporine	0-3	prolactin	Rattus norvegicus	79-88
10841236-10	2000	Thus, reactive oxygen species and/or decreased nitric oxide bioactivity may play an important role in the genesis of both endothelial dysfunction and insulin resistance in patients with CSA.	Cyclosporine	186-189	insulin	Homo sapiens	150-157
11005322-3	2000	Since CsA is an antagonist of cytostatic drugs in P-glycoprotein (Pgp)-mediated transport, increased Pgp expression might contribute to an increased resistance to CsA.	Cyclosporine	6-9	ATP binding cassette subfamily B member 1	Homo sapiens	50-64
11005322-3	2000	Since CsA is an antagonist of cytostatic drugs in P-glycoprotein (Pgp)-mediated transport, increased Pgp expression might contribute to an increased resistance to CsA.	Cyclosporine	6-9	ATP binding cassette subfamily B member 1	Homo sapiens	66-69
11005322-3	2000	Since CsA is an antagonist of cytostatic drugs in P-glycoprotein (Pgp)-mediated transport, increased Pgp expression might contribute to an increased resistance to CsA.	Cyclosporine	163-166	ATP binding cassette subfamily B member 1	Homo sapiens	50-64
11005322-3	2000	Since CsA is an antagonist of cytostatic drugs in P-glycoprotein (Pgp)-mediated transport, increased Pgp expression might contribute to an increased resistance to CsA.	Cyclosporine	163-166	ATP binding cassette subfamily B member 1	Homo sapiens	66-69
11005322-3	2000	Since CsA is an antagonist of cytostatic drugs in P-glycoprotein (Pgp)-mediated transport, increased Pgp expression might contribute to an increased resistance to CsA.	Cyclosporine	163-166	ATP binding cassette subfamily B member 1	Homo sapiens	101-104
11005322-4	2000	METHODS: The sensitivity of lymphocytes at three different concentrations of CsA was tested in a non-radioactive lymphocyte-transformation test and related to Pgp expression as determined by flow cytometry on mononuclear cells.	Cyclosporine	77-80	ATP binding cassette subfamily B member 1	Homo sapiens	159-162
11005322-8	2000	In ATX, sensitivity to CsA was significantly higher than in PTX at a concentration of 1000 ng/ml CsA.	Cyclosporine	23-26	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	3-6
10923859-11	2000	Rifalazil-32-hydroxylation in microsomes was completely inhibited by CYP3A4-specific inhibitors (fluconazole, ketoconazole, miconazole, troleandomycin) and drugs metabolized by CYP3A4 such as cyclosporin A and clarithromycin, indicating that the enzyme responsible for the rifalazil-32-hydroxylation is CYP3A4.	Cyclosporine	192-205	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-75
11005322-8	2000	In ATX, sensitivity to CsA was significantly higher than in PTX at a concentration of 1000 ng/ml CsA.	Cyclosporine	97-100	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	3-6
11005322-10	2000	Analysing the relationship between CsA sensitivity and Pgp expression, no significant heterogeneity could be observed between the different groups.	Cyclosporine	35-38	ATP binding cassette subfamily B member 1	Homo sapiens	55-58
10788473-11	2000	We determined that inhibition of calcineurin activity with cyclosporine prevented PKCalpha, theta, and JNK activation, but did not affect PKCepsilon, beta, lambda, ERK1/2, or p38 activation.	Cyclosporine	59-71	protein kinase C, alpha	Mus musculus	82-90
10809760-6	2000	beta-MHC promoter activation induced by ET-1 was suppressed by pretreatment with the calmodulin inhibitor, W7, the Ca(2+)/calmodulin-dependent kinase II (CaMKII) inhibitor, KN62, and the calcineurin inhibitor, cyclosporin A. beta-MHC promoter activation by ET-1 was also attenuated by overexpression of dominant-negative mutants of CaMKII and calcineurin.	Cyclosporine	210-221	endothelin 1	Rattus norvegicus	40-44
10809760-6	2000	beta-MHC promoter activation induced by ET-1 was suppressed by pretreatment with the calmodulin inhibitor, W7, the Ca(2+)/calmodulin-dependent kinase II (CaMKII) inhibitor, KN62, and the calcineurin inhibitor, cyclosporin A. beta-MHC promoter activation by ET-1 was also attenuated by overexpression of dominant-negative mutants of CaMKII and calcineurin.	Cyclosporine	210-221	calcineurin binding protein 1	Rattus norvegicus	187-208
10809760-8	2000	Pretreatment with KN62 and cyclosporin A strongly suppressed ET-1-induced increases in [(3)H]phenylalanine uptake and in cell size.	Cyclosporine	27-40	endothelin 1	Rattus norvegicus	61-65
10799529-11	2000	Cyclosporin A partially inhibited ISO-stimulated ANF transcription, indicating that calcineurin only partially mediates ANF transcription.	Cyclosporine	0-13	natriuretic peptide A	Homo sapiens	49-52
10786743-4	2000	CYP3A4 is responsible for the metabolism of numerous other therapeutic agents, including those administered concurrently with fentanyl (e.g., nifedipine, lidocaine, erythromycin and cyclosporine).	Cyclosporine	182-194	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
10704938-7	2000	The progressive increase in intracellular peroxides in cell cultures in the range from 0-50 microM CsA was associated with the loss of cell viability and accompanied by significantly higher levels of Mn- and Cu, Zn-superoxide dismutase enzyme activities and mRNAs, and slight increases in catalase activity and mRNA.	Cyclosporine	99-102	catalase	Rattus norvegicus	289-297
10928095-0	2000	Cyclosporine A inhibition of prolactin-dependent up-regulation of BRCA1 protein expression in human breast cell lines.	Cyclosporine	0-14	prolactin	Homo sapiens	29-38
10928095-5	2000	RESULTS AND CONCLUSION: We showed that Prolactin in presence of Cyclosporine A has no effect on BRCA1 protein expression in human breast cell lines.	Cyclosporine	64-78	prolactin	Homo sapiens	39-48
10807671-9	2000	CsA (0.25, 0.5 and 1 mg kg(-1), 5 min after reperfusion) increased survival rate (SAO+CsA=236+/-9 min following the highest dose), reverted the marked hypotension, reduced plasma nitrite/nitrate concentration (11+/-5.2 microM following the highest dose), restored to control values the hyporeactivity to PE, and blunted iNOS protein induction and activity in aortic rings.	Cyclosporine	0-3	nitric oxide synthase 2	Rattus norvegicus	320-324
10704938-9	2000	The non-coordinated regulation of the gene expression of antioxidant enzyme systems, i.e. catalase and Mn- and Cu,Zn-superoxide dismutases, evidenced to a greater extent in hepatocytes from the older group of rats, could be one of the mechanisms involved in CsA toxicity.	Cyclosporine	258-261	catalase	Rattus norvegicus	90-98
10796891-4	2000	Two inhibitors of MPT pore opening, cyclosporin A and bongkrekic acid, prevented TNF-alpha cytotoxicity in the presence of ethanol.	Cyclosporine	36-49	tumor necrosis factor	Homo sapiens	81-90
10772630-5	2000	Known Pgp inhibitors, such as cyclosporin A, nicardipine, verapamil, quinidine, terfenadine, tamoxifen, and vinblastine were demonstrated to inhibit the Pgp-mediated efflux of daunorubicin.	Cyclosporine	30-43	ATP binding cassette subfamily B member 1	Homo sapiens	6-9
10772630-5	2000	Known Pgp inhibitors, such as cyclosporin A, nicardipine, verapamil, quinidine, terfenadine, tamoxifen, and vinblastine were demonstrated to inhibit the Pgp-mediated efflux of daunorubicin.	Cyclosporine	30-43	ATP binding cassette subfamily B member 1	Homo sapiens	153-156
10878284-11	2000	Cyclosporine and FK-506 (Tacrolimus) inhibit the phosphatase activity of calcineurin, thereby suppressing the production of IL-2 and other cytokines.	Cyclosporine	0-12	interleukin 2	Homo sapiens	124-128
10908115-0	2000	The potent immunosuppressive cyclosporin FR901459 inhibits the human P-glycoprotein and formyl peptide receptor functions.	Cyclosporine	29-40	ATP binding cassette subfamily B member 1	Homo sapiens	69-83
10808161-1	2000	BACKGROUND: Cyclosporine induces daily renal hypoperfusion in subjects with normal atrial natriuretic peptide (ANP) levels, but its acute effects in heart transplant patients with increased ANP remain to be determined.	Cyclosporine	12-24	natriuretic peptide A	Homo sapiens	83-109
10810233-0	2000	Role of intrarenal endothelin 1, endothelin 3, and angiotensin II expression in chronic cyclosporin A nephrotoxicity in rats.	Cyclosporine	88-101	angiotensinogen	Rattus norvegicus	51-65
10810233-3	2000	Angiotensin II has recently been implicated as the principal factor responsible for the progression of interstitial fibrosis induced by cyclosporin A (CsA).	Cyclosporine	136-149	angiotensinogen	Rattus norvegicus	0-14
10810233-3	2000	Angiotensin II has recently been implicated as the principal factor responsible for the progression of interstitial fibrosis induced by cyclosporin A (CsA).	Cyclosporine	151-154	angiotensinogen	Rattus norvegicus	0-14
10810233-7	2000	Immunohistochemical results showed that chronic CsA treatment induced moderate secretion of Et1 and Et3 at tubular and glomerular levels and that the local expression of angiotensin II in the treatment groups was more evident than in control animals.	Cyclosporine	48-51	endothelin 1	Rattus norvegicus	92-95
10810233-7	2000	Immunohistochemical results showed that chronic CsA treatment induced moderate secretion of Et1 and Et3 at tubular and glomerular levels and that the local expression of angiotensin II in the treatment groups was more evident than in control animals.	Cyclosporine	48-51	angiotensinogen	Rattus norvegicus	170-184
10810233-10	2000	However, at 56 days, the key finding was the strong correlation of the most important analytical, histological, and immunohistochemical parameters of CsA nephrotoxicity with Et1 mRNA levels (r&gt;0.50, p&lt;0.01).	Cyclosporine	150-153	endothelin 1	Rattus norvegicus	174-177
10810233-11	2000	These results support the hypothesis that the clinical and morphological phenomena linked with CsA nephrotoxicity are related to hypersecretion of endothelins and local expression of angiotensin II in the outer medulla and medullary rays; Et3 and angiotensin II are the first to act, followed subsequently by Et1.	Cyclosporine	95-98	angiotensinogen	Rattus norvegicus	183-197
10810233-11	2000	These results support the hypothesis that the clinical and morphological phenomena linked with CsA nephrotoxicity are related to hypersecretion of endothelins and local expression of angiotensin II in the outer medulla and medullary rays; Et3 and angiotensin II are the first to act, followed subsequently by Et1.	Cyclosporine	95-98	angiotensinogen	Rattus norvegicus	247-261
10810233-11	2000	These results support the hypothesis that the clinical and morphological phenomena linked with CsA nephrotoxicity are related to hypersecretion of endothelins and local expression of angiotensin II in the outer medulla and medullary rays; Et3 and angiotensin II are the first to act, followed subsequently by Et1.	Cyclosporine	95-98	endothelin 1	Rattus norvegicus	309-312
10800942-11	2000	Cyclosporin A, an MPT pore blocker, completely prevented the MTP depolarization as well as the enhanced LDH releases in glucose-deprived/SIN-1-treated astrocytes.	Cyclosporine	0-13	MAPK associated protein 1	Homo sapiens	137-142
10827238-5	2000	The relation of erythropoietin level to the values for hematocrit, serum creatinine, and cyclosporine and other biochemical test results was evaluated.	Cyclosporine	89-101	erythropoietin	Homo sapiens	16-30
10808161-1	2000	BACKGROUND: Cyclosporine induces daily renal hypoperfusion in subjects with normal atrial natriuretic peptide (ANP) levels, but its acute effects in heart transplant patients with increased ANP remain to be determined.	Cyclosporine	12-24	natriuretic peptide A	Homo sapiens	111-114
10838122-3	2000	Results showed that the accumulation of P-gp substrates calcein-AM and vinblastine by BeWo cells or primary cultures of human cytotrophoblasts was significantly enhanced in the presence of a typical P-gp inhibitor, cyclosporin-A, or other inhibitors such as quinidine, verapamil, and dipyridamole.	Cyclosporine	215-228	ATP binding cassette subfamily B member 1	Homo sapiens	40-44
10838122-3	2000	Results showed that the accumulation of P-gp substrates calcein-AM and vinblastine by BeWo cells or primary cultures of human cytotrophoblasts was significantly enhanced in the presence of a typical P-gp inhibitor, cyclosporin-A, or other inhibitors such as quinidine, verapamil, and dipyridamole.	Cyclosporine	215-228	ATP binding cassette subfamily B member 1	Homo sapiens	199-203
10766806-10	2000	The combination of the MPT inhibitors, cyclosporin A, and trifluoperazine, protected Ad5IkappaB-infected hepatocytes from TNFalpha-mediated apoptosis.	Cyclosporine	39-52	tumor necrosis factor	Mus musculus	122-130
10759775-7	2000	Combining LPS and IFN-gamma did not result in a major additional increase, but addition of cyclosporin A further increased levels 2.5-fold both in IFN-gamma- and combination-stimulated cells (P &lt; 0.05).	Cyclosporine	91-104	interferon gamma	Mus musculus	147-156
10809426-3	2000	PATIENTS AND METHODS: Our study evaluates ecNOS gene status and NO metabolites in kidney transplanted patients under chronic CsA treatment with CsA-induced hypertension.	Cyclosporine	125-128	nitric oxide synthase 3	Homo sapiens	42-47
10809426-3	2000	PATIENTS AND METHODS: Our study evaluates ecNOS gene status and NO metabolites in kidney transplanted patients under chronic CsA treatment with CsA-induced hypertension.	Cyclosporine	144-147	nitric oxide synthase 3	Homo sapiens	42-47
10809427-1	2000	BACKGROUND: It is hypothesized that in acute and chronic CsA nephrotoxicity, in vivo models CsA side-effects are mediated by Renin-Angiotensin II (RAS)-TGF-beta-1 pathway.	Cyclosporine	57-60	transforming growth factor, beta 1	Rattus norvegicus	152-162
10809427-1	2000	BACKGROUND: It is hypothesized that in acute and chronic CsA nephrotoxicity, in vivo models CsA side-effects are mediated by Renin-Angiotensin II (RAS)-TGF-beta-1 pathway.	Cyclosporine	92-95	transforming growth factor, beta 1	Rattus norvegicus	152-162
10809427-9	2000	CONCLUSIONS: Our results suggest that chronic CsA administration can induce, in normal fed rats, the process of interstitial fibrogenesis through TGF-beta non-related mechanisms.	Cyclosporine	46-49	transforming growth factor, beta 1	Rattus norvegicus	146-154
10734174-3	2000	An ethyl acetate extract of orange juice did not affect the initial uptake rate of [(3)H]vinblastine but significantly increased the steady-state uptake, as did cyclosporin A (20 microM), an inhibitor of P-gp.	Cyclosporine	161-174	ATP binding cassette subfamily B member 1	Homo sapiens	204-208
10760803-1	2000	In clinical transplantation, the occurrence of cyclosporin A (CsA)-resistant production of IL-2 in vitro correlates with graft rejection in vivo.	Cyclosporine	62-65	interleukin 2	Homo sapiens	91-95
10760803-3	2000	Co-stimulation with ICAM-1 and B7.2 led to strong and CsA-resistant proliferation, which was found to be largely IL-2 dependent.	Cyclosporine	54-57	interleukin 2	Homo sapiens	113-117
10760803-5	2000	In contrast, both ICAM-1 and B7.2 enhanced the half-life of the inducible IL-2 transcript in a CsA-resistant manner.	Cyclosporine	95-98	interleukin 2	Homo sapiens	74-78
10760803-8	2000	We propose that IL-2 transcript accumulation and subsequent T cell proliferation at the low transcriptional rate imposed by CsA are the result of co-stimulation-dependent stabilization of IL-2 mRNA.	Cyclosporine	124-127	interleukin 2	Homo sapiens	16-20
10760803-8	2000	We propose that IL-2 transcript accumulation and subsequent T cell proliferation at the low transcriptional rate imposed by CsA are the result of co-stimulation-dependent stabilization of IL-2 mRNA.	Cyclosporine	124-127	interleukin 2	Homo sapiens	188-192
10783825-1	2000	OBJECTIVE: Increased bioavailability of the P-glycoprotein (Pgp) substrates digoxin and cyclosporin due to erythromycin has been observed in vivo.	Cyclosporine	88-99	ATP binding cassette subfamily B member 1	Homo sapiens	44-58
10783825-1	2000	OBJECTIVE: Increased bioavailability of the P-glycoprotein (Pgp) substrates digoxin and cyclosporin due to erythromycin has been observed in vivo.	Cyclosporine	88-99	ATP binding cassette subfamily B member 1	Homo sapiens	60-63
10760090-11	2000	Neither inhibitor modified the increased iNOS mRNA expression elicited by CsA.	Cyclosporine	74-77	nitric oxide synthase 2	Homo sapiens	41-45
10727524-0	2000	Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant P-glycoprotein with deleted phe(335).	Cyclosporine	8-19	ATP binding cassette subfamily B member 1	Homo sapiens	98-112
10760090-12	2000	Positive staining for both iNOS and p53 proteins was observed in all cell lines incubated with CsA that were inhibited by CHX; L-NAME inhibited only p53 staining.	Cyclosporine	95-98	nitric oxide synthase 2	Homo sapiens	27-31
10760090-12	2000	Positive staining for both iNOS and p53 proteins was observed in all cell lines incubated with CsA that were inhibited by CHX; L-NAME inhibited only p53 staining.	Cyclosporine	95-98	tumor protein p53	Homo sapiens	36-39
10760090-13	2000	CONCLUSIONS: CsA induces apoptosis in various renal cell lines, and this effect is mediated by the induction of iNOS via p53.	Cyclosporine	13-16	nitric oxide synthase 2	Homo sapiens	112-116
10760090-13	2000	CONCLUSIONS: CsA induces apoptosis in various renal cell lines, and this effect is mediated by the induction of iNOS via p53.	Cyclosporine	13-16	tumor protein p53	Homo sapiens	121-124
10708576-5	2000	The increase in multiubiquitinated proteins as well as the stabilization of p53 following CsA addition argues in favor of this hypothesis.	Cyclosporine	90-93	tumor protein p53	Homo sapiens	76-79
10897619-1	2000	MDR1 gene encodes for a transmembranous glycoprotein, gp-170, which acts as a drug export pump and is also a cyclosporine(CsA)-binding protein.	Cyclosporine	109-121	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
10897619-1	2000	MDR1 gene encodes for a transmembranous glycoprotein, gp-170, which acts as a drug export pump and is also a cyclosporine(CsA)-binding protein.	Cyclosporine	109-121	ATP binding cassette subfamily B member 1	Homo sapiens	54-60
10702360-8	2000	The caspase-6 inhibitor, Ac-VEID-CHO, only marginally inhibited CsA-induced apoptosis.	Cyclosporine	64-67	caspase 6	Rattus norvegicus	4-13
10702360-6	2000	After 20 h of CsA incubation apoptosis parameters were further increased and were accompanied by the increased activity of the cysteine protease, caspase-3 (CPP 32), and slightly increased caspase-6 (Mch 2), but not caspase-1 (ICE).	Cyclosporine	14-17	caspase 6	Rattus norvegicus	189-198
10755555-0	2000	Association of glucocorticoids and cyclosporin A or rapamycin prevents E-selectin and IL-8 expression during LPS- and TNFalpha-mediated endothelial cell activation.	Cyclosporine	35-48	C-X-C motif chemokine ligand 8	Homo sapiens	86-90
10702360-6	2000	After 20 h of CsA incubation apoptosis parameters were further increased and were accompanied by the increased activity of the cysteine protease, caspase-3 (CPP 32), and slightly increased caspase-6 (Mch 2), but not caspase-1 (ICE).	Cyclosporine	14-17	caspase 6	Rattus norvegicus	200-205
10755567-0	2000	TGF-beta expression in renal transplant biopsies: a comparative study between cyclosporin-A and tacrolimus.	Cyclosporine	78-91	transforming growth factor beta 1	Homo sapiens	0-8
10755567-4	2000	The current study was designed to measure the expression of TGF-beta(b) in renal transplant biopsy specimens from patients undergoing immunosuppressive therapy with either CsA or tacrolimus (FK506).	Cyclosporine	172-175	transforming growth factor beta 1	Homo sapiens	60-68
10755555-0	2000	Association of glucocorticoids and cyclosporin A or rapamycin prevents E-selectin and IL-8 expression during LPS- and TNFalpha-mediated endothelial cell activation.	Cyclosporine	35-48	tumor necrosis factor	Homo sapiens	118-126
10755567-9	2000	However, biopsy specimens from patients receiving CsA expressed significantly more active TGF-beta(b1) than biopsy specimens from patients receiving FK506 (P&lt;0.0001, Mann-Whitney test).	Cyclosporine	50-53	transforming growth factor beta 1	Homo sapiens	90-98
10755567-10	2000	DISCUSSION: The increased level of active TGF-beta1 expression in renal biopsy specimens of patients receiving CsA may indicate a mechanism of chronic rejection.	Cyclosporine	111-114	transforming growth factor beta 1	Homo sapiens	42-51
10755555-11	2000	It is interesting that in vivo studies confirmed that CsA and GC inhibited EC activation at therapeutic doses (1 mg/kg and 10 mg/kg for GC and CsA, respectively) and showed that the combination of CsA and GC efficiently prevents TNFalpha-mediated induction of E-selectin on cardiac ECs.	Cyclosporine	54-57	tumor necrosis factor	Homo sapiens	229-237
10720632-14	2000	Thus, adding the iNOS blockers iminoethyl-lysine or butylhexahydro-azepin-imine to cyclosporine-A improved graft function and reduced tubulointerstitial lesions.	Cyclosporine	83-97	nitric oxide synthase 2	Rattus norvegicus	17-21
10688837-7	2000	Supernatant of C5-treated mitochondria showed a dose-dependent increase in cytochrome C, which was also inhibited in the presence of cyclosporin A, strongly indicating a direct effect on the inner-membrane pore.	Cyclosporine	133-146	cytochrome c, somatic	Homo sapiens	75-87
11199713-5	2000	Cellulose acetate electrophoresis analysis revealed that RPC-C2A cells synthesized CSA and CSB but not CSC and that 10 ng/ml of TGF-beta increased the production of CSA and CSB in the cell/ECM fraction.	Cyclosporine	83-86	transforming growth factor, beta 1	Rattus norvegicus	128-136
10725273-7	2000	The B/A flux of losartan was inhibited by cyclosporine and vinblastine, inhibitors of P-glycoprotein and MRP.	Cyclosporine	42-54	ATP binding cassette subfamily C member 1	Homo sapiens	105-108
11775252-9	2000	CsA (3 mg/L) can block the efflux pump function of P-gp shown by the significantly increased accumulation and efflux reduction of Rh123 in K562/MDR cells.	Cyclosporine	0-3	ATP binding cassette subfamily B member 1	Homo sapiens	51-55
10741627-0	2000	Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe.	Cyclosporine	14-26	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-115
10741627-1	2000	BACKGROUND: Interindividual differences in the kinetics of cyclosporine (INN, ciclosporin) result in part from variations in the activity of cytochrome P450 3A (CYP3A).	Cyclosporine	59-71	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	141-159
10741627-1	2000	BACKGROUND: Interindividual differences in the kinetics of cyclosporine (INN, ciclosporin) result in part from variations in the activity of cytochrome P450 3A (CYP3A).	Cyclosporine	59-71	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	161-166
10741627-1	2000	BACKGROUND: Interindividual differences in the kinetics of cyclosporine (INN, ciclosporin) result in part from variations in the activity of cytochrome P450 3A (CYP3A).	Cyclosporine	78-89	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	141-159
10741627-1	2000	BACKGROUND: Interindividual differences in the kinetics of cyclosporine (INN, ciclosporin) result in part from variations in the activity of cytochrome P450 3A (CYP3A).	Cyclosporine	78-89	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	161-166
10741627-3	2000	The objective of this study was to examine the usefulness of midazolam as a CYP3A probe to predict cyclosporine clearance.	Cyclosporine	99-111	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	76-81
10741627-12	2000	CONCLUSION: Heterogeneity in CYP3A activity contributes to interpatient differences in cyclosporine dosage requirements after liver transplantation.	Cyclosporine	87-99	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	29-34
11199713-5	2000	Cellulose acetate electrophoresis analysis revealed that RPC-C2A cells synthesized CSA and CSB but not CSC and that 10 ng/ml of TGF-beta increased the production of CSA and CSB in the cell/ECM fraction.	Cyclosporine	165-168	transforming growth factor, beta 1	Rattus norvegicus	128-136
11199713-8	2000	Secreted CSA in the medium was markedly increased by 10 ng/ml of TGF-beta (1.7-fold).	Cyclosporine	9-12	transforming growth factor, beta 1	Rattus norvegicus	65-73
10737718-12	2000	Preincubation of cells with cyclosporine A, which has high affinity for P-gp, did not diminish the levels of ceramide generated upon exposure to PSC 833.	Cyclosporine	28-42	ATP binding cassette subfamily B member 1	Homo sapiens	72-76
10715321-6	2000	Cyp5 displayed peptidylprolyl cis/trans-isomerase and protein refolding activities that were sensitive to cyclosporin A.	Cyclosporine	106-119	cyclophilin 5	Arabidopsis thaliana	0-4
10715321-6	2000	Cyp5 displayed peptidylprolyl cis/trans-isomerase and protein refolding activities that were sensitive to cyclosporin A.	Cyclosporine	106-119	peptidyl-prolyl cis-trans isomerase	Arabidopsis thaliana	15-49
10752642-3	2000	During clinical investigations of drug-drug interactions with therapeutics (terfenadine and cyclosporine) known to be metabolized by CYP3A4, pharmacokinetic interactions were noted upon troglitazone multiple-dose treatments.	Cyclosporine	92-104	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	133-139
10744311-3	2000	Displacement studies using other known PGP ligands, verapamil and cyclosporin A, demonstrated that there was selective binding between vinblastine and the immobilized PGP transporter.	Cyclosporine	66-79	ATP binding cassette subfamily B member 1	Homo sapiens	167-170
10744311-6	2000	The Kd values obtained on the PGP-IAM for cyclosporin A and verapamil were 492+/-21 and 172+/-29 microM, respectively.	Cyclosporine	42-55	ATP binding cassette subfamily B member 1	Homo sapiens	30-33
10671477-3	2000	The calcium, calmodulin-dependent protein phosphatase, calcineurin, stimulates slow fiber-specific gene promoters in cultured skeletal muscle cells, and the calcineurin inhibitor, cyclosporin A, inhibits slow fiber gene expression in vivo, suggesting a key role of calcineurin in activation of the slow muscle fiber phenotype.	Cyclosporine	180-193	calcineurin binding protein 1	Mus musculus	157-178
10706056-2	2000	METHODS: Intracellular interleukin- (IL) 2 was measured in phorbol myristic acid-ionomycin-stimulated peripheral lymphocytes by flow cytometry, after isolation from 14 renal transplant recipients receiving CSA+prednisone, and double-blind rapamycin (rapamycin:placebo=4:1).	Cyclosporine	206-209	interleukin 2	Homo sapiens	23-42
12579726-1	2000	OBJECTIVE: To observe the effects of immunosuppressants triptolide (TL) and cyclosporine A (CSA) on HLA antigens expression induced by interferon-gamma(INF-gamma) in vitro.	Cyclosporine	76-90	interferon gamma	Homo sapiens	135-161
10706056-3	2000	RESULTS: The proportion (%) of CD4+IL-2+ lymphocytes corresponding to CSA levels (mean+/-SD ng/ml) measured preoperatively (TO=O), and on postoperative day 8, before (356+/-63), and 2 hr after the morning dose (Cmax=1567+/-669), decreased from 39+/-16 to 15+/-8 and 3+/-1.6, respectively.	Cyclosporine	70-73	interleukin 2	Homo sapiens	35-39
10706056-4	2000	Reciprocally, unresponsive lymphocytes (%CD4+IL-2-) increased with increasing CSA levels and predicted an EC50 of 249 ng/ml (CSA concentration at which CD4+IL-2- cells increased by 50% over baseline) in an Emax pharmacodynamic model.	Cyclosporine	78-81	interleukin 2	Homo sapiens	45-49
10706056-4	2000	Reciprocally, unresponsive lymphocytes (%CD4+IL-2-) increased with increasing CSA levels and predicted an EC50 of 249 ng/ml (CSA concentration at which CD4+IL-2- cells increased by 50% over baseline) in an Emax pharmacodynamic model.	Cyclosporine	125-128	interleukin 2	Homo sapiens	45-49
10706056-4	2000	Reciprocally, unresponsive lymphocytes (%CD4+IL-2-) increased with increasing CSA levels and predicted an EC50 of 249 ng/ml (CSA concentration at which CD4+IL-2- cells increased by 50% over baseline) in an Emax pharmacodynamic model.	Cyclosporine	125-128	interleukin 2	Homo sapiens	156-160
10688206-2	2000	FK506 and cyclosporin are immunosuppressants which block three antigen-receptor signalling pathways (NFAT, NFkappaB and JNK), through inhibition of calcineurin, and inhibit mature lymphocyte proliferation to antigen.	Cyclosporine	10-21	nuclear factor kappa B subunit 1	Homo sapiens	107-115
10688206-2	2000	FK506 and cyclosporin are immunosuppressants which block three antigen-receptor signalling pathways (NFAT, NFkappaB and JNK), through inhibition of calcineurin, and inhibit mature lymphocyte proliferation to antigen.	Cyclosporine	10-21	mitogen-activated protein kinase 8	Homo sapiens	120-123
10693638-0	2000	A longitudinal study of TGF-beta1 protein levels in renal allograft recipients converted from CsA to MMF or AZA.	Cyclosporine	94-97	transforming growth factor beta 1	Homo sapiens	24-33
10666173-2	2000	Corticosteroids are substrates for P-gp, whose function can be inhibited by cyclosporin.	Cyclosporine	76-87	ATP binding cassette subfamily B member 1	Homo sapiens	35-39
10693638-1	2000	Cyclosporine (CsA) is thought to enhance transforming growth factor (TGF)-beta1 production in vitro and in vivo and this may have a negative effect on long-term graft survival.	Cyclosporine	0-12	transforming growth factor beta 1	Homo sapiens	41-79
10693638-1	2000	Cyclosporine (CsA) is thought to enhance transforming growth factor (TGF)-beta1 production in vitro and in vivo and this may have a negative effect on long-term graft survival.	Cyclosporine	14-17	transforming growth factor beta 1	Homo sapiens	41-79
10681718-16	2000	Some, but not all, of these differences in daunorubicin accumulation and efflux as well as in the effect of cyclo-sporin A can be explained by a heterogenous expression of the mdr1-gene.	Cyclosporine	108-122	ATP binding cassette subfamily B member 1	Homo sapiens	176-180
10706193-5	2000	Human P-glycoprotein has been shown to transport a wide range of structurally unrelated drugs such as digoxin, quinidine, cyclosporine and HIV-1 protease inhibitors.	Cyclosporine	122-134	ATP binding cassette subfamily B member 1	Homo sapiens	6-20
10706193-8	2000	Studies in humans indicate a particular importance of intestinal P-glycoprotein for bioavailability of the immunosuppressant cyclosporine.	Cyclosporine	125-137	ATP binding cassette subfamily B member 1	Homo sapiens	65-79
10791709-4	2000	Our results obtained from the Western blot assays demonstrated clearly that the production of MMP-1 and MMP-3 was significantly inhibited by CyA at similar concentrations found in the serum of patients undergoing CyA-treatment.	Cyclosporine	141-144	matrix metallopeptidase 3	Homo sapiens	104-109
10669849-12	2000	The rotamase activity of the protein, inhibited by cyclosporin A, further confirmed that Bet v 7 belongs to the group of cyclophilins.	Cyclosporine	51-64	FKBP prolyl isomerase 1B	Homo sapiens	4-12
10636889-4	2000	When mdr1 inhibitors (PSC833, cyclosporine A, verapamil) were transiently added to cells with mdr1 up-regulation by pretreatment for 72 h with cadmium, cadmium-induced apoptosis increased significantly and to a percentage similar to that obtained in cells with no mdr1 up-regulation (72-h cadmium: 5.2 +/- 0.9% versus 72-h cadmium + 1-h PSC833: 7.2 +/- 1.4%; p &lt; or = 0.001).	Cyclosporine	30-44	ATP binding cassette subfamily B member 1	Homo sapiens	5-9
10685792-4	2000	RESULTS: At 16 weeks, the cyclosporine group (n = 17), compared with the placebo group (n = 17), had greater decreases in tender joints, swollen joints, patient global assessment, patient self-assessed disability, and C-reactive protein, as well as having more patients with &gt; 20% improvement.	Cyclosporine	26-38	C-reactive protein	Homo sapiens	218-236
10673759-0	2000	Good response to cyclosporine therapy in patients with myelodysplastic syndromes having the HLA-DRB1*1501 allele.	Cyclosporine	17-29	major histocompatibility complex, class II, DR beta 1	Homo sapiens	92-100
10751037-5	2000	Cyclosporin A (20 microM) was present in the uptake media to block potential P-glycoprotein-mediated atorvastatin efflux.	Cyclosporine	0-13	ATP binding cassette subfamily B member 1	Homo sapiens	77-91
10682831-2	2000	The proportion of P-gp and caveolin associated with caveolar microdomains was higher in CH(R)C5 cells grown in the presence of P-gp substrates (cyclosporin A or colchicine) than in untreated CH(R)C5 cells.	Cyclosporine	144-157	glycerol-3-phosphate phosphatase	Cricetulus griseus	18-35
10636889-4	2000	When mdr1 inhibitors (PSC833, cyclosporine A, verapamil) were transiently added to cells with mdr1 up-regulation by pretreatment for 72 h with cadmium, cadmium-induced apoptosis increased significantly and to a percentage similar to that obtained in cells with no mdr1 up-regulation (72-h cadmium: 5.2 +/- 0.9% versus 72-h cadmium + 1-h PSC833: 7.2 +/- 1.4%; p &lt; or = 0.001).	Cyclosporine	30-44	ATP binding cassette subfamily B member 1	Homo sapiens	94-98
10636889-4	2000	When mdr1 inhibitors (PSC833, cyclosporine A, verapamil) were transiently added to cells with mdr1 up-regulation by pretreatment for 72 h with cadmium, cadmium-induced apoptosis increased significantly and to a percentage similar to that obtained in cells with no mdr1 up-regulation (72-h cadmium: 5.2 +/- 0.9% versus 72-h cadmium + 1-h PSC833: 7.2 +/- 1.4%; p &lt; or = 0.001).	Cyclosporine	30-44	ATP binding cassette subfamily B member 1	Homo sapiens	94-98
10639121-3	2000	Unlike Bax/Bak, the cytochrome c release induced by Bid/Bik was Ca(2+)-independent, cyclosporin A-insensitive, and respiration-independent.	Cyclosporine	84-97	cytochrome c, somatic	Homo sapiens	20-32
10639121-3	2000	Unlike Bax/Bak, the cytochrome c release induced by Bid/Bik was Ca(2+)-independent, cyclosporin A-insensitive, and respiration-independent.	Cyclosporine	84-97	BH3 interacting domain death agonist	Homo sapiens	52-55
10639121-3	2000	Unlike Bax/Bak, the cytochrome c release induced by Bid/Bik was Ca(2+)-independent, cyclosporin A-insensitive, and respiration-independent.	Cyclosporine	84-97	BCL2 interacting killer	Homo sapiens	56-59
11261272-7	2000	On NK- and T-cells PRL interferes with Cy-A in two different, dose-dependent ways (subtherapeutical Cy-A increases PRL-binding to its receptor 4 fold; therapeutical Cy-A competes with PRL for binding in a dose dependent manner).	Cyclosporine	39-43	prolactin	Homo sapiens	19-22
10670641-12	2000	These results support the development of a CsA-sensitive, but IL-2-independent, active regulatory mechanism after intrathymic exposure to donor-specific alloantigen and depletion of mature peripheral T cells.	Cyclosporine	43-46	interleukin 2	Homo sapiens	62-66
10623799-2	2000	IL-4 mRNA, constitutively present in basophils, was increased after stimulation by gp120 and was inhibited cyclosporin A and tacrolimus.	Cyclosporine	107-120	interleukin 4	Homo sapiens	0-4
11261272-7	2000	On NK- and T-cells PRL interferes with Cy-A in two different, dose-dependent ways (subtherapeutical Cy-A increases PRL-binding to its receptor 4 fold; therapeutical Cy-A competes with PRL for binding in a dose dependent manner).	Cyclosporine	100-104	prolactin	Homo sapiens	19-22
11261272-7	2000	On NK- and T-cells PRL interferes with Cy-A in two different, dose-dependent ways (subtherapeutical Cy-A increases PRL-binding to its receptor 4 fold; therapeutical Cy-A competes with PRL for binding in a dose dependent manner).	Cyclosporine	100-104	prolactin	Homo sapiens	115-118
11261272-7	2000	On NK- and T-cells PRL interferes with Cy-A in two different, dose-dependent ways (subtherapeutical Cy-A increases PRL-binding to its receptor 4 fold; therapeutical Cy-A competes with PRL for binding in a dose dependent manner).	Cyclosporine	100-104	prolactin	Homo sapiens	115-118
11261272-7	2000	On NK- and T-cells PRL interferes with Cy-A in two different, dose-dependent ways (subtherapeutical Cy-A increases PRL-binding to its receptor 4 fold; therapeutical Cy-A competes with PRL for binding in a dose dependent manner).	Cyclosporine	100-104	prolactin	Homo sapiens	19-22
11261272-7	2000	On NK- and T-cells PRL interferes with Cy-A in two different, dose-dependent ways (subtherapeutical Cy-A increases PRL-binding to its receptor 4 fold; therapeutical Cy-A competes with PRL for binding in a dose dependent manner).	Cyclosporine	100-104	prolactin	Homo sapiens	115-118
11450070-5	2000	The immunosuppressant cyclosporin A (50 microM) partially reduced the ischemia-stimulated IL-8 and MCP-1 secretion by HCEC.	Cyclosporine	22-35	C-X-C motif chemokine ligand 8	Homo sapiens	90-94
11261272-7	2000	On NK- and T-cells PRL interferes with Cy-A in two different, dose-dependent ways (subtherapeutical Cy-A increases PRL-binding to its receptor 4 fold; therapeutical Cy-A competes with PRL for binding in a dose dependent manner).	Cyclosporine	100-104	prolactin	Homo sapiens	115-118
11261272-8	2000	Cy-A inhibits PRL-production on the transcriptional level in pituitary cells.	Cyclosporine	0-4	prolactin	Homo sapiens	14-17
10663638-2	2000	We studied the effects of the Pgp inhibitor, cyclosporin A (CsA), on the cerebrospinal fluid (CSF) penetration of the Pgp substrate, doxorubicin, in non-human primates.	Cyclosporine	60-63	ATP binding cassette subfamily B member 1	Homo sapiens	30-33
10755319-0	2000	Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.	Cyclosporine	20-32	ATP binding cassette subfamily B member 1	Homo sapiens	85-99
10663638-2	2000	We studied the effects of the Pgp inhibitor, cyclosporin A (CsA), on the cerebrospinal fluid (CSF) penetration of the Pgp substrate, doxorubicin, in non-human primates.	Cyclosporine	60-63	ATP binding cassette subfamily B member 1	Homo sapiens	118-121
10755319-0	2000	Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.	Cyclosporine	20-32	ATP binding cassette subfamily B member 1	Homo sapiens	101-105
10755319-1	2000	PURPOSE: The consequences of using cyclosporine (CsA) therapy to modulate P-glycoprotein-mediated multidrug resistance include increased myelosuppression, hyperbilirubinemia, and altered disposition of the cytotoxin.	Cyclosporine	35-47	ATP binding cassette subfamily B member 1	Homo sapiens	74-88
10668858-13	2000	Administration of a CYP3A4 inhibitor with cyclosporin may allow reduction of the dosage and cost of the immunosuppressant.	Cyclosporine	42-53	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	20-26
10634525-2	2000	Diverse groups of drugs have been identified, including cyclosporine A, which can reverse drug resistance by inhibiting P-glycoprotein transport.	Cyclosporine	56-70	ATP binding cassette subfamily B member 1	Homo sapiens	120-134
11122720-4	2000	This article describes the clinical significance of CYP metabolism as the pathways relate to the use of statins, including brief discussions on statins, fibrates, cyclosporine, and calcium channel blockers.	Cyclosporine	163-175	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-55
10642325-0	2000	Cyclosporin A protects against angiotensin II-induced end-organ damage in double transgenic rats harboring human renin and angiotensinogen genes.	Cyclosporine	0-13	angiotensinogen	Rattus norvegicus	31-45
10642325-0	2000	Cyclosporin A protects against angiotensin II-induced end-organ damage in double transgenic rats harboring human renin and angiotensinogen genes.	Cyclosporine	0-13	renin	Homo sapiens	113-118
10642325-0	2000	Cyclosporin A protects against angiotensin II-induced end-organ damage in double transgenic rats harboring human renin and angiotensinogen genes.	Cyclosporine	0-13	angiotensinogen	Homo sapiens	123-138
10642325-2	2000	We tested the hypothesis that the immunosuppressive agent cyclosporine (CsA) protects against the Ang II-induced myocardial and renal damage in dTGR.	Cyclosporine	58-70	angiotensinogen	Rattus norvegicus	98-104
10642325-2	2000	We tested the hypothesis that the immunosuppressive agent cyclosporine (CsA) protects against the Ang II-induced myocardial and renal damage in dTGR.	Cyclosporine	72-75	angiotensinogen	Rattus norvegicus	98-104
10642325-8	2000	The beneficial effects of CsA were, at least in part, mediated by the suppression of IL-6 and iNOS expression.	Cyclosporine	26-29	interleukin 6	Rattus norvegicus	85-89
10642325-8	2000	The beneficial effects of CsA were, at least in part, mediated by the suppression of IL-6 and iNOS expression.	Cyclosporine	26-29	nitric oxide synthase 2	Rattus norvegicus	94-98
10642325-12	2000	Our findings indicate that CsA protects against Ang II-induced end-organ damage and underscore the central role of vascular inflammatory response in the pathogenesis of myocardial and renal damage in dTGR.	Cyclosporine	27-30	angiotensinogen	Rattus norvegicus	48-54
10642325-13	2000	The beneficial effects of CsA in the kidney and heart are mediated, at least in part, by suppression of IL-6 and iNOS expression via NF-kappaB transcriptional pathway.	Cyclosporine	26-29	interleukin 6	Rattus norvegicus	104-108
10642325-13	2000	The beneficial effects of CsA in the kidney and heart are mediated, at least in part, by suppression of IL-6 and iNOS expression via NF-kappaB transcriptional pathway.	Cyclosporine	26-29	nitric oxide synthase 2	Rattus norvegicus	113-117
10686507-4	2000	MCP-1 release reached a maximum at 6-9 h. It was inhibited by treatment with actinomycin D, the immunosuppressant cyclosporin A, and the cytosolic Ca(2+) chelator BAPTA-AM.	Cyclosporine	114-127	mast cell protease 1	Mus musculus	0-5
10778917-8	2000	RESULTS: Cyclosporin (1-5 microg/ml) and rapamycin (1.0-10 nM) but not FK-506 (5-10 nM) inhibited both iNOS and COX-2 expression at mRNA level which led to significant inhibition of NO and PGE2 production.	Cyclosporine	9-20	nitric oxide synthase 2, inducible	Mus musculus	103-107
10778917-10	2000	Inhibition of iNOS and COX-2 mRNA accumulation by cyclosporin and rapamycin seem to be distinct.	Cyclosporine	50-61	nitric oxide synthase 2, inducible	Mus musculus	14-18
11132774-7	2000	However, only basal secretion of interleukin-8 in both undifferentiated and DMSO-differentiated U937 cells was significantly reduced by CsA at the highest concentration (200 ng/ mL).	Cyclosporine	136-139	C-X-C motif chemokine ligand 8	Homo sapiens	33-46
11019782-3	2000	Stable IL-3 transcripts in the PB-3c-derived tumour cell line V2D1 decayed in response to CsA and FK506, but not in response to SB202190.	Cyclosporine	90-93	interleukin 3	Mus musculus	7-11
10729997-5	2000	The absolute number of CD8+CD57+ cells in the patients with grade II-IV acute GVHD was also significantly higher in the tacrolimus group compared with the CsA group.	Cyclosporine	155-158	beta-1,3-glucuronyltransferase 1	Homo sapiens	27-31
10619859-6	2000	Third, levels of cyclosporin A that had marginal effects in CCR1(+/+) mice resulted in permanent allograft acceptance in CCR1(-/-) recipients.	Cyclosporine	17-30	chemokine (C-C motif) receptor 1	Mus musculus	60-64
10619859-6	2000	Third, levels of cyclosporin A that had marginal effects in CCR1(+/+) mice resulted in permanent allograft acceptance in CCR1(-/-) recipients.	Cyclosporine	17-30	chemokine (C-C motif) receptor 1	Mus musculus	121-125
10617104-7	2000	We found prolonged induction of JNK activity in extracts from cyclosporin-treated cells, which suggests an involvement of persistent JNK activation in the initiation of glioma cell apoptosis.	Cyclosporine	62-73	mitogen-activated protein kinase 8	Homo sapiens	32-35
10617104-7	2000	We found prolonged induction of JNK activity in extracts from cyclosporin-treated cells, which suggests an involvement of persistent JNK activation in the initiation of glioma cell apoptosis.	Cyclosporine	62-73	mitogen-activated protein kinase 8	Homo sapiens	133-136
10731632-7	2000	Immunosuppressants FK506 and cyclosporin A were able to induce partial nuclear translocation of GR, suggesting that potentiation of glucocorticoid action by these compounds may also proceed through enhanced GR nuclear transfer.	Cyclosporine	29-42	nuclear receptor subfamily 3 group C member 1	Homo sapiens	96-98
10731632-7	2000	Immunosuppressants FK506 and cyclosporin A were able to induce partial nuclear translocation of GR, suggesting that potentiation of glucocorticoid action by these compounds may also proceed through enhanced GR nuclear transfer.	Cyclosporine	29-42	nuclear receptor subfamily 3 group C member 1	Homo sapiens	207-209
11810478-5	2000	Our results with CSA-ISH showed that the expression of mRNA for the endothelin B receptor was significantly upregulated in hepatic sinusoidal lining cells in cirrhotic human liver tissues compared to control normal liver tissue.	Cyclosporine	17-20	endothelin receptor type B	Homo sapiens	68-89
11200365-3	2000	AIMS: The aim of this work was to examine whether the administration of cyclosporin-A (Cs-A) to STZ-induced diabetic rats inhibits the synthesis of IL-1beta and the expression of the inducible proteins, iNOS and cyclo-oxygenase-2 (COX-2) in retinal cells, and whether the activity of these proteins contribute to BRB breakdown.	Cyclosporine	72-85	interleukin 1 beta	Rattus norvegicus	148-156
11200365-3	2000	AIMS: The aim of this work was to examine whether the administration of cyclosporin-A (Cs-A) to STZ-induced diabetic rats inhibits the synthesis of IL-1beta and the expression of the inducible proteins, iNOS and cyclo-oxygenase-2 (COX-2) in retinal cells, and whether the activity of these proteins contribute to BRB breakdown.	Cyclosporine	72-85	nitric oxide synthase 2	Rattus norvegicus	203-207
11200365-3	2000	AIMS: The aim of this work was to examine whether the administration of cyclosporin-A (Cs-A) to STZ-induced diabetic rats inhibits the synthesis of IL-1beta and the expression of the inducible proteins, iNOS and cyclo-oxygenase-2 (COX-2) in retinal cells, and whether the activity of these proteins contribute to BRB breakdown.	Cyclosporine	87-91	interleukin 1 beta	Rattus norvegicus	148-156
11200365-3	2000	AIMS: The aim of this work was to examine whether the administration of cyclosporin-A (Cs-A) to STZ-induced diabetic rats inhibits the synthesis of IL-1beta and the expression of the inducible proteins, iNOS and cyclo-oxygenase-2 (COX-2) in retinal cells, and whether the activity of these proteins contribute to BRB breakdown.	Cyclosporine	87-91	nitric oxide synthase 2	Rattus norvegicus	203-207
11200365-7	2000	RESULTS AND DISCUSSION: Our results indicated that the levels of IL-1beta and NO in retinas from Cs-A-treated diabetic rats are significantly reduced, as compared to that in non-treated diabetic rats.	Cyclosporine	97-101	interleukin 1 beta	Rattus norvegicus	65-73
11200365-8	2000	The treatment of diabetic rats with Cs-A also significantly inhibited the expression of the inducible proteins, iNOS and COX-2.	Cyclosporine	36-40	nitric oxide synthase 2	Rattus norvegicus	112-116
11132774-8	2000	At therapeutic concentrations in vivo, CsA exerts a predominant effect on IL-8 secretion by human mononuclear phagocytes.	Cyclosporine	39-42	C-X-C motif chemokine ligand 8	Homo sapiens	74-78
11112017-0	2000	Active TGF-beta1 expression in kidney transplantation: a comparative study of cyclosporin-A (CyA) and tacrolimus (FK506).	Cyclosporine	78-91	transforming growth factor beta 1	Homo sapiens	7-16
10617675-11	2000	Although cyclosporine A and reserpine blocked calcein-AM transport by MDR1, these drugs had either minimal or no effect, respectively, on blocking SPGP efflux of calcein-AM.	Cyclosporine	9-23	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	70-74
11112017-0	2000	Active TGF-beta1 expression in kidney transplantation: a comparative study of cyclosporin-A (CyA) and tacrolimus (FK506).	Cyclosporine	93-96	transforming growth factor beta 1	Homo sapiens	7-16
11112017-8	2000	Biopsies from patients receiving CyA expressed significantly more active TGF-beta1 than biopsies from patients receiving tacrolimus (P &lt; 0.0001, Mann-Whitney test).	Cyclosporine	33-36	transforming growth factor beta 1	Homo sapiens	73-82
11112017-9	2000	The increased level of active TGF-beta1 expression in renal biopsies of patients receiving CyA may indicate a mechanism of chronic rejection.	Cyclosporine	91-94	transforming growth factor beta 1	Homo sapiens	30-39
10609952-0	1999	Cyclosporine-induced interstitial fibrosis and arteriolar TGF-beta expression with preserved renal blood flow.	Cyclosporine	0-12	transforming growth factor, beta 1	Rattus norvegicus	58-66
10626821-7	1999	The mitochondrial release of cytochrome c, the activation of caspases as well as nuclear signs of CD437-induced apoptosis are fully prevented by the MPT inhibitory compound cyclosporin A.	Cyclosporine	173-186	cytochrome c, somatic	Homo sapiens	29-41
10609952-3	1999	We investigated the role of renal hemodynamics in CsA-induced transforming growth factor (TGF-beta) expression and interstitial fibrosis.	Cyclosporine	50-53	transforming growth factor, beta 1	Rattus norvegicus	90-98
10609952-7	1999	There was a significant increase in the immunostaining for TGF-beta in the juxtaglomerular arterioles in CsA-treated rats (48.6+/-3.8 vs. 35.1+/-1.1%, CsA vs. VH at 2 weeks, P&lt;0.05 and 59.0+/-3.2 vs. 37.0+/-2.1%, CsA vs. VH at 8 weeks, P=0.0001).	Cyclosporine	105-108	transforming growth factor, beta 1	Rattus norvegicus	59-67
10609952-7	1999	There was a significant increase in the immunostaining for TGF-beta in the juxtaglomerular arterioles in CsA-treated rats (48.6+/-3.8 vs. 35.1+/-1.1%, CsA vs. VH at 2 weeks, P&lt;0.05 and 59.0+/-3.2 vs. 37.0+/-2.1%, CsA vs. VH at 8 weeks, P=0.0001).	Cyclosporine	151-154	transforming growth factor, beta 1	Rattus norvegicus	59-67
10609952-7	1999	There was a significant increase in the immunostaining for TGF-beta in the juxtaglomerular arterioles in CsA-treated rats (48.6+/-3.8 vs. 35.1+/-1.1%, CsA vs. VH at 2 weeks, P&lt;0.05 and 59.0+/-3.2 vs. 37.0+/-2.1%, CsA vs. VH at 8 weeks, P=0.0001).	Cyclosporine	151-154	transforming growth factor, beta 1	Rattus norvegicus	59-67
10609952-10	1999	CONCLUSIONS: Low CsA doses might generate interstitial fibrosis without any decrease in RBF or structural arteriolar lesion evidence, possibly through early macrophage influx and increased TGF-beta expression.	Cyclosporine	17-20	transforming growth factor, beta 1	Rattus norvegicus	189-197
10574961-6	1999	The immunosuppressive drug cyclosporin A binds and inhibits CYP-3 with an IC(50) value of 16 nM, comparable with the range of values found for human cyclophilin A.	Cyclosporine	27-40	peptidylprolyl isomerase F	Homo sapiens	60-65
10592304-3	1999	Following intraventricular administration of cyclosporin A (CsA), detectable cytosolic cytochrome c was dramatically decreased, and about 80% of CA1 neurons survived after ischemia.	Cyclosporine	60-63	cytochrome c, somatic	Homo sapiens	87-99
10570034-0	1999	Ethynylestradiol-mediated induction of hepatic CYP3A9 in female rats: implication for cyclosporine metabolism.	Cyclosporine	86-98	cytochrome P450, family 3, subfamily a, polypeptide 9	Rattus norvegicus	47-53
10600799-5	1999	Measurement of the rate of secretion of very low-density lipoprotein (VLDL) by the liver in vivo showed that cyclosporin treatment led to a significant increase in the rate of hepatic VLDL triglyceride secretion.	Cyclosporine	109-120	CD320 antigen	Mus musculus	70-74
10600799-5	1999	Measurement of the rate of secretion of very low-density lipoprotein (VLDL) by the liver in vivo showed that cyclosporin treatment led to a significant increase in the rate of hepatic VLDL triglyceride secretion.	Cyclosporine	109-120	CD320 antigen	Mus musculus	184-188
10600799-9	1999	These results show that the molecular mechanisms by which cyclosporin causes dyslipoproteinemia may, in part, be mediated by selective activation of SREBP-2, leading to enhanced expression of lipid metabolism genes and hepatic secretion of VLDL triglyceride.	Cyclosporine	58-69	CD320 antigen	Mus musculus	240-244
10606886-1	1999	In an attempt to elucidate the pathogenic role of a CD4+ cytotoxic T-cell clone NT4.2 isolated from the bone marrow of a patient with cyclosporine-dependent aplastic anaemia, we characterized the T-cell clone as well as its cytotoxicity against an autologous Epstein-Barr (EB) virus-transformed B-lymphoblastoid cell line (LCL).	Cyclosporine	134-146	CD4 molecule	Homo sapiens	52-55
10606886-6	1999	Flow cytometric analysis of the peripheral blood of this patient during remission after cyclosporine therapy revealed 1.7% of granulocytes to be deficient in CD59.	Cyclosporine	88-100	CD59 molecule (CD59 blood group)	Homo sapiens	158-162
10570034-8	1999	These findings thus support the notion that the increased CyA-metabolizing capacity of EE(2)-treated female rat liver microsomes is due to the induction of the CYP3A9 enzyme.	Cyclosporine	58-61	cytochrome P450, family 3, subfamily a, polypeptide 9	Rattus norvegicus	160-166
10669119-5	1999	In monocytes the IFNgamma-induced increase in accessory function is prevented only by cyclosporine A (17 +/- 7%) and dexamethasone (59 +/- 9%).	Cyclosporine	86-100	interferon gamma	Homo sapiens	17-25
10642944-7	1999	Cyclosporine reduced renal creatinine clearance significantly and induced renal cortical osteopontin, TGF-beta, endothelin-1 and procollagen alpha 1(I) gene expressions around 13.5 +/- 1.3, 2.4 +/- 0.2, 1.5 +/- 0.1, 1.9 +/- 0.1 folds, respectively.	Cyclosporine	0-12	transforming growth factor, beta 1	Rattus norvegicus	102-110
10642944-7	1999	Cyclosporine reduced renal creatinine clearance significantly and induced renal cortical osteopontin, TGF-beta, endothelin-1 and procollagen alpha 1(I) gene expressions around 13.5 +/- 1.3, 2.4 +/- 0.2, 1.5 +/- 0.1, 1.9 +/- 0.1 folds, respectively.	Cyclosporine	0-12	endothelin 1	Rattus norvegicus	112-151
10642944-10	1999	In conclusion, enalapril or verapamil significantly blunted the cyclosporine-induced osteopontin and TGF-beta gene expressions.	Cyclosporine	64-76	transforming growth factor, beta 1	Rattus norvegicus	101-109
10632522-5	1999	We tested the hypothesis that one of the pathogenetic mechanisms underlying CsA-induced fibrosis is an enhanced IL-6 secretion by gingival fibroblasts (GF) in response to this drug.	Cyclosporine	76-79	interleukin 6	Homo sapiens	112-116
10632522-6	1999	METHODS: The ability of CsA to upregulate GF IL-6 secretion alone or in combination with bacterial challenge or other inflammatory cytokines was tested in an in vitro system.	Cyclosporine	24-27	interleukin 6	Homo sapiens	45-49
10632522-10	1999	RESULTS: We have shown that GF respond to CsA with an increase in IL-6 secretion.	Cyclosporine	42-45	interleukin 6	Homo sapiens	66-70
10632522-12	1999	We have also demonstrated that GF IL-6 responses to bacterial challenge or TNFalpha are downregulated by CsA.	Cyclosporine	105-108	interleukin 6	Homo sapiens	34-38
10594790-11	1999	CsA induced the expression of p53 (P &lt; 0.05) and Bax (P &lt; 0.01) and decreased that of Bcl-2 (P &lt; 0.05).	Cyclosporine	0-3	BCL2, apoptosis regulator	Rattus norvegicus	92-97
10632522-12	1999	We have also demonstrated that GF IL-6 responses to bacterial challenge or TNFalpha are downregulated by CsA.	Cyclosporine	105-108	tumor necrosis factor	Homo sapiens	75-83
10632522-13	1999	However, CsA synergizes with IL-1beta to further upregulate IL-6 secretion, and this effect is shared by phenytoin and nifedipine.	Cyclosporine	9-12	interleukin 6	Homo sapiens	60-64
10726475-0	1999	[Cyclosporin A reverses steroid-resistance induced by P-glycoprotein in patients with SLE].	Cyclosporine	1-14	ATP binding cassette subfamily B member 1	Homo sapiens	54-68
10611763-4	1999	In addition, enhanced levels of circulating endogenous TGF-beta appear to be an instrument of suppression during the development of oral tolerance, cyclosporin treatment, and following administration of retinoic acid.	Cyclosporine	148-159	transforming growth factor beta 1	Homo sapiens	55-63
10570049-6	1999	The efflux of VCR from LLC/cMOAT-1 cells was enhanced compared with LLC/CMV cells and inhibited by CsA and PAK-104P.	Cyclosporine	99-102	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	27-32
10589954-3	1999	We have investigated the inhibitory effects of CsA and FK506 on the direct response of human CD4+ T cells to HUVEC and PAEC and the effect of adding B7-1 transfectants.	Cyclosporine	47-50	CD4 molecule	Homo sapiens	93-96
10589954-6	1999	RESULTS: Proliferative responses and interleukin-2 release were highly sensitive to CsA, the ID50 being significantly less for HUVEC (6.5 ng/ml) than PAEC (15 ng/ml).	Cyclosporine	84-87	interleukin 2	Homo sapiens	37-50
10534504-12	1999	Vascular expression of iNOS protein was decreased by CsA treatment along with decreased tissue accumulation of NO metabolites.	Cyclosporine	53-56	nitric oxide synthase 2	Rattus norvegicus	23-27
10573060-8	1999	Nuclear extracts from the CsA-treated DC revealed a decrease in nuclear translocation of NF-kappaB (p50).	Cyclosporine	26-29	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	89-98
10573060-10	1999	Addition of IL-4 from the start of DC cultures conferred resistance to CsA-induced inhibition of NF-kappaB nuclear translocation and DC maturation.	Cyclosporine	71-74	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	97-106
10624505-5	1999	Sperm sensitivity and susceptibility to cyclosporine even to lower doses increased significantly following withdrawal of bovine serum albumin from the incubating medium.	Cyclosporine	40-52	albumin	Homo sapiens	128-141
10513988-8	1999	Quaternary analogs, which are restricted by a permanent positive charge in transiting the plasma membrane by diffusion, accumulated in Pgp containing I/O vesicles in an ATP-dependent and cyclosporin A-inhibitable manner, which identified them as Pgp substrates.	Cyclosporine	187-200	ATP binding cassette subfamily B member 1	Homo sapiens	135-138
10513988-8	1999	Quaternary analogs, which are restricted by a permanent positive charge in transiting the plasma membrane by diffusion, accumulated in Pgp containing I/O vesicles in an ATP-dependent and cyclosporin A-inhibitable manner, which identified them as Pgp substrates.	Cyclosporine	187-200	ATP binding cassette subfamily B member 1	Homo sapiens	246-249
10555752-7	1999	Growth of tumour cells was also inhibited by the immunosuppressive drugs, cyclosporin A (CsA), FK506 and rapamycin (RPA), known to interfere with the IL-2 pathway in lymphocytes.	Cyclosporine	74-87	interleukin 2	Homo sapiens	150-154
10555752-7	1999	Growth of tumour cells was also inhibited by the immunosuppressive drugs, cyclosporin A (CsA), FK506 and rapamycin (RPA), known to interfere with the IL-2 pathway in lymphocytes.	Cyclosporine	89-92	interleukin 2	Homo sapiens	150-154
10580999-3	1999	We show that blocking of IL-2 synthesis by Cyclosporin A (CsA) suppressed both the Concanavalin A (Con A)- and phorbol myristate acetate (PMA)/ionomycin-induced proliferation of T cells.	Cyclosporine	43-56	interleukin 2	Homo sapiens	25-29
10580999-3	1999	We show that blocking of IL-2 synthesis by Cyclosporin A (CsA) suppressed both the Concanavalin A (Con A)- and phorbol myristate acetate (PMA)/ionomycin-induced proliferation of T cells.	Cyclosporine	58-61	interleukin 2	Homo sapiens	25-29
10531311-12	1999	We show that mtNOS-induced cytochrome c release is not mediated via the mitochondrial permeability transition pore because the release was aggravated by cyclosporin A and abolished by blockade of mitochondrial calcium uptake by ruthenium red.	Cyclosporine	153-166	cytochrome c, somatic	Homo sapiens	27-39
10531385-6	1999	At a concentration of 125 nM, Bax caused the release of the intermembranous proteins cytochrome c and adenylate kinase and the release from the matrix of sequestered calcein, effects prevented by the inhibitor of the PTP cyclosporin A (CSA).	Cyclosporine	221-234	BCL2 associated X, apoptosis regulator	Homo sapiens	30-33
10531385-6	1999	At a concentration of 125 nM, Bax caused the release of the intermembranous proteins cytochrome c and adenylate kinase and the release from the matrix of sequestered calcein, effects prevented by the inhibitor of the PTP cyclosporin A (CSA).	Cyclosporine	221-234	cytochrome c, somatic	Homo sapiens	85-97
10531385-6	1999	At a concentration of 125 nM, Bax caused the release of the intermembranous proteins cytochrome c and adenylate kinase and the release from the matrix of sequestered calcein, effects prevented by the inhibitor of the PTP cyclosporin A (CSA).	Cyclosporine	236-239	BCL2 associated X, apoptosis regulator	Homo sapiens	30-33
10531385-10	1999	CSA prevented the MPT induced by Bax.	Cyclosporine	0-3	BCL2 associated X, apoptosis regulator	Homo sapiens	33-36
10540152-3	1999	Our current study was carried out to investigate the effect of immunosuppressive agents, cyclosporin A (CsA) and dexamethasone, on B7.2 and B7.1 expression on B cells stimulated with the superantigen, toxic shock syndrome toxin-1 (TSST-1).	Cyclosporine	104-107	CD86 antigen	Mus musculus	131-135
10513779-13	1999	Potent CYP3A4 inhibitors, especially cyclosporine, significantly increase the risk.	Cyclosporine	37-49	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	7-13
10540152-3	1999	Our current study was carried out to investigate the effect of immunosuppressive agents, cyclosporin A (CsA) and dexamethasone, on B7.2 and B7.1 expression on B cells stimulated with the superantigen, toxic shock syndrome toxin-1 (TSST-1).	Cyclosporine	104-107	CD80 antigen	Mus musculus	140-144
10540152-5	1999	CsA and dexamethasone significantly down-regulated B7.2+B7.1- but up-regulated B7.2-B7.1+ B cells in the presence or absence of TSST-1 (100 ng/ml).	Cyclosporine	0-3	CD86 antigen	Mus musculus	51-55
10540152-5	1999	CsA and dexamethasone significantly down-regulated B7.2+B7.1- but up-regulated B7.2-B7.1+ B cells in the presence or absence of TSST-1 (100 ng/ml).	Cyclosporine	0-3	CD80 antigen	Mus musculus	56-60
10540152-5	1999	CsA and dexamethasone significantly down-regulated B7.2+B7.1- but up-regulated B7.2-B7.1+ B cells in the presence or absence of TSST-1 (100 ng/ml).	Cyclosporine	0-3	CD86 antigen	Mus musculus	79-83
10540152-5	1999	CsA and dexamethasone significantly down-regulated B7.2+B7.1- but up-regulated B7.2-B7.1+ B cells in the presence or absence of TSST-1 (100 ng/ml).	Cyclosporine	0-3	CD80 antigen	Mus musculus	84-88
10540152-6	1999	Interestingly, the combination of CsA and dexamethasone was much more potent in the inhibition of B7.2 expression than either of these agents alone.	Cyclosporine	34-37	CD86 antigen	Mus musculus	98-102
10540152-7	1999	As CD40 is known to up-regulate B7.2 expression on B cells, the mechanism of B7.2 down-regulation by CsA and dexamethasone was further studied by investigating the effect of these agents on CD40 expression on B cells.	Cyclosporine	101-104	CD86 antigen	Mus musculus	77-81
10540152-10	1999	Anti-CD40 MoAb significantly reversed the effects of CsA or dexamethasone on B7.2 and B7.1 expression, suggesting that T cell engagement of CD40 plays a role in the mechanisms by which CsA and dexamethasone acts on B cells.	Cyclosporine	53-56	CD86 antigen	Mus musculus	77-81
10540152-10	1999	Anti-CD40 MoAb significantly reversed the effects of CsA or dexamethasone on B7.2 and B7.1 expression, suggesting that T cell engagement of CD40 plays a role in the mechanisms by which CsA and dexamethasone acts on B cells.	Cyclosporine	53-56	CD80 antigen	Mus musculus	86-90
10540152-10	1999	Anti-CD40 MoAb significantly reversed the effects of CsA or dexamethasone on B7.2 and B7.1 expression, suggesting that T cell engagement of CD40 plays a role in the mechanisms by which CsA and dexamethasone acts on B cells.	Cyclosporine	185-188	CD86 antigen	Mus musculus	77-81
10540152-10	1999	Anti-CD40 MoAb significantly reversed the effects of CsA or dexamethasone on B7.2 and B7.1 expression, suggesting that T cell engagement of CD40 plays a role in the mechanisms by which CsA and dexamethasone acts on B cells.	Cyclosporine	185-188	CD80 antigen	Mus musculus	86-90
10515221-10	1999	When we compared the frequencies of cytokine-expressing cells in FK506- and CsA-treated patients, we found that the frequency of IL-2-expressing T cells was significantly lower with FK506 (10.9+/-1.61%) than with CsA (16.3 +/- 1.8%; p = 0.03), whereas the frequencies of the other cytokine-expressing cells were not statistically different between the two groups.	Cyclosporine	76-79	interleukin 2	Homo sapiens	129-133
10515221-10	1999	When we compared the frequencies of cytokine-expressing cells in FK506- and CsA-treated patients, we found that the frequency of IL-2-expressing T cells was significantly lower with FK506 (10.9+/-1.61%) than with CsA (16.3 +/- 1.8%; p = 0.03), whereas the frequencies of the other cytokine-expressing cells were not statistically different between the two groups.	Cyclosporine	213-216	interleukin 2	Homo sapiens	129-133
10540152-11	1999	These data demonstrate the modulatory effect of CsA and dexamethasone on B7.2 and B7.1 expression on B cells and the potential role of CD40 in mediating this effect.	Cyclosporine	48-51	CD86 antigen	Mus musculus	73-77
10515221-11	1999	In conclusion, our study clearly demonstrated that studied ex vivo, FK506 and CsA decrease the frequencies of cells expressing IL-2, IL-4 and IL-2/IFN-gamma in vivo but do not affect those expressing IFN-gamma.	Cyclosporine	78-81	interleukin 2	Homo sapiens	127-131
10540152-11	1999	These data demonstrate the modulatory effect of CsA and dexamethasone on B7.2 and B7.1 expression on B cells and the potential role of CD40 in mediating this effect.	Cyclosporine	48-51	CD80 antigen	Mus musculus	82-86
10515221-11	1999	In conclusion, our study clearly demonstrated that studied ex vivo, FK506 and CsA decrease the frequencies of cells expressing IL-2, IL-4 and IL-2/IFN-gamma in vivo but do not affect those expressing IFN-gamma.	Cyclosporine	78-81	interleukin 4	Homo sapiens	133-137
10515221-11	1999	In conclusion, our study clearly demonstrated that studied ex vivo, FK506 and CsA decrease the frequencies of cells expressing IL-2, IL-4 and IL-2/IFN-gamma in vivo but do not affect those expressing IFN-gamma.	Cyclosporine	78-81	interleukin 2	Homo sapiens	142-146
10518828-8	1999	Cytokine gene expression and protein secretion into culture supernatants (IL-4, IL-5, IL-13, and IFN-gamma) were down-regulated in a concentration-dependent manner by either CS or FK in all relevant T-cell subsets.	Cyclosporine	174-176	interleukin 4	Homo sapiens	74-78
10515221-11	1999	In conclusion, our study clearly demonstrated that studied ex vivo, FK506 and CsA decrease the frequencies of cells expressing IL-2, IL-4 and IL-2/IFN-gamma in vivo but do not affect those expressing IFN-gamma.	Cyclosporine	78-81	interferon gamma	Homo sapiens	147-156
10515221-12	1999	Meanwhile, the frequency of IL-2-producing T cells was more affected with FK506 than with CsA and was negatively correlated with the CsA trough level.	Cyclosporine	90-93	interleukin 2	Homo sapiens	28-32
10515221-12	1999	Meanwhile, the frequency of IL-2-producing T cells was more affected with FK506 than with CsA and was negatively correlated with the CsA trough level.	Cyclosporine	133-136	interleukin 2	Homo sapiens	28-32
10518828-8	1999	Cytokine gene expression and protein secretion into culture supernatants (IL-4, IL-5, IL-13, and IFN-gamma) were down-regulated in a concentration-dependent manner by either CS or FK in all relevant T-cell subsets.	Cyclosporine	174-176	interleukin 13	Homo sapiens	86-91
10518828-8	1999	Cytokine gene expression and protein secretion into culture supernatants (IL-4, IL-5, IL-13, and IFN-gamma) were down-regulated in a concentration-dependent manner by either CS or FK in all relevant T-cell subsets.	Cyclosporine	174-176	interferon gamma	Homo sapiens	97-106
10516933-4	1999	The objective of this review is to discuss the effects of P-gp modulation on the pharmacokinetics and the pharmacodynamics of immunosuppressive agents such as cyclosporine, tacrolimus, sirolimus, and corticosteroids.	Cyclosporine	159-171	ATP binding cassette subfamily B member 1	Homo sapiens	58-62
11498961-2	1999	In cultured myocardial cells of neonatal rats, Ang II was used to stimulate hypertrophy and CaN-pathway blocked by CsA(an inhibitor of CaN).	Cyclosporine	115-118	angiotensinogen	Rattus norvegicus	47-53
10501227-4	1999	Cyclosporin A, which inhibits calcineurin through formation of a cyclosporin A/cyclophilin/calcineurin complex, also abolished PACAP-evoked VIP biosynthesis.	Cyclosporine	0-13	vasoactive intestinal peptide	Homo sapiens	140-143
10501227-4	1999	Cyclosporin A, which inhibits calcineurin through formation of a cyclosporin A/cyclophilin/calcineurin complex, also abolished PACAP-evoked VIP biosynthesis.	Cyclosporine	65-78	vasoactive intestinal peptide	Homo sapiens	140-143
10515378-3	1999	CsA stimulates renal fibrosis perhaps through the induction of the potent pro-sclerotic growth factor, transforming growth factor beta (TGFbeta).	Cyclosporine	0-3	transforming growth factor beta 1	Homo sapiens	103-134
10515378-3	1999	CsA stimulates renal fibrosis perhaps through the induction of the potent pro-sclerotic growth factor, transforming growth factor beta (TGFbeta).	Cyclosporine	0-3	transforming growth factor beta 1	Homo sapiens	136-143
10515378-4	1999	Previously, we demonstrated that, in human transplant biopsies, acute CsA toxicity but not acute tubular necrosis is associated with elevated levels of renal TGFbeta protein.	Cyclosporine	70-73	transforming growth factor beta 1	Homo sapiens	158-165
10515378-5	1999	We now examine whether long-term CsA treatment (&gt;1 year) is associated with elevated levels of intra-allograft TGFbeta and whether heightened expression of TGFbeta is clinically significant.	Cyclosporine	33-36	transforming growth factor beta 1	Homo sapiens	114-121
10515378-12	1999	CONCLUSIONS: These results suggest that the majority of CsA-treated patients with biopsy proven chronic fibrosis have elevated levels of intra-graft TGFbeta that correlates with an increased rate of decline in renal function.	Cyclosporine	56-59	transforming growth factor beta 1	Homo sapiens	149-156
11498961-4	1999	The results showed that 3H-leucine incorporation of Ang II-stimulated myocardial cells was 46% higher than control (P &lt; 0.01), which could be inhibited by CsA (0.5-5 micrograms/ml) and PD098059(an inhibitor of MAPK).	Cyclosporine	158-161	angiotensinogen	Rattus norvegicus	52-58
10484394-9	1999	Cyclosporin A, a Ca2+/calmodulin-dependent protein phosphatase (PP2B) inhibitor, decreased caerulein-induced NF-kappaB/Rel activation and IkappaBalpha degradation.	Cyclosporine	0-13	nuclear factor kappa B subunit 1	Homo sapiens	109-118
10484394-9	1999	Cyclosporin A, a Ca2+/calmodulin-dependent protein phosphatase (PP2B) inhibitor, decreased caerulein-induced NF-kappaB/Rel activation and IkappaBalpha degradation.	Cyclosporine	0-13	NFKB inhibitor alpha	Homo sapiens	138-150
10510443-3	1999	Cyclosporin A and FK506 (at 1 microM) also significantly inhibited nitrite production induced by recombinant murine interferon-gamma (rIFNgamma) and recombinant murine interleukin-1beta (rIL-1beta) in J774 and VSMC, respectively.	Cyclosporine	0-13	interferon gamma	Mus musculus	116-132
10471650-0	1999	Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclosporine effect.	Cyclosporine	89-101	interleukin 2	Homo sapiens	25-38
10582320-8	1999	Thus, the inhibitory action of CsA and FK506 under in vitro conditions should occur before the step of acyl group reduction and the effect is likely to be attributable to the inhibition of calcineurin in the signal transduction cascade mechanism of PBAN, in B. mori.	Cyclosporine	31-34	PBAN-type neuropeptides	Bombyx mori	249-253
10510443-3	1999	Cyclosporin A and FK506 (at 1 microM) also significantly inhibited nitrite production induced by recombinant murine interferon-gamma (rIFNgamma) and recombinant murine interleukin-1beta (rIL-1beta) in J774 and VSMC, respectively.	Cyclosporine	0-13	interleukin 1 beta	Mus musculus	168-185
10510443-3	1999	Cyclosporin A and FK506 (at 1 microM) also significantly inhibited nitrite production induced by recombinant murine interferon-gamma (rIFNgamma) and recombinant murine interleukin-1beta (rIL-1beta) in J774 and VSMC, respectively.	Cyclosporine	0-13	interleukin 1 beta	Rattus norvegicus	187-196
10510443-8	1999	Cyclosporin A, but not FK506, suppressed expression of mRNA for NOS2 in a concentration-dependent manner when co-incubated with LPS.	Cyclosporine	0-13	nitric oxide synthase 2, inducible	Mus musculus	64-68
10510443-10	1999	Cyclosporin A suppresses NOS2 gene transcription, but FK506 acts post-transcriptionally to suppress NO generation in VSMC.	Cyclosporine	0-13	nitric oxide synthase 2, inducible	Mus musculus	25-29
10503812-3	1999	Cyclosporin is primarily eliminated via biotransformation by cytochrome P450 (CYP)3A in the gut wall and liver.	Cyclosporine	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	78-84
10503812-15	1999	Polypharmacy may have specific relevance for elderly patients treated with cyclosporin since this agent is a substrate of both CYP3A and P-glycoprotein, both of which are important in the elimination of many commonly used drugs.	Cyclosporine	75-86	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	127-132
10503812-4	1999	Additionally, P-glycoprotein (mdr-1) located in the gastrointestinal epithelium can affect affect blood drug concentrations after oral administration of cyclosporin, presumably by counter-transporting the drug from the systemic circulation back into the gastrointestinal lumen.	Cyclosporine	153-164	ATP binding cassette subfamily B member 1	Homo sapiens	14-28
10503812-15	1999	Polypharmacy may have specific relevance for elderly patients treated with cyclosporin since this agent is a substrate of both CYP3A and P-glycoprotein, both of which are important in the elimination of many commonly used drugs.	Cyclosporine	75-86	ATP binding cassette subfamily B member 1	Homo sapiens	137-151
10503812-4	1999	Additionally, P-glycoprotein (mdr-1) located in the gastrointestinal epithelium can affect affect blood drug concentrations after oral administration of cyclosporin, presumably by counter-transporting the drug from the systemic circulation back into the gastrointestinal lumen.	Cyclosporine	153-164	ATP binding cassette subfamily B member 1	Homo sapiens	30-35
10510183-5	1999	The potassium thiocyanate-stabilized binding of cyclophilin D to mouse brain mitochondrial membranes was completely prevented by cyclosporin A and N-Me-Val-4-cyclosporin A.	Cyclosporine	129-142	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	48-61
10463953-8	1999	In the presence of suboptimal amounts of S100betabeta, FK506, cyclosporin A, and cypermethrin (but not rapamycin) also increased NF-kappaB activity, as measured by immunofluorescence of cells stained with antibody to the active subunit (p65) and by immunoblotting of nuclear extracts.	Cyclosporine	62-75	synaptotagmin 1	Gallus gallus	237-240
10695015-6	1999	The multidrug resistance (MDR)-reversing agents, cyclosporin A (CsA) and PAK-104P, almost completely reversed the resistance to VCR, SN-38 and cisplatin of LLC/cMOAT-1 cells by interacting with the substrate binding site of cMOAT.	Cyclosporine	49-62	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	160-165
10695015-6	1999	The multidrug resistance (MDR)-reversing agents, cyclosporin A (CsA) and PAK-104P, almost completely reversed the resistance to VCR, SN-38 and cisplatin of LLC/cMOAT-1 cells by interacting with the substrate binding site of cMOAT.	Cyclosporine	49-62	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	224-229
10695015-6	1999	The multidrug resistance (MDR)-reversing agents, cyclosporin A (CsA) and PAK-104P, almost completely reversed the resistance to VCR, SN-38 and cisplatin of LLC/cMOAT-1 cells by interacting with the substrate binding site of cMOAT.	Cyclosporine	64-67	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	160-165
10695015-6	1999	The multidrug resistance (MDR)-reversing agents, cyclosporin A (CsA) and PAK-104P, almost completely reversed the resistance to VCR, SN-38 and cisplatin of LLC/cMOAT-1 cells by interacting with the substrate binding site of cMOAT.	Cyclosporine	64-67	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	224-229
10510888-11	1999	One of these strategies is to reverse MDR by using such P-gp inhibitors as verapamil and cyclosporine A.	Cyclosporine	89-103	ATP binding cassette subfamily B member 1	Homo sapiens	56-60
10546153-0	1999	Prolonged skin graft survival by administration of anti-CD80 monoclonal antibody with cyclosporin A.	Cyclosporine	86-99	CD80 molecule	Macaca mulatta	56-60
10482990-6	1999	MRP1 and Pgp function could be blocked completely by 5 microM PAK 104P, while higher concentrations of verapamil, PSC 833 and cyclosporin A were necessary to attain complete blocking of MRP1 compared to Pgp.	Cyclosporine	126-139	ATP binding cassette subfamily C member 1	Homo sapiens	186-190
10480422-0	1999	Blood levels of TGFbeta1 in liver transplant recipients receiving either tacrolimus or micro-emulsified cyclosporine.	Cyclosporine	104-116	transforming growth factor beta 1	Homo sapiens	16-24
10951883-6	1999	Mechanisms of cyclosporin induced hypertension:enhancement of the vasoconstricting effect of endothelin 1, reduced NO production, activation of neurohumoral vasoconstrictors, increased calcium level in cytosols, increased thromboxane A production, reduced production of vasodilatating prostaglandins and activation of the sympathicus.	Cyclosporine	14-25	endothelin 1	Homo sapiens	93-105
10455158-5	1999	The mitogen-activated protein kinase/ERK kinase (MEK) inhibitor PD098059 minimally inhibited PE-induced increases in CSA, but it completely abolished ANF-induced inhibition of PE-induced increases.	Cyclosporine	117-120	Eph receptor B1	Rattus norvegicus	37-40
10480422-2	1999	Cyclosporine (cyclosporin A[CsA]) has been found to increase circulating TGFbeta1 levels in patients (1, 2).	Cyclosporine	0-12	transforming growth factor beta 1	Homo sapiens	73-81
10480422-2	1999	Cyclosporine (cyclosporin A[CsA]) has been found to increase circulating TGFbeta1 levels in patients (1, 2).	Cyclosporine	14-27	transforming growth factor beta 1	Homo sapiens	73-81
10480422-2	1999	Cyclosporine (cyclosporin A[CsA]) has been found to increase circulating TGFbeta1 levels in patients (1, 2).	Cyclosporine	28-31	transforming growth factor beta 1	Homo sapiens	73-81
10499377-0	1999	Cyclosporin A induces prepro endothelin-1 gene transcription in human endothelial cells.	Cyclosporine	0-13	endothelin 1	Homo sapiens	29-41
10499377-1	1999	Cyclosporin A employed in treatment of organ allograft rejection, is associated with hypertension possibly due to endothelin-1.	Cyclosporine	0-13	endothelin 1	Homo sapiens	114-126
10499377-2	1999	We studied transcriptional regulation of endothelin-1 by cyclosporin A in human endothelial cells using cell transfection experiments and reporter gene assays.	Cyclosporine	57-70	endothelin 1	Homo sapiens	41-53
10499377-7	1999	These data demonstrate transcriptional regulation of endothelin-1 over a range of several orders of magnitude in human umbilical vein endothelial cells by cyclosporin A via Ca(2+)-dependent mechanisms.	Cyclosporine	155-168	endothelin 1	Homo sapiens	53-65
10456325-1	1999	An immunosuppressant cyclosporin A (CsA) inhibits T-cell proliferation by blocking the nuclear factor of activated T-cells (NFAT) required for expression of the interleukin-2 (IL-2) gene.	Cyclosporine	36-39	interleukin 2	Homo sapiens	161-174
10459544-7	1999	RESULTS: On light microscopy cytoplasmic swelling, vacuolization, apoptosis, and abnormal immunostaining for insulin were seen in biopsies from patients receiving either FK or CSA.	Cyclosporine	176-179	insulin	Homo sapiens	109-116
10456325-1	1999	An immunosuppressant cyclosporin A (CsA) inhibits T-cell proliferation by blocking the nuclear factor of activated T-cells (NFAT) required for expression of the interleukin-2 (IL-2) gene.	Cyclosporine	36-39	interleukin 2	Homo sapiens	176-180
10456325-6	1999	These results indicate that in activated HBLs, (1) IL-2 is involved in functional expression of the Na/K pump during cell transition from quiescence to proliferation, (2) the cell cycle-associated upregulation of the pump is related to a CsA-sensitive signalling pathway.	Cyclosporine	238-241	interleukin 2	Homo sapiens	51-55
10498809-4	1999	Release of Ca2+ from mitochondria into the cytosol is induced by an uncoupler (FCCP) or by a dithiol cross-linking agent (phenylarsine oxide) and is inhibited by cyclosporin A--a specific inhibitor of the permeability transition pore in the inner mitochondrial membrane.	Cyclosporine	162-175	carbonic anhydrase 2	Rattus norvegicus	11-14
10498809-5	1999	In the presence of oxidizing agents (tert-butyl hydroperoxide and diamide), sub-optimal concentrations of uncoupler induce rapid cyclosporin-sensitive release of Ca2+.	Cyclosporine	129-140	carbonic anhydrase 2	Rattus norvegicus	162-165
10578467-3	1999	The renatured hIL-4 delta 2 inhibited IL-4-stimulated T cell proliferation, and this effect was enhanced by cyclosporin A.	Cyclosporine	108-121	interleukin 4	Homo sapiens	14-19
10578467-3	1999	The renatured hIL-4 delta 2 inhibited IL-4-stimulated T cell proliferation, and this effect was enhanced by cyclosporin A.	Cyclosporine	108-121	interleukin 4	Homo sapiens	15-19
10455332-4	1999	In the presence of quinidine, verapamil and cyclosporin (substrates of the P-glycoprotein (P-gp)), plasma AUCs of ciprofloxacin were 1.5 - 2 fold increased, while biliary clearance (1.5 - 2 fold), intestinal overall and net clearances (2 - 4 fold and 1.5 - 8 fold respectively) decreased.	Cyclosporine	44-55	phosphoglycolate phosphatase	Rattus norvegicus	91-96
10460594-0	1999	High inducibility of heat shock protein 72 (hsp72) in peripheral blood mononuclear cells of aplastic anaemia patients: a reliable marker of immune-mediated aplastic anaemia responsive to cyclosporine therapy.	Cyclosporine	187-199	heat shock protein family A (Hsp70) member 1A	Homo sapiens	21-42
10460594-0	1999	High inducibility of heat shock protein 72 (hsp72) in peripheral blood mononuclear cells of aplastic anaemia patients: a reliable marker of immune-mediated aplastic anaemia responsive to cyclosporine therapy.	Cyclosporine	187-199	heat shock protein family A (Hsp70) member 1A	Homo sapiens	44-49
10460594-5	1999	For 28 untreated AA patients, the proportion of hsp72+ cells in those who later responded to cyclosporine (CyA) (62 +/- 24%) was higher than that in non-responders (19 +/- 13%).	Cyclosporine	93-105	heat shock protein family A (Hsp70) member 1A	Homo sapiens	48-53
10460594-5	1999	For 28 untreated AA patients, the proportion of hsp72+ cells in those who later responded to cyclosporine (CyA) (62 +/- 24%) was higher than that in non-responders (19 +/- 13%).	Cyclosporine	107-110	heat shock protein family A (Hsp70) member 1A	Homo sapiens	48-53
10543726-5	1999	The accumulation of [3H]vinblastine (20 nM), an established P-gp substrate, by the monolayer cells was significantly enhanced in the presence of two P-gp inhibitors (i.e., verapamil and cyclosporin A) and nucleoside transport inhibitors (i.e., dipyridamole and dilazep).	Cyclosporine	186-199	ATP binding cassette subfamily B member 1	Homo sapiens	60-64
10419897-4	1999	However, a strong correlation was observed between the simultaneous activity of MRP1 and Pgp (quantified as the modulation of calcein-AM uptake by cyclosporin A and probenecid) and the LC50 of DNR (r =.77, P &lt;.0001).	Cyclosporine	147-160	ATP binding cassette subfamily C member 1	Homo sapiens	80-84
10543726-5	1999	The accumulation of [3H]vinblastine (20 nM), an established P-gp substrate, by the monolayer cells was significantly enhanced in the presence of two P-gp inhibitors (i.e., verapamil and cyclosporin A) and nucleoside transport inhibitors (i.e., dipyridamole and dilazep).	Cyclosporine	186-199	ATP binding cassette subfamily B member 1	Homo sapiens	149-153
10403741-2	1999	Cyclosporin stimulates transforming growth factor beta (TGF-beta) and may interfere with pancreatic regeneration.	Cyclosporine	0-11	transforming growth factor, beta 1	Rattus norvegicus	56-64
10419902-5	1999	MDR1/P-glycoprotein expression, which was highly correlated with cyclosporine-inhibited efflux, was noted in only 35% of these younger AML patients, distinctly lower than the frequency of 71% we previously reported in AML in the elderly (Blood 89:3323, 1997).	Cyclosporine	65-77	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
10419902-5	1999	MDR1/P-glycoprotein expression, which was highly correlated with cyclosporine-inhibited efflux, was noted in only 35% of these younger AML patients, distinctly lower than the frequency of 71% we previously reported in AML in the elderly (Blood 89:3323, 1997).	Cyclosporine	65-77	ATP binding cassette subfamily B member 1	Homo sapiens	5-19
10419902-11	1999	Only MDR1/P-glycoprotein expression and cyclosporine-inhibited efflux were significantly associated with complete remission (CR) rate (P(MDR1) =.012; P(efflux) =.039) and resistant disease (RD; P(MDR1) =.0007; P(efflux) =.0092).	Cyclosporine	40-52	ATP binding cassette subfamily B member 1	Homo sapiens	137-141
10419902-11	1999	Only MDR1/P-glycoprotein expression and cyclosporine-inhibited efflux were significantly associated with complete remission (CR) rate (P(MDR1) =.012; P(efflux) =.039) and resistant disease (RD; P(MDR1) =.0007; P(efflux) =.0092).	Cyclosporine	40-52	ATP binding cassette subfamily B member 1	Homo sapiens	137-141
10444270-0	1999	Low-density lipoproteins enhance transforming growth factor-beta 1 (TGF-beta 1) and monocyte chemotactic protein-1 (MCP-1) expression induced by cyclosporin in human mesangial cells.	Cyclosporine	145-156	transforming growth factor beta 1	Homo sapiens	33-66
10444270-0	1999	Low-density lipoproteins enhance transforming growth factor-beta 1 (TGF-beta 1) and monocyte chemotactic protein-1 (MCP-1) expression induced by cyclosporin in human mesangial cells.	Cyclosporine	145-156	transforming growth factor beta 1	Homo sapiens	68-78
10444270-4	1999	Thus, the combined effect of CsA and low-density lipoprotein (LDL) on the gene and protein expression of MCP-1 and TGF-beta 1 in cultured human mesangial cells (HMC) was explored.	Cyclosporine	29-32	transforming growth factor beta 1	Homo sapiens	115-125
10444270-6	1999	The simultaneous addition of CsA and LDL did not display any additive effect on target gene expression, but it caused a synergistic effect on MCP-1 and TGF-beta 1 protein secretion into culture medium.	Cyclosporine	29-32	transforming growth factor beta 1	Homo sapiens	152-162
10496299-12	1999	Troglitazone may enhance the activities of cytochrome P450 (CYP) 3A and/or transporter(s) thereby reducing the plasma concentrations of terfenadine, cyclosporin, atorvastatin and fexofenadine.	Cyclosporine	149-160	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-67
10403741-11	1999	TGF-beta1 increased, and remained high in cyclosporin treated groups (cyclosporin alone and cyclosporin plus caerulein).	Cyclosporine	70-81	transforming growth factor, beta 1	Rattus norvegicus	0-9
10403741-11	1999	TGF-beta1 increased, and remained high in cyclosporin treated groups (cyclosporin alone and cyclosporin plus caerulein).	Cyclosporine	70-81	transforming growth factor, beta 1	Rattus norvegicus	0-9
10411567-3	1999	Sulfoxide formation was determined to be cytochrome P-450 (CYP) 3A4-dependent by correlation with CYP3A4-marker nifedipine oxidase activity, inhibition by cyclosporin A and troleandomycin, and inhibition of R- (70%) and S- (64%) sulfoxide formation by anti-3A antibody.	Cyclosporine	155-168	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-67
10384106-4	1999	COX-2 mRNA was induced very early after activation and superinduced by protein synthesis inhibitors, whereas it was inhibited by the immunosuppressive drug cyclosporin A, identifying it as an early T cell activation gene.	Cyclosporine	156-169	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	0-5
10399954-6	1999	Resistance to a P-gp-associated drug, doxorubicin, could be reversed with P-gp circumventing agents such as cyclosporin A and verapamil, but these substances had no effect on resistance to 5-fluorouracil.	Cyclosporine	108-121	ATP binding cassette subfamily B member 1	Homo sapiens	16-20
10399954-6	1999	Resistance to a P-gp-associated drug, doxorubicin, could be reversed with P-gp circumventing agents such as cyclosporin A and verapamil, but these substances had no effect on resistance to 5-fluorouracil.	Cyclosporine	108-121	ATP binding cassette subfamily B member 1	Homo sapiens	74-78
10403800-4	1999	Interestingly, chronic treatment with clinical concentrations of cyclosporin A (0.5-2.5 microM for 8 days) led to a significant increase in Bcl-2 expression, while nucleosomes were similar to control level.	Cyclosporine	65-78	BCL2 apoptosis regulator	Homo sapiens	140-145
10404009-6	1999	The immunosuppressant cyclosporine A (CsA) inhibited T cell tumor necrosis factor alpha and IL-6 production but did not inhibit the T cell induction of IL-6 from hOB.	Cyclosporine	22-36	interleukin 6	Homo sapiens	92-96
10404009-6	1999	The immunosuppressant cyclosporine A (CsA) inhibited T cell tumor necrosis factor alpha and IL-6 production but did not inhibit the T cell induction of IL-6 from hOB.	Cyclosporine	38-41	interleukin 6	Homo sapiens	92-96
10404009-8	1999	The induction of IL-6 mRNA by both activated T cell CM and CsA-treated activated T cell CM was confirmed by Northern blot analysis.	Cyclosporine	59-62	interleukin 6	Homo sapiens	17-21
10393616-9	1999	In 2 other children with acute liver failure, which progressed despite treatment with steroids and azathioprine, the addition of cyclosporin was followed by normalization of prothrombin time.	Cyclosporine	129-140	coagulation factor II, thrombin	Homo sapiens	174-185
10406194-3	1999	Studies were performed to determine whether the immunosuppressants FK506 and cyclosporin A directly influence gene expression of inducible nitric oxide synthase by interleukin 1beta in hepatocytes.	Cyclosporine	77-90	nitric oxide synthase 2	Rattus norvegicus	129-160
10450932-0	1999	Cyclosporine transfer from low- and high-density lipoproteins is partially influenced by lipid transfer protein I triglyceride transfer activity.	Cyclosporine	0-12	cholesteryl ester transfer protein	Homo sapiens	89-113
10450932-7	1999	In addition, when the percent transfer of TG and CSA were determined in the presence of TPI, the percent transfer of TG and CSA from only LDL to HDL were significantly decreased in T150 buffer and human plasma compared to controls.	Cyclosporine	49-52	triosephosphate isomerase 1	Homo sapiens	88-91
10406194-3	1999	Studies were performed to determine whether the immunosuppressants FK506 and cyclosporin A directly influence gene expression of inducible nitric oxide synthase by interleukin 1beta in hepatocytes.	Cyclosporine	77-90	interleukin 1 beta	Rattus norvegicus	164-181
10429418-2	1999	Cyclosporin A (CyA) use has been recently proposed, due to its inhibitory effect on the IL2 and lymphokine release, with a permeabilizing effect on the glomerular membrane.	Cyclosporine	0-13	interleukin 2	Homo sapiens	88-91
10354289-0	1999	Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells.	Cyclosporine	0-14	angiotensinogen	Homo sapiens	28-42
10354289-13	1999	The effects of CsA did not appear to be mediated by calcineurin inhibition because cyclosporine H, which is not immunosuppressive, also increased the Ang II-induced 45Ca2+ efflux.	Cyclosporine	15-18	angiotensinogen	Homo sapiens	150-156
10354289-14	1999	CONCLUSION: These data suggest that CsA preferentially up-regulates the transcription of Ang II receptors, which very likely leads to vasoconstriction in vivo and could be at the origin of CsA-induced hypertension and nephrotoxicity in humans.	Cyclosporine	36-39	angiotensinogen	Homo sapiens	89-95
10354289-14	1999	CONCLUSION: These data suggest that CsA preferentially up-regulates the transcription of Ang II receptors, which very likely leads to vasoconstriction in vivo and could be at the origin of CsA-induced hypertension and nephrotoxicity in humans.	Cyclosporine	189-192	angiotensinogen	Homo sapiens	89-95
10383019-0	1999	Altered flow properties of blood and increased plasma fibrinogen in cyclosporin-treated renal allograft recipients.	Cyclosporine	68-79	fibrinogen beta chain	Homo sapiens	54-64
10334913-3	1999	MDR1 gene expression was associated with the expression of functional P-glycoprotein (gp-170); the function was reversed by verapamil and cyclosporin A.	Cyclosporine	138-151	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
10378008-6	1999	To study the role of Pgp in the resistance to UVA radiation, two MDR modulators or reversing agents (verapamil and cyclosporin A) capable of blocking Pgp activity were used.	Cyclosporine	115-128	ATP binding cassette subfamily B member 1	Homo sapiens	150-153
11819431-0	1999	Cyclosporin A protects Balb/c mice from liver damage induced by superan tigen SEB and D-GalN.	Cyclosporine	0-13	galanin and GMAP prepropeptide	Mus musculus	88-92
11819431-3	1999	The effects induced by SEB and D-GalN on hepatocytes might be mediated by T cells, and could be prevented by cyclosporin A.	Cyclosporine	109-122	galanin and GMAP prepropeptide	Mus musculus	33-37
10334913-3	1999	MDR1 gene expression was associated with the expression of functional P-glycoprotein (gp-170); the function was reversed by verapamil and cyclosporin A.	Cyclosporine	138-151	ATP binding cassette subfamily B member 1	Homo sapiens	70-84
10334913-3	1999	MDR1 gene expression was associated with the expression of functional P-glycoprotein (gp-170); the function was reversed by verapamil and cyclosporin A.	Cyclosporine	138-151	ATP binding cassette subfamily B member 1	Homo sapiens	86-92
10213846-7	1999	The administration of the immunosuppressant drug cyclosporine (5 mg/kg, 5 days) impaired the depressing effect of Freund"s adjuvant injection on CRH, TRH and somatostatin content in median eminence, but not that on GRH.	Cyclosporine	49-61	corticotropin releasing hormone	Rattus norvegicus	145-148
10344751-3	1999	In vivo pharmacokinetic analysis of P-gp transport might identify the capacity of modulation by P-gp substrate modulators, such as cyclosporin A.	Cyclosporine	131-144	ATP binding cassette subfamily B member 1	Homo sapiens	36-40
10344751-3	1999	In vivo pharmacokinetic analysis of P-gp transport might identify the capacity of modulation by P-gp substrate modulators, such as cyclosporin A.	Cyclosporine	131-144	ATP binding cassette subfamily B member 1	Homo sapiens	96-100
10344751-8	1999	These levels were increased after modulation with cyclosporin A in GLC4/P-gp.	Cyclosporine	50-63	ATP binding cassette subfamily B member 1	Homo sapiens	72-76
10342319-7	1999	The dependence of CsA"s induction of p21 was studied using anti-TGF-beta antibody and TGF-beta altered A-549 cells.	Cyclosporine	18-21	transforming growth factor beta 1	Homo sapiens	64-72
10342319-7	1999	The dependence of CsA"s induction of p21 was studied using anti-TGF-beta antibody and TGF-beta altered A-549 cells.	Cyclosporine	18-21	transforming growth factor beta 1	Homo sapiens	86-94
10342319-8	1999	RESULTS: CsA induced p21 mRNA protein expression and stimulated its promoter activity in lymphoid (T cells) and nonlymphoid (human lung adenocarcinoma, A-549 cells).CsA"s induction of p21 was inhibited both by a neutralizing anti-TGF-beta antibody and in TGF-beta-altered A-549 cells, consistent with its effects on p21 requiring TGF-beta.	Cyclosporine	9-12	transforming growth factor beta 1	Homo sapiens	230-238
10342319-8	1999	RESULTS: CsA induced p21 mRNA protein expression and stimulated its promoter activity in lymphoid (T cells) and nonlymphoid (human lung adenocarcinoma, A-549 cells).CsA"s induction of p21 was inhibited both by a neutralizing anti-TGF-beta antibody and in TGF-beta-altered A-549 cells, consistent with its effects on p21 requiring TGF-beta.	Cyclosporine	9-12	transforming growth factor beta 1	Homo sapiens	255-263
10342319-8	1999	RESULTS: CsA induced p21 mRNA protein expression and stimulated its promoter activity in lymphoid (T cells) and nonlymphoid (human lung adenocarcinoma, A-549 cells).CsA"s induction of p21 was inhibited both by a neutralizing anti-TGF-beta antibody and in TGF-beta-altered A-549 cells, consistent with its effects on p21 requiring TGF-beta.	Cyclosporine	9-12	transforming growth factor beta 1	Homo sapiens	255-263
10213846-7	1999	The administration of the immunosuppressant drug cyclosporine (5 mg/kg, 5 days) impaired the depressing effect of Freund"s adjuvant injection on CRH, TRH and somatostatin content in median eminence, but not that on GRH.	Cyclosporine	49-61	somatostatin	Rattus norvegicus	158-170
10213846-8	1999	In the anterior hypothalamus, cyclosporine generally prevented the effect of immunization on hormone levels an revealed a second maximum in TRH at 0400 h. Cyclosporine also restored 24-hour variations in TRH and somatostatin levels of medial hypothalamus of Freund"s adjuvant-injected rats but was unable to modify them in the posterior hypothalamus.	Cyclosporine	30-42	somatostatin	Rattus norvegicus	212-224
10213846-8	1999	In the anterior hypothalamus, cyclosporine generally prevented the effect of immunization on hormone levels an revealed a second maximum in TRH at 0400 h. Cyclosporine also restored 24-hour variations in TRH and somatostatin levels of medial hypothalamus of Freund"s adjuvant-injected rats but was unable to modify them in the posterior hypothalamus.	Cyclosporine	155-167	somatostatin	Rattus norvegicus	212-224
10227994-6	1999	Inhibition of IL-2 production by cyclosporin A, or inhibition of IL-2 signaling by rapamycin or anti-IL-2 neutralizing Abs prevents the decrease in FLIP levels and confers resistance to Fas-mediated apoptosis following T cell activation.	Cyclosporine	33-46	interleukin 2	Homo sapiens	14-18
10367710-10	1999	However, immunoblot and reverse transcriptase-polymerase chain reaction (RT-PCR) analyses indicated that c-kit protein and c-kit mRNA transcripts were increased following the FK506 and CsA treatments in the presence of IL-3.	Cyclosporine	185-188	interleukin 3	Mus musculus	219-223
10365823-6	1999	In vitro, cyclosporine potently inhibited IL-2 and IL-2 receptor expression of activated mononuclear blood cells, but poorly inhibited IL-4 expression.	Cyclosporine	10-22	interleukin 2	Homo sapiens	42-46
10365823-6	1999	In vitro, cyclosporine potently inhibited IL-2 and IL-2 receptor expression of activated mononuclear blood cells, but poorly inhibited IL-4 expression.	Cyclosporine	10-22	interleukin 2	Homo sapiens	51-55
10365823-8	1999	CONCLUSIONS: During liver allograft rejection, IL-2 pathway is down-regulated, while IL-4 expression is increased by cholestasis and poorly inhibited by cyclosporine.	Cyclosporine	153-165	interleukin 4	Homo sapiens	85-89
10365823-9	1999	These data suggest that IL-4 is involved in the mechanisms of liver allograft rejection in patients treated with cyclosporine.	Cyclosporine	113-125	interleukin 4	Homo sapiens	24-28
10342576-2	1999	Because idarubicin is less vulnerable to MDR1-mediated transport and could thereby represent a better companion to MDR1 inhibitors, we assessed the ability of the anti-MDR1 agent cyclosporin A to modulate this function in multidrug resistant T-lymphoblastic CEM cells challenged in vitro with either daunorubicin or idarubicin.	Cyclosporine	179-192	ATP binding cassette subfamily B member 1	Homo sapiens	115-119
10217279-4	1999	Cyclosporin A (5 microM), a calcineurin inhibitor, maximally increased the level of phosphorylated DARPP-32 by 17+/-2-fold.	Cyclosporine	0-13	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	99-107
10217279-7	1999	Incubation of slices in the presence of cyclosporin A plus either okadaic acid or calyculin A, another PP-1/PP-2A inhibitor, caused a synergistic increase in the level of phosphorylated DARPP-32.	Cyclosporine	40-53	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	186-194
10217279-8	1999	The use of Ca2(+)-free/EGTA medium mimicked the effects of cyclosporin A on DARPP-32 phosphorylation, supporting the conclusion that the action of cyclosporin on DARPP-32 phosphorylation was attributable to blockade of the Ca2(+)-dependent activation of calcineurin.	Cyclosporine	59-72	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	76-84
10217279-8	1999	The use of Ca2(+)-free/EGTA medium mimicked the effects of cyclosporin A on DARPP-32 phosphorylation, supporting the conclusion that the action of cyclosporin on DARPP-32 phosphorylation was attributable to blockade of the Ca2(+)-dependent activation of calcineurin.	Cyclosporine	59-72	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	162-170
10217279-8	1999	The use of Ca2(+)-free/EGTA medium mimicked the effects of cyclosporin A on DARPP-32 phosphorylation, supporting the conclusion that the action of cyclosporin on DARPP-32 phosphorylation was attributable to blockade of the Ca2(+)-dependent activation of calcineurin.	Cyclosporine	59-70	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	76-84
10217279-8	1999	The use of Ca2(+)-free/EGTA medium mimicked the effects of cyclosporin A on DARPP-32 phosphorylation, supporting the conclusion that the action of cyclosporin on DARPP-32 phosphorylation was attributable to blockade of the Ca2(+)-dependent activation of calcineurin.	Cyclosporine	59-70	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	162-170
10215697-1	1999	Cytochrome P-450 (CYP) 3A4 accounts for approximately 50% of all P-450s found in the small intestine (Paine et al., 1997) and contributes to the extensive and variable first-pass extraction of drugs such as cyclosporine and saquinavir.	Cyclosporine	207-219	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-26
10374882-3	1999	The resistant KG1a and K562 sublines, which expressed high levels of Pgp, responded to low doses of the cyclosporin SDZ PSC 833, the cyclopeptolide SDZ 280-446, and the cyclopropyldibenzosuberane LY335979 with a dose-dependent growth inhibition.	Cyclosporine	104-115	ATP binding cassette subfamily B member 1	Homo sapiens	69-72
10342576-2	1999	Because idarubicin is less vulnerable to MDR1-mediated transport and could thereby represent a better companion to MDR1 inhibitors, we assessed the ability of the anti-MDR1 agent cyclosporin A to modulate this function in multidrug resistant T-lymphoblastic CEM cells challenged in vitro with either daunorubicin or idarubicin.	Cyclosporine	179-192	ATP binding cassette subfamily B member 1	Homo sapiens	115-119
10342576-8	1999	Altogether, study results in MDR1+ cells incubated with CsA 1500 ng/ml plus idarubicin+idarubicinol 100+20 ng/ml, that are peak levels achievable in vivo with an idarubicin dose &gt; or = 12 mg/m2 plus cyclosporin A 16 mg/kg/d, were in the range of those obtained with standard-dose daunorubicin in MDR1- cells (p=n.s.).	Cyclosporine	56-59	ATP binding cassette subfamily B member 1	Homo sapiens	29-33
10342576-8	1999	Altogether, study results in MDR1+ cells incubated with CsA 1500 ng/ml plus idarubicin+idarubicinol 100+20 ng/ml, that are peak levels achievable in vivo with an idarubicin dose &gt; or = 12 mg/m2 plus cyclosporin A 16 mg/kg/d, were in the range of those obtained with standard-dose daunorubicin in MDR1- cells (p=n.s.).	Cyclosporine	56-59	ATP binding cassette subfamily B member 1	Homo sapiens	299-303
10342576-8	1999	Altogether, study results in MDR1+ cells incubated with CsA 1500 ng/ml plus idarubicin+idarubicinol 100+20 ng/ml, that are peak levels achievable in vivo with an idarubicin dose &gt; or = 12 mg/m2 plus cyclosporin A 16 mg/kg/d, were in the range of those obtained with standard-dose daunorubicin in MDR1- cells (p=n.s.).	Cyclosporine	202-215	ATP binding cassette subfamily B member 1	Homo sapiens	29-33
10342576-9	1999	In summary, an idarubicin plus short-course cyclosporin A combination could be considered for the management of MDR1+ leukemias, where it may represent a more effective and less toxic option than daunorubicin plus continuous infusion cyclosporin A.	Cyclosporine	44-57	ATP binding cassette subfamily B member 1	Homo sapiens	112-116
10198227-3	1999	The initial rates (in percent) for calcein retention by these MDR-1 cells were used to calculate values for the percent initial efflux of calcein-AM through the MDR pump in the presence of the inhibitors PSC833, cyclosporinA, and dexniguldipine.	Cyclosporine	212-224	ATP binding cassette subfamily B member 1	Homo sapiens	62-67
10087047-0	1999	Cyclosporin exerts a direct fibrogenic effect on human tubulointerstitial cells: roles of insulin-like growth factor I, transforming growth factor beta1, and platelet-derived growth factor.	Cyclosporine	0-11	insulin like growth factor 1	Homo sapiens	90-118
10087047-4	1999	CyA did not affect CF secretion of transforming growth factor beta1, but markedly stimulated insulin-like growth factor-I (IGF-I) secretion and inhibited secretion of both IGF-I binding protein-(IGFBP)-3 and IGFBP-2.	Cyclosporine	0-3	insulin like growth factor 1	Homo sapiens	93-121
10087047-4	1999	CyA did not affect CF secretion of transforming growth factor beta1, but markedly stimulated insulin-like growth factor-I (IGF-I) secretion and inhibited secretion of both IGF-I binding protein-(IGFBP)-3 and IGFBP-2.	Cyclosporine	0-3	insulin like growth factor 1	Homo sapiens	123-128
10087047-5	1999	CyA-induced CF collagen synthesis was abrogated by 5 microgram/ml anti-IGF-I receptor antibody, but not by 5 microgram/ml murine nonimmune globulin.	Cyclosporine	0-3	insulin-like growth factor I receptor	Mus musculus	71-85
10077670-5	1999	Calcineurin antagonists such as cyclosporin A and FK506, as well as nonimmunosuppressant analogs of cyclosporin A, significantly enhanced SODV148G- and SODA4V-induced cell death.	Cyclosporine	32-45	superoxide dismutase 1	Homo sapiens	138-146
10385214-12	1999	Diltiazem, erythromycin, nifedipine and cyclosporin (CYP 3A substrates) inhibited halofantrine metabolism.	Cyclosporine	40-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	53-59
10087141-5	1999	Furthermore, glibenclamide is itself a substrate for P-glycoprotein, since the cellular accumulation of [3H]glibenclamide was low and substantially increased by addition of P-glycoprotein substrates (e. g., vinblastine and cyclosporine) only in the P-glycoprotein-expressing cell lines.	Cyclosporine	223-235	ATP binding cassette subfamily B member 1	Homo sapiens	53-67
10087141-5	1999	Furthermore, glibenclamide is itself a substrate for P-glycoprotein, since the cellular accumulation of [3H]glibenclamide was low and substantially increased by addition of P-glycoprotein substrates (e. g., vinblastine and cyclosporine) only in the P-glycoprotein-expressing cell lines.	Cyclosporine	223-235	ATP binding cassette subfamily B member 1	Homo sapiens	173-187
10087141-5	1999	Furthermore, glibenclamide is itself a substrate for P-glycoprotein, since the cellular accumulation of [3H]glibenclamide was low and substantially increased by addition of P-glycoprotein substrates (e. g., vinblastine and cyclosporine) only in the P-glycoprotein-expressing cell lines.	Cyclosporine	223-235	ATP binding cassette subfamily B member 1	Homo sapiens	173-187
10077670-5	1999	Calcineurin antagonists such as cyclosporin A and FK506, as well as nonimmunosuppressant analogs of cyclosporin A, significantly enhanced SODV148G- and SODA4V-induced cell death.	Cyclosporine	100-113	superoxide dismutase 1	Homo sapiens	138-146
10082500-3	1999	ACE inhibitors dilate the efferent glomerular arteriole, an effect that may aggravate the decrease in glomerular filtration rate resulting from cyclosporine-induced vasoconstriction at the afferent glomerular arteriole.	Cyclosporine	144-156	angiotensin I converting enzyme	Homo sapiens	0-3
10073607-0	1999	Intranephron distribution and regulation of endothelin-converting enzyme-1 in cyclosporin A-induced acute renal failure in rats.	Cyclosporine	78-91	endothelin converting enzyme 1	Rattus norvegicus	44-74
10073607-1	1999	Endothelin-1 (ET-1) is thought to play a significant role in acute renal failure induced by cyclosporin A (CsA).	Cyclosporine	92-105	endothelin 1	Rattus norvegicus	0-12
10073607-1	1999	Endothelin-1 (ET-1) is thought to play a significant role in acute renal failure induced by cyclosporin A (CsA).	Cyclosporine	92-105	endothelin 1	Rattus norvegicus	14-18
10073607-1	1999	Endothelin-1 (ET-1) is thought to play a significant role in acute renal failure induced by cyclosporin A (CsA).	Cyclosporine	107-110	endothelin 1	Rattus norvegicus	0-12
10073607-1	1999	Endothelin-1 (ET-1) is thought to play a significant role in acute renal failure induced by cyclosporin A (CsA).	Cyclosporine	107-110	endothelin 1	Rattus norvegicus	14-18
10073607-3	1999	To elicit the role of ECE-1 in the glomerular and tubular dysfunction induced by CsA, the effects of CsA on mRNA and protein expression of ECE-1 in rat kidney and on mRNA expression of prepro-ET-1 and ET A- and B-type receptors in glomeruli were studied.	Cyclosporine	101-104	endothelin converting enzyme 1	Rattus norvegicus	139-144
10073607-5	1999	ECE-1 mRNA expression was downregulated in all nephron segments at 24 h after CsA injection.	Cyclosporine	78-81	endothelin converting enzyme 1	Rattus norvegicus	0-5
10073607-7	1999	CsA rapidly increased prepro-ET-1 mRNA expression in glomeruli at 30 to 60 min after injection; this rapid increase was followed by an increase in plasma ET-1 levels.	Cyclosporine	0-3	endothelin 1	Rattus norvegicus	29-33
10073607-7	1999	CsA rapidly increased prepro-ET-1 mRNA expression in glomeruli at 30 to 60 min after injection; this rapid increase was followed by an increase in plasma ET-1 levels.	Cyclosporine	0-3	endothelin 1	Rattus norvegicus	154-158
10073607-9	1999	It is suggested that downregulation of glomerular and tubular ECE-1 expression may be caused by increased ET-1 synthesis in CsA-induced acute renal failure.	Cyclosporine	124-127	endothelin converting enzyme 1	Rattus norvegicus	62-67
10073607-9	1999	It is suggested that downregulation of glomerular and tubular ECE-1 expression may be caused by increased ET-1 synthesis in CsA-induced acute renal failure.	Cyclosporine	124-127	endothelin 1	Rattus norvegicus	106-110
10225546-4	1999	The aim of this study was to investigate the effects of CsA on the production of 2 cytokines - interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) - by both gingival fibroblasts and peripheral blood mononuclear cells (PBMC).	Cyclosporine	56-59	interleukin 1 beta	Homo sapiens	95-112
10225546-4	1999	The aim of this study was to investigate the effects of CsA on the production of 2 cytokines - interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) - by both gingival fibroblasts and peripheral blood mononuclear cells (PBMC).	Cyclosporine	56-59	interleukin 1 beta	Homo sapiens	114-122
10225546-4	1999	The aim of this study was to investigate the effects of CsA on the production of 2 cytokines - interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) - by both gingival fibroblasts and peripheral blood mononuclear cells (PBMC).	Cyclosporine	56-59	interleukin 6	Homo sapiens	128-141
10225546-4	1999	The aim of this study was to investigate the effects of CsA on the production of 2 cytokines - interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) - by both gingival fibroblasts and peripheral blood mononuclear cells (PBMC).	Cyclosporine	56-59	interleukin 6	Homo sapiens	143-147
10225546-7	1999	RESULTS: CsA inhibited IL-6 production by gingival fibroblasts in a dose-dependent manner.	Cyclosporine	9-12	interleukin 6	Homo sapiens	23-27
10225546-8	1999	In contrast, at a concentration of 2,000 ng/ml, CsA stimulated IL-6 production by PBMC (P &lt;0.05).	Cyclosporine	48-51	interleukin 6	Homo sapiens	63-67
10225546-10	1999	CsA inhibited IL-1beta production by PBMC over the whole concentration range (P &lt;0.05).	Cyclosporine	0-3	interleukin 1 beta	Homo sapiens	14-22
10028970-8	1999	Our findings suggest that immunosuppressants like cyclosporine can promote cancer progression by a direct cellular effect that is independent of its effect on the host"s immune cells, and that cyclosporine-induced TGF-beta production is involved in this.	Cyclosporine	50-62	transforming growth factor beta 1	Homo sapiens	214-222
10022890-3	1999	VEGF also induced TF mRNA expression and gene promoter activation by a cyclosporin A (CsA)-sensitive mechanism.	Cyclosporine	71-84	vascular endothelial growth factor A	Homo sapiens	0-4
10022890-3	1999	VEGF also induced TF mRNA expression and gene promoter activation by a cyclosporin A (CsA)-sensitive mechanism.	Cyclosporine	86-89	vascular endothelial growth factor A	Homo sapiens	0-4
10193825-10	1999	Aspiration biopsy cultures showed failure of cyclosporin A to inhibit interleukin-2 (IL-2) production by infiltrating lymphocytes.	Cyclosporine	45-58	interleukin 2	Homo sapiens	70-83
10193825-10	1999	Aspiration biopsy cultures showed failure of cyclosporin A to inhibit interleukin-2 (IL-2) production by infiltrating lymphocytes.	Cyclosporine	45-58	interleukin 2	Homo sapiens	85-89
10213371-5	1999	Excretion of GS-MF was decreased in presence of the MRP-blocker M K-571.2) Transport experiments with cyclosporin A demonstrated the functional activity of P-gp.	Cyclosporine	102-115	ATP binding cassette subfamily B member 1	Homo sapiens	156-160
10391070-15	1999	CyA reduced the CD4 levels, while the TF increased the levels of CD8 cells, both with a p &lt; 0.05.	Cyclosporine	0-3	CD4 molecule	Homo sapiens	16-19
10071036-1	1999	BACKGROUND: We and others have reported that cyclosporine (CsA) induces increased expression of transforming growth factor-beta1 (TGF-beta1) in vitro as well as in vivo.	Cyclosporine	45-57	transforming growth factor beta 1	Homo sapiens	96-128
10071036-1	1999	BACKGROUND: We and others have reported that cyclosporine (CsA) induces increased expression of transforming growth factor-beta1 (TGF-beta1) in vitro as well as in vivo.	Cyclosporine	45-57	transforming growth factor beta 1	Homo sapiens	130-139
10071036-1	1999	BACKGROUND: We and others have reported that cyclosporine (CsA) induces increased expression of transforming growth factor-beta1 (TGF-beta1) in vitro as well as in vivo.	Cyclosporine	59-62	transforming growth factor beta 1	Homo sapiens	96-128
10071036-1	1999	BACKGROUND: We and others have reported that cyclosporine (CsA) induces increased expression of transforming growth factor-beta1 (TGF-beta1) in vitro as well as in vivo.	Cyclosporine	59-62	transforming growth factor beta 1	Homo sapiens	130-139
9973482-6	1999	Cyclosporin A inhibited Fc epsilon RI-mediated JNK and p38 activation, but did not affect the activation of these kinases when stimulated through the SCFR.	Cyclosporine	0-13	Fc receptor, IgE, high affinity I, alpha polypeptide	Mus musculus	24-37
9973482-7	1999	Wortmannin and cyclosporin A inhibited Fc epsilon RI-mediated production of TNF-alpha and IL-4 in addition to serotonin release in BMMC.	Cyclosporine	15-28	Fc receptor, IgE, high affinity I, alpha polypeptide	Mus musculus	39-52
9973482-7	1999	Wortmannin and cyclosporin A inhibited Fc epsilon RI-mediated production of TNF-alpha and IL-4 in addition to serotonin release in BMMC.	Cyclosporine	15-28	tumor necrosis factor	Mus musculus	76-85
10028970-8	1999	Our findings suggest that immunosuppressants like cyclosporine can promote cancer progression by a direct cellular effect that is independent of its effect on the host"s immune cells, and that cyclosporine-induced TGF-beta production is involved in this.	Cyclosporine	193-205	transforming growth factor beta 1	Homo sapiens	214-222
10092957-15	1999	Nevertheless, care should be taken with the use of known CYP3A4 inhibitors such as erythromycin, ketoconazole and cyclosporin.	Cyclosporine	114-125	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	57-63
10076049-4	1999	CSA-induced contractions were associated with increases in the phosphorylation of the 20 kDa myosin light chains (MLC20) and different isoforms of the small heat shock protein, HSP27.	Cyclosporine	0-3	heat shock protein beta-1	Bos taurus	177-182
10076049-5	1999	Cyclic nucleotide-dependent relaxation of CSA-induced contractions was associated with increases in the phosphorylation of another small heat shock protein, HSP20, and decreases in the phosphorylation of the MLC20, and some isoforms of HSP27.	Cyclosporine	42-45	heat shock protein beta-1	Bos taurus	236-241
10064070-5	1999	Cyclosporin A inhibits TCR-induced IFN-gamma production, but not IL-12/IL-18-induced IFN-gamma production, biochemically discriminating between these pathways.	Cyclosporine	0-13	interferon gamma	Homo sapiens	35-44
10064056-5	1999	Production of both IL-4 by the Th2 clones and IFN-gamma by the Th1 clone were inhibited by the immunosuppressive agent cyclosporin A.	Cyclosporine	119-132	interferon gamma	Mus musculus	46-55
11563402-0	1999	Effects of glucocorticoids and cyclosporine on IL-2 and I kappa B alpha mRNA expression in human peripheral blood mononuclear cells.	Cyclosporine	31-43	interleukin 2	Homo sapiens	47-51
10064056-5	1999	Production of both IL-4 by the Th2 clones and IFN-gamma by the Th1 clone were inhibited by the immunosuppressive agent cyclosporin A.	Cyclosporine	119-132	negative elongation factor complex member C/D, Th1l	Mus musculus	63-66
10084328-6	1999	Both IL-2 or IL-4 overcame the inhibitory effect of CsA on PBMC from HP and controls.	Cyclosporine	52-55	interleukin 2	Homo sapiens	5-9
10084328-6	1999	Both IL-2 or IL-4 overcame the inhibitory effect of CsA on PBMC from HP and controls.	Cyclosporine	52-55	interleukin 4	Homo sapiens	13-17
10084328-7	1999	Conversely, IL-10 or IFN-alpha addition increases the inhibitory effect of CsA on the PR of PBMC from both HP and controls.	Cyclosporine	75-78	interferon alpha 1	Homo sapiens	21-30
9950598-7	1999	The number of T cells staining for IL-3 and IL-5 was reduced, although not to statistical significance, but there was a significant reduction in the number of T cells expressing IL-2 and IFN-gamma (P = 0.03) after CsA treatment compared with initial values.	Cyclosporine	214-217	interleukin 2	Homo sapiens	178-182
9950598-7	1999	The number of T cells staining for IL-3 and IL-5 was reduced, although not to statistical significance, but there was a significant reduction in the number of T cells expressing IL-2 and IFN-gamma (P = 0.03) after CsA treatment compared with initial values.	Cyclosporine	214-217	interferon gamma	Homo sapiens	187-196
9950598-10	1999	CONCLUSIONS: The in vitro effects of CsA translate into a reduction in T cells, a normalization of the CD4-CD8 ratio, a decrease in T-cell activation, and a reduction in T-cell cytokine expression, especially IL-2 and IFN-gamma.	Cyclosporine	37-40	CD4 molecule	Homo sapiens	103-106
9950598-10	1999	CONCLUSIONS: The in vitro effects of CsA translate into a reduction in T cells, a normalization of the CD4-CD8 ratio, a decrease in T-cell activation, and a reduction in T-cell cytokine expression, especially IL-2 and IFN-gamma.	Cyclosporine	37-40	interleukin 2	Homo sapiens	209-213
9950598-10	1999	CONCLUSIONS: The in vitro effects of CsA translate into a reduction in T cells, a normalization of the CD4-CD8 ratio, a decrease in T-cell activation, and a reduction in T-cell cytokine expression, especially IL-2 and IFN-gamma.	Cyclosporine	37-40	interferon gamma	Homo sapiens	218-227
11563402-0	1999	Effects of glucocorticoids and cyclosporine on IL-2 and I kappa B alpha mRNA expression in human peripheral blood mononuclear cells.	Cyclosporine	31-43	NFKB inhibitor alpha	Homo sapiens	56-71
11563402-4	1999	In addition, the authors observed a stimulatory effect on IkappaBalpha mRNA expression by cyclosporine as well in 8 of 10 PBMC preparations studied, suggesting a possible role of calcineurin in the regulation of IkappaBalpha production.	Cyclosporine	90-102	NFKB inhibitor alpha	Homo sapiens	58-70
11563402-4	1999	In addition, the authors observed a stimulatory effect on IkappaBalpha mRNA expression by cyclosporine as well in 8 of 10 PBMC preparations studied, suggesting a possible role of calcineurin in the regulation of IkappaBalpha production.	Cyclosporine	90-102	NFKB inhibitor alpha	Homo sapiens	212-224
10075015-0	1999	Cyclosporin A suppresses the induction of nitric oxide synthesis in interferon-gamma-treated L929 fibroblasts.	Cyclosporine	0-13	interferon gamma	Mus musculus	68-84
9987092-11	1999	Intense staining for endothelin-1, RANTES, and monocyte chemoattractant protein-1 mRNAs selectively localized at tubular epithelial cells was found in biopsies taken from patients with CsA nephrotoxicity, but not in the chronic graft rejection group, whose tubuli had only minimal staining for RANTES mRNA on a few occasions.	Cyclosporine	185-188	endothelin 1	Homo sapiens	21-33
10075015-3	1999	CsA applied simultaneously with IFN-gamma caused a dose-dependent reduction of NO synthesis in L929 cells.	Cyclosporine	0-3	interferon gamma	Mus musculus	32-41
10075015-7	1999	These results indicate that CsA suppresses NO synthesis in L929 cells independent of calcineurin inhibition, and interfering with intracellular pathways involved in the iNOS induction, rather than inhibiting its enzymatic activity.	Cyclosporine	28-31	nitric oxide synthase 2, inducible	Mus musculus	169-173
10500807-4	1999	The apoptotic effect from varying drug type and concentration was compared at 24 hours in CEM-MDR1+ cells, with and without co-incubation with MDR1 functional downregulator cyclosporin A (CSA) used at therapeutic concentration (1500 ng/ml).	Cyclosporine	173-186	ATP binding cassette subfamily B member 1	Homo sapiens	143-147
10083318-0	1999	Pretransplant MLC in the presence of cyclosporine may predict renal allograft survival.	Cyclosporine	37-49	modulator of VRAC current 1	Homo sapiens	14-17
9878697-2	1999	CsA applied simultaneously with iNOS activator IFN-gamma caused dose-dependent reduction of NO synthesis in confluent C6 cells, as determined by measuring accumulation of nitrite, an indicator of NO production, in 48 h culture supernatants.	Cyclosporine	0-3	nitric oxide synthase 2	Rattus norvegicus	32-36
9878697-3	1999	IFN-gamma-induced expression of iNOS, but not interferon regulatory factor-1 (IRF-1) mRNA was reduced in CsA-treated cells.	Cyclosporine	105-108	nitric oxide synthase 2	Rattus norvegicus	32-36
9885221-0	1999	P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833.	Cyclosporine	126-139	ATP binding cassette subfamily B member 1	Homo sapiens	99-113
9989244-5	1999	The release of cytochrome c from mitochondria was caused by Ca2+ and 0.175-0.9 mM peroxynitrite but not by NO, and was prevented by cyclosporin A.	Cyclosporine	132-145	cytochrome c, somatic	Homo sapiens	15-27
10989668-6	1999	Cyclosporin A blocks this mPT, preventing release of pro-apoptotic cytochrome c from mitochondria and subsequent apoptotic cell killing.	Cyclosporine	0-13	cytochrome c, somatic	Homo sapiens	67-79
9989245-9	1999	MPP(+)-induced pore opening and cytochrome c release were blocked by CsA, the Ca2+ uniporter inhibitor ruthenium red, the hydrophobic disulfide reagent N-ethylmaleimide, butacaine, and the free radical scavenging enzymes catalase and superoxide dismutase.	Cyclosporine	69-72	cytochrome c, somatic	Homo sapiens	32-44
10412883-14	1999	ACE inhibition prevents the CsA-induced hypertension, nephrotoxicity and vascular injuries.	Cyclosporine	28-31	angiotensin I converting enzyme	Rattus norvegicus	0-3
10412883-0	1999	Effects of ACE inhibition on cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on a high-sodium diet.	Cyclosporine	29-43	angiotensin I converting enzyme	Rattus norvegicus	11-14
10526062-7	1999	In the control group, serum TNF levels were elevated following reperfusion and peaked at 3 h. When the values at 3 h post reflow were compared, the animals given CsA had significantly lower levels of TNF (170.0 +/- 30.5 pg/ml for group I, 67.6 +/- 13.7 for group II, mean +/- SEM; P &lt; 0.05).	Cyclosporine	162-165	tumor necrosis factor	Rattus norvegicus	28-31
10529553-0	1999	Augmentative effect of cyclosporin A on rat liver regeneration: influence on hepatocyte growth factor and transforming growth factor-beta(1).	Cyclosporine	23-36	transforming growth factor, beta 1	Rattus norvegicus	106-140
10901483-4	1999	It is indicated that AngII-induced activation of calcineurin is through an ATI receptor, may be dependent on the sustained increases of [Ca2+]i, and be regulated by protein kinase C. In a second experiment, we found that cyclosporin (0.1-10micromol/l), a specific inhibitor of calcineurin, decreased the protein synthesis rate in AngII-stimulated cardiomyocytes and the DNA synthesis rate in AngII-treated fibroblasts in a dose-dependent manner.	Cyclosporine	221-232	angiotensinogen	Rattus norvegicus	21-26
10901483-4	1999	It is indicated that AngII-induced activation of calcineurin is through an ATI receptor, may be dependent on the sustained increases of [Ca2+]i, and be regulated by protein kinase C. In a second experiment, we found that cyclosporin (0.1-10micromol/l), a specific inhibitor of calcineurin, decreased the protein synthesis rate in AngII-stimulated cardiomyocytes and the DNA synthesis rate in AngII-treated fibroblasts in a dose-dependent manner.	Cyclosporine	221-232	angiotensinogen	Rattus norvegicus	330-335
10901483-4	1999	It is indicated that AngII-induced activation of calcineurin is through an ATI receptor, may be dependent on the sustained increases of [Ca2+]i, and be regulated by protein kinase C. In a second experiment, we found that cyclosporin (0.1-10micromol/l), a specific inhibitor of calcineurin, decreased the protein synthesis rate in AngII-stimulated cardiomyocytes and the DNA synthesis rate in AngII-treated fibroblasts in a dose-dependent manner.	Cyclosporine	221-232	angiotensinogen	Rattus norvegicus	330-335
10526062-7	1999	In the control group, serum TNF levels were elevated following reperfusion and peaked at 3 h. When the values at 3 h post reflow were compared, the animals given CsA had significantly lower levels of TNF (170.0 +/- 30.5 pg/ml for group I, 67.6 +/- 13.7 for group II, mean +/- SEM; P &lt; 0.05).	Cyclosporine	162-165	tumor necrosis factor	Rattus norvegicus	200-203
9886391-5	1999	TCR-mediated IL-10 gene expression is inhibited by cyclosporin A, but IL-4-mediated IL-10 expression is not.	Cyclosporine	51-64	interleukin 10	Mus musculus	13-18
10526062-10	1999	Our data suggest that modulation of TNF production is one of the mechanisms through which CsA prevents the exacerbation of ischemia/reperfusion injury of the liver.	Cyclosporine	90-93	tumor necrosis factor	Rattus norvegicus	36-39
10704080-3	1999	We measured the effect of CsA on basal and phorbol-myristate-acetate (PMA)-stimulated production of interleukin-6 using the human monocyte cell line U937 differentiated with dimethylsulfoxide (DMSO).	Cyclosporine	26-29	interleukin 6	Homo sapiens	100-113
9930944-4	1999	Both pentoxifylline (66 microg/ml) and cyclosporin A (300 ng/ml) slightly inhibited TNFalpha release without affecting IL-1beta or superoxide generation.	Cyclosporine	39-52	tumor necrosis factor	Homo sapiens	84-92
9930944-4	1999	Both pentoxifylline (66 microg/ml) and cyclosporin A (300 ng/ml) slightly inhibited TNFalpha release without affecting IL-1beta or superoxide generation.	Cyclosporine	39-52	interleukin 1 beta	Homo sapiens	119-127
9930944-6	1999	A combination of methylprednisolone, pentoxifylline, cyclosporin A, and nicotinamide (concentrations for each substance as described above) inhibited TNFalpha generation by 74+/-6% (mean value+/-SEM, mononuclear blood cells from seven diabetic patients) without affecting IL-1beta or superoxide generation.	Cyclosporine	53-66	tumor necrosis factor	Homo sapiens	150-158
9930944-6	1999	A combination of methylprednisolone, pentoxifylline, cyclosporin A, and nicotinamide (concentrations for each substance as described above) inhibited TNFalpha generation by 74+/-6% (mean value+/-SEM, mononuclear blood cells from seven diabetic patients) without affecting IL-1beta or superoxide generation.	Cyclosporine	53-66	interleukin 1 beta	Homo sapiens	272-280
10704080-5	1999	We found that CsA decreases not only IL-6 release but also cytokine synthesis.	Cyclosporine	14-17	interleukin 6	Homo sapiens	37-41
10704080-7	1999	Three possibilities may be advanced to explain the CsA-due decrease in IL-6 production by macrophages: (a) inhibition of the synthesis of an early common regulatory protein, (b) inhibition of cytokine gene transcription, or (c) modulation of post-transcriptional events.	Cyclosporine	51-54	interleukin 6	Homo sapiens	71-75
10704080-13	1999	We conclude that in human macrophages CsA diminishes IL-6 production at post-transcriptional level.	Cyclosporine	38-41	interleukin 6	Homo sapiens	53-57
9858612-2	1999	Cyclosporin A (CsA), a calcineurin antagonist and blocker of interleukin-2 (IL-2) transcription in T cells, was found to inhibit translation of IL-3 mRNA in autocrine mast cell tumor lines.	Cyclosporine	0-13	interleukin 2	Homo sapiens	61-74
9933132-1	1999	Expression of P-glycoprotein (Pgp), the drug efflux pump which mediates multidrug resistance (MDR), has been widely reported in chronic lymphocytic leukaemia (CLL) and improved accumulation of daunorubicin has been reported using the MDR reversing agent cyclosporin A (CSA).	Cyclosporine	269-272	ATP binding cassette subfamily B member 1	Homo sapiens	14-28
9933132-1	1999	Expression of P-glycoprotein (Pgp), the drug efflux pump which mediates multidrug resistance (MDR), has been widely reported in chronic lymphocytic leukaemia (CLL) and improved accumulation of daunorubicin has been reported using the MDR reversing agent cyclosporin A (CSA).	Cyclosporine	269-272	ATP binding cassette subfamily B member 1	Homo sapiens	30-33
9858612-5	1999	The translational inhibition by CsA was specific to oncogenically induced lymphokines IL-3 and IL-4 but not to IL-6, c-jun, and c-myc, which are expressed in the nonmalignant precursor cells.	Cyclosporine	32-35	interleukin 4	Homo sapiens	95-99
9858612-2	1999	Cyclosporin A (CsA), a calcineurin antagonist and blocker of interleukin-2 (IL-2) transcription in T cells, was found to inhibit translation of IL-3 mRNA in autocrine mast cell tumor lines.	Cyclosporine	0-13	interleukin 2	Homo sapiens	76-80
9858612-2	1999	Cyclosporin A (CsA), a calcineurin antagonist and blocker of interleukin-2 (IL-2) transcription in T cells, was found to inhibit translation of IL-3 mRNA in autocrine mast cell tumor lines.	Cyclosporine	15-18	interleukin 2	Homo sapiens	61-74
9858612-2	1999	Cyclosporin A (CsA), a calcineurin antagonist and blocker of interleukin-2 (IL-2) transcription in T cells, was found to inhibit translation of IL-3 mRNA in autocrine mast cell tumor lines.	Cyclosporine	15-18	interleukin 2	Homo sapiens	76-80
9857002-6	1998	Despite elimination of both strong NFAT-binding sites, the IFN-gamma promoter remained completely sensitive to inhibition by cyclosporin.	Cyclosporine	125-136	interferon gamma	Homo sapiens	59-68
10193910-1	1999	Cyclosporine, a calcineurin inhibitor, significantly enhances spontaneous acetylcholine release after a brief tetanus and potentiates the effect of phorbol 12,13-dibutyrate.	Cyclosporine	0-12	calcineurin binding protein 1	Mus musculus	16-37
10419836-4	1999	Pretreatment of mice with cyclosporin (10 mg/kg, po) did not significantly reduce MMP activities, but cyclosporin inhibited neutrophil recruitment, inhibited increase TNF- alpha and inhibited IL-10 decrease.	Cyclosporine	102-113	tumor necrosis factor	Mus musculus	167-177
10419836-4	1999	Pretreatment of mice with cyclosporin (10 mg/kg, po) did not significantly reduce MMP activities, but cyclosporin inhibited neutrophil recruitment, inhibited increase TNF- alpha and inhibited IL-10 decrease.	Cyclosporine	102-113	interleukin 10	Mus musculus	192-197
9857002-7	1998	This suggests that other elements in the IFN-gamma promoter, such as the IFN-gamma proximal element, are sufficient for cyclosporin sensitivity of this gene.	Cyclosporine	120-131	interferon gamma	Homo sapiens	41-50
9857002-7	1998	This suggests that other elements in the IFN-gamma promoter, such as the IFN-gamma proximal element, are sufficient for cyclosporin sensitivity of this gene.	Cyclosporine	120-131	interferon gamma	Homo sapiens	73-82
9884267-2	1998	CsA-associated renal fibrosis has been related to the overproduction of transforming growth factor (TGF)-beta1, a fibrogenic cytokine.	Cyclosporine	0-3	transforming growth factor beta 1	Homo sapiens	72-110
9884267-4	1998	METHODS: We studied the impact of CsA dose reduction in association with MMF on renal function and TGF-beta1, production in 16 long-term renal allograft recipients with suspected CsA nephrotoxicity.	Cyclosporine	34-37	transforming growth factor beta 1	Homo sapiens	99-108
9889794-0	1999	Suppressed endothelin-1 production by FK506 and cyclosporin A in ischemia/reperfusion of rat small intestine.	Cyclosporine	48-61	endothelin 1	Rattus norvegicus	11-23
9889794-10	1999	CONCLUSIONS: FK506 and CsA, particularly the former, maintain microcirculation and protect the tissue from I/R injury by suppressing the production and release of ET-1.	Cyclosporine	23-26	endothelin 1	Rattus norvegicus	163-167
9884267-11	1998	CONCLUSIONS: These short-term results show that MMF introduction allows a CsA dose reduction, which improves renal function, reduces TGF-beta1 production, and improves the control of hypertension, without increasing the incidence of acute rejection.	Cyclosporine	74-77	transforming growth factor beta 1	Homo sapiens	133-142
9843949-3	1998	All of these changes were dependent on Ca2+ and were prevented by cyclosporin A (CsA) and bongkrekic acid, both of which close the PT pores (megachannels), indicating that Bax- and Bak-induced mitochondrial changes were mediated through the opening of these pores.	Cyclosporine	66-79	BCL2 associated X, apoptosis regulator	Homo sapiens	172-175
9886913-8	1998	This supports the inhibition of shear-induced activation of platelets by anti-vWF in the CSA.	Cyclosporine	89-92	von Willebrand factor	Homo sapiens	78-81
9843949-3	1998	All of these changes were dependent on Ca2+ and were prevented by cyclosporin A (CsA) and bongkrekic acid, both of which close the PT pores (megachannels), indicating that Bax- and Bak-induced mitochondrial changes were mediated through the opening of these pores.	Cyclosporine	81-84	BCL2 associated X, apoptosis regulator	Homo sapiens	172-175
11366076-0	1998	Low-dose cyclosporin: government trial recruiting, CD4 count over 500.	Cyclosporine	9-20	CD4 molecule	Homo sapiens	51-54
9820802-4	1998	Binding was prevented by pretreatment of the CyP-D with CsA, but not with cyclosporin H.	Cyclosporine	56-59	peptidylprolyl isomerase F	Homo sapiens	45-50
9846983-6	1998	Cyclosporin A, known to be a potent inhibitor of both calcineurin activation and mitochondrial permeability transition pore opening, inhibited CD99-mediated apoptosis, whereas FK-506, a specific calcineurin inhibitor, did not, indicating the induction of CD99-mediated apoptosis through a calcineurin-independent pathway.	Cyclosporine	0-13	CD99 molecule (Xg blood group)	Homo sapiens	143-147
9846983-6	1998	Cyclosporin A, known to be a potent inhibitor of both calcineurin activation and mitochondrial permeability transition pore opening, inhibited CD99-mediated apoptosis, whereas FK-506, a specific calcineurin inhibitor, did not, indicating the induction of CD99-mediated apoptosis through a calcineurin-independent pathway.	Cyclosporine	0-13	CD99 molecule (Xg blood group)	Homo sapiens	255-259
9846983-8	1998	These results suggest that CD99 engagement induce CsA-inhibitable mitochondrial permeability transition pore opening, followed by a reduction of delta psi m and caspase activation, thereby leading to apoptosis.	Cyclosporine	50-53	CD99 molecule (Xg blood group)	Homo sapiens	27-31
9820802-1	1998	A fusion protein between cyclophilin-D (CyP-D) and glutathione S-transferase (GST) was shown to bind to purified liver inner mitochondrial membranes (IMMs) in a cyclosporin A (CsA)-sensitive manner.	Cyclosporine	161-174	peptidylprolyl isomerase F	Homo sapiens	25-38
9820802-1	1998	A fusion protein between cyclophilin-D (CyP-D) and glutathione S-transferase (GST) was shown to bind to purified liver inner mitochondrial membranes (IMMs) in a cyclosporin A (CsA)-sensitive manner.	Cyclosporine	161-174	peptidylprolyl isomerase F	Homo sapiens	40-45
9820802-1	1998	A fusion protein between cyclophilin-D (CyP-D) and glutathione S-transferase (GST) was shown to bind to purified liver inner mitochondrial membranes (IMMs) in a cyclosporin A (CsA)-sensitive manner.	Cyclosporine	176-179	peptidylprolyl isomerase F	Homo sapiens	25-38
9877451-3	1998	TNF-alpha production in IL-1beta-stimulated or PMA-stimulated hepatocyte cultures was not altered following the addition of dihydrocortisone (&lt; or = 1 microg/ml), dibutyryl-cAMP (db-cAMP, &lt; or = 100 micromol/l), adenosine (&lt; or = 1 mmol/l), thalidomide (&lt; or = 25 microg/ml), or cyclosporine (&lt; or = 300 ng/ml).	Cyclosporine	291-303	tumor necrosis factor	Homo sapiens	0-9
9820802-1	1998	A fusion protein between cyclophilin-D (CyP-D) and glutathione S-transferase (GST) was shown to bind to purified liver inner mitochondrial membranes (IMMs) in a cyclosporin A (CsA)-sensitive manner.	Cyclosporine	176-179	peptidylprolyl isomerase F	Homo sapiens	40-45
9839278-0	1998	CsA and FK506 up-regulate eNOS expression: role of reactive oxygen species and AP-1.	Cyclosporine	0-3	nitric oxide synthase 3	Bos taurus	26-30
9864280-1	1998	PSC 833, a nonimmunosuppressive cyclosporin, is able to inhibit the efflux of antitumor drugs mediated by P-glycoprotein (P-gp).	Cyclosporine	32-43	ATP binding cassette subfamily B member 1	Homo sapiens	106-120
9864280-1	1998	PSC 833, a nonimmunosuppressive cyclosporin, is able to inhibit the efflux of antitumor drugs mediated by P-glycoprotein (P-gp).	Cyclosporine	32-43	ATP binding cassette subfamily B member 1	Homo sapiens	122-126
9839278-1	1998	Cyclosporine A (CsA) and FK506 increase endothelial nitric oxide synthase (eNOS) mRNA expression in cultured bovine aortic endothelial cells (BAEC).	Cyclosporine	0-14	nitric oxide synthase 3	Bos taurus	40-73
9839278-1	1998	Cyclosporine A (CsA) and FK506 increase endothelial nitric oxide synthase (eNOS) mRNA expression in cultured bovine aortic endothelial cells (BAEC).	Cyclosporine	0-14	nitric oxide synthase 3	Bos taurus	75-79
9839278-1	1998	Cyclosporine A (CsA) and FK506 increase endothelial nitric oxide synthase (eNOS) mRNA expression in cultured bovine aortic endothelial cells (BAEC).	Cyclosporine	16-19	nitric oxide synthase 3	Bos taurus	40-73
9839278-1	1998	Cyclosporine A (CsA) and FK506 increase endothelial nitric oxide synthase (eNOS) mRNA expression in cultured bovine aortic endothelial cells (BAEC).	Cyclosporine	16-19	nitric oxide synthase 3	Bos taurus	75-79
9839278-2	1998	CsA appears to increase eNOS mRNA levels mainly by increasing the rate of transcription, although a small contribution of mRNA stabilization could not be ruled out.	Cyclosporine	0-3	nitric oxide synthase 3	Bos taurus	24-28
9839278-5	1998	This upregulation of eNOS mRNA by CsA or GO was abrogated by catalase.	Cyclosporine	34-37	nitric oxide synthase 3	Bos taurus	21-25
9819421-10	1998	Cyclosporin A inhibited Cpr7 interactions with Cns1 but not with Hsp90.	Cyclosporine	0-13	HSP70/90 family co-chaperone CNS1	Saccharomyces cerevisiae S288C	47-51
9820545-6	1998	IL-4 mRNA, constitutively present in basophils, was increased after stimulation by pFv and was inhibited by cyclosporin A and tacrolimus.	Cyclosporine	108-121	interleukin 4	Homo sapiens	0-4
9845356-1	1998	Ca2+ uptake by brain mitochondria induces the release of up to 40% of total cytochrome c in a cyclosporin A-insensitive manner.	Cyclosporine	94-107	cytochrome c, somatic	Homo sapiens	76-88
9914792-0	1998	Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein.	Cyclosporine	24-35	ATP binding cassette subfamily B member 1	Homo sapiens	115-129
9824778-9	1998	Cyclosporine and tacrolimus prevent NF-kappa B activation by inhibiting the action of calcineurin, a phosphatase that indirectly induces I kappa B degradation.	Cyclosporine	0-12	nuclear factor kappa B subunit 1	Homo sapiens	36-46
9774651-5	1998	Cyclosporin A (CsA), an inhibitor of the MPT, blocked TNFalpha-mediated apoptosis and cytochrome c release.	Cyclosporine	0-13	tumor necrosis factor	Rattus norvegicus	54-62
9774651-5	1998	Cyclosporin A (CsA), an inhibitor of the MPT, blocked TNFalpha-mediated apoptosis and cytochrome c release.	Cyclosporine	15-18	tumor necrosis factor	Rattus norvegicus	54-62
9914792-1	1998	The inhibitory effects of SDZ PSC 833 (PSC833), a non-immunosuppressive cyclosporin derivative, on the P-glycoprotein (P-gp)-mediated transport of doxorubicin and vinblastine were compared with those of cyclosporin A (Cs-A).	Cyclosporine	203-216	ATP binding cassette subfamily B member 1	Homo sapiens	119-123
9914792-1	1998	The inhibitory effects of SDZ PSC 833 (PSC833), a non-immunosuppressive cyclosporin derivative, on the P-glycoprotein (P-gp)-mediated transport of doxorubicin and vinblastine were compared with those of cyclosporin A (Cs-A).	Cyclosporine	218-222	ATP binding cassette subfamily B member 1	Homo sapiens	119-123
9914792-3	1998	Both PSC833 and Cs-A inhibited P-gp-mediated transport of doxorubicin and vinblastine in a concentration-dependent manner and increased the intracellular accumulation of doxorubicin and vinblastine in LLC-GA5-COL150 cells.	Cyclosporine	16-20	ATP binding cassette subfamily B member 1	Homo sapiens	31-35
9914792-7	1998	These results indicated that the inhibitory effect of PSC833 on P-gp-mediated transport was 5- to 10-fold more potent than that of Cs-A, and this higher inhibitory effect of PSC833 may be related to the absence of PSC833 transport by P-gp and to the higher lipophilicity of PSC833.	Cyclosporine	131-135	ATP binding cassette subfamily B member 1	Homo sapiens	64-68
9855331-3	1998	All the substrates and inhibitors of CYP3A4 such as the azole antifungals (itraconazole, ketoconazole), cyclosporine, isoniazid, and nifedipine have very high propensity to interfere with vincristine metabolism.	Cyclosporine	104-116	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	37-43
9807033-3	1998	Cyclosporine interferes with several humoral and neural systems which are involved in blood pressure regulation such as the renin-angiotensin system, endothelins, nitric oxide, prostaglandins and the sympathetic nervous system.	Cyclosporine	0-12	renin	Homo sapiens	124-129
9755112-6	1998	Western immunoblotting revealed PPase 2B to be present in cytoskeletal EC fractions, with specific PPase 2B inhibitors such as cyclosporin (200 nM) and deltamethrin (100 nM to 1 microM) attenuating thrombin-induced cytoskeletal protein dephosphorylation, including EC MLC dephosphorylation.	Cyclosporine	127-138	coagulation factor II, thrombin	Homo sapiens	198-206
9780210-7	1998	Ascomycin and cyclosporin A, inhibitors of the Ca2+-dependent phosphatase, calcineurin, also inhibited thapsigargin-induced IL-8 production.	Cyclosporine	14-27	C-X-C motif chemokine ligand 8	Homo sapiens	124-128
9763433-8	1998	These results strongly suggest the existence of two distinct mechanisms leading to cytochrome C release: one stimulated by calcium and inhibited by cyclosporin A, the other Bax dependent, Mg2+ sensitive but cyclosporin insensitive.	Cyclosporine	148-161	cytochrome c, somatic	Homo sapiens	83-95
9763433-8	1998	These results strongly suggest the existence of two distinct mechanisms leading to cytochrome C release: one stimulated by calcium and inhibited by cyclosporin A, the other Bax dependent, Mg2+ sensitive but cyclosporin insensitive.	Cyclosporine	148-159	cytochrome c, somatic	Homo sapiens	83-95
9778221-3	1998	RESULTS: Cyclosporine was found to ameliorate arthritis, suppress interferon-gamma (IFNgamma) production by CD4+ T cells, and reduce TNFalpha expression in arthritic joints.	Cyclosporine	9-21	interferon gamma	Mus musculus	66-82
9778221-3	1998	RESULTS: Cyclosporine was found to ameliorate arthritis, suppress interferon-gamma (IFNgamma) production by CD4+ T cells, and reduce TNFalpha expression in arthritic joints.	Cyclosporine	9-21	interferon gamma	Mus musculus	84-92
9778221-3	1998	RESULTS: Cyclosporine was found to ameliorate arthritis, suppress interferon-gamma (IFNgamma) production by CD4+ T cells, and reduce TNFalpha expression in arthritic joints.	Cyclosporine	9-21	tumor necrosis factor	Mus musculus	133-141
9787942-2	1998	The vasoconstrictive peptide endothelin-1 (ET-1) has been proposed as a mediator of CsA induced hypoperfusion.	Cyclosporine	84-87	endothelin 1	Homo sapiens	29-41
9736460-0	1998	Opposing effects of cyclosporin A and tyrphostin AG-1478 indicate a role for Src protein in the cellular control of mineralization.	Cyclosporine	20-33	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	77-80
9787942-2	1998	The vasoconstrictive peptide endothelin-1 (ET-1) has been proposed as a mediator of CsA induced hypoperfusion.	Cyclosporine	84-87	endothelin 1	Homo sapiens	43-47
9787942-9	1998	Concurrent with the maximum renal hemodynamic effects, plasma ET-1 was elevated with a peak increase of about 40% 4-5 h after CsA ingestion.	Cyclosporine	126-129	endothelin 1	Homo sapiens	62-66
9787942-11	1998	These findings suggest that CsA induced acute vasoconstriction and renal hypoperfusion are mediated by ET-1 and that diltiazem treatment abolishes these pharmacodynamic effects of CsA despite persistent increase of plasma ET-1 levels.	Cyclosporine	28-31	endothelin 1	Homo sapiens	103-107
9736460-8	1998	Under CsA, Src protein quantity decreased on day 8, but its cleavage product (52/54 kDa) was sixfold more abundant then on day 7.	Cyclosporine	6-9	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	11-14
9736460-15	1998	The results indicate that increased Src protein cleavage product on day 8 by CsA is associated with mineralization inhibition, which is opposed by DMSO and 50-microM AG-1478, thus antagonizing the effect of CsA on mineralization.	Cyclosporine	77-80	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	36-39
9736460-15	1998	The results indicate that increased Src protein cleavage product on day 8 by CsA is associated with mineralization inhibition, which is opposed by DMSO and 50-microM AG-1478, thus antagonizing the effect of CsA on mineralization.	Cyclosporine	207-210	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	36-39
9736460-16	1998	Direct or indirect interaction between Src and TPP, antagonistically affected by CsA and AG-1478, is likely to underlay cellular control of mineralization.	Cyclosporine	81-84	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	39-42
9766631-6	1998	Combination of these stimuli with ionomycin resulted in a strongly synergistic increase of CD134 expression, which was blocked by the calcineurin-inhibitor cyclosporin A.	Cyclosporine	156-169	TNF receptor superfamily member 4	Homo sapiens	91-96
9759839-6	1998	Cross-linking CD148 with immobilized anti-CD148 mAb induced vigorous proliferation of anti-CD3 mAb-activated, highly purified peripheral blood T cells in an IL-2-dependent, cyclosporin A-sensitive manner.	Cyclosporine	173-186	interleukin 2	Homo sapiens	157-161
9836144-9	1998	Moreover, a significant interdependence between CSA, SDH activity, GPD activity and MyHC content existed on a fibre-to-fibre basis, suggesting that the MyHC isoform expressed in a fibre is associated with differences in size, oxidative and glycolytic capabilities of muscle fibres.	Cyclosporine	48-51	myosin heavy chain 13	Rattus norvegicus	152-156
9767529-1	1998	BACKGROUND: The immunosuppressive drugs cyclosporine A (CsA) and tacrolimus (FK506) are extruded from cells by the multidrug resistance P-glycoprotein (P-gp), an efflux pump for drugs and xenobiotics, which may limit their therapeutic effectiveness and/or incidence of toxic side effects.	Cyclosporine	56-59	ATP binding cassette subfamily B member 1	Homo sapiens	136-150
9763451-0	1998	Activation and cellular localization of the cyclosporine A-sensitive transcription factor NF-AT in skeletal muscle cells.	Cyclosporine	44-58	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2	Mus musculus	90-95
9763451-1	1998	The widely used immunosuppressant cyclosporine A (CSA) blocks nuclear translocation of the transcription factor, NF-AT (nuclear factor of activated T cells), preventing its activity.	Cyclosporine	34-48	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2	Mus musculus	113-118
9763451-1	1998	The widely used immunosuppressant cyclosporine A (CSA) blocks nuclear translocation of the transcription factor, NF-AT (nuclear factor of activated T cells), preventing its activity.	Cyclosporine	50-53	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2	Mus musculus	113-118
9763451-2	1998	mRNA for several NF-AT isoforms has been shown to exist in cells outside of the immune system, suggesting a possible mechanism for side effects associated with CSA treatment.	Cyclosporine	160-163	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2	Mus musculus	17-22
9765504-8	1998	Inhibitors of Pgp, including verapamil and cyclosporin A, were less effective in reversing resistance of the chimeric Pgp compared with wild-type Pgp, for certain drugs.	Cyclosporine	43-56	ATP binding cassette subfamily B member 1	Homo sapiens	14-17
9765504-8	1998	Inhibitors of Pgp, including verapamil and cyclosporin A, were less effective in reversing resistance of the chimeric Pgp compared with wild-type Pgp, for certain drugs.	Cyclosporine	43-56	ATP binding cassette subfamily B member 1	Homo sapiens	118-121
9765504-8	1998	Inhibitors of Pgp, including verapamil and cyclosporin A, were less effective in reversing resistance of the chimeric Pgp compared with wild-type Pgp, for certain drugs.	Cyclosporine	43-56	ATP binding cassette subfamily B member 1	Homo sapiens	118-121
9765504-9	1998	However, [125I]iodoarylazidoprazosin photoaffinity labeling of the chimeric Pgp and its binding competition with cyclosporin A, showed that cyclosporin A competed for the photoaffinity labeling.	Cyclosporine	113-126	ATP binding cassette subfamily B member 1	Homo sapiens	76-79
9765504-9	1998	However, [125I]iodoarylazidoprazosin photoaffinity labeling of the chimeric Pgp and its binding competition with cyclosporin A, showed that cyclosporin A competed for the photoaffinity labeling.	Cyclosporine	140-153	ATP binding cassette subfamily B member 1	Homo sapiens	76-79
9767529-1	1998	BACKGROUND: The immunosuppressive drugs cyclosporine A (CsA) and tacrolimus (FK506) are extruded from cells by the multidrug resistance P-glycoprotein (P-gp), an efflux pump for drugs and xenobiotics, which may limit their therapeutic effectiveness and/or incidence of toxic side effects.	Cyclosporine	56-59	ATP binding cassette subfamily B member 1	Homo sapiens	152-156
9767529-2	1998	In the present study, we investigated the effect of therapeutic concentrations of CsA and FK506 on the expression of P-gp in cultured endothelial and proximal tubule cells.	Cyclosporine	82-85	ATP binding cassette subfamily B member 1	Homo sapiens	117-121
9767529-4	1998	RESULTS: Following incubation of HAEC with therapeutic concentrations of 0.1 to 1.6 microM CsA up to seven days, P-gp expression increased in a time- and concentration-dependent manner, maximally to 291 +/- 42% of controls with 0.8 microM CsA for seven days.	Cyclosporine	91-94	ATP binding cassette subfamily B member 1	Homo sapiens	113-117
9767529-4	1998	RESULTS: Following incubation of HAEC with therapeutic concentrations of 0.1 to 1.6 microM CsA up to seven days, P-gp expression increased in a time- and concentration-dependent manner, maximally to 291 +/- 42% of controls with 0.8 microM CsA for seven days.	Cyclosporine	239-242	ATP binding cassette subfamily B member 1	Homo sapiens	113-117
9767529-7	1998	Immunocytochemistry revealed increased P-gp expression in the plasma membrane of HAEC and RPTC treated with 0.8 microM CsA, which was reflected by a decrease of P-gp-mediated accumulation of calcein in both cell types.	Cyclosporine	119-122	ATP binding cassette subfamily B member 1	Homo sapiens	39-43
9767529-7	1998	Immunocytochemistry revealed increased P-gp expression in the plasma membrane of HAEC and RPTC treated with 0.8 microM CsA, which was reflected by a decrease of P-gp-mediated accumulation of calcein in both cell types.	Cyclosporine	119-122	ATP binding cassette subfamily B member 1	Homo sapiens	161-165
9767529-8	1998	CONCLUSIONS: The data suggest that the induction of P-gp expression in HAEC and RPTC at concentrations of CsA or FK506 above 0.5 microM is part of the protective answer of cells to toxic concentrations of the drugs and could therefore interfere with the therapeutic effectiveness of CsA in vivo.	Cyclosporine	106-109	ATP binding cassette subfamily B member 1	Homo sapiens	52-56
9767529-8	1998	CONCLUSIONS: The data suggest that the induction of P-gp expression in HAEC and RPTC at concentrations of CsA or FK506 above 0.5 microM is part of the protective answer of cells to toxic concentrations of the drugs and could therefore interfere with the therapeutic effectiveness of CsA in vivo.	Cyclosporine	283-286	ATP binding cassette subfamily B member 1	Homo sapiens	52-56
9753651-3	1998	By contrast, it was observed that dATP is a potent inducer that caused release of cytochrome c in a swelling independent manner, i.e. even in the presence of osmotic support by PEG-1000; in addition this release of cytochrome c is inhibitable by cyclosporin A.	Cyclosporine	246-259	cytochrome c, somatic	Homo sapiens	82-94
9753651-3	1998	By contrast, it was observed that dATP is a potent inducer that caused release of cytochrome c in a swelling independent manner, i.e. even in the presence of osmotic support by PEG-1000; in addition this release of cytochrome c is inhibitable by cyclosporin A.	Cyclosporine	246-259	cytochrome c, somatic	Homo sapiens	215-227
9767461-0	1998	Interleukin-1beta partially alleviates cyclosporin A-induced suppression of IgG1 isotype response to thyroglobulin in BALB/c mice in vivo.	Cyclosporine	39-52	interleukin 1 beta	Mus musculus	0-17
9817191-6	1998	In Group I (n = 7), 12 months of cyclosporin A therapy significantly increased systolic blood pressure and significantly decreased glomerular filtration rate, plasma renin activity and active urinary kallikrein.	Cyclosporine	33-46	renin	Homo sapiens	166-171
9767461-0	1998	Interleukin-1beta partially alleviates cyclosporin A-induced suppression of IgG1 isotype response to thyroglobulin in BALB/c mice in vivo.	Cyclosporine	39-52	immunoglobulin heavy constant gamma 1 (G1m marker)	Mus musculus	76-80
9732409-6	1998	Transport in the basolateral to apical direction was 3-fold greater than apical to basolateral flux for both saquinavir and saquinavir mesylate and was blocked by co-incubation with the established P-gp reversal agents cyclosporine and verapamil.	Cyclosporine	219-231	ATP binding cassette subfamily B member 1	Homo sapiens	198-202
9868865-3	1998	Catalase-deficient C3H/Csb mutant cell strain is markedly more sensitive to the toxicity of hydrogen peroxide compared to wild-type C3H/Csa cell strain.	Cyclosporine	136-139	catalase	Mus musculus	0-8
9738952-6	1998	On the other hand, tetrodotoxin (TTX) and cyclosporin A inhibited only the NaF-induced 45Ca2+ influx (IC50 = 21 mol/l and 28 mol/l, respectively).	Cyclosporine	42-55	C-X-C motif chemokine ligand 8	Homo sapiens	75-78
9712047-0	1998	Cyclosporin A-resistant transactivation of the IL-2 promoter requires activity of okadaic acid-sensitive serine/threonine phosphatases.	Cyclosporine	0-13	interleukin 2	Homo sapiens	47-51
9705263-8	1998	Surprisingly, CyPA-deficient virions remained sensitive to inhibition by CsA, in a manner that depended strongly on the presence of a functional nef gene.	Cyclosporine	73-76	S100 calcium binding protein B	Homo sapiens	145-148
9677321-5	1998	The measured values of the quenching constant, Kq, for interaction of peptides with P-glycoprotein ranged from 200 nM for cyclosporine A to 138 microM for the tripeptide N-acetyl-leucyl-leucyl-norleucinal.	Cyclosporine	122-136	ATP binding cassette subfamily B member 1	Homo sapiens	84-98
9714750-7	1998	Our most recent data shows that a fusion protein of CyP-D and glutathione-S-transferase immobilised to Sepharose specifically binds the ANT from Triton-solubilised inner mitochondrial membranes in a cyclosporin A (CsA) sensitive manner.	Cyclosporine	199-212	peptidylprolyl isomerase F	Homo sapiens	52-57
9714750-7	1998	Our most recent data shows that a fusion protein of CyP-D and glutathione-S-transferase immobilised to Sepharose specifically binds the ANT from Triton-solubilised inner mitochondrial membranes in a cyclosporin A (CsA) sensitive manner.	Cyclosporine	214-217	peptidylprolyl isomerase F	Homo sapiens	52-57
9723955-13	1998	Cyclosporin A significantly stimulated RANTES production at 10(-6) M and IL-8 production at 10(-7) M and 10(-6) M. 5.	Cyclosporine	0-13	C-X-C motif chemokine ligand 8	Homo sapiens	73-77
9756396-3	1998	A biphasic pattern was observed: a 4 h pre-treatment with CsA (1 microM) diminished the fMLP induced [Ca2+]c rise, reactive oxygen species (ROS) production, and beta-glucuronidase release by about 40%, whereas a 20 h pre-treatment increased these responses by about 1.5 fold.	Cyclosporine	58-61	formyl peptide receptor 1	Homo sapiens	88-92
9698296-16	1998	Conversely, PSC inhibited only reactions catalyzed by CYP3A, including cyclosporine A metabolism (IC50 = 6.5 microM) and p-hydroxyphenyl-C3"-paclitaxel formation (Ki = 1.2 microM).	Cyclosporine	71-85	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	54-59
9702422-0	1998	Successful treatment with plasmapheresis, cyclophosphamide, and cyclosporin A in type B syndrome of insulin resistance.	Cyclosporine	64-77	insulin	Homo sapiens	100-107
9664131-1	1998	In an attempt to identify the target protein, P-GP or mrp, of each MDR antagonist, verapamyl (Ver), dipyridamole (Dip), or cyclosporin A (Cy-A), this study was designed to compare the activity of the three afore-mentioned drugs and to test their combined effect on the cidal activity of vincristine (VCR) in five types of wild and the corresponding VCR-resistant cultured cell lines from human leukemia and lymphoma.	Cyclosporine	123-136	ATP binding cassette subfamily C member 1	Homo sapiens	54-57
9702422-14	1998	DISCUSSION: Severe type B insulin resistance may respond favorably to treatment with plasmapheresis and cyclophosphamide followed by cyclosporin A in combination with azathioprin.	Cyclosporine	133-146	insulin	Homo sapiens	26-33
9697878-2	1998	Cyclosporin A (CsA) is an effective downmodulator of Pgp-related MDR in vitro and has already been tested for that purpose in vivo also.	Cyclosporine	15-18	ATP binding cassette subfamily B member 1	Homo sapiens	53-56
9690215-8	1998	The fall in renal iNOS protein in CsA-treated rats was accompanied by a parallel decline in iNOS mRNA abundance and enzymatic activity.	Cyclosporine	34-37	nitric oxide synthase 2	Rattus norvegicus	18-22
9687567-8	1998	Of the mRNAs tested, only those encoding monocyte chemotactic protein-1 (approximately 2-fold over basal) and interleukin-8 (approximately 6-fold over basal) are induced by histamine; both of these responses are suppressed by CsA and FK506.	Cyclosporine	226-229	C-X-C motif chemokine ligand 8	Homo sapiens	110-123
9690215-8	1998	The fall in renal iNOS protein in CsA-treated rats was accompanied by a parallel decline in iNOS mRNA abundance and enzymatic activity.	Cyclosporine	34-37	nitric oxide synthase 2	Rattus norvegicus	92-96
9690215-9	1998	CONCLUSION: Administration of CsA for three weeks resulted in a significant rise in BP together with marked reductions in urinary NOx excretion, and renal and vascular iNOS expression.	Cyclosporine	30-33	nitric oxide synthase 2	Rattus norvegicus	168-172
9723371-0	1998	ecNOS overexpression in CsA-treated renal transplant patients: implications for CsA-induced hypertension.	Cyclosporine	24-27	nitric oxide synthase 3	Homo sapiens	0-5
9655518-4	1998	Although pretreatment with catalase and superoxide dismutase completely abolished reoxygenation-induced generation of ROI, mitochondrial damage was not prevented, as indicated by swelling, loss of the membrane potential, a decrease of the ATP content, and cyclosporin A-sensitive Ca2+ efflux.	Cyclosporine	256-269	catalase	Rattus norvegicus	27-35
9713517-1	1998	The non-immunosuppressive cyclosporine analog SDZ PSC 833 abolished the resistance of human multidrug resistant (MDR-1, P-gp) human promyelocyte leukemia HL-60/VCR cells in vitro to paclitaxel-induced cell cycle- and viability alterations, as well as resistance to paclitaxel-induced radiosensitization.	Cyclosporine	26-38	ATP binding cassette subfamily B member 1	Homo sapiens	113-118
9648082-0	1998	Cyclosporine suppresses rat hepatic cytochrome P450 in a time-dependent manner.	Cyclosporine	0-12	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	36-51
9706856-0	1998	Crevicular fluid interleukin-1beta, tumor necrosis factor-alpha, and interleukin-6 levels in renal transplant patients receiving cyclosporine A.	Cyclosporine	129-143	interleukin 6	Homo sapiens	69-82
9648082-1	1998	BACKGROUND: Cyclosporine is a potent immunosuppressant know to selectively suppress specific cytochrome P450 (P450) isoforms following chronic therapy in the rat.	Cyclosporine	12-24	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	93-108
9714326-0	1998	Cyclosporine A-induced decrease in calbindin-D 28 kDa in rat kidney but not in cerebral cortex and cerebellum.	Cyclosporine	0-14	calbindin 1	Rattus norvegicus	35-49
9717769-9	1998	At 24 hr after Con A treatment, the expression of IFN-gamma mRNA, but not that of TNF-alpha mRNA, was inhibited by cyclosporine A (50 mg/kg, i.p.	Cyclosporine	115-129	interferon gamma	Mus musculus	50-59
9667640-5	1998	In mdr1-negative cells, the median increase in 99Tc(m)-MIBI accumulation with CyA was 30% compared with the mdr1-positive cells with a median increase of 242%, P = 0.009.	Cyclosporine	78-81	ATP binding cassette subfamily B member 1	Homo sapiens	3-7
9603908-0	1998	Cot kinase activates tumor necrosis factor-alpha gene expression in a cyclosporin A-resistant manner.	Cyclosporine	70-83	tumor necrosis factor	Homo sapiens	21-48
9603908-7	1998	TNF-alpha promoter-driven transcription by Cot kinase is partially mediated by MAPK/ERK kinase and is cyclosporin A-resistant.	Cyclosporine	102-115	tumor necrosis factor	Homo sapiens	0-9
9647467-0	1998	Role of reactive oxygen species in the signalling cascade of cyclosporine A-mediated up-regulation of eNOS in vascular endothelial cells.	Cyclosporine	61-75	nitric oxide synthase 3	Bos taurus	102-106
9770112-3	1998	PSC-833 is a non-immunosuppressive cyclosporin derivative that potently and specifically inhibits P-gp.	Cyclosporine	35-46	ATP binding cassette subfamily B member 1	Homo sapiens	98-102
9606192-3	1998	Cyclosporin A, an inhibitor of the Ca2+-dependent phosphatase calcineurin which blocks IL-2 induction, abrogates Ca2+-triggered synergistic JNK activation.	Cyclosporine	0-13	interleukin 2	Homo sapiens	87-91
9606192-3	1998	Cyclosporin A, an inhibitor of the Ca2+-dependent phosphatase calcineurin which blocks IL-2 induction, abrogates Ca2+-triggered synergistic JNK activation.	Cyclosporine	0-13	mitogen-activated protein kinase 8	Homo sapiens	140-143
9647467-2	1998	Cyclosporine A (CsA) increases eNOS mRNA expression in bovine cultured aortic endothelial cells (BAEC).	Cyclosporine	0-14	nitric oxide synthase 3	Bos taurus	31-35
9647467-2	1998	Cyclosporine A (CsA) increases eNOS mRNA expression in bovine cultured aortic endothelial cells (BAEC).	Cyclosporine	16-19	nitric oxide synthase 3	Bos taurus	31-35
9647467-3	1998	As some effects of CsA may be mediated by reactive oxygen species (ROS), present experiments were devoted to test the hypothesis that the CsA-induced eNOS up-regulation could be dependent on an increased synthesis of ROS.	Cyclosporine	138-141	nitric oxide synthase 3	Bos taurus	150-154
9647467-11	1998	The effect of CsA on eNOS mRNA expression was abrogated by catalase, and superoxide dismutase (SOD).	Cyclosporine	14-17	nitric oxide synthase 3	Bos taurus	21-25
9647467-12	1998	In contrast, the antioxidant PDTC augmented eNOS mRNA expression, both in basal conditions and in the presence of CsA.	Cyclosporine	114-117	nitric oxide synthase 3	Bos taurus	44-48
9647467-17	1998	The present results support a role for ROS, particularly superoxide anion and hydrogen peroxide, as mediators of the CsA-induced eNOS mRNA up-regulation.	Cyclosporine	117-120	nitric oxide synthase 3	Bos taurus	129-133
9584155-10	1998	Cyclosporine (CsA), which inhibits stimulus-induced NF-kappaB transcriptional activity, selectively inhibits the stimulus-induced c-Rel nuclear localization and the rapid formation and degradation of c-Rel-IkappaBalpha complexes in the cytosol.	Cyclosporine	0-12	nuclear factor kappa B subunit 1	Homo sapiens	52-61
9584155-10	1998	Cyclosporine (CsA), which inhibits stimulus-induced NF-kappaB transcriptional activity, selectively inhibits the stimulus-induced c-Rel nuclear localization and the rapid formation and degradation of c-Rel-IkappaBalpha complexes in the cytosol.	Cyclosporine	0-12	NFKB inhibitor alpha	Homo sapiens	206-218
9584155-10	1998	Cyclosporine (CsA), which inhibits stimulus-induced NF-kappaB transcriptional activity, selectively inhibits the stimulus-induced c-Rel nuclear localization and the rapid formation and degradation of c-Rel-IkappaBalpha complexes in the cytosol.	Cyclosporine	14-17	nuclear factor kappa B subunit 1	Homo sapiens	52-61
9584155-10	1998	Cyclosporine (CsA), which inhibits stimulus-induced NF-kappaB transcriptional activity, selectively inhibits the stimulus-induced c-Rel nuclear localization and the rapid formation and degradation of c-Rel-IkappaBalpha complexes in the cytosol.	Cyclosporine	14-17	NFKB inhibitor alpha	Homo sapiens	206-218
9584155-11	1998	CsA also inhibits both the prolonged, high rate of IkappaBalpha degradation and the lower level of IkappaBbeta turnover during the second phase of the activation response.	Cyclosporine	0-3	NFKB inhibitor alpha	Homo sapiens	51-63
9777701-0	1998	Effects of cyclosporine A and methotrexate on CD18 expression in recipients of rat cardiac allografts.	Cyclosporine	11-25	integrin subunit beta 2	Rattus norvegicus	46-50
9695116-5	1998	Hence, inhibition of intestinal P-glycoprotein, e.g. by a reversal agent like cyclosporin A, may be a promising strategy for improving the oral bioavailability of P-glycoprotein substrate drugs.	Cyclosporine	78-91	ATP binding cassette subfamily B member 1	Homo sapiens	32-46
9695116-5	1998	Hence, inhibition of intestinal P-glycoprotein, e.g. by a reversal agent like cyclosporin A, may be a promising strategy for improving the oral bioavailability of P-glycoprotein substrate drugs.	Cyclosporine	78-91	ATP binding cassette subfamily B member 1	Homo sapiens	163-177
9575191-0	1998	T lymphocyte activation signals for interleukin-2 production involve activation of MKK6-p38 and MKK7-SAPK/JNK signaling pathways sensitive to cyclosporin A.	Cyclosporine	142-155	interleukin 2	Homo sapiens	36-49
9636621-0	1998	Does cyclosporin promote the secretion of transforming growth factor-beta 1 following pulmonary transplantation?	Cyclosporine	5-16	transforming growth factor beta 1	Homo sapiens	42-75
9575191-0	1998	T lymphocyte activation signals for interleukin-2 production involve activation of MKK6-p38 and MKK7-SAPK/JNK signaling pathways sensitive to cyclosporin A.	Cyclosporine	142-155	mitogen-activated protein kinase kinase 6	Homo sapiens	83-87
9575191-0	1998	T lymphocyte activation signals for interleukin-2 production involve activation of MKK6-p38 and MKK7-SAPK/JNK signaling pathways sensitive to cyclosporin A.	Cyclosporine	142-155	mitogen-activated protein kinase kinase 7	Homo sapiens	96-100
9575191-0	1998	T lymphocyte activation signals for interleukin-2 production involve activation of MKK6-p38 and MKK7-SAPK/JNK signaling pathways sensitive to cyclosporin A.	Cyclosporine	142-155	mitogen-activated protein kinase 9	Homo sapiens	101-105
9575191-0	1998	T lymphocyte activation signals for interleukin-2 production involve activation of MKK6-p38 and MKK7-SAPK/JNK signaling pathways sensitive to cyclosporin A.	Cyclosporine	142-155	mitogen-activated protein kinase 8	Homo sapiens	106-109
9575191-7	1998	Cyclosporin A, a potent immunosuppressant, inhibited activation of both p38 and SAPK/JNK pathways but not the MAPK/extracellular signal-regulated kinase (ERK) pathway.	Cyclosporine	0-13	mitogen-activated protein kinase 14	Homo sapiens	72-75
9575191-7	1998	Cyclosporin A, a potent immunosuppressant, inhibited activation of both p38 and SAPK/JNK pathways but not the MAPK/extracellular signal-regulated kinase (ERK) pathway.	Cyclosporine	0-13	mitogen-activated protein kinase 9	Homo sapiens	80-84
9575191-7	1998	Cyclosporin A, a potent immunosuppressant, inhibited activation of both p38 and SAPK/JNK pathways but not the MAPK/extracellular signal-regulated kinase (ERK) pathway.	Cyclosporine	0-13	mitogen-activated protein kinase 8	Homo sapiens	85-88
9575191-8	1998	Our results indicate that both MKK6 to p38 and MKK7 to SAPK/JNK signaling pathways are activated in a cyclosporin A-sensitive manner and contribute to IL-2 gene expression in T lymphocytes.	Cyclosporine	102-115	mitogen-activated protein kinase kinase 6	Homo sapiens	31-35
9575191-8	1998	Our results indicate that both MKK6 to p38 and MKK7 to SAPK/JNK signaling pathways are activated in a cyclosporin A-sensitive manner and contribute to IL-2 gene expression in T lymphocytes.	Cyclosporine	102-115	mitogen-activated protein kinase 14	Homo sapiens	39-42
9575191-8	1998	Our results indicate that both MKK6 to p38 and MKK7 to SAPK/JNK signaling pathways are activated in a cyclosporin A-sensitive manner and contribute to IL-2 gene expression in T lymphocytes.	Cyclosporine	102-115	mitogen-activated protein kinase kinase 7	Homo sapiens	47-51
9575191-8	1998	Our results indicate that both MKK6 to p38 and MKK7 to SAPK/JNK signaling pathways are activated in a cyclosporin A-sensitive manner and contribute to IL-2 gene expression in T lymphocytes.	Cyclosporine	102-115	mitogen-activated protein kinase 9	Homo sapiens	55-59
9575191-8	1998	Our results indicate that both MKK6 to p38 and MKK7 to SAPK/JNK signaling pathways are activated in a cyclosporin A-sensitive manner and contribute to IL-2 gene expression in T lymphocytes.	Cyclosporine	102-115	mitogen-activated protein kinase 8	Homo sapiens	60-63
9575191-8	1998	Our results indicate that both MKK6 to p38 and MKK7 to SAPK/JNK signaling pathways are activated in a cyclosporin A-sensitive manner and contribute to IL-2 gene expression in T lymphocytes.	Cyclosporine	102-115	interleukin 2	Homo sapiens	151-155
9620363-3	1998	NFAT acts at the antigen receptor response element-2 (ARRE-2) sequence in the IL-2 enhancer and is the nuclear target of T cell stimulation signals and the immunosuppressant drugs cyclosporine (Sandimmune) and FK-506 (tacrolimus), which are potent inhibitors of IL-2 gene transcription.	Cyclosporine	180-192	interleukin 2	Homo sapiens	78-82
9603174-10	1998	Cyclosporine partially, but not completely, inhibits the development of CD30+ cells, and has a greater effect on interferon-gamma production than on interleukin-5 production.	Cyclosporine	0-12	interferon gamma	Homo sapiens	113-129
9613782-11	1998	In addition, CD4+ lymphocytes play an important role in the pathogenesis of CsA-induced GVHD.	Cyclosporine	76-79	CD4 molecule	Homo sapiens	13-16
9603451-3	1998	In the presence of cyclosporin A this induction is almost halved, suggesting that transcription factors of the NFAT family contribute to kappa 3" enhancer induction.	Cyclosporine	19-32	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	111-115
9603452-2	1998	We studied the in vitro effect of CsA on IFN-gamma production.	Cyclosporine	34-37	interferon gamma	Homo sapiens	41-50
9603452-5	1998	IL-2 production was hardly affected by CsA under these stimulating conditions, while IFN-gamma (at the protein and mRNA level) was markedly stimulated by CsA.	Cyclosporine	154-157	interferon gamma	Homo sapiens	85-94
9603452-7	1998	Inhibition of IL-10 production, and to a lesser degree of IL-4 production, by CD4+ cells was responsible for the enhancement of IFN-gamma production in the presence of CsA.	Cyclosporine	168-171	interleukin 4	Homo sapiens	58-62
9603452-7	1998	Inhibition of IL-10 production, and to a lesser degree of IL-4 production, by CD4+ cells was responsible for the enhancement of IFN-gamma production in the presence of CsA.	Cyclosporine	168-171	CD4 molecule	Homo sapiens	78-81
9603452-7	1998	Inhibition of IL-10 production, and to a lesser degree of IL-4 production, by CD4+ cells was responsible for the enhancement of IFN-gamma production in the presence of CsA.	Cyclosporine	168-171	interferon gamma	Homo sapiens	128-137
9603452-8	1998	In conclusion, IFN-gamma production by CD28-co-stimulated CD4+ T cells is resistant to inhibition by CsA and can even be facilitated by CsA as a result of removing a negative regulatory signal which is mainly IL-10 mediated.	Cyclosporine	101-104	interferon gamma	Homo sapiens	15-24
9603452-8	1998	In conclusion, IFN-gamma production by CD28-co-stimulated CD4+ T cells is resistant to inhibition by CsA and can even be facilitated by CsA as a result of removing a negative regulatory signal which is mainly IL-10 mediated.	Cyclosporine	101-104	CD4 molecule	Homo sapiens	58-61
9603452-8	1998	In conclusion, IFN-gamma production by CD28-co-stimulated CD4+ T cells is resistant to inhibition by CsA and can even be facilitated by CsA as a result of removing a negative regulatory signal which is mainly IL-10 mediated.	Cyclosporine	136-139	interferon gamma	Homo sapiens	15-24
9603452-8	1998	In conclusion, IFN-gamma production by CD28-co-stimulated CD4+ T cells is resistant to inhibition by CsA and can even be facilitated by CsA as a result of removing a negative regulatory signal which is mainly IL-10 mediated.	Cyclosporine	136-139	CD4 molecule	Homo sapiens	58-61
9620363-3	1998	NFAT acts at the antigen receptor response element-2 (ARRE-2) sequence in the IL-2 enhancer and is the nuclear target of T cell stimulation signals and the immunosuppressant drugs cyclosporine (Sandimmune) and FK-506 (tacrolimus), which are potent inhibitors of IL-2 gene transcription.	Cyclosporine	180-192	interleukin 2	Homo sapiens	262-266
9713630-7	1998	It was found that CsA inhibits basal secretion of TNF-alpha and IL-8 at 20 and 200 ng ml-1.	Cyclosporine	18-21	tumor necrosis factor	Homo sapiens	50-59
9606735-1	1998	The immunosuppressive drug cyclosporine A (CsA), is metabolized by cytochrome P-450 IIIA.	Cyclosporine	27-41	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	67-83
9606735-1	1998	The immunosuppressive drug cyclosporine A (CsA), is metabolized by cytochrome P-450 IIIA.	Cyclosporine	43-46	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	67-83
9606735-7	1998	Cyclosporin-induced lipid peroxidation and affected cytochrome P-450 may even contribute to cyclosporine nephrotoxicity.	Cyclosporine	0-11	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	52-68
9606735-7	1998	Cyclosporin-induced lipid peroxidation and affected cytochrome P-450 may even contribute to cyclosporine nephrotoxicity.	Cyclosporine	92-104	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	52-68
9606735-14	1998	The specific content of cytochrome P-450 in microsomal liver suspension was increased in group CsA + Sili (1.179 +/- 0.115 nmol/mg prot) compared to control group (0.775 +/- 0.086 nmol/mg prot., p &lt; 0.05) and also CsA group (0.806 +/- 0.098 nmol/mg prot., p &lt; 0.05).	Cyclosporine	95-98	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	24-40
9606735-17	1998	Administration of both drugs (CsA + sili) increased the specific content of cytochrome P-450 in liver microsomes.	Cyclosporine	30-33	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	76-92
9606735-18	1998	This suggests that the effect of silibinin on cyclosporine biotransformation in the liver is via cytochrome P-450.	Cyclosporine	46-58	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	97-113
9713630-7	1998	It was found that CsA inhibits basal secretion of TNF-alpha and IL-8 at 20 and 200 ng ml-1.	Cyclosporine	18-21	C-X-C motif chemokine ligand 8	Homo sapiens	64-68
9583867-6	1998	The percentage of CD4+ T cells producing IL-2 was negatively correlated with the CsA level (Rc=-0.0821, P=0.00002297) but not with prednisolone or azathioprine doses.	Cyclosporine	81-84	interleukin 2	Homo sapiens	41-45
9584827-7	1998	NK effector cell generation stimulated by xenogeneic cells was cyclosporin A (CsA) sensitive and dependent on the presence of autologous responder T lymphocytes, a dependence that was completely reconstituted by the sole addition of human IL-2.	Cyclosporine	63-76	interleukin 2	Homo sapiens	239-243
9584827-7	1998	NK effector cell generation stimulated by xenogeneic cells was cyclosporin A (CsA) sensitive and dependent on the presence of autologous responder T lymphocytes, a dependence that was completely reconstituted by the sole addition of human IL-2.	Cyclosporine	78-81	interleukin 2	Homo sapiens	239-243
9583867-9	1998	CONCLUSIONS: These data suggest that the functional effects of CsA in transplant recipients can be quantitatively determined and that the capacity of CD4+ T cells to produce IL-2 upon stimulation constitutes a functional parameter of CsA effects on the immune system.	Cyclosporine	234-237	interleukin 2	Homo sapiens	174-178
9583867-8	1998	The percentage of CD8+ T cells capable of producing IL-2 was inversely correlated to CsA levels (Rc=-0.0375, P=0.0011).	Cyclosporine	85-88	interleukin 2	Homo sapiens	52-56
9525923-8	1998	A fusion protein containing the cyclophilin domain of matrin CYP exhibits cyclosporin A (CsA)-sensitive, peptidylprolyl cis-trans-isomerase activity that is characteristic of native cyclophilins.	Cyclosporine	74-87	peptidylprolyl isomerase G	Rattus norvegicus	54-64
9565100-8	1998	Low pharmacologic concentrations of tacrolimus/cyclosporine (CsA) and mycophenolic acid (MPA) singly or in combination had no effect on the spontaneous proliferation of DBMC and had significantly less inhibitory activity on MLC responses of DBMC and its purified CD3+ or CD34+ subpopulations, compared with the responses of spleen cells.	Cyclosporine	47-59	CD34 molecule	Homo sapiens	271-275
9565100-8	1998	Low pharmacologic concentrations of tacrolimus/cyclosporine (CsA) and mycophenolic acid (MPA) singly or in combination had no effect on the spontaneous proliferation of DBMC and had significantly less inhibitory activity on MLC responses of DBMC and its purified CD3+ or CD34+ subpopulations, compared with the responses of spleen cells.	Cyclosporine	61-64	CD34 molecule	Homo sapiens	271-275
9525923-8	1998	A fusion protein containing the cyclophilin domain of matrin CYP exhibits cyclosporin A (CsA)-sensitive, peptidylprolyl cis-trans-isomerase activity that is characteristic of native cyclophilins.	Cyclosporine	89-92	peptidylprolyl isomerase like 3	Rattus norvegicus	182-194
9525923-8	1998	A fusion protein containing the cyclophilin domain of matrin CYP exhibits cyclosporin A (CsA)-sensitive, peptidylprolyl cis-trans-isomerase activity that is characteristic of native cyclophilins.	Cyclosporine	74-87	peptidylprolyl isomerase like 3	Rattus norvegicus	182-194
9525923-9	1998	Although total rat liver nuclei contains predominantly CsA-resistant PPIase activity, the corresponding activity in the nuclear matrix is largely CsA-sensitive.	Cyclosporine	55-58	peptidylprolyl isomerase like 3	Rattus norvegicus	69-75
9525923-8	1998	A fusion protein containing the cyclophilin domain of matrin CYP exhibits cyclosporin A (CsA)-sensitive, peptidylprolyl cis-trans-isomerase activity that is characteristic of native cyclophilins.	Cyclosporine	89-92	peptidylprolyl isomerase G	Rattus norvegicus	54-64
9630010-1	1998	Tacrolimus (FK506) and cyclosporin A (CsA) are two potent immunosuppressants mainly metabolized by hepatic cytochrome P-450 3A (CYP3A) monooxygenase.	Cyclosporine	23-36	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	107-126
9630010-1	1998	Tacrolimus (FK506) and cyclosporin A (CsA) are two potent immunosuppressants mainly metabolized by hepatic cytochrome P-450 3A (CYP3A) monooxygenase.	Cyclosporine	23-36	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	128-133
9749227-10	1998	Cyclosporine is metabolised in the liver by cytochrome P450 3A4 dependant enzymes.	Cyclosporine	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	44-63
9630010-1	1998	Tacrolimus (FK506) and cyclosporin A (CsA) are two potent immunosuppressants mainly metabolized by hepatic cytochrome P-450 3A (CYP3A) monooxygenase.	Cyclosporine	38-41	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	107-126
9630010-1	1998	Tacrolimus (FK506) and cyclosporin A (CsA) are two potent immunosuppressants mainly metabolized by hepatic cytochrome P-450 3A (CYP3A) monooxygenase.	Cyclosporine	38-41	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	128-133
9630010-7	1998	It is hypothesized that the interaction between the two drugs relies on a mechanism involving both competition of FK506 and CsA for CYP3A and of their immunophilin complexes for a common site on the calcineurin-calmodulin complex.	Cyclosporine	124-127	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	132-137
9531290-8	1998	Furthermore, B cell proliferation through CD72 was blocked by the immunosuppressive agents cyclosporin A and FK506, indicating the important role for Ca2+-regulated activation events similar to BCR-stimulated cells.	Cyclosporine	91-104	CD72 antigen	Mus musculus	42-46
9605438-0	1998	The cyclosporine A-induced decrease in rat renal calbindin-D28kDa protein as a consequence of a decrease in its mRNA.	Cyclosporine	4-18	calbindin 1	Rattus norvegicus	49-62
9605438-2	1998	We recently reported that relatively high doses of CsA markedly decreased the calcium-binding protein calbindin-D28kDa in kidneys of male Wistar rats, and showed that this decrease could be associated with some of the drug-induced adverse renal effects.	Cyclosporine	51-54	calbindin 1	Rattus norvegicus	102-115
9605438-3	1998	To investigate the events leading to this decrease, the calbindin-D28kDa mRNA level in kidneys of rats treated with 15 or 50 mg/kg/day CsA for 12 days was analysed by reverse transcription followed by polymerase chain reaction.	Cyclosporine	135-138	calbindin 1	Rattus norvegicus	56-69
9605438-5	1998	Thus, the CsA-mediated down-regulation of the renal calbindin-D28kDa protein is most likely the result of a decrease in the calbindin-D28kDa mRNA level.	Cyclosporine	10-13	calbindin 1	Rattus norvegicus	52-65
9605438-5	1998	Thus, the CsA-mediated down-regulation of the renal calbindin-D28kDa protein is most likely the result of a decrease in the calbindin-D28kDa mRNA level.	Cyclosporine	10-13	calbindin 1	Rattus norvegicus	124-137
9566840-15	1998	However, constitutive CYP3A4, which represents 50% of total CYP and metabolises drugs like nifedipine, warfarin, acetaminophen, cyclosporin and FK-506, is reduced during liver regeneration.	Cyclosporine	128-139	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	22-25
9551396-14	1998	Cyclosporine A induced apoptosis is partially mediated by angiotensin II and nitric oxide inhibition, suggesting a role for renal ischemia in this process, and CsA induced apoptosis correlates with interstitial fibrosis.	Cyclosporine	0-14	angiotensinogen	Rattus norvegicus	58-72
9568730-1	1998	A monoclonal antibody (mAb) directed against the extracellular domain of the IFNAR1 chain of the human interferon-alpha (IFN-alpha) receptor (IFN-alphaR), which inhibits activation of the Jak-Stat signal transduction pathway, administered together with a subeffective dose of cyclosporine induced prolonged survival of skin allografts in major histocompatibility complex (MHC) divergent cynomolgus monkeys.	Cyclosporine	276-288	interferon alpha 1	Homo sapiens	121-130
9558194-2	1998	Cyclosporine therapy induced a remission of receptor antibody mediated insulin resistance and controlled clinical manifestations of her systemic lupus erythematosus and dermatomyositis, but had no effect on the sclerodermatous features of her illness.	Cyclosporine	0-12	insulin	Homo sapiens	71-78
9678635-4	1998	Cyclosporin A (CysA 50 microM), another calcineurin inhibitor, showed a similar inhibitory effect on TEA-induced LTP.	Cyclosporine	0-13	calcineurin binding protein 1	Mus musculus	40-61
9516487-2	1998	The cell death resulting from induction of the overexpression of Bax was prevented by inhibition of the mitochondrial permeability transition (MPT) with cyclosporin A (CyA) in combination with the phospholipase A2 inhibitor aristolochic acid (ArA).	Cyclosporine	153-166	BCL2 associated X, apoptosis regulator	Homo sapiens	65-68
9516487-2	1998	The cell death resulting from induction of the overexpression of Bax was prevented by inhibition of the mitochondrial permeability transition (MPT) with cyclosporin A (CyA) in combination with the phospholipase A2 inhibitor aristolochic acid (ArA).	Cyclosporine	168-171	BCL2 associated X, apoptosis regulator	Homo sapiens	65-68
9506530-6	1998	The P-glycoprotein-mediated multidrug resistance (MDR)-reversing agents verapamil, cyclosporin A, quinidine, sodium orthovanadate and tamoxifen significantly increased dox fluorescence at this depth, whereas genistein, indomethacin, probenecid and brefeldin A, which reverse multidrug-resistance-associated protein (MRP) function, exerted no effect.	Cyclosporine	83-96	ATP binding cassette subfamily B member 1	Homo sapiens	4-18
9580169-7	1998	We found that PTH/PTHrP receptor mRNA was unchanged, but PTHrP mRNA, and also transforming growth factor-beta1 mRNA expression as positive control, was about twofold increased in the kidney of CsA-treated rats.	Cyclosporine	193-196	transforming growth factor, beta 1	Rattus norvegicus	78-110
9685211-1	1998	Although the immunosuppressive drugs FK506, rapamycin and cyclosporin A have been reported to potentiate transcriptional activation mediated by a non-saturating concentration of the glucocorticoid receptor agonist dexamethasone, the precise mechanism(s) underlying these responses remains unclear.	Cyclosporine	58-71	nuclear receptor subfamily 3 group C member 1	Homo sapiens	182-205
9506534-9	1998	P-gp function modulators (verapamil and cyclosporin A) were able to modify DOX intracytoplasmic distribution and to increase drug intracellular concentration and cytotoxic effect in melanoma cells.	Cyclosporine	40-53	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
9567214-7	1998	Results from our group and others have suggested that overexpression of P-gp in renal tubular and mesangial cells prevents pharmacological nephrotoxicity by cyclosporin A (CsA).	Cyclosporine	172-175	ATP binding cassette subfamily B member 1	Homo sapiens	72-76
9515964-5	1998	As in T cells, nuclear translocation of NF-ATc in cardiac endothelial cells is controlled by the calcium-regulated phosphatase calcineurin: NF-ATc remains cytoplasmic in normal embryos cultured with cyclosporin A, an inhibitor of calcineurin.	Cyclosporine	199-212	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	40-46
9580328-4	1998	Overexpression of Bcl-2 and pretreatment with either the immunosuppressant cyclosporin A or the glutathione precursor N-acetyl-L-cysteine blocked deltapsi(m) disruption and apoptosis, but not the generation of ROS induced by these compounds.	Cyclosporine	75-88	BCL2 apoptosis regulator	Homo sapiens	18-23
9559874-3	1998	We observe that the release of cytochrome c from purified mitochondria is stimulated by the classical inducers of MPT, and is inhibited by the classical inhibitor of MPT, cyclosporin A (CsA).	Cyclosporine	171-184	cytochrome c, somatic	Homo sapiens	31-43
9559874-3	1998	We observe that the release of cytochrome c from purified mitochondria is stimulated by the classical inducers of MPT, and is inhibited by the classical inhibitor of MPT, cyclosporin A (CsA).	Cyclosporine	186-189	cytochrome c, somatic	Homo sapiens	31-43
9559874-4	1998	After induction of MPT, mitochondrial supernatants gained the activity to induce cleavage of caspase 3 (CPP32) in cytosolic extracts, and this gain of activity was inhibited by CsA pretreatment of mitochondria, and was cancelled by immunodepletion of cytochrome c from the supernatants.	Cyclosporine	177-180	caspase 3	Homo sapiens	93-102
9567214-11	1998	This way, the detoxicant function of P-gp against products of the ras catabolism could mediate their accumulation when the "vacuum cleaner" function is blocked by CsA or tacrolimus, contributing to the initial development of fibroblastic activation that leads to interstitial fibrosis associated with nephrotoxicity by these immunosuppressor drugs.	Cyclosporine	163-166	ATP binding cassette subfamily B member 1	Homo sapiens	37-41
9559874-4	1998	After induction of MPT, mitochondrial supernatants gained the activity to induce cleavage of caspase 3 (CPP32) in cytosolic extracts, and this gain of activity was inhibited by CsA pretreatment of mitochondria, and was cancelled by immunodepletion of cytochrome c from the supernatants.	Cyclosporine	177-180	caspase 3	Homo sapiens	104-109
9559874-4	1998	After induction of MPT, mitochondrial supernatants gained the activity to induce cleavage of caspase 3 (CPP32) in cytosolic extracts, and this gain of activity was inhibited by CsA pretreatment of mitochondria, and was cancelled by immunodepletion of cytochrome c from the supernatants.	Cyclosporine	177-180	cytochrome c, somatic	Homo sapiens	251-263
9640246-7	1998	In sharp contrast T-cell proliferation mediated by anti-CD6 in the presence of TPA was efficiently blocked by CsA.	Cyclosporine	110-113	CD6 molecule	Homo sapiens	56-59
9559874-5	1998	After induction of MPT, mitochondrial supernatants mixed with or without cytosolic extract gained the activity to ladder nuclei, and this gain of activity was inhibited by CsA pretreatment of mitochondria, and cancelled by immunodepletion of cytochrome c from the supernatants.	Cyclosporine	172-175	cytochrome c, somatic	Homo sapiens	242-254
9640246-6	1998	T-cell proliferation mediated through CD6/CD28 was only partially blocked by the immunosuppressive drug, cyclosporin A (CsA), whereas anti-CD28-induced T-cell proliferation in the presence of the phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA), was unaffected.	Cyclosporine	105-118	CD6 molecule	Homo sapiens	38-41
9640246-6	1998	T-cell proliferation mediated through CD6/CD28 was only partially blocked by the immunosuppressive drug, cyclosporin A (CsA), whereas anti-CD28-induced T-cell proliferation in the presence of the phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA), was unaffected.	Cyclosporine	120-123	CD6 molecule	Homo sapiens	38-41
9570481-2	1998	A variety of small molecules, such as verapamil and cyclosporin A, bind to P-glycoprotein and inhibit its ability to pump out antitumor drugs.	Cyclosporine	52-65	ATP binding cassette subfamily B member 1	Homo sapiens	75-89
9498773-9	1998	Moreover, this DNA binding was inhibited by cyclosporin A, indicating that NFATx nuclear translocation was regulated by the calcineurin phosphatase in DP thymocytes.	Cyclosporine	44-57	nuclear factor of activated T cells 3	Homo sapiens	75-80
9532170-0	1998	Prevention of diabetes recurrence after syngeneic islet transplantation in NOD mice by analogues of 1,25(OH)2D3 in combination with cyclosporin A: mechanism of action involves an immune shift from Th1 to Th2.	Cyclosporine	132-145	negative elongation factor complex member C/D, Th1l	Mus musculus	197-200
9484745-0	1998	In vivo expression of transforming growth factor-beta1 in humans: stimulation by cyclosporine.	Cyclosporine	81-93	transforming growth factor beta 1	Homo sapiens	22-54
9484745-2	1998	In an earlier in vitro study, we demonstrated that cyclosporine (CsA) increases TGF-beta1 transcription rate in human T lymphocytes.	Cyclosporine	51-63	transforming growth factor beta 1	Homo sapiens	80-89
9484745-2	1998	In an earlier in vitro study, we demonstrated that cyclosporine (CsA) increases TGF-beta1 transcription rate in human T lymphocytes.	Cyclosporine	65-68	transforming growth factor beta 1	Homo sapiens	80-89
9484745-3	1998	Herein, we explored whether CsA augments the in vivo expression of TGF-beta1 in humans.	Cyclosporine	28-31	transforming growth factor beta 1	Homo sapiens	67-76
9484745-6	1998	RESULTS: Our studies demonstrated a significant increase in TGF-beta1 expression after CsA therapy.	Cyclosporine	87-90	transforming growth factor beta 1	Homo sapiens	60-69
9484745-8	1998	CONCLUSIONS: Our first-time demonstration of a TGF-beta1-selective in vivo stimulatory effect of CsA in humans: (1) advances a TGF-beta1-centered hypothesis for the beneficial (immunosuppression) and detrimental (fibrosis, hypertension) effects of CsA use, and (2) broadens the mechanism of immunosuppressive action of CsA to include heightened expression of an endogenous immunosuppressive cytokine.	Cyclosporine	97-100	transforming growth factor beta 1	Homo sapiens	47-56
9484745-8	1998	CONCLUSIONS: Our first-time demonstration of a TGF-beta1-selective in vivo stimulatory effect of CsA in humans: (1) advances a TGF-beta1-centered hypothesis for the beneficial (immunosuppression) and detrimental (fibrosis, hypertension) effects of CsA use, and (2) broadens the mechanism of immunosuppressive action of CsA to include heightened expression of an endogenous immunosuppressive cytokine.	Cyclosporine	97-100	transforming growth factor beta 1	Homo sapiens	127-136
9484745-8	1998	CONCLUSIONS: Our first-time demonstration of a TGF-beta1-selective in vivo stimulatory effect of CsA in humans: (1) advances a TGF-beta1-centered hypothesis for the beneficial (immunosuppression) and detrimental (fibrosis, hypertension) effects of CsA use, and (2) broadens the mechanism of immunosuppressive action of CsA to include heightened expression of an endogenous immunosuppressive cytokine.	Cyclosporine	248-251	transforming growth factor beta 1	Homo sapiens	47-56
9484745-8	1998	CONCLUSIONS: Our first-time demonstration of a TGF-beta1-selective in vivo stimulatory effect of CsA in humans: (1) advances a TGF-beta1-centered hypothesis for the beneficial (immunosuppression) and detrimental (fibrosis, hypertension) effects of CsA use, and (2) broadens the mechanism of immunosuppressive action of CsA to include heightened expression of an endogenous immunosuppressive cytokine.	Cyclosporine	248-251	transforming growth factor beta 1	Homo sapiens	47-56
9469504-4	1998	Because cyclosporine is metabolized predominantly by CYP3A3/4 isoenzymes, inhibition of this system can lead to the buildup of toxic levels.	Cyclosporine	8-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	53-59
9482283-9	1998	When MCS were incubated with verapamil, cyclosporin A, orthovanadate, and quinidine, which are known to reverse P-glycoprotein (Pgp)-mediated multidrug resistance (MDR), Dox accumulated also in deeper cell layers.	Cyclosporine	40-53	ATP binding cassette subfamily B member 1	Homo sapiens	112-126
9466796-6	1998	We also demonstrated the additive effects of NP2214 and cyclosporine A which act mechanistically distinctly in inhibiting costimulation-induced IL-2 synthesis.	Cyclosporine	56-70	interleukin 2	Homo sapiens	144-148
9482283-9	1998	When MCS were incubated with verapamil, cyclosporin A, orthovanadate, and quinidine, which are known to reverse P-glycoprotein (Pgp)-mediated multidrug resistance (MDR), Dox accumulated also in deeper cell layers.	Cyclosporine	40-53	ATP binding cassette subfamily B member 1	Homo sapiens	128-131
9454803-0	1998	Lipid transfer protein I facilitated transfer of cyclosporine from low- to high-density lipoproteins is only partially dependent on its cholesteryl ester transfer activity.	Cyclosporine	49-61	cholesteryl ester transfer protein	Homo sapiens	0-24
9493129-5	1998	These effects of insulin were completely blocked by cyclosporin-A, an inhibitor of protein phosphatase type 2B (PP2B) which dephosphorylates phospho-tyrosine in addition to phosphoserine/threonine, but not by okadaic acid, an inhibitor of protein phosphatase type 1 and 2A.	Cyclosporine	52-65	insulin	Homo sapiens	17-24
9597807-1	1998	A P-glycoprotein (P-gp) inhibitor, cyclosporin A (CsA) was found to enhance the susceptibility of multidrug resistant (MDR) cancer cells to anti-P-gp antibody-dependent cellular cytolysis (ADCC) by monocytes, but the exact mechanism is unknown.	Cyclosporine	50-53	ATP binding cassette subfamily B member 1	Homo sapiens	2-16
9597807-1	1998	A P-glycoprotein (P-gp) inhibitor, cyclosporin A (CsA) was found to enhance the susceptibility of multidrug resistant (MDR) cancer cells to anti-P-gp antibody-dependent cellular cytolysis (ADCC) by monocytes, but the exact mechanism is unknown.	Cyclosporine	50-53	ATP binding cassette subfamily B member 1	Homo sapiens	18-22
9597807-1	1998	A P-glycoprotein (P-gp) inhibitor, cyclosporin A (CsA) was found to enhance the susceptibility of multidrug resistant (MDR) cancer cells to anti-P-gp antibody-dependent cellular cytolysis (ADCC) by monocytes, but the exact mechanism is unknown.	Cyclosporine	50-53	ATP binding cassette subfamily B member 1	Homo sapiens	145-149
9597807-2	1998	In this study, we examined whether CsA enhanced the susceptibility of MDR cells through its inhibitory effect of P-gp function by using anti-ganglioside GM2 (GM2) monoclonal antibody (Ab), KM966, instead of anti-P-gp Ab, MRK16.	Cyclosporine	35-38	ATP binding cassette subfamily B member 1	Homo sapiens	113-117
9597807-2	1998	In this study, we examined whether CsA enhanced the susceptibility of MDR cells through its inhibitory effect of P-gp function by using anti-ganglioside GM2 (GM2) monoclonal antibody (Ab), KM966, instead of anti-P-gp Ab, MRK16.	Cyclosporine	35-38	ATP binding cassette subfamily B member 1	Homo sapiens	212-216
9597807-3	1998	Monocyte-ADCC induced by both KM966 and MRK16 against P-gp positive human MDR ovarian cancer cells was significantly augmented by addition of CsA.	Cyclosporine	142-145	ATP binding cassette subfamily B member 1	Homo sapiens	54-58
9597807-4	1998	KM966, but not MRK16, induced monocyte-ADCC against P-gp negative human ovarian cancer cells and CsA enhanced this ADCC activity, indicating that suppressive effect of P-gp function by CsA was not essential to the enhancement of ADCC.	Cyclosporine	185-188	ATP binding cassette subfamily B member 1	Homo sapiens	168-172
9465841-1	1998	INTRODUCTION: Sirolimus and cyclosporine (INN, ciclosporin) share the same cytochrome P4503A metabolic pathways, and both drugs are substrates for p-glycoprotein countertransport.	Cyclosporine	28-40	ATP binding cassette subfamily B member 1	Homo sapiens	147-161
9588080-0	1998	[Production of IL-8 by the THP-1 monocyte cell line is regulated differently by cyclosporin and retinoic acid].	Cyclosporine	80-91	C-X-C motif chemokine ligand 8	Homo sapiens	15-19
9588080-0	1998	[Production of IL-8 by the THP-1 monocyte cell line is regulated differently by cyclosporin and retinoic acid].	Cyclosporine	80-91	GLI family zinc finger 2	Homo sapiens	27-32
9588080-7	1998	The aim of the experiment was to find out CsA effect and RA effect on production of IL-8 by THP-1 cell line.	Cyclosporine	42-45	C-X-C motif chemokine ligand 8	Homo sapiens	84-88
9588080-7	1998	The aim of the experiment was to find out CsA effect and RA effect on production of IL-8 by THP-1 cell line.	Cyclosporine	42-45	GLI family zinc finger 2	Homo sapiens	92-97
9588080-11	1998	It was found out that CsA inhibits IL-8 production by stimulated THP-1 monocyte cell line in dose dependence course.	Cyclosporine	22-25	C-X-C motif chemokine ligand 8	Homo sapiens	35-39
9588080-11	1998	It was found out that CsA inhibits IL-8 production by stimulated THP-1 monocyte cell line in dose dependence course.	Cyclosporine	22-25	GLI family zinc finger 2	Homo sapiens	65-70
9465841-1	1998	INTRODUCTION: Sirolimus and cyclosporine (INN, ciclosporin) share the same cytochrome P4503A metabolic pathways, and both drugs are substrates for p-glycoprotein countertransport.	Cyclosporine	47-58	ATP binding cassette subfamily B member 1	Homo sapiens	147-161
9443793-4	1998	CsA administration resulted in a dose-dependent increase in serum osteocalcin levels and in histomorphometric indices of cancellous bone turnover in the axial skeleton.	Cyclosporine	0-3	bone gamma-carboxyglutamate protein	Rattus norvegicus	66-77
9438415-4	1998	Coincubation with 1 microM of this cyclosporin derivative restored the apoptotic potential of 10 ng/ml TNF-alpha.	Cyclosporine	35-46	tumor necrosis factor	Homo sapiens	103-112
10474025-6	1998	Finally, proliferation of B16F10 cells in the presence of several doses of CsA did not vary and CsA increased the amount of IL-1beta mRNA expression.	Cyclosporine	96-99	interleukin 1 beta	Mus musculus	124-132
9595512-5	1998	Heparin (1-20 U/ml) suppressed cyclosporine-induced ET-1 mRNA expression in a dose-dependent manner.	Cyclosporine	31-43	endothelin 1	Rattus norvegicus	52-56
9595512-0	1998	Heparin suppresses cyclosporine-induced endothelin-1 synthesis in rat endothelial cells.	Cyclosporine	19-31	endothelin 1	Rattus norvegicus	40-52
9595512-1	1998	Cyclosporine stimulates vasoconstrictor endothelin-1 (ET-1) synthesis.	Cyclosporine	0-12	endothelin 1	Rattus norvegicus	40-52
9595512-7	1998	These results suggest that heparin suppresses cyclosporine-induced ET-1 mRNA expression via both NO- and calmodulin-dependent pathways.	Cyclosporine	46-58	endothelin 1	Rattus norvegicus	67-71
9595512-1	1998	Cyclosporine stimulates vasoconstrictor endothelin-1 (ET-1) synthesis.	Cyclosporine	0-12	endothelin 1	Rattus norvegicus	54-58
9488111-8	1998	After CsA administration the IL-1beta mRNA was similar to control rats.	Cyclosporine	6-9	interleukin 1 beta	Rattus norvegicus	29-37
9595512-2	1998	This study examined the effect of heparin on cyclosporine-induced ET-1 synthesis in Wistar rat aortic endothelial cells in culture.	Cyclosporine	45-57	endothelin 1	Rattus norvegicus	66-70
9595512-3	1998	Cyclosporine (0.01-5 mumol/L) stimulated ET-1 mRNA expression in a dose-dependent manner.	Cyclosporine	0-12	endothelin 1	Rattus norvegicus	41-45
9524320-1	1998	This study investigates a potential role for TGF beta 1 in the pathogenesis of cyclosporin A-induced gingival overgrowth (CsA-OG).	Cyclosporine	79-92	transforming growth factor beta 1	Homo sapiens	45-55
9749826-5	1998	The increase of IL-8 in astrocyte-rich cultures induced by acidosis was potentiated by treatment with glutamate, which enhanced the increase of cytosolic Ca2+ levels under acidosis, and was affected by extracellular Ca2+ conditions, by cyclosporine A, an inhibitor of calcineurin, and by trifluoperazine, an inhibitor of phospholipase A2.	Cyclosporine	236-250	C-X-C motif chemokine ligand 8	Homo sapiens	16-20
9496739-2	1998	Although no change was observed in superoxide dismutase (SOD) activity, glutathione peroxidase (GSH-Px) and catalase (CAT) activities were found decreased in kidney tissue exposed to CsA for 10 days compared with control tissue.	Cyclosporine	183-186	catalase	Oryctolagus cuniculus	108-116
9525702-6	1998	Nevertheless, there are several pathophysiological situations including unilateral ureteral obstruction, chronic cyclosporin A nephrotoxicity, various models of hypertension, and probably diabetic nephropathy in which ANG II-mediated TGF-beta induction has been demonstrated to play an important role in the progression of the disease.	Cyclosporine	113-126	angiotensinogen	Homo sapiens	218-224
9496739-2	1998	Although no change was observed in superoxide dismutase (SOD) activity, glutathione peroxidase (GSH-Px) and catalase (CAT) activities were found decreased in kidney tissue exposed to CsA for 10 days compared with control tissue.	Cyclosporine	183-186	catalase	Oryctolagus cuniculus	118-121
9422408-2	1997	Recently, calcineurin phosphatase inhibition by cyclosporine or tacrolimus has been postulated to lead to diastolic hypertension through the induction of transforming growth factor-beta (TGF-beta) and resultant endothelin-mediated renal arteriolar vasospasm.	Cyclosporine	48-60	transforming growth factor beta 1	Homo sapiens	154-185
9665007-3	1998	We investigated the effect of tacrolimus and CsA in tissue culture and found that there was indeed a negative effect on human lung small airway epithelial cell proliferation by recombinant transforming growth factor-beta (TGF-beta), which was reversed by anti-TGF-beta.	Cyclosporine	45-48	transforming growth factor beta 1	Homo sapiens	189-220
9665007-3	1998	We investigated the effect of tacrolimus and CsA in tissue culture and found that there was indeed a negative effect on human lung small airway epithelial cell proliferation by recombinant transforming growth factor-beta (TGF-beta), which was reversed by anti-TGF-beta.	Cyclosporine	45-48	transforming growth factor beta 1	Homo sapiens	222-230
9665007-3	1998	We investigated the effect of tacrolimus and CsA in tissue culture and found that there was indeed a negative effect on human lung small airway epithelial cell proliferation by recombinant transforming growth factor-beta (TGF-beta), which was reversed by anti-TGF-beta.	Cyclosporine	45-48	transforming growth factor beta 1	Homo sapiens	260-268
9665007-4	1998	The same effect was seen with CsA at immunosuppressive concentrations, which was also reversed by anti-TGF-beta, whereas no such inhibition was seen with tacrolimus at immunosuppressive doses unless high concentrations were used.	Cyclosporine	30-33	transforming growth factor beta 1	Homo sapiens	103-111
9665007-5	1998	Free TGF-beta was confirmed as being elevated in the supernatant of cell culture wells with standard dose CsA as opposed to low dose CsA or tacrolimus using an ELISA assay.	Cyclosporine	106-109	transforming growth factor beta 1	Homo sapiens	5-13
9665007-5	1998	Free TGF-beta was confirmed as being elevated in the supernatant of cell culture wells with standard dose CsA as opposed to low dose CsA or tacrolimus using an ELISA assay.	Cyclosporine	133-136	transforming growth factor beta 1	Homo sapiens	5-13
9422408-2	1997	Recently, calcineurin phosphatase inhibition by cyclosporine or tacrolimus has been postulated to lead to diastolic hypertension through the induction of transforming growth factor-beta (TGF-beta) and resultant endothelin-mediated renal arteriolar vasospasm.	Cyclosporine	48-60	transforming growth factor beta 1	Homo sapiens	187-195
9416887-6	1997	Inhibition of TF induction in the presence of high CsA blood concentrations was also observed when stimulation of cells was performed with interferon-gamma or interleukin-1beta.	Cyclosporine	51-54	interferon gamma	Homo sapiens	139-155
9416887-6	1997	Inhibition of TF induction in the presence of high CsA blood concentrations was also observed when stimulation of cells was performed with interferon-gamma or interleukin-1beta.	Cyclosporine	51-54	interleukin 1 beta	Homo sapiens	159-176
9415562-10	1997	In the majority of children, there appears to be an anemia of chronic disease which may be secondary to chronic inflammation or an effect of cyclosporine on erythropoietin production.	Cyclosporine	141-153	erythropoietin	Homo sapiens	157-171
9415551-2	1997	Therefore, we asked whether interleukin (IL)-4 and IL-10, cytokines that inhibit cell-mediated immunity, might improve the therapeutic effect of CsA.	Cyclosporine	145-148	interleukin 10	Mus musculus	51-56
9413347-5	1997	Cyclosporine reduced the serum levels of ferritin, interferon-tau, interleukin-6, and soluble interleukin-2 receptor.	Cyclosporine	0-12	interleukin 6	Homo sapiens	67-80
9407429-3	1997	Both tacrolimus and CsA interfere with the early stage of lymphocyte proliferation by blocking interleukin-2 synthesis.	Cyclosporine	20-23	interleukin 2	Homo sapiens	95-108
9403721-3	1997	Angiotensin II has recently been implicated as the principal factor responsible for progression of interstitial fibrosis induced by CsA.	Cyclosporine	132-135	angiotensinogen	Rattus norvegicus	0-14
9403721-9	1997	Intrarenal deposits of angiotensin II were more evident in rats treated with CsA; these deposits also increased with time.	Cyclosporine	77-80	angiotensinogen	Rattus norvegicus	23-37
9440622-2	1997	Thus, in liver transplantation, Fas-Ag expression of hepatocytes and its modification by immunosuppressive agents such as FK 506 or CsA can theoretically influence allograft survival.	Cyclosporine	132-135	Fas (TNF receptor superfamily member 6)	Mus musculus	32-38
9440622-5	1997	When FK 506 or CsA was added, Fas-Ag expression with FK 506 at a concentration of 0.01-0.1 microg/ml was significantly lower than that with CsA (P &lt; 0.05).	Cyclosporine	15-18	Fas (TNF receptor superfamily member 6)	Mus musculus	30-36
9497487-6	1997	In contrast, preincubation with up to 1000 ng/ml of cyclosporin A (CsA) resulted in a reduction in the intracellular IL-2 detected, as observed by a decrease in the proportion of positive cells as well as a fall in the mean fluorescence intensity (MFI).	Cyclosporine	67-70	interleukin 2	Homo sapiens	117-121
9400033-2	1997	For some of these (e.g., cyclosporine, verapamil, midazolam), CYP3A in the intestinal mucosa contributes to their extensive and variable first-pass extraction.	Cyclosporine	25-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-67
9418184-5	1997	The efflux function of P-gP was measured by intracellular accumulation of rhodamine-123 (Rh123; a substrate for P-gP) in the presence or absence of cyclosporin A (which binds to P-gP and inhibits its efflux function).	Cyclosporine	148-161	ATP binding cassette subfamily B member 1	Homo sapiens	23-27
9374532-2	1997	Along with other cytokines, IFN-gamma gene expression is inhibited by the immunosuppressant cyclosporin A.	Cyclosporine	92-105	interferon gamma	Homo sapiens	28-37
9374532-3	1997	We have previously identified an intronic enhancer region (C3) of the IFN-gamma gene that binds the NF-kappaB protein c-Rel and that shows partial DNA sequence homology with the cyclosporin A-sensitive NFAT binding site and the 3"-half of the NF-kappaB consensus site.	Cyclosporine	178-191	interferon gamma	Homo sapiens	70-79
9374532-9	1997	Site-directed mutagenesis and transfection studies demonstrate that calcineurin-inducible transcriptional factors enhance the transcriptional activity of the IFN-gamma promoter through the cyclosporin-sensitive C3-3P site, whereas NF-kappaB proteins functionally interact with the C3-related sites.	Cyclosporine	189-200	interferon gamma	Homo sapiens	158-167
9402948-6	1997	Moreover, the oxidative metabolism of cyclosporin A, a monoxygenase activity depending on CYP3A4, has been monitored directly on the cultured cells by HPLC analysis of extracellular medium.	Cyclosporine	38-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	90-96
9370075-4	1997	It has been shown that p-glycoprotein can be circumvented in vitro by noncytotoxic agents such as verapamil and cyclosporin A, which interact pharmacologically with p-glycoprotein-mediated efflux.	Cyclosporine	112-125	ATP binding cassette subfamily B member 1	Homo sapiens	23-37
9370075-4	1997	It has been shown that p-glycoprotein can be circumvented in vitro by noncytotoxic agents such as verapamil and cyclosporin A, which interact pharmacologically with p-glycoprotein-mediated efflux.	Cyclosporine	112-125	ATP binding cassette subfamily B member 1	Homo sapiens	165-179
9352858-9	1997	Anti-TNF-alpha antibodies inhibited neutrophil infiltration in the submucosa, and cyclosporine A inhibited the tissue expression of TNF-alpha mRNA and the influx of neutrophils into the submucosa and muscularis propria.	Cyclosporine	82-96	tumor necrosis factor	Mus musculus	132-141
9329968-7	1997	Next, we evaluated the effect of cyclosporine (CsA) on iNOS expression and allograft arteriosclerosis.	Cyclosporine	33-45	nitric oxide synthase 2	Rattus norvegicus	55-59
9334390-6	1997	The ability of quinpirole to decrease D1-stimulated DARPP-32 phosphorylation was calcium-dependent and was blocked by the calcineurin inhibitor cyclosporin A, suggesting that the D2 effect involved an increase in intracellular calcium and activation of calcineurin.	Cyclosporine	144-157	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	52-60
9381548-3	1997	Evidence from in vitro studies has suggested that ciprofloxacin can antagonize the cyclosporine (CsA)-dependent inhibition of interleukin-2 production.	Cyclosporine	83-95	interleukin 2	Homo sapiens	126-139
9381548-3	1997	Evidence from in vitro studies has suggested that ciprofloxacin can antagonize the cyclosporine (CsA)-dependent inhibition of interleukin-2 production.	Cyclosporine	97-100	interleukin 2	Homo sapiens	126-139
9344499-4	1997	IL-4 production was completely inhibited by cyclosporin A or by blocking IL-2 activity and its receptor.	Cyclosporine	44-57	interleukin 4	Homo sapiens	0-4
9329968-7	1997	Next, we evaluated the effect of cyclosporine (CsA) on iNOS expression and allograft arteriosclerosis.	Cyclosporine	47-50	nitric oxide synthase 2	Rattus norvegicus	55-59
9329968-8	1997	CsA (10 mg/kg/d) suppressed the expression of iNOS in response to balloon-induced aortic injury.	Cyclosporine	0-3	nitric oxide synthase 2	Rattus norvegicus	46-50
9329968-9	1997	Similarly, CsA inhibited iNOS expression in the aortic allografts, associated with a 65% increase in intimal thickening.	Cyclosporine	11-14	nitric oxide synthase 2	Rattus norvegicus	25-29
9329968-11	1997	Transduction with iNOS using an adenoviral vector suppressed completely the development of allograft arteriosclerosis in both untreated recipients and recipients treated with CsA.	Cyclosporine	175-178	nitric oxide synthase 2	Rattus norvegicus	18-22
9317123-7	1997	EC costimulation of IFN-gamma production is inhibited by cyclosporine.	Cyclosporine	57-69	interferon gamma	Homo sapiens	20-29
9312192-5	1997	In CsA-treated leukocytes stimulated by calcium ionophore, the degree of reduction in CN activity was accompanied by a similar degree of inhibition of each event tested: dephosphorylation of nuclear factor of activated T cell proteins, nuclear DNA binding, activation of a transfected reporter gene construct, IFN-gamma and IL-2 mRNA accumulation, and IFN-gamma production.	Cyclosporine	3-6	interferon gamma	Homo sapiens	310-319
9312192-5	1997	In CsA-treated leukocytes stimulated by calcium ionophore, the degree of reduction in CN activity was accompanied by a similar degree of inhibition of each event tested: dephosphorylation of nuclear factor of activated T cell proteins, nuclear DNA binding, activation of a transfected reporter gene construct, IFN-gamma and IL-2 mRNA accumulation, and IFN-gamma production.	Cyclosporine	3-6	interleukin 2	Homo sapiens	324-328
9312192-5	1997	In CsA-treated leukocytes stimulated by calcium ionophore, the degree of reduction in CN activity was accompanied by a similar degree of inhibition of each event tested: dephosphorylation of nuclear factor of activated T cell proteins, nuclear DNA binding, activation of a transfected reporter gene construct, IFN-gamma and IL-2 mRNA accumulation, and IFN-gamma production.	Cyclosporine	3-6	interferon gamma	Homo sapiens	352-361
9349985-3	1997	The effects of cyclosporine A (CsA), tacrolimus (FK506), and dexamethasone (DEX) on cytokine-induced production of interleukin (IL)-8 in a human colonic cancer cell line (HT-29) were examined.	Cyclosporine	31-34	C-X-C motif chemokine ligand 8	Homo sapiens	115-133
9349985-6	1997	CsA (1, 5, and 10ng/ml) significantly reduced IL-1 beta-induced IL-8 production (by 32%, 41%, and 48%, respectively), and reduced TNF alpha-induced IL-8 production (by 21%, 42%, and 50%, respectively).	Cyclosporine	0-3	interleukin 1 beta	Homo sapiens	46-55
9349985-6	1997	CsA (1, 5, and 10ng/ml) significantly reduced IL-1 beta-induced IL-8 production (by 32%, 41%, and 48%, respectively), and reduced TNF alpha-induced IL-8 production (by 21%, 42%, and 50%, respectively).	Cyclosporine	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	64-68
9349985-6	1997	CsA (1, 5, and 10ng/ml) significantly reduced IL-1 beta-induced IL-8 production (by 32%, 41%, and 48%, respectively), and reduced TNF alpha-induced IL-8 production (by 21%, 42%, and 50%, respectively).	Cyclosporine	0-3	tumor necrosis factor	Homo sapiens	130-139
9349985-6	1997	CsA (1, 5, and 10ng/ml) significantly reduced IL-1 beta-induced IL-8 production (by 32%, 41%, and 48%, respectively), and reduced TNF alpha-induced IL-8 production (by 21%, 42%, and 50%, respectively).	Cyclosporine	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	148-152
9349985-8	1997	The expression of IL-8 mRNA was also inhibited by CsA.	Cyclosporine	50-53	C-X-C motif chemokine ligand 8	Homo sapiens	18-22
9336339-4	1997	The expression of interferon-gamma mRNA in reverse transcriptase-polymerase chain reaction in the ear was inhibited by FK-506 and cyclosporin A.	Cyclosporine	130-143	interferon gamma	Mus musculus	18-34
9336339-6	1997	Contrary to the above in vivo findings, the immunosuppressors, FK-506 and cyclosporin A, inhibited the production of interferon-gamma and interleukin-2 by cultured Th1 cells (1E10.H2 cells) and of interleukin-4 and -5 by Th2 cells (D10.G4.1 cells) in vitro.	Cyclosporine	74-87	interferon gamma	Mus musculus	117-133
9336339-6	1997	Contrary to the above in vivo findings, the immunosuppressors, FK-506 and cyclosporin A, inhibited the production of interferon-gamma and interleukin-2 by cultured Th1 cells (1E10.H2 cells) and of interleukin-4 and -5 by Th2 cells (D10.G4.1 cells) in vitro.	Cyclosporine	74-87	negative elongation factor complex member C/D, Th1l	Mus musculus	164-167
9336339-7	1997	These results indicated that FK-506 and cyclosporin A selectively inhibited the Th1 cell-mediated contact dermatitis and potentiated the Th2 cell-mediated IgE antibody production in vivo.	Cyclosporine	40-53	negative elongation factor complex member C/D, Th1l	Mus musculus	80-83
9336339-9	1997	However, because FK-506 and cyclosporin A inhibited the production of cytokines by both Th1 and Th2 cells in vitro and these two immunosuppressors showed higher selectivity toward inhibiting Th1 cell-mediated reactions by limitations in vivo experiments.	Cyclosporine	28-41	negative elongation factor complex member C/D, Th1l	Mus musculus	88-91
9336339-9	1997	However, because FK-506 and cyclosporin A inhibited the production of cytokines by both Th1 and Th2 cells in vitro and these two immunosuppressors showed higher selectivity toward inhibiting Th1 cell-mediated reactions by limitations in vivo experiments.	Cyclosporine	28-41	negative elongation factor complex member C/D, Th1l	Mus musculus	191-194
9408959-4	1997	Recently, clinical reversal of MDR by noncytotoxic P-gp modulators such as verapamil, cyclosporin A (CsA), and PSC 833 was explored in acute leukemia and multiple myeloma.	Cyclosporine	86-99	ATP binding cassette subfamily B member 1	Homo sapiens	51-55
9351063-8	1997	It is interesting to speculate that this ACE genotype, which is associated with a poor outcome in non-ischaemic heart disease can influence renal sensitivity to cyclosporin and predict the development of morphological injury.	Cyclosporine	161-172	angiotensin I converting enzyme	Homo sapiens	41-44
9408959-4	1997	Recently, clinical reversal of MDR by noncytotoxic P-gp modulators such as verapamil, cyclosporin A (CsA), and PSC 833 was explored in acute leukemia and multiple myeloma.	Cyclosporine	101-104	ATP binding cassette subfamily B member 1	Homo sapiens	51-55
9380680-8	1997	Also, the concentration of vinblastine (Pgp substrate) and cyclosporin A (Pgp modulator) required for 50% inhibition of [125I]IAAP binding to the C-site was increased 5- to 6-fold by cis(Z)-flupentixol without any effect on the N-site.	Cyclosporine	59-72	ATP binding cassette subfamily B member 1	Homo sapiens	74-77
10837558-4	1997	Cyclosporine and tacrolimus are also substrates for p-glycoprotein, which acts as a counter-transport pump, actively transporting cyclosporine and tacrolimus back into the intestinal lumen.	Cyclosporine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	52-66
10837554-13	1997	It is also clear that some of the substrates for CYP3A4 (e.g., cyclosporine, midazolam, nifedipine, verapamil and saquinavir) undergo significant metabolic extraction by the gut wall.	Cyclosporine	63-75	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	49-55
10837558-4	1997	Cyclosporine and tacrolimus are also substrates for p-glycoprotein, which acts as a counter-transport pump, actively transporting cyclosporine and tacrolimus back into the intestinal lumen.	Cyclosporine	130-142	ATP binding cassette subfamily B member 1	Homo sapiens	52-66
10837558-0	1997	Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery.	Cyclosporine	73-85	ATP binding cassette subfamily B member 1	Homo sapiens	55-69
10837558-1	1997	The objective of this section is to evaluate the contributions of hepatic metabolism, intestinal metabolism and intestinal p-glycoprotein to the pharmacokinetics of orally administered cyclosporine and tacrolimus.	Cyclosporine	185-197	ATP binding cassette subfamily B member 1	Homo sapiens	123-137
10837558-10	1997	However, the quantity of intestinal p-glycoprotein accounts for approximately 17% of the variability in oral cyclosporine pharmacokinetics.	Cyclosporine	109-121	ATP binding cassette subfamily B member 1	Homo sapiens	36-50
10837558-2	1997	Cyclosporine and tacrolimus are metabolized primarily by cytochrome P450 3A4 (CYP3A4) in the liver and small intestine.	Cyclosporine	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	57-76
10837558-2	1997	Cyclosporine and tacrolimus are metabolized primarily by cytochrome P450 3A4 (CYP3A4) in the liver and small intestine.	Cyclosporine	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	78-84
10837558-14	1997	It seems that compounds that alter (either induce or inhibit) CYP3A4 and/or p-glycoprotein will alter the oral pharmacokinetics of cyclosporine and tacrolimus.	Cyclosporine	131-143	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-68
10837558-3	1997	There is also evidence that cyclosporine is metabolized to a lesser extent by cytochrome P450 3A5 (CYP3A5).	Cyclosporine	28-40	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	78-97
10837558-14	1997	It seems that compounds that alter (either induce or inhibit) CYP3A4 and/or p-glycoprotein will alter the oral pharmacokinetics of cyclosporine and tacrolimus.	Cyclosporine	131-143	ATP binding cassette subfamily B member 1	Homo sapiens	76-90
10837558-3	1997	There is also evidence that cyclosporine is metabolized to a lesser extent by cytochrome P450 3A5 (CYP3A5).	Cyclosporine	28-40	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	99-105
9313931-15	1997	The interaction of the cyclosporin derivatives with ATPase of P-glycoprotein might present an alternative and/or additional mechanism of action for the modulation of P-glycoprotein function.	Cyclosporine	23-34	ATP binding cassette subfamily B member 1	Homo sapiens	62-76
9313931-0	1997	Interaction of cyclosporin derivatives with the ATPase activity of human P-glycoprotein.	Cyclosporine	15-26	ATP binding cassette subfamily B member 1	Homo sapiens	73-87
9313931-7	1997	While verapamil activated the ATPase, the cyclosporin derivatives inhibited both the substrate-stimulated and the basal P-glycoprotein ATPase.	Cyclosporine	42-53	ATP binding cassette subfamily B member 1	Homo sapiens	120-134
9313931-15	1997	The interaction of the cyclosporin derivatives with ATPase of P-glycoprotein might present an alternative and/or additional mechanism of action for the modulation of P-glycoprotein function.	Cyclosporine	23-34	ATP binding cassette subfamily B member 1	Homo sapiens	166-180
9341769-5	1997	Moreover, lactacystin did not inhibit the nuclear translocation of NF-ATp whereas cyclosporin A inhibited the translocation of both NF-kappa B and NF-ATp.	Cyclosporine	82-95	nuclear factor kappa B subunit 1	Homo sapiens	132-142
9333100-0	1997	Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.	Cyclosporine	98-110	ATP binding cassette subfamily B member 1	Homo sapiens	19-33
9341780-8	1997	In contrast to GC, cyclosporine A inhibited both total and PLA-specific IgE and IgG4 secretion in peripheral blood mononuclear cells and B cell cultures.	Cyclosporine	19-33	phospholipase A2 group IB	Homo sapiens	59-62
9333100-0	1997	Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.	Cyclosporine	98-110	ATP binding cassette subfamily B member 1	Homo sapiens	35-39
9333100-1	1997	Interpatient differences in the oral clearance of cyclosporine (INN, ciclosporin) have been partially attributed to variation in the activity of a single liver enzyme termed CYP3A4.	Cyclosporine	50-62	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	174-180
9309684-3	1997	Unbinding of CyP-M would follow a CsA-dependent or proton-dependent change in conformation of the CyP-M molecule.	Cyclosporine	34-37	peptidylprolyl isomerase F	Homo sapiens	13-18
9333100-1	1997	Interpatient differences in the oral clearance of cyclosporine (INN, ciclosporin) have been partially attributed to variation in the activity of a single liver enzyme termed CYP3A4.	Cyclosporine	69-80	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	174-180
9333100-2	1997	Recently it has been shown that small bowel also contains CYP3A4, as well as P-glycoprotein, a protein able to transport cyclosporine.	Cyclosporine	121-133	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	58-64
9333100-2	1997	Recently it has been shown that small bowel also contains CYP3A4, as well as P-glycoprotein, a protein able to transport cyclosporine.	Cyclosporine	121-133	ATP binding cassette subfamily B member 1	Homo sapiens	77-91
9333100-7	1997	We conclude that intestinal P-glycoprotein plays a significant role in the first-pass elimination of cyclosporine, presumably by being a rate-limiting step in absorption.	Cyclosporine	101-113	ATP binding cassette subfamily B member 1	Homo sapiens	28-42
9333100-8	1997	Drug interactions with cyclosporine previously ascribed to intestinal CYP3A4 may instead be mediated by interactions with intestinal P-glycoprotein.	Cyclosporine	23-35	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	70-76
9333100-8	1997	Drug interactions with cyclosporine previously ascribed to intestinal CYP3A4 may instead be mediated by interactions with intestinal P-glycoprotein.	Cyclosporine	23-35	ATP binding cassette subfamily B member 1	Homo sapiens	133-147
9309684-3	1997	Unbinding of CyP-M would follow a CsA-dependent or proton-dependent change in conformation of the CyP-M molecule.	Cyclosporine	34-37	peptidylprolyl isomerase F	Homo sapiens	98-103
9309684-4	1997	It is interesting that upon binding of CsA the enzymatic activity of CyP-M is inhibited, but it is not clear whether this event plays a role in pore inhibition.	Cyclosporine	39-42	peptidylprolyl isomerase F	Homo sapiens	69-74
9262586-8	1997	The effects of cyclosporin A on endothelium-dependent responses to bradykinin and substance P were overcome by the administration of L-arginine (200 mg/kg intravenously).	Cyclosporine	15-28	kininogen 1	Canis lupus familiaris	67-77
9291185-0	1997	Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy.	Cyclosporine	67-79	angiotensinogen	Rattus norvegicus	0-14
9291185-0	1997	Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy.	Cyclosporine	67-79	transforming growth factor, beta 1	Rattus norvegicus	34-43
9291185-2	1997	In a model of chronic cyclosporine (CsA) nephropathy, we previously showed that TGF-beta1 plays a role in CsA-induced tubulointerstitial fibrosis and arteriolopathy by stimulating extracellular matrix (ECM) protein synthesis and inhibiting ECM degradation through increasing the synthesis of plasminogen activator inhibitor (PAI)-1.	Cyclosporine	22-34	transforming growth factor, beta 1	Rattus norvegicus	80-89
9291185-2	1997	In a model of chronic cyclosporine (CsA) nephropathy, we previously showed that TGF-beta1 plays a role in CsA-induced tubulointerstitial fibrosis and arteriolopathy by stimulating extracellular matrix (ECM) protein synthesis and inhibiting ECM degradation through increasing the synthesis of plasminogen activator inhibitor (PAI)-1.	Cyclosporine	36-39	transforming growth factor, beta 1	Rattus norvegicus	80-89
9291185-2	1997	In a model of chronic cyclosporine (CsA) nephropathy, we previously showed that TGF-beta1 plays a role in CsA-induced tubulointerstitial fibrosis and arteriolopathy by stimulating extracellular matrix (ECM) protein synthesis and inhibiting ECM degradation through increasing the synthesis of plasminogen activator inhibitor (PAI)-1.	Cyclosporine	106-109	transforming growth factor, beta 1	Rattus norvegicus	80-89
9291185-2	1997	In a model of chronic cyclosporine (CsA) nephropathy, we previously showed that TGF-beta1 plays a role in CsA-induced tubulointerstitial fibrosis and arteriolopathy by stimulating extracellular matrix (ECM) protein synthesis and inhibiting ECM degradation through increasing the synthesis of plasminogen activator inhibitor (PAI)-1.	Cyclosporine	106-109	serpin family E member 1	Rattus norvegicus	292-331
9291185-9	1997	These results suggest that CsA-induced fibrosis in this model is independent of renal hemodynamics and is mediated, at least partly, through Ang II induction of TGF-beta1 expression.	Cyclosporine	27-30	angiotensinogen	Rattus norvegicus	141-147
9291185-9	1997	These results suggest that CsA-induced fibrosis in this model is independent of renal hemodynamics and is mediated, at least partly, through Ang II induction of TGF-beta1 expression.	Cyclosporine	27-30	transforming growth factor, beta 1	Rattus norvegicus	161-170
9262586-4	1997	RESULTS: The vasodilator response to bradykinin and substance P was significantly decreased with cyclosporin A (20 mg) administration.	Cyclosporine	97-110	kininogen 1	Canis lupus familiaris	37-47
9262586-5	1997	The average decreases in pulmonary arterial pressure with bradykinin were 5.4 +/- 1.5 mm Hg and 2.4 +/- 0.4 mm Hg before and after cyclosporin A administration, respectively (p = 0.04).	Cyclosporine	131-144	kininogen 1	Canis lupus familiaris	58-68
9262586-9	1997	The decreased response to bradykinin and substance P after cyclosporin A administration was not significantly affected by indomethacin, a cyclooxygenase inhibitor.	Cyclosporine	59-72	kininogen 1	Canis lupus familiaris	26-36
9262586-12	1997	CONCLUSIONS: The present study suggests that cyclosporin A selectively decreases endothelium-dependent responses to bradykinin and substance P without affecting the cyclic guanosine monophosphate-dependent pathway in the canine pulmonary vascular bed.	Cyclosporine	45-58	kininogen 1	Canis lupus familiaris	116-126
9283237-8	1997	Cyclosporine A suppresses production of interleukin-2, a cytokine necessary for the amplification stages of the immune response and critical for the activation of both T and B lymphocytes.	Cyclosporine	0-14	interleukin 2	Homo sapiens	40-53
9285248-6	1997	The inhibitory effect of 6-MPG on the secondary tumor growth was diminished by prior treatment of the primed animals with cyclosporin A and anti-Thy antibody.	Cyclosporine	122-135	N-methylpurine-DNA glycosylase	Mus musculus	27-30
9277043-3	1997	Recent studies on a subset of AA patients characterized by repetitive response to cyclosporine (CyA) therapy revealed a strong association of HLA-DRB1*1501 with susceptibility to such immune-mediated AA.	Cyclosporine	82-94	major histocompatibility complex, class II, DR beta 1	Homo sapiens	142-150
9277043-3	1997	Recent studies on a subset of AA patients characterized by repetitive response to cyclosporine (CyA) therapy revealed a strong association of HLA-DRB1*1501 with susceptibility to such immune-mediated AA.	Cyclosporine	96-99	major histocompatibility complex, class II, DR beta 1	Homo sapiens	142-150
9256171-0	1997	Insulin-like growth factor-I ameliorates delayed kidney graft function and the acute nephrotoxic effects of cyclosporine.	Cyclosporine	108-120	insulin like growth factor 1	Homo sapiens	0-28
9639738-1	1997	OBJECTIVE: To study the relationship between multi-drug-resistance (MDR1) gene expression and the drug resistance of ovarian carcinoma and the reversing potency of drug-resistance modifying agent--cyclosporin A (CsA).	Cyclosporine	197-210	ATP binding cassette subfamily B member 1	Homo sapiens	68-72
9639738-1	1997	OBJECTIVE: To study the relationship between multi-drug-resistance (MDR1) gene expression and the drug resistance of ovarian carcinoma and the reversing potency of drug-resistance modifying agent--cyclosporin A (CsA).	Cyclosporine	212-215	ATP binding cassette subfamily B member 1	Homo sapiens	68-72
9256171-9	1997	Finally we tested whether IGF-I protects against acute cyclosporine nephrotoxicity.	Cyclosporine	55-67	insulin like growth factor 1	Homo sapiens	26-31
9256171-13	1997	IGF-I also ameliorated the nephrotoxicity of cyclosporine, with better values of creatinine and blood urea nitrogen (P&lt;0.05).	Cyclosporine	45-57	insulin like growth factor 1	Homo sapiens	0-5
9256185-0	1997	Interleukin 6 and interferon-gamma gene expression in lung transplant recipients with refractory acute cellular rejection: implications for monitoring and inhibition by treatment with aerosolized cyclosporine.	Cyclosporine	196-208	interleukin 6	Homo sapiens	0-13
9256185-0	1997	Interleukin 6 and interferon-gamma gene expression in lung transplant recipients with refractory acute cellular rejection: implications for monitoring and inhibition by treatment with aerosolized cyclosporine.	Cyclosporine	196-208	interferon gamma	Homo sapiens	18-34
9213009-21	1997	We confirmed previous findings that CsA produces elevated 1,25(OH)2 vitamin D and serum osteocalcin levels.	Cyclosporine	36-39	bone gamma-carboxyglutamate protein	Rattus norvegicus	88-99
9214404-0	1997	Sodium depletion enhances fibrosis and the expression of TGF-beta1 and matrix proteins in experimental chronic cyclosporine nephropathy.	Cyclosporine	111-123	transforming growth factor, beta 1	Rattus norvegicus	57-66
9214404-4	1997	We have previously shown that transforming growth factor-beta1 (TGF-beta1) is involved in the CsA-induced renal fibrosis in rats on a LSD.	Cyclosporine	94-97	transforming growth factor, beta 1	Rattus norvegicus	30-62
9214404-4	1997	We have previously shown that transforming growth factor-beta1 (TGF-beta1) is involved in the CsA-induced renal fibrosis in rats on a LSD.	Cyclosporine	94-97	transforming growth factor, beta 1	Rattus norvegicus	64-73
9214404-11	1997	In addition, CsA-treated rats on a LSD developed a progressive increase in the mRNA expression of TGF-beta1 and the matrix proteins biglycan and type I collagen at 7 and 28 days.	Cyclosporine	13-16	transforming growth factor, beta 1	Rattus norvegicus	98-107
9247567-0	1997	Cyclosporin A interferes with the inducible degradation of NF-kappa B inhibitors, but not with the processing of p105/NF-kappa B1 in T cells.	Cyclosporine	0-13	nuclear factor kappa B subunit 1	Homo sapiens	59-69
9247567-2	1997	Inhibition of T cell activation by the immunosuppressants cyclosporin A (CsA) and FK506 exerts a suppressive effect on the induction of these NF-kappa B-controlled cytokine promoters.	Cyclosporine	58-71	nuclear factor kappa B subunit 1	Homo sapiens	142-152
9247567-2	1997	Inhibition of T cell activation by the immunosuppressants cyclosporin A (CsA) and FK506 exerts a suppressive effect on the induction of these NF-kappa B-controlled cytokine promoters.	Cyclosporine	73-76	nuclear factor kappa B subunit 1	Homo sapiens	142-152
9247567-4	1997	CsA does not interfere with the synthesis of Rel proteins, but prevents the inducible degradation of cytosolic NF-kappa B inhibitors I kappa B alpha and I kappa B beta upon T cell activation.	Cyclosporine	0-3	nuclear factor kappa B subunit 1	Homo sapiens	111-121
9247567-4	1997	CsA does not interfere with the synthesis of Rel proteins, but prevents the inducible degradation of cytosolic NF-kappa B inhibitors I kappa B alpha and I kappa B beta upon T cell activation.	Cyclosporine	0-3	NFKB inhibitor alpha	Homo sapiens	133-148
9247567-5	1997	CsA neither inhibits the processing of the NF-kappa B1 precursor p105 to p50, nor does it "stabilize" the C-terminal portion of p105, I kappa B gamma, which is degraded during p105 processing to mature p50.	Cyclosporine	0-3	nuclear factor kappa B subunit 1	Homo sapiens	128-132
9247567-5	1997	CsA neither inhibits the processing of the NF-kappa B1 precursor p105 to p50, nor does it "stabilize" the C-terminal portion of p105, I kappa B gamma, which is degraded during p105 processing to mature p50.	Cyclosporine	0-3	nuclear factor kappa B subunit 1	Homo sapiens	128-132
9247567-6	1997	These results indicate that CsA interferes with a specific event in the signal-induced degradation of I kappa B alpha and I kappa B beta, but does not affect the processing of NF-kappa B1/p105 to p50.	Cyclosporine	28-31	NFKB inhibitor alpha	Homo sapiens	102-117
9205009-2	1997	Assessment of P-glycoprotein (P-gp) expression and function by means of immunocytochemistry, DNR accumulation, and modulation of resistance and accumulation by the P-gp inhibitor cyclosporin A (CsA) were selected as parameters for multidrug resistance (MDR).	Cyclosporine	194-197	ATP binding cassette subfamily B member 1	Homo sapiens	14-28
9507569-7	1997	Exposure of cyclosporin A and dexamethasone almost completely inhibited the production of IL-6 and IL-8 after 24 hours of treatment.	Cyclosporine	12-25	interleukin 6	Homo sapiens	90-94
9368918-1	1997	The effect of cyclosporine A (CsA) and dihydropyridine calcium channel blocker (CCB) amlodipine on gamma-glutamyl transpeptidase (GGT; EC 2.3.2.2) activity in mouse cerebral cortex was investigated.	Cyclosporine	30-33	gamma-glutamyltransferase 1	Mus musculus	130-133
9368918-5	1997	GGT activity in the cerebral cortex was decreased after treatment with CsA (20 and 40 mg kg-1), but was not changed after treatment with CsA in the 10 mg kg-1 dose as compared to the control group.	Cyclosporine	71-74	gamma-glutamyltransferase 1	Mus musculus	0-3
9368918-6	1997	CsA in doses of 20 and 40 mg kg-1, combined with amlodipine, increased GGT activity as compared to the control group groups received the same doses of CsA without amlodipine and received only amlodipine.	Cyclosporine	0-3	gamma-glutamyltransferase 1	Mus musculus	71-74
9368918-7	1997	However, CsA in the 10 mg kg-1 dose combined with amlodipine decreased GGT activity when compared to the control group, but did not show any statistical difference when compared to the groups treated only with amlodipine or CsA in the same doses.	Cyclosporine	9-12	gamma-glutamyltransferase 1	Mus musculus	71-74
9368918-8	1997	These results suggest that CsA and amlodipine may modulate GGT activity in mouse cerebral cortex.	Cyclosporine	27-30	gamma-glutamyltransferase 1	Mus musculus	59-62
9507569-7	1997	Exposure of cyclosporin A and dexamethasone almost completely inhibited the production of IL-6 and IL-8 after 24 hours of treatment.	Cyclosporine	12-25	C-X-C motif chemokine ligand 8	Homo sapiens	99-103
9192801-0	1997	Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein.	Cyclosporine	121-133	ATP binding cassette subfamily C member 1	Homo sapiens	0-28
9195923-8	1997	Only a small (but undetermined) fraction of the native GR.hsp90 heterocomplexes contain the cyclosporin A-binding immunophilin CyP-40.	Cyclosporine	92-105	nuclear receptor subfamily 3 group C member 1	Homo sapiens	55-57
9192801-0	1997	Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein.	Cyclosporine	121-133	ATP binding cassette subfamily C member 1	Homo sapiens	30-33
9192801-6	1997	One RB enucleated 2 years after failing chemotherapy with cyclosporine, despite radiation and salvage chemotherapy, expressed both p170 and MRP.	Cyclosporine	58-70	ATP binding cassette subfamily C member 1	Homo sapiens	140-143
9192801-8	1997	MRP may result in failure of chemotherapy despite the elimination of p170-expressing clones by cyclosporine.	Cyclosporine	95-107	ATP binding cassette subfamily C member 1	Homo sapiens	0-3
9190906-2	1997	Furthermore we show that IL-10 production by human T cell lines, such as IFN-gamma and IL-2, is inhibited by the immunosuppressive drugs cyclosporin A and FK506.	Cyclosporine	137-150	interferon gamma	Homo sapiens	73-82
9190906-2	1997	Furthermore we show that IL-10 production by human T cell lines, such as IFN-gamma and IL-2, is inhibited by the immunosuppressive drugs cyclosporin A and FK506.	Cyclosporine	137-150	interleukin 2	Homo sapiens	87-91
9208149-0	1997	Suppression by cyclosporin A of interleukin 1 beta-induced expression of group II phospholipase A2 in rat renal mesangial cells.	Cyclosporine	15-28	interleukin 1 beta	Rattus norvegicus	32-50
9208149-7	1997	Incubation of mesangial cells with cyclosporin A inhibited IL-1 beta-induced PLA2 section in a dose-dependent fashion, with an IC50 value of 4.3 microM.	Cyclosporine	35-48	interleukin 1 beta	Rattus norvegicus	59-68
9208149-18	1997	The data presented in this study strongly suggest that the cellular mechanism involved in the IL1 beta-dependent transcriptional upregulation of the PLA2 gene in mesangial cells is a target for the action of cyclosporin A.	Cyclosporine	208-221	interleukin 1 beta	Rattus norvegicus	94-102
9126961-0	1997	Engagement of the signaling lymphocytic activation molecule (SLAM) on activated T cells results in IL-2-independent, cyclosporin A-sensitive T cell proliferation and IFN-gamma production.	Cyclosporine	117-130	signaling lymphocytic activation molecule family member 1	Homo sapiens	18-59
9184637-6	1997	In contrast, the response of activated cells to IL-2 was resistant to CsA.	Cyclosporine	70-73	interleukin 2	Homo sapiens	48-52
9153329-4	1997	We demonstrate the application of CSA for separation of highly polymorphic HLA-A, -B and -Cw alleles and characterisation of HLA identity in related bone marrow donors and patients.	Cyclosporine	34-37	major histocompatibility complex, class I, A	Homo sapiens	75-92
9180163-1	1997	Cyclosporin A (CSA) is an effective inhibitor of the P-glycoprotein (P-gp) activity and has been shown to modulate multidrug resistance (MDR) in in vitro experimental models.	Cyclosporine	0-13	ATP binding cassette subfamily B member 1	Homo sapiens	53-67
9180163-1	1997	Cyclosporin A (CSA) is an effective inhibitor of the P-glycoprotein (P-gp) activity and has been shown to modulate multidrug resistance (MDR) in in vitro experimental models.	Cyclosporine	0-13	ATP binding cassette subfamily B member 1	Homo sapiens	69-73
9177287-0	1997	Cyclosporin A-sensitive calcium signaling represses NFkappaB activation in human bronchial epithelial cells and enhances NFkappaB activation in Jurkat T-cells.	Cyclosporine	0-13	nuclear factor kappa B subunit 1	Homo sapiens	52-60
9177287-0	1997	Cyclosporin A-sensitive calcium signaling represses NFkappaB activation in human bronchial epithelial cells and enhances NFkappaB activation in Jurkat T-cells.	Cyclosporine	0-13	nuclear factor kappa B subunit 1	Homo sapiens	121-129
9177287-5	1997	Nuclear NFkappaB DNA-binding stimulated with PMA was inhibited with ionomycin in epithelial cells and was enhanced with ionomycin in T-cells; CsA reversed both effects of ionomycin.	Cyclosporine	142-145	nuclear factor kappa B subunit 1	Homo sapiens	8-16
9177287-8	1997	Calcium-mediated repression of NFkappaB in epithelial cells was derepressed by CsA, and this establishes a mechanism through which CsA may exert proinflammatory effects in nonlymphoid cells.	Cyclosporine	79-82	nuclear factor kappa B subunit 1	Homo sapiens	31-39
9177287-8	1997	Calcium-mediated repression of NFkappaB in epithelial cells was derepressed by CsA, and this establishes a mechanism through which CsA may exert proinflammatory effects in nonlymphoid cells.	Cyclosporine	131-134	nuclear factor kappa B subunit 1	Homo sapiens	31-39
9168973-5	1997	In addition, SPP-induced NF-kappa B activation was blocked both by cyclosporin A, known to inhibit calcineurin phosphatase activity, and by the antioxidant butylated hydroxyanisole.	Cyclosporine	67-80	nuclear factor kappa B subunit 1	Homo sapiens	25-35
9126961-0	1997	Engagement of the signaling lymphocytic activation molecule (SLAM) on activated T cells results in IL-2-independent, cyclosporin A-sensitive T cell proliferation and IFN-gamma production.	Cyclosporine	117-130	signaling lymphocytic activation molecule family member 1	Homo sapiens	61-65
9126961-0	1997	Engagement of the signaling lymphocytic activation molecule (SLAM) on activated T cells results in IL-2-independent, cyclosporin A-sensitive T cell proliferation and IFN-gamma production.	Cyclosporine	117-130	interleukin 2	Homo sapiens	99-103
9155160-3	1997	Cyclosporine and its analogue, SDZ PSC 833, have demonstrated ability to inhibit P-glycoprotein mediated transport function, restore accumulation defects for anticancer drugs, and reverse resistance in vitro and in vivo.	Cyclosporine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	81-95
9142140-2	1997	Cyclosporin A (CsA), an immunosuppressive drug, is believed to act by opposing the effects of prolactin (PRL) and was reported to influence testicular function.	Cyclosporine	0-13	prolactin	Rattus norvegicus	94-103
9234632-5	1997	Cyclosporin and steroids inhibit the interleukin-2 gene transcription factors NF-AT and AP-1.	Cyclosporine	0-11	interleukin 2	Homo sapiens	37-50
9234632-5	1997	Cyclosporin and steroids inhibit the interleukin-2 gene transcription factors NF-AT and AP-1.	Cyclosporine	0-11	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	88-92
9142140-2	1997	Cyclosporin A (CsA), an immunosuppressive drug, is believed to act by opposing the effects of prolactin (PRL) and was reported to influence testicular function.	Cyclosporine	0-13	prolactin	Rattus norvegicus	105-108
9142140-2	1997	Cyclosporin A (CsA), an immunosuppressive drug, is believed to act by opposing the effects of prolactin (PRL) and was reported to influence testicular function.	Cyclosporine	15-18	prolactin	Rattus norvegicus	94-103
9142140-2	1997	Cyclosporin A (CsA), an immunosuppressive drug, is believed to act by opposing the effects of prolactin (PRL) and was reported to influence testicular function.	Cyclosporine	15-18	prolactin	Rattus norvegicus	105-108
9099725-6	1997	In Jurkat T cells the down-modulation of expression of the SERCA isoform recognized by the PLIM430 antibody appeared concomitantly with the induction of interleukin-2 expression and could be inhibited by the immunosuppressant drug cyclosporine-A.	Cyclosporine	231-245	interleukin 2	Homo sapiens	153-166
9112362-4	1997	Through mechanisms only partially understood, calcium channel blockers and cyclosporine are reported to increase the serum prolactin level, producing gynecomastia in men.	Cyclosporine	75-87	prolactin	Homo sapiens	123-132
9112364-1	1997	BACKGROUND: We have demonstrated that cyclosporine (CsA) stimulates transforming growth factor (TGF) beta1 expression in vitro and that growth of mammalian cells can be arrested by CsA via a TGF-beta1-dependent mechanism.	Cyclosporine	38-50	transforming growth factor beta 1	Homo sapiens	96-99
9112364-1	1997	BACKGROUND: We have demonstrated that cyclosporine (CsA) stimulates transforming growth factor (TGF) beta1 expression in vitro and that growth of mammalian cells can be arrested by CsA via a TGF-beta1-dependent mechanism.	Cyclosporine	38-50	transforming growth factor beta 1	Homo sapiens	191-200
9112364-1	1997	BACKGROUND: We have demonstrated that cyclosporine (CsA) stimulates transforming growth factor (TGF) beta1 expression in vitro and that growth of mammalian cells can be arrested by CsA via a TGF-beta1-dependent mechanism.	Cyclosporine	52-55	transforming growth factor beta 1	Homo sapiens	96-99
9112364-1	1997	BACKGROUND: We have demonstrated that cyclosporine (CsA) stimulates transforming growth factor (TGF) beta1 expression in vitro and that growth of mammalian cells can be arrested by CsA via a TGF-beta1-dependent mechanism.	Cyclosporine	52-55	transforming growth factor beta 1	Homo sapiens	191-200
9112364-1	1997	BACKGROUND: We have demonstrated that cyclosporine (CsA) stimulates transforming growth factor (TGF) beta1 expression in vitro and that growth of mammalian cells can be arrested by CsA via a TGF-beta1-dependent mechanism.	Cyclosporine	181-184	transforming growth factor beta 1	Homo sapiens	191-200
9086008-0	1997	Regression of established tumors expressing P-glycoprotein by combinations of adriamycin, cyclosporin derivatives, and MRK-16 antibodies.	Cyclosporine	90-101	ATP binding cassette subfamily B member 1	Homo sapiens	44-58
9086008-2	1997	Strategies for overcoming this resistance include the use of specific compounds, such as cyclosporin derivatives, that modulate P-glycoprotein function and antibodies that bind to the protein, thereby altering its activity.	Cyclosporine	89-100	ATP binding cassette subfamily B member 1	Homo sapiens	128-142
9086008-17	1997	CONCLUSION: Combination treatment with a cyclosporin derivative and an anti-P-glycoprotein antibody can be effective in circumventing P-glycoprotein-mediated drug resistance.	Cyclosporine	41-52	ATP binding cassette subfamily B member 1	Homo sapiens	134-148
9113492-8	1997	Cyclosporin and tacrolimus cause post-transplant diabetes mellitus by a number of mechanisms, including decreased insulin secretion, increased insulin resistance or a direct toxic effect on the beta cell.	Cyclosporine	0-11	insulin	Homo sapiens	114-121
9130631-10	1997	Cyclosporin A and treatment with anti-IFN-gamma monoclonal antibody blocked the synergistic action of LPS and SEB, indicating that T cell-derived IFN-gamma is the mediator of the observed synergism.	Cyclosporine	0-13	interferon gamma	Mus musculus	146-155
9104801-1	1997	A case of X-linked autoimmune enteropathy was successfully treated with cyclosporine A (CsA) or tacrolimus (FK506) and developed extremely high serum levels of IgE during the immunosuppressive therapy.	Cyclosporine	88-91	immunoglobulin heavy constant epsilon	Homo sapiens	160-163
9104801-2	1997	Serum IgE levels increased from 190 to 1,000-2,500 IU/ml with CsA therapy and as high as 80,000 IU/ml with subsequent FK506 therapy.	Cyclosporine	62-65	immunoglobulin heavy constant epsilon	Homo sapiens	6-9
9101372-20	1997	BGP in the groups receiving Test alone and in combination with CsA remained similar to vehicle.	Cyclosporine	63-66	bone gamma-carboxyglutamate protein	Rattus norvegicus	0-3
9138282-2	1997	Pretreatment with CsA significantly reduced serum alanine aminotransferase (ALT), serum tumor necrosis factor-alpha (TNF-alpha) production, without changing the TNF-alpha mRNA level in the liver, and plasma interferon-gamma (IFN-gamma), following LPS injection in this model.	Cyclosporine	18-21	tumor necrosis factor	Rattus norvegicus	117-126
9108640-3	1997	Six months after transplantation, significant positive correlations were observed between the CsA trough concentration and serum concentrations of triglycerides (r = 0.448, p &lt; 0.01), total cholesterol (r = 0.360, p &lt; 0.05), and apoB (r = 0.418, p &lt; 0.01).	Cyclosporine	94-97	apolipoprotein B	Homo sapiens	235-239
15622762-4	1997	Those who had higher IL-2 levels and higher sIL-2R levels got better responses to cyclosporin A(CsA) and CsA plus antilymphocyte globulin (ALG).	Cyclosporine	82-95	interleukin 2	Homo sapiens	21-25
15622762-4	1997	Those who had higher IL-2 levels and higher sIL-2R levels got better responses to cyclosporin A(CsA) and CsA plus antilymphocyte globulin (ALG).	Cyclosporine	96-99	interleukin 2	Homo sapiens	21-25
15622762-4	1997	Those who had higher IL-2 levels and higher sIL-2R levels got better responses to cyclosporin A(CsA) and CsA plus antilymphocyte globulin (ALG).	Cyclosporine	105-108	interleukin 2	Homo sapiens	21-25
9058783-8	1997	CsA-plug Ca2+-mediated apoptosis was dissected into a two-step process: first, CsA and Ca2+ synergized to induce TGF-beta 1 secretion by B cells; and then TGF-beta 1 and Ca2+ synergistically triggered T and B lymphocyte apoptosis.	Cyclosporine	0-3	transforming growth factor beta 1	Homo sapiens	113-123
9058783-9	1997	Together, our results suggest that lymphocyte apoptosis may play a role in CsA-induced immunosuppression via a TGF-beta-dependent mechanism.	Cyclosporine	75-78	transforming growth factor beta 1	Homo sapiens	111-119
9058783-8	1997	CsA-plug Ca2+-mediated apoptosis was dissected into a two-step process: first, CsA and Ca2+ synergized to induce TGF-beta 1 secretion by B cells; and then TGF-beta 1 and Ca2+ synergistically triggered T and B lymphocyte apoptosis.	Cyclosporine	0-3	transforming growth factor beta 1	Homo sapiens	155-165
9058783-8	1997	CsA-plug Ca2+-mediated apoptosis was dissected into a two-step process: first, CsA and Ca2+ synergized to induce TGF-beta 1 secretion by B cells; and then TGF-beta 1 and Ca2+ synergistically triggered T and B lymphocyte apoptosis.	Cyclosporine	79-82	transforming growth factor beta 1	Homo sapiens	113-123
9068595-2	1997	SDZ PSC 833 (PSC), a nonimmunosuppressive cyclosporine that potently modulates Pgp, is currently under clinical evaluation in patients with cancer.	Cyclosporine	42-54	ATP binding cassette subfamily B member 1	Homo sapiens	79-82
9113092-0	1997	Decrease in kidney calbindin-D 28kDa as a possible mechanism mediating cyclosporine A- and FK-506-induced calciuria and tubular mineralization.	Cyclosporine	71-85	calbindin 1	Rattus norvegicus	19-33
9192065-9	1997	Cyclosporin therapy should be reserved for patients who have a poor response to the first 3-4 days of corticosteroid therapy, particularly those with serum C reactive protein &gt; 45 mg/l and who do not yet have absolute indications for colectomy.	Cyclosporine	0-11	C-reactive protein	Homo sapiens	156-174
9127694-0	1997	Identification of a 37 kDa tacrolimus, sirolimus and cyclosporine binding immunophilin possessing glyceraldehyde 3-phosphate dehydrogenase activity isolated from the Jurkat T cell line.	Cyclosporine	53-65	glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens	98-138
9410612-1	1997	In vitro studies on epithelial cells suggest that cyclosporin (CsA) inhibits a pathway of production of IL-6, which is mediated by TNF alpha and E. coli.	Cyclosporine	50-61	interleukin 6	Homo sapiens	104-108
9410612-6	1997	IL-6, however, displayed a positive reaction only in the control group, while it was invisible in the group of patients with CsA medication.	Cyclosporine	125-128	interleukin 6	Homo sapiens	0-4
9410612-1	1997	In vitro studies on epithelial cells suggest that cyclosporin (CsA) inhibits a pathway of production of IL-6, which is mediated by TNF alpha and E. coli.	Cyclosporine	50-61	tumor necrosis factor	Homo sapiens	131-140
9410612-1	1997	In vitro studies on epithelial cells suggest that cyclosporin (CsA) inhibits a pathway of production of IL-6, which is mediated by TNF alpha and E. coli.	Cyclosporine	63-66	interleukin 6	Homo sapiens	104-108
9410612-1	1997	In vitro studies on epithelial cells suggest that cyclosporin (CsA) inhibits a pathway of production of IL-6, which is mediated by TNF alpha and E. coli.	Cyclosporine	63-66	tumor necrosis factor	Homo sapiens	131-140
9106331-1	1997	Experimental and clinical studies have yet to determine the extent to which methotrexate (MTX) or cyclosporine A (CSA) treatment alone affects the expression in vivo of tumour necrosis factor-alpha (TNF alpha), a cytokine produced primarily by macrophages and believed to be directly involved in the pathogenesis of cardiac allograft rejection.	Cyclosporine	98-112	tumor necrosis factor	Rattus norvegicus	199-208
9106331-1	1997	Experimental and clinical studies have yet to determine the extent to which methotrexate (MTX) or cyclosporine A (CSA) treatment alone affects the expression in vivo of tumour necrosis factor-alpha (TNF alpha), a cytokine produced primarily by macrophages and believed to be directly involved in the pathogenesis of cardiac allograft rejection.	Cyclosporine	114-117	tumor necrosis factor	Rattus norvegicus	199-208
9106331-2	1997	In light of previously published findings from this laboratory examining the effects of combination CSA/MTX treatment, these studies were designed to examine the individual effects of CSA and MTX upon TNF alpha gene expression post-transplant (post-tx) using an accessory cervical heart transplant model in the rat.	Cyclosporine	184-187	tumor necrosis factor	Rattus norvegicus	201-210
9106331-6	1997	While TNF alpha levels were up-regulated during untreated allograft rejection, both TNF alpha RNA and protein were significantly diminished with low-dose combination CSA/MTX treatment, with CSA alone, but not significantly with MTX treatment alone.	Cyclosporine	166-169	tumor necrosis factor	Rattus norvegicus	84-93
9106331-6	1997	While TNF alpha levels were up-regulated during untreated allograft rejection, both TNF alpha RNA and protein were significantly diminished with low-dose combination CSA/MTX treatment, with CSA alone, but not significantly with MTX treatment alone.	Cyclosporine	190-193	tumor necrosis factor	Rattus norvegicus	84-93
9106331-8	1997	Results of these studies indicate that TNF alpha levels are significantly regulated in vivo by CSA but not by MTX treatment.	Cyclosporine	95-98	tumor necrosis factor	Rattus norvegicus	39-48
9073310-5	1997	VX-710 was approximately 2-fold more effective than verapamil, MS-209 and CsA in modulating MRP-mediated multidrug resistance, whereas GF120918 had no significant effect.	Cyclosporine	74-77	ATP binding cassette subfamily C member 1	Homo sapiens	92-95
9038218-10	1997	These data suggest that Phe335 is an important binding site on P-glycoprotein for substrates such as dactinomycin and vinblastine and for inhibitors such as cyclosporine and PSC 833.	Cyclosporine	157-169	ATP binding cassette subfamily B member 1	Homo sapiens	63-77
9032415-0	1997	Detection and quantification of cyclosporine in body fluids using an interleukin-2 reporter-gene assay.	Cyclosporine	32-44	interleukin 2	Homo sapiens	69-82
9032415-6	1997	The assay is very sensitive and selective for immunosuppressive compounds inhibiting IL-2 gene expression such as cyclosporine (CsA) and FK506, their active metabolites and derivatives, but not for others such as rapamycin.	Cyclosporine	114-126	interleukin 2	Homo sapiens	85-89
9032415-6	1997	The assay is very sensitive and selective for immunosuppressive compounds inhibiting IL-2 gene expression such as cyclosporine (CsA) and FK506, their active metabolites and derivatives, but not for others such as rapamycin.	Cyclosporine	128-131	interleukin 2	Homo sapiens	85-89
9074713-9	1997	Two-week infusion of Ang II induced a significant increase in CSA from 0.48 +/- 0.02 mm2 in CON to 0.61 +/- 0.03 mm2.	Cyclosporine	62-65	angiotensinogen	Rattus norvegicus	21-27
9045922-4	1997	Blocking the IL-2 pathway by cyclosporin A, FK506, rapamycin, anti-IL-2 or CD25 antibodies, prevented the development of sensitivity to apoptosis.	Cyclosporine	29-42	interleukin 2	Homo sapiens	13-17
9045922-5	1997	Addition of IL-2 and, to a lesser extent, IL-4, reversed the inhibitory effect of cyclosporin A.	Cyclosporine	82-95	interleukin 2	Homo sapiens	12-16
9045922-5	1997	Addition of IL-2 and, to a lesser extent, IL-4, reversed the inhibitory effect of cyclosporin A.	Cyclosporine	82-95	interleukin 4	Homo sapiens	42-46
9045922-6	1997	Conversely, rIL-7 and recombinant interferon-gamma restored proliferation of peripheral blood lymphocytes stimulated by PHA in the presence of cyclosporin A but did not restore sensitivity to class I-mediated apoptosis.	Cyclosporine	143-156	interferon gamma	Homo sapiens	34-50
9055138-3	1997	A variety of nonchemotherapeutic agents have been shown to inhibit P-glycoprotein-dependent drug efflux including cyclosporin.	Cyclosporine	114-125	ATP binding cassette subfamily B member 1	Homo sapiens	67-81
9067703-1	1997	Among epidermal cytokines, IL-1 and TNF alpha are involved in inflammatory skin reactions and suspected of modulation by immunosuppressive treatment (e.g., cyclosporin A, CsA) or UVB-irradiation, 2 mediators probably being involved in epithelial carcinogenesis.	Cyclosporine	156-169	interleukin 1 beta	Homo sapiens	27-31
9067703-1	1997	Among epidermal cytokines, IL-1 and TNF alpha are involved in inflammatory skin reactions and suspected of modulation by immunosuppressive treatment (e.g., cyclosporin A, CsA) or UVB-irradiation, 2 mediators probably being involved in epithelial carcinogenesis.	Cyclosporine	156-169	tumor necrosis factor	Homo sapiens	36-45
9067703-1	1997	Among epidermal cytokines, IL-1 and TNF alpha are involved in inflammatory skin reactions and suspected of modulation by immunosuppressive treatment (e.g., cyclosporin A, CsA) or UVB-irradiation, 2 mediators probably being involved in epithelial carcinogenesis.	Cyclosporine	171-174	interleukin 1 beta	Homo sapiens	27-31
9067703-1	1997	Among epidermal cytokines, IL-1 and TNF alpha are involved in inflammatory skin reactions and suspected of modulation by immunosuppressive treatment (e.g., cyclosporin A, CsA) or UVB-irradiation, 2 mediators probably being involved in epithelial carcinogenesis.	Cyclosporine	171-174	tumor necrosis factor	Homo sapiens	36-45
9067703-2	1997	We evaluated the effects of 8 micrograms/ml CsA and 100 J/m2 UVB-irradiation on the production and secretion of IL-1 and TNF alpha on normal human epidermal keratinocytes (NHK) and epidermal keratinocyte cell lines either spontaneously transformed (HaCaT) or transformed by human papillomavirus (HPV) type 16 or 18 (EK 16 and EK18), by using ELISA test.	Cyclosporine	44-47	interleukin 1 beta	Homo sapiens	112-116
9067703-2	1997	We evaluated the effects of 8 micrograms/ml CsA and 100 J/m2 UVB-irradiation on the production and secretion of IL-1 and TNF alpha on normal human epidermal keratinocytes (NHK) and epidermal keratinocyte cell lines either spontaneously transformed (HaCaT) or transformed by human papillomavirus (HPV) type 16 or 18 (EK 16 and EK18), by using ELISA test.	Cyclosporine	44-47	tumor necrosis factor	Homo sapiens	121-130
9067703-6	1997	CsA modified significantly the production and secretion of IL1 in most cells whereas slight changes were observed with TNF alpha secretion.	Cyclosporine	0-3	interleukin 1 beta	Homo sapiens	59-62
9067703-9	1997	Taken together, these results show that, in immortalized keratinocytes, the IL-1 and TNF alpha expression was differently affected by treatments with CsA and/or UVB-irradiation as compared to NHK.	Cyclosporine	150-153	interleukin 1 beta	Homo sapiens	76-80
9067703-9	1997	Taken together, these results show that, in immortalized keratinocytes, the IL-1 and TNF alpha expression was differently affected by treatments with CsA and/or UVB-irradiation as compared to NHK.	Cyclosporine	150-153	tumor necrosis factor	Homo sapiens	85-94
9123209-0	1997	High-dose cellular IL-10 exacerbates rejection and reverses effects of cyclosporine and tacrolimus in Mouse cardiac transplantation.	Cyclosporine	71-83	interleukin 10	Mus musculus	19-24
9123401-0	1997	Multidrug resistance gene MDR1 expression: a gene transfection in vitro model and clinical analysis in cyclosporine-treated patients rejecting their renal grafts.	Cyclosporine	103-115	ATP binding cassette subfamily B member 1	Homo sapiens	26-30
9016791-3	1997	In this study, we have demonstrated that C219 inhibits the ATPase activity of P-glycoprotein based on the following findings: 1) the inhibition of total ATPase activity by C219 was selective to P-glycoprotein-positive membranes; 2) the C219-sensitive fraction of ATPase correlated the expression of P-glycoprotein; and 3) modulators of P-glycoprotein ATPase, verapamil and cyclosporin A, affected the C219-sensitive fraction of ATPase.	Cyclosporine	373-386	ATP binding cassette subfamily B member 1	Homo sapiens	78-92
9122996-0	1997	In vivo hyperexpression of transforming growth factor-beta 1 in humans: stimulation by cyclosporine.	Cyclosporine	87-99	transforming growth factor beta 1	Homo sapiens	27-60
8994436-3	1997	In the present study, with the use of rat heart allografts under different doses of cyclosporine A (CsA), we investigated whether the expression of P-selectin is increased during chronic rejection and possibly coexpressed with VCAM-1 on EC.	Cyclosporine	84-98	selectin P	Rattus norvegicus	148-158
9020523-0	1997	The effects of cyclosporin A, dexamethasone and other immunomodulatory drugs on induced expression of IL-3, IL-4 and IL-8 mRNA in a human mast cell line.	Cyclosporine	15-28	interleukin 4	Homo sapiens	108-112
9020523-0	1997	The effects of cyclosporin A, dexamethasone and other immunomodulatory drugs on induced expression of IL-3, IL-4 and IL-8 mRNA in a human mast cell line.	Cyclosporine	15-28	C-X-C motif chemokine ligand 8	Homo sapiens	117-121
9020523-3	1997	Treatment of the cells with the immunosuppressant CsA at 10(-5) M produced a significant inhibition of ionomycin-induced expression of IL-3, IL-4 and IL-8 mRNA, and at 10(-6) M produced a significant inhibition of induced expression of IL-3 and IL-8 but not IL-4.	Cyclosporine	50-53	interleukin 4	Homo sapiens	141-145
9020523-3	1997	Treatment of the cells with the immunosuppressant CsA at 10(-5) M produced a significant inhibition of ionomycin-induced expression of IL-3, IL-4 and IL-8 mRNA, and at 10(-6) M produced a significant inhibition of induced expression of IL-3 and IL-8 but not IL-4.	Cyclosporine	50-53	C-X-C motif chemokine ligand 8	Homo sapiens	150-154
9020523-3	1997	Treatment of the cells with the immunosuppressant CsA at 10(-5) M produced a significant inhibition of ionomycin-induced expression of IL-3, IL-4 and IL-8 mRNA, and at 10(-6) M produced a significant inhibition of induced expression of IL-3 and IL-8 but not IL-4.	Cyclosporine	50-53	C-X-C motif chemokine ligand 8	Homo sapiens	245-249
9020523-3	1997	Treatment of the cells with the immunosuppressant CsA at 10(-5) M produced a significant inhibition of ionomycin-induced expression of IL-3, IL-4 and IL-8 mRNA, and at 10(-6) M produced a significant inhibition of induced expression of IL-3 and IL-8 but not IL-4.	Cyclosporine	50-53	interleukin 4	Homo sapiens	258-262
8994436-3	1997	In the present study, with the use of rat heart allografts under different doses of cyclosporine A (CsA), we investigated whether the expression of P-selectin is increased during chronic rejection and possibly coexpressed with VCAM-1 on EC.	Cyclosporine	100-103	selectin P	Rattus norvegicus	148-158
8994436-10	1997	During intense chronic rejection (5 mg/kg CsA), arterial EC expressed P-selectin (P &lt; .01) and VCAM-1 (P &lt; .05) extensively.	Cyclosporine	42-45	selectin P	Rattus norvegicus	70-80
9116920-0	1997	Development of insulin resistance and elevated blood pressure during therapy with cyclosporine A.	Cyclosporine	82-96	insulin	Homo sapiens	15-22
9209689-0	1997	Implication of CYP 3A in the toxicity of cyclosporin G (CsG), cyclosporin A (CsA) and FK506 on rat hepatocytes in primary culture.	Cyclosporine	62-75	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	15-21
9209689-0	1997	Implication of CYP 3A in the toxicity of cyclosporin G (CsG), cyclosporin A (CsA) and FK506 on rat hepatocytes in primary culture.	Cyclosporine	77-80	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	15-21
9209689-1	1997	FK506, cyclosporin A (CsA), and its structural analog cyclosporin G (CsG) are immunosuppressant drugs mainly metabolized by hepatic cytochrome P-450 3A (CYP 3A) oxygenase.	Cyclosporine	7-20	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	132-151
9209689-1	1997	FK506, cyclosporin A (CsA), and its structural analog cyclosporin G (CsG) are immunosuppressant drugs mainly metabolized by hepatic cytochrome P-450 3A (CYP 3A) oxygenase.	Cyclosporine	7-20	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	153-159
9209689-1	1997	FK506, cyclosporin A (CsA), and its structural analog cyclosporin G (CsG) are immunosuppressant drugs mainly metabolized by hepatic cytochrome P-450 3A (CYP 3A) oxygenase.	Cyclosporine	22-25	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	132-151
9209689-1	1997	FK506, cyclosporin A (CsA), and its structural analog cyclosporin G (CsG) are immunosuppressant drugs mainly metabolized by hepatic cytochrome P-450 3A (CYP 3A) oxygenase.	Cyclosporine	22-25	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	153-159
9209689-12	1997	Our results show that the toxicity of the three drugs in rat hepatocytes is dependent on CYP 3A induction: increased for FK506, decreased for CsA and CsG.	Cyclosporine	142-145	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	89-95
9010037-4	1997	Low-level expression of mdr1 and P-glycoprotein (P-gp), as well as a modest impairment of cellular drug accumulation and partial reversion of resistance to DOX and VP-16 by cyclosporine, confirmed a moderate role of P-gp in conferring drug resistance in P388/SPR cells.	Cyclosporine	173-185	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	24-28
9219509-7	1997	Sensitivity to paclitaxel could be modulated by cyclosporin A in unselected cell lines expressing P-glycoprotein and not in P-glycoprotein-negative cell lines.	Cyclosporine	48-61	ATP binding cassette subfamily B member 1	Homo sapiens	98-112
9272128-7	1997	Our studies of combinations of high-dose cyclosporin (CsA) or PSC 833 with etoposide, doxorubicin, or paclitaxel have produced data regarding the role of Pgp in the clinical pharmacology of these agents.	Cyclosporine	41-52	ATP binding cassette subfamily B member 1	Homo sapiens	154-157
9272128-8	1997	Major pharmacokinetic interactions result from the coadministration of CsA or PSC 833 with MDR-related anticancer agents (e.g., doxorubicin, daunorubicin, etoposide, paclitaxel, and vinblastine).	Cyclosporine	71-74	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	91-94
9052855-0	1997	Pentoxifylline, cyclosporine A and taurolidine inhibit endotoxin-stimulated tumor necrosis factor-alpha production in rat mesangial cell cultures.	Cyclosporine	16-30	tumor necrosis factor	Rattus norvegicus	76-103
9143866-5	1997	The substrates of CYP2D6 such as thioridazine, amitriptyline and metoprolol inhibited the O-demethylation of codeine preferentially, while the substrates of CYP3A4 such as cyclosporine A, midazolam and erythromycin were all strong inhibitors of the N-demethylation of codeine.	Cyclosporine	172-186	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	18-24
9052855-4	1997	We show that lipopolysaccharide-induced production of TNF-alpha in rat mesangial cell cultures is inhibited by pentoxifylline (50 mg/ml), cyclosporine A (0.1 microg/ml) and taurolidine (100 mg/ml).	Cyclosporine	138-152	tumor necrosis factor	Rattus norvegicus	54-63
8977229-7	1997	The completion of HIV-1 reverse transcription was blocked by CsA in infected CD4+ T cells activated by TCR ligation and IL-2, but not in cells stimulated by TCR and CD28 ligation.	Cyclosporine	61-64	interleukin 2	Homo sapiens	120-124
9021546-3	1997	CsA (1-100 ng/ml) did not induce PGE2 formation itself but potentiated TNF-alpha induced PGE2 formation in gingival fibroblasts in a manner dependent on the concentrations of both CsA and TNF-alpha.	Cyclosporine	0-3	tumor necrosis factor	Homo sapiens	71-80
9177492-5	1997	We observed that cyclosporin A and S-9788, which were the most active on MDR reversal, were able to inhibit PKC activity in the KB resistant lines as well as in all C6 lines, whereas verapamil and quinine had only marginal effects on PKC activity.	Cyclosporine	17-30	protein kinase C alpha	Homo sapiens	108-111
9177492-5	1997	We observed that cyclosporin A and S-9788, which were the most active on MDR reversal, were able to inhibit PKC activity in the KB resistant lines as well as in all C6 lines, whereas verapamil and quinine had only marginal effects on PKC activity.	Cyclosporine	17-30	protein kinase C alpha	Homo sapiens	234-237
9177500-4	1997	METHODS: We analysed p53 expression in a group of transplanted, cyclosporin A-treated, KS patients by immunohistochemistry, utilizing the DO-7 (with and without the antigen retrieval pretreatment), and the PAb 240 monoclonal anti-p53 antibodies, the latter of which is able to detect a mutated epitope, and evaluating staining intensity and localization, whether cytoplasmic or nuclear.	Cyclosporine	64-77	tumor protein p53	Homo sapiens	21-24
9021546-3	1997	CsA (1-100 ng/ml) did not induce PGE2 formation itself but potentiated TNF-alpha induced PGE2 formation in gingival fibroblasts in a manner dependent on the concentrations of both CsA and TNF-alpha.	Cyclosporine	0-3	tumor necrosis factor	Homo sapiens	188-197
9021546-3	1997	CsA (1-100 ng/ml) did not induce PGE2 formation itself but potentiated TNF-alpha induced PGE2 formation in gingival fibroblasts in a manner dependent on the concentrations of both CsA and TNF-alpha.	Cyclosporine	180-183	tumor necrosis factor	Homo sapiens	71-80
9021546-4	1997	TNF-alpha (10 ng/ml) stimulated the release of [3H]-arachidonic acid (AA) from prelabelled fibroblasts that was potentiated by CsA (100 ng/ml).	Cyclosporine	127-130	tumor necrosis factor	Homo sapiens	0-9
9001418-1	1997	Using cyclosporin A (CsA) to inhibit P-glycoprotein (P-gp) function we showed previously that there was a discordance between the ability of acute myeloid leukemic (AML) blast cells to accumulate daunorubicin and P-gp antigen expression (Xie et al, Leukemia 1995; 9:1882-1887).	Cyclosporine	6-19	ATP binding cassette subfamily B member 1	Homo sapiens	37-51
9001418-1	1997	Using cyclosporin A (CsA) to inhibit P-glycoprotein (P-gp) function we showed previously that there was a discordance between the ability of acute myeloid leukemic (AML) blast cells to accumulate daunorubicin and P-gp antigen expression (Xie et al, Leukemia 1995; 9:1882-1887).	Cyclosporine	6-19	ATP binding cassette subfamily B member 1	Homo sapiens	53-57
9001418-1	1997	Using cyclosporin A (CsA) to inhibit P-glycoprotein (P-gp) function we showed previously that there was a discordance between the ability of acute myeloid leukemic (AML) blast cells to accumulate daunorubicin and P-gp antigen expression (Xie et al, Leukemia 1995; 9:1882-1887).	Cyclosporine	21-24	ATP binding cassette subfamily B member 1	Homo sapiens	37-51
9001418-1	1997	Using cyclosporin A (CsA) to inhibit P-glycoprotein (P-gp) function we showed previously that there was a discordance between the ability of acute myeloid leukemic (AML) blast cells to accumulate daunorubicin and P-gp antigen expression (Xie et al, Leukemia 1995; 9:1882-1887).	Cyclosporine	21-24	ATP binding cassette subfamily B member 1	Homo sapiens	53-57
9393945-7	1997	Ten minutes preincubation of SMCs with a monoclonal antibody against endothelin-1 (ET-1) significantly prevented the CsA effects at 1 microM.	Cyclosporine	117-120	endothelin 1	Rattus norvegicus	69-81
9126869-0	1997	Cyclosporin-A inhibits human endothelial cells proliferation through interleukin-6-dependent mechanisms.	Cyclosporine	0-13	interleukin 6	Homo sapiens	69-82
9027793-14	1997	It is not specific, but the differential behaviour of CRP in patients receiving cyclosporin helps to distinguish infection from rejection.	Cyclosporine	80-91	C-reactive protein	Homo sapiens	54-57
9031274-7	1997	Urinary oxalate excretion as well as the activities of lactate dehydrogenase, gamma-glutamyltranspeptidase, alkaline phosphatase and inorganic pyrophosphatase enzymes were elevated either in CsA-alone or AmOx-alone treated groups.	Cyclosporine	191-194	inorganic pyrophosphatase 1	Rattus norvegicus	133-158
9381385-0	1997	[The effect of cyclosporin A (Sandimmun) on the level of soluble interleukin-2 receptors in rheumatoid arthritis].	Cyclosporine	15-28	interleukin 2	Homo sapiens	65-78
9034630-2	1996	The aim of this study is to establish the ability of the known NO donor 3-morpholinosydnonimine (SIN-1) to prevent the cyclosporin A-induced contraction by using rat isolated glomeruli and cultured glomerular mesangial cells.	Cyclosporine	119-132	MAPK associated protein 1	Homo sapiens	97-102
8980113-6	1996	The resistance to aureobasidin A conferred by the MDR2/Pgp as well as by the MDR1/Pgp was overcome by vinblastine, verapamil, and cyclosporin A, depending on their concentrations, but not by colchicine.	Cyclosporine	130-143	ATP binding cassette subfamily B member 1	Homo sapiens	55-58
8980113-6	1996	The resistance to aureobasidin A conferred by the MDR2/Pgp as well as by the MDR1/Pgp was overcome by vinblastine, verapamil, and cyclosporin A, depending on their concentrations, but not by colchicine.	Cyclosporine	130-143	ATP binding cassette subfamily B member 1	Homo sapiens	77-81
8980113-6	1996	The resistance to aureobasidin A conferred by the MDR2/Pgp as well as by the MDR1/Pgp was overcome by vinblastine, verapamil, and cyclosporin A, depending on their concentrations, but not by colchicine.	Cyclosporine	130-143	ATP binding cassette subfamily B member 1	Homo sapiens	82-85
8977107-1	1996	Cyclophilins (CyPs) are binding proteins for the immunosuppressive drug cyclosporin A (CsA).	Cyclosporine	72-85	peptidylprolyl isomerase E	Homo sapiens	0-12
8977107-1	1996	Cyclophilins (CyPs) are binding proteins for the immunosuppressive drug cyclosporin A (CsA).	Cyclosporine	87-90	peptidylprolyl isomerase E	Homo sapiens	0-12
9034630-9	1996	In conclusion, a direct constrictive effect of cyclosporin A in isolated glomeruli and mesangial cells can be prevented by the NO donor SIN-1, suggesting an important involvement of the nitric oxide pathway in the cyclosporin A-induced nephrotoxicity.	Cyclosporine	47-60	MAPK associated protein 1	Homo sapiens	136-141
9034630-9	1996	In conclusion, a direct constrictive effect of cyclosporin A in isolated glomeruli and mesangial cells can be prevented by the NO donor SIN-1, suggesting an important involvement of the nitric oxide pathway in the cyclosporin A-induced nephrotoxicity.	Cyclosporine	214-227	MAPK associated protein 1	Homo sapiens	136-141
9014816-8	1996	However, interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) mRNAs were detected in the control reinfected animals on days 3 and/or 9 after reinfection but not on these days in animals undergoing treatment with CsA.	Cyclosporine	213-216	interleukin 2	Homo sapiens	9-22
8939643-3	1996	The immunosuppressants cyclosporin A and FK506, when complexed with immunophilins, inactivate the protein phosphatase calcineurin, resulting in the inhibition of interleukin-2 gene activation.	Cyclosporine	23-36	interleukin 2	Homo sapiens	162-175
9050745-2	1996	CsA caused a dose-related inhibition of interleukin 1beta(IL-1beta) production in both normal and athymic mice, confirming earlier conclusions that this effect is not T cell dependent (ED50s 40 and 53 mg/kg p.o., respectively).	Cyclosporine	0-3	interleukin 1 beta	Mus musculus	40-57
9050745-2	1996	CsA caused a dose-related inhibition of interleukin 1beta(IL-1beta) production in both normal and athymic mice, confirming earlier conclusions that this effect is not T cell dependent (ED50s 40 and 53 mg/kg p.o., respectively).	Cyclosporine	0-3	interleukin 1 beta	Mus musculus	58-66
9050745-5	1996	By contrast, CsA inhibited interleukin 6 (IL-6) production only in normal mice (ED50 27 mg/kg p.o.)	Cyclosporine	13-16	interleukin 6	Mus musculus	27-40
9050745-5	1996	By contrast, CsA inhibited interleukin 6 (IL-6) production only in normal mice (ED50 27 mg/kg p.o.)	Cyclosporine	13-16	interleukin 6	Mus musculus	42-46
9050745-8	1996	The present findings support the authors" original hypothesis, that the inhibitory mechanism of CsA on IL-1beta is not mediated via T cells.	Cyclosporine	96-99	interleukin 1 beta	Mus musculus	103-111
9014816-8	1996	However, interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) mRNAs were detected in the control reinfected animals on days 3 and/or 9 after reinfection but not on these days in animals undergoing treatment with CsA.	Cyclosporine	213-216	interferon gamma	Homo sapiens	34-50
9014816-8	1996	However, interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) mRNAs were detected in the control reinfected animals on days 3 and/or 9 after reinfection but not on these days in animals undergoing treatment with CsA.	Cyclosporine	213-216	interferon gamma	Homo sapiens	52-61
9014823-3	1996	This reduction was insensitive to the addition of cyclosporin A, indicating that the repression by IL-7 is not mediated by phosphatase 2B.	Cyclosporine	50-63	interleukin 7	Homo sapiens	99-103
8974006-3	1996	NFAT acts at the antigen receptor response element-2 (ARRE-2) sequence in the IL-2 enhancer and is the nuclear target of T cell stimulation signals and the immunosuppressant drugs cyclosporine and FK506, which are potent inhibitors of IL-2 gene transcription.	Cyclosporine	180-192	interleukin 2	Homo sapiens	78-82
8977524-6	1996	Cyclosporin A inhibited the proliferation as well as the production of the cytokines, including that of IL-2, IL-4, IL-5, and IFN-gamma, irrespective of the mode of stimulation.	Cyclosporine	0-13	interleukin 2	Homo sapiens	104-108
8977524-6	1996	Cyclosporin A inhibited the proliferation as well as the production of the cytokines, including that of IL-2, IL-4, IL-5, and IFN-gamma, irrespective of the mode of stimulation.	Cyclosporine	0-13	interleukin 4	Homo sapiens	110-114
8977524-6	1996	Cyclosporin A inhibited the proliferation as well as the production of the cytokines, including that of IL-2, IL-4, IL-5, and IFN-gamma, irrespective of the mode of stimulation.	Cyclosporine	0-13	interferon gamma	Homo sapiens	126-135
9115576-1	1996	We conducted a pilot study of immunosuppression with low dose cyclosporine in first degree relatives of diabetic patients with immunologic and metabolic criteria for preclinical diabetes: islet cell antibodies (ICA) &gt; or = 20 Juvenile Diabetes Foundation (JDF) units, first phase insulin response &lt; 10th percentile and impaired glucose tolerance.	Cyclosporine	62-74	insulin	Homo sapiens	283-290
8974006-3	1996	NFAT acts at the antigen receptor response element-2 (ARRE-2) sequence in the IL-2 enhancer and is the nuclear target of T cell stimulation signals and the immunosuppressant drugs cyclosporine and FK506, which are potent inhibitors of IL-2 gene transcription.	Cyclosporine	180-192	interleukin 2	Homo sapiens	235-239
8939917-1	1996	Complete prevention of the killing of L929 fibroblasts by tumor necrosis factor alpha (TNF) in the presence of 0.5 microg/ml actinomycin D (ActD) was obtained with cyclosporin A (CyA), an inhibitor of the mitochondrial permeability transition (MPT), and aristolochic acid (ArA), a phospholipase A2 inhibitor.	Cyclosporine	164-177	tumor necrosis factor	Homo sapiens	58-85
9008098-6	1996	CsA treatment (500 ng/ml) during MLR caused a modest decrease in upregulation of VCAM-1 on EnC (p&lt;0.05), but had no effects on ICAM-1 on both cells.	Cyclosporine	0-3	vascular cell adhesion molecule 1	Homo sapiens	81-87
9008098-7	1996	CsA directly decreased expression of VCAM-1 on MC.	Cyclosporine	0-3	vascular cell adhesion molecule 1	Homo sapiens	37-43
9130372-0	1996	Inhibitory effect of cyclosporin A on prolactin synthesis in GH3 cells.	Cyclosporine	21-34	prolactin	Rattus norvegicus	38-47
9130372-2	1996	In this study, the effects of CsA on prolactin (PRL) synthesis and release were investigated in GH3 cells, a clonal strain of rat pituitary tumor.	Cyclosporine	30-33	prolactin	Rattus norvegicus	37-46
9130372-3	1996	After incubation of confluent GH3 cells with various concentrations of CsA for 24 hr, the PRL content of the media decreased in a dose-dependent manner: by 28.5% with 100 ng/ml CsA (p &lt; 0.01); and 45.8% with 2,000 ng/ml CsA (p &lt; 0.001), compared with control.	Cyclosporine	71-74	prolactin	Rattus norvegicus	90-93
9130372-3	1996	After incubation of confluent GH3 cells with various concentrations of CsA for 24 hr, the PRL content of the media decreased in a dose-dependent manner: by 28.5% with 100 ng/ml CsA (p &lt; 0.01); and 45.8% with 2,000 ng/ml CsA (p &lt; 0.001), compared with control.	Cyclosporine	177-180	prolactin	Rattus norvegicus	90-93
9130372-3	1996	After incubation of confluent GH3 cells with various concentrations of CsA for 24 hr, the PRL content of the media decreased in a dose-dependent manner: by 28.5% with 100 ng/ml CsA (p &lt; 0.01); and 45.8% with 2,000 ng/ml CsA (p &lt; 0.001), compared with control.	Cyclosporine	177-180	prolactin	Rattus norvegicus	90-93
9130372-5	1996	After removal of CsA from the medium, GH3 cells fully recovered normal secretory activity within 24-48 hr, thus indicating that the inhibitory effect of CsA on PRL secretion was reversible.	Cyclosporine	153-156	prolactin	Rattus norvegicus	160-163
9130372-6	1996	Northern blot analysis revealed a decrease in the PRL mRNA level in cells treated with CsA.	Cyclosporine	87-90	prolactin	Rattus norvegicus	50-53
8939917-1	1996	Complete prevention of the killing of L929 fibroblasts by tumor necrosis factor alpha (TNF) in the presence of 0.5 microg/ml actinomycin D (ActD) was obtained with cyclosporin A (CyA), an inhibitor of the mitochondrial permeability transition (MPT), and aristolochic acid (ArA), a phospholipase A2 inhibitor.	Cyclosporine	164-177	tumor necrosis factor	Homo sapiens	87-90
8939917-1	1996	Complete prevention of the killing of L929 fibroblasts by tumor necrosis factor alpha (TNF) in the presence of 0.5 microg/ml actinomycin D (ActD) was obtained with cyclosporin A (CyA), an inhibitor of the mitochondrial permeability transition (MPT), and aristolochic acid (ArA), a phospholipase A2 inhibitor.	Cyclosporine	164-177	phospholipase A2 group IB	Homo sapiens	281-297
8939917-1	1996	Complete prevention of the killing of L929 fibroblasts by tumor necrosis factor alpha (TNF) in the presence of 0.5 microg/ml actinomycin D (ActD) was obtained with cyclosporin A (CyA), an inhibitor of the mitochondrial permeability transition (MPT), and aristolochic acid (ArA), a phospholipase A2 inhibitor.	Cyclosporine	179-182	tumor necrosis factor	Homo sapiens	58-85
8939917-1	1996	Complete prevention of the killing of L929 fibroblasts by tumor necrosis factor alpha (TNF) in the presence of 0.5 microg/ml actinomycin D (ActD) was obtained with cyclosporin A (CyA), an inhibitor of the mitochondrial permeability transition (MPT), and aristolochic acid (ArA), a phospholipase A2 inhibitor.	Cyclosporine	179-182	tumor necrosis factor	Homo sapiens	87-90
8939917-5	1996	CyA plus ArA completely prevented this effect of TNF.	Cyclosporine	0-3	tumor necrosis factor	Homo sapiens	49-52
8943018-6	1996	Cyclosporin A, a potent inhibitor of apoptosis induced by either mIgM or ionomycin, inhibited activation of both SAPK and p38 MAPK, suggesting that stimulation of these kinases may be required for induction of apoptosis.	Cyclosporine	0-13	mitogen-activated protein kinase 9	Homo sapiens	113-117
8943018-6	1996	Cyclosporin A, a potent inhibitor of apoptosis induced by either mIgM or ionomycin, inhibited activation of both SAPK and p38 MAPK, suggesting that stimulation of these kinases may be required for induction of apoptosis.	Cyclosporine	0-13	mitogen-activated protein kinase 14	Homo sapiens	122-125
8916948-7	1996	Electrophoretic mobility shift assay showed that CsA inhibited the LPS-induced activation of the nuclear factor kappa B (NF-kappa B).	Cyclosporine	49-52	nuclear factor kappa B subunit 1	Homo sapiens	97-119
9130372-7	1996	In conclusion, these data suggest that CsA inhibits PRL secretion by reducing the rate of biosynthesis.	Cyclosporine	39-42	prolactin	Rattus norvegicus	52-55
8916948-7	1996	Electrophoretic mobility shift assay showed that CsA inhibited the LPS-induced activation of the nuclear factor kappa B (NF-kappa B).	Cyclosporine	49-52	nuclear factor kappa B subunit 1	Homo sapiens	121-131
8916948-8	1996	As shown by Western blot analysis, CsA treatment decreased the nuclear translocation of NF-kappa B, thereby suggesting the mechanism for the inhibitory effect of CsA on TF induction.	Cyclosporine	35-38	nuclear factor kappa B subunit 1	Homo sapiens	88-98
8916948-8	1996	As shown by Western blot analysis, CsA treatment decreased the nuclear translocation of NF-kappa B, thereby suggesting the mechanism for the inhibitory effect of CsA on TF induction.	Cyclosporine	162-165	nuclear factor kappa B subunit 1	Homo sapiens	88-98
8909298-9	1996	The P-glycoprotein-modulating agents cyclosporin A, PSC833, and verapamil, which have modest reversing effects on MRP-overexpressing cell lines, were weak competitive inhibitors of daunorubicin transport, with Ki values of 35, 84, and 95 microM, respectively.	Cyclosporine	37-50	ATP binding cassette subfamily C member 1	Homo sapiens	114-117
8906804-4	1996	Interference with the IL-2 pathway was achieved by 1) inhibition of cytokine synthesis using cyclosporin A or FK506, 2) neutralization of IL-2 by anti-IL-2 Ab, 3) inhibition of binding to IL-2R by CD25 mAb, and 4) blocking of IL-2R signaling by rapamycin.	Cyclosporine	93-106	interleukin 2	Homo sapiens	22-26
8982402-0	1996	Cyclosporin A down-regulates the LTA4 hydrolase level in human keratinocyte cultures.	Cyclosporine	0-13	leukotriene A4 hydrolase	Homo sapiens	33-47
8982402-9	1996	These results show that cyclosporin A, in contrast to other anti-inflammatory and anti-proliferative compounds, inhibits the level of leukotriene A4 hydrolase in keratinocyte cultures.	Cyclosporine	24-37	leukotriene A4 hydrolase	Homo sapiens	134-158
8982402-10	1996	Since similar cyclosporin A concentrations are obtained during treatment of psoriasis with cyclosporin A, the effect on leukotriene A4 hydrolase may play a role in the anti-inflammatory action of cyclosporin A.	Cyclosporine	14-27	leukotriene A4 hydrolase	Homo sapiens	120-144
8982402-10	1996	Since similar cyclosporin A concentrations are obtained during treatment of psoriasis with cyclosporin A, the effect on leukotriene A4 hydrolase may play a role in the anti-inflammatory action of cyclosporin A.	Cyclosporine	91-104	leukotriene A4 hydrolase	Homo sapiens	120-144
8982402-10	1996	Since similar cyclosporin A concentrations are obtained during treatment of psoriasis with cyclosporin A, the effect on leukotriene A4 hydrolase may play a role in the anti-inflammatory action of cyclosporin A.	Cyclosporine	91-104	leukotriene A4 hydrolase	Homo sapiens	120-144
8945910-8	1996	Inhibition by cyclosporin A of the Ca(2+)-calmodulin-dependent phosphatase calcineurin potentiated constitutive preproET-1 mRNA.	Cyclosporine	14-27	calmodulin 1	Homo sapiens	42-52
8944632-5	1996	Further-more, nordihydroguaiaretic acid inhibited Ca(2+)-dependent proliferation of mitogen-activated human peripheral blood mononuclear cells or Jurkat T cells and specifically blocked Ca(2+)-dependent interleukin 2 production by Jurkat T cells to a degree similar to the immunosuppressant drug cyclosporin A.	Cyclosporine	296-309	interleukin 2	Homo sapiens	203-216
8892677-2	1996	SDZ PSC 833, a non-immunosuppressive cyclosporin analogue reverses multidrug resistance (MDR) in vitro by inhibiting P-glycoprotein (P-gp) mediated drug efflux.	Cyclosporine	37-48	ATP binding cassette subfamily B member 1	Homo sapiens	117-131
8892677-2	1996	SDZ PSC 833, a non-immunosuppressive cyclosporin analogue reverses multidrug resistance (MDR) in vitro by inhibiting P-glycoprotein (P-gp) mediated drug efflux.	Cyclosporine	37-48	ATP binding cassette subfamily B member 1	Homo sapiens	133-137
9076845-2	1996	This study was directed to investigate the effect of Cyclosporine A pretreatment on hepatic injury due to carbon tetrachloride (CCl4) and D-galactosamine.	Cyclosporine	53-67	C-C motif chemokine ligand 4	Rattus norvegicus	128-132
8914030-0	1996	Increased renal tubular expression of transforming growth factor beta in human allografts correlates with cyclosporine toxicity.	Cyclosporine	106-118	transforming growth factor beta 1	Homo sapiens	38-69
8914030-1	1996	Cyclosporine A (CsA) is a potent immunosuppressive drug that inhibits the transcription of several proinflammatory cytokines including interleukin-2.	Cyclosporine	0-14	interleukin 2	Homo sapiens	135-148
8914030-1	1996	Cyclosporine A (CsA) is a potent immunosuppressive drug that inhibits the transcription of several proinflammatory cytokines including interleukin-2.	Cyclosporine	16-19	interleukin 2	Homo sapiens	135-148
8914030-2	1996	In contrast, CsA stimulates transcription of the pleuripotent cytokine, transforming growth factor-beta (TGF beta).	Cyclosporine	13-16	transforming growth factor beta 1	Homo sapiens	72-103
8914030-2	1996	In contrast, CsA stimulates transcription of the pleuripotent cytokine, transforming growth factor-beta (TGF beta).	Cyclosporine	13-16	transforming growth factor beta 1	Homo sapiens	105-113
8914030-7	1996	In biopsies with histological evidence of CsA toxicity, 77% demonstrated intense (2 to 3+) TGF beta immunostaining.	Cyclosporine	42-45	transforming growth factor beta 1	Homo sapiens	91-99
8914030-14	1996	In conclusion, we demonstrate that TGF beta protein levels in renal allografts correlate with CsA effect and differentiate ACT from ATN.	Cyclosporine	94-97	transforming growth factor beta 1	Homo sapiens	35-43
8914030-15	1996	In CsA treated patients who develop ACR, TGF beta levels predict the subsequent clinical course and graft function.	Cyclosporine	3-6	transforming growth factor beta 1	Homo sapiens	41-49
8914030-16	1996	Therefore, evaluating tissue levels of TGF beta may offer unique diagnostic and prognostic benefits in the care of patients receiving CsA based immunosuppression.	Cyclosporine	134-137	transforming growth factor beta 1	Homo sapiens	39-47
8931666-10	1996	These data suggest that CsA modifies the pulsatile secretory pattern of prolactin in pituitary-grafted male rats.	Cyclosporine	24-27	prolactin	Rattus norvegicus	72-81
8931666-1	1996	The interrelationship between the effects of prolactin and cyclosporine (CsA) appears to be very complex and until now poorly understood.	Cyclosporine	73-76	prolactin	Rattus norvegicus	45-54
8931666-2	1996	The aim of the present work was to analyze whether chronic treatment with CsA could modify the episodic secretion of prolactin in male rats and whether the presence of an ectopic pituitary could counteract the effects of the drug on the pulsatile secretion pattern of this hormone.	Cyclosporine	74-77	prolactin	Rattus norvegicus	117-126
8931666-5	1996	Pituitary grafting and/or CsA administration changed the pulsatile secretion pattern of prolactin.	Cyclosporine	26-29	prolactin	Rattus norvegicus	88-97
8931666-7	1996	CsA administration to sham-operated rats increased the relative amplitude of prolactin peaks and diminished the half-life of the hormone, compared with rats of the same group treated with vehicle.	Cyclosporine	0-3	prolactin	Rattus norvegicus	77-86
8931666-8	1996	However, CsA treatment in pituitary grafted rats led to lower mean serum prolactin levels and absolute amplitude, while the frequency, duration, and relative amplitude of prolactin pulses were not modified.	Cyclosporine	9-12	prolactin	Rattus norvegicus	73-82
9125798-8	1996	Recently transforming growth factor (TGF)-beta was shown to be upregulated along with matrix proteins in a model of CsA nephrotoxicity.	Cyclosporine	116-119	transforming growth factor beta 1	Homo sapiens	37-46
9125798-9	1996	Because TGF-beta has immunosuppressive activities, it was suggested that it may contribute not only to CsA nephrotoxicity, but also to the mechanism of action of CsA.	Cyclosporine	103-106	transforming growth factor beta 1	Homo sapiens	8-16
9125798-9	1996	Because TGF-beta has immunosuppressive activities, it was suggested that it may contribute not only to CsA nephrotoxicity, but also to the mechanism of action of CsA.	Cyclosporine	162-165	transforming growth factor beta 1	Homo sapiens	8-16
8900312-1	1996	In T cells stimulated through the T cell receptor (TCR), both cyclosporine (CsA) and glucocorticoids (GC) inhibit the transcription of the IL-2 gene.	Cyclosporine	62-74	interleukin 2	Homo sapiens	139-143
8906214-10	1996	Cyclosporin A inhibited in vivo production of IFN-gamma, IL-4, and IL-5 by approximately 80%, but not that of IL-6.	Cyclosporine	0-13	interferon gamma	Mus musculus	46-55
8900312-1	1996	In T cells stimulated through the T cell receptor (TCR), both cyclosporine (CsA) and glucocorticoids (GC) inhibit the transcription of the IL-2 gene.	Cyclosporine	76-79	interleukin 2	Homo sapiens	139-143
8893053-2	1996	The function of P-glycoprotein was assessed by the accumulation of rhodamine-123 (Rh123) dye in the presence or absence of cyclosporin A (which inhibits Rh123 efflux).	Cyclosporine	123-136	ATP binding cassette subfamily B member 1	Homo sapiens	16-30
8980883-0	1996	Differential suppression of dialysis patients" lymphocyte IFN-gamma production by glucocorticoids and cyclosporine.	Cyclosporine	102-114	interferon gamma	Homo sapiens	58-67
8980883-2	1996	Having previously demonstrated differential suppressive effects of methylprednisolone (MP), prednisolone (P) and cyclosporine (CsA) on dialysis patients" lymphocyte proliferative responses to phytohaemagglutinin (PHA), we studied the effects of these drugs on dialysis patients" lymphocyte IFN-gamma production during mitogenic and allogeneic (MLR) stimulation.	Cyclosporine	113-125	interferon gamma	Homo sapiens	290-299
8855178-3	1996	It has been shown that such prehepatic metabolism contributes substantially to total clearance of CYP3A4 substrates (e.g., cyclosporine) before and even more pronounced during enzyme induction.	Cyclosporine	123-135	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	98-104
8828502-5	1996	On the other hand, cyclosporin A, inhibiting the calcium-dependent serine/threonine phosphatase calcineurin, prevents the dephosphorylation and inactivation of inhibitor-1.	Cyclosporine	19-32	protein phosphatase 1 regulatory inhibitor subunit 1A	Homo sapiens	160-171
8828502-7	1996	Because inhibitor-1 is the main regulator of protein phosphatase 1 activity, these results suggest that protein phosphatase 1 may be the common target of cAMP and cyclosporin A in regulating cell proliferation.	Cyclosporine	163-176	protein phosphatase 1 regulatory inhibitor subunit 1A	Homo sapiens	8-19
8828502-8	1996	We propose that protein-phosphatase 1 stimulates growth in these cells and that cAMP and cyclosporin A block this effect through their actions on inhibitor-1.	Cyclosporine	89-102	protein phosphatase 1 regulatory inhibitor subunit 1A	Homo sapiens	146-157
8891735-3	1996	Here we demonstrate that Dex and CsA, at concentrations that markedly inhibit phytohemagglutinin (PHA)-induced proliferation of normal human peripheral blood lymphocytes, suppress the activation-dependent expression of interleukin 2 (IL-2) and the alpha-chain IL-2 receptor in a dose-dependent fashion without affecting the inducible accumulation and kinetics of either bcl-2 or fas mRNAs.	Cyclosporine	33-36	interleukin 2	Homo sapiens	219-232
8891735-3	1996	Here we demonstrate that Dex and CsA, at concentrations that markedly inhibit phytohemagglutinin (PHA)-induced proliferation of normal human peripheral blood lymphocytes, suppress the activation-dependent expression of interleukin 2 (IL-2) and the alpha-chain IL-2 receptor in a dose-dependent fashion without affecting the inducible accumulation and kinetics of either bcl-2 or fas mRNAs.	Cyclosporine	33-36	interleukin 2	Homo sapiens	234-238
8891735-3	1996	Here we demonstrate that Dex and CsA, at concentrations that markedly inhibit phytohemagglutinin (PHA)-induced proliferation of normal human peripheral blood lymphocytes, suppress the activation-dependent expression of interleukin 2 (IL-2) and the alpha-chain IL-2 receptor in a dose-dependent fashion without affecting the inducible accumulation and kinetics of either bcl-2 or fas mRNAs.	Cyclosporine	33-36	interleukin 2	Homo sapiens	260-264
8891735-3	1996	Here we demonstrate that Dex and CsA, at concentrations that markedly inhibit phytohemagglutinin (PHA)-induced proliferation of normal human peripheral blood lymphocytes, suppress the activation-dependent expression of interleukin 2 (IL-2) and the alpha-chain IL-2 receptor in a dose-dependent fashion without affecting the inducible accumulation and kinetics of either bcl-2 or fas mRNAs.	Cyclosporine	33-36	BCL2 apoptosis regulator	Homo sapiens	370-375
8977369-1	1996	In the present study, a set of two monoclonal antibodies (TRPM1, TRPM2) was used to investigate the macrophage populations in the rat thymus and their different sensitivities to cyclosporine-A (CsA).	Cyclosporine	178-192	transient receptor potential cation channel, subfamily M, member 1	Rattus norvegicus	58-63
8930780-0	1996	Suppression of lymphocyte interleukin-2 receptor expression by glucocorticoids, cyclosporine, or both.	Cyclosporine	80-92	interleukin 2	Homo sapiens	26-39
8898356-8	1996	This latter observation explains the enhanced potency of cyclosporin A as an inhibitor of the mutant Pgp.	Cyclosporine	57-70	ATP binding cassette subfamily B member 1	Homo sapiens	101-104
8953513-4	1996	Acebutolol uptake by K562/ADM cells was, moreover, markedly enhanced, in a concentration-dependent manner, in the presence of the specific P-glycoprotein inhibitors, MS-209 and cyclosporin.	Cyclosporine	177-188	ATP binding cassette subfamily B member 1	Homo sapiens	139-153
8808649-8	1996	Agents that are now being used clinically, or are in advanced stages of development include: cyclosporin A, which interferes with synthesis of the cytokine interleukin 2 (IL2); IL2 toxin, which binds to IL2 receptors on activated T cells, is endocytosed, and kills the cells; and CTLA4Ig, which blocks costimulatory molecules, thus preventing full activation of T cells.	Cyclosporine	93-106	interleukin 2	Homo sapiens	156-169
8808649-8	1996	Agents that are now being used clinically, or are in advanced stages of development include: cyclosporin A, which interferes with synthesis of the cytokine interleukin 2 (IL2); IL2 toxin, which binds to IL2 receptors on activated T cells, is endocytosed, and kills the cells; and CTLA4Ig, which blocks costimulatory molecules, thus preventing full activation of T cells.	Cyclosporine	93-106	interleukin 2	Homo sapiens	171-174
8816436-2	1996	In both cases, induction of TNF-alpha gene transcription can be blocked by the immunosuppressants cyclosporin A and FK506, which suggested a role for the NFAT family of proteins in the regulation of the gene in B cells.	Cyclosporine	98-111	tumor necrosis factor	Homo sapiens	28-37
8816436-7	1996	This new site plays a critical role in the calcium-mediated, cyclosporin A-sensitive induction of TNF-alpha in both A20 B cells and Ar-5 cells.	Cyclosporine	61-74	tumor necrosis factor	Homo sapiens	98-107
8898356-10	1996	We conclude that the G185--&gt;V mutation confers pleiotropic alterations on Pgp, including an altered basal ATPase activity and altered interaction with substrates and the inhibitor cyclosporin A.	Cyclosporine	183-196	ATP binding cassette subfamily B member 1	Homo sapiens	77-80
8885130-3	1996	This elevation in cyclosporine level is possibly due to an interaction between the two drugs resulting from an inhibition of CYP3A4-mediated metabolism of cyclosporine by glibenclamide.	Cyclosporine	18-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	125-131
8885130-3	1996	This elevation in cyclosporine level is possibly due to an interaction between the two drugs resulting from an inhibition of CYP3A4-mediated metabolism of cyclosporine by glibenclamide.	Cyclosporine	155-167	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	125-131
8782646-9	1996	Moreover, treatments of MCF-7/Adr cells with P-glycoprotein (P-gp) modulators, cyclosporin A and verapamil increased doxorubicin and vincristine-induced DNA fragmentation about 1.4- and 2.5-fold, indicating that P-gp is involved in the development of resistance to chemotherapy-induced apoptosis in this cell line.	Cyclosporine	79-92	ATP binding cassette subfamily B member 1	Homo sapiens	212-216
8855292-9	1996	In vitro Bcl-XL induction following ligation of sIgM-required BTK, was cyclosporin A (CsA)-sensitive and dependent on extracellular Ca2+.	Cyclosporine	71-84	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	62-65
8855292-9	1996	In vitro Bcl-XL induction following ligation of sIgM-required BTK, was cyclosporin A (CsA)-sensitive and dependent on extracellular Ca2+.	Cyclosporine	86-89	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	62-65
8853418-3	1996	HSP-70 mRNA was increased immediately after heat shock, returning to baseline by 4 h. HSP-70 protein increased by 1 h after heat shock and declined thereafter, approaching baseline after 72 h. Cells heat shocked at 4 and 24 h prior to CyA exposure were significantly more viable than controls, at CyA concentrations near the median lethal dose (LD50).	Cyclosporine	235-238	heat shock 70 kDa protein 6	Sus scrofa	86-92
8853343-6	1996	This augmentation is correlated with a threefold increase in the endothelial constitutive NO synthase (ecNOS) transcript, which is time dependent and maximal at 24 h. The CsA-induced increase in ecNOS mRNA expression was blocked by actinomycin D but unaltered by cycloheximide.	Cyclosporine	171-174	nitric oxide synthase 3	Bos taurus	103-108
8853343-6	1996	This augmentation is correlated with a threefold increase in the endothelial constitutive NO synthase (ecNOS) transcript, which is time dependent and maximal at 24 h. The CsA-induced increase in ecNOS mRNA expression was blocked by actinomycin D but unaltered by cycloheximide.	Cyclosporine	171-174	nitric oxide synthase 3	Bos taurus	195-200
8853418-3	1996	HSP-70 mRNA was increased immediately after heat shock, returning to baseline by 4 h. HSP-70 protein increased by 1 h after heat shock and declined thereafter, approaching baseline after 72 h. Cells heat shocked at 4 and 24 h prior to CyA exposure were significantly more viable than controls, at CyA concentrations near the median lethal dose (LD50).	Cyclosporine	297-300	heat shock 70 kDa protein 6	Sus scrofa	0-6
8853343-7	1996	Levels of ecNOS protein were also enhanced by CsA after 24 h. These data establish that NO synthesis is moderately enhanced in endothelial cells exposed to CsA for long periods of time and describe a new mode of regulating ecNOS gene expression.	Cyclosporine	46-49	nitric oxide synthase 3	Bos taurus	10-15
8853343-7	1996	Levels of ecNOS protein were also enhanced by CsA after 24 h. These data establish that NO synthesis is moderately enhanced in endothelial cells exposed to CsA for long periods of time and describe a new mode of regulating ecNOS gene expression.	Cyclosporine	46-49	nitric oxide synthase 3	Bos taurus	223-228
8853418-3	1996	HSP-70 mRNA was increased immediately after heat shock, returning to baseline by 4 h. HSP-70 protein increased by 1 h after heat shock and declined thereafter, approaching baseline after 72 h. Cells heat shocked at 4 and 24 h prior to CyA exposure were significantly more viable than controls, at CyA concentrations near the median lethal dose (LD50).	Cyclosporine	297-300	heat shock 70 kDa protein 6	Sus scrofa	86-92
8853343-7	1996	Levels of ecNOS protein were also enhanced by CsA after 24 h. These data establish that NO synthesis is moderately enhanced in endothelial cells exposed to CsA for long periods of time and describe a new mode of regulating ecNOS gene expression.	Cyclosporine	156-159	nitric oxide synthase 3	Bos taurus	10-15
8751470-4	1996	The increased level of IL-6 in this patient decreased to normal within 3 weeks of CsA administration and the patient became symptom-free.	Cyclosporine	82-85	interleukin 6	Homo sapiens	23-27
8853343-7	1996	Levels of ecNOS protein were also enhanced by CsA after 24 h. These data establish that NO synthesis is moderately enhanced in endothelial cells exposed to CsA for long periods of time and describe a new mode of regulating ecNOS gene expression.	Cyclosporine	156-159	nitric oxide synthase 3	Bos taurus	223-228
8949984-4	1996	After 24 h incubation with 15 microM of the modulators, MDR1 gene expression was slightly but significantly decreased by two of them, quinine and cyclosporine A, whereas verapamil and S-9788 had very little effect on this parameter.	Cyclosporine	146-160	ATP binding cassette subfamily B member 1	Homo sapiens	56-60
8809139-0	1996	Susceptibility to clinically manifest cyclosporine A (CsA)-induced autoimmune disease is associated with interferon-gamma (IFN-gamma)-producing CD45RC+RT6- T helper cells.	Cyclosporine	38-52	ADP-ribosyltransferase 2b	Rattus norvegicus	151-154
8809139-0	1996	Susceptibility to clinically manifest cyclosporine A (CsA)-induced autoimmune disease is associated with interferon-gamma (IFN-gamma)-producing CD45RC+RT6- T helper cells.	Cyclosporine	54-57	ADP-ribosyltransferase 2b	Rattus norvegicus	151-154
8809139-6	1996	LEW rats, x-irradiated, syngeneic bone marrow-reconstituted and treated with CsA, showed a marked and persistent, relative expansion of mature CD45RC+, RT6- Th cells.	Cyclosporine	77-80	ADP-ribosyltransferase 2b	Rattus norvegicus	152-155
9816326-2	1996	Cyclosporin blocks P-glycoprotein-induced efflux of vincristine and teniposide in vitro, and possibly modulates responses to carboplatin.	Cyclosporine	0-11	ATP binding cassette subfamily B member 1	Homo sapiens	19-33
8814265-0	1996	Cyclosporin A sensitivity of the HIV-1 long terminal repeat identifies distinct p56lck-dependent pathways activated by CD4 triggering.	Cyclosporine	0-13	CD4 molecule	Homo sapiens	119-122
8814265-4	1996	We show that CD4 triggering activates different pathways of HIV LTR activation which can be identified by their sensitivity to the immunosuppressant cyclosporin A.	Cyclosporine	149-162	CD4 molecule	Homo sapiens	13-16
8814265-5	1996	The response of the inducible cellular transcription factors involved in HIVLTR activation shows that both nuclear factor (NF)-kappa B and NF-AT mediate a cyclosporin A-sensitive response to CD4, while AP-1 is at least in part responsible for the cyclosporin A-insensitive response.	Cyclosporine	155-168	nuclear factor kappa B subunit 1	Homo sapiens	107-134
8814265-5	1996	The response of the inducible cellular transcription factors involved in HIVLTR activation shows that both nuclear factor (NF)-kappa B and NF-AT mediate a cyclosporin A-sensitive response to CD4, while AP-1 is at least in part responsible for the cyclosporin A-insensitive response.	Cyclosporine	155-168	CD4 molecule	Homo sapiens	191-194
8814265-5	1996	The response of the inducible cellular transcription factors involved in HIVLTR activation shows that both nuclear factor (NF)-kappa B and NF-AT mediate a cyclosporin A-sensitive response to CD4, while AP-1 is at least in part responsible for the cyclosporin A-insensitive response.	Cyclosporine	247-260	nuclear factor kappa B subunit 1	Homo sapiens	107-134
8814265-5	1996	The response of the inducible cellular transcription factors involved in HIVLTR activation shows that both nuclear factor (NF)-kappa B and NF-AT mediate a cyclosporin A-sensitive response to CD4, while AP-1 is at least in part responsible for the cyclosporin A-insensitive response.	Cyclosporine	247-260	CD4 molecule	Homo sapiens	191-194
8884530-4	1996	FK506 and CsA inhibit keratinocyte proliferation induced by EGF, TGF-alpha or IL-6.	Cyclosporine	10-13	interleukin 6	Homo sapiens	78-82
8884530-6	1996	These findings might indicate that the effects of FK506 and CsA on proliferation of cultured normal human keratinocytes are probably related to direct effects on growth regulation of keratinocytes via EGF, TGF-alpha or IL-6 stimulation.	Cyclosporine	60-63	interleukin 6	Homo sapiens	219-223
8877921-6	1996	After adding CyA 3 mg/kg daily for 6 months, BMD had increased by 3.9 +/- 0.97%, IGF-1 by 42.4%, DHEAS by 34.2%, BGP by +34.3%.	Cyclosporine	13-16	bone gamma-carboxyglutamate protein	Homo sapiens	113-116
8751470-7	1996	IL-6 production by LNMC was stimulated by IL-2 but inhibited by CsA.	Cyclosporine	64-67	interleukin 6	Homo sapiens	0-4
9592351-5	1996	Good reversal effect was obtained in refractory patients and MDR1 positive relapsing patients by adding CsA (P &lt; 0.01).	Cyclosporine	104-107	ATP binding cassette subfamily B member 1	Homo sapiens	61-65
8702500-8	1996	CsA and FK506 are known to partially overcome Pgp-mediated drug resistance, suggesting the targets of these drugs might regulate Pgp function.	Cyclosporine	0-3	ATP binding cassette subfamily B member 1	Homo sapiens	46-49
8702500-8	1996	CsA and FK506 are known to partially overcome Pgp-mediated drug resistance, suggesting the targets of these drugs might regulate Pgp function.	Cyclosporine	0-3	ATP binding cassette subfamily B member 1	Homo sapiens	129-132
8831211-13	1996	The addition of Ver or CsA to chemotherapy will be a potential circumvention of P-gp-mediated multidrug resistance of renal cell adenocarcinomas.	Cyclosporine	23-26	ATP binding cassette subfamily B member 1	Homo sapiens	80-84
8842452-0	1996	Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation.	Cyclosporine	58-71	ATP binding cassette subfamily B member 1	Homo sapiens	13-27
8842452-2	1996	The interaction of cyclosporin A (CyA) with p-glycoprotein during intestinal uptake was investigated by a combination of in vitro experiments with human Caco-2 cells and an intubation study in healthy volunteers.	Cyclosporine	19-32	ATP binding cassette subfamily B member 1	Homo sapiens	44-58
8842452-21	1996	All data provide evidence that CyA is a substrate of p-glycoprotein in the GI-tract, which might explain the local differences and the high variability in cyclosporin absorption found in vivo.	Cyclosporine	155-166	ATP binding cassette subfamily B member 1	Homo sapiens	53-67
8866405-1	1996	Renal functional impairment paradoxically often seems less severe in kidney than in heart-transplant recipients (KTR and HTR, respectively) when both are submitted to cyclosporine therapy.	Cyclosporine	167-179	telomerase RNA component	Homo sapiens	121-124
8857552-2	1996	Interpatient differences in liver CYP3A4 activity, as measured by the ERMBT, seem to account, for the most part, for interindividual differences in the kinetics of cyclosporin A and FK506.	Cyclosporine	164-177	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	34-40
8707421-2	1996	We previously reported that MRK-16, an anti-P-glycoprotein MAb, enhanced MDR reversal activity of cyclosporin A (CsA) through inhibition of P-glycoprotein-mediated CsA transport.	Cyclosporine	113-116	ATP binding cassette subfamily B member 1	Homo sapiens	44-58
8707421-2	1996	We previously reported that MRK-16, an anti-P-glycoprotein MAb, enhanced MDR reversal activity of cyclosporin A (CsA) through inhibition of P-glycoprotein-mediated CsA transport.	Cyclosporine	113-116	ATP binding cassette subfamily B member 1	Homo sapiens	140-154
8707421-7	1996	P-glycoprotein could not transport PSC833 but could transport CsA.	Cyclosporine	62-65	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
8712218-10	1996	Confocal fluorescence microscopy studies showed that CyA induced an increase in the endothelial surface expression of ICAM-1, VCAM-1, and E-selectin.	Cyclosporine	53-56	vascular cell adhesion molecule 1	Homo sapiens	126-132
8673560-9	1996	Ang II significantly enhanced neointimal CSA (47%, P &lt; .05) compared with the control group infused with NaCl.	Cyclosporine	41-44	angiotensinogen	Rattus norvegicus	0-6
8673560-10	1996	Losartan significantly reduced Ang II-induced neointimal thickening (neointimal CSA, -37%, P &lt; .05).	Cyclosporine	80-83	angiotensinogen	Rattus norvegicus	31-37
8661983-9	1996	All rats receiving CsA had elevated levels of blood glucose and osteocalcin by day 9 and vitamin D at day 20.	Cyclosporine	19-22	bone gamma-carboxyglutamate protein	Rattus norvegicus	64-75
8844498-1	1996	Classically, cyclosporin A has been reported to exert its immunomodulatory action through its effect on T lymphocytes by inhibiting the synthesis of interleukin 2.	Cyclosporine	13-26	interleukin 2	Homo sapiens	149-162
8689812-13	1996	Inhibition of CYP3A4-mediated metabolism probably explains the increased toxicity of lovastatin caused not only by itraconazole but also by cyclosporine, erythromycin, and other inhibitors of CYP3A4.	Cyclosporine	140-152	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	14-20
8766550-0	1996	T cell activation by concanavalin A in the presence of cyclosporin A: immunosuppressor withdrawal induces NFATp translocation and interleukin-2 gene transcription.	Cyclosporine	55-68	interleukin 2	Homo sapiens	130-143
8766550-1	1996	Cyclosporin A (CSA), an immunosuppressive agent used in organ transplantation and to treat some autoimmune diseases, blocks the Ca2+-dependent steps involved in T cell receptor triggering leading to interleukin (IL)-2 production.	Cyclosporine	0-13	interleukin 2	Homo sapiens	199-217
8676442-2	1996	Disruption of cyclophilin A incorporation, either by gag mutations or by cyclosporine A, inhibits virion infectivity, indicating that cyclophilin A plays an essential role in the HIV-1 life cycle.	Cyclosporine	73-87	peptidylprolyl isomerase A	Pan troglodytes	14-27
8676442-5	1996	In contrast, the replication of two outlier (group O) HIV-1 isolates is unaffected by concentrations of cyclosporine A which disrupt cyclophilin A incorporation into virions, indicating that these viruses are capable of replicating independently of cyclophilin A.	Cyclosporine	104-118	peptidylprolyl isomerase A	Pan troglodytes	133-146
8685947-6	1996	Insulin output, stimulated by oral glucose tolerance tests and assessed by the ratio of AUC insulin to AUC glucose, fell gradually after transplantation and was decreased by an elevated serum calcium level and high cyclosporine dose.	Cyclosporine	215-227	insulin	Homo sapiens	0-7
8807571-4	1996	At 0.1 microgram/ml, CsA exhibits a costimulatory effect, with TNF alpha, on ICAM-1 expression.	Cyclosporine	21-24	tumor necrosis factor	Mus musculus	63-72
8807571-7	1996	The concentration dependent effects of CsA on ICAM-1 expression correlate well with ICAM-1 dependent T cell adhesion to TNF alpha stimulated tubular epithelial cells.	Cyclosporine	39-42	tumor necrosis factor	Mus musculus	120-129
8685947-7	1996	The ratio of fasting insulin to glucose, which acts as a marker of peripheral insulin resistance, fell with time after transplantation and was increased by greater body weight, higher prednisolone dose, and lower cyclosporine dose.	Cyclosporine	213-225	insulin	Homo sapiens	21-28
8685947-7	1996	The ratio of fasting insulin to glucose, which acts as a marker of peripheral insulin resistance, fell with time after transplantation and was increased by greater body weight, higher prednisolone dose, and lower cyclosporine dose.	Cyclosporine	213-225	insulin	Homo sapiens	78-85
8685947-8	1996	The inhibitory effect of cyclosporine on both fasting and postprandial insulin output was, however, minor when quantified by multivariate analysis.	Cyclosporine	25-37	insulin	Homo sapiens	71-78
8813640-3	1996	Treatment of mesangial cells with tetranactin, a cyclic antibiotic produced by Streptomyces aureus with a molecular structure similar to cyclosporin A inhibits interleukin 1 beta- and cAMP-dependent group II phospholipase A2 secretion in a dose-dependent manner with IC50 values of 43 and 33 nM, respectively.	Cyclosporine	137-150	interleukin 1 beta	Rattus norvegicus	160-178
8669110-7	1996	Noninhibitory doses of CsA (8 nM) or FK506 (0.2 nM) suppressed mitogen-induced IL-2 production by 60-80% when combined with a noninhibitory dose (25 nM) of Ro 31-8220, indicating the potent synergy between these agents.	Cyclosporine	23-26	interleukin 2	Homo sapiens	79-83
8645994-1	1996	A steady decrease in serum IgE was noted in cardiac transplant recipients receiving a combination of cyclosporin A and prednisolone for immunosuppressive therapy.	Cyclosporine	101-114	immunoglobulin heavy constant epsilon	Homo sapiens	27-30
8799558-8	1996	Measurements in cultured vascular smooth muscle cells (VSMC) of either cytosolic calcium concentration or of 45Ca2+ efflux showed that CsA potentiated the calcium influx to several vasoconstrictor hormones: [Arg]8vasopressin, angiotensin II, endothelin-1 and 5-hydroxytryptamine.	Cyclosporine	135-138	angiotensinogen	Rattus norvegicus	226-240
8799558-8	1996	Measurements in cultured vascular smooth muscle cells (VSMC) of either cytosolic calcium concentration or of 45Ca2+ efflux showed that CsA potentiated the calcium influx to several vasoconstrictor hormones: [Arg]8vasopressin, angiotensin II, endothelin-1 and 5-hydroxytryptamine.	Cyclosporine	135-138	endothelin 1	Rattus norvegicus	242-260
8691629-3	1996	For example, verapamil or cyclosporin A may be useful for p-glycoprotein related multidrug resistance, and amphotericin B, docosahexaenoic acid or 8-chloro cAMP can be used for the modification of cisplatin-resistance.	Cyclosporine	26-39	ATP binding cassette subfamily B member 1	Homo sapiens	58-72
8666790-6	1996	The response is mediated by IL-2 because Ab blocking of the IL-2R inhibits proliferation as does cyclosporin A.	Cyclosporine	97-110	interleukin 2	Homo sapiens	28-32
21544450-5	1996	Dexniguldipine-HCl or cyclosporin A, however, both showed a similarly strong modulating activity on the HeLa-MDR1 transfectant in clear contrast to the effects observed using the pyridine B8909-008, or dexverapamil-HCl, respectively, at the same final concentrations.	Cyclosporine	22-35	ATP binding cassette subfamily B member 1	Homo sapiens	109-113
8792427-3	1996	P-GP efflux function was determined by measuring transmonolayer fluxes of cyclosporin A (CsA) and verapamil, while P-GP expression level was evaluated by Western blot analysis using monoclonal antibody C219.	Cyclosporine	74-87	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
8792427-3	1996	P-GP efflux function was determined by measuring transmonolayer fluxes of cyclosporin A (CsA) and verapamil, while P-GP expression level was evaluated by Western blot analysis using monoclonal antibody C219.	Cyclosporine	89-92	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
8843593-0	1996	Inhibition by CsA and FK506 of the in vitro proliferative response of gamma delta T cells on stimulation with anti-TCR delta monoclonal antibody.	Cyclosporine	14-17	T cell receptor delta chain	Mus musculus	115-124
8843593-4	1996	Using spleen cells from Tg.Tlaa-3-1 mice, we showed that cyclosporin A (CsA) and FK506 inhibited the in vitro proliferative response of gamma delta T cells on stimulation with anti-TCR delta mAb.	Cyclosporine	72-75	T cell receptor delta chain	Mus musculus	181-190
8843593-5	1996	The dose-dependent inhibitory effect of CsA and FK506 on proliferation of gamma delta T cells on stimulation with anti-TCR delta mAb was similar to that on proliferation of alpha beta T cells on stimulation with anti-TCF beta mAb.	Cyclosporine	40-43	T cell receptor delta chain	Mus musculus	119-128
8635866-7	1996	Verapamil and cyclosporin A were only partially effective in blocking P-gp drug efflux in MDR10V compared to Dox40 cells.	Cyclosporine	14-27	ATP binding cassette subfamily B member 1	Homo sapiens	70-74
8967446-13	1996	It was found that MDR1 activity and its inhibition by cyclosporine A or flufenamic acid were unaffected by hypotonicity alone or in combination with Cl- channel blockers.	Cyclosporine	54-68	ATP binding cassette subfamily B member 1	Homo sapiens	18-22
8791998-0	1996	Detection of P-glycoprotein expression by tumoral cells with NBDL-CsA, a fluorescent derivative of cyclosporin A.	Cyclosporine	99-112	ATP binding cassette subfamily B member 1	Homo sapiens	13-27
8791998-2	1996	Though first described as an inhibitor of P-gp function, cyclosporin A (CsA) was more recently shown to behave as a substrate of the P-gp pump.	Cyclosporine	57-70	ATP binding cassette subfamily B member 1	Homo sapiens	133-137
8791998-2	1996	Though first described as an inhibitor of P-gp function, cyclosporin A (CsA) was more recently shown to behave as a substrate of the P-gp pump.	Cyclosporine	72-75	ATP binding cassette subfamily B member 1	Homo sapiens	133-137
8791998-4	1996	MDR-CEM cell treatment by the P-gp blockers restored the [3H]CsA retention to the control Par-CEM cell levels.	Cyclosporine	61-64	ATP binding cassette subfamily B member 1	Homo sapiens	30-34
8803575-12	1996	In contrast, the combination of RIB 5/2 and CsA (1.5 mg/kg) resulted in a reactive increase in levels of CD 8+ lymphocytes as well as an increased expression of RT 1b by the remaining CD 4+ lymphocytes.	Cyclosporine	44-47	RT1 class II, locus B	Rattus norvegicus	161-166
21544450-0	1996	P-glycoprotein-associated resistance to taxol and taxotere and its reversal by dexniguldipine-HCl, dexverapamil-HCl, or cyclosporin A.	Cyclosporine	120-133	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
9172802-3	1996	Peripheral blood mononuclear cells (PBMC), following infection with EBV and CsA treatment, demonstrated increased IL-6 activity in the culture supernatant.	Cyclosporine	76-79	interleukin 6	Homo sapiens	114-118
9172802-6	1996	Expression of IL-6 in T cells appeared to be due mainly to CsA.	Cyclosporine	59-62	interleukin 6	Homo sapiens	14-18
9172802-9	1996	IL-6, which was induced by CsA in PBMC, was also capable of inducing the lytic viral cycle in several EBV-immortalized cells.	Cyclosporine	27-30	interleukin 6	Homo sapiens	0-4
9172802-11	1996	Thus CsA treatment, in promoting both increased numbers of lytic EBV B cells and expression of the EBV paracrine growth factor, IL-6, within the microenvironment of EBV B:T cell and EBV B:monocyte interactions, may lead to increased EBV B-cell immortalization and ultimately result in the promotion of B-cell lymphomas in immunosuppressed patients.	Cyclosporine	5-8	interleukin 6	Homo sapiens	128-132
8726598-8	1996	Thus, the inhibitory effect of interleukin-6 may alter cyclosporine concentrations, which in turn may increase its adverse effects, such as nephrotoxicity.	Cyclosporine	55-67	interleukin 6	Homo sapiens	31-44
8626528-9	1996	Similar to its effect on IL-2 production, cyclosporin A inhibited the induction of NF-MATp35.	Cyclosporine	42-55	interleukin 2	Homo sapiens	25-29
8741004-8	1996	In vitro experiments showed that IL-6 production by lymphoid cells was relatively unaffected by CsA and CCA but IL-2, TNF and IFN-gamma were suppressed by CsA.	Cyclosporine	155-158	interleukin 6	Rattus norvegicus	33-37
9816222-0	1996	Cyclosporin A and PSC 833 prevent up-regulation of MDR1 expression by anthracyclines in a human multidrug-resistant cell line.	Cyclosporine	0-13	ATP binding cassette subfamily B member 1	Homo sapiens	51-55
8741004-8	1996	In vitro experiments showed that IL-6 production by lymphoid cells was relatively unaffected by CsA and CCA but IL-2, TNF and IFN-gamma were suppressed by CsA.	Cyclosporine	155-158	tumor necrosis factor	Rattus norvegicus	118-121
8741004-9	1996	The results indicate that CsA and CCA may modify the response to the arthritic adjuvant by specifically inhibiting IL-2, TNF and IFN-gamma production at the time of adjuvant injection.	Cyclosporine	26-29	tumor necrosis factor	Rattus norvegicus	121-124
8691736-0	1996	Role of transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy.	Cyclosporine	66-78	transforming growth factor, beta 1	Rattus norvegicus	8-41
8691736-6	1996	CsA-treated rats showed a progressive increase in mRNA expression of TGF-beta 1 and matrix proteins at days 7 and 28.	Cyclosporine	0-3	transforming growth factor, beta 1	Rattus norvegicus	69-79
8726416-2	1996	For in vitro assays of spleen cells, the CsA-treated mice had more enhanced cytotoxic activity against YAC1 and P388, while the FK-treated animals had more against P815, YAC1, and P388.	Cyclosporine	41-44	ADP-ribosyltransferase 1	Mus musculus	103-107
8668923-3	1996	The serum antibody response to p17 with Montanide CSA 720 appeared faster and reached a higher titre than with alum.	Cyclosporine	50-53	family with sequence similarity 72 member B	Homo sapiens	31-34
8668923-4	1996	The serum antibody response to p17 in Montanide CSA 720 was further characterized by a higher titre antibody directed against a 30 amino acid segment from the entire protein.	Cyclosporine	48-51	family with sequence similarity 72 member B	Homo sapiens	31-34
8668925-2	1996	Rapamycin was compared to cyclosporine A for its ability to inhibit P-glycoprotein on normal human peripheral blood mononuclear cells (PBMC).	Cyclosporine	26-40	ATP binding cassette subfamily B member 1	Homo sapiens	68-82
8623450-0	1996	Cyclosporine A enhances the vascular reactivity to angiotensin II in the renal microcirculation in rodents.	Cyclosporine	0-14	angiotensinogen	Homo sapiens	51-65
8704690-4	1996	Cyclosporine was used as GVHD prophylaxis in combination with CD4+ and CD8+ depletion, which removed 94.1 +/- 3.2%, 97.0 +/- 5.1%, and 96.7 +/- 3.1% of CD3+, CD4+ and CD8+ cells, respectively.	Cyclosporine	0-12	CD4 molecule	Homo sapiens	158-161
8631809-3	1996	IL-2 production by CsA-treated cells is therefore dramatically reduced.	Cyclosporine	19-22	interleukin 2	Homo sapiens	0-4
8631809-4	1996	We demonstrate here, however, that NFAT can be activated, and significant levels of IL-2 can be produced by the CsA-resistant CD28-signaling pathway.	Cyclosporine	112-115	interleukin 2	Homo sapiens	84-88
8631809-5	1996	In transient transfection assays, both multicopy NFAT- and IL-2 promoter-beta-galactosidase reporter gene constructs could be activated by phorbol 12-myristate 13-acetate (PMA)/alpha-CD28 stimulation, and this activation was resistant to CsA.	Cyclosporine	238-241	interleukin 2	Homo sapiens	59-63
8631809-7	1996	Peripheral blood T cells stimulated with PMA/alphaCD28 produced IL-2 in the presence of CsA.	Cyclosporine	88-91	interleukin 2	Homo sapiens	64-68
8623163-0	1996	Identification of a calcium-inducible, cyclosporine sensitive element in the IFN-gamma promoter that is a potential NFAT binding site.	Cyclosporine	39-51	interferon gamma	Homo sapiens	77-86
8623163-10	1996	These results suggest that the P2 sequence, and probably the P1 sequence, in the IFN-gamma promoter are NFAT binding sites and contribute to the calcium inducibility and CsA sensitivity of IFN-gamma production.	Cyclosporine	170-173	interferon gamma	Homo sapiens	81-90
8623163-10	1996	These results suggest that the P2 sequence, and probably the P1 sequence, in the IFN-gamma promoter are NFAT binding sites and contribute to the calcium inducibility and CsA sensitivity of IFN-gamma production.	Cyclosporine	170-173	interferon gamma	Homo sapiens	189-198
8814894-8	1996	The expression of pro-inflammatory cytokines (interferon-gamma, tumour necrosis factor-alpha, interleukin-6) in and around the grafts was lower in the methylprednisolone- and cyclosporin A-treated groups than in untreated control rats.	Cyclosporine	175-188	interleukin 6	Rattus norvegicus	94-107
8609251-2	1996	The addition of interferon gamma to cyclosporine, given to induce graft-versus-host disease after autologous bone marrow transplantation, increases the extent of the cutaneous eruption.	Cyclosporine	36-48	interferon gamma	Homo sapiens	16-32
9816200-3	1996	CsA has been shown to modify the function of a membrane P-glycoprotein (Pgp) whose overexpression is associated with a multidrug-resistant (MDR1) phenotype.	Cyclosporine	0-3	ATP binding cassette subfamily B member 1	Homo sapiens	56-70
9816200-3	1996	CsA has been shown to modify the function of a membrane P-glycoprotein (Pgp) whose overexpression is associated with a multidrug-resistant (MDR1) phenotype.	Cyclosporine	0-3	ATP binding cassette subfamily B member 1	Homo sapiens	72-75
9816200-3	1996	CsA has been shown to modify the function of a membrane P-glycoprotein (Pgp) whose overexpression is associated with a multidrug-resistant (MDR1) phenotype.	Cyclosporine	0-3	ATP binding cassette subfamily B member 1	Homo sapiens	140-144
9816200-7	1996	Pgp expression was assessed further after prolonged (10-day) treatment with CsA.	Cyclosporine	76-79	ATP binding cassette subfamily B member 1	Homo sapiens	0-3
9816200-11	1996	Similarly, plasma from patients containing immunosuppressive levels of CsA lowered DOX IC50 of the MDR1(+) Hep G2 cells by up to 4-fold.	Cyclosporine	71-74	ATP binding cassette subfamily B member 1	Homo sapiens	99-103
9816200-15	1996	Pharmacological concentrations of cyclosporin analogues, including one nonimmunosuppressive form, enhance DOX cytotoxicity of MDR1(+) HCC cells by modulating drug retention.	Cyclosporine	34-45	ATP binding cassette subfamily B member 1	Homo sapiens	126-130
9816200-16	1996	CsA as found in posttransplant patient plasma enhanced DOX cytotoxicity to human MDR1(+) hepatoma cells in vitro, albeit at less than optimal chemosensitizing concentrations.	Cyclosporine	0-3	ATP binding cassette subfamily B member 1	Homo sapiens	81-85
9816200-18	1996	These findings support our hypothesis that in vivo immunosuppressive levels of CsA may enhance DOX chemotherapeutic efficacy on MDR1(+) HCC cells.	Cyclosporine	79-82	ATP binding cassette subfamily B member 1	Homo sapiens	128-132
8596025-7	1996	Finally, cyclosporin A blocked both IL-2 secretion and bcl-2 induction in response to CD3 plus CD28 stimulation, suggesting a role for endogenous lymphokine production in the induction of bcl-2.	Cyclosporine	9-22	BCL2 apoptosis regulator	Homo sapiens	55-60
8596025-7	1996	Finally, cyclosporin A blocked both IL-2 secretion and bcl-2 induction in response to CD3 plus CD28 stimulation, suggesting a role for endogenous lymphokine production in the induction of bcl-2.	Cyclosporine	9-22	BCL2 apoptosis regulator	Homo sapiens	188-193
8833055-3	1996	This synergy is probably based on different mechanisms of action of the 2 drugs: CsA primarily inhibits the production of interleukin 2 (IL-2) (and other cytokines) at the level of transcription, whereas chloroquine primarily inhibits the responsiveness of T cells to IL-2 stimulation.	Cyclosporine	81-84	interleukin 2	Homo sapiens	122-135
8596025-7	1996	Finally, cyclosporin A blocked both IL-2 secretion and bcl-2 induction in response to CD3 plus CD28 stimulation, suggesting a role for endogenous lymphokine production in the induction of bcl-2.	Cyclosporine	9-22	interleukin 2	Homo sapiens	36-40
8642062-0	1996	Effects of cyclosporin treatment on prolactin pulsatility in chronic hyperprolactinemic male rats.	Cyclosporine	11-22	prolactin	Rattus norvegicus	36-45
8642062-2	1996	This work was designed to analyse (i) if chronic CsA administration could influence the episodic secretion of prolactin in adult male rats; and (ii) the effects of the chronic administration of the drug, in adult animals with elevated plasma prolactin levels.	Cyclosporine	49-52	prolactin	Rattus norvegicus	110-119
8642062-6	1996	CsA administration to sham-operated rats decreased the relative pulse amplitude of prolactin but increased the mean half-life of the hormone, the pulse duration and the mean hormone levels, as compared with rats of the same group treated with vehicle.	Cyclosporine	0-3	prolactin	Rattus norvegicus	83-92
8642062-7	1996	However, CsA treatment to pituitary-grafted rats decreased mean prolactin levels and the absolute amplitude of its peaks and increased the relative amplitude of its pulses, whereas all the other parameters showed no change.	Cyclosporine	9-12	prolactin	Rattus norvegicus	64-73
8642062-8	1996	When considering circulating values of prolactin in plasma from the trunk blood, CsA administration was followed by changes similar to those described when mean values of the serial samples were considered.	Cyclosporine	81-84	prolactin	Rattus norvegicus	39-48
8833055-3	1996	This synergy is probably based on different mechanisms of action of the 2 drugs: CsA primarily inhibits the production of interleukin 2 (IL-2) (and other cytokines) at the level of transcription, whereas chloroquine primarily inhibits the responsiveness of T cells to IL-2 stimulation.	Cyclosporine	81-84	interleukin 2	Homo sapiens	137-141
8833064-3	1996	P-gp can be competitively inhibited by exposure to antirheumatic drugs including antimalarials and cyclosporin A.	Cyclosporine	99-112	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
8833064-9	1996	We hypothesize that antiarthritic effects of the antimalarials and cyclosporine and perhaps glucocorticoids are partially attributable to the inhibition of P-gp function thereby blocking TNF-alpha release by macrophages, TNF-alpha activation of NK cells, and NK cell secretion of cytotoxins in the rheumatoid joint.	Cyclosporine	67-79	ATP binding cassette subfamily B member 1	Homo sapiens	156-160
8833064-9	1996	We hypothesize that antiarthritic effects of the antimalarials and cyclosporine and perhaps glucocorticoids are partially attributable to the inhibition of P-gp function thereby blocking TNF-alpha release by macrophages, TNF-alpha activation of NK cells, and NK cell secretion of cytotoxins in the rheumatoid joint.	Cyclosporine	67-79	tumor necrosis factor	Homo sapiens	187-196
8833064-9	1996	We hypothesize that antiarthritic effects of the antimalarials and cyclosporine and perhaps glucocorticoids are partially attributable to the inhibition of P-gp function thereby blocking TNF-alpha release by macrophages, TNF-alpha activation of NK cells, and NK cell secretion of cytotoxins in the rheumatoid joint.	Cyclosporine	67-79	tumor necrosis factor	Homo sapiens	221-230
8849485-6	1996	Using specific antibodies and inhibitors, we showed that, as in the liver, cytochrome P450 3A (CYP 3A) enzymes are responsible for ciclosporin metabolism in the human small intestine.	Cyclosporine	131-142	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-93
8849485-6	1996	Using specific antibodies and inhibitors, we showed that, as in the liver, cytochrome P450 3A (CYP 3A) enzymes are responsible for ciclosporin metabolism in the human small intestine.	Cyclosporine	131-142	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-101
8849485-7	1996	Of the 28 xenobiotics included in the study, 16 drugs, all well-known CYP 3A inhibitors, inhibited ciclosporin metabolism in the small intestine.	Cyclosporine	99-110	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	70-76
8762014-0	1996	CD45RA+ and CD45RO+ T cells differ in susceptibility to cyclosporin A mediated inhibition of interleukin-2 production.	Cyclosporine	56-69	interleukin 2	Homo sapiens	93-106
8762014-4	1996	The CD4+CD45RO+ memory T cells were shown to be less susceptible to CsA and less dependent on the level of Ca+ ions than the naive CD4+CD45RA+ T cells.	Cyclosporine	68-71	CD4 molecule	Homo sapiens	4-7
8762014-4	1996	The CD4+CD45RO+ memory T cells were shown to be less susceptible to CsA and less dependent on the level of Ca+ ions than the naive CD4+CD45RA+ T cells.	Cyclosporine	68-71	CD4 molecule	Homo sapiens	8-11
8565319-1	1996	The immunosuppressive macrolide rapamycin inhibits cytokine-driven proliferation of lymphocytes, acting at a later stage of T lymphocyte activation than the related compound FK506 or cyclosporin, which block IL-2 transcription.	Cyclosporine	183-194	interleukin 2	Homo sapiens	208-212
8599837-5	1996	Induction of Il-4 promoter by ionomycin was partially inhibited (approximately 50% inhibition) in the presence of as high as 2 microgram/ml cyclosporin A (CsA), an inhibitor of the Ca+/calmodulin-dependent phosphatase calcineurin.	Cyclosporine	155-158	interleukin 4	Homo sapiens	13-17
8599837-6	1996	Under the same conditions, only 0.1 microgram/ml of CsA inhibited by &gt;95% the transactivation of the IL-2 promoter in response to ionomycin and PMA.	Cyclosporine	52-55	interleukin 2	Homo sapiens	104-108
8631992-2	1996	Electrophoretic mobility shift assays using 18-base pair (bp) long oligonucleotides corresponding to the proximal site and nuclear extracts from activated T cells revealed two complexes which were inhibited by cyclosporin A and contained NF-ATc and NF-ATp.	Cyclosporine	210-223	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	238-244
8631992-2	1996	Electrophoretic mobility shift assays using 18-base pair (bp) long oligonucleotides corresponding to the proximal site and nuclear extracts from activated T cells revealed two complexes which were inhibited by cyclosporin A and contained NF-ATc and NF-ATp.	Cyclosporine	210-223	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2	Mus musculus	249-255
8568231-10	1996	However, the promotive effect of IL-7 on IFN-gamma and IL-4 gene expression could be blocked by genistein and cyclosporin A.	Cyclosporine	110-123	interleukin 7	Homo sapiens	33-37
8568231-10	1996	However, the promotive effect of IL-7 on IFN-gamma and IL-4 gene expression could be blocked by genistein and cyclosporin A.	Cyclosporine	110-123	interferon gamma	Homo sapiens	41-50
8568231-10	1996	However, the promotive effect of IL-7 on IFN-gamma and IL-4 gene expression could be blocked by genistein and cyclosporin A.	Cyclosporine	110-123	interleukin 4	Homo sapiens	55-59
8568237-5	1996	Activation of the complex was inhibited by cyclosporin A, and Abs against IFN-gamma severely decreased the amount of complex detected.	Cyclosporine	43-56	interferon gamma	Mus musculus	74-83
8573191-0	1996	Cyclosporine A decreases the protein level of the calcium-binding protein calbindin-D 28kDa in rat kidney.	Cyclosporine	0-14	calbindin 1	Rattus norvegicus	74-88
8573191-7	1996	In kidney homogenates of male Wistar rats treated with 50 mg/kg/d CsA for up to 28 days, calbindin levels were measured by ELISA and were shown to be continuously decreased with prolonged CsA treatment.	Cyclosporine	66-69	calbindin 1	Rattus norvegicus	89-98
8573191-7	1996	In kidney homogenates of male Wistar rats treated with 50 mg/kg/d CsA for up to 28 days, calbindin levels were measured by ELISA and were shown to be continuously decreased with prolonged CsA treatment.	Cyclosporine	188-191	calbindin 1	Rattus norvegicus	89-98
8573191-8	1996	To our knowledge, this is the first report describing the effect of CsA on kidney calbindin-D 28kDa protein levels.	Cyclosporine	68-71	calbindin 1	Rattus norvegicus	82-96
8573191-9	1996	Further studies are needed to elucidate whether the CsA-mediated down-regulation of the calcium-binding protein calbindin-D 28kDa may be a critical factor for the renal adverse effects induced by this drug.	Cyclosporine	52-55	calbindin 1	Rattus norvegicus	112-121
8603842-0	1996	Cyclosporine therapy suppresses ocular and lacrimal gland disease in MRL/Mp-lpr/lpr mice.	Cyclosporine	0-12	Fas (TNF receptor superfamily member 6)	Mus musculus	69-83
8603842-5	1996	METHODS: MRL/lpr mice were administered cyclosporine intraperitoneally at a dosage of 2 mg daily from age 1 to 5 months.	Cyclosporine	40-52	Fas (TNF receptor superfamily member 6)	Mus musculus	9-16
8603842-13	1996	CONCLUSIONS: Chronic cyclosporine therapy, started at an early age, is effective in controlling the autoimmune disease in MRL/lpr mice, including the ocular and lacrimal gland lesions.	Cyclosporine	21-33	Fas (TNF receptor superfamily member 6)	Mus musculus	122-129
8627154-6	1996	CNA alpha -/- T cells remained sensitive to both cyclosporin A and FK506, suggesting that CNA beta or another CNA-like molecule can mediate the action of these immunosuppressive drugs.	Cyclosporine	49-62	protein phosphatase 3, catalytic subunit, beta isoform	Mus musculus	90-98
8552071-2	1996	Previous experiments have demonstrated that in stimulated T cells, a TNF-alpha promoter element, kappa 3, which binds NFATp, is required for the cyclosporin A-sensitive transcriptional activation of the gene.	Cyclosporine	145-158	tumor necrosis factor	Homo sapiens	69-78
8919996-8	1996	As cyclophilin is able to interact with cyclosporin A (CsA), which has been shown to be antischistosomal in mice infected with S. mansoni, the characterization of this S. mansoni cyclophilin homologue may allow a better understanding of the schistosomicidal nature of cyclosporin A and lead to a novel strategy of therapy for schistosomiasis.	Cyclosporine	40-53	cyclophilin	Schistosoma mansoni	3-14
8919996-8	1996	As cyclophilin is able to interact with cyclosporin A (CsA), which has been shown to be antischistosomal in mice infected with S. mansoni, the characterization of this S. mansoni cyclophilin homologue may allow a better understanding of the schistosomicidal nature of cyclosporin A and lead to a novel strategy of therapy for schistosomiasis.	Cyclosporine	40-53	cyclophilin	Schistosoma mansoni	179-190
8919996-8	1996	As cyclophilin is able to interact with cyclosporin A (CsA), which has been shown to be antischistosomal in mice infected with S. mansoni, the characterization of this S. mansoni cyclophilin homologue may allow a better understanding of the schistosomicidal nature of cyclosporin A and lead to a novel strategy of therapy for schistosomiasis.	Cyclosporine	55-58	cyclophilin	Schistosoma mansoni	3-14
8919996-8	1996	As cyclophilin is able to interact with cyclosporin A (CsA), which has been shown to be antischistosomal in mice infected with S. mansoni, the characterization of this S. mansoni cyclophilin homologue may allow a better understanding of the schistosomicidal nature of cyclosporin A and lead to a novel strategy of therapy for schistosomiasis.	Cyclosporine	55-58	cyclophilin	Schistosoma mansoni	179-190
8919996-8	1996	As cyclophilin is able to interact with cyclosporin A (CsA), which has been shown to be antischistosomal in mice infected with S. mansoni, the characterization of this S. mansoni cyclophilin homologue may allow a better understanding of the schistosomicidal nature of cyclosporin A and lead to a novel strategy of therapy for schistosomiasis.	Cyclosporine	268-281	cyclophilin	Schistosoma mansoni	3-14
8834013-3	1996	Corticosteroids inhibit the transcription of a broad spectrum of genes including those encoding monocyte, T cell-derived cytokines and several hemopoietic growth factors, whereas drugs such as cyclosporin A and D-penicillamine interfere with T cell activation more specifically by suppressing interleukin 2 (IL-2) production.	Cyclosporine	193-206	interleukin 2	Homo sapiens	293-306
8671791-3	1996	In CsA-treated patients, tissue-type plasminogen activator was moderately increased compared to patients without CsA (8.4+/-3.3 vs 5.5+/-2.8 ng/ml).	Cyclosporine	3-6	plasminogen activator, tissue type	Homo sapiens	25-58
8633191-3	1996	In contrast, CsA-sensitive IL-2-dependent proliferative responses induced by PHA, anti-CD3 or the purified protein derivative (PPD) of M. tuberculosis were not significantly inhibited by NDGA concentrations as high as 8 microM.	Cyclosporine	13-16	interleukin 2	Homo sapiens	27-31
8834013-3	1996	Corticosteroids inhibit the transcription of a broad spectrum of genes including those encoding monocyte, T cell-derived cytokines and several hemopoietic growth factors, whereas drugs such as cyclosporin A and D-penicillamine interfere with T cell activation more specifically by suppressing interleukin 2 (IL-2) production.	Cyclosporine	193-206	interleukin 2	Homo sapiens	308-312
8834013-7	1996	Reductions in circulating IL-6 and sIL-2R concentrations have also been observed with cyclosporin and corticosteroids, whereas azathioprine reduces IL-6 but not sIL-2R.	Cyclosporine	86-97	interleukin 6	Homo sapiens	26-30
8600637-0	1996	Induction of heat shock protein in cardiac allograft rejection--a cyclosporine-suppressible response.	Cyclosporine	66-78	selenoprotein K	Rattus norvegicus	13-31
8560558-4	1996	Cells from both groups were also stimulated with OKT3 to determine the effect of CsA on the induction of IFN-gamma synthesis.	Cyclosporine	81-84	interferon gamma	Homo sapiens	105-114
8567666-4	1996	Verapamil, cyclosporin A, and a number of other agents that compete with cytotoxic drugs for binding sites on P-glycoprotein can potently reverse MDR, but this is accompanied by severe toxicity in vivo.	Cyclosporine	11-24	ATP binding cassette subfamily B member 1	Homo sapiens	110-124
8560558-7	1996	Likewise, for CsA inhibition of IFN-gamma induction, the IC50 was 18 micrograms/L for PBL in CM compared with 690 micrograms/L for PBL in WB (P &lt; or = 0.005).	Cyclosporine	14-17	interferon gamma	Homo sapiens	32-41
8993775-0	1996	Influence of a DLE-extracted lymphocytic suppressor factor on CsA-induced immunosuppression.	Cyclosporine	62-65	transcription factor CP2	Mus musculus	29-58
8562389-1	1996	HLA-DRB1*1501, a subtype of HLA-DR2, has been shown to be closely associated with a good response to cyclosporine (CyA) therapy in patients with aplastic anaemia (AA).	Cyclosporine	101-113	major histocompatibility complex, class II, DR beta 1	Homo sapiens	0-8
8993775-6	1996	When combined "in vitro" with cyclosporine A (CsA), LSF increased about 20 times the potency of CsA in inducing suppression of mitogen-stimulated lymphocytes.	Cyclosporine	30-44	transcription factor CP2	Mus musculus	52-55
8993775-6	1996	When combined "in vitro" with cyclosporine A (CsA), LSF increased about 20 times the potency of CsA in inducing suppression of mitogen-stimulated lymphocytes.	Cyclosporine	46-49	transcription factor CP2	Mus musculus	52-55
8993775-6	1996	When combined "in vitro" with cyclosporine A (CsA), LSF increased about 20 times the potency of CsA in inducing suppression of mitogen-stimulated lymphocytes.	Cyclosporine	96-99	transcription factor CP2	Mus musculus	52-55
8993775-7	1996	In C57b/6N mice with skin graft from C3H/HeN mice and undergoing immunosuppression with CsA (50 mg/kg/day), the splenocyte LSF content increased about 5 times.	Cyclosporine	88-91	transcription factor CP2	Mus musculus	123-126
8993775-8	1996	However, LSF values returned to normal in mice recovering normal responsiveness due to progressive withdrawal of CsA.	Cyclosporine	113-116	transcription factor CP2	Mus musculus	9-12
8993775-9	1996	These data show that LSF has an important role in the development and maintenance of CsA-induced immunosuppression.	Cyclosporine	85-88	transcription factor CP2	Mus musculus	21-24
8562389-1	1996	HLA-DRB1*1501, a subtype of HLA-DR2, has been shown to be closely associated with a good response to cyclosporine (CyA) therapy in patients with aplastic anaemia (AA).	Cyclosporine	101-113	major histocompatibility complex, class II, DR beta 1	Homo sapiens	0-3
8562389-1	1996	HLA-DRB1*1501, a subtype of HLA-DR2, has been shown to be closely associated with a good response to cyclosporine (CyA) therapy in patients with aplastic anaemia (AA).	Cyclosporine	115-118	major histocompatibility complex, class II, DR beta 1	Homo sapiens	0-8
8562389-1	1996	HLA-DRB1*1501, a subtype of HLA-DR2, has been shown to be closely associated with a good response to cyclosporine (CyA) therapy in patients with aplastic anaemia (AA).	Cyclosporine	115-118	major histocompatibility complex, class II, DR beta 1	Homo sapiens	0-3
8562389-7	1996	These results indicate that although identifying the DRB1*1501 allele in AA patients prior to therapy is predictive of a good response to CyA therapy, it does not have a predictive value for ATG therapy.	Cyclosporine	138-141	major histocompatibility complex, class II, DR beta 1	Homo sapiens	53-57
8944329-11	1996	The data suggest that MPA as well as CsA may be useful as modifying agents in overcoming Pgp-associated multidrug resistance.	Cyclosporine	37-40	ATP binding cassette subfamily B member 1	Homo sapiens	89-92
8944329-8	1996	Incubation with either CsA or MPA plus Adr enhanced Adr toxicity in Pgp+ but not Pgp- cell cultures, whereas TAM had no effect on the sensitivity of any of the cultures.	Cyclosporine	23-26	ATP binding cassette subfamily B member 1	Homo sapiens	68-71
8548874-8	1996	In contrast, the P-glycoprotein inhibitors verapamil and cyclosporin A did not inhibit THP efflux.	Cyclosporine	57-70	ATP binding cassette subfamily B member 1	Homo sapiens	17-31
8549033-1	1996	INTRODUCTION: Cytochrome P4503A (CYP3A) is primarily responsible for the metabolism of cyclosporine and that of many other drugs.	Cyclosporine	87-99	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	14-20
8549033-1	1996	INTRODUCTION: Cytochrome P4503A (CYP3A) is primarily responsible for the metabolism of cyclosporine and that of many other drugs.	Cyclosporine	87-99	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	33-38
8549033-3	1996	One such measure of CYP3A activity is the 14C erythromycin breath test, which has been applied to the prediction of cyclosporine disposition.	Cyclosporine	116-128	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	20-25
8522052-8	1996	Average insulin dose remained lower by 0.2-0.4 U.kg-1.day-1 and glycated hemoglobin by approximately 1% in cyclosporin-treated patients (P &lt; 0.02), who also had less hypoglycemia than the diabetic control subjects (P &lt; 0.05).	Cyclosporine	107-118	insulin	Homo sapiens	8-15
8672855-0	1996	[Expression of the MDR1 gene in five human cell lines of medullary thyroid cancer and reversion of the resistance to doxorubicine by ciclosporin A and verapamil].	Cyclosporine	133-146	ATP binding cassette subfamily B member 1	Homo sapiens	19-23
8655354-0	1996	Longitudinal induced IL-2 mRNA monitoring in renal transplant patients immunosuppressed with cyclosporine and in unmodified canine renal transplant rejection.	Cyclosporine	93-105	interleukin 2	Homo sapiens	21-25
8551205-2	1996	The patient was proven to be cortico-steroid and cyclosporin resistant, but had a trilineage response during subsequent treatment with recombinant human erythropoietin.	Cyclosporine	49-60	erythropoietin	Homo sapiens	153-167
8732432-0	1996	Inhibition of re-expression of surface CD4, but not CD8, on activated human T-lymphocytes by the immunosuppressive drugs dexamethasone and cyclosporine A: correlation with inhibition of proliferation.	Cyclosporine	139-153	CD4 molecule	Homo sapiens	39-42
8732432-1	1996	Our objective was to study the re-expression of CD4 and CD8 on activated human T-lymphocytes in the presence of dexamethasone and cyclosporine A at physiologically relevant concentrations.	Cyclosporine	130-144	CD4 molecule	Homo sapiens	48-51
8732432-9	1996	We concluded that activation of T-lymphocytes results in rapid down-modulation of surface CD3, CD4 and CD8 followed by re-expression which is inhibited in the case of CD4, but not CD8, by dexamethasone and cyclosporine A.	Cyclosporine	206-220	CD4 molecule	Homo sapiens	167-170
8890921-3	1996	It has been shown that glucocorticoids and immunosuppressive agents such as cyclosporin and FK-506 inhibit TNF-alpha generation by T-lymphocytes and monocytes.	Cyclosporine	76-87	tumor necrosis factor	Mus musculus	107-116
8598451-6	1996	The expression of CD40L was blocked by cyclosporine and prostaglandin E2 (PGE2).	Cyclosporine	39-51	CD40 ligand	Homo sapiens	18-23
8598451-7	1996	IL-2 IL-4 partially reversed the inhibition of CD40L expression by cyclosporine, and IL-2 reversed the inhibition by PGE2.	Cyclosporine	67-79	interleukin 2	Homo sapiens	0-9
8598451-7	1996	IL-2 IL-4 partially reversed the inhibition of CD40L expression by cyclosporine, and IL-2 reversed the inhibition by PGE2.	Cyclosporine	67-79	CD40 ligand	Homo sapiens	47-52
8598451-7	1996	IL-2 IL-4 partially reversed the inhibition of CD40L expression by cyclosporine, and IL-2 reversed the inhibition by PGE2.	Cyclosporine	67-79	interleukin 2	Homo sapiens	0-4
8622563-11	1996	CsA binds CyP-40.	Cyclosporine	0-3	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	10-16
8761011-6	1996	The effects of Cyclosporin (CsA) on IL-2 and PRL gene activation and the analysis of the intracellular signaling events downstream IL-2 and PRL receptors suggest coordinate actions of these two cytokines during T cell activation.	Cyclosporine	28-31	interleukin 2	Homo sapiens	36-48
8761011-6	1996	The effects of Cyclosporin (CsA) on IL-2 and PRL gene activation and the analysis of the intracellular signaling events downstream IL-2 and PRL receptors suggest coordinate actions of these two cytokines during T cell activation.	Cyclosporine	28-31	prolactin	Homo sapiens	45-48
8890941-5	1996	We determined that CS inhibited the ability of murine spleen cells to form conjugates with YAC-1 tumor target cells.	Cyclosporine	19-21	ADP-ribosyltransferase 1	Mus musculus	91-96
8884813-0	1996	alpha-(3,4-dimethyoxyphenyl)-3,4-dihydro-6,7-dimethoxy-alpha- [(4-methylphenyl)thio]-2(1H)-isoquinolineheptanenitrile (CL 329,753): a novel chemosensitizing agent for P-glycoprotein-mediated resistance with improved biological properties compared with verapamil and cyclosporine A.	Cyclosporine	266-280	ATP binding cassette subfamily B member 1	Homo sapiens	167-181
8865156-4	1996	Cyclosporin A, which totally blocks IL-2 production of Th1 cells, barely or only partially inhibited PMA- or aCD3-induced proliferation of F1.	Cyclosporine	0-13	interleukin 2	Homo sapiens	36-40
9026809-3	1996	Administration of CsA-treated lymphocytes induced no profound structural changes in lymphocytic subpopulations (CD3, CD4, CD8), but it was followed by a reduction in the baseline high proliferative lymphocytic response to PHA.	Cyclosporine	18-21	CD4 molecule	Homo sapiens	117-120
7490151-5	1995	Cyclosporine induced greater vasoconstrictor responses to norepinephrine and angiotensin II in isolated mesenteric arteries.	Cyclosporine	0-12	angiotensinogen	Rattus norvegicus	77-91
8536380-4	1995	Here we have studied the effect of CsA on kidney generation of TNF-alpha and PAF in puromycin aminonucleoside (PAN) nephrosis as well as on the synthesis of proteoglycans by cultured glomerular epithelial cells.	Cyclosporine	35-38	tumor necrosis factor	Homo sapiens	63-72
8536380-10	1995	CsA also reversed the inhibitory effect of PAF and TNF-alpha on proteoglycan synthesis.	Cyclosporine	0-3	tumor necrosis factor	Homo sapiens	51-60
8536380-13	1995	The beneficial effect of CsA in nephrosis may be due to the recovery of the GBM charge selectivity caused by the normalization of glomerular PAF and TNF-alpha synthesis and the increase in proteoglycan synthesis by glomerular epithelial cells.	Cyclosporine	25-28	tumor necrosis factor	Homo sapiens	149-158
8964650-6	1995	Similarly, PTX and CsA synergistically inhibited the release of IL-2, IFN-gamma and, to a lesser degree, TNF-alpha.	Cyclosporine	19-22	interleukin 2	Homo sapiens	64-68
8964650-6	1995	Similarly, PTX and CsA synergistically inhibited the release of IL-2, IFN-gamma and, to a lesser degree, TNF-alpha.	Cyclosporine	19-22	interferon gamma	Homo sapiens	70-79
8964650-6	1995	Similarly, PTX and CsA synergistically inhibited the release of IL-2, IFN-gamma and, to a lesser degree, TNF-alpha.	Cyclosporine	19-22	tumor necrosis factor	Homo sapiens	105-114
8720179-9	1995	The function of CyP in the schistosome is presently unclear, but since its ligand, cyclosporin A, has antischistosomal activity, its function is expected to be a vital one.	Cyclosporine	83-96	cyclophilin	Schistosoma mansoni	16-19
7488131-0	1995	Interleukin 1 beta-induced expression of nitric oxide synthase in rat renal mesangial cells is suppressed by cyclosporin A.	Cyclosporine	109-122	interleukin 1 beta	Rattus norvegicus	0-18
7482718-7	1995	Patients were receiving cyclosporine (CsA) and prednisolone (pred) at the time of sampling, which are known to interrupt 5" regulation of TNFA transcription in T cells and macrophages and may therefore negate the influence of the -308 polymorphism.	Cyclosporine	24-36	tumor necrosis factor	Homo sapiens	138-142
7482718-7	1995	Patients were receiving cyclosporine (CsA) and prednisolone (pred) at the time of sampling, which are known to interrupt 5" regulation of TNFA transcription in T cells and macrophages and may therefore negate the influence of the -308 polymorphism.	Cyclosporine	38-41	tumor necrosis factor	Homo sapiens	138-142
7488131-2	1995	Here we report that cyclosporin A (CsA) a potent immunosuppressive drug, inhibits IL-1 beta dependent iNOS expression in renal mesangial cells.	Cyclosporine	20-33	interleukin 1 beta	Rattus norvegicus	82-91
7488131-2	1995	Here we report that cyclosporin A (CsA) a potent immunosuppressive drug, inhibits IL-1 beta dependent iNOS expression in renal mesangial cells.	Cyclosporine	20-33	nitric oxide synthase 2	Rattus norvegicus	102-106
7488131-2	1995	Here we report that cyclosporin A (CsA) a potent immunosuppressive drug, inhibits IL-1 beta dependent iNOS expression in renal mesangial cells.	Cyclosporine	35-38	interleukin 1 beta	Rattus norvegicus	82-91
7488131-2	1995	Here we report that cyclosporin A (CsA) a potent immunosuppressive drug, inhibits IL-1 beta dependent iNOS expression in renal mesangial cells.	Cyclosporine	35-38	nitric oxide synthase 2	Rattus norvegicus	102-106
7488131-3	1995	Addition of CsA dose dependently suppresses IL-1 beta-induced nitrite formation (IC50 = 0.9 microM).	Cyclosporine	12-15	interleukin 1 beta	Rattus norvegicus	44-53
7488131-4	1995	Western- and Northern blot analyses of mesangial cell extracts reveal that the inhibition of IL-1 beta-induced nitrite formation by CsA is due to decreased iNOS protein and iNOS mRNA steady state levels.	Cyclosporine	132-135	interleukin 1 beta	Rattus norvegicus	93-102
7488131-4	1995	Western- and Northern blot analyses of mesangial cell extracts reveal that the inhibition of IL-1 beta-induced nitrite formation by CsA is due to decreased iNOS protein and iNOS mRNA steady state levels.	Cyclosporine	132-135	nitric oxide synthase 2	Rattus norvegicus	156-160
7488131-4	1995	Western- and Northern blot analyses of mesangial cell extracts reveal that the inhibition of IL-1 beta-induced nitrite formation by CsA is due to decreased iNOS protein and iNOS mRNA steady state levels.	Cyclosporine	132-135	nitric oxide synthase 2	Rattus norvegicus	173-177
7503774-8	1995	Cremophor El, the vehicle used to administer CsA and PSC intravenously, was also able to inhibit IAAP photolabeling of P-gp.	Cyclosporine	45-48	ATP binding cassette subfamily B member 1	Homo sapiens	119-123
7503774-10	1995	Photolabeling of P-gp with this compound was abolished almost completely by CsA and PSC.	Cyclosporine	76-79	ATP binding cassette subfamily B member 1	Homo sapiens	17-21
8582630-2	1995	A single nuclear mutation, designated cev1 for calcineurin essential for viability, is responsible for the CsA-FK506-sensitive phenotype.	Cyclosporine	107-110	Vma22p	Saccharomyces cerevisiae S288C	38-42
8582630-3	1995	The peptidyl-prolyl cis-trans isomerases cyclophilin A and FKBP12, respectively, mediate CsA and FK506 toxicity in the cev1 mutant strain.	Cyclosporine	89-92	Vma22p	Saccharomyces cerevisiae S288C	119-123
7473140-8	1995	Inhibitor experiments suggest that typical CYP3A substrates/inhibitors (e.g., cyclosporin, epipodophyllotoxins) may significantly interact with paclitaxel in vivo.	Cyclosporine	78-89	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-48
8750397-3	1995	Cyclosporine and tacrolimus are metabolized by the cytochrome P-450 enzyme system.	Cyclosporine	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
8544405-0	1995	Cyclosporine enhances the expression of TGF-beta in the juxtaglomerular cells of the rat kidney.	Cyclosporine	0-12	transforming growth factor, beta 1	Rattus norvegicus	40-48
8544405-2	1995	In this study, we describe evidence of increased amounts of transforming growth factor-beta (TGF-beta) in the kidneys of adult male Wistar rats treated with CsA (5 to 25 mg/kg/day) for four weeks.	Cyclosporine	157-160	transforming growth factor, beta 1	Rattus norvegicus	93-101
7475279-2	1995	Transport function was assessed by measuring the modulating effect of the Pgp inhibitor cyclosporin A (CsA) on the cellular accumulation of daunorubicin, and Pgp antigen expression by surface immunofluorescence using the MRK-16 antibody.	Cyclosporine	88-101	ATP binding cassette subfamily B member 1	Homo sapiens	74-77
7475279-2	1995	Transport function was assessed by measuring the modulating effect of the Pgp inhibitor cyclosporin A (CsA) on the cellular accumulation of daunorubicin, and Pgp antigen expression by surface immunofluorescence using the MRK-16 antibody.	Cyclosporine	103-106	ATP binding cassette subfamily B member 1	Homo sapiens	74-77
8544405-7	1995	The number of interlobular arterioles stained for TGF-beta increased from a control value of 0.07 +/- 0.05/mm2 to 0.31 +/- 0.02/mm2, P &lt; 0.05, and 0.39 +/- 0.07/mm2, P &lt; 0.01, in rats treated with CsA, 12.5 mg/kg/day and 25 mg/kg/day, respectively.	Cyclosporine	203-206	transforming growth factor, beta 1	Rattus norvegicus	50-58
8544405-10	1995	We have therefore observed an association between TGF-beta and CsA-induced nephrotoxicity.	Cyclosporine	63-66	transforming growth factor, beta 1	Rattus norvegicus	50-58
8544405-11	1995	While this does not establish a causal link, it leads us to postulate that TGF-beta, alone or in combination with other growth factors, may play a role in the pathogenesis of CsA induced nephrotoxicity.	Cyclosporine	175-178	transforming growth factor, beta 1	Rattus norvegicus	75-83
7565789-7	1995	CsA decreases both Nur77 protein levels and promoter activity, and the kinetics of CsA inhibition of apoptosis correlates with a decrease in Nur77 protein levels.	Cyclosporine	0-3	nuclear receptor subfamily 4 group A member 1	Homo sapiens	19-24
7565789-7	1995	CsA decreases both Nur77 protein levels and promoter activity, and the kinetics of CsA inhibition of apoptosis correlates with a decrease in Nur77 protein levels.	Cyclosporine	83-86	nuclear receptor subfamily 4 group A member 1	Homo sapiens	141-146
7565789-9	1995	In addition, Nur77 promoter deletion analysis revealed two RSRF (related to serum-responsive factor) binding sites, which can confer calcium and CsA sensitivity on a heterologous promoter.	Cyclosporine	145-148	nuclear receptor subfamily 4 group A member 1	Homo sapiens	13-18
8569758-2	1995	Since the electron-flux from NADPH to cytochrome c via oxidoreductase showed a fairly constant reduction activity from pH 7.0-9.5, the generation of oxygen radicals at the level of P450-Cyclosporine (instead of oxidoreductase-P450) was investigated.	Cyclosporine	186-198	cytochrome c, somatic	Homo sapiens	38-50
7570983-0	1995	Regulation of transforming growth factor-beta 1 and its receptor by cyclosporine in human T lymphocytes.	Cyclosporine	68-80	transforming growth factor beta 1	Homo sapiens	14-47
7570980-8	1995	Although cyclosporine suppressed the secretion of both IL-2 and IFN-gamma, there was no difference in sensitivity to suppression between rejectors and nonrejectors.	Cyclosporine	9-21	interleukin 2	Homo sapiens	55-59
7570980-8	1995	Although cyclosporine suppressed the secretion of both IL-2 and IFN-gamma, there was no difference in sensitivity to suppression between rejectors and nonrejectors.	Cyclosporine	9-21	interferon gamma	Homo sapiens	64-73
7570983-2	1995	We postulated that CsA may induce transforming growth factor (TGF)-beta 1 secretion from human T lymphocytes, a cytokine with immunoregulatory effects that has been implicated in the pathogenesis of wound healing and scarring.	Cyclosporine	19-22	transforming growth factor beta 1	Homo sapiens	34-73
7570983-3	1995	TGF-beta 1 was measured in serum-free supernatants harvested from T lymphocytes stimulated in the presence of CsA by a specific sandwich ELISA.	Cyclosporine	110-113	transforming growth factor beta 1	Homo sapiens	0-10
7570983-4	1995	CsA (10-1000 ng/ml) enhanced TGF-beta 1 secretion by approximately 40-80% in a dose-dependent manner.	Cyclosporine	0-3	transforming growth factor beta 1	Homo sapiens	29-39
7570983-5	1995	Increased TGF-beta 1 secretion in the presence of CsA was accompanied by a 2- to 4-fold increase in TGF-beta 1 mRNA levels due to both enhancement of its nuclear transcription as well as prolongation of TGF-beta 1 mRNA half-life.	Cyclosporine	50-53	transforming growth factor beta 1	Homo sapiens	10-20
7570983-5	1995	Increased TGF-beta 1 secretion in the presence of CsA was accompanied by a 2- to 4-fold increase in TGF-beta 1 mRNA levels due to both enhancement of its nuclear transcription as well as prolongation of TGF-beta 1 mRNA half-life.	Cyclosporine	50-53	transforming growth factor beta 1	Homo sapiens	100-110
7570983-5	1995	Increased TGF-beta 1 secretion in the presence of CsA was accompanied by a 2- to 4-fold increase in TGF-beta 1 mRNA levels due to both enhancement of its nuclear transcription as well as prolongation of TGF-beta 1 mRNA half-life.	Cyclosporine	50-53	transforming growth factor beta 1	Homo sapiens	100-110
7570983-10	1995	Thus, CsA enhances the production of TGF-beta 1 protein as well as the expression of its receptor in activated T lymphocytes.	Cyclosporine	6-9	transforming growth factor beta 1	Homo sapiens	37-47
7570986-5	1995	This nonresponsiveness induced by anti-LFA-3 or anti-IL-2/IL-2R could be overcome by the incorporation of cyclosporine during the first-round stimulation or by incorporation of IL-2 during the second-round stimulation.	Cyclosporine	106-118	interleukin 2	Homo sapiens	53-57
7570986-5	1995	This nonresponsiveness induced by anti-LFA-3 or anti-IL-2/IL-2R could be overcome by the incorporation of cyclosporine during the first-round stimulation or by incorporation of IL-2 during the second-round stimulation.	Cyclosporine	106-118	interleukin 2	Homo sapiens	58-62
8533588-1	1995	Cyclosporin A (CyA) overcomes P-glycoprotein (P-gp) associated multidrug resistance (MDR).	Cyclosporine	0-11	ATP binding cassette subfamily B member 1	Homo sapiens	30-44
8533588-1	1995	Cyclosporin A (CyA) overcomes P-glycoprotein (P-gp) associated multidrug resistance (MDR).	Cyclosporine	0-11	ATP binding cassette subfamily B member 1	Homo sapiens	46-50
7485533-10	1995	These results suggest that cyclosporin-related chronic interstitial injury is mediated by angiotensin II and that the mechanisms promoting the interstitial scarring can be dissociated from glomerular and tubular dysfunction in cyclosporin nephropathy.	Cyclosporine	27-38	angiotensinogen	Rattus norvegicus	90-104
8580276-5	1995	Eight weeks" treatment with the immunosuppressive agents cyclosporin, or with corticosteroids, produced a significant reduction in the percentage of IL-2 secreting cells, although only for the former was there also a reduction in interferon-gamma secreting cells.	Cyclosporine	57-68	interleukin 2	Homo sapiens	149-153
8580276-5	1995	Eight weeks" treatment with the immunosuppressive agents cyclosporin, or with corticosteroids, produced a significant reduction in the percentage of IL-2 secreting cells, although only for the former was there also a reduction in interferon-gamma secreting cells.	Cyclosporine	57-68	interferon gamma	Homo sapiens	230-246
8580276-7	1995	CONCLUSION: Enteral nutrition and cyclosporin can down-regulate lymphokine secretion in the gut in Crohn"s disease.	Cyclosporine	34-45	interleukin 2	Homo sapiens	64-74
8845477-3	1995	Such a distribution seems to be responsible for the transcellular transport of Pgp substrates, including cyclosporin A (CsA), from the basal to the apical side.	Cyclosporine	120-123	ATP binding cassette subfamily B member 1	Homo sapiens	79-82
8845477-5	1995	Nevertheless, the sensitivity of their mitogen-induced proliferation to cytostatics, including doxorubicin and CsA, could be increased by the Pgp blockers.	Cyclosporine	111-114	ATP binding cassette subfamily B member 1	Homo sapiens	142-145
8845477-6	1995	Using isotopically-labeled CsA and tumoral lymphoid cell lines, we now show a higher CsA retention in Pgp-lacking parental ("Par") cells than in Pgp-expressing MDR cells.	Cyclosporine	85-88	ATP binding cassette subfamily B member 1	Homo sapiens	102-105
7554381-3	1995	We here present evidence that Chl, just like cyclosporine A (CsA), inhibits T cell proliferation as induced with immobilized alpha CD3 MoAb in a concentration-dependent manner, at least partly through interfering with the production of IL-2 protein and the induction of IL-2 mRNA.	Cyclosporine	61-64	interleukin 2	Homo sapiens	236-240
8845477-7	1995	The Pgp blockers can restore the CsA retention in the MDR cells to its level in the Par cells.	Cyclosporine	33-36	ATP binding cassette subfamily B member 1	Homo sapiens	4-7
7554381-3	1995	We here present evidence that Chl, just like cyclosporine A (CsA), inhibits T cell proliferation as induced with immobilized alpha CD3 MoAb in a concentration-dependent manner, at least partly through interfering with the production of IL-2 protein and the induction of IL-2 mRNA.	Cyclosporine	61-64	interleukin 2	Homo sapiens	270-274
7554381-7	1995	We conclude that Chl may inhibit functional properties of human T cells, although the drug is 100- to 1000-fold less potent than CsA in inhibiting T cell proliferation and IL-2 production, respectively.	Cyclosporine	129-132	interleukin 2	Homo sapiens	172-176
8589285-8	1995	It was concluded that angiotensin II contributes to the vasculopathy (hyalinosis) induced by CsA.	Cyclosporine	93-96	angiotensinogen	Rattus norvegicus	22-36
7490125-4	1995	Incubation of PMC with cyclosporin A (CsA) or dexamethasone (DEX), each at 10(-6) M for 24 hr, significantly inhibited the induced expression of mRNA for each of the five cytokines, and also inhibited release of biologically active TNF-alpha.	Cyclosporine	23-36	tumor necrosis factor	Rattus norvegicus	232-241
7490125-4	1995	Incubation of PMC with cyclosporin A (CsA) or dexamethasone (DEX), each at 10(-6) M for 24 hr, significantly inhibited the induced expression of mRNA for each of the five cytokines, and also inhibited release of biologically active TNF-alpha.	Cyclosporine	38-41	tumor necrosis factor	Rattus norvegicus	232-241
8589285-9	1995	In contrast, the interstitial fibrosis mediated by CsA can be partially prevented by both an angiotensin II Type I receptor antagonist or by hydralazine and furosemide.	Cyclosporine	51-54	angiotensinogen	Rattus norvegicus	93-107
7547962-7	1995	P-glycoprotein modulators generally demonstrated significantly greater potency (EC50; microM): SDZ PSC 833, 0.08; cyclosporin A, 1.3; verapamil, 4.1; quinidine, 6.4; prazosin, &gt; 300.	Cyclosporine	114-127	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
19077999-3	1995	Visceral involvement, particularly pulmonary interstitial disease, can lead to significant morbidity and mortality.Specific therapy is unavailable to date, but there has been interest in the use of cyclosporine (CSA), because it inhibits interleukin-2 production and affects cytotoxic T cells.	Cyclosporine	198-210	interleukin 2	Homo sapiens	238-251
8563719-14	1995	In vitro release of PRL and GH by ectopic pituitaries was inhibited by previous treatment with CyA and this effect was decreased proportional to the duration of the treatment with the drug, while LH secretion was not modified.	Cyclosporine	95-98	prolactin	Rattus norvegicus	20-23
7545025-3	1995	Because MDR1 efflux function may be modified by drugs such as cyclosporin A, accurate identification of MDR1+/efflux+ AML cases will be critical to identify patients who may benefit from therapies that contain such MDR1 modulators.	Cyclosporine	62-75	ATP binding cassette subfamily B member 1	Homo sapiens	8-12
7545025-3	1995	Because MDR1 efflux function may be modified by drugs such as cyclosporin A, accurate identification of MDR1+/efflux+ AML cases will be critical to identify patients who may benefit from therapies that contain such MDR1 modulators.	Cyclosporine	62-75	ATP binding cassette subfamily B member 1	Homo sapiens	104-108
7545025-3	1995	Because MDR1 efflux function may be modified by drugs such as cyclosporin A, accurate identification of MDR1+/efflux+ AML cases will be critical to identify patients who may benefit from therapies that contain such MDR1 modulators.	Cyclosporine	62-75	ATP binding cassette subfamily B member 1	Homo sapiens	104-108
8846196-3	1995	Combinations of CsA with the riminophenazines also caused augmentative activation of PLA2 and inhibition of Na+, K+-ATPase.	Cyclosporine	16-19	phospholipase A2 group IB	Homo sapiens	85-89
8846196-5	1995	These observations suggest that combinations of CsA with riminophenazines cause interactive enhancement of the activity of PLA2 in MNL leading to lysophospholipid-mediated inactivation of Na+, K+-ATPase and consequent inhibition of the proliferative responses of these cells.	Cyclosporine	48-51	phospholipase A2 group IB	Homo sapiens	123-127
8846199-7	1995	Similarly, cyclosporin A reduced the generation of IL-2 (IC50 = 0.4 microM) and GM-CSF (IC50 = 0.6 microM) while barely affecting the other two cytokines.	Cyclosporine	11-24	interleukin 2	Homo sapiens	51-55
8530534-4	1995	The MIA-promoted TCR-mediated IL-2 production actually required signal transduction that could be inhibited by cyclosporin A, genistein, or H-7.	Cyclosporine	111-124	interleukin 2	Homo sapiens	30-34
8557519-2	1995	We demonstrate that CsA and FK506 inhibited IL-2R (CD25) gene transcription and protein expression after stimulation by anti-CD3 or ionomycin, but not by phorbol ester or IL-2.	Cyclosporine	20-23	interleukin 2	Homo sapiens	44-48
7643878-7	1995	When such transplantations were done in mice immunosuppressed with cyclosporine or FK-506, normal dystrophin mRNA accounted for 31% and 36% of the total dystrophin mRNA, respectively.	Cyclosporine	67-79	dystrophin, muscular dystrophy	Mus musculus	98-108
8586834-0	1995	Cyclosporin-induced renal vasoconstriction is augmented by frusemide and by angiotensin II in humans.	Cyclosporine	0-11	angiotensinogen	Homo sapiens	76-90
8586834-1	1995	OBJECTIVE: To investigate the role of the renin-angiotensin-aldosterone system as a homoeostatic mechanism by examining whether mild activation of the renin-angiotensin-aldosterone system could enhance cyclosporin-induced renal vasoconstriction and hypertension.	Cyclosporine	202-213	renin	Homo sapiens	151-156
8586834-4	1995	We then examined the effect of cyclosporin (10 mg/kg twice a day orally) in the presence of the activated renin-angiotensin-aldosterone system in normal humans.	Cyclosporine	31-42	renin	Homo sapiens	106-111
8586834-6	1995	Co-administration of exogenous angiotensin II with cyclosporin induced a fall in effective renal plasma flow from baseline but no change in glomerular filtration rate.	Cyclosporine	51-62	angiotensinogen	Homo sapiens	31-45
8586834-9	1995	The present findings demonstrate that renin-angiotensin-aldosterone system activation augments cyclosporin-induced renal vasoconstriction but not cyclosporin-induced systemic vasoconstriction.	Cyclosporine	95-106	renin	Homo sapiens	38-43
8586834-10	1995	We suggest that the renin-angiotensin-aldosterone system suppression, which normally occurs with cyclosporin, may be a homoeostatic mechanism to help prevent cyclosporin-induced renal vasoconstriction.	Cyclosporine	97-108	renin	Homo sapiens	20-25
8586834-10	1995	We suggest that the renin-angiotensin-aldosterone system suppression, which normally occurs with cyclosporin, may be a homoeostatic mechanism to help prevent cyclosporin-induced renal vasoconstriction.	Cyclosporine	158-169	renin	Homo sapiens	20-25
7643878-7	1995	When such transplantations were done in mice immunosuppressed with cyclosporine or FK-506, normal dystrophin mRNA accounted for 31% and 36% of the total dystrophin mRNA, respectively.	Cyclosporine	67-79	dystrophin, muscular dystrophy	Mus musculus	153-163
7638755-13	1995	CONCLUSIONS: These results indicate that inhaled cyclosporine is effective therapy for refractory pulmonary rejection and that its mechanism of action is associated with suppression of proinflammatory cytokines IL-6 and interferon-gamma within the allograft.	Cyclosporine	49-61	interleukin 6	Homo sapiens	211-215
7575779-10	1995	Furthermore, the fall in apo(a) was smaller (31% vs. 74%) and the increase in apolipoprotein B (apo B) greater (0.55 (0.15) vs. 0.18 (0.05) grams/l, P = 0.014) in cyA-treated patients.	Cyclosporine	163-166	apolipoprotein B	Homo sapiens	78-94
7635184-10	1995	No inhibitory effect on the IL-2 production by thalidomide could be detected at any of the drug concentrations tested (5-30 micrograms/mL), whereas 10 to 100 ng/mL of cyclosporine inhibited the IL-2 production by 95 to 100%.	Cyclosporine	167-179	interleukin 2	Homo sapiens	194-198
7643015-8	1995	In contrast, IL-12 induction of IFN-gamma cytoplasmic mRNA appears to only partially depend on activation of protein kinase C. Furthermore, both transforming growth factor-beta and genistein, a tyrosine kinase inhibitor, could suppress IL-2 and IL-12 signaling but CsA was generally inactive.	Cyclosporine	265-268	interferon gamma	Homo sapiens	32-41
7643631-4	1995	Downmodulation of Pgp function in these cell lines could be demonstrated with different substances (verapamil, vinblastine, trifluoperazine, cyclosporin A, progesterone and quinidine) and was proven to be consistently higher in the vinblastine selected cells than in their non-selected drug sensitive counterparts.	Cyclosporine	141-154	ATP binding cassette subfamily B member 1	Homo sapiens	18-21
7577422-5	1995	The post-translational and transcriptional pathways for regulation of phospholipase C and phospholipase A2 are described, including consideration of perturbations in these systems that characterize two disease models, namely: acute cyclosporine nephrotoxicity and early diabetic glomerulopathy.	Cyclosporine	232-244	phospholipase A2 group IB	Homo sapiens	90-106
7638755-13	1995	CONCLUSIONS: These results indicate that inhaled cyclosporine is effective therapy for refractory pulmonary rejection and that its mechanism of action is associated with suppression of proinflammatory cytokines IL-6 and interferon-gamma within the allograft.	Cyclosporine	49-61	interferon gamma	Homo sapiens	220-236
7631829-4	1995	Cyclosporins A [half-maximal inhibition constant (K0.5) = 20 nM] and G (K0.5 = 40 nM) blocked [3H]azidopine photolabeling of renal P-glycoprotein at very low concentrations, whereas higher concentrations of cyclosporin C (K0.5 = 500 nM) and metabolites 1, 17, and 21 (K0.5 = 200 nM) were required to inhibit photolabeling.	Cyclosporine	0-14	ATP binding cassette subfamily B member 1	Homo sapiens	131-145
7631829-7	1995	Cyclosporins A, C, and G also enhanced cellular accumulation of [3H]cyclosporin A and several other 3H-labeled compounds known to be transported by P-glycoprotein in multidrug-resistant C5 cells.	Cyclosporine	0-14	ATP binding cassette subfamily B member 1	Homo sapiens	148-162
7631829-0	1995	Differential interaction of human renal P-glycoprotein with various metabolites and analogues of cyclosporin A.	Cyclosporine	97-110	ATP binding cassette subfamily B member 1	Homo sapiens	40-54
7631829-1	1995	Interactions of P-glycoprotein with several analogues and metabolites of cyclosporin A were studied to gain a better understanding of this immunosuppressant"s mechanism of excretion and nephrotoxicity.	Cyclosporine	73-86	ATP binding cassette subfamily B member 1	Homo sapiens	16-30
7631829-8	1995	Differential affinities of cyclosporin A metabolites for P-glycoprotein suggest considerable drug-binding site specificity.	Cyclosporine	27-40	ATP binding cassette subfamily B member 1	Homo sapiens	57-71
7631829-9	1995	Our current hypothesis is that cyclosporin A may be more nephrotoxic than its metabolites by virtue of its superior ability to bind to and competitively inhibit urinary excretion of an endogenous P-glycoprotein substrate.	Cyclosporine	31-44	ATP binding cassette subfamily B member 1	Homo sapiens	196-210
8589211-6	1995	CSA at 10 and 50 micrograms/ml inhibited cell growth and thrombin stimulated release of PGI2 in a time- and dose-dependent manner.	Cyclosporine	0-3	coagulation factor II, thrombin	Homo sapiens	57-65
8541808-1	1995	The effect of cyclosporin A (CsA) on tumor necrosis factor (TNF) or interleukin-6 (IL-6) production was evaluated in vivo in primed or unprimed mice challenged with lipopolysaccharide (LPS).	Cyclosporine	29-32	tumor necrosis factor	Mus musculus	60-63
7621064-7	1995	The percentage of CD4-positive T lymphocytes bearing IL-2 receptor (a marker of T cell activation) in the peripheral blood decreased significantly at 6 weeks (P &lt; .05), but returned to baseline value at 12 weeks, probably due to cyclosporine A dose reduction in seven subjects.	Cyclosporine	232-246	CD4 molecule	Homo sapiens	18-21
7601249-7	1995	Expression of the IL-5, IL-6, and IL-10 genes was resistant to cyclosporine A (CsA), whereas IL-3 and IL-4 gene expression was completely inhibited, indicating the involvement of different signalling pathways in the regulation of these genes.	Cyclosporine	63-77	interleukin 6	Homo sapiens	24-28
7601249-7	1995	Expression of the IL-5, IL-6, and IL-10 genes was resistant to cyclosporine A (CsA), whereas IL-3 and IL-4 gene expression was completely inhibited, indicating the involvement of different signalling pathways in the regulation of these genes.	Cyclosporine	79-82	interleukin 6	Homo sapiens	24-28
8586491-4	1995	Several were inhibitory, and the concentrations which caused a 50% reduction in IL-10 production were 0.38 microM cyclosporin-A, 0.0073 microM dexamethasone, 0.045 microM prednisolone and 0.31 microM cycloheximide.	Cyclosporine	114-127	interleukin 10	Mus musculus	80-85
8541808-1	1995	The effect of cyclosporin A (CsA) on tumor necrosis factor (TNF) or interleukin-6 (IL-6) production was evaluated in vivo in primed or unprimed mice challenged with lipopolysaccharide (LPS).	Cyclosporine	29-32	interleukin 6	Mus musculus	68-81
8541808-3	1995	CsA administration inhibited the TNF production.	Cyclosporine	0-3	tumor necrosis factor	Mus musculus	33-36
7582858-5	1995	CsA in all concentrations significantly (P &lt; 0.001) inhibited both Ca2+ ATPase and NOS activities of rat myocardium and FDP at 1000 microM concentration completely reversed the 1000 microM CsA-inhibited Ca2+ ATPase and cNOS activities of rat myocardium.	Cyclosporine	0-3	carbonic anhydrase 2	Rattus norvegicus	70-81
7564368-0	1995	Tissue- and subtype-specific modulation of angiotensin II receptors by chronic treatment with cyclosporin A, angiotensin-converting enzyme inhibitors and AT1 antagonists.	Cyclosporine	94-107	angiotensinogen	Rattus norvegicus	43-57
7564368-2	1995	In rats treated chronically with CSA, the vasoconstrictor response to angiotensin II (AII) is increased and this increase is modulated by ACEI and angiotensin receptor antagonists.	Cyclosporine	33-36	angiotensinogen	Rattus norvegicus	70-84
7564368-2	1995	In rats treated chronically with CSA, the vasoconstrictor response to angiotensin II (AII) is increased and this increase is modulated by ACEI and angiotensin receptor antagonists.	Cyclosporine	33-36	angiotensinogen	Rattus norvegicus	86-89
7582858-6	1995	These data indicate that CsA may inhibit Ca2+ ATPase and NOS activities in the rat myocardium through interference with its Ca2+/Cam-mediated events and thus may cause myocardial toxicity.	Cyclosporine	25-28	carbonic anhydrase 2	Rattus norvegicus	41-52
7582858-5	1995	CsA in all concentrations significantly (P &lt; 0.001) inhibited both Ca2+ ATPase and NOS activities of rat myocardium and FDP at 1000 microM concentration completely reversed the 1000 microM CsA-inhibited Ca2+ ATPase and cNOS activities of rat myocardium.	Cyclosporine	0-3	carbonic anhydrase 2	Rattus norvegicus	206-217
7582858-5	1995	CsA in all concentrations significantly (P &lt; 0.001) inhibited both Ca2+ ATPase and NOS activities of rat myocardium and FDP at 1000 microM concentration completely reversed the 1000 microM CsA-inhibited Ca2+ ATPase and cNOS activities of rat myocardium.	Cyclosporine	192-195	carbonic anhydrase 2	Rattus norvegicus	70-81
7582858-5	1995	CsA in all concentrations significantly (P &lt; 0.001) inhibited both Ca2+ ATPase and NOS activities of rat myocardium and FDP at 1000 microM concentration completely reversed the 1000 microM CsA-inhibited Ca2+ ATPase and cNOS activities of rat myocardium.	Cyclosporine	192-195	carbonic anhydrase 2	Rattus norvegicus	206-217
7541038-4	1995	Cyclosporin A and FK506 efficiently disrupt the YY1-CyPA and YY1-FKBP12 interactions.	Cyclosporine	0-13	YY1 transcription factor	Homo sapiens	48-51
7541577-0	1995	Implication of cyclosporine in up-regulation of Bcl-2 expression and maintenance of CD8 lymphocytosis in cytomegalovirus-infected allograft recipients.	Cyclosporine	15-27	BCL2 apoptosis regulator	Homo sapiens	48-53
7541577-8	1995	Conversely, we showed that overexpression of Bcl-2 protein in lymphocytes from uninfected allograft recipients, and culture of unstimulated normal lymphocytes with 0.5 micrograms/ml cyclosporine led to an increase in the expression of intracellular Bcl-2.	Cyclosporine	182-194	BCL2 apoptosis regulator	Homo sapiens	45-50
7541577-8	1995	Conversely, we showed that overexpression of Bcl-2 protein in lymphocytes from uninfected allograft recipients, and culture of unstimulated normal lymphocytes with 0.5 micrograms/ml cyclosporine led to an increase in the expression of intracellular Bcl-2.	Cyclosporine	182-194	BCL2 apoptosis regulator	Homo sapiens	249-254
7541577-9	1995	This up-regulation of Bcl-2 protein by cyclosporine suggests the acquisition of resistance to apoptosis.	Cyclosporine	39-51	BCL2 apoptosis regulator	Homo sapiens	22-27
7759865-7	1995	p40cdk6 also increased in amount in cells activated in the presence of cyclosporin A or FK506, drugs that inhibit production of IL-2 and cell proliferation, suggesting that initial induction occurred independently of IL-2-mediated cell cycle progression.	Cyclosporine	71-84	interleukin 2	Homo sapiens	128-132
7541038-4	1995	Cyclosporin A and FK506 efficiently disrupt the YY1-CyPA and YY1-FKBP12 interactions.	Cyclosporine	0-13	YY1 transcription factor	Homo sapiens	61-64
7777516-4	1995	One CsA analog with antiviral activity costimulated the phytohemagglutinin-induced production of interleukin 2 by human lymphocytes.	Cyclosporine	4-7	interleukin 2	Homo sapiens	97-110
7546630-6	1995	Excess NO production is also one of the earliest signs of transplant rejection, and suppression of iNOS expression by immunosuppressant drugs such as cyclosporin A might be one means by which these drugs protect allografts.	Cyclosporine	150-163	nitric oxide synthase 2	Homo sapiens	99-103
8582089-0	1995	Gene expression of endothelin receptors in aortic cells from cyclosporine-induced hypertensive rats.	Cyclosporine	61-73	endothelin 1	Rattus norvegicus	19-29
7544689-9	1995	TGF-beta, dexamethasone, or cyclosporin A also dose dependently inhibited the IL-1 beta induced NO production.	Cyclosporine	28-41	interleukin 1 beta	Rattus norvegicus	78-87
7538541-13	1995	Finally, immunosuppressant cyclosporin A (100 nM) and FK-506 (10 nM) significantly inhibited mast cell adhesion to both fibronectin and laminin (p &lt; 0.05).	Cyclosporine	27-40	fibronectin 1	Homo sapiens	120-131
8582089-8	1995	Thus, increased endothelial preproendothelin-1, and ETA receptor mRNA levels in smooth muscle cells, which are concomitant with the decrease in ETB receptor mRNA levels in endothelium, may contribute to CyA-induced hypertension in rats.	Cyclosporine	203-206	endothelin 1	Rattus norvegicus	28-46
7539138-1	1995	As previously observed for FK506, we report here that cyclosporin A (CsA) treatment of mouse fibroblast cells stably transfected with the mouse mammary tumor virus-chloramphenicol acetyltransferase (MMTV-CAT) reporter plasmid (LMCAT cells) results in potentiation of dexamethasone (Dex)-induced CAT gene expression.	Cyclosporine	54-67	catalase	Homo sapiens	204-207
7594425-13	1995	Cyclosporin-induced renal vasoconstriction appeared to occur when the protective mechanism of plasma renin activity suppression became exhausted.	Cyclosporine	0-11	renin	Homo sapiens	101-106
7674231-0	1995	Cyclosporin A increases somatomedin C insulin-like growth factor I levels in chronic rheumatic diseases.	Cyclosporine	0-13	insulin like growth factor 1	Homo sapiens	24-37
7674231-0	1995	Cyclosporin A increases somatomedin C insulin-like growth factor I levels in chronic rheumatic diseases.	Cyclosporine	0-13	insulin like growth factor 1	Homo sapiens	38-66
7539138-1	1995	As previously observed for FK506, we report here that cyclosporin A (CsA) treatment of mouse fibroblast cells stably transfected with the mouse mammary tumor virus-chloramphenicol acetyltransferase (MMTV-CAT) reporter plasmid (LMCAT cells) results in potentiation of dexamethasone (Dex)-induced CAT gene expression.	Cyclosporine	54-67	catalase	Homo sapiens	229-232
7556412-0	1995	Cyclosporin A is a substance P (tachykinin NK1) receptor antagonist.	Cyclosporine	0-13	tachykinin precursor 1	Homo sapiens	19-56
7556412-1	1995	The immunosuppressive cyclic undecapeptide, cyclosporin A, inhibited the binding of [125I]substance P to tachykinin NK1 receptors expressed by human IM-9 lymphoblastoid cells, U-373 MG human astrocytoma cells and guinea pig lung parenchyma with IC50 values of 425 +/- 58, 783 +/- 180, and 784 +/- 163 nM respectively.	Cyclosporine	44-57	tachykinin precursor 1	Homo sapiens	90-101
7539138-1	1995	As previously observed for FK506, we report here that cyclosporin A (CsA) treatment of mouse fibroblast cells stably transfected with the mouse mammary tumor virus-chloramphenicol acetyltransferase (MMTV-CAT) reporter plasmid (LMCAT cells) results in potentiation of dexamethasone (Dex)-induced CAT gene expression.	Cyclosporine	69-72	catalase	Homo sapiens	204-207
7539138-1	1995	As previously observed for FK506, we report here that cyclosporin A (CsA) treatment of mouse fibroblast cells stably transfected with the mouse mammary tumor virus-chloramphenicol acetyltransferase (MMTV-CAT) reporter plasmid (LMCAT cells) results in potentiation of dexamethasone (Dex)-induced CAT gene expression.	Cyclosporine	69-72	catalase	Homo sapiens	229-232
7539138-2	1995	Potentiation by CsA is observed in cells treated with 10-100 nM Dex but not in cells treated with 1 microM Dex, a concentration of hormone which results in maximum CAT activity.	Cyclosporine	16-19	catalase	Homo sapiens	164-167
7539138-3	1995	At 10 nM Dex, 1-5 microM CsA provokes an approximately 50-fold increase in CAT gene transcription, compared with transcription induced by Dex alone.	Cyclosporine	25-28	catalase	Homo sapiens	75-78
7539138-6	1995	Using a series of CsA, as well as FK506, analogs, including some devoid of calcineurin phosphatase inhibition activity, we conclude that the potentiation effects of these drugs on Dex-induced CAT gene expression in LMCAT cells do not occur through a calcineurin-mediated pathway.	Cyclosporine	18-21	catalase	Homo sapiens	192-195
7556412-3	1995	The cyclosporin compounds also inhibited [125I]neurokinin A binding to human NK2 receptors with potencies slightly less than at NK1 sites.	Cyclosporine	4-15	tachykinin precursor 1	Homo sapiens	47-59
7545487-1	1995	Cyclosporin A (CsA) inhibited interleukin 2 (IL-2), IL-3, interferon gamma (IFN gamma), GM-CSF and tumor necrosis factor alpha (TNF alpha) mRNA expression in spleen cells stimulated with concavalin A (Con A) when determined by the semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) method.	Cyclosporine	0-13	interleukin 2	Homo sapiens	30-43
7556412-3	1995	The cyclosporin compounds also inhibited [125I]neurokinin A binding to human NK2 receptors with potencies slightly less than at NK1 sites.	Cyclosporine	4-15	tachykinin precursor 1	Homo sapiens	77-80
7556412-5	1995	Thus, the cyclosporin A compounds showed selectivity for NK1 and NK2 receptors.	Cyclosporine	10-23	tachykinin precursor 1	Homo sapiens	65-68
7556412-8	1995	In addition, cyclosporin A blocked substance P induced phosphatidylinositol (PI) turnover in U-373 MG cells without blocking the corresponding response to histamine.	Cyclosporine	13-26	tachykinin precursor 1	Homo sapiens	35-46
7545487-1	1995	Cyclosporin A (CsA) inhibited interleukin 2 (IL-2), IL-3, interferon gamma (IFN gamma), GM-CSF and tumor necrosis factor alpha (TNF alpha) mRNA expression in spleen cells stimulated with concavalin A (Con A) when determined by the semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) method.	Cyclosporine	0-13	interleukin 2	Homo sapiens	45-49
7545487-1	1995	Cyclosporin A (CsA) inhibited interleukin 2 (IL-2), IL-3, interferon gamma (IFN gamma), GM-CSF and tumor necrosis factor alpha (TNF alpha) mRNA expression in spleen cells stimulated with concavalin A (Con A) when determined by the semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) method.	Cyclosporine	0-13	interferon gamma	Homo sapiens	58-74
7545487-1	1995	Cyclosporin A (CsA) inhibited interleukin 2 (IL-2), IL-3, interferon gamma (IFN gamma), GM-CSF and tumor necrosis factor alpha (TNF alpha) mRNA expression in spleen cells stimulated with concavalin A (Con A) when determined by the semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) method.	Cyclosporine	0-13	interferon gamma	Homo sapiens	76-85
7545487-1	1995	Cyclosporin A (CsA) inhibited interleukin 2 (IL-2), IL-3, interferon gamma (IFN gamma), GM-CSF and tumor necrosis factor alpha (TNF alpha) mRNA expression in spleen cells stimulated with concavalin A (Con A) when determined by the semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) method.	Cyclosporine	0-13	tumor necrosis factor	Homo sapiens	99-126
7545487-1	1995	Cyclosporin A (CsA) inhibited interleukin 2 (IL-2), IL-3, interferon gamma (IFN gamma), GM-CSF and tumor necrosis factor alpha (TNF alpha) mRNA expression in spleen cells stimulated with concavalin A (Con A) when determined by the semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) method.	Cyclosporine	0-13	tumor necrosis factor	Homo sapiens	128-137
7545487-1	1995	Cyclosporin A (CsA) inhibited interleukin 2 (IL-2), IL-3, interferon gamma (IFN gamma), GM-CSF and tumor necrosis factor alpha (TNF alpha) mRNA expression in spleen cells stimulated with concavalin A (Con A) when determined by the semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) method.	Cyclosporine	15-18	interleukin 2	Homo sapiens	30-43
7545487-1	1995	Cyclosporin A (CsA) inhibited interleukin 2 (IL-2), IL-3, interferon gamma (IFN gamma), GM-CSF and tumor necrosis factor alpha (TNF alpha) mRNA expression in spleen cells stimulated with concavalin A (Con A) when determined by the semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) method.	Cyclosporine	15-18	interleukin 2	Homo sapiens	45-49
7545487-1	1995	Cyclosporin A (CsA) inhibited interleukin 2 (IL-2), IL-3, interferon gamma (IFN gamma), GM-CSF and tumor necrosis factor alpha (TNF alpha) mRNA expression in spleen cells stimulated with concavalin A (Con A) when determined by the semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) method.	Cyclosporine	15-18	interferon gamma	Homo sapiens	58-74
7545487-1	1995	Cyclosporin A (CsA) inhibited interleukin 2 (IL-2), IL-3, interferon gamma (IFN gamma), GM-CSF and tumor necrosis factor alpha (TNF alpha) mRNA expression in spleen cells stimulated with concavalin A (Con A) when determined by the semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) method.	Cyclosporine	15-18	interferon gamma	Homo sapiens	76-85
7545487-1	1995	Cyclosporin A (CsA) inhibited interleukin 2 (IL-2), IL-3, interferon gamma (IFN gamma), GM-CSF and tumor necrosis factor alpha (TNF alpha) mRNA expression in spleen cells stimulated with concavalin A (Con A) when determined by the semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) method.	Cyclosporine	15-18	tumor necrosis factor	Homo sapiens	99-126
7545487-1	1995	Cyclosporin A (CsA) inhibited interleukin 2 (IL-2), IL-3, interferon gamma (IFN gamma), GM-CSF and tumor necrosis factor alpha (TNF alpha) mRNA expression in spleen cells stimulated with concavalin A (Con A) when determined by the semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) method.	Cyclosporine	15-18	tumor necrosis factor	Homo sapiens	128-137
7545487-3	1995	In contrast, both CsA and FK506 enhanced transforming growth factor beta (TGF beta) and IL-1 beta mRNA expression.	Cyclosporine	18-21	transforming growth factor beta 1	Homo sapiens	41-72
7556274-12	1995	Combination of CsA with either an ACE-Inhibitor or an AT2 receptor antagonist prevented the endothelial dysfunction in the rat arta observed after CsA alone.	Cyclosporine	147-150	angiotensin I converting enzyme	Rattus norvegicus	34-37
7545487-3	1995	In contrast, both CsA and FK506 enhanced transforming growth factor beta (TGF beta) and IL-1 beta mRNA expression.	Cyclosporine	18-21	transforming growth factor beta 1	Homo sapiens	74-82
7545487-3	1995	In contrast, both CsA and FK506 enhanced transforming growth factor beta (TGF beta) and IL-1 beta mRNA expression.	Cyclosporine	18-21	interleukin 1 beta	Homo sapiens	88-97
7542098-2	1995	CD40L expression in T cells is transient, requires activation of protein kinase C and a rise in intracellular calcium concentration ([Ca2+]i), and is inhibited by cyclosporin A (CsA).	Cyclosporine	163-176	CD40 ligand	Homo sapiens	0-5
7542098-2	1995	CD40L expression in T cells is transient, requires activation of protein kinase C and a rise in intracellular calcium concentration ([Ca2+]i), and is inhibited by cyclosporin A (CsA).	Cyclosporine	178-181	CD40 ligand	Homo sapiens	0-5
7542098-3	1995	CsA also inhibited T-cell-dependent IL-4-driven IgE synthesis.	Cyclosporine	0-3	interleukin 4	Homo sapiens	36-40
7542098-3	1995	CsA also inhibited T-cell-dependent IL-4-driven IgE synthesis.	Cyclosporine	0-3	immunoglobulin heavy constant epsilon	Homo sapiens	48-51
7543725-8	1995	CsA- and FK506-treated rats, but not those treated with rapamycin, demonstrated high turnover osteoporosis with raised serum 1,25(OH)2D (p &lt; 0.05) and elevated serum osteocalcin (p &lt; 0.05).	Cyclosporine	0-3	bone gamma-carboxyglutamate protein	Rattus norvegicus	169-180
7613160-1	1995	Based on in vitro findings with mouse mast cells and in vivo findings in mice, we report that dexamethasone or cyclosporin A can have at least three actions which interfere with the pathogenesis IgE-, mast-cell-, and cytokine-dependent inflammatory reactions: suppression of the IgE-dependent increase in tumor necrosis factor (TNF)-alpha mRNA by mast cells, inhibition of the IgE-dependent production of TNF-alpha protein by mast cells, and diminution of the responsiveness of target cells to TNF-alpha.	Cyclosporine	111-124	tumor necrosis factor	Mus musculus	305-338
7613160-1	1995	Based on in vitro findings with mouse mast cells and in vivo findings in mice, we report that dexamethasone or cyclosporin A can have at least three actions which interfere with the pathogenesis IgE-, mast-cell-, and cytokine-dependent inflammatory reactions: suppression of the IgE-dependent increase in tumor necrosis factor (TNF)-alpha mRNA by mast cells, inhibition of the IgE-dependent production of TNF-alpha protein by mast cells, and diminution of the responsiveness of target cells to TNF-alpha.	Cyclosporine	111-124	tumor necrosis factor	Mus musculus	405-414
7613160-1	1995	Based on in vitro findings with mouse mast cells and in vivo findings in mice, we report that dexamethasone or cyclosporin A can have at least three actions which interfere with the pathogenesis IgE-, mast-cell-, and cytokine-dependent inflammatory reactions: suppression of the IgE-dependent increase in tumor necrosis factor (TNF)-alpha mRNA by mast cells, inhibition of the IgE-dependent production of TNF-alpha protein by mast cells, and diminution of the responsiveness of target cells to TNF-alpha.	Cyclosporine	111-124	tumor necrosis factor	Mus musculus	494-503
7747414-8	1995	Secretion of IL-2 was suggested by cyclosporin A inhibition.	Cyclosporine	35-48	interleukin 2	Homo sapiens	13-17
7559918-0	1995	Inhibition of cell-mediated cytolysis and P-glycoprotein function in natural killer cells by verapamil isomers and cyclosporine A analogs.	Cyclosporine	115-129	ATP binding cassette subfamily B member 1	Homo sapiens	42-56
7559918-8	1995	Both CsA and PSC maximally inhibited P-gp efflux at 3 microM, but only minimally inhibited cell-mediated cytolysis.	Cyclosporine	5-8	ATP binding cassette subfamily B member 1	Homo sapiens	37-41
7713904-6	1995	By contrast, cyclosporin A that inhibits T cell activation through the interaction of cyclophilin-cyclosporin A complexes with the calmodulin-activated phosphatase, calcineurin, had no effect on PtdSer synthesis.	Cyclosporine	13-26	calmodulin 1	Homo sapiens	131-141
7713904-6	1995	By contrast, cyclosporin A that inhibits T cell activation through the interaction of cyclophilin-cyclosporin A complexes with the calmodulin-activated phosphatase, calcineurin, had no effect on PtdSer synthesis.	Cyclosporine	13-24	calmodulin 1	Homo sapiens	131-141
7606876-0	1995	Ciclosporin-associated arteriolopathy: the renin producing vascular smooth muscle cells are more sensitive to ciclosporin toxicity.	Cyclosporine	0-11	renin	Homo sapiens	43-48
7606876-0	1995	Ciclosporin-associated arteriolopathy: the renin producing vascular smooth muscle cells are more sensitive to ciclosporin toxicity.	Cyclosporine	110-121	renin	Homo sapiens	43-48
7606876-2	1995	CAA affects the part of the afferent arteriole where renin is most abundant, and an effect by Cs on the renin producing smooth muscle cells leading to necrosis has been suggested.	Cyclosporine	94-96	renin	Homo sapiens	104-109
7606876-5	1995	Compared to the control group there was a slight increase in the proportion of renin positive arterioles in the Cs treated group without CAA, but with increasing CAA there was a decrease in the proportion of renin positive arterioles.	Cyclosporine	112-114	renin	Homo sapiens	79-84
7606876-8	1995	Our findings support the possibility that Cs stimulates renin production, and that the renin producing cells are more sensitive to Cs toxicity.	Cyclosporine	42-44	renin	Homo sapiens	56-61
7606876-8	1995	Our findings support the possibility that Cs stimulates renin production, and that the renin producing cells are more sensitive to Cs toxicity.	Cyclosporine	131-133	renin	Homo sapiens	87-92
7534714-4	1995	Flow-cytometric analysis revealed a normal expression of GPI-linked membrane proteins, including CD55, CD59, and CD16 on PMN in all patients treated with CyA, irrespective of response, except for one patient who had a small proportion of GPI-anchored membrane protein-negative cells before therapy.	Cyclosporine	154-157	CD59 molecule (CD59 blood group)	Homo sapiens	103-107
7543780-1	1995	It has been reported that rapamycin (rap), cyclosporin A (CsA) and FK506 have immunosuppressive effect during the activation process of murine T cells.	Cyclosporine	58-61	regulatory associated protein of MTOR, complex 1	Mus musculus	26-29
7543780-3	1995	Rap and CsA strongly inhibit the IL-2-dependent proliferation of TS1 alpha beta cells while they minimally affect the IL-2-mediated proliferation of TS1 beta cells.	Cyclosporine	8-11	interleukin 2	Homo sapiens	33-37
7543780-5	1995	Simultaneous addition of Rap and CsA or Rap and FK506 inhibit the IL-2-mediated proliferation of TS1 beta and TS1 alpha beta cells and therefore FK506 does not revert the inhibition mediated by Rap in TS1 alpha beta cells.	Cyclosporine	33-36	interleukin 2	Homo sapiens	66-70
7547679-5	1995	Furthermore, we show that phorbol esters and cyclosporin A (CsA), which prevent Ca(2+)-dependent apoptosis, up-regulated Bcl-2 expression.	Cyclosporine	60-63	BCL2 apoptosis regulator	Homo sapiens	121-126
7536714-4	1995	The expression of inducible nitric oxide synthase messenger RNA (mRNA) induced by the combination of interleukin-1 alpha and tumor necrosis factor-alpha was inhibited by the cyclosporin A cotreatment.	Cyclosporine	174-187	interleukin 1 alpha	Rattus norvegicus	101-152
7536714-6	1995	Induction of nitrite/nitrate production by the combination of tumor necrosis factor-alpha and bacterial lipopolysaccharide or that of interleukin-1 alpha and interferon gamma (100 U/mL) was also inhibited by cyclosporin A cotreatment.	Cyclosporine	208-221	tumor necrosis factor	Rattus norvegicus	62-89
7536714-6	1995	Induction of nitrite/nitrate production by the combination of tumor necrosis factor-alpha and bacterial lipopolysaccharide or that of interleukin-1 alpha and interferon gamma (100 U/mL) was also inhibited by cyclosporin A cotreatment.	Cyclosporine	208-221	interleukin 1 alpha	Rattus norvegicus	134-153
7547679-6	1995	The effect of CsA on Bcl-2 expression is controlled by calcineurin since we have shown that FK506 but not rapamycin had the same effect on Bcl-2 expression, whereas okadaic acid, an inhibitor of phosphatases 1, 2A and 2C, was ineffective.	Cyclosporine	14-17	BCL2 apoptosis regulator	Homo sapiens	21-26
7547679-6	1995	The effect of CsA on Bcl-2 expression is controlled by calcineurin since we have shown that FK506 but not rapamycin had the same effect on Bcl-2 expression, whereas okadaic acid, an inhibitor of phosphatases 1, 2A and 2C, was ineffective.	Cyclosporine	14-17	BCL2 apoptosis regulator	Homo sapiens	139-144
7876544-6	1995	In AS ETS1 transfectants, IL-2 formation was completely inhibited by cyclosporin A and FK590.	Cyclosporine	69-82	interleukin 2	Homo sapiens	26-30
7536243-6	1995	The suppression of lymphocyte blastogenesis in vitro by cyclosporine or prednisolone was restored by addition of interleukin (IL)-1, IL-2, IL-4, IL-5 or IL-6.	Cyclosporine	56-68	interleukin 2	Homo sapiens	133-137
7536243-6	1995	The suppression of lymphocyte blastogenesis in vitro by cyclosporine or prednisolone was restored by addition of interleukin (IL)-1, IL-2, IL-4, IL-5 or IL-6.	Cyclosporine	56-68	interleukin 4	Homo sapiens	139-143
7536243-6	1995	The suppression of lymphocyte blastogenesis in vitro by cyclosporine or prednisolone was restored by addition of interleukin (IL)-1, IL-2, IL-4, IL-5 or IL-6.	Cyclosporine	56-68	interleukin 6	Homo sapiens	153-157
7896810-7	1995	Kinetic analyses indicate that cyclosporin A, an inhibitor of Pgp, binds to the verapamil and vinblastine binding/transport site(s) in the Pgp.	Cyclosporine	31-44	ATP binding cassette subfamily B member 1	Homo sapiens	62-65
7896810-7	1995	Kinetic analyses indicate that cyclosporin A, an inhibitor of Pgp, binds to the verapamil and vinblastine binding/transport site(s) in the Pgp.	Cyclosporine	31-44	ATP binding cassette subfamily B member 1	Homo sapiens	139-142
7896810-8	1995	Taken together, the results presented herein reveal that the verapamil and vinblastine binding/transport site(s) are in close proximity and that the cyclosporin A binding site spans the common region of these two drug binding/transport site(s) in the Pgp molecule.	Cyclosporine	149-162	ATP binding cassette subfamily B member 1	Homo sapiens	251-254
7540903-2	1995	The efficacy of verapamil and cyclosporine A as modulators of P-glycoprotein, the multidrug resistance (MDR1) gene product, was studied in leukemic blast cells from 56 patients with de novo acute myeloid leukemia (AML) in vitro.	Cyclosporine	30-44	ATP binding cassette subfamily B member 1	Homo sapiens	62-76
7892569-6	1995	Patients with acute graft versus host disease, fever or cyclosporin treatment had significantly higher VIII:C, vWF and tPA.	Cyclosporine	56-67	von Willebrand factor	Homo sapiens	111-114
7892569-6	1995	Patients with acute graft versus host disease, fever or cyclosporin treatment had significantly higher VIII:C, vWF and tPA.	Cyclosporine	56-67	plasminogen activator, tissue type	Homo sapiens	119-122
7599564-5	1995	We also demonstrate that IL-2 is still protective when administered in combination with cyclosporine.	Cyclosporine	88-100	interleukin 2	Homo sapiens	25-29
7540903-2	1995	The efficacy of verapamil and cyclosporine A as modulators of P-glycoprotein, the multidrug resistance (MDR1) gene product, was studied in leukemic blast cells from 56 patients with de novo acute myeloid leukemia (AML) in vitro.	Cyclosporine	30-44	ATP binding cassette subfamily B member 1	Homo sapiens	104-108
7599564-6	1995	These results suggest that IL-2 administered in a sufficient short course to avoid toxicity might have the potential to achieve effective GVHD prophylaxis in humans, even if given in combination with cyclosporine.	Cyclosporine	200-212	interleukin 2	Homo sapiens	27-31
7538492-6	1995	The presence of IFN-gamma and LPS in the culture increased NO2- production by casein-elicited macrophages and partially eliminated the inhibition exerted by CsA and FK506.	Cyclosporine	157-160	interferon gamma	Mus musculus	16-25
9383417-2	1995	In the case of FK506, ascomycin and cyclosporin, the target of the immunophilin-immunosuppressant complex is calcineurin; in the case of rapamycin, the target is FRAP (TOR/RAFT1).	Cyclosporine	36-47	mechanistic target of rapamycin kinase	Homo sapiens	172-177
7540862-0	1995	IL-5 production by CD4+ T cells of asthmatic patients is suppressed by glucocorticoids and the immunosuppressants FK506 and cyclosporin A.	Cyclosporine	124-137	CD4 molecule	Homo sapiens	19-22
7860926-3	1995	Because heart transplant recipients are treated with cyclosporine A, we studied whether administration of cyclosporine A in rats might cause this beta 1-adrenoceptor downregulation.	Cyclosporine	106-120	adrenoceptor beta 1	Rattus norvegicus	146-165
7628296-0	1995	Human liver cytochrome P4503A biotransformation of the cyclosporin derivative SDZ IMM 125.	Cyclosporine	55-66	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	12-18
7779855-10	1995	By initiating cyclosporine treatment at day 0, the synergistic effect of combining cyclosporine and anti-interleukin-2 receptor monoclonal antibodies may result in a lower rejection incidence.	Cyclosporine	14-26	interleukin 2	Homo sapiens	105-118
7860926-8	1995	RESULTS: Both doses of cyclosporine A caused a significant decrease in cardiac beta 1-adrenoceptor density without affecting beta 2-adrenoceptor density.	Cyclosporine	23-37	adrenoceptor beta 1	Rattus norvegicus	79-98
7860926-12	1995	In heart transplant recipients, who undergo long-term treatment with cyclosporine A, there is a very similar beta 1-adrenoceptor down-regulation with time after transplantation.	Cyclosporine	69-83	adrenoceptor beta 1	Rattus norvegicus	109-128
7885289-1	1995	Cyclosporine A (CSA) stimulates vascular endothelial cell production of endothelin-1 (ET-1).	Cyclosporine	0-14	endothelin 1	Rattus norvegicus	72-84
7885289-1	1995	Cyclosporine A (CSA) stimulates vascular endothelial cell production of endothelin-1 (ET-1).	Cyclosporine	0-14	endothelin 1	Rattus norvegicus	86-90
7885289-1	1995	Cyclosporine A (CSA) stimulates vascular endothelial cell production of endothelin-1 (ET-1).	Cyclosporine	16-19	endothelin 1	Rattus norvegicus	72-84
7885289-1	1995	Cyclosporine A (CSA) stimulates vascular endothelial cell production of endothelin-1 (ET-1).	Cyclosporine	16-19	endothelin 1	Rattus norvegicus	86-90
7885289-2	1995	The present study was designed to test two hypotheses: (1) CSA stimulates ET-1 secretion in cultured rat mesangial cells, and (2) cardiac natriuretic peptides, atrial and brain natriuretic peptides (ANP and BNP), inhibit the above-mentioned secretion in these cells.	Cyclosporine	59-62	endothelin 1	Rattus norvegicus	74-78
7885289-3	1995	CSA stimulated ET-1 secretion in a concentration-dependent manner between 10 and 100 ng/mL.	Cyclosporine	0-3	endothelin 1	Rattus norvegicus	15-19
7885289-5	1995	Rat ANP (1-28) and rat BNP-45 exhibited clearly concentration-related inhibition of CSA-induced ET-1 secretion.	Cyclosporine	84-87	natriuretic peptide B	Rattus norvegicus	23-26
7885289-5	1995	Rat ANP (1-28) and rat BNP-45 exhibited clearly concentration-related inhibition of CSA-induced ET-1 secretion.	Cyclosporine	84-87	endothelin 1	Rattus norvegicus	96-100
7885289-8	1995	Addition of a cGMP analog, 8-bromo-cGMP, reduced CSA-induced ET-1 secretion.	Cyclosporine	49-52	endothelin 1	Rattus norvegicus	61-65
7885289-10	1995	These findings suggest that CSA in low concentrations stimulates ET-1 production in cultured rat mesangial cells, and that cardiac natriuretic peptides inhibit this stimulated production, probably through a cGMP-dependent process.	Cyclosporine	28-31	endothelin 1	Rattus norvegicus	65-69
7551978-1	1995	This study evaluates the ability of the immunosuppressive drugs dexamethasone, cyclosporine, FK506 and rapamycin, alone and in combination to suppress interleukin-1 beta (IL-1 beta) secretion in vitro by THP-1 cells when stimulated by lipopolysaccharide.	Cyclosporine	79-91	interleukin 1 beta	Homo sapiens	151-169
7551978-1	1995	This study evaluates the ability of the immunosuppressive drugs dexamethasone, cyclosporine, FK506 and rapamycin, alone and in combination to suppress interleukin-1 beta (IL-1 beta) secretion in vitro by THP-1 cells when stimulated by lipopolysaccharide.	Cyclosporine	79-91	interleukin 1 beta	Homo sapiens	171-180
7551978-4	1995	Cyclosporine, FK506 and rapamycin only partially suppress secretion of IL-1 beta at concentrations within their therapeutic ranges and increasing concentrations of the drugs do not result in further suppression of secretion.	Cyclosporine	0-12	interleukin 1 beta	Homo sapiens	71-80
7551978-7	1995	These data suggest that cyclosporine, FK506 and rapamycin all share a common effect on the production of IL-1 beta, different from that of dexamethasone.	Cyclosporine	24-36	interleukin 1 beta	Homo sapiens	105-114
7781843-3	1995	Cyclosporin (CyA) and nicotinamide (NA), alone or in combination, can preserve this function, as indicated by the parameters of metabolic control (insulin dose, HbA1C).	Cyclosporine	0-11	insulin	Homo sapiens	147-154
7530743-1	1995	FK506 and cyclosporin A (CsA) are immunosuppressive agents that inhibit IL-2 production by activated T cells, but only CsA inhibits IgE activation-induced cytokine transcripts in mouse IL-3-dependent, bone marrow-derived mast cells (BMMC).	Cyclosporine	10-23	interleukin 3	Mus musculus	185-189
7530743-1	1995	FK506 and cyclosporin A (CsA) are immunosuppressive agents that inhibit IL-2 production by activated T cells, but only CsA inhibits IgE activation-induced cytokine transcripts in mouse IL-3-dependent, bone marrow-derived mast cells (BMMC).	Cyclosporine	25-28	interleukin 3	Mus musculus	185-189
7530743-1	1995	FK506 and cyclosporin A (CsA) are immunosuppressive agents that inhibit IL-2 production by activated T cells, but only CsA inhibits IgE activation-induced cytokine transcripts in mouse IL-3-dependent, bone marrow-derived mast cells (BMMC).	Cyclosporine	119-122	interleukin 3	Mus musculus	185-189
7702403-0	1995	Effect of cyclosporin A on interleukin-6 and soluble interleukin-2 receptor in patients with rheumatoid arthritis.	Cyclosporine	10-23	interleukin 6	Homo sapiens	27-40
7702403-1	1995	OBJECTIVE: To investigate the effect of cyclosporin A (CyA) therapy on circulating concentrations of interleukin-6 (IL-6) and soluble interleukin-2 receptor (sIL-2R) in patients with rheumatoid arthritis (RA).	Cyclosporine	40-53	interleukin 6	Homo sapiens	101-114
7702403-1	1995	OBJECTIVE: To investigate the effect of cyclosporin A (CyA) therapy on circulating concentrations of interleukin-6 (IL-6) and soluble interleukin-2 receptor (sIL-2R) in patients with rheumatoid arthritis (RA).	Cyclosporine	40-53	interleukin 6	Homo sapiens	116-120
7702403-1	1995	OBJECTIVE: To investigate the effect of cyclosporin A (CyA) therapy on circulating concentrations of interleukin-6 (IL-6) and soluble interleukin-2 receptor (sIL-2R) in patients with rheumatoid arthritis (RA).	Cyclosporine	55-58	interleukin 6	Homo sapiens	101-114
7702403-1	1995	OBJECTIVE: To investigate the effect of cyclosporin A (CyA) therapy on circulating concentrations of interleukin-6 (IL-6) and soluble interleukin-2 receptor (sIL-2R) in patients with rheumatoid arthritis (RA).	Cyclosporine	55-58	interleukin 6	Homo sapiens	116-120
7531627-11	1995	They further suggest that interference with IL-8 production and/or that of other key chemokines may be an important mechanism underlying the therapeutic efficacy of tacrolimus, and other agents such as cyclosporin A, with similar molecular actions.	Cyclosporine	202-215	C-X-C motif chemokine ligand 8	Homo sapiens	44-48
7822805-4	1995	We report here that either dexamethasone or cyclosporin A can inhibit mouse mast cell TNF-alpha production in vitro, and that these agents also can significantly suppress the tissue swelling and leukocyte infiltration associated with two forms of TNF-alpha-associated inflammation in vivo: the entirely IgE- and mast cell-dependent inflammation at sites of passive cutaneous anaphylaxis reactions and the entirely TNF-alpha-dependent inflammation that is elicited by the direct intradermal injection of recombinant mouse TNF-alpha.	Cyclosporine	44-57	tumor necrosis factor	Mus musculus	86-95
7822805-5	1995	Taken together, our in vitro and in vivo findings in mice indicate that dexamethasone or cyclosporin A can have at least three actions that interfere with the pathogenesis of IgE, mast cell, and cytokine-dependent inflammatory reactions:suppression of the IgE-dependent increase in TNF-alpha mRNA by mast cells, inhibition of the IgE-dependent production of TNF-alpha protein by mast cells, and diminution of the responsiveness of target cells to TNF-alpha.	Cyclosporine	89-102	tumor necrosis factor	Mus musculus	282-291
7781843-3	1995	Cyclosporin (CyA) and nicotinamide (NA), alone or in combination, can preserve this function, as indicated by the parameters of metabolic control (insulin dose, HbA1C).	Cyclosporine	13-16	insulin	Homo sapiens	147-154
7822805-5	1995	Taken together, our in vitro and in vivo findings in mice indicate that dexamethasone or cyclosporin A can have at least three actions that interfere with the pathogenesis of IgE, mast cell, and cytokine-dependent inflammatory reactions:suppression of the IgE-dependent increase in TNF-alpha mRNA by mast cells, inhibition of the IgE-dependent production of TNF-alpha protein by mast cells, and diminution of the responsiveness of target cells to TNF-alpha.	Cyclosporine	89-102	tumor necrosis factor	Mus musculus	358-367
7822805-5	1995	Taken together, our in vitro and in vivo findings in mice indicate that dexamethasone or cyclosporin A can have at least three actions that interfere with the pathogenesis of IgE, mast cell, and cytokine-dependent inflammatory reactions:suppression of the IgE-dependent increase in TNF-alpha mRNA by mast cells, inhibition of the IgE-dependent production of TNF-alpha protein by mast cells, and diminution of the responsiveness of target cells to TNF-alpha.	Cyclosporine	89-102	tumor necrosis factor	Mus musculus	358-367
7861766-10	1995	CCK comitogenic effect occurred even in the presence of cyclosporine.	Cyclosporine	56-68	cholecystokinin	Homo sapiens	0-3
7870067-6	1995	Among protein phosphatase inhibitors, cyclosporin A caused extensive inhibition of bacteria-induced expression of both IL-1 alpha/beta and TNF-alpha mRNA, while okadaic acid in itself caused selective induction of TNF-alpha, but not IL-1 alpha/beta mRNA, with a sharp peak at 0.3 microM concentration.	Cyclosporine	38-51	tumor necrosis factor	Mus musculus	139-148
7828718-2	1995	Our results demonstrate that cyclosporine (i) stimulates TGF-beta 1 promoter-dependent transcription of chloramphenicol acetyl transferase gene in transiently transfected human A-549 cells, (ii) stimulates the synthesis of TGF-beta 1 RNA transcripts in human T cells, and (iii) permits the expression/emergence of DNA regulatory proteins (retinoblastoma control factor-1 (RCF-1) and RCF-2) that bind and regulate TGF-beta 1 promoter activity.	Cyclosporine	29-41	transforming growth factor beta 1	Homo sapiens	223-233
7481073-0	1995	Cyclosporine-induced apoptosis in CD4+ T lymphocytes and computer-simulated analysis: modeling a treatment scenario for HIV infection.	Cyclosporine	0-12	T-cell surface glycoprotein CD4	Canis lupus familiaris	34-37
7481073-3	1995	In this study, we demonstrate that CsA induces apoptosis in the canine CD4+ CD8- T-lymphocyte cell line 401 in a dose- and time-dependent fashion.	Cyclosporine	35-38	T-cell surface glycoprotein CD4	Canis lupus familiaris	71-74
7879232-0	1995	Expression of the multidrug resistance gene MDR-1 in peripheral blood mononuclear cells from cyclosporine-treated renal transplant recipients rejecting their graft.	Cyclosporine	93-105	ATP binding cassette subfamily B member 1	Homo sapiens	44-49
7530217-0	1995	Rapamycin, FK506 and cyclosporin A inhibit human prolactin gene expression.	Cyclosporine	21-34	prolactin	Homo sapiens	49-58
7530217-1	1995	In this work we demonstrate that transcription of the human prolactin gene is inhibited by the immunosuppressants FK506 (IC50 = 25 nM), cyclosporin A (IC50 = 190 nM) and rapamycin (IC50 = 25 nM).	Cyclosporine	136-149	prolactin	Homo sapiens	60-69
7530217-2	1995	Whereas the effect of FK506 and cyclosporin A is specific for prolactin gene transcription, rapamycin has a more general effect on transcription and/or translation in pituitary cells.	Cyclosporine	32-45	prolactin	Homo sapiens	62-71
7828718-0	1995	Stimulation of transforming growth factor-beta 1 transcription by cyclosporine.	Cyclosporine	66-78	transforming growth factor beta 1	Homo sapiens	15-48
7828718-1	1995	In searching for a candidate mechanism for the immunosuppressive as well as fibrogenic consequences of cyclosporine usage, we have explored the hypothesis that cyclosporine stimulates transcription of transforming growth factor-beta 1 (TGF-beta 1), a multifunctional cytokine endowed with immunosuppressive and fibrogenic properties.	Cyclosporine	103-115	transforming growth factor beta 1	Homo sapiens	201-234
7828718-1	1995	In searching for a candidate mechanism for the immunosuppressive as well as fibrogenic consequences of cyclosporine usage, we have explored the hypothesis that cyclosporine stimulates transcription of transforming growth factor-beta 1 (TGF-beta 1), a multifunctional cytokine endowed with immunosuppressive and fibrogenic properties.	Cyclosporine	103-115	transforming growth factor beta 1	Homo sapiens	236-246
7828718-1	1995	In searching for a candidate mechanism for the immunosuppressive as well as fibrogenic consequences of cyclosporine usage, we have explored the hypothesis that cyclosporine stimulates transcription of transforming growth factor-beta 1 (TGF-beta 1), a multifunctional cytokine endowed with immunosuppressive and fibrogenic properties.	Cyclosporine	160-172	transforming growth factor beta 1	Homo sapiens	201-234
7828718-1	1995	In searching for a candidate mechanism for the immunosuppressive as well as fibrogenic consequences of cyclosporine usage, we have explored the hypothesis that cyclosporine stimulates transcription of transforming growth factor-beta 1 (TGF-beta 1), a multifunctional cytokine endowed with immunosuppressive and fibrogenic properties.	Cyclosporine	160-172	transforming growth factor beta 1	Homo sapiens	236-246
7828718-2	1995	Our results demonstrate that cyclosporine (i) stimulates TGF-beta 1 promoter-dependent transcription of chloramphenicol acetyl transferase gene in transiently transfected human A-549 cells, (ii) stimulates the synthesis of TGF-beta 1 RNA transcripts in human T cells, and (iii) permits the expression/emergence of DNA regulatory proteins (retinoblastoma control factor-1 (RCF-1) and RCF-2) that bind and regulate TGF-beta 1 promoter activity.	Cyclosporine	29-41	transforming growth factor beta 1	Homo sapiens	57-67
7828718-2	1995	Our results demonstrate that cyclosporine (i) stimulates TGF-beta 1 promoter-dependent transcription of chloramphenicol acetyl transferase gene in transiently transfected human A-549 cells, (ii) stimulates the synthesis of TGF-beta 1 RNA transcripts in human T cells, and (iii) permits the expression/emergence of DNA regulatory proteins (retinoblastoma control factor-1 (RCF-1) and RCF-2) that bind and regulate TGF-beta 1 promoter activity.	Cyclosporine	29-41	transforming growth factor beta 1	Homo sapiens	223-233
7831306-6	1995	We report here that CsA inhibits the TCR-mediated activation of Nur77 protein in T-cell hybridomas by blocking the DNA binding activity of Nur77 protein rather than its de novo synthesis.	Cyclosporine	20-23	nuclear receptor subfamily 4 group A member 1	Homo sapiens	64-69
7831306-6	1995	We report here that CsA inhibits the TCR-mediated activation of Nur77 protein in T-cell hybridomas by blocking the DNA binding activity of Nur77 protein rather than its de novo synthesis.	Cyclosporine	20-23	nuclear receptor subfamily 4 group A member 1	Homo sapiens	139-144
7831306-7	1995	We also show that CsA mediates its negative effects on the Nur77 DNA binding activity through the N-terminal region of the protein.	Cyclosporine	18-21	nuclear receptor subfamily 4 group A member 1	Homo sapiens	59-64
7831306-8	1995	This complete inhibition of Nur77 protein DNA binding activity may explain how CsA interferes with TCR-mediated apoptosis.	Cyclosporine	79-82	nuclear receptor subfamily 4 group A member 1	Homo sapiens	28-33
7718262-1	1995	A non-immunosuppressive cyclosporin, SDZ PSC 833 (PSC833), shows a reversal effect on multidrug resistance (MDR) by functional modulation of MDR1 gene product, P-glycoprotein.	Cyclosporine	24-35	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	141-145
7828718-3	1995	Our studies demonstrate for the first time that cyclosporine stimulates TGF-beta 1 gene transcription and suggest a novel mechanism of action of cyclosporine.	Cyclosporine	48-60	transforming growth factor beta 1	Homo sapiens	72-82
7828718-3	1995	Our studies demonstrate for the first time that cyclosporine stimulates TGF-beta 1 gene transcription and suggest a novel mechanism of action of cyclosporine.	Cyclosporine	145-157	transforming growth factor beta 1	Homo sapiens	72-82
7810520-10	1995	Graft survival rates were superior in cases treated with combined steroid, cyclosporine and azathioprine or mizoribine, to those treated with other immuno-suppressive regimens, and they decreased as the number of HLA-A, -B and -DR increased.	Cyclosporine	75-87	major histocompatibility complex, class I, A	Homo sapiens	213-230
7572422-5	1995	Finally, several of the agents currently in use for the therapy of glomerular injury, such as corticosteroids and cyclosporine, are known to modulate the production of TNF-alpha.	Cyclosporine	114-126	tumor necrosis factor	Homo sapiens	168-177
8744655-2	1995	The present study examines the in vitro interactions of classical immunosuppressive agents--FK 506 and Cyclosporine A (CsA) with 2-CdA at the level of T and B cells proliferation, expression receptor for interleukin 2 (R-IL-2) and Ig synthesis.	Cyclosporine	103-117	interleukin 2	Homo sapiens	204-217
8744655-2	1995	The present study examines the in vitro interactions of classical immunosuppressive agents--FK 506 and Cyclosporine A (CsA) with 2-CdA at the level of T and B cells proliferation, expression receptor for interleukin 2 (R-IL-2) and Ig synthesis.	Cyclosporine	119-122	interleukin 2	Homo sapiens	204-217
7626853-5	1995	MDR resistance is mediated by GP170, a cell membrane protein, which can be inhibited by several pharmacological agents like verapamil, ciclosporine and S 9788 which are currently being clinically investigated.	Cyclosporine	135-147	ATP binding cassette subfamily B member 1	Homo sapiens	30-35
7628053-1	1995	SDZ PSC 833 (PSC 833) is a cyclosporin A analogue that is under clinical investigation in combination with doxorubicin (Dx) or other anticancer agents as a type-1 multidrug resistance (MDR-1)-reversing agent.	Cyclosporine	27-40	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	185-190
7657047-5	1995	CsA pretreatment significantly reduced the severity of cold-restraint-induced gastric lesions while attenuating the elevated MPO measurements observed during cold-restraint administration.	Cyclosporine	0-3	myeloperoxidase	Homo sapiens	125-128
7828276-3	1995	CA3 and CK2 cells were sensitive to amphotericin B, and resistant to cyclosporin A and aphidicolin, compared with their parental cells.	Cyclosporine	69-82	carbonic anhydrase 3	Homo sapiens	0-3
7657047-8	1995	In conclusion, the results of this study indicate that CsA is capable of inhibiting cold-restraint-induced gastric mucosal injury and can attenuate the cold-restraint-induced increases in gastric MPO measurements.	Cyclosporine	55-58	myeloperoxidase	Homo sapiens	196-199
9700361-1	1995	Cyclosporin A (CsA) inhibits the development of mature thymocytes from their CD4+ CD8+ precursors, but may allow autoreactive cells to mature.	Cyclosporine	0-13	CD4 molecule	Homo sapiens	77-80
9700361-1	1995	Cyclosporin A (CsA) inhibits the development of mature thymocytes from their CD4+ CD8+ precursors, but may allow autoreactive cells to mature.	Cyclosporine	15-18	CD4 molecule	Homo sapiens	77-80
9700361-6	1995	Apoptosis of TCR-V beta 3 + thymocytes caused by Mtv-6, quantified according to the down-regulation of CD4 and CD8 on immature thymocytes, was partially inhibited by CsA, to maximal effect within 24 hours.	Cyclosporine	166-169	CD4 molecule	Homo sapiens	103-106
7781642-5	1995	The results indicate that in contrast to in vitro experiments, where cyclosporine A has been shown to markedly inhibit the demethylation of aminopyrine and to result in a decrease of cytochrome P-450, therapeutic concentrations of cyclosporine A and prednisolone do not impair aminopyrine demethylation in vivo.	Cyclosporine	69-83	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	183-199
8846621-5	1995	Significant amounts of CYP3A are present in the gastrointestinal tract, and may contribute to presystemic extraction of drugs such as cyclosporin.	Cyclosporine	134-145	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	23-28
8835619-0	1995	Serum angiotensin-converting enzyme levels in patients with recent-onset insulin-dependent diabetes after one year of low-dose cyclosporin therapy.	Cyclosporine	127-138	angiotensin I converting enzyme	Homo sapiens	6-35
7718516-12	1995	The activation of CD4+ T cells by anti-CD52 antibodies was inhibited by cyclosporin A, suggesting a role for the calcineurin-dependent signal transduction pathways.	Cyclosporine	72-85	CD4 molecule	Homo sapiens	18-21
8835619-4	1995	In this study we have evaluated the effect of CyA administered to IDDM patients on blood pressure and serum angiotensin-converting enzyme (SACE), an endopeptidase that is an integral part of the renin-angiotensin and bradykinin systems.	Cyclosporine	46-49	angiotensin I converting enzyme	Homo sapiens	108-137
8835619-4	1995	In this study we have evaluated the effect of CyA administered to IDDM patients on blood pressure and serum angiotensin-converting enzyme (SACE), an endopeptidase that is an integral part of the renin-angiotensin and bradykinin systems.	Cyclosporine	46-49	kininogen 1	Homo sapiens	195-227
8587464-1	1995	Urinary endothelin-1 excretion (uET-1/min) has been reported to be elevated under cyclosporin A (CsA) therapy in kidney transplant recipients (KR).	Cyclosporine	97-100	endothelin 1	Homo sapiens	8-20
8587330-5	1995	Inhibition of calcium/calmodulin-dependent phosphatase calcineurin by cyclosporin A, however, stimulated ET-1 mRNA in human endothelial cells.	Cyclosporine	70-83	endothelin 1	Homo sapiens	105-109
7891018-1	1995	This work was designed to investigate the effects of cyclosporine on prolactin secretion by an ectopically grafted heterologous pituitary gland, and on the hypothalamic content of norepinephrine, dopamine and serotonin.	Cyclosporine	53-65	prolactin	Rattus norvegicus	69-78
7891018-2	1995	The administration of cyclosporine prevented the augmentation in plasma prolactin levels which occurred following an ectopic graft of a litter-mate pituitary gland.	Cyclosporine	22-34	prolactin	Rattus norvegicus	72-81
7891018-3	1995	In contrast, in sham-operated rats, cyclosporine increased prolactin levels on day 8 of treatment.	Cyclosporine	36-48	prolactin	Rattus norvegicus	59-68
7891018-10	1995	In vitro release of prolactin from the ectopic gland was markedly decreased in animals treated with cyclosporine for 2 days and this effect was less evident in 8-day treated rats.	Cyclosporine	100-112	prolactin	Rattus norvegicus	20-29
7566619-0	1995	Effect of calcium-channel blocker on tumour necrosis factor alpha (TNF alpha) production in cyclosporin-treated renal transplant recipients.	Cyclosporine	92-103	tumor necrosis factor	Homo sapiens	67-76
7565483-4	1995	Second, ET-1 potently constricts the renal vasculature resulting in increased fluid retention and possibly contributing to glomerular sclerosis; enhanced renal vascular and glomerular ET-1 production and target cell actions may play a role in essential hypertension or hypertension accompanying chronic renal failure, cyclosporine administration, or erythropoietin therapy.	Cyclosporine	318-330	endothelin 1	Homo sapiens	8-12
7566619-1	1995	PURPOSE OF THE STUDY: The influence of calcium-channel blocker treatment on in-vitro TNF alpha production by peripheral blood mononuclear cells (PBMC) from renal transplant recipients treated with cyclosporin was studied.	Cyclosporine	197-208	tumor necrosis factor	Homo sapiens	85-94
7529939-0	1995	Accessory signalling by B7-1 for T cell activation induced by anti-CD2: evidence for IL-2-independent CTL generation and CsA-resistant cytokine production.	Cyclosporine	121-124	CD80 antigen	Mus musculus	24-28
8704277-7	1995	In this study, the interactions of P-glycoprotein with two cyclosporine derivatives, SDZ PSC 833 and cyclosporine A (CsA, Sandimmune), were analyzed.	Cyclosporine	59-71	ATP binding cassette subfamily B member 1	Homo sapiens	35-49
8704277-7	1995	In this study, the interactions of P-glycoprotein with two cyclosporine derivatives, SDZ PSC 833 and cyclosporine A (CsA, Sandimmune), were analyzed.	Cyclosporine	101-115	ATP binding cassette subfamily B member 1	Homo sapiens	35-49
8704277-7	1995	In this study, the interactions of P-glycoprotein with two cyclosporine derivatives, SDZ PSC 833 and cyclosporine A (CsA, Sandimmune), were analyzed.	Cyclosporine	117-120	ATP binding cassette subfamily B member 1	Homo sapiens	35-49
8704277-9	1995	The two cyclosporine analogs competed with the labeling of P-glycoprotein by a photoactive cyclosporine derivative.	Cyclosporine	8-20	ATP binding cassette subfamily B member 1	Homo sapiens	59-73
8704277-9	1995	The two cyclosporine analogs competed with the labeling of P-glycoprotein by a photoactive cyclosporine derivative.	Cyclosporine	91-103	ATP binding cassette subfamily B member 1	Homo sapiens	59-73
8704277-11	1995	However, CsA was transported by P-glycoprotein, whereas SDZ PSC 833 was not actively transported.	Cyclosporine	9-12	ATP binding cassette subfamily B member 1	Homo sapiens	32-46
7529939-7	1995	Moreover, a partial or complete resistance to inhibition with CsA was observed for IL-2 production and CTL generation respectively in the presence of the costimulatory signal derived from B7-1-CD28 interaction.	Cyclosporine	62-65	CD80 antigen	Mus musculus	188-192
8704277-14	1995	In addition, the comparison of the two cyclosporine analogs indicated that limited chemical modifications of MDR reversing agents can affect their potential to inhibit P-glycoprotein function.	Cyclosporine	39-51	ATP binding cassette subfamily B member 1	Homo sapiens	168-182
7705462-6	1994	These data suggest that P-glycoprotein possesses at least two allosterically coupled drug acceptor sites; receptor site 1 which binds vinblastine, doxorubucin, etoposide and cyclosporin A, and receptor site 2 which binds dexniguldipine-HCl and other 1,4-dihydropyridines.	Cyclosporine	174-187	ATP binding cassette subfamily B member 1	Homo sapiens	24-38
7806527-8	1994	These data demonstrate that 1) the signals that lead to induction of competence in T cells stimulate an IL-2-independent and CsA-resistant phase of Cdk4 and cyclin D2 expression, Cdk4 kinase activity, and Cdk2 kinase activity, and 2) IL-2 stimulates a second phase of Cdk4 and cyclin D2 expression and de novo expression of Cdk2 in these cells.	Cyclosporine	125-128	cyclin D2	Homo sapiens	157-166
7806527-8	1994	These data demonstrate that 1) the signals that lead to induction of competence in T cells stimulate an IL-2-independent and CsA-resistant phase of Cdk4 and cyclin D2 expression, Cdk4 kinase activity, and Cdk2 kinase activity, and 2) IL-2 stimulates a second phase of Cdk4 and cyclin D2 expression and de novo expression of Cdk2 in these cells.	Cyclosporine	125-128	interleukin 2	Homo sapiens	234-238
7806527-8	1994	These data demonstrate that 1) the signals that lead to induction of competence in T cells stimulate an IL-2-independent and CsA-resistant phase of Cdk4 and cyclin D2 expression, Cdk4 kinase activity, and Cdk2 kinase activity, and 2) IL-2 stimulates a second phase of Cdk4 and cyclin D2 expression and de novo expression of Cdk2 in these cells.	Cyclosporine	125-128	cyclin D2	Homo sapiens	277-286
7989759-4	1994	Multiple copies of the IL-2 and IL-4 UPS act as inducible enhancers in T cells, and their induction is inhibited by the immunosuppressant cyclosporin A (CsA).	Cyclosporine	138-151	interleukin 2	Homo sapiens	23-27
7989759-4	1994	Multiple copies of the IL-2 and IL-4 UPS act as inducible enhancers in T cells, and their induction is inhibited by the immunosuppressant cyclosporin A (CsA).	Cyclosporine	138-151	interleukin 4	Homo sapiens	32-36
7989759-4	1994	Multiple copies of the IL-2 and IL-4 UPS act as inducible enhancers in T cells, and their induction is inhibited by the immunosuppressant cyclosporin A (CsA).	Cyclosporine	153-156	interleukin 2	Homo sapiens	23-27
7989759-4	1994	Multiple copies of the IL-2 and IL-4 UPS act as inducible enhancers in T cells, and their induction is inhibited by the immunosuppressant cyclosporin A (CsA).	Cyclosporine	153-156	interleukin 4	Homo sapiens	32-36
7994040-7	1994	When the AA patients were assessed for their likelihood to respond to CyA therapy, the response rate in patients with this haplotype (71%) was significantly higher than that of patients with another haplotype associated with HLA-DR2, DRB1*1502-DQA1*0103-DQB1*0601 (36%) and that of patients without HLA-DR2 (35%).	Cyclosporine	70-73	major histocompatibility complex, class II, DR beta 1	Homo sapiens	234-238
7989759-7	1994	Introduction of five or ten spacer nucleotides between both IL-2 UPS sites results in a drastic reduction of inducible UPS activity, both in the loss of suppression by CsA and stimulation by the Ca(2+)-dependent phosphatase calcineurin.	Cyclosporine	168-171	interleukin 2	Homo sapiens	60-64
7982907-11	1994	In contrast, the phorbol 12-myristate 13-acetate/ionomycin-mediated down-regulation of I kappa B alpha was prevented by CsA but not by rapamycin.	Cyclosporine	120-123	NFKB inhibitor alpha	Homo sapiens	87-102
7982959-0	1994	The role of NFATp in cyclosporin A-sensitive tumor necrosis factor-alpha gene transcription.	Cyclosporine	21-34	tumor necrosis factor	Homo sapiens	45-72
7982959-2	1994	Maximal induction of TNF alpha mRNA can be induced by treatment of T cells with calcium ionophores alone, via a calcineurin-dependent process that is blocked by cyclosporin A.	Cyclosporine	161-174	tumor necrosis factor	Homo sapiens	21-30
7982959-3	1994	We have previously identified a promoter element, kappa 3, that is required for calcium-stimulated, cyclosporin A-sensitive induction of the TNF alpha gene in activated T cells.	Cyclosporine	100-113	tumor necrosis factor	Homo sapiens	141-150
7727860-9	1994	These studies have employed "first generation" antagonists such as verapamil and cyclosporine which were toxic at concentrations needed to block P-glycoprotein.	Cyclosporine	81-93	ATP binding cassette subfamily B member 1	Homo sapiens	145-159
7949151-4	1994	PBMC, after infection with EBV and CsA treatment, demonstrated increased interleukin-6 (IL-6) activity in the culture supernatant.	Cyclosporine	35-38	interleukin 6	Homo sapiens	88-92
7949151-7	1994	Expression of IL-6 in T cells appears to be due mainly to CsA.	Cyclosporine	58-61	interleukin 6	Homo sapiens	14-18
7949151-10	1994	IL-6, which is induced by CsA in PBMC, was also capable of inducing the lytic viral cycle in several EBV-immortalized cells.	Cyclosporine	26-29	interleukin 6	Homo sapiens	0-4
7949151-11	1994	CsA, in promoting both increased numbers of lytic EBV B cells and an EBV paracrine factor, IL-6, within the microenvironment of EBV B cell:T cell and EBV B cell:monocyte interactions, may result in increased EBV B-cell immortalization and ultimately lead to the promotion of B-cell lymphomas in immunosuppressed patients.	Cyclosporine	0-3	interleukin 6	Homo sapiens	91-95
7981602-5	1994	Various inhibitors of TCR-mediated apoptosis, including cyclosporin A down-regulate the Nur77 DNA binding activity.	Cyclosporine	56-69	nuclear receptor subfamily 4 group A member 1	Homo sapiens	88-93
7698817-7	1994	The beneficial effect on graft survival of HLA-A mismatching was most pronounced in patients treated with high/medium dose CyA and prednisolone (P = 0.004 overall and P = 0.0007 for HLA-B,DR mismatched transplants).	Cyclosporine	123-126	major histocompatibility complex, class I, A	Homo sapiens	43-48
7698817-8	1994	In conclusion, HLA-A mismatching was associated with enhanced long-term renal graft survival in CyA-treated recipients of HLA-B,DR mismatched transplants.	Cyclosporine	96-99	major histocompatibility complex, class I, A	Homo sapiens	15-20
7696923-4	1994	In the patient treated with cyclosporin A alone, decreasing serum IL-6 and beta-2-microglobulin levels fell as the clinical response evolved.	Cyclosporine	28-41	interleukin 6	Homo sapiens	66-70
7963563-2	1994	Comparing the suppressive effects of tepoxalin and cyclosporin A (CsA) on OKT3-, PMA-, IL-2-, and PMA+ionomycin-induced T cell proliferations revealed marked differences in the mechanism of action between the two compounds.	Cyclosporine	66-69	interleukin 2	Homo sapiens	87-91
7963563-6	1994	Moreover, addition of exogenous IL-2 restored OKT3-induced proliferation to CsA- but not tepoxalin-treated cells.	Cyclosporine	76-79	interleukin 2	Homo sapiens	32-36
7963544-9	1994	IL-2 on postoperative days 8, 9, and 10 to animals receiving the full CyA tolerizing regimen led to acute rejection in four of four animals.	Cyclosporine	70-73	IL2	Sus scrofa	0-4
7700501-0	1994	Cyclosporine modifies the pulsatile secretory patterns of prolactin and luteinizing hormone in normal and pituitary-grafted female rats.	Cyclosporine	0-12	prolactin	Rattus norvegicus	58-67
7700501-1	1994	This study was designed to examine whether cyclosporine (CyA) acts on the endocrine system by modifying the pulsatile secretion pattern of prolactin and LH.	Cyclosporine	43-55	prolactin	Rattus norvegicus	139-148
7700501-1	1994	This study was designed to examine whether cyclosporine (CyA) acts on the endocrine system by modifying the pulsatile secretion pattern of prolactin and LH.	Cyclosporine	57-60	prolactin	Rattus norvegicus	139-148
7700501-4	1994	The mean values of serum prolactin were significantly increased by pituitary grafting and the treatment with CyA further increased them.	Cyclosporine	109-112	prolactin	Rattus norvegicus	25-34
7700501-9	1994	The absolute amplitude of the prolactin peaks was significantly increased in pituitary-grafted as compared to sham-operated animals, and the treatment with CyA further increased this parameter in both groups.	Cyclosporine	156-159	prolactin	Rattus norvegicus	30-39
7974715-3	1994	The IL-2-mediated proliferation of long-term T cell lines generated in this fashion is typically insensitive to the immunosuppressive agent, cyclosporine but sensitive to rapamycin.	Cyclosporine	141-153	interleukin 2	Homo sapiens	4-8
7954421-12	1994	The degree of chemosensitization by verapamil and cyclosporin A was similar in MRP-transfected cells and in cells transfected with the vector alone, suggesting that sensitization involved mechanisms independent of MRP expression.	Cyclosporine	50-63	ATP binding cassette subfamily C member 1	Homo sapiens	79-82
7973537-0	1994	[The effect of long-term cyclosporin and prednisone therapy on insulin secretory reserve].	Cyclosporine	25-36	insulin	Homo sapiens	63-70
7973537-1	1994	Insulin secretory reserve assessed by the method of glucose potentiation of arginine induced insulin secretion is decreased in non-diabetic transplant recipients using triple immunosuppressive therapy with prednisone, cyclosporine, and azathioprine.	Cyclosporine	218-230	insulin	Homo sapiens	0-7
7973537-3	1994	Long-term cyclosporine (ANOVA p = 0.016 compared to control subjects) but not prednisone treatment decreased insulin secretory reserve.	Cyclosporine	10-22	insulin	Homo sapiens	109-116
7895601-7	1994	Other CYP3A substrates (cyclosporin A, naringenin, and midazolam) also demonstrated potent inhibition of terfenadine biotransformation in human liver microsomes (IC50 = 17-24 microM).	Cyclosporine	24-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	6-11
7819078-1	1994	Cyclosporin-A reduces erythropoietin production and, together with the inhibitory effect of cytokines on erythropoiesis, may be potentially responsible for the anaemia observed in some patients after heart transplantation.	Cyclosporine	0-13	erythropoietin	Homo sapiens	22-36
7842716-0	1994	Successful penetrating keratoplasty in a patient with severe atopic keratoconjunctivitis and elevated serum IgE level treated with long-term topical cyclosporin A.	Cyclosporine	149-162	immunoglobulin heavy constant epsilon	Homo sapiens	108-111
7807770-11	1994	Two patients with clinically and histologically suspected CsA nephrotoxicity showed transient increase in plasma ET-1.	Cyclosporine	58-61	endothelin 1	Homo sapiens	113-117
7926302-0	1994	Glutamic acid decarboxylase (GAD65) autoantibodies in prediction of beta-cell function and remission in recent-onset IDDM after cyclosporin treatment.	Cyclosporine	128-139	glutamate decarboxylase 2	Homo sapiens	29-34
7926302-2	1994	We have investigated whether glutamic acid decarboxylase (GAD) autoantibodies (GAD65 Ab) were affected by cyclosporin therapy and were related to subsequent non-insulin-requiring remission and loss of glucagon-stimulated C-peptide response in 132 recent-onset insulin-dependent diabetes mellitus (IDDM) patients treated with cyclosporin or placebo for 12 months.	Cyclosporine	106-117	glutamate decarboxylase 2	Homo sapiens	79-84
21559677-0	1994	Reversion of p-glycoprotein mediated multidrug-resistance to vincristine and adriamycin by psc-833, a cyclosporine derivative in human neuroblastoma cell-lines.	Cyclosporine	102-114	ATP binding cassette subfamily B member 1	Homo sapiens	13-27
7964963-8	1994	Verapamil and cyclosporine (CsA) have been used as competitive inhibitors of the multidrug transporter P-gp in early clinical trials.	Cyclosporine	14-26	ATP binding cassette subfamily B member 1	Homo sapiens	103-107
7964963-8	1994	Verapamil and cyclosporine (CsA) have been used as competitive inhibitors of the multidrug transporter P-gp in early clinical trials.	Cyclosporine	28-31	ATP binding cassette subfamily B member 1	Homo sapiens	103-107
7964963-9	1994	Although these studies show some activity in modulating clinical MDR, both verapamil and CsA manifest considerable toxicities at doses below those required for complete inhibition of P-gp function.	Cyclosporine	89-92	ATP binding cassette subfamily B member 1	Homo sapiens	183-187
7524500-0	1994	Cyclosporin A blocks induction of tumor necrosis factor-alpha in human B lymphocytes.	Cyclosporine	0-13	tumor necrosis factor	Homo sapiens	34-61
7522636-7	1994	Cyclosporin A and FK506 act on two distinct levels of the IL-2 control mechanism.	Cyclosporine	0-13	interleukin 2	Homo sapiens	58-62
7803272-6	1994	During immunosuppressive treatment of AA with anti-thymocyte globulin and cyclosporine A, EPO levels were significantly lower compared with pre-treatment values without a corresponding change in haematocrit.	Cyclosporine	74-88	erythropoietin	Homo sapiens	90-93
7930567-8	1994	Con A-induced activation of NGFI-B gene expression was not overcome by cyclosporin A or by 8Br-cAMP, but was partially prevented by dexamethasone.	Cyclosporine	71-84	nuclear receptor subfamily 4 group A member 1	Homo sapiens	28-34
7522130-2	1994	Although no change in cytoplasmic calcium level ([Ca2+]i) was detectable during antigen-specific signal transduction of 171-CD4+ cells, IL2 induction was inhibited by FK506 and CsA.	Cyclosporine	177-180	interleukin 2	Homo sapiens	136-139
7522130-5	1994	We suggest that IL2 secretion induced by antigen presentation to TCR/CD4/p56lck requires an FK506 and cyclosporin A-sensitive step which may be independent of calcium signaling.	Cyclosporine	102-115	interleukin 2	Homo sapiens	16-19
7522130-5	1994	We suggest that IL2 secretion induced by antigen presentation to TCR/CD4/p56lck requires an FK506 and cyclosporin A-sensitive step which may be independent of calcium signaling.	Cyclosporine	102-115	CD4 molecule	Homo sapiens	69-72
7743602-4	1994	The synergistic interaction of CD40 signals with PMA or CD20 show differential requirements for CD40 crosslinking and different sensitivity to cyclosporine A, suggesting that CD40 receptor may use different effector mechanisms for synergy with calcium-dependent CD20 signals or with calcium-independent signals from PMA.	Cyclosporine	143-157	keratin 20	Homo sapiens	56-60
7743602-4	1994	The synergistic interaction of CD40 signals with PMA or CD20 show differential requirements for CD40 crosslinking and different sensitivity to cyclosporine A, suggesting that CD40 receptor may use different effector mechanisms for synergy with calcium-dependent CD20 signals or with calcium-independent signals from PMA.	Cyclosporine	143-157	keratin 20	Homo sapiens	262-266
8088915-5	1994	We tested the hypothesis that the augmentation of blood pressure by cyclosporine is mediated by a further increase in renal CYP3A activity.	Cyclosporine	68-80	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	124-129
8088915-9	1994	Cyclosporine increased renal (60%) but decreased hepatic (25%) microsomal CYP3A activity in SHR.	Cyclosporine	0-12	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	74-79
8088915-11	1994	Troleandomycin completely inhibited renal CYP3A activity measured after cyclosporine treatment of SHR, which correlated with its attenuation of the cyclosporine-induced blood pressure increase.	Cyclosporine	72-84	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	42-47
8088915-12	1994	These findings suggest that renal CYP3A could play an important role in acute cyclosporine-induced hypertension.	Cyclosporine	78-90	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	34-39
8000516-5	1994	The rationale for the use of low-dose IFN-alpha with cyclosporin A (CyA) is discussed.	Cyclosporine	53-66	interferon alpha 1	Homo sapiens	38-47
8000516-5	1994	The rationale for the use of low-dose IFN-alpha with cyclosporin A (CyA) is discussed.	Cyclosporine	68-71	interferon alpha 1	Homo sapiens	38-47
7808368-4	1994	The existence of drugs (calcium blockers, cyclosporine, tamoxifen, reserpine, quinidine) able to bind themselves to gp170 and to paralyze its activity in vitro is well known.	Cyclosporine	42-54	ATP binding cassette subfamily B member 1	Homo sapiens	116-121
7965756-3	1994	It has been suggested that much of the variability in cyclosporine clearance is due to differences in the cytochrome P450 3A4 (CYP3A4) content in the liver and intestinal mucosa.	Cyclosporine	54-66	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-125
7965756-3	1994	It has been suggested that much of the variability in cyclosporine clearance is due to differences in the cytochrome P450 3A4 (CYP3A4) content in the liver and intestinal mucosa.	Cyclosporine	54-66	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	127-133
7808368-13	1994	Our data suggest a synergy of verapamil and cyclosporine in the inhibition of multidrug resistance induced by gp170, without the occurrence of heavy toxicity.	Cyclosporine	44-56	ATP binding cassette subfamily B member 1	Homo sapiens	110-115
7940896-0	1994	Effect of cyclosporine on interleukin 1(beta) and immunoglobulin production in vitro.	Cyclosporine	10-22	interleukin 1 beta	Homo sapiens	26-45
7940906-0	1994	Cyclosporine inhibits interleukin-2 production during human cellular immune response to pig antigens.	Cyclosporine	0-12	interleukin 2	Homo sapiens	22-35
8077662-5	1994	Furthermore, cyclosporin A, but not rapamycin, blocked the synergistic induction of IL-8 expression achieved with anti-CD3 and anti-CD28 costimulation.	Cyclosporine	13-26	C-X-C motif chemokine ligand 8	Homo sapiens	84-88
20693061-5	1994	We have also shown that concentrations of cyclosporin A (an immunosuppressive drug) down to 1 ng/ml can inhibit the expression of lymphocyte-derived IL-2 mRNA.	Cyclosporine	42-55	interleukin 2	Homo sapiens	149-153
7929104-6	1994	Furthermore, cyclosporin A, which blocked TNF alpha production induced by PKC, strongly inhibited IL-2R alpha and NF.kappa B activation.	Cyclosporine	13-26	tumor necrosis factor	Homo sapiens	42-51
7929104-6	1994	Furthermore, cyclosporin A, which blocked TNF alpha production induced by PKC, strongly inhibited IL-2R alpha and NF.kappa B activation.	Cyclosporine	13-26	nuclear factor kappa B subunit 1	Homo sapiens	114-124
7929104-7	1994	The addition of either TNF alpha or IL-2 partially recovered cyclosporin A-induced IL-2R alpha inhibition, but only TNF alpha completely recovered NF.kappa B activation.	Cyclosporine	61-74	tumor necrosis factor	Homo sapiens	23-32
7929104-7	1994	The addition of either TNF alpha or IL-2 partially recovered cyclosporin A-induced IL-2R alpha inhibition, but only TNF alpha completely recovered NF.kappa B activation.	Cyclosporine	61-74	interleukin 2	Homo sapiens	36-40
8092258-0	1994	Effects of ANG II, ETA, and TxA2 receptor antagonists on cyclosporin A renal vasoconstriction.	Cyclosporine	57-70	angiotensinogen	Rattus norvegicus	11-17
7994262-6	1994	In allogeneic recipients exhibiting no GVHD, serum prolactin levels were positively correlated with serum cyclosporin levels (p &lt; 0.05).	Cyclosporine	106-117	prolactin	Homo sapiens	51-60
8068598-0	1994	Cyclosporin A has divergent effects on plasma LDL cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] levels in renal transplant recipients.	Cyclosporine	0-13	component of oligomeric golgi complex 2	Homo sapiens	63-68
7987622-8	1994	Cyclosporine, a selective immunosuppressant drug, inhibits T lymphocytes by inhibiting expression of interleukin-2 and its receptors.	Cyclosporine	0-12	interleukin 2	Homo sapiens	101-114
8082935-1	1994	The catabolism of various calcium channel blockers through cytochrome P-450 is heterogeneous and may be modified by concomitant use of cyclosporin A.	Cyclosporine	135-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-75
7827283-10	1994	In contrast, CSA, which inhibited proliferation in MLR induced by B-cell lines, also inhibited TNF-alpha.	Cyclosporine	13-16	tumor necrosis factor	Homo sapiens	95-104
8084286-1	1994	The immunosuppressive agent cyclosporine A (CsA) produces in vivo in the rat marked osteopenia and elevation of serum bone gla protein (BGP) that reflects the high bone turnover and increased circulating levels of 1,25-dihydroxyvitamin D [1,25(OH)2D].	Cyclosporine	28-42	bone gamma-carboxyglutamate protein	Rattus norvegicus	118-134
8084286-1	1994	The immunosuppressive agent cyclosporine A (CsA) produces in vivo in the rat marked osteopenia and elevation of serum bone gla protein (BGP) that reflects the high bone turnover and increased circulating levels of 1,25-dihydroxyvitamin D [1,25(OH)2D].	Cyclosporine	28-42	bone gamma-carboxyglutamate protein	Rattus norvegicus	136-139
8084286-1	1994	The immunosuppressive agent cyclosporine A (CsA) produces in vivo in the rat marked osteopenia and elevation of serum bone gla protein (BGP) that reflects the high bone turnover and increased circulating levels of 1,25-dihydroxyvitamin D [1,25(OH)2D].	Cyclosporine	44-47	bone gamma-carboxyglutamate protein	Rattus norvegicus	118-134
8084286-1	1994	The immunosuppressive agent cyclosporine A (CsA) produces in vivo in the rat marked osteopenia and elevation of serum bone gla protein (BGP) that reflects the high bone turnover and increased circulating levels of 1,25-dihydroxyvitamin D [1,25(OH)2D].	Cyclosporine	44-47	bone gamma-carboxyglutamate protein	Rattus norvegicus	136-139
8084286-7	1994	In CsA-treated rats, serum BGP levels were significantly increased (155.2 +/- 30.7 ng/mL v 107.3 +/- 16.8 and 111.5 +/- 13.1 at day 28, P &lt; .05) compared with control and CsH groups, respectively.	Cyclosporine	3-6	bone gamma-carboxyglutamate protein	Rattus norvegicus	27-30
7520875-2	1994	Here we demonstrate that treatment of HeLa cells with low concentrations of CsA (but not of FK506) induces the synthesis of a stress protein, GRP78, located inside the endoplasmic reticulum.	Cyclosporine	76-79	heat shock protein family A (Hsp70) member 5	Homo sapiens	142-147
7824068-7	1994	In addition, the CCCP-induced dephosphorylation of tau was blocked by cyclosporin A, a selective inhibitor of the calcium-dependent phosphatase, calcineurin.	Cyclosporine	70-83	microtubule-associated protein tau	Rattus norvegicus	51-54
7520433-5	1994	Preincubation with the calcineurin inhibitors FK-506 or cyclosporin A strongly enhanced expression of NGFI-A and blocked transcription of NGFI-B, but it had no significant effect on Ca(2+)-stimulated transcription of c-fos.	Cyclosporine	56-69	early growth response 1	Rattus norvegicus	102-108
7520875-6	1994	The mechanism of induction of GRP78 by CsA remains presently unknown.	Cyclosporine	39-42	heat shock protein family A (Hsp70) member 5	Homo sapiens	30-35
7520875-7	1994	Whatever the mechanism involved, GRP78 overexpression might be responsible for some of the physiological effects of CsA.	Cyclosporine	116-119	heat shock protein family A (Hsp70) member 5	Homo sapiens	33-38
7798591-7	1994	Furthermore, flow cytometric analysis using monoclonal antibodies (mAbs) specific for thymocyte subsets confirmed that CsA induces a large decrease in the relative number of mature single positive (SP) CD4+CD8- and CD8+CD4- thymocytes expressing high densities of CD3 and T cell receptor ab (TCR alpha beta) surface molecules, but also a decrease in the absolute number of the other thymocyte subsets.	Cyclosporine	119-122	CD247 antigen	Mus musculus	264-306
8046352-1	1994	The tumor necrosis factor alpha (TNF-alpha) gene is rapidly transcribed in activated T cells via a calcium-dependent pathway that does not require de novo protein synthesis, but is completely blocked by the immunosuppressive drugs cyclosporin A (CsA) and FK506.	Cyclosporine	231-244	tumor necrosis factor	Homo sapiens	4-31
7518859-6	1994	Functional Pgp expression was determined by the effect of CSA on the intracellular accumulation of DXR and VCR.	Cyclosporine	58-61	ATP binding cassette subfamily B member 1	Homo sapiens	11-14
7518859-10	1994	CSA, as well as SDZ PSC 833, but not dexamethasone, increased pretreatment intracellular accumulation of DXR and VCR in Pgp+ PC in three of four and six of six patients, respectively.	Cyclosporine	0-3	ATP binding cassette subfamily B member 1	Homo sapiens	120-123
7518859-13	1994	CONCLUSION: These data indicate that Pgp overexpression is functional in refractory myeloma and that clinical modulation of MDR by CSA is mediated through an inhibition of Pgp-associated drug efflux.	Cyclosporine	131-134	ATP binding cassette subfamily B member 1	Homo sapiens	37-40
7518859-13	1994	CONCLUSION: These data indicate that Pgp overexpression is functional in refractory myeloma and that clinical modulation of MDR by CSA is mediated through an inhibition of Pgp-associated drug efflux.	Cyclosporine	131-134	ATP binding cassette subfamily B member 1	Homo sapiens	172-175
7518859-14	1994	Pgp-expressing PC can be eliminated by clinical treatment with VAD/CSA.	Cyclosporine	67-70	ATP binding cassette subfamily B member 1	Homo sapiens	0-3
8046352-1	1994	The tumor necrosis factor alpha (TNF-alpha) gene is rapidly transcribed in activated T cells via a calcium-dependent pathway that does not require de novo protein synthesis, but is completely blocked by the immunosuppressive drugs cyclosporin A (CsA) and FK506.	Cyclosporine	231-244	tumor necrosis factor	Homo sapiens	33-42
8046352-1	1994	The tumor necrosis factor alpha (TNF-alpha) gene is rapidly transcribed in activated T cells via a calcium-dependent pathway that does not require de novo protein synthesis, but is completely blocked by the immunosuppressive drugs cyclosporin A (CsA) and FK506.	Cyclosporine	246-249	tumor necrosis factor	Homo sapiens	4-31
8046352-1	1994	The tumor necrosis factor alpha (TNF-alpha) gene is rapidly transcribed in activated T cells via a calcium-dependent pathway that does not require de novo protein synthesis, but is completely blocked by the immunosuppressive drugs cyclosporin A (CsA) and FK506.	Cyclosporine	246-249	tumor necrosis factor	Homo sapiens	33-42
8046352-3	1994	The ability of analogues of CsA and FK506 to block calcineurin phosphatase activity correlates completely with their ability to inhibit induction of TNF-alpha mRNA, induction of a TNF-alpha promoter reporter plasmid in transiently transfected T cells, and induction of the kappa 3 binding factor in an electrophoretic mobility shift assay.	Cyclosporine	28-31	tumor necrosis factor	Homo sapiens	149-158
7967349-1	1994	Elevated levels of the vasocontrictor peptide endothelin-1 have been demonstrated in various pathological conditions that are characterized by sodium retention and/or renal vasoconstriction, such as heart failure, hepatorenal syndrome, renal failure and during administration of cyclosporin and radiocontrast.	Cyclosporine	279-290	endothelin 1	Homo sapiens	46-58
8046352-3	1994	The ability of analogues of CsA and FK506 to block calcineurin phosphatase activity correlates completely with their ability to inhibit induction of TNF-alpha mRNA, induction of a TNF-alpha promoter reporter plasmid in transiently transfected T cells, and induction of the kappa 3 binding factor in an electrophoretic mobility shift assay.	Cyclosporine	28-31	tumor necrosis factor	Homo sapiens	180-189
8046352-5	1994	TNF-alpha gene transcription is also highly inducible, CsA-sensitive, and protein synthesis-independent in B cells stimulated through their surface immunoglobulin receptors.	Cyclosporine	55-58	tumor necrosis factor	Homo sapiens	0-9
8046352-6	1994	Using the panel of CsA and FK506 analogues, we show that calcineurin participates in the induction of TNF-alpha transcription in activated B cells.	Cyclosporine	19-22	tumor necrosis factor	Homo sapiens	102-111
7973432-3	1994	METHODS: In vitro secretion of IL-6 by biopsy specimens from patients with active ulcerative colitis was investigated in the presence of cyclosporin-A (CsA) and drugs that have other anti-inflammatory actions.	Cyclosporine	152-155	interleukin 6	Homo sapiens	31-35
7973432-5	1994	RESULTS: Stimulation of control specimens increased IL-6 secretion (median increase, 147%; p &lt; 0.003), which was prevented by CsA.	Cyclosporine	129-132	interleukin 6	Homo sapiens	52-56
8042241-4	1994	The aim of the present study was to determine the effects of low-dose CsA/MTX on the expression of the cytotoxic cytokines, TNF alpha, TNF beta, or lymphotoxin (LT), and the serine proteases HF and C11 (granzymes A and B, respectively) in rat cardiac allografts during rejection.	Cyclosporine	70-73	tumor necrosis factor	Rattus norvegicus	124-133
8042241-5	1994	RNA blot analysis showed significant suppression of TNF alpha, LT, HF, and C11 gene expression on days 1 through 8 post-tx in cardiac allografts from low-dose CsA/MTX-treated recipients compared with untreated allograft controls.	Cyclosporine	159-162	tumor necrosis factor	Rattus norvegicus	52-61
8042241-6	1994	TNF protein levels in cardiac allografts from low-dose CsA/MTX-treated recipients were also found to be significantly reduced on days 1 through 8 post-tx when compared with time-matched untreated allograft controls (P &lt; or = 0.001).	Cyclosporine	55-58	tumor necrosis factor	Rattus norvegicus	0-3
7518925-3	1994	Here, TNF-alpha gene transcription is shown also to be highly and rapidly induced in human B cells after stimulation via the CD40 and interleukin 4 pathways, which similarly is inhibited by CsA and a panel of CsA or FK506 analogues that block calcineurin phosphatase activity.	Cyclosporine	190-193	interleukin 4	Homo sapiens	134-147
7518925-2	1994	Antibody directed at surface immunoglobulin (anti-Ig) on B cells has previously been shown to induce a rapid burst of TNF-alpha gene transcription, which can be blocked by the immunosuppressants cyclosporin A (CsA) and FK506.	Cyclosporine	195-208	tumor necrosis factor	Homo sapiens	118-127
7518925-2	1994	Antibody directed at surface immunoglobulin (anti-Ig) on B cells has previously been shown to induce a rapid burst of TNF-alpha gene transcription, which can be blocked by the immunosuppressants cyclosporin A (CsA) and FK506.	Cyclosporine	210-213	tumor necrosis factor	Homo sapiens	118-127
7518925-3	1994	Here, TNF-alpha gene transcription is shown also to be highly and rapidly induced in human B cells after stimulation via the CD40 and interleukin 4 pathways, which similarly is inhibited by CsA and a panel of CsA or FK506 analogues that block calcineurin phosphatase activity.	Cyclosporine	209-212	tumor necrosis factor	Homo sapiens	6-15
7518925-3	1994	Here, TNF-alpha gene transcription is shown also to be highly and rapidly induced in human B cells after stimulation via the CD40 and interleukin 4 pathways, which similarly is inhibited by CsA and a panel of CsA or FK506 analogues that block calcineurin phosphatase activity.	Cyclosporine	190-193	tumor necrosis factor	Homo sapiens	6-15
7518925-3	1994	Here, TNF-alpha gene transcription is shown also to be highly and rapidly induced in human B cells after stimulation via the CD40 and interleukin 4 pathways, which similarly is inhibited by CsA and a panel of CsA or FK506 analogues that block calcineurin phosphatase activity.	Cyclosporine	209-212	interleukin 4	Homo sapiens	134-147
7518925-7	1994	Thus, TNF-alpha is a necessary autocrine growth factor for human B cells stimulated via two independent CsA-sensitive pathways and plays a role similar to that of interleukin 2 in T-cell proliferation.	Cyclosporine	104-107	tumor necrosis factor	Homo sapiens	6-15
7518620-6	1994	CsA very effectively inhibits expression of IL-2, IFN-gamma, and IL-4, but it inhibits IL-10 expression only 65%.	Cyclosporine	0-3	interferon gamma	Mus musculus	50-59
7518620-6	1994	CsA very effectively inhibits expression of IL-2, IFN-gamma, and IL-4, but it inhibits IL-10 expression only 65%.	Cyclosporine	0-3	interleukin 10	Mus musculus	87-92
7518620-4	1994	Using this method, we studied the time course and effects of CsA and rapamycin on IL-2, IFN-gamma, IL-4, and IL-10 gene expression following Con A stimulation.	Cyclosporine	61-64	interleukin 10	Mus musculus	109-114
7923750-4	1994	Cyclosporine and related agents such as FK-506 and rapamycin selectively inhibit adaptive immune responses by blocking T cell-dependent biosynthesis of lymphokines, particularly interleukin 2 at the level of messenger ribonucleic acid (mRNA) transcription.	Cyclosporine	0-12	interleukin 2	Homo sapiens	178-191
7521483-1	1994	We wished to determine whether chronic inhibition of angiotensin-converting enzyme (ACE) prevents the vascular toxicity of cyclosporine A (Cx).	Cyclosporine	123-137	angiotensin I converting enzyme	Rattus norvegicus	53-82
7518390-6	1994	Using experimental conditions in which these ionophores were unable to modify either the intracellular pH, or the transmembrane potential, or to induce an intracellular ATP depletion, we have shown that mobile ionophores as well as cyclosporin inhibit the P-glycoprotein-mediated efflux of 4"-O-tetrahydropyranyl-adriamycin in K562 resistant cells, whereas gramicidin, a channel-forming ionophore, does not.	Cyclosporine	232-243	ATP binding cassette subfamily B member 1	Homo sapiens	256-270
7521483-1	1994	We wished to determine whether chronic inhibition of angiotensin-converting enzyme (ACE) prevents the vascular toxicity of cyclosporine A (Cx).	Cyclosporine	123-137	angiotensin I converting enzyme	Rattus norvegicus	84-87
7963418-3	1994	Serum osteocalcin levels in patients taking cyclosporin (median, range: 7.8, 4.2-16 ng/ml) were similar to healthy female controls (6.0, 4.7-9.5 ng/ml), and significantly higher than in patients receiving placebo (5.4, 1.0-8.6 ng/ml, p &lt; 0.02).	Cyclosporine	44-55	bone gamma-carboxyglutamate protein	Homo sapiens	6-17
7963418-6	1994	Circulating parathyroid hormone levels were also higher in patients treated with cyclosporin (4.3, 2.0-9.0 pmol/l) than in those with placebo (3.1, 1.1-5.1 pmol/l) (p &lt; 0.001), and healthy controls (2.9, 1.1-6.9 pmol/l) (p &lt; 0.001).	Cyclosporine	81-92	parathyroid hormone	Homo sapiens	12-31
7963418-7	1994	In four patients treated with cyclosporin the parathyroid hormone levels were above normal values.	Cyclosporine	30-41	parathyroid hormone	Homo sapiens	46-65
7608852-8	1994	Likewise, the intraepithelial deposit of CsA in the GO region was found to be related to the inflammatory infiltrate CD4+, CD8+, and CD68+ (r = 0.7432; r = 0.7346; r = 0.77005, respectively).	Cyclosporine	41-44	CD4 molecule	Homo sapiens	117-120
8207793-7	1994	The Tat-mediated increase in IL-2 promoter activity could selectively be blocked by antisense tat or-unlike the analogous effect of human T-cell lymphotropic virus type 1 Tax-by cyclosporin A.	Cyclosporine	178-191	interleukin 2	Homo sapiens	29-33
7911489-4	1994	However, the induction of the IL-3, IL-4, and GM-CSF genes, but not the IL-5, IL-6, and IL-10 genes, was strongly inhibited by cyclosporin A.	Cyclosporine	127-140	interleukin 3	Mus musculus	30-34
7911489-4	1994	However, the induction of the IL-3, IL-4, and GM-CSF genes, but not the IL-5, IL-6, and IL-10 genes, was strongly inhibited by cyclosporin A.	Cyclosporine	127-140	interleukin 6	Mus musculus	78-82
7911489-4	1994	However, the induction of the IL-3, IL-4, and GM-CSF genes, but not the IL-5, IL-6, and IL-10 genes, was strongly inhibited by cyclosporin A.	Cyclosporine	127-140	interleukin 10	Mus musculus	88-93
8207202-6	1994	Cyclosporin A, which prevented lymphokine mRNA transcription, inhibited more than 90% of the IL-2R alpha and NF-kappa B levels induced by TCR/CD3-mediated activation.	Cyclosporine	0-13	nuclear factor kappa B subunit 1	Homo sapiens	109-119
7515910-7	1994	Both CD40L expression and T cell help were blocked by cyclosporin A after TCR cross-linking, and, unlike T cell proliferation, both remained cyclosporin A sensitive during CD28 costimulation.	Cyclosporine	54-67	CD40 ligand	Homo sapiens	5-10
8029023-0	1994	Cyclosporin A sensitivity of the NF-kappa B site of the IL2R alpha promoter in untransformed murine T cells.	Cyclosporine	0-13	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	33-43
8029023-9	1994	Based on these results, we propose that the NF-kappa B site of the IL2R alpha promoter mediates at least part of the CsA sensitivity of IL2R alpha gene induction in untransformed T cells, possibly because de novo synthesis of p105 NF-kappa B is required for sustained IL2R alpha expression.	Cyclosporine	117-120	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	44-54
8029023-9	1994	Based on these results, we propose that the NF-kappa B site of the IL2R alpha promoter mediates at least part of the CsA sensitivity of IL2R alpha gene induction in untransformed T cells, possibly because de novo synthesis of p105 NF-kappa B is required for sustained IL2R alpha expression.	Cyclosporine	117-120	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	226-230
8029023-9	1994	Based on these results, we propose that the NF-kappa B site of the IL2R alpha promoter mediates at least part of the CsA sensitivity of IL2R alpha gene induction in untransformed T cells, possibly because de novo synthesis of p105 NF-kappa B is required for sustained IL2R alpha expression.	Cyclosporine	117-120	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	231-241
8088360-3	1994	Cyclosporine, calcitriol, calcipotriol or dithranol caused a dose-dependent decrease in interleukin-8 binding to cultured human keratinocytes, while interleukin-8 binding to granulocytes was not affected.	Cyclosporine	0-12	C-X-C motif chemokine ligand 8	Homo sapiens	88-101
8088360-3	1994	Cyclosporine, calcitriol, calcipotriol or dithranol caused a dose-dependent decrease in interleukin-8 binding to cultured human keratinocytes, while interleukin-8 binding to granulocytes was not affected.	Cyclosporine	0-12	C-X-C motif chemokine ligand 8	Homo sapiens	149-162
7919458-5	1994	In resistant cells, the ether phospholipid effect on DNR accumulation has also been found after blocking the PgP function by verapamil and cyclosporin A.	Cyclosporine	139-152	ATP binding cassette subfamily B member 1	Homo sapiens	109-112
8004881-7	1994	A parallel twofold increase in AM1 concentrations was observed, followed by a three-fold increase in cyclosporine levels, which peaked 4.8 days after interleukin-6.	Cyclosporine	101-113	interleukin 6	Homo sapiens	150-163
8205621-5	1994	Similar to its effect on IL-2 induction, cyclosporin A (CsA) inhibited the synergistic activation of JNK, and a competitive inhibitor of Jun phosphorylation by JNK inhibited IL-2 promoter activation.	Cyclosporine	56-59	mitogen-activated protein kinase 8	Homo sapiens	101-104
8004881-8	1994	The times of peak cyclosporine and AM1 levels correlated with the time of peak interleukin-6 levels.	Cyclosporine	18-30	interleukin 6	Homo sapiens	79-92
8076438-1	1994	Abnormalities of the renin-angiotensin system after low-dose cyclosporin (5 mg/kg/day or less) have not been adequately defined in patients with normal kidneys.	Cyclosporine	61-72	renin	Homo sapiens	21-26
8076438-12	1994	Circulating angiotensin II rises in patients who develop cyclosporin nephrotoxicity and may be responsible for mediating the hemodynamic effects.	Cyclosporine	57-68	angiotensinogen	Homo sapiens	12-26
8004881-10	1994	CONCLUSIONS: An inflammatory reaction could be an important source of intraindividual variability in cyclosporine pharmacokinetics, possibly through an inhibition of cytochrome P4503A-dependent enzyme activities by endogenous interleukin-6.	Cyclosporine	101-113	interleukin 6	Homo sapiens	226-239
8194690-6	1994	After treatment, the frequency of TNF-alpha secreting cells was reduced in patients receiving cyclosporin A, not reduced in patients with steroids or enteral nutrition, and not changed with treatment in UC.	Cyclosporine	94-107	tumor necrosis factor	Homo sapiens	34-43
7910563-4	1994	There was an inverse relationship between Pgp expression and calcein/AM accumulation, which increased dose-dependently in the presence of cyclosporin A (CsA) and the nonimmunosuppressive analogue SDZ PSC 833 (PSC) in the Pgp-expressing cell lines.	Cyclosporine	153-156	ATP binding cassette subfamily B member 1	Homo sapiens	42-45
8206613-2	1994	Long-term treatment with cyclosporin A impairs endothelium-dependent relaxations and augments contractions to angiotensin II in the rat aorta.	Cyclosporine	25-38	angiotensinogen	Rattus norvegicus	110-124
7889406-1	1994	We show here that ligation of surface immunoglobulin or CD40 receptors in conjunction with interleukin-4 induces the nuclear factor of activated T cells (NF-AT) in normal murine B cells, which is inhibited by cyclosporin (CsA).	Cyclosporine	209-220	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2	Mus musculus	154-159
7889406-1	1994	We show here that ligation of surface immunoglobulin or CD40 receptors in conjunction with interleukin-4 induces the nuclear factor of activated T cells (NF-AT) in normal murine B cells, which is inhibited by cyclosporin (CsA).	Cyclosporine	222-225	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2	Mus musculus	154-159
8206613-9	1994	In contrast, contractions to angiotensin II were augmented by cyclosporin A, lisinopril, and the combination of both but not by D 8731 or D 8731 plus cyclosporin A.	Cyclosporine	62-75	angiotensinogen	Rattus norvegicus	29-43
8206613-10	1994	The data suggest a role for angiotensin II in cyclosporin A-induced endothelial dysfunction.	Cyclosporine	46-59	angiotensinogen	Rattus norvegicus	28-42
8206613-12	1994	The selective augmentation of angiotensin II effects by ACE inhibition and cyclosporin A suggests upregulation of angiotensin receptors in the aortic smooth muscle by these treatments.	Cyclosporine	75-88	angiotensinogen	Rattus norvegicus	30-44
8197611-4	1994	Cyclosporine blood levels were significantly correlated to total plasma cholesterol (P = 0.028), low-density lipoprotein cholesterol (P = 0.022), apolipoprotein B (P = 0.017), and the cholesterol/high-density lipoprotein cholesterol ratio (P &lt; 0.002), but not to plasma triglycerides.	Cyclosporine	0-12	apolipoprotein B	Homo sapiens	146-162
8197611-5	1994	Significant inverse correlations were found between cyclosporine blood levels and high-density lipoprotein cholesterol (P = 0.034), high-density lipoprotein3 cholesterol (P = 0.025), and apolipoprotein A-1 (P = 0.047), but not high-density lipoprotein2 cholesterol.	Cyclosporine	52-64	apolipoprotein A1	Homo sapiens	187-205
8197611-7	1994	After correction for these 7 variables, cyclosporine blood levels remained significantly associated with high-density lipoprotein cholesterol, high-density lipoprotein3 cholesterol, apolipoprotein A-1, apolipoprotein B, low-density lipoprotein cholesterol, and the cholesterol/high-density lipoprotein cholesterol ratio.	Cyclosporine	40-52	apolipoprotein A1	Homo sapiens	182-200
8197611-7	1994	After correction for these 7 variables, cyclosporine blood levels remained significantly associated with high-density lipoprotein cholesterol, high-density lipoprotein3 cholesterol, apolipoprotein A-1, apolipoprotein B, low-density lipoprotein cholesterol, and the cholesterol/high-density lipoprotein cholesterol ratio.	Cyclosporine	40-52	apolipoprotein B	Homo sapiens	202-218
8197617-5	1994	However, CsA augmented the thrombin-induced phosphorylation of the specific PKC substrate p47 in platelets in a dose-dependent fashion.	Cyclosporine	9-12	coagulation factor II, thrombin	Homo sapiens	27-35
8197617-6	1994	CsA did not affect basal [Ca2+]i--however, it increased thrombin-induced calcium influx.	Cyclosporine	0-3	coagulation factor II, thrombin	Homo sapiens	56-64
8204106-8	1994	Compounds such as cyclosporin, triacetyl-oleandomycin and testosterone inhibited the N-demethylation of toremifene metabolism at 80, 89 and 56% vs control, respectively, while the formation of TOR III was inhibited at 78, 82 and 73% vs control and the 4-hydroxylation pathway was inhibited no more than about 50% vs control.	Cyclosporine	18-29	RAR related orphan receptor C	Homo sapiens	193-196
8183344-1	1994	In T cells, cyclosporin A (CsA) exerts its immunosuppressive effect by preventing transcriptional induction of the expression of interleukin(IL)-2.	Cyclosporine	12-25	interleukin 2	Homo sapiens	129-146
8183344-1	1994	In T cells, cyclosporin A (CsA) exerts its immunosuppressive effect by preventing transcriptional induction of the expression of interleukin(IL)-2.	Cyclosporine	27-30	interleukin 2	Homo sapiens	129-146
8071877-7	1994	Noradrenaline (0.3 microM) and vasopressin (0.05 u l-1) induced myogenic responsiveness, resulting in a constant or declining CSA with increasing pressure.	Cyclosporine	126-129	arginine vasopressin	Rattus norvegicus	31-42
8071877-13	1994	During CSA-controlled conditions, noradrenaline and vasopressin induced all-or-none responses to stretch.	Cyclosporine	7-10	arginine vasopressin	Rattus norvegicus	52-63
8071877-16	1994	During CSA-controlled conditions, noradrenaline and vasopressin concentration-response curves also showed all-or-none behaviour.	Cyclosporine	7-10	arginine vasopressin	Rattus norvegicus	52-63
7910403-4	1994	When injected into inflamed rat paws (but not intravenously), IL-1 and CRF produce antinociception, which is reversible by IL-1 receptor antagonist and alpha-helical CRF, respectively, and by the immunosuppressant cyclosporine A.	Cyclosporine	214-228	interleukin 1 beta	Homo sapiens	62-66
7909900-0	1994	Cyclosporin for erythropoietin resistance.	Cyclosporine	0-11	erythropoietin	Homo sapiens	16-30
8184875-5	1994	Following in vivo treatment with cyclosporin peripheral blood CD4/CD8 ratios returned to normal.	Cyclosporine	33-44	CD4 molecule	Homo sapiens	62-65
8184875-10	1994	A response to cyclosporin may be masked by inappropriately low erythropoietin levels.	Cyclosporine	14-25	erythropoietin	Homo sapiens	63-77
8178944-4	1994	Immunosuppression by cyclosporin inhibited the development of glomerulonephritis, decreased class II antigen expression, and abrogated IL-6-mediated effects.	Cyclosporine	21-32	interleukin 6	Mus musculus	135-139
7915506-5	1994	Whereas the cytotoxic effect of Dox was considerably increased by verapamil, cyclosporin A and its non-immunosuppressive analogue SDZ PSC 833 in the Pgp-expressing Dox-resistant sublines, comparatively small effects on the Dox and Vcr sensitivity were observed in the patient samples, irrespective of their Pgp expression.	Cyclosporine	77-90	ATP binding cassette subfamily B member 1	Homo sapiens	149-152
8172854-3	1994	Addition of CsA to the culture medium of HepG2 cells resulted in a dose- and time-dependent decrease in the secretion of apoB-100.	Cyclosporine	12-15	apolipoprotein B	Homo sapiens	121-129
8031258-4	1994	We found that cyclosporin A (CyA) inhibited the IL-5 production from human peripheral lymphocytes induced by IL-2 stimulation.	Cyclosporine	14-27	interleukin 2	Homo sapiens	109-113
8076396-7	1994	Indeed both cyclosporin A and FK506 are effective therapies and evidence suggests that anti-CD4 antibodies may be of great value.	Cyclosporine	12-25	CD4 molecule	Homo sapiens	92-95
8172854-9	1994	The decreased secretion of apoB-100 was accompanied by a diminished secretion of triglycerides (-47%), cholesterol (-18%), and cholesteryl esters (-27%) in the presence of CsA.	Cyclosporine	172-175	apolipoprotein B	Homo sapiens	27-35
8172854-13	1994	Short pulse incubations in the presence of [35S]methionine showed a decrease in the intracellular amount of labeled apoB-100 after an incubation of only 2 through 4 minutes, indicating that the translation was not affected but that inhibition of the apoB-100 secretion by CsA occurred at the cotranslational level.	Cyclosporine	272-275	apolipoprotein B	Homo sapiens	116-124
7986646-0	1994	A small angle X-ray scattering study of the binding of cyclosporin-A to calmodulin.	Cyclosporine	55-68	calmodulin 1	Homo sapiens	72-82
7512591-7	1994	Moreover, cyclosporin A, which inhibited IL-2 more efficiently than rIL-10 in response to anti-CD3 mAb and B7/CD32 transfected fibroblasts, did not reduce and even enhanced IL-5 production.	Cyclosporine	10-23	interleukin 2	Homo sapiens	41-45
7512591-7	1994	Moreover, cyclosporin A, which inhibited IL-2 more efficiently than rIL-10 in response to anti-CD3 mAb and B7/CD32 transfected fibroblasts, did not reduce and even enhanced IL-5 production.	Cyclosporine	10-23	Fc receptor, IgG, low affinity IIb	Mus musculus	110-114
7986646-1	1994	Small angle X-ray scattering (SAXS) was applied to the binding of the immunosuppressant drug cyclosporin-A to the protein calmodulin.	Cyclosporine	93-106	calmodulin 1	Homo sapiens	122-132
8060463-4	1994	Chronic treatment with cyclosporin A significantly augmented contractions to angiotensin II (10(-9)-10(-5) M).	Cyclosporine	23-36	angiotensinogen	Rattus norvegicus	77-91
8060463-8	1994	The preventive effect of diltiazem against the cyclosporin A-induced hypersensitivity to angiotensin II supports the hypothesis of increased calcium influx during cyclosporin A therapy.	Cyclosporine	47-60	angiotensinogen	Rattus norvegicus	89-103
8060463-8	1994	The preventive effect of diltiazem against the cyclosporin A-induced hypersensitivity to angiotensin II supports the hypothesis of increased calcium influx during cyclosporin A therapy.	Cyclosporine	163-176	angiotensinogen	Rattus norvegicus	89-103
7878594-2	1994	Response to CsA was investigated in vitro in 59 healthy subjects by measuring the inhibition of lymphocyte proliferation and interleukin-2 (IL-2) production.	Cyclosporine	12-15	interleukin 2	Homo sapiens	125-138
8159684-4	1994	These changes in [Ca2+]i are completely abolished if the phospholipase A2 (PLA2) activity is inhibited by either 4-bromophenacyl bromide or cyclosporin A.	Cyclosporine	140-153	phospholipase A2 group IB	Homo sapiens	57-73
7878594-2	1994	Response to CsA was investigated in vitro in 59 healthy subjects by measuring the inhibition of lymphocyte proliferation and interleukin-2 (IL-2) production.	Cyclosporine	12-15	interleukin 2	Homo sapiens	140-144
7513912-11	1994	The 1,25-(OH)2-vitamin D and BGP levels in both the CsA and CsG groups were increased on days 14 and 28 (P &lt; 0.05), while FK506 had no effect on these serum levels.	Cyclosporine	52-55	bone gamma-carboxyglutamate protein	Rattus norvegicus	29-32
8159684-4	1994	These changes in [Ca2+]i are completely abolished if the phospholipase A2 (PLA2) activity is inhibited by either 4-bromophenacyl bromide or cyclosporin A.	Cyclosporine	140-153	phospholipase A2 group IB	Homo sapiens	75-79
7641086-5	1994	The first, like cyclosporine, interferes with the action of interleukin 2.	Cyclosporine	16-28	interleukin 2	Homo sapiens	60-73
7908376-0	1994	Treatment of erythropoietin resistance with cyclosporin.	Cyclosporine	44-55	erythropoietin	Homo sapiens	13-27
7518710-8	1994	The mechanism of action is similar to that of cyclosporine in that it ultimately blocks the production of interleukin 2, thereby inhibiting further T-lymphocyte proliferation.	Cyclosporine	46-58	interleukin 2	Homo sapiens	106-119
8054825-6	1994	These findings suggest that CSA at low concentrations strongly stimulates the conversion of cholesterol to PREG (i.e. the rate-limiting step of steroidogenesis), while at middle concentrations it did not affect this early step, but specifically interferes with the intracellular events which transduce the stimulatory signal of ANG-II on the late steps of mineralocorticoid production (i.e. the conversion of B to ALDO).	Cyclosporine	28-31	angiotensinogen	Rattus norvegicus	328-334
8019477-0	1994	Down-modulation of serum erythropoietin levels following cyclosporin A infusion.	Cyclosporine	57-70	erythropoietin	Homo sapiens	25-39
8045668-0	1994	Effect of interferon-gamma, interleukin-2 and interleukin-4 on cyclosporin-A-mediated inhibition of anti-CD3-induced T-lymphocyte proliferation.	Cyclosporine	63-76	interferon gamma	Mus musculus	10-26
8007592-6	1994	Cyclosporine exerted a more marked antidiuretic effect on day 4 compared to day 1, which was augmented by a physiological infusion of vasopressin.	Cyclosporine	0-12	arginine vasopressin	Homo sapiens	134-145
8138066-6	1994	Insulin responses were also decreased in kidney recipients (ARmax = 2,296 +/- 290%) vs. control subjects (4,691 +/- 554%, P = 0.001) and in psoriasis patients treated with cyclosporine (ARmax = 2,153 +/- 390%) vs. control subjects (3,962 +/- 88%, P = 0.011), but not as extreme as that seen in pancreas recipients.	Cyclosporine	172-184	insulin	Homo sapiens	0-7
7512581-2	1994	We show that the SP-augmented IL-2 mRNA signal is totally abrogated by an early addition of cyclosporin A, actinomycin D or cycloheximide.	Cyclosporine	92-105	interleukin 2	Homo sapiens	30-34
8075217-5	1994	Likewise, daily injection of cyclosporin A (Cs-A), a potent inhibitor of T cell function, during the first 3 days of Toxoplasma infection severely exacerbated the infection, in accordance with a marked suppression of the early IFN-gamma production.	Cyclosporine	29-42	interferon gamma	Mus musculus	227-236
8075217-5	1994	Likewise, daily injection of cyclosporin A (Cs-A), a potent inhibitor of T cell function, during the first 3 days of Toxoplasma infection severely exacerbated the infection, in accordance with a marked suppression of the early IFN-gamma production.	Cyclosporine	44-48	interferon gamma	Mus musculus	227-236
8075217-6	1994	In contrast, the administration of Cs-A for 3 consecutive days starting at day 4 had no significant consequence on P. acnes-induced anti-toxoplasma resistance, while it reduced greatly the ability of P. acnes-injected mice to produce IFN-gamma in the later phase of infection.	Cyclosporine	35-39	interferon gamma	Mus musculus	234-243
8007592-10	1994	The cyclosporine induced antidiuresis may indicate a distal nephron effect since cyclosporine augmented the antidiuretic effect of vasopressin, although vasopressin levels per se were not increased by cyclosporine alone.	Cyclosporine	4-16	arginine vasopressin	Homo sapiens	131-142
8007592-10	1994	The cyclosporine induced antidiuresis may indicate a distal nephron effect since cyclosporine augmented the antidiuretic effect of vasopressin, although vasopressin levels per se were not increased by cyclosporine alone.	Cyclosporine	81-93	arginine vasopressin	Homo sapiens	131-142
8007592-10	1994	The cyclosporine induced antidiuresis may indicate a distal nephron effect since cyclosporine augmented the antidiuretic effect of vasopressin, although vasopressin levels per se were not increased by cyclosporine alone.	Cyclosporine	81-93	arginine vasopressin	Homo sapiens	131-142
7518966-3	1994	Although cyclosporine is a known substrate of cytochrome P-450 IIIA, it had no effect on FK 506 metabolism.	Cyclosporine	9-21	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	46-62
8132503-1	1994	Cyclophilin (CyP), a protein with peptidyl-prolyl cis-trans isomerase (rotamase) activity, is the specific cellular target of cyclosporin A.	Cyclosporine	126-139	Cyclophilin	Arabidopsis thaliana	0-11
8159020-0	1994	Combination of cyclosporine and splenectomy suppresses interleukin-6 production and major histocompatibility complex class II expression and prolongs cardiac xenograft survival.	Cyclosporine	15-27	interleukin 6	Rattus norvegicus	55-68
7510704-6	1994	However, the phosphorylation of Hsp27 in vivo is only affected when cells are treated with PP1 and PP2A inhibitors (okadaic acid, calyculin A) or cantharidin (PP2A inhibitor), but not the PP2B inhibitor, cyclosporin A, suggesting PP2A to be the main enzyme dephosphorylating Hsp27 in the cells.	Cyclosporine	204-217	inorganic pyrophosphatase 1	Homo sapiens	91-94
8132503-1	1994	Cyclophilin (CyP), a protein with peptidyl-prolyl cis-trans isomerase (rotamase) activity, is the specific cellular target of cyclosporin A.	Cyclosporine	126-139	Cyclophilin	Arabidopsis thaliana	13-16
8132503-9	1994	In vitro chloroplast import of precursors of other chloroplast proteins was unaffected by concentrations of cyclosporin A which completely inhibit rotamase activity of chloroplast stromal CyP.	Cyclosporine	108-121	Cyclophilin	Arabidopsis thaliana	188-191
7510099-5	1994	Pretreatment of the CD4+ T cells with cyclosporine or mitomycin C did not inhibit oligodendrocyte lysis.	Cyclosporine	38-50	CD4 molecule	Homo sapiens	20-23
8144874-8	1994	This induction did not occur in the presence of cyclosporin A, which inhibits IL-2 secretion.	Cyclosporine	48-61	interleukin 2	Homo sapiens	78-82
8079831-4	1994	The CsA treatment reduced IL-6 levels to normal.	Cyclosporine	4-7	interleukin 6	Rattus norvegicus	26-30
8118035-1	1994	Cremophor (Crem) EL, the vehicle for intravenous delivery of cyclosporin A (CsA), has been reported to counteract multidrug resistance (MDR) in P-glycoprotein (Pgp)-over-expressing cell lines.	Cyclosporine	76-79	ATP binding cassette subfamily B member 1	Homo sapiens	144-158
8118035-1	1994	Cremophor (Crem) EL, the vehicle for intravenous delivery of cyclosporin A (CsA), has been reported to counteract multidrug resistance (MDR) in P-glycoprotein (Pgp)-over-expressing cell lines.	Cyclosporine	76-79	ATP binding cassette subfamily B member 1	Homo sapiens	160-163
7907272-6	1994	The antitumor effect of SPR-901 was abrogated in mice depleted of either L3T4+ or Lyt2+ cells, and in cyclosporin-A-treated mice.	Cyclosporine	102-115	sepiapterin reductase	Mus musculus	24-27
7521274-5	1994	Both CsA and FK506 (at 1 mumol/L) significantly inhibited nitrite production induced by recombinant murine interleukin-1 beta (rIL-1 beta).	Cyclosporine	5-8	interleukin 1 beta	Mus musculus	107-125
8129032-1	1994	We examined the effects of cyclosporine (Cy) on preproendothelin-1 (prepro Et-1) and both Et receptors, A-type (EtA) and B-type (EtB), in rat glomerular mesangial cells.	Cyclosporine	41-43	endothelin 1	Rattus norvegicus	48-66
8129032-2	1994	Cy at 10(-5) mol/L, the concentration relevant to tissue levels in vivo, increased mRNA for prepro Et-1 after both 1 and 3 hours to 183 +/- 14% (n = 8) and 147 +/- 12% (n = 9) of levels seen in control cells.	Cyclosporine	0-2	endothelin 1	Rattus norvegicus	92-103
8129032-9	1994	These results indicate that Cy enhances expression of mRNA for prepro Et-1 and production of mature Et-1 by glomerular mesangial cells.	Cyclosporine	28-30	endothelin 1	Rattus norvegicus	63-74
8129032-9	1994	These results indicate that Cy enhances expression of mRNA for prepro Et-1 and production of mature Et-1 by glomerular mesangial cells.	Cyclosporine	28-30	endothelin 1	Rattus norvegicus	70-74
8137549-6	1994	Cyclosporine inhibited IL-2 receptor expression to a significantly greater degree in cord CD4 and CD8 cells (49.7% and 70.1%) than in adults (17.9% and 30.0%).	Cyclosporine	0-12	CD4 molecule	Homo sapiens	90-93
7521274-5	1994	Both CsA and FK506 (at 1 mumol/L) significantly inhibited nitrite production induced by recombinant murine interleukin-1 beta (rIL-1 beta).	Cyclosporine	5-8	interleukin 1 beta	Rattus norvegicus	127-137
8013282-5	1994	The CYP3A substrate/inhibitor, cyclosporine A (CsA) had little effect on tropisetron hydroxylation (&lt; 10%), whereas CsA and triacetyloleandomycin reduced ondansetron 7- and 8-hydroxylation up to 27%.	Cyclosporine	47-50	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	4-9
8013282-8	1994	The CYP3A specific metabolism of CsA was also competitively inhibited by tropisetron (Ki = 2.1 mM) and ondansetron (Ki = 31 microM).	Cyclosporine	33-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	4-9
7907604-6	1994	Cyclosporin A inhibited IL-4-driven CD40 ligand-dependent IgE isotype switching in PBMC but did not inhibit IgE synthesis induced by CD40 mAb plus IL-4.	Cyclosporine	0-13	interleukin 4	Homo sapiens	24-28
8113679-10	1994	Both agents significantly reduced the expression of CD45RO and the effect of cyclosporin A was reversed by exogenous IL-2.	Cyclosporine	77-90	interleukin 2	Homo sapiens	117-121
8133028-12	1994	In addition, they show that negative regulation by Fc gamma RII is effective in both cyclosporin A-sensitive and insensitive pathways.	Cyclosporine	85-98	Fc receptor, IgG, low affinity IIb	Mus musculus	51-63
8190529-10	1994	Immunosuppressive treatment with cyclosporin therapy in combination with a minimal dose of alternate-day prednisone would then result in optimal post-transplant growth, particularly if the GFR remains above 50 mL/min/1.73 m2).	Cyclosporine	33-44	CD59 molecule (CD59 blood group)	Homo sapiens	213-218
8116045-2	1994	Immunosuppressants such as cyclosporine are considered to constrain cell growth by preventing the production of growth stimulatory cytokines (e.g., interleukin-2).	Cyclosporine	27-39	interleukin 2	Homo sapiens	148-161
8116045-4	1994	We have explored herein the hypothesis that CsA stimulates the production of transforming growth factor-beta (TGF-beta), and restrains new DNA synthesis in mammalian cells via a TGF-beta-dependent mechanism.	Cyclosporine	44-47	transforming growth factor beta 1	Homo sapiens	178-186
8116045-4	1994	We have explored herein the hypothesis that CsA stimulates the production of transforming growth factor-beta (TGF-beta), and restrains new DNA synthesis in mammalian cells via a TGF-beta-dependent mechanism.	Cyclosporine	44-47	transforming growth factor beta 1	Homo sapiens	77-108
8116045-6	1994	Our experimental approach revealed the following: (A) CsA and not cyclosporine H, an inactive analogue of CsA, mediates growth inhibition of TGF-beta-sensitive cells, CCL-64 cells, and A-549 cells; (B) CsA stimulates these mammalian cells to secrete TGF-beta; and (C) TGF-beta induced by CsA is biologically active in inducing cell growth inhibition (demonstrated by the reversal of CsA-associated inhibition with anti-TGF-beta monoclonal antibodies).	Cyclosporine	54-57	transforming growth factor beta 1	Homo sapiens	141-149
8116045-6	1994	Our experimental approach revealed the following: (A) CsA and not cyclosporine H, an inactive analogue of CsA, mediates growth inhibition of TGF-beta-sensitive cells, CCL-64 cells, and A-549 cells; (B) CsA stimulates these mammalian cells to secrete TGF-beta; and (C) TGF-beta induced by CsA is biologically active in inducing cell growth inhibition (demonstrated by the reversal of CsA-associated inhibition with anti-TGF-beta monoclonal antibodies).	Cyclosporine	54-57	transforming growth factor beta 1	Homo sapiens	250-258
8116045-4	1994	We have explored herein the hypothesis that CsA stimulates the production of transforming growth factor-beta (TGF-beta), and restrains new DNA synthesis in mammalian cells via a TGF-beta-dependent mechanism.	Cyclosporine	44-47	transforming growth factor beta 1	Homo sapiens	110-118
8116045-6	1994	Our experimental approach revealed the following: (A) CsA and not cyclosporine H, an inactive analogue of CsA, mediates growth inhibition of TGF-beta-sensitive cells, CCL-64 cells, and A-549 cells; (B) CsA stimulates these mammalian cells to secrete TGF-beta; and (C) TGF-beta induced by CsA is biologically active in inducing cell growth inhibition (demonstrated by the reversal of CsA-associated inhibition with anti-TGF-beta monoclonal antibodies).	Cyclosporine	54-57	transforming growth factor beta 1	Homo sapiens	250-258
8112299-3	1994	Calcineurin, a Ca2+/calmodulin-dependent protein phosphatase, is the FK-506- and CsA-sensitive enzyme required for TcR mediated activation of the IL-2 promoter.	Cyclosporine	81-84	interleukin 2	Homo sapiens	146-150
8116045-6	1994	Our experimental approach revealed the following: (A) CsA and not cyclosporine H, an inactive analogue of CsA, mediates growth inhibition of TGF-beta-sensitive cells, CCL-64 cells, and A-549 cells; (B) CsA stimulates these mammalian cells to secrete TGF-beta; and (C) TGF-beta induced by CsA is biologically active in inducing cell growth inhibition (demonstrated by the reversal of CsA-associated inhibition with anti-TGF-beta monoclonal antibodies).	Cyclosporine	54-57	transforming growth factor beta 1	Homo sapiens	250-258
8116045-7	1994	Our observations suggest that CsA can regulate cell growth via a TGF-beta-dependent mechanism.	Cyclosporine	30-33	transforming growth factor beta 1	Homo sapiens	65-73
8116045-8	1994	Since the multifunctional cytokine TGF-beta can enhance extracellular matrix accumulation as well as augment endothelin production, our findings also advance a mechanism that links, via TGF-beta, the beneficial (immunosuppression) and the harmful (fibrosis, hypertension) consequences of CsA usage.	Cyclosporine	288-291	transforming growth factor beta 1	Homo sapiens	35-43
8116045-8	1994	Since the multifunctional cytokine TGF-beta can enhance extracellular matrix accumulation as well as augment endothelin production, our findings also advance a mechanism that links, via TGF-beta, the beneficial (immunosuppression) and the harmful (fibrosis, hypertension) consequences of CsA usage.	Cyclosporine	288-291	transforming growth factor beta 1	Homo sapiens	186-194
7906657-6	1994	Noteworthy, CsA treatment prevented the gp120-dependent induction of apoptosis by blocking the activation of the Ca(2+)-dependent effector elements such as tTG.	Cyclosporine	12-15	transglutaminase 2	Homo sapiens	156-159
8032008-5	1994	However, the tyrosine kinase antagonist tyrphostin inhibited, whereas sodium orthovanadate, okadaic acid and cyclosporin A, all inhibitors of protein phosphatases, potentiated IL-1 beta induced nitrite release to the medium.	Cyclosporine	109-122	interleukin 1 beta	Rattus norvegicus	176-185
7906507-0	1994	[Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16, and their synergistic modulation of multidrug resistance].	Cyclosporine	41-53	ATP binding cassette subfamily B member 1	Homo sapiens	62-76
7906507-0	1994	[Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16, and their synergistic modulation of multidrug resistance].	Cyclosporine	41-53	mitogen-activated protein kinase kinase kinase 20	Homo sapiens	97-100
7906507-5	1994	Drug accumulation studies revealed that MRK-16 remarkably increased the accumulation of cyclosporine, but not verapamil, in K562/ADM cells.	Cyclosporine	88-100	mitogen-activated protein kinase kinase kinase 20	Homo sapiens	40-43
7906507-6	1994	This increased accumulation of cyclosporine by MRK-16 in K562/ADM cells directly resulted in the enhanced accumulation of vincristine and adriamycin in the cells.	Cyclosporine	31-43	mitogen-activated protein kinase kinase kinase 20	Homo sapiens	47-50
7906507-8	1994	Moreover, while MRK-16 alone did not enhance the sensitivity of the KB-8-5 cells moderately resistant to vincristine, it increased two-fold the reversing effect of cyclosporine at 1 microM, an achievable blood concentration.	Cyclosporine	164-176	mitogen-activated protein kinase kinase kinase 20	Homo sapiens	16-19
8299681-4	1994	Among a series of human cytokines tested, only interferon-alpha and tumor necrosis factor-alpha were shown to protect against Ca(2+)-dependent apoptosis when used alone or in combination with CsA.	Cyclosporine	192-195	tumor necrosis factor	Homo sapiens	47-95
8113833-0	1994	Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer.	Cyclosporine	48-60	interferon gamma	Homo sapiens	17-33
7507511-1	1994	Interaction of CD28/CTLA-4 on T cells with B7 on antigen-presenting cells constitutes an important costimulatory signal for T cells and is responsible for cyclosporin A-resistant interleukin 2 (IL-2) gene expression and potentially also for prevention of anergy induction after T cell receptor triggering.	Cyclosporine	155-168	interleukin 2	Homo sapiens	179-192
7507511-1	1994	Interaction of CD28/CTLA-4 on T cells with B7 on antigen-presenting cells constitutes an important costimulatory signal for T cells and is responsible for cyclosporin A-resistant interleukin 2 (IL-2) gene expression and potentially also for prevention of anergy induction after T cell receptor triggering.	Cyclosporine	155-168	interleukin 2	Homo sapiens	194-198
8113833-1	1994	PURPOSE: We investigated if interferon gamma (IFN-gamma) could augment cyclosporine (CSA)-induced graft-versus-host disease (GVHD) following autologous bone marrow transplant in women with metastatic breast cancer and defined the toxicities of this therapy.	Cyclosporine	71-83	interferon gamma	Homo sapiens	28-55
8113833-1	1994	PURPOSE: We investigated if interferon gamma (IFN-gamma) could augment cyclosporine (CSA)-induced graft-versus-host disease (GVHD) following autologous bone marrow transplant in women with metastatic breast cancer and defined the toxicities of this therapy.	Cyclosporine	85-88	interferon gamma	Homo sapiens	28-55
8113833-11	1994	CONCLUSION: CSA-induced GVHD can be safely augmented by IFN-gamma in women treated with high-dose alkylating agents and autologous bone marrow transplantation.	Cyclosporine	12-15	interferon gamma	Homo sapiens	56-65
8193079-1	1994	Recent clinical studies which showed the therapeutic effect of cyclosporin A and of anti-CD4 MoAb emphasized the role of activated CD4+ T cells infiltrating the lesional skin in the pathogenesis of psoriasis.	Cyclosporine	63-76	CD4 molecule	Homo sapiens	131-134
7511575-0	1994	Cyclosporin A enhances susceptibility of multi-drug resistant human cancer cells to anti-P-glycoprotein antibody-dependent cytotoxicity of monocytes, but not of lymphocytes.	Cyclosporine	0-13	ATP binding cassette subfamily B member 1	Homo sapiens	89-103
8193081-12	1994	Hydrocortisone and cyclosporin A showed similar inhibitory effects on PMA/LPS-increased IL-8 secretion from NHKs but had little effect of restoring IL-1 alpha.	Cyclosporine	19-32	C-X-C motif chemokine ligand 8	Homo sapiens	88-92
7511575-1	1994	Cyclosporin A (CsA) was previously found to bind to P-glycoprotein expressed on multidrug-resistant (MDR) cancer cells.	Cyclosporine	0-13	ATP binding cassette subfamily B member 1	Homo sapiens	52-66
8114683-3	1994	Using a panel of prototypical substrates and inhibitors for specific cytochromes P450, we identified substrates for CYP3A4 (midazolam, erythromycin, cyclosporin, and dexamethasone) as inhibitors of catechol formation from both etoposide and teniposide.	Cyclosporine	149-160	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	116-122
7908481-0	1994	An unexpected increase in circulating IFN-gamma by cyclosporin A in atopic patients: a discrepancy between in vitro and in vivo events.	Cyclosporine	51-64	interferon gamma	Homo sapiens	38-47
7487376-6	1994	The use of two types of potentially nephrotoxic drugs, like NSAID and gentamicin or NSAID with cyclosporin induced significant augmentation of NAG excretion.	Cyclosporine	95-106	N-acetyl-alpha-glucosaminidase	Homo sapiens	143-146
7908481-3	1994	Cy-A, known to inhibit IFN-gamma production in vitro, caused a rapid rise in serum IFN-gamma, but not Il-1 alpha and TNF alpha, levels in the patients and the IFN-gamma levels appeared to be inversely related to the therapeutic efficacy.	Cyclosporine	0-4	interferon gamma	Homo sapiens	23-32
7908481-3	1994	Cy-A, known to inhibit IFN-gamma production in vitro, caused a rapid rise in serum IFN-gamma, but not Il-1 alpha and TNF alpha, levels in the patients and the IFN-gamma levels appeared to be inversely related to the therapeutic efficacy.	Cyclosporine	0-4	interferon gamma	Homo sapiens	83-92
7908481-3	1994	Cy-A, known to inhibit IFN-gamma production in vitro, caused a rapid rise in serum IFN-gamma, but not Il-1 alpha and TNF alpha, levels in the patients and the IFN-gamma levels appeared to be inversely related to the therapeutic efficacy.	Cyclosporine	0-4	interferon gamma	Homo sapiens	83-92
7908481-4	1994	The observed increase in serum IFN-gamma levels during Cy-A therapy may have contributed to a marked clinical improvement of the AD.	Cyclosporine	55-59	interferon gamma	Homo sapiens	31-40
8073829-6	1994	Treatment with cyclosporin, acitretin and the Goeckerman regimen increased the total IFN activity, but did not affect the levels of IFNs nor TNF-alpha.	Cyclosporine	15-26	interferon alpha 1	Homo sapiens	85-88
7879670-5	1994	It has been demonstrated, at least in the laboratory, that resistance mediated by P-glycoprotein may be modulated by a wide variety of compounds, including verapamil and cyclosporine A.	Cyclosporine	170-184	ATP binding cassette subfamily B member 1	Homo sapiens	82-96
7487376-8	1994	The recognition of high NAG enzymuria permits to reduce dosage or discontinue treatment with potentially nephrotoxic drug prior to irreversible renal insufficiency as shown in the case of a patient with psoriatic arthritis treated with simultaneously administered cyclosporin and diclofenac.	Cyclosporine	264-275	N-acetyl-alpha-glucosaminidase	Homo sapiens	24-27
7506079-5	1994	However, the combination of CsA and anti-B7 MoAb B7-24 synergistically blocked allogeneic B cell-induced T-cell proliferation, IL-2 production, and CTL generation.	Cyclosporine	28-31	interleukin 2	Homo sapiens	127-131
8154310-6	1994	Serum BGP levels were significantly elevated in both young and older rats administered CsA, and 1,25-(OH)2D levels were significantly elevated in CsA-treated young rats more than in older rats.	Cyclosporine	87-90	bone gamma-carboxyglutamate protein	Rattus norvegicus	6-9
8123970-5	1994	DATA SYNTHESIS: Ciprofloxacin has been reported to interact with cyclosporine during concomitant use through an interaction with the cytochrome P-450 system or by additive nephrotoxicity.	Cyclosporine	65-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-149
7907953-2	1994	Several phenotypic features that are characteristic of MDR have been described; these include (1) resistance to many structurally and functionally unrelated drugs that have different cellular targets and modes of action; (2) reversal of MDR by certain agents, including verapamil and cyclosporin A; and (3) reduced intracellular drug accumulation relative to that of drug-sensitive cells.	Cyclosporine	284-297	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	55-58
7907953-2	1994	Several phenotypic features that are characteristic of MDR have been described; these include (1) resistance to many structurally and functionally unrelated drugs that have different cellular targets and modes of action; (2) reversal of MDR by certain agents, including verapamil and cyclosporin A; and (3) reduced intracellular drug accumulation relative to that of drug-sensitive cells.	Cyclosporine	284-297	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	237-240
7910786-0	1994	Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH.	Cyclosporine	119-133	ATP binding cassette subfamily B member 1	Homo sapiens	14-28
7798292-5	1994	Coincubation of CsA-treated cells with 10-400 U/ml interleukin-2 (IL-2) could not abrogate this growth inhibition, suggesting an IL-2 independent mechanism of action.	Cyclosporine	16-19	interleukin 2	Homo sapiens	51-64
7590419-8	1994	The analysis of the residual beta cell secretory capacity has shown that C-peptide levels (taken as a marker for insulin secretion) were slightly higher in patients with the spontaneous remission than in those with the cyclosporin-induced remission both in basal conditions and after stimulation with 1 mg of glucagon.	Cyclosporine	219-230	insulin	Homo sapiens	73-82
7590419-9	1994	In the patients with cyclosporin A-induced remission we found an improved basal C-peptide secretion and, even more, we detected a significant improvement in beta cell response to the glucagon stimulation.	Cyclosporine	21-34	insulin	Homo sapiens	80-89
7590419-10	1994	The analysis of the first-phase insulin secretory response (the insulin response to rapidly injected glucose during the intravenous glucose tolerance test) which has been shown to be impaired very early during the development of diabetes, has demonstrated the lack of its recovery both in the spontaneous and in cyclosporin A-induced remissions.	Cyclosporine	312-325	insulin	Homo sapiens	32-39
7590419-10	1994	The analysis of the first-phase insulin secretory response (the insulin response to rapidly injected glucose during the intravenous glucose tolerance test) which has been shown to be impaired very early during the development of diabetes, has demonstrated the lack of its recovery both in the spontaneous and in cyclosporin A-induced remissions.	Cyclosporine	312-325	insulin	Homo sapiens	64-71
7590419-11	1994	The analysis of the molar insulin/C-peptide ratio has detected the impairments of this ratio which remains decreased both in spontaneous and cyclosporin-induced remissions.	Cyclosporine	141-152	insulin	Homo sapiens	26-33
7590419-11	1994	The analysis of the molar insulin/C-peptide ratio has detected the impairments of this ratio which remains decreased both in spontaneous and cyclosporin-induced remissions.	Cyclosporine	141-152	insulin	Homo sapiens	34-43
7798292-5	1994	Coincubation of CsA-treated cells with 10-400 U/ml interleukin-2 (IL-2) could not abrogate this growth inhibition, suggesting an IL-2 independent mechanism of action.	Cyclosporine	16-19	interleukin 2	Homo sapiens	66-70
7798292-5	1994	Coincubation of CsA-treated cells with 10-400 U/ml interleukin-2 (IL-2) could not abrogate this growth inhibition, suggesting an IL-2 independent mechanism of action.	Cyclosporine	16-19	interleukin 2	Homo sapiens	129-133
7907333-9	1994	Interestingly, resistance of F4-6RADR-CsA cells remained reversible for the calcium antagonists verapamil and dihydropyridine B859-35 (dexniguldipine-HCl), indicating that CsA and these compounds interfere with the P glycoprotein function by different pharmacodynamic mechanisms.	Cyclosporine	38-41	ATP binding cassette subfamily B member 1	Homo sapiens	215-229
8167116-8	1994	Serum osteocalcin level was the only significant predictor of lumbar spine bone loss by multiple regression analysis that included age, corticosteroid dose, cyclosporine dose, lean body mass, and body mass index.	Cyclosporine	157-169	bone gamma-carboxyglutamate protein	Homo sapiens	6-17
7907333-12	1994	Results indicate that increased amounts of the P-glycoprotein--besides other, perhaps more important mechanisms that are as yet unknown--partially mediate CsA resistance in F4-6RADR-CsA cells.	Cyclosporine	155-158	ATP binding cassette subfamily B member 1	Homo sapiens	47-61
7907333-12	1994	Results indicate that increased amounts of the P-glycoprotein--besides other, perhaps more important mechanisms that are as yet unknown--partially mediate CsA resistance in F4-6RADR-CsA cells.	Cyclosporine	182-185	ATP binding cassette subfamily B member 1	Homo sapiens	47-61
8167386-0	1994	Effect of cyclosporine A on serum tumor necrosis factor alpha in new-onset type I (insulin-dependent) diabetes mellitus.	Cyclosporine	10-24	tumor necrosis factor	Homo sapiens	34-61
8167386-7	1994	At 1 month, the level of TNF alpha in the CyA group was significantly lower than that observed in the placebo group (22.3 +/- 7.2 versus 53.3 +/- 8.9 pg/mL (P &lt; .05).	Cyclosporine	42-45	tumor necrosis factor	Homo sapiens	25-34
8254211-9	1994	TTK expression was blocked by either cyclosporin A or FK520, which inhibit IL-2 production and could be recovered by the addition of exogenous IL-2.	Cyclosporine	37-50	interleukin 2	Homo sapiens	75-79
8254211-9	1994	TTK expression was blocked by either cyclosporin A or FK520, which inhibit IL-2 production and could be recovered by the addition of exogenous IL-2.	Cyclosporine	37-50	interleukin 2	Homo sapiens	143-147
7921820-1	1994	A total of 106 patients with lichen planus were examined for proliferative activity of peripheral blood lymphocytes and exogenous interleukin-2 effect on recovery of cyclosporin A suppressed proliferative response to mitogen.	Cyclosporine	166-179	interleukin 2	Homo sapiens	130-143
7538609-3	1994	P-glycoprotein also transports MDR modulators such as cyclosporin A, FK506, and calcium channel blockers.	Cyclosporine	54-67	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
8127004-3	1994	CsA effectively inhibited the PGE2 synthesis induced by inflammatory cytokines such as interleukin 1 (IL-1) or tumor necrosis alpha (TNF alpha).	Cyclosporine	0-3	tumor necrosis factor	Rattus norvegicus	133-142
8283927-17	1994	Cyclosporine raises LDL-c and lipoprotein(a).	Cyclosporine	0-12	component of oligomeric golgi complex 2	Homo sapiens	20-25
18476229-9	1994	Cyclosporin which is also a strong Ca(2+) chelating agent also inhibits the P-glycoprotein-mediated efflux of anthracycline.	Cyclosporine	0-11	ATP binding cassette subfamily B member 1	Homo sapiens	76-90
8186461-2	1994	The expression of GM-CSF and IL-2 is inhibited by immunosuppressive drugs such as cyclosporin A (CsA) and FK506.	Cyclosporine	82-95	interleukin 2	Homo sapiens	29-33
8186461-2	1994	The expression of GM-CSF and IL-2 is inhibited by immunosuppressive drugs such as cyclosporin A (CsA) and FK506.	Cyclosporine	97-100	interleukin 2	Homo sapiens	29-33
8302298-11	1994	The immunosuppressive drugs Cyclosporin A and FK506 completely blocked CD28 and CD3 mediated IL-2 production in these transfectants whereas rapamycin had only a partial inhibitory effect.	Cyclosporine	28-41	interleukin 2	Homo sapiens	93-97
7529381-0	1994	In-vitro effects of cyclosporin A, FK506, 6-mercaptopurine, and prednisolone on lymphokine-activated killer cells.	Cyclosporine	20-33	interleukin 2	Homo sapiens	80-90
7870353-4	1994	After CsA withdrawal the GFR increased, median from 74 ml min-1 to 90 ml min-1, (P &lt; 0.04).	Cyclosporine	6-9	CD59 molecule (CD59 blood group)	Homo sapiens	58-63
7870353-4	1994	After CsA withdrawal the GFR increased, median from 74 ml min-1 to 90 ml min-1, (P &lt; 0.04).	Cyclosporine	6-9	CD59 molecule (CD59 blood group)	Homo sapiens	73-78
7936019-9	1994	In conclusion, a switch from Cy to Az 1 year after renal transplantation results in a sustained rise in s-EPO which may in part represent a compensatory phenomenon to bone marrow suppression.	Cyclosporine	29-31	erythropoietin	Homo sapiens	106-109
18475583-0	1994	FK506 and Cyclosporin A Enhance IL-6 Production in Monocytes: A single-Cell Assay.	Cyclosporine	10-23	interleukin 6	Homo sapiens	32-36
18475583-1	1994	The effect of FK506 and cyclosporin A (CsA) on the production of interleukin 6 (IL-6) in adherent monocytes was studied at a single-cell level by the avidinbiotin- peroxidase complex methods.	Cyclosporine	24-37	interleukin 6	Homo sapiens	65-78
18475583-1	1994	The effect of FK506 and cyclosporin A (CsA) on the production of interleukin 6 (IL-6) in adherent monocytes was studied at a single-cell level by the avidinbiotin- peroxidase complex methods.	Cyclosporine	24-37	interleukin 6	Homo sapiens	80-84
8528889-6	1994	We hypothesized that cyclosporin might therefore inhibit IL-2-induced acute CRH release by blocking the dephosphorylation of NOS by calcineurin.	Cyclosporine	21-32	interleukin 2	Homo sapiens	57-61
8059062-11	1994	These alterations in MNL cannot be taken as a model of cellular function in the transplanted heart, but it is reasonable to suggest that elevations of cAMP formation in MNL may contribute to the immunosuppressive effects of the treatment with cyclosporine A or corticosteroids, the mechanism of which could be an alteration of Gs alpha or the catalyst in renal transplant recipients and the catalyst in heart transplant recipients which occurs without any changes of beta-adrenoceptors.	Cyclosporine	243-257	GNAS complex locus	Homo sapiens	327-335
22823114-9	1994	CsA blocks T helper cells through an inhibition of IL-2 gene activation.	Cyclosporine	0-3	interleukin-2	Oryctolagus cuniculus	51-55
7521743-9	1994	Surprisingly, clonal proliferation stimulated by monoclonal antibody against V beta 5 and V beta 11 TCRs was observed in CsA-treated, syngeneically reconstituted B10.BR mice but not in FK506-treated mice, suggesting that CsA may be more likely to induce autoreactivity.	Cyclosporine	121-124	granzyme C	Mus musculus	162-165
8310519-5	1994	The present study also shows that cipro supplemented with CsA and PHA resulted in significant higher concentrations of IL-2 (up to 60 times) and IFN-gamma (4.3 times) as compared with PHA and CsA alone.	Cyclosporine	58-61	interleukin 2	Homo sapiens	119-123
8310519-5	1994	The present study also shows that cipro supplemented with CsA and PHA resulted in significant higher concentrations of IL-2 (up to 60 times) and IFN-gamma (4.3 times) as compared with PHA and CsA alone.	Cyclosporine	58-61	interferon gamma	Homo sapiens	145-154
8310519-7	1994	In parallel, a greater amount of IL-2 and IFN-gamma mRNA was observed in lymphocytes incubated with both cipro and CsA as compared with CsA alone.	Cyclosporine	115-118	interleukin 2	Homo sapiens	33-37
8310519-7	1994	In parallel, a greater amount of IL-2 and IFN-gamma mRNA was observed in lymphocytes incubated with both cipro and CsA as compared with CsA alone.	Cyclosporine	115-118	interferon gamma	Homo sapiens	42-51
8310519-7	1994	In parallel, a greater amount of IL-2 and IFN-gamma mRNA was observed in lymphocytes incubated with both cipro and CsA as compared with CsA alone.	Cyclosporine	136-139	interleukin 2	Homo sapiens	33-37
8310519-7	1994	In parallel, a greater amount of IL-2 and IFN-gamma mRNA was observed in lymphocytes incubated with both cipro and CsA as compared with CsA alone.	Cyclosporine	136-139	interferon gamma	Homo sapiens	42-51
8310519-8	1994	Our results reveal that CsA-dependent inhibition of both IL-2 and IFN-gamma expression is counteracted by high concentrations of cipro.	Cyclosporine	24-27	interleukin 2	Homo sapiens	57-61
8310519-8	1994	Our results reveal that CsA-dependent inhibition of both IL-2 and IFN-gamma expression is counteracted by high concentrations of cipro.	Cyclosporine	24-27	interferon gamma	Homo sapiens	66-75
11271304-0	1994	FK 506 and cyclosporin each block antigen-induced T cell receptor signalling that is dependent on CD4 co-receptor and operates in the absence of detectable cytoplasmic calcium fluxes.	Cyclosporine	11-22	CD4 molecule	Homo sapiens	98-101
11271304-3	1994	Using 171, 171-CD4 (wild-type) and 171-CD4 (mutant), we found that IL-2 secretion was inhibited by FK 506 and cyclosporin but not by rapamycin.	Cyclosporine	110-121	CD4 molecule	Homo sapiens	15-18
11271304-3	1994	Using 171, 171-CD4 (wild-type) and 171-CD4 (mutant), we found that IL-2 secretion was inhibited by FK 506 and cyclosporin but not by rapamycin.	Cyclosporine	110-121	CD4 molecule	Homo sapiens	39-42
11271304-3	1994	Using 171, 171-CD4 (wild-type) and 171-CD4 (mutant), we found that IL-2 secretion was inhibited by FK 506 and cyclosporin but not by rapamycin.	Cyclosporine	110-121	interleukin 2	Homo sapiens	67-71
11271304-5	1994	Thus, although FK 506 and cyclosporin inhibited calcium-dependent signalling to the IL-2 promoter via inhibition of the protein phosphatase calcineurin, it is possible that IL-2 induction via TCR/CD4 requires an FK 506 (and cyclosporin) sensitive step which is independent of cytoplasmic calcium changes.	Cyclosporine	26-37	interleukin 2	Homo sapiens	84-88
11271305-0	1994	Effect of immunosuppressive agents FK 506 and cyclosporin and steroids on the expression of IL-6 and its receptor by stimulated lymphocytes and monocytes.	Cyclosporine	46-57	interleukin 6	Homo sapiens	92-96
11271305-5	1994	Dexamethazone, cyclosporin (CyA), and FK 506 at immunosuppressive concentrations induced a dose-dependent inhibition of IL-6 secretion from adherent monocytes (MO) stimulated with phytohemagglutinin (PHA).	Cyclosporine	15-26	interleukin 6	Homo sapiens	120-124
11271305-5	1994	Dexamethazone, cyclosporin (CyA), and FK 506 at immunosuppressive concentrations induced a dose-dependent inhibition of IL-6 secretion from adherent monocytes (MO) stimulated with phytohemagglutinin (PHA).	Cyclosporine	28-31	interleukin 6	Homo sapiens	120-124
7975651-2	1994	The investigations were carried out on the CFW mice infected with 200 Trichinella spiralis larvae and treated with Cyclosporine A to suppress TH1 lymphocytes.	Cyclosporine	115-129	negative elongation factor complex member C/D, Th1l	Mus musculus	142-145
7941591-5	1994	Resistance to cytostatic drugs due to the p-glycoprotein coded by the MDR-gene is treated by a combination of cyclosporin-A or verapamil and VAD.	Cyclosporine	110-123	ATP binding cassette subfamily B member 1	Homo sapiens	42-56
8119047-4	1993	Macrolides inhibit cytochrome P450IIIA4 (CYP3A4), which appears to be the most common metabolic enzyme in the human liver and is involved in the metabolism of many drugs, including cyclosporin, warfarin and terfenadine.	Cyclosporine	181-192	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-47
8265621-1	1993	Human cytochrome P450 3A4 is recognized as the catalyst for the oxygen-dependent metabolism of a diverse group of medically important chemicals, including the immunosuppressive agent cyclosporin; macrolide antibiotics, such as erythromycin; drugs such as benzphetamine, nifedipine, and cocaine; and steroids; such as cortisol and testosterone to name but a few.	Cyclosporine	183-194	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	6-25
8284217-2	1993	In T lymphoma cells, the activity of the Il-4 promoter/enhancer is stimulated by phorbol esters, Ca++ ionophores and agonists of protein kinase A and inhibited by low doses of the immunosuppressant cyclosporin A.	Cyclosporine	198-211	interleukin 4	Homo sapiens	41-45
8124053-6	1993	CIn and CPAH were significantly impaired in patients treated with CsA.	Cyclosporine	66-69	carboxypeptidase A6	Homo sapiens	8-12
8299242-0	1993	The effects of cyclosporin on renal microsomal cytochrome P-450 systems.	Cyclosporine	15-26	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	47-63
8258320-12	1993	Thus, inhibition of the activation and translocation of PKC-beta by CsA may result in inhibition of IL-2 gene expression in human lymphocytes.	Cyclosporine	68-71	interleukin 2	Homo sapiens	100-104
8299242-1	1993	The effect of CsA on the renal microsomal cytochrome P-450 system was examined by using two animal models.	Cyclosporine	14-17	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	42-58
8106868-1	1993	In a study of the effects on renal allograft survival of HLA mismatching, mismatching for cytomegalovirus (CMV) antibody status, and post-transplant CMV infection, 148 cyclosporin-treated renal transplant recipients were given kidneys optimally matched for HLA-A, -B, and -DR antigens but not matched for CMV antibody status.	Cyclosporine	168-179	major histocompatibility complex, class I, A	Homo sapiens	257-275
8258320-0	1993	Cyclosporin A inhibits T cell receptor-induced interleukin-2 synthesis of human T lymphocytes by selectively preventing a transmembrane signal transduction pathway leading to sustained activation of a protein kinase C isoenzyme, protein kinase C-beta.	Cyclosporine	0-13	interleukin 2	Homo sapiens	47-60
8258320-3	1993	This short term activation and translocation PKC-alpha proved to be cyclosporin A (CsA) insensitive.	Cyclosporine	68-81	protein kinase C alpha	Homo sapiens	45-54
8258320-7	1993	While interleukin-2 (IL-2) synthesis and cellular proliferation were completely inhibited by 200 ng/ml CsA in BMA 030- or BMA 031-stimulated cells, expression of high-affinity IL-2 receptors was not influenced by the immunosuppressive drug.	Cyclosporine	103-106	interleukin 2	Homo sapiens	6-19
8258320-7	1993	While interleukin-2 (IL-2) synthesis and cellular proliferation were completely inhibited by 200 ng/ml CsA in BMA 030- or BMA 031-stimulated cells, expression of high-affinity IL-2 receptors was not influenced by the immunosuppressive drug.	Cyclosporine	103-106	interleukin 2	Homo sapiens	21-25
8258320-7	1993	While interleukin-2 (IL-2) synthesis and cellular proliferation were completely inhibited by 200 ng/ml CsA in BMA 030- or BMA 031-stimulated cells, expression of high-affinity IL-2 receptors was not influenced by the immunosuppressive drug.	Cyclosporine	103-106	interleukin 2	Homo sapiens	176-180
8014003-3	1993	The factors involved in the inadequate Epo production in BMT are discussed, with particular attention to the role of the immunosuppressive drug cyclosporin-A, which has been shown to inhibit Epo production in both in vivo and in vitro models.	Cyclosporine	144-157	erythropoietin	Homo sapiens	191-194
7506454-3	1993	In the present study, we have compared the effects of CsA and FK506 on glucose-stimulated insulin release from the isolated dog pancreatic islets, which have been maintained in culture for 3 days after isolation.	Cyclosporine	54-57	insulin	Homo sapiens	90-97
8245502-6	1993	Significant reductions in both cytokine transcripts and in IL-1 beta immunoreactive protein were noted in the high expression subgroup after 1 week of cyclosporin A therapy, prior to detectable clinical improvement.	Cyclosporine	151-164	interleukin 1 beta	Homo sapiens	59-68
7506454-6	1993	CsA (100 nM), which is a therapeutically relevant concentration, significantly suppressed both the first and second phases of glucose-stimulated insulin release compared with 100 nM FK506.	Cyclosporine	0-3	insulin	Homo sapiens	145-152
8278994-1	1993	Perioperative donor spleen cells plus cyclosporine suppress IL-2 and interferon-gamma production.	Cyclosporine	38-50	interleukin 2	Homo sapiens	60-64
7693039-12	1993	In 8 of 8 P-170+ patients, intracellular daunorubicin accumulation in CD34+ AML blast cells was lower than in CD34- cells, and it increased after cyclosporin addition.	Cyclosporine	146-157	CD34 molecule	Homo sapiens	70-74
8278994-1	1993	Perioperative donor spleen cells plus cyclosporine suppress IL-2 and interferon-gamma production.	Cyclosporine	38-50	interferon gamma	Homo sapiens	69-85
8278994-8	1993	Analysis of sections of recipients" spleens showed that spleen cell/CsA therapy led to significant reductions versus untreated controls, in expression of IL-2, IFN-gamma, and IL-2R.	Cyclosporine	68-71	interleukin 2	Homo sapiens	154-158
8278994-8	1993	Analysis of sections of recipients" spleens showed that spleen cell/CsA therapy led to significant reductions versus untreated controls, in expression of IL-2, IFN-gamma, and IL-2R.	Cyclosporine	68-71	interferon gamma	Homo sapiens	160-169
7693814-5	1993	Basophil releasability in response to anti-IgE, FMLP, and A23187 was diminished by 20 to 60% throughout the course of CsA treatment.	Cyclosporine	118-121	formyl peptide receptor 1	Homo sapiens	48-52
7506668-0	1993	Cyclosporin derivatives inhibit interleukin 1 beta induction of nitric oxide synthase in renal mesangial cells.	Cyclosporine	0-11	interleukin 1 beta	Homo sapiens	32-50
7693814-7	1993	There was a significant correlation between plasma CsA and the decrease of histamine release induced by anti-IgE (rs = -0.66; p &lt; 0.0005), FMLP (rs = -0.59; p &lt; 0.001) and A23187 (rs = -0.68; p &lt; 0.0001).	Cyclosporine	51-54	formyl peptide receptor 1	Homo sapiens	142-146
7693814-9	1993	A rapid and significant reduction of histamine release induced by anti-IgE, FMLP, and A23187 paralleled a sharp increase of CsA plasma levels, which peaked at 5 h and lasted approximately 13 h. This study indicates that oral administration of CsA in normal subjects causes a rapid and significant inhibition of histamine release from basophils.	Cyclosporine	243-246	formyl peptide receptor 1	Homo sapiens	76-80
7506668-2	1993	Addition of cyclosporin A, cyclosporin G or cyclosporin H dose dependently inhibited interleukin 1 beta-induced nitrite generation.	Cyclosporine	12-25	interleukin 1 beta	Homo sapiens	85-103
7506668-4	1993	Time-course studies indicated that cyclosporin A could be added up to 6 h after the interleukin 1 beta stimulus and still caused maximal inhibition of nitrite production.	Cyclosporine	35-48	interleukin 1 beta	Homo sapiens	84-102
7506668-5	1993	Furthermore, interleukin 1 beta increased NO synthase mRNA levels in mesangial cells and this effect was potently suppressed by all three cyclosporin derivatives.	Cyclosporine	138-149	interleukin 1 beta	Homo sapiens	13-31
7507316-6	1993	For instance, CsA and FK 506 inhibit the transcription of IL-3, IL-4, IFN gamma, TNF alpha or GM-CSF by activated T cells, and rapamycin has been shown to block the response to various growth factors such as IL-3, IL-4 or IL-6.	Cyclosporine	14-17	interleukin 4	Homo sapiens	64-68
8241349-3	1993	Cyclosporin A (CyA) suppressed in vitro IL-2 production in one patient, but not in the other.	Cyclosporine	0-13	interleukin 2	Homo sapiens	40-44
7507316-6	1993	For instance, CsA and FK 506 inhibit the transcription of IL-3, IL-4, IFN gamma, TNF alpha or GM-CSF by activated T cells, and rapamycin has been shown to block the response to various growth factors such as IL-3, IL-4 or IL-6.	Cyclosporine	14-17	interferon gamma	Homo sapiens	70-79
7507316-6	1993	For instance, CsA and FK 506 inhibit the transcription of IL-3, IL-4, IFN gamma, TNF alpha or GM-CSF by activated T cells, and rapamycin has been shown to block the response to various growth factors such as IL-3, IL-4 or IL-6.	Cyclosporine	14-17	tumor necrosis factor	Homo sapiens	81-90
7507316-6	1993	For instance, CsA and FK 506 inhibit the transcription of IL-3, IL-4, IFN gamma, TNF alpha or GM-CSF by activated T cells, and rapamycin has been shown to block the response to various growth factors such as IL-3, IL-4 or IL-6.	Cyclosporine	14-17	interleukin 4	Homo sapiens	214-218
7507316-6	1993	For instance, CsA and FK 506 inhibit the transcription of IL-3, IL-4, IFN gamma, TNF alpha or GM-CSF by activated T cells, and rapamycin has been shown to block the response to various growth factors such as IL-3, IL-4 or IL-6.	Cyclosporine	14-17	interleukin 6	Homo sapiens	222-226
7693050-10	1993	The functional MDR1-protein against vincristine was also observed, and its function was inhibited by verapamile and Cyclosporin A.	Cyclosporine	116-129	ATP binding cassette subfamily B member 1	Homo sapiens	15-19
8261782-4	1993	Following treatment with topical cyclosporin, there was a significant reduction in the number of CD4+ cells in both the conjunctival epithelium and substantia propria.	Cyclosporine	33-44	CD4 molecule	Homo sapiens	97-100
8293761-0	1993	Calcium entry blockade may prevent cyclosporin A-induced hypersensitivity to angiotensin II and endothelial dysfunction in the rat aorta.	Cyclosporine	35-48	angiotensinogen	Rattus norvegicus	77-91
8293761-5	1993	Chronic treatment with diltiazem alone did not affect the responsiveness to any of the drugs tested, but the augmentation of contractions to angiotensin II (10(-9) to 10(-6) M) after treatment with cyclosporin, was prevented by co-treatment with diltiazem.	Cyclosporine	198-209	angiotensinogen	Rattus norvegicus	141-155
8112908-9	1993	In our opinion, the increase of atrial natriuretic peptide is a counterregulatory mechanism aimed to compensate the cyclosporine-mediated activation of the renin-angiotensin-aldosterone system.	Cyclosporine	116-128	renin	Homo sapiens	156-161
8228625-2	1993	A dramatic reduction in CCP-1 and CCP-2 gene expression and near absence of cytolytic activity was shown to occur in these cultures when the expression of IL-2 was inhibited by 10(-6) M cyclosporin A (CsA).	Cyclosporine	201-204	granzyme C	Mus musculus	34-39
8228625-5	1993	The expression of CCP-1 and CCP-2 gene products and the induction of MHC-unrestricted cytotoxic activity in anti-CD3-stimulated T cell cultures therefore occur independently of IL-2 synthesis but are regulated by a CsA-sensitive mechanism.	Cyclosporine	215-218	granzyme C	Mus musculus	28-33
8249125-0	1993	Cyclosporine and cremaphor modulate von Willebrand factor release from cultured human endothelial cells.	Cyclosporine	0-12	von Willebrand factor	Homo sapiens	36-57
8228802-5	1993	These IFN-gamma promoter constructs faithfully mirrored expression of the endogenous gene, in that expression required activation both with ionomycin and PMA, was inhibited by cyclosporin A, and was not observed in U937 or THP-1 cells.	Cyclosporine	176-189	interferon gamma	Homo sapiens	6-15
8235597-2	1993	The DNA-binding specificity of NFAT is conferred by NFATp, a phosphoprotein that is a target for the immunosuppressive compounds cyclosporin A and FK506.	Cyclosporine	129-142	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2	Mus musculus	31-35
8235597-2	1993	The DNA-binding specificity of NFAT is conferred by NFATp, a phosphoprotein that is a target for the immunosuppressive compounds cyclosporin A and FK506.	Cyclosporine	129-142	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2	Mus musculus	52-57
7694584-0	1993	Effect of dexamethasone, 6-mercaptopurine and cyclosporine A on intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression.	Cyclosporine	46-60	vascular cell adhesion molecule 1	Homo sapiens	102-135
7694584-4	1993	We found that dexamethasone (4-40 micrograms/mL), the azathioprine metabolite 6-mercaptopurine (10-100 micrograms/mL) and cyclosporine A (0.1-1 microgram/mL) have no effect on the basal and the tumor necrosis factor-alpha- or interleukin-1-stimulated expression of these adhesion molecules.	Cyclosporine	122-136	tumor necrosis factor	Homo sapiens	194-221
7911345-11	1993	Reversal compounds specifically inhibiting Pgp were found, such as verapamil, cyclosporin or quinidine.	Cyclosporine	78-89	ATP binding cassette subfamily B member 1	Homo sapiens	43-46
8281987-7	1993	In rats pretreated with cyclosporin A to suppress the immune system, the antinociceptive effect of TNF alpha was completely inhibited.	Cyclosporine	24-37	tumor necrosis factor	Rattus norvegicus	99-108
8280183-8	1993	Therapeutic agents used in post transplantation treatment such as glucocorticoids and/or cyclosporine may be speculated thus to affect both CETP and HL activities and, by arresting the HDL cycle in a CE-saturated state, do decrease the efficiency of reverse cholesterol extraction at the site of the graft.	Cyclosporine	89-101	cholesteryl ester transfer protein	Homo sapiens	140-144
8406372-0	1993	Endothelins 1 and 3: potent cholestatic agents secreted and excreted by the liver that interact with cyclosporine.	Cyclosporine	101-113	endothelin 1	Rattus norvegicus	0-19
8217446-12	1993	DISCUSSION: The low plasma concentrations of VIP in the patients with heart transplants could be the result of the lack of contribution by the cardiac VIPergic fibres, a reduction of VIP release by the pharmacologically suppressed immune system, the inhibitory effects of cyclosporin on neural function and humoral secretions, and the effects of negative feedback on VIP release of high concentrations of atrial natriuretic peptide.	Cyclosporine	272-283	vasoactive intestinal peptide	Homo sapiens	45-48
8282598-11	1993	The addition of cyclophilin resulted in an increase in the ACE-independent rate constant, an effect that was reversed by the cyclophilin inhibitor cyclosporin A.	Cyclosporine	147-160	angiotensin I converting enzyme	Homo sapiens	59-62
8268127-6	1993	Induction of cyclins D2 and D3 was independent of the cyclosporin A-sensitive calcineurin pathway and of rapamycin-sensitive pathways, despite the ability of rapamycin to severely inhibit entry into S phase.	Cyclosporine	54-67	cyclin D2	Homo sapiens	13-30
8376940-0	1993	Identification of a novel cyclosporin-sensitive element in the human tumor necrosis factor alpha gene promoter.	Cyclosporine	26-37	tumor necrosis factor	Homo sapiens	69-96
8408638-2	1993	Cyclosporine A (CsA) nephrotoxicity is characterized by preglomerular vasoconstriction and decreased efferent arteriolar tone probably related to reduced NO and angiotensin II, respectively.	Cyclosporine	0-14	angiotensinogen	Rattus norvegicus	161-175
8408638-2	1993	Cyclosporine A (CsA) nephrotoxicity is characterized by preglomerular vasoconstriction and decreased efferent arteriolar tone probably related to reduced NO and angiotensin II, respectively.	Cyclosporine	16-19	angiotensinogen	Rattus norvegicus	161-175
8376940-4	1993	We have identified a human TNF-alpha promoter element, kappa 3, which plays a key role in the calcium-mediated inducibility and CsA sensitivity of the gene.	Cyclosporine	128-131	tumor necrosis factor	Homo sapiens	27-36
8376940-7	1993	Induction of the inducible nuclear complexes is rapid, independent of protein synthesis, and blocked by CsA, and thus, exactly parallels the induction of TNF-alpha mRNA by TCR ligands or by calcium ionophore.	Cyclosporine	104-107	tumor necrosis factor	Homo sapiens	154-163
8376940-9	1993	Thus, the TNF-alpha gene is an immediate early gene in activated T cells and provides a new model system in which to study CsA-sensitive gene induction in activated T cells.	Cyclosporine	123-126	tumor necrosis factor	Homo sapiens	10-19
7692641-6	1993	CsA upregulated cell proliferation when it was added in the second culture period in the presence or in the absence of rIL-6, whereas rapamycin had no effect in these cases.	Cyclosporine	0-3	interleukin 6	Rattus norvegicus	119-124
8413248-1	1993	The 40-kDa nuclear protein Tax encoded by human T-cell leukemia virus type I (HTLV-I) can transcriptionally activate the interleukin 2 (IL-2) enhancer even in the presence of the immunosuppressant cyclosporin A, which inhibits the activation of the IL-2 enhancer by T-cell mitogens.	Cyclosporine	197-210	interleukin 2	Homo sapiens	136-140
8413248-1	1993	The 40-kDa nuclear protein Tax encoded by human T-cell leukemia virus type I (HTLV-I) can transcriptionally activate the interleukin 2 (IL-2) enhancer even in the presence of the immunosuppressant cyclosporin A, which inhibits the activation of the IL-2 enhancer by T-cell mitogens.	Cyclosporine	197-210	interleukin 2	Homo sapiens	249-253
8413248-5	1993	In addition, this site is responsible for the cyclosporin A-resistant expression of the IL-2 enhancer in the presence of Tax.	Cyclosporine	46-59	interleukin 2	Homo sapiens	88-92
8212211-10	1993	However, patients with long-term grafts (&gt; 60 days) showed an exaggerated response to CsA, with a fractional increase in plasma ET-1 of 3.67 +/- 0.52 (n = 8) compared with 2.16 +/- 0.28 (n = 10) for patients with more recent grafts (P &lt; 0.05).	Cyclosporine	89-92	endothelin 1	Homo sapiens	131-135
8105571-4	1993	Removal of Thy1+ cells from BM before reconstitution of an inducible strain, C3H/HeN, exacerbated SGVHD when compared with animals given whole BM cells before CsA treatment.	Cyclosporine	159-162	thymus cell antigen 1, theta	Mus musculus	11-15
8212211-0	1993	Cyclosporine-induced elevation in circulating endothelin-1 in patients with solid-organ transplants.	Cyclosporine	0-12	endothelin 1	Homo sapiens	46-58
8397339-2	1993	NFAT, a DNA-binding protein required for interleukin-2 gene transcription, is a potential target for calcineurin, cyclosporin A and FK506.	Cyclosporine	114-127	interleukin 2	Homo sapiens	41-54
8212211-2	1993	Recent data from animal experiments suggest that alterations in renal function induced by high-dose CsA may be mediated by endothelin-1 (ET-1), a potent endothelium-derived vasoconstrictor and mitogenic peptide.	Cyclosporine	100-103	endothelin 1	Homo sapiens	123-135
8212211-2	1993	Recent data from animal experiments suggest that alterations in renal function induced by high-dose CsA may be mediated by endothelin-1 (ET-1), a potent endothelium-derived vasoconstrictor and mitogenic peptide.	Cyclosporine	100-103	endothelin 1	Homo sapiens	137-141
8212211-3	1993	The aim of the present study was to determine the effect of oral CsA on circulating levels of ET-1 in patients receiving standard immunosuppressive therapy following solid-organ transplantation (13 renal, 7 heart, 1 heart-lung, 1 liver).	Cyclosporine	65-68	endothelin 1	Homo sapiens	94-98
8212211-8	1993	In contrast, in the CsA-treated group there was a significant increase in plasma ET-1, reaching a peak at 6 hr (2.45 +/- 0.56 pg/ml, P &lt; 0.03) that followed the peak increase in CsA parent compound and preceded the peak increase in metabolites.	Cyclosporine	20-23	endothelin 1	Homo sapiens	81-85
8212211-8	1993	In contrast, in the CsA-treated group there was a significant increase in plasma ET-1, reaching a peak at 6 hr (2.45 +/- 0.56 pg/ml, P &lt; 0.03) that followed the peak increase in CsA parent compound and preceded the peak increase in metabolites.	Cyclosporine	181-184	endothelin 1	Homo sapiens	81-85
8212211-11	1993	Therefore, oral administration of CsA causes an increase in circulating ET-1 in patients with solid-organ transplants that might contribute to CsA-associated nephrotoxicity and hypertension, particularly during long-term immunosuppressive therapy.	Cyclosporine	34-37	endothelin 1	Homo sapiens	72-76
8212211-11	1993	Therefore, oral administration of CsA causes an increase in circulating ET-1 in patients with solid-organ transplants that might contribute to CsA-associated nephrotoxicity and hypertension, particularly during long-term immunosuppressive therapy.	Cyclosporine	143-146	endothelin 1	Homo sapiens	72-76
8212212-0	1993	Cyclosporine-induced stimulation of the renin-angiotensin system after liver and heart transplantation.	Cyclosporine	0-12	renin	Homo sapiens	40-45
8212212-1	1993	To analyze the status of the renin-angiotensin system in hypertensive transplant recipients on cyclosporine, we prospectively explored 21 cardiac (CTR: 52 +/- 8.2 yr) and 12 liver (LTR: 45 +/- 10 yr) transplant recipients on a normal salt diet with 19 normotensive controls in the same age range.	Cyclosporine	95-107	renin	Homo sapiens	29-34
8221359-22	1993	However, known interactions of cyclosporine with vascular smooth muscle and endothelial cells leading to increased sensitivity to vasopressor hormones and increased circulating levels of endothelin appear as the most likely explanation for the chronic elevation of ANF plasma levels.	Cyclosporine	31-43	natriuretic peptide A	Homo sapiens	265-268
7690250-6	1993	Transport of P-glycoprotein antagonists in SW620 Ad300 cells was also affected by calphostin C. Cyclosporin A transport decreased, while verapamil transport increased.	Cyclosporine	96-109	ATP binding cassette subfamily B member 1	Homo sapiens	13-27
7690250-7	1993	Cyclosporin A in calphostin C-treated cells resulted in additive P-glycoprotein antagonism, while no additive effect could be demonstrated with verapamil, suggesting that the increase in verapamil transport makes it a poorer P-glycoprotein antagonist.	Cyclosporine	0-13	ATP binding cassette subfamily B member 1	Homo sapiens	65-79
7690250-7	1993	Cyclosporin A in calphostin C-treated cells resulted in additive P-glycoprotein antagonism, while no additive effect could be demonstrated with verapamil, suggesting that the increase in verapamil transport makes it a poorer P-glycoprotein antagonist.	Cyclosporine	0-13	ATP binding cassette subfamily B member 1	Homo sapiens	225-239
8221359-23	1993	In this context, ANF may play a key role in moderating the side effects of cyclosporine treatment.	Cyclosporine	75-87	natriuretic peptide A	Homo sapiens	17-20
8103797-3	1993	Cyclosporin A inhibited the transepithelial transport of digoxin mediated by human P-glycoprotein; net basal-to-apical transport across the cell monolayer was 22.8, 21.2, 6.61 and 0.91 pmol/mg of protein/3 hr in the presence of 0, 1, 5 and 10 microM cyclosporin A, respectively.	Cyclosporine	0-13	ATP binding cassette subfamily B member 1	Homo sapiens	83-97
8102639-18	1993	CONCLUSION: High doses of CsA, which achieve blood concentrations capable of reversing P-glycoprotein-mediated anthracycline resistance in vitro, can be incorporated into induction regimens with acceptable nonhematologic toxicity.	Cyclosporine	26-29	ATP binding cassette subfamily B member 1	Homo sapiens	87-101
7689606-9	1993	Treatment of T cells with cyclosporin A or a protein tyrosine kinase inhibitor herbimycin A inhibited ICAM-1 or VCAM-1-promoted activation-induced T cell death.	Cyclosporine	26-39	vascular cell adhesion molecule 1	Homo sapiens	112-118
8103797-3	1993	Cyclosporin A inhibited the transepithelial transport of digoxin mediated by human P-glycoprotein; net basal-to-apical transport across the cell monolayer was 22.8, 21.2, 6.61 and 0.91 pmol/mg of protein/3 hr in the presence of 0, 1, 5 and 10 microM cyclosporin A, respectively.	Cyclosporine	250-263	ATP binding cassette subfamily B member 1	Homo sapiens	83-97
8356404-0	1993	Up-regulation by cyclosporine (CsA) of the in vitro release of soluble CD23 (sCD23) and of the in vitro production of IL-6 and IgM.	Cyclosporine	17-29	interleukin 6	Homo sapiens	118-122
8356404-0	1993	Up-regulation by cyclosporine (CsA) of the in vitro release of soluble CD23 (sCD23) and of the in vitro production of IL-6 and IgM.	Cyclosporine	31-34	interleukin 6	Homo sapiens	118-122
8356404-4	1993	CsA down-regulated the IL-2/IL-6-induced proliferative responses of pre-activated B cells by at least 50%, but it up-regulated IgM production in the same experiments.	Cyclosporine	0-3	interleukin 2	Homo sapiens	23-27
8105569-3	1993	The pathways are differentially susceptible to cyclosporine in vitro, with the CD4+ T helper cell and selfAPC (CD4 approximately sAPC) pathway being the most sensitive.	Cyclosporine	47-59	CD4 molecule	Homo sapiens	79-82
8105569-3	1993	The pathways are differentially susceptible to cyclosporine in vitro, with the CD4+ T helper cell and selfAPC (CD4 approximately sAPC) pathway being the most sensitive.	Cyclosporine	47-59	CD4 molecule	Homo sapiens	111-114
8356404-4	1993	CsA down-regulated the IL-2/IL-6-induced proliferative responses of pre-activated B cells by at least 50%, but it up-regulated IgM production in the same experiments.	Cyclosporine	0-3	interleukin 6	Homo sapiens	28-32
8356404-7	1993	Finally, CsA was shown to inhibit PHA-induced cell proliferation of PBMC and to up-regulate IL-6 production in the same cultures.	Cyclosporine	9-12	interleukin 6	Homo sapiens	92-96
8356404-9	1993	This finding, in combination with the CsA-induced up-regulation of lectin-induced IL-6 production, may have clinical implications in disease states with an ongoing immune activation, where prolonged administration of CsA might be anticipated.	Cyclosporine	38-41	interleukin 6	Homo sapiens	82-86
8356404-9	1993	This finding, in combination with the CsA-induced up-regulation of lectin-induced IL-6 production, may have clinical implications in disease states with an ongoing immune activation, where prolonged administration of CsA might be anticipated.	Cyclosporine	217-220	interleukin 6	Homo sapiens	82-86
8342895-9	1993	In addition, CSR-CSA cycle length correlated with LECT (r = 0.939, p &lt; 0.001).	Cyclosporine	17-20	C-X-C motif chemokine ligand 8	Homo sapiens	50-54
8102154-6	1993	The production of IFN-gamma by IL-12-stimulated neonatal T cells is associated with a small but significant T cell activation evidenced by DNA synthesis and by the expression of the activation markers CD25, CD71, and HLA-DR; moreover, it is inhibited by hydrocortisone, cyclosporin A, and transforming growth factor-beta.	Cyclosporine	270-283	interferon gamma	Homo sapiens	18-27
8348265-4	1993	Cyclosporine A (CsA) markedly reduced the AA-induced increase in IL-6 mRNA.	Cyclosporine	0-14	interleukin 6	Rattus norvegicus	65-69
8348265-4	1993	Cyclosporine A (CsA) markedly reduced the AA-induced increase in IL-6 mRNA.	Cyclosporine	16-19	interleukin 6	Rattus norvegicus	65-69
7691894-7	1993	Staining for CD18 on large epidermal dendritic cells was reduced after cyclosporin (p &lt; 0.02).	Cyclosporine	71-82	integrin subunit beta 2	Homo sapiens	13-17
8393357-1	1993	There is evidence that the inadequate erythropoietin (Epo) production observed in patients undergoing allogeneic bone marrow transplantation (BMT) might be ascribed to an inhibitory effect caused by the immunosuppressive drug cyclosporin A (CsA).	Cyclosporine	241-244	erythropoietin	Homo sapiens	54-57
8393357-2	1993	In this in vitro study, we have evaluated the effects of CsA on the release of Epo in the culture medium by the human Hep3B hepatoma cell line.	Cyclosporine	57-60	erythropoietin	Homo sapiens	79-82
8393357-3	1993	In cultures incubated with both CsA and the nonimmunosuppressive CsA analog MeAla-6, but not with the CsA-unrelated immunosuppressive agent FK-506, the levels of Epo in the medium were significantly reduced in comparison with controls, at concentrations (0.01 to 1.6 mumol/L) not affecting total protein synthetic rate nor the constitutive secretion of alpha-fetoprotein.	Cyclosporine	32-35	erythropoietin	Homo sapiens	162-165
8393357-5	1993	CsA did not affect the expression of the Epo gene, as judged by Northern blot analysis, but caused a significant amount of Epo to remain unsecreted within the cells; almost all (97% of total) of the intracellular Epo was associated with the plasma membrane subcellular fraction.	Cyclosporine	0-3	erythropoietin	Homo sapiens	123-126
8393357-5	1993	CsA did not affect the expression of the Epo gene, as judged by Northern blot analysis, but caused a significant amount of Epo to remain unsecreted within the cells; almost all (97% of total) of the intracellular Epo was associated with the plasma membrane subcellular fraction.	Cyclosporine	0-3	erythropoietin	Homo sapiens	123-126
8393357-6	1993	We conclude that: (1) CsA is able to inhibit Epo release in vitro by Hep3B cells, further supporting the hypothesis that the drug might have a role in the inappropriately low Epo levels observed in BMT patients; (2) the inhibitory effect appears to be specific and not caused by a general impairment of protein synthesis and/or secretion; and (3) the reduced Epo levels found in the medium of CsA-treated Hep3B cultures are supposed to be the consequence of an inability of the cells to correctly process Epo molecules for the secretory pathway.	Cyclosporine	22-25	erythropoietin	Homo sapiens	45-48
8393357-6	1993	We conclude that: (1) CsA is able to inhibit Epo release in vitro by Hep3B cells, further supporting the hypothesis that the drug might have a role in the inappropriately low Epo levels observed in BMT patients; (2) the inhibitory effect appears to be specific and not caused by a general impairment of protein synthesis and/or secretion; and (3) the reduced Epo levels found in the medium of CsA-treated Hep3B cultures are supposed to be the consequence of an inability of the cells to correctly process Epo molecules for the secretory pathway.	Cyclosporine	22-25	erythropoietin	Homo sapiens	175-178
8393357-6	1993	We conclude that: (1) CsA is able to inhibit Epo release in vitro by Hep3B cells, further supporting the hypothesis that the drug might have a role in the inappropriately low Epo levels observed in BMT patients; (2) the inhibitory effect appears to be specific and not caused by a general impairment of protein synthesis and/or secretion; and (3) the reduced Epo levels found in the medium of CsA-treated Hep3B cultures are supposed to be the consequence of an inability of the cells to correctly process Epo molecules for the secretory pathway.	Cyclosporine	22-25	erythropoietin	Homo sapiens	175-178
8393357-6	1993	We conclude that: (1) CsA is able to inhibit Epo release in vitro by Hep3B cells, further supporting the hypothesis that the drug might have a role in the inappropriately low Epo levels observed in BMT patients; (2) the inhibitory effect appears to be specific and not caused by a general impairment of protein synthesis and/or secretion; and (3) the reduced Epo levels found in the medium of CsA-treated Hep3B cultures are supposed to be the consequence of an inability of the cells to correctly process Epo molecules for the secretory pathway.	Cyclosporine	22-25	erythropoietin	Homo sapiens	175-178
8377379-0	1993	CsA, FK506, corticosteroids and rapamycin inhibit TNF alpha production by cultured PTEC.	Cyclosporine	0-3	tumor necrosis factor	Homo sapiens	50-59
8377379-4	1993	The presence of cyclosporin A (CsA) during stimulation with IL-1 alpha inhibited the enhanced TNF alpha production in a dose dependent fashion, with a maximal inhibition of 90% at a concentration of 250 ng/ml.	Cyclosporine	31-34	tumor necrosis factor	Homo sapiens	94-103
7691894-8	1993	The expression of CD18 by large epidermal dendritic cells during treatment correlated strongly with the PASI score at that time and one month after stopping cyclosporin (p &lt; 0.02).	Cyclosporine	157-168	integrin subunit beta 2	Homo sapiens	18-22
8342150-0	1993	Acute cyclosporine-induced renal vasoconstriction is mediated by endothelin-1.	Cyclosporine	6-18	endothelin 1	Rattus norvegicus	65-77
8411796-11	1993	When cyclosporine A is used in combination with prednisone, the immunologic cycle that causes rejection is interrupted twice by virtue of the fact that prednisone prevents the production of IL-1 by macrophages and cyclosporine A with the production of lymphokines, especially IL-2 (T-cell growth factor).	Cyclosporine	5-19	interleukin 2	Homo sapiens	276-280
8342150-2	1993	Plasma levels of the vasoconstrictor peptide endothelin-1 are increased after cyclosporine administration, and endothelin-1 has been shown to cause renal vasoconstriction.	Cyclosporine	78-90	endothelin 1	Rattus norvegicus	45-57
8342150-3	1993	In this study we used in vivo microscopy to investigate the role of endothelin-1 in cyclosporine-induced vasoconstriction.	Cyclosporine	84-96	endothelin 1	Rattus norvegicus	68-80
8342150-12	1993	CONCLUSIONS: The acute renal vasoconstriction induced by cyclosporine is mediated by endothelin-1.	Cyclosporine	57-69	endothelin 1	Rattus norvegicus	85-97
8335896-9	1993	Control animals treated with cyclosporin A showed a similar pattern at day 6 with regard to TGF-beta expression.	Cyclosporine	29-42	transforming growth factor, beta 1	Rattus norvegicus	92-100
8335913-2	1993	NF-AT is thought to consist of two components: a ubiquitous, inducible nuclear component that we have identified as Fos and Jun proteins, and a preexisting, T cell-specific component (NF-ATp) which is the target for the immunosuppressive agents cyclosporin A (CsA) and FK506.	Cyclosporine	245-258	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2	Mus musculus	0-5
8335913-5	1993	Moreover we present evidence that the component that forms the faster-migrating ("lower") nuclear NF-AT complex is derived by a calcium-dependent, cyclosporin-sensitive, posttranslational modification of NF-ATp, and that Fos and Jun proteins stabilize its interaction with DNA.	Cyclosporine	147-158	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2	Mus musculus	204-210
8335913-2	1993	NF-AT is thought to consist of two components: a ubiquitous, inducible nuclear component that we have identified as Fos and Jun proteins, and a preexisting, T cell-specific component (NF-ATp) which is the target for the immunosuppressive agents cyclosporin A (CsA) and FK506.	Cyclosporine	260-263	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2	Mus musculus	0-5
8335913-5	1993	Moreover we present evidence that the component that forms the faster-migrating ("lower") nuclear NF-AT complex is derived by a calcium-dependent, cyclosporin-sensitive, posttranslational modification of NF-ATp, and that Fos and Jun proteins stabilize its interaction with DNA.	Cyclosporine	147-158	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2	Mus musculus	98-103
8335079-6	1993	Furthermore, native IL-8 was found to specifically bind CsA, whereas biologically inactive analogs of CsA were not bound by IL-8.	Cyclosporine	56-59	C-X-C motif chemokine ligand 8	Homo sapiens	20-24
8335079-7	1993	Putative binding sites for CsA on IL-8 could be identified on the basis of structural similarities between IL-8 and cyclophilin.	Cyclosporine	27-30	C-X-C motif chemokine ligand 8	Homo sapiens	34-38
8335079-7	1993	Putative binding sites for CsA on IL-8 could be identified on the basis of structural similarities between IL-8 and cyclophilin.	Cyclosporine	27-30	C-X-C motif chemokine ligand 8	Homo sapiens	107-111
8335079-9	1993	We conclude that the specific binding of CsA to IL-8 may explain some of the anti-inflammatory effects of CsA.	Cyclosporine	41-44	C-X-C motif chemokine ligand 8	Homo sapiens	48-52
8335079-9	1993	We conclude that the specific binding of CsA to IL-8 may explain some of the anti-inflammatory effects of CsA.	Cyclosporine	106-109	C-X-C motif chemokine ligand 8	Homo sapiens	48-52
8222724-7	1993	Intramuscular injection of cyclosporine A significantly reduced the protein extravasation associated with IL-2 injection, but cyclosporine had no effect on inflammation secondary to an intravitreal injection of interleukin-1.	Cyclosporine	27-41	interleukin 2	Homo sapiens	106-110
8222724-7	1993	Intramuscular injection of cyclosporine A significantly reduced the protein extravasation associated with IL-2 injection, but cyclosporine had no effect on inflammation secondary to an intravitreal injection of interleukin-1.	Cyclosporine	27-39	interleukin 2	Homo sapiens	106-110
8325338-6	1993	Apoptosis could also be prevented by cyclosporin A (CsA) treatment and could be re-induced by the addition of IFN-gamma to CsA-treated cells.	Cyclosporine	123-126	interferon gamma	Homo sapiens	110-119
8359107-9	1993	CONCLUSIONS: In this patient, an early start of cyclosporin therapy probably contributed to the maintenance of endogenous insulin secretion, and insulin sensitivity was high because of physical training.	Cyclosporine	48-59	insulin	Homo sapiens	122-129
8500270-0	1993	In vivo and in vitro suppression of T-cell receptor alpha/beta CD4- CD8- T lymphocytes by cyclosporine A.	Cyclosporine	90-104	CD4 molecule	Homo sapiens	63-66
8410056-0	1993	Serum prolactin levels in active multiple sclerosis and during cyclosporin treatment.	Cyclosporine	63-74	prolactin	Homo sapiens	6-15
8410056-6	1993	Acute cyclosporin A (CsA) administration increases circulating prolactin levels in animals and might paradoxically augment some immune reactions.	Cyclosporine	21-24	prolactin	Homo sapiens	63-72
7689806-4	1993	We analyzed the relationship between cyclophilin-binding and immunosuppressive activity (e.g., effect on IL-2 transcription) of cyclosporin derivatives in vitro.	Cyclosporine	128-139	interleukin 2	Homo sapiens	105-109
7689806-9	1993	In the nucleus, CsA interferes with the DNA-binding of inducible transcription factors to their respective DNA motifs within lymphokine promoters by affecting intracellular translocation of transcription factor subunits.	Cyclosporine	16-19	interleukin 2	Homo sapiens	125-135
8515077-5	1993	Lesions with both Th1 and Th2 cells contained a predominant neutrophilic infiltrate at 6 h, and mainly mononuclear cells at 48 h. The inflammatory response with Th2 was blocked by cyclosporin A, by mAb to IL-4 or by soluble rIL-4R.	Cyclosporine	180-193	negative elongation factor complex member C/D, Th1l	Mus musculus	18-21
8500271-8	1993	In contrast to phorbol ester, the induction of IL-2 transcription and cell proliferation in competent cells by soluble mAbs BMA 031 (anti-alpha/beta T-cell receptor) or OKT3 (anti-CD3) was inhibited by cyclosporin A (CsA).	Cyclosporine	217-220	interleukin 2	Homo sapiens	47-51
8500271-10	1993	Alternatively, the data may indicate involvement of different regulatory elements with different sensitivities to CsA for the induction of IL-2 transcription by phorbol ester or antibodies to the CD3-TCR complex.	Cyclosporine	114-117	interleukin 2	Homo sapiens	139-143
8500270-6	1993	CsA also inhibited the cytolytic activity and cytokine production of in vitro cultured TCR alpha/beta+ CD4- CD8- cell lines.	Cyclosporine	0-3	CD4 molecule	Homo sapiens	103-106
8500270-7	1993	Our data suggest that alleviation of the patient"s clinical symptoms resulted from cyclosporine-mediated suppression of proliferation, cytotoxicity, and inflammatory cytokine production of TCR alpha/beta+ CD4- CD8- T lymphocytes in vivo.	Cyclosporine	83-95	CD4 molecule	Homo sapiens	205-208
7691501-2	1993	Cyclosporin is a lipophilic cyclic polypeptide which produces calcium-dependent, specific, reversible inhibition of transcription of interleukin-2 and several other cytokines, most notably in T helper lymphocytes.	Cyclosporine	0-11	interleukin 2	Homo sapiens	133-146
8325202-0	1993	Hypersensitivity to insulin during remissions in cyclosporin-treated IDDM patients.	Cyclosporine	49-60	insulin	Homo sapiens	20-27
7684344-12	1993	Cyclosporin use was associated with a significant decrease in CD45RA antigen density on both CD4+ and CD8+ T-cells.	Cyclosporine	0-11	CD4 molecule	Homo sapiens	62-65
8325202-8	1993	CONCLUSIONS: Cyclosporin A-associated remissions represent an original situation that associates euglycemia with the persistence of low endogenous insulin secretion.	Cyclosporine	13-26	insulin	Homo sapiens	147-154
8325202-9	1993	Cyclosporin A by itself had no influence on sensitivity to insulin, but allowed the reappearance of some insulin secretory capacity that contributed, with the improvement of insulin sensitivity, to the development of the diabetes honeymoon.	Cyclosporine	0-13	insulin	Homo sapiens	105-112
8325202-9	1993	Cyclosporin A by itself had no influence on sensitivity to insulin, but allowed the reappearance of some insulin secretory capacity that contributed, with the improvement of insulin sensitivity, to the development of the diabetes honeymoon.	Cyclosporine	0-13	insulin	Homo sapiens	105-112
8366291-0	1993	Cyclosporin A inhibits nitric oxide production by L929 cells in response to tumor necrosis factor and interferon-gamma.	Cyclosporine	0-13	tumor necrosis factor	Mus musculus	76-97
8366291-0	1993	Cyclosporin A inhibits nitric oxide production by L929 cells in response to tumor necrosis factor and interferon-gamma.	Cyclosporine	0-13	interferon gamma	Mus musculus	102-118
8515659-11	1993	Cyclosporin A has been reported to inhibit secretion of TNF.	Cyclosporine	0-13	tumor necrosis factor	Homo sapiens	56-59
8501418-2	1993	OBJECTIVES: To explore the possible pathogenetic role of erythropoietin (EPO) in the anaemia associated with cyclosporin (Cs) in newly diagnosed patients with insulin-dependent diabetes mellitus (IDDM).	Cyclosporine	109-120	erythropoietin	Homo sapiens	57-71
8501418-2	1993	OBJECTIVES: To explore the possible pathogenetic role of erythropoietin (EPO) in the anaemia associated with cyclosporin (Cs) in newly diagnosed patients with insulin-dependent diabetes mellitus (IDDM).	Cyclosporine	109-120	erythropoietin	Homo sapiens	73-76
8501418-2	1993	OBJECTIVES: To explore the possible pathogenetic role of erythropoietin (EPO) in the anaemia associated with cyclosporin (Cs) in newly diagnosed patients with insulin-dependent diabetes mellitus (IDDM).	Cyclosporine	122-124	erythropoietin	Homo sapiens	57-71
8501418-2	1993	OBJECTIVES: To explore the possible pathogenetic role of erythropoietin (EPO) in the anaemia associated with cyclosporin (Cs) in newly diagnosed patients with insulin-dependent diabetes mellitus (IDDM).	Cyclosporine	122-124	erythropoietin	Homo sapiens	73-76
8515659-12	1993	LPS-stimulated cells treated with cyclosporin A showed no decrease in TNF staining by either flow cytometry analysis or immunohistochemistry, but there was a reduction of TNF in the culture supernatant.	Cyclosporine	34-47	tumor necrosis factor	Homo sapiens	171-174
8322134-8	1993	Inhibition of IFN-alpha (IFN-alpha) synthesizing capacity may be part of the immunosuppression mechanism of action of cyclosporine in patients undergoing transplant.	Cyclosporine	118-130	interferon alpha 1	Homo sapiens	14-23
8278650-4	1993	We have shown that the costimulating activity of interstitial ECM proteins (collagen type I, fibronectin) is abolished in renal allograft recipients treated with cyclosporin A (CsA) but not azathioprine.	Cyclosporine	162-175	fibronectin 1	Homo sapiens	93-104
8278650-4	1993	We have shown that the costimulating activity of interstitial ECM proteins (collagen type I, fibronectin) is abolished in renal allograft recipients treated with cyclosporin A (CsA) but not azathioprine.	Cyclosporine	177-180	fibronectin 1	Homo sapiens	93-104
8322134-8	1993	Inhibition of IFN-alpha (IFN-alpha) synthesizing capacity may be part of the immunosuppression mechanism of action of cyclosporine in patients undergoing transplant.	Cyclosporine	118-130	interferon alpha 1	Homo sapiens	25-34
8097750-4	1993	Such an effect is IL-2-dependent, as shown by IL-2 production induced by anti-CD44 mAb and by complete inhibition of cell proliferation in the presence of anti-IL-2 antibodies or cyclosporin A.	Cyclosporine	179-192	interleukin 2	Homo sapiens	18-22
7685949-0	1993	Effect of FK 506 and cyclosporine on the expression of IL-6 and its receptor on stimulated monocytes.	Cyclosporine	21-33	interleukin 6	Homo sapiens	55-59
8390735-5	1993	Leflunomide partially inhibited IL-2 production of T cells stimulated with anti-CD3 plus PMA or anti-CD28 plus PMA, whereas CsA completely inhibited IL-2 production by T cells stimulated by the CD3 pathway and only partially inhibited IL-2 production by T cells stimulated by the CD28 pathway.	Cyclosporine	124-127	interleukin 2	Homo sapiens	149-153
8390735-5	1993	Leflunomide partially inhibited IL-2 production of T cells stimulated with anti-CD3 plus PMA or anti-CD28 plus PMA, whereas CsA completely inhibited IL-2 production by T cells stimulated by the CD3 pathway and only partially inhibited IL-2 production by T cells stimulated by the CD28 pathway.	Cyclosporine	124-127	interleukin 2	Homo sapiens	149-153
8390735-6	1993	Because comparable levels of IL-2 were produced by CD28-stimulated T cells treated with either CsA or leflunomide, but no inhibition of proliferation was observed in the CsA-treated cultures, we hypothesized that the lowering of IL-2 levels was not the mechanism by which leflunomide inhibited T cell proliferation.	Cyclosporine	95-98	interleukin 2	Homo sapiens	29-33
8482837-6	1993	Cyclosporin A and protein synthesis inhibitors block TNF-alpha secretion, but have no effect on slow lysis mediated by the CTL.	Cyclosporine	0-13	tumor necrosis factor	Homo sapiens	53-62
8387097-11	1993	Our results show that 1) CsH is a more potent formyl peptide receptor antagonist than BocPLPLP; 2) unlike BocPLPLP, CsH is selective; and 3) N-methyl-D-valine which is present at position 11 of the amino acid sequence of CsH but not of other Cs is crucial for FMLP antagonism.	Cyclosporine	25-27	formyl peptide receptor 1	Homo sapiens	260-264
8453556-1	1993	BACKGROUND: Cyclosporine (cyclosporin A, CSA) prolongs the survival of transplanted organs by reducing the transcription of cytokines, especially interleukin-2, that are thought to mediate T-cell expansion and subsequent graft rejection.	Cyclosporine	12-24	interleukin 2	Homo sapiens	146-159
8512668-1	1993	The aim of this study was to investigate the expression of endothelin-1 (ET-1) in the mesenteric arteries of cyclosporine-induced hypertensive rats.	Cyclosporine	109-121	endothelin 1	Rattus norvegicus	59-71
8512668-1	1993	The aim of this study was to investigate the expression of endothelin-1 (ET-1) in the mesenteric arteries of cyclosporine-induced hypertensive rats.	Cyclosporine	109-121	endothelin 1	Rattus norvegicus	73-77
8512668-3	1993	The concentration of ET-1 messenger RNA in the mesenteric arteries of cyclosporine-treated rats (25 mg/kg/day for 6 weeks) was significantly greater than in control rats (P &lt; .05).	Cyclosporine	70-82	endothelin 1	Rattus norvegicus	21-25
8512668-4	1993	We propose that cyclosporine-induced hypertension may be due to an increased synthesis of ET-1 in the resistant vessels.	Cyclosporine	16-28	endothelin 1	Rattus norvegicus	90-94
8484104-1	1993	Trauma and infection activated a murine mucosal IL-6 response in different ways: the IL-6 response to bacteria was sensitive to Cyclosporin A (CsA); the IL-6 response to trauma was not.	Cyclosporine	143-146	interleukin 6	Mus musculus	48-52
8484104-1	1993	Trauma and infection activated a murine mucosal IL-6 response in different ways: the IL-6 response to bacteria was sensitive to Cyclosporin A (CsA); the IL-6 response to trauma was not.	Cyclosporine	143-146	interleukin 6	Mus musculus	85-89
8484104-1	1993	Trauma and infection activated a murine mucosal IL-6 response in different ways: the IL-6 response to bacteria was sensitive to Cyclosporin A (CsA); the IL-6 response to trauma was not.	Cyclosporine	143-146	interleukin 6	Mus musculus	85-89
8484104-2	1993	The aim of the present study was to identify possible activators of the CsA-insensitive IL-6 secretion at the epithelial cell level.	Cyclosporine	72-75	interleukin 6	Mus musculus	88-92
8484104-9	1993	By contrast, the IL-6 response to E. coli Hu734 and TNF-alpha was inhibited by CsA.	Cyclosporine	79-82	interleukin 6	Mus musculus	17-21
8484104-10	1993	These results demonstrated that the inhibitory effect of CsA depends on the stimulus triggering the IL-6 response.	Cyclosporine	57-60	interleukin 6	Mus musculus	100-104
8473282-0	1993	Calcium-dependent cyclosporin A-sensitive activation of the interleukin-2 promoter by p56lck.	Cyclosporine	18-31	interleukin 2	Homo sapiens	60-73
7682237-5	1993	At optimal concentrations of immobilized anti-CD3, the addition of anti-CD28 did not further enhance the generation of CTL activity, but under these conditions generation of CTL activity was almost completely resistant to cyclosporin A (CsA) as a result of CsA-resistant IL-2 production.	Cyclosporine	237-240	interleukin 2	Homo sapiens	271-275
8453556-1	1993	BACKGROUND: Cyclosporine (cyclosporin A, CSA) prolongs the survival of transplanted organs by reducing the transcription of cytokines, especially interleukin-2, that are thought to mediate T-cell expansion and subsequent graft rejection.	Cyclosporine	26-39	interleukin 2	Homo sapiens	146-159
8340231-1	1993	We have developed a rapid (24 hours) quantitative PCR assay to measure the direct effect of cyclosporine on IL-2 mRNA production by activated PBMC cultures from renal transplant patients.	Cyclosporine	92-104	interleukin 2	Homo sapiens	108-112
8458381-4	1993	Furthermore, eosinophil production of IL-8 in the presence of calcium ionophore could be inhibited with the immunomodulating agent cyclosporin A and the protein synthesis inhibitor cycloheximide.	Cyclosporine	131-144	C-X-C motif chemokine ligand 8	Homo sapiens	38-42
8340231-6	1993	Increasing in vitro concentrations of CsA in this group resulted in lower IL-2 mRNA levels and a shift in the peak time to 12-24 hours.	Cyclosporine	38-41	interleukin 2	Homo sapiens	74-78
8340231-8	1993	However, some correlation was found between CsA blood levels and IL-2 mRNA levels.	Cyclosporine	44-47	interleukin 2	Homo sapiens	65-69
8473495-2	1993	We asked whether dexamethasone (Dex) and cyclosporin A (CsA) inhibit IL-2 gene transcription by interfering with the activity of nuclear proteins that bind to the IL-2 promoter.	Cyclosporine	56-59	interleukin 2	Homo sapiens	69-73
8470252-0	1993	Role of cytochrome P-450 in modulating cyclosporine levels in transplant patients.	Cyclosporine	39-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-24
8473495-2	1993	We asked whether dexamethasone (Dex) and cyclosporin A (CsA) inhibit IL-2 gene transcription by interfering with the activity of nuclear proteins that bind to the IL-2 promoter.	Cyclosporine	56-59	interleukin 2	Homo sapiens	163-167
8473495-4	1993	Both Dex and CsA inhibited the binding of transcription factors AP-1 and NF-AT, but not of NF-kB and OCT-1/OAF, to their corresponding sites on the IL-2 gene promoter.	Cyclosporine	13-16	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	64-68
8473495-4	1993	Both Dex and CsA inhibited the binding of transcription factors AP-1 and NF-AT, but not of NF-kB and OCT-1/OAF, to their corresponding sites on the IL-2 gene promoter.	Cyclosporine	13-16	interleukin 2	Homo sapiens	148-152
8473495-8	1993	In contrast, CsA inhibited the IL-2 promoter and the NF-AT, but not the AP-1 and NF-kB plasmids.	Cyclosporine	13-16	interleukin 2	Homo sapiens	31-35
8473495-9	1993	These results suggest that in human T lymphocytes both Dex and CsA inhibited IL-2 gene transcription through interference with transcription factors AP-1 and NF-AT.	Cyclosporine	63-66	interleukin 2	Homo sapiens	77-81
8473495-9	1993	These results suggest that in human T lymphocytes both Dex and CsA inhibited IL-2 gene transcription through interference with transcription factors AP-1 and NF-AT.	Cyclosporine	63-66	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	149-153
8331921-1	1993	Endothelin-1 (ET) is a recently discovered vasoconstrictor peptide which is released by renal vascular endothelial cells in response to a number of pathologic insults including ischemia, endotoxemia, bacteremia, and cyclosporine nephrotoxicity.	Cyclosporine	216-228	endothelin 1	Rattus norvegicus	0-12
8331921-1	1993	Endothelin-1 (ET) is a recently discovered vasoconstrictor peptide which is released by renal vascular endothelial cells in response to a number of pathologic insults including ischemia, endotoxemia, bacteremia, and cyclosporine nephrotoxicity.	Cyclosporine	216-228	endothelin 1	Rattus norvegicus	14-16
7681059-0	1993	Human P-glycoprotein transports cyclosporin A and FK506.	Cyclosporine	32-45	ATP binding cassette subfamily B member 1	Homo sapiens	6-20
7681059-3	1993	Cyclosporin A itself interacts with a common binding site of P-glycoprotein to which Vinca alkaloids and verapamil bind.	Cyclosporine	0-13	ATP binding cassette subfamily B member 1	Homo sapiens	61-75
7681059-4	1993	We were interested to determine whether cyclosporin A and FK506 are substrates for P-glycoprotein to transport, and we studied their transcellular transport.	Cyclosporine	40-53	ATP binding cassette subfamily B member 1	Homo sapiens	83-97
7681059-10	1993	These results indicate that P-glycoprotein transports the immunosuppressive agents cyclosporin A and FK506.	Cyclosporine	83-96	ATP binding cassette subfamily B member 1	Homo sapiens	28-42
8467877-0	1993	Cyclosporine A induces endothelin-1 release from cultured rat vascular smooth muscle cells.	Cyclosporine	0-14	endothelin 1	Rattus norvegicus	23-35
8467877-1	1993	Since vascular smooth muscle cells in culture are capable of secreting endothelin-1 (ET-1), we investigated the effect of cyclosporine A on ET-1 release from rat vascular smooth muscle cells.	Cyclosporine	122-136	endothelin 1	Rattus norvegicus	140-144
8467877-2	1993	Cyclosporine A 10 microM significantly (P &lt; 0.05) enhanced the secretion of ET-1 at 2, 8, 24 and 48 h (6.5 +/- 0.5, 11 +/- 0.7, 19 +/- 0.5, 37 +/- 1.6 fmol/10(6) cells, respectively) compared with vehicle (4.7 +/- 0.3, 8.1 +/- 0.6, 15 +/- 0.4, 27 +/- 2.0 fmol/10(6) cells, respectively).	Cyclosporine	0-14	endothelin 1	Rattus norvegicus	79-83
8467877-3	1993	The cyclosporine-induced synthesis of ET-1 by vascular smooth muscle cell may participate in the pathogenesis of cyclosporine-induced vasoconstriction and vasculopathy via an autocrine regulatory mechanism.	Cyclosporine	4-16	endothelin 1	Rattus norvegicus	38-42
8467877-3	1993	The cyclosporine-induced synthesis of ET-1 by vascular smooth muscle cell may participate in the pathogenesis of cyclosporine-induced vasoconstriction and vasculopathy via an autocrine regulatory mechanism.	Cyclosporine	113-125	endothelin 1	Rattus norvegicus	38-42
8460159-5	1993	Three of these AP1 elements lie within sequences that also associate with factors resembling the CsA-sensitive, T cell-specific transcription factor NFAT.	Cyclosporine	97-100	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	15-18
8213352-6	1993	The effects of three anti-inflammatory or immunosuppressive drugs, prednisolone, indomethacin and cyclosporin A, on IL-1 beta and PGE2 production in zymosan and Bordetella-pertussis-vaccine (BPV)-challenged tissue chambers were also examined.	Cyclosporine	98-111	interleukin 1 beta	Mus musculus	116-125
8213352-7	1993	Oral treatment with prednisolone and cyclosporin A of zymosan-challenged animals showed a dose-dependent reduction of IL-1 beta concentrations, but no effect of indomethacin.	Cyclosporine	37-50	interleukin 1 beta	Mus musculus	118-127
8213352-9	1993	In drug-treated BPV-challenged animals, prednisolone and cyclosporin A also showed a dose-dependent reduction of IL-1 beta, while indomethacin was again ineffective.	Cyclosporine	57-70	interleukin 1 beta	Mus musculus	113-122
8455360-0	1993	Effect of CsA on the expression of renin and angiotensin type 1 receptor genes in the rat kidney.	Cyclosporine	10-13	ATPase H+ transporting accessory protein 2	Rattus norvegicus	35-72
8100456-5	1993	The receptivity to the epithelial cell-derived cytokine IL-7, associated either with antigen-dependent or independent triggering, was almost similarly inhibited by cyclosporin A, forskolin or PKC inhibitor, in sharp contrast to IL-2 receptivity.	Cyclosporine	164-177	interleukin 7	Homo sapiens	56-60
8100456-5	1993	The receptivity to the epithelial cell-derived cytokine IL-7, associated either with antigen-dependent or independent triggering, was almost similarly inhibited by cyclosporin A, forskolin or PKC inhibitor, in sharp contrast to IL-2 receptivity.	Cyclosporine	164-177	interleukin 2	Homo sapiens	228-232
8382312-7	1993	Consistent with this hypothesis is the observation that tax-mediated activation of IL-2 gene expression is resistant to the immunosuppressive affects of cyclosporin A, a property postulated for the CD28RC binding complex.	Cyclosporine	153-166	interleukin 2	Homo sapiens	83-87
8441422-5	1993	The induction of NFAT-1 binding activity can be inhibited by cyclosporin A, potentially accounting for the ability of cyclosporin A to inhibit IL-2 production by T cells.	Cyclosporine	61-74	interleukin 2	Homo sapiens	143-147
8441422-5	1993	The induction of NFAT-1 binding activity can be inhibited by cyclosporin A, potentially accounting for the ability of cyclosporin A to inhibit IL-2 production by T cells.	Cyclosporine	118-131	interleukin 2	Homo sapiens	143-147
8397460-15	1993	In summary, the combination of tamoxifen and cyclosporin A at the concentrations normally seen after clinical administration of these modulators showed significant synergism on the sensitivity to doxorubicin in both low and high MDR1 expressor HCC lines.	Cyclosporine	45-58	ATP binding cassette subfamily B member 1	Homo sapiens	229-233
8382693-9	1993	Cyclosporin A blocked the induction of both cyclin D2 and D3.	Cyclosporine	0-13	cyclin D2	Homo sapiens	44-53
7678867-0	1993	Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance.	Cyclosporine	40-52	mitogen-activated protein kinase kinase kinase 20	Homo sapiens	96-99
7678867-10	1993	Studies of the effect of MRK-16 on cellular accumulation of cyclosporine and verapamil revealed that MRK-16 substantially increased accumulation of cyclosporine in K562/ADM cells, but did not increase accumulation of verapamil.	Cyclosporine	60-72	mitogen-activated protein kinase kinase kinase 20	Homo sapiens	101-104
7678867-10	1993	Studies of the effect of MRK-16 on cellular accumulation of cyclosporine and verapamil revealed that MRK-16 substantially increased accumulation of cyclosporine in K562/ADM cells, but did not increase accumulation of verapamil.	Cyclosporine	148-160	mitogen-activated protein kinase kinase kinase 20	Homo sapiens	101-104
7678867-11	1993	CONCLUSIONS: MRK-16 and cyclosporine synergistically enhanced the antitumor effects of vincristine and doxorubicin because MRK-16 increased cellular accumulation of cyclosporine.	Cyclosporine	165-177	mitogen-activated protein kinase kinase kinase 20	Homo sapiens	13-16
7678867-11	1993	CONCLUSIONS: MRK-16 and cyclosporine synergistically enhanced the antitumor effects of vincristine and doxorubicin because MRK-16 increased cellular accumulation of cyclosporine.	Cyclosporine	165-177	mitogen-activated protein kinase kinase kinase 20	Homo sapiens	123-126
7678867-12	1993	IMPLICATIONS: These results, together with our previous finding that intravenous administration of MRK-16 induced regression of multidrug-resistant subcutaneous tumors in athymic mice, support the hypothesis that the combined use of MRK-16 and cyclosporine might increase the efficacy of antitumor agents against multidrug-resistant tumors expressing P-glycoprotein.	Cyclosporine	244-256	mitogen-activated protein kinase kinase kinase 20	Homo sapiens	99-102
8094079-1	1993	We observed increased levels of mdr-1 mRNA and its protein product P-glycoprotein (Pgp) in the human colon carcinoma cell line, LS 180, and its drug-resistant sublines, LS 180-Ad50 and LS 180-Vb2, after treatment with the Pgp antagonists, verapamil, nifedipine, and cyclosporin A.	Cyclosporine	266-279	ATP binding cassette subfamily B member 1	Homo sapiens	32-37
8094079-1	1993	We observed increased levels of mdr-1 mRNA and its protein product P-glycoprotein (Pgp) in the human colon carcinoma cell line, LS 180, and its drug-resistant sublines, LS 180-Ad50 and LS 180-Vb2, after treatment with the Pgp antagonists, verapamil, nifedipine, and cyclosporin A.	Cyclosporine	266-279	ATP binding cassette subfamily B member 1	Homo sapiens	83-86
8381345-0	1993	Immediate early genes of cytomegalovirus antagonize the inhibitory effects of cyclosporin A on interleukin-2 gene transcription.	Cyclosporine	78-91	interleukin 2	Homo sapiens	95-108
8428779-7	1993	However, in the presence of cyclosporine, the angiotensin II (10(-8) M)-stimulated rise of [Ca2+]i was increased from 296 +/- 22 to 460 +/- 47 nM (p &lt; 0.001).	Cyclosporine	28-40	angiotensinogen	Rattus norvegicus	46-60
8461628-6	1993	In the presence of cyclosporine (10 micrograms/ml), the Ca(2+)-mobilizing effects of angiotensin II (10(-8)M) in smooth muscle cells and of arginine vasopressin (AVP) in mesangial cells were significantly enhanced.	Cyclosporine	19-31	angiotensinogen	Homo sapiens	85-99
8428779-8	1993	ANP (5 x 10(-9) M) blocked the Ca2+ mobilization by angiotensin II (71 +/- 7 versus 69 +/- 7 nM, NS) and also completely inhibited the effect of angiotensin II in the presence of cyclosporine (77 +/- 5 versus 78 +/- 5 nM, NS).	Cyclosporine	179-191	angiotensinogen	Rattus norvegicus	145-159
8428779-9	1993	Basal efflux as well as angiotensin II-stimulated 45Ca2+ efflux were not altered by preincubation with cyclosporine, indicating that the effect of cyclosporine on [Ca2+]i was not due to an inhibition of 45Ca2+ efflux.	Cyclosporine	147-159	angiotensinogen	Rattus norvegicus	24-38
8423336-5	1993	This agent is known to induce IFN-gamma expression in both spleen and kidney in a T cell-independent, cyclosporine-sensitive manner.	Cyclosporine	102-114	interferon gamma	Mus musculus	30-39
8315882-0	1993	[A ciclosporin A responsive case of Behcet"s disease associated with IgA nephropathy].	Cyclosporine	3-16	CD79a molecule	Homo sapiens	69-72
8456418-5	1993	Cyclosporin effectively inhibits the production of interleukin-2 and influences selectively the action of the T lymphocytes.	Cyclosporine	0-11	interleukin 2	Homo sapiens	51-64
8426125-1	1993	We investigated the in vivo effects of cyclosporin A (CsA) on the production of interleukin (IL) 10, a cytokine with major immunosuppressive properties.	Cyclosporine	54-57	interleukin 10	Mus musculus	80-99
8426125-5	1993	Pretreatment with CsA (total dose: 50 mg/kg) before injection of 145-2C11 mAb completely prevented the release of IL-10 in serum as well as IL-10 mRNA accumulation in spleen cells.	Cyclosporine	18-21	interleukin 10	Mus musculus	114-119
8426125-5	1993	Pretreatment with CsA (total dose: 50 mg/kg) before injection of 145-2C11 mAb completely prevented the release of IL-10 in serum as well as IL-10 mRNA accumulation in spleen cells.	Cyclosporine	18-21	interleukin 10	Mus musculus	140-145
8426125-6	1993	In contrast, CsA markedly enhanced LPS-induced IL-10 release (IL-10 serum levels at 6 h: 8.31 +/- 0.43 vs. 0.71 +/- 0.15 U/ml in mice pretreated with CsA vehicle-control, p &lt; 0.001), as well as IL-10 mRNA accumulation in spleen.	Cyclosporine	13-16	interleukin 10	Mus musculus	47-52
8426125-6	1993	In contrast, CsA markedly enhanced LPS-induced IL-10 release (IL-10 serum levels at 6 h: 8.31 +/- 0.43 vs. 0.71 +/- 0.15 U/ml in mice pretreated with CsA vehicle-control, p &lt; 0.001), as well as IL-10 mRNA accumulation in spleen.	Cyclosporine	13-16	interleukin 10	Mus musculus	62-67
8426125-6	1993	In contrast, CsA markedly enhanced LPS-induced IL-10 release (IL-10 serum levels at 6 h: 8.31 +/- 0.43 vs. 0.71 +/- 0.15 U/ml in mice pretreated with CsA vehicle-control, p &lt; 0.001), as well as IL-10 mRNA accumulation in spleen.	Cyclosporine	13-16	interleukin 10	Mus musculus	62-67
8426125-7	1993	We conclude that CsA differentially affects IL-10 production in vivo depending on the nature of the eliciting agent.	Cyclosporine	17-20	interleukin 10	Mus musculus	44-49
8492414-1	1993	Ciclosporine (CS) caused rapid improvement of anemia and increase of CD 4/8 ratio in two patients with pure red cell aplasia (PRCA).	Cyclosporine	0-12	CD4 molecule	Homo sapiens	69-73
8492414-1	1993	Ciclosporine (CS) caused rapid improvement of anemia and increase of CD 4/8 ratio in two patients with pure red cell aplasia (PRCA).	Cyclosporine	14-16	CD4 molecule	Homo sapiens	69-73
8492414-5	1993	CS seems to inhibit the production of cytokines such as IL-2 and IFN-gamma, and it damages the activated suppressor/cytotoxic T cells.	Cyclosporine	0-2	interleukin 2	Homo sapiens	56-60
8492414-5	1993	CS seems to inhibit the production of cytokines such as IL-2 and IFN-gamma, and it damages the activated suppressor/cytotoxic T cells.	Cyclosporine	0-2	interferon gamma	Homo sapiens	65-74
8421989-3	1993	In the present study, we tested whether immunoreactive endothelin-1 could be detected by radioimmunoassay in the plasma of cardiac transplant recipients and if levels correlated with hemodynamic characteristics, cyclosporine level, or renal function as assessed by serum creatinine.	Cyclosporine	212-224	endothelin 1	Homo sapiens	55-67
8434390-2	1993	CD4+ cells from CsA-treated DA rats with long-surviving PVG heart allografts specifically suppress the capacity of naive CD4+ cells to restore allograft rejection in irradiated DA rats, but have normal donor-specific alloreactivity in MLC.	Cyclosporine	16-19	modulator of VRAC current 1	Homo sapiens	235-238
8419467-12	1993	Cyclosporin A blocked induction of IFN-gamma in a dose dependent manner, but failed to significantly inhibit TNF-alpha mRNA or protein expression.	Cyclosporine	0-13	interferon gamma	Mus musculus	35-44
8421500-2	1993	The cyclosporin A/cyclophilin complex inhibits the calcium- and calmodulin-dependent phosphatase, calcineurin, resulting in a failure to activate genes encoding interleukin-2 and other lymphokines.	Cyclosporine	4-17	interleukin 2	Homo sapiens	161-174
8273597-5	1993	IL-2 transcription was greatly inhibited by 1 microM CsA, whereas neither 10 microM rolipram nor 10 microM CI-930 had any effect on steady-state levels of IL-2 mRNA.	Cyclosporine	53-56	interleukin 2	Homo sapiens	0-4
8421501-2	1993	CsA prevents T-cell proliferation by blocking the calcium-activated pathway leading to interleukin-2 transcription.	Cyclosporine	0-3	interleukin 2	Homo sapiens	87-100
7511004-11	1993	Flow cytometric analysis of peripheral blood cells prior to treatment with Cyclosporin-A showed systemic activation of lymphocytes, with high levels of HLA-DR and CD25 expression and a raised CD4/CD8 ratio.	Cyclosporine	75-88	CD4 molecule	Homo sapiens	192-195
8099844-5	1993	P-Glycoprotein inhibitors such as quinidine, verapamil, vincristine, and cyclosporine increased the net A-B flux and inhibited the total B-A flux without affecting the nonspecific flux significantly.	Cyclosporine	73-85	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
8281528-5	1993	), sodium excretion was significantly increased during therapy with lisinopril but only slightly during nitrendipine, indicating that angiotensin-converting enzyme inhibition may improve the sodium-retaining state of heart transplant recipients associated with ciclosporin A.	Cyclosporine	261-274	angiotensin I converting enzyme	Homo sapiens	134-163
22358667-2	1993	Such effect is IL2-dependent, as shown by IL2 production induced by anti-CD44 mAb and by inhibition of cell proliferation in the presence of anti-IL2 antibodies or cyclosporin A (CsA).	Cyclosporine	164-177	interleukin 2	Homo sapiens	15-18
22358667-2	1993	Such effect is IL2-dependent, as shown by IL2 production induced by anti-CD44 mAb and by inhibition of cell proliferation in the presence of anti-IL2 antibodies or cyclosporin A (CsA).	Cyclosporine	179-182	interleukin 2	Homo sapiens	15-18
7763733-2	1993	Such effect is IL2-dependent, as shown by IL2 production induced by anti-CD44 mAb and by inhibition of cell proliferation in the presence of anti-IL2 antibodies or cyclosporin A (CsA).	Cyclosporine	164-177	interleukin 2	Homo sapiens	15-18
7763733-2	1993	Such effect is IL2-dependent, as shown by IL2 production induced by anti-CD44 mAb and by inhibition of cell proliferation in the presence of anti-IL2 antibodies or cyclosporin A (CsA).	Cyclosporine	179-182	interleukin 2	Homo sapiens	15-18
7683610-6	1993	In contrast, and unlike FK-506, CSA caused mesangiolysis (IC50 = 4.5 micrograms.ml-1) and concentration dependently inhibited the interleukin-1 beta (IL-1 beta) stimulated mesangial cell release of TXB2 at nanomolar doses (IC50 = 50 ng.ml-1).	Cyclosporine	32-35	interleukin 1 beta	Rattus norvegicus	130-148
7729184-8	1993	With cyclosporine immunosuppression, hepatocyte survived 12 days and showed OTC activity.	Cyclosporine	5-17	ornithine transcarbamylase	Mus musculus	76-79
7683610-6	1993	In contrast, and unlike FK-506, CSA caused mesangiolysis (IC50 = 4.5 micrograms.ml-1) and concentration dependently inhibited the interleukin-1 beta (IL-1 beta) stimulated mesangial cell release of TXB2 at nanomolar doses (IC50 = 50 ng.ml-1).	Cyclosporine	32-35	interleukin 1 beta	Rattus norvegicus	150-159
7683610-7	1993	In kinetic experiments (6-48 h), CSA 1 ng.ml-1 partially and 1 microgram.ml-1 completely abolished the IL-1 beta augmented mesangial secretion TXB2 at all the time points tested.	Cyclosporine	33-36	interleukin 1 beta	Rattus norvegicus	103-112
7678228-4	1993	In the present report we describe the effects of three immunosuppressive drugs, cyclosporin A (CsA), FK 506, and mycalamide A on mB7-mediated T cell activation.	Cyclosporine	95-98	CD52 antigen	Mus musculus	129-132
7678228-5	1993	The immunophilin ligands CsA and FK 506 block activation of murine CD4+ T cells by the combination of anti-CD3 mAb and CHO-mB7 cells but do not affect activation by CHO-mB7 cells and PMA.	Cyclosporine	25-28	CD52 antigen	Mus musculus	123-126
7678231-7	1993	In this study, the effect of the potent immunosuppressive agents cyclosporin A and FK506 on the activation-induced responsiveness to IL-7-driven proliferation and the concomitant changes in receptor structure have been investigated.	Cyclosporine	65-78	interleukin 7	Homo sapiens	133-137
7678231-15	1993	These observations also have important implications for reported cyclosporin A effects on the thymus where IL-7 can act as a growth factor for thymocytes.	Cyclosporine	65-78	interleukin 7	Homo sapiens	107-111
8320080-9	1993	CsA, on the other hand, inhibited the binding of PE-IL-2 to all stimulant-activated PBMC and had only a slight inhibitory effect on the in vitro release of sIL-2R.	Cyclosporine	0-3	interleukin 2	Homo sapiens	52-56
8419191-4	1993	Cyclosporin A, phorbol esters added at the time of activation, and cAMP agonists all block activation of B cells through membrane immunoglobulin at concentrations at least 100-fold lower than those necessary to block B cell activation by contact with activated Th1 or Th2 helper T cells.	Cyclosporine	0-13	negative elongation factor complex member C/D, Th1l	Mus musculus	261-264
8382242-0	1993	Effects of the blockade of the renin-angiotensin system in cyclosporin-induced hypertension.	Cyclosporine	59-70	renin	Homo sapiens	31-36
8443122-1	1993	Few known genes (IL-2, members of the IL-8 family, interferon-gamma) are induced in T cells only through the combined effect of phorbol myristic acetate (PMA) and a Ca(2+)-ionophore, and expression of only these genes can be fully suppressed by Cyclosporin A (CyA).	Cyclosporine	245-258	C-X-C motif chemokine ligand 8	Homo sapiens	38-42
8443122-1	1993	Few known genes (IL-2, members of the IL-8 family, interferon-gamma) are induced in T cells only through the combined effect of phorbol myristic acetate (PMA) and a Ca(2+)-ionophore, and expression of only these genes can be fully suppressed by Cyclosporin A (CyA).	Cyclosporine	245-258	interferon gamma	Homo sapiens	51-67
8443122-1	1993	Few known genes (IL-2, members of the IL-8 family, interferon-gamma) are induced in T cells only through the combined effect of phorbol myristic acetate (PMA) and a Ca(2+)-ionophore, and expression of only these genes can be fully suppressed by Cyclosporin A (CyA).	Cyclosporine	260-263	C-X-C motif chemokine ligand 8	Homo sapiens	38-42
8443122-1	1993	Few known genes (IL-2, members of the IL-8 family, interferon-gamma) are induced in T cells only through the combined effect of phorbol myristic acetate (PMA) and a Ca(2+)-ionophore, and expression of only these genes can be fully suppressed by Cyclosporin A (CyA).	Cyclosporine	260-263	interferon gamma	Homo sapiens	51-67
8101524-12	1993	The in vitro and in vivo data together suggest that the chemosensitization by CsA is mediated by Pgp.	Cyclosporine	78-81	phosphoglycolate phosphatase	Rattus norvegicus	97-100
8272218-13	1993	The circulating concentration of angiotensin II was significantly less on cyclosporin and nifedipine than on cyclosporin alone (P &lt; 0.05; Student"s t test).	Cyclosporine	74-85	angiotensinogen	Homo sapiens	33-47
8355560-5	1993	Plasma levels of urea, aspartate aminotransferase (AST) and glucose were significantly higher in the cyclosporin A-treated group than the control group.	Cyclosporine	101-114	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	23-49
8355560-5	1993	Plasma levels of urea, aspartate aminotransferase (AST) and glucose were significantly higher in the cyclosporin A-treated group than the control group.	Cyclosporine	101-114	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	51-54
8272218-13	1993	The circulating concentration of angiotensin II was significantly less on cyclosporin and nifedipine than on cyclosporin alone (P &lt; 0.05; Student"s t test).	Cyclosporine	109-120	angiotensinogen	Homo sapiens	33-47
8289993-5	1993	When compared with PAN rats, CS-treated PAN rats had significantly less proteinuria and higher activities of glomerular SOD and CAT (p &lt; 0.01 and p &lt; 0.05, respectively).	Cyclosporine	29-31	catalase	Rattus norvegicus	128-131
7678356-3	1993	It has been shown previously, for example, that cyclosporine may inhibit insulin release from islet tumor cells and rat islets.	Cyclosporine	48-60	insulin	Homo sapiens	73-80
7678356-5	1993	L-683,590 and cyclosporine inhibited insulin release by beta TC3 cells by about 50% and 80%, respectively, at doses that inhibit lymphokine production by T cells.	Cyclosporine	14-26	insulin	Homo sapiens	37-44
7678356-9	1993	Both drugs caused reduced levels of insulin mRNA (by 56 +/- 8.1% and 66 +/- 16% in the presence of L-683,590 and cyclosporine, respectively), accounting for reduced rates of insulin biosynthesis that were also seen.	Cyclosporine	113-125	insulin	Homo sapiens	36-43
7678356-9	1993	Both drugs caused reduced levels of insulin mRNA (by 56 +/- 8.1% and 66 +/- 16% in the presence of L-683,590 and cyclosporine, respectively), accounting for reduced rates of insulin biosynthesis that were also seen.	Cyclosporine	113-125	insulin	Homo sapiens	174-181
7678356-10	1993	Our studies indicate that: (1) both cyclosporine and L-683,590 inhibit insulin release by beta TC3 cells and cultured rat islets after 48 hr (cyclosporine is a more potent inhibitor); (2) neither drug inhibits the release of insulin during the first 4 hr following a glucose stimulus; and (3) their mechanisms of action appear to be similar--both drugs cause reduced levels of insulin mRNA.	Cyclosporine	36-48	insulin	Homo sapiens	71-78
7678356-10	1993	Our studies indicate that: (1) both cyclosporine and L-683,590 inhibit insulin release by beta TC3 cells and cultured rat islets after 48 hr (cyclosporine is a more potent inhibitor); (2) neither drug inhibits the release of insulin during the first 4 hr following a glucose stimulus; and (3) their mechanisms of action appear to be similar--both drugs cause reduced levels of insulin mRNA.	Cyclosporine	36-48	insulin	Homo sapiens	225-232
7678356-10	1993	Our studies indicate that: (1) both cyclosporine and L-683,590 inhibit insulin release by beta TC3 cells and cultured rat islets after 48 hr (cyclosporine is a more potent inhibitor); (2) neither drug inhibits the release of insulin during the first 4 hr following a glucose stimulus; and (3) their mechanisms of action appear to be similar--both drugs cause reduced levels of insulin mRNA.	Cyclosporine	36-48	insulin	Homo sapiens	225-232
7678356-10	1993	Our studies indicate that: (1) both cyclosporine and L-683,590 inhibit insulin release by beta TC3 cells and cultured rat islets after 48 hr (cyclosporine is a more potent inhibitor); (2) neither drug inhibits the release of insulin during the first 4 hr following a glucose stimulus; and (3) their mechanisms of action appear to be similar--both drugs cause reduced levels of insulin mRNA.	Cyclosporine	142-154	insulin	Homo sapiens	71-78
8289993-8	1993	When compared with normal rats, rats receiving CS only had a significantly higher CAT activity and MDA level (p &lt; 0.01 and p &lt; 0.05, respectively).	Cyclosporine	47-49	catalase	Rattus norvegicus	82-85
1281550-5	1992	Moreover, induction of TNF-alpha gene transcription by anti-immunoglobulin was blocked by the immunosuppressants cyclosporin A and FK506.	Cyclosporine	113-126	tumor necrosis factor	Homo sapiens	23-32
1281550-0	1992	Transcription of the tumor necrosis factor alpha gene is rapidly induced by anti-immunoglobulin and blocked by cyclosporin A and FK506 in human B cells.	Cyclosporine	111-124	tumor necrosis factor	Homo sapiens	21-48
1363236-8	1992	Overall, these findings suggested that activated human peripheral blood (PB) CD4+ effectors can lyse TC by at least three distinct mechanisms: (i) a CsA-sensitive directed lysis of SRBC which correlates with exocytosis and presumably occurs via membrane lesions; (ii) a CsA-insensitive directed lysis of NP-modified nucleated TC that does not appear to involve exocytosis and is metabolically distinct; and (iii) a direct TNF-dependent lysis of TNF-sensitive TC.	Cyclosporine	149-152	tumor necrosis factor	Homo sapiens	422-425
1294972-7	1992	Monitoring haptoglobin levels make it possible to detect early endothelial injuries which could be linked to the future arteriolopathy described with CsA therapy.	Cyclosporine	150-153	haptoglobin	Homo sapiens	11-22
1363236-8	1992	Overall, these findings suggested that activated human peripheral blood (PB) CD4+ effectors can lyse TC by at least three distinct mechanisms: (i) a CsA-sensitive directed lysis of SRBC which correlates with exocytosis and presumably occurs via membrane lesions; (ii) a CsA-insensitive directed lysis of NP-modified nucleated TC that does not appear to involve exocytosis and is metabolically distinct; and (iii) a direct TNF-dependent lysis of TNF-sensitive TC.	Cyclosporine	149-152	tumor necrosis factor	Homo sapiens	445-448
1334967-4	1992	Moreover, CsA inhibited the arthritis-induced increases in pituitary POMC and IL-6 mRNA levels and in circulating ACTH and B.	Cyclosporine	10-13	interleukin 6	Rattus norvegicus	78-82
1334967-5	1992	In vitro, CsA reduced the POMC mRNA content of cultured anterior pituitary cells and diminished the stimulatory effects of corticotropin-releasing hormone (CRH) on POMC mRNA expression and ACTH secretion from these cells.	Cyclosporine	10-13	corticotropin releasing hormone	Rattus norvegicus	123-154
1334967-3	1992	In control animals, CsA reduced basal anterior pituitary POMC and IL-6 mRNA and decreased plasma levels of ACTH and B. Adjuvant-injected animals that were treated with CsA showed no clinical signs of AA.	Cyclosporine	20-23	interleukin 6	Rattus norvegicus	66-70
1334967-5	1992	In vitro, CsA reduced the POMC mRNA content of cultured anterior pituitary cells and diminished the stimulatory effects of corticotropin-releasing hormone (CRH) on POMC mRNA expression and ACTH secretion from these cells.	Cyclosporine	10-13	corticotropin releasing hormone	Rattus norvegicus	156-159
1281562-10	1992	CsA 10, 1, 0.1, 0.01 also exerted an enhancing effect on ET-1 secretion in cultured tubular cells.	Cyclosporine	0-3	endothelin 1	Rattus norvegicus	57-61
1284133-2	1992	We confirmed a significant reduction of the basal percentage of CD8+ cells and an increase in the CD4/CD8 ratio in patients with PsA before CsA therapy compared to controls.	Cyclosporine	140-143	CD4 molecule	Homo sapiens	98-101
1284133-6	1992	After the 6 months of CsA therapy we observed a significant increase of CD3+, HLA-DR+, CD3+, CD16+ and/or CD56+, total B, and CD20+, CD5+ cells in the 11 patients with PsA compared to pretreatment values.	Cyclosporine	22-25	keratin 20	Homo sapiens	126-130
1281562-12	1992	The concentrations of FK506 or CsA that induced ET-1 secretion were not cytolytic for tubular cells in vitro.	Cyclosporine	31-34	endothelin 1	Rattus norvegicus	48-52
1281562-13	1992	FK506- or CsA-treated rats showed an increase in serum level of ET-1 in comparison with the control.	Cyclosporine	10-13	endothelin 1	Rattus norvegicus	64-68
1443153-5	1992	A balloon pressure of 20 cmH2O induced a smaller CSA in early phase I [266 (236-324) mm2] than in late phase II [385 (276-474) mm2] (P &lt; 0.05).	Cyclosporine	49-52	troponin T2, cardiac type	Homo sapiens	25-29
1363515-1	1992	Cyclosporin A and verapamil are substrates for P-glycoprotein.	Cyclosporine	0-13	ATP binding cassette subfamily B member 1	Homo sapiens	47-61
1429556-6	1992	Because the ATPase fragment of heat shock cognate 70 (HSC 70) is structurally related to actin, the yeast homologue SSA1 was tested and found to be radiolabeled by the cyclosporin A photoaffinity reagent.	Cyclosporine	168-181	actin	Saccharomyces cerevisiae S288C	89-94
1424421-1	1992	It has been shown recently that cyclosporine is largely metabolized by P450IIIA (CYP3A), an enzyme whose catalytic activity varies significantly among patients.	Cyclosporine	32-44	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	81-86
1363104-5	1992	P-glycoprotein in T cells is a functionally active efflux pump as demonstrated by decreased retention of rhodamine-123 and its increased accumulation by cyclosporin A, an inhibitor of Pgp function.	Cyclosporine	153-166	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
1363104-5	1992	P-glycoprotein in T cells is a functionally active efflux pump as demonstrated by decreased retention of rhodamine-123 and its increased accumulation by cyclosporin A, an inhibitor of Pgp function.	Cyclosporine	153-166	ATP binding cassette subfamily B member 1	Homo sapiens	184-187
1331182-5	1992	The presence of the CMV IE2 gene product abolished the inhibitory effect of CsA on IL-2 promoter activation and gene transcription.	Cyclosporine	76-79	interleukin 2	Homo sapiens	83-87
1400493-6	1992	We illustrate our approach by quantifying the effect of the immunosuppressor cyclosporin A on the accumulation of interleukin-4, interferon-gamma, and interleukin-2 receptor mRNAs in phytohemagglutinin-stimulated human peripheral blood mononuclear cells.	Cyclosporine	77-90	interleukin 4	Homo sapiens	114-127
1431212-5	1992	The effects of hydrocortisone, dexamethasone, calcitriol, acitretin, and cyclosporin A on TNF- or IL-1 beta-induced IL-6 production by HDMEC were determined by ELISA.	Cyclosporine	73-86	tumor necrosis factor	Homo sapiens	90-93
1431212-5	1992	The effects of hydrocortisone, dexamethasone, calcitriol, acitretin, and cyclosporin A on TNF- or IL-1 beta-induced IL-6 production by HDMEC were determined by ELISA.	Cyclosporine	73-86	interleukin 1 beta	Homo sapiens	98-107
1431212-5	1992	The effects of hydrocortisone, dexamethasone, calcitriol, acitretin, and cyclosporin A on TNF- or IL-1 beta-induced IL-6 production by HDMEC were determined by ELISA.	Cyclosporine	73-86	interleukin 6	Homo sapiens	116-120
1400493-6	1992	We illustrate our approach by quantifying the effect of the immunosuppressor cyclosporin A on the accumulation of interleukin-4, interferon-gamma, and interleukin-2 receptor mRNAs in phytohemagglutinin-stimulated human peripheral blood mononuclear cells.	Cyclosporine	77-90	interferon gamma	Homo sapiens	129-145
1490302-7	1992	Our results indicate that cyclosporin therapy induces a reversible increase of plasma cholesterol, LDL-cholesterol, triglycerides, VLDL-triglycerides, and apolipoprotein B and a decrease of HDL-cholesterol, HDL2-cholesterol, and apolipoprotein A-I.	Cyclosporine	26-37	apolipoprotein B	Homo sapiens	155-171
1358068-6	1992	It is concluded that P-gp possesses at least two allosterically coupled drug acceptor sites, receptor site-1 that is selective for vinca alkaloids and cyclosporin A, and receptor site-2 that is selective for 1,4-dihydropyridines.	Cyclosporine	151-164	ATP binding cassette subfamily B member 1	Homo sapiens	21-25
1400432-1	1992	Cyclosporin A (CsA) inhibits T-cell proliferation primarily by blocking the transcription of several early activation genes, especially those of the important T-cell growth factors IL-2 and IL-4.	Cyclosporine	0-13	interleukin 2	Homo sapiens	181-185
1400432-1	1992	Cyclosporin A (CsA) inhibits T-cell proliferation primarily by blocking the transcription of several early activation genes, especially those of the important T-cell growth factors IL-2 and IL-4.	Cyclosporine	0-13	interleukin 4	Homo sapiens	190-194
1400432-1	1992	Cyclosporin A (CsA) inhibits T-cell proliferation primarily by blocking the transcription of several early activation genes, especially those of the important T-cell growth factors IL-2 and IL-4.	Cyclosporine	15-18	interleukin 2	Homo sapiens	181-185
1400432-1	1992	Cyclosporin A (CsA) inhibits T-cell proliferation primarily by blocking the transcription of several early activation genes, especially those of the important T-cell growth factors IL-2 and IL-4.	Cyclosporine	15-18	interleukin 4	Homo sapiens	190-194
1400432-4	1992	Here it is shown that transcription of the IL-2 and IL-4 genes occurs normally throughout this "progression" phase, even in the presence of CsA.	Cyclosporine	140-143	interleukin 2	Homo sapiens	43-47
1400432-4	1992	Here it is shown that transcription of the IL-2 and IL-4 genes occurs normally throughout this "progression" phase, even in the presence of CsA.	Cyclosporine	140-143	interleukin 4	Homo sapiens	52-56
1400432-6	1992	These data indicate that, although the primary initiation of transcription of IL-2 and IL-4 mRNA during induction of competence may be NF-AT-dependent and CsA-sensitive, the augmentation in the progression phase is both NF-AT-independent and CsA-resistant.	Cyclosporine	155-158	interleukin 2	Homo sapiens	78-82
1400432-6	1992	These data indicate that, although the primary initiation of transcription of IL-2 and IL-4 mRNA during induction of competence may be NF-AT-dependent and CsA-sensitive, the augmentation in the progression phase is both NF-AT-independent and CsA-resistant.	Cyclosporine	155-158	interleukin 4	Homo sapiens	87-91
1400432-6	1992	These data indicate that, although the primary initiation of transcription of IL-2 and IL-4 mRNA during induction of competence may be NF-AT-dependent and CsA-sensitive, the augmentation in the progression phase is both NF-AT-independent and CsA-resistant.	Cyclosporine	242-245	interleukin 2	Homo sapiens	78-82
1400432-6	1992	These data indicate that, although the primary initiation of transcription of IL-2 and IL-4 mRNA during induction of competence may be NF-AT-dependent and CsA-sensitive, the augmentation in the progression phase is both NF-AT-independent and CsA-resistant.	Cyclosporine	242-245	interleukin 4	Homo sapiens	87-91
1382703-8	1992	Cyclosporine A decreased cell multiplication in M1 cells without inducing apoptosis, and G-CSF and IL-6 inhibited the cytostatic effect of cyclosporine A.	Cyclosporine	139-153	interleukin 6	Homo sapiens	99-103
1330239-3	1992	CsA at 0.5, 1.0, 5.0 micrograms/ml without PTH and at 5.0 micrograms/ml in the presence of PTH significantly inhibited proliferation, as determined by a tetrazolium colorimetric assay.	Cyclosporine	0-3	parathyroid hormone	Rattus norvegicus	91-94
1490303-0	1992	Effect of cyclosporin on plasma lipoprotein lipase activity in rats.	Cyclosporine	10-21	lipoprotein lipase	Rattus norvegicus	32-50
1490303-2	1992	The treatment with cyclosporin resulted in an increase in plasma triglycerides and non-HDL-cholesterol, and a dose and time-dependent decrease of LPL activity and HDL-cholesterol, mainly because of a fall in the HDL2-cholesterol subfraction.	Cyclosporine	19-30	lipoprotein lipase	Rattus norvegicus	146-149
1490303-4	1992	Our results indicate that the decrease in plasma LPL activity may be responsible for the increase in plasma triglycerides and the decrease in plasma HDL-cholesterol found in rats under cyclosporin treatment.	Cyclosporine	185-196	lipoprotein lipase	Rattus norvegicus	49-52
1490302-7	1992	Our results indicate that cyclosporin therapy induces a reversible increase of plasma cholesterol, LDL-cholesterol, triglycerides, VLDL-triglycerides, and apolipoprotein B and a decrease of HDL-cholesterol, HDL2-cholesterol, and apolipoprotein A-I.	Cyclosporine	26-37	apolipoprotein A1	Homo sapiens	229-247
1382293-1	1992	The inhibitory effects of cyclosporin A (CsA) and FK506 on Fc epsilon receptor type I-initiated increases in cytokine mRNA and the expression of their intracellular binding proteins were studied in interleukin 3 (IL-3)-dependent, mouse bone marrow-derived mast cells (BMMCs).	Cyclosporine	41-44	interleukin 3	Mus musculus	198-217
1456087-6	1992	Compared to control animals (group A), treatment with CsA alone (group B) and PGE2 alone (group C) significantly elevated BGP levels.	Cyclosporine	54-57	bone gamma-carboxyglutamate protein	Rattus norvegicus	122-125
1413071-0	1992	Mechanism of a clinically relevant protocol to induce tolerance: peritransplant spleen cells plus cyclosporine suppress IL-2 and IFN-gamma production.	Cyclosporine	98-110	interleukin 2	Homo sapiens	120-124
1413071-0	1992	Mechanism of a clinically relevant protocol to induce tolerance: peritransplant spleen cells plus cyclosporine suppress IL-2 and IFN-gamma production.	Cyclosporine	98-110	interferon gamma	Homo sapiens	129-138
1382293-2	1992	In BMMCs sensitized with IgE anti-trinitrophenyl, CsA inhibited trinitrophenylated bovine serum albumin-induced increases in mRNA for IL-1 beta, tumor necrosis factor alpha (TNF-alpha), and IL-6 in a dose-related manner (IC50 values of 4, 65, and 130 nM, respectively).	Cyclosporine	50-53	interleukin 1 beta	Mus musculus	134-143
1382293-2	1992	In BMMCs sensitized with IgE anti-trinitrophenyl, CsA inhibited trinitrophenylated bovine serum albumin-induced increases in mRNA for IL-1 beta, tumor necrosis factor alpha (TNF-alpha), and IL-6 in a dose-related manner (IC50 values of 4, 65, and 130 nM, respectively).	Cyclosporine	50-53	tumor necrosis factor	Mus musculus	145-172
1382293-2	1992	In BMMCs sensitized with IgE anti-trinitrophenyl, CsA inhibited trinitrophenylated bovine serum albumin-induced increases in mRNA for IL-1 beta, tumor necrosis factor alpha (TNF-alpha), and IL-6 in a dose-related manner (IC50 values of 4, 65, and 130 nM, respectively).	Cyclosporine	50-53	tumor necrosis factor	Mus musculus	174-183
1382293-2	1992	In BMMCs sensitized with IgE anti-trinitrophenyl, CsA inhibited trinitrophenylated bovine serum albumin-induced increases in mRNA for IL-1 beta, tumor necrosis factor alpha (TNF-alpha), and IL-6 in a dose-related manner (IC50 values of 4, 65, and 130 nM, respectively).	Cyclosporine	50-53	interleukin 6	Mus musculus	190-194
1382293-6	1992	That CsA inhibited IL-1 beta mRNA accumulation in IgE-activated BMMCs with an IC50 similar to that for inhibition of calcineurin activity, whereas the IC50 values were approximately 20-fold higher for the inhibition of TNF-alpha and IL-6 mRNA, suggests that the induction of TNF-alpha and IL-6 is less dependent upon calcineurin activity than is the induction of IL-1 beta.	Cyclosporine	5-8	interleukin 1 beta	Mus musculus	19-28
1382293-6	1992	That CsA inhibited IL-1 beta mRNA accumulation in IgE-activated BMMCs with an IC50 similar to that for inhibition of calcineurin activity, whereas the IC50 values were approximately 20-fold higher for the inhibition of TNF-alpha and IL-6 mRNA, suggests that the induction of TNF-alpha and IL-6 is less dependent upon calcineurin activity than is the induction of IL-1 beta.	Cyclosporine	5-8	tumor necrosis factor	Mus musculus	219-228
1382293-6	1992	That CsA inhibited IL-1 beta mRNA accumulation in IgE-activated BMMCs with an IC50 similar to that for inhibition of calcineurin activity, whereas the IC50 values were approximately 20-fold higher for the inhibition of TNF-alpha and IL-6 mRNA, suggests that the induction of TNF-alpha and IL-6 is less dependent upon calcineurin activity than is the induction of IL-1 beta.	Cyclosporine	5-8	interleukin 6	Mus musculus	233-237
1382293-6	1992	That CsA inhibited IL-1 beta mRNA accumulation in IgE-activated BMMCs with an IC50 similar to that for inhibition of calcineurin activity, whereas the IC50 values were approximately 20-fold higher for the inhibition of TNF-alpha and IL-6 mRNA, suggests that the induction of TNF-alpha and IL-6 is less dependent upon calcineurin activity than is the induction of IL-1 beta.	Cyclosporine	5-8	tumor necrosis factor	Mus musculus	275-284
1382293-6	1992	That CsA inhibited IL-1 beta mRNA accumulation in IgE-activated BMMCs with an IC50 similar to that for inhibition of calcineurin activity, whereas the IC50 values were approximately 20-fold higher for the inhibition of TNF-alpha and IL-6 mRNA, suggests that the induction of TNF-alpha and IL-6 is less dependent upon calcineurin activity than is the induction of IL-1 beta.	Cyclosporine	5-8	interleukin 6	Mus musculus	289-293
1382293-6	1992	That CsA inhibited IL-1 beta mRNA accumulation in IgE-activated BMMCs with an IC50 similar to that for inhibition of calcineurin activity, whereas the IC50 values were approximately 20-fold higher for the inhibition of TNF-alpha and IL-6 mRNA, suggests that the induction of TNF-alpha and IL-6 is less dependent upon calcineurin activity than is the induction of IL-1 beta.	Cyclosporine	5-8	interleukin 1 beta	Mus musculus	363-372
1397785-15	1992	Following discontinuation of cyclosporin A insulin requirements and glycated hemoglobin levels increased while glucagon-stimulated connecting peptide levels declined dramatically.	Cyclosporine	29-42	insulin	Homo sapiens	43-50
1383138-8	1992	CsA was found to exert its effect even when added after 4 h of cultivation, and the kinetic pattern of suppression was similar to that of the suppressive effect on IL-2 production.	Cyclosporine	0-3	interleukin 2	Homo sapiens	164-168
1384614-7	1992	TNF-alpha and IL-6 production by peritoneal macrophages isolated from AJ-injected rats was significantly decreased by CsA treatment at d 7 and 14.	Cyclosporine	118-121	tumor necrosis factor	Rattus norvegicus	0-9
1384614-7	1992	TNF-alpha and IL-6 production by peritoneal macrophages isolated from AJ-injected rats was significantly decreased by CsA treatment at d 7 and 14.	Cyclosporine	118-121	interleukin 6	Rattus norvegicus	14-18
1432999-0	1992	Cyclosporine and chloroquine synergistically inhibit the interferon-gamma production by CD4 positive and CD8 positive synovial T cell clones derived from a patient with rheumatoid arthritis.	Cyclosporine	0-12	interferon gamma	Homo sapiens	57-73
1355105-6	1992	Growth of the cells required activation because cyclosporin A and FK506 blocked stimulator cell-induced IL-2 production and proliferation as well as the spontaneous growth of the lines.	Cyclosporine	48-61	interleukin 2	Homo sapiens	104-108
1363382-7	1992	There was a marked rise in the serum IL-2 level of uremic and post-transplant patients when compared to normal subjects (34.76 +/- 32.16 u/mL and 9.3 +/- 12.7 u/mL vs 4.38 +/- 3.38 u/mL, p &lt; 0.001), but no significant differences were found between the IL-2 level of patients with acute rejection and cyclosporine nephrotoxicity or acute tubular necrosis (3.74 +/- 4.51 u/mL, 1.57 +/- 1.25 u/mL and 6.73 +/- 6.3 u/mL, p &gt; 0.05).	Cyclosporine	304-316	interleukin 2	Homo sapiens	37-41
1432999-1	1992	OBJECTIVE: To investigate synergistic interaction between cyclosporine (Cy) and chloroquine (Chl) in an in vitro system, with regard to interferon-gamma (IFN) production by OKT3 activated T cell clones.	Cyclosporine	58-70	interferon gamma	Mus musculus	136-158
1432999-0	1992	Cyclosporine and chloroquine synergistically inhibit the interferon-gamma production by CD4 positive and CD8 positive synovial T cell clones derived from a patient with rheumatoid arthritis.	Cyclosporine	0-12	CD4 molecule	Homo sapiens	88-91
1432999-1	1992	OBJECTIVE: To investigate synergistic interaction between cyclosporine (Cy) and chloroquine (Chl) in an in vitro system, with regard to interferon-gamma (IFN) production by OKT3 activated T cell clones.	Cyclosporine	72-74	interferon gamma	Mus musculus	136-158
1384815-1	1992	The immunosuppressive drugs FK506 and cyclosporin A have an identical spectrum of activities with respect to IgE receptor (Fc epsilon RI)-mediated exocytosis from mast cells and T cell receptor-mediated transcription of IL-2.	Cyclosporine	38-51	Fc receptor, IgE, high affinity I, alpha polypeptide	Mus musculus	123-136
1496542-10	1992	Furthermore, since CsA and prednisolone are known inhibitors of in vitro IL-2 production, our results indicate that IL-6R generation does not rely exclusively on the presence of IL-2.	Cyclosporine	19-22	interleukin 2	Homo sapiens	73-77
1643634-12	1992	Complete inhibition of the potentiation of MRA by human liver microsomes was found when the CYP3A substrates cyclosporin A and erythromycin were used in the reaction system.	Cyclosporine	109-122	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	92-97
1380130-1	1992	The immunophilins cyclophilin and FK506 binding protein (FKBP) are small, predominantly soluble proteins that bind the immunosuppressant drugs cyclosporin A and FK506, respectively, with high affinity, and which seem to mediate their pharmacological actions.	Cyclosporine	143-156	FK506-binding protein 12kD	Drosophila melanogaster	57-61
1420818-2	1992	u-PA antigen in the sample was immunologically bound to microtitre plate wells by anti-u-PA IgG and the binding of HRP-labelled lectins [Con A (Concanavalin A), WGA (wheat germ agglutinin), PNA (peanut agglutinin), CSA (Scotch broom), GS-I (Groffonia simplicifollia) and SBA (soybean agglutinin)] to the carbohydrate of u-PA was measured.	Cyclosporine	215-218	plasminogen activator, urokinase	Homo sapiens	0-4
1496542-10	1992	Furthermore, since CsA and prednisolone are known inhibitors of in vitro IL-2 production, our results indicate that IL-6R generation does not rely exclusively on the presence of IL-2.	Cyclosporine	19-22	interleukin 6 receptor	Homo sapiens	116-121
1496595-0	1992	Correlation of cyclosporine-induced nephropathy with renal microsomal cytochrome P-450: the preventive effect of verapamil.	Cyclosporine	15-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
1628422-7	1992	In addition, we compared the effect of CsA and its analogs on the expression of the IL-2 gene in a stably transfected Jurkat-cell line (Fgl 5) which contains three copies of NF-AT and the reporter enzyme beta-galactosidase; and on inhibition of proliferation induced by concanavalin A (Con A) or IL-2.	Cyclosporine	39-42	interleukin 2	Homo sapiens	84-88
1497650-0	1992	Correlation between up-regulation of lymphokine mRNA and down-regulation of TcR, CD4, CD8 and lck mRNA as shown by the effect of CsA on activated T lymphocytes.	Cyclosporine	129-132	interleukin 2	Homo sapiens	37-47
1497650-0	1992	Correlation between up-regulation of lymphokine mRNA and down-regulation of TcR, CD4, CD8 and lck mRNA as shown by the effect of CsA on activated T lymphocytes.	Cyclosporine	129-132	CD4 molecule	Homo sapiens	81-84
1497650-3	1992	We showed that cyclosporin A (CsA), which blocks lymphokine expression also inhibits MRC mRNA down-modulation at the transcriptional level, and does not affect mRNA stability.	Cyclosporine	30-33	interleukin 2	Homo sapiens	49-59
1497650-4	1992	The fact that CsA inhibits both lymphokine expression and MRC mRNA down-modulation at transcriptional level supports a model in which similar signals trigger the inverse regulation of these two sets of genes via identical transcriptional factors.	Cyclosporine	14-17	interleukin 2	Homo sapiens	32-42
1634049-8	1992	In contrast, animals implanted intraperitoneally but treated with short-term daily injection of cyclosporine A (28-41 days) did not mount any significant antibody response to human growth hormone throughout the experiment or even when challenged subsequently at weeks 8-10 with purified growth hormone.	Cyclosporine	96-110	growth hormone 1	Homo sapiens	287-301
1380951-3	1992	While 1 microgram/ml CSA and 0.1 microgram/ml FK 506 completely suppressed PHA-stimulated accumulation of mRNA for IL2, IL4, IL9, GM-CSF, TNF-alpha and IFN-gamma in PBMC, flu, keto and TGF-beta failed to inhibit any (except TNF-alpha blocked by TGF-beta).	Cyclosporine	21-24	interleukin 2	Homo sapiens	115-118
1380951-3	1992	While 1 microgram/ml CSA and 0.1 microgram/ml FK 506 completely suppressed PHA-stimulated accumulation of mRNA for IL2, IL4, IL9, GM-CSF, TNF-alpha and IFN-gamma in PBMC, flu, keto and TGF-beta failed to inhibit any (except TNF-alpha blocked by TGF-beta).	Cyclosporine	21-24	interleukin 4	Homo sapiens	120-123
1380951-3	1992	While 1 microgram/ml CSA and 0.1 microgram/ml FK 506 completely suppressed PHA-stimulated accumulation of mRNA for IL2, IL4, IL9, GM-CSF, TNF-alpha and IFN-gamma in PBMC, flu, keto and TGF-beta failed to inhibit any (except TNF-alpha blocked by TGF-beta).	Cyclosporine	21-24	tumor necrosis factor	Homo sapiens	138-147
1380951-3	1992	While 1 microgram/ml CSA and 0.1 microgram/ml FK 506 completely suppressed PHA-stimulated accumulation of mRNA for IL2, IL4, IL9, GM-CSF, TNF-alpha and IFN-gamma in PBMC, flu, keto and TGF-beta failed to inhibit any (except TNF-alpha blocked by TGF-beta).	Cyclosporine	21-24	interferon gamma	Homo sapiens	152-161
1380951-3	1992	While 1 microgram/ml CSA and 0.1 microgram/ml FK 506 completely suppressed PHA-stimulated accumulation of mRNA for IL2, IL4, IL9, GM-CSF, TNF-alpha and IFN-gamma in PBMC, flu, keto and TGF-beta failed to inhibit any (except TNF-alpha blocked by TGF-beta).	Cyclosporine	21-24	transforming growth factor beta 1	Homo sapiens	185-193
1380951-3	1992	While 1 microgram/ml CSA and 0.1 microgram/ml FK 506 completely suppressed PHA-stimulated accumulation of mRNA for IL2, IL4, IL9, GM-CSF, TNF-alpha and IFN-gamma in PBMC, flu, keto and TGF-beta failed to inhibit any (except TNF-alpha blocked by TGF-beta).	Cyclosporine	21-24	tumor necrosis factor	Homo sapiens	224-233
1380951-3	1992	While 1 microgram/ml CSA and 0.1 microgram/ml FK 506 completely suppressed PHA-stimulated accumulation of mRNA for IL2, IL4, IL9, GM-CSF, TNF-alpha and IFN-gamma in PBMC, flu, keto and TGF-beta failed to inhibit any (except TNF-alpha blocked by TGF-beta).	Cyclosporine	21-24	transforming growth factor beta 1	Homo sapiens	245-253
1501157-6	1992	Cyclosporin A gingival enlargement could be differentiated by phenytoin lesions because of the higher length and the parallel distribution of the FN.	Cyclosporine	0-13	fibronectin 1	Homo sapiens	146-148
1620122-5	1992	In a T-cell clone specific for pigeon cytochrome c in the context of I-Ek, Oct-2 was induced by antigen stimulation, with the increase in Oct-2 protein seen first at 3 h after activation and continuing for at least 24 h. Oct-2 mRNA induction during antigen-driven T-cell activation was blocked by cyclosporin A, as well as by protein synthesis inhibitors.	Cyclosporine	297-310	cytochrome c, somatic	Homo sapiens	38-50
1403237-6	1992	In renal transplant recipients, mainly those taking cyclosporine, ACE inhibitors are equally effective compared to calcium antagonists in the control of hypertension, but their renal effects in transplant recipients without renal artery stenosis have not yet been assessed.	Cyclosporine	52-64	angiotensin I converting enzyme	Homo sapiens	66-69
1378960-3	1992	The inhibitory effect of the drug on taurine transport appears to be due to interference with calmodulin-dependent processes because calmodulin antagonists such as W-7, calmidazolium, and CGS 9343B mimic the effects of cyclosporin A.	Cyclosporine	219-232	calmodulin 1	Homo sapiens	94-104
1377361-0	1992	FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin.	Cyclosporine	12-15	interleukin 2	Homo sapiens	44-57
1377361-2	1992	The immunosuppressive drugs, cyclosporin A (CsA) and FK-506, prevent T-cell proliferation by inhibiting a Ca(2+)-dependent event required for induction of interleukin-2 transcription.	Cyclosporine	29-42	interleukin 2	Homo sapiens	155-168
1377361-2	1992	The immunosuppressive drugs, cyclosporin A (CsA) and FK-506, prevent T-cell proliferation by inhibiting a Ca(2+)-dependent event required for induction of interleukin-2 transcription.	Cyclosporine	44-47	interleukin 2	Homo sapiens	155-168
1377361-6	1992	Here we report that transfection of a calcineurin catalytic subunit increases the 50% inhibitory concentration (IC50) of the immunosuppressants FK-506 and CsA, and that a mutant subunit acts in synergy with phorbol ester alone to activate the interleukin-2 promoter in a drug-sensitive manner.	Cyclosporine	155-158	interleukin 2	Homo sapiens	243-256
1378960-3	1992	The inhibitory effect of the drug on taurine transport appears to be due to interference with calmodulin-dependent processes because calmodulin antagonists such as W-7, calmidazolium, and CGS 9343B mimic the effects of cyclosporin A.	Cyclosporine	219-232	calmodulin 1	Homo sapiens	133-143
1351088-10	1992	For a subset of CD4+ CTL, we found that treatment of CTL with cyclosporin A inhibited Ag-induced production of both transmembrane and secreted forms of TNF-alpha but had no effect on cytolysis.	Cyclosporine	62-75	CD4 molecule	Homo sapiens	16-19
1351088-10	1992	For a subset of CD4+ CTL, we found that treatment of CTL with cyclosporin A inhibited Ag-induced production of both transmembrane and secreted forms of TNF-alpha but had no effect on cytolysis.	Cyclosporine	62-75	tumor necrosis factor	Homo sapiens	152-161
1350249-7	1992	Among the six evaluable cases tested with mitoxantrone and CyA, an increase of 50% in CFU-L sensitivity to mitoxantrone was noted in one (of three) P-gp+ patient.	Cyclosporine	59-62	ATP binding cassette subfamily B member 1	Homo sapiens	148-152
1599421-5	1992	The second-order rate constant for cyclosporin A binding to the enzyme was determined from the time-dependence of the inhibition of PPIase by low concentrations of cyclosporin A and found to be 0.9 microM-1.s-1 at 10 degrees C. 3.	Cyclosporine	35-48	peptidylprolyl isomerase like 3	Rattus norvegicus	132-138
1599421-5	1992	The second-order rate constant for cyclosporin A binding to the enzyme was determined from the time-dependence of the inhibition of PPIase by low concentrations of cyclosporin A and found to be 0.9 microM-1.s-1 at 10 degrees C. 3.	Cyclosporine	164-177	peptidylprolyl isomerase like 3	Rattus norvegicus	132-138
1599421-12	1992	268, 153-160] are explained by the use of a short (30 s) preincubation period of the enzyme with cyclosporin, which is insufficient to allow full equilibration of the binding of the inhibitor to the PPIase.	Cyclosporine	97-108	peptidylprolyl isomerase like 3	Rattus norvegicus	199-205
1639529-6	1992	Both the CS and AZA groups exhibited significant elevations of factor IX activity, von Willebrand factor (vWF), D-dimer, protein C and tissue type plasminogen activator (t-PA) levels when compared with the normal controls.	Cyclosporine	9-11	von Willebrand factor	Homo sapiens	83-104
1612813-7	1992	A significant linear relation between Ccr and CPF (r = 0.829, p less than 0.001) was demonstrated in individuals with a transplanted kidney graft treated with CyA.	Cyclosporine	159-162	nuclear receptor subfamily 5 group A member 2	Homo sapiens	46-49
1639529-6	1992	Both the CS and AZA groups exhibited significant elevations of factor IX activity, von Willebrand factor (vWF), D-dimer, protein C and tissue type plasminogen activator (t-PA) levels when compared with the normal controls.	Cyclosporine	9-11	von Willebrand factor	Homo sapiens	106-109
1639529-6	1992	Both the CS and AZA groups exhibited significant elevations of factor IX activity, von Willebrand factor (vWF), D-dimer, protein C and tissue type plasminogen activator (t-PA) levels when compared with the normal controls.	Cyclosporine	9-11	plasminogen activator, tissue type	Homo sapiens	135-168
1639529-6	1992	Both the CS and AZA groups exhibited significant elevations of factor IX activity, von Willebrand factor (vWF), D-dimer, protein C and tissue type plasminogen activator (t-PA) levels when compared with the normal controls.	Cyclosporine	9-11	plasminogen activator, tissue type	Homo sapiens	170-174
1639529-8	1992	Comparison of data from CS and AZA groups revealed higher factor XII activity and vWF concentration in the former group.	Cyclosporine	24-26	von Willebrand factor	Homo sapiens	82-85
1639529-9	1992	In conclusion, transplant recipients treated with long-term cyclosporine and prednisone exhibited significant elevation of plasma vWF, D-dimer and protein C concentrations.	Cyclosporine	60-72	von Willebrand factor	Homo sapiens	130-133
1639529-10	1992	In addition, both CS and AZA-treated transplant recipients showed increased plasma concentrations of D-dimer and t-PA.	Cyclosporine	18-20	plasminogen activator, tissue type	Homo sapiens	113-117
1594347-3	1992	However, HLA-A and -B cadaveric-graft mismatching, which was equivalent between whites and nonwhites prior to 1985 (pre-cyclosporine A era), has significantly favored whites (49% with 0 to 2 HLA-A and -B mismatch vs 16% in nonwhites) since 1985 (P less than .05), and a significantly higher proportion of nonwhite patients (59%) were receiving medical assistance (P less than .0001).	Cyclosporine	120-134	major histocompatibility complex, class I, A	Homo sapiens	9-21
1502562-3	1992	In particular, cyclosporine inhibits the transcription of interleukin 2.	Cyclosporine	15-27	interleukin 2	Homo sapiens	58-71
1353987-11	1992	We could further demonstrate that TNF-alpha production was completely blocked by cyclosporin A.	Cyclosporine	81-94	tumor necrosis factor	Homo sapiens	34-43
1586705-0	1992	Interferon-gamma gene expression in unstimulated bone marrow mononuclear cells predicts a good response to cyclosporine therapy in aplastic anemia.	Cyclosporine	107-119	interferon gamma	Homo sapiens	0-16
1586705-6	1992	Of 13 patients who responded to CyA therapy and achieved transfusion-independence, IFN-gamma mRNA was detected in 12 patients, whereas the mRNA was only detectable in 3 of 10 patients refractory to CyA therapy (P = .003, Fisher"s exact test).	Cyclosporine	32-35	interferon gamma	Homo sapiens	83-92
1521924-4	1992	The effects of the anti-rheumatic drugs indometacin, dexamethasone, cyclophosphamide and cyclosporin A (CsA) on IL-6 levels during FAA were determined.	Cyclosporine	89-102	interleukin 6	Rattus norvegicus	112-116
1427430-1	1992	In this study we have analyzed the activity of Cyclosporin A (CsA) on the "in vitro" production of TNF and IL-3/GM-CSF as a preliminary basis for explaining the successful use of CsA in aplastic patients.	Cyclosporine	62-65	tumor necrosis factor	Homo sapiens	99-102
1427430-1	1992	In this study we have analyzed the activity of Cyclosporin A (CsA) on the "in vitro" production of TNF and IL-3/GM-CSF as a preliminary basis for explaining the successful use of CsA in aplastic patients.	Cyclosporine	179-182	tumor necrosis factor	Homo sapiens	99-102
1427430-5	1992	With these clones we studied the ability of CsA to inhibit TNF and IL-3/GM-CSF production, which was stimulated with specific monoclonal antibodies directed against the CD2 and CD3 surface antigens.	Cyclosporine	44-47	tumor necrosis factor	Homo sapiens	59-62
1427430-6	1992	TNF and IL-3/GM-CSF production displayed a different sensitivity to CsA inhibition.	Cyclosporine	68-71	tumor necrosis factor	Homo sapiens	0-3
1427430-7	1992	In fact, at 400 ng/ml CsA a residual production of IL-3/GM-CSF was present in all clones tested (CD3: 21.8% and CD2: 14.4% of the maximal IL-3/GM-CSF activity), while secretion of TNF was virtually abrogated at 100 ng/ml.	Cyclosporine	22-25	tumor necrosis factor	Homo sapiens	180-183
1521924-4	1992	The effects of the anti-rheumatic drugs indometacin, dexamethasone, cyclophosphamide and cyclosporin A (CsA) on IL-6 levels during FAA were determined.	Cyclosporine	104-107	interleukin 6	Rattus norvegicus	112-116
1521924-5	1992	Complete normalization of serum IL-6 levels was observed with dexamethasone, cyclophosphamide and CsA whereas indometacin only partly reduced serum IL-6 levels.	Cyclosporine	98-101	interleukin 6	Rattus norvegicus	32-36
1317909-0	1992	Atrial natriuretic factor improves renal function and lowers systolic blood pressure in renal allograft recipients treated with cyclosporin A.	Cyclosporine	128-141	natriuretic peptide A	Homo sapiens	0-25
1317909-1	1992	OBJECTIVE: Atrial natriuretic factor (ANF) has several properties which suggest that it may ameliorate cyclosporin A nephrotoxicity.	Cyclosporine	103-116	natriuretic peptide A	Homo sapiens	11-36
1317909-1	1992	OBJECTIVE: Atrial natriuretic factor (ANF) has several properties which suggest that it may ameliorate cyclosporin A nephrotoxicity.	Cyclosporine	103-116	natriuretic peptide A	Homo sapiens	38-41
1317909-2	1992	We therefore investigated the response to a pharmacological dose of ANF in renal transplant recipients treated with cyclosporin A.	Cyclosporine	116-129	natriuretic peptide A	Homo sapiens	68-71
1317909-10	1992	CONCLUSIONS: These results suggest that ANF may have beneficial effects in protecting against cyclosporin A-induced nephrotoxicity and hypertension.	Cyclosporine	94-107	natriuretic peptide A	Homo sapiens	40-43
1373887-5	1992	Both CsA and FK 506 specifically inhibit cellular calcineurin at drug concentrations that inhibit interleukin 2 production in activated T cells.	Cyclosporine	5-8	interleukin 2	Homo sapiens	98-111
1610865-5	1992	Clearance data suggests, however, that the primary mechanism for the interaction is the inhibition cyclosporine metabolism by the cytochrome P-450 system.	Cyclosporine	99-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-146
1348520-2	1992	Previous studies have shown that proliferation of peripheral blood T cells involving the CD28 pathway is associated with cyclosporine A (CsA) resistant IL-2 gene expression.	Cyclosporine	121-135	interleukin 2	Homo sapiens	152-156
1585470-7	1992	Exogenous IL2 substantially reversed the inhibitory effect of CsA but not that of Rapa in Ig production.	Cyclosporine	62-65	interleukin 2	Homo sapiens	10-13
1563100-8	1992	Similarly, exposure of LPMC to cyclosporin A (CyA) and hydrocortisone (HC) at therapeutic levels reduced IL-2 activity to less than 1% of controls.	Cyclosporine	31-44	interleukin 2	Homo sapiens	105-109
1348520-0	1992	CD28-stimulated IL-2 gene expression in Jurkat T cells occurs in part transcriptionally and is cyclosporine-A sensitive.	Cyclosporine	95-109	interleukin 2	Homo sapiens	16-20
1563100-8	1992	Similarly, exposure of LPMC to cyclosporin A (CyA) and hydrocortisone (HC) at therapeutic levels reduced IL-2 activity to less than 1% of controls.	Cyclosporine	46-49	interleukin 2	Homo sapiens	105-109
1503609-1	1992	Cyclosporin A (CsA) is a potent inhibitor of cytokine (IL-2-IL-6, IFN gamma) production by CD4+ T lymphocytes stimulated via the T cell antigen receptor pathway.	Cyclosporine	0-13	interleukin 6	Homo sapiens	60-64
1551401-2	1992	Given that interleukin 2 (IL-2) stimulates proliferation, abolishes anergy, and counteracts apoptotic cell death in T cells in vitro, we tested whether the IL-2 synthesis inhibitor cyclosporin A (CsA) or a vaccinia virus recombinant releasing high amounts of human IL-2 modulate SEB responses in vivo.	Cyclosporine	181-194	interleukin 2	Homo sapiens	156-160
1551527-1	1992	The P450IIIA (CYP3A) cytochromes are a major family of enzymes that play an important role in the metabolism of many medications, including cyclosporine A, as well as some dietary xenobiotics, including aflatoxin B1.	Cyclosporine	140-154	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	14-19
1503609-1	1992	Cyclosporin A (CsA) is a potent inhibitor of cytokine (IL-2-IL-6, IFN gamma) production by CD4+ T lymphocytes stimulated via the T cell antigen receptor pathway.	Cyclosporine	0-13	interferon gamma	Homo sapiens	66-75
1380242-3	1992	Cyclosporin A (CsA) and FK506 inhibit the production of IL-2 in T lymphocytes at the level of gene transcription.	Cyclosporine	15-18	interleukin 2	Homo sapiens	56-60
1380242-6	1992	However, CsA and FK506 inhibit the appearance of DNA binding activity of factors that bind to the NF-AT and AP-1 sites in the IL-2 enhancer.	Cyclosporine	9-12	interleukin 2	Homo sapiens	126-130
1503609-1	1992	Cyclosporin A (CsA) is a potent inhibitor of cytokine (IL-2-IL-6, IFN gamma) production by CD4+ T lymphocytes stimulated via the T cell antigen receptor pathway.	Cyclosporine	15-18	interleukin 6	Homo sapiens	60-64
1380242-7	1992	Since the induction of NF-AT and AP-1 is induced by the same stimuli that stimulate IL-2 production, these results indicate that the immunosuppressant action of CsA and FK506 is exerted at the level of these trans-activating factors.	Cyclosporine	161-164	interleukin 2	Homo sapiens	84-88
1503609-1	1992	Cyclosporin A (CsA) is a potent inhibitor of cytokine (IL-2-IL-6, IFN gamma) production by CD4+ T lymphocytes stimulated via the T cell antigen receptor pathway.	Cyclosporine	15-18	interferon gamma	Homo sapiens	66-75
1566356-5	1992	A possible clinical relevance of these findings is suggested by experiments showing that the CTL against NAM were also more resistant to cyclosporine than CTL against AM.	Cyclosporine	137-149	SH3 and cysteine rich domain 3	Homo sapiens	105-108
1365019-0	1992	Interferon-gamma potentiates the antitumor effect of cyclosporine-induced autoimmunity.	Cyclosporine	53-65	interferon gamma	Homo sapiens	0-16
1365019-5	1992	Since many hematopoietic malignancies express variable levels of class II molecules, we hypothesized that the adjuvant use of interferon-gamma (IFN-gamma) with CsA-induced autoimmunity after autologous/syngeneic BMT may upregulate class II antigens on residual tumor cells and make them more susceptible to attack by the Ia-reactive cells of CsA-induced AIS.	Cyclosporine	160-163	interferon gamma	Homo sapiens	126-142
1365019-5	1992	Since many hematopoietic malignancies express variable levels of class II molecules, we hypothesized that the adjuvant use of interferon-gamma (IFN-gamma) with CsA-induced autoimmunity after autologous/syngeneic BMT may upregulate class II antigens on residual tumor cells and make them more susceptible to attack by the Ia-reactive cells of CsA-induced AIS.	Cyclosporine	160-163	interferon gamma	Homo sapiens	144-153
1365019-5	1992	Since many hematopoietic malignancies express variable levels of class II molecules, we hypothesized that the adjuvant use of interferon-gamma (IFN-gamma) with CsA-induced autoimmunity after autologous/syngeneic BMT may upregulate class II antigens on residual tumor cells and make them more susceptible to attack by the Ia-reactive cells of CsA-induced AIS.	Cyclosporine	342-345	interferon gamma	Homo sapiens	126-142
1365019-5	1992	Since many hematopoietic malignancies express variable levels of class II molecules, we hypothesized that the adjuvant use of interferon-gamma (IFN-gamma) with CsA-induced autoimmunity after autologous/syngeneic BMT may upregulate class II antigens on residual tumor cells and make them more susceptible to attack by the Ia-reactive cells of CsA-induced AIS.	Cyclosporine	342-345	interferon gamma	Homo sapiens	144-153
1602410-0	1992	Cyclosporin-A increases type I procollagen production and mRNA level in human gingival fibroblasts in vitro.	Cyclosporine	0-13	collagen type I alpha 2 chain	Homo sapiens	24-42
1618283-0	1992	Endothelin-1 release from the mesenteric arteries of cyclosporine-treated rats.	Cyclosporine	53-65	endothelin 1	Rattus norvegicus	0-12
1618283-1	1992	The release of endothelin-1 from mesenteric arteries from cyclosporine-treated rats was measured by a specific enzyme immunoassay after purification of the perfusate on an immunoaffinity column.	Cyclosporine	58-70	endothelin 1	Rattus norvegicus	15-27
1618283-2	1992	Mesenteric arteries from cyclosporine-treated rats (25 mg/kg per day for 6 weeks) released a significantly larger amount of endothelin-1 than arteries from vehicle-treated control rats (P less than 0.05).	Cyclosporine	25-37	endothelin 1	Rattus norvegicus	124-136
1539561-1	1992	Both cimetidine and cyclosporine (CsA) are metabolized by the cytochrome P-450 system.	Cyclosporine	20-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
1554358-4	1992	Cyclosporin A (CsA), a potent inhibitor of IL-2 synthesis and cellular proliferation, blocked RB phosphorylation, and this was recovered with exogenous IL-2, indicating a direct involvement of IL-2 in controlling RB phosphorylation.	Cyclosporine	0-13	interleukin 2	Homo sapiens	43-47
1554358-4	1992	Cyclosporin A (CsA), a potent inhibitor of IL-2 synthesis and cellular proliferation, blocked RB phosphorylation, and this was recovered with exogenous IL-2, indicating a direct involvement of IL-2 in controlling RB phosphorylation.	Cyclosporine	0-13	interleukin 2	Homo sapiens	152-156
1554358-4	1992	Cyclosporin A (CsA), a potent inhibitor of IL-2 synthesis and cellular proliferation, blocked RB phosphorylation, and this was recovered with exogenous IL-2, indicating a direct involvement of IL-2 in controlling RB phosphorylation.	Cyclosporine	0-13	interleukin 2	Homo sapiens	152-156
1554358-4	1992	Cyclosporin A (CsA), a potent inhibitor of IL-2 synthesis and cellular proliferation, blocked RB phosphorylation, and this was recovered with exogenous IL-2, indicating a direct involvement of IL-2 in controlling RB phosphorylation.	Cyclosporine	15-18	interleukin 2	Homo sapiens	43-47
1554358-4	1992	Cyclosporin A (CsA), a potent inhibitor of IL-2 synthesis and cellular proliferation, blocked RB phosphorylation, and this was recovered with exogenous IL-2, indicating a direct involvement of IL-2 in controlling RB phosphorylation.	Cyclosporine	15-18	interleukin 2	Homo sapiens	152-156
1554358-4	1992	Cyclosporin A (CsA), a potent inhibitor of IL-2 synthesis and cellular proliferation, blocked RB phosphorylation, and this was recovered with exogenous IL-2, indicating a direct involvement of IL-2 in controlling RB phosphorylation.	Cyclosporine	15-18	interleukin 2	Homo sapiens	152-156
1539561-1	1992	Both cimetidine and cyclosporine (CsA) are metabolized by the cytochrome P-450 system.	Cyclosporine	34-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
17589148-0	1992	The effect of prolactin on cyclosporin in renal transplant patients.	Cyclosporine	27-38	prolactin	Homo sapiens	14-23
17589148-2	1992	This study demonstrates a significant difference in the magnitude and fluctuation in prolactin and cyclosporin concentrations between males and females receiving cyclosporin as the single immunosuppressant.	Cyclosporine	162-173	prolactin	Homo sapiens	85-94
17589148-4	1992	It is proposed that prolactin levels should be taken into account when determining the appropriate dosage regimen of cyclosporin in those patients receiving cyclosporin alone as immunosuppressant therapy.	Cyclosporine	117-128	prolactin	Homo sapiens	20-29
17589148-4	1992	It is proposed that prolactin levels should be taken into account when determining the appropriate dosage regimen of cyclosporin in those patients receiving cyclosporin alone as immunosuppressant therapy.	Cyclosporine	157-168	prolactin	Homo sapiens	20-29
1537307-8	1992	On day 28, serum BGP levels were higher in groups B (Ox; 73.58 +/- 3.63 ng/ml), C (Ox and CsA; 85.05 +/- 9.88), and F (CsA; 81.35 +/- 3.4) compared to group A (control; 46.07 +/- 5.52; P less than 0.05), while 17 beta-estradiol in groups D (Ox, CsA, and EP; 38.65 +/- 2.85) and E (Ox and EP; 41.89 +/- 1.89) prevented this rise (P = 0.01).	Cyclosporine	90-93	bone gamma-carboxyglutamate protein	Rattus norvegicus	17-20
1541147-7	1992	The release of interferon gamma by BAL cells could be further stimulated with concanavalin A and suppressed by cyclosporine.	Cyclosporine	111-123	interferon gamma	Homo sapiens	15-31
1378764-0	1992	Cyclosporin A and FK506 prevent the derepression of the IL-2 gene in mitogen-induced primary T lymphocytes.	Cyclosporine	0-13	interleukin 2	Homo sapiens	56-60
1378764-3	1992	Cyclosporin A (CsA) and FK506 interfere with normal derepression of the IL-2 gene.	Cyclosporine	0-13	interleukin 2	Homo sapiens	72-76
1378764-3	1992	Cyclosporin A (CsA) and FK506 interfere with normal derepression of the IL-2 gene.	Cyclosporine	15-18	interleukin 2	Homo sapiens	72-76
1537307-8	1992	On day 28, serum BGP levels were higher in groups B (Ox; 73.58 +/- 3.63 ng/ml), C (Ox and CsA; 85.05 +/- 9.88), and F (CsA; 81.35 +/- 3.4) compared to group A (control; 46.07 +/- 5.52; P less than 0.05), while 17 beta-estradiol in groups D (Ox, CsA, and EP; 38.65 +/- 2.85) and E (Ox and EP; 41.89 +/- 1.89) prevented this rise (P = 0.01).	Cyclosporine	119-122	bone gamma-carboxyglutamate protein	Rattus norvegicus	17-20
1537307-8	1992	On day 28, serum BGP levels were higher in groups B (Ox; 73.58 +/- 3.63 ng/ml), C (Ox and CsA; 85.05 +/- 9.88), and F (CsA; 81.35 +/- 3.4) compared to group A (control; 46.07 +/- 5.52; P less than 0.05), while 17 beta-estradiol in groups D (Ox, CsA, and EP; 38.65 +/- 2.85) and E (Ox and EP; 41.89 +/- 1.89) prevented this rise (P = 0.01).	Cyclosporine	119-122	bone gamma-carboxyglutamate protein	Rattus norvegicus	17-20
1550785-0	1992	Cyclosporin A induced remission of CD4+ T-CLL associated with eosinophilia and fasciitis.	Cyclosporine	0-13	CD4 molecule	Homo sapiens	35-38
1737094-7	1992	Finally, the chemoprotection afforded by the MDR1 gene could readily be reversed by adding chemosensitizers such as cyclosporin A and R-verapamil to chemotherapy.	Cyclosporine	116-129	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	45-49
1371623-0	1992	Blockade of interleukin-2 production from cloned T cells by cyclosporine and FK 506 assessed by proliferation assays in vitro.	Cyclosporine	60-72	interleukin 2	Homo sapiens	12-25
1375473-4	1992	CsA interacts with an abundant 17 kDa protein, termed cyclophilin, that possesses peptidyl-prolyl cis-trans isomerase (PPIase) activity.	Cyclosporine	0-3	FKBP prolyl isomerase 5	Homo sapiens	82-117
1738921-9	1992	Graft survival was significantly prolonged with combination CsA and anti-TNF therapy, suggesting a synergistic effect against acute cardiac allograft rejection, possibly from CsA and anti-TNF interacting at different levels of the recipient immune response.	Cyclosporine	60-63	tumor necrosis factor	Rattus norvegicus	188-191
1738921-9	1992	Graft survival was significantly prolonged with combination CsA and anti-TNF therapy, suggesting a synergistic effect against acute cardiac allograft rejection, possibly from CsA and anti-TNF interacting at different levels of the recipient immune response.	Cyclosporine	175-178	tumor necrosis factor	Rattus norvegicus	73-76
1728297-5	1992	Treatment of challenged mice with cyclosporin A (CyA) led to an abrogation of the disease as seen by an abrogation of the increase in lung index, lack of IL-1 and TNF-alpha release in the BAL.	Cyclosporine	34-47	tumor necrosis factor	Mus musculus	163-172
1375473-4	1992	CsA interacts with an abundant 17 kDa protein, termed cyclophilin, that possesses peptidyl-prolyl cis-trans isomerase (PPIase) activity.	Cyclosporine	0-3	FKBP prolyl isomerase 5	Homo sapiens	119-125
1375473-8	1992	However, nonimmunosuppressive analogs of CsA and FK-506 are also inhibitory, indicating that inhibition of PPIase activity is not directly implicated in immunosuppression.	Cyclosporine	41-44	FKBP prolyl isomerase 5	Homo sapiens	107-113
1364246-6	1992	Grafts from animals receiving continuous CsA treatment for either 3, 6, or 12 wk contained large clumps of dopamine-beta-hydroxylase (DBH) positive cells in contrast to the few surviving cells observed in nonimmunosuppressed animals.	Cyclosporine	41-44	dopamine beta-hydroxylase	Bos taurus	107-132
1300884-6	1992	In addition, when we systematically determined haptoglobin levels after introduction of CsA treatment, we found asymptomatic hemolytic episodes more frequently.	Cyclosporine	88-91	haptoglobin	Homo sapiens	47-58
1300884-10	1992	This approach could lead to a reduction of the CsA dose in patients presenting low haptoglobin levels, even in the absence of evidence of nephrotoxicity.	Cyclosporine	47-50	haptoglobin	Homo sapiens	83-94
1346997-6	1992	Cyclosporine A was a potent competitive inhibitor of CQA metabolism, providing initial evidence that formation of metabolite I was catalyzed by proteins of the CYP3 gene family.	Cyclosporine	0-14	peptidylprolyl isomerase F	Homo sapiens	160-164
1364246-6	1992	Grafts from animals receiving continuous CsA treatment for either 3, 6, or 12 wk contained large clumps of dopamine-beta-hydroxylase (DBH) positive cells in contrast to the few surviving cells observed in nonimmunosuppressed animals.	Cyclosporine	41-44	dopamine beta-hydroxylase	Bos taurus	134-137
1364246-7	1992	In addition, grafts from animals that had CsA treatment terminated at 3 or 6 wk contained similarly large clumps of DBH-positive cells.	Cyclosporine	42-45	dopamine beta-hydroxylase	Bos taurus	116-119
1371491-5	1992	FK506 or CsA inhibited SEA-induced tumour necrosis factor-alpha (TNF-alpha) production both in monocytes (P less than 0.01) and in lymphocytes (P less than 0.001), at a drug concentration of 1-25 ng/ml for FK506 and 100-500 ng/ml for CsA.	Cyclosporine	9-12	tumor necrosis factor	Homo sapiens	65-74
1313765-0	1992	Effect of endothelin-1 in man: pretreatment with nifedipine, with indomethacin and with cyclosporine A.	Cyclosporine	88-102	endothelin 1	Homo sapiens	10-22
1371491-8	1992	When the cells were stimulated by phorbol ester (phorbol 12-myristate 13-acetate, PMA) plus calcium ionophore (ionomycin), FK506 and CsA inhibited, in a dose-dependent manner, the production of IL-2, IL-4, IL-5, IFN-gamma and TNF-alpha.	Cyclosporine	133-136	interleukin 2	Homo sapiens	194-198
1371491-5	1992	FK506 or CsA inhibited SEA-induced tumour necrosis factor-alpha (TNF-alpha) production both in monocytes (P less than 0.01) and in lymphocytes (P less than 0.001), at a drug concentration of 1-25 ng/ml for FK506 and 100-500 ng/ml for CsA.	Cyclosporine	234-237	tumor necrosis factor	Homo sapiens	65-74
1371491-8	1992	When the cells were stimulated by phorbol ester (phorbol 12-myristate 13-acetate, PMA) plus calcium ionophore (ionomycin), FK506 and CsA inhibited, in a dose-dependent manner, the production of IL-2, IL-4, IL-5, IFN-gamma and TNF-alpha.	Cyclosporine	133-136	interleukin 4	Homo sapiens	200-204
1384862-4	1992	However, the response of the PHA-pulsed T cells to IL-6 was still inhibited by FK-506 or Cs A, but the inhibitory effect gradually decreased as the time in which the PHA-pulsed T cells interacted with IL-6 was prolonged.	Cyclosporine	89-93	interleukin 6	Homo sapiens	51-55
1371491-8	1992	When the cells were stimulated by phorbol ester (phorbol 12-myristate 13-acetate, PMA) plus calcium ionophore (ionomycin), FK506 and CsA inhibited, in a dose-dependent manner, the production of IL-2, IL-4, IL-5, IFN-gamma and TNF-alpha.	Cyclosporine	133-136	interferon gamma	Homo sapiens	212-221
1371491-8	1992	When the cells were stimulated by phorbol ester (phorbol 12-myristate 13-acetate, PMA) plus calcium ionophore (ionomycin), FK506 and CsA inhibited, in a dose-dependent manner, the production of IL-2, IL-4, IL-5, IFN-gamma and TNF-alpha.	Cyclosporine	133-136	tumor necrosis factor	Homo sapiens	226-235
1384862-0	1992	The effects of FK-506 and cyclosporin A on the proliferation of PHA-stimulated T cells in response to IL-2, IL-4 or IL-6.	Cyclosporine	26-39	interleukin 2	Homo sapiens	102-106
1384862-0	1992	The effects of FK-506 and cyclosporin A on the proliferation of PHA-stimulated T cells in response to IL-2, IL-4 or IL-6.	Cyclosporine	26-39	interleukin 4	Homo sapiens	108-112
1384862-0	1992	The effects of FK-506 and cyclosporin A on the proliferation of PHA-stimulated T cells in response to IL-2, IL-4 or IL-6.	Cyclosporine	26-39	interleukin 6	Homo sapiens	116-120
1384862-7	1992	It is likely that the two drugs inhibit the expression of lymphokine receptors, by interfering Ca(2+)-related signals and that IL-6 induces T cell proliferation in a different way than IL-2 and IL-4, which are FK-506- and Cs A-sensitive.	Cyclosporine	222-226	interleukin 6	Homo sapiens	127-131
1384862-7	1992	It is likely that the two drugs inhibit the expression of lymphokine receptors, by interfering Ca(2+)-related signals and that IL-6 induces T cell proliferation in a different way than IL-2 and IL-4, which are FK-506- and Cs A-sensitive.	Cyclosporine	222-226	interleukin 4	Homo sapiens	194-198
1552819-0	1992	Effect of cyclosporin treatment on luteinizing hormone and prolactin.	Cyclosporine	10-21	prolactin	Homo sapiens	59-68
1345790-8	1992	Indeed, this direct cytotoxicity was completely abrogated by anti-TNF-alpha antibody and was sensitive to the metabolic inhibitors (cyclosporin A, CT, cycloheximide, and actinomycin D), all of which blocked CD4+/CD8+ T cell TNF-alpha production.	Cyclosporine	132-145	tumor necrosis factor	Homo sapiens	66-75
1345790-8	1992	Indeed, this direct cytotoxicity was completely abrogated by anti-TNF-alpha antibody and was sensitive to the metabolic inhibitors (cyclosporin A, CT, cycloheximide, and actinomycin D), all of which blocked CD4+/CD8+ T cell TNF-alpha production.	Cyclosporine	132-145	tumor necrosis factor	Homo sapiens	224-233
1552819-1	1992	The effect of cyclosporin A (CsA) treatment on LH and prolactin was investigated.	Cyclosporine	29-32	prolactin	Homo sapiens	54-63
1314975-11	1992	Low-dose s.c. Epo effectively corrects anaemia in graft failure despite azathioprine and/or CsA therapy, without obvious acceleration of graft failure.	Cyclosporine	92-95	erythropoietin	Homo sapiens	14-17
1474936-5	1992	Furthermore, addition of cyclosporin A, which preferentially blocks accumulation of IL-2 mRNA, also inhibited spontaneous proliferation in a dose-dependent manner.	Cyclosporine	25-38	interleukin 2	Homo sapiens	84-88
1528337-8	1992	CPAH and CIn were significantly decreased during Cs treatment.	Cyclosporine	49-51	carboxypeptidase A6	Homo sapiens	0-4
1436287-0	1992	Inhibition of vascular permeability factor production by ciclosporin in minimal change nephrotic syndrome.	Cyclosporine	57-68	vascular endothelial growth factor A	Homo sapiens	14-42
1436287-1	1992	In order to ascertain whether ciclosporin (Cs) has an inhibitory effect on the vascular permeability factor (VPF) production, various quantities of Cs were added to T lymphocyte cultures from 8 children with minimal change nephrotic syndrome (MCNS) and the VPF activity of culture supernatants was assayed.	Cyclosporine	30-41	vascular endothelial growth factor A	Homo sapiens	79-107
1436287-1	1992	In order to ascertain whether ciclosporin (Cs) has an inhibitory effect on the vascular permeability factor (VPF) production, various quantities of Cs were added to T lymphocyte cultures from 8 children with minimal change nephrotic syndrome (MCNS) and the VPF activity of culture supernatants was assayed.	Cyclosporine	43-45	vascular endothelial growth factor A	Homo sapiens	79-107
1436287-1	1992	In order to ascertain whether ciclosporin (Cs) has an inhibitory effect on the vascular permeability factor (VPF) production, various quantities of Cs were added to T lymphocyte cultures from 8 children with minimal change nephrotic syndrome (MCNS) and the VPF activity of culture supernatants was assayed.	Cyclosporine	43-45	vascular endothelial growth factor A	Homo sapiens	109-112
1436287-2	1992	As a result of the addition of Cs, a dose-dependent inhibition of VPF production was seen.	Cyclosporine	31-33	vascular endothelial growth factor A	Homo sapiens	66-69
1436287-3	1992	VPF production was inhibited by a level of between 100 and 250 ng/ml of Cs in vitro.	Cyclosporine	72-74	vascular endothelial growth factor A	Homo sapiens	0-3
1436287-4	1992	The reduction of proteinuria by Cs in MCNS might be due to the inhibition of VPF production.	Cyclosporine	32-34	vascular endothelial growth factor A	Homo sapiens	77-80
1386428-0	1992	[The role of calmodulin and calcium ions in the immunosuppressive mechanism of the action of cyclosporin A].	Cyclosporine	93-106	calmodulin 1	Homo sapiens	13-23
14621841-0	1992	Prophylactic use of the IL-2 receptor-specific monoclonal antibody LO-Tact-1 with cyclosporin A and steroids in renal transplantation.	Cyclosporine	82-95	actin like 7B	Homo sapiens	70-76
1346344-2	1992	In view of the importance of the IL-2 receptors in the expression of antiallograft immunity and the currently existing controversy regarding the effect of CsA on the induction of IL-2 receptors, we explored the effect of cyclosporine on the induction of interleukin-2 receptor alpha and beta in normal human T cells.	Cyclosporine	155-158	interleukin 2	Homo sapiens	179-183
1346344-3	1992	The effect of CsA on the induction of IL-2 receptors was examined at the levels of mRNA expression (with the aid of the polymerase chain reaction), protein (by SDS-PAGE analysis of chemically crosslinked 125I-IL-2 membrane protein complexes and by FACS), and function (by Scatchard analysis of 125I-IL-2 binding to T cells).	Cyclosporine	14-17	interleukin 2	Homo sapiens	38-42
1346344-6	1992	These observations together persuasively demonstrate the ability of CsA to interrupt the emergence of IL-2 receptors on the surface of normal human T cells.	Cyclosporine	68-71	interleukin 2	Homo sapiens	102-106
1954393-6	1991	In contrast, lymphokine production in patients treated with immunosuppressive drugs (cyclosporine A, corticosteroids) was abnormal after stimulation with PMA and ionophore, as well as ConA.	Cyclosporine	85-99	interleukin 2	Homo sapiens	13-23
14621885-1	1992	Since cyclosporin A (CsA), a widely used immunosuppressive drug, strongly suppresses interleukin-2 (IL-2) secretion, it is frequently difficult to estimate T lymphocyte activation in early acute rejection.	Cyclosporine	6-19	interleukin 2	Homo sapiens	85-98
14621885-1	1992	Since cyclosporin A (CsA), a widely used immunosuppressive drug, strongly suppresses interleukin-2 (IL-2) secretion, it is frequently difficult to estimate T lymphocyte activation in early acute rejection.	Cyclosporine	6-19	interleukin 2	Homo sapiens	100-104
14621885-1	1992	Since cyclosporin A (CsA), a widely used immunosuppressive drug, strongly suppresses interleukin-2 (IL-2) secretion, it is frequently difficult to estimate T lymphocyte activation in early acute rejection.	Cyclosporine	21-24	interleukin 2	Homo sapiens	85-98
14621885-1	1992	Since cyclosporin A (CsA), a widely used immunosuppressive drug, strongly suppresses interleukin-2 (IL-2) secretion, it is frequently difficult to estimate T lymphocyte activation in early acute rejection.	Cyclosporine	21-24	interleukin 2	Homo sapiens	100-104
1761234-0	1991	The CYP2 gene of Saccharomyces cerevisiae encodes a cyclosporin A-sensitive peptidyl-prolyl cis-trans isomerase with an N-terminal signal sequence.	Cyclosporine	52-65	peptidylprolyl isomerase CPR2	Saccharomyces cerevisiae S288C	4-8
1783425-5	1991	CsA at concentrations from 100 ng/ml to 1000 ng/ml completely inhibited production of MPIF and IL-2, but had minimal effects on the ability of MPIF to induce isolated macrophage to express PCA.	Cyclosporine	0-3	interleukin 2	Homo sapiens	95-99
1783425-8	1991	These data demonstrate the disparate actions of CsA and dmPGE2 on inhibition of PCA, MPIF and IL-2, and provide a possible mechanism for the beneficial effects of combination CsA and dmPGE2 in patients receiving organ allografts.	Cyclosporine	48-51	interleukin 2	Homo sapiens	94-98
1761234-14	1991	Since both purified Cyps display CsA sensitivity in vitro, our data suggest that Cyp1 and Cyp2 differ in terms of their cellular function and/or localization.	Cyclosporine	33-36	peptidylprolyl isomerase CPR2	Saccharomyces cerevisiae S288C	90-94
1942242-6	1991	Suppression of TNF-alpha secretion by cyclosporin A or by a serine protease inhibitor did not suppress the HIV-1 LTR activation.	Cyclosporine	38-51	tumor necrosis factor	Homo sapiens	15-24
1685551-0	1991	Increased drug accumulation ex vivo with cyclosporin in chronic lymphatic leukemia and its relationship to epitope masking of P-glycoprotein.	Cyclosporine	41-52	ATP binding cassette subfamily B member 1	Homo sapiens	126-140
1726126-6	1991	Drugs such as cyclosporine, 1,25,dihydroxycholecalciferol and pentoxyfylline can block lymphokine and TNF production and thus, may inhibit the inflammatory process.	Cyclosporine	14-26	tumor necrosis factor	Homo sapiens	102-105
1721312-0	1991	FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line.	Cyclosporine	23-35	interleukin 4	Homo sapiens	48-52
1720306-0	1991	Induction of members of the IL-8/NAP-1 gene family in human T lymphocytes is suppressed by cyclosporin A.	Cyclosporine	91-104	C-X-C motif chemokine ligand 8	Homo sapiens	28-32
1786062-2	1991	Cyclosporin A was the maintenance immunosuppressive treatment in all patients after a 2-week course of antithymocyte globulin or anti-IL-2 monoclonal antibody.	Cyclosporine	0-13	interleukin 2	Homo sapiens	134-138
1837120-12	1991	Our data suggest that a combination anti-IL-2 monoclonal antibody, cyclosporin and low-dose steroids can safely be administered to allograft recipients, avoid severe viral infections, and, in our early experience, is as potent as the powerful combination ALG, cyclosporin and high-doses steroids in preventing allograft rejection.	Cyclosporine	67-78	interleukin 2	Homo sapiens	41-45
1837120-12	1991	Our data suggest that a combination anti-IL-2 monoclonal antibody, cyclosporin and low-dose steroids can safely be administered to allograft recipients, avoid severe viral infections, and, in our early experience, is as potent as the powerful combination ALG, cyclosporin and high-doses steroids in preventing allograft rejection.	Cyclosporine	260-271	interleukin 2	Homo sapiens	41-45
1839831-2	1991	Cyclosporin A treatment in the initial phase of activation blocked the second phase activation of a cell population by anti-CD3, IL-2, or concanavalin A (ConA).	Cyclosporine	0-13	interleukin 2	Homo sapiens	129-133
1720306-0	1991	Induction of members of the IL-8/NAP-1 gene family in human T lymphocytes is suppressed by cyclosporin A.	Cyclosporine	91-104	C-X-C motif chemokine ligand 8	Homo sapiens	33-38
1776854-0	1991	Antagonism of prolactin binding by cyclosporine A on MCF7 breast tumour cell line.	Cyclosporine	35-49	prolactin	Homo sapiens	14-23
1776854-1	1991	Cyclosporine A (an immunosuppressive cyclic undercapeptide) acts as an antagonist to prolactin receptors on a breast tumour cell line (MCF7) which is known to express specific prolactin receptors.	Cyclosporine	0-14	prolactin	Homo sapiens	85-94
1776854-1	1991	Cyclosporine A (an immunosuppressive cyclic undercapeptide) acts as an antagonist to prolactin receptors on a breast tumour cell line (MCF7) which is known to express specific prolactin receptors.	Cyclosporine	0-14	prolactin	Homo sapiens	176-185
1776854-2	1991	The competition between cyclosporine A and prolactin to prolactin receptors was demonstrated by measuring the decreased specific 125I-labeled prolactin-binding to prolactin receptors in the presence of increasing concentrations of cyclosporine A.	Cyclosporine	24-38	prolactin	Homo sapiens	56-65
1776854-2	1991	The competition between cyclosporine A and prolactin to prolactin receptors was demonstrated by measuring the decreased specific 125I-labeled prolactin-binding to prolactin receptors in the presence of increasing concentrations of cyclosporine A.	Cyclosporine	24-38	prolactin	Homo sapiens	56-65
1776854-2	1991	The competition between cyclosporine A and prolactin to prolactin receptors was demonstrated by measuring the decreased specific 125I-labeled prolactin-binding to prolactin receptors in the presence of increasing concentrations of cyclosporine A.	Cyclosporine	24-38	prolactin	Homo sapiens	56-65
1776854-2	1991	The competition between cyclosporine A and prolactin to prolactin receptors was demonstrated by measuring the decreased specific 125I-labeled prolactin-binding to prolactin receptors in the presence of increasing concentrations of cyclosporine A.	Cyclosporine	231-245	prolactin	Homo sapiens	43-52
1776854-2	1991	The competition between cyclosporine A and prolactin to prolactin receptors was demonstrated by measuring the decreased specific 125I-labeled prolactin-binding to prolactin receptors in the presence of increasing concentrations of cyclosporine A.	Cyclosporine	231-245	prolactin	Homo sapiens	56-65
1776854-2	1991	The competition between cyclosporine A and prolactin to prolactin receptors was demonstrated by measuring the decreased specific 125I-labeled prolactin-binding to prolactin receptors in the presence of increasing concentrations of cyclosporine A.	Cyclosporine	231-245	prolactin	Homo sapiens	56-65
1776854-2	1991	The competition between cyclosporine A and prolactin to prolactin receptors was demonstrated by measuring the decreased specific 125I-labeled prolactin-binding to prolactin receptors in the presence of increasing concentrations of cyclosporine A.	Cyclosporine	231-245	prolactin	Homo sapiens	56-65
1949174-0	1991	Enhancement of thymic recovery after cyclosporine by recombinant human growth hormone and insulin-like growth factor I.	Cyclosporine	37-49	growth hormone 1	Homo sapiens	71-85
1949174-0	1991	Enhancement of thymic recovery after cyclosporine by recombinant human growth hormone and insulin-like growth factor I.	Cyclosporine	37-49	insulin like growth factor 1	Homo sapiens	90-118
1752284-0	1991	Cyclosporin-A-induced lipid peroxidation in human liver microsomes and its influence on cytochrome P-450.	Cyclosporine	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-104
1752284-1	1991	The present in vitro study using human liver tissue was performed to investigate the effect of cyclosporin A on lipid peroxidation and cytochrome P-450 concentration in isolated liver microsomes.	Cyclosporine	95-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-151
1752284-9	1991	Furthermore, cyclosporin-A-induced microsomal lipid peroxidation was accompanied by a significant dose-dependent decline of the microsomal cytochrome P-450 content.	Cyclosporine	13-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-155
1752284-10	1991	At a cyclosporin A concentration of 300 micrograms ml-1, cytochrome P-450 content was decreased to 49% in comparison to control values.	Cyclosporine	5-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
1752284-11	1991	In the presence of reduced glutathione, cyclosporin A decreased the cytochrome P-450 concentration only to 79% (P less than 0.05).	Cyclosporine	40-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
1721767-4	1991	Although full recovery was not observed in FK506, this finding indicated that FK506 as well as CsA inhibit IL2 secretion from HTL403.	Cyclosporine	95-98	interleukin 2	Homo sapiens	107-110
1832176-8	1991	Finally, in the presence of cyclosporin, anti-CD3-stimulated neonatal lymphocytes secreted Ig only with the combination of IL-2 and IL-4.	Cyclosporine	28-39	interleukin 2	Homo sapiens	123-127
1773683-6	1991	After an average of 71 days of insulin therapy, there was complete remission of PTDM in 5 of 6 diabetic patients, with a corresponding decrease in CsA level.	Cyclosporine	147-150	insulin	Homo sapiens	31-38
1884028-9	1991	We suggest that a subclinical kidney toxicity produced by CsA might have a role in the pathogenesis of the impaired Epo production observed in BMT patients, and may contribute to a delayed erythroid engraftment in at least some BMT patients.	Cyclosporine	58-61	erythropoietin	Homo sapiens	116-119
1832176-8	1991	Finally, in the presence of cyclosporin, anti-CD3-stimulated neonatal lymphocytes secreted Ig only with the combination of IL-2 and IL-4.	Cyclosporine	28-39	interleukin 4	Homo sapiens	132-136
1911152-9	1991	Unfortunately, one of the most effective ingredients of such combination therapies in animal models (anti-CD4) appears to have its tolerogenic potential abrogated by cyclosporin A and FK-506.	Cyclosporine	166-179	CD4 molecule	Homo sapiens	106-109
1654606-5	1991	Although the degree of inhibition by DEX and CsA was different in [3H] TdR incorporation, IL-2 production, and IL-2 receptor expression assays, the inhibitory pattern of these drugs was similar in each of the assays, indicating that human T cell activation is differentially regulated by DEX and CsA depending on the stimulator.	Cyclosporine	45-48	interleukin 2	Homo sapiens	90-94
1897023-11	1991	The indirect evidence of insulin resistance observed in patients treated with CsA plus prednisone is ascribable to corticosteroid treatment.	Cyclosporine	78-81	insulin	Homo sapiens	25-32
1714445-0	1991	Cyclosporin A inhibits an initial step in folding of transferrin within the endoplasmic reticulum.	Cyclosporine	0-13	transferrin	Homo sapiens	53-64
1714445-4	1991	Cyclosporin A causes an approximately 10-min lag in transferrin folding, after which folding resumes at the normal rate.	Cyclosporine	0-13	transferrin	Homo sapiens	52-63
1714445-5	1991	Cyclosporin A also retards transferrin maturation from the endoplasmic reticulum and its secretion, at concentrations that do not affect secretion of other hepatoma proteins.	Cyclosporine	0-13	transferrin	Homo sapiens	27-38
1714445-7	1991	We conclude that an initial stage in transferrin folding is accelerated by an endoplasmic reticulum peptidyl-proline isomerase that is inhibited by cyclosporin A.	Cyclosporine	148-161	transferrin	Homo sapiens	37-48
1654606-5	1991	Although the degree of inhibition by DEX and CsA was different in [3H] TdR incorporation, IL-2 production, and IL-2 receptor expression assays, the inhibitory pattern of these drugs was similar in each of the assays, indicating that human T cell activation is differentially regulated by DEX and CsA depending on the stimulator.	Cyclosporine	45-48	interleukin 2	Homo sapiens	111-115
1942772-4	1991	The glomerular filtration rate and renal plasma flow were significantly depressed below normal values in transplant recipients given cyclosporine, averaging 35 +/- 8 and 325 +/- 94 ml/min/1.73 m2, respectively.	Cyclosporine	133-145	CD59 molecule (CD59 blood group)	Homo sapiens	184-189
1782726-6	1991	However, after one year of treatment, mean serum parathyroid hormone level was significantly lower in the cyclosporin A treatment group, and serum osteocalcin rose significantly.	Cyclosporine	106-119	parathyroid hormone	Homo sapiens	49-68
1782726-8	1991	The changes in parathyroid hormone and osteocalcin following cyclosporin A therapy suggest a reduction in the secondary hyperparathyroidism commonly seen with primary biliary cirrhosis and also an increase in bone formation, respectively.	Cyclosporine	61-74	parathyroid hormone	Homo sapiens	15-34
1782726-8	1991	The changes in parathyroid hormone and osteocalcin following cyclosporin A therapy suggest a reduction in the secondary hyperparathyroidism commonly seen with primary biliary cirrhosis and also an increase in bone formation, respectively.	Cyclosporine	61-74	bone gamma-carboxyglutamate protein	Homo sapiens	39-50
1712901-1	1991	The macrolide FK-506, like the cyclic undecapeptide cyclosporin A (CsA), is a potent immunosuppressant that interferes with the transcriptional activation of several early-phase genes in T lymphocytes, including that for interleukin-2 (IL-2).	Cyclosporine	67-70	interleukin 2	Homo sapiens	221-234
1712901-1	1991	The macrolide FK-506, like the cyclic undecapeptide cyclosporin A (CsA), is a potent immunosuppressant that interferes with the transcriptional activation of several early-phase genes in T lymphocytes, including that for interleukin-2 (IL-2).	Cyclosporine	67-70	interleukin 2	Homo sapiens	236-240
1712901-4	1991	In addition, we studied multimers of several defined promoter elements (NFIL-2A, NF-kappa B, or NF-AT1) which are found in the UAS of the human IL-2 gene and which have been reported to be responsive to CsA when linked to a minimal promoter element (TATA box and transcription start site).	Cyclosporine	203-206	nuclear factor kappa B subunit 1	Homo sapiens	81-91
1712901-7	1991	The induced transcription driven by the IL-2 promoter elements NF-AT1 and NFIL-2A could be blocked completely by FK-506 or CsA.	Cyclosporine	123-126	interleukin 2	Homo sapiens	40-44
1858042-0	1991	The role of intrarenal prostaglandins and angiotensin II in acute cyclosporine-induced vasoconstriction.	Cyclosporine	66-78	angiotensinogen	Rattus norvegicus	42-56
1858042-2	1991	In this study we investigated the role of endogenous prostaglandins and angiotensin II in cyclosporine-induced intrarenal vasoconstriction.	Cyclosporine	90-102	angiotensinogen	Rattus norvegicus	72-86
1678559-4	1991	Previous in vitro studies have shown that the T helper pathway dependent on CD4+ T helper cells and sAPC (CD4-sAPC) is the most susceptible to suppression by cyclosporine.	Cyclosporine	158-170	CD4 molecule	Homo sapiens	76-79
1858042-9	1991	In contrast, local competitive angiotensin II-receptor inhibition with saralasin maintained blood flow after cyclosporine and prevented intrarenal vasoconstriction by cyclosporine.	Cyclosporine	109-121	angiotensinogen	Rattus norvegicus	31-45
1678559-4	1991	Previous in vitro studies have shown that the T helper pathway dependent on CD4+ T helper cells and sAPC (CD4-sAPC) is the most susceptible to suppression by cyclosporine.	Cyclosporine	158-170	CD4 molecule	Homo sapiens	106-114
1858042-9	1991	In contrast, local competitive angiotensin II-receptor inhibition with saralasin maintained blood flow after cyclosporine and prevented intrarenal vasoconstriction by cyclosporine.	Cyclosporine	167-179	angiotensinogen	Rattus norvegicus	31-45
1678559-6	1991	In 58% of patients, a loss of the CD4-sAPC pathway was identified and was correlated with cyclosporine treatment.	Cyclosporine	90-102	CD4 molecule	Homo sapiens	34-37
1858042-10	1991	This suggests that prostaglandins protect against intrarenal vasoconstriction and that acute cyclosporine-induced vasoconstriction is mediated through angiotensin II receptors.	Cyclosporine	93-105	angiotensinogen	Rattus norvegicus	151-165
2071894-5	1991	Second, cyclosporin A, which ameliorates GN in MRL/lpr mice despite autoantibody production, was found to reduce serum IgG3 and mRNA levels, associated with the revision of cationic shift of the serum IgG3 spectrotype seen in isoelectric focusing.	Cyclosporine	8-21	Fas (TNF receptor superfamily member 6)	Mus musculus	51-54
1873480-5	1991	Therefore, we addressed the question of whether the clinical improvement of psoriatic patients during CsA therapy may be due to an inhibition of NAP-1/IL-8 production and secretion from monocytes.	Cyclosporine	102-105	C-X-C motif chemokine ligand 8	Homo sapiens	145-150
1873480-5	1991	Therefore, we addressed the question of whether the clinical improvement of psoriatic patients during CsA therapy may be due to an inhibition of NAP-1/IL-8 production and secretion from monocytes.	Cyclosporine	102-105	C-X-C motif chemokine ligand 8	Homo sapiens	151-155
1916934-2	1991	Numerous studies over the last decade have shown quite clearly that, in vitro, CS inhibits lymphocyte activation at a relatively early stage by preventing the production and release of lymphokines, probably by inhibition of lymphokine gene transcription.	Cyclosporine	79-81	interleukin 2	Homo sapiens	185-195
1647958-3	1991	Cyclosporin A (CsA), whose immunosuppressive effect is attributed mainly to inhibition of interleukin 2 and interferon-gamma expression, interferes in T-B cell interactions.	Cyclosporine	15-18	interferon gamma	Mus musculus	108-124
1717376-1	1991	Cyclosporin (CsA) and FK-506 are structurally distinct fungal metabolites, which exert powerful inhibitory effects on CD4+ T (helper) cell activation and on the secretion of interleukin-2 (IL-2) and other cytokines, including various cell growth factors and interferon-gamma.	Cyclosporine	0-11	interleukin 2	Homo sapiens	174-187
1717376-1	1991	Cyclosporin (CsA) and FK-506 are structurally distinct fungal metabolites, which exert powerful inhibitory effects on CD4+ T (helper) cell activation and on the secretion of interleukin-2 (IL-2) and other cytokines, including various cell growth factors and interferon-gamma.	Cyclosporine	0-11	interleukin 2	Homo sapiens	189-193
1717376-1	1991	Cyclosporin (CsA) and FK-506 are structurally distinct fungal metabolites, which exert powerful inhibitory effects on CD4+ T (helper) cell activation and on the secretion of interleukin-2 (IL-2) and other cytokines, including various cell growth factors and interferon-gamma.	Cyclosporine	0-11	interferon gamma	Homo sapiens	258-274
1860893-4	1991	PRL caused activation of PKC from 10(-12) to 10(-8) M. Antiserum to PRL, a monoclonal antibody directed against the PRL receptor and the immunosuppressive agent cyclosporine A, were able to inhibit PRL-induced proliferation and activation of PKC.	Cyclosporine	161-175	prolactin	Homo sapiens	0-3
1860893-4	1991	PRL caused activation of PKC from 10(-12) to 10(-8) M. Antiserum to PRL, a monoclonal antibody directed against the PRL receptor and the immunosuppressive agent cyclosporine A, were able to inhibit PRL-induced proliferation and activation of PKC.	Cyclosporine	161-175	prolactin	Homo sapiens	68-71
1860893-4	1991	PRL caused activation of PKC from 10(-12) to 10(-8) M. Antiserum to PRL, a monoclonal antibody directed against the PRL receptor and the immunosuppressive agent cyclosporine A, were able to inhibit PRL-induced proliferation and activation of PKC.	Cyclosporine	161-175	prolactin	Homo sapiens	68-71
1860893-4	1991	PRL caused activation of PKC from 10(-12) to 10(-8) M. Antiserum to PRL, a monoclonal antibody directed against the PRL receptor and the immunosuppressive agent cyclosporine A, were able to inhibit PRL-induced proliferation and activation of PKC.	Cyclosporine	161-175	prolactin	Homo sapiens	68-71
2039359-0	1991	Sequential interleukin 2 and interleukin 2 receptor levels distinguish rejection from cyclosporine toxicity in liver allograft recipients.	Cyclosporine	86-98	interleukin 2	Homo sapiens	11-24
1713361-4	1991	FK506 and CsA showed pharmacologic antagonism in inhibiting in vitro proliferation upon phytohemagglutinin, anti-CD3 antibody, and mixed lymphocyte reaction (MLR) stimulation, and interleukin 2 generation by activated normal human peripheral blood lymphocytes.	Cyclosporine	10-13	interleukin 2	Homo sapiens	180-193
1858146-0	1991	Increased urinary excretion of endothelin-1 and its precursor, Big-endothelin-1, in rats chronically treated with cyclosporine.	Cyclosporine	114-126	endothelin 1	Rattus norvegicus	31-43
1858146-0	1991	Increased urinary excretion of endothelin-1 and its precursor, Big-endothelin-1, in rats chronically treated with cyclosporine.	Cyclosporine	114-126	endothelin 1	Rattus norvegicus	67-79
2039359-0	1991	Sequential interleukin 2 and interleukin 2 receptor levels distinguish rejection from cyclosporine toxicity in liver allograft recipients.	Cyclosporine	86-98	interleukin 2	Homo sapiens	29-42
1881046-1	1991	Much is known about the renin-angiotensin system during cyclosporine treatment: plasma renin or prorenin activity seems to be raised in man and animals; hyperplasia of the juxtaglomerular apparatus has been reported in man and animals; renin concentration is known to be increased in animal kidneys; renin-angiotensin-like alterations in vascular contractility have been identified in animal vessels.	Cyclosporine	56-68	renin	Homo sapiens	24-29
1881046-1	1991	Much is known about the renin-angiotensin system during cyclosporine treatment: plasma renin or prorenin activity seems to be raised in man and animals; hyperplasia of the juxtaglomerular apparatus has been reported in man and animals; renin concentration is known to be increased in animal kidneys; renin-angiotensin-like alterations in vascular contractility have been identified in animal vessels.	Cyclosporine	56-68	renin	Homo sapiens	87-92
1881046-1	1991	Much is known about the renin-angiotensin system during cyclosporine treatment: plasma renin or prorenin activity seems to be raised in man and animals; hyperplasia of the juxtaglomerular apparatus has been reported in man and animals; renin concentration is known to be increased in animal kidneys; renin-angiotensin-like alterations in vascular contractility have been identified in animal vessels.	Cyclosporine	56-68	renin	Homo sapiens	87-92
1881046-1	1991	Much is known about the renin-angiotensin system during cyclosporine treatment: plasma renin or prorenin activity seems to be raised in man and animals; hyperplasia of the juxtaglomerular apparatus has been reported in man and animals; renin concentration is known to be increased in animal kidneys; renin-angiotensin-like alterations in vascular contractility have been identified in animal vessels.	Cyclosporine	56-68	renin	Homo sapiens	87-92
1881046-2	1991	Since the major functional side effects of cyclosporine are systemic vasoconstriction and renal vasoconstriction, the renin-angiotensin system could be involved.	Cyclosporine	43-55	renin	Homo sapiens	118-123
1881046-4	1991	Hence, this information is now reviewed and incorporated into a single pathophysiological concept, with the implication that renin activation plays a central role in the pathogenesis of cyclosporine-induced functional and structural lesions, merits further attention.	Cyclosporine	186-198	renin	Homo sapiens	125-130
1710843-7	1991	CsA inhibited IL-6-induced IgG production by CESS cells by 64% at 100 ng/ml and 6-MP inhibited this response by 82% at 250 ng/ml.	Cyclosporine	0-3	interleukin 6	Homo sapiens	14-18
1655819-9	1991	In two of the subpopulations and in both strains at some concentrations, the effect of CS on the relative levels of collagenase and TIMP could account for the decreased collagenase activity; i.e., the level of collagenase was unchanged or decreased, and TIMP production was unchanged or increased.	Cyclosporine	87-89	TIMP metallopeptidase inhibitor 1	Homo sapiens	132-136
1655819-9	1991	In two of the subpopulations and in both strains at some concentrations, the effect of CS on the relative levels of collagenase and TIMP could account for the decreased collagenase activity; i.e., the level of collagenase was unchanged or decreased, and TIMP production was unchanged or increased.	Cyclosporine	87-89	TIMP metallopeptidase inhibitor 1	Homo sapiens	254-258
1896399-2	1991	In kidney transplant patients on CyA or azathioprine respectively, plasma erythropoietin levels were significantly higher during the first three months after transplantation than in normals.	Cyclosporine	33-36	erythropoietin	Homo sapiens	74-88
1710843-11	1991	These experiments clearly demonstrate that CsA, MP and 6-MP have direct inhibitory effects on the response of human B cells to IL-6.	Cyclosporine	43-46	interleukin 6	Homo sapiens	127-131
1904664-2	1991	CsA at 100-1000 ng/ml doses prevented cytoplasmic extracts of cells activated in vitro by OKT3 or MLC from triggering incorporation of radiolabeled nucleotides by resting isolated nuclei.	Cyclosporine	0-3	modulator of VRAC current 1	Homo sapiens	98-101
1904664-3	1991	In addition, nuclei isolated from cells previously treated with 200-1000 ng/ml of CsA were refractory to the potent cytoplasmic signal extracted from OKT3- or MLC-stimulated cells.	Cyclosporine	82-85	modulator of VRAC current 1	Homo sapiens	159-162
2039018-3	1991	The iatrogenic hypertension induced by cyclosporine resembles a low-renin, salt-sensitive form of essential hypertension, which is often controlled with salt restriction and therapies counteracting renal salt acquisition, e.g., diuretics and calcium channel blockers (CCBs).	Cyclosporine	39-51	renin	Homo sapiens	68-73
1646506-6	1991	CsA effectively inhibited the proliferative response and IL-2 production induced with anti-CD3 and Bryo but did not inhibit the response of cells stimulated with anti-CD28 and Bryo.	Cyclosporine	0-3	interleukin 2	Homo sapiens	57-61
1646506-9	1991	Addition of CsA to lymphocytes stimulated with anti-CD3 resulted in the dose-dependent suppression of the proliferative response and IL-2 production (IC50 = 10-25 nM) but less so for IL-2 receptor expression (IC50 = 100-150 nM).	Cyclosporine	12-15	interleukin 2	Homo sapiens	133-137
1646506-14	1991	Taken together, these data suggest that CsA inhibits T cell activation at two distinct levels, leading to inhibition of IL-2 production and inhibition of IL-2 receptor expression.	Cyclosporine	40-43	interleukin 2	Homo sapiens	120-124
1646506-15	1991	Activation of the CD28 pathway partially overcomes the inhibitory activity of CsA on IL-2 production and may be mediated by indirect activation of a cGMP-dependent protein kinase.	Cyclosporine	78-81	interleukin 2	Homo sapiens	85-89
2039018-8	1991	There was some additive inhibition of IL-2 receptor expression at the higher concentrations of verapamil and cyclosporine that were tested.	Cyclosporine	109-121	interleukin 2	Homo sapiens	38-42
1827048-3	1991	However, when monocytes were pretreated with either CsA or CsH for 16 hr prior to the addition of IFN-gamma, HLA-DR expression was increased, probably because of a cyclosporin-induced increase in the number of IFN-gamma receptors.	Cyclosporine	52-55	interferon gamma	Homo sapiens	98-107
1827048-3	1991	However, when monocytes were pretreated with either CsA or CsH for 16 hr prior to the addition of IFN-gamma, HLA-DR expression was increased, probably because of a cyclosporin-induced increase in the number of IFN-gamma receptors.	Cyclosporine	52-55	interferon gamma	Homo sapiens	210-219
1827048-3	1991	However, when monocytes were pretreated with either CsA or CsH for 16 hr prior to the addition of IFN-gamma, HLA-DR expression was increased, probably because of a cyclosporin-induced increase in the number of IFN-gamma receptors.	Cyclosporine	164-175	interferon gamma	Homo sapiens	98-107
1827048-3	1991	However, when monocytes were pretreated with either CsA or CsH for 16 hr prior to the addition of IFN-gamma, HLA-DR expression was increased, probably because of a cyclosporin-induced increase in the number of IFN-gamma receptors.	Cyclosporine	164-175	interferon gamma	Homo sapiens	210-219
1827048-5	1991	IFN-alpha also inhibited the IFN-gamma-induced HLA-DR mRNA expression and showed synergy with CsA at low concentrations but not at high concentrations of the drugs.	Cyclosporine	94-97	interferon alpha 1	Homo sapiens	0-9
1827048-5	1991	IFN-alpha also inhibited the IFN-gamma-induced HLA-DR mRNA expression and showed synergy with CsA at low concentrations but not at high concentrations of the drugs.	Cyclosporine	94-97	interferon gamma	Homo sapiens	29-38
1827048-6	1991	A common mechanistic element in the pathways of CsA and IFN-alpha is proposed.	Cyclosporine	48-51	interferon alpha 1	Homo sapiens	56-65
2055290-5	1991	These sera are devoid of detectable interleukin 3 (IL-3) or granulocyte-macrophage colony-stimulating factor (GM-CSF), but contain large amounts of interleukin 6 (IL-6) that are perfectly correlated with circulating CSA levels.	Cyclosporine	216-219	interleukin 6	Mus musculus	148-161
1711475-2	1991	We show that like IL-1, interleukin 4 (IL-4) can stimulate 3T3 fibroblasts to produce CSA.	Cyclosporine	86-89	interleukin 4	Homo sapiens	24-37
1711475-2	1991	We show that like IL-1, interleukin 4 (IL-4) can stimulate 3T3 fibroblasts to produce CSA.	Cyclosporine	86-89	interleukin 4	Homo sapiens	39-43
1657241-1	1991	It has previously been shown that administration of cyclosporine causes a prompt (within 15 min after infusion) increase in circulating level of endothelin 1 and a pattern of glomerular hypoperfusion and hypofiltration which can be ameliorated with antiendothelin antibody.	Cyclosporine	52-64	endothelin 1	Rattus norvegicus	145-157
1657241-2	1991	We now show that 60 min after cyclosporine, serum endothelin 1 level falls to less than 2.55 +/- 0.31 pg/mL (N = 6), a value comparable to that found in normal animals (less than 2 pg/mL).	Cyclosporine	30-42	endothelin 1	Rattus norvegicus	50-62
1677815-11	1991	In situ hybridization revealed that injected recombinant myocytes remain in discrete foci in adult rodent skeletal muscle and express MDR1 mRNA for at least 30 days in nude mice and cyclosporine-treated rats.	Cyclosporine	182-194	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	134-138
2038191-8	1991	Three-day courses of anti-TNF were moderately effective (13.7 +/- 0.5 days, P less than 0.05 vs control) and were also synergistic with CsA (27.8 +/- 2.2).	Cyclosporine	136-139	tumor necrosis factor	Rattus norvegicus	26-29
2038191-10	1991	Likewise, serum TNF levels were significantly lowered for treated groups vs control (83.1 +/- 14.0 pg/ml for control; 39.5 +/- 13.8 for anti-TNF; and 13.4 +/- 5.4 for anti-TNF + CsA; P less than 0.05 vs control for all groups).	Cyclosporine	178-181	tumor necrosis factor	Rattus norvegicus	16-19
2033128-4	1991	After 15 days of cyclosporine therapy, we observed a dramatic decrease in the total number of T cells and a corresponding decrease in interleukin 2 receptor-positive activated CD25+ cells and in antigen-presenting cells (CD1+ and CD14b+).	Cyclosporine	17-29	interleukin 2	Homo sapiens	134-147
2014542-7	1991	Verapamil or cyclosporine alone inhibited IL-2 production of PHA- and phorbol ester-stimulated peripheral blood mononuclear cells--however, no additive effect was seen when the two drugs were both added to culture, probably because of the very potent inhibition by cyclosporine alone.	Cyclosporine	13-25	interleukin 2	Homo sapiens	42-46
2068574-8	1991	Cyclosporine A interferes with prolactin binding to its receptors on lymphocytes.	Cyclosporine	0-14	prolactin	Homo sapiens	31-40
2041548-7	1991	The CSA distribution of mdx DD-EDL myofibers was significantly shifted toward smaller CSA compared with unoperated mdx EDL, although mean CSA did not differ between the two mdx muscle groups.	Cyclosporine	4-7	dystrophin, muscular dystrophy	Mus musculus	24-27
2068574-12	1991	Suppression of circulating prolactin by bromocriptine appears to improve the immunosuppressive effect of cyclosporine A with significantly less toxicity.	Cyclosporine	105-119	prolactin	Homo sapiens	27-36
2043284-6	1991	NSAIDs inhibit the synthesis of prostaglandins, and consequently vasoconstriction of the afferent arteriole leads to lowering of the glomerular filtration rate (GFR); captopril blocks the formation of angiotensin II (which also leads to a lower GFR), and should be used with caution in patients with stenotic renal arteries; cyclosporin causes vasoconstriction of the afferent arteriole, which is probably mediated by the sympathetic system.	Cyclosporine	325-336	angiotensinogen	Homo sapiens	201-215
1674429-3	1991	By applying the method of immunocytochemical assay, we have demonstrated the appearance of the multidrug-resistant phenotype (P-glycoprotein+ cells, multidrug-resistant cells) in mononuclear cells of the peripheral blood from 32/49 patients receiving triple-drug (azathioprine, steroids, cyclosporine) immunosuppressive therapy after heart transplantation.	Cyclosporine	288-300	ATP binding cassette subfamily B member 1	Homo sapiens	126-140
1715185-0	1991	Cyclosporin A and FK-506 both affect DNA binding of regulatory nuclear proteins to the human interleukin-2 promoter.	Cyclosporine	0-13	interleukin 2	Homo sapiens	93-106
1715185-1	1991	The structurally unrelated immunosuppressive drugs cyclosporin A (Sandimmun) and FK-506 both interfere with the process of T-cell proliferation by blocking the transcription of the T-cell growth factor interleukin-2 (IL-2).	Cyclosporine	51-64	interleukin 2	Homo sapiens	202-215
1715185-1	1991	The structurally unrelated immunosuppressive drugs cyclosporin A (Sandimmun) and FK-506 both interfere with the process of T-cell proliferation by blocking the transcription of the T-cell growth factor interleukin-2 (IL-2).	Cyclosporine	51-64	interleukin 2	Homo sapiens	217-221
1715185-3	1991	We present evidence that the binding by regulatory nuclear proteins to the kappa B element of the IL-2 promoter is affected negatively by cyclosporin A and FK-506 at concentrations paralleling their immunosuppressive activity in vivo.	Cyclosporine	138-151	interleukin 2	Homo sapiens	98-102
1715185-5	1991	FK-506 is 10 to 100 times more potent than cyclosporin A in its ability to inhibit sequence-specific DNA binding and IL-2 production.	Cyclosporine	43-56	interleukin 2	Homo sapiens	117-121
2041548-8	1991	The CSA distribution of control DD-EDL was significantly different and shifted toward smaller CSA from both unoperated control EDL and from mdx DD-EDL distributions.	Cyclosporine	4-7	dystrophin, muscular dystrophy	Mus musculus	140-143
1671400-7	1991	Moreover, IL-2-dependent events may also help in enhancing CD2 hyper-expression because it was only partially inhibitable by cyclosporine, dexamethasone, or Mar-108 (CD25) mAb.	Cyclosporine	125-137	interleukin 2	Homo sapiens	10-14
1672478-4	1991	The results showed that short-term CsA treatment causes a selective and almost complete depletion of both the CD4+8- and CD4-8+ subsets of medullary thymocytes, but that this effect is unrelated to any apparent influence of CsA on the proliferative or developmental potential of prothymocytes in the BM of the treated animals.	Cyclosporine	35-38	Cd48 molecule	Rattus norvegicus	121-126
1671638-6	1991	The MDR modifiers verapamil, Cremophor EL, cyclosporin A and Ro 11-2933/001 had significant effects on DN cytotoxicity, total DN accumulation and efflux, only if P-gp was present.	Cyclosporine	43-56	ATP binding cassette subfamily B member 1	Homo sapiens	162-166
1989345-0	1991	The in vivo effect of cyclosporine on interleukin-6 gene expression in renal transplant recipients.	Cyclosporine	22-34	interleukin 6	Homo sapiens	38-51
1847252-5	1991	PHA plus anti-CD28 or PMA plus anti-CD28-induced IL-2 synthesis was inhibited by genistein, and CsA, though it inhibited the PHA plus PMA-stimulated IL-2 synthesis, failed to have any effect on PMA plus anti-CD28-induced IL-2 synthesis.	Cyclosporine	96-99	interleukin 2	Homo sapiens	149-153
1703684-0	1991	In vivo regulation of cytokine expression: effects of cycloheximide and cyclosporine (CyA) on IFN-gamma and TNF-alpha expression.	Cyclosporine	72-84	interferon gamma	Homo sapiens	94-103
1703684-0	1991	In vivo regulation of cytokine expression: effects of cycloheximide and cyclosporine (CyA) on IFN-gamma and TNF-alpha expression.	Cyclosporine	72-84	tumor necrosis factor	Homo sapiens	108-117
1703684-0	1991	In vivo regulation of cytokine expression: effects of cycloheximide and cyclosporine (CyA) on IFN-gamma and TNF-alpha expression.	Cyclosporine	86-89	interferon gamma	Homo sapiens	94-103
1703684-0	1991	In vivo regulation of cytokine expression: effects of cycloheximide and cyclosporine (CyA) on IFN-gamma and TNF-alpha expression.	Cyclosporine	86-89	tumor necrosis factor	Homo sapiens	108-117
1847252-5	1991	PHA plus anti-CD28 or PMA plus anti-CD28-induced IL-2 synthesis was inhibited by genistein, and CsA, though it inhibited the PHA plus PMA-stimulated IL-2 synthesis, failed to have any effect on PMA plus anti-CD28-induced IL-2 synthesis.	Cyclosporine	96-99	interleukin 2	Homo sapiens	149-153
1985948-2	1991	Peptidyl-prolyl cis-trans-isomerase and the cyclosporin A (CsA)-binding protein cyclophilin are identical, and peptidyl-prolyl cis-trans-isomerase activity is inhibited by the immunosuppressive drug CsA in vitro.	Cyclosporine	44-57	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	59-62
1837465-6	1991	Ro 14-6113 was more effective than CsA in inhibiting IL-2 receptor expression.	Cyclosporine	35-38	interleukin 2 receptor subunit beta	Homo sapiens	53-66
1712536-0	1991	Selective alteration of cytokeratin intermediate filament by cyclosporine A is a lethal toxicity in PTK2 cell cultures.	Cyclosporine	61-75	protein tyrosine kinase 2	Homo sapiens	100-104
2064787-1	1991	The kinetics and extent of uptake of cyclosporin (CSA) in various strata of human cadaver skin upon topical application of several CSA formulations were determined by in vitro diffusion cell experiments.	Cyclosporine	37-48	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	50-53
2064787-1	1991	The kinetics and extent of uptake of cyclosporin (CSA) in various strata of human cadaver skin upon topical application of several CSA formulations were determined by in vitro diffusion cell experiments.	Cyclosporine	37-48	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	131-134
1712536-7	1991	Increased LDH levels into cell culturing media occur soon after cyclosporine exposure to PtK2 cell cultures (5 mM, 2 hr).	Cyclosporine	64-76	protein tyrosine kinase 2	Homo sapiens	89-93
1676547-8	1991	The response via CD2 plus CD28 is IL-2-dependent, as demonstrated by the ability of mAb against the IL-2 receptor to block proliferation, and is almost completely inhibited by cyclosporine A (CsA).	Cyclosporine	176-190	CD28 molecule	Homo sapiens	26-30
1718903-0	1991	Ciclosporin A inhibits mediator release from human Fc epsilon RI+ cells by interacting with cyclophilin.	Cyclosporine	0-13	Fc epsilon receptor Ia	Homo sapiens	51-64
1676547-8	1991	The response via CD2 plus CD28 is IL-2-dependent, as demonstrated by the ability of mAb against the IL-2 receptor to block proliferation, and is almost completely inhibited by cyclosporine A (CsA).	Cyclosporine	192-195	CD28 molecule	Homo sapiens	26-30
1702375-7	1990	Treatment of transfused animals with CyA, but not FK506 for 14 days resulted in minor, transient reduction in peripheral blood OX-19+ and W3/25+ cells, while "sparing" the OX-8+ cells; these changes were not observed in spleens.	Cyclosporine	37-40	AF4/FMR2 family, member 2	Mus musculus	127-132
2269327-4	1990	Here we show that as soon as 4 h after CsA addition, the transcription of the gene encoding the alpha chain (p55) of IL2R was inhibited.	Cyclosporine	39-42	interleukin 2 receptor subunit alpha	Homo sapiens	109-112
2269327-4	1990	Here we show that as soon as 4 h after CsA addition, the transcription of the gene encoding the alpha chain (p55) of IL2R was inhibited.	Cyclosporine	39-42	interleukin 2 receptor subunit alpha	Homo sapiens	117-121
2269327-10	1990	This discrepancy between the effect of CsA on IL2R alpha expression as probed at the mRNA or the protein level can be accounted for by the stability of the IL2R alpha protein after synthesis.	Cyclosporine	39-42	interleukin 2 receptor subunit alpha	Homo sapiens	46-56
2269327-10	1990	This discrepancy between the effect of CsA on IL2R alpha expression as probed at the mRNA or the protein level can be accounted for by the stability of the IL2R alpha protein after synthesis.	Cyclosporine	39-42	interleukin 2 receptor subunit alpha	Homo sapiens	156-166
1761361-3	1991	In nongranulocytopenic mice, the combined treatment with IL-1 and bacterial cells also resulted in a biphasic pattern of CSA response.	Cyclosporine	121-124	interleukin 1 complex	Mus musculus	57-61
2076903-2	1990	Increasing knowledge concerning the action of cytokines on the permeability of the vascular barrier, and the possibility to suppress their production with ciclosporin A (CsA), especially of the cytokine interleukin-2, made its therapeutic use for the treatment of NS reasonable.	Cyclosporine	170-173	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	155-168
1761361-4	1991	However, when IL-1 was administered in concurrence with the cyclo-oxygenase inhibitor indomethacin, sustained CSA levels could be observed for a prolonged period of time.	Cyclosporine	110-113	interleukin 1 complex	Mus musculus	14-18
1761361-5	1991	These data expand upon our previous observations on modulation of CSA by IL-1 in granulocytopenic mice, and further support the concept that IL-1 may have both positive and negative effects on the expression of circulating CSA.	Cyclosporine	66-69	interleukin 1 complex	Mus musculus	73-77
1725322-1	1991	Cyclosporine A (CSA) stimulated endothelin secretion by a cultured renal epithelial cell line, LLC-PK1.	Cyclosporine	0-14	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	16-19
2023061-0	1991	Isolation of cross-reacting compounds to Incstar Cyclo-Trac SP RIA in blood samples obtained from cardiac allograft patients on cyclosporine therapy.	Cyclosporine	128-140	T cell receptor alpha constant	Homo sapiens	55-59
2258695-7	1990	Immune serum obtained from RT1u recipients that had rejected a RT1Aa disparate graft was able, when injected into cyclosporin-treated RT1u recipients, to restore their ability to reject a RT1Aa, but not a third-party RT1c, kidney.	Cyclosporine	114-125	RT1 class II, locus Da	Rattus norvegicus	27-31
2258695-7	1990	Immune serum obtained from RT1u recipients that had rejected a RT1Aa disparate graft was able, when injected into cyclosporin-treated RT1u recipients, to restore their ability to reject a RT1Aa, but not a third-party RT1c, kidney.	Cyclosporine	114-125	RT1 class II, locus Da	Rattus norvegicus	134-138
2125251-3	1990	Sequential measurements after transplantation and during CsA treatment revealed a transient significant increase of median values with highest amounts of vWF:Ag of 362% (2 p less than 0.0001), FVIII:Ag of 398% (2 p less than 0.001) and FVIII:C of 360% (2 p less than 0.0001) (Friedman test).	Cyclosporine	57-60	coagulation factor VIII	Homo sapiens	193-198
2244933-6	1990	Treatment with TSI normalized TxB2 excretion; this was associated with partial protection against CsA induced changes in CCR and NAG enzymuria and the complete prevention of acute proximal tubular vacuolation.	Cyclosporine	98-101	O-GlcNAcase	Rattus norvegicus	129-132
2125251-3	1990	Sequential measurements after transplantation and during CsA treatment revealed a transient significant increase of median values with highest amounts of vWF:Ag of 362% (2 p less than 0.0001), FVIII:Ag of 398% (2 p less than 0.001) and FVIII:C of 360% (2 p less than 0.0001) (Friedman test).	Cyclosporine	57-60	coagulation factor VIII	Homo sapiens	236-241
2125251-10	1990	In contrast to recent reports, plasma vWF levels were not indicative of vascular injury in kidney graft recipients nor was the marked elevation of vWF and FVIII associated with thromboembolic complications ascribed to CsA treatment.	Cyclosporine	218-221	coagulation factor VIII	Homo sapiens	155-160
2242562-2	1990	Fast atom bombardment mass spectrometry of an HPLC fraction co-eluting with 1 eta hydroxy-cyclosporine (M17) indicated that the mass of this metabolite was 2 Da greater than that of cyclosporine.	Cyclosporine	90-102	endothelin receptor type A	Homo sapiens	78-81
2220641-7	1990	Cyclosporine dose was significantly associated with hepatic lipase activity (r = 0.33, p less than 0.02) and inversely associated with lipoprotein lipase activity (r = -0.28, p less than 0.05).	Cyclosporine	0-12	lipase C, hepatic type	Homo sapiens	52-66
2220641-10	1990	In multiple regression analysis, cyclosporine dose was the major source of variation in hepatic lipase activity.	Cyclosporine	33-45	lipase C, hepatic type	Homo sapiens	88-102
1700506-13	1990	Thus, in CsA sensitive individuals, one-tenth of the optimal CsA concentration together with CD25 antibody maintained maximum immunosuppression in vitro.	Cyclosporine	9-12	interleukin 2 receptor subunit alpha	Homo sapiens	93-97
2209764-6	1990	These results suggest that CsA and CsG can increase the cloning efficiency of normal mouse BMC, possibly by inhibiting an endogenous Lyt-2.2+ suppressor cell.	Cyclosporine	27-30	CD8 antigen, alpha chain	Mus musculus	133-138
2228019-5	1990	It has been demonstrated that only the CD3/TcR alpha beta+ J11d- CD25- subpopulation is susceptible to the suppressive effects of CsA among CD4-8- cells, whereas all the other four subpopulations, including CD3/TcR gamma delta+ cells, are resistant.	Cyclosporine	130-133	CD3 antigen, epsilon polypeptide	Mus musculus	39-42
2254041-6	1990	However, the activity of erythrocyte CR1, in the graft recipients under cyclosporin A treatment, was significantly higher than in the patients receiving azathioprine with prednisone.	Cyclosporine	72-85	complement C3b/C4b receptor 1 (Knops blood group)	Homo sapiens	37-40
2219281-1	1990	To evaluate the rate of recurrence of focal segmental glomerulosclerosis (FSGS) in renal transplant patients treated with cyclosporine, we reviewed the outcome of 25 renal Tx performed in 24 patients who had FSGS as their original renal disease.	Cyclosporine	122-134	actinin alpha 4	Homo sapiens	74-78
2398356-5	1990	Apparent penetration of cyclosporin A into the cerebrospinal fluid (CSF) determined with the intravenous bolus injection technique is small with a Kin of 0.79 +/- 0.07 microliter g-1 min-1.	Cyclosporine	24-37	Kin17 DNA and RNA binding protein	Rattus norvegicus	147-150
2219281-5	1990	Ten of 19 patients (55%) given CsA showed recurrence of FSGS; one of them had had recurrence in the first graft treated with Aza.	Cyclosporine	31-34	actinin alpha 4	Homo sapiens	56-60
1724618-2	1990	The cyclic peptides cyclosporin A (CSA) and gramicidin-S (GRS) are shown to bind CaM and inhibit 3",5"-cyclic nucleotide phosphodiesterase (PDE) in a calcium-dependent manner.	Cyclosporine	20-33	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	35-38
2142529-3	1990	Proliferation of these clones induced by anti-CD3 antibody was completely inhibited by cyclosporine A, whereas cyclosporine A had little effect on proliferation induced by recombinant IL-2 or recombinant IL-4.	Cyclosporine	87-101	CD3 antigen, epsilon polypeptide	Mus musculus	46-49
2142529-9	1990	Effects of cyclosporine A and the protein synthesis inhibitors cycloheximide and anisomycin on IL-4 and IL-5 gene expression suggest that these genes are activated by different pathways after anti-CD3 stimulation.	Cyclosporine	11-25	CD3 antigen, epsilon polypeptide	Mus musculus	197-200
2142529-10	1990	Cyclosporine A completely inhibited anti-CD3-induced expression of IL-4 mRNA but not of IL-5 mRNA, and protein-synthesis inhibitors completely inhibited induction of IL-5 mRNA but not of IL-4 mRNA.	Cyclosporine	0-14	CD3 antigen, epsilon polypeptide	Mus musculus	41-44
2382107-5	1990	Sensitivity to CsA was expressed as the ability of the drug to suppress cell proliferation ([3H]thymidine incorporation) and high-affinity interleukin-2 receptor (IL-2R) expression.	Cyclosporine	15-18	interleukin 2 receptor subunit alpha	Homo sapiens	139-161
2214611-0	1990	Urinary excretion of N-acetyl-beta-D-glucosaminidase in patients after cyclosporin-treated corneal grafting.	Cyclosporine	71-82	O-GlcNAcase	Homo sapiens	21-52
2382107-5	1990	Sensitivity to CsA was expressed as the ability of the drug to suppress cell proliferation ([3H]thymidine incorporation) and high-affinity interleukin-2 receptor (IL-2R) expression.	Cyclosporine	15-18	interleukin 2 receptor subunit alpha	Homo sapiens	163-168
2382107-10	1990	The CsA-induced suppression of high-affinity IL-2R expression varied between 57.1 and 98.9%, while suppression of [3H]thymidine incorporation varied between 81.0 and 97.4%.	Cyclosporine	4-7	interleukin 2 receptor subunit alpha	Homo sapiens	45-50
2163257-6	1990	However, cyclosporin A induces a dose-dependent reduction in membrane IL-2 receptor expression which consequently limits the proliferation of the antigen-activated cell.	Cyclosporine	9-22	interleukin 2 receptor subunit beta	Homo sapiens	70-83
1971531-5	1990	Cyclosporine (CsA) prevented diC8 and ionomycin-induced expression of IL-2, IFN-gamma, and H-ras genes.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
2111738-7	1990	Assay of serum colony-stimulating activity (CSA) revealed that (a) cyclophosphamide treatment alone significantly increased the level of circulating CSA, (b) administration of a single dose of IL-1 to neutropenic mice induced an early, further increase in serum CSA, followed by depression, (c) a biphasic pattern of CSA response was also evident in mice repeatedly treated with IL-1.	Cyclosporine	44-47	interleukin 1 complex	Mus musculus	193-197
2111738-7	1990	Assay of serum colony-stimulating activity (CSA) revealed that (a) cyclophosphamide treatment alone significantly increased the level of circulating CSA, (b) administration of a single dose of IL-1 to neutropenic mice induced an early, further increase in serum CSA, followed by depression, (c) a biphasic pattern of CSA response was also evident in mice repeatedly treated with IL-1.	Cyclosporine	149-152	interleukin 1 complex	Mus musculus	193-197
2111738-7	1990	Assay of serum colony-stimulating activity (CSA) revealed that (a) cyclophosphamide treatment alone significantly increased the level of circulating CSA, (b) administration of a single dose of IL-1 to neutropenic mice induced an early, further increase in serum CSA, followed by depression, (c) a biphasic pattern of CSA response was also evident in mice repeatedly treated with IL-1.	Cyclosporine	149-152	interleukin 1 complex	Mus musculus	193-197
2111738-7	1990	Assay of serum colony-stimulating activity (CSA) revealed that (a) cyclophosphamide treatment alone significantly increased the level of circulating CSA, (b) administration of a single dose of IL-1 to neutropenic mice induced an early, further increase in serum CSA, followed by depression, (c) a biphasic pattern of CSA response was also evident in mice repeatedly treated with IL-1.	Cyclosporine	149-152	interleukin 1 complex	Mus musculus	193-197
2374050-3	1990	Evidence accumulates suggesting cyclosporine (CSA) acts as a potent vasoconstricting agent and that antihypertensive medications such as calcium channel blocking agents may offer protection from this effect.	Cyclosporine	32-44	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	46-49
2188853-7	1990	This stimulation was blocked by anti-IL-2 receptor monoclonal antibodies, and was inhibited dose-dependently by cyclosporin-A.	Cyclosporine	112-125	interleukin 2 receptor subunit beta	Homo sapiens	37-50
2333417-1	1990	Nephrotoxicity is the most troublesome side effect of cyclosporin A (CSA) therapy.	Cyclosporine	54-67	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	69-72
2105228-6	1990	Cyclosporine, known to interfere with IL-2 release and responses, completely blocked both ConA- and PMA-induced lymphocyte proliferation but did not interfere with ConA-triggered cluster formation.	Cyclosporine	0-12	interleukin 2	Canis lupus familiaris	38-42
2094690-1	1990	Factors which can account for the poor correlation between whole blood and plasma Cyclosporine (CsA) levels in patients on CsA prophylaxis are evaluated.	Cyclosporine	82-94	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	96-99
2094690-1	1990	Factors which can account for the poor correlation between whole blood and plasma Cyclosporine (CsA) levels in patients on CsA prophylaxis are evaluated.	Cyclosporine	82-94	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	123-126
2312149-0	1990	Anti-CD3 antibody-induced expression of both p55 and p75 chains of the high affinity interleukin-2 receptor on human T lymphocytes is inhibited by cyclosporin A.	Cyclosporine	147-160	interleukin 2 receptor subunit alpha	Homo sapiens	45-48
2312149-0	1990	Anti-CD3 antibody-induced expression of both p55 and p75 chains of the high affinity interleukin-2 receptor on human T lymphocytes is inhibited by cyclosporin A.	Cyclosporine	147-160	interleukin 2 receptor subunit beta	Homo sapiens	53-56
2312149-4	1990	Thus, CsA affected IL-2R expression and/or function at higher concentrations (300 ng/ml).	Cyclosporine	6-9	interleukin 2 receptor subunit alpha	Homo sapiens	19-24
2312149-8	1990	However, addition of rIL-2 reversed CsA inhibition of IL-2R expression.	Cyclosporine	36-39	interleukin 2 receptor subunit alpha	Homo sapiens	54-59
2312149-9	1990	It is concluded that CsA, at least in anti-CD3-stimulated cells, inhibits IL-2R expression and cell proliferation with similar potency.	Cyclosporine	21-24	interleukin 2 receptor subunit alpha	Homo sapiens	74-79
2312149-10	1990	Exogenous rIL-2 reverses CsA inhibition of IL-2R expression.	Cyclosporine	25-28	interleukin 2 receptor subunit alpha	Homo sapiens	43-48
2113225-1	1990	We analysed our population of renal transplant recipients treated with cyclosporin (CsA) and prednisolone with respect to clinically evident de novo malignancies.	Cyclosporine	71-82	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	84-87
34923546-7	2021	In the CSA group, the radiographic parameters showed smaller C4/5 and C5/6 extension angles and C5/6 ROM values and a greater C3/4 flexion angle than the Control group.	Cyclosporine	7-10	interferon induced protein with tetratricopeptide repeats 1	Homo sapiens	61-74
34503301-6	2021	NSCLC cell lines express oncofetal CS-modified proteoglycans that can be specifically detected and targeted by rVAR2 proteins in a CSA-dependent manner.	Cyclosporine	131-134	citrate synthase	Homo sapiens	35-37
2129797-1	1990	We have examined the effect and potential mechanism of Cyclosporin A (CsA) on the Interleukin-2-receptor alpha chain (IL-2R alpha) expression in human T-lymphocytes.	Cyclosporine	70-73	interleukin 2 receptor subunit alpha	Homo sapiens	118-129
2129797-2	1990	CsA pretreatment of PHA-activated T-cells led to 30-50% decrease in Tac antigen surface expression and a concomitant decrease in the steady state IL-2R alpha mRNA levels.	Cyclosporine	0-3	interleukin 2 receptor subunit alpha	Homo sapiens	68-79
2129797-2	1990	CsA pretreatment of PHA-activated T-cells led to 30-50% decrease in Tac antigen surface expression and a concomitant decrease in the steady state IL-2R alpha mRNA levels.	Cyclosporine	0-3	interleukin 2 receptor subunit alpha	Homo sapiens	146-157
2250411-4	1990	The graft volume at 2-3 months after transplantation was smaller (215.9 +/- 30.9 ml, mean +/- SD) in patients who received small amounts of ciclosporin A (CsA) together with azathioprine and steroid than that (270.9 +/- 75.0 ml) in those treated by conventional immunosuppression.	Cyclosporine	155-158	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	140-153
2385448-7	1990	With equal doses of G, urinary NAG excretion was seven times higher in association with CS than in monotherapy.	Cyclosporine	88-90	O-GlcNAcase	Rattus norvegicus	31-34
2184355-6	1990	Those assigned to cyclosporine also had significant decreases in serum levels of bilirubin, alanine aminotransferase, alkaline phosphatase, gamma globulin, and the titer of antimitochondrial antibodies.	Cyclosporine	18-30	glutamic--pyruvic transaminase	Homo sapiens	92-116
2159448-4	1990	Three weeks of daily cyclosporine and cortisone injections depleted L3T4+ cells to 6.0%, Lyt-2+ cells to 20% and anti-MCMV antibody to 10% of untreated mice.	Cyclosporine	21-33	CD8 antigen, alpha chain	Mus musculus	89-94
1967265-8	1990	Transcripts of the gene for the IL-2R p55 chain are also normally elevated during infection, and CsA treatment resulted in an 80% reduction in the percentage of cells transcribing this gene.	Cyclosporine	97-100	interleukin 2 receptor subunit alpha	Homo sapiens	32-37
1967265-8	1990	Transcripts of the gene for the IL-2R p55 chain are also normally elevated during infection, and CsA treatment resulted in an 80% reduction in the percentage of cells transcribing this gene.	Cyclosporine	97-100	interleukin 2 receptor subunit alpha	Homo sapiens	38-41
2250570-1	1990	These experiments were designed to test the hypothesis that cyclosporine A (CSA) inhibits renin secretion and stimulates renal prostaglandin E2 (PGE2) release in vitro.	Cyclosporine	60-74	renin	Rattus norvegicus	90-95
2250570-1	1990	These experiments were designed to test the hypothesis that cyclosporine A (CSA) inhibits renin secretion and stimulates renal prostaglandin E2 (PGE2) release in vitro.	Cyclosporine	76-79	renin	Rattus norvegicus	90-95
2250570-7	1990	These results suggest that the occasional effects of CSA on renin secretion in intact animals must be attributable to indirect and/or chronic effects.	Cyclosporine	53-56	renin	Rattus norvegicus	60-65
33032826-9	2020	CsA was also found to promote the expression of titin, MMP9, EGFR, and PRR15.	Cyclosporine	0-3	titin	Homo sapiens	48-53
11390729-1	2001	BACKGROUND: The new cyclosporin (CsA) formulation, Neoral, has different pharmacokinetics compared with Sandimmune (SIM).	Cyclosporine	20-31	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	33-36
34322871-9	2022	However, in larger fibres, the relationship between MND and CSA was significantly altered in trained versus sedentary PGC-1alpha mKO, suggesting that PGC-1alpha is critical for myonuclear accretion in these fibres.	Cyclosporine	60-63	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	150-160
34400311-8	2021	Their serum eosinophil counts, serum ALT levels, and serum thymus and activation regulated chemokine (TARC) levels were all elevated at the baseline and then significantly decreased during the recovery stage after cyclosporine therapy (p <0.05).	Cyclosporine	214-226	C-C motif chemokine ligand 17	Homo sapiens	59-100
34400311-8	2021	Their serum eosinophil counts, serum ALT levels, and serum thymus and activation regulated chemokine (TARC) levels were all elevated at the baseline and then significantly decreased during the recovery stage after cyclosporine therapy (p <0.05).	Cyclosporine	214-226	C-C motif chemokine ligand 17	Homo sapiens	102-106
34903507-5	2021	A 17% reduction in staining score for PUMA in SCC, but not in BCC, of organ transplant recipients treated with a cyclosporin (CsA)-containing regimen was noted compared to organ transplant recipients without chronic CsA intake (p = 0.0381) PUMA expression in SCC, but not BCC, is significantly reduced by CsA-containing therapy, suggesting a disturbance of apoptosis by iatrogenic immunosuppression with a divergent impact on SCC and BCC.	Cyclosporine	113-124	BCL2 binding component 3	Homo sapiens	38-42
34903507-5	2021	A 17% reduction in staining score for PUMA in SCC, but not in BCC, of organ transplant recipients treated with a cyclosporin (CsA)-containing regimen was noted compared to organ transplant recipients without chronic CsA intake (p = 0.0381) PUMA expression in SCC, but not BCC, is significantly reduced by CsA-containing therapy, suggesting a disturbance of apoptosis by iatrogenic immunosuppression with a divergent impact on SCC and BCC.	Cyclosporine	113-124	BCL2 binding component 3	Homo sapiens	240-244
34903507-5	2021	A 17% reduction in staining score for PUMA in SCC, but not in BCC, of organ transplant recipients treated with a cyclosporin (CsA)-containing regimen was noted compared to organ transplant recipients without chronic CsA intake (p = 0.0381) PUMA expression in SCC, but not BCC, is significantly reduced by CsA-containing therapy, suggesting a disturbance of apoptosis by iatrogenic immunosuppression with a divergent impact on SCC and BCC.	Cyclosporine	126-129	BCL2 binding component 3	Homo sapiens	38-42
34903507-5	2021	A 17% reduction in staining score for PUMA in SCC, but not in BCC, of organ transplant recipients treated with a cyclosporin (CsA)-containing regimen was noted compared to organ transplant recipients without chronic CsA intake (p = 0.0381) PUMA expression in SCC, but not BCC, is significantly reduced by CsA-containing therapy, suggesting a disturbance of apoptosis by iatrogenic immunosuppression with a divergent impact on SCC and BCC.	Cyclosporine	126-129	BCL2 binding component 3	Homo sapiens	240-244
34903507-5	2021	A 17% reduction in staining score for PUMA in SCC, but not in BCC, of organ transplant recipients treated with a cyclosporin (CsA)-containing regimen was noted compared to organ transplant recipients without chronic CsA intake (p = 0.0381) PUMA expression in SCC, but not BCC, is significantly reduced by CsA-containing therapy, suggesting a disturbance of apoptosis by iatrogenic immunosuppression with a divergent impact on SCC and BCC.	Cyclosporine	305-308	BCL2 binding component 3	Homo sapiens	38-42
34903507-5	2021	A 17% reduction in staining score for PUMA in SCC, but not in BCC, of organ transplant recipients treated with a cyclosporin (CsA)-containing regimen was noted compared to organ transplant recipients without chronic CsA intake (p = 0.0381) PUMA expression in SCC, but not BCC, is significantly reduced by CsA-containing therapy, suggesting a disturbance of apoptosis by iatrogenic immunosuppression with a divergent impact on SCC and BCC.	Cyclosporine	305-308	BCL2 binding component 3	Homo sapiens	240-244
34580765-6	2022	After 24 h of incubation, CsA suppressed the PMCA1 protein, which pumps intracellular calcium out of the cell.	Cyclosporine	26-29	ATPase plasma membrane Ca2+ transporting 1	Homo sapiens	45-50
34575860-11	2021	Furthermore, CsA and Tac led to NF-kappaB p65 subunit phosphorylation and nuclear translocation.	Cyclosporine	13-16	RELA proto-oncogene, NF-kB subunit	Homo sapiens	32-45
34445139-5	2021	Inhibitors of SMase (desipramine and GW4869) and MAM (cyclosporin A) activities were also utilized.	Cyclosporine	54-67	sarcoglycan gamma	Homo sapiens	49-52
34439442-6	2021	The administration of CsA also significantly downregulated the renal expression of interferon-gamma, tumor necrosis factor-alpha, interleukin 1 beta, monocyte chemotactic protein 1, intercellular adhesion molecule-1, and vascular cell adhesion molecule 1 genes, and increased renal DNA damage.	Cyclosporine	22-25	vascular cell adhesion molecule 1	Rattus norvegicus	221-254
34109683-12	2021	CsA suppressed the TGF-beta-induced translocation of NFATc3 into the nuclei of hGF.	Cyclosporine	0-3	transforming growth factor alpha	Homo sapiens	19-27
34109683-12	2021	CsA suppressed the TGF-beta-induced translocation of NFATc3 into the nuclei of hGF.	Cyclosporine	0-3	hepatocyte growth factor	Homo sapiens	79-82
34231398-1	2022	PURPOSE: To assess the efficacy and safety of supplementing topical cyclosporine A (CsA) to topical corticosteroids (CS), in the prophylaxis and treatment of corneal graft rejection following penetrating keratoplasty (PK).	Cyclosporine	84-87	citrate synthase	Homo sapiens	117-119
34109683-14	2021	We confirmed that CsA, NIF, and PHT reduced cytosolic calcium levels increased by TGF-beta, while CaCl2 enhanced the TGF-beta-up-regulated NR4A1 expression.	Cyclosporine	18-21	transforming growth factor alpha	Homo sapiens	82-90
34220265-10	2021	Conclusion: Our study reveals that HMGA1 and PSAT1 can be deployed for initial screening of ovarian cancer and drugs cisplatin, bisphenol A, cyclosporin, progesterone, and sunitinib are effective in curbing the epigenetic alteration.	Cyclosporine	141-152	phosphoserine aminotransferase 1	Homo sapiens	45-50
34220265-9	2021	However, hypermethylated seed genes HMGA1 and PSAT1 showcased a good interaction affinity with drugs cisplatin, cyclosporin, bisphenol A, progesterone, and sunitinib, and are crucial in the proliferation of ovarian cancer.	Cyclosporine	112-123	phosphoserine aminotransferase 1	Homo sapiens	46-51
33201059-1	2021	PURPOSE: To compare efficiency and tolerance between topical 0.5% cyclosporine A (CSA) and fluorometholone (FML) for subepithelial infiltrates (SEI) complicating epidemic keratoconjunctivitis.	Cyclosporine	66-80	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	82-85
34127702-0	2021	Lysyl oxidase inhibitors attenuate cyclosporin A-induced nephropathy in mouse.	Cyclosporine	35-48	lysyl oxidase	Mus musculus	0-13
34127702-10	2021	Collectively, our study suggests that Pan-LOX and LOXL2 inhibition can attenuate progressive nephropathy due to CsA administration.	Cyclosporine	112-115	lysyl oxidase	Mus musculus	42-45
33093401-10	2021	RESULTS: The results revealed that allotransplant survival was significantly prolonged in group 4 with CD26i/G-CSF/ALS/CsA treatment compared to those in the other groups.	Cyclosporine	119-122	colony stimulating factor 3	Rattus norvegicus	109-114
2789931-1	1989	The effects of four Ca2+ channel antagonists on the metabolism of cyclosporine (CsA) by human liver microsomes (n = 4) in vitro have been examined.	Cyclosporine	66-78	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	80-83
34122084-5	2021	Moreover, CsA also elevated the levels of intracellular cholesterol (Cho), intracellular reactive oxygen species (ROS) via activation of NADPH oxidase p47phox, serum- and glucocorticoid-induced kinase isoform 1 (Sgk1), and phosphorylated neural precursor cell-expressed developmentally downregulated protein 4-2 (p-Nedd4-2) in the kidney cortex.	Cyclosporine	10-13	serum/glucocorticoid regulated kinase 1	Rattus norvegicus	160-210
34122084-5	2021	Moreover, CsA also elevated the levels of intracellular cholesterol (Cho), intracellular reactive oxygen species (ROS) via activation of NADPH oxidase p47phox, serum- and glucocorticoid-induced kinase isoform 1 (Sgk1), and phosphorylated neural precursor cell-expressed developmentally downregulated protein 4-2 (p-Nedd4-2) in the kidney cortex.	Cyclosporine	10-13	serum/glucocorticoid regulated kinase 1	Rattus norvegicus	212-216
34122084-5	2021	Moreover, CsA also elevated the levels of intracellular cholesterol (Cho), intracellular reactive oxygen species (ROS) via activation of NADPH oxidase p47phox, serum- and glucocorticoid-induced kinase isoform 1 (Sgk1), and phosphorylated neural precursor cell-expressed developmentally downregulated protein 4-2 (p-Nedd4-2) in the kidney cortex.	Cyclosporine	10-13	NEDD4 like E3 ubiquitin protein ligase	Rattus norvegicus	315-322
2813293-5	1989	In an "ER ind group", rats were treated with ER for 5 days, conditions under which the P450IIIA gene subfamily, principally involved in CsA metabolism, was specifically induced, and isolated rat livers were perfused with 60 micrograms 3H-CsA for 20 min.	Cyclosporine	136-139	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	87-95
34122084-8	2021	These results suggest that CsA elevates blood pressure by increasing ENaC activity via a signaling cascade associated with elevation of intracellular ROS, activation of Sgk1, and inactivation of Nedd4-2 in an intracellular cholesterol-dependent manner.	Cyclosporine	27-30	serum/glucocorticoid regulated kinase 1	Rattus norvegicus	169-173
2501389-10	1989	Cyclosporin A, which does not prevent PKC-induced CD69 expression, completely suppressed CD69-induced IL-2 and IFN-gamma gene expression.	Cyclosporine	0-13	CD69 molecule	Homo sapiens	89-93
34122084-8	2021	These results suggest that CsA elevates blood pressure by increasing ENaC activity via a signaling cascade associated with elevation of intracellular ROS, activation of Sgk1, and inactivation of Nedd4-2 in an intracellular cholesterol-dependent manner.	Cyclosporine	27-30	NEDD4 like E3 ubiquitin protein ligase	Rattus norvegicus	195-202
34067576-0	2021	Camel Milk Mitigates Cyclosporine-Induced Renal Damage in Rats: Targeting p38/ERK/JNK MAPKs, NF-kappaB, and Matrix Metalloproteinases.	Cyclosporine	21-33	mitogen activated protein kinase 14	Rattus norvegicus	74-77
34067576-9	2021	These findings propose that camel milk may be a promising agent that inhibits cyclosporine-triggered renal inflammation via curtailing the p38/ERK/JNK MAPK and NF-kappaB pathways, matrix metalloproteinases, and pro-inflammatory cytokines.	Cyclosporine	78-90	mitogen activated protein kinase 14	Rattus norvegicus	139-142
34064311-8	2021	Cyclosporin A fully abolished the PSB-induced NO production in the hippocampus, suggesting a close relationship between nNOS and PP2B activity.	Cyclosporine	0-13	nitric oxide synthase 1	Homo sapiens	120-124
2676910-1	1989	Controlled double-blind studies have demonstrated the efficacy of 14 mg/kg per day cyclosporin A (CsA) in patients with severe psoriasis.	Cyclosporine	83-96	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	98-101
34732623-3	2021	Although cyclosporine (CS) was stopped at 120 days after transplantation, chronic graft-versus-host disease (cGVHD) of the skin developed.	Cyclosporine	9-21	citrate synthase	Homo sapiens	23-25
2816597-8	1989	However, the elevation of urinary NAG index was found in some ciclosporin-treated patients with normal serum Cr.	Cyclosporine	62-73	O-GlcNAcase	Homo sapiens	34-37
2816597-9	1989	The elevation of NAG index without the elevation of urinary FDP occurred in ciclosporin nephrotoxicity.	Cyclosporine	76-87	O-GlcNAcase	Homo sapiens	17-20
2816597-10	1989	The SDS electrophoresis of urinary proteins, urinary FDP, and urinary NAG index can be useful parameters for monitoring ciclosporin nephrotoxicity.	Cyclosporine	120-131	O-GlcNAcase	Homo sapiens	70-73
35606278-6	2022	The association between psoas, paraspinal, abdominal, and central muscle CSA and Bone Mineral density (BMD) at L3, L4, total Lumbar Spine (LS), and right (R) and left (L) hip was estimated in crude and adjusted for age and sex linear regression models.	Cyclosporine	73-76	hedgehog interacting protein	Homo sapiens	171-174
2797718-1	1989	Cyclosporine (cyclosporin A, CsA) is a selective T-cell immunosuppressant that works primarily through inhibition of both antigen presentation and lymphokine production.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	29-32
2674381-2	1989	Two patients had evidence of extremely erratic absorption of the cyclosporine (CSA) used for immunosuppression.	Cyclosporine	65-77	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	79-82
35418571-3	2022	In this study, we show that the lipophilic cyclic peptide, cyclosporin A (CsA), interacted with, and likely induced aggregation, of polymeric, gel-forming mucins (MUC2, MUC5AC and MUC5B) which underpin the mucus gel-networks in the gastrointestinal tract.	Cyclosporine	74-77	mucin 5B, oligomeric mucus/gel-forming	Homo sapiens	180-185
35418571-5	2022	Using rate-zonal centrifugation, purified MUC2, MUC5AC and MUC5B mucins sedimented faster in the presence of CsA, with a significant increase in mucins in the pellet fraction.	Cyclosporine	109-112	mucin 5B, oligomeric mucus/gel-forming	Homo sapiens	59-64
2798309-1	1989	The currently available intravenous dosage form of cyclosporine (CSA), Sandimmune I.V., contains the vehicle, Cremophor EL, which has been implicated in producing anaphylactic reactions in man and animals.	Cyclosporine	51-63	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	65-68
35418571-7	2022	CsA increased MUC5B sedimentation was concentration-dependent, and sedimentation studies using recombinant mucin protein domains suggests CsA most likely causes aggregation of the relatively non-O-glycosylated N-terminal and C-terminal regions of MUC5B.	Cyclosporine	0-3	mucin 5B, oligomeric mucus/gel-forming	Homo sapiens	14-19
35418571-7	2022	CsA increased MUC5B sedimentation was concentration-dependent, and sedimentation studies using recombinant mucin protein domains suggests CsA most likely causes aggregation of the relatively non-O-glycosylated N-terminal and C-terminal regions of MUC5B.	Cyclosporine	0-3	LOC100508689	Homo sapiens	107-112
35418571-7	2022	CsA increased MUC5B sedimentation was concentration-dependent, and sedimentation studies using recombinant mucin protein domains suggests CsA most likely causes aggregation of the relatively non-O-glycosylated N-terminal and C-terminal regions of MUC5B.	Cyclosporine	0-3	mucin 5B, oligomeric mucus/gel-forming	Homo sapiens	247-252
2732228-1	1989	cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine.	Cyclosporine	141-153	potassium voltage-gated channel subfamily A member 3	Homo sapiens	92-97
35418571-7	2022	CsA increased MUC5B sedimentation was concentration-dependent, and sedimentation studies using recombinant mucin protein domains suggests CsA most likely causes aggregation of the relatively non-O-glycosylated N-terminal and C-terminal regions of MUC5B.	Cyclosporine	138-141	mucin 5B, oligomeric mucus/gel-forming	Homo sapiens	14-19
35418571-7	2022	CsA increased MUC5B sedimentation was concentration-dependent, and sedimentation studies using recombinant mucin protein domains suggests CsA most likely causes aggregation of the relatively non-O-glycosylated N-terminal and C-terminal regions of MUC5B.	Cyclosporine	138-141	LOC100508689	Homo sapiens	107-112
35418571-7	2022	CsA increased MUC5B sedimentation was concentration-dependent, and sedimentation studies using recombinant mucin protein domains suggests CsA most likely causes aggregation of the relatively non-O-glycosylated N-terminal and C-terminal regions of MUC5B.	Cyclosporine	138-141	mucin 5B, oligomeric mucus/gel-forming	Homo sapiens	247-252
35418571-9	2022	CsA has partially N-methylated amide groups, this unique molecular structure, not present in daptomycin and polymyxin B, may potentially be involved in interaction with gel-forming mucin.	Cyclosporine	0-3	LOC100508689	Homo sapiens	181-186
35418571-10	2022	Taken together, our results indicate that the interaction of gel-forming mucins with the cyclic peptide CsA is mediated at the N- and C-terminal domains of mucin polymers under physiological conditions.	Cyclosporine	104-107	LOC100508689	Homo sapiens	156-161
35088890-9	2022	These cell lines exhibited higher ABCB1 activity and the ABCB1 inhibitor cyclosporin A enhanced the decrease of cell viability caused by gedatolisib.	Cyclosporine	73-86	ATP binding cassette subfamily B member 1	Canis lupus familiaris	57-62
2647858-0	1989	Antibodies to cyclosporine A (CsA) by a novel route and their use to monitor cyclosporine levels by radioimmunoassay (RIA).	Cyclosporine	14-26	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	30-33
2647858-1	1989	Anti-cyclosporine antibodies were generated in rabbits, using an antigen derived from CsA.	Cyclosporine	5-17	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	86-89
2647858-3	1989	In the presence of CsA, photolysis of BBa results in hydrogen abstraction and random insertion into the cyclosporine molecule, generating a population of CsA with carboxyl groups at various positions.	Cyclosporine	104-116	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	19-22
2647858-3	1989	In the presence of CsA, photolysis of BBa results in hydrogen abstraction and random insertion into the cyclosporine molecule, generating a population of CsA with carboxyl groups at various positions.	Cyclosporine	104-116	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	154-157
2465309-5	1989	In contrast, cyclosporin A and WW.T4 blocked the four antigen-specific functions of the autoimmune myelin basic protein-specific human T cell clones measured.	Cyclosporine	13-26	myelin basic protein	Homo sapiens	99-119
35074592-7	2022	RESULTS: CsA was found to cause a striking increase in liver enzymes, total bilirubin, and malondialdehyde levels while significantly decreasing the levels of albumin, glutathione, and antioxidant enzymes in the treated groups.	Cyclosporine	9-12	albumin	Mus musculus	159-166
2784240-1	1989	Cyclosporine treatment of BALB/c mice (at a dose of 20 mg/kg every other day for 3 weeks) caused a remarkable reduction in the PNA-, L3T4+Lyt-2- subset of thymocytes.	Cyclosporine	0-12	CD8 antigen, alpha chain	Mus musculus	138-143
35074592-11	2022	On the other hand, the levels of PPAR-gamma decreased significantly with CsA.	Cyclosporine	73-76	peroxisome proliferator activated receptor gamma	Mus musculus	33-43
2784240-2	1989	A significant reduction of the L3T4+Lyt-2-subset was also observed in both the lymph node and spleen cells of CsA-treated mice, though the degree of the reduction was lower than that in thymocytes.	Cyclosporine	110-113	CD8 antigen, alpha chain	Mus musculus	36-41
2784240-3	1989	Both lymph node and spleen cells from CsA-treated mice showed a significant increase in the percentage of Thy-1.2 negative, L3T4-Lyt-2- cells (perhaps B cells).	Cyclosporine	38-41	CD8 antigen, alpha chain	Mus musculus	129-134
35126949-10	2022	Experimental results showed that there were 16 cases (14.55%) of CNI-related renal damage in lung transplant recipients and different immunosuppressants, including 10 cases (11.36%) in males, 6 cases (27.27%) in females, 11 cases (12.09%) in tacrolimus group, and 5 cases (26.32%) in cyclosporine A group.	Cyclosporine	284-298	5'-nucleotidase, cytosolic IA	Homo sapiens	65-68
2784240-8	1989	These results suggest that CsA affects both thymus and spleen cells in vivo, preferentially impairing the L3T4+Lyt-2- subset (helper T cells or their precursors) within the thymus.	Cyclosporine	27-30	CD8 antigen, alpha chain	Mus musculus	111-116
2536062-6	1989	Whereas cyclosporin A did not inhibit the effect of PMA, it reduced the effects of agonists to TCR/CD3 and CD28 on the LTR.	Cyclosporine	8-21	CD28 molecule	Homo sapiens	107-111
35126949-12	2022	Compared with MMF before and after administration, CNI dosage of cyclosporine A group and tacrolimus group decreased significantly (P < 0.01).	Cyclosporine	65-79	5'-nucleotidase, cytosolic IA	Homo sapiens	51-54
2536062-8	1989	Thus, PMA activates the NF kappa B sites through a PKC-dependent pathway while ligands to TCR/CD3 and CD28 activate the LTR through a cyclosporin A-sensitive, PKC-dependent pathway of T cell activation.	Cyclosporine	134-147	CD28 molecule	Homo sapiens	102-106
2809194-4	1989	Addition of CsA to organ culture resulted in a decreased cell yield and complete inhibition of the appearance of TCR-alpha beta-bearing, single positive thymocytes (both CD4+CD8- and CD4-CD8+).	Cyclosporine	12-15	T cell receptor alpha constant	Homo sapiens	113-122
2688634-2	1989	P450hA7 metabolized the immunosuppressant drug cyclosporin A and the dihydropyridine calcium channel antagonist nifedipine, but did not metabolize a similar dihydropyridine drug, nicardipine, nor a series of alkoxyresorufin model substrates.	Cyclosporine	47-60	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-7
2783437-4	1989	CsA abrogated the production of L3T4+ T cells and Lyt-2+ T cells in the thymus.	Cyclosporine	0-3	CD8 antigen, alpha chain	Mus musculus	50-55
2805337-0	1989	Evaluation of the Incstar Cyclo-Trac sp kit for the determination of cyclosporine in blood.	Cyclosporine	69-81	T cell receptor alpha constant	Homo sapiens	32-36
2516344-1	1989	Although cyclosporine (CSA) is established in the prevention of allograft rejection, its use has been associated with dose-limiting toxicities, most notably to the kidney and liver.	Cyclosporine	9-21	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	23-26
2785298-1	1989	The effect of in vitro administration of Cyclosporin A (CsA) during mitogen, antigen and alloantigen activation of human T-lymphocytes on high affinity interleukin-2 (IL-2) receptor expression and -turnover and IL-2 production was investigated.	Cyclosporine	41-54	interleukin 2 receptor subunit beta	Homo sapiens	167-181
2785298-1	1989	The effect of in vitro administration of Cyclosporin A (CsA) during mitogen, antigen and alloantigen activation of human T-lymphocytes on high affinity interleukin-2 (IL-2) receptor expression and -turnover and IL-2 production was investigated.	Cyclosporine	56-59	interleukin 2 receptor subunit beta	Homo sapiens	167-181
2539282-3	1989	In the present study using two-color analysis, we monitored the expression of interleukin-2 receptor (IL-2R) and HLA-DR antigen on the T-cells of a group of 51 renal cadaveric allograft recipients receiving cyclosporin, azathioprine, and prednisone for an average of 4 months after transplantation.	Cyclosporine	207-218	interleukin 2 receptor subunit alpha	Homo sapiens	78-100
2588745-1	1989	The aim of the study was to investigate the influence of a pretreatment of the heart donor with cyclosporin (CsA) at 25 or 50 mg kg BW on day -1 on survival time of rat heart allografts in a donor-recipient combination that was different at their major histocompatibility complex (MHC).	Cyclosporine	96-107	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	109-112
2539282-3	1989	In the present study using two-color analysis, we monitored the expression of interleukin-2 receptor (IL-2R) and HLA-DR antigen on the T-cells of a group of 51 renal cadaveric allograft recipients receiving cyclosporin, azathioprine, and prednisone for an average of 4 months after transplantation.	Cyclosporine	207-218	interleukin 2 receptor subunit alpha	Homo sapiens	102-107
2544432-14	1989	CsA blocks the T3-II-induced potentiation of PMA-induced IL2R expression but not the mAb 9.3-induced potentiation.	Cyclosporine	0-3	interleukin 2 receptor subunit alpha	Homo sapiens	57-61
2544432-15	1989	This differential inhibitory effect of CsA on IL2R expression is also seen with db-cAMP and CT. We examined the effects of these two pathways on the expression of the early activation antigen EA 1 and cytoplasmic free calcium.	Cyclosporine	39-42	interleukin 2 receptor subunit alpha	Homo sapiens	46-50
2567675-5	1989	CyA-induced inhibition of both anti-CD3- and anti-CD2-mediated proliferation could not be reversed by addition of either PMA (1 ng/ml) or anti-CD28.	Cyclosporine	0-3	CD28 molecule	Homo sapiens	143-147
2673814-4	1989	Cyclosporin A exerted in both strains an increased fed plasma glucose, decreased glucose tolerance and diminished pancreatic insulin content, however, the Wistar rat strain with the MHC RT1u was more sensitive to the effect of Cyclosporin A, indicated by a more marked alteration of pancreatic B-cells and a delayed recovery after drug withdrawal.	Cyclosporine	0-13	RT1 class II, locus Da	Rattus norvegicus	186-190
2735162-0	1989	[Detection of early pregnancy factor by the rosette inhibition test: use of cyclosporin A].	Cyclosporine	76-89	heat shock protein family E (Hsp10) member 1	Homo sapiens	14-36
2735162-2	1989	In the testing of 10 EPF-positive and 10 EPF-negative sera the immunosuppressive agent cyclosporine A was used for the first time.	Cyclosporine	87-101	heat shock protein family E (Hsp10) member 1	Homo sapiens	21-24
2735162-2	1989	In the testing of 10 EPF-positive and 10 EPF-negative sera the immunosuppressive agent cyclosporine A was used for the first time.	Cyclosporine	87-101	heat shock protein family E (Hsp10) member 1	Homo sapiens	41-44
2673814-4	1989	Cyclosporin A exerted in both strains an increased fed plasma glucose, decreased glucose tolerance and diminished pancreatic insulin content, however, the Wistar rat strain with the MHC RT1u was more sensitive to the effect of Cyclosporin A, indicated by a more marked alteration of pancreatic B-cells and a delayed recovery after drug withdrawal.	Cyclosporine	227-240	RT1 class II, locus Da	Rattus norvegicus	186-190
2522829-1	1989	Two novel models of activation of human peripheral blood quiescent T-cells (T-cells) were utilized herein as probes to analyze the mechanisms and to locate the site of action of cyclosporine (CsA) in the T-cell activation pathway.	Cyclosporine	178-190	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	192-195
2753469-5	1989	Coincubation with CsA (1 micrograms/ml) delayed the "escape" response of CT + PTH treated bones, so that the full "escape" response did not occur until after 48 hr of organ culture.	Cyclosporine	18-21	parathyroid hormone	Mus musculus	78-81
2753469-6	1989	Likewise, a pretreatment of 24 hr with CsA (1 micrograms/ml) was sufficient to delay "escape" from CT inhibition of PTH stimulated bone resorption until after 48 hr of organ culture.	Cyclosporine	39-42	parathyroid hormone	Mus musculus	116-119
2925842-1	1989	Cyclosporine A (CsA) has been used in putative autoimmune diseases after sensitization to unknown antigens.	Cyclosporine	0-14	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	16-19
2649744-9	1989	Administration of mAb OX-19 from Day -14 together with CsA (15 mg/kg) from Days -14 to -8 inclusive (Group 5) resulted in a marked and sustained depletion of OX-19+ cells at rejection but only a modest prolongation of graft survival (27.6 +/- 6.0 days, P = 0.11).	Cyclosporine	55-58	AF4/FMR2 family, member 2	Mus musculus	158-163
2784875-2	1989	While cyclosporine (CsA) present during the macrophage-T cell coculture inhibited antigen presentation effectively, pretreatment (2 hr) of macrophages with the drug also caused marked inhibition regardless of the antigen concentration and order of drug/antigen addition.	Cyclosporine	6-18	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	20-23
2784875-5	1989	Cyclosporine demonstrated saturable binding to macrophages suggesting the existence of CsA-binding sites.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	87-90
2525802-8	1989	Both strains were, however, able to recover from the infection without functional T-helper lympho-cytes and/or the IL-1 IL-2 which had been inhibited by treatment with CsA.	Cyclosporine	168-171	interleukin 1 complex	Mus musculus	115-124
2645701-14	1989	Patients experiencing CsA toxicity (n = 12) showed mild creatinine elevations, normal or negative IL-2(P) and IL-2R(P) levels, and no IL-2(U).	Cyclosporine	22-25	interleukin 2 receptor subunit beta	Homo sapiens	110-115
2977379-4	1988	Kinetic studies revealed that s-IL-2R exhibited the suppressive effects on the proliferative responses of alloantigen stimulated human tonsillar cells, only when added at an early stage, namely 0-48 h after culture onset, whereas cyclosporin A (CsA) exhibited an inhibitory effect only when added at between 0 and 24 h. This implies that s-IL-2R exerts its effect on an early stage of lymphocyte activation.	Cyclosporine	230-243	interleukin 2 receptor subunit beta	Homo sapiens	32-37
2571317-6	1989	Cyclosporine induced a slight increase in AAP and NAG excretion.	Cyclosporine	0-12	O-GlcNAcase	Homo sapiens	50-53
2977379-4	1988	Kinetic studies revealed that s-IL-2R exhibited the suppressive effects on the proliferative responses of alloantigen stimulated human tonsillar cells, only when added at an early stage, namely 0-48 h after culture onset, whereas cyclosporin A (CsA) exhibited an inhibitory effect only when added at between 0 and 24 h. This implies that s-IL-2R exerts its effect on an early stage of lymphocyte activation.	Cyclosporine	245-248	interleukin 2 receptor subunit beta	Homo sapiens	32-37
3263432-7	1988	Treatment with CsA during induction of competence prevented the expression of the 55-kDa IL-2R gene during competence induction and inhibited IL-2 gene expression and IL-2 production in response to PDB in the second phase.	Cyclosporine	15-18	interleukin 2 receptor subunit alpha	Homo sapiens	89-94
3262237-1	1988	Cyclosporine A (CsA) is an important immunosuppressive drug that is widely used in transplantation medicine.	Cyclosporine	0-14	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	16-19
3046689-1	1988	Between 1982 and 1986 51 patients were treated with ciclosporin a (CSA) to prevent graft versus host disease (GvHD) after bone marrow transplantation (BMT).	Cyclosporine	52-65	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	67-70
3056547-6	1988	Treatment of chronic GVHD in this model has shown thalidomide to be better tolerated and more successful than cyclosporine (CSA) or prednisone plus azathioprine.	Cyclosporine	110-122	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	124-127
3242657-1	1988	It is demonstrated that cyclosporine (CsA), a novel fungal-derived immunosuppressive agent, attenuates naloxone-precipitated morphine withdrawal in an unusual dose-dependent manner following direct intracerebroventricular (icv) administration.	Cyclosporine	24-36	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	38-41
3041828-7	1988	Unlike rat models, which suggest cyclosporine-induced stimulation of the renin-angiotensin system, or previous forms of post-transplant hypertension in humans, plasma renin levels were not elevated and blood pressure did not respond to a test dose of captopril.	Cyclosporine	33-45	renin	Rattus norvegicus	73-78
2456233-9	1988	Cross-strain marker anti-CSA antiserum clearly showed that the tenascin-positive fibroblasts were of Balb/c origin.	Cyclosporine	25-28	tenascin C	Mus musculus	63-71
2673064-6	1989	Dermal CD1+DR+ cells (putative Langerhans cells), which are not found in normal skin but are present in lesional psoriasis skin, were virtually cleared from the papillary dermis after CsA therapy.	Cyclosporine	184-187	CD1c molecule	Homo sapiens	7-10
3206533-6	1988	However, 5000 ng/ml CsA significantly (P less than 0.05) reduced the hCG (1 ng/ml)-stimulated T levels, CSCC and 17,20-desmolase activities.	Cyclosporine	20-23	hypertrichosis 2 (generalised, congenital)	Homo sapiens	69-72
2970137-11	1988	IL-3 production is increased significantly in these states of unresponsiveness, an observation also noted during maintenance CsA treatment; this seems to correlate with suppressor activity.	Cyclosporine	125-128	interleukin 3	Rattus norvegicus	0-4
3236762-10	1988	In steroid resistant FSGS 6 children benefited from Cs treatment: 4 went into complete remission, 2 into partial remission.	Cyclosporine	52-54	myosin IE	Homo sapiens	21-27
3066654-9	1988	During the period of administration, CsA led to a decrease of Lyt 1 +/Lyt 2 + ratio in spleen cells and prevented the insulitis in low dose SZ-treated mice.	Cyclosporine	37-40	CD8 antigen, alpha chain	Mus musculus	70-75
3172640-1	1988	A major problem in cyclosporine A (CsA) therapy is its nephrotoxicity, characterized by a marked fall in glomerular filtration rate (GFR).	Cyclosporine	19-33	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	35-38
2837844-9	1988	The results suggest that T4-IL-2R cells that escape cyclosporine inhibition are highly correlated with rejection and enumeration may contribute to increased utility of immune monitoring in these patients.	Cyclosporine	52-64	interleukin 2 receptor subunit beta	Homo sapiens	28-33
3045721-2	1988	In this study, kidney function was measured simultaneously and continuously for 6.6 h with engymetry, after application of a 12 h therapy dose of Cyclosporine A (CsA) of 4.0 +/- 1.8 mg per kg bodyweight (bw).	Cyclosporine	146-160	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	162-165
3293865-13	1988	These results suggest that insulin action at the receptor may be affected by the administration of cyclosporine.	Cyclosporine	99-111	insulin receptor	Homo sapiens	49-57
2965735-7	1988	Cyclosporin A completely inhibited the PWM-induced development of CD25+ cells and related tissue damage.	Cyclosporine	0-13	interleukin 2 receptor subunit alpha	Homo sapiens	66-70
3254185-1	1988	Our group has previously shown that cyclosporine A (CSA) but not cyclosporine G (CSG) causes splenic atrophy in a BALB/c mouse model.	Cyclosporine	36-50	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	52-55
3278422-1	1988	Low-dose cyclosporine (CsA) plus prednisone for induction and maintenance immunosuppression were used in 106 consecutive cadaveric renal transplants.	Cyclosporine	9-21	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	23-26
3201530-1	1988	The evaluation of a radioimmunoassay (RIA) for the monitoring of cyclosporine (CSA) that utilizes a monoclonal antibody specific for the parent compound is described.	Cyclosporine	65-77	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	79-82
3262940-3	1988	Through the use of monoclonal anti-L3T4 and anti-Lyt-2 antibodies together with two-color flow cytofluorometry, we demonstrated that CsA caused a remarkable reduction of L3T4+ Lyt-2- subset and only a slight increase in L3T4+ Lyt-2+ subset in the thymus.	Cyclosporine	133-136	CD8 antigen, alpha chain	Mus musculus	49-54
3262940-3	1988	Through the use of monoclonal anti-L3T4 and anti-Lyt-2 antibodies together with two-color flow cytofluorometry, we demonstrated that CsA caused a remarkable reduction of L3T4+ Lyt-2- subset and only a slight increase in L3T4+ Lyt-2+ subset in the thymus.	Cyclosporine	133-136	CD8 antigen, alpha chain	Mus musculus	176-181
3262940-3	1988	Through the use of monoclonal anti-L3T4 and anti-Lyt-2 antibodies together with two-color flow cytofluorometry, we demonstrated that CsA caused a remarkable reduction of L3T4+ Lyt-2- subset and only a slight increase in L3T4+ Lyt-2+ subset in the thymus.	Cyclosporine	133-136	CD8 antigen, alpha chain	Mus musculus	176-181
3262940-6	1988	The above mentioned results imply that in normal, unprimed mice CsA may preferentially impair L3T4+ Lyt-2- subset (helper T cells and their precursors) residing in the thymic medulla whereas is much less effective against L3T4+ Lyt-2+ subset present in the cortex and L3T4- Lyt-2+ subset.	Cyclosporine	64-67	CD8 antigen, alpha chain	Mus musculus	100-105
3262940-6	1988	The above mentioned results imply that in normal, unprimed mice CsA may preferentially impair L3T4+ Lyt-2- subset (helper T cells and their precursors) residing in the thymic medulla whereas is much less effective against L3T4+ Lyt-2+ subset present in the cortex and L3T4- Lyt-2+ subset.	Cyclosporine	64-67	CD8 antigen, alpha chain	Mus musculus	228-233
3262940-6	1988	The above mentioned results imply that in normal, unprimed mice CsA may preferentially impair L3T4+ Lyt-2- subset (helper T cells and their precursors) residing in the thymic medulla whereas is much less effective against L3T4+ Lyt-2+ subset present in the cortex and L3T4- Lyt-2+ subset.	Cyclosporine	64-67	CD8 antigen, alpha chain	Mus musculus	228-233
2962348-1	1988	Antigen-nonspecific suppressor T cells were identified in spleens of mice rendered unresponsive by sensitization of allogeneic antigen in combination with cyclosporine (CsA) treatment.	Cyclosporine	155-167	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	169-172
2830495-0	1987	T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression.	Cyclosporine	67-79	CD28 molecule	Homo sapiens	35-39
2830495-9	1987	Functional studies revealed that the proliferation induced by CD28 and PMA stimulation was entirely resistant to cyclosporine, in contrast to T-cell activation induced by the CD3-T-cell receptor complex.	Cyclosporine	113-125	CD28 molecule	Homo sapiens	62-66
2830495-11	1987	Furthermore, stimulation by CD28 in combination with immobilized CD3 antibodies caused a striking enhancement of IL-2 mRNA expression that was, in part, resistant to the effects of cyclosporine.	Cyclosporine	181-193	CD28 molecule	Homo sapiens	28-32
3319309-1	1987	We report seven cases out of eight reversible raises (350% of mean increase) of cyclosporine (CsA) plasma levels in patients receiving the new calcium channel blocker nicardipine (Loxen-Sandoz) and CsA after renal transplantation.	Cyclosporine	80-92	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	94-97
3319309-1	1987	We report seven cases out of eight reversible raises (350% of mean increase) of cyclosporine (CsA) plasma levels in patients receiving the new calcium channel blocker nicardipine (Loxen-Sandoz) and CsA after renal transplantation.	Cyclosporine	80-92	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	198-201
2972933-4	1988	There are two different effects, the first of which is that CsA seems to block the differentiation of immature CD4+CD8+ thymocytes into mature CD4+CD8- and CD4-CD8+ cells expressing a high density of T-cell receptors and CD3 molecules.	Cyclosporine	60-63	CD3 antigen, epsilon polypeptide	Mus musculus	221-224
2903210-3	1988	IL-2 transcripts peaked at 8-16 h, and IL-2-R at 24-40 h. Cyclosporin A (CSA) inhibited the synthesis of IL-2, but not IL-2-R mRNA, after stimulation by PHA or anti-CD3.	Cyclosporine	58-71	interleukin 2 receptor subunit alpha	Homo sapiens	39-45
2903210-3	1988	IL-2 transcripts peaked at 8-16 h, and IL-2-R at 24-40 h. Cyclosporin A (CSA) inhibited the synthesis of IL-2, but not IL-2-R mRNA, after stimulation by PHA or anti-CD3.	Cyclosporine	73-76	interleukin 2 receptor subunit alpha	Homo sapiens	39-45
3049805-7	1988	High doses of cyclosporine given for 6 to 8 wk reduced the peritubular Ig deposits, renal Ia and H-2K expression, and specific mRNA for beta 2-microglobulin and MHC genes, but did not reduce anti-DNA antibody levels in serum.	Cyclosporine	14-26	beta-2 microglobulin	Mus musculus	136-156
3262905-6	1988	At two weeks, the animals in the cyclosporine + indomethacin group showed decreased creatinine excretion and increased NAG excretion.	Cyclosporine	33-45	sodium voltage-gated channel alpha subunit 7	Rattus norvegicus	119-122
3570356-1	1987	When administered intraperitoneally to mice 2 days before immunization with a tolerogenic dose (10(9)) of sheep red blood cells (SRBC), cyclosporin A (CsA; 200 mg/kg) strikingly augmented 4-day delayed-type hypersensitivity (DTH) footpad reactions.	Cyclosporine	136-149	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	151-154
2896111-0	1988	Cyclosporin A does not inhibit the PHA-stimulated increase in intracellular Ca2+ concentration but inhibits the increase in E-rosette receptor (CD2) expression and appearance of interleukin-2 receptors (CD25).	Cyclosporine	0-13	interleukin 2 receptor subunit alpha	Homo sapiens	203-207
2896111-1	1988	The immunosuppressive drug cyclosporin A (CsA) inhibits mixed lymphocyte responses, blocks the generation of cytotoxic T lymphocytes, and inhibits the T lymphocyte proliferative response stimulated by polyclonal activators such as phytohemagglutinin (PHA).	Cyclosporine	27-40	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	42-45
3124536-15	1988	The preliminary results of this trial showed that two thirds of the patients with cases of MGL and half of those with FSGS had total or partial remission after long-term treatment with cyclosporine.	Cyclosporine	185-197	actinin alpha 4	Homo sapiens	118-122
3132645-1	1988	We have developed a simple method of sample collection which allows the measurement of cyclosporin (CsA) to be made from blood obtained from a finger stab and collected onto filter paper.	Cyclosporine	87-98	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	100-103
2837053-13	1987	with KLM-583B and cyclosporin A had the lowest antiserum titres to retinal S-antigen.	Cyclosporine	18-31	S-arrestin	Cavia porcellus	67-84
3114680-2	1987	Cyclosporin (CsA) was the sole immunosuppressive in 70% of the cases, and azathioprine-prednisolone in 30%.	Cyclosporine	0-11	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	13-16
3306668-8	1987	Graft functional survival rates were significantly higher (p less than 0.05) in recipients who received azathioprine (AZA) and cyclosporine (CSA) in combination (n = 408) than in those who received CSA without azathioprine (n = 262) or AZA without cyclosporine, (n = 56), with 1 year graft functional survival rates of 47, 38, and 34%, respectively.	Cyclosporine	127-139	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	141-144
3097130-10	1986	CSA blocks at a point before the biosynthesis of Ea1 and after that of T3/T cell receptor loss from the cell surface, at a point close to Ea2 biosynthesis.	Cyclosporine	0-3	CD69 molecule	Homo sapiens	49-52
3769526-1	1986	Cyclosporin A (CsA) was administered to chicks of the Smyth delayed-amelanotic (SDA) line from day of hatch to 4, 8 or 12 weeks of age.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
3531461-0	1986	Effect of short-term cyclosporine administration in rats on renin-angiotensin and thromboxane A2: possible relevance to the reduction in glomerular filtration rate.	Cyclosporine	21-33	renin	Rattus norvegicus	60-65
2830495-12	1987	These studies indicate that the CD28 molecule synergizes with protein kinase C activation to induce IL-2 gene expression and demonstrate that stimulation by the CD28 pathway can cause vigorous T-cell proliferation even in the presence of cyclosporine and that cyclosporine does not prevent transcription of 16-2 mRNA, as has been suggested previously.	Cyclosporine	238-250	CD28 molecule	Homo sapiens	32-36
2830495-12	1987	These studies indicate that the CD28 molecule synergizes with protein kinase C activation to induce IL-2 gene expression and demonstrate that stimulation by the CD28 pathway can cause vigorous T-cell proliferation even in the presence of cyclosporine and that cyclosporine does not prevent transcription of 16-2 mRNA, as has been suggested previously.	Cyclosporine	238-250	CD28 molecule	Homo sapiens	161-165
2830495-12	1987	These studies indicate that the CD28 molecule synergizes with protein kinase C activation to induce IL-2 gene expression and demonstrate that stimulation by the CD28 pathway can cause vigorous T-cell proliferation even in the presence of cyclosporine and that cyclosporine does not prevent transcription of 16-2 mRNA, as has been suggested previously.	Cyclosporine	260-272	CD28 molecule	Homo sapiens	32-36
2830495-12	1987	These studies indicate that the CD28 molecule synergizes with protein kinase C activation to induce IL-2 gene expression and demonstrate that stimulation by the CD28 pathway can cause vigorous T-cell proliferation even in the presence of cyclosporine and that cyclosporine does not prevent transcription of 16-2 mRNA, as has been suggested previously.	Cyclosporine	260-272	CD28 molecule	Homo sapiens	161-165
3307341-0	1987	Cyclosporin A-induced nephrotoxicity in the rat: relationship to increased plasma renin activity.	Cyclosporine	0-13	renin	Rattus norvegicus	82-87
3307341-3	1987	CsA-induced nephrotoxicity, characterized by reduced glomerular filtration rate (GFR) and urinary sodium flow, enzymuria and proximal tubular cell damage was accompanied by elevated plasma renin activity (PRA).	Cyclosporine	0-3	renin	Rattus norvegicus	189-194
3307341-12	1987	CsA nephrotoxicity in the rat is clearly associated with activation of the renin-angiotensin-aldosterone system.	Cyclosporine	0-3	renin	Rattus norvegicus	75-80
2439348-1	1987	Cyclosporin A (CsA) produced dose-dependent membrane depolarization of human peripheral blood lymphocytes.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
3298044-3	1987	Two weeks of intragastric administration of cyclosporin A (5 mg/kg/day or or 20 mg/kg/day) resulted in large increases in plasma renin concentration (23 +/- 5, 70 +/- 12, and 79 +/- 11 ng/ml/hr in control rats and rats receiving 5 mg and 20 mg of cyclosporin A, respectively), with no parallel increments in plasma aldosterone.	Cyclosporine	44-57	renin	Rattus norvegicus	129-134
3298044-7	1987	Thus, cyclosporin A-induced hyperreninemic hypoaldosteronism in the rat depends on opposing renal and adrenal effects, with a direct or feedback stimulation of renin secretion and a specific blockade of ANG II-mediated aldosterone production.	Cyclosporine	6-19	renin	Rattus norvegicus	33-38
2886317-3	1987	The in vitro metabolism of cyclosporin A (CsA) was investigated by rabbit liver microsomes in order to identify the form(s) of cytochrome P-450 responsible for its biotransformation.	Cyclosporine	27-40	cytochrome P-450	Oryctolagus cuniculus	127-143
2886317-3	1987	The in vitro metabolism of cyclosporin A (CsA) was investigated by rabbit liver microsomes in order to identify the form(s) of cytochrome P-450 responsible for its biotransformation.	Cyclosporine	42-45	cytochrome P-450	Oryctolagus cuniculus	127-143
3495054-1	1987	Cyclosporine (CsA) inhibits release of interleukin 2 (IL-2) and hemopoietic growth activities such as interleukin 3 (IL-3) from major histocompatibility complex (MHC)-antigen-activated T cells.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
3549056-2	1987	Free CsA is then adsorbed onto charcoal and removed by centrifugation; CsA complexed with a cyclosporine-binding protein (CsBP) remains in the supernate.	Cyclosporine	71-74	heterogeneous nuclear ribonucleoprotein K	Homo sapiens	92-120
3549056-2	1987	Free CsA is then adsorbed onto charcoal and removed by centrifugation; CsA complexed with a cyclosporine-binding protein (CsBP) remains in the supernate.	Cyclosporine	71-74	heterogeneous nuclear ribonucleoprotein K	Homo sapiens	122-126
3549056-9	1987	These findings may explain the temperature-dependent uptake of CsA by erythrocytes in whole blood and suggest that measurement of CsBP in erythrocytes or lymphocytes may help predict therapeutic response or toxicity after administration of CsA.	Cyclosporine	240-243	heterogeneous nuclear ribonucleoprotein K	Homo sapiens	130-134
3554640-4	1987	Clearance studies 6 weeks after Tx exhibited significantly lower rates in the CsA group: Cin = 47 +/- 16.5 versus 83 +/- 25 ml/min/1.73 sqm, CPAH = 271 +/- 110 versus 503 +/- 181 ml/min/1.73 sqm (P less than 0.001).	Cyclosporine	78-81	pyridoxal phosphatase	Homo sapiens	89-92
3554640-6	1987	The tubular phosphate reabsorption per ml GFR (Tp/Cin) was only slightly lower in the CsA group (0.76 +/- 0.23 mumol/ml versus 0.93 +/- 0.29; P = 0.09).	Cyclosporine	86-89	pyridoxal phosphatase	Homo sapiens	50-53
3274475-0	1987	Increase in N-acetyl-beta-glucosaminidase excretion as a marker of kidney damage in cyclosporine-treated renal allografts.	Cyclosporine	84-96	O-GlcNAcase	Homo sapiens	12-41
3544378-1	1987	Nephrotoxicity and cost are the major problems in the use of cyclosporine (CsA) in renal transplantation.	Cyclosporine	61-73	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	75-78
3544387-1	1987	High-performance thin-layer chromatography (HPTLC) has advantages for the analysis of cyclosporine (CsA) and its metabolites in peripheral blood not shared by the radioimmunoassay (RIA) or high-performance liquid chromatography (HPLC) methods.	Cyclosporine	86-98	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	100-103
3490123-0	1986	Inhibition of T cell cytotoxicity by cyclosporine (CSA), adenosine (Ado) and an inhibitor of adenosine deaminase (ADA).	Cyclosporine	37-49	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	51-54
2871955-3	1986	Cyclosporine (CsA) nephrotoxicity in the rat, characterized by reduced glomerular filtration rate and structural damage to the proximal renal tubule, is associated with elevated activities of the lysosomal hydrolase, N-acetyl-beta-D-glucosaminidase (NAG), in the urine.	Cyclosporine	0-12	O-GlcNAcase	Rattus norvegicus	217-248
2871955-3	1986	Cyclosporine (CsA) nephrotoxicity in the rat, characterized by reduced glomerular filtration rate and structural damage to the proximal renal tubule, is associated with elevated activities of the lysosomal hydrolase, N-acetyl-beta-D-glucosaminidase (NAG), in the urine.	Cyclosporine	0-12	O-GlcNAcase	Rattus norvegicus	250-253
2871955-3	1986	Cyclosporine (CsA) nephrotoxicity in the rat, characterized by reduced glomerular filtration rate and structural damage to the proximal renal tubule, is associated with elevated activities of the lysosomal hydrolase, N-acetyl-beta-D-glucosaminidase (NAG), in the urine.	Cyclosporine	14-17	O-GlcNAcase	Rattus norvegicus	217-248
2871955-3	1986	Cyclosporine (CsA) nephrotoxicity in the rat, characterized by reduced glomerular filtration rate and structural damage to the proximal renal tubule, is associated with elevated activities of the lysosomal hydrolase, N-acetyl-beta-D-glucosaminidase (NAG), in the urine.	Cyclosporine	14-17	O-GlcNAcase	Rattus norvegicus	250-253
3708936-6	1986	There was increased renin secretion from the CSA-treated rats, compared to controls, and the response was dose-dependent.	Cyclosporine	45-48	renin	Rattus norvegicus	20-25
3531461-3	1986	With the present work we have examined the relationship between the reduction in GFR which follows a short-term administration of CyA in rats and the biochemical changes in renin-angiotensin system and renal arachidonic acid metabolism.	Cyclosporine	130-133	renin	Rattus norvegicus	173-178
3708936-9	1986	In animals not pretreated with CSA, the renal cortical slices incubated with CSA demonstrated a stimulation of renin release.	Cyclosporine	77-80	renin	Rattus norvegicus	111-116
3531461-4	1986	Our results show that CyA administration (25 mg/kg/day) for 45 days stimulates renin-angiotensin system with an increase in plasma renin activity.	Cyclosporine	22-25	renin	Rattus norvegicus	79-84
3531461-4	1986	Our results show that CyA administration (25 mg/kg/day) for 45 days stimulates renin-angiotensin system with an increase in plasma renin activity.	Cyclosporine	22-25	renin	Rattus norvegicus	131-136
3708936-11	1986	This data indicates that the renal renin-angiotensin system is activated by CSA and produces a dissociation of the linkage between renal slice prostaglandin release and the renin angiotensin system.	Cyclosporine	76-79	renin	Rattus norvegicus	35-40
3154407-4	1986	Cox regression analysis showed blood transfusion, recipient"s race, HLA mismatch, highest antibody, warm ischemia time, and cyclosporine treatment as significant factors affecting graft survival.	Cyclosporine	124-136	cytochrome c oxidase subunit 8A	Homo sapiens	0-3
2942335-1	1986	Cyclosporine (CsA) is a novel immunosuppressive agent currently used clinically, to prevent rejection of solid organ allografts and to prevent graft-vs.-host disease.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
3519027-3	1986	CyA was found to suppress feeding and drinking and, as a result, lead to volume depletion and weight loss, with a corresponding lowering of blood pressure and renal function and an increase in plasma renin.	Cyclosporine	0-3	renin	Rattus norvegicus	200-205
2942335-5	1986	Cyclosporine was very effective at inhibiting the production of interleukin-2 (IL-2), a soluble lymphokine known to amplify cytotoxic T cell responses and was also capable of preventing IL-2 receptor expression on the precursor cytotoxic T lymphocyte.	Cyclosporine	0-12	interleukin 2 receptor subunit beta	Homo sapiens	186-199
3484729-6	1986	Cy A-induced suppressor T cells carried both Lyt 1 and Lyt 2 surface markers.	Cyclosporine	0-4	CD8 antigen, alpha chain	Mus musculus	55-60
3907030-1	1985	Cyclosporine (CsA) dose adjustment after renal transplantation is generally based on serum, plasma, or whole-blood trough level values.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
4084311-2	1985	The material has been identified by mass spectrometry and by nuclear magnetic resonance spectrometry as an acidic metabolite of cyclosporine in which the eta-methyl group of the cyclosporine-specific nine carbon amino acid #1 has been oxidized to an alpha, beta unsaturated carboxylic acid functionality.	Cyclosporine	128-140	endothelin receptor type A	Homo sapiens	115-118
3160143-2	1985	Human monocytes (M phi) preexposed to cyclosporine (CsA) concentrations ranging between 1.0 and 10.0 micrograms/ml were impaired in their ability to stimulate autologous and allogeneic mixed lymphocyte reactions (MLR) when they were compared with control M phi unexposed to CsA.	Cyclosporine	38-50	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	52-55
3160143-2	1985	Human monocytes (M phi) preexposed to cyclosporine (CsA) concentrations ranging between 1.0 and 10.0 micrograms/ml were impaired in their ability to stimulate autologous and allogeneic mixed lymphocyte reactions (MLR) when they were compared with control M phi unexposed to CsA.	Cyclosporine	38-50	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	274-277
6437025-1	1984	Human monocytes (M phi) exposed to 0.5-20 micrograms/ml of cyclosporine (CsA) produced levels of prostaglandins of the E series (PGE) that were 2-3-fold greater than control M phi cultured in medium alone.	Cyclosporine	59-71	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	73-76
6333351-7	1984	Two of the three patients studied during the early postchemotherapy interval manifested initial serum Meg-CSA elevations seven days before their thrombocytopenic nadirs when platelet counts were still between 100,000/mm3 and 140,000/mm3.	Cyclosporine	106-109	protein tyrosine phosphatase non-receptor type 4	Homo sapiens	102-105
6332315-1	1984	Cyclosporin A (CsA) is a potent immunosuppressive agent, now gaining wide application in human organ transplantation.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
6371955-2	1984	In this study, Cyclosporin A was shown to stimulate renin release in vitro in rat renal cortical slices.	Cyclosporine	15-28	renin	Rattus norvegicus	52-57
6371955-4	1984	This observation strengthens the hypothesis that the intra renal renin-angiotensin system may participate in the mechanism of Cyclosporin A nephrotoxicity.	Cyclosporine	126-139	renin	Rattus norvegicus	65-70
6406595-2	1983	In the present study, we examined the effect of cyclosporin A (CsA) on the expression of Tac antigen by mitogen-stimulated T cells.	Cyclosporine	63-66	interleukin 2 receptor subunit alpha	Homo sapiens	89-100
34052742-12	2021	Only in CA, the MSFC measures correlate significantly with regional CSA CTh.	Cyclosporine	68-71	V-set and immunoglobulin domain containing 2	Homo sapiens	72-75
33993101-3	2021	Here, we found that the immunosuppressant cyclosporin A (CsA) decreased the number of BrdU+, BrdU+/DCX+, BrdU+/NeuN + cells in the hippocampus, impaired learning and memory and inhibited protein levels of the shh signaling pathway, including Shh, Smo and Gli1.	Cyclosporine	42-55	doublecortin	Homo sapiens	99-102
33993101-3	2021	Here, we found that the immunosuppressant cyclosporin A (CsA) decreased the number of BrdU+, BrdU+/DCX+, BrdU+/NeuN + cells in the hippocampus, impaired learning and memory and inhibited protein levels of the shh signaling pathway, including Shh, Smo and Gli1.	Cyclosporine	57-60	doublecortin	Homo sapiens	99-102
33949118-0	2021	Cyclosporine A blocks autophagic flux in tubular epithelial cells by impairing TFEB-mediated lysosomal function.	Cyclosporine	0-14	transcription factor EB	Homo sapiens	79-83
33949118-5	2021	In the present study, we observed that CsA suppressed the activation and expression of transcription factor EB (TFEB) by increasing the activation of mTOR, in turn promoting lysosomal dysfunction and autophagy flux blockade in tubular epithelial cells (TECs) in vivo and in vitro.	Cyclosporine	39-42	transcription factor EB	Homo sapiens	87-110
33752908-4	2021	We exemplify this through our recent discovery that CsA suppresses the potent Wnt inhibitor, secreted frizzled related protein (SFRP)1, in human hair follicles, thereby promoting hair growth and causing hypertrichosis.	Cyclosporine	52-55	secreted frizzled related protein 1	Homo sapiens	128-134
33824463-4	2021	Longitudinal studies of seven patients in Group A showed a gradual decrease in the percentage of HLA(-) granulocytes, with a reciprocal increase in the GPI(-) granulocytes in four patients responding to cyclosporine (CsA) and an increase in the HLA(-) granulocytes with a stable or declining GPI(-) granulocytes in three patients in sustained remission off CsA therapy.	Cyclosporine	203-215	glucose-6-phosphate isomerase	Homo sapiens	152-155
33634990-0	2021	Cyclosporine modulates neutrophil functions via the SIRT6-HIF-1alpha-glycolysis axis to alleviate severe ulcerative colitis.	Cyclosporine	0-12	sirtuin 6	Homo sapiens	52-57
33634990-8	2021	We also observed that CsA-induced functional alternation of neutrophils was initiated through suppressing SIRT6 expression, which is responsible for expression of the downstream signaling molecules (e.g., HIF-1alpha, PFKFB3) and PDK4 ubiquitination, leading to fueling neutrophil glycolysis and TCA cycle.	Cyclosporine	22-25	sirtuin 6	Homo sapiens	106-111
33634990-10	2021	CONCLUSIONS: The data reveal a novel mechanism of CsA in alleviating ASUC by promoting neutrophil HIF-1alpha expression and restricting excessive neutrophil activation in a SIRT6-HIF-1alpha-glycolysis axis, suggesting SIRT6 as a candidate target for maintaining mucosal homeostasis and treating intestinal inflammation.	Cyclosporine	50-53	sirtuin 6	Homo sapiens	173-178
33634990-10	2021	CONCLUSIONS: The data reveal a novel mechanism of CsA in alleviating ASUC by promoting neutrophil HIF-1alpha expression and restricting excessive neutrophil activation in a SIRT6-HIF-1alpha-glycolysis axis, suggesting SIRT6 as a candidate target for maintaining mucosal homeostasis and treating intestinal inflammation.	Cyclosporine	50-53	sirtuin 6	Homo sapiens	218-223
32915508-2	2021	Significant differences in FVIII:C between OSA (FVIII:C1st ) and CSA (FVIII:CChr ) are described as assay discrepancy in nonsevere haemophilia A (HA).	Cyclosporine	65-68	coagulation factor VIII	Homo sapiens	27-32
4084311-2	1985	The material has been identified by mass spectrometry and by nuclear magnetic resonance spectrometry as an acidic metabolite of cyclosporine in which the eta-methyl group of the cyclosporine-specific nine carbon amino acid #1 has been oxidized to an alpha, beta unsaturated carboxylic acid functionality.	Cyclosporine	178-190	endothelin receptor type A	Homo sapiens	115-118
2997534-1	1985	During the course of a long-term oral study in OF-1 mice for the assessment of any carcinogenic potential of the immunosuppressive agent cyclosporine (CS-A), a high incidence of osteomas was found in all treatment groups as well as in controls.	Cyclosporine	137-149	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	151-155
33440765-3	2021	The most common mechanism of mPT is based on the opening of a cyclosporine A (CSA)-sensitive protein channel in the inner membrane.	Cyclosporine	62-76	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	78-81
3910916-4	1985	Both doses of cyclosporine resulted in stimulation of plasma renin activity (PRA) from control values of 5.6 +/- 0.8 ng/ml/hr to 11.6 +/- 2.0 with 10 mg/kg and 26.7 +/- 5.6 with 20 mg/kg.	Cyclosporine	14-26	renin	Rattus norvegicus	61-66
3874703-1	1985	The action of the immunosuppressive agent cyclosporine (CsA) on anti-DNA B-cell responses was investigated in an in vitro system.	Cyclosporine	42-54	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	56-59
2411572-10	1985	The third pattern IgG1 much greater than IgG2a greater than IgG3 approximately equal to IgM was characteristic of anti-CSA antibodies.	Cyclosporine	119-122	Immunoglobulin heavy constant gamma 3	Mus musculus	60-64
3914572-1	1985	The outcome of patients with acute renal failure following cadaveric renal transplant has been evaluated in a prospective, controlled trial, comparing treatment with cyclosporine (CSA) to prednisone, azathioprine, and antilymphocyte globulin (AZA).	Cyclosporine	166-178	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	180-183
3926357-1	1985	The effect of cyclosporine A (CyA) on the expression of the Tac-antigen (IL-2 receptor) on PHA-activated PBMNC was analysed by immunofluorescence.	Cyclosporine	14-28	interleukin 2 receptor subunit alpha	Homo sapiens	60-71
3926357-1	1985	The effect of cyclosporine A (CyA) on the expression of the Tac-antigen (IL-2 receptor) on PHA-activated PBMNC was analysed by immunofluorescence.	Cyclosporine	14-28	interleukin 2 receptor subunit beta	Homo sapiens	73-86
3873657-5	1985	Adding various inhibitors of lymphocyte proliferation to PHA-stimulated cultures revealed that cyclosporin A, dexamethasone, and OKT11A antibody (anti-sheep erythrocyte receptor) diminished levels of c-myc mRNA measured at 3 hr and 24 hr, whereas anti-Tac (anti-IL-2-receptor) inhibited at 24 hr but not at 3 hr.	Cyclosporine	95-108	interleukin 2 receptor subunit beta	Homo sapiens	262-275
3873733-7	1985	The possibility that CsA actually affects interleukin-1 (IL-1) production by macrophages by inhibiting uninvolved T cells could be ruled out.	Cyclosporine	21-24	interleukin 1 complex	Mus musculus	42-55
3873733-7	1985	The possibility that CsA actually affects interleukin-1 (IL-1) production by macrophages by inhibiting uninvolved T cells could be ruled out.	Cyclosporine	21-24	interleukin 1 complex	Mus musculus	57-61
3920796-5	1985	In contrast, IL-2 receptor was expressed on the CsA-treated cells, and the antiproliferative influence of the drug was completely reversed by addition of highly purified human IL-2 to the CsA-treated cells.	Cyclosporine	48-51	interleukin 2 receptor subunit beta	Homo sapiens	13-26
3920796-5	1985	In contrast, IL-2 receptor was expressed on the CsA-treated cells, and the antiproliferative influence of the drug was completely reversed by addition of highly purified human IL-2 to the CsA-treated cells.	Cyclosporine	188-191	interleukin 2 receptor subunit beta	Homo sapiens	13-26
3920796-7	1985	This study suggests that CsA acts by inhibiting IL-2 production (via blockade of IL-2 gene expression) rather than by preventing the expression of the IL-2 receptor.	Cyclosporine	25-28	interleukin 2 receptor subunit beta	Homo sapiens	151-164
3876299-4	1985	The resistance to CsA of the mitogenic activity of IL-1 was unexpected since this response is assumed to be mediated by newly formed IL-2 and CsA inhibits IL-2 production.	Cyclosporine	18-21	interleukin 1 complex	Mus musculus	51-55
3876299-4	1985	The resistance to CsA of the mitogenic activity of IL-1 was unexpected since this response is assumed to be mediated by newly formed IL-2 and CsA inhibits IL-2 production.	Cyclosporine	142-145	interleukin 1 complex	Mus musculus	51-55
3876299-10	1985	Yet, this partial protection by IL-1 was achieved only at CsA concentrations about 100 fold lower than those resisted by thymocytes directly stimulated by IL-1.	Cyclosporine	58-61	interleukin 1 complex	Mus musculus	32-36
6532183-2	1984	The mitogenic activation sequence shows at least one cyclosporin sensitive step at or prior to the rise of cytoplasmic pH (pHi), which normally occurs after exposure to mitogen and which seems to be a permissive condition for initiation of DNA synthesis (S phase of the cell cycle).	Cyclosporine	53-64	glucose-6-phosphate isomerase	Homo sapiens	123-126
6196379-1	1983	To probe the mechanism of suppressor T cell generation in man, we have carried out mixed leukocyte reactions (MLR) in the presence of cyclosporin (CsA), a fungal metabolite which prevents the generation of cytotoxic lymphocytes while permitting activation of suppressor cells.	Cyclosporine	134-145	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	147-150
6193229-8	1983	In this regard, CsA selectively suppresses an early step of human B cell activation and has little inhibitory effect on the subsequent factor-dependent proliferation and differentiation.	Cyclosporine	16-19	B cell linker	Homo sapiens	66-83
32981222-2	2020	The management of EP is challenging: no standardized guidelines exist with literature suggesting cyclosporine or infliximab as first-line therapy.	Cyclosporine	97-109	epiregulin	Homo sapiens	18-20
6863928-1	1983	The purpose of this investigation was to identify and characterize a possible plasma membrane receptor for cyclosporine (CsA) on human lymphoid cells.	Cyclosporine	107-119	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	121-124
6256660-1	1981	Cyclosporin A (CSA) is a fungal metabolite which exerts profound effects on the immune system and has potential as a selective immuno-suppressive agent.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
33149757-9	2020	Interestingly, CsA inhibited CnA-NFAT pathway expression but activated CaMKII signaling.	Cyclosporine	15-18	nuclear factor of activated T-cells 4	Rattus norvegicus	33-37
7005520-1	1980	The new antilymphocytic agent Cyclosporin A was found to inhibit the production and/or secretion of migration inhibitory factor (MIF) in human lymphocytes stimulated by Concanavalin A. Preincubation for one hour with the compound, followed by 8 hr restoration period of the cells in absence of the drug, resulted in moderate decrease in MIF synthesis and/or release.	Cyclosporine	30-43	macrophage migration inhibitory factor	Homo sapiens	100-127
33023428-1	2021	Cyclosporine A (CsA) is a cyclic undecapeptide with strong immunosuppressive potency.	Cyclosporine	0-14	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	16-19
32866465-3	2020	By using immunohistochemical and ELISA techniques, it was found that CsA administration causes a rapid activation of a disintegrin and metalloproteases-17 (ADAM-17), epidermal growth factor receptor (EGFR) and subsequent ERK1/2 phosphorylation in the liver and kidney of albino mice.	Cyclosporine	69-72	mitogen-activated protein kinase 3	Mus musculus	221-227
32866465-4	2020	Furthermore, this study presents mechanistic relevance of this signaling cascade involving reactive oxygen species (ROS)-mediated ADAM-17/EGFR/ERK1/2 activation as indicated by a clear reduction in ADAM-17 and EGFR activities as well as ERK1/2 phosphorylation when the animals pretreated with Polyethylene glycol-superoxide dismutase (PEG-SOD) before CsA administration.	Cyclosporine	351-354	mitogen-activated protein kinase 3	Mus musculus	143-149
32866465-5	2020	Collectively, our findings demonstrate that CsA has the ability to activate ADAM-17-mediated EGFR/ERK1/2 phosphorylation in the liver and kidney of albino mice in ROS-dependent manner.	Cyclosporine	44-47	mitogen-activated protein kinase 3	Mus musculus	98-104
7005520-1	1980	The new antilymphocytic agent Cyclosporin A was found to inhibit the production and/or secretion of migration inhibitory factor (MIF) in human lymphocytes stimulated by Concanavalin A. Preincubation for one hour with the compound, followed by 8 hr restoration period of the cells in absence of the drug, resulted in moderate decrease in MIF synthesis and/or release.	Cyclosporine	30-43	macrophage migration inhibitory factor	Homo sapiens	129-132
7005520-1	1980	The new antilymphocytic agent Cyclosporin A was found to inhibit the production and/or secretion of migration inhibitory factor (MIF) in human lymphocytes stimulated by Concanavalin A. Preincubation for one hour with the compound, followed by 8 hr restoration period of the cells in absence of the drug, resulted in moderate decrease in MIF synthesis and/or release.	Cyclosporine	30-43	macrophage migration inhibitory factor	Homo sapiens	337-340
33949118-5	2021	In the present study, we observed that CsA suppressed the activation and expression of transcription factor EB (TFEB) by increasing the activation of mTOR, in turn promoting lysosomal dysfunction and autophagy flux blockade in tubular epithelial cells (TECs) in vivo and in vitro.	Cyclosporine	39-42	transcription factor EB	Homo sapiens	112-116
32331925-0	2020	Identification of Ribosomal Protein S4, Y-Linked 1 as a cyclosporin A plus corticosteroid resistance gene.	Cyclosporine	56-69	ribosomal protein S4 Y-linked 1	Homo sapiens	18-50
33949118-7	2021	In summary, targeting TFEB-mediated autophagy flux represents a potential therapeutic strategy for CsA-induced nephrotoxicity.	Cyclosporine	99-102	transcription factor EB	Homo sapiens	22-26
32331925-5	2020	Ribosomal Protein S4, Y-Linked 1 (RPS4Y1) was verified to regulate the resistance of CD4+ T cells from male VKH patients to CsA & CS.	Cyclosporine	124-127	ribosomal protein S4 Y-linked 1	Homo sapiens	0-32
32331925-5	2020	Ribosomal Protein S4, Y-Linked 1 (RPS4Y1) was verified to regulate the resistance of CD4+ T cells from male VKH patients to CsA & CS.	Cyclosporine	124-127	ribosomal protein S4 Y-linked 1	Homo sapiens	34-40
32331925-7	2020	Taken together, we identify RPS4Y1 as an important CsA & CS resistance gene in VKH disease.	Cyclosporine	51-54	ribosomal protein S4 Y-linked 1	Homo sapiens	28-34
33377278-2	2021	CsA-induced deterioration of glomerular filtration rate and sodium retention may be related with juxtaglomerular dysregulation due to suppressed cyclooxygenase 2 (COX-2) and stimulated renin biosynthesis.	Cyclosporine	0-3	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	145-161
33377278-2	2021	CsA-induced deterioration of glomerular filtration rate and sodium retention may be related with juxtaglomerular dysregulation due to suppressed cyclooxygenase 2 (COX-2) and stimulated renin biosynthesis.	Cyclosporine	0-3	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	163-168
33377278-3	2021	We tested, whether CsA-induced COX-2 suppression is caused by hyperactive renin-angiotensin system (RAS) and whether RAS inhibition may alleviate the related side effects.	Cyclosporine	19-22	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	31-36
33377278-7	2021	Acute and chronic CsA administration to rats led to RAS activation along with reduced cortical COX-2 expression, creatinine clearance, and fractional sodium excretion.	Cyclosporine	18-21	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	95-100
33377278-11	2021	CONCLUSION: Suppression of juxtaglomerular COX-2 upon CsA results from RAS activation, which overrides the cell-autonomous, COX-2-stimulatory effects of calcineurin inhibition.	Cyclosporine	54-57	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	43-48
33377278-12	2021	Angiotensin II antagonism alleviates CsA nephrotoxicity via the COX-2-dependent normalization of creatinine clearance and sodium excretion.	Cyclosporine	37-40	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	64-69
33615888-9	2021	RESULTS: Our findings showed that CsA treatment induced Nox2 upregulation and oxidative stress.	Cyclosporine	34-37	cytochrome b-245, beta polypeptide	Mus musculus	56-60
31914237-3	2020	Our goal was to utilize a validated RT-qPCR assay in dogs to assess recovery time of the T-cell cytokines IL-2 and IFN-gamma after discontinuation of cyclosporine.	Cyclosporine	150-162	interleukin 2	Canis lupus familiaris	106-110
32774143-0	2020	The Influence of Adalimumab and Cyclosporine A on the Expression Profile of the Genes Related to TGFbeta Signaling Pathways in Keratinocyte Cells Treated with Lipopolysaccharide A.	Cyclosporine	32-46	transforming growth factor alpha	Homo sapiens	97-104
32774143-2	2020	Aim: This study aimed at investigating the effect of CsA and adalimumab on the profile of mRNAs and protein expression associated with transforming growth factor beta (TGFbeta) pathways in human keratinocyte (HaCaT) culture previously exposed to lipopolysaccharide (LPS).	Cyclosporine	53-56	transforming growth factor alpha	Homo sapiens	168-175
32774143-11	2020	Conclusion: Analysis of the microarray expression profile of genes associated with TGFbeta signaling pathways has demonstrated the potential of cyclosporin A and adalimumab to induce changes in their transcriptional activity.	Cyclosporine	144-157	transforming growth factor alpha	Homo sapiens	83-90
33724664-4	2021	Utilizing a combination of in vitro techniques and a mouse model of CNI nephrotoxicity, we found that the CNIs, cyclosporine A (CsA) and tacrolimus (TAC), share a similar mechanism of tubular epithelial kidney cell injury, including mitochondrial dysfunction and release of High Mobility Group Box I (HMGB1).	Cyclosporine	112-126	high mobility group box 1	Mus musculus	301-306
32182109-0	2020	Excessive Cyclosporine-Associated Immunosuppression in a Dog Heterozygous for the MDR1 (ABCB1-1Delta) Mutation.	Cyclosporine	10-22	ATP binding cassette subfamily B member 1	Canis lupus familiaris	82-86
33317956-9	2021	Treatment with prednisolone + theophylline + cyclosporin A inhibited IFN-gamma and TNF-alpha production by SA CD28null CD8+ T and NKT-like cells additively.	Cyclosporine	45-58	CD28 molecule	Homo sapiens	110-114
33160221-1	2021	Measuring cyclosporine A (CsA), an immunosuppressive drug used to prevent heart transplant rejection, concentrations in myocardial biopsies might be more informative than its measurement in whole blood.	Cyclosporine	10-24	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	26-29
31557319-9	2020	Administration of exogenous CD147 enhanced MMP-2 expression in HGFs, whereas treatment with cyclosporine-A, which inhibited CD147 expression, reduced U937-enhanced MMP-2 expression in HGFs.	Cyclosporine	92-106	matrix metallopeptidase 2	Homo sapiens	164-169
33462352-7	2021	Our result showed that Hsa-miR-494-3p was elevated in the serum of patients with CSA-AKI, and also induced in hypoxic reoxygenated HK2 cells.	Cyclosporine	81-84	hexokinase 2	Homo sapiens	131-134
32052895-11	2020	CONCLUSIONS AND CLINICAL IMPORTANCE: Prednisone and cyclosporine both affected expression of IL-2 and IFN-gamma, suggesting that both have the ability to influence results when utilizing pharmacodynamic monitoring of cyclosporine treatment.	Cyclosporine	52-64	interleukin 2	Canis lupus familiaris	93-97
32052895-11	2020	CONCLUSIONS AND CLINICAL IMPORTANCE: Prednisone and cyclosporine both affected expression of IL-2 and IFN-gamma, suggesting that both have the ability to influence results when utilizing pharmacodynamic monitoring of cyclosporine treatment.	Cyclosporine	217-229	interleukin 2	Canis lupus familiaris	93-97
33462352-11	2021	Collectively, we identified that hsa-miR-494-3p, a miRNA induced in both circulation of AKI patients and hypoxia-reoxygenation-treated HK2 cells, enhanced renal inflammation by targeting HtrA3, which may suggest a possible role as a new therapeutic target for CSA-AKI.	Cyclosporine	260-263	hexokinase 2	Homo sapiens	135-138
33176866-8	2020	The in vivo study showed that treatment with ASCs combined with short-term ALS/CsA significantly reduced the B cell population in alloskin tissue, increased the proportion of circulating CD45Ra+/Foxp3+ B cells, and decreased C4d expression in alloskin.	Cyclosporine	79-82	forkhead box P3	Rattus norvegicus	195-200
32393425-0	2020	Effects of cyclosporin A on the pharmacokinetics and toxicities of irinotecan mediated by UGT1A1 in vitro and in vivo.	Cyclosporine	11-24	UDP glucuronosyltransferase family 1 member A1	Rattus norvegicus	90-96
32393425-11	2020	The present study indicated that CsA treatment could enhance the systemic exposure and toxicity of SN-38 by inhibiting the UGT1A1 enzyme.	Cyclosporine	33-36	UDP glucuronosyltransferase family 1 member A1	Rattus norvegicus	123-129
32393425-12	2020	The inhibition of UGT1A1 enzyme might be a critical factor in the failure of CsA improving irinotecan"s treatment index.	Cyclosporine	77-80	UDP glucuronosyltransferase family 1 member A1	Rattus norvegicus	18-24
32440340-5	2020	The protein levels of clusterin, CysC, GSTpi and TIMP-1 significantly increased in the conditioned media of RPTEC/TERT1 cells treated with cisplatin, cyclosporin, aristolochic acid I and gentamicin.	Cyclosporine	150-161	cystatin C	Homo sapiens	33-37
33096599-8	2020	In contrast, CsA induced arteriolopathy, hypoperfusion, a reduction in the glomerular filtration rate, and downregulation of eNOS, angiotensinogen, and AT1R mRNA levels.	Cyclosporine	13-16	angiotensin II receptor, type 1a	Rattus norvegicus	152-156
32030447-1	2020	For patients with pure red cell aplasia (PRCA), cyclosporine (CsA) is the first line therapy.	Cyclosporine	48-60	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	62-65
32894914-9	2020	%CSA(5-10) of three groups were (0.63+-0.15)%, (0.84+-0.18)%, and (0.85+-0.25)% (P<0.01), respectively; %CSA(<5) and %CSA(5-10) of medium-high risk group were lower than low-risk group and control group.	Cyclosporine	1-4	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	105-111
32199645-0	2020	Combination of High-Dose Intravenous Cyclosporine and Plasma Exchange Treatment Is Effective in Post-Transplant Recurrent Focal Segmental Glomerulosclerosis: Results of Case Series.	Cyclosporine	37-49	actinin alpha 4	Homo sapiens	122-156
32045207-4	2020	Variations in the HAXPES derived compositions between individual sample sets were observed, but in general they confirm that the addition of 20 mol% SnF2 improves coverage of the titanium dioxide substrate by CsSnBr3 and decreases the oxidation of SnII to SnIV, while also suppressing formation of secondary Br and Cs species.	Cyclosporine	209-211	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	Homo sapiens	149-153
32894076-12	2020	CONCLUSION: The daily dose of cyclosporine and SNPs of IL-7R (rs1494558) and MBL2 (rs2232365) genes are significantly associated with the development of NODAT in the Malaysian renal transplant population.	Cyclosporine	30-42	interleukin 7 receptor	Homo sapiens	55-60
32529968-6	2020	The molecular mechanisms underlying the effects of CsA were explored, and it was found that CsA could inhibit the increase in CypA, p-Akt, NF-kappaB, and MMP-9 protein expression after middle cerebral artery occlusion, while Claudin-5 expression was decreased.	Cyclosporine	51-54	matrix metallopeptidase 9	Mus musculus	154-159
32529968-6	2020	The molecular mechanisms underlying the effects of CsA were explored, and it was found that CsA could inhibit the increase in CypA, p-Akt, NF-kappaB, and MMP-9 protein expression after middle cerebral artery occlusion, while Claudin-5 expression was decreased.	Cyclosporine	92-95	matrix metallopeptidase 9	Mus musculus	154-159
32285980-9	2020	Symptomatic carriers showed fairly symmetric reduction in CTh/CSA in most of the frontal lobes, in addition to large temporoparietal areas.	Cyclosporine	62-65	V-set and immunoglobulin domain containing 2	Homo sapiens	58-61
32189058-7	2020	PHDi and CsA differentially upregulated the expression of the lipid droplet-associated genes PLIN2, PLIN4 and HILPDA.	Cyclosporine	9-12	perilipin 4	Homo sapiens	100-105
32625210-15	2020	Conclusion: Oral preconditioning with Cyclosporine or Everolimus is feasible in donation after brain death pig kidney transplantation and reduces the expression of TNF-alpha.	Cyclosporine	38-50	tumor necrosis factor	Sus scrofa	164-173
31759087-3	2020	At present, PTP inhibition is obtained only through the use of drugs (e.g. cyclosporine A, CsA) targeting cyclophilin D (CyPD) which is a key modulator, but not a structural component of the PTP.	Cyclosporine	75-89	peptidylprolyl isomerase D	Homo sapiens	106-119
31759087-3	2020	At present, PTP inhibition is obtained only through the use of drugs (e.g. cyclosporine A, CsA) targeting cyclophilin D (CyPD) which is a key modulator, but not a structural component of the PTP.	Cyclosporine	75-89	peptidylprolyl isomerase D	Homo sapiens	121-125
31759087-3	2020	At present, PTP inhibition is obtained only through the use of drugs (e.g. cyclosporine A, CsA) targeting cyclophilin D (CyPD) which is a key modulator, but not a structural component of the PTP.	Cyclosporine	91-94	peptidylprolyl isomerase D	Homo sapiens	106-119
31759087-3	2020	At present, PTP inhibition is obtained only through the use of drugs (e.g. cyclosporine A, CsA) targeting cyclophilin D (CyPD) which is a key modulator, but not a structural component of the PTP.	Cyclosporine	91-94	peptidylprolyl isomerase D	Homo sapiens	121-125
31696965-11	2019	Notably, inactivation of the Cul3-Klhl18 ligase and calcineurin inhibitors FK506 and cyclosporine A that are known immunosuppressant drugs repressed light-induced photoreceptor damage, suggesting potential therapeutic targets.	Cyclosporine	85-99	cullin 3	Mus musculus	29-33
32582860-1	2020	Cyclosporine A (CsA) is a powerful immunosuppressant, but it is an ineffective stand-alone treatment for systemic lupus erythematosus (SLE) due to poor target tissue distribution and renal toxicity.	Cyclosporine	0-14	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	16-19
32084649-7	2019	CsA induced liver injury was evidenced by increased serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin.	Cyclosporine	0-3	glutamic--pyruvic transaminase	Homo sapiens	102-126
31646979-1	2019	BACKGROUND: The purpose of this study was to determine efficacy and safety of cyclosporine A (CsA) for patients with steroid-resistant nephrotic syndrome (SRNS).	Cyclosporine	78-92	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	94-97
31445706-0	2019	Cyclosporin A protects trophoblasts from H2O2-induced oxidative injury via FAK-Src pathway.	Cyclosporine	0-13	protein tyrosine kinase 2	Homo sapiens	75-78
31445706-12	2019	CsA administration suppressed H2O2-induced reduction of FAK and Src phosphorylation.	Cyclosporine	0-3	protein tyrosine kinase 2	Homo sapiens	56-59
31445706-13	2019	Blocking the activation of FAK or Src attenuated the protective effect of CsA on JEG-3 cells in H2O2-induced oxidative injury.	Cyclosporine	74-77	protein tyrosine kinase 2	Homo sapiens	27-30
30725434-7	2019	CsA significantly decreased the Bax/Bcl-2 ratio, cl-casp-9/casp-9, and cl-casp-3/casp-3 in a concentration-dependent manner.	Cyclosporine	0-3	caspase 3	Rattus norvegicus	74-80
31101050-12	2019	Moreover, cyclosporine A, a cholesterol efflux inhibitor, rescued the inhibitory effect induced by the combination of AIBP and APOA-I.	Cyclosporine	10-24	NAD(P)HX epimerase	Mus musculus	118-122
30658157-0	2019	Upregulation of cystathionine-gamma-lyase/hydrogen sulfide pathway underlies the celecoxib counteraction of cyclosporine-induced hypertension and renal insult in rats.	Cyclosporine	108-120	cystathionine gamma-lyase	Rattus norvegicus	16-41
30658157-1	2019	We recently reported that celecoxib, a selective cyclooxygenase-2 (COX2) inhibitor, counteracts the adverse circulatory and renal actions of cyclosporine (CSA).	Cyclosporine	141-153	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	49-65
30658157-1	2019	We recently reported that celecoxib, a selective cyclooxygenase-2 (COX2) inhibitor, counteracts the adverse circulatory and renal actions of cyclosporine (CSA).	Cyclosporine	141-153	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	67-71
30658157-1	2019	We recently reported that celecoxib, a selective cyclooxygenase-2 (COX2) inhibitor, counteracts the adverse circulatory and renal actions of cyclosporine (CSA).	Cyclosporine	155-158	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	49-65
30658157-1	2019	We recently reported that celecoxib, a selective cyclooxygenase-2 (COX2) inhibitor, counteracts the adverse circulatory and renal actions of cyclosporine (CSA).	Cyclosporine	155-158	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	67-71
30658157-3	2019	This prompted us to test the hypothesis that the facilitation of the cystathionine-gamma-lyase (CSE)/hydrogen sulfide (H2S) signaling accounts for such favorable effects of celecoxib on CSA nephrotoxicity.	Cyclosporine	186-189	cystathionine gamma-lyase	Rattus norvegicus	69-94
30658157-3	2019	This prompted us to test the hypothesis that the facilitation of the cystathionine-gamma-lyase (CSE)/hydrogen sulfide (H2S) signaling accounts for such favorable effects of celecoxib on CSA nephrotoxicity.	Cyclosporine	186-189	cystathionine gamma-lyase	Rattus norvegicus	96-99
30658157-5	2019	Celecoxib also reversed the CSA-evoked (i) reductions in the tubular and glomerular protein expression of CSE and levels of H2S, prostaglandin E2 (PGE2), and total antioxidant capacity (TAC), and (ii) increases in inflammatory (tumor necrosis factor-alpha, TNF-alpha), fibrotic (transforming growth factor-beta1, TGF-beta1) and apoptotic (caspase-3) cytokines.	Cyclosporine	28-31	cystathionine gamma-lyase	Rattus norvegicus	106-109
30658157-5	2019	Celecoxib also reversed the CSA-evoked (i) reductions in the tubular and glomerular protein expression of CSE and levels of H2S, prostaglandin E2 (PGE2), and total antioxidant capacity (TAC), and (ii) increases in inflammatory (tumor necrosis factor-alpha, TNF-alpha), fibrotic (transforming growth factor-beta1, TGF-beta1) and apoptotic (caspase-3) cytokines.	Cyclosporine	28-31	caspase 3	Rattus norvegicus	339-348
30658157-8	2019	Together, the increased abundance of renal CSE and H2S and subsequent dampening down of inflammatory, fibrotic, oxidant, and apoptotic pathways play pivotal roles in the capacity of celecoxib to compromise the troublesome hypertensive and nephrotoxic insults caused by CSA in rats.	Cyclosporine	269-272	cystathionine gamma-lyase	Rattus norvegicus	43-46
32440340-6	2020	The messenger RNA levels of clusterin, CysC, GSTpi and TIMP-1 also increased in RPTEC/TERT1 cells treated with cisplatin, cyclosporin, aristolochic acid I and gentamicin, indicating that drug-induced upregulation involves transcriptional activation.	Cyclosporine	122-133	cystatin C	Homo sapiens	39-43
32821484-12	2020	In vitro CSA treatment of CD4+ cells inhibited MDR expression and proinflammatory cytokine production while increasing Foxp3.	Cyclosporine	9-12	forkhead box P3	Homo sapiens	119-124
31911259-2	2020	We analyzed AKI in adult myeloablative CBT recipients who underwent transplantation from 2006 to 2017 for hematologic malignancies using cyclosporine A (CSA)/mycophenolate mofetil immunosuppression.	Cyclosporine	137-151	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	153-156
30925148-2	2019	The enzymatic activity of Cyp is inhibited by cyclosporin A (CsA), an immunosuppressive drug.	Cyclosporine	46-59	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	26-29
30925148-2	2019	The enzymatic activity of Cyp is inhibited by cyclosporin A (CsA), an immunosuppressive drug.	Cyclosporine	61-64	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	26-29
30925148-9	2019	The thermodynamic stability of rCyp was also significantly increased in the presence of CsA, recommending that this protein could be employed to screen new CsA derivatives in the future.	Cyclosporine	88-91	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	31-35
30925148-9	2019	The thermodynamic stability of rCyp was also significantly increased in the presence of CsA, recommending that this protein could be employed to screen new CsA derivatives in the future.	Cyclosporine	156-159	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	31-35
30913036-13	2019	TIMP-2 and MMP-2 were both more active when treated with CsA which may be due to the gelatinase activity of them and that in CsA gingival overgrowth.	Cyclosporine	57-60	matrix metallopeptidase 2	Homo sapiens	11-16
30874894-8	2019	In cultured cardiomyocytes, increased calpain-1 in mitochondria promoted mitochondrial permeability transition pore (mPTP) opening and induced cell death, which were prevented by over-expression of ATP5A1, mito-TEMPO or cyclosporin A, an inhibitor of mPTP opening.	Cyclosporine	220-233	calpain 1	Mus musculus	38-47
29609502-3	2019	METHODS: MC3T3-E1 cells were treated with XMD8-92 (an ERK5 inhibitor) or Cyclosporin A (CsA, a nuclear factor of activated T cells (NFAT) c1 inhibitor) and/or exposed to 12 dyn/cm2 FSS.	Cyclosporine	73-86	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	88-91
30221729-12	2018	Additionally, cyclosporine A attenuated the cardiac hypertrophy induced by KBrO3 in H9c2 cells at concentrations effective to inhibit calcineurin, in addition to reducing mRNA levels of BNP or beta-MHC.	Cyclosporine	14-28	myosin heavy chain 7	Rattus norvegicus	193-201
30401391-2	2018	In this study, we compared renal function after heart transplantation (HT) under EVR with cyclosporine (CSA) or tacrolimus (TAC).	Cyclosporine	90-102	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	104-107
31785014-5	2020	When increasing H3BO3 dosage, the pore size of B,N-Cs could be tuned ranging from micropores to mesopores with BET surface area up to 940 m2/g.	Cyclosporine	49-53	delta/notch like EGF repeat containing	Homo sapiens	111-114
31441337-6	2020	Data Synthesis: Studies demonstrate pharmacokinetic differences between cyclosporine and tacrolimus, particularly with regard to inhibition of 2 hepatic transporters: P-glycoprotein and organic anion transporting polypeptide (OATP).	Cyclosporine	72-84	solute carrier organic anion transporter family member 1A2	Homo sapiens	186-224
31441337-6	2020	Data Synthesis: Studies demonstrate pharmacokinetic differences between cyclosporine and tacrolimus, particularly with regard to inhibition of 2 hepatic transporters: P-glycoprotein and organic anion transporting polypeptide (OATP).	Cyclosporine	72-84	solute carrier organic anion transporter family member 1A2	Homo sapiens	226-230
32169022-5	2020	In-vitro studies: Concentrations of CsA ranging from 250 ng/ml to 500 ng/ml demonstrated oxidative stress caused by an increased production of reactive oxygen species (ROS) and an overexpression of TGM-2 without inducing apoptosis in cells.	Cyclosporine	36-39	transglutaminase 2	Rattus norvegicus	198-203
31597813-1	2019	Phenobarbital (PB) decreases the cyclosporine (CsA) blood level in humans.	Cyclosporine	33-45	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	47-50
30641537-16	2018	CONCLUSION: Visfatin and chemerin correlated with inflammation and may be useful indicators of undifferentiated inflammatory arthritis in obese patients with CSA.	Cyclosporine	158-161	nicotinamide phosphoribosyltransferase	Homo sapiens	12-20
30338826-10	2018	CONCLUSIONS: Cyclosporine protects HK-2 cells from inflammatory injury via regulating mTOR pathway.	Cyclosporine	13-25	hexokinase 2	Homo sapiens	35-39
29960018-1	2018	Cyclosporine A (CsA) is a widely used immunosuppressive agent that greatly reduces the rates of kidney-, heart-, and liver-transplant rejection.	Cyclosporine	0-14	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	16-19
30012208-6	2018	ARPE-19 cells pretreated with CsA under high glucose stress showed markedly down-regulated expressions of Parkin, PINK1 and BNIP3L compared with the cells treated with high glucose (p &lt; 0.05).	Cyclosporine	30-33	BCL2 interacting protein 3 like	Homo sapiens	124-130
29266762-4	2018	We further identified tubular epithelial cells of the kidney as major targets of CsA activity and found that Fn14 (tumor necrosis factor receptor superfamily 12A), the receptor for TWEAK, is a highly CsA-inducible gene in these cells.	Cyclosporine	200-203	tumor necrosis factor receptor superfamily, member 12a	Mus musculus	109-113
29266762-4	2018	We further identified tubular epithelial cells of the kidney as major targets of CsA activity and found that Fn14 (tumor necrosis factor receptor superfamily 12A), the receptor for TWEAK, is a highly CsA-inducible gene in these cells.	Cyclosporine	200-203	tumor necrosis factor (ligand) superfamily, member 12	Mus musculus	181-186
29266762-5	2018	Correlating with this, CsA pretreatment sensitized tubular epithelial cells specifically to the pro-inflammatory activities of recombinant TWEAK in vitro.	Cyclosporine	23-26	tumor necrosis factor (ligand) superfamily, member 12	Mus musculus	139-144
29571015-5	2018	CSA or indomethacin caused: (i) renal tubular atrophy and interstitial fibrosis, (ii) increases in serum creatinine, blood urea nitrogen (BUN), and renal LTD4, LTB4, TNF-alpha, TGF-beta1, and caspase-3, and (iii) decreases in renal PGE2 and total antioxidant capacity (TAC).	Cyclosporine	0-3	caspase 3	Rattus norvegicus	192-201
29501733-8	2018	The results showed the following: (1) CsA induced fibrosis-related protein (MMP2/9), fibroblast phenotype conversion factor (alpha-SMA), and collagen I up-regulation in a dose-dependent manner.	Cyclosporine	38-41	matrix metallopeptidase 2	Homo sapiens	76-82
29501733-9	2018	(2) CsA induced the formation of autophagosomes and up-regulated the expression of Beclin1, LC3B, and the ERK/MAPK pathway in cardiac fibroblasts.	Cyclosporine	4-7	microtubule associated protein 1 light chain 3 beta	Homo sapiens	92-96
29193016-2	2018	Ciclosporin A (CsA) is a widely used, potent immunosuppressant but it is not effective in all patients with atopic dermatitis, and side-effects limit its use.	Cyclosporine	15-18	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	0-13
29863267-0	2018	Antagonism of cortistatin against cyclosporine-induced apoptosis in rat myocardial cells and its effect on myocardial apoptosis gene expression.	Cyclosporine	34-46	cortistatin	Rattus norvegicus	14-25
29863267-1	2018	OBJECTIVE: To investigate the role of cortistatin (CST) on cyclosporine A (CsA)-induced myocardial apoptosis in rats and determine its effect on the expressions of myocardial apoptosis genes.	Cyclosporine	59-73	cortistatin	Rattus norvegicus	38-49
29863267-1	2018	OBJECTIVE: To investigate the role of cortistatin (CST) on cyclosporine A (CsA)-induced myocardial apoptosis in rats and determine its effect on the expressions of myocardial apoptosis genes.	Cyclosporine	59-73	cortistatin	Rattus norvegicus	51-54
29863267-1	2018	OBJECTIVE: To investigate the role of cortistatin (CST) on cyclosporine A (CsA)-induced myocardial apoptosis in rats and determine its effect on the expressions of myocardial apoptosis genes.	Cyclosporine	75-78	cortistatin	Rattus norvegicus	38-49
29863267-1	2018	OBJECTIVE: To investigate the role of cortistatin (CST) on cyclosporine A (CsA)-induced myocardial apoptosis in rats and determine its effect on the expressions of myocardial apoptosis genes.	Cyclosporine	75-78	cortistatin	Rattus norvegicus	51-54
29863267-9	2018	The results of TUNEL staining showed the inhibitory role of CST on the myocardial apoptosis in rats induced by CsA.	Cyclosporine	111-114	cortistatin	Rattus norvegicus	60-63
29863267-10	2018	The detection of apoptosis factors via Real-time PCR revealed that after the induction of CsA, the expressions of Fas, FasL and Bax mRNA in cells were significantly higher than those in control group, but were significantly decreased after administration of CST.	Cyclosporine	90-93	Fas ligand	Rattus norvegicus	119-123
29863267-10	2018	The detection of apoptosis factors via Real-time PCR revealed that after the induction of CsA, the expressions of Fas, FasL and Bax mRNA in cells were significantly higher than those in control group, but were significantly decreased after administration of CST.	Cyclosporine	90-93	cortistatin	Rattus norvegicus	258-261
29863267-11	2018	Western blotting showed that the protein expressions of Caspase 3 and Caspase 9 were remarkably elevated in cells after the use of CsA, but were significantly reduced after administration of CST (p < 0.01).	Cyclosporine	131-134	caspase 3	Rattus norvegicus	56-65
29863267-11	2018	Western blotting showed that the protein expressions of Caspase 3 and Caspase 9 were remarkably elevated in cells after the use of CsA, but were significantly reduced after administration of CST (p < 0.01).	Cyclosporine	131-134	cortistatin	Rattus norvegicus	191-194
29863267-12	2018	CONCLUSIONS: CST contributes to antagonistic function against the CsA-induced apoptosis of rat myocardial cells, and its effect is related to the down-regulation of expressions of apoptotic factors, Fas, FasL, Bax, Caspase 3, and Caspase 9.	Cyclosporine	66-69	cortistatin	Rattus norvegicus	13-16
29618365-9	2018	Treatment with the CypA antagonist CsA in C57Bl/6 mice attenuates MMP-9 responses and enhances BBB repair after injury, demonstrating that MMP-9 plays an important role in the timing of spontaneous BBB repair after TBI.	Cyclosporine	35-38	matrix metallopeptidase 9	Mus musculus	66-71
29618365-9	2018	Treatment with the CypA antagonist CsA in C57Bl/6 mice attenuates MMP-9 responses and enhances BBB repair after injury, demonstrating that MMP-9 plays an important role in the timing of spontaneous BBB repair after TBI.	Cyclosporine	35-38	matrix metallopeptidase 9	Mus musculus	139-144
29369890-12	2018	The cyclosporine group (136.4 +- 35.6%) showed a more pronounced increase from baseline plasma cystatin C to day 3 compared to placebo (115.9 +- 30.8%), difference, 20.6% (95% CI, 10.2 to 31.2%, P &lt; 0.001).	Cyclosporine	4-16	cystatin C	Homo sapiens	95-105
31588792-5	2021	Furthermore, SCE inhibited the upward trend of dUDP and CDP-ethanolamine in the urine of CsA rats, pathways of which are involved in pyrimidine and glycerophospholipid metabolism.	Cyclosporine	89-92	cut-like homeobox 1	Rattus norvegicus	56-59
29202302-1	2018	Two different axial symmetries of the 119Sn chemical shift anisotropy (CSA) in tin dioxide with the asymmetry parameter (eta) of 0 and 0.27 were reported previously based on the analysis of MAS NMR spectra.	Cyclosporine	71-74	endothelin receptor type A	Homo sapiens	121-124
31251898-8	2019	CONCLUSIONS: Pre- and post-reperfusion CsA diminished MDA and caspase-3levels and normalized antioxidant enzymes activities.	Cyclosporine	39-42	caspase 3	Rattus norvegicus	62-71
29206806-1	2018	BACKGROUND: Various immunoassays have been used for cyclosporine A (CsA) analysis in human whole blood; however, they could not fully satisfy the requirements of criteria for accuracy and specificity in CsA measurement.	Cyclosporine	52-66	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	68-71
29387331-4	2018	In patients who fail first-line therapy after approximately 3-5 days of intravenous steroids, medical rescue therapy is indicated with either infliximab (IFX) or cyclosporine (CsA).	Cyclosporine	162-174	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	176-179
31335763-6	2019	We further demonstrated that the anti-fibrotic effects of metformin in kidneys treated with cyclosporine A were associated with decreased phosphorylation of ERK1/2.	Cyclosporine	92-106	mitogen activated protein kinase 3	Rattus norvegicus	157-163
29352246-8	2018	Furthermore, PPIL2 protein level and stability was upregulated after CsA treatment, indicating that PPIL2 might be involved in CsA-mediated repression of EMT in breast cancer.	Cyclosporine	69-72	peptidylprolyl isomerase like 2	Homo sapiens	13-18
29352246-8	2018	Furthermore, PPIL2 protein level and stability was upregulated after CsA treatment, indicating that PPIL2 might be involved in CsA-mediated repression of EMT in breast cancer.	Cyclosporine	69-72	peptidylprolyl isomerase like 2	Homo sapiens	100-105
29352246-8	2018	Furthermore, PPIL2 protein level and stability was upregulated after CsA treatment, indicating that PPIL2 might be involved in CsA-mediated repression of EMT in breast cancer.	Cyclosporine	127-130	peptidylprolyl isomerase like 2	Homo sapiens	13-18
29352246-8	2018	Furthermore, PPIL2 protein level and stability was upregulated after CsA treatment, indicating that PPIL2 might be involved in CsA-mediated repression of EMT in breast cancer.	Cyclosporine	127-130	peptidylprolyl isomerase like 2	Homo sapiens	100-105
29241307-7	2017	Further studiesshowed that intravenous injection of the caspase-9 inhibitor Z-LE(OMe)HD(OMe)-fluoromethylketone(FMK) into the mice could significantly inhibit apoptosis of the platelets and the effect of CSAtreatment when compared to the BMF group, and exerted a better protective effect from apoptosis ifthe caspase-9 inhibitor was combined with the CSA treatment.	Cyclosporine	204-207	caspase 9	Mus musculus	56-65
29267497-0	2017	Endothelin-1 receptor antagonists protect the kidney against the nephrotoxicity induced by cyclosporine-A in normotensive and hypertensive rats.	Cyclosporine	91-105	endothelin receptor type A	Rattus norvegicus	0-21
28432716-9	2017	TAC and CsA, in addition to glucose plus palmitate, induced comparable inhibition of calcineurin and nuclear factor of activated T cells (NFAT); therefore, TAC potentiates glucolipotoxicity in beta cells, possibly by sharing common pathways of beta cell dysfunction.	Cyclosporine	8-11	nuclear factor of activated T-cells 5	Rattus norvegicus	138-142
28405841-5	2017	Two additional patients were included for phenotype analyses, one detected by family screening and the other with cyclosporine-responsive FSGS.	Cyclosporine	114-126	actinin alpha 4	Homo sapiens	138-142
28416371-4	2017	Here we investigated: (i) the interaction of CSA with NSAIDs possessing variable COX1/COX2 selectivities on hemodynamic, left ventricular (LV) and cardiac autonomic and histologic profiles, and (ii) role of NADPH-oxidase (NOX)/Rho-kinase (ROCK) pathway in the interaction.	Cyclosporine	45-48	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	86-90
27567631-1	2017	Cyclosporine A (CsA) induces hypertension after transplantation.	Cyclosporine	0-14	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	16-19
28433160-6	2017	Compared to CSA micelles CSA-TGA micelles remained up to 56.1- fold and 28.6- fold higher degree attached on intestinal and vaginal mucosa, respectively.	Cyclosporine	12-15	T-box transcription factor 1	Homo sapiens	29-32
28054752-9	2017	The data underscore the preferential capacity of selective COX-2 inhibition by celecoxib to mitigate CSA hypertension and consequent alterations in cardiac performance and autonomic balance.	Cyclosporine	101-104	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	59-64
28584448-1	2017	Cyclophilins, a class of peptidyl-prolyl cis-trans isomerase (PPIase) enzymes, are inhibited by cyclosporin A (CsA), an immunosuppressive drug.	Cyclosporine	96-109	AT695_RS12970	Staphylococcus aureus	25-60
28584448-1	2017	Cyclophilins, a class of peptidyl-prolyl cis-trans isomerase (PPIase) enzymes, are inhibited by cyclosporin A (CsA), an immunosuppressive drug.	Cyclosporine	96-109	AT695_RS12970	Staphylococcus aureus	62-68
28584448-1	2017	Cyclophilins, a class of peptidyl-prolyl cis-trans isomerase (PPIase) enzymes, are inhibited by cyclosporin A (CsA), an immunosuppressive drug.	Cyclosporine	111-114	AT695_RS12970	Staphylococcus aureus	25-60
28584448-1	2017	Cyclophilins, a class of peptidyl-prolyl cis-trans isomerase (PPIase) enzymes, are inhibited by cyclosporin A (CsA), an immunosuppressive drug.	Cyclosporine	111-114	AT695_RS12970	Staphylococcus aureus	62-68
28584448-7	2017	rCyp that exists as a monomer in the aqueous solution is truly a cyclophilin as its catalytic activity specifically shows sensitivity to CsA.	Cyclosporine	137-140	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	0-4
28584448-8	2017	rCyp appears to bind CsA with a reasonably high affinity.	Cyclosporine	21-24	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	0-4
28584448-9	2017	Additional investigations reveal that binding of CsA to rCyp alters its structure and shape to some extent.	Cyclosporine	49-52	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	56-60
28584448-11	2017	Unfolding study also indicates that there is substantial extent of thermodynamic stabilization of rCyp in the presence of CsA as well.	Cyclosporine	122-125	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	98-102
28405602-11	2017	Patients with twice daily cyclosporine A (CSA) formulation needed longer to finish the 4-TTMT than patients with the once-daily tacrolimus formulation.	Cyclosporine	26-40	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	42-45
28407688-7	2017	ROS scavengers (NAC or MnTBAP) and mPTP blockers (cyclosporin A or sanglifehrin A) blocked NPC-26-induced AMPK activation and attenuated CRC cell death.	Cyclosporine	50-63	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	106-110
28273124-7	2017	Blockade of CypD by pharmaceutical inhibitor cyclosporine A (CsA) significantly protected against Dex-induced oxidative stress accumulation in gingival tissue.	Cyclosporine	45-59	peptidylprolyl isomerase D	Homo sapiens	12-16
28273124-7	2017	Blockade of CypD by pharmaceutical inhibitor cyclosporine A (CsA) significantly protected against Dex-induced oxidative stress accumulation in gingival tissue.	Cyclosporine	61-64	peptidylprolyl isomerase D	Homo sapiens	12-16
28273124-9	2017	In addition, blockade of CypD by pharmaceutical inhibitor CsA or gene knockdown also restored Dex-induced cell toxicity in HGF-1 cells, as shown by suppressed mitochondrial ROS production, increased CcO activity and decreased apoptosis.	Cyclosporine	58-61	peptidylprolyl isomerase D	Homo sapiens	25-29
28003191-7	2017	Chronic CsA administration caused salt retention and hypertension, along with stimulation of renin and suppression of renal cyclooxygenase 2, pointing to a contribution of endocrine and paracrine mechanisms at long term.	Cyclosporine	8-11	renin	Rattus norvegicus	93-98
28003191-7	2017	Chronic CsA administration caused salt retention and hypertension, along with stimulation of renin and suppression of renal cyclooxygenase 2, pointing to a contribution of endocrine and paracrine mechanisms at long term.	Cyclosporine	8-11	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	124-140
28314264-5	2017	Cyclosporine A induced the inositol requiring enzyme-1alpha (IRE1alpha) arm of the UPR and stabilized neosynthesized proteins in RCC cells.	Cyclosporine	0-14	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	61-70
28314264-6	2017	Toyocamycin, an inhibitor of IRE1alpha, abolished the clonogenic growth of RCC cells and reduced induction of VEGF by cyclosporine A under hypoxia.	Cyclosporine	118-132	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	29-38
28353583-1	2017	The objective of the present study was to assess the effect of cyclosporine (CsA) on the pharmacokinetic parameters of mycophenolic acid (MPA), an active mycophenolate mofetil (MMF) metabolite, and to compare with the effect of everolimus (EVR).Anonymized medical records of 404 kidney recipients were reviewed.	Cyclosporine	63-75	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	77-80
28501872-8	2017	Besides, CsA attenuated I/R injury through suppressing the release of cytochrome-c (CytC), inhibiting cell apoptosis and decreasing the expression levels of cyclophilin-D (Cyp-D), adenine nucleotide translocase 1 (ANT1) and voltage-dependent anion channel 1 (VDAC1).	Cyclosporine	9-12	cytochrome c	Oryctolagus cuniculus	70-82
28501872-8	2017	Besides, CsA attenuated I/R injury through suppressing the release of cytochrome-c (CytC), inhibiting cell apoptosis and decreasing the expression levels of cyclophilin-D (Cyp-D), adenine nucleotide translocase 1 (ANT1) and voltage-dependent anion channel 1 (VDAC1).	Cyclosporine	9-12	cytochrome c	Oryctolagus cuniculus	84-88
28501872-10	2017	CONCLUSION: Our study found that the protective role of CsA on lung I/R injury depends on the inhibition of MPTP and CytC release, suppression of the activation of mitochondrial apoptosis pathway and the expressions of apoptotic-related proteins, as well as the decreased expression levels of ANT1 and VDAC1.	Cyclosporine	56-59	cytochrome c	Oryctolagus cuniculus	117-121
26921303-7	2016	It was observed that CD8(+)CD28(-) T cells from cultures with CsA or RAPA had similar suppressor properties to cells from control cultures, although the drugs influenced the expression of FOXP3.	Cyclosporine	62-65	forkhead box P3	Homo sapiens	188-193
27367933-1	2016	The CD25-binding antibody daclizumab high-yield process (DAC HYP) is an interleukin (IL)-2 signal modulating antibody that shares primary amino acid sequence and CD25 binding affinity with Zenapax , a distinct form of daclizumab, which was approved for the prevention of acute organ rejection in patients receiving renal transplants as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids.	Cyclosporine	387-399	interleukin 2 receptor subunit alpha	Homo sapiens	4-8
27671317-4	2016	Capsaicin, the specific TRPV1 agonist, dose-dependently reduced mitochondrial membrane potential and was blocked by the TRPV1 antagonist capsazepine or the calcineurin inhibitor cyclosporine.	Cyclosporine	178-190	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	24-29
27620209-0	2016	In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy.	Cyclosporine	69-72	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	54-67
27620209-3	2016	Whether immunosuppression with mycophenolate mofetil (MMF) or Ciclosporin A (CsA) influences the cytotoxic effect of CIK cell immunotherapy is still an open issue.	Cyclosporine	77-80	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	62-75
27283486-1	2016	Cyclosporin A (CsA) and dipyridamole (DPy) are potent inhibitors of the P-glycoprotein (P-gp; ABCB1) in vitro.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
27486749-0	2016	In Vitro Inhibition of NFAT5-Mediated Induction of CCL2 in Hyperosmotic Conditions by Cyclosporine and Dexamethasone on Human HeLa-Modified Conjunctiva-Derived Cells.	Cyclosporine	86-98	nuclear factor of activated T cells 5	Homo sapiens	23-28
27486749-3	2016	This work was completed by an analysis of the effects of cyclosporine A (CsA), dexamethasone (Dex) and doxycycline (Dox) on HO-induced CCL2 and NFAT5 induction.	Cyclosporine	73-76	nuclear factor of activated T cells 5	Homo sapiens	144-149
27357441-4	2016	In addition, CsA treatment blocked the CoCl2-induced increases in ROS production and mitochondrial dysfunction, including a decrease in membrane potential, cytochrome c (cyto-c) release, Bax/Bcl-2 imbalance, as well as the ratios of cl-casp-9/casp-9 and cl-casp-3/casp-3 ratios, via the inhibition of p38 and ERK MAPK signaling pathways.	Cyclosporine	13-16	caspase 3	Rattus norvegicus	257-263
27357441-4	2016	In addition, CsA treatment blocked the CoCl2-induced increases in ROS production and mitochondrial dysfunction, including a decrease in membrane potential, cytochrome c (cyto-c) release, Bax/Bcl-2 imbalance, as well as the ratios of cl-casp-9/casp-9 and cl-casp-3/casp-3 ratios, via the inhibition of p38 and ERK MAPK signaling pathways.	Cyclosporine	13-16	caspase 3	Rattus norvegicus	264-270
27357441-4	2016	In addition, CsA treatment blocked the CoCl2-induced increases in ROS production and mitochondrial dysfunction, including a decrease in membrane potential, cytochrome c (cyto-c) release, Bax/Bcl-2 imbalance, as well as the ratios of cl-casp-9/casp-9 and cl-casp-3/casp-3 ratios, via the inhibition of p38 and ERK MAPK signaling pathways.	Cyclosporine	13-16	mitogen activated protein kinase 14	Rattus norvegicus	301-304
27635199-5	2016	RESULTS: SC administration of CsA (30 mg/kg) to rats produced marked elevations in the levels of renal impairment parameters such as urinary protein, N-acetyl-beta-D-glucosaminidase (NAG), serum creatinine (SCr), and blood urea nitrogen (BUN).	Cyclosporine	30-33	O-GlcNAcase	Rattus norvegicus	150-181
27635199-5	2016	RESULTS: SC administration of CsA (30 mg/kg) to rats produced marked elevations in the levels of renal impairment parameters such as urinary protein, N-acetyl-beta-D-glucosaminidase (NAG), serum creatinine (SCr), and blood urea nitrogen (BUN).	Cyclosporine	30-33	O-GlcNAcase	Rattus norvegicus	183-186
27418816-5	2016	RESULTS: Compared with the non-COPD subjects, the COPD patients had lower %CSA&lt;5.	Cyclosporine	75-78	COPD	Homo sapiens	31-35
27418816-5	2016	RESULTS: Compared with the non-COPD subjects, the COPD patients had lower %CSA&lt;5.	Cyclosporine	75-78	COPD	Homo sapiens	50-54
27418816-7	2016	COPD patients with lower %CSA&lt;5 showed significantly increased incidences of severe AE-COPD (Gray"s test; P=0.011).	Cyclosporine	26-29	COPD	Homo sapiens	0-4
27418816-7	2016	COPD patients with lower %CSA&lt;5 showed significantly increased incidences of severe AE-COPD (Gray"s test; P=0.011).	Cyclosporine	26-29	COPD	Homo sapiens	87-94
27418816-8	2016	Furthermore, lower %CSA&lt;5 was significantly associated with severe AE-COPD (hazard ratio, 2.668; 95% confidence interval, 1.225-5.636; P=0.010).	Cyclosporine	20-23	COPD	Homo sapiens	70-77
27418816-9	2016	CONCLUSION: %CSA&lt;5 was associated with an increased risk of severe AE-COPD.	Cyclosporine	13-16	COPD	Homo sapiens	70-77
26887886-2	2016	Currently, FSGS is treated with immunosuppressive therapies, which include calcinuerin inhibitors (cyclosporine), glucocorticoids, B-cell depleting agents (rituximab) and, recently, a T-cell co-stimulatory inhibitor (abatacept).	Cyclosporine	99-111	actinin alpha 4	Homo sapiens	11-15
26013701-0	2015	Endothelin ETA receptor/lipid peroxides/COX-2/TGF-beta1 signalling underlies aggravated nephrotoxicity caused by cyclosporine plus indomethacin in rats.	Cyclosporine	113-125	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	40-45
26013701-5	2015	KEY RESULTS: Oral treatment with CSA or indomethacin elevated serum urea and creatinine, caused renal tubular atrophy and interstitial fibrosis, increased renal TGF-beta1, and reduced immunohistochemical expressions of ETA receptors and COX-2.	Cyclosporine	33-36	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	237-242
26013701-7	2015	Compared with individual treatments, simultaneous CSA/indomethacin exposure caused: (i) greater elevations in serum creatinine and renal MDA; (ii) loss of the compensatory increase in GSH; (iii) renal infiltration of inflammatory cells and worsening of fibrotic and necrotic profiles; and (iv) increased renal ET-1 and decreased ETA receptor and COX-2 expressions.	Cyclosporine	50-53	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	346-351
26013701-9	2015	Furthermore, atrasentan partly reversed the CSA/indomethacin-evoked reductions in the expression of ETA receptor and COX-2 protein.	Cyclosporine	44-47	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	117-122
26013701-10	2015	CONCLUSIONS AND IMPLICATIONS: The exaggerated oxidative insult and associated dysregulation of the ETA receptor/COX-2/TGF-beta1 signalling might account for the aggravated nephrotoxicity caused by the CSA/indomethacin regimen.	Cyclosporine	201-204	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	112-117
25919767-5	2015	RESULTS: Compared to untreated animals, ixazomib alone or in combination with 1/2 dose CsA reduced donor-specific antibody, intragraft transcripts for chemokines CCL-21 and CXCL-13, and CD19 expression in both sensitized and naive transplants.	Cyclosporine	87-90	C-C motif chemokine ligand 21	Rattus norvegicus	162-168
25936769-7	2015	CsA, FK506 and MMF significantly enhanced the expression levels of IDO, whereas RAPA exhibited no apparent effect on IDO.	Cyclosporine	0-3	indoleamine 2,3-dioxygenase 1	Rattus norvegicus	67-70
25970072-11	2015	This novel inhibitor of the MCP-1/CCR2 axis (mNOX-E36), which has already proven efficacy and tolerability in early clinical trials, alleviates acute rejection processes in allogeneic transplantation especially when combined with subtherapeutic doses of CsA.	Cyclosporine	254-257	chemokine (C-C motif) receptor 2	Mus musculus	34-38
26020957-4	2015	We determined the expression of CYPJ in HCC/adjacent normal tissues using Western blot, Northern blot and semi-quantitative RT-PCR, analyzed the biochemical characteristics of CYPJ, and resolved the 3D-structure of CYPJ/Cyclosporin A (CsA) complex.	Cyclosporine	220-233	peptidylprolyl isomerase like 3	Homo sapiens	32-36
25772258-0	2015	Cyclosporin A upregulates ETB receptor in vascular smooth muscle via activation of mitogen-activating protein kinases and NF-kappaB pathways.	Cyclosporine	0-13	endothelin receptor type B	Rattus norvegicus	26-29
25772258-3	2015	We previously showed that CsA increased the mRNA expression and contractile function of endothelin B (ETB) receptor in vascular smooth muscle cells.	Cyclosporine	26-29	endothelin receptor type B	Rattus norvegicus	88-115
25772258-4	2015	The present study was designed to investigate the underlying mechanisms of CsA-induced upregulation of ETB receptor in vasculature.	Cyclosporine	75-78	endothelin receptor type B	Rattus norvegicus	103-106
25772258-5	2015	Rat mesenteric arteries were incubated with CsA in an organ culture system, and results showed that CsA enhanced ETB receptor mRNA in the time- and dose-dependent manner, and increased protein expression levels of ETB receptor after treatment with CsA 10(-5)M for 6h.	Cyclosporine	100-103	endothelin receptor type B	Rattus norvegicus	113-116
25772258-5	2015	Rat mesenteric arteries were incubated with CsA in an organ culture system, and results showed that CsA enhanced ETB receptor mRNA in the time- and dose-dependent manner, and increased protein expression levels of ETB receptor after treatment with CsA 10(-5)M for 6h.	Cyclosporine	100-103	endothelin receptor type B	Rattus norvegicus	214-217
25772258-5	2015	Rat mesenteric arteries were incubated with CsA in an organ culture system, and results showed that CsA enhanced ETB receptor mRNA in the time- and dose-dependent manner, and increased protein expression levels of ETB receptor after treatment with CsA 10(-5)M for 6h.	Cyclosporine	100-103	endothelin receptor type B	Rattus norvegicus	113-116
25772258-5	2015	Rat mesenteric arteries were incubated with CsA in an organ culture system, and results showed that CsA enhanced ETB receptor mRNA in the time- and dose-dependent manner, and increased protein expression levels of ETB receptor after treatment with CsA 10(-5)M for 6h.	Cyclosporine	100-103	endothelin receptor type B	Rattus norvegicus	214-217
25772258-6	2015	Furthermore, CsA induced phosphorylation of extracellular regulated protein kinases 1 and 2 (ERK1/2), p38, and translocation of nuclear factor-kappaB (NF-kappaB) p65 in vasculature.	Cyclosporine	13-16	mitogen activated protein kinase 3	Rattus norvegicus	93-99
25772258-6	2015	Furthermore, CsA induced phosphorylation of extracellular regulated protein kinases 1 and 2 (ERK1/2), p38, and translocation of nuclear factor-kappaB (NF-kappaB) p65 in vasculature.	Cyclosporine	13-16	mitogen activated protein kinase 14	Rattus norvegicus	102-105
25772258-7	2015	Blocking ERK1/2, p38, or NF-kappaB activation with their specific inhibitors markedly attenuated CsA-induced upregulation of ETB receptor mRNA expression and protein levels, and ETB receptor-mediated contraction.	Cyclosporine	97-100	mitogen activated protein kinase 3	Rattus norvegicus	9-15
25772258-7	2015	Blocking ERK1/2, p38, or NF-kappaB activation with their specific inhibitors markedly attenuated CsA-induced upregulation of ETB receptor mRNA expression and protein levels, and ETB receptor-mediated contraction.	Cyclosporine	97-100	mitogen activated protein kinase 14	Rattus norvegicus	17-20
25772258-7	2015	Blocking ERK1/2, p38, or NF-kappaB activation with their specific inhibitors markedly attenuated CsA-induced upregulation of ETB receptor mRNA expression and protein levels, and ETB receptor-mediated contraction.	Cyclosporine	97-100	endothelin receptor type B	Rattus norvegicus	125-128
25772258-7	2015	Blocking ERK1/2, p38, or NF-kappaB activation with their specific inhibitors markedly attenuated CsA-induced upregulation of ETB receptor mRNA expression and protein levels, and ETB receptor-mediated contraction.	Cyclosporine	97-100	endothelin receptor type B	Rattus norvegicus	178-181
25772258-8	2015	In summary, this study showed that mitogen-activating protein kinases (ERK1/2 and p38) and the downstream transcriptional factor NF-kappaB pathways were involved in CsA-induced upregulation of ETB receptor in arterial smooth muscle cells.	Cyclosporine	165-168	mitogen activated protein kinase 3	Rattus norvegicus	71-77
25772258-8	2015	In summary, this study showed that mitogen-activating protein kinases (ERK1/2 and p38) and the downstream transcriptional factor NF-kappaB pathways were involved in CsA-induced upregulation of ETB receptor in arterial smooth muscle cells.	Cyclosporine	165-168	mitogen activated protein kinase 14	Rattus norvegicus	82-85
25772258-8	2015	In summary, this study showed that mitogen-activating protein kinases (ERK1/2 and p38) and the downstream transcriptional factor NF-kappaB pathways were involved in CsA-induced upregulation of ETB receptor in arterial smooth muscle cells.	Cyclosporine	165-168	endothelin receptor type B	Rattus norvegicus	193-196
26036543-9	2015	After randomization, there was significant improvement in fasting plasma glucose, fasting insulin levels, C-peptide levels, and insulin requirement in both groups, whereas HbA1c improved significantly only in the CsA group.	Cyclosporine	213-216	hemoglobin subunit alpha 1	Homo sapiens	172-176
25420893-7	2015	The relative expressions of COX-1 and COX-2 genes to GAPDH revealed that the maximum increase was obtained in the group treated with CyA and vardenafil for both COX-1 and COX-2 genes.	Cyclosporine	133-136	cytochrome c oxidase II, mitochondrial	Mus musculus	38-43
25420893-7	2015	The relative expressions of COX-1 and COX-2 genes to GAPDH revealed that the maximum increase was obtained in the group treated with CyA and vardenafil for both COX-1 and COX-2 genes.	Cyclosporine	133-136	cytochrome c oxidase II, mitochondrial	Mus musculus	171-176
25536542-3	2015	Conflicting results arise from the literature, particularly as concerns cyclosporine (CsA).	Cyclosporine	72-84	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	86-89
25270396-2	2015	Elevated fibroblast growth factor (FGF)-23 in cyclosporine A (CsA) users with SLE are associated with decreased active vitamin D and osteocalcin.	Cyclosporine	46-60	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	62-65
25629977-5	2015	In contrast, mRNA expression levels of hematopoietic and endothelial lineage markers, including Flk1 and Er71, were severely reduced in CsA-treated P19 cells.	Cyclosporine	136-139	kinase insert domain protein receptor	Mus musculus	96-100
25629977-6	2015	Furthermore, expression of Flk1 protein and the percentage of Flk1+ cells were severely reduced in 0.32 muM CsA-treated P19 cells compared to control cells.	Cyclosporine	108-111	kinase insert domain protein receptor	Mus musculus	27-31
25629977-6	2015	Furthermore, expression of Flk1 protein and the percentage of Flk1+ cells were severely reduced in 0.32 muM CsA-treated P19 cells compared to control cells.	Cyclosporine	108-111	kinase insert domain protein receptor	Mus musculus	62-66
25357076-2	2015	One of the most promising immunomodulatory substances whose immunosuppressive effect has revolutionized solid organ transplantation is cyclosporine (CsA).	Cyclosporine	135-147	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	149-152
26087670-2	2015	Immunosuppressive therapy with cyclosporine (CSA) is often successful in reducing proteinuria, but its use is associated with a high relapse rate.	Cyclosporine	31-43	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	45-48
25543494-7	2014	OST-mRNA expression level in As2O3group were higher than that in CsA group and the control group (P &lt; 0.05), while compared with the combined group, there was no significant difference (P &gt; 0.05), but the OST-mRNA expression level in the CsA group was lower than that in the combined group (P &lt; 0.05).	Cyclosporine	244-247	MCF.2 cell line derived transforming sequence like	Homo sapiens	0-3
25156669-3	2014	The biosynthetic gene clusters responsible for two of the most important classes of NRP fungal derived drugs, cyclosporine and the echinocandins, have been recently characterized by genomic sequencing and annotation.	Cyclosporine	110-122	neuropilin 1	Homo sapiens	84-87
24890314-2	2014	In this retrospective cohort study, we analyzed biomarkers of the immunosuppressive effects of cyclosporine A (CSA) by quantifying nuclear factor of activated T cells (NFAT)-regulated gene expression during telaprevir (TVR) therapy in 5 liver transplant patients.	Cyclosporine	95-109	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	111-114
25150603-7	2014	DISCUSSION: Six months after LDLT and uneventful post-LDLT courses, pegylated interferon-alpha2a and ribavirin were administered under immunosuppression with cyclosporine and mycophenolate mofetil.	Cyclosporine	158-170	interferon alpha 2	Homo sapiens	78-96
24947514-11	2014	Furthermore, analyses in kidney tissues from mice that were treated with the CN inhibitor cyclosporine A revealed an in vivo effect of CN on the YB-1 phosphorylation status.	Cyclosporine	90-104	Y box protein 1	Mus musculus	145-149
31446206-0	2019	Effects of cyclosporine and dexamethasone on canine T cell expression of interleukin-2 and interferon-gamma.	Cyclosporine	11-23	interleukin 2	Canis lupus familiaris	73-86
24261911-7	2014	RESULTS: In CsA-treated rats, bcl-2 expression was significantly upregulated, whereas caspase-3 expression was downregulated, along with a reduced number of TUNEL-positive cells.	Cyclosporine	12-15	caspase 3	Rattus norvegicus	86-95
25072153-8	2014	Urinary TNF-alpha, KIM-1 and fibronectin increased in the early phase, and urinary TGF-beta and osteopontin increased in the late phase of CsA nephrotoxicity.	Cyclosporine	139-142	secreted phosphoprotein 1	Rattus norvegicus	96-107
25072153-11	2014	Late increases in urinary osteopontin and TGF-beta indicate chronic CsA nephrotoxicity.	Cyclosporine	68-71	secreted phosphoprotein 1	Rattus norvegicus	26-37
31446206-7	2019	Flow cytometry and qRT-PCR both demonstrated inhibition of IL-2 and IFN-gamma that was concentration-dependent in response to cyclosporine, and was more variable for dexamethasone.	Cyclosporine	126-138	interleukin 2	Canis lupus familiaris	59-63
25484988-5	2014	Under differentiation conditions, intermittent CsA treatment enhanced gene expression of late osteoblastic differentiation markers and activator protein 1 (AP-1) family members.	Cyclosporine	47-50	jun proto-oncogene	Mus musculus	135-154
25484988-5	2014	Under differentiation conditions, intermittent CsA treatment enhanced gene expression of late osteoblastic differentiation markers and activator protein 1 (AP-1) family members.	Cyclosporine	47-50	jun proto-oncogene	Mus musculus	156-160
25484988-6	2014	Superimposing flow upon CsA further enhanced expression of the AP-1 members Fra-1 and c-Jun.	Cyclosporine	24-27	jun proto-oncogene	Mus musculus	63-67
25484988-6	2014	Superimposing flow upon CsA further enhanced expression of the AP-1 members Fra-1 and c-Jun.	Cyclosporine	24-27	jun proto-oncogene	Mus musculus	86-91
31517988-1	2019	BACKGROUND: Topical cyclosporine A (also known as ciclosporin A) (CsA) is an anti-inflammatory that has been widely used to treat inflammatory ocular surface diseases.	Cyclosporine	20-34	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	66-69
25484988-9	2014	Taken together, our study is the first to demonstrate that CsA enhances mechanically-induced gene expression of AP-1 components in bone cells, and suggests that this response requires calcineurin-dependent mechanisms that are independent of inhibiting NFATc1 nuclear accumulation.	Cyclosporine	59-62	jun proto-oncogene	Mus musculus	112-116
31517988-1	2019	BACKGROUND: Topical cyclosporine A (also known as ciclosporin A) (CsA) is an anti-inflammatory that has been widely used to treat inflammatory ocular surface diseases.	Cyclosporine	50-63	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	66-69
24751518-1	2014	Cyclosporine A (CsA) is an immunosuppressive drug that targets cyclophilins, cellular cofactors that regulate the immune system.	Cyclosporine	0-14	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	16-19
31332983-6	2019	Decreased plasma D-dimer levels; and decreased serum IL-2, IL-5, and TNF-alpha levels were reported to be correlated with clinical improvement after CsA treatment.	Cyclosporine	149-152	interleukin 5	Homo sapiens	59-63
31220549-8	2019	UVB irradiation induced Nrf2 degradation is inhibited by co-treatment of cells with W-7, cyclosporin A, SB-216763 or MG-132, which are inhibitors of calmodulin, calcineurin, GSK3beta and the proteasome, respectively.	Cyclosporine	89-102	glycogen synthase kinase 3 alpha	Homo sapiens	174-182
24375637-3	2014	Here we report that cyclosporin A (CsA) can inhibit HBV entry into cultured hepatocytes.	Cyclosporine	20-33	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	35-38
31054961-4	2019	In this study, we found that CsA pretreatment prevented induction of HSPs during heat shock by enhancing the phosphorylation of Ser303 and Ser307 on HSF1 and thus inhibiting its transcriptional activity.	Cyclosporine	29-32	heat shock transcription factor 1	Homo sapiens	149-153
24453045-0	2014	Requirement of miR-144 in CsA induced proliferation and invasion of human trophoblast cells by targeting titin.	Cyclosporine	26-29	titin	Homo sapiens	105-110
24453045-2	2014	In this study, with the treatment of CsA (Cyclosporin A), we showed that miR144 expression levels were decreased while titin mRNA expression levels were increased in human trophoblast (HT) cells, and identified titin as a novel direct target of miR-144.	Cyclosporine	37-40	titin	Homo sapiens	119-124
31054961-5	2019	Suppression of ERK1/2, GSK3beta and CK2 activities attenuated CsA-induced down-regulation of HSP expression and up-regulation of HSF1 phosphorylation.	Cyclosporine	62-65	glycogen synthase kinase 3 beta	Homo sapiens	23-31
24453045-2	2014	In this study, with the treatment of CsA (Cyclosporin A), we showed that miR144 expression levels were decreased while titin mRNA expression levels were increased in human trophoblast (HT) cells, and identified titin as a novel direct target of miR-144.	Cyclosporine	37-40	titin	Homo sapiens	211-216
31054961-5	2019	Suppression of ERK1/2, GSK3beta and CK2 activities attenuated CsA-induced down-regulation of HSP expression and up-regulation of HSF1 phosphorylation.	Cyclosporine	62-65	heat shock transcription factor 1	Homo sapiens	129-133
24508908-10	2014	These findings suggest that neuroprotective effects of CsA during early peroid after SAH may be related to its inhibition of Nur77 dependent apoptosis pathway.	Cyclosporine	55-58	nuclear receptor subfamily 4, group A, member 1	Rattus norvegicus	125-130
31054961-6	2019	CsA interfered with HSF1-SSBP1 complex formation and HSF1 nuclear translocation and recruitment to the HSP70 promoter.	Cyclosporine	0-3	heat shock transcription factor 1	Homo sapiens	20-24
31054961-6	2019	CsA interfered with HSF1-SSBP1 complex formation and HSF1 nuclear translocation and recruitment to the HSP70 promoter.	Cyclosporine	0-3	single stranded DNA binding protein 1	Homo sapiens	25-30
31054961-6	2019	CsA interfered with HSF1-SSBP1 complex formation and HSF1 nuclear translocation and recruitment to the HSP70 promoter.	Cyclosporine	0-3	heat shock transcription factor 1	Homo sapiens	53-57
31054961-8	2019	These results indicate that CsA suppresses HSP induction during heat shock by regulating the phosphorylation and nuclear translocation of HSF1.	Cyclosporine	28-31	heat shock transcription factor 1	Homo sapiens	138-142
24817934-0	2014	Cyclosporine A improves adhesion and invasion of mouse preimplantation embryos via upregulating integrin beta3 and matrix metalloproteinase-9.	Cyclosporine	0-14	matrix metallopeptidase 9	Mus musculus	115-141
30632627-6	2019	CsA was used as a CYP3A1/2 and transporter inhibitor, and olive oil was used as a vehicle.	Cyclosporine	0-3	cytochrome P450, family 3, subfamily a, polypeptide 2	Rattus norvegicus	18-26
24817934-10	2014	In conclusion, CsA in low dosage up-regulates itgbeta3 and MMP-9 expression, and enhances embryonic adhesion and invasion, which is beneficial to the embryo implantation.	Cyclosporine	15-18	matrix metallopeptidase 9	Mus musculus	59-64
25277512-10	2014	As a calcineurin-specific inhibitor, CsA inhibited (3)H-Leu incorporation, surface area, mRNA expressions of ANP, BNP, beta-MHC, CnAbeta and protein expression of CnAbeta of AngII-induced cardiomyocytes.	Cyclosporine	37-40	myosin heavy chain 7	Rattus norvegicus	119-127
30951836-5	2019	In vitro, the resulting ROS generation blocked autophagosome processing and caused accumulation of LC3-II, ubiquitin, and p62, leading to mitochondrial dysfunction and cell death; this outcome was alleviated by cyclosporine A (CsA) pretreatment.	Cyclosporine	211-225	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	122-125
23788374-0	2014	Osteopontin mediating cyclosporine A induced epithelial-to-mesenchymal transition on rat renal tubular epithelial cells.	Cyclosporine	22-36	secreted phosphoprotein 1	Rattus norvegicus	0-11
23788374-1	2014	Osteopontin (OPN) is highly correlated with cyclosporine A (CsA) nephrotoxicity.	Cyclosporine	44-58	secreted phosphoprotein 1	Rattus norvegicus	0-11
23788374-1	2014	Osteopontin (OPN) is highly correlated with cyclosporine A (CsA) nephrotoxicity.	Cyclosporine	44-58	secreted phosphoprotein 1	Rattus norvegicus	13-16
23788374-1	2014	Osteopontin (OPN) is highly correlated with cyclosporine A (CsA) nephrotoxicity.	Cyclosporine	60-63	secreted phosphoprotein 1	Rattus norvegicus	0-11
23788374-1	2014	Osteopontin (OPN) is highly correlated with cyclosporine A (CsA) nephrotoxicity.	Cyclosporine	60-63	secreted phosphoprotein 1	Rattus norvegicus	13-16
23788374-3	2014	OPN knockdown suppresses CsA induced EMT on NRK52E cells, and it also attenuates downregulation of E-cadherin and upregulation of alpha-smooth muscle actin (alpha-SMA) and fibronectin (FN) that are induced by CsA.	Cyclosporine	25-28	secreted phosphoprotein 1	Rattus norvegicus	0-3
23788374-3	2014	OPN knockdown suppresses CsA induced EMT on NRK52E cells, and it also attenuates downregulation of E-cadherin and upregulation of alpha-smooth muscle actin (alpha-SMA) and fibronectin (FN) that are induced by CsA.	Cyclosporine	209-212	secreted phosphoprotein 1	Rattus norvegicus	0-3
23788374-5	2014	Thus, OPN is a causative factor in mediating CsA induced EMT on NRK52E cells.	Cyclosporine	45-48	secreted phosphoprotein 1	Rattus norvegicus	6-9
25199566-2	2014	This study investigated whether CSA protects against corticosterone (CORT)-induced injury in PC12 cells and examined the potential mechanisms underlying this protective effect.	Cyclosporine	32-35	cortistatin	Rattus norvegicus	69-73
25199566-8	2014	However, CSA dose-dependently increased cell viability and decreased LDH release as well as CORT-induced apoptosis.	Cyclosporine	9-12	cortistatin	Rattus norvegicus	92-96
25199566-9	2014	Mechanistically, compared with the CORT-treated group, CSA strongly attenuated intracellular Ca(2+) overload and restored mitochondrial functions, including mPTPs and  Psim.	Cyclosporine	55-58	cortistatin	Rattus norvegicus	35-39
25199566-10	2014	Furthermore, the down-regulation of cytochrome c and ICAD protein expression and the blockage of caspase-3 activity were observed upon CSA treatment.	Cyclosporine	135-138	caspase 3	Rattus norvegicus	97-106
26155135-3	2014	The results showed that both DEX and CsA dose-dependently inhibited the production of eleven cytokines: interleukin (IL)-2, IL-4, IL-5, IL-6, IL-13, IL-17, interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF).	Cyclosporine	37-40	interleukin 5	Homo sapiens	130-134
30689261-8	2019	In relation to non-atopic and late-onset asthma (LOA) phenotypes, we noted the frequency of CD4+ FoxP3+ T cells was lower in individuals with SAR than with CSA.	Cyclosporine	156-159	forkhead box P3	Homo sapiens	97-102
30580651-13	2019	The CsA-CLs group showed a lower level of IL-1beta than the BSS and soft CL groups (p < 0.01), and a lower level of IFN-gamma than the other groups (all p < 0.01).	Cyclosporine	4-7	interleukin-1 alpha	Oryctolagus cuniculus	42-50
31083172-8	2019	The combination of dexamethasone and ciclosporin may be effective option for patients with IgAN and EP concurrently.	Cyclosporine	37-48	IGAN1	Homo sapiens	91-95
30896878-4	2019	CsA treatment increased the phosphorylation of protein kinase B (Akt) and consequently the expression of Cyclin D1.	Cyclosporine	0-3	cyclin D1	Homo sapiens	105-114
30896878-6	2019	Mechanistically, CsA treatment increased reactive oxygen species (ROS) generation, and the intracellular ROS scavenger N-acetyl-cysteine (NAC) attenuated CsA-induced cell proliferation as well as the activation of Akt/Cyclin D1 signaling.	Cyclosporine	154-157	cyclin D1	Homo sapiens	218-227
30776644-4	2019	Treatment of the cells with CsA resulted in decreased expression of the mDC-specific markers (CD80, CD83 and CD88) induced by 27OHChol.	Cyclosporine	28-31	CD80 molecule	Homo sapiens	94-98
24341787-2	2014	Cyclosporine is a calcineurin inhibitor, ultimately exerting its inhibitory effects on T-lymphocytes by decreasing production of cytokines, such as interleukin-2.	Cyclosporine	0-12	interleukin 2	Canis lupus familiaris	148-161
30776644-7	2019	We further investigated the outcomes of CsA treatment on the expression of M1 polarization markers and CD14, a component of the innate immune system.	Cyclosporine	40-43	CD14 molecule	Homo sapiens	103-107
30294794-9	2019	In these cells, BaP significantly reduced AhR expression while this reduction was reversed by CH-223191; however, CsA treatment lowered the AhR expression only at low dose.	Cyclosporine	114-117	aryl hydrocarbon receptor	Homo sapiens	140-143
30294794-12	2019	Considering these findings, the low AhR expression and high beta4 integrin level following BaP and/or CsA treatments may contribute to the higher invasion/migration in MDA-MB-231 cells.	Cyclosporine	102-105	aryl hydrocarbon receptor	Homo sapiens	36-39
30417482-8	2019	After Con A stimulation, only T cells co-treated with ciclosporin achieved a significant proliferation inhibition and reduction of IL-2, IL-10, IL-15, IL-18, IFN-gamma and TNF-alpha.	Cyclosporine	54-65	interleukin 2	Canis lupus familiaris	131-135
30417482-8	2019	After Con A stimulation, only T cells co-treated with ciclosporin achieved a significant proliferation inhibition and reduction of IL-2, IL-10, IL-15, IL-18, IFN-gamma and TNF-alpha.	Cyclosporine	54-65	interleukin 10	Canis lupus familiaris	137-142
30417482-8	2019	After Con A stimulation, only T cells co-treated with ciclosporin achieved a significant proliferation inhibition and reduction of IL-2, IL-10, IL-15, IL-18, IFN-gamma and TNF-alpha.	Cyclosporine	54-65	interleukin 18	Canis lupus familiaris	151-156
30192415-5	2018	CCL18 from M2 macrophages was decreased by dexamethasone and cyclosporine, but not decreased by minocycline.	Cyclosporine	61-73	C-C motif chemokine ligand 18	Homo sapiens	0-5
30338826-8	2018	Cyclosporine treatment greatly reversed the cell damage on HK-2 cells induced by TGF-beta.	Cyclosporine	0-12	hexokinase 2	Homo sapiens	59-63
29914885-8	2018	Both HDACi and cyclosporine A reduced osteoblast expression of the key mineralization enzyme tissue-nonspecific alkaline phosphatase (TNAP; encoded by Alpl).	Cyclosporine	15-29	alkaline phosphatase, biomineralization associated	Homo sapiens	151-155
29380240-2	2018	Previously, we have shown that the calcineurin inhibiting drugs tacrolimus and cyclosporin A reduce adipocyte and myocyte glucose uptakes by reducing the amount of glucose transporter type 4 (GLUT4) at the cell surface, due to an increased internalization rate.	Cyclosporine	79-92	solute carrier family 2 member 4	Homo sapiens	164-190
29380240-2	2018	Previously, we have shown that the calcineurin inhibiting drugs tacrolimus and cyclosporin A reduce adipocyte and myocyte glucose uptakes by reducing the amount of glucose transporter type 4 (GLUT4) at the cell surface, due to an increased internalization rate.	Cyclosporine	79-92	solute carrier family 2 member 4	Homo sapiens	192-197
29266762-3	2018	A deficiency in TWEAK resulted in limited tubulotoxicity after CsA exposure, which correlated with diminished expression of inflammatory cytokines and reduced intraparenchymal infiltration with immune cells.	Cyclosporine	63-66	tumor necrosis factor (ligand) superfamily, member 12	Mus musculus	16-21
29266762-4	2018	We further identified tubular epithelial cells of the kidney as major targets of CsA activity and found that Fn14 (tumor necrosis factor receptor superfamily 12A), the receptor for TWEAK, is a highly CsA-inducible gene in these cells.	Cyclosporine	81-84	tumor necrosis factor receptor superfamily, member 12a	Mus musculus	109-113
29712725-3	2018	CsA is an inhibitor of organic anion transporting polypeptide (OATP)1B1 and CYP3A4, and GEM and its glucuronide (GEM-glu) inhibit OATP1B1 and CYP2C8.	Cyclosporine	0-3	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	142-148
29309904-9	2018	This increased response were diminished by etoricoxib, furegrelate, SQ 29548, cyclosporine A and parthenolide, inhibitors of COX-2, TXA2 synthase, TP receptors, calcineurin and NF-kappaB, respectively.	Cyclosporine	78-92	prostaglandin-endoperoxide synthase 2	Mus musculus	125-130
29704799-1	2018	Overestimation of immunoassays for cyclosporine (CsA) and tacrolimus (TAC) analysis in human whole blood is a problem.	Cyclosporine	35-47	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	49-52
29528074-6	2018	An NFAT inhibitor (CsA) and NF-kappaB inhibitor (PDTC) all markedly reduced Cyclin D1 protein expression.	Cyclosporine	19-22	cyclin D1	Homo sapiens	76-85
29328412-9	2018	CsA significantly decreased the expression levels of IL-10, TNF-alpha, Cyp-D and AIF in the spinal cord of the SCI rats.	Cyclosporine	0-3	peptidylprolyl isomerase F	Rattus norvegicus	71-76
29475508-2	2018	Cyclosporine is a potent immunosuppressive agent that targets T cell production of the cytokines IL-2 and IFN-gamma.	Cyclosporine	0-12	interleukin 2	Canis lupus familiaris	97-101
24142471-8	2014	Drug-induced gingival overgrowth was the single most common type of lesion, and its prevalence was significantly higher for patients using cyclosporine A (CSA; 29%) versus patients using tacrolimus (TAC; 5%, P = 0.007); the prevalence was even higher with the simultaneous use of calcium channel blockers and CSA (47%) or TAC (8%, P = 0.002).	Cyclosporine	139-153	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	155-158
24142471-8	2014	Drug-induced gingival overgrowth was the single most common type of lesion, and its prevalence was significantly higher for patients using cyclosporine A (CSA; 29%) versus patients using tacrolimus (TAC; 5%, P = 0.007); the prevalence was even higher with the simultaneous use of calcium channel blockers and CSA (47%) or TAC (8%, P = 0.002).	Cyclosporine	139-153	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	309-312
29475508-9	2018	Cyclosporine significantly decreased IL-2 and IFN-gamma expression when used alone or in combination with low-dose aspirin.	Cyclosporine	0-12	interleukin 2	Canis lupus familiaris	37-41
29520233-2	2018	Our previous research has resolved the three-dimensional structure of CyPJ and demonstrated the peptidylprolyl cis-trans isomerase (PPIase) activity of CyPJ, which can be inhibited by the common immunosuppressive drug cyclosporine A (CsA).	Cyclosporine	218-232	peptidylprolyl isomerase like 3	Homo sapiens	70-74
29520233-2	2018	Our previous research has resolved the three-dimensional structure of CyPJ and demonstrated the peptidylprolyl cis-trans isomerase (PPIase) activity of CyPJ, which can be inhibited by the common immunosuppressive drug cyclosporine A (CsA).	Cyclosporine	218-232	peptidylprolyl isomerase like 3	Homo sapiens	152-156
29520233-2	2018	Our previous research has resolved the three-dimensional structure of CyPJ and demonstrated the peptidylprolyl cis-trans isomerase (PPIase) activity of CyPJ, which can be inhibited by the common immunosuppressive drug cyclosporine A (CsA).	Cyclosporine	234-237	peptidylprolyl isomerase like 3	Homo sapiens	70-74
29520233-2	2018	Our previous research has resolved the three-dimensional structure of CyPJ and demonstrated the peptidylprolyl cis-trans isomerase (PPIase) activity of CyPJ, which can be inhibited by the common immunosuppressive drug cyclosporine A (CsA).	Cyclosporine	234-237	peptidylprolyl isomerase like 3	Homo sapiens	152-156
29520233-3	2018	Importantly, CyPJ is upregulated in hepatocellular carcinoma (HCC) and promotes tumor growth; CyPJ inhibition by CsA- or siRNA-based knockdown results in a remarkable suppression of HCC.	Cyclosporine	113-116	peptidylprolyl isomerase like 3	Homo sapiens	94-98
29101067-0	2018	FOXP3 rs3761549 polymorphism predicts long-term renal allograft function in patients receiving cyclosporine-based immunosuppressive regimen.	Cyclosporine	95-107	forkhead box P3	Homo sapiens	0-5
29101067-1	2018	AIM: The present study was conducted to determine the effect of FOXP3 single nucleotide polymorphisms (SNPs) on clinical outcomes in CsA-treated renal transplant patients.	Cyclosporine	133-136	forkhead box P3	Homo sapiens	64-69
29391135-5	2018	Correspondingly, the expressions of its target genes NRF 1 and TFAM were reduced in response to CsA treatment.	Cyclosporine	96-99	nuclear respiratory factor 1	Homo sapiens	53-58
29223733-6	2018	Since the pore opening can be inhibited by cyclosporin A, we show that this treatment reduces lipid droplets and mitochondrial swelling in cardiomyocytes, restores DRG neuron survival and inhibits NFAT dephosphorylation.	Cyclosporine	43-56	nuclear factor of activated T-cells 5	Rattus norvegicus	197-201
29129208-5	2017	Ptgs2 expression was also suppressed by inhibitor of Ca2+/calmodulin-dependent protein kinase (CaMKII) KN-93 whereas increment of Nr4a1 content triggered by ouabain was attenuated by inhibitor of Ca2+/calmodulin-dependent protein phosphatase (calcineurin, CaN) cyclosporin A.	Cyclosporine	261-274	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	0-5
29129208-5	2017	Ptgs2 expression was also suppressed by inhibitor of Ca2+/calmodulin-dependent protein kinase (CaMKII) KN-93 whereas increment of Nr4a1 content triggered by ouabain was attenuated by inhibitor of Ca2+/calmodulin-dependent protein phosphatase (calcineurin, CaN) cyclosporin A.	Cyclosporine	261-274	nuclear receptor subfamily 4, group A, member 1	Rattus norvegicus	130-135
29219791-7	2017	In Western blot analysis of extracts from rat kidneys treated with cyclosporine and 5 ng/kg 2AMD, the fibrotic markers, fibronectin and vimentin, were decreased compared with animals treated only with cyclosporine.	Cyclosporine	67-79	vimentin	Rattus norvegicus	136-144
29219791-7	2017	In Western blot analysis of extracts from rat kidneys treated with cyclosporine and 5 ng/kg 2AMD, the fibrotic markers, fibronectin and vimentin, were decreased compared with animals treated only with cyclosporine.	Cyclosporine	201-213	vimentin	Rattus norvegicus	136-144
28569378-1	2017	Cyclosporine A (CsA) is an immunosuppressive drug commonly used in organ transplant patients to prevent allograft rejections.	Cyclosporine	0-14	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	16-19
29381954-1	2017	BACKGROUND: Cyclosporine (CsA) is one of the immunosuppressive drugs, whose pharmacokinetic characteristics vary greatly among individuals.	Cyclosporine	12-24	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	26-29
25379560-10	2014	Independently from the ConA concentration, inhibition of CD25 and CD95 expression was highest preoperatively for sirolimus and on POD-3 for cyclosporine.	Cyclosporine	140-152	interleukin 2 receptor subunit alpha	Homo sapiens	57-61
28761977-9	2017	Calcineurin inhibitors ciclosporin A (CsA) and tacrolimus (FK-506) decreased Fgf23 gene expression and FGF23 protein production.	Cyclosporine	23-36	fibroblast growth factor 23	Rattus norvegicus	77-82
25379560-11	2014	At all time points, inhibition of CD25 and CD95 expression was significantly higher after cyclosporine compared to sirolimus treatment (P &lt; 0.001).	Cyclosporine	90-102	interleukin 2 receptor subunit alpha	Homo sapiens	34-38
28761977-9	2017	Calcineurin inhibitors ciclosporin A (CsA) and tacrolimus (FK-506) decreased Fgf23 gene expression and FGF23 protein production.	Cyclosporine	23-36	fibroblast growth factor 23	Rattus norvegicus	103-108
28761977-9	2017	Calcineurin inhibitors ciclosporin A (CsA) and tacrolimus (FK-506) decreased Fgf23 gene expression and FGF23 protein production.	Cyclosporine	38-41	fibroblast growth factor 23	Rattus norvegicus	77-82
28761977-9	2017	Calcineurin inhibitors ciclosporin A (CsA) and tacrolimus (FK-506) decreased Fgf23 gene expression and FGF23 protein production.	Cyclosporine	38-41	fibroblast growth factor 23	Rattus norvegicus	103-108
28899749-2	2017	Here we investigated whether (i) under conditions of vascular endothelium dysfunction, the immunosuppressant drug cyclosporine (CSA) upregulates EDHF-dependent renal vasodilations through altering CYP4A/CYP2C signaling, and (ii) calcium channel blockers modulate the CSA/EDHF/CYP interaction.	Cyclosporine	114-126	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	197-200
28899749-2	2017	Here we investigated whether (i) under conditions of vascular endothelium dysfunction, the immunosuppressant drug cyclosporine (CSA) upregulates EDHF-dependent renal vasodilations through altering CYP4A/CYP2C signaling, and (ii) calcium channel blockers modulate the CSA/EDHF/CYP interaction.	Cyclosporine	128-131	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	197-200
29149986-2	2017	The aim of this work was to study the effects of cyclosporine (CsA), tacrolimus (FK-506), and rapamycin (RAPA) on the release of three local factors directly implicated in bone-remodeling regulation and apoptosis of human osteoblasts: interleukin (IL)-6, osteoprotegerin, and receptor activator of nuclear factor kappabeta (RANKL).	Cyclosporine	49-61	TNF receptor superfamily member 11b	Homo sapiens	255-270
29149986-2	2017	The aim of this work was to study the effects of cyclosporine (CsA), tacrolimus (FK-506), and rapamycin (RAPA) on the release of three local factors directly implicated in bone-remodeling regulation and apoptosis of human osteoblasts: interleukin (IL)-6, osteoprotegerin, and receptor activator of nuclear factor kappabeta (RANKL).	Cyclosporine	63-66	TNF receptor superfamily member 11b	Homo sapiens	255-270
28875951-11	2017	The mRNA expression of WT-1, Pax2, and Pax8 was downregulated by CsA treatment.	Cyclosporine	65-68	paired box 8	Mus musculus	39-43
28439923-1	2017	RATIONALE: In the determination of immunosuppressive drugs cyclosporine A (CSA), tacrolimus (TARO), sirolimus (SIRO), and everolimus (EVE) in whole blood there is an open debate about which is the best assay between immunochemistry and liquid chromatography/tandem mass spectrometry (LC/MS/MS).	Cyclosporine	59-73	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	75-78
28433160-2	2017	Chitosan-stearic acid-thioglycolic acid (CSA-TGA) conjugate was synthesized via stearic acid linkage to chitosan and later, thioglycolic acid was covalently attached to CSA.	Cyclosporine	41-44	T-box transcription factor 1	Homo sapiens	45-48
28433160-2	2017	Chitosan-stearic acid-thioglycolic acid (CSA-TGA) conjugate was synthesized via stearic acid linkage to chitosan and later, thioglycolic acid was covalently attached to CSA.	Cyclosporine	169-172	T-box transcription factor 1	Homo sapiens	45-48
28433160-3	2017	CSA-TGA and CSA were characterized by degree of amine substitution, thiol group determination, ATR-FTIR and cytotoxicity analysis.	Cyclosporine	0-3	T-box transcription factor 1	Homo sapiens	4-7
28433160-4	2017	Micelle size was 13.40+-9.38 and 26.30+-26.86nm and zeta potential -0.01 and 0.03mV for CSA and CSA-TGA, respectively.	Cyclosporine	96-99	T-box transcription factor 1	Homo sapiens	100-103
28257599-7	2017	Treatment with tacrolimus and cyclosporin render CD4+ CD25- cells more susceptible to Treg control.	Cyclosporine	30-41	interleukin 2 receptor subunit alpha	Homo sapiens	54-58
28315683-0	2017	Klotho ameliorates cyclosporine A-induced nephropathy via PDLIM2/NF-kB p65 signaling pathway.	Cyclosporine	19-33	RELA proto-oncogene, NF-kB subunit	Homo sapiens	71-74
28315683-10	2017	These findings suggest that Klotho can modulate inflammation via PDLIM2/NF-kB p65 pathway in CsA-induced nephropathy.	Cyclosporine	93-96	RELA proto-oncogene, NF-kB subunit	Homo sapiens	78-81
28414804-14	2017	To validate that the observed microRNA and mRNA expression level changes in mice kidney tissue were directly related to CsA treatment, the expression change induced by CsA treatment of three microRNAs (miR-21, miR-186, and miR-709) and three mRNAs (BMPR1a, SMURF1 and SMAD7) were compared in HEK293 cell line.	Cyclosporine	120-123	microRNA 21a	Mus musculus	202-208
28414804-14	2017	To validate that the observed microRNA and mRNA expression level changes in mice kidney tissue were directly related to CsA treatment, the expression change induced by CsA treatment of three microRNAs (miR-21, miR-186, and miR-709) and three mRNAs (BMPR1a, SMURF1 and SMAD7) were compared in HEK293 cell line.	Cyclosporine	120-123	SMAD family member 7	Mus musculus	268-273
28414804-14	2017	To validate that the observed microRNA and mRNA expression level changes in mice kidney tissue were directly related to CsA treatment, the expression change induced by CsA treatment of three microRNAs (miR-21, miR-186, and miR-709) and three mRNAs (BMPR1a, SMURF1 and SMAD7) were compared in HEK293 cell line.	Cyclosporine	168-171	microRNA 21a	Mus musculus	202-208
28414804-14	2017	To validate that the observed microRNA and mRNA expression level changes in mice kidney tissue were directly related to CsA treatment, the expression change induced by CsA treatment of three microRNAs (miR-21, miR-186, and miR-709) and three mRNAs (BMPR1a, SMURF1 and SMAD7) were compared in HEK293 cell line.	Cyclosporine	168-171	SMAD family member 7	Mus musculus	268-273
28469772-1	2017	This study tested the hypothesis that erythropoietin (EPO) and cyclosporine (CsA) could effectively reduce brain infarct area (BIA) in rat after acute ischemic stroke (AIS) through regulating inflammation, oxidative stress, MAPK family signaling and microRNA (miR-223/miR-30a/miR-383).	Cyclosporine	63-75	mitogen activated protein kinase 3	Rattus norvegicus	224-228
24422229-1	2013	Cyclosporine is an immunosuppressive agent that inhibits T-cell function by decreasing production of cytokines such as interleukin-2 (IL-2) and interferon-gamma(IFN-gamma).	Cyclosporine	0-12	interleukin 2	Canis lupus familiaris	119-132
24422229-1	2013	Cyclosporine is an immunosuppressive agent that inhibits T-cell function by decreasing production of cytokines such as interleukin-2 (IL-2) and interferon-gamma(IFN-gamma).	Cyclosporine	0-12	interleukin 2	Canis lupus familiaris	134-138
24422229-3	2013	Our laboratory has developed a quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) assay that measures IL-2 and IFN-gamma gene expression, with the goal of quantifying immunosuppression in dogs treated with cyclosporine.	Cyclosporine	226-238	interleukin 2	Canis lupus familiaris	122-126
28469772-1	2017	This study tested the hypothesis that erythropoietin (EPO) and cyclosporine (CsA) could effectively reduce brain infarct area (BIA) in rat after acute ischemic stroke (AIS) through regulating inflammation, oxidative stress, MAPK family signaling and microRNA (miR-223/miR-30a/miR-383).	Cyclosporine	63-75	microRNA 383	Rattus norvegicus	276-283
28469772-1	2017	This study tested the hypothesis that erythropoietin (EPO) and cyclosporine (CsA) could effectively reduce brain infarct area (BIA) in rat after acute ischemic stroke (AIS) through regulating inflammation, oxidative stress, MAPK family signaling and microRNA (miR-223/miR-30a/miR-383).	Cyclosporine	77-80	mitogen activated protein kinase 3	Rattus norvegicus	224-228
28469772-1	2017	This study tested the hypothesis that erythropoietin (EPO) and cyclosporine (CsA) could effectively reduce brain infarct area (BIA) in rat after acute ischemic stroke (AIS) through regulating inflammation, oxidative stress, MAPK family signaling and microRNA (miR-223/miR-30a/miR-383).	Cyclosporine	77-80	microRNA 383	Rattus norvegicus	276-283
28469772-7	2017	EPO-CsA therapy markedly reduced BIA mainly by suppressing the innate immune response to inflammation, oxidative stress, microRNAs (miR-223/miR-30a/miR-383) and MAPK family signaling.	Cyclosporine	4-7	microRNA 383	Rattus norvegicus	148-155
28469772-7	2017	EPO-CsA therapy markedly reduced BIA mainly by suppressing the innate immune response to inflammation, oxidative stress, microRNAs (miR-223/miR-30a/miR-383) and MAPK family signaling.	Cyclosporine	4-7	mitogen activated protein kinase 3	Rattus norvegicus	161-165
28130342-5	2017	In cultured rat aortic EC, inhibiting calcineurin with cyclosporine A reduced CSE mRNA, CSE protein, and luciferase activity driven by a full-length but not a truncated CSE promoter.	Cyclosporine	55-69	cystathionine gamma-lyase	Rattus norvegicus	78-81
24312564-11	2013	The calcineurin inhibitor ciclosporin and the endogenous "entourage" compound palmitoylethanolamide potentiated the vasodilator response to 2-arachidonoylglycerol, disclosing TRPV1 activation of this monoacylglycerol at nanomolar concentrations.	Cyclosporine	26-37	transient receptor potential cation channel subfamily V member 1	Homo sapiens	175-180
28130342-5	2017	In cultured rat aortic EC, inhibiting calcineurin with cyclosporine A reduced CSE mRNA, CSE protein, and luciferase activity driven by a full-length but not a truncated CSE promoter.	Cyclosporine	55-69	cystathionine gamma-lyase	Rattus norvegicus	88-91
28130342-5	2017	In cultured rat aortic EC, inhibiting calcineurin with cyclosporine A reduced CSE mRNA, CSE protein, and luciferase activity driven by a full-length but not a truncated CSE promoter.	Cyclosporine	55-69	cystathionine gamma-lyase	Rattus norvegicus	88-91
27585667-8	2017	In vivo and in vitro CsA promoted secretion of the TLR ligand HMGB1 by tubular cells upstream of TLR4 activation, and prevention of HMGB1 secretion significantly reduced CsA-induced synthesis of MCP-1, suggesting that HMGB1 may be one of the mediators of CsA-induced TLR4 activation.	Cyclosporine	21-24	high mobility group box 1	Mus musculus	62-67
27585667-8	2017	In vivo and in vitro CsA promoted secretion of the TLR ligand HMGB1 by tubular cells upstream of TLR4 activation, and prevention of HMGB1 secretion significantly reduced CsA-induced synthesis of MCP-1, suggesting that HMGB1 may be one of the mediators of CsA-induced TLR4 activation.	Cyclosporine	170-173	high mobility group box 1	Mus musculus	132-137
27585667-8	2017	In vivo and in vitro CsA promoted secretion of the TLR ligand HMGB1 by tubular cells upstream of TLR4 activation, and prevention of HMGB1 secretion significantly reduced CsA-induced synthesis of MCP-1, suggesting that HMGB1 may be one of the mediators of CsA-induced TLR4 activation.	Cyclosporine	170-173	high mobility group box 1	Mus musculus	132-137
27585667-8	2017	In vivo and in vitro CsA promoted secretion of the TLR ligand HMGB1 by tubular cells upstream of TLR4 activation, and prevention of HMGB1 secretion significantly reduced CsA-induced synthesis of MCP-1, suggesting that HMGB1 may be one of the mediators of CsA-induced TLR4 activation.	Cyclosporine	170-173	high mobility group box 1	Mus musculus	132-137
27585667-8	2017	In vivo and in vitro CsA promoted secretion of the TLR ligand HMGB1 by tubular cells upstream of TLR4 activation, and prevention of HMGB1 secretion significantly reduced CsA-induced synthesis of MCP-1, suggesting that HMGB1 may be one of the mediators of CsA-induced TLR4 activation.	Cyclosporine	170-173	high mobility group box 1	Mus musculus	132-137
23809336-6	2013	The results showed that CsA increased the mRNA expression and contractile function of several G-protein-coupled receptors (GPCRs), such as endothelin receptor type B (ETB ), 5-hydroxytryptamine type 1B (5-HT1B ) and 1D (5-HT1D ), in vascular smooth muscle cells.	Cyclosporine	24-27	endothelin receptor type B	Rattus norvegicus	139-165
27839819-9	2017	Surprisingly, both CsA and the knockdown of PINK1 by small-interfering RNA (siRNA) significantly decreased the LC3-II/LC3-I ratio and the PINK1 and Parkin protein levels in AGE-treated cardiomyocytes.	Cyclosporine	19-22	annexin A3	Rattus norvegicus	111-114
23809336-6	2013	The results showed that CsA increased the mRNA expression and contractile function of several G-protein-coupled receptors (GPCRs), such as endothelin receptor type B (ETB ), 5-hydroxytryptamine type 1B (5-HT1B ) and 1D (5-HT1D ), in vascular smooth muscle cells.	Cyclosporine	24-27	endothelin receptor type B	Rattus norvegicus	167-170
22417245-0	2013	Downregulation of circulating CD4+ CD25(bright) Foxp3+ T cells by cyclosporine therapy and correlation with clinical response in psoriasis patients: report of three cases.	Cyclosporine	66-78	interleukin 2 receptor subunit alpha	Homo sapiens	35-39
27839819-9	2017	Surprisingly, both CsA and the knockdown of PINK1 by small-interfering RNA (siRNA) significantly decreased the LC3-II/LC3-I ratio and the PINK1 and Parkin protein levels in AGE-treated cardiomyocytes.	Cyclosporine	19-22	annexin A3	Rattus norvegicus	118-121
24228106-11	2013	Moreover, CsA pretreatment up-regulated Titin expression, down-regulated E-cadherin expression, improved MMP2 and MMP9 activity, and increased the CXCL12 secretion in JAR cells.	Cyclosporine	10-13	matrix metallopeptidase 2	Homo sapiens	105-109
24228106-11	2013	Moreover, CsA pretreatment up-regulated Titin expression, down-regulated E-cadherin expression, improved MMP2 and MMP9 activity, and increased the CXCL12 secretion in JAR cells.	Cyclosporine	10-13	C-X-C motif chemokine ligand 12	Homo sapiens	147-153
27839819-10	2017	Moreover, CsA treatment or knockdown of PINK1 expression attenuated the increased number of SA-beta-gal positive cells and the upregulated p16 level in cardiomyocytes induced by AGEs.	Cyclosporine	10-13	SH3-domain binding protein 5	Rattus norvegicus	92-99
28274044-4	2017	AIM: This study was undertaken to estimate the AOPP generation by Human Gingival Fibroblasts (HGF) under the influence of CsA and Angiotensin II (Ang II).	Cyclosporine	122-125	hepatocyte growth factor	Homo sapiens	94-97
23521314-1	2013	AIMS: Ciclosporin A (CsA) dosing in immunosuppression after paediatric kidney transplantation remains challenging, and appropriate target CsA exposures (AUCs) are controversial.	Cyclosporine	21-24	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	6-19
27861627-3	2016	Cyclosporin A (CsA) prevented mitochondrial permeability transition pore opening and apoptosis; there was mitochondrial ultrastructural disruption, mitochondrial cytochrome c (cyt c) translocation to the cytoplasm, and subsequent caspase-9 and caspase-3 activation.	Cyclosporine	0-13	caspase 3	Rattus norvegicus	244-253
23868912-10	2013	Chrysin, benzoflavone, and cyclosporin A inhibited Pp-18 efflux in both human and mouse ABCG2.	Cyclosporine	27-40	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	88-93
27861627-3	2016	Cyclosporin A (CsA) prevented mitochondrial permeability transition pore opening and apoptosis; there was mitochondrial ultrastructural disruption, mitochondrial cytochrome c (cyt c) translocation to the cytoplasm, and subsequent caspase-9 and caspase-3 activation.	Cyclosporine	15-18	caspase 3	Rattus norvegicus	244-253
27603548-2	2016	Pre-incubation with cyclosporine A in vitro before simultaneous incubation with probes has been reported to potentiate its inhibitory effects on recombinant human OATP-mediated probe uptake.	Cyclosporine	20-34	solute carrier organic anion transporter family member 1A2	Homo sapiens	163-167
27603548-3	2016	In the present study, the effects of cyclosporine A and rifampicin on recombinant cynomolgus monkey OATP-mediated pitavastatin uptake were investigated in pre- and simultaneous incubation systems.	Cyclosporine	37-51	solute carrier organic anion transporter family member 1A2	Homo sapiens	100-104
27882144-5	2016	As compared with the N group, the mRNA expression levels of MMP-9, VCAM-1 and TNF-alpha were significantly increased in the CHD and RS groups (P&lt;0.05), but were significantly decreased in the groups with CSA intervention, as compared with those without CSA intervention (P&lt;0.05).	Cyclosporine	207-210	matrix metalloproteinase-9	Oryctolagus cuniculus	60-65
27882144-5	2016	As compared with the N group, the mRNA expression levels of MMP-9, VCAM-1 and TNF-alpha were significantly increased in the CHD and RS groups (P&lt;0.05), but were significantly decreased in the groups with CSA intervention, as compared with those without CSA intervention (P&lt;0.05).	Cyclosporine	256-259	matrix metalloproteinase-9	Oryctolagus cuniculus	60-65
27734179-5	2016	Application of this analysis protocol to FKBP12 demonstrated an efficient quantitation of both weak exchange linebroadening contributions and differential residue-specific 15N CSA values.	Cyclosporine	176-179	FKBP prolyl isomerase 1A	Homo sapiens	41-47
27590243-4	2016	Cyclosporine A, a specific CyPA/CD147 signaling pathway inhibitor, was used to manipulate CyPA/CD147 activity.	Cyclosporine	0-14	peptidylprolyl isomerase A	Rattus norvegicus	27-31
27590243-4	2016	Cyclosporine A, a specific CyPA/CD147 signaling pathway inhibitor, was used to manipulate CyPA/CD147 activity.	Cyclosporine	0-14	peptidylprolyl isomerase A	Rattus norvegicus	90-94
27601896-2	2016	To synergistically and completely reverse MDR by simultaneous inhibition of pump and non-pump cellular resistance, three-in-one multifunctional lipid-sodium glycocholate (GcNa) nanocarriers (TMLGNs) have been designed for controlled co-delivery of water-soluble cationic mitoxantrone hydrochloride (MTO), cyclosporine A (CsA - BCRP inhibitor), and GcNa (Bcl-2 inhibitor).	Cyclosporine	305-319	germ cell nuclear acidic peptidase	Homo sapiens	171-175
27601896-2	2016	To synergistically and completely reverse MDR by simultaneous inhibition of pump and non-pump cellular resistance, three-in-one multifunctional lipid-sodium glycocholate (GcNa) nanocarriers (TMLGNs) have been designed for controlled co-delivery of water-soluble cationic mitoxantrone hydrochloride (MTO), cyclosporine A (CsA - BCRP inhibitor), and GcNa (Bcl-2 inhibitor).	Cyclosporine	321-324	germ cell nuclear acidic peptidase	Homo sapiens	171-175
27601896-4	2016	The results of a series of in vitro and in vivo investigations indicated that the TMLGNs were taken up by the resistant cancer cells by an endocytosis pathway that escaped the efflux induced by BCRP, and the simultaneous release of CsA with MTO further efficiently inhibited the efflux of the released MTO by BCRP; meanwhile GcNa induced the apoptosis process, and an associated synergistic antitumor activity and reversion of MDR were achieved because the reversal index was almost 1.0.	Cyclosporine	232-235	germ cell nuclear acidic peptidase	Homo sapiens	325-329
27052254-1	2016	INTRODUCTION: Cyclosporine (CsA) is an effective agent for treating patients with acute steroid-refractory ulcerative colitis (UC).	Cyclosporine	14-26	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	28-31
27319213-5	2016	These facts encouraged us to explore the potential application of CsA as an HBP to actualize intracellular delivery of nanomedicines for tumor therapy.	Cyclosporine	66-69	heme binding protein 1	Homo sapiens	76-79
27319213-9	2016	In conclusion, CsA, a readily obtainable molecule with favorable characteristics, is indeed a good candidate for an HBP, and this study provides solid, novel evidence for the use of HBP-based nanocarriers as effective antitumor drug delivery systems.	Cyclosporine	15-18	heme binding protein 1	Homo sapiens	116-119
27319213-9	2016	In conclusion, CsA, a readily obtainable molecule with favorable characteristics, is indeed a good candidate for an HBP, and this study provides solid, novel evidence for the use of HBP-based nanocarriers as effective antitumor drug delivery systems.	Cyclosporine	15-18	heme binding protein 1	Homo sapiens	182-185
27496445-1	2016	BACKGROUND: Cyclosporine (CsA) is an immunosuppressive agent whose use is associated with adverse effects, including nephrotoxicity.	Cyclosporine	12-24	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	26-29
27103440-6	2016	CYPD inhibitors (cyclosporin A and sanglifehrin A) as well as CYPD shRNAs dramatically attenuated AICAR-induced prostate cancer cell necrosis and cytotoxicity.	Cyclosporine	17-30	peptidylprolyl isomerase D	Homo sapiens	0-4
23689317-1	2013	The calcineurin inhibitor cyclosporine A (CsA) improves survival in endotoxemic mice.	Cyclosporine	26-40	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	42-45
23492557-9	2013	Surprisingly, in a series of cyclosporine derivatives an inverse relationship was found between the inhibition of prolyl oligopeptidase and inhibition of cyclophilin A.	Cyclosporine	29-41	prolyl endopeptidase	Mus musculus	114-135
23121663-4	2013	STUDY DESIGN AND METHODS: We hereby report two patients with a history of relapsed idiopathic TTP, who both received cyclosporin A (CSA) as a prophylactic manner after the remission was achieved.	Cyclosporine	117-130	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	132-135
23953553-1	2013	BACKGROUND: The aim of this study was to demonstrate noninferiority of everolimus with reduced cyclosporine (CsA) vs mycophenolate mofetil (MMF) with reduced CsA in improving renal function.	Cyclosporine	95-107	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	109-112
23755172-11	2014	In association with suppressed MB, CsA increased serum creatinine, caused loss of brush border and dilatation of proximal tubules, tubular atrophy, vacuolization, apoptosis, calcification, and increased neutrophil gelatinase-associated lipocalin expression, leukocyte infiltration, and renal fibrosis.	Cyclosporine	35-38	lipocalin 2	Rattus norvegicus	203-245
23106187-4	2013	This study was directed forward to the identification of the angiotensinogen, angiotensin II (Ang II) and its receptors AT1 /AT2 expression in DIGO tissues and cyclosporine-treated human gingival fibroblast cells.	Cyclosporine	160-172	angiotensin II receptor type 2	Homo sapiens	125-128
23106187-11	2013	In gingival fibroblasts, Ang II and AT1 expressions were increased with cyclosporine incorporation compared to controls.	Cyclosporine	72-84	angiotensin II receptor type 1	Homo sapiens	36-39
23595141-6	2013	Both diazoxide and cyclosporin A exerted significant protective effects on cell viability by ameliorating the decrease in Bcl-2 and the increase in cytochrome c and caspase-3 activity induced by A-beta1-42.	Cyclosporine	19-32	caspase 3	Rattus norvegicus	165-174
23769096-8	2013	VAP-1 was significantly lower among patients treated with tacrolimus than cyclosporine.	Cyclosporine	74-86	amine oxidase copper containing 3	Homo sapiens	0-5
23683031-5	2013	RESULTS: CsA induced marked increases in urine kidney injury molecule-1 (Kim-1) and neutrophil gelatinase-associated lipocalin (NGAL) concentrations (P &lt; 0.05).	Cyclosporine	9-12	lipocalin 2	Rattus norvegicus	84-126
23683031-5	2013	RESULTS: CsA induced marked increases in urine kidney injury molecule-1 (Kim-1) and neutrophil gelatinase-associated lipocalin (NGAL) concentrations (P &lt; 0.05).	Cyclosporine	9-12	lipocalin 2	Rattus norvegicus	128-132
23683031-10	2013	CsA increased the protein expression of bax, cleaved caspase-9, caspase-3 and the activity of caspase-3; however, the anti-apoptotic bcl-2 protein was reduced.	Cyclosporine	0-3	caspase 3	Rattus norvegicus	64-73
23683031-10	2013	CsA increased the protein expression of bax, cleaved caspase-9, caspase-3 and the activity of caspase-3; however, the anti-apoptotic bcl-2 protein was reduced.	Cyclosporine	0-3	caspase 3	Rattus norvegicus	94-103
23593329-8	2013	Anti-OX40L or the NFATc1 inhibitor (CsA) markedly suppressed the cell proliferation induced by anti-OX40.	Cyclosporine	36-39	tumor necrosis factor (ligand) superfamily, member 4	Mus musculus	5-10
23593329-8	2013	Anti-OX40L or the NFATc1 inhibitor (CsA) markedly suppressed the cell proliferation induced by anti-OX40.	Cyclosporine	36-39	tumor necrosis factor receptor superfamily, member 4	Mus musculus	5-9
23755756-1	2013	The aim of this work is to compare the results of a commercially available liquid chromatography tandem mass spectrometry (LC-MS/MS) method in a clinical pathology laboratory for routine Therapeutic Drug Monitoring (TDM) of cyclosporine (CsA) and tacrolimus (Tacr) in pediatric patients with those obtained with the current antibody-conjugated magnetic immunoassay (ACMIA).	Cyclosporine	224-236	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	238-241
27103440-6	2016	CYPD inhibitors (cyclosporin A and sanglifehrin A) as well as CYPD shRNAs dramatically attenuated AICAR-induced prostate cancer cell necrosis and cytotoxicity.	Cyclosporine	17-30	5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase	Homo sapiens	98-103
26082307-4	2016	Simultaneously, Pb-induced caspase-3 activation and apoptosis can be significantly inhibited by three MPTP inhibitors (CsA, DIDS, BA), which target different regulatory components of MPTP (Cyp-D, VDAC, ANT), respectively, demonstrating that Cyp-D, VDAC and ANT participate in MPTP regulation during lead exposure.	Cyclosporine	119-122	caspase 3	Rattus norvegicus	27-36
26082307-4	2016	Simultaneously, Pb-induced caspase-3 activation and apoptosis can be significantly inhibited by three MPTP inhibitors (CsA, DIDS, BA), which target different regulatory components of MPTP (Cyp-D, VDAC, ANT), respectively, demonstrating that Cyp-D, VDAC and ANT participate in MPTP regulation during lead exposure.	Cyclosporine	119-122	peptidylprolyl isomerase F	Rattus norvegicus	189-194
26082307-4	2016	Simultaneously, Pb-induced caspase-3 activation and apoptosis can be significantly inhibited by three MPTP inhibitors (CsA, DIDS, BA), which target different regulatory components of MPTP (Cyp-D, VDAC, ANT), respectively, demonstrating that Cyp-D, VDAC and ANT participate in MPTP regulation during lead exposure.	Cyclosporine	119-122	peptidylprolyl isomerase F	Rattus norvegicus	241-246
26826458-8	2016	More than 50% level of inflammatory factors including TNF-alpha, IFN-gamma, IL-2, IL-12, IL-22 and IL-23 in mouse serum was decreased by curcumin treatment as well as cyclosporine.	Cyclosporine	167-179	interleukin 23, alpha subunit p19	Mus musculus	99-104
26945895-6	2016	Both tropisetron and cyclosporine A markedly prevented the hypertrophic characteristic features, calcineurin overexpression and nuclear localization of NFATc4 while intracellular Ca(2+) was not affected.	Cyclosporine	21-35	nuclear factor of activated T-cells 4	Rattus norvegicus	152-158
27028319-5	2016	Intracellular and secreted IL-10 levels were determined by flow cytometry and Bioplex assay after treating PBMCs with PD98059, tipifarnib and cyclosporin A for blocking of ERK-, T-bet-and FoxP3-dependent pathways, respectively.	Cyclosporine	142-155	forkhead box P3	Homo sapiens	188-193
26997877-6	2016	Our case shows that cyclosporin A is a treatment option for CD2AP-associated nephropathy.	Cyclosporine	20-33	CD2 associated protein	Homo sapiens	60-65
26632647-1	2016	The study examined the effect of dipeptidyl peptidase-4 (DPP-4) inhibitor, vildagliptin, in cyclosporine (CsA)-induced hepatotoxicity.	Cyclosporine	92-104	dipeptidylpeptidase 4	Rattus norvegicus	57-62
26659252-8	2016	Similarly, treatment with chemical inhibitors of calcineurin, such as FK506 and cyclosporin A, or knockdown of calcineurin expression by RNA interference (RNAi), exacerbated the Abeta42-induced rough-eye phenotype.	Cyclosporine	80-93	Calcineurin A1	Drosophila melanogaster	49-60
26704294-5	2016	We have used three cell lines--A549 (human lung carcinoma), SK-Hep-1 (human liver adenocarcinoma), FL (human amniotic normal cells), and two inhibitors of the OATP (cyclosporine A and captopril).	Cyclosporine	165-179	solute carrier organic anion transporter family member 1A2	Homo sapiens	159-163
26259716-4	2016	Interaction studies with low-dose cyclosporine confirmed the role of OATP.	Cyclosporine	34-46	solute carrier organic anion transporter family member 1A2	Homo sapiens	69-73
22934794-0	2013	Association of CD14-260 polymorphisms, red-complex periodontopathogens and gingival crevicular fluid cytokine levels with cyclosporine A-induced gingival overgrowth in renal transplant patients.	Cyclosporine	122-136	CD14 molecule	Homo sapiens	15-19
25594762-6	2016	CsA and FK506 were additionally found to up-regulate the expression of several molecules that play a protective role in bladder tumorigenesis, including p53, p21, and p27, and down-regulate that of oncogenic genes, such as cyclin D1, cyclin D3, and cyclin E, in SVHUC cells with the carcinogen challenge.	Cyclosporine	0-3	cyclin D3	Mus musculus	234-243
22934794-13	2013	However, CD14-260 CT + TT genotypes are associated with the prevalence of red complex periodontopathogens in patients with GO, and may thus play some role in the development of severe CsA-induced GO.	Cyclosporine	184-187	CD14 molecule	Homo sapiens	9-13
22580614-5	2013	The induction of ER stress in glioma cells by CsA was evidenced by detection of unfolded protein response activation (phosphorylation of PERK, accumulation of IRE1alpha) and accumulation of ER stress-associated proteins (BIP and CHOP).	Cyclosporine	46-49	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	159-168
22580614-8	2013	Salubrinal and silencing of PERK and IRE1alpha partially blocked CsA-induced accumulation of LC3-II.	Cyclosporine	65-68	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	37-46
22580614-10	2013	Surprisingly, silencing of autophagy effectors ULK1, Atg5 or Atg7 increased the level of active caspases 3, 7 and PARP degradation in CsA-treated cells.	Cyclosporine	134-137	unc-51 like autophagy activating kinase 1	Homo sapiens	47-51
22580614-10	2013	Surprisingly, silencing of autophagy effectors ULK1, Atg5 or Atg7 increased the level of active caspases 3, 7 and PARP degradation in CsA-treated cells.	Cyclosporine	134-137	autophagy related 7	Homo sapiens	61-65
23242346-9	2013	This dual-death pathway was shut down when pretreated with pan-caspase inhibitor (z-VAD-fmk) and cyclophilin D inhibitor (cyclosporin A).	Cyclosporine	122-135	peptidylprolyl isomerase D	Homo sapiens	97-110
23258544-2	2013	Transplant patients treated with immunosuppressant drugs such as cyclosporine A (CsA), an inhibitor of calcineurin phosphatase, frequently develop similar metabolic complications.	Cyclosporine	65-79	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	81-84
23160799-8	2013	We found that the appropriate concentrations and time-points of CsA-induced the expression of Dvl-1 and subsequent up-regulation of beta-catenin and c-Myc, which is consistent with previously demonstrated concentrations and time-points when H9c2 cells apoptosis occurred.	Cyclosporine	64-67	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	149-154
23160799-10	2013	Dvl-1 down-regulation decreased the apoptotic rate, caspase-3 activity, and the Bax/Bcl-2 ratio in H9c2 cells treated with CsA.	Cyclosporine	123-126	caspase 3	Rattus norvegicus	52-61
23160799-12	2013	Moreover, we further deleted the downstream member beta-catenin by specific siRNA, and found that CsA-induced the Bax/Bcl-2 ratio and the expression of c-Myc, which were attenuated.	Cyclosporine	98-101	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	152-157
22821730-1	2013	Cyclosporine A (CSA), but not tacrolimus (TAC), inhibits hepatitis C virus (HCV) replication in vitro.	Cyclosporine	0-14	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	16-19
24348262-7	2013	Treatment with the calcineurin-inhibitor cyclosporine A abolished FGF23-mediated PTH suppression in PTH-KL(-/-) mice whereas wild-type mice remained responsive.	Cyclosporine	41-55	parathyroid hormone	Mus musculus	81-84
24348262-7	2013	Treatment with the calcineurin-inhibitor cyclosporine A abolished FGF23-mediated PTH suppression in PTH-KL(-/-) mice whereas wild-type mice remained responsive.	Cyclosporine	41-55	parathyroid hormone	Mus musculus	100-103
23555904-7	2013	In comparison, addition of MPA and Cyclosporine A displayed reduced CD107a expression and IFN-gamma production following PMA/Ionomycin stimulation.	Cyclosporine	35-49	lysosomal associated membrane protein 1	Homo sapiens	68-74
26849622-7	2016	The insulin-induced elevation of TRPC6 transcripts was blocked in the presence of tacrolimus, cyclosporine A, and NFAT-inhibitor (each p &lt; 0.01 by ANOVA and Bonferroni"s multiple comparison test).	Cyclosporine	94-108	transient receptor potential cation channel subfamily C member 6	Homo sapiens	33-38
28115789-0	2016	The Usefulness of Determining Neutrophil Gelatinase-Associated Lipocalin Concentration Excreted in the Urine in the Evaluation of Cyclosporine A Nephrotoxicity in Children with Nephrotic Syndrome.	Cyclosporine	130-144	matrix metallopeptidase 2	Homo sapiens	30-51
26616647-8	2016	This higher sensitivity of sh-HERPUD1 HeLa cells to H2O2 was prevented with the mitochondrial permeability transition pore inhibitor cyclosporine A.	Cyclosporine	133-147	homocysteine inducible ER protein with ubiquitin like domain 1	Homo sapiens	30-37
27747732-1	2015	A 26-year-old woman developed symptoms of acute toxicity during cyclosporine (CsA) therapy for graft-versus-host disease prophylaxis.	Cyclosporine	64-76	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	78-81
26276312-0	2015	Co-administration of alpha-lipoic acid and cyclosporine aggravates colon ulceration of acetic acid-induced ulcerative colitis via facilitation of NO/COX-2/miR-210 cascade.	Cyclosporine	43-55	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	149-154
26276312-0	2015	Co-administration of alpha-lipoic acid and cyclosporine aggravates colon ulceration of acetic acid-induced ulcerative colitis via facilitation of NO/COX-2/miR-210 cascade.	Cyclosporine	43-55	microRNA 210	Rattus norvegicus	155-162
26276312-12	2015	Concomitant use of alpha-lipoic acid and cyclosporine significantly increased nitric oxide production, cyclooxygenase-2 and miR-210 gene expression compared to all other studied groups.	Cyclosporine	41-53	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	103-119
26276312-12	2015	Concomitant use of alpha-lipoic acid and cyclosporine significantly increased nitric oxide production, cyclooxygenase-2 and miR-210 gene expression compared to all other studied groups.	Cyclosporine	41-53	microRNA 210	Rattus norvegicus	124-131
26276312-13	2015	The current findings suggest that facilitation of nitric oxide/cyclooxygenase-2/miR-210 cascade constitutes, at least partially, the cellular mechanism by which concurrent use of alpha-lipoic acid and cyclosporine aggravates colon damage.	Cyclosporine	201-213	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	63-79
26276312-13	2015	The current findings suggest that facilitation of nitric oxide/cyclooxygenase-2/miR-210 cascade constitutes, at least partially, the cellular mechanism by which concurrent use of alpha-lipoic acid and cyclosporine aggravates colon damage.	Cyclosporine	201-213	microRNA 210	Rattus norvegicus	80-87
26283324-10	2015	However, Cyclosporine A, a CREB inhibitor, reduced the expression of p-CREB, Egr-3, VCAM-1, Ang1 and Tie2.	Cyclosporine	9-23	early growth response 3	Rattus norvegicus	77-82
22957944-7	2012	Stepwise multiple logistic regression analysis identified four independent predictive factors of response to intravenous ciclosporin: age at hospitalisation (AGE), platelet count (x10(4) /muL) on the first day (PLA), Lichtiger score on the third day (LIC) and total protein (g/dL) on the third day minus total protein on the first day (DeltaTP).	Cyclosporine	121-132	tripartite motif containing 37	Homo sapiens	188-191
26283324-10	2015	However, Cyclosporine A, a CREB inhibitor, reduced the expression of p-CREB, Egr-3, VCAM-1, Ang1 and Tie2.	Cyclosporine	9-23	vascular cell adhesion molecule 1	Rattus norvegicus	84-90
25820785-5	2015	Then the levels of CypD and protein that forms the MPTP were evaluated under the conditions with or without the treatment of Cyclosporin A (CsA), which has been found to disrupt MPTP through the binding of CypD.	Cyclosporine	125-138	peptidylprolyl isomerase F	Rattus norvegicus	19-23
22870958-8	2012	Significantly higher expressions of fatty acid synthase and acetyl-CoA carboxylase 1 and 2 genes were observed in CsA-treated rats.	Cyclosporine	114-117	fatty acid synthase	Rattus norvegicus	36-55
22851699-8	2012	Importantly, activation of the RCAN1 promoter by ionomycin, in control and FHL2 knockdown cells, was abolished by the calcineurin inhibitor cyclosporine, confirming the calcineurin dependence of the response.	Cyclosporine	140-152	regulator of calcineurin 1	Mus musculus	31-36
22327003-4	2012	Among the currently available immunosuppressive agents, cyclosporine, tacrolimus and mycophenolic acid are in vitro substrates of the UGT1A and 2B families of glucuronidation enzymes.	Cyclosporine	56-68	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	134-146
22670785-6	2012	Expression of the peripheral homing receptors CXCR3 (r = 0.44, P &lt; 0.05) and CCR5 (r = 0.45, P &lt; 0.05) on FOXP3+ Tregs correlated with renal allograft function (eGFR) in patients receiving tacrolimus (n = 28), but not cyclosporine A (CsA) (n = 26).	Cyclosporine	224-238	C-X-C motif chemokine receptor 3	Homo sapiens	46-51
22670785-6	2012	Expression of the peripheral homing receptors CXCR3 (r = 0.44, P &lt; 0.05) and CCR5 (r = 0.45, P &lt; 0.05) on FOXP3+ Tregs correlated with renal allograft function (eGFR) in patients receiving tacrolimus (n = 28), but not cyclosporine A (CsA) (n = 26).	Cyclosporine	224-238	forkhead box P3	Homo sapiens	112-117
25820785-5	2015	Then the levels of CypD and protein that forms the MPTP were evaluated under the conditions with or without the treatment of Cyclosporin A (CsA), which has been found to disrupt MPTP through the binding of CypD.	Cyclosporine	125-138	peptidylprolyl isomerase F	Rattus norvegicus	206-210
25820785-5	2015	Then the levels of CypD and protein that forms the MPTP were evaluated under the conditions with or without the treatment of Cyclosporin A (CsA), which has been found to disrupt MPTP through the binding of CypD.	Cyclosporine	140-143	peptidylprolyl isomerase F	Rattus norvegicus	19-23
25820785-5	2015	Then the levels of CypD and protein that forms the MPTP were evaluated under the conditions with or without the treatment of Cyclosporin A (CsA), which has been found to disrupt MPTP through the binding of CypD.	Cyclosporine	140-143	peptidylprolyl isomerase F	Rattus norvegicus	206-210
25820785-8	2015	Interestingly, treatment with CsA significantly improved neurological function and reversed the ischemia-induced increase of CypD and MPTP proteins in ischemia group.	Cyclosporine	30-33	peptidylprolyl isomerase F	Rattus norvegicus	125-129
26375467-12	2015	Treatment of Abcc6 -/- mice with CsA reduced cardiac necrosis and calcification by more than half.	Cyclosporine	33-36	ATP-binding cassette, sub-family C (CFTR/MRP), member 6	Mus musculus	13-18
26057330-1	2015	PURPOSE: To investigate the regulation of matrix metalloproteinase (MMP)-3 and MMP-13 expression over time and in the presence of cyclosporine A (CsA) in primary cultured human pterygium fibroblasts.	Cyclosporine	130-144	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	146-149
25835315-1	2015	OBJECTIVES: We retrospectively examined how the cyclosporine-A (CSA) microemulsion administration mode affected blood CSA levels, as well as how the dose and blood levels of CSA affected its therapeutic effect against systemic lupus erythematosus (SLE).	Cyclosporine	48-62	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	64-67
26144210-2	2015	BraA, this analogue (BraL), and cyclosporine A were tested for their ability to inhibit the proliferation of human T cells upon CD3/CD28 activation.	Cyclosporine	32-46	CD28 molecule	Homo sapiens	132-136
22321150-9	2012	The mRNA expression of MT1-MMP was significantly enhanced after LPS treatment; however, this enhancement was inhibited by CsA.	Cyclosporine	122-125	matrix metallopeptidase 14	Homo sapiens	23-30
26178542-12	2015	We conclude that the majority of children with nephrotic IgAN responded to oral cyclosporine-A.	Cyclosporine	80-94	IGAN1	Homo sapiens	57-61
22678567-0	2012	Cyclosporin A induces apoptosis in H9c2 cardiomyoblast cells through calcium-sensing receptor-mediated activation of the ERK MAPK and p38 MAPK pathways.	Cyclosporine	0-13	mitogen activated protein kinase 3	Rattus norvegicus	125-129
22678567-0	2012	Cyclosporin A induces apoptosis in H9c2 cardiomyoblast cells through calcium-sensing receptor-mediated activation of the ERK MAPK and p38 MAPK pathways.	Cyclosporine	0-13	mitogen activated protein kinase 14	Rattus norvegicus	134-137
22678567-0	2012	Cyclosporin A induces apoptosis in H9c2 cardiomyoblast cells through calcium-sensing receptor-mediated activation of the ERK MAPK and p38 MAPK pathways.	Cyclosporine	0-13	mitogen activated protein kinase 3	Rattus norvegicus	138-142
22678567-5	2012	H9c2 cells were treated with CsA in a dose-dependent manner, and decreased Bcl-2 expression, increased Bax expression, and caspase-3 activation were observed.	Cyclosporine	29-32	caspase 3	Rattus norvegicus	123-132
22678567-6	2012	In a time-dependent manner, CsA increased CaSR expression, activated the extracellularly regulated kinase (ERK) and p38 MAPK pathways, and inactivated the c-Jun N-terminal kinase (JNK) MAPK signaling pathway.	Cyclosporine	28-31	mitogen activated protein kinase 14	Rattus norvegicus	116-119
22678567-6	2012	In a time-dependent manner, CsA increased CaSR expression, activated the extracellularly regulated kinase (ERK) and p38 MAPK pathways, and inactivated the c-Jun N-terminal kinase (JNK) MAPK signaling pathway.	Cyclosporine	28-31	mitogen activated protein kinase 3	Rattus norvegicus	120-124
22678567-6	2012	In a time-dependent manner, CsA increased CaSR expression, activated the extracellularly regulated kinase (ERK) and p38 MAPK pathways, and inactivated the c-Jun N-terminal kinase (JNK) MAPK signaling pathway.	Cyclosporine	28-31	mitogen activated protein kinase 3	Rattus norvegicus	185-189
22678567-7	2012	When H9c2 cardiomyoblast cells pretreated with gadolinium chloride (GdCl(3)), a CaSR activator, were treated with CsA, decreased phosphorylation of ERK1/2, increased phosphorylation of p38, decreased Bcl-2 expression, increased Bax expression, and activated caspase-3 were observed.	Cyclosporine	114-117	mitogen activated protein kinase 3	Rattus norvegicus	148-154
25796200-5	2015	We found that combined treatment with Glu (300 mg/kg) and low-dose (10 or 20mg/kg) CsA strongly ameliorated the development of psoriasis-like skin lesions and reduced the levels of Th1 cytokine (TNF-alpha) and Th17 cytokines (IL-17, IL-22, and IL-23) in the serum and dorsal skin.	Cyclosporine	83-86	interleukin 23, alpha subunit p19	Mus musculus	244-249
25312097-6	2015	RESULTS: Serum TARC level after oral cyclosporine therapy (1013 +- 883 pg/ml) was significantly decreased compared to before therapy (38 194 +- 4678 pg/ml; P &lt; 0.02).	Cyclosporine	37-49	C-C motif chemokine ligand 17	Homo sapiens	15-19
22678567-9	2012	Furthermore, the MEK1/2 inhibitor U0126 and the p38 MAPK inhibitor SB203580 markedly blocked the effect of CsA on cell apoptosis, apoptotic-related protein expression, and caspase-3 activation.	Cyclosporine	107-110	mitogen activated protein kinase kinase 1	Rattus norvegicus	17-23
22678567-9	2012	Furthermore, the MEK1/2 inhibitor U0126 and the p38 MAPK inhibitor SB203580 markedly blocked the effect of CsA on cell apoptosis, apoptotic-related protein expression, and caspase-3 activation.	Cyclosporine	107-110	mitogen activated protein kinase 14	Rattus norvegicus	48-51
25749876-9	2015	Reducing Ror2 expression in the BMSC cell line by siRNA or blocking the downstream signalings with specific inhibitors also demonstrated a suppression of the capacity of the BMSC cell line to promote Wnt5a-dependent migration (including SP600125 and cyclosporine A) and differentiation (cyclosporine A only) of osteoclast precursors.	Cyclosporine	250-264	receptor tyrosine kinase-like orphan receptor 2	Rattus norvegicus	9-13
22678567-9	2012	Furthermore, the MEK1/2 inhibitor U0126 and the p38 MAPK inhibitor SB203580 markedly blocked the effect of CsA on cell apoptosis, apoptotic-related protein expression, and caspase-3 activation.	Cyclosporine	107-110	caspase 3	Rattus norvegicus	172-181
22678567-10	2012	These findings showed that CsA induced apoptosis in H9c2 cells in vitro, and CaSR mediated the degradation of ERK MAPK and the upregulation of the p38 MAPK pathway involved in CsA-induced H9c2 cardiomyoblast cell apoptosis.	Cyclosporine	176-179	mitogen activated protein kinase 14	Rattus norvegicus	147-150
25749876-9	2015	Reducing Ror2 expression in the BMSC cell line by siRNA or blocking the downstream signalings with specific inhibitors also demonstrated a suppression of the capacity of the BMSC cell line to promote Wnt5a-dependent migration (including SP600125 and cyclosporine A) and differentiation (cyclosporine A only) of osteoclast precursors.	Cyclosporine	287-301	receptor tyrosine kinase-like orphan receptor 2	Rattus norvegicus	9-13
22294776-12	2012	Compared to sham treatment, one dose (1 and 5 mg/kg body weight) of CsA significantly reduced kidney tubular cell apoptosis, serum creatinine, blood urea, serum IL-6 and urinary NGAL 2 days after FA injection.	Cyclosporine	68-71	lipocalin 2	Mus musculus	178-182
25839649-6	2015	Furthermore, phamacological inhibition of CaN by CsA markedly attenuated isoflurane induced aberrant CaN/NFATc4 signaling in the hippocampus, and rescued relevant spatial learning and memory impairment of aged rats.	Cyclosporine	49-52	nuclear factor of activated T-cells 4	Rattus norvegicus	105-111
22626517-8	2012	Mice treated with ciclosporin, which is both antiparasitic and immunosuppressive, have a milder, chronic, non-lethal infection and showed a significant reduction only in CD3(+) and CD4(+) T cell numbers.	Cyclosporine	18-29	CD3 antigen, epsilon polypeptide	Mus musculus	170-173
25759460-3	2015	We examined whether CSA is associated with the ALDH2*2 genotype in Japanese.	Cyclosporine	20-23	aldehyde dehydrogenase 2 family member	Homo sapiens	47-52
23060930-1	2012	Calcineurin inhibitors (CNIs) such as cyclosporin A (CSA) and tacrolimus (FK506) are efficacious in patients with steroid-refractory or steroid-dependent ulcerative colitis (UC).	Cyclosporine	38-51	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	53-56
22167589-12	2012	The odds ratio (OR) for IgAN recurrence in patients using cyclosporine was 0.3 (confidence interval 0.1-0.9).	Cyclosporine	58-70	IGAN1	Homo sapiens	24-28
25759460-10	2015	CONCLUSIONS: East Asian variant ALDH2*2 genotypes and, hence, deficient ALDH2 activity were associated with CSA in Japanese.	Cyclosporine	108-111	aldehyde dehydrogenase 2 family member	Homo sapiens	32-37
25759460-10	2015	CONCLUSIONS: East Asian variant ALDH2*2 genotypes and, hence, deficient ALDH2 activity were associated with CSA in Japanese.	Cyclosporine	108-111	aldehyde dehydrogenase 2 family member	Homo sapiens	72-77
25022552-8	2015	Akt and GSK-3beta was strongly phosphorylated after treatment with Ciclosporin A and PQS compared with the model group (P&lt;0.05, P&lt;0.01).	Cyclosporine	67-80	glycogen synthase kinase 3 beta	Rattus norvegicus	8-17
22465323-8	2012	Moreover, addition of cyclosporine A to the conduits with transplanted MSC significantly reduced the ED1 macrophage reaction.	Cyclosporine	22-36	ectodysplasin A	Homo sapiens	101-104
25343528-12	2015	Treatment of VKH patients with corticosteroids and CsA is associated with an increased expression of IL-37, which suggests that corticosteroids and CsA may partly exert their immunosuppressive effect by upregulating IL-37 production.	Cyclosporine	51-54	interleukin 37	Homo sapiens	101-106
22326661-6	2012	The concomitant rise in hepatic mRNA levels of two Il-6 responsive genes, suppressor of cytokine signaling (SOCS) 3 and Il-6 receptor alpha, was blunted in CsA-treated group.	Cyclosporine	156-159	suppressor of cytokine signaling 3	Rattus norvegicus	74-115
22446101-5	2012	Furthermore, cyclosporin A, a calcineurin-specific inhibitor, reduced the ability of GnRH to regulate accumulation of Jun and Atf3 mRNA and to a lesser extent Fos.	Cyclosporine	13-26	activating transcription factor 3	Mus musculus	126-130
25343528-12	2015	Treatment of VKH patients with corticosteroids and CsA is associated with an increased expression of IL-37, which suggests that corticosteroids and CsA may partly exert their immunosuppressive effect by upregulating IL-37 production.	Cyclosporine	51-54	interleukin 37	Homo sapiens	216-221
22466612-2	2012	Cockayne syndrome is a related disorder with defective TCR and consists of two complementation groups, Cockayne syndrome (CS)-A and CS-B, which are caused by mutations in ERCC8 (CSA) and ERCC6 (CSB), respectively.	Cyclosporine	178-181	citrate synthase	Homo sapiens	122-124
25343528-12	2015	Treatment of VKH patients with corticosteroids and CsA is associated with an increased expression of IL-37, which suggests that corticosteroids and CsA may partly exert their immunosuppressive effect by upregulating IL-37 production.	Cyclosporine	148-151	interleukin 37	Homo sapiens	101-106
22466612-2	2012	Cockayne syndrome is a related disorder with defective TCR and consists of two complementation groups, Cockayne syndrome (CS)-A and CS-B, which are caused by mutations in ERCC8 (CSA) and ERCC6 (CSB), respectively.	Cyclosporine	178-181	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	171-176
25343528-12	2015	Treatment of VKH patients with corticosteroids and CsA is associated with an increased expression of IL-37, which suggests that corticosteroids and CsA may partly exert their immunosuppressive effect by upregulating IL-37 production.	Cyclosporine	148-151	interleukin 37	Homo sapiens	216-221
25656942-5	2015	CSA hypertension was associated with renal perivascular fibrosis and divergent changes in immunohistochemical signals of renal arteriolar ETA (increases) and ETB (decreases) receptors.	Cyclosporine	0-3	endothelin receptor type A	Rattus norvegicus	138-141
22546085-2	2012	Cyclosporin A (CsA), an immunosuppressive agent that targets the nuclear factor pathway of activated T-cells (NF-AT) to bind cellular cyclophilins (CyP), dose-dependently inhibited FIPV replication in vitro.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
25656942-5	2015	CSA hypertension was associated with renal perivascular fibrosis and divergent changes in immunohistochemical signals of renal arteriolar ETA (increases) and ETB (decreases) receptors.	Cyclosporine	0-3	endothelin receptor type B	Rattus norvegicus	158-161
22696872-7	2012	RESULTS: The present study showed that cyclosporine induced the nephrotoxicity as appeared by elevation of serum and urinary levels of creatinine, urinary level of beta2 microglobulin, serum levels of ammonia, TGF-beta1 and TNF-alpha and the NAG level while decreased the creatinine clearance.	Cyclosporine	39-51	O-GlcNAcase	Rattus norvegicus	242-245
25656942-6	2015	While these effects of CSA were preserved in rats treated concomitantly with indomethacin (5 mg kg(-1) day(-1)), celecoxib (10 mg kg(-1) day(-1)) abolished the pressor, tachycardic, and fibrotic effects of CSA and normalized the altered renal ETA/ETB receptor expressions.	Cyclosporine	23-26	endothelin receptor type A	Rattus norvegicus	243-246
25656942-6	2015	While these effects of CSA were preserved in rats treated concomitantly with indomethacin (5 mg kg(-1) day(-1)), celecoxib (10 mg kg(-1) day(-1)) abolished the pressor, tachycardic, and fibrotic effects of CSA and normalized the altered renal ETA/ETB receptor expressions.	Cyclosporine	23-26	endothelin receptor type B	Rattus norvegicus	247-250
25656942-7	2015	Selective blockade of ETA receptors by atrasentan (5 mg kg(-1) day(-1)) abolished the pressor response elicited by CSA or CSA plus indomethacin.	Cyclosporine	115-118	endothelin receptor type A	Rattus norvegicus	22-25
25656942-7	2015	Selective blockade of ETA receptors by atrasentan (5 mg kg(-1) day(-1)) abolished the pressor response elicited by CSA or CSA plus indomethacin.	Cyclosporine	122-125	endothelin receptor type A	Rattus norvegicus	22-25
22184139-11	2012	Cyclosporin A, a competitive substrate for ABCB1, restored maturation, plasma membrane expression, and activity of ABCB1-I541F.	Cyclosporine	0-13	ATP binding cassette subfamily B member 1	Canis lupus familiaris	43-48
25793558-2	2015	The aim of this study is to determine whether ischemic or pharmacological postconditioning with cyclosporine A (CsA) might protect the kidney from lethal reperfusion injury.	Cyclosporine	96-110	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	112-115
22184139-11	2012	Cyclosporin A, a competitive substrate for ABCB1, restored maturation, plasma membrane expression, and activity of ABCB1-I541F.	Cyclosporine	0-13	ATP binding cassette subfamily B member 1	Canis lupus familiaris	115-120
25775018-1	2015	Cyclosporin A (CSA) suppresses immune function by blocking the cyclophilin A and calcineurin/NFAT signaling pathways.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
22226864-11	2012	Id1-DBL2X antisera recognized the surface of field isolates from pregnant women, and inhibited CSA-binding of all 8 isolates tested, although to a variable level.	Cyclosporine	95-98	inhibitor of DNA binding 1, HLH protein	Homo sapiens	0-3
25629977-3	2015	CsA induced cardiomyocyte-specific differentiation of P19 cells, with the highest efficiency at a concentration of 0.32 muM during embryoid body (EB) formation via activation of the Wnt signaling pathway molecules, Wnt3a, Wnt5a, and Wnt8a, and the cardiac mesoderm markers, Mixl1, Mesp1, and Mesp2.	Cyclosporine	0-3	wingless-type MMTV integration site family, member 8A	Mus musculus	233-238
22035570-0	2012	A mitochondrial-targeted cyclosporin A with high binding affinity for cyclophilin D yields improved cytoprotection of cardiomyocytes.	Cyclosporine	25-38	peptidylprolyl isomerase F	Rattus norvegicus	70-83
26305401-1	2015	Cyclosporine A (CsA) is widely used as an immunosuppressor in transplantation.	Cyclosporine	0-14	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	16-19
21438096-1	2012	BACKGROUND: Cyclosporine (CsA) or infliximab (IFX) are used as rescue therapies in steroid-refractory, severe attacks of ulcerative colitis (UC).	Cyclosporine	12-24	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	26-29
26448755-4	2015	We found that CD44 cross-linking promoted Foxp3 expression and Treg viability in the setting of CSA treatment.	Cyclosporine	96-99	forkhead box P3	Homo sapiens	42-47
25061717-9	2015	IFN-beta mRNA expression was significantly increased in rotavirus-induced diarrhea mice treated with 5 mg   kg-1   day-1 of CsA, whereas the mRNA expression levels of inflammation-related cytokines (IL-8, IL-10, IFN-gamma, and tumor necrosis factor-alpha) and inflammatory signaling pathways (p38, c-Jun N-terminal kinase, activator protein-1, and nuclear factor-kappa B) were markedly decreased.	Cyclosporine	124-127	mitogen-activated protein kinase 14	Mus musculus	293-296
21480930-7	2012	The treatment with cyclosporine increased the effects of the TKIs on VIMC1 since ABCB1 was expressed in VIMC1.	Cyclosporine	19-31	ATP binding cassette subfamily B member 1	Canis lupus familiaris	81-86
26858893-1	2015	The steroid receptor (SR) complex contains FKBP51 and FKBP52, which bind to tacrolimus (TAC) and cyclophilin 40, which, in turn, bind to cyclosporine (CYA); these influence the intranuclear mobility of steroid-SR complexes.	Cyclosporine	137-149	peptidylprolyl isomerase D	Homo sapiens	97-111
22100870-0	2012	Cyclosporin A and tacrolimus induce renal Erk1/2 pathway via ROS-induced and metalloproteinase-dependent EGF-receptor signaling.	Cyclosporine	0-13	mitogen activated protein kinase 3	Rattus norvegicus	42-48
22100870-8	2012	Our data suggest that CsA and FK506, via ROS-dependent and ADAM17-catalyzed HB-EGF shedding induce the mitogenic ERK1/2 signaling cascade in renal MC.	Cyclosporine	22-25	mitogen activated protein kinase 3	Rattus norvegicus	113-119
26858893-1	2015	The steroid receptor (SR) complex contains FKBP51 and FKBP52, which bind to tacrolimus (TAC) and cyclophilin 40, which, in turn, bind to cyclosporine (CYA); these influence the intranuclear mobility of steroid-SR complexes.	Cyclosporine	151-154	peptidylprolyl isomerase D	Homo sapiens	97-111
24664868-10	2014	Among RA, greater Sharp/van der Heijde scores were associated with lower muscle CSA and muscle density.	Cyclosporine	80-83	spen family transcriptional repressor	Homo sapiens	18-23
24980806-8	2014	The net efflux ratio of GA (C15:1) and GA (C17:1) in both cell models was greater than 2 and markedly reduced by the presence of Cyclosporin A (CsA) or GF120918, inhibitors of P-gp and BCRP, suggesting that GAs are P-gp and BCRP substrates.	Cyclosporine	144-147	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	185-189
24980806-8	2014	The net efflux ratio of GA (C15:1) and GA (C17:1) in both cell models was greater than 2 and markedly reduced by the presence of Cyclosporin A (CsA) or GF120918, inhibitors of P-gp and BCRP, suggesting that GAs are P-gp and BCRP substrates.	Cyclosporine	144-147	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	224-228
24980806-9	2014	The results from a rat bioavailability study also showed that co-administrating CsA intravenously (20mg/kg) could significantly increase GA (C15:1) and GA (C17:1) AUC0-t by 1.46-fold and 1.53-fold and brain concentration levels of 1.43-fold and 1.51-fold, respectively, due to the inhibition of P-gp and BCRP efflux transporters by CsA.	Cyclosporine	80-83	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	304-308
25380887-8	2014	YKL-40, in univariate analysis, was related to NGAL, protein Z, plasmin-antiplasmin complex, mean corpuscular volume, cyclosporine level, and hs-CRP.	Cyclosporine	118-130	chitinase 3 like 1	Homo sapiens	0-6
25380887-10	2014	YKL-40 was predicted by cyclosporine level, NGAL, and hs-CRP, explaining 37% of the variation.	Cyclosporine	24-36	chitinase 3 like 1	Homo sapiens	0-6
25309428-4	2014	Treatment with cyclosporin A (CsA) is effective in normalizing the mitochondrial, apoptotic, and autophagic defects of myofibers in Col6a1 (-/-) mice.	Cyclosporine	15-28	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	30-33
24344232-1	2014	AIMS: Topical ciclosporin A (CsA) is a therapeutic option for dry eye disease (DED) to control ocular surface inflammation and improve tear function.	Cyclosporine	29-32	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-27
25002376-1	2014	The aim of the present study was to evaluate the efficacy of cyclosporine A (CsA) combined with medium/low dose prednisone in the treatment of progressive immunoglobulin A nephropathy (IgAN).	Cyclosporine	77-80	IGAN1	Homo sapiens	185-189
25002376-9	2014	Moreover, at the end of the course, a higher remission rate was observed in patients with Lee"s Grade III IgAN after combined treatment with prednisone and CsA (p &lt; 0.05).	Cyclosporine	156-159	IGAN1	Homo sapiens	106-110
25002376-11	2014	CsA at a dose of 2-3 mg/kg/day in combination with medium/low dose prednisone was effective in inducing remission of IgAN, especially for patients with Lee"s Grade III IgAN, and is a safe and effective choice for short-term treatment of patients with progressive IgAN.	Cyclosporine	0-3	IGAN1	Homo sapiens	117-121
23018139-10	2012	CsA decreased RBF, but increased RVR, tubulointerstitial fibrosis, and alpha-SMA and renal vimentin expression.	Cyclosporine	0-3	vimentin	Rattus norvegicus	91-99
22509094-9	2012	Transforming growth factor-beta1 (TGF-beta1) mRNA transcription in corneal grafts after topical 0.5% FTY720 increased (p&lt;0.05, n=3), while interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) mRNA expression in corneal grafts treated with 1% CsA decreased (p&lt;0.01, p&lt;0.05, respectively).	Cyclosporine	246-249	transforming growth factor, beta 1	Mus musculus	0-32
22509094-9	2012	Transforming growth factor-beta1 (TGF-beta1) mRNA transcription in corneal grafts after topical 0.5% FTY720 increased (p&lt;0.05, n=3), while interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) mRNA expression in corneal grafts treated with 1% CsA decreased (p&lt;0.01, p&lt;0.05, respectively).	Cyclosporine	246-249	transforming growth factor, beta 1	Mus musculus	34-43
22662209-11	2012	Cyclosporin A also inhibited the transcriptional activity driven by the Cox-2 promoter.	Cyclosporine	0-13	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	72-77
22558153-11	2012	TNF-alpha expression in circulating blood revealed significant suppression in the MSC and MSC-CsA treatment groups, as compared to that in controls.	Cyclosporine	94-97	tumor necrosis factor	Sus scrofa	0-9
22558153-12	2012	IHC staining showed CD45 and IL-6 expression were significantly decreased in MSC-CsA treatment groups compared to controls.	Cyclosporine	81-84	interleukin 6	Sus scrofa	29-33
22558153-14	2012	IHC staining of alloskin tissue biopsies revealed a significant increase in the numbers of foxp3(+)T-cells and TGF-beta1 positive cells in the MSC-CsA group compared to the other groups.	Cyclosporine	147-150	transforming growth factor beta 1	Sus scrofa	111-120
21996945-3	2011	This retrospective study analyzes the effectiveness of combined systemic acyclovir and immunosuppressive therapy with cyclosporine A (CSA) or mycophenolate mofetil (MMF) after high-risk keratoplasty in herpetic keratitis.	Cyclosporine	118-132	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	134-137
18622021-6	2008	Osteopontin and betaig-h3 levels increased significantly in CsA-treated rat kidneys, but CL treatment decreased both markers.	Cyclosporine	60-63	secreted phosphoprotein 1	Rattus norvegicus	0-11
18471799-1	2008	Cyclosporin A (CsA), an immunosuppressive drug, has overgrowth effects on human gingival fibroblasts (HGF) in vitro.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
18471799-1	2008	Cyclosporin A (CsA), an immunosuppressive drug, has overgrowth effects on human gingival fibroblasts (HGF) in vitro.	Cyclosporine	0-13	hepatocyte growth factor	Homo sapiens	102-105
18568343-10	2008	Mycophenolic acid dose-corrected trough concentrations were 70% lower in carriers of the UGT1A9 -275T&gt;A/-2152 C&gt;T polymorphism who received cyclosporine (p &lt; 0.01).	Cyclosporine	146-158	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	89-95
18656538-3	2008	Since clinical studies are elaborate, we sought a way to predict the kinetic behaviour of a propylene glycol solution of CsA (CsA-PG) and a liposomal formulation (L-CsA).	Cyclosporine	121-124	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	126-132
18765728-9	2008	The results of this study show that LKT trafficking and LKT-mediated cell death involve dynamin-2 and cyclophilin D, in a process that can be prevented by the mitochondrial membrane-protecting function of CSA.	Cyclosporine	205-208	dynamin 2	Bos taurus	88-97
18506790-8	2008	However, both the antioxidant N-acetyl cysteine (NAC) and the mitochondrial membrane-stabilizing agent cyclosporine A (CsA) partially preserve psi, suppress activation of p38 kinase, and partially protect the cells from Cd(2+)-induced death.	Cyclosporine	103-117	mitogen-activated protein kinase 14	Mus musculus	171-174
18506790-8	2008	However, both the antioxidant N-acetyl cysteine (NAC) and the mitochondrial membrane-stabilizing agent cyclosporine A (CsA) partially preserve psi, suppress activation of p38 kinase, and partially protect the cells from Cd(2+)-induced death.	Cyclosporine	119-122	mitogen-activated protein kinase 14	Mus musculus	171-174
25002376-11	2014	CsA at a dose of 2-3 mg/kg/day in combination with medium/low dose prednisone was effective in inducing remission of IgAN, especially for patients with Lee"s Grade III IgAN, and is a safe and effective choice for short-term treatment of patients with progressive IgAN.	Cyclosporine	0-3	IGAN1	Homo sapiens	168-172
25002376-11	2014	CsA at a dose of 2-3 mg/kg/day in combination with medium/low dose prednisone was effective in inducing remission of IgAN, especially for patients with Lee"s Grade III IgAN, and is a safe and effective choice for short-term treatment of patients with progressive IgAN.	Cyclosporine	0-3	IGAN1	Homo sapiens	168-172
25132585-8	2014	Cyclosporine treatment decreased the expression levels of IGFBP2 and ID1, but increased PPARG expression.	Cyclosporine	0-12	insulin like growth factor binding protein 2	Homo sapiens	58-64
25132585-8	2014	Cyclosporine treatment decreased the expression levels of IGFBP2 and ID1, but increased PPARG expression.	Cyclosporine	0-12	inhibitor of DNA binding 1, HLH protein	Homo sapiens	69-72
24968150-9	2014	However, treatment of KO cells with cyclosporine A causes further delay in folding, indicating the potential existence of another collagen PPIase.	Cyclosporine	36-50	peptidylprolyl isomerase (cyclophilin)-like 3	Mus musculus	139-145
24497284-5	2014	RESULTS: Mass spectra of CsA obtained upon post-column addition of solutions of Ca(II), Cu(II) and Zn(II) showed complexes between cyclosporin and the metal, including [2CsA + Me](2+) and [CsA-H + Me](+).	Cyclosporine	131-142	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	25-28
24632797-5	2014	RESULTS: The levels of vascular endothelial growth factor, nitric oxide synthase 1 and 3, and Ki-67 were found to be significantly different among groups (P&gt;0.001), with patients treated with cyclosporin A showing higher levels of all the analyzed markers compared to control group.	Cyclosporine	195-208	nitric oxide synthase 1	Homo sapiens	59-88
24304835-4	2014	Regardless of AMPK genotype, RyR(R615C) increased fiber CSA by 35%.	Cyclosporine	56-59	ryanodine receptor 1	Sus scrofa	29-32
24304835-9	2014	Thus pigs that possess both AMPKgamma3(R200Q) and RyR(R615C) exhibit increased muscle fiber CSA as well as greater oxidative capacity.	Cyclosporine	92-95	ryanodine receptor 1	Sus scrofa	50-53
24505415-0	2014	The antibody response of pregnant Cameroonian women to VAR2CSA ID1-ID2a, a small recombinant protein containing the CSA-binding site.	Cyclosporine	59-62	inhibitor of DNA binding 1, HLH protein	Homo sapiens	63-66
24505415-12	2014	Currently, ID1-ID2a is a leading vaccine candidate, since it binds to the CSA with the same affinity as the full-length molecule and elicits binding-inhibitory antibodies in animals.	Cyclosporine	74-77	inhibitor of DNA binding 1, HLH protein	Homo sapiens	11-14
24117217-7	2014	Pro-hypertrophic calcineurin/NFAT (nuclear factor of activated T-cells) signalling was elevated markedly in the presence of miR-19b, and the calcineurin inhibitor CsA (cyclosporin A) and the PKC (protein kinase C) inhibitor GF10923X significantly attenuated the miR-19b-mediated increase in cell size and expression of hypertrophic markers.	Cyclosporine	168-181	nuclear factor of activated T-cells 5	Rattus norvegicus	29-33
24694475-11	2014	CONCLUSION: Both the full dose of steroids alone and combined treatment with steroids and a medium dose of CsA remarkably reduced the levels of proteinuria and ameliorated the renal function in the IgAN patients.	Cyclosporine	107-110	IGAN1	Homo sapiens	198-202
24330821-8	2013	The mitochondrial impairment observed in mutant cells and cortical neurons expressing Q104-GFP was prevented by pre-treatment with cyclosporine A (CsA) but not by FK506 (an inhibitor of calcineurin), indicating a potential role for mPTP opening in the mitochondrial dysfunction induced by calcium stress in mutant huntingtin cells.	Cyclosporine	131-145	huntingtin	Homo sapiens	314-324
24330821-8	2013	The mitochondrial impairment observed in mutant cells and cortical neurons expressing Q104-GFP was prevented by pre-treatment with cyclosporine A (CsA) but not by FK506 (an inhibitor of calcineurin), indicating a potential role for mPTP opening in the mitochondrial dysfunction induced by calcium stress in mutant huntingtin cells.	Cyclosporine	147-150	huntingtin	Homo sapiens	314-324
24166946-6	2013	Calcineurin inhibitor cyclosporin A attenuated NS5-mediated inhibition of IFNbeta-induced responses, for example, IFN-sensitive response element driven luciferase, STAT1-dependent PKR mRNA expression, as well as phosphorylation and nuclear translocation of STAT1.	Cyclosporine	22-35	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	47-50
24244623-0	2013	Exposure to nerve growth factor worsens nephrotoxic effect induced by Cyclosporine A in HK-2 cells.	Cyclosporine	70-84	hexokinase 2	Homo sapiens	88-92
24244623-6	2013	Our results showed that in HK-2 cells combined treatment with Cyclosporine A + nerve growth factor induced a significant reduction in cell vitality concomitant with a down-regulation of Cyclin D1 and up-regulation of p21 levels respect to cells treated with Cyclosporine A alone.	Cyclosporine	62-76	hexokinase 2	Homo sapiens	27-31
24244623-6	2013	Our results showed that in HK-2 cells combined treatment with Cyclosporine A + nerve growth factor induced a significant reduction in cell vitality concomitant with a down-regulation of Cyclin D1 and up-regulation of p21 levels respect to cells treated with Cyclosporine A alone.	Cyclosporine	62-76	cyclin D1	Homo sapiens	186-195
24244623-6	2013	Our results showed that in HK-2 cells combined treatment with Cyclosporine A + nerve growth factor induced a significant reduction in cell vitality concomitant with a down-regulation of Cyclin D1 and up-regulation of p21 levels respect to cells treated with Cyclosporine A alone.	Cyclosporine	258-272	hexokinase 2	Homo sapiens	27-31
24244623-8	2013	In addition we observed that the combined exposure to Cyclosporine A + nerve growth factor promoted an up-regulation of p75 (NTR) and its target genes, p53 and BAD leading to the activation of intrinsic apoptosis.	Cyclosporine	54-68	PC4 and SFRS1 interacting protein 1	Homo sapiens	120-123
24244623-8	2013	In addition we observed that the combined exposure to Cyclosporine A + nerve growth factor promoted an up-regulation of p75 (NTR) and its target genes, p53 and BAD leading to the activation of intrinsic apoptosis.	Cyclosporine	54-68	neurotensin receptor 1	Homo sapiens	125-128
23981724-1	2013	Clinical immunosuppression protocols use calcineurin inhibitors, such as cyclosporine A (CsA) or tacrolimus (FK506), or mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus (rapamycin).	Cyclosporine	73-87	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	89-92
24157049-6	2013	RESULTS: CsA treatment caused diabetes, renal dysfunction, tubulointerstitial inflammation (ED-1-positive cells), and fibrosis, which were accompanied by an increase in 8-OHdG production and upregulation of TGF-beta1, caspase-3, and LC3-II.	Cyclosporine	9-12	caspase 3	Rattus norvegicus	218-227
23791640-4	2013	In another experiment, rhodamine 123 was used to quantify the biliary canalicular transporter P-glycoprotein (P-gp, Abcb1a/b) with cyclosporin A as an inhibitor of P-gp activity.	Cyclosporine	131-144	ATP binding cassette subfamily B member 1A	Rattus norvegicus	116-122
18946018-4	2008	Azithromycin elevated the reduced metalloproteinase (MMP)-1 and MMP-2 activities in cyclosporine A-treated renal transplant fibroblasts and normal fibroblasts.	Cyclosporine	84-98	matrix metallopeptidase 2	Homo sapiens	64-69
18946018-5	2008	In cyclosporine A-treated renal transplant fibroblasts, azithromycin blocked the accumulation of total collagen in culture media and the increase in type I collagen mRNA level, but recovered the reduced MMP-2 mRNA level to the control.	Cyclosporine	3-17	matrix metallopeptidase 2	Homo sapiens	203-208
18946018-6	2008	These results suggest that azithromycin may improve CIGO by blocking cyclosporine A-induced cell proliferation and collagen synthesis, and by activating MMP-2 in gingival fibroblasts of persons with cyclosporine A-induced gingival overgrowth.	Cyclosporine	199-213	matrix metallopeptidase 2	Homo sapiens	153-158
18957170-7	2008	PSP exhibited similar and additive inhibitory effects to ciclosporin to suppress activated T cell proliferation, Th1 cytokines and reduce CD3+/CD25+ cell expression, but not Th2 cytokine expression, which helps the cytokine balance shift towards Th2 dominance.	Cyclosporine	57-68	interleukin 2 receptor subunit alpha	Homo sapiens	143-147
18769365-11	2008	Circulating plasma concentrations of CsA and Tac inhibited CYP2C8 wild-type in vitro epoxidation of AA by 17 and 35%, respectively.	Cyclosporine	37-40	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	59-65
18772316-5	2008	After transplant into cyclosporin-immunosuppressed rats, human dopamine neurons improved apomorphine circling in direct relation to the number of surviving dopamine neurons, which was fivefold greater after Noggin treatment than with control human embryonic stem cell transplants differentiated only on PA6 cells.	Cyclosporine	22-33	noggin	Homo sapiens	207-213
23755172-5	2014	CsA alone decreased renal nuclear DNA-encoded oxidative phosphorylation (OXPHOS) protein ATP synthase-beta (AS-beta) by 42%, mitochondrial DNA (mtDNA)-encoded OXPHOS protein NADH dehydrogenase-3 (ND3) by 87% and their associated mRNAs.	Cyclosporine	0-3	arylsulfatase B	Rattus norvegicus	108-115
22580444-11	2013	The Cox regression analysis revealed that previous eyelid reconstruction [relative risk (RR) = 0.035] and combination with subconjunctival implantation of a cyclosporine A drug delivery system (RR = 0.170) were protective factors.	Cyclosporine	157-171	cytochrome c oxidase subunit 8A	Homo sapiens	4-7
22580614-10	2013	Surprisingly, silencing of autophagy effectors ULK1, Atg5 or Atg7 increased the level of active caspases 3, 7 and PARP degradation in CsA-treated cells.	Cyclosporine	134-137	collagen type XI alpha 2 chain	Homo sapiens	114-118
23220213-3	2013	The CyP40 protein has been shown to possess PPIase activity and, similar to other family members, can bind to the immunosuppressant drug cyclosporin A (CsA).	Cyclosporine	137-150	peptidylprolyl isomerase D	Homo sapiens	4-9
23220213-3	2013	The CyP40 protein has been shown to possess PPIase activity and, similar to other family members, can bind to the immunosuppressant drug cyclosporin A (CsA).	Cyclosporine	152-155	peptidylprolyl isomerase D	Homo sapiens	4-9
23248028-4	2013	Recently, the results were published from a National Institutes of Health (NIH)-sponsored multicenter randomized trial comparing cyclosporine (CSA) with a combination of mycophenolate mofetil (MMF) and pulse dexamethasone (DEX) for the treatment of steroid-resistant FSGS.	Cyclosporine	129-141	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	143-146
23295863-10	2013	Fifth, CsA-induced renal cell apoptosis was significantly decreased by blocking the angiotensin II type 1 receptor using losartan.	Cyclosporine	7-10	angiotensin II receptor type 1	Homo sapiens	84-114
23983712-2	2013	Initial treatment with pulsed corticosteroids and cyclophosphamide, intravenous immunoglobulin, and cyclosporine seemed to suppress the activity of interstitial lung disease temporarily, but signs of relapse were detected such as elevation of serum KL-6 level and progressing pulmonary shadows in chest computed tomography scan.	Cyclosporine	100-112	mucin 1, cell surface associated	Homo sapiens	249-253
23106694-1	2013	Cyclosporine (CSA) is an immunosuppressant used for the prevention of graft rejection and graft-versus-host disease (GVHD) during hematopoietic stem cell transplantation.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
18817870-1	2008	Calcineurin inhibitors (CNI) cyclosporine (Csa) and tacrolimus (Tac) are now first intention immunosuppressive drugs in renal transplantation.	Cyclosporine	29-41	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	43-46
18617642-8	2008	Cyclosporine A (100 ng/ml) inhibited proliferation of CD4(+)CD28(null) cells by 33 +/- 11% versus 68 +/- 12% inhibition of CD4(+)CD28(+) (P = 0.025).	Cyclosporine	0-14	CD28 molecule	Homo sapiens	60-64
18617642-8	2008	Cyclosporine A (100 ng/ml) inhibited proliferation of CD4(+)CD28(null) cells by 33 +/- 11% versus 68 +/- 12% inhibition of CD4(+)CD28(+) (P = 0.025).	Cyclosporine	0-14	CD28 molecule	Homo sapiens	129-133
18829531-4	2008	Loss of PRLr-CypA binding, following treatment with the PPI inhibitor cyclosporine A (CsA), or overexpression of a dominant-negative PRLr mutant (P334A) resulted in a loss of PRLr/Jak2-mediated signaling.	Cyclosporine	70-84	prolactin receptor	Homo sapiens	8-12
18829531-4	2008	Loss of PRLr-CypA binding, following treatment with the PPI inhibitor cyclosporine A (CsA), or overexpression of a dominant-negative PRLr mutant (P334A) resulted in a loss of PRLr/Jak2-mediated signaling.	Cyclosporine	86-89	prolactin receptor	Homo sapiens	8-12
23073893-11	2013	The potentiating effect was blocked by cyclosporin A, a specific blocker of the calcineurin-NFAT pathway.	Cyclosporine	39-52	nuclear factor of activated T-cells 5	Rattus norvegicus	92-96
23144461-3	2012	It has been observed that cyclosporin A (CsA) treatment, particularly in transplant patients, may sometimes be linked to the development of TTP.	Cyclosporine	26-39	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	41-44
22869619-8	2012	Thrombin induces a transient increase of MYPT1(pThr696) in BPAECs, whereas its combination with CsA results in maintained phosphorylation levels of both MYPT1(pThr696) and myosin.	Cyclosporine	96-99	protein phosphatase 1 regulatory subunit 12A	Homo sapiens	153-158
22944461-13	2012	Soluble IL-2R suppression implies a mechanism explaining the effects of CsA.	Cyclosporine	72-75	interleukin 2 receptor subunit alpha	Homo sapiens	8-13
22964373-6	2012	Pulmonary function correlated negatively with LAA% (p&lt;0.001) in both groups, yet the correlation with %CSA was significant only in COPD (p&lt;0.001).	Cyclosporine	106-109	COPD	Homo sapiens	134-138
18463679-6	2008	CsA, but not SRL or combined treatment, increased dermal mast cell numbers and TGF-beta1 levels in the skin.	Cyclosporine	0-3	transforming growth factor, beta 1	Mus musculus	79-88
18981654-5	2008	Real-time PCR analyses with Concanavalin A (ConA)-stimulated PBMC obtained from 5 cats revealed that the expression of mRNAs for IL-2, IL-4, IFN- gamma and TNF-alpha was inhibited by CsA in a dose-dependent manner.	Cyclosporine	183-186	interleukin 4	Felis catus	135-139
23086953-7	2012	SIRT6 increases the nuclear levels of the Ca(2+)-dependent transcription factor, nuclear factor of activated T cells (NFAT), and cyclosporin A, a calcineurin inhibitor that reduces NFAT activity, reduces TNF and IL8 expression in SIRT6-overexpressing cells.	Cyclosporine	129-142	sirtuin 6	Homo sapiens	230-235
22869602-8	2012	Mechanistic study indicated that andrographolide induced autophagic cell death by disruption of mitochondrial transmembrane potential and elevation of reactive oxygen species, which were correlated with mitochondrial permeability transition pore Inhibition of cyclophilin D (a component of MPTP) by cyclosporin A or abrogation of its expression by small interfering RNA significantly suppressed the cytotoxicity of andrographolide, suggesting that cyclophilin D may play an important role in mediating andrographolide-induced cytotoxicity.	Cyclosporine	299-312	peptidylprolyl isomerase D	Homo sapiens	260-273
18594870-1	2008	The aim of this study was to determine the effects of cyclosporine A (CyA) on urinary levels of matrix metalloproteinase 2 and 9 (MMP2, MMP9) and their tissue inhibitors 1 and 2 (TIMP1, TIMP2) in steroid-dependent nephrotic syndrome (SDNS).	Cyclosporine	54-68	matrix metallopeptidase 2	Homo sapiens	96-128
22970897-3	2012	This study describes the accuracy and precision of ciclosporin (CsA) strength when compounded as capsules (10 and 300 mg) and solutions (50 and 150 mg/mL).	Cyclosporine	51-62	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	64-67
18594870-1	2008	The aim of this study was to determine the effects of cyclosporine A (CyA) on urinary levels of matrix metalloproteinase 2 and 9 (MMP2, MMP9) and their tissue inhibitors 1 and 2 (TIMP1, TIMP2) in steroid-dependent nephrotic syndrome (SDNS).	Cyclosporine	54-68	matrix metallopeptidase 2	Homo sapiens	130-134
18594870-1	2008	The aim of this study was to determine the effects of cyclosporine A (CyA) on urinary levels of matrix metalloproteinase 2 and 9 (MMP2, MMP9) and their tissue inhibitors 1 and 2 (TIMP1, TIMP2) in steroid-dependent nephrotic syndrome (SDNS).	Cyclosporine	70-73	matrix metallopeptidase 2	Homo sapiens	96-128
18594870-1	2008	The aim of this study was to determine the effects of cyclosporine A (CyA) on urinary levels of matrix metalloproteinase 2 and 9 (MMP2, MMP9) and their tissue inhibitors 1 and 2 (TIMP1, TIMP2) in steroid-dependent nephrotic syndrome (SDNS).	Cyclosporine	70-73	matrix metallopeptidase 2	Homo sapiens	130-134
18929835-11	2008	The density of the beta-NGF in controls was 0.62, and that in CsA-treated, 1.24.	Cyclosporine	62-65	nerve growth factor	Rattus norvegicus	19-27
18929851-2	2008	Among the immunosuppressants, cyclosporine (CsA) can induce neurological side effects.	Cyclosporine	30-42	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	44-47
22972132-5	2012	Topical cyclosporine A (CsA) may improve AKC signs and symptoms, and be used as a corticosteroid sparing agent.	Cyclosporine	8-22	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	24-27
18667415-6	2008	GST-CyP-D pull-down and co-immunoprecipitation studies revealed CsA-sensitive binding of PiC to CyP-D; this increased following diamide treatment.	Cyclosporine	64-67	peptidylprolyl isomerase F	Rattus norvegicus	4-9
18667415-6	2008	GST-CyP-D pull-down and co-immunoprecipitation studies revealed CsA-sensitive binding of PiC to CyP-D; this increased following diamide treatment.	Cyclosporine	64-67	peptidylprolyl isomerase F	Rattus norvegicus	96-101
18667424-2	2008	Inhibition of nuclear factors of activated T cell (NFAT) activation by cyclosporin A (CsA) and VIVIT suppressed PDGF-BB-induced cyclin A expression and CDK2 activity, resulting in blockade of VSMC in the G(1) phase.	Cyclosporine	71-84	nuclear factor of activated T-cells 5	Rattus norvegicus	51-55
22659400-8	2012	These results indicate that inhibition of complex I by rotenone or metformin and displacement of cyclophilin D by cyclosporin A affect the PTP through a common mechanism; and that cells can modulate their PTP response to complex I inhibition by modifying the expression of cyclophilin D, a finding that has major implications for pore modulation in vivo.	Cyclosporine	114-127	peptidylprolyl isomerase D	Homo sapiens	97-110
22846842-7	2012	Following UVB radiation, CsA inhibited UVB-induced DNA damage repair by suppressing the transcription of the DNA repair factor xeroderma pigmentosum C (XPC).	Cyclosporine	25-28	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	152-155
18667424-2	2008	Inhibition of nuclear factors of activated T cell (NFAT) activation by cyclosporin A (CsA) and VIVIT suppressed PDGF-BB-induced cyclin A expression and CDK2 activity, resulting in blockade of VSMC in the G(1) phase.	Cyclosporine	86-89	nuclear factor of activated T-cells 5	Rattus norvegicus	51-55
22846842-10	2012	CsA-induced phosphoinositide 3-kinase(PI3K)/AKT activation was required for both XPC suppression and CypA upregulation.	Cyclosporine	0-3	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	81-84
22846842-12	2012	Our findings identified deregulation of XPC and CypA as key targets of CsA, and UVB damage and PI3K/AKT activation as two principal drivers for CsA-sensitized skin tumorigenesis, further supporting an immunosuppression-independent mechanism of CsA action on skin tumorigenesis.	Cyclosporine	71-74	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	40-43
22670785-6	2012	Expression of the peripheral homing receptors CXCR3 (r = 0.44, P &lt; 0.05) and CCR5 (r = 0.45, P &lt; 0.05) on FOXP3+ Tregs correlated with renal allograft function (eGFR) in patients receiving tacrolimus (n = 28), but not cyclosporine A (CsA) (n = 26).	Cyclosporine	240-243	C-X-C motif chemokine receptor 3	Homo sapiens	46-51
18813114-2	2008	Here, we have analyzed the effects of cyclosporine A (CsA) on the differentiation and functions of dendritic cells (DC2) that induce Th2 T cells.	Cyclosporine	54-57	monoacylglycerol O-acyltransferase 1	Homo sapiens	116-119
22670785-6	2012	Expression of the peripheral homing receptors CXCR3 (r = 0.44, P &lt; 0.05) and CCR5 (r = 0.45, P &lt; 0.05) on FOXP3+ Tregs correlated with renal allograft function (eGFR) in patients receiving tacrolimus (n = 28), but not cyclosporine A (CsA) (n = 26).	Cyclosporine	240-243	forkhead box P3	Homo sapiens	112-117
18813114-3	2008	DC2 were differentiated from monocytes in the presence of CsA and were matured with viral or bacterial agonists (poly[I:C] or lipopolysaccharide).	Cyclosporine	58-61	monoacylglycerol O-acyltransferase 1	Homo sapiens	0-3
18813114-6	2008	Surprisingly, interleukin-10 secretion by immature DC2 was increased after CsA treatment.	Cyclosporine	75-78	monoacylglycerol O-acyltransferase 1	Homo sapiens	51-54
22670785-7	2012	CsA but not tacrolimus reduced surface expression of CXCR3 on FOXP3+ Tregs in renal transplant recipients as correlated to trough levels (r = -0.42, P &lt; 0.05).	Cyclosporine	0-3	C-X-C motif chemokine receptor 3	Homo sapiens	53-58
18813114-7	2008	Internalization was impaired in treated DC2, and CsA decreased the T-cell proliferative capacity of DC2 matured with poly(I:C), but not with lipopolysaccharide.	Cyclosporine	49-52	monoacylglycerol O-acyltransferase 1	Homo sapiens	100-103
18813114-8	2008	In conclusion, CsA altered T-cell activating functions of DC2 with, notably, a regulatory phenotype for immature DC2 and opposite effects on poly(I:C)-matured cells.	Cyclosporine	15-18	monoacylglycerol O-acyltransferase 1	Homo sapiens	58-61
22670785-7	2012	CsA but not tacrolimus reduced surface expression of CXCR3 on FOXP3+ Tregs in renal transplant recipients as correlated to trough levels (r = -0.42, P &lt; 0.05).	Cyclosporine	0-3	forkhead box P3	Homo sapiens	62-67
18813114-8	2008	In conclusion, CsA altered T-cell activating functions of DC2 with, notably, a regulatory phenotype for immature DC2 and opposite effects on poly(I:C)-matured cells.	Cyclosporine	15-18	monoacylglycerol O-acyltransferase 1	Homo sapiens	113-116
22634404-4	2012	CsA attenuated cell growth by inducing a G1 arrest through the inhibition of mTOR complex 1 (mTORC1) signaling.	Cyclosporine	0-3	CREB regulated transcription coactivator 1	Mus musculus	93-99
22634404-6	2012	However, CsA also caused a Ca2+/calmodulin-dependent protein kinase kinase beta (CaMKKbeta)-dependent activation of AMPK, which inhibits mTORC1 signaling; this led to ineffective Akt signaling.	Cyclosporine	9-12	CREB regulated transcription coactivator 1	Mus musculus	137-143
22568654-3	2012	Cyclosporine A (CsA) and tacrolimus (TAC) were associated with greater levels of Nox2 mRNA and epithelial to mesenchymal transition (EMT) in NRK52E cells.	Cyclosporine	0-14	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	16-19
18541310-12	2008	In the ten paired pre- and post-treatment samples, IL-2 mRNA expression was significantly reduced in residual disease tissue following ciclosporin therapy (P=0.013).	Cyclosporine	135-146	interleukin 2	Canis lupus familiaris	51-55
22685264-9	2012	Studies with different protein phosphatase (PP) inhibitors indicated that the NE-mediated translocation of TORC1 was blocked by cyclosporine A, a PP2B inhibitor, but that of TORC2 was blocked by okadaic acid, a PP2A inhibitor.	Cyclosporine	128-142	CREB regulated transcription coactivator 1	Rattus norvegicus	107-112
18971855-1	2008	AIM: To study the efficacy and safety of topical ciclosporin A (CsA) as an adjunctive therapy after surgical treatment of primary pterygium including excision and limbal conjunctival autograft (LCA) with respect to postoperative pain and complications.	Cyclosporine	64-67	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	49-62
18463324-0	2008	Protective effect of COMP-angiopoietin-1 on cyclosporine-induced renal injury in mice.	Cyclosporine	44-56	cartilage oligomeric matrix protein	Mus musculus	21-25
18463324-6	2008	METHODS: CsA-treated mice were injected with recombinant adenovirus expressing either COMP-Ang1 or LacZ.	Cyclosporine	9-12	cartilage oligomeric matrix protein	Mus musculus	86-90
18463324-8	2008	RESULTS: Histologic examination showed that COMP-Ang1 significantly decreased CsA-induced tubular damage and tubulointerstitial fibrosis.	Cyclosporine	78-81	cartilage oligomeric matrix protein	Mus musculus	44-48
22321150-0	2012	Cyclosporine-A inhibits MMP-2 and -9 activities in the presence of Porphyromonas gingivalis lipopolysaccharide: an experiment in human gingival fibroblast and U937 macrophage co-culture.	Cyclosporine	0-14	matrix metallopeptidase 2	Homo sapiens	24-29
18463324-9	2008	CsA-induced increases in macrophage infiltration and expression of MCP-1 and ICAM-1 after CsA treatment were significantly reduced by COMP-Ang1.	Cyclosporine	0-3	intercellular adhesion molecule 1	Mus musculus	77-83
18463324-9	2008	CsA-induced increases in macrophage infiltration and expression of MCP-1 and ICAM-1 after CsA treatment were significantly reduced by COMP-Ang1.	Cyclosporine	0-3	cartilage oligomeric matrix protein	Mus musculus	134-138
18463324-9	2008	CsA-induced increases in macrophage infiltration and expression of MCP-1 and ICAM-1 after CsA treatment were significantly reduced by COMP-Ang1.	Cyclosporine	90-93	intercellular adhesion molecule 1	Mus musculus	77-83
18463324-9	2008	CsA-induced increases in macrophage infiltration and expression of MCP-1 and ICAM-1 after CsA treatment were significantly reduced by COMP-Ang1.	Cyclosporine	90-93	cartilage oligomeric matrix protein	Mus musculus	134-138
18463324-10	2008	Treatment with COMP-Ang1 also decreased the CsA-induced increases in TGF-beta1 and Smad 2/3 levels while increasing Smad 7 levels.	Cyclosporine	44-47	cartilage oligomeric matrix protein	Mus musculus	15-19
18463324-10	2008	Treatment with COMP-Ang1 also decreased the CsA-induced increases in TGF-beta1 and Smad 2/3 levels while increasing Smad 7 levels.	Cyclosporine	44-47	transforming growth factor, beta 1	Mus musculus	69-78
18463324-10	2008	Treatment with COMP-Ang1 also decreased the CsA-induced increases in TGF-beta1 and Smad 2/3 levels while increasing Smad 7 levels.	Cyclosporine	44-47	SMAD family member 7	Mus musculus	116-122
18463324-11	2008	Laser-Doppler sonographic findings and endothelial factor VIII staining revealed that COMP-Ang1 preserved the integrity of peritubular vasculature and intrarenal haemodynamics from the CsA-induced renal injury.	Cyclosporine	185-188	coagulation factor VIII	Mus musculus	51-62
18463324-11	2008	Laser-Doppler sonographic findings and endothelial factor VIII staining revealed that COMP-Ang1 preserved the integrity of peritubular vasculature and intrarenal haemodynamics from the CsA-induced renal injury.	Cyclosporine	185-188	cartilage oligomeric matrix protein	Mus musculus	86-90
18463324-12	2008	COMP-Ang1 inhibited tubular cell apoptosis while increasing tubular cell proliferation in CsA-induced renal injury.	Cyclosporine	90-93	cartilage oligomeric matrix protein	Mus musculus	0-4
18463324-13	2008	CONCLUSIONS: These results indicate that COMP-Ang1 exhibited a protective effect on damaged peritubular capillaries, haemodynamic alteration and inflammation in CsA-induced renal injury.	Cyclosporine	161-164	cartilage oligomeric matrix protein	Mus musculus	41-45
18606654-5	2008	These signals are dependent on CD28-derived PI3K/Akt pathways and resistant to cyclosporin A.	Cyclosporine	79-92	CD28 molecule	Homo sapiens	31-35
18538359-2	2008	Chronic (&gt;or=3h) treatment of cultured bovine adrenal chromaffin cells with cyclosporin A or FK506 decreased IRS-2 protein level by approximately 50% (IC(50)=200 or 10nM), without changing IRS-2 mRNA level, and insulin receptor, insulin-like growth factor-I (IGF-I) receptor, IRS-1, PI3K/PDK-1/Akt/GSK-3beta and ERK1/ERK2 protein levels.	Cyclosporine	79-92	AKT serine/threonine kinase 1	Bos taurus	297-300
18538359-2	2008	Chronic (&gt;or=3h) treatment of cultured bovine adrenal chromaffin cells with cyclosporin A or FK506 decreased IRS-2 protein level by approximately 50% (IC(50)=200 or 10nM), without changing IRS-2 mRNA level, and insulin receptor, insulin-like growth factor-I (IGF-I) receptor, IRS-1, PI3K/PDK-1/Akt/GSK-3beta and ERK1/ERK2 protein levels.	Cyclosporine	79-92	mitogen-activated protein kinase 3	Bos taurus	315-319
18411268-9	2008	Uricosurics, diuretics, and cyclosporine A showed substantial interactions with hOAT10, of which cyclosporine A enhanced [(14)C]urate uptake, providing the first molecular evidence for cyclosporine A-induced hyperuricemia.	Cyclosporine	28-42	solute carrier family 22 member 13	Homo sapiens	80-86
18411268-9	2008	Uricosurics, diuretics, and cyclosporine A showed substantial interactions with hOAT10, of which cyclosporine A enhanced [(14)C]urate uptake, providing the first molecular evidence for cyclosporine A-induced hyperuricemia.	Cyclosporine	97-111	solute carrier family 22 member 13	Homo sapiens	80-86
18411268-9	2008	Uricosurics, diuretics, and cyclosporine A showed substantial interactions with hOAT10, of which cyclosporine A enhanced [(14)C]urate uptake, providing the first molecular evidence for cyclosporine A-induced hyperuricemia.	Cyclosporine	97-111	solute carrier family 22 member 13	Homo sapiens	80-86
18424069-7	2008	The mechanism might be the effect of CsA on the T cells activation because the expression of CD69 and CD25 molecules on T cells was markedly reduced in the presence of CsA.	Cyclosporine	37-40	CD69 molecule	Homo sapiens	93-97
18424069-7	2008	The mechanism might be the effect of CsA on the T cells activation because the expression of CD69 and CD25 molecules on T cells was markedly reduced in the presence of CsA.	Cyclosporine	37-40	interleukin 2 receptor subunit alpha	Homo sapiens	102-106
18424069-7	2008	The mechanism might be the effect of CsA on the T cells activation because the expression of CD69 and CD25 molecules on T cells was markedly reduced in the presence of CsA.	Cyclosporine	168-171	CD69 molecule	Homo sapiens	93-97
18424069-7	2008	The mechanism might be the effect of CsA on the T cells activation because the expression of CD69 and CD25 molecules on T cells was markedly reduced in the presence of CsA.	Cyclosporine	168-171	interleukin 2 receptor subunit alpha	Homo sapiens	102-106
18442787-5	2008	Cyclosporine A and anti-IL-12p40 (in the acute phase) and anti-CD3 (in the chronic phase) treatment attenuated local cytokine levels, improved clinical symptoms (CsA and anti-IL-12p40) and histology (CsA and anti-CD3).	Cyclosporine	0-14	CD3 antigen, epsilon polypeptide	Mus musculus	213-216
18442787-5	2008	Cyclosporine A and anti-IL-12p40 (in the acute phase) and anti-CD3 (in the chronic phase) treatment attenuated local cytokine levels, improved clinical symptoms (CsA and anti-IL-12p40) and histology (CsA and anti-CD3).	Cyclosporine	162-165	CD3 antigen, epsilon polypeptide	Mus musculus	63-66
18184875-10	2008	Furthermore, Western blot demonstrated that inhibition of PP2B with cyclosporin A or small interfering RNA increased the phosphorylation of ERK and p38 MAPK.	Cyclosporine	68-81	mitogen-activated protein kinase 14	Mus musculus	148-156
18216318-5	2008	Syngeneic transplantation or treatment with cyclosporine A following allogeneic transplantation did not impair graft function but did lead to the downregulation of aquaporin-1, -3, and -4 and several solute transporters.	Cyclosporine	44-58	aquaporin 1	Rattus norvegicus	164-187
18076075-0	2008	Crystal structure of human cyclophilin D in complex with its inhibitor, cyclosporin A at 0.96-A resolution.	Cyclosporine	72-85	peptidylprolyl isomerase D	Homo sapiens	27-40
18243104-6	2008	Our findings may explain why patients receiving cyclosporine A for immunosuppressive therapy display excessive hair growth, and unveil a functional role for calcium-NFATc1-CDK4 circuitry in governing stem cell quiescence.	Cyclosporine	48-62	cyclin dependent kinase 4	Homo sapiens	172-176
18574772-9	2008	IL-15-induced CB NK CD69 expression showed increased CsA sensitivity over APB (P=0.012).	Cyclosporine	53-56	CD69 molecule	Homo sapiens	20-24
18440851-2	2008	Previously we have reported the involvement of PKC-beta isoforms in a model of CsA-induced tubulointerstitial fibrosis and we have now further elucidated this role.	Cyclosporine	79-82	protein kinase C beta	Homo sapiens	47-55
18440851-3	2008	Treatment of human proximal tubular epithelial cells with CsA resulted in increased fibronectin production which coincided with increased PKC activity.	Cyclosporine	58-61	protein kinase C beta	Homo sapiens	138-141
18440851-6	2008	Inhibition of PKC-beta completely abrogated the CsA-induced increase in fibronectin secretion demonstrating a direct antifibrotic effect of PKC-beta inhibition.	Cyclosporine	48-51	protein kinase C beta	Homo sapiens	14-22
18440851-6	2008	Inhibition of PKC-beta completely abrogated the CsA-induced increase in fibronectin secretion demonstrating a direct antifibrotic effect of PKC-beta inhibition.	Cyclosporine	48-51	protein kinase C beta	Homo sapiens	140-148
17956469-5	2007	RESULTS: The expression of heparan sulfate proteoglycans was increased in the cyclosporin A group (165% for syndecan-2, 308% for syndecan-4, and 42% for betaglycan) compared with the control group.	Cyclosporine	78-91	syndecan 4	Homo sapiens	129-139
17956473-8	2007	Interleukin-1 and oncostatin M produced a significant increase in the up-regulation of MMP-1, which was reversed when cyclosporin and nifedipine were added to the cell cultures (p &lt; 0.05).	Cyclosporine	118-129	oncostatin M	Homo sapiens	18-30
18089380-1	2007	Sometimes intravenous administration of cyclosporine (CsA) is essential before oral administration is possible.	Cyclosporine	40-52	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	54-57
18089382-1	2007	BACKGROUND: Cyclosporine (CsA) 2-hour postdose (C2) monitoring is recommended to assess CsA exposure and predict clinical outcomes among heart transplant recipients.	Cyclosporine	12-24	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	26-29
18089382-1	2007	BACKGROUND: Cyclosporine (CsA) 2-hour postdose (C2) monitoring is recommended to assess CsA exposure and predict clinical outcomes among heart transplant recipients.	Cyclosporine	12-24	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	88-91
17724614-1	2007	Cyclosporin A (CsA) is an immunosuppressant with severe side effects including gingival overgrowth.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
18064802-1	2007	The calcineurin inhibitors cyclosporine (CsA) and tacrolimus (Tac) are widely used in the prevention of acute rejection after solid organ transplantation.	Cyclosporine	27-39	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	41-44
17651692-4	2007	CsA treatment dramatically reduced the mRNA levels of adipocyte-specific genes (aP2, HSL, PPARgamma, ACS and Adn), compared with control or TNFalpha-treatment, whereas Li(+) pretreatment blocked the inhibitory effects of CsA, and mRNA levels of aP2, HSL, PPARgamma, and ACS were found at or above control levels.	Cyclosporine	0-3	complement factor D	Homo sapiens	109-112
17911470-4	2007	Cyclosporin A (CsA) is an immunosuppressive agent used to treat a wide range of ADs, but there is a large evidences in the literature, both in vitro and in vivo, suggesting that CsA also exerts an inhibitory effect on HCV replication at standard therapeutic dose.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
17911470-4	2007	Cyclosporin A (CsA) is an immunosuppressive agent used to treat a wide range of ADs, but there is a large evidences in the literature, both in vitro and in vivo, suggesting that CsA also exerts an inhibitory effect on HCV replication at standard therapeutic dose.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	178-181
17385075-4	2007	Caspase-3 activation was accompanied by CsA- and FK506-induced cell death and inhibited by NGF.	Cyclosporine	40-43	caspase 3	Rattus norvegicus	0-9
17889153-11	2007	The logistic regression analysis (dependent variable: PTDM; independent variables: age, anti-CD25, tacrolimus vs cyclosporine) showed that treatment with anti-CD25 is an independent risk factor for PTDM (P = .041; OR 3.28; CI 95% 1.04-10.31).	Cyclosporine	113-125	interleukin 2 receptor subunit alpha	Homo sapiens	159-163
17889206-2	2007	The objective of this study was to prospectively assess the impact of conversion from cyclosporine (CsA) to tacrolimus on lung function in patients who developed BOS while receiving CsA-based immunosuppressive therapy.	Cyclosporine	86-98	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	100-103
22321150-2	2012	This in vitro study aimed to evaluate the effect of CsA on the activities of MMPs from the co-culture of human gingival fibroblasts and U937 macrophages in the presence or absence of Porphyromonas gingivalis lipopolysaccharide (LPS).	Cyclosporine	52-55	matrix metallopeptidase 2	Homo sapiens	77-81
22538855-6	2012	Critically, CD8(+)FoxP3(+) T(reg) are exquisitely sensitive to inhibition by cyclosporine but can be massively and specifically expanded in vivo to prevent GVHD by coadministering rapamycin and IL-2 antibody complexes.	Cyclosporine	77-89	forkhead box P3	Homo sapiens	18-23
17578461-8	2007	RESULTS: CsA significantly reduced infarct size (48.8 +/- 5.8% of left ventricle in vehicle + I/R group and 30.3 +/- 2.7% of left ventricle in CsA + I/R, respectively) and decreased caspase-3 activity in the myocardium [(0.62 +/- 0.17)/microg of protein and (0.42 +/- 0.15)/microg of protein, respectively] and relieved the injury of mitochondria.	Cyclosporine	9-12	caspase 3	Rattus norvegicus	182-191
17578461-10	2007	The cardioprotective effects of CsA might be associated with the protection of mitochondria and the inhibition of caspase-3 activity.	Cyclosporine	32-35	caspase 3	Rattus norvegicus	114-123
17031644-9	2007	CONCLUSIONS: CsA, tacrolimus and sirolimus modulate drug transport by Pgp, MRP-1 and BCRP and CsA and sirolimus modulate drug transport by LRP at concentrations that differ from immunosuppressive concentrations and maximum tolerated concentrations.	Cyclosporine	13-16	major vault protein	Homo sapiens	139-142
17031644-9	2007	CONCLUSIONS: CsA, tacrolimus and sirolimus modulate drug transport by Pgp, MRP-1 and BCRP and CsA and sirolimus modulate drug transport by LRP at concentrations that differ from immunosuppressive concentrations and maximum tolerated concentrations.	Cyclosporine	94-97	major vault protein	Homo sapiens	139-142
17460148-9	2007	Neutralizing antibodies against TGF-beta1 and the TGF-beta receptor II significantly reduced the CsA-induced increase in TER.	Cyclosporine	97-100	transforming growth factor beta-1 proprotein	Canis lupus familiaris	32-41
22664025-7	2012	RESULTS: After CsA treatment both RNA and protein levels of ILT3 and ILT4 on NKL cells were increased for 12, 24, or 36 hours.	Cyclosporine	15-18	leukocyte immunoglobulin like receptor B2	Homo sapiens	69-73
22664025-8	2012	CsA at various concentrations inhibited the proliferation of NKL cells to varying degrees; at 36 hours CsA (15 mg/L) showed greater effects on ILT3 and ILT4 expression and less influence on NKL growth.	Cyclosporine	103-106	leukocyte immunoglobulin like receptor B2	Homo sapiens	152-156
22664025-10	2012	CONCLUSIONS: CsA up-regulated the expression of ILT3 and ILT4 on NKL cells, which influenced their cytotoxicity against tumor cells with different expression of HLA-G and proliferation of NKL cells.	Cyclosporine	13-16	leukocyte immunoglobulin like receptor B2	Homo sapiens	57-61
21702050-7	2012	(d) CsA completely blocked the stimulatory effect of CRF(1) and CRF(2) ligands on NFAT activity in NFAT-Luc transfected cells.	Cyclosporine	4-7	nuclear factor of activated T-cells 5	Rattus norvegicus	82-86
17605867-11	2007	Both PF and CsA could downregulate the expression of CD69 on T cells which had been stimulated by PMA plus ionomycin (PF vs CsA, P &gt; 0.05).	Cyclosporine	12-15	CD69 molecule	Homo sapiens	53-57
21702050-7	2012	(d) CsA completely blocked the stimulatory effect of CRF(1) and CRF(2) ligands on NFAT activity in NFAT-Luc transfected cells.	Cyclosporine	4-7	nuclear factor of activated T-cells 5	Rattus norvegicus	99-103
22311511-5	2012	Culturing bone marrow cells in media supplemented with Flt3-L in the presence of the calcineurin/NFAT inhibitor Cyclosporin A increased numbers of differentiated DC.	Cyclosporine	112-125	FMS-like tyrosine kinase 3 ligand	Mus musculus	55-61
17368777-4	2007	As swelling is inhibited by cyclosporine, this suggests that the swelling is due to the opening of a trans-membrane pore (MTP pore) in the mitochondria.	Cyclosporine	28-40	microsomal triglyceride transfer protein	Rattus norvegicus	122-125
17027333-6	2007	CSA patients were more symptomatic (NYHA class 2.9+/-0.5 vs. no SDB 2.57+/-0.5 or OSA 2.57+/-0.5; p&lt;0.05) and had a lower LV-EF (27.4+/-6.6% vs. 29.3+/-2.6%, p&lt;0.05) than OSA patients.	Cyclosporine	0-3	AT-rich interaction domain 1B	Homo sapiens	82-87
17287424-6	2007	CD4(+)CD25(high) cells that expressed FOXP3 underwent homeostatic peripheral expansion during immune reconstitution, more intense in patients who received sirolimus than in those who were given CsA.	Cyclosporine	194-197	forkhead box P3	Homo sapiens	38-43
23573469-1	2012	BACKGROUND: Although the immunosuppressant cyclosporine (CsA) is widely used after kidney transplantation over the long term, there is still no firm consensus on the best way to monitor of CsA blood levels.	Cyclosporine	43-55	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	57-60
23573469-2	2012	OBJECTIVES: Cyclosporine (CsA) assay is critical for the management of renal transplant recipients due to inter- and intra-patient variation in CsA absorption and metabolism.	Cyclosporine	12-24	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	26-29
23573469-2	2012	OBJECTIVES: Cyclosporine (CsA) assay is critical for the management of renal transplant recipients due to inter- and intra-patient variation in CsA absorption and metabolism.	Cyclosporine	12-24	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	144-147
22166375-12	2012	Akt and GSK3beta phosphorylation after reperfusion were significantly increased in sevoflurane and cyclosporine A.	Cyclosporine	99-113	glycogen synthase kinase-3 beta	Cavia porcellus	8-16
17210452-7	2007	An increase in nitrated MnSOD was detected in BAEC treated with CsA and the peroxynitrite donor SIN-1 and recapitulated in recombinant MnSOD, exposed to the conditioned media from BAEC.	Cyclosporine	64-67	superoxide dismutase 2	Homo sapiens	24-29
17202415-4	2007	It was reported recently that long-term CsA treatment was associated with decreased renal expression of TonEBP target genes, including aquaporin-2, urea transporter, and aldose reductase.	Cyclosporine	40-43	nuclear factor of activated T cells 5	Homo sapiens	104-110
17161467-1	2007	Cyclosporine A (CSA) has various biological effects on T cells, including inhibition of interleukin (IL)-15-induced IL-17 production in CD4+ T cells from patients with rheumatoid arthritis (RA).	Cyclosporine	0-14	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	16-19
22045333-7	2012	Addition of PP5 or cyclophilin-binding drug cyclosporine A prevented the association of endogenous CYP40 with HSP90-AGO1 complex and inhibited RISC assembly.	Cyclosporine	44-58	protein argonaute 1-like	Nicotiana tabacum	116-120
17102134-7	2007	Treatment with the calcineurin inhibitors FK506 and cyclosporin A also blocked DREAM-mediated Kv4.2 channel trafficking and calcineurin de-phosphorylated GRK2-phosphorylated DREAM in vitro.	Cyclosporine	52-65	potassium voltage-gated channel interacting protein 3	Homo sapiens	79-84
22155090-4	2012	Our results show that compounds that blocked protein synthesis and apoptosis, together with the CK2 inhibitor DMAT and the PI3K inhibitor apigenin, were the most efficient in preventing CsA toxicity.	Cyclosporine	186-189	casein kinase 2, alpha prime polypeptide	Mus musculus	96-99
17214702-14	2007	CONCLUSION: CD28/B7 blockade delays CD4(+) T cell-mediated rejection after CSA withdrawal in accommodated recipients of hamster heart xenografts.	Cyclosporine	75-78	Cd28 molecule	Rattus norvegicus	12-16
22132303-1	2012	Measurements of Cyclosporine (CsA) systemic exposure permit its dose adjustment in allogenic stem cell transplantation recipients to prevent graft-versus-host disease.	Cyclosporine	16-28	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	30-33
17038001-3	2006	Multivariate analysis identified previous immunosuppressive therapy with antithymocyte-globulin (ATG) and ciclosporin (CsA) as a risk factor for graft rejection (relative risk: 16.6, P = 0.001).	Cyclosporine	106-117	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	119-122
17175300-1	2006	A recent report noted that cyclosporine (CsA) inhibits replication of the hepatitis C virus (HCV) in vitro.	Cyclosporine	27-39	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	41-44
17112860-0	2006	Expression of transforming growth factor-beta receptor II mRNA in cyclosporine-induced gingival overgrowth.	Cyclosporine	66-78	transforming growth factor beta receptor 2	Homo sapiens	14-57
23428559-5	2012	Our results showed that CsA-induced ER stress and involved ER integrated stress response-related proteins (Bip/Grp78, ATF6, IRE1 and CHOP) but not cytoplasmic ER stress-related chaperones (HSP70, HSP40, HSP27, HSP90 and HSP60).	Cyclosporine	24-27	heat shock protein family B (small) member 1	Rattus norvegicus	203-208
17112860-4	2006	The aim of this study was to clarify whether TGF-beta RII is overexpressed in CsA-induced GO.	Cyclosporine	78-81	transforming growth factor beta receptor 2	Homo sapiens	45-57
17274875-4	2006	The present study aimed to evaluate the efficacy of immunosuppressive treatments with cyclosporine A (CSA) alone or CSA combined with antithymocyte globin (ATG) in children with acquired SAA.	Cyclosporine	86-100	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	102-105
21885994-3	2011	Compared with vehicle (olive oil)-treated rats, chronic treatment with CSA (20 mg kg d subcutaneous, for 14 days) increased systolic blood pressure, elevated renal function indices and plasma renin activity, impaired renovascular responsiveness of isolated perfused rat kidneys to endothelium-dependent vasodilations induced by carbachol.	Cyclosporine	71-74	renin	Rattus norvegicus	192-197
22094768-9	2011	The in vivo study revealed that, compared with untreated control, rats administered adipose-derived stem cells along with transient antilymphocyte serum and cyclosporin A treatment had significantly prolonged allotransplant survival (p &lt; 0.001), decreased allotissue rejection, significantly elevated donor cell chimerism, and increased CD4/CD25/Foxp3 regulatory T cells in peripheral blood and alloskin tissue with up-regulation of transforming growth factor-beta and interleukin-10 levels.	Cyclosporine	157-170	interleukin 2 receptor subunit alpha	Homo sapiens	344-348
16939683-2	2006	In situ loop method was used to evaluate the uptake of cyclosporin A (40nmol) at the upper and lower intestine of wild-type and mdr1a/1b knockout mice treated or not treated with dexamethasone (75mg/kg/day, 7 days, i.p.).	Cyclosporine	55-68	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	128-133
16716285-9	2006	An apparent rise in the activities of N-acetyl-beta-D-glucosaminidase, beta-glucuronidase and cathepsin D were seen in the renal tissue of CsA given rats, which were reversed upon treatment with LA.	Cyclosporine	139-142	O-GlcNAcase	Rattus norvegicus	38-69
22094768-9	2011	The in vivo study revealed that, compared with untreated control, rats administered adipose-derived stem cells along with transient antilymphocyte serum and cyclosporin A treatment had significantly prolonged allotransplant survival (p &lt; 0.001), decreased allotissue rejection, significantly elevated donor cell chimerism, and increased CD4/CD25/Foxp3 regulatory T cells in peripheral blood and alloskin tissue with up-regulation of transforming growth factor-beta and interleukin-10 levels.	Cyclosporine	157-170	forkhead box P3	Homo sapiens	349-354
22172253-8	2011	Meanwhile, the cyclosporine group had significantly higher expressions of Foxp3 mRNA and CD4(+)CD25(+)CD127(low) Treg cells than the conventional group (P&lt;0.05).	Cyclosporine	15-27	forkhead box P3	Homo sapiens	74-79
22172253-9	2011	CONCLUSIONS: The expressions of CD4(+)CD25(+)CD127(low) Treg cells and Foxp3 mRNA in children with aplastic anemia increase after cyclosporine treatment.	Cyclosporine	130-142	forkhead box P3	Homo sapiens	71-76
22092633-9	2011	RESULTS: High dosage cyclosporine resulted in significant decreases in IL-2 and IFN-gamma expression (P = .0156, P = .0156), but not IL-4 expression (P = .2188).	Cyclosporine	21-33	interleukin 2	Canis lupus familiaris	71-75
17045935-1	2006	BACKGROUND: Monitoring of the 2-hour post-dose sample (C(2)) for cyclosporine (CsA) has gained favor; however, choosing a single-point surrogate marker of therapeutic effect for a drug with extensive pharmacokinetic variability is problematic and has limitations.	Cyclosporine	65-77	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	79-82
17096891-5	2006	The numbers of CD3(+), CD4(+), CD8(+), CD11a(+), CD18(+) lymphocytes in skin and lung decreased markedly by GTT, GTT + CsA and CsA + MTX treatments.	Cyclosporine	127-130	CD3 antigen, epsilon polypeptide	Mus musculus	15-18
16980037-1	2006	OBJECTIVES: Transforming growth factor-beta(1) (TGF-beta(1)) and its receptors, type 1 (TR-1) and type 2 (TR-2) play important roles in chronic cyclosporine (CsA)-induced nephropathy.	Cyclosporine	144-156	nuclear receptor subfamily 2, group C, member 1	Rattus norvegicus	106-110
16980037-1	2006	OBJECTIVES: Transforming growth factor-beta(1) (TGF-beta(1)) and its receptors, type 1 (TR-1) and type 2 (TR-2) play important roles in chronic cyclosporine (CsA)-induced nephropathy.	Cyclosporine	158-161	nuclear receptor subfamily 2, group C, member 1	Rattus norvegicus	106-110
16980037-4	2006	Therefore, in this study we assessed the effects of Lotensin or Salviae on the chronic CsA-induced upregulation of TGF-beta(1), TR-1, and TR-2 in a rat model.	Cyclosporine	87-90	nuclear receptor subfamily 2, group C, member 1	Rattus norvegicus	138-142
16980037-7	2006	The proteins of TGF-beta(1), TR-1, and TR-2, and the mRNA of TR-1 and TR-2 in the kidneys of CsA-treated rats, were measured by immunohistochemistry (IHC) and in situ hybridization (ISH).	Cyclosporine	93-96	nuclear receptor subfamily 2, group C, member 1	Rattus norvegicus	70-74
16885564-4	2006	Among 12 distinct proteins that exhibited 4-fold differences in expression on comparison of the two infected cell lysates, cyclophilin A, the intracellular reporter of the immunosuppressive drug cyclosporine A, showed a remarkably decreased protein level in cells infected with Ad-FHIT-wt versus Ad-FHIT-Y114F.	Cyclosporine	195-209	fragile histidine triad diadenosine triphosphatase	Homo sapiens	281-285
16885564-4	2006	Among 12 distinct proteins that exhibited 4-fold differences in expression on comparison of the two infected cell lysates, cyclophilin A, the intracellular reporter of the immunosuppressive drug cyclosporine A, showed a remarkably decreased protein level in cells infected with Ad-FHIT-wt versus Ad-FHIT-Y114F.	Cyclosporine	195-209	fragile histidine triad diadenosine triphosphatase	Homo sapiens	299-303
16885564-7	2006	Interestingly, Fhit down-modulation of phosphatase activity of calcineurin, which controls cyclin D1/Cdk4 activation, was reversed by cyclophilin A treatment in a concentration-dependent manner, a reversal that was inhibited by additional cyclosporine A treatment.	Cyclosporine	239-253	fragile histidine triad diadenosine triphosphatase	Homo sapiens	15-19
16885564-7	2006	Interestingly, Fhit down-modulation of phosphatase activity of calcineurin, which controls cyclin D1/Cdk4 activation, was reversed by cyclophilin A treatment in a concentration-dependent manner, a reversal that was inhibited by additional cyclosporine A treatment.	Cyclosporine	239-253	cyclin D1	Homo sapiens	91-100
16885564-7	2006	Interestingly, Fhit down-modulation of phosphatase activity of calcineurin, which controls cyclin D1/Cdk4 activation, was reversed by cyclophilin A treatment in a concentration-dependent manner, a reversal that was inhibited by additional cyclosporine A treatment.	Cyclosporine	239-253	cyclin dependent kinase 4	Homo sapiens	101-105
21912224-4	2011	The translocation activity of NFAT5 was assessed by confocal microscopy and Western immunoblotting after CsA treatment.	Cyclosporine	105-108	nuclear factor of activated T cells 5	Homo sapiens	30-35
21912224-8	2011	Transcriptional activities of NF-kappaB, AP-1, and NFAT1 were not stimulated by CsA; however, nuclear translocation of NFAT5 was markedly upregulated by CsA.	Cyclosporine	153-156	nuclear factor of activated T cells 5	Homo sapiens	119-124
21912224-9	2011	CsA-induced NGF production was markedly decreased on inhibition of NFAT5 or SB20429.	Cyclosporine	0-3	nuclear factor of activated T cells 5	Homo sapiens	67-72
21912224-11	2011	These results suggest that CsA mediates NGF expression through activation of p38 and NFAT5.	Cyclosporine	27-30	nuclear factor of activated T cells 5	Homo sapiens	85-90
21434893-5	2011	Therefore, we studied whether cyclosporine"s metabolic side effects are mediated by WNK4 and NCC.	Cyclosporine	30-42	solute carrier family 12 member 3	Rattus norvegicus	93-96
16814783-4	2006	E2A transcription factors were identified as being upregulated by CsA treatment.	Cyclosporine	66-69	transcription factor 3	Homo sapiens	0-3
16814783-7	2006	These results indicate the important role of the E2A gene products in the progression of CsA-induced EMT and provide novel insights into CsA-induced renal fibrosis.	Cyclosporine	89-92	transcription factor 3	Homo sapiens	49-52
16617166-7	2006	Coincubation with either cyclosporin A (an MPT inhibitor) or the combination of fructose-1,6-diphosphate (a glycolysis substrate) and oligomycin (an ATPase inhibitor) prevented the decrease in DeltaPsim, ATP depletion, and cell death.	Cyclosporine	25-38	dynein axonemal heavy chain 8	Homo sapiens	149-155
16675492-6	2006	Cyclosporin A, which inhibits PTP opening by binding to cyclophilin D (CypD), was significantly more potent in mitochondria from denervated muscle and restored CRC to the level observed in mitochondria from sham-operated muscles.	Cyclosporine	0-13	peptidylprolyl isomerase D	Homo sapiens	56-69
16675492-6	2006	Cyclosporin A, which inhibits PTP opening by binding to cyclophilin D (CypD), was significantly more potent in mitochondria from denervated muscle and restored CRC to the level observed in mitochondria from sham-operated muscles.	Cyclosporine	0-13	peptidylprolyl isomerase D	Homo sapiens	71-75
16704434-2	2006	Response rates with horse anti-thymocyte globulin (h-ATG) plus ciclosporin (CsA) are about 60-70%, and robust responders have an excellent long-term survival.	Cyclosporine	63-74	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	76-79
16722827-1	2006	AIMS: St John"s wort (SJW) decreases the blood concentration of ciclosporin A (CsA), which may result in allograft rejection.	Cyclosporine	79-82	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	64-77
16964645-1	2006	OBJECTIVE: To optimize the best concentration of neuraminidase (Neu) that enhances the migration of neuraminidase (Neu)-treated donor bone marrow cells (dBMCs) to the liver, and observe the influence of short-term cyclosporin A(CsA) application combined with intravenous injection (i.v.)	Cyclosporine	214-227	neuraminidase 1	Homo sapiens	64-67
16964645-1	2006	OBJECTIVE: To optimize the best concentration of neuraminidase (Neu) that enhances the migration of neuraminidase (Neu)-treated donor bone marrow cells (dBMCs) to the liver, and observe the influence of short-term cyclosporin A(CsA) application combined with intravenous injection (i.v.)	Cyclosporine	228-231	neuraminidase 1	Homo sapiens	64-67
16964645-11	2006	Rats in untreated dBMCs group and Neu-treated dBMCs group received CsA (10 mg/kg) through intraperitoneal injection (i.p.)	Cyclosporine	67-70	neuraminidase 1	Homo sapiens	34-37
16732183-9	2006	Active caspase-3 staining and 24-kDa active caspase-3 protein was enhanced in I/R-injured and CsA-treated kidneys, but decreased by Tac, Rap, and MMF.	Cyclosporine	94-97	caspase 3	Rattus norvegicus	7-16
16732183-9	2006	Active caspase-3 staining and 24-kDa active caspase-3 protein was enhanced in I/R-injured and CsA-treated kidneys, but decreased by Tac, Rap, and MMF.	Cyclosporine	94-97	caspase 3	Rattus norvegicus	44-53
16546704-5	2006	CsA and FK506 each dose-dependently inhibited antigen-induced histamine and beta-hexosaminidase secretion and the membrane repolarization phase, with similar IC50s for both actions, approximately 20 nM for CsA and approximately 2 nM for FK506.	Cyclosporine	0-3	O-GlcNAcase	Rattus norvegicus	76-95
16757288-2	2006	We describe the effect of the coadministration of Amprenavir/Ritonavir (APV/r) and FosAmprenavir (FosAPV) on cyclosporine (CsA) concentrations in two patients receiving OLT for end-stage liver disease due to hepatitis C Virus.	Cyclosporine	109-121	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	123-126
16643797-7	2006	CONCLUSION: CsA can inhibit the expressions of CD25 and CD69 on splenocytes, as well as INF-gamma production by splenocytes in a dose dependent manner.	Cyclosporine	12-15	CD69 antigen	Mus musculus	56-60
16634529-0	2006	The role of basic-fibroblast growth factor (b-FGF) in cyclosporine-induced nephrotoxicity.	Cyclosporine	54-66	fibroblast growth factor 2	Rattus norvegicus	12-42
16634529-0	2006	The role of basic-fibroblast growth factor (b-FGF) in cyclosporine-induced nephrotoxicity.	Cyclosporine	54-66	fibroblast growth factor 2	Rattus norvegicus	44-49
16634529-1	2006	BACKGROUND: The effect of the b-fibroblast growth factor (b-FGF) on cyclosporine A (CsA)-induced nephrotoxicity in the rat kidney was investigated.	Cyclosporine	68-82	fibroblast growth factor 2	Rattus norvegicus	30-56
16634529-1	2006	BACKGROUND: The effect of the b-fibroblast growth factor (b-FGF) on cyclosporine A (CsA)-induced nephrotoxicity in the rat kidney was investigated.	Cyclosporine	68-82	fibroblast growth factor 2	Rattus norvegicus	58-63
16634529-1	2006	BACKGROUND: The effect of the b-fibroblast growth factor (b-FGF) on cyclosporine A (CsA)-induced nephrotoxicity in the rat kidney was investigated.	Cyclosporine	84-87	fibroblast growth factor 2	Rattus norvegicus	58-63
16634529-6	2006	CONCLUSION: The angiogenic role of b-FGF was confirmed in normal rats and a possible "protective" role of b-FGF was shown in rat kidney with CsA-induced nephrotoxicity.	Cyclosporine	141-144	fibroblast growth factor 2	Rattus norvegicus	106-111
16442073-6	2006	In this regard, we found that CsA protects filamin in platelets from calpain degradation.	Cyclosporine	30-33	filamin C	Homo sapiens	43-50
16898486-16	2006	During MMF therapy Csa treatment could be reduced from a mean CsA dose 4.3 to 2.9 mg/kg/24 hours (p=0.008).	Cyclosporine	62-65	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	19-22
16504666-3	2006	Herein we describe a patient with biopsy-proven CsA-associated nephrotoxicity and refractory renal allograft rejection who was converted from steroids, CsA, and azathioprine to steroids, sirolimus (RAPA), and low-dose mycophenolate mofetil (MMF).	Cyclosporine	48-51	transcriptional regulating factor 1	Homo sapiens	198-202
16504666-3	2006	Herein we describe a patient with biopsy-proven CsA-associated nephrotoxicity and refractory renal allograft rejection who was converted from steroids, CsA, and azathioprine to steroids, sirolimus (RAPA), and low-dose mycophenolate mofetil (MMF).	Cyclosporine	152-155	transcriptional regulating factor 1	Homo sapiens	198-202
16313313-5	2005	In this setting, use of an IL-2R antagonist with mycophenolate mofetil and steroids with delayed cyclosporine appears to be associated with a low incidence of biopsy-proven rejection and comparable renal function to patients with immediate function.	Cyclosporine	97-109	interleukin 2 receptor subunit alpha	Homo sapiens	27-32
21653632-0	2011	Expression of renal distal tubule transporters TRPM6 and NCC in a rat model of cyclosporine nephrotoxicity and effect of EGF treatment.	Cyclosporine	79-91	solute carrier family 12 member 3	Rattus norvegicus	57-60
16535998-7	2005	The lack of side effects and the relatively quick response suggest that cyclosporin A should be tried as a frontline treatment for patients with acquired FVIII inhibitor.	Cyclosporine	72-85	coagulation factor VIII	Homo sapiens	154-159
16314802-7	2005	Increased osteopontin, TGF-beta1, betaig-h3, and angiotensin II expression in CsA-treated rat kidneys were decreased with FTY720 treatment.	Cyclosporine	78-81	secreted phosphoprotein 1	Rattus norvegicus	10-21
21653632-1	2011	Renal magnesium (Mg(2+)) and sodium (Na(+)) loss are well-known side effects of cyclosporine (CsA) treatment in humans, but the underlying mechanisms still remain unclear.	Cyclosporine	80-92	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	94-97
22016592-2	2011	We studied the regulation of hepatic albumin synthesis by cyclosporin A (CsA) in Huh7 cells.	Cyclosporine	58-71	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	73-76
16242456-8	2005	Cardiac allograft rejection and vasculopathy in the cyclosporine-treated group was associated with prominent myocardial interferon-gamma gene expression, a finding absent in two thirds of the mycophenolate mofetil-treated swine.	Cyclosporine	52-64	interferon gamma	Sus scrofa	120-136
21674474-5	2011	The CaN inhibitor cyclosporine A (CsA) converts a transient phosphorylation of Bcl-10 Ser138 during the immediate early phase of T-cell activation into a persistent state.	Cyclosporine	18-32	BCL10 immune signaling adaptor	Homo sapiens	79-85
21674474-5	2011	The CaN inhibitor cyclosporine A (CsA) converts a transient phosphorylation of Bcl-10 Ser138 during the immediate early phase of T-cell activation into a persistent state.	Cyclosporine	34-37	BCL10 immune signaling adaptor	Homo sapiens	79-85
21440552-0	2011	Cyclosporine attenuates cardiomyocyte hypertrophy induced by RAF1 mutants in Noonan and LEOPARD syndromes.	Cyclosporine	0-12	Raf-1 proto-oncogene, serine/threonine kinase	Rattus norvegicus	61-65
21440552-11	2011	Furthermore, treatment with the calcineurin inhibitor cyclosporine blocked hypertrophy in NRCMs and ARCMs overexpressing RAF1.	Cyclosporine	54-66	Raf-1 proto-oncogene, serine/threonine kinase	Rattus norvegicus	121-125
21435337-1	2011	Experimental cerebral ischemia has been reportedly alleviated by the immunosuppressive agent cyclosporin A (CsA).	Cyclosporine	93-106	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	108-111
21514360-0	2011	The effect of systemic injection of cyclosporin A on the phosphorylation of the PKC substrates MARCKS and GAP43 in the rat hippocampus.	Cyclosporine	36-49	growth associated protein 43	Rattus norvegicus	106-111
21514360-7	2011	The immunoreactivity of p-MARCKS(S152/156) was higher in the CsA group 1h after injection, whereas p-GAP43(S41) immunoreactivity was increased by CsA after 5h.	Cyclosporine	146-149	growth associated protein 43	Rattus norvegicus	101-106
21517850-9	2011	mGluR2/3 activation by its agonist LY354740 (100 ng) in the CA3 reversed the depressive-like behavior induced by cyclosporine-A administration.	Cyclosporine	113-127	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	0-6
20368718-1	2011	Cyclosporine (CsA) is a substrate of cytochrome P450 (CYP) 3A5 and has a narrow therapeutic range with large inter-individual variability.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
21333626-1	2011	Cyclosporine A (CsA) is an immunosuppressive drug commonly used for maintaining chronic immune suppression in organ transplant recipients.	Cyclosporine	0-14	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	16-19
16164223-1	2005	Cyclosporin A(CsA) and tacrolimus (FK506) are important immunosuppressants to inhibit rejection of transplanted organs and to treat various immunological disorders, however those drugs produce major side effects.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
15937522-1	2005	Based on recent evidence that renal cyclooxygenase-2 (COX-2) gene expression is suppressed by immunosuppressive agents such as cyclosporin A (CsA), tacrolimus and dexamethasone, this study aimed to characterize the effect of the new immunosuppressant everolimus on COX-2 expression in the rat kidney.	Cyclosporine	127-140	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	36-52
15937522-1	2005	Based on recent evidence that renal cyclooxygenase-2 (COX-2) gene expression is suppressed by immunosuppressive agents such as cyclosporin A (CsA), tacrolimus and dexamethasone, this study aimed to characterize the effect of the new immunosuppressant everolimus on COX-2 expression in the rat kidney.	Cyclosporine	127-140	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	54-59
15937522-1	2005	Based on recent evidence that renal cyclooxygenase-2 (COX-2) gene expression is suppressed by immunosuppressive agents such as cyclosporin A (CsA), tacrolimus and dexamethasone, this study aimed to characterize the effect of the new immunosuppressant everolimus on COX-2 expression in the rat kidney.	Cyclosporine	127-140	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	265-270
15937522-1	2005	Based on recent evidence that renal cyclooxygenase-2 (COX-2) gene expression is suppressed by immunosuppressive agents such as cyclosporin A (CsA), tacrolimus and dexamethasone, this study aimed to characterize the effect of the new immunosuppressant everolimus on COX-2 expression in the rat kidney.	Cyclosporine	142-145	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	36-52
15937522-1	2005	Based on recent evidence that renal cyclooxygenase-2 (COX-2) gene expression is suppressed by immunosuppressive agents such as cyclosporin A (CsA), tacrolimus and dexamethasone, this study aimed to characterize the effect of the new immunosuppressant everolimus on COX-2 expression in the rat kidney.	Cyclosporine	142-145	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	54-59
15937522-1	2005	Based on recent evidence that renal cyclooxygenase-2 (COX-2) gene expression is suppressed by immunosuppressive agents such as cyclosporin A (CsA), tacrolimus and dexamethasone, this study aimed to characterize the effect of the new immunosuppressant everolimus on COX-2 expression in the rat kidney.	Cyclosporine	142-145	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	265-270
16003241-7	2005	The CNI Cyclosporin and Tacrolimus, and alphaCD25 mAb inhibited in vitro induced FOXP3 gene transcription (range 70%-90%), whereas Rapa did not inhibit the induction.	Cyclosporine	8-19	forkhead box P3	Homo sapiens	81-86
15948868-12	2005	The mRNA expression of COX1 is not affected and COX-2 is decreased in CsA-treated TAL cells.	Cyclosporine	70-73	cytochrome c oxidase II, mitochondrial	Mus musculus	48-53
15948868-14	2005	We concluded that CsA decreased intrarenal PGE2 production in stimulated status mainly by decreasing COX-2 expression.	Cyclosporine	18-21	cytochrome c oxidase II, mitochondrial	Mus musculus	101-106
15799972-7	2005	Moreover, pretreatment with okadaic acid or cyclosporin A blocked the dephosphorylation of GSK-3beta at Ser-9 at 0, 15, and 30 min after KCl-induced depolarization, and the activity of protein phosphatases (PP) 2A and 2B increased at these times.	Cyclosporine	44-57	glycogen synthase kinase 3 beta	Homo sapiens	91-100
21146153-0	2011	Toll like receptor 4 and membrane-bound CD14 expressions in gingivitis, periodontitis and CsA-induced gingival overgrowth.	Cyclosporine	90-93	CD14 molecule	Homo sapiens	40-44
21146153-2	2011	This study was aimed to investigate the expression of TLR4 and membrane-bound CD14 (mCD14) in the gingival tissues of patients with gingivitis, periodontitis and CsA-induced gingival overgrowth.	Cyclosporine	162-165	CD14 molecule	Homo sapiens	78-82
21146153-2	2011	This study was aimed to investigate the expression of TLR4 and membrane-bound CD14 (mCD14) in the gingival tissues of patients with gingivitis, periodontitis and CsA-induced gingival overgrowth.	Cyclosporine	162-165	CD14 antigen	Mus musculus	84-89
21443864-5	2011	In addition, cyclosporin A (CsA), a potent inhibitor of calcineurin, abrogated catestatin-mediated effect on VSMCs, indicating that the calcineurin-NFAT signaling is strongly required for catestatin-induced growth of VSMCs.	Cyclosporine	13-26	nuclear factor of activated T-cells 5	Rattus norvegicus	148-152
21443864-5	2011	In addition, cyclosporin A (CsA), a potent inhibitor of calcineurin, abrogated catestatin-mediated effect on VSMCs, indicating that the calcineurin-NFAT signaling is strongly required for catestatin-induced growth of VSMCs.	Cyclosporine	28-31	nuclear factor of activated T-cells 5	Rattus norvegicus	148-152
21198643-0	2011	Up-regulation of retinoblastoma protein phosphorylation in gingiva after cyclosporine A treatment: an in vivo and in vitro study.	Cyclosporine	73-87	RB transcriptional corepressor 1	Homo sapiens	17-31
21198643-7	2011	RESULTS: Proliferating cell nuclear antigen and cyclin D1 mRNAs (Pcna and Ccnd1, respectively) were expressed more strongly in the gingivae of cyclosporine A-treated animals than in the gingivae of the controls.	Cyclosporine	143-157	cyclin D1	Homo sapiens	48-57
21198643-7	2011	RESULTS: Proliferating cell nuclear antigen and cyclin D1 mRNAs (Pcna and Ccnd1, respectively) were expressed more strongly in the gingivae of cyclosporine A-treated animals than in the gingivae of the controls.	Cyclosporine	143-157	cyclin D1	Homo sapiens	74-79
21198643-8	2011	Immunohistochemical analyses showed that a greater number of gingival cells stained positive for cyclin D1, CDK4 and pRb1 in the cyclosporine A group than in the control group.	Cyclosporine	129-143	cyclin D1	Homo sapiens	97-106
21198643-8	2011	Immunohistochemical analyses showed that a greater number of gingival cells stained positive for cyclin D1, CDK4 and pRb1 in the cyclosporine A group than in the control group.	Cyclosporine	129-143	cyclin dependent kinase 4	Homo sapiens	108-112
21198643-9	2011	Increased expression of cyclin D1, CDK4 and PCNA proteins was observed in HGFs after cyclosporine A treatment.	Cyclosporine	85-99	cyclin D1	Homo sapiens	24-33
21198643-9	2011	Increased expression of cyclin D1, CDK4 and PCNA proteins was observed in HGFs after cyclosporine A treatment.	Cyclosporine	85-99	cyclin dependent kinase 4	Homo sapiens	35-39
21198643-10	2011	The phosphorylation of Rb1 was enhanced in HGFs after treatment with cyclosporine A at concentrations of 10(2)-10(3) ng/mL.	Cyclosporine	69-83	RB transcriptional corepressor 1	Homo sapiens	23-26
21198643-11	2011	CONCLUSION: The increases in cyclin D1, PCNA and CDK4, together with the enhanced phosphorylation of Rb1, suggest that cyclosporine A promotes cell-cycle progression through the G(1)/S transition in the gingiva.	Cyclosporine	119-133	cyclin D1	Homo sapiens	29-38
21198643-11	2011	CONCLUSION: The increases in cyclin D1, PCNA and CDK4, together with the enhanced phosphorylation of Rb1, suggest that cyclosporine A promotes cell-cycle progression through the G(1)/S transition in the gingiva.	Cyclosporine	119-133	cyclin dependent kinase 4	Homo sapiens	49-53
21198643-11	2011	CONCLUSION: The increases in cyclin D1, PCNA and CDK4, together with the enhanced phosphorylation of Rb1, suggest that cyclosporine A promotes cell-cycle progression through the G(1)/S transition in the gingiva.	Cyclosporine	119-133	RB transcriptional corepressor 1	Homo sapiens	101-104
21311961-4	2011	Drugs, e.g., cyclosporin A, can inhibit the permeability transition through their interaction with the mitochondria-specific protein, cyclophilin D, and demonstrate neuroprotection in several animal models.	Cyclosporine	13-26	peptidylprolyl isomerase D	Homo sapiens	134-147
21059349-5	2011	RESULTS: Double dilution tests showed a clear nonlinearity, suggesting that antibody interference not related to heterophilic antibodies had occurred; false-positive concentrations of cyclosporin obtained when using an antibody-conjugated to beta-galactosidase suggested the presence of endogenous antibodies directed against beta-galactosidase.	Cyclosporine	184-195	galactosidase beta 1	Homo sapiens	242-260
21059349-5	2011	RESULTS: Double dilution tests showed a clear nonlinearity, suggesting that antibody interference not related to heterophilic antibodies had occurred; false-positive concentrations of cyclosporin obtained when using an antibody-conjugated to beta-galactosidase suggested the presence of endogenous antibodies directed against beta-galactosidase.	Cyclosporine	184-195	galactosidase beta 1	Homo sapiens	326-344
21124021-6	2011	Occludin was also increased in rat kidneys and MDCK I cells exposed to 100 ng/ml cyclosporine.	Cyclosporine	81-93	occludin	Rattus norvegicus	0-8
15877794-1	2005	Profiling of absorption of cyclosporine (CsA) microemulsion is a concept in therapeutic drug monitoring (TDM) designed to optimize the clinical benefits of the drug in transplant recipients.	Cyclosporine	27-39	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	41-44
21888018-7	2011	RESULTS: Cathepsin D, L, and vascular endothelial growth factor (VEGF)165 mRNA were markedly suppressed in CsA-treated HGFs, whereas cathepsin B, matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of metalloproteinase-1 (TIMP-1) mRNA were not reduced.	Cyclosporine	107-110	cathepsin D	Homo sapiens	9-20
21687603-6	2011	Indeed, Western blot analysis revealed that CyA increased phospho-CaMKII, an active form of CaMKII.	Cyclosporine	44-47	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	66-72
15924835-12	2005	Cyclosporine and CPM induced remission in 100% of patients with MCD, while in Mes.PGN response rate in group-I, II, and III was 100% (n=1), 50%(n=1), and 44.4%(n=4) respectively.	Cyclosporine	0-12	SPG7 matrix AAA peptidase subunit, paraplegin	Homo sapiens	82-85
15924835-14	2005	CONCLUSION: Cyclosporine proved to be a better option for MCD and Mes.PGN, while MPP showed limited response in patients with FSGS.	Cyclosporine	12-24	SPG7 matrix AAA peptidase subunit, paraplegin	Homo sapiens	70-73
21687603-6	2011	Indeed, Western blot analysis revealed that CyA increased phospho-CaMKII, an active form of CaMKII.	Cyclosporine	44-47	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	92-98
21121808-6	2011	Mitochondrial calcium retention capacity, a quantitative assay for mPT, was significantly increased by the CypD inhibitor cyclosporin A in both human brain and liver mitochondria, whereas thiol-reactive compounds and oxidants sensitized mitochondria to calcium-induced mPT.	Cyclosporine	122-135	peptidylprolyl isomerase D	Homo sapiens	107-111
16004552-1	2005	The immunosuppressive drugs cyclosporin (CsA) and tacrolimus (Tac) are widely used to prevent acute rejection following solid-organ transplantation.	Cyclosporine	28-39	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	41-44
15919451-1	2005	The narrow therapeutic window of the immunosuppressive drug cyclosporine (CsA), the interindividual variability of its metabolism, and the immunosuppressive activity/toxicity of some metabolites require investigation to correlate the parent substance and its metabolites and observed clinical parameters.	Cyclosporine	60-72	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	74-77
15681847-4	2005	Intraperitoneal injection of cyclosporine A (CsA), a pharmacological inhibitor of the calcineurin-NFAT activation pathway, suppressed balloon injury-induced neointima formation by 40%.	Cyclosporine	29-43	nuclear factor of activated T-cells 5	Rattus norvegicus	98-102
15681847-4	2005	Intraperitoneal injection of cyclosporine A (CsA), a pharmacological inhibitor of the calcineurin-NFAT activation pathway, suppressed balloon injury-induced neointima formation by 40%.	Cyclosporine	45-48	nuclear factor of activated T-cells 5	Rattus norvegicus	98-102
15681847-8	2005	COX-2 expression was also increased in the right common carotid artery in a time-dependent manner after balloon injury as compared with its levels in uninjured left common carotid artery and both CsA and GFPVIVIT negated this response.	Cyclosporine	196-199	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	0-5
15726383-1	2005	BACKGROUND: Cyclosporine (CsA) is a widely used drug in the treatment of posterior uveitis.	Cyclosporine	12-24	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	26-29
21468162-1	2011	INTRODUCTION: The combination of cyclosporin A (CsA) and mycophenolate mofetil (MMF) has a synergistic immunosuppressive effect and, as a result, it may induce remission of nephrotic syndrome in patients with steroid- and CsA-resistant focal segmental glomerulosclerosis (FSGS).	Cyclosporine	48-51	actinin alpha 4	Homo sapiens	272-276
15788683-7	2005	Moreover, cyclosporin A enhanced nuclear distribution of doxorubicin in 8226/MR20 cells, which also express LRP, and increased doxorubicin cytotoxicity 12-fold without an effect on cellular doxorubicin content, consistent with expression of wild-type BCRP, which does not efflux doxorubicin.	Cyclosporine	10-23	major vault protein	Homo sapiens	108-111
15788683-8	2005	Cyclosporin A also enhanced nuclear doxorubicin distribution in a second cell line with LRP overexpression, HT1080/DR4.	Cyclosporine	0-13	major vault protein	Homo sapiens	88-91
15788683-10	2005	CONCLUSIONS: Cyclosporin A modulates Pgp, MRP-1, BCRP, and LRP, and this broad-spectrum activity may contribute to its clinical efficacy.	Cyclosporine	13-26	major vault protein	Homo sapiens	59-62
21468162-3	2011	PATIENTS AND METHODS: Twenty-seven patients with CsA-resistant FSGS were treated for 12 months with CsA (4mg/kg/day) combined with MMF (2g/day).	Cyclosporine	49-52	actinin alpha 4	Homo sapiens	63-67
21468162-3	2011	PATIENTS AND METHODS: Twenty-seven patients with CsA-resistant FSGS were treated for 12 months with CsA (4mg/kg/day) combined with MMF (2g/day).	Cyclosporine	100-103	actinin alpha 4	Homo sapiens	63-67
15770714-10	2005	After immunostaining of the frozen section, TGFbeta-R1 and FGFR4 are more concentrated in rat liver after CsA plus TAA injury.	Cyclosporine	106-109	fibroblast growth factor receptor 4	Rattus norvegicus	59-64
15770714-11	2005	CONCLUSION: This result suggests that CsA has an alleviated effect on TAA-induced liver injury by increasing the multidrug resistance P-glycoprotein and could be through the regulation of TGFbeta-R1 and FGFR4.	Cyclosporine	38-41	fibroblast growth factor receptor 4	Rattus norvegicus	203-208
21166111-2	2010	After cyclosporine A (CsA) microemulsion administration, effective renal plasma flow (ERPF) and glomerular filtration rate(GFR) are decreased coincident with the maximal concentration (Cmax) of CsA.	Cyclosporine	6-20	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	22-25
21166111-2	2010	After cyclosporine A (CsA) microemulsion administration, effective renal plasma flow (ERPF) and glomerular filtration rate(GFR) are decreased coincident with the maximal concentration (Cmax) of CsA.	Cyclosporine	6-20	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	194-197
15864171-1	2005	OBJECTIVE: The efficacy of intravenous cyclosporin (CSA) in acute severe ulcerative colitis (UC) is well established.	Cyclosporine	39-50	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	52-55
21170880-7	2010	In the collecting duct, CsA may cause hypertension by stimulating the epithelial Na+ channel (ENaC) through a pathway associated with inhibition of ABCA1 and consequent elevation of cholesterol in the cells.	Cyclosporine	24-27	ATP binding cassette subfamily A member 1	Bos taurus	148-153
15852743-1	2005	OBJECTIVE: To evaluate the effect of cyclosporine (CSA) on serum magnesium and its fractional excretion in renal transplant recipients.	Cyclosporine	37-49	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	51-54
20668412-8	2010	Although the mPTP has previously been implicated in the induction of autophagy and selective removal of damaged mitochondria by autophagosomes, mitochondria sequestered by autophagosomes in Bnip3-treated cardiac myocytes had not undergone permeability transition and treatment with the mPTP inhibitor cyclosporine A did not inhibit mitochondrial autophagy in cardiac myocytes.	Cyclosporine	301-315	BCL2/adenovirus E1B interacting protein 3	Mus musculus	190-195
15729167-10	2005	In addition, PFD down-regulated the mRNA expression of CsA-induced p53 and Fas-ligand (P&lt;0.01) and increased that of Bcl-xL, previously reduced by CsA (P&lt;0.01).	Cyclosporine	55-58	Fas ligand	Rattus norvegicus	75-85
15729167-10	2005	In addition, PFD down-regulated the mRNA expression of CsA-induced p53 and Fas-ligand (P&lt;0.01) and increased that of Bcl-xL, previously reduced by CsA (P&lt;0.01).	Cyclosporine	150-153	Bcl2-like 1	Rattus norvegicus	120-126
21244763-1	2010	Cyclosporine A (CsA) effectively controls psoriasis, however, its long-term continuous use is not recommended.	Cyclosporine	0-14	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	16-19
15730912-3	2005	Cyclosporine A (CsA), which is routinely used to prevent the allograft rejection, is reported to have the inhibitory activity on hepatitis B virus (HBV) replication in vitro.	Cyclosporine	0-14	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	16-19
15855806-10	2005	In rats with PHN, CsA induced a significant deterioration of renal function and enhanced urine excretion of thromboxane A2, paralleled by a significant, twofold increase in COX-2 protein expression and renal prostaglandins.	Cyclosporine	18-21	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	173-178
15855806-14	2005	The CsA-induced increase in COX-2 expression and COX-2-dependent prostacyclin may indicate a mechanism that compensates nephrotoxicity in the diseased and CsA-exposed kidney.	Cyclosporine	4-7	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	28-33
15855806-14	2005	The CsA-induced increase in COX-2 expression and COX-2-dependent prostacyclin may indicate a mechanism that compensates nephrotoxicity in the diseased and CsA-exposed kidney.	Cyclosporine	4-7	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	49-54
15855806-14	2005	The CsA-induced increase in COX-2 expression and COX-2-dependent prostacyclin may indicate a mechanism that compensates nephrotoxicity in the diseased and CsA-exposed kidney.	Cyclosporine	155-158	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	28-33
15855806-14	2005	The CsA-induced increase in COX-2 expression and COX-2-dependent prostacyclin may indicate a mechanism that compensates nephrotoxicity in the diseased and CsA-exposed kidney.	Cyclosporine	155-158	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	49-54
16103732-3	2005	In this study, using in vitro and in vivo models, we examined the effects of cyclosporine (CsA) and tacrolimus (TAC) on OPN mRNA and protein expression.	Cyclosporine	77-89	secreted phosphoprotein 1	Mus musculus	120-123
16103732-3	2005	In this study, using in vitro and in vivo models, we examined the effects of cyclosporine (CsA) and tacrolimus (TAC) on OPN mRNA and protein expression.	Cyclosporine	91-94	secreted phosphoprotein 1	Mus musculus	120-123
16103732-4	2005	We also examined if CsA- and TAC-induced OPN expression is dependent on transforming growth factor (TGF)-beta expression.	Cyclosporine	20-23	secreted phosphoprotein 1	Mus musculus	41-44
16103732-7	2005	The expression of OPN was also studied in CsA-treated PTE cells with and without anti-TGF-beta antibody.	Cyclosporine	42-45	secreted phosphoprotein 1	Mus musculus	18-21
16103732-12	2005	OPN may contribute to the CsA- and TAC-induced nephrotoxicity in organ transplant recipients and the increased OPN expression might be mediated by TGF-beta.	Cyclosporine	26-29	secreted phosphoprotein 1	Mus musculus	0-3
15808533-6	2005	Expression of the co-stimulatory molecule CD80 but not CD86 increased on both DC subsets when stimulated with cyclosporine.	Cyclosporine	110-122	CD80 molecule	Homo sapiens	42-46
15459204-6	2004	This putative promoter was active in Jurkat T cells following CD3 and CD28 cross-linking, and its activity was inhibited by cyclosporin A and MAPK inhibitors.	Cyclosporine	124-137	CD28 molecule	Homo sapiens	70-74
20595929-1	2010	BACKGROUND: IL2 receptor antagonist (IL2ra) induction therapy has gained favor due to an excellent safety profile and improved outcomes in randomized trials using cyclosporine-based immunosuppression.	Cyclosporine	163-175	interleukin 2 receptor subunit alpha	Homo sapiens	12-35
15663561-4	2004	OBJECTIVE: We investigated the suppressive effect of dermatologically used AID (cyclosporin A (CsA), lactoferrin (LF), 1 alpha, 25-dihydroxyvitamin D(3) (VD(3)), hydrocortisone (HC), di-methyl-fumarate (DMF), diclofenac (DF)) on both type-1 and type-2 T cells.	Cyclosporine	80-93	activation induced cytidine deaminase	Homo sapiens	75-78
15381199-2	2004	By using DNA array technology, we have previously demonstrated that IRF1 is significantly upregulated during acute rejection in rat heart allografts and is restored to isograft levels when recipients are treated with the immunosuppressants tacrolimus or cyclosporin A (CsA).	Cyclosporine	254-267	interferon regulatory factor 1	Rattus norvegicus	68-72
15381199-2	2004	By using DNA array technology, we have previously demonstrated that IRF1 is significantly upregulated during acute rejection in rat heart allografts and is restored to isograft levels when recipients are treated with the immunosuppressants tacrolimus or cyclosporin A (CsA).	Cyclosporine	269-272	interferon regulatory factor 1	Rattus norvegicus	68-72
15464081-0	2004	Cyclosporine and bromocriptine-induced suppressions of CYP3A1/2 and CYP2C11 are not mediated by prolactin.	Cyclosporine	0-12	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	55-61
15464081-1	2004	The purpose of this study was to determine if the suppression of hepatic CYP3A1/2 (cytochrome P450 3A1/2) and CYP2C11 (cytochrome P450 2C11) by cyclosporine is mediated by prolactin.	Cyclosporine	144-156	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	73-79
15464081-1	2004	The purpose of this study was to determine if the suppression of hepatic CYP3A1/2 (cytochrome P450 3A1/2) and CYP2C11 (cytochrome P450 2C11) by cyclosporine is mediated by prolactin.	Cyclosporine	144-156	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	83-104
15464081-5	2004	Hypoprolactinemia, produced by bromocriptine, caused a significant suppression of CYP3A1/2 activity levels when bromocriptine was administered alone and in combination with cyclosporine (P&lt;0.001, P&lt;0.05; respectively).	Cyclosporine	173-185	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	82-88
15362118-5	2004	The ability of CSA to detect only active N-WASP was demonstrated by in vitro experiments using immunoprecipitation of active N-WASP from EGF-stimulated cells and Cdc42 activation of N-WASP activity.	Cyclosporine	15-18	cell division cycle 42	Homo sapiens	162-167
15254967-1	2004	Cyclosporine A (CsA) is known to have direct toxicity to renal tubular cells.	Cyclosporine	0-14	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	16-19
20595929-1	2010	BACKGROUND: IL2 receptor antagonist (IL2ra) induction therapy has gained favor due to an excellent safety profile and improved outcomes in randomized trials using cyclosporine-based immunosuppression.	Cyclosporine	163-175	interleukin 2 receptor subunit alpha	Homo sapiens	37-42
20588203-1	2010	BACKGROUND: Whether the loss-of-function allele CYP3A5*3 variant is associated with significantly impaired metabolism of cyclosporine A (CsA) in transplant patients is still controversial because of the lack of prospective, large-scale clinical studies performed among diversely ethnic populations.	Cyclosporine	121-135	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	137-140
24900244-0	2010	Facile synthesis of a fluorescent cyclosporin a analogue to study cyclophilin 40 and cyclophilin 18 ligands.	Cyclosporine	34-47	peptidylprolyl isomerase D	Homo sapiens	66-80
15282533-8	2004	Cyclosporine blocked the induction of CD25 expression on alloactivated T cells in vitro but had no detectable effect on CD25 expression by T-regulatory cells.	Cyclosporine	0-12	interleukin 2 receptor subunit alpha	Homo sapiens	38-42
24900244-4	2010	We show the binding of this tracer to Cyp40 and Cyp18 with K D values of 106 +- 13 or 12 +- 1 nM, respectively, by analyzing the anisotropy change and demonstrate its competition with cyclosporin A.	Cyclosporine	184-197	peptidylprolyl isomerase D	Homo sapiens	38-43
20554520-9	2010	Finally, we found that the inhibition of PKC-delta using a dominant negative plasmid significantly decreased the CsA-induced cytoplasmic translocation of HuR and VEGF mRNA stability.	Cyclosporine	113-116	protein kinase C delta	Homo sapiens	41-50
20590696-8	2010	We considered that the present case showed two distinct types of FSGS lesions--one because of VUR and the other because of cyclosporine arteriolopathy--in each native kidney and transplanted kidney.	Cyclosporine	123-135	actinin alpha 4	Homo sapiens	65-69
20540636-12	2010	It was inversely correlated with cyclosporine A (CsA) level (r = -0.499, p = 0.035).	Cyclosporine	33-47	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	49-52
20540642-2	2010	In this study, we investigated the effect of pharmacological doses of CsA on the production of nitric oxide synthases (NOSs) and endothelin (ET) receptors (ETR-A, ETR-B), in human tubular cells [human kidney (HK)-2], to identify any implication of these pathways in CsA nephrotoxicity.	Cyclosporine	70-73	endothelin receptor type A	Homo sapiens	156-161
20540642-5	2010	RESULTS: A dose-dependent induction of synthesis of NO synthases eNOS and iNOS and ET receptors ETR-A and ETR-B was observed, even at therapeutic doses of CsA.	Cyclosporine	155-158	endothelin receptor type A	Homo sapiens	96-101
20226794-9	2010	SIGNIFICANCE: Since CsA binds to cyclophilin D (Cyp-D) in the mitochondrial matrix whereas BKA or ADP binds to adenine nucleotide translocator (ANT) in the IMM, it was suggested that mtMGST1 in the IMM interacts with Cyp-D/ANT and the binding of MPT inhibitors to Cyp-D or ANT causes their conformational change followed by an alteration of mtMGST1 conformation, resulting in decreasing mtMGST1 activity.	Cyclosporine	20-23	peptidylprolyl isomerase F	Rattus norvegicus	33-46
15233825-3	2004	In this open randomized study, we compared the efficacy and safety of administration of cyclosporine (CSA; Neoral) and azathioprine before renal transplantation with the administration of the same schema after transplantation, in HLA haploidentical grafts.	Cyclosporine	88-100	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	102-105
20226794-9	2010	SIGNIFICANCE: Since CsA binds to cyclophilin D (Cyp-D) in the mitochondrial matrix whereas BKA or ADP binds to adenine nucleotide translocator (ANT) in the IMM, it was suggested that mtMGST1 in the IMM interacts with Cyp-D/ANT and the binding of MPT inhibitors to Cyp-D or ANT causes their conformational change followed by an alteration of mtMGST1 conformation, resulting in decreasing mtMGST1 activity.	Cyclosporine	20-23	peptidylprolyl isomerase F	Rattus norvegicus	48-53
15370291-2	2004	To test the hypothesis that estradiol (E2) and cyclosporin A (CsA) can interfere within programmed cell death in human umbilical vein endothelial cells (HUVECs), apoptosis was induced by etoposide with and without E2 or CsA.	Cyclosporine	47-60	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	62-65
20548907-1	2010	BACKGROUND: Patients with severe atopic dermatitis (AD) can benefit from cyclosporin (CSA) treatment.	Cyclosporine	73-84	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	86-89
20357250-8	2010	Addition of cyclosporin A reverted BCR-mediated inhibition, both for BAFF and LPS, suggesting similar regulation of signaling pathways by calcineurin.	Cyclosporine	12-25	tumor necrosis factor (ligand) superfamily, member 13b	Mus musculus	69-73
14766935-9	2004	The PTP blockers bongkrekic acid and cyclosporin A both reduced inhibition of transient K(Ca) currents by mitochondrial depolarization.	Cyclosporine	37-50	protein tyrosine phosphatase, non-receptor type 13	Rattus norvegicus	4-7
20181694-3	2010	Here, we demonstrate that CsA decreases gp120 and gp41 incorporation into HIV-1 virions and that the fusion of these virions with susceptible target cells is impaired.	Cyclosporine	26-29	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	40-45
20181694-6	2010	Thus, cyclosporine blocks HIV-1 infectivity via two independent mechanisms, the first involving HIV-1 CA in target cells and the second involving HIV-1 Env in producer cells.	Cyclosporine	6-18	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	152-155
20305583-7	2010	CONCLUSION: These results demonstrate that inhibition of CD40-CD40L interaction or treatment with rapamycin could be successfully combined with in vitro-expanded Treg cell therapy, but the concomitant use of mycophenolate mofetil or cyclosporine A in this type of Treg cell therapy should be carefully considered.	Cyclosporine	233-247	CD40 antigen	Mus musculus	57-61
15108248-1	2004	Adjusting cyclosporine (CsA) dose based on blood concentration at 2 hours after dose (C(2)) has been shown in prospective clinical trials to reduce the risk of rejection compared with conventional trough monitoring.	Cyclosporine	10-22	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	24-27
15108262-1	2004	It has been demonstrated that achieving therapeutic levels of cyclosporine (CsA) exposure in the first days posttransplant is critical for effective prevention of rejection.	Cyclosporine	62-74	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	76-79
15044094-3	2004	We previously showed that CsA toxicity is mediated by ROS generation as well as by inhibition of peptidyl-prolyl cis-trans isomerase (PPIase) activity of CypA in CsA-treated myoblasts [FASEB J.	Cyclosporine	162-165	peptidylprolyl isomerase (cyclophilin)-like 3	Mus musculus	97-132
15044094-3	2004	We previously showed that CsA toxicity is mediated by ROS generation as well as by inhibition of peptidyl-prolyl cis-trans isomerase (PPIase) activity of CypA in CsA-treated myoblasts [FASEB J.	Cyclosporine	162-165	peptidylprolyl isomerase (cyclophilin)-like 3	Mus musculus	134-140
15044094-5	2004	Since CsA-induced nephrotoxicity is the most significant adverse effect in its clinical utilization, we here investigated the role of CsA inhibition of CypA PPIase activity in its nephrotoxicity using transgenic mouse models.	Cyclosporine	134-137	peptidylprolyl isomerase (cyclophilin)-like 3	Mus musculus	157-163
15044094-10	2004	In conclusion, our data provide in vivo evidence that supplement of CypA PPIase activity allows animal"s resistance toward CsA-induced nephrotoxicity.	Cyclosporine	123-126	peptidylprolyl isomerase (cyclophilin)-like 3	Mus musculus	73-79
15063039-1	2004	The cyclic endecapeptide cyclosporine (CsA), a potent immunosuppressive drug, was incorporated into biodegradable poly (DL-lactide-co-gylcolide) (DL-PLG) 50/50, 65/35 and PEG 5000-70/30 DL-PLG to improve the oral bioavailability and pharmacokinetics.	Cyclosporine	25-37	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	39-42
15063039-1	2004	The cyclic endecapeptide cyclosporine (CsA), a potent immunosuppressive drug, was incorporated into biodegradable poly (DL-lactide-co-gylcolide) (DL-PLG) 50/50, 65/35 and PEG 5000-70/30 DL-PLG to improve the oral bioavailability and pharmacokinetics.	Cyclosporine	25-37	plasminogen	Homo sapiens	149-152
15063039-1	2004	The cyclic endecapeptide cyclosporine (CsA), a potent immunosuppressive drug, was incorporated into biodegradable poly (DL-lactide-co-gylcolide) (DL-PLG) 50/50, 65/35 and PEG 5000-70/30 DL-PLG to improve the oral bioavailability and pharmacokinetics.	Cyclosporine	25-37	plasminogen	Homo sapiens	189-192
20350531-4	2010	Resistance to apoptosis induction by chemotherapeutic drugs can be reversed by cyclosporine A, which effectively inhibits the activity of P-glycoprotein and BCRP, thus demonstrating ABC transporter-mediated drug resistance in KG-1a cells.	Cyclosporine	79-93	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	182-185
15141761-7	2004	RESULTS: Tissue concentrations of doxorubicin and vinblastine in peripheral nerves of the mdr1a(+/+) mice pretreated with 200 mg/kg cyclosporin A were significantly higher than those in the mdr1a(+/+) mice administered doxorubicin or vinblastine alone, suggesting that cyclosporin A inhibited the efflux pump function of p-glycoprotein in the peripheral nerves.	Cyclosporine	132-145	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	90-95
15033175-5	2004	In YAC46 MSNs, NMDA stimulated significantly higher activation of caspase-3 and caspase-9 but not caspase-8, and NMDA-induced caspase-3 and -9 activation was markedly attenuated by cyclosporin A.	Cyclosporine	181-194	caspase 9	Mus musculus	80-89
14565991-3	2004	In the rat atrial preparation, an increase in pacing frequency increased nuclear activity of the calcineurin-sensitive transcription factor, nuclear factor of activated T-cells (NFAT), 2-fold in a cyclosporin A (CsA)-sensitive manner.	Cyclosporine	197-210	nuclear factor of activated T-cells 5	Rattus norvegicus	178-182
14565991-3	2004	In the rat atrial preparation, an increase in pacing frequency increased nuclear activity of the calcineurin-sensitive transcription factor, nuclear factor of activated T-cells (NFAT), 2-fold in a cyclosporin A (CsA)-sensitive manner.	Cyclosporine	212-215	nuclear factor of activated T-cells 5	Rattus norvegicus	178-182
14709642-10	2004	Two individuals responded conversely, indicating that differences in the in vitro response to tacrolimus and CsA among individuals may be attributable to potential heterogeneity in the involvement of the CD28 pathway.	Cyclosporine	109-112	CD28 molecule	Homo sapiens	204-208
20470309-8	2010	In intermediate-risk recipients, IL-2Ra induction was associated with a 26% reduction in the incidence of acute rejection; but this benefit was restricted only to recipients initiated on cyclosporine-based immunosuppressive regimens.	Cyclosporine	187-199	interleukin 2 receptor subunit alpha	Homo sapiens	33-39
20470309-11	2010	CONCLUSION: This registry analysis suggests that IL-2Ra induction may be associated with a reduction in rejection risk in cyclosporine-treated intermediate immunological risk recipients, but not in low-risk renal transplant recipients.	Cyclosporine	122-134	interleukin 2 receptor subunit alpha	Homo sapiens	49-55
20352119-3	2010	The immunosuppressant, cyclosporine A (CsA) has potent anti-HCV activity towards both HCV replicons and the genotype 2a cell culture infectious virus.	Cyclosporine	23-37	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	39-42
15515807-1	2004	Cyclosporine A (CsA) is one of the basic and often used immunosuppressive agents.	Cyclosporine	0-14	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	16-19
20023700-0	2010	FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A.	Cyclosporine	120-133	peptidylprolyl isomerase D	Homo sapiens	11-16
14714970-2	2003	Soon after starting oral cyclosporin A (CyA) the skin lesions healed completely and the interstitial pneumonia promptly improved in parallel with a decrease in serum KL-6.	Cyclosporine	25-38	mucin 1, cell surface associated	Homo sapiens	166-170
20450731-14	2010	The expression of IL-15 mRNA in AB group was significantly lower than that in CsA group (P &lt; 0.01).	Cyclosporine	78-81	interleukin 15	Rattus norvegicus	18-23
14659903-1	2003	Cyclosporin (CsA) or tacrolimus (TRL) is routinely combined with either sirolimus (SRL) or mycophenolate mofetil (MMF) in immunosuppressive regimes in organ transplantation.	Cyclosporine	0-11	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	13-16
20450731-16	2010	But the expression of OPN mRNA in AB group was higher than that in CsA group (P &lt; 0.01).	Cyclosporine	67-70	secreted phosphoprotein 1	Rattus norvegicus	22-25
21448533-3	2010	Cyclosporin (CsA) is a rare cause of PC, scarcely reported in the literature, and should be considered in the differential diagnosis of ICH and papilledema in those patients.	Cyclosporine	0-11	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	13-16
12829603-1	2003	Immunosuppression with antithymocyte globulin (ATG) or cyclosporine (CSA) can be used to treat the cytopenia associated with myelodysplastic syndrome (MDS).	Cyclosporine	55-67	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	69-72
12860007-2	2003	Both cyclosporine-A (CSA) and liposome-encapsulated daunorubicin, DaunoXome (DNX) may reduce the negative impact of MDR.	Cyclosporine	5-19	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	21-24
12860008-2	2003	A Phase II study of Mylotarg, fludarabine, ara-C and the MDR-modifier, cyclosporine (CSA) (MFAC) was conducted in 32 patients with primary resistant (11, 34%) or relapsed (21, 66%) AML.	Cyclosporine	71-83	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	85-88
14599462-8	2003	Cyclosporine A and decylubiquinone, MPT specific inhibitor, prevented the activation of caspase 3, thus showing that diclofenac opened the MPT pore.	Cyclosporine	0-14	caspase 3	Rattus norvegicus	88-97
14527363-8	2003	The expression of caspase-3 mRNA and caspase-3 activity was significantly higher in the CsA-treated group than that of the CsA plus tea polyphenols (TP)-treated group (P &lt; 0.05).	Cyclosporine	88-91	caspase 3	Rattus norvegicus	18-27
14527363-8	2003	The expression of caspase-3 mRNA and caspase-3 activity was significantly higher in the CsA-treated group than that of the CsA plus tea polyphenols (TP)-treated group (P &lt; 0.05).	Cyclosporine	88-91	caspase 3	Rattus norvegicus	37-46
14527363-8	2003	The expression of caspase-3 mRNA and caspase-3 activity was significantly higher in the CsA-treated group than that of the CsA plus tea polyphenols (TP)-treated group (P &lt; 0.05).	Cyclosporine	123-126	caspase 3	Rattus norvegicus	18-27
12949730-8	2003	Bid was required for permeability transition and mitochondria depolarization in addition to the previously defined release of cytochrome c. Permeability transition inhibitors cyclosporin A and aristolochic acid could inhibit mitochondria activation effectively, but not as much as the deletion of the bid gene, and they could not inhibit Bak oligomerization.	Cyclosporine	175-188	BH3 interacting domain death agonist	Mus musculus	0-3
12949730-8	2003	Bid was required for permeability transition and mitochondria depolarization in addition to the previously defined release of cytochrome c. Permeability transition inhibitors cyclosporin A and aristolochic acid could inhibit mitochondria activation effectively, but not as much as the deletion of the bid gene, and they could not inhibit Bak oligomerization.	Cyclosporine	175-188	BH3 interacting domain death agonist	Mus musculus	301-304
12783880-4	2003	In particular, calmodulin antagonists, FK506, and cyclosporin, immunosuppressants that inhibit the calcium-dependent phosphatase calcineurin, suppress ERK1/2 activation by both glucose and GLP-1.	Cyclosporine	50-61	glucagon like peptide 1 receptor	Homo sapiens	189-194
20470282-4	2010	Induction of chronic CsA nephropathy was evaluated according to renal function and pathology and expression of HA, CD44, LYVE-1, ED-1 and alpha-smooth muscle actin (alpha-SMA).	Cyclosporine	21-24	lymphatic vessel endothelial hyaluronan receptor 1	Rattus norvegicus	121-127
20470282-8	2010	HA binding receptor, CD44 and LYVE-1 expression were also upregulated in the CsA groups, and were localized to the area of fibrosis and the peritubular capillaries of the cortex.	Cyclosporine	77-80	lymphatic vessel endothelial hyaluronan receptor 1	Rattus norvegicus	30-36
19965778-10	2010	The calcineurin inhibitor cyclosporin A or the novel NFAT blocker A-285222 prevented glucose-induced OPN expression.	Cyclosporine	26-39	secreted phosphoprotein 1	Mus musculus	101-104
12923450-2	2003	Transforming growth factor (TGF)-beta(1) has been associated with tumor invasion and metastasis, and we have implicated cyclosporine-associated TGF-beta(1) hyperexpression in tumor progression in mice.	Cyclosporine	120-132	transforming growth factor, beta 1	Mus musculus	144-155
12928607-0	2003	[Interstial pneumonia, which activity was reflected on KL-6, associated with dermatomyositis successfully treated with cyclosporin A].	Cyclosporine	119-132	mucin 1, cell surface associated	Homo sapiens	55-59
14523907-2	2003	The CaN inhibitor drugs, such as cyclosporin A (CyA), carried by cyclophillin, and tacrolimus, carried by FK-binding protein-12 (FKBP-12), inhibit the binding with the regulatory subunit CaNB.	Cyclosporine	33-46	FKBP prolyl isomerase 1A	Homo sapiens	106-127
14523907-2	2003	The CaN inhibitor drugs, such as cyclosporin A (CyA), carried by cyclophillin, and tacrolimus, carried by FK-binding protein-12 (FKBP-12), inhibit the binding with the regulatory subunit CaNB.	Cyclosporine	33-46	FKBP prolyl isomerase 1A	Homo sapiens	129-136
14523907-2	2003	The CaN inhibitor drugs, such as cyclosporin A (CyA), carried by cyclophillin, and tacrolimus, carried by FK-binding protein-12 (FKBP-12), inhibit the binding with the regulatory subunit CaNB.	Cyclosporine	48-51	FKBP prolyl isomerase 1A	Homo sapiens	106-127
14523907-2	2003	The CaN inhibitor drugs, such as cyclosporin A (CyA), carried by cyclophillin, and tacrolimus, carried by FK-binding protein-12 (FKBP-12), inhibit the binding with the regulatory subunit CaNB.	Cyclosporine	48-51	FKBP prolyl isomerase 1A	Homo sapiens	129-136
12873538-1	2003	BACKGROUND: Cyclosporin (CsA) dose selection is complicated by significant pharmacokinetic variability between patients.	Cyclosporine	12-23	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	25-28
12777850-15	2003	TGF-beta1 expression was lower in animals treated with cyclosporine, probably because of cellular toxicity.	Cyclosporine	55-67	transforming growth factor beta 1	Sus scrofa	0-9
21220920-3	2010	Some drugs like Cyclosporin-A (CsA) are discussed to interfere with the activity of TonEBP and thereby mediate their nephrotoxic effects.	Cyclosporine	16-29	nuclear factor of activated T-cells 5	Rattus norvegicus	84-90
21220920-3	2010	Some drugs like Cyclosporin-A (CsA) are discussed to interfere with the activity of TonEBP and thereby mediate their nephrotoxic effects.	Cyclosporine	31-34	nuclear factor of activated T-cells 5	Rattus norvegicus	84-90
20190490-4	2010	Intravenous boluses of cyclophosphamide (IVCY) with oral prednisolone and cyclosporin A induced remission of SLE, and a subsequent disappearance of anti-insulin receptor autoantibodies, followed by a recovery of glucose intolerance.	Cyclosporine	74-87	insulin receptor	Homo sapiens	153-169
12730016-7	2003	We found that cyclosporine A (CsA) treatment of TBA B4-3 cells induces a partial inhibition of IFN-gamma secretion, thus indicating a minor role for the calcineurin signaling pathway in IFN-gamma expression.	Cyclosporine	14-28	interferon gamma	Sus scrofa	95-104
12730016-7	2003	We found that cyclosporine A (CsA) treatment of TBA B4-3 cells induces a partial inhibition of IFN-gamma secretion, thus indicating a minor role for the calcineurin signaling pathway in IFN-gamma expression.	Cyclosporine	14-28	interferon gamma	Sus scrofa	186-195
20131116-11	2010	CONCLUSION: After application of nitroglycerin, sBP is reduced immediately in HTX with uncontrolled cyclosporine-induced hypertension.	Cyclosporine	100-112	selenium binding protein 1	Homo sapiens	48-51
12730016-7	2003	We found that cyclosporine A (CsA) treatment of TBA B4-3 cells induces a partial inhibition of IFN-gamma secretion, thus indicating a minor role for the calcineurin signaling pathway in IFN-gamma expression.	Cyclosporine	30-33	interferon gamma	Sus scrofa	95-104
12730016-7	2003	We found that cyclosporine A (CsA) treatment of TBA B4-3 cells induces a partial inhibition of IFN-gamma secretion, thus indicating a minor role for the calcineurin signaling pathway in IFN-gamma expression.	Cyclosporine	30-33	interferon gamma	Sus scrofa	186-195
12697421-8	2003	In addition, anti-inflammatory drugs dexamethasone (DEX) and cyclosporin A (CSA) both blocked activation of JNKS/SAPK and the cell-cell contact induced production of hRPE IL-8 and MCP-1, while activation of p38 and ERK was only inhibited by DEX, but not by CSA.	Cyclosporine	61-74	chemokine (C-X-C motif) ligand 15	Mus musculus	171-175
12697421-8	2003	In addition, anti-inflammatory drugs dexamethasone (DEX) and cyclosporin A (CSA) both blocked activation of JNKS/SAPK and the cell-cell contact induced production of hRPE IL-8 and MCP-1, while activation of p38 and ERK was only inhibited by DEX, but not by CSA.	Cyclosporine	76-79	chemokine (C-X-C motif) ligand 15	Mus musculus	171-175
12570836-1	2003	Cyclosporin A (CSA) has transformed clinical transplantation, both in term of success and of quality-of-life of the patient.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
12694545-6	2003	COS cells transfected with porcine CD80 was able to activate human T cells in a cyclosporine independent manner, demonstrating that porcine CD80 can costimulate human T cells.	Cyclosporine	80-92	CD80 molecule	Homo sapiens	35-39
12694545-6	2003	COS cells transfected with porcine CD80 was able to activate human T cells in a cyclosporine independent manner, demonstrating that porcine CD80 can costimulate human T cells.	Cyclosporine	80-92	CD80 molecule	Homo sapiens	140-144
12672234-3	2003	Our current work highlights the further use of rational drug design and molecular modeling to produce a series of lck inhibitors that demonstrate cellular activity below 100 nM and are as efficacious as cyclosporin A in an in vivo mouse model of anti-CD3-induced IL-2 production.	Cyclosporine	203-216	lymphocyte protein tyrosine kinase	Mus musculus	114-117
12649386-9	2003	Also, the concomitant administration of GH and CsA caused lowered production of 16alpha-, 2alpha-, 6beta-, and 2beta-hydroxytestosterone as compared with the administration of GH with CsA vehicle and as compared with the administration of GH vehicle with CsA.	Cyclosporine	184-187	gonadotropin releasing hormone receptor	Rattus norvegicus	40-42
12649386-9	2003	Also, the concomitant administration of GH and CsA caused lowered production of 16alpha-, 2alpha-, 6beta-, and 2beta-hydroxytestosterone as compared with the administration of GH with CsA vehicle and as compared with the administration of GH vehicle with CsA.	Cyclosporine	184-187	gonadotropin releasing hormone receptor	Rattus norvegicus	176-178
12649386-9	2003	Also, the concomitant administration of GH and CsA caused lowered production of 16alpha-, 2alpha-, 6beta-, and 2beta-hydroxytestosterone as compared with the administration of GH with CsA vehicle and as compared with the administration of GH vehicle with CsA.	Cyclosporine	184-187	gonadotropin releasing hormone receptor	Rattus norvegicus	176-178
12649386-9	2003	Also, the concomitant administration of GH and CsA caused lowered production of 16alpha-, 2alpha-, 6beta-, and 2beta-hydroxytestosterone as compared with the administration of GH with CsA vehicle and as compared with the administration of GH vehicle with CsA.	Cyclosporine	184-187	gonadotropin releasing hormone receptor	Rattus norvegicus	40-42
12649386-9	2003	Also, the concomitant administration of GH and CsA caused lowered production of 16alpha-, 2alpha-, 6beta-, and 2beta-hydroxytestosterone as compared with the administration of GH with CsA vehicle and as compared with the administration of GH vehicle with CsA.	Cyclosporine	184-187	gonadotropin releasing hormone receptor	Rattus norvegicus	176-178
12649386-9	2003	Also, the concomitant administration of GH and CsA caused lowered production of 16alpha-, 2alpha-, 6beta-, and 2beta-hydroxytestosterone as compared with the administration of GH with CsA vehicle and as compared with the administration of GH vehicle with CsA.	Cyclosporine	184-187	gonadotropin releasing hormone receptor	Rattus norvegicus	176-178
19741014-4	2009	Inhibition of cyclophilin D by cyclosporine A (CsA) effectively opposed the MPT only in the presence of ADP and/or Mg(2+).	Cyclosporine	31-45	peptidylprolyl isomerase D	Homo sapiens	14-27
19741014-4	2009	Inhibition of cyclophilin D by cyclosporine A (CsA) effectively opposed the MPT only in the presence of ADP and/or Mg(2+).	Cyclosporine	47-50	peptidylprolyl isomerase D	Homo sapiens	14-27
19897783-6	2009	Cyclosporin also augmented CD54 expression in gingiva of mice injected with lipopolysaccharide.	Cyclosporine	0-11	intercellular adhesion molecule 1	Mus musculus	27-31
20034899-6	2009	RESULTS: CsA can increase fibrin deposition and the expression of TGF-beta1 in the renal tissue, which were significantly reduced after uPA treatment (P&lt;0.05).	Cyclosporine	9-12	plasminogen activator, urokinase	Rattus norvegicus	136-139
19923714-0	2009	Structure of cyclophilin from Leishmania donovani bound to cyclosporin at 2.6 A resolution: correlation between structure and thermodynamic data.	Cyclosporine	59-70	cyclophilin	Leishmania donovani	13-24
12654050-1	2003	Despite the introduction of a variety of new immunosuppressive agents, cyclosporine A (CsA) has maintained a strong position in pediatric transplantation (Tx).	Cyclosporine	71-85	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	87-90
19923714-4	2009	The crystal structure of cyclophilin from L. donovani complexed with cyclosporin has been solved at 2.6 A resolution.	Cyclosporine	69-80	cyclophilin	Leishmania donovani	25-36
18957484-6	2009	RESULTS: Treatment of PBL with leflunomide, cyclosporin A and FK-506 inhibited the IL-15-induced expression of both CD54 and CD69 by PBL, as well as TNF production in co-cultures of activated PBL and THP-1 cells.	Cyclosporine	44-57	CD69 molecule	Homo sapiens	125-129
12529276-7	2003	The upregulation of OPN mRNA and protein expression seen in CsA-treated rat kidneys was decreased 5 wk after CsA withdrawal and was further decreased after 10 wk.	Cyclosporine	60-63	secreted phosphoprotein 1	Rattus norvegicus	20-23
12529276-7	2003	The upregulation of OPN mRNA and protein expression seen in CsA-treated rat kidneys was decreased 5 wk after CsA withdrawal and was further decreased after 10 wk.	Cyclosporine	109-112	secreted phosphoprotein 1	Rattus norvegicus	20-23
12529276-9	2003	These findings suggest that OPN expression and macrophage infiltration decrease after long-term CsA withdrawal in rats with established chronic CsA nephropathy, and this is closely associated with recovery from renal injury.	Cyclosporine	96-99	secreted phosphoprotein 1	Rattus norvegicus	28-31
19857751-3	2009	METHODS: We compared the influence of CsA and MPA on the transcription levels of FOXP3 (Treg marker) and IL17 (TH-17 marker) in activated human peripheral blood mononuclear cells (PBMC).	Cyclosporine	38-41	forkhead box P3	Homo sapiens	81-86
12529276-9	2003	These findings suggest that OPN expression and macrophage infiltration decrease after long-term CsA withdrawal in rats with established chronic CsA nephropathy, and this is closely associated with recovery from renal injury.	Cyclosporine	144-147	secreted phosphoprotein 1	Rattus norvegicus	28-31
19404248-2	2009	There was considerable interindividual variation in the inhibitory effects of cyclosporine (CSA), tacrolimus (TAC), and prednisolone (PRD) but only a small amount of interindividual variation for mycophenolic acid (MPA).	Cyclosporine	78-90	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	92-95
12557154-10	2003	Cyclosporin A also blocked caspase-3 activation.	Cyclosporine	0-13	caspase 3	Rattus norvegicus	27-36
12538738-1	2003	TGF-beta is believed to play a central role in the development of Cyclosporin A (CsA)-induced nephropathy.	Cyclosporine	66-79	transforming growth factor, beta 1	Mus musculus	0-8
19494809-6	2009	UGT1A9*3 carriers displayed a 49% higher MPA AUC(0-12) when treated with tacrolimus and a 54% higher MPA AUC(0-12) when treated with cyclosporine (P &lt; 0.005).	Cyclosporine	133-145	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	0-6
12538738-1	2003	TGF-beta is believed to play a central role in the development of Cyclosporin A (CsA)-induced nephropathy.	Cyclosporine	81-84	transforming growth factor, beta 1	Mus musculus	0-8
12541065-1	2003	Murine macrophages were treated with various doses of cyclosporin A (CsA) to enhance the killing of Leishmania major parasites.	Cyclosporine	54-67	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	69-72
19540300-5	2009	After 63 days CsA intake, sHSPs translocated from a regular sarcomeric pattern to peripheral sarcolemma and intercalated discs, together with actin and desmin.	Cyclosporine	14-17	desmin	Rattus norvegicus	152-158
12636164-1	2003	PURPOSE: Aerosolized cyclosporine (aCsA) has proven to be an effective therapy for refractory acute and chronic rejection in lung transplant (LTx) patients.	Cyclosporine	21-33	acyl-CoA synthetase short chain family member 2	Homo sapiens	35-39
12636164-2	2003	The objective of this study is to evaluate the lung deposition and systemic absorption of aCsA after aerosolized cyclosporine administration in LTx patients in the immediate postoperative period.	Cyclosporine	113-125	acyl-CoA synthetase short chain family member 2	Homo sapiens	90-94
19666510-3	2009	Th2 cells that have upregulated T1ST2 produce IL-13, but not IL-4, in response to IL-33 plus a STAT5 activator in an antigen-independent, NF-kappaB-dependent, cyclosporin A (CsA)-resistant manner.	Cyclosporine	174-177	interleukin 33	Homo sapiens	82-87
19303679-1	2009	Corticosteroids and/or cyclosporine constitute the present therapeutic approach for patients with focal segmental glomerulosclerosis (FSGS).	Cyclosporine	23-35	actinin alpha 4	Homo sapiens	98-132
19303679-1	2009	Corticosteroids and/or cyclosporine constitute the present therapeutic approach for patients with focal segmental glomerulosclerosis (FSGS).	Cyclosporine	23-35	actinin alpha 4	Homo sapiens	134-138
19652395-3	2009	However, the molecular mechanisms underlying CsA-induced proliferation in HGF remain to be elucidated.	Cyclosporine	45-48	hepatocyte growth factor	Homo sapiens	74-77
14753416-0	2003	Calcineurin and cyclophilin D are differential targets of neuroprotection by immunosuppressants CsA and FK506 in ischemic brain damage.	Cyclosporine	96-99	peptidylprolyl isomerase F	Rattus norvegicus	16-29
14753416-5	2003	Both CsA and FK506 are specific inhibitors of immunophilins, (CsA inhibits cyclophilins, FK506 inhibits FKBPs), and of calcineurin, a type 2B Ser/Thr phosphatase that is abundant in the central nervous system.	Cyclosporine	5-8	peptidylprolyl isomerase F	Rattus norvegicus	75-87
14753416-5	2003	Both CsA and FK506 are specific inhibitors of immunophilins, (CsA inhibits cyclophilins, FK506 inhibits FKBPs), and of calcineurin, a type 2B Ser/Thr phosphatase that is abundant in the central nervous system.	Cyclosporine	62-65	peptidylprolyl isomerase F	Rattus norvegicus	75-87
12691305-11	2003	In the case of the combination of CsA with the highest concentrations of both PNAs, significant differences in colony growth inhibition between normal and CML CFU-GM were observed (p = 0.002 and p = 0.005, respectively, for 2-CdA and F-ara-A).	Cyclosporine	34-37	cytidine deaminase	Homo sapiens	226-229
12691305-12	2003	In conclusion, at the concentrations of the drugs used, a subadditive action was observed either between CsA and 2-CdA or between CsA and F-ara-A.	Cyclosporine	105-108	cytidine deaminase	Homo sapiens	115-118
19652395-8	2009	CsA increased the cell viability of HGF in a dose- and time-dependent manner.	Cyclosporine	0-3	hepatocyte growth factor	Homo sapiens	36-39
19652395-9	2009	Significantly, seventeen proteins were overexpressed in the CsA-treated HGF, whereas three proteins were found to be expressed less than the untreated cells.	Cyclosporine	60-63	hepatocyte growth factor	Homo sapiens	72-75
19652395-11	2009	The overexpression of peroxiredoxin 1 (Prx 1) confirmed by Western blotting and reduction of cytosolic reactive oxygen species (ROS) levels in the CsA-treated HGF demonstrated that Prx 1 may play a crucial role in the HGF proliferation induced by CsA.	Cyclosporine	147-150	hepatocyte growth factor	Homo sapiens	159-162
12584041-2	2003	Since OPG is downregulated by glucocorticoids and cyclosporine A in vitro we examined whether immunosuppressive therapy would play a role in the development of transplantation osteoporosis.	Cyclosporine	50-64	TNF receptor superfamily member 11b	Homo sapiens	6-9
19652395-11	2009	The overexpression of peroxiredoxin 1 (Prx 1) confirmed by Western blotting and reduction of cytosolic reactive oxygen species (ROS) levels in the CsA-treated HGF demonstrated that Prx 1 may play a crucial role in the HGF proliferation induced by CsA.	Cyclosporine	147-150	hepatocyte growth factor	Homo sapiens	218-221
19652395-11	2009	The overexpression of peroxiredoxin 1 (Prx 1) confirmed by Western blotting and reduction of cytosolic reactive oxygen species (ROS) levels in the CsA-treated HGF demonstrated that Prx 1 may play a crucial role in the HGF proliferation induced by CsA.	Cyclosporine	247-250	hepatocyte growth factor	Homo sapiens	159-162
19652395-12	2009	Upregulation of Galectin 3 in CsA-treated HGF indicated that it is related to CsA-induced proliferation.	Cyclosporine	30-33	galectin 3	Homo sapiens	16-26
19652395-12	2009	Upregulation of Galectin 3 in CsA-treated HGF indicated that it is related to CsA-induced proliferation.	Cyclosporine	30-33	hepatocyte growth factor	Homo sapiens	42-45
19652395-12	2009	Upregulation of Galectin 3 in CsA-treated HGF indicated that it is related to CsA-induced proliferation.	Cyclosporine	78-81	galectin 3	Homo sapiens	16-26
19652395-12	2009	Upregulation of Galectin 3 in CsA-treated HGF indicated that it is related to CsA-induced proliferation.	Cyclosporine	78-81	hepatocyte growth factor	Homo sapiens	42-45
19391111-8	2009	An increase in the expression of matrix metalloproteinase-2 (MMP-2) was evident in CsA-induced groups of rats, which was moderately reduced in SAC treated rats.	Cyclosporine	83-86	matrix metallopeptidase 2	Rattus norvegicus	33-59
19391111-8	2009	An increase in the expression of matrix metalloproteinase-2 (MMP-2) was evident in CsA-induced groups of rats, which was moderately reduced in SAC treated rats.	Cyclosporine	83-86	matrix metallopeptidase 2	Rattus norvegicus	61-66
19620774-5	2009	Systemic administration of VEGF or LPS in adult mice resulted in cyclosporine A-sensitive reactivation of the DSCR1s promoter and endogenous gene expression in a subset of organs, including the heart and brain.	Cyclosporine	65-79	regulator of calcineurin 1	Mus musculus	110-115
19178644-0	2009	The upregulation of cystatin C in human gingival fibroblasts stimulated with cyclosporine A.	Cyclosporine	77-91	cystatin C	Homo sapiens	20-30
19178644-3	2009	However, little is known about the correlation between cystatin C and cyclosporine A-induced gingival overgrowth.	Cyclosporine	70-84	cystatin C	Homo sapiens	55-65
19178644-4	2009	The aim of this study was to compare cystatin C expression in normal, healthy gingival tissues and cyclosporine A-induced gingival overgrowth specimens and further explore the potential mechanism that may result in cystatin C expression.	Cyclosporine	99-113	cystatin C	Homo sapiens	37-47
19178644-9	2009	RESULTS: The cystatin C staining in gingival tissue was stronger in the cyclosporine A-induced gingival overgrowth group than in the normal gingival group (p &lt; 0.05).	Cyclosporine	72-86	cystatin C	Homo sapiens	13-23
19178644-11	2009	Moreover, cystatin C expression was significantly higher in cyclosporine A-induced gingival overgrowth specimens with higher levels of inflammatory infiltrates (p &lt; 0.05).	Cyclosporine	60-74	cystatin C	Homo sapiens	10-20
19178644-12	2009	A concentration of 200 ng/mL cyclosporine A was found to increase cystatin C expression in HGFs in a time-dependent manner (p &lt; 0.05).	Cyclosporine	29-43	cystatin C	Homo sapiens	66-76
19178644-13	2009	The addition of periodontal pathogens and proinflammatory cytokines significantly increased the expression of cystatin C compared with cyclosporine A alone (p &lt; 0.05).	Cyclosporine	135-149	cystatin C	Homo sapiens	110-120
19178644-14	2009	CONCLUSION: The increased ability of protein accumulation by cystatin C is one of several factors mediating cyclosporine A-induced gingival overgrowth.	Cyclosporine	108-122	cystatin C	Homo sapiens	61-71
19477024-7	2009	The combination of N297A dosing with cyclosporine A (CSA) pretreatment showed a significant decrease of TNFalpha, IL-6 and IP-10 without effect on clinical efficacy.	Cyclosporine	37-51	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	53-56
19477024-7	2009	The combination of N297A dosing with cyclosporine A (CSA) pretreatment showed a significant decrease of TNFalpha, IL-6 and IP-10 without effect on clinical efficacy.	Cyclosporine	37-51	chemokine (C-X-C motif) ligand 10	Mus musculus	123-128
19148693-9	2009	Losartan, CsA or VIV abolished stretch-induced alterations in MMP-2/-9 and MT1-MMP expression and enzyme activity by normalizing the Cn-activity and the DNA binding activity of NFATc1.	Cyclosporine	10-13	matrix metallopeptidase 2	Rattus norvegicus	62-70
19148693-9	2009	Losartan, CsA or VIV abolished stretch-induced alterations in MMP-2/-9 and MT1-MMP expression and enzyme activity by normalizing the Cn-activity and the DNA binding activity of NFATc1.	Cyclosporine	10-13	matrix metallopeptidase 14	Rattus norvegicus	75-82
19393753-0	2009	Effect of FK506 and cyclosporine A on the expression of BDNF, tyrosine kinase B and p75 neurotrophin receptors in astrocytes exposed to simulated ischemia in vitro.	Cyclosporine	20-34	nerve growth factor receptor	Rattus norvegicus	84-87
12592084-2	2003	While systemic cyclosporin (CsA) represents a well-established therapy of psoriasis, its topical use is limited by the difficult penetration of the molecule through the skin and the nail because of its highly lipophilic nature.	Cyclosporine	15-26	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	28-31
20021159-3	2003	As previously reported, cultured rat hepatocytes exposed to CsA exhibited concentration-dependent signs of apoptotic cell injury, including chromatin condensation and fragmentation, increased caspase-3 activity, and release of cytosolic lactate dehydrogenase.	Cyclosporine	60-63	caspase 3	Rattus norvegicus	192-201
12499901-1	2002	BACKGROUND: Population data indicate that cyclosporine (CsA)-based immunosuppression has had relatively little effect on late renal allograft loss.	Cyclosporine	42-54	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	56-59
12445861-10	2002	Further, the results suggest that SDZ IMM125-induced uptake of extracellular calcium is also a redox-sensitive process and that the increased intracellular calcium might directly cause apoptosis by increasing the caspase-3 activity as a central event in the cyclosporine-induced apoptotic mechanism.	Cyclosporine	258-270	caspase 3	Rattus norvegicus	213-222
12452838-9	2002	Cyclosporin A equivalently suppressed DNA-binding activity of the composite NFAT/AP-1 site, promoter activity and protein production of IL-5.	Cyclosporine	0-13	interleukin 5	Homo sapiens	136-140
19393753-1	2009	We investigated whether the immunosuppressive drugs, FK506 and cyclosporine A, increase BDNF protein and/or mRNA expression in ischemic astrocytes and if an increase could be related to changes in the nuclear expression of p-CREB, p-Erk1/2 and p-Akt.	Cyclosporine	63-77	mitogen activated protein kinase 3	Rattus norvegicus	233-239
19357716-1	2009	Osteopontin, a secreted glycoprotein has been implicated in several renal pathological conditions such as those due to ureteral obstruction, ischemia, and cyclosporine toxicity.	Cyclosporine	155-167	secreted phosphoprotein 1	Mus musculus	0-11
12410861-8	2002	Also, in renal transplant patients initially immunosuppressed with rapamycin, cyclosporine and corticosteroids, after the elimination of CSA, a lower blood pressure is achieved.	Cyclosporine	78-90	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	137-140
12445178-6	2002	The administration of prednisolone (PSL) and cyclosporin (CsA) ameliorated laboratory data to a degree, but they did not return to normal.	Cyclosporine	45-56	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	58-61
12228224-5	2002	Caspase-3 activation induced by thapsigargin was blocked by increasing the phosphorylation of Ser-9-GSK3beta with insulin-like growth factor-1 or with the phosphatase inhibitors okadaic acid and calyculin A, but the calcineurin inhibitors FK506 and cyclosporin A were ineffective.	Cyclosporine	249-262	glycogen synthase kinase 3 beta	Homo sapiens	100-108
12377217-1	2002	Cyclosporin A (CsA) specifically inhibits mammalian T cells by preventing activation of transcription factors (termed nuclear factor of activated T cells (NFAT)) involved in cytokine gene expression.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
19481021-3	2009	However, these first-line statins possess a rather modest lipid-lowering effect and selection of alternative statins is limited due to interactions with cyclosporine (CsA).	Cyclosporine	153-165	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	167-170
19318235-5	2009	(3) Cyclosporin A (an inhibitor of the mPTP) inhibited both CaM-induced DeltaPsi(m) depolarization and calcein leakage.	Cyclosporine	4-17	calmodulin 1	Rattus norvegicus	60-63
19210333-1	2009	BACKGROUND AND OBJECTIVE: Membrane type-I matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase-2 (TIMP-2) regulate the activation of MMP-2; however, their roles in the activation of MMP-2 in gingiva during treatment with cyclosporine A are still unknown.	Cyclosporine	241-255	matrix metallopeptidase 2	Homo sapiens	68-71
12469945-2	2002	In the present study, we developed a flow cytometric assay detecting intracellular IL-12 production by human CD14+ monocytes in order to assess the in vitro effects of widely used immunosuppressants, such as cyclosporine (CsA), sirolimus (SRL) and dexamethasone (DXM).	Cyclosporine	208-220	CD14 molecule	Homo sapiens	109-113
12469945-2	2002	In the present study, we developed a flow cytometric assay detecting intracellular IL-12 production by human CD14+ monocytes in order to assess the in vitro effects of widely used immunosuppressants, such as cyclosporine (CsA), sirolimus (SRL) and dexamethasone (DXM).	Cyclosporine	222-225	CD14 molecule	Homo sapiens	109-113
12479636-7	2002	RESULTS: CsA simultaneously stimulated TGF-beta1 expression and production and inhibited expression of MMP-1 and MMP-2 by human gingival fibroblasts, whereas CsA has a slight effect on TIMP-1 and TIMP-2 expression.	Cyclosporine	9-12	matrix metallopeptidase 2	Homo sapiens	113-118
19210333-1	2009	BACKGROUND AND OBJECTIVE: Membrane type-I matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase-2 (TIMP-2) regulate the activation of MMP-2; however, their roles in the activation of MMP-2 in gingiva during treatment with cyclosporine A are still unknown.	Cyclosporine	241-255	matrix metallopeptidase 2	Rattus norvegicus	153-158
19210333-8	2009	The expression of MMP-2 mRNA was unaffected but the expression of MMP-2 protein showed a significant decrease upon treatment with cyclosporine A.	Cyclosporine	130-144	matrix metallopeptidase 2	Rattus norvegicus	18-23
19210333-8	2009	The expression of MMP-2 mRNA was unaffected but the expression of MMP-2 protein showed a significant decrease upon treatment with cyclosporine A.	Cyclosporine	130-144	matrix metallopeptidase 2	Rattus norvegicus	66-71
12351834-1	2002	Cyclophilin from the parasite Leishmania donovani is a protein with peptidylprolyl cis-trans isomerase activity, in addition to being a receptor for the drug cyclosporin.	Cyclosporine	158-169	cyclophilin	Leishmania donovani	0-11
19210333-9	2009	In fibroblast culture medium, the presence of cyclosporine A induced a decrease in MMP-2 activity in a dose-dependent manner.	Cyclosporine	46-60	matrix metallopeptidase 2	Rattus norvegicus	83-88
19210333-11	2009	CONCLUSION: Cyclosporine A inhibits the expression of membrane type-I MMP in gingiva and it may further reduce the activation of MMP-2.	Cyclosporine	12-26	matrix metallopeptidase 2	Rattus norvegicus	129-134
19450280-7	2009	Bioinformatic analysis of NFAT-sites of the group of transcripts similarly regulated by Itk-deficiency and CsA-treatment, followed by chromatin-immunoprecipitation, revealed NFATc1-binding to the Bub1, IL7R, Ctla2a, Ctla2b, and Schlafen1 genes.	Cyclosporine	107-110	interleukin 7 receptor	Homo sapiens	202-206
12207006-2	2002	Data regarding the role of cyclosporine (CsA) and FK-506 in AMT have shown that CsA is less effective than FK-506.	Cyclosporine	27-39	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	41-44
12207006-2	2002	Data regarding the role of cyclosporine (CsA) and FK-506 in AMT have shown that CsA is less effective than FK-506.	Cyclosporine	27-39	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	80-83
19244478-7	2009	Both effects of TG and PE are dependent on NFAT dephosphorylation by CN, as demonstrated by CN inhibition with cyclosporine (CsA).	Cyclosporine	111-123	nuclear factor of activated T-cells 5	Rattus norvegicus	43-47
12395977-1	2002	OBJECTIVE: The aim of the present study was to investigate the effect of grapefruit juice on the pharmacokinetics of cyclosporin A (CsA), as Sandimmun Neoral, and its main metabolites, M1, M9 and M4N, in renal transplant recipients.	Cyclosporine	117-130	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	132-135
12239231-0	2002	Cyclosporine A suppresses cyclooxygenase-2 expression in the rat kidney.	Cyclosporine	0-14	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	26-42
12239231-4	2002	Furthermore, CsA blunted the increase of renocortical COX-2 expression in response to low salt intake or a combination of low-salt diet with the ACE inhibitor ramipril (10 mg/kg per day), which strongly stimulates renocortical COX-2 expression.	Cyclosporine	13-16	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	54-59
19244478-7	2009	Both effects of TG and PE are dependent on NFAT dephosphorylation by CN, as demonstrated by CN inhibition with cyclosporine (CsA).	Cyclosporine	125-128	nuclear factor of activated T-cells 5	Rattus norvegicus	43-47
12239231-4	2002	Furthermore, CsA blunted the increase of renocortical COX-2 expression in response to low salt intake or a combination of low-salt diet with the ACE inhibitor ramipril (10 mg/kg per day), which strongly stimulates renocortical COX-2 expression.	Cyclosporine	13-16	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	227-232
19187006-6	2009	Inhibition of CypD by cyclosporin A or abrogation of its expression by siRNA significantly suppressed the cytotoxicity of HNK, suggesting that CypD may be a key molecule that mediates the cytotoxicity.	Cyclosporine	22-35	peptidylprolyl isomerase D	Homo sapiens	14-18
18794188-2	2009	Given mixed evidence regarding the strength of the relationship between CSA and adolescent pregnancy (Blinn-Pike, Berger, Dixon, Kuschel, &amp; Kaplan, 2002), our objective was to provide an estimate of the effect size of this relationship using updated literature and meta-analytic techniques.	Cyclosporine	72-75	ArfGAP with GTPase domain, ankyrin repeat and PH domain 2	Homo sapiens	108-112
12218323-8	2002	Of note, the upregulated expression of osteopontin mRNA and protein seen in CsA-treated rats was significantly decreased after colchicine treatment.	Cyclosporine	76-79	secreted phosphoprotein 1	Rattus norvegicus	39-50
12364856-8	2002	Concomitantly, CsA markedly up-regulated expression of chemoattractant proteins, osteopontin, and monocyte chemoattractant protein-1.	Cyclosporine	15-18	secreted phosphoprotein 1	Rattus norvegicus	81-92
19460557-2	2009	BACKGROUND: Cyclosporine (CsA) renal toxicity is a well-known side effect.	Cyclosporine	12-24	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	26-29
19359911-13	2009	CsA treatment decreased the HS-induced rise in cytosolic cytochrome c levels and caspase-3 activity (p &lt; 0.05).	Cyclosporine	0-3	caspase 3	Rattus norvegicus	81-90
19359911-14	2009	CONCLUSIONS: These findings demonstrate that CsA protects mitochondrial permeability transition pores to prevent HS-induced release of cytochrome c and caspase-3 activation.	Cyclosporine	45-48	caspase 3	Rattus norvegicus	152-161
19376366-1	2009	Immunosuppressive drugs, such as tacrolimus (FK506) and cyclosporine (CsA), play an essential role in graft survival, preventing rejection.	Cyclosporine	56-68	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	70-73
19136475-4	2009	Xpa/p53 mice exposed to CsA for 39 weeks showed a significantly increased lymphoma incidence as compared with untreated Xpa/p53 mice and CsA-treated wild-type (WT) mice.	Cyclosporine	24-27	xeroderma pigmentosum, complementation group A	Mus musculus	0-3
19136475-4	2009	Xpa/p53 mice exposed to CsA for 39 weeks showed a significantly increased lymphoma incidence as compared with untreated Xpa/p53 mice and CsA-treated wild-type (WT) mice.	Cyclosporine	137-140	xeroderma pigmentosum, complementation group A	Mus musculus	0-3
19136475-5	2009	We excluded concealed genotoxicity of CsA in Xpa/p53 mice by mutant frequency analyses.	Cyclosporine	38-41	xeroderma pigmentosum, complementation group A	Mus musculus	45-48
19066978-1	2009	Cyclosporine (CsA) treatment in immunoglobulin A nephropathy (IgAN) is controversial and has not been widely studied.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
12204109-0	2002	The chaperone activity of protein disulfide isomerase is affected by cyclophilin B and cyclosporin A in vitro.	Cyclosporine	87-100	prolyl 4-hydroxylase subunit beta	Bos taurus	26-53
12204109-4	2002	However, the complex of Cyp B and CsA completely inhibited the chaperone activity of PDI.	Cyclosporine	34-37	prolyl 4-hydroxylase subunit beta	Bos taurus	85-88
12193060-0	2002	HMG-CoA reductase inhibition and PPAR- alpha activation both inhibit cyclosporin A induced endothelin-1 secretion in cultured endothelial cells.	Cyclosporine	69-82	3-hydroxy-3-methylglutaryl-CoA reductase	Bos taurus	0-17
19066978-1	2009	Cyclosporine (CsA) treatment in immunoglobulin A nephropathy (IgAN) is controversial and has not been widely studied.	Cyclosporine	0-12	IGAN1	Homo sapiens	62-66
18716711-2	2009	METHODS: One-hundred and seventy-four cyclosporin (CsA)-treated renal transplant recipients were studied.	Cyclosporine	38-49	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	51-54
12358793-8	2002	Choline uptake by oocytes expressing tCHT1 was inhibited by all three immunosuppressors and also by microinjection of the specific calcineurin autoinhibitory domain A457-481, indicating that the phosphatase calcineurin regulates CHT1 activity and could be the common target of cyclosporin and FK506.	Cyclosporine	277-288	solute carrier family 5 (sodium/choline cotransporter), member 7 L homeolog	Xenopus laevis	38-42
19148552-3	2009	In the present study, we investigated the effects of tacrolimus (FK506) and cyclosporine A, well-known immunosuppressants, on the FGF-2-induced VEGF release in these cells.	Cyclosporine	76-90	fibroblast growth factor 2	Mus musculus	130-135
12097397-4	2002	Cross-linking of neutrophil-expressed CD28 by monoclonal anti-CD28 Ab or B7.1-Ig or B7.2-Ig results in phosphatidylinositol 3-kinase association with CD28 and in wortmannin-sensitive but cyclosporin A-resistant induction and secretion of IFN-gamma.	Cyclosporine	187-200	CD28 molecule	Homo sapiens	38-42
18973526-8	2009	CONCLUSION: Based on the present findings, we suggest that: (1) CsA upregulates the gingival expression of ET-1 and its receptors; and (2) ET(A) and ET(B) have different bioactivities, ET(A) being involved in cell proliferation and ET(B) being associated with iNOS expression.	Cyclosporine	64-67	endothelin receptor type B	Rattus norvegicus	149-154
12097397-4	2002	Cross-linking of neutrophil-expressed CD28 by monoclonal anti-CD28 Ab or B7.1-Ig or B7.2-Ig results in phosphatidylinositol 3-kinase association with CD28 and in wortmannin-sensitive but cyclosporin A-resistant induction and secretion of IFN-gamma.	Cyclosporine	187-200	CD28 molecule	Homo sapiens	62-66
12097397-4	2002	Cross-linking of neutrophil-expressed CD28 by monoclonal anti-CD28 Ab or B7.1-Ig or B7.2-Ig results in phosphatidylinositol 3-kinase association with CD28 and in wortmannin-sensitive but cyclosporin A-resistant induction and secretion of IFN-gamma.	Cyclosporine	187-200	CD28 molecule	Homo sapiens	62-66
18973526-8	2009	CONCLUSION: Based on the present findings, we suggest that: (1) CsA upregulates the gingival expression of ET-1 and its receptors; and (2) ET(A) and ET(B) have different bioactivities, ET(A) being involved in cell proliferation and ET(B) being associated with iNOS expression.	Cyclosporine	64-67	endothelin receptor type A	Rattus norvegicus	185-190
12402553-7	2002	In experimental models of inflammatory RNN and non-inflammatory CPAN nephropathy CsA raised fibronectin production, MP increased deposition of laminine.	Cyclosporine	81-84	DNA fragmentation factor subunit beta	Homo sapiens	64-68
18973526-8	2009	CONCLUSION: Based on the present findings, we suggest that: (1) CsA upregulates the gingival expression of ET-1 and its receptors; and (2) ET(A) and ET(B) have different bioactivities, ET(A) being involved in cell proliferation and ET(B) being associated with iNOS expression.	Cyclosporine	64-67	endothelin receptor type B	Rattus norvegicus	232-237
19094963-6	2009	CSA elicited specific induction of cardiac lineage from mesoderm in a novel mesoderm-specific, NFAT independent fashion.	Cyclosporine	0-3	nuclear factor of activated T-cells 5	Rattus norvegicus	95-99
12065418-5	2002	Moreover, IL-2Ralpha induction is impaired in T lymphocytes from transgenic mice expressing a dominant-negative c-jun construct, or following treatment with cyclosporin A.	Cyclosporine	157-170	jun proto-oncogene	Mus musculus	112-117
19956430-11	2009	Cyclosporin A induces nuclear membrane translocation of NFAT-5 in cultured keratinocytes and raffinose (a hypertonicity inducing agent) induces more nuclear localization of NFAT-5 compared to untreated cells.	Cyclosporine	0-13	nuclear factor of activated T cells 5	Homo sapiens	56-62
19956430-14	2009	CsA and raffinose effects on NFAT-5/TonEBP in cultured keratinocytes suggest diverse intracellular signaling pathways for NFAT-5/TonEBP in these cells, and that NFAT-5/TonEBP might function to translate different extracellular stimuli into appropriate functional responses.	Cyclosporine	0-3	nuclear factor of activated T cells 5	Homo sapiens	29-35
19956430-14	2009	CsA and raffinose effects on NFAT-5/TonEBP in cultured keratinocytes suggest diverse intracellular signaling pathways for NFAT-5/TonEBP in these cells, and that NFAT-5/TonEBP might function to translate different extracellular stimuli into appropriate functional responses.	Cyclosporine	0-3	nuclear factor of activated T cells 5	Homo sapiens	36-42
19956430-14	2009	CsA and raffinose effects on NFAT-5/TonEBP in cultured keratinocytes suggest diverse intracellular signaling pathways for NFAT-5/TonEBP in these cells, and that NFAT-5/TonEBP might function to translate different extracellular stimuli into appropriate functional responses.	Cyclosporine	0-3	nuclear factor of activated T cells 5	Homo sapiens	122-128
19956430-14	2009	CsA and raffinose effects on NFAT-5/TonEBP in cultured keratinocytes suggest diverse intracellular signaling pathways for NFAT-5/TonEBP in these cells, and that NFAT-5/TonEBP might function to translate different extracellular stimuli into appropriate functional responses.	Cyclosporine	0-3	nuclear factor of activated T cells 5	Homo sapiens	129-135
19956430-14	2009	CsA and raffinose effects on NFAT-5/TonEBP in cultured keratinocytes suggest diverse intracellular signaling pathways for NFAT-5/TonEBP in these cells, and that NFAT-5/TonEBP might function to translate different extracellular stimuli into appropriate functional responses.	Cyclosporine	0-3	nuclear factor of activated T cells 5	Homo sapiens	122-128
19956430-14	2009	CsA and raffinose effects on NFAT-5/TonEBP in cultured keratinocytes suggest diverse intracellular signaling pathways for NFAT-5/TonEBP in these cells, and that NFAT-5/TonEBP might function to translate different extracellular stimuli into appropriate functional responses.	Cyclosporine	0-3	nuclear factor of activated T cells 5	Homo sapiens	129-135
18945718-7	2009	Mitochondrial [Ca(2+)] remained elevated long after the end of stimulation in muscle cells from terminally ill Tfam KO mice, and the increase was smaller in the presence of the cyclophilin D-binding inhibitor cyclosporin A.	Cyclosporine	209-222	transcription factor A, mitochondrial	Mus musculus	111-115
19028555-6	2009	The effects were inhibited by cyclosporine A (CsA), suggesting that the activation of NFAT by AhR or HIF-1alpha signaling is calcineurin-dependent.	Cyclosporine	30-44	aryl hydrocarbon receptor	Homo sapiens	94-97
19028555-6	2009	The effects were inhibited by cyclosporine A (CsA), suggesting that the activation of NFAT by AhR or HIF-1alpha signaling is calcineurin-dependent.	Cyclosporine	46-49	aryl hydrocarbon receptor	Homo sapiens	94-97
19218792-3	2009	Here we hypothesized that the immunosuppressant ciclosporin A (CsA), known for its profibrotic side effect, promotes myofibroblast differentiation of BMDC in the postischemic kidney.	Cyclosporine	63-66	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	48-61
19779801-1	2009	Cyclosporine A (CsA) is a well-characterized anti-HCV reagent.	Cyclosporine	0-14	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	16-19
19076452-6	2008	These studies suggest that PTP opening may represent the final common pathway for skeletal muscle fiber death; and provided a rationale for a pilot clinical trial with cyclosporin A in patients affected by UCMD and BM, a study that holds great promise for the future treatment of collagen VI myopathies.	Cyclosporine	168-181	protein tyrosine phosphatase receptor type U	Homo sapiens	27-30
18768853-4	2008	Ionomycin induces p38 phosphorylation through a calcium-dependent, cyclosporine A-inhibitable pathway.	Cyclosporine	67-81	mitogen-activated protein kinase 14	Mus musculus	18-21
18628650-1	2008	A major side effect of the powerful immunosuppressive drug cyclosporine (CsA) is the development of a chronic nephrotoxicity whose mechanisms are not fully understood.	Cyclosporine	59-71	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	73-76
18622283-3	2008	RESULTS: At 12 months, there was a significant improvement in renal function in the reduced TAC versus CsA group with lower serum creatinine (P=0.004) and cystatin C (P&lt;0.001), and higher estimated creatinine clearance (P=0.017).	Cyclosporine	103-106	cystatin C	Homo sapiens	155-165
18560520-5	2008	Downregulation of Grx1 by shRNA results in loss of mitochondrial membrane potential (MMP), which is prevented by the thiol antioxidant, alpha-lipoic acid, or by cyclosporine A, an inhibitor of mitochondrial permeability transition.	Cyclosporine	161-175	glutaredoxin	Homo sapiens	18-22
24459518-7	2008	COMP-Ang1 administration also decreased increased macrophage infiltration, adhesion molecule expression, TGF-beta1, and Smad 2/3 levels in CsA-treated kidneys, while increasing Smad 7 levels.	Cyclosporine	139-142	transforming growth factor, beta 1	Mus musculus	105-114
12036883-0	2002	Effect of rapamycin on the cyclosporin A-resistant CD28-mediated costimulatory pathway.	Cyclosporine	27-40	CD28 molecule	Homo sapiens	51-55
12036883-4	2002	The signaling event mediated by CD28 engagement has been proposed to have 2 components: one is sensitive to the immunosuppressive drug cyclosporin A (CsA), and the other one is CsA-resistant.	Cyclosporine	135-148	CD28 molecule	Homo sapiens	32-36
12036883-4	2002	The signaling event mediated by CD28 engagement has been proposed to have 2 components: one is sensitive to the immunosuppressive drug cyclosporin A (CsA), and the other one is CsA-resistant.	Cyclosporine	150-153	CD28 molecule	Homo sapiens	32-36
12036883-4	2002	The signaling event mediated by CD28 engagement has been proposed to have 2 components: one is sensitive to the immunosuppressive drug cyclosporin A (CsA), and the other one is CsA-resistant.	Cyclosporine	177-180	CD28 molecule	Homo sapiens	32-36
18455125-7	2008	Treatment with the specific pharmacological calcineurin inhibitor cyclosporin A rescues this endothelial defect in DSCR1(-/-) mice, restoring tumor growth.	Cyclosporine	66-79	regulator of calcineurin 1	Mus musculus	115-120
18477227-5	2008	The serum IL-2 receptor, TNF-alpha and IL-5 levels of patients before CsA treatment were statistically higher than those of the control group (P = 0.001), and after 4 weeks of CsA therapy the mean IL-2R, TNF-alpha and IL-5 levels were significantly decreased.	Cyclosporine	176-179	interleukin 2 receptor subunit alpha	Homo sapiens	197-202
18281604-6	2008	Potentiation of VASP Ser(157) phosphorylation by either phosphatase 2B inhibition with cyclosporin or protein kinase A activation with forskolin prolonged, rather than inhibited, the increased permeability caused by H(2)O(2).	Cyclosporine	87-98	vasodilator stimulated phosphoprotein	Homo sapiens	16-20
12109811-8	2002	This fluorescence decrease could be completely prevented by the PTP blocker cyclosporin A.	Cyclosporine	76-89	protein tyrosine phosphatase receptor type U	Homo sapiens	64-67
12029627-6	2002	There was release of mitochondrial cytochrome c into the cytosol and activation of caspase 3, which were prevented by cyclosporine, diallylsulfide, and Trolox.	Cyclosporine	118-130	caspase 3	Rattus norvegicus	83-92
12042638-8	2002	RESULTS: Intrarenal expression of TGF-beta, collagen, fibronectin, MMP-2, MMP-9, and tissue inhibitor of MMP-2 was significantly increased in rats treated with CsA for 180 days compared with untreated rats and those treated for 30 days.	Cyclosporine	160-163	matrix metallopeptidase 2	Rattus norvegicus	67-72
12042638-8	2002	RESULTS: Intrarenal expression of TGF-beta, collagen, fibronectin, MMP-2, MMP-9, and tissue inhibitor of MMP-2 was significantly increased in rats treated with CsA for 180 days compared with untreated rats and those treated for 30 days.	Cyclosporine	160-163	matrix metallopeptidase 2	Rattus norvegicus	105-110
12102473-2	2002	OBJECTIVE: To evaluate the ability of two different combination therapies with prednisone (PDN), methotrexate (MTX) and cyclosporine (CSA) to modulate both TNFalpha transcription and production in early rheumatoid arthritis (RA).	Cyclosporine	120-132	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	134-137
11956176-0	2002	Cyclosporine a and FK506 inhibit transcriptional activity of the human mineralocorticoid receptor: a cell-based model to investigate partial aldosterone resistance in kidney transplantation.	Cyclosporine	0-14	nuclear receptor subfamily 3 group C member 2	Homo sapiens	71-97
11956176-1	2002	Renal transplant recipients treated with cyclosporine A (CsA) and FK506 (tacrolimus) develop signs of hypoaldosteronism despite normal plasma aldosterone levels, suggesting a relative resistance of the distal nephron to aldosterone action.	Cyclosporine	41-55	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	57-60
18374784-9	2008	Endothelin(A) receptor expression was increased in all treatment groups with a synergistic effect seen after cyclosporine A + hydrocortisone treatment.	Cyclosporine	109-123	endothelin receptor type A	Rattus norvegicus	0-22
18375578-5	2008	Cyclosporine A inhibited hypertrophy and NFAT translocation, but not the increased oscillation frequency.	Cyclosporine	0-14	nuclear factor of activated T-cells 5	Rattus norvegicus	41-45
19099959-7	2008	Treatment with SIN alone did not affect gene expressions of bFGF, VEGF, and ET-1 while expressions of bFGF, VEGF, and ET-1 were significantly reduced by combined treatment with SIN and CsA.	Cyclosporine	185-188	fibroblast growth factor 2	Rattus norvegicus	102-106
18212629-8	2008	Interestingly, posttransplant administration of donor Ag-pulsed Rapa DC to rats given perioperative ALS and 21 days CsA significantly delayed graft rejection and promoted long-term (&gt;125 days) graft survival.	Cyclosporine	116-119	transcriptional regulating factor 1	Homo sapiens	64-68
18040888-5	2008	More importantly, metformin, together with the PTP classical inhibitor cyclosporin A (CsA), strongly mitigated the activation of this apoptotic cascade.	Cyclosporine	71-84	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	86-89
17885208-4	2008	Moreover, inactivation of NFATc1 by cyclosporin A treatment attenuates expression of Atp6v0d2 and DC-STAMP and subsequent fusion process of osteoclasts.	Cyclosporine	36-49	dendrocyte expressed seven transmembrane protein	Homo sapiens	98-106
17881460-6	2007	Administration with cyclosporine A (2.5 mg.kg(-1).day(-1)) during the postnatal period remarkably suppressed renal COX-2 expression as assessed by both immunoblotting and immunohistochemistry.	Cyclosporine	20-34	cytochrome c oxidase II, mitochondrial	Mus musculus	115-120
17853438-3	2007	In the present study we used the MPT inhibitor cyclosporine-A (CsA) to preserve mitochondrial NAD(+) pools during PARP-1 activation and thereby provide an estimate of mitochondrial NAD(+) pool size in different cell types.	Cyclosporine	47-61	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	63-66
17853438-6	2007	Inhibition of the mitochondrial permeability transition with cyclosporine-A (CsA) prevented PARP-1-induced NAD(+) depletion to a varying degree in the four cell types tested.	Cyclosporine	61-75	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	77-80
11981427-8	2002	In addition, a short course of cyclosporine therapy synergized with either anti-CD28 monoclonal antibody or CTLA4 immunoglobulin, suggesting that it may be clinically relevant to combine low-dose calcineurin inhibitors with CTLA4 immunoglobulin or anti-B7 antibodies.	Cyclosporine	31-43	CD28 molecule	Homo sapiens	80-84
17959987-6	2007	Cyclosporine"s central actions can be better evaluated in mdr1a knockout mice that lack P-glycoprotein.	Cyclosporine	0-12	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	58-63
11956130-7	2002	Treatment with either cyclosporin A or verapamil prevented increases in heart weight to body weight ratios, interstitial fibrosis, impaired contractility, PKC activation, and changes in the expression patterns of beta-MHC and SERCA2a.	Cyclosporine	22-35	myosin, heavy polypeptide 7, cardiac muscle, beta	Mus musculus	213-221
17959987-9	2007	On the other hand, the lower doses of cyclosporine significantly increased both pentobarbital- and ketamine-induced sleep durations in mdr1a knockout mice.	Cyclosporine	38-50	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	135-140
18021968-2	2007	In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients.	Cyclosporine	94-106	interleukin 2 receptor subunit alpha	Homo sapiens	161-165
11931977-4	2002	Opening of the MTP is inhibited by means of cyclosporine A.	Cyclosporine	44-58	microsomal triglyceride transfer protein	Rattus norvegicus	15-18
11903043-5	2002	The activation of all four caspases was inhibited by cyclosporin A, with the order of susceptibility caspase-8=caspase-9=caspase-6&gt;caspase-3.	Cyclosporine	53-66	caspase 3	Rattus norvegicus	134-143
18021968-2	2007	In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients.	Cyclosporine	94-106	interleukin 2 receptor subunit alpha	Homo sapiens	176-180
11903043-6	2002	To identify the possible locus of cyclosporin A action, we used an antisense oligodeoxynucleotide to suppress the level of cyclophilin-A to&lt;5% of its control value.	Cyclosporine	34-47	peptidylprolyl isomerase A	Rattus norvegicus	123-136
11903043-7	2002	Cyclophilin-A suppression largely reproduced the inhibitory effects of cyclosporin A.	Cyclosporine	71-84	peptidylprolyl isomerase A	Rattus norvegicus	0-13
18021968-2	2007	In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients.	Cyclosporine	94-106	interleukin 2 receptor subunit alpha	Homo sapiens	176-180
11903043-9	2002	It is concluded that neuroprotection by cyclosporin A against excitotoxin-induced apoptosis is, at least partly, due to inhibition of cyclophilin-A.	Cyclosporine	40-53	peptidylprolyl isomerase A	Rattus norvegicus	134-147
18021968-2	2007	In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients.	Cyclosporine	108-111	interleukin 2 receptor subunit alpha	Homo sapiens	161-165
18021968-9	2007	CsA therapy resulted in a reduction in the percentage of CD4(+)CD25(+)CTLA-4(+) and CD4(+)CD25(+)Foxp3(+) regulatory T cells after renal transplantation in both groups (RAR-S and RAR-CH) compared with patients treated with rapamycin or to healthy donors.	Cyclosporine	0-3	interleukin 2 receptor subunit alpha	Homo sapiens	63-67
18021968-9	2007	CsA therapy resulted in a reduction in the percentage of CD4(+)CD25(+)CTLA-4(+) and CD4(+)CD25(+)Foxp3(+) regulatory T cells after renal transplantation in both groups (RAR-S and RAR-CH) compared with patients treated with rapamycin or to healthy donors.	Cyclosporine	0-3	interleukin 2 receptor subunit alpha	Homo sapiens	90-94
18021968-9	2007	CsA therapy resulted in a reduction in the percentage of CD4(+)CD25(+)CTLA-4(+) and CD4(+)CD25(+)Foxp3(+) regulatory T cells after renal transplantation in both groups (RAR-S and RAR-CH) compared with patients treated with rapamycin or to healthy donors.	Cyclosporine	0-3	forkhead box P3	Homo sapiens	97-102
18021968-9	2007	CsA therapy resulted in a reduction in the percentage of CD4(+)CD25(+)CTLA-4(+) and CD4(+)CD25(+)Foxp3(+) regulatory T cells after renal transplantation in both groups (RAR-S and RAR-CH) compared with patients treated with rapamycin or to healthy donors.	Cyclosporine	0-3	arginyl-tRNA synthetase 1	Homo sapiens	169-174
17595192-10	2007	There were no statistically significant changes in the sodium proton exchange (NHE-3) of the proximal tubule although in this renal segment, aquaporin-1 was increased in cyclosporine-treated rats compared with control rats (control 100% +/- 6 vs cyclosporine 119% +/- 6; P &lt; 0.05*).	Cyclosporine	170-182	aquaporin 1	Rattus norvegicus	141-152
11893438-2	2002	AIM: To investigate the influence of ciclosporine A (CsA) on the vasoactive effects of serotonin in human umbilical arteries.	Cyclosporine	53-56	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	37-51
11872239-7	2002	This resulted in increased T-cell expression of CD40 ligand and subsequent B-cell activation, which was reduced by inhibitors of T-cell activation (CsA or anti-CD25 mAb) or by anti-CD40 ligand mAb.	Cyclosporine	148-151	CD40 molecule	Homo sapiens	48-52
11922262-3	2002	The role of cylosporin A (CsA) in aggravating bone loss is controversial.	Cyclosporine	26-29	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	12-24
11992648-0	2002	Modulation of mdr1a and CYP3A gene expression in the intestine and liver as possible cause of changes in the cyclosporin A disposition kinetics by dexamethasone.	Cyclosporine	109-122	ATP binding cassette subfamily B member 1A	Rattus norvegicus	14-19
11992648-15	2002	Our results indicate that the drug interaction between CyA and DEX is a consequence of modulation of P-gp and CYP3A2 gene expression by DEX, with differential dose-dependence.	Cyclosporine	55-58	cytochrome P450, family 3, subfamily a, polypeptide 2	Rattus norvegicus	110-116
12022945-8	2002	The VDAC/ANT/cyclophilin-D complex reconstitutes Ca(2+)- and cyclosporin A-sensitive permeability transition pore activity when incorporated into proteoliposomes.	Cyclosporine	61-74	peptidylprolyl isomerase D	Homo sapiens	13-26
11876576-0	2002	Interaction of cyclosporine A and the renin-angiotensin system; new perspectives.	Cyclosporine	15-29	renin	Rattus norvegicus	38-43
11876576-2	2002	Several lines of evidence suggest an involvement of the renin-angiotensin system (RAS) in CsA toxicity, but the issue is still controversial in more ways than one.	Cyclosporine	90-93	renin	Rattus norvegicus	56-61
11876576-6	2002	CsA increases renin release directly from juxtaglomerular cells.	Cyclosporine	0-3	renin	Rattus norvegicus	14-19
11817583-6	2002	The expression of ADAM-TS4, ADAM-TS5, and MMP-13 was abrogated by the inclusion of 10 microM CSA in the culture medium.	Cyclosporine	93-96	ADAM metallopeptidase with thrombospondin type 1 motif 4	Homo sapiens	18-26
17712479-8	2007	CsA blocked the CORT-induced apoptosis of the Leydig cells.	Cyclosporine	0-3	cortistatin	Rattus norvegicus	16-20
17712479-11	2007	CsA blocked the CORT-induced nuclear translocation of NFAT2 in the Leydig cells.	Cyclosporine	0-3	cortistatin	Rattus norvegicus	16-20
17636278-0	2007	Cyclosporine A induces titin expression via MAPK/ERK signalling and improves proliferative and invasive potential of human trophoblast cells.	Cyclosporine	0-14	titin	Homo sapiens	23-28
17917372-0	2007	Cyclosporine A inhibits the mRNA expressions of IL-2, IL-4 and IFN-gamma, but not TNF-alpha, in canine mononuclear cells.	Cyclosporine	0-14	interleukin 2	Canis lupus familiaris	48-52
17031644-1	2007	PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP).	Cyclosporine	86-89	major vault protein	Homo sapiens	354-357
17490613-6	2007	Cyclosporin A, an inhibitor of the mitochondrial permeability transition (MPT), inhibited MPT opening, the release of cytochrome c and caspase-3 activation.	Cyclosporine	0-13	caspase 3	Rattus norvegicus	135-144
17614361-1	2007	For lung transplant patients, a respirable, inulin-based solid dispersion containing cyclosporine A (CsA) has been developed.	Cyclosporine	85-99	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	101-104
17192829-2	2007	The present study was designed to clarify whether brain pericytes and pericyte-derived transforming growth factor-beta1 (TGF-beta1) participate in cyclosporin A (CsA)-induced dysfunction of the blood-brain barrier (BBB).2.	Cyclosporine	147-160	transforming growth factor, beta 1	Mus musculus	87-119
17192829-2	2007	The present study was designed to clarify whether brain pericytes and pericyte-derived transforming growth factor-beta1 (TGF-beta1) participate in cyclosporin A (CsA)-induced dysfunction of the blood-brain barrier (BBB).2.	Cyclosporine	147-160	transforming growth factor, beta 1	Mus musculus	121-130
17192829-2	2007	The present study was designed to clarify whether brain pericytes and pericyte-derived transforming growth factor-beta1 (TGF-beta1) participate in cyclosporin A (CsA)-induced dysfunction of the blood-brain barrier (BBB).2.	Cyclosporine	162-165	transforming growth factor, beta 1	Mus musculus	87-119
17192829-2	2007	The present study was designed to clarify whether brain pericytes and pericyte-derived transforming growth factor-beta1 (TGF-beta1) participate in cyclosporin A (CsA)-induced dysfunction of the blood-brain barrier (BBB).2.	Cyclosporine	162-165	transforming growth factor, beta 1	Mus musculus	121-130
17192829-4	2007	Exposure to CsA significantly decreased the levels of TGF-beta1 mRNA in brain pericytes in pericyte co-cultures.	Cyclosporine	12-15	transforming growth factor, beta 1	Mus musculus	54-63
17192829-5	2007	Treatment with TGF-beta1 dose-dependently inhibited CsA-induced hyperpermeability and P-glycoprotein dysfunction of MBEC4 cells in pericyte co-cultures.4.	Cyclosporine	52-55	transforming growth factor, beta 1	Mus musculus	15-24
17192829-6	2007	These findings suggest that an inhibition of brain pericyte-derived TGF-beta1 contributes to the occurrence of CsA-induced dysfunction of the BBB.	Cyclosporine	111-114	transforming growth factor, beta 1	Mus musculus	68-77
17322623-1	2007	BACKGROUND: Cyclosporine (CsA), Mycophenolate mofetil (MMF) and prednisolone (PSL) are widely used for the prevention of acute rejection after heart transplantation.	Cyclosporine	12-24	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	26-29
17454396-0	2007	Cyclosporin A has a protective effect with induced upregulation of Hsp70 and nNOS on severe spinal cord ischemic injury in rabbits.	Cyclosporine	0-13	nitric oxide synthase, brain	Oryctolagus cuniculus	77-81
17454396-1	2007	The purpose of this study is to ascertain the neuroprotective effect of cyclosporin A on the 25-min surgical ischemia model in the spinal cords of rabbits with neuropathological correlation and histoimmunochemical analyses measuring HSP70 and neuronal NOS (nNOS).	Cyclosporine	72-85	nitric oxide synthase, brain	Oryctolagus cuniculus	243-255
17454396-1	2007	The purpose of this study is to ascertain the neuroprotective effect of cyclosporin A on the 25-min surgical ischemia model in the spinal cords of rabbits with neuropathological correlation and histoimmunochemical analyses measuring HSP70 and neuronal NOS (nNOS).	Cyclosporine	72-85	nitric oxide synthase, brain	Oryctolagus cuniculus	257-261
17454396-13	2007	There was more expression of HSP70 and nNOS in the cyclosporin groups than in the ischemia groups.	Cyclosporine	51-62	nitric oxide synthase, brain	Oryctolagus cuniculus	39-43
17454396-15	2007	The neuroprotective effect of cyclosporin A against ischemia seems to be related to overexpressions of nNOS and HSP70.	Cyclosporine	30-43	nitric oxide synthase, brain	Oryctolagus cuniculus	103-107
17202415-5	2007	This study tested the hypothesis that long-term CsA treatment reduces the salinity/tonicity of the renal medullary interstitium as a result of inhibition of active sodium transporters, leading to downregulation of TonEBP.	Cyclosporine	48-51	nuclear factor of activated T cells 5	Homo sapiens	214-220
17202415-8	2007	Conversely, 28 d of CsA treatment led to downregulation of TonEBP and overt nephrotoxicity.	Cyclosporine	20-23	nuclear factor of activated T cells 5	Homo sapiens	59-65
17202415-12	2007	It is concluded that the downregulation of TonEBP in the setting of long-term CsA administration is secondary to the reduced tonicity of the renal medullary interstitium.	Cyclosporine	78-81	nuclear factor of activated T cells 5	Homo sapiens	43-49
12489193-2	2002	In this study, we looked at the expression of S100A8/A9 within gingiva from normal and Cyclosporin A (CsA)-induced overgrowth gingiva.	Cyclosporine	102-105	S100 calcium binding protein A8	Homo sapiens	46-52
17264526-3	2007	Under immunosuppressive treatment with cyclosporine A (CSA) the patient developed early-onset (day +33) and ultimately fatal leukoencephalopathy.	Cyclosporine	39-53	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	55-58
12489193-3	2002	In gingiva from the CsA group, several positive S100A8/A9 cells were seen within the connective tissue, whereas in normal gingiva very few positive S100A8/A9 cells were detected.	Cyclosporine	20-23	S100 calcium binding protein A8	Homo sapiens	48-54
17304156-1	2007	Cyclosporine A (CsA) is an immunosuppressive drug widely used in pediatric renal graft recipients.	Cyclosporine	0-14	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	16-19
12478844-0	2002	[Effects of cyclosporin A on expression of FasL and Fas in the contralateral testis after the unilateral testis injured in KM mouse].	Cyclosporine	12-25	Fas ligand (TNF superfamily, member 6)	Mus musculus	43-47
17477024-13	2007	CsA also decreased the inflammation related intrarenal prostglandin production via COX-2 production.	Cyclosporine	0-3	cytochrome c oxidase II, mitochondrial	Mus musculus	83-88
16925466-5	2007	Additive effects of DP+AMP and G-CSF on serum CSA were noted at early intervals after administration of the drugs.	Cyclosporine	46-49	colony stimulating factor 3 (granulocyte)	Mus musculus	31-36
11773888-1	2001	BACKGROUND: Basiliximab (Simulect), a high-affinity chimeric, monoclonal antibody directed against the alpha chain of human interleukin-2 receptor (CD25), reduces the incidence of acute renal allograft rejection when used in combination with cyclosporine (Neoral) and steroids.	Cyclosporine	242-254	interleukin 2 receptor subunit alpha	Homo sapiens	148-152
17028180-4	2006	This activation-induced Foxp3 binding was abrogated by cyclosporin A, suggesting a role for the phosphatase calcineurin in Foxp3 function.	Cyclosporine	55-68	forkhead box P3	Homo sapiens	24-29
11773888-1	2001	BACKGROUND: Basiliximab (Simulect), a high-affinity chimeric, monoclonal antibody directed against the alpha chain of human interleukin-2 receptor (CD25), reduces the incidence of acute renal allograft rejection when used in combination with cyclosporine (Neoral) and steroids.	Cyclosporine	256-262	interleukin 2 receptor subunit alpha	Homo sapiens	148-152
11781620-2	2001	He received low-dose fludarabine/TBI, with infusion of donor PBPC and cyclosporin (CsA)/MMF.	Cyclosporine	70-81	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	83-86
17028180-4	2006	This activation-induced Foxp3 binding was abrogated by cyclosporin A, suggesting a role for the phosphatase calcineurin in Foxp3 function.	Cyclosporine	55-68	forkhead box P3	Homo sapiens	123-128
17114439-0	2006	Cyclosporin A abolishes CD28-mediated resistance to CD95-induced apoptosis via superinduction of caspase-3.	Cyclosporine	0-13	Cd28 molecule	Rattus norvegicus	24-28
17114439-0	2006	Cyclosporin A abolishes CD28-mediated resistance to CD95-induced apoptosis via superinduction of caspase-3.	Cyclosporine	0-13	caspase 3	Rattus norvegicus	97-106
17114439-2	2006	In this study, we show that the immunosuppressive drug cyclosporin A (CsA) fully reverses resistance to CD95-mediated cell death after TCR/CD28 costimulation or superagonistic anti-CD28 mAb stimulation of primary rat lymph node T cells.	Cyclosporine	55-68	Cd28 molecule	Rattus norvegicus	139-143
17114439-2	2006	In this study, we show that the immunosuppressive drug cyclosporin A (CsA) fully reverses resistance to CD95-mediated cell death after TCR/CD28 costimulation or superagonistic anti-CD28 mAb stimulation of primary rat lymph node T cells.	Cyclosporine	55-68	Cd28 molecule	Rattus norvegicus	181-185
17114439-2	2006	In this study, we show that the immunosuppressive drug cyclosporin A (CsA) fully reverses resistance to CD95-mediated cell death after TCR/CD28 costimulation or superagonistic anti-CD28 mAb stimulation of primary rat lymph node T cells.	Cyclosporine	70-73	Cd28 molecule	Rattus norvegicus	139-143
17114439-2	2006	In this study, we show that the immunosuppressive drug cyclosporin A (CsA) fully reverses resistance to CD95-mediated cell death after TCR/CD28 costimulation or superagonistic anti-CD28 mAb stimulation of primary rat lymph node T cells.	Cyclosporine	70-73	Cd28 molecule	Rattus norvegicus	181-185
17114439-5	2006	Furthermore, CsA sensitization to CD95-mediated apoptosis of CD28-activated T cells did not alter mRNA stability of superinduced caspase-3 mRNA, suggesting a transcriptional regulation of the caspase-3 gene.	Cyclosporine	13-16	Cd28 molecule	Rattus norvegicus	61-65
17064727-6	2006	Addition of the PTP inhibitor CsA restored respiratory function to the level observed in mitochondria from sham animals.	Cyclosporine	30-33	protein tyrosine phosphatase, non-receptor type 13	Rattus norvegicus	16-19
17008059-11	2006	Immunosuppressive drugs such as dexamethasone (Dex), tacrolimus and cyclosporine (Cys) inhibited the CCL22 production by MoDCs in the AD patients.	Cyclosporine	68-80	C-C motif chemokine ligand 22	Homo sapiens	101-106
17008059-11	2006	Immunosuppressive drugs such as dexamethasone (Dex), tacrolimus and cyclosporine (Cys) inhibited the CCL22 production by MoDCs in the AD patients.	Cyclosporine	82-85	C-C motif chemokine ligand 22	Homo sapiens	101-106
17032251-0	2006	Modulation of chemokine gene expression in CD133+ cord blood-derived human mast cells by cyclosporin A and dexamethasone.	Cyclosporine	89-102	prominin 1	Homo sapiens	43-48
16716285-10	2006	CsA administration induced significant elevation in lipid peroxidation along with abnormal levels of enzymic (superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, glutathione-S-transferase and glucose-6-phosphate dehydrogenase) and non-enzymic antioxidants (glutathione, vitamins C and E) in the rat kidney.	Cyclosporine	0-3	glucose-6-phosphate dehydrogenase	Rattus norvegicus	219-252
17032751-1	2006	Cyclosporin A (CsA), a calcineurin inhibitor, has been widely used as an immunosuppressant, and is known to induce hyperlipidemia and dyslipoproteinemia with low levels of high-density lipoprotein (HDL).	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
17096891-5	2006	The numbers of CD3(+), CD4(+), CD8(+), CD11a(+), CD18(+) lymphocytes in skin and lung decreased markedly by GTT, GTT + CsA and CsA + MTX treatments.	Cyclosporine	119-122	CD3 antigen, epsilon polypeptide	Mus musculus	15-18
16858688-1	2006	Cyclosporine (CsA) causes a dose-related decrease in renal function in experimental animals and humans.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
16980025-3	2006	Glucocorticoids are well documented to cause bone loss, but the role of cyclosporine (CsA) remains controversial, especially among long-term recipients on low doses of steroid.	Cyclosporine	72-84	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	86-89
16861943-3	2006	RESULTS: There were no significant difference in GFR at week 10 (P=0.61), but GFR was significantly (P=0.029) lower in the Dac-group (52+/-20 ml/min) at month 12 than in the CsA-group (69+/-29 ml/min).	Cyclosporine	174-177	arylacetamide deacetylase	Homo sapiens	123-126
16641133-5	2006	IL-27, which could mimic the effect of IL-12, was however less potent in inducing IFN-gamma production in the presence of CsA and TCR stimulation.	Cyclosporine	122-125	interleukin 27	Homo sapiens	0-5
16723476-1	2006	PURPOSE: To determine the feasibility, safety, and effectiveness of an episcleral or deep scleral lamellar sustained release cyclosporine (CsA) device in a naturally occurring animal model of uveitis.	Cyclosporine	125-137	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	139-142
11770808-4	2001	Cyclosporine (CsA), a fungal decapeptide first introduced in 1983, has significantly improved the outcome of renal transplantation, and remains the first line immunosupressant for pediatric recipients.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
11729242-3	2001	The expression of mRNA for hypertonicity-induced genes (aldose reductase, betaine/gamma-amino-n-butyric acid transporter 1, and heat shock protein 70) is also decreased in the medulla of CsA-treated rats.	Cyclosporine	187-190	aldo-keto reductase family 1 member B1	Rattus norvegicus	56-72
11602850-1	2001	BACKGROUND: Sirolimus (Rapamune, rapamycin, RAPA) is a potent immunosuppressive drug that has reduced the rate of acute rejection episodes by more than 40% in phase III trials when added to an immunosuppression regimen of cyclosporine (CsA) and prednisone.	Cyclosporine	222-234	transcriptional regulating factor 1	Homo sapiens	44-48
11602850-1	2001	BACKGROUND: Sirolimus (Rapamune, rapamycin, RAPA) is a potent immunosuppressive drug that has reduced the rate of acute rejection episodes by more than 40% in phase III trials when added to an immunosuppression regimen of cyclosporine (CsA) and prednisone.	Cyclosporine	236-239	transcriptional regulating factor 1	Homo sapiens	44-48
11601685-11	2001	According to the literature, only methylprednisolone and cyclosporin A increased and decreased cystatin C levels, respectively.	Cyclosporine	57-70	cystatin C	Homo sapiens	95-105
11564166-8	2001	On the other hand, we found that cyclosporin A reduces the overall expression of protein kinase C alpha, betaI, and betaII in cultured murine hair epithelial cells, and reduces the levels of protein kinase C alpha, betaI, betaII, and eta in the particulate fraction from cultured murine hair epithelial cells.	Cyclosporine	33-46	endothelin receptor type A	Mus musculus	106-109
11493443-2	2001	The MDR phenotype often correlates with expression of P-glycoprotein (Pgp), and Pgp antagonists such as cyclosporine (CSA) have been used as chemosensitizing agents in AML.	Cyclosporine	104-116	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	118-121
11683823-1	2001	To determine whether conversion from cyclosporin A (CsA) to tacrolimus (TAC)-based immunosuppressive therapy is safe and might lead to improvement in the clinical side effect profile we studied 55 cardiac allograft recipients.	Cyclosporine	37-50	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	52-55
16730566-1	2006	BACKGROUND: Inadequate cyclosporine (CsA) blood levels are a major risk factor for acute rejection in transplant recipients.	Cyclosporine	23-35	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	37-40
16126800-0	2006	An open label, single dose study to evaluate the safety, efficacy, and effects on CD25 expression of ciclosporin in patients with active rheumatoid arthritis despite treatment with methotrexate and infliximab.	Cyclosporine	101-112	interleukin 2 receptor subunit alpha	Homo sapiens	82-86
16457843-12	2006	However A2a adenosine receptor agonist in combination with CsA significantly reduced the levels of suppressor cytokines IL-4 and IL-10.	Cyclosporine	59-62	interleukin 4	Rattus norvegicus	120-124
16647511-2	2006	Several reports have linked cyclosporine (CsA) with this alteration.	Cyclosporine	28-40	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	42-45
16438932-10	2006	Cyclosporine A (10 microM) and FK506 (0.1 microM) did not affect the basal Mg(2+)uptake (140 +/- 16 and 142 +/- 14 nM/s, respectively), but they inhibited the PTH-stimulated Mg(2+) entry, decreasing it from 248+/-12 to 147 +/- 7 and 148 +/- 14 nM/s, respectively.	Cyclosporine	0-14	parathyroid hormone	Mus musculus	159-162
16438932-13	2006	This PTH-stimulated ERK1/2 activation was inhibited by cyclosporine A and FK506.	Cyclosporine	55-69	parathyroid hormone	Mus musculus	5-8
16517721-8	2006	CD8alpha(+) DC transfer rendered BALB/c mice susceptible to cyclosporine therapy, thereby facilitating long-term graft survival.	Cyclosporine	60-72	CD8 antigen, alpha chain	Mus musculus	0-8
16517728-11	2006	Furthermore, the study identifies essential, positive regulators of the FOXP3 gene and highlights cyclosporin A as an inhibitor of FOXP3 expression contrasting other immunosuppressants such as steroids or rapamycin.	Cyclosporine	98-111	forkhead box P3	Homo sapiens	131-136
16640530-1	2006	Use of C(2) monitoring for cyclosporine A (CsA) microemulsion results in improved clinical outcomes vs. trough (C(0)) monitoring.	Cyclosporine	27-41	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	43-46
17170517-5	2006	The cardiomyogenic effect of Cyclosporin and Verapamil correlated with an expression of early cardiac markers Nkx2.5 and GATA4.	Cyclosporine	29-40	NK2 homeobox 5	Mus musculus	110-116
17717968-1	2006	Cyclosporine (CsA), a member of the family of calcineurin inhibitors, is a cornerstone of the immunosuppressive treatments used after organ transplantation.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
16972021-1	2006	The monitoring of the blood concentration at 2 h (C(2)) after the oral administration of a cyclosporine (CsA) microemulsion was reconfirmed to be useful for the prediction of systemic exposure, the area under the blood concentration-time curve from 0 to 4 h (AUC(0-4)), in a group of Japanese patients, consisting of 33 children aged 5-15 years and 19 young adults aged 16-27 years, with a greater correlation for C(2) (r = 0.927) than the trough concentration (r = 0.488).	Cyclosporine	91-103	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	105-108
16898534-1	2006	Cyclosporin A (CsA) is an immunosuppressive agent used in children for the treatment of steroid-dependent idiopathic nephrotic syndrome (INS).	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
16306627-2	2005	Here, we exploit its modular domain organization and cyclosporine sensitivity to probe the kinetics and mechanism of TRIM5-mediated restriction.	Cyclosporine	53-65	tripartite motif containing 5	Homo sapiens	117-122
11722596-1	2001	OBJECTIVES: Severe neurotoxicity is a recognized complication of cyclosporin A (cyclosporine, CSA).	Cyclosporine	65-78	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	94-97
15998842-9	2005	In chronic model, CsA produced pro-renin and ET upregulation, altered adenosine receptors expression, and reduced Ang, AT(1A), AT(1B), ET(B), and COX-2 mRNA levels.	Cyclosporine	18-21	angiotensin II receptor type 1	Homo sapiens	127-132
16237117-10	2005	Finally, blockade of CD86 but not CD80 rendered xenograft recipients sensitive to daily CsA therapy, leading to indefinite xenograft survival.	Cyclosporine	88-91	CD86 molecule	Homo sapiens	21-25
11436960-1	2001	A 10-year-old boy with a history of heart transplantation had a potentially life-threatening decrease in his cyclosporine (CSA) blood levels during administration of bupropion.	Cyclosporine	109-121	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	123-126
16221205-10	2005	The 24 kD caspase-3, which proved to be an active caspase-3 subunit, was increased in I/R and CsA groups and deceased by tacrolimus, rapamycin, or MMF (P &lt; 0.05), but not 32 kD precursor or 17 kD active caspase-3.	Cyclosporine	94-97	caspase 3	Rattus norvegicus	10-19
11495141-12	2001	CONCLUSIONS: The data from the present study show significantly higher CTGF staining in phenytoin-induced gingival overgrowth tissues compared to controls, cyclosporin A-, or nifedipine-induced gingival overgrowth.	Cyclosporine	156-169	cellular communication network factor 2	Homo sapiens	71-75
11435969-9	2001	CsA alone suppressed cytochrome P450 (CYP) 3A2 protein levels by 39% (P=0.012) and catalytic activity by 30% (P=0.042).	Cyclosporine	0-3	cytochrome P450, family 3, subfamily a, polypeptide 2	Rattus norvegicus	21-46
16221205-10	2005	The 24 kD caspase-3, which proved to be an active caspase-3 subunit, was increased in I/R and CsA groups and deceased by tacrolimus, rapamycin, or MMF (P &lt; 0.05), but not 32 kD precursor or 17 kD active caspase-3.	Cyclosporine	94-97	caspase 3	Rattus norvegicus	50-59
11435969-13	2001	CYP2A1 protein expression and catalytic activity were both significantly reduced in rats given CsA or/and SRL.	Cyclosporine	95-98	cytochrome P450, family 2, subfamily a, polypeptide 1	Rattus norvegicus	0-6
16221205-10	2005	The 24 kD caspase-3, which proved to be an active caspase-3 subunit, was increased in I/R and CsA groups and deceased by tacrolimus, rapamycin, or MMF (P &lt; 0.05), but not 32 kD precursor or 17 kD active caspase-3.	Cyclosporine	94-97	caspase 3	Rattus norvegicus	50-59
11343252-7	2001	Cyclosporin A, glibenclamide and rifamycin SV, all competitive inhibitors of Bsep transport, also reduced the bile salt-stimulated ATPase activity.	Cyclosporine	0-13	dynein, axonemal, heavy chain 8	Mus musculus	131-137
16386613-1	2005	Despite two decades of use, there are limited data on the best way to monitor Cyclosporine (CsA) for heart transplantation.	Cyclosporine	78-90	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	92-95
16109714-3	2005	Here we show that NFATc1 expression precedes that of OSCAR during TRANCE-mediated osteoclastogenesis and that inhibition of NFATc1 by cyclosporin A abolishes TRANCE-induced OSCAR expression and subsequent osteoclast differentiation.	Cyclosporine	134-147	osteoclast associated Ig-like receptor	Homo sapiens	173-178
16030052-14	2005	CONCLUSIONS: In aggregate, these data suggest that CsA is a direct stimulus for EMT in renal tubule epithelial cells and implicate TGF-beta1 and CTGF as mediators of this response.	Cyclosporine	51-54	cellular communication network factor 2	Homo sapiens	145-149
16271221-1	2005	OBJECTIVE: To evaluate the safety and reliability of cyclosporine microemulsion (CsA-ME) C(2) monitoring and to determine the target level of C(2) in Chinese adult liver transplant recipients.	Cyclosporine	53-65	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	81-84
15986223-10	2005	The amount of myostatin, TGF-beta2 and Smad3 mRNA and proteins was increased more markedly in the mice treated with CsA.	Cyclosporine	116-119	SMAD family member 3	Mus musculus	39-44
15986223-11	2005	After 9 days, many satellite cells and/or myoblasts showed apparent co-localization of both MyoD and Smad3 in CsA-, but not in placebo-, treated mice.	Cyclosporine	110-113	SMAD family member 3	Mus musculus	101-106
15986223-12	2005	Our results demonstrated that CsA treatment upregulates Id1 and Smad3 expression and delays skeletal muscle regeneration in vivo.	Cyclosporine	30-33	SMAD family member 3	Mus musculus	64-69
16120063-1	2005	BACKGROUND: Controversy remains about the interaction between mycophenolate mofetil (MMF) and the calcineurin inhibitors cyclosporin (CsA) and tacrolimus (TACR).	Cyclosporine	121-132	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	134-137
16116327-9	2005	LFA-1 blockade on DCs significantly reduced cyclosporine- and tacrolimus-induced DC adhesion (P&lt;0.001).	Cyclosporine	44-56	integrin subunit alpha L	Homo sapiens	0-5
16171442-9	2005	After 60 days of treatment with CsA, gingival overgrowth and significant increase in salivary TGF-beta1, EGF, and IL-6 concentrations were observed; no statistically significant changes were induced by FK-506.	Cyclosporine	32-35	epidermal growth factor like 1	Rattus norvegicus	105-108
16171442-10	2005	CONCLUSION: Within the limits of this experimental study, it can be concluded that CsA, but not FK-506, induced gingival overgrowth associated with an increase of the salivary levels of the cytokines TGF-beta1, EGF, and IL-6.	Cyclosporine	83-86	epidermal growth factor like 1	Rattus norvegicus	211-214
16040734-0	2005	Cyclosporin A specifically affects nuclear PLCbeta1 in immunodepressed heart transplant patients with gingival overgrowth.	Cyclosporine	0-13	phospholipase C beta 1	Homo sapiens	43-51
16245254-6	2005	Treatment with CsA may lead to the nitration of specific proteins such as manganese superoxide dismutase (MnSOD).	Cyclosporine	15-18	superoxide dismutase 2	Homo sapiens	74-104
16245254-6	2005	Treatment with CsA may lead to the nitration of specific proteins such as manganese superoxide dismutase (MnSOD).	Cyclosporine	15-18	superoxide dismutase 2	Homo sapiens	106-111
15784653-13	2005	In general, WW85 had no direct action on expression of the proapoptotic gene, Fas ligand; however, WW85 given alone or with cyclosporine enhanced expression of antiapoptotic genes Bcl-2 and Bcl-xL.	Cyclosporine	124-136	Bcl2-like 1	Rattus norvegicus	190-196
15840681-1	2005	BACKGROUND: Recent developments have proposed the cyclosporin (CsA) concentration at 2 h post-dose (C(2)) as the best single time-point predictor of the extent of CsA exposure and as the optimal basis for monitoring immunosuppressive therapy in renal transplant patients.	Cyclosporine	50-61	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	63-66
15840681-1	2005	BACKGROUND: Recent developments have proposed the cyclosporin (CsA) concentration at 2 h post-dose (C(2)) as the best single time-point predictor of the extent of CsA exposure and as the optimal basis for monitoring immunosuppressive therapy in renal transplant patients.	Cyclosporine	50-61	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	163-166
15800031-10	2005	Additionally, treatment of UCP-2+ cells with cyclosporin A blocked necrosis, indicating the involvement of mitochondrial permeability pore transition in the necrotic death.	Cyclosporine	45-58	uncoupling protein 2	Homo sapiens	27-32
15914972-1	2005	BACKGROUND: Cyclosporine A (CsA) causes distal renal tubular acidosis (RTA) and osteoporosis.	Cyclosporine	12-26	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	28-31
15919482-2	2005	CASE REPORT: Two years after heart transplantation with ATG induction, cyclosporine (CsA; trough levels of 250 ng/mL)-based triple drug immunosuppression), a 23-year-old patient developed a small round lesion within the left lateral liver segment.	Cyclosporine	71-83	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	85-88
15919494-2	2005	Cyclosporine (CsA)-related thrombotic microangiopathy (TMA) was observed in 15 (3.3%) patients.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
15946914-3	2005	In the first week only a few patients achieved the suggested C2 levels (19% &gt; 1500, 50% &gt; 1200 ng/ml) despite an increased cyclosporine (CsA) dose.	Cyclosporine	129-141	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	143-146
15691846-6	2005	We found that intracellular application of the cyclosporin A.cyclophilin A complex (CsA.CyP), a specific inhibitor of calcineurin, significantly decreased desensitization of capsaicin- or proton-activated TRPV1-WT currents.	Cyclosporine	47-60	transient receptor potential cation channel subfamily V member 1	Homo sapiens	205-210
11368098-7	2001	After CsA treatment, both constitutive HSP 25 and alpha B-crystallin immunoreactivity became stronger in glomeruli, proximal tubules and collecting ducts.	Cyclosporine	6-9	heat shock protein family B (small) member 1	Rattus norvegicus	39-45
11368098-7	2001	After CsA treatment, both constitutive HSP 25 and alpha B-crystallin immunoreactivity became stronger in glomeruli, proximal tubules and collecting ducts.	Cyclosporine	6-9	crystallin, alpha B	Rattus norvegicus	50-68
15691846-6	2005	We found that intracellular application of the cyclosporin A.cyclophilin A complex (CsA.CyP), a specific inhibitor of calcineurin, significantly decreased desensitization of capsaicin- or proton-activated TRPV1-WT currents.	Cyclosporine	84-87	transient receptor potential cation channel subfamily V member 1	Homo sapiens	205-210
15799746-2	2005	METHODS: A 41-year-old patient was treated with systemic CsA for c-ANCA positive Wegener"s granulomatosis.	Cyclosporine	57-60	proteinase 3	Homo sapiens	65-71
11357881-5	2001	Cyclosporine A, herbimycin A, LY294002, calphostin C and PD98059 all inhibited anti-Thy-1-induced T lymphocyte proliferation, indicating the involvement of calcineurin, protein tyrosine kinases, phosphatidylinositol 3-kinase, protein kinase C, and MEK1 (MAPK kinase 1), respectively, in Thy-1 signaling.	Cyclosporine	0-14	mitogen-activated protein kinase kinase 1	Mus musculus	248-252
11254887-5	2001	The expression of Bcl-2 and Bax proteins were high in LBC cells and following CsA treatment the expression of these proteins as well as Bcl-XL decreased.	Cyclosporine	78-81	BCL2-like 1	Mus musculus	136-142
11260412-1	2001	BACKGROUND: A clinical trial of cyclosporine in patients with steroid-resistant membranous nephropathy (MGN) was conducted.	Cyclosporine	32-44	helt bHLH transcription factor	Homo sapiens	104-107
11260412-3	2001	Cyclosporine has been shown to be effective in cases of progressive MGN, but it has not been used in controlled studies at an early stage of the disease.	Cyclosporine	0-12	helt bHLH transcription factor	Homo sapiens	68-71
11260412-11	2001	CONCLUSION: This study suggests that cyclosporine is an effective therapeutic agent in the treatment of steroid-resistant cases of MGN.	Cyclosporine	37-49	helt bHLH transcription factor	Homo sapiens	131-134
11274282-2	2001	The primary aim of the present prospective observational study was to test the hypothesis that tapering off prednisolone and cyclosporin (CsA) the first year after transplantation may have beneficial effects on glucose tolerance in renal transplant recipients.	Cyclosporine	125-136	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	138-141
15791000-5	2005	Inhibition of calcineurin by cyclosporin A blocked the effects of vasopressin on ALC-1 promoter activity to approximately 50%.	Cyclosporine	29-42	myosin light chain 4	Homo sapiens	81-86
15748638-4	2005	For example, solid organ transplant patients have elevated rates of skin cancer that are correlated with the dose and length of exposure to immunosuppressive drugs (predominantly cyclosporine A (CsA) and ascomycin (FK506)-related tacrolimus).	Cyclosporine	179-193	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	195-198
11238591-1	2001	Cyclosporin A (CsA) is an immunosuppressive drug that inhibits the activity of transcription factors of the nuclear factor of activated T cells (NFAT) family, interfering with the induction of cytokines and other inducible genes required for the immune response.	Cyclosporine	0-13	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	15-18
15773967-0	2005	Unusual post-transplantation recurrence of focal segmental glomerulosclerosis which resolved with cyclosporine but not with sirolimus.	Cyclosporine	98-110	actinin alpha 4	Homo sapiens	43-77
11228175-1	2001	In a prospective randomized study including 100 kidney transplant recipients, we previously reported on the safety and financial benefits of the coadministration of ketoconazole (keto) to cyclosporine (CsA)-treated kidney transplant recipients.	Cyclosporine	188-200	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	202-205
11327063-0	2001	Matrix metalloproteinases (MMP-8 and -9) and neutrophil elastase in gingival crevicular fluid of cyclosporin-treated patients.	Cyclosporine	97-108	elastase, neutrophil expressed	Homo sapiens	45-64
11327063-11	2001	In contrast, GCF PMN-elastase levels in inflamed CsA GO+ sites were significantly lower than the levels in diseased sites.	Cyclosporine	49-52	elastase, neutrophil expressed	Homo sapiens	17-29
11327063-13	2001	However, low GCF PMN-elastase levels can be an important factor in the pathogenesis of CsA-induced gingival overgrowth.	Cyclosporine	87-90	elastase, neutrophil expressed	Homo sapiens	17-29
11325024-0	2001	Involvement of tyrosine hydroxylase upregulation in cyclosporine-induced hypertension.	Cyclosporine	52-64	tyrosine hydroxylase	Rattus norvegicus	15-35
11325024-5	2001	Moreover, tyrosine hydroxylase (TH) activity and TH mRNA expression in the adrenal medulla of cyclosporine-treated rats were significantly elevated.	Cyclosporine	94-106	tyrosine hydroxylase	Rattus norvegicus	10-30
11325024-5	2001	Moreover, tyrosine hydroxylase (TH) activity and TH mRNA expression in the adrenal medulla of cyclosporine-treated rats were significantly elevated.	Cyclosporine	94-106	tyrosine hydroxylase	Rattus norvegicus	32-34
11325024-5	2001	Moreover, tyrosine hydroxylase (TH) activity and TH mRNA expression in the adrenal medulla of cyclosporine-treated rats were significantly elevated.	Cyclosporine	94-106	tyrosine hydroxylase	Rattus norvegicus	49-51
11325024-6	2001	Administration of the TH inhibitor alphamethyl-p-tyrosine (200 mg/kg, b.i.d., s.c.) for 3 days significantly suppressed cyclosporine-induced increases in systolic blood pressure.	Cyclosporine	120-132	tyrosine hydroxylase	Rattus norvegicus	22-24
15773967-8	2005	This observation points to the effectiveness of cyclosporine for the recurrence of FSGS and indicates that sirolimus should be given with caution in such cases.	Cyclosporine	48-60	actinin alpha 4	Homo sapiens	83-87
11239022-11	2001	CONCLUSIONS: These data suggest that CsA alters ECM synthesis and degradation in MC3T3-E1 osteoblasts by decreasing type I collagen production and increasing MMP-9 activity.	Cyclosporine	37-40	matrix metallopeptidase 9	Mus musculus	158-163
15866683-8	2005	CONCLUSIONS: Between 1987 and 2002, CsA-based immunosuppression combined with MMF and Ste became the most commonly used strategy for both initial and maintenance therapy after kidney transplantation in Germany, yielding the low acute rejection rates particularly when combined with IL-2Ra.	Cyclosporine	36-39	interleukin 2 receptor subunit alpha	Homo sapiens	282-288
11233995-5	2001	Cyclosporin A suppressed the antigen-induced IL-4 production almost completely at 0.3 microM.	Cyclosporine	0-13	interleukin 4	Rattus norvegicus	45-49
16011255-5	2005	RESULTS: Western blotting showed that the expressions of both FasL and NFATc protein were significantly increased in the hippocampus of rat subjected to transient forebrain ischemia in comparison with those of the sham control group, which were markedly reduced by CsA.	Cyclosporine	265-268	Fas ligand	Rattus norvegicus	62-66
11322648-5	2001	Our data thus suggest that the mechanism of cytoprotection of CsA on the cytosolic Ca2+ changes and ALT leakage induced by t-BHP, does not directly correlate with protection of t-BHP-induced changes of mitochondrial membrane potential.	Cyclosporine	62-65	glutamic--pyruvic transaminase	Homo sapiens	100-103
11158413-11	2001	Mean plasma beta TG levels were also significantly higher during cyclosporine therapy compared with tacrolimus (8.14+/-5.54 microg/ml vs 3.66+/-3.32 microg/ml, respectively; P&lt;0.002).	Cyclosporine	65-77	pro-platelet basic protein	Homo sapiens	12-19
15483225-6	2005	Using SB-203580 and cyclosporine A drugs to inhibit both p38- or/and calcineurin-dependent signals, respectively, we have shown that MEF2A phosphorylation and subsequent nuclear translocation are regulated by p38 and calcineurin in a biphasic, time-dependent manner.	Cyclosporine	20-34	myocyte enhancer factor 2A	Homo sapiens	133-138
15848549-9	2005	Of the dose combinations, CSA 7.5 mg/d + RAPA 0.5 mg/d produced the lowest serum creatinine for all time points, and inhibited profibrotic TIMP-1 (P = .017), while increasing antifibrotic MMP-2 (P = .009) mRNA expression, compared to CSA treatment alone.	Cyclosporine	26-29	matrix metallopeptidase 2	Rattus norvegicus	188-193
11243718-2	2001	Cyclosporine induced malondialdehyde formation and hydrogen peroxide production in mitochondria and attenuated the activity of MnSOD and glutathione peroxidase.	Cyclosporine	0-12	superoxide dismutase 2	Homo sapiens	127-132
15695591-9	2005	In addition, the calcineurin inhibitor cyclosporin A suppressed the stimulatory effect of acidification on resorption, implicating NFAT in mediating the actions of acidosis on osteoclast activity.	Cyclosporine	39-52	nuclear factor of activated T-cells 5	Rattus norvegicus	131-135
11136176-1	2001	High treatment costs force the discontinuation of cyclosporine (CSA) in a vast majority of renal transplant recipients in India.	Cyclosporine	50-62	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	64-67
15613074-6	2005	RESULTS: Cyclosporin A induced 23-25% (p &lt; 0.001) increases in the proliferation of rat gingival cells and approximately 130% (p &lt; 0.05) and 60% (p &lt; 0.05) elevations in the mRNA expression levels for TGF-beta1 and FGF-2, respectively.	Cyclosporine	9-22	fibroblast growth factor 2	Rattus norvegicus	224-229
11141501-8	2001	CsA also decreased Bcl-xL levels.	Cyclosporine	0-3	BCL2-like 1	Mus musculus	19-25
15613074-7	2005	On the other hand, exogenous IGF-I induced 8-11% (p &lt; 0.05) increases in the proliferation, but cyclosporin A induced 30-80% (p &lt; 0.05-0.01) reductions in the mRNA expression levels for endogenous IGF-I, IGFR1, IGFBP2, IGFBP3, IGFBP5, and IGFBP6.	Cyclosporine	99-112	insulin-like growth factor 1 receptor	Rattus norvegicus	210-215
15659300-9	2005	In conclusion, decreasing nitric oxide production through inhibiting constitutive nitric oxide synthase may be a mechanism through which cyclosporin A attenuates morphine-induced place preference.	Cyclosporine	137-150	nitric oxide synthase 1, neuronal	Mus musculus	82-103
16201144-8	2005	These effects were completely abolished in the presence of an inhibitor--cyclosporin A (10(-5) mol/l) that demonstrated mitochondrial swelling to be due to the mitochondrial PTP opening.	Cyclosporine	73-86	protein tyrosine phosphatase, non-receptor type 13	Rattus norvegicus	174-177
15365088-6	2005	In accordance, cyclosporin A and the inhibitors of caspase-9 and caspase-3 inhibited cocaine-induced caspase activation and apoptosis.	Cyclosporine	15-28	caspase 3	Rattus norvegicus	65-74
15808571-9	2005	Matrix metalloproteinase-2 expression was decreased by cyclosporine; all doses of pirfenidone significantly reversed this effect.	Cyclosporine	55-67	matrix metallopeptidase 2	Rattus norvegicus	0-26
15575910-4	2004	CsA+Rapa was associated with significantly lower graft survival (74.6% vs. 79.3% at 4 years, p = 0.002) and death-censored graft survival (83.7% vs. 87.2%, p = 0.003) compared to CsA+MMF.	Cyclosporine	0-3	transcriptional regulating factor 1	Homo sapiens	4-8
15575910-4	2004	CsA+Rapa was associated with significantly lower graft survival (74.6% vs. 79.3% at 4 years, p = 0.002) and death-censored graft survival (83.7% vs. 87.2%, p = 0.003) compared to CsA+MMF.	Cyclosporine	179-182	transcriptional regulating factor 1	Homo sapiens	4-8
15575910-5	2004	In multivariate analyses, CsA+Rapa was associated with a significantly increased risk for graft loss, death-censored graft loss and decline in renal function (HR = 1.22, p = 0.002; HR = 1.22, p = 0.018 and HR = 1.25, p &lt; 0.001, respectively).	Cyclosporine	26-29	transcriptional regulating factor 1	Homo sapiens	30-34
15466660-1	2004	Cyclophilin A (CypA), a receptor for the immunosuppressive agent cyclosporin A, is a cis-trans-peptidyl-prolyl isomerase (PPIase).	Cyclosporine	65-78	peptidylprolyl isomerase like 3	Homo sapiens	85-120
15466660-1	2004	Cyclophilin A (CypA), a receptor for the immunosuppressive agent cyclosporin A, is a cis-trans-peptidyl-prolyl isomerase (PPIase).	Cyclosporine	65-78	peptidylprolyl isomerase like 3	Homo sapiens	122-128
15466660-11	2004	Inhibition of PPIase activity of CypA with cyclosporin A also blocks the inhibitory effect of CypA on GC-c activity.	Cyclosporine	43-56	peptidylprolyl isomerase like 3	Homo sapiens	14-20
15476481-8	2004	TPMT nonfunctional mutant alleles were associated with significant reductions in hematological indices and a significant increase in cyclosporine plasma concentrations in the first month post-transplant.	Cyclosporine	133-145	thiopurine S-methyltransferase	Homo sapiens	0-4
15498531-8	2004	CONCLUSIONS: These results indicate that ACMIA is more accurate than mFPIA/TDx, and the difference in the mFPIA/ACMIA ratio between C2-3 and C8-12 was due to the difference in the relative cross-reactivity with CsA metabolites.	Cyclosporine	211-214	nucleolin	Homo sapiens	132-136
15451068-9	2004	These results suggest the sequential mechanism of diclofenac-induced apoptosis of HL-60 cells: ROS generation suppresses Akt activity, thereby activating caspase-8, which stimulates Bid cleavage and induces cytochrome c release and the activation of caspase-9 and-3 in a CsA-insensitive mechanism.	Cyclosporine	271-274	caspase 8	Homo sapiens	154-163
15483743-9	2004	(2) Combined with cyclosporine A (CsA), fluvastatin would further repress CD69 expression, cells proliferation and activity of killer cells, meanwhile significantly induced the secretion of IL-4 and IL-10.	Cyclosporine	18-32	CD69 molecule	Homo sapiens	74-78
15483743-9	2004	(2) Combined with cyclosporine A (CsA), fluvastatin would further repress CD69 expression, cells proliferation and activity of killer cells, meanwhile significantly induced the secretion of IL-4 and IL-10.	Cyclosporine	34-37	CD69 molecule	Homo sapiens	74-78
15233627-8	2004	All these effects of cyclophilin-D overexpression were abolished by cyclosporin A.	Cyclosporine	68-81	peptidylprolyl isomerase D	Homo sapiens	21-34
15367280-1	2004	The aim of this study was to study the incidence of chronic renal dysfunction in patients with more than 5 yr of follow-up following liver transplantation and to evaluate the benefit of decreasing cyclosporine A (CsA) dose combined with mycophenolate mofetil (MMF) on renal function and immune response in these patients.	Cyclosporine	197-211	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	213-216
11604047-10	2001	Since these anti-IL-2R antibodies are well tolerated and since calcineurin inhibitors are intrinsically nephrotoxic, anti-IL-2R antibodies have been used in an attempt to avoid cyclosporin after transplantation.	Cyclosporine	177-188	interleukin 2 receptor subunit alpha	Homo sapiens	122-127
11549851-1	2001	BACKGROUND: Hyperkalemia and metabolic acidosis are common manifestations in patients receiving the immunosuppressive agent cyclosporine A (CsA) and the recently introduced FK506.	Cyclosporine	124-138	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	140-143
11165712-5	2001	Granulysin was studied in phytohemagglutinin (PHA) stimulated cell lines (donor PBL and CD45RO(+) T cells) by FACS, Western blotting, and RT-PCR after pretreating with cyclosporine A (CSA), azathioprine, mycophenolic acid, and steroids.	Cyclosporine	168-182	granulysin	Homo sapiens	0-10
11165712-5	2001	Granulysin was studied in phytohemagglutinin (PHA) stimulated cell lines (donor PBL and CD45RO(+) T cells) by FACS, Western blotting, and RT-PCR after pretreating with cyclosporine A (CSA), azathioprine, mycophenolic acid, and steroids.	Cyclosporine	184-187	granulysin	Homo sapiens	0-10
11165712-9	2001	Granulysin levels were unchanged after azathioprine and mycophenolic acid treatment, decreased after treating activated PBL with steroids and cyclosporine A (CSA), and paradoxically, increased (p &lt; 0.05) after treating CD45RO(+) CTL with CSA.	Cyclosporine	142-156	granulysin	Homo sapiens	0-10
11165712-9	2001	Granulysin levels were unchanged after azathioprine and mycophenolic acid treatment, decreased after treating activated PBL with steroids and cyclosporine A (CSA), and paradoxically, increased (p &lt; 0.05) after treating CD45RO(+) CTL with CSA.	Cyclosporine	158-161	granulysin	Homo sapiens	0-10
11165712-9	2001	Granulysin levels were unchanged after azathioprine and mycophenolic acid treatment, decreased after treating activated PBL with steroids and cyclosporine A (CSA), and paradoxically, increased (p &lt; 0.05) after treating CD45RO(+) CTL with CSA.	Cyclosporine	241-244	granulysin	Homo sapiens	0-10
11256528-17	2001	However, CsA may also be exerting direct effects on NO synthesis through its interactions with both iNOS and cNOS.	Cyclosporine	9-12	nitric oxide synthase 3	Sus scrofa	109-113
15569226-1	2004	BACKGROUND: Mild, transient alanine aminotransferase (ALT) elevations were seen in Phase I studies of caspofungin and cyclosporin A (CsA).	Cyclosporine	133-136	glutamic--pyruvic transaminase	Homo sapiens	28-52
15242822-2	2004	Treatment of the cells with cyclosporine A (CsA) for 4h reduced glutamate-induced cell death by 60% (IC(50) of 7.1microM).	Cyclosporine	28-42	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	44-47
15270855-2	2004	We describe a case of IPEX in which lymphocyte phenotypes were assessed at birth, before initiation of Cyclosporin A therapy, and at frequent intervals to 18 months of age.	Cyclosporine	103-116	forkhead box P3	Homo sapiens	22-26
15205865-1	2004	Cyclosporine (CsA) is a critical-dose drug for which a minor change in absorption can have important clinical implications.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
15205865-4	2004	The limited available clinical evidence has shown that stable renal transplant patients receiving Neoral have a significant reduction in mean CsA trough level after transfer to the Cicloral formulation.	Cyclosporine	181-189	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	142-145
11145094-1	2000	Four major double-blind randomized trials in kidney transplant patients have shown that the interleukin-2 receptor (IL-2R alpha) antagonists declizumab or basiliximab, when added to an immunosuppressive regimen consisting of cyclosporin and prednisone, reduce the incidence of acute rejections after kidney transplantation by 30-40%, during the first 6 months.	Cyclosporine	225-236	interleukin 2 receptor subunit alpha	Homo sapiens	116-127
14871880-10	2004	CsA treatment decreased the expression of AR and Na-K-ATPase-alpha(1) and increased the number of TUNEL-positive renal tubular cells in both the cortex and medulla.	Cyclosporine	0-3	aldo-keto reductase family 1 member B1	Rattus norvegicus	42-44
15196247-6	2004	PD98059, an inhibitor of MAPK kinase (MEK), a component of the p44/42 MAPK pathway, partially inhibited Ag-induced expression of mRNA for all three cytokines while cyclosporin A inhibited Ag-induced IL-4 and IL-6 mRNA more readily than TNF-alpha mRNA.	Cyclosporine	164-177	mitogen activated protein kinase 3	Rattus norvegicus	25-29
15239612-6	2004	RESULTS: CsA treatment inhibited hepatic CYP3A1/2 protein expression, catalytic activity, and mRNA levels.	Cyclosporine	9-12	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	41-49
15239612-11	2004	CONCLUSIONS: Both CYP3A1/2 and Pgp participate in the disposition of CsA and SRL in rats.	Cyclosporine	69-72	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	18-26
15239612-12	2004	Changes in the individual activities of CYP3A1/2 and Pgp may contribute to an interaction between CsA and SRL resulting in unanticipated effects during chronic therapy.	Cyclosporine	98-101	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	40-48
11093160-9	2000	In untransformed human peripheral blood T lymphocytes, these phosphatases function through a cyclosporin A/FK506-resistant co-stimulatory signaling pathway which is common for the accessory receptors CD2 and CD28.	Cyclosporine	93-106	CD28 molecule	Homo sapiens	208-212
14981085-7	2004	Cyclosporin A and FK506, specific inhibitors of the calcium/calmodulin-dependent protein phosphatase (calcineurin), completely eliminated TRESK activation.	Cyclosporine	0-13	potassium channel, two pore domain subfamily K, member 18 L homeolog	Xenopus laevis	138-143
15044094-3	2004	We previously showed that CsA toxicity is mediated by ROS generation as well as by inhibition of peptidyl-prolyl cis-trans isomerase (PPIase) activity of CypA in CsA-treated myoblasts [FASEB J.	Cyclosporine	26-29	peptidylprolyl isomerase (cyclophilin)-like 3	Mus musculus	97-132
11189941-8	2000	These results suggest that both Tc-MIBI and Tc-Tfos are substrates for the MRP transporter and that PSC833, Vrp, CsA and BSO but not GG918 can inhibit MRP activity.	Cyclosporine	113-116	ATP binding cassette subfamily C member 3	Homo sapiens	75-78
11189941-8	2000	These results suggest that both Tc-MIBI and Tc-Tfos are substrates for the MRP transporter and that PSC833, Vrp, CsA and BSO but not GG918 can inhibit MRP activity.	Cyclosporine	113-116	ATP binding cassette subfamily C member 3	Homo sapiens	151-154
15044094-3	2004	We previously showed that CsA toxicity is mediated by ROS generation as well as by inhibition of peptidyl-prolyl cis-trans isomerase (PPIase) activity of CypA in CsA-treated myoblasts [FASEB J.	Cyclosporine	26-29	peptidylprolyl isomerase (cyclophilin)-like 3	Mus musculus	134-140
14744807-12	2004	Pretreatment with the angiotensin (AT(1)) receptor antagonist, losartan, and the endothelin (ET(A) and ET(B)) receptor antagonist, SB 209670, reduced the pressor and mesenteric vasoconstrictor effects of CsA.	Cyclosporine	204-207	endothelin receptor type A	Rattus norvegicus	93-98
11117367-1	2000	Chronic treatment with Sandimmune (cyclosporine A [CsA] dissolved in Cremophor EL [CrEL]) is often associated with hypertension and nephrotoxicity.	Cyclosporine	35-49	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	51-54
11124602-0	2000	Cyclosporin A stimulates ecto-5"-nucleotidase activity in mesangial cells.	Cyclosporine	0-13	5'-nucleotidase ecto	Homo sapiens	25-45
14976124-10	2004	CsA increased the expression of cdk5 and cdk5/p25 mediated by colchicine, a CDK involved in neuronal apoptosis.	Cyclosporine	0-3	cyclin-dependent kinase 5	Rattus norvegicus	32-36
14976124-10	2004	CsA increased the expression of cdk5 and cdk5/p25 mediated by colchicine, a CDK involved in neuronal apoptosis.	Cyclosporine	0-3	cyclin-dependent kinase 5	Rattus norvegicus	41-45
14976124-10	2004	CsA increased the expression of cdk5 and cdk5/p25 mediated by colchicine, a CDK involved in neuronal apoptosis.	Cyclosporine	0-3	lipocalin 2	Rattus norvegicus	46-49
11068017-5	2000	This finding suggests that cyclosporine may increase phenylephrine-induced NO production by accelerating IP3 receptor function in the alpha1-adrenoceptor signaling pathway in C6 cells.	Cyclosporine	27-39	inositol 1,4,5-trisphosphate receptor type 3	Homo sapiens	105-117
14976124-11	2004	After treatment of CGN with colchicine plus CsA, the changes in the p25/p35 ratio pointed to cdk5 activation.	Cyclosporine	44-47	lipocalin 2	Rattus norvegicus	68-71
14976124-11	2004	After treatment of CGN with colchicine plus CsA, the changes in the p25/p35 ratio pointed to cdk5 activation.	Cyclosporine	44-47	cyclin-dependent kinase 5	Rattus norvegicus	93-97
14976124-14	2004	Thus, we propose a new mechanism of modulation of CsA neurotoxicity mediated by cdk5.	Cyclosporine	50-53	cyclin-dependent kinase 5	Rattus norvegicus	80-84
11293243-1	2000	The mitochondrial permeability transition (MPT) resulting from calcium-induced opening of cyclosporin A (CsA)-sensitive megachannels, leading to deenergisation of mitochondria and release of pro-apoptotic cytochrome c, has been implicated in the pathomechanism of excitotoxic neurodegeneration.	Cyclosporine	90-103	cytochrome c	Oryctolagus cuniculus	205-217
11293243-1	2000	The mitochondrial permeability transition (MPT) resulting from calcium-induced opening of cyclosporin A (CsA)-sensitive megachannels, leading to deenergisation of mitochondria and release of pro-apoptotic cytochrome c, has been implicated in the pathomechanism of excitotoxic neurodegeneration.	Cyclosporine	105-108	cytochrome c	Oryctolagus cuniculus	205-217
14767451-11	2004	Serum TARC levels paralleled clinical improvement in patients treated with cyclosporin A.	Cyclosporine	75-88	C-C motif chemokine ligand 17	Homo sapiens	6-10
11293243-3	2000	In vitro experiments demonstrated that the early rapid phase of Ca(2+)-induced swelling of isolated brain mitochondria, and of accompanying cytochrome c release, was strongly inhibited by 0.5 microM CsA.	Cyclosporine	199-202	cytochrome c	Oryctolagus cuniculus	140-152
11091246-8	2000	Although cyclosporin treatment reduced levels of the matrix-degrading enzymes, matrix metalloproteinase (MMP) 2 and MMP-9, this was not statistically significant.	Cyclosporine	9-20	matrix metallopeptidase 2	Rattus norvegicus	79-111
11258483-5	2000	We further demonstrate that co-expression of a constitutively active NFAT and a constitutively active MEKK1 renders the interleukin-2 promoter in Jurkat T lymphocytes resistant to CsA and FK506, whereas Jurkat cells expressing a constitutively active NFAT alone are still sensitive to CsA or FK506.	Cyclosporine	180-183	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	102-107
11258483-5	2000	We further demonstrate that co-expression of a constitutively active NFAT and a constitutively active MEKK1 renders the interleukin-2 promoter in Jurkat T lymphocytes resistant to CsA and FK506, whereas Jurkat cells expressing a constitutively active NFAT alone are still sensitive to CsA or FK506.	Cyclosporine	285-288	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	102-107
11042265-1	2000	Cyclosporin (CsA) inhibits mitochondrial death signaling and opposes tumor necrosis factor (TNF)-induced apoptosis in vitro.	Cyclosporine	0-11	tumor necrosis factor-like	Rattus norvegicus	69-90
11073027-2	2000	As the CD25 saturation fades at days 28-50, cyclosporin concentrations decline and 20% higher doses are required to maintain adequate trough concentrations.	Cyclosporine	44-55	interleukin 2 receptor subunit alpha	Homo sapiens	7-11
11029348-3	2000	For these reasons, we determined whether CsA inhibited the allergen-induced increases in bronchial eosinophils, basophils, eotaxin, interleukin-5 (IL-5), and granulocyte macrophage colony-stimulating factor (GM-CSF).	Cyclosporine	41-44	interleukin 5	Homo sapiens	132-145
11029348-7	2000	CsA significantly inhibited the allergen-induced increases in IL-5 (p = 0.02) and GM-CSF (p = 0.	Cyclosporine	0-3	interleukin 5	Homo sapiens	62-66
14625575-1	2003	We retrospectively analyzed the factors that affect serum cyclosporine (CsA) concentrations up to day 14 after allogeneic hematopoietic stem cell transplantation (HSCT).	Cyclosporine	58-70	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	72-75
14687467-1	2003	OBJECTIVE: To investigate retrospectively the efficacy of cyclosporine A (CsA) in the treatment of membranous lupus nephropathy (MLN).	Cyclosporine	58-72	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	74-77
11019845-1	2000	Cyclosporin A (CsA) absorption is highly variable in BMT patients.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
14659064-1	2003	OBJECTIVE: To investigate the role of renin angiotensin system (RAS) activation in cyclosporine A nephropathy.	Cyclosporine	83-97	renin	Rattus norvegicus	38-43
10964494-1	2000	Cyclosporin A (CsA) has been shown to be efficacious in protecting against ischemic injury after short periods (5 to 10 min) of forebrain ischemia.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
14602422-5	2003	Cyclosporin A (CsA), a poorly water soluble immunosuppressant, was selected as model drug.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
10911372-0	2000	Cyclosporine has a direct effect on the differentiation of a mucin-secreting cell line.	Cyclosporine	0-12	LOC100508689	Homo sapiens	61-66
10911372-3	2000	Since both diseases are linked by a common decrease in mucin-filled goblet cells, this study tests a hypothesis that cyclosporine acts directly on goblet cells to promote their differentiation and production of secretory mucins.	Cyclosporine	117-129	LOC100508689	Homo sapiens	55-60
10911372-5	2000	Cyclosporine induced a dose-dependent increase in intracellular mucin stores.	Cyclosporine	0-12	LOC100508689	Homo sapiens	64-69
10911372-6	2000	A 2-week exposure to 1 microM cyclosporine resulted in an average increase in mucin volume of 94%.	Cyclosporine	30-42	LOC100508689	Homo sapiens	78-83
10911372-8	2000	PSC-833, a nonimmunosuppressive analog of cyclosporine, also increased mucin production.	Cyclosporine	42-54	LOC100508689	Homo sapiens	71-76
14519421-0	2003	Phosphodiesterase type 5 inhibition ameliorates nephrotoxicity induced by cyclosporin A in spontaneous hypertensive rats.	Cyclosporine	74-87	phosphodiesterase 5A	Rattus norvegicus	0-24
10975307-2	2000	Currently, most children with FSGS are treated with cyclosporine and steroids after establishing steroid resistance, and approximately 60% of patients benefit from this therapy.	Cyclosporine	52-64	actinin alpha 4	Homo sapiens	30-34
12967478-3	2003	The aim of this study was to test the efficacy of cyclosporine A (CSA) for prevention of GVHD and to define how CSA inhibits the occurrence of GVHD and the production of soluble interleukin (IL) 2 receptor (sIL-2R) in hu-PBL/SCID mice.	Cyclosporine	50-64	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	66-69
10975307-4	2000	We treated nine children with cyclosporine-resistant primary FSGS with plasma exchange (PE), two with relapsing FSGS after renal transplantation and seven with FSGS in their native kidneys.	Cyclosporine	30-42	actinin alpha 4	Homo sapiens	61-65
10975307-8	2000	We conclude that PE and PIA are a useful option for treatment of steroid- and cyclosporine-resistant FSGS, particularly if applied early in the course of the disease.	Cyclosporine	78-90	actinin alpha 4	Homo sapiens	101-105
12807493-1	2003	Immunomodulators such as cyclosporin A (CsA) and SAR943 (32-deoxorapamycin) inhibit single allergen-induced allergic inflammation such as eosinophilic and lymphocytic infiltration and mRNA expression for interleukin (IL)-4 and IL-5.	Cyclosporine	40-43	interleukin 5	Rattus norvegicus	227-231
12890451-2	2003	We have recently shown that CsA up-regulates the expression of TGF-beta1 and its receptors type I (TbetaR-I) and type II (TbetaR-II) in rat mesangial cells (MCs).	Cyclosporine	28-31	transforming growth factor, beta receptor 2	Rattus norvegicus	122-131
12890451-4	2003	Here, we assessed the effect of PGE1 on CsA induced up-regulation of TGF-beta1, TbetaR-I, TbetaR-II and related matrix production in MCs.	Cyclosporine	40-43	transforming growth factor, beta receptor 2	Rattus norvegicus	90-99
12890451-5	2003	Co-incubation with PGE1 reduced CsA induced up-regulation of TGF-beta1 and TbetaR-II at the mRNA and protein level.	Cyclosporine	32-35	transforming growth factor, beta receptor 2	Rattus norvegicus	75-84
12877359-1	2003	Species differences in the interactions of cyclosporine A (CSA) and tacrolimus (TAC) with the cytochrome P450 (CYP) system in male rat and human liver were investigated in vitro by assessing effects on a series of model reactions for different CYP isoforms.	Cyclosporine	43-57	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	59-62
12730091-6	2003	VLDL-induced NFAT translocation and proliferation were blocked by cyclosporin A and LY294002 involving calcineurin and phosphatidylinositol 3-kinase (PI3K) pathways.	Cyclosporine	66-79	nuclear factor of activated T-cells 5	Rattus norvegicus	13-17
12697421-9	2003	These results suggest that activation of DEX-sensitive, CSA-resistant MEK/ERK and p38 pathways, and activation of NF-kappaB, PKC, and PTK are essential for IL-8 and MCP-1 expression by hRPE cells.	Cyclosporine	56-59	midkine	Mus musculus	70-73
12697421-9	2003	These results suggest that activation of DEX-sensitive, CSA-resistant MEK/ERK and p38 pathways, and activation of NF-kappaB, PKC, and PTK are essential for IL-8 and MCP-1 expression by hRPE cells.	Cyclosporine	56-59	mitogen-activated protein kinase 14	Mus musculus	82-85
10928971-6	2000	Cyclosporin A (CsA) and dexamethasone (DEX) also inhibited the anti-CD3/CD28 induced cytokine production, but were less potent than FK506.	Cyclosporine	0-13	CD28 molecule	Homo sapiens	72-76
12697421-9	2003	These results suggest that activation of DEX-sensitive, CSA-resistant MEK/ERK and p38 pathways, and activation of NF-kappaB, PKC, and PTK are essential for IL-8 and MCP-1 expression by hRPE cells.	Cyclosporine	56-59	chemokine (C-X-C motif) ligand 15	Mus musculus	156-160
10928971-6	2000	Cyclosporin A (CsA) and dexamethasone (DEX) also inhibited the anti-CD3/CD28 induced cytokine production, but were less potent than FK506.	Cyclosporine	15-18	CD28 molecule	Homo sapiens	72-76
10928971-7	2000	FK506 and CsA, but not DEX, specifically inhibited anti-CD3/CD28 induced inflammatory cytokine production without affecting the lipopolysaccaride (LPS) induced effect.	Cyclosporine	10-13	CD28 molecule	Homo sapiens	60-64
12684049-7	2003	The increase of astrocytic GDNF mRNA by ET-1 was inhibited by BAPTA/AM (30 microM) and PD98059 (50 microM), but not by calphostin C, staurosporine, and cyclosporine A.	Cyclosporine	152-166	glial cell derived neurotrophic factor	Rattus norvegicus	27-31
12649386-0	2003	Suppression of hepatic CYP3A1/2 and CYP2C11 by cyclosporine is not mediated by altering growth hormone levels.	Cyclosporine	47-59	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	23-29
12649386-3	2003	Thus, the suppression of P450 by CsA may involve GH as an intermediate.	Cyclosporine	33-36	gonadotropin releasing hormone receptor	Rattus norvegicus	49-51
11275261-6	2000	Surprisingly, cyclosporin A (CsA) also enhances STAT6 induction.	Cyclosporine	29-32	signal transducer and activator of transcription 6	Mus musculus	48-53
12649386-5	2003	CsA alone decreased CYP3A1/2 and CYP2C11 significantly, in a manner similar to that previously found.	Cyclosporine	0-3	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	20-26
12671830-5	2003	On days 1 and 7, the 24-hour urine excretion of N-acetyl-beta-d-glucosaminidase (NAG) and beta-galactosidase (beta-GAL) were significantly (P &lt; .001) lower in CsA-treated rats on the high-protein diet than in those on the standard Rat Chow.	Cyclosporine	162-165	O-GlcNAcase	Rattus norvegicus	48-79
12671830-5	2003	On days 1 and 7, the 24-hour urine excretion of N-acetyl-beta-d-glucosaminidase (NAG) and beta-galactosidase (beta-GAL) were significantly (P &lt; .001) lower in CsA-treated rats on the high-protein diet than in those on the standard Rat Chow.	Cyclosporine	162-165	O-GlcNAcase	Rattus norvegicus	81-84
12502708-4	2003	Verapamil and cyclosporin A, blockers of the multidrug resistance-associated protein, decreased UVA-induced GSH efflux.	Cyclosporine	14-27	ATP binding cassette subfamily C member 3	Homo sapiens	45-84
12514115-9	2003	Hydroxyl radical and superoxide scavengers and inhibition of cathepsin D activity significantly attenuated CsA-induced EC death.	Cyclosporine	107-110	cathepsin D	Homo sapiens	61-72
11275261-7	2000	Both ionomycin and CsA also enhance IL-4-induced transcriptional activity of a STAT6-linked promoter-reporter construct.	Cyclosporine	19-22	signal transducer and activator of transcription 6	Mus musculus	79-84
10886243-5	2000	However, differences between IL-4 on the one hand and IL-5 and IL-13 on the other hand were observed when sensitivity to cyclosporin A (CsA) was studied.	Cyclosporine	121-134	interleukin 5	Homo sapiens	54-58
10886243-5	2000	However, differences between IL-4 on the one hand and IL-5 and IL-13 on the other hand were observed when sensitivity to cyclosporin A (CsA) was studied.	Cyclosporine	136-139	interleukin 5	Homo sapiens	54-58
10947839-6	2000	Inhibition of PP-2B (calcineurin) with cyclosporin A or FK506 reduced Cx43 dephosphorylation and junctional uncoupling seen after hypoxia.	Cyclosporine	39-52	gap junction protein alpha 1	Homo sapiens	70-74
12639820-0	2003	Cyclosporine A up-regulates expression of matrix metalloproteinase 2 and vascular endothelial growth factor in rat heart.	Cyclosporine	0-14	matrix metallopeptidase 2	Rattus norvegicus	42-68
12639820-3	2003	Since the immunosuppressive therapy induces myocardial toxicity, the aim of this study was to evaluate in the myocardium of CsA-treated rats the expression variations of vascular endothelial growth factor (VEGF) and matrix metalloproteinase 2 (MMP2), to verify if: VEGF increased, VEGF increase was associated with MMP2 increase and they could be considered as repair proteins.	Cyclosporine	124-127	matrix metallopeptidase 2	Rattus norvegicus	216-242
12639820-3	2003	Since the immunosuppressive therapy induces myocardial toxicity, the aim of this study was to evaluate in the myocardium of CsA-treated rats the expression variations of vascular endothelial growth factor (VEGF) and matrix metalloproteinase 2 (MMP2), to verify if: VEGF increased, VEGF increase was associated with MMP2 increase and they could be considered as repair proteins.	Cyclosporine	124-127	matrix metallopeptidase 2	Rattus norvegicus	244-248
12639820-3	2003	Since the immunosuppressive therapy induces myocardial toxicity, the aim of this study was to evaluate in the myocardium of CsA-treated rats the expression variations of vascular endothelial growth factor (VEGF) and matrix metalloproteinase 2 (MMP2), to verify if: VEGF increased, VEGF increase was associated with MMP2 increase and they could be considered as repair proteins.	Cyclosporine	124-127	matrix metallopeptidase 2	Rattus norvegicus	315-319
12639820-7	2003	The group II animals (CsA-treated) showed structural degenerative changes with myocardial fibrosis and a clear increase both in MMP2 and VEGF.	Cyclosporine	22-25	matrix metallopeptidase 2	Rattus norvegicus	128-132
12589150-8	2003	At a molecular level, increased expression of angiotensin II protein, osteopontin, and TGF-beta1 mRNAs in the CsA group were significantly decreased with MMF, and further decrease was observed with the combined treatment using MMF and LSRT.	Cyclosporine	110-113	secreted phosphoprotein 1	Rattus norvegicus	70-81
12589161-12	2003	CsA treatment of TOL grafts markedly reduced expression of IL-2, IL-4, and interferon-gamma compared with untreated recipients.	Cyclosporine	0-3	interleukin 4	Rattus norvegicus	65-69
12589161-13	2003	CONCLUSIONS: CsA did not significantly inhibit liver transplant acceptance and allowed some activation of T cells and CD25 expression but almost completely inhibited IL-2 and IL-4, which are required for survival of activated T cells.	Cyclosporine	13-16	interleukin 4	Rattus norvegicus	175-179
12490546-8	2003	Stimulation of transfected cells with AngII or specific AT2-receptor agonists resulted in a significant increase in eNOS promoter activity, which was blocked by CsA, MCIP1, and mutation of an upstream NF-AT site.	Cyclosporine	161-164	angiotensin II receptor, type 2	Mus musculus	56-68
12744774-2	2003	Previous investigations found that costimulation of the CD28 pathway generally mediates CsA-resistant proliferation of T cell receptor (TCR)-activated T lymphocytes.	Cyclosporine	88-91	CD28 molecule	Homo sapiens	56-60
12744774-3	2003	However, here we describe considerable interindividual variation regarding the immunosuppressive effects of CsA (1000 microg/L) on anti-CD3/CD28 T cell costimulation in a human whole blood assay.	Cyclosporine	108-111	CD28 molecule	Homo sapiens	140-144
12666991-8	2003	The results clearly indicate that: 1) mGluR2/3, 4 and 5 are widely expressed in thymic cells; 2) the mGluR5 subtype is expressed most strongly in medullary cells; and 3) cyclosporine-A rapidly inhibits expression of all mGluR subtypes after 2 days of treatment and their complete disappearance after prolonged treatment.	Cyclosporine	170-184	glutamate receptor, ionotropic, kainate 1	Mus musculus	101-107
12691305-9	2003	After the use of CsA in combination with either the highest concentrations of 2-CdA or F-ara-A, statistically significant differences compared with CsA used alone were observed (p = 0.008, p = 0.03 for CsA with 2-CdA, and p = 0.0007, p = 0.005 for CsA with F-ara-A, respectively, for normal and CML CFU-GM).	Cyclosporine	17-20	cytidine deaminase	Homo sapiens	80-83
12691305-9	2003	After the use of CsA in combination with either the highest concentrations of 2-CdA or F-ara-A, statistically significant differences compared with CsA used alone were observed (p = 0.008, p = 0.03 for CsA with 2-CdA, and p = 0.0007, p = 0.005 for CsA with F-ara-A, respectively, for normal and CML CFU-GM).	Cyclosporine	17-20	cytidine deaminase	Homo sapiens	213-216
12401523-0	2003	Modulation of the electrophoretic mobility of the linker for activation of T cells (LAT) by the calcineurin inhibitors CsA and FK506: LAT is a potential substrate for PKC and calcineurin signaling pathways.	Cyclosporine	119-122	linker for activation of T cells	Homo sapiens	84-87
12401523-4	2003	We show that TCR ligation in the presence of FK506 or CsA induced rapid modifications in LAT that modulate the electrophoretic mobility of the molecule in SDS-PAGE.	Cyclosporine	54-57	linker for activation of T cells	Homo sapiens	89-92
12401523-5	2003	Calcineurin, a target for CsA and FK506, dephosphorylated LAT in vitro and restored its electrophoretic mobility.	Cyclosporine	26-29	linker for activation of T cells	Homo sapiens	58-61
12401523-8	2003	These results shed light on the molecular actions of CsA and FK506 in T cells and implicate LAT in mediating the drugs" actions.	Cyclosporine	53-56	linker for activation of T cells	Homo sapiens	92-95
14499669-5	2003	In addition, pretreatment with calcineurin inhibitors, cyclosporin A and FR901725, resulted in blockage of the ionomycin-dependent release of beta-hexosaminidase into the supernatant.	Cyclosporine	55-68	O-GlcNAcase	Rattus norvegicus	142-161
12496186-8	2003	Interestingly, the CCL20 response of mast cells to P. aeruginosa was relatively resistant to inhibition by the corticosteroid dexamethasone, interleukin-10, or cyclosporine, while GM-CSF production was potently inhibited.	Cyclosporine	160-172	C-C motif chemokine ligand 20	Homo sapiens	19-24
12429571-4	2002	Exposure to veratridine (30 micro M, 1 h) produces cytochrome c release to the cytoplasm that seems to be mediated by superoxide anions and that is blocked by cyclosporin A (10 micro M), MnTBAP (10 nM), catalase (100 IU ml(-1)) and vitamin E (50 micro M).	Cyclosporine	159-172	LOC104968582	Bos taurus	51-63
10877919-1	2000	We examined the effects of the immunophilin ligands and calcineurin inhibitors FK506 and cyclosporin A on the survival of rat embryonic dopamine (tyrosine hydroxylase (TH)-immunoreactive) neurons.	Cyclosporine	89-102	tyrosine hydroxylase	Rattus norvegicus	146-166
12451279-0	2002	Role of pharmacologic enhancement of p-450 in cyclosporine overdose.	Cyclosporine	46-58	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	37-42
10887335-5	2000	RESULTS: Dexamethasone, FK506, and cyclosporin A suppressed the production of IL-2, IL-4, and IL-5 by human helper T cells, which shows a similar concentration-response relationship in each case.	Cyclosporine	35-48	interleukin 5	Homo sapiens	94-98
12202955-6	2002	CsA, at 125-2000 ng/ml, similarly inhibited proliferation, but at high doses (1000-2000 ng/ml) it decreased TRAP activity, TRAP+MNC formation, and the expression of TRAP and CTR mRNAs.	Cyclosporine	0-3	calcitonin receptor	Mus musculus	174-177
10777482-4	2000	Cytosolic isoforms of creatine kinase and lactate dehydrogenase (most abundant in fast fibers), as well as mitochondrial creatine kinase and citrate synthase activities (elevated in fast/oxidative fibers) were dose dependently increased by cyclosporin A treatment in soleus muscle, with no change in plantaris.	Cyclosporine	240-253	citrate synthase	Rattus norvegicus	141-157
10849438-10	2000	In contrast to NF-AT-dependent transcription, Vav1-mediated transcriptional induction of the CD28RE/AP element in the interleukin-2 promoter could only partially be inhibited by cyclosporin A, suggesting a dual role of Vav1 for controlling Ca(2+)-dependent and -independent events.	Cyclosporine	178-191	vav guanine nucleotide exchange factor 1	Homo sapiens	46-50
12469783-1	2002	I present a review of the current US Food and Drug Administration (FDA) guidelines for using cyclosporine A (CSA) to treat psoriasis, with particular emphasis on the period for which CSA may be administered.	Cyclosporine	93-107	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	109-112
10851085-4	2000	Furthermore, we demonstrated that the inhibition of the phosphatase activity of calcineurin with FK506 and cyclosporin A resulted in an overall increase in cdk4 kinase activity, suggesting that the phosphatase activity of calcineurin was inhibitory to the kinase activity of cdk4.	Cyclosporine	107-120	cyclin dependent kinase 4	Homo sapiens	156-160
10851085-4	2000	Furthermore, we demonstrated that the inhibition of the phosphatase activity of calcineurin with FK506 and cyclosporin A resulted in an overall increase in cdk4 kinase activity, suggesting that the phosphatase activity of calcineurin was inhibitory to the kinase activity of cdk4.	Cyclosporine	107-120	cyclin dependent kinase 4	Homo sapiens	275-279
10779414-6	2000	Strikingly, the calcineurin inhibitors cyclosporin A (CsA) and FK506 strongly potentiated TCR-induced LAT expression, suggesting that the activation of calcineurin following TCR ligation negatively regulates LAT expression.	Cyclosporine	54-57	linker for activation of T cells	Homo sapiens	102-105
10779414-6	2000	Strikingly, the calcineurin inhibitors cyclosporin A (CsA) and FK506 strongly potentiated TCR-induced LAT expression, suggesting that the activation of calcineurin following TCR ligation negatively regulates LAT expression.	Cyclosporine	54-57	linker for activation of T cells	Homo sapiens	208-211
10779414-8	2000	CsA and FK506 blocked the Ca(++ )ionophores" inhibitory effect on LAT expression.	Cyclosporine	0-3	linker for activation of T cells	Homo sapiens	66-69
10779414-9	2000	Notably, CsA and FK506 preferentially up-regulated TCR-induced LAT expression; under the same conditions, these compounds did not increase the expression of 14 other molecules that previously had been implicated in T-cell activation.	Cyclosporine	9-12	linker for activation of T cells	Homo sapiens	63-66
10779414-11	2000	Furthermore, the potentiation of TCR-induced LAT expression by CsA and FK506 suggests that the action of these agents involves up-regulating the cellular level of critical signaling molecules.	Cyclosporine	63-66	linker for activation of T cells	Homo sapiens	45-48
10810233-7	2000	Immunohistochemical results showed that chronic CsA treatment induced moderate secretion of Et1 and Et3 at tubular and glomerular levels and that the local expression of angiotensin II in the treatment groups was more evident than in control animals.	Cyclosporine	48-51	endothelin 3	Rattus norvegicus	100-103
10810233-8	2000	Besides, the mRNA levels of preproEt3 showed a dramatic increase from 28 days after CsA treatment (control group 0.07+/-0.11 vs. CsA group 0.48+/-0.11, p&lt;0.01), while the mRNA levels of preproEt1 increased from 56 days (control group 0.15+/-0.05 vs. CsA group 0.34+/-0.09, p&lt; 0.05).	Cyclosporine	84-87	endothelin 3	Rattus norvegicus	28-37
10810233-8	2000	Besides, the mRNA levels of preproEt3 showed a dramatic increase from 28 days after CsA treatment (control group 0.07+/-0.11 vs. CsA group 0.48+/-0.11, p&lt;0.01), while the mRNA levels of preproEt1 increased from 56 days (control group 0.15+/-0.05 vs. CsA group 0.34+/-0.09, p&lt; 0.05).	Cyclosporine	129-132	endothelin 3	Rattus norvegicus	28-37
10810233-8	2000	Besides, the mRNA levels of preproEt3 showed a dramatic increase from 28 days after CsA treatment (control group 0.07+/-0.11 vs. CsA group 0.48+/-0.11, p&lt;0.01), while the mRNA levels of preproEt1 increased from 56 days (control group 0.15+/-0.05 vs. CsA group 0.34+/-0.09, p&lt; 0.05).	Cyclosporine	129-132	endothelin 3	Rattus norvegicus	28-37
10810233-11	2000	These results support the hypothesis that the clinical and morphological phenomena linked with CsA nephrotoxicity are related to hypersecretion of endothelins and local expression of angiotensin II in the outer medulla and medullary rays; Et3 and angiotensin II are the first to act, followed subsequently by Et1.	Cyclosporine	95-98	endothelin 3	Rattus norvegicus	239-242
11039311-1	2000	The use of Cyclosporin A (CsA) in treatment nephrotic syndrome in the primary focal and segmental glomerulosclerosis (FSGS) is controversial.	Cyclosporine	26-29	actinin alpha 4	Homo sapiens	118-122
11039311-2	2000	A prospective study was comprised of 10 adult patients with nephrotic syndrome caused by FSGS, treated with CsA and corticosteroids.	Cyclosporine	108-111	actinin alpha 4	Homo sapiens	89-93
11039311-10	2000	These are encouraging results from initial treatment of FSGS with CsA and small doses prednisone.	Cyclosporine	66-69	actinin alpha 4	Homo sapiens	56-60
10760803-3	2000	Co-stimulation with ICAM-1 and B7.2 led to strong and CsA-resistant proliferation, which was found to be largely IL-2 dependent.	Cyclosporine	54-57	CD86 molecule	Homo sapiens	31-35
10760803-5	2000	In contrast, both ICAM-1 and B7.2 enhanced the half-life of the inducible IL-2 transcript in a CsA-resistant manner.	Cyclosporine	95-98	CD86 molecule	Homo sapiens	29-33
10760803-7	2000	This is further suggested by the demonstration that LFA-1 and CD28 acted synergistically to confer CsA resistance in a model of co-stimulation using superantigen-pulsed dendritic cells.	Cyclosporine	99-102	integrin subunit alpha L	Homo sapiens	52-57
10760803-7	2000	This is further suggested by the demonstration that LFA-1 and CD28 acted synergistically to confer CsA resistance in a model of co-stimulation using superantigen-pulsed dendritic cells.	Cyclosporine	99-102	CD28 molecule	Homo sapiens	62-66
10760094-2	2000	The main target for CsA, cyclophilin A (CypA), was found in high levels in epithelial cells of renal proximal tubules.	Cyclosporine	20-23	peptidylprolyl isomerase A	Rattus norvegicus	25-38
10760094-2	2000	The main target for CsA, cyclophilin A (CypA), was found in high levels in epithelial cells of renal proximal tubules.	Cyclosporine	20-23	peptidylprolyl isomerase A	Rattus norvegicus	40-44
10760094-3	2000	In the present study, CypA was immunodetected and characterized following CsA treatment in subcellular fractions of renal cortex.	Cyclosporine	74-77	peptidylprolyl isomerase A	Rattus norvegicus	22-26
10760094-9	2000	The CypA distribution was strongly modified in both BBMs and the soluble fraction after CsA treatment, but its affinity for CsA estimated by photoaffinity labeling was unaffected.	Cyclosporine	88-91	peptidylprolyl isomerase A	Rattus norvegicus	4-8
10760094-9	2000	The CypA distribution was strongly modified in both BBMs and the soluble fraction after CsA treatment, but its affinity for CsA estimated by photoaffinity labeling was unaffected.	Cyclosporine	124-127	peptidylprolyl isomerase A	Rattus norvegicus	4-8
10760094-11	2000	CypA remained associated with the membranes following in vitro incubation of renal BBMs with CsA.	Cyclosporine	93-96	peptidylprolyl isomerase A	Rattus norvegicus	0-4
10897619-1	2000	MDR1 gene encodes for a transmembranous glycoprotein, gp-170, which acts as a drug export pump and is also a cyclosporine(CsA)-binding protein.	Cyclosporine	109-121	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	122-125
10774626-1	2000	The range of cyclosporin (CsA) immunoassays has become the mainstay in many therapeutic drug monitoring laboratories for delivering CsA concentration data to support clinical care of patients after transplantation.	Cyclosporine	13-24	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	26-29
10774626-1	2000	The range of cyclosporin (CsA) immunoassays has become the mainstay in many therapeutic drug monitoring laboratories for delivering CsA concentration data to support clinical care of patients after transplantation.	Cyclosporine	13-24	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	132-135
12385031-2	2002	Here we describe that the phorbol ester PMA and a calcium ionophore had a synergistic effect on both CD69 antigen expression and promoter activity in Jurkat cells, that was sensitive to cyclosporin A (CsA).	Cyclosporine	201-204	CD69 molecule	Homo sapiens	101-105
12385031-3	2002	CD69 promoter analysis indicated that the sequence -78 to +16 contained the elements responsible for PMA and PMA plus calcium ionophore induction, as well as CsA inhibition.	Cyclosporine	158-161	CD69 molecule	Homo sapiens	0-4
12512145-10	2002	CsA markedly upregulated the expression of chemoattractant proteins, osteopontin and monocyte chemoattractant protein-1, concomitantly.	Cyclosporine	0-3	secreted phosphoprotein 1	Rattus norvegicus	69-80
12239209-7	2002	Consistent with this, BMP2 gene expression was increased by ionomycin and suppressed by the calcineurin inhibitor, cyclosporine A.	Cyclosporine	115-129	bone morphogenetic protein 2	Homo sapiens	22-26
12429717-5	2002	However, TNF-alpha-induced DC maturation was affected, as CsA-treated DC expressed lower levels of human leukocyte antigen and costimulatory molecules but sustained levels of CD1a, and less DC expressed DC-lysosomal-associated-membrane-protein (LAMP) and CD83.	Cyclosporine	58-61	CD1a molecule	Homo sapiens	175-179
12429717-5	2002	However, TNF-alpha-induced DC maturation was affected, as CsA-treated DC expressed lower levels of human leukocyte antigen and costimulatory molecules but sustained levels of CD1a, and less DC expressed DC-lysosomal-associated-membrane-protein (LAMP) and CD83.	Cyclosporine	58-61	lysosomal associated membrane protein 3	Homo sapiens	245-249
12244165-4	2002	We find that in the presence but not the absence of EC, NFAT1 can be detected in the nuclei of CsA-treated T cells within 8 h of triggering, reaching a maximal level of 60% of control by 24 h. Glycogen synthase kinase-3beta (GSK-3beta), which rephosphorylates NFAT and promotes nuclear export, is inhibited by EC costimulation.	Cyclosporine	95-98	glycogen synthase kinase 3 beta	Homo sapiens	193-223
12244165-4	2002	We find that in the presence but not the absence of EC, NFAT1 can be detected in the nuclei of CsA-treated T cells within 8 h of triggering, reaching a maximal level of 60% of control by 24 h. Glycogen synthase kinase-3beta (GSK-3beta), which rephosphorylates NFAT and promotes nuclear export, is inhibited by EC costimulation.	Cyclosporine	95-98	glycogen synthase kinase 3 beta	Homo sapiens	225-234
12235233-8	2002	CsA also mediated a significant increase in cellular Ca(2+) mobilization by phenylephrine, vasopressin, and epidermal growth factor (EGF) in the presence of extracellular Ca(2+) concentration.	Cyclosporine	0-3	epidermal growth factor like 1	Rattus norvegicus	108-131
12235233-8	2002	CsA also mediated a significant increase in cellular Ca(2+) mobilization by phenylephrine, vasopressin, and epidermal growth factor (EGF) in the presence of extracellular Ca(2+) concentration.	Cyclosporine	0-3	epidermal growth factor like 1	Rattus norvegicus	133-136
12235233-9	2002	Our data, therefore, demonstrate that CsA accelerates HCG after PHx by, in part, increasing the cellular Ca(2+) pools and the response to EGF and Ca(2+)-mobilizing hormones known to be comitogens for hepatocytes.	Cyclosporine	38-41	epidermal growth factor like 1	Rattus norvegicus	138-141
12234299-9	2002	Thirdly, triptolide (4 to 8 ng/mL), CsA (500 to 2500 ng/mL) and FK506 (1250 ng/mL) inhibited up-regulation of CD40 and B7h mRNA, the effect on B7h and CD40 mRNA expression by CsA and FK506 being greater than that on C3 mRNA expression.	Cyclosporine	36-39	CD40 molecule	Homo sapiens	110-114
12234299-9	2002	Thirdly, triptolide (4 to 8 ng/mL), CsA (500 to 2500 ng/mL) and FK506 (1250 ng/mL) inhibited up-regulation of CD40 and B7h mRNA, the effect on B7h and CD40 mRNA expression by CsA and FK506 being greater than that on C3 mRNA expression.	Cyclosporine	36-39	CD40 molecule	Homo sapiens	151-155
12376808-5	2002	In the cyclosporine (CsA) era, survival of grafts from living related (LRD) and cadaver (CD) donors in Stx-HUS and control patients was 83% versus 70% ( P&lt;0.03) and 77% versus 49% ( P&lt;0.05) at 10 years.	Cyclosporine	7-19	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	21-24
10762208-1	2000	BACKGROUND: Our purpose was to develop and evaluate protocols for selective immunosuppression after liver transplantation using the monoclonal antibodies (mAbs) NDS-61, directed against the interleukin-2 receptor (CD25), and 1A29, directed against the intercellular adhesion molecule-1 (CD54), in combination with subtherapeutic cyclosporine (CsA).	Cyclosporine	329-341	interleukin 2 receptor subunit alpha	Homo sapiens	214-218
10762208-1	2000	BACKGROUND: Our purpose was to develop and evaluate protocols for selective immunosuppression after liver transplantation using the monoclonal antibodies (mAbs) NDS-61, directed against the interleukin-2 receptor (CD25), and 1A29, directed against the intercellular adhesion molecule-1 (CD54), in combination with subtherapeutic cyclosporine (CsA).	Cyclosporine	343-346	interleukin 2 receptor subunit alpha	Homo sapiens	214-218
12376814-8	2002	Focal segmental glomerular sclerosis (FSGS) was present in one patient with CsA dependence on the initial biopsy and in two of six on a subsequent biopsy.	Cyclosporine	76-79	actinin alpha 4	Homo sapiens	38-42
10702360-6	2000	After 20 h of CsA incubation apoptosis parameters were further increased and were accompanied by the increased activity of the cysteine protease, caspase-3 (CPP 32), and slightly increased caspase-6 (Mch 2), but not caspase-1 (ICE).	Cyclosporine	14-17	caspase 3	Rattus norvegicus	146-155
12376814-9	2002	In comparison, seven of nine patients with secondary CsA resistance and ten of ten with primary CsA resistance had FSGS on the initial or subsequent biopsy ( P=0.03).	Cyclosporine	96-99	actinin alpha 4	Homo sapiens	115-119
10702360-6	2000	After 20 h of CsA incubation apoptosis parameters were further increased and were accompanied by the increased activity of the cysteine protease, caspase-3 (CPP 32), and slightly increased caspase-6 (Mch 2), but not caspase-1 (ICE).	Cyclosporine	14-17	caspase 3	Rattus norvegicus	157-163
12376814-12	2002	We conclude that the presence of FSGS, or of C4 and/or C1q, appears to increase the risk of secondary CsA resistance and some of these children rapidly progress to ESRD.	Cyclosporine	102-105	actinin alpha 4	Homo sapiens	33-37
12389077-4	2002	The rCBF was correlated with cyclosporine blood levels.	Cyclosporine	29-41	CCAAT/enhancer binding protein zeta	Rattus norvegicus	4-8
12231430-5	2002	Pretreatment with cyclosporin A augmented the mobility retardation of Amph2 after ECS.	Cyclosporine	18-31	bridging integrator 1	Rattus norvegicus	70-75
10706678-9	2000	Cyclosporin A blocks this differentiation and induces a more B-2-like phenotype in these cells.	Cyclosporine	0-13	bradykinin receptor, beta 2	Mus musculus	61-64
12197897-7	2002	These results indicate that activated Th1-type pulmonary T cells play an important role in the development of corticosteroid- resistant IP in DM/PM and that the increase in CD25+ CD8+ T cells in BALF is a useful indicator for corticosteroid-resistant IP in DM/PM and hence may be an indicator for early use of cyclosporin.	Cyclosporine	310-321	interleukin 2 receptor subunit alpha	Homo sapiens	173-177
24989958-1	2002	We report a patient with IgA nephropathy (IgAN) showing reduction of proteinuria and histological improvement of renal injury with cyclosporin A (CsA) and angiotensin-II receptor blocker (ARB) therapy.	Cyclosporine	131-144	IGAN1	Homo sapiens	42-46
10714397-1	2000	PURPOSE: Cyclosporine (CSA) toxicity represents a common cause of seizures in transplant patients, but the specific mechanisms by which CSA induces seizures are unknown.	Cyclosporine	9-21	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	23-26
12579726-1	2000	OBJECTIVE: To observe the effects of immunosuppressants triptolide (TL) and cyclosporine A (CSA) on HLA antigens expression induced by interferon-gamma(INF-gamma) in vitro.	Cyclosporine	76-90	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	92-95
24989958-1	2002	We report a patient with IgA nephropathy (IgAN) showing reduction of proteinuria and histological improvement of renal injury with cyclosporin A (CsA) and angiotensin-II receptor blocker (ARB) therapy.	Cyclosporine	146-149	IGAN1	Homo sapiens	42-46
24989958-5	2002	These findings seem to indicate that combination therapy with CsA and ARB is effective for achieving histological improvement and protecting against deteriorated renal function, in addition to reducing proteinuria, in IgAN.	Cyclosporine	62-65	IGAN1	Homo sapiens	218-222
12198207-4	2002	We investigated whether CsA up-regulates the expression of TGF-beta1 and its receptors type I (TbetaR-I) and type II (TbetaR-II) in cultured rat MCs, and whether this effect translates into enhanced matrix protein accumulation.	Cyclosporine	24-27	transforming growth factor, beta receptor 2	Rattus norvegicus	118-127
11787589-0	2000	Ionomycin restores taurine transporter activity in cyclosporin-A treated macrophages.	Cyclosporine	51-64	solute carrier family 6 (neurotransmitter transporter, taurine), member 6	Mus musculus	19-38
12198207-8	2002	RESULTS: Compared with untreated controls, CsA stimulated mRNA production of TGF-beta1 (maximum at 72 h, 500 ng/ml CsA: 2.1+/-0.5-fold, P&lt;0.001) and TbetaR-II (maximum at 72 h, 1000 ng/ml CsA: 2.4+/-0.4-fold, P&lt;0.005) time- and dose-dependently.	Cyclosporine	43-46	transforming growth factor, beta receptor 2	Rattus norvegicus	152-161
11787589-7	2000	However, when ionomycin (IM) was added to this system, TAUT activity was recovered only in CSA-treated cells, in a concentration-dependent manner, in order to inhibit voltage gated Ca2+ channels, calmidazolium was added to the RAW264.7 cell line.	Cyclosporine	91-94	solute carrier family 6 (neurotransmitter transporter, taurine), member 6	Mus musculus	55-59
12198207-12	2002	Co-incubation with neutralizing anti-TGF-beta1 antibodies reduced (P&lt;0.05) CsA-induced expression of TbetaR-I (1.0+/-0.1-fold), TbetaR-II (1.3+/-0.1-fold) and PAI-1 (1.3-fold), but not FN production (1.6-fold).	Cyclosporine	78-81	transforming growth factor, beta receptor 2	Rattus norvegicus	131-140
10729995-1	2000	This report details the effects of cyclosporin A (Cs-A) on the clinical course of B-cell chronic lymphocytic leukemia (B-CLL) with an increase in circulating T cells that express CD3, CD8, CD25, CD45RO, and T-cell receptor alpha beta chain.	Cyclosporine	35-48	interleukin 2 receptor subunit alpha	Homo sapiens	189-193
10729995-6	2000	On the other hand, CD19+ cells from the patient were more resistant to Cs-A than those from healthy donors.	Cyclosporine	71-75	CD19 molecule	Homo sapiens	19-23
12411148-7	2002	The expression of caspase-3 mRNA and caspase-3 activity of CsA-treated group was significantly higher than that of CsA plus TP-treated group (P &lt; 0.05).	Cyclosporine	59-62	caspase 3	Rattus norvegicus	18-27
12411148-7	2002	The expression of caspase-3 mRNA and caspase-3 activity of CsA-treated group was significantly higher than that of CsA plus TP-treated group (P &lt; 0.05).	Cyclosporine	59-62	caspase 3	Rattus norvegicus	37-46
10718281-12	2000	In conclusion, CsA significantly lowered moderate to high proteinuria in 6 patients with IgAN.	Cyclosporine	15-18	IGAN1	Homo sapiens	89-93
12411148-7	2002	The expression of caspase-3 mRNA and caspase-3 activity of CsA-treated group was significantly higher than that of CsA plus TP-treated group (P &lt; 0.05).	Cyclosporine	115-118	caspase 3	Rattus norvegicus	18-27
12077116-1	2002	Cyclophilin D (CyPD) is thought to sensitize opening of the mitochondrial permeability transition pore (mPTP) based on the findings that cyclosporin A (CsA), a pseudo-CyPD substrate, hyperpolarizes the mitochondrial membrane potential (DeltaPsi) and inhibits apoptosis.	Cyclosporine	137-150	peptidylprolyl isomerase D	Homo sapiens	0-13
10536367-4	1999	Cyclosporin A (10(-6)-10(-4) M), an inhibitor of Ca(2+)/calmodulin-dependent protein phosphatase activity toward phosphoserine, but not phosphotyrosine and phosphoserine.	Cyclosporine	0-13	calmodulin 1	Rattus norvegicus	56-66
12077116-1	2002	Cyclophilin D (CyPD) is thought to sensitize opening of the mitochondrial permeability transition pore (mPTP) based on the findings that cyclosporin A (CsA), a pseudo-CyPD substrate, hyperpolarizes the mitochondrial membrane potential (DeltaPsi) and inhibits apoptosis.	Cyclosporine	137-150	peptidylprolyl isomerase D	Homo sapiens	15-19
10594746-10	1999	Cyclosporin A (CsA) and FK506 slightly inhibited CD40 and B7-1 expression on Langerhans cells, but not B7-2.	Cyclosporine	0-13	CD40 molecule	Homo sapiens	49-53
12077116-1	2002	Cyclophilin D (CyPD) is thought to sensitize opening of the mitochondrial permeability transition pore (mPTP) based on the findings that cyclosporin A (CsA), a pseudo-CyPD substrate, hyperpolarizes the mitochondrial membrane potential (DeltaPsi) and inhibits apoptosis.	Cyclosporine	137-150	peptidylprolyl isomerase D	Homo sapiens	167-171
10594746-10	1999	Cyclosporin A (CsA) and FK506 slightly inhibited CD40 and B7-1 expression on Langerhans cells, but not B7-2.	Cyclosporine	0-13	CD80 molecule	Homo sapiens	58-62
10594746-10	1999	Cyclosporin A (CsA) and FK506 slightly inhibited CD40 and B7-1 expression on Langerhans cells, but not B7-2.	Cyclosporine	15-18	CD40 molecule	Homo sapiens	49-53
12077116-1	2002	Cyclophilin D (CyPD) is thought to sensitize opening of the mitochondrial permeability transition pore (mPTP) based on the findings that cyclosporin A (CsA), a pseudo-CyPD substrate, hyperpolarizes the mitochondrial membrane potential (DeltaPsi) and inhibits apoptosis.	Cyclosporine	152-155	peptidylprolyl isomerase D	Homo sapiens	0-13
10594746-10	1999	Cyclosporin A (CsA) and FK506 slightly inhibited CD40 and B7-1 expression on Langerhans cells, but not B7-2.	Cyclosporine	15-18	CD80 molecule	Homo sapiens	58-62
10594790-12	1999	CsA up-regulated Fas-L expression (P &lt; 0.001).	Cyclosporine	0-3	Fas ligand	Rattus norvegicus	17-22
12077116-1	2002	Cyclophilin D (CyPD) is thought to sensitize opening of the mitochondrial permeability transition pore (mPTP) based on the findings that cyclosporin A (CsA), a pseudo-CyPD substrate, hyperpolarizes the mitochondrial membrane potential (DeltaPsi) and inhibits apoptosis.	Cyclosporine	152-155	peptidylprolyl isomerase D	Homo sapiens	15-19
12077116-1	2002	Cyclophilin D (CyPD) is thought to sensitize opening of the mitochondrial permeability transition pore (mPTP) based on the findings that cyclosporin A (CsA), a pseudo-CyPD substrate, hyperpolarizes the mitochondrial membrane potential (DeltaPsi) and inhibits apoptosis.	Cyclosporine	152-155	peptidylprolyl isomerase D	Homo sapiens	167-171
12181023-1	2002	Recent studies have shown a good response to immunosuppressive treatment with cyclosporin A (CSA) in patients with the myelodysplastic syndrome (MDS).	Cyclosporine	78-91	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	93-96
10594798-0	1999	A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis.	Cyclosporine	22-34	actinin alpha 4	Homo sapiens	70-104
10594798-2	1999	UNLABELLED: A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis.	Cyclosporine	34-46	actinin alpha 4	Homo sapiens	82-116
10594798-3	1999	BACKGROUND: A clinical trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis (FSGS) was conducted.	Cyclosporine	32-44	actinin alpha 4	Homo sapiens	80-114
10594798-3	1999	BACKGROUND: A clinical trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis (FSGS) was conducted.	Cyclosporine	32-44	actinin alpha 4	Homo sapiens	116-120
10594798-5	1999	METHODS: We conducted a randomized controlled trial in 49 cases of steroid-resistant FSGS comparing 26 weeks of cyclosporine treatment plus low-dose prednisone to placebo plus prednisone.	Cyclosporine	112-124	actinin alpha 4	Homo sapiens	85-89
10594798-13	1999	CONCLUSIONS: These results suggest that cyclosporine is an effective therapeutic agent in the treatment of steroid-resistant cases of FSGS.	Cyclosporine	40-52	actinin alpha 4	Homo sapiens	134-138
10573060-7	1999	RESULTS: Exposure of replicating DC progenitors propagated in GM-CSF or GM-CSF+TGF-beta to CsA reduced costimulatory molecule expression, without affecting MHC antigen expression.	Cyclosporine	91-94	transforming growth factor, beta 1	Mus musculus	79-87
10573060-8	1999	Nuclear extracts from the CsA-treated DC revealed a decrease in nuclear translocation of NF-kappaB (p50).	Cyclosporine	26-29	CD40 antigen	Mus musculus	100-103
10573076-1	1999	BACKGROUND: Cyclosporine (CsA) acts by inhibiting the phosphatase calcineurin (CN), but the time course and extent of inhibition in vivo are unknown.	Cyclosporine	12-24	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	26-29
10521511-4	1999	The specific inhibitors of calcineurin cyclosporin A (CsA) and FK506 could overcome KCl-dependent MEF2A hypophosphorylation.	Cyclosporine	54-57	myocyte enhancer factor 2A	Homo sapiens	98-103
10521511-7	1999	Consistent with this, CsA/FK506 also inhibited MEF2-dependent reporter gene expression.	Cyclosporine	22-25	myocyte enhancer factor 2A	Homo sapiens	47-51
10516356-12	1999	In conclusion, de novo FSGS presents late after transplantation and in association with arteriolar hyalinosis, suggesting these lesions may be related to chronic cyclosporine toxicity.	Cyclosporine	162-174	actinin alpha 4	Homo sapiens	23-27
10552213-6	1999	In contrast, significant suppressive effects of CY on the NiCl(2)- or DNCB-induced augmented expression of CD86 were seen only at concentrations in the range 10(-6) to 10(-5) M, which are more than ten times higher than its effective concentration for T cell suppression.	Cyclosporine	48-50	CD86 molecule	Homo sapiens	107-111
10501227-4	1999	Cyclosporin A, which inhibits calcineurin through formation of a cyclosporin A/cyclophilin/calcineurin complex, also abolished PACAP-evoked VIP biosynthesis.	Cyclosporine	0-13	adenylate cyclase activating polypeptide 1	Homo sapiens	127-132
10501227-4	1999	Cyclosporin A, which inhibits calcineurin through formation of a cyclosporin A/cyclophilin/calcineurin complex, also abolished PACAP-evoked VIP biosynthesis.	Cyclosporine	65-78	adenylate cyclase activating polypeptide 1	Homo sapiens	127-132
10507492-0	1999	Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression.	Cyclosporine	80-92	interleukin 2 receptor subunit alpha	Homo sapiens	12-16
10580348-3	1999	We have previously demonstrated that cyclosporine (CsA) in conjunction with rapamycin (RAPA) potentiates class I+, class II- donor-specific hepatocytes to prolong rat cardiac and small bowel allograft survival.	Cyclosporine	37-49	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	51-54
10471650-1	1999	BACKGROUND: Prediction of cyclosporine (CSA) efficacy and toxicity in individual patients is difficult.	Cyclosporine	26-38	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	40-43
10500467-2	1999	We describe a case story of successful treatment with prednisolone and cyclosporine of an 83-year old female with severe bleeding disorder due to an acquired factor VIII inhibitor.	Cyclosporine	71-83	cytochrome c oxidase subunit 8A	Homo sapiens	165-169
10500467-4	1999	We recommend that treatment of acquired factor VIII inhibitor with cyclosporine is further investigated.	Cyclosporine	67-79	cytochrome c oxidase subunit 8A	Homo sapiens	47-51
10492062-1	1999	BACKGROUND: A large number of drugs have been shown to affect the metabolism of cyclosporin A (CSA) and, since cyclosporin is characterized by a narrow therapeutic range, the consequences of such drug interactions may often be of clinical importance.	Cyclosporine	80-93	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	95-98
10492062-1	1999	BACKGROUND: A large number of drugs have been shown to affect the metabolism of cyclosporin A (CSA) and, since cyclosporin is characterized by a narrow therapeutic range, the consequences of such drug interactions may often be of clinical importance.	Cyclosporine	80-91	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	95-98
10432409-5	1999	The cyclosporine (CsA) dose was adjusted as necessary to maintain site-specific trough whole blood levels.	Cyclosporine	4-16	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	18-21
12240952-6	2002	Cyclosporin A further targeted cyclin D1 transcription.	Cyclosporine	0-13	cyclin D1	Homo sapiens	31-40
12123745-6	2002	At all periods of incubation assayed, CsA induced the activation of AP-1 which was detected by DNA-binding activity of this transcription factor.	Cyclosporine	38-41	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	68-72
12123745-8	2002	We conclude that in rat hepatocyte cultures, CsA induces the transcriptional activation of NF-kappaB, AP-1, and HSF1.	Cyclosporine	45-48	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	102-106
12081566-0	2002	Effects of cyclosporine in osteopontin null mice.	Cyclosporine	11-23	secreted phosphoprotein 1	Mus musculus	27-38
10401019-7	1999	Those 40 cases in which the biopsy showed evidence of CSA or tacrolimus nephrotoxicity had a significantly (P &lt; 0.01) greater SMA level in the corresponding urine samples (0.089 +/- 0.126 microgram/mL; mean +/- SD) than the 49 cases without toxicity (0.018 +/- 0.027 microgram/mL) or 6 control subjects (0.003 +/- 0.007 microgram/mL), although there was considerable overlap of SMA values among these groups.	Cyclosporine	54-57	survival of motor neuron 1, telomeric	Homo sapiens	381-384
10401019-8	1999	The greatest SMA levels were seen in patients with CSA or tacrolimus nephrotoxicity that was likely to be relatively acute, namely those with thrombotic microangiopathy and those without previous biopsy evidence of toxicity.	Cyclosporine	51-54	survival of motor neuron 1, telomeric	Homo sapiens	13-16
12081566-2	2002	We have previously reported that rats with cyclosporine (CsA) nephropathy have increased tubular osteopontin that correlates with the infiltration of macrophages and interstitial fibrosis.	Cyclosporine	43-55	secreted phosphoprotein 1	Rattus norvegicus	97-108
12065751-1	2002	Cyclosporin A (CsA) shows cytoprotective properties in many cellular and in vivo models that may depend on interference of the interaction of cyclophilin A with calcineurin or of cyclophilin D with the mitochondrial permeability transition (PT) pore.	Cyclosporine	0-13	peptidylprolyl isomerase A	Rattus norvegicus	142-155
12065751-1	2002	Cyclosporin A (CsA) shows cytoprotective properties in many cellular and in vivo models that may depend on interference of the interaction of cyclophilin A with calcineurin or of cyclophilin D with the mitochondrial permeability transition (PT) pore.	Cyclosporine	0-13	peptidylprolyl isomerase F	Rattus norvegicus	179-192
12065751-1	2002	Cyclosporin A (CsA) shows cytoprotective properties in many cellular and in vivo models that may depend on interference of the interaction of cyclophilin A with calcineurin or of cyclophilin D with the mitochondrial permeability transition (PT) pore.	Cyclosporine	15-18	peptidylprolyl isomerase A	Rattus norvegicus	142-155
12065751-1	2002	Cyclosporin A (CsA) shows cytoprotective properties in many cellular and in vivo models that may depend on interference of the interaction of cyclophilin A with calcineurin or of cyclophilin D with the mitochondrial permeability transition (PT) pore.	Cyclosporine	15-18	peptidylprolyl isomerase F	Rattus norvegicus	179-192
12069596-5	2002	Furthermore, the ECARs correlated with the expression level of Pgp in the two different cell lines and were reduced in a concentration-dependent manner by cyclosporin A, a potent inhibitor of the Pgp-ATPase.	Cyclosporine	155-168	dynein, axonemal, heavy chain 8	Mus musculus	200-206
10377253-1	1999	Cyclophilin-A is the cytosolic isoform of a family of peptidylproline cis-trans-isomerases that bind cyclosporin A.	Cyclosporine	101-114	peptidylprolyl isomerase A	Rattus norvegicus	0-13
10377253-9	1999	Cyclosporin A conferred some resistance to the peroxide in both types of cell, but protection was greater in cyclophilin-A-suppressed cells, where cyclosporin A increased the survival time 2-fold.	Cyclosporine	0-13	peptidylprolyl isomerase A	Rattus norvegicus	109-122
10377253-9	1999	Cyclosporin A conferred some resistance to the peroxide in both types of cell, but protection was greater in cyclophilin-A-suppressed cells, where cyclosporin A increased the survival time 2-fold.	Cyclosporine	147-160	peptidylprolyl isomerase A	Rattus norvegicus	109-122
10465413-1	1999	Cyclosporin A (CsA) and FK506 are potent natural product immunosuppressants that induce their biological effects by forming an initial complex with cytosolic proteins termed immunophilins.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
10386979-1	1999	Cyclophilin B (CyPB) is a cyclosporin A (CsA)-binding protein mainly located in intracellular vesicles and secreted in biological fluids.	Cyclosporine	26-39	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	41-44
10364029-1	1999	OBJECTIVE: Cyclosporin (CSA) is a promising alternative for patients with severe steroid-refractory ulcerative colitis (UC) previously facing only surgical options.	Cyclosporine	11-22	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	24-27
10382954-6	1999	Additional studies have shown that HC and CsA blocked con A-driven differentiation of CD8+ and CD4+ CD8+ lymph node cells (LNC) and progression of LNC to S + G2/M cell cycle phases, and inhibited IL-1, IL-2 and TGF-beta while enhancing GM-CSF gene expression in BM cells.	Cyclosporine	42-45	interleukin 1 complex	Mus musculus	196-200
10382954-6	1999	Additional studies have shown that HC and CsA blocked con A-driven differentiation of CD8+ and CD4+ CD8+ lymph node cells (LNC) and progression of LNC to S + G2/M cell cycle phases, and inhibited IL-1, IL-2 and TGF-beta while enhancing GM-CSF gene expression in BM cells.	Cyclosporine	42-45	transforming growth factor, beta 1	Mus musculus	211-219
12036883-6	2002	Treatment with rapamycin blocked IL-2 production after activation of human peripheral blood T cells with phorbol ester (PMA) and anti-CD28 (CsA-resistant pathway), whereas this drug did not have any effect on PMA plus ionomycin stimulation (CsA-sensitive pathway).	Cyclosporine	140-143	CD28 molecule	Homo sapiens	134-138
12769262-12	2002	In conclusion, HSP25 and alpha B-crystallin are overexpressed in the rat kidney treated with cyclosporine A but are similar to controls after combined melatonin.	Cyclosporine	93-107	heat shock protein family B (small) member 1	Rattus norvegicus	15-20
10469273-6	1999	Treatment of rats with the glucocorticoid dexamethasone or the immunosuppressant cyclosporin A reduced eosinophil entry into lung tissue and airways but had no apparent effect on eotaxin expression in vivo, indicating that both these drugs inhibit eosinophil recruitment either by an eotaxin-independent mechanism, or by targetting factors that synergise with eotaxin, or an event post eotaxin expression.	Cyclosporine	81-94	C-C motif chemokine ligand 11	Rattus norvegicus	179-186
10469273-6	1999	Treatment of rats with the glucocorticoid dexamethasone or the immunosuppressant cyclosporin A reduced eosinophil entry into lung tissue and airways but had no apparent effect on eotaxin expression in vivo, indicating that both these drugs inhibit eosinophil recruitment either by an eotaxin-independent mechanism, or by targetting factors that synergise with eotaxin, or an event post eotaxin expression.	Cyclosporine	81-94	C-C motif chemokine ligand 11	Rattus norvegicus	284-291
10469273-6	1999	Treatment of rats with the glucocorticoid dexamethasone or the immunosuppressant cyclosporin A reduced eosinophil entry into lung tissue and airways but had no apparent effect on eotaxin expression in vivo, indicating that both these drugs inhibit eosinophil recruitment either by an eotaxin-independent mechanism, or by targetting factors that synergise with eotaxin, or an event post eotaxin expression.	Cyclosporine	81-94	C-C motif chemokine ligand 11	Rattus norvegicus	284-291
10469273-6	1999	Treatment of rats with the glucocorticoid dexamethasone or the immunosuppressant cyclosporin A reduced eosinophil entry into lung tissue and airways but had no apparent effect on eotaxin expression in vivo, indicating that both these drugs inhibit eosinophil recruitment either by an eotaxin-independent mechanism, or by targetting factors that synergise with eotaxin, or an event post eotaxin expression.	Cyclosporine	81-94	C-C motif chemokine ligand 11	Rattus norvegicus	284-291
10349859-4	1999	Cyclosporin A and its nonimmunosuppressive analogue N-methyl-Val-4-cyclosporin A (PKF 220-384) both inhibited swelling and prevented the translocation of cyclophilin D from the matrix to the membranes of cortical mitochondria.	Cyclosporine	0-13	peptidylprolyl isomerase F	Rattus norvegicus	154-167
10414517-9	1999	Cyclosporin A administration led to the most persistent beta-galactosidase activity in neurons at 5 and 8 days.	Cyclosporine	0-13	galactosidase beta 1	Homo sapiens	56-74
10220486-0	1999	Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein.	Cyclosporine	30-43	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	70-75
10217279-7	1999	Incubation of slices in the presence of cyclosporin A plus either okadaic acid or calyculin A, another PP-1/PP-2A inhibitor, caused a synergistic increase in the level of phosphorylated DARPP-32.	Cyclosporine	40-53	protein phosphatase 1 catalytic subunit gamma	Mus musculus	103-107
12769262-12	2002	In conclusion, HSP25 and alpha B-crystallin are overexpressed in the rat kidney treated with cyclosporine A but are similar to controls after combined melatonin.	Cyclosporine	93-107	crystallin, alpha B	Rattus norvegicus	25-43
12066135-8	2002	The decreased expression of Bcl-2 and the ratio of Bcl-2 to Bax protein seen in cyclosporine-treated rat kidneys were significantly increased after colchicine treatment, accompanying a suppression of caspase-3 activity (P &lt;.05).	Cyclosporine	80-92	caspase 3	Rattus norvegicus	200-209
12134947-11	2002	A mixture of GF120918 (2 microM) and cyclosporin A (25 microM) decreased the Papp BL-to-AP/Papp AP-to-BL ratios of AD in MDCK-WT, MDCK-MDR1, and MDCK-MRP2 cells to 1.2,1.8, and 2.3, respectively.	Cyclosporine	37-50	ATP binding cassette subfamily B member 1	Canis lupus familiaris	135-139
12134948-14	2002	CsA (25 microM) greatly decreased the Papp BL-P-AP/Papp AP-to-BL ratios in MDCK-WT and MDCK-MDR1 cells to 1.5 and 3.2, respectively.	Cyclosporine	0-3	ATP binding cassette subfamily B member 1	Canis lupus familiaris	87-96
12134948-17	2002	A mixture of GF120918 (2 microM) and CsA (25 microM) decreased the Papp BL-to-AP/Papp AP-to-BL ratios of CD in MDCK-WT, MDCK-MDR1, and MDCK-MRP2 cells to 1.4, 2.7, and 5.4. respectively.	Cyclosporine	37-40	ATP binding cassette subfamily B member 1	Canis lupus familiaris	125-129
12123203-7	2002	The CsA group showed significant increases in ICE mRNA (0.21 vs. 0.03 amol/microgram total RNA at 4 weeks, p &lt; 0.05) and CPP32 mRNA (0.18 vs. 0.03 amol/microgram total RNA at 4 weeks, p &lt; 0.05), compared with the VH group.	Cyclosporine	4-7	caspase 1	Mus musculus	46-49
12123203-8	2002	The enzymatic activity of ICE (16.6 vs. 7.9 rho mol/microgram/h, p &lt; 0.05) and CPP32 protease (15.6 vs. 2.7 rho mol/microgram/h, p &lt; 0.05) proteases were increased in the CsA group, compared with the VH group.	Cyclosporine	177-180	caspase 1	Mus musculus	26-29
11961080-1	2002	By virtue of its binding to cyclophilin, the cellular receptor for cyclosporine (CsA), we could identify a new compound D-43787 [N-[(1-tert-butyloxycarbonyl)-indolin-2-(S)-carbonyl]-indolin-2-(S)-carbonacid-[N-epsilon-benzyloxycarbonyl)-2-(S)-lysin methylester]-amide] exhibiting immunomodulating properties.	Cyclosporine	67-79	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	81-84
11900796-1	2002	Cyclosporin A (CsA) and other immunophilin-binding agents are known to inactivate neuronal nitric oxide synthase (nNOS).	Cyclosporine	0-13	nitric oxide synthase 1, neuronal	Mus musculus	82-112
11900796-1	2002	Cyclosporin A (CsA) and other immunophilin-binding agents are known to inactivate neuronal nitric oxide synthase (nNOS).	Cyclosporine	0-13	nitric oxide synthase 1, neuronal	Mus musculus	114-118
11900796-1	2002	Cyclosporin A (CsA) and other immunophilin-binding agents are known to inactivate neuronal nitric oxide synthase (nNOS).	Cyclosporine	15-18	nitric oxide synthase 1, neuronal	Mus musculus	82-112
11900796-1	2002	Cyclosporin A (CsA) and other immunophilin-binding agents are known to inactivate neuronal nitric oxide synthase (nNOS).	Cyclosporine	15-18	nitric oxide synthase 1, neuronal	Mus musculus	114-118
11980680-8	2002	CONCLUSIONS: These findings indicate that the R257H variant in the PLC-delta1 gene detected in patients with CSA is associated with enhancement of enzyme activity, and they describe a novel mechanism for the enhanced coronary vasomotility in CSA.	Cyclosporine	109-112	phospholipase C delta 1	Homo sapiens	67-77
12021552-7	2002	It was then shown that PP2 and cyclosporin A strongly inhibited CD25 expression in both clones, while wortmannin and Ro-31-8220 had more limited effects.	Cyclosporine	31-44	interleukin 2 receptor subunit alpha	Homo sapiens	64-68
11966773-10	2002	Pharmacological drugs used in therapy of RA, such as cyclosporin and methotrexate, induced a fourfold increase of IL-17R mRNA expression and augmented the IL-17-stimulated IL-8 expression.	Cyclosporine	53-64	interleukin 17 receptor A	Homo sapiens	114-120
11834839-3	2002	These LFA-1 antagonists bound LFA-1, blocked binding of ICAM-1, and inhibited a mixed lymphocyte reaction (MLR) with potency significantly greater than that of cyclosporine A.	Cyclosporine	160-174	integrin subunit alpha L	Homo sapiens	6-11
10444742-0	1999	Signal recognition particle receptor (SRPR) is downregulated in a rat model of cyclosporin A-induced gingival overgrowth.	Cyclosporine	79-92	SRP receptor subunit alpha	Rattus norvegicus	0-36
10444742-0	1999	Signal recognition particle receptor (SRPR) is downregulated in a rat model of cyclosporin A-induced gingival overgrowth.	Cyclosporine	79-92	SRP receptor subunit alpha	Rattus norvegicus	38-42
11805183-12	2002	A single dose of a signaling anti-CD28 mAb administered at transplantation or in combination with a short course of CsA significantly prolonged recipient survival, normalized function, and preserved the morphology of renal allografts in an established model of chronic rejection.	Cyclosporine	116-119	Cd28 molecule	Rattus norvegicus	34-38
11700317-1	2002	Cyclosporin A (CsA) treatment of HEK 293 cells expressing the rat heart RHE-1 (NCX1.1, EMBL accession number ) or the rat brain RBE-2 (NCX1.5, GenBank(TM) accession number ) Na(+)-Ca(2+) exchanger inhibited their transport activity in a concentration-dependent manner.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
10027932-8	1999	In contrast, treating cells with tyrphostin A23, another tyrosine kinase inhibitor, or cyclosporine A, an immunosuppressant, inhibited SMIT activity in hypertonic cells.	Cyclosporine	87-101	LOC100856716	Canis lupus familiaris	135-139
9973482-6	1999	Cyclosporin A inhibited Fc epsilon RI-mediated JNK and p38 activation, but did not affect the activation of these kinases when stimulated through the SCFR.	Cyclosporine	0-13	mitogen-activated protein kinase 14	Mus musculus	55-58
12136946-2	2002	CsA treatment of T. spiralis-infected guinea pigs caused a significant attenuation of immunological response in lungs by decreasing lymphocyte infiltration into pulmonary alveolar space, inhibiting alveolar macrophage superoxide anion production and lowering both the production of NO metabolites measured in bronchoalveolar lavage fluid and expression of the iNOS protein in lung homogenates, allowing us to speculate that the T. spiralis-dependent immunological response is dependent on lymphocyte T function.	Cyclosporine	0-3	nitric oxide synthase, inducible	Cavia porcellus	360-364
10076049-5	1999	Cyclic nucleotide-dependent relaxation of CSA-induced contractions was associated with increases in the phosphorylation of another small heat shock protein, HSP20, and decreases in the phosphorylation of the MLC20, and some isoforms of HSP27.	Cyclosporine	42-45	heat shock protein beta-6	Bos taurus	157-162
10064053-5	1999	Addition of cyclosporin A completely inhibited TCR-mediated death and FasL cell surface up-regulation, but had no effect on apoptosis induced directly by Fas ligation following TCR stimulation.	Cyclosporine	12-25	Fas ligand (TNF superfamily, member 6)	Mus musculus	70-74
9950598-6	1999	There was a reduction from before CsA treatment to after CsA-treatment in the numbers of HLA-DR+ and IL-2R+ cells (P = 0.03), but the reduction in the epithelial cell HLA-DR expression did not reach significance.	Cyclosporine	57-60	interleukin 2 receptor subunit alpha	Homo sapiens	101-106
11868803-1	2002	OBJECTIVES: Area under the curve (AUC)-based monitoring of cyclosporin (CsA) could help to optimise therapeutic drug monitoring in certain transplant patients in addition to trough concentration monitoring.	Cyclosporine	59-70	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	72-75
10202558-2	1999	The best characterized costimulatory receptor expressed on resting T cells is CD28 which provides poorly-defined cyclosporin-resistant biochemical signal(s) that promote expression of several cytokines/chemokines.	Cyclosporine	113-124	CD28 molecule	Homo sapiens	78-82
10559581-6	1999	Following CsA treatment, a significant decrease in the percentage of activated T cells expressing CD3+CD25+ and CD3+HLA-DR+ was noted at 6 and 12 months.	Cyclosporine	10-13	interleukin 2 receptor subunit alpha	Homo sapiens	102-106
11755317-8	2002	HO-1 induction and ensuing formation of antioxidant metabolites may be a novel pathway by which ANP protects from CsA-dependent nephrotoxicity and preserves renal function.	Cyclosporine	114-117	heme oxygenase 1	Sus scrofa	0-4
11677240-9	2001	The PTP inhibitors cyclosporin A and bongkrekic acid prevented the H(2)O(2)-induced decrease in cell viability and caspase-3 activation.	Cyclosporine	19-32	caspase 3	Rattus norvegicus	115-124
10755366-1	1999	Toxicity of cyclosporine (CsA), an immunosuppressive drug widely used in transplantation, to the transplanted kidney creates a serious side effect.	Cyclosporine	12-24	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	26-29
9850449-2	1998	However, a published case report has indicated a possible interaction of glipizide with cyclosporine (CsA) pharmacokinetics in two renal transplant (tx) patients.	Cyclosporine	88-100	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	102-105
9825816-1	1998	BACKGROUND: Since the introduction of cyclosporine (CsA), 1-year renal allograft survival has improved, but concern persists about the long-term adverse effects of CsA, especially with respect to renal function and blood pressure.	Cyclosporine	38-50	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	52-55
9792908-1	1998	Like cyclosporin A, cyclolinopeptide A binds specifically bovine cyclophilin A, inhibiting its peptidyl-prolyl cis-trans isomerase activity.	Cyclosporine	5-18	peptidyl-prolyl cis-trans isomerase A	Bos taurus	65-78
11742267-0	2001	The immunomodulatory drugs cyclosporin A, mycophenolate mofetil, and sirolimus (rapamycin) inhibit allergen-induced proliferation and IL-5 production by PBMCs from atopic asthmatic patients.	Cyclosporine	27-40	interleukin 5	Homo sapiens	134-138
11742267-1	2001	We have used an optimized, physiologically relevant in vitro assay system to show that in a concentration-dependent fashion the immunomodulatory drugs cyclosporin A, mycophenolate mofetil, and sirolimus (rapamycin), as well as the glucocorticoid dexamethasone, inhibit allergen-driven T-cell proliferation and IL-5 production in PBMCs from allergen-sensitized atopic asthmatic individuals at physiologic concentrations.	Cyclosporine	151-164	interleukin 5	Homo sapiens	310-314
11420061-4	2001	Here, using a rat molar model, it is demonstrated that CyA immunosuppression inhibits the activity of matrix metalloproteinases 2 and 9 in the early phase of granulation tissue in the healing dental socket.	Cyclosporine	55-58	matrix metallopeptidase 2	Rattus norvegicus	102-135
9844139-13	1998	CONCLUSIONS: The present data suggest that ET-1 and ET-3 release by cultured rabbit proximal tubule cells are regulated differently, and that the stimulatory effect of CsA and tacrolimus on ET-1 release is antagonized by HGF and EGF.	Cyclosporine	168-171	pro-epidermal growth factor	Oryctolagus cuniculus	229-232
11532080-0	2001	Influence of the renin-angiotensin system on epidermal growth factor expression in normal and cyclosporine-treated rat kidney.	Cyclosporine	94-106	renin	Rattus norvegicus	17-22
9774651-6	1998	Caspase 3 activation, cytochrome c release, and apoptotic nuclear morphological changes were induced after onset of the MPT and were prevented by CsA.	Cyclosporine	146-149	caspase 3	Rattus norvegicus	0-9
11532080-0	2001	Influence of the renin-angiotensin system on epidermal growth factor expression in normal and cyclosporine-treated rat kidney.	Cyclosporine	94-106	epidermal growth factor like 1	Rattus norvegicus	45-68
11532080-8	2001	In contrast, the CsA-treated rats on the LSD had a significantly lower EGF expression (cortex, 98 vs. 53%; medulla, 94 vs. 14%); however, concomitant administration of LSRT increased the EGF expression (cortex, 91- vs. 3.8-fold; medulla, 19- vs. 2.4-fold) compared with the rats on the NSD.	Cyclosporine	17-20	epidermal growth factor like 1	Rattus norvegicus	71-74
11532080-8	2001	In contrast, the CsA-treated rats on the LSD had a significantly lower EGF expression (cortex, 98 vs. 53%; medulla, 94 vs. 14%); however, concomitant administration of LSRT increased the EGF expression (cortex, 91- vs. 3.8-fold; medulla, 19- vs. 2.4-fold) compared with the rats on the NSD.	Cyclosporine	17-20	epidermal growth factor like 1	Rattus norvegicus	187-190
11532080-9	2001	In the normal and CsA-treated LSD rats, EGF expression was well correlated with PRA.	Cyclosporine	18-21	epidermal growth factor like 1	Rattus norvegicus	40-43
11532080-10	2001	In addition, EGF expression was well correlated with the interstitial fibrosis score (r = 0.664, P &lt; 0.01) or number of TUNEL-positive cells (r = 0.822, P &lt; 0.01) in CsA-treated LSD rats.	Cyclosporine	172-175	epidermal growth factor like 1	Rattus norvegicus	13-16
12214041-0	2001	Cyclosporin A inhibits Al-induced cytochrome c release from mitochondria in aged rabbits.	Cyclosporine	0-13	cytochrome c	Oryctolagus cuniculus	34-46
12575579-6	2001	RESULTS: Chronic CsA-induced nephropathy might be correlated to TGF-beta 1 and renin mRNA up-regulation as well as matric proteins accumulation in interstitium.	Cyclosporine	17-20	renin	Rattus norvegicus	79-84
12575579-8	2001	CONCLUSION: Decreased CsA-related TGF-beta 1 and renin upregulation expression and accumulation of matrix proteins in the kidney might be related to the protective mechanism of CSI on CsA-induced chronic nephrotoxicity.	Cyclosporine	22-25	renin	Rattus norvegicus	49-54
12575579-8	2001	CONCLUSION: Decreased CsA-related TGF-beta 1 and renin upregulation expression and accumulation of matrix proteins in the kidney might be related to the protective mechanism of CSI on CsA-induced chronic nephrotoxicity.	Cyclosporine	184-187	renin	Rattus norvegicus	49-54
11437380-4	2001	ABCG2-ATPase was inhibited by low concentrations of Na-orthovanadate, N-ethylmaleimide and cyclosporin A.	Cyclosporine	91-104	dynein axonemal heavy chain 8	Homo sapiens	6-12
11549208-7	2001	In addition, the higher levels of CsA with docetaxel than with paclitaxel co-administration may be explained by the fact that docetaxel is almost exclusively metabolised by CYP 3A4, whereas paclitaxel is predominantly metabolised by CYP 2C8 and to a lesser extent by CYP 3A4.	Cyclosporine	34-37	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	233-240
11408540-4	2001	Cocaine significantly increased caspase-3 activity that was blocked by the inhibitors of cytochrome c release (cyclosporin A), caspase-3 (Ac-DEVD-CHO), and caspase-9 (Z-LEHD-FMK), respectively.	Cyclosporine	111-124	caspase 3	Bos taurus	32-41
11408540-4	2001	Cocaine significantly increased caspase-3 activity that was blocked by the inhibitors of cytochrome c release (cyclosporin A), caspase-3 (Ac-DEVD-CHO), and caspase-9 (Z-LEHD-FMK), respectively.	Cyclosporine	111-124	LOC104968582	Bos taurus	89-101
11408540-5	2001	In addition, cocaine activated caspase-9, which was blocked by cyclosporin A and Z-LEHD-FMK.	Cyclosporine	63-76	caspase 9	Bos taurus	31-40
11455258-3	2001	AIMS: To determine if urine and serum MIF concentrations: (1) are increased in acute rejection, and (2) can be used as noninvasive tools to discriminate between acute rejection (AR) and cyclosporine nephrotoxicity (CyA toxicity).	Cyclosporine	186-198	macrophage migration inhibitory factor	Homo sapiens	38-41
9829483-1	1998	BACKGROUND: Nitric oxide (NO) has been shown to play a role in cyclosporin (CsA) nephrotoxicity, but its mechanism of action is still unclear.	Cyclosporine	63-74	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	76-79
11455258-3	2001	AIMS: To determine if urine and serum MIF concentrations: (1) are increased in acute rejection, and (2) can be used as noninvasive tools to discriminate between acute rejection (AR) and cyclosporine nephrotoxicity (CyA toxicity).	Cyclosporine	215-218	macrophage migration inhibitory factor	Homo sapiens	38-41
11455258-11	2001	In contrast, urine MIF concentrations in CyA toxicity were not significantly different to normal controls (145+/-119 pg/micromol Cr; P=NS).	Cyclosporine	41-44	macrophage migration inhibitory factor	Homo sapiens	19-22
11399919-1	2001	BACKGROUND/AIM: In idiopathic nephrotic syndrome (INS), ciclosporin A (CsA) was shown to decrease proteinuria, an effect explained by its immunologic and hemodynamic actions.	Cyclosporine	71-74	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	56-69
11442023-1	2001	Cyclosporin A (CsA), an inhibitor of T cell cytokine production, protects mice against staphylococcal enterotoxin B (SEB) intoxication.	Cyclosporine	0-13	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	15-18
11357886-4	2001	Cyclosporin A (CsA) also inhibited the anti-CD3/CD28 induced IL-6 production but was about 100 times less potent than FK506.	Cyclosporine	0-13	CD28 molecule	Homo sapiens	48-52
11357886-4	2001	Cyclosporin A (CsA) also inhibited the anti-CD3/CD28 induced IL-6 production but was about 100 times less potent than FK506.	Cyclosporine	15-18	CD28 molecule	Homo sapiens	48-52
11222921-2	2001	We have previously reported that cyclosporin A (CsA) inhibits the growth and survival of the rat C6 glioma cells due to the inhibition of signaling pathway involving calcineurin and transcription factor nuclear factor of activated T cells (NFAT).	Cyclosporine	33-46	nuclear factor of activated T-cells 5	Rattus norvegicus	240-244
11222921-2	2001	We have previously reported that cyclosporin A (CsA) inhibits the growth and survival of the rat C6 glioma cells due to the inhibition of signaling pathway involving calcineurin and transcription factor nuclear factor of activated T cells (NFAT).	Cyclosporine	48-51	nuclear factor of activated T-cells 5	Rattus norvegicus	240-244
11278005-1	2001	Cyclosporin A (CsA) is a widely used immunosuppressive agent with severe side effects including hypertension.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
11102441-12	2001	These results suggest that pro-caspase-8 is predominantly localized in mitochondria and is released upon apoptotic stimulation through a CsA-sensitive mechanism.	Cyclosporine	137-140	caspase 8	Homo sapiens	31-40
11250896-5	2001	The defective replication phenotype was specific for wild-type HIV-1 since HIV-2/SIV isolates, as well as HIV-1 bearing a gag mutation that confers cyclosporin resistance, replicated the same in PPIA(+/+) and PPIA(-/-) cells.	Cyclosporine	148-159	Pr55(Gag)	Human immunodeficiency virus 1	122-125
11162625-3	2001	We observed that in cells treated with etoposide, cyclosporin A, 4-hydroxynonenal (HNE), or okadaic acid, there was an early reduction in the protein levels of p35, and later also in cdk5 with all treatments except etoposide.	Cyclosporine	50-63	cyclin-dependent kinase 5	Rattus norvegicus	183-187
9872566-7	1998	Immunosuppressants FK506 and cyclosporin A suppressed the K252a-induced cell adhesion and abolished tyrosine phosphorylation of cellular proteins including FAK and paxillin.	Cyclosporine	29-42	protein tyrosine kinase 2	Homo sapiens	156-159
9759839-6	1998	Cross-linking CD148 with immobilized anti-CD148 mAb induced vigorous proliferation of anti-CD3 mAb-activated, highly purified peripheral blood T cells in an IL-2-dependent, cyclosporin A-sensitive manner.	Cyclosporine	173-186	protein tyrosine phosphatase receptor type J	Homo sapiens	14-19
9759839-6	1998	Cross-linking CD148 with immobilized anti-CD148 mAb induced vigorous proliferation of anti-CD3 mAb-activated, highly purified peripheral blood T cells in an IL-2-dependent, cyclosporin A-sensitive manner.	Cyclosporine	173-186	protein tyrosine phosphatase receptor type J	Homo sapiens	42-47
11237286-0	2001	Modulation of beta2 integrin phenotype, adhesion, chemotaxis, and oxidative burst of neutrophils by cyclosporine.	Cyclosporine	100-112	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	14-19
11237286-3	2001	The aim of this work was to evaluate the effect of CsA on beta2 integrins" surface expression, adhesion to human umbilical endothelial cells (HUVECs), chemotaxis and oxidative burst by neutrophils.	Cyclosporine	51-54	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	58-63
11168932-11	2001	CsA-treated rats also had significantly increased TIMP-1 (7.4-fold, P &lt; 0.001), MMP-2, and PAI-1 (all approximately 2-fold, P &lt; 0.02) and decreased MMP-9 (85% reduction, P &lt; 0.001) as compared with controls.	Cyclosporine	0-3	matrix metallopeptidase 2	Rattus norvegicus	83-88
11261685-6	2001	We conclude that Neoral results in an increased bioavailability of cyclosporine (CsA) as compared to Sandimmun in patients with steroid-dependent nephrotic syndrome in remission.	Cyclosporine	67-79	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	81-84
11162519-4	2001	Cyclosporine A, rapamycin, and FK-506 decreased OPG mRNA and protein levels in undifferentiated marrow stromal cells (by 63, 44, and 68%, respectively, P &lt; 0.001).	Cyclosporine	0-14	TNF receptor superfamily member 11b	Homo sapiens	48-51
11162519-7	2001	Cyclosporine A also decreased OPG mRNA and protein production (by 52%, P &lt; 0.001) of CASMC.	Cyclosporine	0-14	TNF receptor superfamily member 11b	Homo sapiens	30-33
11162519-8	2001	In conclusion, immunosuppressants decrease OPG mRNA and protein production and increase RANKL gene expression by marrow stromal cells, and cyclosporine suppresses OPG production in CASMC.	Cyclosporine	139-151	TNF receptor superfamily member 11b	Homo sapiens	163-166
11167679-9	2001	In one patient examined before and 8 days after cyclosporin therapy, 50% or greater reductions were observed in percentages of peripheral blood CD8+/IL-5+, CD8+/IL-13+, CD4+/IL-4+ and CD4+/IL-5+ T lymphocytes following cyclosporin therapy.	Cyclosporine	48-59	interleukin 5	Homo sapiens	149-153
11167679-9	2001	In one patient examined before and 8 days after cyclosporin therapy, 50% or greater reductions were observed in percentages of peripheral blood CD8+/IL-5+, CD8+/IL-13+, CD4+/IL-4+ and CD4+/IL-5+ T lymphocytes following cyclosporin therapy.	Cyclosporine	48-59	interleukin 5	Homo sapiens	189-193
11193184-1	2001	The immunosuppressant drug cyclosporin A (CsA) is known to cause reduction in number, DNA synthesis and function of Langerhans cells (LC).	Cyclosporine	27-40	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	42-45
11133852-12	2001	CD40 ligand expression also decreased at months 3 and 6 in patients taking both concentrations of cyclosporin A.	Cyclosporine	98-111	CD40 molecule	Homo sapiens	0-4
11455576-3	2001	In fact, during treatment and after withdrawal, CY-treated animals remained euglycemic, showed good islet cell preservation and had low levels of Th1 and Th2 cytokines; ICAM-1 positivity within the islets was also found to be relatively low.	Cyclosporine	48-50	intercellular adhesion molecule 1	Mus musculus	169-175
11793432-3	2001	The assay principle is based on competitive immunoassay with G6PDH-labeled cyclosporine and cyclosporine in sample to the anticyclosporine mouse monoclonal antibody binding site.	Cyclosporine	75-87	hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase	Homo sapiens	61-66
9794567-1	1998	BACKGROUND: In renal transplantation the beneficial immunosuppressive effects of cyclosporin (CsA) may be curtailed by its nephrotoxicity, specially in patients receiving a cadaveric allograft from suboptimal donors or at risk of delayed graft function.	Cyclosporine	81-92	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	94-97
11134290-10	2001	Activation was dependent on nuclear factor of activated T cells (NFAT), occurred in cells deficient in the tyrosine kinase p56(lck), and could be blocked by addition of cyclosporin A and by depletion of calcium.	Cyclosporine	169-182	cyclin dependent kinase like 2	Homo sapiens	123-126
9794569-1	1998	BACKGROUND: Immunosuppressive treatment with cyclosporin A (CsA) improves the survival of renal allografts, but is associated with renal vasoconstriction and hypertension.	Cyclosporine	45-58	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	60-63
9733519-3	1998	Administration of the calcineurin inhibitors cyclosporin and FK506 prevented disease in mice that were genetically predisposed to develop HCM as a result of aberrant expression of tropomodulin, myosin light chain-2, or fetal beta-tropomyosin in the heart.	Cyclosporine	45-56	myosin light chain, phosphorylatable, fast skeletal muscle	Mus musculus	194-214
21336903-6	2001	CD28 ligation provides cyclosporin A-resistant biochemical signals to T cells, which are an absolute requirement to drive proliferation and IL-2 production from CD3-stimulated T cells, as well as enhance cell survival (5,6).	Cyclosporine	23-36	CD28 molecule	Homo sapiens	0-4
11769390-1	2001	Multiple clinical trials have been undertaken during last years to assess indications, efficiency and safety of glomerulonephritis treatment with new immunosuppressive drugs as cyclosporine (CsA, Mycophenolate Mophetil (MMF) and Tacrolimus (FK 506).	Cyclosporine	177-189	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	191-194
11104682-7	2000	Furthermore, mobilization of calcium by A23187 and thapsigargin blocked the TNFalpha-mediated induction of RGS16, which was reversed by EGTA and by the immunosuppressants FK506 and cyclosporin A, suggesting that the calcineurin/NF-AT (nuclear factor of activated T cells) pathway may repress the up-regulation process.	Cyclosporine	181-194	regulator of G protein signaling 16	Homo sapiens	107-112
9758340-2	1998	For GVHD suppression, one of the most frequently used regimens has been the combination of cyclosporin (CsA) and a short course of methotrexate (MTX) although the optimal usage of these agents remains unclear.	Cyclosporine	91-102	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	104-107
11078832-5	2000	By contrast, the immunosuppresant drugs cyclosporin A and FK506 abolished the effects of calcium elevation on HSF-1 activation.	Cyclosporine	40-53	heat shock transcription factor 1	Homo sapiens	110-115
11124491-1	2000	BACKGROUND: Management of cyclosporine (CsA)-associated hyperuricemia in heart transplantation (HT) is difficult.	Cyclosporine	26-38	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	40-43
9751843-3	1998	In this simple working hypothesis, mechanisms of clinical amelioration of atopic diseases manifested by glucocorticoids or immunosuppressants such as cyclosporin A or FK506 were easily understood to stem from the inhibition of IL-5 production and gene transcription.	Cyclosporine	150-163	interleukin 5	Homo sapiens	227-231
9705263-5	1998	In single-cycle infection assays, nef-defective virions were partially resistant to cyclosporin A (CsA), a drug that inhibits the binding of CyPA to the HIV-1 Gag precursor and CyPA incorporation into virions.	Cyclosporine	99-102	Pr55(Gag)	Human immunodeficiency virus 1	159-162
11115079-10	2000	Urinary N-acetyl-beta-D-glucosaminidase (NAG) excretion, a marker for renal proximal tubular damage, increased progressively in CsA-treated SHRs on the high-sodium diet.	Cyclosporine	128-131	O-GlcNAcase	Rattus norvegicus	8-39
9723952-8	1998	Cyclosporin A (25 mg/kg) increased [11C]verapamil levels in the brain and testes of mdr1a(+/+) mice in both cases 3.3-fold (P &lt; 0.01 (brain); P &lt; 0.001 (testes)).	Cyclosporine	0-13	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	84-89
9723952-14	1998	[11C]verapamil accumulation in the brain of mdr1a(+/+) mice was increased by cyclosporin A to levels comparable with those in mdr1a(-/-) mice, indicating that reversal of P-gp mediated efflux can be monitored by PET.	Cyclosporine	77-90	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	44-49
9756396-3	1998	A biphasic pattern was observed: a 4 h pre-treatment with CsA (1 microM) diminished the fMLP induced [Ca2+]c rise, reactive oxygen species (ROS) production, and beta-glucuronidase release by about 40%, whereas a 20 h pre-treatment increased these responses by about 1.5 fold.	Cyclosporine	58-61	glucuronidase beta	Homo sapiens	161-179
9706856-1	1998	Cyclosporine A(CsA) is successfully used to prevent graft rejection in organ transplantation and in the treatment of various systemic diseases.	Cyclosporine	0-14	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
11115079-10	2000	Urinary N-acetyl-beta-D-glucosaminidase (NAG) excretion, a marker for renal proximal tubular damage, increased progressively in CsA-treated SHRs on the high-sodium diet.	Cyclosporine	128-131	O-GlcNAcase	Rattus norvegicus	41-44
11074805-6	2000	Following treatment with 0.05% cyclosporine, there was a significant decrease in the number of cells expressing the lymphocyte activation markers CD11a (P&lt;.05) and HLA-DR (P&lt;.05), indicating less activation of lymphocytes as compared with vehicle treatment.	Cyclosporine	31-43	integrin subunit alpha L	Homo sapiens	146-151
9658403-16	1998	Another complex identified in T47D cytosol contained hsp90 and the cyclosporin A-binding cyclophilin of 40 kDa, CYP40, but not hsp70, PR, or GR.	Cyclosporine	67-80	peptidylprolyl isomerase D	Homo sapiens	112-117
11074805-7	2000	Within the Sjogren patient subgroup, those treated with 0.05% cyclosporine also showed a significant decrease in the number of cells positive for CD11a (P&lt;.001) as well as CD3 (P&lt;.03), indicating a reduction in number of activated lymphocytes.	Cyclosporine	62-74	integrin subunit alpha L	Homo sapiens	146-151
11046013-6	2000	The induction of NFATL1 protein, as well as NFATL1-dependent transcription, is inhibited by cyclosporin A and FK506, and expression of constitutively active calcineurin induces NFATL1-dependent transcription.	Cyclosporine	92-105	nuclear factor of activated T cells 5	Homo sapiens	17-23
11046013-6	2000	The induction of NFATL1 protein, as well as NFATL1-dependent transcription, is inhibited by cyclosporin A and FK506, and expression of constitutively active calcineurin induces NFATL1-dependent transcription.	Cyclosporine	92-105	nuclear factor of activated T cells 5	Homo sapiens	44-50
11046013-6	2000	The induction of NFATL1 protein, as well as NFATL1-dependent transcription, is inhibited by cyclosporin A and FK506, and expression of constitutively active calcineurin induces NFATL1-dependent transcription.	Cyclosporine	92-105	nuclear factor of activated T cells 5	Homo sapiens	44-50
11040041-1	2000	The immunosuppressant cyclosporin A inhibits transcription mediated by the nuclear factor of activated T-cells (NFAT), a key regulator of cytokine gene expression in lymphocytes that integrates phospholipase C signaling.	Cyclosporine	22-35	nuclear factor of activated T-cells 5	Rattus norvegicus	112-116
11042265-1	2000	Cyclosporin (CsA) inhibits mitochondrial death signaling and opposes tumor necrosis factor (TNF)-induced apoptosis in vitro.	Cyclosporine	0-11	tumor necrosis factor-like	Rattus norvegicus	92-95
11042265-1	2000	Cyclosporin (CsA) inhibits mitochondrial death signaling and opposes tumor necrosis factor (TNF)-induced apoptosis in vitro.	Cyclosporine	13-16	tumor necrosis factor-like	Rattus norvegicus	69-90
11042265-1	2000	Cyclosporin (CsA) inhibits mitochondrial death signaling and opposes tumor necrosis factor (TNF)-induced apoptosis in vitro.	Cyclosporine	13-16	tumor necrosis factor-like	Rattus norvegicus	92-95
11042265-5	2000	We studied two calcineurin inhibitors, CsA and FK506, and found that each potently inhibited TNF cytotoxicity.	Cyclosporine	39-42	tumor necrosis factor-like	Rattus norvegicus	93-96
10958865-7	2000	Methylprednisolone increased and cyclosporin A decreased serum cystatin C concentrations after 1 week of therapy.	Cyclosporine	33-46	cystatin C	Homo sapiens	63-73
9636359-5	1998	We confirmed the effect of CsA on Gag processing by examining virions produced from CEMx174 cells infected with HIV-1LAI.	Cyclosporine	27-30	Pr55(Gag)	Human immunodeficiency virus 1	34-37
9636359-7	1998	CsA has a direct effect on HIV-1 Gag processing that implicates CypA as having an important role in the maturation of HIV-1 particles.	Cyclosporine	0-3	Pr55(Gag)	Human immunodeficiency virus 1	33-36
9673819-7	1998	Cyclosporine A markedly increased urinary N-acetyl-beta-D-glucosaminidase (NAG) excretion in all dosed groups at the 7th day after treatment, except for rats dosed at 3 HALO.	Cyclosporine	0-14	O-GlcNAcase	Rattus norvegicus	42-73
9673819-7	1998	Cyclosporine A markedly increased urinary N-acetyl-beta-D-glucosaminidase (NAG) excretion in all dosed groups at the 7th day after treatment, except for rats dosed at 3 HALO.	Cyclosporine	0-14	O-GlcNAcase	Rattus norvegicus	75-78
9673819-13	1998	A different time course between Ccr and urine NAG excretion was observed during repeated CsA administration.	Cyclosporine	89-92	O-GlcNAcase	Rattus norvegicus	46-49
9603174-10	1998	Cyclosporine partially, but not completely, inhibits the development of CD30+ cells, and has a greater effect on interferon-gamma production than on interleukin-5 production.	Cyclosporine	0-12	interleukin 5	Homo sapiens	149-162
9569233-4	1998	The half-life (t1/2) of IL-5 mRNA, determined by addition of actinomycin D (ActinoD) or cyclosporin A (CSA) was longer (by &gt;= 2 h) than that of IL-2, IL-3, IL-4, interferon-gamma, or granulocyte/macrophage colony-stimulating factor.	Cyclosporine	88-101	interleukin 5	Homo sapiens	24-28
9569233-4	1998	The half-life (t1/2) of IL-5 mRNA, determined by addition of actinomycin D (ActinoD) or cyclosporin A (CSA) was longer (by &gt;= 2 h) than that of IL-2, IL-3, IL-4, interferon-gamma, or granulocyte/macrophage colony-stimulating factor.	Cyclosporine	103-106	interleukin 5	Homo sapiens	24-28
11048998-4	2000	IL-2 receptor antibodies have been shown to decrease rejection rates when added to a regimen of cyclosporine (CsA), azathioprine and prednisone.	Cyclosporine	96-108	interleukin 2 receptor subunit beta	Homo sapiens	0-13
11048998-4	2000	IL-2 receptor antibodies have been shown to decrease rejection rates when added to a regimen of cyclosporine (CsA), azathioprine and prednisone.	Cyclosporine	96-108	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	110-113
11012899-1	2000	BACKGROUND: Cyclosporine (CsA) has been shown to alter the activity of plasma membrane transporters in kidney epithelial cells.	Cyclosporine	12-24	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	26-29
10999939-0	2000	Cyclosporin A selectively inhibits mitogen-induced cyclooxygenase-2 gene transcription in vascular smooth muscle cells.	Cyclosporine	0-13	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	51-67
10999939-3	2000	Here we examine the effect of CsA on COX-2 mRNA induction in cultured rat vascular smooth muscle cells (VSMC) that natively express the nuclear factor of activated T-cells, a known mediator of CsA-sensitive transcription.	Cyclosporine	30-33	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	37-42
10999939-4	2000	CsA significantly suppresses strong COX-2 mRNA induction caused by the Ca(2+)-mobilizing mitogens UTP, angiotensin II, and platelet-derived growth factor-BB, and the synergistic induction caused by costimulation with ionomycin and a phorbol ester.	Cyclosporine	0-3	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	36-41
10999939-6	2000	CsA strongly inhibits UTP-, angiotensin II-, and platelet-derived growth factor-BB-stimulated COX-2 gene transcription as measured by nuclear run-on or promoter-reporter studies, but has no effect on mRNA induction caused by post-transcriptional stabilization of a distal COX-2 mRNA 3"-untranslated region regulatory element.	Cyclosporine	0-3	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	94-99
10999939-6	2000	CsA strongly inhibits UTP-, angiotensin II-, and platelet-derived growth factor-BB-stimulated COX-2 gene transcription as measured by nuclear run-on or promoter-reporter studies, but has no effect on mRNA induction caused by post-transcriptional stabilization of a distal COX-2 mRNA 3"-untranslated region regulatory element.	Cyclosporine	0-3	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	272-277
10999939-7	2000	These data show that CsA selectively inhibits mitogen-induced COX-2 gene expression by a transcriptional mechanism that may involve the nuclear factor of activated T-cells.	Cyclosporine	21-24	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	62-67
11045663-11	2000	Whereas IL-4 expression was not affected by tacrolimus and was enhanced by CsA, IL-10 expression was more significantly suppressed by tacrolimus than CsA.	Cyclosporine	75-78	interleukin 4	Rattus norvegicus	8-12
10929770-9	2000	Since cyclosporin A, known to be a modifier of p-Gp, also induced reversal of vincristine resistance in the ES-OMC-MN and SFT-8606 cell lines (IC50 6.2 nM and 17 nM, respectively), it is suggested that cyclosporin A acts as a modifier of MDR mediated by LRP.	Cyclosporine	6-19	major vault protein	Homo sapiens	254-257
10844492-2	2000	We describe a case of severe recalcitrant psoriasis responding well to combined cyclosporin and basiliximab (Simulect(R) Novartis Pharmaceuticals UK Ltd), an interleukin-2 receptor (IL-2R; CD25) chimeric monoclonal antibody.	Cyclosporine	80-91	interleukin 2 receptor subunit alpha	Homo sapiens	158-180
10844492-2	2000	We describe a case of severe recalcitrant psoriasis responding well to combined cyclosporin and basiliximab (Simulect(R) Novartis Pharmaceuticals UK Ltd), an interleukin-2 receptor (IL-2R; CD25) chimeric monoclonal antibody.	Cyclosporine	80-91	interleukin 2 receptor subunit alpha	Homo sapiens	189-193
10878286-1	2000	Cyclosporine (cyclosporin A, CsA) has potent immunosuppressive properties, reflecting its ability to block the transcription of cytokine genes in activated T cells.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	29-32
10836367-1	2000	BACKGROUND: Cyclosporine (CsA) nephrotoxicity is a common problem after cardiac transplantation.	Cyclosporine	12-24	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	26-29
10798748-1	2000	BACKGROUND: The theoretical aim of maintenance cyclosporine monotherapy (mCsA) after kidney transplantation is to reduce the incidence of the metabolic complications of corticosteroids and to minimize the adverse effects of excessive long-term immunosuppression.	Cyclosporine	47-59	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	73-77
9558395-3	1998	We report reversal of severe neutropenia associated with T-LGL leukemia in five patients treated with cyclosporine (CSA).	Cyclosporine	102-114	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	116-119
9603452-8	1998	In conclusion, IFN-gamma production by CD28-co-stimulated CD4+ T cells is resistant to inhibition by CsA and can even be facilitated by CsA as a result of removing a negative regulatory signal which is mainly IL-10 mediated.	Cyclosporine	101-104	CD28 molecule	Homo sapiens	39-43
9603452-8	1998	In conclusion, IFN-gamma production by CD28-co-stimulated CD4+ T cells is resistant to inhibition by CsA and can even be facilitated by CsA as a result of removing a negative regulatory signal which is mainly IL-10 mediated.	Cyclosporine	136-139	CD28 molecule	Homo sapiens	39-43
9580581-7	1998	The difference between mdr1a (-/-) and (+/+) brain (cerebrum and cerebellum) penetration depended on SDZ PSC 833 blood concentrations, because this cyclosporin analog apparently governs its own brain penetration by inhibiting the P-glycoprotein pump in mdr1a (+/+) mice.	Cyclosporine	148-159	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	23-28
9583869-1	1998	BACKGROUND: Cyclophilin B (CyPB) is a cyclosporine (CsA)-binding protein, located within intracellular vesicles and secreted in biological fluids.	Cyclosporine	38-50	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	52-55
9565092-1	1998	BACKGROUND: We examined the ability of FTY720, a novel immunosuppressant that prolongs the survival of allografts in experimental animal models, to potentiate the immunosuppressive effects of cyclosporine (CsA) and/or sirolimus (SRL) in vitro and in vivo.	Cyclosporine	192-204	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	206-209
9749227-1	1998	Cyclosporine (CsA) is an immunosuppressor widely used in all postoperative transplantation protocols.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
9601576-0	1998	Tumor necrosis factor-alpha is expressed by monocytes/macrophages following cardiac microembolization and is antagonized by cyclosporine.	Cyclosporine	124-136	tumor necrosis factor	Sus scrofa	0-27
9601576-9	1998	Expression of TNF-alpha in monocytes/macrophages was significantly reduced after pretreatment of pigs with cyclosporine or dexamethasone.	Cyclosporine	107-119	tumor necrosis factor	Sus scrofa	14-23
9601576-13	1998	synthesis of TNF-alpha and inflammatory angiogenesis can be inhibited be treatment with either cyclosporine or dexamethasone.	Cyclosporine	95-107	tumor necrosis factor	Sus scrofa	13-22
10775814-1	2000	OBJECTIVES: This study analyzed the relationship of variability in routine trough cyclosporine (CSA) levels to morbidity after pediatric cardiac transplantation.	Cyclosporine	82-94	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	96-99
9551405-9	1998	Our data indicate that a sizable part of renal vasoconstriction due to CsA is mediated via ET production in large preglomerular arteries and can be avoided by the blockade of ETA receptors.	Cyclosporine	71-74	endothelin receptor type A	Rattus norvegicus	175-178
9608563-7	1998	In dogs immunosuppressed with CsA combined with RS-61443, only a few myoblasts and myotubes expressing beta-Gal were observed 1-2 weeks after the transplantation, but no muscle fibers expressing beta-Gal were observed after 4 weeks, and antibodies against the injected cells were formed.	Cyclosporine	30-33	galactosidase beta 1	Canis lupus familiaris	103-111
9608563-10	1998	When the dogs were immunosuppressed with FK506 combined with CsA and RS-61443, muscle fibers expressing beta-Gal were present 4 weeks after the transplantation and no antibodies reacting with donor myoblasts were detected.	Cyclosporine	61-64	galactosidase beta 1	Canis lupus familiaris	104-112
9640246-6	1998	T-cell proliferation mediated through CD6/CD28 was only partially blocked by the immunosuppressive drug, cyclosporin A (CsA), whereas anti-CD28-induced T-cell proliferation in the presence of the phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA), was unaffected.	Cyclosporine	105-118	CD28 molecule	Homo sapiens	42-46
9640246-6	1998	T-cell proliferation mediated through CD6/CD28 was only partially blocked by the immunosuppressive drug, cyclosporin A (CsA), whereas anti-CD28-induced T-cell proliferation in the presence of the phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA), was unaffected.	Cyclosporine	120-123	CD28 molecule	Homo sapiens	42-46
10775814-8	2000	Cyclosporine variability was measured as the percentage of CSA levels that were considered sub-therapeutic (&lt; or = 100 ng/ml), toxic (&gt; or = 450 ng/ml), or both.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	59-62
10727524-0	2000	Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant P-glycoprotein with deleted phe(335).	Cyclosporine	8-19	dynein axonemal heavy chain 8	Homo sapiens	70-76
10727524-4	2000	Cyclosporine inhibited ATPase activity in both cell types, whereas the cyclosporin D analog valspodar (PSC 833), vinblastine, and dactinomycin stimulated ATPase activity in Dx5 but not in mutant DxP cells.	Cyclosporine	0-12	dynein axonemal heavy chain 8	Homo sapiens	23-29
10727524-4	2000	Cyclosporine inhibited ATPase activity in both cell types, whereas the cyclosporin D analog valspodar (PSC 833), vinblastine, and dactinomycin stimulated ATPase activity in Dx5 but not in mutant DxP cells.	Cyclosporine	71-82	dynein axonemal heavy chain 8	Homo sapiens	154-160
10702360-7	2000	The caspase-3 inhibitor, Ac-DEVD-CHO, inhibited caspase-3 activation and attenuated CsA-induced apoptosis and LDH leakage.	Cyclosporine	84-87	caspase 3	Rattus norvegicus	4-13
10704895-0	2000	Effect of dose on cyclosporine-induced suppression of hepatic cytochrome P450 3A2 and 2C11.	Cyclosporine	18-30	cytochrome P450, family 3, subfamily a, polypeptide 2	Rattus norvegicus	62-90
10609555-8	2000	CsA induced a 85% decrease in calbindin-D28k mRNA levels as well as a 40% and 69% decrease in VDR and 24-OHase mRNA levels, respectively.	Cyclosporine	0-3	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	102-110
10669849-12	2000	The rotamase activity of the protein, inhibited by cyclosporin A, further confirmed that Bet v 7 belongs to the group of cyclophilins.	Cyclosporine	51-64	delta/notch like EGF repeat containing	Homo sapiens	89-92
10771575-11	2000	They reported that cyclosporin is effective for the treatment of this type of FSGS with a remission rate of about 30%.	Cyclosporine	19-30	actinin alpha 4	Homo sapiens	78-82
10661503-6	2000	Furthermore, inhibition of p-gp function by co-administration of cyclosporin A (CsA) with doxorubicin (ADM) in mdr1a(+/+) mice resulted in increased accumulation of ADM in inner ear tissues and hearing impairment similar to that noted in mdr1a(-/-) mice.	Cyclosporine	65-78	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	111-116
10661503-6	2000	Furthermore, inhibition of p-gp function by co-administration of cyclosporin A (CsA) with doxorubicin (ADM) in mdr1a(+/+) mice resulted in increased accumulation of ADM in inner ear tissues and hearing impairment similar to that noted in mdr1a(-/-) mice.	Cyclosporine	65-78	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	238-243
10661503-6	2000	Furthermore, inhibition of p-gp function by co-administration of cyclosporin A (CsA) with doxorubicin (ADM) in mdr1a(+/+) mice resulted in increased accumulation of ADM in inner ear tissues and hearing impairment similar to that noted in mdr1a(-/-) mice.	Cyclosporine	80-83	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	111-116
10661503-6	2000	Furthermore, inhibition of p-gp function by co-administration of cyclosporin A (CsA) with doxorubicin (ADM) in mdr1a(+/+) mice resulted in increased accumulation of ADM in inner ear tissues and hearing impairment similar to that noted in mdr1a(-/-) mice.	Cyclosporine	80-83	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	238-243
10778917-8	2000	RESULTS: Cyclosporin (1-5 microg/ml) and rapamycin (1.0-10 nM) but not FK-506 (5-10 nM) inhibited both iNOS and COX-2 expression at mRNA level which led to significant inhibition of NO and PGE2 production.	Cyclosporine	9-20	cytochrome c oxidase II, mitochondrial	Mus musculus	112-117
10778917-10	2000	Inhibition of iNOS and COX-2 mRNA accumulation by cyclosporin and rapamycin seem to be distinct.	Cyclosporine	50-61	cytochrome c oxidase II, mitochondrial	Mus musculus	23-28
11347860-1	2000	Cyclosporine (CsA) treatment in solid organ transplantation has represented one of the greatest advances in the past 20 years, reducing acute rejection and increasing long-term survival.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
10617117-9	2000	Moreover, agents that suppress mitochondrial calcium uptake (ruthenium red) and membrane permeability transition (cyclosporin A) attenuated AP-1 activation by HNE, suggesting a contribution of mitochondrial alterations to AP-1 activation.	Cyclosporine	114-127	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	140-144
10676915-5	2000	While combined immunosuppression with both antithymocyte globulin (ATG) and cyclosporine A (CSA) produces hematologic improvement in most patients, relapse is common.	Cyclosporine	76-90	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	92-95
11112023-1	2000	Cyclosporine (CsA) reduces nitric oxide (NO) production in medullary thick ascending limb (mTAL) cells.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
11112045-1	2000	Hypertension is a major side effect of cyclosporin (CsA).	Cyclosporine	39-50	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	52-55
10669119-6	1999	Cyclosporine A was also the most effective drug downregulating the expression of accessory molecules (CD54, CD58, CD80 and CD86).	Cyclosporine	0-14	CD58 molecule	Homo sapiens	108-112
10669119-6	1999	Cyclosporine A was also the most effective drug downregulating the expression of accessory molecules (CD54, CD58, CD80 and CD86).	Cyclosporine	0-14	CD80 molecule	Homo sapiens	114-118
10669119-6	1999	Cyclosporine A was also the most effective drug downregulating the expression of accessory molecules (CD54, CD58, CD80 and CD86).	Cyclosporine	0-14	CD86 molecule	Homo sapiens	123-127
10642944-10	1999	In conclusion, enalapril or verapamil significantly blunted the cyclosporine-induced osteopontin and TGF-beta gene expressions.	Cyclosporine	64-76	secreted phosphoprotein 1	Rattus norvegicus	85-96
9458024-1	1998	BACKGROUND: Mothers treated with cyclosporine (CsA) have previously not been allowed to breast-feed due to the reported accumulation of the drug in breast milk.	Cyclosporine	33-45	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	47-50
10589954-2	1999	Previous studies have shown that stimulation of T cells via CD28 or phorbol myristate acetate (PMA) activation is highly resistant to inhibition by cyclosporine A (CsA) and tacrolimus (FK506), as is the response of T cells to phytohemmaglutinin in the presence of endothelial cells.	Cyclosporine	148-162	CD28 molecule	Homo sapiens	60-64
10589954-2	1999	Previous studies have shown that stimulation of T cells via CD28 or phorbol myristate acetate (PMA) activation is highly resistant to inhibition by cyclosporine A (CsA) and tacrolimus (FK506), as is the response of T cells to phytohemmaglutinin in the presence of endothelial cells.	Cyclosporine	164-167	CD28 molecule	Homo sapiens	60-64
10589954-8	1999	Addition of B7-1 transfectants significantly increased interleukin-2 production by T cells/HUVEC and resistance to CsA was greatly increased to an ID50 of &gt; 1000 ng/ml.	Cyclosporine	115-118	CD80 molecule	Homo sapiens	12-16
10531391-1	1999	Treatment of C2-C12 mouse myoblasts with the immunosuppressant drug cyclosporin A (CsA) enhances the increase in acetylcholinesterase (AChE) expression observed during skeletal muscle differentiation.	Cyclosporine	68-81	acetylcholinesterase	Mus musculus	113-133
9659917-3	1998	Inhibition by Cyp-40 required both its C-terminal protein-interaction domain, which bound specifically to c-Myb, and its N-terminal catalytic domain and was blocked by the competitive inhibitor cyclosporin A.	Cyclosporine	194-207	peptidylprolyl isomerase D	Homo sapiens	14-20
10531391-1	1999	Treatment of C2-C12 mouse myoblasts with the immunosuppressant drug cyclosporin A (CsA) enhances the increase in acetylcholinesterase (AChE) expression observed during skeletal muscle differentiation.	Cyclosporine	68-81	acetylcholinesterase	Mus musculus	135-139
9408683-2	1997	We previously noted that low cyclosporine (CsA) levels were a risk factor for early acute rejection in pediatric recipients (1).	Cyclosporine	29-41	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	43-46
10531391-1	1999	Treatment of C2-C12 mouse myoblasts with the immunosuppressant drug cyclosporin A (CsA) enhances the increase in acetylcholinesterase (AChE) expression observed during skeletal muscle differentiation.	Cyclosporine	83-86	acetylcholinesterase	Mus musculus	113-133
10531391-1	1999	Treatment of C2-C12 mouse myoblasts with the immunosuppressant drug cyclosporin A (CsA) enhances the increase in acetylcholinesterase (AChE) expression observed during skeletal muscle differentiation.	Cyclosporine	83-86	acetylcholinesterase	Mus musculus	135-139
10531391-2	1999	The enhanced AChE expression is due primarily to increased mRNA stability because CsA treatment increases the half-life of AChE mRNA, but not the apparent transcriptional rate of the gene.	Cyclosporine	82-85	acetylcholinesterase	Mus musculus	13-17
9457703-3	1997	In this regard, FK506 is analogous to cyclosporin A, which must bind to its immunophilin (cyclophilin A) to display activity.	Cyclosporine	38-51	peptidylprolyl isomerase A	Rattus norvegicus	90-103
10531391-2	1999	The enhanced AChE expression is due primarily to increased mRNA stability because CsA treatment increases the half-life of AChE mRNA, but not the apparent transcriptional rate of the gene.	Cyclosporine	82-85	acetylcholinesterase	Mus musculus	123-127
10531391-8	1999	Conversely, overexpression of a dominant negative calcineurin construct increases AChE mRNA levels, which are further enhanced by CsA.	Cyclosporine	130-133	acetylcholinesterase	Mus musculus	82-86
10531391-9	1999	Thus, a CsA sensitive, calcineurin mediated pathway appears linked to differentiation-induced stabilization of AChE mRNA during myogenesis.	Cyclosporine	8-11	acetylcholinesterase	Mus musculus	111-115
10521511-10	1999	The identification of MEF2 as a novel target of calcineurin may provide in part a biochemical explanation for the therapeutic and toxic effects of immunosuppressants CsA and FK506.	Cyclosporine	166-169	myocyte enhancer factor 2A	Homo sapiens	22-26
9336420-2	1997	OBJECTIVE: To determine whether the clinical benefit and favorable safety profile previously noted with the combination of cyclosporine (CSA) and methotrexate (MTX) given for 24 weeks in patients with rheumatoid arthritis (RA) would be maintained for a further 24 weeks, and whether the addition of CSA in patients who had previously been randomized to receive placebo + MTX would result in clinical benefit.	Cyclosporine	123-135	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	137-140
10540152-9	1999	However, the addition of CsA or dexamethasone significantly down-regulated CD40 expression.	Cyclosporine	25-28	CD40 antigen	Mus musculus	75-79
9399022-1	1997	OBJECTIVE: Sirolimus (RAPA) is a new immunosuppressive drug currently in Phase III clinical trials in combination with cyclosporine A (CsA).	Cyclosporine	119-133	transcriptional regulating factor 1	Homo sapiens	22-26
10540152-10	1999	Anti-CD40 MoAb significantly reversed the effects of CsA or dexamethasone on B7.2 and B7.1 expression, suggesting that T cell engagement of CD40 plays a role in the mechanisms by which CsA and dexamethasone acts on B cells.	Cyclosporine	53-56	CD40 antigen	Mus musculus	5-9
9399022-1	1997	OBJECTIVE: Sirolimus (RAPA) is a new immunosuppressive drug currently in Phase III clinical trials in combination with cyclosporine A (CsA).	Cyclosporine	135-138	transcriptional regulating factor 1	Homo sapiens	22-26
10540152-10	1999	Anti-CD40 MoAb significantly reversed the effects of CsA or dexamethasone on B7.2 and B7.1 expression, suggesting that T cell engagement of CD40 plays a role in the mechanisms by which CsA and dexamethasone acts on B cells.	Cyclosporine	53-56	CD40 antigen	Mus musculus	140-144
10540152-10	1999	Anti-CD40 MoAb significantly reversed the effects of CsA or dexamethasone on B7.2 and B7.1 expression, suggesting that T cell engagement of CD40 plays a role in the mechanisms by which CsA and dexamethasone acts on B cells.	Cyclosporine	185-188	CD40 antigen	Mus musculus	5-9
9344552-1	1997	The immunosuppressant drugs FK506 and cyclosporin A inhibit T-cell proliferation via a common mechanism: calcineurin inhibition following binding to their respective binding proteins, the peptidyl prolyl isomerases FKBP-12 and cyclophilin A.	Cyclosporine	38-51	peptidylprolyl isomerase A	Rattus norvegicus	227-240
10540152-10	1999	Anti-CD40 MoAb significantly reversed the effects of CsA or dexamethasone on B7.2 and B7.1 expression, suggesting that T cell engagement of CD40 plays a role in the mechanisms by which CsA and dexamethasone acts on B cells.	Cyclosporine	185-188	CD40 antigen	Mus musculus	140-144
9409194-1	1997	Twenty-nine children with nephrotic syndrome were treated with cyclosporine (CsA), 100 mg/m2/day for 6 months and prednisone, 2 mg/kg every other day for 1 month and then subsequently 1 mg/kg every other day for 5 months.	Cyclosporine	63-75	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	77-80
9402685-4	1997	CsA reduced the levels of IFN-gamma, IL-2, IL-5 and IL-10, but not IL-4, mRNAs.	Cyclosporine	0-3	interleukin 5	Rattus norvegicus	43-47
9271313-3	1997	We investigated the mechanisms controlling IL-5 messenger RNA (mRNA) expression in human T-lymphocytes in the presence of CsA or FK506.	Cyclosporine	122-125	interleukin 5	Homo sapiens	43-47
9271313-7	1997	CsA and FK506 strongly inhibited cellular IL-5 mRNA expression in response to phytohemagglutinin (PHA), or to phorbol myristate acetate (PMA), and/or calcium ionophore.	Cyclosporine	0-3	interleukin 5	Homo sapiens	42-46
9271313-9	1997	Nuclear run-on assays done with either 7-day cultured PBMC or HSB-2 cells demonstrated striking inhibition of IL-5 gene transcription by both CsA and FK506 at levels reflecting the degree of reduction of total cellular IL-5 mRNA abundance.	Cyclosporine	142-145	interleukin 5	Homo sapiens	110-114
9271313-9	1997	Nuclear run-on assays done with either 7-day cultured PBMC or HSB-2 cells demonstrated striking inhibition of IL-5 gene transcription by both CsA and FK506 at levels reflecting the degree of reduction of total cellular IL-5 mRNA abundance.	Cyclosporine	142-145	interleukin 5	Homo sapiens	219-223
9271313-11	1997	Thus, the inhibitory effect of CsA and FK506 on cellular IL-5 mRNA expression can be explained by inhibition of the rate of IL-5 gene transcription.	Cyclosporine	31-34	interleukin 5	Homo sapiens	57-61
9271313-11	1997	Thus, the inhibitory effect of CsA and FK506 on cellular IL-5 mRNA expression can be explained by inhibition of the rate of IL-5 gene transcription.	Cyclosporine	31-34	interleukin 5	Homo sapiens	124-128
9245491-0	1997	Suppression of dialysis patients" lymphocyte IL-2R expression by glucocorticoids and cyclosporine.	Cyclosporine	85-97	interleukin 2 receptor subunit alpha	Homo sapiens	45-50
9245491-1	1997	Previous studies have shown interindividual heterogeneity in the suppressive effects of glucocorticoids and cyclosporine (CsA) on the proliferation responses of dialysis patients" peripheral blood mononuclear cells (PBMC).	Cyclosporine	108-120	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	122-125
9237665-4	1997	Inhibitors of mitochondrial permeability transition such as bongkrekic acid and a cyclophilin D-binding cyclosporin A derivative, N-methyl-Val-4-cyclosporin A, prevent the mitochondrial as well as all post-mitochondrial signs of apoptosis induced by NO including nuclear DNA fragmentation and exposure of phosphatidylserine residues on the cell surface.	Cyclosporine	104-117	peptidylprolyl isomerase D	Homo sapiens	82-95
9195923-8	1997	Only a small (but undetermined) fraction of the native GR.hsp90 heterocomplexes contain the cyclosporin A-binding immunophilin CyP-40.	Cyclosporine	92-105	peptidylprolyl isomerase D	Homo sapiens	127-133
9179384-0	1997	Cyclosporine A-induced increase in glomerular cyclic GMP in rats and the involvement of the endothelinB receptor.	Cyclosporine	0-14	endothelin receptor type B	Rattus norvegicus	92-112
9193837-3	1997	In addition, PTX decreases cyclosporine (CsA) induced renal endothelial release and vasoconstriction.	Cyclosporine	27-39	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	41-44
9184637-0	1997	In vitro modulation of human, autoreactive MBP-specific CD4 + T-cell clones by cyclosporin A.	Cyclosporine	79-92	myelin basic protein	Homo sapiens	43-46
9180163-1	1997	Cyclosporin A (CSA) is an effective inhibitor of the P-glycoprotein (P-gp) activity and has been shown to modulate multidrug resistance (MDR) in in vitro experimental models.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
9191025-3	1997	Recombinant Cyp40 produced in bacteria has a peptidyl-prolyl cis-trans isomerase activity with a catalytic efficiency (k[cat]/K[m]) of 0.5 x 10(6)M(-1)s(-1), which can be inhibited by cyclosporin A with an IC50 value of 60nM.	Cyclosporine	184-197	peptidylprolyl isomerase CPR6	Saccharomyces cerevisiae S288C	12-17
9158111-3	1997	The second model was one that required a 7-day (10 mg/kg) treatment with cyclosporin A (CsA) to achieve tolerance and used DA donors into Lewis (RT1(1)) recipients.	Cyclosporine	73-86	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	88-91
9439767-4	1997	At different concentrations, both Thd and H-Thd alone inhibited the lymphocyte proliferation induced by alloantigen (MLR), mitogens (Con A, PWM) and superantigen (SEB) with an activity of 50-75% that of CsA, however, in some tests, immunosuppressive potency of H-Thd was shown to be higher than that of Thd.	Cyclosporine	203-206	SET binding protein 1	Homo sapiens	163-166
9142140-14	1997	Combined exposure to CsA and DES enhanced the stimulatory effect of hCG on the accumulation of 17-OH-P in the media.	Cyclosporine	21-24	hypertrichosis 2 (generalised, congenital)	Homo sapiens	68-71
9155951-0	1997	Cyclosporin inhibits intercellular adhesion molecule-1 expression and reduces mast cell numbers in the asebia mouse model of chronic skin inflammation.	Cyclosporine	0-11	intercellular adhesion molecule 1	Mus musculus	21-54
9155951-4	1997	After 3 weeks subcutaneous injection with 5 or 10 mg/kg CsA the expression of ICAM-1 mRNA was determined by semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) and was found to be decreased 2.7-fold (P &lt; 0.001) and three-fold (P &lt; 0.001) relative to controls for 5 and 10 mg/kg treatments, respectively.	Cyclosporine	56-59	intercellular adhesion molecule 1	Mus musculus	78-84
9155951-9	1997	Thus, CsA exhibits a wide range of anti-inflammatory effects including reduction of ICAM-1 expression and mast cell numbers, and may be useful in the treatment of mast cell-mediated dermatoses.	Cyclosporine	6-9	intercellular adhesion molecule 1	Mus musculus	84-90
9097913-5	1997	Quantitative polymerase chain reaction analysis was used to document that both subtherapeutic (1.0 mg/kg) and therapeutic (2.0 or 4.0 mg/kg) CsA doses inhibited the expression of interferon-gamma (IFN-gamma) (P &lt; 0.03) and IL-2 (P &lt; 0.003) mRNA produced by T helper (Th) 1 cells, as well as IL-10 (P &lt; 0.001), but not IL-4 (NS) mRNA produced by Th2 cells.	Cyclosporine	141-144	interleukin 4	Rattus norvegicus	327-331
10495795-1	1997	Accurate monitoring of cyclosporine (CsA) dosage is still a problem, because measurement of the area under the curve (AUC)--the most appropriate indicator of exposure to CsA--requires a number of blood samples to be taken over 12 h, which makes monitoring difficult in day-to-day clinical practice.	Cyclosporine	23-35	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	37-40
9058834-10	1997	A concomitant cyclosporine treatment abrogated the CD3 mAb-induced protection, further pointing to the crucial role of T cell signaling in the effect observed.	Cyclosporine	14-26	CD3 antigen, epsilon polypeptide	Mus musculus	51-54
9075853-8	1997	The mean (+/- SD) CsA trough levels at end point were 187 +/- 63 and 210 +/- 95 ng/ml for CsA- and CsA-ME-treated patients, respectively.	Cyclosporine	18-21	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	90-94
9127694-1	1997	OBJECTIVE: The isolation and partial characterization of a 37 kDa minor immunophilin from the Jurkat cell line which binds to cyclosporine (CsA), Tacrolimus (FK506) and Sirolimus (RAPA).	Cyclosporine	140-143	transcriptional regulating factor 1	Homo sapiens	180-184
9075128-1	1997	BACKGROUND: Deterioration of renal function and rise in blood pressure are clinically important side-effects of cyclosporin (CsA) treatment.	Cyclosporine	112-123	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	125-128
9047145-5	1997	Cyclosporine (CsA) inhibits activation and proliferation of T lymphocytes and is commonly administered after lung transplantation.	Cyclosporine	0-12	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	14-17
9067693-1	1997	Numerous drugs have been reported to alter cyclosporine (CSA) blood levels, most notably, those drugs that interfere with cytochrome P450 metabolism.	Cyclosporine	43-55	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	57-60
9013979-6	1997	Fc(epsilon)RI aggregation-dependent Ltn mRNA expression was detected by 1 to 2 h, maximal at 6 h, independent of de novo protein synthesis, and was inhibited by cyclosporin A and dexamethasone.	Cyclosporine	161-174	Fc epsilon receptor Ia	Homo sapiens	0-13
9020336-2	1997	The combination of a single dose of rapamycin (RAPA) with a short course of cyclosporine (CsA) has been shown to induce transplantation tolerance in the nonfunctional rat heterotopic cardiac transplant model.	Cyclosporine	76-88	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	90-93
8990230-1	1997	The new oral formulation of cyclosporine (CsA), Neoral (CsA-N), results in increased area under the curve (AUC) and decreased intra- and interindividual variation in blood concentrations and other pharmacokinetic (PK) parameters when compared with the current Sand-immune (CsA-S) formulation.	Cyclosporine	28-40	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	42-45
8990230-1	1997	The new oral formulation of cyclosporine (CsA), Neoral (CsA-N), results in increased area under the curve (AUC) and decreased intra- and interindividual variation in blood concentrations and other pharmacokinetic (PK) parameters when compared with the current Sand-immune (CsA-S) formulation.	Cyclosporine	28-40	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	56-59
8990230-1	1997	The new oral formulation of cyclosporine (CsA), Neoral (CsA-N), results in increased area under the curve (AUC) and decreased intra- and interindividual variation in blood concentrations and other pharmacokinetic (PK) parameters when compared with the current Sand-immune (CsA-S) formulation.	Cyclosporine	28-40	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	56-59
9069448-3	1997	It has been suggested that cyclosporin may elevate Lp(a) levels.	Cyclosporine	27-38	lipoprotein(a)	Homo sapiens	51-56
9069448-4	1997	We therefore measured the serum concentration of Lp(a) in 50 renal transplant recipients who were receiving cyclosporin alone as immunosuppressive therapy and 50 who were treated with azathioprine and prednisolone, but not cyclosporin.	Cyclosporine	108-119	lipoprotein(a)	Homo sapiens	49-54
9069448-8	1997	Median Lp(a) concentration in the cyclosporin monotherapy group was 32.0 (range &lt;0.8-140.3) mg/dl and was significantly (p &lt; 0.05) greater than that of the azathioprine and prednisolone group which was 18.3 (range &lt;0.8-167.7) mg/dl.	Cyclosporine	34-45	lipoprotein(a)	Homo sapiens	7-12
9069448-10	1997	The lower level in those on cyclosporin was due to a decrease in the HDL2 subfraction.	Cyclosporine	28-39	junctophilin 3	Homo sapiens	69-73
10518828-8	1999	Cytokine gene expression and protein secretion into culture supernatants (IL-4, IL-5, IL-13, and IFN-gamma) were down-regulated in a concentration-dependent manner by either CS or FK in all relevant T-cell subsets.	Cyclosporine	174-176	interleukin 5	Homo sapiens	80-84
10507492-9	1999	CONCLUSION: During the early posttransplant period anti-CD25 monoclonal antibodies combined with rapamycin and steroids offer a promising baseline therapy to avoid cyclosporine exposure and facilitate recovery from ischemic/reperfusion injuries.	Cyclosporine	164-176	interleukin 2 receptor subunit alpha	Homo sapiens	56-60
10491144-4	1999	We identify the gene encoding the DNA repair enzyme DNA polymerase beta (Pol beta) as a novel CsA-sensitive transcription unit.	Cyclosporine	94-97	DNA polymerase beta	Homo sapiens	52-71
8990387-0	1996	Cyclosporine protects glomeruli from FSGS factor via an increase in glomerular cAMP.	Cyclosporine	0-12	actinin alpha 4	Homo sapiens	37-41
10491144-4	1999	We identify the gene encoding the DNA repair enzyme DNA polymerase beta (Pol beta) as a novel CsA-sensitive transcription unit.	Cyclosporine	94-97	DNA polymerase beta	Homo sapiens	73-81
8990387-1	1996	Cyclosporine (CsA) administration to patients with recurrent focal segmental glomerulosclerosis (FSGS) after transplantation results in remission of proteinuria.	Cyclosporine	0-12	actinin alpha 4	Homo sapiens	97-101
8990387-1	1996	Cyclosporine (CsA) administration to patients with recurrent focal segmental glomerulosclerosis (FSGS) after transplantation results in remission of proteinuria.	Cyclosporine	14-17	actinin alpha 4	Homo sapiens	97-101
10491144-5	1999	Our data show that transcription of pol beta mRNA is induced by Ca2+ and that CsA significantly inhibits PMA/ionomycin- and ionomycin-mediated upregulation of both pol beta mRNA and Pol beta protein.	Cyclosporine	78-81	DNA polymerase beta	Homo sapiens	36-44
8990387-3	1996	The purpose of this study was to determine if the increased glomerular levels of cAMP were related to the protective effects of CsA on an increase in Palbumin by FSGS sera.	Cyclosporine	128-131	actinin alpha 4	Homo sapiens	162-166
8990387-12	1996	We conclude that CsA may have a direct protective effect on the glomerular filtration barrier in FSGS.	Cyclosporine	17-20	actinin alpha 4	Homo sapiens	97-101
10491144-5	1999	Our data show that transcription of pol beta mRNA is induced by Ca2+ and that CsA significantly inhibits PMA/ionomycin- and ionomycin-mediated upregulation of both pol beta mRNA and Pol beta protein.	Cyclosporine	78-81	DNA polymerase beta	Homo sapiens	164-172
8990387-13	1996	We postulate that increased levels of glomerular cAMP by CsA may play an important role in protecting the glomerular Palbumin effect of the FSGS factor and may contribute to remission of proteinuria in FSGS patients.	Cyclosporine	57-60	actinin alpha 4	Homo sapiens	140-144
8990387-13	1996	We postulate that increased levels of glomerular cAMP by CsA may play an important role in protecting the glomerular Palbumin effect of the FSGS factor and may contribute to remission of proteinuria in FSGS patients.	Cyclosporine	57-60	actinin alpha 4	Homo sapiens	202-206
10491144-5	1999	Our data show that transcription of pol beta mRNA is induced by Ca2+ and that CsA significantly inhibits PMA/ionomycin- and ionomycin-mediated upregulation of both pol beta mRNA and Pol beta protein.	Cyclosporine	78-81	DNA polymerase beta	Homo sapiens	182-190
10556553-8	1999	The conditions used to stimulate the PER-117 cells determined whether IL5 production was inhibited by cyclosporin A or dexamethasone.	Cyclosporine	102-115	interleukin 5	Homo sapiens	70-73
8977524-6	1996	Cyclosporin A inhibited the proliferation as well as the production of the cytokines, including that of IL-2, IL-4, IL-5, and IFN-gamma, irrespective of the mode of stimulation.	Cyclosporine	0-13	interleukin 5	Homo sapiens	116-120
8947290-1	1996	INTRODUCTION: Cortical blindness, a rare form of cyclosporine (CSA) neurotoxicity, has previously been described in only nine bone marrow transplant (BMT) recipients.	Cyclosporine	49-61	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	63-66
10401019-7	1999	Those 40 cases in which the biopsy showed evidence of CSA or tacrolimus nephrotoxicity had a significantly (P &lt; 0.01) greater SMA level in the corresponding urine samples (0.089 +/- 0.126 microgram/mL; mean +/- SD) than the 49 cases without toxicity (0.018 +/- 0.027 microgram/mL) or 6 control subjects (0.003 +/- 0.007 microgram/mL), although there was considerable overlap of SMA values among these groups.	Cyclosporine	54-57	survival of motor neuron 1, telomeric	Homo sapiens	129-132
8931845-1	1996	The immunosuppressant drug cyclosporine A (CsA) has emerged as an important new cause of hypertension in both organ transplant recipients and patients with autoimmune diseases.	Cyclosporine	27-41	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	43-46
10454019-9	1999	Our findings showed that the CsA treatment induced clear variations of the activity of the cellular phosphatase and oxidoreductase enzymes from the first days of drug administration.	Cyclosporine	29-32	hydroxysteroid 17-beta dehydrogenase 6	Homo sapiens	116-130
10213846-7	1999	The administration of the immunosuppressant drug cyclosporine (5 mg/kg, 5 days) impaired the depressing effect of Freund"s adjuvant injection on CRH, TRH and somatostatin content in median eminence, but not that on GRH.	Cyclosporine	49-61	thyrotropin releasing hormone	Rattus norvegicus	150-153
10213846-8	1999	In the anterior hypothalamus, cyclosporine generally prevented the effect of immunization on hormone levels an revealed a second maximum in TRH at 0400 h. Cyclosporine also restored 24-hour variations in TRH and somatostatin levels of medial hypothalamus of Freund"s adjuvant-injected rats but was unable to modify them in the posterior hypothalamus.	Cyclosporine	30-42	thyrotropin releasing hormone	Rattus norvegicus	140-143
10213846-8	1999	In the anterior hypothalamus, cyclosporine generally prevented the effect of immunization on hormone levels an revealed a second maximum in TRH at 0400 h. Cyclosporine also restored 24-hour variations in TRH and somatostatin levels of medial hypothalamus of Freund"s adjuvant-injected rats but was unable to modify them in the posterior hypothalamus.	Cyclosporine	30-42	thyrotropin releasing hormone	Rattus norvegicus	204-207
10213846-8	1999	In the anterior hypothalamus, cyclosporine generally prevented the effect of immunization on hormone levels an revealed a second maximum in TRH at 0400 h. Cyclosporine also restored 24-hour variations in TRH and somatostatin levels of medial hypothalamus of Freund"s adjuvant-injected rats but was unable to modify them in the posterior hypothalamus.	Cyclosporine	155-167	thyrotropin releasing hormone	Rattus norvegicus	140-143
10213846-8	1999	In the anterior hypothalamus, cyclosporine generally prevented the effect of immunization on hormone levels an revealed a second maximum in TRH at 0400 h. Cyclosporine also restored 24-hour variations in TRH and somatostatin levels of medial hypothalamus of Freund"s adjuvant-injected rats but was unable to modify them in the posterior hypothalamus.	Cyclosporine	155-167	thyrotropin releasing hormone	Rattus norvegicus	204-207
10399863-1	1999	Cyclosporin A (CsA) induces neurological side effects in up to 40% of patients.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
10202617-2	1999	The introduction of a microemulsion preparation, CsA-ME (Neoral), with less variable pharmacokinetics, has made it possible to attempt to define its use more closely.	Cyclosporine	57-63	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	49-52
10201902-7	1999	Furthermore, we have observed that TCR-mediated neosynthesis of FLICE-like inhibitory protein mRNA is suppressed either by protein tyrosine kinase inhibitors or cyclosporin A.	Cyclosporine	161-174	caspase 8	Homo sapiens	64-69
10087047-4	1999	CyA did not affect CF secretion of transforming growth factor beta1, but markedly stimulated insulin-like growth factor-I (IGF-I) secretion and inhibited secretion of both IGF-I binding protein-(IGFBP)-3 and IGFBP-2.	Cyclosporine	0-3	insulin like growth factor binding protein 2	Homo sapiens	208-215
10199738-0	1999	Transforming growth factor (TGF)-beta mimics and anti-TGF-beta antibody abrogates the in vivo effects of cyclosporine: demonstration of a direct role of TGF-beta in immunosuppression and nephrotoxicity of cyclosporine.	Cyclosporine	105-117	transforming growth factor, beta 1	Mus musculus	54-62
10199738-0	1999	Transforming growth factor (TGF)-beta mimics and anti-TGF-beta antibody abrogates the in vivo effects of cyclosporine: demonstration of a direct role of TGF-beta in immunosuppression and nephrotoxicity of cyclosporine.	Cyclosporine	105-117	transforming growth factor, beta 1	Mus musculus	153-161
10199738-0	1999	Transforming growth factor (TGF)-beta mimics and anti-TGF-beta antibody abrogates the in vivo effects of cyclosporine: demonstration of a direct role of TGF-beta in immunosuppression and nephrotoxicity of cyclosporine.	Cyclosporine	205-217	transforming growth factor, beta 1	Mus musculus	54-62
10199738-1	1999	BACKGROUND: Cyclosporine (CsA) has been shown to induce the expression of transforming growth factor (TGF)-beta both in vitro and in vivo.	Cyclosporine	12-24	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	26-29
10198566-8	1999	The inhibitory effect of the FSGS factor on NO production persisted despite addition of indomethacin (0.1-1 mumol/L) or cyclosporine (25 micrograms/mL) to test media.	Cyclosporine	120-132	actinin alpha 4	Homo sapiens	29-33
10028970-7	1999	In vivo, cyclosporine enhances tumour growth in immunodeficient SCID-beige mice; anti-TGF-beta monoclonal antibodies but not control antibodies prevent the cyclosporine-induced increase in the number of metastases.	Cyclosporine	156-168	transforming growth factor, beta 1	Mus musculus	86-94
10500807-4	1999	The apoptotic effect from varying drug type and concentration was compared at 24 hours in CEM-MDR1+ cells, with and without co-incubation with MDR1 functional downregulator cyclosporin A (CSA) used at therapeutic concentration (1500 ng/ml).	Cyclosporine	173-186	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	188-191
10073260-5	1999	Cyclosporine"s efficacy in other glomerulopathies, such as IgA nephropathy (IgAN) and membranoproliferative glomerulonephritis (MPGN) remains poorly studied and, given the risk of nephrotoxicity, cannot be recommended for treatment of these entities until further data are available.	Cyclosporine	0-12	IGAN1	Homo sapiens	76-80
10989666-2	1999	The discovery that cyclosporin A (CsA) inhibits the pore proved instrumental.	Cyclosporine	19-32	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	34-37
10338283-6	1999	Histological assays at day 9 revealed that there was a significant increase in TH-immunoreactive neurons in the nigra of CsA-treated rats compared to that of the vehicle-treated rats.	Cyclosporine	121-124	tyrosine hydroxylase	Rattus norvegicus	79-81
9890306-0	1999	Beneficial effect of serotonin 5-HT2-receptor antagonism on renal blood flow autoregulation in cyclosporin-treated rats.	Cyclosporine	95-106	5-hydroxytryptamine receptor 2A	Rattus norvegicus	21-45
10353612-0	1999	The effect of cyclosporine administration on growth hormone release and serum concentrations of insulin-like growth factor-I in male rats.	Cyclosporine	14-26	gonadotropin releasing hormone receptor	Rattus norvegicus	45-59
10078836-2	1999	Cyclosporin A (cyclosporine, CSA) is an immunosuppressive drug with a narrow therapeutic index.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	29-32
8912887-4	1996	We also found that CsA-treatment decreased the expression of lck kinase of T cells and the production of IL-2 in response to concanavalin A (ConA), with minimum effect on IL-4 production.	Cyclosporine	19-22	lymphocyte protein tyrosine kinase	Mus musculus	61-64
8900321-1	1996	Hyperkalemia is the most frequent electrolyte abnormality found in whole organ transplant recipients receiving either cyclosporine (CsA) or tacrolimus (FK506).	Cyclosporine	118-130	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	132-135
8824230-8	1996	On the other hand, both PP1 and PP2B activities but not PP2A activity of cell extracts were suppressed by the addition of cyclosporin A or FK506 in the culture medium.	Cyclosporine	122-135	protein phosphatase 1 catalytic subunit gamma	Mus musculus	24-27
8840947-1	1996	Cyclosporine-associated thrombotic microangiopathy (CsA-TMA) is characterized by anemia, acute renal failure, and renal TMA.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	52-55
10381131-7	1998	Clone 16 was identified as cyclophilin-A, the receptor for the immunosuppressant drug cyclosporin A.	Cyclosporine	86-97	peptidylprolyl isomerase A	Rattus norvegicus	27-40
9843854-0	1998	CsA-sensitive purine-box transcriptional regulator in bronchial epithelial cells contains NF45, NF90, and Ku.	Cyclosporine	0-3	interleukin enhancer binding factor 2	Homo sapiens	90-94
8930454-9	1996	The absolute cyclosporine (CsA) requirement (mg/d) increased by approximately 33% (p = NS), and there was also a significant increase in the weight adjusted CsA requirement from 1.8 to 3.5 mg/kg/d (p = 0.02, ANOVA) following GBP in order to maintain similar TDX trough CsA levels.	Cyclosporine	13-25	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	27-30
8855292-9	1996	In vitro Bcl-XL induction following ligation of sIgM-required BTK, was cyclosporin A (CsA)-sensitive and dependent on extracellular Ca2+.	Cyclosporine	71-84	BCL2-like 1	Mus musculus	9-15
8855292-9	1996	In vitro Bcl-XL induction following ligation of sIgM-required BTK, was cyclosporin A (CsA)-sensitive and dependent on extracellular Ca2+.	Cyclosporine	86-89	BCL2-like 1	Mus musculus	9-15
8884530-4	1996	FK506 and CsA inhibit keratinocyte proliferation induced by EGF, TGF-alpha or IL-6.	Cyclosporine	10-13	transforming growth factor alpha	Homo sapiens	65-74
8884530-6	1996	These findings might indicate that the effects of FK506 and CsA on proliferation of cultured normal human keratinocytes are probably related to direct effects on growth regulation of keratinocytes via EGF, TGF-alpha or IL-6 stimulation.	Cyclosporine	60-63	transforming growth factor alpha	Homo sapiens	206-215
9878167-9	1998	Finally, Tat caused a delayed and progressive mitochondrial membrane depolarization, and cyclosporin A prevented Tat-induced apoptosis, suggesting an important role for mitochondrial membrane permeability transition in Tat-induced apoptosis.	Cyclosporine	89-102	tyrosine aminotransferase	Homo sapiens	113-116
9878167-9	1998	Finally, Tat caused a delayed and progressive mitochondrial membrane depolarization, and cyclosporin A prevented Tat-induced apoptosis, suggesting an important role for mitochondrial membrane permeability transition in Tat-induced apoptosis.	Cyclosporine	89-102	tyrosine aminotransferase	Homo sapiens	113-116
9834096-1	1998	We have studied the effects of the immunosuppressive drug cyclosporin A (CsA) on the generation of inositol 1,4,5-trisphosphate (IP3) and intracellular Ca2+ levels elicited upon ligation of murine macrophage receptors for alpha2-macroglobulin, bradykinin, epidermal growth factor, and platelet-derived growth factor.	Cyclosporine	58-71	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	73-76
9850164-4	1998	The target tissue of cyclosporin A-induced autoimmunity, i.e. the skin and tongue, were also examined for expression of CD80 and CD86.	Cyclosporine	21-34	CD86 molecule	Rattus norvegicus	129-133
9819421-10	1998	Cyclosporin A inhibited Cpr7 interactions with Cns1 but not with Hsp90.	Cyclosporine	0-13	peptidylprolyl isomerase CPR7	Saccharomyces cerevisiae S288C	24-28
9870481-3	1998	We have previously demonstrated an enhancement of agonist-mediated platelet activation by cyclosporine and tacrolimus which was associated with increased phosphorylation of two intracellular platelet proteins, p20 and p40.	Cyclosporine	90-102	interleukin 9	Homo sapiens	218-221
9804931-0	1998	MPP+ induced SH-SY5Y apoptosis is potentiated by cyclosporin A and inhibited by aristolochic acid.	Cyclosporine	49-62	M-phase phosphoprotein 6	Homo sapiens	0-3
8764025-0	1996	Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophilin A.	Cyclosporine	0-14	Pr55(Gag)	Human immunodeficiency virus 1	86-89
8764025-2	1996	Cyclosporine A and nonimmunosuppressive analogs bind with high affinity to cyclophilin A, compete with Gag for binding to cyclophilin A, and prevent incorporation of cyclophilin A into virions; in parallel with the disruption of cyclophilin A incorporation into virions, there is a linear reduction in the initiation of reverse transcription after infection of a T cell.	Cyclosporine	0-14	Pr55(Gag)	Human immunodeficiency virus 1	103-106
8764025-5	1996	That Gag"s functional dependence on cyclophilin A can be differentiated genetically from its ability to bind cyclophilin A is further demonstrated by the rescue of a mutation precluding cyclophilin A packaging by a mutation conferring cyclosporine A resistance.	Cyclosporine	235-249	Pr55(Gag)	Human immunodeficiency virus 1	5-8
9804931-2	1998	Paradoxically, CSA potentiated rather than inhibited MPP+ induced apoptosis.	Cyclosporine	15-18	M-phase phosphoprotein 6	Homo sapiens	53-56
9762012-0	1998	Cellular signaling mechanisms for stimulation of growth hormone secretion and growth hormone primary transcripts by immunosuppressant agents, FK506 and cyclosporin A, in cultured rat pituitary cells.	Cyclosporine	152-165	gonadotropin releasing hormone receptor	Rattus norvegicus	78-92
8806510-0	1996	Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction.	Cyclosporine	35-49	Pr55(Gag)	Human immunodeficiency virus 1	114-117
8806510-2	1996	HIV-1 replication is inhibited by cyclosporine A, an immunosuppressive drug which binds with high affinity to cyclophilin A and precludes interaction with the Gag polyprotein.	Cyclosporine	34-48	Pr55(Gag)	Human immunodeficiency virus 1	159-162
8806510-4	1996	Rather, the effectiveness of cyclosporine A and related compounds at inhibiting HIV-1 replication correlates with cyclophilin A-binding affinity and with the ability to disrupt the interaction between cyclophilin A and the HIV-1 Gag polyprotein.	Cyclosporine	29-43	Pr55(Gag)	Human immunodeficiency virus 1	229-232
8766550-1	1996	Cyclosporin A (CSA), an immunosuppressive agent used in organ transplantation and to treat some autoimmune diseases, blocks the Ca2+-dependent steps involved in T cell receptor triggering leading to interleukin (IL)-2 production.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
9762012-4	1998	FK506 and CsA increased GH release in a dose-dependent manner and inhibited calcineurin (CaN) activity in the cultured pituitary cells.	Cyclosporine	10-13	gonadotropin releasing hormone receptor	Rattus norvegicus	24-26
9762012-9	1998	These results suggest that the immunosuppressants, FK506 and CsA, stimulate GH release by inhibiting CaN activity which results in the activation of the PKA system in the rat somatotropes.	Cyclosporine	61-64	gonadotropin releasing hormone receptor	Rattus norvegicus	76-78
9755112-6	1998	Western immunoblotting revealed PPase 2B to be present in cytoskeletal EC fractions, with specific PPase 2B inhibitors such as cyclosporin (200 nM) and deltamethrin (100 nM to 1 microM) attenuating thrombin-induced cytoskeletal protein dephosphorylation, including EC MLC dephosphorylation.	Cyclosporine	127-138	inorganic pyrophosphatase 2	Homo sapiens	32-39
9757134-1	1998	Cyclophilin A from the bovine parasite Trypanosoma brucei brucei has been cloned, expressed in Escherichia coli, purified and crystallized in the presence of cyclosporin A using ammonium sulfate as a precipitant.	Cyclosporine	158-171	peptidyl-prolyl cis-trans isomerase A	Bos taurus	0-13
8757947-4	1996	We have found that CsA- and FK506-treated cells did not exhibit transcription of FasL mRNA after activation and were lacking functional FasL protein on their surface as determined by staining and the ability to induce apoptosis in Fas+ target cells.	Cyclosporine	19-22	Fas ligand (TNF superfamily, member 6)	Mus musculus	136-140
8757947-9	1996	We therefore conclude that CsA and FK506 block activation-induced apoptosis in T cell hybridomas predominantly by interfering with activation signals leading to FasL expression and, further, that the regulation of the expression of Fas and FasL on activated T cells is differentially controlled.	Cyclosporine	27-30	Fas ligand (TNF superfamily, member 6)	Mus musculus	161-165
8757947-9	1996	We therefore conclude that CsA and FK506 block activation-induced apoptosis in T cell hybridomas predominantly by interfering with activation signals leading to FasL expression and, further, that the regulation of the expression of Fas and FasL on activated T cells is differentially controlled.	Cyclosporine	27-30	Fas ligand (TNF superfamily, member 6)	Mus musculus	240-244
8757955-0	1996	Primary porcine endothelial cells express membrane-bound B7-2 (CD86) and a soluble factor that co-stimulate cyclosporin A-resistant and CD28-dependent human T cell proliferation.	Cyclosporine	108-121	CD86 molecule	Homo sapiens	63-67
8757955-4	1996	The CsA-resistant component is completely suppressed either by blocking with anti-CD28 F(ab) fragments or CTLA-4-Ig.	Cyclosporine	4-7	CD28 molecule	Homo sapiens	82-86
8757955-8	1996	These findings demonstrate that primary unstimulated porcine EC can co-stimulate CsA-resistant human T cell proliferation through binding of membrane bound, constitutively expressed EC B7-2 (CD86) to human T cell CD28, providing one of the first demonstrations of functional B7-2 on cells outside the immune system.	Cyclosporine	81-84	CD86 molecule	Homo sapiens	185-189
8757955-8	1996	These findings demonstrate that primary unstimulated porcine EC can co-stimulate CsA-resistant human T cell proliferation through binding of membrane bound, constitutively expressed EC B7-2 (CD86) to human T cell CD28, providing one of the first demonstrations of functional B7-2 on cells outside the immune system.	Cyclosporine	81-84	CD86 molecule	Homo sapiens	191-195
8757955-8	1996	These findings demonstrate that primary unstimulated porcine EC can co-stimulate CsA-resistant human T cell proliferation through binding of membrane bound, constitutively expressed EC B7-2 (CD86) to human T cell CD28, providing one of the first demonstrations of functional B7-2 on cells outside the immune system.	Cyclosporine	81-84	CD28 molecule	Homo sapiens	213-217
8807571-2	1996	We have examined the effect of CsA on the expression of the beta 2 integrin, LFA-1, and its counter receptor, ICAM-1, on a renal Ag-specific murine T cell clone and Ag-expressing renal tubular epithelial cells.	Cyclosporine	31-34	intercellular adhesion molecule 1	Mus musculus	110-116
8807571-3	1996	We have found that CsA has a concentration dependent effect on the expression of both ICAM-1 mRNA and gene product on renal tubular cells.	Cyclosporine	19-22	intercellular adhesion molecule 1	Mus musculus	86-92
9806427-1	1998	Cyclosporin A (CsA) at concentrations up to 1 microM induced apoptosis in a dose-dependent manner in cultured rat hepatocytes for 48 h in the presence of insulin and epidermal growth factor (EGF).	Cyclosporine	0-13	epidermal growth factor like 1	Rattus norvegicus	166-189
8807571-4	1996	At 0.1 microgram/ml, CsA exhibits a costimulatory effect, with TNF alpha, on ICAM-1 expression.	Cyclosporine	21-24	intercellular adhesion molecule 1	Mus musculus	77-83
9806427-1	1998	Cyclosporin A (CsA) at concentrations up to 1 microM induced apoptosis in a dose-dependent manner in cultured rat hepatocytes for 48 h in the presence of insulin and epidermal growth factor (EGF).	Cyclosporine	0-13	epidermal growth factor like 1	Rattus norvegicus	191-194
8807571-5	1996	CsA at 1 to 5 micrograms/ml exhibits concentration dependent inhibition of ICAM-1 cell surface expression by the tubular cells.	Cyclosporine	0-3	intercellular adhesion molecule 1	Mus musculus	75-81
9806427-1	1998	Cyclosporin A (CsA) at concentrations up to 1 microM induced apoptosis in a dose-dependent manner in cultured rat hepatocytes for 48 h in the presence of insulin and epidermal growth factor (EGF).	Cyclosporine	15-18	epidermal growth factor like 1	Rattus norvegicus	166-189
8807571-7	1996	The concentration dependent effects of CsA on ICAM-1 expression correlate well with ICAM-1 dependent T cell adhesion to TNF alpha stimulated tubular epithelial cells.	Cyclosporine	39-42	intercellular adhesion molecule 1	Mus musculus	46-52
8807571-7	1996	The concentration dependent effects of CsA on ICAM-1 expression correlate well with ICAM-1 dependent T cell adhesion to TNF alpha stimulated tubular epithelial cells.	Cyclosporine	39-42	intercellular adhesion molecule 1	Mus musculus	84-90
9806427-1	1998	Cyclosporin A (CsA) at concentrations up to 1 microM induced apoptosis in a dose-dependent manner in cultured rat hepatocytes for 48 h in the presence of insulin and epidermal growth factor (EGF).	Cyclosporine	15-18	epidermal growth factor like 1	Rattus norvegicus	191-194
8807571-9	1996	Our studies support the conclusion that CsA may bidirectionally alter ICAM-1 dependent cellular adhesive interactions.	Cyclosporine	40-43	intercellular adhesion molecule 1	Mus musculus	70-76
9709036-1	1998	The immunosuppressive fungal products cyclosporin A (CsA) and FK506 bind with high affinity to intracellular receptor proteins: cyclophilin (CYP) is one of the receptors for CsA and FK506-binding protein (FKBP) is one of the receptors for FK506.	Cyclosporine	38-51	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	53-56
8807571-10	1996	The inhibition of cytokine stimulated ICAM-1 expression at higher CsA concentrations would contribute to the overall immunosuppressive effect of the drug.	Cyclosporine	66-69	intercellular adhesion molecule 1	Mus musculus	38-44
8693288-8	1996	Therefore, although professional APC can apparently provide multiple costimulatory signals for direct activation of CD8+ T cells, the signal derived from CD80/CD86 is unique in providing CsA-resistance.	Cyclosporine	187-190	CD80 molecule	Homo sapiens	154-158
8693288-8	1996	Therefore, although professional APC can apparently provide multiple costimulatory signals for direct activation of CD8+ T cells, the signal derived from CD80/CD86 is unique in providing CsA-resistance.	Cyclosporine	187-190	CD86 molecule	Homo sapiens	159-163
8647944-1	1996	The mouse mdr1a (also called mdr3) P-GP is abundant in the blood-brain barrier, and its absence in mdr1a (-/-) mice leads to highly increased levels of the drugs ivermectin, vinblastine, digoxin, and cyclosporin A in the brain.	Cyclosporine	200-213	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	99-104
8633383-1	1996	In vitro studies have shown that the immunosuppressive property of cyclosporine (CsA) depends on its ability to inhibit the phosphatase activity of calcineurin, a critical enzyme for T cell activation.	Cyclosporine	67-79	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	81-84
9709036-1	1998	The immunosuppressive fungal products cyclosporin A (CsA) and FK506 bind with high affinity to intracellular receptor proteins: cyclophilin (CYP) is one of the receptors for CsA and FK506-binding protein (FKBP) is one of the receptors for FK506.	Cyclosporine	38-51	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	174-177
9746235-1	1998	Frequent monitoring of immunosuppressive drug cyclosporine A (CsA) in blood samples of tissue transplant patients is required in clinical practice because of the narrow therapeutic range between the immunosuppressive effect and the toxic effect of this drug.	Cyclosporine	46-60	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	62-65
8665934-2	1996	The pore is blocked by cyclosporin A (CSA).	Cyclosporine	23-36	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	38-41
8707349-5	1996	Most important, the addition of mouse cells transfected with human B7-1 (CD80), a natural ligand for CD28, provided a potent accessory signal for GM-CSF production by activated T cells, which could not be blocked by cyclosporin A.	Cyclosporine	216-229	CD80 molecule	Homo sapiens	67-71
9062818-4	1996	CsA may alter the Ca2+/Cam-dependent NOS activity by interacting with rat kidney Ca2+/calmodulin dependent events.	Cyclosporine	0-3	calmodulin 1	Rattus norvegicus	23-26
8724887-1	1996	Cyclosporine (CsA) is effective in treating steroid-dependent (SDNS) and steroid-resistant (SRNS) nephrotic syndrome (NS) in children, but because of the potential for chronic nephrotoxicity, its long-term use is controversial.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
8631809-4	1996	We demonstrate here, however, that NFAT can be activated, and significant levels of IL-2 can be produced by the CsA-resistant CD28-signaling pathway.	Cyclosporine	112-115	CD28 molecule	Homo sapiens	126-130
8631809-5	1996	In transient transfection assays, both multicopy NFAT- and IL-2 promoter-beta-galactosidase reporter gene constructs could be activated by phorbol 12-myristate 13-acetate (PMA)/alpha-CD28 stimulation, and this activation was resistant to CsA.	Cyclosporine	238-241	galactosidase beta 1	Homo sapiens	73-91
8631809-5	1996	In transient transfection assays, both multicopy NFAT- and IL-2 promoter-beta-galactosidase reporter gene constructs could be activated by phorbol 12-myristate 13-acetate (PMA)/alpha-CD28 stimulation, and this activation was resistant to CsA.	Cyclosporine	238-241	CD28 molecule	Homo sapiens	183-187
8636095-1	1996	After accumulation of a Ca2+ load, the addition of uncoupler to respiring rat liver mitochondria is followed by opening of the permeability transition pore (MTP), a voltage-dependent channel sensitive to cyclosporin A.	Cyclosporine	204-217	microsomal triglyceride transfer protein	Rattus norvegicus	157-160
8630412-9	1996	Sequential specimens from remitting patients receiving treatment with the Pgp modulator cyclosporin-A showed emergence of the LRP phenotype despite a decrease or loss of Pgp at the time of treatment failure (P =.0304).	Cyclosporine	88-101	major vault protein	Homo sapiens	126-129
8522995-6	1996	Activation of the ATPase was reversed by phorbol 12-myristate 13-acetate, an activator of protein kinase C, indicating that activation of Na+,K(+)-ATPase is due to decreased phosphorylation by protein kinase C. W-7 or cyclosporin, both inhibitors of calcineurin, prevented the activation of Na+,K(+)-ATPase by glutamate.	Cyclosporine	218-229	dynein axonemal heavy chain 8	Homo sapiens	18-24
8522995-6	1996	Activation of the ATPase was reversed by phorbol 12-myristate 13-acetate, an activator of protein kinase C, indicating that activation of Na+,K(+)-ATPase is due to decreased phosphorylation by protein kinase C. W-7 or cyclosporin, both inhibitors of calcineurin, prevented the activation of Na+,K(+)-ATPase by glutamate.	Cyclosporine	218-229	dynein axonemal heavy chain 8	Homo sapiens	147-153
8522995-6	1996	Activation of the ATPase was reversed by phorbol 12-myristate 13-acetate, an activator of protein kinase C, indicating that activation of Na+,K(+)-ATPase is due to decreased phosphorylation by protein kinase C. W-7 or cyclosporin, both inhibitors of calcineurin, prevented the activation of Na+,K(+)-ATPase by glutamate.	Cyclosporine	218-229	dynein axonemal heavy chain 8	Homo sapiens	147-153
9705263-5	1998	In single-cycle infection assays, nef-defective virions were partially resistant to cyclosporin A (CsA), a drug that inhibits the binding of CyPA to the HIV-1 Gag precursor and CyPA incorporation into virions.	Cyclosporine	84-97	Pr55(Gag)	Human immunodeficiency virus 1	159-162
9698296-16	1998	Conversely, PSC inhibited only reactions catalyzed by CYP3A, including cyclosporine A metabolism (IC50 = 6.5 microM) and p-hydroxyphenyl-C3"-paclitaxel formation (Ki = 1.2 microM).	Cyclosporine	71-85	PSC	Homo sapiens	12-15
9658084-1	1998	Human immunodeficiency virus type 1 (HIV-1) Gag and the cellular protein cyclophilin A form an essential complex in the virion core: virions produced by proviruses encoding Gag mutants with decreased cyclophilin A affinity exhibit attenuated infectivity, as do virions produced in the presence of the competitive inhibitor cyclosporine.	Cyclosporine	323-335	Pr55(Gag)	Human immunodeficiency virus 1	44-47
8622563-7	1996	Nevertheless, if Dex and TGF-beta 1 were dosed together with one of these immunosuppressants, suppressions of histamine and ischemic edema were 53%, 45% (FK506), 45%, 49% (CsA), 44%, 48% (Rapa) and 39%, 51% (DSP), respectively.	Cyclosporine	172-175	transforming growth factor, beta 1	Mus musculus	25-35
9658084-2	1998	The A224E Gag mutant has no effect on cyclophilin A affinity but renders HIV-1 replication cyclosporine resistant in Jurkat T cells.	Cyclosporine	91-103	Pr55(Gag)	Human immunodeficiency virus 1	10-13
8730435-0	1996	Renin immunochemistry, sodium excretion and relative heart weight in cyclosporine- or alimentary-induced magnesium deficiency in rats.	Cyclosporine	69-81	renin	Rattus norvegicus	0-5
9723377-0	1998	Verapamil prevents cyclosporine-induced hypertension by modulating endothelin A receptor expression in rat kidney membranes.	Cyclosporine	19-31	endothelin receptor type A	Rattus norvegicus	67-88
9721433-1	1998	Based on the findings above, a number of conclusions can be made regarding the distribution, pharmacokinetics, and therapeutic range investigations with RAPA: (a) the majority of the drug is sequestered in erythrocytes, resulting in whole blood concentrations being considerably higher than plasma concentrations; (b) the drug is metabolized by the same cytochrome P450 3A enzyme involved in the metabolism of CsA and FK506.	Cyclosporine	410-413	transcriptional regulating factor 1	Homo sapiens	153-157
8545866-8	1995	(5) Cyclosporine (CsA) toxicity was implicated in only 3 recipients, who had mild diffuse interstitial fibrosis in association with elevated CsA levels.	Cyclosporine	4-16	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	18-21
8545869-8	1995	Cumulative prednisone dose (mg/kg) as well as cyclosporine (CsA) dose (mg/kg) at one year was not significantly different between obese and nonobese patients.	Cyclosporine	46-58	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	60-63
9648859-1	1998	Cyclosporin A (CsA) exerts its immunosuppressive effect by inhibiting the activity of nuclear factor of activated T cells (NFAT), thus preventing transcriptional induction of several cytokine genes.	Cyclosporine	0-13	nuclear factor of activated T-cells 5	Rattus norvegicus	123-127
8530342-5	1995	gp39 promoter function in transfectants was inhibited by cyclosporin A, as is expression of the endogenous gp39 gene in T-lineage cells.	Cyclosporine	57-70	chitinase 3 like 1	Homo sapiens	0-4
9648859-1	1998	Cyclosporin A (CsA) exerts its immunosuppressive effect by inhibiting the activity of nuclear factor of activated T cells (NFAT), thus preventing transcriptional induction of several cytokine genes.	Cyclosporine	15-18	nuclear factor of activated T-cells 5	Rattus norvegicus	123-127
9648859-4	1998	Here, we report that NFAT DNA-binding activity is present in the nuclear extracts from C6 glioma cells and that CsA treatment inhibits the formation of a functional NFAT complex.	Cyclosporine	112-115	nuclear factor of activated T-cells 5	Rattus norvegicus	21-25
8610498-1	1995	INTRODUCTION: Cortical blindness, a rare form of cyclosporine (CSA) neurotoxicity, has previously been described in only nine bone marrow transplant (BMT) recipients.	Cyclosporine	49-61	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	63-66
9648859-4	1998	Here, we report that NFAT DNA-binding activity is present in the nuclear extracts from C6 glioma cells and that CsA treatment inhibits the formation of a functional NFAT complex.	Cyclosporine	112-115	nuclear factor of activated T-cells 5	Rattus norvegicus	165-169
9733605-0	1998	Curcumin blocks cyclosporine A-resistant CD28 costimulatory pathway of human T-cell proliferation.	Cyclosporine	16-30	CD28 molecule	Homo sapiens	41-45
9645800-7	1998	The expression of PDGF-A mRNA of cardiac allograft was also significantly suppressed in the MT-treated group when compared with the CsA-treated group (P&lt;0.01).	Cyclosporine	132-135	platelet derived growth factor subunit A	Rattus norvegicus	18-24
8578771-11	1995	The effects of the cytochrome P450 inhibitors, ketoconazole and metyrapone, indicated that P450 played a role in the toxicity of CsA but not tamoxifen.	Cyclosporine	129-132	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	30-34
8578771-11	1995	The effects of the cytochrome P450 inhibitors, ketoconazole and metyrapone, indicated that P450 played a role in the toxicity of CsA but not tamoxifen.	Cyclosporine	129-132	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	91-95
9841506-4	1998	Multidrug-resistant Chinese hamster ovary (CHO) C5 cells accumulated less [3H]NPE than parental drug-sensitive Aux-B1 cells, and Mdr1p substrates, verapamil and cyclosporin A, increased this surfactant"s accumulation in C5 cells.	Cyclosporine	161-174	ATP binding cassette subfamily B member 1	Canis lupus familiaris	129-134
9686959-1	1998	Patients with steroid-resistant focal and segmental glomerulosclerosis (FSGS) have a poor prognosis but may benefit from high-dose methylprednisolone or cyclosporine A therapy.	Cyclosporine	153-167	actinin alpha 4	Homo sapiens	72-76
8774943-1	1995	Using electrophoretic mobility-shift assay (EMSA), we examined changes in DNA-binding activities of transcriptional factor-activated protein-1 (AP-1), which is a Fos-Jun protein complex, onto its responsive element TRE in the hippocampus and amygdaloid nucleus of rats stimulated with pentylenetetrazol (PTZ) injection, and also investigated the effects of a single administration of the immunosuppressant cyclosporin A (CsA).	Cyclosporine	406-419	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	116-142
8774943-1	1995	Using electrophoretic mobility-shift assay (EMSA), we examined changes in DNA-binding activities of transcriptional factor-activated protein-1 (AP-1), which is a Fos-Jun protein complex, onto its responsive element TRE in the hippocampus and amygdaloid nucleus of rats stimulated with pentylenetetrazol (PTZ) injection, and also investigated the effects of a single administration of the immunosuppressant cyclosporin A (CsA).	Cyclosporine	406-419	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	144-148
8774943-1	1995	Using electrophoretic mobility-shift assay (EMSA), we examined changes in DNA-binding activities of transcriptional factor-activated protein-1 (AP-1), which is a Fos-Jun protein complex, onto its responsive element TRE in the hippocampus and amygdaloid nucleus of rats stimulated with pentylenetetrazol (PTZ) injection, and also investigated the effects of a single administration of the immunosuppressant cyclosporin A (CsA).	Cyclosporine	421-424	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	116-142
8774943-1	1995	Using electrophoretic mobility-shift assay (EMSA), we examined changes in DNA-binding activities of transcriptional factor-activated protein-1 (AP-1), which is a Fos-Jun protein complex, onto its responsive element TRE in the hippocampus and amygdaloid nucleus of rats stimulated with pentylenetetrazol (PTZ) injection, and also investigated the effects of a single administration of the immunosuppressant cyclosporin A (CsA).	Cyclosporine	421-424	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	144-148
8774943-5	1995	This therapeutic effect of single CsA pretreatment may be based, in part, on the effects on the TRE-binding activity of AP-1 in the brain.	Cyclosporine	34-37	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	120-124
7490125-0	1995	Induced expression of mRNA for IL-5, IL-6, TNF-alpha, MIP-2 and IFN-gamma in immunologically activated rat peritoneal mast cells: inhibition by dexamethasone and cyclosporin A.	Cyclosporine	162-175	interleukin 5	Rattus norvegicus	31-35
7490125-0	1995	Induced expression of mRNA for IL-5, IL-6, TNF-alpha, MIP-2 and IFN-gamma in immunologically activated rat peritoneal mast cells: inhibition by dexamethasone and cyclosporin A.	Cyclosporine	162-175	C-X-C motif chemokine ligand 2	Rattus norvegicus	54-59
7560060-2	1995	We show here that the mouse mdr1a and the human MDR1 P-glycoprotein actively transport ivermectin, dexamethasone, digoxin, and cyclosporin A and, to a lesser extent, morphine across a polarized kidney epithelial cell layer in vitro.	Cyclosporine	127-140	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	28-33
7560060-3	1995	Injection of these radio-labeled drugs in mdr1a (-/-) and wild-type mice resulted in markedly (20- to 50-fold) higher levels of radioactivity in mdr1a (-/-) brain for digoxin and cyclosporin A, with more moderate effects for dexamethasone (2- to 3-fold) and morphine (1.7-fold).	Cyclosporine	179-192	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	42-47
7560060-4	1995	Digoxin and cyclosporin A were also more slowly eliminated from mdr1a (-/-) mice.	Cyclosporine	12-25	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	64-69
9625027-3	1998	Other medications, e.g., rifampin and phenobarbital, which also induce p450 3A activity, have been reported to significantly decrease cyclosporine (CsA) concentrations.	Cyclosporine	134-146	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	148-151
7595701-1	1995	PURPOSE: An unusually high incidence of anaphylactoid reactions was observed during a phase I/II trial of high-dose intravenous cyclosporine (CsA) therapy to attenuate tumor multidrug resistance (MDR).	Cyclosporine	128-140	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	142-145
19077999-3	1995	Visceral involvement, particularly pulmonary interstitial disease, can lead to significant morbidity and mortality.Specific therapy is unavailable to date, but there has been interest in the use of cyclosporine (CSA), because it inhibits interleukin-2 production and affects cytotoxic T cells.	Cyclosporine	198-210	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	212-215
8563719-0	1995	Cyclosporine effects on in vitro responsiveness of anterior pituitary hormone release to dopamine and thyrotropin-releasing hormone in young female rats.	Cyclosporine	0-12	thyrotropin releasing hormone	Rattus norvegicus	102-131
8563719-14	1995	In vitro release of PRL and GH by ectopic pituitaries was inhibited by previous treatment with CyA and this effect was decreased proportional to the duration of the treatment with the drug, while LH secretion was not modified.	Cyclosporine	95-98	gonadotropin releasing hormone receptor	Rattus norvegicus	28-30
7676485-0	1995	Administration of intragraft interleukin-4 prolongs cardiac allograft survival in rats treated with donor-specific transfusion/cyclosporine.	Cyclosporine	127-139	interleukin 4	Rattus norvegicus	29-42
7673124-1	1995	In complex with the peptidyl-prolyl isomerase cyclophilin A, the immunosuppressive antifungal drug cyclosporin A (CsA) inhibits a Ca2+/calmodulin-dependent protein phosphatase, calcineurin, which regulates signal transduction.	Cyclosporine	99-112	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	114-117
8575571-3	1995	To assess this, we compared the inhibitory effects of FK506 and cyclosporin A on production of granulocyte/macrophage colony-stimulating factor and interleukin-5 by interleukin-2- or Dermatophagoides farinae-stimulated mononuclear cells from patients with asthma, and their contribution to proliferation and survival of eosinophils in vitro.	Cyclosporine	64-77	interleukin 5	Homo sapiens	148-161
8586406-0	1995	[The use of measuring serum soluble IL-2 receptor levels in cyclosporine-A treated lupus nephritis].	Cyclosporine	60-74	interleukin 2 receptor subunit beta	Homo sapiens	36-49
8557519-2	1995	We demonstrate that CsA and FK506 inhibited IL-2R (CD25) gene transcription and protein expression after stimulation by anti-CD3 or ionomycin, but not by phorbol ester or IL-2.	Cyclosporine	20-23	interleukin 2 receptor subunit alpha	Homo sapiens	44-49
8557519-2	1995	We demonstrate that CsA and FK506 inhibited IL-2R (CD25) gene transcription and protein expression after stimulation by anti-CD3 or ionomycin, but not by phorbol ester or IL-2.	Cyclosporine	20-23	interleukin 2 receptor subunit alpha	Homo sapiens	51-55
7657624-0	1995	The cyclosporin A-binding immunophilin CyP-40 and the FK506-binding immunophilin hsp56 bind to a common site on hsp90 and exist in independent cytosolic heterocomplexes with the untransformed glucocorticoid receptor.	Cyclosporine	4-17	glucocorticoid receptor	Oryctolagus cuniculus	192-215
7657624-5	1995	In this work, we show that both untransformed glucocorticoid receptor and hsp90 heterocomplexes contain CyP-40, a 40-kDa immunophilin of the cyclosporin A-binding class.	Cyclosporine	141-154	glucocorticoid receptor	Oryctolagus cuniculus	46-69
7634349-8	1995	Finally, both the CD3 plus CD27 and the CD28 plus CD27-stimulated T cell proliferation is sensitive to inhibition by CsA.	Cyclosporine	117-120	CD28 molecule	Homo sapiens	40-44
7621064-7	1995	The percentage of CD4-positive T lymphocytes bearing IL-2 receptor (a marker of T cell activation) in the peripheral blood decreased significantly at 6 weeks (P &lt; .05), but returned to baseline value at 12 weeks, probably due to cyclosporine A dose reduction in seven subjects.	Cyclosporine	232-246	interleukin 2 receptor subunit beta	Homo sapiens	53-66
7601249-7	1995	Expression of the IL-5, IL-6, and IL-10 genes was resistant to cyclosporine A (CsA), whereas IL-3 and IL-4 gene expression was completely inhibited, indicating the involvement of different signalling pathways in the regulation of these genes.	Cyclosporine	63-77	interleukin 5	Homo sapiens	18-22
7601249-7	1995	Expression of the IL-5, IL-6, and IL-10 genes was resistant to cyclosporine A (CsA), whereas IL-3 and IL-4 gene expression was completely inhibited, indicating the involvement of different signalling pathways in the regulation of these genes.	Cyclosporine	79-82	interleukin 5	Homo sapiens	18-22
7752996-2	1995	Preliminary reports suggest some effect of cyclosporine (CSA), both alone or in combination with steroids and/or vinblastine, in untreated cases.	Cyclosporine	43-55	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	57-60
9610399-6	1998	Furthermore, cyclosporin A (200 nM), an inhibitor of the mitochondrial permeability transition pore (PTP), abolished total CICR.	Cyclosporine	13-26	corepressor interacting with RBPJ, 1	Mus musculus	123-127
9681677-1	1998	FcepsilonRI-mediated exocytosis of preformed mediators from mast cells and basophils (e.g. histamine, serotonin, beta-hexosaminidase) is sensitive to the immunosuppressants cyclosporin A and FK506 (IC50 200 and 4 nM, respectively) but not rapamycin.	Cyclosporine	173-186	O-GlcNAcase	Rattus norvegicus	113-132
9582553-3	1998	A recent study suggested that cyclosporine (CsA) increased plasma homocyst(e)ine concentration in interfering with folate-assisted remethylation of homocysteine.	Cyclosporine	30-42	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	44-47
7476967-0	1995	Interaction of the progesterone receptor with binding proteins for FK506 and cyclosporin A.	Cyclosporine	77-90	progesterone receptor	Homo sapiens	19-40
7582858-6	1995	These data indicate that CsA may inhibit Ca2+ ATPase and NOS activities in the rat myocardium through interference with its Ca2+/Cam-mediated events and thus may cause myocardial toxicity.	Cyclosporine	25-28	calmodulin 1	Rattus norvegicus	129-132
7540976-3	1995	Three mutations that confer dominant CsA resistance are single amino acid substitutions (T350K, T350R, Y377F) in the calcineurin A catalytic subunit CMP1.	Cyclosporine	37-40	calcineurin catalytic subunit A	Saccharomyces cerevisiae S288C	149-153
7540976-8	1995	Double mutant calcineurin A subunits (Y377F, W388C CMP1 and Y419F, W430C CMP2) confer resistance to CsA, to FK506 and to CsA plus FK506.	Cyclosporine	100-103	calcineurin catalytic subunit A	Saccharomyces cerevisiae S288C	51-55
7540976-8	1995	Double mutant calcineurin A subunits (Y377F, W388C CMP1 and Y419F, W430C CMP2) confer resistance to CsA, to FK506 and to CsA plus FK506.	Cyclosporine	121-124	calcineurin catalytic subunit A	Saccharomyces cerevisiae S288C	51-55
7601144-2	1995	Pore opening is blocked by cyclosporin A (CSA).	Cyclosporine	27-40	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	42-45
8582089-8	1995	Thus, increased endothelial preproendothelin-1, and ETA receptor mRNA levels in smooth muscle cells, which are concomitant with the decrease in ETB receptor mRNA levels in endothelium, may contribute to CyA-induced hypertension in rats.	Cyclosporine	203-206	endothelin receptor type A	Rattus norvegicus	52-55
7770925-2	1995	In lymphocytes in vitro, cyclosporine (CsA) blocks the phosphatase activity of the enzyme calcineurin, preventing cytokine induction.	Cyclosporine	25-37	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	39-42
7539771-1	1995	The opening of the cyclosporin A-sensitive permeability transition pore (MTP) in deenergized mitochondria was induced only at millimolar Ca2+.	Cyclosporine	19-32	microsomal triglyceride transfer protein	Rattus norvegicus	73-76
7772474-0	1995	Effects of cyclosporin and ultraviolet radiation on growth and ornithine decarboxylase activity in cultured human epidermal keratinocytes.	Cyclosporine	11-22	ornithine decarboxylase 1	Homo sapiens	63-86
7772474-3	1995	CyA (5 micrograms/ml) inhibited ODC activity, ODC mRNA level, and cell growth induced by 50 ng/ml EGF.	Cyclosporine	0-3	ornithine decarboxylase 1	Homo sapiens	32-35
7772474-3	1995	CyA (5 micrograms/ml) inhibited ODC activity, ODC mRNA level, and cell growth induced by 50 ng/ml EGF.	Cyclosporine	0-3	ornithine decarboxylase 1	Homo sapiens	46-49
9506530-6	1998	The P-glycoprotein-mediated multidrug resistance (MDR)-reversing agents verapamil, cyclosporin A, quinidine, sodium orthovanadate and tamoxifen significantly increased dox fluorescence at this depth, whereas genistein, indomethacin, probenecid and brefeldin A, which reverse multidrug-resistance-associated protein (MRP) function, exerted no effect.	Cyclosporine	83-96	ATP binding cassette subfamily C member 3	Homo sapiens	275-314
9506530-6	1998	The P-glycoprotein-mediated multidrug resistance (MDR)-reversing agents verapamil, cyclosporin A, quinidine, sodium orthovanadate and tamoxifen significantly increased dox fluorescence at this depth, whereas genistein, indomethacin, probenecid and brefeldin A, which reverse multidrug-resistance-associated protein (MRP) function, exerted no effect.	Cyclosporine	83-96	ATP binding cassette subfamily C member 3	Homo sapiens	316-319
9545147-1	1998	STUDY OBJECTIVE: To evaluate the utility of cyclosporine (CsA) trough concentrations as a monitoring tool for acute graft rejections and CsA nephrotoxicity.	Cyclosporine	44-56	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	58-61
9545156-1	1998	We attempted to characterize circadian variations in pharmacokinetic parameters of a new formulation of cyclosporine (CsA) in nine cardiac allograft recipients.	Cyclosporine	104-116	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	118-121
9448137-1	1998	BACKGROUND: Tacrolimus (FK506) is an immunosuppressive drug 50-100 times more potent than cyclosporine (CsA), the current mainstay of organ transplant rejection therapy.	Cyclosporine	90-102	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	104-107
9846420-4	1998	Patients were induced with intravenous cyclosporine (CsA) then switched to Neoral or Sandimmune.	Cyclosporine	39-51	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	53-56
7667170-1	1995	This study documents a pharmacokinetic interaction between carbamazepine and cyclosporine (CsA) in pediatric renal transplant recipients.	Cyclosporine	77-89	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	91-94
7542793-3	1995	Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.	Cyclosporine	81-84	peptidylprolyl isomerase A	Rattus norvegicus	0-13
9422406-3	1997	METHODS: Twenty-eight cyclosporine (CsA)-treated renal transplant recipients (21 cadaveric, 5 living, 2 simultaneous kidney-pancreas) with progressive deterioration of renal function were prospectively enrolled in a clinical trial and had their immunosuppressive regimen changed 24.3+/-7.7 months after transplant.	Cyclosporine	22-34	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	36-39
9442391-1	1997	The isolation of Cyclosporin A (CsA) from cultures of the fungus Tolypocladium inflatum and its subsequent elucidation of immunosuppressive properties by Borel et al.	Cyclosporine	17-30	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	32-35
7717993-5	1995	Independent expression of two domains of CyP-40 permitted dissociation of N-terminal isomerase and CsA binding activity from the hsp90 binding site, which is located at the FKBP-59-like C-terminal region.	Cyclosporine	99-102	peptidylprolyl isomerase D	Homo sapiens	41-47
7744028-4	1995	The weak affinity of CyP-40 for cyclosporin A was postulated to arise from a histidine residue that replaces a tryptophan residue critical for cyclosporin A binding and highly conserved in other cyclophilins that have high affinity for cyclosporin A.	Cyclosporine	32-45	peptidylprolyl isomerase D	Homo sapiens	21-27
7744028-4	1995	The weak affinity of CyP-40 for cyclosporin A was postulated to arise from a histidine residue that replaces a tryptophan residue critical for cyclosporin A binding and highly conserved in other cyclophilins that have high affinity for cyclosporin A.	Cyclosporine	143-156	peptidylprolyl isomerase D	Homo sapiens	21-27
7744028-4	1995	The weak affinity of CyP-40 for cyclosporin A was postulated to arise from a histidine residue that replaces a tryptophan residue critical for cyclosporin A binding and highly conserved in other cyclophilins that have high affinity for cyclosporin A.	Cyclosporine	143-156	peptidylprolyl isomerase D	Homo sapiens	21-27
7536243-6	1995	The suppression of lymphocyte blastogenesis in vitro by cyclosporine or prednisolone was restored by addition of interleukin (IL)-1, IL-2, IL-4, IL-5 or IL-6.	Cyclosporine	56-68	interleukin 5	Homo sapiens	145-149
7892569-6	1995	Patients with acute graft versus host disease, fever or cyclosporin treatment had significantly higher VIII:C, vWF and tPA.	Cyclosporine	56-67	cytochrome c oxidase subunit 8A	Homo sapiens	103-107
7842214-1	1995	The aim of the present study was to identify factors determining the delivery to and distribution of aerosolized cyclosporine A (CSA) in the lungs of patients with severe pulmonary allograft rejection.	Cyclosporine	113-127	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	129-132
7829874-0	1995	Levels of skin-derived antileukoproteinase (SKALP)/elafin in serum correlate with disease activity during treatment of severe psoriasis with cyclosporin A.	Cyclosporine	141-154	peptidase inhibitor 3	Homo sapiens	10-42
7829874-0	1995	Levels of skin-derived antileukoproteinase (SKALP)/elafin in serum correlate with disease activity during treatment of severe psoriasis with cyclosporin A.	Cyclosporine	141-154	peptidase inhibitor 3	Homo sapiens	44-49
7829874-0	1995	Levels of skin-derived antileukoproteinase (SKALP)/elafin in serum correlate with disease activity during treatment of severe psoriasis with cyclosporin A.	Cyclosporine	141-154	peptidase inhibitor 3	Homo sapiens	51-57
7829874-7	1995	The results indicate that 1) SKALP/elafin determination in serum rather than in urine is the preferred method, because the decrease in serum SKALP levels during therapy is more pronounced and correlated better with the clinical course of the patients; 2) SKALP/elafin levels in serum decreased during cyclosporin A treatment (p &lt; 0.05); and 3) SKALP/elafin levels in serum correlate with the PASI score (p &lt; 0.01).	Cyclosporine	301-314	peptidase inhibitor 3	Homo sapiens	141-146
7829874-7	1995	The results indicate that 1) SKALP/elafin determination in serum rather than in urine is the preferred method, because the decrease in serum SKALP levels during therapy is more pronounced and correlated better with the clinical course of the patients; 2) SKALP/elafin levels in serum decreased during cyclosporin A treatment (p &lt; 0.05); and 3) SKALP/elafin levels in serum correlate with the PASI score (p &lt; 0.01).	Cyclosporine	301-314	peptidase inhibitor 3	Homo sapiens	141-146
7829874-7	1995	The results indicate that 1) SKALP/elafin determination in serum rather than in urine is the preferred method, because the decrease in serum SKALP levels during therapy is more pronounced and correlated better with the clinical course of the patients; 2) SKALP/elafin levels in serum decreased during cyclosporin A treatment (p &lt; 0.05); and 3) SKALP/elafin levels in serum correlate with the PASI score (p &lt; 0.01).	Cyclosporine	301-314	peptidase inhibitor 3	Homo sapiens	141-146
8744655-2	1995	The present study examines the in vitro interactions of classical immunosuppressive agents--FK 506 and Cyclosporine A (CsA) with 2-CdA at the level of T and B cells proliferation, expression receptor for interleukin 2 (R-IL-2) and Ig synthesis.	Cyclosporine	103-117	cytidine deaminase	Homo sapiens	131-134
8744655-2	1995	The present study examines the in vitro interactions of classical immunosuppressive agents--FK 506 and Cyclosporine A (CsA) with 2-CdA at the level of T and B cells proliferation, expression receptor for interleukin 2 (R-IL-2) and Ig synthesis.	Cyclosporine	119-122	cytidine deaminase	Homo sapiens	131-134
7833280-2	1995	The treatment with cyclosporine was based on the hypothesis that immune-mediated bone-marrow damage is the common pathogenetic mechanism of aplasia and PNH, with lack of GPI-linked ligands for an immune attack (i.e. LFA-3, CD58) rendering PNH cells a growth advantage over other bone marrow cells.	Cyclosporine	19-31	CD58 molecule	Homo sapiens	216-221
7833280-2	1995	The treatment with cyclosporine was based on the hypothesis that immune-mediated bone-marrow damage is the common pathogenetic mechanism of aplasia and PNH, with lack of GPI-linked ligands for an immune attack (i.e. LFA-3, CD58) rendering PNH cells a growth advantage over other bone marrow cells.	Cyclosporine	19-31	CD58 molecule	Homo sapiens	223-227
9548474-6	1997	In contrast, cross-linking of CD47 in the presence of CD28 mAb or phorbol ester induces vigorous T cell proliferation that is sensitive to cyclosporin A.	Cyclosporine	139-152	CD28 molecule	Homo sapiens	54-58
8808174-5	1995	Thus, the hypothesis that CsA may have Ca2+/calmodulin antagonistic properties is supported by the present study.	Cyclosporine	26-29	calmodulin 1	Rattus norvegicus	44-54
7566298-9	1995	For TP patients, Lp(a) and serum creatinine correlated (p = 0.004), and mean Lp(a) for 71 TP on ciclosporin A exceeded that for the other 23 patients (p &lt; 0.03).	Cyclosporine	96-109	lipoprotein(a)	Homo sapiens	77-82
9370178-1	1997	Calcium antagonists may reduce the nephrotoxicity of cyclosporine (CsA), allowing CsA to be introduced immediately after renal transplantation and thereby obviating the need for sequential induction therapy with a monoclonal or polyclonal antibody.	Cyclosporine	53-65	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	67-70
7806527-3	1994	This up-regulation of Cdk4 mRNA and protein was resistant to the immunosuppressant drugs cyclosporin A (CsA) and FK506.	Cyclosporine	89-102	cyclin dependent kinase 4	Homo sapiens	22-26
7806527-3	1994	This up-regulation of Cdk4 mRNA and protein was resistant to the immunosuppressant drugs cyclosporin A (CsA) and FK506.	Cyclosporine	104-107	cyclin dependent kinase 4	Homo sapiens	22-26
7806527-8	1994	These data demonstrate that 1) the signals that lead to induction of competence in T cells stimulate an IL-2-independent and CsA-resistant phase of Cdk4 and cyclin D2 expression, Cdk4 kinase activity, and Cdk2 kinase activity, and 2) IL-2 stimulates a second phase of Cdk4 and cyclin D2 expression and de novo expression of Cdk2 in these cells.	Cyclosporine	125-128	cyclin dependent kinase 4	Homo sapiens	148-152
7806527-8	1994	These data demonstrate that 1) the signals that lead to induction of competence in T cells stimulate an IL-2-independent and CsA-resistant phase of Cdk4 and cyclin D2 expression, Cdk4 kinase activity, and Cdk2 kinase activity, and 2) IL-2 stimulates a second phase of Cdk4 and cyclin D2 expression and de novo expression of Cdk2 in these cells.	Cyclosporine	125-128	cyclin dependent kinase 4	Homo sapiens	179-183
7806527-8	1994	These data demonstrate that 1) the signals that lead to induction of competence in T cells stimulate an IL-2-independent and CsA-resistant phase of Cdk4 and cyclin D2 expression, Cdk4 kinase activity, and Cdk2 kinase activity, and 2) IL-2 stimulates a second phase of Cdk4 and cyclin D2 expression and de novo expression of Cdk2 in these cells.	Cyclosporine	125-128	cyclin dependent kinase 2	Homo sapiens	205-209
7806527-8	1994	These data demonstrate that 1) the signals that lead to induction of competence in T cells stimulate an IL-2-independent and CsA-resistant phase of Cdk4 and cyclin D2 expression, Cdk4 kinase activity, and Cdk2 kinase activity, and 2) IL-2 stimulates a second phase of Cdk4 and cyclin D2 expression and de novo expression of Cdk2 in these cells.	Cyclosporine	125-128	cyclin dependent kinase 4	Homo sapiens	179-183
7806527-8	1994	These data demonstrate that 1) the signals that lead to induction of competence in T cells stimulate an IL-2-independent and CsA-resistant phase of Cdk4 and cyclin D2 expression, Cdk4 kinase activity, and Cdk2 kinase activity, and 2) IL-2 stimulates a second phase of Cdk4 and cyclin D2 expression and de novo expression of Cdk2 in these cells.	Cyclosporine	125-128	cyclin dependent kinase 2	Homo sapiens	324-328
9370178-1	1997	Calcium antagonists may reduce the nephrotoxicity of cyclosporine (CsA), allowing CsA to be introduced immediately after renal transplantation and thereby obviating the need for sequential induction therapy with a monoclonal or polyclonal antibody.	Cyclosporine	53-65	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	82-85
9404561-0	1997	Effects of rapamycin, cyclosporin A, and dexamethasone on interleukin 5-induced eosinophil degranulation and prolonged survival.	Cyclosporine	22-35	interleukin 5	Homo sapiens	58-71
9404561-8	1997	Cyclosporin A and rapamycin significantly inhibited IL-5-enhanced ECP release in a concentration-dependent fashion, whereas dexamethasone did not.	Cyclosporine	0-13	interleukin 5	Homo sapiens	52-56
9438176-1	1997	We investigated the influence of cyclosporine A (CsA) on key plasma membrane ion transport systems Na+/K(+)-ATPase, Na+/K+/2Cl- cotransporter, and H+/K(+)-ATPase in MDCK cells and two subtypes, C7 and C11, serving as a model system to study principal (C7) and intercalated (C11) cell properties of the distal nephron.	Cyclosporine	33-47	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	49-52
7528676-7	1994	We previously reported that ligation of either sIg or CD40 receptors, in conjunction with IL-4, induces the transcription factor, nuclear factor of activated T cells (NF-AT) in B cells, via a CsA/FK506-sensitive pathway.	Cyclosporine	192-195	CD40 antigen	Mus musculus	54-58
9527588-5	1997	Only the use of systemic cyclosporin A (CSA) treatment appears for the first time to have a significant positive effect on the outcome.	Cyclosporine	25-38	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	40-43
7980456-1	1994	Cyclophilin A, the major intracellular binding protein for the immunosuppressive drug cyclosporin A (CsA), was studied in human keratinocytes during differentiation both in vivo and in vitro.	Cyclosporine	86-99	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	101-104
7821232-7	1994	The mechanism of CsA nephrotoxicity is to be related to a cytochrome P-450 induction.	Cyclosporine	17-20	cytochrome P-450	Oryctolagus cuniculus	58-74
9315696-1	1997	Cyclosporin A sensitive swelling of mitochondria isolated from control mouse livers and from the livers of transgenic mice expressing human ubiquitous mitochondrial creatine kinase occurred in the presence of both 40 microM calcium and 5 microM atractyloside which was accompanied by a 2.5-fold increase over state 4 respiration rates.	Cyclosporine	0-13	creatine kinase, mitochondrial 1B	Homo sapiens	140-180
7957566-12	1994	These data provide a model for CD28 signal transduction and support a role for PI-3 kinase in mediating the CD28 calcium-independent, cyclosporin A-insensitive costimulatory signal.	Cyclosporine	134-147	CD28 molecule	Homo sapiens	108-112
9327337-2	1997	Cyclophilins (Cyps), the main binding proteins for the immunosuppressive drug cyclosporine A, have been suggested to function as cytokines.	Cyclosporine	78-92	peptidylprolyl isomerase like 2	Homo sapiens	0-12
7523141-0	1994	T cell receptor-induced Fas ligand expression in cytotoxic T lymphocyte clones is blocked by protein tyrosine kinase inhibitors and cyclosporin A.	Cyclosporine	132-145	Fas ligand	Rattus norvegicus	24-34
7523141-8	1994	Finally, the implication of the Ca2+/calmodulin-dependent protein phosphatase calcineurin in Fas ligand induction was demonstrated by the partial inhibition of Fas ligand induction with cyclosporin A.	Cyclosporine	186-199	Fas ligand	Rattus norvegicus	93-103
7523141-8	1994	Finally, the implication of the Ca2+/calmodulin-dependent protein phosphatase calcineurin in Fas ligand induction was demonstrated by the partial inhibition of Fas ligand induction with cyclosporin A.	Cyclosporine	186-199	Fas ligand	Rattus norvegicus	160-170
9286955-8	1997	High-dose cyclosporin A (CsA) treatment significantly reduced both PDGF-AA and PDGF-R alpha expression in intimal cells.	Cyclosporine	10-23	platelet derived growth factor receptor alpha	Rattus norvegicus	79-91
7851854-1	1994	A case of primary sclerosing cholangitis (PSC) successfully treated with cyclosporine is described.	Cyclosporine	73-85	PSC	Homo sapiens	42-45
7851854-4	1994	Cyclosporine seems to be a promising drug for the treatment of patients with PSC.	Cyclosporine	0-12	PSC	Homo sapiens	77-80
7929104-6	1994	Furthermore, cyclosporin A, which blocked TNF alpha production induced by PKC, strongly inhibited IL-2R alpha and NF.kappa B activation.	Cyclosporine	13-26	interleukin 2 receptor subunit alpha	Homo sapiens	98-109
7929104-7	1994	The addition of either TNF alpha or IL-2 partially recovered cyclosporin A-induced IL-2R alpha inhibition, but only TNF alpha completely recovered NF.kappa B activation.	Cyclosporine	61-74	interleukin 2 receptor subunit alpha	Homo sapiens	83-94
9286955-8	1997	High-dose cyclosporin A (CsA) treatment significantly reduced both PDGF-AA and PDGF-R alpha expression in intimal cells.	Cyclosporine	25-28	platelet derived growth factor receptor alpha	Rattus norvegicus	79-91
9270064-0	1997	Cyclosporin A attenuates the decrease in tyrosine hydroxylase immunoreactivity in nigrostriatal dopaminergic neurons and in striatal dopamine content in rats with intrastriatal injection of 6-hydroxydopamine.	Cyclosporine	0-13	tyrosine hydroxylase	Rattus norvegicus	41-61
8083194-11	1994	The immunosuppressive drug cyclosporin A reduced induction of PGHS-2 mRNA expression by 5-HT, indicating interference with the signaling cascade, most likely with the Ser/Thr phosphatase calcineurin.	Cyclosporine	27-40	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	62-68
9396174-2	1997	Cyclosporin (CsA) has been proposed in the management of patients with acute ulcerative colitis (UC) in whom standard therapy failed and who were candidates for colectomy.	Cyclosporine	0-11	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	13-16
9237102-5	1997	The induction of non-responsiveness was not due to modulation of the TCR-CD3 complex, and required partial activation of the T cells in that it was accompanied by an increase in cell size and was inhibited by addition of cyclosporin A.	Cyclosporine	221-234	CD3 antigen, epsilon polypeptide	Mus musculus	73-76
9237106-7	1997	rIL-2-induced IL-5 expression was resistant to cyclosporin A (CsA), whereas IL-5 expression elicited by PHA was inhibited by CsA, at doses as low as 10 ng/ml.	Cyclosporine	125-128	interleukin 5	Homo sapiens	76-80
9237106-10	1997	The resistance of IL-2 receptor (IL-2R) signalling to CsA and RAP indicates that the IL-2R and the TCR are associated with different pathways regulating IL-5 expression.	Cyclosporine	54-57	interleukin 2 receptor subunit beta	Homo sapiens	18-31
9237106-10	1997	The resistance of IL-2 receptor (IL-2R) signalling to CsA and RAP indicates that the IL-2R and the TCR are associated with different pathways regulating IL-5 expression.	Cyclosporine	54-57	interleukin 2 receptor subunit beta	Homo sapiens	33-38
9210502-1	1997	BACKGROUND: One-to-one (mg:mg) conversion from the conventional to the microemulsion formulation of cyclosporine (CsA) is advocated as a simple way to use the new therapeutic regimen.	Cyclosporine	100-112	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	114-117
9210511-1	1997	BACKGROUND: The side effects of cyclosporine (CsA)-including nephrotoxicity and abnormal differentiation of thymocytes developing in the thymus-can be decreased or even avoided using targeted conjugates of CsA, where both targeting moiety and drug are bound to water-soluble polymeric carrier based on N-(2-hydroxypropyl) methacrylamide (HPMA).	Cyclosporine	32-44	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	46-49
9210511-1	1997	BACKGROUND: The side effects of cyclosporine (CsA)-including nephrotoxicity and abnormal differentiation of thymocytes developing in the thymus-can be decreased or even avoided using targeted conjugates of CsA, where both targeting moiety and drug are bound to water-soluble polymeric carrier based on N-(2-hydroxypropyl) methacrylamide (HPMA).	Cyclosporine	32-44	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	206-209
9192801-0	1997	Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein.	Cyclosporine	121-133	RB transcriptional corepressor 1	Homo sapiens	49-63
9234374-0	1997	Prevention of high risk corneal graft rejection using cyclosporine A (CsA) incorporated into a collagen matrix.	Cyclosporine	54-68	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	70-73
7925281-4	1994	Furthermore, transcriptional, but not DNA-binding, activity of AP-1 is cyclosporin sensitive and requires tyrosine phosphorylation.	Cyclosporine	71-82	jun proto-oncogene	Mus musculus	63-67
8092258-1	1994	The renin-angiotensin system, endothelin (ET), and vasoconstrictor prostaglandins have been reported in separate studies to mediate the renal vasoconstrictor effect of cyclosporin A (CsA).	Cyclosporine	168-181	renin	Rattus norvegicus	4-9
8092258-1	1994	The renin-angiotensin system, endothelin (ET), and vasoconstrictor prostaglandins have been reported in separate studies to mediate the renal vasoconstrictor effect of cyclosporin A (CsA).	Cyclosporine	183-186	renin	Rattus norvegicus	4-9
8068598-0	1994	Cyclosporin A has divergent effects on plasma LDL cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] levels in renal transplant recipients.	Cyclosporine	0-13	lipoprotein(a)	Homo sapiens	74-88
8068598-0	1994	Cyclosporin A has divergent effects on plasma LDL cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] levels in renal transplant recipients.	Cyclosporine	0-13	lipoprotein(a)	Homo sapiens	90-95
8068598-6	1994	The effect(s) of cyclosporin A on Lp(a) was studied in two groups of renal transplantation patients.	Cyclosporine	17-30	lipoprotein(a)	Homo sapiens	34-39
8083343-4	1994	Simultaneous injection of cyclosporin A reduced such effects of anti-CD3.	Cyclosporine	26-39	CD3 antigen, epsilon polypeptide	Mus musculus	69-72
9234374-1	1997	The aim of this work was to compare the efficacy of cyclosporine (CsA) collagen shields and fragments in suppressing experimental allograft rejection in an animal model for high risk keratoplasty.	Cyclosporine	52-64	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	66-69
9142140-11	1997	Although CsA did not affect in vitro release of testosterone, it reduced the stimulatory influence of DES pretreatment on testicular responses to hCG in vitro.	Cyclosporine	9-12	hypertrichosis 2 (generalised, congenital)	Homo sapiens	146-149
9112364-0	1997	In vivo hyperexpression of transforming growth factor-beta1 in mice: stimulation by cyclosporine.	Cyclosporine	84-96	transforming growth factor, beta 1	Mus musculus	27-59
9112364-2	1997	Herein, we have explored whether CsA stimulates TGF-beta1 hyperexpression in vivo.	Cyclosporine	33-36	transforming growth factor, beta 1	Mus musculus	48-57
9112364-4	1997	RESULTS: CsA pretreatment augmented TGF-beta1 protein expression and increased intrarenal display of TGF-beta1 mRNA.	Cyclosporine	9-12	transforming growth factor, beta 1	Mus musculus	36-45
9112364-4	1997	RESULTS: CsA pretreatment augmented TGF-beta1 protein expression and increased intrarenal display of TGF-beta1 mRNA.	Cyclosporine	9-12	transforming growth factor, beta 1	Mus musculus	101-110
9112364-7	1997	Moreover, prevention of TGF-beta1 hyperexpression might prevent CsA-associated renal fibrosis, as TGF-beta1 is a fibrogenic cytokine.	Cyclosporine	64-67	transforming growth factor, beta 1	Mus musculus	24-33
9112364-7	1997	Moreover, prevention of TGF-beta1 hyperexpression might prevent CsA-associated renal fibrosis, as TGF-beta1 is a fibrogenic cytokine.	Cyclosporine	64-67	transforming growth factor, beta 1	Mus musculus	98-107
9032343-7	1997	These studies indicate that, as with other proline-containing peptides or cyclosporine A, HIV-1 Gag directly contacts residues in the hydrophobic pocket of CyPA.	Cyclosporine	74-88	Pr55(Gag)	Human immunodeficiency virus 1	96-99
9016791-3	1997	In this study, we have demonstrated that C219 inhibits the ATPase activity of P-glycoprotein based on the following findings: 1) the inhibition of total ATPase activity by C219 was selective to P-glycoprotein-positive membranes; 2) the C219-sensitive fraction of ATPase correlated the expression of P-glycoprotein; and 3) modulators of P-glycoprotein ATPase, verapamil and cyclosporin A, affected the C219-sensitive fraction of ATPase.	Cyclosporine	373-386	dynein axonemal heavy chain 8	Homo sapiens	59-65
8994436-10	1997	During intense chronic rejection (5 mg/kg CsA), arterial EC expressed P-selectin (P &lt; .01) and VCAM-1 (P &lt; .05) extensively.	Cyclosporine	42-45	vascular cell adhesion molecule 1	Rattus norvegicus	98-104
9009275-0	1997	Cyclosporin A-sensitive induction of the Epstein-Barr virus lytic switch is mediated via a novel pathway involving a MEF2 family member.	Cyclosporine	0-13	myocyte enhancer factor 2A	Homo sapiens	117-121
9009275-7	1997	These studies identify Zp as prototypic of a novel class of CsA-sensitive and NFAT-dependent promoters defined by the presence of MEF2 sites.	Cyclosporine	60-63	myocyte enhancer factor 2A	Homo sapiens	130-134
9008597-1	1997	OBJECTIVE: To evaluate the efficacy of long-term treatment with cyclosporin A (CSA) in systemic lupus erythematosus (SLE).	Cyclosporine	64-77	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	79-82
9116920-1	1997	OBJECTIVES: Essential hypertension and insulin resistance frequently coexist; cyclosporine A (CsA) is known to induce hypertension which has been used as a model for essential hypertension.	Cyclosporine	78-92	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	94-97
9126869-1	1997	Cyclosporine A (CsA) is a widely used immunosuppressant which possesses significant side effects including nephrotoxicity and systemic arterial hypertension.	Cyclosporine	0-14	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	16-19
9032771-8	1997	However, when mice were pretreated with the T-cell immunosuppressant cyclosporin A, the significantly increased ACTH and corticosterone production in response to SEB was dramatically attenuated.	Cyclosporine	69-82	pro-opiomelanocortin-alpha	Mus musculus	112-116
8093097-0	1994	Evidence that inhibition of phorbol ester-induced superoxide anion formation by cyclosporin A in phagocytes is not mediated by direct inhibition of protein kinase C. Cyclosporin A (CsA) has been reported to inhibit phorbol myristate acetate (PMA)-induced superoxide anion (O2-) formation in human neutrophils and murine macrophages.	Cyclosporine	80-93	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	181-184
8093097-0	1994	Evidence that inhibition of phorbol ester-induced superoxide anion formation by cyclosporin A in phagocytes is not mediated by direct inhibition of protein kinase C. Cyclosporin A (CsA) has been reported to inhibit phorbol myristate acetate (PMA)-induced superoxide anion (O2-) formation in human neutrophils and murine macrophages.	Cyclosporine	166-179	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	181-184
7520433-5	1994	Preincubation with the calcineurin inhibitors FK-506 or cyclosporin A strongly enhanced expression of NGFI-A and blocked transcription of NGFI-B, but it had no significant effect on Ca(2+)-stimulated transcription of c-fos.	Cyclosporine	56-69	nuclear receptor subfamily 4, group A, member 1	Rattus norvegicus	138-144
7519613-0	1994	Cloning and expression of cyclosporin A- and FK506-sensitive nuclear factor of activated T-cells: NF45 and NF90.	Cyclosporine	26-39	interleukin enhancer binding factor 2	Homo sapiens	98-102
7519613-11	1994	Histidine-tagged NF45 and NF90 proteins, affinity-purified on nickel chelate columns, encode a NF-AT DNA-binding activity that is enhanced following T-cell stimulation, and this enhancement is blocked when T-cells are stimulated in the presence of cyclosporin A or FK506.	Cyclosporine	248-261	interleukin enhancer binding factor 2	Homo sapiens	17-21
8075536-1	1994	The three-dimensional NMR solution structure of the cyclophilin A (Cyp)-cyclosporin A (CsA) complex was determined, and here we provide a detailed description of the analysis of the NMR data and the structure calculation.	Cyclosporine	72-85	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	87-90
7787866-7	1994	The absorption followed a zero order kinetic, demonstrating an inverse correlation between cyclosporine dose (mg/kg) and AUC/dose (r = -0.55, RIE-MoSP and r = -0.42, RIE-MoNP).	Cyclosporine	91-103	dual specificity phosphatase 23	Homo sapiens	146-150
7515910-7	1994	Both CD40L expression and T cell help were blocked by cyclosporin A after TCR cross-linking, and, unlike T cell proliferation, both remained cyclosporin A sensitive during CD28 costimulation.	Cyclosporine	141-154	CD28 molecule	Homo sapiens	172-176
8029023-4	1994	The CsA sensitivity of IL2R alpha mRNA induction represented a direct effect on the TCR/CD3 response, and was not due to CsA-sensitive release of the lymphokines IL2 or tumour necrosis factor alpha (TNF alpha) and consequent lymphokine-mediated induction of IL2R alpha mRNA.	Cyclosporine	4-7	CD3 antigen, epsilon polypeptide	Mus musculus	88-91
7889406-1	1994	We show here that ligation of surface immunoglobulin or CD40 receptors in conjunction with interleukin-4 induces the nuclear factor of activated T cells (NF-AT) in normal murine B cells, which is inhibited by cyclosporin (CsA).	Cyclosporine	209-220	CD40 antigen	Mus musculus	56-60
7889406-1	1994	We show here that ligation of surface immunoglobulin or CD40 receptors in conjunction with interleukin-4 induces the nuclear factor of activated T cells (NF-AT) in normal murine B cells, which is inhibited by cyclosporin (CsA).	Cyclosporine	222-225	CD40 antigen	Mus musculus	56-60
8183372-3	1994	The signalling pathways used by CD28 are unlike those used by the CD3/T-cell receptor in that they are resistant to cyclosporin A and independent of changes in cyclic AMP concentrations.	Cyclosporine	116-129	CD28 molecule	Homo sapiens	32-36
7514602-3	1994	Chemical cross-linking studies with disuccinimidyl suberate in the presence of either cyclophilin A, B, or C in complex with cyclosporin A or FK506 binding protein-FK506 result on the other hand in the apparently exclusive and strictly immunosuppressant-dependent formation of covalent immunophilin-calcineurin B subunit products.	Cyclosporine	125-138	peptidyl-prolyl cis-trans isomerase A	Bos taurus	86-99
8031258-0	1994	[Cyclosporin A inhibits interleukin 5 (IL-5) production from human peripheral lymphocytes].	Cyclosporine	1-14	interleukin 5	Homo sapiens	24-37
8031258-0	1994	[Cyclosporin A inhibits interleukin 5 (IL-5) production from human peripheral lymphocytes].	Cyclosporine	1-14	interleukin 5	Homo sapiens	39-43
8031258-4	1994	We found that cyclosporin A (CyA) inhibited the IL-5 production from human peripheral lymphocytes induced by IL-2 stimulation.	Cyclosporine	14-27	interleukin 5	Homo sapiens	48-52
9044461-8	1997	Lp(a) levels in renal transplant patients treated with cyclosporin (median = 6) and not receiving cyclosporin (median = 13) were similar and did not differ from controls.	Cyclosporine	55-66	lipoprotein(a)	Homo sapiens	0-5
8970613-1	1996	Transplant immunosuppression using either cyclosporine (CsA) or tacrolimus (FK506) leads to renal vasoconstriction and nephrotoxicity.	Cyclosporine	42-54	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	56-59
8996767-1	1996	We studied the impact of early cyclosporine (CSA) levels on the incidence of rejection in pediatric transplant recipients.	Cyclosporine	31-43	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	45-48
11666894-5	1996	The isotropic chemical shift in the solid state is 355.1 ppm, and its chemical shift anisotropy (CSA, Deltasigma) is -596 ppm with an asymmetry parameter (eta) of 0.64.	Cyclosporine	97-100	endothelin receptor type A	Homo sapiens	155-158
8910334-9	1996	The immunosuppressive agent, cyclosporin A, blocked both cytokine induction and NGF-activated survival promotion but not survival promotion activated by IL-3 or stem cell factor, suggesting that NGF enhanced RPMC survival by increasing cytokine production.	Cyclosporine	29-42	nerve growth factor	Rattus norvegicus	80-83
8910334-9	1996	The immunosuppressive agent, cyclosporin A, blocked both cytokine induction and NGF-activated survival promotion but not survival promotion activated by IL-3 or stem cell factor, suggesting that NGF enhanced RPMC survival by increasing cytokine production.	Cyclosporine	29-42	nerve growth factor	Rattus norvegicus	195-198
8980883-2	1996	Having previously demonstrated differential suppressive effects of methylprednisolone (MP), prednisolone (P) and cyclosporine (CsA) on dialysis patients" lymphocyte proliferative responses to phytohaemagglutinin (PHA), we studied the effects of these drugs on dialysis patients" lymphocyte IFN-gamma production during mitogenic and allogeneic (MLR) stimulation.	Cyclosporine	113-125	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	127-130
8946679-4	1996	CsA addition at the sensitizing phase of primary mixed lymphocyte reaction (MLR) resulted in the inhibition of both p40 and p70 IL-12 production in a dose-dependent manner.	Cyclosporine	0-3	interleukin 9	Homo sapiens	116-119
8185690-1	1994	OBJECTIVE: To investigate whether low-dose cyclosporin A (CSA) is safe and effective in comparison with chloroquine (CQ) in patients with early rheumatoid arthritis (RA).	Cyclosporine	43-56	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	58-61
7512591-7	1994	Moreover, cyclosporin A, which inhibited IL-2 more efficiently than rIL-10 in response to anti-CD3 mAb and B7/CD32 transfected fibroblasts, did not reduce and even enhanced IL-5 production.	Cyclosporine	10-23	CD3 antigen, epsilon polypeptide	Mus musculus	95-98
8072258-8	1994	In patients with FSGS on RB1 and RB2, serum creatinine at the end of CsA treatment was 130.6 +/- 60.1 mumol/liter, significantly greater (P = 0.022) than the corresponding levels in the subset with MCD (87.3 +/- 24.8).	Cyclosporine	69-72	RB transcriptional corepressor 1	Homo sapiens	25-28
8190466-3	1994	Steroid-sparing strategies with more specific agents such as cyclosporine (Cyclosporin A, CSA) have been suggested as the first line treatment for this disease.	Cyclosporine	61-73	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	90-93
7878594-4	1994	To explain these differences, the CD28-B7, co-stimulatory pathway for T-cell activation was explored since it is the only CsA-resistant pathway known so far.	Cyclosporine	122-125	CD28 molecule	Homo sapiens	34-38
7923894-11	1994	Renal function was impaired by CyA powder at 20 mg/kg per day and plasma renin activity (PRA) was increased by all doses of CyA powder.	Cyclosporine	124-127	renin	Rattus norvegicus	73-78
8151326-1	1994	PURPOSE: To study the effects of cyclosporine (CsA), a modulator of multidrug resistance (MDR), on the pharmacokinetics and toxicities of doxorubicin.	Cyclosporine	33-45	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	47-50
8129032-0	1994	Divergent expression of EtA and EtB receptors in response to cyclosporine in mesangial cells.	Cyclosporine	61-73	endothelin receptor type A	Rattus norvegicus	24-27
8129032-0	1994	Divergent expression of EtA and EtB receptors in response to cyclosporine in mesangial cells.	Cyclosporine	61-73	endothelin receptor type B	Rattus norvegicus	32-35
8129032-7	1994	In contrast, EtB mRNA increased with Cy (10(-5) mol/L) up to 129 +/- 8% (n = 6) at 1 hour and 265 +/- 62% (n = 3) at 3 hours.	Cyclosporine	37-39	endothelin receptor type B	Rattus norvegicus	13-16
8129032-8	1994	A similar effect was seen with the lower dose of Cy: EtB expression increased to 129 +/- 9% (n = 6) of control value at 1 hour and 253 +/- 74% (n = 4) at 3 hours.	Cyclosporine	49-51	endothelin receptor type B	Rattus norvegicus	53-56
8129032-10	1994	Further, Cy has differential effects on EtA and EtB, affecting EtA minimally while markedly increasing the expression of EtB.	Cyclosporine	9-11	endothelin receptor type A	Rattus norvegicus	40-43
8129032-10	1994	Further, Cy has differential effects on EtA and EtB, affecting EtA minimally while markedly increasing the expression of EtB.	Cyclosporine	9-11	endothelin receptor type B	Rattus norvegicus	48-51
8129032-10	1994	Further, Cy has differential effects on EtA and EtB, affecting EtA minimally while markedly increasing the expression of EtB.	Cyclosporine	9-11	endothelin receptor type A	Rattus norvegicus	63-66
8129032-10	1994	Further, Cy has differential effects on EtA and EtB, affecting EtA minimally while markedly increasing the expression of EtB.	Cyclosporine	9-11	endothelin receptor type B	Rattus norvegicus	121-124
8137548-10	1994	Treatment with low-dose cyclosporin A (CsA) or FK506 in combination with BRC has proved more effective than either drug alone in suppression of T cell proliferation and CD25 antigen expression.	Cyclosporine	24-37	interleukin 2 receptor subunit alpha	Homo sapiens	169-173
8137548-10	1994	Treatment with low-dose cyclosporin A (CsA) or FK506 in combination with BRC has proved more effective than either drug alone in suppression of T cell proliferation and CD25 antigen expression.	Cyclosporine	39-42	interleukin 2 receptor subunit alpha	Homo sapiens	169-173
8137549-6	1994	Cyclosporine inhibited IL-2 receptor expression to a significantly greater degree in cord CD4 and CD8 cells (49.7% and 70.1%) than in adults (17.9% and 30.0%).	Cyclosporine	0-12	interleukin 2 receptor subunit beta	Homo sapiens	23-36
8809021-3	1996	The biochemical signals provided by CD28 are cyclosporin A-resistant and complement those provided by the T cell antigen receptor to allow full activation of T cells.	Cyclosporine	45-56	CD28 molecule	Homo sapiens	36-40
8076427-0	1994	Vasoconstrictor responses to components of the renin-angiotensin system in cyclosporin-induced hypertension in the rat.	Cyclosporine	75-86	renin	Rattus norvegicus	47-52
8076427-2	1994	Since plasma renin activity is increased in cyclosporin A (CsA)-induced hypertension in the rat, the role of the vascular renin-angiotensin system (RAS) in CsA-induced hypertension was investigated in rat mesenteric resistance vessels.	Cyclosporine	59-62	renin	Rattus norvegicus	13-18
8076427-2	1994	Since plasma renin activity is increased in cyclosporin A (CsA)-induced hypertension in the rat, the role of the vascular renin-angiotensin system (RAS) in CsA-induced hypertension was investigated in rat mesenteric resistance vessels.	Cyclosporine	156-159	renin	Rattus norvegicus	122-127
8899150-0	1996	Hypercoagulability and high lipoprotein(a) levels in patients with aplastic anemia receiving cyclosporine.	Cyclosporine	93-105	lipoprotein(a)	Homo sapiens	28-42
8196271-6	1994	CsA induced a dramatic decrease in GFR, 0.14 in CsA versus 0.67 ml/min/100 g in control, P &lt; 0.001, and increased urinary excretion of N-acetyl beta-D-glucosaminidase (NAG), 21 in CsA versus 13 IU/gCr in control rats, P &lt; 0.001.	Cyclosporine	0-3	O-GlcNAcase	Rattus norvegicus	138-169
8794888-2	1996	CsA and FK506 associate with intracellular binding proteins (i.e., CsA with cyclophilin A and FK506 with FKBP12) to form protein/drug complexes that suppress the immune system by preventing activation of T cells in response to antigen presentation.	Cyclosporine	0-3	FKBP prolyl isomerase 1A pseudogene 2	Homo sapiens	105-111
8196271-6	1994	CsA induced a dramatic decrease in GFR, 0.14 in CsA versus 0.67 ml/min/100 g in control, P &lt; 0.001, and increased urinary excretion of N-acetyl beta-D-glucosaminidase (NAG), 21 in CsA versus 13 IU/gCr in control rats, P &lt; 0.001.	Cyclosporine	0-3	O-GlcNAcase	Rattus norvegicus	171-174
7507731-11	1994	Both the CD11bhi CD19+ B cells and the T cells in myeloma PBMCs had active CsA-inhibited dye efflux, but monocytes lacked the ability to efflux dye.	Cyclosporine	75-78	CD19 molecule	Homo sapiens	17-21
7507511-1	1994	Interaction of CD28/CTLA-4 on T cells with B7 on antigen-presenting cells constitutes an important costimulatory signal for T cells and is responsible for cyclosporin A-resistant interleukin 2 (IL-2) gene expression and potentially also for prevention of anergy induction after T cell receptor triggering.	Cyclosporine	155-168	CD28 molecule	Homo sapiens	15-19
8794888-2	1996	CsA and FK506 associate with intracellular binding proteins (i.e., CsA with cyclophilin A and FK506 with FKBP12) to form protein/drug complexes that suppress the immune system by preventing activation of T cells in response to antigen presentation.	Cyclosporine	67-70	FKBP prolyl isomerase 1A pseudogene 2	Homo sapiens	105-111
8781610-1	1996	Cyclosporine (CsA) is an immunosuppressive drug requiring dose individualization and regular control due to its highly variable pharmacokinetics.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
8781623-8	1996	Antilymphocyte induction therapy type had no influence, but the amount of immunosuppression with prednisone and cyclosporine (CsA) at 3 months posttransplant was significantly lower in those patients who experienced late rejection.	Cyclosporine	112-124	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	126-129
8702500-7	1996	Similarly, murine mdr3 expression confers resistance to the immunosuppressants cyclosporin A (CsA) and FK506 in a CsA-FK506-sensitive vph6 mutant yeast strain.	Cyclosporine	79-92	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	18-22
8702500-7	1996	Similarly, murine mdr3 expression confers resistance to the immunosuppressants cyclosporin A (CsA) and FK506 in a CsA-FK506-sensitive vph6 mutant yeast strain.	Cyclosporine	94-97	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	18-22
8702500-7	1996	Similarly, murine mdr3 expression confers resistance to the immunosuppressants cyclosporin A (CsA) and FK506 in a CsA-FK506-sensitive vph6 mutant yeast strain.	Cyclosporine	114-117	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	18-22
8773590-8	1996	The stimulatory effects of anti-CD69 mAb on both glycolysis and Ca2+ levels were inhibited by cyclosporin A.	Cyclosporine	94-107	CD69 molecule	Homo sapiens	32-36
8164449-8	1994	The EtB receptor mRNA at 1, 3, 6, 24 hours was 164 +/- 22, 157 +/- 15, 148 +/- 14, 116 +/- 18% (compared with controls, P &lt; 0.01 at 3 hr and P &lt; 0.05 at 1 and 6 hr), while the mRNA expression for EtA was not affected by Cs treatment.	Cyclosporine	226-228	endothelin receptor type B	Rattus norvegicus	4-7
8075981-1	1994	BACKGROUND: Cyclophilin (CyP) is a ubiquitious intracellular protein that binds the immunosuppressive drug cyclosporin A (CsA).	Cyclosporine	107-120	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	122-125
8302545-4	1994	Cyclosporine (CSA) given systemically prevents graft rejection, but because of the potential side effects and cost, the duration of treatment is an important factor.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
8693538-2	1996	In this article, we show that PVG.RT1u recipients can be rendered permanently and specifically tolerant to R8 kidney allografts by administration of four weekly donor-specific transfusions (DST) combined with a 7-day course of cyclosporine given with the first DST.	Cyclosporine	227-239	RT1 class II, locus Da	Rattus norvegicus	34-38
8712229-1	1996	Immunoglobulin A nephropathy (IgAN) frequently recurs in patients after renal transplantation (RT) on a conventional regimen of immunosuppressive therapy, but little is known about the influence of cyclosporine (Cs) on such a recurrence.	Cyclosporine	212-214	IGAN1	Homo sapiens	30-34
8647944-1	1996	The mouse mdr1a (also called mdr3) P-GP is abundant in the blood-brain barrier, and its absence in mdr1a (-/-) mice leads to highly increased levels of the drugs ivermectin, vinblastine, digoxin, and cyclosporin A in the brain.	Cyclosporine	200-213	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	10-15
8647944-1	1996	The mouse mdr1a (also called mdr3) P-GP is abundant in the blood-brain barrier, and its absence in mdr1a (-/-) mice leads to highly increased levels of the drugs ivermectin, vinblastine, digoxin, and cyclosporin A in the brain.	Cyclosporine	200-213	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	29-33
8738760-1	1996	The commonly used immunosuppressive regimen after orthotopic heart transplantation consists of cyclosporine (CsA), azathioprine (AZA), and steroids.	Cyclosporine	95-107	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	109-112
7514309-4	1994	After 2 or 4 weeks of CSA treatment there were no more differences in the urinary AAP between CSA and control rats, but the urinary excretion of NAG was increased: 29.6 IU/g Cr, CSA vs. 20.9 IU/g Cr, control, p &lt; .03 on day 14 and 26.9 IU/g Cr, CSA vs. 21.5 IU/g Cr, control, p &lt; .008 on day 28.	Cyclosporine	22-25	O-GlcNAcase	Rattus norvegicus	145-148
8003314-1	1994	Cyclosporin A (CSA) is an immunosuppressive agent that has provided new approaches in transplantation medicine and in the treatment of autoimmune diseases.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
8209426-0	1994	Cyclosporin A resistance of herpes simplex virus-induced "fusion from within" as a phenotypical marker of mutations in the Syn 3 locus of the glycoprotein B gene.	Cyclosporine	0-13	synapsin III	Homo sapiens	123-128
8181542-0	1993	Increased endothelial gene expression of angiotensin AT1A receptor in cyclosporine induced hypertensive rats.	Cyclosporine	70-82	angiotensin II receptor, type 1a	Rattus norvegicus	53-57
8181542-1	1993	We examined the gene expression of angiotensin AT1A receptors in aortic endothelial cells of cyclosporine induced hypertensive rats using reverse transcribed polymerase chain reaction method.	Cyclosporine	93-105	angiotensin II receptor, type 1a	Rattus norvegicus	47-51
8181542-2	1993	The gene expression of angiotensin AT1A receptors in aortic endothelial cells of cyclosporine induced hypertensive rats showed a two-fold increase when compared with that in normotensive control rats.	Cyclosporine	81-93	angiotensin II receptor, type 1a	Rattus norvegicus	35-39
8181542-3	1993	These results raise a possibility that the up-regulation of endothelial angiotensin AT1A receptors participates in the pathogenesis of cyclosporine induced hypertension.	Cyclosporine	135-147	angiotensin II receptor, type 1a	Rattus norvegicus	84-88
8258320-0	1993	Cyclosporin A inhibits T cell receptor-induced interleukin-2 synthesis of human T lymphocytes by selectively preventing a transmembrane signal transduction pathway leading to sustained activation of a protein kinase C isoenzyme, protein kinase C-beta.	Cyclosporine	0-13	protein kinase C beta	Homo sapiens	229-250
8258320-4	1993	After 90 min of stimulation PKC-beta was translocated to and remained bound to the plasma membranes for up to 4 h. Preincubation of human lymphocytes with 200 ng/ml CsA specifically and completely abolished the sustained activation of PKC-beta.	Cyclosporine	165-168	protein kinase C beta	Homo sapiens	28-36
8258320-4	1993	After 90 min of stimulation PKC-beta was translocated to and remained bound to the plasma membranes for up to 4 h. Preincubation of human lymphocytes with 200 ng/ml CsA specifically and completely abolished the sustained activation of PKC-beta.	Cyclosporine	165-168	protein kinase C beta	Homo sapiens	235-243
8304053-7	1993	We conclude that M-CSF is responsible for the majority of the CSA released by PTH- and PTHrP-treated rat osteoblasts.	Cyclosporine	62-65	colony stimulating factor 1	Rattus norvegicus	17-22
8278994-8	1993	Analysis of sections of recipients" spleens showed that spleen cell/CsA therapy led to significant reductions versus untreated controls, in expression of IL-2, IFN-gamma, and IL-2R.	Cyclosporine	68-71	interleukin 2 receptor subunit alpha	Homo sapiens	175-180
8738767-5	1996	CsA concentration measured by monoclonal specific immunoassays [(TDx FPIA, radioimmunoassay (RIA) Cyclo-Trac, and EMIT] was well correlated with those from HPLC (r = 0.99-1.00); results from EMIT were very close to those from HPLC, whereas results from RIA Cyclo-Trac and TDx were slightly overestimated (10-20%).	Cyclosporine	0-3	T cell receptor alpha constant	Homo sapiens	104-108
8223876-5	1993	By gel mobility shift analysis, cyclosporin A-sensitive NFAT-binding induction and enhancement of AP-1 binding activity could be detected in nuclear extracts of both Jurkat and peripheral blood T cells after simultaneous CD69 and protein kinase C stimulation.	Cyclosporine	32-45	CD69 molecule	Homo sapiens	221-225
8738767-5	1996	CsA concentration measured by monoclonal specific immunoassays [(TDx FPIA, radioimmunoassay (RIA) Cyclo-Trac, and EMIT] was well correlated with those from HPLC (r = 0.99-1.00); results from EMIT were very close to those from HPLC, whereas results from RIA Cyclo-Trac and TDx were slightly overestimated (10-20%).	Cyclosporine	0-3	T cell receptor alpha constant	Homo sapiens	263-267
8412131-3	1993	Because inhibiting TNF with anti-TNF antibodies prolongs cardiac allograft survival and is synergistic with cyclosporine (CsA), enhanced graft survival could result from inhibiting TNF via LPS pretreatment.	Cyclosporine	122-125	tumor necrosis factor-like	Rattus norvegicus	19-22
8738767-6	1996	Nonspecific methods (TDx polyclonal and nonspecific RIA Cyclo-Trac) measured CsA concentrations 3-4 times higher than those found by HPLC.	Cyclosporine	77-80	T cell receptor alpha constant	Homo sapiens	62-66
8621208-1	1996	Increasing evidence suggests that endothelin, a potent vasoconstrictor, is implicated in cyclosporin A (CsA)-induced nephrotoxicity.	Cyclosporine	89-102	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	104-107
8768028-1	1996	BACKGROUND: The improvement in ocular inflammation in patients with cyclosporine A resistant Behcet disease (CyA) during therapy of severe aphthosis with recombinant interferon-alpha 2b (IFN alpha) prompted its evaluation for treatment of refractory autoimmune uveitis.	Cyclosporine	68-82	interferon alpha 2	Homo sapiens	166-185
8359233-10	1993	Taken together, our results suggest the existence of a labile mRNA regulatory protein or proteins, whose actions include destabilization of both c-fms and CSF-1 transcripts after inhibition of TPA-induced monocytic differentiation by dex or CsA.	Cyclosporine	241-244	colony stimulating factor 1 receptor	Homo sapiens	145-150
8400080-1	1993	The isolated perfused rat kidney (IPK) was used to study the acute effects of cyclosporin A (CsA) and its metabolites (M1, M17, M18, M21 and M-COOH).	Cyclosporine	78-91	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	93-96
8400080-9	1993	Cyclosporine metabolite levels in patient blood often greatly exceed levels of the parent drug; these studies suggest that the metabolites may contribute significantly to CsA nephrotoxicity in patients.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	171-174
8768028-1	1996	BACKGROUND: The improvement in ocular inflammation in patients with cyclosporine A resistant Behcet disease (CyA) during therapy of severe aphthosis with recombinant interferon-alpha 2b (IFN alpha) prompted its evaluation for treatment of refractory autoimmune uveitis.	Cyclosporine	68-82	interferon alpha 2	Homo sapiens	187-196
8768028-2	1996	METHOD: IFN alpha was used in 18 patients with posterior uveitis, nine with Behcet disease and nine with primary uveitis (mean evolution time 3.8 years) previously treated with corticosteroids (18), CyA (16) and azathioprine (1).	Cyclosporine	199-202	interferon alpha 2	Homo sapiens	8-17
8601324-1	1996	OBJECTIVES: We wish to examine the role of lipoproteins in the transport and cellular uptake of cyclosporine (CsA) and tacrolimus.	Cyclosporine	96-108	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	110-113
8613950-1	1996	When applied to rat liver mitochondria in contact with Ca++, cyclosporine A (CsA) induced both an accumulation of this ion and a decrease in oxidative phosphorylation.	Cyclosporine	61-75	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	77-80
8260594-6	1993	The immunomodulating agents, methotrexate, cyclosporin A (CSA) and HWA486 profoundly inhibited both joint TNF levels and paw swelling.	Cyclosporine	43-56	tumor necrosis factor-like	Rattus norvegicus	106-109
8260594-6	1993	The immunomodulating agents, methotrexate, cyclosporin A (CSA) and HWA486 profoundly inhibited both joint TNF levels and paw swelling.	Cyclosporine	58-61	tumor necrosis factor-like	Rattus norvegicus	106-109
8639516-3	1996	Also, the binding affinity of cyclosporin A (CsA) to the different PPIases varies in IC(50) values from 6 nM for human PPIase hCyPA and 84 nM for the human hCyPB to over 120 nM for B. subtilis and 3000 nM for E. coli.	Cyclosporine	30-43	peptidylprolyl isomerase like 3	Homo sapiens	67-73
8315386-11	1993	These results show that, like alpha/beta T cells, V gamma 3+ thymocytes differentiate from TCRlow precursors to cells with a mature phenotype and that CsA inhibits this transition.	Cyclosporine	151-154	T cell receptor gamma, variable 3	Mus musculus	50-59
8355445-11	1993	On the other hand, CsA suppressed IL-2 receptor expression and proliferation of helper T cell clone.	Cyclosporine	19-22	interleukin 2 receptor subunit beta	Homo sapiens	34-47
8365828-14	1993	The strength of the anti-CD3 model is evidenced by the fact that two known immunosuppressive compounds (CsA and TCDD) have distinct and opposite effects on T-cell activation.	Cyclosporine	104-107	CD3 antigen, epsilon polypeptide	Mus musculus	25-28
7682237-0	1993	CD28 ligation by monoclonal antibodies or B7/BB1 provides an accessory signal for the cyclosporin A-resistant generation of cytotoxic T cell activity.	Cyclosporine	86-99	CD28 molecule	Homo sapiens	0-4
7682237-0	1993	CD28 ligation by monoclonal antibodies or B7/BB1 provides an accessory signal for the cyclosporin A-resistant generation of cytotoxic T cell activity.	Cyclosporine	86-99	CD80 molecule	Homo sapiens	45-48
7682237-10	1993	We conclude that CD28 ligation provides a major accessory signal for the CsA-resistant generation of CTL activity and that CD28-B7 interaction also enhances cytotoxic effector functions of CTL.	Cyclosporine	73-76	CD28 molecule	Homo sapiens	17-21
8489193-1	1993	Cyclosporine (CsA) has played a major role in the development of organ transplantation.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
7679116-6	1993	Moreover, dephosphorylation of NF-ATp in cell extracts is inhibited by prior treatment of T cells with the immunosuppressive drugs cyclosporin A or FK506, which inhibit the phosphatase activity of calcineurin when complexed with their specific binding proteins, cyclophilin and FK506-binding protein.	Cyclosporine	131-144	nuclear factor of activated T cells 1	Bos taurus	31-37
7679116-7	1993	This work identifies NF-ATp as a DNA-binding phosphoprotein and a target for the drug/immunophilin/calcineurin complexes thought to mediate the inhibition of interleukin-2 gene induction by cyclosporin A and FK506.	Cyclosporine	190-203	nuclear factor of activated T cells 1	Bos taurus	21-27
7678245-3	1993	This paper reports an investigation on the minimal requirements for induction of the mitochondrial cyclosporin A-sensitive permeability transition pore (MTP).	Cyclosporine	99-112	microsomal triglyceride transfer protein	Rattus norvegicus	153-156
8639516-3	1996	Also, the binding affinity of cyclosporin A (CsA) to the different PPIases varies in IC(50) values from 6 nM for human PPIase hCyPA and 84 nM for the human hCyPB to over 120 nM for B. subtilis and 3000 nM for E. coli.	Cyclosporine	45-48	peptidylprolyl isomerase like 3	Homo sapiens	67-73
8639516-10	1996	In conclusion, our studies suggest that the unique histidine residues H90 and H109 in B. subtilis PPIase are, at least in part, responsible for its intermediate CsA affinity and that the v52 residue confers the low conversion rate.	Cyclosporine	161-164	peptidylprolyl isomerase like 3	Homo sapiens	98-104
8602846-0	1996	Cyclosporin A potentiates estradiol-induced expression of the cathepsin D gene in MCF7 breast cancer cells.	Cyclosporine	0-13	cathepsin D	Homo sapiens	62-73
8602846-2	1996	We have used Northern analysis to determine the influence of cyclosporin A on the expression of the estrogen-inducible cathepsin D gene in human MCF7 breast cancer cells.	Cyclosporine	61-74	cathepsin D	Homo sapiens	119-130
8602846-3	1996	We report that 1-3 microM cyclosporin A can potentiate cathepsin D mRNA expression by up to 2-fold in cells treated with 10(-12) to 10(-10) M estradiol.	Cyclosporine	26-39	cathepsin D	Homo sapiens	55-66
8602846-6	1996	Our results suggest that the increased potency of estradiol in the presence of cyclosporin A is associated with an enhanced transcriptional activity of the estrogen receptor and support a role for receptor-associated cyclophilin-40 in the activation process.	Cyclosporine	79-92	peptidylprolyl isomerase D	Homo sapiens	217-231
8596025-7	1996	Finally, cyclosporin A blocked both IL-2 secretion and bcl-2 induction in response to CD3 plus CD28 stimulation, suggesting a role for endogenous lymphokine production in the induction of bcl-2.	Cyclosporine	9-22	CD28 molecule	Homo sapiens	95-99
8660300-2	1996	In addition, hCyP-60 contains a tyrosine residue (Tyr 389) instead of a tryptophan residue found in most eukaryotic cyclophilins at a position important for cyclosporin binding.	Cyclosporine	157-168	peptidylprolyl isomerase like 2	Homo sapiens	13-20
8785399-1	1996	Forty-one patients with a nephrotic syndrome and biopsy-proven membranous nephropathy were administered a 3 to 6-month course of cyclosporine (CsA;4 to 5 mg/kg per day).	Cyclosporine	129-141	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	143-146
8419309-10	1993	We show that at variance from the case of cyclosporin A, MTP inhibition by the phospholipase A2 inhibitors nupercaine and trifluoperazine is Ca(2+)-competitive and is presumably related to interference by these drugs with Ca2+ binding to the internal regulatory site.	Cyclosporine	42-55	microsomal triglyceride transfer protein	Rattus norvegicus	57-60
8785405-0	1996	Accumulation of acidic renin isoforms in kidneys of cyclosporine-A-treated rats.	Cyclosporine	52-66	renin	Rattus norvegicus	23-28
8255521-3	1993	We measured the serum concentration of Lp(a) in 58 renal transplant recipients (40 male, 18 female) on cyclosporin monotherapy, and in 58 age- and sex-matched controls.	Cyclosporine	103-114	lipoprotein(a)	Homo sapiens	39-44
8302414-1	1993	We studied 20 kidney transplant recipients who had received Sandimmune cyclosporine A (CSA) capsules for an average of 7.9 months at a mean dose of 312 mg/day.	Cyclosporine	71-85	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	87-90
8785405-1	1996	Chronic cyclosporin A (CsA) treatment results in major hemodynamic changes in the renal microvasculature and in expression of the intrarenal renin angiotensin system.	Cyclosporine	8-21	renin	Rattus norvegicus	141-146
8785405-1	1996	Chronic cyclosporin A (CsA) treatment results in major hemodynamic changes in the renal microvasculature and in expression of the intrarenal renin angiotensin system.	Cyclosporine	23-26	renin	Rattus norvegicus	141-146
8785405-2	1996	Changes in renin expression in kidneys of CsA-treated rats include the recruitment of immunoreactive renin in afferent arterioles and in the juxtaglomerular apparatus.	Cyclosporine	42-45	renin	Rattus norvegicus	11-16
8785405-2	1996	Changes in renin expression in kidneys of CsA-treated rats include the recruitment of immunoreactive renin in afferent arterioles and in the juxtaglomerular apparatus.	Cyclosporine	42-45	renin	Rattus norvegicus	101-106
8785405-3	1996	This study presents evidence that an acidic isoform of renin is increased in kidneys of CsA-treated rats.	Cyclosporine	88-91	renin	Rattus norvegicus	55-60
8785405-5	1996	Silver-stained two-dimensional gels of renin separated from kidney homogenate with pepstatin agarose confirm the presence of an acidic renin isoform in CsA-treated rats.	Cyclosporine	152-155	renin	Rattus norvegicus	39-44
8785405-5	1996	Silver-stained two-dimensional gels of renin separated from kidney homogenate with pepstatin agarose confirm the presence of an acidic renin isoform in CsA-treated rats.	Cyclosporine	152-155	renin	Rattus norvegicus	135-140
8785405-7	1996	Renin enzymatic activity also increased in kidney homogenate of CsA-treated rats relative to duration of treatment with CsA (r2 = 0.486, P &lt; 0.001).	Cyclosporine	64-67	renin	Rattus norvegicus	0-5
8785405-9	1996	The acidic renin isoform identified in kidney homogenate of CsA-treated rats may be involved in the vascular changes that are seen in this model.	Cyclosporine	60-63	renin	Rattus norvegicus	11-16
8708940-1	1996	Cyclosporine (CsA) is a selective immunosuppressant widely used in clinical therapy.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
8600637-8	1996	The HSP72 response in cyclosporine-treated allografts was significantly reduced at 4 and 6 days posttransplantation compared with the untreated allografts.	Cyclosporine	22-34	heat shock protein family A (Hsp70) member 1A	Rattus norvegicus	4-9
8960365-5	1996	CIF inhibited induction of either construct as did cyclosporine, which is known to block activation of the NFAT element.	Cyclosporine	51-63	nuclear factor of activated T cells 1	Bos taurus	107-111
8828007-6	1996	CsA also induced depletion of anti-CD3 stimulated normal DP thymocytes.	Cyclosporine	0-3	CD3 antigen, epsilon polypeptide	Mus musculus	35-38
9172006-1	1996	In the present work, we have studied the prediction of blood cyclosporine (CsA) concentrations in haematological patients with multidrug resistance by means of total body weight, 25, 50 and 75 adipose factor dosing body weight, and lean body weight using the Bayesian method (BM) and non-linear least squares method (NLLSM) during the second course of CsA treatment.	Cyclosporine	61-73	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	75-78
8808110-4	1996	In addition to the work presented in this study, there have been many reports of the potential effectiveness of cyclosporine (CSA) on reducing the proteinuria of FSGS.	Cyclosporine	112-124	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	126-129
8950833-7	1996	Pentoxifylline (40 mumol/L), retinoic acid (0.01 mmol/L) and cyclosporin A (0.08 mumol/L) inhibited TF expression when added concurrently with LPS or TNF, but not when added 4 h after stimulation.	Cyclosporine	61-74	LOC101909187	Bos taurus	100-102
8950833-9	1996	In contrast, exposure to LPS or TNF for 6 h induced marked expression of TF mRNA, which was inhibited by treatment with pentoxifylline, retinoic acid and cyclosporin A.	Cyclosporine	154-167	LOC101909187	Bos taurus	73-75
8788211-10	1995	Cyclosporin A treatment induced only minor alterations in CD69 expression.	Cyclosporine	0-13	CD69 molecule	Homo sapiens	58-62
8566003-10	1995	This effect was sensitive to the immunosuppressive drug cyclosporin A, indicating that calcium-induced CD69 expression is mediated by the protein phosphatase calcineurin.	Cyclosporine	56-69	CD69 molecule	Homo sapiens	103-107
8566023-0	1995	Identification of an ionomycin/cyclosporin A-responsive element within the human T cell receptor gamma enhancer.	Cyclosporine	31-44	T cell receptor gamma locus	Homo sapiens	81-102
7490151-3	1995	We conducted the present study to determine whether the specific endothelin type A (ETA) receptor antagonist FR 139317 prevents cyclosporine-induced hypertension and whether cyclosporine increases ETA receptor mRNA in blood vessels.	Cyclosporine	174-186	endothelin receptor type A	Rattus norvegicus	197-200
7490151-7	1995	Cyclosporine (25 mg/kg per day) given for 4 weeks increased ETA receptor mRNA expression in the rat aorta and mesenteric artery (170% and 176%, respectively).	Cyclosporine	0-12	endothelin receptor type A	Rattus norvegicus	60-63
7490151-9	1995	These results indicate that cyclosporine may increase blood pressure by increasing not only endothelin production but also ETA receptor in the vasculature.	Cyclosporine	28-40	endothelin receptor type A	Rattus norvegicus	123-126
7490151-10	1995	The specific ETA receptor antagonist FR 139317 may prevent the hypertension induced by cyclosporine.	Cyclosporine	87-99	endothelin receptor type A	Rattus norvegicus	13-16
7503774-6	1995	Cyclosporin A (CsA) and its derivative PSC 833 (PSC) were the most effective inhibitors of IAAP binding among the drugs tested.	Cyclosporine	0-13	PSC	Homo sapiens	39-42
7503774-6	1995	Cyclosporin A (CsA) and its derivative PSC 833 (PSC) were the most effective inhibitors of IAAP binding among the drugs tested.	Cyclosporine	0-13	PSC	Homo sapiens	48-51
8605709-2	1995	Fifteen renal transplant hypertensive and proteinuric patients on triple drug treatment with cyclosporin (CSA), azathioprine and methylprednisolone entered the therapeutic protocol of this study.	Cyclosporine	93-104	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	106-109
8748119-6	1995	Despite the fact these drugs did not modulate the actions of glucocorticoids on corticotrope cells, both FK506 and CsA were potent stimulators of basal beta-endorphin secretion (4-6 fold) from rat anterior pituitary cultures and AtT20 cells.	Cyclosporine	115-118	pro-opiomelanocortin-alpha	Mus musculus	152-166
8748119-7	1995	In addition, FK506 and CsA potentiated beta-endorphin secretion induced by corticotropin releasing factor (CRF) and phorbol ester, but had no apparent acute (60 min) effect on POMC hnRNA levels.	Cyclosporine	23-26	pro-opiomelanocortin-alpha	Mus musculus	39-53
8748119-9	1995	Taken together these data suggest that FK506 and CsA do not alter GR activation or function in corticotrope cells, however, they are potent but short lived stimulators of POMC-derived peptide secretion.	Cyclosporine	49-52	pro-opiomelanocortin-alpha	Mus musculus	171-175
8748119-10	1995	The observation that CsA and FK506 stimulate POMC-derived peptide secretion, and potentiate both phorbol ester and CRF induced secretion, suggests that these immunosuppressant drugs are acting upon a common point within these intracellular pathways.	Cyclosporine	21-24	pro-opiomelanocortin-alpha	Mus musculus	45-49
8569758-1	1995	The role of pH in uncoupling the electron-flux between oxidoreductase and cytochrome P450 (P450) or P450 and cyclosporine (CyA) and resulting in the generation of oxygen radicals was investigated in vitro in rat and human liver microsomal preparations.	Cyclosporine	123-126	hydroxysteroid 17-beta dehydrogenase 6	Homo sapiens	55-69
8569758-2	1995	Since the electron-flux from NADPH to cytochrome c via oxidoreductase showed a fairly constant reduction activity from pH 7.0-9.5, the generation of oxygen radicals at the level of P450-Cyclosporine (instead of oxidoreductase-P450) was investigated.	Cyclosporine	186-198	hydroxysteroid 17-beta dehydrogenase 6	Homo sapiens	55-69
7488022-5	1995	Both CsA and FK506 cause disruption of the CnA1 delta-AID interaction, whereas their presence permits CnA1 delta to bind more strongly to CnB.	Cyclosporine	5-8	calcineurin catalytic subunit A	Saccharomyces cerevisiae S288C	43-47
7570986-5	1995	This nonresponsiveness induced by anti-LFA-3 or anti-IL-2/IL-2R could be overcome by the incorporation of cyclosporine during the first-round stimulation or by incorporation of IL-2 during the second-round stimulation.	Cyclosporine	106-118	CD58 molecule	Homo sapiens	39-44
7570986-5	1995	This nonresponsiveness induced by anti-LFA-3 or anti-IL-2/IL-2R could be overcome by the incorporation of cyclosporine during the first-round stimulation or by incorporation of IL-2 during the second-round stimulation.	Cyclosporine	106-118	interleukin 2 receptor subunit alpha	Homo sapiens	58-63
8480143-0	1993	Cyclosporin treatment in rheumatoid arthritis is associated with an increased serum activity of beta-glucuronidase.	Cyclosporine	0-11	glucuronidase beta	Homo sapiens	96-114
8589285-3	1995	At Day 35, CsA-treated rats had tubular injury, arteriolopathy of the afferent arteriole, increased expression of the monocyte-macrophage adhesive protein osteopontin, interstitial macrophage infiltration, increased interstitial transforming growth factor-beta expression, and interstitial fibrosis.	Cyclosporine	11-14	secreted phosphoprotein 1	Rattus norvegicus	155-166
8480143-2	1993	In 10 patients with RA the serum beta-gluc was repeatedly determined after the initiation of a treatment with cyclosporin for one year.	Cyclosporine	110-121	glucuronidase beta	Homo sapiens	33-42
8081779-1	1993	Since cyclosporine A(CsA) was introduced into transplantation medicine to prevent graft-versus-host disease (GvHD) as well as graft rejection, side-effects became obvious.	Cyclosporine	6-20	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	21-24
8081782-1	1993	Cyclosporine A (CSA) is the standard immunosuppressive agent used in human cardiac transplantation to prevent rejection; however, adverse side effects have been reported at therapeutic doses.	Cyclosporine	0-14	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	16-19
1429556-3	1992	Sequence analysis of the 43-kDa protein purified from calf thymus and subsequent Western analysis of CsA affinity-purified material from Jurkat extracts identified the 43-kDa component as actin.	Cyclosporine	101-104	actin epsilon 1	Bos taurus	188-193
1382988-3	1992	We have previously shown that T cell receptor/CD3-mediated induction of apoptosis in a murine T cell hybridoma is inhibited by the immunosuppressive drugs cyclosporin A (CsA) and FK506.	Cyclosporine	155-168	CD3 antigen, epsilon polypeptide	Mus musculus	46-49
1382988-3	1992	We have previously shown that T cell receptor/CD3-mediated induction of apoptosis in a murine T cell hybridoma is inhibited by the immunosuppressive drugs cyclosporin A (CsA) and FK506.	Cyclosporine	170-173	CD3 antigen, epsilon polypeptide	Mus musculus	46-49
8589285-5	1995	The pathogenesis of CsA nephropathy involves the expression of osteopontin by tubular epithelial cells, the level of which closely correlates with the degree of macrophage infiltration and interstitial fibrosis in all groups (r = 0.79 and 0.74, respectively; P &lt; 0.001).	Cyclosporine	20-23	secreted phosphoprotein 1	Rattus norvegicus	63-74
7560060-0	1995	Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.	Cyclosporine	124-137	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	15-20
7493917-0	1995	Multidrug resistance-associated protein-mediated multidrug resistance modulated by cyclosporin A in a human bladder cancer cell line.	Cyclosporine	83-96	ATP binding cassette subfamily C member 3	Homo sapiens	0-39
1403040-1	1992	PURPOSE: To determine the maximum-tolerated dose (MTD) of cyclosporine (CsA) infusion administered with etoposide for 3 days in patients with cancer.	Cyclosporine	58-70	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	72-75
8575571-6	1995	Interleukin-5 production by stimulated mononuclear cells was also inhibited both by FK506 and cyclosporin A.	Cyclosporine	94-107	interleukin 5	Homo sapiens	0-13
1403041-1	1992	PURPOSE: To determine the effects of high-dose cyclosporine (CsA) infusion on the pharmacokinetics of etoposide in patients with cancer.	Cyclosporine	47-59	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	61-64
8557519-1	1995	We investigated the transcription and expression of the interleukin-2 receptor (IL-2R, CD25) in human T-lymphocytes after different modes of T-lymphocyte stimulation in the presence of the immunosuppressants cyclosporin (CsA) and tacrolimus (FK506) as well as the structurally related macrolide rapamycin.	Cyclosporine	208-219	interleukin 2 receptor subunit alpha	Homo sapiens	56-78
8557519-1	1995	We investigated the transcription and expression of the interleukin-2 receptor (IL-2R, CD25) in human T-lymphocytes after different modes of T-lymphocyte stimulation in the presence of the immunosuppressants cyclosporin (CsA) and tacrolimus (FK506) as well as the structurally related macrolide rapamycin.	Cyclosporine	208-219	interleukin 2 receptor subunit alpha	Homo sapiens	80-85
8557519-1	1995	We investigated the transcription and expression of the interleukin-2 receptor (IL-2R, CD25) in human T-lymphocytes after different modes of T-lymphocyte stimulation in the presence of the immunosuppressants cyclosporin (CsA) and tacrolimus (FK506) as well as the structurally related macrolide rapamycin.	Cyclosporine	221-224	interleukin 2 receptor subunit alpha	Homo sapiens	56-78
7666081-1	1995	PURPOSE: To determine the maximal-tolerated dose (MTD) of infusional cyclosporine (CSA) with fixed-dose carboplatin (CBDCA).	Cyclosporine	69-81	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	83-86
1338979-7	1992	Although CsA is a competitive inhibitor of PPIase activity, it can complex with enzymatically inactive cyclophilins and inhibit the phosphatase activity of calcineurin.	Cyclosporine	9-12	peptidylprolyl isomerase like 3	Homo sapiens	43-49
7593550-3	1995	The present experiments examined the effects of combined treatment with subtherapeutic doses of cyclosporine A (CsA) and 1,25(OH)2D3 on the evolution of experimental autoimmune encephalomyelitis (EAE) in SJL mice.	Cyclosporine	96-110	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	112-115
1500789-0	1992	The effect of cyclosporin A (CSA) on murine visceral toxocariasis canis.	Cyclosporine	14-27	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	29-32
1500789-1	1992	Swiss mice experimentally infected with T. canis were treated by Cyclosporin A (CSA).	Cyclosporine	65-78	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	80-83
7544037-6	1995	Both CsA and vehicle inhibited IL-4-stimulated VCAM-1 expression in a dose-dependent manner (from [OD mU, mean +/- SEM] 230 +/- 5 to 165 +/- 3 for CsA 50 ng/ml, and to 181 +/- 6 for the corresponding vehicle concentration; P &lt; 0.05 for both comparisons).	Cyclosporine	5-8	interleukin-4	Oryctolagus cuniculus	31-35
7544037-6	1995	Both CsA and vehicle inhibited IL-4-stimulated VCAM-1 expression in a dose-dependent manner (from [OD mU, mean +/- SEM] 230 +/- 5 to 165 +/- 3 for CsA 50 ng/ml, and to 181 +/- 6 for the corresponding vehicle concentration; P &lt; 0.05 for both comparisons).	Cyclosporine	147-150	interleukin-4	Oryctolagus cuniculus	31-35
7608202-10	1995	Cyclosporin A, a potent inhibitor of the calmodulin-dependent phosphatase calcineurin, blocked the induction of NFAT-DNA binding activity, implicating calcineurin as a key signaling enzyme in this pathway.	Cyclosporine	0-13	nuclear factor of activated T-cells 5	Rattus norvegicus	112-116
11850697-1	1995	The effect of a standard regimen of the investigational macrolide antibiotic, dirithromycin, on the single-dose kinetics of orally administered cyclosporine (CSA) was investigated in healthy young males and on the steady-state disposition kinetics of cyclosporine in a panel of renal transplant patients.	Cyclosporine	144-156	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	158-161
11850697-15	1995	The magnitude of the pharmacokinetic changes for CSA during dirithromycin treatment (&lt;15% in normal subjects and 15--20% in renal transplant patients) when considered in the context of the therapeutic range of cyclosporine concentrations was relatively small, and not likely to warrant special attention to the dosing of CSA in such patients beyond routine whole-blood CSA and serum creatinine monitoring.	Cyclosporine	213-225	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	49-52
9049391-5	1995	As a selection marker we used the cyclosporin A resistance of fusion which was shown to be a unique characteristic of syn 3 locus mutants.	Cyclosporine	34-47	synapsin III	Homo sapiens	118-123
1325148-6	1992	We have performed a study in renal graft recipients in order to assess the usefulness of circulating S-IL-2R particularly to discriminate the origin of renal failure in cases of rejection or of cyclosporin-A (CsA)-induced nephrotoxicity.	Cyclosporine	194-207	interleukin 2 receptor subunit alpha	Homo sapiens	103-108
1325148-6	1992	We have performed a study in renal graft recipients in order to assess the usefulness of circulating S-IL-2R particularly to discriminate the origin of renal failure in cases of rejection or of cyclosporin-A (CsA)-induced nephrotoxicity.	Cyclosporine	209-212	interleukin 2 receptor subunit alpha	Homo sapiens	103-108
1323728-0	1992	Endothelin-1 receptor antagonist: effects on endothelin- and cyclosporine-treated mesangial cells.	Cyclosporine	61-73	endothelin receptor type A	Homo sapiens	0-21
1323728-9	1992	Exposure of mesangial cells to Cs (10(-5) M) for 60 minutes caused a significant increase in MLCP, on average, by 38 +/- 6% above control (P less than 0.0005), while cells exposed to Cs in the presence of EtA increased MLCP significantly less, by only 15 +/- 9%.	Cyclosporine	31-33	endothelin receptor type A	Homo sapiens	205-208
1315036-3	1992	With [Ser(32P15]RII as substrate, the concentrations of the cyclosporin A.cyclophilin A and cyclosporin A.cyclophilin B complexes, which cause 50% inhibition of calcineurin activity, are 120 and 50 nM, respectively.	Cyclosporine	60-73	peptidyl-prolyl cis-trans isomerase A	Bos taurus	74-87
1348520-0	1992	CD28-stimulated IL-2 gene expression in Jurkat T cells occurs in part transcriptionally and is cyclosporine-A sensitive.	Cyclosporine	95-109	CD28 molecule	Homo sapiens	0-4
1348520-2	1992	Previous studies have shown that proliferation of peripheral blood T cells involving the CD28 pathway is associated with cyclosporine A (CsA) resistant IL-2 gene expression.	Cyclosporine	121-135	CD28 molecule	Homo sapiens	89-93
1551527-1	1992	The P450IIIA (CYP3A) cytochromes are a major family of enzymes that play an important role in the metabolism of many medications, including cyclosporine A, as well as some dietary xenobiotics, including aflatoxin B1.	Cyclosporine	140-154	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	4-12
7582858-3	1995	The present studies were undertaken to study the effects of CsA on rat myocardial Ca2+, calmodulin (Cam)-dependent enzymes such as Ca2+ ATPase and nitric oxide synthase (NOS) and the role of FDP in attenuating these changes in vitro.	Cyclosporine	60-63	calmodulin 1	Rattus norvegicus	88-98
1311721-8	1992	Treatment of mitotically stimulated lymphocytes with cyclosporin, which inhibits proliferation, blocked the increase in p19/nm23; treatment of the leukemia cell line HL-60 with dimethylsulfoxide, which induces terminal differentiation, resulted in diminished levels of p19/nm23.	Cyclosporine	53-64	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	124-128
7582858-3	1995	The present studies were undertaken to study the effects of CsA on rat myocardial Ca2+, calmodulin (Cam)-dependent enzymes such as Ca2+ ATPase and nitric oxide synthase (NOS) and the role of FDP in attenuating these changes in vitro.	Cyclosporine	60-63	calmodulin 1	Rattus norvegicus	100-103
1311721-8	1992	Treatment of mitotically stimulated lymphocytes with cyclosporin, which inhibits proliferation, blocked the increase in p19/nm23; treatment of the leukemia cell line HL-60 with dimethylsulfoxide, which induces terminal differentiation, resulted in diminished levels of p19/nm23.	Cyclosporine	53-64	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	273-277
7541038-4	1995	Cyclosporin A and FK506 efficiently disrupt the YY1-CyPA and YY1-FKBP12 interactions.	Cyclosporine	0-13	FKBP prolyl isomerase 1A	Homo sapiens	65-71
7544983-1	1995	Hypertension, which develops after organ transplantation during immunosuppression with cyclosporine (CSA), is often associated with a loss of nocturnal decrease in blood pressure.	Cyclosporine	87-99	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	101-104
7794760-1	1995	Cyclosporin A (CSA) exhibits greater multidrug resistance (MDR) modulating activity in vitro than other MDR modulators such as verapamil and quinidine.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
1545136-5	1992	GM-CSF bioactivity increased in cell supernatants from keratinocytes exposed in vitro to 1 microgram/ml cyclosporin for up to 24 h. GM-CSF and IL-1 mRNA levels in keratinocytes cultured under similar conditions or in the presence of lipopolysaccharide also increased.	Cyclosporine	104-115	interleukin 1 complex	Mus musculus	143-147
1531395-2	1992	When class II antigens are matched, long-term specific tolerance across complete MHC class I antigen barriers can uniformly be induced by a 12-day perioperative course of cyclosporine.	Cyclosporine	171-183	MHC class I antigen	Homo sapiens	81-100
7549062-5	1995	Increased doses of systemically administered cyclosporin-A (CSA) were necessary to maintain therapeutic levels for 2 patients.	Cyclosporine	45-58	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	60-63
7579056-7	1995	At 1 yr after transplantation, CsA-treated patients had significantly higher Lp(a) levels (CsA: median, 105 (interquartile range 42 to 340) mg/L; Aza-Pred: 46 (25 to 176) mg/L; P &lt; 0.05).	Cyclosporine	31-34	lipoprotein(a)	Homo sapiens	77-82
1346494-1	1992	Cyclosporin A (CsA), a cyclic peptide of 11 amino acids isolated from the fungus Tolypoclodium inflatum Gams, is the principle drug used for immunosuppression in organ transplant patients.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
1728297-5	1992	Treatment of challenged mice with cyclosporin A (CyA) led to an abrogation of the disease as seen by an abrogation of the increase in lung index, lack of IL-1 and TNF-alpha release in the BAL.	Cyclosporine	34-47	interleukin 1 complex	Mus musculus	154-158
1370254-1	1992	Suppressor T cell (Ts) lines specific for myelin basic protein (MBP)-reactive helper T cell (Th) clones were generated from two patients with multiple sclerosis (MS) following a primary culture of peripheral blood mononuclear cells (PBMC) with MBP and cyclosporine A (CsA).	Cyclosporine	252-266	myelin basic protein	Homo sapiens	64-67
1370254-1	1992	Suppressor T cell (Ts) lines specific for myelin basic protein (MBP)-reactive helper T cell (Th) clones were generated from two patients with multiple sclerosis (MS) following a primary culture of peripheral blood mononuclear cells (PBMC) with MBP and cyclosporine A (CsA).	Cyclosporine	268-271	myelin basic protein	Homo sapiens	42-62
1370254-1	1992	Suppressor T cell (Ts) lines specific for myelin basic protein (MBP)-reactive helper T cell (Th) clones were generated from two patients with multiple sclerosis (MS) following a primary culture of peripheral blood mononuclear cells (PBMC) with MBP and cyclosporine A (CsA).	Cyclosporine	268-271	myelin basic protein	Homo sapiens	64-67
1371491-8	1992	When the cells were stimulated by phorbol ester (phorbol 12-myristate 13-acetate, PMA) plus calcium ionophore (ionomycin), FK506 and CsA inhibited, in a dose-dependent manner, the production of IL-2, IL-4, IL-5, IFN-gamma and TNF-alpha.	Cyclosporine	133-136	interleukin 5	Homo sapiens	206-210
1346344-2	1992	In view of the importance of the IL-2 receptors in the expression of antiallograft immunity and the currently existing controversy regarding the effect of CsA on the induction of IL-2 receptors, we explored the effect of cyclosporine on the induction of interleukin-2 receptor alpha and beta in normal human T cells.	Cyclosporine	221-233	interleukin 2 receptor subunit alpha	Homo sapiens	254-282
1346344-5	1992	Our experimental design revealed that (A) CsA inhibits the induction of IL-2 receptor alpha and beta in normal human T cells, (B) the inhibitory activity is realized by a direct effect on T cells, and (C) the inhibitory activity is detectable at the pretranslational level--CsA significantly reduced the induction of mRNA encoding IL-2 receptor alpha and IL-2 receptor beta.	Cyclosporine	42-45	interleukin 2 receptor subunit alpha	Homo sapiens	72-91
1346344-5	1992	Our experimental design revealed that (A) CsA inhibits the induction of IL-2 receptor alpha and beta in normal human T cells, (B) the inhibitory activity is realized by a direct effect on T cells, and (C) the inhibitory activity is detectable at the pretranslational level--CsA significantly reduced the induction of mRNA encoding IL-2 receptor alpha and IL-2 receptor beta.	Cyclosporine	42-45	interleukin 2 receptor subunit alpha	Homo sapiens	331-350
1346344-5	1992	Our experimental design revealed that (A) CsA inhibits the induction of IL-2 receptor alpha and beta in normal human T cells, (B) the inhibitory activity is realized by a direct effect on T cells, and (C) the inhibitory activity is detectable at the pretranslational level--CsA significantly reduced the induction of mRNA encoding IL-2 receptor alpha and IL-2 receptor beta.	Cyclosporine	42-45	interleukin 2 receptor subunit beta	Homo sapiens	355-373
14621852-3	1992	The use of cyclosporine (CSA) means new problems for the pregnant women and the fetus: the risk of congenital abnormalities, fetal growth retardation, hepato- and nephrotoxicity.	Cyclosporine	11-23	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	25-28
7579056-10	1995	Multiple linear regression analysis showed an independent correlation between the use of Pred and HDL cholesterol level, whereas the use of CsA was independently associated with the concentration of Lp(a).	Cyclosporine	140-143	lipoprotein(a)	Homo sapiens	199-204
7536397-10	1995	Immunohistochemistry revealed that the occluded epicardial arteries of cardiac allografts with low dose CsA expressed VCAM-1 on the endothelium.	Cyclosporine	104-107	vascular cell adhesion molecule 1	Rattus norvegicus	118-124
7536397-11	1995	Higher CsA doses significantly reduced the expression of endothelial VCAM-1.	Cyclosporine	7-10	vascular cell adhesion molecule 1	Rattus norvegicus	69-75
7536397-16	1995	Arteriosclerotic alterations associated with increased expression of arterial endothelial VCAM-1 were totally down-regulated by high doses of CsA.	Cyclosporine	142-145	vascular cell adhesion molecule 1	Rattus norvegicus	90-96
7534790-13	1995	We conclude that CD28 costimulatory signals augment superantigen-induced TCR signals by converging onto common TCR effector pathways involving the activation of phospholipase C gamma 1 and PKC and by generating a cyclosporin A-sensitive pathway.	Cyclosporine	213-226	CD28 molecule	Homo sapiens	17-21
7774069-1	1995	Our studies on the treatment of psoriasis with cyclosporine A (CSA) have demonstrated efficacy at doses &lt; 5 mg/kg/day.	Cyclosporine	47-61	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	63-66
7538492-7	1995	Both drugs acted directly on the nitric oxide synthase (NOS), since CsA and FK506 reduced by 35% and by 17%, respectively, NOS activity in the crude cytosolic fraction.	Cyclosporine	68-71	nitric oxide synthase 1, neuronal	Mus musculus	33-54
7540862-0	1995	IL-5 production by CD4+ T cells of asthmatic patients is suppressed by glucocorticoids and the immunosuppressants FK506 and cyclosporin A.	Cyclosporine	124-137	interleukin 5	Homo sapiens	0-4
7540862-6	1995	Dexamethasone, FK506 and cyclosporin A suppressed IL-5 production in vitro in a dose-dependent manner.	Cyclosporine	25-38	interleukin 5	Homo sapiens	50-54
7780063-0	1995	Endothelin A receptor mediates functional but not structural damage in chronic cyclosporine nephrotoxicity.	Cyclosporine	79-91	endothelin receptor type A	Rattus norvegicus	0-21
7780063-8	1995	Chronic antagonism of the EtA receptor preserved renal function: GFR was 0.15 +/- 0.03 mL/min per 100 g body wt, and RPF was 0.32 +/- 0.08/100 g body wt (P &lt; 0.05 for GFR versus CsA).	Cyclosporine	181-184	endothelin receptor type A	Rattus norvegicus	26-29
7878758-1	1995	We tested the hypothesis that there would be a difference in the unwanted side effects of cyclosporine (CsA) when heart transplant patients received CsA once a day versus half the dose twice a day.	Cyclosporine	90-102	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	104-107
7478116-1	1995	Cyclosporin A (CsA) can reduce proteinuria in various forms of human and experimental glomerulonephritis.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
7632436-1	1995	Cyclosporine A (CsA) has been shown to be an effective therapeutic agent for a wide variety of cutaneous diseases yet its exact mechanism of action is still unclear, although one well-defined effect of CsA is the inhibition of T-cell-derived cytokine expression.	Cyclosporine	0-14	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	16-19
7632436-1	1995	Cyclosporine A (CsA) has been shown to be an effective therapeutic agent for a wide variety of cutaneous diseases yet its exact mechanism of action is still unclear, although one well-defined effect of CsA is the inhibition of T-cell-derived cytokine expression.	Cyclosporine	0-14	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	202-205
7989765-4	1994	The day 7 NK cell responses in beta 2-m-/- mice, but not in normal C57BL/6 animals, were cyclosporin A sensitive and coincided with IL-2 production and high affinity IL-2R expression on NK cells.	Cyclosporine	89-102	beta-2 microglobulin	Mus musculus	31-39
7982907-2	1994	CD28 signaling is resistant to the immunosuppressant cyclosporin A (CsA) but sensitive to the immunosuppressant rapamycin.	Cyclosporine	53-66	CD28 molecule	Homo sapiens	0-4
7982907-2	1994	CD28 signaling is resistant to the immunosuppressant cyclosporin A (CsA) but sensitive to the immunosuppressant rapamycin.	Cyclosporine	68-71	CD28 molecule	Homo sapiens	0-4
7899577-1	1994	Cyclosporin A (CsA)-induced nephrotoxicity is characterized by a decrease in the glomerular filtration rate (GFR) which is associated with a large increase in renal vascular resistance (RVR).	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
7743602-4	1994	The synergistic interaction of CD40 signals with PMA or CD20 show differential requirements for CD40 crosslinking and different sensitivity to cyclosporine A, suggesting that CD40 receptor may use different effector mechanisms for synergy with calcium-dependent CD20 signals or with calcium-independent signals from PMA.	Cyclosporine	143-157	CD40 molecule	Homo sapiens	31-35
7524221-0	1994	Individual susceptibility to cyclosporine: possible involvement of the CD28/CD80 (B7/BB1) pathway.	Cyclosporine	29-41	CD28 molecule	Homo sapiens	71-75
7524221-0	1994	Individual susceptibility to cyclosporine: possible involvement of the CD28/CD80 (B7/BB1) pathway.	Cyclosporine	29-41	CD80 molecule	Homo sapiens	76-80
7524221-0	1994	Individual susceptibility to cyclosporine: possible involvement of the CD28/CD80 (B7/BB1) pathway.	Cyclosporine	29-41	CD80 molecule	Homo sapiens	82-88
7940850-0	1994	Design and evaluation of a computer tool to aid early management of cyclosporine therapy after heart and heart-lung transplantation.	Cyclosporine	68-80	activation induced cytidine deaminase	Homo sapiens	44-47
8077662-5	1994	Furthermore, cyclosporin A, but not rapamycin, blocked the synergistic induction of IL-8 expression achieved with anti-CD3 and anti-CD28 costimulation.	Cyclosporine	13-26	CD28 molecule	Homo sapiens	132-136
7527575-1	1994	The nephrotoxicity of cyclosporin A (CSA) after chronic treatment is well known and includes in later stages tubular atrophy associated with interstitial fibrosis.	Cyclosporine	22-35	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	37-40
1721462-0	1991	The ability of myelin basic protein-sensitised leukocytes to adoptively transfer experimental allergic encephalomyelitis following coculture with FK 506, cyclosporine, or prednisolone.	Cyclosporine	154-166	myelin basic protein	Homo sapiens	15-35
7986722-7	1994	Unexpectedly, PRCA in two B19 DNA-positive patients remitted after antilymphocyte globulin or cyclosporin A therapy, suggesting that the clinical course of B19-induced PRCA may be indistinguishable from other forms of PRCA.	Cyclosporine	94-107	eva-1 homolog C	Homo sapiens	26-29
1892753-5	1991	On the other hand, ornithine decarboxylase activity, the rate limiting enzyme of polyamine biosynthesis which converts ornithine to putrescine, was decreased by CsA treatment.	Cyclosporine	161-164	ornithine decarboxylase 1	Homo sapiens	19-42
1892753-7	1991	This suppression of ornithine decarboxylase by CsA is more likely to occur by indirect effects on translation and/or transcription rather than a direct effect on the enzyme.	Cyclosporine	47-50	ornithine decarboxylase 1	Homo sapiens	20-43
7986722-7	1994	Unexpectedly, PRCA in two B19 DNA-positive patients remitted after antilymphocyte globulin or cyclosporin A therapy, suggesting that the clinical course of B19-induced PRCA may be indistinguishable from other forms of PRCA.	Cyclosporine	94-107	eva-1 homolog C	Homo sapiens	156-159
1717376-1	1991	Cyclosporin (CsA) and FK-506 are structurally distinct fungal metabolites, which exert powerful inhibitory effects on CD4+ T (helper) cell activation and on the secretion of interleukin-2 (IL-2) and other cytokines, including various cell growth factors and interferon-gamma.	Cyclosporine	0-11	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	13-16
7518925-3	1994	Here, TNF-alpha gene transcription is shown also to be highly and rapidly induced in human B cells after stimulation via the CD40 and interleukin 4 pathways, which similarly is inhibited by CsA and a panel of CsA or FK506 analogues that block calcineurin phosphatase activity.	Cyclosporine	190-193	CD40 molecule	Homo sapiens	125-129
7518925-3	1994	Here, TNF-alpha gene transcription is shown also to be highly and rapidly induced in human B cells after stimulation via the CD40 and interleukin 4 pathways, which similarly is inhibited by CsA and a panel of CsA or FK506 analogues that block calcineurin phosphatase activity.	Cyclosporine	209-212	CD40 molecule	Homo sapiens	125-129
7516408-5	1994	The proliferative effect of anti-CD28 and IL-12 is resistant to moderate doses of cyclosporin A and is largely independent of endogenous IL-2, IL-12, in synergy with anti-CD28 or B7-transfected cells, is most effective in inducing interferon gamma (IFN-gamma) production, but production of tumor necrosis factor alpha and granulocyte/macrophage colony-stimulating factor is also observed.	Cyclosporine	82-95	CD28 molecule	Homo sapiens	33-37
2056124-3	1991	Infusion of cyclosporine (CSA) hemodynamically parallels ET action, and knowing that CSA effects EC, we hypothesize that the vasoconstrictive effects of CSA are a result of ET synthesis by EC.	Cyclosporine	12-24	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	26-29
1833542-6	1991	A statistically significant correlation between CR1 numbers and CH50 values was found in patients with SLE, while in 3 patients with RA 4 months of therapy with cyclosporine A led to a further 30% reduction in CR1 number.	Cyclosporine	161-175	complement C3b/C4b receptor 1 (Knops blood group)	Homo sapiens	210-213
2031507-1	1991	Cyclosporin A (CSA) is an immunosuppressive agent that in experimental models has antiproliferative activity against colon cancer and other human neoplasms.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
1854886-3	1991	Treatment of this disease with cyclosporin-A (CSA) therefore appears to be sensible.	Cyclosporine	31-44	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	46-49
1646506-0	1991	The effect of the CD28 activation pathway on the immunosuppressive action of cyclosporine.	Cyclosporine	77-89	CD28 molecule	Homo sapiens	18-22
1646506-1	1991	The effect of the CD28 activation pathway on the immunosuppressive action of CsA was assessed.	Cyclosporine	77-80	CD28 molecule	Homo sapiens	18-22
1646506-9	1991	Addition of CsA to lymphocytes stimulated with anti-CD3 resulted in the dose-dependent suppression of the proliferative response and IL-2 production (IC50 = 10-25 nM) but less so for IL-2 receptor expression (IC50 = 100-150 nM).	Cyclosporine	12-15	interleukin 2 receptor subunit beta	Homo sapiens	183-196
1646506-10	1991	In comparison, the proliferative response and IL-2 production elicited by anti-CD3 + anti-CD28 was more resistant to the effects of CsA (IC50 = 100-200 nM).	Cyclosporine	132-135	CD28 molecule	Homo sapiens	90-94
1646506-11	1991	However, IL-2 receptor expression exhibited comparable sensitivity to CsA (IC50 = 100-200 nM) in the presence of anti-CD28.	Cyclosporine	70-73	interleukin 2 receptor subunit beta	Homo sapiens	9-22
1646506-12	1991	Combination drug:drug studies revealed that CsA and the protein kinase C inhibitor H-7 were additive for both anti-CD3 and anti-CD3 plus anti-CD28 response.	Cyclosporine	44-47	CD28 molecule	Homo sapiens	142-146
1646506-13	1991	On the other hand, the cGMP-dependent protein kinase inhibitor H-8 was synergistic with CsA in inhibiting the response of lymphocytes to anti-CD3 plus anti-CD28 but only additive for responses to anti-CD3.	Cyclosporine	88-91	CD28 molecule	Homo sapiens	156-160
1646506-14	1991	Taken together, these data suggest that CsA inhibits T cell activation at two distinct levels, leading to inhibition of IL-2 production and inhibition of IL-2 receptor expression.	Cyclosporine	40-43	interleukin 2 receptor subunit beta	Homo sapiens	154-167
1646506-15	1991	Activation of the CD28 pathway partially overcomes the inhibitory activity of CsA on IL-2 production and may be mediated by indirect activation of a cGMP-dependent protein kinase.	Cyclosporine	78-81	CD28 molecule	Homo sapiens	18-22
2033128-4	1991	After 15 days of cyclosporine therapy, we observed a dramatic decrease in the total number of T cells and a corresponding decrease in interleukin 2 receptor-positive activated CD25+ cells and in antigen-presenting cells (CD1+ and CD14b+).	Cyclosporine	17-29	interleukin 2 receptor subunit alpha	Homo sapiens	176-180
2002285-9	1991	Five to 10 min after CsA exposure eta = 2.62-2.68 P and plateaus at eta = 2.31-2.51 P 20-120 min after exposure.	Cyclosporine	21-24	endothelin receptor type A	Homo sapiens	34-37
2029952-4	1991	Ten patients (11 pregnancies) were treated with ciclosporin A (CsA).	Cyclosporine	63-66	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	48-61
1862749-0	1991	Different inhibitory actions of cyclosporine A and cyclosporine A-acetate on lipopolysaccharide-, interleukin 1-, 1,25 dihydroxyvitamin D3- and parathyroid hormone-stimulated calcium and lysosomal enzyme release from mouse calvaria in vitro.	Cyclosporine	32-46	parathyroid hormone	Mus musculus	144-163
1903312-4	1991	Whereas the PRCA repeatedly responded to immunosuppression with high-dose cyclosporin A (CSA) and CSA plus plasmapheresis, IFN antibody production continued during treatment with cyclophosphamide and CSA.	Cyclosporine	74-87	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	89-92
1994547-2	1991	The recent demonstration that cyclophilin is a CsA-sensitive prolyl-peptidyl-isomerase (PPIase), has prompted speculation that CsA immunosuppression is mediated by PPIase interaction with activation signals like ADR.	Cyclosporine	47-50	peptidylprolyl isomerase like 3	Homo sapiens	88-94
1994547-2	1991	The recent demonstration that cyclophilin is a CsA-sensitive prolyl-peptidyl-isomerase (PPIase), has prompted speculation that CsA immunosuppression is mediated by PPIase interaction with activation signals like ADR.	Cyclosporine	127-130	peptidylprolyl isomerase like 3	Homo sapiens	88-94
1994547-2	1991	The recent demonstration that cyclophilin is a CsA-sensitive prolyl-peptidyl-isomerase (PPIase), has prompted speculation that CsA immunosuppression is mediated by PPIase interaction with activation signals like ADR.	Cyclosporine	127-130	peptidylprolyl isomerase like 3	Homo sapiens	164-170
1994547-13	1991	Addition of 1.5 or 3 mM CsA to resting cytoplasm, primed with PPIase (5035 +/- 75 cpm), resulted in 3HTPP incorporation of 6575 +/- 152 and 5076 +/- 168 cpm, respectively.	Cyclosporine	24-27	peptidylprolyl isomerase like 3	Homo sapiens	62-68
1994547-14	1991	Thus, PPIase activation of ADR is CsA-resistant.	Cyclosporine	34-37	peptidylprolyl isomerase like 3	Homo sapiens	6-12
7916931-0	1994	Polyarteritis nodosa type vasculitis in a patient with familial Mediterranean fever treated with cyclosporin A.	Cyclosporine	97-110	MEFV innate immuity regulator, pyrin	Homo sapiens	55-83
7916931-1	1994	Patients with amyloidosis secondary to familial Mediterranean fever (FMF) are known to tolerate cyclosporin A poorly.	Cyclosporine	96-109	MEFV innate immuity regulator, pyrin	Homo sapiens	39-67
8207202-6	1994	Cyclosporin A, which prevented lymphokine mRNA transcription, inhibited more than 90% of the IL-2R alpha and NF-kappa B levels induced by TCR/CD3-mediated activation.	Cyclosporine	0-13	interleukin 2 receptor subunit alpha	Homo sapiens	93-104
8009178-1	1994	Cyclosporin (CsA) is a potent immunosuppressive drug widely used in organ transplantation.	Cyclosporine	0-11	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	13-16
8072246-2	1994	The mechanism of this nephrotoxicity is not well understood; however, recent studies suggest that cyclophilin (cyp) is responsible for mediating the immunosuppressive action of CsA through the interaction with the Ca(2+)- and calmodulin-dependent phosphatase, calcineurin.	Cyclosporine	177-180	peptidyl-prolyl isomerase G (cyclophilin G)	Mus musculus	98-109
8072246-2	1994	The mechanism of this nephrotoxicity is not well understood; however, recent studies suggest that cyclophilin (cyp) is responsible for mediating the immunosuppressive action of CsA through the interaction with the Ca(2+)- and calmodulin-dependent phosphatase, calcineurin.	Cyclosporine	177-180	peptidyl-prolyl isomerase G (cyclophilin G)	Mus musculus	111-114
8072246-6	1994	Our data showed that the distribution of cyp C mRNA was uneven, and it mainly existed in segments that are relatively sensitive to CsA toxicity.	Cyclosporine	131-134	peptidyl-prolyl isomerase G (cyclophilin G)	Mus musculus	41-44
8072246-8	1994	By CsA administration, the signal for cyp C mRNA PCR product was increased.	Cyclosporine	3-6	peptidyl-prolyl isomerase G (cyclophilin G)	Mus musculus	38-41
8072246-9	1994	These results suggest that cyp C may play some role in the renal tubular disorder observed in CsA nephrotoxicity.	Cyclosporine	94-97	peptidyl-prolyl isomerase G (cyclophilin G)	Mus musculus	27-30
8160773-6	1994	This follicular response to CYP can be manipulated pharmacologically: systemic cyclosporine A shifts it toward a mild form of dystrophic anagen, thus retarding CYP-IA and prolonging "primary recovery".	Cyclosporine	79-93	peptidyl-prolyl isomerase G (cyclophilin G)	Mus musculus	28-31
8160773-6	1994	This follicular response to CYP can be manipulated pharmacologically: systemic cyclosporine A shifts it toward a mild form of dystrophic anagen, thus retarding CYP-IA and prolonging "primary recovery".	Cyclosporine	79-93	peptidyl-prolyl isomerase G (cyclophilin G)	Mus musculus	160-163
8045668-0	1994	Effect of interferon-gamma, interleukin-2 and interleukin-4 on cyclosporin-A-mediated inhibition of anti-CD3-induced T-lymphocyte proliferation.	Cyclosporine	63-76	CD3 antigen, epsilon polypeptide	Mus musculus	105-108
7907604-0	1994	Cyclosporin A inhibits CD40 ligand expression in T lymphocytes.	Cyclosporine	0-13	CD40 molecule	Homo sapiens	23-27
7907604-4	1994	CD40 ligand expression was inhibited by pretreatment of T cells with cyclosporin A.	Cyclosporine	69-82	CD40 molecule	Homo sapiens	0-4
7907604-5	1994	Cyclosporin A analogues inhibited CD40 ligand expression with a potency mirroring the ability of each compound to inhibit calcineurin activity, indicating that calcineurin plays a key role in CD40 ligand gene expression.	Cyclosporine	0-13	CD40 molecule	Homo sapiens	34-38
7907604-5	1994	Cyclosporin A analogues inhibited CD40 ligand expression with a potency mirroring the ability of each compound to inhibit calcineurin activity, indicating that calcineurin plays a key role in CD40 ligand gene expression.	Cyclosporine	0-13	CD40 molecule	Homo sapiens	192-196
7907604-6	1994	Cyclosporin A inhibited IL-4-driven CD40 ligand-dependent IgE isotype switching in PBMC but did not inhibit IgE synthesis induced by CD40 mAb plus IL-4.	Cyclosporine	0-13	CD40 molecule	Homo sapiens	36-40
7907604-8	1994	These results suggest that patients receiving cyclosporin A may be deficient in CD40 ligand-dependent T cell help.	Cyclosporine	46-59	CD40 molecule	Homo sapiens	80-84
8196271-9	1994	CsA at this dose caused a reduced GFR (0.29 ml/min/100 g) and an increased urinary NAG (20 IU/gCr) (P &lt; 0.01 vs. control for both).	Cyclosporine	0-3	O-GlcNAcase	Rattus norvegicus	83-86
7511575-1	1994	Cyclosporin A (CsA) was previously found to bind to P-glycoprotein expressed on multidrug-resistant (MDR) cancer cells.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
8129618-1	1994	The effect of the immune modulator, Cyclosporin A (CsA) on vaccinia virus replication has been examined in cell cultures.	Cyclosporine	36-49	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	51-54
7506079-7	1994	However, low CsA concentrations, when combined with an agent blocking B7-CD28 interaction, can potentially achieve complete immunosuppression.	Cyclosporine	13-16	CD28 molecule	Homo sapiens	73-77
7988626-1	1994	The pharmacokinetic parameters of cyclosporine (CsA) were determined in 23 kidney transplant recipients and 19 children with nephrotic syndrome, after intravenous and oral administration.	Cyclosporine	34-46	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	48-51
7512393-0	1994	Regulation of interleukin-5 production by peripheral blood mononuclear cells from atopic patients with FK506, cyclosporin A and glucocorticoid.	Cyclosporine	110-123	interleukin 5	Homo sapiens	14-27
7512393-3	1994	IL-5 induction in vitro was completely inhibited by immunosuppressant FK506, cyclosporin A and dexamethasone.	Cyclosporine	77-90	interleukin 5	Homo sapiens	0-4
8254211-9	1994	TTK expression was blocked by either cyclosporin A or FK520, which inhibit IL-2 production and could be recovered by the addition of exogenous IL-2.	Cyclosporine	37-50	TTK protein kinase	Homo sapiens	0-3
8302298-11	1994	The immunosuppressive drugs Cyclosporin A and FK506 completely blocked CD28 and CD3 mediated IL-2 production in these transfectants whereas rapamycin had only a partial inhibitory effect.	Cyclosporine	28-41	CD28 molecule	Homo sapiens	71-75
8265636-1	1993	Cyclophilin is a cellular receptor for the immunosuppressive drug cyclosporin A (CsA).	Cyclosporine	66-79	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	81-84
8258320-9	1993	Lysophosphatid acyltransferase-catalyzed incorporation of cis-polyunsaturated fatty acids might represent another mechanism of signal transduction implicated in the activation and translocation of PKC-beta, which is specifically inhibited by CsA.	Cyclosporine	242-245	protein kinase C beta	Homo sapiens	197-205
8258320-12	1993	Thus, inhibition of the activation and translocation of PKC-beta by CsA may result in inhibition of IL-2 gene expression in human lymphocytes.	Cyclosporine	68-71	protein kinase C beta	Homo sapiens	56-64
7510323-1	1993	The immunosuppressants FK506 and cyclosporin A (CsA) bound to their receptors, FKBP12 or cyclophilin, inhibit the Ca2+/calmodulin-dependent protein phosphatase, calcineurin, preventing T cell activation or, in yeast, recovery from alpha-mating factor arrest.	Cyclosporine	33-46	peptidylprolyl isomerase FPR1	Saccharomyces cerevisiae S288C	79-85
7510323-1	1993	The immunosuppressants FK506 and cyclosporin A (CsA) bound to their receptors, FKBP12 or cyclophilin, inhibit the Ca2+/calmodulin-dependent protein phosphatase, calcineurin, preventing T cell activation or, in yeast, recovery from alpha-mating factor arrest.	Cyclosporine	48-51	peptidylprolyl isomerase FPR1	Saccharomyces cerevisiae S288C	79-85
7510323-7	1993	Overexpression of CNA1 or CNA2, in conjunction with CNB1, results in a significant decrease in hypersensitivity to FK506 and CsA.	Cyclosporine	125-128	calcineurin catalytic subunit A	Saccharomyces cerevisiae S288C	18-22
8158305-0	1993	Increased gene expression of angiotensin II type 1A receptor in aortic smooth muscle cells of cyclosporin A-induced hypertensive rats.	Cyclosporine	94-107	angiotensin II receptor, type 1a	Rattus norvegicus	29-60
7507316-1	1993	The cyclic peptide Cyclosporine A (CsA) is best known as the immunosuppressive drug which has revolutionized organ transplantation.	Cyclosporine	35-38	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	19-33
8293761-7	1993	Endothelium-dependent relaxations to calcitonin gene-related peptide (CGRP, 10(-10) to 10(-7) M) and acetylcholine (10(-8) to 10(-5) M) were reduced in cyclosporin A treated rats.	Cyclosporine	152-165	calcitonin-related polypeptide alpha	Rattus norvegicus	37-68
8293761-7	1993	Endothelium-dependent relaxations to calcitonin gene-related peptide (CGRP, 10(-10) to 10(-7) M) and acetylcholine (10(-8) to 10(-5) M) were reduced in cyclosporin A treated rats.	Cyclosporine	152-165	calcitonin-related polypeptide alpha	Rattus norvegicus	70-74
8228625-2	1993	A dramatic reduction in CCP-1 and CCP-2 gene expression and near absence of cytolytic activity was shown to occur in these cultures when the expression of IL-2 was inhibited by 10(-6) M cyclosporin A (CsA).	Cyclosporine	201-204	granzyme B	Mus musculus	24-29
8228625-5	1993	The expression of CCP-1 and CCP-2 gene products and the induction of MHC-unrestricted cytotoxic activity in anti-CD3-stimulated T cell cultures therefore occur independently of IL-2 synthesis but are regulated by a CsA-sensitive mechanism.	Cyclosporine	215-218	granzyme B	Mus musculus	18-23
8406372-9	1993	Endothelin-3 secretion in bile, however, was decreased in livers perfused with cyclosporine compared with secretion in controls.	Cyclosporine	79-91	endothelin 3	Rattus norvegicus	0-12
8359233-0	1993	Posttranscriptional regulation of colony-stimulating factor-1 (CSF-1) and CSF-1 receptor gene expression during inhibition of phorbol-ester-induced monocytic differentiation by dexamethasone and cyclosporin A: potential involvement of a destabilizing protein.	Cyclosporine	195-208	colony stimulating factor 1 receptor	Homo sapiens	74-88
8359233-3	1993	The present studies demonstrate that dexamethasone (dex) and cyclosporin A (CsA) resulted in inhibition of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced monocytic differentiation of HL60 cells, as well as TPA induction of c-fms and CSF-1 transcripts.	Cyclosporine	61-74	colony stimulating factor 1 receptor	Homo sapiens	227-232
8359233-3	1993	The present studies demonstrate that dexamethasone (dex) and cyclosporin A (CsA) resulted in inhibition of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced monocytic differentiation of HL60 cells, as well as TPA induction of c-fms and CSF-1 transcripts.	Cyclosporine	76-79	colony stimulating factor 1 receptor	Homo sapiens	227-232
8359233-6	1993	Measurements of c-fms transcript half-life confirmed post-transcriptional regulation of c-fms transcript levels after the addition of dex or CsA to TPA, both of which resulted in a decrease in c-fms mRNA half-life.	Cyclosporine	141-144	colony stimulating factor 1 receptor	Homo sapiens	16-21
8359233-6	1993	Measurements of c-fms transcript half-life confirmed post-transcriptional regulation of c-fms transcript levels after the addition of dex or CsA to TPA, both of which resulted in a decrease in c-fms mRNA half-life.	Cyclosporine	141-144	colony stimulating factor 1 receptor	Homo sapiens	88-93
8359233-6	1993	Measurements of c-fms transcript half-life confirmed post-transcriptional regulation of c-fms transcript levels after the addition of dex or CsA to TPA, both of which resulted in a decrease in c-fms mRNA half-life.	Cyclosporine	141-144	colony stimulating factor 1 receptor	Homo sapiens	88-93
8356404-0	1993	Up-regulation by cyclosporine (CsA) of the in vitro release of soluble CD23 (sCD23) and of the in vitro production of IL-6 and IgM.	Cyclosporine	17-29	Fc epsilon receptor II	Homo sapiens	71-75
8356404-0	1993	Up-regulation by cyclosporine (CsA) of the in vitro release of soluble CD23 (sCD23) and of the in vitro production of IL-6 and IgM.	Cyclosporine	31-34	Fc epsilon receptor II	Homo sapiens	71-75
8394698-2	1993	Binding to recombinant human cyclophilin A and B was rapid and saturable, and correlated with the in vitro immunosuppressive activity of cyclosporin derivatives.	Cyclosporine	137-148	peptidyl-prolyl cis-trans isomerase A	Bos taurus	29-42
8394698-8	1993	In vivo labelling of Jurkat T-cells revealed, that cyclophilin A and calcineurin A are the main labeled proteins, which form complexes in the presence of active cyclosporin.	Cyclosporine	161-172	peptidyl-prolyl cis-trans isomerase A	Bos taurus	51-64
7687429-9	1993	Both immunosuppressive agents enhanced the calcium-dependent release of adrenocorticotropic hormone into the medium, once more, FK506 was 10-fold more potent than cyclosporin A.	Cyclosporine	163-176	pro-opiomelanocortin-alpha	Mus musculus	72-99
7689244-7	1993	After treatment with cyclosporine A, changes in the activities of N-acetyl-beta-D-glucosaminidase were found only in the proximal tubules.	Cyclosporine	21-35	O-GlcNAcase	Rattus norvegicus	66-97
7689244-13	1993	The variety of alterations occurring within the lysosomes along the proximal tubules of cyclosporine-A-treated rats implies the convoluted part as the site of increased release of N-acetyl-beta-D-glucosaminidase into the urine.	Cyclosporine	88-102	O-GlcNAcase	Rattus norvegicus	180-211
8513493-3	1993	Cyclosporin A efficiently disrupts the Gag-CyPA interaction and less efficiently disrupts the Gag-CyPB interaction.	Cyclosporine	0-13	Pr55(Gag)	Human immunodeficiency virus 1	39-42
8513493-3	1993	Cyclosporin A efficiently disrupts the Gag-CyPA interaction and less efficiently disrupts the Gag-CyPB interaction.	Cyclosporine	0-13	Pr55(Gag)	Human immunodeficiency virus 1	94-97
8509368-2	1993	We have reported previously the isolation and preliminary characterization of a 40-kDa cyclosporin A (CsA)-binding protein, cyclophilin-40 (CyP-40).	Cyclosporine	87-100	peptidylprolyl isomerase D	Homo sapiens	124-138
8509368-2	1993	We have reported previously the isolation and preliminary characterization of a 40-kDa cyclosporin A (CsA)-binding protein, cyclophilin-40 (CyP-40).	Cyclosporine	87-100	peptidylprolyl isomerase D	Homo sapiens	140-146
8509368-2	1993	We have reported previously the isolation and preliminary characterization of a 40-kDa cyclosporin A (CsA)-binding protein, cyclophilin-40 (CyP-40).	Cyclosporine	102-105	peptidylprolyl isomerase D	Homo sapiens	124-138
8509368-2	1993	We have reported previously the isolation and preliminary characterization of a 40-kDa cyclosporin A (CsA)-binding protein, cyclophilin-40 (CyP-40).	Cyclosporine	102-105	peptidylprolyl isomerase D	Homo sapiens	140-146
8509368-8	1993	Employing a new assay for calcineurin protein phosphatase activity to compare the effects of CyP-40.CsA and CyP-18.CsA complexes, IC50 values of 320 nM +/- 20 and 195 nM +/- 15, respectively, were obtained.	Cyclosporine	100-103	peptidylprolyl isomerase D	Homo sapiens	93-99
8509368-9	1993	A chemical cross-linking study revealed that CyP-40 competes for 125I-CyP-18 binding to calcineurin in the presence of CsA.	Cyclosporine	119-122	peptidylprolyl isomerase D	Homo sapiens	45-51
8500270-5	1993	T-cell HLA-DR and IL2R expression was reduced by cyclosporine, but CD45RO remained intact on virtually all circulating T cells.	Cyclosporine	49-61	interleukin 2 receptor subunit alpha	Homo sapiens	18-22
8500270-6	1993	CsA also inhibited the cytolytic activity and cytokine production of in vitro cultured TCR alpha/beta+ CD4- CD8- cell lines.	Cyclosporine	0-3	T cell receptor alpha constant	Homo sapiens	87-96
8500270-7	1993	Our data suggest that alleviation of the patient"s clinical symptoms resulted from cyclosporine-mediated suppression of proliferation, cytotoxicity, and inflammatory cytokine production of TCR alpha/beta+ CD4- CD8- T lymphocytes in vivo.	Cyclosporine	83-95	T cell receptor alpha constant	Homo sapiens	189-198
8366291-3	1993	Because the immunosuppressive drug cyclosporin A (CsA) inhibits several types of immune-mediated killing, we were interested in what effect CsA would have on TNF-mediated cytotoxicity as well as NO production.	Cyclosporine	35-48	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	50-53
8516819-2	1993	The present study was conducted to compare for the first time a cyclosporine-based quadruple immunosuppressive regimen including a monoclonal IL-2 receptor antibody or ATG as induction therapy after orthotopic liver transplantation.	Cyclosporine	64-76	interleukin 2 receptor subunit beta	Homo sapiens	142-155
7683315-9	1993	These observations are consistent with the view that cyclosporin A inactivates a RHAMM-directed inhibitory mechanism.	Cyclosporine	53-66	hyaluronan mediated motility receptor	Homo sapiens	81-86
7683633-2	1993	The T-cell-targeting immunosuppressants, FK506 and cyclosporin A (CsA), suppressed proliferation of the HAM/TSP-derived T-cell lines, H89-59, H89-79 and H109.	Cyclosporine	51-64	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	66-69
8100562-1	1993	The synergistic effect of MRK-16, a monoclonal antibody against P-glycoprotein, and cyclosporin A (CsA) on the modulation of vincristine resistance was studied by isobologram analysis in three different, highly multidrug-resistant tumor cells.	Cyclosporine	99-102	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	84-97
8453556-1	1993	BACKGROUND: Cyclosporine (cyclosporin A, CSA) prolongs the survival of transplanted organs by reducing the transcription of cytokines, especially interleukin-2, that are thought to mediate T-cell expansion and subsequent graft rejection.	Cyclosporine	12-24	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	41-44
8475567-6	1993	Cyclosporine and FK506 had similar effects on the frequency of IL-5 gene expression in rejecting and nonrejecting allografts.	Cyclosporine	0-12	interleukin 5	Homo sapiens	63-67
8445424-1	1993	PURPOSE: We investigated if graft-versus-host disease (GVHD), which is associated with an antitumor effect, could be induced in women with advanced breast cancer by treatment with cyclosporine (CSA) following reinfusion of purged autologous marrow after treatment with high-dose chemotherapy and defined the toxicities of this approach.	Cyclosporine	180-192	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	194-197
8455360-1	1993	To determine whether Cyclosporine A (CsA) alters the intrarenal expression of the renin and type 1 angiotensin II receptor genes, male adult Sprague-Dawley rats were given 25 mg/kg/day CsA s.c. for three weeks (CsA, N = 20) and were compared to pair-fed vehicle treated rats (Con, N = 20).	Cyclosporine	21-35	renin	Rattus norvegicus	82-87
8455360-1	1993	To determine whether Cyclosporine A (CsA) alters the intrarenal expression of the renin and type 1 angiotensin II receptor genes, male adult Sprague-Dawley rats were given 25 mg/kg/day CsA s.c. for three weeks (CsA, N = 20) and were compared to pair-fed vehicle treated rats (Con, N = 20).	Cyclosporine	37-40	renin	Rattus norvegicus	82-87
8455360-4	1993	The percentage of juxtaglomerular apparatuses containing renin was higher in the CsA (84 +/- 5.5%) than in the Con (61 +/- 6.7%) group, (P &lt; 0.05).	Cyclosporine	81-84	renin	Rattus norvegicus	57-62
7511004-11	1993	Flow cytometric analysis of peripheral blood cells prior to treatment with Cyclosporin-A showed systemic activation of lymphocytes, with high levels of HLA-DR and CD25 expression and a raised CD4/CD8 ratio.	Cyclosporine	75-88	interleukin 2 receptor subunit alpha	Homo sapiens	163-167
8293040-1	1993	Use of the immunosuppressant drug cyclosporine A (CSA) has resulted in improved renal graft survival.	Cyclosporine	34-48	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	50-53
8103687-5	1993	Cyclosporin treatment significantly decreased T cells and normalized the distribution and antigen expression of intraepidermal Langerhans cells, increasing the number of CD1+ dendritic cells.	Cyclosporine	0-11	CD1c molecule	Homo sapiens	170-173
7678231-0	1993	Inhibition of activation-induced changes in the structure of the T cell interleukin-7 receptor by cyclosporin A and FK506.	Cyclosporine	98-111	interleukin 7 receptor	Homo sapiens	72-94
7678231-14	1993	As reported for IL-2R and IL-4R, our data also show that the expression of another T cell growth factor receptor is sensitive to the effects of cyclosporin A and FK506.	Cyclosporine	144-157	interleukin 2 receptor subunit alpha	Homo sapiens	16-21
8188457-0	1993	Effect of cyclosporin on the activity of cytidine deaminase and adenosine deaminase in the serum and polymorphonuclear leukocytes of patients with rheumatoid arthritis.	Cyclosporine	10-21	cytidine deaminase	Homo sapiens	41-59
8188457-3	1993	A dramatic increase (10-fold or more) in CDA activity was observed in the cells of some patients after only one month of cyclosporin therapy.	Cyclosporine	121-132	cytidine deaminase	Homo sapiens	41-44
8188457-8	1993	Cyclosporin increased both CDA and ADA activities in PMNLs of RA patients.	Cyclosporine	0-11	cytidine deaminase	Homo sapiens	27-30
1363199-3	1992	Drug resistance in the cell line RPMI 8226 dox 40, expressing a high level of Pgp, was almost completely reversed by the novel non-immunosuppressive cyclosporin A (CsA) analog SDZ PSC-833 (PSC), while the chemosensitizers verapamil, CsA and quinine, in clinically achievable concentrations, were much less effective.	Cyclosporine	149-162	PSC	Homo sapiens	180-183
1363199-3	1992	Drug resistance in the cell line RPMI 8226 dox 40, expressing a high level of Pgp, was almost completely reversed by the novel non-immunosuppressive cyclosporin A (CsA) analog SDZ PSC-833 (PSC), while the chemosensitizers verapamil, CsA and quinine, in clinically achievable concentrations, were much less effective.	Cyclosporine	149-162	PSC	Homo sapiens	189-192
1363199-3	1992	Drug resistance in the cell line RPMI 8226 dox 40, expressing a high level of Pgp, was almost completely reversed by the novel non-immunosuppressive cyclosporin A (CsA) analog SDZ PSC-833 (PSC), while the chemosensitizers verapamil, CsA and quinine, in clinically achievable concentrations, were much less effective.	Cyclosporine	164-167	PSC	Homo sapiens	180-183
1363199-3	1992	Drug resistance in the cell line RPMI 8226 dox 40, expressing a high level of Pgp, was almost completely reversed by the novel non-immunosuppressive cyclosporin A (CsA) analog SDZ PSC-833 (PSC), while the chemosensitizers verapamil, CsA and quinine, in clinically achievable concentrations, were much less effective.	Cyclosporine	164-167	PSC	Homo sapiens	189-192
1363199-3	1992	Drug resistance in the cell line RPMI 8226 dox 40, expressing a high level of Pgp, was almost completely reversed by the novel non-immunosuppressive cyclosporin A (CsA) analog SDZ PSC-833 (PSC), while the chemosensitizers verapamil, CsA and quinine, in clinically achievable concentrations, were much less effective.	Cyclosporine	233-236	PSC	Homo sapiens	180-183
1363199-3	1992	Drug resistance in the cell line RPMI 8226 dox 40, expressing a high level of Pgp, was almost completely reversed by the novel non-immunosuppressive cyclosporin A (CsA) analog SDZ PSC-833 (PSC), while the chemosensitizers verapamil, CsA and quinine, in clinically achievable concentrations, were much less effective.	Cyclosporine	233-236	PSC	Homo sapiens	189-192
1362075-5	1992	CyA modulates the UV irradiation-induced changes by: (i) inhibiting the UVB- and PUVA-induced ICAM-1 expression by keratinocytes and (ii) suppressing the PUVA-induced upregulation of CD11a expression by macrophages (72 +/- 12% of Ki-M8+ macrophages express CD11a with PUVA, compared with 20 +/- 5% with CyA + PUVA, P &lt; 0.001).	Cyclosporine	0-3	integrin subunit alpha L	Homo sapiens	183-188
1362075-5	1992	CyA modulates the UV irradiation-induced changes by: (i) inhibiting the UVB- and PUVA-induced ICAM-1 expression by keratinocytes and (ii) suppressing the PUVA-induced upregulation of CD11a expression by macrophages (72 +/- 12% of Ki-M8+ macrophages express CD11a with PUVA, compared with 20 +/- 5% with CyA + PUVA, P &lt; 0.001).	Cyclosporine	0-3	integrin subunit alpha L	Homo sapiens	257-262
1345628-4	1992	The two practical measures that would help in distinguishing acute rejection from cyclosporine-induced toxicity are 1) a trial of cyclosporine dose-reduction and subsequent assessment of renal function, and 2) histologic assessment of the renal allograft biopsy specimen.	Cyclosporine	82-94	VPS52 subunit of GARP complex	Homo sapiens	112-117
1281562-6	1992	The damage induced by FK506 and CsA was characterized by a direct cytotoxic effect on tubular cells, as expressed by release of 3H thymidine from prelabeled cells, N-acetyl-beta-D-glucosaminidase release, and cell detachment.	Cyclosporine	32-35	O-GlcNAcase	Rattus norvegicus	164-195
1440857-1	1992	We raised rabbit antisera against homogeneous bovine cyclophilin A (CypA) and we report their use for its immunofluorescent and immunochemical detection without resorting to cyclosporine binding.	Cyclosporine	174-186	peptidyl-prolyl cis-trans isomerase A	Bos taurus	53-66
1440857-1	1992	We raised rabbit antisera against homogeneous bovine cyclophilin A (CypA) and we report their use for its immunofluorescent and immunochemical detection without resorting to cyclosporine binding.	Cyclosporine	174-186	peptidyl-prolyl cis-trans isomerase A	Bos taurus	68-72
1493564-1	1992	Cyclosporine (CsA) has played a major role in the development of organ transplantation.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
1490302-7	1992	Our results indicate that cyclosporin therapy induces a reversible increase of plasma cholesterol, LDL-cholesterol, triglycerides, VLDL-triglycerides, and apolipoprotein B and a decrease of HDL-cholesterol, HDL2-cholesterol, and apolipoprotein A-I.	Cyclosporine	26-37	junctophilin 3	Homo sapiens	207-211
1452414-15	1992	Concurrently, anti-CD3-induced increases in the percentage of CD4+ and CD8+ cells cycling were inhibited by CsA.	Cyclosporine	108-111	CD3 antigen, epsilon polypeptide	Mus musculus	19-22
1922610-6	1991	A time course study indicated that the ability of PBMC from transplants to release IL-1 alpha and beta promptly decreased following the operation, possibly owing to prednisolone and ciclosporin immunosuppressive therapy.	Cyclosporine	182-193	interleukin 1 alpha	Homo sapiens	83-93
1784623-1	1991	Ciclosporin (CsA) is metabolized exclusively by the hepatic cytochrome P-450 mixed function oxidase system.	Cyclosporine	0-11	Cytochrome P450 1A1	Canis lupus familiaris	60-76
1784623-1	1991	Ciclosporin (CsA) is metabolized exclusively by the hepatic cytochrome P-450 mixed function oxidase system.	Cyclosporine	13-16	Cytochrome P450 1A1	Canis lupus familiaris	60-76
1676547-8	1991	The response via CD2 plus CD28 is IL-2-dependent, as demonstrated by the ability of mAb against the IL-2 receptor to block proliferation, and is almost completely inhibited by cyclosporine A (CsA).	Cyclosporine	176-190	CD2 molecule	Homo sapiens	17-20
1676547-8	1991	The response via CD2 plus CD28 is IL-2-dependent, as demonstrated by the ability of mAb against the IL-2 receptor to block proliferation, and is almost completely inhibited by cyclosporine A (CsA).	Cyclosporine	192-195	CD2 molecule	Homo sapiens	17-20
2047704-1	1991	The purpose of this study was to investigate the effects of interleukin-1 alpha (IL-1 alpha) infusion and the ability of cyclosporin A (CYA) to alter IL-1 alpha-induced effects on bone in vivo and in vitro and lymphoid organs in vivo.	Cyclosporine	121-134	interleukin 1 alpha	Mus musculus	150-160
2047704-1	1991	The purpose of this study was to investigate the effects of interleukin-1 alpha (IL-1 alpha) infusion and the ability of cyclosporin A (CYA) to alter IL-1 alpha-induced effects on bone in vivo and in vitro and lymphoid organs in vivo.	Cyclosporine	136-139	interleukin 1 alpha	Mus musculus	150-160
2047704-3	1991	Hypercalcemia was induced in mice treated with IL-1 alpha compared to controls and CYA treated mice, and decreased urinary calcium excretion was present in IL-1 alpha and CYA groups.	Cyclosporine	171-174	interleukin 1 alpha	Mus musculus	47-57
2047704-8	1991	In summary, interleukin-1 alpha was effective in stimulating hypercalcemia and bone resorption both in vivo and in vitro but cyclosporin A was effective in inhibiting IL-1 alpha-mediated bone resorption only in vitro.	Cyclosporine	125-138	interleukin 1 alpha	Mus musculus	167-177
1987692-4	1991	Similarly, cyclosporine potentiated the inhibitory effects of rapamycin upon proliferation of IL-2 (CTLL-2) and IL-6 (MH60.BSF-2) lymphokine-dependent cell lines.	Cyclosporine	11-23	interleukin 2	Mus musculus	94-98
1643712-1	1992	Cyclosporin A (CsA) is currently the most selective immunosuppressant used clinically to prevent organ rejection after transplantation.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
1380951-3	1992	While 1 microgram/ml CSA and 0.1 microgram/ml FK 506 completely suppressed PHA-stimulated accumulation of mRNA for IL2, IL4, IL9, GM-CSF, TNF-alpha and IFN-gamma in PBMC, flu, keto and TGF-beta failed to inhibit any (except TNF-alpha blocked by TGF-beta).	Cyclosporine	21-24	interleukin 9	Homo sapiens	125-128
1521932-3	1992	Besides confirming the finding that exogenous IL-1 leads to a rapid increase in CSF detection, we obtained evidence that IL-1 may also result in the production of cyclo-oxygenase pathway products that down-regulate the IL-1-induced burst in CSA and CSF-1 levels.	Cyclosporine	241-244	interleukin 1 complex	Mus musculus	46-50
1521932-3	1992	Besides confirming the finding that exogenous IL-1 leads to a rapid increase in CSF detection, we obtained evidence that IL-1 may also result in the production of cyclo-oxygenase pathway products that down-regulate the IL-1-induced burst in CSA and CSF-1 levels.	Cyclosporine	241-244	interleukin 1 complex	Mus musculus	121-125
1521932-3	1992	Besides confirming the finding that exogenous IL-1 leads to a rapid increase in CSF detection, we obtained evidence that IL-1 may also result in the production of cyclo-oxygenase pathway products that down-regulate the IL-1-induced burst in CSA and CSF-1 levels.	Cyclosporine	241-244	interleukin 1 complex	Mus musculus	121-125
1585469-11	1992	This inverse association between TPMT activity and allograft function was again found among 30 patients receiving triple therapy (azathioprine, CsA, prednisolone).	Cyclosporine	144-147	thiopurine S-methyltransferase	Homo sapiens	33-37
1348520-2	1992	Previous studies have shown that proliferation of peripheral blood T cells involving the CD28 pathway is associated with cyclosporine A (CsA) resistant IL-2 gene expression.	Cyclosporine	121-135	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	137-140
1544925-9	1992	Cyp-40 possesses peptidyl-prolyl cis-trans isomerase activity which is less sensitive to inhibition by cyclosporin A (IC50 = 300 nM) than is CyP-18 (IC50 = 20 nM).	Cyclosporine	103-116	peptidylprolyl isomerase D	Bos taurus	0-6
1372027-1	1992	Cyclosporine (CSA) decreases lymphokine synthesis and keratinocyte proliferation in vitro, but its in vivo mechanism of action in treating recalcitrant psoriasis is incompletely understood.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
1549853-0	1992	Cyclosporine metabolism by P450IIIA in rat enterocytes--another determinant of oral bioavailability?	Cyclosporine	0-12	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	27-35
1549853-1	1992	Cyclosporine is converted to its major metabolites (M-17, M-1, and M-21) in human liver by enzymes belonging to the P450IIIA subfamily.	Cyclosporine	0-12	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	116-124
1549853-5	1992	This metabolism appeared to be catalyzed by P450IIIA, because pretreatment of rats with the P450IIIA inducer dexamethasone significantly increased the rate of CsA metabolism in enterocyte microsomes and preincubation of enterocyte microsomes with anti-P450IIIA IgG inhibited the production of CsA metabolites by greater than 95%.	Cyclosporine	159-162	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	44-52
1549853-5	1992	This metabolism appeared to be catalyzed by P450IIIA, because pretreatment of rats with the P450IIIA inducer dexamethasone significantly increased the rate of CsA metabolism in enterocyte microsomes and preincubation of enterocyte microsomes with anti-P450IIIA IgG inhibited the production of CsA metabolites by greater than 95%.	Cyclosporine	159-162	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	92-100
1549853-5	1992	This metabolism appeared to be catalyzed by P450IIIA, because pretreatment of rats with the P450IIIA inducer dexamethasone significantly increased the rate of CsA metabolism in enterocyte microsomes and preincubation of enterocyte microsomes with anti-P450IIIA IgG inhibited the production of CsA metabolites by greater than 95%.	Cyclosporine	159-162	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	92-100
1549853-5	1992	This metabolism appeared to be catalyzed by P450IIIA, because pretreatment of rats with the P450IIIA inducer dexamethasone significantly increased the rate of CsA metabolism in enterocyte microsomes and preincubation of enterocyte microsomes with anti-P450IIIA IgG inhibited the production of CsA metabolites by greater than 95%.	Cyclosporine	293-296	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	44-52
1549853-5	1992	This metabolism appeared to be catalyzed by P450IIIA, because pretreatment of rats with the P450IIIA inducer dexamethasone significantly increased the rate of CsA metabolism in enterocyte microsomes and preincubation of enterocyte microsomes with anti-P450IIIA IgG inhibited the production of CsA metabolites by greater than 95%.	Cyclosporine	293-296	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	92-100
1549853-5	1992	This metabolism appeared to be catalyzed by P450IIIA, because pretreatment of rats with the P450IIIA inducer dexamethasone significantly increased the rate of CsA metabolism in enterocyte microsomes and preincubation of enterocyte microsomes with anti-P450IIIA IgG inhibited the production of CsA metabolites by greater than 95%.	Cyclosporine	293-296	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	92-100
1549853-6	1992	To determine if enterocyte P450IIIA metabolizes CsA in vivo, rats were pretreated with the P450IIIA inducer dexamethasone, the P450IIIA inhibitor erythromycin, or vehicle alone.	Cyclosporine	48-51	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	27-35
1549853-10	1992	We conclude that P450IIIA in jejunal enterocytes readily metabolizes CsA.	Cyclosporine	69-72	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	17-25
1371158-1	1992	The ability of cyclosporine (CSA) and FK506 to inhibit cytokine production by factor-dependent murine mast cell lines was investigated.	Cyclosporine	15-27	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	29-32
1370254-1	1992	Suppressor T cell (Ts) lines specific for myelin basic protein (MBP)-reactive helper T cell (Th) clones were generated from two patients with multiple sclerosis (MS) following a primary culture of peripheral blood mononuclear cells (PBMC) with MBP and cyclosporine A (CsA).	Cyclosporine	252-266	myelin basic protein	Homo sapiens	42-62
1289145-6	1992	A further 4 patients with retinal vasculitis who had been treated with cyclosporin A demonstrated a 32% reduction in IL2-R expression over a 3-month period.	Cyclosporine	71-84	interleukin 2 receptor subunit alpha	Homo sapiens	117-122
1370570-0	1992	Novel monoclonal antibodies to cyclosporine A: characterization and epitope mapping with cyclosporine analogs and cyclophilin.	Cyclosporine	31-45	peptidyl-prolyl isomerase G (cyclophilin G)	Mus musculus	114-125
1370570-0	1992	Novel monoclonal antibodies to cyclosporine A: characterization and epitope mapping with cyclosporine analogs and cyclophilin.	Cyclosporine	31-43	peptidyl-prolyl isomerase G (cyclophilin G)	Mus musculus	114-125
1370570-5	1992	Binding to Cs was also studied by ELISA in competition with cyclophilin (CyP), a Cs-binding protein whose epitope specificity has been well characterized.	Cyclosporine	11-13	peptidyl-prolyl isomerase G (cyclophilin G)	Mus musculus	60-71
1370570-5	1992	Binding to Cs was also studied by ELISA in competition with cyclophilin (CyP), a Cs-binding protein whose epitope specificity has been well characterized.	Cyclosporine	11-13	peptidyl-prolyl isomerase G (cyclophilin G)	Mus musculus	73-76
1528337-8	1992	CPAH and CIn were significantly decreased during Cs treatment.	Cyclosporine	49-51	pyridoxal phosphatase	Homo sapiens	9-12
14621721-1	1992	Cyclosporin (CyA) has been demonstrated to increase the vascular resistance of renal allografts (RVR), whereas calcium channel blocking agents like nifedipine may counteract this effect.	Cyclosporine	0-11	nuclear receptor subfamily 1 group D member 2	Homo sapiens	97-100
1717584-1	1991	BALB/c mice were immunized with a mixture of two anti-cyclosporine (CsA) mAb, H4 1.3 and D3 1.3, which recognize CsA amino acid residues reported to be important for its biologic activity and for its interaction with a CsA-binding protein, cyclophilin.	Cyclosporine	54-66	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	68-71
1717584-1	1991	BALB/c mice were immunized with a mixture of two anti-cyclosporine (CsA) mAb, H4 1.3 and D3 1.3, which recognize CsA amino acid residues reported to be important for its biologic activity and for its interaction with a CsA-binding protein, cyclophilin.	Cyclosporine	54-66	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	113-116
2287150-3	1990	When KM-102CM and KM-103CM were fractionated by DEAE-cellulose chromatography and treated with antiserum against granulocyte-monocyte colony stimulating factor (GM-CSF) these colony stimulating activity (CSA) and burst promoting activity (BPA) contained in these media were neutralized by the antiserum and thus proved to be basically identical to GM-CSF.	Cyclosporine	204-207	colony stimulating factor 2	Homo sapiens	113-159
2287150-3	1990	When KM-102CM and KM-103CM were fractionated by DEAE-cellulose chromatography and treated with antiserum against granulocyte-monocyte colony stimulating factor (GM-CSF) these colony stimulating activity (CSA) and burst promoting activity (BPA) contained in these media were neutralized by the antiserum and thus proved to be basically identical to GM-CSF.	Cyclosporine	204-207	colony stimulating factor 2	Homo sapiens	161-167
1717584-1	1991	BALB/c mice were immunized with a mixture of two anti-cyclosporine (CsA) mAb, H4 1.3 and D3 1.3, which recognize CsA amino acid residues reported to be important for its biologic activity and for its interaction with a CsA-binding protein, cyclophilin.	Cyclosporine	54-66	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	113-116
1835198-3	1991	administration of 20 mg/kg of CsA but not vehicle to adult male Sprague-Dawley rats resulted in a significant fall in glomerular filtration rate from 0.85 +/- 0.10 and renal plasma flow (RPF) 2.45 +/- 0.14 ml/min/100 g body wt to values at 20 min of 0.47 +/- 0.03 and 1.01 +/- 0.12 ml/min/100 g body wt (P less than 0.01), respectively, without a fall in mean arterial pressure.	Cyclosporine	30-33	ribosome production factor 2 homolog	Rattus norvegicus	168-193
1949170-5	1991	Kidney proximal tubule damage following CsA treatment alone was also reduced in animals coadministered DAZ, as indicated by reduced urinary excretion of N-acetyl-beta-D-glucosaminidase (NAG) (9.7 vs. 14.1 U/g creatinine) and by histological examination of kidney sections.	Cyclosporine	40-43	O-GlcNAcase	Rattus norvegicus	153-184
1949170-5	1991	Kidney proximal tubule damage following CsA treatment alone was also reduced in animals coadministered DAZ, as indicated by reduced urinary excretion of N-acetyl-beta-D-glucosaminidase (NAG) (9.7 vs. 14.1 U/g creatinine) and by histological examination of kidney sections.	Cyclosporine	40-43	O-GlcNAcase	Rattus norvegicus	186-189
1679377-7	1991	Finally, costimulation by PI-LFA-3, but not by EC, is completely suppressed by cyclosporine A.	Cyclosporine	79-93	CD58 molecule	Homo sapiens	29-34
2092302-1	1990	Cyclosporin A (CsA), administered in 5 daily subcutaneous doses of 50 mg/kg to MF1 mice immediately following infection with Hymenolepis diminuta enhanced parasite growth relative to controls.	Cyclosporine	15-18	forkhead box C1	Mus musculus	79-82
1915562-1	1991	Cyclosporin A (CSA) is an immunosuppressive drug, which blocks selective activation pathways in T and B cells.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
2175057-0	1990	Plasma thrombomodulin levels as an indicator of vascular injury caused by cyclosporine nephrotoxicity.	Cyclosporine	74-86	thrombomodulin	Homo sapiens	7-21
2220641-7	1990	Cyclosporine dose was significantly associated with hepatic lipase activity (r = 0.33, p less than 0.02) and inversely associated with lipoprotein lipase activity (r = -0.28, p less than 0.05).	Cyclosporine	0-12	lipoprotein lipase	Homo sapiens	135-153
1755407-1	1991	To clarify the distribution and the kinetics of ciclosporin (CSA) in the lymphatic system, we measured the CSA level of the lymph from the thoracic duct drainage (TDD) and that of the peripheral blood after oral or intravenous administration of CSA in 13 TDD pretreated patients.	Cyclosporine	48-59	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	61-64
2173663-10	1990	This interpretation is supported by the findings that cyclosporin, which abrogates the activation of lymphocytes by Ca2(+)-dependent stimuli, inhibits B cell proliferation induced by anti-Ig plus IL4, but not the response to PBu2 plus IL4.	Cyclosporine	54-65	interleukin 4	Mus musculus	196-199
2173663-10	1990	This interpretation is supported by the findings that cyclosporin, which abrogates the activation of lymphocytes by Ca2(+)-dependent stimuli, inhibits B cell proliferation induced by anti-Ig plus IL4, but not the response to PBu2 plus IL4.	Cyclosporine	54-65	interleukin 4	Mus musculus	235-238
1680870-7	1991	cyclosporine A (CsA) and dipyridamole (DPM) could modulate the acquired resistance and completely restore the cytotoxic effects of HHT and adriamycin as determined by the clonogenic assay.	Cyclosporine	0-14	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	16-19
2228019-5	1990	It has been demonstrated that only the CD3/TcR alpha beta+ J11d- CD25- subpopulation is susceptible to the suppressive effects of CsA among CD4-8- cells, whereas all the other four subpopulations, including CD3/TcR gamma delta+ cells, are resistant.	Cyclosporine	130-133	T cell receptor alpha variable 6-3	Mus musculus	43-46
2228019-5	1990	It has been demonstrated that only the CD3/TcR alpha beta+ J11d- CD25- subpopulation is susceptible to the suppressive effects of CsA among CD4-8- cells, whereas all the other four subpopulations, including CD3/TcR gamma delta+ cells, are resistant.	Cyclosporine	130-133	T cell receptor alpha variable 6-3	Mus musculus	211-214
2228019-6	1990	Thus, all of the TcR alpha beta-bearing cells, including CD4-8- cells but none of the TcR alpha beta- cells, are CsA sensitive.	Cyclosporine	113-116	T cell receptor alpha variable 6-3	Mus musculus	17-20
2228019-7	1990	Because it is known that CsA inhibits the TcR-mediated signalling events in mature T cells and that signallings mediated via the interaction of TcR with major histocompatibility complex (MHC) molecules on thymic stroma cells are crucial for thymic selection of T cells, these results indicate that TcR alpha beta-bearing CD4-8- cells but not TcR gamma delta-bearing CD4-8- cells undergo thymic positive selection.	Cyclosporine	25-28	T cell receptor alpha variable 6-3	Mus musculus	42-45
2369902-2	1990	Using protein extracts from El4 lymphoma cells we show that the binding of lymphocyte-specific factors interacting with the two so-called purine boxes (Pu-boxes) of the interleukin 2 (IL-2) enhancer are missing in CsA-treated cells.	Cyclosporine	214-217	interleukin 2	Mus musculus	169-182
2369902-2	1990	Using protein extracts from El4 lymphoma cells we show that the binding of lymphocyte-specific factors interacting with the two so-called purine boxes (Pu-boxes) of the interleukin 2 (IL-2) enhancer are missing in CsA-treated cells.	Cyclosporine	214-217	interleukin 2	Mus musculus	184-188
2369902-6	1990	These observations support the conclusion that the suppression of factor binding to the Pu-boxes by CsA impairs the activity of IL-2 and of further lymphokine genes, thereby inhibiting the synthesis of lymphokines in T lymphocytes.	Cyclosporine	100-103	interleukin 2	Mus musculus	128-132
2354864-4	1990	Phorbol dibutyrate (PDB), an effective T cell mitogen, and cyclosporin A, an inhibitor of T cell mitogenesis in this species, are both capable of regulating the expression of this IL-2-binding molecule on Xenopus immunocytes.	Cyclosporine	59-72	interleukin 2	Rattus norvegicus	180-184
2162073-0	1990	Cyclosporine A induced lipid peroxidation and influence on glucose-6-phosphatase in rat hepatic and renal microsomes.	Cyclosporine	0-14	glucose-6-phosphatase catalytic subunit 1	Rattus norvegicus	59-80
2162073-3	1990	Furthermore the influence of CsA on the microsomal enzyme glucose-6-phosphatase was investigated.	Cyclosporine	29-32	glucose-6-phosphatase catalytic subunit 1	Rattus norvegicus	58-79
2162073-8	1990	Regarding the microsomal enzyme, CsA decreased the specific activity of glucose-6-phosphatase in a time- and concentration-dependent fashion.	Cyclosporine	33-36	glucose-6-phosphatase catalytic subunit 1	Rattus norvegicus	72-93
1967264-7	1990	Although pretreatment with AcD, CsA, or ChT strongly inhibits production of IL-2, TNF and IFN-gamma, only clones pretreated with AcD lose cytolytic activity against Ag-pulsed, Ia-bearing LK cells.	Cyclosporine	32-35	interleukin 2	Mus musculus	76-80
2250570-5	1990	This inhibitory effect might be explained by the previous findings of others, that CSA inhibits phospholipase A2 activity, thereby decreasing arachidonic acid production, the rate-limiting step in PG synthesis.	Cyclosporine	83-86	phospholipase A2 group IB	Rattus norvegicus	96-112
33764520-9	2021	CSA re-stimulated LN cells from vaccinated mice after challenge infection secreted comparable IL-4 and IL-10 but reduced IFN-gamma, as compared to controls.	Cyclosporine	0-3	interleukin 4	Mus musculus	94-98
33804393-9	2021	Moreover, in silico docking analysis revealed that the structure of compound 9 was a good fit for the cyclosporin A binding cavity of CypA.	Cyclosporine	102-115	peptidylprolyl isomerase A	Homo sapiens	134-138
33784877-9	2021	Medications such as celecoxib, cyclosporine or colchicine can impact on COVID-19, in addition to its anti-inflammatory effect, through inhibition of TF.	Cyclosporine	31-43	coagulation factor III, tissue factor	Homo sapiens	149-151
20163160-11	2010	Verapamil is an inhibitor of P-gp mediated uptake; elevation of cyclosporine uptake in the presence of 5 muM verapamil was compromised by the presence of 25 mM HEPES.	Cyclosporine	64-76	phosphoglycolate phosphatase	Homo sapiens	29-33
9605152-8	1998	CsA (10 mg/kg) significantly inhibited elevations of IL-2 and IFN-gamma mRNA, while slightly inhibiting that of CD3 mRNA in allografts.	Cyclosporine	0-3	interleukin 2	Rattus norvegicus	53-57
9605152-8	1998	CsA (10 mg/kg) significantly inhibited elevations of IL-2 and IFN-gamma mRNA, while slightly inhibiting that of CD3 mRNA in allografts.	Cyclosporine	0-3	interferon gamma	Rattus norvegicus	62-71
9605152-10	1998	FTY720 (0.1 mg/kg) combined with CsA (10 mg/kg) almost completely suppressed the intragraft expressions of mRNA for IL-2, IFN-gamma, and CD3.	Cyclosporine	33-36	interleukin 2	Rattus norvegicus	116-120
9605152-10	1998	FTY720 (0.1 mg/kg) combined with CsA (10 mg/kg) almost completely suppressed the intragraft expressions of mRNA for IL-2, IFN-gamma, and CD3.	Cyclosporine	33-36	interferon gamma	Rattus norvegicus	122-131
34856420-1	2022	Cyclosporine A and methotrexate (CSA/MTX) is the standard graft-versus-host disease (GVHD) prophylaxis regimen for matched sibling donor (MSD) allogeneic hematopoietic cell transplantation (allo-HCT).	Cyclosporine	33-36	metaxin 1	Homo sapiens	37-40
34439442-6	2021	The administration of CsA also significantly downregulated the renal expression of interferon-gamma, tumor necrosis factor-alpha, interleukin 1 beta, monocyte chemotactic protein 1, intercellular adhesion molecule-1, and vascular cell adhesion molecule 1 genes, and increased renal DNA damage.	Cyclosporine	22-25	interferon gamma	Rattus norvegicus	83-99
34439442-6	2021	The administration of CsA also significantly downregulated the renal expression of interferon-gamma, tumor necrosis factor-alpha, interleukin 1 beta, monocyte chemotactic protein 1, intercellular adhesion molecule-1, and vascular cell adhesion molecule 1 genes, and increased renal DNA damage.	Cyclosporine	22-25	C-C motif chemokine ligand 2	Rattus norvegicus	150-180
34220265-9	2021	However, hypermethylated seed genes HMGA1 and PSAT1 showcased a good interaction affinity with drugs cisplatin, cyclosporin, bisphenol A, progesterone, and sunitinib, and are crucial in the proliferation of ovarian cancer.	Cyclosporine	112-123	high mobility group AT-hook 1	Homo sapiens	36-41
35241487-0	2022	Experimental and modeling evidence supporting the trans-inhibition mechanism for preincubation time-dependent, long-lasting inhibition of organic anion transporting polypeptide (OATP) 1B1 by cyclosporine A.	Cyclosporine	191-205	solute carrier organic anion transporter family member 1B1	Homo sapiens	138-187
1864010-1	1991	A study was conducted to quantify soluble IL-2 receptor (sIL-2R) levels in sera of 57 chronic plaque psoriasis patients and correlate these measurements with disease activity and the number of IL-2R-positive (CD25+) lymphocytes in lesional biopsies of 11 cyclosporin A (CsA) and 13 psoralen plus ultraviolet radiation (PUVA) treated patients.	Cyclosporine	270-273	interleukin 2 receptor subunit beta	Homo sapiens	42-55
35241487-1	2022	Cyclosporine A (CsA) and rifampin are potent inhibitors of organic anion transporting polypeptide (OATP) 1B1 and are widely used to assess the risk for drug-drug interactions.	Cyclosporine	0-14	solute carrier organic anion transporter family member 1B1	Homo sapiens	59-108
35241487-1	2022	Cyclosporine A (CsA) and rifampin are potent inhibitors of organic anion transporting polypeptide (OATP) 1B1 and are widely used to assess the risk for drug-drug interactions.	Cyclosporine	16-19	solute carrier organic anion transporter family member 1B1	Homo sapiens	59-108
35241487-2	2022	CsA displays preincubation time-dependent, long-lasting inhibition of OATP1B1 in vitro and in rats in vivo, and a proposed mechanism is the trans-inhibition by which CsA inhibits OATP1B1 from the inside of cells.	Cyclosporine	0-3	solute carrier organic anion transporter family member 1B1	Homo sapiens	70-77
35241487-2	2022	CsA displays preincubation time-dependent, long-lasting inhibition of OATP1B1 in vitro and in rats in vivo, and a proposed mechanism is the trans-inhibition by which CsA inhibits OATP1B1 from the inside of cells.	Cyclosporine	0-3	solute carrier organic anion transporter family member 1B1	Homo sapiens	179-186
35241487-2	2022	CsA displays preincubation time-dependent, long-lasting inhibition of OATP1B1 in vitro and in rats in vivo, and a proposed mechanism is the trans-inhibition by which CsA inhibits OATP1B1 from the inside of cells.	Cyclosporine	166-169	solute carrier organic anion transporter family member 1B1	Homo sapiens	70-77
35241487-2	2022	CsA displays preincubation time-dependent, long-lasting inhibition of OATP1B1 in vitro and in rats in vivo, and a proposed mechanism is the trans-inhibition by which CsA inhibits OATP1B1 from the inside of cells.	Cyclosporine	166-169	solute carrier organic anion transporter family member 1B1	Homo sapiens	179-186
1864013-1	1991	We examined the effects of cyclosporin A (CsA) administered in vivo on the capacity of peripheral blood mononuclear cells (PBMC) from kidney transplant recipients to express IL-2 receptor (IL-2R) gene at the level of mRNA after mitogen stimulation in vitro.	Cyclosporine	42-45	interleukin 2 receptor subunit beta	Homo sapiens	174-187
35241487-6	2022	When the OATP1B1-mediated uptake of (3H)estradiol-17beta-glucuronide was measured following preincubation with CsA for 5 to 120 min, apparent Ki values became lower with longer preincubation.	Cyclosporine	111-114	solute carrier organic anion transporter family member 1B1	Homo sapiens	9-16
1864013-1	1991	We examined the effects of cyclosporin A (CsA) administered in vivo on the capacity of peripheral blood mononuclear cells (PBMC) from kidney transplant recipients to express IL-2 receptor (IL-2R) gene at the level of mRNA after mitogen stimulation in vitro.	Cyclosporine	42-45	interleukin 2 receptor subunit beta	Homo sapiens	189-194
35241487-10	2022	Significance Statement In vitro data and kinetic modeling support that preincubation time-dependent, long-lasting inhibition of OATP1B1 by CsA can be explained by the extensive intracellular binding and reversible OATP1B1 inhibition intracellularly (trans-inhibition) as well as extracellularly (cis-inhibition).	Cyclosporine	139-142	solute carrier organic anion transporter family member 1B1	Homo sapiens	128-135
1864013-3	1991	However, in a study of Northern blotting using cDNA for IL-2R (anti-alpha chain specific), both the 3500 and 1400 bp families of IL-2R mRNA were remarkably decreased in PBMC from CsA-prednisolone-treated recipients compared with azathioprine-prednisolone-treated recipients and normal individuals.	Cyclosporine	179-182	interleukin 2 receptor subunit beta	Homo sapiens	56-61
35241487-10	2022	Significance Statement In vitro data and kinetic modeling support that preincubation time-dependent, long-lasting inhibition of OATP1B1 by CsA can be explained by the extensive intracellular binding and reversible OATP1B1 inhibition intracellularly (trans-inhibition) as well as extracellularly (cis-inhibition).	Cyclosporine	139-142	solute carrier organic anion transporter family member 1B1	Homo sapiens	214-221
35033536-9	2022	Similar to CsA treatment, knockdown of cyclophilin A or B by siRNA augmented the UPR marker CHOP and cCas-3 levels, while deletion of PERK or ATF6 blunted CsA-induced UPR.	Cyclosporine	155-158	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	134-138
35033536-9	2022	Similar to CsA treatment, knockdown of cyclophilin A or B by siRNA augmented the UPR marker CHOP and cCas-3 levels, while deletion of PERK or ATF6 blunted CsA-induced UPR.	Cyclosporine	155-158	activating transcription factor 6	Homo sapiens	142-146
1864013-3	1991	However, in a study of Northern blotting using cDNA for IL-2R (anti-alpha chain specific), both the 3500 and 1400 bp families of IL-2R mRNA were remarkably decreased in PBMC from CsA-prednisolone-treated recipients compared with azathioprine-prednisolone-treated recipients and normal individuals.	Cyclosporine	179-182	interleukin 2 receptor subunit beta	Homo sapiens	129-134
1864013-4	1991	These studies demonstrated that CsA could inhibit IL-2R gene expression at the level of mRNA at physiological concentration.	Cyclosporine	32-35	interleukin 2 receptor subunit beta	Homo sapiens	50-55
2071894-5	1991	Second, cyclosporin A, which ameliorates GN in MRL/lpr mice despite autoantibody production, was found to reduce serum IgG3 and mRNA levels, associated with the revision of cationic shift of the serum IgG3 spectrotype seen in isoelectric focusing.	Cyclosporine	8-21	Immunoglobulin heavy constant gamma 3	Mus musculus	119-123
2071894-5	1991	Second, cyclosporin A, which ameliorates GN in MRL/lpr mice despite autoantibody production, was found to reduce serum IgG3 and mRNA levels, associated with the revision of cationic shift of the serum IgG3 spectrotype seen in isoelectric focusing.	Cyclosporine	8-21	Immunoglobulin heavy constant gamma 3	Mus musculus	201-205
1956679-0	1991	[Successful cyclosporin therapy of acquired hemophilia caused by factor VIII (VIII:C) inhibiting antibody].	Cyclosporine	12-23	cytochrome c oxidase subunit 8A	Homo sapiens	72-76
1956679-0	1991	[Successful cyclosporin therapy of acquired hemophilia caused by factor VIII (VIII:C) inhibiting antibody].	Cyclosporine	12-23	cytochrome c oxidase subunit 8A	Homo sapiens	78-82
2054356-1	1991	Cyclosporin A (CsA), a potent immunosuppressant, is known to bind with high specificity to cyclophilin (CyP), a 17.7 kDa protein with peptidyl-prolyl isomerase activity.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
2060630-1	1991	Recently the identity of the peptidyl-prolyl cis-trans isomerase (PPIase), which accelerates the cis/trans isomerization of prolyl peptide bonds and cyclophilin, the binding protein for the immunosuppressive drug Cyclosporin A (CsA), was discovered.	Cyclosporine	228-231	peptidylprolyl isomerase like 3	Homo sapiens	66-72
35013107-12	2022	In addition, a PI3K inhibitor (LY-294002) and a Nrf2 inhibitor (ML385) observably attenuated the protective effects of MET on MGO-induced apoptosis and ROS generation by inhibiting the Nrf2/HO-1 pathways, while a ROS scavenger (NAC) and a permeability transition pores inhibitor (CsA) completely reversed these effects.	Cyclosporine	280-283	SAFB like transcription modulator	Homo sapiens	119-122
34994326-0	2022	Cyclosporine Ameliorates Silica-Induced Autoimmune Hepatitis in Rat Model by Altering the Expression of Toll-Like Receptor-4, Interleukin-2 and Tumor Necrosis Factor-alpha.	Cyclosporine	0-12	interleukin 2	Rattus norvegicus	126-139
2045671-5	1991	In this report, the activity of TGF-beta closely resembles that of Cyclosporine A (CsA).	Cyclosporine	67-81	transforming growth factor, beta 1	Mus musculus	32-40
2676016-6	1989	Antibody to Lf completely abrogated the suppressive effects observed with Lf, whereas antibody to IL-1 ablated the induction by monocyte-conditioned medium of CSA release by fibroblasts.	Cyclosporine	159-162	interleukin 1 alpha	Homo sapiens	98-102
2045671-5	1991	In this report, the activity of TGF-beta closely resembles that of Cyclosporine A (CsA).	Cyclosporine	83-86	transforming growth factor, beta 1	Mus musculus	32-40
1827045-8	1991	The acquisition of NK1.1, B220, and lytic activity by this triple-negative subset was readily inhibited by cyclosporine A (CSA).	Cyclosporine	107-121	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	123-126
2807375-11	1989	The high-affinity IL-2 response is completely resistant to the action of cyclosporin A (CsA), but the low-affinity IL-2 response, although of much larger amplitude, can be almost completely suppressed by CsA.	Cyclosporine	204-207	interleukin 2	Mus musculus	115-119
2807375-12	1989	Together, these results demonstrate that resting CD4+ thymocytes can be induced to proliferation and lymphokine secretion by IL-2 alone in a process that is dependent on interaction with accessory cells, involves CD4 adhesion molecules and triggers activation through a CsA-sensitive pathway.	Cyclosporine	270-273	interleukin 2	Mus musculus	125-129
2006526-7	1991	In Fischer rats, CsA caused a 35% decrease in Ccr (P = 0.01), a 33% decrease in sodium excretion (P = 0.02), and a greater than 2-fold increase in NAG excretion (P = 0.03), while V, glucose excretion, and UTxB2V did not change.	Cyclosporine	17-20	O-GlcNAcase	Rattus norvegicus	147-150
2006526-8	1991	Although similar changes in sodium and NAG excretion were seen after CsA administration in SD rats, Ccr was not affected.	Cyclosporine	69-72	O-GlcNAcase	Rattus norvegicus	39-42
2060129-1	1991	Cyclosporine (CsA) is extensively metabolized, with over 14 metabolites having been characterized to date.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
2060136-1	1991	The immunosuppressive action of cyclosporine (CsA) in vivo is thought to primarily involve its inhibitory effect on lymphokine production by T lymphocytes.	Cyclosporine	32-44	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	46-49
1705509-10	1991	This contrasts with anti-CD28/PMA-induced T cell proliferation, which is resistant to CsA and PGE2.	Cyclosporine	86-89	CD28 molecule	Homo sapiens	25-29
1847252-1	1991	In the present investigation, we compared the immunosuppressive effects of genistein and CsA on anti-CD28 stimulated human T cell proliferation, IL-2 production, and IL-2R expression.	Cyclosporine	89-92	CD28 molecule	Homo sapiens	101-105
1847252-3	1991	In contrast, proliferation of T cells stimulated with PMA plus anti-CD28 is resistant to the inhibitory effects of CsA.	Cyclosporine	115-118	CD28 molecule	Homo sapiens	68-72
1847252-5	1991	PHA plus anti-CD28 or PMA plus anti-CD28-induced IL-2 synthesis was inhibited by genistein, and CsA, though it inhibited the PHA plus PMA-stimulated IL-2 synthesis, failed to have any effect on PMA plus anti-CD28-induced IL-2 synthesis.	Cyclosporine	96-99	CD28 molecule	Homo sapiens	14-18
1847252-5	1991	PHA plus anti-CD28 or PMA plus anti-CD28-induced IL-2 synthesis was inhibited by genistein, and CsA, though it inhibited the PHA plus PMA-stimulated IL-2 synthesis, failed to have any effect on PMA plus anti-CD28-induced IL-2 synthesis.	Cyclosporine	96-99	CD28 molecule	Homo sapiens	36-40
1847252-5	1991	PHA plus anti-CD28 or PMA plus anti-CD28-induced IL-2 synthesis was inhibited by genistein, and CsA, though it inhibited the PHA plus PMA-stimulated IL-2 synthesis, failed to have any effect on PMA plus anti-CD28-induced IL-2 synthesis.	Cyclosporine	96-99	CD28 molecule	Homo sapiens	36-40
1954315-3	1991	CS inhibits IL-2 production (and several other lymphokines) at a pretranscriptional level, but does not usually prevent the antigen-specific priming of T cells, such that T cells may be poised to respond as soon as CS is withdrawn.	Cyclosporine	0-2	interleukin 2	Mus musculus	12-16
2810368-0	1989	Crystallization and preliminary X-ray investigation of a complex between a Fab fragment and its antigen, cyclosporin.	Cyclosporine	105-116	FA complementation group B	Homo sapiens	75-78
2810368-1	1989	Preliminary crystallographic data are given for a complex between the cyclic undecapeptide cyclosporin and the Fab fragment of an anti-cyclosporin monoclonal antibody.	Cyclosporine	91-102	FA complementation group B	Homo sapiens	111-114
2810368-1	1989	Preliminary crystallographic data are given for a complex between the cyclic undecapeptide cyclosporin and the Fab fragment of an anti-cyclosporin monoclonal antibody.	Cyclosporine	135-146	FA complementation group B	Homo sapiens	111-114
2600452-7	1989	It is concluded that CsA in doses used for immunosuppression in clinical practice is a very potent and more effective inhibitor of ODC activity and polyamine synthesis in vivo than DFMO.	Cyclosporine	21-24	ornithine decarboxylase 1	Rattus norvegicus	131-134
2600452-8	1989	This ODC inhibitory effect of CsA is a further detail to elucidate the up to now incompletely understood mechanisms of action of this immunosuppressive agent.	Cyclosporine	30-33	ornithine decarboxylase 1	Rattus norvegicus	5-8
2668410-7	1989	Addition of 10 micrograms/ml cyclosporine A to the medium abolishes the effect of 2-ME and of all of the cytokines except IL-2 and IL-6.	Cyclosporine	29-43	interleukin 2	Mus musculus	122-126
2502200-4	1989	CSA could be in part inhibited by pretreating NK cell culture supernatants with a specific goat anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) antiserum.	Cyclosporine	0-3	colony stimulating factor 2	Homo sapiens	96-149
2502200-4	1989	CSA could be in part inhibited by pretreating NK cell culture supernatants with a specific goat anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) antiserum.	Cyclosporine	0-3	colony stimulating factor 2	Homo sapiens	151-157
2504764-4	1989	Macrophages (m phi) from CsA-Pred-treated recipients displayed 60.0% inhibition (5.1 +/- 0.7 U/ml; N = 20; P less than 0.01) of interleukin-1 (IL-1) production compared with normal individuals (13.0 +/- 2.9 U/ml; N = 21).	Cyclosporine	25-28	interleukin 1 alpha	Homo sapiens	128-141
2504764-4	1989	Macrophages (m phi) from CsA-Pred-treated recipients displayed 60.0% inhibition (5.1 +/- 0.7 U/ml; N = 20; P less than 0.01) of interleukin-1 (IL-1) production compared with normal individuals (13.0 +/- 2.9 U/ml; N = 21).	Cyclosporine	25-28	interleukin 1 alpha	Homo sapiens	143-147
2504764-7	1989	These studies demonstrated that combination therapy of CsA with steroid inhibits both gamma-IFN and IL-1 gene expression at the level of mRNA at physiological concentrations.	Cyclosporine	55-58	interleukin 1 alpha	Homo sapiens	100-104
2784016-0	1989	Blocking of interleukin-2 production, but not the tissue destruction induced by cytotoxic T cells, by cyclosporine.	Cyclosporine	102-114	interleukin 2	Mus musculus	12-25
2784016-4	1989	Treatment of CTL with cyclosporine in vitro prevents their production of lymphokines like interleukin 2 but has no effect on cell-mediated cytotoxicity.	Cyclosporine	22-34	interleukin 2	Mus musculus	90-103
2784016-6	1989	We confirmed the differential effect of CsA on CTL function in vitro with bulk-culture anti-Epa-1 CTL-CsA pretreatment of CTL abrogated IL-2 production but did not affect CMC.	Cyclosporine	40-43	epidermal antigen 1	Mus musculus	92-97
2784016-6	1989	We confirmed the differential effect of CsA on CTL function in vitro with bulk-culture anti-Epa-1 CTL-CsA pretreatment of CTL abrogated IL-2 production but did not affect CMC.	Cyclosporine	102-105	epidermal antigen 1	Mus musculus	92-97
2784016-6	1989	We confirmed the differential effect of CsA on CTL function in vitro with bulk-culture anti-Epa-1 CTL-CsA pretreatment of CTL abrogated IL-2 production but did not affect CMC.	Cyclosporine	102-105	interleukin 2	Mus musculus	136-140
2784016-8	1989	Therefore, when CTL are treated with CsA in such a way that they lose their capacity to produce IL-2, their cytotoxic activity in vitro as well as their ability to directly and indirectly mediate tissue destruction in vivo are left intact.	Cyclosporine	37-40	interleukin 2	Mus musculus	96-100
3048437-9	1988	In this system, the granulopoietic effect of IL-1 derives not from a direct effect on myeloid progenitors, but from its ability to recruit CSA production by other cells.	Cyclosporine	139-142	interleukin 1 alpha	Homo sapiens	45-49
3262385-9	1988	These results indicate that IL-1 enhances the recovery of cells in LTBMC by stimulating the proliferation of HPC with the concurrent release of CSA from stromal cells, without diminishing the number of HPC.	Cyclosporine	144-147	interleukin 1 alpha	Homo sapiens	28-32
3172850-2	1988	This report suggests that low-density lipoprotein not only functions as an important carrier of cyclosporine in plasma but also facilitates transport of cyclosporine across the cell membrane by means of the low-density lipoprotein receptor.	Cyclosporine	153-165	low density lipoprotein receptor	Homo sapiens	207-239
2458149-5	1988	The kinetics of IL-1- and poly(rI).poly(rC)-induced CSA release were found to be different, in that poly(rI).poly(rC)-induced CSA production occurred more slowly.	Cyclosporine	126-129	interleukin 1 alpha	Homo sapiens	16-20
2458149-6	1988	Anti-IL-1 antiserum was able to completely neutralize the IL-1-induced CSA release, but had no effect on poly(rI).poly(rC)-induced CSF production, suggesting that the latter effect was mediated by other mechanisms than IL-1 in supernatant.	Cyclosporine	71-74	interleukin 1 alpha	Homo sapiens	5-9
2458149-6	1988	Anti-IL-1 antiserum was able to completely neutralize the IL-1-induced CSA release, but had no effect on poly(rI).poly(rC)-induced CSF production, suggesting that the latter effect was mediated by other mechanisms than IL-1 in supernatant.	Cyclosporine	71-74	interleukin 1 alpha	Homo sapiens	58-62
2458149-6	1988	Anti-IL-1 antiserum was able to completely neutralize the IL-1-induced CSA release, but had no effect on poly(rI).poly(rC)-induced CSF production, suggesting that the latter effect was mediated by other mechanisms than IL-1 in supernatant.	Cyclosporine	71-74	interleukin 1 alpha	Homo sapiens	58-62
3262002-15	1988	It was found that most CSA was attributable to GM-CSF, whereas BPA was mainly related to the presence of IL-3.	Cyclosporine	23-26	colony stimulating factor 2	Homo sapiens	47-53
2974765-0	1988	Presence of an IL-3-producing suppressor T cell resistant to cyclosporin A in the peripheral blood of patients with systemic lupus erythematosus.	Cyclosporine	61-74	interleukin 3	Homo sapiens	15-19
3261818-0	1988	Cimetidine reduces cyclosporine inhibition of interleukin-2 production.	Cyclosporine	19-31	interleukin 2	Mus musculus	46-59
3261818-2	1988	Cyclosporine achieves its immunosuppressive effect mainly through inhibition of IL-2 production.	Cyclosporine	0-12	interleukin 2	Mus musculus	80-84
3261818-3	1988	A recent clinical report of renal allograft recipients with elevated serum creatinine levels while on a histamine type-2 receptor antagonist raised concern whether the cimetidine increase in IL-2 production was counterbalancing the cyclosporine inhibition of IL-2 and thereby increasing alloreactivity to the transplant.	Cyclosporine	232-244	interleukin 2	Mus musculus	259-263
3261818-5	1988	Cimetidine (10(-4) and 10(-5) M) completely reversed the cyclosporine (0.1 ng/ml and 1 ng/ml)-induced 25 and 41% inhibitions of IL-2, respectively.	Cyclosporine	57-69	interleukin 2	Mus musculus	128-132
3261818-6	1988	Cyclosporine (10 ng/ml) reduced IL-2 by 64% and cimetidine partially reversed this inhibition to 48%.	Cyclosporine	0-12	interleukin 2	Mus musculus	32-36
3261818-7	1988	All cimetidine groups which reduced the cyclosporine effect on IL-2 were statistically significant (P less than 0.05).	Cyclosporine	40-52	interleukin 2	Mus musculus	63-67
3047930-3	1988	A significantly increased mIg incidence was observed in heart Tx patients, patients over 40 years of age, and those receiving azathioprine or antithymocyte globulin in addition to prednisolone and cyclosporine as immunosuppressive treatment.	Cyclosporine	197-209	chemokine (C-X-C motif) ligand 9	Mus musculus	26-29
3070501-0	1988	[Serum gastrin level in patients treated with cyclosporin A or azathioprine with prednisone after kidney transplantation].	Cyclosporine	46-59	gastrin	Homo sapiens	7-14
2970137-2	1988	In these studies, the efficacy of adjunctive subtherapeutic doses of CsA given to immunologically enhanced heart graft recipients or to animals treated with an anti-IL-2 receptor monoclonal antibody (ART18) are described.	Cyclosporine	69-72	interleukin 2	Rattus norvegicus	165-169
3066654-1	1988	We have investigated the effects of an oral cyclosporin (CsA) treatment on "autoimmune" diabetes induced in CD1 male mice by 5 low doses (40 mg/kg/day) of streptozotocin (SZ).	Cyclosporine	44-55	CD1 antigen complex	Mus musculus	108-111
3066654-1	1988	We have investigated the effects of an oral cyclosporin (CsA) treatment on "autoimmune" diabetes induced in CD1 male mice by 5 low doses (40 mg/kg/day) of streptozotocin (SZ).	Cyclosporine	57-60	CD1 antigen complex	Mus musculus	108-111
2968691-0	1988	Alloreactive suppressor T cells and cytokine (gamma-IFN, interleukin 1, 2, and 3) production in cyclosporine-treated mice.	Cyclosporine	96-108	interleukin 2	Mus musculus	46-80
3260420-0	1988	Inhibition of parathyroid hormone and interleukin 1-stimulated bone resorption by cyclosporine A but not by cyclosporine H or F.	Cyclosporine	82-96	interleukin 1 alpha	Homo sapiens	38-51
2965988-3	1988	Antigen-driven production of interleukin-2 (IL-2) and antigen-driven proliferation were inhibited in a dose-dependent manner and to a similar extent at each of the respective cyclosporin concentrations.	Cyclosporine	175-186	interleukin 2	Rattus norvegicus	29-42
2965988-3	1988	Antigen-driven production of interleukin-2 (IL-2) and antigen-driven proliferation were inhibited in a dose-dependent manner and to a similar extent at each of the respective cyclosporin concentrations.	Cyclosporine	175-186	interleukin 2	Rattus norvegicus	44-48
2965988-6	1988	Inhibition of IL-2 production was lost if a maximally inhibitory dose of cyclosporin was added to the cultures later than 8 hr after antigen stimulation, while proliferation was still suppressed to 50% by cyclosporin added as late as 12 hr and could not be restored by addition of SCM.	Cyclosporine	73-84	interleukin 2	Rattus norvegicus	14-18
2965988-6	1988	Inhibition of IL-2 production was lost if a maximally inhibitory dose of cyclosporin was added to the cultures later than 8 hr after antigen stimulation, while proliferation was still suppressed to 50% by cyclosporin added as late as 12 hr and could not be restored by addition of SCM.	Cyclosporine	205-216	interleukin 2	Rattus norvegicus	14-18
3236341-12	1988	Phospholipase A activity was decreased and increased 35% and 15%, respectively, in urinary proximal tubular cells from patients receiving G and CsA.	Cyclosporine	144-147	phospholipase A and acyltransferase 1	Homo sapiens	0-15
2966482-4	1988	These results strongly implicate CyP or a related protein in the mechanism of action of cyclosporine.	Cyclosporine	88-100	peptidylprolyl isomerase G	Homo sapiens	33-36
3280473-5	1988	Administration of Cyclosporin A (CsA) prevented pulmonary rejection and was also shown to block the formation of specific cytotoxic effector cells and the development of responsiveness to IL-2.	Cyclosporine	18-31	interleukin 2	Rattus norvegicus	188-192
3280473-5	1988	Administration of Cyclosporin A (CsA) prevented pulmonary rejection and was also shown to block the formation of specific cytotoxic effector cells and the development of responsiveness to IL-2.	Cyclosporine	33-36	interleukin 2	Rattus norvegicus	188-192
2962794-1	1988	Cyclosporine (CsA) was previously reported to effectively suppress the induction of experimental autoimmune uveoretinitis (EAU) in rats immunized with S-antigen.	Cyclosporine	0-12	S-antigen visual arrestin	Rattus norvegicus	151-160
2962794-1	1988	Cyclosporine (CsA) was previously reported to effectively suppress the induction of experimental autoimmune uveoretinitis (EAU) in rats immunized with S-antigen.	Cyclosporine	14-17	S-antigen visual arrestin	Rattus norvegicus	151-160
2977607-4	1988	Proliferative responses and IL2 production were partially restored in mice given immunosuppressive therapy with azathioprine, cyclosporin A or Sch 24937 a drug whose inhibitory effects on cellular and humoral immune responses in mice have recently been described.	Cyclosporine	126-139	interleukin 2	Mus musculus	28-31
3258857-5	1988	Hydrocortisone and cyclosporine were potent inhibitors (active in the nM range) of both stages of IL-2 production, suggesting that neither is an IL-1 receptor antagonist.	Cyclosporine	19-31	interleukin 2	Mus musculus	98-102
3121725-8	1987	Unlike IFN-gamma production induced by Con A, IFN-gamma production induced by IL-2 was not accompanied by an elevation of intracellular Ca2+ levels, did not require physiologic extracellular Ca2+ levels, and was not inhibited by the immunosuppressive agent cyclosporin A.	Cyclosporine	257-270	interleukin 2	Mus musculus	78-82
3500229-7	1987	Production of Eo-CSF in vitro was inhibited by hydrocortisone or cyclosporin A.	Cyclosporine	65-78	colony stimulating factor 2	Homo sapiens	17-20
3316242-3	1987	High EGF concentrations (100-200 ng/ml) showed inhibitory effects on proliferation and to a greater extent on CSA production.	Cyclosporine	110-113	epidermal growth factor	Homo sapiens	5-8
3097147-1	1987	Prolactin (PRL)-stimulated ornithine decarboxylase (ODC) activity and subsequent proliferation are inhibited by the cyclopeptides cyclosporine (CsA) and didemnin B (DB) in Nb 2 node lymphoma cells.	Cyclosporine	130-142	ornithine decarboxylase 1	Rattus norvegicus	27-50
3097147-1	1987	Prolactin (PRL)-stimulated ornithine decarboxylase (ODC) activity and subsequent proliferation are inhibited by the cyclopeptides cyclosporine (CsA) and didemnin B (DB) in Nb 2 node lymphoma cells.	Cyclosporine	130-142	ornithine decarboxylase 1	Rattus norvegicus	52-55
3097147-1	1987	Prolactin (PRL)-stimulated ornithine decarboxylase (ODC) activity and subsequent proliferation are inhibited by the cyclopeptides cyclosporine (CsA) and didemnin B (DB) in Nb 2 node lymphoma cells.	Cyclosporine	144-147	ornithine decarboxylase 1	Rattus norvegicus	27-50
3097147-1	1987	Prolactin (PRL)-stimulated ornithine decarboxylase (ODC) activity and subsequent proliferation are inhibited by the cyclopeptides cyclosporine (CsA) and didemnin B (DB) in Nb 2 node lymphoma cells.	Cyclosporine	144-147	ornithine decarboxylase 1	Rattus norvegicus	52-55
3331798-0	1987	[Detection using scintigraphy with monoclonal anti-myosin in recurring myocarditis treated with cyclosporin A in a heart transplant candidate].	Cyclosporine	96-109	myosin heavy chain 14	Homo sapiens	51-57
3550987-3	1987	Unlike the conventional immunosuppressants, cyclosporine does not interfere with DNA metabolism, but it selectively and reversibly inhibits lymphocyte T-helper activation by inhibiting the production of interleukin-2 which plays a role in immune response development.	Cyclosporine	44-56	interleukin 2	Rattus norvegicus	203-216
3099440-10	1987	Allograft mononuclear cell infiltrates in cyclosporine (CsA) vs. azathioprine-treated patients revealed significantly fewer Leu 2 (P less than .05) and Leu M1 (P less than .05) cell populations in CsA patients during acute rejection.	Cyclosporine	42-54	deleted in lymphocytic leukemia 1	Homo sapiens	124-129
3099440-10	1987	Allograft mononuclear cell infiltrates in cyclosporine (CsA) vs. azathioprine-treated patients revealed significantly fewer Leu 2 (P less than .05) and Leu M1 (P less than .05) cell populations in CsA patients during acute rejection.	Cyclosporine	56-59	deleted in lymphocytic leukemia 1	Homo sapiens	124-129
2944961-6	1986	The proliferation of HTL in response to PMA + A23187 could be completely inhibited either by cyclosporine A (CsA) or by PC61.5, a monoclonal antibody directed against the murine IL 2 receptor; however, the proliferation of CTL in response to PMA alone was not affected either by CsA or by PC61.5.	Cyclosporine	93-107	interleukin 2	Mus musculus	178-182
2944961-6	1986	The proliferation of HTL in response to PMA + A23187 could be completely inhibited either by cyclosporine A (CsA) or by PC61.5, a monoclonal antibody directed against the murine IL 2 receptor; however, the proliferation of CTL in response to PMA alone was not affected either by CsA or by PC61.5.	Cyclosporine	279-282	interleukin 2	Mus musculus	178-182
3096619-11	1986	In addition, the data suggest distinct, but co-operative pathways of IL-2 receptor induction, controlled by elevated Ca2+ alone and by protein kinase C. Subsequent intracellular events of T cell activation by A23187/PMA may be quite similar to those triggered by Con A, since both kinds of stimulation are blocked by agents such as cyclosporin A, dbcAMP and K+ channel blockers.	Cyclosporine	332-345	interleukin 2	Mus musculus	69-73
1954315-6	1991	CS may enhance immune responses by inactivating suppressor cells, by altering Th1/Th2 antagonism (e.g., CS promotes a protective Th1-type response in BALB/c mice infected with Leishmania major), or by promoting T cell activation through a CS-resistant IL-2-independent T cell activation/differentiation pathway.	Cyclosporine	0-2	heart and neural crest derivatives expressed 2	Mus musculus	82-85
1954315-6	1991	CS may enhance immune responses by inactivating suppressor cells, by altering Th1/Th2 antagonism (e.g., CS promotes a protective Th1-type response in BALB/c mice infected with Leishmania major), or by promoting T cell activation through a CS-resistant IL-2-independent T cell activation/differentiation pathway.	Cyclosporine	0-2	interleukin 2	Mus musculus	252-256
1954315-6	1991	CS may enhance immune responses by inactivating suppressor cells, by altering Th1/Th2 antagonism (e.g., CS promotes a protective Th1-type response in BALB/c mice infected with Leishmania major), or by promoting T cell activation through a CS-resistant IL-2-independent T cell activation/differentiation pathway.	Cyclosporine	104-106	heart and neural crest derivatives expressed 2	Mus musculus	82-85
1954315-6	1991	CS may enhance immune responses by inactivating suppressor cells, by altering Th1/Th2 antagonism (e.g., CS promotes a protective Th1-type response in BALB/c mice infected with Leishmania major), or by promoting T cell activation through a CS-resistant IL-2-independent T cell activation/differentiation pathway.	Cyclosporine	104-106	interleukin 2	Mus musculus	252-256
1954315-6	1991	CS may enhance immune responses by inactivating suppressor cells, by altering Th1/Th2 antagonism (e.g., CS promotes a protective Th1-type response in BALB/c mice infected with Leishmania major), or by promoting T cell activation through a CS-resistant IL-2-independent T cell activation/differentiation pathway.	Cyclosporine	104-106	heart and neural crest derivatives expressed 2	Mus musculus	82-85
1954315-6	1991	CS may enhance immune responses by inactivating suppressor cells, by altering Th1/Th2 antagonism (e.g., CS promotes a protective Th1-type response in BALB/c mice infected with Leishmania major), or by promoting T cell activation through a CS-resistant IL-2-independent T cell activation/differentiation pathway.	Cyclosporine	104-106	interleukin 2	Mus musculus	252-256
1723035-3	1991	There was no correlation with rejection episodes but we found an increase in this CD3+CD5--population in patients on cyclosporin, and we suggest that these cells may be involved in the mechanism of action of this drug.	Cyclosporine	117-128	CD5 molecule	Homo sapiens	86-89
3758306-7	1986	Contrary to the known peroxisomal inducers, cyclosporin A decreases beta oxidation of fatty acids in addition to catalase and urate oxidase activities in isolated peroxisomes which may suggest an inhibition of certain steps in protein synthesis.	Cyclosporine	44-57	urate oxidase	Rattus norvegicus	126-139
1804642-1	1991	Pretreatment of rat vascular smooth muscle cells with cyclosporin A caused concentration- and time-dependent enhancement of both angiotensin II- and platelet-derived growth factor-stimulated cellular functions, which may be related to a rise in vascular tone.	Cyclosporine	54-67	myotrophin	Rattus norvegicus	166-179
3485573-1	1986	The effect of the immunosuppressive drug cyclosporin A (CS-A) on immunity to the facultative intracellular bacterium Listeria monocytogenes was investigated in unprimed and primed mice.	Cyclosporine	41-54	heat shock protein 9	Mus musculus	56-60
1724964-5	1991	The activities of amylase and lipase in the pancreas also decreased in the CsA-treated rats.	Cyclosporine	75-78	lipase G, endothelial type	Rattus norvegicus	30-36
1724964-9	1991	These results strongly suggest that prolonged treatment with CsA may induce the suppression of pancreatic exocrine functions by decreasing the contents of amylase and lipase as well as the number of muscarinic receptors, possibly by the inhibition of the syntheses of protein and DNA in the exocrine pancreas.	Cyclosporine	61-64	lipase G, endothelial type	Rattus norvegicus	167-173
3489788-1	1986	Cyclosporine A (CsA), one compound in the family of cyclosporines, has effectively modulated the course of S-antigen induced experimental autoimmune uveitis (EAU).	Cyclosporine	0-14	S-antigen visual arrestin	Rattus norvegicus	107-116
1721613-3	1991	Cyclosporin A (CsA) has been shown to block activation-driven T-cell apoptosis, an effect which may account for the perturbations of TcR repertoire selection caused by this agent in vivo.	Cyclosporine	0-13	T cell receptor alpha variable 6-3	Mus musculus	133-136
3489788-1	1986	Cyclosporine A (CsA), one compound in the family of cyclosporines, has effectively modulated the course of S-antigen induced experimental autoimmune uveitis (EAU).	Cyclosporine	16-19	S-antigen visual arrestin	Rattus norvegicus	107-116
1721613-3	1991	Cyclosporin A (CsA) has been shown to block activation-driven T-cell apoptosis, an effect which may account for the perturbations of TcR repertoire selection caused by this agent in vivo.	Cyclosporine	15-18	T cell receptor alpha variable 6-3	Mus musculus	133-136
2046382-5	1991	Furthermore, immunodulating therapeutic strategies, represented by cyclosporin-A discontinuation or alpha interferon treatment, may successfully reduce the Ph1+ cell population even after a full relapse.	Cyclosporine	67-80	alanine--glyoxylate and serine--pyruvate aminotransferase	Homo sapiens	156-159
3878756-2	1985	Puromycin, 5-azacytidine, actinomycin D, cyclosporin A, dexamethasone, indomethacin, colchicine, quinacrine, chlorpromazine but not tunicamycin can effectively inhibit the in vitro modification of HLA-B27-positive lymphocytes from normal individuals.	Cyclosporine	41-54	major histocompatibility complex, class I, B	Homo sapiens	197-202
2238059-8	1990	TLI therapy resembles anti-CD4 therapy and CsA in that each results in an IL-2-"depleted" state.	Cyclosporine	43-46	interleukin 2	Mus musculus	74-78
3879814-10	1985	Cyclosporin A, an immunosuppressive agent, markedly reduced the accumulation of c-myc mRNA that was induced by ConA but only slightly diminished the accumulation of c-myc mRNA that was induced by rIL2.	Cyclosporine	0-13	interleukin 2	Rattus norvegicus	196-200
3936119-5	1985	However unlike DEX, CSA (1-30 micrograms/ml) caused inhibition of phospholipase A2 (PLA2) activity when assayed on the hydrolysis of a synthetic substrate by pancreatic PLA2 in a cell-free system.	Cyclosporine	20-23	phospholipase A2 group IB	Rattus norvegicus	66-82
3936119-5	1985	However unlike DEX, CSA (1-30 micrograms/ml) caused inhibition of phospholipase A2 (PLA2) activity when assayed on the hydrolysis of a synthetic substrate by pancreatic PLA2 in a cell-free system.	Cyclosporine	20-23	phospholipase A2 group IB	Rattus norvegicus	84-88
3936119-5	1985	However unlike DEX, CSA (1-30 micrograms/ml) caused inhibition of phospholipase A2 (PLA2) activity when assayed on the hydrolysis of a synthetic substrate by pancreatic PLA2 in a cell-free system.	Cyclosporine	20-23	phospholipase A2 group IB	Rattus norvegicus	169-173
3936119-6	1985	The direct inhibition of PLA2 might well be a manifestation of the fundamental activity of CSA on immunocompetent cells.	Cyclosporine	91-94	phospholipase A2 group IB	Rattus norvegicus	25-29
1978708-5	1990	Using (a) TH2 clones that varied in the amount of IL 5 secreted, (b) a neutralizing monoclonal antibody against IL 5 and (c) T cell clones pretreated with cyclosporin A to inhibit cytokine secretion, we found that IL 5 was essential for induction of IgG1 synthesis by TH2 but not TH1 T cells.	Cyclosporine	155-168	heart and neural crest derivatives expressed 2	Mus musculus	268-271
2279783-2	1990	When spleen cells were preincubated with high doses of CsA and washed, the normal lymphocyte response to stimulation with mitogen (concanavalin-A) and lymphokine (interleukin-2) was not affected.	Cyclosporine	55-58	interleukin 2	Mus musculus	163-176
1974563-9	1990	Because it has been reported that cyclosporin A interferes with thymocytes maturation and blocks the transition from double to single positive cells, its effect was measured on CD27 induction.	Cyclosporine	34-47	CD27 molecule	Homo sapiens	177-181
1974563-10	1990	Cyclosporin A did not inhibit CD25 expression induced by both Con A and PMA+ionomycin, but under these conditions it inhibited the induction of CD27.	Cyclosporine	0-13	CD27 molecule	Homo sapiens	144-148
3898488-2	1985	Matching for HLA-B plus HLA-DR resulted in a significant correlation with graft outcome, in patients with or without cyclosporine treatment (P less than 0.0001).	Cyclosporine	117-129	major histocompatibility complex, class I, B	Homo sapiens	13-18
3898488-4	1985	A high (86 +/- 3%) graft survival rate was obtained in 161 cyclosporine-treated recipients with 0 HLA-B,-DR mismatches.	Cyclosporine	59-71	major histocompatibility complex, class I, B	Homo sapiens	98-103
2411572-10	1985	The third pattern IgG1 much greater than IgG2a greater than IgG3 approximately equal to IgM was characteristic of anti-CSA antibodies.	Cyclosporine	119-122	immunoglobulin heavy variable V1-9	Mus musculus	41-46
3927172-4	1985	In vivo MHC class II antigen expression by canine endothelial cells is therefore dependent on factors, probably the lymphokine gamma-interferon produced by the immune system, whose secretion is inhibited by cyclosporin A.	Cyclosporine	207-220	HLA class II histocompatibility antigen, DQ beta 2 chain	Canis lupus familiaris	8-28
3160142-0	1985	Effect of cyclosporine on MHC class II antigen expression on arterial and venous endothelium in vitro.	Cyclosporine	10-22	HLA class II histocompatibility antigen, DQ beta 2 chain	Canis lupus familiaris	26-46
3160142-9	1985	It is postulated that a possible mode of action of CsA in prolongation of allograft survival is based on prevention of the induction of MHC class II antigen expression by endothelial cells.	Cyclosporine	51-54	HLA class II histocompatibility antigen, DQ beta 2 chain	Canis lupus familiaris	136-156
3925604-0	1985	Restoration of T cell responsiveness to interleukin-2 in recipients of pancreatic islet xenografts treated with cyclosporine.	Cyclosporine	112-124	interleukin 2	Rattus norvegicus	40-53
2402785-10	1990	Hence, cathepsin B and L stimulation was induced by CsA per se.	Cyclosporine	52-55	cathepsin B	Rattus norvegicus	7-18
2859508-4	1985	Haemostatic tests in cyclosporin-treated and azathioprine-treated patients and normal subjects (10 in each group) showed increased concentrations of factor VIII C, fibrinogen, antithrombin III, and protein C in the cyclosporin-treated patients.	Cyclosporine	21-32	serpin family C member 1	Homo sapiens	176-192
2197329-3	1990	Cyclosporin A is thought to inhibit transcription that suggests that IL-2 and IL-3 are regulated primarily at the transcriptional level while GM-CSF is not.	Cyclosporine	0-13	interleukin 2	Mus musculus	69-73
2227790-7	1990	On one hand, rats injected of hr IL-2 2.5 X 10(5)U/rat intraperitoneally for 14 days showed slight proteinuria on the 14th day, and the proteinuria was also inhibited by oral administration of CYA 25 mg/kg.	Cyclosporine	193-196	interleukin 2	Rattus norvegicus	33-37
1980302-6	1990	CSA treatment resulted in a decrease in creatinine clearance, urine flow and body weight and a significant increase in serum and lung ACE activities (436 +/- 9 vs 391 +/- 7 nmol mL-1 min-1, P less than 0.001; 184 +/- 8 vs 142 +/- 10 nmol mg-1 min-1 P less than 0.01, respectively).	Cyclosporine	0-3	L1 cell adhesion molecule	Mus musculus	178-188
2142529-9	1990	Effects of cyclosporine A and the protein synthesis inhibitors cycloheximide and anisomycin on IL-4 and IL-5 gene expression suggest that these genes are activated by different pathways after anti-CD3 stimulation.	Cyclosporine	11-25	interleukin 4	Mus musculus	95-99
2142529-9	1990	Effects of cyclosporine A and the protein synthesis inhibitors cycloheximide and anisomycin on IL-4 and IL-5 gene expression suggest that these genes are activated by different pathways after anti-CD3 stimulation.	Cyclosporine	11-25	interleukin 5	Mus musculus	104-108
2142529-10	1990	Cyclosporine A completely inhibited anti-CD3-induced expression of IL-4 mRNA but not of IL-5 mRNA, and protein-synthesis inhibitors completely inhibited induction of IL-5 mRNA but not of IL-4 mRNA.	Cyclosporine	0-14	interleukin 4	Mus musculus	67-71
2168118-6	1990	Furthermore, most of the V beta 8+ cells in the medulla of chimeras given cyclosporin A for 3 weeks after reconstitution appeared to be CD4+8+ thymocytes which bear a low concentration of TCR exist in the thymic medulla at a relatively early stage when donor-derived Ia+ cells have already settled there.	Cyclosporine	74-87	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	188-191
1971531-5	1990	Cyclosporine (CsA) prevented diC8 and ionomycin-induced expression of IL-2, IFN-gamma, and H-ras genes.	Cyclosporine	0-12	HRas proto-oncogene, GTPase	Homo sapiens	91-96
1971791-2	1990	CsA specifically inhibited the generation of cells expressing high levels of alpha/beta TcR/CD3 complexes and a mature phenotype defined by CD4 and CD8 surface markers.	Cyclosporine	0-3	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	88-91
2306292-8	1990	The favorable effect of CsA on AIA is likely due to a blockade of T cell activation via an inhibition of production of lymphokines such as interleukin-2 and gamma-interferon.	Cyclosporine	24-27	interleukin 2	Rattus norvegicus	139-152
2138344-0	1990	Thromboxane receptor blockade improves cyclosporine nephrotoxicity in rats.	Cyclosporine	39-51	thromboxane A2 receptor	Rattus norvegicus	0-20
2312149-8	1990	However, addition of rIL-2 reversed CsA inhibition of IL-2R expression.	Cyclosporine	36-39	interleukin 2	Rattus norvegicus	21-26
2312149-10	1990	Exogenous rIL-2 reverses CsA inhibition of IL-2R expression.	Cyclosporine	25-28	interleukin 2	Rattus norvegicus	10-15
2312149-11	1990	This might be due to binding of rIL-2 to receptors which escape CsA inhibition, thereby up-regulating receptor expression which is drug resistant.	Cyclosporine	64-67	interleukin 2	Rattus norvegicus	32-37
34936540-0	2022	High-content Screen Identifies Cyclosporin A as a Novel ABCA3-specific Molecular Corrector.	Cyclosporine	31-44	ATP binding cassette subfamily A member 3	Homo sapiens	56-61
34936540-8	2022	Cyclosporin A (CsA) was identified as a potent corrector, specific for some, but not all ABCA3 variants.	Cyclosporine	15-18	ATP binding cassette subfamily A member 3	Homo sapiens	89-94
34852234-6	2021	Moreover, targeting CypA by cyclosporine A exhibits promising efficacy against chemoresistant CRC when combined with chemotherapeutics.	Cyclosporine	28-42	peptidylprolyl isomerase A	Homo sapiens	20-24
34552510-8	2021	Compared to the placebo group, the CsA group had dramatically lower endometrial CD56+ cell and CD57+ cell concentrations at the luteal phase of the second menstrual cycle (P < 0.05).	Cyclosporine	35-38	neural cell adhesion molecule 1	Homo sapiens	80-84
34109683-5	2021	In the DIGO mouse model, CsA inhibited the up-regulation of Nr4a1 expression induced by periodontal disease (PD) in gingival tissue, but not that of Col1a1 and Pai1.	Cyclosporine	25-28	nuclear receptor subfamily 4, group A, member 1	Mus musculus	60-65
34220265-10	2021	Conclusion: Our study reveals that HMGA1 and PSAT1 can be deployed for initial screening of ovarian cancer and drugs cisplatin, bisphenol A, cyclosporin, progesterone, and sunitinib are effective in curbing the epigenetic alteration.	Cyclosporine	141-152	high mobility group AT-hook 1	Homo sapiens	35-40
34096287-5	2021	CsO exhibited a higher plasma concentration than CsA, which resulted from minimal CypA binding and lower accumulation in red blood cells and moderate oral bioavailability (F = 12%).	Cyclosporine	49-52	peptidylprolyl isomerase A	Homo sapiens	82-86
6234255-1	1984	Cyclosporine (CsA) has been shown to be effective in preventing S-antigen (S-Ag) induced experimental autoimmune uveitis (EAU) in Lewis rats.	Cyclosporine	0-12	S-antigen visual arrestin	Rattus norvegicus	64-73
6234255-1	1984	Cyclosporine (CsA) has been shown to be effective in preventing S-antigen (S-Ag) induced experimental autoimmune uveitis (EAU) in Lewis rats.	Cyclosporine	0-12	S-antigen visual arrestin	Rattus norvegicus	75-79
6234255-1	1984	Cyclosporine (CsA) has been shown to be effective in preventing S-antigen (S-Ag) induced experimental autoimmune uveitis (EAU) in Lewis rats.	Cyclosporine	14-17	S-antigen visual arrestin	Rattus norvegicus	64-73
6234255-1	1984	Cyclosporine (CsA) has been shown to be effective in preventing S-antigen (S-Ag) induced experimental autoimmune uveitis (EAU) in Lewis rats.	Cyclosporine	14-17	S-antigen visual arrestin	Rattus norvegicus	75-79
34316222-13	2021	After treatment with CsA for 45 days, the lysozyme protein was still decreasing and the inflammation protein (S100-A12) was not identified.	Cyclosporine	21-24	lysozyme	Canis lupus familiaris	42-50
6234255-2	1984	Alterations in the humoral immune responses associated with CsA therapy are illustrated by lower peak and delayed production of circulating anti-S-Ag antibodies in a proportional relationship to the dose of CsA in EAU.	Cyclosporine	60-63	S-antigen visual arrestin	Rattus norvegicus	145-149
6234255-2	1984	Alterations in the humoral immune responses associated with CsA therapy are illustrated by lower peak and delayed production of circulating anti-S-Ag antibodies in a proportional relationship to the dose of CsA in EAU.	Cyclosporine	207-210	S-antigen visual arrestin	Rattus norvegicus	145-149
34124083-17	2021	The cyclosporin A- and stanozolol-treated mice showed higher serum erythropoietin (corrected by hemoglobin level) and higher erythropoietin receptor levels in bone marrow mononuclear cells than the other groups (P < 0.05).	Cyclosporine	4-17	erythropoietin	Mus musculus	67-81
34124083-17	2021	The cyclosporin A- and stanozolol-treated mice showed higher serum erythropoietin (corrected by hemoglobin level) and higher erythropoietin receptor levels in bone marrow mononuclear cells than the other groups (P < 0.05).	Cyclosporine	4-17	erythropoietin receptor	Mus musculus	125-148
34067576-0	2021	Camel Milk Mitigates Cyclosporine-Induced Renal Damage in Rats: Targeting p38/ERK/JNK MAPKs, NF-kappaB, and Matrix Metalloproteinases.	Cyclosporine	21-33	mitogen-activated protein kinase 8	Rattus norvegicus	82-85
34427166-5	2020	PTEN knockdown not only promoted CsA-induced overgrowth of human HGFs but also reversed the repressive effects of miR-26-5p on CsA-induced overgrowth of HGFs.	Cyclosporine	33-36	phosphatase and tensin homolog	Homo sapiens	0-4
34427166-5	2020	PTEN knockdown not only promoted CsA-induced overgrowth of human HGFs but also reversed the repressive effects of miR-26-5p on CsA-induced overgrowth of HGFs.	Cyclosporine	127-130	phosphatase and tensin homolog	Homo sapiens	0-4
34427166-6	2020	Our results revealed that miRNA-26-5p could repress CsA-induced overgrowth of human HGFs by regulating PTEN/PI3K/AKT pathway.	Cyclosporine	52-55	phosphatase and tensin homolog	Homo sapiens	103-107
35218062-9	2022	In addition, we found that the cyclosporine A-mediated inhibition of CypA did not prevent the formation of the CypA and AIF complex; rather, this only suppressed genomic DNA fragmentation.	Cyclosporine	31-45	peptidylprolyl isomerase A	Homo sapiens	69-73
35387841-7	2022	In a mouse allogeneic graft-versus-host disease model, Nr4a1 mediated tolerance by promoting Treg cell differentiation in mice administered cyclosporine A, prolonging the survival of recipients.	Cyclosporine	140-154	nuclear receptor subfamily 4, group A, member 1	Mus musculus	55-60
35387841-8	2022	Furthermore, activation of Nr4a1 via its agonist partially restored Treg cell differentiation, which was suppressed by cyclosporine A treatment.	Cyclosporine	119-133	nuclear receptor subfamily 4, group A, member 1	Mus musculus	27-32
35272142-2	2022	Here, we show that CsA alone stimulates ICAM-1 overexpression in human pulmonary microvascular endothelial cells (HPMECs) through Toll-Like Receptor 4 (TLR4) and NF-kappaB activation.	Cyclosporine	19-22	toll like receptor 4	Homo sapiens	130-150
35272142-2	2022	Here, we show that CsA alone stimulates ICAM-1 overexpression in human pulmonary microvascular endothelial cells (HPMECs) through Toll-Like Receptor 4 (TLR4) and NF-kappaB activation.	Cyclosporine	19-22	toll like receptor 4	Homo sapiens	152-156
35510329-8	2022	CYA treatment increased hippocampal BDNF protein levels prevented by co-administration of ALA (with or without Crt) or fluoxetine.	Cyclosporine	0-3	brain derived neurotrophic factor	Mus musculus	36-40
35418571-3	2022	In this study, we show that the lipophilic cyclic peptide, cyclosporin A (CsA), interacted with, and likely induced aggregation, of polymeric, gel-forming mucins (MUC2, MUC5AC and MUC5B) which underpin the mucus gel-networks in the gastrointestinal tract.	Cyclosporine	74-77	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	169-175
35418571-5	2022	Using rate-zonal centrifugation, purified MUC2, MUC5AC and MUC5B mucins sedimented faster in the presence of CsA, with a significant increase in mucins in the pellet fraction.	Cyclosporine	109-112	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	48-54
35603336-5	2022	A 61-year-old woman with a history of anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis and interstitial pneumonia was administered with long-term oral methylprednisolone and cyclosporine.	Cyclosporine	205-217	interferon induced with helicase C domain 1	Homo sapiens	43-85
35073210-7	2022	Exposure of cultured human renal proximal tubular HK-2 cells to CsA induced expression of fibronectin and sPRR production, but the fibrotic response was attenuated by PRO20 and siRNA-mediated PRR knockdown.	Cyclosporine	64-67	small proline-rich protein 1A	Rattus norvegicus	106-110
35074592-9	2022	Moreover, CsA triggered a notable increase in the levels of apoptotic marker P53.	Cyclosporine	10-13	transformation related protein 53, pseudogene	Mus musculus	77-80
6327823-2	1984	The same concentration (0.25 microgram/ml) of CsA that produced optimal inhibition of the T cell proliferative response to concanavalin A (Con A) was also very effective at inhibiting IL 2 production and the induction of IL 2 responsiveness, as well as the expression of the IL 2 and transferrin receptors when measured 72 hr after mitogen activation.	Cyclosporine	46-49	interleukin 2	Mus musculus	184-188
6327823-2	1984	The same concentration (0.25 microgram/ml) of CsA that produced optimal inhibition of the T cell proliferative response to concanavalin A (Con A) was also very effective at inhibiting IL 2 production and the induction of IL 2 responsiveness, as well as the expression of the IL 2 and transferrin receptors when measured 72 hr after mitogen activation.	Cyclosporine	46-49	interleukin 2	Mus musculus	221-225
6327823-2	1984	The same concentration (0.25 microgram/ml) of CsA that produced optimal inhibition of the T cell proliferative response to concanavalin A (Con A) was also very effective at inhibiting IL 2 production and the induction of IL 2 responsiveness, as well as the expression of the IL 2 and transferrin receptors when measured 72 hr after mitogen activation.	Cyclosporine	46-49	interleukin 2	Mus musculus	221-225
6327823-4	1984	These results suggest that inhibition of the maturation of receptor expression is secondary to an early effect of CsA in blocking the induction of IL 2 responsiveness or to an arrest in the sequence of events required for maturation of T cells that bear high densities of these receptors.	Cyclosporine	114-117	interleukin 2	Mus musculus	147-151
6145646-0	1984	Cyclosporine inhibits prolactin induction of ornithine decarboxylase in rat tissues.	Cyclosporine	0-12	ornithine decarboxylase 1	Rattus norvegicus	45-68
6145646-1	1984	Cyclosporine (CyA), formerly cyclosporin A, significantly inhibited the ability of prolactin (PRL) to elevate ornithine decarboxylase (ODC) activity in a variety of rat tissues.	Cyclosporine	0-12	ornithine decarboxylase 1	Rattus norvegicus	110-133
6145646-1	1984	Cyclosporine (CyA), formerly cyclosporin A, significantly inhibited the ability of prolactin (PRL) to elevate ornithine decarboxylase (ODC) activity in a variety of rat tissues.	Cyclosporine	0-12	ornithine decarboxylase 1	Rattus norvegicus	135-138
6145646-1	1984	Cyclosporine (CyA), formerly cyclosporin A, significantly inhibited the ability of prolactin (PRL) to elevate ornithine decarboxylase (ODC) activity in a variety of rat tissues.	Cyclosporine	14-17	ornithine decarboxylase 1	Rattus norvegicus	110-133
6145646-1	1984	Cyclosporine (CyA), formerly cyclosporin A, significantly inhibited the ability of prolactin (PRL) to elevate ornithine decarboxylase (ODC) activity in a variety of rat tissues.	Cyclosporine	14-17	ornithine decarboxylase 1	Rattus norvegicus	135-138
6145646-1	1984	Cyclosporine (CyA), formerly cyclosporin A, significantly inhibited the ability of prolactin (PRL) to elevate ornithine decarboxylase (ODC) activity in a variety of rat tissues.	Cyclosporine	29-42	ornithine decarboxylase 1	Rattus norvegicus	110-133
6145646-1	1984	Cyclosporine (CyA), formerly cyclosporin A, significantly inhibited the ability of prolactin (PRL) to elevate ornithine decarboxylase (ODC) activity in a variety of rat tissues.	Cyclosporine	29-42	ornithine decarboxylase 1	Rattus norvegicus	135-138
6301584-7	1983	Both CSF-alpha and mouse spleen conditioned medium also contain eosinophil colony-stimulating activity (CSA), whereas inactive CSFs with no effect on mature eosinophils, CSF-beta, and mouse lung conditioned medium also lack eosinophil CSA.	Cyclosporine	104-107	colony stimulating factor 2	Homo sapiens	5-8
6308952-3	1983	The immunosuppressive drugs cyclosporin A (CyA) and methylprednisolone (MP) abolished the elaboration of the lymphokine leukocyte migration inhibitory factor (LIF) by mononuclear cells challenged by recall antigen.	Cyclosporine	28-41	LIF interleukin 6 family cytokine	Homo sapiens	159-162
6308952-3	1983	The immunosuppressive drugs cyclosporin A (CyA) and methylprednisolone (MP) abolished the elaboration of the lymphokine leukocyte migration inhibitory factor (LIF) by mononuclear cells challenged by recall antigen.	Cyclosporine	43-46	LIF interleukin 6 family cytokine	Homo sapiens	159-162
35074592-10	2022	CsA activated the Wnt/beta-catenin pathway by increasing WNT3a expression, frizzled receptor-7, beta-catenin, and c-myc.	Cyclosporine	0-3	wingless-type MMTV integration site family, member 3A	Mus musculus	18-21
35074592-10	2022	CsA activated the Wnt/beta-catenin pathway by increasing WNT3a expression, frizzled receptor-7, beta-catenin, and c-myc.	Cyclosporine	0-3	wingless-type MMTV integration site family, member 3A	Mus musculus	57-62
35242122-7	2022	Consistent with disruption of viral cloaking and innate immune evasion, treatment with Cyp inhibitors such as cyclosporine A (CsA) restores antiviral innate immunity and induces expression of a subset of antiviral genes that restrict viral infection, which may help to explain the broad antiviral spectrum of CsA.	Cyclosporine	110-124	peptidylprolyl isomerase G	Homo sapiens	87-90
35242122-7	2022	Consistent with disruption of viral cloaking and innate immune evasion, treatment with Cyp inhibitors such as cyclosporine A (CsA) restores antiviral innate immunity and induces expression of a subset of antiviral genes that restrict viral infection, which may help to explain the broad antiviral spectrum of CsA.	Cyclosporine	126-129	peptidylprolyl isomerase G	Homo sapiens	87-90
35242122-7	2022	Consistent with disruption of viral cloaking and innate immune evasion, treatment with Cyp inhibitors such as cyclosporine A (CsA) restores antiviral innate immunity and induces expression of a subset of antiviral genes that restrict viral infection, which may help to explain the broad antiviral spectrum of CsA.	Cyclosporine	309-312	peptidylprolyl isomerase G	Homo sapiens	87-90
35484739-4	2022	The role of nuclear-targeted nanoparticles in CSA in relation to PI3K/Akt/mTOR pathway was then analyzed through detection of autophagy-related proteins pathway-related proteins.	Cyclosporine	46-49	mechanistic target of rapamycin kinase	Mus musculus	74-78
35484739-9	2022	Our present study demonstrated that the nucleartargeted nanoparticles could regulate the growth of bEnd.3 cells in CSA and promote autophagy of cells through blockage of the PI3K/Akt/mTOR signaling pathway.	Cyclosporine	115-118	mechanistic target of rapamycin kinase	Mus musculus	183-187
2595779-12	1989	In the CsA-treated allogeneic group, after CsA treatment interruption, S-R-IL-2 levels significantly increased, reaching a plateau at day 37.	Cyclosporine	7-10	interleukin 2	Rattus norvegicus	75-79
2486550-6	1989	Cyclosporine is a lipophilic drug that is transported in the plasma, largely in association with lipoproteins, and may require the low-density lipoprotein (LDL) receptor for internalization into cells.	Cyclosporine	0-12	low density lipoprotein receptor	Homo sapiens	131-169
2551284-0	1989	Cyclosporine increases endothelin-1 binding site density in cardiac cell membranes.	Cyclosporine	0-12	endothelin 1	Mus musculus	23-35
2551284-2	1989	Cyclosporine-treated mice were used to investigate whether a cyclosporine dose regime which produces cardiac fibrosis and calcification alters the density of the specific binding sites for the endothelial-derived vasoconstrictor polypeptide, endothelin-1.	Cyclosporine	61-73	endothelin 1	Mus musculus	242-254
2551284-4	1989	This increase in endothelin-1 binding site density could contribute to the cytotoxic effects of cyclosporine.	Cyclosporine	96-108	endothelin 1	Mus musculus	17-29
2600452-0	1989	Dose-dependent inhibition by cyclosporine A of the induction of pancreatic ornithine decarboxylase (ODC) in rats.	Cyclosporine	29-43	ornithine decarboxylase 1	Rattus norvegicus	75-98
6216375-2	1982	TLp obtained at the time of decreasing neutrophil counts, increased CSA elaboration (p less than 0.056) when incubated at a 1:1 ratio with MOb.	Cyclosporine	68-71	cysteine rich protein 3	Homo sapiens	0-3
6216375-3	1982	Increasing the TLp to MOb ratios to 3:1 or 5:1 progressively decreased CSA.	Cyclosporine	71-74	cysteine rich protein 3	Homo sapiens	15-18
33999413-10	2022	In U937 cells, the extra-supplied CyPA increased MMP-9 mRNA and enzyme activity, whereas the CyPA inhibitor, cyclosporine A, suppressed the LPS- and co-culture-enhanced MMP-9.	Cyclosporine	109-123	peptidylprolyl isomerase A	Homo sapiens	93-97
2600452-0	1989	Dose-dependent inhibition by cyclosporine A of the induction of pancreatic ornithine decarboxylase (ODC) in rats.	Cyclosporine	29-43	ornithine decarboxylase 1	Rattus norvegicus	100-103
2600452-1	1989	The effect of cyclosporine A (CsA) and alpha-difluoromethylornithine (DFMO) on the camostate-induced increase in pancreatic ornithine decarboxylase (ODC) activity and polyamine biosynthesis has been studied in vivo.	Cyclosporine	14-28	ornithine decarboxylase 1	Rattus norvegicus	124-147
2567675-5	1989	CyA-induced inhibition of both anti-CD3- and anti-CD2-mediated proliferation could not be reversed by addition of either PMA (1 ng/ml) or anti-CD28.	Cyclosporine	0-3	CD2 molecule	Homo sapiens	50-53
2787474-10	1989	(v) In T cells treated with phytohemagglutinin, tetradecanoylphorbol acetate, and cyclosporin A, the modulation of lck expression was associated primarily with changes in levels of type II transcripts.	Cyclosporine	82-95	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	115-118
2499483-0	1989	Synergy between interleukin 4 and interleukin 2 conveys resistance to cyclosporin A during primary in vitro activation of murine CD8 cytotoxic T cell precursors.	Cyclosporine	70-83	interleukin 4	Mus musculus	16-29
33993340-0	2021	Selective involution of thymic medulla by cyclosporine A with a decrease of mature thymic epithelia, XCR1+ dendritic cells, and epithelium-free areas containing Foxp3+ thymic regulatory T cells.	Cyclosporine	42-56	X-C motif chemokine receptor 1	Rattus norvegicus	101-105
33993101-0	2021	Cyclosporin A impairs neurogenesis and cognitive abilities in brain development via the IFN-gamma-Shh-BDNF pathway.	Cyclosporine	0-13	sonic hedgehog signaling molecule	Homo sapiens	98-101
33993101-3	2021	Here, we found that the immunosuppressant cyclosporin A (CsA) decreased the number of BrdU+, BrdU+/DCX+, BrdU+/NeuN + cells in the hippocampus, impaired learning and memory and inhibited protein levels of the shh signaling pathway, including Shh, Smo and Gli1.	Cyclosporine	42-55	sonic hedgehog signaling molecule	Homo sapiens	209-212
33993101-3	2021	Here, we found that the immunosuppressant cyclosporin A (CsA) decreased the number of BrdU+, BrdU+/DCX+, BrdU+/NeuN + cells in the hippocampus, impaired learning and memory and inhibited protein levels of the shh signaling pathway, including Shh, Smo and Gli1.	Cyclosporine	42-55	sonic hedgehog signaling molecule	Homo sapiens	242-245
33993101-3	2021	Here, we found that the immunosuppressant cyclosporin A (CsA) decreased the number of BrdU+, BrdU+/DCX+, BrdU+/NeuN + cells in the hippocampus, impaired learning and memory and inhibited protein levels of the shh signaling pathway, including Shh, Smo and Gli1.	Cyclosporine	42-55	smoothened, frizzled class receptor	Homo sapiens	247-250
33993101-3	2021	Here, we found that the immunosuppressant cyclosporin A (CsA) decreased the number of BrdU+, BrdU+/DCX+, BrdU+/NeuN + cells in the hippocampus, impaired learning and memory and inhibited protein levels of the shh signaling pathway, including Shh, Smo and Gli1.	Cyclosporine	57-60	sonic hedgehog signaling molecule	Homo sapiens	209-212
33993101-3	2021	Here, we found that the immunosuppressant cyclosporin A (CsA) decreased the number of BrdU+, BrdU+/DCX+, BrdU+/NeuN + cells in the hippocampus, impaired learning and memory and inhibited protein levels of the shh signaling pathway, including Shh, Smo and Gli1.	Cyclosporine	57-60	sonic hedgehog signaling molecule	Homo sapiens	242-245
33993101-3	2021	Here, we found that the immunosuppressant cyclosporin A (CsA) decreased the number of BrdU+, BrdU+/DCX+, BrdU+/NeuN + cells in the hippocampus, impaired learning and memory and inhibited protein levels of the shh signaling pathway, including Shh, Smo and Gli1.	Cyclosporine	57-60	smoothened, frizzled class receptor	Homo sapiens	247-250
32822562-0	2021	Nicorandil prevents the nephrotoxic effect of cyclosporine-A in albino rats through modulation of HIF-1alpha/VEGF /eNOS signaling.	Cyclosporine	46-60	vascular endothelial growth factor A	Rattus norvegicus	109-113
32822562-9	2021	Cyclosporine decreased the renal expression levels (P<0.001) of HIF-1alpha, eNOS, and VEGF inducing endothelial dysfunction and the triggered inflammation, and upregulated the pro-fibrotic marker transforming growth factor (TGF-beta).	Cyclosporine	0-12	vascular endothelial growth factor A	Rattus norvegicus	86-90
32822562-13	2021	Nicorandil reversed the disturbed HIF-1alpha/VEGF/eNOS pathway created by cyclosporine.	Cyclosporine	74-86	vascular endothelial growth factor A	Rattus norvegicus	45-49
33361281-3	2021	CyPA mediates immunosuppressive action of the cyclic undecapeptide cyclosporine A and is also involved in multiple cellular processes such as protein folding, intracellular trafficking, signal transduction, and transcriptional regulation.	Cyclosporine	67-81	peptidylprolyl isomerase A	Homo sapiens	0-4
33492451-2	2021	Besides acting as an intracellular receptor for cyclosporine A, CypA plays a vital role in microorganismal infections, cardiovascular diseases, liver diseases, kidney diseases, neurodegeneration, cancer, rheumatoid arthritis, periodontitis, sepsis, asthma, and aging.	Cyclosporine	48-62	peptidylprolyl isomerase A	Homo sapiens	64-68
33634990-8	2021	We also observed that CsA-induced functional alternation of neutrophils was initiated through suppressing SIRT6 expression, which is responsible for expression of the downstream signaling molecules (e.g., HIF-1alpha, PFKFB3) and PDK4 ubiquitination, leading to fueling neutrophil glycolysis and TCA cycle.	Cyclosporine	22-25	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	217-223
2499483-0	1989	Synergy between interleukin 4 and interleukin 2 conveys resistance to cyclosporin A during primary in vitro activation of murine CD8 cytotoxic T cell precursors.	Cyclosporine	70-83	interleukin 2	Mus musculus	34-47
2499483-1	1989	Even though cyclosporin A (CsA) suppresses in vitro production of lymphokines such as interleukin 2 (IL 2) and responsiveness of cytotoxic T cell (CTL) precursors to IL 2, thereby inhibiting the in vitro generation of CTL, in vivo CsA does not affect the induction of alloreactive CTL.	Cyclosporine	12-25	interleukin 2	Mus musculus	86-99
2499483-1	1989	Even though cyclosporin A (CsA) suppresses in vitro production of lymphokines such as interleukin 2 (IL 2) and responsiveness of cytotoxic T cell (CTL) precursors to IL 2, thereby inhibiting the in vitro generation of CTL, in vivo CsA does not affect the induction of alloreactive CTL.	Cyclosporine	12-25	interleukin 2	Mus musculus	101-105
2499483-1	1989	Even though cyclosporin A (CsA) suppresses in vitro production of lymphokines such as interleukin 2 (IL 2) and responsiveness of cytotoxic T cell (CTL) precursors to IL 2, thereby inhibiting the in vitro generation of CTL, in vivo CsA does not affect the induction of alloreactive CTL.	Cyclosporine	12-25	interleukin 2	Mus musculus	166-170
2499483-1	1989	Even though cyclosporin A (CsA) suppresses in vitro production of lymphokines such as interleukin 2 (IL 2) and responsiveness of cytotoxic T cell (CTL) precursors to IL 2, thereby inhibiting the in vitro generation of CTL, in vivo CsA does not affect the induction of alloreactive CTL.	Cyclosporine	27-30	interleukin 2	Mus musculus	86-99
2499483-1	1989	Even though cyclosporin A (CsA) suppresses in vitro production of lymphokines such as interleukin 2 (IL 2) and responsiveness of cytotoxic T cell (CTL) precursors to IL 2, thereby inhibiting the in vitro generation of CTL, in vivo CsA does not affect the induction of alloreactive CTL.	Cyclosporine	27-30	interleukin 2	Mus musculus	101-105
2499483-1	1989	Even though cyclosporin A (CsA) suppresses in vitro production of lymphokines such as interleukin 2 (IL 2) and responsiveness of cytotoxic T cell (CTL) precursors to IL 2, thereby inhibiting the in vitro generation of CTL, in vivo CsA does not affect the induction of alloreactive CTL.	Cyclosporine	27-30	interleukin 2	Mus musculus	166-170
2499483-3	1989	Using an in vitro model system in which the requirement for antigen-presenting cells during primary activation of resting murine CD8 T cells is bypassed by immobilized anti-CD3 monoclonal antibodies, we here describe conditions in which IL 4 conveys CsA resistance to murine CD8 T cells triggered by immobilized anti-CD3 monoclonal antibodies to respond to IL 2.	Cyclosporine	250-253	interleukin 4	Mus musculus	237-241
2499483-4	1989	CsA resistance of IL 4 and IL 2-responsive CD8 T cell parallels conditions in which signals provided by IL 4 and IL 2 synergize with each other.	Cyclosporine	0-3	interleukin 4	Mus musculus	18-22
2499483-4	1989	CsA resistance of IL 4 and IL 2-responsive CD8 T cell parallels conditions in which signals provided by IL 4 and IL 2 synergize with each other.	Cyclosporine	0-3	interleukin 2	Mus musculus	27-31
2499483-4	1989	CsA resistance of IL 4 and IL 2-responsive CD8 T cell parallels conditions in which signals provided by IL 4 and IL 2 synergize with each other.	Cyclosporine	0-3	interleukin 4	Mus musculus	18-31
2499483-6	1989	In addition to the known pleiotropic effects of IL 4, our results define an IL 4-dependent, CsA-resistant signal pathway which allows CTL differentiation in the absence of significant cell proliferation.	Cyclosporine	92-95	interleukin 4	Mus musculus	76-80
2669795-9	1989	Cy-A (100 ng/ml) inhibited completely Con-A activation of DP splenic cells cytotoxic to islet cells, and this was accompanied by a similar inhibition of interleukin-2 (IL-2) production.	Cyclosporine	0-4	interleukin 2	Rattus norvegicus	153-166
2669795-9	1989	Cy-A (100 ng/ml) inhibited completely Con-A activation of DP splenic cells cytotoxic to islet cells, and this was accompanied by a similar inhibition of interleukin-2 (IL-2) production.	Cyclosporine	0-4	interleukin 2	Rattus norvegicus	168-172
2669795-10	1989	Also Cy-A (300 ng/ml) inhibited partially (approximately 65%) IL-2 activation of DP splenic cells cytotoxic to islet cells.	Cyclosporine	5-9	interleukin 2	Rattus norvegicus	62-66
2723960-2	1989	These results are explained by possible protection of the liposomes by cyclosporin A against phospholipase A2 hydrolysis.	Cyclosporine	71-84	phospholipase A2 group IB	Rattus norvegicus	93-109
2525802-6	1989	Infection and CsA treatment, respectively, reduced or abolished the capacity of spleen cells to produce IL-2.	Cyclosporine	14-17	interleukin 2	Mus musculus	104-108
2492047-2	1989	Cyclosporin A inhibits TCR-mediated exocytosis by only selectively inhibits TCR-mediated lytic activity by cloned CTL.	Cyclosporine	0-13	T cell receptor alpha variable 6-3	Mus musculus	23-26
2492047-2	1989	Cyclosporin A inhibits TCR-mediated exocytosis by only selectively inhibits TCR-mediated lytic activity by cloned CTL.	Cyclosporine	0-13	T cell receptor alpha variable 6-3	Mus musculus	76-79
2662838-1	1989	In patients with heart transplant, the combined determination of serum beta 2-microglobulin and urinary neopterin, as rejection marker, prevented the interference by renal function and cyclosporin therapy.	Cyclosporine	185-196	beta-2-microglobulin	Homo sapiens	71-91
3141033-6	1988	Six recipients of allografts and cyclosporine (CsA) were normoglycemic when CsA trough serum levels were greater than 300 micrograms/L, although the fasting plasma glucose level was higher than that in autograft recipients.	Cyclosporine	33-45	albumin	Canis lupus familiaris	47-50
3063418-0	1988	Enhanced beta 2-microglobulin levels in lymphocyte culture supernatants from patients with idiopathic nephrotic syndrome: inhibition of lymphocyte activation by cyclosporine.	Cyclosporine	161-173	beta-2-microglobulin	Homo sapiens	9-29
33618532-10	2021	RESULTS: In our study, serum MCP-1 levels were significantly higher in cyclosporine and tacrolimus groups than in sirolimus (p<0.05).	Cyclosporine	71-83	C-C motif chemokine ligand 2	Homo sapiens	29-34
3063418-4	1988	In 13 patients treated with cyclosporine (Cs) (3-4.5 mg/kg/d) during 3 months, beta 2m levels were within the normal range.	Cyclosporine	28-40	beta-2-microglobulin	Homo sapiens	79-86
3063418-4	1988	In 13 patients treated with cyclosporine (Cs) (3-4.5 mg/kg/d) during 3 months, beta 2m levels were within the normal range.	Cyclosporine	42-44	beta-2-microglobulin	Homo sapiens	79-86
3063418-5	1988	Although the beta 2m of 7 Cs patients without proteinuria was lower than 5 Cs patients with residual proteinuria, the difference was not statistically significant.	Cyclosporine	26-28	beta-2-microglobulin	Homo sapiens	13-20
3063418-9	1988	In vitro addition of Cs (100 ng/ml) inhibited both beta 2m and VPF elevations observed in active INS.	Cyclosporine	21-23	beta-2-microglobulin	Homo sapiens	51-58
3063418-11	1988	High levels of beta 2m in LCS from INS are the consequence of an enhanced cellular synthesis and they are inhibited by Pr and Cs.	Cyclosporine	126-128	beta-2-microglobulin	Homo sapiens	15-22
2458149-4	1988	Similar to IL-1, the synthetical double-stranded RNA poly(rI).poly(rC) also stimulated release of CSA by fibroblasts.	Cyclosporine	98-101	interleukin 1 alpha	Homo sapiens	11-15
2458149-5	1988	The kinetics of IL-1- and poly(rI).poly(rC)-induced CSA release were found to be different, in that poly(rI).poly(rC)-induced CSA production occurred more slowly.	Cyclosporine	52-55	interleukin 1 alpha	Homo sapiens	16-20
2896111-0	1988	Cyclosporin A does not inhibit the PHA-stimulated increase in intracellular Ca2+ concentration but inhibits the increase in E-rosette receptor (CD2) expression and appearance of interleukin-2 receptors (CD25).	Cyclosporine	0-13	CD2 molecule	Homo sapiens	144-147
2963862-4	1988	First, CTL activation in the presence of high dose cyclosporin A was partially reconstituted with IL-2, although no detectable IFN-gamma was produced in such cultures.	Cyclosporine	51-64	interleukin 2	Mus musculus	98-102
3342035-3	1988	Furthermore, CsH, like CsA, inhibits the Ca2+/calmodulin-dependent phosphorylation of the elongation factor 2 (EF-2) in vitro and the TPA-induced increases in the amount of EF-2 in vivo.	Cyclosporine	23-26	eukaryotic translation elongation factor 2	Mus musculus	90-109
3342035-3	1988	Furthermore, CsH, like CsA, inhibits the Ca2+/calmodulin-dependent phosphorylation of the elongation factor 2 (EF-2) in vitro and the TPA-induced increases in the amount of EF-2 in vivo.	Cyclosporine	23-26	eukaryotic translation elongation factor 2	Mus musculus	111-115
3143680-9	1988	Since CS-A and MTX have been reported to be effective in the treatment of RA, their activity in the LAF, Fn, CRP, albumin and iron assays of the AA rat suggests that these immunological and serological parameters may be useful in identifying potential antirheumatic drugs and distinguishing them from standard NSAIDs.	Cyclosporine	6-10	fibronectin 1	Rattus norvegicus	105-107
3257564-4	1988	Cyclosporin A inhibited the synthesis of IL-4 mRNA in the T-cell line 2.19, which had been induced by concanavalin A.	Cyclosporine	0-13	interleukin 4	Mus musculus	41-45
3273203-0	1988	Ciclosporin inhibits phorbol-ester-induced hyperplastic transformation and tumor promotion in mouse skin probably by suppression of Ca2+/calmodulin-dependent processes such as phosphorylation of elongation factor 2.	Cyclosporine	0-11	eukaryotic translation elongation factor 2	Mus musculus	195-214
3273203-3	1988	Phosphorylation of EF-2 is dependent on Ca2+ and calmodulin, and inhibition of EF-2 phosphorylation by CsA is due to an interaction of CsA with calmodulin.	Cyclosporine	103-106	eukaryotic translation elongation factor 2	Mus musculus	79-83
3273203-3	1988	Phosphorylation of EF-2 is dependent on Ca2+ and calmodulin, and inhibition of EF-2 phosphorylation by CsA is due to an interaction of CsA with calmodulin.	Cyclosporine	135-138	eukaryotic translation elongation factor 2	Mus musculus	79-83
3273203-5	1988	Since CsA inhibits specifically 12-O-tetradecanoylphorbol-13-acetate (TAP)-stimulated but not basal protein synthesis in epidermis, it is proposed that Ca2+/calmodulin-dependent phosphorylation of EF-2 is involved in the induction of the hyperplastic response by TPA and that CsA suppresses TPA effects by inhibition of EF-2-phosphorylation and perhaps other calmodulin-dependent processes.	Cyclosporine	6-9	eukaryotic translation elongation factor 2	Mus musculus	197-201
3273203-5	1988	Since CsA inhibits specifically 12-O-tetradecanoylphorbol-13-acetate (TAP)-stimulated but not basal protein synthesis in epidermis, it is proposed that Ca2+/calmodulin-dependent phosphorylation of EF-2 is involved in the induction of the hyperplastic response by TPA and that CsA suppresses TPA effects by inhibition of EF-2-phosphorylation and perhaps other calmodulin-dependent processes.	Cyclosporine	6-9	eukaryotic translation elongation factor 2	Mus musculus	320-324
2453616-8	1987	The possible induction of IL-2 by ABPP was further investigated by using cyclosporin A (CsA) to inhibit IL-2 production in vivo.	Cyclosporine	73-86	interleukin 2	Mus musculus	26-30
2453616-8	1987	The possible induction of IL-2 by ABPP was further investigated by using cyclosporin A (CsA) to inhibit IL-2 production in vivo.	Cyclosporine	73-86	interleukin 2	Mus musculus	104-108
2453616-8	1987	The possible induction of IL-2 by ABPP was further investigated by using cyclosporin A (CsA) to inhibit IL-2 production in vivo.	Cyclosporine	88-91	interleukin 2	Mus musculus	26-30
2453616-8	1987	The possible induction of IL-2 by ABPP was further investigated by using cyclosporin A (CsA) to inhibit IL-2 production in vivo.	Cyclosporine	88-91	interleukin 2	Mus musculus	104-108
3474062-4	1987	Immunosuppression of host CD-1 mice was achieved by cyclosporine given daily after tumor implantation, cyclophosphamide given preimplantation combined with cyclosporine, or whole-body irradiation given preimplantation.	Cyclosporine	52-64	CD1 antigen complex	Mus musculus	26-30
3299147-0	1987	[Effects of cyclosporin on blood gastrin after kidney transplant].	Cyclosporine	12-23	gastrin	Homo sapiens	33-40
32615169-10	2021	Cyclosporine led to a more pronounced global transcriptome reversion and normalised Th17/IL23 signalling, whereas dupilumab led to a stronger increase of epidermal differentiation markers.	Cyclosporine	0-12	interleukin 23 subunit alpha	Homo sapiens	89-93
2884260-12	1987	Drugs like dexamethasone and cyclosporin, which affect the early part of G1, inhibited PCNA expression; whereas cytarabine (ara-C) and hydroxyurea, which affect the S-phase and prevent DNA synthesis, did not block PCNA expression.	Cyclosporine	29-40	proliferating cell nuclear antigen	Homo sapiens	87-91
2884260-12	1987	Drugs like dexamethasone and cyclosporin, which affect the early part of G1, inhibited PCNA expression; whereas cytarabine (ara-C) and hydroxyurea, which affect the S-phase and prevent DNA synthesis, did not block PCNA expression.	Cyclosporine	29-40	proliferating cell nuclear antigen	Homo sapiens	214-218
33339864-6	2020	From 32 datasets, the top ranked gene was PPIA, encoding cyclophilin A, a druggable target using cyclosporine.	Cyclosporine	97-109	peptidylprolyl isomerase A	Homo sapiens	42-46
3496224-7	1987	However, the increased expression of the TCR beta-chain gene and the induction of the IL 2 gene were not linked since expression of TCR beta-chain mRNA was increased to a similar degree in EL4+ and IL 2-nonproducing EL4- sublines, and cyclosporin A selectively blocked TPA-induced IL 2-gene expression in EL4+ cells without affecting the increase in TCR beta-chain mRNA.	Cyclosporine	235-248	interleukin 2	Mus musculus	86-90
32090669-9	2020	Interestingly, when PPARgamma activity was inhibited by T0070907, an effective and specific PPARgamma inhibitor, the therapeutic effect of EPO was significantly attenuated.Conclusion: Taken together, above results shown the protective effect of EPO on cyclosporine A-induced renal injury and confirmed that EPO"s anti-inflammation and antioxidative stress involving the PPAR gamma/TLR4/TGFbeta1 axis.	Cyclosporine	252-266	erythropoietin	Rattus norvegicus	139-142
32090669-9	2020	Interestingly, when PPARgamma activity was inhibited by T0070907, an effective and specific PPARgamma inhibitor, the therapeutic effect of EPO was significantly attenuated.Conclusion: Taken together, above results shown the protective effect of EPO on cyclosporine A-induced renal injury and confirmed that EPO"s anti-inflammation and antioxidative stress involving the PPAR gamma/TLR4/TGFbeta1 axis.	Cyclosporine	252-266	erythropoietin	Rattus norvegicus	245-248
32090669-9	2020	Interestingly, when PPARgamma activity was inhibited by T0070907, an effective and specific PPARgamma inhibitor, the therapeutic effect of EPO was significantly attenuated.Conclusion: Taken together, above results shown the protective effect of EPO on cyclosporine A-induced renal injury and confirmed that EPO"s anti-inflammation and antioxidative stress involving the PPAR gamma/TLR4/TGFbeta1 axis.	Cyclosporine	252-266	erythropoietin	Rattus norvegicus	245-248
3123380-0	1987	Cyclosporine and dexamethasone inhibit T-lymphocyte MHC class II antigens and IL-2 receptor expression in experimental autoimmune uveitis.	Cyclosporine	0-12	interleukin 2	Rattus norvegicus	78-82
32866465-3	2020	By using immunohistochemical and ELISA techniques, it was found that CsA administration causes a rapid activation of a disintegrin and metalloproteases-17 (ADAM-17), epidermal growth factor receptor (EGFR) and subsequent ERK1/2 phosphorylation in the liver and kidney of albino mice.	Cyclosporine	69-72	epidermal growth factor receptor	Mus musculus	166-198
32866465-3	2020	By using immunohistochemical and ELISA techniques, it was found that CsA administration causes a rapid activation of a disintegrin and metalloproteases-17 (ADAM-17), epidermal growth factor receptor (EGFR) and subsequent ERK1/2 phosphorylation in the liver and kidney of albino mice.	Cyclosporine	69-72	epidermal growth factor receptor	Mus musculus	200-204
32866465-4	2020	Furthermore, this study presents mechanistic relevance of this signaling cascade involving reactive oxygen species (ROS)-mediated ADAM-17/EGFR/ERK1/2 activation as indicated by a clear reduction in ADAM-17 and EGFR activities as well as ERK1/2 phosphorylation when the animals pretreated with Polyethylene glycol-superoxide dismutase (PEG-SOD) before CsA administration.	Cyclosporine	351-354	epidermal growth factor receptor	Mus musculus	138-142
32866465-5	2020	Collectively, our findings demonstrate that CsA has the ability to activate ADAM-17-mediated EGFR/ERK1/2 phosphorylation in the liver and kidney of albino mice in ROS-dependent manner.	Cyclosporine	44-47	epidermal growth factor receptor	Mus musculus	93-97
3123380-3	1987	In the present report, we examined the effect of corticosteroids and cyclosporine (CsA) on the expression of IL-2 receptors and Ia antigens by the T-cells, which constituted the major cellular component of the ocular infiltration during the period of peak ocular inflammatory activity in experimental autoimmune uveoretinitis (EAU).	Cyclosporine	69-81	interleukin 2	Rattus norvegicus	109-113
32939624-9	2020	Application of the cyclophilin inhibitor cyclosporine A suppressed gravitropic recovery, indicating that SlCyp1 must be active in the target tissue to affect the gravitropic response.	Cyclosporine	41-55	peptidyl-prolyl cis-trans isomerase	Solanum lycopersicum	19-30
3123380-3	1987	In the present report, we examined the effect of corticosteroids and cyclosporine (CsA) on the expression of IL-2 receptors and Ia antigens by the T-cells, which constituted the major cellular component of the ocular infiltration during the period of peak ocular inflammatory activity in experimental autoimmune uveoretinitis (EAU).	Cyclosporine	83-86	interleukin 2	Rattus norvegicus	109-113
32187393-10	2020	Interestingly, cyclosporine A (CsA), a CypD inhibitor, significantly reversed the drop in MMP and the DNA damage, as well as ROS accumulation caused by T-2.	Cyclosporine	15-29	acetyl-CoA acetyltransferase 1	Homo sapiens	152-155
3123380-6	1987	CsA treatment resulted not only in the inhibition of IL-2 receptors on T-cells, but also in the prevention of the induction of Ia antigen expression on T-cells and other non-lymphoid cells.	Cyclosporine	0-3	interleukin 2	Rattus norvegicus	53-57
32187393-10	2020	Interestingly, cyclosporine A (CsA), a CypD inhibitor, significantly reversed the drop in MMP and the DNA damage, as well as ROS accumulation caused by T-2.	Cyclosporine	31-34	acetyl-CoA acetyltransferase 1	Homo sapiens	152-155
2444832-7	1987	DIA and CSA were also separated on chromatofocusing chromatography, because isoelectric point of DIA was mainly less than 4.0 and that of CSA was 4.3-5.7.	Cyclosporine	8-11	LIF interleukin 6 family cytokine	Homo sapiens	97-100
32471743-7	2020	Luciferase reporter assay confirmed that ZEB2 was a direct downstream target regulated by miR-200a and ZEB2 was indeed increased after the administration of CsA.	Cyclosporine	157-160	zinc finger E-box binding homeobox 2	Homo sapiens	41-45
32471743-7	2020	Luciferase reporter assay confirmed that ZEB2 was a direct downstream target regulated by miR-200a and ZEB2 was indeed increased after the administration of CsA.	Cyclosporine	157-160	zinc finger E-box binding homeobox 2	Homo sapiens	103-107
32471743-8	2020	We demonstrated that knockdown of ZEB2 hampered the CsA-induced HGFs proliferation and the elevated cell proliferation due to inhibition of miR-200a was reversed by repression of ZEB2.	Cyclosporine	52-55	zinc finger E-box binding homeobox 2	Homo sapiens	34-38
32471743-9	2020	CONCLUSION: Our results showed that insufficient miR-200a in HGFs caused by CsA administration may lead to gingival enlargement mediated by the upregulation of ZEB2.	Cyclosporine	76-79	zinc finger E-box binding homeobox 2	Homo sapiens	160-164
3495054-1	1987	Cyclosporine (CsA) inhibits release of interleukin 2 (IL-2) and hemopoietic growth activities such as interleukin 3 (IL-3) from major histocompatibility complex (MHC)-antigen-activated T cells.	Cyclosporine	0-12	interleukin 3	Homo sapiens	102-121
3494043-5	1987	Bromocriptine plus low-dose cyclosporine led to more marked decreases in the incidence of EAU and anti-S-antigen antibody titers as well as in the lymphocyte proliferative assay (P less than 0.01 for males, P less than 0.0005 for females).	Cyclosporine	28-40	S-antigen visual arrestin	Rattus norvegicus	103-112
3274841-0	1987	Impact of HLA-DR and combined HLA-B and HLA-DR matching on early graft outcome under cyclosporine therapy.	Cyclosporine	85-97	major histocompatibility complex, class I, B	Homo sapiens	30-35
3079033-0	1987	Serum beta 2 microglobulin levels are relatively depressed in cyclosporine A-treated patients who undergo kidney graft rejection.	Cyclosporine	62-76	beta-2-microglobulin	Homo sapiens	6-26
3079156-0	1987	Effects of anti-IL 2 receptor monoclonal antibody and cyclosporine on IL 2 receptor-positive cells infiltrating cardiac allografts in the rat.	Cyclosporine	54-66	interleukin 2	Rattus norvegicus	70-74
3530428-13	1986	The effect of post-transplant immunosuppression, in our case cyclosporin A, on the interaction between normal and Ph1-positive hemopoietic cells, may deserve further attention.	Cyclosporine	61-74	alanine--glyoxylate and serine--pyruvate aminotransferase	Homo sapiens	114-117
3490494-4	1986	Purified native IL-1 and recombinant IL-1 stimulated endothelial cells to release CSA.	Cyclosporine	82-85	interleukin 1 alpha	Homo sapiens	16-20
3490494-4	1986	Purified native IL-1 and recombinant IL-1 stimulated endothelial cells to release CSA.	Cyclosporine	82-85	interleukin 1 alpha	Homo sapiens	37-41
3490494-7	1986	We conclude that IL-1 induces the release of CSA by vascular endothelial cells, that IL-1 is constitutively produced by monocytes in vitro, and that MRA and IL-1 are biologically, biophysically and, immunologically identical.	Cyclosporine	45-48	interleukin 1 alpha	Homo sapiens	17-21
3489759-3	1986	We show that activation of resting B cells by B cell-stimulatory factor-1 (BSF-1) is resistant to CS, whereas stimulation by anti-Ig antibodies is not, which is in agreement with earlier findings.	Cyclosporine	98-100	interleukin 4	Mus musculus	46-73
3489759-3	1986	We show that activation of resting B cells by B cell-stimulatory factor-1 (BSF-1) is resistant to CS, whereas stimulation by anti-Ig antibodies is not, which is in agreement with earlier findings.	Cyclosporine	98-100	interleukin 4	Mus musculus	75-80
3489759-5	1986	In contrast, the stimulation of large (presumably preactivated) B cells by B cell growth factor II to synthesize DNA or to secrete Ig is inhibited by low concentrations of CS.	Cyclosporine	172-174	interleukin 5	Mus musculus	75-98
3503117-3	1986	Daily subcutaneous injections of Cyclosporine (CsA) (20 mg/kg) from the day of immunization totally prevented the ocular disease, clinically and histologically, confirming earlier experiments in S-antigen induced experimental autoimmune uveoretinitis in rats.	Cyclosporine	33-45	S-antigen visual arrestin	Rattus norvegicus	195-204
3503117-3	1986	Daily subcutaneous injections of Cyclosporine (CsA) (20 mg/kg) from the day of immunization totally prevented the ocular disease, clinically and histologically, confirming earlier experiments in S-antigen induced experimental autoimmune uveoretinitis in rats.	Cyclosporine	47-50	S-antigen visual arrestin	Rattus norvegicus	195-204
3020748-1	1986	In 83 renal transplant recipients, serum beta 2 microglobulin (beta 2m) levels were significantly elevated during pretransplant uremia, rejection, cyclosporine-induced nephrotoxicity, and infections.	Cyclosporine	147-159	beta-2-microglobulin	Homo sapiens	41-61
3020748-1	1986	In 83 renal transplant recipients, serum beta 2 microglobulin (beta 2m) levels were significantly elevated during pretransplant uremia, rejection, cyclosporine-induced nephrotoxicity, and infections.	Cyclosporine	147-159	beta-2-microglobulin	Homo sapiens	63-70
3020748-4	1986	Patients with stable renal allograft function receiving cyclosporine showed significantly higher serum beta 2m (P less than 0.001) and serum creatinine (P less than 0.01) levels than azathioprine treated patients.	Cyclosporine	56-68	beta-2-microglobulin	Homo sapiens	103-110
2871955-7	1986	Urine levels of gamma-glutamyl transpeptidase (gamma GT) are also increased following CsA administration indicating an injurious effect on the brush border of the renal tubule.	Cyclosporine	86-89	gamma-glutamyltransferase 1	Rattus norvegicus	16-45
2871955-7	1986	Urine levels of gamma-glutamyl transpeptidase (gamma GT) are also increased following CsA administration indicating an injurious effect on the brush border of the renal tubule.	Cyclosporine	86-89	gamma-glutamyltransferase 1	Rattus norvegicus	47-55
3000211-1	1985	Cyclosporin (Cs) inhibits the elaboration of the lymphokine leukocyte migration inhibitory factor (LIF) from human blood mononuclear cells (MNC) stimulated with recall antigen.	Cyclosporine	0-11	LIF interleukin 6 family cytokine	Homo sapiens	99-102
32434054-5	2020	Cyclophilin A (CyPA), the most important immunophilin and endogenous ligand of cyclosporine A (CsA), is strongly involved in several detrimental cardiovascular processes, such as calcification.	Cyclosporine	79-93	peptidylprolyl isomerase A	Homo sapiens	0-13
32434054-5	2020	Cyclophilin A (CyPA), the most important immunophilin and endogenous ligand of cyclosporine A (CsA), is strongly involved in several detrimental cardiovascular processes, such as calcification.	Cyclosporine	79-93	peptidylprolyl isomerase A	Homo sapiens	15-19
32434054-5	2020	Cyclophilin A (CyPA), the most important immunophilin and endogenous ligand of cyclosporine A (CsA), is strongly involved in several detrimental cardiovascular processes, such as calcification.	Cyclosporine	95-98	peptidylprolyl isomerase A	Homo sapiens	0-13
32434054-5	2020	Cyclophilin A (CyPA), the most important immunophilin and endogenous ligand of cyclosporine A (CsA), is strongly involved in several detrimental cardiovascular processes, such as calcification.	Cyclosporine	95-98	peptidylprolyl isomerase A	Homo sapiens	15-19
31914237-3	2020	Our goal was to utilize a validated RT-qPCR assay in dogs to assess recovery time of the T-cell cytokines IL-2 and IFN-gamma after discontinuation of cyclosporine.	Cyclosporine	150-162	interferon gamma	Canis lupus familiaris	115-124
32692785-7	2020	We found that TBB (a casein kinase II inhibitor), AR and LiCl (GSK-3 inhibitors), cyclosporin A (calcineurin inhibitor), and Saracatinib (Fyn kinase inhibitor) caused robust inhibition of OA-induced monomeric and oligomeric p-tau in both N2a and CTX culture.	Cyclosporine	82-95	microtubule associated protein tau	Homo sapiens	226-229
32692785-9	2020	This study provides a comprehensive view of potential drug candidates (TBB, CsA, AR, and Saracatinib), and their efficacy against tau hyperphosphorylation and oligomerization processes.	Cyclosporine	76-79	microtubule associated protein tau	Homo sapiens	130-133
32708451-9	2020	We showed that the in-vitro inhibition of PPIA with ciclosporin A (CsA) resulted in downregulation of PPIA and fibronectin (FN1) expression and significantly reduced their secretion.	Cyclosporine	52-65	peptidylprolyl isomerase A	Homo sapiens	42-46
32708451-9	2020	We showed that the in-vitro inhibition of PPIA with ciclosporin A (CsA) resulted in downregulation of PPIA and fibronectin (FN1) expression and significantly reduced their secretion.	Cyclosporine	52-65	peptidylprolyl isomerase A	Homo sapiens	102-106
32708451-9	2020	We showed that the in-vitro inhibition of PPIA with ciclosporin A (CsA) resulted in downregulation of PPIA and fibronectin (FN1) expression and significantly reduced their secretion.	Cyclosporine	67-70	peptidylprolyl isomerase A	Homo sapiens	42-46
32708451-9	2020	We showed that the in-vitro inhibition of PPIA with ciclosporin A (CsA) resulted in downregulation of PPIA and fibronectin (FN1) expression and significantly reduced their secretion.	Cyclosporine	67-70	peptidylprolyl isomerase A	Homo sapiens	102-106
32052895-11	2020	CONCLUSIONS AND CLINICAL IMPORTANCE: Prednisone and cyclosporine both affected expression of IL-2 and IFN-gamma, suggesting that both have the ability to influence results when utilizing pharmacodynamic monitoring of cyclosporine treatment.	Cyclosporine	52-64	interferon gamma	Canis lupus familiaris	102-111
32052895-11	2020	CONCLUSIONS AND CLINICAL IMPORTANCE: Prednisone and cyclosporine both affected expression of IL-2 and IFN-gamma, suggesting that both have the ability to influence results when utilizing pharmacodynamic monitoring of cyclosporine treatment.	Cyclosporine	217-229	interferon gamma	Canis lupus familiaris	102-111
32116062-6	2020	Finally, the impact of PINK1 overexpression on the PQ or PQ + CsA-modulated fibronectin and collagen I expression in A549 cells was tested.Results: PQ exposure significantly increased the levels of hydroxyproline and collagen I expression and collagen fiber accumulation in the lung of rats, which were mitigated by CsA treatment.	Cyclosporine	62-65	fibronectin 1	Rattus norvegicus	76-87
32108853-2	2020	This study has demonstrated that iron in varying concentrations (up to 400 microM) causes an increase in alpha-synuclein content in SH-SY5Y cells associated with mitochondrial depolarization, decreased cellular ATP content and loss of cell viability during incubation up to 96 h. Knocking-down alpha-synuclein expression prevents cytotoxic actions of iron, which can also be prevented by cyclosporine A (a blocker of mitochondrial permeability transition pore).	Cyclosporine	388-402	synuclein alpha	Homo sapiens	105-120
32215175-7	2020	The protective effects of TRAP1 may be exerted via the inhibition of mitochondrial permeability transition pore (mPTP) opening, and the damage caused by TRAP1 knockdown can be partially reversed by treatment with the mPTP opening inhibitor cyclosporin A (CsA).	Cyclosporine	240-253	TNF receptor-associated protein 1	Rattus norvegicus	26-31
32215175-7	2020	The protective effects of TRAP1 may be exerted via the inhibition of mitochondrial permeability transition pore (mPTP) opening, and the damage caused by TRAP1 knockdown can be partially reversed by treatment with the mPTP opening inhibitor cyclosporin A (CsA).	Cyclosporine	240-253	TNF receptor-associated protein 1	Rattus norvegicus	153-158
32215175-7	2020	The protective effects of TRAP1 may be exerted via the inhibition of mitochondrial permeability transition pore (mPTP) opening, and the damage caused by TRAP1 knockdown can be partially reversed by treatment with the mPTP opening inhibitor cyclosporin A (CsA).	Cyclosporine	255-258	TNF receptor-associated protein 1	Rattus norvegicus	26-31
32215175-7	2020	The protective effects of TRAP1 may be exerted via the inhibition of mitochondrial permeability transition pore (mPTP) opening, and the damage caused by TRAP1 knockdown can be partially reversed by treatment with the mPTP opening inhibitor cyclosporin A (CsA).	Cyclosporine	255-258	TNF receptor-associated protein 1	Rattus norvegicus	153-158
3000211-1	1985	Cyclosporin (Cs) inhibits the elaboration of the lymphokine leukocyte migration inhibitory factor (LIF) from human blood mononuclear cells (MNC) stimulated with recall antigen.	Cyclosporine	13-15	LIF interleukin 6 family cytokine	Homo sapiens	99-102
3000211-5	1985	The results indicate that intracellular cyclic GMP is a major factor involved in the reversal of Cs-induced inhibition of LIF-production.	Cyclosporine	97-99	LIF interleukin 6 family cytokine	Homo sapiens	122-125
3901986-1	1985	The use of locally applied cyclosporine was investigated in the retinal S-antigen-induced experimental autoimmune uveitis (EAU) model in Lewis rats.	Cyclosporine	27-39	S-antigen visual arrestin	Rattus norvegicus	64-81
3896556-9	1985	Cyclosporin A completely suppressed the increase of T1 and T2 in group 2.	Cyclosporine	0-13	brachyury 2	Rattus norvegicus	52-61
3875495-4	1985	The patients" serum CSA titer for unfractionated bone marrow cells rose markedly with the addition of a small amount of diluted control rabbit serum (control serum) into the CSA assay system, while it did not rise with addition of the same amount of diluted rabbit antiserum against partially purified human urinary colony-stimulating factor (CSF) (antiserum).	Cyclosporine	20-23	colony stimulating factor 2	Homo sapiens	316-341
3875495-4	1985	The patients" serum CSA titer for unfractionated bone marrow cells rose markedly with the addition of a small amount of diluted control rabbit serum (control serum) into the CSA assay system, while it did not rise with addition of the same amount of diluted rabbit antiserum against partially purified human urinary colony-stimulating factor (CSF) (antiserum).	Cyclosporine	20-23	colony stimulating factor 2	Homo sapiens	343-346
2988760-8	1985	A simple, rapid assay for a new human CSA with pluripotent hematopoietic stimulating activity (pluripoietin) is described based on stimulation of [3H]glucosamine incorporation.	Cyclosporine	38-41	colony stimulating factor 3	Homo sapiens	95-107
31666189-6	2020	Meanwhile, the addition of hepcidin stimulated CD36-mediated Dil-labeled-ox-LDL uptake and inhibited the LXRalpha-ABCA1/G1 pathway-dependent cholesterol efflux in macrophages, which was significantly reversed by 27-hydroxycholesterol but further exacerbated by cyclosporin A, a selective inhibitor of CYP27A1.	Cyclosporine	261-274	hepcidin antimicrobial peptide	Homo sapiens	27-35
32321312-3	2020	In the co-culture, we found that CsA inhibited the expression of cyclophilin A (CyPA), CD147 and the activities of MMPs, which were all induced by P.g-LPS.	Cyclosporine	33-36	peptidylprolyl isomerase A	Homo sapiens	65-78
2991164-1	1985	The induction of ornithine decarboxylase (ODC) in the rat spleen and thymus in response to prolactin shows a dose-dependent sensitivity to cyclosporine (CsA), a known immunosuppressive drug.	Cyclosporine	139-151	ornithine decarboxylase 1	Rattus norvegicus	17-40
32321312-3	2020	In the co-culture, we found that CsA inhibited the expression of cyclophilin A (CyPA), CD147 and the activities of MMPs, which were all induced by P.g-LPS.	Cyclosporine	33-36	peptidylprolyl isomerase A	Homo sapiens	80-84
32321312-3	2020	In the co-culture, we found that CsA inhibited the expression of cyclophilin A (CyPA), CD147 and the activities of MMPs, which were all induced by P.g-LPS.	Cyclosporine	33-36	basigin (Ok blood group)	Homo sapiens	87-92
32321312-4	2020	We also found that P.g-LPS and recombinant human CyPA increased activation of ERK1/2 and IkappaB (an NF-kappaB inhibitory protein), but CsA and the anti-CD147 antibody significantly inhibited these effects.	Cyclosporine	136-139	peptidylprolyl isomerase A	Homo sapiens	49-53
2991164-1	1985	The induction of ornithine decarboxylase (ODC) in the rat spleen and thymus in response to prolactin shows a dose-dependent sensitivity to cyclosporine (CsA), a known immunosuppressive drug.	Cyclosporine	139-151	ornithine decarboxylase 1	Rattus norvegicus	42-45
32321312-5	2020	Taken together, CsA in the presence of P.g-LPS might suppress MMP activities by blocking the CyPA/CD147 interaction that results in the inhibition of ERK1/2 and NF-kappaB signaling by interfering with the phosphorylation of ERK1/2 and IkappaB.	Cyclosporine	16-19	peptidylprolyl isomerase A	Homo sapiens	93-97
32321312-5	2020	Taken together, CsA in the presence of P.g-LPS might suppress MMP activities by blocking the CyPA/CD147 interaction that results in the inhibition of ERK1/2 and NF-kappaB signaling by interfering with the phosphorylation of ERK1/2 and IkappaB.	Cyclosporine	16-19	basigin (Ok blood group)	Homo sapiens	98-103
2991164-1	1985	The induction of ornithine decarboxylase (ODC) in the rat spleen and thymus in response to prolactin shows a dose-dependent sensitivity to cyclosporine (CsA), a known immunosuppressive drug.	Cyclosporine	153-156	ornithine decarboxylase 1	Rattus norvegicus	17-40
2991164-1	1985	The induction of ornithine decarboxylase (ODC) in the rat spleen and thymus in response to prolactin shows a dose-dependent sensitivity to cyclosporine (CsA), a known immunosuppressive drug.	Cyclosporine	153-156	ornithine decarboxylase 1	Rattus norvegicus	42-45
2991164-2	1985	Marked inhibition of prolactin-stimulated ODC activity occurred at 0.12 mg CsA/kg body weight, and nearly total inhibition was detected at 1.2 mg CsA/kg, a dose comparable to that used to suppress organ rejection processes.	Cyclosporine	75-78	ornithine decarboxylase 1	Rattus norvegicus	42-45
2991164-3	1985	CsA blocked ODC induction in response to prolactin injection in both intact and hypophysectomized rats, suggestive of a direct effect of prolactin on spleen and thymus.	Cyclosporine	0-3	ornithine decarboxylase 1	Rattus norvegicus	12-15
3873657-5	1985	Adding various inhibitors of lymphocyte proliferation to PHA-stimulated cultures revealed that cyclosporin A, dexamethasone, and OKT11A antibody (anti-sheep erythrocyte receptor) diminished levels of c-myc mRNA measured at 3 hr and 24 hr, whereas anti-Tac (anti-IL-2-receptor) inhibited at 24 hr but not at 3 hr.	Cyclosporine	95-108	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	200-205
3873733-8	1985	We conclude that CsA-induced inhibition of T cell functions (proliferation and IL-2 production) is partially due to the effect of the drug on the accessory function of macrophages.	Cyclosporine	17-20	interleukin 2	Mus musculus	79-83
3876299-4	1985	The resistance to CsA of the mitogenic activity of IL-1 was unexpected since this response is assumed to be mediated by newly formed IL-2 and CsA inhibits IL-2 production.	Cyclosporine	18-21	interleukin 2	Mus musculus	133-137
3876299-4	1985	The resistance to CsA of the mitogenic activity of IL-1 was unexpected since this response is assumed to be mediated by newly formed IL-2 and CsA inhibits IL-2 production.	Cyclosporine	142-145	interleukin 2	Mus musculus	155-159
3871429-1	1985	The effective inhibition of S-antigen (S-Ag) induced experimental autoimmune uveitis (EAU) by Cyclosporine (CsA) suggests strongly the important role of T-cells in the modulation of this disease.	Cyclosporine	94-106	S-antigen visual arrestin	Rattus norvegicus	28-37
3871429-1	1985	The effective inhibition of S-antigen (S-Ag) induced experimental autoimmune uveitis (EAU) by Cyclosporine (CsA) suggests strongly the important role of T-cells in the modulation of this disease.	Cyclosporine	94-106	S-antigen visual arrestin	Rattus norvegicus	39-43
3871429-1	1985	The effective inhibition of S-antigen (S-Ag) induced experimental autoimmune uveitis (EAU) by Cyclosporine (CsA) suggests strongly the important role of T-cells in the modulation of this disease.	Cyclosporine	108-111	S-antigen visual arrestin	Rattus norvegicus	28-37
3871429-1	1985	The effective inhibition of S-antigen (S-Ag) induced experimental autoimmune uveitis (EAU) by Cyclosporine (CsA) suggests strongly the important role of T-cells in the modulation of this disease.	Cyclosporine	108-111	S-antigen visual arrestin	Rattus norvegicus	39-43
3871429-5	1985	Lymphocyte preparations from lymph nodes draining the site of S-Ag immunization from CsA-treated animals demonstrated a different T-cell subset profile than did controls.	Cyclosporine	85-88	S-antigen visual arrestin	Rattus norvegicus	62-66
3871429-8	1985	These data suggest that CsA appears to prevent the development of inducer cells in the lymph nodes draining the S-Ag immunization site, the T-cell subgroup the authors have seen capable of inducing EAU.	Cyclosporine	24-27	S-antigen visual arrestin	Rattus norvegicus	112-116
3887372-0	1985	Monitoring of NK-1 and NK-15 subsets and natural killer activity in kidney transplant recipients receiving cyclosporine.	Cyclosporine	107-119	tachykinin receptor 1	Homo sapiens	14-18
3890320-5	1985	Thus, beta 2-microglobulin might be a sensitive indicator of nephrotoxicity and of value for the evaluation of the long-term side effects of Cyclosporin A particularly in patients with extrarenal disease.	Cyclosporine	141-154	beta-2-microglobulin	Homo sapiens	6-26
6442537-4	1984	Incubation of Con-A-activated lymphocytes with the immunosuppressive agent CS-A caused an additional increase in calcium uptake, whereas no change in calcium uptake was observed when resting lymphocytes or B-cells activated by LPS were incubated with cyclosporin.	Cyclosporine	251-262	heat shock protein 9	Mus musculus	75-79
6220075-6	1983	Inhibition of interleukin 2 (IL 2) generation by cyclosporin A, such that the antibody response of normal spleen cells is entirely abrogated, has minimal effects on the T cell-replacing activity of 8MGuo.	Cyclosporine	49-62	interleukin 2	Mus musculus	14-27
6220075-6	1983	Inhibition of interleukin 2 (IL 2) generation by cyclosporin A, such that the antibody response of normal spleen cells is entirely abrogated, has minimal effects on the T cell-replacing activity of 8MGuo.	Cyclosporine	49-62	interleukin 2	Mus musculus	29-33
6762338-2	1982	The mechanism of action of the immunosuppressive drug, cyclosporin A (CyA), was analyzed with respect to antigen-induced production of the human lymphokine, leukocyte migration inhibitory factor (LIF).	Cyclosporine	55-68	LIF interleukin 6 family cytokine	Homo sapiens	157-194
31830614-4	2020	Furthermore, the encapsulated CsA was biologically active, as shown in vitro on mouse splenocytes, reflected by inhibition of both cell proliferation and of interleukin (IL)-2 secretion.	Cyclosporine	30-33	interleukin 2	Mus musculus	157-175
32055439-4	2020	We report a patient with anti-MDA5 Ab-positive RP-ILD who was refractory to intensive therapies including steroids, cyclosporine, and intravenous cyclophosphamide, and then treated by PE to prevent the progression of RP-ILD.	Cyclosporine	116-128	interferon induced with helicase C domain 1	Homo sapiens	30-34
31993137-10	2020	This finding suggests that CSA019598 may play a prominent role in regulating ADH.	Cyclosporine	27-36	alcohol dehydrogenase 1A (class I), alpha polypeptide	Homo sapiens	77-80
30587068-9	2019	MDR1 overexpression increased the resistance of LLC-PK1 cells to tacrolimus, cyclosporine A, sirolimus and everolimus.	Cyclosporine	77-91	ATP-binding cassette, sub-family B (MDR/TAP), member 1	Sus scrofa	0-4
31666122-12	2019	The actions of LMCD1 were dependent on calcineurin, as its inhibition using cyclosporine A reverted the observed hypertrophic phenotype.	Cyclosporine	76-90	LIM and cysteine-rich domains 1	Mus musculus	15-20
31344002-0	2019	Treatment With Cyclosporine A for Statin-Naive Anti-HMGCR Antibody-Associated Necrotizing Myopathy.	Cyclosporine	15-29	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	52-57
31340913-0	2019	[Role of TGF-beta1/ILK/FSP1 signaling pathway in cyclosporin A-induced epithelialmesenchymal transition in cultured renal tubular epithelial cells].	Cyclosporine	49-62	integrin-linked kinase	Rattus norvegicus	19-22
31340913-1	2019	OBJECTIVE: To explore the role of transforming growth factor-beta1/integrin-linked kinase/fibroblast-specific protein 1 (TGF- beta1/ILK/FSP1) signaling pathway in cyclosporine A (CsA)-induced renal tubular epithelial cell transdifferentiation.	Cyclosporine	163-177	integrin-linked kinase	Rattus norvegicus	132-135
31340913-1	2019	OBJECTIVE: To explore the role of transforming growth factor-beta1/integrin-linked kinase/fibroblast-specific protein 1 (TGF- beta1/ILK/FSP1) signaling pathway in cyclosporine A (CsA)-induced renal tubular epithelial cell transdifferentiation.	Cyclosporine	179-182	integrin-linked kinase	Rattus norvegicus	132-135
31340913-5	2019	RESULTS: Compared with the blank control cells, the cells treated with CsA showed significantly increased levels of TGF-beta1, ILK and FSP-1 mRNAs and proteins (P &amp;lt; 0.05).	Cyclosporine	71-74	integrin-linked kinase	Rattus norvegicus	127-130
31340913-9	2019	CONCLUSIONS: The activation of TGF-beta1/ILK/FSP-1 signaling pathway is an important mechanism for CsA-induced transdifferentiation in rat renal tubular epithelial cells.	Cyclosporine	99-102	integrin-linked kinase	Rattus norvegicus	41-44
31340913-10	2019	ILK participates in CsA-induced epithelialmesenchymal transition of renal tubular epithelial cells.	Cyclosporine	20-23	integrin-linked kinase	Rattus norvegicus	0-3
6762338-2	1982	The mechanism of action of the immunosuppressive drug, cyclosporin A (CyA), was analyzed with respect to antigen-induced production of the human lymphokine, leukocyte migration inhibitory factor (LIF).	Cyclosporine	55-68	LIF interleukin 6 family cytokine	Homo sapiens	196-199
6762338-2	1982	The mechanism of action of the immunosuppressive drug, cyclosporin A (CyA), was analyzed with respect to antigen-induced production of the human lymphokine, leukocyte migration inhibitory factor (LIF).	Cyclosporine	70-73	LIF interleukin 6 family cytokine	Homo sapiens	157-194
6762338-2	1982	The mechanism of action of the immunosuppressive drug, cyclosporin A (CyA), was analyzed with respect to antigen-induced production of the human lymphokine, leukocyte migration inhibitory factor (LIF).	Cyclosporine	70-73	LIF interleukin 6 family cytokine	Homo sapiens	196-199
6459373-7	1982	Cyclosporin A rendered Con A-treated T cells unresponsive to IL 2, made lectin-stimulated OKT4+ lymphocytes unable to respond to IL 1, and inhibited the synthesis of IL 2.	Cyclosporine	0-13	interleukin 2	Mus musculus	166-170
6456149-0	1981	Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2.	Cyclosporine	0-13	interleukin 1 alpha	Homo sapiens	107-120
7204576-2	1981	Cyclosporin A (CS-A), a selective inhibitor of T lymphocytes, is reported here to prevent S antigen (S-Ag) induced uveitis in Lewis rats.	Cyclosporine	0-13	S-antigen visual arrestin	Rattus norvegicus	90-99
30725434-7	2019	CsA significantly decreased the Bax/Bcl-2 ratio, cl-casp-9/casp-9, and cl-casp-3/casp-3 in a concentration-dependent manner.	Cyclosporine	0-3	BCL2 associated X, apoptosis regulator	Rattus norvegicus	32-35
31156436-7	2019	Pharmacokinetic evaluation of CsA was carried out using non-compartmental analysis (NCA) and population pharmacokinetics (popPK).	Cyclosporine	30-33	CEA cell adhesion molecule 6	Homo sapiens	84-87
7204576-2	1981	Cyclosporin A (CS-A), a selective inhibitor of T lymphocytes, is reported here to prevent S antigen (S-Ag) induced uveitis in Lewis rats.	Cyclosporine	0-13	S-antigen visual arrestin	Rattus norvegicus	101-105
7006707-10	1981	Recent results have shown that a major defect of the athymic nude mouse is the inability to produce TCGF and that some immunosuppressive agents, such as glucocorticosteroids and cyclosporin-A, exert their effects on T cells by disrupting the TCGF-T-cell interaction.	Cyclosporine	178-191	interleukin 2	Mus musculus	100-104
30925820-6	2019	In addition, the intestinal permeability of CAPB was also enhanced by ketoconazole and cyclosporine A.	Cyclosporine	87-101	EPH receptor B2	Homo sapiens	44-48
30913036-2	2019	The aim of this study was to determine the possible role of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) on extra-cellular matrix (ECM) homeostasis when treated with different levels of CsA and its difference between fetal and adult human gingival fibroblasts (HGFs).	Cyclosporine	212-215	matrix metallopeptidase 1	Homo sapiens	118-122
30913036-6	2019	Results MMP-1 level increased with the treatment of CsA when treated with 50 and 150 ng/mL of CsA (p = 0.02 and p = 0.04) as TIMP-1 decreased (p < 0.0001) in adult group; while in the fetal group, TIMP-1 level increased with treatment of 150 ng/mL (p < 0.0001).	Cyclosporine	52-55	matrix metallopeptidase 1	Homo sapiens	8-13
30913036-6	2019	Results MMP-1 level increased with the treatment of CsA when treated with 50 and 150 ng/mL of CsA (p = 0.02 and p = 0.04) as TIMP-1 decreased (p < 0.0001) in adult group; while in the fetal group, TIMP-1 level increased with treatment of 150 ng/mL (p < 0.0001).	Cyclosporine	94-97	matrix metallopeptidase 1	Homo sapiens	8-13
30913036-10	2019	The study showed that CsA affects secretion of MMPs and TIMPs.	Cyclosporine	22-25	matrix metallopeptidase 1	Homo sapiens	47-51
30648591-11	2019	KBrO3 increased the protein levels of these signals and the specific inhibitor, such as cyclosporine A and tacrolimus, attenuated the signaling in H9c2 cells at concentrations sufficient to inhibit calcineurin in addition to the reduction of mRNA levels of UBE3A, similar to ANP or BNP.	Cyclosporine	88-102	ubiquitin protein ligase E3A	Rattus norvegicus	257-262
30391882-0	2018	Vitamin E inhibits cyclosporin A-induced CTGF and TIMP-1 expression by repressing ROS-mediated activation of TGF-beta/Smad signaling pathway in rat liver.	Cyclosporine	19-32	cellular communication network factor 2	Rattus norvegicus	41-45
7006707-10	1981	Recent results have shown that a major defect of the athymic nude mouse is the inability to produce TCGF and that some immunosuppressive agents, such as glucocorticosteroids and cyclosporin-A, exert their effects on T cells by disrupting the TCGF-T-cell interaction.	Cyclosporine	178-191	interleukin 2	Mus musculus	242-246
7471514-7	1980	In contrast, there was a highly significant correlation between levels of CSA and C3d.	Cyclosporine	74-77	endogenous retrovirus group K member 13	Homo sapiens	82-85
6447256-1	1980	Cyclosporin A (CS-A) is an unusual endecapeptide isolated from the fungi Cylindrocarpon lucidum Booth and Trichoderma polysporum.	Cyclosporine	0-13	heat shock protein 9	Mus musculus	15-19
33548873-9	2021	Interestingly, not only cyclosporin, but also leuprorelin and cetrorelix showed metabolites whose formation was CYP (NADPH) dependent in liver S9.	Cyclosporine	24-35	peptidylprolyl isomerase G	Homo sapiens	112-115
29932236-7	2018	In vivo, EPO-BMSCs showed higher ability to improve renal function than BMSCs, and in CsA-induced rats treated with EPO-BMSCs, interstitial lymphocyte infiltration, tubular swelling, necrosis, and interstitial fibrosis decreased.	Cyclosporine	86-89	erythropoietin	Rattus norvegicus	9-12
29932236-7	2018	In vivo, EPO-BMSCs showed higher ability to improve renal function than BMSCs, and in CsA-induced rats treated with EPO-BMSCs, interstitial lymphocyte infiltration, tubular swelling, necrosis, and interstitial fibrosis decreased.	Cyclosporine	86-89	erythropoietin	Rattus norvegicus	116-119
29932236-8	2018	We demonstrated that pretreatment with 500 IU/mL EPO before infusion markedly increased the homing ability of BMSCs, and obviously ameliorate CsA-induced nephrotoxicity in rats.	Cyclosporine	142-145	erythropoietin	Rattus norvegicus	49-52
29863267-10	2018	The detection of apoptosis factors via Real-time PCR revealed that after the induction of CsA, the expressions of Fas, FasL and Bax mRNA in cells were significantly higher than those in control group, but were significantly decreased after administration of CST.	Cyclosporine	90-93	BCL2 associated X, apoptosis regulator	Rattus norvegicus	128-131
29359498-5	2018	Compared with the HC group, the mTBI group at TP2 showed lower CSA within several areas.	Cyclosporine	63-66	transition protein 2	Homo sapiens	46-49
29255993-6	2018	Up to 1% of the patients was exposed to a contraindicated drug-drug interaction, the most frequent drug-drug interaction involving influx-transporter (i.e., OATP1B1) interactions between simvastatin or rosuvastatin with cyclosporin.	Cyclosporine	220-231	solute carrier organic anion transporter family member 1B1	Homo sapiens	157-164
29393366-8	2018	In addition, D-pinitol increased the level of sirtuin 1 (Sirt1), and the total and nuclear expression levels of nuclear erythroid factor 2-related factor 2 (Nrf2), suggesting that activation of the Sirt1 and Nrf2 pathways may induce the cellular antioxidant system against CsA-induced nephropathy.	Cyclosporine	273-276	sirtuin 1	Mus musculus	198-203
29411011-13	2018	CsA also reduced the H2O2-induced NFATc3 dephosphorylation (and nuclear translocation), and also suppressed the H2O2-induced elevation in profibrotic ECM genes (TGFbeta1, Col1A1, and periostin), both in normal and in glaucoma LC cells.	Cyclosporine	0-3	periostin	Homo sapiens	183-192
33829060-8	2021	Receiver operating characteristic curve analysis showed that CSA at the MN7 level had the highest diagnostic accuracy for DPN in group B, with a threshold value of 12.42 mm2.	Cyclosporine	61-64	HERC2 pseudogene 2	Homo sapiens	72-75
33528601-6	2021	The P-gp inhibitors, Valspodar (Val) and cyclosporin (CsA), as positive compounds, were detected to characterize the chip"s activity, and the KD of Val and CsA were 14.09 muM and 16.41 muM, respectively.	Cyclosporine	41-52	phosphoglycolate phosphatase	Homo sapiens	4-8
29224938-6	2018	In analyses adjusted for sex, age, and height, the cIMT was higher in subjects transplanted for chronic/cirrhotic liver disease and lower in subjects on cyclosporine (n = 9) than tacrolimus (n = 71).	Cyclosporine	153-165	CIMT	Homo sapiens	51-55
33528601-6	2021	The P-gp inhibitors, Valspodar (Val) and cyclosporin (CsA), as positive compounds, were detected to characterize the chip"s activity, and the KD of Val and CsA were 14.09 muM and 16.41 muM, respectively.	Cyclosporine	156-159	phosphoglycolate phosphatase	Homo sapiens	4-8
33529962-7	2021	Studies investigating the mechanism demonstrated that CSA induced oxidative stress via causing glutathione reduction and NOS activation by negatively regulating glutaminase (GLS), which proved to be highly dependent on IDH mutant type glioblastoma.	Cyclosporine	54-57	glutaminase	Homo sapiens	161-172
29423002-12	2018	NDUFA4 interfere inhibits antagonistic effect of ciclosporin A on apoptosis and decrease up-regulative effect of ciclosporin A on neuron growth.	Cyclosporine	49-62	NDUFA4 mitochondrial complex associated	Homo sapiens	0-6
29423002-12	2018	NDUFA4 interfere inhibits antagonistic effect of ciclosporin A on apoptosis and decrease up-regulative effect of ciclosporin A on neuron growth.	Cyclosporine	113-126	NDUFA4 mitochondrial complex associated	Homo sapiens	0-6
29423002-13	2018	NDUFA4 over-expression enhances antagonistic effect of ciclosporin A on apoptosis and increases up-regulative effect of ciclosporin A on neuron growth.	Cyclosporine	55-68	NDUFA4 mitochondrial complex associated	Homo sapiens	0-6
29423002-13	2018	NDUFA4 over-expression enhances antagonistic effect of ciclosporin A on apoptosis and increases up-regulative effect of ciclosporin A on neuron growth.	Cyclosporine	120-133	NDUFA4 mitochondrial complex associated	Homo sapiens	0-6
33529962-7	2021	Studies investigating the mechanism demonstrated that CSA induced oxidative stress via causing glutathione reduction and NOS activation by negatively regulating glutaminase (GLS), which proved to be highly dependent on IDH mutant type glioblastoma.	Cyclosporine	54-57	glutaminase	Homo sapiens	174-177
29423002-15	2018	Meanwhile, NDUFA4 regulates the antagonistic effect of ciclosporin A on apoptosis and the up-regulative effect of ciclosporin A on neuron growth.	Cyclosporine	55-68	NDUFA4 mitochondrial complex associated	Homo sapiens	11-17
29423002-15	2018	Meanwhile, NDUFA4 regulates the antagonistic effect of ciclosporin A on apoptosis and the up-regulative effect of ciclosporin A on neuron growth.	Cyclosporine	114-127	NDUFA4 mitochondrial complex associated	Homo sapiens	11-17
33529962-7	2021	Studies investigating the mechanism demonstrated that CSA induced oxidative stress via causing glutathione reduction and NOS activation by negatively regulating glutaminase (GLS), which proved to be highly dependent on IDH mutant type glioblastoma.	Cyclosporine	54-57	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	219-222
33529962-8	2021	Finally, GLS overexpression reversed the CSA-induced anti-glioma effects in vitro and in vivo, which indicated that the reduction of GLS contributed to the CSA-induced proliferation inhibition and apoptosis in HOG-IDH1-mu cells.	Cyclosporine	41-44	glutaminase	Homo sapiens	9-12
33529962-8	2021	Finally, GLS overexpression reversed the CSA-induced anti-glioma effects in vitro and in vivo, which indicated that the reduction of GLS contributed to the CSA-induced proliferation inhibition and apoptosis in HOG-IDH1-mu cells.	Cyclosporine	41-44	glutaminase	Homo sapiens	133-136
33529962-8	2021	Finally, GLS overexpression reversed the CSA-induced anti-glioma effects in vitro and in vivo, which indicated that the reduction of GLS contributed to the CSA-induced proliferation inhibition and apoptosis in HOG-IDH1-mu cells.	Cyclosporine	156-159	glutaminase	Homo sapiens	9-12
33529962-8	2021	Finally, GLS overexpression reversed the CSA-induced anti-glioma effects in vitro and in vivo, which indicated that the reduction of GLS contributed to the CSA-induced proliferation inhibition and apoptosis in HOG-IDH1-mu cells.	Cyclosporine	156-159	glutaminase	Homo sapiens	133-136
28887287-7	2017	Uptake of simvastatin acid was significantly increased by known (benzylpenicillin and estrone-3-sulfate) and potential (indoxyl sulfate and cyclosporine) substrates of OATP3A1.	Cyclosporine	140-152	solute carrier organic anion transporter family member 3A1	Homo sapiens	168-175
32810615-2	2021	As a substrate of cytochrome P450 3A enzyme (CYP3A) and P-glycoprotein (P-gp), the oral pharmacokinetics of CsA is susceptible to disease status and concomitant medications.	Cyclosporine	108-111	phosphoglycolate phosphatase	Homo sapiens	72-76
32810615-15	2021	CONCLUSIONS: DSS-induced colitis significantly altered oral CsA disposition through regulating intestinal and hepatic P-gp and CYP3A.	Cyclosporine	60-63	phosphoglycolate phosphatase	Homo sapiens	118-122
33530839-13	2021	Interestingly, NAC+CsA treatment improved histological alterations, cytochrome c, and 3-nitrotyrosine immunoreactivities and liver GSH, serum AST/ALT levels caused by APAP.	Cyclosporine	19-22	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	142-145
28633807-0	2017	Differential induction of ATF3 and HO-1 in myeloid cells and keratinocytes via Dimethylfumarate or Cyclosporine A.	Cyclosporine	99-113	activating transcription factor 3	Homo sapiens	26-30
28633807-0	2017	Differential induction of ATF3 and HO-1 in myeloid cells and keratinocytes via Dimethylfumarate or Cyclosporine A.	Cyclosporine	99-113	heme oxygenase 1	Homo sapiens	35-39
28633807-9	2017	RESULTS: In the present study, we could show that ATF3 is induced in PBMCs by DMF and weakly by Ebselen, while CsA is the most prominent inducer of ATF3 in keratinocytes without enhancing HO-1 transcription.	Cyclosporine	111-114	activating transcription factor 3	Homo sapiens	148-152
28633807-13	2017	CONCLUSIONS: Taken together, our results shed light into the different carcinogenic potential of CsA and DMF, which both target ATF3.	Cyclosporine	97-100	activating transcription factor 3	Homo sapiens	128-132
28633807-14	2017	Collectively our data demonstrate that CsA strongly induces pro-carcinogenic ATF3 in keratinocytes, whereas ATF3 induction by DMF in myeloid cells acts anti-inflammatory.	Cyclosporine	39-42	activating transcription factor 3	Homo sapiens	77-81
33530839-13	2021	Interestingly, NAC+CsA treatment improved histological alterations, cytochrome c, and 3-nitrotyrosine immunoreactivities and liver GSH, serum AST/ALT levels caused by APAP.	Cyclosporine	19-22	glutamic pyruvic transaminase, soluble	Mus musculus	146-149
32925004-9	2021	This case showed cyclosporine-A (CSA) had a positive effect on ADAMTS13 activity.	Cyclosporine	17-31	ADAM metallopeptidase with thrombospondin type 1 motif 13	Homo sapiens	63-71
28479356-5	2017	The time profiles of RPG and the inhibitors were analyzed by PBPK models, considering the inhibition of OATP1B1 and CYP3A4 by CsA or OATP1B1 inhibition by GEM and its glucuronide and the mechanism-based inhibition of CYP2C8 by GEM glucuronide.	Cyclosporine	126-129	solute carrier organic anion transporter family member 1B1	Homo sapiens	104-111
28479356-6	2017	RPG-CsA interaction was closely predicted using a reported in vitro Ki,OATP1B1 value in the presence of CsA preincubation.	Cyclosporine	4-7	solute carrier organic anion transporter family member 1B1	Homo sapiens	71-78
32925004-9	2021	This case showed cyclosporine-A (CSA) had a positive effect on ADAMTS13 activity.	Cyclosporine	33-36	ADAM metallopeptidase with thrombospondin type 1 motif 13	Homo sapiens	63-71
32918834-10	2021	CSA was lower in SMA 3 (p<0.0001), SMA 3a (p<0.0001), and SMA 3b (p=0.0006) than in controls, but did not correlate with clinical scores or electrophysiologic results.	Cyclosporine	0-3	GUSB pseudogene 14	Homo sapiens	17-22
27557477-5	2017	Efflux transport of rebamipide was inhibited by cyclosporine A, a P-gp inhibitor, and probenecid, which is a general MRP inhibitor, but not by Ko143, a BCRP inhibitor.	Cyclosporine	48-62	phosphoglycolate phosphatase	Homo sapiens	66-70
32907979-7	2020	Cyclosporin A treatment, mutating the CYPA-binding loop in the capsid or CYPA-knockout eliminated SIVcpzPts" resistance to PF74 in HeLa cells.	Cyclosporine	0-13	peptidylprolyl isomerase A	Homo sapiens	38-42
27557477-5	2017	Efflux transport of rebamipide was inhibited by cyclosporine A, a P-gp inhibitor, and probenecid, which is a general MRP inhibitor, but not by Ko143, a BCRP inhibitor.	Cyclosporine	48-62	MARCKS like 1	Homo sapiens	117-120
32090669-0	2020	PPAR gamma/TLR4/TGF-beta1 axis mediates the protection effect of erythropoietin on cyclosporin A-induced chronic nephropathy in rat.	Cyclosporine	83-96	erythropoietin	Rattus norvegicus	65-79
28663197-6	2017	Treatment of neurons with the calcineurin inhibitors FK506 or cyclosporin A resulted in nuclear accumulation of phospho-HDAC1 and was neuroprotective.	Cyclosporine	62-75	histone deacetylase 1	Mus musculus	120-125
32090669-2	2020	The present study investigates the improving effect of erythropoietin (EPO) on cyclosporine A induce renal injury in rats and further explores its possible mechanism.Methods: Recombinant adenovirus for expression of EPO was constructed and injected into kidney with multipoint.	Cyclosporine	79-93	erythropoietin	Rattus norvegicus	55-69
32090669-2	2020	The present study investigates the improving effect of erythropoietin (EPO) on cyclosporine A induce renal injury in rats and further explores its possible mechanism.Methods: Recombinant adenovirus for expression of EPO was constructed and injected into kidney with multipoint.	Cyclosporine	79-93	erythropoietin	Rattus norvegicus	71-74
32843478-5	2020	These effects of CsA involve at least two of the stress-activated protein kinases (GCN2 and PERK) that act on the translational machinery to slow down protein synthesis via phosphorylation of the eukaryotic initiation factor (eIF) 2alpha and thereby induce the ISR.	Cyclosporine	17-20	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	92-96
28824190-3	2017	After the test for anti-melanoma differentiation-associated gene 5 (MDA5) antibody came out positive, we doubled the cyclosporine dose and her condition improved.	Cyclosporine	117-129	interferon induced with helicase C domain 1	Homo sapiens	68-72
28473245-19	2017	Co-administration of Phela 15mg/kg/day orally for 21 days with CsA led to stoppage and reversal of the immunosppressive effects of CsA that were exhibited as increased IL-2, IL-10, CD4 and CD8 counts, implying that Phela stimulates the cell mediate immunity (CMI).	Cyclosporine	63-66	interleukin 2	Rattus norvegicus	168-172
28473245-19	2017	Co-administration of Phela 15mg/kg/day orally for 21 days with CsA led to stoppage and reversal of the immunosppressive effects of CsA that were exhibited as increased IL-2, IL-10, CD4 and CD8 counts, implying that Phela stimulates the cell mediate immunity (CMI).	Cyclosporine	63-66	interleukin 10	Rattus norvegicus	174-179
28473245-19	2017	Co-administration of Phela 15mg/kg/day orally for 21 days with CsA led to stoppage and reversal of the immunosppressive effects of CsA that were exhibited as increased IL-2, IL-10, CD4 and CD8 counts, implying that Phela stimulates the cell mediate immunity (CMI).	Cyclosporine	131-134	interleukin 2	Rattus norvegicus	168-172
33121398-2	2021	CypA, the intracellular target protein for the immunosuppressant cyclosporine A (CsA), plays important cellular roles through peptidyl-prolyl cis-trans isomerase (PPIase).	Cyclosporine	65-79	peptidylprolyl isomerase A	Homo sapiens	0-4
28947964-9	2017	In particular, GAG could reverse a decline in CD4+FoxP3+ Tregs resulted from CsA treatments.	Cyclosporine	77-80	forkhead box P3	Mus musculus	50-55
33121398-2	2021	CypA, the intracellular target protein for the immunosuppressant cyclosporine A (CsA), plays important cellular roles through peptidyl-prolyl cis-trans isomerase (PPIase).	Cyclosporine	81-84	peptidylprolyl isomerase A	Homo sapiens	0-4
32987693-3	2020	Cyclosporine A (CsA) is an inhibitor of OATPs, P-gp, MRP2, BCRP and CYP3As.	Cyclosporine	0-14	phosphoglycolate phosphatase	Homo sapiens	47-51
28432342-4	2017	DCs incubated with cyclosporin a (CsA) or dexamethasone (DEX) showed a lower methylation and higher mRNA expression of IRF8 in active VKH patients.	Cyclosporine	19-32	interferon regulatory factor 8	Homo sapiens	119-123
28432342-4	2017	DCs incubated with cyclosporin a (CsA) or dexamethasone (DEX) showed a lower methylation and higher mRNA expression of IRF8 in active VKH patients.	Cyclosporine	34-37	interferon regulatory factor 8	Homo sapiens	119-123
32987693-3	2020	Cyclosporine A (CsA) is an inhibitor of OATPs, P-gp, MRP2, BCRP and CYP3As.	Cyclosporine	0-14	BCR pseudogene 1	Homo sapiens	59-63
32987693-3	2020	Cyclosporine A (CsA) is an inhibitor of OATPs, P-gp, MRP2, BCRP and CYP3As.	Cyclosporine	16-19	phosphoglycolate phosphatase	Homo sapiens	47-51
32987693-3	2020	Cyclosporine A (CsA) is an inhibitor of OATPs, P-gp, MRP2, BCRP and CYP3As.	Cyclosporine	16-19	BCR pseudogene 1	Homo sapiens	59-63
32894076-12	2020	CONCLUSION: The daily dose of cyclosporine and SNPs of IL-7R (rs1494558) and MBL2 (rs2232365) genes are significantly associated with the development of NODAT in the Malaysian renal transplant population.	Cyclosporine	30-42	mannose binding lectin 2	Homo sapiens	77-81
32595898-6	2020	Results: CsA was found to upregulate Oct4 transcript in a dose-dependent manner (p < 0.05).	Cyclosporine	9-12	POU class 5 homeobox 1	Homo sapiens	37-41
32595898-7	2020	CsA also dose-dependently increased Oct4 protein expression (p < 0.05).	Cyclosporine	0-3	POU class 5 homeobox 1	Homo sapiens	36-40
32595898-8	2020	The lentivirus expressing sh-Oct4 successfully prevented the CsA-induced Oct4 mRNA and protein in HGFs (p < 0.05).	Cyclosporine	61-64	POU class 5 homeobox 1	Homo sapiens	29-33
32595898-8	2020	The lentivirus expressing sh-Oct4 successfully prevented the CsA-induced Oct4 mRNA and protein in HGFs (p < 0.05).	Cyclosporine	61-64	POU class 5 homeobox 1	Homo sapiens	73-77
32595898-10	2020	Furthermore, double knockdown with pluripotency-associated transcription factor Nanog showed that the down-regulation of Oct4/Nanog by lentiviral infection significantly inhibited CsA-stimulated cell growth (p < 0.05).	Cyclosporine	180-183	POU class 5 homeobox 1	Homo sapiens	121-125
32595898-11	2020	Conclusion: Taken together, CsA was first found to upregulate Oct4 mRNA and protein expression in HGFs.	Cyclosporine	28-31	POU class 5 homeobox 1	Homo sapiens	62-66
32469166-0	2020	Annexin V in children with idiopathic nephrotic syndrome treated with cyclosporine A.	Cyclosporine	70-84	annexin A5	Homo sapiens	0-9
32469166-15	2020	Annexin V seems to be a more sensitive indicator of tubular damage in the course of CsA therapy than UM, though large, multicenter studies are needed.	Cyclosporine	84-87	annexin A5	Homo sapiens	0-9
31932642-10	2020	Meanwhile, CsA treatment significantly reduced serum IL-1beta, TNF-alpha, and IL-17 levels (P &lt; 0.01), decreased the seizure scores and prolonged the latency to seizure (P &lt; 0.01).	Cyclosporine	11-14	interleukin 17A	Rattus norvegicus	78-83
31654209-5	2020	In the presence of Ca2+, AGM also activated the Bcl-2 family protein Bax, a key factor in inducing MOMP, which is inactivated by CsA.	Cyclosporine	129-132	BCL2 associated X, apoptosis regulator	Rattus norvegicus	69-72
31901416-7	2020	The time-dependent inhibition of OATP1B1 was also noted and may be a mechanism underlying the in vitro-in vivo differences in the inhibition constant of cyclosporine A.	Cyclosporine	153-167	solute carrier organic anion transporter family member 1B1	Homo sapiens	33-40
31812822-0	2020	Taguchi L16 optimization approach for simultaneous removal of Cs+ and Sr2+ ions by a novel scavenger.	Cyclosporine	62-64	immunoglobulin kappa variable 3D-15	Homo sapiens	8-11
31618620-10	2019	We found that H2O2 promoted the colocalization of VDAC1 and Bax, which was partially inhibited by intervention with CsA or Atr.	Cyclosporine	116-119	BCL2 associated X, apoptosis regulator	Rattus norvegicus	60-63
31703927-7	2019	However, the reduced OATP1B1 activity by preincubation with pazopanib was more rapidly recovered than CsA.	Cyclosporine	102-105	solute carrier organic anion transporter family member 1B1	Homo sapiens	21-28
31446206-0	2019	Effects of cyclosporine and dexamethasone on canine T cell expression of interleukin-2 and interferon-gamma.	Cyclosporine	11-23	interferon gamma	Canis lupus familiaris	91-107
31240637-7	2019	CONCLUSION: Cyclosporine is a safe and effective treatment for PPP with few adverse effects, which might be related to the regulation of IL-23 and TNF-alpha.	Cyclosporine	12-24	interleukin 23 subunit alpha	Homo sapiens	137-142
31220549-8	2019	UVB irradiation induced Nrf2 degradation is inhibited by co-treatment of cells with W-7, cyclosporin A, SB-216763 or MG-132, which are inhibitors of calmodulin, calcineurin, GSK3beta and the proteasome, respectively.	Cyclosporine	89-102	GA binding protein transcription factor subunit alpha	Homo sapiens	24-28
31085259-10	2019	In conclusion, etoposide transport across MDCKII MRP2 cells was modulated by cyclosporin A, an inhibitor of MRP2 and P-gp, but not by specific P-gp inhibitors (valspodar and zosuquidar), which suggests that etoposide transport is primarily influenced by MRP2.	Cyclosporine	77-90	PGP	Canis lupus familiaris	117-121
30951836-5	2019	In vitro, the resulting ROS generation blocked autophagosome processing and caused accumulation of LC3-II, ubiquitin, and p62, leading to mitochondrial dysfunction and cell death; this outcome was alleviated by cyclosporine A (CsA) pretreatment.	Cyclosporine	227-230	microtubule-associated protein 1 light chain 3 alpha	Rattus norvegicus	99-105
30689261-7	2019	In addition, among the atopic and early-onset asthma (EOA), the frequency of CD4+ CTLA-4+ T cells was lower in the SAR group than the CSA group.	Cyclosporine	134-137	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	82-88
30814280-5	2019	Adaptation of N57A HIV-1LAI selected for a second CA mutation, G94D, which rescued the N57A infectivity defect in HIV-1LAI but not HIV-1NL4-3 The rescue of N57A by G94D in HIV-1LAI is abrogated by CsA treatment in some cell types, demonstrating that this rescue is CypA dependent.	Cyclosporine	197-200	peptidylprolyl isomerase A	Homo sapiens	265-269
30776644-4	2019	Treatment of the cells with CsA resulted in decreased expression of the mDC-specific markers (CD80, CD83 and CD88) induced by 27OHChol.	Cyclosporine	28-31	CD83 molecule	Homo sapiens	100-104
30457174-6	2019	Treatment with calcineurin inhibitor cyclosporin A (CsA) or FK506 suppressed cell proliferation and induced apoptotic cell death in both MYCN-amplified and MYCN-non-amplified NB cell lines.	Cyclosporine	52-55	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	137-141
30457174-6	2019	Treatment with calcineurin inhibitor cyclosporin A (CsA) or FK506 suppressed cell proliferation and induced apoptotic cell death in both MYCN-amplified and MYCN-non-amplified NB cell lines.	Cyclosporine	52-55	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	156-160
30457174-8	2019	c-Myc, MYCN, and beta-catenin were downregulated at the mRNA and protein levels in CsA or FK506-treated NB cells.	Cyclosporine	83-86	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	0-5
30457174-8	2019	c-Myc, MYCN, and beta-catenin were downregulated at the mRNA and protein levels in CsA or FK506-treated NB cells.	Cyclosporine	83-86	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	7-11
30457174-8	2019	c-Myc, MYCN, and beta-catenin were downregulated at the mRNA and protein levels in CsA or FK506-treated NB cells.	Cyclosporine	83-86	catenin beta 1	Homo sapiens	17-29
30417482-8	2019	After Con A stimulation, only T cells co-treated with ciclosporin achieved a significant proliferation inhibition and reduction of IL-2, IL-10, IL-15, IL-18, IFN-gamma and TNF-alpha.	Cyclosporine	54-65	interferon gamma	Canis lupus familiaris	158-167
30417482-8	2019	After Con A stimulation, only T cells co-treated with ciclosporin achieved a significant proliferation inhibition and reduction of IL-2, IL-10, IL-15, IL-18, IFN-gamma and TNF-alpha.	Cyclosporine	54-65	tumor necrosis factor	Canis lupus familiaris	172-181
30359668-0	2018	A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjogren"s syndrome.	Cyclosporine	50-64	nuclear receptor subfamily 5 group A member 1	Homo sapiens	8-32
30359668-3	2018	To overcome these limitations, we invented a new strategy to carry CsA by fusing its cognate human receptor, cyclophilin A (CypA), to a 73 kDa elastin-like polypeptide (ELP) termed A192 using recombinant protein expression.	Cyclosporine	67-70	peptidylprolyl isomerase A	Homo sapiens	109-122
30359668-3	2018	To overcome these limitations, we invented a new strategy to carry CsA by fusing its cognate human receptor, cyclophilin A (CypA), to a 73 kDa elastin-like polypeptide (ELP) termed A192 using recombinant protein expression.	Cyclosporine	67-70	peptidylprolyl isomerase A	Homo sapiens	124-128
30359668-3	2018	To overcome these limitations, we invented a new strategy to carry CsA by fusing its cognate human receptor, cyclophilin A (CypA), to a 73 kDa elastin-like polypeptide (ELP) termed A192 using recombinant protein expression.	Cyclosporine	67-70	nuclear receptor subfamily 5 group A member 1	Homo sapiens	143-167
30388019-7	2018	In particular, we noted that the cytotoxicity of cyclosporine A was significantly augmented in the presence of the unconjugated bile acids deoxycholic acid (DCA) and chenodeoxycholic acid (CDCA) in P-gp positive cell lines, as compared to their taurine/glycine-conjugated counterparts, implicating P-gp in the molecular response.	Cyclosporine	49-63	phosphoglycolate phosphatase	Homo sapiens	198-202
30388019-7	2018	In particular, we noted that the cytotoxicity of cyclosporine A was significantly augmented in the presence of the unconjugated bile acids deoxycholic acid (DCA) and chenodeoxycholic acid (CDCA) in P-gp positive cell lines, as compared to their taurine/glycine-conjugated counterparts, implicating P-gp in the molecular response.	Cyclosporine	49-63	phosphoglycolate phosphatase	Homo sapiens	298-302
30391882-3	2018	In the present study, it was found that administration of CsA causes a rapid activation of TGF-beta/Smad signaling cascade and subsequent expression of the profibrotic genes connective tissue growth factor (CTGF) and tissue inhibitors of matrix metallproteinases-1 (TIMP-1) in rat liver.	Cyclosporine	58-61	cellular communication network factor 2	Rattus norvegicus	174-205
30391882-3	2018	In the present study, it was found that administration of CsA causes a rapid activation of TGF-beta/Smad signaling cascade and subsequent expression of the profibrotic genes connective tissue growth factor (CTGF) and tissue inhibitors of matrix metallproteinases-1 (TIMP-1) in rat liver.	Cyclosporine	58-61	cellular communication network factor 2	Rattus norvegicus	207-211
30344674-8	2018	CsA treatment resulted in the decreased expression of insulin and PPIB; however, it also increased the phosphorylation of PERK, and upregulated the expression of PERK, BIP, CHOP and cleaved caspase-3.	Cyclosporine	0-3	DNA-damage inducible transcript 3	Mus musculus	173-177
29932236-0	2018	Bone mesenchymal stem cells pretreated with erythropoietin enhance the effect to ameliorate cyclosporine A-induced nephrotoxicity in rats.	Cyclosporine	92-106	erythropoietin	Rattus norvegicus	44-58
27870307-9	2017	Moreover, pharmacological inhibition of NFATc3 activation by Cyclosporin A, a well-described inhibitor of calcineurin, phenocopies the loss of GJIC in control cells.	Cyclosporine	61-74	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 3	Mus musculus	40-46
28340811-5	2017	As compared with tacrolimus, the CsA group had higher rates of both class II DSAs and C1q-binding DSAs (20% vs 4.4%, P = .008, and 18% vs 0%, P = .003, respectively).	Cyclosporine	33-36	complement C1q A chain	Homo sapiens	86-89
27815505-5	2016	Cyclosporine A stabilizes Ets-2 mRNA and protein when the cells are activated.	Cyclosporine	0-14	ETS proto-oncogene 2, transcription factor	Homo sapiens	26-31
26738448-0	2016	Cyclosporine A promotes cell proliferation, collagen and alpha-smooth muscle actin expressions in rat gingival fibroblasts by Smad3 activation and miR-29b suppression.	Cyclosporine	0-14	actin gamma 2, smooth muscle	Rattus norvegicus	57-82
26738448-6	2016	RESULTS: We found that cyclosporine A increased cell proliferation, COL1 and alpha-SMA expressions in rat gingival fibroblasts.	Cyclosporine	23-37	actin gamma 2, smooth muscle	Rattus norvegicus	77-86
26738448-8	2016	Moreover, Smad3 knockdown and miR-29b overexpression reversed cyclosporine A-enhanced cell proliferation, COL1 and alpha-SMA expressions in gingival fibroblasts.	Cyclosporine	62-76	actin gamma 2, smooth muscle	Rattus norvegicus	115-124
27755569-6	2016	CONCLUSIONS: These data provide evidence that CsA can inhibit the expression of dectin-1 and proinflammatory cytokines through dectin-1 when HCECs are stimulated by A. fumigatus or curdlan.	Cyclosporine	46-49	C-type lectin domain containing 7A	Homo sapiens	127-135
29932236-3	2018	We pretreated bone mesenchymal stem cells (BMSCs) with erythropoietin (EPO) to investigate their positive effect on cyclosporine A (CsA)-induced nephrotoxicity.	Cyclosporine	116-130	erythropoietin	Rattus norvegicus	55-69
29932236-3	2018	We pretreated bone mesenchymal stem cells (BMSCs) with erythropoietin (EPO) to investigate their positive effect on cyclosporine A (CsA)-induced nephrotoxicity.	Cyclosporine	116-130	erythropoietin	Rattus norvegicus	71-74
29932236-3	2018	We pretreated bone mesenchymal stem cells (BMSCs) with erythropoietin (EPO) to investigate their positive effect on cyclosporine A (CsA)-induced nephrotoxicity.	Cyclosporine	132-135	erythropoietin	Rattus norvegicus	55-69
29932236-3	2018	We pretreated bone mesenchymal stem cells (BMSCs) with erythropoietin (EPO) to investigate their positive effect on cyclosporine A (CsA)-induced nephrotoxicity.	Cyclosporine	132-135	erythropoietin	Rattus norvegicus	71-74
29932236-5	2018	To investigate the therapeutic effects of BMSCs pretreated with EPO in CsA-induced nephrotoxicity, we established CsA-induced in vitro and in vivo toxicity models.	Cyclosporine	71-74	erythropoietin	Rattus norvegicus	64-67
30220530-0	2018	The mTOR-inhibitor Sirolimus decreases the cyclosporine-induced expression of the oncogene ATF3 in human keratinocytes.	Cyclosporine	43-55	activating transcription factor 3	Homo sapiens	91-95
30220530-6	2018	RESULTS: We show that Sirolimus downregulates the expression of ATF3 induced by cyclosporine or cyclosporine plus UV-radiation in keratinocytes.	Cyclosporine	80-92	activating transcription factor 3	Homo sapiens	64-68
30220530-6	2018	RESULTS: We show that Sirolimus downregulates the expression of ATF3 induced by cyclosporine or cyclosporine plus UV-radiation in keratinocytes.	Cyclosporine	96-108	activating transcription factor 3	Homo sapiens	64-68
30220530-7	2018	In line with this we demonstrate a decrease in ATF3 expression, by incubating 3D skin equivalents with Sirolimus prior to cyclosporine and UV-light.	Cyclosporine	122-134	activating transcription factor 3	Homo sapiens	47-51
30335563-11	2018	Conclusion and Relevance: High-dose cyclosporine regimen as a P-gp modulator is required to improve the efficacy of systemic chemotherapy with caution in pediatric patients with retinoblastoma.	Cyclosporine	36-48	phosphoglycolate phosphatase	Homo sapiens	62-66
30014468-9	2018	Chronic administration of CsA increased concentrations of fasting glucose and Cystatin C and produced marked s kidney alteration of parenchyma which was reversed by concomitant administration of TQ.	Cyclosporine	26-29	cystatin C	Rattus norvegicus	78-88
29712725-3	2018	CsA is an inhibitor of organic anion transporting polypeptide (OATP)1B1 and CYP3A4, and GEM and its glucuronide (GEM-glu) inhibit OATP1B1 and CYP2C8.	Cyclosporine	0-3	solute carrier organic anion transporter family member 1B1	Homo sapiens	63-71
29712725-3	2018	CsA is an inhibitor of organic anion transporting polypeptide (OATP)1B1 and CYP3A4, and GEM and its glucuronide (GEM-glu) inhibit OATP1B1 and CYP2C8.	Cyclosporine	0-3	solute carrier organic anion transporter family member 1B1	Homo sapiens	130-137
29712725-8	2018	The DDIs were then simulated using the established PBPK models with previously obtained in vitro inhibition constants of CsA or GEM/GEM-glu against the OATP1B1 and cytochrome P450s.	Cyclosporine	121-124	solute carrier organic anion transporter family member 1B1	Homo sapiens	152-159
27629937-3	2016	Specifically, the Km value of morphine to OATP2B1 (57.58 +- 8.90 muM) is 1.4-time more than that of M6G (80.31 +- 21.75 muM); Cyclosporine A (CsA), an inhibitor of OATP2B1, can inhibit their intracellular accumulations with IC50 = 3.90 +- 0.50 muM for morphine and IC50 = 6.04 +- 0.86 muM for M6G, respectively.	Cyclosporine	126-140	solute carrier organic anion transporter family member 2B1	Homo sapiens	42-49
29663071-0	2018	Cyclosporine A responsive congenital nephrotic syndrome with single heterozygous variants in NPHS1, NPHS2, and PLCE1.	Cyclosporine	0-14	phospholipase C epsilon 1	Homo sapiens	111-116
27629937-3	2016	Specifically, the Km value of morphine to OATP2B1 (57.58 +- 8.90 muM) is 1.4-time more than that of M6G (80.31 +- 21.75 muM); Cyclosporine A (CsA), an inhibitor of OATP2B1, can inhibit their intracellular accumulations with IC50 = 3.90 +- 0.50 muM for morphine and IC50 = 6.04 +- 0.86 muM for M6G, respectively.	Cyclosporine	142-145	solute carrier organic anion transporter family member 2B1	Homo sapiens	42-49
29328412-9	2018	CsA significantly decreased the expression levels of IL-10, TNF-alpha, Cyp-D and AIF in the spinal cord of the SCI rats.	Cyclosporine	0-3	interleukin 10	Rattus norvegicus	53-58
29475508-2	2018	Cyclosporine is a potent immunosuppressive agent that targets T cell production of the cytokines IL-2 and IFN-gamma.	Cyclosporine	0-12	interferon gamma	Canis lupus familiaris	106-115
27185957-6	2016	There was an increased risk of NMSC in patients taking CSA (RR = 2.51, 95% CI: 1.23, 5.13) and D-Pen (RR 3.49, 95% CI: 1.34, 4.63) in addition to MTX, but not for patients taking AZA or LEF.	Cyclosporine	55-58	metaxin 1	Homo sapiens	146-149
29475508-9	2018	Cyclosporine significantly decreased IL-2 and IFN-gamma expression when used alone or in combination with low-dose aspirin.	Cyclosporine	0-12	interferon gamma	Canis lupus familiaris	46-55
27486749-0	2016	In Vitro Inhibition of NFAT5-Mediated Induction of CCL2 in Hyperosmotic Conditions by Cyclosporine and Dexamethasone on Human HeLa-Modified Conjunctiva-Derived Cells.	Cyclosporine	86-98	C-C motif chemokine ligand 2	Homo sapiens	51-55
29289721-11	2018	administration of a sub-effective dose of BD1047 potentiated the pharmacological effect of cyclosporin A (a calcineurin inhibitor) on both the formalin-induced reduction in phospho-serine levels of aromatase and nociceptive behavior.	Cyclosporine	91-104	cytochrome P450, family 19, subfamily a, polypeptide 1	Mus musculus	198-207
27486749-3	2016	This work was completed by an analysis of the effects of cyclosporine A (CsA), dexamethasone (Dex) and doxycycline (Dox) on HO-induced CCL2 and NFAT5 induction.	Cyclosporine	73-76	C-C motif chemokine ligand 2	Homo sapiens	135-139
27357441-4	2016	In addition, CsA treatment blocked the CoCl2-induced increases in ROS production and mitochondrial dysfunction, including a decrease in membrane potential, cytochrome c (cyto-c) release, Bax/Bcl-2 imbalance, as well as the ratios of cl-casp-9/casp-9 and cl-casp-3/casp-3 ratios, via the inhibition of p38 and ERK MAPK signaling pathways.	Cyclosporine	13-16	BCL2 associated X, apoptosis regulator	Rattus norvegicus	187-190
27635199-8	2016	In addition, CsA caused increases in the levels of malondialdehyde (MDA) and decreases in superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), glutathione reductase (GSR), glutathione-S-transferase (GST), and glutathione in kidney homogenate, which were reversed significantly by both doses of RG.	Cyclosporine	13-16	glutathione-disulfide reductase	Rattus norvegicus	151-172
27635199-8	2016	In addition, CsA caused increases in the levels of malondialdehyde (MDA) and decreases in superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), glutathione reductase (GSR), glutathione-S-transferase (GST), and glutathione in kidney homogenate, which were reversed significantly by both doses of RG.	Cyclosporine	13-16	hematopoietic prostaglandin D synthase	Rattus norvegicus	180-205
27635199-8	2016	In addition, CsA caused increases in the levels of malondialdehyde (MDA) and decreases in superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), glutathione reductase (GSR), glutathione-S-transferase (GST), and glutathione in kidney homogenate, which were reversed significantly by both doses of RG.	Cyclosporine	13-16	hematopoietic prostaglandin D synthase	Rattus norvegicus	207-210
29670817-9	2018	The largest increase was observed in a child with a heterozygous PMP22 point mutation (nerve CSA fivefold larger than a control and twofold larger than a child with CMT1A).	Cyclosporine	93-96	peripheral myelin protein 22	Homo sapiens	65-70
26894526-1	2016	OBJECTIVE: To identify the possible biological roles of keratinocyte growth factor (KGF), connective tissue growth factor (CTGF) and transforming growth factor-beta (TGF-beta) in cyclosporine-A (CsA) and phenytoin (PNT)-induced gingival overgrowth (GO) and to correlate them with each other.	Cyclosporine	179-193	cellular communication network factor 2	Rattus norvegicus	90-121
26894526-1	2016	OBJECTIVE: To identify the possible biological roles of keratinocyte growth factor (KGF), connective tissue growth factor (CTGF) and transforming growth factor-beta (TGF-beta) in cyclosporine-A (CsA) and phenytoin (PNT)-induced gingival overgrowth (GO) and to correlate them with each other.	Cyclosporine	179-193	cellular communication network factor 2	Rattus norvegicus	123-127
29225189-6	2018	Luteolin and cyclosporine A (CsA) which was a positive control also substantially reduced OVA-specific IgE levels, eotaxin 2 levels, and CCR3 expression in BAL Fluid.	Cyclosporine	13-27	chemokine (C-C motif) ligand 24	Mus musculus	115-124
29225189-6	2018	Luteolin and cyclosporine A (CsA) which was a positive control also substantially reduced OVA-specific IgE levels, eotaxin 2 levels, and CCR3 expression in BAL Fluid.	Cyclosporine	29-32	chemokine (C-C motif) ligand 24	Mus musculus	115-124
29219791-7	2017	In Western blot analysis of extracts from rat kidneys treated with cyclosporine and 5 ng/kg 2AMD, the fibrotic markers, fibronectin and vimentin, were decreased compared with animals treated only with cyclosporine.	Cyclosporine	67-79	fibronectin 1	Rattus norvegicus	120-131
26555407-3	2016	We report a case of an unplanned pregnancy discovered at 21 weeks of gestation in a female HTx patient aged 40 years treated with EVL and cyclosporine (CyA).	Cyclosporine	138-150	Zic family member 3	Homo sapiens	91-94
26555407-3	2016	We report a case of an unplanned pregnancy discovered at 21 weeks of gestation in a female HTx patient aged 40 years treated with EVL and cyclosporine (CyA).	Cyclosporine	152-155	Zic family member 3	Homo sapiens	91-94
29219791-7	2017	In Western blot analysis of extracts from rat kidneys treated with cyclosporine and 5 ng/kg 2AMD, the fibrotic markers, fibronectin and vimentin, were decreased compared with animals treated only with cyclosporine.	Cyclosporine	201-213	fibronectin 1	Rattus norvegicus	120-131
28790108-3	2017	Cyclophilin A (CypA) is a cytosolic protein that belongs to the peptidyl-prolyl isomerase (PPIase) family and the major intracellular target of the immunosuppressive drug cyclosporin A (CsA).	Cyclosporine	171-184	peptidylprolyl isomerase A	Homo sapiens	0-13
28790108-3	2017	Cyclophilin A (CypA) is a cytosolic protein that belongs to the peptidyl-prolyl isomerase (PPIase) family and the major intracellular target of the immunosuppressive drug cyclosporin A (CsA).	Cyclosporine	171-184	peptidylprolyl isomerase A	Homo sapiens	15-19
28790108-3	2017	Cyclophilin A (CypA) is a cytosolic protein that belongs to the peptidyl-prolyl isomerase (PPIase) family and the major intracellular target of the immunosuppressive drug cyclosporin A (CsA).	Cyclosporine	186-189	peptidylprolyl isomerase A	Homo sapiens	0-13
28790108-3	2017	Cyclophilin A (CypA) is a cytosolic protein that belongs to the peptidyl-prolyl isomerase (PPIase) family and the major intracellular target of the immunosuppressive drug cyclosporin A (CsA).	Cyclosporine	186-189	peptidylprolyl isomerase A	Homo sapiens	15-19
28551242-5	2017	Cyclosporin A suppressed the MPTP opening, depolarization of the mitochondrial membrane potential, activities of caspase-9 and caspase-3, apoptosis rate, myofibril fragmentation index, reactive oxygen species generation, and Ca2+ levels.	Cyclosporine	0-13	caspase 9	Homo sapiens	113-122
28899749-0	2017	CYP4A/CYP2C modulation of the interaction of calcium channel blockers with cyclosporine on EDHF-mediated renal vasodilations in rats.	Cyclosporine	75-87	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	6-11
28899749-2	2017	Here we investigated whether (i) under conditions of vascular endothelium dysfunction, the immunosuppressant drug cyclosporine (CSA) upregulates EDHF-dependent renal vasodilations through altering CYP4A/CYP2C signaling, and (ii) calcium channel blockers modulate the CSA/EDHF/CYP interaction.	Cyclosporine	114-126	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	203-208
28899749-2	2017	Here we investigated whether (i) under conditions of vascular endothelium dysfunction, the immunosuppressant drug cyclosporine (CSA) upregulates EDHF-dependent renal vasodilations through altering CYP4A/CYP2C signaling, and (ii) calcium channel blockers modulate the CSA/EDHF/CYP interaction.	Cyclosporine	128-131	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	203-208
28899749-10	2017	Renal protein expression of CYP2C and CYP4A as well as their vasoactive products (EETs/20-HETE) were increased in CSA-treated rats.	Cyclosporine	114-117	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	28-33
28899749-11	2017	Whereas the CYP2C/EETs effects of CSA were abolished by verapamil and intensified by nifedipine, the CYP4A/20-HETE effects were reduced by either CCB.	Cyclosporine	34-37	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	12-17
29073235-10	2017	Finally, the calcineurin inhibitor FK506 and Cyclosporin A reversed the effect of SFKs inhibition on NFAT1.	Cyclosporine	45-58	nuclear factor of activated T cells 2	Homo sapiens	101-106
29296854-9	2017	These data demonstrate the superiority of prednisone over CSA as an adjunct to PEX in the suppression of the anti-ADAMTS13 antibodies and improvement in ADAMTS13 activity.	Cyclosporine	58-61	ADAM metallopeptidase with thrombospondin type 1 motif 13	Homo sapiens	114-122
29296854-9	2017	These data demonstrate the superiority of prednisone over CSA as an adjunct to PEX in the suppression of the anti-ADAMTS13 antibodies and improvement in ADAMTS13 activity.	Cyclosporine	58-61	ADAM metallopeptidase with thrombospondin type 1 motif 13	Homo sapiens	153-161
28675836-4	2017	The clinical failure of first and second generation P-gp inhibitors (such as verapamil and cyclosporine analogs) has led to the discovery of third generation potent P-gp inhibitors (tariquidar, zosuquidar, laniquidar).	Cyclosporine	91-103	phosphoglycolate phosphatase	Homo sapiens	165-169
27596067-8	2017	A significant increase in renal contents of malondialdehyde, myeloperoxidase, and tumor necrosis factor-alpha with a significant decrease in renal reduced glutathione, superoxide dismutase activities, and nitric oxide (NOx) content was detected upon CsA administration.	Cyclosporine	250-253	myeloperoxidase	Rattus norvegicus	61-109
28584011-3	2017	Daily treatment of mice with cyclosporine A or tacrolimus for 1 week significantly decreased CD4+/FoxP3+ regulatory T cells in the spleen and lymph nodes, as well as induced hypertension, vascular injury and dysfunction, and glomerular mesangial expansion in mice.	Cyclosporine	29-43	forkhead box P3	Mus musculus	98-103
28527347-2	2017	Plumieride restores the suppressed cell mediated, humoral immune response and also enhances the release of TNF- alpha, IFN-gamma, and IL-2 (Th-1) in immune compromised cyclosporine and cyclophosphamide treated balb/c mice.	Cyclosporine	168-180	interleukin 2	Mus musculus	134-138
28706520-7	2017	Notably, NFAT antagonism by cyclosporin A or FK506 impaired IL-22 upregulation at normothermia and entirely prevented its enhanced expression upon hypothermic culture conditions.	Cyclosporine	28-41	interleukin 22	Mus musculus	60-65
26660633-8	2016	Moreover, exposing cells to tolvaptan in the presence of cyclosporine A, an inhibitor of the drug efflux transporters, significantly increased the intracellular levels of tolvaptan sulfate and decreased the cell viability in HEK293/SULT1C3 cells.	Cyclosporine	57-71	sulfotransferase family 1C member 3	Homo sapiens	232-239
26792730-4	2016	Utilizing human Jurkat T cells, we demonstrate that CrkII-SH3N binding of C3G is inhibited by cyclosporin A (CsA) plus FK506 that inhibit the cyclophilin A (CypA) and FK506 binding protein (FKBP) peptidyl-prolyl cis-trans isomerases (PPIases; also termed immunophilins), respectively.	Cyclosporine	94-107	peptidylprolyl isomerase A	Homo sapiens	142-155
26792730-4	2016	Utilizing human Jurkat T cells, we demonstrate that CrkII-SH3N binding of C3G is inhibited by cyclosporin A (CsA) plus FK506 that inhibit the cyclophilin A (CypA) and FK506 binding protein (FKBP) peptidyl-prolyl cis-trans isomerases (PPIases; also termed immunophilins), respectively.	Cyclosporine	94-107	peptidylprolyl isomerase A	Homo sapiens	157-161
26792730-4	2016	Utilizing human Jurkat T cells, we demonstrate that CrkII-SH3N binding of C3G is inhibited by cyclosporin A (CsA) plus FK506 that inhibit the cyclophilin A (CypA) and FK506 binding protein (FKBP) peptidyl-prolyl cis-trans isomerases (PPIases; also termed immunophilins), respectively.	Cyclosporine	109-112	peptidylprolyl isomerase A	Homo sapiens	142-155
26792730-4	2016	Utilizing human Jurkat T cells, we demonstrate that CrkII-SH3N binding of C3G is inhibited by cyclosporin A (CsA) plus FK506 that inhibit the cyclophilin A (CypA) and FK506 binding protein (FKBP) peptidyl-prolyl cis-trans isomerases (PPIases; also termed immunophilins), respectively.	Cyclosporine	109-112	peptidylprolyl isomerase A	Homo sapiens	157-161
25967121-10	2016	Cyclosporine administration rapidly normalized the abundance of phospho-NKCC2 in SORLA-deficient mice, and a functional interaction between calcineurin Abeta and SORLA was further corroborated by binding assays in rat kidney extracts.	Cyclosporine	0-12	sortilin-related receptor, LDLR class A repeats-containing	Mus musculus	81-86
25967121-10	2016	Cyclosporine administration rapidly normalized the abundance of phospho-NKCC2 in SORLA-deficient mice, and a functional interaction between calcineurin Abeta and SORLA was further corroborated by binding assays in rat kidney extracts.	Cyclosporine	0-12	sortilin-related receptor, LDLR class A repeats-containing	Mus musculus	162-167
26782505-9	2015	T cell Foxp3 mRNA expression was significantly higher in the sirolimus-treated than in the cyclosporine (53.7 vs 40.2%, P &lt; 0.05) and control groups (P &lt; 0.01), but was significantly lower in the cyclosporine group than in controls (23.6 vs 40.2%, P &lt; 0.01).	Cyclosporine	91-103	forkhead box P3	Mus musculus	7-12
26782505-9	2015	T cell Foxp3 mRNA expression was significantly higher in the sirolimus-treated than in the cyclosporine (53.7 vs 40.2%, P &lt; 0.05) and control groups (P &lt; 0.01), but was significantly lower in the cyclosporine group than in controls (23.6 vs 40.2%, P &lt; 0.01).	Cyclosporine	202-214	forkhead box P3	Mus musculus	7-12
26666562-6	2015	We demonstrated that delayed cyclosporin treatment afforded neurorestoration in three complementary models of PD including the Thy1-alpha-synuclein transgenic mouse, a novel AAV-alpha-synuclein mouse model, and the MPTP mouse model.	Cyclosporine	29-40	synuclein, alpha	Mus musculus	132-147
26666562-6	2015	We demonstrated that delayed cyclosporin treatment afforded neurorestoration in three complementary models of PD including the Thy1-alpha-synuclein transgenic mouse, a novel AAV-alpha-synuclein mouse model, and the MPTP mouse model.	Cyclosporine	29-40	synuclein, alpha	Mus musculus	178-193
26408697-5	2015	We further observed that loss of mitochondrial membrane potential and increase in reactive oxygen species content, release of mitochondrial cytochrome c, caspase-9 activation, and apoptotic cell death induced by CHM-1, were suppressed by treatment with cyclosporine A, and by the overexpression of constitutively active AKT1 or GRP78.	Cyclosporine	253-267	caspase 9	Homo sapiens	154-163
26225924-8	2015	Also, a high protein expression of Bax with decreased Bcl-2 was revealed in the renal tissue of the CsA treated group.	Cyclosporine	100-103	BCL2 associated X, apoptosis regulator	Rattus norvegicus	35-38
26317213-5	2015	The present study reports the biochemical characterization of an Arabidopsis cyclophilin, AtCyp19-3, which demonstrated that this protein is enzymatically active and possesses peptidyl-prolyl cis-trans isomerase (PPIase) activity that is specifically inhibited by CsA with an inhibition constant (Ki) of 18.75 nM.	Cyclosporine	264-267	rotamase CYP 3	Arabidopsis thaliana	90-97
26004871-10	2015	Cell surface Gb3 expression of resistant cells was annihilated by PPMP whereas cyclosporin A decreased Gb3 and MDR1 expression in H1299 cells.	Cyclosporine	79-92	alpha 1,4-galactosyltransferase (P blood group)	Homo sapiens	103-106
25485719-10	2015	CSA (calcineurin inhibitor) and KN93 (CaMKII inhibitor) inhibit A23187-induced the increase in myocardin expression.	Cyclosporine	0-3	myocardin	Rattus norvegicus	95-104
25638160-4	2015	In bladder cancer cell lines, cyclosporine A (CsA) and tacrolimus (FK506), immunosuppressant drugs/non-selective NFAT inhibitors, attenuated NFATc1 expression and its nuclear translocation, NFAT transcriptional activity, and the expression of cyclooxygenase-2 and c-myc, downstream targets of NFATc1.	Cyclosporine	30-44	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	264-269
25638160-4	2015	In bladder cancer cell lines, cyclosporine A (CsA) and tacrolimus (FK506), immunosuppressant drugs/non-selective NFAT inhibitors, attenuated NFATc1 expression and its nuclear translocation, NFAT transcriptional activity, and the expression of cyclooxygenase-2 and c-myc, downstream targets of NFATc1.	Cyclosporine	46-49	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	264-269
25629977-3	2015	CsA induced cardiomyocyte-specific differentiation of P19 cells, with the highest efficiency at a concentration of 0.32 muM during embryoid body (EB) formation via activation of the Wnt signaling pathway molecules, Wnt3a, Wnt5a, and Wnt8a, and the cardiac mesoderm markers, Mixl1, Mesp1, and Mesp2.	Cyclosporine	0-3	mesoderm posterior 2	Mus musculus	292-297
25629977-4	2015	Interestingly, cotreatment of P19 cells with CsA plus dimethyl sulfoxide (DMSO) during EB formation significantly increases cardiac differentiation.	Cyclosporine	45-48	cyclin dependent kinase inhibitor 2D	Mus musculus	30-33
25629977-5	2015	In contrast, mRNA expression levels of hematopoietic and endothelial lineage markers, including Flk1 and Er71, were severely reduced in CsA-treated P19 cells.	Cyclosporine	136-139	cyclin dependent kinase inhibitor 2D	Mus musculus	148-151
25629977-6	2015	Furthermore, expression of Flk1 protein and the percentage of Flk1+ cells were severely reduced in 0.32 muM CsA-treated P19 cells compared to control cells.	Cyclosporine	108-111	cyclin dependent kinase inhibitor 2D	Mus musculus	120-123
25629977-7	2015	CsA significantly modulated mRNA expression levels of the cell cycle molecules, p53 and Cyclins D1, D2, and E2 in P19 cells during EB formation.	Cyclosporine	0-3	transformation related protein 53, pseudogene	Mus musculus	80-83
25629977-7	2015	CsA significantly modulated mRNA expression levels of the cell cycle molecules, p53 and Cyclins D1, D2, and E2 in P19 cells during EB formation.	Cyclosporine	0-3	cyclin dependent kinase inhibitor 2D	Mus musculus	114-117
25629977-8	2015	Moreover, CsA significantly increased cell death and reduced cell number in P19 cells during EB formation.	Cyclosporine	10-13	cyclin dependent kinase inhibitor 2D	Mus musculus	76-79
25629977-9	2015	These results demonstrate that CsA induces cardiac differentiation but inhibits hemato-endothelial differentiation via activation of the Wnt signaling pathway, followed by modulation of cell lineage-determining genes in P19 cells during EB formation.	Cyclosporine	31-34	wingless-type MMTV integration site family, member 3A	Mus musculus	137-140
25629977-9	2015	These results demonstrate that CsA induces cardiac differentiation but inhibits hemato-endothelial differentiation via activation of the Wnt signaling pathway, followed by modulation of cell lineage-determining genes in P19 cells during EB formation.	Cyclosporine	31-34	cyclin dependent kinase inhibitor 2D	Mus musculus	220-223
25653502-4	2015	The increased uptake of catalposide via the OAT3, OATP1B1, and OATP1B3 transporters was decreased to basal levels in the presence of representative inhibitors such as probenecid, furosemide, and cimetidine (for OAT3) and cyclosporin A, gemfibrozil, and rifampin (for OATP1B1 and OATP1B3).	Cyclosporine	221-234	solute carrier family 22 member 8	Homo sapiens	44-48
25868349-5	2015	Cyclosporine A blocked the inhibitory effect of TS-13.	Cyclosporine	0-14	TS13	Homo sapiens	48-53
25333459-8	2015	IL-2 expression was increased in the allogeneic acute rejection group and was inhibited in mice treated with CsA and FK506.	Cyclosporine	109-112	interleukin 2	Mus musculus	0-4
26299169-11	2015	Ins2 gene expressions in rats receiving tacrolimus-cyclosporin and rats receiving the vehicle were comparable.	Cyclosporine	51-62	insulin 2	Rattus norvegicus	0-4
24623479-6	2014	Propagation of this uncertainty had a marginal effect on the prediction of repaglinide OATP1B1-mediated DDI with cyclosporine; however, sensitivity of the predicted magnitude of repaglinide metabolic DDI was high.	Cyclosporine	113-125	solute carrier organic anion transporter family member 1B1	Homo sapiens	87-94
24785081-0	2014	Role of protein kinase A signaling pathway in cyclosporine nephrotoxicity.	Cyclosporine	46-58	protein kinase cAMP-activated catalytic subunit alpha	Sus scrofa	8-24
28650422-4	2017	The present study is aim at evaluating the Val effect in alleviation of CsA nephrotoxicity by probable increase in renal Klotho expression and/or reducing oxidative stress.	Cyclosporine	72-75	Klotho	Rattus norvegicus	121-127
28650422-9	2017	RESULTS: Cyclosporine A treatment reduced renal expression and serum levels of Klotho, improved malondialdehyde and 8-hydroxy-deoxy guanosine levels, and also deteriorated renal function.	Cyclosporine	9-23	Klotho	Rattus norvegicus	79-85
28650422-11	2017	CONCLUSIONS: Administration of Val might lead to amelioration of CsA nephrotoxicity by probably diminishing CsA-induced renal Klotho downregulation and oxidative stress.	Cyclosporine	65-68	Klotho	Rattus norvegicus	126-132
28650422-11	2017	CONCLUSIONS: Administration of Val might lead to amelioration of CsA nephrotoxicity by probably diminishing CsA-induced renal Klotho downregulation and oxidative stress.	Cyclosporine	108-111	Klotho	Rattus norvegicus	126-132
28414804-14	2017	To validate that the observed microRNA and mRNA expression level changes in mice kidney tissue were directly related to CsA treatment, the expression change induced by CsA treatment of three microRNAs (miR-21, miR-186, and miR-709) and three mRNAs (BMPR1a, SMURF1 and SMAD7) were compared in HEK293 cell line.	Cyclosporine	120-123	microRNA 709	Mus musculus	223-230
28414804-14	2017	To validate that the observed microRNA and mRNA expression level changes in mice kidney tissue were directly related to CsA treatment, the expression change induced by CsA treatment of three microRNAs (miR-21, miR-186, and miR-709) and three mRNAs (BMPR1a, SMURF1 and SMAD7) were compared in HEK293 cell line.	Cyclosporine	120-123	SMAD specific E3 ubiquitin protein ligase 1	Mus musculus	257-263
28414804-14	2017	To validate that the observed microRNA and mRNA expression level changes in mice kidney tissue were directly related to CsA treatment, the expression change induced by CsA treatment of three microRNAs (miR-21, miR-186, and miR-709) and three mRNAs (BMPR1a, SMURF1 and SMAD7) were compared in HEK293 cell line.	Cyclosporine	168-171	microRNA 709	Mus musculus	223-230
28414804-14	2017	To validate that the observed microRNA and mRNA expression level changes in mice kidney tissue were directly related to CsA treatment, the expression change induced by CsA treatment of three microRNAs (miR-21, miR-186, and miR-709) and three mRNAs (BMPR1a, SMURF1 and SMAD7) were compared in HEK293 cell line.	Cyclosporine	168-171	SMAD specific E3 ubiquitin protein ligase 1	Mus musculus	257-263
28469772-1	2017	This study tested the hypothesis that erythropoietin (EPO) and cyclosporine (CsA) could effectively reduce brain infarct area (BIA) in rat after acute ischemic stroke (AIS) through regulating inflammation, oxidative stress, MAPK family signaling and microRNA (miR-223/miR-30a/miR-383).	Cyclosporine	63-75	microRNA 223	Rattus norvegicus	260-267
28469772-1	2017	This study tested the hypothesis that erythropoietin (EPO) and cyclosporine (CsA) could effectively reduce brain infarct area (BIA) in rat after acute ischemic stroke (AIS) through regulating inflammation, oxidative stress, MAPK family signaling and microRNA (miR-223/miR-30a/miR-383).	Cyclosporine	77-80	microRNA 223	Rattus norvegicus	260-267
28469772-7	2017	EPO-CsA therapy markedly reduced BIA mainly by suppressing the innate immune response to inflammation, oxidative stress, microRNAs (miR-223/miR-30a/miR-383) and MAPK family signaling.	Cyclosporine	4-7	erythropoietin	Rattus norvegicus	0-3
28469772-7	2017	EPO-CsA therapy markedly reduced BIA mainly by suppressing the innate immune response to inflammation, oxidative stress, microRNAs (miR-223/miR-30a/miR-383) and MAPK family signaling.	Cyclosporine	4-7	microRNA 223	Rattus norvegicus	132-139
28131632-1	2017	We conducted a pilot study on the feasibility of CD56-enriched donor cell infusion after post-transplantation cyclophosphamide (PTCy) for 10 patients with advanced myeloid malignancies undergoing haploidentical peripheral blood stem cell transplantation with cyclosporine alone as graft-versus-host disease (GVHD) prophylaxis and compared the outcome and immune reconstitution with a control group of 20 patients undergoing the same without CD56-enriched donor cell infusion.	Cyclosporine	259-271	neural cell adhesion molecule 1	Homo sapiens	49-53
28131632-8	2017	Our preliminary data show that CD56+ donor cell infusion after PTCy and short-course cyclosporine is feasible with prompt engraftment, rapid reconstitution of CD4+T cells, Tregs and NK cells and reduced incidence of acute GVHD.	Cyclosporine	85-97	neural cell adhesion molecule 1	Homo sapiens	31-35
28062572-1	2017	Cyclophilin A (CypA), a well-recognized receptor for anti-inflammatory drug cyclosporine A (CsA) is a ubiquitous and multifunctional protein.	Cyclosporine	76-90	peptidylprolyl isomerase A	Homo sapiens	0-13
28062572-1	2017	Cyclophilin A (CypA), a well-recognized receptor for anti-inflammatory drug cyclosporine A (CsA) is a ubiquitous and multifunctional protein.	Cyclosporine	76-90	peptidylprolyl isomerase A	Homo sapiens	15-19
28062572-1	2017	Cyclophilin A (CypA), a well-recognized receptor for anti-inflammatory drug cyclosporine A (CsA) is a ubiquitous and multifunctional protein.	Cyclosporine	92-95	peptidylprolyl isomerase A	Homo sapiens	0-13
28062572-1	2017	Cyclophilin A (CypA), a well-recognized receptor for anti-inflammatory drug cyclosporine A (CsA) is a ubiquitous and multifunctional protein.	Cyclosporine	92-95	peptidylprolyl isomerase A	Homo sapiens	15-19
28114946-9	2017	Specifically, the rate of permeability of Rhodamine 123 across the BBB model (0.6 +- 0.1 x 10-3, n = 4), increased 14-fold in the presence of the P-gp inhibitor verapamil (14.7 +- 7.5 x 10-3, n = 3) and eightfold with the addition of Cyclosporine A (8.8 +- 1.8 x 10-3, n = 3).	Cyclosporine	234-248	phosphoglycolate phosphatase	Homo sapiens	146-150
27033630-2	2017	Besides acting as a cellular receptor for immunosuppressive drug cyclosporine A (CsA), CypA is involved in various cellular activities.	Cyclosporine	65-79	peptidylprolyl isomerase A	Homo sapiens	87-91
24785081-2	2014	The purpose of this study was to evaluate the effect of inhibiting the protein kinase A (PKA) signaling pathway in nephrotoxicity caused by cyclosporine from the assessment of cell viability, pro-inflammatory cytokines, and nitric oxide (NO) production in LLC-PK1 and MDCK cell lines.	Cyclosporine	140-152	protein kinase cAMP-activated catalytic subunit alpha	Sus scrofa	71-87
24785081-2	2014	The purpose of this study was to evaluate the effect of inhibiting the protein kinase A (PKA) signaling pathway in nephrotoxicity caused by cyclosporine from the assessment of cell viability, pro-inflammatory cytokines, and nitric oxide (NO) production in LLC-PK1 and MDCK cell lines.	Cyclosporine	140-152	protein kinase cAMP-activated catalytic subunit alpha	Sus scrofa	89-92
24785081-3	2014	Cyclosporine proved to be cytotoxic for both cell lines, as assessed by the mitochondrial enzyme activity assay (MTT), caused DNA fragmentation, determined by flow cytometry using the propidium iodide dye, and activated the PKA pathway (western blot assay).	Cyclosporine	0-12	protein kinase cAMP-activated catalytic subunit alpha	Sus scrofa	224-227
24785081-6	2014	The NO production was increased when cells were pre-incubated with H89 followed by cyclosporine, and this production was dependent on the PKA pathway in LLC-PK1 and MDCK cells lines.	Cyclosporine	83-95	protein kinase cAMP-activated catalytic subunit alpha	Sus scrofa	138-141
24785081-7	2014	Therefore, considering the present study"s results, it can be concluded that the inhibition of PKA signaling pathway can aid in reducing the degree of nephrotoxicity caused by cyclosporine.	Cyclosporine	176-188	protein kinase cAMP-activated catalytic subunit alpha	Sus scrofa	95-98
25072153-10	2014	In conclusion, early increases in urinary KIM-1, TNF-alpha, and fibronectin and elevated microalbuminuria indicate acute CsA nephrotoxicity.	Cyclosporine	121-124	hepatitis A virus cellular receptor 1	Rattus norvegicus	42-47
25484988-6	2014	Superimposing flow upon CsA further enhanced expression of the AP-1 members Fra-1 and c-Jun.	Cyclosporine	24-27	fos-like antigen 1	Mus musculus	76-81
25035868-5	2014	Here, we found that the immunosuppressants FK506 and cyclosporin A, both known as calcineurin inhibitors, complemented the high-temperature stress-induced growth defect of rsp5(A401E) strain.	Cyclosporine	53-66	NEDD4 family E3 ubiquitin-protein ligase	Saccharomyces cerevisiae S288C	172-176
23782056-2	2014	The aim of this study was to investigate the expression of PTEN in subjects using cyclosporine A and to analyze the relationship between PTEN and cell proliferation marker, proliferating cell nuclear antigen (PCNA), in cyclosporine A-induced gingival overgrowth.	Cyclosporine	82-96	phosphatase and tensin homolog	Homo sapiens	59-63
23782056-2	2014	The aim of this study was to investigate the expression of PTEN in subjects using cyclosporine A and to analyze the relationship between PTEN and cell proliferation marker, proliferating cell nuclear antigen (PCNA), in cyclosporine A-induced gingival overgrowth.	Cyclosporine	219-233	phosphatase and tensin homolog	Homo sapiens	59-63
23782056-2	2014	The aim of this study was to investigate the expression of PTEN in subjects using cyclosporine A and to analyze the relationship between PTEN and cell proliferation marker, proliferating cell nuclear antigen (PCNA), in cyclosporine A-induced gingival overgrowth.	Cyclosporine	219-233	phosphatase and tensin homolog	Homo sapiens	137-141
23782056-2	2014	The aim of this study was to investigate the expression of PTEN in subjects using cyclosporine A and to analyze the relationship between PTEN and cell proliferation marker, proliferating cell nuclear antigen (PCNA), in cyclosporine A-induced gingival overgrowth.	Cyclosporine	219-233	proliferating cell nuclear antigen	Homo sapiens	173-207
23782056-2	2014	The aim of this study was to investigate the expression of PTEN in subjects using cyclosporine A and to analyze the relationship between PTEN and cell proliferation marker, proliferating cell nuclear antigen (PCNA), in cyclosporine A-induced gingival overgrowth.	Cyclosporine	219-233	proliferating cell nuclear antigen	Homo sapiens	209-213
27033630-2	2017	Besides acting as a cellular receptor for immunosuppressive drug cyclosporine A (CsA), CypA is involved in various cellular activities.	Cyclosporine	81-84	peptidylprolyl isomerase A	Homo sapiens	87-91
27890239-5	2017	This article identifies a potential role for interleukin-22 in driving SCC proliferation, particularly in solid organ transplant recipients taking cyclosporine.	Cyclosporine	147-159	serpin family B member 3	Homo sapiens	71-74
27250819-4	2017	In vitro drug release studies have demonstrated that the sustained release of CsA from PLGA/CsA NPs occurs over ~25 h. The in vivo study presented here showed that injured animals that received PLGA/CsA NPs through the tail vein, exhibited a significant up-regulation of growth-associated protein-43 (GAP-43) expression and an increased number of GAP-43-stained neurons compared with animals that received CsA or the vehicle alone.	Cyclosporine	78-81	growth associated protein 43	Homo sapiens	271-299
27250819-4	2017	In vitro drug release studies have demonstrated that the sustained release of CsA from PLGA/CsA NPs occurs over ~25 h. The in vivo study presented here showed that injured animals that received PLGA/CsA NPs through the tail vein, exhibited a significant up-regulation of growth-associated protein-43 (GAP-43) expression and an increased number of GAP-43-stained neurons compared with animals that received CsA or the vehicle alone.	Cyclosporine	78-81	growth associated protein 43	Homo sapiens	301-307
27250819-4	2017	In vitro drug release studies have demonstrated that the sustained release of CsA from PLGA/CsA NPs occurs over ~25 h. The in vivo study presented here showed that injured animals that received PLGA/CsA NPs through the tail vein, exhibited a significant up-regulation of growth-associated protein-43 (GAP-43) expression and an increased number of GAP-43-stained neurons compared with animals that received CsA or the vehicle alone.	Cyclosporine	78-81	growth associated protein 43	Homo sapiens	347-353
27840960-7	2017	Moreover, MPTP blockage with cyclosporin A prevented the translocation of Bax, and inhibited oxidative stress-induced apoptotic killing in the HBx-expressing HL-7702 cells.	Cyclosporine	29-42	X protein	Hepatitis B virus	143-146
27893767-6	2016	Consistent with those findings, translocation of NFATc2 is limited, but still dependent on Ca2+ influx as demonstrated by sensitivity to cyclosporin A (CsA) treatment.	Cyclosporine	137-150	nuclear factor of activated T cells 2	Homo sapiens	49-55
27893767-6	2016	Consistent with those findings, translocation of NFATc2 is limited, but still dependent on Ca2+ influx as demonstrated by sensitivity to cyclosporin A (CsA) treatment.	Cyclosporine	152-155	nuclear factor of activated T cells 2	Homo sapiens	49-55
27603548-4	2016	Pre-incubation with cyclosporine A, but not with rifampicin, decreased the apparent IC50 values on recombinant cynomolgus monkey OATP1B1- and OATP1B3-mediated pitavastatin uptake.	Cyclosporine	20-34	solute carrier organic anion transporter family member 1B1	Homo sapiens	129-136
27447836-3	2016	Of these, 12 metabolites were significantly higher in plasma samples from volunteers dosed with the OATP1B1 inhibitor, cyclosporine (CSA) vs. placebo (q-value &lt; 0.2).	Cyclosporine	119-131	solute carrier organic anion transporter family member 1B1	Homo sapiens	100-107
27447836-3	2016	Of these, 12 metabolites were significantly higher in plasma samples from volunteers dosed with the OATP1B1 inhibitor, cyclosporine (CSA) vs. placebo (q-value &lt; 0.2).	Cyclosporine	133-136	solute carrier organic anion transporter family member 1B1	Homo sapiens	100-107
27882144-5	2016	As compared with the N group, the mRNA expression levels of MMP-9, VCAM-1 and TNF-alpha were significantly increased in the CHD and RS groups (P&lt;0.05), but were significantly decreased in the groups with CSA intervention, as compared with those without CSA intervention (P&lt;0.05).	Cyclosporine	207-210	vascular cell adhesion protein 1	Oryctolagus cuniculus	67-73
27882144-5	2016	As compared with the N group, the mRNA expression levels of MMP-9, VCAM-1 and TNF-alpha were significantly increased in the CHD and RS groups (P&lt;0.05), but were significantly decreased in the groups with CSA intervention, as compared with those without CSA intervention (P&lt;0.05).	Cyclosporine	207-210	tumor necrosis factor	Oryctolagus cuniculus	78-87
27882144-5	2016	As compared with the N group, the mRNA expression levels of MMP-9, VCAM-1 and TNF-alpha were significantly increased in the CHD and RS groups (P&lt;0.05), but were significantly decreased in the groups with CSA intervention, as compared with those without CSA intervention (P&lt;0.05).	Cyclosporine	256-259	tumor necrosis factor	Oryctolagus cuniculus	78-87
27309728-10	2016	The levels of TNF, IL-4, IL-5, and IL-13 were significantly decreased after treatment with cyclosporine.	Cyclosporine	91-103	interleukin 4	Mus musculus	19-23
27309728-10	2016	The levels of TNF, IL-4, IL-5, and IL-13 were significantly decreased after treatment with cyclosporine.	Cyclosporine	91-103	interleukin 5	Mus musculus	25-29
27903993-9	2016	RESULTS: The mean serum level of klotho was significantly lower in the cyclosporine group compared with control and valsartan groups.	Cyclosporine	71-83	Klotho	Rattus norvegicus	33-39
27903993-13	2016	CONCLUSIONS: Administration of valsartan may lead to attenuation of the nephrotoxic side effect of cyclosporine via enhancing klotho and decreasing oxidative stress levels.	Cyclosporine	99-111	Klotho	Rattus norvegicus	126-132
27020855-9	2016	Administration of cyclosporin A, which stabilizes synaptopodin, reduced LPS-induced proteinuria significantly in wild-type mice but to a lesser extent in TRPC6 knockout mice.	Cyclosporine	18-31	synaptopodin	Mus musculus	50-62
27791127-3	2016	Here, we present evidence that loss of CSA or CSB in a neuroblastoma cell line converges on mitochondrial dysfunction caused by defects in ribosomal DNA transcription and activation of the DNA damage sensor poly-ADP ribose polymerase 1 (PARP1).	Cyclosporine	39-42	Poly [ADP-ribose] polymerase;Poly [ADP-ribose] polymerase 1	Caenorhabditis elegans	207-235
27791127-3	2016	Here, we present evidence that loss of CSA or CSB in a neuroblastoma cell line converges on mitochondrial dysfunction caused by defects in ribosomal DNA transcription and activation of the DNA damage sensor poly-ADP ribose polymerase 1 (PARP1).	Cyclosporine	39-42	Poly [ADP-ribose] polymerase;Poly [ADP-ribose] polymerase 1	Caenorhabditis elegans	237-242
27699266-0	2016	Cyclosporine A immunosuppression drives catastrophic squamous cell carcinoma through IL-22.	Cyclosporine	0-14	interleukin 22	Mus musculus	85-90
27699266-5	2016	Eighteen of 114 OTRs developed catastrophic SCC, which was strongly associated with CSA treatment.	Cyclosporine	84-87	serpin family B member 3	Homo sapiens	44-47
27699266-6	2016	We found that CSA drives T cell polarization toward IL-22-producing T22 cells, and CSA treatment increased IL-22 receptor in SCC cells.	Cyclosporine	14-17	interleukin 22	Mus musculus	52-57
27699266-6	2016	We found that CSA drives T cell polarization toward IL-22-producing T22 cells, and CSA treatment increased IL-22 receptor in SCC cells.	Cyclosporine	83-86	interleukin 22	Mus musculus	107-112
27699266-6	2016	We found that CSA drives T cell polarization toward IL-22-producing T22 cells, and CSA treatment increased IL-22 receptor in SCC cells.	Cyclosporine	83-86	serpin family B member 3	Homo sapiens	125-128
24862982-5	2014	A significant correlation between sonographic and electrophysiological findings in the MMN group was found only between cMAP and CSA of the median nerve at the upper arm (r = 0.851, p &lt; 0.001).	Cyclosporine	129-132	cystatin F	Homo sapiens	120-124
27699266-8	2016	CSA potentiated rescue by IL-22 of serum-starved SCC cells; treatment of SCC cells with IL-22 and CSA increased both their migratory and invasive capacity.	Cyclosporine	0-3	interleukin 22	Mus musculus	26-31
27699266-8	2016	CSA potentiated rescue by IL-22 of serum-starved SCC cells; treatment of SCC cells with IL-22 and CSA increased both their migratory and invasive capacity.	Cyclosporine	0-3	serpin family B member 3	Homo sapiens	49-52
27699266-10	2016	We found that catastrophic SCC in OTRs is associated with CSA use, which may be acting by favoring T22 polarization.	Cyclosporine	58-61	serpin family B member 3	Homo sapiens	27-30
27007325-8	2016	In cytokine assay, we noticed increasing levels of IL-17 with increasing doses of concanavalin A in control group and in group of dams treated with cyclosporine A, mycophenolate mofetil and prednisone.	Cyclosporine	148-162	interleukin 17A	Rattus norvegicus	51-56
27496439-9	2016	Mofetil mycophenolate (MMF)contributed to the change of TLR4 expression in the CsA group but not in the Tac group.	Cyclosporine	79-82	toll like receptor 4	Homo sapiens	56-60
26994210-4	2016	The prototypic inhibitor CsA (cyclosporin A) of both cyclophilins as well as the new water-soluble MM258 derivative prevented this suppression.	Cyclosporine	30-43	peptidylprolyl isomerase A	Homo sapiens	53-65
27170302-11	2016	In addition, we show that cyclosporine-based immunosuppression, classically used in allogeneic cell transplantation, exclusively impacts the miR-206 expression.	Cyclosporine	26-38	microRNA 206	Canis lupus familiaris	141-148
24968842-7	2014	A significant decrease in IL-2 was observed in OA group and OA+CsA group, especially the latter.	Cyclosporine	63-66	interleukin 2	Rattus norvegicus	26-30
24968842-9	2014	The increments of serum IL-10 level and T cell percentage were more prominent in OA+CsA group than in the other two intervention groups.	Cyclosporine	84-87	interleukin 10	Rattus norvegicus	24-29
24353324-0	2014	Magnesium loss in cyclosporine-treated patients is related to renal epidermal growth factor downregulation.	Cyclosporine	18-30	epidermal growth factor	Homo sapiens	68-91
24353324-3	2014	We hypothesize that CsA-induced hypomagnesaemia is due to a renal magnesium leak, also in patients, resulting from a downregulation of the renal EGF production, thereby inhibiting the activation of TRPM6.	Cyclosporine	20-23	epidermal growth factor	Homo sapiens	145-148
24353324-8	2014	The urinary EGF excretion was significantly decreased in the CsA group and was a predictor of the FE Mg(2+) in the two groups.	Cyclosporine	61-64	epidermal growth factor	Homo sapiens	12-15
24353324-10	2014	CONCLUSIONS: In CsA-treated patients, the association of a low urinary EGF excretion and a decreased renal Mg(2+) reabsorption is in accordance with in vitro and animal studies.	Cyclosporine	16-19	epidermal growth factor	Homo sapiens	71-74
24782683-10	2014	Additionally, interleukin-1 blockade appears to be effective treatment of macrophage activation syndrome, one of the most dangerous complications of JIA; specifically, anakinra in combination with cyclosporine and corticosteroids may obviate the need for cytotoxic approaches.	Cyclosporine	197-209	interleukin 1 alpha	Homo sapiens	14-27
24573171-13	2014	CONCLUSIONS: Topical 0.5% S1P1 agonist is as effective as 1% CsA, and both can effectively prolong the survival of corneal allografts in mice.	Cyclosporine	61-64	sphingosine-1-phosphate receptor 1	Mus musculus	26-30
24532135-8	2014	It was found that CNPase substrate, 2",3"-cAMP (5 muM) and, a non-competitive CNPase inhibitor, atractyloside (5 muM), were able to increase the level of CNPase phosphorylation in calcium-overloaded mitochondria, while CsA (mPTP blocker) was able to strong suppress the phosphorylation of the enzyme.	Cyclosporine	219-222	2',3'-cyclic nucleotide 3' phosphodiesterase	Rattus norvegicus	18-24
24532135-8	2014	It was found that CNPase substrate, 2",3"-cAMP (5 muM) and, a non-competitive CNPase inhibitor, atractyloside (5 muM), were able to increase the level of CNPase phosphorylation in calcium-overloaded mitochondria, while CsA (mPTP blocker) was able to strong suppress the phosphorylation of the enzyme.	Cyclosporine	219-222	2',3'-cyclic nucleotide 3' phosphodiesterase	Rattus norvegicus	78-84
24532135-8	2014	It was found that CNPase substrate, 2",3"-cAMP (5 muM) and, a non-competitive CNPase inhibitor, atractyloside (5 muM), were able to increase the level of CNPase phosphorylation in calcium-overloaded mitochondria, while CsA (mPTP blocker) was able to strong suppress the phosphorylation of the enzyme.	Cyclosporine	219-222	2',3'-cyclic nucleotide 3' phosphodiesterase	Rattus norvegicus	78-84
23886114-6	2014	OATP1B1 and OATP1B3-mediated transport of bilirubin was confirmed and inhibition was determined for atazanavir, rifampicin, indinavir, amprenavir, cyclosporine, rifamycin SV and saquinavir.	Cyclosporine	147-159	solute carrier organic anion transporter family member 1B1	Homo sapiens	0-7
26950856-5	2016	These effects were abrogated by BAY 60-2770 as well as cyclosporin A and SB-216763, which prevented mPTP opening and inhibited glycogen synthase kinase-3beta (GSK-3beta), respectively.	Cyclosporine	55-68	glycogen synthase kinase 3 beta	Mus musculus	127-157
26950856-5	2016	These effects were abrogated by BAY 60-2770 as well as cyclosporin A and SB-216763, which prevented mPTP opening and inhibited glycogen synthase kinase-3beta (GSK-3beta), respectively.	Cyclosporine	55-68	glycogen synthase kinase 3 beta	Mus musculus	159-168
27041481-2	2016	Cyclophilin A (Cyp A) is a target protein implicated in the mechanism of action of immunosuppressive compounds such as Cyclosporine A (CsA).	Cyclosporine	135-138	peptidylprolyl isomerase A	Homo sapiens	0-13
24479545-3	2014	Disruption of CypA binding to CA, either by genetic means or by the competitive inhibitor cyclosporine A (CsA), reduces the efficiency of HIV-1 transduction in some cells but not in others.	Cyclosporine	90-104	peptidylprolyl isomerase A	Homo sapiens	14-18
24479545-3	2014	Disruption of CypA binding to CA, either by genetic means or by the competitive inhibitor cyclosporine A (CsA), reduces the efficiency of HIV-1 transduction in some cells but not in others.	Cyclosporine	106-109	peptidylprolyl isomerase A	Homo sapiens	14-18
27041481-2	2016	Cyclophilin A (Cyp A) is a target protein implicated in the mechanism of action of immunosuppressive compounds such as Cyclosporine A (CsA).	Cyclosporine	135-138	peptidylprolyl isomerase A	Homo sapiens	15-20
27041481-6	2016	The same than CsA, Gracilin H, A and Tetrahydroaplysulphurin-1 were able to inhibit phosphatase activity once the complex between Cyp A-CsA/Spongionella compounds was formed.	Cyclosporine	14-17	peptidylprolyl isomerase A	Homo sapiens	130-135
25309926-2	2014	It has been shown earlier that combined treatment with UIC2 anti-Pgp monoclonal antibody (mAb) and cyclosporine A (CSA) is an effective way of blocking Pgp function.	Cyclosporine	99-113	phosphoglycolate phosphatase	Homo sapiens	152-155
27041481-6	2016	The same than CsA, Gracilin H, A and Tetrahydroaplysulphurin-1 were able to inhibit phosphatase activity once the complex between Cyp A-CsA/Spongionella compounds was formed.	Cyclosporine	136-139	peptidylprolyl isomerase A	Homo sapiens	130-135
25309926-2	2014	It has been shown earlier that combined treatment with UIC2 anti-Pgp monoclonal antibody (mAb) and cyclosporine A (CSA) is an effective way of blocking Pgp function.	Cyclosporine	115-118	phosphoglycolate phosphatase	Homo sapiens	65-68
25309926-2	2014	It has been shown earlier that combined treatment with UIC2 anti-Pgp monoclonal antibody (mAb) and cyclosporine A (CSA) is an effective way of blocking Pgp function.	Cyclosporine	115-118	phosphoglycolate phosphatase	Homo sapiens	152-155
26826458-8	2016	More than 50% level of inflammatory factors including TNF-alpha, IFN-gamma, IL-2, IL-12, IL-22 and IL-23 in mouse serum was decreased by curcumin treatment as well as cyclosporine.	Cyclosporine	167-179	interleukin 2	Mus musculus	76-80
26155135-3	2014	The results showed that both DEX and CsA dose-dependently inhibited the production of eleven cytokines: interleukin (IL)-2, IL-4, IL-5, IL-6, IL-13, IL-17, interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF).	Cyclosporine	37-40	colony stimulating factor 2	Homo sapiens	227-275
26826458-8	2016	More than 50% level of inflammatory factors including TNF-alpha, IFN-gamma, IL-2, IL-12, IL-22 and IL-23 in mouse serum was decreased by curcumin treatment as well as cyclosporine.	Cyclosporine	167-179	interleukin 22	Mus musculus	89-94
26155135-3	2014	The results showed that both DEX and CsA dose-dependently inhibited the production of eleven cytokines: interleukin (IL)-2, IL-4, IL-5, IL-6, IL-13, IL-17, interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF).	Cyclosporine	37-40	colony stimulating factor 2	Homo sapiens	277-283
26155135-3	2014	The results showed that both DEX and CsA dose-dependently inhibited the production of eleven cytokines: interleukin (IL)-2, IL-4, IL-5, IL-6, IL-13, IL-17, interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF).	Cyclosporine	37-40	colony stimulating factor 3	Homo sapiens	289-326
26936128-13	2016	Pretreatment with CsA, therefore, inhibits HNK-triggered regulated necrosis and reverses dephosphorylation of Akt, eIF4E-binding protein 1 and S6 kinase.	Cyclosporine	18-21	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	115-138
26155135-3	2014	The results showed that both DEX and CsA dose-dependently inhibited the production of eleven cytokines: interleukin (IL)-2, IL-4, IL-5, IL-6, IL-13, IL-17, interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF).	Cyclosporine	37-40	colony stimulating factor 3	Homo sapiens	328-333
27028319-5	2016	Intracellular and secreted IL-10 levels were determined by flow cytometry and Bioplex assay after treating PBMCs with PD98059, tipifarnib and cyclosporin A for blocking of ERK-, T-bet-and FoxP3-dependent pathways, respectively.	Cyclosporine	142-155	T-box transcription factor 21	Homo sapiens	178-183
26190674-4	2016	In this model, PSC833 and ivermectin potently inhibited P-gp function; cyclosporine and verapamil moderately inhibited P-gp function, whereas ketoconazole, itraconazole, diazepam, and its metabolites had no effect on P-gp function.	Cyclosporine	71-83	phosphoglycolate phosphatase	Homo sapiens	119-123
24325305-2	2014	Our aim was to analyze the rate of CMV infection in HTx patients receiving treatment with cyclosporine (CsA) or tacrolimus (Tac).	Cyclosporine	90-102	Zic family member 3	Homo sapiens	52-55
24325305-2	2014	Our aim was to analyze the rate of CMV infection in HTx patients receiving treatment with cyclosporine (CsA) or tacrolimus (Tac).	Cyclosporine	104-107	Zic family member 3	Homo sapiens	52-55
24325305-13	2014	This was the first study to demonstrate a lower rate of CMV infection in patients treated with Tac vs. those treated with CsA after HTx.	Cyclosporine	122-125	Zic family member 3	Homo sapiens	132-135
25379560-10	2014	Independently from the ConA concentration, inhibition of CD25 and CD95 expression was highest preoperatively for sirolimus and on POD-3 for cyclosporine.	Cyclosporine	140-152	Fas cell surface death receptor	Homo sapiens	66-70
25379560-11	2014	At all time points, inhibition of CD25 and CD95 expression was significantly higher after cyclosporine compared to sirolimus treatment (P &lt; 0.001).	Cyclosporine	90-102	Fas cell surface death receptor	Homo sapiens	43-47
26190674-4	2016	In this model, PSC833 and ivermectin potently inhibited P-gp function; cyclosporine and verapamil moderately inhibited P-gp function, whereas ketoconazole, itraconazole, diazepam, and its metabolites had no effect on P-gp function.	Cyclosporine	71-83	phosphoglycolate phosphatase	Homo sapiens	119-123
25594762-6	2016	CsA and FK506 were additionally found to up-regulate the expression of several molecules that play a protective role in bladder tumorigenesis, including p53, p21, and p27, and down-regulate that of oncogenic genes, such as cyclin D1, cyclin D3, and cyclin E, in SVHUC cells with the carcinogen challenge.	Cyclosporine	0-3	transformation related protein 53, pseudogene	Mus musculus	153-156
26795951-2	2016	Here we show that AS and cyclosporine A (CsA) exerted synergistic inhibitory effect on cell growth and c-Myc expression in HCT116 cells.	Cyclosporine	25-39	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	103-108
24422229-1	2013	Cyclosporine is an immunosuppressive agent that inhibits T-cell function by decreasing production of cytokines such as interleukin-2 (IL-2) and interferon-gamma(IFN-gamma).	Cyclosporine	0-12	interferon gamma	Canis lupus familiaris	144-170
24422229-3	2013	Our laboratory has developed a quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) assay that measures IL-2 and IFN-gamma gene expression, with the goal of quantifying immunosuppression in dogs treated with cyclosporine.	Cyclosporine	226-238	interferon gamma	Canis lupus familiaris	131-140
23809336-6	2013	The results showed that CsA increased the mRNA expression and contractile function of several G-protein-coupled receptors (GPCRs), such as endothelin receptor type B (ETB ), 5-hydroxytryptamine type 1B (5-HT1B ) and 1D (5-HT1D ), in vascular smooth muscle cells.	Cyclosporine	24-27	5-hydroxytryptamine receptor 1D	Rattus norvegicus	220-226
26795951-2	2016	Here we show that AS and cyclosporine A (CsA) exerted synergistic inhibitory effect on cell growth and c-Myc expression in HCT116 cells.	Cyclosporine	41-44	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	103-108
23665451-5	2013	In this study, we evaluated whether the chiHIV vector efficiently transduces human cells, and the transduction efficiency might increase by a CypA inhibitor (cyclosporine) and a proteasome inhibitor (MG132).	Cyclosporine	158-170	peptidylprolyl isomerase A	Homo sapiens	142-146
26788461-9	2016	Cyclosporine A and tacrolimus suppress immune reactions by inhibiting the phosphatase calcineurin-dependent activation of NFAT1.	Cyclosporine	0-14	nuclear factor of activated T cells 2	Homo sapiens	122-127
23778874-9	2013	Addition of CsA prevented IOBA-NHC from cell death by blocking MPTP opening, DeltaPsim loss, Fas/FasL, and caspase activation.	Cyclosporine	12-15	Fas ligand	Homo sapiens	97-101
27008801-13	2016	The experiment data revealed that cyclosporin A up-regulated FOSL1 in the first 24 h, afterwards down-regulating its expression.	Cyclosporine	34-47	FOS like 1, AP-1 transcription factor subunit	Homo sapiens	61-66
23778874-11	2013	CsA further promoted T-cell apoptosis, DeltaPsim loss, and upregulation of Fas/FasL/caspase.	Cyclosporine	0-3	Fas ligand	Homo sapiens	79-83
23778874-14	2013	CsA promoted T-cell apoptosis via upregulating Fas/FasL and caspase activities with a minimal effect on MPTP.	Cyclosporine	0-3	Fas ligand	Homo sapiens	51-55
23777496-6	2013	CsA significantly reduced both IL-12/23p40 and IL-23 production by LPS-stimulated THP-1 cells, but not in LPS-stimulated macrophage-like differentiated THP-1 cells.	Cyclosporine	0-3	interleukin 23 subunit alpha	Homo sapiens	47-52
23777496-8	2013	CsA inhibits not only IL-12/23p40 and IL-12p70, but also heterodimeric IL-23 production by human monocytes, which may be one possible mechanism for the therapeutic efficacy of CsA in psoriasis.	Cyclosporine	0-3	interleukin 23 subunit alpha	Homo sapiens	71-76
23777496-8	2013	CsA inhibits not only IL-12/23p40 and IL-12p70, but also heterodimeric IL-23 production by human monocytes, which may be one possible mechanism for the therapeutic efficacy of CsA in psoriasis.	Cyclosporine	176-179	interleukin 23 subunit alpha	Homo sapiens	71-76
26426935-8	2016	Amelogenin expression was increased by treatment with cyclosporin A, which is an inducer of anagen in the hair follicle, whereas the level of Lamp-1 and -2 was decreased by cyclosporin A treatment.	Cyclosporine	173-186	lysosomal-associated membrane protein 1	Rattus norvegicus	142-155
23683031-5	2013	RESULTS: CsA induced marked increases in urine kidney injury molecule-1 (Kim-1) and neutrophil gelatinase-associated lipocalin (NGAL) concentrations (P &lt; 0.05).	Cyclosporine	9-12	hepatitis A virus cellular receptor 1	Rattus norvegicus	47-71
23683031-5	2013	RESULTS: CsA induced marked increases in urine kidney injury molecule-1 (Kim-1) and neutrophil gelatinase-associated lipocalin (NGAL) concentrations (P &lt; 0.05).	Cyclosporine	9-12	hepatitis A virus cellular receptor 1	Rattus norvegicus	73-78
23683031-10	2013	CsA increased the protein expression of bax, cleaved caspase-9, caspase-3 and the activity of caspase-3; however, the anti-apoptotic bcl-2 protein was reduced.	Cyclosporine	0-3	BCL2 associated X, apoptosis regulator	Rattus norvegicus	40-43
22934840-10	2013	Importantly, fibroblast monolayers and 3D cultures treated with a combination of IL-1beta and CsA showed a decrease in the MMP-1/TIMP-1 ratio.	Cyclosporine	94-97	matrix metallopeptidase 1	Homo sapiens	123-128
22934840-11	2013	CONCLUSIONS: These data support the hypothesis that inflammation may alter the pathogenesis of CsA-induced gingival enlargement by promoting a synergistic decrease in the MMP-1/TIMP-1 ratio.	Cyclosporine	95-98	matrix metallopeptidase 1	Homo sapiens	171-176
23593196-13	2013	Inhibition of ABCB1 with XR9576 and cyclosporin A enhanced the cytotoxicity of BI 2536 to ABCB1-overexpressing cancer cells, HCT-15-Pgp, and decreased the IC50 value of BI 2536 by several orders of magnitude.	Cyclosporine	36-49	phosphoglycolate phosphatase	Homo sapiens	132-135
26188334-6	2015	Cyclosporine A increased the association of CNP with complexes I and III, supporting the idea of the involvement of these complexes in mPTP function.	Cyclosporine	0-14	2',3'-cyclic nucleotide 3' phosphodiesterase	Rattus norvegicus	44-47
22580614-5	2013	The induction of ER stress in glioma cells by CsA was evidenced by detection of unfolded protein response activation (phosphorylation of PERK, accumulation of IRE1alpha) and accumulation of ER stress-associated proteins (BIP and CHOP).	Cyclosporine	46-49	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	137-141
22580614-7	2013	Decrease of phosphorylation of 4E-BP1, p70S6K1 and its downstream target S6 ribosomal protein demonstrate inhibition of mTOR signaling by CsA.	Cyclosporine	138-141	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	31-37
22580614-8	2013	Salubrinal and silencing of PERK and IRE1alpha partially blocked CsA-induced accumulation of LC3-II.	Cyclosporine	65-68	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	28-32
23331973-0	2013	Cyclosporine A drives a Th17- and Th2-mediated posttransplant obliterative airway disease.	Cyclosporine	0-14	heart and neural crest derivatives expressed 2	Mus musculus	34-37
23331973-8	2013	In conclusion, CsA treatment unbalances T helper alloreactivity and favors Th2 and Th17 as coexisting pathways mediating chronic rejection of heterotopic tracheal allografts.	Cyclosporine	15-18	heart and neural crest derivatives expressed 2	Mus musculus	75-78
23498817-6	2013	RESULTS: Overexpression of PKCK2 noted with CsA treatment was prevented by emodin, a low-molecular-weight PKCK2 inhibitor, which dampend drug-induced up-regulation phosphorylated p53 and activation of caspases 3, 7, and 8.	Cyclosporine	44-47	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	179-182
26283324-10	2015	However, Cyclosporine A, a CREB inhibitor, reduced the expression of p-CREB, Egr-3, VCAM-1, Ang1 and Tie2.	Cyclosporine	9-23	cAMP responsive element binding protein 1	Rattus norvegicus	27-31
26283324-10	2015	However, Cyclosporine A, a CREB inhibitor, reduced the expression of p-CREB, Egr-3, VCAM-1, Ang1 and Tie2.	Cyclosporine	9-23	cAMP responsive element binding protein 1	Rattus norvegicus	71-75
26150050-6	2015	The combined clearance of 6beta-hydroxycortisol and 6beta-hydroxycortisone correlated significantly with cyclosporine pharmacokinetics (p &lt; 0.001) after oral dose of a BCS 1 formulation, whereas no relationships were seen after administration of tacrolimus and sirolimus formulations, both of which belonged to BCS 2.	Cyclosporine	105-117	BCS1 homolog, ubiquinol-cytochrome c reductase complex chaperone	Homo sapiens	171-176
23498817-7	2013	In addition, emodin prevented increased Bax/Bcl-2 ratio induced by CsA.	Cyclosporine	67-70	BCL2 associated X, apoptosis regulator	Rattus norvegicus	40-43
26030368-1	2015	Cyclophilins are peptidyl cis-trans prolyl isomerases (PPIases), whose activity is typically inhibited by cyclosporine A (CsA), a potent immunosuppressor.	Cyclosporine	106-120	peptidylprolyl isomerase A	Homo sapiens	0-12
23450662-6	2013	Moreover, in patients, down-modulation of CD16 and CD6 on CD56(dim) NK cells was observed with significant differences between Cyclosporin A- and Tac-treated patients.	Cyclosporine	127-140	neural cell adhesion molecule 1	Homo sapiens	58-62
26030368-1	2015	Cyclophilins are peptidyl cis-trans prolyl isomerases (PPIases), whose activity is typically inhibited by cyclosporine A (CsA), a potent immunosuppressor.	Cyclosporine	122-125	peptidylprolyl isomerase A	Homo sapiens	0-12
26030368-5	2015	Although highly homologous, CY and the archetypal cyclophilin A (CyPA) present distinct catalytic and CsA-binding activities owing to unique structural features between these cylophilins.	Cyclosporine	102-105	peptidylprolyl isomerase A	Homo sapiens	50-63
26030368-5	2015	Although highly homologous, CY and the archetypal cyclophilin A (CyPA) present distinct catalytic and CsA-binding activities owing to unique structural features between these cylophilins.	Cyclosporine	102-105	peptidylprolyl isomerase A	Homo sapiens	65-69
25808405-11	2015	Administering IL-6 abrogated allograft tolerance induced by kaempferol and cyclosporine via diminishing CD4+FoxP3+ Tregs.	Cyclosporine	75-87	forkhead box P3	Mus musculus	108-113
23233735-6	2013	Correspondingly, a 1.5- to five-fold reduction (P = 0.07) or a two- to three-fold increase (P &lt; 0.001) was found in cell clusters overexpressing mutant p53 in chronically UV-exposed skin of mice that had been fed rapamycin or cyclosporine, respectively.	Cyclosporine	229-241	transformation related protein 53, pseudogene	Mus musculus	155-158
26049746-5	2015	EPHOSS can be mitigated by collecting and processing cells in lowered (3%) oxygen, or in ambient air in the presence of, cyclosporine A which effects the mitochondrial permeability transition pore, resulting in increased HSC collections.	Cyclosporine	121-135	fucosyltransferase 1 (H blood group)	Homo sapiens	221-224
23134420-6	2013	When we chronically expose WT cells to cyclosporine A and FK-506 we find that catecholamine release per vesicle and pre-spike foot (PSF) signal parameters are decreased, similar to that in RCAN1(ox) cells.	Cyclosporine	39-53	regulator of calcineurin 1	Homo sapiens	189-194
25738284-2	2015	CypA is the major cellular target for the immunosuppressive drug cyclosporin A and mediates its actions.	Cyclosporine	65-78	peptidylprolyl isomerase A	Homo sapiens	0-4
23160799-0	2013	Knockdown of dishevelled-1 attenuates cyclosporine A-induced apoptosis in H9c2 cardiomyoblast cells.	Cyclosporine	38-52	dishevelled segment polarity protein 1	Rattus norvegicus	13-26
23160799-5	2013	However, whether Dvl-1 is involved in CsA-induced apoptosis remains to be determined.	Cyclosporine	38-41	dishevelled segment polarity protein 1	Rattus norvegicus	17-22
23160799-6	2013	The aim of this study was to explore the role of Dvl-1 in CsA-induced apoptosis in H9c2 cardiomyoblast cells and to investigate the role of the Wnt/beta-catenin signaling cascade in this progress.	Cyclosporine	58-61	dishevelled segment polarity protein 1	Rattus norvegicus	49-54
23160799-8	2013	We found that the appropriate concentrations and time-points of CsA-induced the expression of Dvl-1 and subsequent up-regulation of beta-catenin and c-Myc, which is consistent with previously demonstrated concentrations and time-points when H9c2 cells apoptosis occurred.	Cyclosporine	64-67	dishevelled segment polarity protein 1	Rattus norvegicus	94-99
23160799-8	2013	We found that the appropriate concentrations and time-points of CsA-induced the expression of Dvl-1 and subsequent up-regulation of beta-catenin and c-Myc, which is consistent with previously demonstrated concentrations and time-points when H9c2 cells apoptosis occurred.	Cyclosporine	64-67	catenin beta 1	Rattus norvegicus	132-144
23160799-10	2013	Dvl-1 down-regulation decreased the apoptotic rate, caspase-3 activity, and the Bax/Bcl-2 ratio in H9c2 cells treated with CsA.	Cyclosporine	123-126	dishevelled segment polarity protein 1	Rattus norvegicus	0-5
23160799-10	2013	Dvl-1 down-regulation decreased the apoptotic rate, caspase-3 activity, and the Bax/Bcl-2 ratio in H9c2 cells treated with CsA.	Cyclosporine	123-126	BCL2 associated X, apoptosis regulator	Rattus norvegicus	80-83
23160799-12	2013	Moreover, we further deleted the downstream member beta-catenin by specific siRNA, and found that CsA-induced the Bax/Bcl-2 ratio and the expression of c-Myc, which were attenuated.	Cyclosporine	98-101	catenin beta 1	Rattus norvegicus	51-63
26293090-11	2015	The expression of MCP-1 in the PDTC group was also significantly lower than the CsA group (1.15 +- 0.27 vs 1.58 +- 0.17; P = .016).	Cyclosporine	80-83	C-C motif chemokine ligand 2	Rattus norvegicus	18-23
23160799-12	2013	Moreover, we further deleted the downstream member beta-catenin by specific siRNA, and found that CsA-induced the Bax/Bcl-2 ratio and the expression of c-Myc, which were attenuated.	Cyclosporine	98-101	BCL2 associated X, apoptosis regulator	Rattus norvegicus	114-117
23331687-1	2013	BACKGROUND: Ciclosporin (CSA) is approved for the treatment of canine atopic dermatitis.	Cyclosporine	12-23	albumin	Canis lupus familiaris	25-28
23258196-12	2013	RUS decreased CsA-induced increased expression of Bax/Bcl-2 ratio.	Cyclosporine	14-17	BCL2 associated X, apoptosis regulator	Rattus norvegicus	50-53
23258196-13	2013	The expressions of ED-1, alpha-SMA, TGF-beta(1), Smad2/3, Smad4 and p-JNK were increased in CsA-treated rats, which were attenuated by RUS.	Cyclosporine	92-95	actin gamma 2, smooth muscle	Rattus norvegicus	25-34
23382681-10	2013	Conversely, synthetic Nod1 stimulating agonists given to CsA-treated mice significantly increased renal resistance to UPEC.	Cyclosporine	57-60	nucleotide-binding oligomerization domain containing 1	Mus musculus	22-26
23382681-11	2013	Renal transplant recipients receiving CsA exhibited similar decrease in NOD1 expression and neutrophil phagocytosis of E. coli.	Cyclosporine	38-41	nucleotide-binding oligomerization domain containing 1	Mus musculus	72-76
23382681-12	2013	The findings suggest that such mechanism of NFATc1-dependent inhibition of Nod1-mediated innate immune response together with the decrease in Tlr4-mediated production of chemoattractant chemokines caused by CsA may contribute to sensitizing kidney grafts to APN.	Cyclosporine	207-210	nucleotide-binding oligomerization domain containing 1	Mus musculus	75-79
25796200-5	2015	We found that combined treatment with Glu (300 mg/kg) and low-dose (10 or 20mg/kg) CsA strongly ameliorated the development of psoriasis-like skin lesions and reduced the levels of Th1 cytokine (TNF-alpha) and Th17 cytokines (IL-17, IL-22, and IL-23) in the serum and dorsal skin.	Cyclosporine	83-86	interleukin 22	Mus musculus	233-238
25500744-10	2015	CsA reduced Ccr, induced urinary proteins and up-regulated COL-I, TGF-beta1, CTGF and PAI-1 gene expression with a significant development of TIF.	Cyclosporine	0-3	cellular communication network factor 2	Rattus norvegicus	77-81
25500744-10	2015	CsA reduced Ccr, induced urinary proteins and up-regulated COL-I, TGF-beta1, CTGF and PAI-1 gene expression with a significant development of TIF.	Cyclosporine	0-3	serpin family E member 2	Rattus norvegicus	86-91
25522788-6	2015	Patients of the CASLAMB trial received CAS in combination with cyclosporine A (CsA), which leads to an increased AUC0-24h of CAS hypothetically due to an inhibition of the hepatic transport protein OATP1B1 by CsA.	Cyclosporine	63-77	solute carrier organic anion transporter family member 1B1	Homo sapiens	198-205
23124115-12	2012	Osteopontin antibodies and cyclosporine A, which blocks the opening of mPTP, have markedly inhibited the expression of osteopontin and urinary stone formation in animal models.	Cyclosporine	27-41	secreted phosphoprotein 1	Homo sapiens	119-130
23342381-5	2012	The CypA binding pattern of truncated NS5A genotypes correlated with the susceptibility of these replicons to CsA.	Cyclosporine	110-113	peptidylprolyl isomerase A	Homo sapiens	4-8
25522788-6	2015	Patients of the CASLAMB trial received CAS in combination with cyclosporine A (CsA), which leads to an increased AUC0-24h of CAS hypothetically due to an inhibition of the hepatic transport protein OATP1B1 by CsA.	Cyclosporine	79-82	solute carrier organic anion transporter family member 1B1	Homo sapiens	198-205
25631176-7	2015	In prostate cancer cell lines, CsA and FK506 inhibited NFATc1 expression and its nuclear translocation, NFAT transcriptional activity, and the expression of c-myc, a downstream target of NFAT.	Cyclosporine	31-34	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	157-162
25831991-8	2015	Significant differences in immunosuppression were found in plasma renalase in patients maintained on cyclosporine (p=0.027).	Cyclosporine	101-113	renalase, FAD dependent amine oxidase	Homo sapiens	66-74
23051746-5	2012	Mitochondrial-targeted CaMKII inhibitory protein or cyclosporin A, an mPTP antagonist with clinical efficacy in ischaemia reperfusion injury, equivalently prevent mPTP opening, DeltaPsim deterioration and diminish mitochondrial disruption and programmed cell death in response to ischaemia reperfusion injury.	Cyclosporine	52-65	calcium/calmodulin-dependent protein kinase II gamma	Mus musculus	23-29
22903029-0	2012	The molecular mechanisms of the effect of Dexamethasone and Cyclosporin A on TLR4 /NF-kappaB signaling pathway activation in oral lichen planus.	Cyclosporine	60-73	toll like receptor 4	Homo sapiens	77-81
22870958-8	2012	Significantly higher expressions of fatty acid synthase and acetyl-CoA carboxylase 1 and 2 genes were observed in CsA-treated rats.	Cyclosporine	114-117	acetyl-CoA carboxylase alpha	Rattus norvegicus	60-90
25831991-9	2015	CONCLUSIONS: Renalase was shown to be strong predictor of decreased glomerular filtration rate and was significantly higher in the group of patients on cyclosporine.	Cyclosporine	152-164	renalase, FAD dependent amine oxidase	Homo sapiens	13-21
25420893-1	2015	We investigated the renal protective effects of phophodiesterase type 5 (PDE5) inhibitors in mice with cyclosporine A (CyA; a calcineurin phosphatase inhibitor) induced nephrotoxicity.	Cyclosporine	103-117	phosphodiesterase 5A, cGMP-specific	Mus musculus	48-71
22669532-7	2012	Among nine selected compounds, vindesine, temsirolimus, and cyclosporine were found to be more potent TERT inhibitors than the standard inhibitor, curcumin.	Cyclosporine	60-72	telomerase reverse transcriptase	Homo sapiens	102-106
25420893-1	2015	We investigated the renal protective effects of phophodiesterase type 5 (PDE5) inhibitors in mice with cyclosporine A (CyA; a calcineurin phosphatase inhibitor) induced nephrotoxicity.	Cyclosporine	103-117	phosphodiesterase 5A, cGMP-specific	Mus musculus	73-77
25576488-4	2015	SHP was found to be repressed by steatotic drugs (valproate, doxycycline, tetracycline, and cyclosporin A) in cultured hepatic cells and the livers of different animal models of NAFLD: iatrogenic (tetracycline-treated rats), genetic (glycine N-methyltransferase-deficient mice), and nutritional (mice fed a methionine- and choline-deficient diet).	Cyclosporine	92-105	nuclear receptor subfamily 0, group B, member 2	Rattus norvegicus	0-3
25353064-0	2015	Cyclosporine A enhances gingival beta-catenin stability via Wnt signaling.	Cyclosporine	0-14	catenin beta 1	Rattus norvegicus	33-45
22971315-8	2012	CONCLUSION: Although conjunctival SCC has been described following cyclosporine treatment for organ transplantation, this report describes a case of conjunctival SCC following lower-dose cyclosporine treatment for psoriasis in a patient who had previous psoralen plus ultraviolet A (PUVA) treatment.	Cyclosporine	187-199	serpin family B member 3	Homo sapiens	162-165
25353064-1	2015	BACKGROUND: Cyclosporine A (CsA) increases beta-catenin messenger RNA (mRNA) and protein expression.	Cyclosporine	12-26	catenin beta 1	Rattus norvegicus	43-55
25353064-1	2015	BACKGROUND: Cyclosporine A (CsA) increases beta-catenin messenger RNA (mRNA) and protein expression.	Cyclosporine	28-31	catenin beta 1	Rattus norvegicus	43-55
22773077-7	2012	The paracellular permeability enhancers sodium caprate and EDTA, the P-gp inhibitor verapamil and the multidrug resistance related protein (MRP) inhibitors cyclosporine and MK571 could concentration-dependently increase the Papp-values, while the uptake (OATP) transporter inhibitors diclofenac sodium and indomethacin could concentration-dependently decrease the P(app)-values.	Cyclosporine	156-168	phosphoglycolate phosphatase	Homo sapiens	69-73
25353064-9	2015	RESULTS: In rats treated with CsA, overgrowth of gingivae was observed, and altered expression of genes related to Wnt/beta-catenin signaling was detected by the microarray.	Cyclosporine	30-33	catenin beta 1	Rattus norvegicus	119-131
25353064-10	2015	The gingival mRNA and protein expression profiles for genes associated with Wnt/beta-catenin signaling further confirmed the effect of CsA: beta-catenin and Dvl-1 expression increased, but APC and axin-1 expression decreased.	Cyclosporine	135-138	catenin beta 1	Rattus norvegicus	80-92
25353064-10	2015	The gingival mRNA and protein expression profiles for genes associated with Wnt/beta-catenin signaling further confirmed the effect of CsA: beta-catenin and Dvl-1 expression increased, but APC and axin-1 expression decreased.	Cyclosporine	135-138	catenin beta 1	Rattus norvegicus	140-152
25353064-10	2015	The gingival mRNA and protein expression profiles for genes associated with Wnt/beta-catenin signaling further confirmed the effect of CsA: beta-catenin and Dvl-1 expression increased, but APC and axin-1 expression decreased.	Cyclosporine	135-138	dishevelled segment polarity protein 1	Rattus norvegicus	157-162
22555451-1	2012	Cyclophilin, a cytosolic receptor for the immunosuppressive drug cyclosporin A, plays a role in diverse pathophysiologies along with its receptor, CD147.	Cyclosporine	65-78	basigin (Ok blood group)	Homo sapiens	147-152
22678567-5	2012	H9c2 cells were treated with CsA in a dose-dependent manner, and decreased Bcl-2 expression, increased Bax expression, and caspase-3 activation were observed.	Cyclosporine	29-32	BCL2 associated X, apoptosis regulator	Rattus norvegicus	103-106
22678567-6	2012	In a time-dependent manner, CsA increased CaSR expression, activated the extracellularly regulated kinase (ERK) and p38 MAPK pathways, and inactivated the c-Jun N-terminal kinase (JNK) MAPK signaling pathway.	Cyclosporine	28-31	mitogen-activated protein kinase 8	Rattus norvegicus	155-178
25353064-11	2015	Western blotting and immunohistochemistry showed decreases in beta-catenin serine phosphorylation (33/37) and ubiquitinylation in the gingivae of CsA-treated rats.	Cyclosporine	146-149	catenin beta 1	Rattus norvegicus	62-74
25353064-12	2015	CONCLUSION: CsA-enhanced gingival beta-catenin stability may be involved in gene upregulation or beta-catenin degradation via the Wnt/beta-catenin pathway.	Cyclosporine	12-15	catenin beta 1	Rattus norvegicus	34-46
25353064-12	2015	CONCLUSION: CsA-enhanced gingival beta-catenin stability may be involved in gene upregulation or beta-catenin degradation via the Wnt/beta-catenin pathway.	Cyclosporine	12-15	catenin beta 1	Rattus norvegicus	97-109
25353064-12	2015	CONCLUSION: CsA-enhanced gingival beta-catenin stability may be involved in gene upregulation or beta-catenin degradation via the Wnt/beta-catenin pathway.	Cyclosporine	12-15	catenin beta 1	Rattus norvegicus	97-109
25377120-4	2015	Cyclosporine A, FK506, rapamycin and juglone are known PPIase inhibitors.	Cyclosporine	0-14	FKBP prolyl isomerase 7	Homo sapiens	55-61
22678567-6	2012	In a time-dependent manner, CsA increased CaSR expression, activated the extracellularly regulated kinase (ERK) and p38 MAPK pathways, and inactivated the c-Jun N-terminal kinase (JNK) MAPK signaling pathway.	Cyclosporine	28-31	mitogen-activated protein kinase 8	Rattus norvegicus	180-183
25414411-4	2015	Effects of cyclosporine A (CsA), rifampin, and gemfibrozil on OATP1B1-mediated uptake of 12 substrate drugs were examined in OATP1B1-expressing human embryonic kidney 293 cells.	Cyclosporine	27-30	solute carrier organic anion transporter family member 1B1	Homo sapiens	62-69
22613676-8	2012	In contrast to RPM and FTY720, MMF, LEF, CsA, and Cy markedly decreased the levels of Ag-specific CD4(+)KJ1-26(+)CD25(+)Foxp3(+) Tregs during immune response.	Cyclosporine	41-44	forkhead box P3	Mus musculus	120-125
22613676-10	2012	The stronger inhibiting effects of MMF, LEF, CsA and Cy on CD4(+)CD25(+)Foxp3(+) Tregs than on T effectors may block the host immune tolerance potentiality.	Cyclosporine	45-48	forkhead box P3	Mus musculus	72-77
25414411-7	2015	Preincubation potentiated the inhibitory effect of CsA on OATP1B1 with similar magnitude regardless of the substrates.	Cyclosporine	51-54	solute carrier organic anion transporter family member 1B1	Homo sapiens	58-65
25452304-4	2015	In CsA-treated allograft recipient mice, CD11b(+) Gr1(+) myeloid-derived suppressor cells (MDSCs) were functional suppressive immune modulators that resulted in fewer gamma interferon (IFN-gamma)-producing CD8(+) T cells and CD4(+) T cells (T(H)1 T helper cells) and more interleukin 4 (IL-4)-producing CD4(+) T cells (T(H2)) and prolonged allogeneic skin graft survival.	Cyclosporine	3-6	interleukin 4	Mus musculus	272-285
25452304-4	2015	In CsA-treated allograft recipient mice, CD11b(+) Gr1(+) myeloid-derived suppressor cells (MDSCs) were functional suppressive immune modulators that resulted in fewer gamma interferon (IFN-gamma)-producing CD8(+) T cells and CD4(+) T cells (T(H)1 T helper cells) and more interleukin 4 (IL-4)-producing CD4(+) T cells (T(H2)) and prolonged allogeneic skin graft survival.	Cyclosporine	3-6	interleukin 4	Mus musculus	287-291
22525195-3	2012	This pilot study hypothesized that ciclosporin would have a modulatory effect on the cytokine and TLR mRNA expression of canine progenitor epidermal keratinocytes in response to TLR2 agonists.	Cyclosporine	35-46	toll like receptor 2	Canis lupus familiaris	178-182
25452304-7	2015	Mechanistically, CsA treatment enhanced the expression of indoleamine 2,3-dioxygenase (IDO) and the suppressive activities of MDSCs in allograft recipients.	Cyclosporine	17-20	indoleamine 2,3-dioxygenase 1	Mus musculus	58-85
22525195-5	2012	Ciclosporin alone did not alter the expression levels of these transcripts but in the presence of ciclosporin, TNF-alpha mRNA expression was upregulated in response to all three agonists and both TNF-alpha and IL-8 transcript abundance was increased in response to Pam3CSK4.	Cyclosporine	0-11	tumor necrosis factor	Canis lupus familiaris	196-205
22525195-5	2012	Ciclosporin alone did not alter the expression levels of these transcripts but in the presence of ciclosporin, TNF-alpha mRNA expression was upregulated in response to all three agonists and both TNF-alpha and IL-8 transcript abundance was increased in response to Pam3CSK4.	Cyclosporine	0-11	C-X-C motif chemokine ligand 8	Canis lupus familiaris	210-214
25452304-7	2015	Mechanistically, CsA treatment enhanced the expression of indoleamine 2,3-dioxygenase (IDO) and the suppressive activities of MDSCs in allograft recipients.	Cyclosporine	17-20	indoleamine 2,3-dioxygenase 1	Mus musculus	87-90
22525195-5	2012	Ciclosporin alone did not alter the expression levels of these transcripts but in the presence of ciclosporin, TNF-alpha mRNA expression was upregulated in response to all three agonists and both TNF-alpha and IL-8 transcript abundance was increased in response to Pam3CSK4.	Cyclosporine	98-109	tumor necrosis factor	Canis lupus familiaris	111-120
25266172-3	2015	In this study, we found that 46 miRNAs were significantly altered in human proximal tubular epithelial cells (HPTECs) following exposure to cyclosporine A (CsA), particularly miR-21 (5.47 +- 0.47-fold versus vehicle, P = 0.002).	Cyclosporine	156-159	microRNA 21	Homo sapiens	175-181
22525195-5	2012	Ciclosporin alone did not alter the expression levels of these transcripts but in the presence of ciclosporin, TNF-alpha mRNA expression was upregulated in response to all three agonists and both TNF-alpha and IL-8 transcript abundance was increased in response to Pam3CSK4.	Cyclosporine	98-109	tumor necrosis factor	Canis lupus familiaris	196-205
22525195-5	2012	Ciclosporin alone did not alter the expression levels of these transcripts but in the presence of ciclosporin, TNF-alpha mRNA expression was upregulated in response to all three agonists and both TNF-alpha and IL-8 transcript abundance was increased in response to Pam3CSK4.	Cyclosporine	98-109	C-X-C motif chemokine ligand 8	Canis lupus familiaris	210-214
22525195-6	2012	The enhanced responsiveness of canine keratinocytes to TLR2 agonists in response to ciclosporin may imply that administration of this drug might enhance the innate immune barrier of skin.	Cyclosporine	84-95	toll like receptor 2	Canis lupus familiaris	55-59
25266172-10	2015	Collectively, our results suggest that miR-21 mediates CsA nephrotoxicity via PTEN/AKT signaling pathway.	Cyclosporine	55-58	microRNA 21	Homo sapiens	39-45
22416070-4	2012	In renal tubular cells, cytotoxic concentrations of cyclosporine A (CsA) inhibited both gene and protein expression of adherent and tight junction proteins (E-cadherin, ZO-1, claudin-1, and beta-catenin) and increased vimentin expression, without involvement of transforming growth factor beta1 or caspase activity.	Cyclosporine	52-66	catenin beta 1	Homo sapiens	190-202
22416070-4	2012	In renal tubular cells, cytotoxic concentrations of cyclosporine A (CsA) inhibited both gene and protein expression of adherent and tight junction proteins (E-cadherin, ZO-1, claudin-1, and beta-catenin) and increased vimentin expression, without involvement of transforming growth factor beta1 or caspase activity.	Cyclosporine	52-66	vimentin	Homo sapiens	218-226
25266172-10	2015	Collectively, our results suggest that miR-21 mediates CsA nephrotoxicity via PTEN/AKT signaling pathway.	Cyclosporine	55-58	phosphatase and tensin homolog	Homo sapiens	78-82
22416070-4	2012	In renal tubular cells, cytotoxic concentrations of cyclosporine A (CsA) inhibited both gene and protein expression of adherent and tight junction proteins (E-cadherin, ZO-1, claudin-1, and beta-catenin) and increased vimentin expression, without involvement of transforming growth factor beta1 or caspase activity.	Cyclosporine	68-71	catenin beta 1	Homo sapiens	190-202
22416070-4	2012	In renal tubular cells, cytotoxic concentrations of cyclosporine A (CsA) inhibited both gene and protein expression of adherent and tight junction proteins (E-cadherin, ZO-1, claudin-1, and beta-catenin) and increased vimentin expression, without involvement of transforming growth factor beta1 or caspase activity.	Cyclosporine	68-71	vimentin	Homo sapiens	218-226
22446101-5	2012	Furthermore, cyclosporin A, a calcineurin-specific inhibitor, reduced the ability of GnRH to regulate accumulation of Jun and Atf3 mRNA and to a lesser extent Fos.	Cyclosporine	13-26	FBJ osteosarcoma oncogene	Mus musculus	159-162
25629977-2	2015	Therefore, we investigated the effects and the molecular mechanisms behind the actions of CsA on cell lineage determination of P19 cells.	Cyclosporine	90-93	cyclin dependent kinase inhibitor 2D	Mus musculus	127-130
25629977-3	2015	CsA induced cardiomyocyte-specific differentiation of P19 cells, with the highest efficiency at a concentration of 0.32 muM during embryoid body (EB) formation via activation of the Wnt signaling pathway molecules, Wnt3a, Wnt5a, and Wnt8a, and the cardiac mesoderm markers, Mixl1, Mesp1, and Mesp2.	Cyclosporine	0-3	cyclin dependent kinase inhibitor 2D	Mus musculus	54-57
25629977-3	2015	CsA induced cardiomyocyte-specific differentiation of P19 cells, with the highest efficiency at a concentration of 0.32 muM during embryoid body (EB) formation via activation of the Wnt signaling pathway molecules, Wnt3a, Wnt5a, and Wnt8a, and the cardiac mesoderm markers, Mixl1, Mesp1, and Mesp2.	Cyclosporine	0-3	wingless-type MMTV integration site family, member 3A	Mus musculus	182-185
25629977-3	2015	CsA induced cardiomyocyte-specific differentiation of P19 cells, with the highest efficiency at a concentration of 0.32 muM during embryoid body (EB) formation via activation of the Wnt signaling pathway molecules, Wnt3a, Wnt5a, and Wnt8a, and the cardiac mesoderm markers, Mixl1, Mesp1, and Mesp2.	Cyclosporine	0-3	wingless-type MMTV integration site family, member 3A	Mus musculus	215-220
26305401-0	2015	TMBIM6 (transmembrane BAX inhibitor motif containing 6) enhances autophagy and reduces renal dysfunction in a cyclosporine A-induced nephrotoxicity model.	Cyclosporine	110-124	transmembrane BAX inhibitor motif containing 6	Mus musculus	0-6
22564605-10	2012	This result suggests that CsA may dysregulate MMPs in endothelial cells.	Cyclosporine	26-29	matrix metallopeptidase 1	Homo sapiens	46-50
22696872-7	2012	RESULTS: The present study showed that cyclosporine induced the nephrotoxicity as appeared by elevation of serum and urinary levels of creatinine, urinary level of beta2 microglobulin, serum levels of ammonia, TGF-beta1 and TNF-alpha and the NAG level while decreased the creatinine clearance.	Cyclosporine	39-51	beta-2 microglobulin	Rattus norvegicus	164-183
25385493-9	2015	CONCLUSIONS: Shh, regulated by TGF-beta, mediates CsA-altered gingival matrix homeostasis.	Cyclosporine	50-53	sonic hedgehog signaling molecule	Homo sapiens	13-16
25051958-7	2014	More importantly, a pharmacological inhibition of CN by cyclosporine A (CsA) ameliorated the alpha-syn-induced loss of mDA neurons.	Cyclosporine	56-70	synuclein, alpha	Mus musculus	93-102
22316009-9	2012	Based on our rat data, we estimated a similar value at 5.6 muM blood CsA concentration, 588% increase in Lop brain distribution.	Cyclosporine	69-72	lop	Drosophila melanogaster	105-108
22343435-13	2012	Cobalt pretreatment also reduced the CsA-induced phosphorylation of NF-kappaB and the CsA-induced expression of vimentin and alpha-smooth muscle actin, suggesting the attenuation of inflammation and fibrosis.	Cyclosporine	86-89	vimentin	Homo sapiens	112-120
25051958-7	2014	More importantly, a pharmacological inhibition of CN by cyclosporine A (CsA) ameliorated the alpha-syn-induced loss of mDA neurons.	Cyclosporine	72-75	synuclein, alpha	Mus musculus	93-102
24823913-2	2014	Cyclosporine A enhances the proliferation of gingival cells; however, the relationships of SHH to cyclosporine A or to cyclosporine A-enhanced gingival cell proliferation have not been described.	Cyclosporine	98-112	sonic hedgehog signaling molecule	Homo sapiens	91-94
24823913-4	2014	RESULTS: In human gingival fibroblasts, cyclosporine A treatment increased the expression of SHH transcripts and SHH protein, and stimulated cell proliferation; the addition of cyclopamine, an SHH signaling inhibitor, suppressed cyclosporine A-enhanced cell proliferation.	Cyclosporine	40-54	sonic hedgehog signaling molecule	Homo sapiens	93-96
24823913-4	2014	RESULTS: In human gingival fibroblasts, cyclosporine A treatment increased the expression of SHH transcripts and SHH protein, and stimulated cell proliferation; the addition of cyclopamine, an SHH signaling inhibitor, suppressed cyclosporine A-enhanced cell proliferation.	Cyclosporine	40-54	sonic hedgehog signaling molecule	Homo sapiens	113-116
24823913-4	2014	RESULTS: In human gingival fibroblasts, cyclosporine A treatment increased the expression of SHH transcripts and SHH protein, and stimulated cell proliferation; the addition of cyclopamine, an SHH signaling inhibitor, suppressed cyclosporine A-enhanced cell proliferation.	Cyclosporine	40-54	sonic hedgehog signaling molecule	Homo sapiens	113-116
24823913-6	2014	CONCLUSION: Cyclosporine A up-regulates gingival SHH expression in vitro and in vivo, and the inhibition of the SHH pathway counteracts the stimulatory effect of cyclosporine A on gingival fibroblast proliferation.	Cyclosporine	12-26	sonic hedgehog signaling molecule	Homo sapiens	49-52
24823913-6	2014	CONCLUSION: Cyclosporine A up-regulates gingival SHH expression in vitro and in vivo, and the inhibition of the SHH pathway counteracts the stimulatory effect of cyclosporine A on gingival fibroblast proliferation.	Cyclosporine	162-176	sonic hedgehog signaling molecule	Homo sapiens	49-52
24823913-6	2014	CONCLUSION: Cyclosporine A up-regulates gingival SHH expression in vitro and in vivo, and the inhibition of the SHH pathway counteracts the stimulatory effect of cyclosporine A on gingival fibroblast proliferation.	Cyclosporine	162-176	sonic hedgehog signaling molecule	Homo sapiens	112-115
24823913-7	2014	Therefore, we suggest that SHH mediates a novel molecular mechanism for cyclosporine A-induced gingival complications.	Cyclosporine	72-86	sonic hedgehog signaling molecule	Homo sapiens	27-30
25096221-5	2014	Although the treatment with rituximab had limited efficacy (specifically, only for hemolysis), subsequent cyclosporine therapy led to prompt recovery of erythropoiesis with the disappearance of anti-EPOR antibody and oligoclonal T cells.	Cyclosporine	106-118	erythropoietin receptor	Homo sapiens	199-203
25096221-6	2014	This is the first case report of anti-EPOR antibody-associated PRCA in a patient with malignant lymphoma treated successfully with cyclosporine.	Cyclosporine	131-143	erythropoietin receptor	Homo sapiens	38-42
25048953-6	2014	Cyclic peptides, which bind and inhibit cyclophilins without having immunosuppressive properties, have been generated by chemical modifications of cyclosporin A.	Cyclosporine	147-160	peptidylprolyl isomerase A	Homo sapiens	40-52
25124319-7	2014	COX-1 and COX-2 was localized to epithelium and connective tissue in human gingival tissue sections from cyclosporine induced gingival overgrowth.	Cyclosporine	105-117	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	0-5
24960264-5	2014	An increase in glucose-6-phosphatase protein levels (68%, p &lt; 0.05) and in protein-tyrosine phosphatase 1B (163%, p &lt; 0.05), a negative regulator of insulin was observed in the CsA-treated group in the liver, indicating enhanced gluconeogenesis and increased insulin resistance.	Cyclosporine	183-186	glucose-6-phosphatase catalytic subunit 1	Rattus norvegicus	15-36
24737737-8	2014	We found that CsA reduced proteinuria and repaired FP effacement of PAN-induced nephropathy, restored expression of nephrin, synaptopodin, cofilin-1, pho-cofilin-1 both in vivo and in vitro.	Cyclosporine	14-17	NPHS1 adhesion molecule, nephrin	Rattus norvegicus	116-123
24847056-3	2014	Induction of BCATc by TCR in WT cells is prevented by the calcineurin-nuclear factor of activated T cells (NFAT) inhibitor, cyclosporin A (CsA), suggesting that NFAT controls BCATc expression.	Cyclosporine	124-137	branched chain aminotransferase 1, cytosolic	Mus musculus	13-18
24847056-3	2014	Induction of BCATc by TCR in WT cells is prevented by the calcineurin-nuclear factor of activated T cells (NFAT) inhibitor, cyclosporin A (CsA), suggesting that NFAT controls BCATc expression.	Cyclosporine	124-137	branched chain aminotransferase 1, cytosolic	Mus musculus	175-180
24847056-3	2014	Induction of BCATc by TCR in WT cells is prevented by the calcineurin-nuclear factor of activated T cells (NFAT) inhibitor, cyclosporin A (CsA), suggesting that NFAT controls BCATc expression.	Cyclosporine	139-142	branched chain aminotransferase 1, cytosolic	Mus musculus	13-18
24847056-3	2014	Induction of BCATc by TCR in WT cells is prevented by the calcineurin-nuclear factor of activated T cells (NFAT) inhibitor, cyclosporin A (CsA), suggesting that NFAT controls BCATc expression.	Cyclosporine	139-142	branched chain aminotransferase 1, cytosolic	Mus musculus	175-180
24509533-0	2014	The oncogene ATF3 is potentiated by cyclosporine A and ultraviolet light A. Cutaneous squamous cell carcinoma (SCC) represents the most important cutaneous complication following organ transplantation.	Cyclosporine	36-50	activating transcription factor 3	Homo sapiens	13-17
24509533-0	2014	The oncogene ATF3 is potentiated by cyclosporine A and ultraviolet light A. Cutaneous squamous cell carcinoma (SCC) represents the most important cutaneous complication following organ transplantation.	Cyclosporine	36-50	serpin family B member 3	Homo sapiens	111-114
24768635-8	2014	Moreover, when ATF3 knockdown cells were exposed to CsA, a prompt induction of CHOP was observed, which stimulated ROS production and induced cell death-related genes as compared to wild type.	Cyclosporine	52-55	activating transcription factor 3	Homo sapiens	15-19
24768635-9	2014	Taken together, our data demonstrate that ATF3 plays a pivotal role in the attenuation of CsA-induced nephrotoxicity by downregulating CHOP and ROS production mediated by ER stress.	Cyclosporine	90-93	activating transcription factor 3	Homo sapiens	42-46
24582422-3	2014	In this model, ivermectin, cyclosporin, verapamil, loperamide and ketoconazole inhibited P-gp function with IC50 values ranging from 0.1 to 3.7 mumol/L.	Cyclosporine	27-38	PGP	Canis lupus familiaris	89-93
22171718-6	2012	Expression of FASLG was augmented in cells stably overexpressing NFATC2 and suppressed in cells either pretreated with the calcineurin inhibitor ciclosporin A (CsA) or expressing the specific peptide inhibitor of NFAT, VIVIT.	Cyclosporine	145-158	Fas ligand	Homo sapiens	14-19
22171718-6	2012	Expression of FASLG was augmented in cells stably overexpressing NFATC2 and suppressed in cells either pretreated with the calcineurin inhibitor ciclosporin A (CsA) or expressing the specific peptide inhibitor of NFAT, VIVIT.	Cyclosporine	160-163	Fas ligand	Homo sapiens	14-19
21692632-0	2012	Immunohistochemical analysis of CD45RO+ T cells and vascular endothelial growth factor expression in cyclosporin A-induced rat gingival tissue.	Cyclosporine	101-114	vascular endothelial growth factor A	Rattus norvegicus	52-86
21692632-1	2012	BACKGROUND: The aim of this study is to evaluate CD4(+), CD8(+), and CD45RO(+) T cells, and vascular endothelial growth factor (VEGF) expression in cyclosporin A (CsA)-induced rat overgrown gingival tissue during an 8-week period.	Cyclosporine	148-161	vascular endothelial growth factor A	Rattus norvegicus	92-126
21692632-1	2012	BACKGROUND: The aim of this study is to evaluate CD4(+), CD8(+), and CD45RO(+) T cells, and vascular endothelial growth factor (VEGF) expression in cyclosporin A (CsA)-induced rat overgrown gingival tissue during an 8-week period.	Cyclosporine	148-161	vascular endothelial growth factor A	Rattus norvegicus	128-132
21692632-1	2012	BACKGROUND: The aim of this study is to evaluate CD4(+), CD8(+), and CD45RO(+) T cells, and vascular endothelial growth factor (VEGF) expression in cyclosporin A (CsA)-induced rat overgrown gingival tissue during an 8-week period.	Cyclosporine	163-166	vascular endothelial growth factor A	Rattus norvegicus	92-126
21692632-7	2012	RESULTS: CD4(+), CD8(+), and CD45RO(+) T cells, and VEGF expression were more prevalent in the CsA-treated group than in the control group (P &lt;0.05).	Cyclosporine	95-98	vascular endothelial growth factor A	Rattus norvegicus	52-56
21692632-9	2012	CONCLUSION: Based on our findings, we conclude that VEGF, a major regulator of angiogenesis, and CD4(+), CD8(+), and CD45RO(+) memory T cells play a key role in CsA-induced gingival overgrowth.	Cyclosporine	161-164	vascular endothelial growth factor A	Rattus norvegicus	52-56
23018139-9	2012	CsA associated with CS induced higher periglomerular alpha-SMA and renal nitrotyrosine expression.	Cyclosporine	0-3	actin gamma 2, smooth muscle	Rattus norvegicus	59-62
23018139-10	2012	CsA decreased RBF, but increased RVR, tubulointerstitial fibrosis, and alpha-SMA and renal vimentin expression.	Cyclosporine	0-3	actin gamma 2, smooth muscle	Rattus norvegicus	77-80
22316150-6	2012	In the absence of a functional CypA, e.g., by the addition of an inhibitor such as cyclosporine A (CsA), HIV-1 has reduced infectivity.	Cyclosporine	83-97	peptidylprolyl isomerase A	Homo sapiens	31-35
22316150-6	2012	In the absence of a functional CypA, e.g., by the addition of an inhibitor such as cyclosporine A (CsA), HIV-1 has reduced infectivity.	Cyclosporine	99-102	peptidylprolyl isomerase A	Homo sapiens	31-35
22240838-5	2012	The pretreatment of OATP1B1- and OATP1B3-expressing cells with 0.5-10 microM CsA, but not TCR, resulted in a reduction in their activity, even after washing out CsA from the incubation media.	Cyclosporine	161-164	solute carrier organic anion transporter family member 1B1	Homo sapiens	20-27
22240838-6	2012	Preincubating the cells with CsA significantly enhanced its inhibitory effects on OATP1B1 and OATP1B3 by coincubation at 0.1-1 microM.	Cyclosporine	29-32	solute carrier organic anion transporter family member 1B1	Homo sapiens	82-89
22240838-7	2012	Preincubation with 1 microM CsA caused a reduction in OATP1B1 activity for at least 18 h after its removal.	Cyclosporine	28-31	solute carrier organic anion transporter family member 1B1	Homo sapiens	54-61
22240838-10	2012	Thus, CsA has a long-lasting inhibitory effect on OATP1B1 and OATP1B3.	Cyclosporine	6-9	solute carrier organic anion transporter family member 1B1	Homo sapiens	50-57
22536543-4	2012	We found that anti-TNF-alpha, antibiotics, anti-IL-12p40, anti-alpha4beta7 integrin, CTLA4-Ig, and anti-IL-6 effectively prevented onset of colitis, whereas TNFR-Fc and cyclosporine did not.	Cyclosporine	169-181	TNF receptor superfamily member 1A	Homo sapiens	157-161
22124122-7	2012	Cyclosporine A inhibits the Wnt5a and calcium-induced activation of NF-kappaB and BCL-6 in Ramos cells, supporting a role of beta-catenin-independent Wnt/Ca(2+)/NFAT/NF-kappaB-BCL-6 signaling.	Cyclosporine	0-14	catenin beta 1	Homo sapiens	125-137
22509094-14	2012	The 0.5% FTY720 increased TGF-beta1 mRNA expression and decreases infiltration of CD4+ T cells in corneal grafts, while topical 1% CsA down-regulated the expression of IL-2 and IFN-gamma.	Cyclosporine	131-134	interleukin 2	Mus musculus	168-172
22986347-8	2012	CsA administration increased p-FoxO1 expression and decreased p-FoxO3a expression, whereas concurrent statin treatment reversed these changes, increased the expression of the antioxidant enzymes MnSOD and hemeoxygenase-1 and decreased the expression of the pro-apoptotic protein Bim.	Cyclosporine	0-3	forkhead box O1	Mus musculus	31-36
23028901-7	2012	These results suggest that CsA promotes Th2 bias at the maternal-fetal interface by increasing Th2-type cytokine production in trophoblasts with the aid of DSCs and DICs, while inhibiting Th1-type cytokine production in DICs and TNF-alpha production in all investigated cells.	Cyclosporine	27-30	heart and neural crest derivatives expressed 2	Mus musculus	95-98
24632637-10	2014	CsA, an MPTP opening inhibitor, prevented mitochondrial Deltapsim disruption, Opa-1 processing and Drp-1 translocation to the mitochondria therefore protecting Mn-exposed cells from mitochondrial disruption and apoptosis.	Cyclosporine	0-3	collapsin response mediator protein 1	Rattus norvegicus	99-104
24304835-9	2014	Thus pigs that possess both AMPKgamma3(R200Q) and RyR(R615C) exhibit increased muscle fiber CSA as well as greater oxidative capacity.	Cyclosporine	92-95	protein kinase AMP-activated non-catalytic subunit gamma 3	Sus scrofa	28-38
24200080-4	2014	Cyclophilin A (CypA) and other members of this family are inhibited by cyclosporin A (CsA) which sensitized diverse drug-resistant tumor cell lines in vitro to cisplatin.	Cyclosporine	71-84	peptidylprolyl isomerase A	Homo sapiens	0-13
24200080-4	2014	Cyclophilin A (CypA) and other members of this family are inhibited by cyclosporin A (CsA) which sensitized diverse drug-resistant tumor cell lines in vitro to cisplatin.	Cyclosporine	71-84	peptidylprolyl isomerase A	Homo sapiens	15-19
24200080-4	2014	Cyclophilin A (CypA) and other members of this family are inhibited by cyclosporin A (CsA) which sensitized diverse drug-resistant tumor cell lines in vitro to cisplatin.	Cyclosporine	86-89	peptidylprolyl isomerase A	Homo sapiens	0-13
24200080-4	2014	Cyclophilin A (CypA) and other members of this family are inhibited by cyclosporin A (CsA) which sensitized diverse drug-resistant tumor cell lines in vitro to cisplatin.	Cyclosporine	86-89	peptidylprolyl isomerase A	Homo sapiens	15-19
24724465-6	2014	The aim of our study was to assess an impact of classical P-gp inhibitors (verapamil and cyclosporin A) in the reversion of multidrug resistance in canine mammary cancer cells.	Cyclosporine	89-102	PGP	Canis lupus familiaris	58-62
24166946-6	2013	Calcineurin inhibitor cyclosporin A attenuated NS5-mediated inhibition of IFNbeta-induced responses, for example, IFN-sensitive response element driven luciferase, STAT1-dependent PKR mRNA expression, as well as phosphorylation and nuclear translocation of STAT1.	Cyclosporine	22-35	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	180-183
23804750-3	2013	Using a Caenorhabditis elegans model for DMD as a pharmacologic and genetic tool, we found that cyclosporine A (CsA) reduces muscle degeneration at low dose and acts, at least in part, through a mitochondrial cyclophilin D, CYN-1.	Cyclosporine	96-110	Peptidyl-prolyl cis-trans isomerase 1	Caenorhabditis elegans	224-229
23804750-3	2013	Using a Caenorhabditis elegans model for DMD as a pharmacologic and genetic tool, we found that cyclosporine A (CsA) reduces muscle degeneration at low dose and acts, at least in part, through a mitochondrial cyclophilin D, CYN-1.	Cyclosporine	112-115	Peptidyl-prolyl cis-trans isomerase 1	Caenorhabditis elegans	224-229
24036456-5	2013	Mitochondrial alteration and subsequent apoptotic cell death in ONTD-treated Bel-7402 cells could be blocked by addition of exogenous antioxidants N-acetylcystein (NAC), GSH and the MTP inhibitor cyclosporin A (CsA).	Cyclosporine	196-209	metallothionein 1B	Homo sapiens	182-185
24036456-5	2013	Mitochondrial alteration and subsequent apoptotic cell death in ONTD-treated Bel-7402 cells could be blocked by addition of exogenous antioxidants N-acetylcystein (NAC), GSH and the MTP inhibitor cyclosporin A (CsA).	Cyclosporine	211-214	metallothionein 1B	Homo sapiens	182-185
24227937-4	2013	CypA, a cytosolic binding protein of the immunosuppressive drug cyclosporine A, is overexpressed in many cancer types and often associated with malignant transformation.	Cyclosporine	64-78	peptidylprolyl isomerase A	Homo sapiens	0-4
23667148-3	2013	Although cyclosporine A has also been shown to inhibit FoxP3(+) Tregs both in vitro and in vivo, the role of ORAI channel inhibition in natural Tregs (nTregs) or inducible Tregs (iTregs) has not been investigated.	Cyclosporine	9-23	forkhead box P3	Mus musculus	55-60
23667148-5	2013	In contrast, cyclosporin A inhibited FoxP3 expression in both nTregs and iTregs.	Cyclosporine	13-26	forkhead box P3	Mus musculus	37-42
23440887-5	2013	Among them, saquinavir and ritonavir in addition to CsA exhibited long-lasting inhibitory effects on OATP1B1-mediated transport of E1 S at &gt;= 5 and 25 muM, respectively, even after they were washed out from the incubation buffer.	Cyclosporine	52-55	solute carrier organic anion transporter family member 1B1	Homo sapiens	101-108
23440887-8	2013	The present study firstly showed that saquinavir and ritonavir as well as CsA have long-lasting inhibitory effects on OATP1B1.	Cyclosporine	74-77	solute carrier organic anion transporter family member 1B1	Homo sapiens	118-125
23990993-7	2013	Additionally, CsA inhibited SOCS-1 expression (the key negative regulator of IFN-alpha/beta), but not SOCS-2 or SOCS-3.	Cyclosporine	14-17	suppressor of cytokine signaling 1	Homo sapiens	28-34
23849880-4	2013	A drug template for CypA inhibition is cyclosporine A (CsA), a cyclic undecapeptide that simultaneously binds to both CypA and the Ca(2+)-dependent phosphatase calcineurin (CN), and can attenuate immune responses.	Cyclosporine	39-53	peptidylprolyl isomerase A	Homo sapiens	20-24
22615963-9	2012	Finally, CsA could enhance the binding between CypA and M1.	Cyclosporine	9-12	peptidylprolyl isomerase A	Homo sapiens	47-51
22615963-10	2012	The above results suggested that CsA inhibited the replication of influenza A virus through CypA-dependent and -independent pathways.	Cyclosporine	33-36	peptidylprolyl isomerase A	Homo sapiens	92-96
23849880-4	2013	A drug template for CypA inhibition is cyclosporine A (CsA), a cyclic undecapeptide that simultaneously binds to both CypA and the Ca(2+)-dependent phosphatase calcineurin (CN), and can attenuate immune responses.	Cyclosporine	39-53	peptidylprolyl isomerase A	Homo sapiens	118-122
22662209-10	2012	Cyclosporin A abolished NFATc1 dephosphorylation and translocation to the nucleus.	Cyclosporine	0-13	nuclear factor of activated T-cells 1	Rattus norvegicus	24-30
23849880-4	2013	A drug template for CypA inhibition is cyclosporine A (CsA), a cyclic undecapeptide that simultaneously binds to both CypA and the Ca(2+)-dependent phosphatase calcineurin (CN), and can attenuate immune responses.	Cyclosporine	55-58	peptidylprolyl isomerase A	Homo sapiens	20-24
23849880-4	2013	A drug template for CypA inhibition is cyclosporine A (CsA), a cyclic undecapeptide that simultaneously binds to both CypA and the Ca(2+)-dependent phosphatase calcineurin (CN), and can attenuate immune responses.	Cyclosporine	55-58	peptidylprolyl isomerase A	Homo sapiens	118-122
23849880-5	2013	Synthetic modifications of the CsA scaffold allows for selective binding to CypA and CN separately, thus providing access to novel, non-immunosuppressive antiviral agents.	Cyclosporine	31-34	peptidylprolyl isomerase A	Homo sapiens	76-80
23834842-5	2013	Indeed, using the calcineurin inhibitor Cyclosporine A to inhibit signaling downstream of PLCgamma, we found that Cyclosporine A attenuated antigen-specific Tconv proliferation but permitted IL-2-induced regulatory T cell expansion in vitro and in vivo.	Cyclosporine	40-54	interleukin 2	Mus musculus	191-195
23834842-5	2013	Indeed, using the calcineurin inhibitor Cyclosporine A to inhibit signaling downstream of PLCgamma, we found that Cyclosporine A attenuated antigen-specific Tconv proliferation but permitted IL-2-induced regulatory T cell expansion in vitro and in vivo.	Cyclosporine	114-128	interleukin 2	Mus musculus	191-195
23765110-8	2013	Concomitant treatment of CsA and NAC translocated FoxO1 from the cytoplasm to the nucleus, implicating dephosphorylation of FoxO1 by NAC in p-AKT/p-FoxO1 pathway.	Cyclosporine	25-28	forkhead box O1	Mus musculus	50-55
23765110-8	2013	Concomitant treatment of CsA and NAC translocated FoxO1 from the cytoplasm to the nucleus, implicating dephosphorylation of FoxO1 by NAC in p-AKT/p-FoxO1 pathway.	Cyclosporine	25-28	forkhead box O1	Mus musculus	124-129
23765110-8	2013	Concomitant treatment of CsA and NAC translocated FoxO1 from the cytoplasm to the nucleus, implicating dephosphorylation of FoxO1 by NAC in p-AKT/p-FoxO1 pathway.	Cyclosporine	25-28	forkhead box O1	Mus musculus	124-129
23922933-0	2013	Crosstalk between Shh and TGF-beta signaling in cyclosporine-enhanced cell proliferation in human gingival fibroblasts.	Cyclosporine	48-60	sonic hedgehog signaling molecule	Homo sapiens	18-21
23922933-5	2013	However, Shh pathway involvement in cyclosporine-enhanced gingival proliferation and the existence of crosstalk with the TGF-beta pathway remain unclear.	Cyclosporine	36-48	sonic hedgehog signaling molecule	Homo sapiens	9-12
23922933-6	2013	METHODOLOGY/PRINCIPAL FINDINGS: Cyclosporine enhanced mRNA and protein levels of TGF-beta and Shh in human gingival fibroblasts (RT-PCR and western blotting).	Cyclosporine	32-44	sonic hedgehog signaling molecule	Homo sapiens	94-97
23922933-7	2013	A TGF-beta pathway inhibitor mitigated cyclosporine-enhanced cell proliferation and an Shh pathway inhibitor attenuated cyclosporine-enhanced proliferation in fibroblasts (MTS assay and/or RT-PCR of PCNA).	Cyclosporine	120-132	sonic hedgehog signaling molecule	Homo sapiens	87-90
23922933-9	2013	The TGF-beta pathway inhibitor mitigated cyclosporine-upregulated Shh expression, but the Shh pathway inhibitor did not alter cyclosporine-upregulated TGF-beta expression.	Cyclosporine	41-53	sonic hedgehog signaling molecule	Homo sapiens	66-69
23922933-10	2013	CONCLUSIONS/SIGNIFICANCE: The TGF-beta and Shh pathways mediate cyclosporine-enhanced gingival fibroblast proliferation.	Cyclosporine	64-76	sonic hedgehog signaling molecule	Homo sapiens	43-46
23922933-11	2013	Exogenous TGF-beta increased Shh expression, and inhibition of TGF-beta signaling abrogated the cyclosporine-induced upregulation of Shh expression; however, TGF-beta expression appeared unchanged by enhanced or inhibited Shh signaling.	Cyclosporine	96-108	sonic hedgehog signaling molecule	Homo sapiens	133-136
23922933-11	2013	Exogenous TGF-beta increased Shh expression, and inhibition of TGF-beta signaling abrogated the cyclosporine-induced upregulation of Shh expression; however, TGF-beta expression appeared unchanged by enhanced or inhibited Shh signaling.	Cyclosporine	96-108	sonic hedgehog signaling molecule	Homo sapiens	133-136
23922933-12	2013	This is the first study demonstrating the role of Shh in cyclosporine-enhanced gingival cell proliferation; moreover, it defines a hierarchical crosstalk pattern in which TGF-beta regulates Shh in gingival fibroblasts.	Cyclosporine	57-69	sonic hedgehog signaling molecule	Homo sapiens	50-53
23922933-12	2013	This is the first study demonstrating the role of Shh in cyclosporine-enhanced gingival cell proliferation; moreover, it defines a hierarchical crosstalk pattern in which TGF-beta regulates Shh in gingival fibroblasts.	Cyclosporine	57-69	sonic hedgehog signaling molecule	Homo sapiens	190-193
23922933-13	2013	Understanding the regulation of cyclosporine-related Shh and TGF-beta signaling and crosstalk in gingival overgrowth will clarify the mechanism of cyclosporine-induced gingival enlargement and help develop targeted therapeutics for blocking these pathways, which can be applied in pre-clinical and clinical settings.	Cyclosporine	32-44	sonic hedgehog signaling molecule	Homo sapiens	53-56
23922933-13	2013	Understanding the regulation of cyclosporine-related Shh and TGF-beta signaling and crosstalk in gingival overgrowth will clarify the mechanism of cyclosporine-induced gingival enlargement and help develop targeted therapeutics for blocking these pathways, which can be applied in pre-clinical and clinical settings.	Cyclosporine	147-159	sonic hedgehog signaling molecule	Homo sapiens	53-56
23895850-5	2013	The changes in LCX ostium lumen CSA was correlated with the changes of LCX ostium EEM CSA but not the LCX ostium P and M CSA.	Cyclosporine	32-35	tet methylcytosine dioxygenase 1	Homo sapiens	15-18
22289749-6	2012	In patients treated with the ATG plus CsA combination therapy, the response rate was relatively high for children whose disease course was less than six months, bone marrow hematopoietic area was more than 40%, had no severe infections, and experienced granulocyte colony stimulating factor (G-CSF) reaction during the early treatment; however, it was not related to AA subtypes and age.	Cyclosporine	38-41	colony stimulating factor 3	Homo sapiens	253-290
22289749-6	2012	In patients treated with the ATG plus CsA combination therapy, the response rate was relatively high for children whose disease course was less than six months, bone marrow hematopoietic area was more than 40%, had no severe infections, and experienced granulocyte colony stimulating factor (G-CSF) reaction during the early treatment; however, it was not related to AA subtypes and age.	Cyclosporine	38-41	colony stimulating factor 3	Homo sapiens	292-297
21968143-0	2011	The effect of low-dose Continuous Erythropoietin receptor activator in an experimental model of acute Cyclosporine A induced renal injury.	Cyclosporine	102-116	erythropoietin	Rattus norvegicus	34-48
23895850-5	2013	The changes in LCX ostium lumen CSA was correlated with the changes of LCX ostium EEM CSA but not the LCX ostium P and M CSA.	Cyclosporine	32-35	tet methylcytosine dioxygenase 1	Homo sapiens	71-74
22399088-10	2011	Conversely, LPO content decreased by 18.97% and 24.06% and MPO level by 42.86% and 18.66% after FK-506 and CsA treatment.	Cyclosporine	107-110	myeloperoxidase	Rattus norvegicus	59-62
23895850-5	2013	The changes in LCX ostium lumen CSA was correlated with the changes of LCX ostium EEM CSA but not the LCX ostium P and M CSA.	Cyclosporine	32-35	tet methylcytosine dioxygenase 1	Homo sapiens	71-74
23895850-5	2013	The changes in LCX ostium lumen CSA was correlated with the changes of LCX ostium EEM CSA but not the LCX ostium P and M CSA.	Cyclosporine	86-89	tet methylcytosine dioxygenase 1	Homo sapiens	15-18
23895850-5	2013	The changes in LCX ostium lumen CSA was correlated with the changes of LCX ostium EEM CSA but not the LCX ostium P and M CSA.	Cyclosporine	86-89	tet methylcytosine dioxygenase 1	Homo sapiens	71-74
23895850-5	2013	The changes in LCX ostium lumen CSA was correlated with the changes of LCX ostium EEM CSA but not the LCX ostium P and M CSA.	Cyclosporine	86-89	tet methylcytosine dioxygenase 1	Homo sapiens	71-74
23895850-7	2013	The changes of LCX ostium lumen CSA were correlated with the those of the LCX ostium EEM CSA (R=0.432, P=0.02).	Cyclosporine	32-35	tet methylcytosine dioxygenase 1	Homo sapiens	15-18
23523711-3	2013	In the present study, we found that with CsA administration, the expression of TRAIL and FasL predominantly on NK cells from renal transplantation patients was increased at day 5 after operation and went down to normal level on day 13.	Cyclosporine	41-44	Fas ligand	Homo sapiens	89-93
23523711-7	2013	We conclude that CsA may inhibit the transplant rejection partially by down-regulating the expression of TRAIL and FasL on NK cells.	Cyclosporine	17-20	Fas ligand	Homo sapiens	115-119
22221192-4	2013	OBJECTIVE: To detect the effects of methotrexate, cyclosporine and PUVA on OPN expression in psoriatic plaques, and whether these changes correlate with clinical response.	Cyclosporine	50-62	secreted phosphoprotein 1	Homo sapiens	75-78
23152531-8	2013	Furthermore, upon fractionation of intracellular membranes in density gradients, CypA was found to cosediment with membranous EAV replication structures, which could be prevented by CsA treatment.	Cyclosporine	182-185	peptidylprolyl isomerase A	Homo sapiens	81-85
23268659-3	2013	In the present study, the principal components of backbone amide-(15)N CSA tensors have been determined using density functional theory for a 16.7 kDa membrane-bound paramagnetic heme containing protein, cytochrome-b(5) (cytb(5)).	Cyclosporine	71-74	cytochrome b5 type A	Homo sapiens	204-219
23258196-13	2013	The expressions of ED-1, alpha-SMA, TGF-beta(1), Smad2/3, Smad4 and p-JNK were increased in CsA-treated rats, which were attenuated by RUS.	Cyclosporine	92-95	SMAD family member 2	Rattus norvegicus	49-56
23258196-13	2013	The expressions of ED-1, alpha-SMA, TGF-beta(1), Smad2/3, Smad4 and p-JNK were increased in CsA-treated rats, which were attenuated by RUS.	Cyclosporine	92-95	SMAD family member 4	Rattus norvegicus	58-63
23295863-6	2013	First, CsA could upregulate Fas/Fas ligand, downregulate Bcl-2/Bcl-XL, and increase caspase-1 and caspase-3.	Cyclosporine	7-10	Fas ligand	Homo sapiens	32-42
23116562-4	2013	The efflux activity of P-gp was assessed by performing in vitro uptake studies on isolated mitochondria with Rhodamine 123 (Rho-123) alone and in the presence of P-gp inhibitors (quinidine and cyclosporine A) using fluorimetry and flow cytometry analysis.	Cyclosporine	193-207	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	23-27
23146841-0	2013	Effect of mycophenolic acid on cyclosporin A-induced fibronectin expression in rat mesangial cells.	Cyclosporine	31-44	fibronectin 1	Rattus norvegicus	53-64
23146841-4	2013	These results suggest that MPA may ameliorate CsA-induced FBN production by modulating the Smad signaling pathway.	Cyclosporine	46-49	fibronectin 1	Rattus norvegicus	58-61
23144461-0	2012	Cyclosporin A impairs the secretion and activity of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeat).	Cyclosporine	0-13	ADAM metallopeptidase with thrombospondin type 1 motif 13	Homo sapiens	52-60
22869619-8	2012	Thrombin induces a transient increase of MYPT1(pThr696) in BPAECs, whereas its combination with CsA results in maintained phosphorylation levels of both MYPT1(pThr696) and myosin.	Cyclosporine	96-99	myosin heavy chain 14	Homo sapiens	172-178
22841788-11	2012	NFATc3 expression was activated by stimuli that increase intracellular calcium levels, and activation was prevented by the calcineurin blocker cyclosporin A or A-285222.	Cyclosporine	143-156	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 3	Mus musculus	0-6
22846339-5	2012	Dogs were treated with cyclosporin A for 3 weeks, which reduced calcineurin activity, as determined by mRNA expression levels of regulator of calcineurin 1 exon 4, but which was unable to prevent structural, contractile, or electrical remodeling and arrhythmias.	Cyclosporine	23-36	regulator of calcineurin 1	Canis lupus familiaris	129-155
23024272-6	2012	The tissue specificity of these DHSs mirrored the activity of the IL-3 gene, and included a highly inducible cyclosporin A-sensitive enhancer at -37 kb that increased IL-3 promoter activity 40-fold.	Cyclosporine	109-122	interleukin 3	Homo sapiens	167-171
18673375-1	2008	BACKGROUND: The cyclophilin A (CypA)-cyclosporine (CsA) complex promotes immune response.	Cyclosporine	51-54	peptidylprolyl isomerase A	Homo sapiens	16-29
18673375-1	2008	BACKGROUND: The cyclophilin A (CypA)-cyclosporine (CsA) complex promotes immune response.	Cyclosporine	51-54	peptidylprolyl isomerase A	Homo sapiens	31-35
18673375-2	2008	The variation at the CypA gene could explain CsA-pharmacokinetics and clinical outcomes among CsA-treated patients.	Cyclosporine	45-48	peptidylprolyl isomerase A	Homo sapiens	21-25
18673375-2	2008	The variation at the CypA gene could explain CsA-pharmacokinetics and clinical outcomes among CsA-treated patients.	Cyclosporine	94-97	peptidylprolyl isomerase A	Homo sapiens	21-25
18673375-12	2008	Replication of this study in other populations is necessary to define the role of CypA-variants in the main clinical outcomes among CsA-treated kidney-transplanted patients.	Cyclosporine	132-135	peptidylprolyl isomerase A	Homo sapiens	82-86
18765728-9	2008	The results of this study show that LKT trafficking and LKT-mediated cell death involve dynamin-2 and cyclophilin D, in a process that can be prevented by the mitochondrial membrane-protecting function of CSA.	Cyclosporine	205-208	peptidylprolyl isomerase F	Bos taurus	102-115
18986456-6	2008	We found significantly increased IGFBP-3 expression levels in the psoriatic group compared with levels in patients with other, nonproliferative inflammatory skin diseases, and we demonstrated differences in distribution pattern before and after systemic treatment with Mtx or CsA.	Cyclosporine	276-279	insulin like growth factor binding protein 3	Homo sapiens	33-40
18986456-8	2008	Before treatment with Mtx or CsA, IGFBP-3 expression was limited to the basal layer and suprapapillary region.	Cyclosporine	29-32	insulin like growth factor binding protein 3	Homo sapiens	34-41
18946018-4	2008	Azithromycin elevated the reduced metalloproteinase (MMP)-1 and MMP-2 activities in cyclosporine A-treated renal transplant fibroblasts and normal fibroblasts.	Cyclosporine	84-98	matrix metallopeptidase 1	Homo sapiens	34-59
18957170-0	2008	Polysaccharopeptide mimics ciclosporin-mediated Th1/Th2 cytokine balance for suppression of activated human T cell proliferation by MAPKp38 and STAT5 pathways.	Cyclosporine	27-38	signal transducer and activator of transcription 5A	Homo sapiens	144-149
18816083-8	2008	In addition, pretreatment of KB/V cells with a CyPA-binding immunosuppressive drug, cyclosporine A (CsA), enhanced their chemosensitivity to VCR and 5-Fu.	Cyclosporine	84-98	peptidylprolyl isomerase A	Homo sapiens	47-51
18816083-8	2008	In addition, pretreatment of KB/V cells with a CyPA-binding immunosuppressive drug, cyclosporine A (CsA), enhanced their chemosensitivity to VCR and 5-Fu.	Cyclosporine	100-103	peptidylprolyl isomerase A	Homo sapiens	47-51
18618151-0	2008	Protective effect of Epo on oxidative renal injury in rats with cyclosporine nephrotoxicity.	Cyclosporine	64-76	erythropoietin	Rattus norvegicus	21-24
18829531-4	2008	Loss of PRLr-CypA binding, following treatment with the PPI inhibitor cyclosporine A (CsA), or overexpression of a dominant-negative PRLr mutant (P334A) resulted in a loss of PRLr/Jak2-mediated signaling.	Cyclosporine	86-89	peptidylprolyl isomerase A	Homo sapiens	13-17
19262158-0	2008	Cyclosporin A inhibits CD11a/CD18 adhesion molecules due to inhibition of TNFalpha and IL-1 beta levels in the mouse model of pleurisy induced by carrageenan.	Cyclosporine	0-13	integrin alpha L	Mus musculus	23-28
19262158-4	2008	In the present work we evaluated whether CsA was able to downregulate CD11a/CD18 adhesion molecule in the lungs, as well as TNFalpha and IL-1 beta levels in the fluid leakage of the pleural cavity in this model.	Cyclosporine	41-44	integrin alpha L	Mus musculus	70-75
19262158-5	2008	Our results showed that CsA significantly decreased CD11a/CD18 in the lungs, as well as TNFalpha and IL-1 beta levels in the fluid leakage of the pleural cavity 4 h and 48 h after pleurisy induction.	Cyclosporine	24-27	integrin alpha L	Mus musculus	52-57
18981654-5	2008	Real-time PCR analyses with Concanavalin A (ConA)-stimulated PBMC obtained from 5 cats revealed that the expression of mRNAs for IL-2, IL-4, IFN- gamma and TNF-alpha was inhibited by CsA in a dose-dependent manner.	Cyclosporine	183-186	interleukin 2	Felis catus	129-133
18981654-5	2008	Real-time PCR analyses with Concanavalin A (ConA)-stimulated PBMC obtained from 5 cats revealed that the expression of mRNAs for IL-2, IL-4, IFN- gamma and TNF-alpha was inhibited by CsA in a dose-dependent manner.	Cyclosporine	183-186	tumor necrosis factor	Felis catus	156-165
18981654-6	2008	Moreover, an enzyme-linked immunospot (ELISPOT) assay, which is capable of detecting IL-2 secreting cells as single spots, revealed that the frequency of IL-2 secreting cells in ConA-stimulated feline PBMC was significantly reduced in the presence of CsA.	Cyclosporine	251-254	interleukin 2	Felis catus	154-158
20209781-4	2008	The aim of this study was to identify the presence and localization of CCN2/CTGF and CCN1/Cyr61, members of the same molecular family, in gingival tissues of cyclosporin A- and nifedipine-treated rats, by immunohistochemistry.	Cyclosporine	158-171	cellular communication network factor 2	Rattus norvegicus	76-80
18929835-10	2008	The density of the MCP-1 in controls was 0.68, and in CsA-treated, 1.43.	Cyclosporine	54-57	C-C motif chemokine ligand 2	Rattus norvegicus	19-24
18929835-13	2008	CONCLUSIONS: Our data suggested that among several cytokines elevated levels of the LIX, MCP-1, beta-NGF, and TIMP-1 are the contributing factors to CsA-induced nephropathy.	Cyclosporine	149-152	C-C motif chemokine ligand 2	Rattus norvegicus	89-94
18929866-0	2008	Rapamycin and cyclosporine have different effects on expression of Ang-1 and Ang-2 and Tie2 in rat renal allograft with chronic allograft nephropathy.	Cyclosporine	14-26	angiopoietin 1	Rattus norvegicus	67-72
18929866-2	2008	This study of cardiac allografts investigated whether there is a difference between rapamycin and cyclosporine A (CsA) in the ability to affect expression of Ang1, Ang2, and Tie2 in rat renal allografts with chronic allograft nephropathy (CAN).	Cyclosporine	98-112	angiopoietin 1	Rattus norvegicus	158-162
18929866-2	2008	This study of cardiac allografts investigated whether there is a difference between rapamycin and cyclosporine A (CsA) in the ability to affect expression of Ang1, Ang2, and Tie2 in rat renal allografts with chronic allograft nephropathy (CAN).	Cyclosporine	114-117	angiopoietin 1	Rattus norvegicus	158-162
18929866-14	2008	CONCLUSIONS: Our results show that compared with CsA, rapamycin modulates the expression of Ang1, Ang2, and Tie2 in rat renal allografts with CAN, which suggests that rapamycin may improve the long-term survival of renal allografts through its vasculoprotective properties.	Cyclosporine	49-52	angiopoietin 1	Rattus norvegicus	92-96
18541310-13	2008	Treatment with ciclosporin seemed to result in decreased expression of IFNgamma mRNA in AF lesions but this was not statistically significant.	Cyclosporine	15-26	interferon gamma	Canis lupus familiaris	71-79
18705750-7	2008	The levels of enzymic antioxidants such as superoxide dismutase, catalase and glutathione-S-transferase and non-enzymic antioxidants (vitamin C, vitamin E and reduced glutathione) were also decreased in CsA-treated rats.	Cyclosporine	203-206	hematopoietic prostaglandin D synthase	Rattus norvegicus	78-103
22960764-3	2012	METHODS: After whole-blood activation with the gamma(c) cytokines IL-2, IL-7, and IL-15, STAT5 phosphorylation was determined in T cells of de novo kidney transplantation patients treated with tofacitinib/basiliximab (n=5), calcineurin inhibitor (CNI) (cyclosporine A)/basiliximab (n=4) or CNI (tacrolimus)-based immunosuppression (n=6).	Cyclosporine	253-267	signal transducer and activator of transcription 5A	Homo sapiens	89-94
22906739-4	2012	The binding affinity of compound 1a to CypA has been confirmed by Fortebio"s Octet RED system and the increased phosphorylation of ERK in H446 cells is observed by treatment with both compound 1a and CsA.	Cyclosporine	200-203	peptidylprolyl isomerase A	Homo sapiens	39-43
22846842-8	2012	In addition, CsA compromised the UVB-induced checkpoint function by upregulating the molecular chaperone protein cyclophilin A (CypA).	Cyclosporine	13-16	peptidylprolyl isomerase A	Homo sapiens	113-126
22846842-8	2012	In addition, CsA compromised the UVB-induced checkpoint function by upregulating the molecular chaperone protein cyclophilin A (CypA).	Cyclosporine	13-16	peptidylprolyl isomerase A	Homo sapiens	128-132
22846842-10	2012	CsA-induced phosphoinositide 3-kinase(PI3K)/AKT activation was required for both XPC suppression and CypA upregulation.	Cyclosporine	0-3	peptidylprolyl isomerase A	Homo sapiens	101-105
22634404-6	2012	However, CsA also caused a Ca2+/calmodulin-dependent protein kinase kinase beta (CaMKKbeta)-dependent activation of AMPK, which inhibits mTORC1 signaling; this led to ineffective Akt signaling.	Cyclosporine	9-12	calcium/calmodulin dependent protein kinase kinase 2	Homo sapiens	81-90
22664025-7	2012	RESULTS: After CsA treatment both RNA and protein levels of ILT3 and ILT4 on NKL cells were increased for 12, 24, or 36 hours.	Cyclosporine	15-18	leukocyte immunoglobulin like receptor B4	Homo sapiens	60-64
22664025-8	2012	CsA at various concentrations inhibited the proliferation of NKL cells to varying degrees; at 36 hours CsA (15 mg/L) showed greater effects on ILT3 and ILT4 expression and less influence on NKL growth.	Cyclosporine	103-106	leukocyte immunoglobulin like receptor B4	Homo sapiens	143-147
22664025-10	2012	CONCLUSIONS: CsA up-regulated the expression of ILT3 and ILT4 on NKL cells, which influenced their cytotoxicity against tumor cells with different expression of HLA-G and proliferation of NKL cells.	Cyclosporine	13-16	leukocyte immunoglobulin like receptor B4	Homo sapiens	48-52
22044301-7	2012	Inhibition of HIF-1alpha activity by cyclosporine A (CsA) inhibited a rise in VEGF production in response to CoCl(2) as well as 8-Br-cAMP.	Cyclosporine	37-51	hypoxia inducible factor 1, alpha subunit	Mus musculus	14-24
22044301-7	2012	Inhibition of HIF-1alpha activity by cyclosporine A (CsA) inhibited a rise in VEGF production in response to CoCl(2) as well as 8-Br-cAMP.	Cyclosporine	53-56	hypoxia inducible factor 1, alpha subunit	Mus musculus	14-24
22158076-9	2012	Cyclosporin A (5 muM), but not FK506, increased cathepsin B release from lysosomes.	Cyclosporine	0-13	cathepsin B	Rattus norvegicus	48-59
22158076-10	2012	CONCLUSIONS: Cyclosporin A selectively opens the ZG K channel and induces cathepsin B release from lysosomes, which cause increased in situ lysis of ZGs and may aggravate or fuel acute allograft pancreatitis following hypoxia-reperfusion injury.	Cyclosporine	13-26	cathepsin B	Rattus norvegicus	74-85
22331067-4	2012	In addition, we show that stimulation of T cells in the absence of IKKbeta activity promotes the time-dependent and cyclosporine-sensitive expression of negative regulators of T cell signaling leading to a hyporesponsive state of T cells.	Cyclosporine	116-128	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	67-74
18654672-6	2008	Furthermore, the induction of immune tolerance--via oral delivery of cyclosporine A and azathioprine for two months at the time of initiation of ERT with recombinant human alpha-L-iduronidase--improved enzyme uptake in organs.	Cyclosporine	69-83	alpha-L-iduronidase	Homo sapiens	172-191
22068911-5	2012	In addition, we demonstrated that IL-32gamma induced the expression of dendritic cell-specific transmembrane protein (DC-STAMP) and nuclear factor of activated T cells cytoplasmic 1 (NFATc1), and NFATc1 inactivation by cyclosporine treatment attenuated the effect of IL-32gamma.	Cyclosporine	219-231	interleukin 32	Homo sapiens	34-44
22155090-5	2012	We also identified GSK3, MMPs and PKC pathways as potential targets to prevent CsA damage.	Cyclosporine	79-82	glycogen synthase kinase 3 beta	Mus musculus	19-23
22240838-0	2012	Long-lasting inhibitory effects of cyclosporin A, but not tacrolimus, on OATP1B1- and OATP1B3-mediated uptake.	Cyclosporine	35-48	solute carrier organic anion transporter family member 1B1	Homo sapiens	73-80
22240838-1	2012	Cyclosporin A (CsA) causes a number of clinically relevant drug-drug interactions (DDIs) by inhibiting OATP1B1 and OATP1B3.	Cyclosporine	0-13	solute carrier organic anion transporter family member 1B1	Homo sapiens	103-110
22240838-1	2012	Cyclosporin A (CsA) causes a number of clinically relevant drug-drug interactions (DDIs) by inhibiting OATP1B1 and OATP1B3.	Cyclosporine	15-18	solute carrier organic anion transporter family member 1B1	Homo sapiens	103-110
22240838-5	2012	The pretreatment of OATP1B1- and OATP1B3-expressing cells with 0.5-10 microM CsA, but not TCR, resulted in a reduction in their activity, even after washing out CsA from the incubation media.	Cyclosporine	77-80	solute carrier organic anion transporter family member 1B1	Homo sapiens	20-27
22126908-7	2012	RESULTS: CsA-treated rats developed mild hyperuricemia with arteriolar hyalinosis, tubular atrophy, striped interstitial fibrosis, increased cell proliferation and decreased VEGF expression.	Cyclosporine	9-12	vascular endothelial growth factor A	Rattus norvegicus	174-178
23428559-5	2012	Our results showed that CsA-induced ER stress and involved ER integrated stress response-related proteins (Bip/Grp78, ATF6, IRE1 and CHOP) but not cytoplasmic ER stress-related chaperones (HSP70, HSP40, HSP27, HSP90 and HSP60).	Cyclosporine	24-27	activating transcription factor 6	Rattus norvegicus	118-122
23428559-5	2012	Our results showed that CsA-induced ER stress and involved ER integrated stress response-related proteins (Bip/Grp78, ATF6, IRE1 and CHOP) but not cytoplasmic ER stress-related chaperones (HSP70, HSP40, HSP27, HSP90 and HSP60).	Cyclosporine	24-27	DNA-damage inducible transcript 3	Rattus norvegicus	133-137
23428559-5	2012	Our results showed that CsA-induced ER stress and involved ER integrated stress response-related proteins (Bip/Grp78, ATF6, IRE1 and CHOP) but not cytoplasmic ER stress-related chaperones (HSP70, HSP40, HSP27, HSP90 and HSP60).	Cyclosporine	24-27	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	189-194
23428559-5	2012	Our results showed that CsA-induced ER stress and involved ER integrated stress response-related proteins (Bip/Grp78, ATF6, IRE1 and CHOP) but not cytoplasmic ER stress-related chaperones (HSP70, HSP40, HSP27, HSP90 and HSP60).	Cyclosporine	24-27	heat shock protein family D (Hsp60) member 1	Rattus norvegicus	220-225
23028901-1	2012	Our previous study has demonstrated that cyclosporine A (CsA) administration in vivo induces Th2 bias at the maternal-fetal interface, leading to improved murine pregnancy outcomes.	Cyclosporine	57-60	heart and neural crest derivatives expressed 2	Mus musculus	93-96
20142917-0	2008	Utility of C-2 (Cyclosporine) monitoring in postrenal transplant patients: A study in the Indian population.	Cyclosporine	16-28	complement C2	Homo sapiens	11-14
23028901-2	2012	Here, we investigated how CsA treatment in vitro induced Th2 bias at the human maternal-fetal interface in early pregnancy.	Cyclosporine	26-29	heart and neural crest derivatives expressed 2	Mus musculus	57-60
23028901-7	2012	These results suggest that CsA promotes Th2 bias at the maternal-fetal interface by increasing Th2-type cytokine production in trophoblasts with the aid of DSCs and DICs, while inhibiting Th1-type cytokine production in DICs and TNF-alpha production in all investigated cells.	Cyclosporine	27-30	heart and neural crest derivatives expressed 2	Mus musculus	40-43
18538359-2	2008	Chronic (&gt;or=3h) treatment of cultured bovine adrenal chromaffin cells with cyclosporin A or FK506 decreased IRS-2 protein level by approximately 50% (IC(50)=200 or 10nM), without changing IRS-2 mRNA level, and insulin receptor, insulin-like growth factor-I (IGF-I) receptor, IRS-1, PI3K/PDK-1/Akt/GSK-3beta and ERK1/ERK2 protein levels.	Cyclosporine	79-92	insulin receptor substrate 1	Bos taurus	279-284
22615870-6	2012	The role of P-gp was strengthened by partial reversal of the DOX and vinorelbine resistance by cyclosporine A.	Cyclosporine	95-109	phosphoglycolate phosphatase	Homo sapiens	12-16
18448283-10	2008	CONCLUSIONS: The increase in CETP activity and suppression in LPL activity following CsA and RAPA treatment observed in the present study may be associated with elevated LDL cholesterol levels and hypertriglyceridemia seen in patients administered these drugs.	Cyclosporine	85-88	lipoprotein lipase	Homo sapiens	62-65
18385230-0	2008	Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro.	Cyclosporine	101-113	peptidylprolyl isomerase A	Homo sapiens	0-13
18385230-4	2008	A strong correlation between CsA resistance and reduced dependency on cyclophilin A (CyPA) for replication was identified.	Cyclosporine	29-32	peptidylprolyl isomerase A	Homo sapiens	70-83
18385230-4	2008	A strong correlation between CsA resistance and reduced dependency on cyclophilin A (CyPA) for replication was identified.	Cyclosporine	29-32	peptidylprolyl isomerase A	Homo sapiens	85-89
18385230-8	2008	Depletion of CyPA alone in the CsA-resistant replicon cells eliminated CsA resistance, indicating that CyPA is the chief mediator of the observed CsA resistance.	Cyclosporine	31-34	peptidylprolyl isomerase A	Homo sapiens	13-17
18385230-8	2008	Depletion of CyPA alone in the CsA-resistant replicon cells eliminated CsA resistance, indicating that CyPA is the chief mediator of the observed CsA resistance.	Cyclosporine	71-74	peptidylprolyl isomerase A	Homo sapiens	13-17
18385230-8	2008	Depletion of CyPA alone in the CsA-resistant replicon cells eliminated CsA resistance, indicating that CyPA is the chief mediator of the observed CsA resistance.	Cyclosporine	71-74	peptidylprolyl isomerase A	Homo sapiens	13-17
18385230-10	2008	An interaction between CyPA and HCV RNA as well as the viral polymerase that is sensitive to CsA treatment in wild-type but not in resistant replicons was detected.	Cyclosporine	93-96	peptidylprolyl isomerase A	Homo sapiens	23-27
18385230-11	2008	These findings reveal the molecular mechanism of CsA resistance and identify CyPA as a critical cellular cofactor for HCV replication and infection.	Cyclosporine	49-52	peptidylprolyl isomerase A	Homo sapiens	77-81
17999162-5	2008	The numbers of cells undergoing apoptosis/necrosis, as well as of those displaying the activation of apoptosis-inducing enzymes of caspase family, were respectively increased or reduced by THF/nC60/70 or C60/70(OH)n. The antioxidant N-acetylcysteine and mitochondrial permeability transition inhibitor cyclosporin A each partly blocked the cytotoxic action of TNF, indicating the involvement of oxidative stress and mitochondrial dysfunction in the TNF cytotoxicity.	Cyclosporine	302-315	thin fur	Mus musculus	189-192
18065803-14	2008	We previously reported that one child with truncating mutation in PLCE1 responded to cyclosporine therapy.	Cyclosporine	85-97	phospholipase C epsilon 1	Homo sapiens	66-71
18182482-5	2008	In this study, we show that cyclosporin A and PSC833 treatment of NCX2- and NCX3-transfected HEK 293 cells also resulted in dose-dependent down-regulation of surface expression and transport activity of the two brain NCX proteins; however, whereas CsA had no effect on total cell NCX protein expression, PSC833 reduced mRNA and cell protein expression of NCX2 and NCX3.	Cyclosporine	28-41	solute carrier family 8 member A2	Homo sapiens	66-70
18182482-5	2008	In this study, we show that cyclosporin A and PSC833 treatment of NCX2- and NCX3-transfected HEK 293 cells also resulted in dose-dependent down-regulation of surface expression and transport activity of the two brain NCX proteins; however, whereas CsA had no effect on total cell NCX protein expression, PSC833 reduced mRNA and cell protein expression of NCX2 and NCX3.	Cyclosporine	28-41	solute carrier family 8 member A2	Homo sapiens	355-359
18182482-5	2008	In this study, we show that cyclosporin A and PSC833 treatment of NCX2- and NCX3-transfected HEK 293 cells also resulted in dose-dependent down-regulation of surface expression and transport activity of the two brain NCX proteins; however, whereas CsA had no effect on total cell NCX protein expression, PSC833 reduced mRNA and cell protein expression of NCX2 and NCX3.	Cyclosporine	248-251	solute carrier family 8 member A2	Homo sapiens	66-70
18230621-9	2008	These results, thus, argue for the existence of an alternative Bax/Bak-independent apoptotic mechanism that involves cyclosporine A-sensitive mitochondrial membrane permeability.	Cyclosporine	117-131	BCL2-antagonist/killer 1	Mus musculus	67-70
18184875-9	2008	Application of cyclosporin A or FK506, inhibitors of PP2B, significantly decreased ROMK channels, and the effect of PP2B inhibitors was abolished by blocking p38 mitogen-activated protein kinase (MAPK) and ERK.	Cyclosporine	15-28	potassium inwardly-rectifying channel, subfamily J, member 1	Mus musculus	83-87
18216318-8	2008	Treatment with cyclosporine A improves the regulation of solute and water by preventing the downregulation of aquaporin-2 and epithelial sodium channel, even though many other transporter genes remain downregulated.	Cyclosporine	15-29	aquaporin 2	Rattus norvegicus	110-121
17962511-6	2008	In addition, dasatinib combined with cyclosporine A or rapamycin led to a much more potent inhibition of T-cell activation, suggesting that targeted inhibition of Lck could be a useful adjunct for enhanced immunomodulation.	Cyclosporine	37-51	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	163-166
17982500-6	2008	After topical Cys treatment, significant improvements were found in symptom scores, corneal sensitivity, tear evaporation rate, TBUT, vital staining scores, goblet cells density, conjunctival squamous metaplasia grade, inflammatory cell numbers and the MUC5AC expression.	Cyclosporine	14-17	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	253-259
18095667-2	2008	Its immunosuppressive activity is due to the formation of a complex with cyclophilin A (Cyp), in which the cis 9MeLeu-10MeLeu amide bond of CsA assumes a trans conformation.	Cyclosporine	140-143	peptidylprolyl isomerase G	Homo sapiens	73-86
18095667-2	2008	Its immunosuppressive activity is due to the formation of a complex with cyclophilin A (Cyp), in which the cis 9MeLeu-10MeLeu amide bond of CsA assumes a trans conformation.	Cyclosporine	140-143	peptidylprolyl isomerase G	Homo sapiens	88-91
17936633-7	2008	The results displayed that only compound 3c was P-gp inhibitor as Elacridar, while compound 3a and reference compounds Cyclosporin A and Verapamil modulated P-gp activity saturating the efflux pump as substrates.	Cyclosporine	119-132	phosphoglycolate phosphatase	Homo sapiens	157-161
18220553-9	2008	Release of Cyclosporine A from GMS SLN followed Higuchi equation better than first order while release from GPS SLN followed first order better than Higuchi model.	Cyclosporine	11-25	sarcolipin	Homo sapiens	35-38
18574772-7	2008	RESULTS: CsA decreased CD3- CD56+ NK cell recovery in anti-CD3-stimulated CB MNC 5-day cultures, an effect that could be counteracted by IL-15; comparable effects were observed with APB.	Cyclosporine	9-12	neural cell adhesion molecule 1	Homo sapiens	28-32
17940134-5	2008	The directional transport disappeared on addition of cyclosporin A, a P-gp inhibitor.	Cyclosporine	53-66	phosphoglycolate phosphatase	Homo sapiens	70-74
17960138-9	2008	EGFR or phosphoinositide 3-kinase inhibitors protected from cyclosporine-triggered cell death without decreasing ROS.	Cyclosporine	60-72	epidermal growth factor receptor	Mus musculus	0-4
17960138-11	2008	Our results show that EGFR mediates the cytotoxic effects of cyclosporine through an ROS-independent mechanism.	Cyclosporine	61-73	epidermal growth factor receptor	Mus musculus	22-26
17933973-8	2007	IDO gene transfer combined with low-dose cyclosporin A (CsA) was more effective than CsA alone (P &lt; 0.05).	Cyclosporine	56-59	indoleamine 2,3-dioxygenase 1	Homo sapiens	0-3
17933973-8	2007	IDO gene transfer combined with low-dose cyclosporin A (CsA) was more effective than CsA alone (P &lt; 0.05).	Cyclosporine	85-88	indoleamine 2,3-dioxygenase 1	Homo sapiens	0-3
17956473-0	2007	Gingival fibroblasts grown from cyclosporin-treated patients show a reduced production of matrix metalloproteinase-1 (MMP-1) compared with normal gingival fibroblasts, and cyclosporin down-regulates the production of MMP-1 stimulated by pro-inflammatory cytokines.	Cyclosporine	32-43	matrix metallopeptidase 1	Homo sapiens	90-116
21802460-5	2011	The covering of skin allografts with CsA-loaded nanofibers significantly attenuated the local production of the proinflammatory cytokines IL-2, IFN-gamma and IL-17.	Cyclosporine	37-40	interleukin 2	Mus musculus	138-142
17956473-0	2007	Gingival fibroblasts grown from cyclosporin-treated patients show a reduced production of matrix metalloproteinase-1 (MMP-1) compared with normal gingival fibroblasts, and cyclosporin down-regulates the production of MMP-1 stimulated by pro-inflammatory cytokines.	Cyclosporine	32-43	matrix metallopeptidase 1	Homo sapiens	118-123
17956473-0	2007	Gingival fibroblasts grown from cyclosporin-treated patients show a reduced production of matrix metalloproteinase-1 (MMP-1) compared with normal gingival fibroblasts, and cyclosporin down-regulates the production of MMP-1 stimulated by pro-inflammatory cytokines.	Cyclosporine	32-43	matrix metallopeptidase 1	Homo sapiens	217-222
17956473-0	2007	Gingival fibroblasts grown from cyclosporin-treated patients show a reduced production of matrix metalloproteinase-1 (MMP-1) compared with normal gingival fibroblasts, and cyclosporin down-regulates the production of MMP-1 stimulated by pro-inflammatory cytokines.	Cyclosporine	172-183	matrix metallopeptidase 1	Homo sapiens	217-222
17956473-2	2007	The aim of this study was to investigate the interaction among interleukin-1, oncostatin M, cyclosporin and nifedipine in promoting the up-regulation of matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of metalloproteinase by gingival fibroblasts.	Cyclosporine	92-103	matrix metallopeptidase 1	Homo sapiens	153-179
17956473-2	2007	The aim of this study was to investigate the interaction among interleukin-1, oncostatin M, cyclosporin and nifedipine in promoting the up-regulation of matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of metalloproteinase by gingival fibroblasts.	Cyclosporine	92-103	matrix metallopeptidase 1	Homo sapiens	181-186
21918035-7	2011	However, vectorial transport across LLC-OCT1/MDR1 cells was identified, which was inhibited by the MDR1 inhibitor cyclosporine A, clearly indicating that YM155 is in fact a substrate of MDR1.	Cyclosporine	114-128	ATP-binding cassette, sub-family B (MDR/TAP), member 1	Sus scrofa	45-49
17956473-7	2007	RESULTS: Fibroblasts obtained from patients with cyclosporin-induced gingival overgrowth produced significantly lower levels of MMP-1 than control fibroblasts (p &lt; 0.001); tissue inhibitor of metalloproteinase-1 levels were significantly lower (p &lt; 0.05), and the ratio of MMP-1 to tissue inhibitor of metalloproteinase-1 was reduced, in the conditioned medium of patients with cyclosporin-induced gingival overgrowth compared with controls.	Cyclosporine	49-60	matrix metallopeptidase 1	Homo sapiens	128-133
17956473-7	2007	RESULTS: Fibroblasts obtained from patients with cyclosporin-induced gingival overgrowth produced significantly lower levels of MMP-1 than control fibroblasts (p &lt; 0.001); tissue inhibitor of metalloproteinase-1 levels were significantly lower (p &lt; 0.05), and the ratio of MMP-1 to tissue inhibitor of metalloproteinase-1 was reduced, in the conditioned medium of patients with cyclosporin-induced gingival overgrowth compared with controls.	Cyclosporine	49-60	matrix metallopeptidase 1	Homo sapiens	279-284
17956473-8	2007	Interleukin-1 and oncostatin M produced a significant increase in the up-regulation of MMP-1, which was reversed when cyclosporin and nifedipine were added to the cell cultures (p &lt; 0.05).	Cyclosporine	118-129	interleukin 1 alpha	Homo sapiens	0-13
17956473-8	2007	Interleukin-1 and oncostatin M produced a significant increase in the up-regulation of MMP-1, which was reversed when cyclosporin and nifedipine were added to the cell cultures (p &lt; 0.05).	Cyclosporine	118-129	matrix metallopeptidase 1	Homo sapiens	87-92
17998872-4	2007	RESULTS: A brief treatment of Serp-1 alone, or a subtherapeutic dose of CsA, resulted in a marked decrease in intragraft macrophage infiltration and downregulation of toll-like receptor (TLR)-2, TLR4 and MyD88 at 48 hours posttransplantation, which was associated with significantly reduced numbers of mature dendritic cells.	Cyclosporine	72-75	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	204-209
22032989-5	2011	Tandem affinity purification and immunoprecipitations combined with mass spectrometry studies indicate that CSA and CSB associate within a Cullin Ring Ubiquitin Ligase complex responsible, under certain circumstances, for p53 ubiquitination.	Cyclosporine	108-111	CDK2 associated cullin domain 1	Homo sapiens	139-145
21963115-1	2011	Potent cyclophilin A (CypA) inhibitors such as non-immunosuppressive cyclosporin A (CsA) derivatives have been already used in clinical trials in patients with viral infections.	Cyclosporine	69-82	peptidylprolyl isomerase A	Homo sapiens	7-20
17970686-3	2007	SPARC (secreted protein, acidic, and rich in cysteine) regulates cell-matrix interactions, binding to structural matrix proteins, and is induced by cyclosporin A (CsA).	Cyclosporine	148-161	secreted protein acidic and cysteine rich	Homo sapiens	0-5
21963115-1	2011	Potent cyclophilin A (CypA) inhibitors such as non-immunosuppressive cyclosporin A (CsA) derivatives have been already used in clinical trials in patients with viral infections.	Cyclosporine	69-82	peptidylprolyl isomerase A	Homo sapiens	22-26
17970686-3	2007	SPARC (secreted protein, acidic, and rich in cysteine) regulates cell-matrix interactions, binding to structural matrix proteins, and is induced by cyclosporin A (CsA).	Cyclosporine	163-166	secreted protein acidic and cysteine rich	Homo sapiens	0-5
21963115-1	2011	Potent cyclophilin A (CypA) inhibitors such as non-immunosuppressive cyclosporin A (CsA) derivatives have been already used in clinical trials in patients with viral infections.	Cyclosporine	84-87	peptidylprolyl isomerase A	Homo sapiens	7-20
21963115-1	2011	Potent cyclophilin A (CypA) inhibitors such as non-immunosuppressive cyclosporin A (CsA) derivatives have been already used in clinical trials in patients with viral infections.	Cyclosporine	84-87	peptidylprolyl isomerase A	Homo sapiens	22-26
21963115-6	2011	However, in the context of the CsA framework a net charge of -7 clustered at the amino acid side chain of position 1 resulted in slightly improved CypA inhibition.	Cyclosporine	31-34	peptidylprolyl isomerase A	Homo sapiens	147-151
22092633-9	2011	RESULTS: High dosage cyclosporine resulted in significant decreases in IL-2 and IFN-gamma expression (P = .0156, P = .0156), but not IL-4 expression (P = .2188).	Cyclosporine	21-33	interferon gamma	Canis lupus familiaris	80-89
17728232-5	2007	Notably, these mutations also enhanced viral resistance to the drug cyclosporine A, indicating a reduced dependence of the compensated virus on CypA that is normally essential for optimal infectivity.	Cyclosporine	68-82	peptidylprolyl isomerase A	Homo sapiens	144-148
22092633-10	2011	Low dosage cyclosporine was associated with a significant decrease in IFN-gamma expression (P = .0156), while IL-2 expression was not affected (P = .1094).	Cyclosporine	11-23	interferon gamma	Canis lupus familiaris	70-79
21844115-10	2011	Although the use of cyclosporine A (CyA) was associated with hypertension (p &lt; 0.05), those who received a lower cumulative dose of CyA had thicker CIMT (r (s) = -0.33, p =0.01) and CyA use remained an independent predictor of CIMT during linear regression analysis.	Cyclosporine	135-138	CIMT	Homo sapiens	151-155
22046132-8	2011	Conversely, inhibition of cyclophilins by cyclosporine A (CspA) blocked the replication of CoVs of all genera, including SARS-CoV, human CoV-229E and -NL-63, feline CoV, as well as avian infectious bronchitis virus.	Cyclosporine	42-56	peptidylprolyl isomerase A	Homo sapiens	26-38
22046132-8	2011	Conversely, inhibition of cyclophilins by cyclosporine A (CspA) blocked the replication of CoVs of all genera, including SARS-CoV, human CoV-229E and -NL-63, feline CoV, as well as avian infectious bronchitis virus.	Cyclosporine	58-62	peptidylprolyl isomerase A	Homo sapiens	26-38
21946207-0	2011	[Expression and mechanism of osteoactivin in the kidney  of SD rats after acute cyclosporine A toxicity].	Cyclosporine	80-94	glycoprotein nmb	Rattus norvegicus	29-41
21946207-1	2011	OBJECTIVE: To determine the expression and mechanism of osteoactivin (OA) in the kidney by establishing SD rat model of acute cyclosporine A (CsA) toxicity.	Cyclosporine	126-140	glycoprotein nmb	Rattus norvegicus	56-68
21946207-1	2011	OBJECTIVE: To determine the expression and mechanism of osteoactivin (OA) in the kidney by establishing SD rat model of acute cyclosporine A (CsA) toxicity.	Cyclosporine	126-140	glycoprotein nmb	Rattus norvegicus	70-72
21946207-1	2011	OBJECTIVE: To determine the expression and mechanism of osteoactivin (OA) in the kidney by establishing SD rat model of acute cyclosporine A (CsA) toxicity.	Cyclosporine	142-145	glycoprotein nmb	Rattus norvegicus	56-68
21946207-1	2011	OBJECTIVE: To determine the expression and mechanism of osteoactivin (OA) in the kidney by establishing SD rat model of acute cyclosporine A (CsA) toxicity.	Cyclosporine	142-145	glycoprotein nmb	Rattus norvegicus	70-72
21946207-9	2011	After CsA gavage, the relative mRNA expressions of OA, MMP-13, and Col III significantly increased with time.	Cyclosporine	6-9	glycoprotein nmb	Rattus norvegicus	51-53
21946207-11	2011	CONCLUSION: OA expresses in the kidney of SD rats after acute CsA toxicity and mainly expresses in the tubular epithelial cells and renal interstitium.	Cyclosporine	62-65	glycoprotein nmb	Rattus norvegicus	12-14
21946207-12	2011	OA is more sensitive to the damage of kidney tissue caused by CsA than by SCr.	Cyclosporine	62-65	glycoprotein nmb	Rattus norvegicus	0-2
21946207-13	2011	The early-phase up-regulation of OA expression in the tubular epithelium in response to renal injury caused by acute CsA toxicity might play a key role in triggering the renal interstitial fibrosis via activating expression of MMPs and collagen remodeling in SD rats.	Cyclosporine	117-120	glycoprotein nmb	Rattus norvegicus	33-35
21781066-1	2011	OBJECTIVE: The aim of this study is to determine serum levels of soluble forms of CD26/dipeptidyl-peptidase IV (DPP-IV) and adenosine deaminase (ADA), thought to be markers of T-cell activation, and changes in their levels in response to cyclosporine, etanercept, and psoralen plus ultraviolet A (PUVA) treatments with respect to disease activity.	Cyclosporine	238-250	dipeptidyl peptidase 4	Homo sapiens	82-110
21781066-1	2011	OBJECTIVE: The aim of this study is to determine serum levels of soluble forms of CD26/dipeptidyl-peptidase IV (DPP-IV) and adenosine deaminase (ADA), thought to be markers of T-cell activation, and changes in their levels in response to cyclosporine, etanercept, and psoralen plus ultraviolet A (PUVA) treatments with respect to disease activity.	Cyclosporine	238-250	dipeptidyl peptidase 4	Homo sapiens	112-118
21622902-6	2011	ERK inhibition significantly decreased CsA-stimulated Nrf-2 nuclear translocation and HO-1 mRNA expression.	Cyclosporine	39-42	heme oxygenase 1	Homo sapiens	86-90
21622902-8	2011	These findings suggest that CsA-stimulated HO-1 expression is mediated through the activation of ERK, and that Nrf-2 plays a protective role against CsA-induced gingival fibrosis by modulating collagen turnover-related genes.	Cyclosporine	28-31	heme oxygenase 1	Homo sapiens	43-47
21593166-4	2011	CypA inhibitors such as cyclosporine (CsA) have been shown to inhibit hepatitis C virus (HCV) replication.	Cyclosporine	24-36	peptidylprolyl isomerase A	Homo sapiens	0-4
21593166-4	2011	CypA inhibitors such as cyclosporine (CsA) have been shown to inhibit hepatitis C virus (HCV) replication.	Cyclosporine	38-41	peptidylprolyl isomerase A	Homo sapiens	0-4
21635950-7	2011	CD3(+)CD56(+)NKT cells were also lower during immunosuppressive therapy with tacrolimus (0.03+-0.01/HPF) than with cyclosporine (0.1+-0.003/HPF), cyclosporine/MMF (0.1+-0.003/HPF) or sirolimus (0.1+-0.01/HPF) treatment.	Cyclosporine	115-127	neural cell adhesion molecule 1	Homo sapiens	6-10
21635950-7	2011	CD3(+)CD56(+)NKT cells were also lower during immunosuppressive therapy with tacrolimus (0.03+-0.01/HPF) than with cyclosporine (0.1+-0.003/HPF), cyclosporine/MMF (0.1+-0.003/HPF) or sirolimus (0.1+-0.01/HPF) treatment.	Cyclosporine	146-158	neural cell adhesion molecule 1	Homo sapiens	6-10
21489988-9	2011	CypA indeed interacts with NS5A-D3, and this interaction is completely abolished by cyclosporin A.	Cyclosporine	84-97	peptidylprolyl isomerase A	Homo sapiens	0-4
20351753-8	2011	The Down"s syndrome candidate region-1 (DSCR1), an endogenous calcineurin inhibitor, overexpression and subsequent calcineurin inhibition significantly reduced GSIS in cells expressing the R325 but not the W325 variant, suggesting that differing susceptibility to CsA may be due to different interactions with calcineurin.	Cyclosporine	264-267	regulator of calcineurin 1	Homo sapiens	40-45
21333626-0	2011	Procarcinogenic effects of cyclosporine A are mediated through the activation of TAK1/TAB1 signaling pathway.	Cyclosporine	27-41	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	81-85
21146153-0	2011	Toll like receptor 4 and membrane-bound CD14 expressions in gingivitis, periodontitis and CsA-induced gingival overgrowth.	Cyclosporine	90-93	toll like receptor 4	Homo sapiens	0-20
21146153-2	2011	This study was aimed to investigate the expression of TLR4 and membrane-bound CD14 (mCD14) in the gingival tissues of patients with gingivitis, periodontitis and CsA-induced gingival overgrowth.	Cyclosporine	162-165	toll like receptor 4	Homo sapiens	54-58
21490080-7	2011	RESULTS: Compared with the control group, acidic buffer or plus cyclosporine A post-conditioning significantly improved myocardial performance, decreased cytochrome C release into the cytosol, increased Bcl-2 expression and decreased Bax expression, decreased sensitivity of mPTP-opening to [Ca2+] and the rate of apoptosis after reperfusion.	Cyclosporine	64-78	BCL2 associated X, apoptosis regulator	Rattus norvegicus	234-237
21316383-9	2011	Subsequent studies with the MPT inhibitor cyclosporine A showed that cyclosporine A (CYC; 10mg/kg) reduced HIF-1alpha induction in APAP treated mice at 1 and 4h and did not inhibit the metabolism of APAP (depletion of hepatic non-protein sulfhydryls and hepatic protein adduct levels).	Cyclosporine	69-83	hypoxia inducible factor 1, alpha subunit	Mus musculus	107-117
21316383-9	2011	Subsequent studies with the MPT inhibitor cyclosporine A showed that cyclosporine A (CYC; 10mg/kg) reduced HIF-1alpha induction in APAP treated mice at 1 and 4h and did not inhibit the metabolism of APAP (depletion of hepatic non-protein sulfhydryls and hepatic protein adduct levels).	Cyclosporine	85-88	hypoxia inducible factor 1, alpha subunit	Mus musculus	107-117
21233311-1	2011	We evaluated the role of granulocyte colony-stimulating factor (G-CSF) in patients with severe aplastic anemia (SAA) treated with antithymocyte globulin (ATG) and cyclosporine (CSA).	Cyclosporine	163-175	colony stimulating factor 3	Homo sapiens	64-69
21453156-8	2011	RESULTS: Cyclosporine, dexamethasone, cyclosporine-dexamethasone combination, and CTLA4-Ig caused a significant decrease in IL-2, IFN-gamma, and GM-CSF production.	Cyclosporine	9-21	interleukin 2	Felis catus	124-128
21453156-8	2011	RESULTS: Cyclosporine, dexamethasone, cyclosporine-dexamethasone combination, and CTLA4-Ig caused a significant decrease in IL-2, IFN-gamma, and GM-CSF production.	Cyclosporine	9-21	granulocyte-macrophage colony-stimulating factor	Felis catus	145-151
21453156-8	2011	RESULTS: Cyclosporine, dexamethasone, cyclosporine-dexamethasone combination, and CTLA4-Ig caused a significant decrease in IL-2, IFN-gamma, and GM-CSF production.	Cyclosporine	38-50	interleukin 2	Felis catus	124-128
21453156-8	2011	RESULTS: Cyclosporine, dexamethasone, cyclosporine-dexamethasone combination, and CTLA4-Ig caused a significant decrease in IL-2, IFN-gamma, and GM-CSF production.	Cyclosporine	38-50	granulocyte-macrophage colony-stimulating factor	Felis catus	145-151
21198643-7	2011	RESULTS: Proliferating cell nuclear antigen and cyclin D1 mRNAs (Pcna and Ccnd1, respectively) were expressed more strongly in the gingivae of cyclosporine A-treated animals than in the gingivae of the controls.	Cyclosporine	143-157	proliferating cell nuclear antigen	Homo sapiens	9-43
17919240-9	2007	RESULTS: NIM811, as well as cyclosporine, suppressed the transcription and synthesis of collagen and stimulated the production of MMP-1 with a concomitant enhancement of collagenase activity, although it did not change the expression of TIMP-1.	Cyclosporine	28-40	matrix metallopeptidase 1	Homo sapiens	130-135
21198643-7	2011	RESULTS: Proliferating cell nuclear antigen and cyclin D1 mRNAs (Pcna and Ccnd1, respectively) were expressed more strongly in the gingivae of cyclosporine A-treated animals than in the gingivae of the controls.	Cyclosporine	143-157	proliferating cell nuclear antigen	Homo sapiens	65-69
18005851-7	2007	The immunosuppressants rapamycin, cyclosporine A, and methylprednisolone significantly inhibited the expansion of regulatory T cells upon stimulation with alloantigen, whereas mycophenolic acid and the costimulatory blockers, anti-CD40L and CTLA4Ig, did not.	Cyclosporine	34-48	CD40 ligand	Mus musculus	231-236
21198643-9	2011	Increased expression of cyclin D1, CDK4 and PCNA proteins was observed in HGFs after cyclosporine A treatment.	Cyclosporine	85-99	proliferating cell nuclear antigen	Homo sapiens	44-48
17651692-4	2007	CsA treatment dramatically reduced the mRNA levels of adipocyte-specific genes (aP2, HSL, PPARgamma, ACS and Adn), compared with control or TNFalpha-treatment, whereas Li(+) pretreatment blocked the inhibitory effects of CsA, and mRNA levels of aP2, HSL, PPARgamma, and ACS were found at or above control levels.	Cyclosporine	0-3	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	101-104
21198643-11	2011	CONCLUSION: The increases in cyclin D1, PCNA and CDK4, together with the enhanced phosphorylation of Rb1, suggest that cyclosporine A promotes cell-cycle progression through the G(1)/S transition in the gingiva.	Cyclosporine	119-133	proliferating cell nuclear antigen	Homo sapiens	40-44
17651692-4	2007	CsA treatment dramatically reduced the mRNA levels of adipocyte-specific genes (aP2, HSL, PPARgamma, ACS and Adn), compared with control or TNFalpha-treatment, whereas Li(+) pretreatment blocked the inhibitory effects of CsA, and mRNA levels of aP2, HSL, PPARgamma, and ACS were found at or above control levels.	Cyclosporine	0-3	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	270-273
17596534-6	2007	Furthermore, CsA exposure lead to a reduction of telomere length, increased p53 serine 15 phosphorylation, and caused an upregulation of the cell cycle inhibitor p21(Kip1) (CDKN1A) mRNA levels.	Cyclosporine	13-16	cyclin dependent kinase inhibitor 1B	Homo sapiens	166-170
21245207-9	2011	Certain drugs (e.g., cyclosporine) potently inhibit OATP1B1, causing clinically significant drug interactions.	Cyclosporine	21-33	solute carrier organic anion transporter family member 1B1	Homo sapiens	52-59
17645631-13	2007	Erythropoietin has a significant angiogenic effect in rat kidney with CsA-induced nephrotoxicity, similar to the effect of the other angiogenic factor bFGF.	Cyclosporine	70-73	erythropoietin	Rattus norvegicus	0-14
21285761-14	2011	Flow cytometric analysis revealed a significant increase in the percentage of CD4+/CD25+ and CD4+/FoxP3+ T cells in both the blood and graft in the mesenchymal stem cell/irradiation/cyclosporine A group.	Cyclosporine	182-196	forkhead box P3	Sus scrofa	98-103
17467222-0	2007	Cyclosporine A inhibits acetylcholinesterase activity in rats experimentally demyelinated with ethidium bromide.	Cyclosporine	0-14	acetylcholinesterase	Rattus norvegicus	24-44
17467222-2	2007	In this work, we investigated the effect of the cyclosporine A on the acetylcholinesterase activity in the cerebral cortex, striatum, hippocampus, hypothalamus, cerebellum and pons of the rats experimentally demyelinated by ethidium bromide.	Cyclosporine	48-62	acetylcholinesterase	Rattus norvegicus	70-90
17467222-6	2007	In conclusion, the present investigation demonstrated that cyclosporine A is an inhibitor of acetylcholinesterase activity and this effect is increased after an event of toxic demyelination of the central nervous system.	Cyclosporine	59-73	acetylcholinesterase	Rattus norvegicus	93-113
17308321-10	2007	Using flow cytometry and fluorescein isothiocyanate-labelled annexin V as a probe for PS, we demonstrated an increased binding of this marker to a CsA-treated platelet population.	Cyclosporine	147-150	annexin A5	Homo sapiens	61-70
21216355-9	2011	The combination of the ABCB1 and ABCC transporter substrate calcein-AM with inhibitors cyclosporine A, PSC833 and MK571 resulted in a concentration-dependent fluorescence increase of up to 3-fold, whereas reversin 205 caused a slight, but not concentration-dependent fluorescence increase.	Cyclosporine	87-101	ATP-dependent translocase ABCB1	Oncorhynchus mykiss	23-28
21249202-4	2011	METHODS AND FINDINGS: Purified brain mitochondria of Pink1-/- mice showed impaired Ca2+ storage capacity, resulting in increased Ca2+ induced mitochondrial permeability transition (mPT) that was rescued by cyclosporine A.	Cyclosporine	206-220	PTEN induced putative kinase 1	Mus musculus	53-58
17549302-3	2007	Consistent with the importance of this pathway for tissue factor induction, treatment of endothelial cells with the Ca(++) chelator BAPTA-AM, as well as the calcineurin inhibitor cyclosporin A, partially inhibited VEGF-induced tissue factor upregulation.	Cyclosporine	179-192	coagulation factor III, tissue factor	Homo sapiens	51-64
17549302-3	2007	Consistent with the importance of this pathway for tissue factor induction, treatment of endothelial cells with the Ca(++) chelator BAPTA-AM, as well as the calcineurin inhibitor cyclosporin A, partially inhibited VEGF-induced tissue factor upregulation.	Cyclosporine	179-192	coagulation factor III, tissue factor	Homo sapiens	227-240
21094139-7	2011	ILY induced early growth response-1 (EGR-1) expression and it was inhibited by the pre-treatment with cyclosporine A, indicating that the calcineurin/NFAT pathway was involved in EGR-1 expression in response to ILY.	Cyclosporine	102-116	early growth response 1	Homo sapiens	179-184
17188247-11	2007	The long-term exposure (48 h) of cells to genistein caused Mcl-1 down-regulation and Bad cleavage; furthermore, cyclosporin A (an inhibitor of mitochondrial permeability transition pore) almost completely abolished genistein-induced loss of mitochondrial membrane potential, and induced a 30% reverse of apoptosis caused by long-term treatment (48 h) of genistein, suggesting the involvement of mitochondrial stress in the late phase of genistein-induced effect.	Cyclosporine	112-125	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	59-64
21358177-10	2011	Tacrolimus and cyclosporine increased fibronectin and TGF-beta expression and matrix deposition.	Cyclosporine	15-27	fibronectin 1	Rattus norvegicus	38-49
21888018-7	2011	RESULTS: Cathepsin D, L, and vascular endothelial growth factor (VEGF)165 mRNA were markedly suppressed in CsA-treated HGFs, whereas cathepsin B, matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of metalloproteinase-1 (TIMP-1) mRNA were not reduced.	Cyclosporine	107-110	matrix metallopeptidase 1	Homo sapiens	174-179
17502025-26	2007	CsA inhibits IL-2 gene transcripts, so it can reduce development of the pathologic lesion of obliterative bronchiolitis to a certain degree.	Cyclosporine	0-3	interleukin 2	Rattus norvegicus	13-17
19939655-7	2011	The results demonstrated that CsA treatment decreases blood levels of interleukins 1alpha (IL-1alpha), 1beta (IL-1beta) and interleukin 2 (IL-2), but does not alter interleukin 6 (IL-6) and IFN-gamma levels.	Cyclosporine	30-33	interleukin 2	Rattus norvegicus	124-137
19939655-7	2011	The results demonstrated that CsA treatment decreases blood levels of interleukins 1alpha (IL-1alpha), 1beta (IL-1beta) and interleukin 2 (IL-2), but does not alter interleukin 6 (IL-6) and IFN-gamma levels.	Cyclosporine	30-33	interleukin 2	Rattus norvegicus	139-143
19939655-7	2011	The results demonstrated that CsA treatment decreases blood levels of interleukins 1alpha (IL-1alpha), 1beta (IL-1beta) and interleukin 2 (IL-2), but does not alter interleukin 6 (IL-6) and IFN-gamma levels.	Cyclosporine	30-33	interleukin 18	Rattus norvegicus	190-199
21901144-4	2011	Furthermore, we show that infiltration of implanted gliomas by amoeboid, Iba1-positive cells can be reduced by a systematically injected cyclosporine A (CsA) two or eight days after cell inoculation.	Cyclosporine	137-151	allograft inflammatory factor 1	Homo sapiens	73-77
16586042-0	2007	Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis.	Cyclosporine	15-29	melanocyte inducing transcription factor	Homo sapiens	157-161
16586042-6	2007	Addition of tacrolimus or cyclosporine A resulted in a decrease in the number of TRAP-positive multinucleated cells (TRAP+ MNCs) and a decrease in the extent of lacunar resorption pit formation as compared to the control cultures; thus, human monocyte-osteoclast differentiation was more effectively inhibited at the late stage and addition of tacrolimus or cyclosporine A resulted in a decrease in the mRNA expression of NFATc1, c-Jun, and MITF at the late stage.	Cyclosporine	26-40	melanocyte inducing transcription factor	Homo sapiens	441-445
16586042-7	2007	Our results suggest that tacrolimus or cyclosporine A acts directly on human osteoclast precursors in RA patients and exerts their immunosuppressive effects on human monocyte-osteoclast formation via targeting both the calcineurin-dependent NFAT pathway and activation pathway for c-Jun or MITF.	Cyclosporine	39-53	melanocyte inducing transcription factor	Homo sapiens	290-294
21901144-4	2011	Furthermore, we show that infiltration of implanted gliomas by amoeboid, Iba1-positive cells can be reduced by a systematically injected cyclosporine A (CsA) two or eight days after cell inoculation.	Cyclosporine	153-156	allograft inflammatory factor 1	Homo sapiens	73-77
21212461-3	2010	Here we report that the NAD+-dependent deacetylase SIRT3 deacetylates the regulatory component of the mPTP, cyclophilin D (CypD) on lysine 166, adjacent to the binding site of cyclosporine A, a CypD inhibitor.	Cyclosporine	176-190	sirtuin 3	Mus musculus	51-56
17180728-8	2007	The second generation antihistamines terfenadine and loratadine, achieved substantial brain penetration, which was further enhanced by Pgp inhibition by cyclosporin A (CSA).	Cyclosporine	153-166	PGP	Canis lupus familiaris	135-138
17180728-8	2007	The second generation antihistamines terfenadine and loratadine, achieved substantial brain penetration, which was further enhanced by Pgp inhibition by cyclosporin A (CSA).	Cyclosporine	168-171	PGP	Canis lupus familiaris	135-138
21212461-4	2010	Cardiac myocytes from mice lacking SIRT3 exhibit an age-dependent increase in mitochondrial swelling due to increased mPTP opening, a phenotype that is rescued by cyclosporine A.	Cyclosporine	163-177	sirtuin 3	Mus musculus	35-40
21267404-8	2010	Moreover, cyclosporine A, which is known as a calcineurin inhibitor blocking NFAT activation, enhanced tyrosinase activity and melanin content.	Cyclosporine	10-24	tyrosinase	Mus musculus	103-113
16636798-12	2007	As compared to cyclosporin A, these compounds showed reduced cellular toxicity and increased potency of BCRP and Pgp inhibition.	Cyclosporine	15-28	BCR pseudogene 1	Homo sapiens	104-108
20589831-8	2010	In addition, LTD(4)-stimulated migration through increased activation of focal adhesion kinase (FAK) and paxillin which were blocked by Akt inhibitor and cyclosporine A.	Cyclosporine	154-168	PTK2 protein tyrosine kinase 2	Mus musculus	73-94
17389650-6	2007	Activation of Jurkat T-cells and mouse primary spleen cells induces binding of Ku80 and NF90 to the IL-2 promoter in vivo, and decreases binding of Ku70 to the IL-2 promoter in vivo, and these dynamic changes are inhibited by immunosuppressants cyclosporin A and triptolide.	Cyclosporine	245-258	X-ray repair complementing defective repair in Chinese hamster cells 6	Mus musculus	148-152
17178259-9	2006	Cyclosporine (INN, ciclosporin) inhibits CYP3A4, P-glycoprotein (multidrug resistance protein 1), organic anion transporting polypeptide 1B1 (OATP1B1), and some other hepatic uptake transporters.	Cyclosporine	0-12	solute carrier organic anion transporter family member 1B1	Homo sapiens	98-140
17178259-9	2006	Cyclosporine (INN, ciclosporin) inhibits CYP3A4, P-glycoprotein (multidrug resistance protein 1), organic anion transporting polypeptide 1B1 (OATP1B1), and some other hepatic uptake transporters.	Cyclosporine	0-12	solute carrier organic anion transporter family member 1B1	Homo sapiens	142-149
17178259-9	2006	Cyclosporine (INN, ciclosporin) inhibits CYP3A4, P-glycoprotein (multidrug resistance protein 1), organic anion transporting polypeptide 1B1 (OATP1B1), and some other hepatic uptake transporters.	Cyclosporine	19-30	solute carrier organic anion transporter family member 1B1	Homo sapiens	98-140
17178259-9	2006	Cyclosporine (INN, ciclosporin) inhibits CYP3A4, P-glycoprotein (multidrug resistance protein 1), organic anion transporting polypeptide 1B1 (OATP1B1), and some other hepatic uptake transporters.	Cyclosporine	19-30	solute carrier organic anion transporter family member 1B1	Homo sapiens	142-149
17175233-12	2006	In CsA-treated allografts moderate VEGF expression was seen already 5 days after transplantation; the expression increased at 90 days after transplantation.	Cyclosporine	3-6	vascular endothelial growth factor A	Rattus norvegicus	35-39
20589831-8	2010	In addition, LTD(4)-stimulated migration through increased activation of focal adhesion kinase (FAK) and paxillin which were blocked by Akt inhibitor and cyclosporine A.	Cyclosporine	154-168	PTK2 protein tyrosine kinase 2	Mus musculus	96-99
20638447-4	2010	Cyclosporin A pretreatment disrupted peripheral vesicle clustering, presumably due to increasing synapsin phosphorylated state.	Cyclosporine	0-13	Synapsin	Drosophila melanogaster	97-105
20540932-10	2010	Molecules known to interact with OATPs, including cyclosporin A, rifampicin, and glibenclamide, each demonstrated concentration-dependent inhibition of 8-FcA transport by OATP1B1 and OATP1B3.	Cyclosporine	50-63	solute carrier organic anion transporter family member 1B1	Homo sapiens	171-178
20602248-5	2010	Here, we discuss structural and functional aspects of the human cyclophilins and their interaction with various intra-cellular targets that can be under the control of CsA or its complexes with diverse cyclophilins that are selectively expressed in different cellular compartments.	Cyclosporine	168-171	peptidylprolyl isomerase A	Homo sapiens	64-76
16631347-7	2006	Results show that CsA-conditioned animals displayed significant immunosuppression in the spleen after recall, measured by in vitro T-lymphocyte proliferation, and IL-2 production.	Cyclosporine	18-21	interleukin 2	Mus musculus	163-167
20602248-5	2010	Here, we discuss structural and functional aspects of the human cyclophilins and their interaction with various intra-cellular targets that can be under the control of CsA or its complexes with diverse cyclophilins that are selectively expressed in different cellular compartments.	Cyclosporine	168-171	peptidylprolyl isomerase A	Homo sapiens	202-214
21129263-8	2010	CsA lowers the abnormal activation of IFN-gamma/T-bet and IL-12/STAT4 pathways to correct Th1 hyperpolarization, which may reduce the abnormally activated cell-mediated immunity and relax hematopoietic depression of AA patients.	Cyclosporine	0-3	T-box transcription factor 21	Homo sapiens	48-53
20681522-10	2010	In this work, we show that knockdown of cell CypA using targeting siRNA (without any CsA treatment) results in a reduction in the level of NCX1 surface expression, a decrease in the level of Na(+)-dependent Ca(2+) uptake, and no change in the total amount of cell NCX1 protein in NCX1.5-transfected HEK 293 cells and nontransfected H9c2 cells that express NCX1.1 naturally.	Cyclosporine	85-88	peptidylprolyl isomerase A	Homo sapiens	45-49
20681522-13	2010	Overexpression of CypA or its R55A mutant, which exhibits a substantially reduced PPIase activity, alleviated the reduction of NCX1 surface expression caused by CsA treatment, suggesting that the PPIase domain was probably not mandatory for NCX1 functional expression.	Cyclosporine	161-164	peptidylprolyl isomerase A	Homo sapiens	18-22
20945139-1	2010	The fungal cyclic peptide cyclosporin A (CsA) and fungal macrolide compound sanglifehrin A (SFA) have been developed as immunosuppressive drugs and both bind to cyclophilin A (CypA).	Cyclosporine	41-44	peptidylprolyl isomerase A	Homo sapiens	161-174
20945139-1	2010	The fungal cyclic peptide cyclosporin A (CsA) and fungal macrolide compound sanglifehrin A (SFA) have been developed as immunosuppressive drugs and both bind to cyclophilin A (CypA).	Cyclosporine	41-44	peptidylprolyl isomerase A	Homo sapiens	176-180
20554520-9	2010	Finally, we found that the inhibition of PKC-delta using a dominant negative plasmid significantly decreased the CsA-induced cytoplasmic translocation of HuR and VEGF mRNA stability.	Cyclosporine	113-116	ELAV like RNA binding protein 1	Homo sapiens	154-157
21994697-4	2010	Importantly, Cyclosporine A derivatives that lack immunosuppressive function efficiently block the CyPA-NS5A interaction and inhibit HCV in cell culture, an animal model, and human trials.	Cyclosporine	13-27	peptidylprolyl isomerase A	Homo sapiens	99-103
20818071-5	2010	RESULTS: The concentrations of serum CK-Mb and cTnI decreased more in the Mp+IR group and the CsA+IR group than those of the IR group.	Cyclosporine	94-97	troponin I3, cardiac type	Canis lupus familiaris	47-51
20561905-11	2010	In contrast to the pro-inflammatory cytokines, the serum levels and the pancreatic tissue mRNA expression of IL-10 were markedly increased by the injection of CsA.	Cyclosporine	159-162	interleukin 10	Rattus norvegicus	109-114
20410216-8	2010	Drp1 dephosphorylation could be suppressed by cyclosporine A and FK506, two calcineurin inhibitors.	Cyclosporine	46-60	collapsin response mediator protein 1	Rattus norvegicus	0-4
20410216-9	2010	Importantly, cyclosporine A and FK506 could also prevent mitochondrial fragmentation, Bax accumulation, cytochrome c release, and apoptosis following ATP depletion in RPTC.	Cyclosporine	13-27	BCL2 associated X, apoptosis regulator	Rattus norvegicus	86-89
20413672-4	2010	First, CN inhibitors, cyclosporine A (CysA) and tacrolimus (FK506) inhibited the Ang II-induced elevation of CYP11B2 mRNA level.	Cyclosporine	22-36	cytochrome P450 family 11 subfamily B member 2	Homo sapiens	109-116
20413672-4	2010	First, CN inhibitors, cyclosporine A (CysA) and tacrolimus (FK506) inhibited the Ang II-induced elevation of CYP11B2 mRNA level.	Cyclosporine	38-42	cytochrome P450 family 11 subfamily B member 2	Homo sapiens	109-116
20440443-8	2010	CD4+ and CD8+ T-cell infiltration and interleukin (IL)-2 mRNA levels were decreased in TMC/CsA-cotreated rats, whereas IL-10 levels were increased.	Cyclosporine	91-94	interleukin 2	Rattus norvegicus	38-56
20662321-5	2010	Kinetic analysis indicated a noncompetitive inhibition of Ver-stimulated P-gp ATPase activity and a competitive inhibition of CJX2-stimulated P-gp ATPase activity by CJZ3, moreover, the effect of CsA on CJZ3-stimulated and Ver-stimulated P-gp ATPase activity showed a non-competitive and a competitive inhibition respectively.	Cyclosporine	196-199	phosphoglycolate phosphatase	Homo sapiens	142-146
20662321-5	2010	Kinetic analysis indicated a noncompetitive inhibition of Ver-stimulated P-gp ATPase activity and a competitive inhibition of CJX2-stimulated P-gp ATPase activity by CJZ3, moreover, the effect of CsA on CJZ3-stimulated and Ver-stimulated P-gp ATPase activity showed a non-competitive and a competitive inhibition respectively.	Cyclosporine	196-199	phosphoglycolate phosphatase	Homo sapiens	142-146
20662321-6	2010	CJZ3 and CJX2 can bind P-gp either on overlapping sites or distinct but interacting sites, while CJZ3 and Ver as well as CsA can bind P-gp on separated sites in K562/DOX cells.	Cyclosporine	121-124	phosphoglycolate phosphatase	Homo sapiens	134-138
20431509-4	2010	There are also genetic predictors of pharmacodynamics, including IMPDH1 for mycophenolate and ABCB1 for cyclosporine that may identify individuals at particular risk of efficacy failure or toxicity with a given drug.	Cyclosporine	104-116	inosine monophosphate dehydrogenase 1	Homo sapiens	65-71
20152898-1	2010	The enzyme arylsulfatase B (N-acetylgalactosamine 4-sulfatase; ASB; ARSB), which removes 4-sulfate groups from the nonreducing end of chondroitin-4-sulfate (C4S;CSA) and dermatan sulfate, has cellular effects, beyond those associated with the lysosomal storage disease mucopolysaccharidosis VI.	Cyclosporine	161-164	arylsulfatase B	Homo sapiens	11-26
20152898-1	2010	The enzyme arylsulfatase B (N-acetylgalactosamine 4-sulfatase; ASB; ARSB), which removes 4-sulfate groups from the nonreducing end of chondroitin-4-sulfate (C4S;CSA) and dermatan sulfate, has cellular effects, beyond those associated with the lysosomal storage disease mucopolysaccharidosis VI.	Cyclosporine	161-164	arylsulfatase B	Homo sapiens	28-61
20152898-1	2010	The enzyme arylsulfatase B (N-acetylgalactosamine 4-sulfatase; ASB; ARSB), which removes 4-sulfate groups from the nonreducing end of chondroitin-4-sulfate (C4S;CSA) and dermatan sulfate, has cellular effects, beyond those associated with the lysosomal storage disease mucopolysaccharidosis VI.	Cyclosporine	161-164	arylsulfatase B	Homo sapiens	63-66
20152898-1	2010	The enzyme arylsulfatase B (N-acetylgalactosamine 4-sulfatase; ASB; ARSB), which removes 4-sulfate groups from the nonreducing end of chondroitin-4-sulfate (C4S;CSA) and dermatan sulfate, has cellular effects, beyond those associated with the lysosomal storage disease mucopolysaccharidosis VI.	Cyclosporine	161-164	arylsulfatase B	Homo sapiens	68-72
20152898-1	2010	The enzyme arylsulfatase B (N-acetylgalactosamine 4-sulfatase; ASB; ARSB), which removes 4-sulfate groups from the nonreducing end of chondroitin-4-sulfate (C4S;CSA) and dermatan sulfate, has cellular effects, beyond those associated with the lysosomal storage disease mucopolysaccharidosis VI.	Cyclosporine	161-164	complement C4A (Rodgers blood group)	Homo sapiens	157-160
20132841-2	2010	CsA inhibits isomerase activity of cellular-encoded cyclophilin proteins, of which cyclophilin A (CypA) in particular is required for HCV replication.	Cyclosporine	0-3	peptidylprolyl isomerase A	Homo sapiens	98-102
16870295-5	2006	The PyK2 phosphorylation level declined after treatment of 2 microg/ml CsA, 5 microM CPA and 25 microM U73122, but not changed apparently after 50 microM ryanodine treatment.	Cyclosporine	71-74	protein tyrosine kinase 2 beta	Homo sapiens	4-8
17058898-0	2006	[Interaction of cyclosporin with CSE inhibitors].	Cyclosporine	16-27	choreoathetosis/spasticity, episodic (paroxysmal choreoathetosis/spasticity)	Homo sapiens	33-36
16737676-1	2006	Peptidyl prolyl cis/trans isomerase cyclophilin A (CypA) serves as a cellular receptor for the important immunosuppressant drug, cyclosporin A.	Cyclosporine	129-142	peptidylprolyl isomerase A	Homo sapiens	36-49
16737676-1	2006	Peptidyl prolyl cis/trans isomerase cyclophilin A (CypA) serves as a cellular receptor for the important immunosuppressant drug, cyclosporin A.	Cyclosporine	129-142	peptidylprolyl isomerase A	Homo sapiens	51-55
16670920-0	2006	Elevated gene expression of MMP-1, MMP-10, and TIMP-1 reveal changes of molecules involved in turn-over of extracellular matrix in cyclosporine-induced gingival overgrowth.	Cyclosporine	131-143	matrix metallopeptidase 1	Homo sapiens	28-33
20350531-4	2010	Resistance to apoptosis induction by chemotherapeutic drugs can be reversed by cyclosporine A, which effectively inhibits the activity of P-glycoprotein and BCRP, thus demonstrating ABC transporter-mediated drug resistance in KG-1a cells.	Cyclosporine	79-93	BCR pseudogene 1	Homo sapiens	157-161
20604838-4	2010	Therefore, we evaluated whether the ciclosporin derivative, NIM811 reduces mPT and ameliorates delayed neuronal death in the hippocampal CA1 sectors in mice when subjected to transient forebrain ischaemia.	Cyclosporine	36-47	carbonic anhydrase 1	Mus musculus	137-140
20604838-9	2010	RESULTS: Both delayed neuronal injury and apoptosis in the hippocampal CA1 sectors were significantly ameliorated at 72 h after transient forebrain ischaemia in the mice treated with 100 mg/kg NIM811 or 50 mg/kg ciclosporin.	Cyclosporine	212-223	carbonic anhydrase 1	Mus musculus	71-74
20089655-7	2010	The inflammatory response and serum ALT/AST level were reduced when the chemotactic effect of CypA was inhibited by cyclosporine and anti-CD147 antibody.	Cyclosporine	116-128	glutamic pyruvic transaminase, soluble	Mus musculus	36-39
20089655-7	2010	The inflammatory response and serum ALT/AST level were reduced when the chemotactic effect of CypA was inhibited by cyclosporine and anti-CD147 antibody.	Cyclosporine	116-128	peptidylprolyl isomerase A	Homo sapiens	94-98
20450731-17	2010	At Day 5 post-transplantation, both the expressions of PFP and GraB mRNA in AB and CsA groups was lower than that in AR group (P &lt; 0.01).	Cyclosporine	83-86	granzyme B	Rattus norvegicus	63-67
20470282-4	2010	Induction of chronic CsA nephropathy was evaluated according to renal function and pathology and expression of HA, CD44, LYVE-1, ED-1 and alpha-smooth muscle actin (alpha-SMA).	Cyclosporine	21-24	CD44 molecule (Indian blood group)	Rattus norvegicus	115-119
20470282-4	2010	Induction of chronic CsA nephropathy was evaluated according to renal function and pathology and expression of HA, CD44, LYVE-1, ED-1 and alpha-smooth muscle actin (alpha-SMA).	Cyclosporine	21-24	actin gamma 2, smooth muscle	Rattus norvegicus	138-163
20470282-4	2010	Induction of chronic CsA nephropathy was evaluated according to renal function and pathology and expression of HA, CD44, LYVE-1, ED-1 and alpha-smooth muscle actin (alpha-SMA).	Cyclosporine	21-24	actin gamma 2, smooth muscle	Rattus norvegicus	165-174
16815483-9	2006	Cyclosporin A (CsA), an indirect inhibitor of protein phosphatase 2B (PP2B) and a potential inhibitor of ABC transporter A1 (ABCA1), suppressed all of these apoA-I-induced cellular events.	Cyclosporine	0-13	apolipoprotein A1	Rattus norvegicus	157-163
20470282-8	2010	HA binding receptor, CD44 and LYVE-1 expression were also upregulated in the CsA groups, and were localized to the area of fibrosis and the peritubular capillaries of the cortex.	Cyclosporine	77-80	CD44 molecule (Indian blood group)	Rattus norvegicus	21-25
16815483-9	2006	Cyclosporin A (CsA), an indirect inhibitor of protein phosphatase 2B (PP2B) and a potential inhibitor of ABC transporter A1 (ABCA1), suppressed all of these apoA-I-induced cellular events.	Cyclosporine	15-18	apolipoprotein A1	Rattus norvegicus	157-163
16815483-12	2006	CsA thus interferes with cellular cholesterol homeostasis independently of PP2B inhibition, perhaps by direct inhibition of ABCA1 reactivity to exogenous apoA-I, although PP2B may be involved in the lipid release step.	Cyclosporine	0-3	apolipoprotein A1	Rattus norvegicus	154-160
20470282-9	2010	In the CsA groups, ED-1 and alpha-SMA were predominantly expressed in fibrotic areas in which HA had accumulated.	Cyclosporine	7-10	actin gamma 2, smooth muscle	Rattus norvegicus	28-37
21249305-5	2010	Additionally, these CsA-treated DCs show decreased production of IL-2 and IL-12 and increased IL-10 secretion when stimulated with LPS, indicating an effect on the polarization of the immune response.	Cyclosporine	20-23	interleukin 2	Mus musculus	65-69
20029328-6	2009	Although the expression of aquaporin-2, NaPi-2, and paracellin-1 mRNAs tended to increase in kidneys with a reduced nephron mass, NaPi-2 mRNA levels decreased in 1/2K rats exposed to CsA/SRL for 28 days (P&lt;0.05).	Cyclosporine	183-186	aquaporin 2	Rattus norvegicus	27-38
20029328-6	2009	Although the expression of aquaporin-2, NaPi-2, and paracellin-1 mRNAs tended to increase in kidneys with a reduced nephron mass, NaPi-2 mRNA levels decreased in 1/2K rats exposed to CsA/SRL for 28 days (P&lt;0.05).	Cyclosporine	183-186	claudin 16	Rattus norvegicus	52-64
20029328-7	2009	In contrast, low KIM-1 mRNA expression in control 2K rats increased fourfold in untreated 1/2K (P&lt;0.05), and 50- to 200-fold in CsA/SRL-treated 1/2K (P=0.01).	Cyclosporine	131-134	hepatitis A virus cellular receptor 1	Rattus norvegicus	17-22
19956540-1	2009	BACKGROUND: The allochimeric MHC class I molecule [alpha1h1/u]-RT1.Aa that contains donor-type (Wistar Furth, WF; RT1u) epitopes displayed on recipient-type (ACI, RT1a) administered in conjunction with sub-therapeutic dose of cyclosporine (CsA) induces indefinite survival of heterotopic cardiac allografts in rat model.	Cyclosporine	226-238	major histocompatibility complex, class I, B	Homo sapiens	29-49
19956540-1	2009	BACKGROUND: The allochimeric MHC class I molecule [alpha1h1/u]-RT1.Aa that contains donor-type (Wistar Furth, WF; RT1u) epitopes displayed on recipient-type (ACI, RT1a) administered in conjunction with sub-therapeutic dose of cyclosporine (CsA) induces indefinite survival of heterotopic cardiac allografts in rat model.	Cyclosporine	240-243	major histocompatibility complex, class I, B	Homo sapiens	29-49
19925383-11	2009	MDR1 haplotypes and CYP3A5*3 genotypes can be related to C(2) and C(0) of CsA, respectively.	Cyclosporine	74-77	complement C2	Homo sapiens	57-61
19577762-7	2009	Treatment with anti-CCR5 mAb plus CsA significantly inhibited the progression of CAV.	Cyclosporine	34-37	caveolin 1, caveolae protein	Mus musculus	81-84
19674198-6	2009	MMP-26 expression in cancer cells (p = 0.04) and that of MMP-9 in neutrophils (p = 0.005) were more abundant in SCCs of patients using cyclosporine.	Cyclosporine	135-147	matrix metallopeptidase 26	Homo sapiens	0-6
19698865-6	2009	Compared with group II, treatment with pioglitazone with low-dose cyclosporine (group IV) significantly suppressed graft infiltration of CD4/CD8 T lymphocytes and serum concentrations of interleukin 2 and interferon gamma, leading to extended graft survival up to 60 days.	Cyclosporine	66-78	interleukin 2	Rattus norvegicus	187-200
19698865-6	2009	Compared with group II, treatment with pioglitazone with low-dose cyclosporine (group IV) significantly suppressed graft infiltration of CD4/CD8 T lymphocytes and serum concentrations of interleukin 2 and interferon gamma, leading to extended graft survival up to 60 days.	Cyclosporine	66-78	interferon gamma	Rattus norvegicus	205-221
19666510-3	2009	Th2 cells that have upregulated T1ST2 produce IL-13, but not IL-4, in response to IL-33 plus a STAT5 activator in an antigen-independent, NF-kappaB-dependent, cyclosporin A (CsA)-resistant manner.	Cyclosporine	174-177	signal transducer and activator of transcription 5A	Homo sapiens	95-100
19664129-0	2009	Renal tubular expression of Toll-like receptor 4 in cyclosporine nephrotoxicity.	Cyclosporine	52-64	toll like receptor 4	Homo sapiens	28-48
19664129-9	2009	As hypoxia was shown to be a strong stimulus for TLR4 expression, it can be said that TLR4 is influenced by both direct toxicity and impediment of renal microcirculation in human CsA nephrotoxicity.	Cyclosporine	179-182	toll like receptor 4	Homo sapiens	86-90
19652395-11	2009	The overexpression of peroxiredoxin 1 (Prx 1) confirmed by Western blotting and reduction of cytosolic reactive oxygen species (ROS) levels in the CsA-treated HGF demonstrated that Prx 1 may play a crucial role in the HGF proliferation induced by CsA.	Cyclosporine	147-150	peroxiredoxin 1	Homo sapiens	22-37
19652395-11	2009	The overexpression of peroxiredoxin 1 (Prx 1) confirmed by Western blotting and reduction of cytosolic reactive oxygen species (ROS) levels in the CsA-treated HGF demonstrated that Prx 1 may play a crucial role in the HGF proliferation induced by CsA.	Cyclosporine	147-150	peroxiredoxin 1	Homo sapiens	181-186
19652395-11	2009	The overexpression of peroxiredoxin 1 (Prx 1) confirmed by Western blotting and reduction of cytosolic reactive oxygen species (ROS) levels in the CsA-treated HGF demonstrated that Prx 1 may play a crucial role in the HGF proliferation induced by CsA.	Cyclosporine	247-250	peroxiredoxin 1	Homo sapiens	22-37
19652395-11	2009	The overexpression of peroxiredoxin 1 (Prx 1) confirmed by Western blotting and reduction of cytosolic reactive oxygen species (ROS) levels in the CsA-treated HGF demonstrated that Prx 1 may play a crucial role in the HGF proliferation induced by CsA.	Cyclosporine	247-250	peroxiredoxin 1	Homo sapiens	39-44
19652395-11	2009	The overexpression of peroxiredoxin 1 (Prx 1) confirmed by Western blotting and reduction of cytosolic reactive oxygen species (ROS) levels in the CsA-treated HGF demonstrated that Prx 1 may play a crucial role in the HGF proliferation induced by CsA.	Cyclosporine	247-250	peroxiredoxin 1	Homo sapiens	181-186
19680534-8	2009	By selecting for resistance against the cyclosporine analogue DEBIO-025 that targets CypA in a dose-dependent manner, we identified two mutations (V2440A and V2440L) close to the cleavage site between nonstructural protein 5A and the RNA-dependent RNA polymerase in nonstructural protein 5B that slow down cleavage kinetics at this site and reduce CypA dependence of viral replication.	Cyclosporine	40-52	peptidylprolyl isomerase A	Homo sapiens	85-89
19680534-8	2009	By selecting for resistance against the cyclosporine analogue DEBIO-025 that targets CypA in a dose-dependent manner, we identified two mutations (V2440A and V2440L) close to the cleavage site between nonstructural protein 5A and the RNA-dependent RNA polymerase in nonstructural protein 5B that slow down cleavage kinetics at this site and reduce CypA dependence of viral replication.	Cyclosporine	40-52	peptidylprolyl isomerase A	Homo sapiens	348-352
19719970-0	2009	Lactadherin and procoagulant activities of red blood cells in cyclosporine induced thrombosis.	Cyclosporine	62-74	milk fat globule EGF and factor V/VIII domain containing	Homo sapiens	0-11
19719970-4	2009	Therefore, we propose that such alterations in RBCs membranes play a role in cyclosporine-induced coagulopathy and this disorder may be rectified by lactadherin, a phosphatidylserine binding protein.	Cyclosporine	77-89	milk fat globule EGF and factor V/VIII domain containing	Homo sapiens	149-160
19148693-9	2009	Losartan, CsA or VIV abolished stretch-induced alterations in MMP-2/-9 and MT1-MMP expression and enzyme activity by normalizing the Cn-activity and the DNA binding activity of NFATc1.	Cyclosporine	10-13	nuclear factor of activated T-cells 1	Rattus norvegicus	177-183
19393753-1	2009	We investigated whether the immunosuppressive drugs, FK506 and cyclosporine A, increase BDNF protein and/or mRNA expression in ischemic astrocytes and if an increase could be related to changes in the nuclear expression of p-CREB, p-Erk1/2 and p-Akt.	Cyclosporine	63-77	cAMP responsive element binding protein 1	Rattus norvegicus	225-229
19145636-5	2009	Moreover, the expression of Th1/Th2 mRNA cytokines (IL-2, IL-4, IL-5, IL-13) from mouse splenocytes was inhibited severely as was cyclosporine A.	Cyclosporine	130-144	heart and neural crest derivatives expressed 2	Mus musculus	32-35
19145636-5	2009	Moreover, the expression of Th1/Th2 mRNA cytokines (IL-2, IL-4, IL-5, IL-13) from mouse splenocytes was inhibited severely as was cyclosporine A.	Cyclosporine	130-144	interleukin 2	Mus musculus	52-56
19145636-5	2009	Moreover, the expression of Th1/Th2 mRNA cytokines (IL-2, IL-4, IL-5, IL-13) from mouse splenocytes was inhibited severely as was cyclosporine A.	Cyclosporine	130-144	interleukin 4	Mus musculus	58-62
19145636-5	2009	Moreover, the expression of Th1/Th2 mRNA cytokines (IL-2, IL-4, IL-5, IL-13) from mouse splenocytes was inhibited severely as was cyclosporine A.	Cyclosporine	130-144	interleukin 5	Mus musculus	64-68
19543052-13	2009	The CD4/CD25 regulatory-like T-cell expression in the circulating blood and allo-skin significantly increased in the MSC-BMT-CsA group.	Cyclosporine	125-128	interleukin 2 receptor subunit alpha	Sus scrofa	8-12
19380579-9	2009	We then mutated residues that reside in the hydrophobic pocket of CypA where proline-containing peptide substrates and cyclosporine A bind and that are vital for the enzymatic or the hydrophobic pocket binding activity of CypA.	Cyclosporine	119-133	peptidylprolyl isomerase A	Homo sapiens	66-70
19899977-10	2009	In quantitative PCR, cyclosporin A suppressed the expression of IL-4 and IL-5 mRNA but did not suppress the expression of transforming growth factor (TGF)-beta 1, whereas betamethasone suppressed the expression of IL-4, IL-5, and TGF-beta 1.	Cyclosporine	21-34	interleukin 4	Mus musculus	64-68
19899977-10	2009	In quantitative PCR, cyclosporin A suppressed the expression of IL-4 and IL-5 mRNA but did not suppress the expression of transforming growth factor (TGF)-beta 1, whereas betamethasone suppressed the expression of IL-4, IL-5, and TGF-beta 1.	Cyclosporine	21-34	interleukin 5	Mus musculus	73-77
19899977-11	2009	CONCLUSION: The results suggest that cyclosporin A eye drops inhibited fibrosis and inflammatory cell infiltration by the suppression of Th2 cytokine production in repeatedly antigen-challenged conjunctiva without affecting the early-phase reaction.	Cyclosporine	37-50	heart and neural crest derivatives expressed 2	Mus musculus	137-140
19210333-1	2009	BACKGROUND AND OBJECTIVE: Membrane type-I matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase-2 (TIMP-2) regulate the activation of MMP-2; however, their roles in the activation of MMP-2 in gingiva during treatment with cyclosporine A are still unknown.	Cyclosporine	241-255	TIMP metallopeptidase inhibitor 2	Rattus norvegicus	77-116
19210333-1	2009	BACKGROUND AND OBJECTIVE: Membrane type-I matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase-2 (TIMP-2) regulate the activation of MMP-2; however, their roles in the activation of MMP-2 in gingiva during treatment with cyclosporine A are still unknown.	Cyclosporine	241-255	TIMP metallopeptidase inhibitor 2	Rattus norvegicus	118-124
19210333-2	2009	Therefore, the expressions of membrane type-I MMP and TIMP-2, as well as MMP-2, in gingivae upon treatment with cyclosporine A were examined in vivo and in vitro.	Cyclosporine	112-126	TIMP metallopeptidase inhibitor 2	Rattus norvegicus	54-60
19344364-8	2009	Furthermore, the plasma VWF antigen level is also enhanced in CsA-treated mice, and small interfering RNA-mediated knockdown of the alpha and beta isoforms of the PP2B-A subunit in HUVECs enhanced VWF secretion.	Cyclosporine	62-65	Von Willebrand factor	Mus musculus	24-27
19344364-8	2009	Furthermore, the plasma VWF antigen level is also enhanced in CsA-treated mice, and small interfering RNA-mediated knockdown of the alpha and beta isoforms of the PP2B-A subunit in HUVECs enhanced VWF secretion.	Cyclosporine	62-65	Von Willebrand factor	Mus musculus	197-200
19211263-7	2009	Noncovalent complexes of holomyoglobin and the protein-ligand complex between CypA and cyclosporin A (CsA) were also investigated at a neutral pH using the CSI-MS method.	Cyclosporine	87-100	peptidylprolyl isomerase A	Homo sapiens	78-82
19211263-7	2009	Noncovalent complexes of holomyoglobin and the protein-ligand complex between CypA and cyclosporin A (CsA) were also investigated at a neutral pH using the CSI-MS method.	Cyclosporine	102-105	peptidylprolyl isomerase A	Homo sapiens	78-82
19627009-6	2009	Simultaneously, the level of IL-2 and IL-4 in leukemia mice treated with FK506 and CSA decreased significantly than those of intact or leukemia control mice.	Cyclosporine	83-86	interleukin 2	Mus musculus	29-33
19627009-6	2009	Simultaneously, the level of IL-2 and IL-4 in leukemia mice treated with FK506 and CSA decreased significantly than those of intact or leukemia control mice.	Cyclosporine	83-86	interleukin 4	Mus musculus	38-42
19504633-6	2009	Eight hours after Con A treatment, mGST1 level was up-regulated to 1.2 approximately 1.5 folds of control with or without Cs A treatment.	Cyclosporine	122-126	G1 to S phase transition 1	Mus musculus	35-40
19376375-4	2009	Systolic (SBP) and diastolic blood pressure (DBP) values were higher (P &lt; .001) in both the CsA (146.2 +/- 4.5 and 124.9 +/- 4.5 mm Hg) and SRL (148.9 +/- 4.8 and 126.4 +/- 6.0 mm Hg) groups vs the controls (115.9 +/- 3.3 and 99.1 +/- 2.0 mm Hg).	Cyclosporine	95-98	spermine binding protein	Rattus norvegicus	10-13
19161974-1	2009	The oxidation of critical cysteines/related thiols of adenine nucleotide translocase (ANT) is believed to be an important event of the Ca(2+)-induced mitochondrial permeability transition (MPT), a process mediated by a cyclosporine A/ADP-sensitive permeability transition pores (PTP) opening.	Cyclosporine	219-233	solute carrier family 25 member 6	Homo sapiens	86-89
19136475-4	2009	Xpa/p53 mice exposed to CsA for 39 weeks showed a significantly increased lymphoma incidence as compared with untreated Xpa/p53 mice and CsA-treated wild-type (WT) mice.	Cyclosporine	24-27	transformation related protein 53, pseudogene	Mus musculus	4-7
19136475-4	2009	Xpa/p53 mice exposed to CsA for 39 weeks showed a significantly increased lymphoma incidence as compared with untreated Xpa/p53 mice and CsA-treated wild-type (WT) mice.	Cyclosporine	24-27	transformation related protein 53, pseudogene	Mus musculus	124-127
19136475-4	2009	Xpa/p53 mice exposed to CsA for 39 weeks showed a significantly increased lymphoma incidence as compared with untreated Xpa/p53 mice and CsA-treated wild-type (WT) mice.	Cyclosporine	137-140	transformation related protein 53, pseudogene	Mus musculus	4-7
19254251-2	2009	An immune-mediated aetiopathogenesis is suggested by T-cell infiltration, upregulated cytokine gene expression, clinical response to ciclosporin therapy and a strong genetic association with the DLA-DRB1*00101 allele.	Cyclosporine	133-144	DLA class II histocompatibility antigen, DR-1 beta chain	Canis lupus familiaris	195-203
16780547-5	2006	Interestingly, when employed with a low dose of CsA (1 mg/kg/day), a cooperative action of PEG molecules and HO-1 in immune reactions could result in the complete survival of transplanted islets for 100 days without islet function impairment.	Cyclosporine	48-51	heme oxygenase 1	Homo sapiens	109-113
16466920-6	2006	Some of them were more effective inhibitors at concentrations lower than a standard P-gp efflux inhibitor cyclosporin A.	Cyclosporine	106-119	phosphoglycolate phosphatase	Homo sapiens	84-88
16395583-9	2006	The CYP inhibitor, cyclosporin A, partially mimics the effects of the dgt mutation in inhibiting auxin-induced adventitious root initiation in tomato hypocotyl sections and reducing the auxin-induced expression of the early auxin response genes, LeIAA10 and 11.	Cyclosporine	19-32	peptidyl-prolyl cis-trans isomerase	Solanum lycopersicum	4-7
19499554-1	2009	Water molecules doing time: Atomic-resolution crystal structures of the PPIase domain of cyclophilin G, alone and in complex with cyclosporin A, and together with MD simulations and calorimetry, reveal how trapped water molecules influence the thermodynamic profile of a protein-ligand interaction.	Cyclosporine	130-143	peptidylprolyl isomerase G	Homo sapiens	89-102
16739070-4	2006	At 10 microM, it efficiently competes with the photoactivatable cyclosporin A analogue (SDZ 212 - 122) for the binding to Pgp and accumulates [3H]-VBL to a higher extent than cyclosporin A or cnidiadin.	Cyclosporine	64-77	PGP	Canis lupus familiaris	122-125
16408277-7	2006	Pharmacological inhibition of calcineurin by cyclosporin A blocks IGF-1-induced cyclin D1 and p21Cip1expression significantly (P &lt; 0.05).	Cyclosporine	45-58	insulin-like growth factor 1	Rattus norvegicus	66-71
18704644-4	2009	Wild-type U2OS cells treated with cyclosporine A (CsA), a peptidyl-prolyl isomerase inhibitor, displayed the same phenotype as knockdown CypA cells, suggesting that the isomerase activity of CypA is required to maintain a normal phenotype.	Cyclosporine	34-48	peptidylprolyl isomerase A	Homo sapiens	191-195
16671876-10	2006	Thus, CsA may downregulate E-cadherin gene expression, leading to the epithelial cell proliferation of gingival overgrowth.	Cyclosporine	6-9	cadherin 1	Rattus norvegicus	27-37
18704644-4	2009	Wild-type U2OS cells treated with cyclosporine A (CsA), a peptidyl-prolyl isomerase inhibitor, displayed the same phenotype as knockdown CypA cells, suggesting that the isomerase activity of CypA is required to maintain a normal phenotype.	Cyclosporine	50-53	peptidylprolyl isomerase A	Homo sapiens	191-195
18790238-3	2008	Previously, we demonstrated that activation of Akt/protein kinase B protects against cyclosporine nephrotoxicity and prevents apoptosis.	Cyclosporine	85-97	protein tyrosine kinase 2 beta	Homo sapiens	51-67
18538359-2	2008	Chronic (&gt;or=3h) treatment of cultured bovine adrenal chromaffin cells with cyclosporin A or FK506 decreased IRS-2 protein level by approximately 50% (IC(50)=200 or 10nM), without changing IRS-2 mRNA level, and insulin receptor, insulin-like growth factor-I (IGF-I) receptor, IRS-1, PI3K/PDK-1/Akt/GSK-3beta and ERK1/ERK2 protein levels.	Cyclosporine	79-92	insulin like growth factor 1	Bos taurus	232-260
18367226-5	2008	This inhibitory action depended upon the interaction of the CypA moiety with HIV-1 capsid and disruption of CypA and capsid interaction by cyclosporine A enhanced the HIV-1 susceptibility of OWM cells even in the absence of functional TRIM5alpha.	Cyclosporine	139-153	peptidylprolyl isomerase A	Homo sapiens	108-112
17847068-7	2008	Cyclosporin A and trifluoperazine, inhibitors of permeability transition pore in mitochondria, were significantly potent in inhibiting 4-HEB cell toxicity.	Cyclosporine	0-13	transcription factor 12	Homo sapiens	137-140
17901929-5	2008	Gemfibrozil and cyclosporine inhibition data obtained in human embryonic kidney cells expressing OATP1B1 and hepatic input concentration ([I]in) were used for qualitative zoning of 14 transporter-mediated DDIs.	Cyclosporine	16-28	solute carrier organic anion transporter family member 1B1	Homo sapiens	97-104
18387391-7	2008	In the CyA group, post-treatment urinary EGF levels were significantly reduced (from 35 +/- 15.8 to 28.3 +/- 17.9 ng/mg creatinine; P &lt;0.034), whereas the urinary IL-6 levels were not affected by CyA or PPS treatment in the whole group.	Cyclosporine	7-10	epidermal growth factor	Homo sapiens	41-44
18259766-7	2008	Cytokine expression analysis at the site of skin graft showed that CsA treatment significantly decreased pro-inflammatory cytokines IFN-gamma and IL-2 and reduced TNF-alpha gene expression; however, the level of TNF-alpha is high in MSC-treated and not immunosuppressed rats.	Cyclosporine	67-70	interferon gamma	Rattus norvegicus	132-141
18259766-7	2008	Cytokine expression analysis at the site of skin graft showed that CsA treatment significantly decreased pro-inflammatory cytokines IFN-gamma and IL-2 and reduced TNF-alpha gene expression; however, the level of TNF-alpha is high in MSC-treated and not immunosuppressed rats.	Cyclosporine	67-70	interleukin 2	Rattus norvegicus	146-150
18299432-4	2008	It was demonstrated that administration of CsA at the window of implantation significantly up-regulated the expression of CTLA-4, while down-regulating the levels of CD80, CD86, and CD28 at the materno-fetal interface in the CBA/J x DBA/2 abortion-prone matings, and the embryo resorption rate of the abortion-prone matings reduced significantly after CsA treatment, implying that modulation of costimulatory molecule expression by CsA might contribute to preventing the fetus from maternal immune attack.	Cyclosporine	43-46	CD28 antigen	Mus musculus	182-186
18320611-8	2008	Methylprednisolone and CsA increased the expression levels of Bak gene in newborn rats.	Cyclosporine	23-26	BCL2-antagonist/killer 1	Rattus norvegicus	62-65
19099959-7	2008	Treatment with SIN alone did not affect gene expressions of bFGF, VEGF, and ET-1 while expressions of bFGF, VEGF, and ET-1 were significantly reduced by combined treatment with SIN and CsA.	Cyclosporine	185-188	vascular endothelial growth factor A	Rattus norvegicus	108-112
18095667-3	2008	The mechanism of the conformational inversion has not been delineated, but it has been postulated that metal ions binding induces a conformational change that enables CsA to bind Cyp.	Cyclosporine	167-170	peptidylprolyl isomerase G	Homo sapiens	179-182
18434710-6	2008	RESULTS: Short-term treatment of CsA for 7 days activated both the ER stress response (induction of BiP mRNA and protein) and the proapoptotic response (upregulation of caspase 12 and CHOP mRNAs and proteins).	Cyclosporine	33-36	DNA-damage inducible transcript 3	Rattus norvegicus	184-188
16545729-1	2006	We previously reported results in 71 patients with advanced hematologic malignancies given HLA-matched unrelated granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell (G-PBMC) grafts after fludarabine 90 mg/m(2), 2 Gy of total body irradiation, and postgrafting mycophenolate mofetil (MMF) 15 mg/kg twice daily and cyclosporine 6.25 mg/kg twice daily orally.	Cyclosporine	343-355	colony stimulating factor 3	Homo sapiens	113-150
16584346-10	2006	In both in vitro and in vivo experiments, greater PCNA expression after CsA treatment was demonstrated.	Cyclosporine	72-75	proliferating cell nuclear antigen	Homo sapiens	50-54
16299069-4	2006	In the complex with its target (Cyp), CsA adopts a conformation with all trans peptide bonds and this feature is very important for its pharmacological action.	Cyclosporine	38-41	peptidylprolyl isomerase G	Homo sapiens	32-35
16458199-5	2006	Cd2+-induced apoptosis was mitochondrial dependent since cyclosporin A protected the cells from this metal.	Cyclosporine	57-70	CD2 molecule	Homo sapiens	0-3
16926534-0	2006	Effect of cyclosporine and sirolimus on the expression of connective tissue growth factor in rat experimental chronic nephrotoxicity.	Cyclosporine	10-22	cellular communication network factor 2	Rattus norvegicus	58-89
16926534-3	2006	We tried to determine the effect of two commonly used immunosuppressants, cyclosporine (CsA) and sirolimus (SRL), on CTGF expression in a model of chronic nephrotoxicity.	Cyclosporine	74-86	cellular communication network factor 2	Rattus norvegicus	117-121
16926534-3	2006	We tried to determine the effect of two commonly used immunosuppressants, cyclosporine (CsA) and sirolimus (SRL), on CTGF expression in a model of chronic nephrotoxicity.	Cyclosporine	88-91	cellular communication network factor 2	Rattus norvegicus	117-121
16926534-7	2006	RESULTS: At 28 days, both CsA doses were capable of inhibiting CTGF mRNA expression to levels similar to control.	Cyclosporine	26-29	cellular communication network factor 2	Rattus norvegicus	63-67
18434710-7	2008	However, long-term treatment with CsA for 28 days decreased BiP and further increased CHOP.	Cyclosporine	34-37	DNA-damage inducible transcript 3	Rattus norvegicus	86-90
18819249-12	2008	IL-10 mRNA expression in grafted liver was higher and IFN-gamma mRNA was lower in vIL-10 and CsA-treated animals, compared with other groups.	Cyclosporine	93-96	interleukin 10	Rattus norvegicus	0-5
18819249-12	2008	IL-10 mRNA expression in grafted liver was higher and IFN-gamma mRNA was lower in vIL-10 and CsA-treated animals, compared with other groups.	Cyclosporine	93-96	interferon gamma	Rattus norvegicus	54-63
17885208-4	2008	Moreover, inactivation of NFATc1 by cyclosporin A treatment attenuates expression of Atp6v0d2 and DC-STAMP and subsequent fusion process of osteoclasts.	Cyclosporine	36-49	ATPase H+ transporting V0 subunit d2	Homo sapiens	85-93
18021968-9	2007	CsA therapy resulted in a reduction in the percentage of CD4(+)CD25(+)CTLA-4(+) and CD4(+)CD25(+)Foxp3(+) regulatory T cells after renal transplantation in both groups (RAR-S and RAR-CH) compared with patients treated with rapamycin or to healthy donors.	Cyclosporine	0-3	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	70-76
17609268-0	2007	Fusion of cyclophilin A to Fv1 enables cyclosporine-sensitive restriction of human and feline immunodeficiency viruses.	Cyclosporine	39-51	peptidylprolyl isomerase A	Homo sapiens	10-23
17609268-0	2007	Fusion of cyclophilin A to Fv1 enables cyclosporine-sensitive restriction of human and feline immunodeficiency viruses.	Cyclosporine	39-51	Friend virus susceptibility 1	Mus musculus	27-30
17609268-4	2007	Infectivity is rescued by agents such as cyclosporine that disrupt CypA binding to its substrates.	Cyclosporine	41-53	peptidylprolyl isomerase A	Homo sapiens	67-71
17609268-7	2007	Like TRIMCyp, Fv1-Cyp restricts HIV-1 and FIV and is sensitive to inhibition by cyclosporine.	Cyclosporine	80-92	Friend virus susceptibility 1	Mus musculus	14-17
17609268-7	2007	Like TRIMCyp, Fv1-Cyp restricts HIV-1 and FIV and is sensitive to inhibition by cyclosporine.	Cyclosporine	80-92	peptidylprolyl isomerase G	Homo sapiens	9-12
17609268-10	2007	This notion is supported by the observation that infectivity of Fv1-Cyp restricted virus can be rescued by cyclosporine for several hours after infection, whereas virus restricted by TRIMCyp is terminally restricted after around 40 min.	Cyclosporine	107-119	Friend virus susceptibility 1	Mus musculus	64-67
17609268-10	2007	This notion is supported by the observation that infectivity of Fv1-Cyp restricted virus can be rescued by cyclosporine for several hours after infection, whereas virus restricted by TRIMCyp is terminally restricted after around 40 min.	Cyclosporine	107-119	peptidylprolyl isomerase G	Homo sapiens	68-71
17917372-0	2007	Cyclosporine A inhibits the mRNA expressions of IL-2, IL-4 and IFN-gamma, but not TNF-alpha, in canine mononuclear cells.	Cyclosporine	0-14	interferon gamma	Canis lupus familiaris	63-72
17917372-4	2007	However, CsA hardly inhibited the mRNA expression of TNF-alpha.	Cyclosporine	9-12	tumor necrosis factor	Canis lupus familiaris	53-62
17596340-10	2007	Inhibition of NFATc2 by VIVIT or cyclosporine restored Kv1.5 expression and current, decreased [Ca(2+)](i), [K(+)](i), bcl-2, and Delta Psi m, leading to decreased proliferation and increased apoptosis in vitro.	Cyclosporine	33-45	nuclear factor of activated T cells 2	Homo sapiens	14-20
16579703-0	2006	Increased expression of vascular endothelial growth factor in cyclosporin A-induced gingival overgrowth in rats.	Cyclosporine	62-75	vascular endothelial growth factor A	Rattus norvegicus	24-58
17584603-11	2007	CONCLUSION: Vav1-Rac inhibitor 6-thio-GTP prolongs allograft survival alone or in combination with CsA by suppression of alloreactive T cell activation.	Cyclosporine	99-102	vav 1 oncogene	Mus musculus	12-16
16579703-3	2006	The aim of this experimental study was to examine the role of vascular endothelial growth factor (VEGF) in the pathogenesis of CsA-induced gingival overgrowth.	Cyclosporine	127-130	vascular endothelial growth factor A	Rattus norvegicus	62-96
16579703-3	2006	The aim of this experimental study was to examine the role of vascular endothelial growth factor (VEGF) in the pathogenesis of CsA-induced gingival overgrowth.	Cyclosporine	127-130	vascular endothelial growth factor A	Rattus norvegicus	98-102
16579703-10	2006	The biochemical findings showed that in vivo VEGF expression was higher in the CsA group compared to the control group (P &lt;0.001).	Cyclosporine	79-82	vascular endothelial growth factor A	Rattus norvegicus	45-49
16579703-11	2006	CONCLUSION: The results of this study suggest that increased VEGF expression may be associated with the pathogenesis of CsA-induced gingival overgrowth.	Cyclosporine	120-123	vascular endothelial growth factor A	Rattus norvegicus	61-65
17516993-3	2007	As the sterol 27-hydroxylase (CYP27A1) inhibition by CsA is well known, we evaluated the effect of another immunosuppressive drug, RAPA, on this enzyme in HepG2 mitochondria, which confirmed the dose-dependent inhibition of mitochondrial CYP27A1 by cyclosporine (10-20 microM), while the inhibition by RAPA required a higher dose (50-100 microM).	Cyclosporine	53-56	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	7-28
16568834-9	2006	An immunosuppressant cyclosporine A taken at antiproliferative concentration decreased phosphorylation of both STAT5 and STAT3 by 1.5-2.0 times at early stages, as well as at late stages of activation.	Cyclosporine	21-35	signal transducer and activator of transcription 5A	Homo sapiens	111-116
17516993-3	2007	As the sterol 27-hydroxylase (CYP27A1) inhibition by CsA is well known, we evaluated the effect of another immunosuppressive drug, RAPA, on this enzyme in HepG2 mitochondria, which confirmed the dose-dependent inhibition of mitochondrial CYP27A1 by cyclosporine (10-20 microM), while the inhibition by RAPA required a higher dose (50-100 microM).	Cyclosporine	53-56	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	30-37
16249890-11	2005	However, the expression of the CD95 receptor was similarly and strongly abated at D5 in the epidermis of IVIg- and CsA-treated patients, while it was conversely increased in the two patients under supportive care only.	Cyclosporine	115-118	Fas cell surface death receptor	Homo sapiens	31-35
17516993-3	2007	As the sterol 27-hydroxylase (CYP27A1) inhibition by CsA is well known, we evaluated the effect of another immunosuppressive drug, RAPA, on this enzyme in HepG2 mitochondria, which confirmed the dose-dependent inhibition of mitochondrial CYP27A1 by cyclosporine (10-20 microM), while the inhibition by RAPA required a higher dose (50-100 microM).	Cyclosporine	249-261	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	7-28
16249890-13	2005	IVIg and CsA treatments thus appeared to exert no obvious effect on the inflammatory infiltrate, but both abated the expression of the CD95 receptor in the skin of TEN patients.	Cyclosporine	9-12	Fas cell surface death receptor	Homo sapiens	135-139
17516993-3	2007	As the sterol 27-hydroxylase (CYP27A1) inhibition by CsA is well known, we evaluated the effect of another immunosuppressive drug, RAPA, on this enzyme in HepG2 mitochondria, which confirmed the dose-dependent inhibition of mitochondrial CYP27A1 by cyclosporine (10-20 microM), while the inhibition by RAPA required a higher dose (50-100 microM).	Cyclosporine	249-261	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	30-37
15956028-0	2005	Provinol prevents CsA-induced nephrotoxicity by reducing reactive oxygen species, iNOS, and NF-kB expression.	Cyclosporine	18-21	nuclear factor kappa B subunit 1	Rattus norvegicus	92-97
17545536-1	2007	PURPOSE: Increased clearance of drugs, such as oral cyclosporine, that are CYP3A and/or ABCB1 (P-gp/MDR1) substrates was reported in African-American compared with Caucasian patients.	Cyclosporine	52-64	phosphoglycolate phosphatase	Homo sapiens	95-99
15956028-7	2005	However, PV prevented these negative effects through a protective mechanism that involved reduction of both oxidative stress and increased iNOS and NF-kB expression induced by CsA.	Cyclosporine	176-179	nuclear factor kappa B subunit 1	Rattus norvegicus	148-153
17220244-0	2007	Interactions of cyclosporin a with breast cancer resistance protein.	Cyclosporine	16-29	ATP binding cassette subfamily G member 2	Canis lupus familiaris	35-67
16387092-0	2005	Correlation between cyclosporine-induced nephrotoxicity in reduced nephron mass and expression of kidney injury molecule-1 and aquaporin-2 gene.	Cyclosporine	20-32	hepatitis A virus cellular receptor 1	Rattus norvegicus	98-122
16387092-0	2005	Correlation between cyclosporine-induced nephrotoxicity in reduced nephron mass and expression of kidney injury molecule-1 and aquaporin-2 gene.	Cyclosporine	20-32	aquaporin 2	Rattus norvegicus	127-138
16387092-6	2005	The KIM-1 expression in the 2K SRL-CsA group was significantly upregulated compared with that in the 2K SRL alone and 2K CsA alone groups (P = .02).	Cyclosporine	35-38	hepatitis A virus cellular receptor 1	Rattus norvegicus	4-9
16387092-6	2005	The KIM-1 expression in the 2K SRL-CsA group was significantly upregulated compared with that in the 2K SRL alone and 2K CsA alone groups (P = .02).	Cyclosporine	121-124	hepatitis A virus cellular receptor 1	Rattus norvegicus	4-9
16387092-10	2005	SRL-CsA-induced nephrotoxicity resulted in overexpression of KIM-1, suggesting injury to the proximal tubule.	Cyclosporine	4-7	hepatitis A virus cellular receptor 1	Rattus norvegicus	61-66
16387179-7	2005	Treatment with cyclosporine reduced type I collagen and TIMP-1 expression and enhanced MMP-1 expression.	Cyclosporine	15-27	matrix metallopeptidase 1	Homo sapiens	87-92
17220244-1	2007	The objective of this study was to investigate whether cyclosporin A (CsA) is a modulator for breast cancer resistance protein (BCRP).	Cyclosporine	55-68	ATP binding cassette subfamily G member 2	Canis lupus familiaris	94-126
16177646-5	2005	RESULTS: Long-term CsA treatment upregulated TLR2 and TLR4 mRNA and protein expression on renal tubular cells, and these were accompanied by increased MYD88, NF-kappaB and AP-1 expression.	Cyclosporine	19-22	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	151-156
16177646-6	2005	Putative TLR ligand (HSP70) was also significantly increased in CsA-treated rat kidney compared with vehicle-treated rat kidney.	Cyclosporine	64-67	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	21-26
16002416-10	2005	We found that PAI-1 4G allele was associated with progression to renal failure in the group of CsA-treated patients.	Cyclosporine	95-98	serpin family E member 1	Homo sapiens	14-19
16002416-11	2005	Our results are in agreement with the hypothesis, raised after experimental results obtained in mouse models, that the effect of ACE polymorphisms on blood pressure is detectable once environmental factors, like CsA treatment in our case, overcome physiological homeostatic mechanisms.	Cyclosporine	212-215	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	129-132
16048605-7	2005	In patients on CsA (n = 21), CrCl decreased significantly at 1 month post-OLT (42.6 +/- 26.6 mL/min/1.73 m(2)) when compared with pretransplantation, and 3, 12 and 60 months post-OLT (p &lt; 0.05).	Cyclosporine	15-18	CRCL	Homo sapiens	29-33
15998670-5	2005	Treatment with a short course of cobra venom factor and maintenance cyclosporine resulted in long-term acceptance of both Fgl-2+/+ and Fgl-2-/- grafts.	Cyclosporine	68-80	fibrinogen like 2	Homo sapiens	122-127
15998670-5	2005	Treatment with a short course of cobra venom factor and maintenance cyclosporine resulted in long-term acceptance of both Fgl-2+/+ and Fgl-2-/- grafts.	Cyclosporine	68-80	fibrinogen like 2	Homo sapiens	135-140
15998670-6	2005	On withdrawal of cyclosporine, Fgl-2+/+ grafts developed features of AVR; in contrast, Fgl-2-/- grafts again developed acute cellular rejection.	Cyclosporine	17-29	fibrinogen like 2	Homo sapiens	31-36
15799972-7	2005	Moreover, pretreatment with okadaic acid or cyclosporin A blocked the dephosphorylation of GSK-3beta at Ser-9 at 0, 15, and 30 min after KCl-induced depolarization, and the activity of protein phosphatases (PP) 2A and 2B increased at these times.	Cyclosporine	44-57	protein phosphatase 2 phosphatase activator	Homo sapiens	185-220
15896784-4	2005	Here, we report that (1) GD3 specifically induces gradual depolarizations of the inner membrane by a mechanism that differs from the permeability transition, and (2) the GD3-induced depolarizations are suppressed by cyclosporin A.	Cyclosporine	216-229	GRDX	Homo sapiens	25-28
15896784-4	2005	Here, we report that (1) GD3 specifically induces gradual depolarizations of the inner membrane by a mechanism that differs from the permeability transition, and (2) the GD3-induced depolarizations are suppressed by cyclosporin A.	Cyclosporine	216-229	GRDX	Homo sapiens	170-173
15890490-6	2005	Our aim was, therefore, to analyze the effect of CsA and FK506 on SPARC gene expression.	Cyclosporine	49-52	secreted protein acidic and cysteine rich	Homo sapiens	66-71
15890490-7	2005	METHODS: Cultured human gingival fibroblasts were incubated with CsA, FK506 or with their vehicle (VH) for 24, 48 and 72 h. SPARC gene expression was determined by RT-PCR.	Cyclosporine	65-68	secreted protein acidic and cysteine rich	Homo sapiens	124-129
15890490-8	2005	RESULTS: SPARC mRNA levels tended to increase 72 h after CsA treatment, whilst they are undetectable in FK506-treated fibroblasts, compared to VH.	Cyclosporine	57-60	secreted protein acidic and cysteine rich	Homo sapiens	9-14
15890490-9	2005	CONCLUSION: This gene expression profile is consistent with the involvement of SPARC in the mechanisms leading to the development of CsA-induced GO.	Cyclosporine	133-136	secreted protein acidic and cysteine rich	Homo sapiens	79-84
15907480-2	2005	Immunodepressant cyclosporin A at anti-proliferative doses diminished the induction of alpha1 protein in activated lymphocytes.	Cyclosporine	17-30	adrenoceptor alpha 1D	Homo sapiens	87-93
15832403-2	2005	We synthesized a series of electrophilic cyclosporin (CsA) derivatives by varying electrophiles and linker lengths, prepared a series of nucleophilic cysteine mutations on the surface of cyclophilin A (Cyp), and examined their reactivity and specificity in proximity-accelerated reactions.	Cyclosporine	54-57	peptidylprolyl isomerase G	Homo sapiens	187-200
15848720-3	2005	Therefore, this study was designed to assess pharmacodynamic (PD) effects of the combination cyclosporin (CsA) plus mycophenolate mofetil (MMF) on lymphocyte functions in peripheral blood of stable heart transplant recipients (HTx) using our established FACS assays.	Cyclosporine	93-104	Zic family member 3	Homo sapiens	227-230
15848720-3	2005	Therefore, this study was designed to assess pharmacodynamic (PD) effects of the combination cyclosporin (CsA) plus mycophenolate mofetil (MMF) on lymphocyte functions in peripheral blood of stable heart transplant recipients (HTx) using our established FACS assays.	Cyclosporine	106-109	Zic family member 3	Homo sapiens	227-230
15848720-11	2005	CONCLUSION: For the first time, the immunosuppressive effects of the combination CsA plus MMF were quantified in whole blood of human HTx at different time points.	Cyclosporine	81-84	Zic family member 3	Homo sapiens	134-137
15729167-10	2005	In addition, PFD down-regulated the mRNA expression of CsA-induced p53 and Fas-ligand (P&lt;0.01) and increased that of Bcl-xL, previously reduced by CsA (P&lt;0.01).	Cyclosporine	55-58	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	67-70
15639493-8	2005	CsA decreased the number of SRY+ SMCs in the lesions, restricted medial destruction, and improved survival of allogenic SMCs after seeding in injured arteries.	Cyclosporine	0-3	sex determining region Y	Rattus norvegicus	28-31
15614148-5	2004	RESULTS: CsA-induced tubular cell apoptosis; cellular infiltration; and increase of Fas, Bax, TGF-beta protein expression with significant tubulointerstitial fibrosis, and reduced Bcl2 protein expression.	Cyclosporine	9-12	BCL2 associated X, apoptosis regulator	Rattus norvegicus	89-92
15614148-7	2004	CONCLUSIONS: These findings suggest that chronic CsA nephrotoxicity is related to Bax and Bcl2-related apoptosis pathways, and that alpha-MSH can attenuate the CsA-induced tubulointerstitial fibrosis as well as tubular cell apoptosis.	Cyclosporine	49-52	BCL2 associated X, apoptosis regulator	Rattus norvegicus	82-85
15584866-7	2004	In contrast to all other putative antagonists, which are discussed in detail herein, one Jak3 inhibitor, NC1153, shows at least 40-fold greater selective inhibition for Jak3 than for Jak2, is robustly synergistic with calcineurin antagonists, and, either alone or in combination with cyclosporin, produces no adverse effects in rodents preconditioned to be at heightened risk for nephrotoxicity, bone marrow suppression, or altered lipid metabolism.	Cyclosporine	284-295	Janus kinase 3	Homo sapiens	89-93
15464081-0	2004	Cyclosporine and bromocriptine-induced suppressions of CYP3A1/2 and CYP2C11 are not mediated by prolactin.	Cyclosporine	0-12	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	68-75
15464081-1	2004	The purpose of this study was to determine if the suppression of hepatic CYP3A1/2 (cytochrome P450 3A1/2) and CYP2C11 (cytochrome P450 2C11) by cyclosporine is mediated by prolactin.	Cyclosporine	144-156	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	110-117
15464081-1	2004	The purpose of this study was to determine if the suppression of hepatic CYP3A1/2 (cytochrome P450 3A1/2) and CYP2C11 (cytochrome P450 2C11) by cyclosporine is mediated by prolactin.	Cyclosporine	144-156	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	119-139
15175422-6	2004	Testosterone, verapamil, quinidine, and cyclosporine A were selected as P-gp inhibitors.	Cyclosporine	40-54	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	72-76
15337272-3	2004	Perfusion of oocytes with either cyclosporin A or deltamethrin, considered to be diagnostic inhibitors of the protein phosphatase calcineurin, at 10 microM blocked spontaneous downregulation.	Cyclosporine	33-46	protein phosphatase 3, catalytic subunit, alpha isozyme L homeolog	Xenopus laevis	130-141
15337272-5	2004	The use of a calcineurin inhibitor such as cyclosporin A provides an effective means of stabilizing the expression of Nav1.8 sodium channels in oocytes for functional and pharmacological studies.	Cyclosporine	43-56	protein phosphatase 3, catalytic subunit, alpha isozyme L homeolog	Xenopus laevis	13-24
15377466-1	2004	BACKGROUND AND OBJECTIVES: In a previous study we showed that patients with severe aplastic anemia (SAA) treated with anti-lymphocyte globulin (ALG), cyclosporin (CyA) and granulocyte colony-stimulating factor (G-CSF) 5 micro g/kg/day had an encouraging outcome.	Cyclosporine	150-161	colony stimulating factor 3	Homo sapiens	172-209
15377466-1	2004	BACKGROUND AND OBJECTIVES: In a previous study we showed that patients with severe aplastic anemia (SAA) treated with anti-lymphocyte globulin (ALG), cyclosporin (CyA) and granulocyte colony-stimulating factor (G-CSF) 5 micro g/kg/day had an encouraging outcome.	Cyclosporine	150-161	colony stimulating factor 3	Homo sapiens	211-216
15339989-7	2004	In this murine model of CsA nephropathy under ACE blockade, plasminogen activator inhibitor-1 (PAI-1) expression was decreased in tubular epithelial cells, possibly leading to conversion of plasminogen to plasmin by plasminogen activator and subsequent activation of matrix metalloproteinases.	Cyclosporine	24-27	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	46-49
15339989-7	2004	In this murine model of CsA nephropathy under ACE blockade, plasminogen activator inhibitor-1 (PAI-1) expression was decreased in tubular epithelial cells, possibly leading to conversion of plasminogen to plasmin by plasminogen activator and subsequent activation of matrix metalloproteinases.	Cyclosporine	24-27	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	60-93
15339989-7	2004	In this murine model of CsA nephropathy under ACE blockade, plasminogen activator inhibitor-1 (PAI-1) expression was decreased in tubular epithelial cells, possibly leading to conversion of plasminogen to plasmin by plasminogen activator and subsequent activation of matrix metalloproteinases.	Cyclosporine	24-27	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	95-100
15316361-10	2004	In the B6 to GFP-B/c strain combination, everolimus and CsA strongly prevented heart rejection under treatment, partly suppressed neointima formation, and completely prevented SMA-positive host (GFP) cell accumulation.	Cyclosporine	56-59	immunoglobulin mu binding protein 2	Mus musculus	176-179
17220244-1	2007	The objective of this study was to investigate whether cyclosporin A (CsA) is a modulator for breast cancer resistance protein (BCRP).	Cyclosporine	55-68	ATP binding cassette subfamily G member 2	Canis lupus familiaris	128-132
17220244-1	2007	The objective of this study was to investigate whether cyclosporin A (CsA) is a modulator for breast cancer resistance protein (BCRP).	Cyclosporine	70-73	ATP binding cassette subfamily G member 2	Canis lupus familiaris	94-126
17220244-1	2007	The objective of this study was to investigate whether cyclosporin A (CsA) is a modulator for breast cancer resistance protein (BCRP).	Cyclosporine	70-73	ATP binding cassette subfamily G member 2	Canis lupus familiaris	128-132
17220244-3	2007	CsA inhibited BCRP or BCRP R482T mutant-associated ATPase with an IC(50) of 26.1 and 7.3 microM (31,388 and 8779 ng/ml), respectively, indicating that CsA is a modulator for BCRP and its R482T mutant.	Cyclosporine	0-3	ATP binding cassette subfamily G member 2	Canis lupus familiaris	14-18
17220244-3	2007	CsA inhibited BCRP or BCRP R482T mutant-associated ATPase with an IC(50) of 26.1 and 7.3 microM (31,388 and 8779 ng/ml), respectively, indicating that CsA is a modulator for BCRP and its R482T mutant.	Cyclosporine	0-3	ATP binding cassette subfamily G member 2	Canis lupus familiaris	22-26
15289793-16	2004	The in vitro results demonstrate that rosuvastatin is a good substrate for OATP-C-mediated hepatic uptake (association constant, 8.5 +/- 1.1 micromol/L) and that cyclosporine is an effective inhibitor of this process (50% inhibition constant, 2.2 +/- 0.4 micromol/L when the rosuvastatin concentration was 5 micromol/L).	Cyclosporine	162-174	solute carrier organic anion transporter family member 1B1	Homo sapiens	75-81
17220244-3	2007	CsA inhibited BCRP or BCRP R482T mutant-associated ATPase with an IC(50) of 26.1 and 7.3 microM (31,388 and 8779 ng/ml), respectively, indicating that CsA is a modulator for BCRP and its R482T mutant.	Cyclosporine	0-3	ATP binding cassette subfamily G member 2	Canis lupus familiaris	22-26
15289793-18	2004	Cyclosporine inhibition of OATP-C-mediated rosuvastatin hepatic uptake may be the mechanism of the drug-drug interaction.	Cyclosporine	0-12	solute carrier organic anion transporter family member 1B1	Homo sapiens	27-33
17220244-3	2007	CsA inhibited BCRP or BCRP R482T mutant-associated ATPase with an IC(50) of 26.1 and 7.3 microM (31,388 and 8779 ng/ml), respectively, indicating that CsA is a modulator for BCRP and its R482T mutant.	Cyclosporine	151-154	ATP binding cassette subfamily G member 2	Canis lupus familiaris	14-18
15191592-10	2004	CONCLUSIONS: The findings of the present study indicate alterations in GCF t-PA and PAI-2 levels in CsA-induced gingival overgrowth and might suggest involvement of the plasminogen activating system in the pathogenesis of this side-effect of CsA therapy.	Cyclosporine	100-103	serpin family B member 2	Homo sapiens	84-89
17220244-3	2007	CsA inhibited BCRP or BCRP R482T mutant-associated ATPase with an IC(50) of 26.1 and 7.3 microM (31,388 and 8779 ng/ml), respectively, indicating that CsA is a modulator for BCRP and its R482T mutant.	Cyclosporine	151-154	ATP binding cassette subfamily G member 2	Canis lupus familiaris	22-26
15191592-10	2004	CONCLUSIONS: The findings of the present study indicate alterations in GCF t-PA and PAI-2 levels in CsA-induced gingival overgrowth and might suggest involvement of the plasminogen activating system in the pathogenesis of this side-effect of CsA therapy.	Cyclosporine	242-245	serpin family B member 2	Homo sapiens	84-89
17220244-3	2007	CsA inhibited BCRP or BCRP R482T mutant-associated ATPase with an IC(50) of 26.1 and 7.3 microM (31,388 and 8779 ng/ml), respectively, indicating that CsA is a modulator for BCRP and its R482T mutant.	Cyclosporine	151-154	ATP binding cassette subfamily G member 2	Canis lupus familiaris	22-26
17220244-6	2007	The inhibitory constant (K(i)) of CsA toward BCRP was 6.7 microM (8507 ng/ml) and 7.8 microM (9380 ng/ml) when using E3S or MTX, respectively, as a BCRP substrate.	Cyclosporine	34-37	ATP binding cassette subfamily G member 2	Canis lupus familiaris	45-49
17220244-6	2007	The inhibitory constant (K(i)) of CsA toward BCRP was 6.7 microM (8507 ng/ml) and 7.8 microM (9380 ng/ml) when using E3S or MTX, respectively, as a BCRP substrate.	Cyclosporine	34-37	ATP binding cassette subfamily G member 2	Canis lupus familiaris	148-152
15251423-5	2004	Treatment with cyclosporin A at higher concentrations resulted in superior histologic preservation of lymphoid tissue structures and seemed to further prevent the expression of CD95 by CD3(+) cells and the activation in tissue culture of CD21(+) cells.	Cyclosporine	15-28	Fas cell surface death receptor	Homo sapiens	177-181
17220244-7	2007	The inhibitory potency of CsA on BCRP wild type or its R482T mutant was lower than that on P-glycoprotein.	Cyclosporine	26-29	ATP binding cassette subfamily G member 2	Canis lupus familiaris	33-37
17220244-8	2007	The present studies demonstrate that CsA is an inhibitor but not a substrate for BCRP, and has low potential to cause drug-drug interactions with BCRP substrate drugs due to its weak inhibitory effect on BCRP and BCRP R482T mutant at its normal therapeutic blood concentrations (200-400 ng/ml) (Blood 91:362-363, 1998).	Cyclosporine	37-40	ATP binding cassette subfamily G member 2	Canis lupus familiaris	146-150
17220244-8	2007	The present studies demonstrate that CsA is an inhibitor but not a substrate for BCRP, and has low potential to cause drug-drug interactions with BCRP substrate drugs due to its weak inhibitory effect on BCRP and BCRP R482T mutant at its normal therapeutic blood concentrations (200-400 ng/ml) (Blood 91:362-363, 1998).	Cyclosporine	37-40	ATP binding cassette subfamily G member 2	Canis lupus familiaris	146-150
17220244-8	2007	The present studies demonstrate that CsA is an inhibitor but not a substrate for BCRP, and has low potential to cause drug-drug interactions with BCRP substrate drugs due to its weak inhibitory effect on BCRP and BCRP R482T mutant at its normal therapeutic blood concentrations (200-400 ng/ml) (Blood 91:362-363, 1998).	Cyclosporine	37-40	ATP binding cassette subfamily G member 2	Canis lupus familiaris	146-150
17299004-0	2007	Ciclosporin reduces paracellin-1 expression and magnesium transport in thick ascending limb cells.	Cyclosporine	0-11	claudin 16	Mus musculus	20-32
17299004-4	2007	We hypothesize that CsA reduces the expression and function of paracellin-1 and accounts for the observed renal Mg2+ wasting.	Cyclosporine	20-23	claudin 16	Mus musculus	63-75
15010473-7	2004	Either RRAT or RGET was sufficient for PKA activation of hClC-2 at pH(o) 7.4, as long as phosphatase inhibitors (cyclosporin A or endothal) were present.	Cyclosporine	113-126	chloride voltage-gated channel 2	Homo sapiens	57-63
17299004-7	2007	Real-time PCR and western blotting were used to test the CsA effects on paracellin-1 expression of cultured cTAL cells.	Cyclosporine	57-60	claudin 16	Mus musculus	72-84
17299004-11	2007	CsA (100 ng/ml) incubation for 24 h induced a decrease of paracellin-1 mRNA by 89.4% and paracellin-1 protein by 75.4%.	Cyclosporine	0-3	claudin 16	Mus musculus	58-70
17299004-11	2007	CsA (100 ng/ml) incubation for 24 h induced a decrease of paracellin-1 mRNA by 89.4% and paracellin-1 protein by 75.4%.	Cyclosporine	0-3	claudin 16	Mus musculus	89-101
17336708-3	2007	METHODS: We measured basal and in vivo stimulated AKT and P70 S6 kinase (P70(S6K)) phosphorylation in PBMCs from 37 cyclosporine A-treated patients, 10 of whom had Kaposi sarcoma, before and 6 months after conversion to rapamycin therapy.	Cyclosporine	116-130	ribosomal protein S6 kinase B1	Homo sapiens	58-61
15068461-1	2004	A 19-year-old woman with severe HLA B27 spondyloarthropathy whose disease was controlled on cyclosporin, methotrexate and prednisolone had human papillomavirus infection and developed cervical dysplasia and a large number of cutaneous and vulval warts.	Cyclosporine	92-103	major histocompatibility complex, class I, B	Homo sapiens	32-37
17214638-4	2007	However, little is known about the correlation between PAI-1 and cyclosporin A-induced gingival overgrowth.	Cyclosporine	65-78	serpin family E member 1	Homo sapiens	55-60
15129317-0	2004	Nail psoriasis: combined therapy with systemic cyclosporin and topical calcipotriol.	Cyclosporine	47-58	CD244 molecule	Homo sapiens	0-4
15129317-9	2004	RESULTS: Both cyclosporin alone and a combination of cyclosporin with topical calcipotriol twice a day were useful for treating nail psoriasis after three months of therapy although the combined therapy showed a better overall result in both mild and severe nail psoriasis.	Cyclosporine	14-25	CD244 molecule	Homo sapiens	128-132
15129317-9	2004	RESULTS: Both cyclosporin alone and a combination of cyclosporin with topical calcipotriol twice a day were useful for treating nail psoriasis after three months of therapy although the combined therapy showed a better overall result in both mild and severe nail psoriasis.	Cyclosporine	53-64	CD244 molecule	Homo sapiens	128-132
15129317-9	2004	RESULTS: Both cyclosporin alone and a combination of cyclosporin with topical calcipotriol twice a day were useful for treating nail psoriasis after three months of therapy although the combined therapy showed a better overall result in both mild and severe nail psoriasis.	Cyclosporine	53-64	CD244 molecule	Homo sapiens	258-262
17214638-5	2007	The aim of this study was to investigate the effects of cyclosporin A on the expression of PAI-1 mRNA and protein in human gingival fibroblasts human gingival fibroblasts in vitro and to compare PAI-1 expression in normal healthy gingival tissues and cyclosporin A-induced gingival overgrowth specimens in vivo.	Cyclosporine	56-69	serpin family E member 1	Homo sapiens	91-96
17214638-5	2007	The aim of this study was to investigate the effects of cyclosporin A on the expression of PAI-1 mRNA and protein in human gingival fibroblasts human gingival fibroblasts in vitro and to compare PAI-1 expression in normal healthy gingival tissues and cyclosporin A-induced gingival overgrowth specimens in vivo.	Cyclosporine	251-264	serpin family E member 1	Homo sapiens	91-96
17214638-8	2007	RESULTS: Investigations of the time dependence of PAI-1 mRNA expression in human gingival fibroblasts treated with 200 ng/ml of cyclosporin A revealed a rapid accumulation of the transcript: a significant signal was first detectable after 1 h of exposure and the signal remained elevated throughout the 24-h incubation period (p &lt; 0.05).	Cyclosporine	128-141	serpin family E member 1	Homo sapiens	50-55
14969736-2	2004	We investigated the effect of intra-carotid infusion of 5-10 mg/kg of cyclosporin A (CsA) on the neuronal survival in CA1 sector of hippocampus and on the subcellular localization of cytochrome C in the model of 5 min gerbil brain ischemia.	Cyclosporine	70-83	carbonic anhydrase 1	Rattus norvegicus	118-121
17214638-9	2007	Cyclosporin A was also found to up-regulate PAI-1 protein in a time-dependent manner (p &lt; 0.05).	Cyclosporine	0-13	serpin family E member 1	Homo sapiens	44-49
14969736-2	2004	We investigated the effect of intra-carotid infusion of 5-10 mg/kg of cyclosporin A (CsA) on the neuronal survival in CA1 sector of hippocampus and on the subcellular localization of cytochrome C in the model of 5 min gerbil brain ischemia.	Cyclosporine	85-88	carbonic anhydrase 1	Rattus norvegicus	118-121
17214638-10	2007	The PAI-1 staining in gingival tissue was stronger in the cyclosporin A-induced gingival overgrowth group than in the normal gingival group (p &lt; 0.05).	Cyclosporine	58-71	serpin family E member 1	Homo sapiens	4-9
14743390-8	2004	The mononuclear cells resulting from high cyclosporin treatment (1,000 ng/ml) were cathepsin K (CTSK) and tartrate-resistant acid phosphatase (TRAP) positive but expression of calcitonin receptor (CTR) was downregulated by more than 30-fold.	Cyclosporine	42-53	cathepsin K	Homo sapiens	83-94
17214638-11	2007	In the cyclosporin A-induced gingival overgrowth group, intensive staining for PAI-1 expression was observed mainly in the cytoplasm of fibroblasts, endothelial cells and inflammatory cells.	Cyclosporine	7-20	serpin family E member 1	Homo sapiens	79-84
14743390-8	2004	The mononuclear cells resulting from high cyclosporin treatment (1,000 ng/ml) were cathepsin K (CTSK) and tartrate-resistant acid phosphatase (TRAP) positive but expression of calcitonin receptor (CTR) was downregulated by more than 30-fold.	Cyclosporine	42-53	cathepsin K	Homo sapiens	96-100
17214638-12	2007	CONCLUSION: These findings suggest that the up-regulation of PAI-1 may play an important part in the molecular pathogenesis of cyclosporin A-induced gingival overgrowth.	Cyclosporine	127-140	serpin family E member 1	Homo sapiens	61-66
15147634-11	2004	Furthermore, the strong expression of Bax in satellite cells can explain the temporary nature of the neurotoxic effect commonly observed after cyclosporine-A administration.	Cyclosporine	143-157	BCL2 associated X, apoptosis regulator	Rattus norvegicus	38-41
17335659-8	2007	IL-10 was upregulated in long-term survival recipients following splenectomy + CsA.	Cyclosporine	79-82	interleukin 10	Rattus norvegicus	0-5
15180435-6	2004	We found that, relative to HL cells, SML cells overexpress the calcineurin-activated transcription factor nuclear factor of activated T cells 1 (NFAT-1), which exists in a cyclosporine A (CsA)-sensitive dephosphorylated, constitutively active state.	Cyclosporine	172-186	nuclear factor of activated T cells 2	Homo sapiens	145-151
15180435-6	2004	We found that, relative to HL cells, SML cells overexpress the calcineurin-activated transcription factor nuclear factor of activated T cells 1 (NFAT-1), which exists in a cyclosporine A (CsA)-sensitive dephosphorylated, constitutively active state.	Cyclosporine	188-191	nuclear factor of activated T cells 2	Homo sapiens	145-151
15013323-0	2004	Cyclosporine-A induced nephrotoxicity is associated with decreased renal bone morphogenetic protein-7 expression in rats.	Cyclosporine	0-14	bone morphogenetic protein 7	Rattus norvegicus	73-101
15013323-1	2004	The aim of our study was to investigate bone morphogenetic protein-7 (BMP-7) expression in a rat model of chronic cyclosporine (CsA) toxicity compare with healthy controls, as well as the influence of treatment with the angiotensin-converting enzyme inhibitor (ACEI) quinapril.	Cyclosporine	114-126	bone morphogenetic protein 7	Rattus norvegicus	40-68
15013323-1	2004	The aim of our study was to investigate bone morphogenetic protein-7 (BMP-7) expression in a rat model of chronic cyclosporine (CsA) toxicity compare with healthy controls, as well as the influence of treatment with the angiotensin-converting enzyme inhibitor (ACEI) quinapril.	Cyclosporine	114-126	bone morphogenetic protein 7	Rattus norvegicus	70-75
15013323-1	2004	The aim of our study was to investigate bone morphogenetic protein-7 (BMP-7) expression in a rat model of chronic cyclosporine (CsA) toxicity compare with healthy controls, as well as the influence of treatment with the angiotensin-converting enzyme inhibitor (ACEI) quinapril.	Cyclosporine	128-131	bone morphogenetic protein 7	Rattus norvegicus	40-68
15013323-1	2004	The aim of our study was to investigate bone morphogenetic protein-7 (BMP-7) expression in a rat model of chronic cyclosporine (CsA) toxicity compare with healthy controls, as well as the influence of treatment with the angiotensin-converting enzyme inhibitor (ACEI) quinapril.	Cyclosporine	128-131	bone morphogenetic protein 7	Rattus norvegicus	70-75
15013323-7	2004	CsA-treated rats displayed significantly decreased BMP-7 expression compared with healthy controls (P &lt;.0005).	Cyclosporine	0-3	bone morphogenetic protein 7	Rattus norvegicus	51-56
15013323-8	2004	BMP-7 expression was higher among the CsA + Q group than the the group CsA group.	Cyclosporine	38-41	bone morphogenetic protein 7	Rattus norvegicus	0-5
15013323-9	2004	In a rat model histologic changes characteristic of CsA-induced nephrotoxicity are associated with decreased expression of BMP-7, which seems to be at least partially restored by ACE inhibition.	Cyclosporine	52-55	bone morphogenetic protein 7	Rattus norvegicus	123-128
14678967-4	2003	Antioxidants (N-acetyl-L-cysteine and Tiron) and inhibitors of mitochondrial permeability transition (cyclosporine A and bongkrekic acid) inhibit Ad.mda-7-induced mitochondrial dysfunction and apoptosis.	Cyclosporine	102-116	interleukin 24	Homo sapiens	149-154
14555277-9	2003	Although CsA did not affect RANKL-induced osteoclast generation in the culture of monocytes alone, it completely rescued the T-cell-induced inhibition of osteoclast formation and strongly inhibited the production of GM-CSF and IFN-gamma.	Cyclosporine	9-12	colony stimulating factor 2	Homo sapiens	216-222
12949730-8	2003	Bid was required for permeability transition and mitochondria depolarization in addition to the previously defined release of cytochrome c. Permeability transition inhibitors cyclosporin A and aristolochic acid could inhibit mitochondria activation effectively, but not as much as the deletion of the bid gene, and they could not inhibit Bak oligomerization.	Cyclosporine	175-188	BCL2-antagonist/killer 1	Mus musculus	338-341
12947345-1	2003	BACKGROUND: We have previously shown that endothelial injury by cyclosporin A (CyA) is associated with an increased endothelin-1 (ET-1) release.	Cyclosporine	64-77	endothelin 1	Mus musculus	116-128
12947345-1	2003	BACKGROUND: We have previously shown that endothelial injury by cyclosporin A (CyA) is associated with an increased endothelin-1 (ET-1) release.	Cyclosporine	64-77	endothelin 1	Mus musculus	130-134
12947345-1	2003	BACKGROUND: We have previously shown that endothelial injury by cyclosporin A (CyA) is associated with an increased endothelin-1 (ET-1) release.	Cyclosporine	79-82	endothelin 1	Mus musculus	116-128
12947345-1	2003	BACKGROUND: We have previously shown that endothelial injury by cyclosporin A (CyA) is associated with an increased endothelin-1 (ET-1) release.	Cyclosporine	79-82	endothelin 1	Mus musculus	130-134
12947345-2	2003	We now sought to determine, in an animal model of angiogenesis, if inhibiting the effect of ET-1 on endothelial cells (ECs) would reverse the CyA-mediated endothelial injury in an animal model of angiogenesis.	Cyclosporine	142-145	endothelin 1	Mus musculus	92-96
12611882-8	2003	Both the early release of proteins like cytochrome c and Hsp60 from the mitochondria as well as the later translocation of the active caspase-9/-3 are partially inhibited by cyclosporin A, an inhibitor of mitochondrial membrane permeabilization.	Cyclosporine	174-187	caspase 9	Homo sapiens	134-143
12697421-8	2003	In addition, anti-inflammatory drugs dexamethasone (DEX) and cyclosporin A (CSA) both blocked activation of JNKS/SAPK and the cell-cell contact induced production of hRPE IL-8 and MCP-1, while activation of p38 and ERK was only inhibited by DEX, but not by CSA.	Cyclosporine	61-74	C-C motif chemokine ligand 2	Homo sapiens	180-185
12697421-8	2003	In addition, anti-inflammatory drugs dexamethasone (DEX) and cyclosporin A (CSA) both blocked activation of JNKS/SAPK and the cell-cell contact induced production of hRPE IL-8 and MCP-1, while activation of p38 and ERK was only inhibited by DEX, but not by CSA.	Cyclosporine	76-79	C-C motif chemokine ligand 2	Homo sapiens	180-185
12717193-5	2003	RESULTS: Cyclosporine significantly abrogated the effect of anti-CD45RB therapy.	Cyclosporine	9-21	protein tyrosine phosphatase, receptor type, C	Mus musculus	65-69
12747447-3	2003	The aim of this study was to investigate the effect of cyclosporin on matrix metalloproteinases (MMP)-1 and tissue inhibitors of MMP (TIMP)-1 expression at the mRNA, protein, and enzyme activity levels.	Cyclosporine	55-66	matrix metallopeptidase 1	Homo sapiens	70-103
12747447-7	2003	RESULTS: Results indicated that cyclosporin inhibited MMP-1 expression at both the mRNA and protein level in a dose- and time-dependent fashion.	Cyclosporine	32-43	matrix metallopeptidase 1	Homo sapiens	54-59
12868191-7	2003	RESULTS: In children treated with cyclosporine A increased concentrations of t-PA and PAI-1 were found (p &lt; 0.01).	Cyclosporine	34-48	serpin family E member 1	Homo sapiens	86-91
12868191-10	2003	CONCLUSION: Children with remission of idiopathic nephrotic syndrome treated with cyclosporine A show increased concentration of t-PA and PAI-1 and thrombinogenesis.	Cyclosporine	82-96	serpin family E member 1	Homo sapiens	138-143
12614449-8	2003	RESULTS: Ascomycin (0.01 nm to 1 micro m) and cyclosporin A (0.1 nm to 10 micro m) strikingly inhibited (maximally 100%) anti-IgE-induced histamine and cytokine release from basophils, and these actions were unaffected by IL-3 priming.	Cyclosporine	46-59	interleukin 3	Homo sapiens	222-226
12668872-4	2003	In addition, in vitro binding assays demonstrated a direct interaction of CypA with the PRLR, in the presence or absence of cyclosporine.	Cyclosporine	124-136	peptidylprolyl isomerase A	Homo sapiens	74-78
12631117-0	2003	Nitric oxide modulates vascular endothelial growth factor and receptors in chronic cyclosporine nephrotoxicity.	Cyclosporine	83-95	vascular endothelial growth factor A	Rattus norvegicus	23-57
12631117-2	2003	We have previously shown that VEGF is up-regulated in a model of chronic cyclosporine (CsA) nephrotoxicity and that l-arginine (l-Arg) improved while N-nitro-l-arginine-methyl ester (L-NAME) worsened fibrosis.	Cyclosporine	73-85	vascular endothelial growth factor A	Rattus norvegicus	30-34
12631117-2	2003	We have previously shown that VEGF is up-regulated in a model of chronic cyclosporine (CsA) nephrotoxicity and that l-arginine (l-Arg) improved while N-nitro-l-arginine-methyl ester (L-NAME) worsened fibrosis.	Cyclosporine	87-90	vascular endothelial growth factor A	Rattus norvegicus	30-34
12631117-7	2003	VEGF mRNA and protein expressions increased with CsA, further increased with L-NAME and became significantly reduced with L-Arg.	Cyclosporine	49-52	vascular endothelial growth factor A	Rattus norvegicus	0-4
12631117-13	2003	The actions of VEGF in this model remain speculative, but it is probable that VEGF plays a role, either independently or through nitric oxide, in CsA-induced fibrosis.	Cyclosporine	146-149	vascular endothelial growth factor A	Rattus norvegicus	78-82
12581324-5	2003	This review presents the information available supporting cyclosporin drug concentration drawn two hours post dose (C-2) in children who have been transplanted as the best single indicator of CsA exposure.	Cyclosporine	58-69	complement C2	Homo sapiens	116-119
12581324-5	2003	This review presents the information available supporting cyclosporin drug concentration drawn two hours post dose (C-2) in children who have been transplanted as the best single indicator of CsA exposure.	Cyclosporine	192-195	complement C2	Homo sapiens	116-119
12558459-7	2003	Cyclosporin-treated patients on the other hand show several-fold higher systemic exposure of all statins, both those that are metabolised by CYP3A4 and fluvastatin (metabolised by CYP2C9).	Cyclosporine	0-11	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	180-186
12472767-6	2003	RESULTS: CsA reduced the CCr and up-regulated TGF-beta, collagen I and fibronectin mRNA expression with a significant development of arteriolopathy, and reduced EGF mRNA levels.	Cyclosporine	9-12	fibronectin 1	Rattus norvegicus	71-82
12472590-5	2002	Inhibitors of T-cell functions, such as cyclosporin A and hydrocortisone, decreased induction of PTTG mRNA expression.	Cyclosporine	40-53	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	97-101
12475968-6	2002	Wild-type Ets1 negatively affects GM-CSF transcription on Ca(2+) stimulation in the presence of cyclosporin A, which inhibits calcineurin.	Cyclosporine	96-109	ETS proto-oncogene 1, transcription factor	Homo sapiens	10-14
12475968-6	2002	Wild-type Ets1 negatively affects GM-CSF transcription on Ca(2+) stimulation in the presence of cyclosporin A, which inhibits calcineurin.	Cyclosporine	96-109	colony stimulating factor 2	Homo sapiens	34-40
12408978-1	2002	NFAT (nuclear factor of activated T cells) plays a pivotal role in inducible gene transcription during the immune response and functions as a major target for immunosuppressive drugs such as cyclosporin A and FK-506.	Cyclosporine	191-204	nuclear factor of activated T cells 2	Homo sapiens	0-4
12411407-0	2002	Cyclosporine A regulate oxidative stress-induced apoptosis in cardiomyocytes: mechanisms via ROS generation, iNOS and Hsp70.	Cyclosporine	0-14	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	118-123
12411407-13	2002	Pre-treatment with CsA at concentration of 0.01-1.0 micro M for 24 h produced up-regulation of heat shock protein 70 (Hsp 70), inducible nitric oxide synthase (iNOS) and also induced NO production, indicating that these factors might be associated with the cell protective effects of CsA.	Cyclosporine	19-22	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	95-116
12411407-13	2002	Pre-treatment with CsA at concentration of 0.01-1.0 micro M for 24 h produced up-regulation of heat shock protein 70 (Hsp 70), inducible nitric oxide synthase (iNOS) and also induced NO production, indicating that these factors might be associated with the cell protective effects of CsA.	Cyclosporine	19-22	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	118-124
12411407-15	2002	These results suggest that CsA could protect the oxidative stress-induced cardiomyocyte apoptosis not only by preventing the loss of DeltaPsim in mitochondria, but also through ROS generation, Hsp70, and iNOS up-regulation.	Cyclosporine	27-30	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	193-198
17202334-11	2007	However, cyclosporin A, an inhibitor of the Ca(2+)-dependent phosphatase calcineurin, had similar effects on FOXO1 mRNA expression as the PI3K inhibitor LY294002.	Cyclosporine	9-22	forkhead box O1	Mus musculus	109-114
12479636-3	2002	The aim of this study was to investigate the potential role of TGF-beta1 in the pathogenesis of CsA-induced gingival overgrowth, exploring a possible autocrine stimulation of TGF-beta1 as a cellular regulator of synthesis of matrix metalloproteinases (MMPs) and its tissue inhibitors (TIMPs).	Cyclosporine	96-99	matrix metallopeptidase 1	Homo sapiens	252-256
12479636-7	2002	RESULTS: CsA simultaneously stimulated TGF-beta1 expression and production and inhibited expression of MMP-1 and MMP-2 by human gingival fibroblasts, whereas CsA has a slight effect on TIMP-1 and TIMP-2 expression.	Cyclosporine	9-12	matrix metallopeptidase 1	Homo sapiens	103-108
17164721-9	2006	CD4CD25Treg cells expressed slightly lower levels of Foxp3 in CsA-treated mice.	Cyclosporine	62-65	forkhead box P3	Mus musculus	53-58
17175314-1	2006	We previously confirmed that losartan (LOS), an angiotensin-II (A-II) receptor blocker, diminished plasminogen activator inhibitor-1 (PAI-1) in cyclosporine (CsA)-treated renal graft recipients.	Cyclosporine	144-156	serpin family E member 1	Homo sapiens	134-139
17175314-1	2006	We previously confirmed that losartan (LOS), an angiotensin-II (A-II) receptor blocker, diminished plasminogen activator inhibitor-1 (PAI-1) in cyclosporine (CsA)-treated renal graft recipients.	Cyclosporine	158-161	serpin family E member 1	Homo sapiens	134-139
17098234-2	2006	In the presence of sub-threshold calcium, recombinant SOUL provoked mitochondrial permeability transition (mPT) in vitro that was inhibited by cyclosporine A (CsA).	Cyclosporine	143-157	heme binding protein 2	Mus musculus	54-58
17098234-2	2006	In the presence of sub-threshold calcium, recombinant SOUL provoked mitochondrial permeability transition (mPT) in vitro that was inhibited by cyclosporine A (CsA).	Cyclosporine	159-162	heme binding protein 2	Mus musculus	54-58
17098234-4	2006	Flow cytometry analysis showed that SOUL promoted necrotic death in A23187 and etoposide treated cells, which effect was prevented by CsA.	Cyclosporine	134-137	heme binding protein 2	Mus musculus	36-40
17114339-7	2006	In contrast, DSCR1-1L, regulated by a different promoter than DSCR1-4, activates NFAT and its proangiogenic activity is inhibited by cyclosporin, an inhibitor of calcineurin.	Cyclosporine	133-144	regulator of calcineurin 1	Homo sapiens	13-18
17114339-7	2006	In contrast, DSCR1-1L, regulated by a different promoter than DSCR1-4, activates NFAT and its proangiogenic activity is inhibited by cyclosporin, an inhibitor of calcineurin.	Cyclosporine	133-144	regulator of calcineurin 1	Homo sapiens	62-67
16716285-10	2006	CsA administration induced significant elevation in lipid peroxidation along with abnormal levels of enzymic (superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, glutathione-S-transferase and glucose-6-phosphate dehydrogenase) and non-enzymic antioxidants (glutathione, vitamins C and E) in the rat kidney.	Cyclosporine	0-3	glutathione-disulfide reductase	Rattus norvegicus	166-187
16716285-10	2006	CsA administration induced significant elevation in lipid peroxidation along with abnormal levels of enzymic (superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, glutathione-S-transferase and glucose-6-phosphate dehydrogenase) and non-enzymic antioxidants (glutathione, vitamins C and E) in the rat kidney.	Cyclosporine	0-3	hematopoietic prostaglandin D synthase	Rattus norvegicus	189-214
17019514-7	2006	Exposure of erythrocytes to cyclosporine triggered annexin V binding and significantly enhanced the increased annexin V binding both following glucose depletion and after hyperosmotic or isotonic cell shrinkage.	Cyclosporine	28-40	annexin A5	Homo sapiens	51-60
12437524-10	2002	CONCLUSIONS: Non-myeloablative conditioning containing fludarabine and/or Campath 1H, with cyclosporin A given post-transplant, effectively prevents anti-D formation in RhD-negative recipients of a RhD-positive graft.	Cyclosporine	91-104	Rh blood group D antigen	Homo sapiens	169-172
12437524-10	2002	CONCLUSIONS: Non-myeloablative conditioning containing fludarabine and/or Campath 1H, with cyclosporin A given post-transplant, effectively prevents anti-D formation in RhD-negative recipients of a RhD-positive graft.	Cyclosporine	91-104	Rh blood group D antigen	Homo sapiens	198-201
12395106-3	2002	In this study, we show that the addition of Abeta to isolated mouse brain mitochondria can directly induce cytochrome c (Cyt c) release and mitochondrial swelling, which were partially inhibited by cyclosporin A (CsA).	Cyclosporine	198-211	amyloid beta (A4) precursor protein	Mus musculus	44-49
12395106-3	2002	In this study, we show that the addition of Abeta to isolated mouse brain mitochondria can directly induce cytochrome c (Cyt c) release and mitochondrial swelling, which were partially inhibited by cyclosporin A (CsA).	Cyclosporine	213-216	amyloid beta (A4) precursor protein	Mus musculus	44-49
12438949-6	2002	RESULTS: Discontinuation of cyclosporine and daily plasma exchange increased the ADAMTS13 activity, which was followed by resolution of the microangiopathic hemolysis and improvement of the graft function.	Cyclosporine	28-40	ADAM metallopeptidase with thrombospondin type 1 motif 13	Homo sapiens	81-89
12357034-4	2002	We report the crystal structure of a Cyp/CsA/Cn ternary complex, determined to a resolution of 3.1 A. Residues 3-9 of CsA, particularly N-methyl leucines 4 and 6, and Trp-121 of Cyp form a composite surface for interaction with Cn.	Cyclosporine	41-44	peptidylprolyl isomerase G	Homo sapiens	37-40
12357034-4	2002	We report the crystal structure of a Cyp/CsA/Cn ternary complex, determined to a resolution of 3.1 A. Residues 3-9 of CsA, particularly N-methyl leucines 4 and 6, and Trp-121 of Cyp form a composite surface for interaction with Cn.	Cyclosporine	41-44	peptidylprolyl isomerase G	Homo sapiens	178-181
12357034-4	2002	We report the crystal structure of a Cyp/CsA/Cn ternary complex, determined to a resolution of 3.1 A. Residues 3-9 of CsA, particularly N-methyl leucines 4 and 6, and Trp-121 of Cyp form a composite surface for interaction with Cn.	Cyclosporine	118-121	peptidylprolyl isomerase G	Homo sapiens	37-40
12379312-6	2002	Mutations introduced into these sites abolished NF-AT binding and impaired the promoter activity, as did cyclosporin A (CsA), an inhibitor of nuclear transport of NF-ATs.	Cyclosporine	105-118	nuclear factor of activated T cells 2	Homo sapiens	48-53
12379312-6	2002	Mutations introduced into these sites abolished NF-AT binding and impaired the promoter activity, as did cyclosporin A (CsA), an inhibitor of nuclear transport of NF-ATs.	Cyclosporine	120-123	nuclear factor of activated T cells 2	Homo sapiens	48-53
12386643-8	2002	PAC1 expression was significantly increased in the patient groups that received azathioprine and cyclosporine.	Cyclosporine	97-109	ADCYAP receptor type I	Homo sapiens	0-4
12207006-0	2002	Cyclosporin A blocks muscle differentiation by inducing oxidative stress and inhibiting the peptidyl-prolyl-cis-trans isomerase activity of cyclophilin A: cyclophilin A protects myoblasts from cyclosporin A-induced cytotoxicity.	Cyclosporine	0-13	peptidylprolyl isomerase A	Homo sapiens	140-153
12207006-0	2002	Cyclosporin A blocks muscle differentiation by inducing oxidative stress and inhibiting the peptidyl-prolyl-cis-trans isomerase activity of cyclophilin A: cyclophilin A protects myoblasts from cyclosporin A-induced cytotoxicity.	Cyclosporine	0-13	peptidylprolyl isomerase A	Homo sapiens	155-168
12207006-0	2002	Cyclosporin A blocks muscle differentiation by inducing oxidative stress and inhibiting the peptidyl-prolyl-cis-trans isomerase activity of cyclophilin A: cyclophilin A protects myoblasts from cyclosporin A-induced cytotoxicity.	Cyclosporine	193-206	peptidylprolyl isomerase A	Homo sapiens	140-153
12207006-0	2002	Cyclosporin A blocks muscle differentiation by inducing oxidative stress and inhibiting the peptidyl-prolyl-cis-trans isomerase activity of cyclophilin A: cyclophilin A protects myoblasts from cyclosporin A-induced cytotoxicity.	Cyclosporine	193-206	peptidylprolyl isomerase A	Homo sapiens	155-168
12364628-2	2002	METHODS: Sixteen patients who were still active despite combination therapy with optimal doses of methotrexate (MTX 15-17.5 mg/week) and cyclosporin A (CsA 2.5-3.5 mg/day) received infliximab.	Cyclosporine	137-150	IK cytokine	Homo sapiens	152-157
12364856-8	2002	Concomitantly, CsA markedly up-regulated expression of chemoattractant proteins, osteopontin, and monocyte chemoattractant protein-1.	Cyclosporine	15-18	C-C motif chemokine ligand 2	Rattus norvegicus	98-132
12218175-4	2002	The CyPA-CsA complex binds to a composite surface formed by the catalytic and regulatory subunits of CN, where the complex of FK506 and its binding protein FKBP also binds.	Cyclosporine	9-12	peptidylprolyl isomerase A	Homo sapiens	4-8
14989426-8	2002	Regarding cyclosporin A (CyA), considerable evidence shows that the treatment of RA patients induces a decrease in IL-1Ra levels.	Cyclosporine	10-23	interleukin 1 receptor antagonist	Homo sapiens	115-121
14989426-8	2002	Regarding cyclosporin A (CyA), considerable evidence shows that the treatment of RA patients induces a decrease in IL-1Ra levels.	Cyclosporine	25-28	interleukin 1 receptor antagonist	Homo sapiens	115-121
17019514-7	2006	Exposure of erythrocytes to cyclosporine triggered annexin V binding and significantly enhanced the increased annexin V binding both following glucose depletion and after hyperosmotic or isotonic cell shrinkage.	Cyclosporine	28-40	annexin A5	Homo sapiens	110-119
17096891-5	2006	The numbers of CD3(+), CD4(+), CD8(+), CD11a(+), CD18(+) lymphocytes in skin and lung decreased markedly by GTT, GTT + CsA and CsA + MTX treatments.	Cyclosporine	127-130	integrin alpha L	Mus musculus	39-44
16990701-0	2006	Inhibition of arachidonic acid release by cytosolic phospholipase A2 is involved in the antiapoptotic effect of FK506 and cyclosporin a on astrocytes exposed to simulated ischemia in vitro.	Cyclosporine	122-135	phospholipase A2 group IVA	Rattus norvegicus	42-68
16990701-1	2006	In the present study, we investigated whether the protective effect of FK506 and cyclosporin A (CsA) against in vitro ischemic injury of astrocytes might be mediated through attenuation of cytosolic isoform of phospholipase A(2) (cPLA(2)) expression and activity as well as inhibition of arachidonic acid (AA) release.	Cyclosporine	81-94	phospholipase A2 group IB	Rattus norvegicus	210-228
16990701-1	2006	In the present study, we investigated whether the protective effect of FK506 and cyclosporin A (CsA) against in vitro ischemic injury of astrocytes might be mediated through attenuation of cytosolic isoform of phospholipase A(2) (cPLA(2)) expression and activity as well as inhibition of arachidonic acid (AA) release.	Cyclosporine	81-94	phospholipase A2 group IVA	Rattus norvegicus	230-237
16990701-1	2006	In the present study, we investigated whether the protective effect of FK506 and cyclosporin A (CsA) against in vitro ischemic injury of astrocytes might be mediated through attenuation of cytosolic isoform of phospholipase A(2) (cPLA(2)) expression and activity as well as inhibition of arachidonic acid (AA) release.	Cyclosporine	96-99	phospholipase A2 group IB	Rattus norvegicus	210-228
16990701-1	2006	In the present study, we investigated whether the protective effect of FK506 and cyclosporin A (CsA) against in vitro ischemic injury of astrocytes might be mediated through attenuation of cytosolic isoform of phospholipase A(2) (cPLA(2)) expression and activity as well as inhibition of arachidonic acid (AA) release.	Cyclosporine	96-99	phospholipase A2 group IVA	Rattus norvegicus	230-237
16990701-3	2006	Obtained data suggest the cross-talk between the action of 0.25 - 10 microM CsA as well as 1 microM FK506 on calcineurin (CaN) and cPLA(2) in anti-apoptotic signal transduction pathways.	Cyclosporine	76-79	phospholipase A2 group IVA	Rattus norvegicus	131-138
16990701-6	2006	Our findings document a key role either for CaN or cPLA(2) expression attenuation and AA release inhibition in the antiapoptotic effect of FK506 and CsA in ischemic astrocytes.	Cyclosporine	149-152	phospholipase A2 group IVA	Rattus norvegicus	51-58
16980029-14	2006	RESULTS: CsA and FK506 stimulated gene expression and protein production of TGF-beta1, smad2, and smad3, but inhibited expression of smad7 both in VSMC and in the transplanted kidney.	Cyclosporine	9-12	SMAD family member 2	Rattus norvegicus	87-92
16980029-19	2006	CsA and FK506 can cause CAN, owing to up-regulated expression of smad2 and smad3, and down-regulation of smad7 expression.	Cyclosporine	0-3	SMAD family member 2	Rattus norvegicus	65-70
16980033-10	2006	The early expression of H60 mRNA on day 3 in the CsA-treated group might relate to the toxicity of CsA.	Cyclosporine	49-52	histocompatibility 60a	Mus musculus	24-27
16735444-8	2006	Likewise, treatment of wild-type mice with cyclosporin A to inhibit calcineurin produces a similarly impaired urine-concentrating response to vasopressin and alterations in AQP2 phosphorylation and trafficking.	Cyclosporine	43-56	aquaporin 2	Mus musculus	173-177
16724420-3	2006	Here we show that the MDR1 inhibitor, cyclosporin A (CsA) can deplete Gaucher lymphoid cell lines of accumulated glucosyl ceramide and Fabry cell lines of globotriaosyl ceramide (Gb3), by preventing de novo synthesis.	Cyclosporine	38-51	alpha 1,4-galactosyltransferase (P blood group)	Homo sapiens	179-182
16671876-0	2006	Cyclosporin-induced downregulation of the expression of E-cadherin during proliferation of edentulous gingival epithelium in rats.	Cyclosporine	0-11	cadherin 1	Rattus norvegicus	56-66
16671876-1	2006	BACKGROUND: To examine the role of E-cadherin in epithelial hyperplasia of cyclosporin A (CsA)-induced gingival enlargement, mRNA and protein levels of E-cadherin, beta-catenin, proliferating cell nuclear antigen (PCNA), and Cyclin D1 were examined in the edentulous gingiva of rats following CsA treatment.	Cyclosporine	75-88	cadherin 1	Rattus norvegicus	35-45
16671876-1	2006	BACKGROUND: To examine the role of E-cadherin in epithelial hyperplasia of cyclosporin A (CsA)-induced gingival enlargement, mRNA and protein levels of E-cadherin, beta-catenin, proliferating cell nuclear antigen (PCNA), and Cyclin D1 were examined in the edentulous gingiva of rats following CsA treatment.	Cyclosporine	75-88	cadherin 1	Rattus norvegicus	152-162
16671876-6	2006	RESULTS: The mRNA expression of E-cadherin was significantly weaker in the CsA-treated group than the control group at both times.	Cyclosporine	75-78	cadherin 1	Rattus norvegicus	32-42
16671876-7	2006	Using IHC staining, a weaker level of membrane-bonded E-cadherin was also observed in the gingival epithelial cells in the CsA group than in controls.	Cyclosporine	123-126	cadherin 1	Rattus norvegicus	54-64
16671876-8	2006	By contrast, significantly stronger beta-catenin and Cyclin D1 mRNA expressions and protein levels were found in CsA-treated rats than controls by RT-PCR and immunohistochemistry at week 4, whereas PCNA production was stronger at both times.	Cyclosporine	113-116	catenin beta 1	Rattus norvegicus	36-48
16671876-9	2006	CONCLUSIONS: CsA treatment reduced the production of E-cadherin but increased the production of beta-catenin, Cyclin D1, and PCNA.	Cyclosporine	13-16	cadherin 1	Rattus norvegicus	53-63
16671876-9	2006	CONCLUSIONS: CsA treatment reduced the production of E-cadherin but increased the production of beta-catenin, Cyclin D1, and PCNA.	Cyclosporine	13-16	catenin beta 1	Rattus norvegicus	96-108
16530163-9	2006	Inclusion of cyclosporine A (10 microM), an inhibitor of mitochondrial permeability transition, oxidative stress, and toxicity, prevented the induction of HIF-1alpha.	Cyclosporine	13-27	hypoxia inducible factor 1, alpha subunit	Mus musculus	155-165
16457843-12	2006	However A2a adenosine receptor agonist in combination with CsA significantly reduced the levels of suppressor cytokines IL-4 and IL-10.	Cyclosporine	59-62	interleukin 10	Rattus norvegicus	129-134
16571786-4	2006	We find that Vpr coimmunoprecipitates with CypA and that this interaction is disrupted by substitution of proline-35 of Vpr as well as incubation with the CypA inhibitor cyclosporine A (CsA).	Cyclosporine	186-189	peptidylprolyl isomerase A	Homo sapiens	155-159
16571786-7	2006	CsA abolished CypA-Vpr binding but had no effect on induction of G2 arrest or Vpr steady-state levels.	Cyclosporine	0-3	peptidylprolyl isomerase A	Homo sapiens	14-18
16376427-0	2006	The usage of alternative splice sites in Mus musculus synaptotagmin-like 2 gene is modulated by cyclosporin A and FK506 in T-lymphocytes.	Cyclosporine	96-109	synaptotagmin-like 2	Mus musculus	54-74
16372262-2	2006	CypA is an abundantly expressed cytosolic protein, target of the immunosuppressive drug cyclosporin A (CsA), for which a variety of functions has been described.	Cyclosporine	88-101	peptidylprolyl isomerase A	Homo sapiens	0-4
16372262-2	2006	CypA is an abundantly expressed cytosolic protein, target of the immunosuppressive drug cyclosporin A (CsA), for which a variety of functions has been described.	Cyclosporine	103-106	peptidylprolyl isomerase A	Homo sapiens	0-4
16458528-3	2006	Recently, we demonstrated that CsA up-regulates the expression of transforming growth factor-beta1 (TGF-beta1), its receptors type I (TbetaR-I) and type II (TbetaR-II), as well as related matrix protein synthesis in mesangial cells (MCs).	Cyclosporine	31-34	transforming growth factor beta receptor 1	Homo sapiens	126-142
16199531-2	2005	To address this issue, we sought viruses for CypA independence using Debio-025, a cyclosporine A (CsA) analog that disrupts CypA-capsid interaction.	Cyclosporine	98-101	peptidylprolyl isomerase A	Homo sapiens	124-128
12009308-2	2002	Treatment with CsA increased the BH4 content and the expression of mRNA level of GTP cyclohydrolase I, the rate-limiting enzyme of BH4 synthesis.	Cyclosporine	15-18	GTP cyclohydrolase 1	Mus musculus	81-101
16332239-0	2005	Upregulation of transforming growth factor-beta1 and vascular endothelial growth factor gene and protein expression in cyclosporin-induced overgrown edentulous gingiva in rats.	Cyclosporine	119-130	vascular endothelial growth factor A	Rattus norvegicus	53-87
16311095-4	2005	The aim of the study was to evaluate the LDL receptor uptake of CsA-transported LDL (CsA-LDL) compared with normal LDL in normal and CsA-treated lymphocytes.	Cyclosporine	85-88	low density lipoprotein receptor	Homo sapiens	41-53
12447904-2	2002	This review summarizes immunochemical and crystallographic studies of the interaction between the Fab of monoclonal antibody R45-45-11 and Cs.	Cyclosporine	139-141	FA complementation group B	Homo sapiens	98-101
16311095-4	2005	The aim of the study was to evaluate the LDL receptor uptake of CsA-transported LDL (CsA-LDL) compared with normal LDL in normal and CsA-treated lymphocytes.	Cyclosporine	85-88	low density lipoprotein receptor	Homo sapiens	41-53
16311095-11	2005	Our data show that CsA-LDL is internalized more than normal LDL via the LDL receptor in both human healthy and CsA-treated lymphocytes.	Cyclosporine	19-22	low density lipoprotein receptor	Homo sapiens	72-84
12124198-5	2002	Biomechanical induction of DSCR1 mRNA was partially blocked by calcineurin inhibition with cyclosporine A (30 +/- 5%, n = 3, P &lt; 0.01).	Cyclosporine	91-105	regulator of calcineurin 1	Rattus norvegicus	27-32
12124198-6	2002	DSCR1 promoter-reporter experiments showed that mechanical strain induced DSCR1 promoter activity by 2.3-fold and that this induction was completely inhibited by cyclosporin A.	Cyclosporine	162-175	regulator of calcineurin 1	Rattus norvegicus	0-5
16311095-11	2005	Our data show that CsA-LDL is internalized more than normal LDL via the LDL receptor in both human healthy and CsA-treated lymphocytes.	Cyclosporine	111-114	low density lipoprotein receptor	Homo sapiens	72-84
16311095-12	2005	CsA-treated lymphocytes, in comparison to normal lymphocytes, exhibit a reduced LDL receptor activity.	Cyclosporine	0-3	low density lipoprotein receptor	Homo sapiens	80-92
16354247-9	2005	CONCLUSIONS: Determination of the levels of leukocyte CyP mRNA may be of assistance in cyclosporine A therapy.	Cyclosporine	87-101	peptidylprolyl isomerase G	Homo sapiens	54-57
12181673-8	2002	Pre-treatment of the HIV-1 inocula with CsA, blocking the function of virus-associated CypA, did not inhibit the ensuing yield of infection.	Cyclosporine	40-43	peptidylprolyl isomerase A	Homo sapiens	87-91
16354543-9	2005	Histopathological examinations of the CA1 sector of the hippocampus verified the neuroprotective properties of MP and CsA.	Cyclosporine	118-121	carbonic anhydrase 1	Rattus norvegicus	38-41
12358793-1	2002	The immunosuppressor cyclosporin A inhibits the peptidyl-prolyl-cis/trans-isomerase activity of cyclophilins and the resulting complex inhibits the phosphatase activity of calcineurin.	Cyclosporine	21-34	protein phosphatase 3, catalytic subunit, alpha isozyme L homeolog	Xenopus laevis	172-183
16176581-5	2005	RESULTS: Activation of allo- and mitogen stimulated lymphocytes resulted in increased expression of cyclins, IL-2 and pro-inflammatory cytokines, which was inhibited by cyclosporine.	Cyclosporine	169-181	interleukin 2	Rattus norvegicus	109-113
12358793-8	2002	Choline uptake by oocytes expressing tCHT1 was inhibited by all three immunosuppressors and also by microinjection of the specific calcineurin autoinhibitory domain A457-481, indicating that the phosphatase calcineurin regulates CHT1 activity and could be the common target of cyclosporin and FK506.	Cyclosporine	277-288	protein phosphatase 3, catalytic subunit, alpha isozyme L homeolog	Xenopus laevis	131-142
12110003-0	2002	Angiotensin II regulation of vascular endothelial growth factor and receptors Flt-1 and KDR/Flk-1 in cyclosporine nephrotoxicity.	Cyclosporine	101-113	vascular endothelial growth factor A	Rattus norvegicus	29-63
12071854-3	2002	The increased transport of C6-NBD-PS is mediated by MDR1 Pgp, shown by transport reduction nearly to the level of controls in the presence of MDR1 Pgp inhibitors [PSC 833, cyclosporin A and dexniguldipine hydrochloride (Dex)].	Cyclosporine	172-185	phosphoglycolate phosphatase	Homo sapiens	57-60
15986223-11	2005	After 9 days, many satellite cells and/or myoblasts showed apparent co-localization of both MyoD and Smad3 in CsA-, but not in placebo-, treated mice.	Cyclosporine	110-113	myogenic differentiation 1	Mus musculus	92-96
12071854-3	2002	The increased transport of C6-NBD-PS is mediated by MDR1 Pgp, shown by transport reduction nearly to the level of controls in the presence of MDR1 Pgp inhibitors [PSC 833, cyclosporin A and dexniguldipine hydrochloride (Dex)].	Cyclosporine	172-185	phosphoglycolate phosphatase	Homo sapiens	147-150
16153081-5	2005	The apical (AP) to basolateral (BL) permeation of CsA through Caco-2 cell monolayers after 24 h of transport was significantly higher (1.8 and 2.3 times in absence and presence of IF, respectively) in the case of CsA loaded in VB12-modified polymeric micelles, compared to CsA in unmodified micelles.	Cyclosporine	50-53	cobalamin binding intrinsic factor	Homo sapiens	180-182
12100194-16	2002	In our clinical study, all the mean trough levels in 17 patients treated with cyclosporin 3 mg kg-1 daily were within the therapeutic range (&lt; 200 ng mL-1).	Cyclosporine	78-89	L1 cell adhesion molecule	Mus musculus	153-157
11943775-1	2002	Cyclophilin A (CyPA), a ubiquitously distributed intracellular protein, is a peptidylprolyl cis-trans-isomerase and the major target of the potent immunosuppressive drug cyclosporin A.	Cyclosporine	170-183	peptidylprolyl isomerase A	Homo sapiens	0-13
12085006-0	2002	Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production.	Cyclosporine	15-27	interleukin 10	Rattus norvegicus	148-162
12134949-8	2002	The efflux of the modified prodrug could be inhibited by GF120918 (an inhibitor for P-gp) and cyclosporin A (an inhibitor for P-gp and MRP2).	Cyclosporine	94-107	PGP	Canis lupus familiaris	126-130
12042638-8	2002	RESULTS: Intrarenal expression of TGF-beta, collagen, fibronectin, MMP-2, MMP-9, and tissue inhibitor of MMP-2 was significantly increased in rats treated with CsA for 180 days compared with untreated rats and those treated for 30 days.	Cyclosporine	160-163	fibronectin 1	Rattus norvegicus	54-65
11985515-7	2002	CsA and FK506 even prevented AICD by down-modulation of CD95L.	Cyclosporine	0-3	Fas ligand	Homo sapiens	56-61
11986378-4	2002	Enhancement of mGlu5 function, by inhibition of PKA or by activation of group II mGlu receptors, was prevented by the protein phosphatase 2B (PP2B) inhibitor cyclosporin A.	Cyclosporine	158-171	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	48-51
11981427-8	2002	In addition, a short course of cyclosporine therapy synergized with either anti-CD28 monoclonal antibody or CTLA4 immunoglobulin, suggesting that it may be clinically relevant to combine low-dose calcineurin inhibitors with CTLA4 immunoglobulin or anti-B7 antibodies.	Cyclosporine	31-43	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	108-113
11981427-8	2002	In addition, a short course of cyclosporine therapy synergized with either anti-CD28 monoclonal antibody or CTLA4 immunoglobulin, suggesting that it may be clinically relevant to combine low-dose calcineurin inhibitors with CTLA4 immunoglobulin or anti-B7 antibodies.	Cyclosporine	31-43	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	224-229
11959131-5	2002	We found that treatment of CsA (20 microM) alone caused 20-30% cell death, which was apparently (30-40%) enhanced by diltiazem at 100 microg/ml, accompanied by more severe DNA fragmentation, activation of caspases, and a decreased level of Bcl-2.	Cyclosporine	27-30	BCL2 apoptosis regulator	Canis lupus familiaris	240-245
11959131-6	2002	The caspase inhibitor ZVAD-fmk or Bcl-2 overexpression was capable of suppressing apoptosis induced by the synergistic effect of diltiazem and CsA.	Cyclosporine	143-146	BCL2 apoptosis regulator	Canis lupus familiaris	34-39
11959131-8	2002	The rescue of cells from CsA-induced apoptosis by A23187 was correlated with AKT activation, BAD phosphorylation, and caspase-3 inactivation.	Cyclosporine	25-28	caspase 3	Canis lupus familiaris	118-127
11920576-6	2002	Furthermore, we have found that the induction of RANKL expression is solely dependent on TCR activation-induced Ca2+ mobilization since its expression can be blocked by cyclosporine A and TMB-8, a Ca2+ mobilization inhibitor.	Cyclosporine	169-183	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	49-54
11986604-8	2002	The protective effects of cyclosporine and tacrolimus treatment before reperfusion correlated with 42% and 43% reductions in tissue polymorphonuclear leukocyte (myeloperoxidase) content (P &lt;.008) and marked reductions in bronchoalveolar lavage leukocyte accumulation (P &lt;.01).	Cyclosporine	26-38	myeloperoxidase	Rattus norvegicus	161-176
11901205-7	2002	Molecular analyzes showed that the beneficial effects of targeting of LIGHT in CsA-treated recipients were accompanied by decreased intragraft expression of interferon (IFN)-gamma, plus IFN-gamma-induced chemokine, inducible protein-10, and its receptor, CXCR3.	Cyclosporine	79-82	chemokine (C-X-C motif) receptor 3	Mus musculus	255-260
11901205-8	2002	Treatment of LIGHT+/+ allograft recipients with HVEM-Ig plus CsA also enhanced mean allograft survival (21 days) versus wild-type controls receiving HVEM-Ig (mean of 7 days) or CsA alone (P &lt; 0.001).	Cyclosporine	177-180	tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator)	Mus musculus	48-52
12009870-8	2002	Furthermore, Cyp A incorporation was inhibited by cyclosporin in all cases.	Cyclosporine	50-61	peptidylprolyl isomerase A	Homo sapiens	13-18
11773045-5	2002	Cyclosporin A inhibited these apoA-I-mediated reactions and suppressed apoA-I-mediated cholesterol release.	Cyclosporine	0-13	apolipoprotein A1	Rattus norvegicus	30-36
11773045-5	2002	Cyclosporin A inhibited these apoA-I-mediated reactions and suppressed apoA-I-mediated cholesterol release.	Cyclosporine	0-13	apolipoprotein A1	Rattus norvegicus	71-77
15975916-4	2005	This calcium-dependent transcription of DSCR1.4 was inhibited by the calcineurin inhibitors cyclosporin A and FK506.	Cyclosporine	92-105	regulator of calcineurin 1	Homo sapiens	40-45
15980236-0	2005	Down-regulation of IFN-gamma-producing CD56+ T cells after combined low-dose cyclosporine/prednisone treatment in patients with Behcet"s uveitis.	Cyclosporine	77-89	neural cell adhesion molecule 1	Homo sapiens	39-43
15980236-1	2005	PURPOSE: To investigate the effects of combined low-dose cyclosporine and prednisone (Cs/Pd) treatment on circulating CD56+ T cells in patients with Behcet"s uveitis.	Cyclosporine	57-69	neural cell adhesion molecule 1	Homo sapiens	118-122
15784653-10	2005	A decrease was also shown in nitrotyrosine, poly(ADP-ribose) polymerase (PARP) activation, and lipid peroxide formation by WW85 that was potentiated when given in combination with cyclosporine.	Cyclosporine	180-192	poly (ADP-ribose) polymerase 1	Rattus norvegicus	44-71
15784653-10	2005	A decrease was also shown in nitrotyrosine, poly(ADP-ribose) polymerase (PARP) activation, and lipid peroxide formation by WW85 that was potentiated when given in combination with cyclosporine.	Cyclosporine	180-192	poly (ADP-ribose) polymerase 1	Rattus norvegicus	73-77
16113782-5	2005	We demonstrate the expression of ADAMTS13 in liver homogenates and a parenchyma liver cell culture system Hep3B, supporting the hypothesis that liver is an important source of plasma ADAMTS13, whereas there was no alteration in gene expression after stimulation of liver cells with proinflammatory stimuli such as endotoxin, TNF-alpha, IL-6, IL-1beta as well as immuno-suppressive agents, such as cyclosporine A, a variety of steroids as well as doxycycline.	Cyclosporine	397-411	ADAM metallopeptidase with thrombospondin type 1 motif 13	Homo sapiens	33-41
16316932-7	2005	Cyclosporin A significantly inhibited OATP1B1 and P-gp, whereas only moderate inhibition was observed on MRP2.	Cyclosporine	0-13	solute carrier organic anion transporter family member 1B1	Homo sapiens	38-45
16316932-7	2005	Cyclosporin A significantly inhibited OATP1B1 and P-gp, whereas only moderate inhibition was observed on MRP2.	Cyclosporine	0-13	phosphoglycolate phosphatase	Homo sapiens	50-54
15853967-7	2005	A dose-dependent increase in the number of mineralized nodules occurred in cultures of cementoblastoma-derived cells treated with cyclosporin A, and RT-PCR analyses showed significantly higher levels of expression of alkaline phosphatase, bone sialoprotein, type I collagen, matrix metalloproteinase-1, osteocalcin, osteopontin, and Cbfa1.	Cyclosporine	130-143	matrix metallopeptidase 1	Homo sapiens	239-301
15853967-7	2005	A dose-dependent increase in the number of mineralized nodules occurred in cultures of cementoblastoma-derived cells treated with cyclosporin A, and RT-PCR analyses showed significantly higher levels of expression of alkaline phosphatase, bone sialoprotein, type I collagen, matrix metalloproteinase-1, osteocalcin, osteopontin, and Cbfa1.	Cyclosporine	130-143	secreted phosphoprotein 1	Homo sapiens	316-327
15671024-4	2005	Treatment with cyclosporin A significantly reduced surface expression of CD147 and of CD8-CD147 fusion protein carrying the extracellular domain of CD8 fused to the transmembrane and cytoplasmic domains of CD147, but did not affect expression of CD8.	Cyclosporine	15-28	basigin (Ok blood group)	Homo sapiens	73-78
15671024-4	2005	Treatment with cyclosporin A significantly reduced surface expression of CD147 and of CD8-CD147 fusion protein carrying the extracellular domain of CD8 fused to the transmembrane and cytoplasmic domains of CD147, but did not affect expression of CD8.	Cyclosporine	15-28	basigin (Ok blood group)	Homo sapiens	90-95
15671024-4	2005	Treatment with cyclosporin A significantly reduced surface expression of CD147 and of CD8-CD147 fusion protein carrying the extracellular domain of CD8 fused to the transmembrane and cytoplasmic domains of CD147, but did not affect expression of CD8.	Cyclosporine	15-28	basigin (Ok blood group)	Homo sapiens	90-95
15777799-1	2005	Calcineurin was found as a positive regulator of chondrogenesis in chondrifying chicken micromass cultures (HDCs), as cyclosporine A (CsA) reduced both the amount of cartilage and the expression of mRNAs of aggrecan and the chondrogenic transcription factor Sox9.	Cyclosporine	118-132	SRY-box 9	Gallus gallus	258-262
15777799-1	2005	Calcineurin was found as a positive regulator of chondrogenesis in chondrifying chicken micromass cultures (HDCs), as cyclosporine A (CsA) reduced both the amount of cartilage and the expression of mRNAs of aggrecan and the chondrogenic transcription factor Sox9.	Cyclosporine	134-137	SRY-box 9	Gallus gallus	258-262
15777799-3	2005	Expression of both the mRNA and the unphosphorylated protein Sox9 was decreased, while its phosphorylation was stimulated by either H(2)O(2) or CsA.	Cyclosporine	144-147	SRY-box 9	Gallus gallus	61-65
15777799-5	2005	The ERK inhibitor PD098059 attenuated the depletion of cartilage matrix as well as decreased the expression and phosphorylation of Sox9 in cultures treated with H(2)O(2) or CsA.	Cyclosporine	173-176	SRY-box 9	Gallus gallus	131-135
15744065-3	2005	Since cyclosporin A (MDR1 P-gp inhibitor) but not MK571 (MRP1 inhibitor) inhibited SAL-induced PS externalization, it was suggested that MDR1 P-gp is involved in this phenomenon.	Cyclosporine	6-19	phosphoglycolate phosphatase	Homo sapiens	26-30
15744065-3	2005	Since cyclosporin A (MDR1 P-gp inhibitor) but not MK571 (MRP1 inhibitor) inhibited SAL-induced PS externalization, it was suggested that MDR1 P-gp is involved in this phenomenon.	Cyclosporine	6-19	phosphoglycolate phosphatase	Homo sapiens	142-146
15728480-5	2005	Cyclosporin A and FK506, which target calcineurin and thereby inhibit TCR-mediated Ca(2+) signal pathways, block IL-6-mediated c-Maf expression.	Cyclosporine	0-13	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	70-73
15848601-0	2005	Inhibition of plasminogen activator inhibitor-1 by angiotensin II receptor blockers on cyclosporine-treated renal allograft recipients.	Cyclosporine	87-99	serpin family E member 1	Homo sapiens	14-47
15848601-2	2005	To further evaluate the mechanism, we performed another clinical study focusing on the change in plasma plasminogen activator inhibitor-1 (PAI-1) levels among cyclosporine (CyA)-treated renal allograft recipients.	Cyclosporine	159-171	serpin family E member 1	Homo sapiens	104-137
15848601-2	2005	To further evaluate the mechanism, we performed another clinical study focusing on the change in plasma plasminogen activator inhibitor-1 (PAI-1) levels among cyclosporine (CyA)-treated renal allograft recipients.	Cyclosporine	159-171	serpin family E member 1	Homo sapiens	139-144
15848601-2	2005	To further evaluate the mechanism, we performed another clinical study focusing on the change in plasma plasminogen activator inhibitor-1 (PAI-1) levels among cyclosporine (CyA)-treated renal allograft recipients.	Cyclosporine	173-176	serpin family E member 1	Homo sapiens	104-137
12096783-1	2002	To determine the effect of cyclosporine A (CsA) on constitutive and activation-induced CD28 expression, mouse T cells were exposed to CsA (0.1 microM) in the absence or presence of anti-CD3 monoclonal antibody (mAb).	Cyclosporine	43-46	CD28 antigen	Mus musculus	87-91
15848601-2	2005	To further evaluate the mechanism, we performed another clinical study focusing on the change in plasma plasminogen activator inhibitor-1 (PAI-1) levels among cyclosporine (CyA)-treated renal allograft recipients.	Cyclosporine	173-176	serpin family E member 1	Homo sapiens	139-144
12096783-3	2002	CsA treatment prevented activation-induced CD28 expression but did not affect constitutive CD28 expression.	Cyclosporine	0-3	CD28 antigen	Mus musculus	43-47
12096783-4	2002	Inhibition of inducible CD28 expression by CsA was not rapidly reversible, requiring 48h of restimulation in the absence of CsA for CD28 expression to return to control levels.	Cyclosporine	43-46	CD28 antigen	Mus musculus	24-28
15744817-0	2005	Impact of cyclosporin on podocyte ZO-1 expression in puromycin aminonucleoside nephrosis rats.	Cyclosporine	10-21	tight junction protein 1	Rattus norvegicus	34-38
15744817-9	2005	CsA treatment for 20 days in the PAN rats inhibited the increase in ZO-1 protein expression by 71.1% (p&lt;0.05).	Cyclosporine	0-3	tight junction protein 1	Rattus norvegicus	68-72
15744817-10	2005	CsA treatment significantly diminished the glomerular ZO-1 expression in the PAN rats as assessed by immunohistochemistry.	Cyclosporine	0-3	tight junction protein 1	Rattus norvegicus	54-58
12096783-6	2002	However, the inhibitory effect of CsA on activation-induced CD28 expression was maintained in the presence of exogenous IL-2 (250 U/mL).	Cyclosporine	34-37	CD28 antigen	Mus musculus	60-64
15744817-11	2005	CsA treatment significantly reduced proteinuria and the diminished glomerular ZO-1 expression in a PAN nephrosis rat model.	Cyclosporine	0-3	tight junction protein 1	Rattus norvegicus	78-82
12096783-6	2002	However, the inhibitory effect of CsA on activation-induced CD28 expression was maintained in the presence of exogenous IL-2 (250 U/mL).	Cyclosporine	34-37	interleukin 2	Mus musculus	120-124
12096783-7	2002	We conclude that CsA, by inhibiting activation-induced expression of costimulatory CD28 molecules by T lymphocytes, may interfere with the ability of CD28 to provide an optimal costimulatory signal for sustained IL-2 production following T-cell activation.	Cyclosporine	17-20	CD28 antigen	Mus musculus	83-87
12096783-7	2002	We conclude that CsA, by inhibiting activation-induced expression of costimulatory CD28 molecules by T lymphocytes, may interfere with the ability of CD28 to provide an optimal costimulatory signal for sustained IL-2 production following T-cell activation.	Cyclosporine	17-20	CD28 antigen	Mus musculus	150-154
15613074-7	2005	On the other hand, exogenous IGF-I induced 8-11% (p &lt; 0.05) increases in the proliferation, but cyclosporin A induced 30-80% (p &lt; 0.05-0.01) reductions in the mRNA expression levels for endogenous IGF-I, IGFR1, IGFBP2, IGFBP3, IGFBP5, and IGFBP6.	Cyclosporine	99-112	insulin-like growth factor 1	Rattus norvegicus	203-208
12096783-7	2002	We conclude that CsA, by inhibiting activation-induced expression of costimulatory CD28 molecules by T lymphocytes, may interfere with the ability of CD28 to provide an optimal costimulatory signal for sustained IL-2 production following T-cell activation.	Cyclosporine	17-20	interleukin 2	Mus musculus	212-216
11865967-6	2002	However, patients who were started on tacrolimus or cyclosporine had an initial decline in expression of P-gp on CD4 T cells.	Cyclosporine	52-64	phosphoglycolate phosphatase	Homo sapiens	105-109
15613074-7	2005	On the other hand, exogenous IGF-I induced 8-11% (p &lt; 0.05) increases in the proliferation, but cyclosporin A induced 30-80% (p &lt; 0.05-0.01) reductions in the mRNA expression levels for endogenous IGF-I, IGFR1, IGFBP2, IGFBP3, IGFBP5, and IGFBP6.	Cyclosporine	99-112	insulin-like growth factor binding protein 3	Rattus norvegicus	225-231
15613074-7	2005	On the other hand, exogenous IGF-I induced 8-11% (p &lt; 0.05) increases in the proliferation, but cyclosporin A induced 30-80% (p &lt; 0.05-0.01) reductions in the mRNA expression levels for endogenous IGF-I, IGFR1, IGFBP2, IGFBP3, IGFBP5, and IGFBP6.	Cyclosporine	99-112	insulin-like growth factor binding protein 5	Rattus norvegicus	233-239
15666382-7	2005	Among the 12 delayed absorbers, 11 had peak CsA concentration at C(4).	Cyclosporine	44-47	complement C4A (Rodgers blood group)	Homo sapiens	65-69
15629515-5	2005	RESULTS: Acetaminophen-induced ALT leakage was attenuated by co-administration of cyclosporin A.	Cyclosporine	82-95	glutamic pyruvic transaminase, soluble	Mus musculus	31-34
15617745-8	2005	Soluble thrombomodulin levels in the culture supernatant were elevated by the addition of cyclosporin A.	Cyclosporine	90-103	thrombomodulin	Homo sapiens	8-22
15466861-5	2004	PC1-mediated activation of NFAT was completely inhibited by the calcineurin inhibitor, cyclosporin A.	Cyclosporine	87-100	polycystin 1, transient receptor potential channel interacting	Mus musculus	0-3
15466660-1	2004	Cyclophilin A (CypA), a receptor for the immunosuppressive agent cyclosporin A, is a cis-trans-peptidyl-prolyl isomerase (PPIase).	Cyclosporine	65-78	peptidylprolyl isomerase A	Homo sapiens	0-13
15466660-1	2004	Cyclophilin A (CypA), a receptor for the immunosuppressive agent cyclosporin A, is a cis-trans-peptidyl-prolyl isomerase (PPIase).	Cyclosporine	65-78	peptidylprolyl isomerase A	Homo sapiens	15-19
15466660-11	2004	Inhibition of PPIase activity of CypA with cyclosporin A also blocks the inhibitory effect of CypA on GC-c activity.	Cyclosporine	43-56	peptidylprolyl isomerase A	Homo sapiens	33-37
15466660-11	2004	Inhibition of PPIase activity of CypA with cyclosporin A also blocks the inhibitory effect of CypA on GC-c activity.	Cyclosporine	43-56	peptidylprolyl isomerase A	Homo sapiens	94-98
15466660-11	2004	Inhibition of PPIase activity of CypA with cyclosporin A also blocks the inhibitory effect of CypA on GC-c activity.	Cyclosporine	43-56	natriuretic peptide receptor 3	Homo sapiens	102-106
15533818-3	2004	X-CypA belongs to the superfamily of the immunophilin/PPIase proteins that can bind the immunosuppressant drug Cyclosporin A.	Cyclosporine	111-124	peptidylprolyl isomerase A (cyclophilin A) L homeolog	Xenopus laevis	2-6
15533818-3	2004	X-CypA belongs to the superfamily of the immunophilin/PPIase proteins that can bind the immunosuppressant drug Cyclosporin A.	Cyclosporine	111-124	peptidylprolyl isomerase A (cyclophilin A) L homeolog	Xenopus laevis	41-53
15289018-1	2004	Cyclosporin A (CsA) inhibits the P-gp pump that can be responsible for failure of cytostatic treatment in acute myeloid leukaemia (AML).	Cyclosporine	0-13	phosphoglycolate phosphatase	Homo sapiens	33-37
15289018-1	2004	Cyclosporin A (CsA) inhibits the P-gp pump that can be responsible for failure of cytostatic treatment in acute myeloid leukaemia (AML).	Cyclosporine	15-18	phosphoglycolate phosphatase	Homo sapiens	33-37
15283571-0	2004	Thermodynamic analysis of cyclosporin a binding to cyclophilin a in a lung tumor tissue lysate.	Cyclosporine	26-39	peptidylprolyl isomerase A	Homo sapiens	51-64
15283571-2	2004	A SUPREX-derived binding free energy (i.e. DeltaDeltaG(f) value) and dissociation constant (i.e., K(d) value) were determined for the binding of cyclosporin A (CsA) to a cyclophilin A (CypA) sample in which the protein was a component of a tissue lysate derived from fresh frozen lung tumor.	Cyclosporine	145-158	peptidylprolyl isomerase A	Homo sapiens	170-183
15283571-2	2004	A SUPREX-derived binding free energy (i.e. DeltaDeltaG(f) value) and dissociation constant (i.e., K(d) value) were determined for the binding of cyclosporin A (CsA) to a cyclophilin A (CypA) sample in which the protein was a component of a tissue lysate derived from fresh frozen lung tumor.	Cyclosporine	145-158	peptidylprolyl isomerase A	Homo sapiens	185-189
15283571-2	2004	A SUPREX-derived binding free energy (i.e. DeltaDeltaG(f) value) and dissociation constant (i.e., K(d) value) were determined for the binding of cyclosporin A (CsA) to a cyclophilin A (CypA) sample in which the protein was a component of a tissue lysate derived from fresh frozen lung tumor.	Cyclosporine	160-163	peptidylprolyl isomerase A	Homo sapiens	170-183
15283571-2	2004	A SUPREX-derived binding free energy (i.e. DeltaDeltaG(f) value) and dissociation constant (i.e., K(d) value) were determined for the binding of cyclosporin A (CsA) to a cyclophilin A (CypA) sample in which the protein was a component of a tissue lysate derived from fresh frozen lung tumor.	Cyclosporine	160-163	peptidylprolyl isomerase A	Homo sapiens	185-189
15283571-3	2004	The DeltaDeltaG(f) and K(d) values determined by SUPREX for CsA binding to CypA in this unpurified protein sample, 4.7 +/- 0.8 kcal/mol and 77 +/- 17 nM, respectively, were comparable to the those obtained when SUPREX was used to analyze the binding of CsA to a highly purified CypA sample, 4.2 +/- 1.0 kcal/mol and 32 +/- 20 nM, respectively.	Cyclosporine	60-63	peptidylprolyl isomerase A	Homo sapiens	75-79
15283571-3	2004	The DeltaDeltaG(f) and K(d) values determined by SUPREX for CsA binding to CypA in this unpurified protein sample, 4.7 +/- 0.8 kcal/mol and 77 +/- 17 nM, respectively, were comparable to the those obtained when SUPREX was used to analyze the binding of CsA to a highly purified CypA sample, 4.2 +/- 1.0 kcal/mol and 32 +/- 20 nM, respectively.	Cyclosporine	60-63	peptidylprolyl isomerase A	Homo sapiens	278-282
15283571-3	2004	The DeltaDeltaG(f) and K(d) values determined by SUPREX for CsA binding to CypA in this unpurified protein sample, 4.7 +/- 0.8 kcal/mol and 77 +/- 17 nM, respectively, were comparable to the those obtained when SUPREX was used to analyze the binding of CsA to a highly purified CypA sample, 4.2 +/- 1.0 kcal/mol and 32 +/- 20 nM, respectively.	Cyclosporine	253-256	peptidylprolyl isomerase A	Homo sapiens	75-79
15283571-4	2004	Moreover, the SUPREX-derived K(d) values determined in this work were both in the range of those previously reported for the CypA-CsA complex.	Cyclosporine	130-133	peptidylprolyl isomerase A	Homo sapiens	125-129
15163634-6	2004	We further demonstrated that a recombinant truncated mutant huntingtin protein, but not a wild-type, directly induced mitochondrial permeability transition (MPT) pore opening in isolated mouse liver mitochondria, an effect that was prevented completely by cyclosporin A (CSA) and ATP.	Cyclosporine	256-269	huntingtin	Mus musculus	60-70
15163634-6	2004	We further demonstrated that a recombinant truncated mutant huntingtin protein, but not a wild-type, directly induced mitochondrial permeability transition (MPT) pore opening in isolated mouse liver mitochondria, an effect that was prevented completely by cyclosporin A (CSA) and ATP.	Cyclosporine	271-274	huntingtin	Mus musculus	60-70
15163634-9	2004	The mutant huntingtin protein-induced MPT pore opening was accompanied by a significant release of cytochrome c, an effect completely inhibited by CSA.	Cyclosporine	147-150	huntingtin	Mus musculus	11-21
15207740-2	2004	Cyclosporin A (CsA), cyclosporin B (CsB), cyclosporin H (CsH), and FK506 all inhibited receptor activator of NFkappaB ligand (RANKL)-stimulated tartrate-resistant acid phosphatase (TRAP) activity and generation of TRAP+ multinucleated cells in the cultures.	Cyclosporine	15-18	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	87-124
15207740-2	2004	Cyclosporin A (CsA), cyclosporin B (CsB), cyclosporin H (CsH), and FK506 all inhibited receptor activator of NFkappaB ligand (RANKL)-stimulated tartrate-resistant acid phosphatase (TRAP) activity and generation of TRAP+ multinucleated cells in the cultures.	Cyclosporine	15-18	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	126-131
15207740-5	2004	Further evidence that late stages were more sensitive to inhibition was obtained in experiments in which CsA was present for different segments of the RANKL-stimulated culture period.	Cyclosporine	105-108	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	151-156
15263820-5	2004	Moreover, VEGF-stimulated induction of DSCR1 was blocked by anti-VEGF receptor-2 monoclonal antibody (mAb), or the specific calcineurin inhibitors cyclosporin A and FK506.	Cyclosporine	147-160	regulator of calcineurin 1	Homo sapiens	39-44
15153553-9	2004	Furthermore, inhibition of calcineurin with cyclosporin A (CsA) alters AQP2 localization and phosphorylation in principal cells of CD.	Cyclosporine	44-57	aquaporin 2	Homo sapiens	71-75
12450285-6	2002	Although the spinal cords removed from rats treated with cyclosporine prior to adenovirus injection contained substantially more neurons staining for beta-Gal at 7 days (67% of total neurons), the decay in the number of stained neurons was not paralleled by a decline in motor neuron density.	Cyclosporine	57-69	galactosidase, beta 1	Rattus norvegicus	150-158
11836403-9	2002	Using this system, we found that Vpr-CypA rescues the infectivity of viruses lacking CypA, either produced in the presence of CsA or mutated in the CypA packaging signal of CA.	Cyclosporine	126-129	peptidylprolyl isomerase A	Homo sapiens	37-41
11890899-1	2002	FK506 (Tacrolimus) and cyclosporin A exert their immunosuppressive effects via a common mechanism, calcineurin inhibition, after binding to intracellular proteins termed immunophilins: FK506-binding protein (FKBP) and cyclophilin.	Cyclosporine	23-36	FK506 binding protein 1a	Mus musculus	185-206
11890899-1	2002	FK506 (Tacrolimus) and cyclosporin A exert their immunosuppressive effects via a common mechanism, calcineurin inhibition, after binding to intracellular proteins termed immunophilins: FK506-binding protein (FKBP) and cyclophilin.	Cyclosporine	23-36	FK506 binding protein 1a	Mus musculus	208-212
11694517-1	2002	The immunosuppressive agents cyclosporin A (CsA) and tacrolimus (FK506) bind to unrelated intracellular immunophilin receptors, cyclophilin (CyP) and FK506-binding protein (FKBP), respectively.	Cyclosporine	29-42	peptidylprolyl isomerase G	Homo sapiens	128-139
11694517-1	2002	The immunosuppressive agents cyclosporin A (CsA) and tacrolimus (FK506) bind to unrelated intracellular immunophilin receptors, cyclophilin (CyP) and FK506-binding protein (FKBP), respectively.	Cyclosporine	29-42	peptidylprolyl isomerase G	Homo sapiens	141-144
11694517-1	2002	The immunosuppressive agents cyclosporin A (CsA) and tacrolimus (FK506) bind to unrelated intracellular immunophilin receptors, cyclophilin (CyP) and FK506-binding protein (FKBP), respectively.	Cyclosporine	44-47	peptidylprolyl isomerase G	Homo sapiens	128-139
11694517-1	2002	The immunosuppressive agents cyclosporin A (CsA) and tacrolimus (FK506) bind to unrelated intracellular immunophilin receptors, cyclophilin (CyP) and FK506-binding protein (FKBP), respectively.	Cyclosporine	44-47	peptidylprolyl isomerase G	Homo sapiens	141-144
12022945-8	2002	The VDAC/ANT/cyclophilin-D complex reconstitutes Ca(2+)- and cyclosporin A-sensitive permeability transition pore activity when incorporated into proteoliposomes.	Cyclosporine	61-74	solute carrier family 25 member 6	Homo sapiens	9-12
11823439-4	2002	The cyclophilin inhibitor cyclosporin A slows pre-mRNA splicing in vitro, and we show that its inhibition of the second step of splicing is caused by blocking the action of USA-CyP within its complex with hPrp18.	Cyclosporine	26-39	pre-mRNA processing factor 18	Homo sapiens	205-211
12587781-1	2002	The aim of this work is a comparison of single and repeated peroral administration of cyclosporine (CsA) and the interaction of repeated administration of CsA and 7-methoxytacrine (MEOTA) on the activity of acetylcholinesterase (AChE) in the frontal cortex, hippocampus, septum, and basal ganglia in rats.	Cyclosporine	155-158	acetylcholinesterase	Rattus norvegicus	207-227
12587781-1	2002	The aim of this work is a comparison of single and repeated peroral administration of cyclosporine (CsA) and the interaction of repeated administration of CsA and 7-methoxytacrine (MEOTA) on the activity of acetylcholinesterase (AChE) in the frontal cortex, hippocampus, septum, and basal ganglia in rats.	Cyclosporine	155-158	acetylcholinesterase	Rattus norvegicus	229-233
12587781-2	2002	Both single and repeated administration of CsA diminished the activity of AChE in the frontal cortex, septum and basal ganglia, while the enzyme activity in the hippocampus was diminished only in the case of repeated CsA, as well as repeated CsA + MEOTA administration.	Cyclosporine	43-46	acetylcholinesterase	Rattus norvegicus	74-78
12221903-12	2002	In recipients with stable graft function we found a correlation between CsA concentration and tPA activity (p = 0.04), as well as an association between the dose of CsA and uPA-Ant concentration in plasma (p = 0.049).	Cyclosporine	165-168	solute carrier family 25 member 6	Homo sapiens	177-180
12221903-18	2002	The results of our study suggest a stimulatory effect of CsA on tPA and PAI-I plasma activities as well as on uPA-Ant concentration, while prednisone in turn seems to enhance PAI-I activity in plasma and decrease uPA expression.	Cyclosporine	57-60	serpin family E member 1	Homo sapiens	72-75
12221903-18	2002	The results of our study suggest a stimulatory effect of CsA on tPA and PAI-I plasma activities as well as on uPA-Ant concentration, while prednisone in turn seems to enhance PAI-I activity in plasma and decrease uPA expression.	Cyclosporine	57-60	serpin family E member 1	Homo sapiens	175-178
15153553-9	2004	Furthermore, inhibition of calcineurin with cyclosporin A (CsA) alters AQP2 localization and phosphorylation in principal cells of CD.	Cyclosporine	59-62	aquaporin 2	Homo sapiens	71-75
15153553-11	2004	Similarly, CsA treatment results in a further increase in urine output compared with diabetes alone, suggesting a functional consequence of inhibiting calcineurin-mediated regulation of AQP2.	Cyclosporine	11-14	aquaporin 2	Homo sapiens	186-190
15153516-9	2004	However, cyclosporin A, an inhibitor of calcineurin-mediated NFAT activation, caused substantial inhibition of NGF-induced MIP-1beta production both in the absence and presence of C3a.	Cyclosporine	9-22	C-C motif chemokine ligand 4	Homo sapiens	123-132
15128834-5	2004	Th1 cell activation was dependent on the presence of APCs and could be blocked by cyclosporine.	Cyclosporine	82-94	amyloid P component, serum	Homo sapiens	53-57
15183848-2	2004	In CsA-induced gingival enlargement, quantitative modifications of the extracellular matrix components occur, and collagen (COL) metabolism and matrix metalloproteinases (MMPs) have been suggested as being the main targets.	Cyclosporine	3-6	matrix metallopeptidase 1	Homo sapiens	171-175
15183848-10	2004	Our data suggest that COL accumulation during CsA-induced gingival overgrowth may be mainly sustained by an altered COL-I degradation due to decreased MMP-1 activity.	Cyclosporine	46-49	matrix metallopeptidase 1	Homo sapiens	151-156
14967819-7	2004	asGCS ODN-7 was shown to be more efficient in reversing drug resistance than either the GCS chemical inhibitor d-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or the P-glycoprotein blocking agents verapamil and cyclosporin A.	Cyclosporine	220-233	UDP-glucose ceramide glucosyltransferase	Homo sapiens	2-5
15019079-6	2004	In the presence of verapamil (100 microM) and CsA (10 microM), potent inhibitors of P-glyprotein (P-gp)/MRP2 (cMOAT), the P(appBL-AP)/P(appAP-BL) ratio was decreased from 3.4 to 1.4 and 1.3, respectively, and permeation of apical to basolateral was enhanced approximately two-fold.	Cyclosporine	46-49	phosphoglycolate phosphatase	Homo sapiens	84-96
11756172-12	2002	Induction of TF expression by OxPAPC was partially inhibited by cyclosporin A, known to block calcineurin, a Ca(++)-dependent phosphatase upstream of NFAT.	Cyclosporine	64-77	coagulation factor III, tissue factor	Homo sapiens	13-15
12210730-6	2002	These results are further evidenced by the effect of RB on both calcineurin (CN) and NFAT binding activity in vitro, suggesting that the interaction of RB with CypA interferes with the CsA:CypA complex and blocks CsA-inhibited CN activity.	Cyclosporine	185-188	peptidylprolyl isomerase A	Homo sapiens	160-164
12210730-6	2002	These results are further evidenced by the effect of RB on both calcineurin (CN) and NFAT binding activity in vitro, suggesting that the interaction of RB with CypA interferes with the CsA:CypA complex and blocks CsA-inhibited CN activity.	Cyclosporine	185-188	peptidylprolyl isomerase A	Homo sapiens	189-193
11740384-5	2001	were used to induce ischemic tolerance in Sprague-Dawley rats, and the induction of heat shock protein (hsp) 70 by CsA or FK506 was evaluated overtime.	Cyclosporine	115-118	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	84-111
11729242-3	2001	The expression of mRNA for hypertonicity-induced genes (aldose reductase, betaine/gamma-amino-n-butyric acid transporter 1, and heat shock protein 70) is also decreased in the medulla of CsA-treated rats.	Cyclosporine	187-190	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	128-149
11729242-4	2001	CsA inhibits the increase of betaine/gamma-amino-n-butyric acid transporter 1 and heat shock protein 70 mRNA in osmotically stressed MDCK cells, blocks cell proliferation under isotonic conditions, and augments hypertonicity-induced apoptosis.	Cyclosporine	0-3	heat shock 70 kDa protein 1	Canis lupus familiaris	82-103
11737856-10	2001	However, Lip-Cl(2)MDP in C6(-) rats resulted in a prolongation of graft survival to 11 +/- 2.3 days (P &lt; 0.05 vs. untreated C6(-) rats), while treatment with CsA alone in these rats led to more than 70 days" survival in four out of six grafts (61 +/- 16 days).	Cyclosporine	161-164	complement C6	Rattus norvegicus	25-30
11737856-14	2001	In CsA-treated C6(-) rats, the grafts harvested at 70 days after transplantation had a normal morphology, with a minimal cellular infiltrate.	Cyclosporine	3-6	complement C6	Rattus norvegicus	15-20
11557243-13	2001	Cyclosporin inhibited the loss of IkappaBalpha protein from the cytoplasm and prevented NF-kappaB binding activity in the nucleus.	Cyclosporine	0-11	NFKB inhibitor alpha	Rattus norvegicus	34-46
11579312-0	2001	Coadministration of either cyclosporine or steroids with humanized monoclonal antibodies against CD80 and CD86 successfully prolong allograft survival after life supporting renal transplantation in cynomolgus monkeys.	Cyclosporine	27-39	T-lymphocyte activation antigen CD80	Macaca fascicularis	97-101
11579312-16	2001	In addition, combining CsA with mAbs directed against the CD80 and CD86 receptors significantly prolongs graft survival when compared to CsA monotherapy.	Cyclosporine	23-26	T-lymphocyte activation antigen CD80	Macaca fascicularis	58-62
11579312-16	2001	In addition, combining CsA with mAbs directed against the CD80 and CD86 receptors significantly prolongs graft survival when compared to CsA monotherapy.	Cyclosporine	137-140	T-lymphocyte activation antigen CD80	Macaca fascicularis	58-62
11548882-6	2001	IGF-1-mediated ARVM hypertrophy was also attenuated by cyclosporine A (calcineurin inhibitor), and staurosporine and chelerythrine (protein kinase C inhibitors).	Cyclosporine	55-69	insulin-like growth factor 1	Rattus norvegicus	0-5
11548882-7	2001	IGF-1 markedly increased calcineurin activity (8.7 +/- 1.2 to 98.0 +/- 54.3 pmol x h(-1) mg(-1), p &lt; 0.01), and this activation was completely blocked by pre-treatment with cyclosporine A (8.5 +/- 11.4pmol x h(-1) x mg(-1), p &lt; 0.01) and chelerythrine (2.3 +/- 2.7 pmol x h(-1) mg(-1), p &lt; 0.01).	Cyclosporine	176-190	insulin-like growth factor 1	Rattus norvegicus	0-5
11548882-9	2001	Increased mRNA expression of atrial natriuretic factor by IGF-1 was inhibited by cyclosporine A (p &lt; 0.01).	Cyclosporine	81-95	insulin-like growth factor 1	Rattus norvegicus	58-63
11548882-11	2001	The fact that elevated calcineurin activity and induced atrial natriuretic factor mRNA expression by IGF-1 were blocked by cyclosporine A further supports the hypothesis that calcineurin is critically involved in IGF-1-induced ARVM hypertrophy.	Cyclosporine	123-137	insulin-like growth factor 1	Rattus norvegicus	101-106
11548882-11	2001	The fact that elevated calcineurin activity and induced atrial natriuretic factor mRNA expression by IGF-1 were blocked by cyclosporine A further supports the hypothesis that calcineurin is critically involved in IGF-1-induced ARVM hypertrophy.	Cyclosporine	123-137	insulin-like growth factor 1	Rattus norvegicus	213-218
11356833-7	2001	In contrast to phorbol ester plus calcium ionophore A23187, Cot kinase increases both COX-2 promoter activity and NFAT-mediated transactivation in a cyclosporin A-independent manner.	Cyclosporine	149-162	nuclear factor of activated T cells 2	Homo sapiens	114-118
11390463-3	2001	SFA interacts with high affinity with the CsA binding side of CypA and inhibits its peptidyl-prolyl isomerase activity.	Cyclosporine	42-45	peptidylprolyl isomerase A	Homo sapiens	62-66
11440739-9	2001	With both techniques, we found that CsA suppressed the expression of interferon-gamma mRNA and interleukin-2 (IL-2) mRNA.	Cyclosporine	36-39	interferon gamma	Rattus norvegicus	69-85
11440739-9	2001	With both techniques, we found that CsA suppressed the expression of interferon-gamma mRNA and interleukin-2 (IL-2) mRNA.	Cyclosporine	36-39	interleukin 2	Rattus norvegicus	95-108
11440739-9	2001	With both techniques, we found that CsA suppressed the expression of interferon-gamma mRNA and interleukin-2 (IL-2) mRNA.	Cyclosporine	36-39	interleukin 2	Rattus norvegicus	110-114
11278494-1	2001	The majority of the effects of cyclosporin A (CsA) on cells is caused by the inhibition of phosphatase activity of calcineurin (CN) by the cyclophilin A (CyPA)-CsA complex formed in the cytoplasm.	Cyclosporine	31-44	cyclophilin a	Leishmania donovani	139-152
11278494-1	2001	The majority of the effects of cyclosporin A (CsA) on cells is caused by the inhibition of phosphatase activity of calcineurin (CN) by the cyclophilin A (CyPA)-CsA complex formed in the cytoplasm.	Cyclosporine	31-44	cyclophilin a	Leishmania donovani	154-158
11278494-1	2001	The majority of the effects of cyclosporin A (CsA) on cells is caused by the inhibition of phosphatase activity of calcineurin (CN) by the cyclophilin A (CyPA)-CsA complex formed in the cytoplasm.	Cyclosporine	46-49	cyclophilin a	Leishmania donovani	139-152
11278494-1	2001	The majority of the effects of cyclosporin A (CsA) on cells is caused by the inhibition of phosphatase activity of calcineurin (CN) by the cyclophilin A (CyPA)-CsA complex formed in the cytoplasm.	Cyclosporine	46-49	cyclophilin a	Leishmania donovani	154-158
15019079-6	2004	In the presence of verapamil (100 microM) and CsA (10 microM), potent inhibitors of P-glyprotein (P-gp)/MRP2 (cMOAT), the P(appBL-AP)/P(appAP-BL) ratio was decreased from 3.4 to 1.4 and 1.3, respectively, and permeation of apical to basolateral was enhanced approximately two-fold.	Cyclosporine	46-49	phosphoglycolate phosphatase	Homo sapiens	98-102
14970329-7	2004	Immunosuppressive drugs known to prevent T cell deletion in vivo, such as cyclosporin A or FK506, blocked Bim up-regulation and rescued T cells from death receptor-independent AICD, whereas rapamycin, which allows the development of stable immunological tolerance, did not exhibit these activities.	Cyclosporine	74-87	BCL2 like 11	Homo sapiens	106-109
11278494-1	2001	The majority of the effects of cyclosporin A (CsA) on cells is caused by the inhibition of phosphatase activity of calcineurin (CN) by the cyclophilin A (CyPA)-CsA complex formed in the cytoplasm.	Cyclosporine	160-163	cyclophilin a	Leishmania donovani	139-152
11278494-1	2001	The majority of the effects of cyclosporin A (CsA) on cells is caused by the inhibition of phosphatase activity of calcineurin (CN) by the cyclophilin A (CyPA)-CsA complex formed in the cytoplasm.	Cyclosporine	160-163	cyclophilin a	Leishmania donovani	154-158
14733770-12	2004	CsA 10(-6) mol/L and H7 50 micromol/L inhibited UII-stimulated CaN activity by 45% (P &lt; 0.01) and 21% (P &lt; 0.05), respectively, while PD98059 50 micromol/L had no effect on CaN activity (P &gt; 0.05).	Cyclosporine	0-3	urotensin 2	Homo sapiens	48-51
11278494-3	2001	The presence of structurally altered CyPA with lower affinity for CsA had been suggested to be the cause of resistance.	Cyclosporine	66-69	cyclophilin a	Leishmania donovani	37-41
14733770-13	2004	CsA 10(-6) mol/L inhibited UII-stimulated PKC activity by 14% (P &lt; 0.05), while having no effect on MAPK activity (P &gt; 0.05).	Cyclosporine	0-3	urotensin 2	Homo sapiens	27-30
14663460-5	2003	Clinical cyclosporine efficacy was assessed by a decreasing rate (percentage) of urinary protein 1 week after cyclosporine therapy.	Cyclosporine	9-21	secretoglobin family 1A member 1	Homo sapiens	81-98
11349731-0	2001	Cyclosporine induces myocardial connective tissue growth factor in spontaneously hypertensive rats on high-sodium diet.	Cyclosporine	0-12	cellular communication network factor 2	Rattus norvegicus	32-63
11349731-3	2001	Whether the CsA-induced myocardial changes are associated with the induction of connective tissue growth factor (CTGF), a recently found polypeptide implicated in extracellular matrix synthesis, is not known.	Cyclosporine	12-15	cellular communication network factor 2	Rattus norvegicus	80-111
11349731-3	2001	Whether the CsA-induced myocardial changes are associated with the induction of connective tissue growth factor (CTGF), a recently found polypeptide implicated in extracellular matrix synthesis, is not known.	Cyclosporine	12-15	cellular communication network factor 2	Rattus norvegicus	113-117
11349731-9	2001	CsA increased myocardial CTGF, collagen I, and collagen III mRNA expressions by 91%, 198%, and 151%, respectively.	Cyclosporine	0-3	cellular communication network factor 2	Rattus norvegicus	25-29
11349731-11	2001	Blockade of the renin-angiotensin system prevented vascular damage and the CsA-induced CTGF, collagen I, and collagen III mRNA overexpressions in the heart.	Cyclosporine	75-78	cellular communication network factor 2	Rattus norvegicus	87-91
15989499-12	2001	Drug interactions between cyclosporin and HMG-CoA reductase inhibitors are a limiting factor to their use.	Cyclosporine	26-37	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	42-59
11569920-1	2001	The immunosuppressant cyclosporin A (CsA)-sensitive nuclear factor of activated T cells 1 (NFAT1) has been known to be a transcriptional regulator of cytokine and viral genes during the immune response.	Cyclosporine	22-35	nuclear factor of activated T cells 2	Homo sapiens	91-96
11569920-1	2001	The immunosuppressant cyclosporin A (CsA)-sensitive nuclear factor of activated T cells 1 (NFAT1) has been known to be a transcriptional regulator of cytokine and viral genes during the immune response.	Cyclosporine	37-40	nuclear factor of activated T cells 2	Homo sapiens	91-96
11354286-3	2001	METHODS: The sensitivity to DOR and the chemosensitizing effects of Cys were assessed by using two human HCC cell lines, PLC/PRF/5 and Hep-3B, and their DOR-resistant sublines, PLC/DOR and 3B/DOR.	Cyclosporine	68-71	heparan sulfate proteoglycan 2	Homo sapiens	121-124
11354286-7	2001	When 5 micromol/L Cys was added to the culture, the 50% inhibiting concentration (IC50) of DOR was reduced from 0.93 +/- 0.29 microg/mL to 0.32 +/- 0.10 microg/mL in PLC/PRF/5, and from 0.25 +/- 0.07 microg/mL to 0.09 +/- 0.04 microg/mL in Hep-3B.	Cyclosporine	18-21	heparan sulfate proteoglycan 2	Homo sapiens	166-169
11354286-8	2001	Furthermore, in the presence of 5 micromol/L Cys, the IC50 of DOR was reduced from 48.63 +/- 17.04 microg/mL to 0.49 +/- 0.14 microg/mL in PLC/DOR, and from 4.60 +/- 1.22 microg/mL to 0.15 +/- 0.06 microg/mL in 3B/DOR.	Cyclosporine	45-48	heparan sulfate proteoglycan 2	Homo sapiens	139-142
11327083-0	2001	Epidermal growth factor in saliva and serum of patients with cyclosporin-induced gingival overgrowth.	Cyclosporine	61-72	epidermal growth factor	Homo sapiens	0-23
11327083-1	2001	The purpose of this study was to investigate the presence of epidermal growth factor (EGF) in patients receiving cyclosporin therapy who had gingival overgrowth and to determine whether there were any differences between these patients and normal healthy controls.	Cyclosporine	113-124	epidermal growth factor	Homo sapiens	61-84
11327083-1	2001	The purpose of this study was to investigate the presence of epidermal growth factor (EGF) in patients receiving cyclosporin therapy who had gingival overgrowth and to determine whether there were any differences between these patients and normal healthy controls.	Cyclosporine	113-124	epidermal growth factor	Homo sapiens	86-89
11327083-6	2001	EGF concentrations were found to be significantly higher in the saliva of patients with cyclosporin-induced gingival overgrowth compared to the control group (401.2 +/- 31.1 pg/ml and 144.3 +/- 31.4 pg/ml, respectively), whereas the results were reversed in the serum (67.0 +/- 15.6 pg/ml and 141.6 +/- 17.7 pg/ml, respectively).	Cyclosporine	88-99	epidermal growth factor	Homo sapiens	0-3
11327083-8	2001	This study thus demonstrated an increase in EGF levels in the saliva and a decrease of EGF in the serum of patients with cyclosporin-induced gingival overgrowth.	Cyclosporine	121-132	epidermal growth factor	Homo sapiens	87-90
12687202-4	2001	CsA downregulates PMA/ionomycin-induced LTalpha at both transcription and protein expression levels, whereas it downregulates LTbeta at the transcript but not at the protein expression levels.	Cyclosporine	0-3	lymphotoxin beta	Homo sapiens	126-132
11121417-6	2001	Both the Ca(2+)/calmodulin-dependent protein kinase II inhibitor KN62 and the calcineurin inhibitor cyclosporin A enhanced TFP-dependent increase of Egr-1, suggesting that the Ca(2+)/calmodulindependent pathway plays a role in regulation of Egr-1 expression in HT1080 cells.	Cyclosporine	100-113	early growth response 1	Homo sapiens	149-154
11121417-6	2001	Both the Ca(2+)/calmodulin-dependent protein kinase II inhibitor KN62 and the calcineurin inhibitor cyclosporin A enhanced TFP-dependent increase of Egr-1, suggesting that the Ca(2+)/calmodulindependent pathway plays a role in regulation of Egr-1 expression in HT1080 cells.	Cyclosporine	100-113	early growth response 1	Homo sapiens	241-246
11325024-7	2001	Phosphorylation of cyclic AMP responsive element-binding protein (CREB) and its binding activity to DNA in the nuclear fraction from the adrenal medulla of cyclosporine-treated rats were much higher than that of the control rats.	Cyclosporine	156-168	cAMP responsive element binding protein 1	Rattus norvegicus	19-64
11325024-7	2001	Phosphorylation of cyclic AMP responsive element-binding protein (CREB) and its binding activity to DNA in the nuclear fraction from the adrenal medulla of cyclosporine-treated rats were much higher than that of the control rats.	Cyclosporine	156-168	cAMP responsive element binding protein 1	Rattus norvegicus	66-70
11325024-9	2001	These results suggest that cyclosporine increased blood pressure via activation of the catecholamine synthetic pathway due to the activation of transcription factor CREB.	Cyclosporine	27-39	cAMP responsive element binding protein 1	Rattus norvegicus	165-169
11226376-5	2001	We conclude that the increases in cyclin D1, PCNA, and cyclin E, together with the invariable level of p27, clearly show that CsA induces hepatocytes to proliferate.	Cyclosporine	126-129	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	103-106
11423728-2	2001	This study was performed to evaluate the effect of heat-shock protein (HSP)70 induction with sodium arsenite (SA) on ischemia/reperfusion (I/R) or cyclosporin A (CsA)-induced injuries in rat kidney.	Cyclosporine	147-160	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	51-77
11516824-1	2001	Recent studies have shown that cyclosporin A, a specific antagonist of calcineurin, a phosphatase, ameliorates neuronal cell death in the CA1 sector of the hippocampus after forebrain ischemia in animal models.	Cyclosporine	31-44	carbonic anhydrase 1	Rattus norvegicus	138-141
11516824-5	2001	Based on these observations, we attempted to investigate how cyclosporin A treatment would affect the changes of phosphorylated CREB (pCREB), BDNF and its receptor tyrosine kinase B (TrkB) after forebrain ischemia in rats.	Cyclosporine	61-74	cAMP responsive element binding protein 1	Rattus norvegicus	128-132
11093160-9	2000	In untransformed human peripheral blood T lymphocytes, these phosphatases function through a cyclosporin A/FK506-resistant co-stimulatory signaling pathway which is common for the accessory receptors CD2 and CD28.	Cyclosporine	93-106	CD2 molecule	Homo sapiens	200-203
11082422-11	2000	The cocaine-induced decrease in the Bcl-2 protein was not affected by cyclosporin A but was partially blocked by caspase-3 inhibitor Ac-DEVD-CHO.	Cyclosporine	70-83	BCL2 apoptosis regulator	Bos taurus	36-41
11206060-3	2000	In vitro, the CyPB/CsA complex is more effective in inhibiting calcineurin than the CyPA/CsA and CyPC/CsA complexes, pointing to fine structural differences in the calcineurin-binding region.	Cyclosporine	89-92	peptidylprolyl isomerase A	Homo sapiens	84-88
11206060-3	2000	In vitro, the CyPB/CsA complex is more effective in inhibiting calcineurin than the CyPA/CsA and CyPC/CsA complexes, pointing to fine structural differences in the calcineurin-binding region.	Cyclosporine	89-92	peptidylprolyl isomerase A	Homo sapiens	84-88
10973968-13	2000	By using cyclosporin A and PGF(2)alpha treatment, we established that inhibition of NUR77 DNA binding in vivo prevents PGF(2)alpha induction of the 20alpha-HSD gene in the corpus luteum.	Cyclosporine	9-22	nuclear receptor subfamily 4, group A, member 1	Mus musculus	84-89
11085753-6	2000	Second, CXCR3(-/)- allograft recipients treated with a brief, subtherapeutic course of cyclosporin A maintained their allografts permanently and without evidence of chronic rejection.	Cyclosporine	87-100	chemokine (C-X-C motif) receptor 3	Mus musculus	8-13
14627911-7	2003	Mean CsA trough levels were 114 ng/mL before and 98 ng/mL 1 year after conversion.	Cyclosporine	5-8	L1 cell adhesion molecule	Mus musculus	55-59
14579277-4	2003	Only very high doses of cyclosporin A and FK506 inhibited macrophage proliferation induced by growth factors, such as M-CSF, granulocyte-macrophage (GM)-CSF or IL-3.	Cyclosporine	24-37	colony stimulating factor 1	Homo sapiens	118-123
11062164-0	2000	Cyclosporin A inhibits chromium(VI)-induced apoptosis and mitochondrial cytochrome c release and restores clonogenic survival in CHO cells.	Cyclosporine	0-13	cytochrome c	Cricetulus griseus	72-84
14579277-4	2003	Only very high doses of cyclosporin A and FK506 inhibited macrophage proliferation induced by growth factors, such as M-CSF, granulocyte-macrophage (GM)-CSF or IL-3.	Cyclosporine	24-37	colony stimulating factor 2	Homo sapiens	125-156
11062164-8	2000	Co-treatment of these cells with csA inhibited the release of cyt c and abrogated Cr(VI)-induced apoptosis as determined by a reduction in internucleosomal DNA fragmentation.	Cyclosporine	33-36	cytochrome c	Cricetulus griseus	62-67
14579277-4	2003	Only very high doses of cyclosporin A and FK506 inhibited macrophage proliferation induced by growth factors, such as M-CSF, granulocyte-macrophage (GM)-CSF or IL-3.	Cyclosporine	24-37	interleukin 3	Homo sapiens	160-164
11029348-3	2000	For these reasons, we determined whether CsA inhibited the allergen-induced increases in bronchial eosinophils, basophils, eotaxin, interleukin-5 (IL-5), and granulocyte macrophage colony-stimulating factor (GM-CSF).	Cyclosporine	41-44	colony stimulating factor 2	Homo sapiens	158-206
14530907-7	2003	Additional inhibitors of phalloidin uptake mediated by SLC21A6 included the immunosuppressive drugs cyclosporin A, FK506, and rapamycin, whereas alpha-amanitin was only a weak inhibitor.	Cyclosporine	100-113	solute carrier organic anion transporter family member 1B1	Homo sapiens	55-62
11029348-7	2000	CsA significantly inhibited the allergen-induced increases in IL-5 (p = 0.02) and GM-CSF (p = 0.	Cyclosporine	0-3	colony stimulating factor 2	Homo sapiens	82-88
11073168-0	2000	Improvement of extrathymic T cell type of large granular lymphocyte (LGL) leukemia by cyclosporin A: the serum level of Fas ligand is a marker of LGL leukemia activity.	Cyclosporine	86-99	Fas ligand	Homo sapiens	120-130
11023989-5	2000	All these effects can be blocked by cyclosporin A, suggesting that GD3 is acting at the level of the permeability transition pore complex.	Cyclosporine	36-49	GRDX	Homo sapiens	67-70
11034368-3	2000	However, there are significant differences in the signaling pathways used by these agents, because 1) LPS-induced, but not CI-induced, DC differentiation required TNF-alpha production; and 2) cyclosporin A inhibited differentiation induced by CI, but not that induced by LPS.	Cyclosporine	192-205	interferon regulatory factor 6	Homo sapiens	271-274
10975829-8	2000	Cyclosporin down-regulated the expression of the PAI-1 gene.	Cyclosporine	0-11	serpin family E member 1	Homo sapiens	49-54
14530907-8	2003	Cyclosporin A was a most potent competitive inhibitor for SLC21A6-mediated phalloidin transport with a K(i) value of 51 nM.	Cyclosporine	0-13	solute carrier organic anion transporter family member 1B1	Homo sapiens	58-65
14765557-11	2003	(6) Significant suppression of scavenger-receptors class B type I (SR-BI) mRNA levels was found in the plasma-CSA group, although no significant differences in SRBI protein levels were seen between groups.	Cyclosporine	110-113	scavenger receptor class B, member 1	Rattus norvegicus	31-65
14765557-11	2003	(6) Significant suppression of scavenger-receptors class B type I (SR-BI) mRNA levels was found in the plasma-CSA group, although no significant differences in SRBI protein levels were seen between groups.	Cyclosporine	110-113	scavenger receptor class B, member 1	Rattus norvegicus	67-72
12897779-3	2003	In certain nonhuman primate cells, the CA-CypA interaction is essential for restriction: HIV-1 infectivity is increased &gt;100-fold by cyclosporin A (CsA), a competitive inhibitor of the interaction, or by an HIV-1 CA mutation that disrupts CypA binding.	Cyclosporine	136-149	peptidylprolyl isomerase A	Homo sapiens	42-46
12897779-3	2003	In certain nonhuman primate cells, the CA-CypA interaction is essential for restriction: HIV-1 infectivity is increased &gt;100-fold by cyclosporin A (CsA), a competitive inhibitor of the interaction, or by an HIV-1 CA mutation that disrupts CypA binding.	Cyclosporine	136-149	peptidylprolyl isomerase A	Homo sapiens	242-246
12897779-3	2003	In certain nonhuman primate cells, the CA-CypA interaction is essential for restriction: HIV-1 infectivity is increased &gt;100-fold by cyclosporin A (CsA), a competitive inhibitor of the interaction, or by an HIV-1 CA mutation that disrupts CypA binding.	Cyclosporine	151-154	peptidylprolyl isomerase A	Homo sapiens	42-46
12897779-3	2003	In certain nonhuman primate cells, the CA-CypA interaction is essential for restriction: HIV-1 infectivity is increased &gt;100-fold by cyclosporin A (CsA), a competitive inhibitor of the interaction, or by an HIV-1 CA mutation that disrupts CypA binding.	Cyclosporine	151-154	peptidylprolyl isomerase A	Homo sapiens	242-246
12903777-6	2000	However, CS"s immunosuppression was mainly through the decrease of IL-2 production.	Cyclosporine	9-11	interleukin 2	Mus musculus	67-71
12871122-6	2003	CsA is cytoprotective in many cellular and animal models, but protection may result from either inhibition of the MPT through an interaction with CYP D or inhibition of calcineurin-mediated dephosphorylation of BAD through an interaction with CYP A.	Cyclosporine	0-3	peptidylprolyl isomerase A	Homo sapiens	243-248
12819040-9	2003	Blockade of calcineurin activity by cyclosporine A completely normalized Ang II-induced CTGF overexpression in heart and kidney, suppressed the inflammatory response, and mitigated Ang II-induced cell proliferation and apoptosis.	Cyclosporine	36-50	cellular communication network factor 2	Rattus norvegicus	88-92
10966874-4	2000	It is a cyclosporin A (CsA) sensitive CyP with a MW of 19.4kDa.	Cyclosporine	8-21	peptidylprolyl isomerase G	Homo sapiens	38-41
12848778-4	2003	The clinical relevance of this SNP on oral bioavailability of a known P-gp substrate, cyclosporin, was assessed in 10 stable Chinese heart transplant patients.	Cyclosporine	86-97	phosphoglycolate phosphatase	Homo sapiens	70-74
10966874-4	2000	It is a cyclosporin A (CsA) sensitive CyP with a MW of 19.4kDa.	Cyclosporine	23-26	peptidylprolyl isomerase G	Homo sapiens	38-41
10966874-5	2000	The PPIase activity and CsA sensitivity of this CyP is higher at higher salt concentration in the medium.	Cyclosporine	24-27	peptidylprolyl isomerase G	Homo sapiens	48-51
12890451-7	2003	Whereas a low PGE(1) concentration decreased CsA induced production of fibronectin (FN) and plasminogen activator inhibitor type-1 (PAI-1), a higher PGE1 concentration did not change FN production, but further increased PAI-1 production.	Cyclosporine	45-48	fibronectin 1	Rattus norvegicus	71-82
11042226-4	2000	Polarised transport of doxorubicin in the Caco-2 and the LLC-PK1:MDR1 cell lines could be inhibited by the P-gp inhibitors SDZ-PSC 833 (PSC 833), cyclosporin A (CsA), verapamil and quinine, but not by the inhibitors for the organic cation carrier systems cimetidine and tetraethylammonium (TEA).	Cyclosporine	146-159	ATP-binding cassette, sub-family B (MDR/TAP), member 1	Sus scrofa	65-69
12890451-7	2003	Whereas a low PGE(1) concentration decreased CsA induced production of fibronectin (FN) and plasminogen activator inhibitor type-1 (PAI-1), a higher PGE1 concentration did not change FN production, but further increased PAI-1 production.	Cyclosporine	45-48	fibronectin 1	Rattus norvegicus	84-86
12890451-7	2003	Whereas a low PGE(1) concentration decreased CsA induced production of fibronectin (FN) and plasminogen activator inhibitor type-1 (PAI-1), a higher PGE1 concentration did not change FN production, but further increased PAI-1 production.	Cyclosporine	45-48	serpin family E member 2	Rattus norvegicus	92-130
12775958-6	2003	Late lumen cross-sectional area (CSA) loss, plaque CSA growth, and plaque volume in the stent determined by IVUS were dose-relatedly decreased (33-62% at 1.25 mg/kg BID to 66-92% at 5 mg/kg BID, depending on the parameter) compared with controls.	Cyclosporine	33-36	BH3 interacting domain death agonist	Sus scrofa	165-168
10925268-0	2000	In vitro and in vivo transfection of p21 gene enhances cyclosporin A-mediated inhibition of lymphocyte proliferation.	Cyclosporine	55-68	H3 histone pseudogene 16	Homo sapiens	37-40
10925268-1	2000	Cyclosporine has potent antiproliferative properties, some of which may be via the induction of the cyclin inhibitor p21.	Cyclosporine	0-12	proliferating cell nuclear antigen	Homo sapiens	100-106
10925268-1	2000	Cyclosporine has potent antiproliferative properties, some of which may be via the induction of the cyclin inhibitor p21.	Cyclosporine	0-12	H3 histone pseudogene 16	Homo sapiens	117-120
10925268-4	2000	This in vitro transfection of p21 resulted in the inhibition of spontaneous and mitogen-induced cellular proliferation ([3H]thymidine uptake) and also augmented the antiproliferative effects of cyclosporine.	Cyclosporine	194-206	H3 histone pseudogene 16	Homo sapiens	30-33
10925271-4	2000	This costimulation functions independently of CD28, and unlike costimulation through CD28, is susceptible to inhibition by cyclosporin A.	Cyclosporine	123-136	CD28 antigen	Mus musculus	85-89
10949181-0	2000	Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: implications for tolerance induction.	Cyclosporine	24-38	CD40 ligand	Mus musculus	92-97
12826232-6	2003	Cytokine analysis revealed significantly reduced expression of interleukin-2 (IL-2), interferon-gamma (IFN-gamma) and granzyme B in the day 3 specimens of the CCM and CCM CsA-treated allografts compared with the nontreated allograft controls.	Cyclosporine	171-174	interleukin 2	Rattus norvegicus	63-76
10949181-4	2000	RESULTS: Concomitant use of cyclosporin A or methylprednisolone, but not rapamycin or mycophenolate, inhibited CD154 mAb-induced allograft survival.	Cyclosporine	28-41	CD40 ligand	Mus musculus	111-116
11042477-18	2000	Furthermore, administration of exogenous IL-2 might be able to abrogate the protection from OAD by CsA therapy.	Cyclosporine	99-102	interleukin 2	Rattus norvegicus	41-45
12826232-6	2003	Cytokine analysis revealed significantly reduced expression of interleukin-2 (IL-2), interferon-gamma (IFN-gamma) and granzyme B in the day 3 specimens of the CCM and CCM CsA-treated allografts compared with the nontreated allograft controls.	Cyclosporine	171-174	interleukin 2	Rattus norvegicus	78-82
11275261-7	2000	Both ionomycin and CsA also enhance IL-4-induced transcriptional activity of a STAT6-linked promoter-reporter construct.	Cyclosporine	19-22	interleukin 4	Mus musculus	36-40
10933163-0	2000	Cyclosporine inhibits class II major histocompatibility antigen presentation by xenogeneic endothelial cells to human T lymphocytes by altering expression of the class II transcriptional activator gene.	Cyclosporine	0-12	class II major histocompatibility complex transactivator	Homo sapiens	162-196
12826232-6	2003	Cytokine analysis revealed significantly reduced expression of interleukin-2 (IL-2), interferon-gamma (IFN-gamma) and granzyme B in the day 3 specimens of the CCM and CCM CsA-treated allografts compared with the nontreated allograft controls.	Cyclosporine	171-174	interferon gamma	Rattus norvegicus	85-101
12826232-6	2003	Cytokine analysis revealed significantly reduced expression of interleukin-2 (IL-2), interferon-gamma (IFN-gamma) and granzyme B in the day 3 specimens of the CCM and CCM CsA-treated allografts compared with the nontreated allograft controls.	Cyclosporine	171-174	interferon gamma	Rattus norvegicus	103-112
12649386-0	2003	Suppression of hepatic CYP3A1/2 and CYP2C11 by cyclosporine is not mediated by altering growth hormone levels.	Cyclosporine	47-59	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	36-43
12649386-5	2003	CsA alone decreased CYP3A1/2 and CYP2C11 significantly, in a manner similar to that previously found.	Cyclosporine	0-3	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	33-40
10933163-5	2000	The effect of CsA on class II MHC antigen mRNA expression was also analyzed and related to class II transcriptional activator (CIITA) mRNA expression.	Cyclosporine	14-17	class II major histocompatibility complex transactivator	Homo sapiens	91-125
12671830-5	2003	On days 1 and 7, the 24-hour urine excretion of N-acetyl-beta-d-glucosaminidase (NAG) and beta-galactosidase (beta-GAL) were significantly (P &lt; .001) lower in CsA-treated rats on the high-protein diet than in those on the standard Rat Chow.	Cyclosporine	162-165	galactosidase, beta 1	Rattus norvegicus	90-108
10933163-10	2000	Pretreatment of PAECs with CsA for 4 hr before coculture with human peripheral blood leukocytes efficiently blocked the induction on PAECs of E-selectin and class II MHC antigens and inhibited overexpression of class I antigens.	Cyclosporine	27-30	selectin E	Homo sapiens	142-152
12671830-5	2003	On days 1 and 7, the 24-hour urine excretion of N-acetyl-beta-d-glucosaminidase (NAG) and beta-galactosidase (beta-GAL) were significantly (P &lt; .001) lower in CsA-treated rats on the high-protein diet than in those on the standard Rat Chow.	Cyclosporine	162-165	galactosidase, beta 1	Rattus norvegicus	110-118
12634401-3	2003	Our results show that the infectivity of virions depleted of CyPA by treatment with cyclosporine A could be restored by NERT treatment, while mutants in the CyPA binding loop of capsid could only be partially restored.	Cyclosporine	84-98	peptidylprolyl isomerase A	Homo sapiens	61-65
10920278-6	2000	Overexpression of Bcl-2 and cyclosporin A treatment inhibited the nuclear import and FasL expression, and as a result, both inhibited apoptosis.	Cyclosporine	28-41	Fas ligand	Homo sapiens	85-89
10867130-2	2000	Since Pgp-mediated efflux of cytotoxic drugs can be inhibited by the cyclosporine analogue, PSC 833, we investigated the use of this agent with a 5-day mitoxantrone/etoposide regimen in patients over age 55 with newly diagnosed AML.	Cyclosporine	69-81	phosphoglycolate phosphatase	Homo sapiens	6-9
10891114-2	2000	In a standardized assay that measures Pgp function by the Pgp-mediated efflux of the calcein-AM Pgp substrate and uses human lymphoblastoid MDR-CEM (VBL(100)) cells as highly resistant Pgp-expressing cells and the cyclic undecapeptide cyclosporin A (CsA) as a reference MDR-reversing agent (IC(50) of 3.4 microM), AbA was found to be a more active Pgp inhibitor (IC(50) of 2.3 microM).	Cyclosporine	235-248	phosphoglycolate phosphatase	Homo sapiens	38-41
10891114-2	2000	In a standardized assay that measures Pgp function by the Pgp-mediated efflux of the calcein-AM Pgp substrate and uses human lymphoblastoid MDR-CEM (VBL(100)) cells as highly resistant Pgp-expressing cells and the cyclic undecapeptide cyclosporin A (CsA) as a reference MDR-reversing agent (IC(50) of 3.4 microM), AbA was found to be a more active Pgp inhibitor (IC(50) of 2.3 microM).	Cyclosporine	235-248	phosphoglycolate phosphatase	Homo sapiens	58-61
10891114-2	2000	In a standardized assay that measures Pgp function by the Pgp-mediated efflux of the calcein-AM Pgp substrate and uses human lymphoblastoid MDR-CEM (VBL(100)) cells as highly resistant Pgp-expressing cells and the cyclic undecapeptide cyclosporin A (CsA) as a reference MDR-reversing agent (IC(50) of 3.4 microM), AbA was found to be a more active Pgp inhibitor (IC(50) of 2.3 microM).	Cyclosporine	235-248	phosphoglycolate phosphatase	Homo sapiens	58-61
10891114-2	2000	In a standardized assay that measures Pgp function by the Pgp-mediated efflux of the calcein-AM Pgp substrate and uses human lymphoblastoid MDR-CEM (VBL(100)) cells as highly resistant Pgp-expressing cells and the cyclic undecapeptide cyclosporin A (CsA) as a reference MDR-reversing agent (IC(50) of 3.4 microM), AbA was found to be a more active Pgp inhibitor (IC(50) of 2.3 microM).	Cyclosporine	235-248	phosphoglycolate phosphatase	Homo sapiens	58-61
10891114-2	2000	In a standardized assay that measures Pgp function by the Pgp-mediated efflux of the calcein-AM Pgp substrate and uses human lymphoblastoid MDR-CEM (VBL(100)) cells as highly resistant Pgp-expressing cells and the cyclic undecapeptide cyclosporin A (CsA) as a reference MDR-reversing agent (IC(50) of 3.4 microM), AbA was found to be a more active Pgp inhibitor (IC(50) of 2.3 microM).	Cyclosporine	235-248	phosphoglycolate phosphatase	Homo sapiens	58-61
10891114-2	2000	In a standardized assay that measures Pgp function by the Pgp-mediated efflux of the calcein-AM Pgp substrate and uses human lymphoblastoid MDR-CEM (VBL(100)) cells as highly resistant Pgp-expressing cells and the cyclic undecapeptide cyclosporin A (CsA) as a reference MDR-reversing agent (IC(50) of 3.4 microM), AbA was found to be a more active Pgp inhibitor (IC(50) of 2.3 microM).	Cyclosporine	250-253	phosphoglycolate phosphatase	Homo sapiens	38-41
10891114-2	2000	In a standardized assay that measures Pgp function by the Pgp-mediated efflux of the calcein-AM Pgp substrate and uses human lymphoblastoid MDR-CEM (VBL(100)) cells as highly resistant Pgp-expressing cells and the cyclic undecapeptide cyclosporin A (CsA) as a reference MDR-reversing agent (IC(50) of 3.4 microM), AbA was found to be a more active Pgp inhibitor (IC(50) of 2.3 microM).	Cyclosporine	250-253	phosphoglycolate phosphatase	Homo sapiens	58-61
10891114-2	2000	In a standardized assay that measures Pgp function by the Pgp-mediated efflux of the calcein-AM Pgp substrate and uses human lymphoblastoid MDR-CEM (VBL(100)) cells as highly resistant Pgp-expressing cells and the cyclic undecapeptide cyclosporin A (CsA) as a reference MDR-reversing agent (IC(50) of 3.4 microM), AbA was found to be a more active Pgp inhibitor (IC(50) of 2.3 microM).	Cyclosporine	250-253	phosphoglycolate phosphatase	Homo sapiens	58-61
10891114-2	2000	In a standardized assay that measures Pgp function by the Pgp-mediated efflux of the calcein-AM Pgp substrate and uses human lymphoblastoid MDR-CEM (VBL(100)) cells as highly resistant Pgp-expressing cells and the cyclic undecapeptide cyclosporin A (CsA) as a reference MDR-reversing agent (IC(50) of 3.4 microM), AbA was found to be a more active Pgp inhibitor (IC(50) of 2.3 microM).	Cyclosporine	250-253	phosphoglycolate phosphatase	Homo sapiens	58-61
10891114-2	2000	In a standardized assay that measures Pgp function by the Pgp-mediated efflux of the calcein-AM Pgp substrate and uses human lymphoblastoid MDR-CEM (VBL(100)) cells as highly resistant Pgp-expressing cells and the cyclic undecapeptide cyclosporin A (CsA) as a reference MDR-reversing agent (IC(50) of 3.4 microM), AbA was found to be a more active Pgp inhibitor (IC(50) of 2.3 microM).	Cyclosporine	250-253	phosphoglycolate phosphatase	Homo sapiens	58-61
10736526-8	2000	The number of CD4(+), CD8(+), T cell receptor (TCR) alpha ss-bearing cells and TCRgamma delta-bearing cells decreased markedly in the peripheral blood of CsA-treated chickens compared to those of untreated chickens.	Cyclosporine	154-157	Ig heavy chain Mem5-like	Gallus gallus	30-57
10914799-0	2000	Phenytoin and cyclosporin A suppress the expression of MMP-1, TIMP-1, and cathepsin L, but not cathepsin B in cultured gingival fibroblasts.	Cyclosporine	14-27	matrix metallopeptidase 1	Homo sapiens	55-60
10844628-3	2000	Using a rat renal transplant model, the purpose of this study was to examine the effects of CsA on the 5-lipoxygenase (5-LO) pathway of AA metabolism.	Cyclosporine	92-95	arachidonate 5-lipoxygenase	Rattus norvegicus	103-117
10779414-6	2000	Strikingly, the calcineurin inhibitors cyclosporin A (CsA) and FK506 strongly potentiated TCR-induced LAT expression, suggesting that the activation of calcineurin following TCR ligation negatively regulates LAT expression.	Cyclosporine	54-57	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	90-93
10779414-6	2000	Strikingly, the calcineurin inhibitors cyclosporin A (CsA) and FK506 strongly potentiated TCR-induced LAT expression, suggesting that the activation of calcineurin following TCR ligation negatively regulates LAT expression.	Cyclosporine	54-57	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	174-177
10779414-9	2000	Notably, CsA and FK506 preferentially up-regulated TCR-induced LAT expression; under the same conditions, these compounds did not increase the expression of 14 other molecules that previously had been implicated in T-cell activation.	Cyclosporine	9-12	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	51-54
10779414-11	2000	Furthermore, the potentiation of TCR-induced LAT expression by CsA and FK506 suggests that the action of these agents involves up-regulating the cellular level of critical signaling molecules.	Cyclosporine	63-66	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	33-36
10755555-11	2000	It is interesting that in vivo studies confirmed that CsA and GC inhibited EC activation at therapeutic doses (1 mg/kg and 10 mg/kg for GC and CsA, respectively) and showed that the combination of CsA and GC efficiently prevents TNFalpha-mediated induction of E-selectin on cardiac ECs.	Cyclosporine	54-57	selectin E	Homo sapiens	260-270
10718363-5	2000	When cyclosporin A was added simultaneously with RO20-1724, an inhibitor of cyclic nucleotide phosphodiesterase, or with prostaglandin E1, a stimulator of adenylate cyclase, it markedly enhanced the growth inhibitory and differentiation effects of these cAMP-stimulating agents.	Cyclosporine	5-18	small nucleolar RNA, H/ACA box 73A	Homo sapiens	135-172
11450070-5	2000	The immunosuppressant cyclosporin A (50 microM) partially reduced the ischemia-stimulated IL-8 and MCP-1 secretion by HCEC.	Cyclosporine	22-35	C-C motif chemokine ligand 2	Homo sapiens	99-104
11268345-6	2000	IL-2 mRNA synthesis in lymphoid cells obtained from animals after IS and after IS in combination with the administration in vitro of the cytotoxic drug CsA to the splenic lymphocytes was inhibited (30% and 99%), accordingly, as compared with control rats.	Cyclosporine	152-155	interleukin 2	Rattus norvegicus	0-4
10695938-4	2000	METHODS: LTB4 and PAF levels were detected in gingival crevicular fluid (GCF) samples from renal transplant patients receiving CsA therapy and exhibiting CsA GO, from patients with gingivitis and from periodontally healthy subjects.	Cyclosporine	127-130	PCNA clamp associated factor	Homo sapiens	18-21
10695938-15	2000	In CsA-treated patients, alterations in LTB4 and PAF levels might play a role in CsA GO through some asyet unknown mechanism.	Cyclosporine	3-6	PCNA clamp associated factor	Homo sapiens	49-52
10777122-7	2000	IL-1Ra serum levels significantly dropped in the CyA group after two weeks, whereas in the MTX group the significant decrease was first seen after 3 months of treatment.	Cyclosporine	49-52	interleukin 1 receptor antagonist	Homo sapiens	0-6
10586059-11	1999	Cyclosporin A and FK506, but not KN-62, blocked Ca2+ ionophore-mediated inhibition of Pyk2 expression, implicating calcineurin in down-regulating Pyk2 expression.	Cyclosporine	0-13	protein tyrosine kinase 2 beta	Homo sapiens	86-90
10586059-11	1999	Cyclosporin A and FK506, but not KN-62, blocked Ca2+ ionophore-mediated inhibition of Pyk2 expression, implicating calcineurin in down-regulating Pyk2 expression.	Cyclosporine	0-13	protein tyrosine kinase 2 beta	Homo sapiens	146-150
12633900-0	2003	Cyclosporine A inhibits acetylcholinesterase activity in selected parts of the rat brain.	Cyclosporine	0-14	acetylcholinesterase	Rattus norvegicus	24-44
10574997-1	1999	It has been reported that immunosuppressant cyclosporin A or FK506 binds to immunophilins in the cell and that these immunophilins make a complex with molecular chaperones HSP70 or HSP90.	Cyclosporine	44-57	heat shock protein 90 alpha family class A member 1	Homo sapiens	181-186
12633900-2	2003	We investigated the effect of CsA on the activity of acetylcholinesterase (AChE) in the frontal cortex, hippocampus, septum, and basal ganglia.	Cyclosporine	30-33	acetylcholinesterase	Rattus norvegicus	53-73
10600799-4	1999	Using a mouse model, we treated Swiss-Webster mice for 6 days with a daily dose of 20 microg/g body wt of cyclosporin and observed significant elevations of plasma cholesterol, triglyceride, and apolipoprotein B (apoB) levels relative to vehicle-alone treated control animals.	Cyclosporine	106-117	apolipoprotein B	Mus musculus	195-211
12633900-2	2003	We investigated the effect of CsA on the activity of acetylcholinesterase (AChE) in the frontal cortex, hippocampus, septum, and basal ganglia.	Cyclosporine	30-33	acetylcholinesterase	Rattus norvegicus	75-79
10600799-4	1999	Using a mouse model, we treated Swiss-Webster mice for 6 days with a daily dose of 20 microg/g body wt of cyclosporin and observed significant elevations of plasma cholesterol, triglyceride, and apolipoprotein B (apoB) levels relative to vehicle-alone treated control animals.	Cyclosporine	106-117	apolipoprotein B	Mus musculus	213-217
12633900-5	2003	Both lower and higher doses of CsA decreased AChE activity in the frontal cortex and hippocampus to practically the same extent.	Cyclosporine	31-34	acetylcholinesterase	Rattus norvegicus	45-49
12633900-6	2003	On the contrary, AChE activity was more diminished in the case of the higher dose of CsA used in the septum and basal ganglia.	Cyclosporine	85-88	acetylcholinesterase	Rattus norvegicus	17-21
12612437-8	2003	Therefore, induction of P-gp might also be considered in patients receiving CsA after liver transplantation for hepatocellular carcinoma and chemotherapy as an adjuvant treatment for the prevention of tumor recurrence.	Cyclosporine	76-79	phosphoglycolate phosphatase	Homo sapiens	24-28
12639820-0	2003	Cyclosporine A up-regulates expression of matrix metalloproteinase 2 and vascular endothelial growth factor in rat heart.	Cyclosporine	0-14	vascular endothelial growth factor A	Rattus norvegicus	73-107
12639820-3	2003	Since the immunosuppressive therapy induces myocardial toxicity, the aim of this study was to evaluate in the myocardium of CsA-treated rats the expression variations of vascular endothelial growth factor (VEGF) and matrix metalloproteinase 2 (MMP2), to verify if: VEGF increased, VEGF increase was associated with MMP2 increase and they could be considered as repair proteins.	Cyclosporine	124-127	vascular endothelial growth factor A	Rattus norvegicus	170-204
12639820-3	2003	Since the immunosuppressive therapy induces myocardial toxicity, the aim of this study was to evaluate in the myocardium of CsA-treated rats the expression variations of vascular endothelial growth factor (VEGF) and matrix metalloproteinase 2 (MMP2), to verify if: VEGF increased, VEGF increase was associated with MMP2 increase and they could be considered as repair proteins.	Cyclosporine	124-127	vascular endothelial growth factor A	Rattus norvegicus	206-210
12639820-3	2003	Since the immunosuppressive therapy induces myocardial toxicity, the aim of this study was to evaluate in the myocardium of CsA-treated rats the expression variations of vascular endothelial growth factor (VEGF) and matrix metalloproteinase 2 (MMP2), to verify if: VEGF increased, VEGF increase was associated with MMP2 increase and they could be considered as repair proteins.	Cyclosporine	124-127	vascular endothelial growth factor A	Rattus norvegicus	265-269
12639820-3	2003	Since the immunosuppressive therapy induces myocardial toxicity, the aim of this study was to evaluate in the myocardium of CsA-treated rats the expression variations of vascular endothelial growth factor (VEGF) and matrix metalloproteinase 2 (MMP2), to verify if: VEGF increased, VEGF increase was associated with MMP2 increase and they could be considered as repair proteins.	Cyclosporine	124-127	vascular endothelial growth factor A	Rattus norvegicus	265-269
12639820-7	2003	The group II animals (CsA-treated) showed structural degenerative changes with myocardial fibrosis and a clear increase both in MMP2 and VEGF.	Cyclosporine	22-25	vascular endothelial growth factor A	Rattus norvegicus	137-141
12589161-12	2003	CsA treatment of TOL grafts markedly reduced expression of IL-2, IL-4, and interferon-gamma compared with untreated recipients.	Cyclosporine	0-3	interleukin 2	Rattus norvegicus	59-63
12589161-12	2003	CsA treatment of TOL grafts markedly reduced expression of IL-2, IL-4, and interferon-gamma compared with untreated recipients.	Cyclosporine	0-3	interferon gamma	Rattus norvegicus	75-91
12589161-13	2003	CONCLUSIONS: CsA did not significantly inhibit liver transplant acceptance and allowed some activation of T cells and CD25 expression but almost completely inhibited IL-2 and IL-4, which are required for survival of activated T cells.	Cyclosporine	13-16	interleukin 2	Rattus norvegicus	166-170
12604310-8	2003	Cyclosporin A, which prevents TCR signaling, inhibited IFNgamma production by approximately 50%.	Cyclosporine	0-13	interleukin 18	Rattus norvegicus	55-63
12538813-7	2003	Saturable OATP2-mediated uptake of [(14)C]CER was observed and was also inhibited by CsA, with a K(i) value of 0.2 microM.	Cyclosporine	85-88	solute carrier organic anion transporter family member 1B1	Homo sapiens	10-15
12538813-8	2003	These results suggest that the DDI between CER and CsA involves the inhibition of transporter-mediated uptake of CER and, at least in part, its OATP2-mediated uptake.	Cyclosporine	51-54	solute carrier organic anion transporter family member 1B1	Homo sapiens	144-149
12538813-11	2003	From these results, we conclude that the DDI between CER and CsA is mainly due to the inhibition of transporter (at least partly OATP2)-mediated uptake in the liver.	Cyclosporine	61-64	solute carrier organic anion transporter family member 1B1	Homo sapiens	129-134
12591379-0	2003	Conversion of C-0 to C-2 monitoring of cyclosporine in stable kidney transplant patients.	Cyclosporine	39-51	complement C2	Homo sapiens	21-24
12533600-6	2003	We demonstrated that exposure of neostriatal slices to 8-bromo-cAMP, dopamine, calyculin A, or cyclosporine A, but not to 10 nM okadaic acid, promotes the phosphorylation of neostriatal InsP3R1 by PKA in vivo.	Cyclosporine	95-109	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	197-200
10678498-4	1999	Pretreatment of cyclosporin alone, but not in combination with FTY720, significantly reduced the accumulation of PMN and led to lower myeloperoxidase levels in the damaged liver.	Cyclosporine	16-27	myeloperoxidase	Rattus norvegicus	134-149
10594790-11	1999	CsA induced the expression of p53 (P &lt; 0.05) and Bax (P &lt; 0.01) and decreased that of Bcl-2 (P &lt; 0.05).	Cyclosporine	0-3	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	30-33
10594790-11	1999	CsA induced the expression of p53 (P &lt; 0.05) and Bax (P &lt; 0.01) and decreased that of Bcl-2 (P &lt; 0.05).	Cyclosporine	0-3	BCL2 associated X, apoptosis regulator	Rattus norvegicus	52-55
10573060-10	1999	Addition of IL-4 from the start of DC cultures conferred resistance to CsA-induced inhibition of NF-kappaB nuclear translocation and DC maturation.	Cyclosporine	71-74	interleukin 4	Mus musculus	12-16
10573315-5	1999	DISCUSSION: Rhabdomyolysis has been reported in patients treated with other 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors when used in combination with cyclosporine.	Cyclosporine	175-187	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	76-133
10607425-5	1999	Cyclosporin A inhibits induction of JNK function by TCR/CD28, PMA/ionomycin, ceramide, or H(2)O(2), but not induction by UV light or hyperosmolar sorbitol.	Cyclosporine	0-13	CD28 antigen	Mus musculus	56-60
10550628-10	1999	On the basis of these results and those obtained under heat and cold stresses, it is suggested that csa is directly induced by the substrate of its encoded enzyme PHGPX, and that salt induction occurs mainly via the production of reactive oxygen species and hydroperoxides.	Cyclosporine	100-103	glutathione peroxidase 4	Homo sapiens	163-168
10491310-0	1999	Cyclosporine downregulates Fas ligand expression on vascular endothelial cells: implication for accelerated vasculopathy by immunosuppressive therapy.	Cyclosporine	0-12	Fas ligand	Homo sapiens	27-37
10482841-13	1999	CONCLUSION: The differential activities of cyclosporin A and dexamethasone on inflammatory cell influx, particularly neutrophils, or cytokine expression such as IL-10 and IFN-gamma may underlie their contrasting effects on BHR.	Cyclosporine	43-56	interferon gamma	Rattus norvegicus	171-180
10486755-1	1999	The affinity capillary electrophoretic separation of the complex of the enzyme cyclophilin (Cyp) with the immunosuppressive drug cyclosporin A (CsA) from uncomplexed Cyp and CsA in phosphate buffer (pH 8) under non-denaturing conditions by equilibrium-mixture analysis is reported.	Cyclosporine	129-142	peptidylprolyl isomerase G	Homo sapiens	79-90
10486755-1	1999	The affinity capillary electrophoretic separation of the complex of the enzyme cyclophilin (Cyp) with the immunosuppressive drug cyclosporin A (CsA) from uncomplexed Cyp and CsA in phosphate buffer (pH 8) under non-denaturing conditions by equilibrium-mixture analysis is reported.	Cyclosporine	129-142	peptidylprolyl isomerase G	Homo sapiens	92-95
10486755-1	1999	The affinity capillary electrophoretic separation of the complex of the enzyme cyclophilin (Cyp) with the immunosuppressive drug cyclosporin A (CsA) from uncomplexed Cyp and CsA in phosphate buffer (pH 8) under non-denaturing conditions by equilibrium-mixture analysis is reported.	Cyclosporine	144-147	peptidylprolyl isomerase G	Homo sapiens	79-90
10486755-1	1999	The affinity capillary electrophoretic separation of the complex of the enzyme cyclophilin (Cyp) with the immunosuppressive drug cyclosporin A (CsA) from uncomplexed Cyp and CsA in phosphate buffer (pH 8) under non-denaturing conditions by equilibrium-mixture analysis is reported.	Cyclosporine	144-147	peptidylprolyl isomerase G	Homo sapiens	92-95
10486755-1	1999	The affinity capillary electrophoretic separation of the complex of the enzyme cyclophilin (Cyp) with the immunosuppressive drug cyclosporin A (CsA) from uncomplexed Cyp and CsA in phosphate buffer (pH 8) under non-denaturing conditions by equilibrium-mixture analysis is reported.	Cyclosporine	174-177	peptidylprolyl isomerase G	Homo sapiens	79-90
12393716-5	2003	Lymphotactin (Ltn), macrophage inflammatory protein (MIP)-1alpha, and MIP-1beta were all rapidly induced and sensitive to cyclosporine treatment.	Cyclosporine	122-134	C-C motif chemokine ligand 3	Homo sapiens	20-64
10428836-7	1999	The mitochondrial effects of GD3 ganglioside are selective, in that they cannot be mimicked by either GD1a or GM3 gangliosides, and they are fully sensitive to cyclosporin A, which inhibits both the mitochondrial permeability transition in situ and the onset of apoptosis induced by GD3 ganglioside.	Cyclosporine	160-173	GRDX	Homo sapiens	29-32
10428836-7	1999	The mitochondrial effects of GD3 ganglioside are selective, in that they cannot be mimicked by either GD1a or GM3 gangliosides, and they are fully sensitive to cyclosporin A, which inhibits both the mitochondrial permeability transition in situ and the onset of apoptosis induced by GD3 ganglioside.	Cyclosporine	160-173	GRDX	Homo sapiens	283-286
10419897-4	1999	However, a strong correlation was observed between the simultaneous activity of MRP1 and Pgp (quantified as the modulation of calcein-AM uptake by cyclosporin A and probenecid) and the LC50 of DNR (r =.77, P &lt;.0001).	Cyclosporine	147-160	phosphoglycolate phosphatase	Homo sapiens	89-92
10444270-0	1999	Low-density lipoproteins enhance transforming growth factor-beta 1 (TGF-beta 1) and monocyte chemotactic protein-1 (MCP-1) expression induced by cyclosporin in human mesangial cells.	Cyclosporine	145-156	C-C motif chemokine ligand 2	Homo sapiens	84-114
12393716-5	2003	Lymphotactin (Ltn), macrophage inflammatory protein (MIP)-1alpha, and MIP-1beta were all rapidly induced and sensitive to cyclosporine treatment.	Cyclosporine	122-134	C-C motif chemokine ligand 4	Homo sapiens	70-79
12795666-6	2003	Cyclosporine (CsA) microemulsion was begun on POD 1, and dosed asymmetrically at 12-h intervals to reach a daytime Cav of 650 ng/mL (utilizing 2-h and 6-h levels), while PM doses were adjusted to an AM trough of 300 ng/mL.	Cyclosporine	0-12	caveolin 2	Homo sapiens	115-118
12594849-8	2003	Cyclosporin A strongly inhibited IL-4, but not IL-10 secretion.	Cyclosporine	0-13	interleukin 4	Mus musculus	33-37
10444270-0	1999	Low-density lipoproteins enhance transforming growth factor-beta 1 (TGF-beta 1) and monocyte chemotactic protein-1 (MCP-1) expression induced by cyclosporin in human mesangial cells.	Cyclosporine	145-156	C-C motif chemokine ligand 2	Homo sapiens	116-121
10444270-4	1999	Thus, the combined effect of CsA and low-density lipoprotein (LDL) on the gene and protein expression of MCP-1 and TGF-beta 1 in cultured human mesangial cells (HMC) was explored.	Cyclosporine	29-32	C-C motif chemokine ligand 2	Homo sapiens	105-110
10444270-6	1999	The simultaneous addition of CsA and LDL did not display any additive effect on target gene expression, but it caused a synergistic effect on MCP-1 and TGF-beta 1 protein secretion into culture medium.	Cyclosporine	29-32	C-C motif chemokine ligand 2	Homo sapiens	142-147
10403741-14	1999	Cyclosporin alone also increased SMA immunoreactive cells, despite the absence of inflammatory infiltration and fairly conserved pancreatic structure.	Cyclosporine	0-11	actin alpha 2, smooth muscle	Rattus norvegicus	33-36
12351644-8	2002	Pretreatment with cyclosporin A before radiotherapy protected HepG2 cells from the therapeutic combination of GD3 plus ionizing radiation.	Cyclosporine	18-31	GRDX	Homo sapiens	110-113
12490806-0	2002	Fructose-1,6-diphosphate alone and in combination with cyclosporine potentiates rat cardiac allograft survival and inhibits lymphocyte proliferation and interleukin-2 expression.	Cyclosporine	55-67	interleukin 2	Rattus norvegicus	153-166
10439313-2	1999	Drugs including CsA are substrates of the P-glycoprotein-170 (Pgp-170) cell surface pump.	Cyclosporine	16-19	phosphoglycolate phosphatase	Homo sapiens	62-65
10439313-3	1999	Although the mechanism of action of CsA is complex, we determined that Pgp-170 might be expressed differentially between these two diseases.	Cyclosporine	36-39	phosphoglycolate phosphatase	Homo sapiens	71-74
12434394-6	2002	p-Glycoprotein (p-gp)inhibitors, such as verapamil (100 microM) and cyclosporin A (CsA, 20 microM) significantly (p &lt; 0.05) inhibited P(BA) but significantly (p &lt; 0.05) enhanced P(AB).	Cyclosporine	68-81	phosphoglycolate phosphatase	Homo sapiens	16-20
12434394-6	2002	p-Glycoprotein (p-gp)inhibitors, such as verapamil (100 microM) and cyclosporin A (CsA, 20 microM) significantly (p &lt; 0.05) inhibited P(BA) but significantly (p &lt; 0.05) enhanced P(AB).	Cyclosporine	83-86	phosphoglycolate phosphatase	Homo sapiens	16-20
12215435-7	2002	Furthermore, the DNA binding activity of the CRE-binding protein (CREB) decreases through cyclosporine treatment and this is mediated by cyclosporine-induced reduction of CREB steady-state levels.	Cyclosporine	90-102	cAMP responsive element binding protein 1	Rattus norvegicus	45-64
12215435-7	2002	Furthermore, the DNA binding activity of the CRE-binding protein (CREB) decreases through cyclosporine treatment and this is mediated by cyclosporine-induced reduction of CREB steady-state levels.	Cyclosporine	90-102	cAMP responsive element binding protein 1	Rattus norvegicus	66-70
12215435-7	2002	Furthermore, the DNA binding activity of the CRE-binding protein (CREB) decreases through cyclosporine treatment and this is mediated by cyclosporine-induced reduction of CREB steady-state levels.	Cyclosporine	90-102	cAMP responsive element binding protein 1	Rattus norvegicus	171-175
12215435-7	2002	Furthermore, the DNA binding activity of the CRE-binding protein (CREB) decreases through cyclosporine treatment and this is mediated by cyclosporine-induced reduction of CREB steady-state levels.	Cyclosporine	137-149	cAMP responsive element binding protein 1	Rattus norvegicus	45-64
12215435-7	2002	Furthermore, the DNA binding activity of the CRE-binding protein (CREB) decreases through cyclosporine treatment and this is mediated by cyclosporine-induced reduction of CREB steady-state levels.	Cyclosporine	137-149	cAMP responsive element binding protein 1	Rattus norvegicus	66-70
12215435-7	2002	Furthermore, the DNA binding activity of the CRE-binding protein (CREB) decreases through cyclosporine treatment and this is mediated by cyclosporine-induced reduction of CREB steady-state levels.	Cyclosporine	137-149	cAMP responsive element binding protein 1	Rattus norvegicus	171-175
12215435-8	2002	These results demonstrate that cyclosporine can inhibit proliferation of acinar cells by targeting the cyclin D1 promoter at the proximal CRE via a reduction of CREB protein abundance.	Cyclosporine	31-43	cAMP responsive element binding protein 1	Rattus norvegicus	161-165
12409674-6	2002	RESULTS: Cyclosporine, tacrolimus, and anti-IL-2R monoclonal antibody therapy abrogated the effect of a single-dose protocol of anti-CD154 therapy.	Cyclosporine	9-21	CD40 ligand	Mus musculus	133-138
12512145-10	2002	CsA markedly upregulated the expression of chemoattractant proteins, osteopontin and monocyte chemoattractant protein-1, concomitantly.	Cyclosporine	0-3	C-C motif chemokine ligand 2	Rattus norvegicus	85-119
12698985-3	2002	MATERIALS AND METHODS: We chose 3 model drugs that are metabolized by distinct cytochrome P450 (CYP) isoforms (theophylline, phenytoin and cyclosporine for CYPIA2, CYP2C9/2C19 and CYP3A4, respectively).	Cyclosporine	139-151	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	156-162
12698985-3	2002	MATERIALS AND METHODS: We chose 3 model drugs that are metabolized by distinct cytochrome P450 (CYP) isoforms (theophylline, phenytoin and cyclosporine for CYPIA2, CYP2C9/2C19 and CYP3A4, respectively).	Cyclosporine	139-151	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	164-170
12429717-5	2002	However, TNF-alpha-induced DC maturation was affected, as CsA-treated DC expressed lower levels of human leukocyte antigen and costimulatory molecules but sustained levels of CD1a, and less DC expressed DC-lysosomal-associated-membrane-protein (LAMP) and CD83.	Cyclosporine	58-61	CD83 molecule	Homo sapiens	255-259
12154086-8	2002	Compared with cyclophilin 18, the enzymatic activity carried by the PPIase domain of Moca-cyp is low, exhibits characteristic substrate specificity, and shows a reduced sensitivity to the drug cyclosporin A (CsA).	Cyclosporine	193-206	Moca-cyp	Drosophila melanogaster	85-93
12154086-8	2002	Compared with cyclophilin 18, the enzymatic activity carried by the PPIase domain of Moca-cyp is low, exhibits characteristic substrate specificity, and shows a reduced sensitivity to the drug cyclosporin A (CsA).	Cyclosporine	208-211	Moca-cyp	Drosophila melanogaster	85-93
12361387-2	2002	By use of photoaffinity-labeled cyclosporins and membranes from Pgp-expressing cells, it was recently shown that in vitro, Pgp molecules could bind a large cyclosporin domain involving residues 4-9 as well as the side chain of residue 1.	Cyclosporine	32-43	phosphoglycolate phosphatase	Homo sapiens	123-126
12361387-3	2002	Tumor cell MDR can also be reversed by a product more distantly related to cyclosporin with the structure [Thr(2), Leu(5), D-Hiv(8), Leu(10)]-CsA (SDZ 214-103).	Cyclosporine	75-86	tripartite motif containing 13	Homo sapiens	115-120
12361387-6	2002	Our SAR are compatible with the in vitro-defined Pgp binding domain model and further disclose that in vivo Pgp inhibition is favored by larger hydrophobic side chains on cyclosporin residues 1, 4, 6, and 8 and a smaller one on residue 7, although with no effect on the residue 5 side chain; moreover, larger hydrophobic side chains on other residues 2, 3, 10, and 11 (outside the in vitro-defined Pgp binding domain) also favor the eventual inhibition of Pgp function.	Cyclosporine	171-182	phosphoglycolate phosphatase	Homo sapiens	49-52
12361387-6	2002	Our SAR are compatible with the in vitro-defined Pgp binding domain model and further disclose that in vivo Pgp inhibition is favored by larger hydrophobic side chains on cyclosporin residues 1, 4, 6, and 8 and a smaller one on residue 7, although with no effect on the residue 5 side chain; moreover, larger hydrophobic side chains on other residues 2, 3, 10, and 11 (outside the in vitro-defined Pgp binding domain) also favor the eventual inhibition of Pgp function.	Cyclosporine	171-182	phosphoglycolate phosphatase	Homo sapiens	108-111
12361387-6	2002	Our SAR are compatible with the in vitro-defined Pgp binding domain model and further disclose that in vivo Pgp inhibition is favored by larger hydrophobic side chains on cyclosporin residues 1, 4, 6, and 8 and a smaller one on residue 7, although with no effect on the residue 5 side chain; moreover, larger hydrophobic side chains on other residues 2, 3, 10, and 11 (outside the in vitro-defined Pgp binding domain) also favor the eventual inhibition of Pgp function.	Cyclosporine	171-182	phosphoglycolate phosphatase	Homo sapiens	108-111
12361387-6	2002	Our SAR are compatible with the in vitro-defined Pgp binding domain model and further disclose that in vivo Pgp inhibition is favored by larger hydrophobic side chains on cyclosporin residues 1, 4, 6, and 8 and a smaller one on residue 7, although with no effect on the residue 5 side chain; moreover, larger hydrophobic side chains on other residues 2, 3, 10, and 11 (outside the in vitro-defined Pgp binding domain) also favor the eventual inhibition of Pgp function.	Cyclosporine	171-182	phosphoglycolate phosphatase	Homo sapiens	108-111
12361387-10	2002	Because CsA and SDZ 214-103 show largely different conformations when free in solution, but remarkably similar ones when bound to the cytosolic cyclophilins, SAR for Pgp inhibition must similarly include requirements for occurrence of suitable conformers for insertion in the cell membrane, sufficient conformational plasticity for gaining access to Pgp binding sites, and an adequate conformer structure there to achieve such binding with a high enough affinity and possibly escape from sequestration on cyclophilins.	Cyclosporine	8-11	phosphoglycolate phosphatase	Homo sapiens	166-169
12135707-4	2002	Preincubation of pNFAT-TA-Luc-transfected cells with cyclosporine A (0.1 microM) and FK506 (0.01 microM) abrogated the gal-1-induced expression of the reporter luciferase (Luc).	Cyclosporine	53-67	galectin 1	Homo sapiens	119-124
12352326-7	2002	At baseline, in cyclosporine-and tacrolimus-treated patients, p22 and TGF-beta mRNA were similarly increased in comparison with normotensive healthy controls (0.90 +/- 0.05 d.u.	Cyclosporine	16-28	calcineurin like EF-hand protein 1	Homo sapiens	62-65
12352326-9	2002	Endothelial NOS mRNA was increased in cyclosporine-and tacrolimus-treated patients in comparison with controls (0.92 +/- 0.09, 0.96 +/- 0.04, and 0.37 +/- 0.05 respectively; p &lt; 0.001), whereas no difference was found between patients and controls in HO-1 mRNA.	Cyclosporine	38-50	heme oxygenase 1	Homo sapiens	254-258
12352326-11	2002	Ramipril also reduced p22 (to 0.83 +/- 0.05 in cyclosporine, p &lt; 0.03 and to 0.81 +/- 0.08 in tacrolimus; p &lt; 0.01) and TGF-beta mRNA (to 0.72 +/- 01 in cyclosporine, p &lt; 0.02, and to 0.73 +/- 0.05 in tacrolimus; p &lt; 0.01) with no difference between groups, but it did not change HO-1 and ecNOS mRNA.	Cyclosporine	47-59	calcineurin like EF-hand protein 1	Homo sapiens	22-25
12351666-0	2002	Keratinocyte growth factor receptor is up-regulated in cyclosporin A-induced gingival hyperplasia.	Cyclosporine	55-68	fibroblast growth factor receptor 2	Homo sapiens	0-35
12244165-4	2002	We find that in the presence but not the absence of EC, NFAT1 can be detected in the nuclei of CsA-treated T cells within 8 h of triggering, reaching a maximal level of 60% of control by 24 h. Glycogen synthase kinase-3beta (GSK-3beta), which rephosphorylates NFAT and promotes nuclear export, is inhibited by EC costimulation.	Cyclosporine	95-98	nuclear factor of activated T cells 2	Homo sapiens	56-61
12234299-9	2002	Thirdly, triptolide (4 to 8 ng/mL), CsA (500 to 2500 ng/mL) and FK506 (1250 ng/mL) inhibited up-regulation of CD40 and B7h mRNA, the effect on B7h and CD40 mRNA expression by CsA and FK506 being greater than that on C3 mRNA expression.	Cyclosporine	36-39	CD274 molecule	Homo sapiens	119-122
12234299-9	2002	Thirdly, triptolide (4 to 8 ng/mL), CsA (500 to 2500 ng/mL) and FK506 (1250 ng/mL) inhibited up-regulation of CD40 and B7h mRNA, the effect on B7h and CD40 mRNA expression by CsA and FK506 being greater than that on C3 mRNA expression.	Cyclosporine	36-39	CD274 molecule	Homo sapiens	143-146
12234299-9	2002	Thirdly, triptolide (4 to 8 ng/mL), CsA (500 to 2500 ng/mL) and FK506 (1250 ng/mL) inhibited up-regulation of CD40 and B7h mRNA, the effect on B7h and CD40 mRNA expression by CsA and FK506 being greater than that on C3 mRNA expression.	Cyclosporine	175-178	CD274 molecule	Homo sapiens	119-122
12376814-10	2002	C4 and/or C1q were present on the initial biopsy in one patient with CsA dependence as compared to six of nine with secondary CsA resistance ( P=0.02).	Cyclosporine	69-72	complement C1q A chain	Homo sapiens	10-13
12376814-12	2002	We conclude that the presence of FSGS, or of C4 and/or C1q, appears to increase the risk of secondary CsA resistance and some of these children rapidly progress to ESRD.	Cyclosporine	102-105	complement C1q A chain	Homo sapiens	55-58
12389075-7	2002	Unsurprisingly, both cyclosporin A and tacrolimus significantly inhibited IL-2 and IL-2Rbeta at both time points.	Cyclosporine	21-34	interleukin 2	Rattus norvegicus	74-78
12110686-5	2002	CsA significantly increased leukocyte binding to activated HIMEC, but paradoxically decreased endothelial expression of cell adhesion molecules (E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule-1).	Cyclosporine	0-3	selectin E	Homo sapiens	145-155
12009308-3	2002	2,4-Diamino-6-hydroxypyrimidine, an inhibitor of GTP cyclohydrolase I, strongly reduced the CsA-induced increase in BH4 content.	Cyclosporine	92-95	GTP cyclohydrolase 1	Mus musculus	49-69
12009308-5	2002	These findings suggest that CsA stimulates BH4 synthesis via a de novo pathway with the induction of GTP cyclohydrolase I.	Cyclosporine	28-31	GTP cyclohydrolase 1	Mus musculus	101-121
12009308-7	2002	The CsA-stimulated L-citrulline formation was attenuated by the co-treatment with GTP cyclohydrolase I inhibitor.	Cyclosporine	4-7	GTP cyclohydrolase 1	Mus musculus	82-102
12218939-1	2002	BACKGROUND: The purpose of our study was to determine the antileukemic effects of cyclosporin A (CsA) and its interaction with a new purine analogue, 2-chlorodeoxyadenosine (2-CdA, cladribine) on P388 murine leukemia in vivo.	Cyclosporine	97-100	cytidine deaminase	Mus musculus	176-179
12198207-11	2002	CsA (500 ng/ml) also enhanced the production of FN (1.6-fold, P&lt;0.05) and PAI-1 (2.0-fold, P&lt;0.05).	Cyclosporine	0-3	serpin family E member 2	Rattus norvegicus	77-82
12198207-12	2002	Co-incubation with neutralizing anti-TGF-beta1 antibodies reduced (P&lt;0.05) CsA-induced expression of TbetaR-I (1.0+/-0.1-fold), TbetaR-II (1.3+/-0.1-fold) and PAI-1 (1.3-fold), but not FN production (1.6-fold).	Cyclosporine	78-81	serpin family E member 2	Rattus norvegicus	162-167
12165512-4	2002	The most conserved sequence lies 4.5 kb upstream of the IL-3 gene and it encompassed an inducible cyclosporin A-sensitive DH site.	Cyclosporine	98-111	interleukin 3	Homo sapiens	56-60
12110003-0	2002	Angiotensin II regulation of vascular endothelial growth factor and receptors Flt-1 and KDR/Flk-1 in cyclosporine nephrotoxicity.	Cyclosporine	101-113	kinase insert domain receptor	Rattus norvegicus	88-91
12110003-0	2002	Angiotensin II regulation of vascular endothelial growth factor and receptors Flt-1 and KDR/Flk-1 in cyclosporine nephrotoxicity.	Cyclosporine	101-113	kinase insert domain receptor	Rattus norvegicus	92-97
12110003-3	2002	We have previously shown that VEGF is up-regulated in a chronic cyclosporine (CsA) nephrotoxicity model.	Cyclosporine	64-76	vascular endothelial growth factor A	Rattus norvegicus	30-34
12110003-3	2002	We have previously shown that VEGF is up-regulated in a chronic cyclosporine (CsA) nephrotoxicity model.	Cyclosporine	78-81	vascular endothelial growth factor A	Rattus norvegicus	30-34
12110003-8	2002	VEGF mRNA and protein expressions increased with CsA and became significantly reduced with Ang II blockade.	Cyclosporine	49-52	vascular endothelial growth factor A	Rattus norvegicus	0-4
12123745-8	2002	We conclude that in rat hepatocyte cultures, CsA induces the transcriptional activation of NF-kappaB, AP-1, and HSF1.	Cyclosporine	45-48	heat shock transcription factor 1	Rattus norvegicus	112-116
12123745-10	2002	Thus, at 22 hr of incubation, the CsA-induced activation of HSF1 is accompanied by the reduction of the positive effect of CsA on NF-kappaB activation at earlier time points.	Cyclosporine	34-37	heat shock transcription factor 1	Rattus norvegicus	60-64
12123745-10	2002	Thus, at 22 hr of incubation, the CsA-induced activation of HSF1 is accompanied by the reduction of the positive effect of CsA on NF-kappaB activation at earlier time points.	Cyclosporine	123-126	heat shock transcription factor 1	Rattus norvegicus	60-64
12135671-11	2002	Moreover, cyclosporin A, which is known to modulate NFAT activation, reduced CTLA-4 protein expression in adult and UCB T cells.	Cyclosporine	10-23	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	77-83
12081598-0	2002	Osteopontin in cyclosporine toxicity.	Cyclosporine	15-27	secreted phosphoprotein 1	Homo sapiens	0-11
12374046-8	2002	The immunological changes in AD patients treated with cyclosporine include eosinophil count reduction, besides lower levels of E-selectin, and soluble CD30 (known as disease markers), but overall, it corrects the imbalance between Th1 and Th2 response present in these kinds of diseases.	Cyclosporine	54-66	selectin E	Homo sapiens	127-137
12181799-7	2002	Under the combination of CsA and CTLA4Ig, the mean survival time was significantly prolonged to (28.8 +/- 3.5) days (P &lt; 0.05) with the lowest level of IL-2 in serum of recipients.	Cyclosporine	25-28	interleukin 2	Rattus norvegicus	155-159
10466081-5	1999	These findings let us hypothesize that when there are lower concentrations of CsA in lymphocytes there is an increase of cellular metabolism induced by Glyburide that leads to an increase in IL-2 secretion and in IL-2 receptor expression on cellular surface restoring these levels to normal or slightly above normal levels.	Cyclosporine	78-81	interleukin 2	Rattus norvegicus	191-195
10466081-5	1999	These findings let us hypothesize that when there are lower concentrations of CsA in lymphocytes there is an increase of cellular metabolism induced by Glyburide that leads to an increase in IL-2 secretion and in IL-2 receptor expression on cellular surface restoring these levels to normal or slightly above normal levels.	Cyclosporine	78-81	interleukin 2	Rattus norvegicus	213-217
11943775-1	2002	Cyclophilin A (CyPA), a ubiquitously distributed intracellular protein, is a peptidylprolyl cis-trans-isomerase and the major target of the potent immunosuppressive drug cyclosporin A.	Cyclosporine	170-183	peptidylprolyl isomerase A	Homo sapiens	15-19
12066135-8	2002	The decreased expression of Bcl-2 and the ratio of Bcl-2 to Bax protein seen in cyclosporine-treated rat kidneys were significantly increased after colchicine treatment, accompanying a suppression of caspase-3 activity (P &lt;.05).	Cyclosporine	80-92	BCL2 associated X, apoptosis regulator	Rattus norvegicus	60-63
12134947-6	2002	The substrate activity of AD for MRP2 was determined by using cyclosporin A, a known MRP2 and P-gp inhibitor.	Cyclosporine	62-75	PGP	Canis lupus familiaris	94-98
12134948-8	2002	The substrate activity of CD for MRP2 was determined by using cyclosporin A (CsA), a known MRP2 and P-gp inhibitor.	Cyclosporine	62-75	PGP	Canis lupus familiaris	100-104
12134948-8	2002	The substrate activity of CD for MRP2 was determined by using cyclosporin A (CsA), a known MRP2 and P-gp inhibitor.	Cyclosporine	77-80	PGP	Canis lupus familiaris	100-104
11966513-0	2002	P-glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes.	Cyclosporine	65-76	phosphoglycolate phosphatase	Homo sapiens	0-18
11966513-1	2002	AIM: To assess the role of P-glycoprotein-170 (P-gp) in transporting cortisol and ciclosporin from human intestinal epithelium and T lymphocytes.	Cyclosporine	82-93	phosphoglycolate phosphatase	Homo sapiens	27-45
11966513-1	2002	AIM: To assess the role of P-glycoprotein-170 (P-gp) in transporting cortisol and ciclosporin from human intestinal epithelium and T lymphocytes.	Cyclosporine	82-93	phosphoglycolate phosphatase	Homo sapiens	47-51
11966513-8	2002	CONCLUSIONS: P-gp inhibitors significantly increase intracellular cortisol and ciclosporin levels in human intestinal epithelium and T lymphocytes in a dose-dependent manner, demonstrating a potential mechanism for overcoming poor response to immunosuppressant therapy in refractory inflammatory bowel disease.	Cyclosporine	79-90	phosphoglycolate phosphatase	Homo sapiens	13-17
12123203-10	2002	Levels of p53 protein also increased in the CsA group.	Cyclosporine	44-47	transformation related protein 53, pseudogene	Mus musculus	10-13
11827957-0	2002	Tumor suppressor p53 mediates apoptotic cell death triggered by cyclosporin A.	Cyclosporine	64-77	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	17-20
11827957-3	2002	We report that CsA treatment results in increased level of the p53 tumor suppressor, its nuclear accumulation, and transcriptional activation of p53-dependent genes.	Cyclosporine	15-18	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	63-66
11827957-3	2002	We report that CsA treatment results in increased level of the p53 tumor suppressor, its nuclear accumulation, and transcriptional activation of p53-dependent genes.	Cyclosporine	15-18	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	145-148
11827957-6	2002	Importantly, we demonstrate that glioma cells stably transfected with a mutant p53 (p53Val135) fail to increase p21 and Bax protein levels and are less sensitive to CsA-induced apoptosis.	Cyclosporine	165-168	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	79-82
11827957-7	2002	Furthermore, primary fibroblasts from p53-/- knockout mice are significantly more resistant to CsA-induced apoptosis compared with their corresponding counterparts containing functional p53.	Cyclosporine	95-98	transformation related protein 53, pseudogene	Mus musculus	38-41
11827957-8	2002	Together, our results suggest that the apoptotic program activated by CsA can be mediated by activation of p53 tumor suppressor and potentiation of its ability to initiate apoptosis.	Cyclosporine	70-73	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	107-110
12169208-5	2002	The induction of Adss1 gene expression was blocked by cyclosporin A in vitro, suggesting that calcineurin, a calmodulin activated phosphatase, is involved in this signaling pathway.	Cyclosporine	54-67	adenylosuccinate synthase 1	Rattus norvegicus	17-22
11836403-4	2002	Preventing CypA incorporation, either by mutations in the binding region of CA or by the presence of CsA, abrogates virus infectivity.	Cyclosporine	101-104	peptidylprolyl isomerase A	Homo sapiens	11-15
11843663-0	2002	Response to cyclosporine in a patient with disseminated granuloma annulare associated with CD4+/CD8+(dim)/CD56+ large granular lymphocytic leukemia.	Cyclosporine	12-24	neural cell adhesion molecule 1	Homo sapiens	106-110
12064514-7	2002	Recombinant calcineurin introduced into cells that have previously been treated with okadaic acid and cyclosporin A, which are inhibitors of phosphatases (PP1/PP2A and PP2B), has a direct effect on the phosphorylation status on all phosphorylation sites studied.	Cyclosporine	102-115	protein phosphatase 2 phosphatase activator	Homo sapiens	159-163
11869045-7	2002	We conclude that the relative presence of autoregulatory T cells with a CD45RClow T-helper cell phenotype may be a critical determinant in susceptibility to CsA-AI.	Cyclosporine	157-160	protein tyrosine phosphatase, receptor type, C	Rattus norvegicus	72-76
11818450-0	2002	Cyclosporin A inhibition of macrophage colony-stimulating factor (M-CSF) production by activated human T lymphocytes.	Cyclosporine	0-13	colony stimulating factor 1	Homo sapiens	28-64
11818450-0	2002	Cyclosporin A inhibition of macrophage colony-stimulating factor (M-CSF) production by activated human T lymphocytes.	Cyclosporine	0-13	colony stimulating factor 1	Homo sapiens	66-71
11856485-4	2002	The K(i) values for P-gp of cyclosporine and verapamil were 1.09 and 540 microM, respectively, and that of bromocriptine was 6.52 microM in a calcein-AM efflux assay using porcine kidney epithelial LLC-PK1 and L-MDR1 cells, overexpressing human P-gp.	Cyclosporine	28-40	phosphoglycolate phosphatase	Homo sapiens	20-24
11856485-4	2002	The K(i) values for P-gp of cyclosporine and verapamil were 1.09 and 540 microM, respectively, and that of bromocriptine was 6.52 microM in a calcein-AM efflux assay using porcine kidney epithelial LLC-PK1 and L-MDR1 cells, overexpressing human P-gp.	Cyclosporine	28-40	ATP-binding cassette, sub-family B (MDR/TAP), member 1	Sus scrofa	212-216
11856485-4	2002	The K(i) values for P-gp of cyclosporine and verapamil were 1.09 and 540 microM, respectively, and that of bromocriptine was 6.52 microM in a calcein-AM efflux assay using porcine kidney epithelial LLC-PK1 and L-MDR1 cells, overexpressing human P-gp.	Cyclosporine	28-40	phosphoglycolate phosphatase	Homo sapiens	245-249
11755317-0	2002	Atrial natriuretic peptide reduces cyclosporin toxicity in renal cells: role of cGMP and heme oxygenase-1.	Cyclosporine	35-46	natriuretic peptides A	Sus scrofa	0-26
11755317-1	2002	Using cultured proximal renal tubular epithelial cells (LLC-PK1), the present study investigates the effect of atrial natriuretic peptide (ANP) on cytotoxicity induced by cyclosporin A (CsA).	Cyclosporine	171-184	natriuretic peptides A	Sus scrofa	111-137
11786111-10	2002	1,25DHC and low-dose CsA both decreased interleukin (IL)-2 and IL-12 expression levels in serum and allografts, and a combination treatment produced the strongest attenuation of IL-2 and IL-12 expression.	Cyclosporine	21-24	interleukin 12B	Rattus norvegicus	63-68
11786111-10	2002	1,25DHC and low-dose CsA both decreased interleukin (IL)-2 and IL-12 expression levels in serum and allografts, and a combination treatment produced the strongest attenuation of IL-2 and IL-12 expression.	Cyclosporine	21-24	interleukin 2	Rattus norvegicus	178-182
11786111-10	2002	1,25DHC and low-dose CsA both decreased interleukin (IL)-2 and IL-12 expression levels in serum and allografts, and a combination treatment produced the strongest attenuation of IL-2 and IL-12 expression.	Cyclosporine	21-24	interleukin 12B	Rattus norvegicus	187-192
11786111-12	2002	In contrast, combination of 1,25DHC and low-dose CsA showed a significant increase in IL-10 expression levels whereas IL-4 expression was not elevated.	Cyclosporine	49-52	interleukin 10	Rattus norvegicus	86-91
11641409-9	2001	The cyclosporin A binding pocket is important for Cpr1p function, since cyclosporin A binding-deficient mutants failed to complement FBPase import in Deltacpr1 and Deltavid22 mutants.	Cyclosporine	4-17	peptidylprolyl isomerase CPR1	Saccharomyces cerevisiae S288C	50-55
11641409-9	2001	The cyclosporin A binding pocket is important for Cpr1p function, since cyclosporin A binding-deficient mutants failed to complement FBPase import in Deltacpr1 and Deltavid22 mutants.	Cyclosporine	72-85	peptidylprolyl isomerase CPR1	Saccharomyces cerevisiae S288C	50-55
11740384-11	2001	CONCLUSIONS: Pretreatment with low-dose CsA or FK506 prevents subsequent I/R injury, and this effect may be related to the induction of hsp70.	Cyclosporine	40-43	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	136-141
11704825-5	2001	Surprisingly, cyclosporin A (CsA), a known inhibitor of the mitochondrial permeability transition (MPT) pore, inhibited beta(2)m-induced apoptosis in HL-60/ADR cells but not in HL-60 and HL-60/VCR cells, suggesting that the pro-apoptotic effect of beta(2)m in these cells is not through MPT pore formation.	Cyclosporine	14-27	beta-2-microglobulin	Homo sapiens	120-128
11704825-5	2001	Surprisingly, cyclosporin A (CsA), a known inhibitor of the mitochondrial permeability transition (MPT) pore, inhibited beta(2)m-induced apoptosis in HL-60/ADR cells but not in HL-60 and HL-60/VCR cells, suggesting that the pro-apoptotic effect of beta(2)m in these cells is not through MPT pore formation.	Cyclosporine	14-27	beta-2-microglobulin	Homo sapiens	248-256
11704825-5	2001	Surprisingly, cyclosporin A (CsA), a known inhibitor of the mitochondrial permeability transition (MPT) pore, inhibited beta(2)m-induced apoptosis in HL-60/ADR cells but not in HL-60 and HL-60/VCR cells, suggesting that the pro-apoptotic effect of beta(2)m in these cells is not through MPT pore formation.	Cyclosporine	29-32	beta-2-microglobulin	Homo sapiens	120-128
11704825-5	2001	Surprisingly, cyclosporin A (CsA), a known inhibitor of the mitochondrial permeability transition (MPT) pore, inhibited beta(2)m-induced apoptosis in HL-60/ADR cells but not in HL-60 and HL-60/VCR cells, suggesting that the pro-apoptotic effect of beta(2)m in these cells is not through MPT pore formation.	Cyclosporine	29-32	beta-2-microglobulin	Homo sapiens	248-256
11758901-7	2001	Moreover, the reduction of OVA-induced antibody production in serum of the cyclosporin A (CyA) -treated rats can be significantly restored and the IL-2 generation in murine splenocytes was stimulated, following oral administrations of Rooibos tea extract.	Cyclosporine	75-88	interleukin 2	Rattus norvegicus	147-151
11758901-7	2001	Moreover, the reduction of OVA-induced antibody production in serum of the cyclosporin A (CyA) -treated rats can be significantly restored and the IL-2 generation in murine splenocytes was stimulated, following oral administrations of Rooibos tea extract.	Cyclosporine	90-93	interleukin 2	Rattus norvegicus	147-151
11438525-11	2001	Electrophoretic mobility shift experiments with primary Th (T helper) cells showed the formation of a specific, T-cell receptor-inducible complex at this site that is sensitive to cyclosporin A and supershifted with anti-NFATc2 in both Th1 and Th2 cells.	Cyclosporine	180-193	nuclear factor of activated T cells 2	Homo sapiens	221-227
11420061-1	2001	Cyclosporin A (CyA) is a cyclic peptide used as an immunosuppressive agent because it can block the synthesis of interleukin-2 and other cytokines produced by CD4+ lymphocytes.	Cyclosporine	0-13	interleukin 2	Rattus norvegicus	113-126
11509642-3	2001	Although activation-induced FasL-mediated cytotoxicity in control T cells was sensitive to the immunosuppressant cyclosporin A, we observed that functional FasL expression of GVHD T cells became increasingly cyclosporin A unresponsive.	Cyclosporine	113-126	Fas ligand	Homo sapiens	28-32
11509642-3	2001	Although activation-induced FasL-mediated cytotoxicity in control T cells was sensitive to the immunosuppressant cyclosporin A, we observed that functional FasL expression of GVHD T cells became increasingly cyclosporin A unresponsive.	Cyclosporine	208-221	Fas ligand	Homo sapiens	28-32
11778653-9	2001	CsA also downregulated the surface expression of FasL in activated T cells.	Cyclosporine	0-3	Fas ligand	Homo sapiens	49-53
11473646-0	2001	Osteopontin expression in human cyclosporine toxicity.	Cyclosporine	32-44	secreted phosphoprotein 1	Homo sapiens	0-11
11473646-6	2001	In the biopsies with cyclosporine toxicity, osteopontin expression was widespread and demonstrated moderate immunohistochemical signal intensity that did not correlate with the number of interstitial macrophages present.	Cyclosporine	21-33	secreted phosphoprotein 1	Homo sapiens	44-55
11473646-7	2001	CONCLUSIONS: Strong osteopontin protein and mRNA expression by tubular epithelium was observed in pretransplant donor biopsies and in biopsies with cyclosporine toxicity without an inflammatory cell infiltration.	Cyclosporine	148-160	secreted phosphoprotein 1	Homo sapiens	20-31
11345389-12	2001	Compared with the control group, 1) histological scores were significantly lower in the FTY group but unchanged in the CsA group; 2) virus concentration was significantly higher in the CsA group but not in the FTY group; 3) expressions of IL-2, IL-12 and IFN-gamma in the heart were suppressed in both the FTY and CsA groups, though suppression was weaker in the FTY group; 4) TNF-alpha and NO were significantly increased in the CsA group but not in the FTY group.	Cyclosporine	185-188	interleukin 2	Mus musculus	239-243
11345389-12	2001	Compared with the control group, 1) histological scores were significantly lower in the FTY group but unchanged in the CsA group; 2) virus concentration was significantly higher in the CsA group but not in the FTY group; 3) expressions of IL-2, IL-12 and IFN-gamma in the heart were suppressed in both the FTY and CsA groups, though suppression was weaker in the FTY group; 4) TNF-alpha and NO were significantly increased in the CsA group but not in the FTY group.	Cyclosporine	185-188	interleukin 2	Mus musculus	239-243
11345389-12	2001	Compared with the control group, 1) histological scores were significantly lower in the FTY group but unchanged in the CsA group; 2) virus concentration was significantly higher in the CsA group but not in the FTY group; 3) expressions of IL-2, IL-12 and IFN-gamma in the heart were suppressed in both the FTY and CsA groups, though suppression was weaker in the FTY group; 4) TNF-alpha and NO were significantly increased in the CsA group but not in the FTY group.	Cyclosporine	185-188	interleukin 2	Mus musculus	239-243
10405334-4	1999	Treatment with cyclosporin A (CSA), which facilitates closure of the mitochondrial permeability transition pore (PTP), was able to reverse the decrease in DeltaPsi(M) in pre-apoptotic PC12 cells but not in the senescent EJ-p53 cells.	Cyclosporine	15-28	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	223-226
11313484-5	2001	These alterations are suppressed by cyclosporine and are not observed in cell lines that express a mutant MLL protein without PHD fingers.	Cyclosporine	36-48	lysine methyltransferase 2A	Homo sapiens	106-109
10405334-4	1999	Treatment with cyclosporin A (CSA), which facilitates closure of the mitochondrial permeability transition pore (PTP), was able to reverse the decrease in DeltaPsi(M) in pre-apoptotic PC12 cells but not in the senescent EJ-p53 cells.	Cyclosporine	30-33	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	223-226
10466441-0	1999	Granulocyte colony-stimulating factor-supported combined immunosuppressive therapy (antilymphocyte globulin, cyclosporine, and methylprednisolone) in patients with aplastic anemia: tolerability, efficacy, and changes in the progenitor cell compartment.	Cyclosporine	109-121	colony stimulating factor 3	Homo sapiens	0-37
11160247-5	2001	We have previously reported that CD95L expression requires both protein kinase C (PKC) translocation and Ca2+ mobilization and is inhibited by cyclosporin A, and dexamethasone.	Cyclosporine	143-156	Fas ligand	Homo sapiens	33-38
10384103-7	1999	Calcineurin antagonists cyclosporin A and the FK-506 analogue, ascomycin, diminished costimulatory molecule and CD83 expression, as well as formation of dendritic processes in CI-treated myeloid cells, and strongly attenuated the T cell allosensitizing capacity of CI-treated HL-60 cells.	Cyclosporine	24-37	CD83 molecule	Homo sapiens	112-116
11455576-3	2001	In fact, during treatment and after withdrawal, CY-treated animals remained euglycemic, showed good islet cell preservation and had low levels of Th1 and Th2 cytokines; ICAM-1 positivity within the islets was also found to be relatively low.	Cyclosporine	48-50	heart and neural crest derivatives expressed 2	Mus musculus	154-157
10382954-6	1999	Additional studies have shown that HC and CsA blocked con A-driven differentiation of CD8+ and CD4+ CD8+ lymph node cells (LNC) and progression of LNC to S + G2/M cell cycle phases, and inhibited IL-1, IL-2 and TGF-beta while enhancing GM-CSF gene expression in BM cells.	Cyclosporine	42-45	interleukin 2	Mus musculus	202-206
11134290-10	2001	Activation was dependent on nuclear factor of activated T cells (NFAT), occurred in cells deficient in the tyrosine kinase p56(lck), and could be blocked by addition of cyclosporin A and by depletion of calcium.	Cyclosporine	169-182	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	127-130
11135579-6	2001	In addition, treatment with cyclosporin A blocks anti-CD45RB-induced CTLA-4 expression and promotes acute rejection.	Cyclosporine	28-41	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	69-75
11516824-6	2001	Phosphorylation of CREB was kept augmented throughout the time course examined in cyclosporin A-treated animals, while it ceased without cyclosporin A.	Cyclosporine	82-95	cAMP responsive element binding protein 1	Rattus norvegicus	19-23
11516824-7	2001	Reverse transcription-polymerase chain reaction revealed prolonged maintenance of BDNF mRNA expression in the CA1 sector of cyclosporin A-treated animals.	Cyclosporine	124-137	carbonic anhydrase 1	Rattus norvegicus	110-113
11516824-9	2001	The mechanisms by which cyclosporin A protects the CA1 region from neuronal cell death in forebrain ischemia may involve the interaction of pCREB, BDNF and TrkB.	Cyclosporine	24-37	carbonic anhydrase 1	Rattus norvegicus	51-54
11108662-4	2000	Inhibition of MRP2-mediated efflux activity by sulfinpyrazone or cyclosporin A completely reversed GSTP1-1-associated resistance-a result indicating that GSTP1-1-mediated cytoprotection is absolutely dependent on MRP2 efflux activity.	Cyclosporine	65-78	glutathione S-transferase pi 1	Homo sapiens	99-106
11108662-4	2000	Inhibition of MRP2-mediated efflux activity by sulfinpyrazone or cyclosporin A completely reversed GSTP1-1-associated resistance-a result indicating that GSTP1-1-mediated cytoprotection is absolutely dependent on MRP2 efflux activity.	Cyclosporine	65-78	glutathione S-transferase pi 1	Homo sapiens	154-161
11023705-12	2000	These results indicate that CsA impairs the guanylyl cyclase activity mainly in the glomerulus by the decrease in NPR population and/or by direct inhibition, suggesting that the ANP/NPR system might be involved in CsA-induced nephrotoxicity.	Cyclosporine	28-31	neuronal pentraxin receptor	Rattus norvegicus	114-117
11023705-12	2000	These results indicate that CsA impairs the guanylyl cyclase activity mainly in the glomerulus by the decrease in NPR population and/or by direct inhibition, suggesting that the ANP/NPR system might be involved in CsA-induced nephrotoxicity.	Cyclosporine	28-31	neuronal pentraxin receptor	Rattus norvegicus	182-185
11023705-12	2000	These results indicate that CsA impairs the guanylyl cyclase activity mainly in the glomerulus by the decrease in NPR population and/or by direct inhibition, suggesting that the ANP/NPR system might be involved in CsA-induced nephrotoxicity.	Cyclosporine	214-217	neuronal pentraxin receptor	Rattus norvegicus	182-185
11059862-0	2000	HSP70 induction by cyclosporine A in cultured rat hepatocytes: effect of vitamin E succinate.	Cyclosporine	19-33	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	0-5
11059862-1	2000	BACKGROUND/AIMS: The effect of vitamin E succinate was studied in vitro against cyclosporine A (CsA) cytotoxicity in reference to the induction of heat shock protein 70 (HSP70) in rat hepatocytes.	Cyclosporine	80-94	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	170-175
11059862-4	2000	HSP70 also increased in parallel to CsA concentration, and apoptosis showed a biphasic change, increasing at concentrations between 0 and 10 microM and decreasing from 10 to 50 microM.	Cyclosporine	36-39	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	0-5
11059862-8	2000	CONCLUSIONS: We conclude that in primary hepatocyte cultures, peroxide generation and cytotoxicity induced by CsA was accompanied by HSP70 induction and that the CsA cytotoxicity significantly decreased in the presence of vitamin E succinate parallel to a disappearance in HSP70 and to an increase in apoptosis.	Cyclosporine	110-113	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	273-278
11131658-1	2000	OBJECTIVE: To characterize the chemosensitivity of wild type and multidrug resistant canine cell lines and determine the relative potency of the P-glycoprotein (Pgp) modulators verapamil, tamoxifen and a cyclosporin-A analog (PSC833).	Cyclosporine	204-217	PGP	Canis lupus familiaris	161-164
11045663-9	2000	The optimal doses of CsA and tacrolimus had similar inhibitory effects on Th1 type cytokine IL-2 and interferon [INF]-gamma), inflammatory cytokine (IL-1beta and tumor necrosis factor [TNF]-alpha), and cytotoxic factor (granzyme B and perforin) mRNA expression.	Cyclosporine	21-24	granzyme B	Rattus norvegicus	220-230
11045663-11	2000	Whereas IL-4 expression was not affected by tacrolimus and was enhanced by CsA, IL-10 expression was more significantly suppressed by tacrolimus than CsA.	Cyclosporine	150-153	interleukin 10	Rattus norvegicus	80-85
10972680-8	2000	In addition, the CsA-induced up-regulated expression of TGF-beta1, PAI-1, and the matrix proteins biglycan, fibronectin, and collagen I was significantly increased with L-NAME and strikingly improved with L-Arg.	Cyclosporine	17-20	fibronectin 1	Rattus norvegicus	108-119
10886556-10	2000	(alpha1)I and (alpha2)IV collagen synthesis was increased in cyclosporine-treated endothelial and epithelial cells, respectively.	Cyclosporine	61-73	adrenoceptor alpha 1D	Homo sapiens	1-7
10929770-9	2000	Since cyclosporin A, known to be a modifier of p-Gp, also induced reversal of vincristine resistance in the ES-OMC-MN and SFT-8606 cell lines (IC50 6.2 nM and 17 nM, respectively), it is suggested that cyclosporin A acts as a modifier of MDR mediated by LRP.	Cyclosporine	6-19	phosphoglycolate phosphatase	Homo sapiens	47-51
10798772-10	2000	Cyclosporine treatment reduced insulin and GLUT-2 gene expression in in vitro culture.	Cyclosporine	0-12	solute carrier family 2 member 2	Rattus norvegicus	43-49
10725704-9	2000	Furthermore, this down-regulation is not mediated by the ligand, IFN-gamma, but results from TCR engagement and can be inhibited by cyclosporin A.	Cyclosporine	132-145	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	93-96
10708576-2	2000	Here we demonstrate that low doses of CsA are able to induce the expression of the heat shock protein HSP27 and its hyperphosphorylation.	Cyclosporine	38-41	heat shock protein family B (small) member 1	Homo sapiens	102-107
10708576-4	2000	Since these factors have been shown to be activated by proteasome inhibition, we tested the hypothesis that the inhibitory action of CsA on the proteasome might be responsible for the activation of HSFs and the subsequent expression of HSP27.	Cyclosporine	133-136	heat shock protein family B (small) member 1	Homo sapiens	236-241
10708576-6	2000	The kidney BSC-1 cells are highly responsive to the addition of CsA: the possible link between HSP27 induction and hyperphosphorylation and nephrotoxicity is discussed.	Cyclosporine	64-67	heat shock protein family B (small) member 1	Homo sapiens	95-100
10755555-0	2000	Association of glucocorticoids and cyclosporin A or rapamycin prevents E-selectin and IL-8 expression during LPS- and TNFalpha-mediated endothelial cell activation.	Cyclosporine	35-48	selectin E	Homo sapiens	71-81
10692420-4	2000	P-gp (but not MRP) inhibitors, e.g. ketoconazole or cyclosporin A (CsA) prevented the increased Gb(3) and VT sensitivity, concomitant with increased vinblastine sensitivity.	Cyclosporine	52-65	PGP	Canis lupus familiaris	0-4
10692420-4	2000	P-gp (but not MRP) inhibitors, e.g. ketoconazole or cyclosporin A (CsA) prevented the increased Gb(3) and VT sensitivity, concomitant with increased vinblastine sensitivity.	Cyclosporine	67-70	PGP	Canis lupus familiaris	0-4
10609555-8	2000	CsA induced a 85% decrease in calbindin-D28k mRNA levels as well as a 40% and 69% decrease in VDR and 24-OHase mRNA levels, respectively.	Cyclosporine	0-3	vitamin D receptor	Rattus norvegicus	94-97
10791709-3	2000	To investigate the production and activity of matrix metalloproteinases (MMPs) in the CyA-induced gingival overgrowth, 2 well-documented models were utilized: the in vivo CyA-induced rat gingival overgrowth and primary cultures of human gingival fibroblasts treated with CyA.	Cyclosporine	86-89	matrix metallopeptidase 1	Homo sapiens	73-77
10791709-4	2000	Our results obtained from the Western blot assays demonstrated clearly that the production of MMP-1 and MMP-3 was significantly inhibited by CyA at similar concentrations found in the serum of patients undergoing CyA-treatment.	Cyclosporine	141-144	matrix metallopeptidase 1	Homo sapiens	94-99
10640627-2	2000	To investigate the role of PP in the regulation of the phosphorylation of MAP1b and MAP2, we used okadaic acid and cyclosporin A to selectively inhibit PP2A and PP2B activities, respectively, in metabolically competent rat brain slices.	Cyclosporine	115-128	microtubule-associated protein 1B	Rattus norvegicus	74-79
10347253-3	1999	Because inhibition of CREB/CRE-directed transcription by cyclosporin A and FK506 has previously been observed by using synthetic minienhancers, reporter fusion genes were constructed to examine the effect of cyclosporin A and FK506 on the transcriptional activity of CRE-containing natural promoters.	Cyclosporine	57-70	cAMP responsive element binding protein 1	Rattus norvegicus	22-26
11819433-1	1999	AIM:To explore the expression of perforin and granzyme B genes mRNAto judge the effect of immunosuppression in acute rejection of liver transplantation.METHODS: The expression of perforin and granzyme B genes mRNA was examined by reverse transcription-polymerase chain reaction (RT-PCR) in hamster to rat liver grafts under the immunosuppression of cyclosporine or/and splenectomy.	Cyclosporine	349-361	granzyme B	Rattus norvegicus	46-56
11819433-2	1999	Histological findings were studied comparatively.RESULTS:Cyclosporine could obviously decrease the cellular infiltration, and completely repress the expression of mRNA for perforin and granzyme B, but could not change severe hepatocyte necrosis and hemorrhage.	Cyclosporine	57-69	granzyme B	Rattus norvegicus	185-195
10640627-2	2000	To investigate the role of PP in the regulation of the phosphorylation of MAP1b and MAP2, we used okadaic acid and cyclosporin A to selectively inhibit PP2A and PP2B activities, respectively, in metabolically competent rat brain slices.	Cyclosporine	115-128	microtubule-associated protein 2	Rattus norvegicus	84-88
10342319-3	1999	In this study, we examined whether cyclosporine A (CsA) suppresses the cell cycle progression through the induction of the cell cycle inhibitor p21.	Cyclosporine	35-49	H3 histone pseudogene 16	Homo sapiens	144-147
10342319-3	1999	In this study, we examined whether cyclosporine A (CsA) suppresses the cell cycle progression through the induction of the cell cycle inhibitor p21.	Cyclosporine	51-54	H3 histone pseudogene 16	Homo sapiens	144-147
10342319-7	1999	The dependence of CsA"s induction of p21 was studied using anti-TGF-beta antibody and TGF-beta altered A-549 cells.	Cyclosporine	18-21	H3 histone pseudogene 16	Homo sapiens	37-40
10342319-8	1999	RESULTS: CsA induced p21 mRNA protein expression and stimulated its promoter activity in lymphoid (T cells) and nonlymphoid (human lung adenocarcinoma, A-549 cells).CsA"s induction of p21 was inhibited both by a neutralizing anti-TGF-beta antibody and in TGF-beta-altered A-549 cells, consistent with its effects on p21 requiring TGF-beta.	Cyclosporine	9-12	H3 histone pseudogene 16	Homo sapiens	21-24
11261272-6	2000	Low-dose cyclosporin A (Cy-A) after autologous STx induces an autologous graft versus host (GvH) and probably graft versus tumor (GvT) effect.	Cyclosporine	9-22	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2	Homo sapiens	47-50
11261272-6	2000	Low-dose cyclosporin A (Cy-A) after autologous STx induces an autologous graft versus host (GvH) and probably graft versus tumor (GvT) effect.	Cyclosporine	24-28	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2	Homo sapiens	47-50
10674906-2	2000	We report here 9 cases of neutropenic HLH, of which 8 were treated with cyclosporin (CSA, 2-6 mg/kg/day; continuous infusion, or 6 mg/kg/day; per os, for periods ranging from 9 days to &gt;8 weeks) in the initial neutropenic phase during induction treatment using corticosteroids and etoposide.	Cyclosporine	72-83	IK cytokine	Homo sapiens	85-93
10342319-8	1999	RESULTS: CsA induced p21 mRNA protein expression and stimulated its promoter activity in lymphoid (T cells) and nonlymphoid (human lung adenocarcinoma, A-549 cells).CsA"s induction of p21 was inhibited both by a neutralizing anti-TGF-beta antibody and in TGF-beta-altered A-549 cells, consistent with its effects on p21 requiring TGF-beta.	Cyclosporine	9-12	H3 histone pseudogene 16	Homo sapiens	184-187
10781832-1	2000	Cyclosporin A (CsA), a fungal metabolite used in organ transplantation, blocks the immune responses by interfering with early activation signals preventing the induction of the IL2 gene.	Cyclosporine	0-13	interleukin 2	Mus musculus	177-180
10342319-8	1999	RESULTS: CsA induced p21 mRNA protein expression and stimulated its promoter activity in lymphoid (T cells) and nonlymphoid (human lung adenocarcinoma, A-549 cells).CsA"s induction of p21 was inhibited both by a neutralizing anti-TGF-beta antibody and in TGF-beta-altered A-549 cells, consistent with its effects on p21 requiring TGF-beta.	Cyclosporine	9-12	H3 histone pseudogene 16	Homo sapiens	184-187
10367710-0	1999	FK506 and cyclosporin A inhibit stem cell factor-dependent cell proliferation/survival, while inducing upregulation of c-kit expression in cells of the mast cell line MC/9.	Cyclosporine	10-23	kit ligand	Mus musculus	32-48
10781832-1	2000	Cyclosporin A (CsA), a fungal metabolite used in organ transplantation, blocks the immune responses by interfering with early activation signals preventing the induction of the IL2 gene.	Cyclosporine	15-18	interleukin 2	Mus musculus	177-180
10367710-0	1999	FK506 and cyclosporin A inhibit stem cell factor-dependent cell proliferation/survival, while inducing upregulation of c-kit expression in cells of the mast cell line MC/9.	Cyclosporine	10-23	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	119-124
10718281-0	2000	Long term treatment of IgA nephropathy with cyclosporine A.	Cyclosporine	44-58	immunoglobulin heavy variable 4-38-2-like	Homo sapiens	23-26
10367710-6	1999	FK506 and CsA inhibited the SCF-dependent, but not the IL-3 dependent, stimulatory effects on MC/9 cell proliferation/survival.	Cyclosporine	10-13	kit ligand	Mus musculus	28-31
10367710-8	1999	FK506 and CsA inhibited the SCF-dependent rescue effect from apoptosis.	Cyclosporine	10-13	kit ligand	Mus musculus	28-31
10367710-10	1999	However, immunoblot and reverse transcriptase-polymerase chain reaction (RT-PCR) analyses indicated that c-kit protein and c-kit mRNA transcripts were increased following the FK506 and CsA treatments in the presence of IL-3.	Cyclosporine	185-188	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	105-110
10593895-2	1999	Calcineurin is the target of the immunosuppressive drugs cyclosporin A and FK506 complexed with their cytoplasmic receptors cyclophilin and FKBP12, respectively.	Cyclosporine	57-70	FKBP prolyl isomerase 1A pseudogene 1	Homo sapiens	140-146
10367710-10	1999	However, immunoblot and reverse transcriptase-polymerase chain reaction (RT-PCR) analyses indicated that c-kit protein and c-kit mRNA transcripts were increased following the FK506 and CsA treatments in the presence of IL-3.	Cyclosporine	185-188	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	123-128
10367710-11	1999	In addition, MC/9 cells pretreated with FK506 or CsA showed an increased adhesiveness to NIH/3T3 cells that express membrane-bound SCF.	Cyclosporine	49-52	kit ligand	Mus musculus	131-134
10367710-13	1999	These results indicate that FK506 and CsA, while inducing c-kit of MC/9 cells, selectively inhibit the SCF-dependent stimulatory effects on MC/9 cell proliferation/survival by a mechanism independent of, or at point(s) distal to, the c-kit-MAP kinase pathway.	Cyclosporine	38-41	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	58-63
10367710-13	1999	These results indicate that FK506 and CsA, while inducing c-kit of MC/9 cells, selectively inhibit the SCF-dependent stimulatory effects on MC/9 cell proliferation/survival by a mechanism independent of, or at point(s) distal to, the c-kit-MAP kinase pathway.	Cyclosporine	38-41	kit ligand	Mus musculus	103-106
10367710-13	1999	These results indicate that FK506 and CsA, while inducing c-kit of MC/9 cells, selectively inhibit the SCF-dependent stimulatory effects on MC/9 cell proliferation/survival by a mechanism independent of, or at point(s) distal to, the c-kit-MAP kinase pathway.	Cyclosporine	38-41	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	234-239
10363688-8	1999	Interestingly, we found that administration of cyclosporine prior to, at the same time as, or after administration of the CD45RB monoclonal antibody had a detrimental effect on graft survival compared to mAb treated alone (16.6+/-0.4 days, 25+/-2.3 days, and 35.3+/-0.9 days respectively vs. 74.5 days, p&lt;0.01).	Cyclosporine	47-59	protein tyrosine phosphatase, receptor type, C	Mus musculus	122-126
10208939-5	1999	Both cyclosporin treatment and alteration of Gly89 or Pro90 in the CypA-binding site of CA caused a 5- to 20-fold decrease in CypA incorporation.	Cyclosporine	5-16	peptidylprolyl isomerase A	Homo sapiens	67-71
10208939-5	1999	Both cyclosporin treatment and alteration of Gly89 or Pro90 in the CypA-binding site of CA caused a 5- to 20-fold decrease in CypA incorporation.	Cyclosporine	5-16	peptidylprolyl isomerase A	Homo sapiens	126-130
10232563-16	1999	In patients on NEO, the concentration of CsA 2 hr after dosing (C2) closely reflected AUC0-6 (r2 = 0.93), whereas there was a poorer correlation in patients on SIM (r2 = 0.73) CONCLUSIONS: Cmax and/or AUC0-6 may provide better markers than trough levels for monitoring CsA-based immune suppression after orthotopic liver transplantation.	Cyclosporine	15-18	IK cytokine	Homo sapiens	41-46
10227426-4	1999	In contrast, the level of IFN-gamma mRNA was suppressed at the first attack by CsA and peaked at the second attack.	Cyclosporine	79-82	interferon gamma	Rattus norvegicus	26-35
10030847-7	1999	Under costimulatory conditions, IL-5 synthesis was only minimally inhibited by high concentrations of CSA, and at CSA concentrations of less than 125 ng/ml, IL-5 was significantly increased above control values.	Cyclosporine	102-105	interleukin 5	Mus musculus	32-36
10030847-9	1999	Of the cytokine mRNAs examined in the lungs of CSA-pretreated, antigen-challenged mice, IL-5 mRNA levels were the least reduced, paralleling the resistance of IL-5 to CSA observed in vitro and suggesting a role for CD28 in the in vivo induction of IL-5.	Cyclosporine	47-50	interleukin 5	Mus musculus	88-92
10030847-9	1999	Of the cytokine mRNAs examined in the lungs of CSA-pretreated, antigen-challenged mice, IL-5 mRNA levels were the least reduced, paralleling the resistance of IL-5 to CSA observed in vitro and suggesting a role for CD28 in the in vivo induction of IL-5.	Cyclosporine	47-50	interleukin 5	Mus musculus	159-163
10030847-9	1999	Of the cytokine mRNAs examined in the lungs of CSA-pretreated, antigen-challenged mice, IL-5 mRNA levels were the least reduced, paralleling the resistance of IL-5 to CSA observed in vitro and suggesting a role for CD28 in the in vivo induction of IL-5.	Cyclosporine	47-50	CD28 antigen	Mus musculus	215-219
10030847-9	1999	Of the cytokine mRNAs examined in the lungs of CSA-pretreated, antigen-challenged mice, IL-5 mRNA levels were the least reduced, paralleling the resistance of IL-5 to CSA observed in vitro and suggesting a role for CD28 in the in vivo induction of IL-5.	Cyclosporine	47-50	interleukin 5	Mus musculus	159-163
10206323-7	1999	The steady-state uptake of BTL by LLC-GA5-COL300 cells, expressing human P-gp, was significantly increased in the presence of 20 microM cyclosporin A (another P-gp inhibitor), which had no effect in the LLC-PK1 host cells.	Cyclosporine	136-149	phosphoglycolate phosphatase	Homo sapiens	73-77
10072494-7	1999	Although the specific defect leading to this hyperactivation has not been identified, we also demonstrate that scurfy T cells are less sensitive than normal controls to inhibitors of tyrosine kinases such as genistein and herbimycin A, and the immunosuppressant cyclosporin A.	Cyclosporine	262-275	forkhead box P3	Mus musculus	111-117
10022890-3	1999	VEGF also induced TF mRNA expression and gene promoter activation by a cyclosporin A (CsA)-sensitive mechanism.	Cyclosporine	71-84	coagulation factor III, tissue factor	Homo sapiens	18-20
10022890-3	1999	VEGF also induced TF mRNA expression and gene promoter activation by a cyclosporin A (CsA)-sensitive mechanism.	Cyclosporine	86-89	coagulation factor III, tissue factor	Homo sapiens	18-20
9933022-6	1999	Cyclosporin A and herbimycin A, which suppress c-fos and c-jun gene expressions, respectively, blocked the cisplatin-induced increase in ERCC-1 mRNA.	Cyclosporine	0-13	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	137-143
9933022-7	1999	This effect of cyclosporin A or herbimycin A on the down-regulation of ERCC-1 correlates with enhanced cytotoxicity of cisplatin in this system.	Cyclosporine	15-28	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	71-77
9973482-7	1999	Wortmannin and cyclosporin A inhibited Fc epsilon RI-mediated production of TNF-alpha and IL-4 in addition to serotonin release in BMMC.	Cyclosporine	15-28	interleukin 4	Mus musculus	90-94
10076049-4	1999	CSA-induced contractions were associated with increases in the phosphorylation of the 20 kDa myosin light chains (MLC20) and different isoforms of the small heat shock protein, HSP27.	Cyclosporine	0-3	myosin regulatory light chain 12B	Bos taurus	114-119
10076049-5	1999	Cyclic nucleotide-dependent relaxation of CSA-induced contractions was associated with increases in the phosphorylation of another small heat shock protein, HSP20, and decreases in the phosphorylation of the MLC20, and some isoforms of HSP27.	Cyclosporine	42-45	myosin regulatory light chain 12B	Bos taurus	208-213
10064070-5	1999	Cyclosporin A inhibits TCR-induced IFN-gamma production, but not IL-12/IL-18-induced IFN-gamma production, biochemically discriminating between these pathways.	Cyclosporine	0-13	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	23-26
10064053-5	1999	Addition of cyclosporin A completely inhibited TCR-mediated death and FasL cell surface up-regulation, but had no effect on apoptosis induced directly by Fas ligation following TCR stimulation.	Cyclosporine	12-25	T cell receptor alpha variable 6-3	Mus musculus	47-50
10064056-5	1999	Production of both IL-4 by the Th2 clones and IFN-gamma by the Th1 clone were inhibited by the immunosuppressive agent cyclosporin A.	Cyclosporine	119-132	interleukin 4	Mus musculus	19-23
10064056-5	1999	Production of both IL-4 by the Th2 clones and IFN-gamma by the Th1 clone were inhibited by the immunosuppressive agent cyclosporin A.	Cyclosporine	119-132	heart and neural crest derivatives expressed 2	Mus musculus	31-34
9987092-11	1999	Intense staining for endothelin-1, RANTES, and monocyte chemoattractant protein-1 mRNAs selectively localized at tubular epithelial cells was found in biopsies taken from patients with CsA nephrotoxicity, but not in the chronic graft rejection group, whose tubuli had only minimal staining for RANTES mRNA on a few occasions.	Cyclosporine	185-188	C-C motif chemokine ligand 2	Homo sapiens	47-81
10051052-8	1999	The addition of clinically relevant concentrations of CsA (200-1,000 ng/mL) or tacrolimus (10-25 ng/mL) resulted in a dose-dependent inhibition of the UDPGT enzyme by both agents with tacrolimus, which was approximately 60-fold more efficient as an inhibitor.	Cyclosporine	54-57	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	151-156
10051052-9	1999	The calculated inhibition constants (KI) of tacrolimus and CsA for the purified UDPGT were 27.3+/-5.6 ng/ml and 2,518+/-1473 ng/ml.	Cyclosporine	59-62	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	80-85
10083066-0	1999	Administration of exogenous interleukin-2 enhances obliterative airway disease in cyclosporine-treated rats following tracheal allografts.	Cyclosporine	82-94	interleukin 2	Rattus norvegicus	28-41
9915863-6	1999	As with egr-3, expression of egr-2 was blocked by cyclosporin A.	Cyclosporine	50-63	early growth response 3	Homo sapiens	8-13
9915863-6	1999	As with egr-3, expression of egr-2 was blocked by cyclosporin A.	Cyclosporine	50-63	early growth response 2	Homo sapiens	29-34
9878697-3	1999	IFN-gamma-induced expression of iNOS, but not interferon regulatory factor-1 (IRF-1) mRNA was reduced in CsA-treated cells.	Cyclosporine	105-108	interferon gamma	Rattus norvegicus	0-9
10412950-5	1999	Since cyclosporin and macrolide immunosuppressants inhibit calcineurin (CaN) phosphatase and FKBP12 peptideprolyl isomerase (FKBP12 PPI) activity, studies were conducted to determine if these effects are directly related to the inhibitory effects these immunosuppressants have on P-glycoprotein function.	Cyclosporine	6-17	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	93-99
9886391-5	1999	TCR-mediated IL-10 gene expression is inhibited by cyclosporin A, but IL-4-mediated IL-10 expression is not.	Cyclosporine	51-64	T cell receptor alpha variable 6-3	Mus musculus	0-3
10586202-4	1999	CD45RO intragraft expression and its index (CD45RO/CD45), measured by reverse transcription polymerase chain reaction (RT-PCR), were significantly elevated in untreated and half-dose CsA-treated allografts as early as postoperative day (POD) 4, when rejection of intestinal allografts was not detected by routine pathology.	Cyclosporine	183-186	protein tyrosine phosphatase, receptor type, C	Rattus norvegicus	0-4
10586202-4	1999	CD45RO intragraft expression and its index (CD45RO/CD45), measured by reverse transcription polymerase chain reaction (RT-PCR), were significantly elevated in untreated and half-dose CsA-treated allografts as early as postoperative day (POD) 4, when rejection of intestinal allografts was not detected by routine pathology.	Cyclosporine	183-186	protein tyrosine phosphatase, receptor type, C	Rattus norvegicus	44-48
10189702-5	1999	This Ca(2+)-stimulated phosphatase activity was inhibited by CsA, suggesting the presence of both cytosolic CyP and calcineurin-like protein phosphatase in guard cells.	Cyclosporine	61-64	peptidylprolyl isomerase G	Homo sapiens	108-111
9820802-1	1998	A fusion protein between cyclophilin-D (CyP-D) and glutathione S-transferase (GST) was shown to bind to purified liver inner mitochondrial membranes (IMMs) in a cyclosporin A (CsA)-sensitive manner.	Cyclosporine	161-174	glutathione S-transferase kappa 1	Homo sapiens	51-76
9820802-1	1998	A fusion protein between cyclophilin-D (CyP-D) and glutathione S-transferase (GST) was shown to bind to purified liver inner mitochondrial membranes (IMMs) in a cyclosporin A (CsA)-sensitive manner.	Cyclosporine	161-174	glutathione S-transferase kappa 1	Homo sapiens	78-81
9820802-1	1998	A fusion protein between cyclophilin-D (CyP-D) and glutathione S-transferase (GST) was shown to bind to purified liver inner mitochondrial membranes (IMMs) in a cyclosporin A (CsA)-sensitive manner.	Cyclosporine	176-179	glutathione S-transferase kappa 1	Homo sapiens	51-76
9820802-1	1998	A fusion protein between cyclophilin-D (CyP-D) and glutathione S-transferase (GST) was shown to bind to purified liver inner mitochondrial membranes (IMMs) in a cyclosporin A (CsA)-sensitive manner.	Cyclosporine	176-179	glutathione S-transferase kappa 1	Homo sapiens	78-81
9843511-3	1998	Here we show that HBx activates NF-AT by a cyclosporin A-sensitive mechanism involving dephosphorylation and nuclear translocation of the transcription factor.	Cyclosporine	43-56	X protein	Hepatitis B virus	18-21
9843511-6	1998	Immunofluorescence analysis demonstrated that HBx induces the nuclear translocation of NF-AT, which can be blocked by the immunosuppressive drug cyclosporin A.	Cyclosporine	145-158	X protein	Hepatitis B virus	46-49
9819402-0	1998	Utilization of an NF-ATp binding promoter element for EGR3 expression in T cells but not fibroblasts provides a molecular model for the lymphoid cell-specific effect of cyclosporin A.	Cyclosporine	169-182	nuclear factor of activated T cells 2	Homo sapiens	18-24
9819402-0	1998	Utilization of an NF-ATp binding promoter element for EGR3 expression in T cells but not fibroblasts provides a molecular model for the lymphoid cell-specific effect of cyclosporin A.	Cyclosporine	169-182	early growth response 3	Homo sapiens	54-58
9819402-3	1998	To investigate this issue, we performed a detailed comparative analysis of the promoter regulating the two-signal-dependent (Ca2+ ionophore plus phorbol myristate acetate [PMA]), CsA-sensitive expression of EGR3 in T cells and the one-signal-dependent (PMA), CsA-insensitive expression of EGR3 in fibroblasts.	Cyclosporine	179-182	early growth response 3	Homo sapiens	207-211
9819402-3	1998	To investigate this issue, we performed a detailed comparative analysis of the promoter regulating the two-signal-dependent (Ca2+ ionophore plus phorbol myristate acetate [PMA]), CsA-sensitive expression of EGR3 in T cells and the one-signal-dependent (PMA), CsA-insensitive expression of EGR3 in fibroblasts.	Cyclosporine	179-182	early growth response 3	Homo sapiens	289-293
9819402-3	1998	To investigate this issue, we performed a detailed comparative analysis of the promoter regulating the two-signal-dependent (Ca2+ ionophore plus phorbol myristate acetate [PMA]), CsA-sensitive expression of EGR3 in T cells and the one-signal-dependent (PMA), CsA-insensitive expression of EGR3 in fibroblasts.	Cyclosporine	259-262	early growth response 3	Homo sapiens	207-211
9813336-8	1998	In contrast, when CsA was given to animals with a needle insertion, CA1 damage was dramatically ameliorated, whether treatment was initiated 1 week before ischemia, or 30 min after the start of recirculation.	Cyclosporine	18-21	carbonic anhydrase 1	Rattus norvegicus	68-71
9794788-4	1998	In contrast, treatment with cyclosporin A, which inhibits the Ca2+/calmodulin-dependent protein phosphatase 2B or calcineurin, increased both egr-1 and c-fos mRNA production and the DNA-binding activity of the Egr-1 and AP-1 transcription factors in response to the intracellular Ca+ concentration ([Ca2+]i)-increasing agents A23187 or cyclopiazonic acid.	Cyclosporine	28-41	early growth response 1	Mus musculus	142-147
9794788-4	1998	In contrast, treatment with cyclosporin A, which inhibits the Ca2+/calmodulin-dependent protein phosphatase 2B or calcineurin, increased both egr-1 and c-fos mRNA production and the DNA-binding activity of the Egr-1 and AP-1 transcription factors in response to the intracellular Ca+ concentration ([Ca2+]i)-increasing agents A23187 or cyclopiazonic acid.	Cyclosporine	28-41	FBJ osteosarcoma oncogene	Mus musculus	152-157
9794788-4	1998	In contrast, treatment with cyclosporin A, which inhibits the Ca2+/calmodulin-dependent protein phosphatase 2B or calcineurin, increased both egr-1 and c-fos mRNA production and the DNA-binding activity of the Egr-1 and AP-1 transcription factors in response to the intracellular Ca+ concentration ([Ca2+]i)-increasing agents A23187 or cyclopiazonic acid.	Cyclosporine	28-41	early growth response 1	Mus musculus	210-215
9794788-5	1998	Enhancement of the Ca2+-induced c-fos and egr-1 expression by cyclosporin A was correlated with the capability of this agent to inhibit calcineurin phosphatase activity in ELM-I-1 cells.	Cyclosporine	62-75	FBJ osteosarcoma oncogene	Mus musculus	32-37
9794788-5	1998	Enhancement of the Ca2+-induced c-fos and egr-1 expression by cyclosporin A was correlated with the capability of this agent to inhibit calcineurin phosphatase activity in ELM-I-1 cells.	Cyclosporine	62-75	early growth response 1	Mus musculus	42-47
9820947-11	1998	The immunoreactivity of p53 was significantly decreased, whereas the bcl-2 level was increased after CsA administration.	Cyclosporine	101-104	BCL2 apoptosis regulator	Canis lupus familiaris	69-74
11038783-2	1998	METHODS: The expression of perforin and granzyme B gene mRNA was examined by RT-PCR in hamster to rat liver grafts under the immunosuppression of cyclosporine and splenectomy.	Cyclosporine	146-158	granzyme B	Rattus norvegicus	40-50
9758892-0	1998	IL-5-producing T cells that induce airway eosinophilia and hyperresponsiveness are suppressed by dexamethasone and cyclosporin A in mice.	Cyclosporine	115-128	interleukin 5	Mus musculus	0-4
10531391-5	1999	Myoblasts and myotubes of C2-C12 cells express similar amounts of cyclophilin A and FKBP12, immunophilins known to be intracellular-binding targets for CsA and tacrolimus, respectively.	Cyclosporine	152-155	FK506 binding protein 1a	Mus musculus	84-90
10486755-1	1999	The affinity capillary electrophoretic separation of the complex of the enzyme cyclophilin (Cyp) with the immunosuppressive drug cyclosporin A (CsA) from uncomplexed Cyp and CsA in phosphate buffer (pH 8) under non-denaturing conditions by equilibrium-mixture analysis is reported.	Cyclosporine	174-177	peptidylprolyl isomerase G	Homo sapiens	92-95
10403741-12	1999	Rats treated with cyclosporin and caerulein showed severe pancreatic weight reduction, abundant inflammatory infiltrates, increased SMA immunoreactive interstitial cells, high collagen content, and delayed collagenase response.	Cyclosporine	18-29	actin alpha 2, smooth muscle	Rattus norvegicus	132-135
10466081-1	1999	The effects of simultaneous administrations of Cyclosporin A (CsA) and Glyburide on the immune system of rats has been evaluated in terms of Interleukin-2 (IL-2) production by Concanavalin A (ConA) stimulated splenocytes and exogenous IL-2 binding capacity.	Cyclosporine	47-60	interleukin 2	Rattus norvegicus	141-154
10466081-1	1999	The effects of simultaneous administrations of Cyclosporin A (CsA) and Glyburide on the immune system of rats has been evaluated in terms of Interleukin-2 (IL-2) production by Concanavalin A (ConA) stimulated splenocytes and exogenous IL-2 binding capacity.	Cyclosporine	47-60	interleukin 2	Rattus norvegicus	156-160
10466081-1	1999	The effects of simultaneous administrations of Cyclosporin A (CsA) and Glyburide on the immune system of rats has been evaluated in terms of Interleukin-2 (IL-2) production by Concanavalin A (ConA) stimulated splenocytes and exogenous IL-2 binding capacity.	Cyclosporine	62-65	interleukin 2	Rattus norvegicus	141-154
10466081-1	1999	The effects of simultaneous administrations of Cyclosporin A (CsA) and Glyburide on the immune system of rats has been evaluated in terms of Interleukin-2 (IL-2) production by Concanavalin A (ConA) stimulated splenocytes and exogenous IL-2 binding capacity.	Cyclosporine	62-65	interleukin 2	Rattus norvegicus	156-160
10466081-2	1999	The inhibitory effect of Cyclosporin A on IL-2 production of lymphoid cells is well known.	Cyclosporine	25-38	interleukin 2	Rattus norvegicus	42-46
10466081-3	1999	Spleen cells from rats receiving CsA had reduced levels of IL-2 when compared to untreated controls or rats receiving Glyburide only.	Cyclosporine	33-36	interleukin 2	Rattus norvegicus	59-63
10504034-8	1999	Western-blot analysis revealed significant induction of P450, (similar to CYP2B4 of the rabbit P450 isozyme) in kidneys from rats treated with cyclosporin but not in those from rats receiving FK-506 or rapamycin.	Cyclosporine	143-154	cytochrome P450 2B4	Oryctolagus cuniculus	74-80
10509867-0	1999	Cyclosporine A-induced prostacyclin release is maintained by extracellular calcium in rat aortic endothelial cells: role of protein kinase C. Chronic treatment with the immunosuppressive drug Cyclosporine A (CsA) is associated with increased intracellular calcium in vascular smooth muscle cells, which may activate phospholipase A2.	Cyclosporine	0-14	phospholipase A2 group IB	Rattus norvegicus	316-332
10509867-0	1999	Cyclosporine A-induced prostacyclin release is maintained by extracellular calcium in rat aortic endothelial cells: role of protein kinase C. Chronic treatment with the immunosuppressive drug Cyclosporine A (CsA) is associated with increased intracellular calcium in vascular smooth muscle cells, which may activate phospholipase A2.	Cyclosporine	192-206	phospholipase A2 group IB	Rattus norvegicus	316-332
10429984-0	1999	Expression of the psoriasis-associated antigen, Pso p27, is inhibited by cyclosporin A.	Cyclosporine	73-86	interferon alpha inducible protein 27	Homo sapiens	52-55
10454224-4	1999	Lymphocyte transformation was suppressed by both compounds, while IL-2 mRNA expression was suppressed by CsA but not by TBTO, and both compounds suppressed IL-2R mRNA expression in splenocytes but not in thymocytes.	Cyclosporine	105-108	interleukin 2	Rattus norvegicus	66-70
10362751-6	1999	Additionally, therapeutic CsA treatment decreased the number of IFN-gamma-producing CD4(+) naive and memory T cells in the spleen.	Cyclosporine	26-29	interferon gamma	Rattus norvegicus	64-73
10342319-0	1999	Cyclosporine induces the expression of the cyclin inhibitor p21.	Cyclosporine	0-12	proliferating cell nuclear antigen	Homo sapiens	43-49
10342319-0	1999	Cyclosporine induces the expression of the cyclin inhibitor p21.	Cyclosporine	0-12	H3 histone pseudogene 16	Homo sapiens	60-63
10397175-9	1999	In response to [Ca2+]i-increasing agents in ELM-I-1 cells, both, egr-1 and c-fos mRNA expression increased significantly after the inhibition of calcineurin by cyclosporine A.	Cyclosporine	160-174	early growth response 1	Mus musculus	65-70
10397175-9	1999	In response to [Ca2+]i-increasing agents in ELM-I-1 cells, both, egr-1 and c-fos mRNA expression increased significantly after the inhibition of calcineurin by cyclosporine A.	Cyclosporine	160-174	FBJ osteosarcoma oncogene	Mus musculus	75-80
10397175-10	1999	Cyclosporin A exerted stimulatory effects on the egr-1 and c-fos expression also at lower (150-400 nM) intracellular Ca2+ levels.	Cyclosporine	0-13	early growth response 1	Mus musculus	49-54
10397175-10	1999	Cyclosporin A exerted stimulatory effects on the egr-1 and c-fos expression also at lower (150-400 nM) intracellular Ca2+ levels.	Cyclosporine	0-13	FBJ osteosarcoma oncogene	Mus musculus	59-64
10224279-3	1999	In addition, cyclosporin A not only inhibits nuclear import of HIV-1 DNA but also inhibits expression of c-Myc protein.	Cyclosporine	13-26	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	105-110
10201902-7	1999	Furthermore, we have observed that TCR-mediated neosynthesis of FLICE-like inhibitory protein mRNA is suppressed either by protein tyrosine kinase inhibitors or cyclosporin A.	Cyclosporine	161-174	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	35-38
10087047-4	1999	CyA did not affect CF secretion of transforming growth factor beta1, but markedly stimulated insulin-like growth factor-I (IGF-I) secretion and inhibited secretion of both IGF-I binding protein-(IGFBP)-3 and IGFBP-2.	Cyclosporine	0-3	insulin like growth factor binding protein 3	Homo sapiens	172-203
10361889-3	1999	This anti-Fas antibody-induced elevation of ALT was inhibited by treatment with CsA (10, 30 and 100 mg/kg) in a dose-dependent manner.	Cyclosporine	80-83	glutamic pyruvic transaminase, soluble	Mus musculus	44-47
10227700-4	1999	METHODS: The transcellular bidirectional flux of drugs that are (i) CYP3A-and/or P-gp substrates (Vinblastine, Cyclosporine, Digoxin, Fexofenadine, Losartan) or that are (ii) primary CYP3A-substrates (Felodipine, Nifedipine) was evaluated across MDCK-MDR1 cell monolayers with or without GJ, verifying monolayer integrity at all times.	Cyclosporine	111-123	PGP	Canis lupus familiaris	81-85
10070171-8	1999	HMGCoA reductase inhibitors may ameliorate interstitial fibrosis complicating CsA therapy via direct actions on human renal cortical fibroblasts.	Cyclosporine	78-81	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-16
10022916-3	1999	Furthermore, pharmacological studies demonstrate that the drug cyclosporin A inhibits both NFAT activation and IL-2 expression.	Cyclosporine	63-76	interleukin 2	Mus musculus	111-115
10025742-5	1999	After adjustment for age, kidney transplant recipients receiving cyclosporine, azathioprine, and prednisolone had a significantly (2.8 times) higher risk of cutaneous SCC relative to those receiving azathioprine and prednisolone.	Cyclosporine	65-77	serpin family B member 3	Homo sapiens	167-170
10195358-0	1999	Soluble E-selectin correlates with disease activity in cyclosporin A-treated patients with atopic dermatitis.	Cyclosporine	55-68	selectin E	Homo sapiens	8-18
10470441-3	1999	It results from these investigations that the molecular mechanism of the CLA action is the same as that of cyclosporin A and FK-506 compound, i.e. it consists in formation of the complex with cyclophilin and inhibition--in this form--of the phosphatase activity of calcineurin.	Cyclosporine	107-120	selectin P ligand	Homo sapiens	73-76
10353612-2	1999	Accordingly, growth hormone (GH) secretion, circulating insulin-like growth factor I (IGF-I) and IGF binding proteins (IGFBPs) in response to cyclosporin A (CsA) treatment were examined in adult male Wistar rats.	Cyclosporine	142-155	insulin-like growth factor binding protein 3	Rattus norvegicus	119-125
10353612-2	1999	Accordingly, growth hormone (GH) secretion, circulating insulin-like growth factor I (IGF-I) and IGF binding proteins (IGFBPs) in response to cyclosporin A (CsA) treatment were examined in adult male Wistar rats.	Cyclosporine	157-160	insulin-like growth factor binding protein 3	Rattus norvegicus	119-125
10353612-3	1999	Cyclosporine administration (5, 10 or 20 mg/Kg daily) over 8 days did not modify the body weight, but it did decrease serum concentration of corticosterone and increased serum IGF-I and GH levels.	Cyclosporine	0-12	insulin-like growth factor 1	Rattus norvegicus	176-181
10353612-4	1999	Rats treated with 5 and 10 mg/Kg of cyclosporine had similar levels of serum IGFBPs to control rats, but there was an increase in circulating IGFBP-3 and IGFPB-1,2 in the group treated with 20 mg/Kg of CsA.	Cyclosporine	36-48	insulin-like growth factor binding protein 3	Rattus norvegicus	77-83
10353612-4	1999	Rats treated with 5 and 10 mg/Kg of cyclosporine had similar levels of serum IGFBPs to control rats, but there was an increase in circulating IGFBP-3 and IGFPB-1,2 in the group treated with 20 mg/Kg of CsA.	Cyclosporine	36-48	insulin-like growth factor binding protein 3	Rattus norvegicus	142-149
10353612-8	1999	These data suggest that cyclosporine increases circulating IGF-I and GH by stimulating pituitary GH release.	Cyclosporine	24-36	insulin-like growth factor 1	Rattus norvegicus	59-64
9858612-0	1999	Cyclosporin A promotes translational silencing of autocrine interleukin-3 via ribosome-associated deadenylation.	Cyclosporine	0-13	interleukin 3	Homo sapiens	60-73
9858612-2	1999	Cyclosporin A (CsA), a calcineurin antagonist and blocker of interleukin-2 (IL-2) transcription in T cells, was found to inhibit translation of IL-3 mRNA in autocrine mast cell tumor lines.	Cyclosporine	0-13	interleukin 3	Homo sapiens	144-148
9858612-2	1999	Cyclosporin A (CsA), a calcineurin antagonist and blocker of interleukin-2 (IL-2) transcription in T cells, was found to inhibit translation of IL-3 mRNA in autocrine mast cell tumor lines.	Cyclosporine	15-18	interleukin 3	Homo sapiens	144-148
9858612-5	1999	The translational inhibition by CsA was specific to oncogenically induced lymphokines IL-3 and IL-4 but not to IL-6, c-jun, and c-myc, which are expressed in the nonmalignant precursor cells.	Cyclosporine	32-35	interleukin 3	Homo sapiens	86-90
10742982-6	1999	Numerous investigations with drugs such as digoxin, etoposide, cyclosporine, vinblastine, Taxol, loperamide, dom-peridone, and ondansteron demonstrate that P-gp has an important role in determining the pharmacokinetics of substrate drugs.	Cyclosporine	63-75	phosphoglycolate phosphatase	Homo sapiens	156-160
9734605-6	1998	The administration of CsA did not significantly increase total cortical interstitial collagen deposition, whereas alpha-smooth muscle actin expression was significantly increased in all CsA-treated rats.	Cyclosporine	186-189	actin gamma 2, smooth muscle	Rattus norvegicus	114-139
9734605-9	1998	PAI-1 antigen, present in proximal tubular lysosomes in kidneys from all experimental groups, stained very intensely in atrophic tubules in CsA-treated rats.	Cyclosporine	140-143	serpin family E member 2	Rattus norvegicus	0-5
9705263-5	1998	In single-cycle infection assays, nef-defective virions were partially resistant to cyclosporin A (CsA), a drug that inhibits the binding of CyPA to the HIV-1 Gag precursor and CyPA incorporation into virions.	Cyclosporine	84-97	peptidylprolyl isomerase A	Homo sapiens	177-181
9705263-5	1998	In single-cycle infection assays, nef-defective virions were partially resistant to cyclosporin A (CsA), a drug that inhibits the binding of CyPA to the HIV-1 Gag precursor and CyPA incorporation into virions.	Cyclosporine	99-102	peptidylprolyl isomerase A	Homo sapiens	141-145
9705263-5	1998	In single-cycle infection assays, nef-defective virions were partially resistant to cyclosporin A (CsA), a drug that inhibits the binding of CyPA to the HIV-1 Gag precursor and CyPA incorporation into virions.	Cyclosporine	99-102	peptidylprolyl isomerase A	Homo sapiens	177-181
9705263-8	1998	Surprisingly, CyPA-deficient virions remained sensitive to inhibition by CsA, in a manner that depended strongly on the presence of a functional nef gene.	Cyclosporine	73-76	peptidylprolyl isomerase A	Homo sapiens	14-18
9705263-10	1998	They further suggest that in addition to blocking the CyPA-Gag interaction, CsA can also inhibit HIV-1 replication through a novel mechanism involving suppression of Nef-directed enhancement of virus infectivity.	Cyclosporine	76-79	peptidylprolyl isomerase A	Homo sapiens	54-58
9714750-7	1998	Our most recent data shows that a fusion protein of CyP-D and glutathione-S-transferase immobilised to Sepharose specifically binds the ANT from Triton-solubilised inner mitochondrial membranes in a cyclosporin A (CsA) sensitive manner.	Cyclosporine	199-212	solute carrier family 25 member 6	Homo sapiens	136-139
9714750-7	1998	Our most recent data shows that a fusion protein of CyP-D and glutathione-S-transferase immobilised to Sepharose specifically binds the ANT from Triton-solubilised inner mitochondrial membranes in a cyclosporin A (CsA) sensitive manner.	Cyclosporine	214-217	solute carrier family 25 member 6	Homo sapiens	136-139
9723954-0	1998	Evidence that cyclosporin A and dexamethasone inhibit allergic airway eosinophilic inflammation via suppression of interleukin-5 synthesis by T cells.	Cyclosporine	14-27	interleukin 5	Mus musculus	115-128
9723954-8	1998	Cyclosporin A (10, 100 ng ml(-1)) and dexamethasone (10, 100 ng ml(-1) suppressed the production of IL-5 as well as IL-2 and IL-4 by FJ17 in vitro.	Cyclosporine	0-13	interleukin 5	Mus musculus	100-104
9723954-8	1998	Cyclosporin A (10, 100 ng ml(-1)) and dexamethasone (10, 100 ng ml(-1) suppressed the production of IL-5 as well as IL-2 and IL-4 by FJ17 in vitro.	Cyclosporine	0-13	interleukin 2	Mus musculus	116-120
9723954-8	1998	Cyclosporin A (10, 100 ng ml(-1)) and dexamethasone (10, 100 ng ml(-1) suppressed the production of IL-5 as well as IL-2 and IL-4 by FJ17 in vitro.	Cyclosporine	0-13	interleukin 4	Mus musculus	125-129
9723954-10	1998	Subcutaneously administered cyclosporin A (30 mg kg(-1)) and dexamethasone (10 mg kg(-1)) inhibited antigen-induced mRNA expression of IL-2 and IL-5, increase of BALF eosinophils and bronchial hyperresponsiveness of FJ17-transferred mice in vivo.	Cyclosporine	28-41	interleukin 2	Mus musculus	135-139
9723954-10	1998	Subcutaneously administered cyclosporin A (30 mg kg(-1)) and dexamethasone (10 mg kg(-1)) inhibited antigen-induced mRNA expression of IL-2 and IL-5, increase of BALF eosinophils and bronchial hyperresponsiveness of FJ17-transferred mice in vivo.	Cyclosporine	28-41	interleukin 5	Mus musculus	144-148
9723954-13	1998	The results clearly indicated that the suppression of IL-5 synthesis by T cells is involved in the effects of cyclosporin A and dexamethasone to inhibit allergic airway eosinophilic inflammation.	Cyclosporine	110-123	interleukin 5	Mus musculus	54-58
9713517-1	1998	The non-immunosuppressive cyclosporine analog SDZ PSC 833 abolished the resistance of human multidrug resistant (MDR-1, P-gp) human promyelocyte leukemia HL-60/VCR cells in vitro to paclitaxel-induced cell cycle- and viability alterations, as well as resistance to paclitaxel-induced radiosensitization.	Cyclosporine	26-38	phosphoglycolate phosphatase	Homo sapiens	120-124
9717775-5	1998	CsA inhibited the Con A-induced IL-2 mRNA expression completely, whereas DEX only partially inhibited it.	Cyclosporine	0-3	interleukin 2	Mus musculus	32-36
9636359-3	1998	We studied chaperone effects on Gag precursor processing using cyclosporin A (CsA) to bind CypA and prevent its interaction with p55Gag.	Cyclosporine	78-81	peptidylprolyl isomerase A	Homo sapiens	91-95
9636359-7	1998	CsA has a direct effect on HIV-1 Gag processing that implicates CypA as having an important role in the maturation of HIV-1 particles.	Cyclosporine	0-3	peptidylprolyl isomerase A	Homo sapiens	64-68
9636386-0	1998	Activation of COL3A1 promoter activity by cyclosporine.	Cyclosporine	42-54	collagen type III alpha 1 chain	Homo sapiens	14-20
9639064-7	1998	Both dexamethasone (10 mg/kg x 3) and cyclosporin A (10 mg/kg x 3) inhibited these findings and an increase in eosinophil peroxidase in the lung.	Cyclosporine	38-51	eosinophil peroxidase	Rattus norvegicus	111-132
9568730-1	1998	A monoclonal antibody (mAb) directed against the extracellular domain of the IFNAR1 chain of the human interferon-alpha (IFN-alpha) receptor (IFN-alphaR), which inhibits activation of the Jak-Stat signal transduction pathway, administered together with a subeffective dose of cyclosporine induced prolonged survival of skin allografts in major histocompatibility complex (MHC) divergent cynomolgus monkeys.	Cyclosporine	276-288	interferon alpha and beta receptor subunit 1	Homo sapiens	77-83
9530286-5	1998	Cell-based approaches to evaluate the ability of these protease inhibitors to compete for transport of known P-gp substrates showed that all three HIV-1 protease inhibitors were capable of inhibiting the transport of some of the known P-gp substrates but their effects were generally weaker than other documented P-gp modulators such as verapamil or cyclosporin A.	Cyclosporine	350-363	phosphoglycolate phosphatase	Homo sapiens	109-113
9530286-5	1998	Cell-based approaches to evaluate the ability of these protease inhibitors to compete for transport of known P-gp substrates showed that all three HIV-1 protease inhibitors were capable of inhibiting the transport of some of the known P-gp substrates but their effects were generally weaker than other documented P-gp modulators such as verapamil or cyclosporin A.	Cyclosporine	350-363	phosphoglycolate phosphatase	Homo sapiens	235-239
9530286-5	1998	Cell-based approaches to evaluate the ability of these protease inhibitors to compete for transport of known P-gp substrates showed that all three HIV-1 protease inhibitors were capable of inhibiting the transport of some of the known P-gp substrates but their effects were generally weaker than other documented P-gp modulators such as verapamil or cyclosporin A.	Cyclosporine	350-363	phosphoglycolate phosphatase	Homo sapiens	235-239
9649703-11	1998	Furthermore, we investigated the effect of CsA on the expression of collagen alpha1(I), fibronectin and matrix metalloprotease 1 genes in dermal fibroblasts from untreated donors.	Cyclosporine	43-46	fibronectin 1	Rattus norvegicus	88-99
9532170-0	1998	Prevention of diabetes recurrence after syngeneic islet transplantation in NOD mice by analogues of 1,25(OH)2D3 in combination with cyclosporin A: mechanism of action involves an immune shift from Th1 to Th2.	Cyclosporine	132-145	heart and neural crest derivatives expressed 2	Mus musculus	204-207
9468493-3	1998	Stimuli that increase [Ca2+]i such as CD3 cross-linking or ionomycin, but not activation of protein kinase C, were found to induce FasL enhancer transcription in a cyclosporin-sensitive manner.	Cyclosporine	164-175	Fas ligand	Homo sapiens	131-135
9973638-7	1998	Anti-M-CSF but not anti-IL-6 antibody abrogated CSA in KPB-M15-CM.	Cyclosporine	48-51	colony stimulating factor 1	Homo sapiens	5-10
9659917-3	1998	Inhibition by Cyp-40 required both its C-terminal protein-interaction domain, which bound specifically to c-Myb, and its N-terminal catalytic domain and was blocked by the competitive inhibitor cyclosporin A.	Cyclosporine	194-207	MYB proto-oncogene, transcription factor	Homo sapiens	106-111
9439728-8	1997	In contrast, inclusion of cyclosporin A (CsA) into the cultures specifically arrested IL-2 transcription in EL-4 cells without any stabilizing effect.	Cyclosporine	26-39	interleukin 2	Mus musculus	86-90
9439728-8	1997	In contrast, inclusion of cyclosporin A (CsA) into the cultures specifically arrested IL-2 transcription in EL-4 cells without any stabilizing effect.	Cyclosporine	41-44	interleukin 2	Mus musculus	86-90
9439728-9	1997	VT exposure in the presence of CsA markedly prolonged the half-life of IL-2 mRNA in a dose-dependent manner.	Cyclosporine	31-34	interleukin 2	Mus musculus	71-75
9353327-4	1997	p27 exhibits isomerase activity with a kcat/Km of 0.18 microM-1 s-1 for a peptide substrate; this activity is inhibited by cyclosporin A but is not affected by FK506.	Cyclosporine	123-136	interferon alpha inducible protein 27	Homo sapiens	0-3
9490580-8	1997	In contrast to CSA, performance of CSE was more time consuming (CSA: 8 +/- 3 min, CSE: 15 +/- 8 min; P = 0.0003), and the total dose of local anaesthetics was higher in the CSE group (CSA: 3.2 +/- 1 ml, CSE: 9.7 +/- 5 ml; P &lt; 0.0001).	Cyclosporine	64-67	choreoathetosis/spasticity, episodic (paroxysmal choreoathetosis/spasticity)	Homo sapiens	35-38
18020528-3	1997	HMG-CoA reductase inhibitors have been proven to be effective in lowering serum cholesterol concentrations in kidney and heart graft recipients receiving long term cyclosporin immunosuppression, and are therefore the drugs of choice in patients requiring treatment for hypercholesterolaemia after organ transplantation.	Cyclosporine	164-175	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-17
9430427-5	1997	Apoptotic cell death at 72 h in the presence of 10 U/ml interleukin 5 was increased by addition of cyclosporin H, an analogue of cyclosporin A without cyclophilin binding activity, in a concentration-dependent (0.3 to 3 microM) manner.	Cyclosporine	129-142	interleukin 5	Mus musculus	56-69
9344417-5	1997	Furthermore, similar inhibition constants were estimated for the reversible inhibition of human Cyp18 by cyclosporin A (CsA) with both the proteolytically coupled and the novel uncoupled PPIase assay.	Cyclosporine	120-123	FKBP prolyl isomerase 7	Homo sapiens	187-193
9381529-10	1997	CONCLUSIONS: Lysosomotropic amines in combination with cyclosporine appear to be synergistic in the suppression of T-cell proliferation to MiHC and MHC.	Cyclosporine	55-67	baculoviral IAP repeat-containing 3	Mus musculus	139-143
9328321-10	1997	We conclude that treatment with hydrocortisone and/or cyclosporine induces increased plasma levels of LDL cholesterol because of reduced hepatic LDL receptor activity.	Cyclosporine	54-66	low density lipoprotein receptor	Homo sapiens	145-157
9336339-6	1997	Contrary to the above in vivo findings, the immunosuppressors, FK-506 and cyclosporin A, inhibited the production of interferon-gamma and interleukin-2 by cultured Th1 cells (1E10.H2 cells) and of interleukin-4 and -5 by Th2 cells (D10.G4.1 cells) in vitro.	Cyclosporine	74-87	interleukin 2	Mus musculus	138-151
9336339-6	1997	Contrary to the above in vivo findings, the immunosuppressors, FK-506 and cyclosporin A, inhibited the production of interferon-gamma and interleukin-2 by cultured Th1 cells (1E10.H2 cells) and of interleukin-4 and -5 by Th2 cells (D10.G4.1 cells) in vitro.	Cyclosporine	74-87	interleukin 4	Mus musculus	197-217
9336339-6	1997	Contrary to the above in vivo findings, the immunosuppressors, FK-506 and cyclosporin A, inhibited the production of interferon-gamma and interleukin-2 by cultured Th1 cells (1E10.H2 cells) and of interleukin-4 and -5 by Th2 cells (D10.G4.1 cells) in vitro.	Cyclosporine	74-87	heart and neural crest derivatives expressed 2	Mus musculus	221-224
9336339-7	1997	These results indicated that FK-506 and cyclosporin A selectively inhibited the Th1 cell-mediated contact dermatitis and potentiated the Th2 cell-mediated IgE antibody production in vivo.	Cyclosporine	40-53	heart and neural crest derivatives expressed 2	Mus musculus	137-140
9336339-9	1997	However, because FK-506 and cyclosporin A inhibited the production of cytokines by both Th1 and Th2 cells in vitro and these two immunosuppressors showed higher selectivity toward inhibiting Th1 cell-mediated reactions by limitations in vivo experiments.	Cyclosporine	28-41	heart and neural crest derivatives expressed 2	Mus musculus	96-99
9380739-1	1997	HIV-1 specifically incorporates the peptidyl prolyl isomerase cyclophilin A (CyPA), the cytosolic receptor for the immunosuppressant cyclosporin A (CsA).	Cyclosporine	148-151	peptidylprolyl isomerase A	Homo sapiens	62-75
9380739-1	1997	HIV-1 specifically incorporates the peptidyl prolyl isomerase cyclophilin A (CyPA), the cytosolic receptor for the immunosuppressant cyclosporin A (CsA).	Cyclosporine	148-151	peptidylprolyl isomerase A	Homo sapiens	77-81
9380739-2	1997	HIV-1 replication is inhibited by CsA as well as by nonimmunosuppressive CsA analogues that bind to CyPA and interfere with its virion association.	Cyclosporine	73-76	peptidylprolyl isomerase A	Homo sapiens	100-104
9380739-5	1997	We report here that the transfer of HIV-1 CA residues 86-93, which form part of an exposed loop, to the corresponding position in SIVmac resulted in the efficient incorporation of CyPA and conferred an HIV-1-like sensitivity to a nonimmunosuppressive cyclosporin.	Cyclosporine	251-262	peptidylprolyl isomerase A	Homo sapiens	180-184
9380739-9	1997	By demonstrating that CyPA-binding-site residues can induce cyclosporin sensitivity in a heterologous context, this study provides direct in vivo evidence that the exposed loop between helices IV and V of HIV-1 CA not merely constitutes a docking site for CyPA but is a functional target of this cellular protein.	Cyclosporine	60-71	peptidylprolyl isomerase A	Homo sapiens	22-26
9380739-9	1997	By demonstrating that CyPA-binding-site residues can induce cyclosporin sensitivity in a heterologous context, this study provides direct in vivo evidence that the exposed loop between helices IV and V of HIV-1 CA not merely constitutes a docking site for CyPA but is a functional target of this cellular protein.	Cyclosporine	60-71	peptidylprolyl isomerase A	Homo sapiens	256-260
9326417-5	1997	The addition of either sirolimus or cyclosporine to CTLA4-Ig increased graft survival over that achieved with CTLA4-Ig alone.	Cyclosporine	36-48	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	52-57
9326417-5	1997	The addition of either sirolimus or cyclosporine to CTLA4-Ig increased graft survival over that achieved with CTLA4-Ig alone.	Cyclosporine	36-48	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	110-115
9326417-8	1997	CONCLUSION: These data suggest that CTLA4-Ig may be effective clinically in combination with cyclosporine or sirolimus but offers no additional effectiveness in combination with antilymphocyte serum with or without donor-specific bone marrow.	Cyclosporine	93-105	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	36-41
9261445-1	1997	Human immunodeficiency virus type 1 (HIV-1) incorporates the cellular peptidyl-prolyl cis-trans isomerase cyclophilin A (CyPA), the cytosolic receptor for the immunosuppressant cyclosporin A (CsA).	Cyclosporine	177-190	peptidylprolyl isomerase A	Homo sapiens	121-125
9261445-1	1997	Human immunodeficiency virus type 1 (HIV-1) incorporates the cellular peptidyl-prolyl cis-trans isomerase cyclophilin A (CyPA), the cytosolic receptor for the immunosuppressant cyclosporin A (CsA).	Cyclosporine	192-195	peptidylprolyl isomerase A	Homo sapiens	121-125
9261445-2	1997	CsA inhibits the incorporation of CyPA and reduces HIV-1 virion infectivity but is inactive against closely related primate lentiviruses that do not interact with CyPA.	Cyclosporine	0-3	peptidylprolyl isomerase A	Homo sapiens	34-38
9261445-4	1997	CsA, which disrupts the interaction with CA, binds at the active site of CyPA.	Cyclosporine	0-3	peptidylprolyl isomerase A	Homo sapiens	73-77
9261445-8	1997	One CyPA mutant with a substantially decreased sensitivity to CsA was incorporated with wild-type efficiency, demonstrating that the requirements for binding to CsA and to HIV-1 CA are not identical.	Cyclosporine	62-65	peptidylprolyl isomerase A	Homo sapiens	4-8
9261445-8	1997	One CyPA mutant with a substantially decreased sensitivity to CsA was incorporated with wild-type efficiency, demonstrating that the requirements for binding to CsA and to HIV-1 CA are not identical.	Cyclosporine	161-164	peptidylprolyl isomerase A	Homo sapiens	4-8
9402685-4	1997	CsA reduced the levels of IFN-gamma, IL-2, IL-5 and IL-10, but not IL-4, mRNAs.	Cyclosporine	0-3	interferon gamma	Rattus norvegicus	26-35
9402685-4	1997	CsA reduced the levels of IFN-gamma, IL-2, IL-5 and IL-10, but not IL-4, mRNAs.	Cyclosporine	0-3	interleukin 2	Rattus norvegicus	37-41
9402685-4	1997	CsA reduced the levels of IFN-gamma, IL-2, IL-5 and IL-10, but not IL-4, mRNAs.	Cyclosporine	0-3	interleukin 10	Rattus norvegicus	52-57
9288115-9	1997	Expression of IL-2 and IFN-gamma was near undetectable in CTLA4Ig and cyclophosphamide rats but was only moderately reduced by cyclosporine and antilymphocyte serum.	Cyclosporine	127-139	interleukin 2	Rattus norvegicus	14-18
9288115-9	1997	Expression of IL-2 and IFN-gamma was near undetectable in CTLA4Ig and cyclophosphamide rats but was only moderately reduced by cyclosporine and antilymphocyte serum.	Cyclosporine	127-139	interferon gamma	Rattus norvegicus	23-32
9247148-2	1997	gp120-apoptosis of the Th1 clone 103 was inhibited by Cyclosporin A, the PTK inhibitors Genistein and PNU152518, as well as the anti-oxidants Ascorbic Acid and Glutathione.	Cyclosporine	54-67	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	0-5
9247148-3	1997	Cyclosporin A interfered with CD95L expression, Ascorbic Acid and Glutathione inhibited cell death triggered by CD95/CD95L interaction; Genistein and PNU152518 acted on both steps.	Cyclosporine	0-13	Fas ligand	Homo sapiens	30-35
9247148-3	1997	Cyclosporin A interfered with CD95L expression, Ascorbic Acid and Glutathione inhibited cell death triggered by CD95/CD95L interaction; Genistein and PNU152518 acted on both steps.	Cyclosporine	0-13	Fas cell surface death receptor	Homo sapiens	30-34
9214404-14	1997	Most of the changes in the immunofluorescence deposition of the glycoproteins tenascin and fibronectin EDA+ were in the tubulointerstitium and vessels of the kidneys of rats on a LSD and were mostly significant at 28 days, in accordance with the characteristic histology of chronic CsA nephropathy.	Cyclosporine	282-285	fibronectin 1	Rattus norvegicus	91-102
9195923-2	1997	The immunophilin, which can be of the FK506- or cyclosporin A-binding class, binds to hsp90 via its tetratricopeptide repeat (TPR) domain, and different receptor heterocomplexes exist depending upon which immunophilin occupies the TPR-binding region of hsp90.	Cyclosporine	48-61	heat shock protein 90 alpha family class A member 1	Homo sapiens	86-91
9195923-8	1997	Only a small (but undetermined) fraction of the native GR.hsp90 heterocomplexes contain the cyclosporin A-binding immunophilin CyP-40.	Cyclosporine	92-105	heat shock protein 90 alpha family class A member 1	Homo sapiens	58-63
9186871-9	1997	In all rats, PAI-1 immunostaining was found mainly in intracellular vesicles (lysosomes) in proximal tubules, which stained most intensely in fibrotic areas of kidneys from CsA-treated rats.	Cyclosporine	173-176	serpin family E member 2	Rattus norvegicus	13-18
9186871-10	1997	Cholesterol feeding enhanced the CsA-induced elevation of renal PAI-1 immunostaining to a significant level.	Cyclosporine	33-36	serpin family E member 2	Rattus norvegicus	64-69
9186871-11	1997	These results show that, although serum creatinine, PAI-1 staining and T cell influx were significantly increased in the cholesterol-fed CsA-treated group compared to the other groups, renal CsA-induced histological lesions were not influenced by cholesterol feeding after short-term (3 weeks) CsA administration.	Cyclosporine	137-140	serpin family E member 2	Rattus norvegicus	52-57
9186871-12	1997	To what extent the more pronounced proximal tubular PAI-1 (inhibitor of matrix degradation) immunostaining in fibrotic areas in the cortex of cholesterol-fed CsA-treated rats contributes to the progression of CsA-induced renal fibrosis remains to be determined.	Cyclosporine	158-161	serpin family E member 2	Rattus norvegicus	52-57
9144255-4	1997	This is because overexpression of CyPA and a CyPA mutant that is deficient in CsA binding activity reverses CsA-induced reduction in functional receptor expression.	Cyclosporine	78-81	peptidylprolyl isomerase A (cyclophilin A) L homeolog	Xenopus laevis	45-49
9144255-4	1997	This is because overexpression of CyPA and a CyPA mutant that is deficient in CsA binding activity reverses CsA-induced reduction in functional receptor expression.	Cyclosporine	108-111	peptidylprolyl isomerase A (cyclophilin A) L homeolog	Xenopus laevis	34-38
9144255-4	1997	This is because overexpression of CyPA and a CyPA mutant that is deficient in CsA binding activity reverses CsA-induced reduction in functional receptor expression.	Cyclosporine	108-111	peptidylprolyl isomerase A (cyclophilin A) L homeolog	Xenopus laevis	45-49
9203968-6	1997	Treatment of IL-2 -/- mice with cyclosporin A significantly delayed mortality.	Cyclosporine	32-45	interleukin 2	Mus musculus	13-17
9163728-5	1997	A functional assay using flow cytometry showed decreased accumulation of daunorubicin in these sublines as compared to that of AML-2, which was reversed by cyclosporin A or cyanide.	Cyclosporine	156-169	RUNX family transcription factor 3	Homo sapiens	127-132
9097913-5	1997	Quantitative polymerase chain reaction analysis was used to document that both subtherapeutic (1.0 mg/kg) and therapeutic (2.0 or 4.0 mg/kg) CsA doses inhibited the expression of interferon-gamma (IFN-gamma) (P &lt; 0.03) and IL-2 (P &lt; 0.003) mRNA produced by T helper (Th) 1 cells, as well as IL-10 (P &lt; 0.001), but not IL-4 (NS) mRNA produced by Th2 cells.	Cyclosporine	141-144	interferon gamma	Rattus norvegicus	179-195
9097913-5	1997	Quantitative polymerase chain reaction analysis was used to document that both subtherapeutic (1.0 mg/kg) and therapeutic (2.0 or 4.0 mg/kg) CsA doses inhibited the expression of interferon-gamma (IFN-gamma) (P &lt; 0.03) and IL-2 (P &lt; 0.003) mRNA produced by T helper (Th) 1 cells, as well as IL-10 (P &lt; 0.001), but not IL-4 (NS) mRNA produced by Th2 cells.	Cyclosporine	141-144	interferon gamma	Rattus norvegicus	197-206
9097913-5	1997	Quantitative polymerase chain reaction analysis was used to document that both subtherapeutic (1.0 mg/kg) and therapeutic (2.0 or 4.0 mg/kg) CsA doses inhibited the expression of interferon-gamma (IFN-gamma) (P &lt; 0.03) and IL-2 (P &lt; 0.003) mRNA produced by T helper (Th) 1 cells, as well as IL-10 (P &lt; 0.001), but not IL-4 (NS) mRNA produced by Th2 cells.	Cyclosporine	141-144	interleukin 2	Rattus norvegicus	226-230
9097913-5	1997	Quantitative polymerase chain reaction analysis was used to document that both subtherapeutic (1.0 mg/kg) and therapeutic (2.0 or 4.0 mg/kg) CsA doses inhibited the expression of interferon-gamma (IFN-gamma) (P &lt; 0.03) and IL-2 (P &lt; 0.003) mRNA produced by T helper (Th) 1 cells, as well as IL-10 (P &lt; 0.001), but not IL-4 (NS) mRNA produced by Th2 cells.	Cyclosporine	141-144	interleukin 10	Rattus norvegicus	297-302
9097913-7	1997	However, heart allografts from rat recipients treated with synergistic SRL/CsA doses displayed reduced levels of IFN-gamma (P &lt; 0.01), IL-2 (P &lt; 0.001) and IL-10 (P &lt; 0.001) mRNA.	Cyclosporine	75-78	interferon gamma	Rattus norvegicus	113-122
9097913-7	1997	However, heart allografts from rat recipients treated with synergistic SRL/CsA doses displayed reduced levels of IFN-gamma (P &lt; 0.01), IL-2 (P &lt; 0.001) and IL-10 (P &lt; 0.001) mRNA.	Cyclosporine	75-78	interleukin 2	Rattus norvegicus	138-142
9097913-7	1997	However, heart allografts from rat recipients treated with synergistic SRL/CsA doses displayed reduced levels of IFN-gamma (P &lt; 0.01), IL-2 (P &lt; 0.001) and IL-10 (P &lt; 0.001) mRNA.	Cyclosporine	75-78	interleukin 10	Rattus norvegicus	162-167
9096609-0	1997	Reversal of cyclosporine-inhibited low-density lipoprotein receptor activity in HepG2 cells by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.	Cyclosporine	12-24	low density lipoprotein receptor	Homo sapiens	35-67
9096609-0	1997	Reversal of cyclosporine-inhibited low-density lipoprotein receptor activity in HepG2 cells by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.	Cyclosporine	12-24	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	95-142
9096609-5	1997	Different concentrations of cyclosporine and HMG-CoA reductase inhibitors, which were within the range of therapeutic concentrations used in humans, were added to the culture medium and the cellular LDL receptor activity was then measured.	Cyclosporine	28-40	low density lipoprotein receptor	Homo sapiens	199-211
9096609-6	1997	The results show that HMG-CoA reductase inhibitors reverse the down-regulatory effect of cyclosporine on LDL receptor activity, thus further supporting our previous findings and also providing a rationale for the already established treatment in cyclosporine-induced hypercholesterolemia with HMG-CoA reductase inhibitors.	Cyclosporine	89-101	low density lipoprotein receptor	Homo sapiens	105-117
9096609-6	1997	The results show that HMG-CoA reductase inhibitors reverse the down-regulatory effect of cyclosporine on LDL receptor activity, thus further supporting our previous findings and also providing a rationale for the already established treatment in cyclosporine-induced hypercholesterolemia with HMG-CoA reductase inhibitors.	Cyclosporine	246-258	low density lipoprotein receptor	Homo sapiens	105-117
9125450-11	1997	This assumption was supported by a second series of experiments in which CA1 damage in hyperglycemic rats was prevented by cyclosporin A, a virtually specific inhibitor of the MPT.	Cyclosporine	123-136	carbonic anhydrase 1	Rattus norvegicus	73-76
9075347-1	1997	The drug cyclosporin A (CsA) exerts its immunosuppressive action by binding to the cytosolic protein, cyclophilin (CyP) and, as a complex, binding to and inhibiting the calcium/calmodulin-dependent serine threonine phosphatase, calcineurin.	Cyclosporine	9-22	peptidylprolyl isomerase G	Homo sapiens	102-113
9075347-1	1997	The drug cyclosporin A (CsA) exerts its immunosuppressive action by binding to the cytosolic protein, cyclophilin (CyP) and, as a complex, binding to and inhibiting the calcium/calmodulin-dependent serine threonine phosphatase, calcineurin.	Cyclosporine	9-22	peptidylprolyl isomerase G	Homo sapiens	115-118
9075347-1	1997	The drug cyclosporin A (CsA) exerts its immunosuppressive action by binding to the cytosolic protein, cyclophilin (CyP) and, as a complex, binding to and inhibiting the calcium/calmodulin-dependent serine threonine phosphatase, calcineurin.	Cyclosporine	24-27	peptidylprolyl isomerase G	Homo sapiens	102-113
9075347-1	1997	The drug cyclosporin A (CsA) exerts its immunosuppressive action by binding to the cytosolic protein, cyclophilin (CyP) and, as a complex, binding to and inhibiting the calcium/calmodulin-dependent serine threonine phosphatase, calcineurin.	Cyclosporine	24-27	peptidylprolyl isomerase G	Homo sapiens	115-118
9075347-5	1997	Both proteins were calcium- and calmodulin-dependent and were inhibited by mammalian cyclophilin complexed with cyclosporin A (IC50 values of 0.75 microgram CyP for H. microstoma and 0.90 microgram CyP for H. diminuta).	Cyclosporine	112-125	peptidylprolyl isomerase G	Homo sapiens	85-96
9075347-5	1997	Both proteins were calcium- and calmodulin-dependent and were inhibited by mammalian cyclophilin complexed with cyclosporin A (IC50 values of 0.75 microgram CyP for H. microstoma and 0.90 microgram CyP for H. diminuta).	Cyclosporine	112-125	peptidylprolyl isomerase G	Homo sapiens	157-160
12671222-0	1999	Decreased Cyclosporin A requirement with anti-ICAM-1 and anti-LFA-1 in a peripheral nerve allotransplantation model.	Cyclosporine	10-23	integrin subunit alpha L	Rattus norvegicus	62-67
9034151-8	1997	In contrast, the calcineurin inhibitor cyclosporin A, which inhibits DPK cell differentiation as well as positive selection, inhibits expression of Egr-2 and Egr-3, but not Egr-1.	Cyclosporine	39-52	early growth response 2	Mus musculus	148-153
9034151-8	1997	In contrast, the calcineurin inhibitor cyclosporin A, which inhibits DPK cell differentiation as well as positive selection, inhibits expression of Egr-2 and Egr-3, but not Egr-1.	Cyclosporine	39-52	early growth response 1	Mus musculus	173-178
9067703-0	1997	Differences in responses of interleukin-1 and tumor necrosis factor alpha production and secretion to cyclosporin-A and ultraviolet B-irradiation by normal and transformed keratinocyte cultures.	Cyclosporine	102-115	interleukin 1 alpha	Homo sapiens	28-73
10363590-8	1999	The percentage of detectable serum IL-2 level was 45% in the allograft control group, but was undetectable in groups treated with the most effective dose of tacrolimus or CyA at days 3 and 6 after grafting.	Cyclosporine	171-174	interleukin 2	Rattus norvegicus	35-39
9354965-8	1997	The activities of renal and hepatic ATPase, glucose-6-phosphatase as well as the concentrations of thiols were decreased significantly (p &lt; 0.001) when cyclosporin A was administered under hyperoxaluric condition.	Cyclosporine	155-168	glucose-6-phosphatase catalytic subunit 1	Rattus norvegicus	44-65
9857002-6	1998	Despite elimination of both strong NFAT-binding sites, the IFN-gamma promoter remained completely sensitive to inhibition by cyclosporin.	Cyclosporine	125-136	nuclear factor of activated T cells 2	Homo sapiens	35-39
9843854-0	1998	CsA-sensitive purine-box transcriptional regulator in bronchial epithelial cells contains NF45, NF90, and Ku.	Cyclosporine	0-3	interleukin enhancer binding factor 3	Homo sapiens	96-100
9051725-0	1997	Cyclosporine A-induced contractions and prostacyclin release are maintained by extracellular calcium in rat aortic rings: role of protein kinase C. Chronic treatment with the immunosuppressive drug, Cyclosporine A (CsA), is associated with increased intracellular calcium in vascular smooth muscle cells, which may cause vasoconstriction and/or activate phospholipase A2.	Cyclosporine	0-14	phospholipase A2 group IB	Rattus norvegicus	354-370
9051725-0	1997	Cyclosporine A-induced contractions and prostacyclin release are maintained by extracellular calcium in rat aortic rings: role of protein kinase C. Chronic treatment with the immunosuppressive drug, Cyclosporine A (CsA), is associated with increased intracellular calcium in vascular smooth muscle cells, which may cause vasoconstriction and/or activate phospholipase A2.	Cyclosporine	199-213	phospholipase A2 group IB	Rattus norvegicus	354-370
9884067-4	1998	Cyclosporin A and FK506 caused a concentration-dependent contraction in guinea-pig isolated bronchus, which was significantly attenuated by NK-1 and NK-2 receptor antagonists.	Cyclosporine	0-13	substance-K receptor	Cavia porcellus	149-162
9839278-0	1998	CsA and FK506 up-regulate eNOS expression: role of reactive oxygen species and AP-1.	Cyclosporine	0-3	Jun proto-oncogene, AP-1 transcription factor subunit	Bos taurus	79-83
9839278-7	1998	Electrophoretic mobility shift assays were consistent with an increase in AP-1 DNA-binding activity in BAEC treated with CsA or glucose oxidase.	Cyclosporine	121-124	Jun proto-oncogene, AP-1 transcription factor subunit	Bos taurus	74-78
9042589-0	1997	Diurnal changes in cyclosporine effect on ornithine decarboxylase and noradrenergic and cholinergic activities in submaxillary lymph nodes.	Cyclosporine	19-31	ornithine decarboxylase 1	Rattus norvegicus	42-65
9839279-0	1998	Cyclosporine A induces apoptosis in murine tubular epithelial cells: role of caspases.	Cyclosporine	0-14	caspase 8	Mus musculus	77-85
9042589-1	1997	Diurnal changes in cyclosporine efficacy to affect ornithine decarboxylase activity, [3H]norepinephrine uptake and [3H]choline conversion into [3H]acetylcholine were examined in rat submaxillary lymph nodes.	Cyclosporine	19-31	ornithine decarboxylase 1	Rattus norvegicus	51-74
9042589-2	1997	Cyclosporine (5 or 20 mg/kg) caused a dose-dependent decrease in lymph node ornithine decarboxylase, being active at 5 or 20 mg/kg in Freund"s adjuvant-treated rats, and at 20 mg/kg in rats treated with the adjuvant"s vehicle.	Cyclosporine	0-12	ornithine decarboxylase 1	Rattus norvegicus	76-99
9839279-6	1998	Peptide inhibitors of caspases such as zVAD-fmk (which inhibits caspases 8 and 9) and DEVD-CHO (which inhibits caspase 3 and related caspases) prevented CsA-induced apoptosis in MCT cells, although zVAD-fmk was effective at lower concentrations.	Cyclosporine	153-156	caspase 8	Mus musculus	22-30
9042589-7	1997	After unilateral sympathetic denervation (by superior cervical ganglionectomy) and/or unilateral parasympathetic decentralization (by chorda tympani section), cyclosporine (5 mg/kg) decreased Freund"s adjuvant-induced activation of lymph node ornithine decarboxylase when injected at 17:00 or 01:00 h. On the sham-operated side, cyclosporine was effective when injected at 17:00 h only.	Cyclosporine	159-171	ornithine decarboxylase 1	Rattus norvegicus	243-266
9839279-6	1998	Peptide inhibitors of caspases such as zVAD-fmk (which inhibits caspases 8 and 9) and DEVD-CHO (which inhibits caspase 3 and related caspases) prevented CsA-induced apoptosis in MCT cells, although zVAD-fmk was effective at lower concentrations.	Cyclosporine	153-156	caspase 8	Mus musculus	64-80
9839279-7	1998	CONCLUSION: These data suggest that tubular cell apoptosis mediated by caspases may play a role in CsA nephrotoxicity and that the microenvironment modulates resistance to CsA lethality as low local levels of survival factors may potentiate nephrotoxicity.	Cyclosporine	99-102	caspase 8	Mus musculus	71-79
9819402-4	1998	As a result, we identified a 27-bp promoter element functionally interacting with transcription factors NF-ATp and NF-ATc that is crucial for the CsA-sensitive expression of the EGR3 gene in T cells.	Cyclosporine	146-149	nuclear factor of activated T cells 2	Homo sapiens	104-110
8999806-6	1997	Furthermore, the dephosphorylated NF-AT1 can be rapidly rephosphorylated when the cells are incubated with cyclosporin A, an immunosuppressant inhibiting the serine/threonine phosphatase calcineurin.	Cyclosporine	107-120	nuclear factor of activated T cells 2	Homo sapiens	34-40
9819402-4	1998	As a result, we identified a 27-bp promoter element functionally interacting with transcription factors NF-ATp and NF-ATc that is crucial for the CsA-sensitive expression of the EGR3 gene in T cells.	Cyclosporine	146-149	early growth response 3	Homo sapiens	178-182
9020523-0	1997	The effects of cyclosporin A, dexamethasone and other immunomodulatory drugs on induced expression of IL-3, IL-4 and IL-8 mRNA in a human mast cell line.	Cyclosporine	15-28	interleukin 3	Homo sapiens	102-106
9020523-3	1997	Treatment of the cells with the immunosuppressant CsA at 10(-5) M produced a significant inhibition of ionomycin-induced expression of IL-3, IL-4 and IL-8 mRNA, and at 10(-6) M produced a significant inhibition of induced expression of IL-3 and IL-8 but not IL-4.	Cyclosporine	50-53	interleukin 3	Homo sapiens	135-139
9819402-5	1998	In contrast, the same element was without function in fibroblasts, and other, CsA-insensitive promoter regions were found to be responsible for EGR3 gene expression in these cells.	Cyclosporine	78-81	early growth response 3	Homo sapiens	144-148
9020523-3	1997	Treatment of the cells with the immunosuppressant CsA at 10(-5) M produced a significant inhibition of ionomycin-induced expression of IL-3, IL-4 and IL-8 mRNA, and at 10(-6) M produced a significant inhibition of induced expression of IL-3 and IL-8 but not IL-4.	Cyclosporine	50-53	interleukin 3	Homo sapiens	236-240
9020523-4	1997	At both concentrations of CsA, expression of IL-3 was inhibited to a greater extent than that of the other two cytokines.	Cyclosporine	26-29	interleukin 3	Homo sapiens	45-49
9819402-7	1998	The differential usage of an NF-AT binding site explains the selective effect of CsA on EGR3 gene expression in T cells versus fibroblasts and may represent one of the basic mechanisms underlying the tissue specificity of CsA.	Cyclosporine	81-84	nuclear factor of activated T cells 2	Homo sapiens	29-34
9020523-7	1997	In conclusion, this study shows that cytokine expression, particularly of IL-3, is inhibited in a human mast cell line by CsA and DEX.	Cyclosporine	122-125	interleukin 3	Homo sapiens	74-78
9819402-7	1998	The differential usage of an NF-AT binding site explains the selective effect of CsA on EGR3 gene expression in T cells versus fibroblasts and may represent one of the basic mechanisms underlying the tissue specificity of CsA.	Cyclosporine	81-84	early growth response 3	Homo sapiens	88-92
9043670-3	1997	These are devoid of immunosuppressive activity in vitro but they have binding affinity for cyclophilin A (CypA) similar to that of CsA and thus represent a new class of cyclosporin antagonists.	Cyclosporine	169-180	peptidylprolyl isomerase A	Homo sapiens	91-104
9846517-5	1998	Vit E minimized the adverse effects of CsA on kidney function and the glomerular synthesis of these compounds.	Cyclosporine	39-42	vitrin	Rattus norvegicus	0-3
9043670-3	1997	These are devoid of immunosuppressive activity in vitro but they have binding affinity for cyclophilin A (CypA) similar to that of CsA and thus represent a new class of cyclosporin antagonists.	Cyclosporine	169-180	peptidylprolyl isomerase A	Homo sapiens	106-110
9043670-5	1997	A comparison of this NMR data with X-ray crystallographic analysis of a CypA/CsA derivative complex demonstrates that the solution structure does not correspond to the bioactive conformation.	Cyclosporine	77-80	peptidylprolyl isomerase A	Homo sapiens	72-76
9846517-7	1998	Treatment with Vit E prevented these effects, suggesting a possible role for antioxidants in the prevention of CsA nephrotoxicity.	Cyclosporine	111-114	vitrin	Rattus norvegicus	15-18
9840924-9	1998	While the activation of the IL-2 promoter and an NFAT-driven minimal promoter by Tpl-2 was fully blocked by the dominant negative mutant NFAT delta418, it was only partially blocked by the calcineurin inhibitor cyclosporin A suggesting that the Tpl-2-mediated NFAT activation is under the control of a combination of calcineurin-dependent and independent pathways.	Cyclosporine	211-224	mitogen-activated protein kinase kinase kinase 8	Mus musculus	81-86
9815538-6	1997	In vitro, CsA significantly enhanced the efficacy of PCL against lung (Lu-CSF-1 and 3LL) and oropharyngeal (CSCC-20) cancer cell lines.	Cyclosporine	10-13	colony stimulating factor 1	Homo sapiens	74-87
9794788-0	1998	Stimulation of the Ca2+-mediated egr-1 and c-fos expression in murine erythroleukaemia cells by cyclosporin A.	Cyclosporine	96-109	early growth response 1	Mus musculus	33-38
9794788-0	1998	Stimulation of the Ca2+-mediated egr-1 and c-fos expression in murine erythroleukaemia cells by cyclosporin A.	Cyclosporine	96-109	FBJ osteosarcoma oncogene	Mus musculus	43-48
9762012-6	1998	Protein kinase A (PKA) inhibitors, H-89 and HA-1004 and EGTA blocked FK506- and CsA-induced GH release.	Cyclosporine	80-83	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	0-16
9762012-6	1998	Protein kinase A (PKA) inhibitors, H-89 and HA-1004 and EGTA blocked FK506- and CsA-induced GH release.	Cyclosporine	80-83	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	18-21
9762012-9	1998	These results suggest that the immunosuppressants, FK506 and CsA, stimulate GH release by inhibiting CaN activity which results in the activation of the PKA system in the rat somatotropes.	Cyclosporine	61-64	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	153-156
9759885-6	1998	Stem cell factor (SCF)-induced activation of JNK and p38 was insensitive to wortmannin, cyclosporin A, and FK506 whereas activation of these kinases through Fc epsilonRI was sensitive to these drugs.	Cyclosporine	88-101	kit ligand	Mus musculus	18-21
27406861-7	1997	G-CSF may be useful in the treatment of severe resistant infections and it may be of benefit when used after treatment with ATG and cyclosporin.	Cyclosporine	132-143	colony stimulating factor 3	Homo sapiens	0-5
9709036-1	1998	The immunosuppressive fungal products cyclosporin A (CsA) and FK506 bind with high affinity to intracellular receptor proteins: cyclophilin (CYP) is one of the receptors for CsA and FK506-binding protein (FKBP) is one of the receptors for FK506.	Cyclosporine	38-51	peptidylprolyl isomerase G	Homo sapiens	128-139
9709036-1	1998	The immunosuppressive fungal products cyclosporin A (CsA) and FK506 bind with high affinity to intracellular receptor proteins: cyclophilin (CYP) is one of the receptors for CsA and FK506-binding protein (FKBP) is one of the receptors for FK506.	Cyclosporine	38-51	peptidylprolyl isomerase G	Homo sapiens	141-144
9767457-7	1998	Moreover extended studies demonstrated that in cultured rat spleen cells the expression of lymphotactin mRNA was markedly induced by phytohaemagglutinin (PHA) or phorbol myristate acetate (PMA), and such induction was inhibited by the immunosuppressive drugs FK506 and cyclosporin.	Cyclosporine	269-280	X-C motif chemokine ligand 1	Rattus norvegicus	91-103
8970375-2	1996	CSA efficacy was demonstrated by inhibition of interleukin-2 (IL-2) production from phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear (PBMN) cells.	Cyclosporine	0-3	interleukin 2	Felis catus	47-60
9767457-9	1998	FK506 and cyclosporin inhibition of lymphotactin expression is likely to represent an important molecular mechanism of the action of the drugs.	Cyclosporine	10-21	X-C motif chemokine ligand 1	Rattus norvegicus	36-48
8970375-2	1996	CSA efficacy was demonstrated by inhibition of interleukin-2 (IL-2) production from phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear (PBMN) cells.	Cyclosporine	0-3	interleukin 2	Felis catus	62-66
9705263-5	1998	In single-cycle infection assays, nef-defective virions were partially resistant to cyclosporin A (CsA), a drug that inhibits the binding of CyPA to the HIV-1 Gag precursor and CyPA incorporation into virions.	Cyclosporine	84-97	peptidylprolyl isomerase A	Homo sapiens	141-145
8906804-6	1996	While the addition of rIL-2 reversed the inhibitory effect of cyclosporin A and FK506, the addition of rIL-4, rIL-7, or rIFN-gamma did not, although these cytokines induced progression into the S phase of the cell cycle.	Cyclosporine	62-75	interleukin 2	Rattus norvegicus	22-27
9808867-8	1998	The use of cyclosporine A levels &gt; 3 mg/kg/day, HMG-CoA-reductase inhibitors and calcium antagonists has been shown to decrease the progression of CAV.	Cyclosporine	11-25	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	51-68
8912887-1	1996	The most evident immunosuppressive effect of cyclosporin A (CsA) on T cells is suppression of interleukin-2 (IL-2) production through the suppression of type-2B serine/threonine-specific phosphatase, calcineurin.	Cyclosporine	60-63	interleukin 2	Mus musculus	94-107
8912887-1	1996	The most evident immunosuppressive effect of cyclosporin A (CsA) on T cells is suppression of interleukin-2 (IL-2) production through the suppression of type-2B serine/threonine-specific phosphatase, calcineurin.	Cyclosporine	60-63	interleukin 2	Mus musculus	109-113
8912887-4	1996	We also found that CsA-treatment decreased the expression of lck kinase of T cells and the production of IL-2 in response to concanavalin A (ConA), with minimum effect on IL-4 production.	Cyclosporine	19-22	interleukin 2	Mus musculus	105-109
8912887-4	1996	We also found that CsA-treatment decreased the expression of lck kinase of T cells and the production of IL-2 in response to concanavalin A (ConA), with minimum effect on IL-4 production.	Cyclosporine	19-22	interleukin 4	Mus musculus	171-175
9010851-9	1996	The complex of CsA or FK506 with CyP or FKBP, respectively, inhibits the activation of calcineurin.	Cyclosporine	15-18	peptidylprolyl isomerase G	Homo sapiens	33-36
8906214-10	1996	Cyclosporin A inhibited in vivo production of IFN-gamma, IL-4, and IL-5 by approximately 80%, but not that of IL-6.	Cyclosporine	0-13	interleukin 4	Mus musculus	57-61
8906214-10	1996	Cyclosporin A inhibited in vivo production of IFN-gamma, IL-4, and IL-5 by approximately 80%, but not that of IL-6.	Cyclosporine	0-13	interleukin 5	Mus musculus	67-71
8906215-5	1996	Cyclosporin A, FK-506, and cyclophosphamide clearly inhibited the antigen-induced increase of IL-5 and eosinophils in BALF.	Cyclosporine	0-13	interleukin 5	Mus musculus	94-98
8901600-7	1996	Competitive reverse transcriptase-PCR and immunohistological analysis of allografts at 8, 16, and 24 weeks showed attenuation of lymphocyte and macrophage infiltration and activation in the CTLA4Ig-treated animals, as compared with cyclosporine-alone treated controls.	Cyclosporine	232-244	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	190-195
8930631-5	1996	CsA (1.6 micrograms/ml for 10 days) inhibited the growth of keratinocytes, which never reached confluence; most cells appeared small and roundish, only some stained for cytokeratins and few for vimentin.	Cyclosporine	0-3	vimentin	Homo sapiens	194-202
8816436-2	1996	In both cases, induction of TNF-alpha gene transcription can be blocked by the immunosuppressants cyclosporin A and FK506, which suggested a role for the NFAT family of proteins in the regulation of the gene in B cells.	Cyclosporine	98-111	nuclear factor of activated T cells 2	Homo sapiens	154-158
8830822-4	1996	Drug exposure was estimated by the average CsA concentration (Cav), which was defined as a time-corrected (tau, hours) expression of the area under the concentration-time curve (AUC), i.e., Cav = (AUC/tau).	Cyclosporine	43-46	caveolin 2	Homo sapiens	62-65
8830822-4	1996	Drug exposure was estimated by the average CsA concentration (Cav), which was defined as a time-corrected (tau, hours) expression of the area under the concentration-time curve (AUC), i.e., Cav = (AUC/tau).	Cyclosporine	43-46	caveolin 2	Homo sapiens	190-193
8830822-6	1996	The present study examines the results of serial pharmacokinetic profiling of a cohort of 204 patients treated for up to 5 years with CsA doses selected to achieve target Cav values.	Cyclosporine	134-137	caveolin 2	Homo sapiens	171-174
8809139-0	1996	Susceptibility to clinically manifest cyclosporine A (CsA)-induced autoimmune disease is associated with interferon-gamma (IFN-gamma)-producing CD45RC+RT6- T helper cells.	Cyclosporine	38-52	interferon gamma	Rattus norvegicus	105-121
8809139-0	1996	Susceptibility to clinically manifest cyclosporine A (CsA)-induced autoimmune disease is associated with interferon-gamma (IFN-gamma)-producing CD45RC+RT6- T helper cells.	Cyclosporine	38-52	interferon gamma	Rattus norvegicus	123-132
8809139-0	1996	Susceptibility to clinically manifest cyclosporine A (CsA)-induced autoimmune disease is associated with interferon-gamma (IFN-gamma)-producing CD45RC+RT6- T helper cells.	Cyclosporine	54-57	interferon gamma	Rattus norvegicus	105-121
8809139-0	1996	Susceptibility to clinically manifest cyclosporine A (CsA)-induced autoimmune disease is associated with interferon-gamma (IFN-gamma)-producing CD45RC+RT6- T helper cells.	Cyclosporine	54-57	interferon gamma	Rattus norvegicus	123-132
8814265-0	1996	Cyclosporin A sensitivity of the HIV-1 long terminal repeat identifies distinct p56lck-dependent pathways activated by CD4 triggering.	Cyclosporine	0-13	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	80-86
8884530-4	1996	FK506 and CsA inhibit keratinocyte proliferation induced by EGF, TGF-alpha or IL-6.	Cyclosporine	10-13	epidermal growth factor	Homo sapiens	60-63
8884530-6	1996	These findings might indicate that the effects of FK506 and CsA on proliferation of cultured normal human keratinocytes are probably related to direct effects on growth regulation of keratinocytes via EGF, TGF-alpha or IL-6 stimulation.	Cyclosporine	60-63	epidermal growth factor	Homo sapiens	201-204
8880226-0	1996	Dexamethasone or cyclosporin A inhibits stem cell factor-dependent secretory responses of rat peritoneal mast cells in vitro.	Cyclosporine	17-30	KIT ligand	Rattus norvegicus	40-56
8880226-2	1996	In this study we report that the anti-inflammatory glucocorticoid dexamethasone (DEX) and the immunosuppressive cyclosporin A (CsA) are both effective inhibitors of SCF-induced degranulation of rat peritoneal mast cells in vitro, measured as release of serotonin (5-HT).	Cyclosporine	112-125	KIT ligand	Rattus norvegicus	165-168
8880226-2	1996	In this study we report that the anti-inflammatory glucocorticoid dexamethasone (DEX) and the immunosuppressive cyclosporin A (CsA) are both effective inhibitors of SCF-induced degranulation of rat peritoneal mast cells in vitro, measured as release of serotonin (5-HT).	Cyclosporine	127-130	KIT ligand	Rattus norvegicus	165-168
8880226-4	1996	CsA produced a similar degree of inhibition of degranulation induced by SCF, anti-IgE or ionophore, but was without effect on the response to compound 48/80.	Cyclosporine	0-3	KIT ligand	Rattus norvegicus	72-75
8880226-6	1996	We conclude that both DEX and CsA inhibit components of the secretion-coupling pathways that are triggered following either SCF receptor engagement or cross-linking of IgE, but that these drug differentially influence mast cell secretion induced by compound 48/80 or the calcium ionophore A23187.	Cyclosporine	30-33	KIT ligand	Rattus norvegicus	124-127
8688451-2	1996	The permeability transition pore (MTP) is a high conductance channel of the mitochondrial inner membrane inhibited by cyclosporin A.	Cyclosporine	118-131	metallothionein 1B	Homo sapiens	34-37
8844128-6	1996	However, CsA at higher concentrations inhibited the histamine release induced by anti-IgE antibody or substance P more markedly than FK506.	Cyclosporine	9-12	tachykinin 1	Mus musculus	102-113
9808867-8	1998	The use of cyclosporine A levels &gt; 3 mg/kg/day, HMG-CoA-reductase inhibitors and calcium antagonists has been shown to decrease the progression of CAV.	Cyclosporine	11-25	caveolin 2	Homo sapiens	150-153
9703316-11	1998	Also, the effect of troglitazone on LDL catabolism was studied in the presence of cyclosporine, an immunosuppressant drug that reduces LDL catabolism mainly by decreasing LDL receptor activity.	Cyclosporine	82-94	low density lipoprotein receptor	Homo sapiens	171-183
9703316-12	1998	The results showed that troglitazone can compensate for the reduced LDL receptor activity induced by cyclosporine, but that cyclosporine had a residual effect on the action of troglitazone.	Cyclosporine	101-113	low density lipoprotein receptor	Homo sapiens	68-80
9740060-5	1998	The discovery of calbindin-D 28 kDa being involved in CsA toxicity has evolved from the application of 2-DE and has not been reported previously, proving that proteomics can provide essential information in mechanistic toxicology.	Cyclosporine	54-57	calbindin 1	Homo sapiens	17-31
9664131-1	1998	In an attempt to identify the target protein, P-GP or mrp, of each MDR antagonist, verapamyl (Ver), dipyridamole (Dip), or cyclosporin A (Cy-A), this study was designed to compare the activity of the three afore-mentioned drugs and to test their combined effect on the cidal activity of vincristine (VCR) in five types of wild and the corresponding VCR-resistant cultured cell lines from human leukemia and lymphoma.	Cyclosporine	123-136	phosphoglycolate phosphatase	Homo sapiens	46-50
9664131-1	1998	In an attempt to identify the target protein, P-GP or mrp, of each MDR antagonist, verapamyl (Ver), dipyridamole (Dip), or cyclosporin A (Cy-A), this study was designed to compare the activity of the three afore-mentioned drugs and to test their combined effect on the cidal activity of vincristine (VCR) in five types of wild and the corresponding VCR-resistant cultured cell lines from human leukemia and lymphoma.	Cyclosporine	138-142	phosphoglycolate phosphatase	Homo sapiens	46-50
9688340-0	1998	Behaviorally conditioned immunosuppression using cyclosporine A: central nervous system reduces IL-2 production via splenic innervation.	Cyclosporine	49-63	interleukin 2	Rattus norvegicus	96-100
9687567-8	1998	Of the mRNAs tested, only those encoding monocyte chemotactic protein-1 (approximately 2-fold over basal) and interleukin-8 (approximately 6-fold over basal) are induced by histamine; both of these responses are suppressed by CsA and FK506.	Cyclosporine	226-229	C-C motif chemokine ligand 2	Homo sapiens	41-71
9723388-0	1998	Additive effect of cyclosporine and low density lipoproteins on transforming growth factor-beta 1 and monocyte chemotactic protein-1 expression in human mesangial cells.	Cyclosporine	19-31	C-C motif chemokine ligand 2	Homo sapiens	102-132
9675023-1	1998	The calcium- and calmodulin-activated protein phosphatase calcineurin (CN) is the target for the immunosuppressive drugs FK506 and cyclosporin A (CsA) when bound to their intracellular receptor proteins, the immunophilins known as FK506-binding protein (FKBP) and cyclophilin A (CypA), respectively.	Cyclosporine	131-144	peptidylprolyl isomerase A	Homo sapiens	264-277
9675023-1	1998	The calcium- and calmodulin-activated protein phosphatase calcineurin (CN) is the target for the immunosuppressive drugs FK506 and cyclosporin A (CsA) when bound to their intracellular receptor proteins, the immunophilins known as FK506-binding protein (FKBP) and cyclophilin A (CypA), respectively.	Cyclosporine	131-144	peptidylprolyl isomerase A	Homo sapiens	279-283
9675023-1	1998	The calcium- and calmodulin-activated protein phosphatase calcineurin (CN) is the target for the immunosuppressive drugs FK506 and cyclosporin A (CsA) when bound to their intracellular receptor proteins, the immunophilins known as FK506-binding protein (FKBP) and cyclophilin A (CypA), respectively.	Cyclosporine	146-149	peptidylprolyl isomerase A	Homo sapiens	264-277
9675023-1	1998	The calcium- and calmodulin-activated protein phosphatase calcineurin (CN) is the target for the immunosuppressive drugs FK506 and cyclosporin A (CsA) when bound to their intracellular receptor proteins, the immunophilins known as FK506-binding protein (FKBP) and cyclophilin A (CypA), respectively.	Cyclosporine	146-149	peptidylprolyl isomerase A	Homo sapiens	279-283
9675023-10	1998	Inhibition of CN by the CsA x CypA complex was not time-dependent, but the data did conform to a competitive inhibition model like FK506 x FKBP.	Cyclosporine	24-27	peptidylprolyl isomerase A	Homo sapiens	30-34
9632757-4	1998	Activation-induced expression of Egr-3, like that of FasL, was inhibited by cyclosporin A, whereas expression of Egr-1 was unaffected.	Cyclosporine	76-89	early growth response 3	Homo sapiens	33-38
9632757-4	1998	Activation-induced expression of Egr-3, like that of FasL, was inhibited by cyclosporin A, whereas expression of Egr-1 was unaffected.	Cyclosporine	76-89	Fas ligand	Homo sapiens	53-57
9667228-6	1998	In a supplementary study separating the effects of the two immunosuppressants, the kidney IGF-I changes and renal growth were primarily affected by CsA, while the changes in IGFBPs appeared to be caused by prednisolone treatment.	Cyclosporine	148-151	insulin-like growth factor 1	Rattus norvegicus	90-95
8704176-3	1996	Activation of the IL-5 promoter required costimulation of T cells with phorbol ester (phorbol 12-myristate 13-acetate [PMA]) and cyclic adenosine 3",5"-monophosphate (cAMP), but was blocked by the immunosuppressive drug, cyclosporin A (CsA).	Cyclosporine	236-239	interleukin 5	Mus musculus	18-22
9667228-7	1998	In conclusion, immunosuppression with prednisolone and CsA was followed by less kidney IGF-I accumulation and compensatory renal growth compared with placebo treatment.	Cyclosporine	55-58	insulin-like growth factor 1	Rattus norvegicus	87-92
9616142-2	1998	There was a good correlation between MRP expression and the modulatory effect of probenecid (a specific modulator of MRP) on the calcein efflux (r = .91, P = .0003) and between Pgp expression and the modulatory effect of CsA on calcein-AM uptake (r = .96, P &lt; .0001).	Cyclosporine	221-224	MARCKS like 1	Homo sapiens	37-40
8661983-11	1996	Rats receiving IGF-I 200 microg/kg and IGF-I 600 microg/kg gained more weight than either vehicle- or CsA-treated animals, attesting to IGF-1"s anabolic properties.	Cyclosporine	102-105	insulin-like growth factor 1	Rattus norvegicus	136-141
8661983-14	1996	IGF-I increased endocortical matrix synthesis, as evidenced by the increases in the percent endocortical osteoid perimeter, an effect negated by the addition of CsA.	Cyclosporine	161-164	insulin-like growth factor 1	Rattus norvegicus	0-5
8766550-0	1996	T cell activation by concanavalin A in the presence of cyclosporin A: immunosuppressor withdrawal induces NFATp translocation and interleukin-2 gene transcription.	Cyclosporine	55-68	nuclear factor of activated T cells 2	Homo sapiens	106-111
8807571-1	1996	In contrast to the well characterized suppressive effect of cyclosporine A (CsA) on IL-2 gene transcription in T cells, other immunosuppressive effects of CsA have received less attention.	Cyclosporine	76-79	interleukin 2	Mus musculus	84-88
8807571-2	1996	We have examined the effect of CsA on the expression of the beta 2 integrin, LFA-1, and its counter receptor, ICAM-1, on a renal Ag-specific murine T cell clone and Ag-expressing renal tubular epithelial cells.	Cyclosporine	31-34	integrin alpha L	Mus musculus	60-82
8807571-6	1996	Although CsA does not inhibit ICAM-1 on T cells, it does inhibit surface expression of LFA-1.	Cyclosporine	9-12	integrin alpha L	Mus musculus	87-92
9714326-1	1998	Recently, we reported that in rat, cyclosporine A (CsA) markedly decreases the levels of calbindin-D (CABP-D) 28 kDa in kidney.	Cyclosporine	35-49	S100 calcium binding protein G	Rattus norvegicus	102-106
8668213-3	1996	When expressed in Jurkat T cells, recombinant NFAT1 is regulated, as expected, by the calmodulin-dependent phosphatase calcineurin, and its function is inhibited by the immunosuppressive agent cyclosporin A (CsA).	Cyclosporine	193-206	nuclear factor of activated T cells 2	Homo sapiens	46-51
8668213-3	1996	When expressed in Jurkat T cells, recombinant NFAT1 is regulated, as expected, by the calmodulin-dependent phosphatase calcineurin, and its function is inhibited by the immunosuppressive agent cyclosporin A (CsA).	Cyclosporine	208-211	nuclear factor of activated T cells 2	Homo sapiens	46-51
9714326-1	1998	Recently, we reported that in rat, cyclosporine A (CsA) markedly decreases the levels of calbindin-D (CABP-D) 28 kDa in kidney.	Cyclosporine	51-54	S100 calcium binding protein G	Rattus norvegicus	102-106
8668213-4	1996	Transactivation by recombinant NFAT1 in Jurkat T cells requires dual stimulation with ionomycin and phorbol 12-myristate 13-acetate; this activity is potentiated by coexpression of constitutively active calcineurin and is inhibited by CsA.	Cyclosporine	235-238	nuclear factor of activated T cells 2	Homo sapiens	31-36
9714326-3	1998	In this study, we investigated whether, in addition to the kidney, CsA also has an effect on CABP-D 28 kDa in rat brain.	Cyclosporine	67-70	S100 calcium binding protein G	Rattus norvegicus	93-97
9614221-6	1998	The apoptosis-enhancing action of mutant PS-1 was prevented by antioxidants (propyl gallate and glutathione), zVAD-fmk, and cyclosporin A, indicating requirements of reactive oxygen species (ROS), caspases, and mitochondrial permeability transition in the cell death process.	Cyclosporine	124-137	presenilin 1	Rattus norvegicus	41-45
8679570-1	1996	Binding of mitochondrial cyclophilin (CyP) to the inner mitochondrial membrane is induced by treatment of mitochondria with thiol reagents or oxidative stress and correlates with a sensitization to [Ca2+] of the cyclosporin A-sensitive mitochondrial permeability transition pore (MTP) [Connern, C. P., &amp; Halestrap, A. P. (1994) Biochem.	Cyclosporine	212-225	peptidylprolyl isomerase G	Homo sapiens	25-36
8679570-1	1996	Binding of mitochondrial cyclophilin (CyP) to the inner mitochondrial membrane is induced by treatment of mitochondria with thiol reagents or oxidative stress and correlates with a sensitization to [Ca2+] of the cyclosporin A-sensitive mitochondrial permeability transition pore (MTP) [Connern, C. P., &amp; Halestrap, A. P. (1994) Biochem.	Cyclosporine	212-225	peptidylprolyl isomerase G	Homo sapiens	38-41
9647467-15	1998	Electrophoretic mobility shift assays were consistent with an increase in AP-1 DNA-binding activity in BAEC treated with CsA or glucose oxidase.	Cyclosporine	121-124	Jun proto-oncogene, AP-1 transcription factor subunit	Bos taurus	74-78
8662717-3	1996	The Ca2+-induced suppression of c-myb mRNA could be inhibited by the calmodulin antagonists trifluoperazine and calmidazolium, as well as by cyclosporin A, an inhibitor of the Ca2+/calmodulin-dependent protein phosphatase 2B (calcineurin).	Cyclosporine	141-154	myeloblastosis oncogene	Mus musculus	32-37
8662717-5	1996	In cyclosporin A-treated ELM-I-1 cells, a close correlation could be demonstrated between the antagonization of the Ca2+ effect on c-myb mRNA levels and inhibition of the calcineurin phophatase activity.	Cyclosporine	3-16	myeloblastosis oncogene	Mus musculus	131-136
9620082-1	1998	PURPOSE: To determine whether a p-glycoprotein (P-gp) drug efflux pump exists in cultured rabbit conjunctival epithelial cells (RCEs) to restrict the absorption of cyclosporin A (CSA) and other lipophilic drugs such as verapamil and dexamethasone.	Cyclosporine	164-177	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	32-46
8662717-7	1996	The erythropoietin-induced down-regulation of c-myb mRNA levels could be demonstrated also in the presence of EGTA and was resistant to calmodulin antagonists and cyclosporin A.	Cyclosporine	163-176	erythropoietin	Mus musculus	4-18
8662717-7	1996	The erythropoietin-induced down-regulation of c-myb mRNA levels could be demonstrated also in the presence of EGTA and was resistant to calmodulin antagonists and cyclosporin A.	Cyclosporine	163-176	myeloblastosis oncogene	Mus musculus	46-51
9620082-1	1998	PURPOSE: To determine whether a p-glycoprotein (P-gp) drug efflux pump exists in cultured rabbit conjunctival epithelial cells (RCEs) to restrict the absorption of cyclosporin A (CSA) and other lipophilic drugs such as verapamil and dexamethasone.	Cyclosporine	164-177	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	48-52
24178476-1	1996	The mixture of products obtained by alkaline treatment of cyclosporin A was analyzed by HPLC-continuous-flow-FAB/MS.	Cyclosporine	58-71	FA complementation group B	Homo sapiens	109-112
8843593-7	1996	The proliferative response of gamma delta T cells among spleen cells from TCR alpha beta-depleted Tg.Tlaa-3-1 mice was also inhibited by CsA and FK506, suggesting that the inhibition directly affected gamma delta T cells without mediation by alpha beta T cells.	Cyclosporine	137-140	T cell receptor alpha chain	Mus musculus	74-83
9620082-1	1998	PURPOSE: To determine whether a p-glycoprotein (P-gp) drug efflux pump exists in cultured rabbit conjunctival epithelial cells (RCEs) to restrict the absorption of cyclosporin A (CSA) and other lipophilic drugs such as verapamil and dexamethasone.	Cyclosporine	179-182	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	48-52
9620082-12	1998	CONCLUSIONS: There may exist a P-gp-mediated drug efflux pump on the apical aspect of the rabbit conjunctiva to restrict the absorption of cyclosporin A and other lipophilic drugs.	Cyclosporine	139-152	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	31-35
9663696-9	1998	The protection conferred by cyclosporin-A on swelling induced by the isoforms, when present in low concentrations, may suggest that cyclosporin-A binds to a mitochondrial membrane site protecting the membrane against the phospholipase A2 attack.	Cyclosporine	28-41	phospholipase A2 group IB	Rattus norvegicus	221-237
9663696-9	1998	The protection conferred by cyclosporin-A on swelling induced by the isoforms, when present in low concentrations, may suggest that cyclosporin-A binds to a mitochondrial membrane site protecting the membrane against the phospholipase A2 attack.	Cyclosporine	132-145	phospholipase A2 group IB	Rattus norvegicus	221-237
8631904-9	1996	Addition of cyclosporin A, even in the presence of ongoing ionomycin stimulation, results in rephosphorylation of NFAT1, its reappearance in the cytoplasm, and a return of its DNA binding activity to low levels.	Cyclosporine	12-25	nuclear factor of activated T cells 2	Homo sapiens	114-119
9576485-6	1998	CD38 signaling appeared to share with TCR/CD3 the ability to induce apoptotic cell death in Jurkat T cells, an event paralleled by specific up-regulation of the Fas molecule and inhibited by cyclosporin A.	Cyclosporine	191-204	CD38 molecule	Homo sapiens	0-4
8601217-4	1996	While cyclosporin A abrogated CD2-mediated proliferation in peripheral blood mononuclear cells, it had no effect on CD2-induced apoptosis in the HTLV-I-infected cell lines.	Cyclosporine	6-19	CD2 molecule	Homo sapiens	30-33
8814894-8	1996	The expression of pro-inflammatory cytokines (interferon-gamma, tumour necrosis factor-alpha, interleukin-6) in and around the grafts was lower in the methylprednisolone- and cyclosporin A-treated groups than in untreated control rats.	Cyclosporine	175-188	interferon gamma	Rattus norvegicus	46-92
8630412-9	1996	Sequential specimens from remitting patients receiving treatment with the Pgp modulator cyclosporin-A showed emergence of the LRP phenotype despite a decrease or loss of Pgp at the time of treatment failure (P =.0304).	Cyclosporine	88-101	phosphoglycolate phosphatase	Homo sapiens	74-77
8630412-9	1996	Sequential specimens from remitting patients receiving treatment with the Pgp modulator cyclosporin-A showed emergence of the LRP phenotype despite a decrease or loss of Pgp at the time of treatment failure (P =.0304).	Cyclosporine	88-101	phosphoglycolate phosphatase	Homo sapiens	170-173
8601841-8	1996	The refined model also shows that steric hindrance to attachment of cyclosporin A (CsA) prevents E. coli CyPA forming a complex with CsA.	Cyclosporine	68-81	peptidylprolyl isomerase A	Homo sapiens	105-109
8601841-8	1996	The refined model also shows that steric hindrance to attachment of cyclosporin A (CsA) prevents E. coli CyPA forming a complex with CsA.	Cyclosporine	83-86	peptidylprolyl isomerase A	Homo sapiens	105-109
8601841-8	1996	The refined model also shows that steric hindrance to attachment of cyclosporin A (CsA) prevents E. coli CyPA forming a complex with CsA.	Cyclosporine	133-136	peptidylprolyl isomerase A	Homo sapiens	105-109
8601841-9	1996	Thus, the extra amino acid residue of E. coli CyPA, polar Gln89, lies along the pathway to the hydrophobic pocket of CyPA and seems to prevent the access hydrophobic part of CsA to the cleft of CyPA.	Cyclosporine	174-177	peptidylprolyl isomerase A	Homo sapiens	46-50
8601841-9	1996	Thus, the extra amino acid residue of E. coli CyPA, polar Gln89, lies along the pathway to the hydrophobic pocket of CyPA and seems to prevent the access hydrophobic part of CsA to the cleft of CyPA.	Cyclosporine	174-177	peptidylprolyl isomerase A	Homo sapiens	117-121
8601841-9	1996	Thus, the extra amino acid residue of E. coli CyPA, polar Gln89, lies along the pathway to the hydrophobic pocket of CyPA and seems to prevent the access hydrophobic part of CsA to the cleft of CyPA.	Cyclosporine	174-177	peptidylprolyl isomerase A	Homo sapiens	117-121
8934780-4	1996	Cyclosporin A pre-treatment inhibited the antigen-induced nasal symptoms, nasal eosinophilia and increased levels of histamine and IL-5 in nasal lavage fluid in the +/+ mice.	Cyclosporine	0-13	interleukin 5	Mus musculus	131-135
9576485-6	1998	CD38 signaling appeared to share with TCR/CD3 the ability to induce apoptotic cell death in Jurkat T cells, an event paralleled by specific up-regulation of the Fas molecule and inhibited by cyclosporin A.	Cyclosporine	191-204	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	38-41
9574534-4	1998	The critical role of CD95/CD95-L interaction was supported by complete inhibition in the presence of the antagonist CD95 mAb ZB4 and by blocking CD95-L synthesis and surface expression by cycloheximide, cyclosporin A, EGTA, or cytochalasin B.	Cyclosporine	203-216	Fas cell surface death receptor	Homo sapiens	21-25
9574534-4	1998	The critical role of CD95/CD95-L interaction was supported by complete inhibition in the presence of the antagonist CD95 mAb ZB4 and by blocking CD95-L synthesis and surface expression by cycloheximide, cyclosporin A, EGTA, or cytochalasin B.	Cyclosporine	203-216	Fas ligand	Homo sapiens	26-32
9574534-4	1998	The critical role of CD95/CD95-L interaction was supported by complete inhibition in the presence of the antagonist CD95 mAb ZB4 and by blocking CD95-L synthesis and surface expression by cycloheximide, cyclosporin A, EGTA, or cytochalasin B.	Cyclosporine	203-216	Fas cell surface death receptor	Homo sapiens	26-30
9574534-4	1998	The critical role of CD95/CD95-L interaction was supported by complete inhibition in the presence of the antagonist CD95 mAb ZB4 and by blocking CD95-L synthesis and surface expression by cycloheximide, cyclosporin A, EGTA, or cytochalasin B.	Cyclosporine	203-216	Fas cell surface death receptor	Homo sapiens	26-30
9529174-9	1998	Both myeloperoxidase activity and the number of neutrophils accumulating in the liver 24 hours after reperfusion in animals treated with AZA, CsA, FK506, and RPM were significantly lower than in untreated animals.	Cyclosporine	142-145	myeloperoxidase	Rattus norvegicus	5-20
9472618-4	1998	It was demonstrated that analogues with strong Cyp-binding activity, such as CsC, CsG and [MeAla6]CsA, also exhibit a strong antiviral effect.	Cyclosporine	98-101	peptidylprolyl isomerase G	Homo sapiens	47-50
8623884-6	1996	RESULTS: Three weeks after topical cyclosporine treatment, there was marked clinical improvement and a statistically significant reduction in the number of epithelial and stromal class II MHC+ cells, UCHL1+ T cells, and stromal IgA+ and IgG+ plasma cells.	Cyclosporine	35-47	ubiquitin C-terminal hydrolase L1	Homo sapiens	200-205
8929823-6	1996	When Neoral-CsA was tested, the Jab flux of 3H-CsA was the highest and increased almost linearly even after an incubate time of 240 min.	Cyclosporine	12-15	suppressor of cytokine signaling 1	Homo sapiens	32-35
8929823-7	1996	The Jab flux of 3H-CsA when Sandimmune-CsA or ethanol/FBS-CsA were used as vehicle was lower and reached a maximal rate by 120 min.	Cyclosporine	19-22	suppressor of cytokine signaling 1	Homo sapiens	4-7
8929823-7	1996	The Jab flux of 3H-CsA when Sandimmune-CsA or ethanol/FBS-CsA were used as vehicle was lower and reached a maximal rate by 120 min.	Cyclosporine	39-42	suppressor of cytokine signaling 1	Homo sapiens	4-7
8671791-0	1996	Elevated plasminogen activator inhibitor levels in cyclosporin-treated renal allograft recipients.	Cyclosporine	51-62	serpin family E member 1	Homo sapiens	9-40
8671791-4	1996	The plasminogen activator inhibitor (PAI) activity in plasma was clearly increased in CsA-treated patients: 14.5+/-8.8 vs 7.2+/-3.2 in normal controls and 8.5+/-2.4 AU/ml in patients without CsA.	Cyclosporine	86-89	serpin family E member 1	Homo sapiens	4-35
8671791-4	1996	The plasminogen activator inhibitor (PAI) activity in plasma was clearly increased in CsA-treated patients: 14.5+/-8.8 vs 7.2+/-3.2 in normal controls and 8.5+/-2.4 AU/ml in patients without CsA.	Cyclosporine	86-89	serpin family E member 1	Homo sapiens	37-40
8671791-4	1996	The plasminogen activator inhibitor (PAI) activity in plasma was clearly increased in CsA-treated patients: 14.5+/-8.8 vs 7.2+/-3.2 in normal controls and 8.5+/-2.4 AU/ml in patients without CsA.	Cyclosporine	191-194	serpin family E member 1	Homo sapiens	4-35
8671791-4	1996	The plasminogen activator inhibitor (PAI) activity in plasma was clearly increased in CsA-treated patients: 14.5+/-8.8 vs 7.2+/-3.2 in normal controls and 8.5+/-2.4 AU/ml in patients without CsA.	Cyclosporine	191-194	serpin family E member 1	Homo sapiens	37-40
8671791-7	1996	Hypercholesterolaemia, obesity, and steroid-induced diabetes could be identified as risk factors for elevated plasma PAI activity in CsA-treated patients.	Cyclosporine	133-136	serpin family E member 1	Homo sapiens	117-120
8567677-1	1996	Mammalian mitochondria possess an inner membrane channel, the permeability transition pore (MTP), which can be inhibited by nanomolar concentrations of cyclosporin (CS) A.	Cyclosporine	152-163	metallothionein 1B	Homo sapiens	92-95
8567677-1	1996	Mammalian mitochondria possess an inner membrane channel, the permeability transition pore (MTP), which can be inhibited by nanomolar concentrations of cyclosporin (CS) A.	Cyclosporine	165-167	metallothionein 1B	Homo sapiens	92-95
8576111-3	1996	Inhibition of calcineurin by the immunosuppressive drugs cyclosporin A and FK506 prevents dephosphorylation of NFATp and its translocation to the nucleus.	Cyclosporine	57-70	nuclear factor of activated T cells 2	Homo sapiens	111-116
8987246-9	1996	Haemopoietic growth factors such as G-CSF, when given after immunosuppressive therapy such as antilymphocyte globulin and cyclosporin for aplastic anaemia, may act partly by reducing the increased level of apoptosis, resulting in improved stem cell survival.	Cyclosporine	122-133	colony stimulating factor 3	Homo sapiens	36-41
9472618-6	1998	The data obtained suggest a correlation between the ability of CsA to block VV replication and Cyp binding activity, and indicate the involvement of Cyps in the VV replicative cycle.	Cyclosporine	63-66	peptidylprolyl isomerase G	Homo sapiens	95-98
9454803-7	1998	The percent transfer of CSA from LDL to HDL was significantly decreased in the presence of TP2.	Cyclosporine	24-27	transition protein 2	Homo sapiens	91-94
9454803-8	1998	However, the percent transfer of CSA from HDL to LDL in the presence of TP2 was not significantly different compared to controls.	Cyclosporine	33-36	transition protein 2	Homo sapiens	72-75
9551911-3	1998	We also found that cyclosporin was not able to fully inhibit the TCR induction of death molecule mRNAs or TCR-induced apoptosis, although it could completely turn off IL-2 expression.	Cyclosporine	19-30	interleukin 2	Mus musculus	167-171
9434804-8	1998	Therefore, the use of a CD4-CDR3 peptide can complement and potentiate the immunosuppressive effects of CsA in the prevention of GVHD following allogeneic BMT.	Cyclosporine	104-107	cerebellar degeneration-related 3	Mus musculus	28-32
9792336-6	1998	Chronic treatment with inhibitors of IL-2 synthesis/release such as cyclosporin or dexamethasone during the sensitization phase reduced the oedematogenic response due to SEA challenge by 51% and 55%, respectively.	Cyclosporine	68-79	interleukin 2	Rattus norvegicus	37-41
9416887-5	1997	Increased monocyte TF expression in transplant recipients was shown to be adversely affected by treatment with CsA: TF induction was markedly reduced by CsA serum concentrations reaching peak CsA drug levels.	Cyclosporine	111-114	coagulation factor III, tissue factor	Homo sapiens	19-21
9416887-5	1997	Increased monocyte TF expression in transplant recipients was shown to be adversely affected by treatment with CsA: TF induction was markedly reduced by CsA serum concentrations reaching peak CsA drug levels.	Cyclosporine	111-114	coagulation factor III, tissue factor	Homo sapiens	116-118
9416887-5	1997	Increased monocyte TF expression in transplant recipients was shown to be adversely affected by treatment with CsA: TF induction was markedly reduced by CsA serum concentrations reaching peak CsA drug levels.	Cyclosporine	153-156	coagulation factor III, tissue factor	Homo sapiens	19-21
9416887-5	1997	Increased monocyte TF expression in transplant recipients was shown to be adversely affected by treatment with CsA: TF induction was markedly reduced by CsA serum concentrations reaching peak CsA drug levels.	Cyclosporine	153-156	coagulation factor III, tissue factor	Homo sapiens	116-118
9416887-5	1997	Increased monocyte TF expression in transplant recipients was shown to be adversely affected by treatment with CsA: TF induction was markedly reduced by CsA serum concentrations reaching peak CsA drug levels.	Cyclosporine	153-156	coagulation factor III, tissue factor	Homo sapiens	19-21
9416887-5	1997	Increased monocyte TF expression in transplant recipients was shown to be adversely affected by treatment with CsA: TF induction was markedly reduced by CsA serum concentrations reaching peak CsA drug levels.	Cyclosporine	153-156	coagulation factor III, tissue factor	Homo sapiens	116-118
9416887-6	1997	Inhibition of TF induction in the presence of high CsA blood concentrations was also observed when stimulation of cells was performed with interferon-gamma or interleukin-1beta.	Cyclosporine	51-54	coagulation factor III, tissue factor	Homo sapiens	14-16
9416887-7	1997	As shown by reverse transcription-polymerase chain reaction and electrophoretic mobility shift assay, respectively, treatment with CsA leads to decreased TF mRNA expression and reduced activation of the NF-kappaB transcription factor, which is known to contribute to the induction of the TF promotor in human monocytes.	Cyclosporine	131-134	coagulation factor III, tissue factor	Homo sapiens	154-156
8706784-6	1996	In contrast, GM-CSF accounted for 0-42% of CSA from aged humans.	Cyclosporine	43-46	colony stimulating factor 2	Homo sapiens	13-19
9416887-7	1997	As shown by reverse transcription-polymerase chain reaction and electrophoretic mobility shift assay, respectively, treatment with CsA leads to decreased TF mRNA expression and reduced activation of the NF-kappaB transcription factor, which is known to contribute to the induction of the TF promotor in human monocytes.	Cyclosporine	131-134	coagulation factor III, tissue factor	Homo sapiens	288-290
9416887-8	1997	CONCLUSIONS: This study demonstrates that TF activation, occurring in mononuclear cells of cardiac transplant recipients, is inhibited by treatment with CsA.	Cyclosporine	153-156	coagulation factor III, tissue factor	Homo sapiens	42-44
9416887-9	1997	Inhibition of monocyte TF induction by CsA may contribute to its successful use in cardiac transplant medicine and might be useful in managing further settings of vascular pathology also known to involve TF expression and NF-kappaB activation.	Cyclosporine	39-42	coagulation factor III, tissue factor	Homo sapiens	23-25
8558203-1	1996	PURPOSE: Cyclosporin A has been shown to reverse paclitaxel resistance in vitro by inhibiting P-gp function.	Cyclosporine	9-22	phosphoglycolate phosphatase	Homo sapiens	94-98
9416887-9	1997	Inhibition of monocyte TF induction by CsA may contribute to its successful use in cardiac transplant medicine and might be useful in managing further settings of vascular pathology also known to involve TF expression and NF-kappaB activation.	Cyclosporine	39-42	coagulation factor III, tissue factor	Homo sapiens	204-206
9435481-7	1997	When hepatocytes were reperfused with cyclosporin A (0.5-1 microM) at pH 7.4, the MPT was prevented and cell viability remained &gt; 80%, although pHi increased to 7.2.	Cyclosporine	38-51	glucose-6-phosphate isomerase	Rattus norvegicus	147-150
9505216-8	1997	Three out of six clinical failures were also negative for Pgp immunostaining one of which exhibited sinergistic effect between ETO and CSA.	Cyclosporine	135-138	phosphoglycolate phosphatase	Homo sapiens	58-61
9345062-6	1997	The role of P-glycoprotein 170 (P-gp), the multidrug transporter, was defined by cyclosporin A (CsA)-sensitive dye export.	Cyclosporine	81-94	phosphoglycolate phosphatase	Homo sapiens	12-30
9345062-6	1997	The role of P-glycoprotein 170 (P-gp), the multidrug transporter, was defined by cyclosporin A (CsA)-sensitive dye export.	Cyclosporine	81-94	phosphoglycolate phosphatase	Homo sapiens	32-36
9345062-6	1997	The role of P-glycoprotein 170 (P-gp), the multidrug transporter, was defined by cyclosporin A (CsA)-sensitive dye export.	Cyclosporine	96-99	phosphoglycolate phosphatase	Homo sapiens	12-30
9345062-6	1997	The role of P-glycoprotein 170 (P-gp), the multidrug transporter, was defined by cyclosporin A (CsA)-sensitive dye export.	Cyclosporine	96-99	phosphoglycolate phosphatase	Homo sapiens	32-36
9328321-0	1997	Additive inhibitory effect of hydrocortisone and cyclosporine on low-density lipoprotein receptor activity in cultured HepG2 cells.	Cyclosporine	49-61	low density lipoprotein receptor	Homo sapiens	65-97
9328321-3	1997	In previous studies, we have shown that the immunosuppressive drug cyclosporine inhibits catabolism of low-density lipoproteins (LDL) mainly by reducing the expression of LDL-receptor messenger RNA (mRNA), thus explaining the increased plasma levels of LDL cholesterol observed in patients treated with cyclosporine.	Cyclosporine	67-79	low density lipoprotein receptor	Homo sapiens	171-183
9328321-3	1997	In previous studies, we have shown that the immunosuppressive drug cyclosporine inhibits catabolism of low-density lipoproteins (LDL) mainly by reducing the expression of LDL-receptor messenger RNA (mRNA), thus explaining the increased plasma levels of LDL cholesterol observed in patients treated with cyclosporine.	Cyclosporine	303-315	low density lipoprotein receptor	Homo sapiens	171-183
9328321-9	1997	The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor fluvastatin reverses the inhibitory effect of both hydrocortisone and cyclosporine.	Cyclosporine	142-154	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	4-61
9299338-6	1997	15N spin relaxation times and NMR lineshape analyses for CypA in the free form and complexed with cyclosporin A (CsA) revealed transitions of polypeptide loops surrounding the ligand-binding site from locally flexible conformations in the free protein, some of which include well-defined conformational equilibria, to well-defined spatial arrangements in the CypA-CsA complex.	Cyclosporine	98-111	peptidylprolyl isomerase A	Homo sapiens	57-61
9299338-6	1997	15N spin relaxation times and NMR lineshape analyses for CypA in the free form and complexed with cyclosporin A (CsA) revealed transitions of polypeptide loops surrounding the ligand-binding site from locally flexible conformations in the free protein, some of which include well-defined conformational equilibria, to well-defined spatial arrangements in the CypA-CsA complex.	Cyclosporine	98-111	peptidylprolyl isomerase A	Homo sapiens	359-363
9299338-6	1997	15N spin relaxation times and NMR lineshape analyses for CypA in the free form and complexed with cyclosporin A (CsA) revealed transitions of polypeptide loops surrounding the ligand-binding site from locally flexible conformations in the free protein, some of which include well-defined conformational equilibria, to well-defined spatial arrangements in the CypA-CsA complex.	Cyclosporine	113-116	peptidylprolyl isomerase A	Homo sapiens	57-61
9299338-6	1997	15N spin relaxation times and NMR lineshape analyses for CypA in the free form and complexed with cyclosporin A (CsA) revealed transitions of polypeptide loops surrounding the ligand-binding site from locally flexible conformations in the free protein, some of which include well-defined conformational equilibria, to well-defined spatial arrangements in the CypA-CsA complex.	Cyclosporine	113-116	peptidylprolyl isomerase A	Homo sapiens	359-363
9299338-7	1997	Compared to the crystal structure of free CypA, where the ligand-binding area is extensively involved in lattice contacts, the NMR structure presents a highly relevant reference for studies of changes in structure and internal mobility of the binding pocket upon ligand binding, and possible consequences of this conformational variability for calcineurin recognition by the CypA-CsA complex.	Cyclosporine	380-383	peptidylprolyl isomerase A	Homo sapiens	42-46
8981665-5	1996	Treatment of the macrophages with cyclosporin A, an inhibitor of sterol 27-hydroxylase, reduced the excretion of the 27-hydroxylated products by more than 90%, with a concomitant accumulation of intracellular cholesterol.	Cyclosporine	34-47	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	65-86
8758815-10	1996	The greater inhibitory rates of CsA+DDP regimen (81.4%) was also shown in vivo studies when compared with DDP alone regimen (49.1%) (P &lt; 0.01).	Cyclosporine	32-35	translocase of inner mitochondrial membrane 8A	Homo sapiens	106-109
8758815-13	1996	This study suggests that CsA may be used clinically as an antitumor enhancement of DDP for the treatment of ovarian adenocarcinoma.	Cyclosporine	25-28	translocase of inner mitochondrial membrane 8A	Homo sapiens	83-86
8719269-0	1995	Cyclosporin A dramatically ameliorates CA1 hippocampal damage following transient forebrain ischaemia in the rat.	Cyclosporine	0-13	carbonic anhydrase 1	Rattus norvegicus	39-42
7497521-0	1995	Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF).	Cyclosporine	102-113	vascular endothelial growth factor A	Rattus norvegicus	128-162
7497521-4	1995	Cyclosporin A (CSA) is an immunomodulating agent that inhibits IL-2 and other cytokine production involved in early antigen activation of T-cells.	Cyclosporine	0-13	interleukin 2	Rattus norvegicus	63-67
7497521-4	1995	Cyclosporin A (CSA) is an immunomodulating agent that inhibits IL-2 and other cytokine production involved in early antigen activation of T-cells.	Cyclosporine	15-18	interleukin 2	Rattus norvegicus	63-67
8536380-4	1995	Here we have studied the effect of CsA on kidney generation of TNF-alpha and PAF in puromycin aminonucleoside (PAN) nephrosis as well as on the synthesis of proteoglycans by cultured glomerular epithelial cells.	Cyclosporine	35-38	PCNA clamp associated factor	Homo sapiens	77-80
8536380-10	1995	CsA also reversed the inhibitory effect of PAF and TNF-alpha on proteoglycan synthesis.	Cyclosporine	0-3	PCNA clamp associated factor	Homo sapiens	43-46
8536380-13	1995	The beneficial effect of CsA in nephrosis may be due to the recovery of the GBM charge selectivity caused by the normalization of glomerular PAF and TNF-alpha synthesis and the increase in proteoglycan synthesis by glomerular epithelial cells.	Cyclosporine	25-28	PCNA clamp associated factor	Homo sapiens	141-144
8566029-5	1995	Because CSA blocks interleukin-2 (IL-2) gene expression, we have analyzed the effect of this cytokine on memory T helper cell development.	Cyclosporine	8-11	interleukin 2	Mus musculus	19-32
8566029-5	1995	Because CSA blocks interleukin-2 (IL-2) gene expression, we have analyzed the effect of this cytokine on memory T helper cell development.	Cyclosporine	8-11	interleukin 2	Mus musculus	34-38
8566029-8	1995	We found that CD4+ cells primed in the absence of IL-2, provoked either by IL-2 gene transcription blockade by CSA or by treatment with anti-IL-2R antibodies, afford the best helper functions.	Cyclosporine	111-114	interleukin 2	Mus musculus	75-79
8643162-4	1995	The most potent vitamin D3 metabolite 1,25(OH)2 D3 (Vit D3) shares certain immunomodulatory properties with CsA.	Cyclosporine	108-111	vitrin	Rattus norvegicus	52-55
9288794-5	1997	Cyclosporin A inhibited induction of CD95 mRNA and CD95-L mRNA and blocked drug-mediated apoptosis.	Cyclosporine	0-13	Fas cell surface death receptor	Homo sapiens	37-41
9288794-5	1997	Cyclosporin A inhibited induction of CD95 mRNA and CD95-L mRNA and blocked drug-mediated apoptosis.	Cyclosporine	0-13	Fas ligand	Homo sapiens	51-57
9305737-4	1997	While the interconversion rate is too slow to measure by kinetic NMR methods in the absence of CyPA, these methods, saturation transfer and NOE experiments, established that CyPA enhanced the rate of trans-cis interconversion, a process inhibited by cyclosporin A (CsA).	Cyclosporine	250-263	peptidylprolyl isomerase A	Homo sapiens	174-178
8566132-0	1995	Effect of stress and cyclosporine on ornithine decarboxylase activity in rat submaxillary lymph nodes.	Cyclosporine	21-33	ornithine decarboxylase 1	Rattus norvegicus	37-60
8566132-6	1995	Cyclosporine administration (5 or 20 mg/kg) significantly decreased Freund"s adjuvant-induced ornithine decarboxylase activity in the submaxillary lymph nodes of control rats, but failed to modify it in turpentine oil-stressed animals.	Cyclosporine	0-12	ornithine decarboxylase 1	Rattus norvegicus	94-117
8566132-7	1995	In this latter group, a higher (40 mg/kg) dose of cyclosporine decreased ornithine decarboxylase activity on the innervated side only.	Cyclosporine	50-62	ornithine decarboxylase 1	Rattus norvegicus	73-96
9305737-4	1997	While the interconversion rate is too slow to measure by kinetic NMR methods in the absence of CyPA, these methods, saturation transfer and NOE experiments, established that CyPA enhanced the rate of trans-cis interconversion, a process inhibited by cyclosporin A (CsA).	Cyclosporine	265-268	peptidylprolyl isomerase A	Homo sapiens	174-178
7490125-0	1995	Induced expression of mRNA for IL-5, IL-6, TNF-alpha, MIP-2 and IFN-gamma in immunologically activated rat peritoneal mast cells: inhibition by dexamethasone and cyclosporin A.	Cyclosporine	162-175	interferon gamma	Rattus norvegicus	64-73
9341769-5	1997	Moreover, lactacystin did not inhibit the nuclear translocation of NF-ATp whereas cyclosporin A inhibited the translocation of both NF-kappa B and NF-ATp.	Cyclosporine	82-95	nuclear factor of activated T cells 2	Homo sapiens	147-153
9237106-7	1997	rIL-2-induced IL-5 expression was resistant to cyclosporin A (CsA), whereas IL-5 expression elicited by PHA was inhibited by CsA, at doses as low as 10 ng/ml.	Cyclosporine	62-65	interleukin 2	Rattus norvegicus	0-5
9237106-7	1997	rIL-2-induced IL-5 expression was resistant to cyclosporin A (CsA), whereas IL-5 expression elicited by PHA was inhibited by CsA, at doses as low as 10 ng/ml.	Cyclosporine	125-128	interleukin 2	Rattus norvegicus	0-5
7549508-6	1995	Moreover, FK-506, mizoribine and cyclophosphamide clearly inhibited the antigen-induced IL-5 production and cyclosporin A showed the tendency to inhibit IL-5 production.	Cyclosporine	108-121	interleukin 5	Mus musculus	153-157
9186871-0	1997	Cholesterol feeding accentuates the cyclosporine-induced elevation of renal plasminogen activator inhibitor type 1.	Cyclosporine	36-48	serpin family E member 2	Rattus norvegicus	76-114
8575571-0	1995	FK506 and cyclosporin A inhibit granulocyte/macrophage colony-stimulating factor production by mononuclear cells in asthma.	Cyclosporine	10-23	colony stimulating factor 2	Homo sapiens	32-80
9144472-8	1997	Next, in an effort to determine critical transcription factors that regulate CD95 ligand expression, we demonstrate a cyclosporin A-sensitive nuclear factor-AT response element in the promoter region of this gene that is critical for optimal CD95 ligand reporter activity in stimulated T cells.	Cyclosporine	118-131	Fas cell surface death receptor	Homo sapiens	77-81
8575571-3	1995	To assess this, we compared the inhibitory effects of FK506 and cyclosporin A on production of granulocyte/macrophage colony-stimulating factor and interleukin-5 by interleukin-2- or Dermatophagoides farinae-stimulated mononuclear cells from patients with asthma, and their contribution to proliferation and survival of eosinophils in vitro.	Cyclosporine	64-77	colony stimulating factor 2	Homo sapiens	95-143
7657645-0	1995	Phosphorylation of the transcription factor NFATp inhibits its DNA binding activity in cyclosporin A-treated human B and T cells.	Cyclosporine	87-100	nuclear factor of activated T cells 2	Homo sapiens	44-49
7657645-1	1995	Cyclosporin A (CsA) exerts its immunosuppressive effect by inhibiting the activity of nuclear factor of activated T cells (NFAT), thus preventing transcriptional induction of several cytokine genes.	Cyclosporine	0-13	nuclear factor of activated T cells 2	Homo sapiens	123-127
7657645-1	1995	Cyclosporin A (CsA) exerts its immunosuppressive effect by inhibiting the activity of nuclear factor of activated T cells (NFAT), thus preventing transcriptional induction of several cytokine genes.	Cyclosporine	15-18	nuclear factor of activated T cells 2	Homo sapiens	123-127
7657645-3	1995	Here we report that CsA treatment of Raji B and Jurkat T cell lines yields a phosphorylated form of NFATp that is inhibited in DNA-binding and in its ability to form an NFAT complex with Fos and Jun.	Cyclosporine	20-23	nuclear factor of activated T cells 2	Homo sapiens	100-105
7657645-3	1995	Here we report that CsA treatment of Raji B and Jurkat T cell lines yields a phosphorylated form of NFATp that is inhibited in DNA-binding and in its ability to form an NFAT complex with Fos and Jun.	Cyclosporine	20-23	nuclear factor of activated T cells 2	Homo sapiens	100-104
7657645-4	1995	Immunoblot analyses and metabolic labeling with [32P]orthophosphate show that CsA alters NFATp migration on SDS-polyacrylamide gel electrophoresis by increasing its phosphorylation level without affecting subcellular distribution.	Cyclosporine	78-81	nuclear factor of activated T cells 2	Homo sapiens	89-94
7657645-6	1995	These data point to a new mechanism for CsA-sensitive regulation of NFATp in which dephosphorylation is critical for DNA binding.	Cyclosporine	40-43	nuclear factor of activated T cells 2	Homo sapiens	68-73
7650486-2	1995	We report here that the nuclear factor of activated T cells (NFATp), a cyclosporin A (CsA)-sensitive factor that regulates the transcription of several cytokines, mediates CD16-induced activation of cytokine genes in human NK cells.	Cyclosporine	71-84	nuclear factor of activated T cells 2	Homo sapiens	61-66
7650486-2	1995	We report here that the nuclear factor of activated T cells (NFATp), a cyclosporin A (CsA)-sensitive factor that regulates the transcription of several cytokines, mediates CD16-induced activation of cytokine genes in human NK cells.	Cyclosporine	86-89	nuclear factor of activated T cells 2	Homo sapiens	61-66
7650689-1	1995	Analysis of the contact surface of the cyclophilin A (CypA)/cyclosporin A (CsA, 1) crystal structure delineates a unique cavity between both molecules in the vicinity of the Abu-2 side chain atoms of 1 (Abu pocket).	Cyclosporine	60-73	peptidylprolyl isomerase A	Homo sapiens	39-52
7650689-1	1995	Analysis of the contact surface of the cyclophilin A (CypA)/cyclosporin A (CsA, 1) crystal structure delineates a unique cavity between both molecules in the vicinity of the Abu-2 side chain atoms of 1 (Abu pocket).	Cyclosporine	60-73	peptidylprolyl isomerase A	Homo sapiens	54-58
7650689-1	1995	Analysis of the contact surface of the cyclophilin A (CypA)/cyclosporin A (CsA, 1) crystal structure delineates a unique cavity between both molecules in the vicinity of the Abu-2 side chain atoms of 1 (Abu pocket).	Cyclosporine	75-78	peptidylprolyl isomerase A	Homo sapiens	39-52
7650689-1	1995	Analysis of the contact surface of the cyclophilin A (CypA)/cyclosporin A (CsA, 1) crystal structure delineates a unique cavity between both molecules in the vicinity of the Abu-2 side chain atoms of 1 (Abu pocket).	Cyclosporine	75-78	peptidylprolyl isomerase A	Homo sapiens	54-58
7579569-3	1995	The aim of our study was to determine whether the blockade of P-gp by cyclosporine A (CsA) dissolved in Cremophor EL (Crem) inhibits cortisol secretion in rabbits.	Cyclosporine	70-84	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	62-66
7579569-3	1995	The aim of our study was to determine whether the blockade of P-gp by cyclosporine A (CsA) dissolved in Cremophor EL (Crem) inhibits cortisol secretion in rabbits.	Cyclosporine	86-89	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	62-66
8564191-2	1995	Administration of cyclosporine A (CsA; 50 mg kg-1 day-1, s.c.) for 14 days produced an increase in both systolic (SBP) and diastolic (DBP) blood pressure by 60 and 25 mmHg, respectively.	Cyclosporine	18-32	spermine binding protein	Rattus norvegicus	114-117
8564191-2	1995	Administration of cyclosporine A (CsA; 50 mg kg-1 day-1, s.c.) for 14 days produced an increase in both systolic (SBP) and diastolic (DBP) blood pressure by 60 and 25 mmHg, respectively.	Cyclosporine	34-37	spermine binding protein	Rattus norvegicus	114-117
8564191-10	1995	Maximal catechol-O-methyltransferase activity (Vmax) in homogenates of renal tissues obtained from rats treated with CsA for 7 or 14 days was significantly higher than that in vehicle-treated rats; Km (22.3 +/- 1.5 microM) values for COMT did not differ between the three groups of rats.	Cyclosporine	117-120	catechol-O-methyltransferase	Rattus norvegicus	234-238
9144472-8	1997	Next, in an effort to determine critical transcription factors that regulate CD95 ligand expression, we demonstrate a cyclosporin A-sensitive nuclear factor-AT response element in the promoter region of this gene that is critical for optimal CD95 ligand reporter activity in stimulated T cells.	Cyclosporine	118-131	Fas cell surface death receptor	Homo sapiens	242-246
9152064-8	1997	The greatest increase in IL-1ra levels was observed in patients with Behcet disease who received a combination of cyclosporine and corticosteroids.	Cyclosporine	114-126	interleukin 1 receptor antagonist	Homo sapiens	25-31
9152064-9	1997	CONCLUSIONS: Because IL-1ra is one of the natural immunomodulating molecules, the significant increase of serum IL-1ra levels, especially after combined treatment with cyclosporine and corticosteroids, could indicate that the therapeutic effects of this regimen may be mediated through its effects on this molecule.	Cyclosporine	168-180	interleukin 1 receptor antagonist	Homo sapiens	21-27
9152064-9	1997	CONCLUSIONS: Because IL-1ra is one of the natural immunomodulating molecules, the significant increase of serum IL-1ra levels, especially after combined treatment with cyclosporine and corticosteroids, could indicate that the therapeutic effects of this regimen may be mediated through its effects on this molecule.	Cyclosporine	168-180	interleukin 1 receptor antagonist	Homo sapiens	112-118
9126965-11	1997	In contrast to the regulation of IL-2 and IL-2R expression, which is inhibited by cyclosporin A-, but not rapamycin-dependent signal transduction pathways, CTLA-4 expression is inhibited by either cyclosporin A or rapamycin.	Cyclosporine	82-95	interleukin 2	Mus musculus	33-37
9133464-8	1997	These data indicate that the mechanism of action of CTLA4Ig in attenuating chronic rejection is cyclosporine sensitive, and that strategies implying combination of CTLA4Ig and cyclosporine may not be clinically desirable.	Cyclosporine	96-108	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	52-57
9133476-11	1997	Furthermore, the parallel emergence of alloreactive NK cells and CTL only in the presence of CsA/IL-2 indicated that CsA interfered with alloreactive NK cell-associated suppression of CTL activated by allogeneic tissue.	Cyclosporine	117-120	interleukin 2	Rattus norvegicus	97-101
9086008-12	1997	Incubation of both cell types in vitro with either MRK-16 and ADM or one of the cyclosporin derivatives and ADM inhibited cell growth minimally; however, ternary treatment with MRK-16, one of the cyclosporin derivatives, and ADM dramatically reduced the growth of both cell types.	Cyclosporine	196-207	ciliogenesis associated kinase 1	Homo sapiens	177-180
9175313-1	1997	BACKGROUND AND OBJECTIVE: We previously reported that patients with acquired severe aplastic anemia (SAA) treated with antilymphocyte globulin (ALG), 6-methylprednisolone, cyclosporin A (CyA) and granulocyte colony-stimulating factor (G-CSF) can mobilize peripheral blood hemopoietic progenitors (PBHP).	Cyclosporine	172-185	colony stimulating factor 3	Homo sapiens	235-240
7583777-1	1995	The effects of cyclosporin A (CsA), FK506 and rapamycin (Rapa) on the intracellular localization of a mutated rabbit progesterone receptor (PR) which lacks the main constitutive nuclear localization signal (NLS) (delta 638-642) and is cytoplasmic in the absence of progesterone (Prog), were assayed by indirect immunofluorescence in Lcl3 cells, a mouse L-cell line stably expressing this mutant.	Cyclosporine	15-28	progesterone receptor	Oryctolagus cuniculus	117-138
7583777-1	1995	The effects of cyclosporin A (CsA), FK506 and rapamycin (Rapa) on the intracellular localization of a mutated rabbit progesterone receptor (PR) which lacks the main constitutive nuclear localization signal (NLS) (delta 638-642) and is cytoplasmic in the absence of progesterone (Prog), were assayed by indirect immunofluorescence in Lcl3 cells, a mouse L-cell line stably expressing this mutant.	Cyclosporine	30-33	progesterone receptor	Oryctolagus cuniculus	117-138
9032343-7	1997	These studies indicate that, as with other proline-containing peptides or cyclosporine A, HIV-1 Gag directly contacts residues in the hydrophobic pocket of CyPA.	Cyclosporine	74-88	peptidylprolyl isomerase A	Homo sapiens	156-160
7634349-8	1995	Finally, both the CD3 plus CD27 and the CD28 plus CD27-stimulated T cell proliferation is sensitive to inhibition by CsA.	Cyclosporine	117-120	CD27 molecule	Homo sapiens	27-31
7634349-8	1995	Finally, both the CD3 plus CD27 and the CD28 plus CD27-stimulated T cell proliferation is sensitive to inhibition by CsA.	Cyclosporine	117-120	CD27 molecule	Homo sapiens	50-54
9075347-5	1997	Both proteins were calcium- and calmodulin-dependent and were inhibited by mammalian cyclophilin complexed with cyclosporin A (IC50 values of 0.75 microgram CyP for H. microstoma and 0.90 microgram CyP for H. diminuta).	Cyclosporine	112-125	peptidylprolyl isomerase G	Homo sapiens	198-201
7634349-10	1995	Furthermore, signaling through CD27 appears to involve Ca(2+)-dependent mechanisms sensitive to CsA.	Cyclosporine	96-99	CD27 molecule	Homo sapiens	31-35
9016720-1	1997	BACKGROUND: Cyclophilin A (CyPA), a receptor of the immunosuppressive drug cyclosporin A, catalyzes the cis-trans isomerization of peptidyl-prolyl bonds and is required for the infectious activity of human immunodeficiency virus type 1 (HIV-1).	Cyclosporine	75-88	peptidylprolyl isomerase A	Homo sapiens	27-31
9031274-7	1997	Urinary oxalate excretion as well as the activities of lactate dehydrogenase, gamma-glutamyltranspeptidase, alkaline phosphatase and inorganic pyrophosphatase enzymes were elevated either in CsA-alone or AmOx-alone treated groups.	Cyclosporine	191-194	gamma-glutamyltransferase 1	Rattus norvegicus	78-106
7604782-2	1995	Although 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are more tolerable as low density lipoprotein cholesterol (LDL-C)-lowering agents than other classes of drugs, their use in transplant patients has been limited due to potentially serious interactions with cyclosporine.	Cyclosporine	284-296	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	9-66
7621861-3	1995	Generation of both the anergic state and the increased p59fyn activity was prevented in the presence of calcium-free medium, cycloheximide (CHX), or cyclosporin A (CsA), and could be mimicked by the calcium ionophore ionomycin.	Cyclosporine	164-167	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	55-61
9249940-6	1997	The decrease in IL-2 production was directly related to the presence of CyA in vivo.	Cyclosporine	72-75	interleukin 2	Mus musculus	16-20
8970607-3	1996	The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors are powerful cholesterol-lowering drugs, but their broad use in transplant recipients has been hindered by concerns about interactions with cyclosporine.	Cyclosporine	213-225	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	4-61
7621867-10	1995	In L3 and L alpha beta cells, transcription of the endogenous IL-2 gene was suppressed by cyclosporin A and enhanced by cycloheximide.	Cyclosporine	90-103	interleukin 2	Mus musculus	62-66
7590732-0	1995	Cyclophilin A, the major intracellular receptor for the immunosuppressant cyclosporin A, maps to chromosome 7p11.2-p13: four pseudogenes map to chromosomes 3, 10, 14, and 18.	Cyclosporine	74-87	peptidylprolyl isomerase A	Homo sapiens	0-13
7590732-1	1995	Cyclophilin A (CyP-A), the major intracellular receptor for the immunosuppressant cyclosporin A (CsA), is a member of the immunophilin class of proteins, which all possess peptidyl-prolyl cis-trans isomerase activity and, therefore, are believed to be involved in protein folding and/or intracellular protein transport.	Cyclosporine	82-95	peptidylprolyl isomerase A	Homo sapiens	0-13
8970385-5	1996	Peribronchial and perivascular lymphocyte cuffing and the accumulation of macrophages at the ends of bronchioles were exacerbated (p &lt; 0.05) in IL-2-treated mice at Day 14 and reduced (p &lt; 0.05) in CYA-treated mice at Day 7.	Cyclosporine	204-207	interleukin 2	Mus musculus	147-151
7590732-1	1995	Cyclophilin A (CyP-A), the major intracellular receptor for the immunosuppressant cyclosporin A (CsA), is a member of the immunophilin class of proteins, which all possess peptidyl-prolyl cis-trans isomerase activity and, therefore, are believed to be involved in protein folding and/or intracellular protein transport.	Cyclosporine	82-95	peptidylprolyl isomerase A	Homo sapiens	15-20
7590732-1	1995	Cyclophilin A (CyP-A), the major intracellular receptor for the immunosuppressant cyclosporin A (CsA), is a member of the immunophilin class of proteins, which all possess peptidyl-prolyl cis-trans isomerase activity and, therefore, are believed to be involved in protein folding and/or intracellular protein transport.	Cyclosporine	97-100	peptidylprolyl isomerase A	Homo sapiens	0-13
7590732-1	1995	Cyclophilin A (CyP-A), the major intracellular receptor for the immunosuppressant cyclosporin A (CsA), is a member of the immunophilin class of proteins, which all possess peptidyl-prolyl cis-trans isomerase activity and, therefore, are believed to be involved in protein folding and/or intracellular protein transport.	Cyclosporine	97-100	peptidylprolyl isomerase A	Homo sapiens	15-20
7602099-4	1995	Like the human GM-CSF enhancer, this element formed a cyclosporin A-inhibitable DNase I-hypersensitive site in the murine T cell line EL4 upon activation with phorbol ester and calcium ionophore.	Cyclosporine	54-67	colony stimulating factor 2	Homo sapiens	15-21
7540976-8	1995	Double mutant calcineurin A subunits (Y377F, W388C CMP1 and Y419F, W430C CMP2) confer resistance to CsA, to FK506 and to CsA plus FK506.	Cyclosporine	100-103	calcineurin catalytic subunit A	Saccharomyces cerevisiae S288C	73-77
7540976-8	1995	Double mutant calcineurin A subunits (Y377F, W388C CMP1 and Y419F, W430C CMP2) confer resistance to CsA, to FK506 and to CsA plus FK506.	Cyclosporine	121-124	calcineurin catalytic subunit A	Saccharomyces cerevisiae S288C	73-77
7602131-6	1995	When the binding data were analyzed in terms of the known crystallographic structure of the CS/Fab complex, it could be shown that modifications of CS residues located in the central part of the binding site drastically affect affinity, while modifications of residues located at the periphery are more easily accommodated.	Cyclosporine	92-94	FA complementation group B	Homo sapiens	95-98
7602131-6	1995	When the binding data were analyzed in terms of the known crystallographic structure of the CS/Fab complex, it could be shown that modifications of CS residues located in the central part of the binding site drastically affect affinity, while modifications of residues located at the periphery are more easily accommodated.	Cyclosporine	148-150	FA complementation group B	Homo sapiens	95-98
7644557-8	1995	These results indicate that the inhibitory effects of CSA on the synthesis of LTs and 5-HETE in intact cells are attributable to a modulatory action on a step in the series of intracellular events that includes the activation of 5-lipoxygenase, which are initiated by Ca2+ influx and end in the release of metabolites from the cell membrane, rather than to a direct inhibitory action on enzymes in the LT biosynthetic pathway.	Cyclosporine	54-57	arachidonate 5-lipoxygenase	Rattus norvegicus	229-243
7556412-1	1995	The immunosuppressive cyclic undecapeptide, cyclosporin A, inhibited the binding of [125I]substance P to tachykinin NK1 receptors expressed by human IM-9 lymphoblastoid cells, U-373 MG human astrocytoma cells and guinea pig lung parenchyma with IC50 values of 425 +/- 58, 783 +/- 180, and 784 +/- 163 nM respectively.	Cyclosporine	44-57	tachykinin receptor 1	Homo sapiens	116-119
7556412-3	1995	The cyclosporin compounds also inhibited [125I]neurokinin A binding to human NK2 receptors with potencies slightly less than at NK1 sites.	Cyclosporine	4-15	tachykinin receptor 1	Homo sapiens	128-131
7556412-5	1995	Thus, the cyclosporin A compounds showed selectivity for NK1 and NK2 receptors.	Cyclosporine	10-23	tachykinin receptor 1	Homo sapiens	57-60
7556412-9	1995	This novel pharmacological profile of the cyclosporin A compounds as NK1 receptor antagonists does not appear to correlate with other known in vitro cyclosporin A functions.	Cyclosporine	42-55	tachykinin receptor 1	Homo sapiens	69-81
7613145-3	1995	The immunosuppressive agents CsA and FK506 enhanced the release of leukotriene B4 (LTB4) from human neutrophil granulocytes dependent on the priming with G-CSF and IL-3.	Cyclosporine	29-32	colony stimulating factor 3	Homo sapiens	154-159
7613145-3	1995	The immunosuppressive agents CsA and FK506 enhanced the release of leukotriene B4 (LTB4) from human neutrophil granulocytes dependent on the priming with G-CSF and IL-3.	Cyclosporine	29-32	interleukin 3	Homo sapiens	164-168
7722312-9	1995	However, we demonstrate that the constitutive nuclear ARE-associated factors react with Abs, raised to NF-ATp and NF-ATc, preferentially bind to the ARE but not to the NF-AT binding site and are cyclosporin A sensitive.	Cyclosporine	195-208	nuclear factor of activated T cells 2	Homo sapiens	103-109
7722312-9	1995	However, we demonstrate that the constitutive nuclear ARE-associated factors react with Abs, raised to NF-ATp and NF-ATc, preferentially bind to the ARE but not to the NF-AT binding site and are cyclosporin A sensitive.	Cyclosporine	195-208	nuclear factor of activated T cells 2	Homo sapiens	103-108
7536714-6	1995	Induction of nitrite/nitrate production by the combination of tumor necrosis factor-alpha and bacterial lipopolysaccharide or that of interleukin-1 alpha and interferon gamma (100 U/mL) was also inhibited by cyclosporin A cotreatment.	Cyclosporine	208-221	interferon gamma	Rattus norvegicus	158-185
7536243-6	1995	The suppression of lymphocyte blastogenesis in vitro by cyclosporine or prednisolone was restored by addition of interleukin (IL)-1, IL-2, IL-4, IL-5 or IL-6.	Cyclosporine	56-68	interleukin 1 alpha	Homo sapiens	113-131
7530743-1	1995	FK506 and cyclosporin A (CsA) are immunosuppressive agents that inhibit IL-2 production by activated T cells, but only CsA inhibits IgE activation-induced cytokine transcripts in mouse IL-3-dependent, bone marrow-derived mast cells (BMMC).	Cyclosporine	10-23	interleukin 2	Mus musculus	72-76
7530743-1	1995	FK506 and cyclosporin A (CsA) are immunosuppressive agents that inhibit IL-2 production by activated T cells, but only CsA inhibits IgE activation-induced cytokine transcripts in mouse IL-3-dependent, bone marrow-derived mast cells (BMMC).	Cyclosporine	25-28	interleukin 2	Mus musculus	72-76
7856751-7	1995	Modulation of P-gp in MDCK cells after chronic stimulation with CsA for 7, 30, and 60 days was analyzed by flow cytometry.	Cyclosporine	64-67	PGP	Canis lupus familiaris	14-18
7856751-10	1995	Our findings suggest that in non-neoplastic cells, CsA may stimulate P-gp as a mechanism of detoxification.	Cyclosporine	51-54	PGP	Canis lupus familiaris	69-73
8943883-5	1996	This was further confirmed by blocking the function of Pgp in the leukaemic cell lines with a cyclosporine A derivative, which had no influence on SDCC.	Cyclosporine	94-108	phosphoglycolate phosphatase	Homo sapiens	55-58
10064360-6	1996	Does any significant correlation between serum beta-2-M levels and blood cyclosporine A concentration exit?	Cyclosporine	73-87	beta-2-microglobulin	Homo sapiens	47-55
10064360-13	1996	Presence a significant positive correlation between serum beta-2-M level and blood cyclosporine A concentration suggest that beta-2-M level can be a good parametr to define cyclosporine A tubular toxicity.	Cyclosporine	83-97	beta-2-microglobulin	Homo sapiens	58-66
10064360-13	1996	Presence a significant positive correlation between serum beta-2-M level and blood cyclosporine A concentration suggest that beta-2-M level can be a good parametr to define cyclosporine A tubular toxicity.	Cyclosporine	83-97	beta-2-microglobulin	Homo sapiens	125-133
7853852-10	1995	RESULTS: CyA given early delayed the rise in anti-MPO and anti-glomerular basement membrane levels and ameliorated tissue injury, whereas CyA given late, although suppressing the rise in anti-MPO and anti-glomerular basement membrane antibodies, caused a marked exacerbation of vasculitis.	Cyclosporine	9-12	myeloperoxidase	Rattus norvegicus	50-53
10064360-13	1996	Presence a significant positive correlation between serum beta-2-M level and blood cyclosporine A concentration suggest that beta-2-M level can be a good parametr to define cyclosporine A tubular toxicity.	Cyclosporine	173-187	beta-2-microglobulin	Homo sapiens	58-66
10064360-13	1996	Presence a significant positive correlation between serum beta-2-M level and blood cyclosporine A concentration suggest that beta-2-M level can be a good parametr to define cyclosporine A tubular toxicity.	Cyclosporine	173-187	beta-2-microglobulin	Homo sapiens	125-133
8943481-5	1996	Interstitial expression of SPARC was most prominent in passive Heyman nephritis (PHN), chronic cyclosporine A (CsA) nephropathy, and the remnant kidney model and, to a lesser extent, in angiotensin II (Ang II)-infused animals.	Cyclosporine	95-109	secreted protein acidic and cysteine rich	Homo sapiens	27-32
7839437-9	1995	The combination of 2.5 mg/kg CsA with 0.05 mg/kg RAPA extended graft survival to 18.2 +/- 2.9 d (P &lt; 0.01), and 5.0 mg/kg CsA with 0.1 mg/kg RAPA prolonged survival to 23.0 +/- 9.0 d (P &lt; 0.01).	Cyclosporine	29-32	transcriptional regulating factor 1	Mus musculus	144-148
7839455-13	1995	These results demonstrate that TNFR:Fc can be safely administered and is effective in prolonging renal allograft survival and in delaying the onset of rejection when administered alone or in combination with cyclosporine.	Cyclosporine	208-220	TNF receptor superfamily member 1A	Homo sapiens	31-35
8943481-5	1996	Interstitial expression of SPARC was most prominent in passive Heyman nephritis (PHN), chronic cyclosporine A (CsA) nephropathy, and the remnant kidney model and, to a lesser extent, in angiotensin II (Ang II)-infused animals.	Cyclosporine	111-114	secreted protein acidic and cysteine rich	Homo sapiens	27-32
8916948-5	1996	CsA exerted a dose-dependent inhibitory effect on LPS-induced monocyte/macrophage PCA, which was identified as TF activity based on functional and immunologic characterization.	Cyclosporine	0-3	coagulation factor III, tissue factor	Homo sapiens	111-113
7829860-1	1995	Cyclophilins A and B (CyPA and CyPB) are known to be the main binding proteins for cyclosporin A (CsA), a potent immunosuppressive drug.	Cyclosporine	83-96	peptidylprolyl isomerase A	Homo sapiens	22-26
7829860-1	1995	Cyclophilins A and B (CyPA and CyPB) are known to be the main binding proteins for cyclosporin A (CsA), a potent immunosuppressive drug.	Cyclosporine	98-101	peptidylprolyl isomerase A	Homo sapiens	22-26
8916948-6	1996	As shown by reverse transcriptase-polymerase chain reaction, CsA reduced the transcription of the TF gene in LPS-stimulated monocytes/macrophages.	Cyclosporine	61-64	coagulation factor III, tissue factor	Homo sapiens	98-100
8916948-8	1996	As shown by Western blot analysis, CsA treatment decreased the nuclear translocation of NF-kappa B, thereby suggesting the mechanism for the inhibitory effect of CsA on TF induction.	Cyclosporine	35-38	coagulation factor III, tissue factor	Homo sapiens	169-171
8916948-8	1996	As shown by Western blot analysis, CsA treatment decreased the nuclear translocation of NF-kappa B, thereby suggesting the mechanism for the inhibitory effect of CsA on TF induction.	Cyclosporine	162-165	coagulation factor III, tissue factor	Homo sapiens	169-171
8932288-3	1996	In renal allografts in animals on long-term CsA therapy, there is important up-regulation of transforming growth factor-beta, Hsp70, and endothelin as compared with control animals.	Cyclosporine	44-47	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	126-131
7814389-9	1995	We show that in astrocytoma cells, okadaic acid and cyclosporin A (an inhibitor of calcineurin) both potentiate the Ca2+ elevations due to low doses of CIF, thapsigargin, or carbachol.	Cyclosporine	52-65	protein phosphatase 3, catalytic subunit, alpha isozyme L homeolog	Xenopus laevis	83-94
8932288-4	1996	Conversely, interleukin-2 receptor, interferon-gamma, and tumor necrosis factor-alpha in kidney grafts in this group were expressed at lower levels compared with those noted in chronically rejecting grafts in control animals that had received only CsA for 10 days after transplantation.	Cyclosporine	248-251	interferon gamma	Rattus norvegicus	36-85
8857935-1	1996	We studied the effects of eight antibiotics, cyclosporin and corticosteroids on the in vitro secretion of GM-CSF and G-CSF by monocytes.	Cyclosporine	45-56	colony stimulating factor 2	Homo sapiens	106-112
7529414-4	1995	They interrupt the cytoplasmic portion of T-cell signaling by forming a complex with a binding protein--FKBP12 in the case of FK506 and rapamycin and cyclophilin A (CyPA) in the case of cyclosporin A (CsA).	Cyclosporine	186-199	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	104-110
7529414-4	1995	They interrupt the cytoplasmic portion of T-cell signaling by forming a complex with a binding protein--FKBP12 in the case of FK506 and rapamycin and cyclophilin A (CyPA) in the case of cyclosporin A (CsA).	Cyclosporine	186-199	peptidylprolyl isomerase A	Homo sapiens	150-163
7529414-4	1995	They interrupt the cytoplasmic portion of T-cell signaling by forming a complex with a binding protein--FKBP12 in the case of FK506 and rapamycin and cyclophilin A (CyPA) in the case of cyclosporin A (CsA).	Cyclosporine	186-199	peptidylprolyl isomerase A	Homo sapiens	165-169
7529414-4	1995	They interrupt the cytoplasmic portion of T-cell signaling by forming a complex with a binding protein--FKBP12 in the case of FK506 and rapamycin and cyclophilin A (CyPA) in the case of cyclosporin A (CsA).	Cyclosporine	201-204	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	104-110
7529414-4	1995	They interrupt the cytoplasmic portion of T-cell signaling by forming a complex with a binding protein--FKBP12 in the case of FK506 and rapamycin and cyclophilin A (CyPA) in the case of cyclosporin A (CsA).	Cyclosporine	201-204	peptidylprolyl isomerase A	Homo sapiens	150-163
7529414-4	1995	They interrupt the cytoplasmic portion of T-cell signaling by forming a complex with a binding protein--FKBP12 in the case of FK506 and rapamycin and cyclophilin A (CyPA) in the case of cyclosporin A (CsA).	Cyclosporine	201-204	peptidylprolyl isomerase A	Homo sapiens	165-169
8561422-1	1995	The objective of the present study was to determine the effect of cyclosporine (CSA) on coronary artery reactivity.	Cyclosporine	66-78	albumin	Canis lupus familiaris	80-83
8561422-10	1995	Cyclosporine blood levels averaged 453 +/- 226 nmol/l and 1087 +/- 199 nmol/l after injections of 5 and 10 mg of CSA, respectively.	Cyclosporine	0-12	albumin	Canis lupus familiaris	113-116
7529995-3	1995	The existence of a slow cis-trans interconversion of an imidic bond in the inhibitor molecule during the course of the formation of the CsA-CyP18cy complex (where CyP18cy is human 18 kDa cytosolic CyP) prompted us to investigate the reaction of the peptidomacrolides FK506, ascomycin and rapamycin with two specific binding-proteins in more detail.	Cyclosporine	136-139	peptidylprolyl isomerase G	Homo sapiens	140-143
7723593-6	1995	Taken together with the observation that CsA and IPD-1151T suppressed IL-4 and IL-5 production by CA-stimulated D10 cells in vitro, the present results strongly suggest that agents capable of down-regulating Th2 cell cytokine production may attenuate allergic inflammation by impairing the recruitment of eosinophils that is mediated by Th2 cells.	Cyclosporine	41-44	interleukin 4	Mus musculus	70-74
7723593-6	1995	Taken together with the observation that CsA and IPD-1151T suppressed IL-4 and IL-5 production by CA-stimulated D10 cells in vitro, the present results strongly suggest that agents capable of down-regulating Th2 cell cytokine production may attenuate allergic inflammation by impairing the recruitment of eosinophils that is mediated by Th2 cells.	Cyclosporine	41-44	interleukin 5	Mus musculus	79-83
7982959-0	1994	The role of NFATp in cyclosporin A-sensitive tumor necrosis factor-alpha gene transcription.	Cyclosporine	21-34	nuclear factor of activated T cells 2	Homo sapiens	12-17
7875042-4	1994	Verapamil and cyclosporin (CsA), both inhibitors of P-gp, enhanced accumulation of indo-1 in these cells and therefore allowed for improved intracellular calcium measurements.	Cyclosporine	14-25	phosphoglycolate phosphatase	Homo sapiens	52-56
7875042-4	1994	Verapamil and cyclosporin (CsA), both inhibitors of P-gp, enhanced accumulation of indo-1 in these cells and therefore allowed for improved intracellular calcium measurements.	Cyclosporine	27-30	phosphoglycolate phosphatase	Homo sapiens	52-56
7528676-7	1994	We previously reported that ligation of either sIg or CD40 receptors, in conjunction with IL-4, induces the transcription factor, nuclear factor of activated T cells (NF-AT) in B cells, via a CsA/FK506-sensitive pathway.	Cyclosporine	192-195	interleukin 4	Mus musculus	90-94
7698817-7	1994	The beneficial effect on graft survival of HLA-A mismatching was most pronounced in patients treated with high/medium dose CyA and prednisolone (P = 0.004 overall and P = 0.0007 for HLA-B,DR mismatched transplants).	Cyclosporine	123-126	major histocompatibility complex, class I, B	Homo sapiens	182-187
7698817-8	1994	In conclusion, HLA-A mismatching was associated with enhanced long-term renal graft survival in CyA-treated recipients of HLA-B,DR mismatched transplants.	Cyclosporine	96-99	major histocompatibility complex, class I, B	Homo sapiens	122-127
7526495-1	1994	The microbial products FK506 and CsA are potent immunosuppressive agents that prevent early transcriptional events in TcR-mediated activation.	Cyclosporine	33-36	T cell receptor alpha variable 6-3	Mus musculus	118-121
7523141-0	1994	T cell receptor-induced Fas ligand expression in cytotoxic T lymphocyte clones is blocked by protein tyrosine kinase inhibitors and cyclosporin A.	Cyclosporine	132-145	T cell receptor alpha variable 12-3	Rattus norvegicus	0-15
7519613-0	1994	Cloning and expression of cyclosporin A- and FK506-sensitive nuclear factor of activated T-cells: NF45 and NF90.	Cyclosporine	26-39	interleukin enhancer binding factor 3	Homo sapiens	107-111
7519613-11	1994	Histidine-tagged NF45 and NF90 proteins, affinity-purified on nickel chelate columns, encode a NF-AT DNA-binding activity that is enhanced following T-cell stimulation, and this enhancement is blocked when T-cells are stimulated in the presence of cyclosporin A or FK506.	Cyclosporine	248-261	interleukin enhancer binding factor 3	Homo sapiens	26-30
7988651-0	1994	The effect of different corticosteroids and cyclosporin A on interleukin-4 and interleukin-5 release from murine TH2-type T cells.	Cyclosporine	44-57	heart and neural crest derivatives expressed 2	Mus musculus	113-116
7988651-3	1994	In order to examine the effects of corticosteroids and cyclosporin A on anti-CD3-induced production of interleukin-4 and interleukin-5 we used the murine TH2-type cell clone D10.G4.1.	Cyclosporine	55-68	interleukin 4	Mus musculus	103-116
7518620-4	1994	Using this method, we studied the time course and effects of CsA and rapamycin on IL-2, IFN-gamma, IL-4, and IL-10 gene expression following Con A stimulation.	Cyclosporine	61-64	interleukin 2	Mus musculus	82-86
7518620-6	1994	CsA very effectively inhibits expression of IL-2, IFN-gamma, and IL-4, but it inhibits IL-10 expression only 65%.	Cyclosporine	0-3	interleukin 2	Mus musculus	44-48
8031755-11	1994	However, Cyp-C tolerates a greater variety of structures on Cs at position 2 than Cyp-A does, suggesting that this residue of CsA might not be in tight contact with Cyp-C.	Cyclosporine	126-129	peptidylprolyl isomerase G	Homo sapiens	9-12
8031755-11	1994	However, Cyp-C tolerates a greater variety of structures on Cs at position 2 than Cyp-A does, suggesting that this residue of CsA might not be in tight contact with Cyp-C.	Cyclosporine	126-129	peptidylprolyl isomerase A	Homo sapiens	82-87
8031755-11	1994	However, Cyp-C tolerates a greater variety of structures on Cs at position 2 than Cyp-A does, suggesting that this residue of CsA might not be in tight contact with Cyp-C.	Cyclosporine	126-129	peptidylprolyl isomerase C	Homo sapiens	9-14
15299416-0	1994	Crystallization of the complex between cyclophilin A and cyclosporin derivatives: the use of cross-seeding.	Cyclosporine	57-68	peptidylprolyl isomerase A	Homo sapiens	39-52
15299416-7	1994	In this crystal form, CsA has no packing interactions with neighbouring molecules and these crystals could be used to cross-seed other CypA/CsA analog complexes.	Cyclosporine	22-25	peptidylprolyl isomerase A	Homo sapiens	135-139
15299416-7	1994	In this crystal form, CsA has no packing interactions with neighbouring molecules and these crystals could be used to cross-seed other CypA/CsA analog complexes.	Cyclosporine	140-143	peptidylprolyl isomerase A	Homo sapiens	135-139
15299416-8	1994	Nine different CypA/ CsA analog complexes could be crystallized using this technique, most of them yielding highly diffracting crystals, quickly solvable by Fourier difference methods.	Cyclosporine	21-24	peptidylprolyl isomerase A	Homo sapiens	15-19
8075536-0	1994	Determination of the NMR solution structure of the cyclophilin A-cyclosporin A complex.	Cyclosporine	65-78	peptidylprolyl isomerase G	Homo sapiens	51-64
8075536-1	1994	The three-dimensional NMR solution structure of the cyclophilin A (Cyp)-cyclosporin A (CsA) complex was determined, and here we provide a detailed description of the analysis of the NMR data and the structure calculation.	Cyclosporine	72-85	peptidylprolyl isomerase G	Homo sapiens	52-65
8075536-1	1994	The three-dimensional NMR solution structure of the cyclophilin A (Cyp)-cyclosporin A (CsA) complex was determined, and here we provide a detailed description of the analysis of the NMR data and the structure calculation.	Cyclosporine	72-85	peptidylprolyl isomerase G	Homo sapiens	67-70
7787867-8	1994	In contrast, patients with ATN and concomitance of acute rejection or CSA nephrotoxicity presented elevated beta 2M and creatinine serum levels.	Cyclosporine	70-73	beta-2-microglobulin	Homo sapiens	108-115
7787867-10	1994	However, serum beta 2M levels seemed to be useful in diagnosing acute rejection or CSA nephrotoxicity in patients with ATN.	Cyclosporine	83-86	beta-2-microglobulin	Homo sapiens	15-22
8013656-3	1994	Bovine cyclophilin-B possesses the peptidylproline cis-trans isomerase activity which is inhibited by nM concentrations of CsA.	Cyclosporine	123-126	peptidylprolyl isomerase B	Bos taurus	7-20
8029023-4	1994	The CsA sensitivity of IL2R alpha mRNA induction represented a direct effect on the TCR/CD3 response, and was not due to CsA-sensitive release of the lymphokines IL2 or tumour necrosis factor alpha (TNF alpha) and consequent lymphokine-mediated induction of IL2R alpha mRNA.	Cyclosporine	4-7	interleukin 2	Mus musculus	23-26
7889406-1	1994	We show here that ligation of surface immunoglobulin or CD40 receptors in conjunction with interleukin-4 induces the nuclear factor of activated T cells (NF-AT) in normal murine B cells, which is inhibited by cyclosporin (CsA).	Cyclosporine	209-220	interleukin 4	Mus musculus	91-104
7889406-1	1994	We show here that ligation of surface immunoglobulin or CD40 receptors in conjunction with interleukin-4 induces the nuclear factor of activated T cells (NF-AT) in normal murine B cells, which is inhibited by cyclosporin (CsA).	Cyclosporine	222-225	interleukin 4	Mus musculus	91-104
8183344-0	1994	Cyclosporin A inhibits growth of autocrine tumour cell lines by destabilizing interleukin-3 mRNA.	Cyclosporine	0-13	interleukin 3	Homo sapiens	78-91
8183344-6	1994	Transcripts from exogenous IL-3 genes lacking the (A+U)-rich element (ARE) in the 3" untranslated terminal repeat could not be destabilized, suggesting that at least part of this sequence, which is known to mediate decay of short-lived mRNA, participates in a CsA-sensitive regulatory mechanism.	Cyclosporine	260-263	interleukin 3	Homo sapiens	27-31
7514602-3	1994	Chemical cross-linking studies with disuccinimidyl suberate in the presence of either cyclophilin A, B, or C in complex with cyclosporin A or FK506 binding protein-FK506 result on the other hand in the apparently exclusive and strictly immunosuppressant-dependent formation of covalent immunophilin-calcineurin B subunit products.	Cyclosporine	125-138	protein phosphatase 3 regulatory subunit B, alpha	Bos taurus	299-312
7510704-4	1994	Measurements of enzyme activity of lysates derived from inhibitor-treated cells indicated that Hsp27 phosphatase activity is equally sensitive to okadaic acid (PPI/PP2A inhibitor) and cyclosporin (PP2B inhibitor) and that both okadaic acid and cyclosporin treatment inhibited Hsp27 phosphatase activity additively.	Cyclosporine	184-195	heat shock protein family B (small) member 1	Homo sapiens	95-100
7510704-4	1994	Measurements of enzyme activity of lysates derived from inhibitor-treated cells indicated that Hsp27 phosphatase activity is equally sensitive to okadaic acid (PPI/PP2A inhibitor) and cyclosporin (PP2B inhibitor) and that both okadaic acid and cyclosporin treatment inhibited Hsp27 phosphatase activity additively.	Cyclosporine	244-255	heat shock protein family B (small) member 1	Homo sapiens	95-100
7510704-6	1994	However, the phosphorylation of Hsp27 in vivo is only affected when cells are treated with PP1 and PP2A inhibitors (okadaic acid, calyculin A) or cantharidin (PP2A inhibitor), but not the PP2B inhibitor, cyclosporin A, suggesting PP2A to be the main enzyme dephosphorylating Hsp27 in the cells.	Cyclosporine	204-217	heat shock protein family B (small) member 1	Homo sapiens	32-37
8113685-8	1994	This result, and similar results in cyclosporin A-treated cells, imply that individual IL-2 transcription factors cannot stably bind their target sequences in vivo without coengagement of all other distinct factors at neighboring sites.	Cyclosporine	36-49	interleukin 2	Mus musculus	87-91
8133028-6	1994	Treatment with cyclosporin A prevented the expression of egr-2 induced by slg cross-linking, but did not inhibit egr-1 expression.	Cyclosporine	15-28	early growth response 2	Mus musculus	57-62
7906541-3	1994	We have constructed a soluble bacterial fusion protein between the cyclophilin-homologous domain of the NK-TR molecule and glutathione S-transferase (GST) to test for the presence of peptidylprolyl cis-trans-isomerase and chaperone activities and for cyclosporin A binding.	Cyclosporine	251-264	natural killer cell triggering receptor	Homo sapiens	104-109
7906657-0	1994	HIV-1 gp120-dependent induction of apoptosis in antigen-specific human T cell clones is characterized by "tissue" transglutaminase expression and prevented by cyclosporin A.	Cyclosporine	159-172	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	6-11
7906657-1	1994	We investigated the effect of cyclosporin (CsA) on HIV-gp120-dependent induction of cell death by apoptosis of human T cell clones specific for influenza virus haemagglutinin and restricted by HLA-DR1.	Cyclosporine	30-41	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	55-60
8857935-6	1996	Cyclosporin efficiently down-regulated GM-CSF secretion by T lymphocytes and had also a minor effect on CSF secretion by endothelial cells, whereas monocyte secretion was unaffected.	Cyclosporine	0-11	colony stimulating factor 2	Homo sapiens	39-45
7906657-1	1994	We investigated the effect of cyclosporin (CsA) on HIV-gp120-dependent induction of cell death by apoptosis of human T cell clones specific for influenza virus haemagglutinin and restricted by HLA-DR1.	Cyclosporine	43-46	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	55-60
8857935-6	1996	Cyclosporin efficiently down-regulated GM-CSF secretion by T lymphocytes and had also a minor effect on CSF secretion by endothelial cells, whereas monocyte secretion was unaffected.	Cyclosporine	0-11	colony stimulating factor 2	Homo sapiens	42-45
7906657-6	1994	Noteworthy, CsA treatment prevented the gp120-dependent induction of apoptosis by blocking the activation of the Ca(2+)-dependent effector elements such as tTG.	Cyclosporine	12-15	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	40-45
8857935-7	1996	Stimulated T lymphocytes derived from patients under treatment with cyclosporin had impaired capacity to secrete GM-CSF compared to controls.	Cyclosporine	68-79	colony stimulating factor 2	Homo sapiens	113-119
8939689-0	1996	Controlling programmed cell death with a cyclophilin-cyclosporin-based chemical inducer of dimerization.	Cyclosporine	53-64	peptidylprolyl isomerase G	Homo sapiens	41-52
8939689-5	1996	Here we describe the synthesis of a novel CID, (CsA)2, that has two identical protein-binding surfaces derived from the immunosuppressant cyclosporin A (CsA).	Cyclosporine	138-151	IK cytokine	Homo sapiens	48-53
8939689-7	1996	RESULTS: (CsA)2 was synthesized in six synthetic steps and 30% overall yield from cyclosporin.	Cyclosporine	82-93	IK cytokine	Homo sapiens	10-15
8854765-8	1996	These results indicated that HVI.CHP allowed the high-dose CsA infusion required for P-gp inhibition in the liver and could reduce extraregional CsA leakage.	Cyclosporine	59-62	PGP	Canis lupus familiaris	85-89
8931986-1	1996	One pathological feature of chronic cyclosporin A (Cs-A) nephrotoxicity is striped interstitial fibrosis, the pathogenesis of which is not completely understood.	Cyclosporine	36-49	heat shock protein 9	Mus musculus	51-55
8312269-1	1994	Cyclophilin (CyP) is the 17.8-kDa cytosolic receptor of the immunosuppressant cyclosporin A (CsA) and also a peptidyl prolyl cis-trans isomerase (PPIase).	Cyclosporine	78-91	peptidylprolyl isomerase G	Homo sapiens	0-11
8312269-1	1994	Cyclophilin (CyP) is the 17.8-kDa cytosolic receptor of the immunosuppressant cyclosporin A (CsA) and also a peptidyl prolyl cis-trans isomerase (PPIase).	Cyclosporine	78-91	peptidylprolyl isomerase G	Homo sapiens	13-16
8312269-1	1994	Cyclophilin (CyP) is the 17.8-kDa cytosolic receptor of the immunosuppressant cyclosporin A (CsA) and also a peptidyl prolyl cis-trans isomerase (PPIase).	Cyclosporine	93-96	peptidylprolyl isomerase G	Homo sapiens	0-11
8312269-1	1994	Cyclophilin (CyP) is the 17.8-kDa cytosolic receptor of the immunosuppressant cyclosporin A (CsA) and also a peptidyl prolyl cis-trans isomerase (PPIase).	Cyclosporine	93-96	peptidylprolyl isomerase G	Homo sapiens	13-16
7507731-10	1994	Flow cytometric analysis of rhodamine 123 dye efflux indicated a functional P-gp that was efficiently blocked by verapamil or cyclosporin A (CsA).	Cyclosporine	141-144	phosphoglycolate phosphatase	Homo sapiens	76-80
7507511-1	1994	Interaction of CD28/CTLA-4 on T cells with B7 on antigen-presenting cells constitutes an important costimulatory signal for T cells and is responsible for cyclosporin A-resistant interleukin 2 (IL-2) gene expression and potentially also for prevention of anergy induction after T cell receptor triggering.	Cyclosporine	155-168	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	20-26
8108881-5	1994	CTLp directed against HLA-B antigens were also found to be less sensitive to CsA, which suggests that their high affinity is due to previous priming.	Cyclosporine	77-80	major histocompatibility complex, class I, B	Homo sapiens	22-27
8781333-9	1996	The results show that cyclosporine reduces LDL binding and uptake by mainly inhibiting the LDL receptor-mediated pathway.	Cyclosporine	22-34	low density lipoprotein receptor	Homo sapiens	91-103
8781333-12	1996	We also found that cyclosporine reduces the expression of the LDL receptor messenger RNA (mRNA) by about 40%.	Cyclosporine	19-31	low density lipoprotein receptor	Homo sapiens	62-74
8781333-13	1996	Thus, the interpretation of this study is that cyclosporine can cause an increase in LDL-cholesterol in the plasma of transplantation patients by reducing the catabolism of LDL in the liver by inhibiting mainly the LDL receptor-mediated catabolism through an effect on LDL receptor synthesis.	Cyclosporine	47-59	low density lipoprotein receptor	Homo sapiens	215-227
8781333-13	1996	Thus, the interpretation of this study is that cyclosporine can cause an increase in LDL-cholesterol in the plasma of transplantation patients by reducing the catabolism of LDL in the liver by inhibiting mainly the LDL receptor-mediated catabolism through an effect on LDL receptor synthesis.	Cyclosporine	47-59	low density lipoprotein receptor	Homo sapiens	269-281
7506953-0	1994	Cyclosporin A and cyclosporin SDZ PSC 833 enhance anti-CD5 ricin A-chain immunotoxins in human leukemic T cells.	Cyclosporine	18-29	CD5 molecule	Homo sapiens	55-58
8781605-2	1996	Increased generation of oxygen derived free radicals (ODFR) and enhanced activity of phospholipase A2 (PLA2) have been observed in experimental animals following treatment with CsA.	Cyclosporine	177-180	phospholipase A2 group IB	Rattus norvegicus	85-101
8075981-0	1994	Crystal structures of cyclophilin A complexed with cyclosporin A and N-methyl-4-[(E)-2-butenyl]-4,4-dimethylthreonine cyclosporin A.	Cyclosporine	51-64	peptidylprolyl isomerase A	Homo sapiens	22-35
8781605-2	1996	Increased generation of oxygen derived free radicals (ODFR) and enhanced activity of phospholipase A2 (PLA2) have been observed in experimental animals following treatment with CsA.	Cyclosporine	177-180	phospholipase A2 group IB	Rattus norvegicus	103-107
8075981-1	1994	BACKGROUND: Cyclophilin (CyP) is a ubiquitious intracellular protein that binds the immunosuppressive drug cyclosporin A (CsA).	Cyclosporine	107-120	peptidylprolyl isomerase G	Homo sapiens	12-23
8918695-5	1996	Surprisingly, blocking experiments with sIL-4R and anti-IL-4 mAb revealed that in three out of four Th2 cell clones this effect of IL-1 was IL-4-independent and could also not be blocked by cyclosporin A (CsA).	Cyclosporine	205-208	interleukin 1 alpha	Homo sapiens	131-135
8075981-1	1994	BACKGROUND: Cyclophilin (CyP) is a ubiquitious intracellular protein that binds the immunosuppressive drug cyclosporin A (CsA).	Cyclosporine	107-120	peptidylprolyl isomerase G	Homo sapiens	25-28
8168430-7	1994	Cell proliferation and IL-2 production were inhibited by both benzene and cyclosporin A, effects more clearly demonstrated using SEA than con A.	Cyclosporine	74-87	interleukin 2	Mus musculus	23-27
8291099-5	1994	CsA, a potent inhibitor of Ca(2+)-induced increase in permeability of the mitochondrial membrane, completely prevented mAST release on reoxygenation.	Cyclosporine	0-3	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	119-123
8291099-6	1994	We conclude that during reoxygenation of hypoxic liver, mAST leaks into the cytosol in a Ca(2+)-dependent, CsA-sensitive manner.	Cyclosporine	107-110	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	56-60
8525502-10	1994	The reduction of TCR gamma delta+ thymocytes was not due to the modulation of TCR molecules and could be reversed by Cyclosporin A (CsA).	Cyclosporine	117-130	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	17-20
8525502-10	1994	The reduction of TCR gamma delta+ thymocytes was not due to the modulation of TCR molecules and could be reversed by Cyclosporin A (CsA).	Cyclosporine	132-135	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	17-20
7693482-0	1993	Cyclosporin A enhances T cell-mediated induction of E-selectin.	Cyclosporine	0-13	selectin E	Homo sapiens	52-62
7693482-1	1993	In a fetal intestinal organ culture model of intestinal inflammation, activation of T cells by a lectin, superantigen or anti-CD3 antibodies induces E-selectin expression which peaks 6-10 h after activation and disappears by 24 h. We now show that addition of cyclosporin A (Cys A) increases the number of E-selectin-expressing endothelial cells and the intensity of expression, and it prolongs expression up to at least 60 h after stimulation.	Cyclosporine	260-273	selectin E	Homo sapiens	149-159
7693482-1	1993	In a fetal intestinal organ culture model of intestinal inflammation, activation of T cells by a lectin, superantigen or anti-CD3 antibodies induces E-selectin expression which peaks 6-10 h after activation and disappears by 24 h. We now show that addition of cyclosporin A (Cys A) increases the number of E-selectin-expressing endothelial cells and the intensity of expression, and it prolongs expression up to at least 60 h after stimulation.	Cyclosporine	275-280	selectin E	Homo sapiens	149-159
7693482-3	1993	Furthermore, other immunosuppressive agents FK506 and dexamethasone inhibit E-selectin expression, indicating that the enhancement observed in the presence of Cys A is not a consequence of general immunosuppression.	Cyclosporine	159-164	selectin E	Homo sapiens	76-86
7694584-4	1993	We found that dexamethasone (4-40 micrograms/mL), the azathioprine metabolite 6-mercaptopurine (10-100 micrograms/mL) and cyclosporine A (0.1-1 microgram/mL) have no effect on the basal and the tumor necrosis factor-alpha- or interleukin-1-stimulated expression of these adhesion molecules.	Cyclosporine	122-136	interleukin 1 alpha	Homo sapiens	226-239
8712218-10	1996	Confocal fluorescence microscopy studies showed that CyA induced an increase in the endothelial surface expression of ICAM-1, VCAM-1, and E-selectin.	Cyclosporine	53-56	selectin E	Homo sapiens	138-148
8823683-15	1996	Some drugs (prednisone and cyclosporine) inhibit the release of GZB and PF.	Cyclosporine	27-39	granzyme B	Homo sapiens	64-67
8668213-5	1996	Immunocytochemical analysis indicates that recombinant NFAT1 localizes in the cytoplasm of transiently transfected T cells and translocates into the nucleus in a CsA-sensitive manner following ionomycin stimulation.	Cyclosporine	162-165	nuclear factor of activated T cells 2	Homo sapiens	55-60
8813640-3	1996	Treatment of mesangial cells with tetranactin, a cyclic antibiotic produced by Streptomyces aureus with a molecular structure similar to cyclosporin A inhibits interleukin 1 beta- and cAMP-dependent group II phospholipase A2 secretion in a dose-dependent manner with IC50 values of 43 and 33 nM, respectively.	Cyclosporine	137-150	phospholipase A2 group IB	Rattus norvegicus	208-224
8832486-8	1996	The apparent cyclosporin binding affinity (Kd) to erythrocytes under in-vivo conditions averaged 452.2 +/- 47.6 nM (543.5 +/- 57.2 ng mL-1) for group A and 419.4 +/- 41.2 nM (504.1 +/- 49.5 ng mL-1) for group B, whereas apparent cyclosporin binding capacity (Bmax) of the blood cell averaged 0.83 +/- 0.07 nmol mL-1 for group A and 0.78 +/- 0.07 nmol mL-1 for group B.	Cyclosporine	13-24	L1 cell adhesion molecule	Mus musculus	134-138
8832486-8	1996	The apparent cyclosporin binding affinity (Kd) to erythrocytes under in-vivo conditions averaged 452.2 +/- 47.6 nM (543.5 +/- 57.2 ng mL-1) for group A and 419.4 +/- 41.2 nM (504.1 +/- 49.5 ng mL-1) for group B, whereas apparent cyclosporin binding capacity (Bmax) of the blood cell averaged 0.83 +/- 0.07 nmol mL-1 for group A and 0.78 +/- 0.07 nmol mL-1 for group B.	Cyclosporine	13-24	L1 cell adhesion molecule	Mus musculus	193-197
8832486-8	1996	The apparent cyclosporin binding affinity (Kd) to erythrocytes under in-vivo conditions averaged 452.2 +/- 47.6 nM (543.5 +/- 57.2 ng mL-1) for group A and 419.4 +/- 41.2 nM (504.1 +/- 49.5 ng mL-1) for group B, whereas apparent cyclosporin binding capacity (Bmax) of the blood cell averaged 0.83 +/- 0.07 nmol mL-1 for group A and 0.78 +/- 0.07 nmol mL-1 for group B.	Cyclosporine	13-24	L1 cell adhesion molecule	Mus musculus	193-197
8832486-8	1996	The apparent cyclosporin binding affinity (Kd) to erythrocytes under in-vivo conditions averaged 452.2 +/- 47.6 nM (543.5 +/- 57.2 ng mL-1) for group A and 419.4 +/- 41.2 nM (504.1 +/- 49.5 ng mL-1) for group B, whereas apparent cyclosporin binding capacity (Bmax) of the blood cell averaged 0.83 +/- 0.07 nmol mL-1 for group A and 0.78 +/- 0.07 nmol mL-1 for group B.	Cyclosporine	13-24	L1 cell adhesion molecule	Mus musculus	351-367
8837256-8	1996	In four of these patients, the ACR had been reversed successfully before the development of antibodies, and in the last patient the ACR was reversed by a second course of Minnesota-ALG and increasing the dose of Cyclosporine.	Cyclosporine	212-224	acrosin	Homo sapiens	132-135
8658705-0	1996	Fas antigen expression and apoptosis induction of in vitro cultured hepatocytes with high concentrations of cyclosporine A.	Cyclosporine	108-122	Fas cell surface death receptor	Homo sapiens	0-11
8796279-0	1996	Cyclosporine A decreases kallikrein and BK2 mRNA expression in the rat renal cortex.	Cyclosporine	0-14	kallikrein related-peptidase 5 like	Rattus norvegicus	25-35
8301156-5	1993	Results indicate that the neutrophils from rats treated with maintenance doses of cyclosporine and IFN-gamma still had increased IFN-gamma-modulated fMLP-induced respiratory burst and that maintenance cyclosporine therapy can inhibit the IFN-gamma-mediated accelerated rejection without compromising the antimicrobial effects of IFN-gamma treatment.	Cyclosporine	82-94	interferon gamma	Rattus norvegicus	129-138
8301156-5	1993	Results indicate that the neutrophils from rats treated with maintenance doses of cyclosporine and IFN-gamma still had increased IFN-gamma-modulated fMLP-induced respiratory burst and that maintenance cyclosporine therapy can inhibit the IFN-gamma-mediated accelerated rejection without compromising the antimicrobial effects of IFN-gamma treatment.	Cyclosporine	82-94	interferon gamma	Rattus norvegicus	129-138
8301156-5	1993	Results indicate that the neutrophils from rats treated with maintenance doses of cyclosporine and IFN-gamma still had increased IFN-gamma-modulated fMLP-induced respiratory burst and that maintenance cyclosporine therapy can inhibit the IFN-gamma-mediated accelerated rejection without compromising the antimicrobial effects of IFN-gamma treatment.	Cyclosporine	82-94	interferon gamma	Rattus norvegicus	129-138
8301156-5	1993	Results indicate that the neutrophils from rats treated with maintenance doses of cyclosporine and IFN-gamma still had increased IFN-gamma-modulated fMLP-induced respiratory burst and that maintenance cyclosporine therapy can inhibit the IFN-gamma-mediated accelerated rejection without compromising the antimicrobial effects of IFN-gamma treatment.	Cyclosporine	201-213	interferon gamma	Rattus norvegicus	99-108
8301156-5	1993	Results indicate that the neutrophils from rats treated with maintenance doses of cyclosporine and IFN-gamma still had increased IFN-gamma-modulated fMLP-induced respiratory burst and that maintenance cyclosporine therapy can inhibit the IFN-gamma-mediated accelerated rejection without compromising the antimicrobial effects of IFN-gamma treatment.	Cyclosporine	201-213	interferon gamma	Rattus norvegicus	129-138
8301156-5	1993	Results indicate that the neutrophils from rats treated with maintenance doses of cyclosporine and IFN-gamma still had increased IFN-gamma-modulated fMLP-induced respiratory burst and that maintenance cyclosporine therapy can inhibit the IFN-gamma-mediated accelerated rejection without compromising the antimicrobial effects of IFN-gamma treatment.	Cyclosporine	201-213	interferon gamma	Rattus norvegicus	129-138
8301156-5	1993	Results indicate that the neutrophils from rats treated with maintenance doses of cyclosporine and IFN-gamma still had increased IFN-gamma-modulated fMLP-induced respiratory burst and that maintenance cyclosporine therapy can inhibit the IFN-gamma-mediated accelerated rejection without compromising the antimicrobial effects of IFN-gamma treatment.	Cyclosporine	201-213	interferon gamma	Rattus norvegicus	129-138
8796279-1	1996	The effect of subcutaneous injection of cyclosporine (20 mg/kg/day for 3 days) on the expression of kallikrein (Kal) and bradykinin 2 receptor (BK2) mRNA in the rat renal cortex was examined.	Cyclosporine	40-52	kallikrein related-peptidase 5 like	Rattus norvegicus	100-110
8359233-10	1993	Taken together, our results suggest the existence of a labile mRNA regulatory protein or proteins, whose actions include destabilization of both c-fms and CSF-1 transcripts after inhibition of TPA-induced monocytic differentiation by dex or CsA.	Cyclosporine	241-244	colony stimulating factor 1	Homo sapiens	155-160
8377379-4	1993	The presence of cyclosporin A (CsA) during stimulation with IL-1 alpha inhibited the enhanced TNF alpha production in a dose dependent fashion, with a maximal inhibition of 90% at a concentration of 250 ng/ml.	Cyclosporine	31-34	interleukin 1 alpha	Homo sapiens	60-70
8796279-1	1996	The effect of subcutaneous injection of cyclosporine (20 mg/kg/day for 3 days) on the expression of kallikrein (Kal) and bradykinin 2 receptor (BK2) mRNA in the rat renal cortex was examined.	Cyclosporine	40-52	kallikrein related-peptidase 5 like	Rattus norvegicus	112-115
8796279-2	1996	CsA decreased significantly Kal and BK2 mRNA expression in the kidney cortex.	Cyclosporine	0-3	kallikrein related-peptidase 5 like	Rattus norvegicus	28-31
8796279-3	1996	These results indicate that the kallikrein-kinin system may participate in the genesis or the aggravation of the renal haemodynamic effect induced by long term administration of CsA.	Cyclosporine	178-181	kallikrein related-peptidase 5 like	Rattus norvegicus	32-42
8784785-1	1996	BACKGROUND: The immunophilins are proteins that mediate actions of immunosuppressant drugs such as FK506 and cyclosporin A by binding to calcineurin, inhibiting its phosphatase activity, and increasing the phosphorylation level of transcription factors required for interleukin 2 formation.	Cyclosporine	109-122	interleukin 2	Rattus norvegicus	266-279
8612348-5	1996	We assessed the effects of standard immunosuppressant cyclosporin A (CsA) on IL-2 production and on allograft survival to estimate the intensity of rejection in this acute rejection model.	Cyclosporine	54-67	interleukin 2	Mus musculus	77-81
8612348-5	1996	We assessed the effects of standard immunosuppressant cyclosporin A (CsA) on IL-2 production and on allograft survival to estimate the intensity of rejection in this acute rejection model.	Cyclosporine	69-72	interleukin 2	Mus musculus	77-81
8625972-4	1996	Egr-2 expression/activity was selectively inhibited by the immunosuppressive drug cyclosporin A, and antisense oligonucleotide blockade of Egr-2 activity elicited a dose-dependent inhibition of B cell proliferation.	Cyclosporine	82-95	early growth response 2	Homo sapiens	0-5
7687744-3	1993	We found that overexpression of cyclophilin A or B or FKBP12 increased T-cell sensitivity to CsA or FK506, respectively, demonstrating that they are able to mediate the inhibitory effects of their respective immunosuppressants in vivo.	Cyclosporine	93-96	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	54-60
8411796-11	1993	When cyclosporine A is used in combination with prednisone, the immunologic cycle that causes rejection is interrupted twice by virtue of the fact that prednisone prevents the production of IL-1 by macrophages and cyclosporine A with the production of lymphokines, especially IL-2 (T-cell growth factor).	Cyclosporine	5-19	interleukin 1 alpha	Homo sapiens	190-194
7687618-10	1993	Consistent with its effects on normal T cells, cyclosporin A partially inhibited the response of DN T cells to TCR cross-linking and CD28 ligation.	Cyclosporine	47-60	T cell receptor alpha variable 6-3	Mus musculus	111-114
7687618-10	1993	Consistent with its effects on normal T cells, cyclosporin A partially inhibited the response of DN T cells to TCR cross-linking and CD28 ligation.	Cyclosporine	47-60	CD28 antigen	Mus musculus	133-137
8741004-8	1996	In vitro experiments showed that IL-6 production by lymphoid cells was relatively unaffected by CsA and CCA but IL-2, TNF and IFN-gamma were suppressed by CsA.	Cyclosporine	155-158	interleukin 2	Rattus norvegicus	112-116
8741004-8	1996	In vitro experiments showed that IL-6 production by lymphoid cells was relatively unaffected by CsA and CCA but IL-2, TNF and IFN-gamma were suppressed by CsA.	Cyclosporine	155-158	interferon gamma	Rattus norvegicus	126-135
8741004-9	1996	The results indicate that CsA and CCA may modify the response to the arthritic adjuvant by specifically inhibiting IL-2, TNF and IFN-gamma production at the time of adjuvant injection.	Cyclosporine	26-29	interleukin 2	Rattus norvegicus	115-119
8741004-9	1996	The results indicate that CsA and CCA may modify the response to the arthritic adjuvant by specifically inhibiting IL-2, TNF and IFN-gamma production at the time of adjuvant injection.	Cyclosporine	26-29	interferon gamma	Rattus norvegicus	129-138
8730113-10	1996	From a societal perspective, the incremental cost of CyA was $2,886 and $3,731 between Aza and D-Pen, respectively.	Cyclosporine	53-56	proprotein convertase subtilisin/kexin type 1 inhibitor	Homo sapiens	97-100
8668925-6	1996	CsA is approximately 100-fold more effective on inhibition of PBMC P-gp than is RAPA.	Cyclosporine	0-3	phosphoglycolate phosphatase	Homo sapiens	67-71
8623224-0	1996	The inhibition of T-cell-receptor-induced Fas ligand upregulation by cyclosporine and FK 506.	Cyclosporine	69-81	Fas ligand	Homo sapiens	42-52
8552071-2	1996	Previous experiments have demonstrated that in stimulated T cells, a TNF-alpha promoter element, kappa 3, which binds NFATp, is required for the cyclosporin A-sensitive transcriptional activation of the gene.	Cyclosporine	145-158	nuclear factor of activated T cells 2	Homo sapiens	118-123
8671791-8	1996	Hypofibrinolysis induced by elevated PAI levels and increased LDL cholesterol may contribute to the increased thrombogenicity and accelerated atherosclerosis observed in cyclosporin-treated patients.	Cyclosporine	170-181	serpin family E member 1	Homo sapiens	37-40
8828007-0	1996	Cross-linking the TCR complex induces apoptosis in CD4+8+ thymocytes in the presence of cyclosporin A.	Cyclosporine	88-101	T cell receptor alpha variable 6-3	Mus musculus	18-21
8828007-8	1996	These data verify that TCR cross-linking alone is insufficient to induce apoptosis of DP thymocytes and further suggest that TCR stimulation activates a CsA-sensitive protective pathway that interferes with signaling events leading to apoptosis in DP thymocytes.	Cyclosporine	153-156	T cell receptor alpha variable 6-3	Mus musculus	23-26
8828007-8	1996	These data verify that TCR cross-linking alone is insufficient to induce apoptosis of DP thymocytes and further suggest that TCR stimulation activates a CsA-sensitive protective pathway that interferes with signaling events leading to apoptosis in DP thymocytes.	Cyclosporine	153-156	T cell receptor alpha variable 6-3	Mus musculus	125-128
8820113-6	1996	In contrast, 10 mu M cyclosporin was found to inhibit the esterification of cholesterol and to increase the cellular level of free cholesterol resulting in suppression of LDL receptor activity.	Cyclosporine	21-32	low density lipoprotein receptor	Homo sapiens	171-183
8950833-7	1996	Pentoxifylline (40 mumol/L), retinoic acid (0.01 mmol/L) and cyclosporin A (0.08 mumol/L) inhibited TF expression when added concurrently with LPS or TNF, but not when added 4 h after stimulation.	Cyclosporine	61-74	tumor necrosis factor	Bos taurus	150-153
8950833-9	1996	In contrast, exposure to LPS or TNF for 6 h induced marked expression of TF mRNA, which was inhibited by treatment with pentoxifylline, retinoic acid and cyclosporin A.	Cyclosporine	154-167	tumor necrosis factor	Bos taurus	32-35
8758815-1	1996	OBJECTIVES: To investigate the enhanced impact of cyclosporin A (CsA) on antitumor activity of cisplatin (DDP) for human ovarian cancer cells.	Cyclosporine	65-68	translocase of inner mitochondrial membrane 8A	Homo sapiens	106-109
8758815-7	1996	RESULTS: IN VITRO STUDIES, DDP combined with CsA exhibited a synergistic cytotoxic effect on COC1 and COC1/DDP cells.	Cyclosporine	45-48	translocase of inner mitochondrial membrane 8A	Homo sapiens	107-110
8524402-2	1995	CaN is the target of the immunosuppressive drugs cyclosporin A and FK506, which inhibit CaN after forming complexes with cytoplasmic binding proteins (cyclophilin and FKBP12, respectively).	Cyclosporine	49-62	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	167-173
7479966-3	1995	Cyclosporin A prevents the dephosphorylation and the nuclear translocation of NFAT1 in T cells, B cells, macrophages, and mast cells, delineating at least one mechanism that contributes to the profound immunosuppressive effects of this compound.	Cyclosporine	0-13	nuclear factor of activated T cells 2	Homo sapiens	78-83
7592882-5	1995	Moreover, drugs that interfere with TCR-mediated signals, such as cyclosporin A and staurosporin, prevented both apoptosis and the appearance of the RNA-binding factors.	Cyclosporine	66-79	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	36-39
8580076-6	1995	Blocking experiments with cyclosporin A indicated that the intracellular pathways used by the CD28 and CD44 molecules appear to be different.	Cyclosporine	26-39	CD28 antigen	Mus musculus	94-98
7594578-4	1995	Most of the TCR-alpha beta i-IEL whose development was inhibited by CSA belonged to the CD4-CD8+ alpha alpha subset.	Cyclosporine	68-71	T cell receptor alpha chain	Mus musculus	12-21
7686148-1	1993	Calcineurin (CaN), a Ca2+/calmodulin-dependent serine/threonine phosphatase, has been shown to be inhibited by the complex of the immunosuppressant cyclosporin A (CsA) and its receptor, cyclophilin (CyP), but not by either alone.	Cyclosporine	163-166	peptidylprolyl isomerase G	Homo sapiens	186-197
7686148-1	1993	Calcineurin (CaN), a Ca2+/calmodulin-dependent serine/threonine phosphatase, has been shown to be inhibited by the complex of the immunosuppressant cyclosporin A (CsA) and its receptor, cyclophilin (CyP), but not by either alone.	Cyclosporine	163-166	peptidylprolyl isomerase G	Homo sapiens	199-202
7686148-3	1993	In the presence of cyclosporin, 125I-CyP, shown to bind to CsA, is extensively cross-linked to the B subunit of CaN but not the catalytic A subunit.	Cyclosporine	19-30	peptidylprolyl isomerase G	Homo sapiens	37-40
7686148-3	1993	In the presence of cyclosporin, 125I-CyP, shown to bind to CsA, is extensively cross-linked to the B subunit of CaN but not the catalytic A subunit.	Cyclosporine	59-62	peptidylprolyl isomerase G	Homo sapiens	37-40
7686148-4	1993	However, the A subunit is required for binding of the CyP.CsA complex, since cross-linking to recombinant B subunit alone does not occur.	Cyclosporine	58-61	peptidylprolyl isomerase G	Homo sapiens	54-57
7686148-8	1993	CyP.CsA cross-linking to CaN is Ca2+/calmodulin-dependent with intact CaN, but Ca2+/calmodulin-independent after digestion to remove the calmodulin binding and autoinhibitory domain.	Cyclosporine	4-7	peptidylprolyl isomerase G	Homo sapiens	0-3
8515077-5	1993	Lesions with both Th1 and Th2 cells contained a predominant neutrophilic infiltrate at 6 h, and mainly mononuclear cells at 48 h. The inflammatory response with Th2 was blocked by cyclosporin A, by mAb to IL-4 or by soluble rIL-4R.	Cyclosporine	180-193	heart and neural crest derivatives expressed 2	Mus musculus	26-29
8515077-5	1993	Lesions with both Th1 and Th2 cells contained a predominant neutrophilic infiltrate at 6 h, and mainly mononuclear cells at 48 h. The inflammatory response with Th2 was blocked by cyclosporin A, by mAb to IL-4 or by soluble rIL-4R.	Cyclosporine	180-193	heart and neural crest derivatives expressed 2	Mus musculus	161-164
8500271-9	1993	This implies that in activated T cells there is a step between activation of the CD3-TCR complex and the point(s) of action of phorbol ester that is susceptible to CsA in activated cells.	Cyclosporine	164-167	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	85-88
8500271-10	1993	Alternatively, the data may indicate involvement of different regulatory elements with different sensitivities to CsA for the induction of IL-2 transcription by phorbol ester or antibodies to the CD3-TCR complex.	Cyclosporine	114-117	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	200-203
8500615-4	1993	Thus p59fyn could replace the calcium ionophore but not activation of protein kinase C. The activation by p59fyn plus PMA was blocked by EGTA and by the immunosuppressant drug cyclosporin A.	Cyclosporine	176-189	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	5-11
8500615-4	1993	Thus p59fyn could replace the calcium ionophore but not activation of protein kinase C. The activation by p59fyn plus PMA was blocked by EGTA and by the immunosuppressant drug cyclosporin A.	Cyclosporine	176-189	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	106-112
7685932-7	1993	FK506 and CsA-treated animals had better survival and diminished neutrophil liver infiltration, as well as MPO and MDA levels.	Cyclosporine	10-13	myeloperoxidase	Rattus norvegicus	107-110
8486928-5	1993	The insensitivity of secretion of several easily detectable polypeptides to inhibition by CsA offers a promising approach to further define the CsA-resistant and calcineurin-independent molecular pathways of TCR-triggered T cell activation.	Cyclosporine	90-93	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	208-211
8486928-5	1993	The insensitivity of secretion of several easily detectable polypeptides to inhibition by CsA offers a promising approach to further define the CsA-resistant and calcineurin-independent molecular pathways of TCR-triggered T cell activation.	Cyclosporine	144-147	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	208-211
8473282-0	1993	Calcium-dependent cyclosporin A-sensitive activation of the interleukin-2 promoter by p56lck.	Cyclosporine	18-31	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	86-92
8473282-7	1993	The activation was sensitive to EGTA and cyclosporin A, indicating that p56lck functions at an early stage of the calcium-mediated pathway.	Cyclosporine	41-54	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	72-78
8459203-6	1993	Cyclosporine A, which blocks positive selection of TCR-alpha/beta T cells, also inhibited gamma/delta tg+ T cell development.	Cyclosporine	0-14	T cell receptor alpha chain	Mus musculus	51-60
8383016-7	1993	The maximal effect of the ACE inhibitor enalaprilat (5 mg) was an increase in CSA from 7.7 +/- 0.7 to 8.4 +/- 0.8 mm2 and an increase in APV from 36 +/- 10 to 53 +/- 20 cm/sec, with an increase in coronary blood flow from 82 +/- 25 to 122 +/- 41 mL/min.	Cyclosporine	78-81	angiotensin I converting enzyme	Canis lupus familiaris	26-29
8461254-8	1993	Stimulation of IL-5 expression by PMA was relatively resistant to the immuno- suppressive drug cyclosporin A although inhibition did occur at very high levels.	Cyclosporine	95-108	interleukin 5	Mus musculus	15-19
7682200-3	1993	The effects of IL-2 production and its antagonists: cyclosporine A (CsA) and FK506 on liver regeneration were thus studied by measuring in vivo incorporation of Bromodeoxyuridine (BrdU).	Cyclosporine	68-71	interleukin 2	Mus musculus	15-19
7682200-6	1993	On the other hand, treatment with CsA and FK506, which inhibit IL-2 production, increased the mitotic indices of the regenerating livers.	Cyclosporine	34-37	interleukin 2	Mus musculus	63-67
7682200-8	1993	Based on these results, CsA and FK506 would appear to stimulate liver cell proliferation by suppressing IL-2 production and inhibiting of NK cell activity.	Cyclosporine	24-27	interleukin 2	Mus musculus	104-108
8434390-10	1993	These studies demonstrate that the CD4+ suppressor cell from CsA-treated rats with long-surviving grafts is short-lived; its survival is dependent upon contact with specific alloantigens and cytokines, one of which is IL-2.	Cyclosporine	61-64	interleukin 2	Rattus norvegicus	218-222
8434391-9	1993	IL-2 production by W3/25+ cells from CsA-treated rats was similar to that by W3/25+ cells from naive rats.	Cyclosporine	37-40	interleukin 2	Mus musculus	0-4
8438318-0	1993	Interleukin-2 reverses the ability of cyclosporine to induce tolerance to class I disparate kidney allografts in miniature swine.	Cyclosporine	38-50	interleukin 2	Sus scrofa	0-13
8419309-10	1993	We show that at variance from the case of cyclosporin A, MTP inhibition by the phospholipase A2 inhibitors nupercaine and trifluoperazine is Ca(2+)-competitive and is presumably related to interference by these drugs with Ca2+ binding to the internal regulatory site.	Cyclosporine	42-55	phospholipase A2 group IB	Rattus norvegicus	79-95
8421501-1	1993	Human cyclophilin A (CypA), a ubiquitous intracellular protein of 165 amino acids, is the major receptor for the cyclic undecapeptide immunosuppressant drug cyclosporin A (CsA), which prevents allograft rejection after transplant surgery and is efficacious in the field of autoimmune diseases.	Cyclosporine	172-175	peptidylprolyl isomerase A	Homo sapiens	6-19
8421501-1	1993	Human cyclophilin A (CypA), a ubiquitous intracellular protein of 165 amino acids, is the major receptor for the cyclic undecapeptide immunosuppressant drug cyclosporin A (CsA), which prevents allograft rejection after transplant surgery and is efficacious in the field of autoimmune diseases.	Cyclosporine	172-175	peptidylprolyl isomerase A	Homo sapiens	21-25
8421501-7	1993	Here we describe the crystal structure of a decameric CypA-CsA complex.	Cyclosporine	59-62	peptidylprolyl isomerase A	Homo sapiens	54-58
8419191-4	1993	Cyclosporin A, phorbol esters added at the time of activation, and cAMP agonists all block activation of B cells through membrane immunoglobulin at concentrations at least 100-fold lower than those necessary to block B cell activation by contact with activated Th1 or Th2 helper T cells.	Cyclosporine	0-13	heart and neural crest derivatives expressed 2	Mus musculus	268-271
8420038-0	1993	The effect of cyclosporine treatment on the expression of genes encoding granzyme A and perforin in the infiltrate of mouse heart transplants.	Cyclosporine	14-26	granzyme A	Mus musculus	73-83
8420038-2	1993	The expression of genes encoding the cytotoxic T cell associated serine protease granzyme A and perforin was analyzed in cellular infiltrates of MHC mismatched (H-2d--&gt;H-2k) heterotopic heart transplants both in immunosuppressed recipients treated with cyclosporine and in untreated recipients.	Cyclosporine	256-268	granzyme A	Mus musculus	81-91
8420043-0	1993	The effects of cyclosporine on HILDA/LIF gene expression in human T cells.	Cyclosporine	15-27	LIF interleukin 6 family cytokine	Homo sapiens	31-36
8420043-0	1993	The effects of cyclosporine on HILDA/LIF gene expression in human T cells.	Cyclosporine	15-27	LIF interleukin 6 family cytokine	Homo sapiens	37-40
8420043-1	1993	We examined the effect of cyclosporine on HILDA/LIF gene expression in alloreactive human T lymphocyte clones (ATLCs) 2B11 and 2F7 obtained from cells infiltrating a rejected human kidney graft.	Cyclosporine	26-38	LIF interleukin 6 family cytokine	Homo sapiens	42-47
8420043-1	1993	We examined the effect of cyclosporine on HILDA/LIF gene expression in alloreactive human T lymphocyte clones (ATLCs) 2B11 and 2F7 obtained from cells infiltrating a rejected human kidney graft.	Cyclosporine	26-38	LIF interleukin 6 family cytokine	Homo sapiens	48-51
8420043-7	1993	Our results show that HILDA/LIF mRNA accumulation and protein secretion in 2B11 and 2F7 clones were strongly inhibited in a dose-dependent manner by CsA, in both stimulation conditions.	Cyclosporine	149-152	LIF interleukin 6 family cytokine	Homo sapiens	22-27
8846199-7	1995	Similarly, cyclosporin A reduced the generation of IL-2 (IC50 = 0.4 microM) and GM-CSF (IC50 = 0.6 microM) while barely affecting the other two cytokines.	Cyclosporine	11-24	colony stimulating factor 2	Homo sapiens	80-86
8530534-4	1995	The MIA-promoted TCR-mediated IL-2 production actually required signal transduction that could be inhibited by cyclosporin A, genistein, or H-7.	Cyclosporine	111-124	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	17-20
7544037-0	1995	The direct effect of injectable cyclosporine and its vehicle, cremophor, on endothelial vascular cell adhesion molecule-1 expression.	Cyclosporine	32-44	vascular cell adhesion protein 1	Oryctolagus cuniculus	88-121
8420043-7	1993	Our results show that HILDA/LIF mRNA accumulation and protein secretion in 2B11 and 2F7 clones were strongly inhibited in a dose-dependent manner by CsA, in both stimulation conditions.	Cyclosporine	149-152	LIF interleukin 6 family cytokine	Homo sapiens	28-31
8420043-8	1993	Maximal inhibition of HILDA/LIF transcripts and protein secretion (60-90%) was observed within the range of 75-500 ng/ml CsA.	Cyclosporine	121-124	LIF interleukin 6 family cytokine	Homo sapiens	22-27
8420043-8	1993	Maximal inhibition of HILDA/LIF transcripts and protein secretion (60-90%) was observed within the range of 75-500 ng/ml CsA.	Cyclosporine	121-124	LIF interleukin 6 family cytokine	Homo sapiens	28-31
7544037-3	1995	Treatment with parenteral cyclosporine (CsA) to prevent graft rejection in rabbits receiving heterotopic heart transplantation reduced VCAM-1 expression in coronary arteries not only in transplanted, but also in native rabbit hearts.	Cyclosporine	26-38	vascular cell adhesion protein 1	Oryctolagus cuniculus	135-141
7544037-3	1995	Treatment with parenteral cyclosporine (CsA) to prevent graft rejection in rabbits receiving heterotopic heart transplantation reduced VCAM-1 expression in coronary arteries not only in transplanted, but also in native rabbit hearts.	Cyclosporine	40-43	vascular cell adhesion protein 1	Oryctolagus cuniculus	135-141
1284133-6	1992	After the 6 months of CsA therapy we observed a significant increase of CD3+, HLA-DR+, CD3+, CD16+ and/or CD56+, total B, and CD20+, CD5+ cells in the 11 patients with PsA compared to pretreatment values.	Cyclosporine	22-25	neural cell adhesion molecule 1	Homo sapiens	106-110
1284133-6	1992	After the 6 months of CsA therapy we observed a significant increase of CD3+, HLA-DR+, CD3+, CD16+ and/or CD56+, total B, and CD20+, CD5+ cells in the 11 patients with PsA compared to pretreatment values.	Cyclosporine	22-25	CD5 molecule	Homo sapiens	106-109
7544037-6	1995	Both CsA and vehicle inhibited IL-4-stimulated VCAM-1 expression in a dose-dependent manner (from [OD mU, mean +/- SEM] 230 +/- 5 to 165 +/- 3 for CsA 50 ng/ml, and to 181 +/- 6 for the corresponding vehicle concentration; P &lt; 0.05 for both comparisons).	Cyclosporine	5-8	vascular cell adhesion protein 1	Oryctolagus cuniculus	47-53
7544037-6	1995	Both CsA and vehicle inhibited IL-4-stimulated VCAM-1 expression in a dose-dependent manner (from [OD mU, mean +/- SEM] 230 +/- 5 to 165 +/- 3 for CsA 50 ng/ml, and to 181 +/- 6 for the corresponding vehicle concentration; P &lt; 0.05 for both comparisons).	Cyclosporine	147-150	vascular cell adhesion protein 1	Oryctolagus cuniculus	47-53
1429556-6	1992	Because the ATPase fragment of heat shock cognate 70 (HSC 70) is structurally related to actin, the yeast homologue SSA1 was tested and found to be radiolabeled by the cyclosporin A photoaffinity reagent.	Cyclosporine	168-181	Hsp70 family ATPase SSA1	Saccharomyces cerevisiae S288C	116-120
7544037-9	1995	Administration of both CsA and vehicle significantly reduced VCAM-1 expression compared with saline.	Cyclosporine	23-26	vascular cell adhesion protein 1	Oryctolagus cuniculus	61-67
1382703-8	1992	Cyclosporine A decreased cell multiplication in M1 cells without inducing apoptosis, and G-CSF and IL-6 inhibited the cytostatic effect of cyclosporine A.	Cyclosporine	139-153	colony stimulating factor 3	Homo sapiens	89-94
7639278-1	1995	P-glycoprotein 170 (P-gp), the multidrug transport pump, excludes drugs from the interior of cells and is inhibited by agents such as cyclosporin A (CsA), verapamil, and FK-506, which are also substrates for the P-gp pump.	Cyclosporine	134-147	phosphoglycolate phosphatase	Homo sapiens	0-18
1338979-7	1992	Although CsA is a competitive inhibitor of PPIase activity, it can complex with enzymatically inactive cyclophilins and inhibit the phosphatase activity of calcineurin.	Cyclosporine	9-12	peptidylprolyl isomerase A	Homo sapiens	103-115
7639278-1	1995	P-glycoprotein 170 (P-gp), the multidrug transport pump, excludes drugs from the interior of cells and is inhibited by agents such as cyclosporin A (CsA), verapamil, and FK-506, which are also substrates for the P-gp pump.	Cyclosporine	134-147	phosphoglycolate phosphatase	Homo sapiens	20-24
1353189-4	1992	Cyclosporin is one of several non-cytotoxic drugs that can block the function of PgP.	Cyclosporine	0-11	phosphoglycolate phosphatase	Homo sapiens	81-84
7639278-1	1995	P-glycoprotein 170 (P-gp), the multidrug transport pump, excludes drugs from the interior of cells and is inhibited by agents such as cyclosporin A (CsA), verapamil, and FK-506, which are also substrates for the P-gp pump.	Cyclosporine	134-147	phosphoglycolate phosphatase	Homo sapiens	212-216
7639278-1	1995	P-glycoprotein 170 (P-gp), the multidrug transport pump, excludes drugs from the interior of cells and is inhibited by agents such as cyclosporin A (CsA), verapamil, and FK-506, which are also substrates for the P-gp pump.	Cyclosporine	149-152	phosphoglycolate phosphatase	Homo sapiens	0-18
1497650-0	1992	Correlation between up-regulation of lymphokine mRNA and down-regulation of TcR, CD4, CD8 and lck mRNA as shown by the effect of CsA on activated T lymphocytes.	Cyclosporine	129-132	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	76-79
1497650-0	1992	Correlation between up-regulation of lymphokine mRNA and down-regulation of TcR, CD4, CD8 and lck mRNA as shown by the effect of CsA on activated T lymphocytes.	Cyclosporine	129-132	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	94-97
7639278-1	1995	P-glycoprotein 170 (P-gp), the multidrug transport pump, excludes drugs from the interior of cells and is inhibited by agents such as cyclosporin A (CsA), verapamil, and FK-506, which are also substrates for the P-gp pump.	Cyclosporine	149-152	phosphoglycolate phosphatase	Homo sapiens	20-24
7639278-1	1995	P-glycoprotein 170 (P-gp), the multidrug transport pump, excludes drugs from the interior of cells and is inhibited by agents such as cyclosporin A (CsA), verapamil, and FK-506, which are also substrates for the P-gp pump.	Cyclosporine	149-152	phosphoglycolate phosphatase	Homo sapiens	212-216
7639278-6	1995	Normal blood and splenic T- or B-cells included 50-80% of cells with surface P-gp (MRK-16+), which mediated CsA-sensitive dye export.	Cyclosporine	108-111	phosphoglycolate phosphatase	Homo sapiens	77-81
1628422-1	1992	Cyclosporin (CsA) is an immunosuppressant which binds to cyclophilin (Cyp).	Cyclosporine	0-11	peptidylprolyl isomerase G	Homo sapiens	57-68
1628422-1	1992	Cyclosporin (CsA) is an immunosuppressant which binds to cyclophilin (Cyp).	Cyclosporine	0-11	peptidylprolyl isomerase G	Homo sapiens	70-73
1628422-1	1992	Cyclosporin (CsA) is an immunosuppressant which binds to cyclophilin (Cyp).	Cyclosporine	13-16	peptidylprolyl isomerase G	Homo sapiens	57-68
1628422-1	1992	Cyclosporin (CsA) is an immunosuppressant which binds to cyclophilin (Cyp).	Cyclosporine	13-16	peptidylprolyl isomerase G	Homo sapiens	70-73
7639278-8	1995	Thymus included 30% of P-gp+ cells mediating CsA-sensitive dye export, including CD3-4-8- progenitors and mature CD3hi CD4+8- or CD4-8+ thymocytes.	Cyclosporine	45-48	phosphoglycolate phosphatase	Homo sapiens	23-27
7639278-12	1995	Drug export by P-gp may protect lymphocytes from toxic effects of CsA, and may contribute to the immunosuppressive effects of such drugs.	Cyclosporine	66-69	phosphoglycolate phosphatase	Homo sapiens	15-19
7631788-10	1995	Cyclosporin A reduced MPO activity, and 5-aminosalicylic acid reduced the colonic damage score, whereas lidocaine and two inhibitors of leukotriene synthesis did not significantly affect either of these parameters.	Cyclosporine	0-13	myeloperoxidase	Rattus norvegicus	22-25
1628422-2	1992	The relationship between Cyp binding and immunosuppression has been questioned since one of the analogs of CsA, N-methyl-L-alanyl6 cyclosporin (methyl-alanyl CsA) binds to Cyp but is not immunosuppressive.	Cyclosporine	107-110	peptidylprolyl isomerase G	Homo sapiens	172-175
8589211-9	1995	CSA 1 microgram/ml and dexamethasone 1 microgram/ml together were additive in reducing PGI2 release and increasing PAI-1 secretion.	Cyclosporine	0-3	serpin family E member 1	Homo sapiens	115-120
7602099-2	1995	In humans, the GM-CSF and IL-3 genes are regulated by a cyclosporin A-inhibitable enhancer located 3 kb upstream of the GM-CSF gene that is inducible by signals that mimic TCR activation.	Cyclosporine	56-69	colony stimulating factor 2	Homo sapiens	15-21
7602099-2	1995	In humans, the GM-CSF and IL-3 genes are regulated by a cyclosporin A-inhibitable enhancer located 3 kb upstream of the GM-CSF gene that is inducible by signals that mimic TCR activation.	Cyclosporine	56-69	interleukin 3	Homo sapiens	26-30
7602099-2	1995	In humans, the GM-CSF and IL-3 genes are regulated by a cyclosporin A-inhibitable enhancer located 3 kb upstream of the GM-CSF gene that is inducible by signals that mimic TCR activation.	Cyclosporine	56-69	colony stimulating factor 2	Homo sapiens	120-126
7541038-4	1995	Cyclosporin A and FK506 efficiently disrupt the YY1-CyPA and YY1-FKBP12 interactions.	Cyclosporine	0-13	peptidylprolyl isomerase A	Homo sapiens	52-56
1512072-3	1992	Cyclosporin A (CsA) and prednisolone inhibited in different ways the responsiveness of PHA pre-stimulated blood mononuclear cells (PBMC) to rIL-2, as measured by [3H]TdR incorporation.	Cyclosporine	15-18	interleukin 2	Rattus norvegicus	140-145
7577442-2	1995	We used a monoclonal antibody, anti-CSA, which reacts with only one of strain variants of the hsc74.	Cyclosporine	36-39	heat shock protein 9	Mus musculus	94-99
1512072-6	1992	EGTA inhibited sIL-2R release in the same manner when used alone, and reversed the CsA- and prednisolone-induced enhancement of sIL-2R release by rIL-2 induced lymphoblasts, when used in combination with CsA or prednisolone.	Cyclosporine	83-86	interleukin 2	Rattus norvegicus	146-151
1512072-6	1992	EGTA inhibited sIL-2R release in the same manner when used alone, and reversed the CsA- and prednisolone-induced enhancement of sIL-2R release by rIL-2 induced lymphoblasts, when used in combination with CsA or prednisolone.	Cyclosporine	204-207	interleukin 2	Rattus norvegicus	146-151
1512072-10	1992	Both CsA and prednisolone inhibited the rIL-2-induced enhancement of [3H]TdR incorporation by both T-cell subsets.	Cyclosporine	5-8	interleukin 2	Rattus norvegicus	40-45
7577442-3	1995	By immunostaining with anti-CSA antibody, the hsc74 protein was constitutively detected in C3H embryos from 1-cell to blastocyst stage, but no signals were detectable in C57BL/6 embryos.	Cyclosporine	28-31	heat shock protein 9	Mus musculus	46-51
7543564-0	1995	ICAM-1 and VCAM-1 expression in accelerated cardiac allograft arteriopathy and myocardial rejection are influenced differently by cyclosporine A and tumour necrosis factor-alpha blockade.	Cyclosporine	130-144	ICAM-1	Oryctolagus cuniculus	0-6
1377699-3	1992	The addition of IL-1 to these cultures increased the level of CSA and, specifically, of granulocyte colony-stimulating factor (G-CSF) released.	Cyclosporine	62-65	interleukin 1 alpha	Homo sapiens	16-20
1377699-4	1992	Anti-GM-CSF antibody neutralized BPA and CSA in normal naive LTC CM but only the CSA in the CM from IL-1-stimulated LTC.	Cyclosporine	41-44	colony stimulating factor 2	Homo sapiens	5-11
1377699-4	1992	Anti-GM-CSF antibody neutralized BPA and CSA in normal naive LTC CM but only the CSA in the CM from IL-1-stimulated LTC.	Cyclosporine	81-84	interleukin 1 alpha	Homo sapiens	100-104
7543564-0	1995	ICAM-1 and VCAM-1 expression in accelerated cardiac allograft arteriopathy and myocardial rejection are influenced differently by cyclosporine A and tumour necrosis factor-alpha blockade.	Cyclosporine	130-144	vascular cell adhesion protein 1	Oryctolagus cuniculus	11-17
7543564-4	1995	The selective reduction of the coronary arteriopathy with TNFsr was associated with somewhat reduced expression of these adhesion molecules in the arteries, whereas CsA also suppressed myocardial rejection and markedly decreased both vascular and myocyte expression of ICAM-1 and VCAM-1.	Cyclosporine	165-168	ICAM-1	Oryctolagus cuniculus	269-275
7545487-1	1995	Cyclosporin A (CsA) inhibited interleukin 2 (IL-2), IL-3, interferon gamma (IFN gamma), GM-CSF and tumor necrosis factor alpha (TNF alpha) mRNA expression in spleen cells stimulated with concavalin A (Con A) when determined by the semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) method.	Cyclosporine	0-13	interleukin 3	Homo sapiens	52-56
1631924-4	1992	Large differences between mismatch groups for the early years were observed, but within the cyclosporine era only HLA-B showed a statistically significant difference in half-lives (13.2 versus 9.0 years, for 0 and 2 mismatches respectively, P = 0.013).	Cyclosporine	92-104	major histocompatibility complex, class I, B	Homo sapiens	114-119
7545487-1	1995	Cyclosporin A (CsA) inhibited interleukin 2 (IL-2), IL-3, interferon gamma (IFN gamma), GM-CSF and tumor necrosis factor alpha (TNF alpha) mRNA expression in spleen cells stimulated with concavalin A (Con A) when determined by the semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) method.	Cyclosporine	0-13	colony stimulating factor 2	Homo sapiens	88-94
7545487-1	1995	Cyclosporin A (CsA) inhibited interleukin 2 (IL-2), IL-3, interferon gamma (IFN gamma), GM-CSF and tumor necrosis factor alpha (TNF alpha) mRNA expression in spleen cells stimulated with concavalin A (Con A) when determined by the semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) method.	Cyclosporine	15-18	interleukin 3	Homo sapiens	52-56
7545487-1	1995	Cyclosporin A (CsA) inhibited interleukin 2 (IL-2), IL-3, interferon gamma (IFN gamma), GM-CSF and tumor necrosis factor alpha (TNF alpha) mRNA expression in spleen cells stimulated with concavalin A (Con A) when determined by the semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) method.	Cyclosporine	15-18	colony stimulating factor 2	Homo sapiens	88-94
7672715-8	1995	Thus, the use of cyclosporin A and rhG-CSF in our patient induced a complete recovery of hemopoiesis, and this may be explained by a synergic effect induced by the capacity of cyclosporin A to remove inhibitory factors and the stimulatory activity of rhG-CSF.	Cyclosporine	17-30	colony stimulating factor 2	Homo sapiens	255-258
1588036-12	1992	Cyclosporin A completely abrogates perforin induction by A23187 but only slightly inhibits the effect of rIL-2 on perforin mRNA expression.	Cyclosporine	0-13	interleukin 2	Rattus norvegicus	105-110
1501415-11	1992	We demonstrate that chronic cyclosporine administration activates the renin-angiotensin-aldosterone system, suppresses circulating ANF, and results in chronic sodium retention.	Cyclosporine	28-40	natriuretic peptide A	Canis lupus familiaris	131-134
1427430-1	1992	In this study we have analyzed the activity of Cyclosporin A (CsA) on the "in vitro" production of TNF and IL-3/GM-CSF as a preliminary basis for explaining the successful use of CsA in aplastic patients.	Cyclosporine	62-65	interleukin 3	Homo sapiens	107-111
7672715-8	1995	Thus, the use of cyclosporin A and rhG-CSF in our patient induced a complete recovery of hemopoiesis, and this may be explained by a synergic effect induced by the capacity of cyclosporin A to remove inhibitory factors and the stimulatory activity of rhG-CSF.	Cyclosporine	176-189	colony stimulating factor 2	Homo sapiens	39-42
7672715-8	1995	Thus, the use of cyclosporin A and rhG-CSF in our patient induced a complete recovery of hemopoiesis, and this may be explained by a synergic effect induced by the capacity of cyclosporin A to remove inhibitory factors and the stimulatory activity of rhG-CSF.	Cyclosporine	176-189	colony stimulating factor 2	Homo sapiens	255-258
7536769-12	1995	Cyclosporin A, a specific inhibitor of calcineurin, blocked the impact of ionophore on both basal and phorbol-induced levels of L-selectin mRNA.	Cyclosporine	0-13	selectin L	Homo sapiens	128-138
1427430-1	1992	In this study we have analyzed the activity of Cyclosporin A (CsA) on the "in vitro" production of TNF and IL-3/GM-CSF as a preliminary basis for explaining the successful use of CsA in aplastic patients.	Cyclosporine	62-65	colony stimulating factor 2	Homo sapiens	112-118
1427430-1	1992	In this study we have analyzed the activity of Cyclosporin A (CsA) on the "in vitro" production of TNF and IL-3/GM-CSF as a preliminary basis for explaining the successful use of CsA in aplastic patients.	Cyclosporine	179-182	interleukin 3	Homo sapiens	107-111
1427430-1	1992	In this study we have analyzed the activity of Cyclosporin A (CsA) on the "in vitro" production of TNF and IL-3/GM-CSF as a preliminary basis for explaining the successful use of CsA in aplastic patients.	Cyclosporine	179-182	colony stimulating factor 2	Homo sapiens	112-118
7534716-4	1995	In plasma from patients who received recombinant human granulocyte colony-stimulating factor (rhG-CSF), in addition to an autograft, CSA reached a maximum earlier (7 days).	Cyclosporine	133-136	colony stimulating factor 3	Homo sapiens	55-92
1427430-5	1992	With these clones we studied the ability of CsA to inhibit TNF and IL-3/GM-CSF production, which was stimulated with specific monoclonal antibodies directed against the CD2 and CD3 surface antigens.	Cyclosporine	44-47	interleukin 3	Homo sapiens	67-71
1427430-5	1992	With these clones we studied the ability of CsA to inhibit TNF and IL-3/GM-CSF production, which was stimulated with specific monoclonal antibodies directed against the CD2 and CD3 surface antigens.	Cyclosporine	44-47	colony stimulating factor 2	Homo sapiens	72-78
1427430-5	1992	With these clones we studied the ability of CsA to inhibit TNF and IL-3/GM-CSF production, which was stimulated with specific monoclonal antibodies directed against the CD2 and CD3 surface antigens.	Cyclosporine	44-47	CD2 molecule	Homo sapiens	169-172
1427430-6	1992	TNF and IL-3/GM-CSF production displayed a different sensitivity to CsA inhibition.	Cyclosporine	68-71	interleukin 3	Homo sapiens	8-12
1427430-6	1992	TNF and IL-3/GM-CSF production displayed a different sensitivity to CsA inhibition.	Cyclosporine	68-71	colony stimulating factor 2	Homo sapiens	13-19
7534716-11	1995	Neither IL-3 nor GM-CSF was detected in plasma; however, antibody to GM-CSF reduced CSA in all samples after intensive therapy.	Cyclosporine	84-87	colony stimulating factor 2	Homo sapiens	69-75
1427430-7	1992	In fact, at 400 ng/ml CsA a residual production of IL-3/GM-CSF was present in all clones tested (CD3: 21.8% and CD2: 14.4% of the maximal IL-3/GM-CSF activity), while secretion of TNF was virtually abrogated at 100 ng/ml.	Cyclosporine	22-25	interleukin 3	Homo sapiens	51-55
7534790-13	1995	We conclude that CD28 costimulatory signals augment superantigen-induced TCR signals by converging onto common TCR effector pathways involving the activation of phospholipase C gamma 1 and PKC and by generating a cyclosporin A-sensitive pathway.	Cyclosporine	213-226	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	73-76
1427430-7	1992	In fact, at 400 ng/ml CsA a residual production of IL-3/GM-CSF was present in all clones tested (CD3: 21.8% and CD2: 14.4% of the maximal IL-3/GM-CSF activity), while secretion of TNF was virtually abrogated at 100 ng/ml.	Cyclosporine	22-25	colony stimulating factor 2	Homo sapiens	56-62
1427430-7	1992	In fact, at 400 ng/ml CsA a residual production of IL-3/GM-CSF was present in all clones tested (CD3: 21.8% and CD2: 14.4% of the maximal IL-3/GM-CSF activity), while secretion of TNF was virtually abrogated at 100 ng/ml.	Cyclosporine	22-25	CD2 molecule	Homo sapiens	112-115
1427430-7	1992	In fact, at 400 ng/ml CsA a residual production of IL-3/GM-CSF was present in all clones tested (CD3: 21.8% and CD2: 14.4% of the maximal IL-3/GM-CSF activity), while secretion of TNF was virtually abrogated at 100 ng/ml.	Cyclosporine	22-25	interleukin 3	Homo sapiens	138-142
1427430-7	1992	In fact, at 400 ng/ml CsA a residual production of IL-3/GM-CSF was present in all clones tested (CD3: 21.8% and CD2: 14.4% of the maximal IL-3/GM-CSF activity), while secretion of TNF was virtually abrogated at 100 ng/ml.	Cyclosporine	22-25	colony stimulating factor 2	Homo sapiens	143-149
7534790-13	1995	We conclude that CD28 costimulatory signals augment superantigen-induced TCR signals by converging onto common TCR effector pathways involving the activation of phospholipase C gamma 1 and PKC and by generating a cyclosporin A-sensitive pathway.	Cyclosporine	213-226	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	111-114
1315036-3	1992	With [Ser(32P15]RII as substrate, the concentrations of the cyclosporin A.cyclophilin A and cyclosporin A.cyclophilin B complexes, which cause 50% inhibition of calcineurin activity, are 120 and 50 nM, respectively.	Cyclosporine	60-73	peptidylprolyl isomerase B	Bos taurus	106-119
7722411-1	1995	The transcription factor NFATp (nuclear factor of activated T cells, preexisting) is likely to regulate the cyclosporin-sensitive transcription of cytokine genes and other activation-associated genes during the immune response.	Cyclosporine	108-119	nuclear factor of activated T cells 2	Homo sapiens	25-30
1315036-3	1992	With [Ser(32P15]RII as substrate, the concentrations of the cyclosporin A.cyclophilin A and cyclosporin A.cyclophilin B complexes, which cause 50% inhibition of calcineurin activity, are 120 and 50 nM, respectively.	Cyclosporine	92-105	peptidylprolyl isomerase B	Bos taurus	106-119
1551401-2	1992	Given that interleukin 2 (IL-2) stimulates proliferation, abolishes anergy, and counteracts apoptotic cell death in T cells in vitro, we tested whether the IL-2 synthesis inhibitor cyclosporin A (CsA) or a vaccinia virus recombinant releasing high amounts of human IL-2 modulate SEB responses in vivo.	Cyclosporine	181-194	interleukin 2	Mus musculus	26-30
1551401-2	1992	Given that interleukin 2 (IL-2) stimulates proliferation, abolishes anergy, and counteracts apoptotic cell death in T cells in vitro, we tested whether the IL-2 synthesis inhibitor cyclosporin A (CsA) or a vaccinia virus recombinant releasing high amounts of human IL-2 modulate SEB responses in vivo.	Cyclosporine	181-194	interleukin 2	Mus musculus	156-160
7876544-6	1995	In AS ETS1 transfectants, IL-2 formation was completely inhibited by cyclosporin A and FK590.	Cyclosporine	69-82	ETS proto-oncogene 1, transcription factor	Homo sapiens	6-10
7551979-4	1995	In this study soluble E-selectin levels in renal allograft recipients were compared with the incidence of rejection, acute tubular necrosis (ATN), cyclosporin A (CyA) toxicity, and use of orthoclone OKT3 (muromonab-CD3) to establish whether early endothelial activation and inflammatory damage could be detected.	Cyclosporine	162-165	selectin E	Homo sapiens	22-32
7870067-6	1995	Among protein phosphatase inhibitors, cyclosporin A caused extensive inhibition of bacteria-induced expression of both IL-1 alpha/beta and TNF-alpha mRNA, while okadaic acid in itself caused selective induction of TNF-alpha, but not IL-1 alpha/beta mRNA, with a sharp peak at 0.3 microM concentration.	Cyclosporine	38-51	interleukin 1 alpha	Mus musculus	119-129
7529939-7	1995	Moreover, a partial or complete resistance to inhibition with CsA was observed for IL-2 production and CTL generation respectively in the presence of the costimulatory signal derived from B7-1-CD28 interaction.	Cyclosporine	62-65	interleukin 2	Mus musculus	83-87
7529939-7	1995	Moreover, a partial or complete resistance to inhibition with CsA was observed for IL-2 production and CTL generation respectively in the presence of the costimulatory signal derived from B7-1-CD28 interaction.	Cyclosporine	62-65	CD28 antigen	Mus musculus	193-197
7530227-12	1994	These data suggest that FKS1 provides a unique cellular function which, when absent, increases FK506 and CsA sensitivity by making the CNs (or a CN-dependent function) essential.	Cyclosporine	105-108	calcineurin catalytic subunit A	Saccharomyces cerevisiae S288C	135-137
7529175-1	1994	The peptidyl-prolyl isomerases FKBP12 and cyclophilin A (immunophilins) form complexes with the immunosuppressants FK506 and cyclosporin A that inhibit the phosphatase calcineurin.	Cyclosporine	125-138	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	31-37
7529175-4	1994	By affinity chromatography, both FKBP12 and cyclophilin A bind calcineurin A in the absence of ligand, and FK506 and cyclosporin A respectively potentiate these interactions.	Cyclosporine	117-130	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	33-39
7981602-5	1994	Various inhibitors of TCR-mediated apoptosis, including cyclosporin A down-regulate the Nur77 DNA binding activity.	Cyclosporine	56-69	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	22-25
7696923-4	1994	In the patient treated with cyclosporin A alone, decreasing serum IL-6 and beta-2-microglobulin levels fell as the clinical response evolved.	Cyclosporine	28-41	beta-2-microglobulin	Homo sapiens	75-95
7524680-2	1994	The charged states of the histidine residues in FKBP and CyP, which were characterized by their pKa values, have been determined in the absence and presence of the immunosuppressant ligands, ascomycin and cyclosporin A (CsA), respectively, by using a heteronuclear two-dimensional NMR method.	Cyclosporine	205-218	peptidylprolyl isomerase G	Homo sapiens	57-60
7524680-2	1994	The charged states of the histidine residues in FKBP and CyP, which were characterized by their pKa values, have been determined in the absence and presence of the immunosuppressant ligands, ascomycin and cyclosporin A (CsA), respectively, by using a heteronuclear two-dimensional NMR method.	Cyclosporine	220-223	peptidylprolyl isomerase G	Homo sapiens	57-60
7524680-7	1994	His-126, which is part of the CsA and substrate binding site, has a pKa of 6.3 in free CyP.	Cyclosporine	30-33	peptidylprolyl isomerase G	Homo sapiens	87-90
7825978-8	1994	The addition of S9788, cyclosporin A and verapamil (5 microM) led to a T1/2 of 90, 30 and 20 min respectively.	Cyclosporine	23-36	CD5 molecule	Homo sapiens	71-92
7703979-1	1994	A cyclosporine derivative, dihydrocyclosporine D, was used for the evaluation of milk fat globule membrane (MFGM) as an emulsifier of lipophilic cyclopeptides.	Cyclosporine	2-14	milk fat globule EGF and factor V/VIII domain containing	Rattus norvegicus	108-112
7703979-2	1994	As compared with olive oil formulation, MFGM emulsion significantly enhanced the blood and lymphatic fluid concentrations of the cyclosporine derivative after intraduodenal dosing in rats.	Cyclosporine	129-141	milk fat globule EGF and factor V/VIII domain containing	Rattus norvegicus	40-44
7868299-4	1994	In cell titration restimulation assays, CsA-treated, but not control T-cells, were also markedly unresponsive to accessory cell-independent stimuli provided by immobilized anti-CD3 antibody or rIL2, combined to phorbol ester.	Cyclosporine	40-43	interleukin 2	Rattus norvegicus	193-197
7868299-6	1994	In contrast, primary T-cells activated by a CsA-resistant pathway (rIL2 plus phorbol ester) and treated with CsA, did not develop unresponsiveness, compared to controls.	Cyclosporine	44-47	interleukin 2	Rattus norvegicus	67-71
7868299-7	1994	When primary T-cells were stimulated with rIL2 plus phorbol ester in the presence of the calcium ionophore ionomycin, treatment with CsA resulted in marked unresponsiveness of the T-cells, compared to untreated controls.	Cyclosporine	133-136	interleukin 2	Rattus norvegicus	42-46
7930569-4	1994	However, comparative studies using extracts of D10.G4.1 cells treated with the cellular activators Con A and PMA and the inhibitors cycloheximide and cyclosporin A indicated that the binding activities to the conserved elements in the IL-5 and GM-CSF genes (designated NF-IL-5A and NF-GM-CSFA, respectively) are regulated by different signaling pathways.	Cyclosporine	150-163	interleukin 5	Mus musculus	235-239
7856857-0	1994	Comparative binding studies of cyclophilins to cyclosporin A and derivatives by fluorescence measurements.	Cyclosporine	47-60	peptidylprolyl isomerase C	Homo sapiens	31-43
7856857-1	1994	The interaction of cyclosporin A and cyclosporin derivatives with cyclophilins A, B, and C has been investigated by means of fluorescence measurement techniques.	Cyclosporine	19-32	peptidylprolyl isomerase C	Homo sapiens	66-78
7856857-1	1994	The interaction of cyclosporin A and cyclosporin derivatives with cyclophilins A, B, and C has been investigated by means of fluorescence measurement techniques.	Cyclosporine	19-30	peptidylprolyl isomerase C	Homo sapiens	66-78
7522130-5	1994	We suggest that IL2 secretion induced by antigen presentation to TCR/CD4/p56lck requires an FK506 and cyclosporin A-sensitive step which may be independent of calcium signaling.	Cyclosporine	102-115	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	73-79
1543461-1	1992	We sought to determine if cyclosporine, which has been shown to suppress corneal allograft rejection, could also suppress corneal neovascularization induced by interleukin 2.	Cyclosporine	26-38	interleukin 2	Mus musculus	160-173
1543461-5	1992	Cyclosporine causes a significant reduction in interleukin 2-induced corneal neovascularization that may, in part, account for its ability to prolong corneal allograft survival in high-risk cases.	Cyclosporine	0-12	interleukin 2	Mus musculus	47-60
8000855-0	1994	Thymocytes bearing high-density T cell receptor and CD2 are selectively eliminated in cyclosporine-induced thymic atrophy.	Cyclosporine	86-98	CD2 molecule	Homo sapiens	52-55
1311721-8	1992	Treatment of mitotically stimulated lymphocytes with cyclosporin, which inhibits proliferation, blocked the increase in p19/nm23; treatment of the leukemia cell line HL-60 with dimethylsulfoxide, which induces terminal differentiation, resulted in diminished levels of p19/nm23.	Cyclosporine	53-64	interleukin 23 subunit alpha	Homo sapiens	120-123
1311721-8	1992	Treatment of mitotically stimulated lymphocytes with cyclosporin, which inhibits proliferation, blocked the increase in p19/nm23; treatment of the leukemia cell line HL-60 with dimethylsulfoxide, which induces terminal differentiation, resulted in diminished levels of p19/nm23.	Cyclosporine	53-64	interleukin 23 subunit alpha	Homo sapiens	269-272
7521212-2	1994	The MTP is a voltage-dependent channel blocked by cyclosporin A with Ki in the nanomolar range.	Cyclosporine	50-63	metallothionein 1B	Homo sapiens	4-7
1538126-8	1992	IL-4 production could be inhibited by cyclosporin A and required extracellular calcium, whereas cell cycle arrest did not.	Cyclosporine	38-51	interleukin 4	Mus musculus	0-4
1545136-3	1992	Because cyclosporin inhibits interleukin 2 release from T cells, it has been suggested that cyclosporin may function as an anti-inflammatory agent within the epidermis through inhibition of keratinocyte cytokine release.	Cyclosporine	8-19	interleukin 2	Mus musculus	29-42
1545136-3	1992	Because cyclosporin inhibits interleukin 2 release from T cells, it has been suggested that cyclosporin may function as an anti-inflammatory agent within the epidermis through inhibition of keratinocyte cytokine release.	Cyclosporine	92-103	interleukin 2	Mus musculus	29-42
1545136-6	1992	The lack of inhibition of GM-CSF expression following cyclosporin treatment is consistent with recent observations in T cells and is opposite to the effect of cyclosporin on interleukin 2.	Cyclosporine	159-170	interleukin 2	Mus musculus	174-187
7988651-0	1994	The effect of different corticosteroids and cyclosporin A on interleukin-4 and interleukin-5 release from murine TH2-type T cells.	Cyclosporine	44-57	interleukin 4	Mus musculus	61-74
7988651-0	1994	The effect of different corticosteroids and cyclosporin A on interleukin-4 and interleukin-5 release from murine TH2-type T cells.	Cyclosporine	44-57	interleukin 5	Mus musculus	79-92
8065374-0	1994	Structure-activity relationships for the interaction between cyclosporin A derivatives and the Fab fragment of a monoclonal antibody.	Cyclosporine	61-74	FA complementation group B	Homo sapiens	95-98
1311469-0	1992	Inhibition of CD27 expression by cyclosporine A; role of IL-2.	Cyclosporine	33-47	CD27 molecule	Homo sapiens	14-18
8065374-1	1994	The crystallographic structure of a complex between cyclosporin A and the Fab fragment of monoclonal antibody R45-45-11 has been solved to 2.65 A resolution (Altschuh et al., 1992a, Science 256, 92; Vix et al., 1993, Proteins 15, 339), yielding a precise three-dimensional picture of interacting surfaces.	Cyclosporine	52-65	FA complementation group B	Homo sapiens	74-77
8065374-3	1994	The equilibrium binding constant of the Fab fragment for a set of cyclosporin analogs was obtained by measuring in a biosensor instrument the dependence of complex formation on Fab concentration, at constant analog concentrations.	Cyclosporine	66-77	FA complementation group B	Homo sapiens	40-43
8065374-3	1994	The equilibrium binding constant of the Fab fragment for a set of cyclosporin analogs was obtained by measuring in a biosensor instrument the dependence of complex formation on Fab concentration, at constant analog concentrations.	Cyclosporine	66-77	FA complementation group B	Homo sapiens	177-180
20693003-5	1994	Cyclosporin A (1 mug/ml) totally inhibited the expression of IL-2 mRNA in murine mixed lymphocyte cultures and induced a 40% inhibition of IL-2 mRNA in splenocytes isolated from mice repetitively exposed (5 x 100 mg/kg over 10 days).	Cyclosporine	0-13	interleukin 2	Mus musculus	61-65
20693003-5	1994	Cyclosporin A (1 mug/ml) totally inhibited the expression of IL-2 mRNA in murine mixed lymphocyte cultures and induced a 40% inhibition of IL-2 mRNA in splenocytes isolated from mice repetitively exposed (5 x 100 mg/kg over 10 days).	Cyclosporine	0-13	interleukin 2	Mus musculus	139-143
1373246-4	1992	Cyclosporin A also caused redistribution of cathepsin B from the lysosomal fraction to the zymogen fraction, indicating colocalization of lysosomal enzymes with pancreatic digestive enzymes.	Cyclosporine	0-13	cathepsin B	Rattus norvegicus	44-55
8042241-4	1994	The aim of the present study was to determine the effects of low-dose CsA/MTX on the expression of the cytotoxic cytokines, TNF alpha, TNF beta, or lymphotoxin (LT), and the serine proteases HF and C11 (granzymes A and B, respectively) in rat cardiac allografts during rejection.	Cyclosporine	70-73	lymphotoxin alpha	Rattus norvegicus	135-143
7518620-6	1994	CsA very effectively inhibits expression of IL-2, IFN-gamma, and IL-4, but it inhibits IL-10 expression only 65%.	Cyclosporine	0-3	interleukin 4	Mus musculus	65-69
1475634-14	1992	Thus, for example, cyclosporin A inhibits in vitro the bone resorbing activity of interleukin 1, 1,25-dihydroxy-vitamin D3, parathyroid hormone and prostaglandin E2 by apparently non-T-cell effects, while in vivo protects against bone and cartilage loss in adjuvant arthritis.	Cyclosporine	19-32	interleukin 1 alpha	Homo sapiens	82-95
8031755-7	1994	The binding of recombinant human Cyp-A, -B, and -C to cyclosporin A (CsA) was studied by immunochemical methods.	Cyclosporine	54-67	peptidylprolyl isomerase A	Homo sapiens	33-38
8031755-7	1994	The binding of recombinant human Cyp-A, -B, and -C to cyclosporin A (CsA) was studied by immunochemical methods.	Cyclosporine	69-72	peptidylprolyl isomerase A	Homo sapiens	33-38
8031755-8	1994	The relative affinity of Cyp-C for CsA is lower by a factor of 2 than that of Cyp-A, which itself is 10-fold lower than that of Cyp-B.	Cyclosporine	35-38	peptidylprolyl isomerase C	Homo sapiens	25-30
8031755-9	1994	Cross-reactivity studies with a series of Cs derivatives showed that Cyp-C binds CsA with a fine specificity similar to that of Cyp-A and Cyp-B.	Cyclosporine	81-84	peptidylprolyl isomerase G	Homo sapiens	69-72
7813402-0	1994	Differentiation by preparative continuous free flow-isoelectric focusing of cyclosporin A inhibitable peptidyl-prolyl cis/trans isomerase of human erythrocytes.	Cyclosporine	76-89	FKBP prolyl isomerase like	Homo sapiens	102-137
1743298-0	1991	1H, 13C and 15N backbone assignments of cyclophilin when bound to cyclosporin A (CsA) and preliminary structural characterization of the CsA binding site.	Cyclosporine	81-84	peptidylprolyl isomerase G	Homo sapiens	40-51
1744118-2	1991	Cyclophilin (CyP), a major cytosolic protein possessing peptidyl-prolyl cis-trans isomerase activity, has been implicated as the specific receptor of the immunosuppressive drug cyclosporin A (CsA).	Cyclosporine	177-190	peptidylprolyl isomerase G	Homo sapiens	0-11
1744118-2	1991	Cyclophilin (CyP), a major cytosolic protein possessing peptidyl-prolyl cis-trans isomerase activity, has been implicated as the specific receptor of the immunosuppressive drug cyclosporin A (CsA).	Cyclosporine	177-190	peptidylprolyl isomerase G	Homo sapiens	13-16
1744118-2	1991	Cyclophilin (CyP), a major cytosolic protein possessing peptidyl-prolyl cis-trans isomerase activity, has been implicated as the specific receptor of the immunosuppressive drug cyclosporin A (CsA).	Cyclosporine	192-195	peptidylprolyl isomerase G	Homo sapiens	0-11
1744118-2	1991	Cyclophilin (CyP), a major cytosolic protein possessing peptidyl-prolyl cis-trans isomerase activity, has been implicated as the specific receptor of the immunosuppressive drug cyclosporin A (CsA).	Cyclosporine	192-195	peptidylprolyl isomerase G	Homo sapiens	13-16
1744118-12	1991	From both equilibrium considerations and the results of kinetic characterizations it is proposed that of these three CyP proteins, hCyP1 is the most likely intracellular target for CsA.	Cyclosporine	181-184	peptidylprolyl isomerase G	Homo sapiens	117-120
1744118-12	1991	From both equilibrium considerations and the results of kinetic characterizations it is proposed that of these three CyP proteins, hCyP1 is the most likely intracellular target for CsA.	Cyclosporine	181-184	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	131-136
7813402-6	1994	For each isoform of the enzyme the peptidyl-prolyl cis/trans isomerase activity of the separated proteins was inhibited by cyclosporin A but was resistant toward FK 506.	Cyclosporine	123-136	FKBP prolyl isomerase like	Homo sapiens	35-70
8002040-1	1994	The three-dimensional structures of cyclosporin A complexed with cyclophilin A or Fab fragment of a monoclonal antibody were compared.	Cyclosporine	36-49	FA complementation group B	Homo sapiens	82-85
1661090-1	1991	Important side effects of cyclosporin (CSA) are renal insufficiency and hypertension.	Cyclosporine	26-37	albumin	Canis lupus familiaris	39-42
1837119-7	1991	Some risk factors for mIg could be identified: the patient"s age (a risk factor only in women); the duration of dialysis; the occurrence of prior CMV infection; treatment with cyclosporine.	Cyclosporine	176-188	chemokine (C-X-C motif) ligand 9	Mus musculus	22-25
1960417-2	1991	Here we show that the generation of interferon-gamma producing cells (IFN-gamma pc) in rat spleen cell cultures stimulated with concanavalin A (ConA) is dose-dependently inhibited by a wide variety of immunosuppressants such as cyclosporin A, FK506, hydrocortisone, dexamethasone, azathioprine and ART-18, a monoclonal antibody (mAb) with established immunosuppressive activity in organ transplantation and autoimmunity.	Cyclosporine	228-241	interferon gamma	Rattus norvegicus	36-52
1960417-2	1991	Here we show that the generation of interferon-gamma producing cells (IFN-gamma pc) in rat spleen cell cultures stimulated with concanavalin A (ConA) is dose-dependently inhibited by a wide variety of immunosuppressants such as cyclosporin A, FK506, hydrocortisone, dexamethasone, azathioprine and ART-18, a monoclonal antibody (mAb) with established immunosuppressive activity in organ transplantation and autoimmunity.	Cyclosporine	228-241	interferon gamma	Rattus norvegicus	70-79
1932305-1	1991	This case report describes the clinical use of recombinant human interleukin-3 as adjunct to immunosuppressive therapy with antilymphocyte globulin, cyclosporin A, and methylprednisolone for refractory severe aplastic anemia.	Cyclosporine	149-162	interleukin 3	Homo sapiens	65-78
1884028-4	1991	Serum Epo levels measured in CsA-treated animals were then compared with the predicted levels, which had been calculated in a reference population of normal, either intact or anemic, mice.	Cyclosporine	29-32	erythropoietin	Mus musculus	6-9
1884028-5	1991	In CsA-treated, intact animals both hematocrit and serum Epo levels were not significantly different from controls.	Cyclosporine	3-6	erythropoietin	Mus musculus	57-60
1884028-6	1991	However, serum Epo levels in CsA-treated, anemic mice were significantly lower than those expected in a control population of untreated, anemic mice with similar degrees of anemia.	Cyclosporine	29-32	erythropoietin	Mus musculus	15-18
1884028-8	1991	Therefore, therapeutical doses of CsA appear to affect the production of Epo under conditions in which the demand of the hormone is increased, as in response to anemia.	Cyclosporine	34-37	erythropoietin	Mus musculus	73-76
1720317-0	1991	Serum levels of alpha-1 microglobulin and beta-2 microglobulin in bone marrow transplant recipients treated with cyclosporin A.	Cyclosporine	113-126	beta-2-microglobulin	Homo sapiens	42-62
1720317-2	1991	In comparison to pre-transplant levels, the highest levels of alpha 1m and beta 2m were found during impairment of renal function, i.e., during cyclosporin-induced nephrotoxicity and during treatment with other nephrotoxic drugs (P less than 0.001).	Cyclosporine	144-155	beta-2-microglobulin	Homo sapiens	75-82
8002040-3	1994	In addition, cyclophilin A and the Fab fragment had related arrangements of the aromatic amino acids in their binding sites, implying that antibody independently utilizes similar structural themes for binding cyclosporin A as cyclophilin A.	Cyclosporine	209-222	FA complementation group B	Homo sapiens	35-38
7911489-4	1994	However, the induction of the IL-3, IL-4, and GM-CSF genes, but not the IL-5, IL-6, and IL-10 genes, was strongly inhibited by cyclosporin A.	Cyclosporine	127-140	interleukin 4	Mus musculus	36-40
8204886-3	1994	The induction of IL-5 mRNA by phorbol 12-myristate 13-acetate (PMA) stimulation was found to be cyclosporin A-resistant, in contrast to the induction of IL-2 and GM-CSF mRNAs.	Cyclosporine	96-109	interleukin 5	Mus musculus	17-21
8068174-1	1994	The transcription factor NF-ATp is a target in activated T cells for the calcium-regulated phosphatase calcineurin, and is therefore a secondary target for the immunosuppressive drugs cyclosporin A and FK506.	Cyclosporine	184-197	nuclear factor of activated T cells 2	Homo sapiens	25-31
1788988-3	1991	Cyclosporine and its metabolites, isolated from human bile and identified by FAB mass spectrometry and 1H-n.m.r.	Cyclosporine	0-12	FA complementation group B	Homo sapiens	77-80
8006458-0	1994	Cyclosporin A enhances cytokine and phorbol ester-induced fibroblast collagenase expression.	Cyclosporine	0-13	matrix metallopeptidase 1	Homo sapiens	58-80
8197205-3	1994	The CsA-binding pocket in CypB has the same structure as in CypA and cyclosporin shows a similar bound conformation and network of interactions in both CypB and CypA complexes.	Cyclosporine	4-7	peptidylprolyl isomerase A	Homo sapiens	60-64
1652374-3	1991	Cyp C mRNA is expressed in a restricted subset of tissues relative to cyclophilins A and B, but is present in those tissues reported to be most affected by CsA therapy.	Cyclosporine	156-159	peptidylprolyl isomerase C	Homo sapiens	0-5
1652374-4	1991	A cyp C fusion protein has peptidyl-prolyl isomerase activity, and CsA inhibits this activity.	Cyclosporine	67-70	peptidylprolyl isomerase C	Homo sapiens	2-7
8197205-3	1994	The CsA-binding pocket in CypB has the same structure as in CypA and cyclosporin shows a similar bound conformation and network of interactions in both CypB and CypA complexes.	Cyclosporine	4-7	peptidylprolyl isomerase A	Homo sapiens	161-165
1652374-5	1991	Using the cyp C fusion protein as an affinity ligand to probe cellular extracts, we find that the cyp C fusion protein binds specifically to a 77 kd protein in the absence of CsA, while in the presence of CsA it instead binds specifically to a 55 kd protein.	Cyclosporine	175-178	peptidylprolyl isomerase C	Homo sapiens	98-103
1652374-5	1991	Using the cyp C fusion protein as an affinity ligand to probe cellular extracts, we find that the cyp C fusion protein binds specifically to a 77 kd protein in the absence of CsA, while in the presence of CsA it instead binds specifically to a 55 kd protein.	Cyclosporine	205-208	peptidylprolyl isomerase C	Homo sapiens	98-103
8197205-3	1994	The CsA-binding pocket in CypB has the same structure as in CypA and cyclosporin shows a similar bound conformation and network of interactions in both CypB and CypA complexes.	Cyclosporine	69-80	peptidylprolyl isomerase A	Homo sapiens	161-165
1652374-6	1991	We propose that the p77 is involved in cyp C native function and that the p55 is involved in signal transduction events blocked by treatment with immunosuppressive levels of CsA.	Cyclosporine	174-177	H3 histone pseudogene 44	Homo sapiens	74-77
8197617-5	1994	However, CsA augmented the thrombin-induced phosphorylation of the specific PKC substrate p47 in platelets in a dose-dependent fashion.	Cyclosporine	9-12	pleckstrin	Homo sapiens	90-93
1712901-4	1991	In addition, we studied multimers of several defined promoter elements (NFIL-2A, NF-kappa B, or NF-AT1) which are found in the UAS of the human IL-2 gene and which have been reported to be responsive to CsA when linked to a minimal promoter element (TATA box and transcription start site).	Cyclosporine	203-206	nuclear factor of activated T cells 2	Homo sapiens	96-102
7925680-8	1994	As for the immune responses to S-antigen in drug-treated rats, bucillamine suppressed the lymphocyte proliferation to S-antigen, which was further suppressed by combination therapy with CYA.	Cyclosporine	186-189	S-antigen visual arrestin	Rattus norvegicus	118-127
1712901-7	1991	The induced transcription driven by the IL-2 promoter elements NF-AT1 and NFIL-2A could be blocked completely by FK-506 or CsA.	Cyclosporine	123-126	nuclear factor of activated T cells 2	Homo sapiens	63-69
1871809-2	1991	To explore a potential relationship between the multiple systemic effects of CsA and the cellular and tissue distribution of CYP, thirty-three different normal porcine tissues were examined using an immunohistochemical technique.	Cyclosporine	77-80	peptidylprolyl isomerase G	Homo sapiens	125-128
1871809-10	1991	Generally, greater CYP-specific staining was noted in organs amenable to CsA immunosuppression (heart, liver, kidney), compared with organs deemed more immunologically vulnerable when allografted under CsA (pancreas, lung, small bowel).	Cyclosporine	73-76	peptidylprolyl isomerase G	Homo sapiens	19-22
1871809-11	1991	Similarly, CYP-immunospecific staining was abundant in tissues susceptible to CsA toxicities (neural tissue, smooth muscle, kidney, liver).	Cyclosporine	78-81	peptidylprolyl isomerase G	Homo sapiens	11-14
1871809-12	1991	This detailed immunohistological examination affords a correlation between CYP content and sensitivity to CsA.	Cyclosporine	106-109	peptidylprolyl isomerase G	Homo sapiens	75-78
1712484-1	1991	Investigations of the actions and interactions of the immunophilin ligands FK506, cyclosporin A (CsA), rapamycin, and 506BD suggest that complexes of FK506 with an FK506-binding protein or of CsA with a cyclophilin (CsA-binding protein) inhibit the T-cell receptor-mediated signal transduction that results in the transcription of interleukin 2.	Cyclosporine	97-100	interleukin 2	Rattus norvegicus	331-344
1647958-3	1991	Cyclosporin A (CsA), whose immunosuppressive effect is attributed mainly to inhibition of interleukin 2 and interferon-gamma expression, interferes in T-B cell interactions.	Cyclosporine	15-18	interleukin 2	Mus musculus	90-103
1717364-7	1991	The enhanced NK activity seen in rats treated with the lower doses of CsA may be due to the increase in IL-2 production, while enhancement of NK activity at higher doses may be due to other mechanisms.	Cyclosporine	70-73	interleukin 2	Rattus norvegicus	104-108
8045668-0	1994	Effect of interferon-gamma, interleukin-2 and interleukin-4 on cyclosporin-A-mediated inhibition of anti-CD3-induced T-lymphocyte proliferation.	Cyclosporine	63-76	interleukin 2	Mus musculus	28-41
8045668-0	1994	Effect of interferon-gamma, interleukin-2 and interleukin-4 on cyclosporin-A-mediated inhibition of anti-CD3-induced T-lymphocyte proliferation.	Cyclosporine	63-76	interleukin 4	Mus musculus	46-59
8045668-1	1994	It is generally believed that cyclosporin A (CsA) inhibits T-cell activation largely by blocking interleukin (IL)-2 production, although CsA also inhibits the secretion of other growth-promoting lymphokines.	Cyclosporine	45-48	interleukin 2	Mus musculus	97-115
8045668-4	1994	IL-2 and IL-4, in combination, were able to largely reverse the immunosuppressive activity of CsA.	Cyclosporine	94-97	interleukin 2	Mus musculus	0-4
8045668-4	1994	IL-2 and IL-4, in combination, were able to largely reverse the immunosuppressive activity of CsA.	Cyclosporine	94-97	interleukin 4	Mus musculus	9-13
8206106-0	1994	Cyclosporine effect on ornithine decarboxylase activity in rat submaxillary lymph nodes.	Cyclosporine	0-12	ornithine decarboxylase 1	Rattus norvegicus	23-46
8206106-2	1994	This study was performed: (1) to assess whether cyclosporine affected the increase in submaxillary lymph node ornithine decarboxylase activity induced by complete Freund"s adjuvant injection to rats bearing a regional parasympathetic decentralization; (2) to examine the effect of cyclosporine on cholinergic markers in submaxillary lymph nodes of rats injected with complete Freund"s adjuvant or its vehicle.	Cyclosporine	48-60	ornithine decarboxylase 1	Rattus norvegicus	110-133
1917291-2	1991	MeAla6-cyclosporin A (MeAla6-CsA) is a unique CsA analog that shows weak immunosuppressive activity and yet binds strongly to the proposed cytosolic protein receptor, cyclophilin (CyP).	Cyclosporine	29-32	peptidylprolyl isomerase G	Homo sapiens	167-178
8206106-8	1994	Parasympathetic decentralization of the submaxillary lymph nodes was followed, 2 weeks later, by a significant inhibition of cyclosporine activity on Freund"s adjuvant-induced ornithine decarboxylase.	Cyclosporine	125-137	ornithine decarboxylase 1	Rattus norvegicus	176-199
1917291-2	1991	MeAla6-cyclosporin A (MeAla6-CsA) is a unique CsA analog that shows weak immunosuppressive activity and yet binds strongly to the proposed cytosolic protein receptor, cyclophilin (CyP).	Cyclosporine	29-32	peptidylprolyl isomerase G	Homo sapiens	180-183
8112299-3	1994	Calcineurin, a Ca2+/calmodulin-dependent protein phosphatase, is the FK-506- and CsA-sensitive enzyme required for TcR mediated activation of the IL-2 promoter.	Cyclosporine	81-84	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	115-118
7905417-3	1994	Transfected cells were capable of responding to both muscarinic agonists and TCR ligands by inducing interleukin-2 secretion that was sensitive to cyclosporin A and dexamethasone.	Cyclosporine	147-160	T cell receptor alpha variable 6-3	Mus musculus	77-80
7905417-3	1994	Transfected cells were capable of responding to both muscarinic agonists and TCR ligands by inducing interleukin-2 secretion that was sensitive to cyclosporin A and dexamethasone.	Cyclosporine	147-160	interleukin 2	Mus musculus	101-114
8155595-9	1994	Cyclosporin A inhibited both the IL-4 promoter activity and activation of the inducible nuclear protein.	Cyclosporine	0-13	interleukin 4	Mus musculus	33-37
8155596-4	1994	Transgene expression is inducible by mitogens, restricted to T cells, and diminished by immunosuppressive agents, such as cyclosporin A, at concentrations known to suppress IL-2 transcription.	Cyclosporine	122-135	interleukin 2	Mus musculus	173-177
8193294-3	1994	In addition to obesity, steroid use, and reduced renal function, cyclosporine plays an independent role in elevating cholesterol levels, with particular reference to the modulation of the low-density lipoprotein receptor.	Cyclosporine	65-77	low density lipoprotein receptor	Homo sapiens	188-220
7507493-6	1994	Mutations in calcineurin A or B subunits or the inhibitory compounds FK506 and cyclosporin A restore growth of pmc1 mutants in high Ca2+ media.	Cyclosporine	79-92	calcium-transporting ATPase PMC1	Saccharomyces cerevisiae S288C	111-115
8186461-2	1994	The expression of GM-CSF and IL-2 is inhibited by immunosuppressive drugs such as cyclosporin A (CsA) and FK506.	Cyclosporine	82-95	colony stimulating factor 2	Homo sapiens	18-24
8186461-2	1994	The expression of GM-CSF and IL-2 is inhibited by immunosuppressive drugs such as cyclosporin A (CsA) and FK506.	Cyclosporine	97-100	colony stimulating factor 2	Homo sapiens	18-24
7970125-9	1994	Soluble TNF-R also proved to be useful for the differentiation of cyclosporin nephrotoxicity.	Cyclosporine	66-77	TNF receptor superfamily member 1A	Homo sapiens	8-13
8528889-6	1994	We hypothesized that cyclosporin might therefore inhibit IL-2-induced acute CRH release by blocking the dephosphorylation of NOS by calcineurin.	Cyclosporine	21-32	corticotropin releasing hormone	Homo sapiens	76-79
8265636-0	1993	Crystal structure of murine cyclophilin C complexed with immunosuppressive drug cyclosporin A.	Cyclosporine	80-93	peptidylprolyl isomerase C	Mus musculus	28-41
7510323-7	1993	Overexpression of CNA1 or CNA2, in conjunction with CNB1, results in a significant decrease in hypersensitivity to FK506 and CsA.	Cyclosporine	125-128	calcineurin catalytic subunit A	Saccharomyces cerevisiae S288C	26-30
7509138-7	1993	Both the FKBP/FK-506 complex and the Cyp/CsA complex can bind to calcineurin, thereby inhibiting its phosphatase activity.	Cyclosporine	41-44	peptidylprolyl isomerase G	Homo sapiens	37-40
7507316-6	1993	For instance, CsA and FK 506 inhibit the transcription of IL-3, IL-4, IFN gamma, TNF alpha or GM-CSF by activated T cells, and rapamycin has been shown to block the response to various growth factors such as IL-3, IL-4 or IL-6.	Cyclosporine	14-17	interleukin 3	Homo sapiens	58-62
7507316-6	1993	For instance, CsA and FK 506 inhibit the transcription of IL-3, IL-4, IFN gamma, TNF alpha or GM-CSF by activated T cells, and rapamycin has been shown to block the response to various growth factors such as IL-3, IL-4 or IL-6.	Cyclosporine	14-17	colony stimulating factor 2	Homo sapiens	94-100
7507316-6	1993	For instance, CsA and FK 506 inhibit the transcription of IL-3, IL-4, IFN gamma, TNF alpha or GM-CSF by activated T cells, and rapamycin has been shown to block the response to various growth factors such as IL-3, IL-4 or IL-6.	Cyclosporine	14-17	interleukin 3	Homo sapiens	208-212
8228625-2	1993	A dramatic reduction in CCP-1 and CCP-2 gene expression and near absence of cytolytic activity was shown to occur in these cultures when the expression of IL-2 was inhibited by 10(-6) M cyclosporin A (CsA).	Cyclosporine	201-204	interleukin 2	Mus musculus	155-159
8228625-3	1993	The inhibitory effect of CsA could not be eliminated by the addition to culture of recombinant IL-2 at concentrations typically present in anti-CD3-stimulated T cell culture supernatants.	Cyclosporine	25-28	interleukin 2	Mus musculus	95-99
7509460-8	1993	These results support the notion that the interaction of drug-immunophilin complexes with calcineurin may be the molecular basis of cyclosporin A/FK506-induced inhibition of CREB/CRE-mediated gene transcription.	Cyclosporine	132-145	cAMP responsive element binding protein 1	Rattus norvegicus	174-178
7509460-9	1993	The ability to interfere with CREB/CRE-mediated gene transcription represents a novel mechanism of cyclosporin A/FK506 action which may underlie pharmacological effects and toxic manifestations of these potent immunuosuppressive drugs.	Cyclosporine	99-112	cAMP responsive element binding protein 1	Rattus norvegicus	30-34
7691614-6	1993	Induction of apoptosis by anti-CD2 mAb was prevented by cyclosporine A and FK 506.	Cyclosporine	56-70	CD2 molecule	Homo sapiens	31-34
1706397-9	1991	Interestingly, pretreatment of basophils with drugs that either inhibited or enhanced histamine release (isobutylmethylxanthine and cyclosporin A vs cytochalasin B, respectively) significantly decreased the magnitude of anti-IgE-induced CD11b up-regulation; down-regulation of Leu 8 expression was also partially inhibited by treatment with isobutylmethylaxanthine.	Cyclosporine	132-145	selectin L	Homo sapiens	277-282
1706398-9	1991	IL-3 (3 and 10 ng/ml), but not IL-1 beta (10 and 100 ng/ml), reversed the inhibitory effect of both FK-506 and CsA on basophils challenged with anti-IgE or A23187.	Cyclosporine	111-114	interleukin 3	Homo sapiens	0-4
2004448-0	1991	Determination of cyclosporine by a competitive binding assay with cyclophilin.	Cyclosporine	17-29	peptidylprolyl isomerase G	Homo sapiens	66-77
2004448-1	1991	A competitive protein-binding assay for cyclosporine based on use of the intracellular cyclosporine-binding protein cyclophilin (CYP) was used to measure cyclosporin A (CsA) and its bioactive metabolites in whole blood.	Cyclosporine	40-52	peptidylprolyl isomerase G	Homo sapiens	116-127
2004448-1	1991	A competitive protein-binding assay for cyclosporine based on use of the intracellular cyclosporine-binding protein cyclophilin (CYP) was used to measure cyclosporin A (CsA) and its bioactive metabolites in whole blood.	Cyclosporine	40-52	peptidylprolyl isomerase G	Homo sapiens	129-132
2004448-1	1991	A competitive protein-binding assay for cyclosporine based on use of the intracellular cyclosporine-binding protein cyclophilin (CYP) was used to measure cyclosporin A (CsA) and its bioactive metabolites in whole blood.	Cyclosporine	87-99	peptidylprolyl isomerase G	Homo sapiens	116-127
2004448-1	1991	A competitive protein-binding assay for cyclosporine based on use of the intracellular cyclosporine-binding protein cyclophilin (CYP) was used to measure cyclosporin A (CsA) and its bioactive metabolites in whole blood.	Cyclosporine	87-99	peptidylprolyl isomerase G	Homo sapiens	129-132
2004448-1	1991	A competitive protein-binding assay for cyclosporine based on use of the intracellular cyclosporine-binding protein cyclophilin (CYP) was used to measure cyclosporin A (CsA) and its bioactive metabolites in whole blood.	Cyclosporine	154-167	peptidylprolyl isomerase G	Homo sapiens	116-127
2004448-1	1991	A competitive protein-binding assay for cyclosporine based on use of the intracellular cyclosporine-binding protein cyclophilin (CYP) was used to measure cyclosporin A (CsA) and its bioactive metabolites in whole blood.	Cyclosporine	154-167	peptidylprolyl isomerase G	Homo sapiens	129-132
2004448-1	1991	A competitive protein-binding assay for cyclosporine based on use of the intracellular cyclosporine-binding protein cyclophilin (CYP) was used to measure cyclosporin A (CsA) and its bioactive metabolites in whole blood.	Cyclosporine	169-172	peptidylprolyl isomerase G	Homo sapiens	129-132
2004448-2	1991	CYP from cytoplasmic extracts or erythrocyte lysates was applied in the binding assay with use of [3H]CsA as tracer and charcoal adsorption for separating bound from free tracer.	Cyclosporine	102-105	peptidylprolyl isomerase G	Homo sapiens	0-3
8397339-2	1993	NFAT, a DNA-binding protein required for interleukin-2 gene transcription, is a potential target for calcineurin, cyclosporin A and FK506.	Cyclosporine	114-127	nuclear factor of activated T cells 2	Homo sapiens	0-4
8359233-0	1993	Posttranscriptional regulation of colony-stimulating factor-1 (CSF-1) and CSF-1 receptor gene expression during inhibition of phorbol-ester-induced monocytic differentiation by dexamethasone and cyclosporin A: potential involvement of a destabilizing protein.	Cyclosporine	195-208	colony stimulating factor 1	Homo sapiens	63-68
8359233-3	1993	The present studies demonstrate that dexamethasone (dex) and cyclosporin A (CsA) resulted in inhibition of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced monocytic differentiation of HL60 cells, as well as TPA induction of c-fms and CSF-1 transcripts.	Cyclosporine	61-74	colony stimulating factor 1	Homo sapiens	237-242
8359233-3	1993	The present studies demonstrate that dexamethasone (dex) and cyclosporin A (CsA) resulted in inhibition of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced monocytic differentiation of HL60 cells, as well as TPA induction of c-fms and CSF-1 transcripts.	Cyclosporine	76-79	colony stimulating factor 1	Homo sapiens	237-242
8325363-0	1993	Interaction of cyclosporin A with an Fab fragment or cyclophilin.	Cyclosporine	15-28	FA complementation group B	Homo sapiens	37-40
8325363-2	1993	Different conformers of the immunosuppressant cyclosporin A have been observed in structural studies of the isolated molecule and of its complex with cyclophilin or with an Fab fragment.	Cyclosporine	46-59	FA complementation group B	Homo sapiens	173-176
8314748-4	1993	Cell killing by cyanide was prevented when the phospholipase A2 inhibitor butacaine was added together with CyA.	Cyclosporine	108-111	phospholipase A2 group IB	Rattus norvegicus	47-63
8335079-3	1993	Cyclosporin A (CsA) exerts immunosuppressive activities by binding to immunoregulatory proteins termed cyclophilins.	Cyclosporine	15-18	peptidylprolyl isomerase A	Homo sapiens	103-115
8518284-6	1993	Sequence alignment with human T-cell cyclophilin based on secondary structure homology implicates several residues in E. coli cyclophilin that may be crucial for binding the peptide substrate AC-A-A-P-A-AMC and the immunosuppressive drug cyclosporin A.	Cyclosporine	238-251	peptidylprolyl isomerase A	Homo sapiens	30-48
8513493-3	1993	Cyclosporin A efficiently disrupts the Gag-CyPA interaction and less efficiently disrupts the Gag-CyPB interaction.	Cyclosporine	0-13	peptidylprolyl isomerase A	Homo sapiens	43-47
7688178-6	1993	We conclude that cyclosporine can be an effective treatment for cyclic neutropenia associated with autoimmunity since G-CSF may cause exacerbations of autoimmune disorders.	Cyclosporine	17-29	colony stimulating factor 3	Homo sapiens	118-123
1705513-1	1991	Structurally unrelated, FK-506 and cyclosporin (CsA) bind to and inhibit the action of distinct cytoplasmic receptors, FK-506-binding protein (FKBP) and cyclophilin (CyP), respectively.	Cyclosporine	35-46	peptidylprolyl isomerase G	Homo sapiens	153-164
1705513-1	1991	Structurally unrelated, FK-506 and cyclosporin (CsA) bind to and inhibit the action of distinct cytoplasmic receptors, FK-506-binding protein (FKBP) and cyclophilin (CyP), respectively.	Cyclosporine	35-46	peptidylprolyl isomerase G	Homo sapiens	166-169
1705513-1	1991	Structurally unrelated, FK-506 and cyclosporin (CsA) bind to and inhibit the action of distinct cytoplasmic receptors, FK-506-binding protein (FKBP) and cyclophilin (CyP), respectively.	Cyclosporine	48-51	peptidylprolyl isomerase G	Homo sapiens	153-164
1705513-1	1991	Structurally unrelated, FK-506 and cyclosporin (CsA) bind to and inhibit the action of distinct cytoplasmic receptors, FK-506-binding protein (FKBP) and cyclophilin (CyP), respectively.	Cyclosporine	48-51	peptidylprolyl isomerase G	Homo sapiens	166-169
8518523-6	1993	Cyclosporin A induced a decrease in creatinine clearance with a decrease in fractional excretion of beta 2-microglobulin; sodium excretion was similar in the two treated groups and a transient decrease in fractional excretion of uric acid was seen only in patients receiving cyclosporin A.	Cyclosporine	0-13	beta-2-microglobulin	Homo sapiens	100-120
8471594-3	1993	We evaluated the role of cyclosporine A in blocking the antibody response in patients with melanoma treated with XMMME-001-RTA.	Cyclosporine	25-39	MAS related GPR family member F	Homo sapiens	113-126
8471594-19	1993	XMMME-001-RTA is safe when given repeatedly with cyclosporine.	Cyclosporine	49-61	MAS related GPR family member F	Homo sapiens	0-13
1825240-2	1991	Treatment with cyclosporine or ART-18, an anti-interleukin 2 receptor (IL-2[R]) mAb monoclonal antibody, abrogates accelerated rejection and prolongs mean Tx survival to 42 days and 16 days, respectively.	Cyclosporine	15-27	interleukin 2	Rattus norvegicus	71-75
8460105-0	1993	Crystallographic analysis of the interaction between cyclosporin A and the Fab fragment of a monoclonal antibody.	Cyclosporine	53-66	FA complementation group B	Homo sapiens	75-78
1825240-13	1991	However, only CsA or ART-18+CsA therapy abolished or markedly decreased elaboration of IL-2, interferon gamma, and tissue necrosis factor alpha.	Cyclosporine	14-17	interleukin 2	Rattus norvegicus	87-91
1825240-13	1991	However, only CsA or ART-18+CsA therapy abolished or markedly decreased elaboration of IL-2, interferon gamma, and tissue necrosis factor alpha.	Cyclosporine	14-17	interferon gamma	Rattus norvegicus	93-109
1825240-13	1991	However, only CsA or ART-18+CsA therapy abolished or markedly decreased elaboration of IL-2, interferon gamma, and tissue necrosis factor alpha.	Cyclosporine	28-31	interleukin 2	Rattus norvegicus	87-91
1825240-13	1991	However, only CsA or ART-18+CsA therapy abolished or markedly decreased elaboration of IL-2, interferon gamma, and tissue necrosis factor alpha.	Cyclosporine	28-31	interferon gamma	Rattus norvegicus	93-109
1825248-11	1991	Addition of rIL-2 reversed only partially CsA-induced inhibition.	Cyclosporine	42-45	interleukin 2	Rattus norvegicus	12-17
8460105-1	1993	The structure of the complex between cyclosporin A and the Fab fragment of a monoclonal antibody has been established by crystallographic analysis to 2.65 A resolution.	Cyclosporine	37-50	FA complementation group B	Homo sapiens	59-62
8460159-1	1993	Granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin 3 (IL-3) are pleiotropic hemopoietic growth factors whose genes are closely linked and induced in T lymphocytes in a cyclosporin A (CsA)-sensitive fashion.	Cyclosporine	191-204	colony stimulating factor 2	Homo sapiens	0-48
8460159-1	1993	Granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin 3 (IL-3) are pleiotropic hemopoietic growth factors whose genes are closely linked and induced in T lymphocytes in a cyclosporin A (CsA)-sensitive fashion.	Cyclosporine	191-204	colony stimulating factor 2	Homo sapiens	50-56
8460159-1	1993	Granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin 3 (IL-3) are pleiotropic hemopoietic growth factors whose genes are closely linked and induced in T lymphocytes in a cyclosporin A (CsA)-sensitive fashion.	Cyclosporine	191-204	interleukin 3	Homo sapiens	62-81
8460159-1	1993	Granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin 3 (IL-3) are pleiotropic hemopoietic growth factors whose genes are closely linked and induced in T lymphocytes in a cyclosporin A (CsA)-sensitive fashion.	Cyclosporine	206-209	colony stimulating factor 2	Homo sapiens	0-48
8460159-1	1993	Granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin 3 (IL-3) are pleiotropic hemopoietic growth factors whose genes are closely linked and induced in T lymphocytes in a cyclosporin A (CsA)-sensitive fashion.	Cyclosporine	206-209	colony stimulating factor 2	Homo sapiens	50-56
8460159-1	1993	Granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin 3 (IL-3) are pleiotropic hemopoietic growth factors whose genes are closely linked and induced in T lymphocytes in a cyclosporin A (CsA)-sensitive fashion.	Cyclosporine	206-209	interleukin 3	Homo sapiens	62-81
8460159-3	1993	We located an inducible DNase I hypersensitive site, 3 kb upstream of the GM-CSF gene, that functioned as a strong CsA-sensitive enhancer of both the GM-CSF and IL-3 promoters.	Cyclosporine	115-118	colony stimulating factor 2	Homo sapiens	74-80
8460159-3	1993	We located an inducible DNase I hypersensitive site, 3 kb upstream of the GM-CSF gene, that functioned as a strong CsA-sensitive enhancer of both the GM-CSF and IL-3 promoters.	Cyclosporine	115-118	colony stimulating factor 2	Homo sapiens	150-156
8460159-3	1993	We located an inducible DNase I hypersensitive site, 3 kb upstream of the GM-CSF gene, that functioned as a strong CsA-sensitive enhancer of both the GM-CSF and IL-3 promoters.	Cyclosporine	115-118	interleukin 3	Homo sapiens	161-165
8460159-7	1993	We propose that the intergenic enhancer described here is required for the correctly regulated activation of both GM-CSF and IL-3 gene expression in T cells and that it mediates the CsA sensitivity of the GM-CSF/IL-3 locus.	Cyclosporine	182-185	colony stimulating factor 2	Homo sapiens	114-120
8460159-7	1993	We propose that the intergenic enhancer described here is required for the correctly regulated activation of both GM-CSF and IL-3 gene expression in T cells and that it mediates the CsA sensitivity of the GM-CSF/IL-3 locus.	Cyclosporine	182-185	interleukin 3	Homo sapiens	125-129
8460159-7	1993	We propose that the intergenic enhancer described here is required for the correctly regulated activation of both GM-CSF and IL-3 gene expression in T cells and that it mediates the CsA sensitivity of the GM-CSF/IL-3 locus.	Cyclosporine	182-185	colony stimulating factor 2	Homo sapiens	205-211
8460159-7	1993	We propose that the intergenic enhancer described here is required for the correctly regulated activation of both GM-CSF and IL-3 gene expression in T cells and that it mediates the CsA sensitivity of the GM-CSF/IL-3 locus.	Cyclosporine	182-185	interleukin 3	Homo sapiens	212-216
8343198-13	1993	Elevated HMG-CoA reductase inhibitory activity has been observed when simvastatin was administered concurrently with cyclosporin, possibly increasing the risk of myopathy and subsequent rhabdomyolysis which are associated with simvastatin use.	Cyclosporine	117-128	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	9-26
8441422-5	1993	The induction of NFAT-1 binding activity can be inhibited by cyclosporin A, potentially accounting for the ability of cyclosporin A to inhibit IL-2 production by T cells.	Cyclosporine	61-74	nuclear factor of activated T cells 2	Homo sapiens	17-23
8441422-5	1993	The induction of NFAT-1 binding activity can be inhibited by cyclosporin A, potentially accounting for the ability of cyclosporin A to inhibit IL-2 production by T cells.	Cyclosporine	118-131	nuclear factor of activated T cells 2	Homo sapiens	17-23
24190647-6	1993	Patients on cyclosporin A treatment showed remarkable reduction of alpha 1 and alpha 2 collagen chains and significantly prominent split products.The results of our study could be explained either by the activation of collagenase or as a consequence of cyclophilin (peptidyl-prolyl cis-trans-isomerase) inhibition.	Cyclosporine	12-25	adrenoceptor alpha 1D	Homo sapiens	67-86
8423782-0	1993	Transforming growth factor beta and cyclosporin A inhibit the inducible activity of the interleukin-2 gene in T cells through a noncanonical octamer-binding site.	Cyclosporine	36-49	interleukin 2	Mus musculus	88-101
1363199-3	1992	Drug resistance in the cell line RPMI 8226 dox 40, expressing a high level of Pgp, was almost completely reversed by the novel non-immunosuppressive cyclosporin A (CsA) analog SDZ PSC-833 (PSC), while the chemosensitizers verapamil, CsA and quinine, in clinically achievable concentrations, were much less effective.	Cyclosporine	149-162	phosphoglycolate phosphatase	Homo sapiens	78-81
1363199-3	1992	Drug resistance in the cell line RPMI 8226 dox 40, expressing a high level of Pgp, was almost completely reversed by the novel non-immunosuppressive cyclosporin A (CsA) analog SDZ PSC-833 (PSC), while the chemosensitizers verapamil, CsA and quinine, in clinically achievable concentrations, were much less effective.	Cyclosporine	164-167	phosphoglycolate phosphatase	Homo sapiens	78-81
1363199-3	1992	Drug resistance in the cell line RPMI 8226 dox 40, expressing a high level of Pgp, was almost completely reversed by the novel non-immunosuppressive cyclosporin A (CsA) analog SDZ PSC-833 (PSC), while the chemosensitizers verapamil, CsA and quinine, in clinically achievable concentrations, were much less effective.	Cyclosporine	233-236	phosphoglycolate phosphatase	Homo sapiens	78-81
1286060-5	1992	In addition, self-reactive T cell hybridomas were isolated from the IL-2 receptor+ population present in CsA-treated mice.	Cyclosporine	105-108	interleukin 2	Mus musculus	68-72
1280373-2	1992	CS administration (15 milligrams, twice a day) for 14 days caused a significant increase in serum amylase levels, pancreatic amylase and cathepsin B content and mild acinar cell vacuolization and interstitial edema.	Cyclosporine	0-2	cathepsin B	Rattus norvegicus	137-148
1280373-3	1992	CS also caused the redistribution of cathepsin B activity from the lysosomal fraction to the zymogen fraction, indicating colocalization of lysosomal enzyme with pancreatic digestive enzymes.	Cyclosporine	0-2	cathepsin B	Rattus norvegicus	37-48
1453463-9	1992	In addition, CyP A is a closed beta-barrel so that neither the immunosuppressive drug cyclosporin A (CsA) nor the proline-containing substrate can bind to the hydrophobic core of the CyP A barrel, while the hydrophobic core of most other barrels is open for ligation.	Cyclosporine	86-99	peptidylprolyl isomerase A	Homo sapiens	13-18
1453463-9	1992	In addition, CyP A is a closed beta-barrel so that neither the immunosuppressive drug cyclosporin A (CsA) nor the proline-containing substrate can bind to the hydrophobic core of the CyP A barrel, while the hydrophobic core of most other barrels is open for ligation.	Cyclosporine	101-104	peptidylprolyl isomerase A	Homo sapiens	13-18
1457427-8	1992	IL-2 mRNA was significantly greater in the untreated allografts when compared with isografts (p &lt; 0.05) and cyclosporine-treated allografts (p &lt; 0.05).	Cyclosporine	111-123	interleukin 2	Rattus norvegicus	0-4
1363283-5	1992	This percentage was significantly higher (p = 0.002) than the proportion of positive cases (15%) observed after regimens containing either intermediate doses of Ara-C or cyclosporine A, a P-gp modulator.	Cyclosporine	170-184	phosphoglycolate phosphatase	Homo sapiens	188-192
1401906-6	1992	When CsA capable of interfering with IL-2 production and T cell proliferation was administered before CP treatment in CP-induced tolerance system, the number of CD4+V beta 6+ T cells in periphery did not increase on day 0 and 3, but increased on day 7 in contrast to the decreased number of those in CP-induced tolerant mice.	Cyclosporine	5-8	interleukin 2	Mus musculus	37-41
1384815-1	1992	The immunosuppressive drugs FK506 and cyclosporin A have an identical spectrum of activities with respect to IgE receptor (Fc epsilon RI)-mediated exocytosis from mast cells and T cell receptor-mediated transcription of IL-2.	Cyclosporine	38-51	interleukin 2	Mus musculus	220-224
1628422-2	1992	The relationship between Cyp binding and immunosuppression has been questioned since one of the analogs of CsA, N-methyl-L-alanyl6 cyclosporin (methyl-alanyl CsA) binds to Cyp but is not immunosuppressive.	Cyclosporine	158-161	peptidylprolyl isomerase G	Homo sapiens	172-175
1628422-4	1992	Cyp is a peptidyl-prolyl isomerase which is abundant in all human tissues, yet the activities of CsA are mostly confined to inhibition of T cell and thymocyte activation, and to neuro- and nephro-toxicity and are independent of inhibition of the isomerase.	Cyclosporine	97-100	peptidylprolyl isomerase G	Homo sapiens	0-3
1380951-3	1992	While 1 microgram/ml CSA and 0.1 microgram/ml FK 506 completely suppressed PHA-stimulated accumulation of mRNA for IL2, IL4, IL9, GM-CSF, TNF-alpha and IFN-gamma in PBMC, flu, keto and TGF-beta failed to inhibit any (except TNF-alpha blocked by TGF-beta).	Cyclosporine	21-24	colony stimulating factor 2	Homo sapiens	130-136
1639529-7	1992	In addition, CS group showed a significant elevation of alpha 2-macroglobulin activity and AZA group showed a significant reduction in factor XII activity when compared with the normal controls.	Cyclosporine	13-15	alpha-2-macroglobulin	Homo sapiens	56-77
1501415-9	1992	ANF was suppressed in the animals receiving cyclosporine.	Cyclosporine	44-56	natriuretic peptide A	Canis lupus familiaris	0-3
1521927-1	1992	Out of the 29 cyclosporin (CS) metabolites defined so far seven representatives were isolated from the bile of liver grafted patients, purified by HPLC and characterized by FAB-MS and/or 1H-NMR.	Cyclosporine	14-25	FA complementation group B	Homo sapiens	173-176
1521927-1	1992	Out of the 29 cyclosporin (CS) metabolites defined so far seven representatives were isolated from the bile of liver grafted patients, purified by HPLC and characterized by FAB-MS and/or 1H-NMR.	Cyclosporine	27-29	FA complementation group B	Homo sapiens	173-176
1625057-0	1992	The effect of cyclosporin A on cationized bovine serum albumin-induced nephropathy in NZW rabbits.	Cyclosporine	14-27	albumin	Oryctolagus cuniculus	49-62
1566062-1	1992	The conformation of the immunosuppressive drug cyclosporin A (CsA) in a complex with a Fab molecule has been established by crystallographic analysis to 2.65 angstrom resolution.	Cyclosporine	62-65	FA complementation group B	Homo sapiens	87-90
1566062-3	1992	Because the surfaces of CsA interacting with cyclophilin or with the Fab are not identical, these results suggest that the conformation of CsA observed in the bound form preexists in aqueous solution and is not produced by interaction with the proteins.	Cyclosporine	139-142	FA complementation group B	Homo sapiens	69-72
1385733-0	1992	Thromboxane receptor blockade attenuates chronic cyclosporine nephrotoxicity and improves survival in rats with renal isograft.	Cyclosporine	49-61	thromboxane A2 receptor	Rattus norvegicus	0-20
1553029-0	1992	Action of cyclosporine on fever induced in rats by intrahypothalamic injection of macrophage inflammatory protein-1 (MIP-1).	Cyclosporine	10-22	zinc finger protein 667	Rattus norvegicus	82-115
1553029-0	1992	Action of cyclosporine on fever induced in rats by intrahypothalamic injection of macrophage inflammatory protein-1 (MIP-1).	Cyclosporine	10-22	zinc finger protein 667	Rattus norvegicus	117-122
1553029-4	1992	Pretreatment of the anterior hypothalamic pre-optic area with 1.0 microgram cyclosporine A (CsA), delivered in a volume of 0.5 microliter, delayed the onset of the fever induced by 5.6 pg MIP-1, injected at the same site.	Cyclosporine	76-90	zinc finger protein 667	Rattus norvegicus	188-193
1553029-4	1992	Pretreatment of the anterior hypothalamic pre-optic area with 1.0 microgram cyclosporine A (CsA), delivered in a volume of 0.5 microliter, delayed the onset of the fever induced by 5.6 pg MIP-1, injected at the same site.	Cyclosporine	92-95	zinc finger protein 667	Rattus norvegicus	188-193
1553029-7	1992	By this route, CsA also delayed the rise in temperature but the fever induced by 5.6 pg MIP-1 reached the same magnitude as that after MIP-1 alone.	Cyclosporine	15-18	zinc finger protein 667	Rattus norvegicus	88-93
1731346-3	1992	We have intervened prophylactically in RadLV-induced preleukemia by using cyclosporin-A (CSA), which inhibits IL-4 production, and an immunotoxin (ITx) that kills PL cells.	Cyclosporine	74-87	interleukin 4	Mus musculus	110-114
2057119-0	1991	Autoimmune haemolytic anaemia related to cyclosporin with ABO-compatible kidney donor and recipient.	Cyclosporine	41-52	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	58-61
1898996-4	1991	Administration of CsA following syngeneic bone marrow transplantation leads to a developmental arrest of mature CD4+ and CD8+ T lymphocytes in the thymus and a marked reduction in cells expressing the alpha beta T cell receptor.	Cyclosporine	18-21	CD8a molecule	Homo sapiens	121-124
1731346-3	1992	We have intervened prophylactically in RadLV-induced preleukemia by using cyclosporin-A (CSA), which inhibits IL-4 production, and an immunotoxin (ITx) that kills PL cells.	Cyclosporine	89-92	interleukin 4	Mus musculus	110-114
1731346-4	1992	CSA efficiently inhibited IL-4 secretion from RadLV-induced PL and leukemic cells, and its administration to PL mice caused a significant delay in their death.	Cyclosporine	0-3	interleukin 4	Mus musculus	26-30
1377926-5	1992	Mixed lymphocyte reaction and proliferative responses to rIL-2, PHA and Con-A, which were declined by CsA, were not affected by FK.	Cyclosporine	102-105	interleukin 2	Rattus norvegicus	57-62
1577095-6	1992	The total number of cells, their differential counts, the number of HPC, and the concentrations of CSA in culture supernatants were similar for long-term cultures containing HILDA/LIF and for controls.	Cyclosporine	99-102	LIF interleukin 6 family cytokine	Homo sapiens	174-179
1577097-5	1992	The increased CSA activity was mainly due to granulocyte colony-stimulating factor (G-CSF) as studied by the effects of neutralizing antibodies.	Cyclosporine	14-17	colony stimulating factor 3	Homo sapiens	45-82
1577097-5	1992	The increased CSA activity was mainly due to granulocyte colony-stimulating factor (G-CSF) as studied by the effects of neutralizing antibodies.	Cyclosporine	14-17	colony stimulating factor 3	Homo sapiens	84-89
14621723-5	1992	Some predisposing factors for mIg emergence could be identified: 1. age, but only in women, 2. duration of dialysis, 3. occurrence of prior cytomegalovirus infection, and 4. immunosuppressive regimen including cyclosporine.	Cyclosporine	210-222	chemokine (C-X-C motif) ligand 9	Mus musculus	30-33
1743298-1	1991	The backbone 1H, 13C and 15N chemical shifts of cyclophilin (CyP) when bound to cyclosporin A (CsA) have been assigned from heteronuclear two- and three-dimensional NMR experiments involving selectively 15N- and uniformly 15N- and 15N,13C-labeled cyclophilin.	Cyclosporine	95-98	peptidylprolyl isomerase G	Homo sapiens	48-59
1743298-1	1991	The backbone 1H, 13C and 15N chemical shifts of cyclophilin (CyP) when bound to cyclosporin A (CsA) have been assigned from heteronuclear two- and three-dimensional NMR experiments involving selectively 15N- and uniformly 15N- and 15N,13C-labeled cyclophilin.	Cyclosporine	95-98	peptidylprolyl isomerase G	Homo sapiens	61-64
1743298-2	1991	From an analysis of the 1H and 15N chemical shifts of CyP that change upon binding to CsA and from CyP/CsA NOEs, we have determined the regions of cyclophilin involved in binding to CsA.	Cyclosporine	86-89	peptidylprolyl isomerase G	Homo sapiens	54-57
1743298-2	1991	From an analysis of the 1H and 15N chemical shifts of CyP that change upon binding to CsA and from CyP/CsA NOEs, we have determined the regions of cyclophilin involved in binding to CsA.	Cyclosporine	86-89	peptidylprolyl isomerase G	Homo sapiens	147-158
1743298-2	1991	From an analysis of the 1H and 15N chemical shifts of CyP that change upon binding to CsA and from CyP/CsA NOEs, we have determined the regions of cyclophilin involved in binding to CsA.	Cyclosporine	103-106	peptidylprolyl isomerase G	Homo sapiens	147-158
1761234-1	1991	Cells of Saccharomyces cerevisiae contain a major cytosolic cyclophilin (Cyp)-related peptidyl-prolyl cis-trans isomerase (PPIase) which is the target for cyclosporin A (CsA) cytotoxicity and which is encoded by the CYP1 gene [Haendler et al., Gene 83 (1989) 39-46].	Cyclosporine	155-168	peptidylprolyl isomerase CPR1	Saccharomyces cerevisiae S288C	216-220
1761234-12	1991	Whereas cells containing a genomic disruption of CYP1 exhibited a CsA-resistant phenotype, genomic disruption of CYP2 had no effect on CsA sensitivity.	Cyclosporine	66-69	peptidylprolyl isomerase CPR1	Saccharomyces cerevisiae S288C	49-53
1761234-13	1991	This suggests that the CYP1 gene product is the primary cellular target for CsA toxicity in yeast.	Cyclosporine	76-79	peptidylprolyl isomerase CPR1	Saccharomyces cerevisiae S288C	23-27
1761234-14	1991	Since both purified Cyps display CsA sensitivity in vitro, our data suggest that Cyp1 and Cyp2 differ in terms of their cellular function and/or localization.	Cyclosporine	33-36	peptidylprolyl isomerase CPR1	Saccharomyces cerevisiae S288C	81-85
1721394-0	1991	Synexin: a target protein for toxic effects of cyclosporine and FK 506 in endocrine cells.	Cyclosporine	47-59	annexin A7	Homo sapiens	0-7
1836439-8	1991	From these results, it is speculated that CS suppresses not only interleukin 2 (IL-2) production as previously reported, but also the expression of Ia antigens and IL-2R.	Cyclosporine	42-44	interleukin 2	Rattus norvegicus	65-78
1836439-8	1991	From these results, it is speculated that CS suppresses not only interleukin 2 (IL-2) production as previously reported, but also the expression of Ia antigens and IL-2R.	Cyclosporine	42-44	interleukin 2	Rattus norvegicus	80-84
1926345-10	1991	This was observed to be in contrast to the immunosuppressive activity observed with cyclosporine treatment of mice (150 mg/kg) for the ex vivo suppression of splenocyte production of IL-2.	Cyclosporine	84-96	interleukin 2	Mus musculus	183-187
1986468-4	1991	Available data cannot otherwise distinguish which cyclosporine-treated recipients of ABO-unmatched kidneys and livers (30-40% of total) will develop graft antibody.	Cyclosporine	50-62	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	85-88
1930203-5	1991	Inhibition of lymphoid proliferation with cyclosporin also resulted in reduced Op18 levels.	Cyclosporine	42-53	stathmin 1	Homo sapiens	79-83
2269432-6	1990	The cDNA was engineered for expression in Escherichia coli, and the resulting recombinant protein, like mammalian Cyps, exhibited a peptidyl-prolyl cis-trans isomerase (PPIase) activity which was sensitive to inhibition by cyclosporin A in vitro.	Cyclosporine	223-236	peptidylprolyl isomerase like 1	Homo sapiens	132-167
2269432-6	1990	The cDNA was engineered for expression in Escherichia coli, and the resulting recombinant protein, like mammalian Cyps, exhibited a peptidyl-prolyl cis-trans isomerase (PPIase) activity which was sensitive to inhibition by cyclosporin A in vitro.	Cyclosporine	223-236	peptidylprolyl isomerase like 1	Homo sapiens	169-175
1832493-10	1991	Cyclosporin A also inhibited the down-modulation of lck mRNA by increasing its transcription with no effect on its stability.	Cyclosporine	0-13	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	52-55
1832493-11	1991	Since, lck mRNA down-modulation was always associated with lymphokine mRNA induction, and since CsA blocks both lymphokine transcription and lck decrease of transcription, this indicates that these genes might share common regulatory pathways leading to their inverse transcriptional regulation.	Cyclosporine	96-99	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	141-144
1907919-1	1991	The general way to induce the synthesis of lymphokines by T cells is the stimulation through the T cell receptor (TcR) complex which results in an increase of intracellular [Ca2+] and in the activation of a tyrosine kinase as well as of protein kinase C. Lymphokine production induced via the TcR is inhibited by the immunosuppressive drug cyclosporin A (CsA).	Cyclosporine	340-353	T cell receptor alpha variable 6-3	Mus musculus	97-112
1907919-1	1991	The general way to induce the synthesis of lymphokines by T cells is the stimulation through the T cell receptor (TcR) complex which results in an increase of intracellular [Ca2+] and in the activation of a tyrosine kinase as well as of protein kinase C. Lymphokine production induced via the TcR is inhibited by the immunosuppressive drug cyclosporin A (CsA).	Cyclosporine	340-353	T cell receptor alpha variable 6-3	Mus musculus	114-117
1907919-1	1991	The general way to induce the synthesis of lymphokines by T cells is the stimulation through the T cell receptor (TcR) complex which results in an increase of intracellular [Ca2+] and in the activation of a tyrosine kinase as well as of protein kinase C. Lymphokine production induced via the TcR is inhibited by the immunosuppressive drug cyclosporin A (CsA).	Cyclosporine	355-358	T cell receptor alpha variable 6-3	Mus musculus	97-112
1907919-1	1991	The general way to induce the synthesis of lymphokines by T cells is the stimulation through the T cell receptor (TcR) complex which results in an increase of intracellular [Ca2+] and in the activation of a tyrosine kinase as well as of protein kinase C. Lymphokine production induced via the TcR is inhibited by the immunosuppressive drug cyclosporin A (CsA).	Cyclosporine	355-358	T cell receptor alpha variable 6-3	Mus musculus	114-117
2071889-8	1991	Therefore, the development of CsA-induced autoreactive T cells as assessed by V beta TCR expression showed strain variation that did not correlate with the induction of syngeneic GVHD and suggested that other mechanisms may be involved in the development of this autoimmune phenomenon.	Cyclosporine	30-33	T cell receptor alpha variable 6-3	Mus musculus	85-88
2054356-0	1991	NMR studies of [U-13C]cyclosporin A bound to cyclophilin: bound conformation and portions of cyclosporin involved in binding.	Cyclosporine	22-33	peptidylprolyl isomerase G	Homo sapiens	45-56
2054356-1	1991	Cyclosporin A (CsA), a potent immunosuppressant, is known to bind with high specificity to cyclophilin (CyP), a 17.7 kDa protein with peptidyl-prolyl isomerase activity.	Cyclosporine	0-13	peptidylprolyl isomerase G	Homo sapiens	91-102
2054356-1	1991	Cyclosporin A (CsA), a potent immunosuppressant, is known to bind with high specificity to cyclophilin (CyP), a 17.7 kDa protein with peptidyl-prolyl isomerase activity.	Cyclosporine	0-13	peptidylprolyl isomerase G	Homo sapiens	104-107
1915567-0	1991	Effect of cyclosporine on ornithine decarboxylase activity in rat submaxillary lymph nodes: modulation by sympathetic nerves.	Cyclosporine	10-22	ornithine decarboxylase 1	Rattus norvegicus	26-49
1915567-8	1991	The results indicate that an appropriate sympathetic neural environment is needed for cyclosporine to have an effect on ornithine decarboxylase activity in lymphoid tissue.	Cyclosporine	86-98	ornithine decarboxylase 1	Rattus norvegicus	120-143
1827045-8	1991	The acquisition of NK1.1, B220, and lytic activity by this triple-negative subset was readily inhibited by cyclosporine A (CSA).	Cyclosporine	107-121	killer cell lectin-like receptor subfamily B member 1C	Mus musculus	19-24
1906747-5	1991	In contrast, rec-IL-2 shortened heart allograft survival both in untreated and in cyclosporine-treated recipients.	Cyclosporine	82-94	interleukin 2	Rattus norvegicus	17-21
1906747-6	1991	Rec-IFN-gamma partially reversed the effects of rec-IL-2 in cyclosporine-treated rats.	Cyclosporine	60-72	interferon gamma	Rattus norvegicus	4-13
11282491-1	2001	Cyclosporin A, a substrate of P-glycoprotein (P-gp), is known to cause cholestasis in humans and in rat experimental models.	Cyclosporine	0-13	ATP binding cassette subfamily B member 1	Homo sapiens	30-44
1906747-6	1991	Rec-IFN-gamma partially reversed the effects of rec-IL-2 in cyclosporine-treated rats.	Cyclosporine	60-72	interleukin 2	Rattus norvegicus	52-56
1875895-9	1991	Cyclosporine A, which can suppress the IL-2 production of lymphocytes, promoted liver regeneration 45% over the control at a dose of 10 mg/kg.	Cyclosporine	0-14	interleukin 2	Mus musculus	39-43
11282491-1	2001	Cyclosporin A, a substrate of P-glycoprotein (P-gp), is known to cause cholestasis in humans and in rat experimental models.	Cyclosporine	0-13	ATP binding cassette subfamily B member 1	Homo sapiens	46-50
1672640-0	1991	Interleukin 2/interleukin 4-independent T helper cell generation during an in vitro antigenic stimulation of mouse spleen cells in the presence of cyclosporin A.	Cyclosporine	147-160	interleukin 2	Mus musculus	0-13
1672640-0	1991	Interleukin 2/interleukin 4-independent T helper cell generation during an in vitro antigenic stimulation of mouse spleen cells in the presence of cyclosporin A.	Cyclosporine	147-160	interleukin 4	Mus musculus	14-27
1672640-6	1991	Lymphokine genes transcription analysis confirms that the inhibition of interleukin (IL) 2/IL 4 gene expression is one target of CsA action.	Cyclosporine	129-132	interleukin 2	Mus musculus	72-90
1672640-6	1991	Lymphokine genes transcription analysis confirms that the inhibition of interleukin (IL) 2/IL 4 gene expression is one target of CsA action.	Cyclosporine	129-132	interleukin 4	Mus musculus	91-95
2026447-0	1991	Distribution of the cyclosporine binding protein cyclophilin in human tissues.	Cyclosporine	20-32	peptidylprolyl isomerase G	Homo sapiens	49-60
2026447-1	1991	Cyclophilin (CYP) is the major intracellular binding protein for the immunosuppressive drug cyclosporine (CS).	Cyclosporine	92-104	peptidylprolyl isomerase G	Homo sapiens	0-11
2026447-1	1991	Cyclophilin (CYP) is the major intracellular binding protein for the immunosuppressive drug cyclosporine (CS).	Cyclosporine	92-104	peptidylprolyl isomerase G	Homo sapiens	13-16
2026447-1	1991	Cyclophilin (CYP) is the major intracellular binding protein for the immunosuppressive drug cyclosporine (CS).	Cyclosporine	106-108	peptidylprolyl isomerase G	Homo sapiens	0-11
2026447-1	1991	Cyclophilin (CYP) is the major intracellular binding protein for the immunosuppressive drug cyclosporine (CS).	Cyclosporine	106-108	peptidylprolyl isomerase G	Homo sapiens	13-16
1671400-7	1991	Moreover, IL-2-dependent events may also help in enhancing CD2 hyper-expression because it was only partially inhibitable by cyclosporine, dexamethasone, or Mar-108 (CD25) mAb.	Cyclosporine	125-137	CD2 molecule	Homo sapiens	59-62
1705509-9	1991	T cells activated by anti-CD5/PMA are sensitive to inhibition by cyclosporin A (CsA) and by prostaglandin E2 (PGE2).	Cyclosporine	65-78	CD5 molecule	Homo sapiens	26-29
1705509-9	1991	T cells activated by anti-CD5/PMA are sensitive to inhibition by cyclosporin A (CsA) and by prostaglandin E2 (PGE2).	Cyclosporine	80-83	CD5 molecule	Homo sapiens	26-29
1705513-4	1991	We have shown that FK-506, like CsA, is able to inhibit T cell activation mediated not only by the T cell receptor-CD3 complex, but also via another surface molecule, CD2.	Cyclosporine	32-35	CD2 molecule	Homo sapiens	167-170
1985948-0	1991	Cyclosporin A slows collagen triple-helix formation in vivo: indirect evidence for a physiologic role of peptidyl-prolyl cis-trans-isomerase.	Cyclosporine	0-13	peptidylprolyl isomerase like 1	Homo sapiens	105-140
1906396-1	1991	A study was made of changes in the ratio of CD4+/CD8+ in patients who had received cadaverous kidneys and who were under treatment with a combination of cyclosporin A + azathioprine + cor ticosteroids.	Cyclosporine	153-166	CD8a molecule	Homo sapiens	49-52
1804641-9	1991	Cholestasis and rejection shift the ciclosporin metabolite pattern in blood and urine to higher concentrations of M19 and M1A, whereas the concentrations of other metabolites and ciclosporin were not significantly affected.	Cyclosporine	36-47	ubiquinol-cytochrome c reductase complex assembly factor 2	Homo sapiens	114-117
1725322-1	1991	Cyclosporine A (CSA) stimulated endothelin secretion by a cultured renal epithelial cell line, LLC-PK1.	Cyclosporine	0-14	prokineticin 1	Homo sapiens	99-102
1826940-1	1991	Effect of the immunosuppressive agent, ciclosporin (CS), on bovine serum albumin (BSA) nephritis in rats was evaluated.	Cyclosporine	39-50	albumin	Rattus norvegicus	67-80
1690774-2	1990	Cyclosporin A (CSA) inhibits IgE receptor-mediated exocytosis from rat basophilic leukemia (RBL) cells and human peripheral blood basophils in a dose-dependent manner over the therapeutic range of CSA concentrations achieved in vivo.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
1690774-2	1990	Cyclosporin A (CSA) inhibits IgE receptor-mediated exocytosis from rat basophilic leukemia (RBL) cells and human peripheral blood basophils in a dose-dependent manner over the therapeutic range of CSA concentrations achieved in vivo.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	197-200
1968924-3	1990	Cyclosporine A (CsA) inhibits T lymphocyte activation in vitro by blocking at a pretranslational level the production of IL-2 and other cytokines.	Cyclosporine	0-14	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	16-19
2108610-1	1990	For the purpose to establish the reliability of SRCA using clinical materials, a histological assessment under the suppression of host reaction was introduced; 1) for the immune suppression cyclosporin A (CsA) was used, 2) to overcome the heterogeneity of fragments, the numbers of implants were increased to ten per group (two pieces/kidney), 3) time flame was 6 days as original, 4) the amounts of drugs were essentially similar to those of Bogden"s original method.	Cyclosporine	190-203	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	205-208
2293908-2	1990	Decreased levels of autoantibodies against DNA, histones, cardiolipin, RNP, Sm, Ro (SS-A), and La (SS-B) were detected in the sera of patients with uveitis receiving cyclosporine A or cyclosporine A plus bromocriptine following 3 months of treatment.	Cyclosporine	166-180	small RNA binding exonuclease protection factor La	Homo sapiens	99-103
2311397-0	1990	Therapeutic drug monitoring of cyclosporine (CSA).	Cyclosporine	31-43	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	45-48
2262069-8	1990	Simultaneous treatment with CsA resulted in a significant inhibition of camostate-induced increases in ODC, SAM-DC as well as putrescine and spermidine and furthermore caused a nearly complete inhibition of the increase of all trophic parameters, while CCK plasma levels were not altered.	Cyclosporine	28-31	adenosylmethionine decarboxylase 1	Rattus norvegicus	108-114
2301008-6	1990	The administration of hCG to the CsA-treated rats restored the reproductive organ weights (testis 1.56 +/- 0.043 g; seminal vesicle 1.04 +/- 0.05 g; prostate 0.70 +/- 0.06 g) and sperm counts (testicular 7.88 +/- 1.0 x 10(7)/100 mg tissue; epididymal 59.86 +/- 4.16 x 10(7)/100 mg tissue; P less than 0.05) Serum levels of testosterone (18.63 +/- 4.45 ng/ml) and LH (431.65 +/- 31.41 ng/ml) were significantly elevated, as compared with control and CsA-treated groups (P less than 0.05).	Cyclosporine	33-36	chorionic gonadotropin subunit beta 5	Homo sapiens	22-25
2301008-6	1990	The administration of hCG to the CsA-treated rats restored the reproductive organ weights (testis 1.56 +/- 0.043 g; seminal vesicle 1.04 +/- 0.05 g; prostate 0.70 +/- 0.06 g) and sperm counts (testicular 7.88 +/- 1.0 x 10(7)/100 mg tissue; epididymal 59.86 +/- 4.16 x 10(7)/100 mg tissue; P less than 0.05) Serum levels of testosterone (18.63 +/- 4.45 ng/ml) and LH (431.65 +/- 31.41 ng/ml) were significantly elevated, as compared with control and CsA-treated groups (P less than 0.05).	Cyclosporine	449-452	chorionic gonadotropin subunit beta 5	Homo sapiens	22-25
2301008-8	1990	CsA reduced the kidney weight (1.17 +/- 0.02 vs. 1.27 +/- 0.03 g; P less than 0.05) and increased the levels of serum creatinine (0.97 +/- 0.07 vs. 0.59 +/- 0.03 mg/dl; P less than 0.05): these changes were ameliorated by the administration of hCG (kidney weight 1.35 +/- 0.03 g; creatinine 0.76 +/- 0.09 mg/dl).	Cyclosporine	0-3	chorionic gonadotropin subunit beta 5	Homo sapiens	244-247
33760995-0	2021	Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy.	Cyclosporine	69-81	solute carrier family 5 member 2	Rattus norvegicus	0-30
33233866-5	2020	Conventional and recently developed agents for treating AD such as steroid, calcineurin inhibitors, cyclosporine, dupilumab, and JAK inhibitors inhibit the IL-13/IL-4-JAK-STAT6/STAT3 axis, while older remedies such as coal tar and glyteer are antioxidative AHR agonists.	Cyclosporine	100-112	aryl hydrocarbon receptor	Homo sapiens	257-260
34791051-14	2021	IMB-presence predicted arthritis development in ACPA-positive CSA (adjusted HR 2.2(1.0-4.7)), but not in ACPA-negative CSA-patients (0.8(0.4-1.7)).	Cyclosporine	62-65	proteinase 3	Homo sapiens	48-52
34791051-16	2021	IMB precedes development of clinical arthritis, particularly in ACPA-positive CSA.	Cyclosporine	78-81	proteinase 3	Homo sapiens	64-68
34409648-4	2021	We report a 12-year-old boy with GATA2 deficiency and generalized verrucosis that worsened after cyclosporine use following bone marrow transplant.	Cyclosporine	97-109	GATA binding protein 2	Homo sapiens	33-38
34870124-6	2021	Results: The CSA values were greater on the amputated sides than the non-amputated sides for SN (p=0.001), TN (p=0.001), and CPN (p=0.015), regardless of the activity level.	Cyclosporine	13-16	C-type lectin domain family 3 member B	Homo sapiens	107-109
34445576-6	2021	Interestingly, the specific inhibition of NFAT factors by cyclosporine A, completely blocked RCC cell motility induced by CD40 ligation.	Cyclosporine	58-72	CD40 molecule	Homo sapiens	122-126
34445576-8	2021	Moreover, CD40-CD40L interaction induced a cytoskeleton reorganization and increased the expression of integrin beta1 on RCC cell lines, and this effect was reversed by cyclosporine A and NFAT inhibition.	Cyclosporine	169-183	CD40 molecule	Homo sapiens	10-14
34153880-4	2021	In this study, we demonstrate the CSA recoupling of strongly dipolar coupled 1H spins using the Cnn1(9003601805400360180900) sequence.	Cyclosporine	34-37	calponin 1	Homo sapiens	96-100
34276002-2	2021	We previously identified a phospholipase C (PLC) -delta1 gene variant that results in enhanced PLC activity in patients with CSA and developed a CSA animal model by generating vascular smooth muscle cell-specific human variant PLC-delta1 overexpression (PLC-TG) mice.	Cyclosporine	125-128	phospholipase C delta 1	Homo sapiens	27-56
34276002-2	2021	We previously identified a phospholipase C (PLC) -delta1 gene variant that results in enhanced PLC activity in patients with CSA and developed a CSA animal model by generating vascular smooth muscle cell-specific human variant PLC-delta1 overexpression (PLC-TG) mice.	Cyclosporine	145-148	phospholipase C delta 1	Homo sapiens	27-56
34276002-2	2021	We previously identified a phospholipase C (PLC) -delta1 gene variant that results in enhanced PLC activity in patients with CSA and developed a CSA animal model by generating vascular smooth muscle cell-specific human variant PLC-delta1 overexpression (PLC-TG) mice.	Cyclosporine	145-148	phospholipase C delta 1	Homo sapiens	227-237
34381450-7	2021	p70 S6 kinase and mTOR were reduced by CsA with/without CHBP at 2 weeks, so were S6 ribosomal protein and GSK-3beta at 8 weeks, with reduced CASP-3 at both time points.	Cyclosporine	39-42	glycogen synthase kinase 3 alpha	Mus musculus	106-115
34263471-6	2021	A substantial (p < .05) increase in the activity of E-NTPDase (ATP and ADP as substrate) without any notable difference in the action of ecto-5" nucleotidase was facilitated by cyclosporine-induction when compared to the CTRL.	Cyclosporine	177-189	5' nucleotidase, ecto	Rattus norvegicus	137-157
34089287-8	2021	Through screening and molecular docking, PRKDC, CUL7, CUL1, HSPA8, HSPA4 and SIRT7 were the most likely multi-target mechanism of Cyclosporin A in the treatment of vitiligo.	Cyclosporine	130-143	cullin 1	Homo sapiens	54-58
34089287-9	2021	CONCLUSIONS: In our study, Cyclosporin A might not only affect the repair of DNA strands by targeting PRKDC, but also affected the innate and adaptive immune function of vitiligo patients by the targets of CUL1, CUL7 and HSP70.	Cyclosporine	27-40	cullin 1	Homo sapiens	206-210
35588871-10	2022	CsA also enhanced TP receptor, as well as p-ERK1/2, p-p38, p- IkappaBalpha, p-NF-kappaB p65 protein levels and decreased IkappaBalpha protein expression, demonstrating that CsA induced TP receptor enhanced-vasoconstriction via activation of MAPK and NF-kappaB pathways.	Cyclosporine	0-3	mitogen activated protein kinase 3	Rattus norvegicus	44-50
35588871-10	2022	CsA also enhanced TP receptor, as well as p-ERK1/2, p-p38, p- IkappaBalpha, p-NF-kappaB p65 protein levels and decreased IkappaBalpha protein expression, demonstrating that CsA induced TP receptor enhanced-vasoconstriction via activation of MAPK and NF-kappaB pathways.	Cyclosporine	0-3	mitogen activated protein kinase 14	Rattus norvegicus	54-57
35043423-7	2022	Estimated baseline target antigen (CD25) level was lower is patients cotreated with cyclosporine (p=0.026).	Cyclosporine	84-96	interleukin 2 receptor subunit alpha	Homo sapiens	35-39
35561427-7	2022	Moreover, lower doses of SDH showed the similar or better efficacy than cyclosporine A (CsA) and mesalazine in DSS- or TNBS-induced colitis animals.	Cyclosporine	88-91	serine dehydratase	Homo sapiens	25-28
35143644-2	2022	We performed a prospective randomized, multicenter, phase III trial to study whether posttransplant cyclophosphamide (PT-Cy) combined with a short course of cyclosporine A (CsA) would result in a reduction of severe GVHD and improvement of GVHD-free, relapse free survival (GRFS) as compared to the combination of CsA and mycophenolic acid (MPA) after non-myeloablative (NMA) matched related and unrelated peripheral blood alloHSCT.	Cyclosporine	157-171	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	173-176
35143644-2	2022	We performed a prospective randomized, multicenter, phase III trial to study whether posttransplant cyclophosphamide (PT-Cy) combined with a short course of cyclosporine A (CsA) would result in a reduction of severe GVHD and improvement of GVHD-free, relapse free survival (GRFS) as compared to the combination of CsA and mycophenolic acid (MPA) after non-myeloablative (NMA) matched related and unrelated peripheral blood alloHSCT.	Cyclosporine	157-171	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	314-317
35606904-1	2022	Despite the common use of cyclosporine (CsA) for acute graft-versus-host disease (aGVHD) prophylaxis following allogeneic stem cell transplant, the optimal CsA trough target remains unknown.	Cyclosporine	26-38	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	40-43
35593990-12	2022	Inhibition of CypD by cyclosporin A was found to reverse PM2.5-induced mPTP opening and H9C2 cell death.	Cyclosporine	22-35	peptidylprolyl isomerase F	Rattus norvegicus	14-18
35629245-9	2022	Cyclosporine was observed in a significantly greater proportion of patients with elevated GGT, and SNPs in PPAR-alpha were significantly associated with an increased risk of this adverse event.	Cyclosporine	0-12	gamma-glutamyltransferase light chain 5 pseudogene	Homo sapiens	90-93
35553638-10	2022	Cyclosporine A and prednisolone synergistically increased GCR expression and inhibited pro-inflammatory cytokine production by CD28null CD8- T and NKT-like cells.	Cyclosporine	0-14	CD28 molecule	Homo sapiens	127-131
2789115-0	1989	In vitro and in vivo action of cyclosporin A on the induction of human interleukin-2 receptor alpha and beta chains.	Cyclosporine	31-44	interleukin 2 receptor subunit alpha	Homo sapiens	71-99
2789115-4	1989	Normal lymphocytes treated in vitro with CyA showed significant inhibition of alpha chain IL-2R expression both at the mRNA and the membrane level.	Cyclosporine	41-44	interleukin 2 receptor subunit beta	Homo sapiens	90-95
2543699-2	1989	Prior results indicated that stimulation of T cells by anti-CD28 mAb plus PMA could induce IL-2 expression and T cell proliferation that was entirely resistant to cyclosporine.	Cyclosporine	163-175	CD28 molecule	Homo sapiens	60-64
2543699-6	1989	The addition of anti-CD28 to T cells stimulated with PMA plus calcium ionophore induced a 5- to 100-fold increase in IL-2 gene expression and secretion that was resistant to cyclosporine.	Cyclosporine	174-186	CD28 molecule	Homo sapiens	21-25
2543699-9	1989	The signal provided by CD28 is distinct from that of CD3 because although anti-CD28 plus PMA-induced proliferation is resistant to cyclosporine, anti-CD3 or anti-CD3 plus PMA-induced IL-2 expression is sensitive.	Cyclosporine	131-143	CD28 molecule	Homo sapiens	23-27
2732228-12	1989	Clear differences were also detected in their catalytic activities toward the immunosuppressive drug cyclosporine, with two hydroxylated metabolites (M1 and M17) and one demethylated metabolite (M21) formed by hPCN1 but only one metabolite (M1) formed by hPCN3.	Cyclosporine	101-113	potassium voltage-gated channel subfamily A member 3	Homo sapiens	255-260
2735909-4	1989	From 0.001 to 1 microgram/ml, CsA dose-dependently inhibited lipopolysaccharide (LPS) induced secreted bioactivity; at doses above 10 micrograms/ml CSA was directly toxic to CFA-MO.	Cyclosporine	30-33	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	148-151
2796968-0	1989	[The inhibition of interleukin 2 (IL-2) receptor gene expression in kidney transplant recipients treated with ciclosporin: preliminary report].	Cyclosporine	110-121	interleukin 2 receptor subunit beta	Homo sapiens	34-48
2525288-5	1989	Adoptive transfer of SpL, T cells and 0 x 8+ cells from UV-DL and CsA-treated recipients of W/F heart allografts at 20 or 180 days after transplantation led to significant donor-specific graft prolongation in naive syngeneic hosts, while adoptive transfer of W3/25+ cells, in this group, did not affect test graft survival.	Cyclosporine	66-69	sphingosine-1-phosphate lyase 1	Homo sapiens	21-24
2660359-5	1989	Plasma MBP concentrations were within the normal range in both acute rejection and cyclosporine nephrotoxicity.	Cyclosporine	83-95	myelin basic protein	Homo sapiens	7-10
2651520-6	1989	In the thymus, the generation of CD4+CD8+ thymocytes was not affected by CsA treatment, and CD4-CD8- thymocytes of CsA-treated mice expressed surface markers characteristic of normal CD4-CD8- thymocytes, and exhibited normal functional activity when stimulated with anti-CD3 antibody.	Cyclosporine	115-118	CD3 antigen, epsilon polypeptide	Mus musculus	271-274
2656579-0	1989	Alleviation of cyclosporin-induced immune suppression by the cytokine inducer ADA-202-718.	Cyclosporine	15-26	adenosine deaminase	Mus musculus	78-89
2656579-6	1989	ADA (1 mg/kg) also stimulated the splenic IgM plaque-forming cell response to SRBC and prevented CsA (25 mg/kg)-induced suppression of humoral immunity.	Cyclosporine	97-100	adenosine deaminase	Mus musculus	0-3
2656579-7	1989	In vitro, ADA (2 micrograms/ml) inhibited CsA-induced suppression of T cell proliferation, the effect being most marked at lower inhibitory concentrations of CsA.	Cyclosporine	42-45	adenosine deaminase	Mus musculus	10-13
2656579-7	1989	In vitro, ADA (2 micrograms/ml) inhibited CsA-induced suppression of T cell proliferation, the effect being most marked at lower inhibitory concentrations of CsA.	Cyclosporine	158-161	adenosine deaminase	Mus musculus	10-13
2656579-8	1989	These data illustrate the capacity of ADA to augment or restore T cell responses in experimental animals and are consistent with the view that CsA acts in these experimental in vivo systems by inhibition of cytokine production.	Cyclosporine	143-146	adenosine deaminase	Mus musculus	38-41
2783946-11	1989	Furthermore, IL-4 could augment proliferation and IL-2R expression of T cells stimulated with PHA in the presence of cyclosporin A, which blocks endogenous cytokine production or anti-Tac.	Cyclosporine	117-130	interleukin 2 receptor subunit alpha	Homo sapiens	50-55
2465550-5	1989	The activation pathway induced by stimulation of CD28 is distinct from other biochemical pathways that induce lymphokines/cytokines because CD28 stimulation can induce lymphokine/cytokine gene expression in the presence of the immunosuppressant cyclosporine.	Cyclosporine	245-257	CD28 molecule	Homo sapiens	49-53
2465550-5	1989	The activation pathway induced by stimulation of CD28 is distinct from other biochemical pathways that induce lymphokines/cytokines because CD28 stimulation can induce lymphokine/cytokine gene expression in the presence of the immunosuppressant cyclosporine.	Cyclosporine	245-257	CD28 molecule	Homo sapiens	140-144
2652679-0	1989	Effective prophylaxis of early post-transplant urinary tract infections (UTI) in the cyclosporine (CSA) era.	Cyclosporine	85-97	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	99-102
2468619-1	1989	Cyclosporin A (CsA) is now widely used in the prevention/treatment of graft rejection and in the treatment of some human inflammatory diseases.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
2671565-3	1989	Serum from IL-1 injected mice showed marked granulocyte/macrophage CSA (GM-CSA), but little megakaryocyte CSA (Meg-CSA).	Cyclosporine	67-70	interleukin 1 complex	Mus musculus	11-15
2671565-3	1989	Serum from IL-1 injected mice showed marked granulocyte/macrophage CSA (GM-CSA), but little megakaryocyte CSA (Meg-CSA).	Cyclosporine	75-78	interleukin 1 complex	Mus musculus	11-15
2623745-1	1989	The authors recently demonstrated that cyclosporine (CsA) treatment of mice caused a remarkable reduction of L3T4+Lyt-2- subset in the thymocytes as well as the striking decrease in the size and cellularity of the thymic medulla.	Cyclosporine	39-51	CD8 antigen, alpha chain	Mus musculus	114-119
3075679-1	1988	The in vivo administration of the immunosuppressive drug, Cyclosporin A (CSA), has allowed us to define IL-2 dependent and IL-2 independent pathways of T cell activation in vivo.	Cyclosporine	58-71	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	73-76
3136569-3	1988	Addition of recombinant IL-2 only partially restored 4AS growth inhibition, suggesting that another antigen-induced activation signal such as IL-2-receptor expression could be impaired by CsA.	Cyclosporine	188-191	interleukin 2 receptor subunit beta	Homo sapiens	142-155
3136569-4	1988	Using 125I-labeled human recombinant IL-2 and 125I-labeled 33B3.1 (a MoAb directed against TAC antigen), we found that expression of both high and low affinity sites was decreased when clone cells were stimulated with D.BLCL in the presence of CsA and exogenous IL-2 (about 50% inhibition in the presence of 500 ng/ml of CsA).	Cyclosporine	244-247	interleukin 2 receptor subunit alpha	Homo sapiens	91-102
3136569-4	1988	Using 125I-labeled human recombinant IL-2 and 125I-labeled 33B3.1 (a MoAb directed against TAC antigen), we found that expression of both high and low affinity sites was decreased when clone cells were stimulated with D.BLCL in the presence of CsA and exogenous IL-2 (about 50% inhibition in the presence of 500 ng/ml of CsA).	Cyclosporine	321-324	interleukin 2 receptor subunit alpha	Homo sapiens	91-102
3136044-1	1988	Potential side-effects of the immunosuppressive drug cyclosporine (also cyclosporin A, CsA) on ovarian endocrine function have been investigated using granulosa cells isolated from immature estrogen-primed rats and cultured in a chemically defined medium.	Cyclosporine	53-65	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	87-90
3292818-0	1988	Cyclosporine A enhances renin secretion and production in isolated juxtaglomerular cells.	Cyclosporine	0-14	renin	Rattus norvegicus	24-29
3292818-1	1988	Stimulation of the renin-angiotensin system is a major side effect of the fungoid immunosuppressant cyclosporine A (CyA).	Cyclosporine	100-114	renin	Rattus norvegicus	19-24
3292818-1	1988	Stimulation of the renin-angiotensin system is a major side effect of the fungoid immunosuppressant cyclosporine A (CyA).	Cyclosporine	116-119	renin	Rattus norvegicus	19-24
3292818-7	1988	Our results indicate that cyclosporine A stimulates renin secretion and renin synthesis by a direct effect on renal juxtaglomerular cells.	Cyclosporine	26-40	renin	Rattus norvegicus	52-57
3292818-7	1988	Our results indicate that cyclosporine A stimulates renin secretion and renin synthesis by a direct effect on renal juxtaglomerular cells.	Cyclosporine	26-40	renin	Rattus norvegicus	72-77
3423015-0	1987	Prolonged urinary excretion of 51chromium label from cyclosporine-pretreated human fetal splenocytes following infusion in the NOD mouse.	Cyclosporine	53-65	atrophin 1	Homo sapiens	127-130
2962343-1	1987	We examined the correlation between cyclosporine (CsA) levels and in vitro assays of immune function and hematopoiesis.	Cyclosporine	36-48	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	50-53
3680246-4	1987	Transcription studies in vitro indicated that S100 extracts from CsA-treated cells were unable to carry out faithful transcription of cloned mouse rDNA, even though RNA polymerase I levels of control and treated cell extracts were similar.	Cyclosporine	65-68	S100 calcium binding protein A1	Mus musculus	46-50
2958556-13	1987	These data suggest that, in respect to this particular T cell line, IL-1 is directly growth-promoting or, alternatively, induces the production of undetectable, intermediate growth factor(s) resistant to inhibition by cyclosporine A.	Cyclosporine	218-232	interleukin 1 complex	Mus musculus	68-72
3504965-3	1987	The simulation of the crystalline state (MDC) concerns a system of 4 unit cells containing 16 cyclosporin A molecules and 22 water molecules, which is simulated using crystalline periodic boundary conditions.	Cyclosporine	94-107	C-C motif chemokine ligand 22	Homo sapiens	41-44
3141538-10	1987	The guinea-pigs treated subcutaneously with EDTA and cyclosporin A showed the lowest antiserum titres to retinal S-antigen.	Cyclosporine	53-66	S-arrestin	Cavia porcellus	105-122
3500500-6	1987	Ciclosporin (CsA; 25 mg/kg/day per os) from the time of immunization, did not affect the incidence of W3/25+ cells in spleen or lymph nodes, but abrogated Cy-induced eosinophilia and reduced the extent of B-cell proliferation.	Cyclosporine	0-11	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	13-16
3672611-0	1987	Beneficial effects of calcium antagonist pretreatment and albumin infusion on cyclosporine A-induced impairment of kidney microcirculation in mice.	Cyclosporine	78-92	albumin	Mus musculus	58-65
3478162-3	1987	CsA profoundly reduced DTH skin reactions to SAg and PPD, and prevented vitreal inflammation assessed at 17 days and retinal damage.	Cyclosporine	0-3	S-arrestin	Cavia porcellus	45-48
3478162-4	1987	Lymphocytes from the draining lymph nodes but not spleens of immunized guinea pigs showed a proliferative response to SAg which was suppressed by CsA administration.	Cyclosporine	146-149	S-arrestin	Cavia porcellus	118-121
3620471-1	1987	This study examined the effects of the mitogen, prolactin and the cell cycle inhibitors, cyclosporin A and neomycin sulfate, on expression of the proto-oncogenes c-fos and c-myc in the rat lymphoma Nb-2 cell line.	Cyclosporine	89-102	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	172-177
3497063-6	1987	Also, the actual ratio between neutrophilic and monocyte/macrophage colonies was reduced when compared to cultures stimulated in the presence of CSA, indicating that IL-1 increased myeloid differentiation.	Cyclosporine	145-148	interleukin 1 complex	Mus musculus	166-170
3497063-8	1987	Cultures with anti-CSA demonstrated a reduced number of CFU-GM when plated in the presence of CSA but not with IL-1, demonstrating the specificity of IL-1 to stimulate CFU-GM in the presence of anti-CSA antibody.	Cyclosporine	19-22	interleukin 1 complex	Mus musculus	150-154
3497063-8	1987	Cultures with anti-CSA demonstrated a reduced number of CFU-GM when plated in the presence of CSA but not with IL-1, demonstrating the specificity of IL-1 to stimulate CFU-GM in the presence of anti-CSA antibody.	Cyclosporine	94-97	interleukin 1 complex	Mus musculus	150-154
3497063-8	1987	Cultures with anti-CSA demonstrated a reduced number of CFU-GM when plated in the presence of CSA but not with IL-1, demonstrating the specificity of IL-1 to stimulate CFU-GM in the presence of anti-CSA antibody.	Cyclosporine	94-97	interleukin 1 complex	Mus musculus	150-154
3096881-1	1986	The effect of cyclosporine A (CsA) on the mitogen-induced expression of Interleukin 2 receptor (IL2R) and transferrin receptor (TR) was monitored using receptor-specific monoclonal antibodies and flow cytometry.	Cyclosporine	30-33	interleukin 2 receptor subunit alpha	Homo sapiens	72-94
3096881-1	1986	The effect of cyclosporine A (CsA) on the mitogen-induced expression of Interleukin 2 receptor (IL2R) and transferrin receptor (TR) was monitored using receptor-specific monoclonal antibodies and flow cytometry.	Cyclosporine	30-33	interleukin 2 receptor subunit alpha	Homo sapiens	96-100
3096881-2	1986	For all mitogens tested (PHA, Con A, OKT3, and Leu 4), expression of IL2R and TR, as well as DNA synthesis (3H-thymidine incorporation), were significantly reduced in the presence of CsA (0.5 microgram/ml).	Cyclosporine	183-186	interleukin 2 receptor subunit alpha	Homo sapiens	69-73
3096881-3	1986	Titration experiments in the OKT3 system, the mitogen system most profoundly affected by CsA, revealed that CsA concentrations as low as 0.05 microgram/ml inhibited IL2R and TR expression and DNA synthesis, and that changes in DNA synthesis reflected changes in IL2R and TR expression.	Cyclosporine	108-111	interleukin 2 receptor subunit alpha	Homo sapiens	165-169
3096881-3	1986	Titration experiments in the OKT3 system, the mitogen system most profoundly affected by CsA, revealed that CsA concentrations as low as 0.05 microgram/ml inhibited IL2R and TR expression and DNA synthesis, and that changes in DNA synthesis reflected changes in IL2R and TR expression.	Cyclosporine	108-111	interleukin 2 receptor subunit alpha	Homo sapiens	262-266
3096881-4	1986	The addition of exogenous IL2 partially abrogated the CsA-mediated inhibition of all three activation parameters (IL2R, TR, DNA synthesis) in response to PHA, OKT3, and Leu 4.	Cyclosporine	54-57	interleukin 2 receptor subunit alpha	Homo sapiens	114-118
3096881-6	1986	These findings indicate that CsA inhibits mitogen-induced expression of IL2R and TR, and for some mitogen systems, this inhibition appears, at least in part, to be secondary to decreased IL2 production.	Cyclosporine	29-32	interleukin 2 receptor subunit alpha	Homo sapiens	72-76
3090749-0	1986	Increased factor VIII as an index of vascular injury in cyclosporine nephrotoxicity.	Cyclosporine	56-68	cytochrome c oxidase subunit 8A	Homo sapiens	17-21
3090749-1	1986	Very high plasma concentrations of factor-VIII-related antigen (RAG) (VIII-RAG) were found in renal allograft recipients during periods of nephrotoxicity induced by cyclosporine.	Cyclosporine	165-177	cytochrome c oxidase subunit 8A	Homo sapiens	42-46
3090749-1	1986	Very high plasma concentrations of factor-VIII-related antigen (RAG) (VIII-RAG) were found in renal allograft recipients during periods of nephrotoxicity induced by cyclosporine.	Cyclosporine	165-177	cytochrome c oxidase subunit 8A	Homo sapiens	70-74
3090749-2	1986	In eight recipients, who were investigated at weekly intervals, levels of factor-VIII-RAG fell toward normal as the dose of cyclosporine was reduced.	Cyclosporine	124-136	cytochrome c oxidase subunit 8A	Homo sapiens	81-85
3526606-1	1986	Endothelial injury associated with cyclosporine (CSA) therapy in the absence of rejection has resulted in irreversible intrarenal allograft thrombosis and transplant loss.	Cyclosporine	35-47	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	49-52
2874646-3	1986	Within 24 h, significant increases in urinary N-acetyl-beta-D-glucosaminidase (NAG) and gamma-glutamyl transpeptidase (gamma GT) activity were observed at both doses of CsA.	Cyclosporine	169-172	O-GlcNAcase	Rattus norvegicus	46-77
2874646-3	1986	Within 24 h, significant increases in urinary N-acetyl-beta-D-glucosaminidase (NAG) and gamma-glutamyl transpeptidase (gamma GT) activity were observed at both doses of CsA.	Cyclosporine	169-172	O-GlcNAcase	Rattus norvegicus	79-82
3519782-1	1986	The immunosuppressant cyclosporine (CSA) has shown usefulness in both animal and human transplantation.	Cyclosporine	22-34	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	36-39
3003975-1	1986	Cyclosporine (CsA), a potent immunosuppressant for the prevention of transplant rejection, modulates T lymphocyte activation by blocking antigen stimulation and the production of interleukin-2.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
3003976-1	1986	The effectiveness of cyclosporine (CsA) as immunosuppressive agent in human kidney graft rejection is well established.	Cyclosporine	21-33	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	35-38
6595666-1	1984	Total growth of transplanted human or rodent tumors in the subrenal capsule of mice was much improved by treatment with cyclosporine (CSA, cyclosporin A).	Cyclosporine	120-132	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	134-137
6237152-0	1984	Cyclosporine therapy of rat heart allograft recipients and release of interleukins (IL 1, IL 2, IL 3): a role for IL 3 in graft tolerance?	Cyclosporine	0-12	interleukin 3	Rattus norvegicus	114-118
6237152-1	1984	LEW rat recipients of (LEW X BN)F1 strain heterotopic cardiac transplants treated with cyclosporine A (CsA) (15 mg/kg/day intramuscularly, 7 days) retain grafts indefinitely despite drug withdrawal.	Cyclosporine	87-101	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	103-106
6385229-9	1984	The main difference between the cyclosporin group and the conventionally treated group was significantly elevated levels of factor VIII procoagulant antigen (VIII: CAg) (cyclosporin A treated group: VIII: CAg 435 +/- 145%, conventionally treated group: VIII: CAg 215 +/- 99%).	Cyclosporine	32-43	cytochrome c oxidase subunit 8A	Homo sapiens	131-135
6385229-9	1984	The main difference between the cyclosporin group and the conventionally treated group was significantly elevated levels of factor VIII procoagulant antigen (VIII: CAg) (cyclosporin A treated group: VIII: CAg 435 +/- 145%, conventionally treated group: VIII: CAg 215 +/- 99%).	Cyclosporine	32-43	cytochrome c oxidase subunit 8A	Homo sapiens	158-162
6385229-9	1984	The main difference between the cyclosporin group and the conventionally treated group was significantly elevated levels of factor VIII procoagulant antigen (VIII: CAg) (cyclosporin A treated group: VIII: CAg 435 +/- 145%, conventionally treated group: VIII: CAg 215 +/- 99%).	Cyclosporine	32-43	cytochrome c oxidase subunit 8A	Homo sapiens	158-162
6385229-9	1984	The main difference between the cyclosporin group and the conventionally treated group was significantly elevated levels of factor VIII procoagulant antigen (VIII: CAg) (cyclosporin A treated group: VIII: CAg 435 +/- 145%, conventionally treated group: VIII: CAg 215 +/- 99%).	Cyclosporine	32-43	cytochrome c oxidase subunit 8A	Homo sapiens	158-162
6385229-9	1984	The main difference between the cyclosporin group and the conventionally treated group was significantly elevated levels of factor VIII procoagulant antigen (VIII: CAg) (cyclosporin A treated group: VIII: CAg 435 +/- 145%, conventionally treated group: VIII: CAg 215 +/- 99%).	Cyclosporine	170-183	cytochrome c oxidase subunit 8A	Homo sapiens	131-135
6385229-9	1984	The main difference between the cyclosporin group and the conventionally treated group was significantly elevated levels of factor VIII procoagulant antigen (VIII: CAg) (cyclosporin A treated group: VIII: CAg 435 +/- 145%, conventionally treated group: VIII: CAg 215 +/- 99%).	Cyclosporine	170-183	cytochrome c oxidase subunit 8A	Homo sapiens	158-162
6385229-9	1984	The main difference between the cyclosporin group and the conventionally treated group was significantly elevated levels of factor VIII procoagulant antigen (VIII: CAg) (cyclosporin A treated group: VIII: CAg 435 +/- 145%, conventionally treated group: VIII: CAg 215 +/- 99%).	Cyclosporine	170-183	cytochrome c oxidase subunit 8A	Homo sapiens	158-162
6385229-9	1984	The main difference between the cyclosporin group and the conventionally treated group was significantly elevated levels of factor VIII procoagulant antigen (VIII: CAg) (cyclosporin A treated group: VIII: CAg 435 +/- 145%, conventionally treated group: VIII: CAg 215 +/- 99%).	Cyclosporine	170-183	cytochrome c oxidase subunit 8A	Homo sapiens	158-162
6231749-0	1984	The effect of cyclosporine on ornithine decarboxylase induction with mitogens, antigens, and lymphokines.	Cyclosporine	14-26	ornithine decarboxylase 1	Homo sapiens	30-53
6231749-4	1984	The immunosuppressive agent cyclosporine was found to inhibit both the mitogen and alloantigen stimulated induction of ODC in lymphocytes in a manner that parallels inhibition of subsequent 3H-thymidine incorporation.	Cyclosporine	28-40	ornithine decarboxylase 1	Homo sapiens	119-122
6231749-7	1984	Cyclosporine inhibited the induction of ODC when T lymphocytes were combined with monocytes or growth factors.	Cyclosporine	0-12	ornithine decarboxylase 1	Homo sapiens	40-43
6231749-9	1984	The inhibition of ODC induction and polyamine synthesis by cyclosporine adds insight into its mode of action on the mechanisms involved in early T cell activation.	Cyclosporine	59-71	ornithine decarboxylase 1	Homo sapiens	18-21
6371955-0	1984	Stimulation of renin release from rat renal cortical slices by cyclosporin A.	Cyclosporine	63-76	renin	Rattus norvegicus	15-20
6371955-1	1984	Cyclosporin A is known to produce increases in plasma and kidney renin in vivo.	Cyclosporine	0-13	renin	Rattus norvegicus	65-70
6984422-13	1982	The mitogenic responses of T cells induced by kappa, lambda and iota CGN were significantly inhibited by cyclosporin A (CyA) treatment (250 ng/ml) and Con A and PHA responses were also inhibited by CyA addition.	Cyclosporine	105-118	cingulin	Homo sapiens	69-72
6753070-0	1982	Cyclosporin A-induced increases in renin storage and release.	Cyclosporine	0-13	renin	Rattus norvegicus	35-40
6753070-2	1982	Renin release from incubated renal cortical slices was increased in rats treated with 25 or 50 mg/kg/day of CyA for 3 to 7 days.	Cyclosporine	108-111	renin	Rattus norvegicus	0-5
6980868-1	1982	Cyclosporin A (CSA) in vitro inhibited the spontaneous cytotoxic activity of mouse spleen cells against YAC target cells in a 4 hr 51Cr release assay.	Cyclosporine	0-13	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	15-18
34041632-2	2021	Recently, the drugs most commonly used for the treatment of psoriasis include methotrexate (MTX), cyclosporine (CsA), acitretin, dexamethasone, and salicylic acid.	Cyclosporine	98-110	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	112-115
32720851-0	2021	Successful treatment with cyclosporine and anti-tumour necrosis factor agent for deficiency of adenosine deaminase-2.	Cyclosporine	26-38	adenosine deaminase 2	Homo sapiens	95-116
33896035-2	2021	The aim of this study is analyzing the results of switching cyclosporine (CSA) to tacrolimus because of acute GvHD, engraftment syndrome (ES), persistent low level of CSA, or various CSA-associated adverse events in the first 100 days of pediatric HSCT.	Cyclosporine	60-72	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	74-77
33794964-1	2021	BACKGROUND: To evaluate cyclosporine A (CSA)-related neurotoxicity after haploidentical hematopoietic stem cell transplantation (HID-HSCT) in children with hematopathy.	Cyclosporine	24-38	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	40-43
33079185-5	2021	Among the chemicals and cytokines examined, in the presence of forskolin and rolipram, cyclosporine A (CsA) and fibroblast growth factors (FGFs: FGF2 and FGF10) effectively enhanced the expansion of mPGCLCs in vitro (~50-fold on average).	Cyclosporine	87-101	fibroblast growth factor 2	Mus musculus	145-149
32860837-13	2020	In addition, cyclosporine A prevented EMT induced by PMCA4 inhibition by suppressing the NFATc1-ZEB1 pathway.	Cyclosporine	13-27	ATPase plasma membrane Ca2+ transporting 4	Homo sapiens	53-58
32905741-3	2020	RESULTS: A significant increase was observed in CD2AP, ACTN4, podocin and also MMP9 and 2, cystatin C levels in the cyclosporine A group following treatment for four weeks, whereas a decrease was found in nephrin gene expression than the control group.	Cyclosporine	116-130	CD2-associated protein	Rattus norvegicus	48-53
33046783-4	2020	Indeed, CsA-sensitive tPT-mediated apoptosis could be induced by bisindolylpyrrole at > 5 muM in HeLa cells cultured in 0.1% FBS, depending on CypD and VDAC1/2, as shown by siRNA knockdown experiments.	Cyclosporine	8-11	voltage dependent anion channel 1	Homo sapiens	152-159
32449990-10	2020	CONCLUSION: Taken together, these results reveal for the first time Gal-8 as a fibrogenic stimulus exerted through beta1-integrin/FAK pathways in human gingival fibroblasts, which can be triggered by cyclosporine.	Cyclosporine	200-212	protein tyrosine kinase 2	Homo sapiens	130-133
32222391-13	2020	CONCLUSION: The study results suggest that in KTX metabolic transformations and transport, especially of cyclosporine, dependence on the genetic variability of CYP3A4, UGT1A9, and MDR1 may contribute to kidney damage.	Cyclosporine	105-117	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	168-174
32569592-9	2020	In addition, exposure to CsA resulted in an increased expression of Bax, and a decreased expresion in that of Bcl-2, with a concomitant up-regulation of the Bax/Bcl-2, c-Caspase-3/p-Caspase-3 ratio and cytochrome c level.	Cyclosporine	25-28	caspase 3	Rattus norvegicus	170-179
33134777-4	2020	Results: Samples containing FVIII products (NovoEight, Elocta, and Nuwiq) gave higher levels when measured with CSA compared to OSA.	Cyclosporine	112-115	coagulation factor VIII	Homo sapiens	28-33
32162654-2	2020	Since the immunosuppressant cyclosporine-A produces pEMT in TECs and inhibits the peptidyl-prolyl isomerase (PPIase) activity of cyclophilin (Cyp) proteins, we hypothesized that cyclophilins could regulate TEC phenotype.	Cyclosporine	28-42	peptidyl-prolyl isomerase G (cyclophilin G)	Mus musculus	129-140
32162654-2	2020	Since the immunosuppressant cyclosporine-A produces pEMT in TECs and inhibits the peptidyl-prolyl isomerase (PPIase) activity of cyclophilin (Cyp) proteins, we hypothesized that cyclophilins could regulate TEC phenotype.	Cyclosporine	28-42	peptidyl-prolyl isomerase G (cyclophilin G)	Mus musculus	142-145
31680236-7	2020	RESULTS: CsA suppressed the proliferation of hPDLSCs but enhanced osteogenic differentiation as determined by ALP and ARS staining and PCR of osteogenic transcripts.	Cyclosporine	9-12	RIEG2	Homo sapiens	118-121
32058973-8	2020	In parallel, chemical inhibition of the Cam/Calcineurin pathway by Cyclosporin A or FK506 also reduces CDTa phenotypes, potentially opening new avenues for treating CDIs.	Cyclosporine	67-80	Calcineurin A1	Drosophila melanogaster	44-55
32049108-8	2020	At 15 days, less bone formation was observed in the CSDs filled with DBB, a smaller volume of mineralized tissue was observed in the CSDs filled with HA/TCP, and the expression levels of BMP2 and osteocalcin were lower in the CCP group compared to the CTR group.	Cyclosporine	226-229	bone morphogenetic protein 2	Rattus norvegicus	187-191
32049108-9	2020	The use of cyclosporine impaired bone repair in CSD, and this effect can be partially explained by the suppression of BMP2 and osteocalcin expression.	Cyclosporine	11-23	bone morphogenetic protein 2	Rattus norvegicus	118-122
31634673-5	2020	EXPERIMENTS: Here, the competition between the monovalent Cs+ and the divalent Ca2+ cation for adsorption at the muscovite mica basal plane was investigated using surface X-ray diffraction.	Cyclosporine	58-60	MHC class I polypeptide-related sequence A	Homo sapiens	123-127
31283681-1	2020	BACKGROUND: After patients receive hematopoietic stem cell transplantation (HSCT), both cyclosporine (CsA) and tacrolimus (TAC) in combination with methotrexate (MTX) are recommended as the standard prophylaxis strategy for graft-versus-host disease (GVHD) by the European Group of Blood and Marrow Transplantation (EBMT).	Cyclosporine	88-100	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	102-105
31930240-0	2020	A first principles study of the spin-orbit coupling effect in LiM (M = Na, K, Rb, Cs) molecules.	Cyclosporine	82-84	PDZ and LIM domain 5	Homo sapiens	62-65
31930240-1	2020	The spin-orbit (SO) interactions in low-lying electronic states of the LiM (M = Na, K, Rb, Cs) molecular series are studied through ab initio calculations of potential energy curves and SO coupling matrix elements as functions of the interatomic distance, R. Two different approaches are employed: (a) the Fock-space relativistic coupled-cluster calculations (FS-RCC) which directly yield full relativistic energies, Urel(R); the SO coupling functions, xiso(R), are extracted a posteriori through projecting scalar-relativistic wave functions onto the subspaces spanned by their full-relativistic counterparts; (b) the evaluation of the scalar-relativistic electronic energies, Usr(R), and relevant xiso(R) functions using the configuration interaction method with core-valence correlation accounted for using core polarization potentials (CI-CPP).	Cyclosporine	91-93	PDZ and LIM domain 5	Homo sapiens	71-74
31880435-8	2020	Thus, the extent and the relative rate of the NH4+ ion exchange in [NH4   {Co2(Lcat)3}](PF6) by Cs+ and K+ ions across the organic/aqueous phase boundary at room temperature have been studied by in situ 59Co NMR experiments.	Cyclosporine	96-98	sperm associated antigen 17	Homo sapiens	88-91
31963361-9	2020	The administration of cyclosporine A was followed by down-regulation of other genes: COL7A1, the transmembrane receptors ITGB2 and ITGB4, and the basement membrane constituents LAMA2 and LAMB1.	Cyclosporine	22-36	integrin subunit beta 4	Homo sapiens	131-136
31963361-9	2020	The administration of cyclosporine A was followed by down-regulation of other genes: COL7A1, the transmembrane receptors ITGB2 and ITGB4, and the basement membrane constituents LAMA2 and LAMB1.	Cyclosporine	22-36	laminin subunit alpha 2	Homo sapiens	177-182
31794606-5	2020	Intriguingly, although NFAT is activated in both DLBCL subtypes, long-term calcineurin inhibition with cyclosporin A or FK506, both clinically approved drugs, triggers potent cytotoxicity specifically in ABC DLBCL cells.	Cyclosporine	103-116	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	204-207
31339772-6	2019	Inhibition of mPTP opening using the CypD inhibitor cyclosporin A or siRNA for p53 in ATP-depleted HK-2 cells prevented mitochondrial membrane depolarization and reduced apoptosis.	Cyclosporine	52-65	peptidylprolyl isomerase F	Rattus norvegicus	37-41
31495071-4	2019	5-ALA/SFC significantly inhibited apoptosis in CsA-treated mProx24 cells with increases in heme oxygenase (HO)-1, nuclear factor E2-related factor 2 (Nrf2), and p38, and Erk-1/2 phosphorylation.	Cyclosporine	47-50	mitogen-activated protein kinase 14	Mus musculus	161-164
31495071-4	2019	5-ALA/SFC significantly inhibited apoptosis in CsA-treated mProx24 cells with increases in heme oxygenase (HO)-1, nuclear factor E2-related factor 2 (Nrf2), and p38, and Erk-1/2 phosphorylation.	Cyclosporine	47-50	mitogen-activated protein kinase 3	Mus musculus	170-177
31446206-10	2019	Suppression of IL-2 and IFN-gamma in activated T cells may have potential as an indicator of the efficacy of cyclosporine and glucocorticoids in suppressing canine T cell function in vivo, and may therefore be of value for characterizing the immunosuppression induced by these drugs in clinical patients.	Cyclosporine	109-121	interleukin 2	Canis lupus familiaris	15-19
31540546-8	2019	The FGF23-mediated hypertrophic growth of NRVM and induction of NFAT target genes were attenuated by cyclosporine A, losartan and spironolactone.	Cyclosporine	101-115	fibroblast growth factor 23	Rattus norvegicus	4-9
31085229-0	2019	Neonatal treatment with cyclosporine A restores neurogenesis and spinogenesis in the Ts65Dn model of Down syndrome.	Cyclosporine	24-38	reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65	Mus musculus	85-91
31085229-5	2019	In the framework of an in vitro drug-screening campaign of FDA/EMA-approved drugs, we found that the immunosuppressant cyclosporine A (CSA) restored proliferation, acquisition of a neuronal phenotype, and maturation of neural progenitor cells (NPCs) from the subventricular zone (SVZ) of the lateral ventricle of Ts65Dn mice.	Cyclosporine	119-133	reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65	Mus musculus	313-319
31085229-5	2019	In the framework of an in vitro drug-screening campaign of FDA/EMA-approved drugs, we found that the immunosuppressant cyclosporine A (CSA) restored proliferation, acquisition of a neuronal phenotype, and maturation of neural progenitor cells (NPCs) from the subventricular zone (SVZ) of the lateral ventricle of Ts65Dn mice.	Cyclosporine	135-138	reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65	Mus musculus	313-319
31085229-6	2019	Based on these findings, we treated Ts65Dn mice with CSA in the postnatal period P3-P15.	Cyclosporine	53-56	reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65	Mus musculus	36-42
31085229-9	2019	In hippocampal homogenates from Ts65Dn mice, we found that CSA normalized the excessive levels of p21, a key determinant of proliferation impairment.	Cyclosporine	59-62	reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65	Mus musculus	32-38
31243130-1	2019	Previously, the cyclophilin inhibitors cyclosporine (CsA) and alisporivir (ALV) were shown to inhibit the replication of diverse RNA viruses, including arteriviruses and coronaviruses, which both belong to the order Nidovirales In this study, we aimed to identify arterivirus proteins involved in the mode of action of cyclophilin inhibitors and to investigate how these compounds inhibit arterivirus RNA synthesis in the infected cell.	Cyclosporine	39-51	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	53-56
31243130-8	2019	Previously, the cyclophilin inhibitors cyclosporine (CsA) and alisporivir (ALV) were shown to inhibit the replication of diverse nidoviruses (both arteriviruses and coronaviruses), and they may thus represent a class of pan-nidovirus inhibitors.	Cyclosporine	39-51	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	53-56
31489369-4	2019	Liver mitochondria from Ant1, Ant2, and Ant4 deficient mice were highly refractory to Ca2+-induced MPTP formation, and when also given cyclosporine A (CsA), the MPTP was completely inhibited.	Cyclosporine	135-149	solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 5	Mus musculus	30-34
31489369-4	2019	Liver mitochondria from Ant1, Ant2, and Ant4 deficient mice were highly refractory to Ca2+-induced MPTP formation, and when also given cyclosporine A (CsA), the MPTP was completely inhibited.	Cyclosporine	151-154	solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 5	Mus musculus	30-34
31028822-3	2019	We demonstrate that cyclosporine therapy activated the IRE1alpha branch of the unfolded protein response (UPR) and stimulated the TGFbeta1 signaling pathway in the kidneys of male mice.	Cyclosporine	20-32	endoplasmic reticulum (ER) to nucleus signalling 1	Mus musculus	55-64
31028822-3	2019	We demonstrate that cyclosporine therapy activated the IRE1alpha branch of the unfolded protein response (UPR) and stimulated the TGFbeta1 signaling pathway in the kidneys of male mice.	Cyclosporine	20-32	transforming growth factor, beta 1	Mus musculus	130-138
30977158-1	2019	OBJECTIVE: Immunosuppressive therapy (IST) with horse anti-thymocyte globulin (hATG) and cyclosporine (CsA) is considered one of the first-line therapies in patients (pts) with acquired aplastic anemia (AA).	Cyclosporine	89-101	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	103-106
31213546-2	2019	Cyclosporin A inhibits pore opening by binding to cyclophilin D, which interacts with the pore.	Cyclosporine	0-13	peptidylprolyl isomerase D	Homo sapiens	50-63
30664361-13	2019	CONCLUSIONS: This study indicates that the three CsA formulations effectively modulated TLR4, TGFbeta1, IL1, and IL6 pathways to reduce corneal epithelium lesions in a mouse model of severe dry eye.	Cyclosporine	49-52	transforming growth factor, beta 1	Mus musculus	94-102
30664361-13	2019	CONCLUSIONS: This study indicates that the three CsA formulations effectively modulated TLR4, TGFbeta1, IL1, and IL6 pathways to reduce corneal epithelium lesions in a mouse model of severe dry eye.	Cyclosporine	49-52	interleukin 1 complex	Mus musculus	104-107
30663866-4	2019	After ciclosporin treatment, IL-10, IFNgamma and TNFalpha production was significantly reduced after stimulation with PMA/I compared to pre-treatment.	Cyclosporine	6-17	interleukin 10	Canis lupus familiaris	29-34
30659827-8	2019	More interestingly, DN3 mediated MMP decrease, release of cytochrome c, the expression of VDAC and CypD and apoptosis were blocked by the pretreatment of VDAC1 inhibitor (4, 4"-diisothiocyanatostilbene-2,2"-disulfonic acid, DIDS) and CypD inhibitor (cyclosporine A, CsA).	Cyclosporine	250-264	voltage dependent anion channel 1	Homo sapiens	154-159
30659827-8	2019	More interestingly, DN3 mediated MMP decrease, release of cytochrome c, the expression of VDAC and CypD and apoptosis were blocked by the pretreatment of VDAC1 inhibitor (4, 4"-diisothiocyanatostilbene-2,2"-disulfonic acid, DIDS) and CypD inhibitor (cyclosporine A, CsA).	Cyclosporine	266-269	voltage dependent anion channel 1	Homo sapiens	154-159
30542943-2	2019	Prophylaxis with cyclosporine A (CsA) is the backbone of GvHD prevention.	Cyclosporine	17-31	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	33-36
30879580-13	2019	CONCLUSION: Rituximab and switching tacrolimus to cyclosporine, in conjunction with plasmapheresis, appeared to be effective and safe in children with recurrent FSGS.	Cyclosporine	50-62	actinin alpha 4	Homo sapiens	161-165
30378503-14	2019	We also demonstrated that CsA could inhibit the expression of NFATc1 and its downstream genes COX-2, c-Myc, MMP-9, and MMP-2 in OSCC cells.	Cyclosporine	26-29	matrix metallopeptidase 2	Homo sapiens	119-124
30403017-9	2018	In western blot, caspase-3 was significantly increased in MCT group, and was attenuated in CsA treatment.	Cyclosporine	91-94	caspase 3	Rattus norvegicus	17-26
30481230-1	2018	Cyclosporine A (CsA), a widely used immunosuppressive drug, exerts nephrotoxic activities, as demonstrated by increased tubulointerstitial fibrosis, inflammation and podocyte damage.	Cyclosporine	0-14	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	16-19
30713473-1	2018	Cyclosporin A (CsA) is known to have an immunosuppressive action.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
30420769-0	2018	Cyclosporine A binding to COX-2 reveals a novel signaling pathway that activates the IRE1alpha unfolded protein response sensor.	Cyclosporine	0-14	cytochrome c oxidase II, mitochondrial	Mus musculus	26-31
30420769-0	2018	Cyclosporine A binding to COX-2 reveals a novel signaling pathway that activates the IRE1alpha unfolded protein response sensor.	Cyclosporine	0-14	endoplasmic reticulum (ER) to nucleus signalling 1	Mus musculus	85-94
30420769-4	2018	Molecular interaction and modeling analyses identified a novel interaction site for cyclosporine with COX-2 which caused enhancement of COX-2 enzymatic activity required for activation of the IRE1alpha branch of the UPR.	Cyclosporine	84-96	cytochrome c oxidase II, mitochondrial	Mus musculus	102-107
30420769-4	2018	Molecular interaction and modeling analyses identified a novel interaction site for cyclosporine with COX-2 which caused enhancement of COX-2 enzymatic activity required for activation of the IRE1alpha branch of the UPR.	Cyclosporine	84-96	cytochrome c oxidase II, mitochondrial	Mus musculus	136-141
30420769-4	2018	Molecular interaction and modeling analyses identified a novel interaction site for cyclosporine with COX-2 which caused enhancement of COX-2 enzymatic activity required for activation of the IRE1alpha branch of the UPR.	Cyclosporine	84-96	endoplasmic reticulum (ER) to nucleus signalling 1	Mus musculus	192-201
30420769-5	2018	Cyclosporine-dependent activation of COX-2 and IRE1alpha in mice indicated that cyclosporine-COX-2-IRE1alpha signaling pathway was functional in vivo.	Cyclosporine	0-12	cytochrome c oxidase II, mitochondrial	Mus musculus	37-42
30420769-5	2018	Cyclosporine-dependent activation of COX-2 and IRE1alpha in mice indicated that cyclosporine-COX-2-IRE1alpha signaling pathway was functional in vivo.	Cyclosporine	0-12	endoplasmic reticulum (ER) to nucleus signalling 1	Mus musculus	47-56
30420769-5	2018	Cyclosporine-dependent activation of COX-2 and IRE1alpha in mice indicated that cyclosporine-COX-2-IRE1alpha signaling pathway was functional in vivo.	Cyclosporine	0-12	cytochrome c oxidase II, mitochondrial	Mus musculus	93-98
30420769-5	2018	Cyclosporine-dependent activation of COX-2 and IRE1alpha in mice indicated that cyclosporine-COX-2-IRE1alpha signaling pathway was functional in vivo.	Cyclosporine	0-12	endoplasmic reticulum (ER) to nucleus signalling 1	Mus musculus	99-108
30420769-5	2018	Cyclosporine-dependent activation of COX-2 and IRE1alpha in mice indicated that cyclosporine-COX-2-IRE1alpha signaling pathway was functional in vivo.	Cyclosporine	80-92	cytochrome c oxidase II, mitochondrial	Mus musculus	37-42
30420769-5	2018	Cyclosporine-dependent activation of COX-2 and IRE1alpha in mice indicated that cyclosporine-COX-2-IRE1alpha signaling pathway was functional in vivo.	Cyclosporine	80-92	endoplasmic reticulum (ER) to nucleus signalling 1	Mus musculus	47-56
30420769-5	2018	Cyclosporine-dependent activation of COX-2 and IRE1alpha in mice indicated that cyclosporine-COX-2-IRE1alpha signaling pathway was functional in vivo.	Cyclosporine	80-92	cytochrome c oxidase II, mitochondrial	Mus musculus	93-98
30420769-5	2018	Cyclosporine-dependent activation of COX-2 and IRE1alpha in mice indicated that cyclosporine-COX-2-IRE1alpha signaling pathway was functional in vivo.	Cyclosporine	80-92	endoplasmic reticulum (ER) to nucleus signalling 1	Mus musculus	99-108
30420769-6	2018	These findings identify COX-2 as a new IRE1alpha binding partner and regulator of the IRE1alpha branch of the UPR pathway, and establishes the mechanism underlying cytotoxicity associated with chronic cyclosporine exposure.	Cyclosporine	201-213	cytochrome c oxidase II, mitochondrial	Mus musculus	24-29
30420769-6	2018	These findings identify COX-2 as a new IRE1alpha binding partner and regulator of the IRE1alpha branch of the UPR pathway, and establishes the mechanism underlying cytotoxicity associated with chronic cyclosporine exposure.	Cyclosporine	201-213	endoplasmic reticulum (ER) to nucleus signalling 1	Mus musculus	39-48
30420769-6	2018	These findings identify COX-2 as a new IRE1alpha binding partner and regulator of the IRE1alpha branch of the UPR pathway, and establishes the mechanism underlying cytotoxicity associated with chronic cyclosporine exposure.	Cyclosporine	201-213	endoplasmic reticulum (ER) to nucleus signalling 1	Mus musculus	86-95
30007437-5	2018	This study evaluates whether the expressions of matrix metalloproteinases (MMP-2 and MMP-9) induced by CsA are calcineurin isoform specific.	Cyclosporine	103-106	matrix metallopeptidase 2	Homo sapiens	75-80
29605535-14	2018	Resveratrol also increases levels of osteocalcin and osteopontin in normal and CsA-treated rats.	Cyclosporine	79-82	secreted phosphoprotein 1	Rattus norvegicus	53-64
29594315-2	2018	We previously reported that MITA correctly reflected the change in mRNA of human whole-blood cells treated with dexamethasone, cyclosporine, FK506, or several other immunosuppressive drugs.	Cyclosporine	127-139	stimulator of interferon response cGAMP interactor 1	Mus musculus	28-32
29550215-5	2018	We also demonstrate that an estrogen receptor beta (ERbeta) antagonist inhibits MPT and knockout of ERbeta decreases the sensitivity of mitochondria to the CypD inhibitor, cyclosporine A.	Cyclosporine	172-186	estrogen receptor 2 (beta)	Mus musculus	100-106
29333572-12	2018	Moreover, kidney caspase-3 expression that was triggered by CSA and/or gamma radiation was decreased.	Cyclosporine	60-63	caspase 3	Rattus norvegicus	17-26
29051147-0	2018	Organic Anion-Transporting Polypeptide (OATP)-Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver.	Cyclosporine	108-122	solute carrier organic anion transporter family, member 1a6	Mus musculus	0-38
29051147-0	2018	Organic Anion-Transporting Polypeptide (OATP)-Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver.	Cyclosporine	108-122	solute carrier organic anion transporter family, member 1a6	Mus musculus	40-44
29051147-2	2018	Cyclosporine A, a strong OATP inhibitor, has been reported to increase the systemic exposure of rosuvastatin, an OATP substrate, by 7.1-fold in clinical studies.	Cyclosporine	0-14	solute carrier organic anion transporter family, member 1a6	Mus musculus	25-29
29051147-2	2018	Cyclosporine A, a strong OATP inhibitor, has been reported to increase the systemic exposure of rosuvastatin, an OATP substrate, by 7.1-fold in clinical studies.	Cyclosporine	0-14	solute carrier organic anion transporter family, member 1a6	Mus musculus	113-117
28158898-2	2018	Previously we have shown (i) cyclosporine-inducing ER stress in human gingival fibroblasts (HGF), (ii) increased matrix protein expression, and (iii) interference with mitochondrial pro- and anti-apoptotic factors.	Cyclosporine	29-41	hepatocyte growth factor	Homo sapiens	92-95
28158898-4	2018	HGF incubated with cyclosporine, or without melatonin/4PBA/statin.	Cyclosporine	19-31	hepatocyte growth factor	Homo sapiens	0-3
29069656-4	2018	CsA induced the inhibition of lipopolysaccharide- induced activation of collecting duct cells due to the downregulation of the expression of TLR4 via the microRNA Let-7i.	Cyclosporine	0-3	microRNA let-7i	Homo sapiens	154-169
29069656-6	2018	This effect was also observed in CsA-treated infected kidneys, where the expression of Let-7i was increased.	Cyclosporine	33-36	microRNA let-7i	Homo sapiens	87-93
29069656-7	2018	Treatment with a synthetic Let-7i mimic reproduced the effects of CsA.	Cyclosporine	66-69	microRNA let-7i	Homo sapiens	27-33
29069656-8	2018	Conversely, pretreatment with an anti-Let-7i antagonised the effects of CsA and rescued the innate immune response of collecting duct cells against UPEC.	Cyclosporine	72-75	microRNA let-7i	Homo sapiens	38-44
29069656-9	2018	Thus, the utilisation of an anti-Let-7i during kidney transplantation may protect CsA-treated patients from ascending bacterial infection.	Cyclosporine	82-85	microRNA let-7i	Homo sapiens	33-39
29629324-0	2018	Immunohistochemical Analysis of the Role Connective Tissue Growth Factor in Drug-induced Gingival Overgrowth in Response to Phenytoin, Cyclosporine, and Nifedipine.	Cyclosporine	135-147	cellular communication network factor 2	Homo sapiens	41-72
29629324-1	2018	Objective: To evaluate for the presence of connective tissue growth factor (CTGF) in drug (phenytoin, cyclosporine, and nifedipine)-induced gingival overgrowth (DIGO) and to compare it with healthy controls in the absence of overgrowth.	Cyclosporine	102-114	cellular communication network factor 2	Homo sapiens	43-74
29629324-1	2018	Objective: To evaluate for the presence of connective tissue growth factor (CTGF) in drug (phenytoin, cyclosporine, and nifedipine)-induced gingival overgrowth (DIGO) and to compare it with healthy controls in the absence of overgrowth.	Cyclosporine	102-114	cellular communication network factor 2	Homo sapiens	76-80
29629324-9	2018	In the study, we compared the levels of CTGF in DIGO induced by three most commonly used drugs phenytoin, cyclosporine, and nifedipine.	Cyclosporine	106-118	cellular communication network factor 2	Homo sapiens	40-44
29629324-10	2018	By comparing the levels of CTGF, we find that cyclosporine induces the production of least amount of CTGF.	Cyclosporine	46-58	cellular communication network factor 2	Homo sapiens	27-31
29629324-10	2018	By comparing the levels of CTGF, we find that cyclosporine induces the production of least amount of CTGF.	Cyclosporine	46-58	cellular communication network factor 2	Homo sapiens	101-105
29237963-1	2017	BACKGROUND: Trough cyclosporine (CsA) blood level can influence incidence of graft-versus-host disease (GVHD) and relapse in patients with acute leukemia undergoing allogeneic hematopoietic stem cell transplant (HSCT).	Cyclosporine	19-31	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	33-36
28913661-3	2017	In this study, we generated an energy-based pharmacophore model by using the crystal structure of CypD-cyclosporine A (CsA) complex and performed virtual screening of ChemDiv database, which yielded forty-five potential hit compounds with novel scaffolds.	Cyclosporine	119-122	peptidylprolyl isomerase D	Homo sapiens	98-102
2226679-0	1990	Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multidrug-resistant human leukemic cell lines and normal bone marrow.	Cyclosporine	61-73	host cell factor C1	Homo sapiens	25-30
2226679-5	1990	However, cyclosporine specifically enhanced the cytotoxicity of VP-16 in the MDR leukemia cells, reducing the IC-50 to the same level as the parental sensitive cells.	Cyclosporine	9-21	host cell factor C1	Homo sapiens	64-69
2226679-7	1990	In a mixing experiment that included K562/DOX cells and normal bone marrow, cyclosporine increased the toxicity of VP-16 to the resistant leukemic cells by nearly 20-fold.	Cyclosporine	76-88	host cell factor C1	Homo sapiens	115-120
1826940-1	1991	Effect of the immunosuppressive agent, ciclosporin (CS), on bovine serum albumin (BSA) nephritis in rats was evaluated.	Cyclosporine	52-54	albumin	Rattus norvegicus	67-80
2080714-5	1990	From the analysis of the colonies induced in semisolid medium by multi-CSA and recombinant murine granulocyte-macrophage colony stimulating factor (rmGM-CSF), a dose-dependent disappearance specific to the macrophage-containing colonies emerged.	Cyclosporine	71-74	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	98-146
28516402-1	2017	Calcineurin inhibitors (CIs) such as cyclosporine A (CSA) and tacrolimus often cause renal dysfunction, resulting in increased serum creatinine, hyperkalemia, and hyperuricemia.	Cyclosporine	37-51	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	53-56
2197329-3	1990	Cyclosporin A is thought to inhibit transcription that suggests that IL-2 and IL-3 are regulated primarily at the transcriptional level while GM-CSF is not.	Cyclosporine	0-13	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	142-148
1972761-0	1990	Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine.	Cyclosporine	149-161	ATP binding cassette subfamily B member 4	Homo sapiens	23-27
28373092-1	2017	The aim of this study was to investigate whether Cyclosporine A (CsA) attenuates early brain injury by alleviating matrix metalloproteinase 9 (MMP-9) associated blood-brain barrier (BBB) disruption after subarachnoid hemorrhage (SAH).	Cyclosporine	65-68	matrix metallopeptidase 9	Mus musculus	115-141
28373092-1	2017	The aim of this study was to investigate whether Cyclosporine A (CsA) attenuates early brain injury by alleviating matrix metalloproteinase 9 (MMP-9) associated blood-brain barrier (BBB) disruption after subarachnoid hemorrhage (SAH).	Cyclosporine	65-68	matrix metallopeptidase 9	Mus musculus	143-148
28373092-6	2017	Our results suggest that CsA exert a neuroprotective role in SAH pathophysiology, possibly by alleviating MMP-9 associated BBB disruption.	Cyclosporine	25-28	matrix metallopeptidase 9	Mus musculus	106-111
1972761-4	1990	In vitro drug uptake studies by on-line flow cytometry showed that in leukemia cells expressing either mdr1 or mdr3, the steady-state accumulation of daunorubicin could be significantly increased by addition of cyclosporine and, to a lesser extent, by verapamil.	Cyclosporine	211-223	ATP binding cassette subfamily B member 4	Homo sapiens	111-115
27451286-3	2017	Using an mRNA microarray on microdissected tubules from a rat model of cyclosporin A toxicity to describe the related epithelial-specific transcriptional signature in vivo, we found that cyclosporin A induces pathways dependent on the transcription factor ATF4 and identified nuclear protein transcriptional regulator 1 (Nupr1), a stress response gene induced by ATF4, as the gene most strongly upregulated.	Cyclosporine	187-200	nuclear protein 1, transcriptional regulator	Rattus norvegicus	276-319
1972761-5	1990	Because cyclosporine and verapamil are known as inhibitors of the mdr1-encoded P-glycoprotein drug-efflux pump, and because the mdr1 and mdr3 genes are highly homologous, our data suggest that the mdr3 gene encodes a functional drug pump in B-cell lymphocytic leukemias.	Cyclosporine	8-20	ATP binding cassette subfamily B member 4	Homo sapiens	197-201
27451286-3	2017	Using an mRNA microarray on microdissected tubules from a rat model of cyclosporin A toxicity to describe the related epithelial-specific transcriptional signature in vivo, we found that cyclosporin A induces pathways dependent on the transcription factor ATF4 and identified nuclear protein transcriptional regulator 1 (Nupr1), a stress response gene induced by ATF4, as the gene most strongly upregulated.	Cyclosporine	187-200	nuclear protein 1, transcriptional regulator	Rattus norvegicus	321-326
2140386-7	1990	In addition, lymphokine production by TH1 clones was more sensitive to inhibition by cholera toxin, 8-bromoadenosine 3":5"-cyclic monophosphate, and cyclosporin A than was lymphokine production by TH2 clones.	Cyclosporine	149-162	negative elongation factor complex member C/D	Homo sapiens	38-41
27771871-6	2017	Administration of either IPostC or CsA alone in nondiabetic animals significantly reduced CK, TNF-alpha, IL-1beta, and IL-6 concentrations, increased the p-GSK3beta and Bcl-2, and decreased the level of apoptosis (P &lt; 0.05) but had no effect on diabetic hearts.	Cyclosporine	35-38	glycogen synthase kinase 3 beta	Rattus norvegicus	156-164
2344354-9	1990	At higher [Ca2+] (greater than 0.3 microM), swelling became progressively inhibited by cyclosporin, although the increase in matrix PPi was slightly greater in the presence than in the absence of cyclosporin.	Cyclosporine	87-98	carbonic anhydrase 2	Homo sapiens	11-14
28736029-7	2017	Urinary NGAL excretion also increased significantly in the CsA group.	Cyclosporine	59-62	lipocalin 2	Rattus norvegicus	8-12
27904031-3	2016	We examined the interaction between TS andALDH2*2as a risk factor for CSA to better understand the disease pathogenesis.Methods and Results:The study subjects comprised 410 patients (258 men, 152 women; mean age, 66.3+-11.5) in whom intracoronary injection of acetylcholine was performed on suspicion of CSA.ALDH2genotyping was performed by direct application of the Taqman polymerase chain reaction system.	Cyclosporine	70-73	aldehyde dehydrogenase 2 family member	Homo sapiens	42-47
2344354-17	1990	It is suggested that there are two mechanisms for the increase in mitochondrial volume induced by Ca2+: a PPi-mediated mechanism that is insensitive to cyclosporin and an additional Ca2(+)-mediated effect that is inhibited by cyclosporin.	Cyclosporine	152-163	carbonic anhydrase 2	Homo sapiens	98-101
27904031-6	2016	Multivariable logistic regression analysis revealed thatALDH2*2and TS were significant risk factors for CSA (P&lt;0.001 and P=0.002, respectively).ALDH2*2exacerbated TS risk for CSA more than the multiplicative effects of each.	Cyclosporine	104-107	aldehyde dehydrogenase 2 family member	Homo sapiens	56-61
27904031-7	2016	CONCLUSIONS: ALDH2*2synergistically exacerbates TS risk for CSA, probably through aldehydes.	Cyclosporine	60-63	aldehyde dehydrogenase 2 family member	Homo sapiens	13-18
2344354-17	1990	It is suggested that there are two mechanisms for the increase in mitochondrial volume induced by Ca2+: a PPi-mediated mechanism that is insensitive to cyclosporin and an additional Ca2(+)-mediated effect that is inhibited by cyclosporin.	Cyclosporine	226-237	carbonic anhydrase 2	Homo sapiens	98-101
2344354-17	1990	It is suggested that there are two mechanisms for the increase in mitochondrial volume induced by Ca2+: a PPi-mediated mechanism that is insensitive to cyclosporin and an additional Ca2(+)-mediated effect that is inhibited by cyclosporin.	Cyclosporine	226-237	carbonic anhydrase 2	Homo sapiens	182-185
2141571-5	1990	However, up-regulation of IL 4R by its own ligand or IL 2 and the growth-promoting effect of IL 4 on activated, IL 4R+ T cells were CsA resistant.	Cyclosporine	132-135	interleukin 4 receptor	Homo sapiens	112-117
2141571-7	1990	It is concluded that the inhibitory effect of CsA on IL 4R expression may contribute to the immunosuppressive effect of the drug.	Cyclosporine	46-49	interleukin 4 receptor	Homo sapiens	53-58
1971791-2	1990	CsA specifically inhibited the generation of cells expressing high levels of alpha/beta TcR/CD3 complexes and a mature phenotype defined by CD4 and CD8 surface markers.	Cyclosporine	0-3	CD8a molecule	Homo sapiens	148-151
2180152-0	1990	Inhibition of insulin release by cyclosporine and production of peripheral insulin resistance in the dog.	Cyclosporine	33-45	insulin	Canis lupus familiaris	14-21
2180152-11	1990	The areas under the insulin curve (AUCI) for 0-20 min of the insulin response curve were 2033 +/- 203, 1089 +/- 187, 1038 +/- 179, and 972 +/- 161 uU/min/dl at 0, 2, 6, and 10 weeks, P(F3, 15 = 13.1) less than 0.001, indicating a 50% reduction during CsA treatment.	Cyclosporine	251-254	insulin	Canis lupus familiaris	20-27
2180152-11	1990	The areas under the insulin curve (AUCI) for 0-20 min of the insulin response curve were 2033 +/- 203, 1089 +/- 187, 1038 +/- 179, and 972 +/- 161 uU/min/dl at 0, 2, 6, and 10 weeks, P(F3, 15 = 13.1) less than 0.001, indicating a 50% reduction during CsA treatment.	Cyclosporine	251-254	insulin	Canis lupus familiaris	61-68
2180152-12	1990	CsA did not affect basal Rd, but peripheral insulin resistance was noted in the insulin-stimulated state.	Cyclosporine	0-3	insulin	Canis lupus familiaris	80-87
2180152-17	1990	CsA administration produces abnormal glucose homeostasis by reducing pancreatic insulin release, in addition to inducing peripheral insulin resistance.	Cyclosporine	0-3	insulin	Canis lupus familiaris	80-87
2309333-0	1990	Decreased kallikrein excretion in renal transplant treated with cyclosporine A.	Cyclosporine	64-78	kallikrein related peptidase 4	Homo sapiens	10-20
27564782-4	2016	Cyclosporine-based IS was associated with increased risks of pneumonia (aHR 1.17; P &lt; 0.001), sepsis (aHR 1.16; P &lt; 0.001), AR (aOR 1.43; P &lt; 0.001), and graft failure (aHR 1.39; P &lt; 0.001), but less diabetes (aHR 0.83; P &lt; 0.001).	Cyclosporine	0-12	aryl hydrocarbon receptor	Homo sapiens	72-75
27564782-4	2016	Cyclosporine-based IS was associated with increased risks of pneumonia (aHR 1.17; P &lt; 0.001), sepsis (aHR 1.16; P &lt; 0.001), AR (aOR 1.43; P &lt; 0.001), and graft failure (aHR 1.39; P &lt; 0.001), but less diabetes (aHR 0.83; P &lt; 0.001).	Cyclosporine	0-12	aryl hydrocarbon receptor	Homo sapiens	105-108
27564782-4	2016	Cyclosporine-based IS was associated with increased risks of pneumonia (aHR 1.17; P &lt; 0.001), sepsis (aHR 1.16; P &lt; 0.001), AR (aOR 1.43; P &lt; 0.001), and graft failure (aHR 1.39; P &lt; 0.001), but less diabetes (aHR 0.83; P &lt; 0.001).	Cyclosporine	0-12	aryl hydrocarbon receptor	Homo sapiens	105-108
27564782-4	2016	Cyclosporine-based IS was associated with increased risks of pneumonia (aHR 1.17; P &lt; 0.001), sepsis (aHR 1.16; P &lt; 0.001), AR (aOR 1.43; P &lt; 0.001), and graft failure (aHR 1.39; P &lt; 0.001), but less diabetes (aHR 0.83; P &lt; 0.001).	Cyclosporine	0-12	aryl hydrocarbon receptor	Homo sapiens	105-108
26948033-5	2016	We also found that miR-377 was required for CsA-induced apoptosis, because inhibition of miR-377 expression markedly reduced the ability of CsA to induce cardiomyocyte apoptosis.	Cyclosporine	44-47	microRNA 377	Homo sapiens	19-26
26948033-5	2016	We also found that miR-377 was required for CsA-induced apoptosis, because inhibition of miR-377 expression markedly reduced the ability of CsA to induce cardiomyocyte apoptosis.	Cyclosporine	44-47	microRNA 377	Homo sapiens	89-96
26948033-5	2016	We also found that miR-377 was required for CsA-induced apoptosis, because inhibition of miR-377 expression markedly reduced the ability of CsA to induce cardiomyocyte apoptosis.	Cyclosporine	140-143	microRNA 377	Homo sapiens	19-26
26948033-5	2016	We also found that miR-377 was required for CsA-induced apoptosis, because inhibition of miR-377 expression markedly reduced the ability of CsA to induce cardiomyocyte apoptosis.	Cyclosporine	140-143	microRNA 377	Homo sapiens	89-96
26948033-8	2016	Our data suggested that CsA induced cardiomyocyte apoptosis through the miR-377-XIAP/NRP2 axis.	Cyclosporine	24-27	microRNA 377	Homo sapiens	72-79
2298966-6	1990	Abnormal expression of keratinocyte intercellular adhesion molecule-1 (ICAM-1), which was present before therapy, became undetectable after 1 week of cyclosporine therapy, before any significant clinical and histologic change.	Cyclosporine	150-162	intercellular adhesion molecule 1	Homo sapiens	36-69
27440884-5	2016	Moreover, when TRIM5 activity was blocked by the nonimmunosuppressive analog of cyclosporine (CsA), sarcosine-3(4-methylbenzoate)-CsA (SmBz-CsA), we found a significant reduction in CD107a/MIP-1beta expression in HIV-1-specific CD8(+) T cells.	Cyclosporine	80-92	tripartite motif containing 5	Homo sapiens	15-20
27440884-5	2016	Moreover, when TRIM5 activity was blocked by the nonimmunosuppressive analog of cyclosporine (CsA), sarcosine-3(4-methylbenzoate)-CsA (SmBz-CsA), we found a significant reduction in CD107a/MIP-1beta expression in HIV-1-specific CD8(+) T cells.	Cyclosporine	94-97	tripartite motif containing 5	Homo sapiens	15-20
2298966-6	1990	Abnormal expression of keratinocyte intercellular adhesion molecule-1 (ICAM-1), which was present before therapy, became undetectable after 1 week of cyclosporine therapy, before any significant clinical and histologic change.	Cyclosporine	150-162	intercellular adhesion molecule 1	Homo sapiens	71-77
2136906-4	1990	CD4+ cells from rats with long survival grafts specifically lack the capacity to restore PVG heart graft rejection, and can also inhibit the capacity of naive T cells to restore rejection, while in the first few weeks post-transplant, both CD4+ and CD8+ T cells from CSA-treated hosts have the capacity to effect PVG graft rejection.	Cyclosporine	267-270	Cd4 molecule	Rattus norvegicus	0-3
27580845-6	2016	Treatment with CsA and FK506 also inhibited PAN-induced podocytes apoptosis, which was associated with the induction of Bcl-xL and inhibition of Bax, cleaved caspase 3, and cleaved PARP expression.	Cyclosporine	15-18	BCL2-like 1	Mus musculus	120-126
27580845-7	2016	Further studies revealed that CsA and FK506 inhibited PAN-induced p38 and JNK signaling, thereby protecting podocytes from PAN-induced injury.	Cyclosporine	30-33	mitogen-activated protein kinase 14	Mus musculus	66-69
2136906-5	1990	In this study, we demonstrated the CD4+ suppressor cells also had the capacity to inhibit restoration of rejection by CD4+ cells from CSA-treated DA rats recently transplanted with PVG hearts, and from rats sensitized to third party, but not from those specifically sensitized to PVG.	Cyclosporine	134-137	Cd4 molecule	Rattus norvegicus	35-38
2136906-5	1990	In this study, we demonstrated the CD4+ suppressor cells also had the capacity to inhibit restoration of rejection by CD4+ cells from CSA-treated DA rats recently transplanted with PVG hearts, and from rats sensitized to third party, but not from those specifically sensitized to PVG.	Cyclosporine	134-137	Cd4 molecule	Rattus norvegicus	118-121
27531839-7	2016	The effect of ANI on destabilization was prevented by the protein phosphatase 2B (calcineurin, CaN) inhibitors cyclosporine A (CsA) and FK-506 and the protein phosphatase 1 (PP1) inhibitors calyculin A (CA) and okadaic acid (OA).	Cyclosporine	127-130	protein phosphatase 1 catalytic subunit gamma	Mus musculus	174-177
2136906-7	1990	These results showed that the CD4+ suppressor cell was capable of overriding the capacity to effect rejection of the CD4+ cell and activated CD8+ cells that were present in the CSA-treated host shortly after transplantation.	Cyclosporine	177-180	Cd4 molecule	Rattus norvegicus	30-33
2136906-7	1990	These results showed that the CD4+ suppressor cell was capable of overriding the capacity to effect rejection of the CD4+ cell and activated CD8+ cells that were present in the CSA-treated host shortly after transplantation.	Cyclosporine	177-180	Cd4 molecule	Rattus norvegicus	117-120
2136906-13	1990	These studies demonstrated the CD4+ suppressive cell identified in rats with specific unresponsiveness induced by CSA therapy had many features of the suppressor inducer cell identified in in vitro studies of the alloimmune response.	Cyclosporine	114-117	Cd4 molecule	Rattus norvegicus	31-34
2113213-2	1990	Anti-recipient ABO antibodies were found in two of 34 patients treated with cyclosporin.	Cyclosporine	76-87	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	15-18
1700314-0	1990	Ca2+ release in permeabilized human neutrophils induced by ciclosporin.	Cyclosporine	59-70	carbonic anhydrase 2	Homo sapiens	0-3
29029404-7	2017	Inhibition of CypD by cyclosporine A (CsA) clearly inhibited the QC-mediated loss of mitochondrial membrane potential and mitochondrial cell death.	Cyclosporine	22-36	peptidylprolyl isomerase D	Homo sapiens	14-18
29029404-7	2017	Inhibition of CypD by cyclosporine A (CsA) clearly inhibited the QC-mediated loss of mitochondrial membrane potential and mitochondrial cell death.	Cyclosporine	38-41	peptidylprolyl isomerase D	Homo sapiens	14-18
1700314-3	1990	Ciclosporin (500 ng/ml) induced a transient increase in free Ca2+ concentration (maximum delta pCa, 0.41 +/- 0.17).	Cyclosporine	0-11	carbonic anhydrase 2	Homo sapiens	61-64
1700314-6	1990	The experiments suggest that ciclosporin may induce a release of Ca2+ from cellular organelles, e.g. the endoplasmic reticulum, and a partial reuptake in mitochondria.	Cyclosporine	29-40	carbonic anhydrase 2	Homo sapiens	65-68
1700314-7	1990	A release of cellular Ca2+ may play a role in ciclosporin-induced hypertension.	Cyclosporine	46-57	carbonic anhydrase 2	Homo sapiens	22-25
27109380-4	2016	The classic immunosuppressive drug cyclosporin A (CsA) can bind to cyclophilin (CyP) and compete with CN for the NFAT LxVP motif.	Cyclosporine	35-48	peptidyl-prolyl isomerase G (cyclophilin G)	Mus musculus	67-78
34971589-9	2022	Mechanistically, we showed that the effect of trehalose was attributed to increased nuclear translocation of transcription factor EB (TFEB), and this effect could be mimicked by TFEB overexpression and inhibited by TFEB gene silencing or treatment with cyclosporin A (CsA), a calcineurin inhibitor.	Cyclosporine	253-266	transcription factor EB	Mus musculus	134-138
27109380-4	2016	The classic immunosuppressive drug cyclosporin A (CsA) can bind to cyclophilin (CyP) and compete with CN for the NFAT LxVP motif.	Cyclosporine	35-48	peptidyl-prolyl isomerase G (cyclophilin G)	Mus musculus	80-83
27109380-4	2016	The classic immunosuppressive drug cyclosporin A (CsA) can bind to cyclophilin (CyP) and compete with CN for the NFAT LxVP motif.	Cyclosporine	50-53	peptidyl-prolyl isomerase G (cyclophilin G)	Mus musculus	67-78
27109380-4	2016	The classic immunosuppressive drug cyclosporin A (CsA) can bind to cyclophilin (CyP) and compete with CN for the NFAT LxVP motif.	Cyclosporine	50-53	peptidyl-prolyl isomerase G (cyclophilin G)	Mus musculus	80-83
34971589-9	2022	Mechanistically, we showed that the effect of trehalose was attributed to increased nuclear translocation of transcription factor EB (TFEB), and this effect could be mimicked by TFEB overexpression and inhibited by TFEB gene silencing or treatment with cyclosporin A (CsA), a calcineurin inhibitor.	Cyclosporine	268-271	transcription factor EB	Mus musculus	134-138
34826977-1	2021	Purpose: To evaluate the effect of topical cyclosporine 0.05% and osmoprotective lubricating eye drops on patients with dry eye disease (DED) with inflammation as measured by raised tear matrix metalloproteinases (MMP-9).	Cyclosporine	43-55	matrix metallopeptidase 9	Homo sapiens	214-219
34826977-11	2021	Conclusion: Topical osmoprotective lubricating eye drops and cyclosporine A 0.05% reduce inflammation in cases of DED, which correlates with improvement in OSDI scores, ocular surface staining, and reduction in inflammation as measured by levels of tear MMP-9.	Cyclosporine	61-75	matrix metallopeptidase 9	Homo sapiens	254-259
34224738-8	2021	CsA suppressed activation of ITK in cultured CD4+ T cells and calcineurin-containing microclusters adjacent to the T cell receptor signaling complex.	Cyclosporine	0-3	CD4 antigen	Mus musculus	45-48
34347214-3	2021	AdoMet decreased mitochondrial membrane potential and Ca2+ retention capacity, and these effects were fully prevented by cyclosporin A and ADP, indicating mitochondrial permeability transition (mPT) induction.	Cyclosporine	121-134	methionine adenosyltransferase 1A	Rattus norvegicus	0-6
34565275-6	2021	CsA increased caspase-3 activity, Bax, TOS, MDA, TAS, and MPO levels, and the administration of DAPA with CsA significantly reduced this increase in levels (p < 0.001, p < 0.001, p < 0.001, p < 0.001, p < 0.001, and p < 0.001, respectively).	Cyclosporine	0-3	caspase 3	Mus musculus	14-23
34565275-6	2021	CsA increased caspase-3 activity, Bax, TOS, MDA, TAS, and MPO levels, and the administration of DAPA with CsA significantly reduced this increase in levels (p < 0.001, p < 0.001, p < 0.001, p < 0.001, p < 0.001, and p < 0.001, respectively).	Cyclosporine	0-3	BCL2-associated X protein	Mus musculus	34-37
34565275-6	2021	CsA increased caspase-3 activity, Bax, TOS, MDA, TAS, and MPO levels, and the administration of DAPA with CsA significantly reduced this increase in levels (p < 0.001, p < 0.001, p < 0.001, p < 0.001, p < 0.001, and p < 0.001, respectively).	Cyclosporine	0-3	myeloperoxidase	Mus musculus	58-61
34604411-5	2021	We aimed to determine the correlation between the serum levels of IL-15 and IP-10 cytokines with CMV infection, CMV viral load, and cyclosporine as a major immunosuppressive treatment after transplantation.	Cyclosporine	132-144	interleukin 15	Homo sapiens	66-71
34604411-5	2021	We aimed to determine the correlation between the serum levels of IL-15 and IP-10 cytokines with CMV infection, CMV viral load, and cyclosporine as a major immunosuppressive treatment after transplantation.	Cyclosporine	132-144	C-X-C motif chemokine ligand 10	Homo sapiens	76-81
34079822-9	2021	Troglitazone, BSP and erythrosine B were identified as pan-SLC10 inhibitors, whereas cyclosporine A, irbesartan, ginkgolic acid 17:1, and betulinic acid only inhibited NTCP and SOAT, but not ASBT.	Cyclosporine	85-99	solute carrier family 10 member 6	Homo sapiens	177-181
34064311-9	2021	Surprisingly, cyclosporin A alone impaired short-term plasticity in CA1 by decreasing paired-pulse facilitation, which suggests bi-directionality of the influences of PP2B in the hippocampus.	Cyclosporine	14-27	carbonic anhydrase 1	Homo sapiens	68-71
34427166-3	2020	CsA treatment significantly downregulated the expressions of miR-26-5p and PTEN and upregulated the expressions of PI3K and p-AKT in both rat gingival tissues and HGFs.	Cyclosporine	0-3	phosphatase and tensin homolog	Rattus norvegicus	75-79
35272142-2	2022	Here, we show that CsA alone stimulates ICAM-1 overexpression in human pulmonary microvascular endothelial cells (HPMECs) through Toll-Like Receptor 4 (TLR4) and NF-kappaB activation.	Cyclosporine	19-22	intercellular adhesion molecule 1	Homo sapiens	40-46
35272142-3	2022	In HPMECs, CsA treatment significantly worsened the overexpression of ICAM-1 induced by high-dose irradiation (15 Gy).	Cyclosporine	11-14	intercellular adhesion molecule 1	Homo sapiens	70-76
35272142-4	2022	This additive effect of CsA was also observed when ICAM-1 overexpression was induced by another pathway (Ca2+ entry) in macrovascular endothelial cells.	Cyclosporine	24-27	intercellular adhesion molecule 1	Homo sapiens	51-57
35073210-7	2022	Exposure of cultured human renal proximal tubular HK-2 cells to CsA induced expression of fibronectin and sPRR production, but the fibrotic response was attenuated by PRO20 and siRNA-mediated PRR knockdown.	Cyclosporine	64-67	ATPase H+ transporting accessory protein 2	Homo sapiens	192-195
35306230-3	2022	Utilizing the male non-obese diabetic (NOD) mouse model of SS, this work: 1) identifies clinically-relevant elevations in cytokines (IL-17A, IL-2) in LG-derived CD4+ T cells; and 2) explores tissue-specific immunosuppression of SS using a novel protein-based drug carrier to concentrate cyclosporine A (CsA) directly in the LG.	Cyclosporine	287-301	CD4 antigen	Mus musculus	161-164
35306230-3	2022	Utilizing the male non-obese diabetic (NOD) mouse model of SS, this work: 1) identifies clinically-relevant elevations in cytokines (IL-17A, IL-2) in LG-derived CD4+ T cells; and 2) explores tissue-specific immunosuppression of SS using a novel protein-based drug carrier to concentrate cyclosporine A (CsA) directly in the LG.	Cyclosporine	303-306	CD4 antigen	Mus musculus	161-164
35092471-8	2022	Moreover, we found that ferulic acid remarkably prevented cyclosporine-mediated nephrotoxicity by restoring the anti-oxidant system through activating the Nrf2/HO-1 axis.	Cyclosporine	58-70	heme oxygenase 1	Rattus norvegicus	160-164
35074592-10	2022	CsA activated the Wnt/beta-catenin pathway by increasing WNT3a expression, frizzled receptor-7, beta-catenin, and c-myc.	Cyclosporine	0-3	catenin (cadherin associated protein), beta 1	Mus musculus	22-34
35074592-10	2022	CsA activated the Wnt/beta-catenin pathway by increasing WNT3a expression, frizzled receptor-7, beta-catenin, and c-myc.	Cyclosporine	0-3	catenin (cadherin associated protein), beta 1	Mus musculus	96-108
2612091-6	1989	The percent change after one year for CyA group vs the placebo group are as follows: total cholesterol, -22 vs -8%; LDL cholesterol -33 vs -25%; free cholesterol, -39 vs -14%; total phospholipids, -46 vs -23%; and LCAT activity, +/- 236 vs +/- 43%.	Cyclosporine	38-41	lecithin-cholesterol acyltransferase	Homo sapiens	214-218
27155398-6	2016	Cyclosporin A (CSA) was used to block the activation of calcineurin/NFATc4 pathway in ET-1-treated cardiomyocytes and the expression of LTCC alpha1C were examined.	Cyclosporine	0-13	nuclear factor of activated T-cells 4	Rattus norvegicus	68-74
27155398-6	2016	Cyclosporin A (CSA) was used to block the activation of calcineurin/NFATc4 pathway in ET-1-treated cardiomyocytes and the expression of LTCC alpha1C were examined.	Cyclosporine	15-18	nuclear factor of activated T-cells 4	Rattus norvegicus	68-74
2575078-4	1989	However, if the marrow is depleted of either Thy-1+ or Lyt-1+ cells, thymic regeneration is severely inhibited by CsA.	Cyclosporine	114-117	CD5 antigen	Mus musculus	55-60
27011383-4	2016	M-I uptake was also inhibited by cyclosporin A, an inhibitor for hepatic uptake transporters including organic anion transporting polypeptide (OATP).	Cyclosporine	33-46	solute carrier organic anion transporter family member 1A2	Homo sapiens	103-141
27011383-4	2016	M-I uptake was also inhibited by cyclosporin A, an inhibitor for hepatic uptake transporters including organic anion transporting polypeptide (OATP).	Cyclosporine	33-46	solute carrier organic anion transporter family member 1A2	Homo sapiens	143-147
26676223-0	2016	Effects of oral cyclosporine on canine T-cell expression of IL-2 and IFN-gamma across a 12-h dosing interval.	Cyclosporine	16-28	interleukin 2	Canis lupus familiaris	60-64
2809194-4	1989	Addition of CsA to organ culture resulted in a decreased cell yield and complete inhibition of the appearance of TCR-alpha beta-bearing, single positive thymocytes (both CD4+CD8- and CD4-CD8+).	Cyclosporine	12-15	CD8a molecule	Homo sapiens	174-177
26950727-1	2016	BACKGROUND: We hypothesized that nicotinamide adenosine diphosphate oxidase 2 (Nox2) plays an important role in cyclosporine A (CsA)-induced chronic hypoxia.	Cyclosporine	112-126	cytochrome b-245, beta polypeptide	Mus musculus	33-77
26950727-1	2016	BACKGROUND: We hypothesized that nicotinamide adenosine diphosphate oxidase 2 (Nox2) plays an important role in cyclosporine A (CsA)-induced chronic hypoxia.	Cyclosporine	112-126	cytochrome b-245, beta polypeptide	Mus musculus	79-83
26950727-1	2016	BACKGROUND: We hypothesized that nicotinamide adenosine diphosphate oxidase 2 (Nox2) plays an important role in cyclosporine A (CsA)-induced chronic hypoxia.	Cyclosporine	128-131	cytochrome b-245, beta polypeptide	Mus musculus	33-77
26950727-1	2016	BACKGROUND: We hypothesized that nicotinamide adenosine diphosphate oxidase 2 (Nox2) plays an important role in cyclosporine A (CsA)-induced chronic hypoxia.	Cyclosporine	128-131	cytochrome b-245, beta polypeptide	Mus musculus	79-83
26950727-7	2016	Immunohistochemical analyses of kidney biopsies from liver transplant recipients with chronic CsA nephrotoxicity showed significantly greater Nox2, alpha-smooth muscle actin and picrosirius levels compared with controls.	Cyclosporine	94-97	cytochrome b-245, beta polypeptide	Mus musculus	142-146
26950727-8	2016	CONCLUSIONS: These studies suggest that Nox2 is a modulator of CsA-induced hypoxia upstream of HIF-1alpha and define the molecular characteristics that could be used for the diagnosis and monitoring of chronic calcineurin inhibitor nephrotoxicity.	Cyclosporine	63-66	cytochrome b-245, beta polypeptide	Mus musculus	40-44
27266681-1	2016	OBJECTIVE: To assess the effectiveness and safety of the conversion therapy from traditional cyclosporine (CsA) triple immunosuppression therapy to sirolimus (SRL) combined with low dose CsA and prednisone (Pred) in renal transplantation recipients in a five-year follow-up period.	Cyclosporine	93-105	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	107-110
2809194-4	1989	Addition of CsA to organ culture resulted in a decreased cell yield and complete inhibition of the appearance of TCR-alpha beta-bearing, single positive thymocytes (both CD4+CD8- and CD4-CD8+).	Cyclosporine	12-15	CD8a molecule	Homo sapiens	187-190
2809194-5	1989	Furthermore, the generation of CD4+CD8+ thymocytes was markedly inhibited by CsA treatment, whereas the development of CD3-, CD4-CD8+ thymocytes and TCR-gamma delta-bearing, CD4-CD8- thymocytes was not affected.	Cyclosporine	77-80	CD8a molecule	Homo sapiens	35-38
2802615-1	1989	Adult human liver contains a form of cytochrome P450, termed HLp, that resembles the glucocorticoid-inducible cytochrome P450p in rat liver in its structure, function, and regulation and catalyzes the oxidation of such clinically important substrates as cyclosporin, nifedipine, erythromycin, and midazolam.	Cyclosporine	254-265	HLP	Homo sapiens	61-64
26954342-8	2016	Anti-inflammatory cytokine IL-4 was decreased in the LPS group but was increased in (LPS+CsA) group (P&lt;0.05).	Cyclosporine	89-92	interleukin 4	Rattus norvegicus	27-31
2479656-1	1989	Suppressor cells specific for the acetylcholine receptor (AChR) can readily be induced by culturing spleen cells from rats with experimental autoimmune myasthenia gravis in medium containing cyclosporine A plus AChR.	Cyclosporine	191-205	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	34-56
26972380-1	2016	Cyclosporine A (CsA) is a well-known immunosuppressive agent used as rescue therapy in severe steroid-refractory ulcerative colitis (UC).	Cyclosporine	0-14	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	16-19
27088859-1	2016	BACKGROUND: Animal studies have highlighted the role of vascular mineralocorticoid receptor during Cyclosporine A-induced nephrotoxicity.	Cyclosporine	99-113	nuclear receptor subfamily 3 group C member 2	Homo sapiens	65-91
26794875-1	2016	In the present work, the feasibility of cyclosporine A lipid nanoparticles (CsA LN) for oral administration was investigated.	Cyclosporine	40-54	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	76-79
1701825-1	1990	Cyclosporin A (CSA), FK506, and glucocorticosteroids all inhibit the production of lymphokines by decreasing lymphokine gene expression.	Cyclosporine	0-13	chorionic somatomammotropin hormone 1	Homo sapiens	15-18
2258695-7	1990	Immune serum obtained from RT1u recipients that had rejected a RT1Aa disparate graft was able, when injected into cyclosporin-treated RT1u recipients, to restore their ability to reject a RT1Aa, but not a third-party RT1c, kidney.	Cyclosporine	114-125	RT1 class I, locus A	Rattus norvegicus	63-68
2258695-7	1990	Immune serum obtained from RT1u recipients that had rejected a RT1Aa disparate graft was able, when injected into cyclosporin-treated RT1u recipients, to restore their ability to reject a RT1Aa, but not a third-party RT1c, kidney.	Cyclosporine	114-125	RT1 class I, locus A	Rattus norvegicus	188-193
1977512-2	1990	Verapamil and cyclosporin A, two well known resistance modifiers of MDR, were found to significantly potentiate the action of VCR (60-fold) and to a lesser degree also of VP-16 and daunorubicin (dnr).	Cyclosporine	14-27	host cell factor C1	Homo sapiens	171-176
2479656-1	1989	Suppressor cells specific for the acetylcholine receptor (AChR) can readily be induced by culturing spleen cells from rats with experimental autoimmune myasthenia gravis in medium containing cyclosporine A plus AChR.	Cyclosporine	191-205	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	58-62
2479131-4	1989	This study analyzes CD45R expression on circulating T cells and T cells infiltrating renal allografts in patients undergoing rejection and/or cyclosporine nephrotoxicity.	Cyclosporine	142-154	protein tyrosine phosphatase receptor type C	Homo sapiens	20-25
2517811-2	1989	Cyclosporin A could dramatically inhibit the synthesis of interleukin 2, whereas it did not affect the interleukin 2-dependent proliferation of bovine T blasts.	Cyclosporine	0-13	interleukin 2	Bos taurus	58-71
2530675-0	1989	Cyclosporine A treatment induces changes in CD45R (restricted common leukocyte antigen) expression in the mixed lymphocyte reaction.	Cyclosporine	0-14	protein tyrosine phosphatase receptor type C	Homo sapiens	44-49
2570112-8	1989	Optimal doses of CsA inhibited TPA-induced ODC activity, TGase activity, arachidonic acid release, and interleukin-1 beta (IL-1 beta) mRNA to the same degree (approximately 80%), despite measurement at widely different times (30 min-12 h) required to obtain maximal induction by TPA.	Cyclosporine	17-20	ornithine decarboxylase, structural 1	Mus musculus	43-46
2651768-10	1989	The most likely candidates are the immunosuppressive drugs, such as cyclosporine and prednisone, which decrease MHC antigen expression.	Cyclosporine	68-80	major histocompatibility complex, class I, C	Homo sapiens	112-115
2705209-0	1989	Effect of platelet-activating factor antagonist on cyclosporine nephrotoxicity.	Cyclosporine	51-63	PCNA clamp associated factor	Rattus norvegicus	10-36
2705209-12	1989	Thus, this study suggests that PAF may participate in CsA nephrotoxicity.	Cyclosporine	54-57	PCNA clamp associated factor	Rattus norvegicus	31-34
2522254-0	1989	Prevention of acute cyclosporine nephrotoxicity by atrial natriuretic factor after ischemia in the rat.	Cyclosporine	20-32	natriuretic peptide A	Rattus norvegicus	51-76
2522254-1	1989	The present experimental study investigates whether the atrial natriuretic factor (ANF) is able to prevent the nephrotoxic effects of cyclosporine infused after 30 min of warm renal ischemia in the rat.	Cyclosporine	134-146	natriuretic peptide A	Rattus norvegicus	56-81
2522254-1	1989	The present experimental study investigates whether the atrial natriuretic factor (ANF) is able to prevent the nephrotoxic effects of cyclosporine infused after 30 min of warm renal ischemia in the rat.	Cyclosporine	134-146	natriuretic peptide A	Rattus norvegicus	83-86
2522254-5	1989	Moreover, the natriuretic ANF effects remained unaffected by high plasma CsA peak levels: indeed, other parameters of renal function--urinary flow, urinary sodium concentration and excretion rates, and urinary sodium reabsorption and fractional excretion rates, were significantly increased in ANF alone or CsA/ANF groups.	Cyclosporine	307-310	natriuretic peptide A	Rattus norvegicus	26-29
2603807-0	1989	The effect of cyclosporine on urinary kallikrein excretion in patients with rheumatoid arthritis.	Cyclosporine	14-26	kallikrein related peptidase 4	Homo sapiens	38-48
2261949-7	1990	CyA abrogates the increase in both serum CSF and CFU-GM.	Cyclosporine	0-3	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	41-44
2228019-5	1990	It has been demonstrated that only the CD3/TcR alpha beta+ J11d- CD25- subpopulation is susceptible to the suppressive effects of CsA among CD4-8- cells, whereas all the other four subpopulations, including CD3/TcR gamma delta+ cells, are resistant.	Cyclosporine	130-133	interleukin 2 receptor, alpha chain	Mus musculus	65-69
2228019-5	1990	It has been demonstrated that only the CD3/TcR alpha beta+ J11d- CD25- subpopulation is susceptible to the suppressive effects of CsA among CD4-8- cells, whereas all the other four subpopulations, including CD3/TcR gamma delta+ cells, are resistant.	Cyclosporine	130-133	CD4 antigen	Mus musculus	140-143
2228019-6	1990	Thus, all of the TcR alpha beta-bearing cells, including CD4-8- cells but none of the TcR alpha beta- cells, are CsA sensitive.	Cyclosporine	113-116	CD4 antigen	Mus musculus	57-60
2228019-7	1990	Because it is known that CsA inhibits the TcR-mediated signalling events in mature T cells and that signallings mediated via the interaction of TcR with major histocompatibility complex (MHC) molecules on thymic stroma cells are crucial for thymic selection of T cells, these results indicate that TcR alpha beta-bearing CD4-8- cells but not TcR gamma delta-bearing CD4-8- cells undergo thymic positive selection.	Cyclosporine	25-28	CD4 antigen	Mus musculus	321-324
2228019-7	1990	Because it is known that CsA inhibits the TcR-mediated signalling events in mature T cells and that signallings mediated via the interaction of TcR with major histocompatibility complex (MHC) molecules on thymic stroma cells are crucial for thymic selection of T cells, these results indicate that TcR alpha beta-bearing CD4-8- cells but not TcR gamma delta-bearing CD4-8- cells undergo thymic positive selection.	Cyclosporine	25-28	CD4 antigen	Mus musculus	366-369
2387345-1	1990	We studied the effects of two modulators of multidrug resistance (MDR), cyclosporine and verapamil, on the cytotoxicity of etoposide (VP-16) in normal bone marrow cells.	Cyclosporine	72-84	host cell factor C1	Homo sapiens	134-139
26671075-11	2016	No positive treatment effects were seen on biomarker levels in any of the models, whereas significant increases in 24 h UCH-L1 levels were seen with CsA (20 mg/kg) after CCI and 24 h GFAP levels in both CsA treated groups in the PBBI model.	Cyclosporine	149-152	ubiquitin C-terminal hydrolase L1	Rattus norvegicus	120-126
26975474-3	2016	The peptidyl prolyl cis-trans isomerase activity of cyclophilin D was stimulated by the thioredoxin system, while it was decreased by cyclosporin A and the thioredoxin reductase inhibitor auranofin.	Cyclosporine	134-147	peptidylprolyl isomerase F	Rattus norvegicus	52-65
26595644-4	2016	Perioperative administration of recombinant Lcn2:siderophore:Fe complex (rLcn2) to recipients resulted in functional and morphological amelioration of the allograft at day 7 almost as efficiently as daily immunosuppression with cyclosporine A (CsA).	Cyclosporine	228-242	lipocalin 2	Mus musculus	44-48
26595644-4	2016	Perioperative administration of recombinant Lcn2:siderophore:Fe complex (rLcn2) to recipients resulted in functional and morphological amelioration of the allograft at day 7 almost as efficiently as daily immunosuppression with cyclosporine A (CsA).	Cyclosporine	244-247	lipocalin 2	Mus musculus	44-48
26603313-0	2016	The protective effect of neutralizing high-mobility group box1 against chronic cyclosporine nephrotoxicity in mice.	Cyclosporine	79-91	high mobility group box 1	Mus musculus	38-62
26603313-3	2016	This study was designed to determine whether neutralizing HMGB1 prevents chronic CsA nephrotoxicity.	Cyclosporine	81-84	high mobility group box 1	Mus musculus	58-63
26603313-7	2016	RESULTS: Anti-HMGB1 administration prevented the increases in serum creatinine and 24h albuminuria and the decrease in creatinine clearance associated with CsA treatment.	Cyclosporine	156-159	high mobility group box 1	Mus musculus	14-19
26603313-8	2016	Increased tubulointerstitial fibrosis and transforming growth factor (TGF)-beta immunohistochemical staining associated with CsA treatment were also prevented by anti-HMGB1 administration.	Cyclosporine	125-128	high mobility group box 1	Mus musculus	167-172
26603313-10	2016	In cultured tubular cells, anti-HMGB1 pretreatment also prevented the increases in fibronectin and collagen IV levels associated with CsA treatment.	Cyclosporine	134-137	high mobility group box 1	Mus musculus	32-37
26603313-11	2016	CONCLUSIONS: Neutralizing HMGB1 with an anti-HMGB1 antibody ameliorated chronic CsA nephrotoxicity via inhibition of the TLR4 signaling pathway.	Cyclosporine	80-83	high mobility group box 1	Mus musculus	26-31
26603313-11	2016	CONCLUSIONS: Neutralizing HMGB1 with an anti-HMGB1 antibody ameliorated chronic CsA nephrotoxicity via inhibition of the TLR4 signaling pathway.	Cyclosporine	80-83	high mobility group box 1	Mus musculus	45-50
27150150-9	2016	Moreover, cyclosporin A, an inhibitor of pore formation in the mitochondrial membrane, attenuated compound C-induced SESN2 induction.	Cyclosporine	10-23	sestrin 2	Homo sapiens	117-122
27374283-1	2016	Cyclosporine (CSA), which is one of the substrates of ATP binding cassette subfamily B member 1 (ABCB1), is widely used as an immunosuppressant in patients undergoing transplantation.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
27298826-7	2016	The following biochemical changes were observed in CsA-treated animals: increased levels of ALT, AST, and bilirubin in the serum, statistically significant changes in oxidative stress parameters, and lipid peroxidation products in the liver supernatants: MDA+4HAE, GSH, GSSG, caspase 3 activity, and ADP/ATP, NAD(+)/NADH, and NADP(+)/NADPH ratios.	Cyclosporine	51-54	caspase 3	Rattus norvegicus	276-285
26496921-6	2016	Furthermore, we show that inhibition of the interaction with calcineurin inhibitor, cyclosporin A (CsA), leads to the retention of ATOH8 to the cytoplasm, suggesting that the interaction renders nuclear localization of ATOH8 which may be critical to control its activity as transcription factor.	Cyclosporine	84-97	atonal bHLH transcription factor 8	Homo sapiens	131-136
26496921-6	2016	Furthermore, we show that inhibition of the interaction with calcineurin inhibitor, cyclosporin A (CsA), leads to the retention of ATOH8 to the cytoplasm, suggesting that the interaction renders nuclear localization of ATOH8 which may be critical to control its activity as transcription factor.	Cyclosporine	84-97	atonal bHLH transcription factor 8	Homo sapiens	219-224
26496921-6	2016	Furthermore, we show that inhibition of the interaction with calcineurin inhibitor, cyclosporin A (CsA), leads to the retention of ATOH8 to the cytoplasm, suggesting that the interaction renders nuclear localization of ATOH8 which may be critical to control its activity as transcription factor.	Cyclosporine	99-102	atonal bHLH transcription factor 8	Homo sapiens	131-136
26496921-6	2016	Furthermore, we show that inhibition of the interaction with calcineurin inhibitor, cyclosporin A (CsA), leads to the retention of ATOH8 to the cytoplasm, suggesting that the interaction renders nuclear localization of ATOH8 which may be critical to control its activity as transcription factor.	Cyclosporine	99-102	atonal bHLH transcription factor 8	Homo sapiens	219-224
25799977-9	2016	Cyclosporin A and BAPTA-AM inhibited NFATc4 translocation, indicating the activation of the Ca(2+)/calcineurin/NFAT pathway.	Cyclosporine	0-13	nuclear factor of activated T-cells 4	Rattus norvegicus	37-43
25799977-9	2016	Cyclosporin A and BAPTA-AM inhibited NFATc4 translocation, indicating the activation of the Ca(2+)/calcineurin/NFAT pathway.	Cyclosporine	0-13	nuclear factor of activated T-cells 5	Rattus norvegicus	37-41
26374844-3	2015	In a mouse model of lethal mitochondrial myopathy, the muscle-specific Tfam knock-out (KO) mouse, we previously demonstrated an excessive mitochondrial Ca(2+) uptake in isolated muscle fibers that could be inhibited by the cyclophilin D (CypD) inhibitor, cyclosporine A (CsA).	Cyclosporine	271-274	transcription factor A, mitochondrial	Mus musculus	71-75
26374844-5	2015	We tested the effect of CsA treatment on Tfam KO mice during the transition from a mild to terminal myopathy.	Cyclosporine	24-27	transcription factor A, mitochondrial	Mus musculus	41-45
26374844-7	2015	Importantly, CsA treatment prolonged the lifespan of these muscle-specific Tfam KO mice.	Cyclosporine	13-16	transcription factor A, mitochondrial	Mus musculus	75-79
26017975-11	2015	The effects of TNF on NFATc1 and TRPC6 expression were blocked by cyclosporine A but were not blocked by the pan-TRP inhibitor SKF-96365.	Cyclosporine	66-80	transient receptor potential cation channel subfamily C member 6	Homo sapiens	33-38
2603807-1	1989	The effect of cyclosporine (6 to 8 mg/kg/24 hr) on urinary kallikrein excretion is summarized for 9 patients with rheumatoid arthritis using a specific kallikrein radioimmunoassay.	Cyclosporine	14-26	kallikrein related peptidase 4	Homo sapiens	59-69
2603807-5	1989	Patients in the subgroup with low baseline values also decreased their kallikrein excretion in response to cyclosporine therapy, and two of the four in this group experienced elevations of BUN such that therapy was terminated.	Cyclosporine	107-119	kallikrein related peptidase 4	Homo sapiens	71-81
2603807-7	1989	The data suggest that changes in urinary kallikrein excretion rates may be an indicator or predictor of cyclosporine nephrotoxicity.	Cyclosporine	104-116	kallikrein related peptidase 4	Homo sapiens	41-51
26163364-1	2015	Cyclophilin A (CyPA) was originally discovered in bovine thymocytes as a cytosolic binding protein of the immunosuppressive drug cyclosporine A.	Cyclosporine	129-143	peptidyl-prolyl cis-trans isomerase A	Bos taurus	0-13
26163364-1	2015	Cyclophilin A (CyPA) was originally discovered in bovine thymocytes as a cytosolic binding protein of the immunosuppressive drug cyclosporine A.	Cyclosporine	129-143	peptidyl-prolyl cis-trans isomerase A	Bos taurus	15-19
2119535-3	1990	In this study, CsA induced alterations in rat renal cortical microsomal NADPH cytochrome P-450 reductase activity, microsomal and mitochondrial lipid peroxidation, and renal cortical glutathione levels were investigated.	Cyclosporine	15-18	cytochrome p450 oxidoreductase	Rattus norvegicus	72-104
2119535-5	1990	CsA produced a significant uncompetitive inhibition of renal NADPH cytochrome P-450 reductase activity.	Cyclosporine	0-3	cytochrome p450 oxidoreductase	Rattus norvegicus	61-93
2344354-0	1990	Partial inhibition by cyclosporin A of the swelling of liver mitochondria in vivo and in vitro induced by sub-micromolar [Ca2+], but not by butyrate.	Cyclosporine	22-35	carbonic anhydrase 2	Homo sapiens	122-125
2603807-8	1989	Decreased kallikrein excretion rates could also be a factor in the diminished renal blood flow reported in patients treated with cyclosporine.	Cyclosporine	129-141	kallikrein related peptidase 4	Homo sapiens	10-20
3061073-1	1988	Administration of CsA (15 mg/kg/day) prolonged the survival of DA (RT1a) rat fetal pancreas transplanted to the renal subcapular site of both PVG (RT1c) and Lewis (RT1(1] recipients.	Cyclosporine	18-21	RT1 class I, locus A	Rattus norvegicus	67-71
3061073-3	1988	CsA treatment prevented the induction of MHC antigen within allografts.	Cyclosporine	0-3	major histocompatibility complex, class I, C	Homo sapiens	41-44
3061073-4	1988	Whereas at day 4, both rejecting and CsA treated grafts showed donor class I MHC expression on duct epithelium and islet cells, only rejecting grafts displayed class I MHC induction on acinar cells.	Cyclosporine	37-40	major histocompatibility complex, class I, C	Homo sapiens	77-80
3061073-5	1988	Rejecting grafts showed strong induction of class II MHC antigen expression on duct epithelium from day 4 onward but this was completely prevented by CsA treatment.	Cyclosporine	150-153	major histocompatibility complex, class I, C	Homo sapiens	53-56
26086773-11	2015	BCAA prevented the Dex-induced decrease in CSA.	Cyclosporine	43-46	AT-rich interaction domain 4B	Rattus norvegicus	0-4
3061073-8	1988	These results show a favorable effect of CsA on rat fetal pancreas allografts with a reduction in MHC antigen expression within the graft and prolonged survival of insulin-rich endocrine tissue.	Cyclosporine	41-44	major histocompatibility complex, class I, C	Homo sapiens	98-101
2972933-4	1988	There are two different effects, the first of which is that CsA seems to block the differentiation of immature CD4+CD8+ thymocytes into mature CD4+CD8- and CD4-CD8+ cells expressing a high density of T-cell receptors and CD3 molecules.	Cyclosporine	60-63	CD4 antigen	Mus musculus	111-114
25656942-8	2015	Alternatively, BQ788 (ETB receptor blocker, 0.1 mg kg(-1) day(-1)) caused celecoxib-sensitive elevations in SBP and potentiated the pressor response evoked by CSA.	Cyclosporine	159-162	endothelin receptor type B	Rattus norvegicus	22-25
2972933-4	1988	There are two different effects, the first of which is that CsA seems to block the differentiation of immature CD4+CD8+ thymocytes into mature CD4+CD8- and CD4-CD8+ cells expressing a high density of T-cell receptors and CD3 molecules.	Cyclosporine	60-63	CD4 antigen	Mus musculus	143-146
26448755-1	2015	Cyclosporine A (CSA) is an immunosuppressive agent that specifically targets T cells and also increases the percentage of pro-tolerogenic CD4+Foxp3+ regulatory T cells (Treg) through unknown mechanisms.	Cyclosporine	0-14	forkhead box P3	Homo sapiens	142-147
2972933-4	1988	There are two different effects, the first of which is that CsA seems to block the differentiation of immature CD4+CD8+ thymocytes into mature CD4+CD8- and CD4-CD8+ cells expressing a high density of T-cell receptors and CD3 molecules.	Cyclosporine	60-63	CD4 antigen	Mus musculus	143-146
26448755-1	2015	Cyclosporine A (CSA) is an immunosuppressive agent that specifically targets T cells and also increases the percentage of pro-tolerogenic CD4+Foxp3+ regulatory T cells (Treg) through unknown mechanisms.	Cyclosporine	16-19	forkhead box P3	Homo sapiens	142-147
3124536-15	1988	The preliminary results of this trial showed that two thirds of the patients with cases of MGL and half of those with FSGS had total or partial remission after long-term treatment with cyclosporine.	Cyclosporine	185-197	C-type lectin domain containing 10A	Homo sapiens	91-94
25119556-10	2015	CONCLUSIONS: CsA inhibited the expressions of gelatinase MMPs and EMMPRIN and partially prevented the periodontal breakdown in ligature-induced experimental periodontitis.	Cyclosporine	13-16	matrix metallopeptidase 2	Rattus norvegicus	57-61
25119556-11	2015	The CsA-induced attenuation of periodontal bone loss was strongly correlated positively with the expressions of MMP-2, MMP-9, and EMMPRIN in gingiva.	Cyclosporine	4-7	matrix metallopeptidase 2	Rattus norvegicus	112-117
3132648-0	1988	A permissive effect of cyclosporin on the development of isohaemagglutinins of graft origin in ABO-mismatched organ transplantation.	Cyclosporine	23-34	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	95-98
3314787-6	1987	In acquired immunodeficiency syndrome, graft-vs-host disease, and cyclosporine therapy, there is an expansion of cytotoxic/suppressor (CD8) lymphocytes.	Cyclosporine	66-78	CD8a molecule	Homo sapiens	135-138
24983307-1	2015	BACKGROUND: Everolimus and cyclosporine A (CsA) exhibit synergistic immunosuppressive activity when used in combination.	Cyclosporine	27-41	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	43-46
2369611-1	1990	The interaction of cyclosporin A and dansyl cyclosporin A with bovine and wheat germ calmodulin has been monitored by measurements of induced changes in dansyl and bound toluidinyl naphthalene sulfonate fluorescence.	Cyclosporine	19-32	CaM5	Triticum aestivum	85-95
26068524-5	2015	Our studies indicated that berberine uptake was significantly suppressed by rifampicin, cyclosporine A and glycyrrhizic acid, which act as specific inhibitors of different Oatp isoforms (Oatp1a1, Oatp1a4 and Oatp1b2) in rat hepatocytes.	Cyclosporine	88-102	solute carrier organic anion transporter family member 1A2	Homo sapiens	172-176
3299911-11	1987	glucose-stimulated insulin output correlated with the individual mean CsA trough level (r = 0.71, P less than 0.015).	Cyclosporine	70-73	insulin	Canis lupus familiaris	19-26
2369611-5	1990	The binding of cyclosporin alters the physical properties of calmodulin and, in particular, reduces the localized rotational mobility of a fluorescent probe.	Cyclosporine	15-26	CaM5	Triticum aestivum	61-71
2141571-0	1990	Inhibition of interleukin 4 receptor expression on human lymphoid cells by cyclosporin.	Cyclosporine	75-86	interleukin 4 receptor	Homo sapiens	14-36
2141571-4	1990	CsA inhibited anti-CD3 antibody-induced up-regulation of IL 4 receptor (IL 4R)-associated proteins as well as the expression of high-affinity binding sites.	Cyclosporine	0-3	interleukin 4 receptor	Homo sapiens	57-70
2141571-4	1990	CsA inhibited anti-CD3 antibody-induced up-regulation of IL 4 receptor (IL 4R)-associated proteins as well as the expression of high-affinity binding sites.	Cyclosporine	0-3	interleukin 4 receptor	Homo sapiens	72-77
2141571-5	1990	However, up-regulation of IL 4R by its own ligand or IL 2 and the growth-promoting effect of IL 4 on activated, IL 4R+ T cells were CsA resistant.	Cyclosporine	132-135	interleukin 4 receptor	Homo sapiens	26-31
25475976-4	2014	In the kidney, PACAP is protective in models of diabetic nephropathy, myeloma kidney injury, cisplatin-, gentamycin- and cyclosporin-induced damages.	Cyclosporine	121-132	adenylate cyclase activating polypeptide 1	Homo sapiens	15-20
3612448-7	1987	Animals treated with dexamethasone and both dexamethasone and cyclosporine increased their complement of liver DNA 2.5 fold, to 80% of that originally present.	Cyclosporine	62-74	DNA replication helicase/nuclease 2	Rattus norvegicus	111-116
25073034-9	2014	RESULTS: Epidermal growth factor expression was increased in CsA-treated allografts which developed intense chronic changes on day 90.	Cyclosporine	61-64	epidermal growth factor like 1	Rattus norvegicus	9-32
3036114-7	1987	PMA, bombesin, and thrombin act via kinase C. PDGF and vanadate cause additional stimulation of the Na+/H+ exchanger by a kinase C-independent pathway, inhibitable by cyclosporin A.	Cyclosporine	167-180	gastrin releasing peptide	Homo sapiens	5-13
25004245-2	2014	OBJECTIVE: To investigate the effects of cyclosporine A (CsA) and tacrolimus on glucose uptake and insulin signaling in human adipocytes and their impact on the regulation of cellular trafficking of the glucose transporter 4 (GLUT4).	Cyclosporine	57-60	solute carrier family 2 member 4	Homo sapiens	203-224
25004245-4	2014	Furthermore, we studied effects of CsA and tacrolimus on the regulation of cellular trafficking of GLUT4 in differentiated human preadipocytes and L6 cells.	Cyclosporine	35-38	solute carrier family 2 member 4	Homo sapiens	99-104
2436810-4	1987	Here, we compared the effect of the immunosuppressant cyclosporine A (CsA) on Ly-6A induction by IFN and concanavalin A (Con A).	Cyclosporine	70-73	lymphocyte antigen 6 complex, locus A	Mus musculus	78-83
25004245-6	2014	Although phosphorylation at Tyr1146 of the insulin receptor was inhibited by tacrolimus, the phosphorylation and/or protein levels of the insulin signaling proteins IRS1/2, p85-PI3K, PKB, AS160, and mTORC1, as well as GLUT4 and GLUT1, were unchanged by CsA or tacrolimus.	Cyclosporine	253-256	insulin receptor	Homo sapiens	43-59
25004245-7	2014	Furthermore, CsA and tacrolimus reduced the GLUT4 amount localized at the cell surface of differentiated human preadipocytes and L6 cells in the presence of insulin.	Cyclosporine	13-16	solute carrier family 2 member 4	Homo sapiens	44-49
25004245-9	2014	CONCLUSIONS: These results suggest that therapeutic concentrations of CsA and tacrolimus can inhibit glucose uptake independent of insulin signaling by removing GLUT4 from the cell surface via an increased rate of endocytosis.	Cyclosporine	70-73	solute carrier family 2 member 4	Homo sapiens	161-166
2436810-6	1987	In contrast, at doses as low as 50 ng/ml, CsA prevented the enhancement of Ly-6A expression in Con A-treated T-cell cultures.	Cyclosporine	42-45	lymphocyte antigen 6 complex, locus A	Mus musculus	75-80
2436810-11	1987	Taken together, these data suggest that the inhibition by CsA of Ly-6A induction in Con A-treated T cells reflects the known inhibitory effects of the drug on IFN-gamma secretion.	Cyclosporine	58-61	lymphocyte antigen 6 complex, locus A	Mus musculus	65-70
24947867-7	2014	The OATP1A2-, OATP2B1-, and OCT1-mediated quercetin uptake was inhibited by known inhibitors such as naringin, cyclosporin A, and quinidine, respectively.	Cyclosporine	111-124	solute carrier organic anion transporter family member 1A2	Homo sapiens	4-11
3079641-9	1986	Retrospective analysis of 21 consecutive cyclosporine-treated BMT patients receiving marrow lacking ABO or D antigens present in the recipient showed that (1) 15/18 patients tested had red cell antibody production against recipient red cell antigens; (2) despite the frequent presence of antibody specific for recipient red cell antigens, only 3/21 patients developed clinically significant hemolysis; (3) clinical hemolysis could not be predicted by donor or recipient red cell antibody titers.	Cyclosporine	41-53	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	100-103
3484729-6	1986	Cy A-induced suppressor T cells carried both Lyt 1 and Lyt 2 surface markers.	Cyclosporine	0-4	CD5 antigen	Mus musculus	45-50
2414319-5	1985	Uninfected passaged endothelial cells produce CSA when stimulated by the continual presence of a factor present in medium conditioned by peripheral blood monocytes (MCM).	Cyclosporine	46-49	methylmalonyl-CoA mutase	Homo sapiens	165-168
2414319-6	1985	Within 4 h of infection with HSV-I, endothelial cells no longer produced CSA in response to MCM.	Cyclosporine	73-76	methylmalonyl-CoA mutase	Homo sapiens	92-95
2858508-11	1985	The addition of CsA at concentrations as low as 0.1 micrograms/ml inhibited not only IFN-gamma production by alloantigen-stimulated spleen cells, but also IFN-alpha/beta production by alloantigen-stimulated bone marrow cells.	Cyclosporine	16-19	interferon alpha	Mus musculus	155-164
6352158-4	1983	Rejections in patients receiving cyclosporin-A alone as post-transplantation immunosuppressive medication were characterized by a significantly higher peak SAA level than rejections in patients receiving cyclosporin-A in combination with methylprednisolone (539 +/- 53 mg/l, mean +/- SEM, vs 226 +/- 9 mg/l, P less than 0.01).	Cyclosporine	33-46	serum amyloid A1 cluster	Homo sapiens	156-159
7204576-2	1981	Cyclosporin A (CS-A), a selective inhibitor of T lymphocytes, is reported here to prevent S antigen (S-Ag) induced uveitis in Lewis rats.	Cyclosporine	0-13	chorionic somatomammotropin hormone 1	Homo sapiens	15-19
33377278-8	2021	Evaluation of major distal salt transporters, NKCC2 and NCC, showed increased levels of their activating phosphorylation upon CsA.	Cyclosporine	126-129	solute carrier family 12 member 1	Rattus norvegicus	46-51
33548873-9	2021	Interestingly, not only cyclosporin, but also leuprorelin and cetrorelix showed metabolites whose formation was CYP (NADPH) dependent in liver S9.	Cyclosporine	24-35	2,4-dienoyl-CoA reductase 1	Homo sapiens	117-122
33676539-8	2021	METHODS: In our study, hAPP mice were treated with vehicle, nocodazole (NCZ, microtubule inhibitor to block P-gp internalization), or a combination of NCZ and the P-gp inhibitor cyclosporin A (CSA).	Cyclosporine	178-191	phosphoglycolate phosphatase	Mus musculus	163-167
24486136-1	2014	Mycophenolic acid (MPA) is an immunosuppressant used in transplant rejection, often in combination with cyclosporine (CsA) and tacrolimus (Tac).	Cyclosporine	104-116	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	118-121
24915078-4	2014	In addition, each crystal form contains a PEG 400 molecule bound to the same region along with a second PEG 400 site in CypD-t which occupies the cyclosporine A inhibitor binding site of CypD.	Cyclosporine	146-160	peptidylprolyl isomerase D	Homo sapiens	120-124
24915078-4	2014	In addition, each crystal form contains a PEG 400 molecule bound to the same region along with a second PEG 400 site in CypD-t which occupies the cyclosporine A inhibitor binding site of CypD.	Cyclosporine	146-160	peptidylprolyl isomerase D	Homo sapiens	187-191
24786238-4	2014	Cyclosporine (CsA) is an immunosuppressant that is highly effective for severe disease, but its mechanism in AD skin lesions has not been studied.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
24656168-7	2014	Moreover, ACC1 and FAS protein expression was increased after 3weeks (&gt;100%, p&lt;0.01), while HSL was increased after 9weeks of CsA treatment.	Cyclosporine	132-135	lipase E, hormone sensitive type	Rattus norvegicus	98-101
24508908-0	2014	Cyclosporin A ameliorates early brain injury after subarachnoid hemorrhage through inhibition of a Nur77 dependent apoptosis pathway.	Cyclosporine	0-13	nuclear receptor subfamily 4, group A, member 1	Rattus norvegicus	99-104
24508908-4	2014	CsA, a Nur77 inhibitor, can abolish DNA binding activity of Nur77, further inhibit the Nur77 dependent apoptosis pathway.	Cyclosporine	0-3	nuclear receptor subfamily 4, group A, member 1	Rattus norvegicus	7-12
24508908-4	2014	CsA, a Nur77 inhibitor, can abolish DNA binding activity of Nur77, further inhibit the Nur77 dependent apoptosis pathway.	Cyclosporine	0-3	nuclear receptor subfamily 4, group A, member 1	Rattus norvegicus	60-65
24508908-4	2014	CsA, a Nur77 inhibitor, can abolish DNA binding activity of Nur77, further inhibit the Nur77 dependent apoptosis pathway.	Cyclosporine	0-3	nuclear receptor subfamily 4, group A, member 1	Rattus norvegicus	60-65
24508908-8	2014	CsA markedly decreased expressions of Nur77, p-Nur77, Bcl-2 and cyto C, and inhibited apoptosis.Improvement of neurological deficit, alleviation of brain edema and amelioration of EBI were obtained after prophylactic use of CsA.	Cyclosporine	0-3	nuclear receptor subfamily 4, group A, member 1	Rattus norvegicus	38-43
24508908-8	2014	CsA markedly decreased expressions of Nur77, p-Nur77, Bcl-2 and cyto C, and inhibited apoptosis.Improvement of neurological deficit, alleviation of brain edema and amelioration of EBI were obtained after prophylactic use of CsA.	Cyclosporine	0-3	nuclear receptor subfamily 4, group A, member 1	Rattus norvegicus	47-52
24658577-3	2014	As such, the combination of IL-2 and a calcineurin inhibitor (Cyclosporine A; CsA) expands Tregs while inhibiting Tconv proliferation and protects against a mouse model of multiple sclerosis.	Cyclosporine	62-76	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	78-81
23624721-9	2014	Using cyclosporin A as an inhibitor, we revealed that NF-ATc1 directly regulates OC-STAMP and P2X7 receptor expression during LPA-stimulated osteoclast fusion.	Cyclosporine	6-19	osteoclast stimulatory transmembrane protein	Homo sapiens	81-89
24462674-0	2014	Celecoxib offsets the negative renal influences of cyclosporine via modulation of the TGF-beta1/IL-2/COX-2/endothelin ET(B) receptor cascade.	Cyclosporine	51-63	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	101-106
24462674-6	2014	We also report that cortical glomerular and medullary tubular protein expressions of COX-2 and ET(B) receptors were reduced by CSA and restored to near-control values in rats treated simultaneously with celecoxib.	Cyclosporine	127-130	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	85-90
24291639-6	2014	Furthermore, cyclosporin A (CsA) and knockdown of nuclear factor of activated T-cells c3 (NFATc3) inhibited the expression of COX-2 induced by ET-1, and NFATc3 could also bound to the -GGAAA- sequence in the promoter region of rat COX-2 gene, indicating that calcineurin/NFATc3 signaling participated in the transcriptional regulation of COX-2 following ET-1 treatment.	Cyclosporine	13-26	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	126-131
24291639-6	2014	Furthermore, cyclosporin A (CsA) and knockdown of nuclear factor of activated T-cells c3 (NFATc3) inhibited the expression of COX-2 induced by ET-1, and NFATc3 could also bound to the -GGAAA- sequence in the promoter region of rat COX-2 gene, indicating that calcineurin/NFATc3 signaling participated in the transcriptional regulation of COX-2 following ET-1 treatment.	Cyclosporine	13-26	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	231-236
24291639-6	2014	Furthermore, cyclosporin A (CsA) and knockdown of nuclear factor of activated T-cells c3 (NFATc3) inhibited the expression of COX-2 induced by ET-1, and NFATc3 could also bound to the -GGAAA- sequence in the promoter region of rat COX-2 gene, indicating that calcineurin/NFATc3 signaling participated in the transcriptional regulation of COX-2 following ET-1 treatment.	Cyclosporine	13-26	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	231-236
24291639-6	2014	Furthermore, cyclosporin A (CsA) and knockdown of nuclear factor of activated T-cells c3 (NFATc3) inhibited the expression of COX-2 induced by ET-1, and NFATc3 could also bound to the -GGAAA- sequence in the promoter region of rat COX-2 gene, indicating that calcineurin/NFATc3 signaling participated in the transcriptional regulation of COX-2 following ET-1 treatment.	Cyclosporine	28-31	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	126-131
2141324-3	1990	Purified CD8+ responder cells were inhibited as effectively by CsA as unfractionated cells, suggesting that CsA has a direct, lymphokine-independent effect on CD8+ cells.	Cyclosporine	63-66	CD8a molecule	Homo sapiens	9-12
2141324-3	1990	Purified CD8+ responder cells were inhibited as effectively by CsA as unfractionated cells, suggesting that CsA has a direct, lymphokine-independent effect on CD8+ cells.	Cyclosporine	108-111	CD8a molecule	Homo sapiens	9-12
2141324-3	1990	Purified CD8+ responder cells were inhibited as effectively by CsA as unfractionated cells, suggesting that CsA has a direct, lymphokine-independent effect on CD8+ cells.	Cyclosporine	108-111	CD8a molecule	Homo sapiens	159-162
2323839-0	1990	Expression of the mdr3 gene in prolymphocytic leukemia: association with cyclosporin-A-induced increase in drug accumulation.	Cyclosporine	73-86	ATP binding cassette subfamily B member 4	Homo sapiens	18-22
2323839-9	1990	Since cyclosporin A is an inhibitor of the mdr1-encoded P-glycoprotein drug pump, these data suggest that in PLL cells mdr3 also codes for a drug efflux pump.	Cyclosporine	6-19	ATP binding cassette subfamily B member 4	Homo sapiens	119-123
24523831-6	2014	Cyclosporine A was administered, which led to a dramatic recovery from anemia, and stabilized her alanine aminotransferase levels.	Cyclosporine	0-14	glutamic--pyruvic transaminase	Homo sapiens	98-122
33606519-7	2021	This study, for the first time, reports the molecules like cyclosporine, calcitriol, and estradiol as candidate drugs with the binding ability to the host proteases, TMPRSS2, and cathepsin B/L.	Cyclosporine	59-71	cathepsin B	Homo sapiens	179-190
24942911-1	2014	BACKGROUND/AIMS: Cyclosporine (CsA) is a calcineurin inhibitor widely used as an immunosuppressant in organ transplantation.	Cyclosporine	17-29	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	31-34
33001576-10	2021	Pathway enrichment analyses revealed different precursors and pathways highlighting the relevance of AA and LOX pathway in CSA and RA, respectively.	Cyclosporine	123-126	lysyl oxidase	Homo sapiens	108-111
24971338-9	2014	Conversion to SRL prevented CsA-induced renal damage evolution (absent/mild grade lesions), while NGAL (serum versus urine) seems to be a feasible biomarker of CsA replacement to SRL.	Cyclosporine	160-163	lipocalin 2	Rattus norvegicus	98-102
24656003-8	2014	By contrast, EPOR expression was higher in kidneys from CsA-treated rats than in vehicle-treated rats.	Cyclosporine	56-59	erythropoietin receptor	Rattus norvegicus	13-17
33317956-9	2021	Treatment with prednisolone + theophylline + cyclosporin A inhibited IFN-gamma and TNF-alpha production by SA CD28null CD8+ T and NKT-like cells additively.	Cyclosporine	45-58	CD8a molecule	Homo sapiens	119-122
33462352-11	2021	Collectively, we identified that hsa-miR-494-3p, a miRNA induced in both circulation of AKI patients and hypoxia-reoxygenation-treated HK2 cells, enhanced renal inflammation by targeting HtrA3, which may suggest a possible role as a new therapeutic target for CSA-AKI.	Cyclosporine	260-263	HtrA serine peptidase 3	Homo sapiens	187-192
32090669-0	2020	PPAR gamma/TLR4/TGF-beta1 axis mediates the protection effect of erythropoietin on cyclosporin A-induced chronic nephropathy in rat.	Cyclosporine	83-96	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	0-10
24744855-2	2013	Cyclophilin D is a key component of the MPT pore, therefore, the purpose of this study was to test the efficacy of a novel cyclosporine (CsA) dosing scheme as a therapeutic alternative for HFpEF.	Cyclosporine	123-135	peptidylprolyl isomerase F	Sus scrofa	0-13
24744855-2	2013	Cyclophilin D is a key component of the MPT pore, therefore, the purpose of this study was to test the efficacy of a novel cyclosporine (CsA) dosing scheme as a therapeutic alternative for HFpEF.	Cyclosporine	137-140	peptidylprolyl isomerase F	Sus scrofa	0-13
32090669-9	2020	Interestingly, when PPARgamma activity was inhibited by T0070907, an effective and specific PPARgamma inhibitor, the therapeutic effect of EPO was significantly attenuated.Conclusion: Taken together, above results shown the protective effect of EPO on cyclosporine A-induced renal injury and confirmed that EPO"s anti-inflammation and antioxidative stress involving the PPAR gamma/TLR4/TGFbeta1 axis.	Cyclosporine	252-266	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	20-29
32843478-5	2020	These effects of CsA involve at least two of the stress-activated protein kinases (GCN2 and PERK) that act on the translational machinery to slow down protein synthesis via phosphorylation of the eukaryotic initiation factor (eIF) 2alpha and thereby induce the ISR.	Cyclosporine	17-20	eukaryotic translation initiation factor 2 alpha kinase 4	Homo sapiens	83-87
32843478-5	2020	These effects of CsA involve at least two of the stress-activated protein kinases (GCN2 and PERK) that act on the translational machinery to slow down protein synthesis via phosphorylation of the eukaryotic initiation factor (eIF) 2alpha and thereby induce the ISR.	Cyclosporine	17-20	eukaryotic translation initiation factor 2A	Homo sapiens	196-237
23851154-11	2013	Cyclosporine A group: there were differences in thrombospondin-1, TCR, 2,3-bisphosphoglycerate, sodium channel beta-1, gig18 and TCR.	Cyclosporine	0-14	thrombospondin 1	Rattus norvegicus	48-64
33096599-8	2020	In contrast, CsA induced arteriolopathy, hypoperfusion, a reduction in the glomerular filtration rate, and downregulation of eNOS, angiotensinogen, and AT1R mRNA levels.	Cyclosporine	13-16	nitric oxide synthase 3	Rattus norvegicus	125-129
32987693-3	2020	Cyclosporine A (CsA) is an inhibitor of OATPs, P-gp, MRP2, BCRP and CYP3As.	Cyclosporine	0-14	ATP binding cassette subfamily C member 2	Homo sapiens	53-57
1695425-1	1990	Cyclosporin A (CS-A) partly inhibited IgE-mediated histamine release from human lung tissue in vitro (chopped and collagenase-dispersed preparations).	Cyclosporine	0-13	chorionic somatomammotropin hormone 1	Homo sapiens	15-19
32987693-3	2020	Cyclosporine A (CsA) is an inhibitor of OATPs, P-gp, MRP2, BCRP and CYP3As.	Cyclosporine	16-19	ATP binding cassette subfamily C member 2	Homo sapiens	53-57
23942768-10	2013	Notably, two of our patients who were treated with low-dose glucocorticoids plus other milder immunosuppressive drugs (methotrexate and cyclosporine) also developed CMV-UGT.	Cyclosporine	136-148	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	169-172
32529968-6	2020	The molecular mechanisms underlying the effects of CsA were explored, and it was found that CsA could inhibit the increase in CypA, p-Akt, NF-kappaB, and MMP-9 protein expression after middle cerebral artery occlusion, while Claudin-5 expression was decreased.	Cyclosporine	92-95	peptidylprolyl isomerase A	Mus musculus	126-130
24228106-11	2013	Moreover, CsA pretreatment up-regulated Titin expression, down-regulated E-cadherin expression, improved MMP2 and MMP9 activity, and increased the CXCL12 secretion in JAR cells.	Cyclosporine	10-13	titin	Homo sapiens	40-45
33805042-6	2021	Interestingly, drugs widely used to treat skin inflammation, the calcineurin inhibitors tacrolimus and cyclosporine and the glucocorticoid dexamethasone, significantly decreased TRPA1 expression.	Cyclosporine	103-115	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	178-183
32529968-6	2020	The molecular mechanisms underlying the effects of CsA were explored, and it was found that CsA could inhibit the increase in CypA, p-Akt, NF-kappaB, and MMP-9 protein expression after middle cerebral artery occlusion, while Claudin-5 expression was decreased.	Cyclosporine	92-95	claudin 5	Mus musculus	225-234
32464051-6	2020	Here, to realize targeted intracellular cyclosporine A (CsA) delivery, we designed a lipoprotein biomimetic nanocarrier by incorporating CsA in the core and decorating a matrix metalloproteinase-9 activatable cell-penetrating peptide onto the surface of the lipoprotein-mimic nanocarrier.	Cyclosporine	40-54	matrix metallopeptidase 9	Homo sapiens	170-196
33032826-9	2020	CsA was also found to promote the expression of titin, MMP9, EGFR, and PRR15.	Cyclosporine	0-3	matrix metallopeptidase 9	Homo sapiens	55-59
33032826-9	2020	CsA was also found to promote the expression of titin, MMP9, EGFR, and PRR15.	Cyclosporine	0-3	proline rich 15	Homo sapiens	71-76
23929936-3	2013	Cyclosporine A (CsA) and rifampicin (RIF), typical OATP inhibitors, inhibited active uptake of pitavastatin into monkey hepatocytes with half-maximal inhibitory concentration values comparable with those in human hepatocytes.	Cyclosporine	16-19	solute carrier organic anion transporter family member 1A2	Homo sapiens	51-55
32464051-6	2020	Here, to realize targeted intracellular cyclosporine A (CsA) delivery, we designed a lipoprotein biomimetic nanocarrier by incorporating CsA in the core and decorating a matrix metalloproteinase-9 activatable cell-penetrating peptide onto the surface of the lipoprotein-mimic nanocarrier.	Cyclosporine	56-59	matrix metallopeptidase 9	Homo sapiens	170-196
24084745-3	2013	In the JCI papers that are the subject of this Hindsight, we showed that loss of Mdr1a (Abcb1a) had a profound effect on the tissue distribution and especially the brain accumulation of a range of drugs frequently used in humans, including dexamethasone, digoxin, cyclosporin A, ondansetron, domperidone, and loperamide.	Cyclosporine	264-277	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	81-86
24084745-3	2013	In the JCI papers that are the subject of this Hindsight, we showed that loss of Mdr1a (Abcb1a) had a profound effect on the tissue distribution and especially the brain accumulation of a range of drugs frequently used in humans, including dexamethasone, digoxin, cyclosporin A, ondansetron, domperidone, and loperamide.	Cyclosporine	264-277	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	88-94
34915361-6	2022	The mitochondrial permeability transition pore inhibitor cyclosporine A exclusively diminished the CBD-induced PINK1/Parkin activation and its associated mitochondrial effects.	Cyclosporine	57-71	PTEN induced kinase 1	Homo sapiens	111-116
32625210-5	2020	The aim of this project is to investigate the effects of (oral) donor preconditioning with a calcineurin inhibitor (Cyclosporine) vs. an inhibitor of mammalian target for Rapamycin (Everolimus) compared to the conventional administration of steroid in the setting of donation after brain death in porcine renal transplantation.	Cyclosporine	116-128	calcineurin binding protein 1	Homo sapiens	93-114
32307754-5	2020	We found inefficient thermogenic respiration due to futile proton leak in Fmr1 KO mitochondria caused by coenzyme Q (CoQ) deficiency and an open cyclosporine-sensitive channel.	Cyclosporine	145-157	fragile X messenger ribonucleoprotein 1	Mus musculus	74-78
24250211-1	2013	We report that one 18-year-old female patient with no epilepsia history developed severe epileptiform seizures while she was receiving "ciclosporin A (CsA)-mycophenolate-methylprednisolone" antirejection therapy after combining one week"s voriconazole administration following allogeneic hematopoietic stem cell transplantation (allo-HSCT) for myelodysplastic syndromes (MDS).	Cyclosporine	136-149	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	151-154
24133577-8	2013	In addition, CsA increased the phosphorylation of NF-kappaB p65 and the inhibitor I-kappaB in human trophoblasts in a time-related manner.	Cyclosporine	13-16	RELA proto-oncogene, NF-kB subunit	Homo sapiens	60-63
32595898-10	2020	Furthermore, double knockdown with pluripotency-associated transcription factor Nanog showed that the down-regulation of Oct4/Nanog by lentiviral infection significantly inhibited CsA-stimulated cell growth (p < 0.05).	Cyclosporine	180-183	Nanog homeobox	Homo sapiens	80-85
34339964-3	2021	Here, we present for the first time a drug interaction profile of ALK-TKIs, crizotinib and alectinib, and immunosuppressive agent cyclosporine A in kidney transplant recipients diagnosed with ALK+ lung cancer.	Cyclosporine	130-144	ALK receptor tyrosine kinase	Homo sapiens	192-195
23712757-0	2013	Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporin.	Cyclosporine	143-154	solute carrier organic anion transporter family member 1A2	Homo sapiens	127-131
34339964-7	2021	Hence, the therapy of ALK+ NSCLC with ALK-TKIs in organ transplant recipients treated with cyclosporine A may be feasible and effective.	Cyclosporine	91-105	ALK receptor tyrosine kinase	Homo sapiens	22-25
32595898-10	2020	Furthermore, double knockdown with pluripotency-associated transcription factor Nanog showed that the down-regulation of Oct4/Nanog by lentiviral infection significantly inhibited CsA-stimulated cell growth (p < 0.05).	Cyclosporine	180-183	Nanog homeobox	Homo sapiens	126-131
34339964-7	2021	Hence, the therapy of ALK+ NSCLC with ALK-TKIs in organ transplant recipients treated with cyclosporine A may be feasible and effective.	Cyclosporine	91-105	ALK receptor tyrosine kinase	Homo sapiens	38-41
23712757-3	2013	OBJECTIVE: The objective of this study was to evaluate the effect of a potent OATP inhibitor, ciclosporin, on danoprevir pharmacokinetics, when administered as danoprevir/ritonavir.	Cyclosporine	94-105	solute carrier organic anion transporter family member 1A2	Homo sapiens	78-82
23990993-5	2013	We found that CsA treatment of HT-29 cells before, during, and after viral infection efficiently inhibited Wa strain RV replication and restored IFN-beta expression in a HT-29 cell line model.	Cyclosporine	14-17	interferon beta 1	Homo sapiens	145-153
32040235-0	2020	Hydrogen-rich water alleviates cyclosporine A-induced nephrotoxicity via the Keap1/Nrf2 signaling pathway.	Cyclosporine	31-45	Kelch-like ECH-associated protein 1	Rattus norvegicus	77-82
23990993-6	2013	Exploring the underlying mechanisms showed that CsA promoted Interferon Regulatory Factor-5 (IRF-5) expression (a key positive regulator of the type I IFN signaling pathway), but not IRF-1, IRF-3, or IRF-7.	Cyclosporine	48-51	interferon regulatory factor 5	Homo sapiens	93-98
34426105-2	2021	Ciclosporin, a calcineurin inhibitor, is characterized by beneficial antiviral and immunomodulatory effects.	Cyclosporine	0-11	calcineurin binding protein 1	Homo sapiens	15-36
32040235-14	2020	In conclusion, HRW restored the balance of redox status, suppressed oxidative stress damage, and improved kidney function induced by CsA via activation of the Keap1/Nrf2 signaling pathway.	Cyclosporine	133-136	Kelch-like ECH-associated protein 1	Rattus norvegicus	159-164
32349277-6	2020	Based on the results of Drug-LGIR, we applied cyclosporine A or local steroid (triamcinolone) therapy to two monkeys, and successfully suppressed RPE-related immune rejections with RPE grafts, which survived without any signs of rejection under drug administration.	Cyclosporine	46-60	ribulose-5-phosphate-3-epimerase	Homo sapiens	146-149
34502402-4	2021	Addition of cyclosporin A, a blocker of mitochondrial permeability transition pore (mPTP), antioxidant trolox, or inositol 1,4,5-trisphosphate receptor (IP3R) blocker caffeine in the presence of rotenone reduced the elevated rate and the amplitude of the signals implying sensitivity to reactive oxygen species (ROS), and involvement of mitochondrial mPTP together with IP3R.	Cyclosporine	12-25	inositol 1,4,5-trisphosphate receptor, type 1	Rattus norvegicus	153-157
34502402-4	2021	Addition of cyclosporin A, a blocker of mitochondrial permeability transition pore (mPTP), antioxidant trolox, or inositol 1,4,5-trisphosphate receptor (IP3R) blocker caffeine in the presence of rotenone reduced the elevated rate and the amplitude of the signals implying sensitivity to reactive oxygen species (ROS), and involvement of mitochondrial mPTP together with IP3R.	Cyclosporine	12-25	inositol 1,4,5-trisphosphate receptor, type 1	Rattus norvegicus	370-374
23639789-9	2013	In contrast, Ngb knockdown significantly increased OGD-induced neuron death, and increased OGD-induced mitochondrial NAD(+) release and Cyt c release as well, and these outcomes could be rescued by CsA pretreatment.	Cyclosporine	198-201	neuroglobin	Mus musculus	13-16
23777496-0	2013	Ciclosporin A inhibits production of interleukin-12/23p40 and interleukin-23 by the human monocyte cell line, THP-1.	Cyclosporine	0-13	interleukin 37	Homo sapiens	62-76
23499865-5	2013	CsA treatment down-regulates expression of gluconeogenic gene including Pepck, G6Pase and Pgc1alpha, leading to a decrease in blood glucose level and an improvement of glucose tolerance in the obese animals.	Cyclosporine	0-3	glucose-6-phosphatase, catalytic	Mus musculus	79-85
32349277-6	2020	Based on the results of Drug-LGIR, we applied cyclosporine A or local steroid (triamcinolone) therapy to two monkeys, and successfully suppressed RPE-related immune rejections with RPE grafts, which survived without any signs of rejection under drug administration.	Cyclosporine	46-60	ribulose-5-phosphate-3-epimerase	Homo sapiens	181-184
23499865-5	2013	CsA treatment down-regulates expression of gluconeogenic gene including Pepck, G6Pase and Pgc1alpha, leading to a decrease in blood glucose level and an improvement of glucose tolerance in the obese animals.	Cyclosporine	0-3	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	90-99
23499865-6	2013	RT-PCR analysis of genes involved in adipocyte differentiation and lipid metabolism in white adipose tissue reveal that CsA application reduces expression of Ppargamma, Fas and Scd 1.	Cyclosporine	120-123	peroxisome proliferator activated receptor gamma	Mus musculus	158-167
23436429-5	2013	In our study, we investigated RCAN1 and SOD1 expression in long-term CsA-treated mouse brain.	Cyclosporine	69-72	regulator of calcineurin 1	Mus musculus	30-35
34483914-1	2021	Remdesivir, a prodrug targeting RNA-dependent-RNA-polymerase, and cyclosporine, a calcineurin inhibitor, individually exerted inhibitory activity against human coronavirus OC43 (HCoV-OC43) in HCT-8 and MRC-5 cells at EC50 values of 96 +- 34 ~ 85 +- 23 nM and 2,920 +- 364 ~ 4,419 +- 490 nM, respectively.	Cyclosporine	66-78	calcineurin binding protein 1	Homo sapiens	82-103
34439442-6	2021	The administration of CsA also significantly downregulated the renal expression of interferon-gamma, tumor necrosis factor-alpha, interleukin 1 beta, monocyte chemotactic protein 1, intercellular adhesion molecule-1, and vascular cell adhesion molecule 1 genes, and increased renal DNA damage.	Cyclosporine	22-25	intercellular adhesion molecule 1	Rattus norvegicus	182-215
23436429-6	2013	Using Western blot, we found that chronic CsA treatment had caused significant up-regulation of RCAN1-1L and RCAN1-4 protein isoforms after 25 days in mouse brain.	Cyclosporine	42-45	regulator of calcineurin 1	Mus musculus	96-101
32027049-6	2020	MPA/AZA-sparing, mTORi-based, and cyclosporine-based maintenance ISx regimens were associated with significantly higher payments.	Cyclosporine	34-46	intestine specific homeobox	Homo sapiens	65-68
23436429-6	2013	Using Western blot, we found that chronic CsA treatment had caused significant up-regulation of RCAN1-1L and RCAN1-4 protein isoforms after 25 days in mouse brain.	Cyclosporine	42-45	regulator of calcineurin 1	Mus musculus	109-116
34127702-10	2021	Collectively, our study suggests that Pan-LOX and LOXL2 inhibition can attenuate progressive nephropathy due to CsA administration.	Cyclosporine	112-115	lysyl oxidase-like 2	Mus musculus	50-55
32068662-5	2020	MMP-9 expression is blunted by a diverse array of molecular factors, such as tissue inhibitors of metalloproteinases, cyclosporine A (CyA), PES_103, epigalloccatechin-3-gallate (EGCG), N-acetylcysteine (NaC), ascorbate, tetracyclines, and corticosteroids.	Cyclosporine	118-132	matrix metallopeptidase 9	Homo sapiens	0-5
35458953-3	2022	The CSA is then coupled to the end of a slab Tamm plasmon (STP-) resonator, which is composed of a quasicrystal-like reflector formed by the patterning of a silicon slab and an interfacing tungsten slab.	Cyclosporine	4-7	thyroid hormone receptor interactor 10	Homo sapiens	59-62
35183993-12	2022	Further, RNA-seq analysis of colonic epithelium revealed C0127 combined with CSA chiefly regulated chemokines and cytokines in IL-17 signaling pathway.	Cyclosporine	77-80	interleukin 17A	Mus musculus	127-132
2807375-12	1989	Together, these results demonstrate that resting CD4+ thymocytes can be induced to proliferation and lymphokine secretion by IL-2 alone in a process that is dependent on interaction with accessory cells, involves CD4 adhesion molecules and triggers activation through a CsA-sensitive pathway.	Cyclosporine	270-273	CD4 antigen	Mus musculus	49-52
2682268-0	1989	Interaction of cyclosporine-A with the renin-angiotensin system in canine veins.	Cyclosporine	15-29	renin	Canis lupus familiaris	39-44
2682268-5	1989	infusion of the renin inhibitor H-77 (0.1 mg/kg/h) reversed the inhibition of bradykinin by both clopamide and cyclosporine-A.	Cyclosporine	111-125	renin	Canis lupus familiaris	16-21
2526799-5	1989	Furthermore, proliferation of CD8+CD11- cells, considered a cytotoxic T cell subset, were inhibited significantly more in anti-IL2 RAb-treated MLR culture than in CsA-treated MLR culture.	Cyclosporine	163-166	CD8a molecule	Homo sapiens	30-33
2784322-4	1989	In the epidermis of the cyclosporin-injected plaques, total and HLA-DR+ CD4+ and CD8+ T cell numbers were significantly decreased compared to corresponding plaques treated with placebo (total CD4+, total CD8+, DR+ CD4+, P less than 0.01; DR+ CD8+, P less than 0.02).	Cyclosporine	24-35	CD8a molecule	Homo sapiens	81-84
2784322-4	1989	In the epidermis of the cyclosporin-injected plaques, total and HLA-DR+ CD4+ and CD8+ T cell numbers were significantly decreased compared to corresponding plaques treated with placebo (total CD4+, total CD8+, DR+ CD4+, P less than 0.01; DR+ CD8+, P less than 0.02).	Cyclosporine	24-35	CD8a molecule	Homo sapiens	204-207
2784322-4	1989	In the epidermis of the cyclosporin-injected plaques, total and HLA-DR+ CD4+ and CD8+ T cell numbers were significantly decreased compared to corresponding plaques treated with placebo (total CD4+, total CD8+, DR+ CD4+, P less than 0.01; DR+ CD8+, P less than 0.02).	Cyclosporine	24-35	CD8a molecule	Homo sapiens	204-207
2784322-5	1989	Similarly, T lymphocyte numbers in the dermis were decreased in the cyclosporin compared to placebo-treated plaques; the reduction in total CD4+ and DR+ CD8+ T cell numbers was statistically significant (P less than 0.05).	Cyclosporine	68-79	CD8a molecule	Homo sapiens	153-156
2623737-4	1989	Thymuses from CsA-treated mice lacked the SP L3T4(CD4)+ subset, DN and double positive (DP) thymocytes were still present.	Cyclosporine	14-17	CD4 antigen	Mus musculus	50-53
3042442-8	1988	The data reveal that CsA can dissociate between the production of IL3 and GM-CSF, suggesting that these two CSFs are regulated by different mechanisms.	Cyclosporine	21-24	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	74-80
32068662-5	2020	MMP-9 expression is blunted by a diverse array of molecular factors, such as tissue inhibitors of metalloproteinases, cyclosporine A (CyA), PES_103, epigalloccatechin-3-gallate (EGCG), N-acetylcysteine (NaC), ascorbate, tetracyclines, and corticosteroids.	Cyclosporine	134-137	matrix metallopeptidase 9	Homo sapiens	0-5
31840415-8	2020	However, the PRP-2 group showed larger CSA than saline groups.	Cyclosporine	39-42	major prion protein	Oryctolagus cuniculus	13-16
23519664-1	2013	Cyclophilins belong to a family of proteins that bind to the immunosuppressive drug cyclosporin A (CsA).	Cyclosporine	84-97	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	99-102
23167600-10	2013	In cyclosporine-treated allografts VEGF-C/VEGFR-3 pathway was strongly upregulated leading to extensive lymphangiogenesis 60 days after transplantation.	Cyclosporine	3-15	Fms related receptor tyrosine kinase 4	Rattus norvegicus	42-49
32019593-0	2020	Cyclosporine-a attenuates retinal inflammation by inhibiting HMGB-1 formation in rats with type 2 diabetes mellitus.	Cyclosporine	0-14	high mobility group box 1	Rattus norvegicus	61-67
31654209-4	2020	Cyclosporin A (CsA), a powerful inhibitor of MPT, enhanced the AGM-mediated inhibition of swelling, and surprisingly, prevented the release of cyt c and Smac/DIABLO.	Cyclosporine	0-13	diablo, IAP-binding mitochondrial protein	Rattus norvegicus	153-157
31654209-4	2020	Cyclosporin A (CsA), a powerful inhibitor of MPT, enhanced the AGM-mediated inhibition of swelling, and surprisingly, prevented the release of cyt c and Smac/DIABLO.	Cyclosporine	0-13	diablo, IAP-binding mitochondrial protein	Rattus norvegicus	158-164
31654209-4	2020	Cyclosporin A (CsA), a powerful inhibitor of MPT, enhanced the AGM-mediated inhibition of swelling, and surprisingly, prevented the release of cyt c and Smac/DIABLO.	Cyclosporine	15-18	diablo, IAP-binding mitochondrial protein	Rattus norvegicus	153-157
3411194-0	1988	Effect of cyclosporine on urinary kallikrein excretion in patients with rheumatoid arthritis.	Cyclosporine	10-22	kallikrein related peptidase 4	Homo sapiens	34-44
3411194-1	1988	The effect of cyclosporine (6 to 8 mg/kg/day) on urinary kallikrein excretion was examined in 10 patients with rheumatoid arthritis by using a radioimmunoassay for kallikrein, a product of renal tubular biosynthesis.	Cyclosporine	14-26	kallikrein related peptidase 4	Homo sapiens	57-67
31654209-4	2020	Cyclosporin A (CsA), a powerful inhibitor of MPT, enhanced the AGM-mediated inhibition of swelling, and surprisingly, prevented the release of cyt c and Smac/DIABLO.	Cyclosporine	15-18	diablo, IAP-binding mitochondrial protein	Rattus norvegicus	158-164
31677118-12	2020	This study revealed an important role of MRP2 in the pharmacokinetics of deferasirox and drew attention to drug combination with MRP2 inhibitors like cyclosporine and methotrexate in deferasirox therapy.	Cyclosporine	150-162	ATP binding cassette subfamily C member 2	Homo sapiens	129-133
3066654-9	1988	During the period of administration, CsA led to a decrease of Lyt 1 +/Lyt 2 + ratio in spleen cells and prevented the insulitis in low dose SZ-treated mice.	Cyclosporine	37-40	CD5 antigen	Mus musculus	62-67
31618620-10	2019	We found that H2O2 promoted the colocalization of VDAC1 and Bax, which was partially inhibited by intervention with CsA or Atr.	Cyclosporine	116-119	voltage-dependent anion channel 1	Rattus norvegicus	50-55
31502276-0	2019	Case of Hailey-Hailey disease with a novel missense/in-frame deletion mutation in ATP2C1 successfully treated with cyclosporine.	Cyclosporine	115-127	ATPase secretory pathway Ca2+ transporting 1	Homo sapiens	82-88
3260048-5	1988	CsA prevented maintenance of high alloantibody titers to RT1A antigens in Lewis rats transfused repeatedly following sensitization.	Cyclosporine	0-3	RT1 class I, locus A	Rattus norvegicus	57-61
3260048-6	1988	IgG alloantibody subclass responses were also altered by CsA with significant reduction in titers of IgG1, 2a, and 2b against RT1A antigens in rats transfused repeatedly; CsA did not, however, suppress IgG2c alloantibody levels in these animals.	Cyclosporine	57-60	RT1 class I, locus A	Rattus norvegicus	126-130
3289146-10	1988	At 4 hr after oral CsA (group C), there was a reduction in the basal-to-peak insulin difference (37.2 +/- 9.1 vs. 22.5 +/- 4.1) and K values (-3.20 +/- 0.4 vs. -1.96 +/- 0.3), with the change in K values being statistically significant (P less than 0.05).	Cyclosporine	19-22	insulin	Canis lupus familiaris	77-84
31646917-1	2019	Cyclophilin A (CypA), an 18 kDa multi-functional protein with cis-trans isomerase activity, is both a ligand for cyclosporine A and a proinflammatory factor.	Cyclosporine	113-127	peptidylprolyl isomerase A	Mus musculus	0-13
3381308-0	1988	Cyclosporine inhibits ornithine decarboxylase gene expression and acute inflammation in response to phorbol ester treatment of hairless mouse skin.	Cyclosporine	0-12	ornithine decarboxylase, structural 1	Mus musculus	22-45
31646917-1	2019	Cyclophilin A (CypA), an 18 kDa multi-functional protein with cis-trans isomerase activity, is both a ligand for cyclosporine A and a proinflammatory factor.	Cyclosporine	113-127	peptidylprolyl isomerase A	Mus musculus	15-19
31408067-0	2019	A PepT1 mediated medicinal nano-system for targeted delivery of cyclosporine A to alleviate acute severe ulcerative colitis.	Cyclosporine	64-78	solute carrier family 15 (oligopeptide transporter), member 1	Mus musculus	2-7
31611804-11	2019	Our results confirmed the higher risk of DILI after CsA administration in healthy and BRIC2 patients.	Cyclosporine	52-55	ATP binding cassette subfamily B member 11	Homo sapiens	86-91
31222723-10	2019	As ABCA1 can be blocked by cyclosporine A, these results suggest further investigation of the possible use of statins to treat CsA-induced hypertension.	Cyclosporine	27-41	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	3-8
31227843-11	2019	In contrast, CsA had no impact on cholesterol efflux in M0 and M1 macrophages, but significantly augmented expression of ABCA1 and 27-hydroxylase in M2 macrophages.	Cyclosporine	13-16	ATP binding cassette subfamily A member 1	Homo sapiens	121-126
31592422-2	2019	Herein, a self-powered photodetector is developed with broadband response ranging from deep ultraviolet to near-infrared by combining FA1- x Cs x PbI3 perovskite with PdSe2 layer, a newly discovered TMDs material.	Cyclosporine	141-143	FA complementation group A	Homo sapiens	134-137
31054961-3	2019	However, the roles and regulatory mechanisms by which CsA modulates HSP expression remain largely unknown.	Cyclosporine	54-57	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	68-71
31054961-5	2019	Suppression of ERK1/2, GSK3beta and CK2 activities attenuated CsA-induced down-regulation of HSP expression and up-regulation of HSF1 phosphorylation.	Cyclosporine	62-65	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	93-96
31054961-8	2019	These results indicate that CsA suppresses HSP induction during heat shock by regulating the phosphorylation and nuclear translocation of HSF1.	Cyclosporine	28-31	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	43-46
24282430-6	2013	In addition, apoptotic cells, infiltrated inflammatory cells, and active caspase-3+ cells were greatly reduced by HBSP in the both IR and IR + CsA groups.	Cyclosporine	143-146	caspase 3	Rattus norvegicus	73-82
24282430-8	2013	Taken together, it has been demonstrated, for the first time, that HBSP effectively improved renal function and tissue damage caused by IR and/or CsA, which might be through reducing caspase-3 activation and synthesis, apoptosis, and inflammation.	Cyclosporine	146-149	caspase 3	Rattus norvegicus	183-192
30908976-0	2019	Analysis of HMQC experiments applied to a spin 1/2 nucleus subject to very large CSA.	Cyclosporine	81-84	spindlin 1	Homo sapiens	42-50
30908976-5	2019	The results show that for spectra of species with very large CSA, HP is little efficient, but that both DANTE and SLP provide efficient excitation profiles over a wide range of CSA values.	Cyclosporine	177-180	DAN domain BMP antagonist family member 5	Homo sapiens	104-109
23555748-1	2013	The aim of this study was to investigate whether hATMSCs protect against cyclosporine (CsA)-induced renal injury.	Cyclosporine	73-85	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	87-90
31108847-5	2019	In this study, we investigated whether secretion of the IL-22BP isoforms could be modulated by pharmacological targeting of GRP94 and cyclophilin B, either by means of geldanamycin, that binds to the ADP/ATP pocket shared by HSP90 paralogs, or by cyclosporin A, which causes depletion of ER cyclophilin B levels through secretion.	Cyclosporine	247-260	interleukin 22 receptor subunit alpha 2	Homo sapiens	56-63
22869619-3	2012	METHODS AND RESULTS: Exposure of bovine or human pulmonary artery endothelial cells (BPAECs or HPAECs) to the CN inhibitor cyclosporin A (CsA) induces a rise in intracellular Ca(2+) and increases the phosphorylation level of cofilin(Ser3) and MYPT1(Thr696) in a Ca(2+)-and Rho-kinase-dependent manner.	Cyclosporine	123-136	cofilin 1	Homo sapiens	225-232
22869619-3	2012	METHODS AND RESULTS: Exposure of bovine or human pulmonary artery endothelial cells (BPAECs or HPAECs) to the CN inhibitor cyclosporin A (CsA) induces a rise in intracellular Ca(2+) and increases the phosphorylation level of cofilin(Ser3) and MYPT1(Thr696) in a Ca(2+)-and Rho-kinase-dependent manner.	Cyclosporine	123-136	protein phosphatase 1 regulatory subunit 12A	Homo sapiens	243-248
22869619-3	2012	METHODS AND RESULTS: Exposure of bovine or human pulmonary artery endothelial cells (BPAECs or HPAECs) to the CN inhibitor cyclosporin A (CsA) induces a rise in intracellular Ca(2+) and increases the phosphorylation level of cofilin(Ser3) and MYPT1(Thr696) in a Ca(2+)-and Rho-kinase-dependent manner.	Cyclosporine	138-141	cofilin 1	Homo sapiens	225-232
22869619-3	2012	METHODS AND RESULTS: Exposure of bovine or human pulmonary artery endothelial cells (BPAECs or HPAECs) to the CN inhibitor cyclosporin A (CsA) induces a rise in intracellular Ca(2+) and increases the phosphorylation level of cofilin(Ser3) and MYPT1(Thr696) in a Ca(2+)-and Rho-kinase-dependent manner.	Cyclosporine	138-141	protein phosphatase 1 regulatory subunit 12A	Homo sapiens	243-248
22974004-1	2012	Cyclosporine (CSA) is the most commonly used medication for GVHD prophylaxis.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
23057591-10	2012	In summary, our study suggests a key role for PDZK1, CD147, JAK/STAT, and AKT signaling in CsA-induced nephrotoxicity and proposes mechanistic explanations on why rats fed a low-salt diet have higher sensitivity to CsA.	Cyclosporine	91-94	PDZ domain containing 1	Rattus norvegicus	46-51
22572818-6	2012	This Wnt1 effect did not depend on glycogen synthase kinase-3beta (GSK3beta), beta-catenin, or activator protein-1, but was blocked by cyclosporine A (CsA).	Cyclosporine	135-149	wingless-type MMTV integration site family, member 1	Mus musculus	5-9
22572818-6	2012	This Wnt1 effect did not depend on glycogen synthase kinase-3beta (GSK3beta), beta-catenin, or activator protein-1, but was blocked by cyclosporine A (CsA).	Cyclosporine	151-154	wingless-type MMTV integration site family, member 1	Mus musculus	5-9
22572818-9	2012	Concomitant overexpression of VEGF-C or feeding of animals with CsA restored lymphangiogenesis and metastasis in Wnt1(+) melanoma.	Cyclosporine	64-67	wingless-type MMTV integration site family, member 1	Mus musculus	113-117
22669715-12	2012	Treatment with corticosteroids and cyclosporine A (CsA) resolved the intraocular inflammation in association with an upregulation of IL-27 and a downregulation of IL-17.	Cyclosporine	35-49	interleukin 27	Homo sapiens	133-138
22669715-12	2012	Treatment with corticosteroids and cyclosporine A (CsA) resolved the intraocular inflammation in association with an upregulation of IL-27 and a downregulation of IL-17.	Cyclosporine	51-54	interleukin 27	Homo sapiens	133-138
22502817-12	2012	The levels of mRNA of IL-15 were lower in the syngenic transplanted group compared to the CsA-treated transplanted.	Cyclosporine	90-93	interleukin 15	Rattus norvegicus	22-27
22495096-8	2012	RESULTS: CsA up-regulated CXCL12 and CXCR4 expression in human first-trimester cytotrophoblast cells, but not in DSCs.	Cyclosporine	9-12	C-X-C motif chemokine ligand 12	Homo sapiens	26-32
22495096-9	2012	Blocking the mitogen-activated proteinkinase/extracellular signal-regulated kinase (MAPK/ERK1/2) signaling by U0126 abrogated the CsA-induced increase in CXCL12 and CXCR4 expression and neutralizing antibodies to CXCL12 or CXCR4 completely inhibited the CsA-induced increase in cell number, invasion and MMP-9 and MMP-2 activity of cytotrophoblast.	Cyclosporine	130-133	C-X-C motif chemokine ligand 12	Homo sapiens	154-160
22495096-9	2012	Blocking the mitogen-activated proteinkinase/extracellular signal-regulated kinase (MAPK/ERK1/2) signaling by U0126 abrogated the CsA-induced increase in CXCL12 and CXCR4 expression and neutralizing antibodies to CXCL12 or CXCR4 completely inhibited the CsA-induced increase in cell number, invasion and MMP-9 and MMP-2 activity of cytotrophoblast.	Cyclosporine	130-133	C-X-C motif chemokine ligand 12	Homo sapiens	213-219
22495096-9	2012	Blocking the mitogen-activated proteinkinase/extracellular signal-regulated kinase (MAPK/ERK1/2) signaling by U0126 abrogated the CsA-induced increase in CXCL12 and CXCR4 expression and neutralizing antibodies to CXCL12 or CXCR4 completely inhibited the CsA-induced increase in cell number, invasion and MMP-9 and MMP-2 activity of cytotrophoblast.	Cyclosporine	130-133	matrix metallopeptidase 2	Homo sapiens	314-319
22495096-10	2012	CsA also significantly promoted the activity of MMP-9 and MMP-2 in DSCs, but this was unaffected by CXCL12 or CXCR4 neutralizing antibody.	Cyclosporine	0-3	matrix metallopeptidase 2	Homo sapiens	58-63
22211698-0	2012	Interleukin-17- and protease-activated receptor 2-mediated production of CXCL1 and CXCL8 modulated by cyclosporine A, vitamin D3 and glucocorticoids in human keratinocytes.	Cyclosporine	102-116	F2R like trypsin receptor 1	Homo sapiens	0-49
22211698-7	2012	These results suggest that the IL-17-induced pro-inflammatory reaction is enhanced by the activation of PAR2 in keratinocytes, and that the effect of PAR2 is differentially modulated by cyclosporine A, the active form of vitamin D(3)  and glucocorticoids.	Cyclosporine	186-200	F2R like trypsin receptor 1	Homo sapiens	150-154
22375069-2	2012	The immunosuppressants cyclosporine A (CsA) and tacrolimus (TRL) also inhibit calcineurin (CLN) in the brain.	Cyclosporine	23-37	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	39-42
22471287-9	2012	CsA, but not everolimus, inhibits both T(reg) development and expression of CXCR3 and CCR5 on CD4(+) T cell subsets.	Cyclosporine	0-3	C-X-C motif chemokine receptor 3	Homo sapiens	76-81
22564605-8	2012	In contrast, MMP-2 activity was decreased after CsA treatment; MMP-2 = 79.	Cyclosporine	48-51	matrix metallopeptidase 2	Homo sapiens	13-18
22564605-8	2012	In contrast, MMP-2 activity was decreased after CsA treatment; MMP-2 = 79.	Cyclosporine	48-51	matrix metallopeptidase 2	Homo sapiens	63-68
21621841-5	2012	In vitro data show that PACAP protects tubular cells against oxidative stress, myeloma light chain, cisplatin, cyclosporine-A and hypoxia.	Cyclosporine	111-125	adenylate cyclase activating polypeptide 1	Homo sapiens	24-29
22483459-7	2012	The increased expression of caspase-3 and number of TUNEL-positive cells in the CsA group were decreased with concomitant paricalcitol treatment.	Cyclosporine	80-83	caspase 3	Rattus norvegicus	28-37
22334041-10	2012	In single-SNP adjusted analysis, nine SNPs in the XPC, CYP2C9, PAX4, MTRR, and GAN genes were associated with cyclosporine nephrotoxicity.	Cyclosporine	110-122	paired box 4	Homo sapiens	63-67
21900845-6	2012	CSA increased in both the LIR and HI groups (6.3% and 6.1%, respectively).	Cyclosporine	0-3	CD300c molecule	Homo sapiens	26-29
3279575-7	1988	Our data indicate that ABO major mismatched BMT can be associated with significant immunohematologic consequences, some of which occur more frequently in association with cyclosporine administration.	Cyclosporine	171-183	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	23-26
3412862-0	1988	Time-dependent effect of cyclosporin-A on the TSH-receptor antibody synthesis in patients with Graves" disease.	Cyclosporine	25-38	thyroid stimulating hormone receptor	Homo sapiens	46-58
3412862-3	1988	These results prompted us to investigate the in vitro influence of CyA on the synthesis of TSH receptor antibody by a patient"s lymphocytes (with highest antibody concentration) in response to thyroid membrane antigen.	Cyclosporine	67-70	thyroid stimulating hormone receptor	Homo sapiens	91-103
22394628-9	2012	With CsA treatment,  The proportion of CD14(+); T cells was lower than BLM model group at the same time point,  especially on the 4th day.	Cyclosporine	5-8	CD14 antigen	Mus musculus	39-43
31118889-8	2019	Okadaic acid (a PP1/PP2A inhibitor) reduced mitochondrial length with the up-regulated DRP1-S616 phosphorylation, while CsA (a PP2B inhibitor) increased it with the elevated DRP1-S637 phosphorylation.	Cyclosporine	120-123	dynamin 1-like	Rattus norvegicus	174-178
22236010-8	2012	Meanwhile, CD16(+) /IDO(+) and FoxP3(+) -expressing cells were lower in biopsies from CsA treatment compared to patients treated with Belatacept.	Cyclosporine	86-89	forkhead box P3	Homo sapiens	31-36
31118889-9	2019	Co-treatment of okadaic acid or CsA with perampanel attenuated the reductions in DRP1-S616 and -S637 phosphorylation without changing DRP1 expression level, respectively.	Cyclosporine	32-35	dynamin 1-like	Rattus norvegicus	81-85
31118889-9	2019	Co-treatment of okadaic acid or CsA with perampanel attenuated the reductions in DRP1-S616 and -S637 phosphorylation without changing DRP1 expression level, respectively.	Cyclosporine	32-35	dynamin 1-like	Rattus norvegicus	134-138
22225545-4	2012	In the present study, we examined the effect of cyclosporine A (CsA), a PPIase inhibitor, on SIV replication.	Cyclosporine	48-62	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	64-67
22062948-6	2012	The Rho kinase (ROK) inhibitor, Y27632, prevented CsA and CsA/SRL-induced cofilin phosphorylation and actin remodelling, reduced the TER increase and prevented the rise in claudin-7 levels caused by the drugs.	Cyclosporine	50-53	claudin 7	Homo sapiens	172-181
22062948-6	2012	The Rho kinase (ROK) inhibitor, Y27632, prevented CsA and CsA/SRL-induced cofilin phosphorylation and actin remodelling, reduced the TER increase and prevented the rise in claudin-7 levels caused by the drugs.	Cyclosporine	58-61	claudin 7	Homo sapiens	172-181
30663770-13	2019	CONCLUSIONS: Multiple doses of BG decreased the oral bioavailability of CsA in rats significantly, which may be mainly attributable to inhibition of absorption of CsA in intestine and induction of P-gp.	Cyclosporine	72-75	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	197-201
22062948-10	2012	Thus the Rho/Rho kinase pathway was involved in mediating CsA and CsA/SRL-induced cytoskeleton rearrangement and TER changes via claudin-7 expression.	Cyclosporine	58-61	claudin 7	Homo sapiens	129-138
22848341-0	2012	CXCL12/CXCR4 axis triggers the activation of EGF receptor and ERK signaling pathway in CsA-induced proliferation of human trophoblast cells.	Cyclosporine	87-90	C-X-C motif chemokine ligand 12	Homo sapiens	0-6
22848341-6	2012	RESULTS: Low concentration of CsA promoted the secretion of CXCL12, and recombinant human CXCL12 promoted the phosphorylation of EGFR in primary human trophoblast cells and choriocarcinoma cell line JEG-3.	Cyclosporine	30-33	C-X-C motif chemokine ligand 12	Homo sapiens	60-66
22848341-7	2012	The inhibition of CXCL12 or CXCR4 by either neutralizing antibodies or small interfering RNA (siRNA) could completely block the CsA-induced EGFR phosphorylation.	Cyclosporine	128-131	C-X-C motif chemokine ligand 12	Homo sapiens	18-24
22848341-9	2012	CsA promoted the activation of ERK in JEG-3 cells, which was markedly abrogated in the presence of CXCL12 siRNA, or CXCR4 siRNA, or AG1478.	Cyclosporine	0-3	C-X-C motif chemokine ligand 12	Homo sapiens	99-105
22848341-10	2012	CONCLUSIONS: CsA may promote EGFR activation via CXCL12/CXCR4 axis, and EGFR downstream ERK signaling pathway may be involved in the CsA-induced proliferation of human trophoblast cells.	Cyclosporine	13-16	C-X-C motif chemokine ligand 12	Homo sapiens	49-55
31019850-4	2019	Prior research has discovered a dose-dependent decrease in tyrosinase activity and pigment formation in cultured melanocytes due to cyclosporine - an effect opposite to what was observed in our case.	Cyclosporine	132-144	tyrosinase	Homo sapiens	59-69
22172885-3	2011	Standard therapy for recurrent posttransplantation FSGS includes the use of intensive plasmapheresis (PP) in conjunction with cyclophosphamide or high-dose cyclosporine.	Cyclosporine	156-168	actinin alpha 4	Homo sapiens	51-55
2888824-11	1987	The coadoptive transfer of cells resulted in the suppression of resistance afforded by the W3/25+ cells by OX8+ cells, which could be augmented in vitro by cyclosporin A.	Cyclosporine	156-169	Cd4 molecule	Rattus norvegicus	91-96
3117720-2	1987	Cyclosporine (CsA) has been reported to inhibit ODC activity in vitro.	Cyclosporine	0-12	ornithine decarboxylase, structural 1	Mus musculus	48-51
30463973-7	2019	Silencing the expression of CAV-1 or FKBP52 with short interfering RNAs or the inhibition of CyA by cyclosporine resulted in significant decrease in NS1 secretion, again without affecting virion release.	Cyclosporine	100-112	influenza virus NS1A binding protein	Homo sapiens	149-152
3117720-2	1987	Cyclosporine (CsA) has been reported to inhibit ODC activity in vitro.	Cyclosporine	14-17	ornithine decarboxylase, structural 1	Mus musculus	48-51
3097143-13	1987	However, although grafts of CsA-treated animals continued to remain IL 2R- and failed to stain with the macrophage activation marker A1-3, ART-18-treated rats showed increasing infiltration by both IL 2R+ mononuclear cells and A1-3+ macrophages, as well as increasing perivascular and interstitial fibrin deposition, prior to rejection by day 22.	Cyclosporine	28-31	UDP glucuronosyltransferase family 1 member A6	Rattus norvegicus	227-231
3097130-10	1986	CSA blocks at a point before the biosynthesis of Ea1 and after that of T3/T cell receptor loss from the cell surface, at a point close to Ea2 biosynthesis.	Cyclosporine	0-3	calcium voltage-gated channel subunit alpha1 A	Homo sapiens	138-141
21605084-1	2011	We tested whether inhibition of mitochondrial membrane potential dissipation by CsA (ciclosporin A) would prevent doxorubicin-induced myocardial and mitochondrial dysfunction.	Cyclosporine	80-83	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	85-98
30679998-11	2019	However, the protective effects of Nrf2 overexpression on PQ-challenged A549 cells were abrogated following cyclosporine A treatment, a competitive inhibitor of P-gp, which also increased intracellular PQ levels.	Cyclosporine	108-122	phosphoglycolate phosphatase	Mus musculus	161-165
21556823-0	2011	Protection by endogenous FGF-2 against isoproterenol-induced cardiac dysfunction is attenuated by cyclosporine A.	Cyclosporine	98-112	fibroblast growth factor 2	Mus musculus	25-30
21556823-2	2011	However, previously we found that chronic elevation in cardiac FGF-2 levels in transgenic mice was associated with exaggerated, cyclosporine A-preventable, cellular infiltration after isoproterenol-induced injury, suggestive of an adverse outcome, although this was not examined with functional studies.	Cyclosporine	128-142	fibroblast growth factor 2	Mus musculus	63-68
21556823-9	2011	Our data also suggest that cyclosporine A-sensitive infiltrating cell population(s) may contribute to the sustained beneficial effect of FGF-2 in vivo.	Cyclosporine	27-41	fibroblast growth factor 2	Mus musculus	137-142
2881198-6	1986	NAG and AAP were more frequently elevated during treatment with cyclosporine A (21/29), than with azathioprine (10/23).	Cyclosporine	64-78	serpin family F member 2	Homo sapiens	8-11
30417482-8	2019	After Con A stimulation, only T cells co-treated with ciclosporin achieved a significant proliferation inhibition and reduction of IL-2, IL-10, IL-15, IL-18, IFN-gamma and TNF-alpha.	Cyclosporine	54-65	interleukin 15	Canis lupus familiaris	144-149
30377903-8	2019	Intriguingly, a functional inhibitor of ABCA1 cyclosporine A negated the neuroprotective effects of SPFs or T0901317.	Cyclosporine	46-60	ATP binding cassette subfamily A member 1	Rattus norvegicus	40-45
22089787-1	2011	A 12-year-old girl with a history of steroid and cyclosporine (CsA) resistant nephrotic syndrome owing to focal and segmental glomerulosclerosis (FSGS) has progressed to end-stage renal disease (ESRD) for which she underwent hemodialysis for 18 months before she successfully received a fully matched kidney transplant from her sister at the age of nine years.	Cyclosporine	49-61	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	63-66
21723035-7	2011	As expected, cyclosporin A, an inhibitor of membrane potential transition, inhibited 4-HPR-induced loss of MMP and apoptosis in U87MG cells, indicating that loss of MMP plays a pivotal role in 4-HPR-induced apoptosis.	Cyclosporine	13-26	haptoglobin-related protein	Homo sapiens	87-90
30189151-6	2019	Topical CsA treatment induced a significant reduction in CD4 and IL-17 expressions (P &lt; 0.05); post-treatment levels were same as normals (P &gt; 0.05).	Cyclosporine	8-11	interleukin 17A	Homo sapiens	65-70
21723035-7	2011	As expected, cyclosporin A, an inhibitor of membrane potential transition, inhibited 4-HPR-induced loss of MMP and apoptosis in U87MG cells, indicating that loss of MMP plays a pivotal role in 4-HPR-induced apoptosis.	Cyclosporine	13-26	haptoglobin-related protein	Homo sapiens	195-198
30391882-3	2018	In the present study, it was found that administration of CsA causes a rapid activation of TGF-beta/Smad signaling cascade and subsequent expression of the profibrotic genes connective tissue growth factor (CTGF) and tissue inhibitors of matrix metallproteinases-1 (TIMP-1) in rat liver.	Cyclosporine	58-61	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	217-264
30391882-3	2018	In the present study, it was found that administration of CsA causes a rapid activation of TGF-beta/Smad signaling cascade and subsequent expression of the profibrotic genes connective tissue growth factor (CTGF) and tissue inhibitors of matrix metallproteinases-1 (TIMP-1) in rat liver.	Cyclosporine	58-61	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	266-272
30344674-0	2018	Inhibition of peptidyl-prolyl cis-trans isomerase B mediates cyclosporin A-induced apoptosis of islet beta cells.	Cyclosporine	61-74	peptidylprolyl isomerase B	Mus musculus	14-51
30344674-8	2018	CsA treatment resulted in the decreased expression of insulin and PPIB; however, it also increased the phosphorylation of PERK, and upregulated the expression of PERK, BIP, CHOP and cleaved caspase-3.	Cyclosporine	0-3	peptidylprolyl isomerase B	Mus musculus	66-70
30344674-8	2018	CsA treatment resulted in the decreased expression of insulin and PPIB; however, it also increased the phosphorylation of PERK, and upregulated the expression of PERK, BIP, CHOP and cleaved caspase-3.	Cyclosporine	0-3	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	122-126
30344674-8	2018	CsA treatment resulted in the decreased expression of insulin and PPIB; however, it also increased the phosphorylation of PERK, and upregulated the expression of PERK, BIP, CHOP and cleaved caspase-3.	Cyclosporine	0-3	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	162-166
30344674-9	2018	The results indicated that CsA could induce pancreatic beta cell dysfunction and the potential mechanism underlying this phenomenon may be PPIB-associated proinsulin misfolding, which in turn induces ER stress in beta cells.	Cyclosporine	27-30	peptidylprolyl isomerase B	Mus musculus	139-143
30344674-9	2018	The results indicated that CsA could induce pancreatic beta cell dysfunction and the potential mechanism underlying this phenomenon may be PPIB-associated proinsulin misfolding, which in turn induces ER stress in beta cells.	Cyclosporine	27-30	insulin II	Mus musculus	155-165
30367813-6	2018	RESULTS CsA treatment significantly attenuated LPS-induced lung histopathological changes (P&lt;.05), myeloperoxidase (MPO) activity (P&lt;.05) and lung wet-to-dry weight ratio (P&lt;.05).	Cyclosporine	8-11	myeloperoxidase	Mus musculus	102-117
30367813-6	2018	RESULTS CsA treatment significantly attenuated LPS-induced lung histopathological changes (P&lt;.05), myeloperoxidase (MPO) activity (P&lt;.05) and lung wet-to-dry weight ratio (P&lt;.05).	Cyclosporine	8-11	myeloperoxidase	Mus musculus	119-122
30367813-9	2018	Furthermore, we demonstrated that there was a significant difference between the high-CsA group and low-CsA group in lung injury score (P&lt;.05), mtDNA (P&lt;.05), and MPO (P&lt;.05).	Cyclosporine	86-89	myeloperoxidase	Mus musculus	169-172
30052684-6	2018	Furthermore, we demonstrate that restoring this NFATc1-motif to the Zp-P variant in the context of the intact EBV B95.8 strain genome greatly enhances lytic viral reactivation in response to the NFATc1-activating agent, ionomycin, and this effect is blocked by the NFAT inhibitory agent, cyclosporine, as well as NFATc1 siRNA.	Cyclosporine	288-300	nuclear factor of activated T cells 1	Homo sapiens	48-54
21839714-8	2011	Accordingly, calcineurin inhibition by cyclosporine decreased TRPC6 expression and reduced proteinuria in doxorubicin nephropathy, whereas podocyte-specific inducible expression of a constitutively active NFAT mutant increased TRPC6 expression and induced severe proteinuria.	Cyclosporine	39-51	transient receptor potential cation channel subfamily C member 6	Homo sapiens	62-67
3024491-7	1986	CSA did suppress immunity in Balb/c mice to an allogeneic C57B1 lymphoma, EL4.	Cyclosporine	0-3	epilepsy 4	Mus musculus	74-77
30052684-6	2018	Furthermore, we demonstrate that restoring this NFATc1-motif to the Zp-P variant in the context of the intact EBV B95.8 strain genome greatly enhances lytic viral reactivation in response to the NFATc1-activating agent, ionomycin, and this effect is blocked by the NFAT inhibitory agent, cyclosporine, as well as NFATc1 siRNA.	Cyclosporine	288-300	nuclear factor of activated T cells 1	Homo sapiens	195-201
22128263-6	2011	Pretreatment of cyclosporine A blocked the increases of RCAN1.4 stimulated by IL-1beta or AGE-BSA, suggesting that activation of CaN is required for the RCAN1.4 induction.	Cyclosporine	16-30	regulator of calcineurin 1	Mus musculus	56-61
22128263-6	2011	Pretreatment of cyclosporine A blocked the increases of RCAN1.4 stimulated by IL-1beta or AGE-BSA, suggesting that activation of CaN is required for the RCAN1.4 induction.	Cyclosporine	16-30	regulator of calcineurin 1	Mus musculus	153-158
30052684-6	2018	Furthermore, we demonstrate that restoring this NFATc1-motif to the Zp-P variant in the context of the intact EBV B95.8 strain genome greatly enhances lytic viral reactivation in response to the NFATc1-activating agent, ionomycin, and this effect is blocked by the NFAT inhibitory agent, cyclosporine, as well as NFATc1 siRNA.	Cyclosporine	288-300	nuclear factor of activated T cells 1	Homo sapiens	195-201
29986516-8	2018	P-glycoprotein inhibitors cyclosporine A and verapamil fail to restore JC-1 loading of the R and T cells to an extent similar to that observed in S cells.	Cyclosporine	26-40	phosphoglycolate phosphatase	Mus musculus	0-14
21773745-5	2011	Another inhibitor of cyclophilin A, the primary intracellular target of CsA, had no effect on AQP2 expression.	Cyclosporine	72-75	peptidylprolyl isomerase A	Rattus norvegicus	21-34
21640771-5	2011	After administration, FK506 and CsA mainly distribute within erythrocytes owing to the presence into these cells of immunophilins that bind the drugs with very high affinity (FKBP12 for FK506 and cyclophilin A for CsA); therefore, a new strategy aimed to increase the amount of FK506/CsA carried by erythrocytes by increasing the intra-erythrocytic concentration of the respective binding proteins has been developed.	Cyclosporine	32-35	FKBP prolyl isomerase 1A pseudogene 2	Homo sapiens	175-181
21640771-5	2011	After administration, FK506 and CsA mainly distribute within erythrocytes owing to the presence into these cells of immunophilins that bind the drugs with very high affinity (FKBP12 for FK506 and cyclophilin A for CsA); therefore, a new strategy aimed to increase the amount of FK506/CsA carried by erythrocytes by increasing the intra-erythrocytic concentration of the respective binding proteins has been developed.	Cyclosporine	214-217	FKBP prolyl isomerase 1A pseudogene 2	Homo sapiens	175-181
21640771-5	2011	After administration, FK506 and CsA mainly distribute within erythrocytes owing to the presence into these cells of immunophilins that bind the drugs with very high affinity (FKBP12 for FK506 and cyclophilin A for CsA); therefore, a new strategy aimed to increase the amount of FK506/CsA carried by erythrocytes by increasing the intra-erythrocytic concentration of the respective binding proteins has been developed.	Cyclosporine	214-217	FKBP prolyl isomerase 1A pseudogene 2	Homo sapiens	175-181
21240873-1	2011	INTRODUCTION: The aim of the study was to compare efficacy of cyclosporine (CsA) very low exposure with everolimus high exposure, with respect to CsA standard exposure with enteric-coated mycophenolate sodium (EC-MPS) therapy.	Cyclosporine	62-74	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	76-79
21341336-6	2011	Moreover, pretreatment of CsA, a cyclophilin D ligand that inhibits mitochondria potential uncoupling, prevented the activation of caspase-9 and caspase-3, but not caspase-8, and the apoptosis of MG-63 cells, triggered by corosolic acid.	Cyclosporine	26-29	peptidylprolyl isomerase D	Homo sapiens	33-46
21677130-0	2011	Cyclosporine-resistant, Rab27a-independent mobilization of intracellular preformed CD40 ligand mediates antigen-specific T cell help in vitro.	Cyclosporine	0-12	CD40 molecule	Homo sapiens	83-87
21474652-6	2011	Ntcp-mediated transport of CDCGamF was inhibited by taurocholate, cyclosporin, actin depolymerization, and an inhibitor of atypical PKC-zeta.	Cyclosporine	66-77	solute carrier family 10 member 1	Rattus norvegicus	0-4
21751955-3	2011	Induction therapy with the nondepleting IL-2 receptor antagonists basiliximab and daclizumab, added to cyclosporine-based regimens, reduces the incidence of acute rejection without side effects.	Cyclosporine	103-115	interleukin 2 receptor subunit beta	Homo sapiens	40-53
21839257-1	2011	OBJECTIVE: The pharmacokinetics of cyclosporine (CsA) depend on numerous factors over the transplantation course.	Cyclosporine	35-47	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	49-52
21336534-3	2011	The purpose of the current study was to test the efficacy of polymeric micellar formulation of CsA (PM-CsA) in suppressing immune responses by either T cells or dendritic cells (DCs).	Cyclosporine	95-98	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	100-106
21776863-0	2011	[Apoptosis and expression of Bcl-2 and caspase-3 in ciclosporin-induced gingival overgrowth of rats].	Cyclosporine	52-63	caspase 3	Rattus norvegicus	39-48
21776863-1	2011	OBJECTIVE: To observe the effect of Ciclosporin (CsP) on apoptosis and expression of the associated protein Bcl-2, Caspase-3 in gingival epithelium of rats in order to approach the mechanism of CsP-induced gingival epithelium overgrowth.	Cyclosporine	36-47	caspase 3	Rattus norvegicus	115-124
21382357-3	2011	So we will discuss the effect of CIPC, pretreatment with nimodipine, MK801 and cyclosporine A on the expression of the CaN, cbl-b and p-AKT in the hippocampus neurons.	Cyclosporine	79-93	Cbl proto-oncogene B	Rattus norvegicus	124-129
21382357-14	2011	Nimodipine and cyclosporine A can reduce the expression of CaN and cbl-b, and increase the expression of p-AKT, via a moderate increase in the concentration of intracellular calcium and inhibition of the activity of CaN; MK801 counteracts the effect of CIPC.	Cyclosporine	15-29	Cbl proto-oncogene B	Rattus norvegicus	67-72
21382357-14	2011	Nimodipine and cyclosporine A can reduce the expression of CaN and cbl-b, and increase the expression of p-AKT, via a moderate increase in the concentration of intracellular calcium and inhibition of the activity of CaN; MK801 counteracts the effect of CIPC.	Cyclosporine	15-29	CLOCK-interacting pacemaker	Rattus norvegicus	253-257
3011336-9	1986	Studies on isolated tubular fragments in vitro, exposed to CsA exhibited an inhibition of the cytosolic malate dehydrogenase isoenzyme, which could be interpreted as a possible source of the CsA induced tubular alteration.	Cyclosporine	59-62	malate dehydrogenase 1	Rattus norvegicus	94-124
3011336-9	1986	Studies on isolated tubular fragments in vitro, exposed to CsA exhibited an inhibition of the cytosolic malate dehydrogenase isoenzyme, which could be interpreted as a possible source of the CsA induced tubular alteration.	Cyclosporine	191-194	malate dehydrogenase 1	Rattus norvegicus	94-124
2425369-0	1986	Inhibition of MHC product induction may contribute to the immunosuppressive action of ciclosporin.	Cyclosporine	86-97	major histocompatibility complex, class I, C	Homo sapiens	14-17
3875406-3	1985	However, in contrast to the tumor reported by us previously, the conditioned media of this tumor (G-2-T-CM) contained only very weak m-CSA (86 colonies/ml), although h-CSA was very strong (7332 colonies/ml).	Cyclosporine	135-138	proline-rich coiled-coil 2A	Mus musculus	98-101
3898496-0	1985	Occurrence of isohemagglutinins of graft origin after transplantation of an ABO-unmatched renal allograft is related to the cyclosporine medication.	Cyclosporine	124-136	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	76-79
2411572-10	1985	The third pattern IgG1 much greater than IgG2a greater than IgG3 approximately equal to IgM was characteristic of anti-CSA antibodies.	Cyclosporine	119-122	LOC105243590	Mus musculus	18-22
6327823-2	1984	The same concentration (0.25 microgram/ml) of CsA that produced optimal inhibition of the T cell proliferative response to concanavalin A (Con A) was also very effective at inhibiting IL 2 production and the induction of IL 2 responsiveness, as well as the expression of the IL 2 and transferrin receptors when measured 72 hr after mitogen activation.	Cyclosporine	46-49	transferrin	Mus musculus	284-295
6349041-1	1983	Skin allografting was performed in rats treated with cyclosporine using strain combinations that differed across the RT1.A (class I) or RT1.B (class II) loci of the major histocompatibility complex (MHC) or across non-MHC loci.	Cyclosporine	53-65	RT1 class I, locus A	Rattus norvegicus	117-122
6349041-8	1983	There was a differential effect of cyclosporine treatment depending upon the genetic differences involved: a skin graft across an RT1.A (class I) difference was indefinitely prolonged, one across an RT1.B (class II) or RT1.AB difference was slightly prolonged (9 to 12 days and 12.5 to 16.5 days, respectively) and a graft across non-MHC differences was not affected.	Cyclosporine	35-47	RT1 class I, locus A	Rattus norvegicus	130-135
6216375-3	1982	Increasing the TLp to MOb ratios to 3:1 or 5:1 progressively decreased CSA.	Cyclosporine	71-74	sphingomyelin synthase 1	Homo sapiens	22-25
305946-7	1978	These observations show that the increased serum CSA seen with neutropenia is due to a true increase in CSF and not to a decline in circulating inhibitors.	Cyclosporine	49-52	colony stimulating factor 2	Rattus norvegicus	104-107
33405191-3	2021	METHOD: P-gp modulation in rats was performed by using P-gp inducer (150 mg/kg rifampicin) and P-gp inhibitor (10 mg/kg cyclosporine A) for 14 days prior to be infected with Helicobacter pylori (H. pylori).	Cyclosporine	120-134	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	8-12
33974505-2	2021	In this study, we aimed to identify the association of CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms with CsA concentrations in patients with allogeneic hematopoietic cell transplantation (allo-HSCT) based on the route of administration.A total of 40 allo-HSCT recipients receiving CsA were genotyped for CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms.	Cyclosporine	123-126	ATP binding cassette subfamily C member 2	Homo sapiens	337-342
33999413-10	2022	In U937 cells, the extra-supplied CyPA increased MMP-9 mRNA and enzyme activity, whereas the CyPA inhibitor, cyclosporine A, suppressed the LPS- and co-culture-enhanced MMP-9.	Cyclosporine	109-123	matrix metallopeptidase 9	Homo sapiens	169-174
33993101-3	2021	Here, we found that the immunosuppressant cyclosporin A (CsA) decreased the number of BrdU+, BrdU+/DCX+, BrdU+/NeuN + cells in the hippocampus, impaired learning and memory and inhibited protein levels of the shh signaling pathway, including Shh, Smo and Gli1.	Cyclosporine	42-55	GLI family zinc finger 1	Homo sapiens	255-259
33993101-0	2021	Cyclosporin A impairs neurogenesis and cognitive abilities in brain development via the IFN-gamma-Shh-BDNF pathway.	Cyclosporine	0-13	brain derived neurotrophic factor	Homo sapiens	102-106
33993101-3	2021	Here, we found that the immunosuppressant cyclosporin A (CsA) decreased the number of BrdU+, BrdU+/DCX+, BrdU+/NeuN + cells in the hippocampus, impaired learning and memory and inhibited protein levels of the shh signaling pathway, including Shh, Smo and Gli1.	Cyclosporine	57-60	GLI family zinc finger 1	Homo sapiens	255-259
32822562-0	2021	Nicorandil prevents the nephrotoxic effect of cyclosporine-A in albino rats through modulation of HIF-1alpha/VEGF /eNOS signaling.	Cyclosporine	46-60	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	98-108
32822562-0	2021	Nicorandil prevents the nephrotoxic effect of cyclosporine-A in albino rats through modulation of HIF-1alpha/VEGF /eNOS signaling.	Cyclosporine	46-60	nitric oxide synthase 3	Rattus norvegicus	115-119
32822562-9	2021	Cyclosporine decreased the renal expression levels (P<0.001) of HIF-1alpha, eNOS, and VEGF inducing endothelial dysfunction and the triggered inflammation, and upregulated the pro-fibrotic marker transforming growth factor (TGF-beta).	Cyclosporine	0-12	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	64-74
32822562-9	2021	Cyclosporine decreased the renal expression levels (P<0.001) of HIF-1alpha, eNOS, and VEGF inducing endothelial dysfunction and the triggered inflammation, and upregulated the pro-fibrotic marker transforming growth factor (TGF-beta).	Cyclosporine	0-12	nitric oxide synthase 3	Rattus norvegicus	76-80
32822562-9	2021	Cyclosporine decreased the renal expression levels (P<0.001) of HIF-1alpha, eNOS, and VEGF inducing endothelial dysfunction and the triggered inflammation, and upregulated the pro-fibrotic marker transforming growth factor (TGF-beta).	Cyclosporine	0-12	transforming growth factor alpha	Rattus norvegicus	224-232
32822562-13	2021	Nicorandil reversed the disturbed HIF-1alpha/VEGF/eNOS pathway created by cyclosporine.	Cyclosporine	74-86	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	34-44
32822562-13	2021	Nicorandil reversed the disturbed HIF-1alpha/VEGF/eNOS pathway created by cyclosporine.	Cyclosporine	74-86	nitric oxide synthase 3	Rattus norvegicus	50-54
34041060-8	2021	There are significant correlations between cross clamp time and cTnI and CKMB levels in patients taking CsA.	Cyclosporine	104-107	troponin I3, cardiac type	Homo sapiens	64-68
34041060-9	2021	In patients with both diabetes and hypertension, postsurgical cTnI and CKMB levels decrease significantly in CsA compared to placebo group on 24, 48, and 72 h (P < 0.05).	Cyclosporine	109-112	troponin I3, cardiac type	Homo sapiens	62-66
34041060-10	2021	Moreover, patients with old MI, both postsurgical cTnI and CKMB levels decrease significantly in CsA compared to placebo group on 24 h and 48 h (P < 0.05).	Cyclosporine	97-100	troponin I3, cardiac type	Homo sapiens	50-54
33492449-9	2021	In the in vivo PET study, the SUVmean ratio in tumors [calculated as after treatment (2nd PET scan)/before treatment of MRP1 inhibitors (1st PET scan)] of the mice treated with MRP1 inhibitors was significantly higher than those of control mice (cyclosporine A: 2.6 +- 0.7, lapatinib: 2.2 +- 0.7, MK-571: 2.2 +- 0.7, control: 1.2 +- 0.2, p < 0.05).	Cyclosporine	246-260	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	120-124
33492449-9	2021	In the in vivo PET study, the SUVmean ratio in tumors [calculated as after treatment (2nd PET scan)/before treatment of MRP1 inhibitors (1st PET scan)] of the mice treated with MRP1 inhibitors was significantly higher than those of control mice (cyclosporine A: 2.6 +- 0.7, lapatinib: 2.2 +- 0.7, MK-571: 2.2 +- 0.7, control: 1.2 +- 0.2, p < 0.05).	Cyclosporine	246-260	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	177-181
33349888-2	2021	In this study, experimental skin infection with Mus musculus papillomavirus 1 resulted in robust development of cutaneous papillomas in cyclosporine A-treated C57BL/6J mice deficient for the murine cathelicidin-related antimicrobial peptide (CRAMP), in contrast to wild-type controls.	Cyclosporine	136-150	cathelicidin antimicrobial peptide	Mus musculus	198-240
33349888-2	2021	In this study, experimental skin infection with Mus musculus papillomavirus 1 resulted in robust development of cutaneous papillomas in cyclosporine A-treated C57BL/6J mice deficient for the murine cathelicidin-related antimicrobial peptide (CRAMP), in contrast to wild-type controls.	Cyclosporine	136-150	cathelicidin antimicrobial peptide	Mus musculus	242-247
33370971-3	2020	She developed CsA toxicity manifesting as gum hyperplasia with multiple episodes of gum bleed.	Cyclosporine	14-17	OTU deubiquitinase with linear linkage specificity	Homo sapiens	42-45
33370971-3	2020	She developed CsA toxicity manifesting as gum hyperplasia with multiple episodes of gum bleed.	Cyclosporine	14-17	OTU deubiquitinase with linear linkage specificity	Homo sapiens	84-87
33370971-7	2020	Gum hyperplasia is a commonly reported toxic effect of CsA.	Cyclosporine	55-58	OTU deubiquitinase with linear linkage specificity	Homo sapiens	0-3
32696520-6	2020	Cyclosporin A, a potent calcineurin inhibitor, suppresses nuclear retention of Nfatc1, abrogates hair follicle cycle delay, and promotes hair growth in Sirt7-/- mice.	Cyclosporine	0-13	sirtuin 7	Mus musculus	152-157
29663071-0	2018	Cyclosporine A responsive congenital nephrotic syndrome with single heterozygous variants in NPHS1, NPHS2, and PLCE1.	Cyclosporine	0-14	NPHS1 adhesion molecule, nephrin	Homo sapiens	93-98
29520233-2	2018	Our previous research has resolved the three-dimensional structure of CyPJ and demonstrated the peptidylprolyl cis-trans isomerase (PPIase) activity of CyPJ, which can be inhibited by the common immunosuppressive drug cyclosporine A (CsA).	Cyclosporine	218-232	peptidylprolyl isomerase like 1	Homo sapiens	96-130
32439507-8	2020	The gene expression of phagocytosis-associated genes, major histocompatibility complex (MHC) class II and p47phox, and anti-virus antibody levels increased in the CsA group due to virus reactivation in the infected cells but not in the Dex and Dex & CsA groups, indicating that Dex effectively suppressed monocyte/macrophage function and antibody production.	Cyclosporine	163-166	neutrophil cytosolic factor 1	Homo sapiens	106-113
21446974-2	2011	The vasoconstrictor impact of cyclosporine (CsA) and to a lesser extent tacrolimus, in both acute and chronic settings, results from a decrease in vasodilators and increase in vasconconstrictors while direct tubular toxicity results from blockade of mitochondrial permeability transition pores and inhibition of prolyl isomerase.	Cyclosporine	30-42	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	44-47
29520233-2	2018	Our previous research has resolved the three-dimensional structure of CyPJ and demonstrated the peptidylprolyl cis-trans isomerase (PPIase) activity of CyPJ, which can be inhibited by the common immunosuppressive drug cyclosporine A (CsA).	Cyclosporine	218-232	peptidylprolyl isomerase like 1	Homo sapiens	132-138
29520233-2	2018	Our previous research has resolved the three-dimensional structure of CyPJ and demonstrated the peptidylprolyl cis-trans isomerase (PPIase) activity of CyPJ, which can be inhibited by the common immunosuppressive drug cyclosporine A (CsA).	Cyclosporine	234-237	peptidylprolyl isomerase like 1	Homo sapiens	96-130
29520233-2	2018	Our previous research has resolved the three-dimensional structure of CyPJ and demonstrated the peptidylprolyl cis-trans isomerase (PPIase) activity of CyPJ, which can be inhibited by the common immunosuppressive drug cyclosporine A (CsA).	Cyclosporine	234-237	peptidylprolyl isomerase like 1	Homo sapiens	132-138
32505466-0	2020	Cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection.	Cyclosporine	0-12	calcineurin binding protein 1	Homo sapiens	28-49
29670817-10	2018	Nerve CSA was moderately increased in two children-one with a heterozygous mutation in MPZ and the other of unknown genetic etiology.	Cyclosporine	6-9	myelin protein zero	Homo sapiens	87-90
32692785-7	2020	We found that TBB (a casein kinase II inhibitor), AR and LiCl (GSK-3 inhibitors), cyclosporin A (calcineurin inhibitor), and Saracatinib (Fyn kinase inhibitor) caused robust inhibition of OA-induced monomeric and oligomeric p-tau in both N2a and CTX culture.	Cyclosporine	82-95	calcineurin binding protein 1	Homo sapiens	97-118
21716180-6	2011	Malignancy occurred in 5.2% of patients on cyclosporine (CSA), azathioprine (AZA) and prednisone (P); in 3.4% of patients on mofetil mycophenolate (MMF) with CSA and P; in 3.3% of patients on MMF with tacrolimus (TAC) and P; and in 2 of 20 patients (10%) receiving AZA with P 15 years after transplantation.	Cyclosporine	43-55	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	57-60
29391135-8	2018	Mechanistically, CREB was involved in the inhibitory effects of CsA in mitochondrial biogenesis.	Cyclosporine	64-67	cAMP responsive element binding protein 1	Homo sapiens	17-21
29136370-4	2017	Western blot showed that OTA induced cytochrome c (cyt-c) release and caspase-3 activation, which could be suppressed by inhibition of mPTP opening with cyclosporin A.	Cyclosporine	153-166	cytochrome c	Sus scrofa	37-49
29136370-4	2017	Western blot showed that OTA induced cytochrome c (cyt-c) release and caspase-3 activation, which could be suppressed by inhibition of mPTP opening with cyclosporin A.	Cyclosporine	153-166	cytochrome c	Sus scrofa	51-56
21257749-4	2011	While FK-506 had no effect, CsA reduced NaDC1-mediated citrate transport by lowering heterologous carrier expression (as well as endogenous carrier expression in HEK293 cells), indicating that calcineurin is not involved.	Cyclosporine	28-31	solute carrier family 13 member 2	Homo sapiens	40-45
32471244-4	2020	Diltiazem (DTZ) and cyclosporin A (CsA) were first confirmed to be potent MRP2 inhibitors in vitro.	Cyclosporine	20-33	ATP binding cassette subfamily C member 2	Rattus norvegicus	74-78
28976551-0	2017	miR-181c protects CsA-induced renal damage and fibrosis through inhibiting EMT.	Cyclosporine	18-21	microRNA 181c	Mus musculus	0-8
32471244-4	2020	Diltiazem (DTZ) and cyclosporin A (CsA) were first confirmed to be potent MRP2 inhibitors in vitro.	Cyclosporine	35-38	ATP binding cassette subfamily C member 2	Rattus norvegicus	74-78
32281308-8	2020	After inhibition of PINK1/PARKIN-mediated mitophagy by CSA and PINK1-shRNA, the senescence of NPCs induced by compression was strongly rescued.	Cyclosporine	55-58	PTEN induced kinase 1	Rattus norvegicus	20-25
21257749-7	2011	We have thus identified for the first time a regulatory partner for NaDC1, and have gained novel mechanistic insight into the effect of CsA on renal citrate transport and kidney stone disease, as well as into the regulation of membrane transporters in general.	Cyclosporine	136-139	solute carrier family 13 member 2	Homo sapiens	68-73
28976551-5	2017	miR-181c mimics or inhibitors attenuate or aggravate CsA-induced EMT gene changes, respectively.	Cyclosporine	53-56	microRNA 181c	Mus musculus	0-8
20947539-1	2011	BACKGROUND: Renin-angiotensin-aldosterone system (RAAS) activation plays an important role in cyclosporine (CsA)-induced nephropathy.	Cyclosporine	94-106	renin	Rattus norvegicus	12-17
32393425-4	2020	At present, most studies focused on the inhibition of bile excretion by cyclosporin A through the transporters MRP2 and MDR1 and its effect the irinotecan treatment in vivo.	Cyclosporine	72-85	ATP binding cassette subfamily C member 2	Rattus norvegicus	111-115
28976551-6	2017	Importantly, in Nrf2-/- mice, CsA-induced renal damage, fibrosis, and EMT gene changes are restored by miR-181c mimics.	Cyclosporine	30-33	microRNA 181c	Mus musculus	103-111
32393425-4	2020	At present, most studies focused on the inhibition of bile excretion by cyclosporin A through the transporters MRP2 and MDR1 and its effect the irinotecan treatment in vivo.	Cyclosporine	72-85	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	120-124
20947539-1	2011	BACKGROUND: Renin-angiotensin-aldosterone system (RAAS) activation plays an important role in cyclosporine (CsA)-induced nephropathy.	Cyclosporine	108-111	renin	Rattus norvegicus	12-17
28976551-8	2017	Collectively, our data support the notion that miR-181c may serve as an important factor for protecting renal tissues from CsA-induced nephrotoxicity.	Cyclosporine	123-126	microRNA 181c	Mus musculus	47-55
29149986-2	2017	The aim of this work was to study the effects of cyclosporine (CsA), tacrolimus (FK-506), and rapamycin (RAPA) on the release of three local factors directly implicated in bone-remodeling regulation and apoptosis of human osteoblasts: interleukin (IL)-6, osteoprotegerin, and receptor activator of nuclear factor kappabeta (RANKL).	Cyclosporine	49-61	TNF superfamily member 11	Homo sapiens	324-329
20947539-5	2011	Biochemical analysis showed that the plasma renin activity (PRA) and serum concentration of aldosterone were significantly increased in the CsA group compared with the control group and significantly decreased in the CsA-GTE group compared with the CsA group.	Cyclosporine	140-143	renin	Rattus norvegicus	44-49
29149986-2	2017	The aim of this work was to study the effects of cyclosporine (CsA), tacrolimus (FK-506), and rapamycin (RAPA) on the release of three local factors directly implicated in bone-remodeling regulation and apoptosis of human osteoblasts: interleukin (IL)-6, osteoprotegerin, and receptor activator of nuclear factor kappabeta (RANKL).	Cyclosporine	63-66	TNF superfamily member 11	Homo sapiens	324-329
20947539-5	2011	Biochemical analysis showed that the plasma renin activity (PRA) and serum concentration of aldosterone were significantly increased in the CsA group compared with the control group and significantly decreased in the CsA-GTE group compared with the CsA group.	Cyclosporine	217-220	renin	Rattus norvegicus	44-49
29083842-0	2017	Retraction: Inhibition of Arachidonic Acid Release by Cytosolic Phospholipase A2 Is Involved in the Antiapoptotic Effect of FK506 and Cyclosporin A on Astrocytes Exposed to Simulated Ischemia In Vitro	Cyclosporine	134-147	phospholipase A2 group IVA	Homo sapiens	54-80
20947539-5	2011	Biochemical analysis showed that the plasma renin activity (PRA) and serum concentration of aldosterone were significantly increased in the CsA group compared with the control group and significantly decreased in the CsA-GTE group compared with the CsA group.	Cyclosporine	217-220	renin	Rattus norvegicus	44-49
20947539-6	2011	The total level of renin protein expression was significantly higher in the CsA group than in the control group, and it was lower in the CsA-GTE group than in the CsA group.	Cyclosporine	76-79	renin	Rattus norvegicus	19-24
20947539-6	2011	The total level of renin protein expression was significantly higher in the CsA group than in the control group, and it was lower in the CsA-GTE group than in the CsA group.	Cyclosporine	137-140	renin	Rattus norvegicus	19-24
20947539-7	2011	CONCLUSIONS: CsA treatment increases the PRA and intrarenal renin levels and induces nephrotoxicity.	Cyclosporine	13-16	renin	Rattus norvegicus	60-65
32362695-8	2020	Significantly higher microbial biomass carbon (42 %) and nitrogen (79 %) were found in surface soil (0-15 cm depth) under CSA based scenarios (Sc2, Sc3 and Sc4) at harvest stage of wheat over CT based/ conventional scenario (Sc1).	Cyclosporine	122-125	anthocyanin regulatory R-S protein-like	Zea mays	225-228
30986119-4	2020	IL-6 and MMP-9 were significantly decreased in both groups at 12 weeks.Conclusions: Both nanoemulsion and conventional cyclosporin A improved ocular signs, symptoms, and conjunctival inflammation.	Cyclosporine	119-132	matrix metallopeptidase 9	Homo sapiens	9-14
32116062-6	2020	Finally, the impact of PINK1 overexpression on the PQ or PQ + CsA-modulated fibronectin and collagen I expression in A549 cells was tested.Results: PQ exposure significantly increased the levels of hydroxyproline and collagen I expression and collagen fiber accumulation in the lung of rats, which were mitigated by CsA treatment.	Cyclosporine	62-65	PTEN induced kinase 1	Rattus norvegicus	23-28
32116062-7	2020	Furthermore, treatment with CsA significantly improved the PQ-decreased MMP and abrogated PQ-upregulated PINK1 and Parkin expression in the lungs of rats.	Cyclosporine	28-31	PTEN induced kinase 1	Rattus norvegicus	105-110
32116062-9	2020	The later effect of CsA was abrogated by PINK1 overexpression in A549 cells.Conclusions: Therefore, CsA can inhibit the PQ-induced mitophagy and pulmonary fibrosis by attenuating the PINK1/Parkin signaling.	Cyclosporine	20-23	PTEN induced kinase 1	Rattus norvegicus	41-46
32116062-9	2020	The later effect of CsA was abrogated by PINK1 overexpression in A549 cells.Conclusions: Therefore, CsA can inhibit the PQ-induced mitophagy and pulmonary fibrosis by attenuating the PINK1/Parkin signaling.	Cyclosporine	100-103	PTEN induced kinase 1	Rattus norvegicus	41-46
32116062-9	2020	The later effect of CsA was abrogated by PINK1 overexpression in A549 cells.Conclusions: Therefore, CsA can inhibit the PQ-induced mitophagy and pulmonary fibrosis by attenuating the PINK1/Parkin signaling.	Cyclosporine	100-103	PTEN induced kinase 1	Rattus norvegicus	183-188
21624207-1	2011	OBJECTIVE: To systematically evaluate the clinical effects of cyclosporine A (CsA) and tacrolimus, which are calcineurin inhibitors, on lupus nephritis.	Cyclosporine	62-76	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	78-81
28709912-6	2017	Inhibition of P-gp by oral pre-treatment with cyclosporine A increased the bioavailability of the P-gp substrates (ampicillin and ranitidine) in males and females (p&lt;0.05), and to a greater extent in males, but had no influence on the bioavailability of metformin in either male or female rats.	Cyclosporine	46-60	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	14-18
28709912-6	2017	Inhibition of P-gp by oral pre-treatment with cyclosporine A increased the bioavailability of the P-gp substrates (ampicillin and ranitidine) in males and females (p&lt;0.05), and to a greater extent in males, but had no influence on the bioavailability of metformin in either male or female rats.	Cyclosporine	46-60	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	98-102
28957350-12	2017	CyA pretreatment and/or RIP3(-/-) mice decreased Bax/Bcl2 expression; however, it did lead to an overall change in the levels of AST, ALT and LDH or necrotic injury.	Cyclosporine	0-3	BCL2-associated X protein	Mus musculus	49-52
32274223-0	2020	Primary Cutaneous CD30+ Anaplastic Large T Cell Lymphoma in a Patient Treated with Cyclosporine for Actinic Reticuloid.	Cyclosporine	83-95	TNF receptor superfamily member 8	Homo sapiens	18-22
32274223-6	2020	The association between cyclosporine treatment and development of C-ALCL and other CD30+ lymphoproliferative disorders has previously been reported in patients with atopic dermatitis, psoriasis, and transplant patients.	Cyclosporine	24-36	TNF receptor superfamily member 8	Homo sapiens	83-87
28969068-5	2017	Treatment with corticosteroids and cyclosporine (CsA) resulted in a decrease of the methylation level of GATA3 and TGF-beta in inactive BD patients.	Cyclosporine	35-47	GATA binding protein 3	Homo sapiens	105-110
32183695-0	2020	Cyclosporine a directly affects human and mouse b cell migration in vitro by disrupting a hIF-1 alphadependent, o2 sensing, molecular switch.	Cyclosporine	0-14	immunoglobulin kappa variable 1D-39	Homo sapiens	90-114
28969068-5	2017	Treatment with corticosteroids and cyclosporine (CsA) resulted in a decrease of the methylation level of GATA3 and TGF-beta in inactive BD patients.	Cyclosporine	49-52	GATA binding protein 3	Homo sapiens	105-110
28724911-3	2017	Interestingly, the calcineurin inhibitor (CNI) cyclosporine A (CsA), an immunosuppressant used to prevent allograft rejection, can also increase the risk of RCC in transplant patients.	Cyclosporine	47-61	calcineurin binding protein 1	Homo sapiens	19-40
31923502-4	2020	Indeed, the QG-Cs exhibited much higher antioxidant activities (reducing powers, NO, and DPPH radical scavenging activities), in vitro binding properties (fat, bile acid, and cholesterol binding capacities), and pancreatic lipase inhibition activities than that of QG.	Cyclosporine	15-17	pancreatic lipase	Homo sapiens	212-229
28369518-11	2017	To determine the functional consequences of this CnA hyperactivation, we administered cyclosporine A, an inhibitor of CnA, to DM1 mice.	Cyclosporine	86-100	protein phosphatase 3, catalytic subunit, alpha isoform	Mus musculus	118-121
32170198-4	2020	HCAECs stimulated with sera from patients with KD treated with cyclosporine A (CsA) showed decreased proliferation, angiogenesis, NFATc1 and inflammatory molecules levels as compared with results for untreated HCAECs.	Cyclosporine	63-77	nuclear factor of activated T cells 1	Homo sapiens	130-136
32170198-4	2020	HCAECs stimulated with sera from patients with KD treated with cyclosporine A (CsA) showed decreased proliferation, angiogenesis, NFATc1 and inflammatory molecules levels as compared with results for untreated HCAECs.	Cyclosporine	79-82	nuclear factor of activated T cells 1	Homo sapiens	130-136
28315683-0	2017	Klotho ameliorates cyclosporine A-induced nephropathy via PDLIM2/NF-kB p65 signaling pathway.	Cyclosporine	19-33	klotho	Homo sapiens	0-6
28315683-2	2017	To investigate the molecular mechanism of Klotho on inflammation in cyclosporine A (CsA) induced nephropathy, the mice were transfected with adenovirus mediated Klotho gene and treated with cyclosporine A (CsA; 30 mg/kg/day) for 4 weeks.	Cyclosporine	68-82	klotho	Mus musculus	42-48
31546104-2	2019	We show here that an apical-basal polarity (A-BP) protein, Lgl1, is present in the postsynaptic density and negatively regulates glutamatergic synapse numbers by antagonizing the atypical protein kinase Cs (aPKCs).	Cyclosporine	203-205	LLGL scribble cell polarity complex component 1	Homo sapiens	59-63
28315683-2	2017	To investigate the molecular mechanism of Klotho on inflammation in cyclosporine A (CsA) induced nephropathy, the mice were transfected with adenovirus mediated Klotho gene and treated with cyclosporine A (CsA; 30 mg/kg/day) for 4 weeks.	Cyclosporine	84-87	klotho	Mus musculus	42-48
28315683-4	2017	The results showed that Ad-klotho significantly reduced serum creatinine (Scr) and blood urea nitrogen (BUN) caused by CsA, and significantly increased creatinine clearance.	Cyclosporine	119-122	klotho	Homo sapiens	27-33
28315683-10	2017	These findings suggest that Klotho can modulate inflammation via PDLIM2/NF-kB p65 pathway in CsA-induced nephropathy.	Cyclosporine	93-96	klotho	Homo sapiens	28-34
28414804-14	2017	To validate that the observed microRNA and mRNA expression level changes in mice kidney tissue were directly related to CsA treatment, the expression change induced by CsA treatment of three microRNAs (miR-21, miR-186, and miR-709) and three mRNAs (BMPR1a, SMURF1 and SMAD7) were compared in HEK293 cell line.	Cyclosporine	120-123	microRNA 186	Mus musculus	210-217
31702204-1	2019	We report an experimental and theoretical study of the low-temperature specific heat C and magnetic susceptibility chi of the layered anisotropic triangular-lattice spin-1/2 Heisenberg antiferromagnets Cs_{2}CuCl_{4-x}Br_{x} with x=0, 1, 2, and 4.	Cyclosporine	202-204	spindlin 1	Homo sapiens	165-171
28414804-14	2017	To validate that the observed microRNA and mRNA expression level changes in mice kidney tissue were directly related to CsA treatment, the expression change induced by CsA treatment of three microRNAs (miR-21, miR-186, and miR-709) and three mRNAs (BMPR1a, SMURF1 and SMAD7) were compared in HEK293 cell line.	Cyclosporine	120-123	bone morphogenetic protein receptor, type 1A	Mus musculus	249-255
28414804-14	2017	To validate that the observed microRNA and mRNA expression level changes in mice kidney tissue were directly related to CsA treatment, the expression change induced by CsA treatment of three microRNAs (miR-21, miR-186, and miR-709) and three mRNAs (BMPR1a, SMURF1 and SMAD7) were compared in HEK293 cell line.	Cyclosporine	168-171	microRNA 186	Mus musculus	210-217
28414804-14	2017	To validate that the observed microRNA and mRNA expression level changes in mice kidney tissue were directly related to CsA treatment, the expression change induced by CsA treatment of three microRNAs (miR-21, miR-186, and miR-709) and three mRNAs (BMPR1a, SMURF1 and SMAD7) were compared in HEK293 cell line.	Cyclosporine	168-171	bone morphogenetic protein receptor, type 1A	Mus musculus	249-255
31206607-1	2019	The treatment of choice for patients with severe aplastic anaemia (SAA) includes immunosuppressive therapy (IST) with anti-thymocyte globulin (ATG) and ciclosporin A.	Cyclosporine	152-165	serum amyloid A1 cluster	Homo sapiens	67-70
28469772-1	2017	This study tested the hypothesis that erythropoietin (EPO) and cyclosporine (CsA) could effectively reduce brain infarct area (BIA) in rat after acute ischemic stroke (AIS) through regulating inflammation, oxidative stress, MAPK family signaling and microRNA (miR-223/miR-30a/miR-383).	Cyclosporine	63-75	microRNA 30a	Rattus norvegicus	268-275
28469772-1	2017	This study tested the hypothesis that erythropoietin (EPO) and cyclosporine (CsA) could effectively reduce brain infarct area (BIA) in rat after acute ischemic stroke (AIS) through regulating inflammation, oxidative stress, MAPK family signaling and microRNA (miR-223/miR-30a/miR-383).	Cyclosporine	77-80	microRNA 30a	Rattus norvegicus	268-275
28469772-7	2017	EPO-CsA therapy markedly reduced BIA mainly by suppressing the innate immune response to inflammation, oxidative stress, microRNAs (miR-223/miR-30a/miR-383) and MAPK family signaling.	Cyclosporine	4-7	microRNA 30a	Rattus norvegicus	140-147
28009901-0	2017	Aloe activated P-glycoprotein and CYP 3A: a study on the serum kinetics of aloe and its interaction with cyclosporine in rats.	Cyclosporine	105-117	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	15-29
30924169-0	2019	Cyclosporine A improves pregnancy outcomes in women with recurrent pregnancy loss and elevated Th1/Th2 ratio.	Cyclosporine	0-14	negative elongation factor complex member C/D	Homo sapiens	95-98
28009901-3	2017	Cyclosporine (CSP), an immunosuppressant with a narrow therapeutic window, is a probe substrate of P-glycoprotein (P-gp), an efflux pump, and CYP 3A4.	Cyclosporine	0-12	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	99-113
30924169-2	2019	Since, the successful pregnancy occurs in T helper 2 (Th2)-dominant situation and since, Th1 type immunity is related to pregnancy failure, we investigated the effects of cyclosporine on Th1 and Th2 cells in RPL women.	Cyclosporine	171-183	negative elongation factor complex member C/D	Homo sapiens	187-190
28009901-3	2017	Cyclosporine (CSP), an immunosuppressant with a narrow therapeutic window, is a probe substrate of P-glycoprotein (P-gp), an efflux pump, and CYP 3A4.	Cyclosporine	0-12	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	115-119
30924169-9	2019	Given this, cyclosporine treatment for RPL patients with elevated Th1/Th2 ratio can result in improved pregnancy outcome.	Cyclosporine	12-24	negative elongation factor complex member C/D	Homo sapiens	66-69
28009901-3	2017	Cyclosporine (CSP), an immunosuppressant with a narrow therapeutic window, is a probe substrate of P-glycoprotein (P-gp), an efflux pump, and CYP 3A4.	Cyclosporine	14-17	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	99-113
28009901-3	2017	Cyclosporine (CSP), an immunosuppressant with a narrow therapeutic window, is a probe substrate of P-glycoprotein (P-gp), an efflux pump, and CYP 3A4.	Cyclosporine	14-17	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	115-119
32063673-4	2019	Here, we use high level ab initio simulation techniques to explore the effect of lattice compression on the formamidinium (FA) lead iodide compound, FA1-x Cs x PbI3 (x = 0, 0.25).	Cyclosporine	155-157	FA complementation group A	Homo sapiens	149-152
27919682-3	2017	Here, we show that the inhibitory effect of CsA on transforming growth factor-beta2 (TGF-beta2)-induced myofibroblasts in primary cultured human pterygium fibroblasts.	Cyclosporine	44-47	transforming growth factor beta 2	Homo sapiens	85-94
31101050-12	2019	Moreover, cyclosporine A, a cholesterol efflux inhibitor, rescued the inhibitory effect induced by the combination of AIBP and APOA-I.	Cyclosporine	10-24	apolipoprotein A-I	Mus musculus	127-133
30799725-1	2019	Aim: This study aimed to investigate the effect of and mechanism involved in the IL-17 SNP on cyclosporine metabolism and outcomes of liver transplantation (LT).	Cyclosporine	94-106	interleukin 17A	Homo sapiens	81-86
30799725-7	2019	Cyclosporine concentration was associated with the different IL-17 genotype (p < 0.05).	Cyclosporine	0-12	interleukin 17A	Homo sapiens	61-66
30799725-11	2019	Conclusion: This study revealed the possible association of IL-17 G-197A with cyclosporine metabolism and transplant rejection after LT, which might be partly related to the upregulations of CYP3A4/5 dependent on PXR.	Cyclosporine	78-90	interleukin 17A	Homo sapiens	60-65
30913036-9	2019	TIMP-2 level increased in all wells significantly when treated with CsA (p < 0.0001).	Cyclosporine	68-71	TIMP metallopeptidase inhibitor 2	Homo sapiens	0-6
30913036-13	2019	TIMP-2 and MMP-2 were both more active when treated with CsA which may be due to the gelatinase activity of them and that in CsA gingival overgrowth.	Cyclosporine	57-60	TIMP metallopeptidase inhibitor 2	Homo sapiens	0-6
30826814-0	2019	Expression of S100B Protein in Ischemia/Reperfusion-Induced Brain Injury After Cyclosporine Therapy: A Biochemical Serum Marker with Prognostic Value?	Cyclosporine	79-91	S100 calcium binding protein B	Rattus norvegicus	14-19
30826814-3	2019	This study investigated the effect of cyclosporine on S100B serum levels and the severity of brain tissue damage in a rat model of cerebral ischemia-reperfusion (I/R).	Cyclosporine	38-50	S100 calcium binding protein B	Rattus norvegicus	54-59
30826814-10	2019	S100B serum levels were significantly elevated in Cyclosporine-treated rats compared with untreated Control rats during the reperfusion phase.	Cyclosporine	50-62	S100 calcium binding protein B	Rattus norvegicus	0-5
30826814-12	2019	CONCLUSIONS Cyclosporine seems to affect both ischemia-reperfusion brain tissue damage and S100B protein serum levels.	Cyclosporine	12-24	S100 calcium binding protein B	Rattus norvegicus	91-96
30547226-10	2019	In support of this, the calcineurin inhibitor, cyclosporin A, prevented the Ca2+-induced decrease in cell surface CFTR.	Cyclosporine	47-60	calcineurin binding protein 1	Homo sapiens	24-45
30031690-7	2018	Collectively, these data show that the yeast PTP is regulated by Cpr3, endogenous matrix Ca2+, and reactive oxygen species, and that it is involved in yeast death; furthermore, ATP synthase dimers play a key role in CsA-sensitive pore formation, while AACs are dispensable.	Cyclosporine	216-219	peptidylprolyl isomerase CPR3	Saccharomyces cerevisiae S288C	65-69
30391882-0	2018	Vitamin E inhibits cyclosporin A-induced CTGF and TIMP-1 expression by repressing ROS-mediated activation of TGF-beta/Smad signaling pathway in rat liver.	Cyclosporine	19-32	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	50-56
30241022-7	2018	The increase of sAA was 80.70 (SD = 109.67) U/mL, being greater for the CSA group than the VRG group.	Cyclosporine	72-75	amylase alpha 1A	Homo sapiens	16-19
30376962-0	2018	Are Adverse Events Induced by the Acute Administration of Calcineurin Inhibitor Cyclosporine A Behaviorally Conditioned in Healthy Male Volunteers?	Cyclosporine	80-94	calcineurin binding protein 1	Homo sapiens	58-79
30230584-5	2018	Herein, we report a case of a 6-year-old Taiwanese boy with GPP and homozygous mutation at c.115+6T&gt;C within the IL-36 receptor antagonist (IL36RN) gene, who was treated successfully with secukinumab after failure of prior methotrexate, acitretin, cyclosporin A, etanercept and adalimumab.	Cyclosporine	251-264	interleukin 36 receptor antagonist	Homo sapiens	116-141
30230584-5	2018	Herein, we report a case of a 6-year-old Taiwanese boy with GPP and homozygous mutation at c.115+6T&gt;C within the IL-36 receptor antagonist (IL36RN) gene, who was treated successfully with secukinumab after failure of prior methotrexate, acitretin, cyclosporin A, etanercept and adalimumab.	Cyclosporine	251-264	interleukin 36 receptor antagonist	Homo sapiens	143-149
30386683-0	2018	Matrix Metalloproteinase 9 Point-of-Care Immunoassay Result Predicts Response to Topical Cyclosporine Treatment in Dry Eye Disease.	Cyclosporine	89-101	matrix metallopeptidase 9	Homo sapiens	0-26
30386683-1	2018	Purpose: We evaluate a matrix metalloproteinase-9 (MMP-9) point-of-care immunoassay (InflammaDry) as a prognostic tool for topical cyclosporine treatment.	Cyclosporine	131-143	matrix metallopeptidase 9	Homo sapiens	23-49
30386683-1	2018	Purpose: We evaluate a matrix metalloproteinase-9 (MMP-9) point-of-care immunoassay (InflammaDry) as a prognostic tool for topical cyclosporine treatment.	Cyclosporine	131-143	matrix metallopeptidase 9	Homo sapiens	51-56
30386683-10	2018	MMP-9-positive patients responded more favorably to topical cyclosporine than did MMP-9-negative patients.	Cyclosporine	60-72	matrix metallopeptidase 9	Homo sapiens	0-5
30032157-10	2018	Among 3 THSD7A-associated IMN patients, 1 patient had elevated serum anti-THSD7A antibody levels, which was below detectable levels after achieving partial proteinuria remission with combined glucocorticoid and cyclosporine treatment.	Cyclosporine	211-223	thrombospondin type 1 domain containing 7A	Homo sapiens	8-14
30032157-10	2018	Among 3 THSD7A-associated IMN patients, 1 patient had elevated serum anti-THSD7A antibody levels, which was below detectable levels after achieving partial proteinuria remission with combined glucocorticoid and cyclosporine treatment.	Cyclosporine	211-223	thrombospondin type 1 domain containing 7A	Homo sapiens	74-80
30021619-8	2018	Interestingly, pretreatment of M. bovis-infected macrophages with cyclosporine A, a mitochondrial permeability transition pore inhibitor, abolished AIF and Endo G nuclear translocation.	Cyclosporine	66-80	allograft inflammatory factor 1	Bos taurus	148-151
30012208-6	2018	ARPE-19 cells pretreated with CsA under high glucose stress showed markedly down-regulated expressions of Parkin, PINK1 and BNIP3L compared with the cells treated with high glucose (p &lt; 0.05).	Cyclosporine	30-33	PTEN induced kinase 1	Homo sapiens	114-119
21199863-8	2011	For instance, Bcl10 was found to be hyperphosphorylated in Jurkat T cells upon treatment with CsA or EGTA-AM, and calcineurin dephosphorylated Bcl10 in vivo and in vitro.	Cyclosporine	94-97	BCL10 immune signaling adaptor	Homo sapiens	14-19
21298017-8	2011	Notably, cyclosporine represses HNF4alpha gene and protein expression and its DNA-binding activity at consensus sequences to AGT, AGTR1, ACE, and ACE2.	Cyclosporine	9-21	angiotensin II receptor type 1	Homo sapiens	130-135
21298017-8	2011	Notably, cyclosporine represses HNF4alpha gene and protein expression and its DNA-binding activity at consensus sequences to AGT, AGTR1, ACE, and ACE2.	Cyclosporine	9-21	angiotensin converting enzyme 2	Homo sapiens	146-150
20861484-7	2011	Foxp3 was expressed at a similar level in CD4+ T cells from healthy donors, colchicine-treated patients, and cyclosporine-treated patients, whereas infliximab-treated patients expressed much higher percentages of Foxp3+ cells.	Cyclosporine	109-121	forkhead box P3	Homo sapiens	0-5
20940715-9	2011	When mitochondrial damage was aggravated by ATR in the ATR+CsA+shock group, the CsA did not protect.	Cyclosporine	59-62	ATR serine/threonine kinase	Rattus norvegicus	44-47
20940715-9	2011	When mitochondrial damage was aggravated by ATR in the ATR+CsA+shock group, the CsA did not protect.	Cyclosporine	80-83	ATR serine/threonine kinase	Rattus norvegicus	55-58
21691056-6	2011	CsA and tacrolimus reduced mRNA abundance in TRPV5 (CsA: 64 +- 3% of control; tacrolimus: 50 +- 3%) calbindin-D28k (CsA: 62 +- 4%; tacrolimus: 43 +- 3%), and vitamin D receptor (CsA: 52 +- 3%; tacrolimus: 58 +- 2%, all p &lt; 0.05).	Cyclosporine	0-3	transient receptor potential cation channel subfamily V member 5	Homo sapiens	45-50
21691056-8	2011	The immunofluorescence staining study demonstrated a 50% reduction of TRPV5 and calbindin-D28k by CsA and tacrolimus.	Cyclosporine	98-101	transient receptor potential cation channel subfamily V member 5	Homo sapiens	70-75
21760716-1	2011	PURPOSE: To investigate the role of postoperative topical 0.05% cyclosporine A (CsA) eye drops (Restasis( ), Allergan Pharmaceutical) in the prevention of recurrence among patients with primary pterygium treated with bare-sclera technique.	Cyclosporine	64-78	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	80-83
22470391-3	2011	RESULTS: CyA induced apoptosis at 24 h and nuclear translocation of phosphorylated (p)-Smad2/3 at 3 h, which was continued till 24 h. CyA enhanced the expression of p-ERK at 1 h, which was continued till 24 h, and of p-p38MAPK at 1-6 h, which returned to control level at 12 h. CyA did not affect JNK.	Cyclosporine	9-12	SMAD family member 2	Homo sapiens	87-94
22470391-3	2011	RESULTS: CyA induced apoptosis at 24 h and nuclear translocation of phosphorylated (p)-Smad2/3 at 3 h, which was continued till 24 h. CyA enhanced the expression of p-ERK at 1 h, which was continued till 24 h, and of p-p38MAPK at 1-6 h, which returned to control level at 12 h. CyA did not affect JNK.	Cyclosporine	134-137	SMAD family member 2	Homo sapiens	87-94
22470391-3	2011	RESULTS: CyA induced apoptosis at 24 h and nuclear translocation of phosphorylated (p)-Smad2/3 at 3 h, which was continued till 24 h. CyA enhanced the expression of p-ERK at 1 h, which was continued till 24 h, and of p-p38MAPK at 1-6 h, which returned to control level at 12 h. CyA did not affect JNK.	Cyclosporine	134-137	SMAD family member 2	Homo sapiens	87-94
21980535-7	2011	Moreover, we also observed that CK2 inhibition protected against CsA-induced cytotoxicity.	Cyclosporine	65-68	casein kinase 2, alpha prime polypeptide	Mus musculus	32-35
21328998-6	2010	CsA suppressed apoptosis as well as CytC release and caspase-3 activity (P &lt; 0.01).	Cyclosporine	0-3	caspase 3	Rattus norvegicus	53-62
20726688-5	2010	Amongst the last is the calcineurin inhibitor (CNI) (cyclosporine A (CsA) and tacrolimus)-related nephrotoxicity.	Cyclosporine	53-67	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	69-72
20567855-11	2010	Cyclosporine (versus tacrolimus) was independently associated with greater SBP-Z and DBP-Z (p=0.001).	Cyclosporine	0-12	selenium binding protein 1	Homo sapiens	75-78
20551288-4	2010	Calcineurin (Cn) is proposed as the Ser(275) phosphatase, because its inhibitor cyclosporin A (CsA) stabilizes phospho-Ser(275) and retains TORC2 in the cytoplasm.	Cyclosporine	80-93	CREB regulated transcription coactivator 2	Mus musculus	140-145
20551288-4	2010	Calcineurin (Cn) is proposed as the Ser(275) phosphatase, because its inhibitor cyclosporin A (CsA) stabilizes phospho-Ser(275) and retains TORC2 in the cytoplasm.	Cyclosporine	95-98	CREB regulated transcription coactivator 2	Mus musculus	140-145
20551288-9	2010	CsA, but not OA, stabilized the phosphogroup at Ser(307), suggesting that differential dephosphorylation at Ser(171) and Ser(307) cooperatively regulate TORC2 activity and that the nuclear localization of TORC2 is insufficient to function as a coactivator.	Cyclosporine	0-3	CREB regulated transcription coactivator 2	Mus musculus	153-158
20551288-9	2010	CsA, but not OA, stabilized the phosphogroup at Ser(307), suggesting that differential dephosphorylation at Ser(171) and Ser(307) cooperatively regulate TORC2 activity and that the nuclear localization of TORC2 is insufficient to function as a coactivator.	Cyclosporine	0-3	CREB regulated transcription coactivator 2	Mus musculus	205-210
20883533-1	2010	Cyclosporin A (CsA), rapamycin (Rapa) and mycophenolic acid (MPA) are frequently used for GVHD prophylaxis and treatment after allogeneic stem cell transplantation (SCT).	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
20519340-1	2010	The aim of this study was to investigate the potential of calcineurin inhibitors [cyclosporine A (CsA) and tacrolimus (Tac)] to inhibit cellular uptake of atorvastatin mediated by the liver-specific organic anion-transporting polypeptide 1B1 (OATP1B1) in vitro.	Cyclosporine	82-96	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	98-101
20542069-1	2010	Cyclosporin A (CsA) is an immunosuppressive drug.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
27839819-9	2017	Surprisingly, both CsA and the knockdown of PINK1 by small-interfering RNA (siRNA) significantly decreased the LC3-II/LC3-I ratio and the PINK1 and Parkin protein levels in AGE-treated cardiomyocytes.	Cyclosporine	19-22	PTEN induced kinase 1	Rattus norvegicus	138-143
27839819-10	2017	Moreover, CsA treatment or knockdown of PINK1 expression attenuated the increased number of SA-beta-gal positive cells and the upregulated p16 level in cardiomyocytes induced by AGEs.	Cyclosporine	10-13	cyclin-dependent kinase inhibitor 2A	Rattus norvegicus	139-142
29746028-19	2017	After CsA treatment, CD3 level in maternal blood was higher in successful group than abortion group but CD8 level was decreased after CsA treatment.	Cyclosporine	6-9	CD8a molecule	Homo sapiens	104-107
20814124-10	2010	Combination therapy with micro-emulsion form of cyclosporine A, prednisolone and azathioprine developed more UTI (P= 0.0418).	Cyclosporine	48-62	alpha-1-microglobulin/bikunin precursor	Homo sapiens	109-112
29746028-19	2017	After CsA treatment, CD3 level in maternal blood was higher in successful group than abortion group but CD8 level was decreased after CsA treatment.	Cyclosporine	134-137	CD8a molecule	Homo sapiens	104-107
27890239-5	2017	This article identifies a potential role for interleukin-22 in driving SCC proliferation, particularly in solid organ transplant recipients taking cyclosporine.	Cyclosporine	147-159	interleukin 22	Homo sapiens	45-59
20458598-6	2010	The immunosuppressive regimen for the second transplantation consisted of tacrolimus and prednisolone; cyclosporine (CsA), mycophenolate mofetil, and prednisolone had been used for the first transplantation.	Cyclosporine	103-115	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	117-120
29375638-9	2017	Furthermore, the serum levels of motilin and SP were significantly higher and the CCK mRNA expressions in intestine and hypothalamus were downregulated in SA and CSA groups.	Cyclosporine	162-165	motilin	Rattus norvegicus	33-40
20566410-1	2010	AIMS: To investigate whether hypoxia-inducible factor (HIF) 1alpha and cyclosporin A (CsA) can regulate MICA/B expression and affect NK cytotoxicity during ischemia/reperfusion (I/R) injury.	Cyclosporine	86-89	MHC class I polypeptide-related sequence A	Homo sapiens	104-108
20566410-7	2010	Moreover, CsA can inhibit HIF-1alpha and MICB expression but upregulates MICA expression during H/R.	Cyclosporine	10-13	MHC class I polypeptide-related sequence B	Homo sapiens	41-45
20566410-7	2010	Moreover, CsA can inhibit HIF-1alpha and MICB expression but upregulates MICA expression during H/R.	Cyclosporine	10-13	MHC class I polypeptide-related sequence A	Homo sapiens	73-77
29375638-9	2017	Furthermore, the serum levels of motilin and SP were significantly higher and the CCK mRNA expressions in intestine and hypothalamus were downregulated in SA and CSA groups.	Cyclosporine	162-165	cholecystokinin	Rattus norvegicus	82-85
29375638-11	2017	Conclusion: Both SA and CSA enhanced gastrointestinal motility and increased serum levels of motilin and SP in chronically stressed rats via downregulating CCK mRNA expressions in intestine and hypothalamus.	Cyclosporine	24-27	motilin	Rattus norvegicus	93-100
20527820-7	2010	The known binding interaction between CsA and CypA was detected using both the MALDI- and LC-MS-based readouts described here.	Cyclosporine	38-41	peptidyl-prolyl cis-trans isomerase A	Bos taurus	46-50
29375638-11	2017	Conclusion: Both SA and CSA enhanced gastrointestinal motility and increased serum levels of motilin and SP in chronically stressed rats via downregulating CCK mRNA expressions in intestine and hypothalamus.	Cyclosporine	24-27	cholecystokinin	Rattus norvegicus	156-159
27287416-9	2016	Furthermore, the therapeutic enhancement by tariquidar was compared to that of the less specific and less potent Pgp inhibitor cyclosporine A.	Cyclosporine	127-141	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	113-116
20361354-3	2010	Cyclosporine A (CsA) is a potent immunosuppressive agent which prevents allograft rejection in organ transplantation and various immunological diseases.	Cyclosporine	0-14	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	16-19
27020855-9	2016	Administration of cyclosporin A, which stabilizes synaptopodin, reduced LPS-induced proteinuria significantly in wild-type mice but to a lesser extent in TRPC6 knockout mice.	Cyclosporine	18-31	transient receptor potential cation channel, subfamily C, member 6	Mus musculus	154-159
27020855-10	2016	Furthermore, administration of cyclosporin A reversed the LPS-induced increase in podocyte surface expression of TRPC6 in wild-type mice.	Cyclosporine	31-44	transient receptor potential cation channel, subfamily C, member 6	Mus musculus	113-118
21122398-1	2010	OBJECTIVE: To explore the efficiency and side-effects of the combination of cyclosporine A (CsA) and thalidomide in patients with myelodysplastic syndromes (MDS).	Cyclosporine	76-90	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	92-95
27742194-4	2016	The proinflammatory effects of FGF23 are inhibited by an isoform-specific FGFR4 blocking antibody and by cyclosporine, a calcineurin inhibitor.	Cyclosporine	105-117	fibroblast growth factor 23	Homo sapiens	31-36
27742194-4	2016	The proinflammatory effects of FGF23 are inhibited by an isoform-specific FGFR4 blocking antibody and by cyclosporine, a calcineurin inhibitor.	Cyclosporine	105-117	calcineurin binding protein 1	Homo sapiens	121-142
28955949-0	2016	Anti-IL-17A blocking antibody reduces cyclosporin A-induced relapse in experimental autoimmune encephalomyelitis mice.	Cyclosporine	38-51	interleukin 17A	Mus musculus	5-11
20614016-1	2010	BACKGROUND: Cyclosporin A (CsA) has important anti-microbial activity against parasites of the genus Leishmania, suggesting CsA-binding cyclophilins (CyPs) as potential drug targets.	Cyclosporine	12-25	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	27-30
20614016-1	2010	BACKGROUND: Cyclosporin A (CsA) has important anti-microbial activity against parasites of the genus Leishmania, suggesting CsA-binding cyclophilins (CyPs) as potential drug targets.	Cyclosporine	12-25	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	124-127
28955949-3	2016	We hypothesized that CsA withdrawal induces IL-17 production that could be responsible for relapse, and examined the effect of anti-IL-17A antibody on relapse induced after CsA withdrawal in mouse experimental autoimmune encephalomyelitis (EAE).	Cyclosporine	21-24	interleukin 17A	Mus musculus	44-49
20025887-6	2010	Swelling of mitochondria is a characteristic of mitochondrial permeability transition pore (mPTP) opening, but Bnip3-mediated mitochondrial swelling was insensitive to cyclosporine A, an inhibitor of the mPTP and independent of cyclophilin D (cypD), an essential component of the mPTP.	Cyclosporine	168-182	BCL2/adenovirus E1B interacting protein 3	Mus musculus	111-116
28955949-5	2016	After discontinuation of CsA the production of IL-17A was increased and the severity of relapse in EAE was reduced by treatment with anti-IL-17A antibody.	Cyclosporine	25-28	interleukin 17A	Mus musculus	47-53
29867731-11	2018	Finally, the mitophagy inhibitor, CsA, significantly reduced intracellular zinc ion content and ZnT3 expression.	Cyclosporine	34-37	solute carrier family 30 (zinc transporter), member 3	Mus musculus	96-100
28955949-5	2016	After discontinuation of CsA the production of IL-17A was increased and the severity of relapse in EAE was reduced by treatment with anti-IL-17A antibody.	Cyclosporine	25-28	interleukin 17A	Mus musculus	138-144
28955949-6	2016	These results suggest that the resumption of T cell immune responses after CsA withdrawal leads to a burst of IL-17A production that is at least partially responsible for relapse in EAE mice.	Cyclosporine	75-78	interleukin 17A	Mus musculus	110-116
20620516-6	2010	Conversely, the percentage of CD4(+)Foxp3(+) Tregs in the liver graft and blood decreased in the cyclosporine group.	Cyclosporine	97-109	forkhead box P3	Rattus norvegicus	36-41
25283267-4	2016	The dp-8 (8-mer) CSA yielded the most effective response among promoting collagen type II protein secretions compared with other groups.	Cyclosporine	17-20	dipeptidyl peptidase 8	Homo sapiens	4-8
20620545-7	2010	The CsA+ATRA group showed a marked reduction in PCNA- and CD68-positive cells: namely, 33.96 +/- 8.65% versus 60.17 +/- 17.74% (P &lt; .01) and 17.63 +/- 4.24% versus 32.13 +/- 9.26 (P &lt; .01), respectively.	Cyclosporine	4-7	Cd68 molecule	Rattus norvegicus	58-62
20620545-8	2010	RT-PCR analysis showed that relative PDGF-A mRNA content in the CsA+ATRA group was significantly decreased compared with the CsA group (0.46 +/- 0.08 vs 0.94 +/- 0.11; P &lt; .01).	Cyclosporine	64-67	platelet derived growth factor subunit A	Rattus norvegicus	37-43
20620545-8	2010	RT-PCR analysis showed that relative PDGF-A mRNA content in the CsA+ATRA group was significantly decreased compared with the CsA group (0.46 +/- 0.08 vs 0.94 +/- 0.11; P &lt; .01).	Cyclosporine	125-128	platelet derived growth factor subunit A	Rattus norvegicus	37-43
20416375-8	2010	Using a PXR reporter gene assay, cyclosporin A - but not FK506 - was shown to be a direct PXR activator, and also to induce expression of the classic PXR-regulated CYP3A4 gene in human hepatocytes and in a cell line null for the FXR, a nuclear receptor with similar properties to the PXR.	Cyclosporine	33-46	nuclear receptor subfamily 1 group H member 4	Homo sapiens	229-232
27083969-11	2016	Expression of matrix metalloproteinase-9 was stronger in CMC-CaCl2-CsA treatment group at 7 days after surgery.	Cyclosporine	67-70	matrix metallopeptidase 9	Rattus norvegicus	14-40
20418503-7	2010	ER-Nix cells, but not mitochondrial-Nix cells, showed dissipation of mitochondrial inner membrane potential, Deltapsi(m), and were protected from cell death by cyclosporine A or ppif ablation, implicating the mitochondrial permeability transition pore (MPTP).	Cyclosporine	160-174	BCL2/adenovirus E1B interacting protein 3-like	Mus musculus	3-6
29530563-6	2018	In addition, while the P-gp inhibitor CsA increased the intestinal uptake of ranitidine in both male and female rats, a greater extent of intestinal transport modulation was observed in males compared to females.	Cyclosporine	38-41	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	23-27
29734357-9	2018	Compared with the untreated and CsA eye drop groups, an implanted CsA DDS markedly decreased the CD11b+ and CD8+ T cell infiltration in the corneal grafts.	Cyclosporine	66-69	integrin subunit alpha M	Homo sapiens	97-102
29734357-10	2018	CsA DDS treatment also greatly reduced the CD4+ T cell density and the expression of interferon-gamma, interleukin-2 (IL-2), IL-6, CD80, and CD86 mRNA both in the corneal graft and iris-ciliary body (all p &lt; 0.01).	Cyclosporine	0-3	T-lymphocyte activation antigen CD80	Oryctolagus cuniculus	131-135
29734357-10	2018	CsA DDS treatment also greatly reduced the CD4+ T cell density and the expression of interferon-gamma, interleukin-2 (IL-2), IL-6, CD80, and CD86 mRNA both in the corneal graft and iris-ciliary body (all p &lt; 0.01).	Cyclosporine	0-3	T-lymphocyte activation antigen CD86	Oryctolagus cuniculus	141-145
29501733-9	2018	(2) CsA induced the formation of autophagosomes and up-regulated the expression of Beclin1, LC3B, and the ERK/MAPK pathway in cardiac fibroblasts.	Cyclosporine	4-7	beclin 1	Homo sapiens	83-90
27065451-8	2016	Furthermore, induced FCRL5 expression required elevation of intracellular Ca(++) and was partially blocked by cyclosporine A, a calcineurin inhibitor.	Cyclosporine	110-124	Fc receptor like 5	Homo sapiens	21-26
29501733-10	2018	(3) CsA induced NRP-2 down-regulation and WDFY-1 up-regulation.	Cyclosporine	4-7	neuropilin 2	Homo sapiens	16-21
29352737-7	2018	The addition of 2 5 ng/ml cyclosporin A and 1 microM prednisolone inhibit IFN-gamma/TNF-alpha production significantly by CD8+ Pgp+ T cells from BOS patients.	Cyclosporine	26-39	CD8a molecule	Homo sapiens	122-125
29618365-9	2018	Treatment with the CypA antagonist CsA in C57Bl/6 mice attenuates MMP-9 responses and enhances BBB repair after injury, demonstrating that MMP-9 plays an important role in the timing of spontaneous BBB repair after TBI.	Cyclosporine	35-38	peptidylprolyl isomerase A	Mus musculus	19-23
20439767-3	2010	The method, which involves making thermodynamic measurements of protein-folding reactions in complex biological mixtures to detect protein-drug interactions, is demonstrated in an experiment to identify yeast protein targets of the immunosuppressive drug, cyclosporin A (CsA).	Cyclosporine	256-269	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	271-274
27041481-9	2016	In these conditions nuclear NFATc1 levels were diminished either by CsA or Gracilin A, L, and Tetrahydroaplysulphurin-1 treatment.	Cyclosporine	68-71	nuclear factor of activated T cells 1	Homo sapiens	28-34
20436708-0	2010	Effects of cyclosporin A therapy combined with steroids and angiotensin converting enzyme inhibitors on childhood IgA nephropathy.	Cyclosporine	11-24	IGAN1	Homo sapiens	114-129
29703381-0	2018	Activation of P-glycoprotein and CYP 3A by Coptidis Rhizoma in vivo: Using cyclosporine as a probe substrate in rats.	Cyclosporine	75-87	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	14-28
29703381-3	2018	Cyclosporine (CSP), an important immunosuppressant with narrow therapeutic window, is employed as a probe substrate of P-glycoprotein (P-gp) and CYP3A4 in order to investigate the in vivo modulation effect of CR on P-gp and CYP3A4.	Cyclosporine	0-12	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	119-133
27041481-10	2016	Moreover, as happens with CsA due to the inhibition of NFATc1, Interleukine-2 (IL-2) released to the culture medium was significantly decreased with all Spongionella compounds.	Cyclosporine	26-29	nuclear factor of activated T cells 1	Homo sapiens	55-61
29703381-3	2018	Cyclosporine (CSP), an important immunosuppressant with narrow therapeutic window, is employed as a probe substrate of P-glycoprotein (P-gp) and CYP3A4 in order to investigate the in vivo modulation effect of CR on P-gp and CYP3A4.	Cyclosporine	0-12	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	135-139
27104614-7	2016	In this study, we analyzed the anti-HCV properties of the novel cyclosporine A (CsA) derivate-STG-175.	Cyclosporine	64-78	chromosome 6 open reading frame 15	Homo sapiens	94-97
29703381-3	2018	Cyclosporine (CSP), an important immunosuppressant with narrow therapeutic window, is employed as a probe substrate of P-glycoprotein (P-gp) and CYP3A4 in order to investigate the in vivo modulation effect of CR on P-gp and CYP3A4.	Cyclosporine	0-12	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	215-219
29703381-3	2018	Cyclosporine (CSP), an important immunosuppressant with narrow therapeutic window, is employed as a probe substrate of P-glycoprotein (P-gp) and CYP3A4 in order to investigate the in vivo modulation effect of CR on P-gp and CYP3A4.	Cyclosporine	14-17	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	119-133
29703381-3	2018	Cyclosporine (CSP), an important immunosuppressant with narrow therapeutic window, is employed as a probe substrate of P-glycoprotein (P-gp) and CYP3A4 in order to investigate the in vivo modulation effect of CR on P-gp and CYP3A4.	Cyclosporine	14-17	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	135-139
29703381-3	2018	Cyclosporine (CSP), an important immunosuppressant with narrow therapeutic window, is employed as a probe substrate of P-glycoprotein (P-gp) and CYP3A4 in order to investigate the in vivo modulation effect of CR on P-gp and CYP3A4.	Cyclosporine	14-17	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	215-219
28418009-0	2018	Effect of UMOD genotype on long-term graft survival after kidney transplantation in patients treated with cyclosporine-based therapy.	Cyclosporine	106-118	uromodulin	Homo sapiens	10-14
20427863-1	2010	Several generic cyclosporine (CsA) formulations have been developed over the last decade and are now widely available.	Cyclosporine	16-28	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	30-33
20089806-6	2010	We show that the VSMC differentiation marker genes smooth muscle alpha-actin (ACTA2), transgelin (TAGLN), smoothelin (SMTN), and myocardin (MYOCD) are all down-regulated by CSA in VSMC monoculture, whereas cyclin-dependent kinase inhibitor-1A (CDKN1A) and matrix metalloproteinase-3 (MMP3) are up-regulated.	Cyclosporine	173-176	cyclin-dependent kinase inhibitor 1A	Rattus norvegicus	206-242
20089806-6	2010	We show that the VSMC differentiation marker genes smooth muscle alpha-actin (ACTA2), transgelin (TAGLN), smoothelin (SMTN), and myocardin (MYOCD) are all down-regulated by CSA in VSMC monoculture, whereas cyclin-dependent kinase inhibitor-1A (CDKN1A) and matrix metalloproteinase-3 (MMP3) are up-regulated.	Cyclosporine	173-176	cyclin-dependent kinase inhibitor 1A	Rattus norvegicus	244-250
20023700-7	2010	Under knockdown conditions, the inhibitory effects of TPR ligands, cyclosporine A (CsA) and FK506, on AR activity were not observed, indicating that Cyp40 and FKBP51 are the targets of CsA and FK506, respectively.	Cyclosporine	185-188	peptidylprolyl isomerase D	Homo sapiens	149-154
27104614-7	2016	In this study, we analyzed the anti-HCV properties of the novel cyclosporine A (CsA) derivate-STG-175.	Cyclosporine	80-83	chromosome 6 open reading frame 15	Homo sapiens	94-97
20023700-8	2010	Our findings show that FKBP51 and Cyp40 are positive regulators of AR that can be selectively targeted by CsA and FK506 to achieve inhibition of androgen-induced cell proliferation.	Cyclosporine	106-109	peptidylprolyl isomerase D	Homo sapiens	34-39
27028319-5	2016	Intracellular and secreted IL-10 levels were determined by flow cytometry and Bioplex assay after treating PBMCs with PD98059, tipifarnib and cyclosporin A for blocking of ERK-, T-bet-and FoxP3-dependent pathways, respectively.	Cyclosporine	142-155	interleukin 10	Homo sapiens	27-32
19903662-3	2010	The goal of this study was to compare the effects of cyclosporine A and rapamycin on the induction and suppressive functions of human CD4(+)CD25(+) Tregs in vitro.	Cyclosporine	53-67	interleukin 2 receptor subunit alpha	Homo sapiens	140-144
19903662-4	2010	METHODS: CD4(+)CD25(+) Tregs were induced in two-way mixed lymphocyte reaction (MLR) in the presence of rapamycin (Treg-Rapa) or cyclosporine A (Treg-CsA).	Cyclosporine	129-143	interleukin 2 receptor subunit alpha	Homo sapiens	15-19
25594762-6	2016	CsA and FK506 were additionally found to up-regulate the expression of several molecules that play a protective role in bladder tumorigenesis, including p53, p21, and p27, and down-regulate that of oncogenic genes, such as cyclin D1, cyclin D3, and cyclin E, in SVHUC cells with the carcinogen challenge.	Cyclosporine	0-3	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	158-161
19903662-8	2010	RESULTS: Although both rapamycin and cyclosporine A suppressed the induction of CD4(+)CD25(+) Tregs during MLRs, this effect was significantly more pronounced in cells cultured with cyclosporine.	Cyclosporine	37-51	interleukin 2 receptor subunit alpha	Homo sapiens	86-90
19903662-8	2010	RESULTS: Although both rapamycin and cyclosporine A suppressed the induction of CD4(+)CD25(+) Tregs during MLRs, this effect was significantly more pronounced in cells cultured with cyclosporine.	Cyclosporine	37-49	interleukin 2 receptor subunit alpha	Homo sapiens	86-90
29411011-13	2018	CsA also reduced the H2O2-induced NFATc3 dephosphorylation (and nuclear translocation), and also suppressed the H2O2-induced elevation in profibrotic ECM genes (TGFbeta1, Col1A1, and periostin), both in normal and in glaucoma LC cells.	Cyclosporine	0-3	collagen type I alpha 1 chain	Homo sapiens	171-177
25594762-6	2016	CsA and FK506 were additionally found to up-regulate the expression of several molecules that play a protective role in bladder tumorigenesis, including p53, p21, and p27, and down-regulate that of oncogenic genes, such as cyclin D1, cyclin D3, and cyclin E, in SVHUC cells with the carcinogen challenge.	Cyclosporine	0-3	cyclin-dependent kinase inhibitor 1B	Mus musculus	167-170
25594762-6	2016	CsA and FK506 were additionally found to up-regulate the expression of several molecules that play a protective role in bladder tumorigenesis, including p53, p21, and p27, and down-regulate that of oncogenic genes, such as cyclin D1, cyclin D3, and cyclin E, in SVHUC cells with the carcinogen challenge.	Cyclosporine	0-3	cyclin D1	Mus musculus	223-232
27853675-11	2016	Rats received CsA were detected to have significantly (p&lt;0.05) higher plasma 8-OHdG, MDA, PCG, urea, and creatinine levels in comparison to other groups.	Cyclosporine	14-17	psoriasis susceptibility 1 candidate 2	Rattus norvegicus	93-96
28967329-4	2018	Cyclosporine A (CsA) is thought to inhibit mPT by binding to cyclophilin D and has been shown to be effective in models of CNS injury.	Cyclosporine	0-14	peptidylprolyl isomerase D	Rattus norvegicus	61-74
28967329-4	2018	Cyclosporine A (CsA) is thought to inhibit mPT by binding to cyclophilin D and has been shown to be effective in models of CNS injury.	Cyclosporine	16-19	peptidylprolyl isomerase D	Rattus norvegicus	61-74
20145520-1	2010	BACKGROUND: The effect of cyclosporine A (CsA) on polyomavirus BK virus (BKV) replication remains unclear.	Cyclosporine	26-40	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	42-45
19994912-5	2010	Cyclosporine affected the following groups of proteins: calcium homeostasis (regucalcin, calbindin), cytoskeleton (vimentin, caldesmon), response to hypoxia and mitochondrial function (prolyl 4-hydroxylase, proteasome, NADH dehydrogenase), and cell metabolism (kidney aminoacylase, pyruvate dehydrogenase, fructose-1,6-bis phosphate).	Cyclosporine	0-12	vimentin	Rattus norvegicus	115-123
28115789-7	2016	The aim of this study was to assess the suitability of the NGAL concentration in the urine as a potential biomarker of the CsA nephrotoxicity.	Cyclosporine	123-126	lipocalin 2	Homo sapiens	59-63
28917111-11	2017	PET imaging showed that [11C]PF-3274167 uptake in rat brain was very low in basal conditions but increased significantly after the administration of ciclosporin, suggesting that it is a substrate of the P-gp.	Cyclosporine	149-160	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	203-207
28115789-11	2016	The relationship between NGAL excreted in urine and the time of CsA treatment, concentration of CsA in blood serum, and other biochemical parameters was assessed.	Cyclosporine	64-67	lipocalin 2	Homo sapiens	25-29
28115789-17	2016	Statistically significant correlation between NGAL urine concentration and the time of CsA therapy indicates potential benefits of using this biomarker in the monitoring of nephrotoxicity in case of prolonged CsA therapy.	Cyclosporine	87-90	lipocalin 2	Homo sapiens	46-50
28115789-17	2016	Statistically significant correlation between NGAL urine concentration and the time of CsA therapy indicates potential benefits of using this biomarker in the monitoring of nephrotoxicity in case of prolonged CsA therapy.	Cyclosporine	209-212	lipocalin 2	Homo sapiens	46-50
27624386-5	2017	nNOS-mediated neuronal differentiation is controlled by calcineurin since cyclosporin A (CsA), a calcineurin inhibitor, decreased nNOS activation and NO production, and inhibited neurite outgrowth.	Cyclosporine	74-87	nitric oxide synthase 1	Rattus norvegicus	0-4
19580368-2	2010	In our previously reported double-blinded, placebo-controlled trial comparing inhaled cyclosporine (ACsA) to aerosol placebo, the rate of bronchiolitis-free survival improved.	Cyclosporine	86-98	acyl-CoA synthetase short chain family member 2	Homo sapiens	100-104
27624386-5	2017	nNOS-mediated neuronal differentiation is controlled by calcineurin since cyclosporin A (CsA), a calcineurin inhibitor, decreased nNOS activation and NO production, and inhibited neurite outgrowth.	Cyclosporine	74-87	nitric oxide synthase 1	Rattus norvegicus	130-134
27624386-5	2017	nNOS-mediated neuronal differentiation is controlled by calcineurin since cyclosporin A (CsA), a calcineurin inhibitor, decreased nNOS activation and NO production, and inhibited neurite outgrowth.	Cyclosporine	89-92	nitric oxide synthase 1	Rattus norvegicus	0-4
26937363-1	2016	AIMS: This study was carried out to identify and outline the degree of relationship between immunophenotyped macrophages expressing CD163 and PDGF-B in cyclosporine-A, phenytoin, and nifedipine-induced gingival overgrowth.	Cyclosporine	152-166	platelet derived growth factor subunit B	Rattus norvegicus	142-148
21088703-6	2010	The release of Rh123 can be controlled by the mitochondrial membrane permeability transition (PT) pore, as targeting an inner membrane component of the PT pore by cyclosporin A (CsA) inhibited Rh123 release.	Cyclosporine	163-176	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	178-181
20851384-7	2010	Co-administration of temsirolimus and CsA also reduced DTH and IL-2 levels in B6D2F1 mice, demonstrating involvement of the mTORC1 pathway.	Cyclosporine	38-41	CREB regulated transcription coactivator 1	Mus musculus	124-130
27624386-5	2017	nNOS-mediated neuronal differentiation is controlled by calcineurin since cyclosporin A (CsA), a calcineurin inhibitor, decreased nNOS activation and NO production, and inhibited neurite outgrowth.	Cyclosporine	89-92	nitric oxide synthase 1	Rattus norvegicus	130-134
26937363-13	2016	In addition, CD163 and PDGF-B upregulated in cyclosporine-A-induced GO compared to phenytoin and nifedipine medications.	Cyclosporine	45-59	platelet derived growth factor subunit B	Rattus norvegicus	23-29
26497925-6	2016	The capacity of MRP4 to confer resistance to As(III) was further confirmed by a dramatic decrease in the IC50 values with the addition of MK571, an MRP4 inhibitor, and cyclosporine A, a well-known broad-spectrum inhibitor of ABC transporters.	Cyclosporine	168-182	ATP binding cassette subfamily C member 4	Homo sapiens	16-20
28724911-3	2017	Interestingly, the calcineurin inhibitor (CNI) cyclosporine A (CsA), an immunosuppressant used to prevent allograft rejection, can also increase the risk of RCC in transplant patients.	Cyclosporine	63-66	calcineurin binding protein 1	Homo sapiens	19-40
28473245-19	2017	Co-administration of Phela 15mg/kg/day orally for 21 days with CsA led to stoppage and reversal of the immunosppressive effects of CsA that were exhibited as increased IL-2, IL-10, CD4 and CD8 counts, implying that Phela stimulates the cell mediate immunity (CMI).	Cyclosporine	63-66	Cd4 molecule	Rattus norvegicus	181-184
28473245-19	2017	Co-administration of Phela 15mg/kg/day orally for 21 days with CsA led to stoppage and reversal of the immunosppressive effects of CsA that were exhibited as increased IL-2, IL-10, CD4 and CD8 counts, implying that Phela stimulates the cell mediate immunity (CMI).	Cyclosporine	131-134	Cd4 molecule	Rattus norvegicus	181-184
20652037-2	2010	Close therapeutic drug monitoring of Cyclosporine (CsA) in transplant outpatients is a favourable procedure to maintain the long-term blood drug levels within their respective narrow therapeutic ranges.	Cyclosporine	37-49	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	51-54
20131116-10	2010	The reduction in sBP was correlated to cyclosporine A levels (p = 0.04 after 50microg nitroglycerin; p = 0.05 after 100 microg nitroglycerin).	Cyclosporine	39-53	selenium binding protein 1	Homo sapiens	17-20
28416371-8	2017	The CSA/diclofenac regimen, but not individual treatments, increased cardiac NOX2 expression and caused more cardiac structural damage.	Cyclosporine	4-7	cytochrome b-245 beta chain	Rattus norvegicus	77-81
24933330-8	2015	Cyclosporin A, Chlorpromazine, and Troglitazone inhibited Mrp2-mediated biliary transport, correlating with in vivo findings.	Cyclosporine	0-13	ATP binding cassette subfamily C member 2	Rattus norvegicus	58-62
28416371-9	2017	The inhibition of NOX by diphenyleneiodonium reversed CSA/diclofenac-evoked increases in MAP, decreases in HRV and Tau, cardiac structural damage, and increased NOX2 expression.	Cyclosporine	54-57	cytochrome b-245 beta chain	Rattus norvegicus	161-165
28416371-11	2017	In conclusion, CSA/diclofenac-treated female rats exhibit exacerbated hemodynamic, autonomic, LV, and histopathologic disturbances via ROCK-independent NOX2 upregulation.	Cyclosporine	15-18	cytochrome b-245 beta chain	Rattus norvegicus	152-156
28947964-9	2017	In particular, GAG could reverse a decline in CD4+FoxP3+ Tregs resulted from CsA treatments.	Cyclosporine	77-80	CD4 antigen	Mus musculus	46-49
26193170-3	2015	Therefore, in this study the kinetics of cyclosporine A (CsA) and the dynamics of CsA-induced cyclophilin B (Cyp-B) secretion were investigated in three widely used hepatic in vitro models: primary rat hepatocytes (PRH), primary human hepatocytes (PHH) and HepaRG cells.	Cyclosporine	82-85	peptidylprolyl isomerase B	Rattus norvegicus	94-107
28619100-10	2017	Cyclosporin A (CsA) exhibited suppressive effects on ORFV replication through the inhibition of CypB.	Cyclosporine	0-13	peptidylprolyl isomerase B	Homo sapiens	96-100
28619100-10	2017	Cyclosporin A (CsA) exhibited suppressive effects on ORFV replication through the inhibition of CypB.	Cyclosporine	15-18	peptidylprolyl isomerase B	Homo sapiens	96-100
26193170-3	2015	Therefore, in this study the kinetics of cyclosporine A (CsA) and the dynamics of CsA-induced cyclophilin B (Cyp-B) secretion were investigated in three widely used hepatic in vitro models: primary rat hepatocytes (PRH), primary human hepatocytes (PHH) and HepaRG cells.	Cyclosporine	82-85	peptidylprolyl isomerase B	Rattus norvegicus	109-114
26193170-7	2015	All cell systems took up CsA rapidly from the medium after initial exposure and all showed a time- and concentration-dependent Cyp-B cellular depletion and extracellular secretion.	Cyclosporine	25-28	peptidylprolyl isomerase B	Homo sapiens	127-132
26318285-8	2015	FK506 and cyclosporine A, inhibitors of calcineurin activation, determined that calcineurin was associated with the iron-induced changes in mitochondrial morphology and the phosphorylation levels of Drp1.	Cyclosporine	10-24	collapsin response mediator protein 1	Mus musculus	199-203
27690155-16	2017	Continuous tubular Hif upregulation via Vhl-KO worsens the outcome of chronic CsA-induced renal toxicity.	Cyclosporine	78-81	von Hippel-Lindau tumor suppressor	Mus musculus	40-43
28003191-3	2017	Kidneys were recently shown to display activation of the furosemide-sensitive Na-K-2Cl cotransporter (NKCC2) of the thick ascending limb and the thiazide-sensitive Na-Cl cotransporter (NCC) of the distal convoluted tubule upon calcineurin inhibition using cyclosporin A (CsA).	Cyclosporine	256-269	solute carrier family 12 member 1	Rattus norvegicus	102-107
28003191-3	2017	Kidneys were recently shown to display activation of the furosemide-sensitive Na-K-2Cl cotransporter (NKCC2) of the thick ascending limb and the thiazide-sensitive Na-Cl cotransporter (NCC) of the distal convoluted tubule upon calcineurin inhibition using cyclosporin A (CsA).	Cyclosporine	271-274	solute carrier family 12 member 1	Rattus norvegicus	102-107
28003191-6	2017	Acute administration of CsA to Wistar rats rapidly augmented phosphorylation levels of NKCC2, NCC, and their activating kinases suggesting intraepithelial activating effects.	Cyclosporine	24-27	solute carrier family 12 member 1	Rattus norvegicus	87-92
26595473-4	2015	Significant interactions with CSA emerged for MGLL at the gene level (p = .009), and for rs604300 within MGLL (DeltaR2 = .007, p &lt; .001), the latter of which survived SNP-level Bonferroni correction and was significant in an additional sample with similar directional effects (N = 859; DeltaR2 = .005, p = .026).	Cyclosporine	30-33	monoglyceride lipase	Homo sapiens	46-50
28278322-6	2017	Treatment with systemic corticosteroid and cyclosporin A (CsA) decreased the methylation level of GATA3 and TGF-beta in association with an increased mRNA expression of molecules and reduced disease activity.	Cyclosporine	43-56	GATA binding protein 3	Homo sapiens	98-103
28278322-6	2017	Treatment with systemic corticosteroid and cyclosporin A (CsA) decreased the methylation level of GATA3 and TGF-beta in association with an increased mRNA expression of molecules and reduced disease activity.	Cyclosporine	58-61	GATA binding protein 3	Homo sapiens	98-103
26259607-10	2015	The increases of HSPA8 and ENO1 levels were also detected in CM of HK-2 cells treated with other nephrotoxic agents, such as HgCl2, NaAsO2, cisplatin, amphotericin B, and cyclosporine A.	Cyclosporine	171-185	heat shock protein family A (Hsp70) member 8	Homo sapiens	17-22
30895027-3	2017	Materials and methods: The effect of CsA on HGFs was used to elucidate whether Nanog expression could be induced by CsA using quantitative real-time reverse transcription-polymerase chain reaction and Western blotting.	Cyclosporine	37-40	Nanog homeobox	Homo sapiens	79-84
30895027-3	2017	Materials and methods: The effect of CsA on HGFs was used to elucidate whether Nanog expression could be induced by CsA using quantitative real-time reverse transcription-polymerase chain reaction and Western blotting.	Cyclosporine	116-119	Nanog homeobox	Homo sapiens	79-84
30895027-4	2017	Cell growth in CsA-treated HGFs with Nanog lentivirus-mediated short hairpin RNA interference knockdown was evaluated by tetrazolium bromide reduction assay.	Cyclosporine	15-18	Nanog homeobox	Homo sapiens	37-42
30895027-5	2017	Results: CsA upregulated Nanog transcript in HGFs in a dose-dependent manner (P &lt; 0.05).	Cyclosporine	9-12	Nanog homeobox	Homo sapiens	25-30
30895027-6	2017	CsA was also shown to increase Nanog protein expression in HGFs in a dose-dependent manner (P &lt; 0.05).	Cyclosporine	0-3	Nanog homeobox	Homo sapiens	31-36
30895027-7	2017	In addition, downregulation of Nanog by lentiviral infection significantly inhibited CsA-stimulated cell growth in HGFs (P &lt; 0.05).	Cyclosporine	85-88	Nanog homeobox	Homo sapiens	31-36
30895027-8	2017	Conclusion: CsA upregulated Nanog expression and cell growth in HGFs, while silencing Nanog effectively reversed these phenomena.	Cyclosporine	12-15	Nanog homeobox	Homo sapiens	28-33
30895027-9	2017	Nanog may act as a major switch in the pathogenesis of CsA-induced gingival overgrowth.	Cyclosporine	55-58	Nanog homeobox	Homo sapiens	0-5
28328822-12	2017	The inner distance of longus colli was significantly shorter (P = 0.032 and P = 0.026) and CSA significantly smaller (P = 0.041 and P = 0.035), at C3/4 and C4/5 in the vertigo group than in the nonvertigo group.	Cyclosporine	91-94	complement C3	Homo sapiens	147-160
28244807-0	2017	NFATC1 genotypes affect acute rejection and long-term graft function in cyclosporine-treated renal transplant recipients.	Cyclosporine	72-84	nuclear factor of activated T cells 1	Homo sapiens	0-6
28244807-6	2017	CONCLUSION: Detecting NFATC1 polymorphisms could help predict CsA efficacy in renal transplant patients.	Cyclosporine	62-65	nuclear factor of activated T cells 1	Homo sapiens	22-28
28848192-7	2017	ELISA analysis of splenocytes revealed a reduced interferon (IFN)-gamma/IL-17 ratio in CsA-treated, conditioned but not reexposed, and conditioned animals.	Cyclosporine	87-90	interleukin 17A	Mus musculus	72-77
28501872-8	2017	Besides, CsA attenuated I/R injury through suppressing the release of cytochrome-c (CytC), inhibiting cell apoptosis and decreasing the expression levels of cyclophilin-D (Cyp-D), adenine nucleotide translocase 1 (ANT1) and voltage-dependent anion channel 1 (VDAC1).	Cyclosporine	9-12	ADP/ATP translocase 1	Oryctolagus cuniculus	180-212
28501872-8	2017	Besides, CsA attenuated I/R injury through suppressing the release of cytochrome-c (CytC), inhibiting cell apoptosis and decreasing the expression levels of cyclophilin-D (Cyp-D), adenine nucleotide translocase 1 (ANT1) and voltage-dependent anion channel 1 (VDAC1).	Cyclosporine	9-12	ADP/ATP translocase 1	Oryctolagus cuniculus	214-218
28501872-10	2017	CONCLUSION: Our study found that the protective role of CsA on lung I/R injury depends on the inhibition of MPTP and CytC release, suppression of the activation of mitochondrial apoptosis pathway and the expressions of apoptotic-related proteins, as well as the decreased expression levels of ANT1 and VDAC1.	Cyclosporine	56-59	ADP/ATP translocase 1	Oryctolagus cuniculus	293-297
27822214-6	2016	Similar to a well-known immunosuppressive agent cyclosporine A (CsA), Gracilin H, A, L, and tetrahydroaplysulphurin-1 were able to reduce the CD147 membrane expression and to block the release of Cyp A to the medium.	Cyclosporine	48-62	basigin	Mus musculus	142-147
27822214-6	2016	Similar to a well-known immunosuppressive agent cyclosporine A (CsA), Gracilin H, A, L, and tetrahydroaplysulphurin-1 were able to reduce the CD147 membrane expression and to block the release of Cyp A to the medium.	Cyclosporine	64-67	basigin	Mus musculus	142-147
27822214-6	2016	Similar to a well-known immunosuppressive agent cyclosporine A (CsA), Gracilin H, A, L, and tetrahydroaplysulphurin-1 were able to reduce the CD147 membrane expression and to block the release of Cyp A to the medium.	Cyclosporine	64-67	peptidylprolyl isomerase A	Mus musculus	196-201
27755569-7	2016	The active form of vitamin D, 1,25(OH)2D3, and VDR signaling pathway regulate the inhibition of CsA.	Cyclosporine	96-99	vitamin D receptor	Homo sapiens	47-50
26921303-5	2016	The aim of this study was to evaluate the influence of the immunosuppressive drugs cyclosporine A (CsA) and rapamycin (RAPA) on the level, suppressor properties, and phenotype of human CD8(+)CD28(-) T cells in vitro.	Cyclosporine	83-97	CD8a molecule	Homo sapiens	185-188
26921303-5	2016	The aim of this study was to evaluate the influence of the immunosuppressive drugs cyclosporine A (CsA) and rapamycin (RAPA) on the level, suppressor properties, and phenotype of human CD8(+)CD28(-) T cells in vitro.	Cyclosporine	99-102	CD8a molecule	Homo sapiens	185-188
26921303-7	2016	It was observed that CD8(+)CD28(-) T cells from cultures with CsA or RAPA had similar suppressor properties to cells from control cultures, although the drugs influenced the expression of FOXP3.	Cyclosporine	62-65	CD8a molecule	Homo sapiens	21-24
27318696-9	2016	Moreover, calcineurin inhibitors, cyclosporine A and FK506, partially reversed TRPV2 activation-induced inhibition of brown adipocyte differentiation.	Cyclosporine	34-48	transient receptor potential cation channel, subfamily V, member 2	Mus musculus	79-84
27306529-0	2016	Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.	Cyclosporine	95-107	calcineurin binding protein 1	Homo sapiens	0-21
19785645-6	2009	Some drugs may inhibit OATP transporters (e.g. cyclosporine) causing pharmacokinetic drug-drug interactions.	Cyclosporine	47-59	solute carrier organic anion transporter family member 1A2	Homo sapiens	23-27
19589390-4	2009	The effect of CsA on CJX1-stimulated and Ver-stimulated P-gp ATPase activity was non-competitive and competitive inhibition, respectively.	Cyclosporine	14-17	dynein axonemal heavy chain 8	Homo sapiens	61-67
19523970-8	2009	Vit E pretreatment inhibited the effects that CsA induced on mitochondrial structure and function in LLC-PK1 cells and avoided apoptosis.	Cyclosporine	46-49	vitrin	Sus scrofa	0-3
19701239-8	2009	Treatment with the ser/thr phosphatase inhibitors, cyclosporine (2 micromol/L), calyculin A (2 micromol/L) or okadaic acid (1 micromol/L), caused a significant positive shift in V(1/2) and a decrease in the conductance of KCNQ4 channels.	Cyclosporine	51-63	potassium voltage-gated channel subfamily Q member 4	Homo sapiens	222-227
19608730-5	2009	Cyclosporine was shown to upregulate the expression of TGF-beta in the colonic tissue, enhance the expression of p-Smad2 and cFLIP in epithelial cells, and inhibit caspase-8 activity but not caspase-1 or -9.	Cyclosporine	0-12	caspase 8	Homo sapiens	164-173
19382208-5	2009	However, the efficacy of CsA to protect cytotoxic brain edema in ALF is problematic because it poorly crosses the blood-brain barrier, which is relatively intact in ALF.	Cyclosporine	25-28	afamin	Homo sapiens	65-68
27256251-8	2016	The expression of MDR3 on the plasma membrane and transport activity of A364V was rescued by a pharmacological chaperone, cyclosporin A.	Cyclosporine	122-135	ATP binding cassette subfamily B member 4	Homo sapiens	18-22
26894526-1	2016	OBJECTIVE: To identify the possible biological roles of keratinocyte growth factor (KGF), connective tissue growth factor (CTGF) and transforming growth factor-beta (TGF-beta) in cyclosporine-A (CsA) and phenytoin (PNT)-induced gingival overgrowth (GO) and to correlate them with each other.	Cyclosporine	179-193	fibroblast growth factor 7	Rattus norvegicus	84-87
26894526-15	2016	KGF plays a greater role in CsA- induced GO than in PNT- induced GO.	Cyclosporine	28-31	fibroblast growth factor 7	Rattus norvegicus	0-3
26283324-10	2015	However, Cyclosporine A, a CREB inhibitor, reduced the expression of p-CREB, Egr-3, VCAM-1, Ang1 and Tie2.	Cyclosporine	9-23	angiogenin	Rattus norvegicus	92-96
26500550-12	2015	Penciclovir transport by OAT2-tv1 was sensitive to large (e.g., cyclosporine A) and small (e.g., allopurinol) organic compounds, as well as organic anions, cations and neutral compounds, highlighting the multiselectivity of OAT2-tv1.	Cyclosporine	64-78	solute carrier family 22 member 7	Homo sapiens	25-29
26500550-13	2015	The potencies with which indomethacin, furosemide, cyclosporine A and cimetidine inhibited OAT2-tv1 are in good agreement with previous studies using this variant, but inconsistent with studies using OAT2 with an unidentified sequence.	Cyclosporine	51-65	solute carrier family 22 member 7	Homo sapiens	91-95
26160968-2	2015	Because sirolimus (SIR) and calcineurin inhibitor-either cyclosporine (CsA) or tacrolimus-have become more common as graft-versus-host disease (GVHD) prophylaxis, we are witnessing a higher frequency of this complication.	Cyclosporine	57-69	calcineurin binding protein 1	Homo sapiens	28-49
27045291-7	2016	Similarily, ~4% of B-cells in HS and even fewer in CsA or tacrolimus treated patients produced IL-10 (0.5% and 1.5%, p&lt;0.05) and this was confirmed both in non-transplanted CsA-treated healthy subjects and in in vitro co-culture experiments.	Cyclosporine	51-54	interleukin 10	Homo sapiens	95-100
26160968-2	2015	Because sirolimus (SIR) and calcineurin inhibitor-either cyclosporine (CsA) or tacrolimus-have become more common as graft-versus-host disease (GVHD) prophylaxis, we are witnessing a higher frequency of this complication.	Cyclosporine	71-74	calcineurin binding protein 1	Homo sapiens	28-49
25947324-2	2015	We, therefore, studied if a potent P-gp and MRP modulator, cyclosporin A (CysA), can modulate the MTX concentration in the rat brain.	Cyclosporine	59-72	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	35-39
26972494-8	2016	Furthermore, both cyclosporine A (P-glycoprotein inhibitor) and MK-571 (MRP-2 inhibitor) significantly increased the cellular uptake and transport of (+)-catechin and puerarin.	Cyclosporine	18-32	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	34-48
25947324-2	2015	We, therefore, studied if a potent P-gp and MRP modulator, cyclosporin A (CysA), can modulate the MTX concentration in the rat brain.	Cyclosporine	59-72	ATP binding cassette subfamily C member 2	Rattus norvegicus	44-47
25947324-2	2015	We, therefore, studied if a potent P-gp and MRP modulator, cyclosporin A (CysA), can modulate the MTX concentration in the rat brain.	Cyclosporine	74-78	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	35-39
25947324-2	2015	We, therefore, studied if a potent P-gp and MRP modulator, cyclosporin A (CysA), can modulate the MTX concentration in the rat brain.	Cyclosporine	74-78	ATP binding cassette subfamily C member 2	Rattus norvegicus	44-47
26324318-6	2015	These cytokines and LPS can induce P-gp expression through the STAT3/Nf-kappab pathway, contributing to a decrease of cyclosporine A retention, which can be reversed by the application of a P-gp inhibitor.	Cyclosporine	118-132	phosphoglycolate phosphatase	Mus musculus	35-39
26324318-6	2015	These cytokines and LPS can induce P-gp expression through the STAT3/Nf-kappab pathway, contributing to a decrease of cyclosporine A retention, which can be reversed by the application of a P-gp inhibitor.	Cyclosporine	118-132	phosphoglycolate phosphatase	Mus musculus	190-194
26276498-3	2015	However, the effects of CSA on preterm delivery (PTB), a leading cause of neonatal mortality, remain poorly understood.	Cyclosporine	24-27	polypyrimidine tract binding protein 1	Homo sapiens	49-52
26276498-9	2015	Women with a history of CSA had 2.6 to 4.8-fold increased odds of PTB as compared with women without a history of CSA.	Cyclosporine	24-27	polypyrimidine tract binding protein 1	Homo sapiens	66-69
26276498-12	2015	Given the ubiquity of CSA, as well as the clinical and public health significance of PTB, more rigorously designed epidemiologic studies on the association between CSA and PTB are warranted.	Cyclosporine	164-167	polypyrimidine tract binding protein 1	Homo sapiens	172-175
25976221-8	2015	Whether 2-DG inhibits the CsA-induced necrosis and apoptosis by inhibiting the RIP3 signaling pathway remains to be elucidated.	Cyclosporine	26-29	receptor-interacting serine-threonine kinase 3	Rattus norvegicus	79-83
25808405-11	2015	Administering IL-6 abrogated allograft tolerance induced by kaempferol and cyclosporine via diminishing CD4+FoxP3+ Tregs.	Cyclosporine	75-87	CD4 antigen	Mus musculus	104-107
25976987-4	2015	NFATc1 knockdown using inducible short hairpin RNA or pharmacological NFAT inhibition with cyclosporine A (CsA) or VIVIT significantly augmented sorafenib-induced apoptosis of FLT3-ITD+ cells.	Cyclosporine	91-105	nuclear factor of activated T cells 1	Homo sapiens	0-6
25976987-4	2015	NFATc1 knockdown using inducible short hairpin RNA or pharmacological NFAT inhibition with cyclosporine A (CsA) or VIVIT significantly augmented sorafenib-induced apoptosis of FLT3-ITD+ cells.	Cyclosporine	107-110	nuclear factor of activated T cells 1	Homo sapiens	0-6
25796200-5	2015	We found that combined treatment with Glu (300 mg/kg) and low-dose (10 or 20mg/kg) CsA strongly ameliorated the development of psoriasis-like skin lesions and reduced the levels of Th1 cytokine (TNF-alpha) and Th17 cytokines (IL-17, IL-22, and IL-23) in the serum and dorsal skin.	Cyclosporine	83-86	interleukin 17A	Mus musculus	226-231
25785492-2	2015	CsA, a hydrophobic peptide that is also a substrate for P-glycoprotein, is a well-known immunosuppressive agent.	Cyclosporine	0-3	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	56-70
25810391-4	2015	In CD4 T cells, PD-1 induction following TCR stimulation required NFAT, as the calcineurin/NFAT pathway inhibitor cyclosporin A was able to block PD-1 induction in a manner similar to that seen in CD8 T cells.	Cyclosporine	114-127	transcription factor NFAT	Sus scrofa	66-70
25810391-4	2015	In CD4 T cells, PD-1 induction following TCR stimulation required NFAT, as the calcineurin/NFAT pathway inhibitor cyclosporin A was able to block PD-1 induction in a manner similar to that seen in CD8 T cells.	Cyclosporine	114-127	transcription factor NFAT	Sus scrofa	91-95
25714796-6	2015	CsA reduced the proportion of CD4(+) T cells and the level of IFN-gamma.	Cyclosporine	0-3	CD4 antigen	Mus musculus	30-33
25631176-0	2015	The role of NFATc1 in prostate cancer progression: cyclosporine A and tacrolimus inhibit cell proliferation, migration, and invasion.	Cyclosporine	51-65	nuclear factor of activated T cells 1	Homo sapiens	12-18
25631176-7	2015	In prostate cancer cell lines, CsA and FK506 inhibited NFATc1 expression and its nuclear translocation, NFAT transcriptional activity, and the expression of c-myc, a downstream target of NFAT.	Cyclosporine	31-34	nuclear factor of activated T cells 1	Homo sapiens	55-61
25631176-12	2015	Thus, NFATc1 inactivation, especially using CsA and FK506, has the potential of being a therapeutic approach for not only hormone-naive but also castration-resistant prostate cancers.	Cyclosporine	44-47	nuclear factor of activated T cells 1	Homo sapiens	6-12
25591474-1	2015	Cyclosporine, a calcineurin inhibitor, is successfully used as an immunosuppressant in transplant medicine.	Cyclosporine	0-12	calcineurin binding protein 1	Homo sapiens	16-37
26855194-0	2016	Cyclosporine A Inhibits the T-bet-Dependent Antitumor Response of CD8(+) T Cells.	Cyclosporine	0-14	T-box 21	Mus musculus	28-33
26855194-9	2016	Further analyses showed that T-bet was downregulated by CsA (but not Rapa) in CD8(+) T cells and that cancer cytotoxicity was profoundly inhibited in the absence of T-bet.	Cyclosporine	56-59	T-box 21	Mus musculus	29-34
26855194-10	2016	CsA reduces T-bet-dependent cancer immunosurveillance by CD8(+) T cells.	Cyclosporine	0-3	T-box 21	Mus musculus	12-17
26792730-4	2016	Utilizing human Jurkat T cells, we demonstrate that CrkII-SH3N binding of C3G is inhibited by cyclosporin A (CsA) plus FK506 that inhibit the cyclophilin A (CypA) and FK506 binding protein (FKBP) peptidyl-prolyl cis-trans isomerases (PPIases; also termed immunophilins), respectively.	Cyclosporine	94-107	Rap guanine nucleotide exchange factor 1	Homo sapiens	74-77
26792730-4	2016	Utilizing human Jurkat T cells, we demonstrate that CrkII-SH3N binding of C3G is inhibited by cyclosporin A (CsA) plus FK506 that inhibit the cyclophilin A (CypA) and FK506 binding protein (FKBP) peptidyl-prolyl cis-trans isomerases (PPIases; also termed immunophilins), respectively.	Cyclosporine	109-112	Rap guanine nucleotide exchange factor 1	Homo sapiens	74-77
26792730-6	2016	Treatment of Jurkat T cells with CsA plus FK506 led to a time-dependent conformational change in overexpressed human CrkII1-236 protein-containing FRET-based biosensor, supporting the accumulation of cis conformers of human CrkII1-236 in the presence of PPIase inhibitors.	Cyclosporine	33-36	FKBP prolyl isomerase 3	Homo sapiens	254-260
26463642-6	2016	A calcineurin inhibitor, cyclosporine has been used as an immunosuppressive agent in corneal transplantation since the 1980"s.	Cyclosporine	25-37	calcineurin binding protein 1	Homo sapiens	2-23
26782505-8	2015	The CD4+ cell proportion decreased significantly (41.25 vs 69.22%, P &lt; 0.01) and slightly (65.21 vs 69.22, P &gt; 0.05) in the cyclosporine and sirolimus groups, respectively.	Cyclosporine	130-142	CD4 antigen	Mus musculus	4-7
26385159-4	2015	In previous studies mPT was inhibited by cyclosporine A which, beside CypD, inhibits cyclophilin A, B, C and calcineurin, regulating cell death and inflammatory pathways.	Cyclosporine	41-55	peptidylprolyl isomerase A	Mus musculus	85-120
26408697-5	2015	We further observed that loss of mitochondrial membrane potential and increase in reactive oxygen species content, release of mitochondrial cytochrome c, caspase-9 activation, and apoptotic cell death induced by CHM-1, were suppressed by treatment with cyclosporine A, and by the overexpression of constitutively active AKT1 or GRP78.	Cyclosporine	253-267	chondromodulin	Homo sapiens	212-217
26324318-5	2015	The results revealed reduced retention of cyclosporine A in PMBC over-expressing P-gp in a TNBS-treated group and enhanced secretion of the cytokines IL-1beta, IL-6, IL-17, and TNF-alpha as well as LPS in plasma.	Cyclosporine	42-56	phosphoglycolate phosphatase	Mus musculus	81-85
25936769-6	2015	The results showed that expression levels of HO-1 were significantly upregulated in response to treatment with CsA, FK506, RAPA and MMF, whereas the expression levels of IL-7 were markedly downregulated by treatment with the above immunosuppressants.	Cyclosporine	111-114	heme oxygenase 1	Rattus norvegicus	45-49
25970072-11	2015	This novel inhibitor of the MCP-1/CCR2 axis (mNOX-E36), which has already proven efficacy and tolerability in early clinical trials, alleviates acute rejection processes in allogeneic transplantation especially when combined with subtherapeutic doses of CsA.	Cyclosporine	254-257	chemokine (C-C motif) ligand 2	Mus musculus	28-33
25883698-6	2015	Calcineurin inhibitor, which includes cyclosporine, pimecrolimus and tacrolimus, impairs calcineurin-induced up-regulation of IL-2 expression, resulting in increased susceptibility to invasive fungal diseases.	Cyclosporine	38-50	calcineurin binding protein 1	Homo sapiens	0-21
25661468-7	2015	Here, we describe a very unusual neuropsychiatric side effect of tacrolimus and its resolution with another calcineurin inhibitor, cyclosporine, in an adolescent renal transplant recipient.	Cyclosporine	131-143	calcineurin binding protein 1	Homo sapiens	108-129
25894208-6	2015	As extracellular CyPA-inhibitor we used the recently described CsA-derivate MM284.	Cyclosporine	63-66	peptidylprolyl isomerase A	Mus musculus	17-21
25420893-7	2015	The relative expressions of COX-1 and COX-2 genes to GAPDH revealed that the maximum increase was obtained in the group treated with CyA and vardenafil for both COX-1 and COX-2 genes.	Cyclosporine	133-136	glyceraldehyde-3-phosphate dehydrogenase	Mus musculus	53-58
19560530-6	2009	RESULTS: TPT treatment enhanced the expression of FoxP3 in CD4+ cells, whereas CsA inhibited the FoxP3 expression.	Cyclosporine	79-82	forkhead box P3	Rattus norvegicus	97-102
19666510-3	2009	Th2 cells that have upregulated T1ST2 produce IL-13, but not IL-4, in response to IL-33 plus a STAT5 activator in an antigen-independent, NF-kappaB-dependent, cyclosporin A (CsA)-resistant manner.	Cyclosporine	159-172	interleukin 33	Homo sapiens	82-87
19451286-0	2009	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.	Cyclosporine	0-12	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	114-117
19617341-3	2009	We have previously demonstrated P-gp activity at the human BBB using PET of (11)C-verapamil distribution into the brain in the absence and presence of the P-gp inhibitor cyclosporine-A (CsA).	Cyclosporine	170-184	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	186-189
25270396-2	2015	Elevated fibroblast growth factor (FGF)-23 in cyclosporine A (CsA) users with SLE are associated with decreased active vitamin D and osteocalcin.	Cyclosporine	46-60	fibroblast growth factor 23	Homo sapiens	9-42
25619112-8	2015	There was significant nuclear translocation of AIF as hair follicles transitioned from anagen to late catagen phase; this was inhibited by CsA, likely due to reduced cyclophilin A expression and attenuated AIF release from mitochondria.	Cyclosporine	139-142	peptidylprolyl isomerase A	Mus musculus	166-179
25354724-9	2015	Dexamethasone and cyclosporin A significantly reduced IL-17 and IFN-gamma production in PBMCs and dexamethasone up-regulated IL-10 production in activated PBMCs from healthy subjects.	Cyclosporine	18-31	interleukin 17A	Homo sapiens	54-59
25418342-8	2015	alpha5 and beta1 integrin were downregulated at all treatment concentrations of CsA while alpha2 integrin presented this effect at concentrations above 1 microg/mL (p &lt; 0.05).	Cyclosporine	80-83	integrin subunit beta 1	Homo sapiens	11-25
25353064-10	2015	The gingival mRNA and protein expression profiles for genes associated with Wnt/beta-catenin signaling further confirmed the effect of CsA: beta-catenin and Dvl-1 expression increased, but APC and axin-1 expression decreased.	Cyclosporine	135-138	axin 1	Rattus norvegicus	197-203
25573697-2	2015	For this reason, a decrease in cyclosporine (CsA) dosage has been proposed when combining this drug with telaprevir.	Cyclosporine	31-43	chorionic somatomammotropin hormone 1	Homo sapiens	45-48
25638160-0	2015	Cyclosporine A and tacrolimus inhibit bladder cancer growth through down-regulation of NFATc1.	Cyclosporine	0-14	nuclear factor of activated T cells 1	Homo sapiens	87-93
25638160-4	2015	In bladder cancer cell lines, cyclosporine A (CsA) and tacrolimus (FK506), immunosuppressant drugs/non-selective NFAT inhibitors, attenuated NFATc1 expression and its nuclear translocation, NFAT transcriptional activity, and the expression of cyclooxygenase-2 and c-myc, downstream targets of NFATc1.	Cyclosporine	30-44	nuclear factor of activated T cells 1	Homo sapiens	141-147
25638160-4	2015	In bladder cancer cell lines, cyclosporine A (CsA) and tacrolimus (FK506), immunosuppressant drugs/non-selective NFAT inhibitors, attenuated NFATc1 expression and its nuclear translocation, NFAT transcriptional activity, and the expression of cyclooxygenase-2 and c-myc, downstream targets of NFATc1.	Cyclosporine	30-44	nuclear factor of activated T cells 1	Homo sapiens	293-299
25638160-4	2015	In bladder cancer cell lines, cyclosporine A (CsA) and tacrolimus (FK506), immunosuppressant drugs/non-selective NFAT inhibitors, attenuated NFATc1 expression and its nuclear translocation, NFAT transcriptional activity, and the expression of cyclooxygenase-2 and c-myc, downstream targets of NFATc1.	Cyclosporine	46-49	nuclear factor of activated T cells 1	Homo sapiens	141-147
25638160-4	2015	In bladder cancer cell lines, cyclosporine A (CsA) and tacrolimus (FK506), immunosuppressant drugs/non-selective NFAT inhibitors, attenuated NFATc1 expression and its nuclear translocation, NFAT transcriptional activity, and the expression of cyclooxygenase-2 and c-myc, downstream targets of NFATc1.	Cyclosporine	46-49	nuclear factor of activated T cells 1	Homo sapiens	293-299
25638160-9	2015	Thus, NFATc1 inactivation, especially using CsA and FK506, has the potential of being a therapeutic approach for bladder cancer.	Cyclosporine	44-47	nuclear factor of activated T cells 1	Homo sapiens	6-12
25629977-3	2015	CsA induced cardiomyocyte-specific differentiation of P19 cells, with the highest efficiency at a concentration of 0.32 muM during embryoid body (EB) formation via activation of the Wnt signaling pathway molecules, Wnt3a, Wnt5a, and Wnt8a, and the cardiac mesoderm markers, Mixl1, Mesp1, and Mesp2.	Cyclosporine	0-3	Mix1 homeobox-like 1 (Xenopus laevis)	Mus musculus	274-279
25629977-3	2015	CsA induced cardiomyocyte-specific differentiation of P19 cells, with the highest efficiency at a concentration of 0.32 muM during embryoid body (EB) formation via activation of the Wnt signaling pathway molecules, Wnt3a, Wnt5a, and Wnt8a, and the cardiac mesoderm markers, Mixl1, Mesp1, and Mesp2.	Cyclosporine	0-3	mesoderm posterior 1	Mus musculus	281-286
25629977-7	2015	CsA significantly modulated mRNA expression levels of the cell cycle molecules, p53 and Cyclins D1, D2, and E2 in P19 cells during EB formation.	Cyclosporine	0-3	cyclin D1	Mus musculus	88-110
25617835-9	2015	The mean inlet CSA was 8.7 mm2 in healthy controls and 14.6mm2 in CTS group (P&lt;0.001).	Cyclosporine	15-18	transthyretin	Homo sapiens	66-69
25444857-1	2015	Cysteine dioxygenase (CDO) is a non-heme mononuclear iron enzyme that catalyzes the oxygen-dependent oxidation of L-cysteine (Cys) to produce L-cysteine sulfinic acid (CSA).	Cyclosporine	168-171	cysteine dioxygenase 1, cytosolic	Mus musculus	0-20
25444857-1	2015	Cysteine dioxygenase (CDO) is a non-heme mononuclear iron enzyme that catalyzes the oxygen-dependent oxidation of L-cysteine (Cys) to produce L-cysteine sulfinic acid (CSA).	Cyclosporine	168-171	cysteine dioxygenase 1, cytosolic	Mus musculus	22-25
25747979-7	2015	P-gp inhibition by cyclosporine A (CsA) increased absorptive permeability of morin 2.4-fold but decreased the efflux of morin by 52%, which was consistent with increased plasma concentration of morin in the pretreatment of CsA in rats.	Cyclosporine	19-33	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	0-4
25747979-7	2015	P-gp inhibition by cyclosporine A (CsA) increased absorptive permeability of morin 2.4-fold but decreased the efflux of morin by 52%, which was consistent with increased plasma concentration of morin in the pretreatment of CsA in rats.	Cyclosporine	35-38	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	0-4
25747979-7	2015	P-gp inhibition by cyclosporine A (CsA) increased absorptive permeability of morin 2.4-fold but decreased the efflux of morin by 52%, which was consistent with increased plasma concentration of morin in the pretreatment of CsA in rats.	Cyclosporine	223-226	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	0-4
25264342-8	2015	These results indicated that P-gp strictly limited the intestinal absorption of aliskiren in mice and monkeys, and also that the effects of intestinal P-gp inhibition by CsA or zosuquidar on the pharmacokinetics of aliskiren were sensitively reproduced in monkeys.	Cyclosporine	170-173	phosphoglycolate phosphatase	Mus musculus	151-155
25333459-0	2015	IL-15 is decreased upon CsA and FK506 treatment of acute rejection following heart transplantation in mice.	Cyclosporine	24-27	interleukin 15	Mus musculus	0-5
25333459-1	2015	The aim of this study was to investigate the effect of cyclosporine A (CsA) and tacrolimus (FK506) on interleukin-15 (IL-15) production during acute rejection following heart transplantation in mice.	Cyclosporine	55-69	interleukin 15	Mus musculus	102-116
25333459-1	2015	The aim of this study was to investigate the effect of cyclosporine A (CsA) and tacrolimus (FK506) on interleukin-15 (IL-15) production during acute rejection following heart transplantation in mice.	Cyclosporine	55-69	interleukin 15	Mus musculus	118-123
25333459-1	2015	The aim of this study was to investigate the effect of cyclosporine A (CsA) and tacrolimus (FK506) on interleukin-15 (IL-15) production during acute rejection following heart transplantation in mice.	Cyclosporine	71-74	interleukin 15	Mus musculus	102-116
25333459-1	2015	The aim of this study was to investigate the effect of cyclosporine A (CsA) and tacrolimus (FK506) on interleukin-15 (IL-15) production during acute rejection following heart transplantation in mice.	Cyclosporine	71-74	interleukin 15	Mus musculus	118-123
25333459-6	2015	Compared to the allogeneic acute rejection group, IL-15 expression was significantly decreased in the CsA- and FK506-treated allogeneic rejection groups.	Cyclosporine	102-105	interleukin 15	Mus musculus	50-55
25333459-9	2015	In conclusion, increased IL-15 expression in rejected murine heart grafts may be reduced by CsA and FK506 in vivo.	Cyclosporine	92-95	interleukin 15	Mus musculus	25-30
24760622-6	2014	Moreover, we evaluated Klotho mRNA expression and protein secretion in HK-2 tubular cells treated with cyclosporin A (CyA) and rhEPO, alone or in combination.	Cyclosporine	103-116	klotho	Homo sapiens	23-29
25226385-12	2014	On the other hand cyclosporin A (CSA) affected both NFATc1 activation and cell growth, definitively linking P2X7R stimulation to NFATc1 and cell proliferation.	Cyclosporine	18-31	nuclear factor of activated T cells 1	Homo sapiens	52-58
25226385-12	2014	On the other hand cyclosporin A (CSA) affected both NFATc1 activation and cell growth, definitively linking P2X7R stimulation to NFATc1 and cell proliferation.	Cyclosporine	18-31	nuclear factor of activated T cells 1	Homo sapiens	129-135
25226385-12	2014	On the other hand cyclosporin A (CSA) affected both NFATc1 activation and cell growth, definitively linking P2X7R stimulation to NFATc1 and cell proliferation.	Cyclosporine	33-36	nuclear factor of activated T cells 1	Homo sapiens	52-58
25226385-12	2014	On the other hand cyclosporin A (CSA) affected both NFATc1 activation and cell growth, definitively linking P2X7R stimulation to NFATc1 and cell proliferation.	Cyclosporine	33-36	nuclear factor of activated T cells 1	Homo sapiens	129-135
25089522-5	2014	Cyclosporin A attenuated Ad-Ankrd1-enhanced cardiomyocyte hypertrophy.	Cyclosporine	0-13	ankyrin repeat domain 1 (cardiac muscle)	Mus musculus	28-34
24582363-7	2014	Moreover, co-administration of CsA with CS2 can reverse or alleviate the above apoptotic damage effects of CS2 on testicular germ cells.	Cyclosporine	31-34	calsyntenin 2	Rattus norvegicus	107-110
24932812-0	2014	Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus.	Cyclosporine	135-149	calcineurin binding protein 1	Homo sapiens	113-134
24555822-9	2014	The P-gp inhibitors cyclosporine and elacridar (i.e. GF120918A) markedly enhanced SNX-2112 absorption in all four intestinal segments (i.e. duodenum, jejunum, ileum and colon) and the fold change ranged from 3.1 to 14.1.	Cyclosporine	20-32	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	4-8
19458944-1	2009	BACKGROUND: Trough- or 2-h post-dose (C2) blood cyclosporine (CsA) concentrations are used for prediction of efficacy and toxicity of CsA in transplant recipients concomitantly treated with antiproliferative agents, but information on utility of blood CsA levels in patients treated with proliferation signal inhibitors (PSIs), such as everolimus, is sparse.	Cyclosporine	48-60	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	62-65
19458944-1	2009	BACKGROUND: Trough- or 2-h post-dose (C2) blood cyclosporine (CsA) concentrations are used for prediction of efficacy and toxicity of CsA in transplant recipients concomitantly treated with antiproliferative agents, but information on utility of blood CsA levels in patients treated with proliferation signal inhibitors (PSIs), such as everolimus, is sparse.	Cyclosporine	48-60	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	134-137
19458944-1	2009	BACKGROUND: Trough- or 2-h post-dose (C2) blood cyclosporine (CsA) concentrations are used for prediction of efficacy and toxicity of CsA in transplant recipients concomitantly treated with antiproliferative agents, but information on utility of blood CsA levels in patients treated with proliferation signal inhibitors (PSIs), such as everolimus, is sparse.	Cyclosporine	48-60	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	134-137
19542435-6	2009	Col(V) plus CsA was associated with alloantigen-induced expression of IL-10 in mediastinal lymph node or splenic T cells, intragraft expression of IL-10 and Foxp3 in perivascular and peribronchiolar mononuclear cells, and constitutive production of IL-10 from allograft alveolar macrophages.	Cyclosporine	12-15	forkhead box P3	Rattus norvegicus	157-162
19386625-2	2009	A physiologically realistic EHC model was proposed to estimate and assess the impact of cyclosporine (CsA) dose on the extent of EHC of MPA and MPAG.	Cyclosporine	88-100	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	102-105
19211914-6	2009	That is, after the reconstitution of the gelsolin-treated skinned smooth muscle strips with pure actin, the Ca(2+)-dependent force development was partially restored, but the Ca(2+)-induced reduction in CSA occurred once.	Cyclosporine	203-206	gelsolin	Cavia porcellus	41-49
19403878-8	2009	CsA effect on (11)C radioactivity distribution was interpreted as P-gp inhibition.	Cyclosporine	0-3	LOW QUALITY PROTEIN: glycerol-3-phosphate phosphatase	Macaca nemestrina	66-70
18486150-3	2009	We have proposed that cyclosporin A (CsA), despite being a calcineurin inhibitor, will activate PKC in B cells, thus promoting Epstein-Barr virus (EBV)-induced transformation.	Cyclosporine	22-35	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	37-40
25595785-9	2015	Amelioration of AD progression by cyclosporin A treatment was well correlated with downregulation of IL-31 expressions in CD4(+) T cells and total ear residual cells.	Cyclosporine	34-47	CD4 antigen	Mus musculus	122-125
19233265-6	2009	Embryos treated in utero with the calcineurin inhibitor cyclosporine-A showed cytoplasmic NFATc1, diminished podoplanin and FGFR-3 expression by the lymphatics and irregular patterning of the LEC sprouts coming off the jugular lymph sac, which suggests a role for calcineurin-NFAT signaling in lymphatic patterning.	Cyclosporine	56-70	fibroblast growth factor receptor 3	Mus musculus	124-130
25648341-0	2015	Elevated expression of matrix metalloproteinase-9 and inflammatory cytokines in keratoconus patients is inhibited by cyclosporine A.	Cyclosporine	117-131	matrix metallopeptidase 9	Homo sapiens	23-49
19154769-14	2009	Internucleosomal DNA fragmentation in MIA IIa but not in MIA IIb was sensitive to glycine (5mM), inhibitor of NMDA receptor MK-801 (10microM) and PTP inhibitor cyclosporine A (10microM).	Cyclosporine	160-174	protein tyrosine phosphatase receptor type U	Homo sapiens	146-149
25648341-9	2015	Cyclosporine A treatment significantly reduced the mRNA expression levels of IL6 and TNFalpha in both short- and long-term treatments; however, it reduced MMP9 levels only in long-term treatment in cultured corneal epithelial cells.	Cyclosporine	0-14	matrix metallopeptidase 9	Homo sapiens	155-159
19228691-5	2009	A cyclophilin D inhibitor, cyclosporine A, disrupts the CypD-Bcl2 interaction.	Cyclosporine	27-41	peptidylprolyl isomerase D	Homo sapiens	2-15
25648341-12	2015	Cyclosporine A treatment reduced MMP9 and inflammatory cytokine levels in an in vitro inflammation model system.	Cyclosporine	0-14	matrix metallopeptidase 9	Homo sapiens	33-37
19228691-5	2009	A cyclophilin D inhibitor, cyclosporine A, disrupts the CypD-Bcl2 interaction.	Cyclosporine	27-41	peptidylprolyl isomerase D	Homo sapiens	56-60
25452304-4	2015	In CsA-treated allograft recipient mice, CD11b(+) Gr1(+) myeloid-derived suppressor cells (MDSCs) were functional suppressive immune modulators that resulted in fewer gamma interferon (IFN-gamma)-producing CD8(+) T cells and CD4(+) T cells (T(H)1 T helper cells) and more interleukin 4 (IL-4)-producing CD4(+) T cells (T(H2)) and prolonged allogeneic skin graft survival.	Cyclosporine	3-6	CD4 antigen	Mus musculus	225-228
19228691-7	2009	Gain- and loss-of-function experiments confirm that CypD has a limiting effect on cytochrome c release from mitochondria and that such an effect of CypD is cyclosporine A- and Bcl2-dependent.	Cyclosporine	156-170	peptidylprolyl isomerase D	Homo sapiens	52-56
19228691-7	2009	Gain- and loss-of-function experiments confirm that CypD has a limiting effect on cytochrome c release from mitochondria and that such an effect of CypD is cyclosporine A- and Bcl2-dependent.	Cyclosporine	156-170	peptidylprolyl isomerase D	Homo sapiens	148-152
25452304-4	2015	In CsA-treated allograft recipient mice, CD11b(+) Gr1(+) myeloid-derived suppressor cells (MDSCs) were functional suppressive immune modulators that resulted in fewer gamma interferon (IFN-gamma)-producing CD8(+) T cells and CD4(+) T cells (T(H)1 T helper cells) and more interleukin 4 (IL-4)-producing CD4(+) T cells (T(H2)) and prolonged allogeneic skin graft survival.	Cyclosporine	3-6	CD4 antigen	Mus musculus	303-306
25629977-3	2015	CsA induced cardiomyocyte-specific differentiation of P19 cells, with the highest efficiency at a concentration of 0.32 muM during embryoid body (EB) formation via activation of the Wnt signaling pathway molecules, Wnt3a, Wnt5a, and Wnt8a, and the cardiac mesoderm markers, Mixl1, Mesp1, and Mesp2.	Cyclosporine	0-3	wingless-type MMTV integration site family, member 5A	Mus musculus	222-227
26448755-4	2015	We found that CD44 cross-linking promoted Foxp3 expression and Treg viability in the setting of CSA treatment.	Cyclosporine	96-99	CD44 molecule (Indian blood group)	Homo sapiens	14-18
24179369-3	2009	Uveitis improved and urine beta2-MG normalized with low dose systemic predonisolone and cyclosporin A.	Cyclosporine	88-101	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	27-32
25049068-4	2015	Target C2 levels were lower in the RAD group because RAD is known to potentiate CsA nephrotoxicity.	Cyclosporine	80-83	RRAD, Ras related glycolysis inhibitor and calcium channel regulator	Homo sapiens	35-38
19150448-10	2009	Specific calcineurin inhibition with cyclosporine A and FK506 or NFAT inhibition with 11R-VIVIT reversed the stretch or alpha-1-adrenergic induced decrease of NGF.	Cyclosporine	37-51	nerve growth factor	Rattus norvegicus	159-162
18973526-3	2009	The roles of the endothelin receptors A and B (ET(A) and ET(B)) in CsA-enhanced expression of PCNA and iNOS were examined in cultured human gingival fibroblasts pretreated with receptor antagonists, by immunocytochemistry and RT-PCR, respectively.	Cyclosporine	67-70	endothelin receptor type A	Homo sapiens	47-52
18973526-4	2009	RESULTS: The mRNA expression of ET-1, ET(A) and ET(B), as well as of PCNA and iNOS, was significantly greater in edentulous gingiva that received CsA compared with control gingiva.	Cyclosporine	146-149	endothelin receptor type A	Rattus norvegicus	38-43
18973526-4	2009	RESULTS: The mRNA expression of ET-1, ET(A) and ET(B), as well as of PCNA and iNOS, was significantly greater in edentulous gingiva that received CsA compared with control gingiva.	Cyclosporine	146-149	endothelin receptor type B	Rattus norvegicus	48-53
18973526-6	2009	In fibroblast cultures, enhanced mRNA expression of ET-1, ET(A) and ET(B) was observed after CsA treatment at the concentrations of 10 and 100 ng/mL.	Cyclosporine	93-96	endothelin receptor type A	Rattus norvegicus	58-63
18973526-6	2009	In fibroblast cultures, enhanced mRNA expression of ET-1, ET(A) and ET(B) was observed after CsA treatment at the concentrations of 10 and 100 ng/mL.	Cyclosporine	93-96	endothelin receptor type B	Rattus norvegicus	68-73
18973526-7	2009	Cyclosporine A-enhanced PCNA expression was somewhat reduced by blockade of ET(A), but not ET(B), whereas iNOS expression was somewhat reduced by blockade of ET(B).	Cyclosporine	0-14	endothelin receptor type A	Rattus norvegicus	76-81
18973526-8	2009	CONCLUSION: Based on the present findings, we suggest that: (1) CsA upregulates the gingival expression of ET-1 and its receptors; and (2) ET(A) and ET(B) have different bioactivities, ET(A) being involved in cell proliferation and ET(B) being associated with iNOS expression.	Cyclosporine	64-67	endothelin receptor type A	Rattus norvegicus	139-144
19252740-4	2009	Furthermore, cyclosporine treatment of the insulinoma-1E cell line resulted in remarkable reduction in HNF4alpha protein and INS1 as well as INS2 gene expression, while transcript expression of HNF4alpha, apolipoprotein C2, glycerolkinase, pyruvatekinase and aldolase B was repressed in treated Caco-2 cells.	Cyclosporine	13-25	apolipoprotein C2	Homo sapiens	205-222
19799203-1	2009	AIM: Evaluation of cyclosporine (CSA) withdrawal safety and efficacy in children late after kidney transplantation.	Cyclosporine	19-31	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	33-36
19249558-1	2009	We have reported that cyclosporine (CsA) has direct effect to promote Epstein-Barr virus (EBV) transformation of human peripheral blood B lymphocytes.	Cyclosporine	22-34	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	36-39
18694850-3	2008	In the present review we have focused our attention on the possible role of cyclosporine A (CsA), anti-Tumour Necrosis Factor (TNF) alpha agents in the treatment of HIV or HCV infected autoimmune patients.	Cyclosporine	76-90	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	92-95
18594870-10	2008	The MMP2/TIMP2 ratio in NS children treated with CyA was significantly lower in comparison with healthy controls (p &lt; 0.01).	Cyclosporine	49-52	matrix metallopeptidase 2	Homo sapiens	4-8
18929835-13	2008	CONCLUSIONS: Our data suggested that among several cytokines elevated levels of the LIX, MCP-1, beta-NGF, and TIMP-1 are the contributing factors to CsA-induced nephropathy.	Cyclosporine	149-152	nerve growth factor	Rattus norvegicus	96-104
18845086-6	2008	Between two treatment group, the expression of CD4(+)T cells and the expression of CD28 and ICOS on CD8(+)T cells in CsA-treated group were much higher than those in FK506-treated group (P&lt;0.05), and there was no significant difference between two treatment groups in other indexes.	Cyclosporine	117-120	CD28 molecule	Homo sapiens	83-87
20059863-3	2008	This investigation aimed to quantify the circulating T and B cells of mice treated with the immunosuppressive agents dexamethasone (Dx), cyclosporine (CsA) and cyclophosphamide (CY), as well as to observe the behaviour of lymphocytic populations in the spleen of these animals.	Cyclosporine	137-149	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	151-154
18567920-7	2008	CSA and HAb18G/CD147 antagonistic peptide AP-9 against CD147, respectively, dramatically decreased MMP-2 and MMP-9 expression, both in the absence or presence of CypA.	Cyclosporine	0-3	matrix metallopeptidase 2	Homo sapiens	99-104
18720690-1	2008	The prevailing notion in dermatology is that mycophenolate mofetil (MMF) is safer than cyclosporine (CsA), but that CsA has greater efficacy.	Cyclosporine	87-99	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	101-104
18448056-2	2008	cyclosporine (CsA) has proved effective in controlling acute attacks of ulcerative colitis unresponsive to IV steroids.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
24328896-13	2014	Annexin V-PE/7-AAD analysis showed 5 microg/ml PpIX could induce about 24% cell apoptosis, which was inhibited by cyclosporin A (CsA), an inhibitor of mitochondrial permeability transition pore.	Cyclosporine	114-127	annexin A5	Mus musculus	0-9
24328896-13	2014	Annexin V-PE/7-AAD analysis showed 5 microg/ml PpIX could induce about 24% cell apoptosis, which was inhibited by cyclosporin A (CsA), an inhibitor of mitochondrial permeability transition pore.	Cyclosporine	129-132	annexin A5	Mus musculus	0-9
24925208-5	2014	Therefore, we developed and evaluated the application, reliability and validity of a novel adverse effects scoring system in renal transplant recipients receiving calcineurin inhibitor (cyclosporine or tacrolimus) and mycophenolic acid based immunosuppressive therapy.	Cyclosporine	186-198	calcineurin binding protein 1	Homo sapiens	163-184
24968842-6	2014	RESULTS: In OA+CsA group, renal allograft survival was markedly prolonged and CD4(+) and CD8(+) T cell infiltration in the graft significantly decreased as compared to other groups.	Cyclosporine	15-18	Cd4 molecule	Rattus norvegicus	78-81
24853130-7	2014	Transition from CsA-induced renal dysfunction to nephrotoxicity is accompanied by modification of molecular mechanisms and biomarkers, being mTOR one of the key players for kidney lesion evolution, thus suggesting, by mean of molecular evidences, that early CsA replacement by mTOR inhibitors is indeed the better therapeutic choice to prevent chronic allograft nephropathy.	Cyclosporine	16-19	mechanistic target of rapamycin kinase	Rattus norvegicus	277-281
24631962-3	2014	The study was aimed to investigate whether the mycelia glycoproteins of Cordyceps sobolifera (CSP) exert prevention effects on CsA-induced nephrotoxicity.	Cyclosporine	127-130	DnaJ heat shock protein family (Hsp40) member C5	Rattus norvegicus	94-97
24631962-7	2014	CsA impaired urea clearance and creatinine clearance were significantly improved by concomitant administration of CSP.	Cyclosporine	0-3	DnaJ heat shock protein family (Hsp40) member C5	Rattus norvegicus	114-117
24631962-8	2014	TUNEL histochemical stain revealed that CSP significantly decreased CsA-induced apoptosis in renal tubular cells.	Cyclosporine	68-71	DnaJ heat shock protein family (Hsp40) member C5	Rattus norvegicus	40-43
24631962-10	2014	In assessment of CSP protection of renal tubule function, we found that CSP restored CsA induced magnesium wasting by increasing the magnesium reabsorption channels TRMP6 and TRMP7.	Cyclosporine	85-88	DnaJ heat shock protein family (Hsp40) member C5	Rattus norvegicus	72-75
25049068-4	2015	Target C2 levels were lower in the RAD group because RAD is known to potentiate CsA nephrotoxicity.	Cyclosporine	80-83	RRAD, Ras related glycolysis inhibitor and calcium channel regulator	Homo sapiens	53-56
25061717-9	2015	IFN-beta mRNA expression was significantly increased in rotavirus-induced diarrhea mice treated with 5 mg   kg-1   day-1 of CsA, whereas the mRNA expression levels of inflammation-related cytokines (IL-8, IL-10, IFN-gamma, and tumor necrosis factor-alpha) and inflammatory signaling pathways (p38, c-Jun N-terminal kinase, activator protein-1, and nuclear factor-kappa B) were markedly decreased.	Cyclosporine	124-127	interferon beta 1, fibroblast	Mus musculus	0-8
24823913-5	2014	Up-regulated expression of SHH and up-regulation of proliferating cell nuclear antigen transcripts and protein were observed in the edentulous gingiva of cyclosporine A-treated rats.	Cyclosporine	154-168	sonic hedgehog signaling molecule	Rattus norvegicus	27-30
25554991-14	2014	Our results indicate that both PPAR-gamma agonists used in the experiment may play an important role in protecting against CsA-induced damage in the kidney.	Cyclosporine	123-126	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	31-41
25238936-1	2014	A 55-year-old female with T-cell large granular lymphocytic leukemia (T-LGL) (CD8+) was initially treated with anti-thymocyte globulin and then cyclosporine due to anemia/neutropenia.	Cyclosporine	144-156	CD8a molecule	Homo sapiens	78-81
25003316-3	2014	In the present study we investigated calcineurin dependent or independent cytotoxic effects of CsA, a calcineurin inhibitor, in cervical cancerous SiHa cells.	Cyclosporine	95-98	calcineurin binding protein 1	Homo sapiens	102-123
25132229-9	2014	Importantly, long-term CsA treatment in NPC1 mice reduced reactive microgliosis, restored the survival of newly generated neurons in the OB and improved overall performance on the olfactory test.	Cyclosporine	23-26	NPC1 like intracellular cholesterol transporter 1	Mus musculus	40-44
24980806-8	2014	The net efflux ratio of GA (C15:1) and GA (C17:1) in both cell models was greater than 2 and markedly reduced by the presence of Cyclosporin A (CsA) or GF120918, inhibitors of P-gp and BCRP, suggesting that GAs are P-gp and BCRP substrates.	Cyclosporine	144-147	phosphoglycolate phosphatase	Mus musculus	176-180
24980806-8	2014	The net efflux ratio of GA (C15:1) and GA (C17:1) in both cell models was greater than 2 and markedly reduced by the presence of Cyclosporin A (CsA) or GF120918, inhibitors of P-gp and BCRP, suggesting that GAs are P-gp and BCRP substrates.	Cyclosporine	144-147	phosphoglycolate phosphatase	Mus musculus	215-219
24560449-1	2014	BACKGROUND/PURPOSE: Transforming growth factor-beta (TGF-beta) plays an important role in the pathogenesis of cyclosporine A (CsA)-induced gingival overgrowth (GO).	Cyclosporine	110-124	chorionic somatomammotropin hormone 1	Homo sapiens	126-129
24528288-7	2014	We also prospectively evaluated the expression pattern of CX3CR1 during treatment with antithymocyte globulin plus cyclosporine in 11 patients with severe AA.	Cyclosporine	115-127	C-X3-C motif chemokine receptor 1	Homo sapiens	58-64
25225668-5	2014	In addition, cyclophilin A increased Crk SH3 domain-binding guanine-nucleotide releasing factor (C3G) binding to CrkII, whereas inhibitors of immunophilins, such as cyclosporine A (CsA) and FK506, inhibited CrkII, but not CrkI association with C3G.	Cyclosporine	181-184	Rap guanine nucleotide exchange factor 1	Homo sapiens	97-100
25309428-4	2014	Treatment with cyclosporin A (CsA) is effective in normalizing the mitochondrial, apoptotic, and autophagic defects of myofibers in Col6a1 (-/-) mice.	Cyclosporine	15-28	collagen, type VI, alpha 1	Mus musculus	132-138
24909182-5	2014	We retrospectively analyzed the HLA-G 14-bp INS/DEL polymorphism of HLA-G gene in patients with moderate to severe plaque psoriasis: 21 treated with acitretin, 16 with cyclosporine, 11 with anti-TNF-alpha.	Cyclosporine	168-180	major histocompatibility complex, class I, G	Homo sapiens	68-73
24631962-11	2014	CONCLUSION: The results suggested that CSP had a significant suppressive activity on CsA-induced apoptosis and protective activity against nephron loss possibly via its restoring activity by increasing the magnesium reabsorption channels TRMP6 and TRMP7 on CsA induced magnesium wasting.	Cyclosporine	85-88	DnaJ heat shock protein family (Hsp40) member C5	Rattus norvegicus	39-42
24631962-11	2014	CONCLUSION: The results suggested that CSP had a significant suppressive activity on CsA-induced apoptosis and protective activity against nephron loss possibly via its restoring activity by increasing the magnesium reabsorption channels TRMP6 and TRMP7 on CsA induced magnesium wasting.	Cyclosporine	257-260	DnaJ heat shock protein family (Hsp40) member C5	Rattus norvegicus	39-42
24353324-3	2014	We hypothesize that CsA-induced hypomagnesaemia is due to a renal magnesium leak, also in patients, resulting from a downregulation of the renal EGF production, thereby inhibiting the activation of TRPM6.	Cyclosporine	20-23	transient receptor potential cation channel subfamily M member 6	Homo sapiens	198-203
24670298-8	2014	Activated CB T cells were more sensitive to CsA than activated PB T cells, which might be explained by the lower NFATc1 expression and cytokine secretion.	Cyclosporine	44-47	nuclear factor of activated T cells 1	Homo sapiens	113-119
24817934-0	2014	Cyclosporine A improves adhesion and invasion of mouse preimplantation embryos via upregulating integrin beta3 and matrix metalloproteinase-9.	Cyclosporine	0-14	integrin beta 3	Mus musculus	96-110
24310293-10	2014	Furthermore, TCR signaling-induced expression of proximal Runx1 was blocked by treatment of cells with cyclosporin A.	Cyclosporine	103-116	runt related transcription factor 1	Mus musculus	58-63
24272483-5	2014	We also found that treatment with small molecule inhibitors of cyclophilins, including the approved drug cyclosporine, greatly reduced the viability of glioblastoma multiforme cells.	Cyclosporine	105-117	peptidylprolyl isomerase B	Homo sapiens	63-75
25277512-10	2014	As a calcineurin-specific inhibitor, CsA inhibited (3)H-Leu incorporation, surface area, mRNA expressions of ANP, BNP, beta-MHC, CnAbeta and protein expression of CnAbeta of AngII-induced cardiomyocytes.	Cyclosporine	37-40	natriuretic peptide A	Rattus norvegicus	109-112
26155135-3	2014	The results showed that both DEX and CsA dose-dependently inhibited the production of eleven cytokines: interleukin (IL)-2, IL-4, IL-5, IL-6, IL-13, IL-17, interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF).	Cyclosporine	37-40	interleukin 17A	Homo sapiens	149-154
24492412-8	2014	On day 7 of DSS treatment, the concentrations of cyclosporine A (CsA), a substrate of both CYP3A and P-gp, were significantly higher than controls.	Cyclosporine	65-68	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	91-96
24492412-8	2014	On day 7 of DSS treatment, the concentrations of cyclosporine A (CsA), a substrate of both CYP3A and P-gp, were significantly higher than controls.	Cyclosporine	65-68	phosphoglycolate phosphatase	Mus musculus	101-105
24492412-9	2014	These results indicated the existence of a second inflammatory response in the liver and upper small intestine of mice with DSS-induced colitis, and bioavailability of CsA was increased by the dysfunction of CYP3A and P-gp in these organs.	Cyclosporine	168-171	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	208-213
24492412-9	2014	These results indicated the existence of a second inflammatory response in the liver and upper small intestine of mice with DSS-induced colitis, and bioavailability of CsA was increased by the dysfunction of CYP3A and P-gp in these organs.	Cyclosporine	168-171	phosphoglycolate phosphatase	Mus musculus	218-222
23809336-6	2013	The results showed that CsA increased the mRNA expression and contractile function of several G-protein-coupled receptors (GPCRs), such as endothelin receptor type B (ETB ), 5-hydroxytryptamine type 1B (5-HT1B ) and 1D (5-HT1D ), in vascular smooth muscle cells.	Cyclosporine	24-27	5-hydroxytryptamine receptor 1B	Rattus norvegicus	174-201
23809336-6	2013	The results showed that CsA increased the mRNA expression and contractile function of several G-protein-coupled receptors (GPCRs), such as endothelin receptor type B (ETB ), 5-hydroxytryptamine type 1B (5-HT1B ) and 1D (5-HT1D ), in vascular smooth muscle cells.	Cyclosporine	24-27	5-hydroxytryptamine receptor 1B	Rattus norvegicus	203-209
24036158-8	2013	Cyclosporine, vincristine, and vinblastine inhibited MRP2 only, whereas 6-mercaptopurine inhibited MRP4 transport activity only.	Cyclosporine	0-12	ATP binding cassette subfamily C member 2	Homo sapiens	53-57
24064216-0	2013	Mutations in intracellular loops 1 and 3 lead to misfolding of human P-glycoprotein (ABCB1) that can be rescued by cyclosporine A, which reduces its association with chaperone Hsp70.	Cyclosporine	115-129	heat shock protein family A (Hsp70) member 4	Homo sapiens	176-181
24107224-7	2013	We observed a change in (15)N CSA for most residues of cytb5 in the complex, as compared to free cytb5, suggesting a dynamic interaction between the oppositely charged surfaces of anionic cytb5 and cationic cytP450.	Cyclosporine	30-33	cytochrome b5	Oryctolagus cuniculus	55-60
18504214-9	2008	CONCLUSION: Continuous administration of low-dose uPA may reduce interstitial fibrin deposition and alleviate renal interstitial inflammation in rats with chronic CsA nephropathy, possibly by reducing the number of macrophages and TGF-beta1 expression in the renal tissue.	Cyclosporine	163-166	plasminogen activator, urokinase	Rattus norvegicus	50-53
18504170-7	2008	CONCLUSIONS: It is proposed that the enhancing effect of CsA on hepatocyte proliferation is by means of an indirect mechanism that can be attributed to a) reduced immunogenicity of the regenerating liver as a result of inhibition of class I and II MHC hepatocyte expression and b) increased PGE2 synthesis in the liver mediated by its action on EP1 receptor.	Cyclosporine	57-60	prostaglandin E receptor 1	Rattus norvegicus	345-348
18259730-0	2008	Differential modulation of agonist and antagonist structure activity relations for rat TRPV1 by cyclosporin A and other protein phosphatase inhibitors.	Cyclosporine	96-109	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	87-92
18259730-3	2008	We demonstrate here that the structure activity relations of TRPV1, as determined by (45)Ca(2) uptake, were substantially altered by treatment of the cells with cyclosporin A, an inhibitor of protein phosphatase 2B.	Cyclosporine	161-174	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	61-66
24737737-0	2014	Cyclosporine A protects podocytes via stabilization of cofilin-1 expression in the unphosphorylated state.	Cyclosporine	0-14	cofilin 1	Rattus norvegicus	55-64
24737737-4	2014	Other studies showed that CsA could regulate cofilin-1 directly within tubular epithelial cells.	Cyclosporine	26-29	cofilin 1	Rattus norvegicus	45-54
24737737-8	2014	We found that CsA reduced proteinuria and repaired FP effacement of PAN-induced nephropathy, restored expression of nephrin, synaptopodin, cofilin-1, pho-cofilin-1 both in vivo and in vitro.	Cyclosporine	14-17	cofilin 1	Rattus norvegicus	139-148
24737737-8	2014	We found that CsA reduced proteinuria and repaired FP effacement of PAN-induced nephropathy, restored expression of nephrin, synaptopodin, cofilin-1, pho-cofilin-1 both in vivo and in vitro.	Cyclosporine	14-17	cofilin 1	Rattus norvegicus	154-163
24737737-10	2014	The protective effect of CsA was diminished when cofilin-1 was knocked down compared to negative control.	Cyclosporine	25-28	cofilin 1	Rattus norvegicus	49-58
24737737-12	2014	The protective effect of CsA decreased significantly when cofilin-1 and synaptopodin were simultaneously knocked down compared to only cofilin-1 knock down.	Cyclosporine	25-28	cofilin 1	Rattus norvegicus	58-67
24737737-12	2014	The protective effect of CsA decreased significantly when cofilin-1 and synaptopodin were simultaneously knocked down compared to only cofilin-1 knock down.	Cyclosporine	25-28	cofilin 1	Rattus norvegicus	135-144
24737737-13	2014	In conclusion, the antiproteinuric effect of CsA is derived from the stabilization of the podocyte actin cytoskeleton by upregulating expression of cofilin-1, which was independent of its effect on synaptopodin.	Cyclosporine	45-48	cofilin 1	Rattus norvegicus	148-157
25132585-1	2014	Cyclosporine, a calcineurin inhibitor, is a potent immunosuppressive agent that acts chiefly through the inactivation of T-lymphocytes.	Cyclosporine	0-12	calcineurin binding protein 1	Homo sapiens	16-37
24703255-7	2014	Although cyclosporine, azathioprine, and methotrexate increased muscle Daf levels when used alone, upon co-treatment with prednisone only azathioprine maintained myotube Daf levels close to basal.	Cyclosporine	9-21	CD55 molecule, decay accelerating factor for complement	Mus musculus	71-74
24307660-3	2014	She was unresponsive to cyclosporine A, methylprednisolone, intravenous immunoglobulin, and mycophenolate mofetil and the symptoms could only be controlled after plasma exchange and subsequent use of rituximab, in addition to cyclosporine A and mycophenolate mofetil maintenance.	Cyclosporine	226-240	Src homology 2 domain containing E	Homo sapiens	0-3
24632637-10	2014	CsA, an MPTP opening inhibitor, prevented mitochondrial Deltapsim disruption, Opa-1 processing and Drp-1 translocation to the mitochondria therefore protecting Mn-exposed cells from mitochondrial disruption and apoptosis.	Cyclosporine	0-3	OPA1, mitochondrial dynamin like GTPase	Rattus norvegicus	78-83
24559268-11	2014	Increased apoptotic cell death and a high ratio of B cell leukaemia/lymphoma 2 (Bcl-2)-associated X protein (Bax) to Bcl-2 in CsA-treated mice were also significantly ameliorated by OA treatment.	Cyclosporine	126-129	BCL2-associated X protein	Mus musculus	109-112
24505415-0	2014	The antibody response of pregnant Cameroonian women to VAR2CSA ID1-ID2a, a small recombinant protein containing the CSA-binding site.	Cyclosporine	59-62	inhibitor of DNA binding 2	Homo sapiens	67-71
24505415-12	2014	Currently, ID1-ID2a is a leading vaccine candidate, since it binds to the CSA with the same affinity as the full-length molecule and elicits binding-inhibitory antibodies in animals.	Cyclosporine	74-77	inhibitor of DNA binding 2	Homo sapiens	15-19
24550776-5	2014	In the presence of the PP2B blocker cyclosporin A, CF stimulation elicited iLTP in Camk2b (-) (/) (-) mice, but not in Camk2a (-) (/) (-) mice.	Cyclosporine	36-49	calcium/calmodulin-dependent protein kinase II, beta	Mus musculus	83-89
24502637-9	2014	The findings of these experiments suggested that in hyperlipidemia the expression and (or) the functional activity of P-glycoprotein was diminished, leading to greater hepatic and renal uptake of cyclosporine A, and renal cellular toxicity.	Cyclosporine	196-210	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	118-132
25484446-3	2014	We have introduced an MAS approach that permits site-resolved determination of CSA tensors of protons forming chemical bonds with labeled spin-1/2 nuclei in fully protonated solids with multiple sites, including organic molecules and proteins.	Cyclosporine	79-82	spindlin 1	Homo sapiens	138-146
18094068-7	2008	The CsA group displayed a significant increase in the number of circulating EPCs (sca-1+KDR+ and c-kit+CD31+ EPCs, both P &lt; 0.05).	Cyclosporine	4-7	kinase insert domain protein receptor	Mus musculus	88-91
24055605-6	2013	Consistent with this, MxB associates with CypA, and shRNA-mediated CypA depletion or cyclosporine A treatment resulted in the loss of MxB inhibition of HIV-1.	Cyclosporine	85-99	MX dynamin like GTPase 2	Homo sapiens	134-137
24228106-11	2013	Moreover, CsA pretreatment up-regulated Titin expression, down-regulated E-cadherin expression, improved MMP2 and MMP9 activity, and increased the CXCL12 secretion in JAR cells.	Cyclosporine	10-13	matrix metallopeptidase 9	Homo sapiens	114-118
23845694-8	2013	The exposure of HMEC-1 to CSA and TAC+SIR significantly increased the expression of ICAM-1 (157.5 +- 11.6 and 153.4 +- 9.5 MGV, respectively, versus 105.7 +- 6.5 MGV in controls [both P &lt; .05]).	Cyclosporine	26-29	intercellular adhesion molecule 1	Homo sapiens	84-90
23173828-8	2013	The addition of PD98059, LY294002, NAC, curcumin, EGCG, and SB203580 markedly inhibited TGM-2 expression induced by CsA (P &lt;0.05).	Cyclosporine	116-119	X-linked Kx blood group	Homo sapiens	35-38
23173828-10	2013	In addition, TGM-2 induced by CsA is downregulated by PD98059, LY294002, NAC, curcumin, EGCG, and SB203580.	Cyclosporine	30-33	X-linked Kx blood group	Homo sapiens	73-76
23492557-9	2013	Surprisingly, in a series of cyclosporine derivatives an inverse relationship was found between the inhibition of prolyl oligopeptidase and inhibition of cyclophilin A.	Cyclosporine	29-41	peptidylprolyl isomerase A	Mus musculus	154-167
23677648-0	2013	A new recombinant MnSOD prevents the cyclosporine A-induced renal impairment.	Cyclosporine	37-51	superoxide dismutase 2	Rattus norvegicus	18-23
23677648-4	2013	The present study aims to investigate in vivo the effects of a new recombinant mitochondrial manganese-containing superoxide dismutase (rMnSOD), a strong antioxidant, on the CsA-induced nephotoxicity.	Cyclosporine	174-177	superoxide dismutase 2	Rattus norvegicus	136-142
23677648-11	2013	RESULTS: CsA-treated rats showed a severe decrease in GFR (0.34 +- 0.17 versus 0.94 +- 0.10 in control, P &lt; 0.001) which was prevented by rMnSOD co-administration (0.77 +- 0.10).	Cyclosporine	9-12	superoxide dismutase 2	Rattus norvegicus	141-147
23677648-15	2013	CONCLUSIONS: Administration of rMnSOD prevents CsA-mediated impairment of the GFR along with morphological alteration.	Cyclosporine	47-50	superoxide dismutase 2	Rattus norvegicus	31-37
24113044-12	2013	Furthermore, CsA or CsA-NP (5 mg/ml) completely inhibited the H2O2-induced release of cytochrome C.	Cyclosporine	13-16	cytochrome c	Sus scrofa	86-98
23683031-7	2013	In CsA-treated rat kidneys, the protein expression of NOX4 and p22phox was reduced by BIL (P &lt; 0.05).	Cyclosporine	3-6	NADPH oxidase 4	Rattus norvegicus	54-58
22934840-8	2013	Conversely, 3D cultures responded to CsA treatment with a reduction in MMP-10 secretion.	Cyclosporine	37-40	matrix metallopeptidase 10	Homo sapiens	71-77
23622648-13	2013	Renal over expression of mTOR in the CsA-treated group, associated with renal dysfunction and structural damage, reinforces the potential beneft of SRL as a strategy to reduce CsA-evoked nephrotoxicity.	Cyclosporine	176-179	mechanistic target of rapamycin kinase	Rattus norvegicus	25-29
22580614-4	2013	We demonstrate that cyclosporine A (CsA, an immunophilin/calcineurin inhibitor) induces cell death with some apoptotic features but also accompanied by the appearance of numerous cytoplasmic vacuoles, immunostained for endoplasmic reticulum (ER) and autophagy markers.	Cyclosporine	36-39	calcineurin binding protein 1	Homo sapiens	57-78
23331973-5	2013	In secondary mixed lymphocyte cultures, CsA dramatically decreased donor-specific IFN-gamma production, enhanced IL-17 production and did not affect IL-13.	Cyclosporine	40-43	interleukin 17A	Homo sapiens	113-118
23450662-6	2013	Moreover, in patients, down-modulation of CD16 and CD6 on CD56(dim) NK cells was observed with significant differences between Cyclosporin A- and Tac-treated patients.	Cyclosporine	127-140	Fc gamma receptor IIIa	Homo sapiens	42-46
23936793-3	2013	Flow cytometry showed that the number of CD4(+) and CD8(+) cells and the level of IFN- gamma decreased significantly in the groups treated with cyclosporin A.	Cyclosporine	144-157	CD8a molecule	Homo sapiens	52-55
24655971-13	2014	CONCLUSION: A high-dose MZR regimen including CNI (CsA or FK), steroid, and anti-CD20 and anti-CD25 antibodies without splenectomy was effective and safe in ABO-i renal transplantation.	Cyclosporine	51-54	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	157-160
24359682-8	2013	The inhibitory potency of the model inhibitors cyclosporine A, troglitazone and ketoconazole was characterized against TCA uptake into BSEP/Bsep containing membrane vesicles.	Cyclosporine	47-61	ATP binding cassette subfamily B member 11	Homo sapiens	135-139
24013073-0	2013	Capsaicin pretreatment increased the bioavailability of cyclosporin in rats: involvement of P-glycoprotein and CYP 3A inhibition.	Cyclosporine	56-67	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	92-106
24166946-6	2013	Calcineurin inhibitor cyclosporin A attenuated NS5-mediated inhibition of IFNbeta-induced responses, for example, IFN-sensitive response element driven luciferase, STAT1-dependent PKR mRNA expression, as well as phosphorylation and nuclear translocation of STAT1.	Cyclosporine	22-35	signal transducer and activator of transcription 1	Homo sapiens	164-169
24166946-6	2013	Calcineurin inhibitor cyclosporin A attenuated NS5-mediated inhibition of IFNbeta-induced responses, for example, IFN-sensitive response element driven luciferase, STAT1-dependent PKR mRNA expression, as well as phosphorylation and nuclear translocation of STAT1.	Cyclosporine	22-35	signal transducer and activator of transcription 1	Homo sapiens	257-262
24034056-0	2013	Acute renal failure caused by hyperuremic acidemia in ABO-incompatible kidney transplant maintained with cyclosporine and high-dose mizoribine: a case report.	Cyclosporine	105-117	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	54-57
18042735-7	2008	Cyclosporin A and tacrolimus, both potent inhibitors of the calcium/calmodulin-dependent phosphatase calcineurin, stimulated the enzymatic activity of cellular DLK in an in vitro kinase assay.	Cyclosporine	0-13	mitogen-activated protein kinase kinase kinase 12	Mus musculus	160-163
23339626-0	2013	The pharmacokinetic interaction between mycophenolic acid and cyclosporine revisited: a commentary on "Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus".	Cyclosporine	62-74	ATP binding cassette subfamily C member 2	Homo sapiens	151-192
18042735-8	2008	Immunocytochemistry revealed that the overexpression of DLK but not its kinase-dead mutant induced apoptosis and enhanced cyclosporin A-induced apoptosis to a higher extent than the drug alone.	Cyclosporine	122-135	mitogen-activated protein kinase kinase kinase 12	Mus musculus	56-59
18042735-9	2008	Moreover, in the presence of DLK, the effective concentration for cyclosporin A-caused apoptosis was similar to its known IC(50) value for the inhibition of calcineurin activity in beta cells.	Cyclosporine	66-79	mitogen-activated protein kinase kinase kinase 12	Mus musculus	29-32
18042735-10	2008	These data suggest that cyclosporin A through inhibition of calcineurin activates DLK, thereby leading to beta-cell apoptosis.	Cyclosporine	24-37	mitogen-activated protein kinase kinase kinase 12	Mus musculus	82-85
23791640-4	2013	In another experiment, rhodamine 123 was used to quantify the biliary canalicular transporter P-glycoprotein (P-gp, Abcb1a/b) with cyclosporin A as an inhibitor of P-gp activity.	Cyclosporine	131-144	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	94-108
23791640-4	2013	In another experiment, rhodamine 123 was used to quantify the biliary canalicular transporter P-glycoprotein (P-gp, Abcb1a/b) with cyclosporin A as an inhibitor of P-gp activity.	Cyclosporine	131-144	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	110-114
23791640-4	2013	In another experiment, rhodamine 123 was used to quantify the biliary canalicular transporter P-glycoprotein (P-gp, Abcb1a/b) with cyclosporin A as an inhibitor of P-gp activity.	Cyclosporine	131-144	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	164-168
23765110-0	2013	Influence of N-acetylcysteine on Klotho expression and its signaling pathway in experimental model of chronic cyclosporine nephropathy in mice.	Cyclosporine	110-122	klotho	Mus musculus	33-39
18030500-1	2008	The aim of our study was to investigate the effect of tangerine juice on the pharmacokinetics of cyclosporine A (CsA), in children who had received a renal transplant.	Cyclosporine	97-111	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	113-116
23743217-1	2013	The discovery of the first calcineurin inhibitor (CNI), cyclosporine, represents a watershed event in the history of immunosuppression, as it was the first drug shown to reversibly inhibit T-lymphocyte function, therefore allowing for one of the major breakthroughs in modern medicine, that of organ transplantation.	Cyclosporine	56-68	calcineurin binding protein 1	Homo sapiens	27-48
18287024-5	2008	Hypertrophy and NFAT translocation but not the increased frequency of [Ca(2+)] transients were inhibited by the calcineurin inhibitor cyclosporine A.	Cyclosporine	134-148	nuclear factor of activated T-cells 5	Rattus norvegicus	16-20
23530471-5	2013	RESULTS: Papain-induced nuclear translocation of NFAT, producing GM-CSF, was partly inhibited by ciclosporin.	Cyclosporine	97-108	colony stimulating factor 2	Canis lupus familiaris	65-71
17665197-7	2008	Simultaneous treatment of CD19-positive cell lines with scFvCD19:sTRAIL and valproic acid (VPA) or Cyclosporin A induced strongly synergistic apoptosis.	Cyclosporine	99-112	CD19 molecule	Homo sapiens	26-30
22983163-7	2013	The assay was validated by performing dose-response testing of rapamycin and cyclosporine A, which had previously been reported to inhibit IL-17, and determining, for the first time, their in vitro potencies (IC(50)s of 80 +- 23 pM and 223 +- 52 nM, respectively).	Cyclosporine	77-91	interleukin 17A	Homo sapiens	139-144
24348262-7	2013	Treatment with the calcineurin-inhibitor cyclosporine A abolished FGF23-mediated PTH suppression in PTH-KL(-/-) mice whereas wild-type mice remained responsive.	Cyclosporine	41-55	fibroblast growth factor 23	Mus musculus	66-71
24113044-13	2013	CONCLUSIONS: These results suggest that CsA-NP and CsA could protect the oxidative stress-induced ASC apoptosis through decreasing the activation of caspase-3 and inhibiting the release of cytochrome C.	Cyclosporine	40-43	cytochrome c	Sus scrofa	189-201
23332985-1	2013	OBJECTIVE: By binding to cyclophilin D, cyclosporine A (CsA) inhibits mitochondrial permeability transition pore (mPTP) opening and prevents mitochondrial dysfunction and ultimately cell death after ischemia-reperfusion (IR) injury in cardiac muscle.	Cyclosporine	56-59	peptidylprolyl isomerase D	Rattus norvegicus	25-38
23142004-6	2012	For a spin-1/2 with a large CSA (up to 1MHz and more) we show using calculations and simulations that the result is a recoupling signal that takes maximal values DeltaS/S(0) of ~0.6-0.7, beyond the saturation limit of 0.5, defined by equal contribution of all transitions.	Cyclosporine	28-31	spindlin 1	Homo sapiens	6-12
22749977-2	2012	Although oral bioavailability of cyclosporine A (CsA) was decreased by increased first-pass metabolism through CYP3A and P-glycoprotein (P-gp) specifically in the upper small intestine after liver I/R, the mechanism responsible for them remained to be clarified.	Cyclosporine	33-47	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	121-135
17922928-1	2008	Cyclophilins are target molecules for cyclosporin A (CsA), an immunosuppressive antimicrobial drug.	Cyclosporine	38-51	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	53-56
23332985-13	2013	Incomplete Vmax protection might be due to low cyclophilin D expression in gastrocnemius, preventing CsA from blocking mPTP opening.	Cyclosporine	101-104	peptidylprolyl isomerase D	Rattus norvegicus	47-60
22749977-2	2012	Although oral bioavailability of cyclosporine A (CsA) was decreased by increased first-pass metabolism through CYP3A and P-glycoprotein (P-gp) specifically in the upper small intestine after liver I/R, the mechanism responsible for them remained to be clarified.	Cyclosporine	33-47	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	137-141
22749977-2	2012	Although oral bioavailability of cyclosporine A (CsA) was decreased by increased first-pass metabolism through CYP3A and P-glycoprotein (P-gp) specifically in the upper small intestine after liver I/R, the mechanism responsible for them remained to be clarified.	Cyclosporine	49-52	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	121-135
19246887-2	2008	We aimed to assess the benefit of the combination of antithymocyte globulin (ATG) and cyclosporine (CsA).	Cyclosporine	86-98	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	100-103
23352844-13	2013	Collectively, our findings suggest that combination treatment of Glu and low-dose CsA leads to the therapeutic effects in Df-induced AD-like skin lesion in NC/Nga mice through inhibition of IgE, inflammatory cellular infiltrate, and recovery of skin barrier function via a mechanism that may inhibition of Th2-mediated immune responses, in part, increment of CD4(+)CD25(+) Treg cells.	Cyclosporine	82-85	CD4 antigen	Mus musculus	359-362
22749977-2	2012	Although oral bioavailability of cyclosporine A (CsA) was decreased by increased first-pass metabolism through CYP3A and P-glycoprotein (P-gp) specifically in the upper small intestine after liver I/R, the mechanism responsible for them remained to be clarified.	Cyclosporine	49-52	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	137-141
22749977-3	2012	In the present study, the effect of Trolox (an alpha-tocopherol analogue) on the decreased oral absorption of CsA through elevated intestinal CYP3A and P-gp after liver I/R and their regulations were investigated.	Cyclosporine	110-113	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	152-156
22749977-9	2012	These results demonstrate that Trolox ameliorates the decreased oral absorption of CsA through elevated intestinal CYP3A and P-gp by preventing oxidative stress, where the biliary lithocholic acid may be responsible for the elevated transcription of CYP3A specifically in the upper small intestine after liver I/R.	Cyclosporine	83-86	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	125-129
18354729-0	2008	Methotrexate and cyclosporine treatments modify the activities of dipeptidyl peptidase IV and prolyl oligopeptidase in murine macrophages.	Cyclosporine	17-29	prolyl endopeptidase	Mus musculus	94-115
22670785-6	2012	Expression of the peripheral homing receptors CXCR3 (r = 0.44, P &lt; 0.05) and CCR5 (r = 0.45, P &lt; 0.05) on FOXP3+ Tregs correlated with renal allograft function (eGFR) in patients receiving tacrolimus (n = 28), but not cyclosporine A (CsA) (n = 26).	Cyclosporine	224-238	C-C motif chemokine receptor 5	Homo sapiens	80-84
23378759-1	2013	A novel method to prepare cyclosporin A encapsulated liposomes was introduced using supercritical fluid of carbon dioxide (SCF-CO(2)) as an antisolvent.	Cyclosporine	26-39	KIT ligand	Homo sapiens	123-126
23293472-11	2012	Moreover, the IL-18 levels between cancer patients and controls with in of combined mode chewers smokers and alcohol (CSA), smokers with alcohol showed significant difference (P &lt; 0.01) than controls.	Cyclosporine	118-121	interleukin 18	Homo sapiens	14-19
18354729-3	2008	In thioglycolate-elicited Mphis, methotrexate increased DPPIV (99-110%) and POP (60%), while cyclosporine inhibited POP (21%).	Cyclosporine	93-105	prolyl endopeptidase	Mus musculus	116-119
18354729-6	2008	Methotrexate was revealed to exert prevalent action over that of cyclosporine on proinflammatory Mphi POP.	Cyclosporine	65-77	prolyl endopeptidase	Mus musculus	102-105
18354729-7	2008	The opposite effects of methotrexate and cyclosporine on POP activity might influence the availability of the nociceptive mediators bradykinin and substance P in proinflammatory Mphis.	Cyclosporine	41-53	prolyl endopeptidase	Mus musculus	57-60
22773077-7	2012	The paracellular permeability enhancers sodium caprate and EDTA, the P-gp inhibitor verapamil and the multidrug resistance related protein (MRP) inhibitors cyclosporine and MK571 could concentration-dependently increase the Papp-values, while the uptake (OATP) transporter inhibitors diclofenac sodium and indomethacin could concentration-dependently decrease the P(app)-values.	Cyclosporine	156-168	chromosome 19 open reading frame 48	Homo sapiens	102-138
22773077-7	2012	The paracellular permeability enhancers sodium caprate and EDTA, the P-gp inhibitor verapamil and the multidrug resistance related protein (MRP) inhibitors cyclosporine and MK571 could concentration-dependently increase the Papp-values, while the uptake (OATP) transporter inhibitors diclofenac sodium and indomethacin could concentration-dependently decrease the P(app)-values.	Cyclosporine	156-168	chromosome 19 open reading frame 48	Homo sapiens	140-143
22678567-0	2012	Cyclosporin A induces apoptosis in H9c2 cardiomyoblast cells through calcium-sensing receptor-mediated activation of the ERK MAPK and p38 MAPK pathways.	Cyclosporine	0-13	calcium-sensing receptor	Rattus norvegicus	69-93
23285492-10	2004	Similar results were obtained with the WT rodents when they were intravenously infused with rhodamine-123 in the presence of cyclosporine A, an inhibitor of P-gp (6).	Cyclosporine	125-139	phosphoglycolate phosphatase	Mus musculus	157-161
23677660-1	2012	Calcineurin inhibitor encephalopathy (CIE) is a rare condition occurring in patients who are undergoing treatment with drugs from the calcineurin inhibitor (CI) family of immunosuppressants, either cyclosporine (CsA) or tacrolimus (TAC, FK506).	Cyclosporine	198-210	calcineurin binding protein 1	Homo sapiens	0-21
22678567-2	2012	Our group has shown that CsA induces myocardium cell apoptosis in vivo and increases calcium-sensing receptor (CaSR) expression.	Cyclosporine	25-28	calcium-sensing receptor	Rattus norvegicus	85-109
22678567-2	2012	Our group has shown that CsA induces myocardium cell apoptosis in vivo and increases calcium-sensing receptor (CaSR) expression.	Cyclosporine	25-28	calcium-sensing receptor	Rattus norvegicus	111-115
22678567-4	2012	The purpose of this study was to determine whether CaSR plays an essential role in CsA-induced apoptosis in H9c2 cells and to investigate the role of the mitogen-activated protein kinase (MAPK) signaling cascade in this process.	Cyclosporine	83-86	calcium-sensing receptor	Rattus norvegicus	51-55
22678567-6	2012	In a time-dependent manner, CsA increased CaSR expression, activated the extracellularly regulated kinase (ERK) and p38 MAPK pathways, and inactivated the c-Jun N-terminal kinase (JNK) MAPK signaling pathway.	Cyclosporine	28-31	calcium-sensing receptor	Rattus norvegicus	42-46
22678567-7	2012	When H9c2 cardiomyoblast cells pretreated with gadolinium chloride (GdCl(3)), a CaSR activator, were treated with CsA, decreased phosphorylation of ERK1/2, increased phosphorylation of p38, decreased Bcl-2 expression, increased Bax expression, and activated caspase-3 were observed.	Cyclosporine	114-117	calcium-sensing receptor	Rattus norvegicus	80-84
23677660-1	2012	Calcineurin inhibitor encephalopathy (CIE) is a rare condition occurring in patients who are undergoing treatment with drugs from the calcineurin inhibitor (CI) family of immunosuppressants, either cyclosporine (CsA) or tacrolimus (TAC, FK506).	Cyclosporine	198-210	calcineurin binding protein 1	Homo sapiens	134-155
22678567-10	2012	These findings showed that CsA induced apoptosis in H9c2 cells in vitro, and CaSR mediated the degradation of ERK MAPK and the upregulation of the p38 MAPK pathway involved in CsA-induced H9c2 cardiomyoblast cell apoptosis.	Cyclosporine	176-179	calcium-sensing receptor	Rattus norvegicus	77-81
23677660-1	2012	Calcineurin inhibitor encephalopathy (CIE) is a rare condition occurring in patients who are undergoing treatment with drugs from the calcineurin inhibitor (CI) family of immunosuppressants, either cyclosporine (CsA) or tacrolimus (TAC, FK506).	Cyclosporine	198-210	calcineurin binding protein 1	Homo sapiens	38-40
23677660-1	2012	Calcineurin inhibitor encephalopathy (CIE) is a rare condition occurring in patients who are undergoing treatment with drugs from the calcineurin inhibitor (CI) family of immunosuppressants, either cyclosporine (CsA) or tacrolimus (TAC, FK506).	Cyclosporine	212-215	calcineurin binding protein 1	Homo sapiens	0-21
23677660-1	2012	Calcineurin inhibitor encephalopathy (CIE) is a rare condition occurring in patients who are undergoing treatment with drugs from the calcineurin inhibitor (CI) family of immunosuppressants, either cyclosporine (CsA) or tacrolimus (TAC, FK506).	Cyclosporine	212-215	calcineurin binding protein 1	Homo sapiens	38-40
22644589-10	2012	However, CsA treatment increased (18)F-MPPF free fraction, which is responsible for a misleading, P-gp unrelated enhanced brain uptake.	Cyclosporine	9-12	phosphoglycolate phosphatase	Mus musculus	98-102
22957440-11	2012	Meanwhile, RIP3 and ROS are involved in CsA-induced necroptosis.	Cyclosporine	40-43	receptor-interacting serine-threonine kinase 3	Rattus norvegicus	11-15
22613676-8	2012	In contrast to RPM and FTY720, MMF, LEF, CsA, and Cy markedly decreased the levels of Ag-specific CD4(+)KJ1-26(+)CD25(+)Foxp3(+) Tregs during immune response.	Cyclosporine	41-44	CD4 antigen	Mus musculus	98-101
22613676-10	2012	The stronger inhibiting effects of MMF, LEF, CsA and Cy on CD4(+)CD25(+)Foxp3(+) Tregs than on T effectors may block the host immune tolerance potentiality.	Cyclosporine	45-48	CD4 antigen	Mus musculus	59-62
22626517-8	2012	Mice treated with ciclosporin, which is both antiparasitic and immunosuppressive, have a milder, chronic, non-lethal infection and showed a significant reduction only in CD3(+) and CD4(+) T cell numbers.	Cyclosporine	18-29	CD4 antigen	Mus musculus	181-184
22670785-6	2012	Expression of the peripheral homing receptors CXCR3 (r = 0.44, P &lt; 0.05) and CCR5 (r = 0.45, P &lt; 0.05) on FOXP3+ Tregs correlated with renal allograft function (eGFR) in patients receiving tacrolimus (n = 28), but not cyclosporine A (CsA) (n = 26).	Cyclosporine	240-243	C-C motif chemokine receptor 5	Homo sapiens	80-84
22568654-3	2012	Cyclosporine A (CsA) and tacrolimus (TAC) were associated with greater levels of Nox2 mRNA and epithelial to mesenchymal transition (EMT) in NRK52E cells.	Cyclosporine	0-14	cytochrome b-245 beta chain	Rattus norvegicus	81-85
22729026-1	2012	PURPOSE OF REVIEW: The purpose of the review is to review the pathophysiology, available data, and our current recommendations for calcineurin inhibitor (cyclosporine and tacrolimus) treatment in antihistamine refractory chronic idiopathic urticaria (CIU) patients.	Cyclosporine	154-166	calcineurin binding protein 1	Homo sapiens	131-152
22803008-13	2012	The effects of 50 nM CsA on osteonectin and Col-I were similar to those of the FK506 groups, but in the 500 nM CsA group, most of the genes were less expressed compared to the control.	Cyclosporine	21-24	secreted protein acidic and cysteine rich	Rattus norvegicus	28-39
21869731-3	2012	We investigated whether kidney-specific Mrp2 deficiency enhances acute CsA nephrotoxicity in rats.	Cyclosporine	71-74	ATP binding cassette subfamily C member 2	Rattus norvegicus	40-44
21869731-13	2012	Furthermore, CsA increased Mdr1 protein abundance to a greater extent in Mrp2-/- than in wild-type kidneys.	Cyclosporine	13-16	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	27-31
21869731-13	2012	Furthermore, CsA increased Mdr1 protein abundance to a greater extent in Mrp2-/- than in wild-type kidneys.	Cyclosporine	13-16	ATP binding cassette subfamily C member 2	Rattus norvegicus	73-77
21869731-15	2012	The high Mdr1 abundance may at least in part prevent exaggerated CsA accumulation in Mrp2-/- kidneys.	Cyclosporine	65-68	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	9-13
21869731-15	2012	The high Mdr1 abundance may at least in part prevent exaggerated CsA accumulation in Mrp2-/- kidneys.	Cyclosporine	65-68	ATP binding cassette subfamily C member 2	Rattus norvegicus	85-89
18776723-0	2008	Expression of ammonia transporters, Rhbg and Rhcg, in chronic cyclosporine nephropathy in rats.	Cyclosporine	62-74	Rh family B glycoprotein	Rattus norvegicus	36-40
18776723-2	2008	The current study was performed to evaluate the influence of CsA-induced renal injury on the ammonia transporter family members, Rh B-glycoprotein (Rhbg) and Rh C-glycoprotein (Rhcg).	Cyclosporine	61-64	Rh family B glycoprotein	Rattus norvegicus	129-146
17996694-2	2007	Using MACS-purified CD4 cells, we found that rapamycin and cyclosporine A (CsA) potently inhibited the TGFbeta and IL-6-induced generation of IL-17-producing cells.	Cyclosporine	59-73	myristoylated alanine rich protein kinase C substrate	Homo sapiens	6-10
17996694-2	2007	Using MACS-purified CD4 cells, we found that rapamycin and cyclosporine A (CsA) potently inhibited the TGFbeta and IL-6-induced generation of IL-17-producing cells.	Cyclosporine	75-78	myristoylated alanine rich protein kinase C substrate	Homo sapiens	6-10
17760822-0	2007	Cyclosporin-A inhibits the expression of cyclooxygenase-2 in gingiva.	Cyclosporine	0-13	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	41-57
17760822-2	2007	In this study, the gingival expression of cyclooxygenase-2 after cyclosporine A therapy was examined in vivo and in vitro.	Cyclosporine	65-79	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	42-58
17760822-7	2007	Significantly lower expression of cyclooxygenase-2 and interleukin-1beta mRNA, but higher interleukin-6 expression, were observed in gingiva from cyclosporine A-treated rats than in those from the control rats.	Cyclosporine	146-160	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	34-50
17760822-9	2007	Immunohistochemistry revealed that fewer gingival stromal cells were positively stained for cyclooxygenase-2 in cyclosporine A-treated rats.	Cyclosporine	112-126	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	92-108
17760822-10	2007	In cultured cells, significantly less cyclooxygenase-2 mRNA was detected after treatment with cyclosporine A.	Cyclosporine	94-108	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	38-54
17760822-11	2007	CONCLUSION: The expression of cyclooxygenase-2 was lower in the plaque nonretentive gingivae and the in vitro gingival cells upon treatment with cyclosporine A.	Cyclosporine	145-159	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	30-46
17760822-12	2007	Thus, we propose that cyclosporine A inhibits the expression of gingival cyclooxygenase-2.	Cyclosporine	22-36	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	73-89
17553872-0	2007	Cyclosporine inhibits mouse cytomegalovirus infection via a cyclophilin-dependent pathway specifically in neural stem/progenitor cells.	Cyclosporine	0-12	peptidyl-prolyl isomerase G (cyclophilin G)	Mus musculus	60-71
17553872-4	2007	This activity of Cs appears to be mediated via cyclophilin (CyP) rather than via calcineurin.	Cyclosporine	17-19	peptidyl-prolyl isomerase G (cyclophilin G)	Mus musculus	47-58
17553872-4	2007	This activity of Cs appears to be mediated via cyclophilin (CyP) rather than via calcineurin.	Cyclosporine	17-19	peptidyl-prolyl isomerase G (cyclophilin G)	Mus musculus	60-63
17496208-5	2007	Bosentan uptake into Chinese hamster ovary cells expressing these OATP transporters was efficiently inhibited by cyclosporin A and rifampicin with IC(50) values significantly below their effective plasma concentrations in humans.	Cyclosporine	113-126	solute carrier organic anion transporter family member 1A2	Homo sapiens	66-70
17522232-6	2007	Infection of CypA knockout Jurkat cells or treatment of Jurkat cells with cyclosporine A eliminated the Vif-sensitive inhibition and resulted in replication profiles that were similar for wild-type and vif-deficient SIVagm.	Cyclosporine	74-88	vif protein	Simian immunodeficiency virus	104-107
22416070-4	2012	In renal tubular cells, cytotoxic concentrations of cyclosporine A (CsA) inhibited both gene and protein expression of adherent and tight junction proteins (E-cadherin, ZO-1, claudin-1, and beta-catenin) and increased vimentin expression, without involvement of transforming growth factor beta1 or caspase activity.	Cyclosporine	52-66	claudin 1	Homo sapiens	175-184
22416070-4	2012	In renal tubular cells, cytotoxic concentrations of cyclosporine A (CsA) inhibited both gene and protein expression of adherent and tight junction proteins (E-cadherin, ZO-1, claudin-1, and beta-catenin) and increased vimentin expression, without involvement of transforming growth factor beta1 or caspase activity.	Cyclosporine	68-71	claudin 1	Homo sapiens	175-184
22538855-6	2012	Critically, CD8(+)FoxP3(+) T(reg) are exquisitely sensitive to inhibition by cyclosporine but can be massively and specifically expanded in vivo to prevent GVHD by coadministering rapamycin and IL-2 antibody complexes.	Cyclosporine	77-89	CD8a molecule	Homo sapiens	12-15
22329558-0	2012	Expansion of CD8+/perforin+ T-cells predicts response to ciclosporin A therapy in patients with erythroid hypoplasia/aplasia.	Cyclosporine	57-70	CD8a molecule	Homo sapiens	13-16
17504846-2	2007	The present retrospective study investigated 86 children with SRNS due to FSGS and MCNS and found improved rates of complete remission in children with idiopathic FSGS and MCNS after combination therapies using ciclosporin A (CSA) and prednisolone (PRED).	Cyclosporine	211-224	actinin alpha 4	Homo sapiens	163-167
17504846-2	2007	The present retrospective study investigated 86 children with SRNS due to FSGS and MCNS and found improved rates of complete remission in children with idiopathic FSGS and MCNS after combination therapies using ciclosporin A (CSA) and prednisolone (PRED).	Cyclosporine	211-224	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	226-229
22416070-5	2012	CsA upregulated transcriptional repressors (Snail, Slug, and Twist) of the adherent and tight junction proteins were studied.	Cyclosporine	0-3	snail family transcriptional repressor 2	Homo sapiens	51-55
22664025-10	2012	CONCLUSIONS: CsA up-regulated the expression of ILT3 and ILT4 on NKL cells, which influenced their cytotoxicity against tumor cells with different expression of HLA-G and proliferation of NKL cells.	Cyclosporine	13-16	major histocompatibility complex, class I, G	Homo sapiens	161-166
17493526-13	2007	The percentage of CD4+CD25+ T cells was higher in the CsA group.	Cyclosporine	54-57	interleukin 2 receptor subunit alpha	Homo sapiens	22-26
22044301-7	2012	Inhibition of HIF-1alpha activity by cyclosporine A (CsA) inhibited a rise in VEGF production in response to CoCl(2) as well as 8-Br-cAMP.	Cyclosporine	37-51	vascular endothelial growth factor A	Mus musculus	78-82
17580150-8	2007	There was weak expression in the RAPA group but significant, increased expression of CTGF in glomeruli and interstitial area in the CSA group (P &lt; .01) both by immunohistochemical staining or real-time polymerase chain reaction detection.	Cyclosporine	132-135	cellular communication network factor 2	Homo sapiens	85-89
22044301-7	2012	Inhibition of HIF-1alpha activity by cyclosporine A (CsA) inhibited a rise in VEGF production in response to CoCl(2) as well as 8-Br-cAMP.	Cyclosporine	53-56	vascular endothelial growth factor A	Mus musculus	78-82
21702050-4	2012	Our data are as follows: (a) The calcineurin inhibitor cyclosporine A (CsA) blocked norepinephrine secretion induced by ligands of either CRF type 1 (CRF(1)) or 2 (CRF(2)) receptors on PC12 cells.	Cyclosporine	55-69	corticotropin releasing hormone receptor 1	Rattus norvegicus	138-148
21702050-4	2012	Our data are as follows: (a) The calcineurin inhibitor cyclosporine A (CsA) blocked norepinephrine secretion induced by ligands of either CRF type 1 (CRF(1)) or 2 (CRF(2)) receptors on PC12 cells.	Cyclosporine	55-69	corticotropin releasing hormone receptor 1	Rattus norvegicus	150-156
17382306-7	2007	Nevertheless, histological studies showed that: i) a significant number of CsA-treated rats presented growing axons, although they deviated perpendicularly at the edge of the stumps, surrounding them, ii) the expression of GAP-43 in animals treated with CsA was higher than that observed in the control group.	Cyclosporine	75-78	growth associated protein 43	Rattus norvegicus	223-229
21702050-4	2012	Our data are as follows: (a) The calcineurin inhibitor cyclosporine A (CsA) blocked norepinephrine secretion induced by ligands of either CRF type 1 (CRF(1)) or 2 (CRF(2)) receptors on PC12 cells.	Cyclosporine	55-69	corticotropin releasing hormone receptor 2	Rattus norvegicus	164-169
17382306-7	2007	Nevertheless, histological studies showed that: i) a significant number of CsA-treated rats presented growing axons, although they deviated perpendicularly at the edge of the stumps, surrounding them, ii) the expression of GAP-43 in animals treated with CsA was higher than that observed in the control group.	Cyclosporine	254-257	growth associated protein 43	Rattus norvegicus	223-229
17382306-9	2007	In summary, CsA administered at the dosing-regimen that promotes neuroprotection in SC contused rats induces both GAP-43 expression and axonal growth; however, it failed to generate functional connections in SC transected animals.	Cyclosporine	12-15	growth associated protein 43	Rattus norvegicus	114-120
21702050-4	2012	Our data are as follows: (a) The calcineurin inhibitor cyclosporine A (CsA) blocked norepinephrine secretion induced by ligands of either CRF type 1 (CRF(1)) or 2 (CRF(2)) receptors on PC12 cells.	Cyclosporine	71-74	corticotropin releasing hormone receptor 1	Rattus norvegicus	138-148
21702050-4	2012	Our data are as follows: (a) The calcineurin inhibitor cyclosporine A (CsA) blocked norepinephrine secretion induced by ligands of either CRF type 1 (CRF(1)) or 2 (CRF(2)) receptors on PC12 cells.	Cyclosporine	71-74	corticotropin releasing hormone receptor 1	Rattus norvegicus	150-156
17542337-1	2007	AIMS: Single daily dose cyclosporine (SDD-CsA) might be a new option providing comparable efficacy, increased compliance and less nephrotoxicity compared to standard twice-daily dose cyclosporine (TDD-CsA).	Cyclosporine	24-36	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	42-45
17542337-5	2007	13 patients were treated primarily with single daily dose cyclosporine (pSDD-CsA).	Cyclosporine	58-70	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	77-80
21702050-4	2012	Our data are as follows: (a) The calcineurin inhibitor cyclosporine A (CsA) blocked norepinephrine secretion induced by ligands of either CRF type 1 (CRF(1)) or 2 (CRF(2)) receptors on PC12 cells.	Cyclosporine	71-74	corticotropin releasing hormone receptor 2	Rattus norvegicus	164-169
21702050-7	2012	(d) CsA completely blocked the stimulatory effect of CRF(1) and CRF(2) ligands on NFAT activity in NFAT-Luc transfected cells.	Cyclosporine	4-7	corticotropin releasing hormone receptor 1	Rattus norvegicus	53-59
21702050-7	2012	(d) CsA completely blocked the stimulatory effect of CRF(1) and CRF(2) ligands on NFAT activity in NFAT-Luc transfected cells.	Cyclosporine	4-7	corticotropin releasing hormone receptor 2	Rattus norvegicus	64-69
22764568-5	2012	The pretreatment with cyclosporine A, a P-gp inhibitor, greatly increased the intestinal absorption of quinidine given at a dose of 0.1 mg/kg.	Cyclosporine	22-36	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	40-44
17362315-1	2007	The purpose of this study was to estimate the response rate of 26-h continuous infusion cyclosporine A (CSA) combined with carboplatin (CBDCA) and subcutaneous alpha-interferon (IFN), in recurrent ovarian cancer (OC), and to measure their effects on CBDCA pharmacokinetics.	Cyclosporine	88-102	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	104-107
17312153-3	2007	Because TGF-beta1 expression by these T cells can be decreased by cyclosporin A, a NF-AT inhibitor, NF-AT-mediated TGF-beta1 expression in T cells was addressed by characterizing a NF-AT response element in the TGF-beta1 promoter.	Cyclosporine	66-79	transforming growth factor, beta 1	Mus musculus	8-17
17312153-3	2007	Because TGF-beta1 expression by these T cells can be decreased by cyclosporin A, a NF-AT inhibitor, NF-AT-mediated TGF-beta1 expression in T cells was addressed by characterizing a NF-AT response element in the TGF-beta1 promoter.	Cyclosporine	66-79	transforming growth factor, beta 1	Mus musculus	115-124
22419339-3	2012	Currently, more than 90% of all liver transplant recipients are treated with the calcineurin inhibitor cyclosporine or tacrolimus.	Cyclosporine	103-115	calcineurin binding protein 1	Homo sapiens	81-102
17312153-3	2007	Because TGF-beta1 expression by these T cells can be decreased by cyclosporin A, a NF-AT inhibitor, NF-AT-mediated TGF-beta1 expression in T cells was addressed by characterizing a NF-AT response element in the TGF-beta1 promoter.	Cyclosporine	66-79	transforming growth factor, beta 1	Mus musculus	115-124
22419339-18	2012	This ongoing trial studies total withdrawal of immunosuppression in patients who receive a calcineurin inhibitor (cyclosporine or tacrolimus) or mycophenolate mofetil as the only immunosuppressive agent.	Cyclosporine	114-126	calcineurin binding protein 1	Homo sapiens	91-112
17127700-1	2007	BACKGROUND: Renal outcome after ciclosporin (CsA) is not clear in most studies involving patients with many renal comorbid conditions.	Cyclosporine	32-43	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	45-48
22169469-9	2012	These results demonstrated that the CsA decreased the efflux of spinosin through the inhibition of P-glycoprotein (P-gp) efflux transporter and it might be used as a group of P-gp substrate.	Cyclosporine	36-39	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	99-113
17227295-5	2007	RESULTS: In group I, at time points C0 and C2, increased CsA-PK significantly inhibited expression of IL-2, IFN-gamma, PCNA and CD25 (P &lt; 0.05).	Cyclosporine	57-60	interleukin 2 receptor subunit alpha	Homo sapiens	128-132
17210452-8	2007	We propose that CsA promotes nitration of specific molecular targets, such as MnSOD, within vascular endothelial cells.	Cyclosporine	16-19	superoxide dismutase 2	Homo sapiens	78-83
22068911-5	2012	In addition, we demonstrated that IL-32gamma induced the expression of dendritic cell-specific transmembrane protein (DC-STAMP) and nuclear factor of activated T cells cytoplasmic 1 (NFATc1), and NFATc1 inactivation by cyclosporine treatment attenuated the effect of IL-32gamma.	Cyclosporine	219-231	nuclear factor of activated T cells 1	Homo sapiens	196-202
22184128-7	2012	FK506 and CsA inhibited PCNA effects.	Cyclosporine	10-13	proliferating cell nuclear antigen	Rattus norvegicus	24-28
17357450-0	2007	[Modulation of cyclosporin a on the expression of MMP-9 AND MMP-2 of the first-trimester human trophoblast cells].	Cyclosporine	15-28	matrix metallopeptidase 2	Homo sapiens	60-65
17357450-1	2007	The aim of this study was to explore whether cyclosporine A (CsA) can modulate expression of MMP-9 and MMP-2 and invasion of the first-trimester human trophoblast cells.	Cyclosporine	45-59	matrix metallopeptidase 2	Homo sapiens	103-108
22423500-0	2012	A case of refractory adult-onset Still"s disease with high serum interleukin-18 levels treated with monitoring of serum levels of cyclosporine.	Cyclosporine	130-142	interleukin 18	Homo sapiens	65-79
17357450-1	2007	The aim of this study was to explore whether cyclosporine A (CsA) can modulate expression of MMP-9 and MMP-2 and invasion of the first-trimester human trophoblast cells.	Cyclosporine	61-64	matrix metallopeptidase 2	Homo sapiens	103-108
17357450-3	2007	The effect of CsA on the transcription and translation of MMP-9 and MMP-2 was determined by Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and Gelatin Zymography.	Cyclosporine	14-17	matrix metallopeptidase 2	Homo sapiens	68-73
17357450-6	2007	These results above indicate that CsA can induce the expression of MMP-9 and MMP-2 through activating MAPK/ERK1/2, which contributes to the improved invasion of the first-trimester human trophoblast cells.	Cyclosporine	34-37	matrix metallopeptidase 2	Homo sapiens	77-82
22423500-5	2012	The use of CsA accompanied by C2 and trough level monitoring should be considered for refractory AOSD patients with high levels of serum IL-18.	Cyclosporine	11-14	interleukin 18	Homo sapiens	137-142
17117422-2	2007	Using small animal positron emission tomography (PET), we investigated how P-gp and its blockade with Cyclosporin A (CsA) affect rodent brain uptake of [(11)C](R)-(-)-RWAY, a radioligand for brain 5-HT(1A) receptors.	Cyclosporine	102-115	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	117-120
22778498-10	2012	Furthermore, cyclosporin A pretreatment partially inhibited the HMGB1-induced cardiomyocyte hypertrophy.	Cyclosporine	13-26	high mobility group box 1	Rattus norvegicus	64-69
17102134-7	2007	Treatment with the calcineurin inhibitors FK506 and cyclosporin A also blocked DREAM-mediated Kv4.2 channel trafficking and calcineurin de-phosphorylated GRK2-phosphorylated DREAM in vitro.	Cyclosporine	52-65	potassium voltage-gated channel subfamily D member 2	Homo sapiens	94-99
17102134-7	2007	Treatment with the calcineurin inhibitors FK506 and cyclosporin A also blocked DREAM-mediated Kv4.2 channel trafficking and calcineurin de-phosphorylated GRK2-phosphorylated DREAM in vitro.	Cyclosporine	52-65	potassium voltage-gated channel interacting protein 3	Homo sapiens	174-179
22986347-8	2012	CsA administration increased p-FoxO1 expression and decreased p-FoxO3a expression, whereas concurrent statin treatment reversed these changes, increased the expression of the antioxidant enzymes MnSOD and hemeoxygenase-1 and decreased the expression of the pro-apoptotic protein Bim.	Cyclosporine	0-3	BCL2-like 11 (apoptosis facilitator)	Mus musculus	279-282
16835406-0	2007	Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity.	Cyclosporine	82-94	nuclear receptor subfamily 3 group C member 2	Homo sapiens	0-26
22449377-1	2012	In addition to antiasthmatic effect, the cysteinyl leukotriene receptor 1 (CysLT1) antagonist montelukast shows renoprotective effect during ischemia/reperfusion and cyclosporine-induced renal damage.	Cyclosporine	166-178	cysteinyl leukotriene receptor 1	Rattus norvegicus	41-73
23428559-5	2012	Our results showed that CsA-induced ER stress and involved ER integrated stress response-related proteins (Bip/Grp78, ATF6, IRE1 and CHOP) but not cytoplasmic ER stress-related chaperones (HSP70, HSP40, HSP27, HSP90 and HSP60).	Cyclosporine	24-27	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	107-110
22449377-1	2012	In addition to antiasthmatic effect, the cysteinyl leukotriene receptor 1 (CysLT1) antagonist montelukast shows renoprotective effect during ischemia/reperfusion and cyclosporine-induced renal damage.	Cyclosporine	166-178	cysteinyl leukotriene receptor 1	Rattus norvegicus	75-81
16835406-1	2007	Recent studies from our laboratory have shown that the mineralocorticoid receptor (MR) blockade with spironolactone (Sp) prevented renal dysfunction and reduced renal injury in both acute and chronic cyclosporine (CsA) nephrotoxicity.	Cyclosporine	200-212	nuclear receptor subfamily 3 group C member 2	Homo sapiens	55-81
16835406-1	2007	Recent studies from our laboratory have shown that the mineralocorticoid receptor (MR) blockade with spironolactone (Sp) prevented renal dysfunction and reduced renal injury in both acute and chronic cyclosporine (CsA) nephrotoxicity.	Cyclosporine	200-212	nuclear receptor subfamily 3 group C member 2	Homo sapiens	83-85
16835406-1	2007	Recent studies from our laboratory have shown that the mineralocorticoid receptor (MR) blockade with spironolactone (Sp) prevented renal dysfunction and reduced renal injury in both acute and chronic cyclosporine (CsA) nephrotoxicity.	Cyclosporine	214-217	nuclear receptor subfamily 3 group C member 2	Homo sapiens	55-81
22320241-1	2012	Early conversion to a calcineurin-inhibitor (CNI)-free maintenance immunosuppression with sirolimus (SRL), mycophenolate mofetil (MMF) and steroids was associated with an improved 1-year renal function as compared with a cyclosporine (CsA)-based regimen (SMART core-study).	Cyclosporine	221-233	calcineurin binding protein 1	Homo sapiens	22-43
23428559-5	2012	Our results showed that CsA-induced ER stress and involved ER integrated stress response-related proteins (Bip/Grp78, ATF6, IRE1 and CHOP) but not cytoplasmic ER stress-related chaperones (HSP70, HSP40, HSP27, HSP90 and HSP60).	Cyclosporine	24-27	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	111-116
22320241-1	2012	Early conversion to a calcineurin-inhibitor (CNI)-free maintenance immunosuppression with sirolimus (SRL), mycophenolate mofetil (MMF) and steroids was associated with an improved 1-year renal function as compared with a cyclosporine (CsA)-based regimen (SMART core-study).	Cyclosporine	235-238	calcineurin binding protein 1	Homo sapiens	22-43
16835406-1	2007	Recent studies from our laboratory have shown that the mineralocorticoid receptor (MR) blockade with spironolactone (Sp) prevented renal dysfunction and reduced renal injury in both acute and chronic cyclosporine (CsA) nephrotoxicity.	Cyclosporine	214-217	nuclear receptor subfamily 3 group C member 2	Homo sapiens	83-85
16835406-10	2007	In conclusion, MR blockade with Sp prevented the progression of renal injury in preexisting chronic CsA nephropathy.	Cyclosporine	100-103	nuclear receptor subfamily 3 group C member 2	Homo sapiens	15-17
23428559-7	2012	In addition, suppression of Bip/Grp78-enhanced CsA-induced cell death and CsA-induced TV formation and Bip/Grp78 overexpression had a characteristic striped pattern in the tubulointerstitium.	Cyclosporine	47-50	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	28-31
22316009-0	2012	P-glycoprotein-based loperamide-cyclosporine drug interaction at the rat blood-brain barrier: prediction from in vitro studies and extrapolation to humans.	Cyclosporine	32-44	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	0-14
23428559-7	2012	In addition, suppression of Bip/Grp78-enhanced CsA-induced cell death and CsA-induced TV formation and Bip/Grp78 overexpression had a characteristic striped pattern in the tubulointerstitium.	Cyclosporine	47-50	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	32-37
22184139-12	2012	Cyclosporin A also improved maturation of ABCB4-I541F in Madin-Darby canine kidney cells.	Cyclosporine	0-13	ATP binding cassette subfamily B member 4	Canis lupus familiaris	42-47
23428559-7	2012	In addition, suppression of Bip/Grp78-enhanced CsA-induced cell death and CsA-induced TV formation and Bip/Grp78 overexpression had a characteristic striped pattern in the tubulointerstitium.	Cyclosporine	74-77	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	28-31
22184139-13	2012	In HepG(2) cells transfected with ABCB4-I541F cDNA, cyclosporin A allowed a significant amount of the mutant protein to reach the membrane of bile canaliculi.	Cyclosporine	52-65	ATP binding cassette subfamily B member 4	Canis lupus familiaris	34-39
23428559-7	2012	In addition, suppression of Bip/Grp78-enhanced CsA-induced cell death and CsA-induced TV formation and Bip/Grp78 overexpression had a characteristic striped pattern in the tubulointerstitium.	Cyclosporine	74-77	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	32-37
22226864-3	2012	We previously demonstrated that antibodies induced by NTS-DBL1X-Id1-DBL2X efficiently block parasite binding to CSA in a similar manner to antibodies induced by the full-length extracellular part of VAR2CSA.	Cyclosporine	112-115	inhibitor of DNA binding 1, HLH protein	Mus musculus	64-67
23428559-8	2012	In summary, we demonstrate that CsA-induced TV was a potentially reversible process in which Bip/Grp78 overexpression is essential for TV formation.	Cyclosporine	32-35	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	93-96
22226864-10	2012	Anti-FCR3 anti-Id1-DBL2X antibodies also efficiently block the adhesion of erythrocytes infected by the HB3 parasite line to CSA.	Cyclosporine	125-128	inhibitor of DNA binding 1, HLH protein	Mus musculus	15-18
22226864-12	2012	MAJOR CONCLUSIONS: We raised high-titer antibodies against several parts of the protein, and identified Id1-DBL2X as the minimal VAR2CSA fragment inducing antibodies with CSA-binding inhibitory efficiency in the same range as the full-length extracellular part of VAR2CSA.	Cyclosporine	133-136	inhibitor of DNA binding 1, HLH protein	Mus musculus	104-107
23428559-8	2012	In summary, we demonstrate that CsA-induced TV was a potentially reversible process in which Bip/Grp78 overexpression is essential for TV formation.	Cyclosporine	32-35	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	97-102
23428559-9	2012	It is possible that Bip/Grp78 expression and TV formation may be involved in cellular defense mechanism against CsA nephrotoxicity.	Cyclosporine	112-115	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	20-23
23428559-9	2012	It is possible that Bip/Grp78 expression and TV formation may be involved in cellular defense mechanism against CsA nephrotoxicity.	Cyclosporine	112-115	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	24-29
23028901-6	2012	CsA increased IL-10 and IL-4 production in trophoblasts co-cultured with DSCs and DICs although CsA treatment did not affect IL-10 or IL-4 production in any of the cells when cultured alone.	Cyclosporine	0-3	interleukin 10	Homo sapiens	14-19
22792343-13	2012	Furthermore, cyclosporine treatment significantly attenuated the increase in cortical cytochrome-c and lactate levels.	Cyclosporine	13-25	cytochrome c	Sus scrofa	86-98
21895616-4	2012	METHODS: The patient"s immunosuppression was switched from the calcineurin inhibitor ciclosporin to the mTOR inhibitor everolimus.	Cyclosporine	85-96	calcineurin binding protein 1	Homo sapiens	63-84
21692632-1	2012	BACKGROUND: The aim of this study is to evaluate CD4(+), CD8(+), and CD45RO(+) T cells, and vascular endothelial growth factor (VEGF) expression in cyclosporin A (CsA)-induced rat overgrown gingival tissue during an 8-week period.	Cyclosporine	148-161	Cd4 molecule	Rattus norvegicus	49-52
21692632-7	2012	RESULTS: CD4(+), CD8(+), and CD45RO(+) T cells, and VEGF expression were more prevalent in the CsA-treated group than in the control group (P &lt;0.05).	Cyclosporine	95-98	Cd4 molecule	Rattus norvegicus	9-12
21692632-9	2012	CONCLUSION: Based on our findings, we conclude that VEGF, a major regulator of angiogenesis, and CD4(+), CD8(+), and CD45RO(+) memory T cells play a key role in CsA-induced gingival overgrowth.	Cyclosporine	161-164	Cd4 molecule	Rattus norvegicus	97-100
21802460-5	2011	The covering of skin allografts with CsA-loaded nanofibers significantly attenuated the local production of the proinflammatory cytokines IL-2, IFN-gamma and IL-17.	Cyclosporine	37-40	interleukin 17A	Mus musculus	158-163
21989206-1	2011	AIMS: Cyclophilin A (CypA) is an immunophilin that acts as a receptor for the immunosuppressant drug cyclosporine A (CsA).	Cyclosporine	117-120	peptidylprolyl isomerase A	Mus musculus	21-25
22079035-9	2012	Cyclosporin A studies indicate that the fast liver and kidney clearance kinetics is mediated by P-glycoprotein (Pgp), supporting the potential interest of this radiotracer for imaging Pgp function associated with multidrug-resistant tumours.	Cyclosporine	0-13	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	96-110
22079035-9	2012	Cyclosporin A studies indicate that the fast liver and kidney clearance kinetics is mediated by P-glycoprotein (Pgp), supporting the potential interest of this radiotracer for imaging Pgp function associated with multidrug-resistant tumours.	Cyclosporine	0-13	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	112-115
22079035-9	2012	Cyclosporin A studies indicate that the fast liver and kidney clearance kinetics is mediated by P-glycoprotein (Pgp), supporting the potential interest of this radiotracer for imaging Pgp function associated with multidrug-resistant tumours.	Cyclosporine	0-13	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	184-187
22115032-8	2011	Protein band of 170 kDa manifested the existence of P-gp in the rBMECs, and the findings of cyclosporin A-sensitive decrease of Rho123 efflux confirmed the presence of P-gp activity.	Cyclosporine	92-105	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	168-172
22124337-13	2012	CONCLUSION: The dual blocking of CCR5/CXCR3 can be useful in decreasing rejection, with or without CsA.	Cyclosporine	99-102	C-X-C motif chemokine receptor 3	Rattus norvegicus	38-43
22124122-7	2012	Cyclosporine A inhibits the Wnt5a and calcium-induced activation of NF-kappaB and BCL-6 in Ramos cells, supporting a role of beta-catenin-independent Wnt/Ca(2+)/NFAT/NF-kappaB-BCL-6 signaling.	Cyclosporine	0-14	BCL6 transcription repressor	Homo sapiens	82-87
22124122-7	2012	Cyclosporine A inhibits the Wnt5a and calcium-induced activation of NF-kappaB and BCL-6 in Ramos cells, supporting a role of beta-catenin-independent Wnt/Ca(2+)/NFAT/NF-kappaB-BCL-6 signaling.	Cyclosporine	0-14	BCL6 transcription repressor	Homo sapiens	176-181
22986347-0	2012	Statin upregulates the expression of klotho, an anti-aging gene, in experimental cyclosporine nephropathy.	Cyclosporine	81-93	klotho	Mus musculus	37-43
22241958-6	2011	Hence, we evaluated the expression the 41 genes as a function of in vitro radioresistance in the NCI-60 cancer cell line panel and found cyclophilin B (PPIB), a peptidylprolyl isomerase and target of cyclosporine A (CsA), had the strongest direct correlation.	Cyclosporine	200-214	peptidylprolyl isomerase B	Homo sapiens	152-156
22986347-1	2012	BACKGROUND: We recently reported that long-term cyclosporine (CsA)-induced oxidative stress is associated with decreased expression of klotho, an anti-aging gene.	Cyclosporine	48-60	klotho	Mus musculus	135-141
22986347-1	2012	BACKGROUND: We recently reported that long-term cyclosporine (CsA)-induced oxidative stress is associated with decreased expression of klotho, an anti-aging gene.	Cyclosporine	62-65	klotho	Mus musculus	135-141
22986347-2	2012	This study evaluated whether the antioxidant effect of statin might upregulate klotho expression in CsA-induced renal injury.	Cyclosporine	100-103	klotho	Mus musculus	79-85
22986347-5	2012	Second, the effect of statin on klotho expression was evaluated in experimental chronic CsA nephropathy in mice.	Cyclosporine	88-91	klotho	Mus musculus	32-38
22986347-8	2012	CsA administration increased p-FoxO1 expression and decreased p-FoxO3a expression, whereas concurrent statin treatment reversed these changes, increased the expression of the antioxidant enzymes MnSOD and hemeoxygenase-1 and decreased the expression of the pro-apoptotic protein Bim.	Cyclosporine	0-3	forkhead box O3	Mus musculus	64-70
23028916-3	2012	We show that IL-15 exerts growth factor activity on both CD4(+) and CD8(+) T cells in a TCR-dependent and Cyclosporin A-sensitive manner.	Cyclosporine	106-119	interleukin 15	Mus musculus	13-18
22241958-6	2011	Hence, we evaluated the expression the 41 genes as a function of in vitro radioresistance in the NCI-60 cancer cell line panel and found cyclophilin B (PPIB), a peptidylprolyl isomerase and target of cyclosporine A (CsA), had the strongest direct correlation.	Cyclosporine	216-219	peptidylprolyl isomerase B	Homo sapiens	152-156
22241958-7	2011	Functional inhibition of PPIB by small interfering RNA depletion or CsA treatment leads to radiosensitization in cancer cells and reduced cellular DNA repair.	Cyclosporine	68-71	peptidylprolyl isomerase B	Homo sapiens	25-29
22094768-9	2011	The in vivo study revealed that, compared with untreated control, rats administered adipose-derived stem cells along with transient antilymphocyte serum and cyclosporin A treatment had significantly prolonged allotransplant survival (p &lt; 0.001), decreased allotissue rejection, significantly elevated donor cell chimerism, and increased CD4/CD25/Foxp3 regulatory T cells in peripheral blood and alloskin tissue with up-regulation of transforming growth factor-beta and interleukin-10 levels.	Cyclosporine	157-170	interleukin 10	Homo sapiens	472-486
22768295-7	2012	In wild-type mice, the co-administration of cyclosporin A, a known P-gp inhibitor, resulted in a 6-fold increase in the accumulation of quinacrine in the brain.	Cyclosporine	44-57	phosphoglycolate phosphatase	Mus musculus	67-71
21434893-0	2011	Cyclosporine metabolic side effects: association with the WNK4 system.	Cyclosporine	0-12	WNK lysine deficient protein kinase 4	Rattus norvegicus	58-62
21434893-5	2011	Therefore, we studied whether cyclosporine"s metabolic side effects are mediated by WNK4 and NCC.	Cyclosporine	30-42	WNK lysine deficient protein kinase 4	Rattus norvegicus	84-88
21434893-11	2011	In mDCT cells, cyclosporine caused a rise in WNK4 mRNA levels and also a threefold rise in WNK4 protein content.	Cyclosporine	15-27	WNK lysine deficient protein kinase 4	Rattus norvegicus	45-49
21434893-11	2011	In mDCT cells, cyclosporine caused a rise in WNK4 mRNA levels and also a threefold rise in WNK4 protein content.	Cyclosporine	15-27	WNK lysine deficient protein kinase 4	Rattus norvegicus	91-95
21707758-2	2011	We investigated the mechanisms of CsA-induced NER reduction by assessing all xeroderma pigmentosum (XP) genes (XPA-XPG).	Cyclosporine	34-37	ERCC excision repair 5, endonuclease	Homo sapiens	115-118
22310597-5	2012	Because the abnormally elevated C(t) was falsely measured by the ACMIA method, we restarted tacrolimus However, the calcineurin inhibitor was subsequently converted to cyclosporine at day 21 after renal transplantation.	Cyclosporine	168-180	calcineurin binding protein 1	Homo sapiens	116-137
21707758-3	2011	Western blot analyses revealed that XPA and XPG protein expression was reduced in normal human GM00637 fibroblasts exposed to 0.1 and 0.5 mum CsA.	Cyclosporine	142-145	ERCC excision repair 5, endonuclease	Homo sapiens	44-47
21989206-1	2011	AIMS: Cyclophilin A (CypA) is an immunophilin that acts as a receptor for the immunosuppressant drug cyclosporine A (CsA).	Cyclosporine	101-115	peptidylprolyl isomerase A	Mus musculus	6-19
21707758-6	2011	CsA-induced reduction in NER could be complemented by the overexpression of either XPA or XPG protein.	Cyclosporine	0-3	ERCC excision repair 5, endonuclease	Homo sapiens	90-93
21989206-1	2011	AIMS: Cyclophilin A (CypA) is an immunophilin that acts as a receptor for the immunosuppressant drug cyclosporine A (CsA).	Cyclosporine	101-115	peptidylprolyl isomerase A	Mus musculus	21-25
21989206-1	2011	AIMS: Cyclophilin A (CypA) is an immunophilin that acts as a receptor for the immunosuppressant drug cyclosporine A (CsA).	Cyclosporine	117-120	peptidylprolyl isomerase A	Mus musculus	6-19
21707758-9	2011	Our data indicate that the CsA-induced inhibition of NER is a result of downregulation of XPA and XPG protein in a calcineurin-dependent manner.	Cyclosporine	27-30	ERCC excision repair 5, endonuclease	Homo sapiens	98-101
21871837-5	2011	We report a 35 year-old sAA male patient who initially underwent IST using rabbit ATG and Cyclosporine A (CsA).	Cyclosporine	90-104	serum amyloid A1 cluster	Homo sapiens	24-27
22118788-4	2011	After the first month, maintenance therapy mostly consists in the association of several immunosuppressants, mainly corticosteroids, an antimetabolic agent (azathioprine or mycophenolate mofetil) and a calcineurin inhibitor (cyclosporine or tacrolimus).	Cyclosporine	225-237	calcineurin binding protein 1	Homo sapiens	202-223
21871837-5	2011	We report a 35 year-old sAA male patient who initially underwent IST using rabbit ATG and Cyclosporine A (CsA).	Cyclosporine	106-109	serum amyloid A1 cluster	Homo sapiens	24-27
21911813-6	2011	CyA upregulated cell-surface intercellular adhesion molecule-1 expression (215 +- 13% of control; P&lt;0.001), as determined by flow cytometry.	Cyclosporine	0-3	intercellular adhesion molecule 1	Homo sapiens	29-62
18708634-6	2008	Since 20% CSA increase also induced a significant phosphorylation of CK8-ser431, we suggest CK phosphorylation might lower the tensile force of the transcellular CK network, which could explain the morphological observations.	Cyclosporine	10-13	keratin 8	Homo sapiens	69-72
18765728-8	2008	Incubation with CSA depleted mitochondrial dynamin-2 in BL-3 cells, making it unavailable for vesicle scission and LKT internalization.	Cyclosporine	16-19	dynamin 2	Homo sapiens	43-52
18725544-1	2008	This study examined the contribution of changes in regulation of intestinal and hepatic cytochrome P450 3A (CYP3A) and multidrug resistance transporter 1 (Mdr1) to absorption of cyclosporine A (CsA) in a rat nephrosis model.	Cyclosporine	178-192	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	155-159
17389782-2	2007	Ciclosporin A (CsA) is used in resistant cases, but also as a first-line treatment, due to the serious side effects of cytotoxic drugs.	Cyclosporine	15-18	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	0-13
17069579-1	2007	We present the results of two consecutively performed cohort studies that evaluated the clinical effects of corticosteroids or cyclosporin as an adjunct to plasma exchange (PE) for the treatment of an acute episode of thrombotic thrombocytopenic purpura (TTP).	Cyclosporine	127-138	ZFP36 ring finger protein	Homo sapiens	218-259
18957170-0	2008	Polysaccharopeptide mimics ciclosporin-mediated Th1/Th2 cytokine balance for suppression of activated human T cell proliferation by MAPKp38 and STAT5 pathways.	Cyclosporine	27-38	negative elongation factor complex member C/D	Homo sapiens	48-51
21653632-0	2011	Expression of renal distal tubule transporters TRPM6 and NCC in a rat model of cyclosporine nephrotoxicity and effect of EGF treatment.	Cyclosporine	79-91	transient receptor potential cation channel, subfamily M, member 6	Rattus norvegicus	47-52
18957170-7	2008	PSP exhibited similar and additive inhibitory effects to ciclosporin to suppress activated T cell proliferation, Th1 cytokines and reduce CD3+/CD25+ cell expression, but not Th2 cytokine expression, which helps the cytokine balance shift towards Th2 dominance.	Cyclosporine	57-68	negative elongation factor complex member C/D	Homo sapiens	113-116
17069579-3	2007	These data suggest that cyclosporin may have advantages over corticosteroids as an adjunct to PE therapy in the initial treatment of idiopathic TTP.	Cyclosporine	24-35	ZFP36 ring finger protein	Homo sapiens	144-147
21946207-9	2011	After CsA gavage, the relative mRNA expressions of OA, MMP-13, and Col III significantly increased with time.	Cyclosporine	6-9	matrix metallopeptidase 13	Rattus norvegicus	55-61
21946207-13	2011	The early-phase up-regulation of OA expression in the tubular epithelium in response to renal injury caused by acute CsA toxicity might play a key role in triggering the renal interstitial fibrosis via activating expression of MMPs and collagen remodeling in SD rats.	Cyclosporine	117-120	matrix metallopeptidase 13	Rattus norvegicus	227-231
17464771-1	2007	Cyclosporin A (CSA) and tacrolimus (FK506) are two common immunosuppressive agents used post blood and marrow transplantation.	Cyclosporine	0-13	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
18980530-0	2008	Upregulation of heme oxygenase-1 expression in gingiva after cyclosporin A treatment.	Cyclosporine	61-74	heme oxygenase 1	Rattus norvegicus	16-32
18980530-1	2008	BACKGROUND: Heme oxygenase (HO)-1 is a stress-inducible protein that confers cytoprotection, but its role in gingiva during cyclosporin A (CsA) therapy is unknown.	Cyclosporine	139-142	heme oxygenase 1	Rattus norvegicus	12-33
21781066-1	2011	OBJECTIVE: The aim of this study is to determine serum levels of soluble forms of CD26/dipeptidyl-peptidase IV (DPP-IV) and adenosine deaminase (ADA), thought to be markers of T-cell activation, and changes in their levels in response to cyclosporine, etanercept, and psoralen plus ultraviolet A (PUVA) treatments with respect to disease activity.	Cyclosporine	238-250	adenosine deaminase	Homo sapiens	145-148
18980530-2	2008	We used in vivo and in vitro models to investigate the expression of mRNA and protein for HO-1 in gingiva upon CsA treatment.	Cyclosporine	111-114	heme oxygenase 1	Rattus norvegicus	90-94
18980530-8	2008	RESULTS: Mean gingival HO-1 mRNA expression was greater in the CsA group than in the control animals (P = 0.076).	Cyclosporine	63-66	heme oxygenase 1	Rattus norvegicus	23-27
18980530-9	2008	IHC staining for HO-1 protein was significantly greater in the gingivae of CsA-treated rats than in those of the control group.	Cyclosporine	75-78	heme oxygenase 1	Rattus norvegicus	17-21
18980530-10	2008	In fibroblast cultures, expression of HO-1 mRNA and protein also increased significantly after CsA treatment.	Cyclosporine	95-98	heme oxygenase 1	Rattus norvegicus	38-42
17181650-1	2007	The proliferation signal inhibitor everolimus (Certican), has demonstrated efficacy with full-dose cyclosporine (CsA) (Neoral).	Cyclosporine	99-111	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	113-116
21749729-2	2011	We report a 22-month-old girl with sJIA who developed severe MAS but was successfully treated with corticosteroids, cyclosporin A, and non-steroidal anti-inflammatory drugs by monitoring serum IL-18 levels.	Cyclosporine	116-129	interleukin 18	Homo sapiens	193-198
17180587-2	2006	Alanine aminotransferase (ALT) elevations were seen in phase I studies of patients receiving caspofungin and cyclosporine A (CyA).	Cyclosporine	109-123	glutamic--pyruvic transaminase	Homo sapiens	0-24
17180587-2	2006	Alanine aminotransferase (ALT) elevations were seen in phase I studies of patients receiving caspofungin and cyclosporine A (CyA).	Cyclosporine	125-128	glutamic--pyruvic transaminase	Homo sapiens	0-24
18980530-11	2008	CONCLUSION: CsA upregulates the gingival expression of HO-1, which may exert a cytoprotective effect.	Cyclosporine	12-15	heme oxygenase 1	Rattus norvegicus	55-59
21178983-6	2011	Cyclosporine A treatment during DS maintained the number of NK/NKT cells in the conjunctiva, increased IL-13 mRNA in NK+ cells, and decreased IFN-gamma and IL-17A mRNA transcripts in NK+ and NK- populations.	Cyclosporine	0-14	interleukin 17A	Mus musculus	156-162
18992197-1	2008	AIM: To study the clinical significance of early diagnosis and differential diagnosis of IL-18 by observing its changes in renal allograft recipients with infection, acute rejection and CsA-induced nephrotoxicity.	Cyclosporine	186-189	interleukin 18	Homo sapiens	89-94
21343230-6	2011	In C57Bl mice with chronic EAE or SJL mice with RR EAE, pharmacological inhibition of PARP-1 reduced CNS DC migration and demyelination as well as neurological impairment to an extent similar to that achieved with the potent immunosuppressant cyclosporine A.	Cyclosporine	243-257	poly (ADP-ribose) polymerase family, member 1	Mus musculus	86-92
21514360-0	2011	The effect of systemic injection of cyclosporin A on the phosphorylation of the PKC substrates MARCKS and GAP43 in the rat hippocampus.	Cyclosporine	36-49	myristoylated alanine rich protein kinase C substrate	Rattus norvegicus	95-101
19060372-11	2008	Compared with the normal-dose CsA group, the chronic rejection lesions of the anti-ICOS-Ab combined with low-dose CsA treatment group significantly were alleviated in the long-term survival grafts, and the proportion of CD4+CD25+ regulatory T cell increased in peripheral blood.	Cyclosporine	114-117	Cd4 molecule	Rattus norvegicus	220-223
21514360-7	2011	The immunoreactivity of p-MARCKS(S152/156) was higher in the CsA group 1h after injection, whereas p-GAP43(S41) immunoreactivity was increased by CsA after 5h.	Cyclosporine	61-64	myristoylated alanine rich protein kinase C substrate	Rattus norvegicus	26-32
21737631-3	2011	MATERIALS AND METHODS: Single-pass antegrade ILP (A-ILP) was performed with doxorubicin in rats bearing a pulmonary sarcoma nodule which were either untreated or received P-gp inhibitors cyclosporin, valspodar or the vehicle, Cremophor , only.	Cyclosporine	187-198	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	171-175
18817631-1	2008	AIM: To evaluate the effects of cyclosporin A and itraconazole, which were used as inhibitors of P-glycoprotein (P-gp) and/or cytochrome P450 (CYP) 3A4 on the pharmacokinetics of atorvastatin in rats.	Cyclosporine	32-45	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	97-111
18776037-7	2008	Chronic exposure to CsA abolished intracellular Ca(2+) homeostasis and decreased mRNA transcription of the CCH1 gene for the plasma membrane Ca(2+) channel in yeast-form cells.	Cyclosporine	20-23	Cch1p	Saccharomyces cerevisiae S288C	107-111
21737631-8	2011	CONCLUSION: P-gp modulation with cyclosporin or valspodar fails to increase the tumor uptake of doxorubin administered by A-ILP.	Cyclosporine	33-44	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	12-16
18694572-7	2008	RESULTS: At a 2 microg/mL dose, CyA treated HAEC revealed a 44-fold increase in the expression of hairy enhancer of split-related protein 1 (HESR1) and 1.73-fold down-regulation of transcripts encoding for the vascular endothelial growth factor (VEGF) receptor (VEGFR2).	Cyclosporine	32-35	kinase insert domain receptor	Homo sapiens	262-268
21415249-6	2011	The ratios of IC50 values obtained from the biliary excretion index over the IC(50, QTLI) were 1.34, 1.94, and 1.94, but ratios over IC50 values in CDF uptake by Mrp2-expressing membrane vesicles varied more: 6.69, 3.07, and 2.43 for rifampicin, cyclosporine, and MK-571, respectively.	Cyclosporine	246-258	ATP binding cassette subfamily C member 2	Rattus norvegicus	162-166
18594870-1	2008	The aim of this study was to determine the effects of cyclosporine A (CyA) on urinary levels of matrix metalloproteinase 2 and 9 (MMP2, MMP9) and their tissue inhibitors 1 and 2 (TIMP1, TIMP2) in steroid-dependent nephrotic syndrome (SDNS).	Cyclosporine	54-68	matrix metallopeptidase 9	Homo sapiens	136-140
18594870-1	2008	The aim of this study was to determine the effects of cyclosporine A (CyA) on urinary levels of matrix metalloproteinase 2 and 9 (MMP2, MMP9) and their tissue inhibitors 1 and 2 (TIMP1, TIMP2) in steroid-dependent nephrotic syndrome (SDNS).	Cyclosporine	70-73	matrix metallopeptidase 9	Homo sapiens	136-140
20209781-4	2008	The aim of this study was to identify the presence and localization of CCN2/CTGF and CCN1/Cyr61, members of the same molecular family, in gingival tissues of cyclosporin A- and nifedipine-treated rats, by immunohistochemistry.	Cyclosporine	158-171	cellular communication network factor 1	Rattus norvegicus	90-95
21517850-9	2011	mGluR2/3 activation by its agonist LY354740 (100 ng) in the CA3 reversed the depressive-like behavior induced by cyclosporine-A administration.	Cyclosporine	113-127	carbonic anhydrase 3	Rattus norvegicus	60-63
18929835-12	2008	The density of the TIMP-1 in controls 1.13, and in CsA-treated, 1.40.	Cyclosporine	51-54	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	19-25
18929866-0	2008	Rapamycin and cyclosporine have different effects on expression of Ang-1 and Ang-2 and Tie2 in rat renal allograft with chronic allograft nephropathy.	Cyclosporine	14-26	angiogenin, ribonuclease A family, member 2	Rattus norvegicus	77-82
21401729-3	2011	Tacr- compared with CsA-based immunosuppression was independently associated with increased IL-2 (P&lt;0.0001, CD4 cells; P=0.014, CD8 cells) and CD4 cell IL-4 responses (P=0.046; stepwise logistic regression) resulting in physiological responses in Tacr/Aza patients as compared with 25 healthy controls.	Cyclosporine	20-23	CD8a molecule	Homo sapiens	131-134
18929866-2	2008	This study of cardiac allografts investigated whether there is a difference between rapamycin and cyclosporine A (CsA) in the ability to affect expression of Ang1, Ang2, and Tie2 in rat renal allografts with chronic allograft nephropathy (CAN).	Cyclosporine	98-112	angiogenin, ribonuclease A family, member 2	Rattus norvegicus	164-168
18929866-2	2008	This study of cardiac allografts investigated whether there is a difference between rapamycin and cyclosporine A (CsA) in the ability to affect expression of Ang1, Ang2, and Tie2 in rat renal allografts with chronic allograft nephropathy (CAN).	Cyclosporine	114-117	angiogenin, ribonuclease A family, member 2	Rattus norvegicus	164-168
21421030-4	2011	Co-administration of Danshen did not affect the plasma concentration profiles and pharmacokinetic parameters of docetaxel and clopidogrel, whereas cyclosporine A, a P-gp and CYP3A inhibitor, significantly influenced the pharmacokinetics of co-administered docetaxel and clopidogrel.	Cyclosporine	147-161	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	165-169
18929866-14	2008	CONCLUSIONS: Our results show that compared with CsA, rapamycin modulates the expression of Ang1, Ang2, and Tie2 in rat renal allografts with CAN, which suggests that rapamycin may improve the long-term survival of renal allografts through its vasculoprotective properties.	Cyclosporine	49-52	angiogenin, ribonuclease A family, member 2	Rattus norvegicus	98-102
18667424-2	2008	Inhibition of nuclear factors of activated T cell (NFAT) activation by cyclosporin A (CsA) and VIVIT suppressed PDGF-BB-induced cyclin A expression and CDK2 activity, resulting in blockade of VSMC in the G(1) phase.	Cyclosporine	71-84	cyclin dependent kinase 2	Rattus norvegicus	152-156
18667424-2	2008	Inhibition of nuclear factors of activated T cell (NFAT) activation by cyclosporin A (CsA) and VIVIT suppressed PDGF-BB-induced cyclin A expression and CDK2 activity, resulting in blockade of VSMC in the G(1) phase.	Cyclosporine	86-89	cyclin dependent kinase 2	Rattus norvegicus	152-156
18813114-6	2008	Surprisingly, interleukin-10 secretion by immature DC2 was increased after CsA treatment.	Cyclosporine	75-78	interleukin 10	Homo sapiens	14-28
21292993-0	2011	Accumulation of CD4+ T cells in the colon of CsA-treated mice following myeloablative conditioning and bone marrow transplantation.	Cyclosporine	45-48	CD4 antigen	Mus musculus	16-19
21292993-5	2011	Time-course studies revealed a significant increase in migration of CD4(+) T cells into the colon during CsA therapy, as well as significantly elevated mRNA levels of TNF-alpha, proinflammatory chemokines, and cell adhesion molecules in colonic tissue of CsA-treated animals compared with BMT controls, as early as day 14 post-BMT.	Cyclosporine	105-108	CD4 antigen	Mus musculus	68-71
21292993-6	2011	Homing studies revealed a greater migration of labeled CD4(+) T cells into the gut of CsA-treated mice at day 21 post-BMT than control animals via CsA-induced upregulation of mucosal addressin cell adhesion molecule.	Cyclosporine	86-89	CD4 antigen	Mus musculus	55-58
21292993-6	2011	Homing studies revealed a greater migration of labeled CD4(+) T cells into the gut of CsA-treated mice at day 21 post-BMT than control animals via CsA-induced upregulation of mucosal addressin cell adhesion molecule.	Cyclosporine	147-150	CD4 antigen	Mus musculus	55-58
21146153-0	2011	Toll like receptor 4 and membrane-bound CD14 expressions in gingivitis, periodontitis and CsA-induced gingival overgrowth.	Cyclosporine	90-93	ATP binding cassette subfamily A member 1	Homo sapiens	25-39
21146153-2	2011	This study was aimed to investigate the expression of TLR4 and membrane-bound CD14 (mCD14) in the gingival tissues of patients with gingivitis, periodontitis and CsA-induced gingival overgrowth.	Cyclosporine	162-165	ATP binding cassette subfamily A member 1	Homo sapiens	63-77
21270823-0	2011	Keratinocyte secretion of cyclophilin B via the constitutive pathway is regulated through its cyclosporin-binding site.	Cyclosporine	94-105	peptidylprolyl isomerase B	Homo sapiens	26-39
21461940-3	2011	Our aim was to detect the active sites of Cd2+ in the mitochondrial membrane treatments with cyclosporin A (CsA) and EGTA on the mitochondrial permeability transition (MPT) induced by low and high concentrations of Cd2+.	Cyclosporine	93-106	Cd2 molecule	Rattus norvegicus	42-45
19356088-1	2008	Cyclosporin A (CsA) is a P-glycoprotein (P-gp) inhibitor clinically used as an immunosuppressant.	Cyclosporine	0-13	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	41-45
21461940-3	2011	Our aim was to detect the active sites of Cd2+ in the mitochondrial membrane treatments with cyclosporin A (CsA) and EGTA on the mitochondrial permeability transition (MPT) induced by low and high concentrations of Cd2+.	Cyclosporine	93-106	Cd2 molecule	Rattus norvegicus	215-218
19356088-1	2008	Cyclosporin A (CsA) is a P-glycoprotein (P-gp) inhibitor clinically used as an immunosuppressant.	Cyclosporine	15-18	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	25-39
21461940-3	2011	Our aim was to detect the active sites of Cd2+ in the mitochondrial membrane treatments with cyclosporin A (CsA) and EGTA on the mitochondrial permeability transition (MPT) induced by low and high concentrations of Cd2+.	Cyclosporine	108-111	Cd2 molecule	Rattus norvegicus	42-45
19356088-1	2008	Cyclosporin A (CsA) is a P-glycoprotein (P-gp) inhibitor clinically used as an immunosuppressant.	Cyclosporine	15-18	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	41-45
21461940-3	2011	Our aim was to detect the active sites of Cd2+ in the mitochondrial membrane treatments with cyclosporin A (CsA) and EGTA on the mitochondrial permeability transition (MPT) induced by low and high concentrations of Cd2+.	Cyclosporine	108-111	Cd2 molecule	Rattus norvegicus	215-218
18538359-2	2008	Chronic (&gt;or=3h) treatment of cultured bovine adrenal chromaffin cells with cyclosporin A or FK506 decreased IRS-2 protein level by approximately 50% (IC(50)=200 or 10nM), without changing IRS-2 mRNA level, and insulin receptor, insulin-like growth factor-I (IGF-I) receptor, IRS-1, PI3K/PDK-1/Akt/GSK-3beta and ERK1/ERK2 protein levels.	Cyclosporine	79-92	pyruvate dehydrogenase kinase 1	Bos taurus	291-296
18538359-2	2008	Chronic (&gt;or=3h) treatment of cultured bovine adrenal chromaffin cells with cyclosporin A or FK506 decreased IRS-2 protein level by approximately 50% (IC(50)=200 or 10nM), without changing IRS-2 mRNA level, and insulin receptor, insulin-like growth factor-I (IGF-I) receptor, IRS-1, PI3K/PDK-1/Akt/GSK-3beta and ERK1/ERK2 protein levels.	Cyclosporine	79-92	glycogen synthase kinase 3 beta	Bos taurus	301-310
21453156-9	2011	Cyclosporine and cyclosporine-dexamethasone, but not human CTLA4-Ig, caused a significant decrease in IL-10 production.	Cyclosporine	0-12	interleukin 10	Homo sapiens	102-107
18538359-8	2008	Cyclosporin A or FK506 increased serine-phosphorylation and ubiquitination of IRS-2.	Cyclosporine	0-13	insulin receptor substrate 2	Cricetulus griseus	78-83
21453156-9	2011	Cyclosporine and cyclosporine-dexamethasone, but not human CTLA4-Ig, caused a significant decrease in IL-10 production.	Cyclosporine	17-29	interleukin 10	Homo sapiens	102-107
18424069-0	2008	Cyclosporin A inhibits the production of IL-17 by memory Th17 cells from healthy individuals and patients with rheumatoid arthritis.	Cyclosporine	0-13	interleukin 17A	Homo sapiens	41-46
18424069-5	2008	The addition of CsA into cell cultures significantly inhibited the IL-17 production by Th17 cells at protein and at mRNA levels.	Cyclosporine	16-19	interleukin 17A	Homo sapiens	67-72
21114560-4	2011	Based on analyses of the areas under concentration-time curves (AUC) pre- and post-CsA treatment, plasma glucose concentrations were significantly higher (AUC without baseline correction 31.0 mmol/L/min greater; P = 0.021) and serum insulin concentrations were significantly lower (AUC without baseline correction 217.1 muIU/mL/min lower; P = 0.044) following CsA treatment.	Cyclosporine	83-86	insulin	Canis lupus familiaris	233-240
18424069-6	2008	Compared to the PBMCs from normal individuals, PBMCs from the patients with RA produced higher levels of IL-17 that was also significantly inhibited by CsA both at protein and at mRNA levels.	Cyclosporine	152-155	interleukin 17A	Homo sapiens	105-110
18424069-8	2008	Taken together, these results demonstrated that CsA suppressed the IL-17 production and inhibited the Th17 cells differentiation from both healthy individuals and patients with RA.	Cyclosporine	48-51	interleukin 17A	Homo sapiens	67-72
18442787-5	2008	Cyclosporine A and anti-IL-12p40 (in the acute phase) and anti-CD3 (in the chronic phase) treatment attenuated local cytokine levels, improved clinical symptoms (CsA and anti-IL-12p40) and histology (CsA and anti-CD3).	Cyclosporine	0-14	interleukin 12b	Mus musculus	175-183
18442787-5	2008	Cyclosporine A and anti-IL-12p40 (in the acute phase) and anti-CD3 (in the chronic phase) treatment attenuated local cytokine levels, improved clinical symptoms (CsA and anti-IL-12p40) and histology (CsA and anti-CD3).	Cyclosporine	162-165	interleukin 12b	Mus musculus	24-32
18026717-5	2008	In NRK-52E cells, CsA dose-dependently decreased TRPM6 expression without affecting TRPM7 expression.	Cyclosporine	18-21	transient receptor potential cation channel, subfamily M, member 6	Rattus norvegicus	49-54
18230621-9	2008	These results, thus, argue for the existence of an alternative Bax/Bak-independent apoptotic mechanism that involves cyclosporine A-sensitive mitochondrial membrane permeability.	Cyclosporine	117-131	BCL2-associated X protein	Mus musculus	63-66
17889571-10	2008	The presence of Cy favoured erythroid differentiation and maturation and reduced the percentage of non-erythroid CD45(+) cells (2% with Cy versus 5% without Cy).	Cyclosporine	16-18	protein tyrosine phosphatase receptor type C	Homo sapiens	113-117
17906976-9	2008	Consistent with this, cell surface trapping of ABCA1 with cyclosporin A (CsA) results in increased apoA-I binding but reduced internalisation.	Cyclosporine	58-71	ATP binding cassette subfamily A member 1	Homo sapiens	47-52
17906976-9	2008	Consistent with this, cell surface trapping of ABCA1 with cyclosporin A (CsA) results in increased apoA-I binding but reduced internalisation.	Cyclosporine	73-76	ATP binding cassette subfamily A member 1	Homo sapiens	47-52
18243104-6	2008	Our findings may explain why patients receiving cyclosporine A for immunosuppressive therapy display excessive hair growth, and unveil a functional role for calcium-NFATc1-CDK4 circuitry in governing stem cell quiescence.	Cyclosporine	48-62	nuclear factor of activated T cells 1	Homo sapiens	165-171
18574772-3	2008	METHODS: CsA was added to anti-CD3+/-IL-15-stimulated CB and APB mononuclear cells (MNC) for a 5-day incubation.	Cyclosporine	9-12	interleukin 15	Homo sapiens	37-42
18574772-5	2008	Magnetic bead-purified CB and APB NK cells were stimulated with IL-15 for 18 h under the influence of CsA.	Cyclosporine	102-105	interleukin 15	Homo sapiens	64-69
18574772-7	2008	RESULTS: CsA decreased CD3- CD56+ NK cell recovery in anti-CD3-stimulated CB MNC 5-day cultures, an effect that could be counteracted by IL-15; comparable effects were observed with APB.	Cyclosporine	9-12	interleukin 15	Homo sapiens	137-142
18574772-8	2008	Short-term (18-h) experiments revealed that CsA down-regulated K562 cytotoxicity of IL-15-activated (P=0.018) but not resting (P=0.268) purified CB NK cells.	Cyclosporine	44-47	interleukin 15	Homo sapiens	84-89
18574772-9	2008	IL-15-induced CB NK CD69 expression showed increased CsA sensitivity over APB (P=0.012).	Cyclosporine	53-56	interleukin 15	Homo sapiens	0-5
18574772-10	2008	CsA down-regulated K562 cell-induced CD54 (P=0.028) but not perforin (P=0.416) expression of IL-15-activated CB NK cells.	Cyclosporine	0-3	intercellular adhesion molecule 1	Homo sapiens	37-41
18574772-10	2008	CsA down-regulated K562 cell-induced CD54 (P=0.028) but not perforin (P=0.416) expression of IL-15-activated CB NK cells.	Cyclosporine	0-3	interleukin 15	Homo sapiens	93-98
18574772-13	2008	These results may be used to improve the design of IL-15-activated NK cell adoptive immunotherapy in cancer patients receiving CsA post-CB transplantation.	Cyclosporine	127-130	interleukin 15	Homo sapiens	51-56
17956469-5	2007	RESULTS: The expression of heparan sulfate proteoglycans was increased in the cyclosporin A group (165% for syndecan-2, 308% for syndecan-4, and 42% for betaglycan) compared with the control group.	Cyclosporine	78-91	syndecan 2	Homo sapiens	108-118
17956469-5	2007	RESULTS: The expression of heparan sulfate proteoglycans was increased in the cyclosporin A group (165% for syndecan-2, 308% for syndecan-4, and 42% for betaglycan) compared with the control group.	Cyclosporine	78-91	transforming growth factor beta receptor 3	Homo sapiens	153-163
17998872-7	2007	CONCLUSION: Observed suppressive effects of Serp-1 on early innate immune response components such as TLR-2 and 4, and on adaptive responses such as T-cell intragraft infiltration suggests that Serp-1 may modulate the transition from innate to adaptive immunity, exhibiting a synergistic effect on allograft survival when used in combination with a subtherapeutic dose of CsA.	Cyclosporine	372-375	Serine protease inhibitor	Rattus norvegicus	44-50
17998872-7	2007	CONCLUSION: Observed suppressive effects of Serp-1 on early innate immune response components such as TLR-2 and 4, and on adaptive responses such as T-cell intragraft infiltration suggests that Serp-1 may modulate the transition from innate to adaptive immunity, exhibiting a synergistic effect on allograft survival when used in combination with a subtherapeutic dose of CsA.	Cyclosporine	372-375	Serine protease inhibitor	Rattus norvegicus	194-200
18005864-3	2007	The present study examines CsA sensitivity of IL-15-driven CB CD4(+) T cell survival, activation and proliferation, comparing adult peripheral blood (APB) CD4(+) T cell responses.	Cyclosporine	27-30	interleukin 15	Homo sapiens	46-51
17724614-0	2007	cAMP-response element binding protein (CREB) regulates cyclosporine-A-mediated down-regulation of cathepsin B and L synthesis.	Cyclosporine	55-69	cAMP responsive element binding protein 1	Homo sapiens	39-43
17724614-0	2007	cAMP-response element binding protein (CREB) regulates cyclosporine-A-mediated down-regulation of cathepsin B and L synthesis.	Cyclosporine	55-69	cathepsin B	Homo sapiens	98-109
17176368-9	2006	TPMT heterozygosity was associated with significant reductions in haematological indices and a significant decrease in cyclosporine plasma concentrations in the first year after renal transplantation.	Cyclosporine	119-131	thiopurine S-methyltransferase	Homo sapiens	0-4
17114439-7	2006	Taken together, these findings suggest that CsA promotes sensitivity to CD95-mediated apoptosis in CD28-stimulated T cells by superinduction of the caspase-3 gene via a mechanism involving suppression of the calcineurin pathway.	Cyclosporine	44-47	Cd28 molecule	Rattus norvegicus	99-103
17114439-7	2006	Taken together, these findings suggest that CsA promotes sensitivity to CD95-mediated apoptosis in CD28-stimulated T cells by superinduction of the caspase-3 gene via a mechanism involving suppression of the calcineurin pathway.	Cyclosporine	44-47	caspase 3	Rattus norvegicus	148-157
17096767-6	2006	Here, we report a patient who was considered to be at very high risk for post-transplant recurrence of FSGS, because of the established risk factors, who was successfully retransplanted after a course of pretransplant plasmapheresis, followed by post-transplant plasmapheresis and the use of cyclosporine.	Cyclosporine	292-304	actinin alpha 4	Homo sapiens	103-107
17101321-3	2006	Cyclosporine A (CsA) specifically inhibits HCV replication through blocking the viral RNA polymerase enzyme NS5B.	Cyclosporine	0-14	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	16-19
16998264-1	2006	BACKGROUND: The purpose of this study was to characterize the pharmacokinetics of cyclosporine (CsA) in Japanese heart transplant patients, and to optimise the monitoring strategy based on measurements of the area under the curve of plasma concentration absorption phase or 2 h post-dose concentrations (C(2)).	Cyclosporine	82-94	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	96-99
16890730-6	2006	Cyclosporin A treatment resulted in a decrease in atrial natriuretic factor mRNA expression (p &lt;0.05) and a marked shift in myosin heavy chain A-to-B ratios toward normal (p &lt;0.01) and an increase in smooth muscle cross sectional area (p &lt;0.05).	Cyclosporine	0-13	natriuretic peptides A	Oryctolagus cuniculus	50-75
16625421-4	2006	Cyclosporin A (CsA), trifluoperazine and aristolochic acid, inhibitors of mitochondrial permeability transition, significantly attenuated the MPP(+)-induced mitochondrial damage leading to caspase-3 activation, increased oxidative stress and cell death.	Cyclosporine	0-13	caspase 3	Rattus norvegicus	189-198
16625421-4	2006	Cyclosporin A (CsA), trifluoperazine and aristolochic acid, inhibitors of mitochondrial permeability transition, significantly attenuated the MPP(+)-induced mitochondrial damage leading to caspase-3 activation, increased oxidative stress and cell death.	Cyclosporine	15-18	caspase 3	Rattus norvegicus	189-198
16980055-11	2006	CsA treatment caused proteolytic cleavage of caspase-3 and induced the degradation of 116-kDa PARP into 89-kDa fragment.	Cyclosporine	0-3	caspase 3	Rattus norvegicus	45-54
16980055-13	2006	CONCLUSIONS: In this study, CsA induced apoptosis by up-regulating proapoptotic factors, caspase-3 and -6, p53, Bax, cleaving PARP, and down-regulating antiapoptotic factor, Bcl-2, and cIAP.	Cyclosporine	28-31	caspase 3	Rattus norvegicus	89-105
16618940-9	2006	Pups that were exposed antenatally to CsA presented several pathologic findings in all immature parenchyma and an increase in iNOS and MMP2 expression.	Cyclosporine	38-41	matrix metallopeptidase 2	Rattus norvegicus	135-139
16643975-6	2006	Inhibition of Cyp A function by cyclosporine significantly decreased the efficiency of TRIM5alpha-mediated restriction only when the restricted virus capsid interacted with Cyp A.	Cyclosporine	32-44	tripartite motif containing 5	Homo sapiens	87-97
16507778-4	2006	All animals except those receiving only CSA exhibited delayed or absent immune responses against hFVIII.	Cyclosporine	40-43	coagulation factor VIII	Homo sapiens	97-103
16785541-4	2006	Our findings from both primary cell types are different from that previously reported in transformed cells and show that the amount of CypA incorporated into virions is variable and that CsA inhibits HIV-1 infection at both early and late phases of virus replication, the stage affected is determined by the sequence of HIV-1 Gag.	Cyclosporine	187-190	Pr55(Gag)	Human immunodeficiency virus 1	326-329
16805961-4	2006	Because both drugs are transported via P-glycoprotein and breast cancer resistance protein and metabolized by cytochrome P450 3A2, the interaction of imatinib mesilate with these proteins may be responsible for the increased intestinal absorption of ciclosporin in rats.	Cyclosporine	250-261	cytochrome P450, family 3, subfamily a, polypeptide 2	Rattus norvegicus	110-129
16778365-1	2006	Long-term treatment of childhood nephrotic syndrome (NS) and rheumatic diseases with cyclosporine A (CsA) given as a single daily dose may yield better results and allow safer use of the drug than the conventional twice-daily dosing.	Cyclosporine	85-99	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	101-104
16778365-4	2006	The initial daily dose of CsA (Neoral) was 2.0 mg/kg, given as a single daily dose before breakfast.	Cyclosporine	31-37	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	26-29
16716758-1	2006	BACKGROUND &amp; AIMS: Cyclosporine (CSA) has been shown to be effective in steroid-refractory ulcerative colitis (UC) and as an alternative to glucocorticosteroids in patients with severe attacks of UC.	Cyclosporine	23-35	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	37-40
16641261-6	2006	The effect of cyclosporine A on HIV-1 infectivity is dependent on TRIM5alpha expression, and expression of simian TRIM5alpha in permissive feline cells renders them able to restrict HIV-1 in a cyclosporine A-sensitive way.	Cyclosporine	14-28	tripartite motif containing 5	Homo sapiens	66-76
16641261-6	2006	The effect of cyclosporine A on HIV-1 infectivity is dependent on TRIM5alpha expression, and expression of simian TRIM5alpha in permissive feline cells renders them able to restrict HIV-1 in a cyclosporine A-sensitive way.	Cyclosporine	193-207	tripartite motif containing 5	Homo sapiens	114-124
16652084-1	2006	Cyclosporine (CSA) is a widely used immunosuppressive agent, predominantly for transplant patients.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
16438932-13	2006	This PTH-stimulated ERK1/2 activation was inhibited by cyclosporine A and FK506.	Cyclosporine	55-69	mitogen-activated protein kinase 3	Mus musculus	20-26
16458528-3	2006	Recently, we demonstrated that CsA up-regulates the expression of transforming growth factor-beta1 (TGF-beta1), its receptors type I (TbetaR-I) and type II (TbetaR-II), as well as related matrix protein synthesis in mesangial cells (MCs).	Cyclosporine	31-34	transforming growth factor beta receptor 2	Homo sapiens	157-166
16246479-6	2006	Caspase 3 activation was markedly inhibited by cyclosporin A (CsA) and Ac-DEVD-CHO.	Cyclosporine	47-60	caspase 3	Rattus norvegicus	0-9
16246479-6	2006	Caspase 3 activation was markedly inhibited by cyclosporin A (CsA) and Ac-DEVD-CHO.	Cyclosporine	62-65	caspase 3	Rattus norvegicus	0-9
16817590-4	2006	The exact mechanism of action of CsA is unknown; however, CsA has the ability to act on the immune system by blocking the biosynthesis of some lymphokines produced by T lymphocytes and interleukin-2 synthesis at the transcriptional level.	Cyclosporine	58-61	interleukin 2	Macaca mulatta	185-198
17124044-5	2006	For patients treated with immunosuppressive therapy (IST), antithymocyte globulin (ATG) and cyclosporin (CSA) remain the standard regimen with excellent overall survival but less impressive failure-free survival due to nonresponse, relapse and later clonal disorders.	Cyclosporine	92-103	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	105-108
16622732-10	2006	Northern blot analysis revealed that the CsA-treated group showed an increase in the expression of OCN, OPN, and cathepsin K mRNAs on day 8 compared with the controls.	Cyclosporine	41-44	secreted phosphoprotein 1	Rattus norvegicus	104-107
16541194-1	2006	The effects of berberine (BBR) on the pharmacokinetics of ciclosporin A (CsA) were examined in healthy volunteers.	Cyclosporine	58-71	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	73-76
21114560-6	2011	There was a negative correlation between baseline uncorrected insulin AUC and trough serum log CsA concentrations (r = -0.70, P = 0.005).	Cyclosporine	95-98	insulin	Canis lupus familiaris	62-69
21281954-3	2011	CsA exhibited potent anti-JEV activity in various mammalian cell lines through the inhibition of CypB.	Cyclosporine	0-3	peptidylprolyl isomerase B	Homo sapiens	97-101
17705187-5	2007	Among these proteins, cyclophilin A (CypA), the major target for the potent immunosuppressive drug cyclosporin A, was found decreased in HBsAg positive transgenic mouse liver and in a stable cell line expressing HBsAg when compared to their controls.	Cyclosporine	99-112	peptidylprolyl isomerase A	Mus musculus	22-35
17705187-5	2007	Among these proteins, cyclophilin A (CypA), the major target for the potent immunosuppressive drug cyclosporin A, was found decreased in HBsAg positive transgenic mouse liver and in a stable cell line expressing HBsAg when compared to their controls.	Cyclosporine	99-112	peptidylprolyl isomerase A	Mus musculus	37-41
17651692-4	2007	CsA treatment dramatically reduced the mRNA levels of adipocyte-specific genes (aP2, HSL, PPARgamma, ACS and Adn), compared with control or TNFalpha-treatment, whereas Li(+) pretreatment blocked the inhibitory effects of CsA, and mRNA levels of aP2, HSL, PPARgamma, and ACS were found at or above control levels.	Cyclosporine	0-3	transcription factor AP-2 alpha	Homo sapiens	80-83
21262237-1	2011	AIMS: Cyclosporin A, a calcineurin inhibitor, produces neurotoxicity with relatively high frequency in organ-transplanted patients.	Cyclosporine	6-19	calcineurin binding protein 1	Homo sapiens	23-44
17651692-4	2007	CsA treatment dramatically reduced the mRNA levels of adipocyte-specific genes (aP2, HSL, PPARgamma, ACS and Adn), compared with control or TNFalpha-treatment, whereas Li(+) pretreatment blocked the inhibitory effects of CsA, and mRNA levels of aP2, HSL, PPARgamma, and ACS were found at or above control levels.	Cyclosporine	0-3	lipase E, hormone sensitive type	Homo sapiens	85-88
17651692-4	2007	CsA treatment dramatically reduced the mRNA levels of adipocyte-specific genes (aP2, HSL, PPARgamma, ACS and Adn), compared with control or TNFalpha-treatment, whereas Li(+) pretreatment blocked the inhibitory effects of CsA, and mRNA levels of aP2, HSL, PPARgamma, and ACS were found at or above control levels.	Cyclosporine	0-3	transcription factor AP-2 alpha	Homo sapiens	245-248
17651692-4	2007	CsA treatment dramatically reduced the mRNA levels of adipocyte-specific genes (aP2, HSL, PPARgamma, ACS and Adn), compared with control or TNFalpha-treatment, whereas Li(+) pretreatment blocked the inhibitory effects of CsA, and mRNA levels of aP2, HSL, PPARgamma, and ACS were found at or above control levels.	Cyclosporine	0-3	lipase E, hormone sensitive type	Homo sapiens	250-253
17889127-8	2007	At 3 months" posttransplant, patients treated with CyA showed significantly higher levels of IL-6 (P = .05), SAA (P = .03), and sIL-2R (P = .008) compared with patients treated with TC.	Cyclosporine	51-54	serum amyloid A1 cluster	Homo sapiens	109-112
17889127-12	2007	CONCLUSIONS: Patients treated with CyA displayed significantly higher levels of inflammatory markers (IL-6, SAA, sIL-2R) at 3 and 12 months" posttransplantation, independent of age, gender, time on dialysis, diabetes mellitus (preRT and de novo postRT), and renal function measured by serum creatinine.	Cyclosporine	35-38	serum amyloid A1 cluster	Homo sapiens	108-111
21393977-0	2011	Primary cutaneous CD30+ lymphoproliferative disorder in an atopic dermatitis patient on cyclosporine therapy.	Cyclosporine	88-100	TNF receptor superfamily member 8	Homo sapiens	18-22
17612897-6	2007	PBM CD80 expression was significantly inhibited in CSA-treated animals, but increased in Dex-treated animals.	Cyclosporine	51-54	Cd80 molecule	Rattus norvegicus	4-8
20813770-0	2011	Angiotensin II blockade upregulates the expression of Klotho, the anti-ageing gene, in an experimental model of chronic cyclosporine nephropathy.	Cyclosporine	120-132	klotho	Mus musculus	54-60
20813770-3	2011	This study evaluated the association between Klotho expression and RAS in cyclosporine (CsA)-induced renal injury.	Cyclosporine	74-86	klotho	Mus musculus	45-51
20813770-3	2011	This study evaluated the association between Klotho expression and RAS in cyclosporine (CsA)-induced renal injury.	Cyclosporine	88-91	klotho	Mus musculus	45-51
20813770-8	2011	RESULTS: CsA treatment decreased Klotho mRNA and protein in mouse kidney in a dose-dependent and time-dependent manner, but a concurrent treatment with losartan, an angiotensin II type 1 (AT1) receptor blocker, reversed the decrease in Klotho expression with histological improvement.	Cyclosporine	9-12	klotho	Mus musculus	33-39
20813770-8	2011	RESULTS: CsA treatment decreased Klotho mRNA and protein in mouse kidney in a dose-dependent and time-dependent manner, but a concurrent treatment with losartan, an angiotensin II type 1 (AT1) receptor blocker, reversed the decrease in Klotho expression with histological improvement.	Cyclosporine	9-12	klotho	Mus musculus	236-242
21343581-3	2011	Many younger patients who respond to immunosuppressive therapy with drugs such as antithymocyte globulin and cyclosporine have clonal expansions of cytotoxic CD8(+) T cells that suppress normal hematopoiesis, as well as expansion of CD4(+) helper T-cell subsets that promote and sustain autoimmunity.	Cyclosporine	109-121	CD8a molecule	Homo sapiens	158-161
21084295-7	2011	Increase in intracellular concentration of Ca(2+) leads to rapid translocation of eIF6 from the cytoplasm to the nucleus, an event that is blocked by specific calcineurin inhibitors cyclosporin A or FK520.	Cyclosporine	182-195	eukaryotic translation initiation factor 6	Homo sapiens	82-86
21365122-6	2011	Splenocytes from autologous MSC-plus-CsA-treated rats exhibited a reduced mixed lymphocyte reaction (MLR)-proliferative response to donor stimulators and increased interleukin (IL)-10 release.	Cyclosporine	37-40	interleukin 10	Homo sapiens	164-183
21365122-8	2011	The use of autologous MSC-plus-CsA downregulated immune responses, inducing donor-specific T-cell hyporesponsiveness by reducing the production of proinflammatory cytokines and inducing antiinflammatory cytokine production, especially that of IL-10, during the early posttransplantation period.	Cyclosporine	31-34	interleukin 10	Homo sapiens	243-248
21391435-1	2011	The aim of this study was to investigate whether Cyclosporin-A (CsA)-induced myocardial injury is mediated by elevating the intracellular calcium concentration ([Ca2+]i) through the Calcium sensing receptor (CaSR).	Cyclosporine	49-62	calcium-sensing receptor	Rattus norvegicus	182-206
21391435-1	2011	The aim of this study was to investigate whether Cyclosporin-A (CsA)-induced myocardial injury is mediated by elevating the intracellular calcium concentration ([Ca2+]i) through the Calcium sensing receptor (CaSR).	Cyclosporine	49-62	calcium-sensing receptor	Rattus norvegicus	208-212
21391435-1	2011	The aim of this study was to investigate whether Cyclosporin-A (CsA)-induced myocardial injury is mediated by elevating the intracellular calcium concentration ([Ca2+]i) through the Calcium sensing receptor (CaSR).	Cyclosporine	64-67	calcium-sensing receptor	Rattus norvegicus	182-206
21391435-1	2011	The aim of this study was to investigate whether Cyclosporin-A (CsA)-induced myocardial injury is mediated by elevating the intracellular calcium concentration ([Ca2+]i) through the Calcium sensing receptor (CaSR).	Cyclosporine	64-67	calcium-sensing receptor	Rattus norvegicus	208-212
21391435-6	2011	CaSR mRNA and protein expression increased at 4 h after CsA treatment.	Cyclosporine	56-59	calcium-sensing receptor	Rattus norvegicus	0-4
21391435-10	2011	Moreover, CsA-induced cardiomyocyte injury was related to CaSR-mediated intracellular calcium overload.	Cyclosporine	10-13	calcium-sensing receptor	Rattus norvegicus	58-62
22194945-5	2011	We showed that CsA induced TGF-beta1 and decreased MMP-9 expression dose-dependently in fragments of human AAAs in vitro, and in animal models of AAA in vivo.	Cyclosporine	15-18	matrix metallopeptidase 9	Homo sapiens	51-56
21980535-3	2011	Kidney androgen-regulated protein (KAP) is exclusively expressed in kidney proximal tubule cells, interacts with the CsA-binding protein cyclophilin B and its expression diminishes in kidneys of CsA-treated mice.	Cyclosporine	117-120	peptidylprolyl isomerase B	Mus musculus	137-150
21901144-5	2011	The up-regulated levels of IL-10 and GM-CSF, increased expression of genes characteristic for the alternative and pro-invasive phenotype (arg-1, mt1-mmp, cxcl14) in glioma-derived CD11b(+) cells as well as enhanced angiogenesis and tumor growth were reduced in CsA-treated mice.	Cyclosporine	261-264	integrin subunit alpha M	Homo sapiens	180-185
21028918-7	2010	Nearly all regimens include a calcineurin inhibitor (either ciclosporin [cyclosporine] or tacrolimus).	Cyclosporine	60-71	calcineurin binding protein 1	Homo sapiens	30-51
21068647-8	2010	In the cyclosporine group, two equations demonstrated the highest predictive power, one that used four time points in the first 6 hours postdose (r2 = 0.84, MPPE 1.6%, MAPE 7.8%) and one that used four time points in the first 4 hours postdose (r2 = 0.76, MPPE -0.8%, MAPE 10.2%).	Cyclosporine	7-19	metallophosphoesterase 1	Homo sapiens	157-163
17392048-8	2007	Treating osteoblasts with low concentrations of CsA (&lt;1 microM) increases fra-2 gene expression and protein levels in a dose-dependent manner as well as AP-1 DNA-binding activity.	Cyclosporine	48-51	FOS like 2, AP-1 transcription factor subunit	Homo sapiens	77-82
16586042-0	2007	Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis.	Cyclosporine	15-29	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	148-153
16586042-1	2007	In the present study, we aimed to determine whether tacrolimus (FK506) and cyclosporine A act directly on human osteoclast precursors obtained from patients with rheumatoid arthritis (RA) and influence monocyte-osteoclast differentiation induced by receptor activator of NF-kappaB ligand (RANKL) in vitro, the stage at which differentiation was affected and the manner in which tacrolimus or cyclosporine A affected the osteoclast signaling pathway.	Cyclosporine	75-89	TNF superfamily member 11	Homo sapiens	249-287
16586042-1	2007	In the present study, we aimed to determine whether tacrolimus (FK506) and cyclosporine A act directly on human osteoclast precursors obtained from patients with rheumatoid arthritis (RA) and influence monocyte-osteoclast differentiation induced by receptor activator of NF-kappaB ligand (RANKL) in vitro, the stage at which differentiation was affected and the manner in which tacrolimus or cyclosporine A affected the osteoclast signaling pathway.	Cyclosporine	75-89	TNF superfamily member 11	Homo sapiens	289-294
16586042-6	2007	Addition of tacrolimus or cyclosporine A resulted in a decrease in the number of TRAP-positive multinucleated cells (TRAP+ MNCs) and a decrease in the extent of lacunar resorption pit formation as compared to the control cultures; thus, human monocyte-osteoclast differentiation was more effectively inhibited at the late stage and addition of tacrolimus or cyclosporine A resulted in a decrease in the mRNA expression of NFATc1, c-Jun, and MITF at the late stage.	Cyclosporine	26-40	nuclear factor of activated T cells 1	Homo sapiens	422-428
16586042-6	2007	Addition of tacrolimus or cyclosporine A resulted in a decrease in the number of TRAP-positive multinucleated cells (TRAP+ MNCs) and a decrease in the extent of lacunar resorption pit formation as compared to the control cultures; thus, human monocyte-osteoclast differentiation was more effectively inhibited at the late stage and addition of tacrolimus or cyclosporine A resulted in a decrease in the mRNA expression of NFATc1, c-Jun, and MITF at the late stage.	Cyclosporine	26-40	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	430-435
16586042-7	2007	Our results suggest that tacrolimus or cyclosporine A acts directly on human osteoclast precursors in RA patients and exerts their immunosuppressive effects on human monocyte-osteoclast formation via targeting both the calcineurin-dependent NFAT pathway and activation pathway for c-Jun or MITF.	Cyclosporine	39-53	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	281-286
17490541-7	2007	After treatment with cyclosporine A, 9 out of 11 patients got good response, and CD3(+), CD8(+) cells in the responding patient decreased, the ratio of CD4(+)/CD8(+) returned to normal, and gammadelta T cells also decreased to normal range.	Cyclosporine	21-35	CD8a molecule	Homo sapiens	89-92
17490541-7	2007	After treatment with cyclosporine A, 9 out of 11 patients got good response, and CD3(+), CD8(+) cells in the responding patient decreased, the ratio of CD4(+)/CD8(+) returned to normal, and gammadelta T cells also decreased to normal range.	Cyclosporine	21-35	CD8a molecule	Homo sapiens	159-162
17161467-0	2007	Cyclosporine A inhibits IL-15-induced IL-17 production in CD4+ T cells via down-regulation of PI3K/Akt and NF-kappaB.	Cyclosporine	0-14	interleukin 15	Homo sapiens	24-29
17161467-0	2007	Cyclosporine A inhibits IL-15-induced IL-17 production in CD4+ T cells via down-regulation of PI3K/Akt and NF-kappaB.	Cyclosporine	0-14	interleukin 17A	Homo sapiens	38-43
17161467-1	2007	Cyclosporine A (CSA) has various biological effects on T cells, including inhibition of interleukin (IL)-15-induced IL-17 production in CD4+ T cells from patients with rheumatoid arthritis (RA).	Cyclosporine	0-14	interleukin 17A	Homo sapiens	116-121
17202802-4	2007	In addition, 20 muM cyclosporine inhibited CYP2C19 and CYP2D6 activities by 29% and 30%, respectively.	Cyclosporine	20-32	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	43-50
16997418-1	2006	Aerosolized cyclosporine was the first calcineurin inhibitor to be developed for inhaled administration.	Cyclosporine	12-24	calcineurin binding protein 1	Homo sapiens	39-60
16939683-0	2006	Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporin A absorption, and effect of dexamethasone in small intestine of mice.	Cyclosporine	60-73	phosphoglycolate phosphatase	Mus musculus	32-46
16939683-0	2006	Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporin A absorption, and effect of dexamethasone in small intestine of mice.	Cyclosporine	60-73	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	51-56
16939683-1	2006	We examined whether the oral bioavailability of cyclosporin A is controlled primarily by P-glycoprotein (P-gp) or CYP3A in the small intestine.	Cyclosporine	48-61	phosphoglycolate phosphatase	Mus musculus	89-103
16939683-1	2006	We examined whether the oral bioavailability of cyclosporin A is controlled primarily by P-glycoprotein (P-gp) or CYP3A in the small intestine.	Cyclosporine	48-61	phosphoglycolate phosphatase	Mus musculus	105-109
16939683-8	2006	These results suggest that, under physiological conditions, the oral bioavailability of cyclosporin A is mainly controlled by CYP3A in the upper intestine, rather than liver, but when P-gp is induced by steroid, the intestinal absorption of cyclosporin A may be inhibited.	Cyclosporine	88-101	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	126-131
16939683-8	2006	These results suggest that, under physiological conditions, the oral bioavailability of cyclosporin A is mainly controlled by CYP3A in the upper intestine, rather than liver, but when P-gp is induced by steroid, the intestinal absorption of cyclosporin A may be inhibited.	Cyclosporine	88-101	phosphoglycolate phosphatase	Mus musculus	184-188
16939683-8	2006	These results suggest that, under physiological conditions, the oral bioavailability of cyclosporin A is mainly controlled by CYP3A in the upper intestine, rather than liver, but when P-gp is induced by steroid, the intestinal absorption of cyclosporin A may be inhibited.	Cyclosporine	241-254	phosphoglycolate phosphatase	Mus musculus	184-188
16716285-9	2006	An apparent rise in the activities of N-acetyl-beta-D-glucosaminidase, beta-glucuronidase and cathepsin D were seen in the renal tissue of CsA given rats, which were reversed upon treatment with LA.	Cyclosporine	139-142	glucuronidase, beta	Rattus norvegicus	71-89
17056460-0	2006	Combined low dose cyclosporine and prednisone down-regulate natural killer cell-like effector functions of CD8brightCD56+ T cells in patients with active Behcet uveitis.	Cyclosporine	18-30	CD8a molecule	Homo sapiens	107-110
17056460-1	2006	PURPOSE: To investigate the changes of effector-related phenotypic markers and the natural killer (NK)-like effector functions of CD8(bright)CD56+ T cells in patients with Behcet uveitis after combined cyclosporine and prednisone (Cs/Pd) treatment.	Cyclosporine	202-214	CD8a molecule	Homo sapiens	130-133
16880206-3	2006	Here, we report that Fyn, NFAT, and ERK signaling influence ICOS expression as various chemical inhibitors, such as PP2 that targets Src kinases, U0126 that targets MEK1/2, and cyclosporin A or FK506 that targets calcineurin and thereby affects NFAT, attenuate T cell receptor-mediated ICOS induction.	Cyclosporine	177-190	Fyn proto-oncogene	Mus musculus	21-24
16880206-3	2006	Here, we report that Fyn, NFAT, and ERK signaling influence ICOS expression as various chemical inhibitors, such as PP2 that targets Src kinases, U0126 that targets MEK1/2, and cyclosporin A or FK506 that targets calcineurin and thereby affects NFAT, attenuate T cell receptor-mediated ICOS induction.	Cyclosporine	177-190	inducible T cell co-stimulator	Mus musculus	60-64
16670920-0	2006	Elevated gene expression of MMP-1, MMP-10, and TIMP-1 reveal changes of molecules involved in turn-over of extracellular matrix in cyclosporine-induced gingival overgrowth.	Cyclosporine	131-143	matrix metallopeptidase 10	Homo sapiens	35-41
16815483-9	2006	Cyclosporin A (CsA), an indirect inhibitor of protein phosphatase 2B (PP2B) and a potential inhibitor of ABC transporter A1 (ABCA1), suppressed all of these apoA-I-induced cellular events.	Cyclosporine	0-13	ATP binding cassette subfamily A member 1	Rattus norvegicus	105-123
16815483-9	2006	Cyclosporin A (CsA), an indirect inhibitor of protein phosphatase 2B (PP2B) and a potential inhibitor of ABC transporter A1 (ABCA1), suppressed all of these apoA-I-induced cellular events.	Cyclosporine	0-13	ATP binding cassette subfamily A member 1	Rattus norvegicus	125-130
16815483-9	2006	Cyclosporin A (CsA), an indirect inhibitor of protein phosphatase 2B (PP2B) and a potential inhibitor of ABC transporter A1 (ABCA1), suppressed all of these apoA-I-induced cellular events.	Cyclosporine	15-18	ATP binding cassette subfamily A member 1	Rattus norvegicus	105-123
16815483-9	2006	Cyclosporin A (CsA), an indirect inhibitor of protein phosphatase 2B (PP2B) and a potential inhibitor of ABC transporter A1 (ABCA1), suppressed all of these apoA-I-induced cellular events.	Cyclosporine	15-18	ATP binding cassette subfamily A member 1	Rattus norvegicus	125-130
16815483-12	2006	CsA thus interferes with cellular cholesterol homeostasis independently of PP2B inhibition, perhaps by direct inhibition of ABCA1 reactivity to exogenous apoA-I, although PP2B may be involved in the lipid release step.	Cyclosporine	0-3	ATP binding cassette subfamily A member 1	Rattus norvegicus	124-129
16980037-1	2006	OBJECTIVES: Transforming growth factor-beta(1) (TGF-beta(1)) and its receptors, type 1 (TR-1) and type 2 (TR-2) play important roles in chronic cyclosporine (CsA)-induced nephropathy.	Cyclosporine	144-156	transmembrane protein with EGF-like and two follistatin-like domains 1	Rattus norvegicus	88-92
16980037-1	2006	OBJECTIVES: Transforming growth factor-beta(1) (TGF-beta(1)) and its receptors, type 1 (TR-1) and type 2 (TR-2) play important roles in chronic cyclosporine (CsA)-induced nephropathy.	Cyclosporine	158-161	transmembrane protein with EGF-like and two follistatin-like domains 1	Rattus norvegicus	88-92
16980037-4	2006	Therefore, in this study we assessed the effects of Lotensin or Salviae on the chronic CsA-induced upregulation of TGF-beta(1), TR-1, and TR-2 in a rat model.	Cyclosporine	87-90	transmembrane protein with EGF-like and two follistatin-like domains 1	Rattus norvegicus	128-132
16980037-7	2006	The proteins of TGF-beta(1), TR-1, and TR-2, and the mRNA of TR-1 and TR-2 in the kidneys of CsA-treated rats, were measured by immunohistochemistry (IHC) and in situ hybridization (ISH).	Cyclosporine	93-96	transmembrane protein with EGF-like and two follistatin-like domains 1	Rattus norvegicus	61-65
16980051-0	2006	Comparison of cyclosporine versus mycophenolate mofetil on expression of Fractalkine and CX3CR1 in chronic allograft nephropathy.	Cyclosporine	14-26	C-X3-C motif chemokine receptor 1	Rattus norvegicus	89-95
16980051-1	2006	INTRODUCTION: We sought to investigate whether there was a difference between cyclosporine (CsA) and mycophenolate mofetil (MMF) to affect the expression of Fractalkine/CX3CR1 in chronic allograft nephropathy (CAN).	Cyclosporine	78-90	C-X3-C motif chemokine receptor 1	Rattus norvegicus	169-175
16980051-1	2006	INTRODUCTION: We sought to investigate whether there was a difference between cyclosporine (CsA) and mycophenolate mofetil (MMF) to affect the expression of Fractalkine/CX3CR1 in chronic allograft nephropathy (CAN).	Cyclosporine	92-95	C-X3-C motif chemokine receptor 1	Rattus norvegicus	169-175
16980051-11	2006	The expression of Fractalkine/CX3CR1 in grafted kidneys at all the time points was significantly less in the MMF than in the CsA group or the control group (P &lt; .05).	Cyclosporine	125-128	C-X3-C motif chemokine receptor 1	Rattus norvegicus	30-36
16885564-4	2006	Among 12 distinct proteins that exhibited 4-fold differences in expression on comparison of the two infected cell lysates, cyclophilin A, the intracellular reporter of the immunosuppressive drug cyclosporine A, showed a remarkably decreased protein level in cells infected with Ad-FHIT-wt versus Ad-FHIT-Y114F.	Cyclosporine	195-209	peptidylprolyl isomerase A	Mus musculus	123-136
16885564-7	2006	Interestingly, Fhit down-modulation of phosphatase activity of calcineurin, which controls cyclin D1/Cdk4 activation, was reversed by cyclophilin A treatment in a concentration-dependent manner, a reversal that was inhibited by additional cyclosporine A treatment.	Cyclosporine	239-253	peptidylprolyl isomerase A	Mus musculus	134-147
16803872-4	2006	Moreover, TNF-alpha-induced anchorage-independent cell growth was significantly inhibited by NFAT3 siRNA and cyclosporine A, a chemical inhibitor for the calcineurin/NFAT pathway, which suggests the importance of NFAT3 in regulating TNF-alpha-induced anchorage-independent cell growth.	Cyclosporine	109-123	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 4	Mus musculus	213-218
16252067-0	2006	Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp).	Cyclosporine	0-14	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	140-154
16252067-0	2006	Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp).	Cyclosporine	0-14	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	156-160
16252067-0	2006	Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp).	Cyclosporine	16-19	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	140-154
16252067-0	2006	Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp).	Cyclosporine	16-19	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	156-160
16252067-7	2006	These results pointed to a pharmacokinetic drug interaction between CsA and amisulpride most likely caused by inhibition of P-gp.	Cyclosporine	68-71	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	124-128
16704652-2	2006	OBJECTIVES: To elucidate the role of IL-12 in the pathogenesis of psoriasis and to study the effect of ciclosporin A (CsA) on Th1 deviation of this disease.	Cyclosporine	103-116	negative elongation factor complex member C/D	Homo sapiens	126-129
16704652-2	2006	OBJECTIVES: To elucidate the role of IL-12 in the pathogenesis of psoriasis and to study the effect of ciclosporin A (CsA) on Th1 deviation of this disease.	Cyclosporine	118-121	negative elongation factor complex member C/D	Homo sapiens	126-129
16704652-8	2006	CONCLUSIONS: Our results suggest that IL-12 production by monocytes may have a critical role in the pathogenesis of psoriasis, and that the therapeutic effect of CsA on psoriasis may be achieved by correcting the deviation of the Th1/Th2 balance.	Cyclosporine	162-165	negative elongation factor complex member C/D	Homo sapiens	230-233
16797290-0	2006	Urinary transforming growth factor-beta-induced gene-h3 (betaig-h3) as a sensitive predictor in chronic cyclosporine nephrotoxicity.	Cyclosporine	104-116	transforming growth factor beta induced	Homo sapiens	57-66
16797290-9	2006	Urinary betaig-h3 levels decreased from 173.4+/-26.0 to 64.9+/-14.4 ng/mg creatinine at 1 month after discontinuation of CyA or reduction in CyA dosage (P&lt;.01) despite unchanged serum creatinine levels.	Cyclosporine	121-124	transforming growth factor beta induced	Homo sapiens	8-17
16797290-9	2006	Urinary betaig-h3 levels decreased from 173.4+/-26.0 to 64.9+/-14.4 ng/mg creatinine at 1 month after discontinuation of CyA or reduction in CyA dosage (P&lt;.01) despite unchanged serum creatinine levels.	Cyclosporine	141-144	transforming growth factor beta induced	Homo sapiens	8-17
16671876-9	2006	CONCLUSIONS: CsA treatment reduced the production of E-cadherin but increased the production of beta-catenin, Cyclin D1, and PCNA.	Cyclosporine	13-16	proliferating cell nuclear antigen	Rattus norvegicus	125-129
16643797-7	2006	CONCLUSION: CsA can inhibit the expressions of CD25 and CD69 on splenocytes, as well as INF-gamma production by splenocytes in a dose dependent manner.	Cyclosporine	12-15	interleukin 2 receptor, alpha chain	Mus musculus	47-51
16584346-9	2006	In vivo: higher mRNA and protein expressions of EGF and EGF-R were also observed in the gingival tissues of CsA-treated rats.	Cyclosporine	108-111	epidermal growth factor receptor	Rattus norvegicus	56-61
16428077-5	2006	Cyclosporin treatment increased caspase 3 activity, hematocrit and osmolality, while urinary protein, creatinine and uric acid were unaltered.	Cyclosporine	0-11	caspase 3	Mus musculus	32-41
16467444-1	2006	The calcineurin inhibitor cyclosporine (CsA) induces a fibrogenic response that may lead to scarring of the renal allograft.	Cyclosporine	26-38	calcineurin binding protein 1	Homo sapiens	4-25
16272406-9	2006	Although CsA can inhibit Mrp2, our data suggest that it may also inhibit the hepatic glucuronidation of MPA in Wistar rats.	Cyclosporine	9-12	ATP binding cassette subfamily C member 2	Rattus norvegicus	25-29
16356829-4	2006	Cyclosporin A (MRP2 inhibitor) but not PSC833 (P-gp inhibitor) showed a similar effect on PhIP transport.	Cyclosporine	0-13	ATP binding cassette subfamily C member 2	Homo sapiens	15-19
16546941-0	2006	The relationship between proliferating cell nuclear antigen expression and histomorphometrical alterations in cyclosporin A-induced gingival overgrowth in rats.	Cyclosporine	110-123	proliferating cell nuclear antigen	Rattus norvegicus	25-59
16546941-1	2006	The aim of this study was to investigate the relationship between Proliferating Cell Nuclear Antigen (PCNA) expression and histomorphometrical alterations in cyclosporin A (CsA)-induced gingival overgrowth with or without microbial dental plaque accumulation.	Cyclosporine	158-171	proliferating cell nuclear antigen	Rattus norvegicus	66-100
16546941-1	2006	The aim of this study was to investigate the relationship between Proliferating Cell Nuclear Antigen (PCNA) expression and histomorphometrical alterations in cyclosporin A (CsA)-induced gingival overgrowth with or without microbial dental plaque accumulation.	Cyclosporine	158-171	proliferating cell nuclear antigen	Rattus norvegicus	102-106
16546941-1	2006	The aim of this study was to investigate the relationship between Proliferating Cell Nuclear Antigen (PCNA) expression and histomorphometrical alterations in cyclosporin A (CsA)-induced gingival overgrowth with or without microbial dental plaque accumulation.	Cyclosporine	173-176	proliferating cell nuclear antigen	Rattus norvegicus	66-100
16546941-1	2006	The aim of this study was to investigate the relationship between Proliferating Cell Nuclear Antigen (PCNA) expression and histomorphometrical alterations in cyclosporin A (CsA)-induced gingival overgrowth with or without microbial dental plaque accumulation.	Cyclosporine	173-176	proliferating cell nuclear antigen	Rattus norvegicus	102-106
16259758-5	2005	In the presence of ciclosporin and verapamil, potent inhibitors of P-glycoprotein (P-gp)/MRP2, the absorptive transport was enhanced and secretory efflux was diminished.	Cyclosporine	19-30	ATP binding cassette subfamily C member 2	Homo sapiens	89-93
16307158-8	2005	Moreover, in favour of non-endotoxin-mediated white cell activation, the calcineurin inhibitor, cyclosporin-A, which did not alter endotoxin-induced TNF-alpha production, decreased TNF-alpha produced by unstimulated cultured cells in patients to values not significantly greater than those in controls.	Cyclosporine	96-109	calcineurin binding protein 1	Homo sapiens	73-94
16041025-10	2005	The IFN-gamma-inducing effect of NcAg was blocked by cyclosporine, a specific ligand for CyP, in a dose-dependent manner.	Cyclosporine	53-65	interferon gamma	Bos taurus	4-13
16041025-11	2005	Furthermore, cyclosporine abolished IFN-gamma production by PBMC from naive cows as well as PBMC and CD4(+) T cells from infected/immunized cows.	Cyclosporine	13-25	interferon gamma	Bos taurus	36-45
16027085-1	2005	OBJECTIVE: To observe the effects of cyclosporin A (CsA) on gene expression profiles of NIT-1 pancreatic beta cells cell line using microarray technique.	Cyclosporine	52-55	nitrilase 1	Mus musculus	88-93
16027085-6	2005	CONCLUSIONS: CsA treatment for 24 h induces changes in the gene expression profiles of NIT-1 pancreatic beta cells.	Cyclosporine	13-16	nitrilase 1	Mus musculus	87-92
15972687-6	2005	Blocking cyclophilin-CD147 interactions by targeting CD147 (using anti-CD147 Ab) or cyclophilin (using nonimmunosuppressive cyclosporine A analog) reduced tissue neutrophilia by up to 50%, with a concurrent decrease in tissue pathology.	Cyclosporine	124-138	basigin	Mus musculus	21-26
16495873-2	2006	Patients who undergo a renal transplant also require a pharmacological immunosuppressor therapy with cyclosporine (CsA) as well as anti-hypertensive calcium channel-blockers (CCBs); the former suppresses interferon and interleukin-2 production thus interfering with T cell cell-mediated activity, while the latter are used in order to counteract the nephrotoxicity of CsA which causes the local release, of thromboxane A2 with vascular vasoconstriction in the kidney.	Cyclosporine	101-113	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	115-118
16321613-8	2005	RESULTS: At visit 1, cyclosporine-treated patients had significantly enhanced CD62P and PAC1 expression and platelet-leukocyte aggregate formation, as well as elevated sCD40L concentrations, compared with tacrolimus-treated patients (all P &lt; .03).	Cyclosporine	21-33	dual specificity phosphatase 2	Homo sapiens	88-92
16107580-1	2005	Cyclosporine A (CsA) and tacrolimus have been associated with an increased risk for diabetes after transplantation, whereas sirolimus is deemed to be devoid of any effect on glucose metabolism.	Cyclosporine	0-14	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	16-19
16030052-13	2005	CsA-induced EMT was also associated with increased expression of connective tissue growth factor (CTGF) suggesting that this molecule may serve as downstream mediator of TGF-beta1 pro-fibrotic activity in this setting.	Cyclosporine	0-3	cellular communication network factor 2	Homo sapiens	65-96
16030052-13	2005	CsA-induced EMT was also associated with increased expression of connective tissue growth factor (CTGF) suggesting that this molecule may serve as downstream mediator of TGF-beta1 pro-fibrotic activity in this setting.	Cyclosporine	0-3	cellular communication network factor 2	Homo sapiens	98-102
16223670-10	2005	RESULTS: CyA-treated ATX and euthymic control mice showed good engraftment of the allogeneic thymic tissue at the time of exploratory laparotomy, whereas non-CyA-treated ATX and euthymic controls had rejected the grafts.	Cyclosporine	9-12	diencephalon/mesencephalon homeobox 1	Mus musculus	21-24
16223670-10	2005	RESULTS: CyA-treated ATX and euthymic control mice showed good engraftment of the allogeneic thymic tissue at the time of exploratory laparotomy, whereas non-CyA-treated ATX and euthymic controls had rejected the grafts.	Cyclosporine	9-12	diencephalon/mesencephalon homeobox 1	Mus musculus	170-173
16298579-1	2005	Cyclosporine A (CsA) is one of the keystones in immunosuppressive treatment after solid organ transplantation, despite its major side effects such as nephrotoxicity.	Cyclosporine	0-14	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	16-19
16128906-9	2005	There was a significant decrease (P&lt;0.05) in erythrocyte GSH concentration and G6PD activity in cyclosporine A animals.	Cyclosporine	99-113	glucose-6-phosphate dehydrogenase	Rattus norvegicus	82-86
15890444-2	2005	In chronically cannulated rats, microinjection of the calcineurin selective inhibitor cyclosporin A increased phosphorylation of NMDAR NR1 subunits at serine 896 and serine 897 in the injected dorsal striatum.	Cyclosporine	86-99	glutamate ionotropic receptor NMDA type subunit 1	Rattus norvegicus	135-138
16182762-1	2005	BACKGROUND: Basiliximab, a chimeric monoclonal antibody (mAb) directed against the alpha chain of the interleukin-2 (IL-2) receptor (CD25), has been extensively evaluated as induction therapy for kidney transplant recipients, more frequently in combination with a cyclosporine-based regimen.	Cyclosporine	264-276	interleukin 2 receptor subunit beta	Homo sapiens	117-131
16182762-1	2005	BACKGROUND: Basiliximab, a chimeric monoclonal antibody (mAb) directed against the alpha chain of the interleukin-2 (IL-2) receptor (CD25), has been extensively evaluated as induction therapy for kidney transplant recipients, more frequently in combination with a cyclosporine-based regimen.	Cyclosporine	264-276	interleukin 2 receptor subunit alpha	Homo sapiens	133-137
15940041-6	2005	Increased levels of angiotensin II, intrarenal CRP, osteopontin, and TGF-beta1 in CsA-treated rat kidney were reduced by treatment with either LSRT or PRVT and were further decreased by the combination of the two drugs.	Cyclosporine	82-85	secreted phosphoprotein 1	Rattus norvegicus	52-63
16044913-0	2005	[Cyclosporin a induces titin expression in human trophoblast cells through the MEK/ERK1/2 signal pathway].	Cyclosporine	1-14	titin	Homo sapiens	23-28
16044913-1	2005	To investigate the role of MEK/ERK1/2 signal pathway in the regulation of cyclosporin A(CsA) -induced titin expression in human trophoblast cells.	Cyclosporine	74-87	titin	Homo sapiens	102-107
16044913-1	2005	To investigate the role of MEK/ERK1/2 signal pathway in the regulation of cyclosporin A(CsA) -induced titin expression in human trophoblast cells.	Cyclosporine	88-91	titin	Homo sapiens	102-107
16044913-5	2005	These results indicated that MEK/ERK1/2 signal pathway may play an important role in the expression of titin in human trophoblast induced by cyclosporin A.	Cyclosporine	141-154	titin	Homo sapiens	103-108
15809055-10	2005	Hsp72 protein levels were higher in FO (3.6-fold) and FO+CsA (5.2-fold) than Con rats, with the values being significantly higher in the FO+CsA than FO rats.	Cyclosporine	57-60	heat shock protein family A (Hsp70) member 1A	Rattus norvegicus	0-5
15809055-10	2005	Hsp72 protein levels were higher in FO (3.6-fold) and FO+CsA (5.2-fold) than Con rats, with the values being significantly higher in the FO+CsA than FO rats.	Cyclosporine	140-143	heat shock protein family A (Hsp70) member 1A	Rattus norvegicus	0-5
15880019-2	2005	These effects have been confirmed by clinical studies in which everolimus demonstrated comparable efficacy to azathioprine and mycophenolate mofetil in heart and renal transplantation, respectively, when combined with full-dose cyclosporine (CsA; Neoral).	Cyclosporine	228-240	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	242-245
15880022-4	2005	RESULTS: The first case study demonstrates that stable graft function can be achieved in an "old-for-old" kidney transplant patient, who receives everolimus in combination with reduced-exposure cyclosporine (CsA).	Cyclosporine	194-206	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	208-211
15849538-12	2005	ETA receptor expression in the aorta was increased after CsA treatment, but BH4 treatment prevented CsA-induced ETA over-expression (P=0.004).	Cyclosporine	57-60	endothelin receptor type A	Rattus norvegicus	0-3
15849538-12	2005	ETA receptor expression in the aorta was increased after CsA treatment, but BH4 treatment prevented CsA-induced ETA over-expression (P=0.004).	Cyclosporine	100-103	endothelin receptor type A	Rattus norvegicus	112-115
15710339-1	2005	Cyclosporin A (CsA) inhibits interleukin (IL)-2 production, activation and proliferation of human peripheral T cells (HPTC) costimulated with simultaneous engagement of T cell receptor (TCR)/CD3 and CD28.	Cyclosporine	15-18	CD28 molecule	Homo sapiens	199-203
15710339-2	2005	We demonstrated that 10 ng/ml CsA, which reduced the proliferation of HPTC costimulated with anti-CD3 and anti-CD28 by half, prevented NF-AT and NF-kappaB from migrating into the nucleus.	Cyclosporine	30-33	CD28 molecule	Homo sapiens	111-115
15710339-4	2005	CsA, which was added to HPTC simultaneously with the engagement of both CD3 and CD28 or the 1-h-delayed engagement of CD28 after prior TCR/CD3-triggering, inhibited NF-kappaB p65/RelA from binding to the target DNA fragment, followed by reduction of HPTC proliferation in response to the costimulation.	Cyclosporine	0-3	CD28 molecule	Homo sapiens	80-84
15710339-4	2005	CsA, which was added to HPTC simultaneously with the engagement of both CD3 and CD28 or the 1-h-delayed engagement of CD28 after prior TCR/CD3-triggering, inhibited NF-kappaB p65/RelA from binding to the target DNA fragment, followed by reduction of HPTC proliferation in response to the costimulation.	Cyclosporine	0-3	CD28 molecule	Homo sapiens	118-122
15710339-4	2005	CsA, which was added to HPTC simultaneously with the engagement of both CD3 and CD28 or the 1-h-delayed engagement of CD28 after prior TCR/CD3-triggering, inhibited NF-kappaB p65/RelA from binding to the target DNA fragment, followed by reduction of HPTC proliferation in response to the costimulation.	Cyclosporine	0-3	RELA proto-oncogene, NF-kB subunit	Homo sapiens	175-178
15710339-4	2005	CsA, which was added to HPTC simultaneously with the engagement of both CD3 and CD28 or the 1-h-delayed engagement of CD28 after prior TCR/CD3-triggering, inhibited NF-kappaB p65/RelA from binding to the target DNA fragment, followed by reduction of HPTC proliferation in response to the costimulation.	Cyclosporine	0-3	RELA proto-oncogene, NF-kB subunit	Homo sapiens	179-183
15710339-5	2005	When CsA was added 30 min after the delayed engagement of CD28 following the prior engagement of TCR/CD3, these inhibitory effects were diminished.	Cyclosporine	5-8	CD28 molecule	Homo sapiens	58-62
15710339-6	2005	Antisense NF-kappaB p65/RelA oligonucleotides inhibited p65/RelA mRNA expression, diminished IL-2 mRNA expression in the costimulated HPTC and reduced HPTC proliferation to the same extent as CsA added simultaneously with the costimulation.	Cyclosporine	192-195	RELA proto-oncogene, NF-kB subunit	Homo sapiens	20-23
15710339-6	2005	Antisense NF-kappaB p65/RelA oligonucleotides inhibited p65/RelA mRNA expression, diminished IL-2 mRNA expression in the costimulated HPTC and reduced HPTC proliferation to the same extent as CsA added simultaneously with the costimulation.	Cyclosporine	192-195	RELA proto-oncogene, NF-kB subunit	Homo sapiens	24-28
15710339-6	2005	Antisense NF-kappaB p65/RelA oligonucleotides inhibited p65/RelA mRNA expression, diminished IL-2 mRNA expression in the costimulated HPTC and reduced HPTC proliferation to the same extent as CsA added simultaneously with the costimulation.	Cyclosporine	192-195	RELA proto-oncogene, NF-kB subunit	Homo sapiens	60-64
15710339-8	2005	These findings indicate that the major effects of CsA on the early phase of CD28-mediated costimulation in the presence of TCR/CD3 signaling are to inhibit NF-kappaB/RelA from translocating into the nucleus and binding to the target DNA sequence in the IL-2 gene promoter region, which induces IL-2 expression leading to HPTC proliferation.	Cyclosporine	50-53	CD28 molecule	Homo sapiens	76-80
15710339-8	2005	These findings indicate that the major effects of CsA on the early phase of CD28-mediated costimulation in the presence of TCR/CD3 signaling are to inhibit NF-kappaB/RelA from translocating into the nucleus and binding to the target DNA sequence in the IL-2 gene promoter region, which induces IL-2 expression leading to HPTC proliferation.	Cyclosporine	50-53	RELA proto-oncogene, NF-kB subunit	Homo sapiens	166-170
15734424-14	2005	This is the first demonstration of ERK 1/2 inhibition afforded by CSA.	Cyclosporine	66-69	mitogen activated protein kinase 3	Rattus norvegicus	35-42
15528977-4	2005	Peripheral blood mononuclear cell (PBMC) proliferation in the presence of L-778,123 and/or cyclosporine (CsA) was determined by [3H]thymidine incorporation.	Cyclosporine	91-103	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	105-108
16044165-5	2005	Computational dissection of these transcriptional profiles in activated T cells uncovers a novel regulatory synergy between IGF-1 and CD28 costimulation that modulates NF-kappaB and AP1 pathways through signaling cascades sensitive to cyclosporin A and wortmannin.	Cyclosporine	235-248	CD28 molecule	Homo sapiens	134-138
15516239-1	2004	BACKGROUND: Cyclosporine (CsA) is a widely used immunosuppressive agent in kidney transplant patients.	Cyclosporine	12-24	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	26-29
15319455-5	2004	On the other hand, cyclosporin A (a calcineurin-NFAT inhibitor) or EGTA (a calcium chelator) significantly blocked the depolarization-induced GHRH gene transcription.	Cyclosporine	19-32	nuclear factor of activated T-cells 5	Rattus norvegicus	48-52
15319455-5	2004	On the other hand, cyclosporin A (a calcineurin-NFAT inhibitor) or EGTA (a calcium chelator) significantly blocked the depolarization-induced GHRH gene transcription.	Cyclosporine	19-32	growth hormone releasing hormone	Rattus norvegicus	142-146
15572199-1	2004	Secretoneurin (SN) was detected in the aqueous humor (AH) of patients treated topically with tobramycine eye drops alone or tobramycine and cyclosporine A, tobramycine and diclofenac or tobramycine and rimexolone.	Cyclosporine	140-154	secretogranin II	Homo sapiens	0-13
15572199-1	2004	Secretoneurin (SN) was detected in the aqueous humor (AH) of patients treated topically with tobramycine eye drops alone or tobramycine and cyclosporine A, tobramycine and diclofenac or tobramycine and rimexolone.	Cyclosporine	140-154	secretogranin II	Homo sapiens	15-17
15383526-3	2004	Although cyclosporin A (CsA), an inhibitory ligand of cyclophilin A, is a widely used immunosuppressive drug, it causes arterial hypertension in part by impairing eNOS-dependent vasodilation.	Cyclosporine	9-22	peptidyl-prolyl cis-trans isomerase A	Bos taurus	54-67
15383526-3	2004	Although cyclosporin A (CsA), an inhibitory ligand of cyclophilin A, is a widely used immunosuppressive drug, it causes arterial hypertension in part by impairing eNOS-dependent vasodilation.	Cyclosporine	24-27	peptidyl-prolyl cis-trans isomerase A	Bos taurus	54-67
15383526-8	2004	However, CsA treatment decreased cholesterol content in caveolae and displaced eNOS from caveolae, which may be caused by CsA disrupting the association of caveolin-1 and cyclophilin A.	Cyclosporine	9-12	peptidyl-prolyl cis-trans isomerase A	Bos taurus	171-184
15383526-8	2004	However, CsA treatment decreased cholesterol content in caveolae and displaced eNOS from caveolae, which may be caused by CsA disrupting the association of caveolin-1 and cyclophilin A.	Cyclosporine	122-125	peptidyl-prolyl cis-trans isomerase A	Bos taurus	171-184
15599881-1	2004	Cyclosporine (CsA) has been the cornerstone of immunosuppression for organ transplantation since its introduction.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
15599881-5	2004	Moreover, the measurement of CsA at peak, around 2 hours after Neoral administration, proved to be a reliable index of the drug exposure, thus allowing efficient drug monitoring.	Cyclosporine	63-69	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	29-32
15684649-0	2004	Downregulation of amyloid precursor protein (APP) expression following post-traumatic cyclosporin-A administration.	Cyclosporine	86-99	amyloid-beta A4 protein	Ovis aries	18-43
15621114-2	2004	Blood levels of cyclosporine (CsA) necessary to avoid rejection may vary with different drug combinations.	Cyclosporine	16-28	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	30-33
15355478-0	2004	Cyclosporine treatment decreases the percentage of cutaneous lymphocyte antigen (CLA)(+)CD4(+) T cells in children with severe atopic dermatitis.	Cyclosporine	0-12	major histocompatibility complex, class II, DO alpha	Homo sapiens	61-79
15184995-1	2004	PURPOSE: To determine the response rate to 26-h continuous infusion cyclosporine A (CSA) combined with a fixed dose level of carboplatin (CBDCA) in patients with recurrent ovarian cancer, and to determine the effect of CSA on the pharmacokinetics of CBDCA.	Cyclosporine	68-82	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	84-87
15501456-2	2004	We showed that Curcumin is a potent inhibitor of Cyclosporin A resistant T cell CD28 co-stimulation pathway.	Cyclosporine	49-62	CD28 molecule	Homo sapiens	80-84
15363984-0	2004	Neuroprotective and neurotoxic effects of cyclosporine A on transient focal ischemia in mdr1a knockout mice.	Cyclosporine	42-56	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	88-93
15363984-1	2004	The proper dose of cyclosporine A as a neuroprotective agent was investigated using the middle cerebral artery occlusion model of mdr1a knockout mice.	Cyclosporine	19-33	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	130-135
21085665-1	2010	Cyclophilins (Cyps), the intracellular receptors for Cyclosporine A (CsA), are responsible for peptidyl-prolyl cis-trans isomerisation and for chaperoning several membrane proteins.	Cyclosporine	69-72	peptidylprolyl isomerase B	Homo sapiens	0-12
15531003-2	2004	In the past decade, immunosuppressive drugs such as cyclosporine (CsA) and cyclophosphamide have been introduced for the treatment of SRNS, but data on long-term clinical outcome (over years) are lacking.	Cyclosporine	52-64	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	66-69
15353287-1	2004	Cyclophilin (CyP) is a cytosolic receptor of immunosuppressive drug cyclosporin A (CsA).	Cyclosporine	68-81	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	83-86
21085665-9	2010	These data indicate that CypB through its interaction with Na/K-beta1 might regulate maturation and trafficking of the pump through the secretory pathway, offering new insights into the relationship between cyclophilins and the nephrotoxic effects of CsA.	Cyclosporine	251-254	peptidylprolyl isomerase B	Homo sapiens	25-29
15461875-3	2004	Cyclosporine (CsA) inhibits the proliferation and the IL-2 dependent expansion of T-lymphocytes.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
20852052-6	2010	In rabbit atrial myocytes, an overnight stimulation with endothelin-1, angiotensin II, and phenylephrine induced nuclear accumulation of NFATc1 that was sensitive to calcineurin inhibitors (cyclosporin A or inhibitor of NFAT-calcineurin association-6) and prevented by the IP(3) receptor inhibitor 2-aminoethoxydiphenyl borate.	Cyclosporine	190-203	endothelin-1	Oryctolagus cuniculus	57-69
20839931-9	2010	CsA but not the high-cholesterol diet induced significant elevation in MDA, protein carbonyl and CYP2E1 activities in the kidney.	Cyclosporine	0-3	cytochrome P450 2E1	Oryctolagus cuniculus	97-103
15864347-8	2005	A more profound attenuation of fibro-obliteration was seen when CXCR2(-/-) mice received cyclosporin A.	Cyclosporine	89-102	chemokine (C-X-C motif) receptor 2	Mus musculus	64-69
20839931-12	2010	CsA-enhanced rabbit kidney ROS and CYP2E1 activities.	Cyclosporine	0-3	cytochrome P450 2E1	Oryctolagus cuniculus	35-41
15919474-3	2005	In support of the induced-differentiation model, CD5 can be induced on spleen B-2 cells in vitro after stimulation via surface IgM receptors, an induction that is blocked by cyclosporine (CsA).	Cyclosporine	174-186	CD5 antigen	Mus musculus	49-52
21129263-8	2010	CsA lowers the abnormal activation of IFN-gamma/T-bet and IL-12/STAT4 pathways to correct Th1 hyperpolarization, which may reduce the abnormally activated cell-mediated immunity and relax hematopoietic depression of AA patients.	Cyclosporine	0-3	signal transducer and activator of transcription 4	Homo sapiens	64-69
15919474-3	2005	In support of the induced-differentiation model, CD5 can be induced on spleen B-2 cells in vitro after stimulation via surface IgM receptors, an induction that is blocked by cyclosporine (CsA).	Cyclosporine	188-191	CD5 antigen	Mus musculus	49-52
15919474-4	2005	We examined whether mouse peritoneal cavity CD5+ B-1a cells could be reduced by CsA/tacrolimus.	Cyclosporine	80-83	CD5 antigen	Mus musculus	44-47
15919474-6	2005	injection of various doses of CsA/tacrolimus decreased the percentage of PerC CD5+ B-1a cells and increased B-2 cells in a dose-dependent fashion.	Cyclosporine	30-33	CD5 antigen	Mus musculus	78-81
21129263-8	2010	CsA lowers the abnormal activation of IFN-gamma/T-bet and IL-12/STAT4 pathways to correct Th1 hyperpolarization, which may reduce the abnormally activated cell-mediated immunity and relax hematopoietic depression of AA patients.	Cyclosporine	0-3	negative elongation factor complex member C/D	Homo sapiens	90-93
20681522-5	2010	Binding of CsA to cyclophilins inhibits both PPIase and chaperone activities.	Cyclosporine	11-14	peptidylprolyl isomerase like 1	Homo sapiens	45-51
20795858-0	2010	Topical cyclosporine in thyroid orbitopathy-related dry eye: clinical findings, conjunctival epithelial apoptosis, and MMP-9 expression.	Cyclosporine	8-20	matrix metallopeptidase 9	Homo sapiens	119-124
15711594-0	2005	The immunosuppressive drugs cyclosporin A and tacrolimus inhibit membrane depolarization-induced CREB transcriptional activity at the coactivator level.	Cyclosporine	28-41	cAMP responsive element binding protein 1	Homo sapiens	97-101
20795858-15	2010	CONCLUSIONS: Topical CsA treatment appears to improve the signs and symptoms of dry eye and inhibits apoptosis and MMP-9 expression in conjunctival epithelial cells in TO-related dry eye patients after 2 months of treatment.	Cyclosporine	21-24	matrix metallopeptidase 9	Homo sapiens	115-120
20505521-0	2010	Role of PPAR gamma/nitric oxide synthase signaling in the cyclosporine-induced attenuation of endothelium-dependent renovascular vasodilation.	Cyclosporine	58-70	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	8-18
20505521-2	2010	This study investigated the role of peroxisome proliferator-activated receptor gamma (PPAR gamma)/nitric oxide synthase (NOS) signaling in the CSA-induced attenuation of endothelium-dependent vasodilations in phenylephrine-preconstricted perfused kidneys of rats.	Cyclosporine	143-146	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	36-84
20505521-2	2010	This study investigated the role of peroxisome proliferator-activated receptor gamma (PPAR gamma)/nitric oxide synthase (NOS) signaling in the CSA-induced attenuation of endothelium-dependent vasodilations in phenylephrine-preconstricted perfused kidneys of rats.	Cyclosporine	143-146	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	86-96
20663037-8	2010	Both PSP and ciclosporin blocked the reduction of the CD4/CD8 ratio in stimulated lymphocytes.	Cyclosporine	13-24	CD8a molecule	Homo sapiens	58-61
20571464-1	2010	Chronic calcineurin inhibitor (CNI)-induced nephrotoxicity is associated with prolonged use of cyclosporine and tacrolimus and has been observed after all types of transplantation, as well as during treatment of autoimmune disease.	Cyclosporine	95-107	calcineurin binding protein 1	Homo sapiens	8-29
20562737-7	2010	RESULTS: Treatment with CsA or FK alone significantly decreased KLOTHO expression and increased urinary 8-OHdG excretion compared with VH treatment but SRL treatment did not.	Cyclosporine	24-27	klotho	Mus musculus	64-70
20562737-8	2010	Treatment SRL+CsA or SRL+FK further decreased KLOTHO expression and increased urinary 8-OHdG excretion compared with treatment of CsA or FK alone.	Cyclosporine	14-17	klotho	Mus musculus	46-52
20562737-10	2010	Treatment of CsA or FK alone increased renal ectopic calcification and serum intact parathyroid hormone level and decreased renal FGF23 expression compared with VH treatment (P&lt;0.05) but SRL treatment did not.	Cyclosporine	13-16	fibroblast growth factor 23	Mus musculus	130-135
20489142-9	2010	Nifedipine- and cyclosporine A-induced gingival overgrowth tissues similarly contain diminished E-cadherin and elevated levels of FSP-1 and fibronectin, but normal levels of alphavbeta6 integrin.	Cyclosporine	16-30	S100 calcium binding protein A4	Homo sapiens	130-135
20583270-4	2010	We explored whether the transcription factor NFATc1, a direct as well as indirect target of CsA, can be used as a potential biomarker to determine the individual immunosuppressive activity of CsA.	Cyclosporine	92-95	nuclear factor of activated T cells 1	Homo sapiens	45-51
20583270-7	2010	We found that added CsA inhibits both the expression of NFATc1 and IL-2 in T cells of stimulated whole blood samples with IC(50) values of 200 and 150 nM, respectively.	Cyclosporine	20-23	nuclear factor of activated T cells 1	Homo sapiens	56-62
20583270-9	2010	Further experiments have to demonstrate whether the parallel cytometric measurement of NFATc1 and IL-2 in whole blood is a good predictor of individual CsA efficacy and toxicity in CsA-treated patients.	Cyclosporine	152-155	nuclear factor of activated T cells 1	Homo sapiens	87-93
20583270-9	2010	Further experiments have to demonstrate whether the parallel cytometric measurement of NFATc1 and IL-2 in whole blood is a good predictor of individual CsA efficacy and toxicity in CsA-treated patients.	Cyclosporine	181-184	nuclear factor of activated T cells 1	Homo sapiens	87-93
20565370-4	2010	Induction therapy was given to 94 patients (82.4%), and maintenance immunosuppression consisted of calcineurin inhibitor (cyclosporin microemulsion or tacrolimus), together with mycophenolate mofetil and prednisone.	Cyclosporine	122-133	calcineurin binding protein 1	Homo sapiens	99-120
20871770-9	2010	CONCLUSION: The findings of the present study suggest that CsA can modify the expression of TNF-alpha and RANTES in drug-induced human gingival overgrowth.	Cyclosporine	59-62	C-C motif chemokine ligand 5	Homo sapiens	106-112
15248059-1	2004	Clinical trials in adult liver and heart recipients have shown that management of cyclosporine (CsA) dose with 2-h levels (C2) leads to lower rejection rates and serum creatinine levels compared with C0 monitoring.	Cyclosporine	82-94	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	96-99
15526904-14	2004	HSP72, HSP47, and HSP25 were clearly induced and expressed in CsA-treated animals.	Cyclosporine	62-65	heat shock protein family A (Hsp70) member 1A	Rattus norvegicus	0-5
15526904-14	2004	HSP72, HSP47, and HSP25 were clearly induced and expressed in CsA-treated animals.	Cyclosporine	62-65	heat shock protein family B (small) member 1	Rattus norvegicus	18-23
20508866-3	2010	This study was designed to investigate the influence of cyclosporine A (CsA) on IL-17 production by peripheral blood mononuclear cells (PBMCs) from BD patients in vitro and in vivo.	Cyclosporine	56-70	interleukin 17A	Homo sapiens	80-85
20508866-3	2010	This study was designed to investigate the influence of cyclosporine A (CsA) on IL-17 production by peripheral blood mononuclear cells (PBMCs) from BD patients in vitro and in vivo.	Cyclosporine	72-75	interleukin 17A	Homo sapiens	80-85
20043941-5	2010	CsA-treatment resulted in a significant reduction of absolute numbers of circulating CD4(+) and CD8alpha(+) T-lymphocytes by up to 82 and 65%, respectively (P&lt;0.05).	Cyclosporine	0-3	CD8a molecule	Homo sapiens	96-104
15518736-13	2004	Patients who received cyclosporine (CSA), prednisone (Pred), and mycophenolate mofetil (MMF) showed better graft survival than ones on CSA, Pred, and azathioprine (Aza) (P = .18).	Cyclosporine	22-34	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	36-39
15736855-10	2005	The data indicate that CsA increased blood pressure, which may be due to decreased baroreceptor reflex sensitivity mediated via activation of the renin-angiotensin-aldosterone system.	Cyclosporine	23-26	renin	Canis lupus familiaris	146-151
20406686-8	2010	Naive CD8(+) T-lymphocytes increased versus baseline in the cyclosporine cohort at months 1 and 3, but remained unchanged with sirolimus.	Cyclosporine	60-72	CD8a molecule	Homo sapiens	6-9
15812357-6	2005	Verapamil, cyclosporine, known to reverse the MDR phenotype affects equally IM9-Vinc IM9-Tax and Im9 cells.	Cyclosporine	11-23	nuclear paraspeckle assembly transcript 1	Homo sapiens	80-84
15308100-1	2004	Cyclophilin A (CypA/Ppia) is a peptidyl-prolyl isomerase (PPIase) that binds the immunosuppressive drug cyclosporine.	Cyclosporine	104-116	peptidylprolyl isomerase (cyclophilin)-like 3	Mus musculus	31-56
15308100-1	2004	Cyclophilin A (CypA/Ppia) is a peptidyl-prolyl isomerase (PPIase) that binds the immunosuppressive drug cyclosporine.	Cyclosporine	104-116	peptidylprolyl isomerase (cyclophilin)-like 3	Mus musculus	58-64
15149317-0	2004	Electroporation-mediated HGF gene transfer ameliorated cyclosporine nephrotoxicity.	Cyclosporine	55-67	hepatocyte growth factor	Homo sapiens	25-28
20406686-10	2010	The proportion of memory CD8(+) T-lymphocytes decreased at months 1 and 3 compared to baseline in the CsA arm, but did not change in the sirolimus cohort.	Cyclosporine	102-105	CD8a molecule	Homo sapiens	25-28
15149317-1	2004	BACKGROUND: The clinical utility of cyclosporine A (CsA) has been limited by its nephrotoxicity, which is characterized by tubular atrophy, interstitial fibrosis, and progressive renal impairment.	Cyclosporine	36-50	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	52-55
15149320-0	2004	Cyclosporine A attenuates the natriuretic action of loop diuretics by inhibition of renal COX-2 expression.	Cyclosporine	0-14	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	90-95
20136702-6	2010	In the presence of 1.0-10 microm CsA, the expression of catalase decreased while that of the ER stress markers, ER luminal binding protein (BiP) and inositol-requiring enzyme 1 alpha (IRE1alpha), increased as compared those levels in untreated cells.	Cyclosporine	33-36	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	140-143
15149320-2	2004	Recently, we found that cyclosporine A (CsA) inhibits renal COX-2 expression.	Cyclosporine	24-38	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	60-65
15149320-2	2004	Recently, we found that cyclosporine A (CsA) inhibits renal COX-2 expression.	Cyclosporine	40-43	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	60-65
15149320-7	2004	Basal as well as furosemide-induced stimulation of plasma renin activity (PRA) and of renal renin mRNA was further enhanced by CsA.	Cyclosporine	127-130	renin	Rattus norvegicus	92-97
15149320-10	2004	CONCLUSION: Taken together, our data suggest that CsA acts as an antinatriuretic, likely by the inhibition of COX-2-mediated renal prostanoid formation.	Cyclosporine	50-53	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	110-115
15192137-8	2004	The risk of graft loss was significantly higher for cyclosporine (CsA), prednisone (P) and azathioprine (Az) than for CsA + P, which in turn was higher than for CsA + P plus polyclonal antibodies [antilymphocyte globulin (ALG)/antithymocyte globulin (ATG)].	Cyclosporine	52-64	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	66-69
15167603-1	2004	BACKGROUND: Transforming growth factor (TGF)beta is implicated in the pathogenesis of cyclosporine A (CsA) nephrotoxicity.	Cyclosporine	86-100	transforming growth factor, beta 1	Mus musculus	40-48
15167603-1	2004	BACKGROUND: Transforming growth factor (TGF)beta is implicated in the pathogenesis of cyclosporine A (CsA) nephrotoxicity.	Cyclosporine	102-105	transforming growth factor, beta 1	Mus musculus	40-48
15167603-6	2004	RESULTS: After 2 weeks of CsA administration, plasma and renal TGF beta 1 levels increased to the maximum and then declined toward the baseline levels.	Cyclosporine	26-29	transforming growth factor, beta 1	Mus musculus	63-73
15167603-11	2004	CONCLUSION: The introduction of TGF beta RII/IgG Fc by gene transfer effectively abrogated CsA-induced tubulointerstitial alterations.	Cyclosporine	91-94	transforming growth factor, beta 1	Mus musculus	32-40
15016128-1	2004	BACKGROUND: Cyclosporine (CsA) 2-h post-dose levels (C(2)) correlate better with the area-under-the-curve compared with trough levels.	Cyclosporine	12-24	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	26-29
14767060-5	2004	Because cyclin D1 mRNA was induced normally in the cyclosporin A-treated cells, we analyzed the half-life of cyclin D1 in the presence of cyclosporin A and found no difference from control cells.	Cyclosporine	51-64	cyclin D1	Homo sapiens	109-118
14767060-6	2004	However, cyclosporin A treatment dramatically reduced cyclin D1 protein synthesis.	Cyclosporine	9-22	cyclin D1	Homo sapiens	54-63
17216084-13	2004	Therapies being evaluated for dry eye, including cyclosporine A, P2Y2 agonists, gefarnate, 15-(S)-HETE, and corticosteroids, may be efficacious due to their effect on mucin gene expression and secretion.	Cyclosporine	49-63	LOC100508689	Homo sapiens	167-172
15065825-1	2004	Post-lung transplant use of aerosol cyclosporin (ACsA) is considered by examining the relationship between deposited aerosol dose and effect.	Cyclosporine	36-47	acyl-CoA synthetase short chain family member 2	Homo sapiens	49-53
15041317-5	2004	Induction therapy with OKT3, polyclonal antibodies, and more recently with anti IL-2R monoclonal antibodies allowed the delay of introduction cyclosporine in patients showing posttransplant graft dysfunction.	Cyclosporine	142-154	interleukin 2 receptor subunit alpha	Homo sapiens	80-85
15041327-1	2004	Six hundred thirty-eight cadaveric kidney transplant patients between 1983 and 2001 were treated with cyclosporine (CsA) for 87 +/- 58 months.	Cyclosporine	102-114	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	116-119
15041336-1	2004	Cyclosporine A (CsA) was introduced to pediatric renal transplantation more than 20 years ago, and it has greatly improved graft survival and made transplantation the treatment of choice for children with end-stage renal failure.	Cyclosporine	0-14	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	16-19
15084935-1	2004	BACKGROUND: Cyclosporine (CsA) is a substrate for the MDR-1 gene product P-glycoprotein (P-gp).	Cyclosporine	12-24	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	26-29
14962228-6	2004	The lack of side-effects and the relatively quick response suggest that cyclosporin may be tried as front line treatment for patients with acquired FVIII inhibitors.	Cyclosporine	72-83	coagulation factor VIII	Homo sapiens	148-153
14693832-7	2004	RESULTS: Cyclosporine A caused a 37% decrease in hMR molecules on PBL in 75% of renal transplant recipients, and this effect was attributable to the downregulation of hMR transcription.	Cyclosporine	9-23	mannose receptor C-type 1	Homo sapiens	49-52
14693832-7	2004	RESULTS: Cyclosporine A caused a 37% decrease in hMR molecules on PBL in 75% of renal transplant recipients, and this effect was attributable to the downregulation of hMR transcription.	Cyclosporine	9-23	mannose receptor C-type 1	Homo sapiens	167-170
14693832-9	2004	CONCLUSIONS: Decreases in hMR protein and RNA in PBL of transplant recipients revealed an inhibitory effect of cyclosporine A on hMR transcription.	Cyclosporine	111-125	mannose receptor C-type 1	Homo sapiens	26-29
14693832-9	2004	CONCLUSIONS: Decreases in hMR protein and RNA in PBL of transplant recipients revealed an inhibitory effect of cyclosporine A on hMR transcription.	Cyclosporine	111-125	mannose receptor C-type 1	Homo sapiens	129-132
14697940-1	2003	Gastric emptying time (GET) appears to be a rate-limiting factor in the absorption of cyclosporine-A (CsA) and may be responsible for intra- and interpatient variability of CsA bioavailability.	Cyclosporine	86-100	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	102-105
14697998-1	2003	Cyclosporine (CsA), a calcineurin inhibitor, has been associated with endothelial dysfunction in transplant patients.	Cyclosporine	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	14-17
14565935-5	2003	Thus, whereas CsA and FK506 strongly enhanced TCR- and phorbol myristate acetate-induced LAT expression in T cells, rapamycin effectively inhibited activation-induced LAT expression.	Cyclosporine	14-17	linker for activation of T cells	Homo sapiens	89-92
14565935-9	2003	Given the important role of LAT in initiating T cell activation, our data suggests that the effects of rapamycin, CsA and FK506 on T cell activation involve regulating early T cell signaling.	Cyclosporine	114-117	linker for activation of T cells	Homo sapiens	28-31
14761114-7	2003	Immunohistochemistry showed that i) integrin alpha2 expression is restricted to the gingival epithelium of cyclosporin A-treated patients, ii) the reduction of alpha6 integrin expression in cyclosporin A-treated gingiva is due to loss of expression at focal contacts and iii) beta1 integrin is evenly distributed in the three populations with an intensity decrease in periodontitis and cyclosporin A-treated gingiva.	Cyclosporine	107-120	integrin subunit alpha 2	Homo sapiens	36-51
14761114-7	2003	Immunohistochemistry showed that i) integrin alpha2 expression is restricted to the gingival epithelium of cyclosporin A-treated patients, ii) the reduction of alpha6 integrin expression in cyclosporin A-treated gingiva is due to loss of expression at focal contacts and iii) beta1 integrin is evenly distributed in the three populations with an intensity decrease in periodontitis and cyclosporin A-treated gingiva.	Cyclosporine	190-203	integrin subunit alpha 2	Homo sapiens	36-51
14761114-7	2003	Immunohistochemistry showed that i) integrin alpha2 expression is restricted to the gingival epithelium of cyclosporin A-treated patients, ii) the reduction of alpha6 integrin expression in cyclosporin A-treated gingiva is due to loss of expression at focal contacts and iii) beta1 integrin is evenly distributed in the three populations with an intensity decrease in periodontitis and cyclosporin A-treated gingiva.	Cyclosporine	190-203	integrin subunit alpha 2	Homo sapiens	36-51
12857937-7	2003	Cyclosporin A, an inhibitor of the mitochondrial permeability pore, partially decreased mitochondrial depolarization, caspase 3 activation, and caspase 9 activation, suggesting a role for mitochondrial dysfunction in these events.	Cyclosporine	0-13	caspase 9	Mus musculus	144-153
14550820-7	2003	RESULTS: CsA and FK 506 reduced the presence graft-infiltrating leukocytes (CD4, CD8, CD11a, CD18) in the PVS of intra- and epicardial arteries when compared with control animals.	Cyclosporine	9-12	integrin subunit alpha L	Homo sapiens	86-91
12929192-5	2003	Soleus from the CsA-treated animals showed an increase in both basal (+85%) and maximal (+37%) mitochondrial respiration (P &lt; 0.001), consistent with a 24% increase in citrate synthase activity, whereas the apparent Km for adenosine diphosphate was unchanged.	Cyclosporine	16-19	citrate synthase	Rattus norvegicus	171-187
12919912-3	2003	RESULTS: Cyclosporin A reduced insulin release in the cell culture after 24 and 48 h exposure and decreased Nuox23, Cox7c and Atp5K mRNA expressions.	Cyclosporine	9-22	ATP synthase, H+ transporting, mitochondrial F1F0 complex, subunit E	Mus musculus	126-131
12953048-2	2003	Trials of cyclosporine (CsA) treatment of nephrosis, the rationale of which was based on pathophysiologic considerations, have shown that this immunophillin modulator is effective in inducing and maintaining remission in patients suffering from idiopathic nephrotic syndrome.	Cyclosporine	10-22	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	24-27
12811838-5	2003	Furthermore, anti-CD3-induced IL-12/IL-18 responsiveness was fully abrogated in the presence of cyclosporin A whereas IL-2-induced IL-12/IL-18 responsiveness was not, reminiscent of the previously reported IL-12+IL-18 innate pathway of T cell activation.	Cyclosporine	96-109	interleukin 18	Mus musculus	36-41
12807493-1	2003	Immunomodulators such as cyclosporin A (CsA) and SAR943 (32-deoxorapamycin) inhibit single allergen-induced allergic inflammation such as eosinophilic and lymphocytic infiltration and mRNA expression for interleukin (IL)-4 and IL-5.	Cyclosporine	25-38	interleukin 4	Rattus norvegicus	204-222
12807493-1	2003	Immunomodulators such as cyclosporin A (CsA) and SAR943 (32-deoxorapamycin) inhibit single allergen-induced allergic inflammation such as eosinophilic and lymphocytic infiltration and mRNA expression for interleukin (IL)-4 and IL-5.	Cyclosporine	25-38	interleukin 5	Rattus norvegicus	227-231
12807493-1	2003	Immunomodulators such as cyclosporin A (CsA) and SAR943 (32-deoxorapamycin) inhibit single allergen-induced allergic inflammation such as eosinophilic and lymphocytic infiltration and mRNA expression for interleukin (IL)-4 and IL-5.	Cyclosporine	40-43	interleukin 4	Rattus norvegicus	204-222
12626344-6	2003	MIP-3 beta mRNA and protein expression in BALF cells was suppressed by dexamethasone and cyclosporine A in vitro.	Cyclosporine	89-103	C-C motif chemokine ligand 19	Homo sapiens	0-10
12711602-6	2003	Drug substrates that either enhance (calcein acetoxymethyl ester, demecolcine, and vinblastine) or inhibit (cyclosporin A and trans-(E)-flupentixol) ATPase activity of Cys-less or untreated mutant I306C P-glycoprotein did not affect the activity of MTS-verapamil-treated mutant I306C.	Cyclosporine	108-121	dynein axonemal heavy chain 8	Homo sapiens	149-155
12773514-5	2003	Downstream signaling routes involved mitogen-activated protein kinase (MAPK) kinase (MEK)1/extracellular signal-regulated kinase (ERK), p38 MAPK, and calcineurin, as MICA expression was prevented by U0126, SB202190, cyclosporin A, and FK506.	Cyclosporine	216-229	MHC class I polypeptide-related sequence A	Homo sapiens	166-170
12787063-6	2003	When rats were treated with neuroprotective doses of cyclosporin A, but not with FK 506, the redistribution of apoptosis-inducing factor and cytochrome c was reduced and fodrin breakdown products and active caspase-3 immuno-reactivity was diminished whereas the extracellular calcium concentration was unaffected.	Cyclosporine	53-66	caspase 3	Rattus norvegicus	207-216
12766570-1	2003	C(2) Cyclosporine (CsA) level, as a surrogate of area under the time-concentration curve (AUC) 0-4 hours, is a good predictor of drug absorption and clinical outcome after kidney transplantation.	Cyclosporine	5-17	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	19-22
12838495-5	2003	We present the data from studies of cyclosporine (CSA) and mycophenolate mofetil (MMF) treatment of IMN with their level of evidence in support of efficacy.	Cyclosporine	36-48	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	50-53
12586829-13	2003	Finally, CsA increased vHL-ODD interaction during hypoxia.	Cyclosporine	9-12	von Hippel-Lindau tumor suppressor	Homo sapiens	23-26
12698077-11	2003	Treatment with CsA alone led to a decrease in bFGF expression, whereas SN alone did not affect gene expression.	Cyclosporine	15-18	fibroblast growth factor 2	Rattus norvegicus	46-50
12698077-12	2003	SN in combination with CsA, however, markedly reduced expression of bFGF, vascular endothelial growth factor, and endothelin 1.	Cyclosporine	23-26	fibroblast growth factor 2	Rattus norvegicus	68-72
12709079-1	2003	Calcineurin inhibition with tacrolimus has been used after renal transplantation (RTPL) as rescue therapy for insufficient immunological control or if cyclosporin A (CSA) toxicity occurred.	Cyclosporine	151-164	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	166-169
12646197-1	2003	Tacrolimus (Tac) is more immunosuppressive drug compared to cyclosporine (CsA).	Cyclosporine	60-72	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	74-77
12644839-9	2003	Our results indicate that the combination of cyclosporin A and Taxol is effective in the reversal of Taxol resistance through the inhibition of PI3 kinase-AKT1 pathway.	Cyclosporine	45-58	peptidase inhibitor 3	Homo sapiens	144-147
12604669-9	2003	The secondary increase was associated with spreading of the dye from punctate staining to whole-cell distribution, and was delayed significantly by the MTP inhibitor cyclosporin A and the smooth endoplasmic reticulum Ca(2+) ATPase inhibitor thapsigargin.	Cyclosporine	166-179	microsomal triglyceride transfer protein	Rattus norvegicus	152-155
12773967-6	2003	The IL-2R mAbs have been used with a variety of maintenance immunosuppression regimens double therapy with cyclosporine and prednisone, triple therapy with cyclosporine, azathioprine and prednisone and with newer regimens such as cyclosporine or tacrolimus, mycophenolate mofetil (MMF) and prednisone, and most recently with sirolimus, MMF and prednisone.	Cyclosporine	107-119	interleukin 2 receptor subunit alpha	Homo sapiens	4-9
12773967-6	2003	The IL-2R mAbs have been used with a variety of maintenance immunosuppression regimens double therapy with cyclosporine and prednisone, triple therapy with cyclosporine, azathioprine and prednisone and with newer regimens such as cyclosporine or tacrolimus, mycophenolate mofetil (MMF) and prednisone, and most recently with sirolimus, MMF and prednisone.	Cyclosporine	156-168	interleukin 2 receptor subunit alpha	Homo sapiens	4-9
12773967-6	2003	The IL-2R mAbs have been used with a variety of maintenance immunosuppression regimens double therapy with cyclosporine and prednisone, triple therapy with cyclosporine, azathioprine and prednisone and with newer regimens such as cyclosporine or tacrolimus, mycophenolate mofetil (MMF) and prednisone, and most recently with sirolimus, MMF and prednisone.	Cyclosporine	156-168	interleukin 2 receptor subunit alpha	Homo sapiens	4-9
11758550-0	2001	Comments on experimental use of intravenous cyclosporine (CsA) alone to treat severe ulcerative colitis.	Cyclosporine	44-56	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	58-61
11557554-9	2001	Moreover, cyclosporin A, an inhibitor of mitochondrial permeability transition, attenuated staurosporine-induced apoptosis and necrosis through the inhibition of DeltaPsi(m) reduction, cytochrome c release, and caspase-3 activation.	Cyclosporine	10-23	caspase 3	Rattus norvegicus	211-220
11607878-0	2001	Cyclosporin a treatment is able to revert the decrease in circulating GH and IGF-I and the increase in IGFBPs induced by adjuvant arthritis.	Cyclosporine	0-13	gonadotropin releasing hormone receptor	Rattus norvegicus	70-72
11607878-1	2001	The aim of this study was to find out whether cyclosporin A administration is able to revert the decrease in circulating growth hormone (GH) and insulin-like growth factor-I (IGF-I) and the increase in IGF-binding proteins (IGFBPs) levels caused by adjuvant-induced arthritis in rats.	Cyclosporine	46-59	gonadotropin releasing hormone receptor	Rattus norvegicus	121-135
11607878-1	2001	The aim of this study was to find out whether cyclosporin A administration is able to revert the decrease in circulating growth hormone (GH) and insulin-like growth factor-I (IGF-I) and the increase in IGF-binding proteins (IGFBPs) levels caused by adjuvant-induced arthritis in rats.	Cyclosporine	46-59	gonadotropin releasing hormone receptor	Rattus norvegicus	137-139
11607878-9	2001	These results indicate that the effects of cyclosporin administration on the GH-IGF-IGFBPs system may partly mediate its beneficial effect on body weight in arthritic rats.	Cyclosporine	43-54	gonadotropin releasing hormone receptor	Rattus norvegicus	77-79
11605779-1	2001	Like cyclosporine (CsA), tacrolimus acts through the inhibition of renal phosphatase calcineurin.	Cyclosporine	5-17	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	19-22
11701197-2	2001	The present study was aimed at elucidating the pharmacological characterization of cyclosporine A (CsA)-induced kaolin intake in rats.	Cyclosporine	83-97	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	99-102
11571448-3	2001	We hypothesized that the addition of mycophenolate mofetil (MMF) and a humanized monoclonal anti-CD25 antibody (daclizumab) to a cyclosporine (CsA microemulsion)-based immunosuppression protocol would permit transplantation without steroids.	Cyclosporine	129-141	interleukin 2 receptor subunit alpha	Homo sapiens	97-101
11468554-0	2001	Expression of vascular endothelial growth factor and its receptors Flt-1 and KDR/Flk-1 in chronic cyclosporine nephrotoxicity.	Cyclosporine	98-110	Fms related receptor tyrosine kinase 1	Rattus norvegicus	67-72
11468554-5	2001	At 7 days, CsA up-regulated the expression of Flt-1 and KDR/Flk-1 receptors; however, at 28 days, Flt-1 remained unchanged whereas KDR/Flk-1 expression declined.	Cyclosporine	11-14	Fms related receptor tyrosine kinase 1	Rattus norvegicus	46-51
11438213-5	2001	RESULTS: Although we observed differential CsA sensitivity of T-cell activation marker (CD69, CD45RO, CD25) upregulation comparing UCB and adult, we did not observe any significant difference in CsA sensitivity of T-cell effector functions.	Cyclosporine	43-46	CD69 molecule	Homo sapiens	88-92
11438213-5	2001	RESULTS: Although we observed differential CsA sensitivity of T-cell activation marker (CD69, CD45RO, CD25) upregulation comparing UCB and adult, we did not observe any significant difference in CsA sensitivity of T-cell effector functions.	Cyclosporine	43-46	interleukin 2 receptor subunit alpha	Homo sapiens	102-106
11423565-3	2001	It is widely known that treatment with cyclosporin A (CsA), which can inhibit calcineurin/NFAT signaling, results in glomerular dysfunction characterized by a decrease of GFR or glomerulosclerosis, suggesting that NFAT might regulate the glomerular function.	Cyclosporine	39-52	nuclear factor of activated T-cells 5	Rattus norvegicus	90-94
11423565-3	2001	It is widely known that treatment with cyclosporin A (CsA), which can inhibit calcineurin/NFAT signaling, results in glomerular dysfunction characterized by a decrease of GFR or glomerulosclerosis, suggesting that NFAT might regulate the glomerular function.	Cyclosporine	39-52	nuclear factor of activated T-cells 5	Rattus norvegicus	214-218
11423565-3	2001	It is widely known that treatment with cyclosporin A (CsA), which can inhibit calcineurin/NFAT signaling, results in glomerular dysfunction characterized by a decrease of GFR or glomerulosclerosis, suggesting that NFAT might regulate the glomerular function.	Cyclosporine	54-57	nuclear factor of activated T-cells 5	Rattus norvegicus	90-94
11423565-3	2001	It is widely known that treatment with cyclosporin A (CsA), which can inhibit calcineurin/NFAT signaling, results in glomerular dysfunction characterized by a decrease of GFR or glomerulosclerosis, suggesting that NFAT might regulate the glomerular function.	Cyclosporine	54-57	nuclear factor of activated T-cells 5	Rattus norvegicus	214-218
11423565-7	2001	Furthermore, CsA inhibited endothelin-1-induced cyclooxygenase-2 (COX-2) expression in mesangial cells.	Cyclosporine	13-16	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	48-64
11423565-7	2001	Furthermore, CsA inhibited endothelin-1-induced cyclooxygenase-2 (COX-2) expression in mesangial cells.	Cyclosporine	13-16	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	66-71
11506745-4	2001	CsA demonstrated a rich matrix of inhibitory effects on T cells (CD3(+)), B cells (CD19(+)), dendritic cells (DC) (CD11c(+)), and basophils (CD123(+)) but not on monocytes (CD14(+)) (n = 3).	Cyclosporine	0-3	integrin subunit alpha X	Homo sapiens	115-120
11506745-4	2001	CsA demonstrated a rich matrix of inhibitory effects on T cells (CD3(+)), B cells (CD19(+)), dendritic cells (DC) (CD11c(+)), and basophils (CD123(+)) but not on monocytes (CD14(+)) (n = 3).	Cyclosporine	0-3	CD14 molecule	Homo sapiens	173-177
11323421-3	2001	In the present work, we demonstrate that the immunosuppressant cyclosporin A (CSA) reduces the frequency of IP(3)-dependent [Ca(2+)](i) oscillations in intact hepatocytes, apparently by altering the local Ca(2+) gradients.	Cyclosporine	63-76	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	78-81
11408039-5	2001	Cyclosporin A suppressed the antigen-induced accumulation of activated (CD25+) CD4+ T lymphocytes and eosinophils in the lung, interleukin-5 mRNA expression in lung tissue and airway hyperreactivity.	Cyclosporine	0-13	interleukin 5	Rattus norvegicus	127-140
11279073-8	2001	Inhibition of endogenous calcineurin with cyclosporin A decreased MKP-1 protein levels and increased p38 activation in response to agonist stimulation.	Cyclosporine	42-55	mitogen-activated protein kinase 14	Mus musculus	101-104
1691537-8	1990	Both krox-24 and krox-20 encode proteins containing zinc-binding fingers, and are likely to regulate gene transcription, and this is the first report of gene control mechanisms being specifically affected by CsA and by FK.	Cyclosporine	208-211	early growth response 1	Mus musculus	5-12
2307086-6	1990	The preoperative hepatic cytosol content of ornithine decarboxylase, thymidine kinase, and estrogen receptor was significantly greater (P less than 0.05) in rats pretreated with cyclosporine than in those treated with the vehicle alone.	Cyclosporine	178-190	ornithine decarboxylase 1	Rattus norvegicus	44-67
2307086-6	1990	The preoperative hepatic cytosol content of ornithine decarboxylase, thymidine kinase, and estrogen receptor was significantly greater (P less than 0.05) in rats pretreated with cyclosporine than in those treated with the vehicle alone.	Cyclosporine	178-190	estrogen receptor 1	Rattus norvegicus	69-108
2307086-7	1990	A significant increase in ornithine decarboxylase and thymidine kinase activities occurred after partial hepatectomy in both the cyclosporine-pretreated and vehicle-pretreated animals.	Cyclosporine	129-141	ornithine decarboxylase 1	Rattus norvegicus	26-49
1689761-10	1990	To assess the IL-2 dependence of in vivo NK cell expansion, poly(I:C)-treated athymic mice were given cyclosporin A (CsA), an agent that regulates IL-2 production at the level of gene transcription.	Cyclosporine	117-120	interleukin 2	Mus musculus	147-151
2162879-5	1990	The inhibitory effect of cyclosporin on the acetylcholine response was most marked in the presence of methylene blue, which is an inhibitor of EDRF.	Cyclosporine	25-36	alpha hemoglobin stabilizing protein	Homo sapiens	143-147
2303747-8	1990	The addition of cyclosporin A (CsA) to cultures of 8-E and 8-5 clones together with antigen also resulted in the complete inhibition of cellular proliferation in association with the suppression of IL2 and IL4 production.	Cyclosporine	16-29	interleukin 2	Mus musculus	198-201
2303747-8	1990	The addition of cyclosporin A (CsA) to cultures of 8-E and 8-5 clones together with antigen also resulted in the complete inhibition of cellular proliferation in association with the suppression of IL2 and IL4 production.	Cyclosporine	16-29	interleukin 4	Mus musculus	206-209
2303747-8	1990	The addition of cyclosporin A (CsA) to cultures of 8-E and 8-5 clones together with antigen also resulted in the complete inhibition of cellular proliferation in association with the suppression of IL2 and IL4 production.	Cyclosporine	31-34	interleukin 2	Mus musculus	198-201
2303747-8	1990	The addition of cyclosporin A (CsA) to cultures of 8-E and 8-5 clones together with antigen also resulted in the complete inhibition of cellular proliferation in association with the suppression of IL2 and IL4 production.	Cyclosporine	31-34	interleukin 4	Mus musculus	206-209
2104902-0	1990	IL-2 can enhance the cyclosporin A-mediated inhibition of Theileria parva-infected T cell proliferation.	Cyclosporine	21-34	interleukin 2	Rattus norvegicus	0-4
2104902-5	1990	The cyclosporin A-mediated inhibition of Con-A stimulated lymphoblasts was, over a period of 5 days, largely abrogated by human rIL-2.	Cyclosporine	4-17	interleukin 2	Rattus norvegicus	128-133
2104902-6	1990	In the short term, rIL-2 could also alleviate the growth inhibition of T. parva-infected cells caused by treatment with cyclosporin A.	Cyclosporine	120-133	interleukin 2	Rattus norvegicus	19-24
2104902-7	1990	In the long term, however, rIL-2 enhanced the cyclosporin A-mediated inhibition of T. parva-infected cells, gradually leading to their complete growth arrest.	Cyclosporine	46-59	interleukin 2	Rattus norvegicus	27-32
2104902-9	1990	The fact that IL-2 can enhance the inhibition caused by cyclosporin A could be of relevance for the immunosuppressive activity of cyclosporin A.	Cyclosporine	56-69	interleukin 2	Rattus norvegicus	14-18
2104902-9	1990	The fact that IL-2 can enhance the inhibition caused by cyclosporin A could be of relevance for the immunosuppressive activity of cyclosporin A.	Cyclosporine	130-143	interleukin 2	Rattus norvegicus	14-18
2104905-0	1990	Coordinate expression of src family protooncogenes in T cell activation and its modulation by cyclosporine.	Cyclosporine	94-106	Rous sarcoma oncogene	Mus musculus	25-28
2129987-4	1990	It is likely that the up-take of CsA by macrophages, when incapsulated into liposomes is dramatically enhanced; these cells have been pointed out at targets for IL2 inhibition by CsA.	Cyclosporine	33-36	interleukin 2	Rattus norvegicus	161-164
2129987-4	1990	It is likely that the up-take of CsA by macrophages, when incapsulated into liposomes is dramatically enhanced; these cells have been pointed out at targets for IL2 inhibition by CsA.	Cyclosporine	179-182	interleukin 2	Rattus norvegicus	161-164
2136819-0	1990	Thromboxane receptor blockade attenuates the toxic effect of cyclosporine in experimental renal transplantation.	Cyclosporine	61-73	thromboxane A2 receptor	Rattus norvegicus	0-20
2262069-8	1990	Simultaneous treatment with CsA resulted in a significant inhibition of camostate-induced increases in ODC, SAM-DC as well as putrescine and spermidine and furthermore caused a nearly complete inhibition of the increase of all trophic parameters, while CCK plasma levels were not altered.	Cyclosporine	28-31	ornithine decarboxylase 1	Rattus norvegicus	103-106
2295296-9	1990	Unexpectedly the preoperative levels of ornithine decarboxylase (P less than 0.01) and thymidine kinase activity (P less than 0.01) were significantly greater in the rats treated with cyclosporine as compared to the vehicle treated controls.	Cyclosporine	184-196	ornithine decarboxylase 1	Rattus norvegicus	40-63
2295296-10	1990	As expected, ornithine decarboxylase activity (at 6 hr) and thymidine kinase activity (at 24 hr) rose and peaked in response to a partial hepatectomy but were significantly greater (P less than 0.05) in the rats treated with cyclosporine as compared to the vehicle.	Cyclosporine	225-237	ornithine decarboxylase 1	Rattus norvegicus	13-36
33803842-0	2021	A Novel Dipeptidyl Peptidase-4 Inhibitor DA-1229 Ameliorates Tubulointerstitial Fibrosis in Cyclosporine Nephrotoxicity in Mice.	Cyclosporine	92-104	dipeptidylpeptidase 4	Mus musculus	8-30
33803842-2	2021	The roles of DPP-4 and its inhibitors in cyclosporine nephrotoxicity are not fully understood.	Cyclosporine	41-53	dipeptidylpeptidase 4	Mus musculus	13-18
33803842-9	2021	Our results suggest that DPP-4 inhibition by DA-1229 provides renoprotective effects in an animal model of cyclosporine nephrotoxicity via antioxidant, anti-inflammatory, and anti-fibrotic mechanisms.	Cyclosporine	107-119	dipeptidylpeptidase 4	Mus musculus	25-30
33803842-10	2021	DPP-4 inhibition may be a useful new therapeutic approach for the management of progressive renal disease in cyclosporine nephrotoxicity.	Cyclosporine	109-121	dipeptidylpeptidase 4	Mus musculus	0-5
33233866-5	2020	Conventional and recently developed agents for treating AD such as steroid, calcineurin inhibitors, cyclosporine, dupilumab, and JAK inhibitors inhibit the IL-13/IL-4-JAK-STAT6/STAT3 axis, while older remedies such as coal tar and glyteer are antioxidative AHR agonists.	Cyclosporine	100-112	signal transducer and activator of transcription 6	Homo sapiens	171-176
8070349-3	1994	The aim of this study was to investigate whether administration of IFN gamma to rats would favorably modify the high turnover osteopenia caused by CsA.	Cyclosporine	147-150	interferon gamma	Rattus norvegicus	67-76
34922024-9	2022	In terms of the predictors of GI symptoms, it was determined that mycophenolate mofetil (MMF) was effective in the development of reflux and diarrhoea, cyclosporine in the development of diarrhoea and constipation, and tacrolimus in the development of indigestion, which are (p < 0.05).	Cyclosporine	152-164	G protein subunit alpha i1	Homo sapiens	30-32
34927415-2	2022	Here, using human kidney-specific microvascular endothelial cells (HKMECs), we showed that CsA inhibited NFAT1 activation and impaired VEGF signaling in these ECs in a dose- and time-dependent manner.	Cyclosporine	91-94	nuclear factor of activated T cells 2	Homo sapiens	105-110
34788311-18	2021	MAGEH1 gene expression was not altered by CsA-induced cytotoxic injury, whereas GADD45G gene expression was increased significantly upon CsA treatment.	Cyclosporine	42-45	growth arrest and DNA damage inducible gamma	Homo sapiens	80-87
34788311-18	2021	MAGEH1 gene expression was not altered by CsA-induced cytotoxic injury, whereas GADD45G gene expression was increased significantly upon CsA treatment.	Cyclosporine	137-140	growth arrest and DNA damage inducible gamma	Homo sapiens	80-87
34788311-22	2021	Accordingly, CsA-induced apoptosis was significantly decreased in MAGEH1 siRNA and GADD45G siRNA transfected HK-2 cells.	Cyclosporine	13-16	growth arrest and DNA damage inducible gamma	Homo sapiens	83-90
34788311-23	2021	CsA-induced activation of caspase-7 and caspase-9 was inhibited in MAGEH1 knockdown HRE stable cells, and similarly in GADD45G knockdown HRE stable cells.	Cyclosporine	0-3	caspase 7	Homo sapiens	26-35
34788311-23	2021	CsA-induced activation of caspase-7 and caspase-9 was inhibited in MAGEH1 knockdown HRE stable cells, and similarly in GADD45G knockdown HRE stable cells.	Cyclosporine	0-3	caspase 9	Homo sapiens	40-49
34776485-0	2021	A Case of Anti-MDA-5 Antibody-positive Dermatomyositis with Rapidly Progressive Interstitial Pneumonia Presenting with Nephrotic Syndrome during Treatment with Corticosteroids and Cyclosporine.	Cyclosporine	180-192	interferon induced with helicase C domain 1	Homo sapiens	15-20
34776485-1	2021	A 50-year-old Japanese woman with anti-melanoma differentiation-associated gene 5 antibody (anti-MDA-5 antibody)-positive dermatomyositis presenting with rapidly progressive interstitial pneumonia was treated with corticosteroids and cyclosporine.	Cyclosporine	234-246	interferon induced with helicase C domain 1	Homo sapiens	39-81
34776485-1	2021	A 50-year-old Japanese woman with anti-melanoma differentiation-associated gene 5 antibody (anti-MDA-5 antibody)-positive dermatomyositis presenting with rapidly progressive interstitial pneumonia was treated with corticosteroids and cyclosporine.	Cyclosporine	234-246	interferon induced with helicase C domain 1	Homo sapiens	97-102
34533641-8	2021	Treatment with cyclosporin A, used in vitro for the inhibition of CypA, resulted in a 3-log reduction in CHPV titer and an undetectable level of CypA in comparison to an untreated control.	Cyclosporine	15-28	peptidylprolyl isomerase A	Homo sapiens	66-70
34533641-8	2021	Treatment with cyclosporin A, used in vitro for the inhibition of CypA, resulted in a 3-log reduction in CHPV titer and an undetectable level of CypA in comparison to an untreated control.	Cyclosporine	15-28	peptidylprolyl isomerase A	Homo sapiens	145-149
34324305-9	2021	Moreover, the SDA system realized the precise intracellular miR-21 imaging in living cells, which is attributed to the reciprocal amplification property between CSA reactions and DNAzyme biocatalysis.	Cyclosporine	161-164	microRNA 21	Homo sapiens	60-66
34381450-7	2021	p70 S6 kinase and mTOR were reduced by CsA with/without CHBP at 2 weeks, so were S6 ribosomal protein and GSK-3beta at 8 weeks, with reduced CASP-3 at both time points.	Cyclosporine	39-42	mechanistic target of rapamycin kinase	Mus musculus	18-22
34350189-7	2021	Finally, chromatin immunoprecipitation (ChIP) assays showed that NFATc1 potentially binds the promoter region of H-Ras and the binding efficiency was significantly enhanced by the overexpression of H-Ras G12V , which was abolished by treatment with the calcineurin/NFAT pathway inhibitors cyclosporine A (CsA) or VIVIT.	Cyclosporine	289-303	HRas proto-oncogene, GTPase	Homo sapiens	113-118
34350189-7	2021	Finally, chromatin immunoprecipitation (ChIP) assays showed that NFATc1 potentially binds the promoter region of H-Ras and the binding efficiency was significantly enhanced by the overexpression of H-Ras G12V , which was abolished by treatment with the calcineurin/NFAT pathway inhibitors cyclosporine A (CsA) or VIVIT.	Cyclosporine	289-303	HRas proto-oncogene, GTPase	Homo sapiens	198-203
34350189-7	2021	Finally, chromatin immunoprecipitation (ChIP) assays showed that NFATc1 potentially binds the promoter region of H-Ras and the binding efficiency was significantly enhanced by the overexpression of H-Ras G12V , which was abolished by treatment with the calcineurin/NFAT pathway inhibitors cyclosporine A (CsA) or VIVIT.	Cyclosporine	305-308	HRas proto-oncogene, GTPase	Homo sapiens	113-118
34350189-7	2021	Finally, chromatin immunoprecipitation (ChIP) assays showed that NFATc1 potentially binds the promoter region of H-Ras and the binding efficiency was significantly enhanced by the overexpression of H-Ras G12V , which was abolished by treatment with the calcineurin/NFAT pathway inhibitors cyclosporine A (CsA) or VIVIT.	Cyclosporine	305-308	HRas proto-oncogene, GTPase	Homo sapiens	198-203
35588871-10	2022	CsA also enhanced TP receptor, as well as p-ERK1/2, p-p38, p- IkappaBalpha, p-NF-kappaB p65 protein levels and decreased IkappaBalpha protein expression, demonstrating that CsA induced TP receptor enhanced-vasoconstriction via activation of MAPK and NF-kappaB pathways.	Cyclosporine	0-3	NFKB inhibitor alpha	Rattus norvegicus	62-74
35588871-10	2022	CsA also enhanced TP receptor, as well as p-ERK1/2, p-p38, p- IkappaBalpha, p-NF-kappaB p65 protein levels and decreased IkappaBalpha protein expression, demonstrating that CsA induced TP receptor enhanced-vasoconstriction via activation of MAPK and NF-kappaB pathways.	Cyclosporine	0-3	NFKB inhibitor alpha	Rattus norvegicus	121-133
35588871-10	2022	CsA also enhanced TP receptor, as well as p-ERK1/2, p-p38, p- IkappaBalpha, p-NF-kappaB p65 protein levels and decreased IkappaBalpha protein expression, demonstrating that CsA induced TP receptor enhanced-vasoconstriction via activation of MAPK and NF-kappaB pathways.	Cyclosporine	173-176	NFKB inhibitor alpha	Rattus norvegicus	62-74
35588871-10	2022	CsA also enhanced TP receptor, as well as p-ERK1/2, p-p38, p- IkappaBalpha, p-NF-kappaB p65 protein levels and decreased IkappaBalpha protein expression, demonstrating that CsA induced TP receptor enhanced-vasoconstriction via activation of MAPK and NF-kappaB pathways.	Cyclosporine	173-176	NFKB inhibitor alpha	Rattus norvegicus	121-133
35212420-0	2022	Quercetin boosts nitric oxide levels and modulates the activities of arginase, acetylcholinesterase and adenosine deaminase in the corpus cavernosum of cyclosporine-treated rats.	Cyclosporine	152-164	acetylcholinesterase	Rattus norvegicus	79-99
35212420-7	2022	Cyclosporine elevated arginase, AChE and ADA activity while lowering NO levels.	Cyclosporine	0-12	acetylcholinesterase	Rattus norvegicus	32-36
35623257-1	2022	Herein, novel laser-responsive multi-functional nanoparticles (NPs-Lip@PTX/CyA/Ce6) were fabricated with bovine serum albumins (BSA) based nanoparticles, which simultaneously carried chemotherapeutic drug paclitaxel (PTX) and P-gp inhibitor cyclosporin A (CyA), as core and photosensitizer agent Chlorin e6 (Ce6) loaded Tf-modified liposomal bilayer as shell.	Cyclosporine	241-254	phosphoglycolate phosphatase	Homo sapiens	226-230
35623257-1	2022	Herein, novel laser-responsive multi-functional nanoparticles (NPs-Lip@PTX/CyA/Ce6) were fabricated with bovine serum albumins (BSA) based nanoparticles, which simultaneously carried chemotherapeutic drug paclitaxel (PTX) and P-gp inhibitor cyclosporin A (CyA), as core and photosensitizer agent Chlorin e6 (Ce6) loaded Tf-modified liposomal bilayer as shell.	Cyclosporine	256-259	phosphoglycolate phosphatase	Homo sapiens	226-230
35081433-7	2022	In a DES rabbit model, a single dose of Lys-CNGs (50 mug mL-1) can effectively alleviate the signs of DES within 4 days, whereas multiple treatments of 10-fold higher concentration of cyclosporine A are needed to achieve similar therapeutic effects (one dose every 12 h; 500 mug mL-1).	Cyclosporine	184-198	L1 cell adhesion molecule	Mus musculus	279-283
2595372-2	1989	Cyclosporin A was found to specifically inhibit the appearance of DNA binding activity of NF-AT, AP-3, and to a lesser extent NF-kappa B, nuclear proteins that appear to be important in the transcriptional activation of the genes for interleukin-2 and its receptor, as well as several other lymphokines.	Cyclosporine	0-13	interleukin 2	Mus musculus	234-264
2546636-7	1989	The identity of EBV-B cell derived M-CSA with human urinary CSF-1 was confirmed by a complete neutralization of macrophage CSA by an antihuman urinary CSF-1 antiserum.	Cyclosporine	37-40	colony stimulating factor 1	Homo sapiens	60-65
2504764-0	1989	Combination therapy of cyclosporine with steroid inhibits gamma-interferon and interleukin-1 gene expression at the level of mRNA synthesis in vivo.	Cyclosporine	23-35	interleukin 1 alpha	Homo sapiens	79-92
2665219-3	1989	Mismatching for HLA-B and DR antigens was also found to correlate with transplant survival in highly sensitized patients and in patients transplanted since 1981, the "cyclosporine era."	Cyclosporine	167-179	major histocompatibility complex, class I, B	Homo sapiens	16-21
2568932-7	1989	treatment with 15 mg/kg/day of CsA; (b) both populations of single-positive thymocytes reappear within 2 weeks of termination of CsA and (c) irradiation and bone marrow reconstitution of these CsA-treated mice results in reconstitution of normal numbers of L3T4+ and Ly-2+ cells, but the L3T4+ T cells to not provide T helper function, as determined by interleukin 2 production and cytotoxic T lymphocytes generation.	Cyclosporine	31-34	interleukin 2	Mus musculus	353-366
2784780-5	1989	As CsA is known to block the signalling cascade initiated by perturbation of T-cell receptor (TcR), it is suggested that both the Ia expression in the thymus and the signalling via receptors on thymocytes, the signals presumably generated by TcR binding to class II MHC molecules, might be necessary for phenotypic differentiation of class II MHC-restricted T cells (CD4+8- cells), but not for class I MHC-restricted T cells (CD4-8+).	Cyclosporine	3-6	T cell receptor alpha variable 6-3	Mus musculus	77-92
2784780-5	1989	As CsA is known to block the signalling cascade initiated by perturbation of T-cell receptor (TcR), it is suggested that both the Ia expression in the thymus and the signalling via receptors on thymocytes, the signals presumably generated by TcR binding to class II MHC molecules, might be necessary for phenotypic differentiation of class II MHC-restricted T cells (CD4+8- cells), but not for class I MHC-restricted T cells (CD4-8+).	Cyclosporine	3-6	T cell receptor alpha variable 6-3	Mus musculus	94-97
2784780-5	1989	As CsA is known to block the signalling cascade initiated by perturbation of T-cell receptor (TcR), it is suggested that both the Ia expression in the thymus and the signalling via receptors on thymocytes, the signals presumably generated by TcR binding to class II MHC molecules, might be necessary for phenotypic differentiation of class II MHC-restricted T cells (CD4+8- cells), but not for class I MHC-restricted T cells (CD4-8+).	Cyclosporine	3-6	T cell receptor alpha variable 6-3	Mus musculus	242-245
2480848-4	1989	However, cyclosporin A, in similar experiments, markedly inhibited the release of interferon gamma.	Cyclosporine	9-22	interferon gamma	Rattus norvegicus	82-98
2522049-4	1989	The present study investigates the effect of different concentrations of CsA added in vitro, or of different doses of CsA administered in vivo, on the ability of murine spleen cells to produce interleukin 2 and to generate cytotoxic T lymphocytes in vitro when stimulated with TNP-self or H-2 alloantigens.	Cyclosporine	73-76	interleukin 2	Mus musculus	193-206
2522049-4	1989	The present study investigates the effect of different concentrations of CsA added in vitro, or of different doses of CsA administered in vivo, on the ability of murine spleen cells to produce interleukin 2 and to generate cytotoxic T lymphocytes in vitro when stimulated with TNP-self or H-2 alloantigens.	Cyclosporine	118-121	interleukin 2	Mus musculus	193-206
2576219-4	1989	Cyclosporin A (CsA) markedly inhibited TCR-independent production of lymphokine mRNA and protein at concentrations where IL-2-dependent stimulation of lymphokine production and proliferation was unaffected.	Cyclosporine	0-13	T cell receptor alpha variable 6-3	Mus musculus	39-42
2576219-4	1989	Cyclosporin A (CsA) markedly inhibited TCR-independent production of lymphokine mRNA and protein at concentrations where IL-2-dependent stimulation of lymphokine production and proliferation was unaffected.	Cyclosporine	0-13	interleukin 2	Mus musculus	121-125
2576219-4	1989	Cyclosporin A (CsA) markedly inhibited TCR-independent production of lymphokine mRNA and protein at concentrations where IL-2-dependent stimulation of lymphokine production and proliferation was unaffected.	Cyclosporine	15-18	T cell receptor alpha variable 6-3	Mus musculus	39-42
2576219-4	1989	Cyclosporin A (CsA) markedly inhibited TCR-independent production of lymphokine mRNA and protein at concentrations where IL-2-dependent stimulation of lymphokine production and proliferation was unaffected.	Cyclosporine	15-18	interleukin 2	Mus musculus	121-125
2576219-8	1989	On the other hand, when Ca2(+)-dependent (CsA-sensitive) pathways are activated by TCR binding or by a Ca2+ ionophore, production of high levels of all three lymphokines can be induced.	Cyclosporine	42-45	T cell receptor alpha variable 6-3	Mus musculus	83-86
2625778-2	1989	When administered daily on days 0-14 after immunization with S-antigen, CsA was the most effective of all in inhibiting EAU followed by CsG: 20-30 mg/kg/day of CsG appeared to have the same effect as 5 mg/kg/day of CsA.	Cyclosporine	72-75	S-antigen visual arrestin	Rattus norvegicus	61-70
2645532-0	1989	Beta-2-microglobulin for differentiation between ciclosporin A nephrotoxicity and graft rejection in renal transplant recipients.	Cyclosporine	49-62	beta-2-microglobulin	Homo sapiens	0-20
2645532-7	1989	We conclude that parallel determination of beta 2-microglobulin in serum and urine allows to differentiate between ciclosporin A nephrotoxicity and rejection in 91% of the cases.	Cyclosporine	115-128	beta-2-microglobulin	Homo sapiens	43-63
2461819-0	1988	Amylase, isoamylase, and lipase activities in cyclosporine-treated rats.	Cyclosporine	46-58	lipase G, endothelial type	Rattus norvegicus	25-31
3262657-0	1988	IL-4 bypasses the immune suppressive effect of cyclosporin A during the in vitro induction of murine cytotoxic T lymphocytes.	Cyclosporine	47-60	interleukin 4	Mus musculus	0-4
3262657-1	1988	We have analyzed at the clonal level the effect of IL-4 on the immune suppressive action of cyclosporin A (CsA) during the in vitro primary activation of anti-MHC alloantigen-reactive murine CD8+ CTL.	Cyclosporine	92-105	interleukin 4	Mus musculus	51-55
3262657-1	1988	We have analyzed at the clonal level the effect of IL-4 on the immune suppressive action of cyclosporin A (CsA) during the in vitro primary activation of anti-MHC alloantigen-reactive murine CD8+ CTL.	Cyclosporine	107-110	interleukin 4	Mus musculus	51-55
2904172-4	1988	Ciclosporin A (CyA) inhibited T-cell DNA synthesis after activation via CD2 and CD3.	Cyclosporine	0-13	CD2 molecule	Homo sapiens	72-75
3051564-11	1988	Cyclosporine significantly augmented the level of TPL activity in HUVEC stimulated with rIL-1 alpha, rIL-1 beta, and rTNF alpha and in MNC and M stimulated with rIL-1 alpha, rIL-1 beta, and rIL-2.	Cyclosporine	0-12	interleukin 2	Rattus norvegicus	190-195
3043795-0	1988	Cyclophilin, a primary molecular target for cyclosporine.	Cyclosporine	44-56	peptidylprolyl isomerase G	Homo sapiens	0-11
3043795-3	1988	Our laboratory has presented evidence that cyclophilin (CYP), a low-molecular-weight (Mr 17,737) basic protein, is the primary cytosolic receptor for CsA.	Cyclosporine	150-153	peptidylprolyl isomerase G	Homo sapiens	43-54
3043795-3	1988	Our laboratory has presented evidence that cyclophilin (CYP), a low-molecular-weight (Mr 17,737) basic protein, is the primary cytosolic receptor for CsA.	Cyclosporine	150-153	peptidylprolyl isomerase G	Homo sapiens	56-59
3043795-4	1988	The high affinity of CYP for CsA (Kd 30 nM) and specificity for immunosuppressive cyclosporine analogs implicate CYP as a pivotal regulator of T cell and B cell activation.	Cyclosporine	29-32	peptidylprolyl isomerase G	Homo sapiens	21-24
3043795-4	1988	The high affinity of CYP for CsA (Kd 30 nM) and specificity for immunosuppressive cyclosporine analogs implicate CYP as a pivotal regulator of T cell and B cell activation.	Cyclosporine	29-32	peptidylprolyl isomerase G	Homo sapiens	113-116
3043795-4	1988	The high affinity of CYP for CsA (Kd 30 nM) and specificity for immunosuppressive cyclosporine analogs implicate CYP as a pivotal regulator of T cell and B cell activation.	Cyclosporine	82-94	peptidylprolyl isomerase G	Homo sapiens	21-24
3043795-4	1988	The high affinity of CYP for CsA (Kd 30 nM) and specificity for immunosuppressive cyclosporine analogs implicate CYP as a pivotal regulator of T cell and B cell activation.	Cyclosporine	82-94	peptidylprolyl isomerase G	Homo sapiens	113-116
3043795-8	1988	The ability of CsA to suppress expression of several lymphokine and proto-oncogene products via a transcriptional control mechanism suggests that CYP may function at some level in a signaling pathway linking membrane receptor stimulation to gene regulatory elements in lymphocytes, and possibly nonlymphoid cell types as well.	Cyclosporine	15-18	peptidylprolyl isomerase G	Homo sapiens	146-149
3133410-2	1988	This response of T cells to IL-4 plus PMA is independent of the action of IL-2 as judged by 1) the lack of IL-2 in supernatants of stimulated cells, 2) the failure to detect IL-2 mRNA in stimulated cells by in situ hybridization, 3) the inability of anti-IL-2R antibody and of anti-IL-2 antibody to block responses to IL-4 plus PMA, and 4) the failure of cyclosporin A to block responses.	Cyclosporine	355-368	interleukin 4	Mus musculus	28-32
2447983-5	1988	A second IL 1 pulse induced CSA release in an identical manner, as did the primary stimulation, indicating that the CSA released was actively produced.	Cyclosporine	28-31	interleukin 1 alpha	Homo sapiens	9-13
2447983-5	1988	A second IL 1 pulse induced CSA release in an identical manner, as did the primary stimulation, indicating that the CSA released was actively produced.	Cyclosporine	116-119	interleukin 1 alpha	Homo sapiens	9-13
3257444-9	1988	A significant rise in CSA occurred between 3 and 6 h after injection of purified IL-1, and a significant increase in BM CFU-GM developed 48 h after injection.	Cyclosporine	22-25	interleukin 1 alpha	Homo sapiens	81-85
3116843-7	1987	We speculate that therapy with CyA and prednisone inhibited the production of interleukins-1 and -2 from monocytes and T-cells, respectively, and was responsible for the reduction of the T gamma cell fraction and B-cell leukemic mass in this patient.	Cyclosporine	31-34	interleukin 1 alpha	Homo sapiens	78-99
3141538-9	1987	PLA2 activity in the aqueous humour and the MPO levels measured from iris-ciliary body homogenate were significantly lower in the groups treated subcutaneously with EDTA or cyclosporin A as compared with the untreated EAU-controls.	Cyclosporine	173-186	myeloperoxidase	Cavia porcellus	44-47
3672608-0	1987	Retardation of renal growth and ornithine decarboxylase activity by cyclosporine after uninephrectomy in rats.	Cyclosporine	68-80	ornithine decarboxylase 1	Rattus norvegicus	32-55
3672608-3	1987	Cyclosporine has been shown to attenuate induction of renal ornithine decarboxylase activity in response to other tropic hormones, such as prolactin, thyroxine, and dexamethasone.	Cyclosporine	0-12	ornithine decarboxylase 1	Rattus norvegicus	60-83
3672608-4	1987	These studies were undertaken to evaluate the effects of cyclosporine on induction of renal ornithine decarboxylase activity and growth in response to the serum renotropic factor.	Cyclosporine	57-69	ornithine decarboxylase 1	Rattus norvegicus	92-115
3672608-7	1987	Administration of 25.0 mg/kg/day of cyclosporine also reduced the activity of ornithine decarboxylase in the growing kidney.	Cyclosporine	36-48	ornithine decarboxylase 1	Rattus norvegicus	78-101
3114369-5	1987	Furthermore, inhibition of this proliferative response with an anti-IL 4 monoclonal antibody or cyclosporine indicated that IL 4 functions as an autocrine growth factor.	Cyclosporine	96-108	interleukin 4	Mus musculus	124-128
3498003-5	1987	Inhibitors of T cell activation, cyclosporin A and anti-LFA-1 antibody, blocked the induction of c-fos and c-ets-1 mRNAs without reducing the levels of c-myc and c-ets-2.	Cyclosporine	33-46	ETS proto-oncogene 1, transcription factor	Homo sapiens	107-114
3118092-7	1987	Interleukin 2 production was completely inhibited by CSA, modestly inhibited by MP and not inhibited by 6-MP.	Cyclosporine	53-56	interleukin 2	Mus musculus	0-13
3110354-1	1987	We investigated the ability of cyclosporin A (CsA) and transforming growth factor beta (TGF-beta) to modulate the production of TNF-alpha and TNF-beta and IFN-gamma by unseparated, nonadherent, and adherent PBMC.	Cyclosporine	31-44	lymphotoxin A	Mus musculus	142-150
3499914-0	1987	Evidence for a B-cell memory-forming factor (BMFF) able to reconstitute cyclosporin-A-induced suppression of the secondary response.	Cyclosporine	72-85	signal recognition particle 72	Homo sapiens	15-43
3499914-0	1987	Evidence for a B-cell memory-forming factor (BMFF) able to reconstitute cyclosporin-A-induced suppression of the secondary response.	Cyclosporine	72-85	signal recognition particle 72	Homo sapiens	45-49
3494996-1	1987	Although cyclosporin A (CsA), an immunosuppressive drug, has been shown to inhibit the production of certain lymphokines, including interleukin 2 (IL-2), interleukin 3 (IL-3), and gamma-interferon, its effect on the production of granulocyte/macrophage colony-stimulating factor (GM-CSF) has not been evaluated.	Cyclosporine	24-27	interleukin 2	Mus musculus	132-145
3494996-1	1987	Although cyclosporin A (CsA), an immunosuppressive drug, has been shown to inhibit the production of certain lymphokines, including interleukin 2 (IL-2), interleukin 3 (IL-3), and gamma-interferon, its effect on the production of granulocyte/macrophage colony-stimulating factor (GM-CSF) has not been evaluated.	Cyclosporine	24-27	interleukin 2	Mus musculus	147-151
3494996-8	1987	Expression of the GM-CSF gene in EL-4 cells was detected independent of CsA, whereas CsA inhibited the expression of the IL-2 gene.	Cyclosporine	85-88	interleukin 2	Mus musculus	121-125
3494996-9	1987	The present data show that production of IL-2 and IL-3, but not that of GM-CSF, is inhibited by CsA and suggest a differential control mechanism for lymphokine synthesis in T lymphocytes.	Cyclosporine	96-99	interleukin 2	Mus musculus	41-45
2951271-0	1987	Cyclosporin A enhances streptozocin-induced diabetes in CD-1 mice.	Cyclosporine	0-13	CD1 antigen complex	Mus musculus	56-60
2951271-1	1987	Cyclosporin A (CYA), when administered to CD-1 mice treated with a subdiabetogenic dose of Streptozocin (STZ), exacerbated the STZ-induced insulitis and elevated the plasma glucose levels, parallel to a reduction of the insulin content of the pancreas.	Cyclosporine	0-13	CD1 antigen complex	Mus musculus	42-46
3537128-3	1987	We have used cyclosporin A (CS-A) treatment as a tool by which the mechanisms of immune-mediated pathology might be dissected.	Cyclosporine	13-26	heat shock protein 9	Mus musculus	28-32
3560286-7	1987	This alteration has never been described before in CSA therapy and its meaning is not clear; however, it does suggest that there occur modifications in the lipid metabolism or in the phagocytic function of the mesangial cells when cyclosporine A is administered over long periods.	Cyclosporine	231-245	albumin	Canis lupus familiaris	51-54
3501185-4	1987	Dexamethasone and Cyclosporin A (CsA) which inhibit early events of T cell activation and the expression of the interleukin-2 (IL-2) and gamma-interferon (gamma-IFN) genes also markedly suppress the expression of c-myc mRNA in Con A, and Con A + TPA-activated thymocytes.	Cyclosporine	18-31	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	213-218
3501185-4	1987	Dexamethasone and Cyclosporin A (CsA) which inhibit early events of T cell activation and the expression of the interleukin-2 (IL-2) and gamma-interferon (gamma-IFN) genes also markedly suppress the expression of c-myc mRNA in Con A, and Con A + TPA-activated thymocytes.	Cyclosporine	33-36	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	213-218
3100433-0	1986	Specific immunosuppressive therapy by monoclonal anti-IL 2 receptor antibody and its synergistic action with cyclosporin.	Cyclosporine	109-120	interleukin 2	Rattus norvegicus	54-58
2428033-0	1986	Cyclosporin A prevents induction of the interleukin 2 receptor gene in cultured murine thymocytes.	Cyclosporine	0-13	interleukin 2	Mus musculus	40-53
2428033-4	1986	Cyclosporin A, an immunosuppressive cyclic peptide of fungal origin, prevents in T lymphocytes the activation of a set(s) of genes encoding lymphokines and the IL-2 receptor but does not affect their expression once they have been activated.	Cyclosporine	0-13	interleukin 2	Mus musculus	160-164
2424984-4	1986	However, reconstitution of CsA blocked cultures with IL 2 restores the activation of the suppressor T cells, but fails to significantly restore the activation of CTL in these same cultures.	Cyclosporine	27-30	interleukin 2	Mus musculus	53-57
3487640-1	1986	The binding of [3H]cyclosporine A (CsA) to BALB/c mouse spleen cells was examined with a novel centrifugation assay which rapidly removes free [3H]CsA from cell surfaces with a minimal loss of low affinity specifically bound [3H]CsA.	Cyclosporine	19-33	heat shock protein 9	Mus musculus	35-38
3487640-1	1986	The binding of [3H]cyclosporine A (CsA) to BALB/c mouse spleen cells was examined with a novel centrifugation assay which rapidly removes free [3H]CsA from cell surfaces with a minimal loss of low affinity specifically bound [3H]CsA.	Cyclosporine	19-33	heat shock protein 9	Mus musculus	147-150
3487640-1	1986	The binding of [3H]cyclosporine A (CsA) to BALB/c mouse spleen cells was examined with a novel centrifugation assay which rapidly removes free [3H]CsA from cell surfaces with a minimal loss of low affinity specifically bound [3H]CsA.	Cyclosporine	19-33	heat shock protein 9	Mus musculus	147-150
2874646-3	1986	Within 24 h, significant increases in urinary N-acetyl-beta-D-glucosaminidase (NAG) and gamma-glutamyl transpeptidase (gamma GT) activity were observed at both doses of CsA.	Cyclosporine	169-172	gamma-glutamyltransferase 1	Rattus norvegicus	88-117
2874646-3	1986	Within 24 h, significant increases in urinary N-acetyl-beta-D-glucosaminidase (NAG) and gamma-glutamyl transpeptidase (gamma GT) activity were observed at both doses of CsA.	Cyclosporine	169-172	gamma-glutamyltransferase 1	Rattus norvegicus	119-127
3517164-3	1986	Simultaneous treatment of the mice with IL 2-containing murine lymphokine preparations or with recombinant human IL 2 reverses the effect of CsA on the induction of contact sensitivity.	Cyclosporine	141-144	interleukin 2	Mus musculus	40-44
3517164-4	1986	Recombinant IL 2 also reverses the inhibition by CsA of the effector phase.	Cyclosporine	49-52	interleukin 2	Mus musculus	12-16
3517164-8	1986	We conclude that inhibition of IL 2 production is of paramount importance for the inhibitory effect of CsA on contact sensitivity, but that additional effects are involved in the inhibition of antibody production to both T-dependent and T-independent antigens.	Cyclosporine	103-106	interleukin 2	Mus musculus	31-35
3528611-12	1986	Urinary beta 2-microglobulin was still increased by 85% nine months after CyA treatment.	Cyclosporine	74-77	beta-2-microglobulin	Homo sapiens	8-28
3707614-1	1986	Cyclosporin A (CsA), an orally active immunosuppressive agent, was shown to inhibit cytochrome P-450 dependent biotransformation of drugs in the mouse.	Cyclosporine	0-13	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	84-100
3707614-1	1986	Cyclosporin A (CsA), an orally active immunosuppressive agent, was shown to inhibit cytochrome P-450 dependent biotransformation of drugs in the mouse.	Cyclosporine	15-18	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	84-100
3707614-5	1986	CsA interacted directly with cytochrome P-450, causing a reverse type I spectral change in hepatic microsomes.	Cyclosporine	0-3	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	29-45
3707614-7	1986	These results suggest that CsA has the potential to cause drug interactions involving inhibition of drug biotransformation, particularly of drugs that are metabolised by the same types of cytochrome P-450 which oxidise benzo[a]pyrene and theophylline.	Cyclosporine	27-30	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	188-204
3864858-1	1985	The ability of cyclosporine to prevent the increase in Ia and H-2K expression that occurs in mice with graft-vs-host disease (GVHD) was examined by means of absorption, indirect immunofluorescent staining (IIF), and indirect immunoperoxidase staining (IIP).	Cyclosporine	15-27	histocompatibility 2, K1, K region	Mus musculus	62-66
3864858-5	1985	Treatment with cyclosporine reduced the amount of donor Ia and H-2K in spleens, and prevented the enhanced expression of recipient Ia and H-2K in kidneys in a dose-dependent manner.	Cyclosporine	15-27	histocompatibility 2, K1, K region	Mus musculus	63-67
3864858-5	1985	Treatment with cyclosporine reduced the amount of donor Ia and H-2K in spleens, and prevented the enhanced expression of recipient Ia and H-2K in kidneys in a dose-dependent manner.	Cyclosporine	15-27	histocompatibility 2, K1, K region	Mus musculus	138-142
3871750-6	1985	Cyclosporine was also unique in its effect on the immune responses of the rats by selectively inhibiting only the specific T-cell-mediated responses to S-antigen (delayed skin response and lymphocyte response in culture), while having no negative effect on antibody production or the lymphocyte response to the polyclonal mitogen, concanavalin A.	Cyclosporine	0-12	S-antigen visual arrestin	Rattus norvegicus	152-161
6379854-2	1984	Previous studies have shown that cyclosporin A (CyA) prevents the elaboration of the lymphokine leucocyte migration inhibitory factor (LIF).	Cyclosporine	33-46	LIF interleukin 6 family cytokine	Homo sapiens	135-138
6379854-2	1984	Previous studies have shown that cyclosporin A (CyA) prevents the elaboration of the lymphokine leucocyte migration inhibitory factor (LIF).	Cyclosporine	48-51	LIF interleukin 6 family cytokine	Homo sapiens	135-138
6379854-5	1984	Because the putative binding of IL-1 showed saturability, reversibility (with CyA as a probe), and tissue specificity consistent with a known target for the monokine, we propose that IL-1 interacts with a receptor-like structure on T cells.	Cyclosporine	78-81	interleukin 1 alpha	Homo sapiens	32-36
6379854-5	1984	Because the putative binding of IL-1 showed saturability, reversibility (with CyA as a probe), and tissue specificity consistent with a known target for the monokine, we propose that IL-1 interacts with a receptor-like structure on T cells.	Cyclosporine	78-81	interleukin 1 alpha	Homo sapiens	183-187
6600715-0	1983	Cyclosporin A: alterations of the cellular immune response in S-antigen-induced experimental autoimmune uveitis.	Cyclosporine	0-13	S-antigen visual arrestin	Rattus norvegicus	62-71
6600715-1	1983	We have previously shown that Cyclosporin A (CsA) is effective in preventing S-antigen (S-Ag)-induced experimental autoimmune uveitis (EAU).	Cyclosporine	30-43	S-antigen visual arrestin	Rattus norvegicus	77-86
6600715-1	1983	We have previously shown that Cyclosporin A (CsA) is effective in preventing S-antigen (S-Ag)-induced experimental autoimmune uveitis (EAU).	Cyclosporine	30-43	S-antigen visual arrestin	Rattus norvegicus	88-92
6600715-1	1983	We have previously shown that Cyclosporin A (CsA) is effective in preventing S-antigen (S-Ag)-induced experimental autoimmune uveitis (EAU).	Cyclosporine	45-48	S-antigen visual arrestin	Rattus norvegicus	77-86
6600715-1	1983	We have previously shown that Cyclosporin A (CsA) is effective in preventing S-antigen (S-Ag)-induced experimental autoimmune uveitis (EAU).	Cyclosporine	45-48	S-antigen visual arrestin	Rattus norvegicus	88-92
6600715-3	1983	Lymph nodes draining the site of S-Ag immunization were significantly smaller in the CsA-treated animals when compared to the nonprotected group (p less than 0.01), and also showed profound histologic alterations when compared to controls.	Cyclosporine	85-88	S-antigen visual arrestin	Rattus norvegicus	33-37
6288144-1	1982	Murine bone marrow and adherence-separated spleen cells cultured on hydrophobic, gas-permeable Teflon foils (petriperm dishes) can be shown to synthesize and secrete erythropoietin (Epo) and colony-stimulating activity (CSA) simultaneously into the surrounding medium.	Cyclosporine	220-223	erythropoietin	Mus musculus	182-185
6759372-2	1982	The influence of cyclosporin A (CyA) and methylprednisolone (MP) on the elaboration of the human lymphokine, leukocyte migration inhibitory factor (LIF) was investigated.	Cyclosporine	17-30	LIF interleukin 6 family cytokine	Homo sapiens	109-146
6759372-2	1982	The influence of cyclosporin A (CyA) and methylprednisolone (MP) on the elaboration of the human lymphokine, leukocyte migration inhibitory factor (LIF) was investigated.	Cyclosporine	17-30	LIF interleukin 6 family cytokine	Homo sapiens	148-151
7049288-4	1982	4 The immunosuppressive agent, cyclosporin-A (20 mg/kg daily) was able to prolong skin allograft survival and prevent the changes in histamine and HDC activity in allografts.	Cyclosporine	31-44	histidine decarboxylase	Oryctolagus cuniculus	147-150
33580874-10	2021	Both EX527 and Cyclosporine A (CsA), which are inhibitors of SIRT1 and mitophagy, markedly alleviated the inhibition of oxidative stress and mitochondrial dysfunction caused by Apelin-36.	Cyclosporine	15-29	sirtuin 1	Mus musculus	61-66
33580874-10	2021	Both EX527 and Cyclosporine A (CsA), which are inhibitors of SIRT1 and mitophagy, markedly alleviated the inhibition of oxidative stress and mitochondrial dysfunction caused by Apelin-36.	Cyclosporine	31-34	sirtuin 1	Mus musculus	61-66
33631201-6	2021	Although BLECs were still undergoing transcriptional changes over time, a targeted transcriptome analysis (TempO-Seq) indicated a time and concentration dependent activation of ATF4, XBP1, Nrf2 and p53 stress response pathways under CsA treatment.	Cyclosporine	233-236	X-box binding protein 1	Homo sapiens	183-187
33853687-7	2021	Notably, adding CsA to MSCs after IFNgamma pre-stimulation enhances MSC production of IDO.	Cyclosporine	16-19	indoleamine 2,3-dioxygenase 1	Homo sapiens	86-89
33853687-8	2021	Mechanistically, we identified that CsA reduces SOCS1 expression to facilitate enhanced IDO production in IFNgamma pre-stimulated MSCs.	Cyclosporine	36-39	suppressor of cytokine signaling 1	Homo sapiens	48-53
33853687-8	2021	Mechanistically, we identified that CsA reduces SOCS1 expression to facilitate enhanced IDO production in IFNgamma pre-stimulated MSCs.	Cyclosporine	36-39	indoleamine 2,3-dioxygenase 1	Homo sapiens	88-91
33852232-6	2021	The results revealed that, the administration of CsA induced a significant increase in neuronal AChE, BChE, arginase, TBARS level, but decreased nitric oxide (NO) level.	Cyclosporine	49-52	acetylcholinesterase	Rattus norvegicus	96-100
33916864-5	2021	Because the presence of the anti-MDA5 antibody is a strong predictor of a worse prognosis, combination treatment with glucocorticoids (GCs) and calcineurin inhibitors (CNIs; tacrolimus (TAC) or cyclosporin A (CsA)) is recommended for patients with anti-MDA5 antibody-positive DM/CADM-ILD.	Cyclosporine	194-207	interferon induced with helicase C domain 1	Homo sapiens	33-37
33916864-5	2021	Because the presence of the anti-MDA5 antibody is a strong predictor of a worse prognosis, combination treatment with glucocorticoids (GCs) and calcineurin inhibitors (CNIs; tacrolimus (TAC) or cyclosporin A (CsA)) is recommended for patients with anti-MDA5 antibody-positive DM/CADM-ILD.	Cyclosporine	209-212	interferon induced with helicase C domain 1	Homo sapiens	33-37
33448057-8	2021	CsA-induced oxidative stress, HO-1, TGF-beta1, and type II EMT were also rescued by antioxidants treatment.	Cyclosporine	0-3	heme oxygenase 1	Homo sapiens	30-34
32794232-2	2021	The result revealed that CsA-stressed rats treated with captopril and extracts (ALE and ABE) had lowered ACE, arginase, AChE, PDE-5, ADA activities, and TBARS level, coupled with improved SOD and catalase activities compared with untreated CsA-stressed rats, which had reversed these biochemicals compared to normal rats.	Cyclosporine	25-28	acetylcholinesterase	Rattus norvegicus	120-124
33637715-8	2021	In addition, the CnA inhibitor cyclosporin A and p-ERK1/2 inhibitor U0126 improved HG-induced cardiomyocyte hypertrophy by promoting and inhibiting phosphorylation of Drp1 at S637 and S616, respectively.	Cyclosporine	31-44	collapsin response mediator protein 1	Rattus norvegicus	167-171
15624117-4	2005	Half the rats were treated with the P-glycoprotein inhibitor cyclosporine A (CsA) (200 mg/kg) 2 h prior to NT administration, and the other half served as a control group.	Cyclosporine	61-75	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	36-50
15624117-8	2005	These results suggest that inhibition of P-gp by CsA increases the accumulation of NT in the brain.	Cyclosporine	49-52	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	41-45
15590628-7	2005	Calpeptin and the mitochondrial permeability transition pore antagonist cyclosporin A also inhibited calcium-induced AIF release from mouse liver mitochondria, implicating the involvement of an endogenous mitochondrial calpain in release of AIF during permeability transition.	Cyclosporine	72-85	apoptosis-inducing factor, mitochondrion-associated 1	Mus musculus	117-120
15590628-7	2005	Calpeptin and the mitochondrial permeability transition pore antagonist cyclosporin A also inhibited calcium-induced AIF release from mouse liver mitochondria, implicating the involvement of an endogenous mitochondrial calpain in release of AIF during permeability transition.	Cyclosporine	72-85	apoptosis-inducing factor, mitochondrion-associated 1	Mus musculus	241-244
15729165-6	2005	Finally, a 14-day treatment with cyclosporine (CsA)-induced nephrotoxicity in syngeneic kidney transplants correlated with both increased ICAM-1 protein expression and infiltration with leukocytes.	Cyclosporine	33-45	intercellular adhesion molecule 1	Homo sapiens	138-144
15729165-6	2005	Finally, a 14-day treatment with cyclosporine (CsA)-induced nephrotoxicity in syngeneic kidney transplants correlated with both increased ICAM-1 protein expression and infiltration with leukocytes.	Cyclosporine	47-50	intercellular adhesion molecule 1	Homo sapiens	138-144
15729165-8	2005	CONCLUSIONS: ME/PS-modified ICAM-1 antisense oligo is very effective in inhibiting the ICAM-1-dependent mechanism of graft infiltration and tissue damage involved in allograft rejection, ischemic-reperfusion injury, and CsA-induced nephrotoxicity.	Cyclosporine	220-223	intercellular adhesion molecule 1	Homo sapiens	28-34
15729165-8	2005	CONCLUSIONS: ME/PS-modified ICAM-1 antisense oligo is very effective in inhibiting the ICAM-1-dependent mechanism of graft infiltration and tissue damage involved in allograft rejection, ischemic-reperfusion injury, and CsA-induced nephrotoxicity.	Cyclosporine	220-223	intercellular adhesion molecule 1	Homo sapiens	87-93
15792352-11	2005	Treatment with CsA restored both protein and enzyme activities of GPX and MnSOD but not catalase.	Cyclosporine	15-18	superoxide dismutase 2	Rattus norvegicus	74-79
15353404-12	2005	CsA and [AD-Ser](8) CsA prevented most hensin staining and the reduction of apical surface; PNA caps were more prominent.	Cyclosporine	0-3	deleted in malignant brain tumors 1 protein	Oryctolagus cuniculus	39-45
15353404-12	2005	CsA and [AD-Ser](8) CsA prevented most hensin staining and the reduction of apical surface; PNA caps were more prominent.	Cyclosporine	20-23	deleted in malignant brain tumors 1 protein	Oryctolagus cuniculus	39-45
15604871-16	2005	Dry eye + CsA mice showed less activated caspase-3 staining than the dry eye control and the dry eye + vehicle groups.	Cyclosporine	10-13	caspase 3	Mus musculus	41-50
16463674-6	2005	It was found that Ang II could increase the c-fos protein expression, which could be inhibited by CsA in a dose-dependent manner.	Cyclosporine	98-101	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	44-49
16463674-9	2005	It was concluded that CsA can suppress the Ang II-induced c-fos protein expression and [Ca2+]i elevation in single cardiomyocyte, which might play a role in the prevention of Ang II-induced cardiomyocyte hypertrophy by CsA.	Cyclosporine	22-25	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	58-63
16463674-9	2005	It was concluded that CsA can suppress the Ang II-induced c-fos protein expression and [Ca2+]i elevation in single cardiomyocyte, which might play a role in the prevention of Ang II-induced cardiomyocyte hypertrophy by CsA.	Cyclosporine	219-222	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	58-63
16237888-1	2005	"Gingival enlargement" is the term now used to describe medication-related gingival overgrowth or gingival hyperplasia (AAP, 2004), a condition commonly induced by three main classes of drugs: anticonvulsants, antihypertensive calcium antagonists and the immunosuppressant cyclosporin.	Cyclosporine	273-284	serpin family F member 2	Homo sapiens	120-123
16238120-8	2005	In addition, genes encoding kallistatin as well as B1 and B2 receptors were investigated in CaCo cells cultures after exposure with cyclosporine A (200-800 ng/ml) in vitro.	Cyclosporine	132-146	serpin family A member 4	Homo sapiens	28-39
15614148-0	2004	The effect of alpha-melanocyte-stimulating hormone on renal tubular cell apoptosis and tubulointerstitial fibrosis in cyclosporine A nephrotoxicity.	Cyclosporine	118-132	proopiomelanocortin	Rattus norvegicus	14-50
15614148-7	2004	CONCLUSIONS: These findings suggest that chronic CsA nephrotoxicity is related to Bax and Bcl2-related apoptosis pathways, and that alpha-MSH can attenuate the CsA-induced tubulointerstitial fibrosis as well as tubular cell apoptosis.	Cyclosporine	160-163	proopiomelanocortin	Rattus norvegicus	132-141
15560892-9	2004	Besides, DTT added following a low Cd2+ pulse in KCl medium containing exogenous Ca2+ induced a substantial enhancing of sustained Cd2+ stimulation of mitochondrial basal respiration and the stimulation was CsA-sensitive, while the activation promoted by low [Cd2+] alone was totally eliminated by DTT supplement.	Cyclosporine	207-210	Cd2 molecule	Rattus norvegicus	131-134
15560892-9	2004	Besides, DTT added following a low Cd2+ pulse in KCl medium containing exogenous Ca2+ induced a substantial enhancing of sustained Cd2+ stimulation of mitochondrial basal respiration and the stimulation was CsA-sensitive, while the activation promoted by low [Cd2+] alone was totally eliminated by DTT supplement.	Cyclosporine	207-210	Cd2 molecule	Rattus norvegicus	131-134
15560892-10	2004	We observed the similar respiratory activation earlier when high concentrations of Cd2+ in the absence of added Ca2+ were used but it was completely CsA-insensitive.	Cyclosporine	149-152	Cd2 molecule	Rattus norvegicus	83-86
15663561-9	2004	The first group, including CsA and LF, inhibited non-selectively T cell proliferation, chemokine receptor expression and cytokine production, with CsA as the most potent drug tested.	Cyclosporine	27-30	C-X-C motif chemokine receptor 4	Homo sapiens	87-105
15496263-3	2004	For most patients, optimal current immunosuppression in the first year after transplantation consists of combination therapy with a calcineurin inhibitor (eg, cyclosporine or tacrolimus), corticosteroids, and an antimetabolite agent (eg, azathioprine or mycophenolate mofetil).	Cyclosporine	159-171	calcineurin binding protein 1	Homo sapiens	132-153
15626898-7	2004	Microscopic damage score, myeloperoxidase activity, tumor necrosis factor alpha (TNF-alpha), and interleukin-6 in colonic tissue were significantly diminished by CsA.	Cyclosporine	162-165	myeloperoxidase	Mus musculus	26-41
15626898-9	2004	TNF-alpha-induced ICAM-1 and VCAM-1 expression in primary cultures of human umbilical vein endothelial cells was reduced by co-incubation with CsA.	Cyclosporine	143-146	intercellular adhesion molecule 1	Homo sapiens	18-24
15381200-9	2004	Recipients treated with DL and delayed CsA had a reduced level of intra-graft interleukin (IL)-2, interferon (IFN)-gamma, IL-4, and IL-4R mRNA expression and reduced infiltrate compared to DL alone.	Cyclosporine	39-42	interleukin 4 receptor	Homo sapiens	132-137
15555450-5	2004	FK506, CsA and DEX suppressed significantly the expressions of IL-18 mRNA and its protein (P&lt;0.001) in LPS/PHA-stimulated whole blood cell from LN patients.	Cyclosporine	7-10	interleukin 18	Homo sapiens	63-68
15555450-6	2004	The inhibitory effects of FK506, CsA and DEX on the IL-18 protein expression in LN patients were stronger than that in normal control group (P&lt;0.01 or P&lt;0.05).	Cyclosporine	33-36	interleukin 18	Homo sapiens	52-57
15362118-5	2004	The ability of CSA to detect only active N-WASP was demonstrated by in vitro experiments using immunoprecipitation of active N-WASP from EGF-stimulated cells and Cdc42 activation of N-WASP activity.	Cyclosporine	15-18	WASP like actin nucleation promoting factor	Homo sapiens	41-47
15362118-5	2004	The ability of CSA to detect only active N-WASP was demonstrated by in vitro experiments using immunoprecipitation of active N-WASP from EGF-stimulated cells and Cdc42 activation of N-WASP activity.	Cyclosporine	15-18	WASP like actin nucleation promoting factor	Homo sapiens	125-131
15362118-5	2004	The ability of CSA to detect only active N-WASP was demonstrated by in vitro experiments using immunoprecipitation of active N-WASP from EGF-stimulated cells and Cdc42 activation of N-WASP activity.	Cyclosporine	15-18	WASP like actin nucleation promoting factor	Homo sapiens	125-131
15362118-6	2004	In cell staining experiments, N-WASP is maximally accessible to CSA 40 sec after EGF stimulation and this activated N-WASP is in the nucleation zone.	Cyclosporine	64-67	WASP like actin nucleation promoting factor	Homo sapiens	30-36
15482640-9	2004	These results demonstrate that bioavailability of ciclosporin is markedly reduced by MPS pulse treatment, and the mechanism of this interaction was confirmed to involve enhancement of small-intestinal P-gp function and decrease in bile secretion.	Cyclosporine	50-61	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	201-205
15561259-9	2004	CONCLUSION: The bioavailability of CsA was lower in PK-1 than in PK-2.	Cyclosporine	35-38	prokineticin 1	Homo sapiens	52-56
15561259-9	2004	CONCLUSION: The bioavailability of CsA was lower in PK-1 than in PK-2.	Cyclosporine	35-38	prokineticin 2	Homo sapiens	65-69
15257056-5	2004	PX3.102 improved tracheal allograft lumen patency (*P&lt;0.01 vs. vehicle and P=0.14 vs. cyclosporine A) but not epithelialization (P&gt;0.2 vs. vehicle).	Cyclosporine	89-103	pannexin 3	Homo sapiens	0-3
15257056-7	2004	PX3.102 markedly suppressed antigen-specific lymphocyte proliferation in vitro at a concentration 10 times lower than cyclosporine A.	Cyclosporine	118-132	pannexin 3	Homo sapiens	0-3
15229940-10	2004	The upregulation of synoviocyte COX-2 expression by supernatants from stimulated T cells was partially inhibited by addition of neutralizing antibodies against IL-17 or TNF-a or by treatment of T cells with cyclosporin A prior to stimulation.	Cyclosporine	207-220	interleukin 17A	Homo sapiens	160-165
15110893-2	2004	We have investigated whether the Pgp inhibitors cyclosporin A, valspodar (PSC833) and elacridar (GF120918) increase the accumulation of docetaxel in the brain.	Cyclosporine	48-61	phosphoglycolate phosphatase	Mus musculus	33-36
15110893-5	2004	Cyclosporin A, valspodar and elacridar significantly increased the brain concentrations of docetaxel in wild-type mice to 38%, 56% and 59%, respectively, of those achieved in Pgp knockout mice.	Cyclosporine	0-13	phosphoglycolate phosphatase	Mus musculus	175-178
15093807-10	2004	In addition, there is evidence from studies in renal transplant recipients that everolimus plus reduced exposure cyclosporine is effective and well tolerated-with the regimen having a reduced potential for CNI-related nephrotoxicity and for other CNI-related cardiovascular side effects.	Cyclosporine	113-125	calcineurin binding protein 1	Homo sapiens	247-250
15044094-3	2004	We previously showed that CsA toxicity is mediated by ROS generation as well as by inhibition of peptidyl-prolyl cis-trans isomerase (PPIase) activity of CypA in CsA-treated myoblasts [FASEB J.	Cyclosporine	162-165	peptidylprolyl isomerase A	Mus musculus	154-158
15044094-5	2004	Since CsA-induced nephrotoxicity is the most significant adverse effect in its clinical utilization, we here investigated the role of CsA inhibition of CypA PPIase activity in its nephrotoxicity using transgenic mouse models.	Cyclosporine	134-137	peptidylprolyl isomerase A	Mus musculus	152-156
15044094-7	2004	However, CsA-induced nephrotoxicity was virtually suppressed in CypA/wt mice, but exacerbated in CypA/R55A mice, compared to that of littermates.	Cyclosporine	9-12	peptidylprolyl isomerase A	Mus musculus	64-68
15044094-7	2004	However, CsA-induced nephrotoxicity was virtually suppressed in CypA/wt mice, but exacerbated in CypA/R55A mice, compared to that of littermates.	Cyclosporine	9-12	peptidylprolyl isomerase A	Mus musculus	97-101
15044094-8	2004	Also, life expectancy was extended in CypA/wt mice and shortened in CypA/R55A mice during CsA administration.	Cyclosporine	90-93	peptidylprolyl isomerase A	Mus musculus	68-72
15044094-10	2004	In conclusion, our data provide in vivo evidence that supplement of CypA PPIase activity allows animal"s resistance toward CsA-induced nephrotoxicity.	Cyclosporine	123-126	peptidylprolyl isomerase A	Mus musculus	68-72
15176436-8	2004	In the presence of P-glycoprotein (P-gp) inhibitor, cyclosporine or verapamil, the apical-to-basolateral transport of quinacrine increased.	Cyclosporine	52-64	phosphoglycolate phosphatase	Mus musculus	19-33
15039293-5	2004	Moreover, berberine was processed through hepatobiliary excretion against a concentration gradient based on the bile-to-blood distribution ratio (AUC(bile)/AUC(blood)); the active berberine efflux might be affected by P-gp and OCT since coadministration of berberine and CsA or quinidine at the same dosage of 10 mg kg(-1) significantly decreased the berberine amount in bile.	Cyclosporine	271-274	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	218-222
15033175-5	2004	In YAC46 MSNs, NMDA stimulated significantly higher activation of caspase-3 and caspase-9 but not caspase-8, and NMDA-induced caspase-3 and -9 activation was markedly attenuated by cyclosporin A.	Cyclosporine	181-194	caspase 3	Mus musculus	66-75
15033175-5	2004	In YAC46 MSNs, NMDA stimulated significantly higher activation of caspase-3 and caspase-9 but not caspase-8, and NMDA-induced caspase-3 and -9 activation was markedly attenuated by cyclosporin A.	Cyclosporine	181-194	caspase 3	Mus musculus	126-142
14743390-7	2004	Treatment with cyclosporin A, a known NFATc1 inhibitor, resulted in a blockade of osteoclast formation.	Cyclosporine	15-28	nuclear factor of activated T cells 1	Homo sapiens	38-44
15000258-6	2004	RESULTS: FK506 and CsA at concentrations of 1-10 ng/mL inhibited the growth of both HLE and HuH-7 and those immunosuppressors at concentrations over 100 ng/mL exhibited cytotoxicity on these cells.	Cyclosporine	19-22	MIR7-3 host gene	Homo sapiens	92-97
14565991-9	2004	However, in the presence of CsA, c-fos mRNA levels were significantly augmented by increased pacing frequency.	Cyclosporine	28-31	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	33-38
14687580-4	2004	Cyclosporine A was able to block the initial STAT1 activation, but STAT3 activation was only partially affected.	Cyclosporine	0-14	signal transducer and activator of transcription 1	Mus musculus	45-50
14688381-6	2004	Beginning on the day of bone marrow transplantation, groups of control and CsA-treated animals were treated with mAb against either CD4 or CD8 for 21 days.	Cyclosporine	75-78	CD4 antigen	Mus musculus	132-135
14583657-9	2004	CONCLUSION: The increase in blood pressure by LPD was associated with the higher amount of sucrose contained in LPD and the decrease in NO generation caused by the Arg depletion in rats with post-CsA nephropathy.	Cyclosporine	196-199	acyl-CoA synthetase bubblegum family member 1	Rattus norvegicus	46-49
14648594-7	2003	In this study, CsA also inhibited the ammonia-induced aquaporin 4 (AQP4) upregulation, which had been shown previously to be increased in cultured astrocytes by ammonia treatment.	Cyclosporine	15-18	aquaporin 4	Homo sapiens	54-65
14648594-7	2003	In this study, CsA also inhibited the ammonia-induced aquaporin 4 (AQP4) upregulation, which had been shown previously to be increased in cultured astrocytes by ammonia treatment.	Cyclosporine	15-18	aquaporin 4	Homo sapiens	67-71
14638906-9	2003	Apoptosis induced by CsA is associated with the translocation of Bax to the mitochondria and Bax antisense oligodeoxynucleotides protected from CsA-induced apoptosis.	Cyclosporine	144-147	BCL2-associated X protein	Mus musculus	93-96
14534356-1	2003	The apparent inhibition constant, Kapp, for the blockade of P-glycoprotein (P-gp) by four drugs, verapamil, cyclosporin A, XR9576 (tariquidar), and vinblastine, was measured by studying their ability to inhibit daunorubicin and calcein-AM efflux from four strains of Ehrlich cells with different levels of drug resistance and P-gp content.	Cyclosporine	108-121	phosphoglycolate phosphatase	Mus musculus	60-74
14534356-1	2003	The apparent inhibition constant, Kapp, for the blockade of P-glycoprotein (P-gp) by four drugs, verapamil, cyclosporin A, XR9576 (tariquidar), and vinblastine, was measured by studying their ability to inhibit daunorubicin and calcein-AM efflux from four strains of Ehrlich cells with different levels of drug resistance and P-gp content.	Cyclosporine	108-121	phosphoglycolate phosphatase	Mus musculus	76-80
14642487-4	2003	Cyclosporin A (CsA) at 0, 10, 15, 25, 35, and 50 mg/kg of body weight was used as a P-gp modulator.	Cyclosporine	0-13	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	84-88
14642487-4	2003	Cyclosporin A (CsA) at 0, 10, 15, 25, 35, and 50 mg/kg of body weight was used as a P-gp modulator.	Cyclosporine	15-18	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	84-88
14550820-1	2003	BACKGROUND: The purpose of the study was to evaluate the effects of cyclosporine (CsA), FK 506 and mycophenolate mofetil (MMF) on graft-infiltrating leukocytes (CD4, CD8, CD11a, CD18) after cardiac transplantation in rats.	Cyclosporine	68-80	Cd4 molecule	Rattus norvegicus	161-164
14551032-1	2003	Understanding the physiological role of CD30 would be an important step forward in transplants because CD30+ T cells can be induced by alloantigens even in the presence of immunosuppressives such as cyclosporine (Csa) and hence can act as regulatory cells in allograft.	Cyclosporine	199-211	TNF receptor superfamily member 8	Homo sapiens	40-44
14551032-1	2003	Understanding the physiological role of CD30 would be an important step forward in transplants because CD30+ T cells can be induced by alloantigens even in the presence of immunosuppressives such as cyclosporine (Csa) and hence can act as regulatory cells in allograft.	Cyclosporine	199-211	TNF receptor superfamily member 8	Homo sapiens	103-107
14551032-1	2003	Understanding the physiological role of CD30 would be an important step forward in transplants because CD30+ T cells can be induced by alloantigens even in the presence of immunosuppressives such as cyclosporine (Csa) and hence can act as regulatory cells in allograft.	Cyclosporine	213-216	TNF receptor superfamily member 8	Homo sapiens	40-44
14551032-1	2003	Understanding the physiological role of CD30 would be an important step forward in transplants because CD30+ T cells can be induced by alloantigens even in the presence of immunosuppressives such as cyclosporine (Csa) and hence can act as regulatory cells in allograft.	Cyclosporine	213-216	TNF receptor superfamily member 8	Homo sapiens	103-107
12954456-9	2003	Similarly, myo-inositol effectively restored the taurine transport activity suppressed by cyclosporin A (0.5 and 50 nM) in murine macrophages (p &lt; 0.01).	Cyclosporine	90-103	synaptopodin 2	Mus musculus	11-14
12890213-0	2003	CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab.	Cyclosporine	63-74	TNF receptor superfamily member 8	Homo sapiens	0-4
12890213-6	2003	We report a patient with erythrodermic psoriasis treated with ciclosporin and infliximab who developed a CD30+ T-cell lymphoma.	Cyclosporine	62-73	TNF receptor superfamily member 8	Homo sapiens	105-109
12626638-8	2003	Potent P-gp inhibitors, such as PSC833 or CsA, partially canceled the asymmetry.	Cyclosporine	42-45	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	7-11
12782105-8	2003	Although DNB-induced inhibition of SDH was significantly decreased by CsA pretreatment in brainstem astrocytes after 0.5 and 2h and with a second pore inhibitor, bongkrekic acid (BKA) after 5h, both inhibitors failed to reduce inhibition of SDH activity in cortical astrocytes.	Cyclosporine	70-73	serine dehydratase	Rattus norvegicus	35-38
12782105-9	2003	These data suggest that DNB-induced inhibition of SDH may be independent of differential regional activation of the mtPTP complex in astrocytes and that an unidentified cyclosporin A-inhibitable factor mediates DNB-induced loss of SDH function.	Cyclosporine	169-182	serine dehydratase	Rattus norvegicus	231-234
12817897-0	2003	Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.	Cyclosporine	36-49	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	10-24
12817897-2	2003	Cyclosporin A (CsA) was used to modulate P-gp and cMOAT/MRP2.	Cyclosporine	0-13	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	41-45
12817897-2	2003	Cyclosporin A (CsA) was used to modulate P-gp and cMOAT/MRP2.	Cyclosporine	0-13	ATP binding cassette subfamily C member 2	Rattus norvegicus	50-55
12817897-2	2003	Cyclosporin A (CsA) was used to modulate P-gp and cMOAT/MRP2.	Cyclosporine	0-13	ATP binding cassette subfamily C member 2	Rattus norvegicus	56-60
12817897-2	2003	Cyclosporin A (CsA) was used to modulate P-gp and cMOAT/MRP2.	Cyclosporine	15-18	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	41-45
12817897-2	2003	Cyclosporin A (CsA) was used to modulate P-gp and cMOAT/MRP2.	Cyclosporine	15-18	ATP binding cassette subfamily C member 2	Rattus norvegicus	50-55
12817897-2	2003	Cyclosporin A (CsA) was used to modulate P-gp and cMOAT/MRP2.	Cyclosporine	15-18	ATP binding cassette subfamily C member 2	Rattus norvegicus	56-60
12826168-1	2003	BACKGROUND: The MTHFR C677T mutation and elevated atherogenic lipoprotein levels are known as cardiovascular risk factors in patients with renal transplantation treated with cyclosporine (CsA).	Cyclosporine	174-186	methylenetetrahydrofolate reductase	Homo sapiens	16-21
12826168-1	2003	BACKGROUND: The MTHFR C677T mutation and elevated atherogenic lipoprotein levels are known as cardiovascular risk factors in patients with renal transplantation treated with cyclosporine (CsA).	Cyclosporine	188-191	methylenetetrahydrofolate reductase	Homo sapiens	16-21
12611882-8	2003	Both the early release of proteins like cytochrome c and Hsp60 from the mitochondria as well as the later translocation of the active caspase-9/-3 are partially inhibited by cyclosporin A, an inhibitor of mitochondrial membrane permeabilization.	Cyclosporine	174-187	heat shock protein family D (Hsp60) member 1	Homo sapiens	57-62
12868191-0	2003	[Concentration of tissue plasminogen activator and its inhibitor 1 in cyclosporine A-treated children with idiopathic nephrotic syndrome].	Cyclosporine	70-84	chromosome 20 open reading frame 181	Homo sapiens	18-46
12868191-7	2003	RESULTS: In children treated with cyclosporine A increased concentrations of t-PA and PAI-1 were found (p &lt; 0.01).	Cyclosporine	34-48	chromosome 20 open reading frame 181	Homo sapiens	77-81
12868191-10	2003	CONCLUSION: Children with remission of idiopathic nephrotic syndrome treated with cyclosporine A show increased concentration of t-PA and PAI-1 and thrombinogenesis.	Cyclosporine	82-96	chromosome 20 open reading frame 181	Homo sapiens	129-133
12606707-8	2003	Binding of BIG1, BIG2, and ARF to membranes was also increased by L-732,531, an agonist structurally related to FK506, but was not increased by a related antagonist, L-685,818, nor by cyclosporin A or rapamycin.	Cyclosporine	184-197	ADP ribosylation factor guanine nucleotide exchange factor 1	Homo sapiens	11-15
12606707-8	2003	Binding of BIG1, BIG2, and ARF to membranes was also increased by L-732,531, an agonist structurally related to FK506, but was not increased by a related antagonist, L-685,818, nor by cyclosporin A or rapamycin.	Cyclosporine	184-197	ADP ribosylation factor guanine nucleotide exchange factor 2	Homo sapiens	17-21
12728666-7	2003	We found an increased concentration of F1 + 2 prothrombin fragments in children treated with CsA, while in children after 8 weeks of glicocorticoid therapy the concentration of this marker was comparable to that in the controls.	Cyclosporine	93-96	coagulation factor XII	Homo sapiens	39-45
12771475-0	2003	Primary cutaneous CD30+ large T-cell lymphoma in a patient with psoriasis treated with cyclosporine.	Cyclosporine	87-99	TNF receptor superfamily member 8	Homo sapiens	18-22
12771475-1	2003	We report the case of a 61-year-old woman who developed an anaplastic CD30+ cutaneous T-cell lymphoma during oral cyclosporine (CsA) therapy for recalcitrant psoriasis.	Cyclosporine	114-126	TNF receptor superfamily member 8	Homo sapiens	70-74
12771475-1	2003	We report the case of a 61-year-old woman who developed an anaplastic CD30+ cutaneous T-cell lymphoma during oral cyclosporine (CsA) therapy for recalcitrant psoriasis.	Cyclosporine	128-131	TNF receptor superfamily member 8	Homo sapiens	70-74
12771475-6	2003	To our knowledge, this is the first case of primary cutaneous CD30+ anaplastic large T-cell lymphoma in a patient treated with CsA for psoriasis.	Cyclosporine	127-130	TNF receptor superfamily member 8	Homo sapiens	62-66
15618715-4	2003	However, cloxacillin, cyclosporin A and midecamycin inhibited BSEP, and cyclosporin A and midecamycin inhibited MRP2 with an inhibition constant close to the clinical concentration.	Cyclosporine	72-85	ATP binding cassette subfamily C member 2	Rattus norvegicus	112-116
15618715-5	2003	By comparing the inhibition potential between rat and human CMVs, the inhibition of BSEP- and MRP2-mediated transport by midecamycin and cyclosporin A was relatively similar whereas the inhibitory effect on BSEP-mediated transport by cloxacillin and glibenclamide was more marked in humans than in rats.	Cyclosporine	137-150	ATP binding cassette subfamily B member 11	Homo sapiens	84-88
15618715-5	2003	By comparing the inhibition potential between rat and human CMVs, the inhibition of BSEP- and MRP2-mediated transport by midecamycin and cyclosporin A was relatively similar whereas the inhibitory effect on BSEP-mediated transport by cloxacillin and glibenclamide was more marked in humans than in rats.	Cyclosporine	137-150	ATP binding cassette subfamily C member 2	Homo sapiens	94-98
12887261-15	2003	In the current immunosuppressive regimens, a calcineurin inhibitor, either tacrolimus or cyclosporin, is the essential basic standard immunosuppressant.	Cyclosporine	89-100	calcineurin binding protein 1	Homo sapiens	45-66
12644037-1	2003	Cyclosporine A (CsA) reduces liver canalicular membrane (CM) fluidity to cause a disproportionate reduction of biliary lipid secretion (the uncoupling phenomenon) without affecting adenosine triphosphate-dependent (ABC) transporters except for Mdr1.	Cyclosporine	0-14	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	244-248
12644037-1	2003	Cyclosporine A (CsA) reduces liver canalicular membrane (CM) fluidity to cause a disproportionate reduction of biliary lipid secretion (the uncoupling phenomenon) without affecting adenosine triphosphate-dependent (ABC) transporters except for Mdr1.	Cyclosporine	16-19	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	244-248
12644037-6	2003	Hydrophilic bile salts significantly inhibited cholestasis after CsA injection by increasing CM fluidity and by increasing the expression of Mrp2 and Bsep, whereas Mdr1 and Mdr2 were unaltered.	Cyclosporine	65-68	ATP binding cassette subfamily C member 2	Rattus norvegicus	141-145
12499886-9	2002	CONCLUSION: Collectively, these findings support the utility of combined treatment with captopril and CsA in the multitherapeutic management of organ transplant and, possibly, a strategy to decrease the dose of the calcineurin inhibitor in kidney-transplant recipients.	Cyclosporine	102-105	calcineurin binding protein 1	Homo sapiens	215-236
12374807-3	2002	Blocking TCR.CD3-directed NFAT activation with cyclosporin A provokes a partial re-expression of CD3gamma gene transcripts and surface complexes in a time- and dose-dependent manner.	Cyclosporine	47-60	CD3 gamma subunit of T-cell receptor complex	Homo sapiens	97-105
12421236-7	2002	CONCLUSIONS: The present observations, contrary to expectation, reveal that lower cell densities of CD4+ T cells and lower CD4/CD8 ratios are associated with responsiveness to CsA in combination therapy, suggesting that pharmacological actions other than suppression of CD4+ T cells explain the efficacy of CsA in patients with chronic IP.	Cyclosporine	176-179	CD8a molecule	Homo sapiens	127-130
12502559-6	2002	Reduced surface expression of the Na(+)/Ca(2+) exchanger NCX1 is also observed when HEK293 cells expressing the transporter are treated with cyclosporin A (CsA) or with PSC833.	Cyclosporine	141-154	nascent polypeptide associated complex subunit alpha 2	Homo sapiens	34-45
12502559-6	2002	Reduced surface expression of the Na(+)/Ca(2+) exchanger NCX1 is also observed when HEK293 cells expressing the transporter are treated with cyclosporin A (CsA) or with PSC833.	Cyclosporine	156-159	nascent polypeptide associated complex subunit alpha 2	Homo sapiens	34-45
12479636-7	2002	RESULTS: CsA simultaneously stimulated TGF-beta1 expression and production and inhibited expression of MMP-1 and MMP-2 by human gingival fibroblasts, whereas CsA has a slight effect on TIMP-1 and TIMP-2 expression.	Cyclosporine	9-12	TIMP metallopeptidase inhibitor 2	Homo sapiens	196-202
12095984-1	2002	Cyclosporin A (CsA) inhibits opening of the mitochondrial permeability transition pore (MPTP), a critical event in some forms of necrotic and apoptotic cell death, by binding to cyclophilin D (CyP-D) and inhibiting its peptidyl-prolyl cis-trans isomerase (PPIase) activity.	Cyclosporine	0-13	peptidylprolyl isomerase D	Rattus norvegicus	178-191
12095984-1	2002	Cyclosporin A (CsA) inhibits opening of the mitochondrial permeability transition pore (MPTP), a critical event in some forms of necrotic and apoptotic cell death, by binding to cyclophilin D (CyP-D) and inhibiting its peptidyl-prolyl cis-trans isomerase (PPIase) activity.	Cyclosporine	0-13	peptidylprolyl isomerase D	Rattus norvegicus	193-198
12095984-1	2002	Cyclosporin A (CsA) inhibits opening of the mitochondrial permeability transition pore (MPTP), a critical event in some forms of necrotic and apoptotic cell death, by binding to cyclophilin D (CyP-D) and inhibiting its peptidyl-prolyl cis-trans isomerase (PPIase) activity.	Cyclosporine	15-18	peptidylprolyl isomerase D	Rattus norvegicus	178-191
12095984-1	2002	Cyclosporin A (CsA) inhibits opening of the mitochondrial permeability transition pore (MPTP), a critical event in some forms of necrotic and apoptotic cell death, by binding to cyclophilin D (CyP-D) and inhibiting its peptidyl-prolyl cis-trans isomerase (PPIase) activity.	Cyclosporine	15-18	peptidylprolyl isomerase D	Rattus norvegicus	193-198
12426765-0	2002	A Japanese case of severe refractory adult Still"s disease: serum interleukin-18 is a possible marker of the response to low-dose cyclosporin A therapy.	Cyclosporine	130-143	interleukin 18	Homo sapiens	66-80
12426765-5	2002	The serum interleukin-18 level was monitored throughout treatment and was found to be a potentially useful marker of disease activity as well as of the response to cyclosporin A therapy.	Cyclosporine	164-177	interleukin 18	Homo sapiens	10-24
12425850-0	2002	Effects of cyclosporin A on the levels of intercellular adhesion molecule-1 expressed by oral fibroblasts.	Cyclosporine	11-24	intercellular adhesion molecule 1	Homo sapiens	42-75
12425850-1	2002	OBJECTIVE: To investigate the effects of cyclosporin A (CSA) on the level of intercellular adhesion molecule-1 (ICAM-1) expressed by oral fibroblasts (FB).	Cyclosporine	41-54	intercellular adhesion molecule 1	Homo sapiens	77-110
12425850-1	2002	OBJECTIVE: To investigate the effects of cyclosporin A (CSA) on the level of intercellular adhesion molecule-1 (ICAM-1) expressed by oral fibroblasts (FB).	Cyclosporine	41-54	intercellular adhesion molecule 1	Homo sapiens	112-118
12425850-1	2002	OBJECTIVE: To investigate the effects of cyclosporin A (CSA) on the level of intercellular adhesion molecule-1 (ICAM-1) expressed by oral fibroblasts (FB).	Cyclosporine	56-59	intercellular adhesion molecule 1	Homo sapiens	77-110
12425850-1	2002	OBJECTIVE: To investigate the effects of cyclosporin A (CSA) on the level of intercellular adhesion molecule-1 (ICAM-1) expressed by oral fibroblasts (FB).	Cyclosporine	56-59	intercellular adhesion molecule 1	Homo sapiens	112-118
12425850-3	2002	Then the levels of ICAM-1 expressed by fibroblasts incubated with or without CSA in the presence of 10% fetal calf serum for 48 hours at 37 degrees C in 5% CO(2) and air were monitored by using cell-based ELISA for ICAM-1.	Cyclosporine	77-80	intercellular adhesion molecule 1	Homo sapiens	19-25
12425850-5	2002	CONCLUSIONS: CSA reduces the levels of ICAM-1 expressed by oral mucosal FB, and may be useful in the treatment of some oral mucosal disorders.	Cyclosporine	13-16	intercellular adhesion molecule 1	Homo sapiens	39-45
12193060-0	2002	HMG-CoA reductase inhibition and PPAR- alpha activation both inhibit cyclosporin A induced endothelin-1 secretion in cultured endothelial cells.	Cyclosporine	69-82	endothelin 1	Bos taurus	91-103
12128165-3	2002	This efflux was concentration dependent and subject to inhibition by the P-gp substrates verapamil and cyclosporin A.	Cyclosporine	103-116	phosphoglycolate phosphatase	Mus musculus	73-77
12140451-3	2002	We report a cutaneous CD30(+) T-cell lymphoma in a patient with atopic eczema during low-dose cyclosporin monotherapy.	Cyclosporine	94-105	TNF receptor superfamily member 8	Homo sapiens	22-26
12087018-0	2002	IA-2 antibody-negative status predicts remission and recovery of C-peptide levels in type 1 diabetic patients treated with cyclosporin.	Cyclosporine	123-134	protein tyrosine phosphatase receptor type N	Homo sapiens	0-4
12087018-5	2002	RESEARCH DESIGN AND METHODS: IA-2 antibodies were determined by radioligand binding assay in sera from patients recruited into the Canadian-European cyclosporin trial.	Cyclosporine	149-160	protein tyrosine phosphatase receptor type N	Homo sapiens	29-33
12087018-8	2002	Cyclosporin caused significant reduction in insulin requirements and significant increases in C-peptide secretion mainly in patients negative for IA-2 antibodies.	Cyclosporine	0-11	protein tyrosine phosphatase receptor type N	Homo sapiens	146-150
12087018-9	2002	Analysis of GAD antibodies in combination with antibodies to IA-2 indicated that the group most resistant to cyclosporin were IA-2 antibody positive, GAD antibody negative.	Cyclosporine	109-120	glutamate decarboxylase 1	Homo sapiens	12-15
12087018-9	2002	Analysis of GAD antibodies in combination with antibodies to IA-2 indicated that the group most resistant to cyclosporin were IA-2 antibody positive, GAD antibody negative.	Cyclosporine	109-120	protein tyrosine phosphatase receptor type N	Homo sapiens	61-65
12087018-9	2002	Analysis of GAD antibodies in combination with antibodies to IA-2 indicated that the group most resistant to cyclosporin were IA-2 antibody positive, GAD antibody negative.	Cyclosporine	109-120	protein tyrosine phosphatase receptor type N	Homo sapiens	126-130
12113888-1	2002	Cyclosporine A and steroids are effective against rheumatoid arthritis and also known as substrates of P-glycoprotein (P-gp).	Cyclosporine	0-14	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	103-117
12113888-1	2002	Cyclosporine A and steroids are effective against rheumatoid arthritis and also known as substrates of P-glycoprotein (P-gp).	Cyclosporine	0-14	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	119-123
12065418-5	2002	Moreover, IL-2Ralpha induction is impaired in T lymphocytes from transgenic mice expressing a dominant-negative c-jun construct, or following treatment with cyclosporin A.	Cyclosporine	157-170	interleukin 2 receptor, alpha chain	Mus musculus	10-20
12008048-3	2002	Similar changes were observed if cells were treated with the calcineurin inhibitor Cyclosporin-A.	Cyclosporine	83-96	calcineurin binding protein 1	Homo sapiens	61-82
12107549-2	2002	METHODS: Three sublines were developed from the sensitive Ehrlich ascites tumour cell line (EHR2) and six sublines from the EHR2/DNR cell line positive for P-glycoprotein (PGP) by treatment with daunorubicin (DNR), a combination of DNR and verapamil (VER), or a combination of DNR and cyclosporin A (CsA).	Cyclosporine	285-298	phosphoglycolate phosphatase	Mus musculus	172-175
12107549-2	2002	METHODS: Three sublines were developed from the sensitive Ehrlich ascites tumour cell line (EHR2) and six sublines from the EHR2/DNR cell line positive for P-glycoprotein (PGP) by treatment with daunorubicin (DNR), a combination of DNR and verapamil (VER), or a combination of DNR and cyclosporin A (CsA).	Cyclosporine	300-303	phosphoglycolate phosphatase	Mus musculus	172-175
12112443-9	2002	In addition, results from functional studies show that the accumulation of the P-glycoprotein substrate digoxin by RBE4 monolayer cells is significantly enhanced in the presence of standard P-glycoprotein inhibitors (verapamil, cyclosporin A, PSC 833), protease inhibitors (saquinavir, ritonavir, indinavir), and the metabolic inhibitor, sodium azide.	Cyclosporine	228-241	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	79-93
12042638-8	2002	RESULTS: Intrarenal expression of TGF-beta, collagen, fibronectin, MMP-2, MMP-9, and tissue inhibitor of MMP-2 was significantly increased in rats treated with CsA for 180 days compared with untreated rats and those treated for 30 days.	Cyclosporine	160-163	matrix metallopeptidase 9	Rattus norvegicus	74-79
11956130-7	2002	Treatment with either cyclosporin A or verapamil prevented increases in heart weight to body weight ratios, interstitial fibrosis, impaired contractility, PKC activation, and changes in the expression patterns of beta-MHC and SERCA2a.	Cyclosporine	22-35	ATPase, Ca++ transporting, cardiac muscle, slow twitch 2	Mus musculus	226-233
11903043-5	2002	The activation of all four caspases was inhibited by cyclosporin A, with the order of susceptibility caspase-8=caspase-9=caspase-6&gt;caspase-3.	Cyclosporine	53-66	caspase 8	Rattus norvegicus	101-110
12133455-15	2002	The prophylaxis effect of CsA + MTX with or without MMF was better than that of MMF alone, synergism between MMF of 10 or 30 mg.kg(-1).d(-1) and CsA + MTX was better than that of MMF of 60 mg.kg(-1).d(-1) and CsA + MTX.	Cyclosporine	26-29	metaxin 1	Mus musculus	151-154
12133455-15	2002	The prophylaxis effect of CsA + MTX with or without MMF was better than that of MMF alone, synergism between MMF of 10 or 30 mg.kg(-1).d(-1) and CsA + MTX was better than that of MMF of 60 mg.kg(-1).d(-1) and CsA + MTX.	Cyclosporine	26-29	metaxin 1	Mus musculus	151-154
12133455-15	2002	The prophylaxis effect of CsA + MTX with or without MMF was better than that of MMF alone, synergism between MMF of 10 or 30 mg.kg(-1).d(-1) and CsA + MTX was better than that of MMF of 60 mg.kg(-1).d(-1) and CsA + MTX.	Cyclosporine	145-148	metaxin 1	Mus musculus	32-35
12133455-15	2002	The prophylaxis effect of CsA + MTX with or without MMF was better than that of MMF alone, synergism between MMF of 10 or 30 mg.kg(-1).d(-1) and CsA + MTX was better than that of MMF of 60 mg.kg(-1).d(-1) and CsA + MTX.	Cyclosporine	145-148	metaxin 1	Mus musculus	32-35
11790791-6	2002	The induction of the mitochondrial permeability transition (MPT) was documented by the cyclosporin A (CyA) sensitivity of the release of cytochrome c, the release of malate dehydrogenase from the mitochondrial matrix, the loss of the mitochondrial membrane potential, and the pronounced swelling of these organelles, as assessed by electron microscopy.	Cyclosporine	102-105	malic enzyme 1	Homo sapiens	166-186
11918846-1	2002	AIM: To study whether P-glycoprotein (P-gp) inhibitor cyclosporin A (CsA) enhanced the protection of nimodipine (NMD) against brain damage.	Cyclosporine	54-67	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	22-36
11918846-1	2002	AIM: To study whether P-glycoprotein (P-gp) inhibitor cyclosporin A (CsA) enhanced the protection of nimodipine (NMD) against brain damage.	Cyclosporine	54-67	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	38-42
11918846-1	2002	AIM: To study whether P-glycoprotein (P-gp) inhibitor cyclosporin A (CsA) enhanced the protection of nimodipine (NMD) against brain damage.	Cyclosporine	69-72	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	22-36
11918846-1	2002	AIM: To study whether P-glycoprotein (P-gp) inhibitor cyclosporin A (CsA) enhanced the protection of nimodipine (NMD) against brain damage.	Cyclosporine	69-72	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	38-42
11918846-10	2002	CONCLUSION: P-gp inhibitor CsA may enhance the protection of NMD against brain damage.	Cyclosporine	27-30	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	12-16
11877340-7	2002	The accumulation of NBD-octreotide in capillary lumens was inhibited in a concentration-dependent manner by unlabelled octreotide, by verapamil, PSC-833 and cyclosporin A, potent inhibitors of p-glycoprotein, and by leucotriene C(4), a strong modulator of Mrp2.	Cyclosporine	157-170	ATP binding cassette subfamily C member 2	Homo sapiens	256-260
11831844-5	2002	In this report, we demonstrate that recombinant BNip3 (rBNip3) induces mitochondrial permeability transition (MPT) and cytochrome c release from isolated mitochondria, which are inhibited by the PT inhibitor cyclosporin A (CsA).	Cyclosporine	208-221	BCL2 interacting protein 3	Rattus norvegicus	55-61
11831844-5	2002	In this report, we demonstrate that recombinant BNip3 (rBNip3) induces mitochondrial permeability transition (MPT) and cytochrome c release from isolated mitochondria, which are inhibited by the PT inhibitor cyclosporin A (CsA).	Cyclosporine	223-226	BCL2 interacting protein 3	Rattus norvegicus	55-61
12806026-18	2002	Interestingly, soluble Fas-ligand secretion and CD8+ cell apoptosis, but not CD8+ cell cytolitic activity, are completely inhibited by Cyclosporin A, which specifically blocks the activation of the calcineurin/calmodulin pathway.	Cyclosporine	135-148	CD8a molecule	Homo sapiens	48-51
12003193-7	2002	These studies were performed in the presence or absence of cyclosporin A (CsA), a competitive inhibitor of Pgp.	Cyclosporine	74-77	phosphoglycolate phosphatase	Mus musculus	107-110
11739114-4	2002	The hyperosmotic solution in the presence of the P-gp inhibitors (verapamil or cyclosporin A) elicited RVI in the tubules from the WT mice but not from the KO mice.	Cyclosporine	79-92	phosphoglycolate phosphatase	Mus musculus	49-53
11817583-6	2002	The expression of ADAM-TS4, ADAM-TS5, and MMP-13 was abrogated by the inclusion of 10 microM CSA in the culture medium.	Cyclosporine	93-96	ADAM metallopeptidase with thrombospondin type 1 motif 5	Homo sapiens	28-36
11817607-0	2002	Cyclosporine differentially regulates interleukin-10, interleukin-15, and tumor necrosis factor a production by rheumatoid synoviocytes.	Cyclosporine	0-12	interleukin 10	Homo sapiens	38-52
11817607-0	2002	Cyclosporine differentially regulates interleukin-10, interleukin-15, and tumor necrosis factor a production by rheumatoid synoviocytes.	Cyclosporine	0-12	interleukin 15	Homo sapiens	54-68
11709325-2	2001	The typical substrates for P glycoprotein, i.e., cyclosporine, colchicine, and erythromycin, inhibited the biliary clearance of rhodamine-123, whereas a substrate for organic cation transporter, cimetidine, did not inhibit clearance, suggesting that rhodamine-123 is transported mainly by P glycoprotein.	Cyclosporine	49-61	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	27-41
11709325-2	2001	The typical substrates for P glycoprotein, i.e., cyclosporine, colchicine, and erythromycin, inhibited the biliary clearance of rhodamine-123, whereas a substrate for organic cation transporter, cimetidine, did not inhibit clearance, suggesting that rhodamine-123 is transported mainly by P glycoprotein.	Cyclosporine	49-61	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	289-303
11681844-12	2001	CD8(+) lymphocytes and microglia cells are most likely important effector cells in the late, cyclosporin A-resistant rejection process.	Cyclosporine	93-106	CD8a molecule	Homo sapiens	0-3
11592084-3	2001	Mouse cyclophilin C-associated protein (mCyCAP) is also a secreted glycoprotein that binds with high affinity to cyclophilin C in the absence of the immunosuppressive drug cyclosporin A.	Cyclosporine	172-185	lectin, galactoside-binding, soluble, 3 binding protein	Mus musculus	40-46
11745716-0	2001	Influence of P-glycoprotein on the transplacental passage of cyclosporine.	Cyclosporine	61-73	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	13-27
11745716-8	2001	Our findings indicate that P-glycoprotein pumps cyclosporine out of the trophoblast cells of the rat placenta in the ATP-dependent manner and restricts the passage of cyclosporine across the placental barrier.	Cyclosporine	48-60	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	27-41
11745716-8	2001	Our findings indicate that P-glycoprotein pumps cyclosporine out of the trophoblast cells of the rat placenta in the ATP-dependent manner and restricts the passage of cyclosporine across the placental barrier.	Cyclosporine	167-179	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	27-41
11579291-2	2001	Allografts obliterate within 3 weeks, the immunosuppression cyclosporine (CsA)-azathioprine (AZA)-methylprednisolone (MP) delays OB, but OB is prevented when AZA is switched to 40-0-(2-hydroxyethyl)-rapamycin (RAD).	Cyclosporine	60-72	RRAD, Ras related glycolysis inhibitor and calcium channel regulator	Homo sapiens	210-213
11579291-2	2001	Allografts obliterate within 3 weeks, the immunosuppression cyclosporine (CsA)-azathioprine (AZA)-methylprednisolone (MP) delays OB, but OB is prevented when AZA is switched to 40-0-(2-hydroxyethyl)-rapamycin (RAD).	Cyclosporine	74-77	RRAD, Ras related glycolysis inhibitor and calcium channel regulator	Homo sapiens	210-213
11745792-6	2001	ApoA-I, the major protein component of HDL, and intact LDL particles showed the most significant effects of CSA uptake and toxicity.	Cyclosporine	108-111	apolipoprotein A1	Sus scrofa	0-6
11745792-7	2001	The uptake and toxicity of CSA was effectively reduced with elevated LDL concentrations but showed a significant increase (p &lt; 0.05) when incubated with elevated concentrations of apoA-I.	Cyclosporine	27-30	apolipoprotein A1	Sus scrofa	183-189
11745792-10	2001	LDL and apoA-I are identified as the major effectors of CSA toxicity and uptake in LLC-PK(1) cells.	Cyclosporine	56-59	apolipoprotein A1	Sus scrofa	8-14
11548882-9	2001	Increased mRNA expression of atrial natriuretic factor by IGF-1 was inhibited by cyclosporine A (p &lt; 0.01).	Cyclosporine	81-95	natriuretic peptide A	Rattus norvegicus	29-54
11548882-11	2001	The fact that elevated calcineurin activity and induced atrial natriuretic factor mRNA expression by IGF-1 were blocked by cyclosporine A further supports the hypothesis that calcineurin is critically involved in IGF-1-induced ARVM hypertrophy.	Cyclosporine	123-137	natriuretic peptide A	Rattus norvegicus	56-81
11589784-6	2001	Cholestasis secondary to cyclosporine A could be related to reduction in mRNA expression of GSH synthesising enzymes and Mrp2, leading to reduced protection against oxidative stress and reduced bile acid-independent bile flow.	Cyclosporine	25-39	ATP binding cassette subfamily C member 2	Rattus norvegicus	121-125
11703521-0	2001	Transient CD30+ nodal transformation of cutaneous T-cell lymphoma associated with cyclosporine treatment.	Cyclosporine	82-94	TNF receptor superfamily member 8	Homo sapiens	10-14
11438213-1	2001	OBJECTIVE: Cyclosporin A (CsA), effective in prophylaxis and treatment of graft-vs-host disease (GVHD) after human allogeneic transplantation, blunts T-cell responses by inhibiting nuclear factor of activated T cells-1 (NFAT1) activation.	Cyclosporine	11-24	nuclear factor of activated T cells 1	Homo sapiens	181-218
11438213-1	2001	OBJECTIVE: Cyclosporin A (CsA), effective in prophylaxis and treatment of graft-vs-host disease (GVHD) after human allogeneic transplantation, blunts T-cell responses by inhibiting nuclear factor of activated T cells-1 (NFAT1) activation.	Cyclosporine	11-24	nuclear factor of activated T cells 1	Homo sapiens	220-225
11438213-1	2001	OBJECTIVE: Cyclosporin A (CsA), effective in prophylaxis and treatment of graft-vs-host disease (GVHD) after human allogeneic transplantation, blunts T-cell responses by inhibiting nuclear factor of activated T cells-1 (NFAT1) activation.	Cyclosporine	26-29	nuclear factor of activated T cells 1	Homo sapiens	181-218
11458978-0	2001	In vivo induction of hepatic p-glycoprotein by cyclosporine in the rat.	Cyclosporine	47-59	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	29-43
11458978-1	2001	The objective of the present study was to investigate the regulation of P-glycoprotein by cyclosporine, a known inhibitor of CYP3A, at different dosage levels and lengths of treatment.	Cyclosporine	90-102	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	72-86
11458978-6	2001	Significant induction of hepatic P-glycoprotein was found in rats given cyclosporine.	Cyclosporine	72-84	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	33-47
11458978-8	2001	Low doses of cyclosporine also induced P-glycoprotein but not to a significant extent, indicating a dose-dependent effect.	Cyclosporine	13-25	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	39-53
11458978-10	2001	Fourteen days after the discontinuation of cyclosporine treatment, P-glycoprotein levels returned to near the control values.	Cyclosporine	43-55	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	67-81
11458978-11	2001	As a drug efflux transporter, the induction of P-glycoprotein by cyclosporine may decrease the hepatic metabolism of P-glycoprotein substrates.	Cyclosporine	65-77	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	47-61
11458978-11	2001	As a drug efflux transporter, the induction of P-glycoprotein by cyclosporine may decrease the hepatic metabolism of P-glycoprotein substrates.	Cyclosporine	65-77	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	117-131
11458978-12	2001	Therefore this induction of hepatic P-glycoprotein and suppression of hepatic CYP3A may have a coordinate effect on the metabolism of cyclosporine.	Cyclosporine	134-146	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	36-50
11440739-0	2001	Cyclosporin A treatment modulates cytokine mRNA expression by inflammatory cells extracted from the spinal cord of rats with experimental autoimmune encephalomyelitis induced by inoculation with myelin basic protein.	Cyclosporine	0-13	myelin basic protein	Rattus norvegicus	195-215
11451170-0	2001	Identification of cyclosporine A and tacrolimus glucuronidation in human liver and the gastrointestinal tract by a differentially expressed UDP-glucuronosyltransferase: UGT2B7.	Cyclosporine	18-32	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	169-175
11451170-7	2001	Analyses using recombinant UDPglucuronosyltransferases identified UGT2B7 as a human UDP-glucuronosyltransferase with specific activity toward cyclosporine A and tacrolimus.	Cyclosporine	142-156	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	66-72
11340086-10	2001	BK-stimulated dephosphorylation of Thr-497 and NO release are blocked by the calcineurin inhibitor, cyclosporin A.	Cyclosporine	100-113	kininogen 1	Bos taurus	0-2
11380530-4	2001	During the mild hypoxaemia and the first 10 min of the recovery period, Q and CSA of MGA increased (maximal changes: +84 and +20%, respectively).	Cyclosporine	78-81	MAX dimerization protein MGA	Homo sapiens	85-88
11334874-0	2001	Chronic cyclosporine administration induces renal P-glycoprotein in rats.	Cyclosporine	8-20	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	50-64
11334874-1	2001	The effect of cyclosporine doses on renal P-glycoprotein expression was examined.	Cyclosporine	14-26	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	42-56
11334874-5	2001	Western blot analysis showed that cyclosporine administered orally at 10 and 30 mg/kg/day and subcutaneously at 15 mg/kg/day induced significantly renal P-glycoprotein expression.	Cyclosporine	34-46	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	153-167
11334874-6	2001	After discontinuation of cyclosporine, renal P-glycoprotein returned to pre-dosing levels in oral groups, whereas the return was incomplete in subcutaneous groups.	Cyclosporine	25-37	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	45-59
11334874-7	2001	These results indicate that cyclosporine induces renal P-glycoprotein overexpression a dose-dependent manner.	Cyclosporine	28-40	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	55-69
11254887-4	2001	In addition, the role of apoptosis inhibitors (Bcl-2 and Bcl-x) and the apoptosis inducer (Bax) in CsA induced-apoptosis was evaluated.	Cyclosporine	99-102	BCL2-associated X protein	Mus musculus	91-94
11254887-5	2001	The expression of Bcl-2 and Bax proteins were high in LBC cells and following CsA treatment the expression of these proteins as well as Bcl-XL decreased.	Cyclosporine	78-81	BCL2-associated X protein	Mus musculus	28-31
12687202-4	2001	CsA downregulates PMA/ionomycin-induced LTalpha at both transcription and protein expression levels, whereas it downregulates LTbeta at the transcript but not at the protein expression levels.	Cyclosporine	0-3	lymphotoxin alpha	Homo sapiens	40-47
11238591-0	2001	Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2.	Cyclosporine	84-97	vascular endothelial growth factor A	Mus musculus	24-58
11222523-1	2001	PURPOSE: To test the hypothesis that beneficial effects of Cyclosporin A (CsA; Sandimmune; Sandoz, Basel, Switzerland) in treating keratoconjunctivitis sicca (KCS) include an effect on the mucin-producing conjunctival goblet cells independent of CsA"s effect on lacrimation.	Cyclosporine	59-72	mucin	Canis lupus familiaris	189-194
11222523-11	2001	At 4 and 6 weeks (after 2 and 4 weeks of topical treatment), intraepithelial mucin quantities were significantly greater (P: &lt; 0.05) in CsA-treated KCS eyes (14.4 and 13.1 microm(2)/microm, respectively) compared with pretreatment KCS (7.4 microm(2)/microm) eyes and vehicle-treated KCS eyes (7.3 and 8.5 microm(2)/microm, respectively).	Cyclosporine	139-142	mucin	Canis lupus familiaris	77-82
11222523-13	2001	CONCLUSIONS: Topical 2% CsA restored in vivo conjunctival mucin stores to control levels over a 4-week period, determined by computer-assisted morphometry of sequential conjunctival biopsy specimens from eyes of dogs with surgically induced KCS.	Cyclosporine	24-27	mucin	Canis lupus familiaris	58-63
11558493-2	2001	We did a randomised controlled trial of mycophenolate mofetil monotherapy in liver transplant patients who developed renal failure associated with calcineurin-inhibitor (ciclosporin or tacrolimus) immunosuppressive therapy.	Cyclosporine	170-181	calcineurin binding protein 1	Homo sapiens	147-168
11226376-5	2001	We conclude that the increases in cyclin D1, PCNA, and cyclin E, together with the invariable level of p27, clearly show that CsA induces hepatocytes to proliferate.	Cyclosporine	126-129	proliferating cell nuclear antigen	Rattus norvegicus	45-49
11217075-5	2001	TM-BBB cells are able to undergo efflux transport of cyclosporin A, which is a substrate for P-gp transport activity.	Cyclosporine	53-66	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	93-97
11516824-0	2001	Involvement of the brain-derived neurotrophic factor/TrkB pathway in neuroprotecive effect of cyclosporin A in forebrain ischemia.	Cyclosporine	94-107	brain-derived neurotrophic factor	Rattus norvegicus	19-52
11516824-5	2001	Based on these observations, we attempted to investigate how cyclosporin A treatment would affect the changes of phosphorylated CREB (pCREB), BDNF and its receptor tyrosine kinase B (TrkB) after forebrain ischemia in rats.	Cyclosporine	61-74	brain-derived neurotrophic factor	Rattus norvegicus	142-146
11263551-8	2001	The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.	Cyclosporine	91-103	calcineurin binding protein 1	Homo sapiens	4-25
10978330-9	2000	Another observation that MRP2 inhibitor, cyclosporine A, failed to inhibit R1230A specifically, indicated the existence of its binding site within TM16.	Cyclosporine	41-55	ATP binding cassette subfamily C member 2	Homo sapiens	25-29
11169414-3	2000	ICOS requires both phorbol 12-myristate 13-acetate and ionomycin for full induction, and is sensitive to Cyclosporin A.	Cyclosporine	105-118	inducible T cell costimulator	Homo sapiens	0-4
11206060-3	2000	In vitro, the CyPB/CsA complex is more effective in inhibiting calcineurin than the CyPA/CsA and CyPC/CsA complexes, pointing to fine structural differences in the calcineurin-binding region.	Cyclosporine	19-22	peptidylprolyl isomerase B	Homo sapiens	14-18
11206060-3	2000	In vitro, the CyPB/CsA complex is more effective in inhibiting calcineurin than the CyPA/CsA and CyPC/CsA complexes, pointing to fine structural differences in the calcineurin-binding region.	Cyclosporine	89-92	peptidylprolyl isomerase B	Homo sapiens	14-18
11206060-3	2000	In vitro, the CyPB/CsA complex is more effective in inhibiting calcineurin than the CyPA/CsA and CyPC/CsA complexes, pointing to fine structural differences in the calcineurin-binding region.	Cyclosporine	89-92	peptidylprolyl isomerase B	Homo sapiens	14-18
11206060-7	2000	These results strongly suggest that the three amino acids G77, D155, and D158 are directly involved in the interaction of CyPB/CsA with calcineurin, in agreement with their exposed position.	Cyclosporine	127-130	peptidylprolyl isomerase B	Homo sapiens	122-126
11206060-8	2000	The G77, D155, and D158 residues are not maintained in CyPA and might therefore account for the higher affinity of the CyPB/CsA complex for calcineurin.	Cyclosporine	124-127	peptidylprolyl isomerase B	Homo sapiens	119-123
11073891-13	2000	Cyclosporin A significantly reduced the LIF-induced increase in [(3)H]phenylalanine uptake.	Cyclosporine	0-13	LIF, interleukin 6 family cytokine	Rattus norvegicus	40-43
11293243-10	2000	After 24 h degeneration of the CA1 pyramidal neurones close to a microdialysis probes was observed, which was partially prevented in CsA-treated rabbits.	Cyclosporine	133-136	carbonic anhydrase 1	Oryctolagus cuniculus	31-34
11069439-1	2000	AIMS: The aim of the study was to investigate the pharmacokinetics and metabolism of the new immunosuppressant SDZ RAD during concomitant therapy with cyclosporin in stable renal transplant patients.	Cyclosporine	151-162	RRAD, Ras related glycolysis inhibitor and calcium channel regulator	Homo sapiens	115-118
11091246-8	2000	Although cyclosporin treatment reduced levels of the matrix-degrading enzymes, matrix metalloproteinase (MMP) 2 and MMP-9, this was not statistically significant.	Cyclosporine	9-20	matrix metallopeptidase 9	Rattus norvegicus	116-121
11035054-3	2000	Interestingly, cyclosporin A further augmented RXRalpha expression, indicating the involvement of calcineurin pathways in the process.	Cyclosporine	15-28	retinoid X receptor alpha	Homo sapiens	47-55
11033075-7	2000	When verapamil or cyclosporin A, potent modulators of P-gp, was added to the apical medium together with unlabeled VLB, enhanced basolateral-to-apical transport of [3H]VLB was disappeared.	Cyclosporine	18-31	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	54-58
11053632-0	2000	Switch from cyclosporine A to tacrolimus in renal transplant recipients: impact on Th1, Th2, and monokine responses.	Cyclosporine	12-26	negative elongation factor complex member C/D	Homo sapiens	83-86
10925268-9	2000	The mitogen (anti-CD3)-induced proliferation of splenocytes from p21-overexpressing mice was significantly decreased, and again this effect was augmented by cotreatment with cyclosporine.	Cyclosporine	174-186	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	65-68
10931158-10	2000	CsA reduces expression of CD54 and its ligands.	Cyclosporine	0-3	intercellular adhesion molecule 1	Rattus norvegicus	26-30
10933163-3	2000	In the present study, we investigated in vitro whether CsA could alter the antigenicity of activated porcine aortic endothelial cells (PAECs) by reducing class I and class II MHC antigen expression.	Cyclosporine	55-58	major histocompatibility complex, class I, C	Homo sapiens	175-178
10933163-4	2000	METHODS: The effect of CsA on MHC antigen expression during tumor necrosis factor (TNF)-alpha- or lymphocyte-mediated PAEC activation was evaluated in vitro by flow cytometry and correlated to the ability of porcine ECs to promote human T lymphocyte proliferation.	Cyclosporine	23-26	major histocompatibility complex, class I, C	Homo sapiens	30-33
10933163-5	2000	The effect of CsA on class II MHC antigen mRNA expression was also analyzed and related to class II transcriptional activator (CIITA) mRNA expression.	Cyclosporine	14-17	major histocompatibility complex, class I, C	Homo sapiens	30-33
10933163-6	2000	RESULTS: Flow cytometry analysis showed that TNF-alpha-mediated induction of class II MHC antigen expression on PAECs was completely inhibited by CsA, whereas expression of class I MHC was reduced by 50%.	Cyclosporine	146-149	major histocompatibility complex, class I, C	Homo sapiens	86-89
10933163-10	2000	Pretreatment of PAECs with CsA for 4 hr before coculture with human peripheral blood leukocytes efficiently blocked the induction on PAECs of E-selectin and class II MHC antigens and inhibited overexpression of class I antigens.	Cyclosporine	27-30	major histocompatibility complex, class I, C	Homo sapiens	166-169
10933163-13	2000	CONCLUSION: Our study indicates that CsA could play a role in preventing porcine MHC antigens being directly presented to human T lymphocytes by xenogeneic ECs.	Cyclosporine	37-40	major histocompatibility complex, class I, C	Homo sapiens	81-84
10887328-8	2000	This DNA-binding activity was inhibited by cyclosporin A, which indicated that NFATx nuclear translocation in CD4(+)CD8(+) thymocytes was regulated by calcineurin phosphatase.	Cyclosporine	43-56	CD8a molecule	Homo sapiens	116-119
10930191-0	2000	Effects of chronic neutral endopeptidase inhibition in rats with cyclosporine-induced hypertension.	Cyclosporine	65-77	membrane metallo-endopeptidase	Rattus norvegicus	19-40
10915175-1	2000	Liver allograft survival rates of 50% to 60% are reported in blood group A, group B, group O (ABO)-incompatible mismatched grafts even when aggressive immunosuppressive protocols, including plasmapheresis, OKT(3), cyclophosphamide, cyclosporine, prostaglandin E(1), and steroids, are used.	Cyclosporine	232-244	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	94-97
11249625-5	2000	Combination of ICAM-1 antisense phosphorothioate oligonucleotide and cyclosporine (CsA) produced a potent synergistic interaction on allograft survival in comparison with each drug alone.	Cyclosporine	83-86	intercellular adhesion molecule 1	Homo sapiens	15-21
10736526-8	2000	The number of CD4(+), CD8(+), T cell receptor (TCR) alpha ss-bearing cells and TCRgamma delta-bearing cells decreased markedly in the peripheral blood of CsA-treated chickens compared to those of untreated chickens.	Cyclosporine	154-157	CD8a molecule	Gallus gallus	22-25
10820430-7	2000	Our functional analysis of P-gp showed a modest effect of P-gp modulators (CsA, verapamil, PSC 833) on the uptake of colchicine (a substrate of P-gp) by astrocytes, whereas they increased by about 50% the uptake of vincristine (a common substrate of P-gp and MRP) by astrocytes.	Cyclosporine	75-78	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	27-31
10820430-7	2000	Our functional analysis of P-gp showed a modest effect of P-gp modulators (CsA, verapamil, PSC 833) on the uptake of colchicine (a substrate of P-gp) by astrocytes, whereas they increased by about 50% the uptake of vincristine (a common substrate of P-gp and MRP) by astrocytes.	Cyclosporine	75-78	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	58-62
10820430-7	2000	Our functional analysis of P-gp showed a modest effect of P-gp modulators (CsA, verapamil, PSC 833) on the uptake of colchicine (a substrate of P-gp) by astrocytes, whereas they increased by about 50% the uptake of vincristine (a common substrate of P-gp and MRP) by astrocytes.	Cyclosporine	75-78	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	58-62
10820430-7	2000	Our functional analysis of P-gp showed a modest effect of P-gp modulators (CsA, verapamil, PSC 833) on the uptake of colchicine (a substrate of P-gp) by astrocytes, whereas they increased by about 50% the uptake of vincristine (a common substrate of P-gp and MRP) by astrocytes.	Cyclosporine	75-78	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	58-62
10820430-7	2000	Our functional analysis of P-gp showed a modest effect of P-gp modulators (CsA, verapamil, PSC 833) on the uptake of colchicine (a substrate of P-gp) by astrocytes, whereas they increased by about 50% the uptake of vincristine (a common substrate of P-gp and MRP) by astrocytes.	Cyclosporine	75-78	ATP binding cassette subfamily C member 2	Rattus norvegicus	259-262
10928095-0	2000	Cyclosporine A inhibition of prolactin-dependent up-regulation of BRCA1 protein expression in human breast cell lines.	Cyclosporine	0-14	BRCA1 DNA repair associated	Homo sapiens	66-71
10928095-2	2000	In this work, we studied the effects of Cyclosporine A and the competition with Prolactin on BRCA1 protein expression in vitro.	Cyclosporine	40-54	BRCA1 DNA repair associated	Homo sapiens	93-98
10872745-6	2000	Similarly, in the current study, amyloid-induced mitochondrial iron trapping was significantly attenuated by co-administration of the HO-1 transcriptional suppressor, dexamethasone (DEX) or the MTP blocker, cyclosporin A (CSA).	Cyclosporine	222-225	heme oxygenase 1	Rattus norvegicus	134-138
10800943-2	2000	The effects of cyclosporin A (CsA) on Ca2+ accumulation and MPT pore assembly were compared with those obtained with ubiquinone 0 (Ubo), a quinone that is a stronger MPT blocker than CsA, when tested on muscle and liver mitochondria.	Cyclosporine	30-33	carbonic anhydrase 2	Homo sapiens	38-41
10800943-9	2000	However, CsA eliminated the Ca2+ release accompanying the first Ca2+ pulse.	Cyclosporine	9-12	carbonic anhydrase 2	Homo sapiens	28-31
10800943-9	2000	However, CsA eliminated the Ca2+ release accompanying the first Ca2+ pulse.	Cyclosporine	9-12	carbonic anhydrase 2	Homo sapiens	64-67
10836388-0	2000	Comparison between tacrolimus and cyclosporine as immunosuppressive agents compatible with tolerance induction by CD4/CD8 blockade.	Cyclosporine	34-46	CD4 antigen	Mus musculus	114-117
10760803-3	2000	Co-stimulation with ICAM-1 and B7.2 led to strong and CsA-resistant proliferation, which was found to be largely IL-2 dependent.	Cyclosporine	54-57	intercellular adhesion molecule 1	Homo sapiens	20-26
10760803-5	2000	In contrast, both ICAM-1 and B7.2 enhanced the half-life of the inducible IL-2 transcript in a CsA-resistant manner.	Cyclosporine	95-98	intercellular adhesion molecule 1	Homo sapiens	18-24
10702360-5	2000	Four hours after CsA treatment, chromatin condensation and fragmentation and the number of TUNEL- and Annexin V-positive cells increased dose-dependently without any observable enzyme leakage, which indicated the integrity of the outer cell membrane.	Cyclosporine	17-20	annexin A5	Rattus norvegicus	102-111
10702360-6	2000	After 20 h of CsA incubation apoptosis parameters were further increased and were accompanied by the increased activity of the cysteine protease, caspase-3 (CPP 32), and slightly increased caspase-6 (Mch 2), but not caspase-1 (ICE).	Cyclosporine	14-17	caspase 1	Rattus norvegicus	216-225
10702360-6	2000	After 20 h of CsA incubation apoptosis parameters were further increased and were accompanied by the increased activity of the cysteine protease, caspase-3 (CPP 32), and slightly increased caspase-6 (Mch 2), but not caspase-1 (ICE).	Cyclosporine	14-17	caspase 1	Rattus norvegicus	227-230
10679127-0	2000	High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism.	Cyclosporine	100-113	interleukin 17A	Homo sapiens	15-20
10679127-0	2000	High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism.	Cyclosporine	100-113	interleukin 15	Homo sapiens	55-60
10679127-0	2000	High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism.	Cyclosporine	100-113	interleukin 17A	Homo sapiens	79-84
10679127-7	2000	Moreover, PMA + ionomycin-triggered IL-17 secretion is completely or partially blocked in the presence of low doses of cyclosporin A or high doses of methylprednisolone, respectively.	Cyclosporine	119-132	interleukin 17A	Homo sapiens	36-41
10679127-9	2000	Thus, our results suggest for the first time that IL-15 may represent a physiological trigger that via cyclosporin A and steroid sensitive pathways leads to the overproduction of IL-17 in the joints of rheumatoid arthritis patients.	Cyclosporine	103-116	interleukin 15	Homo sapiens	50-55
10679127-9	2000	Thus, our results suggest for the first time that IL-15 may represent a physiological trigger that via cyclosporin A and steroid sensitive pathways leads to the overproduction of IL-17 in the joints of rheumatoid arthritis patients.	Cyclosporine	103-116	interleukin 17A	Homo sapiens	179-184
10685792-0	2000	Divergent effect of cyclosporine on Th1/Th2 type cytokines in patients with severe, refractory rheumatoid arthritis.	Cyclosporine	20-32	negative elongation factor complex member C/D	Homo sapiens	36-39
10685792-1	2000	OBJECTIVE: To investigate the effect of cyclosporine on cytokine production, especially on T helper 1 (Th1) and T helper 2 (Th2) type cytokines, in patients with rheumatoid arthritis (RA).	Cyclosporine	40-52	negative elongation factor complex member C/D	Homo sapiens	103-106
10685792-6	2000	The degree of IL-10 increases correlated strongly with the degree of IL-12 decreases in the cyclosporine group (r = 0.572, p = 0.016).	Cyclosporine	92-104	interleukin 10	Homo sapiens	14-19
10685792-8	2000	Within the cyclosporine group, the improved patients (n = 10) compared to the non-improved patients (n = 7) had a greater increase in circulating IL-10 (median 172.0 vs 85.2%; p = 0.01).	Cyclosporine	11-23	interleukin 10	Homo sapiens	146-151
10685792-9	2000	The rate of increase of IL-10 strongly correlated with the rate of improvement of joint scores (r = 0.718, p = 0.001) after administration of cyclosporine.	Cyclosporine	142-154	interleukin 10	Homo sapiens	24-29
10685792-10	2000	CONCLUSION: Our results suggest that the therapeutic effect of cyclosporine is achieved by correcting a Th1/Th2 imbalance (a shift of Th1 type to Th2 type), which may be involved in the pathogenesis of RA; and that circulating IL-10 is useful to assess the clinical improvements in patients with RA after administration of cyclosporine.	Cyclosporine	63-75	negative elongation factor complex member C/D	Homo sapiens	104-107
10685792-10	2000	CONCLUSION: Our results suggest that the therapeutic effect of cyclosporine is achieved by correcting a Th1/Th2 imbalance (a shift of Th1 type to Th2 type), which may be involved in the pathogenesis of RA; and that circulating IL-10 is useful to assess the clinical improvements in patients with RA after administration of cyclosporine.	Cyclosporine	63-75	negative elongation factor complex member C/D	Homo sapiens	134-137
10685792-10	2000	CONCLUSION: Our results suggest that the therapeutic effect of cyclosporine is achieved by correcting a Th1/Th2 imbalance (a shift of Th1 type to Th2 type), which may be involved in the pathogenesis of RA; and that circulating IL-10 is useful to assess the clinical improvements in patients with RA after administration of cyclosporine.	Cyclosporine	63-75	interleukin 10	Homo sapiens	227-232
10685792-10	2000	CONCLUSION: Our results suggest that the therapeutic effect of cyclosporine is achieved by correcting a Th1/Th2 imbalance (a shift of Th1 type to Th2 type), which may be involved in the pathogenesis of RA; and that circulating IL-10 is useful to assess the clinical improvements in patients with RA after administration of cyclosporine.	Cyclosporine	323-335	negative elongation factor complex member C/D	Homo sapiens	104-107
10685792-10	2000	CONCLUSION: Our results suggest that the therapeutic effect of cyclosporine is achieved by correcting a Th1/Th2 imbalance (a shift of Th1 type to Th2 type), which may be involved in the pathogenesis of RA; and that circulating IL-10 is useful to assess the clinical improvements in patients with RA after administration of cyclosporine.	Cyclosporine	323-335	negative elongation factor complex member C/D	Homo sapiens	134-137
10648640-5	2000	The Mdr1 modulators cyclosporin A and vinblastine did not inhibit binding, which is different from Mdr1.	Cyclosporine	20-33	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	4-8
11450070-0	2000	Indomethacin and cyclosporin a inhibit in vitro ischemia-induced expression of ICAM-1 and chemokines in human brain endothelial cells.	Cyclosporine	17-30	intercellular adhesion molecule 1	Homo sapiens	79-85
10729997-5	2000	The absolute number of CD8+CD57+ cells in the patients with grade II-IV acute GVHD was also significantly higher in the tacrolimus group compared with the CsA group.	Cyclosporine	155-158	CD8a molecule	Homo sapiens	23-26
10648003-6	2000	The effects of the immunosuppressants dexamethasone, cyclosporin A (CA), and cortisol differ in their capacity to influence CD163 mRNA levels.	Cyclosporine	53-66	CD163 molecule	Homo sapiens	124-129
10641981-5	2000	Intravenous cyclosporine also requires CrEL and has been associated with pancreatitis.	Cyclosporine	12-24	REL proto-oncogene, NF-kB subunit	Homo sapiens	39-43
11076396-7	2000	BSEP is a vulnerable target for inhibition by estrogen metabolites, drugs such as cyclosporine A, and abnormal bile salt metabolites, all of which can cause retention of bile salts and consequently intrahepatic cholestasis.	Cyclosporine	82-96	ATP binding cassette subfamily B member 11	Homo sapiens	0-4
10592304-3	1999	Following intraventricular administration of cyclosporin A (CsA), detectable cytosolic cytochrome c was dramatically decreased, and about 80% of CA1 neurons survived after ischemia.	Cyclosporine	60-63	carbonic anhydrase 1	Homo sapiens	145-148
10574997-1	1999	It has been reported that immunosuppressant cyclosporin A or FK506 binds to immunophilins in the cell and that these immunophilins make a complex with molecular chaperones HSP70 or HSP90.	Cyclosporine	44-57	heat shock protein family A (Hsp70) member 4	Homo sapiens	172-177
10600799-0	1999	Cyclosporin-induced dyslipoproteinemia is associated with selective activation of SREBP-2.	Cyclosporine	0-11	sterol regulatory element binding factor 2	Mus musculus	82-89
10600799-9	1999	These results show that the molecular mechanisms by which cyclosporin causes dyslipoproteinemia may, in part, be mediated by selective activation of SREBP-2, leading to enhanced expression of lipid metabolism genes and hepatic secretion of VLDL triglyceride.	Cyclosporine	58-69	sterol regulatory element binding factor 2	Mus musculus	149-156
10612271-3	1999	Calcineurin inhibitor-induced acute renal failure may occur as early as a few weeks or months after initiation of cyclosporin therapy.	Cyclosporine	114-125	calcineurin binding protein 1	Homo sapiens	0-21
10658936-9	1999	CsA decreased plasma renin significantly and increased the urinary excretion rate of prostaglandin E2 (PgE2), 6-keto-prostaglandin F1alpha (6-keto-PgF1alpha) and thromboxane B2(TxB2) when compared to the control day.	Cyclosporine	0-3	immunoglobulin kappa variable 5-2	Homo sapiens	174-181
10573060-7	1999	RESULTS: Exposure of replicating DC progenitors propagated in GM-CSF or GM-CSF+TGF-beta to CsA reduced costimulatory molecule expression, without affecting MHC antigen expression.	Cyclosporine	91-94	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	62-68
10573060-7	1999	RESULTS: Exposure of replicating DC progenitors propagated in GM-CSF or GM-CSF+TGF-beta to CsA reduced costimulatory molecule expression, without affecting MHC antigen expression.	Cyclosporine	91-94	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	72-78
10573082-10	1999	If given only after the transplant, IL-10 either had no effect on graft survival or (at high dosage) accelerated rejection and prevented the immunosuppressive effect of cyclosporine.	Cyclosporine	169-181	interleukin 10	Homo sapiens	36-41
10607425-5	1999	Cyclosporin A inhibits induction of JNK function by TCR/CD28, PMA/ionomycin, ceramide, or H(2)O(2), but not induction by UV light or hyperosmolar sorbitol.	Cyclosporine	0-13	mitogen-activated protein kinase 8	Mus musculus	36-39
10537053-7	1999	Furthermore, the P-gp blocker cyclosporin A induced a large increase in apical to basal permeability of vincristine.	Cyclosporine	30-43	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	17-21
10502402-0	1999	Murine TRAIL (TNF-related apoptosis inducing ligand) expression induced by T cell activation is blocked by rapamycin, cyclosporin A, and inhibitors of phosphatidylinositol 3-kinase, protein kinase C, and protein tyrosine kinases: evidence for TRAIL induction via the T cell receptor signaling pathway.	Cyclosporine	118-131	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	7-12
10502402-0	1999	Murine TRAIL (TNF-related apoptosis inducing ligand) expression induced by T cell activation is blocked by rapamycin, cyclosporin A, and inhibitors of phosphatidylinositol 3-kinase, protein kinase C, and protein tyrosine kinases: evidence for TRAIL induction via the T cell receptor signaling pathway.	Cyclosporine	118-131	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	14-51
10502402-0	1999	Murine TRAIL (TNF-related apoptosis inducing ligand) expression induced by T cell activation is blocked by rapamycin, cyclosporin A, and inhibitors of phosphatidylinositol 3-kinase, protein kinase C, and protein tyrosine kinases: evidence for TRAIL induction via the T cell receptor signaling pathway.	Cyclosporine	118-131	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	243-248
10502402-8	1999	In addition, TRAIL induction was inhibited by cyclosporin A, implicating the Ca(2+)/calmodulin-dependent protein phosphatase calcineurin.	Cyclosporine	46-59	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	13-18
10547073-9	1999	CD40L, the calcium chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N",N"-tetraacetic acid-acetoxymethyl ester, and cyclosporin A all prevented anti-IgM-induced p27Kip1 accumulation, suggesting that both the decrease in c-Myc expression and an increase in free calcium are necessary for p27Kip1 up-regulation.	Cyclosporine	110-123	cyclin-dependent kinase inhibitor 1B	Mus musculus	155-162
10547073-9	1999	CD40L, the calcium chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N",N"-tetraacetic acid-acetoxymethyl ester, and cyclosporin A all prevented anti-IgM-induced p27Kip1 accumulation, suggesting that both the decrease in c-Myc expression and an increase in free calcium are necessary for p27Kip1 up-regulation.	Cyclosporine	110-123	cyclin-dependent kinase inhibitor 1B	Mus musculus	281-288
10504468-3	1999	Cell cycle arrest induced by CsA was coincident with elevated p53 levels.	Cyclosporine	29-32	tumor protein p53	Sus scrofa	62-65
10504468-4	1999	It is possible that trans-activating p21 may mediate the halting of the cell cycle through the CsA-induced accumulation of p53.	Cyclosporine	95-98	tumor protein p53	Sus scrofa	123-126
10477599-1	1999	Single C motif-1 (SCM-1)/lymphotactin is a C-type chemokine whose expression is activation dependent, cyclosporin A sensitive and restricted to CD8+ T cells, double-negative thymocytes, gammadelta-type T cells, and NK cells.	Cyclosporine	102-115	X-C motif chemokine ligand 1	Homo sapiens	0-16
10477599-1	1999	Single C motif-1 (SCM-1)/lymphotactin is a C-type chemokine whose expression is activation dependent, cyclosporin A sensitive and restricted to CD8+ T cells, double-negative thymocytes, gammadelta-type T cells, and NK cells.	Cyclosporine	102-115	X-C motif chemokine ligand 1	Homo sapiens	18-23
10477599-1	1999	Single C motif-1 (SCM-1)/lymphotactin is a C-type chemokine whose expression is activation dependent, cyclosporin A sensitive and restricted to CD8+ T cells, double-negative thymocytes, gammadelta-type T cells, and NK cells.	Cyclosporine	102-115	X-C motif chemokine ligand 1	Homo sapiens	25-37
10477599-4	1999	The luciferase reporter gene under the control of the 5" flanking region of 0.7 kb was strongly induced upon activation with anti-CD3 or PHA plus PMA only in SCM-1-producer T cell lines through a cyclosporin A-sensitive mechanism.	Cyclosporine	196-209	X-C motif chemokine ligand 1	Homo sapiens	158-163
10526580-6	1999	Dexamethasone was found to potentiate CTLA-4 expression in a dose-dependent manner with an EC50 effective concentration 50%) of about 10(-8) M. In contrast, other immunosuppressive agents, such as rapamycin or cyclosporin A had no or an inhibitory effect on CTLA-4 expression, respectively.	Cyclosporine	210-223	cytotoxic T-lymphocyte-associated protein 4	Mus musculus	38-44
10482841-9	1999	Cyclosporin A had no significant effect on BHR and neutrophil accumulation but reduced the number of bronchoalveolar lavage eosinophils (P &lt;.002), airway submucosal eosinophils, and CD4(+) and CD8(+) T cells (P &lt;.02).	Cyclosporine	0-13	Cd4 molecule	Rattus norvegicus	185-188
10455158-4	1999	ANF alone had no effect but inhibited PE-induced increases in CSA by approximately 50%.	Cyclosporine	62-65	natriuretic peptide A	Rattus norvegicus	0-3
10421658-8	1999	Cyclosporin A competitively inhibited human and rat MRP2-mediated transport of [(3)H]MGB, with K(i) values of 21 and 10 micromol/L, respectively.	Cyclosporine	0-13	ATP binding cassette subfamily C member 2	Rattus norvegicus	52-56
10454019-4	1999	AcP and ALP activity increased 1 day after CsA administration and became similar to the control by the day 30.	Cyclosporine	43-46	ATHS	Homo sapiens	8-11
10386979-1	1999	Cyclophilin B (CyPB) is a cyclosporin A (CsA)-binding protein mainly located in intracellular vesicles and secreted in biological fluids.	Cyclosporine	26-39	peptidylprolyl isomerase B	Homo sapiens	0-13
10386979-1	1999	Cyclophilin B (CyPB) is a cyclosporin A (CsA)-binding protein mainly located in intracellular vesicles and secreted in biological fluids.	Cyclosporine	26-39	peptidylprolyl isomerase B	Homo sapiens	15-19
10382954-6	1999	Additional studies have shown that HC and CsA blocked con A-driven differentiation of CD8+ and CD4+ CD8+ lymph node cells (LNC) and progression of LNC to S + G2/M cell cycle phases, and inhibited IL-1, IL-2 and TGF-beta while enhancing GM-CSF gene expression in BM cells.	Cyclosporine	42-45	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	236-242
10408980-0	1999	Effects of cyclosporin A treatment on clinical course and inflammatory cell apoptosis in experimental autoimmune encephalomyelitis induced in Lewis rats by inoculation with myelin basic protein.	Cyclosporine	11-24	myelin basic protein	Rattus norvegicus	173-193
10408980-12	1999	CsA treatment caused an increase in the percentages of CD5+ and TCR alphabeta+ cells that were apoptotic.	Cyclosporine	0-3	Cd5 molecule	Rattus norvegicus	55-58
10220486-4	1999	Intestinal excretion of [3H]IVM and [3H]CSA was enhanced in PGP (+/+) animals.	Cyclosporine	40-43	phosphoglycolate phosphatase	Mus musculus	60-63
10217279-7	1999	Incubation of slices in the presence of cyclosporin A plus either okadaic acid or calyculin A, another PP-1/PP-2A inhibitor, caused a synergistic increase in the level of phosphorylated DARPP-32.	Cyclosporine	40-53	protein phosphatase 2, regulatory subunit A, alpha	Mus musculus	108-113
10101139-10	1999	In addition, CsA accelerated the recovery and/or prevented the decrease of caffeine elimination 24 h after PHx but not at later time points, indicating an early, but unsustained, beneficial effect of CsA on the recovery of CYP1A2-mediated activities.	Cyclosporine	13-16	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	223-229
10101139-10	1999	In addition, CsA accelerated the recovery and/or prevented the decrease of caffeine elimination 24 h after PHx but not at later time points, indicating an early, but unsustained, beneficial effect of CsA on the recovery of CYP1A2-mediated activities.	Cyclosporine	200-203	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	223-229
10206323-7	1999	The steady-state uptake of BTL by LLC-GA5-COL300 cells, expressing human P-gp, was significantly increased in the presence of 20 microM cyclosporin A (another P-gp inhibitor), which had no effect in the LLC-PK1 host cells.	Cyclosporine	136-149	phosphoglycolate phosphatase	Mus musculus	159-163
10213371-5	1999	Excretion of GS-MF was decreased in presence of the MRP-blocker M K-571.2) Transport experiments with cyclosporin A demonstrated the functional activity of P-gp.	Cyclosporine	102-115	chromosome 19 open reading frame 48	Homo sapiens	52-55
9933022-6	1999	Cyclosporin A and herbimycin A, which suppress c-fos and c-jun gene expressions, respectively, blocked the cisplatin-induced increase in ERCC-1 mRNA.	Cyclosporine	0-13	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	57-62
9973482-6	1999	Cyclosporin A inhibited Fc epsilon RI-mediated JNK and p38 activation, but did not affect the activation of these kinases when stimulated through the SCFR.	Cyclosporine	0-13	mitogen-activated protein kinase 8	Mus musculus	47-50
10084328-7	1999	Conversely, IL-10 or IFN-alpha addition increases the inhibitory effect of CsA on the PR of PBMC from both HP and controls.	Cyclosporine	75-78	interleukin 10	Homo sapiens	12-17
9950598-10	1999	CONCLUSIONS: The in vitro effects of CsA translate into a reduction in T cells, a normalization of the CD4-CD8 ratio, a decrease in T-cell activation, and a reduction in T-cell cytokine expression, especially IL-2 and IFN-gamma.	Cyclosporine	37-40	CD8a molecule	Homo sapiens	107-110
9987092-11	1999	Intense staining for endothelin-1, RANTES, and monocyte chemoattractant protein-1 mRNAs selectively localized at tubular epithelial cells was found in biopsies taken from patients with CsA nephrotoxicity, but not in the chronic graft rejection group, whose tubuli had only minimal staining for RANTES mRNA on a few occasions.	Cyclosporine	185-188	C-C motif chemokine ligand 5	Homo sapiens	35-41
9987092-11	1999	Intense staining for endothelin-1, RANTES, and monocyte chemoattractant protein-1 mRNAs selectively localized at tubular epithelial cells was found in biopsies taken from patients with CsA nephrotoxicity, but not in the chronic graft rejection group, whose tubuli had only minimal staining for RANTES mRNA on a few occasions.	Cyclosporine	185-188	C-C motif chemokine ligand 5	Homo sapiens	294-300
10559581-9	1999	CONCLUSION: Although there is evidence for systemic immune activation in psoriasis, sIL-2R is the most consistently increased activation marker, related to the Th1 immune response, that may be used as a marker for monitoring disease activity and response to treatment with CsA in psoriatic patients.	Cyclosporine	273-276	negative elongation factor complex member C/D	Homo sapiens	160-163
10529615-0	1999	Overexpression of CD11b on eosinophils in atopic dermatitis: downregulation by cyclosporin A and upregulation by interleukin 5.	Cyclosporine	79-92	integrin subunit alpha M	Homo sapiens	18-23
10529615-4	1999	Treatment of AD with cyclosporin A resulted in clinical improvement as well as reduction in the expression of CD11b.	Cyclosporine	21-34	integrin subunit alpha M	Homo sapiens	110-115
9862768-4	1999	Ileal ranitidine secretion was concentration dependent and significantly reduced by the P-glycoprotein (P-gp) substrates verapamil and cyclosporin.	Cyclosporine	135-146	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	88-102
9862768-4	1999	Ileal ranitidine secretion was concentration dependent and significantly reduced by the P-glycoprotein (P-gp) substrates verapamil and cyclosporin.	Cyclosporine	135-146	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	104-108
19823813-2	2010	It has been reported that, in humans, CyA is metabolized by cytochrome P450 (CYP) 3A or excreted by P-glycoprotein/multidrug resistant protein (MRP) 2.	Cyclosporine	38-41	ATP binding cassette subfamily C member 2	Homo sapiens	100-150
10067059-7	1999	RFP induces cytochrome P450 3A in the liver to decrease the activities of many drugs, such as cyclosporin A, tacrolimus, protease inhibitor, itraconazole, and clarithromycin.	Cyclosporine	94-107	tripartite motif containing 27	Homo sapiens	0-3
19758343-0	2010	Serum levels of IL-18 and sIL-2R in patients with alopecia areata receiving combined therapy with oral cyclosporine and steroids.	Cyclosporine	103-115	interleukin 18	Homo sapiens	16-21
9841882-1	1998	Cyclophilin B (CyPB) is a cyclosporin A (CsA)-binding protein, mainly associated with the secretory pathway, and is released in biological fluids.	Cyclosporine	41-44	peptidylprolyl isomerase B	Homo sapiens	0-13
9841882-1	1998	Cyclophilin B (CyPB) is a cyclosporin A (CsA)-binding protein, mainly associated with the secretory pathway, and is released in biological fluids.	Cyclosporine	41-44	peptidylprolyl isomerase B	Homo sapiens	15-19
9841882-2	1998	We recently reported that CyPB specifically binds to T-lymphocytes and promotes enhanced incorporation of CsA.	Cyclosporine	106-109	peptidylprolyl isomerase B	Homo sapiens	26-30
21249305-0	2010	Cyclosporin A-treated dendritic cells may affect the outcome of organ transplantation by decreasing CD4+CD25+ regulatory T cell proliferation.	Cyclosporine	0-13	CD4 antigen	Mus musculus	100-103
9841882-9	1998	The conclusion that CyPB binding to the type I site is distinct from the interactions with GAG was based on the findings that it was (1) resistant to NaCl wash and GAG-degrading enzyme treatments, (2) reduced in the presence of CsA or cyclophilin C, and (3) unmodified in the presence of either the N-terminal peptide of CyPB or protamine.	Cyclosporine	228-231	peptidylprolyl isomerase B	Homo sapiens	20-24
20190468-4	2010	SCF production was reduced in bone marrow stromal cells; however, it was restored in vitro and in vivo after cyclosporine-A treatment.	Cyclosporine	109-123	KIT ligand	Homo sapiens	0-3
19816049-0	2010	BMP-7 blocks the cyclosporine-A-induced epithelial-to-mesenchymal transition in renal tubular epithelial cells.	Cyclosporine	17-31	bone morphogenetic protein 7	Homo sapiens	0-5
19897783-5	2009	In human gingival fibroblasts, cyclosporin alone did not induce evident inflammatory responses, but augmented the expression of CD54 and the production of interleukin (IL)-6 and IL-8 induced by TLR ligands, whereas phenytoin attenuated those responses.	Cyclosporine	31-42	intercellular adhesion molecule 1	Homo sapiens	128-132
9892468-7	1998	Cyclosporin A (CsA) (30 microM), an inhibitor of cMOAT at higher concentrations, inhibited the preferential apical export of GS-B from cMOAT-transfected cells.	Cyclosporine	0-13	ATP binding cassette subfamily C member 2	Rattus norvegicus	49-54
9892468-7	1998	Cyclosporin A (CsA) (30 microM), an inhibitor of cMOAT at higher concentrations, inhibited the preferential apical export of GS-B from cMOAT-transfected cells.	Cyclosporine	0-13	ATP binding cassette subfamily C member 2	Rattus norvegicus	135-140
9892468-7	1998	Cyclosporin A (CsA) (30 microM), an inhibitor of cMOAT at higher concentrations, inhibited the preferential apical export of GS-B from cMOAT-transfected cells.	Cyclosporine	15-18	ATP binding cassette subfamily C member 2	Rattus norvegicus	49-54
19951574-15	2009	After co-incubation with cyclosporine A (CsA), specific inhibitor to P-glycoprotein, the second phase of insulin secretion was reduced significantly while the first phase was not influenced.	Cyclosporine	25-39	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	69-83
9892468-7	1998	Cyclosporin A (CsA) (30 microM), an inhibitor of cMOAT at higher concentrations, inhibited the preferential apical export of GS-B from cMOAT-transfected cells.	Cyclosporine	15-18	ATP binding cassette subfamily C member 2	Rattus norvegicus	135-140
9844139-10	1998	CsA and tacrolimus (0.5 to 5000 microgram/liter) induced a significant, dose-dependent increase of ET-1 and ET-3 release by PT-1 cells with a maximum stimulation at a CsA concentration of 500 microgram/liter (P &lt; 0.001) and a tacrolimus concentration of 50 microgram/liter (P &lt; 0.001).	Cyclosporine	0-3	endothelin-1	Oryctolagus cuniculus	99-112
9844139-10	1998	CsA and tacrolimus (0.5 to 5000 microgram/liter) induced a significant, dose-dependent increase of ET-1 and ET-3 release by PT-1 cells with a maximum stimulation at a CsA concentration of 500 microgram/liter (P &lt; 0.001) and a tacrolimus concentration of 50 microgram/liter (P &lt; 0.001).	Cyclosporine	167-170	endothelin-1	Oryctolagus cuniculus	99-112
9844139-12	1998	Coincubation of PT-1 cells with CsA or tacrolimus and HGF or EGF also resulted in a marked reduction of ET-1 release.	Cyclosporine	32-35	endothelin-1	Oryctolagus cuniculus	104-108
9844139-13	1998	CONCLUSIONS: The present data suggest that ET-1 and ET-3 release by cultured rabbit proximal tubule cells are regulated differently, and that the stimulatory effect of CsA and tacrolimus on ET-1 release is antagonized by HGF and EGF.	Cyclosporine	168-171	endothelin-1	Oryctolagus cuniculus	43-56
9844139-13	1998	CONCLUSIONS: The present data suggest that ET-1 and ET-3 release by cultured rabbit proximal tubule cells are regulated differently, and that the stimulatory effect of CsA and tacrolimus on ET-1 release is antagonized by HGF and EGF.	Cyclosporine	168-171	hepatocyte growth factor	Oryctolagus cuniculus	221-224
19951574-15	2009	After co-incubation with cyclosporine A (CsA), specific inhibitor to P-glycoprotein, the second phase of insulin secretion was reduced significantly while the first phase was not influenced.	Cyclosporine	41-44	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	69-83
18957484-6	2009	RESULTS: Treatment of PBL with leflunomide, cyclosporin A and FK-506 inhibited the IL-15-induced expression of both CD54 and CD69 by PBL, as well as TNF production in co-cultures of activated PBL and THP-1 cells.	Cyclosporine	44-57	interleukin 15	Homo sapiens	83-88
18957484-6	2009	RESULTS: Treatment of PBL with leflunomide, cyclosporin A and FK-506 inhibited the IL-15-induced expression of both CD54 and CD69 by PBL, as well as TNF production in co-cultures of activated PBL and THP-1 cells.	Cyclosporine	44-57	intercellular adhesion molecule 1	Homo sapiens	116-120
18957484-8	2009	Likewise, leflunomide, cyclosporin A and FK-506 all inhibited IL-17 production in IL-15-activated PBL.	Cyclosporine	23-36	interleukin 17A	Homo sapiens	62-67
18957484-8	2009	Likewise, leflunomide, cyclosporin A and FK-506 all inhibited IL-17 production in IL-15-activated PBL.	Cyclosporine	23-36	interleukin 15	Homo sapiens	82-87
19710169-9	2009	Consistent with these in vivo observations, endothelial cells exposed to CsA within specific time windows in tissue culture were unable to form tubular structures and their cellular responses to VEGF-A were blunted.	Cyclosporine	73-76	vascular endothelial growth factor A	Mus musculus	195-201
19638290-5	2009	In addition, the 14-bp polymorphism of the HLA-G gene is related to the absorber status of cyclosporine of each individual patient, and is useful for determining the oral dose of cyclosporine to manage patients (to adjust immunosuppressive protocols) so as to minimize the risk of a low or high immunosuppression and the side effects in the early stages of heart transplantation.	Cyclosporine	91-103	major histocompatibility complex, class I, G	Homo sapiens	43-48
19638290-5	2009	In addition, the 14-bp polymorphism of the HLA-G gene is related to the absorber status of cyclosporine of each individual patient, and is useful for determining the oral dose of cyclosporine to manage patients (to adjust immunosuppressive protocols) so as to minimize the risk of a low or high immunosuppression and the side effects in the early stages of heart transplantation.	Cyclosporine	179-191	major histocompatibility complex, class I, G	Homo sapiens	43-48
19703135-3	2009	We hypothesise that prednisone and cyclosporin A contributed to insulin resistance in a prediabetic dog with suboptimal endogenous insulin concentration and that the degree of insulin resistance decreased when cyclosporin A therapy was discontinued.	Cyclosporine	35-48	insulin	Canis lupus familiaris	64-71
19703135-3	2009	We hypothesise that prednisone and cyclosporin A contributed to insulin resistance in a prediabetic dog with suboptimal endogenous insulin concentration and that the degree of insulin resistance decreased when cyclosporin A therapy was discontinued.	Cyclosporine	35-48	insulin	Canis lupus familiaris	131-138
19703135-3	2009	We hypothesise that prednisone and cyclosporin A contributed to insulin resistance in a prediabetic dog with suboptimal endogenous insulin concentration and that the degree of insulin resistance decreased when cyclosporin A therapy was discontinued.	Cyclosporine	35-48	insulin	Canis lupus familiaris	131-138
19494809-7	2009	Cyclosporine-treated UGT1A8*2/*2 (518GG) patients had an 18% higher MPA AUC(0-12) compared with noncarriers.	Cyclosporine	0-12	UDP glucuronosyltransferase family 1 member A8	Homo sapiens	21-27
19674198-6	2009	MMP-26 expression in cancer cells (p = 0.04) and that of MMP-9 in neutrophils (p = 0.005) were more abundant in SCCs of patients using cyclosporine.	Cyclosporine	135-147	matrix metallopeptidase 9	Homo sapiens	57-62
19641137-7	2009	However, retrovirus-mediated expression of NFATc1 in pOCs rescued the defect in pOC fusion, despite the presence of U0126 and cyclosporin A.	Cyclosporine	126-139	nuclear factor of activated T cells 1	Homo sapiens	43-49
19698865-6	2009	Compared with group II, treatment with pioglitazone with low-dose cyclosporine (group IV) significantly suppressed graft infiltration of CD4/CD8 T lymphocytes and serum concentrations of interleukin 2 and interferon gamma, leading to extended graft survival up to 60 days.	Cyclosporine	66-78	Cd4 molecule	Rattus norvegicus	137-140
19215635-11	2009	In addition, BDNF Val66Met and 5-HTTLPR polymorphisms seemed to moderate the effect of CSA on adult depressive symptoms.	Cyclosporine	87-90	brain derived neurotrophic factor	Homo sapiens	13-17
19635906-4	2009	This promotion of IL-2 production was resistant to cyclosporin A treatment, suggesting that CD44 costimulation may promote IL-2 production through bypassing FoxP3-mediated suppression of NFAT.	Cyclosporine	51-64	CD44 antigen	Mus musculus	92-96
19620774-5	2009	Systemic administration of VEGF or LPS in adult mice resulted in cyclosporine A-sensitive reactivation of the DSCR1s promoter and endogenous gene expression in a subset of organs, including the heart and brain.	Cyclosporine	65-79	vascular endothelial growth factor A	Mus musculus	27-31
19505981-7	2009	As expected, cyclosporine treatment decreased nuclear translocation of calcineurin/NFAT in alpha(2A)/alpha(2C)ARKO mice, which was associated with improved ventricular function and a pronounced anti-remodelling effect.	Cyclosporine	13-25	adrenergic receptor, alpha 2c	Mus musculus	101-109
19393753-0	2009	Effect of FK506 and cyclosporine A on the expression of BDNF, tyrosine kinase B and p75 neurotrophin receptors in astrocytes exposed to simulated ischemia in vitro.	Cyclosporine	20-34	brain-derived neurotrophic factor	Rattus norvegicus	56-60
19393753-1	2009	We investigated whether the immunosuppressive drugs, FK506 and cyclosporine A, increase BDNF protein and/or mRNA expression in ischemic astrocytes and if an increase could be related to changes in the nuclear expression of p-CREB, p-Erk1/2 and p-Akt.	Cyclosporine	63-77	brain-derived neurotrophic factor	Rattus norvegicus	88-92
19393753-4	2009	FK506 and cyclosporine A (at 1000nM and 0.25microM, respectively) stimulated the expression and release of BDNF in cultured rat cerebral cortical astrocytes exposed to OGD.	Cyclosporine	10-24	brain-derived neurotrophic factor	Rattus norvegicus	107-111
19473348-6	2009	In the CsA treatment group, the mean CCT before and after six months of treatment were 517.4 +/- 36.2 and 546.5 +/- 32.4 microm, respectively (p &lt; 0.001); yielding an average CCT increase of 29.1 +/- 8.0 microm (5.62 per cent) from baseline.	Cyclosporine	7-10	CCT	Homo sapiens	37-40
19473348-6	2009	In the CsA treatment group, the mean CCT before and after six months of treatment were 517.4 +/- 36.2 and 546.5 +/- 32.4 microm, respectively (p &lt; 0.001); yielding an average CCT increase of 29.1 +/- 8.0 microm (5.62 per cent) from baseline.	Cyclosporine	7-10	CCT	Homo sapiens	178-181
19525466-12	2009	Moreover, the administration of cyclosporin A markedly inhibited (99m)Tc-mebrofenin excretion in healthy rats, with no further effect on already impaired (99m)Tc-mebrofenin excretion in HsdAMC:TR-Abcc2 mutant rats.	Cyclosporine	32-45	ATP binding cassette subfamily C member 2	Rattus norvegicus	196-201
19543052-13	2009	The CD4/CD25 regulatory-like T-cell expression in the circulating blood and allo-skin significantly increased in the MSC-BMT-CsA group.	Cyclosporine	125-128	CD4 molecule	Sus scrofa	4-7
19494299-9	2009	Thymus-dependent Ag-induced CD154 expression was inhibited by cyclosporin A, suggesting that CD154 functionally associates with T cells.	Cyclosporine	62-75	CD40 ligand	Danio rerio	28-33
19494299-9	2009	Thymus-dependent Ag-induced CD154 expression was inhibited by cyclosporin A, suggesting that CD154 functionally associates with T cells.	Cyclosporine	62-75	CD40 ligand	Danio rerio	93-98
19519602-10	2009	Interestingly, the cyclosporine-treated group revealed an unexpected tendency between circulating 1,25D and FGF23 on day 21.	Cyclosporine	19-31	fibroblast growth factor 23	Homo sapiens	108-113
19344364-7	2009	Serine phosphorylation of Munc18c, which promotes granule exocytosis in other secretory cells, is increased in CsA-treated HUVECs, suggesting that this process may be involved in CsA-mediated WPB exocytosis.	Cyclosporine	111-114	syntaxin binding protein 3	Homo sapiens	26-33
19746191-9	2009	Pretreatment with Cyclosporin A raised brain uptake indicating that [(123)I]-7 is transported by P-glycoprotein (P-gp) pumps.	Cyclosporine	18-31	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	97-111
19746191-9	2009	Pretreatment with Cyclosporin A raised brain uptake indicating that [(123)I]-7 is transported by P-glycoprotein (P-gp) pumps.	Cyclosporine	18-31	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	113-117
19450280-7	2009	Bioinformatic analysis of NFAT-sites of the group of transcripts similarly regulated by Itk-deficiency and CsA-treatment, followed by chromatin-immunoprecipitation, revealed NFATc1-binding to the Bub1, IL7R, Ctla2a, Ctla2b, and Schlafen1 genes.	Cyclosporine	107-110	nuclear factor of activated T cells 1	Homo sapiens	174-180
19450280-7	2009	Bioinformatic analysis of NFAT-sites of the group of transcripts similarly regulated by Itk-deficiency and CsA-treatment, followed by chromatin-immunoprecipitation, revealed NFATc1-binding to the Bub1, IL7R, Ctla2a, Ctla2b, and Schlafen1 genes.	Cyclosporine	107-110	BUB1 mitotic checkpoint serine/threonine kinase	Homo sapiens	196-200
19235203-8	2009	Treatment of BPAEC with Cn inhibitors (cyclosporin A and FK506) hindered recovery of the cells from thrombin-induced EC dysfunction.	Cyclosporine	39-52	coagulation factor II, thrombin	Bos taurus	100-108
19204148-11	2009	Finally, pretreatment with two pharmacological inhibitors of calcineurin, cyclosporin A, and FK-506, but not with MAPK inhibitors, blocked JAM-C induction in activated T cells.	Cyclosporine	74-87	junctional adhesion molecule 3	Homo sapiens	139-144
19201990-6	2009	In addition, the intracellular accumulation of the MRP2 substrate glutathione methylfluorescein was increased by 50 microM MK571 (4.3-fold), 500 microM indomethacin (2.6-fold), and 50 microM cyclosporin A (2.1-fold) but not by 500 microM sulfinpyrazone.	Cyclosporine	191-204	ATP binding cassette subfamily C member 2	Homo sapiens	51-55
19153804-17	2009	Blood group of donor and recipient, time to onset of diuresis and primary immunosuppression (mainly CsA) were significant risk factors in hemolytic anemia in patients after ABO non-identical living donor kidney transplantation.	Cyclosporine	100-103	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	173-176
19575969-16	2009	J2 and CsA groups only showed a small number of CD4(+) and CD8(+) T-lymphocytes in the grafts.	Cyclosporine	7-10	CD4 antigen	Mus musculus	48-51
19112104-4	2009	Here we report that hensin secretion and matrix assembly were inhibited by the peptidylprolyl cis-trans isomerase (PPIase) inhibitors cyclosporin A (CsA) and a derivative of cyclosporin A with modifications in the d-Ser side chain (Cs9) but not by the calcineurin pathway inhibitor FK506.	Cyclosporine	134-147	deleted in malignant brain tumors 1 protein	Oryctolagus cuniculus	20-26
19112104-4	2009	Here we report that hensin secretion and matrix assembly were inhibited by the peptidylprolyl cis-trans isomerase (PPIase) inhibitors cyclosporin A (CsA) and a derivative of cyclosporin A with modifications in the d-Ser side chain (Cs9) but not by the calcineurin pathway inhibitor FK506.	Cyclosporine	149-152	deleted in malignant brain tumors 1 protein	Oryctolagus cuniculus	20-26
19112104-4	2009	Here we report that hensin secretion and matrix assembly were inhibited by the peptidylprolyl cis-trans isomerase (PPIase) inhibitors cyclosporin A (CsA) and a derivative of cyclosporin A with modifications in the d-Ser side chain (Cs9) but not by the calcineurin pathway inhibitor FK506.	Cyclosporine	174-187	deleted in malignant brain tumors 1 protein	Oryctolagus cuniculus	20-26
19112104-6	2009	Cyclophilin A was produced and secreted into the media to a much greater extent than cyclophilins B and C. Our results also identified the direct CsA-sensitive interaction of cyclophilin A with hensin, suggesting that cyclophilin A is the PPIase that mediates the polymerization and matrix assembly of hensin.	Cyclosporine	146-149	deleted in malignant brain tumors 1 protein	Oryctolagus cuniculus	194-200
19112104-6	2009	Cyclophilin A was produced and secreted into the media to a much greater extent than cyclophilins B and C. Our results also identified the direct CsA-sensitive interaction of cyclophilin A with hensin, suggesting that cyclophilin A is the PPIase that mediates the polymerization and matrix assembly of hensin.	Cyclosporine	146-149	deleted in malignant brain tumors 1 protein	Oryctolagus cuniculus	302-308
19091785-5	2009	Since CsA is an inhibitor of the ATP-binding cassette A1 (ABCA1) transporter, we employed 4,4"-diisothiocyanatostilbene-2,2"-disulfonic acid (DIDS), another ABCA1 inhibitor, and found that DIDS mimicked the effects of CsA on ENaC basal and cholesterol-induced activity but without any additive effect if combined with CsA.	Cyclosporine	6-9	ATP binding cassette subfamily A member 1	Homo sapiens	33-56
19091785-5	2009	Since CsA is an inhibitor of the ATP-binding cassette A1 (ABCA1) transporter, we employed 4,4"-diisothiocyanatostilbene-2,2"-disulfonic acid (DIDS), another ABCA1 inhibitor, and found that DIDS mimicked the effects of CsA on ENaC basal and cholesterol-induced activity but without any additive effect if combined with CsA.	Cyclosporine	6-9	ATP binding cassette subfamily A member 1	Homo sapiens	58-63
19091785-5	2009	Since CsA is an inhibitor of the ATP-binding cassette A1 (ABCA1) transporter, we employed 4,4"-diisothiocyanatostilbene-2,2"-disulfonic acid (DIDS), another ABCA1 inhibitor, and found that DIDS mimicked the effects of CsA on ENaC basal and cholesterol-induced activity but without any additive effect if combined with CsA.	Cyclosporine	6-9	ATP binding cassette subfamily A member 1	Homo sapiens	157-162
19148552-3	2009	In the present study, we investigated the effects of tacrolimus (FK506) and cyclosporine A, well-known immunosuppressants, on the FGF-2-induced VEGF release in these cells.	Cyclosporine	76-90	vascular endothelial growth factor A	Mus musculus	144-148
19013229-7	2009	Activity of efflux transporters was confirmed in both placental primocultures and cryopreserved trophoblasts by an approximately 60% inhibition with cyclosporin A and valspodar for P-gp and 55% with elacridar for bcrp.	Cyclosporine	149-162	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	181-185
19070591-2	2009	We explored the hypothesis that CsA may result in complement-mediated endothelial cell lysis induced by down-regulation of decay-accelerating factor (DAF) in hyperlipidemic patients.	Cyclosporine	32-35	CD55 molecule (Cromer blood group)	Homo sapiens	123-148
19070591-2	2009	We explored the hypothesis that CsA may result in complement-mediated endothelial cell lysis induced by down-regulation of decay-accelerating factor (DAF) in hyperlipidemic patients.	Cyclosporine	32-35	CD55 molecule (Cromer blood group)	Homo sapiens	150-153
19070591-5	2009	CsA exposure led to decreased DAF expression and aggravated cell lysis of the HUVECs pre-incubated with ox-LDL, in a dose-dependent fashion.	Cyclosporine	0-3	CD55 molecule (Cromer blood group)	Homo sapiens	30-33
19070591-7	2009	These observations provide new evidence that hyperlipidemic patients treated with CsA may have an increased vascular risk, at least in part through complement-mediated EC lysis following down-regulated DAF expression.	Cyclosporine	82-85	CD55 molecule (Cromer blood group)	Homo sapiens	202-205
19111511-4	2009	as control group and the treated-group rats were co-administered with kadsurenone and CsA; P-gp inhibitor.	Cyclosporine	86-89	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	91-95
18976289-9	2009	Cyclosporine A, TGF-beta1 and angiotensin II increased Nox-2 mRNA levels 2- to 7-fold in vitro (NRK52E cells).	Cyclosporine	0-14	cytochrome b-245 beta chain	Rattus norvegicus	55-60
19691367-2	2009	Maintenance therapy typically consists of a triple-drug regimen including corticosteroids, a calcineurin inhibitor (ciclosporin or tacrolimus) and either a purine synthesis antagonist (mycophenolate mofetil or azathioprine) or a mammalian target of rapamycin inhibitor (sirolimus or everolimus).	Cyclosporine	116-127	calcineurin binding protein 1	Homo sapiens	93-114
19076452-4	2008	Consistently, the Col6a1(-/-) myopathic mice could be cured with cyclosporin A through inhibition of cyclophilin D, a matrix protein that sensitizes the pore to opening.	Cyclosporine	65-78	collagen, type VI, alpha 1	Mus musculus	18-24
24459527-9	2008	TRPM6 is regulated at the transcriptional level by acid-base status, 17beta-estradiol, and both FK506 and cyclosporine.	Cyclosporine	106-118	transient receptor potential cation channel subfamily M member 6	Homo sapiens	0-5
18791174-7	2008	In contrast, hRPE exposure to cyclosporine (Cys) and the cytokine IL-10 for 6 hours increased caspase-12S mRNA expression.	Cyclosporine	30-42	ribulose-5-phosphate-3-epimerase	Homo sapiens	13-17
18791174-7	2008	In contrast, hRPE exposure to cyclosporine (Cys) and the cytokine IL-10 for 6 hours increased caspase-12S mRNA expression.	Cyclosporine	44-47	ribulose-5-phosphate-3-epimerase	Homo sapiens	13-17
18791174-8	2008	Compared to Cys and IL-10, the ER stress activators tunicamycin and thapsigargin were even more potent enhancers of hRPE caspase-12S gene expression.	Cyclosporine	12-15	ribulose-5-phosphate-3-epimerase	Homo sapiens	116-120
18804502-9	2008	Inhibitor of caspase-3 (Z-DEVD-FMK, 100microM), and a mitochondrial permeability transition pore blocker, cyclosporine A (2microM) protected PC12 cells against alpha-synuclein or amyloid beta evoked cell death.	Cyclosporine	106-120	synuclein alpha	Rattus norvegicus	160-175
18587562-9	2008	Finally, repeated exposure to either cocaine or cyclosporine for 22 days increased synapsin I phosphorylation at the calcineurin-sensitive Ser 62/67 site, demonstrating a common downstream target for both calcineurin and cocaine.	Cyclosporine	48-60	synapsin I	Rattus norvegicus	83-93
18582542-5	2008	Pretreatment with SB202190 (p38 MAPK inhibitor) and cyclosporine A (inhibitor of mitochondria permeability transition pore) rescued cell viability, DeltaPsim and cytochrome c release of PLA2-treated cells.	Cyclosporine	52-66	phospholipase A2 group IIA	Homo sapiens	186-190
18445599-8	2008	This stimulatory effect of CypB was reversed by the immunosuppressive drug cyclosporin A, which inhibits the enzymatic activity of CypB.	Cyclosporine	75-88	peptidylprolyl isomerase B	Homo sapiens	27-31
18445599-8	2008	This stimulatory effect of CypB was reversed by the immunosuppressive drug cyclosporin A, which inhibits the enzymatic activity of CypB.	Cyclosporine	75-88	peptidylprolyl isomerase B	Homo sapiens	131-135
18337250-6	2008	Cyclosporin A blocked the inhibitory effect of JNK on mitochondria respiration, suggesting JNK was directly inducing mitochondrial permeability transition in isolated mitochondria from mice treated with APAP plus JNK inhibitor.	Cyclosporine	0-13	mitogen-activated protein kinase 8	Mus musculus	47-50
18337250-6	2008	Cyclosporin A blocked the inhibitory effect of JNK on mitochondria respiration, suggesting JNK was directly inducing mitochondrial permeability transition in isolated mitochondria from mice treated with APAP plus JNK inhibitor.	Cyclosporine	0-13	mitogen-activated protein kinase 8	Mus musculus	91-94
18337250-6	2008	Cyclosporin A blocked the inhibitory effect of JNK on mitochondria respiration, suggesting JNK was directly inducing mitochondrial permeability transition in isolated mitochondria from mice treated with APAP plus JNK inhibitor.	Cyclosporine	0-13	mitogen-activated protein kinase 8	Mus musculus	91-94
18424002-9	2008	Pretreatment of P-glycoprotein inhibitors verapamil or cyclosporin A significantly increased the brain remaining percentage of [(125)I]hAbeta (1-40).	Cyclosporine	55-68	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	16-30
18200064-3	2008	We localized Th17 cells predominantly to the dermis of psoriasis skin lesions, confirmed that IL-17 mRNA increased with disease activity, and demonstrated that IL-17 mRNA expression normalized with cyclosporine therapy.	Cyclosporine	198-210	interleukin 17A	Homo sapiens	160-165
18021262-7	2008	Cyclosporine A and dexamethasone, but not 5"-azacytidine, treatments of cells in differentiation medium restored the V1aR level to that measured in proliferating L6C5 cells, thus confirming the role of post-transcriptional mechanisms in the modulation of V1aR expression.	Cyclosporine	0-14	arginine vasopressin receptor 1A	Rattus norvegicus	117-121
18021262-7	2008	Cyclosporine A and dexamethasone, but not 5"-azacytidine, treatments of cells in differentiation medium restored the V1aR level to that measured in proliferating L6C5 cells, thus confirming the role of post-transcriptional mechanisms in the modulation of V1aR expression.	Cyclosporine	0-14	arginine vasopressin receptor 1A	Rattus norvegicus	255-259
18191430-10	2008	In conclusion, we found that Bax/Bak-mediated MOMP is a key mechanism of diclofenac-induced lethal cell injury in human hepatocytes, and that CsA can prevent MOMP through inhibition of Bax activation.	Cyclosporine	142-145	BCL2 antagonist/killer 1	Homo sapiens	33-36
18299432-4	2008	It was demonstrated that administration of CsA at the window of implantation significantly up-regulated the expression of CTLA-4, while down-regulating the levels of CD80, CD86, and CD28 at the materno-fetal interface in the CBA/J x DBA/2 abortion-prone matings, and the embryo resorption rate of the abortion-prone matings reduced significantly after CsA treatment, implying that modulation of costimulatory molecule expression by CsA might contribute to preventing the fetus from maternal immune attack.	Cyclosporine	43-46	cytotoxic T-lymphocyte-associated protein 4	Mus musculus	122-128
18094529-7	2008	In contrast, supplementation of cyclosporin A, which blocks cytochrome c upregulation, inhibited tyrosine phosphorylation of sperm proteins.	Cyclosporine	32-45	cytochrome c	Sus scrofa	60-72
18095667-4	2008	In this work, we solved the structures of CsA in sodium dodecyl sulfate (SDS) micelles (which enhance its solubility and mimic the hydrophobic environment clinically used for drug delivery) and its complex with Dy(III) ion, whose coordination chemistry is frequently used to reproduce the effect of Ca(II).	Cyclosporine	42-45	carbonic anhydrase 2	Homo sapiens	299-305
18434710-6	2008	RESULTS: Short-term treatment of CsA for 7 days activated both the ER stress response (induction of BiP mRNA and protein) and the proapoptotic response (upregulation of caspase 12 and CHOP mRNAs and proteins).	Cyclosporine	33-36	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	100-103
18434710-6	2008	RESULTS: Short-term treatment of CsA for 7 days activated both the ER stress response (induction of BiP mRNA and protein) and the proapoptotic response (upregulation of caspase 12 and CHOP mRNAs and proteins).	Cyclosporine	33-36	caspase 12	Rattus norvegicus	169-179
18434710-7	2008	However, long-term treatment with CsA for 28 days decreased BiP and further increased CHOP.	Cyclosporine	34-37	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	60-63
18245969-0	2008	Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production.	Cyclosporine	42-54	transforming growth factor beta 2	Homo sapiens	112-144
18245969-1	2008	PURPOSE: To evaluate the effects of sequential treatment with artificial tears and cyclosporine emulsion on conjunctival goblet cell density and production of transforming growth factor (TGF)-beta2 in patients with dry eye disease.	Cyclosporine	83-95	transforming growth factor beta 2	Homo sapiens	159-197
18245969-8	2008	The number of TGF-beta2-positive goblet cells was also noted to increase after 6 and 12 weeks of cyclosporine therapy (P &lt; 0.001).	Cyclosporine	97-109	transforming growth factor beta 2	Homo sapiens	14-23
18245969-9	2008	CONCLUSIONS: Cyclosporine emulsion, but not artificial tears, increases goblet cell density and production of the immunoregulatory factor TGF-beta2 in the bulbar conjunctiva in patients with dry eye.	Cyclosporine	13-25	transforming growth factor beta 2	Homo sapiens	138-147
19016371-9	2008	However, with 45/52 (86.5%) the tetramer technology was superior to the CSA, which detected 34/52 (65.4%) based on CD8(+) T cells and 41/52 (78.8%) based on both CD4(+) and CD8(+) T cells.	Cyclosporine	72-75	CD8a molecule	Homo sapiens	115-118
18569092-0	2008	Cyclosporin a Up-regulates B7-DC expression on dendritic cells in an IL-4-dependent manner in vitro, which is associated with decreased allostimulatory capacity of dendritic cells.	Cyclosporine	0-13	programmed cell death 1 ligand 2	Homo sapiens	27-32
18569092-3	2008	Furthermore, Cyclosporin A treatment inhibited production of Interferon-gammaand TNF-alpha, Interleukin-12p70, but increased production of the Interleukin-10 of DC.	Cyclosporine	13-26	interleukin 10	Homo sapiens	143-157
18569092-4	2008	Thus, up-regulated expression of B7-DC may be responsible for Cyclosporin A-mediated inhibitory effects on allostimulatory capacity of DC.	Cyclosporine	62-75	programmed cell death 1 ligand 2	Homo sapiens	33-38
17885208-4	2008	Moreover, inactivation of NFATc1 by cyclosporin A treatment attenuates expression of Atp6v0d2 and DC-STAMP and subsequent fusion process of osteoclasts.	Cyclosporine	36-49	nuclear factor of activated T cells 1	Homo sapiens	26-32
17965024-10	2007	RACK1 binds to the catalytic domain of calcineurin and is required for HIF-1alpha degradation induced by the calcineurin inhibitor cyclosporine A.	Cyclosporine	131-145	receptor for activated C kinase 1	Homo sapiens	0-5
17853438-3	2007	In the present study we used the MPT inhibitor cyclosporine-A (CsA) to preserve mitochondrial NAD(+) pools during PARP-1 activation and thereby provide an estimate of mitochondrial NAD(+) pool size in different cell types.	Cyclosporine	47-61	poly (ADP-ribose) polymerase family, member 1	Mus musculus	114-120
17853438-6	2007	Inhibition of the mitochondrial permeability transition with cyclosporine-A (CsA) prevented PARP-1-induced NAD(+) depletion to a varying degree in the four cell types tested.	Cyclosporine	61-75	poly (ADP-ribose) polymerase family, member 1	Mus musculus	92-98
17998872-2	2007	Here we have determined the potential of a myxoma viral serpin, Serp-1, with proven anti-inflammatory and antiatherogenic actions, to modulate innate immunity and contribute synergistically with CsA in the prevention of acute cardiac allograft rejection.	Cyclosporine	195-198	Serine protease inhibitor	Rattus norvegicus	64-70
17474134-0	2007	Does cyclosporin A affect CCR5 and CXCR4 expression in primary HIV-1-infected patients?	Cyclosporine	5-18	C-C motif chemokine receptor 5	Homo sapiens	26-30
17474134-0	2007	Does cyclosporin A affect CCR5 and CXCR4 expression in primary HIV-1-infected patients?	Cyclosporine	5-18	C-X-C motif chemokine receptor 4	Homo sapiens	35-40
17474134-2	2007	No information exists on the effect of cyclosporin A (CsA) on expression of CCR5 and CXCR4.	Cyclosporine	54-57	C-C motif chemokine receptor 5	Homo sapiens	76-80
17474134-2	2007	No information exists on the effect of cyclosporin A (CsA) on expression of CCR5 and CXCR4.	Cyclosporine	54-57	C-X-C motif chemokine receptor 4	Homo sapiens	85-90
17664251-1	2007	The objective of this study was to investigate the transport kinetics of cyclosporin A, a well known substrate for P-glycoprotein (P-gp), across the blood-brain barrier (BBB), and the expression of the transporter in the brain of streptozotocin-induced diabetic rats.	Cyclosporine	73-86	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	115-129
17664251-1	2007	The objective of this study was to investigate the transport kinetics of cyclosporin A, a well known substrate for P-glycoprotein (P-gp), across the blood-brain barrier (BBB), and the expression of the transporter in the brain of streptozotocin-induced diabetic rats.	Cyclosporine	73-86	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	131-135
17955939-5	2007	Compared to untreated rats, high-dose HC-1 enhanced type I and II fiber CSA by 77% and 55%, respectively; myosin ATPase activity (type II fiber percentage) were lower, but soleus muscle-to-body weight ratio did not change.	Cyclosporine	72-75	Hypercalciuria QTL 1	Rattus norvegicus	38-42
17595192-0	2007	Ciclosporin-induced hypertension is associated with increased sodium transporter of the loop of Henle (NKCC2).	Cyclosporine	0-11	solute carrier family 12 member 1	Rattus norvegicus	103-108
17595192-8	2007	The densitometric analysis of the renal immunoblot showed an increase in the Na-K-2Cl cotransporter of the loop of Henle (NKCC2) in cyclosporine-treated rats (178% +/- 36) compared with control rats (100% +/- 18; P &lt; 0.05*).	Cyclosporine	132-144	solute carrier family 12 member 1	Rattus norvegicus	122-127
17845805-11	2007	Co-administration of CsA increased PB levels in brain and enhanced anticonvulsive effects of PB by inhibiting P-GP function.	Cyclosporine	21-24	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	110-114
17609666-4	2007	To elucidate whether radiation therapy reduces P-gp expression and function in the brain, right hemispheres of rats were irradiated with single doses of 2-25 Gy followed by 10 mg kg(-1) of the P-gp substrate cyclosporine A (CsA) intravenously (i.v.	Cyclosporine	208-222	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	193-197
17668045-8	2007	Induction of epithelial mesenchymal transition in renal epithelial cells with cyclosporin-A, which causes renal fibrosis as a side effect, induced cadherin-9 expression.	Cyclosporine	78-91	cadherin 9	Homo sapiens	147-157
17626207-5	2007	Higher concentrations of cyclosporine A, which interacts with cyclophilin D to delay mPTP opening, were necessary to increase the Ca2+ uptake capacity of synaptic versus nonsynaptic mitochondria.	Cyclosporine	25-39	peptidylprolyl isomerase D	Rattus norvegicus	62-75
17626207-10	2007	The high levels of cyclophilin D in neuronal mitochondria result in their greater vulnerability to mPT and in higher levels of cyclosporine A being required to inhibit mPTP opening.	Cyclosporine	127-141	peptidylprolyl isomerase D	Rattus norvegicus	19-32
17410097-10	2007	These results show that compared with CsA, SRL caused a significant decrease in the Th1 lymphocyte subset associated with a significant reduction of IL-12 release.	Cyclosporine	38-41	negative elongation factor complex member C/D	Homo sapiens	84-87
17594162-7	2007	RESULTS: CsA-induced renal injury was associated with increased the expression of C3, C4d, and MAC (C9 and upregulation of complement regulatory proteins (CD 46 and CD55).	Cyclosporine	9-12	CD46 antigen, complement regulatory protein	Mus musculus	155-160
17594162-7	2007	RESULTS: CsA-induced renal injury was associated with increased the expression of C3, C4d, and MAC (C9 and upregulation of complement regulatory proteins (CD 46 and CD55).	Cyclosporine	9-12	CD55 molecule, decay accelerating factor for complement	Mus musculus	165-169
17321721-5	2007	We demonstrate that transcriptional activation of p21WAF1/Cip1 expression correlated with induction of ERK1/2 and c-Jun phosphorylation in CsA-treated glioblastoma cells.	Cyclosporine	139-142	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	114-119
17321721-9	2007	It suggests that CsA activates p53-independent, transcriptional activation p21WAF1/Cip1 expression, mediated by ERK/c-Jun/AP-1 signaling pathway.	Cyclosporine	17-20	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	116-121
24459497-6	2007	There is some evidence that TonEBP regulates expression of UT-A in vivo; (1) during the renal development of the urinary concentrating ability, expression of TonEBP precedes that of UT-A1; (2) in transgenic mice expressing a dominant negative form of TonEBP, expression of UT-A1 and UT-A2 is severely impaired; (3) in treatment with cyclosporine A, TonEBP was significantly downregulated after 28 days.	Cyclosporine	333-347	nuclear factor of activated T cells 5	Mus musculus	28-34
17207946-9	2007	Significant permeability enhancement of SQV across rat jejunum was observed in the presence of cyclosporine 10 microM (P-gp inhibitor).	Cyclosporine	95-107	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	119-123
17461532-0	2007	Induction of PPAR gamma mRNA and protein expression by rosiglitazone in chronic cyclosporine nephropathy in the rat.	Cyclosporine	80-92	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	13-23
17461532-1	2007	PURPOSE: We recently reported that rosiglitazone (RGTZ), a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, has a protective effect against cyclosporine (CsA)- induced renal injury.	Cyclosporine	161-173	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	59-107
17461532-1	2007	PURPOSE: We recently reported that rosiglitazone (RGTZ), a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, has a protective effect against cyclosporine (CsA)- induced renal injury.	Cyclosporine	175-178	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	59-107
17461532-1	2007	PURPOSE: We recently reported that rosiglitazone (RGTZ), a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, has a protective effect against cyclosporine (CsA)- induced renal injury.	Cyclosporine	175-178	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	109-118
17461532-2	2007	Here we report the effect of RGTZ on peroxisome proliferator-activated receptor gamma (PPARgamma) expression in an experimental model of chronic cyclosporine (CsA) nephropathy.	Cyclosporine	145-157	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	37-85
17461532-2	2007	Here we report the effect of RGTZ on peroxisome proliferator-activated receptor gamma (PPARgamma) expression in an experimental model of chronic cyclosporine (CsA) nephropathy.	Cyclosporine	145-157	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	87-96
17461532-2	2007	Here we report the effect of RGTZ on peroxisome proliferator-activated receptor gamma (PPARgamma) expression in an experimental model of chronic cyclosporine (CsA) nephropathy.	Cyclosporine	159-162	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	37-85
17461532-2	2007	Here we report the effect of RGTZ on peroxisome proliferator-activated receptor gamma (PPARgamma) expression in an experimental model of chronic cyclosporine (CsA) nephropathy.	Cyclosporine	159-162	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	87-96
17461532-7	2007	PPARgamma protein expression in CsA-treated rat kidneys was significantly less than in the VH group.	Cyclosporine	32-35	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	0-9
17461532-8	2007	However, concomitant administration of RGTZ restored PPARgamma protein expression in the kidneys of the CsA- reated rats.	Cyclosporine	104-107	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	53-62
17202418-1	2007	The effects of the immunosuppressants cyclosporin A (CsA) and tacrolimus (FK506) on the IL-1beta-induced matrix metalloproteinase-9 (MMP-9) were investigated.	Cyclosporine	53-56	matrix metallopeptidase 9	Homo sapiens	105-131
17202418-1	2007	The effects of the immunosuppressants cyclosporin A (CsA) and tacrolimus (FK506) on the IL-1beta-induced matrix metalloproteinase-9 (MMP-9) were investigated.	Cyclosporine	53-56	matrix metallopeptidase 9	Homo sapiens	133-138
17202418-3	2007	It is demonstrated that CsA, in contrast to FK506, reduced the IL-1beta-induced MMP-9 content in conditioned media of mesangial cells, which coincides with a reduction in the cytokine-induced MMP-9 mRNA level.	Cyclosporine	24-27	matrix metallopeptidase 9	Homo sapiens	80-85
17202418-3	2007	It is demonstrated that CsA, in contrast to FK506, reduced the IL-1beta-induced MMP-9 content in conditioned media of mesangial cells, which coincides with a reduction in the cytokine-induced MMP-9 mRNA level.	Cyclosporine	24-27	matrix metallopeptidase 9	Homo sapiens	192-197
17202418-5	2007	Moreover, CsA caused a dose-dependent inhibition on the IL-1beta-induced luciferase activity of a 1.3-kb MMP-9 promoter fragment.	Cyclosporine	10-13	matrix metallopeptidase 9	Homo sapiens	105-110
17202418-10	2007	It is interesting that only the JNK inhibitor SP600125 impaired the cytokine-triggered MMP-9 level, suggesting that CsA, via inhibition of the JNK pathway, negatively interferes with the NF-kappaB-dependent transcriptional control of MMP-9.	Cyclosporine	116-119	matrix metallopeptidase 9	Homo sapiens	87-92
17202418-10	2007	It is interesting that only the JNK inhibitor SP600125 impaired the cytokine-triggered MMP-9 level, suggesting that CsA, via inhibition of the JNK pathway, negatively interferes with the NF-kappaB-dependent transcriptional control of MMP-9.	Cyclosporine	116-119	matrix metallopeptidase 9	Homo sapiens	234-239
17202418-11	2007	Interference with MMP-9 transcription may account for the accumulation of extracellular matrix underlying the high fibrotic potential of CsA during anti-inflammatory therapies with calcineurin inhibitors.	Cyclosporine	137-140	matrix metallopeptidase 9	Homo sapiens	18-23
17201457-29	2007	Ciclosporin inhibits biliary excretion of MPAG by MRP-2, reducing enterohepatic recirculation of MPA.	Cyclosporine	0-11	ATP binding cassette subfamily C member 2	Homo sapiens	50-55
17072859-8	2007	Inhibiting CnA with cyclosporin A (CsA) leads to nephron deficit in rat metanephric organ cultures and apoptosis in various renal cell lines.	Cyclosporine	20-33	protein phosphatase 3, catalytic subunit, alpha isoform	Mus musculus	11-14
17072859-8	2007	Inhibiting CnA with cyclosporin A (CsA) leads to nephron deficit in rat metanephric organ cultures and apoptosis in various renal cell lines.	Cyclosporine	35-38	protein phosphatase 3, catalytic subunit, alpha isoform	Mus musculus	11-14
17365275-2	2007	P-gp inhibitors, such as cyclosporin A, quinidine and verapamil, enhanced the apparent brain uptake of [3H]BNP by 1.5-fold.	Cyclosporine	25-38	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	0-4
17164721-8	2006	More CD4CD25Treg cells expressing high levels of CD44 and CD45RB, and less CD4CD25Treg cells expressing CD62L were observed in CsA-treated mice, compared with the control mice.	Cyclosporine	127-130	CD44 antigen	Mus musculus	49-53
17164721-10	2006	Furthermore, CsA markedly impaired the immunosuppressive function of CD4CD25Treg cells.	Cyclosporine	13-16	CD4 antigen	Mus musculus	69-72
17164721-11	2006	CONCLUSIONS: CsA significantly impaired the development and function of CD4CD25Treg cells.	Cyclosporine	13-16	CD4 antigen	Mus musculus	72-75
17175307-17	2006	We concluded that patients with early CAN who are switched to SRL and low-dose CsA have a significant attenuation of the rate of GFR declination when compared with patients who receive MMF or AZA addition.	Cyclosporine	79-82	Rap guanine nucleotide exchange factor 5	Homo sapiens	129-132
17053191-8	2006	Trapping ABCA1 on the cell surface with cyclosporin A enhanced apoA-I binding but decreased its internalization and transcytosis.	Cyclosporine	40-53	ATP binding cassette subfamily A member 1	Homo sapiens	9-14
17096891-5	2006	The numbers of CD3(+), CD4(+), CD8(+), CD11a(+), CD18(+) lymphocytes in skin and lung decreased markedly by GTT, GTT + CsA and CsA + MTX treatments.	Cyclosporine	127-130	CD4 antigen	Mus musculus	23-26
17042130-10	2006	Cyclosporine inhibits CD8 activation and thus may reduce epidermal destruction.	Cyclosporine	0-12	CD8a molecule	Homo sapiens	22-25
16760228-7	2006	The well known cholestatic drugs, rifampicin, rifamycin SV, glibenclamide, and cyclosporin A, reduced the basal-to-apical transport and the apical efflux clearance of taurocholate across NTCP- and BSEP-coexpressing cell monolayers.	Cyclosporine	79-92	ATP binding cassette subfamily B member 11	Homo sapiens	197-201
16911495-8	2006	Cyclosporine interacts with MPA by inhibiting the multidrug resistance-associated protein 2 (MRP2).	Cyclosporine	0-12	ATP binding cassette subfamily C member 2	Homo sapiens	50-91
16911495-8	2006	Cyclosporine interacts with MPA by inhibiting the multidrug resistance-associated protein 2 (MRP2).	Cyclosporine	0-12	ATP binding cassette subfamily C member 2	Homo sapiens	93-97
16793245-2	2006	Cyclosporin A (CsA) as an essential immunosuppressive drug has potentially cholestatic adverse effects on the liver, but increases the expression of mdr1.	Cyclosporine	0-13	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	149-153
16793245-2	2006	Cyclosporin A (CsA) as an essential immunosuppressive drug has potentially cholestatic adverse effects on the liver, but increases the expression of mdr1.	Cyclosporine	15-18	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	149-153
16793245-11	2006	The similar effects of V and CsA on BA transport and metabolism can be explained by mdr1 mediated disturbances of cellular ATP transport rather than by inhibition of individual BA transporters.	Cyclosporine	29-32	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	84-88
16960140-7	2006	The current findings could be relevant for the osteoporosis seen in patients given the calcineurin inhibitor cyclosporine to prevent transplant rejection, although the results need to be reconciled with aspects of the clinical picture.	Cyclosporine	109-121	calcineurin binding protein 1	Homo sapiens	87-108
16353156-6	2006	Cyclosporin A, a competitive inhibitor of Pgp, increased the intracellular accumulation of DOX and reduced the resistance to it.	Cyclosporine	0-13	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	42-45
16671876-8	2006	By contrast, significantly stronger beta-catenin and Cyclin D1 mRNA expressions and protein levels were found in CsA-treated rats than controls by RT-PCR and immunohistochemistry at week 4, whereas PCNA production was stronger at both times.	Cyclosporine	113-116	proliferating cell nuclear antigen	Rattus norvegicus	198-202
16549191-11	2006	On the hepatectomy surface, Ki-67 indices and TGF-alpha expressions were higher in the CyA group and lower in the SRL and MMF groups compared with the control group (P &lt; .01).	Cyclosporine	87-90	transforming growth factor alpha	Rattus norvegicus	46-55
16404147-9	2005	Finally, to begin to characterize the TCR-mediated signaling pathway(s) required for IL-17 production, we showed that IL-17 expression is sensitive to cyclosporin-A and MAPK inhibitors, suggesting the involvement of the calcineurin/NFAT and MAPK signaling pathways.	Cyclosporine	151-164	interleukin 17A	Mus musculus	85-90
16404147-9	2005	Finally, to begin to characterize the TCR-mediated signaling pathway(s) required for IL-17 production, we showed that IL-17 expression is sensitive to cyclosporin-A and MAPK inhibitors, suggesting the involvement of the calcineurin/NFAT and MAPK signaling pathways.	Cyclosporine	151-164	interleukin 17A	Mus musculus	118-123
16297055-7	2005	Patients with cyclosporine (n = 42) as first-line immunosuppression displayed more often immunoreactivity to IA-2 and IAA than patients treated with tacrolimus (n = 49) (31% vs. 14%, P = 0.04; 67% vs. 47%, P = 0.04).	Cyclosporine	14-26	protein tyrosine phosphatase receptor type N	Homo sapiens	109-113
16297055-11	2005	Patients with cyclosporine for immunosuppression and withdrawal of glucocorticoids therapy were more often immunoreactive to IAA and IA-2.	Cyclosporine	14-26	protein tyrosine phosphatase receptor type N	Homo sapiens	133-137
16051742-1	2005	The peripheral benzodiazepine receptor (pBR) ligand, PK11195, promotes mitochondrial apoptosis and blocks P-glycoprotein (Pgp)-mediated drug efflux to chemosensitize cancer cells at least as well or better than the Pgp modulator, cyclosporine A (CSA).	Cyclosporine	230-244	translocator protein	Homo sapiens	4-38
16051742-1	2005	The peripheral benzodiazepine receptor (pBR) ligand, PK11195, promotes mitochondrial apoptosis and blocks P-glycoprotein (Pgp)-mediated drug efflux to chemosensitize cancer cells at least as well or better than the Pgp modulator, cyclosporine A (CSA).	Cyclosporine	230-244	translocator protein	Homo sapiens	40-43
16051742-1	2005	The peripheral benzodiazepine receptor (pBR) ligand, PK11195, promotes mitochondrial apoptosis and blocks P-glycoprotein (Pgp)-mediated drug efflux to chemosensitize cancer cells at least as well or better than the Pgp modulator, cyclosporine A (CSA).	Cyclosporine	246-249	translocator protein	Homo sapiens	4-38
16051742-1	2005	The peripheral benzodiazepine receptor (pBR) ligand, PK11195, promotes mitochondrial apoptosis and blocks P-glycoprotein (Pgp)-mediated drug efflux to chemosensitize cancer cells at least as well or better than the Pgp modulator, cyclosporine A (CSA).	Cyclosporine	246-249	translocator protein	Homo sapiens	40-43
16221205-9	2005	The 45 kD or 20 kD caspase-1 was increased by I/R or CsA, respectively, and decreased by rapamycin (P &lt; 0.05).	Cyclosporine	53-56	caspase 1	Rattus norvegicus	19-28
16109714-3	2005	Here we show that NFATc1 expression precedes that of OSCAR during TRANCE-mediated osteoclastogenesis and that inhibition of NFATc1 by cyclosporin A abolishes TRANCE-induced OSCAR expression and subsequent osteoclast differentiation.	Cyclosporine	134-147	nuclear factor of activated T cells 1	Homo sapiens	124-130
16109714-3	2005	Here we show that NFATc1 expression precedes that of OSCAR during TRANCE-mediated osteoclastogenesis and that inhibition of NFATc1 by cyclosporin A abolishes TRANCE-induced OSCAR expression and subsequent osteoclast differentiation.	Cyclosporine	134-147	TNF superfamily member 11	Homo sapiens	158-164
15994335-8	2005	The calcineurin inhibitor cyclosporin A also blocks the dephosphorylation of TRPC6 and prevents the disassociation of M1 mAChRs.	Cyclosporine	26-39	transient receptor potential cation channel, subfamily C, member 6	Rattus norvegicus	77-82
15986223-7	2005	In contrast, a significant increase in MRF4 mRNA was seen in CsA-administered mice compared to the placebo-treated mice at 4 and 9 days post surgery.	Cyclosporine	61-64	myogenic factor 6	Mus musculus	39-43
15986223-8	2005	In CsA-treated mice, the level of Id1 mRNA was elevated at day 9 relative to the placebo-treated mice.	Cyclosporine	3-6	inhibitor of DNA binding 1, HLH protein	Mus musculus	34-37
15986223-9	2005	After 6 days, the CsA-treated mice possessed more abundant proliferating cell nuclear antigen (PCNA) and cyclin D1 protein in many satellite cells and/or myoblast-like cells in the regenerating muscle.	Cyclosporine	18-21	proliferating cell nuclear antigen	Mus musculus	59-93
15986223-9	2005	After 6 days, the CsA-treated mice possessed more abundant proliferating cell nuclear antigen (PCNA) and cyclin D1 protein in many satellite cells and/or myoblast-like cells in the regenerating muscle.	Cyclosporine	18-21	proliferating cell nuclear antigen	Mus musculus	95-99
15986223-9	2005	After 6 days, the CsA-treated mice possessed more abundant proliferating cell nuclear antigen (PCNA) and cyclin D1 protein in many satellite cells and/or myoblast-like cells in the regenerating muscle.	Cyclosporine	18-21	cyclin D1	Mus musculus	105-114
15986223-12	2005	Our results demonstrated that CsA treatment upregulates Id1 and Smad3 expression and delays skeletal muscle regeneration in vivo.	Cyclosporine	30-33	inhibitor of DNA binding 1, HLH protein	Mus musculus	56-59
15951832-6	2005	Cellular [(11)C]carvedilol accumulation in GLC(4), GLC(4)/P-gp, and GLC(4)/Adr cells increased three-fold in the GLC(4)/P-gp cells after pretreatment with cyclosporin A (CsA) whereas no effect of MK571 could be determined in the GLC(4)/Adr cells.	Cyclosporine	155-168	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	120-124
15951832-6	2005	Cellular [(11)C]carvedilol accumulation in GLC(4), GLC(4)/P-gp, and GLC(4)/Adr cells increased three-fold in the GLC(4)/P-gp cells after pretreatment with cyclosporin A (CsA) whereas no effect of MK571 could be determined in the GLC(4)/Adr cells.	Cyclosporine	170-173	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	120-124
15951832-10	2005	In vivo PET experiments were performed with and without P-gp modulation by CsA.	Cyclosporine	75-78	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	56-60
15879595-6	2005	TCR-induced IL-21 gene expression was inhibited by cyclosporin A and FK506.	Cyclosporine	51-64	interleukin 21	Homo sapiens	12-17
15879595-7	2005	Correspondingly, the IL-21 5"-regulatory region contains three NFAT binding sites, and induction of IL-21 promoter activity was impaired when these sites were mutated or following treatment with cyclosporin A.	Cyclosporine	195-208	interleukin 21	Homo sapiens	21-26
15879595-7	2005	Correspondingly, the IL-21 5"-regulatory region contains three NFAT binding sites, and induction of IL-21 promoter activity was impaired when these sites were mutated or following treatment with cyclosporin A.	Cyclosporine	195-208	interleukin 21	Homo sapiens	100-105
15899924-2	2005	Immunosuppressive drugs, such as FK506 and cyclosporin A, block the priming of alloreactive CD4 T(h) cells and the subsequent induction of allospecific CD8 cytotoxic effector T cells and inhibit allograft rejection.	Cyclosporine	43-56	CD8a molecule	Homo sapiens	152-155
15935056-0	2005	Synapsin associates with cyclophilin B in an ATP- and cyclosporin A-dependent manner.	Cyclosporine	54-67	peptidylprolyl isomerase B	Rattus norvegicus	25-38
15858844-1	2005	Recently, we found that potent P-glycoprotein (P-gp) inhibitors, such as verapamil and cyclosporin A, markedly modulated the pharmacokinetics of digoxin in rats, whereas they did not affect beta-methyldigoxin pharmacokinetics significantly.	Cyclosporine	87-100	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	31-45
15858844-1	2005	Recently, we found that potent P-glycoprotein (P-gp) inhibitors, such as verapamil and cyclosporin A, markedly modulated the pharmacokinetics of digoxin in rats, whereas they did not affect beta-methyldigoxin pharmacokinetics significantly.	Cyclosporine	87-100	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	47-51
15888147-6	2005	The addition of retinoids or corticosteroids to the cell culture inhibited the UVB-induced suppression of both ATP2A2 and ATP2C1 mRNA levels, and UVB-induced suppression of ATP2C1 mRNA was also inhibited by the addition of ciclosporin, tacrolimus and vitamin D(3).	Cyclosporine	223-234	ATPase secretory pathway Ca2+ transporting 1	Homo sapiens	173-179
15716327-1	2005	Cyclosporin A (CsA) and FK506 suppress T cell activation by inhibiting calcineurin and the calcineurin-dependent transcription factors nuclear factor of activated T cells (NFATc), which are central regulators of T cell function.	Cyclosporine	0-13	nuclear factor of activated T cells 1	Homo sapiens	172-177
15716327-1	2005	Cyclosporin A (CsA) and FK506 suppress T cell activation by inhibiting calcineurin and the calcineurin-dependent transcription factors nuclear factor of activated T cells (NFATc), which are central regulators of T cell function.	Cyclosporine	15-18	nuclear factor of activated T cells 1	Homo sapiens	172-177
15919497-4	2005	Renal function (GFR) deteriorated progressively under cyclosporine (creatinine: baseline 1.5 mg/dL; delta(Cyc) = +1.4 mg/dL within 3 years; GFR: delta(Cyc) = -35 mL/min within 3 years).	Cyclosporine	54-66	Rap guanine nucleotide exchange factor 5	Homo sapiens	16-19
15671024-4	2005	Treatment with cyclosporin A significantly reduced surface expression of CD147 and of CD8-CD147 fusion protein carrying the extracellular domain of CD8 fused to the transmembrane and cytoplasmic domains of CD147, but did not affect expression of CD8.	Cyclosporine	15-28	CD8a molecule	Homo sapiens	86-89
15671024-4	2005	Treatment with cyclosporin A significantly reduced surface expression of CD147 and of CD8-CD147 fusion protein carrying the extracellular domain of CD8 fused to the transmembrane and cytoplasmic domains of CD147, but did not affect expression of CD8.	Cyclosporine	15-28	CD8a molecule	Homo sapiens	148-151
15671024-4	2005	Treatment with cyclosporin A significantly reduced surface expression of CD147 and of CD8-CD147 fusion protein carrying the extracellular domain of CD8 fused to the transmembrane and cytoplasmic domains of CD147, but did not affect expression of CD8.	Cyclosporine	15-28	CD8a molecule	Homo sapiens	148-151
15858052-7	2005	This was critically dependent on Ca2+ ion uptake and extrusion, because inhibition of the mitochondrial Ca2+ ion uniporter by Ru360 and the mitochondrial Na+/Ca2+ ion exchanger by 7-chloro-5-(2-chlorophenyl)-1,5-dihydro-4,1-benzothiazepin-2(3H)-one but not the inhibitor of mitochondrial permeability transition pore, cyclosporin A, decreased the SLE-associated mitochondrial depolarization.	Cyclosporine	318-331	carbonic anhydrase 2	Homo sapiens	33-36
15858052-7	2005	This was critically dependent on Ca2+ ion uptake and extrusion, because inhibition of the mitochondrial Ca2+ ion uniporter by Ru360 and the mitochondrial Na+/Ca2+ ion exchanger by 7-chloro-5-(2-chlorophenyl)-1,5-dihydro-4,1-benzothiazepin-2(3H)-one but not the inhibitor of mitochondrial permeability transition pore, cyclosporin A, decreased the SLE-associated mitochondrial depolarization.	Cyclosporine	318-331	carbonic anhydrase 2	Homo sapiens	104-107
15858052-7	2005	This was critically dependent on Ca2+ ion uptake and extrusion, because inhibition of the mitochondrial Ca2+ ion uniporter by Ru360 and the mitochondrial Na+/Ca2+ ion exchanger by 7-chloro-5-(2-chlorophenyl)-1,5-dihydro-4,1-benzothiazepin-2(3H)-one but not the inhibitor of mitochondrial permeability transition pore, cyclosporin A, decreased the SLE-associated mitochondrial depolarization.	Cyclosporine	318-331	carbonic anhydrase 2	Homo sapiens	104-107
15802827-1	2005	The contribution of P-glycoprotein (P-gp) to the intestinal absorption of cyclosporin A (CsA) was investigated by comparing the in vivo pharmacokinetics of CsA in P-gp knockout mice versus wild-type mice following both oral and intravenous administration and by examining the transport of CsA across Caco-2 cell monolayers.	Cyclosporine	89-92	phosphoglycolate phosphatase	Mus musculus	20-34
15802827-1	2005	The contribution of P-glycoprotein (P-gp) to the intestinal absorption of cyclosporin A (CsA) was investigated by comparing the in vivo pharmacokinetics of CsA in P-gp knockout mice versus wild-type mice following both oral and intravenous administration and by examining the transport of CsA across Caco-2 cell monolayers.	Cyclosporine	156-159	phosphoglycolate phosphatase	Mus musculus	163-167
15802827-1	2005	The contribution of P-glycoprotein (P-gp) to the intestinal absorption of cyclosporin A (CsA) was investigated by comparing the in vivo pharmacokinetics of CsA in P-gp knockout mice versus wild-type mice following both oral and intravenous administration and by examining the transport of CsA across Caco-2 cell monolayers.	Cyclosporine	156-159	phosphoglycolate phosphatase	Mus musculus	163-167
15802827-2	2005	The apparent oral bioavailability of CsA in P-gp knockout mice was 1.55-fold larger than in wild-type mice, leading to an apparent absolute bioavailability of 41.8%.	Cyclosporine	37-40	phosphoglycolate phosphatase	Mus musculus	44-48
15802827-4	2005	These results suggest that the involvement of P-gp in the intestinal absorption of CsA is not as profound as was previously thought.	Cyclosporine	83-86	phosphoglycolate phosphatase	Mus musculus	46-50
15749732-3	2005	The effects of IFN-gamma and cyclosporin A (CsA) on the expression of mIL-15 were also investigated.	Cyclosporine	44-47	interleukin 15	Mus musculus	70-76
15773954-6	2005	An individualized approach to choice of calcineurin inhibitor, by which cyclosporine or tacrolimus are selected based on the patient"s particular risk profile, may thus help to reduce the toll of cardiovascular mortality among renal transplant recipients in the future.	Cyclosporine	72-84	calcineurin binding protein 1	Homo sapiens	40-61
15715928-9	2005	In SMC pretreated with cyclosporin A (CsA), the absorbance of cells stimulated by PE decreased by 36.7%, but could not be further altered by the additional treatment of SNAP, Sp-8-pCPT-cGMPS, and Rp-8-pCPT-cGMPS.	Cyclosporine	23-36	Sp8 transcription factor	Rattus norvegicus	175-179
15715928-9	2005	In SMC pretreated with cyclosporin A (CsA), the absorbance of cells stimulated by PE decreased by 36.7%, but could not be further altered by the additional treatment of SNAP, Sp-8-pCPT-cGMPS, and Rp-8-pCPT-cGMPS.	Cyclosporine	38-41	Sp8 transcription factor	Rattus norvegicus	175-179
15848549-9	2005	Of the dose combinations, CSA 7.5 mg/d + RAPA 0.5 mg/d produced the lowest serum creatinine for all time points, and inhibited profibrotic TIMP-1 (P = .017), while increasing antifibrotic MMP-2 (P = .009) mRNA expression, compared to CSA treatment alone.	Cyclosporine	26-29	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	139-145
15684491-0	2005	In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats.	Cyclosporine	19-32	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	107-121
15684491-1	2005	In this study, the in vivo effects of cyclosporin A (CsA) and ketoconazole (KCZ), which are used as inhibitors of P-glycoprotein (Pgp) and cytochrome P450 (CYP) 3A, respectively, on the pharmacokinetics of rhodamine 123 (Rho123), nelfinavir (NFV) and erythromycin (EM) were evaluated in rats.	Cyclosporine	38-51	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	114-128
15684491-1	2005	In this study, the in vivo effects of cyclosporin A (CsA) and ketoconazole (KCZ), which are used as inhibitors of P-glycoprotein (Pgp) and cytochrome P450 (CYP) 3A, respectively, on the pharmacokinetics of rhodamine 123 (Rho123), nelfinavir (NFV) and erythromycin (EM) were evaluated in rats.	Cyclosporine	38-51	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	130-133
15620875-5	2005	Inhibition of P-gp by cyclosporin A (CsA) significantly reduced secretory flux of compounds known to be P-pg substrates, but only enhanced the absorptive flux of compounds with high efflux ratio (&gt;100).	Cyclosporine	22-35	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	14-18
15620875-5	2005	Inhibition of P-gp by cyclosporin A (CsA) significantly reduced secretory flux of compounds known to be P-pg substrates, but only enhanced the absorptive flux of compounds with high efflux ratio (&gt;100).	Cyclosporine	37-40	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	14-18
15469936-4	2004	Two mutations situated on the face of C-18, predicted to be involved in its interaction with the ligand cyclosporin A, were shown to be critical for CCR5-binding and the inhibition of HIV-1 fusion and infectivity.	Cyclosporine	104-117	C-C motif chemokine receptor 5	Homo sapiens	149-153
15621770-5	2004	After rapid tapering of cyclosporin, serum levels of AST and ALP normalized in parallel with recovery of complete chimerism on day 134.	Cyclosporine	24-35	ATHS	Homo sapiens	61-64
15483743-9	2004	(2) Combined with cyclosporine A (CsA), fluvastatin would further repress CD69 expression, cells proliferation and activity of killer cells, meanwhile significantly induced the secretion of IL-4 and IL-10.	Cyclosporine	18-32	interleukin 10	Homo sapiens	199-204
15483743-9	2004	(2) Combined with cyclosporine A (CsA), fluvastatin would further repress CD69 expression, cells proliferation and activity of killer cells, meanwhile significantly induced the secretion of IL-4 and IL-10.	Cyclosporine	34-37	interleukin 10	Homo sapiens	199-204
15324353-0	2004	Long-term cyclosporin A exposure suppresses cathepsin-B and -L activity in gingival fibroblasts.	Cyclosporine	10-23	cathepsin B	Homo sapiens	44-62
15324353-10	2004	Accumulation of cathepsin-B, -H and -L mRNA was markedly suppressed by long-term cyclosporin A exposure, whereas accumulation of another lysosomal enzyme N-acetyl-beta-D-glucosaminidase mRNA, which is involved in remodeling of gingival epithelium, was not apparently impaired in cyclosporin A-treated cells.	Cyclosporine	81-94	cathepsin B	Homo sapiens	16-38
15324353-12	2004	In addition, we demonstrated that long-term cyclosporin A exposure significantly suppressed not only the activity of the active form of cathepsin-(B + L) compared to the activity in non-treated cells (p = 0.0458), but also the activity of the active form of cathepsin-B (p &lt; 0.0001) in human gingival fibroblasts.	Cyclosporine	44-57	cathepsin B	Homo sapiens	136-148
15324353-12	2004	In addition, we demonstrated that long-term cyclosporin A exposure significantly suppressed not only the activity of the active form of cathepsin-(B + L) compared to the activity in non-treated cells (p = 0.0458), but also the activity of the active form of cathepsin-B (p &lt; 0.0001) in human gingival fibroblasts.	Cyclosporine	44-57	cathepsin B	Homo sapiens	258-269
15324353-13	2004	CONCLUSION: The decreased ability of protein degradation by not only cathepsin-L but also cathepsin-B is, at least, one of the several factors developing the cyclosporin A-induced gingival overgrowth.	Cyclosporine	158-171	cathepsin B	Homo sapiens	90-101
15638123-4	2004	To detect the activity of Pgp, verapamil (Ver) or cyclosporine A (CsA) has to be used as Pgp inhibitors.	Cyclosporine	50-64	phosphoglycolate phosphatase	Mus musculus	89-92
15638123-4	2004	To detect the activity of Pgp, verapamil (Ver) or cyclosporine A (CsA) has to be used as Pgp inhibitors.	Cyclosporine	66-69	phosphoglycolate phosphatase	Mus musculus	26-29
15638123-4	2004	To detect the activity of Pgp, verapamil (Ver) or cyclosporine A (CsA) has to be used as Pgp inhibitors.	Cyclosporine	66-69	phosphoglycolate phosphatase	Mus musculus	89-92
15207740-2	2004	Cyclosporin A (CsA), cyclosporin B (CsB), cyclosporin H (CsH), and FK506 all inhibited receptor activator of NFkappaB ligand (RANKL)-stimulated tartrate-resistant acid phosphatase (TRAP) activity and generation of TRAP+ multinucleated cells in the cultures.	Cyclosporine	15-18	acid phosphatase 5, tartrate resistant	Mus musculus	144-179
15207740-2	2004	Cyclosporin A (CsA), cyclosporin B (CsB), cyclosporin H (CsH), and FK506 all inhibited receptor activator of NFkappaB ligand (RANKL)-stimulated tartrate-resistant acid phosphatase (TRAP) activity and generation of TRAP+ multinucleated cells in the cultures.	Cyclosporine	15-18	acid phosphatase 5, tartrate resistant	Mus musculus	181-185
15207740-2	2004	Cyclosporin A (CsA), cyclosporin B (CsB), cyclosporin H (CsH), and FK506 all inhibited receptor activator of NFkappaB ligand (RANKL)-stimulated tartrate-resistant acid phosphatase (TRAP) activity and generation of TRAP+ multinucleated cells in the cultures.	Cyclosporine	15-18	acid phosphatase 5, tartrate resistant	Mus musculus	214-218
15207740-7	2004	When CsA or FK506 were added for 1 day to cultures in which osteoclasts had already formed, the numbers of TRAP+ osteoclasts decreased.	Cyclosporine	5-8	acid phosphatase 5, tartrate resistant	Mus musculus	107-111
15207740-8	2004	Treatment with CsA or FK506 produced nuclear fragmentation and disruption of the multinucleated osteoclasts and an increase in caspase-3 activity.	Cyclosporine	15-18	caspase 3	Mus musculus	127-136
15615187-9	2004	On the other hand, SAA rejection in operation, acute allograft rejection and infection is present in spite of cyclosporine A and steroids therapy.	Cyclosporine	110-124	serum amyloid A1 cluster	Homo sapiens	19-22
15615187-10	2004	Different reaction of SAA and CRP in transplant patients to cyclosporine A therapy helps in differentiation between the infection and rejection.	Cyclosporine	60-74	serum amyloid A1 cluster	Homo sapiens	22-25
15147420-6	2004	Analysis of the T-cell recovery in ASCT- and ASCT/CsA-treated mice showed that CsA induced an increase in the number of CD4+ 25+ T cells, suggesting that the lack of GVHD in ASCT/CsA treated-mice could be related to the expansion of this CD4 T-cell subset.	Cyclosporine	79-82	CD4 antigen	Mus musculus	120-123
15147420-6	2004	Analysis of the T-cell recovery in ASCT- and ASCT/CsA-treated mice showed that CsA induced an increase in the number of CD4+ 25+ T cells, suggesting that the lack of GVHD in ASCT/CsA treated-mice could be related to the expansion of this CD4 T-cell subset.	Cyclosporine	79-82	CD4 antigen	Mus musculus	238-241
15147420-6	2004	Analysis of the T-cell recovery in ASCT- and ASCT/CsA-treated mice showed that CsA induced an increase in the number of CD4+ 25+ T cells, suggesting that the lack of GVHD in ASCT/CsA treated-mice could be related to the expansion of this CD4 T-cell subset.	Cyclosporine	79-82	CD4 antigen	Mus musculus	120-123
15147420-6	2004	Analysis of the T-cell recovery in ASCT- and ASCT/CsA-treated mice showed that CsA induced an increase in the number of CD4+ 25+ T cells, suggesting that the lack of GVHD in ASCT/CsA treated-mice could be related to the expansion of this CD4 T-cell subset.	Cyclosporine	79-82	CD4 antigen	Mus musculus	238-241
15187451-6	2004	The apparent uptake of PTZ by the brain increased in the presence of P-gp inhibitors such as cyclosporin A, quinidine, verapamil and vinblastine after the carotid injection.	Cyclosporine	93-106	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	69-73
15153516-9	2004	However, cyclosporin A, an inhibitor of calcineurin-mediated NFAT activation, caused substantial inhibition of NGF-induced MIP-1beta production both in the absence and presence of C3a.	Cyclosporine	9-22	complement C3	Homo sapiens	180-183
14978191-0	2004	Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats.	Cyclosporine	0-13	ATP binding cassette subfamily C member 2	Rattus norvegicus	120-161
14978191-7	2004	In conclusion, it is suggested that there is an efficient MPAG transport mediated by Mrp2 on the bile canalicular membrane of rat hepatocytes and that the therapeutic range of CsA potentially interferes with Mrp2.	Cyclosporine	176-179	ATP binding cassette subfamily C member 2	Rattus norvegicus	208-212
15192777-3	2004	The calcineurin inhibitor (cyclosporine A = 9, tacrolimus = 3) was reduced by 50 %, and rapamycin added to reach a target level of 8 - 12 ng/dL.	Cyclosporine	27-41	calcineurin binding protein 1	Homo sapiens	4-25
15128834-5	2004	Th1 cell activation was dependent on the presence of APCs and could be blocked by cyclosporine.	Cyclosporine	82-94	negative elongation factor complex member C/D	Homo sapiens	0-3
14684381-9	2004	In summary, 1) CCK released by chronic camostat feeding induces pancreatic growth in mice; 2) this growth is blocked by treatment with both CsA and FK506, indicating a role for CN; 3) CCK stimulation also increases CN protein.	Cyclosporine	140-143	cholecystokinin	Mus musculus	15-18
14684381-9	2004	In summary, 1) CCK released by chronic camostat feeding induces pancreatic growth in mice; 2) this growth is blocked by treatment with both CsA and FK506, indicating a role for CN; 3) CCK stimulation also increases CN protein.	Cyclosporine	140-143	cholecystokinin	Mus musculus	184-187
14960594-5	2004	Sub-micromolar concentrations of cyclosporin A blocked MPT and cell death, suggesting that MPT is a necessary step linking PARP-1 activation to cell death.	Cyclosporine	33-46	poly (ADP-ribose) polymerase family, member 1	Mus musculus	123-129
14960594-9	2004	Furthermore, both cyclosporin A and NAD(+) blocked translocation of the apoptosis-inducing factor from mitochondria to nuclei, a step previously shown necessary for PARP-1-induced cell death.	Cyclosporine	18-31	poly (ADP-ribose) polymerase family, member 1	Mus musculus	165-171
15044094-0	2004	Transgenic mice overexpressing cyclophilin A are resistant to cyclosporin A-induced nephrotoxicity via peptidyl-prolyl cis-trans isomerase activity.	Cyclosporine	62-75	peptidylprolyl isomerase A	Mus musculus	31-44
15044094-1	2004	Cyclosporin A (CsA) suppresses immune reaction by inhibiting calcineurin activity after forming complex with cyclophilins and is currently widely used as an immunosuppressive drug.	Cyclosporine	0-13	peptidylprolyl isomerase A	Mus musculus	109-121
15044094-1	2004	Cyclosporin A (CsA) suppresses immune reaction by inhibiting calcineurin activity after forming complex with cyclophilins and is currently widely used as an immunosuppressive drug.	Cyclosporine	15-18	peptidylprolyl isomerase A	Mus musculus	109-121
15044094-3	2004	We previously showed that CsA toxicity is mediated by ROS generation as well as by inhibition of peptidyl-prolyl cis-trans isomerase (PPIase) activity of CypA in CsA-treated myoblasts [FASEB J.	Cyclosporine	26-29	peptidylprolyl isomerase A	Mus musculus	154-158
15031334-3	2004	Here, we investigated protective effects of HGF gene therapy on CsA-induced nephrotoxicity by using an electroporation-mediated gene transfer method.	Cyclosporine	64-67	hepatocyte growth factor	Rattus norvegicus	44-47
15031334-7	2004	Morphological assessment revealed that HGF gene transfer reduced CsA-induced initial tubular injury and inhibited interstitial infiltration of ED-1-positive macrophages.	Cyclosporine	65-68	hepatocyte growth factor	Rattus norvegicus	39-42
15031334-9	2004	Finally, HGF gene transfer significantly reduced striped interstitial phenotypic alterations and fibrosis in CsA-treated rats, as assessed by alpha-smooth muscle actin expression and Masson"s trichrome staining.	Cyclosporine	109-112	hepatocyte growth factor	Rattus norvegicus	9-12
15031334-10	2004	CONCLUSIONS: These results suggest that HGF may prevent CsA-induced tubulointerstitial fibrosis, indicating that HGF gene transfer may provide a potential strategy for preventing renal fibrosis.	Cyclosporine	56-59	hepatocyte growth factor	Rattus norvegicus	40-43
15031334-10	2004	CONCLUSIONS: These results suggest that HGF may prevent CsA-induced tubulointerstitial fibrosis, indicating that HGF gene transfer may provide a potential strategy for preventing renal fibrosis.	Cyclosporine	56-59	hepatocyte growth factor	Rattus norvegicus	113-116
15110634-10	2004	Cyclosporine (but not tacrolimus) increased the expression of (alpha2)IV collagen and TIMP2 in isolated glomeruli.	Cyclosporine	0-12	TIMP metallopeptidase inhibitor 2	Homo sapiens	86-91
15019079-6	2004	In the presence of verapamil (100 microM) and CsA (10 microM), potent inhibitors of P-glyprotein (P-gp)/MRP2 (cMOAT), the P(appBL-AP)/P(appAP-BL) ratio was decreased from 3.4 to 1.4 and 1.3, respectively, and permeation of apical to basolateral was enhanced approximately two-fold.	Cyclosporine	46-49	ATP binding cassette subfamily C member 2	Homo sapiens	104-108
15019079-6	2004	In the presence of verapamil (100 microM) and CsA (10 microM), potent inhibitors of P-glyprotein (P-gp)/MRP2 (cMOAT), the P(appBL-AP)/P(appAP-BL) ratio was decreased from 3.4 to 1.4 and 1.3, respectively, and permeation of apical to basolateral was enhanced approximately two-fold.	Cyclosporine	46-49	ATP binding cassette subfamily C member 2	Homo sapiens	110-115
14976124-11	2004	After treatment of CGN with colchicine plus CsA, the changes in the p25/p35 ratio pointed to cdk5 activation.	Cyclosporine	44-47	cyclin-dependent kinase 5 regulatory subunit 1	Rattus norvegicus	72-75
15108766-4	2004	Compared with specimens from FK506-treated patients (n = 20), specimens from CyA-treated patients (n = 43) showed a significant increase in tubulointerstitial CD68-positive cells (1.5 +/- 0.9 vs. 0.9 +/- 0.8, p &lt; 0.01), although no significant differences were observed in NF-kappaB activation.	Cyclosporine	77-80	CD68 molecule	Homo sapiens	159-163
14747548-6	2004	However, transferring these amino acids to the C terminus of HIV-1 Nef is insufficient to induce cyclosporine resistance in HIV-1.	Cyclosporine	97-109	Nef	Human immunodeficiency virus 1	67-70
14672695-6	2004	Treatment of the Huh7/Rep-Feo cells with CsA resulted in suppression of the replication of the HCV replicon in a dose-dependent manner, with an IC50 of approximately 0.5 microg/ml.	Cyclosporine	41-44	MIR7-3 host gene	Homo sapiens	17-21
15341497-9	2004	The calcineurin inhibitor ciclosporin (cyclosporine) not only induces these same adverse effects as corticosteroids but is also nephrotoxic.	Cyclosporine	26-37	calcineurin binding protein 1	Homo sapiens	4-25
15341497-9	2004	The calcineurin inhibitor ciclosporin (cyclosporine) not only induces these same adverse effects as corticosteroids but is also nephrotoxic.	Cyclosporine	39-51	calcineurin binding protein 1	Homo sapiens	4-25
15619640-1	2004	Calcineurin-inhibitor induced pain syndrome (CIPS) is a newly described entity with a characteristic feature of sudden onset of severe lower limb pain, and high levels of cyclosporine or tacrolimus may be involved in the pathogenesis.	Cyclosporine	171-183	calcineurin binding protein 1	Homo sapiens	0-21
15782552-5	2004	Cyclosporine A, a potent calcineurin inhibitor, has been used as a second line therapy.	Cyclosporine	0-14	calcineurin binding protein 1	Homo sapiens	25-46
14967313-3	2004	OBJECTIVE: This study evaluated whether the acute administration of CsA significantly interfered in leukocyte migration, exudation, myeloperoxidase (MPO) and adenosine-deaminase activities and nitrate/nitrite levels, in a mouse model of pleurisy.	Cyclosporine	68-71	myeloperoxidase	Mus musculus	132-147
14967313-3	2004	OBJECTIVE: This study evaluated whether the acute administration of CsA significantly interfered in leukocyte migration, exudation, myeloperoxidase (MPO) and adenosine-deaminase activities and nitrate/nitrite levels, in a mouse model of pleurisy.	Cyclosporine	68-71	myeloperoxidase	Mus musculus	149-152
14967313-7	2004	At this time, CsA (1 mg/kg, 1 h before) also decreased nitrate/nitrite levels and MPO activity (P&lt;0.01).	Cyclosporine	14-17	myeloperoxidase	Mus musculus	82-85
14967313-9	2004	CONCLUSIONS: These results indicate that the acute administration of CsA is able to reduce the two leukocyte populations that occur both at 4 and 48 h after pleurisy induction, late exudation (48 h), MPO activity (4 h) and nitrate/nitrite levels (4 and 48 h).	Cyclosporine	69-72	myeloperoxidase	Mus musculus	200-203
14534356-2	2003	For daunorubicin as a transport substrate, Kapp was independent of [P-gp] for verapamil but increased strictly linearly with [P-gp] for vinblastine, cyclosporin A, and XR9576.	Cyclosporine	149-162	phosphoglycolate phosphatase	Mus musculus	126-130
14625552-8	2003	Treatment of Col6a1-/- mice with CsA rescued the muscle ultrastructural defects and markedly decreased the number of apoptotic nuclei in vivo.	Cyclosporine	33-36	collagen, type VI, alpha 1	Mus musculus	13-19
14579273-6	2003	Cyclosporin A, but not concanamycin A, an H+-ATPase vacuolar inhibitor which affects perforin and granzyme release, strongly reduced the sHLA-I-mediated CD8-dependent IFN-gamma production but did not affect cytolytic activity of NK cells, suggesting that different biochemical pathways are involved.	Cyclosporine	0-13	CD8a molecule	Homo sapiens	153-156
14579273-7	2003	Altogether, these findings indicate that CD8 engagement by sHLA-I activates a cyclosporin A-dependent pathway leading to production and secretion of IFN-gamma which may play a role in the regulation of innate immune responses in humans.	Cyclosporine	78-91	CD8a molecule	Homo sapiens	41-44
14554103-6	2003	In addition, in the presence of rotenone both Cd2+-produced activation of the resting state respiration in KCl medium and Cd2+-induced swelling in sucrose medium of succinate-energized mitochondria were more sensitive to cyclosporin A than the same Cd2+ effects obtained on mitochondria oxidizing succinate (without rotenone) or glutamate plus malate.	Cyclosporine	221-234	Cd2 molecule	Rattus norvegicus	46-49
14554103-6	2003	In addition, in the presence of rotenone both Cd2+-produced activation of the resting state respiration in KCl medium and Cd2+-induced swelling in sucrose medium of succinate-energized mitochondria were more sensitive to cyclosporin A than the same Cd2+ effects obtained on mitochondria oxidizing succinate (without rotenone) or glutamate plus malate.	Cyclosporine	221-234	Cd2 molecule	Rattus norvegicus	122-125
14554103-6	2003	In addition, in the presence of rotenone both Cd2+-produced activation of the resting state respiration in KCl medium and Cd2+-induced swelling in sucrose medium of succinate-energized mitochondria were more sensitive to cyclosporin A than the same Cd2+ effects obtained on mitochondria oxidizing succinate (without rotenone) or glutamate plus malate.	Cyclosporine	221-234	Cd2 molecule	Rattus norvegicus	122-125
12967638-9	2003	Cyclosporin A and FK506, the calcineurin inhibitors, significantly inhibited the increases in both c-fos expression and protein synthesis.	Cyclosporine	0-13	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	99-104
12957134-8	2003	CsA or H2O2 treatment promoted LMP1 positive population to 43% and 41% after 4 weeks of culture.	Cyclosporine	0-3	PDZ and LIM domain 7	Homo sapiens	31-35
12847265-6	2003	Finally, to test the in vivo relevance of our findings, we showed that GM-CSF restored the survival of dexamethasone- or cyclosporine A-immunosuppressed mice from an otherwise lethal infection with Salmonella typhimurium.	Cyclosporine	121-135	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	71-77
12853075-4	2003	the cyclosporine A (CsA)-sensitivity in PUFA-induced membrane permeability transition, (iv).	Cyclosporine	4-18	pumilio RNA binding family member 3	Homo sapiens	40-44
12853075-4	2003	the cyclosporine A (CsA)-sensitivity in PUFA-induced membrane permeability transition, (iv).	Cyclosporine	20-23	pumilio RNA binding family member 3	Homo sapiens	40-44
12855665-2	2003	We have determined the efficacy of several (putative) inhibitors of Pgp (cyclosporin A, PSC833, GF120918, and Cremophor EL) on the penetration of paclitaxel into the mouse brain.	Cyclosporine	73-86	phosphoglycolate phosphatase	Mus musculus	68-71
12890451-2	2003	We have recently shown that CsA up-regulates the expression of TGF-beta1 and its receptors type I (TbetaR-I) and type II (TbetaR-II) in rat mesangial cells (MCs).	Cyclosporine	28-31	transforming growth factor, beta receptor 1	Rattus norvegicus	99-107
12890451-4	2003	Here, we assessed the effect of PGE1 on CsA induced up-regulation of TGF-beta1, TbetaR-I, TbetaR-II and related matrix production in MCs.	Cyclosporine	40-43	transforming growth factor, beta receptor 1	Rattus norvegicus	80-88
12697421-9	2003	These results suggest that activation of DEX-sensitive, CSA-resistant MEK/ERK and p38 pathways, and activation of NF-kappaB, PKC, and PTK are essential for IL-8 and MCP-1 expression by hRPE cells.	Cyclosporine	56-59	chemokine (C-C motif) ligand 2	Mus musculus	165-170
12742481-1	2003	Calcineurin inhibitor drugs (CNI), primarily cyclosporine then tacrolimus, have been the centerpieces of maintenance immunosuppression for kidney transplantation since their introduction in the 1980s.	Cyclosporine	45-57	calcineurin binding protein 1	Homo sapiens	0-21
12742499-2	2003	The most intriguing biological characteristic of SRL emerged after demonstration of its potent synergism with cyclosporine (CsA).	Cyclosporine	110-122	chorionic somatomammotropin hormone 1	Homo sapiens	124-127
12698107-7	2003	In cyclosporine- or FK506-treated mice, T-cell proliferation was suppressed in the CD4 subset but not in the CD8 subset.	Cyclosporine	3-15	CD4 antigen	Mus musculus	83-86
12673668-2	2003	In this study, we aimed to investigate whether cyclosporin A (CsA), a P-gp inhibitor, potentiates EPS induced by DOM.	Cyclosporine	62-65	phosphoglycolate phosphatase	Mus musculus	70-74
12673668-8	2003	These results suggest that CsA increases the brain distribution of DOM by inhibiting P-gp at the BBB, and potentiates catalepsy by increasing the occupancies of the D(1) and D(2) receptors.	Cyclosporine	27-30	phosphoglycolate phosphatase	Mus musculus	85-89
12612437-0	2003	Cyclosporine a augments P-glycoprotein expression in the regenerating rat liver.	Cyclosporine	0-14	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	24-38
12612437-2	2003	Previous studies showed that the immunosuppressive agent cyclosporine A (CsA) modulates P-gp and exerts a hepatotrophic influence in the regenerating liver.	Cyclosporine	57-71	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	88-92
12612437-2	2003	Previous studies showed that the immunosuppressive agent cyclosporine A (CsA) modulates P-gp and exerts a hepatotrophic influence in the regenerating liver.	Cyclosporine	73-76	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	88-92
12612437-6	2003	In CsA pretreated animals, P-gp levels were increased even in normal hepatocytes by 34%, and an additional augmentation was seen in hepatocytes from 24 and 48 h regenerating livers (60% and 56%, respectively).	Cyclosporine	3-6	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	27-31
12612437-7	2003	In summary, we demonstrate for the first time that CsA has an additive effect on the expression of P-glycoprotein during liver regeneration in the rat.	Cyclosporine	51-54	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	99-113
12664199-9	2003	Thus STG grafts have a larger CSA and closer graft-tunnel fit than BTB grafts in a clinical setting.	Cyclosporine	30-33	chromosome 6 open reading frame 15	Homo sapiens	5-8
12490546-8	2003	Stimulation of transfected cells with AngII or specific AT2-receptor agonists resulted in a significant increase in eNOS promoter activity, which was blocked by CsA, MCIP1, and mutation of an upstream NF-AT site.	Cyclosporine	161-164	nitric oxide synthase 3	Rattus norvegicus	116-120
12571628-4	2003	Administration of cyclosporine A (CsA) significantly promoted not only recovery of the injured airway epithelium but also SeV-mediated IL-10 expression (CsA- versus CsA+ =228+/-78 versus 3627+/-1372 pg/graft with 5 x 10(7) pfu), thereby suggesting the requirement of epithelia for efficient gene transfer.	Cyclosporine	18-32	interleukin 10	Homo sapiens	135-140
12571628-4	2003	Administration of cyclosporine A (CsA) significantly promoted not only recovery of the injured airway epithelium but also SeV-mediated IL-10 expression (CsA- versus CsA+ =228+/-78 versus 3627+/-1372 pg/graft with 5 x 10(7) pfu), thereby suggesting the requirement of epithelia for efficient gene transfer.	Cyclosporine	34-37	interleukin 10	Homo sapiens	135-140
12571628-4	2003	Administration of cyclosporine A (CsA) significantly promoted not only recovery of the injured airway epithelium but also SeV-mediated IL-10 expression (CsA- versus CsA+ =228+/-78 versus 3627+/-1372 pg/graft with 5 x 10(7) pfu), thereby suggesting the requirement of epithelia for efficient gene transfer.	Cyclosporine	153-156	interleukin 10	Homo sapiens	135-140
12571628-4	2003	Administration of cyclosporine A (CsA) significantly promoted not only recovery of the injured airway epithelium but also SeV-mediated IL-10 expression (CsA- versus CsA+ =228+/-78 versus 3627+/-1372 pg/graft with 5 x 10(7) pfu), thereby suggesting the requirement of epithelia for efficient gene transfer.	Cyclosporine	153-156	interleukin 10	Homo sapiens	135-140
12571628-6	2003	As a result, luminal loss was significantly prevented in allografts treated with SeV-IL-10 (luminal opening, all control groups: 0% respectively, and SeV-IL-10 5 x 10(7) pfu: 25.7+/-10.5%), an effect that was enhanced by short-term CsA treatment (SeV-IL-10 5 x 10(7) pfu with CsA: 63.7+/-12.7%).	Cyclosporine	232-235	interleukin 10	Homo sapiens	85-90
12571628-6	2003	As a result, luminal loss was significantly prevented in allografts treated with SeV-IL-10 (luminal opening, all control groups: 0% respectively, and SeV-IL-10 5 x 10(7) pfu: 25.7+/-10.5%), an effect that was enhanced by short-term CsA treatment (SeV-IL-10 5 x 10(7) pfu with CsA: 63.7+/-12.7%).	Cyclosporine	276-279	interleukin 10	Homo sapiens	85-90
12543899-10	2003	Immunophenotyping indicated expansion of CD8(+) and CD25(+) lymphocyte subsets following allo-stimulation that was inhibited by increasing concentrations of CsA.	Cyclosporine	157-160	CD8a molecule	Homo sapiens	41-44
12608699-4	2003	Electron microscopic examination of pyramidal neurones in the CA1 sector of the hippocampus in the vicinity of the microdialysis probe after NMDA application demonstrated swelling of mitochondria, which was prevented by cyclosporin A.	Cyclosporine	220-233	carbonic anhydrase 1	Oryctolagus cuniculus	62-65
12427739-4	2003	VEGF-induced NFATc1 nuclear translocation was inhibited by either cyclosporin A or a calcineurin-specific peptide inhibitor; these findings suggest that VEGF stimulates NFATc1 nuclear import in human pulmonary valve endothelial cells by a calcineurin-dependent mechanism.	Cyclosporine	66-79	nuclear factor of activated T cells 1	Homo sapiens	13-19
12427739-5	2003	Importantly, both cyclosporin A and the calcineurin-specific peptide inhibitor reduced VEGF-induced human pulmonary valve endothelial cell proliferation, indicating a functional role for NFATc1 in endothelial growth.	Cyclosporine	18-31	nuclear factor of activated T cells 1	Homo sapiens	187-193
12505729-6	2003	RESULTS: PD analyses suggested that in NHS samples containing CsA+SRL (n=5), (1) PMA-Ionomycin-stimulated T-cell expression of intracellular IL-2, TNF-alpha, and IFN-gamma was inhibited by CsA, and minimally by SRL, and (2) the two agents inhibited pokeweed mitogen (PWM)-stimulated B-cell expression of CD54 and CD95, but not CD86 (ICAM-1, Fas antigen, and B7.2), synergistically.	Cyclosporine	62-65	intercellular adhesion molecule 1	Homo sapiens	304-308
12505729-7	2003	With CD54 as the model biomarker, contour plots also predicted a wide range of concentration mixtures of the two agents across which an EC(50) could be predicted for CsA+SRL in a population (e.g., CsA-72 ng/ml+SRL 15 ng/ml, n=5), as well as in the individual subject (e.g., CsA-0 ng/ml+SRL-13.75 ng/ml in NHS-D310).	Cyclosporine	166-169	intercellular adhesion molecule 1	Homo sapiens	5-9
12505729-9	2003	The EC(50) contour plot for CD54 suggested a nearly identical CsA concentration of 120 ng/ml in the presence of 10 ng/ml of sirolimus.	Cyclosporine	62-65	intercellular adhesion molecule 1	Homo sapiens	28-32
12533600-6	2003	We demonstrated that exposure of neostriatal slices to 8-bromo-cAMP, dopamine, calyculin A, or cyclosporine A, but not to 10 nM okadaic acid, promotes the phosphorylation of neostriatal InsP3R1 by PKA in vivo.	Cyclosporine	95-109	inositol 1,4,5-trisphosphate receptor, type 1	Rattus norvegicus	186-193
12393716-5	2003	Lymphotactin (Ltn), macrophage inflammatory protein (MIP)-1alpha, and MIP-1beta were all rapidly induced and sensitive to cyclosporine treatment.	Cyclosporine	122-134	X-C motif chemokine ligand 1	Homo sapiens	0-12
12393716-5	2003	Lymphotactin (Ltn), macrophage inflammatory protein (MIP)-1alpha, and MIP-1beta were all rapidly induced and sensitive to cyclosporine treatment.	Cyclosporine	122-134	X-C motif chemokine ligand 1	Homo sapiens	14-17
12401520-2	2003	By Northern blotting analyses and transient transfection assays, we herein show that transactivation of grp78 by OA--&gt;HS is abolished by an intracellular calcium chelator, bis(aminophenoxy)ethane N,N"-tetraacetic acid (BAPTA), and an inhibitor of mitochondrial Ca(2+) uniporter, ruthenium red (RR), while unaffected by cyclosporin A (CsA), an inhibitor of mitochondrial permeability transition pore (MTP).	Cyclosporine	322-335	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	104-109
12401520-2	2003	By Northern blotting analyses and transient transfection assays, we herein show that transactivation of grp78 by OA--&gt;HS is abolished by an intracellular calcium chelator, bis(aminophenoxy)ethane N,N"-tetraacetic acid (BAPTA), and an inhibitor of mitochondrial Ca(2+) uniporter, ruthenium red (RR), while unaffected by cyclosporin A (CsA), an inhibitor of mitochondrial permeability transition pore (MTP).	Cyclosporine	337-340	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	104-109
12490612-12	2003	Protein levels of the apical sodium-dependent bile salt transporter (Asbt) were 2-fold increased in distal ileum of CsA-treated rats, due to post-transcriptional events.	Cyclosporine	116-119	solute carrier family 10 member 2	Rattus norvegicus	22-67
12490612-12	2003	Protein levels of the apical sodium-dependent bile salt transporter (Asbt) were 2-fold increased in distal ileum of CsA-treated rats, due to post-transcriptional events.	Cyclosporine	116-119	solute carrier family 10 member 2	Rattus norvegicus	69-73
12490612-14	2003	Our results strongly suggest that CsA enhances efficacy of intestinal cholate reabsorption through increased Asbt protein expression in the distal ileum, which contributes to maintenance of cholate pool size in CsA-treated rats.	Cyclosporine	34-37	solute carrier family 10 member 2	Rattus norvegicus	109-113
12490612-14	2003	Our results strongly suggest that CsA enhances efficacy of intestinal cholate reabsorption through increased Asbt protein expression in the distal ileum, which contributes to maintenance of cholate pool size in CsA-treated rats.	Cyclosporine	211-214	solute carrier family 10 member 2	Rattus norvegicus	109-113
12490797-0	2002	Role of endogenous vascular endothelial growth factor in tubular cell protection against acute cyclosporine toxicity.	Cyclosporine	95-107	vascular endothelial growth factor A	Mus musculus	19-53
12490797-1	2002	BACKGROUND: Recent studies have shown that exogenous administration of vascular endothelial growth factor (VEGF) is protective against cyclosporine A (CsA) renal toxicity.	Cyclosporine	151-154	vascular endothelial growth factor A	Mus musculus	71-105
12490797-1	2002	BACKGROUND: Recent studies have shown that exogenous administration of vascular endothelial growth factor (VEGF) is protective against cyclosporine A (CsA) renal toxicity.	Cyclosporine	151-154	vascular endothelial growth factor A	Mus musculus	107-111
12490797-3	2002	Our objective was to examine whether endogenous VEGF has a significant role in the renal response against CsA toxicity.	Cyclosporine	106-109	vascular endothelial growth factor A	Mus musculus	48-52
12490797-4	2002	METHODS: In vivo, we used high-dose (50-150 mg/kg/day) CsA +/- specific goat anti-mouse VEGF blocking monoclonal antibody (alpha-VEGF) in mice.	Cyclosporine	55-58	vascular endothelial growth factor A	Mus musculus	129-133
12490797-6	2002	RESULTS: alpha-VEGF markedly enhanced CsA renal toxicity, inducing severe tubular damage and increased blood urea nitrogen.	Cyclosporine	38-41	vascular endothelial growth factor A	Mus musculus	15-19
12490797-7	2002	In animals treated with CsA + alpha-VEGF, damage progressed to generalized tubular injury (histology) and apoptosis (terminal deoxynucleotide transferase-mediated dUTP nick-end labeling) with associated anemia and reticulocytosis (18 days of treatment).	Cyclosporine	24-27	vascular endothelial growth factor A	Mus musculus	36-40
12490797-10	2002	Of specific interest, CsA toxicity in MCT increased significantly in the presence of alpha-VEGF.	Cyclosporine	22-25	vascular endothelial growth factor A	Mus musculus	91-95
12490797-11	2002	CONCLUSIONS: Endogenous VEGF has a relevant role in the renal tubular defense against CsA toxicity.	Cyclosporine	86-89	vascular endothelial growth factor A	Mus musculus	24-28
12427482-1	2002	Cyclosporin, an immunosuppressant with a narrow therapeutic window, is a substrate for both CYP3A4 and P-glycoprotein (Pgp).	Cyclosporine	0-11	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	103-117
12427482-1	2002	Cyclosporin, an immunosuppressant with a narrow therapeutic window, is a substrate for both CYP3A4 and P-glycoprotein (Pgp).	Cyclosporine	0-11	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	119-122
12427482-11	2002	It is suggested that concurrent use of quercetin or quercetin-containing dietary supplement or herbs with cyclosporin or other medications whose absorption and metabolism are mediated by Pgp and/or CYP3A4 should require close monitoring.	Cyclosporine	106-117	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	187-190
12466241-0	2002	The effects of the cyclosporin A, a P-glycoprotein inhibitor, on the pharmacokinetics of baicalein in the rat: a microdialysis study.	Cyclosporine	19-32	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	36-50
12466241-6	2002	The P-glycoprotein inhibitor cyclosporin A was used to help delineate its roles.	Cyclosporine	29-42	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	4-18
12421236-5	2002	CD4/CD8 ratios of CsA responders were also significantly lower than those of non-responders (0.315 +/- 0.070 vs 1.975 +/- 0.965, P=0.0463).	Cyclosporine	18-21	CD8a molecule	Homo sapiens	4-7
12405759-0	2002	Determination of naringin in rat blood, brain, liver, and bile using microdialysis and its interaction with cyclosporin a, a p-glycoprotein modulator.	Cyclosporine	108-121	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	125-139
12202955-6	2002	CsA, at 125-2000 ng/ml, similarly inhibited proliferation, but at high doses (1000-2000 ng/ml) it decreased TRAP activity, TRAP+MNC formation, and the expression of TRAP and CTR mRNAs.	Cyclosporine	0-3	acid phosphatase 5, tartrate resistant	Mus musculus	108-112
12202955-6	2002	CsA, at 125-2000 ng/ml, similarly inhibited proliferation, but at high doses (1000-2000 ng/ml) it decreased TRAP activity, TRAP+MNC formation, and the expression of TRAP and CTR mRNAs.	Cyclosporine	0-3	acid phosphatase 5, tartrate resistant	Mus musculus	123-127
12202955-6	2002	CsA, at 125-2000 ng/ml, similarly inhibited proliferation, but at high doses (1000-2000 ng/ml) it decreased TRAP activity, TRAP+MNC formation, and the expression of TRAP and CTR mRNAs.	Cyclosporine	0-3	acid phosphatase 5, tartrate resistant	Mus musculus	123-127
12202955-7	2002	FK506 had no effect on cell proliferation or TRAP activity at concentrations up to 2000 ng/ml; however, like CsA, 1000 ng/ml FK506 inhibited TRAP+MNC formation and the expression of TRAP and CTR mRNAs.	Cyclosporine	109-112	acid phosphatase 5, tartrate resistant	Mus musculus	141-145
12202955-7	2002	FK506 had no effect on cell proliferation or TRAP activity at concentrations up to 2000 ng/ml; however, like CsA, 1000 ng/ml FK506 inhibited TRAP+MNC formation and the expression of TRAP and CTR mRNAs.	Cyclosporine	109-112	acid phosphatase 5, tartrate resistant	Mus musculus	141-145
12404239-10	2002	Cyclosporin A, rifampicin, and glibenclamide were proved to be competitive inhibitors of BSEP taurocholate transport, with inhibition constant values of 9.5 micromol/L, 31 micromol/L, and 27.5 micromol/L, respectively.	Cyclosporine	0-13	ATP binding cassette subfamily B member 11	Homo sapiens	89-93
12270545-5	2002	Conversely, we show that CsA and FK506 completely inhibit SEA-induced IL-10 protein production and mRNA expression.	Cyclosporine	25-28	interleukin 10	Homo sapiens	70-75
12388663-12	2002	(125)I-DPDPE and [(3)H]morphine coadministered with 0.01% P85 and cyclosporin-A increased cellular uptake compared with control (p &lt; 0.01) and compared with cyclosporin-A coadministration without P85 (p &lt; 0.01 and p &lt; 0.05, respectively).	Cyclosporine	66-79	phosphoinositide-3-kinase regulatory subunit 2	Homo sapiens	199-202
12388663-12	2002	(125)I-DPDPE and [(3)H]morphine coadministered with 0.01% P85 and cyclosporin-A increased cellular uptake compared with control (p &lt; 0.01) and compared with cyclosporin-A coadministration without P85 (p &lt; 0.01 and p &lt; 0.05, respectively).	Cyclosporine	160-173	phosphoinositide-3-kinase regulatory subunit 2	Homo sapiens	58-61
12361387-6	2002	Our SAR are compatible with the in vitro-defined Pgp binding domain model and further disclose that in vivo Pgp inhibition is favored by larger hydrophobic side chains on cyclosporin residues 1, 4, 6, and 8 and a smaller one on residue 7, although with no effect on the residue 5 side chain; moreover, larger hydrophobic side chains on other residues 2, 3, 10, and 11 (outside the in vitro-defined Pgp binding domain) also favor the eventual inhibition of Pgp function.	Cyclosporine	171-182	sarcosine dehydrogenase	Homo sapiens	4-7
12235265-9	2002	Consistent with published reports, sirolimus was a good inhibitor of P-glycoprotein, inhibiting polarized basolateral-to-apical flux of rhodamine 123 with an IC(50) of 0.625 to 1.25 microM (cyclosporine caused &gt;80% inhibition at 5 microM).	Cyclosporine	190-202	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	69-83
12239305-4	2002	The primary events in reactivation were shown to involve dephosphorylation of the myocyte enhancer factor 2D (MEF-2D) transcription factor via the cyclosporin A-sensitive, calcium-mediated signaling pathway.	Cyclosporine	147-160	myocyte enhancer factor 2D	Homo sapiens	82-108
12239305-4	2002	The primary events in reactivation were shown to involve dephosphorylation of the myocyte enhancer factor 2D (MEF-2D) transcription factor via the cyclosporin A-sensitive, calcium-mediated signaling pathway.	Cyclosporine	147-160	myocyte enhancer factor 2D	Homo sapiens	110-116
12530470-2	2002	The aim of this study was to use the P-glycoprotein (P-glycoprotein) inhibitors cyclosporin A, verapamil and the monoclonal antibody C219 in in vivo and in vitro models of intestinal absorption to determine the role of P-glycoprotein in berberine absorption.	Cyclosporine	80-93	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	37-51
12530470-2	2002	The aim of this study was to use the P-glycoprotein (P-glycoprotein) inhibitors cyclosporin A, verapamil and the monoclonal antibody C219 in in vivo and in vitro models of intestinal absorption to determine the role of P-glycoprotein in berberine absorption.	Cyclosporine	80-93	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	53-67
12530470-2	2002	The aim of this study was to use the P-glycoprotein (P-glycoprotein) inhibitors cyclosporin A, verapamil and the monoclonal antibody C219 in in vivo and in vitro models of intestinal absorption to determine the role of P-glycoprotein in berberine absorption.	Cyclosporine	80-93	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	53-67
12110686-5	2002	CsA significantly increased leukocyte binding to activated HIMEC, but paradoxically decreased endothelial expression of cell adhesion molecules (E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule-1).	Cyclosporine	0-3	intercellular adhesion molecule 1	Homo sapiens	157-190
12197897-7	2002	These results indicate that activated Th1-type pulmonary T cells play an important role in the development of corticosteroid- resistant IP in DM/PM and that the increase in CD25+ CD8+ T cells in BALF is a useful indicator for corticosteroid-resistant IP in DM/PM and hence may be an indicator for early use of cyclosporin.	Cyclosporine	310-321	CD8a molecule	Homo sapiens	179-182
12231370-6	2002	RESULTS: Exposure to cyclosporine and mycophenolate mofetil was associated with a dose-dependent decrease in endothelium-dependent relaxations to serotonin (an agonist that binds to 5-HT1D receptors coupled to Gi-protein) but no impairment of relaxations to bradykinin (an agonist that binds to B2 receptors coupled to Gq-proteins).	Cyclosporine	21-33	5-hydroxytryptamine receptor 1D	Homo sapiens	182-188
12198207-4	2002	We investigated whether CsA up-regulates the expression of TGF-beta1 and its receptors type I (TbetaR-I) and type II (TbetaR-II) in cultured rat MCs, and whether this effect translates into enhanced matrix protein accumulation.	Cyclosporine	24-27	transforming growth factor, beta receptor 1	Rattus norvegicus	95-103
12198207-12	2002	Co-incubation with neutralizing anti-TGF-beta1 antibodies reduced (P&lt;0.05) CsA-induced expression of TbetaR-I (1.0+/-0.1-fold), TbetaR-II (1.3+/-0.1-fold) and PAI-1 (1.3-fold), but not FN production (1.6-fold).	Cyclosporine	78-81	transforming growth factor, beta receptor 1	Rattus norvegicus	104-112
12153635-9	2002	Neoadventitial ECM density was significantly higher in the cyclosporin-treated group than in animals with untreated allografts, as were mRNA levels of collagen 3 and tissue inhibitor of metalloproteinase 1.	Cyclosporine	59-70	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	151-205
12123747-5	2002	In cells incubated in the presence of CsA, there was an increase in the expression and activity of MnSOD and CuZnSOD but not in that of catalase and GPx.	Cyclosporine	38-41	superoxide dismutase 2	Rattus norvegicus	99-104
12123747-6	2002	However, when hepatocytes were coincubated with CsA and VitE, an increase in the expression and activity in all antioxidant enzymes (MnSOD, CuZnSOD, catalase and GPx) was observed.	Cyclosporine	48-51	superoxide dismutase 2	Rattus norvegicus	133-138
12169874-6	2002	The increased CA125 level is related to the degree of proteinuria and after prednisolone and cyclosporine therapy, proteinuria and the CA125 level gradually decreased.	Cyclosporine	93-105	mucin 16, cell surface associated	Homo sapiens	14-19
12169874-6	2002	The increased CA125 level is related to the degree of proteinuria and after prednisolone and cyclosporine therapy, proteinuria and the CA125 level gradually decreased.	Cyclosporine	93-105	mucin 16, cell surface associated	Homo sapiens	135-140
12087018-9	2002	Analysis of GAD antibodies in combination with antibodies to IA-2 indicated that the group most resistant to cyclosporin were IA-2 antibody positive, GAD antibody negative.	Cyclosporine	109-120	glutamate decarboxylase 1	Homo sapiens	150-153
12081594-8	2002	Nevertheless, in most patients with P/CsA treatment, T cell infiltrates were observed in skin biopsies from the site of KLH challenge, while expression of intercellular cell adhesion molecule-1 (ICAM-1) expression in challenged skin was significantly decreased in these patients.	Cyclosporine	38-41	intercellular adhesion molecule 1	Homo sapiens	155-193
12081594-8	2002	Nevertheless, in most patients with P/CsA treatment, T cell infiltrates were observed in skin biopsies from the site of KLH challenge, while expression of intercellular cell adhesion molecule-1 (ICAM-1) expression in challenged skin was significantly decreased in these patients.	Cyclosporine	38-41	intercellular adhesion molecule 1	Homo sapiens	195-201
12374046-8	2002	The immunological changes in AD patients treated with cyclosporine include eosinophil count reduction, besides lower levels of E-selectin, and soluble CD30 (known as disease markers), but overall, it corrects the imbalance between Th1 and Th2 response present in these kinds of diseases.	Cyclosporine	54-66	TNF receptor superfamily member 8	Homo sapiens	151-155
12374046-8	2002	The immunological changes in AD patients treated with cyclosporine include eosinophil count reduction, besides lower levels of E-selectin, and soluble CD30 (known as disease markers), but overall, it corrects the imbalance between Th1 and Th2 response present in these kinds of diseases.	Cyclosporine	54-66	negative elongation factor complex member C/D	Homo sapiens	231-234
12069596-5	2002	Furthermore, the ECARs correlated with the expression level of Pgp in the two different cell lines and were reduced in a concentration-dependent manner by cyclosporin A, a potent inhibitor of the Pgp-ATPase.	Cyclosporine	155-168	phosphoglycolate phosphatase	Mus musculus	63-66
12069596-5	2002	Furthermore, the ECARs correlated with the expression level of Pgp in the two different cell lines and were reduced in a concentration-dependent manner by cyclosporin A, a potent inhibitor of the Pgp-ATPase.	Cyclosporine	155-168	phosphoglycolate phosphatase	Mus musculus	196-199
11943775-1	2002	Cyclophilin A (CyPA), a ubiquitously distributed intracellular protein, is a peptidylprolyl cis-trans-isomerase and the major target of the potent immunosuppressive drug cyclosporin A.	Cyclosporine	170-183	peptidylprolyl isomerase like 1	Homo sapiens	77-111
12064814-11	2002	In addition, the effect of CsA at 3 mg/kg, applied intraperitoneally or intracolonically was, in part, expressed in decreasing the numbers of CD25+ cells within colonic mucosa/submucosa (P &lt; 0.05).	Cyclosporine	27-30	interleukin 2 receptor, alpha chain	Mus musculus	142-146
12076523-6	2002	The increased sensitivity of isolated mitochondria to Ca2+-induced swelling, Ca2+ release, depolarization of DeltaPsi and uncoupling of respiration promoted by VP-16, which are prevented by cyclosporine A proving that VP-16 induces the MPT, are also efficiently prevented by ascorbate, the primary reductant of the phenoxyl radicals produced by VP-16.	Cyclosporine	190-204	host cell factor C1	Homo sapiens	160-165
12076523-6	2002	The increased sensitivity of isolated mitochondria to Ca2+-induced swelling, Ca2+ release, depolarization of DeltaPsi and uncoupling of respiration promoted by VP-16, which are prevented by cyclosporine A proving that VP-16 induces the MPT, are also efficiently prevented by ascorbate, the primary reductant of the phenoxyl radicals produced by VP-16.	Cyclosporine	190-204	host cell factor C1	Homo sapiens	218-223
12076523-6	2002	The increased sensitivity of isolated mitochondria to Ca2+-induced swelling, Ca2+ release, depolarization of DeltaPsi and uncoupling of respiration promoted by VP-16, which are prevented by cyclosporine A proving that VP-16 induces the MPT, are also efficiently prevented by ascorbate, the primary reductant of the phenoxyl radicals produced by VP-16.	Cyclosporine	190-204	host cell factor C1	Homo sapiens	218-223
11978192-8	2002	Cyclosporin A (CsA) inhibited both the basal and the drug-stimulated ATPase activity of P-gp with high affinity.	Cyclosporine	0-13	phosphoglycolate phosphatase	Bos taurus	88-92
11978192-8	2002	Cyclosporin A (CsA) inhibited both the basal and the drug-stimulated ATPase activity of P-gp with high affinity.	Cyclosporine	15-18	phosphoglycolate phosphatase	Bos taurus	88-92
11978192-13	2002	CsA, Ver, and VCR could bin d P-gp either on overlapping sites or distant but interacting sites, while CsA, Dox, and Tet could independently bind P-gp on separated sites on blood-brain barrier.	Cyclosporine	0-3	phosphoglycolate phosphatase	Bos taurus	30-34
12123203-7	2002	The CsA group showed significant increases in ICE mRNA (0.21 vs. 0.03 amol/microgram total RNA at 4 weeks, p &lt; 0.05) and CPP32 mRNA (0.18 vs. 0.03 amol/microgram total RNA at 4 weeks, p &lt; 0.05), compared with the VH group.	Cyclosporine	4-7	caspase 3	Mus musculus	124-129
12123203-8	2002	The enzymatic activity of ICE (16.6 vs. 7.9 rho mol/microgram/h, p &lt; 0.05) and CPP32 protease (15.6 vs. 2.7 rho mol/microgram/h, p &lt; 0.05) proteases were increased in the CsA group, compared with the VH group.	Cyclosporine	177-180	caspase 3	Mus musculus	82-87
12123203-9	2002	The ratio between bax and bcl-2 protein increased significantly in the CsA group (5.3-fold), compared with the VH group.	Cyclosporine	71-74	BCL2-associated X protein	Mus musculus	18-21
11880334-9	2002	Exposure of cells from WT mice to the hyperosmotic mannitol solution including the P-gp inhibitor cyclosporin A increased J(H) (at pH(i) 6.30) to an extent similar to that in cells from KO mice exposed to hyperosmotic mannitol alone.	Cyclosporine	98-111	phosphoglycolate phosphatase	Mus musculus	83-87
11907091-6	2002	NFAT-containing complexes were altered in B cells treated with the NFAT inhibitor cyclosporin A and correlated with a repression of CD21 gene transcription implicating NFAT transcriptional control.	Cyclosporine	82-95	complement receptor 2	Mus musculus	132-136
11897974-3	2002	The relation between the chirality of the drug mefloquine and the intracellular concentrations of the drug cyclosporine is illustrated by examining the effect of the enantiomers of mefloquine on the transport activity of P-glycoprotein (Pgp).	Cyclosporine	107-119	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	221-235
11897974-3	2002	The relation between the chirality of the drug mefloquine and the intracellular concentrations of the drug cyclosporine is illustrated by examining the effect of the enantiomers of mefloquine on the transport activity of P-glycoprotein (Pgp).	Cyclosporine	107-119	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	237-240
11897974-5	2002	The results demonstrated that (+)-mefloquine competitively displaced the Pgp substrate cyclosporine whereas (-)-mefloquine had no effect on cyclosporine-Pgp binding.	Cyclosporine	87-99	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	73-76
11923685-8	2002	The CsA-treated mothers and their pups (15 and 25 mg/kg/day dose) had a significant increase in the percentage of CD4+CD8+ thymocytes and a significant decrease in the percentages of CD4+, CD3hi, and T-cell receptor (TCR)hi thymocyte phenotype subsets and CD4/CD8 ratios.	Cyclosporine	4-7	CD8a molecule	Homo sapiens	118-121
11923685-8	2002	The CsA-treated mothers and their pups (15 and 25 mg/kg/day dose) had a significant increase in the percentage of CD4+CD8+ thymocytes and a significant decrease in the percentages of CD4+, CD3hi, and T-cell receptor (TCR)hi thymocyte phenotype subsets and CD4/CD8 ratios.	Cyclosporine	4-7	CD8a molecule	Homo sapiens	260-263
11966773-10	2002	Pharmacological drugs used in therapy of RA, such as cyclosporin and methotrexate, induced a fourfold increase of IL-17R mRNA expression and augmented the IL-17-stimulated IL-8 expression.	Cyclosporine	53-64	interleukin 17A	Homo sapiens	114-119
11861816-2	2002	Plasma concentrations of grepafloxacin and levofloxacin after intravenous and intraintestinal administration were increased by cyclosporin A, a P-glycoprotein inhibitor, in rats.	Cyclosporine	127-140	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	144-158
11796340-3	2002	This secretory transport of grepafloxacin was diminished by both probenecid, an MRP2 inhibitor, and cyclosporine, a P-gp inhibitor.	Cyclosporine	100-112	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	116-120
11905054-4	2002	Cyclosporin, prednisolone, fluticasone, ketotifen, and clemastine inhibited SCF production from cultured epithelial cells, but cromoglicate and suplatast did not.	Cyclosporine	0-11	KIT ligand	Homo sapiens	76-79
11700317-1	2002	Cyclosporin A (CsA) treatment of HEK 293 cells expressing the rat heart RHE-1 (NCX1.1, EMBL accession number ) or the rat brain RBE-2 (NCX1.5, GenBank(TM) accession number ) Na(+)-Ca(2+) exchanger inhibited their transport activity in a concentration-dependent manner.	Cyclosporine	0-13	nascent polypeptide associated complex subunit alpha	Rattus norvegicus	174-182
11726837-2	2001	Hyperuricemia and gout have been associated with the use of the calcineurin inhibitor, cyclosporine.	Cyclosporine	87-99	calcineurin binding protein 1	Homo sapiens	64-85
11696436-7	2001	Lptn mRNA was found to be up-regulated on stimulation with phorbol-12-myristate-13-acetate and concanavalin A in T cells isolated from peripheral blood, which could be prevented by dexamethasone, cyclosporine A, and FK506.	Cyclosporine	196-210	X-C motif chemokine ligand 1	Homo sapiens	0-4
11750417-0	2001	CD4 and CD8 cytokine-producing T cells are transiently reduced following cyclosporine intake: maximal inhibition occurs at 2 hours coincidental with drug C(max).	Cyclosporine	73-85	CD8a molecule	Homo sapiens	8-11
11718240-2	2001	ADM ototoxicity may be induced by combination therapy with CsA because extrusion of ADM from the inner ear by p-glycoprotein (p-gp), which acts as an extrusion pump and is expressed on the surface of endothelial cells of capillary blood vessels, might be inhibited by CsA.	Cyclosporine	59-62	phosphoglycolate phosphatase	Mus musculus	110-124
11718240-2	2001	ADM ototoxicity may be induced by combination therapy with CsA because extrusion of ADM from the inner ear by p-glycoprotein (p-gp), which acts as an extrusion pump and is expressed on the surface of endothelial cells of capillary blood vessels, might be inhibited by CsA.	Cyclosporine	59-62	phosphoglycolate phosphatase	Mus musculus	126-130
11718240-2	2001	ADM ototoxicity may be induced by combination therapy with CsA because extrusion of ADM from the inner ear by p-glycoprotein (p-gp), which acts as an extrusion pump and is expressed on the surface of endothelial cells of capillary blood vessels, might be inhibited by CsA.	Cyclosporine	268-271	phosphoglycolate phosphatase	Mus musculus	110-124
11718240-2	2001	ADM ototoxicity may be induced by combination therapy with CsA because extrusion of ADM from the inner ear by p-glycoprotein (p-gp), which acts as an extrusion pump and is expressed on the surface of endothelial cells of capillary blood vessels, might be inhibited by CsA.	Cyclosporine	268-271	phosphoglycolate phosphatase	Mus musculus	126-130
11718240-10	2001	However, ADM ototoxicity was induced by combination therapy with CsA, indicating that CsA has an inhibitory action on p-gp function in the auditory pathway, including the inner ear.	Cyclosporine	86-89	phosphoglycolate phosphatase	Mus musculus	118-122
11438525-11	2001	Electrophoretic mobility shift experiments with primary Th (T helper) cells showed the formation of a specific, T-cell receptor-inducible complex at this site that is sensitive to cyclosporin A and supershifted with anti-NFATc2 in both Th1 and Th2 cells.	Cyclosporine	180-193	negative elongation factor complex member C/D	Homo sapiens	236-239
11544273-8	2001	However, in the presence of subtherapeutic levels of CsA, graft survival time was significantly increased in the CX(3)CR1(-/-) mice.	Cyclosporine	53-56	chemokine (C-X3-C motif) receptor 1	Mus musculus	113-121
11513883-7	2001	In contrast, cells treated with the immunosuppressants FTY720 and cyclosporin A appear to contain only the novel cleavage fragment of eIF4GI and to lack those characteristic of cells treated with anti-Fas antiserum.	Cyclosporine	66-79	eukaryotic translation initiation factor 4 gamma 1	Homo sapiens	134-140
11487508-4	2001	TUNEL-positive staining was observed only in neurons that developed pyknotic morphology after treatment with 8 microM CsA for 24 - 72 h. Immunocytochemical staining with an anti-GFAP monoclonal antibody revealed that astrocytes from mixed neuronal/glial cultures were unaffected by exposure to CsA at doses toxic for neurons and all TUNEL-positive cells were neurons.	Cyclosporine	118-121	glial fibrillary acidic protein	Homo sapiens	178-182
11487508-4	2001	TUNEL-positive staining was observed only in neurons that developed pyknotic morphology after treatment with 8 microM CsA for 24 - 72 h. Immunocytochemical staining with an anti-GFAP monoclonal antibody revealed that astrocytes from mixed neuronal/glial cultures were unaffected by exposure to CsA at doses toxic for neurons and all TUNEL-positive cells were neurons.	Cyclosporine	294-297	glial fibrillary acidic protein	Homo sapiens	178-182
11710806-8	2001	For the first time, we have shown that Cd2+-induced swelling in all media under study is susceptible to cyclosporin A (CSA), a high-potency inhibitor of the mitochondrial permeability transition (PT) pore.	Cyclosporine	104-117	Cd2 molecule	Rattus norvegicus	39-42
11710806-8	2001	For the first time, we have shown that Cd2+-induced swelling in all media under study is susceptible to cyclosporin A (CSA), a high-potency inhibitor of the mitochondrial permeability transition (PT) pore.	Cyclosporine	119-122	Cd2 molecule	Rattus norvegicus	39-42
11406149-5	2001	The expression of CD8alpha in mitogen-stimulated CD4(+) cells was blocked completely by calcineurin inhibitors (cyclosporine A and FK-506), and partially by rapamycin and SDZ-RAD.	Cyclosporine	112-126	Cd4 molecule	Rattus norvegicus	49-52
11399937-7	2001	RESULTS: Significant reductions were observed with respect to the percentages of CD4+ and CD23+ cells in the conjunctival impression cytology specimens and clinical and symptom scores following treatment with topical CsA, while no change occurred in the percentages of CD8+ and CD45RA+ cells.	Cyclosporine	217-220	CD8a molecule	Homo sapiens	269-272
11391226-10	2001	CONCLUSIONS: In combination with Neoral and corticosteroids, RAD doses of 2 mg and 4 mg/day resulted in lower rates of acute rejection episodes and efficacy failure than the 1 mg/day dose and were significantly more effective in reducing the severity of rejection.	Cyclosporine	33-39	RRAD, Ras related glycolysis inhibitor and calcium channel regulator	Homo sapiens	61-64
11311876-9	2001	administration of CsA in a dose of 10 mg/kg increased the tissue concentration of CsA 2- to 3-fold, when compared to the i.v.	Cyclosporine	18-21	IK cytokine	Rattus norvegicus	82-87
11237863-10	2001	Only expression of the transporter P-glycoprotein was increased by cyclosporin A.	Cyclosporine	67-80	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	35-49
12899339-7	2001	It was also found that CsA slightly reduced the mRNA level of ANF gene in AngII-stimulated cardiomyocytes.	Cyclosporine	23-26	natriuretic peptide A	Rattus norvegicus	62-65
11162625-3	2001	We observed that in cells treated with etoposide, cyclosporin A, 4-hydroxynonenal (HNE), or okadaic acid, there was an early reduction in the protein levels of p35, and later also in cdk5 with all treatments except etoposide.	Cyclosporine	50-63	cyclin-dependent kinase 5 regulatory subunit 1	Rattus norvegicus	160-163
11181432-0	2001	Upregulation of vasopressin V1A receptor mRNA and protein in vascular smooth muscle cells following cyclosporin A treatment.	Cyclosporine	100-113	arginine vasopressin receptor 1A	Rattus norvegicus	16-40
11181432-14	2001	A direct effect of CsA on the V1AR promoter was investigated using VSMC transfected with a V1AR promoter-luciferase reporter construct.	Cyclosporine	19-22	arginine vasopressin receptor 1A	Rattus norvegicus	30-34
11181432-15	2001	Surprisingly, CsA did not increase, but rather slightly reduced V1AR promoter activity.	Cyclosporine	14-17	arginine vasopressin receptor 1A	Rattus norvegicus	64-68
11181432-18	2001	Measurement of V1AR mRNA decay in the presence of the transcription inhibitor actinomycin D revealed that CsA increased the half-life of V1AR mRNA about 2 fold.	Cyclosporine	106-109	arginine vasopressin receptor 1A	Rattus norvegicus	15-19
11181432-18	2001	Measurement of V1AR mRNA decay in the presence of the transcription inhibitor actinomycin D revealed that CsA increased the half-life of V1AR mRNA about 2 fold.	Cyclosporine	106-109	arginine vasopressin receptor 1A	Rattus norvegicus	137-141
11181432-20	2001	In conclusion, CsA increased the response of VSMC to AVP by upregulating V1AR expression through stabilization of its mRNA.	Cyclosporine	15-18	arginine vasopressin receptor 1A	Rattus norvegicus	73-77
11440199-5	2001	We reported previously that a murine neuroblastoma (NB-P2) cell line can partially differentiate into neurons when treated with cyclosporin A (CyS-A), implicating a role for CyP-A in neuronal differentiation (Hovland et al.	Cyclosporine	128-141	peptidylprolyl isomerase A	Mus musculus	174-179
11440199-5	2001	We reported previously that a murine neuroblastoma (NB-P2) cell line can partially differentiate into neurons when treated with cyclosporin A (CyS-A), implicating a role for CyP-A in neuronal differentiation (Hovland et al.	Cyclosporine	143-148	peptidylprolyl isomerase A	Mus musculus	174-179
11460925-0	2001	Ca2+ induces a cyclosporin A-insensitive permeability transition pore in isolated potato tuber mitochondria mediated by reactive oxygen species.	Cyclosporine	15-28	carbonic anhydrase 2	Homo sapiens	0-3
11460925-6	2001	The lack of inhibition of potato mitochondrial permeabilization by cyclosporin A is in contrast to the inhibition of the peptidylprolyl cis-trans isomerase activity, that is related to the cyclosporin A-binding protein cyclophilin.	Cyclosporine	189-202	peptidyl-prolyl cis-trans isomerase-like	Solanum tuberosum	219-230
11160247-8	2001	Activation-induced RANKL expression is blocked by cyclosporin A, but not by dexamethasone.	Cyclosporine	50-63	TNF superfamily member 11	Homo sapiens	19-24
11168932-11	2001	CsA-treated rats also had significantly increased TIMP-1 (7.4-fold, P &lt; 0.001), MMP-2, and PAI-1 (all approximately 2-fold, P &lt; 0.02) and decreased MMP-9 (85% reduction, P &lt; 0.001) as compared with controls.	Cyclosporine	0-3	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	50-56
11168932-11	2001	CsA-treated rats also had significantly increased TIMP-1 (7.4-fold, P &lt; 0.001), MMP-2, and PAI-1 (all approximately 2-fold, P &lt; 0.02) and decreased MMP-9 (85% reduction, P &lt; 0.001) as compared with controls.	Cyclosporine	0-3	matrix metallopeptidase 9	Rattus norvegicus	154-159
11168932-12	2001	Treatment with alpha-TGF-beta in CsA-treated rats significantly prevented the reduction in creatinine clearance (0.58 +/- 0.03 mL/min, P = 0.009 vs. CsA alone), the increase in afferent arteriolar hyalinosis (P &lt; 0.05 vs. CsA alone), normalized alpha 1(I) collagen mRNA levels, and attenuated CsA effects on TGF-beta1, TIMP-1, and MMP-9.	Cyclosporine	33-36	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	322-328
11168932-12	2001	Treatment with alpha-TGF-beta in CsA-treated rats significantly prevented the reduction in creatinine clearance (0.58 +/- 0.03 mL/min, P = 0.009 vs. CsA alone), the increase in afferent arteriolar hyalinosis (P &lt; 0.05 vs. CsA alone), normalized alpha 1(I) collagen mRNA levels, and attenuated CsA effects on TGF-beta1, TIMP-1, and MMP-9.	Cyclosporine	33-36	matrix metallopeptidase 9	Rattus norvegicus	334-339
11175814-1	2001	Interleukin-12 (IL-12) and IL-18 induce synergistic transcription of interferon gamma (IFN-gamma) that is T cell receptor (TCR)-independent, not inhibited by cyclosporin A and requires new protein synthesis.	Cyclosporine	158-171	interleukin 18	Homo sapiens	27-32
11169217-9	2001	The fact that CsA blocks the production of IL-10, which itself has important immunosuppressive properties, should be taken into account in defining immunosuppressive treatment schedules which include the use of CsA.	Cyclosporine	14-17	interleukin 10	Homo sapiens	43-48
11169217-9	2001	The fact that CsA blocks the production of IL-10, which itself has important immunosuppressive properties, should be taken into account in defining immunosuppressive treatment schedules which include the use of CsA.	Cyclosporine	211-214	interleukin 10	Homo sapiens	43-48
11267610-0	2001	Effect of cyclosporine withdrawal on IL-10 production in kidney transplant recipients.	Cyclosporine	10-22	interleukin 10	Homo sapiens	37-42
11228102-0	2001	Preventive effect of platelet-activating factor antagonist, Y-24180, against cyclosporine-induced acute nephrotoxicity.	Cyclosporine	77-89	PCNA clamp associated factor	Rattus norvegicus	21-47
11228102-10	2001	The present study showed that a PAF receptor antagonist, Y-24180, has the preventive effect against CsA-induced acute renal failure, which indicates that PAF may partly be involved in the mechanism of renal vasoconstriction induced by CsA.	Cyclosporine	100-103	PCNA clamp associated factor	Rattus norvegicus	32-35
11228102-10	2001	The present study showed that a PAF receptor antagonist, Y-24180, has the preventive effect against CsA-induced acute renal failure, which indicates that PAF may partly be involved in the mechanism of renal vasoconstriction induced by CsA.	Cyclosporine	100-103	PCNA clamp associated factor	Rattus norvegicus	154-157
11228102-10	2001	The present study showed that a PAF receptor antagonist, Y-24180, has the preventive effect against CsA-induced acute renal failure, which indicates that PAF may partly be involved in the mechanism of renal vasoconstriction induced by CsA.	Cyclosporine	235-238	PCNA clamp associated factor	Rattus norvegicus	32-35
11228102-10	2001	The present study showed that a PAF receptor antagonist, Y-24180, has the preventive effect against CsA-induced acute renal failure, which indicates that PAF may partly be involved in the mechanism of renal vasoconstriction induced by CsA.	Cyclosporine	235-238	PCNA clamp associated factor	Rattus norvegicus	154-157
11212278-10	2001	This is in contrast to P-gp substrates such as cyclosporin A and verapamil, which lose their activity within 60 min, suggesting that XR9576 is not transported by P-gp.	Cyclosporine	47-60	phosphoglycolate phosphatase	Mus musculus	23-27
11978968-1	2001	The cyclophilins are members of a highly conserved, ubiquitous family, and play an important role in protein folding, immunosuppression by cyclosporin A (CsA), and infection of HIV-1 virions.	Cyclosporine	139-152	peptidylprolyl isomerase like 4	Homo sapiens	4-16
11978968-1	2001	The cyclophilins are members of a highly conserved, ubiquitous family, and play an important role in protein folding, immunosuppression by cyclosporin A (CsA), and infection of HIV-1 virions.	Cyclosporine	154-157	peptidylprolyl isomerase like 4	Homo sapiens	4-16
11208926-4	2001	In the presence of cyclosporin A and the quinoline-derivative MK571, inhibitors of multidrug resistance proteins (MRP1 and MRP2), glutathione disulfide accumulated in cells and the release of glutathione disulfide from astrocytes during H2O2 stress was potently inhibited, suggesting a contribution of MRP1 or MRP2 in the release of glutathione disulfide from astrocytes.	Cyclosporine	19-32	ATP binding cassette subfamily C member 1	Rattus norvegicus	114-118
11208926-4	2001	In the presence of cyclosporin A and the quinoline-derivative MK571, inhibitors of multidrug resistance proteins (MRP1 and MRP2), glutathione disulfide accumulated in cells and the release of glutathione disulfide from astrocytes during H2O2 stress was potently inhibited, suggesting a contribution of MRP1 or MRP2 in the release of glutathione disulfide from astrocytes.	Cyclosporine	19-32	ATP binding cassette subfamily C member 2	Rattus norvegicus	123-127
11208926-4	2001	In the presence of cyclosporin A and the quinoline-derivative MK571, inhibitors of multidrug resistance proteins (MRP1 and MRP2), glutathione disulfide accumulated in cells and the release of glutathione disulfide from astrocytes during H2O2 stress was potently inhibited, suggesting a contribution of MRP1 or MRP2 in the release of glutathione disulfide from astrocytes.	Cyclosporine	19-32	ATP binding cassette subfamily C member 1	Rattus norvegicus	302-306
11208926-4	2001	In the presence of cyclosporin A and the quinoline-derivative MK571, inhibitors of multidrug resistance proteins (MRP1 and MRP2), glutathione disulfide accumulated in cells and the release of glutathione disulfide from astrocytes during H2O2 stress was potently inhibited, suggesting a contribution of MRP1 or MRP2 in the release of glutathione disulfide from astrocytes.	Cyclosporine	19-32	ATP binding cassette subfamily C member 2	Rattus norvegicus	310-314
11516824-7	2001	Reverse transcription-polymerase chain reaction revealed prolonged maintenance of BDNF mRNA expression in the CA1 sector of cyclosporin A-treated animals.	Cyclosporine	124-137	brain-derived neurotrophic factor	Rattus norvegicus	82-86
11516824-8	2001	The protein expression of BDNF and TrkB appeared to be up-regulated in cyclosporin A-treated animals, whereas it was transiently up-regulated but decreased to the marginal level of expression without cyclosporin A.From these results we suggest that cyclosporin A induces pCREB by an inhibition of calcineurin, resulting in the induction of BDNF.	Cyclosporine	71-84	brain-derived neurotrophic factor	Rattus norvegicus	26-30
11516824-8	2001	The protein expression of BDNF and TrkB appeared to be up-regulated in cyclosporin A-treated animals, whereas it was transiently up-regulated but decreased to the marginal level of expression without cyclosporin A.From these results we suggest that cyclosporin A induces pCREB by an inhibition of calcineurin, resulting in the induction of BDNF.	Cyclosporine	71-84	brain-derived neurotrophic factor	Rattus norvegicus	340-344
11516824-8	2001	The protein expression of BDNF and TrkB appeared to be up-regulated in cyclosporin A-treated animals, whereas it was transiently up-regulated but decreased to the marginal level of expression without cyclosporin A.From these results we suggest that cyclosporin A induces pCREB by an inhibition of calcineurin, resulting in the induction of BDNF.	Cyclosporine	200-213	brain-derived neurotrophic factor	Rattus norvegicus	26-30
11516824-8	2001	The protein expression of BDNF and TrkB appeared to be up-regulated in cyclosporin A-treated animals, whereas it was transiently up-regulated but decreased to the marginal level of expression without cyclosporin A.From these results we suggest that cyclosporin A induces pCREB by an inhibition of calcineurin, resulting in the induction of BDNF.	Cyclosporine	200-213	brain-derived neurotrophic factor	Rattus norvegicus	26-30
11516824-9	2001	The mechanisms by which cyclosporin A protects the CA1 region from neuronal cell death in forebrain ischemia may involve the interaction of pCREB, BDNF and TrkB.	Cyclosporine	24-37	brain-derived neurotrophic factor	Rattus norvegicus	147-151
11113570-9	2000	The efflux of [(14)C]mefloquine from GPNT cells was decreased when the cells were incubated with the P-gp modulators, verapamil, cyclosporin A or chlorpromazine, suggesting that MQ could be a P-gp substrate.	Cyclosporine	129-142	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	101-105
11113570-9	2000	The efflux of [(14)C]mefloquine from GPNT cells was decreased when the cells were incubated with the P-gp modulators, verapamil, cyclosporin A or chlorpromazine, suggesting that MQ could be a P-gp substrate.	Cyclosporine	129-142	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	192-196
11095661-1	2000	Inbred miniature swine that are treated for 12 d with a high dose of cyclosporin A develop tolerance to MHC class II matched, class I-mismatched renal allografts.	Cyclosporine	69-82	MHC class II histocompatibility antigen SLA-DRB1	Sus scrofa	104-116
10964923-1	2000	The immunosuppressive drug cyclosporin A (CsA) inhibited the hCRT-1 cDNA-induced creatine uptake in Xenopus oocytes and the endogenous creatine uptake in cultured C(2)C(12) muscle cells in a dose- and time-dependent manner.	Cyclosporine	42-45	hyaluronan and proteoglycan link protein 1	Homo sapiens	61-67
11068023-6	2000	Modulation of P-glycoprotein was achieved by injection of cyclosporin A (50 mg/kg) 30 min prior to injection of [18F]MPPF.The distribution of 18F-derived radioactivity corresponded to regional 5-HT1A receptor density as known from autoradiography.	Cyclosporine	58-71	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	14-28
11068023-7	2000	Modulation of P-glycoprotein with cyclosporin A caused a 5- to 10-fold increase in the uptake of [18F]MPPF.	Cyclosporine	34-47	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	14-28
11074805-5	2000	RESULTS: In cyclosporine-treated eyes, biopsy results of conjunctivae showed decreases in the number of cells positive for CD3, CD4, and CD8, while in vehicle-treated eyes, results showed increases in these markers, although these differences were not statistically significant.	Cyclosporine	12-24	CD8a molecule	Homo sapiens	137-140
11108662-4	2000	Inhibition of MRP2-mediated efflux activity by sulfinpyrazone or cyclosporin A completely reversed GSTP1-1-associated resistance-a result indicating that GSTP1-1-mediated cytoprotection is absolutely dependent on MRP2 efflux activity.	Cyclosporine	65-78	ATP binding cassette subfamily C member 2	Homo sapiens	14-18
11023705-1	2000	In order to elucidate the involvement of the atrial natriuretic peptide (ANP) and its receptor (natriuretic peptide receptor; NPR) system in cyclosporine-induced nephrotoxicity, we investigated the cyclosporine A (CsA)-induced changes in characteristics of the NPR/guanylyl cyclase system in the glomerulus and inner medulla of the rat kidney.	Cyclosporine	198-212	natriuretic peptide A	Rattus norvegicus	45-71
11023705-7	2000	Direct application of CsA to normal glomerular membrane completely abolished the ANP-induced guanylyl cyclase activation.	Cyclosporine	22-25	natriuretic peptide A	Rattus norvegicus	81-84
11023705-8	2000	Binding studies, using(125)I-ANP, revealed that B(max)was decreased in the CsA group, while K(d)was not affected in the glomerulus.	Cyclosporine	75-78	natriuretic peptide A	Rattus norvegicus	29-32
11023705-12	2000	These results indicate that CsA impairs the guanylyl cyclase activity mainly in the glomerulus by the decrease in NPR population and/or by direct inhibition, suggesting that the ANP/NPR system might be involved in CsA-induced nephrotoxicity.	Cyclosporine	28-31	natriuretic peptide A	Rattus norvegicus	178-181
11023705-12	2000	These results indicate that CsA impairs the guanylyl cyclase activity mainly in the glomerulus by the decrease in NPR population and/or by direct inhibition, suggesting that the ANP/NPR system might be involved in CsA-induced nephrotoxicity.	Cyclosporine	214-217	natriuretic peptide A	Rattus norvegicus	178-181
11062266-10	2000	Moreover, when calcineurin signaling is compromised with cyclosporin A, muscles from OV wild-type mice display a lower molecular weight form of CnA, originally detected in failing hearts, whereas CnA* muscles are spared this manifestation.	Cyclosporine	57-70	protein phosphatase 3, catalytic subunit, alpha isoform	Mus musculus	144-147
11061569-1	2000	Tacrolimus (FK-506) and cyclosporin A (CsA) are calcineurin antagonists used widely as T-cell immunosuppressants; however, their relative efficacy on the production of interleukin-18 (IL-18) remains undefined.	Cyclosporine	24-37	interleukin 18	Homo sapiens	168-182
11061569-1	2000	Tacrolimus (FK-506) and cyclosporin A (CsA) are calcineurin antagonists used widely as T-cell immunosuppressants; however, their relative efficacy on the production of interleukin-18 (IL-18) remains undefined.	Cyclosporine	24-37	interleukin 18	Homo sapiens	184-189
11061569-1	2000	Tacrolimus (FK-506) and cyclosporin A (CsA) are calcineurin antagonists used widely as T-cell immunosuppressants; however, their relative efficacy on the production of interleukin-18 (IL-18) remains undefined.	Cyclosporine	39-42	interleukin 18	Homo sapiens	168-182
11061569-1	2000	Tacrolimus (FK-506) and cyclosporin A (CsA) are calcineurin antagonists used widely as T-cell immunosuppressants; however, their relative efficacy on the production of interleukin-18 (IL-18) remains undefined.	Cyclosporine	39-42	interleukin 18	Homo sapiens	184-189
10987825-11	2000	The activation of caspases was accompanied by the release of cytochrome c from mitochondria into the cytosol, which was partially prevented by cyclosporin A in the case of NO donors.	Cyclosporine	143-156	caspase 1	Rattus norvegicus	18-26
10964515-4	2000	The founding member of the family, cyclophilin A (CyPA), is an abundant, ubiquitously expressed protein of unknown function that binds with nanomolar affinity to CsA.	Cyclosporine	162-165	peptidylprolyl isomerase A	Mus musculus	35-48
10964515-4	2000	The founding member of the family, cyclophilin A (CyPA), is an abundant, ubiquitously expressed protein of unknown function that binds with nanomolar affinity to CsA.	Cyclosporine	162-165	peptidylprolyl isomerase A	Mus musculus	50-54
11053632-8	2000	Our data show that switching of immunosuppressive therapy from CsA to tacrolimus results in suppression of costimulatory ligands, adhesion molecules, Th1 responses and CD4 helper activity.	Cyclosporine	63-66	negative elongation factor complex member C/D	Homo sapiens	150-153
10901449-8	2000	Uptake in hooded rat sarcoma (HSN) cells, which express Pgp, is significantly increased in the presence of the MDR modulator cyclosporin A.	Cyclosporine	125-138	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	56-59
10799873-7	2000	Cyclosporine inhibited CTL expansion and cytotoxicity similarly in both EC- and BLC-stimulated cultures but did not affect the phenotype of those CTL that did emerge.	Cyclosporine	0-12	C-X-C motif chemokine ligand 13	Homo sapiens	80-83
10799902-0	2000	Expression of IFN-inducible T cell alpha chemoattractant by human endothelial cells is cyclosporin A-resistant and promotes T cell adhesion: implications for cyclosporin A-resistant immune inflammation.	Cyclosporine	87-100	C-X-C motif chemokine ligand 11	Homo sapiens	14-56
10799902-0	2000	Expression of IFN-inducible T cell alpha chemoattractant by human endothelial cells is cyclosporin A-resistant and promotes T cell adhesion: implications for cyclosporin A-resistant immune inflammation.	Cyclosporine	158-171	C-X-C motif chemokine ligand 11	Homo sapiens	14-56
10799902-6	2000	Finally, the expression of I-TAC by EC is resistant to the immunosuppressive drug cyclosporin A, suggesting that I-TAC may contribute to the chronic immune inflammation characteristic of graft arteriosclerosis.	Cyclosporine	82-95	C-X-C motif chemokine ligand 11	Homo sapiens	27-32
10788473-11	2000	We determined that inhibition of calcineurin activity with cyclosporine prevented PKCalpha, theta, and JNK activation, but did not affect PKCepsilon, beta, lambda, ERK1/2, or p38 activation.	Cyclosporine	59-71	mitogen-activated protein kinase 8	Mus musculus	103-106
10828723-7	2000	After 6 weeks of CsA treatment, not only was there a significant difference between serum sCD30 levels before (mean 135.7) and after (mean 96.2) treatment but even the serum ECP levels before (mean 57.78) and after (mean 18.69) therapy showed an important reduction.	Cyclosporine	17-20	ribonuclease A family member 3	Homo sapiens	174-177
10828723-11	2000	CONCLUSIONS: In this study, CsA therapy results in clinical improvement together with a statistically significant reduction in sCD30 and ECP serum levels in AD patients.	Cyclosporine	28-31	ribonuclease A family member 3	Homo sapiens	137-140
10700027-5	2000	CsA increased this uptake 5-6-fold, not only due to P-gp modulation in the BBB but also to a 2-fold higher plasma AUC.	Cyclosporine	0-3	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	52-56
10700027-7	2000	These results indicate that the cerebral uptake of beta-adrenoceptor ligands can be increased by administration of P-gp modulators such as CsA without affecting regional distribution in the brain.	Cyclosporine	139-142	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	115-119
10732847-7	2000	These results suggest that activation of leukocytes occurs through the induction of ICAM-1 in the coronary circulation in the patients with CSA with organic stenosis.	Cyclosporine	140-143	intercellular adhesion molecule 1	Homo sapiens	84-90
10708100-0	2000	Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin.	Cyclosporine	284-296	interleukin-2	Macaca fascicularis	117-130
10708100-3	2000	CsA and anti-IL-2 receptor mAb are drugs that reduce cytokine synthesis and block IL-2-mediated lymphocyte stimulation, respectively.	Cyclosporine	0-3	interleukin-2	Macaca fascicularis	82-86
10693870-4	2000	The effect of CSA on the expression of TGFbeta and PDGF-B was also examined in cultured synovial cells.	Cyclosporine	14-17	platelet-derived growth factor subunit B	Oryctolagus cuniculus	51-57
10648470-6	2000	Cyclosporin A, rifamycin SV, rifampicin, and glibenclamide cis-inhibited Bsep-mediated bile salt transport to similar extents as ATP-dependent taurocholate transport in cLPM vesicles.	Cyclosporine	0-13	ATP binding cassette subfamily B member 11	Homo sapiens	73-77
10674624-0	2000	Cyclosporine-A enhances choline acetyltransferase immunoreactivity in the septal region of adult rats.	Cyclosporine	0-14	choline O-acetyltransferase	Rattus norvegicus	24-49
10661503-6	2000	Furthermore, inhibition of p-gp function by co-administration of cyclosporin A (CsA) with doxorubicin (ADM) in mdr1a(+/+) mice resulted in increased accumulation of ADM in inner ear tissues and hearing impairment similar to that noted in mdr1a(-/-) mice.	Cyclosporine	65-78	phosphoglycolate phosphatase	Mus musculus	27-31
10661503-6	2000	Furthermore, inhibition of p-gp function by co-administration of cyclosporin A (CsA) with doxorubicin (ADM) in mdr1a(+/+) mice resulted in increased accumulation of ADM in inner ear tissues and hearing impairment similar to that noted in mdr1a(-/-) mice.	Cyclosporine	80-83	phosphoglycolate phosphatase	Mus musculus	27-31
11741243-9	2000	[3H]-Cyclosporin A uptake by TM-BBB was significantly increased in the presence of 100 micromol/l verapamil and vincristine, suggesting that TM-BBB exhibits efflux transport activity via P-gp.	Cyclosporine	5-18	phosphoglycolate phosphatase	Mus musculus	187-191
11261266-0	2000	[Serum soluble CD44 isoform variant 5 level in patients with seropositive rheumatoid arthritis treated with cyclosporin A].	Cyclosporine	108-121	CD44 molecule (Indian blood group)	Homo sapiens	15-19
10943139-3	2000	We report a patient with a severe CsA induced toxic leukoencephalopathy in whom clinical symptoms (complete loss of brainstem functions, coma) and morphological changes in CCT and CMRI were completely reversible after immunosuppression with CsA has been stopped.	Cyclosporine	34-37	CCT	Homo sapiens	172-175
10943139-3	2000	We report a patient with a severe CsA induced toxic leukoencephalopathy in whom clinical symptoms (complete loss of brainstem functions, coma) and morphological changes in CCT and CMRI were completely reversible after immunosuppression with CsA has been stopped.	Cyclosporine	241-244	CCT	Homo sapiens	172-175
10669119-6	1999	Cyclosporine A was also the most effective drug downregulating the expression of accessory molecules (CD54, CD58, CD80 and CD86).	Cyclosporine	0-14	intercellular adhesion molecule 1	Homo sapiens	102-106
10531391-5	1999	Myoblasts and myotubes of C2-C12 cells express similar amounts of cyclophilin A and FKBP12, immunophilins known to be intracellular-binding targets for CsA and tacrolimus, respectively.	Cyclosporine	152-155	peptidylprolyl isomerase A	Mus musculus	66-79
10518828-7	1999	Antigen-induced proliferation of ragweed-specific Th0, Th1, or Th2 clones was inhibited by either CS or FK.	Cyclosporine	98-100	negative elongation factor complex member C/D	Homo sapiens	55-58
10518828-10	1999	CONCLUSION: CS and FK promote equivalent down-regulation of Th0, Th1, and Th2 responses; however, IL-5 generation is relatively insensitive to the immunomodulatory effects of calcineurin antagonists.	Cyclosporine	12-14	negative elongation factor complex member C/D	Homo sapiens	65-68
10455332-4	1999	In the presence of quinidine, verapamil and cyclosporin (substrates of the P-glycoprotein (P-gp)), plasma AUCs of ciprofloxacin were 1.5 - 2 fold increased, while biliary clearance (1.5 - 2 fold), intestinal overall and net clearances (2 - 4 fold and 1.5 - 8 fold respectively) decreased.	Cyclosporine	44-55	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	75-89
10455332-5	1999	The weak effect obtained with cyclosporin as compared to verapamil and especially quinidine, suggests, for ciprofloxacin, the existence of transport systems distinct from the P-gp, as the OCT1 transporter which could be inhibited by quinidine.	Cyclosporine	30-41	solute carrier family 22 member 1	Rattus norvegicus	188-192
10428761-4	1999	In a more severe rejection model (Brown-Norway RT1(n) rat kidney into Lewis RT1(1) rat), Met-RANTES significantly augmented low-dose cyclosporin A treatment to reduce all aspects of renal injury including interstitial inflammation (score 71.00 +/- 6.10 vs. 157.30 +/- 21.30).	Cyclosporine	133-146	C-C motif chemokine ligand 5	Rattus norvegicus	93-99
10504034-9	1999	Histochemical studies clearly demonstrated a form of P450 such as CYP4A2 in the proximal tubules of rats treated with cyclosporin, but not in those of rats treated with FK-506 or rapamycin.	Cyclosporine	118-129	cytochrome P450, family 4, subfamily a, polypeptide 2	Rattus norvegicus	66-72
10381759-6	1999	In addition, the uptake of [14C]HSR-903 by K562/ADM cells was significantly increased in the presence of cyclosporin A and ATP-depleting agents.	Cyclosporine	105-118	HSR	Homo sapiens	32-35
10381759-8	1999	The steady-state uptake of HSR-903 by a monolayer of primary cultured bovine brain capillary endothelial cells was increased in the presence of several quinolone antibacterial agents or anionic compounds, such as 4,4"-diisothiocyanatostilbene-2,2"-disulfonic acid, and in bicarbonate ion-free medium, as well as by P-gp inhibitors (cyclosporin A and quinidine).	Cyclosporine	332-345	HSR	Homo sapiens	27-30
10362751-6	1999	Additionally, therapeutic CsA treatment decreased the number of IFN-gamma-producing CD4(+) naive and memory T cells in the spleen.	Cyclosporine	26-29	Cd4 molecule	Rattus norvegicus	84-87
10413615-1	1999	Cyclophilins are an evolutionarily conserved family of proteins which serve as the intracellular receptors for the immunosuppressive drug cyclosporin A.	Cyclosporine	138-151	peptidylprolyl isomerase B	Mus musculus	0-12
10391367-8	1999	A second group of CsA- versus vehicle-treated rats was sacrificed at 24 h postinjury to compare the density of damaged axons displaying beta amyloid precursor protein (APP) immunoreactivity, a signature protein of axonal perturbation and disconnection.	Cyclosporine	18-21	amyloid beta precursor protein	Rattus norvegicus	136-166
10226890-3	1999	We examined whether an anti-ICAM-1 (1A29), anti-LFA-1 alpha (WT.1), or anti-CD-18 (WT.3) could reduce the immunosuppressive dose of cyclosporin A (CsA) when used in combination.	Cyclosporine	132-145	intercellular adhesion molecule 1	Rattus norvegicus	28-34
10087047-0	1999	Cyclosporin exerts a direct fibrogenic effect on human tubulointerstitial cells: roles of insulin-like growth factor I, transforming growth factor beta1, and platelet-derived growth factor.	Cyclosporine	0-11	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	147-152
10361889-4	1999	Anti-Fas antibody administration elevated CPP32-like protease activity at 3 hr in mouse liver, and this elevation of CPP32-like activity was inhibited by treatment with CsA.	Cyclosporine	169-172	caspase 3	Mus musculus	42-47
10361889-4	1999	Anti-Fas antibody administration elevated CPP32-like protease activity at 3 hr in mouse liver, and this elevation of CPP32-like activity was inhibited by treatment with CsA.	Cyclosporine	169-172	caspase 3	Mus musculus	117-122
10361889-5	1999	The present results show that CsA treatment inhibits the anti-Fas antibody-induced apoptotic process of hepatitis, at least in part, by affecting a reaction upstream of CPP32-like protease activation.	Cyclosporine	30-33	caspase 3	Mus musculus	169-174
10435045-8	1999	ADM positively correlated with endothelin, atrial natriuretic peptide (ANP) and cyclosporine.	Cyclosporine	80-92	adrenomedullin	Homo sapiens	0-3
10435045-12	1999	CONCLUSIONS: Circulating ADM is increased after heart transplantation, in relation to hypertension, endothelin, cyclosporine and ANP.	Cyclosporine	112-124	adrenomedullin	Homo sapiens	25-28
9933022-6	1999	Cyclosporin A and herbimycin A, which suppress c-fos and c-jun gene expressions, respectively, blocked the cisplatin-induced increase in ERCC-1 mRNA.	Cyclosporine	0-13	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	47-52
10023637-5	1999	Micropuncture measurements in CsA-treated animals showed that a reduction in GFR (0.49 +/- 0.24 v 0.88 +/- 0.26 mL/min; P &lt; 0.05; CsA-treated v untreated rats) is associated with a significant increase in glomerular capillary pressure (Pgc; 63.1 +/- 2.1 v 52.8 +/- 2.8 mm Hg; P &lt; 0.01) and efferent arteriolar resistance, whereas single-nephron (SN) GFR and ultrafiltration coefficient (Kf) are both importantly reduced (34.0 +/- 11.7 v 68.9 +/- 23.8 nL/min; P &lt; 0.05 and 1.04 +/- 0.33 v 4.40 +/- 2.36 nL/min/mm Hg; P &lt; 0.01, respectively).	Cyclosporine	30-33	progastricsin	Rattus norvegicus	239-242
10500791-2	1999	There was a good correlation between MRP1 expression and the modulatory effect of probenecid (a specific modulator of MRP1) on the calcein efflux (r = 0.91, p = 0.0003) and between Pgp expression and the modulatory effect of CsA on calcein-AM uptake (r = 0.96, p &lt; 0.0001).	Cyclosporine	225-228	CD9 molecule	Homo sapiens	37-41
10500791-2	1999	There was a good correlation between MRP1 expression and the modulatory effect of probenecid (a specific modulator of MRP1) on the calcein efflux (r = 0.91, p = 0.0003) and between Pgp expression and the modulatory effect of CsA on calcein-AM uptake (r = 0.96, p &lt; 0.0001).	Cyclosporine	225-228	CD9 molecule	Homo sapiens	118-122
10500791-4	1999	In 53 AML patients, there was also a good correlation between MRP1 expression (measured by RT/PCR and by MRPm6 expression by flow cytometry) and the modulatory effect of probenecid on the calcein fluorescence (r = 0.92, p &lt; 0.0001) and between Pgp expression as measured by UIC2 antibody binding on flow cytometry and the modulatory effect of CsA on calcein-AM uptake (r = 0.83, p &lt; 0.0001).	Cyclosporine	346-349	CD9 molecule	Homo sapiens	62-66
10036921-1	1999	PURPOSE: We assessed the suppressive effect of a combination of cyclosporin (an immunosuppressive agent) and allopurinol (a xanthine oxidase inhibitor and radical scavenger) on experimental autoimmune uveoretinitis (EAU) in Lewis rats, induced by interphotoreceptor retinoid-binding protein (IRBP).	Cyclosporine	64-75	retinol binding protein 3	Rattus norvegicus	247-290
10036921-1	1999	PURPOSE: We assessed the suppressive effect of a combination of cyclosporin (an immunosuppressive agent) and allopurinol (a xanthine oxidase inhibitor and radical scavenger) on experimental autoimmune uveoretinitis (EAU) in Lewis rats, induced by interphotoreceptor retinoid-binding protein (IRBP).	Cyclosporine	64-75	retinol binding protein 3	Rattus norvegicus	292-296
10036921-3	1999	We administrated cyclosporin and/or allopurinol to the IRBP-immunized Lewis rats.	Cyclosporine	17-28	retinol binding protein 3	Rattus norvegicus	55-59
12671222-0	1999	Decreased Cyclosporin A requirement with anti-ICAM-1 and anti-LFA-1 in a peripheral nerve allotransplantation model.	Cyclosporine	10-23	intercellular adhesion molecule 1	Rattus norvegicus	46-52
10714211-4	1999	In a severe rejection model (Brown-Norway RT1n rat kidney into Lewis RT1(1) rat), Met-RANTES significantly augmented low-dose cyclosporin A treatment to reduce all aspects of renal injury including interstitial inflammation (score 71.00 +/- 6.10 vs. 157.30 +/- 21.30).	Cyclosporine	126-139	C-C motif chemokine ligand 5	Rattus norvegicus	86-92
9843949-3	1998	All of these changes were dependent on Ca2+ and were prevented by cyclosporin A (CsA) and bongkrekic acid, both of which close the PT pores (megachannels), indicating that Bax- and Bak-induced mitochondrial changes were mediated through the opening of these pores.	Cyclosporine	66-79	BCL2 antagonist/killer 1	Homo sapiens	181-184
9843949-3	1998	All of these changes were dependent on Ca2+ and were prevented by cyclosporin A (CsA) and bongkrekic acid, both of which close the PT pores (megachannels), indicating that Bax- and Bak-induced mitochondrial changes were mediated through the opening of these pores.	Cyclosporine	81-84	BCL2 antagonist/killer 1	Homo sapiens	181-184
9874241-3	1998	The cyclophilin-D in the fusion was functionally normal as judged by its peptidylprolyl cis-trans-isomerase activity and its inhibition by cyclosporin A.	Cyclosporine	139-152	peptidylprolyl isomerase D	Rattus norvegicus	4-17
9850164-4	1998	The target tissue of cyclosporin A-induced autoimmunity, i.e. the skin and tongue, were also examined for expression of CD80 and CD86.	Cyclosporine	21-34	Cd80 molecule	Rattus norvegicus	120-124
9819402-4	1998	As a result, we identified a 27-bp promoter element functionally interacting with transcription factors NF-ATp and NF-ATc that is crucial for the CsA-sensitive expression of the EGR3 gene in T cells.	Cyclosporine	146-149	nuclear factor of activated T cells 1	Homo sapiens	115-121
9870481-3	1998	We have previously demonstrated an enhancement of agonist-mediated platelet activation by cyclosporine and tacrolimus which was associated with increased phosphorylation of two intracellular platelet proteins, p20 and p40.	Cyclosporine	90-102	tubulin polymerization promoting protein family member 3	Homo sapiens	210-213
9865295-0	1998	Enhanced efficacy of repeated anti-CD8 monoclonal antibody therapy by high-dose cyclosporine treatment.	Cyclosporine	80-92	CD8a molecule	Homo sapiens	35-38
9806956-1	1998	PSC 833, a nonimmunosuppressive cyclosporin, is a potent inhibitor of the efflux of antitumor drugs mediated by P-glycoprotein and thus has been introduced in clinical trials as an agent to overcome multidrug resistance.	Cyclosporine	32-43	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	112-126
9806391-12	1998	After treatment of rejection with cyclosporine, no apoptotic nuclei could be identified in allografts and uptake of 99mTc-annexin V decreased to baseline.	Cyclosporine	34-46	annexin A5	Rattus norvegicus	122-131
9821664-3	1998	Co-administration of cyclosporin, a P-glycoprotein inhibitor, significantly reduced tubular secretion of rhodamine 123.	Cyclosporine	21-32	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	36-50
9732409-3	1998	G185 cells, which highly express P-gp, are resistant to saquinavir-mediated cytotoxicity, and co-administration of cyclosporine reversed this resistance.	Cyclosporine	115-127	phosphoglycolate phosphatase	Mus musculus	33-37
9712905-11	1998	Dephosphorylation of CRHSP-24 was completely inhibited by pretreatment of acini with cyclosporin A or FK506.	Cyclosporine	85-98	calcium regulated heat stable protein 1	Rattus norvegicus	21-29
9705263-5	1998	In single-cycle infection assays, nef-defective virions were partially resistant to cyclosporin A (CsA), a drug that inhibits the binding of CyPA to the HIV-1 Gag precursor and CyPA incorporation into virions.	Cyclosporine	84-97	Nef	Human immunodeficiency virus 1	34-37
9594016-2	1998	Treating CFTR-expressing 3T3 cells with either of the two specific PP2B blockers cyclosporin A (CsA, 1 microM) or deltamethrin (DM, 30 nM) caused rapid activation of CFTR in cell-attached patches.	Cyclosporine	96-99	cystic fibrosis transmembrane conductance regulator	Mus musculus	9-13
9594016-2	1998	Treating CFTR-expressing 3T3 cells with either of the two specific PP2B blockers cyclosporin A (CsA, 1 microM) or deltamethrin (DM, 30 nM) caused rapid activation of CFTR in cell-attached patches.	Cyclosporine	96-99	cystic fibrosis transmembrane conductance regulator	Mus musculus	166-170
9594016-3	1998	As determined by noise analysis of multi channel patches, DM- or CsA-activated CFTR displayed gating kinetics comparable to those of forskolin-activated CFTR.	Cyclosporine	65-68	cystic fibrosis transmembrane conductance regulator	Mus musculus	79-83
9584155-10	1998	Cyclosporine (CsA), which inhibits stimulus-induced NF-kappaB transcriptional activity, selectively inhibits the stimulus-induced c-Rel nuclear localization and the rapid formation and degradation of c-Rel-IkappaBalpha complexes in the cytosol.	Cyclosporine	0-12	REL proto-oncogene, NF-kB subunit	Homo sapiens	130-135
9584155-10	1998	Cyclosporine (CsA), which inhibits stimulus-induced NF-kappaB transcriptional activity, selectively inhibits the stimulus-induced c-Rel nuclear localization and the rapid formation and degradation of c-Rel-IkappaBalpha complexes in the cytosol.	Cyclosporine	0-12	REL proto-oncogene, NF-kB subunit	Homo sapiens	200-205
9584155-10	1998	Cyclosporine (CsA), which inhibits stimulus-induced NF-kappaB transcriptional activity, selectively inhibits the stimulus-induced c-Rel nuclear localization and the rapid formation and degradation of c-Rel-IkappaBalpha complexes in the cytosol.	Cyclosporine	14-17	REL proto-oncogene, NF-kB subunit	Homo sapiens	130-135
9584155-10	1998	Cyclosporine (CsA), which inhibits stimulus-induced NF-kappaB transcriptional activity, selectively inhibits the stimulus-induced c-Rel nuclear localization and the rapid formation and degradation of c-Rel-IkappaBalpha complexes in the cytosol.	Cyclosporine	14-17	REL proto-oncogene, NF-kB subunit	Homo sapiens	200-205
9584155-11	1998	CsA also inhibits both the prolonged, high rate of IkappaBalpha degradation and the lower level of IkappaBbeta turnover during the second phase of the activation response.	Cyclosporine	0-3	NFKB inhibitor beta	Homo sapiens	99-110
9610733-7	1998	In vitro experiments performed with renal BBMs showed that the inhibition of P-gp photolabeling by cyclosporin A (CsA), verapamil and vinblastine could be reversed by performing washing steps to remove these drugs before incubating the samples with IAAP.	Cyclosporine	99-112	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	77-81
9610733-7	1998	In vitro experiments performed with renal BBMs showed that the inhibition of P-gp photolabeling by cyclosporin A (CsA), verapamil and vinblastine could be reversed by performing washing steps to remove these drugs before incubating the samples with IAAP.	Cyclosporine	114-117	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	77-81
9610733-9	1998	Pre-incubation of intact CHRC5 cells with PSC, CsA and verapamil also inhibited P-gp photolabeling and increased rhodamine 123 accumulation.	Cyclosporine	47-50	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	80-84
9545370-1	1998	Cyclophilins (CyPs) define a family of proteins binding to the immunosuppressive drug cyclosporin A (CsA).	Cyclosporine	86-99	peptidylprolyl isomerase like 1	Homo sapiens	0-12
9545370-1	1998	Cyclophilins (CyPs) define a family of proteins binding to the immunosuppressive drug cyclosporin A (CsA).	Cyclosporine	101-104	peptidylprolyl isomerase like 1	Homo sapiens	0-12
9513853-0	1998	Cyclosporine dosage can be reduced when used in combination with an anti-intercellular adhesion molecule-1 monoclonal antibody in rats undergoing heterotopic heart transplantation.	Cyclosporine	0-12	intercellular adhesion molecule 1	Rattus norvegicus	73-106
9513853-12	1998	CONCLUSIONS: Although monotherapy with an ICAM-1 antagonist alone may not be beneficial in preventing acute rejection episodes after organ transplantation, combination therapy of an anti-ICAM-1 monoclonal antibody may allow for a reduction in the dose of cyclosporine necessary for immune suppression.	Cyclosporine	255-267	intercellular adhesion molecule 1	Rattus norvegicus	187-193
9515090-0	1998	Differential Line Broadening in the Presence of Quadrupolar-CSA Interference The formalism for calculating the lineshape of a spin 1/2 J-coupled to a high-spin nucleus undergoing quadrupolar and chemical shift anisotropy (CSA) relaxations is derived in the case where the tensors of both interactions are noncoincident and nonaxial.	Cyclosporine	60-63	spindlin 1	Homo sapiens	126-134
9507739-7	1998	Furthermore, administration of cyclosporine and anti-CD8 monoclonal antibodies to II-4+ recipients prolonged xenograft survival to at least the same extent as allograft survival, demonstrating that the strength of cell-mediated xenograft rejection resides in the CD4+ indirect response.	Cyclosporine	31-43	CD4 antigen	Mus musculus	263-266
9869896-0	1998	Cyclosporin A decreases lymphocyte migration to the heart allograft through suppression of their L-selectin expression.	Cyclosporine	0-13	selectin L	Rattus norvegicus	97-107
9434804-8	1998	Therefore, the use of a CD4-CDR3 peptide can complement and potentiate the immunosuppressive effects of CsA in the prevention of GVHD following allogeneic BMT.	Cyclosporine	104-107	CD4 antigen	Mus musculus	24-27
9665011-1	1998	In patients receiving cyclosporine A (CyA)-based immunosuppressive therapy, Ca2+ channel blockers (CCBs) prevent the development of CyA-related nephrotoxicity in which increased Ca2+ content plays an important role.	Cyclosporine	22-36	carbonic anhydrase 2	Homo sapiens	76-79
9665011-1	1998	In patients receiving cyclosporine A (CyA)-based immunosuppressive therapy, Ca2+ channel blockers (CCBs) prevent the development of CyA-related nephrotoxicity in which increased Ca2+ content plays an important role.	Cyclosporine	22-36	carbonic anhydrase 2	Homo sapiens	178-181
9665011-1	1998	In patients receiving cyclosporine A (CyA)-based immunosuppressive therapy, Ca2+ channel blockers (CCBs) prevent the development of CyA-related nephrotoxicity in which increased Ca2+ content plays an important role.	Cyclosporine	38-41	carbonic anhydrase 2	Homo sapiens	76-79
9665011-1	1998	In patients receiving cyclosporine A (CyA)-based immunosuppressive therapy, Ca2+ channel blockers (CCBs) prevent the development of CyA-related nephrotoxicity in which increased Ca2+ content plays an important role.	Cyclosporine	38-41	carbonic anhydrase 2	Homo sapiens	178-181
9665011-5	1998	Therefore we suggest that the switch from S to SN is effective in reducing elevated intracellular Ca2+ levels.	Cyclosporine	47-49	carbonic anhydrase 2	Homo sapiens	98-101
9440547-7	1997	CONCLUSIONS: The results indicate that administration of cyclosporine and interferon-gamma after PBSC transplantation can induce autocytotoxic CD8+ T cells, even though it may not produce autologous graft-versus-host disease.	Cyclosporine	57-69	CD8a molecule	Homo sapiens	143-146
9548474-6	1997	In contrast, cross-linking of CD47 in the presence of CD28 mAb or phorbol ester induces vigorous T cell proliferation that is sensitive to cyclosporin A.	Cyclosporine	139-152	CD47 molecule	Homo sapiens	30-34
9367995-8	1997	Pretreatment of COS cells with cyclosporin A significantly enhanced epidermal growth factor-induced serine 383 Elk-1 phosphorylation whereas ionomycin inhibited the Elk-1 phosphorylation.	Cyclosporine	31-44	ETS transcription factor ELK1	Homo sapiens	111-116
9367995-10	1997	The identification of calcineurin as the major Elk-1 phosphatase may provide a mechanism for Elk-1 regulation by Ca2+ signals as well as a possible biochemical basis for the neurotoxicity and nephrotoxicity of the immunosuppressant drug cyclosporin A.	Cyclosporine	237-250	ETS transcription factor ELK1	Homo sapiens	47-52
9396464-5	1997	Before estradiol administration, ET-1 induced significant dose-dependent decreases in CSA, APV, and CBF.	Cyclosporine	86-89	endothelin-1	Sus scrofa	33-37
9404561-8	1997	Cyclosporin A and rapamycin significantly inhibited IL-5-enhanced ECP release in a concentration-dependent fashion, whereas dexamethasone did not.	Cyclosporine	0-13	ribonuclease A family member 3	Homo sapiens	66-69
9353152-6	1997	The results revealed that CsA blocks maturation of double-positive TCR(int) to double-positive TCR(high) thymocytes and preferentially inhibits the development of mature CD4 single-positive thymocytes.	Cyclosporine	26-29	Cd4 molecule	Rattus norvegicus	170-173
9353152-7	1997	Furthermore, CsA administration resulted in a reduced expression of the costimulatory CD2 molecule.	Cyclosporine	13-16	Cd2 molecule	Rattus norvegicus	86-89
9349628-0	1997	Inhibition of CREB- and cAMP response element-mediated gene transcription by the immunosuppressive drugs cyclosporin A and FK506 in T cells.	Cyclosporine	105-118	cAMP responsive element binding protein 1	Homo sapiens	14-18
9349628-1	1997	The clinically important immunosuppressant drugs cyclosporin A and FK506 (tacrolimus) inhibit in T-cells calcineurin phosphatase activity and nuclear translocation of the cytosolic component of the transcription factor nuclear factor of activated T-cells (NF-ATc) that is involved in the induction of early genes during T-cell activation.	Cyclosporine	49-62	nuclear factor of activated T cells 1	Homo sapiens	256-262
9349628-3	1997	Previous studies in pancreatic islet cell lines have shown that cyclosporin A and FK506 through inhibition of calcineurin interfere also with the function of the transcription factor cAMP response element binding protein (CREB) that is activated by cAMP and calcium signals and binds to cAMP/calcium response elements (CRE).	Cyclosporine	64-77	cAMP responsive element binding protein 1	Homo sapiens	183-220
9295165-6	1997	These results indicate that RA-induced enhancement of LTC4 production and its inhibition by DEX and CSA was determined by post-transcriptional regulation of LTC4 synthase.	Cyclosporine	100-103	leukotriene C4 synthase	Rattus norvegicus	157-170
9378502-2	1997	We have recently demonstrated that both free CyPB and CyPB-CsA complex specifically bind to peripheral blood T lymphocytes and are internalized.	Cyclosporine	59-62	peptidylprolyl isomerase B	Homo sapiens	54-58
9378502-10	1997	Finally, we demonstrated that CyPB-receptor-positive cells, isolated on CyPB sulphydryl-coupled affinity matrices, are more sensitive to CyPB-complexed CsA than mixed peripheral blood lymphocytes, suggesting that CyPB potentiates CsA activity through the binding of the complex.	Cyclosporine	152-155	peptidylprolyl isomerase B	Homo sapiens	30-34
9378502-10	1997	Finally, we demonstrated that CyPB-receptor-positive cells, isolated on CyPB sulphydryl-coupled affinity matrices, are more sensitive to CyPB-complexed CsA than mixed peripheral blood lymphocytes, suggesting that CyPB potentiates CsA activity through the binding of the complex.	Cyclosporine	152-155	peptidylprolyl isomerase B	Homo sapiens	72-76
9378502-10	1997	Finally, we demonstrated that CyPB-receptor-positive cells, isolated on CyPB sulphydryl-coupled affinity matrices, are more sensitive to CyPB-complexed CsA than mixed peripheral blood lymphocytes, suggesting that CyPB potentiates CsA activity through the binding of the complex.	Cyclosporine	152-155	peptidylprolyl isomerase B	Homo sapiens	72-76
9378502-10	1997	Finally, we demonstrated that CyPB-receptor-positive cells, isolated on CyPB sulphydryl-coupled affinity matrices, are more sensitive to CyPB-complexed CsA than mixed peripheral blood lymphocytes, suggesting that CyPB potentiates CsA activity through the binding of the complex.	Cyclosporine	152-155	peptidylprolyl isomerase B	Homo sapiens	72-76
9378502-10	1997	Finally, we demonstrated that CyPB-receptor-positive cells, isolated on CyPB sulphydryl-coupled affinity matrices, are more sensitive to CyPB-complexed CsA than mixed peripheral blood lymphocytes, suggesting that CyPB potentiates CsA activity through the binding of the complex.	Cyclosporine	230-233	peptidylprolyl isomerase B	Homo sapiens	30-34
9378502-11	1997	Taken together, our results demonstrate that CyPB-binding sites are mainly associated with resting cells of the helper T lymphocyte, and that CyPB might modulate the distribution of CsA through the drug targeting to sensitive cells.	Cyclosporine	182-185	peptidylprolyl isomerase B	Homo sapiens	45-49
9378502-11	1997	Taken together, our results demonstrate that CyPB-binding sites are mainly associated with resting cells of the helper T lymphocyte, and that CyPB might modulate the distribution of CsA through the drug targeting to sensitive cells.	Cyclosporine	182-185	peptidylprolyl isomerase B	Homo sapiens	142-146
9262363-5	1997	The increased basolateral-to-apical transport in LLC-GA5-COL150 monolayers was completely inhibited by cyclosporin A and quinidine to the level observed in LLC-PK1 monolayers.	Cyclosporine	103-116	prokineticin 1	Homo sapiens	160-163
9247567-4	1997	CsA does not interfere with the synthesis of Rel proteins, but prevents the inducible degradation of cytosolic NF-kappa B inhibitors I kappa B alpha and I kappa B beta upon T cell activation.	Cyclosporine	0-3	NFKB inhibitor beta	Homo sapiens	153-167
9247567-6	1997	These results indicate that CsA interferes with a specific event in the signal-induced degradation of I kappa B alpha and I kappa B beta, but does not affect the processing of NF-kappa B1/p105 to p50.	Cyclosporine	28-31	NFKB inhibitor beta	Homo sapiens	122-136
9261213-10	1997	In contrast, P-glycoprotein functions for the secretion of drugs into the intestinal lumen, thereby decreasing intestinal absorption of an immunosuppressive, cyclosporin A and a 5-HT3 receptor antagonist, azasetron.	Cyclosporine	158-171	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	13-27
9190906-2	1997	Furthermore we show that IL-10 production by human T cell lines, such as IFN-gamma and IL-2, is inhibited by the immunosuppressive drugs cyclosporin A and FK506.	Cyclosporine	137-150	interleukin 10	Homo sapiens	25-30
9190912-4	1997	Anti-CD3 activation of G0 T cells in the presence of cyclosporin A or rapamycin inhibited the down-regulation of p27Kip1, the cellular levels of the inhibitor remained high, and the cells remained in the G1 phase.	Cyclosporine	53-66	cyclin-dependent kinase inhibitor 1B	Mus musculus	113-120
9126965-11	1997	In contrast to the regulation of IL-2 and IL-2R expression, which is inhibited by cyclosporin A-, but not rapamycin-dependent signal transduction pathways, CTLA-4 expression is inhibited by either cyclosporin A or rapamycin.	Cyclosporine	82-95	interleukin 2 receptor, alpha chain	Mus musculus	42-47
9126965-12	1997	Thus, synergistic induction of CTLA-4 expression requires both cyclosporin A- and rapamycin-dependent signals.	Cyclosporine	63-76	cytotoxic T-lymphocyte-associated protein 4	Mus musculus	31-37
9224413-4	1997	All rats received daily low-dose cyclosporine (CsA) 2 mg/kg/day by gavage.	Cyclosporine	33-45	IK cytokine	Rattus norvegicus	47-53
9112364-1	1997	BACKGROUND: We have demonstrated that cyclosporine (CsA) stimulates transforming growth factor (TGF) beta1 expression in vitro and that growth of mammalian cells can be arrested by CsA via a TGF-beta1-dependent mechanism.	Cyclosporine	38-50	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	101-106
9112364-1	1997	BACKGROUND: We have demonstrated that cyclosporine (CsA) stimulates transforming growth factor (TGF) beta1 expression in vitro and that growth of mammalian cells can be arrested by CsA via a TGF-beta1-dependent mechanism.	Cyclosporine	52-55	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	101-106
9161877-4	1997	Under either condition, CsA but not CPZ prevented concurrent increases in splenic ornithine decarboxylase (ODC) activity, a putative index of T-cell proliferation/differentiation.	Cyclosporine	24-27	ornithine decarboxylase, structural 1	Mus musculus	82-105
9161877-4	1997	Under either condition, CsA but not CPZ prevented concurrent increases in splenic ornithine decarboxylase (ODC) activity, a putative index of T-cell proliferation/differentiation.	Cyclosporine	24-27	ornithine decarboxylase, structural 1	Mus musculus	107-110
9009275-3	1997	It is shown here that CsA sensitivity maps to three sites (ZIA, ZIB and ZID) that bind the serum response factor-related protein MEF2D.	Cyclosporine	22-25	serum response factor	Homo sapiens	91-112
9009275-3	1997	It is shown here that CsA sensitivity maps to three sites (ZIA, ZIB and ZID) that bind the serum response factor-related protein MEF2D.	Cyclosporine	22-25	myocyte enhancer factor 2D	Homo sapiens	129-134
9009275-4	1997	A synthetic promoter containing multiple copies of a MEF2D site from Zp, in conjunction with a CREB/AP-1 site (ZII) from Zp, exhibits CsA-sensitive inducibility.	Cyclosporine	134-137	myocyte enhancer factor 2D	Homo sapiens	53-58
9249940-7	1997	When CyA treatment was continued throughout the period during which unresponsiveness to the graft is induced by anti-CD4 mAb therapy, 50% of the grafted hearts were rejected once the CyA was discontinued.	Cyclosporine	5-8	CD4 antigen	Mus musculus	117-120
9072300-15	1996	Significant decrease of proteinuria/GFR ratio strongly suggests some non-hemodynamic mechanisms of cyclosporine action in these patients.	Cyclosporine	99-111	Rap guanine nucleotide exchange factor 5	Homo sapiens	36-39
8943377-7	1996	Drugs blocking at G1 (cyclosporin A, mimosine) or S (hydroxyurea) phase inhibited the up-regulation of CTLA4 induced by anti-CD3 mAb, suggesting that entry into the cell cycle was necessary to increase the expression of CTLA4.	Cyclosporine	22-35	cytotoxic T-lymphocyte-associated protein 4	Mus musculus	103-108
8958274-0	1996	The lesions of cyclosporine-induced autoimmune disease can be equally well elicited by CD4 or CD8 effector T cells.	Cyclosporine	15-27	Cd4 molecule	Rattus norvegicus	87-90
8944692-6	1996	Daunorubicin, vinblastine, etoposide, cyclosporin, and PSC-833, substrates/modulators of P-glycoprotein, were also potent inhibitors of E217G transport, and E217G competitively inhibited the ATP-dependent transport of daunorubicin.	Cyclosporine	38-49	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	89-103
8937936-11	1996	This is of great interest since recent information has suggested that the immunosuppressive effect of cyclosporine is at least partially mediated through TGF-beta 2.	Cyclosporine	102-114	transforming growth factor beta 2	Homo sapiens	154-164
8781606-7	1996	CsA levels fell in both groups after transplantation, mirroring the fall in AUC insulin, and implicating CsA as a major cause of peripheral resistance to insulin.	Cyclosporine	105-108	insulin	Canis lupus familiaris	154-161
8702699-6	1996	Cyclosporin-A, another calcineurin inhibitor, also prevented the augmented cAMP response.	Cyclosporine	0-13	calcineurin binding protein 1	Homo sapiens	23-44
8881695-0	1996	Modulation of serum eosinophil cationic protein levels by cyclosporin in severe atopic dermatitis.	Cyclosporine	58-69	ribonuclease A family member 3	Homo sapiens	20-47
8712218-10	1996	Confocal fluorescence microscopy studies showed that CyA induced an increase in the endothelial surface expression of ICAM-1, VCAM-1, and E-selectin.	Cyclosporine	53-56	intercellular adhesion molecule 1	Homo sapiens	118-124
8652191-11	1996	Thus, although CsA administration attenuated spleen cell activation and was associated with a marked attenuation of airway responsiveness in mice with genetically hyperresponsive airways, CD4+ and CD8+ T cells do not appear to mediate this response.	Cyclosporine	15-18	CD4 antigen	Mus musculus	188-191
8647944-1	1996	The mouse mdr1a (also called mdr3) P-GP is abundant in the blood-brain barrier, and its absence in mdr1a (-/-) mice leads to highly increased levels of the drugs ivermectin, vinblastine, digoxin, and cyclosporin A in the brain.	Cyclosporine	200-213	phosphoglycolate phosphatase	Mus musculus	35-39
8691064-7	1996	Blood monocytes stimulated by lipopolysaccharide and treated with hydrocortisone, 5-aminosalicylic acid, or cyclosporin A showed reduced MCP-1 expression and production in the presence of these agents.	Cyclosporine	108-121	chemokine (C-C motif) ligand 2	Mus musculus	137-142
8661172-2	1996	Although there is evidence that prolactin may be a significant immunotropic hormone that can counteract the immunosuppressive effects of drugs such as cyclosporine, morphine, or glucocorticoids, it remains unknown whether prolactin administration has any salutary effects on the depressed immune responses following severe hemorrhage.	Cyclosporine	151-163	prolactin	Mus musculus	32-41
8928836-0	1996	Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues.	Cyclosporine	0-13	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	50-64
8928836-3	1996	Interaction of CsA with PGP was further investigated by treating rats with daily subcutaneous injections of CsA (10 mg.kg-1.day-1).	Cyclosporine	15-18	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	24-27
8928836-5	1996	This induction was a reversible process, since after cessation of CsA administration PGP levels declined to reach values similar to those of the control groups.	Cyclosporine	66-69	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	85-88
8928836-8	1996	These results demonstrate that CsA induces reversible overexpression of PGP in the rat.	Cyclosporine	31-34	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	72-75
8726667-0	1996	Preventive effect of hepatocyte growth factor on acute side effects of cyclosporin A in mice.	Cyclosporine	71-84	hepatocyte growth factor	Mus musculus	21-45
8704690-4	1996	Cyclosporine was used as GVHD prophylaxis in combination with CD4+ and CD8+ depletion, which removed 94.1 +/- 3.2%, 97.0 +/- 5.1%, and 96.7 +/- 3.1% of CD3+, CD4+ and CD8+ cells, respectively.	Cyclosporine	0-12	CD8a molecule	Homo sapiens	167-170
8598229-0	1996	Strong increase in the percentage of the CD8bright+ CD28- T-cells and delayed engraftment associated with cyclosporine-induced autologous GVHD.	Cyclosporine	106-118	CD8a molecule	Homo sapiens	41-44
8605941-5	1996	Appearance of the STAT1 factor is significantly reduced in the presence of cyclosporin A, and blocked by cycloheximide, indicating that its activation is dependent upon a protein(s) synthesized in response to initial signaling events.	Cyclosporine	75-88	signal transducer and activator of transcription 1	Homo sapiens	18-23
8671822-0	1996	Prevention of cyclosporin nephrotoxicity with a platelet-activating factor (PAF) antagonist.	Cyclosporine	14-25	PCNA clamp associated factor	Rattus norvegicus	48-74
8671822-0	1996	Prevention of cyclosporin nephrotoxicity with a platelet-activating factor (PAF) antagonist.	Cyclosporine	14-25	PCNA clamp associated factor	Rattus norvegicus	76-79
8671822-3	1996	CsA enhances platelet-activating factor (PAF) synthesis in mesangial cells in vitro.	Cyclosporine	0-3	PCNA clamp associated factor	Rattus norvegicus	13-39
8671822-3	1996	CsA enhances platelet-activating factor (PAF) synthesis in mesangial cells in vitro.	Cyclosporine	0-3	PCNA clamp associated factor	Rattus norvegicus	41-44
8671822-5	1996	METHODS: The in situ autoperfused rat kidney model was used to investigate whether PAF plays a role in the haemodynamic injury induced by CsA.	Cyclosporine	138-141	PCNA clamp associated factor	Rattus norvegicus	83-86
8671822-11	1996	CONCLUSIONS: We have demonstrated that the PAF antagonist BN 52021 can minimize the alteration of renal function induced by CsA.	Cyclosporine	124-127	PCNA clamp associated factor	Rattus norvegicus	43-46
8627154-6	1996	CNA alpha -/- T cells remained sensitive to both cyclosporin A and FK506, suggesting that CNA beta or another CNA-like molecule can mediate the action of these immunosuppressive drugs.	Cyclosporine	49-62	protein phosphatase 3, catalytic subunit, alpha isoform	Mus musculus	0-3
8627154-7	1996	CNA alpha -/- mice provide an animal model for dissecting the physiologic functions of calcineurin as well as the effects of FK506 and CsA.	Cyclosporine	135-138	protein phosphatase 3, catalytic subunit, alpha isoform	Mus musculus	0-3
8828007-0	1996	Cross-linking the TCR complex induces apoptosis in CD4+8+ thymocytes in the presence of cyclosporin A.	Cyclosporine	88-101	CD4 antigen	Mus musculus	51-54
9026809-3	1996	Administration of CsA-treated lymphocytes induced no profound structural changes in lymphocytic subpopulations (CD3, CD4, CD8), but it was followed by a reduction in the baseline high proliferative lymphocytic response to PHA.	Cyclosporine	18-21	CD8a molecule	Homo sapiens	122-125
8851819-11	1996	The modulation of Pgp levels by IMM did not parallel the changes in 3A levels, indicating that Pgp regulation is most likely due to a direct effect of the cyclosporin rather than a co-regulation mechanism linked to 3A or P4501A modulation.	Cyclosporine	155-166	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	95-98
7586731-0	1995	Direct inhibition of human CD8+ lymphocyte activation by cyclosporine A and Rapamune-Sirolimus.	Cyclosporine	57-71	CD8a molecule	Homo sapiens	27-30
7586731-2	1995	In this study the direct effects of RAP and CsA on a highly purified population of CD8+ lymphocytes were examined.	Cyclosporine	44-47	CD8a molecule	Homo sapiens	83-86
7586742-8	1995	As a possible effector mechanism CD4+ T-cells in the acute-phase of CsA-AI may cause the observed activation of macrophages and keratinocytes.	Cyclosporine	68-71	Cd4 molecule	Rattus norvegicus	33-36
8580076-6	1995	Blocking experiments with cyclosporin A indicated that the intracellular pathways used by the CD28 and CD44 molecules appear to be different.	Cyclosporine	26-39	CD44 antigen	Mus musculus	103-107
7594578-4	1995	Most of the TCR-alpha beta i-IEL whose development was inhibited by CSA belonged to the CD4-CD8+ alpha alpha subset.	Cyclosporine	68-71	CD4 antigen	Mus musculus	88-91
8748119-7	1995	In addition, FK506 and CsA potentiated beta-endorphin secretion induced by corticotropin releasing factor (CRF) and phorbol ester, but had no apparent acute (60 min) effect on POMC hnRNA levels.	Cyclosporine	23-26	corticotropin releasing hormone	Mus musculus	75-105
7474947-7	1995	For the in situ detection of CsA binding sites, a photolabile cyclosporine derivative (PL-CS) was used that allowed the detection of covalently bound CsA by Ab.	Cyclosporine	62-74	chorionic somatomammotropin hormone 1	Homo sapiens	29-32
7474947-7	1995	For the in situ detection of CsA binding sites, a photolabile cyclosporine derivative (PL-CS) was used that allowed the detection of covalently bound CsA by Ab.	Cyclosporine	62-74	chorionic somatomammotropin hormone 1	Homo sapiens	150-153
7559604-7	1995	In vitro, both wild-type and CNB1-G2A mutant proteins formed complexes with both cyclophilin A-cyclosporin A (CsA) and FKBP12-FK506 that contained calcineurin A. Interestingly, expression of the nonmyristoylated CNB1-G2A mutant protein rendered yeast cells partially resistant to the immunosuppressant CsA, but not to FK506.	Cyclosporine	95-108	calcineurin regulatory subunit B	Saccharomyces cerevisiae S288C	29-33
7559604-7	1995	In vitro, both wild-type and CNB1-G2A mutant proteins formed complexes with both cyclophilin A-cyclosporin A (CsA) and FKBP12-FK506 that contained calcineurin A. Interestingly, expression of the nonmyristoylated CNB1-G2A mutant protein rendered yeast cells partially resistant to the immunosuppressant CsA, but not to FK506.	Cyclosporine	110-113	calcineurin regulatory subunit B	Saccharomyces cerevisiae S288C	29-33
7559604-7	1995	In vitro, both wild-type and CNB1-G2A mutant proteins formed complexes with both cyclophilin A-cyclosporin A (CsA) and FKBP12-FK506 that contained calcineurin A. Interestingly, expression of the nonmyristoylated CNB1-G2A mutant protein rendered yeast cells partially resistant to the immunosuppressant CsA, but not to FK506.	Cyclosporine	302-305	calcineurin regulatory subunit B	Saccharomyces cerevisiae S288C	29-33
7559465-2	1995	Cyclophilins comprise a highly conserved family of proteins which are the primary targets of the potent immunosuppressive drug, cyclosporin A (CsA), and which display peptidyl prolyl cis-trans-isomerase (PPIase) activity.	Cyclosporine	128-141	peptidylprolyl isomerase like 1	Bos taurus	0-12
7559465-2	1995	Cyclophilins comprise a highly conserved family of proteins which are the primary targets of the potent immunosuppressive drug, cyclosporin A (CsA), and which display peptidyl prolyl cis-trans-isomerase (PPIase) activity.	Cyclosporine	143-146	peptidylprolyl isomerase like 1	Bos taurus	0-12
7559465-2	1995	Cyclophilins comprise a highly conserved family of proteins which are the primary targets of the potent immunosuppressive drug, cyclosporin A (CsA), and which display peptidyl prolyl cis-trans-isomerase (PPIase) activity.	Cyclosporine	143-146	peptidylprolyl isomerase like 1	Bos taurus	204-210
7559465-5	1995	These proteins represent a new class of cyclophilins with novel structural features and greatly reduced PPIase and CsA binding activities in comparison to other known cyclophilins.	Cyclosporine	115-118	peptidylprolyl isomerase like 1	Bos taurus	40-52
7583777-2	1995	CsA alone, at 5-10 microM concentrations, induced almost complete nuclear transfer of the PR-mutant within 18 h. In contrast, FK506 and Rapa at the same concentrations had no effect.	Cyclosporine	0-3	progesterone receptor	Mus musculus	90-92
8590036-0	1995	Vascular expression of clusterin in experimental cyclosporine nephrotoxicity.	Cyclosporine	49-61	clusterin	Rattus norvegicus	23-32
8590036-2	1995	We have examined the expression of the clusterin gene in the kidney during the development of cyclosporine (CyA)-induced nephrotoxicity in the rat using in situ hybridization histochemistry.	Cyclosporine	94-106	clusterin	Rattus norvegicus	39-48
8590036-2	1995	We have examined the expression of the clusterin gene in the kidney during the development of cyclosporine (CyA)-induced nephrotoxicity in the rat using in situ hybridization histochemistry.	Cyclosporine	108-111	clusterin	Rattus norvegicus	39-48
8590036-8	1995	Clusterin expression was also seen in afferent arterioles, the glomerular capsule and transitional epithelium of the renal pelvis of kidney sections from rats treated with CyA for 6 weeks.	Cyclosporine	172-175	clusterin	Rattus norvegicus	0-9
7582858-5	1995	CsA in all concentrations significantly (P &lt; 0.001) inhibited both Ca2+ ATPase and NOS activities of rat myocardium and FDP at 1000 microM concentration completely reversed the 1000 microM CsA-inhibited Ca2+ ATPase and cNOS activities of rat myocardium.	Cyclosporine	0-3	nitric oxide synthase 3	Rattus norvegicus	222-226
7582858-5	1995	CsA in all concentrations significantly (P &lt; 0.001) inhibited both Ca2+ ATPase and NOS activities of rat myocardium and FDP at 1000 microM concentration completely reversed the 1000 microM CsA-inhibited Ca2+ ATPase and cNOS activities of rat myocardium.	Cyclosporine	192-195	nitric oxide synthase 3	Rattus norvegicus	222-226
7598699-0	1995	Effect of the p-glycoprotein inhibitor, cyclosporin A, on the distribution of rhodamine-123 to the brain: an in vivo microdialysis study in freely moving rats.	Cyclosporine	40-53	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	14-28
7598699-2	1995	This study examined the effect of a p-glycoprotein inhibitor, cyclosporin A, on the distribution to the brain of a p-glycoprotein substrate, rhodamine-123, in freely moving rats using intracerebral microdialysis coupled with on-line HPLC analysis.	Cyclosporine	62-75	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	36-50
7598699-2	1995	This study examined the effect of a p-glycoprotein inhibitor, cyclosporin A, on the distribution to the brain of a p-glycoprotein substrate, rhodamine-123, in freely moving rats using intracerebral microdialysis coupled with on-line HPLC analysis.	Cyclosporine	62-75	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	115-129
7745957-0	1995	The inhibitor cytokine interleukin-1 receptor antagonist synergistically augments cyclosporine immunosuppression in a rat cardiac allograft model.	Cyclosporine	82-94	interleukin 1 receptor antagonist	Rattus norvegicus	23-56
7534714-4	1995	Flow-cytometric analysis revealed a normal expression of GPI-linked membrane proteins, including CD55, CD59, and CD16 on PMN in all patients treated with CyA, irrespective of response, except for one patient who had a small proportion of GPI-anchored membrane protein-negative cells before therapy.	Cyclosporine	154-157	CD55 molecule (Cromer blood group)	Homo sapiens	97-101
7534714-4	1995	Flow-cytometric analysis revealed a normal expression of GPI-linked membrane proteins, including CD55, CD59, and CD16 on PMN in all patients treated with CyA, irrespective of response, except for one patient who had a small proportion of GPI-anchored membrane protein-negative cells before therapy.	Cyclosporine	154-157	Fc gamma receptor IIIa	Homo sapiens	113-117
7540861-3	1995	We report that anti-mu induced CD5 expression on B-2 cells was inhibited by CsA as well as FK-520 and rapamycin.	Cyclosporine	76-79	CD5 antigen	Mus musculus	31-34
7540861-5	1995	When we used either CD4+CD8+ thymocytes or peripheral T cells activated by phorbol ester and ionomycin, the cell surface induction of CD5 was also partially blocked by CsA, FK-520 and rapamycin.	Cyclosporine	168-171	CD4 antigen	Mus musculus	20-23
7540861-5	1995	When we used either CD4+CD8+ thymocytes or peripheral T cells activated by phorbol ester and ionomycin, the cell surface induction of CD5 was also partially blocked by CsA, FK-520 and rapamycin.	Cyclosporine	168-171	CD5 antigen	Mus musculus	134-137
7540861-12	1995	We conclude that in both B and T cells the induction of CD5 requires transcriptional regulation, and that the inhibition of CD5 expression by the immunosuppressive drugs CsA, FK-520 and rapamycin requires drug-immunophilin complex formation.	Cyclosporine	170-173	CD5 antigen	Mus musculus	124-127
7851006-9	1995	Cyclosporin A, in contrast, inhibited both Th1 and Th2 cytokine production by PHA-stimulated PBMC.	Cyclosporine	0-13	negative elongation factor complex member C/D	Homo sapiens	43-46
7599379-3	1995	Cyclosporin A (CSA) is a potent inhibitor of Pgp.	Cyclosporine	0-13	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	45-48
7599379-3	1995	Cyclosporin A (CSA) is a potent inhibitor of Pgp.	Cyclosporine	15-18	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	45-48
7599379-6	1995	CONCLUSION: The mechanism of protection by CSA and its relationship to Pgp remain uncertain.	Cyclosporine	43-46	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	71-74
9700361-1	1995	Cyclosporin A (CsA) inhibits the development of mature thymocytes from their CD4+ CD8+ precursors, but may allow autoreactive cells to mature.	Cyclosporine	0-13	CD8a molecule	Homo sapiens	82-85
9700361-1	1995	Cyclosporin A (CsA) inhibits the development of mature thymocytes from their CD4+ CD8+ precursors, but may allow autoreactive cells to mature.	Cyclosporine	15-18	CD8a molecule	Homo sapiens	82-85
9700361-5	1995	An exceptional subset of CD8 SP thymocytes, expressing CD45RA, did not respond to CsA for about 10 days, indicating that they are distantly derived from a CsA-sensitive precursor.	Cyclosporine	155-158	CD8a molecule	Homo sapiens	25-28
9700361-6	1995	Apoptosis of TCR-V beta 3 + thymocytes caused by Mtv-6, quantified according to the down-regulation of CD4 and CD8 on immature thymocytes, was partially inhibited by CsA, to maximal effect within 24 hours.	Cyclosporine	166-169	CD8a molecule	Homo sapiens	111-114
8904025-2	1995	Cyclosporin A at lower doses (0.1--1,000 ng/ml) stimulated cathepsin B, H, L+B.	Cyclosporine	0-13	cathepsin B	Sus scrofa	59-70
8904025-5	1995	The higher dose of cyclosporin A also enhanced cellular lipid peroxide content after an exposure of 4 and 10 h. Co-incubation with superoxide dismutase (40 U/ml) did not ameliorate the inhibition of cathepsin B activity induced by the high dose of cyclosporin A.	Cyclosporine	19-32	cathepsin B	Sus scrofa	199-210
8904025-8	1995	A rise in cytosolic Ca2+ concentration, but not an enhanced lipid peroxidation, may be involved in the suppression of cathepsin B activity induced by the higher dose of cyclosporin A.	Cyclosporine	169-182	cathepsin B	Sus scrofa	118-129
7530227-4	1994	We and others have defined the Saccharomyces cerevisiae FKS1 gene by recessive mutations resulting in 100-1000-fold hypersensitivity to FK506 and CsA (as compared to wild type), but which do not affect sensitivity to a variety of other antifungal drugs.	Cyclosporine	146-149	1,3-beta-D-glucan synthase	Saccharomyces cerevisiae S288C	56-60
7530227-12	1994	These data suggest that FKS1 provides a unique cellular function which, when absent, increases FK506 and CsA sensitivity by making the CNs (or a CN-dependent function) essential.	Cyclosporine	105-108	1,3-beta-D-glucan synthase	Saccharomyces cerevisiae S288C	24-28
7809931-8	1994	Based on these results in isolated rat renal arterioles, it is suggested that CsA-induced constriction in AA is likely mediated by sequential activation of ET and PAF.	Cyclosporine	78-81	PCNA clamp associated factor	Rattus norvegicus	163-166
7986214-5	1994	The ATP-dependent and QND-sensitive efflux of CsA from the brain strongly indicates that P-gp in the brain capillary endothelial cells functions as an efflux pump under the physiological state, and that P-gp-mediated efflux of CsA is a major mechanism of the restricted transfer from blood into the brain.	Cyclosporine	46-49	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	203-207
7986214-5	1994	The ATP-dependent and QND-sensitive efflux of CsA from the brain strongly indicates that P-gp in the brain capillary endothelial cells functions as an efflux pump under the physiological state, and that P-gp-mediated efflux of CsA is a major mechanism of the restricted transfer from blood into the brain.	Cyclosporine	227-230	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	89-93
7986214-5	1994	The ATP-dependent and QND-sensitive efflux of CsA from the brain strongly indicates that P-gp in the brain capillary endothelial cells functions as an efflux pump under the physiological state, and that P-gp-mediated efflux of CsA is a major mechanism of the restricted transfer from blood into the brain.	Cyclosporine	227-230	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	203-207
7980643-6	1994	These data suggest that CsA increased arachidonic acid omega-hydroxylation activity by the induction of CYP4A2.	Cyclosporine	24-27	cytochrome P450, family 4, subfamily a, polypeptide 2	Rattus norvegicus	104-110
7980643-7	1994	The specific induction of CYP4A2 may be related to CsA-induced nephrotoxicity and elevated blood pressure, because omega-hydroxyarachidonic acid is a potent vasoconstrictor.	Cyclosporine	51-54	cytochrome P450, family 4, subfamily a, polypeptide 2	Rattus norvegicus	26-32
7930569-4	1994	However, comparative studies using extracts of D10.G4.1 cells treated with the cellular activators Con A and PMA and the inhibitors cycloheximide and cyclosporin A indicated that the binding activities to the conserved elements in the IL-5 and GM-CSF genes (designated NF-IL-5A and NF-GM-CSFA, respectively) are regulated by different signaling pathways.	Cyclosporine	150-163	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	244-250
7798591-7	1994	Furthermore, flow cytometric analysis using monoclonal antibodies (mAbs) specific for thymocyte subsets confirmed that CsA induces a large decrease in the relative number of mature single positive (SP) CD4+CD8- and CD8+CD4- thymocytes expressing high densities of CD3 and T cell receptor ab (TCR alpha beta) surface molecules, but also a decrease in the absolute number of the other thymocyte subsets.	Cyclosporine	119-122	CD4 antigen	Mus musculus	202-205
7798591-7	1994	Furthermore, flow cytometric analysis using monoclonal antibodies (mAbs) specific for thymocyte subsets confirmed that CsA induces a large decrease in the relative number of mature single positive (SP) CD4+CD8- and CD8+CD4- thymocytes expressing high densities of CD3 and T cell receptor ab (TCR alpha beta) surface molecules, but also a decrease in the absolute number of the other thymocyte subsets.	Cyclosporine	119-122	CD4 antigen	Mus musculus	219-222
7608852-8	1994	Likewise, the intraepithelial deposit of CsA in the GO region was found to be related to the inflammatory infiltrate CD4+, CD8+, and CD68+ (r = 0.7432; r = 0.7346; r = 0.77005, respectively).	Cyclosporine	41-44	CD8a molecule	Homo sapiens	123-126
7608852-8	1994	Likewise, the intraepithelial deposit of CsA in the GO region was found to be related to the inflammatory infiltrate CD4+, CD8+, and CD68+ (r = 0.7432; r = 0.7346; r = 0.77005, respectively).	Cyclosporine	41-44	CD68 molecule	Homo sapiens	133-137
7911489-4	1994	However, the induction of the IL-3, IL-4, and GM-CSF genes, but not the IL-5, IL-6, and IL-10 genes, was strongly inhibited by cyclosporin A.	Cyclosporine	127-140	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	46-52
8197205-1	1994	The crystal structure of a complex between recombinant human cyclophilin B (CypB) and a cyclosporin A (CsA) analog has been determined and refined at 1.85-A resolution to a crystallographic R factor of 16.0%.	Cyclosporine	103-106	peptidylprolyl isomerase B	Homo sapiens	61-74
8197205-1	1994	The crystal structure of a complex between recombinant human cyclophilin B (CypB) and a cyclosporin A (CsA) analog has been determined and refined at 1.85-A resolution to a crystallographic R factor of 16.0%.	Cyclosporine	103-106	peptidylprolyl isomerase B	Homo sapiens	76-80
8197205-3	1994	The CsA-binding pocket in CypB has the same structure as in CypA and cyclosporin shows a similar bound conformation and network of interactions in both CypB and CypA complexes.	Cyclosporine	4-7	peptidylprolyl isomerase B	Homo sapiens	26-30
8197205-3	1994	The CsA-binding pocket in CypB has the same structure as in CypA and cyclosporin shows a similar bound conformation and network of interactions in both CypB and CypA complexes.	Cyclosporine	4-7	peptidylprolyl isomerase B	Homo sapiens	152-156
8197205-3	1994	The CsA-binding pocket in CypB has the same structure as in CypA and cyclosporin shows a similar bound conformation and network of interactions in both CypB and CypA complexes.	Cyclosporine	69-80	peptidylprolyl isomerase B	Homo sapiens	26-30
8197205-3	1994	The CsA-binding pocket in CypB has the same structure as in CypA and cyclosporin shows a similar bound conformation and network of interactions in both CypB and CypA complexes.	Cyclosporine	69-80	peptidylprolyl isomerase B	Homo sapiens	152-156
8172879-3	1994	We wished to determine if Ser939/941 is also important for efficient interaction of P-gp with structurally different modulating agents, a cyclic peptide (cyclosporin A, CsA), a diaminoquinazoline (CP100356), and a chiral, tricyclic structure (CP117227).	Cyclosporine	154-167	phosphoglycolate phosphatase	Mus musculus	84-88
8184875-5	1994	Following in vivo treatment with cyclosporin peripheral blood CD4/CD8 ratios returned to normal.	Cyclosporine	33-44	CD8a molecule	Homo sapiens	66-69
8050549-6	1994	Pretreatment of the guinea-pigs with cyclosporin or betamethasone elicited a marked inhibition of the accumulation of eosinophils in the peribronchial area induced by aerosolized PAF (100 micrograms.ml-1) or LTB4 (5 micrograms.ml-1).	Cyclosporine	37-48	prostaglandin reductase 1	Cavia porcellus	208-212
8050549-8	1994	However, cyclosporin and betamethasone may also reduce the chemotactic activity of PAF and LTB4 on guinea-pig eosinophils.	Cyclosporine	9-20	prostaglandin reductase 1	Cavia porcellus	91-95
8071057-10	1994	It can be concluded that corticosteroids show another inhibition pattern than CsA: corticosteroids affect mainly TH2-type T-cells, while CsA primarily inhibits the TH1-type T-cell response.	Cyclosporine	137-140	negative elongation factor complex member C/D	Homo sapiens	164-167
8082644-1	1994	Cyclophilins are a class of enzymes that are thought to be involved in protein folding by accelerating the isomerization of Xaa-Pro peptide bonds and that mediate the immunosuppressive effect of cyclosporin A.	Cyclosporine	195-208	peptidylprolyl isomerase B	Mus musculus	0-12
8206106-9	1994	In rats injected with complete Freund"s adjuvant or its vehicle, sympathetic denervation of submaxillary lymph nodes achieved by unilateral superior cervical ganglionectomy, augmented the stimulatory activity of cyclosporine on choline acetyltransferase and neuronal choline uptake.	Cyclosporine	212-224	choline O-acetyltransferase	Rattus norvegicus	228-253
7912496-4	1994	Both cyclosporin A and rhodamine inhibited photoaffinity labeling of immunoprecipitated P-glycoprotein with azidopine, indicating binding to hepatic P-glycoprotein.	Cyclosporine	5-18	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	88-102
7912496-4	1994	Both cyclosporin A and rhodamine inhibited photoaffinity labeling of immunoprecipitated P-glycoprotein with azidopine, indicating binding to hepatic P-glycoprotein.	Cyclosporine	5-18	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	149-163
8196271-9	1994	CsA at this dose caused a reduced GFR (0.29 ml/min/100 g) and an increased urinary NAG (20 IU/gCr) (P &lt; 0.01 vs. control for both).	Cyclosporine	0-3	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	94-97
8114793-6	1994	Cells expressing CD4 and CD8 antigens were observed in the injected muscles of mice treated with CsA alone.	Cyclosporine	97-100	CD4 antigen	Mus musculus	17-20
7887301-4	1994	The activation of calcineurin and the nuclear import of NF-ATc can both be blocked by cyclosporin A or FK506 in complex with their respective immunophilins.	Cyclosporine	86-99	nuclear factor of activated T cells 1	Homo sapiens	56-62
7987977-14	1994	The action of cyclosporine and S 9788 on the retention of daunorubicinol proves that at least a part of the efflux of C-13 alcohol metabolites of anthracyclines is mediated by Pgp.	Cyclosporine	14-26	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	176-179
7987977-15	1994	This study shows that S 9788, cyclosporine, and verapamil are MDR modulators in hepatocytes with high-level Pgp expression.	Cyclosporine	30-42	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	108-111
7800215-0	1994	Prevention of acute cyclosporin nephrotoxicity by verapamil and atrial natriuretic factor in the rat.	Cyclosporine	20-31	natriuretic peptide A	Rattus norvegicus	64-89
7800215-3	1994	The present experimental study investigates whether verapamil or atrial natriuretic factor (ANF) are able to prevent the nephrotoxicity of CsA.	Cyclosporine	139-142	natriuretic peptide A	Rattus norvegicus	65-90
7800215-3	1994	The present experimental study investigates whether verapamil or atrial natriuretic factor (ANF) are able to prevent the nephrotoxicity of CsA.	Cyclosporine	139-142	natriuretic peptide A	Rattus norvegicus	92-95
8125519-10	1993	Treatment of infected mice with cyclosporin A ablates antigen-specific IL-9 production when tested in vitro without affecting its production after polyclonal T cell stimulation.	Cyclosporine	32-45	interleukin 9	Mus musculus	71-75
7510323-7	1993	Overexpression of CNA1 or CNA2, in conjunction with CNB1, results in a significant decrease in hypersensitivity to FK506 and CsA.	Cyclosporine	125-128	calcineurin regulatory subunit B	Saccharomyces cerevisiae S288C	52-56
7504660-0	1993	The in vitro action of FK 565, bleomycin and cyclosporin A on different cell populations, with respect to the release of GM-CSF in the mouse.	Cyclosporine	45-58	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	121-127
7504660-1	1993	The experimental immunostimulatory tripeptide FK 565, the anti-tumor antibiotic Bleomycin and the immunosuppressive agent Cyclosporin A were examined for their in vitro effects on granulocyte-macrophage colony stimulating factor (GM-CSF) production utilizing different cell populations from three distinct murine stains.	Cyclosporine	122-135	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	180-228
7504660-5	1993	Cyclosporin A was found to inhibit the release of GM-CSF from BALB/c mice, however, no effect was observed in either "nude" or "Scid" mice.	Cyclosporine	0-13	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	50-56
8105783-0	1993	Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter, P-glycoprotein.	Cyclosporine	24-37	phosphoglycolate phosphatase	Bos taurus	97-111
8105783-4	1993	The uptake of CsA by primary cultured bovine BCEC was time-dependent, and the steady-state uptake of CsA was increased in the presence of several multidrug resistance reversing agents including verapamil and steroid hormones and the substrate of P-gp in BCEC, vincristine.	Cyclosporine	14-17	phosphoglycolate phosphatase	Bos taurus	246-250
8105783-4	1993	The uptake of CsA by primary cultured bovine BCEC was time-dependent, and the steady-state uptake of CsA was increased in the presence of several multidrug resistance reversing agents including verapamil and steroid hormones and the substrate of P-gp in BCEC, vincristine.	Cyclosporine	101-104	phosphoglycolate phosphatase	Bos taurus	246-250
8105783-6	1993	Furthermore, in the presence of an anti-P-gp monoclonal antibody, MRK16, at a 10 micrograms/mL concentration, the uptake of CsA was increased approximately 3-fold.	Cyclosporine	124-127	phosphoglycolate phosphatase	Bos taurus	40-44
8105783-7	1993	These results suggest that the low permeability of CsA into the brain is caused by the active efflux from BCEC by P-gp present in the luminal surface of cells.	Cyclosporine	51-54	phosphoglycolate phosphatase	Bos taurus	114-118
7691894-9	1993	CONCLUSIONS: Persistence of epidermal staining for CD 54 in psoriasis is compatible with a good clinical response to cyclosporin.	Cyclosporine	117-128	intercellular adhesion molecule 1	Homo sapiens	51-56
8513493-3	1993	Cyclosporin A efficiently disrupts the Gag-CyPA interaction and less efficiently disrupts the Gag-CyPB interaction.	Cyclosporine	0-13	peptidylprolyl isomerase B	Homo sapiens	98-102
8500270-0	1993	In vivo and in vitro suppression of T-cell receptor alpha/beta CD4- CD8- T lymphocytes by cyclosporine A.	Cyclosporine	90-104	CD8a molecule	Homo sapiens	68-71
8500270-6	1993	CsA also inhibited the cytolytic activity and cytokine production of in vitro cultured TCR alpha/beta+ CD4- CD8- cell lines.	Cyclosporine	0-3	CD8a molecule	Homo sapiens	108-111
8500270-7	1993	Our data suggest that alleviation of the patient"s clinical symptoms resulted from cyclosporine-mediated suppression of proliferation, cytotoxicity, and inflammatory cytokine production of TCR alpha/beta+ CD4- CD8- T lymphocytes in vivo.	Cyclosporine	83-95	CD8a molecule	Homo sapiens	210-213
7680897-8	1993	Cyclosporin A inhibited ionomycin-induced T cell CD7 upregulation at the level of CD7 mRNA transcription and elongation.	Cyclosporine	0-13	CD7 molecule	Homo sapiens	49-52
7680897-8	1993	Cyclosporin A inhibited ionomycin-induced T cell CD7 upregulation at the level of CD7 mRNA transcription and elongation.	Cyclosporine	0-13	CD7 molecule	Homo sapiens	82-85
8428779-0	1993	Atrial natriuretic peptide blunts the cellular effects of cyclosporine in smooth muscle.	Cyclosporine	58-70	natriuretic peptide A	Rattus norvegicus	0-26
8428779-8	1993	ANP (5 x 10(-9) M) blocked the Ca2+ mobilization by angiotensin II (71 +/- 7 versus 69 +/- 7 nM, NS) and also completely inhibited the effect of angiotensin II in the presence of cyclosporine (77 +/- 5 versus 78 +/- 5 nM, NS).	Cyclosporine	179-191	natriuretic peptide A	Rattus norvegicus	0-3
7511004-11	1993	Flow cytometric analysis of peripheral blood cells prior to treatment with Cyclosporin-A showed systemic activation of lymphocytes, with high levels of HLA-DR and CD25 expression and a raised CD4/CD8 ratio.	Cyclosporine	75-88	CD8a molecule	Homo sapiens	196-199
7678231-14	1993	As reported for IL-2R and IL-4R, our data also show that the expression of another T cell growth factor receptor is sensitive to the effects of cyclosporin A and FK506.	Cyclosporine	144-157	interleukin 4 receptor	Homo sapiens	26-31
8188457-0	1993	Effect of cyclosporin on the activity of cytidine deaminase and adenosine deaminase in the serum and polymorphonuclear leukocytes of patients with rheumatoid arthritis.	Cyclosporine	10-21	adenosine deaminase	Homo sapiens	64-83
1450403-9	1992	Cyclosporine A inhibited the A23187- and Con A + A23187-induced IL-4R mRNA accumulation, whereas Con A-, PMA-, and Con A + PMA-induced IL-4R mRNA expression was not affected by this drug.	Cyclosporine	0-14	interleukin 4 receptor	Homo sapiens	64-69
1336994-0	1992	Prolactin and prolactin secretagogues reverse immunosuppression in mice treated with cysteamine, glucocorticoids, or cyclosporin-A.	Cyclosporine	117-130	prolactin	Mus musculus	0-9
1336994-0	1992	Prolactin and prolactin secretagogues reverse immunosuppression in mice treated with cysteamine, glucocorticoids, or cyclosporin-A.	Cyclosporine	117-130	prolactin	Mus musculus	14-23
1362075-5	1992	CyA modulates the UV irradiation-induced changes by: (i) inhibiting the UVB- and PUVA-induced ICAM-1 expression by keratinocytes and (ii) suppressing the PUVA-induced upregulation of CD11a expression by macrophages (72 +/- 12% of Ki-M8+ macrophages express CD11a with PUVA, compared with 20 +/- 5% with CyA + PUVA, P &lt; 0.001).	Cyclosporine	0-3	intercellular adhesion molecule 1	Homo sapiens	94-100
1334967-4	1992	Moreover, CsA inhibited the arthritis-induced increases in pituitary POMC and IL-6 mRNA levels and in circulating ACTH and B.	Cyclosporine	10-13	proopiomelanocortin	Rattus norvegicus	69-73
1334967-5	1992	In vitro, CsA reduced the POMC mRNA content of cultured anterior pituitary cells and diminished the stimulatory effects of corticotropin-releasing hormone (CRH) on POMC mRNA expression and ACTH secretion from these cells.	Cyclosporine	10-13	proopiomelanocortin	Rattus norvegicus	26-30
1334967-5	1992	In vitro, CsA reduced the POMC mRNA content of cultured anterior pituitary cells and diminished the stimulatory effects of corticotropin-releasing hormone (CRH) on POMC mRNA expression and ACTH secretion from these cells.	Cyclosporine	10-13	proopiomelanocortin	Rattus norvegicus	164-168
1280373-2	1992	CS administration (15 milligrams, twice a day) for 14 days caused a significant increase in serum amylase levels, pancreatic amylase and cathepsin B content and mild acinar cell vacuolization and interstitial edema.	Cyclosporine	0-2	amylase 2a3	Rattus norvegicus	114-132
1449518-2	1992	Cyclosporin A (CsA) is a potent inhibitor of the prooxidant-induced release of Ca2+ from isolated mitochondria.	Cyclosporine	15-18	carbonic anhydrase 2	Homo sapiens	79-82
1440857-7	1992	During CsA treatment murine liver can increase its CypA content much more than spleen.	Cyclosporine	7-10	peptidylprolyl isomerase A	Mus musculus	51-55
1440857-8	1992	In summary, we demonstrated that cells known to be resistant to the effects of CsA have high levels of CypA.	Cyclosporine	79-82	peptidylprolyl isomerase A	Mus musculus	103-107
1440857-10	1992	Taken together these results suggest that CypA plays a role in cell cycle progression and that sensitivity to CsA may not be simply a reflection of the baseline CypA levels, but may also be affected by the regulation of these levels.	Cyclosporine	110-113	peptidylprolyl isomerase A	Mus musculus	161-165
1440857-11	1992	Further work is needed in order to delineate the role of CypA in the cell cycle and its relation to the action of CsA.	Cyclosporine	114-117	peptidylprolyl isomerase A	Mus musculus	57-61
1452414-15	1992	Concurrently, anti-CD3-induced increases in the percentage of CD4+ and CD8+ cells cycling were inhibited by CsA.	Cyclosporine	108-111	CD4 antigen	Mus musculus	62-65
1394118-5	1992	The calmodulin antagonist cyclosporine A, which does not suppress PKC activity, very effectively inhibits the TPA-induced edema and down regulation of PKC.	Cyclosporine	26-40	calmodulin 2	Mus musculus	4-14
1432999-0	1992	Cyclosporine and chloroquine synergistically inhibit the interferon-gamma production by CD4 positive and CD8 positive synovial T cell clones derived from a patient with rheumatoid arthritis.	Cyclosporine	0-12	CD8a molecule	Homo sapiens	105-108
1620122-5	1992	In a T-cell clone specific for pigeon cytochrome c in the context of I-Ek, Oct-2 was induced by antigen stimulation, with the increase in Oct-2 protein seen first at 3 h after activation and continuing for at least 24 h. Oct-2 mRNA induction during antigen-driven T-cell activation was blocked by cyclosporin A, as well as by protein synthesis inhibitors.	Cyclosporine	297-310	POU class 2 homeobox 2	Homo sapiens	75-80
1620122-5	1992	In a T-cell clone specific for pigeon cytochrome c in the context of I-Ek, Oct-2 was induced by antigen stimulation, with the increase in Oct-2 protein seen first at 3 h after activation and continuing for at least 24 h. Oct-2 mRNA induction during antigen-driven T-cell activation was blocked by cyclosporin A, as well as by protein synthesis inhibitors.	Cyclosporine	297-310	POU class 2 homeobox 2	Homo sapiens	138-143
1620122-5	1992	In a T-cell clone specific for pigeon cytochrome c in the context of I-Ek, Oct-2 was induced by antigen stimulation, with the increase in Oct-2 protein seen first at 3 h after activation and continuing for at least 24 h. Oct-2 mRNA induction during antigen-driven T-cell activation was blocked by cyclosporin A, as well as by protein synthesis inhibitors.	Cyclosporine	297-310	POU class 2 homeobox 2	Homo sapiens	138-143
1586749-4	1992	In seven consecutive minor ABO-incompatible unrelated-donor bone marrow transplant recipients receiving cyclosporine without posttransplant methotrexate, we observed excessive hemolysis.	Cyclosporine	104-116	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	27-30
1350608-0	1992	CD4 antibody therapy and cyclosporin A differentially affect HLA-DR and ICAM-1 expression in psoriatic skin.	Cyclosporine	25-38	intercellular adhesion molecule 1	Homo sapiens	72-78
1534319-0	1992	Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity.	Cyclosporine	60-72	host cell factor C1	Homo sapiens	100-105
1534319-1	1992	Cyclosporin A reverses multidrug resistance (MDR) and increases the in vivo cytostatic activity and toxicity of the anticancer agent etoposide (VP 16-213).	Cyclosporine	0-13	host cell factor C1	Homo sapiens	144-149
1533441-8	1992	On the basis of binding, reconstitution and cotransfection experiments, we propose that activation of NF-AT occurs in at least two stages: a CsA-sensitive stage involving modification and/or translocation of the pre-existing NF-AT complex, and a CsA-insensitive stage involving the addition of newly synthesized Fos or Fos/Jun proteins to the pre-existing complex.	Cyclosporine	141-144	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	312-315
1533441-8	1992	On the basis of binding, reconstitution and cotransfection experiments, we propose that activation of NF-AT occurs in at least two stages: a CsA-sensitive stage involving modification and/or translocation of the pre-existing NF-AT complex, and a CsA-insensitive stage involving the addition of newly synthesized Fos or Fos/Jun proteins to the pre-existing complex.	Cyclosporine	141-144	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	319-322
1349283-4	1992	This increased expression of P-gp was associated with decreased intracellular retention of doxorubicin, which could be restored by compounds such as verapamil and cyclosporin; doxorubicin (and also vincristine) was more cytotoxic to early than to late cultures.	Cyclosporine	163-174	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	29-33
1565646-3	1992	Surprisingly, N-terminal sequencing and tryptic mapping studies revealed that sp18 and cyclophilin, an intracellular protein that binds the immunosuppressive drug cyclosporin A, are highly homologous.	Cyclosporine	163-176	peptidylprolyl isomerase A	Mus musculus	78-82
1565646-4	1992	The in vitro chemotactic activity of sp18 on monocytes was blocked by cyclosporin A but not by cyclosporin H, a structural analog of cyclosporin A that does not bind cyclophilin.	Cyclosporine	70-83	peptidylprolyl isomerase A	Mus musculus	37-41
1565646-7	1992	The observation that sp18/cyclophilin exhibits proinflammatory activity and is secreted by macrophages in response to endotoxin suggests that this protein may function as a cytokine, and invites the hypothesis that the immunosuppressive action of cyclosporin A results in part from interaction with an extracellular form of cyclophilin released as a mediator of immune and inflammatory functions.	Cyclosporine	247-260	peptidylprolyl isomerase A	Mus musculus	21-25
1371950-1	1992	Cyclosporin A (CsA) was tested for its modulatory effects on the mIgM-mediated signaling of G0*-associated increases in class II MHC expression, G1-related RNA synthesis, and S phase-related DNA synthesis in human B cells.	Cyclosporine	15-18	major histocompatibility complex, class I, C	Homo sapiens	129-132
1557689-0	1992	Effects of cyclosporine on insulin secretion and insulin sensitivity in dogs with intrasplenic islet autotransplants.	Cyclosporine	11-23	insulin	Canis lupus familiaris	27-34
1819724-0	1991	Nephrotoxicity of cyclosporine: the role of platelet-activating factor and thromboxane.	Cyclosporine	18-30	PCNA clamp associated factor	Rattus norvegicus	44-70
1721312-0	1991	FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line.	Cyclosporine	23-35	interleukin 10	Homo sapiens	57-62
1674801-0	1991	Epidermal ICAM-1 in psoriasis after long-term cyclosporin.	Cyclosporine	46-57	intercellular adhesion molecule 1	Homo sapiens	10-16
2045675-1	1991	The inhibitory effect of cyclosporine A (CsA) on the activity of ornithine decarboxylase (ODC) induced by phorbol ester tumor promoter has been reported.	Cyclosporine	41-44	ornithine decarboxylase, structural 1	Mus musculus	65-88
2045675-1	1991	The inhibitory effect of cyclosporine A (CsA) on the activity of ornithine decarboxylase (ODC) induced by phorbol ester tumor promoter has been reported.	Cyclosporine	41-44	ornithine decarboxylase, structural 1	Mus musculus	90-93
2045675-2	1991	In the present study, the effects of CsA on ODC activity induced by ultraviolet-B (UV-B) and PUVA in the skin of the SKH/hr 1 hairless mouse were investigated.	Cyclosporine	37-40	ornithine decarboxylase, structural 1	Mus musculus	44-47
2045675-4	1991	On the other hand, if CsA was applied simultaneously with 3 J/cm2 UV-A 1 h after treatment with 0.3% 8-methoxypsoralen, PUVA-induced ODC activity was suppressed by about 60% at 12 and 24 h after UV-A irradiation.	Cyclosporine	22-25	ornithine decarboxylase, structural 1	Mus musculus	133-136
2045675-6	1991	The inhibition of PUVA-induced ODC activity by CsA may have been caused in part by the decrease in ODC mRNA level and in part by a post-transcriptional regulation mechanism.	Cyclosporine	47-50	ornithine decarboxylase, structural 1	Mus musculus	31-34
2045675-6	1991	The inhibition of PUVA-induced ODC activity by CsA may have been caused in part by the decrease in ODC mRNA level and in part by a post-transcriptional regulation mechanism.	Cyclosporine	47-50	ornithine decarboxylase, structural 1	Mus musculus	99-102
1904494-0	1991	HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.	Cyclosporine	57-71	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	0-17
2015706-10	1991	CsA treatment produced marked clinical improvement, accompanied by the loss of CD54 expression on keratinocytes.	Cyclosporine	0-3	intercellular adhesion molecule 1	Homo sapiens	79-83
1706598-0	1991	Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase.	Cyclosporine	22-35	peptidylprolyl isomerase like 1	Homo sapiens	103-138
1706598-2	1991	The Ki values of cyclosporins A, G and H for the peptidyl-prolyl cis-trans isomerase (PPIase) of liver and heart mitochondria are about 2, 20 and 500 nM respectively.	Cyclosporine	17-31	peptidylprolyl isomerase like 1	Homo sapiens	49-84
1706598-2	1991	The Ki values of cyclosporins A, G and H for the peptidyl-prolyl cis-trans isomerase (PPIase) of liver and heart mitochondria are about 2, 20 and 500 nM respectively.	Cyclosporine	17-31	peptidylprolyl isomerase like 1	Homo sapiens	86-92
2000394-5	1991	Moreover, we show that hCyPB is a peptidyl-prolyl cis-trans isomerase which can be inhibited by cyclosporin A.	Cyclosporine	96-109	peptidylprolyl isomerase B	Homo sapiens	23-28
2000394-9	1991	Northern blot analyses show that hCyPB mRNA is expressed in the Jurkat T-cell line, consistent with its possible target role in cyclosporin A-mediated immunosuppression.	Cyclosporine	128-141	peptidylprolyl isomerase B	Homo sapiens	33-38
1848730-0	1991	Decrease in endothelial cell-dependent protein C activation induced by thrombomodulin by treatment with cyclosporine.	Cyclosporine	104-116	thrombomodulin	Bos taurus	71-85
1848730-2	1991	To explore possible mechanisms involved, we examined the effects of CSA on the activation of protein C by thrombomodulin.	Cyclosporine	68-71	thrombomodulin	Bos taurus	106-120
1848730-5	1991	As compared to control, a significant fall in thrombomodulin activity occurred after 24-hr incubation with 100 (70.8 +/- 15.8%, P less than 0.05), 1000 (64.9 +/- 16.6%, P less than 0.05), or 10,000 (28.9 +/- 12.3%, P less than 0.05) ng/ml of CSA.	Cyclosporine	242-245	thrombomodulin	Bos taurus	46-60
1848730-6	1991	A comparable inhibition of thrombomodulin activity was also observed in cultured renal artery endothelial cells (67.5 +/- 12.6%, P less than 0.05), after 24-hr incubation with 5000 ng/ml CSA.	Cyclosporine	187-190	thrombomodulin	Bos taurus	27-41
1848730-7	1991	In cells incubated with 5000 ng/ml of CSA for 4 hr, thrombomodulin activity fell by almost 15% (85.6 +/- 8.3%, P less than 0.05) and tended to plateau between 7 hr (73.8 +/- 12.7%, P less than 0.05), and 24 hr of incubation (72.7 +/- 8.9%, P less than 0.05).	Cyclosporine	38-41	thrombomodulin	Bos taurus	52-66
1848730-8	1991	These results indicate that CSA produces a time- and dose-dependent reduction in thrombomodulin activity of cultured endothelial cells, downregulating the protein C anticoagulant pathway, thereby increasing the risk of thrombosis.	Cyclosporine	28-31	thrombomodulin	Bos taurus	81-95
1671051-7	1991	Although cyclosporin A inhibited CD4 cells to fragment target DNA during the early phase (90 min) of E:T interaction, this inhibition was not sustained in the later phase (210 min) of the assay.	Cyclosporine	9-22	CD4 antigen	Mus musculus	33-36
9779838-0	1998	Circulating levels of interleukin 10 and other cytokines in rheumatoid arthritis treated with cyclosporin A or combination therapy.	Cyclosporine	94-107	interleukin 10	Homo sapiens	22-36
9779838-11	1998	CONCLUSION: During treatment with either CyA or CyA plus hydroxychloroquine, IL-10 levels decreased significantly.	Cyclosporine	41-44	interleukin 10	Homo sapiens	77-82
9779838-11	1998	CONCLUSION: During treatment with either CyA or CyA plus hydroxychloroquine, IL-10 levels decreased significantly.	Cyclosporine	48-51	interleukin 10	Homo sapiens	77-82
33627489-7	2021	Retrospective study of 247 patients who were diagnosed with kidney damage receiving cyclosporine or cisplatin in combination with the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin showed significant (P < 0.001) improvement of kidney function, as well as reduction in creatinine and uric acid, markers of kidney damage.	Cyclosporine	84-96	solute carrier family 5 member 2	Homo sapiens	134-164
32905741-3	2020	RESULTS: A significant increase was observed in CD2AP, ACTN4, podocin and also MMP9 and 2, cystatin C levels in the cyclosporine A group following treatment for four weeks, whereas a decrease was found in nephrin gene expression than the control group.	Cyclosporine	116-130	cystatin C	Rattus norvegicus	91-101
32905741-3	2020	RESULTS: A significant increase was observed in CD2AP, ACTN4, podocin and also MMP9 and 2, cystatin C levels in the cyclosporine A group following treatment for four weeks, whereas a decrease was found in nephrin gene expression than the control group.	Cyclosporine	116-130	NPHS1 adhesion molecule, nephrin	Rattus norvegicus	205-212
33330573-0	2020	Case Report: Treatment of Anti-MDA5-Positive Amyopathic Dermatomyositis Accompanied by a Rapidly Progressive Interstitial Lung Diseases With Methylprednisolone Pulse Therapy Combined With Cyclosporine A and Hydroxychloroquine.	Cyclosporine	188-202	interferon induced with helicase C domain 1	Homo sapiens	31-35
33046783-7	2020	In mitochondrial suspensions, bisindolylpyrrole triggered CsA-sensitive swelling, which was suppressed selectively by pretreatment with PKCepsilon, but not in the co-presence of tubulin.	Cyclosporine	58-61	protein kinase C epsilon	Homo sapiens	136-146
32739890-1	2020	This drug-drug interaction (DDI) study determined the effect of cyclosporine, an inhibitor of OATP1B3 and P-gp, on the pharmacokinetics (PK) of fevipiprant, an oral, highly selective, competitive antagonist of the prostaglandin D2 receptor 2 and a substrate of the two transporters.	Cyclosporine	64-76	phosphoglycolate phosphatase	Homo sapiens	106-110
32449990-0	2020	Galectin-8 mediates fibrogenesis induced by cyclosporine in human gingival fibroblasts.	Cyclosporine	44-56	galectin 8	Homo sapiens	0-10
32449990-3	2020	Here, we study the role of galectin-8 (Gal-8) in the response of gingival connective tissue cells to cyclosporine.	Cyclosporine	101-113	galectin 8	Homo sapiens	27-37
9800954-8	1998	In mixed lymphocyte cultures performed with peripheral blood mononuclear cells (PBMC) from normal subjects, IL-10 decreased the cell proliferation in a dose-dependent manner, and this immunosuppression was synergistic with that of cyclosporine or FK506.	Cyclosporine	231-243	interleukin 10	Homo sapiens	108-113
32449990-3	2020	Here, we study the role of galectin-8 (Gal-8) in the response of gingival connective tissue cells to cyclosporine.	Cyclosporine	101-113	galectin 8	Homo sapiens	39-44
32449990-8	2020	Cyclosporine and tumor necrosis factor alpha (TNF-alpha) increased Gal-8 protein levels.	Cyclosporine	0-12	galectin 8	Homo sapiens	67-72
9800954-10	1998	Thus, IL-10 therapy in association with cyclosporine or FK506 might be proposed after liver transplantation.	Cyclosporine	40-52	interleukin 10	Homo sapiens	6-11
32449990-9	2020	Finally, silencing of galectin-8 in NIH3T3 cells abolished cyclosporine-induced fibronectin protein levels.	Cyclosporine	59-71	fibronectin 1	Mus musculus	80-91
32449990-10	2020	CONCLUSION: Taken together, these results reveal for the first time Gal-8 as a fibrogenic stimulus exerted through beta1-integrin/FAK pathways in human gingival fibroblasts, which can be triggered by cyclosporine.	Cyclosporine	200-212	galectin 8	Homo sapiens	68-73
9751629-11	1998	This resistance is reversible by the Pgp-reversing agents cyclosporin A, PSC833, and verapamil, suggesting a conservation in some functions of Pgps across large evolutionary distance.	Cyclosporine	58-71	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	37-40
9734605-11	1998	In contrast, the expression of tissue inhibitor of matrix metalloproteinase type 1 (TIMP-1) was significantly increased after CsA treatment.	Cyclosporine	126-129	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	31-82
32236695-7	2020	Unexpectedly, the whole blood-based protocol that uses additional alpha-CD49d co-stimulation was less susceptible to CsA and prednisolone despite prolonged drug exposure in the test tube.	Cyclosporine	117-120	integrin subunit alpha 4	Homo sapiens	72-77
9734605-11	1998	In contrast, the expression of tissue inhibitor of matrix metalloproteinase type 1 (TIMP-1) was significantly increased after CsA treatment.	Cyclosporine	126-129	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	84-90
9734605-13	1998	ISH of selected renal sections of CsA-treated rats identified the cells responsible for the increased TIMP-1 message transcription after CsA administration, mainly as interstitial cells and also as visceral and parietal epithelial cells.	Cyclosporine	34-37	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	102-108
9734605-13	1998	ISH of selected renal sections of CsA-treated rats identified the cells responsible for the increased TIMP-1 message transcription after CsA administration, mainly as interstitial cells and also as visceral and parietal epithelial cells.	Cyclosporine	137-140	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	102-108
9734605-14	1998	CONCLUSIONS: These results suggest that the locally increased expression of TIMP-1 rather than a decrease of matrix metalloprotease expression, contributes to the development of CsA-induced focal interstitial fibrosis in the rat.	Cyclosporine	178-181	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	76-82
32569592-0	2020	Cyclosporine a induces testicular injury via mitochondrial apoptotic pathway by regulation of mir-34a and sirt-1 in male rats: The rescue effect of curcumin.	Cyclosporine	0-14	microRNA 34a	Rattus norvegicus	94-101
32569592-3	2020	The present study aimed to characterize the role of mir-34a/sirt-1 in CsA induced testicular injury alone or in combination with curcumin.	Cyclosporine	70-73	microRNA 34a	Rattus norvegicus	52-59
32569592-9	2020	In addition, exposure to CsA resulted in an increased expression of Bax, and a decreased expresion in that of Bcl-2, with a concomitant up-regulation of the Bax/Bcl-2, c-Caspase-3/p-Caspase-3 ratio and cytochrome c level.	Cyclosporine	25-28	BCL2 associated X, apoptosis regulator	Rattus norvegicus	68-71
9705263-5	1998	In single-cycle infection assays, nef-defective virions were partially resistant to cyclosporin A (CsA), a drug that inhibits the binding of CyPA to the HIV-1 Gag precursor and CyPA incorporation into virions.	Cyclosporine	99-102	Nef	Human immunodeficiency virus 1	34-37
32569592-9	2020	In addition, exposure to CsA resulted in an increased expression of Bax, and a decreased expresion in that of Bcl-2, with a concomitant up-regulation of the Bax/Bcl-2, c-Caspase-3/p-Caspase-3 ratio and cytochrome c level.	Cyclosporine	25-28	BCL2 associated X, apoptosis regulator	Rattus norvegicus	157-160
32569592-10	2020	Meanwhile, exposure to CsA increased the expression of mir-34a and decreased sirt-1 protein level in the testis tissue samples compared to the control group.	Cyclosporine	23-26	microRNA 34a	Rattus norvegicus	55-62
9705263-10	1998	They further suggest that in addition to blocking the CyPA-Gag interaction, CsA can also inhibit HIV-1 replication through a novel mechanism involving suppression of Nef-directed enhancement of virus infectivity.	Cyclosporine	76-79	Nef	Human immunodeficiency virus 1	166-169
9723952-14	1998	[11C]verapamil accumulation in the brain of mdr1a(+/+) mice was increased by cyclosporin A to levels comparable with those in mdr1a(-/-) mice, indicating that reversal of P-gp mediated efflux can be monitored by PET.	Cyclosporine	77-90	phosphoglycolate phosphatase	Mus musculus	171-175
9723952-16	1998	We conclude that cyclosporin A can fully block the P-gp function in the blood brain barrier and the testes and that PET enables the in vivo measurement of P-gp function and reversal of its function non-invasively.	Cyclosporine	17-30	phosphoglycolate phosphatase	Mus musculus	51-55
32787951-11	2020	DHMEQ treatment also had an inhibitory effect on the increased expression of chemokines, monocyte chemoattractant protein-1, and chemokine (c-c motif) ligand 5 due to repeated CsA administration, which inhibited the infiltration of macrophages and neutrophils into the renal tissue.	Cyclosporine	176-179	C-C motif chemokine ligand 2	Rattus norvegicus	89-123
32422433-4	2020	Application of drugs that target either calcineurin (cyclosporine A) or FKBP12 (tacrolimus known as FK506 and sirolimus known as rapamycin) caused a decrease in TMEM16A activity.	Cyclosporine	53-67	anoctamin 1	Homo sapiens	161-168
32422433-7	2020	Rapamycin decreased TMEM16A activity in cells pre-treated with cyclosporine A or FK506.	Cyclosporine	63-77	anoctamin 1	Homo sapiens	20-27
9723955-13	1998	Cyclosporin A significantly stimulated RANTES production at 10(-6) M and IL-8 production at 10(-7) M and 10(-6) M. 5.	Cyclosporine	0-13	C-C motif chemokine ligand 5	Homo sapiens	39-45
9723510-0	1998	Cyclosporine A is associated with a shift of the Th1/Th2 balance in liver transplant patients.	Cyclosporine	0-14	negative elongation factor complex member C/D	Homo sapiens	49-52
32655650-5	2020	Aquaporin-2 (AQP2) protein expression decreased in cyclosporine-treated rat kidneys (cortex, 78+-8%, p<0.05; medulla, 80+-1%, p<0.05).	Cyclosporine	51-63	aquaporin 2	Rattus norvegicus	0-11
32655650-5	2020	Aquaporin-2 (AQP2) protein expression decreased in cyclosporine-treated rat kidneys (cortex, 78+-8%, p<0.05; medulla, 80+-1%, p<0.05).	Cyclosporine	51-63	aquaporin 2	Rattus norvegicus	13-17
32655650-9	2020	In both Experiment I and II, GLUT2 protein expression in the renal cortex was decreased by cyclosporine treatment (Experiment I, 55+-6%, p<0.005; Experiment II, 88+-3%, p<0.05).	Cyclosporine	91-103	solute carrier family 2 member 2	Rattus norvegicus	29-34
32595898-0	2020	The regulation of Oct4 in human gingival fibroblasts stimulated by cyclosporine A: Preliminary observations.	Cyclosporine	67-81	POU class 5 homeobox 1	Homo sapiens	18-22
9618535-7	1998	The VirD2-cyclophilin interaction is disrupted in vitro by cyclosporin A, which also inhibits Agrobacterium-mediated transformation of Arabidopsis and tobacco.	Cyclosporine	59-72	type IV secretion system T-DNA border endonuclease VirD2	Agrobacterium tumefaciens	4-9
32595898-3	2020	The aim of this study was to investigate the effects of CsA on the expression of Oct4 in cultured human gingival fibroblasts (HGFs) in vitro.	Cyclosporine	56-59	POU class 5 homeobox 1	Homo sapiens	81-85
32595898-4	2020	Materials and methods: The effects of CsA on HGFs were used to elucidate whether Oct4 expression could be induced by CsA by using quantitative real-time reverse transcription-polymerase chain reaction and western blot.	Cyclosporine	38-41	POU class 5 homeobox 1	Homo sapiens	81-85
32595898-4	2020	Materials and methods: The effects of CsA on HGFs were used to elucidate whether Oct4 expression could be induced by CsA by using quantitative real-time reverse transcription-polymerase chain reaction and western blot.	Cyclosporine	117-120	POU class 5 homeobox 1	Homo sapiens	81-85
32595898-5	2020	Cell growth in CsA-treated HGFs with Oct4 lentiviral-mediated shRNAi knockdown was evaluated by tetrazolium bromide reduction assay.	Cyclosporine	15-18	POU class 5 homeobox 1	Homo sapiens	37-41
9662091-11	1998	However, in the cyclosporine- and FK506-treated groups, the PCNA index in bronchial surface epithelium was suppressed to less than 5% at 3 and 5 days.	Cyclosporine	16-28	proliferating cell nuclear antigen	Rattus norvegicus	60-64
9636382-0	1998	Effect of cyclosporine and Sirolimus on interleukin-15-driven proliferation of OKT3-preactivated human lymphocytes.	Cyclosporine	10-22	interleukin 15	Homo sapiens	40-54
9603174-10	1998	Cyclosporine partially, but not completely, inhibits the development of CD30+ cells, and has a greater effect on interferon-gamma production than on interleukin-5 production.	Cyclosporine	0-12	TNF receptor superfamily member 8	Homo sapiens	72-76
32373541-8	2020	More importantly, HDFs pretreated with cyclosporine A or phenformin to induce ATF3 expression inhibited melanoma cell growth in vitro and in vivo.	Cyclosporine	39-53	activating transcription factor 3	Homo sapiens	78-82
32085719-10	2020	The expression of L. donovani cyclophilin A (LdCyPA) in promastigotes and intracellular amastigotes and the expression of cyclophilin A (CyPA) in RAW 264.7 cells were found to be significantly downregulated in the CsA-treated group compared to those in the untreated group.	Cyclosporine	214-217	cyclophilin a	Leishmania donovani	122-135
31963361-9	2020	The administration of cyclosporine A was followed by down-regulation of other genes: COL7A1, the transmembrane receptors ITGB2 and ITGB4, and the basement membrane constituents LAMA2 and LAMB1.	Cyclosporine	22-36	laminin subunit beta 1	Homo sapiens	187-192
31880466-7	2020	From the calculation results of PiA for the copolymer and PNIPAAm hydrogels, it was found that the high hydrophilic copolymer surface more significantly enhanced the ion effect of structure-making cations (i.e., Li+) compared with borderline (Na+) and structure-breaking (K+ and Cs+) cations.	Cyclosporine	279-281	RPTOR independent companion of MTOR complex 2	Homo sapiens	32-35
31634494-8	2020	The interruption of interaction between CypA and N protein by CsA and its derivatives suggest a mechanism how CypA inhibitors suppress viral replication.	Cyclosporine	62-65	peptidylprolyl isomerase A	Homo sapiens	40-44
31634494-8	2020	The interruption of interaction between CypA and N protein by CsA and its derivatives suggest a mechanism how CypA inhibitors suppress viral replication.	Cyclosporine	62-65	peptidylprolyl isomerase A	Homo sapiens	110-114
31631469-6	2019	The expression of TNF-alpha was downregulated during therapy, IL23A was upregulated during CsA treatment, while the expression of IFN-gamma and IL17 were higher after 42 days and lower after 84 days compared to 0 days of CsA treatment.	Cyclosporine	91-94	interleukin 23 subunit alpha	Homo sapiens	62-67
31446206-7	2019	Flow cytometry and qRT-PCR both demonstrated inhibition of IL-2 and IFN-gamma that was concentration-dependent in response to cyclosporine, and was more variable for dexamethasone.	Cyclosporine	126-138	interferon gamma	Canis lupus familiaris	68-77
31446206-10	2019	Suppression of IL-2 and IFN-gamma in activated T cells may have potential as an indicator of the efficacy of cyclosporine and glucocorticoids in suppressing canine T cell function in vivo, and may therefore be of value for characterizing the immunosuppression induced by these drugs in clinical patients.	Cyclosporine	109-121	interferon gamma	Canis lupus familiaris	24-33
30991038-7	2019	By contrast, the P-gp inhibitor cyclosporine A significantly increased intracellular concentration of rhodamine-123 and prothionamide (p &lt; 0.001 and 0.05, respectively).	Cyclosporine	32-46	phosphoglycolate phosphatase	Homo sapiens	17-21
31489369-4	2019	Liver mitochondria from Ant1, Ant2, and Ant4 deficient mice were highly refractory to Ca2+-induced MPTP formation, and when also given cyclosporine A (CsA), the MPTP was completely inhibited.	Cyclosporine	135-149	solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 4	Mus musculus	24-28
31489369-4	2019	Liver mitochondria from Ant1, Ant2, and Ant4 deficient mice were highly refractory to Ca2+-induced MPTP formation, and when also given cyclosporine A (CsA), the MPTP was completely inhibited.	Cyclosporine	151-154	solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 4	Mus musculus	24-28
31489369-5	2019	Moreover, liver mitochondria from mice with quadruple deletion of Ant1, Ant2, Ant4, and Ppif (cyclophilin D, target of CsA) lacked Ca2+-induced MPTP formation.	Cyclosporine	119-122	solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 4	Mus musculus	66-70
31109455-0	2019	Intracellular cholesterol stimulates ENaC by interacting with phosphatidylinositol-4,5-bisphosphate and mediates cyclosporine A-induced hypertension.	Cyclosporine	113-127	sodium channel, nonvoltage-gated 1 alpha	Mus musculus	37-41
31109455-1	2019	We have previously shown that blockade of ATP-binding cassette transporter A1 (ABCA1) with cyclosporine A (CsA) stimulates the epithelial sodium channel (ENaC) in cultured distal nephron cells.	Cyclosporine	91-105	sodium channel, nonvoltage-gated 1 alpha	Mus musculus	154-158
31109455-1	2019	We have previously shown that blockade of ATP-binding cassette transporter A1 (ABCA1) with cyclosporine A (CsA) stimulates the epithelial sodium channel (ENaC) in cultured distal nephron cells.	Cyclosporine	107-110	sodium channel, nonvoltage-gated 1 alpha	Mus musculus	154-158
31109455-9	2019	These data suggest that elevation of intracellular Cho due to blockade of ABCA1 stimulates ENaC, which may contribute to CsA-induced hypertension.	Cyclosporine	121-124	sodium channel, nonvoltage-gated 1 alpha	Mus musculus	91-95
30982223-3	2019	The current study investigated the effect of OATP1B1 genotype c.521T&gt;C (OATP1B1-Val174Ala) on the extent of interaction between cyclosporin A (CsA) and pravastatin, and associated endogenous biomarkers of the transporter (HDA, TDA, CP-I, and CP-III), in 20 healthy volunteers.	Cyclosporine	131-144	solute carrier organic anion transporter family member 1B1	Homo sapiens	45-52
30982223-3	2019	The current study investigated the effect of OATP1B1 genotype c.521T&gt;C (OATP1B1-Val174Ala) on the extent of interaction between cyclosporin A (CsA) and pravastatin, and associated endogenous biomarkers of the transporter (HDA, TDA, CP-I, and CP-III), in 20 healthy volunteers.	Cyclosporine	131-144	solute carrier organic anion transporter family member 1B1	Homo sapiens	75-82
30982223-3	2019	The current study investigated the effect of OATP1B1 genotype c.521T&gt;C (OATP1B1-Val174Ala) on the extent of interaction between cyclosporin A (CsA) and pravastatin, and associated endogenous biomarkers of the transporter (HDA, TDA, CP-I, and CP-III), in 20 healthy volunteers.	Cyclosporine	146-149	solute carrier organic anion transporter family member 1B1	Homo sapiens	45-52
30982223-3	2019	The current study investigated the effect of OATP1B1 genotype c.521T&gt;C (OATP1B1-Val174Ala) on the extent of interaction between cyclosporin A (CsA) and pravastatin, and associated endogenous biomarkers of the transporter (HDA, TDA, CP-I, and CP-III), in 20 healthy volunteers.	Cyclosporine	146-149	solute carrier organic anion transporter family member 1B1	Homo sapiens	75-82
30982223-8	2019	Overall, these results suggest that OATP1B1 genotype can modulate the effects of CsA on biomarker levels; the extent of modulation differs among the biomarkers.	Cyclosporine	81-84	solute carrier organic anion transporter family member 1B1	Homo sapiens	36-43
30731172-9	2019	For the systemic treatment of nail psoriasis acitretin, methotrexate, cyclosporine, small molecules, and biologics may be employed.	Cyclosporine	70-82	CD244 molecule	Homo sapiens	30-34
30663866-4	2019	After ciclosporin treatment, IL-10, IFNgamma and TNFalpha production was significantly reduced after stimulation with PMA/I compared to pre-treatment.	Cyclosporine	6-17	interferon gamma	Canis lupus familiaris	36-44
30663866-4	2019	After ciclosporin treatment, IL-10, IFNgamma and TNFalpha production was significantly reduced after stimulation with PMA/I compared to pre-treatment.	Cyclosporine	6-17	tumor necrosis factor	Canis lupus familiaris	49-57
31413881-3	2019	New approaches based on CypA are currently being developed for the treatment of limb ischemia, neutralization of the side effects of Cyclosporine A (CsA) therapy, etc.	Cyclosporine	133-147	peptidylprolyl isomerase A	Homo sapiens	24-28
31413881-3	2019	New approaches based on CypA are currently being developed for the treatment of limb ischemia, neutralization of the side effects of Cyclosporine A (CsA) therapy, etc.	Cyclosporine	149-152	peptidylprolyl isomerase A	Homo sapiens	24-28
30332552-4	2019	Several molecules have been used to avoid or even reverse Cd2+-induced mitochondrial injury, for instance, cyclosporin A, resveratrol, dithiocarbamates, and even EDTA.	Cyclosporine	107-120	CD2 molecule	Homo sapiens	58-61
30794682-11	2019	RESULTS: Expression of the GADD45gamma gene was significantly upregulated in response to treatment with CsA and cisplatin.	Cyclosporine	104-107	growth arrest and DNA damage inducible gamma	Homo sapiens	27-38
30794682-13	2019	The activation of caspase-3 and caspase-7 as well as caspase-9 induced by cisplatin or CsA was reduced by silencing of GADD45gamma, and was augmented by the overexpression of GADD45gamma, indicating that caspase activation is dependent on the expression of GADD45gamma.	Cyclosporine	87-90	caspase 7	Homo sapiens	32-41
30794682-13	2019	The activation of caspase-3 and caspase-7 as well as caspase-9 induced by cisplatin or CsA was reduced by silencing of GADD45gamma, and was augmented by the overexpression of GADD45gamma, indicating that caspase activation is dependent on the expression of GADD45gamma.	Cyclosporine	87-90	caspase 9	Homo sapiens	53-62
30794682-13	2019	The activation of caspase-3 and caspase-7 as well as caspase-9 induced by cisplatin or CsA was reduced by silencing of GADD45gamma, and was augmented by the overexpression of GADD45gamma, indicating that caspase activation is dependent on the expression of GADD45gamma.	Cyclosporine	87-90	growth arrest and DNA damage inducible gamma	Homo sapiens	119-130
30794682-13	2019	The activation of caspase-3 and caspase-7 as well as caspase-9 induced by cisplatin or CsA was reduced by silencing of GADD45gamma, and was augmented by the overexpression of GADD45gamma, indicating that caspase activation is dependent on the expression of GADD45gamma.	Cyclosporine	87-90	growth arrest and DNA damage inducible gamma	Homo sapiens	175-186
30794682-13	2019	The activation of caspase-3 and caspase-7 as well as caspase-9 induced by cisplatin or CsA was reduced by silencing of GADD45gamma, and was augmented by the overexpression of GADD45gamma, indicating that caspase activation is dependent on the expression of GADD45gamma.	Cyclosporine	87-90	caspase 9	Homo sapiens	18-25
30794682-13	2019	The activation of caspase-3 and caspase-7 as well as caspase-9 induced by cisplatin or CsA was reduced by silencing of GADD45gamma, and was augmented by the overexpression of GADD45gamma, indicating that caspase activation is dependent on the expression of GADD45gamma.	Cyclosporine	87-90	growth arrest and DNA damage inducible gamma	Homo sapiens	175-186
30378503-14	2019	We also demonstrated that CsA could inhibit the expression of NFATc1 and its downstream genes COX-2, c-Myc, MMP-9, and MMP-2 in OSCC cells.	Cyclosporine	26-29	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	101-106
30483129-11	2018	Moreover, the present study reveals that combination of radicicol, VER-155008, cyclosporine A, and FK506, which are specific pharmacological inhibitors of Hsp90, Hsp70, Cyps, and FKBPs, respectively, resulted in a stronger inhibition of intoxication of cells with C2 toxin compared to application of the single inhibitors.	Cyclosporine	79-93	heat shock protein 90 alpha family class A member 1	Homo sapiens	155-160
30198892-8	2018	This first structure of the CypA-ALV complex shows that the binding of ALV is highly similar to that of CsA.	Cyclosporine	104-107	peptidylprolyl isomerase A	Homo sapiens	28-32
29417209-2	2018	We present a case of anti-MDA5 antibody-associated RP-ILD in a patient with arthritis but with no other clinical signs suggestive of DM or CADM successfully treated with a combination of cyclophosphamide, cyclosporine and corticoids.	Cyclosporine	205-217	interferon induced with helicase C domain 1	Homo sapiens	26-30
29643244-7	2018	Treatment of SUN1-expressing cells with cyclosporine (CsA) significantly reduced the sensitivity of the virus to SUN1, and an HIV-1 mutant containing CA-G89A, which does not interact with cyclophilin A (CypA), was resistant to SUN1 overexpression.	Cyclosporine	54-57	peptidylprolyl isomerase A	Homo sapiens	203-207
29108648-3	2018	Here, we studied the effects of CsA in allergen-induced lung inflammation in mice and found that CsA decreased the number of lung ILC2s and attenuated papain-induced activation of ILC2s accompanied with IL-5 expression.	Cyclosporine	97-100	interleukin 5	Mus musculus	203-207
29133357-8	2018	MDSCs also prevented the CsA-induced increase in fibronectin in microvascular and glomerular endothelial cells.	Cyclosporine	25-28	fibronectin 1	Mus musculus	49-60
29069656-4	2018	CsA induced the inhibition of lipopolysaccharide- induced activation of collecting duct cells due to the downregulation of the expression of TLR4 via the microRNA Let-7i.	Cyclosporine	0-3	toll like receptor 4	Homo sapiens	141-145
28608233-4	2018	The PTP opener salicylic acid induced a fluorescence increase with a vitality decrease in a manner sensitive to the PTP inhibitor ciclosporin, while ciclosporin alone was effective in significantly preventing both fluorescence increase and viability decrease by NMDA as seen with an NMDAR antagonist.	Cyclosporine	130-141	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	283-288
28608233-4	2018	The PTP opener salicylic acid induced a fluorescence increase with a vitality decrease in a manner sensitive to the PTP inhibitor ciclosporin, while ciclosporin alone was effective in significantly preventing both fluorescence increase and viability decrease by NMDA as seen with an NMDAR antagonist.	Cyclosporine	149-160	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	283-288
28640392-5	2017	A histopathological analysis showed that both cyclosporin A and tacrolimus exacerbated the NOD1-mediated coronary arteritis in a dose-dependent manner.	Cyclosporine	46-59	nucleotide-binding oligomerization domain containing 1	Mus musculus	91-95
28403511-0	2017	Decrease in serum IL-32 level in patients with atopic dermatitis after cyclosporine treatment.	Cyclosporine	71-83	interleukin 32	Homo sapiens	18-23
28729360-2	2017	In addition to its role as a host-cell receptor for cyclosporine A, CypA has diverse functions in inflammatory conditions and diseases.	Cyclosporine	52-66	peptidylprolyl isomerase A	Homo sapiens	68-72
32188225-6	2017	Compared with the BMF group, the CSA and flavone groups had significantly higher and expressions of caspase family proteins (all P<0.05) whereas the levels of Cyt C, PS, Ca2+, and expressions of Bak and Bax were reduced (all P<0.05).	Cyclosporine	33-36	BCL2-antagonist/killer 1	Mus musculus	195-198
28472720-14	2017	CONCLUSIONS: The process of EMT in CsA-induced rat gingival overgrowth is associated with increased expression of TGF-beta1, ZEB1, and ZEB2, and decreased expression of E-cadherin.	Cyclosporine	35-38	cadherin 1	Rattus norvegicus	169-179
28583823-16	2017	HCC cells incubated with the calcineurin inhibitor cyclosporin A had decreased nuclear level of NFAT1.	Cyclosporine	51-64	nuclear factor of activated T cells 2	Homo sapiens	96-101
28535976-6	2017	Epigallocatechin gallate, cyclosporin A, rifampicin, and telmisartan inhibited cilostazol uptake in OATP1B1/1B3-HEK293 cells with Ki values close to their clinical plasma concentration, which suggested possible drug-drug interactions in humans via OATP1B1/1B3.	Cyclosporine	26-39	solute carrier organic anion transporter family member 1B1	Homo sapiens	100-107
28824190-3	2017	After the test for anti-melanoma differentiation-associated gene 5 (MDA5) antibody came out positive, we doubled the cyclosporine dose and her condition improved.	Cyclosporine	117-129	interferon induced with helicase C domain 1	Homo sapiens	19-66
27858342-7	2017	Further analysis demonstrated that OATP1B1 inhibition by rifampin or cyclosporine in the existing inhibitor models needs to be approximately tenfold stronger to recapitulate the observed DDI with these two inhibitors.	Cyclosporine	69-81	solute carrier organic anion transporter family member 1B1	Homo sapiens	35-42
27858342-8	2017	CONCLUSION: Through quantitative assessment of the effect of OATP1B1 genetic polymorphism and inhibitors of transporters and metabolizing enyzmes via PBPK modeling, we confirmed the importance of OATP1B1 in the disposition of these two statins, and explored potential causes for under-prediction of the inhibitory effect of rifampin and cyclosporine.	Cyclosporine	337-349	solute carrier organic anion transporter family member 1B1	Homo sapiens	61-68
27858342-8	2017	CONCLUSION: Through quantitative assessment of the effect of OATP1B1 genetic polymorphism and inhibitors of transporters and metabolizing enyzmes via PBPK modeling, we confirmed the importance of OATP1B1 in the disposition of these two statins, and explored potential causes for under-prediction of the inhibitory effect of rifampin and cyclosporine.	Cyclosporine	337-349	solute carrier organic anion transporter family member 1B1	Homo sapiens	196-203
28115173-0	2017	Cyclosporine counteracts endotoxemia-evoked reductions in blood pressure and cardiac autonomic dysfunction via central sGC/MAPKs signaling in rats.	Cyclosporine	0-12	guanylate cyclase 1 soluble subunit beta 2	Rattus norvegicus	119-122
28115173-2	2017	We tested the hypothesis that central phosphoinositide-3-kinase (PI3K)/soluble guanylate cyclase (sGC)/mitogen activated protein kinases (MAPKs) cascade modulates the CSA counteraction of endotoxic hypotension and cardiac autonomic dysfunction.	Cyclosporine	167-170	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma	Rattus norvegicus	38-63
28115173-2	2017	We tested the hypothesis that central phosphoinositide-3-kinase (PI3K)/soluble guanylate cyclase (sGC)/mitogen activated protein kinases (MAPKs) cascade modulates the CSA counteraction of endotoxic hypotension and cardiac autonomic dysfunction.	Cyclosporine	167-170	guanylate cyclase 1 soluble subunit beta 2	Rattus norvegicus	98-101
28115173-11	2017	Together, while central sGC/MAPKs circuits modulate the CSA counteraction of endotoxic manifestations, the recruitment of individual MAPKs into this interaction depends on the nature of the cardiovascular response.	Cyclosporine	56-59	guanylate cyclase 1 soluble subunit beta 2	Rattus norvegicus	24-27
26961540-8	2017	From the further evaluation with the typical inhibitors of each transporter, it was confirmed that BPS is a substrate for P-gp, BCRP, OAT3, OATP1B1, OATP1B3 and MRP2, because the typical inhibitor, cyclosporine, had no effects on BPS transport by BSEP.	Cyclosporine	198-210	phosphoglycolate phosphatase	Homo sapiens	122-126
26961540-8	2017	From the further evaluation with the typical inhibitors of each transporter, it was confirmed that BPS is a substrate for P-gp, BCRP, OAT3, OATP1B1, OATP1B3 and MRP2, because the typical inhibitor, cyclosporine, had no effects on BPS transport by BSEP.	Cyclosporine	198-210	BCR pseudogene 1	Homo sapiens	128-132
26961540-8	2017	From the further evaluation with the typical inhibitors of each transporter, it was confirmed that BPS is a substrate for P-gp, BCRP, OAT3, OATP1B1, OATP1B3 and MRP2, because the typical inhibitor, cyclosporine, had no effects on BPS transport by BSEP.	Cyclosporine	198-210	solute carrier organic anion transporter family member 1B1	Homo sapiens	140-147
27796696-0	2017	Klotho mitigates cyclosporine A (CsA)-induced epithelial-mesenchymal transition (EMT) and renal fibrosis in rats.	Cyclosporine	17-31	Klotho	Rattus norvegicus	0-6
27796696-0	2017	Klotho mitigates cyclosporine A (CsA)-induced epithelial-mesenchymal transition (EMT) and renal fibrosis in rats.	Cyclosporine	33-36	Klotho	Rattus norvegicus	0-6
27796696-2	2017	The aim of this study was to investigate the effect of Klotho administration on epithelial-mesenchymal transition (EMT) and renal fibrosis induced by cyclosporine A (CsA) in rats.	Cyclosporine	150-164	Klotho	Rattus norvegicus	55-61
27796696-2	2017	The aim of this study was to investigate the effect of Klotho administration on epithelial-mesenchymal transition (EMT) and renal fibrosis induced by cyclosporine A (CsA) in rats.	Cyclosporine	166-169	Klotho	Rattus norvegicus	55-61
27796696-7	2017	RESULTS: Administration of CsA for 28 days induced renal damage, decreased Klotho expression and activated the EMT response (demonstrated as increased TGF-beta1 and alpha-SMA expression accompanied by decreased in E-cadherin expression).	Cyclosporine	27-30	Klotho	Rattus norvegicus	75-81
27796696-7	2017	RESULTS: Administration of CsA for 28 days induced renal damage, decreased Klotho expression and activated the EMT response (demonstrated as increased TGF-beta1 and alpha-SMA expression accompanied by decreased in E-cadherin expression).	Cyclosporine	27-30	cadherin 1	Rattus norvegicus	214-224
27796696-9	2017	CONCLUSIONS: Klotho inhibits CsA-induced EMT and renal fibrosis in rats.	Cyclosporine	29-32	Klotho	Rattus norvegicus	13-19
27796696-10	2017	Klotho may serve as a therapeutic agent to minimize CsA-induced renal fibrosis.	Cyclosporine	52-55	Klotho	Rattus norvegicus	0-6
27664163-3	2017	We showed that while cerebral I/R injury is accompanied by loss of MMP, mitochondrial swelling and programmed cell death, pretreatment with cyclosporine-A (CsA) as a potent inhibitor of CypD, led to partial but significant reduction in necroptosis markers, RIP1 and RIP3 as well as activity of glutamate-ammonia ligase (GLUL) and glutamate dehydrogenase 1 (GLUD1), downstream enzymes of RIP3.	Cyclosporine	140-154	receptor interacting serine/threonine kinase 1	Homo sapiens	257-261
27664163-3	2017	We showed that while cerebral I/R injury is accompanied by loss of MMP, mitochondrial swelling and programmed cell death, pretreatment with cyclosporine-A (CsA) as a potent inhibitor of CypD, led to partial but significant reduction in necroptosis markers, RIP1 and RIP3 as well as activity of glutamate-ammonia ligase (GLUL) and glutamate dehydrogenase 1 (GLUD1), downstream enzymes of RIP3.	Cyclosporine	140-154	glutamate dehydrogenase 1	Homo sapiens	357-362
27664163-3	2017	We showed that while cerebral I/R injury is accompanied by loss of MMP, mitochondrial swelling and programmed cell death, pretreatment with cyclosporine-A (CsA) as a potent inhibitor of CypD, led to partial but significant reduction in necroptosis markers, RIP1 and RIP3 as well as activity of glutamate-ammonia ligase (GLUL) and glutamate dehydrogenase 1 (GLUD1), downstream enzymes of RIP3.	Cyclosporine	156-159	receptor interacting serine/threonine kinase 1	Homo sapiens	257-261
27664163-3	2017	We showed that while cerebral I/R injury is accompanied by loss of MMP, mitochondrial swelling and programmed cell death, pretreatment with cyclosporine-A (CsA) as a potent inhibitor of CypD, led to partial but significant reduction in necroptosis markers, RIP1 and RIP3 as well as activity of glutamate-ammonia ligase (GLUL) and glutamate dehydrogenase 1 (GLUD1), downstream enzymes of RIP3.	Cyclosporine	156-159	glutamate dehydrogenase 1	Homo sapiens	357-362
28190860-7	2017	Although prednisolone and cyclosporine therapy has controlled the T-cell LPD, this patient awaits allogeneic hematopoietic cell transplantation to achieve a complete cure of his APDS.	Cyclosporine	26-38	acyl-CoA synthetase bubblegum family member 1	Homo sapiens	73-76
28736029-10	2017	Regarding the effects of apelin, our results indicate that apelin provides protection against CsA-induced tubular injury by activating nitric oxide and/or the NFATc1 pathway.	Cyclosporine	94-97	nuclear factor of activated T-cells 1	Rattus norvegicus	159-165
26738448-10	2016	CONCLUSIONS: These results suggest that cyclosporine A promotes cell proliferation, collagen and alpha-SMA expressions in rat gingival fibroblasts by Smad3 activation and miR-29b suppression.	Cyclosporine	40-54	actin gamma 2, smooth muscle	Rattus norvegicus	97-106
27769261-9	2016	Up-regulation of Hsp90 and associated decrease in pro-inflammatory cytokine production was found in CD28nullCD8+ T and NKT-like cells in the presence of 10 muM prednisolone and 2.5 ng/mL cyclosporine A.	Cyclosporine	187-201	heat shock protein 90 alpha family class A member 1	Homo sapiens	17-22
27755569-0	2016	1,25(OH)2D3 and VDR Signaling Pathways Regulate the Inhibition of Dectin-1 Caused by Cyclosporine A in Response to Aspergillus Fumigatus in Human Corneal Epithelial Cells.	Cyclosporine	85-99	C-type lectin domain containing 7A	Homo sapiens	66-74
27755569-1	2016	BACKGROUND: The objective of this study is to observe whether cyclosporine A (CsA) inhibits the expression of dectin-1 in human corneal epithelial cells infected with Aspergillus fumigatus (A. fumigatus) and to investigate the molecular mechanisms of the inhibition.	Cyclosporine	62-76	C-type lectin domain containing 7A	Homo sapiens	110-118
27755569-1	2016	BACKGROUND: The objective of this study is to observe whether cyclosporine A (CsA) inhibits the expression of dectin-1 in human corneal epithelial cells infected with Aspergillus fumigatus (A. fumigatus) and to investigate the molecular mechanisms of the inhibition.	Cyclosporine	78-81	C-type lectin domain containing 7A	Homo sapiens	110-118
27755569-5	2016	Dectin-1 and proinflammatory cytokine expression levels were higher when HCECs were pretreated with VDR inhibitor and CsA compared to pretreatment with CsA alone, while dectin-1 and proinflammatory cytokine levels were lower when HCECs were pretreated with 1,25(OH)2D3 and CsA compared to pretreatment with CsA alone.	Cyclosporine	118-121	C-type lectin domain containing 7A	Homo sapiens	0-8
27755569-5	2016	Dectin-1 and proinflammatory cytokine expression levels were higher when HCECs were pretreated with VDR inhibitor and CsA compared to pretreatment with CsA alone, while dectin-1 and proinflammatory cytokine levels were lower when HCECs were pretreated with 1,25(OH)2D3 and CsA compared to pretreatment with CsA alone.	Cyclosporine	152-155	C-type lectin domain containing 7A	Homo sapiens	0-8
27755569-5	2016	Dectin-1 and proinflammatory cytokine expression levels were higher when HCECs were pretreated with VDR inhibitor and CsA compared to pretreatment with CsA alone, while dectin-1 and proinflammatory cytokine levels were lower when HCECs were pretreated with 1,25(OH)2D3 and CsA compared to pretreatment with CsA alone.	Cyclosporine	152-155	C-type lectin domain containing 7A	Homo sapiens	0-8
27755569-5	2016	Dectin-1 and proinflammatory cytokine expression levels were higher when HCECs were pretreated with VDR inhibitor and CsA compared to pretreatment with CsA alone, while dectin-1 and proinflammatory cytokine levels were lower when HCECs were pretreated with 1,25(OH)2D3 and CsA compared to pretreatment with CsA alone.	Cyclosporine	152-155	C-type lectin domain containing 7A	Homo sapiens	0-8
27755569-6	2016	CONCLUSIONS: These data provide evidence that CsA can inhibit the expression of dectin-1 and proinflammatory cytokines through dectin-1 when HCECs are stimulated by A. fumigatus or curdlan.	Cyclosporine	46-49	C-type lectin domain containing 7A	Homo sapiens	80-88
26547660-10	2016	In the cyclosporine A-treated rats, the expression of TGF-beta1 and TIMP-1 was significantly upregulated, whereas expression of the MMP-1 was downregulated, along with thicker and denser collagen fibers.	Cyclosporine	7-21	matrix metallopeptidase 1	Rattus norvegicus	132-137
26547660-12	2016	CONCLUSIONS: Cyclosporine A enhanced gingival fibrous overgrowth via upregulation of the TGF-beta1 and TIMP-1 expression, and downregulation of MMP-1 expression.	Cyclosporine	13-27	matrix metallopeptidase 1	Rattus norvegicus	144-149
26547660-13	2016	Tan IIA can effectively prevent cyclosporine A-induced gingival fibrous overgrowth in rats by downregulating TGF-beta1 and TIMP-1 expression, and upregulating MMP-1 expression.	Cyclosporine	32-46	matrix metallopeptidase 1	Rattus norvegicus	159-164
27642560-4	2016	Experiments with CyPA-specific siRNA, or with cyclosporine A, an inhibitor of CyPA, confirmed that H2O2-mediated upregulation of HCMV replication is specifically mediated by upregulation of CyPA expression.	Cyclosporine	46-60	peptidylprolyl isomerase A	Homo sapiens	78-82
27642560-4	2016	Experiments with CyPA-specific siRNA, or with cyclosporine A, an inhibitor of CyPA, confirmed that H2O2-mediated upregulation of HCMV replication is specifically mediated by upregulation of CyPA expression.	Cyclosporine	46-60	peptidylprolyl isomerase A	Homo sapiens	78-82
27486749-9	2016	p38 MAPK (p38), c-Jun NH2-terminal kinase (JNK) and NFkB inhibitors, CsA and Dex induced a partial inhibition of HO-induced CCL2, while Dox and extracellular signal-regulated kinase (ERK) inhibitor did not.	Cyclosporine	69-72	C-C motif chemokine ligand 2	Homo sapiens	124-128
29949699-3	2016	Immunosuppression caused by cyclosporin (daily dose 5 mg/kg, p.o., for 13 days) worsened brain ischemia outcome, as manifested by increased mortality, more severe neurological marker score, increased levels of brain damage markers (NSE and MBP) in the blood serum, decrease in muscle strength and locomotor activity, and impairment of orientation and research activity as compared to animals with brain ischemia and intact immunity.	Cyclosporine	28-39	enolase 2	Rattus norvegicus	232-235
27279606-7	2016	Interestingly, the infectivity of wild-type or P90A virus could be rescued from the MX2-independent IFN-alpha-induced blocks in THP-1 cells by treatment with cyclosporine (Cs) or its nonimmunosuppressive analogue SDZ-NIM811, indicating that Cs-sensitive host cell cyclophilins other than CypA contribute to the activity of IFN-alpha-induced blocks.	Cyclosporine	158-170	peptidylprolyl isomerase A	Homo sapiens	288-292
26676223-0	2016	Effects of oral cyclosporine on canine T-cell expression of IL-2 and IFN-gamma across a 12-h dosing interval.	Cyclosporine	16-28	interferon gamma	Canis lupus familiaris	69-78
26950727-8	2016	CONCLUSIONS: These studies suggest that Nox2 is a modulator of CsA-induced hypoxia upstream of HIF-1alpha and define the molecular characteristics that could be used for the diagnosis and monitoring of chronic calcineurin inhibitor nephrotoxicity.	Cyclosporine	63-66	hypoxia inducible factor 1, alpha subunit	Mus musculus	95-105
27210831-8	2016	In vivo patch assay showed the core-shell assembling of CSA-DPS can reconstruct cellular arrangements and microenvironmental niches as dominated by PPARalpha signal in ASCs to induce the greater hair induction than MA-DPS or DP spheres alone.	Cyclosporine	56-59	peroxisome proliferator activated receptor alpha	Rattus norvegicus	148-157
26994210-4	2016	The prototypic inhibitor CsA (cyclosporin A) of both cyclophilins as well as the new water-soluble MM258 derivative prevented this suppression.	Cyclosporine	25-28	peptidylprolyl isomerase A	Homo sapiens	53-65
27169750-4	2016	At the studied concentrations, cyclosporine A and chlorpromazine induced early ROCK activity, resulting in permanent MLC2 phosphorylation and BC constriction.	Cyclosporine	31-45	myosin light chain 2	Homo sapiens	117-121
27242720-6	2016	In M. pulmonis-infected mice model, pathologic patterns are strikingly different according to host cell-mediated immunity (CMI) levels; treatment with interleukin-2 lead to marked cellular bronchitis in the small airways and treatment with prednisolone or cyclosporin-A lead to neutrophils and exudates in the alveolar lumen.	Cyclosporine	256-269	interleukin 2	Mus musculus	151-164
26713664-8	2016	Finally, CsA blocks calcineurin, a protein implied in I/R damage but calcineurin inhibition could contribute to protection towards I/R damage only when Rcan1, a calcineurin natural inhibitor, expression is low.	Cyclosporine	9-12	regulator of calcineurin 1	Homo sapiens	152-157
26844915-4	2016	Cyclosporine A alone was found to significantly increase serum creatinine, blood urea nitrogen, lactate dehydrogenase, urinary micrototal protein, renal thiobarbituric acid reactive substance, Bax, cytosol cytochrome c release and nuclear factor kappa B activation.	Cyclosporine	0-14	BCL2 associated X, apoptosis regulator	Rattus norvegicus	193-196
26754588-0	2016	Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study.	Cyclosporine	72-84	dipeptidyl peptidase 4	Homo sapiens	11-33
26754588-2	2016	However, the glucose-lowering efficacies of various DPP-4 inhibitors and their effects on blood cyclosporine levels have not been fully investigated.	Cyclosporine	96-108	dipeptidyl peptidase 4	Homo sapiens	52-57
26802601-9	2016	The results of our study suggest an association between the CCL2 gene rs1024611 G allele and PTDM in patients treated with tacrolimus or cyclosporine.	Cyclosporine	137-149	C-C motif chemokine ligand 2	Homo sapiens	60-64
26353895-8	2016	Cyclosporine is an inhibitor of OATP1B1/3, BCRP and P-gp, and a mild inhibitor of CYP3A; cyclosporine causes a significant increase in simeprevir plasma concentrations, and coadministration is not recommended.	Cyclosporine	0-12	solute carrier organic anion transporter family member 1B1	Homo sapiens	32-41
26047793-6	2016	HLA mismatches and cyclosporine A were independently associated with increased risk of C1q-binding de novo DSA.	Cyclosporine	19-33	complement C1q A chain	Homo sapiens	87-90
26603313-10	2016	In cultured tubular cells, anti-HMGB1 pretreatment also prevented the increases in fibronectin and collagen IV levels associated with CsA treatment.	Cyclosporine	134-137	fibronectin 1	Mus musculus	83-94
26752561-9	2016	Moreover, inhibition of PPIA with cyclosporine A blocked cell growth of the cell lines, the effect size was associated with the PPIA expression levels.	Cyclosporine	34-48	peptidylprolyl isomerase A	Homo sapiens	24-28
26752561-9	2016	Moreover, inhibition of PPIA with cyclosporine A blocked cell growth of the cell lines, the effect size was associated with the PPIA expression levels.	Cyclosporine	34-48	peptidylprolyl isomerase A	Homo sapiens	128-132
26264861-2	2016	CsA has been shown to be a safe and highly effective immunosuppressive drug that binds with the protein Cyclophilin A (CypA) at active sites.	Cyclosporine	0-3	peptidylprolyl isomerase A	Homo sapiens	104-117
26264861-2	2016	CsA has been shown to be a safe and highly effective immunosuppressive drug that binds with the protein Cyclophilin A (CypA) at active sites.	Cyclosporine	0-3	peptidylprolyl isomerase A	Homo sapiens	119-123
26264861-4	2016	In this project, we elucidate the binding of CsA to CypA at the molecular level by computing their electron structures and revealing their interactions.	Cyclosporine	45-48	peptidylprolyl isomerase A	Homo sapiens	52-56
26264861-6	2016	We have identified the wave function of CypA, the biological active residues and active atoms of CypA and CsA, the interaction site between CypA and CsA, and the hydrogen bonds in the ligand CsA binding site.	Cyclosporine	106-109	peptidylprolyl isomerase A	Homo sapiens	40-44
25727073-0	2015	Cyclosporine Does Not Prevent Microvascular Loss in Transplantation but Can Synergize With a Neutrophil Elastase Inhibitor, Elafin, to Maintain Graft Perfusion During Acute Rejection.	Cyclosporine	0-12	elastase, neutrophil expressed	Mus musculus	93-112
25642000-5	2015	In Sample 1, the association between CSA and sensation seeking was moderated by DRD4 genotype; this gene x environment interaction effect, however, was not replicated in Sample 2.	Cyclosporine	37-40	dopamine receptor D4	Homo sapiens	80-84
25698201-9	2015	The p70S6K phosphorylation in patients receiving a sirolimus (19.5 +- 7.7) was significantly lower than in HC (50.1 +- 11.3, P &lt; 0.001), tacrolimus (37.7 +- 15.7, P &lt; 0.001) or cyclosporine treated patients (41.7 +- 11.7, P &lt; 0.001).	Cyclosporine	183-195	ribosomal protein S6 kinase B1	Homo sapiens	4-10
25193101-1	2015	Calcineurin (CN) is the target of the immunophilin-immunosuppressant complex, cyclophilin/cyclosporin A (CyP/CsA).	Cyclosporine	90-103	peptidylprolyl isomerase G	Homo sapiens	105-108
25193101-7	2015	Using isothermal titration calorimetry (ITC), we found that the RCAN1-1L/CN or CyP/CsA/CN interactions were exothermic with a dissociation constant of 0.46 muM or 0.17 muM, respectively.	Cyclosporine	83-86	peptidylprolyl isomerase G	Homo sapiens	79-82
25385493-0	2015	Role of Shh and TGF in cyclosporine-enhanced expression of collagen and alpha-SMA by gingival fibroblast.	Cyclosporine	23-35	sonic hedgehog signaling molecule	Homo sapiens	8-11
25385493-4	2015	The effect of Shh on CsA-induced alterations was further evaluated by the extra-supplement or inhibition of Shh or TGF-beta.	Cyclosporine	21-24	sonic hedgehog signaling molecule	Homo sapiens	14-17
25385493-4	2015	The effect of Shh on CsA-induced alterations was further evaluated by the extra-supplement or inhibition of Shh or TGF-beta.	Cyclosporine	21-24	sonic hedgehog signaling molecule	Homo sapiens	108-111
25385493-5	2015	RESULTS: Cyclosporine-A enhanced COL1, alpha-SMA, Shh and TGF-beta expressions in human gingival fibroblasts.	Cyclosporine	9-23	sonic hedgehog signaling molecule	Homo sapiens	50-53
25385493-6	2015	The exogenous Shh/TGF-beta augmented the expression of COL1 and alpha-SMA, and the Shh/TGF-beta inhibition suppressed the CsA-enhanced COL1 and alpha-SMA expressions.	Cyclosporine	122-125	sonic hedgehog signaling molecule	Homo sapiens	14-17
25385493-6	2015	The exogenous Shh/TGF-beta augmented the expression of COL1 and alpha-SMA, and the Shh/TGF-beta inhibition suppressed the CsA-enhanced COL1 and alpha-SMA expressions.	Cyclosporine	122-125	sonic hedgehog signaling molecule	Homo sapiens	83-86
25618585-9	2015	Hypoxia increased CsA-induced PAI-1 protein expression than normoxic conditions (p &lt; 0.05).	Cyclosporine	18-21	serpin family E member 1	Homo sapiens	30-35
25464205-6	2015	Cyclosporine A (CsA), an inhibitor of mitophagy, blocked Cd-induced mitophagy and PINK1/Parkin pathway but failed to suppress ROS increase, revealing that ROS are the causes rather than the results of Cd-induced mitophagy.	Cyclosporine	0-14	PTEN induced putative kinase 1	Mus musculus	82-87
25464205-6	2015	Cyclosporine A (CsA), an inhibitor of mitophagy, blocked Cd-induced mitophagy and PINK1/Parkin pathway but failed to suppress ROS increase, revealing that ROS are the causes rather than the results of Cd-induced mitophagy.	Cyclosporine	16-19	PTEN induced putative kinase 1	Mus musculus	82-87
27442391-17	2015	Also, patients with recessive mutations in PLCE1 may respond fully to the treatment with steroids or cyclosporine A.	Cyclosporine	101-115	phospholipase C epsilon 1	Homo sapiens	43-48
25743766-5	2015	CyPA was initially discovered as the intracellular receptor of the immunosuppressive drug cyclosporine 30 years ago.	Cyclosporine	90-102	peptidylprolyl isomerase A	Homo sapiens	0-4
25280976-2	2014	Calcium channel blockers (CCBs) are considered to be the best treatment for CsA-induced hypertension, but they may alter the exposure and the effect of CsA by inhibiting the CYP3A4 pathway of CsA metabolism or P-gp.	Cyclosporine	152-155	phosphoglycolate phosphatase	Homo sapiens	210-214
25280976-2	2014	Calcium channel blockers (CCBs) are considered to be the best treatment for CsA-induced hypertension, but they may alter the exposure and the effect of CsA by inhibiting the CYP3A4 pathway of CsA metabolism or P-gp.	Cyclosporine	152-155	phosphoglycolate phosphatase	Homo sapiens	210-214
25240837-8	2014	This process was probably due to curcumin-induced down-regulation of P-gp drug transporter, since cyclosporine A, a P-gp blocker, also inhibited the glucosylceramide synthase activity.	Cyclosporine	98-112	phosphoglycolate phosphatase	Homo sapiens	69-73
25240837-8	2014	This process was probably due to curcumin-induced down-regulation of P-gp drug transporter, since cyclosporine A, a P-gp blocker, also inhibited the glucosylceramide synthase activity.	Cyclosporine	98-112	phosphoglycolate phosphatase	Homo sapiens	116-120
25240837-8	2014	This process was probably due to curcumin-induced down-regulation of P-gp drug transporter, since cyclosporine A, a P-gp blocker, also inhibited the glucosylceramide synthase activity.	Cyclosporine	98-112	UDP-glucose ceramide glucosyltransferase	Homo sapiens	149-174
25299210-8	2014	At the same CsA doses, apoptotic cell death was apparent as indicated by nuclear and DNA fragmentation and increased p53 expression.	Cyclosporine	12-15	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	117-120
25299210-11	2014	Manganese superoxide dismutase (Mn-SOD) showed a similar dose-dependent reduction in cells undergoing apoptosis, while levels of the intracellular calcium ion exchange maker calbindin-D9k were decreased in apoptosis (1.0 to 5 microM CsA), but unchanged in autophagy.	Cyclosporine	233-236	S100 calcium binding protein G	Rattus norvegicus	174-187
24947867-7	2014	The OATP1A2-, OATP2B1-, and OCT1-mediated quercetin uptake was inhibited by known inhibitors such as naringin, cyclosporin A, and quinidine, respectively.	Cyclosporine	111-124	solute carrier organic anion transporter family member 2B1	Homo sapiens	14-21
24990953-6	2014	This "hyperoxidation" phenotype could be duplicated by incubating cells with the cyclophilin inhibitor cyclosporine A, a treatment that triggered efficient ER depletion of cyclophilins B and C by inducing their secretion to the medium.	Cyclosporine	103-117	peptidylprolyl isomerase C	Homo sapiens	172-192
24732633-10	2014	Further, cyclosporin A (CsA), the Cyp-D inhibitor, prevented gemcitabine-induced MST1/Cyp-D mitochondrial complexation and cancer cell death.	Cyclosporine	24-27	macrophage stimulating 1	Homo sapiens	81-85
25505597-3	2014	In an in vivo study on the locust, we found an increased uptake of the two well-known Pgp substrates, rhodamine 123 and loperamide after co-administration with the Pgp inhibitors cyclosporine A or verapamil.	Cyclosporine	179-193	phosphoglycolate phosphatase	Homo sapiens	86-89
25505597-3	2014	In an in vivo study on the locust, we found an increased uptake of the two well-known Pgp substrates, rhodamine 123 and loperamide after co-administration with the Pgp inhibitors cyclosporine A or verapamil.	Cyclosporine	179-193	phosphoglycolate phosphatase	Homo sapiens	164-167
24980261-7	2014	The increase of PKM2 and EF-1gamma levels in conditioned media was also observed in the presence of other nephrotoxic agents with different cytotoxic mechanisms such as CdCl2, HgCl2, and cyclosporine A.	Cyclosporine	187-201	pyruvate kinase M1/2	Homo sapiens	16-20
24980261-7	2014	The increase of PKM2 and EF-1gamma levels in conditioned media was also observed in the presence of other nephrotoxic agents with different cytotoxic mechanisms such as CdCl2, HgCl2, and cyclosporine A.	Cyclosporine	187-201	eukaryotic translation elongation factor 1 gamma	Homo sapiens	25-34
23907422-6	2014	RESULTS: CsA and PhT stimulated TGF-beta and Cat B production and inhibited expression of MMP-1 by fibroblasts.	Cyclosporine	9-12	matrix metallopeptidase 1	Homo sapiens	90-95
24548567-11	2014	This indicates at least that the antitumor action of cyclosporin A is mediated by the NK-1 receptor.	Cyclosporine	53-66	tachykinin receptor 1	Homo sapiens	86-99
24941799-0	2014	[The mechanism of ciclosporin A regulating the expression of LOX-1 on vascular endothelium of hyperlipidemic rats].	Cyclosporine	18-31	oxidized low density lipoprotein receptor 1	Rattus norvegicus	61-66
24941799-1	2014	OBJECTIVE: To observe the influence of Ciclosporin A (CsA) on the expression of lectin-like oxidized low-density lipoprotein (ox-LDL) receptor-1 (LOX-1) on vascular endothelium of hyperlipidemic rats.	Cyclosporine	39-52	oxidized low density lipoprotein receptor 1	Rattus norvegicus	146-151
24941799-1	2014	OBJECTIVE: To observe the influence of Ciclosporin A (CsA) on the expression of lectin-like oxidized low-density lipoprotein (ox-LDL) receptor-1 (LOX-1) on vascular endothelium of hyperlipidemic rats.	Cyclosporine	54-57	oxidized low density lipoprotein receptor 1	Rattus norvegicus	146-151
24941799-6	2014	RESULTS: An obviously up-regulated expression of LOX-1 on vascular endothelium of hyperlipidemic rats treated with CsA was observed (P &lt; 0.05), but not the serum level of ox-LDL (P &gt; 0.05).	Cyclosporine	115-118	oxidized low density lipoprotein receptor 1	Rattus norvegicus	49-54
24941799-9	2014	CONCLUSION: CsA can significantly upregulate the expression of LOX-1 on vascular endothelium of hyperlipidemic rats through not only ox-LDL/LOX-1 pathway but also ROS/CRP pathway, which could cause the probability of occurrence of atherosclerosis.	Cyclosporine	12-15	oxidized low density lipoprotein receptor 1	Rattus norvegicus	63-68
24941799-9	2014	CONCLUSION: CsA can significantly upregulate the expression of LOX-1 on vascular endothelium of hyperlipidemic rats through not only ox-LDL/LOX-1 pathway but also ROS/CRP pathway, which could cause the probability of occurrence of atherosclerosis.	Cyclosporine	12-15	oxidized low density lipoprotein receptor 1	Rattus norvegicus	140-145
24941805-8	2014	RESULTS: Compared with other groups, CsA+Talpha1 group had significant lower IL-1alpha, IL-2, IL-6, IL-17, and significant higher IL-10 at 1 d, 7 d, 14 d, 21 d after the treatments (P &lt; 0.05).	Cyclosporine	37-40	interleukin 1 alpha	Mus musculus	77-86
24941805-8	2014	RESULTS: Compared with other groups, CsA+Talpha1 group had significant lower IL-1alpha, IL-2, IL-6, IL-17, and significant higher IL-10 at 1 d, 7 d, 14 d, 21 d after the treatments (P &lt; 0.05).	Cyclosporine	37-40	interleukin 2	Mus musculus	88-92
24663101-2	2014	Interference with cyclophilin A binding, either by mutations in the HIV-1 capsid protein (CA) or by the drug cyclosporine A (CsA), inhibits HIV-1 replication in cell culture.	Cyclosporine	109-123	peptidylprolyl isomerase A	Homo sapiens	18-31
24663101-2	2014	Interference with cyclophilin A binding, either by mutations in the HIV-1 capsid protein (CA) or by the drug cyclosporine A (CsA), inhibits HIV-1 replication in cell culture.	Cyclosporine	125-128	peptidylprolyl isomerase A	Homo sapiens	18-31
24462674-0	2014	Celecoxib offsets the negative renal influences of cyclosporine via modulation of the TGF-beta1/IL-2/COX-2/endothelin ET(B) receptor cascade.	Cyclosporine	51-63	interleukin 2	Rattus norvegicus	96-100
24462674-3	2014	Ten-day treatment with CSA (20 mg/kg/day) significantly increased biochemical indices of renal function (serum urea, creatinine), inflammation (interleukin-2, IL-2) and fibrosis (transforming growth factor-beta1, TGF-beta1).	Cyclosporine	23-26	interleukin 2	Rattus norvegicus	144-157
24462674-3	2014	Ten-day treatment with CSA (20 mg/kg/day) significantly increased biochemical indices of renal function (serum urea, creatinine), inflammation (interleukin-2, IL-2) and fibrosis (transforming growth factor-beta1, TGF-beta1).	Cyclosporine	23-26	interleukin 2	Rattus norvegicus	159-163
24462674-8	2014	Together, the data suggest that the facilitation of the interplay between the TGF-beta1/IL-2/COX-2 pathway and the endothelin ET(B) receptors constitutes the cellular mechanism by which celecoxib ameliorates the nephrotoxic manifestations of CSA in rats.	Cyclosporine	242-245	interleukin 2	Rattus norvegicus	88-92
24586910-2	2014	We retrospectively studied outcomes, prognostic factors, and their relations with survival rate in patients with DM-A/SIP treated with early cyclosporine A (CSA)/GC combination therapy and 2-hour postdose blood concentration monitoring.	Cyclosporine	141-155	major histocompatibility complex, class II, DM alpha	Homo sapiens	113-121
24586910-3	2014	METHODS: This study comprised 32 DM-A/SIP patients who were simultaneously treated with CSA and prednisolone.	Cyclosporine	88-91	major histocompatibility complex, class II, DM alpha	Homo sapiens	33-41
24656003-0	2014	Expression of erythropoietin and its receptor in kidneys from normal and cyclosporine-treated rats.	Cyclosporine	73-85	erythropoietin	Rattus norvegicus	14-28
24656003-7	2014	EPO protein expression decreased significantly in kidneys from CsA-treated rats.	Cyclosporine	63-66	erythropoietin	Rattus norvegicus	0-3
24656003-10	2014	Long-term treatment with CsA suppresses renal endogenous EPO expression, resulting in anemia.	Cyclosporine	25-28	erythropoietin	Rattus norvegicus	57-60
24656003-11	2014	Increases in apoptotic cell death and betaig-h3 expression are closely associated with inhibition of EPO expression in chronic CsA nephrotoxicity.	Cyclosporine	127-130	erythropoietin	Rattus norvegicus	101-104
23438824-8	2013	Taken together, these results suggested that CIN is an apoptotic inducer that acts on the mitochondrial death pathway in PLC/PRF/5 cells and its effect could be blocked by CsA and z-VAD-fmk.	Cyclosporine	172-175	heparan sulfate proteoglycan 2	Homo sapiens	121-124
23853103-5	2013	METHODS: A randomized, double-blind prospective trial among recent onset type 1 diabetes patients has been designed using Cyclosporine A and a proton-pump inhibitor, which increases gastrin levels and has been shown to work through the Reg receptor to transform pancreatic duct cells into islets.	Cyclosporine	122-136	gastrin	Homo sapiens	182-189
23853103-5	2013	METHODS: A randomized, double-blind prospective trial among recent onset type 1 diabetes patients has been designed using Cyclosporine A and a proton-pump inhibitor, which increases gastrin levels and has been shown to work through the Reg receptor to transform pancreatic duct cells into islets.	Cyclosporine	122-136	exostosin like glycosyltransferase 3	Homo sapiens	236-248
24133577-6	2013	We found that treatment with CsA promotes PCNA expression and migration of human trophoblast in a dose-associated manner.	Cyclosporine	29-32	proliferating cell nuclear antigen	Homo sapiens	42-46
24133577-7	2013	Blocking of the MAPK3/1 signal abrogated the enhanced PCNA expression and migration in trophoblasts by CsA.	Cyclosporine	103-106	proliferating cell nuclear antigen	Homo sapiens	54-58
24133577-10	2013	Accordingly, the CsA-induced enhancement of PCNA expression and migration in trophoblasts was also decreased.	Cyclosporine	17-20	proliferating cell nuclear antigen	Homo sapiens	44-48
24133577-12	2013	Thus, our results suggest that CsA promotes PCNA expression and migration of human trophoblasts via MAPK-mediated NF-kappaB activation.	Cyclosporine	31-34	proliferating cell nuclear antigen	Homo sapiens	44-48
23846495-11	2013	Finally, cyclosporine A and CyPA-peptidyl-prolyl cis-trans isomerase mutant, R55A, inhibited AngII-stimulated CyPA and p47phox association in VSMC, suggesting that peptidyl-prolyl cis-trans isomerase activity was required for their interaction.	Cyclosporine	9-23	peptidylprolyl isomerase A	Homo sapiens	110-114
23504655-8	2013	When the NK1 receptor antagonist CsA was added at a dose of IC50, we found a significant decrease in cell growth (p&lt;0.001) in all culture conditions, including the control group.	Cyclosporine	33-36	tachykinin receptor 1	Homo sapiens	9-21
23777496-3	2013	We investigated how CsA affects production of IL-12/23p40 and IL-23 production by the human monocyte cell line, THP-1, which is able to differentiate into macrophage-like cells or normal human keratinocytes (NHKs).	Cyclosporine	20-23	interleukin 23 subunit alpha	Homo sapiens	62-67
23499865-7	2013	The productions of pro-inflammatory cytokines (IL-1beta, IL-2, IL-12 and TNFalpha) and JNK activity were remarkably reduced in the CsA-treated obese animals.	Cyclosporine	131-134	interleukin 2	Mus musculus	57-61
23404080-4	2013	It has been demonstrated that when ferrocene-induced iron-overloaded mice were fed the cyclosporin A (CsA), a specific inhibitor of the mPTP, diet (10 mg/kg/day) for 50 days, liver-to-body weight ratio, serum levels of alanine transaminase (ALT) and aspartate transaminase (AST), ROS production, mitochondrial swelling, loss of mitochondrial membrane potential (Deltapsi) and hepatocyte apoptosis decreased.	Cyclosporine	102-105	glutamic pyruvic transaminase, soluble	Mus musculus	219-239
23404080-4	2013	It has been demonstrated that when ferrocene-induced iron-overloaded mice were fed the cyclosporin A (CsA), a specific inhibitor of the mPTP, diet (10 mg/kg/day) for 50 days, liver-to-body weight ratio, serum levels of alanine transaminase (ALT) and aspartate transaminase (AST), ROS production, mitochondrial swelling, loss of mitochondrial membrane potential (Deltapsi) and hepatocyte apoptosis decreased.	Cyclosporine	102-105	glutamic pyruvic transaminase, soluble	Mus musculus	241-244
23404080-4	2013	It has been demonstrated that when ferrocene-induced iron-overloaded mice were fed the cyclosporin A (CsA), a specific inhibitor of the mPTP, diet (10 mg/kg/day) for 50 days, liver-to-body weight ratio, serum levels of alanine transaminase (ALT) and aspartate transaminase (AST), ROS production, mitochondrial swelling, loss of mitochondrial membrane potential (Deltapsi) and hepatocyte apoptosis decreased.	Cyclosporine	102-105	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	250-272
23404080-4	2013	It has been demonstrated that when ferrocene-induced iron-overloaded mice were fed the cyclosporin A (CsA), a specific inhibitor of the mPTP, diet (10 mg/kg/day) for 50 days, liver-to-body weight ratio, serum levels of alanine transaminase (ALT) and aspartate transaminase (AST), ROS production, mitochondrial swelling, loss of mitochondrial membrane potential (Deltapsi) and hepatocyte apoptosis decreased.	Cyclosporine	102-105	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	274-277
23302718-8	2013	Cyclosporine treatment significantly reduced proteinuria in rats with passive Heymann nephritis, concomitant with downregulation of c-mip in podocytes.	Cyclosporine	0-12	c-Maf-inducing protein	Rattus norvegicus	132-137
23224887-2	2013	We have shown that cyclosporin A (CsA) treatment of NCX1-, NCX2-, or NCX3-transfected HEK 293 cells and non-transfected H9c2, L6, and aortic smooth muscle cells, which express NCX1 protein naturally, reduces NCX surface expression and transport activity but has no impact on total cell NCX protein.	Cyclosporine	34-37	solute carrier family 8 member A2	Homo sapiens	59-63
23224887-3	2013	Similar effect on functional expression of NCX1 protein can be obtained also without CsA treatment by knockdown of cell cyclophilin A (CypA), one of the cellular receptor of CsA.	Cyclosporine	174-177	peptidylprolyl isomerase A	Homo sapiens	120-133
23224887-3	2013	Similar effect on functional expression of NCX1 protein can be obtained also without CsA treatment by knockdown of cell cyclophilin A (CypA), one of the cellular receptor of CsA.	Cyclosporine	174-177	peptidylprolyl isomerase A	Homo sapiens	135-139
23224887-4	2013	This suggests that CypA has a role in acquisition of function competence of NCX1 protein.Unlike CsA treatment, which affects the functional expression of all three mammalian NCX proteins similarly, FK506 and rapamycin treatment modulates only the functional expression of NCX2 and NCX3 proteins.	Cyclosporine	96-99	peptidylprolyl isomerase A	Homo sapiens	19-23
22902549-9	2013	Cyp inhibitors such as cyclosporine A (CsA) or non-immunosuppressive derivates such as alisporivir and SCY-635, prevent IRF9-CypA complex formation.	Cyclosporine	23-37	peptidylprolyl isomerase G	Homo sapiens	0-3
22902549-9	2013	Cyp inhibitors such as cyclosporine A (CsA) or non-immunosuppressive derivates such as alisporivir and SCY-635, prevent IRF9-CypA complex formation.	Cyclosporine	23-37	peptidylprolyl isomerase A	Homo sapiens	125-129
22902549-9	2013	Cyp inhibitors such as cyclosporine A (CsA) or non-immunosuppressive derivates such as alisporivir and SCY-635, prevent IRF9-CypA complex formation.	Cyclosporine	39-42	peptidylprolyl isomerase G	Homo sapiens	0-3
22902549-9	2013	Cyp inhibitors such as cyclosporine A (CsA) or non-immunosuppressive derivates such as alisporivir and SCY-635, prevent IRF9-CypA complex formation.	Cyclosporine	39-42	peptidylprolyl isomerase A	Homo sapiens	125-129
23382681-0	2013	Cyclosporine A impairs nucleotide binding oligomerization domain (Nod1)-mediated innate antibacterial renal defenses in mice and human transplant recipients.	Cyclosporine	0-14	nucleotide-binding oligomerization domain containing 1	Mus musculus	66-70
23382681-7	2013	In addition, CsA markedly inhibited Nod1 expression in neutrophils, macrophages, and renal dendritic cells.	Cyclosporine	13-16	nucleotide-binding oligomerization domain containing 1	Mus musculus	36-40
23382681-8	2013	CsA, acting through inhibition of the nuclear factor of activated T-cells (NFATs), also markedly downregulated Nod1 in neutrophils and macrophages.	Cyclosporine	0-3	nucleotide-binding oligomerization domain containing 1	Mus musculus	111-115
23597461-9	2013	Our study also confirmed the superiority of ATG/ALG + CsA regimen \[64.8% (95%CI 57.9% - 71.7%)\] over ATG/ALG alone \[32.6% (95%CI 15.7% - 49.5%)\] with regard to 5-year OS (P &lt; 0.01); but the addition of recombinant human granulocyte colony-stimulating factor (rhG-CSF) to ATG/ALG had no benefit in terms of OS.	Cyclosporine	54-57	colony stimulating factor 3	Homo sapiens	227-264
23152499-7	2012	We show that cyclosporine A added to a sample containing NS5B(Delta21), NS5A-D2, and CypA specifically inhibits the interaction between CypA and NS5A-D2 without altering the one between NS5A-D2 and NS5B(Delta21).	Cyclosporine	13-27	peptidylprolyl isomerase A	Homo sapiens	85-89
23152499-7	2012	We show that cyclosporine A added to a sample containing NS5B(Delta21), NS5A-D2, and CypA specifically inhibits the interaction between CypA and NS5A-D2 without altering the one between NS5A-D2 and NS5B(Delta21).	Cyclosporine	13-27	peptidylprolyl isomerase A	Homo sapiens	136-140
23285477-10	2012	Lower mean cumulative doses of cyclosporine A (CyA) and mycophenolic acid (MPA) (P&lt;0.05) each were associated with thickened CIMT.	Cyclosporine	31-45	CIMT	Homo sapiens	128-132
23285477-10	2012	Lower mean cumulative doses of cyclosporine A (CyA) and mycophenolic acid (MPA) (P&lt;0.05) each were associated with thickened CIMT.	Cyclosporine	47-50	CIMT	Homo sapiens	128-132
23057591-8	2012	Here, CsA increased phospho-JAK2 and phospho-STAT3 levels and reduced the phospho-IKKgamma and p65 proteins, thus activating NF-kappaB signaling.	Cyclosporine	6-9	signal transducer and activator of transcription 3	Rattus norvegicus	45-50
22718120-3	2012	Expression of NFATc2 was constitutive in vitro and in vivo in human melanoma, and cyclosporin A (CsA) treatment of melanoma cells led to downmodulation of NFATc2.	Cyclosporine	82-95	nuclear factor of activated T cells 2	Homo sapiens	155-161
22718120-3	2012	Expression of NFATc2 was constitutive in vitro and in vivo in human melanoma, and cyclosporin A (CsA) treatment of melanoma cells led to downmodulation of NFATc2.	Cyclosporine	97-100	nuclear factor of activated T cells 2	Homo sapiens	14-20
22718120-3	2012	Expression of NFATc2 was constitutive in vitro and in vivo in human melanoma, and cyclosporin A (CsA) treatment of melanoma cells led to downmodulation of NFATc2.	Cyclosporine	97-100	nuclear factor of activated T cells 2	Homo sapiens	155-161
22903029-10	2012	In the present study, we found that Dexamethasone and Cyclosporine A negatively regulated NF-kappaB signaling pathway under LPS simulation in HaCaT cells by inhibiting TLR4 expression, on the other hand, Cyclosporine A could inhibit HaCaT cell proliferation by the induction of the apoptosis of HaCaT cells to protect OLP from the destruction of epidermal cells effectively.	Cyclosporine	54-68	toll like receptor 4	Homo sapiens	168-172
22814863-12	2012	We treated cells with CyclosporinA (CsA), which binds to the matrix chaperone cyclophilin-D and regulates PTP opening.	Cyclosporine	22-34	peptidylprolyl isomerase F	Bos taurus	78-91
22814863-12	2012	We treated cells with CyclosporinA (CsA), which binds to the matrix chaperone cyclophilin-D and regulates PTP opening.	Cyclosporine	36-39	peptidylprolyl isomerase F	Bos taurus	78-91
22751784-6	2012	Pharmacological inhibition of calcineurin can be achieved using the natural product and immunosuppressive drug cyclosporin A, which inhibits calcineurin by binding to the immunophilin Cpr1.	Cyclosporine	111-124	peptidylprolyl isomerase CPR1	Saccharomyces cerevisiae S288C	184-188
22980762-5	2012	Over the 21 months a small decrease in CSA(max) and increase in lipid fraction and T(2) was observed in the MFC(DMD) in some muscles.	Cyclosporine	39-42	dystrophin	Homo sapiens	108-116
22929409-7	2012	Also, the CsA sensitivity of IFN-gamma (r = 0.131, P &lt; 0.0001) and GM-CSF (r = 0.036, P &lt; 0.01) were inversely correlated with chronological age.	Cyclosporine	10-13	colony stimulating factor 2	Homo sapiens	70-76
22822477-6	2012	Immunosuppressive drugs, such as tacrolimus (FK506) and cyclosporine A (CsA), were used to inhibit T cell interactions under the physiologic model of T cell migration at a ratio of 5 : 4.3 : 3.9 (E-selectin : ICAM-1 : VCAM-1).	Cyclosporine	72-75	selectin E	Homo sapiens	196-206
22846842-12	2012	Our findings identified deregulation of XPC and CypA as key targets of CsA, and UVB damage and PI3K/AKT activation as two principal drivers for CsA-sensitized skin tumorigenesis, further supporting an immunosuppression-independent mechanism of CsA action on skin tumorigenesis.	Cyclosporine	71-74	peptidylprolyl isomerase A	Homo sapiens	48-52
22971315-8	2012	CONCLUSION: Although conjunctival SCC has been described following cyclosporine treatment for organ transplantation, this report describes a case of conjunctival SCC following lower-dose cyclosporine treatment for psoriasis in a patient who had previous psoralen plus ultraviolet A (PUVA) treatment.	Cyclosporine	67-79	serpin family B member 3	Homo sapiens	34-37
22971315-8	2012	CONCLUSION: Although conjunctival SCC has been described following cyclosporine treatment for organ transplantation, this report describes a case of conjunctival SCC following lower-dose cyclosporine treatment for psoriasis in a patient who had previous psoralen plus ultraviolet A (PUVA) treatment.	Cyclosporine	187-199	serpin family B member 3	Homo sapiens	34-37
22820192-3	2012	Previously, we have shown that immunosuppressive drug, cyclosporine A (CsA) directly alters tumor phenotype of cutaneous squamous cell carcinomas (SCCs) by activating TGF-beta and TAK1/TAB1 signaling pathways.	Cyclosporine	55-69	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	180-184
22820192-3	2012	Previously, we have shown that immunosuppressive drug, cyclosporine A (CsA) directly alters tumor phenotype of cutaneous squamous cell carcinomas (SCCs) by activating TGF-beta and TAK1/TAB1 signaling pathways.	Cyclosporine	71-74	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	180-184
22790389-8	2012	RESULTS: CsA treatment increased the expressions of LC3-II and beclin-1 in the kidney in a dose-dependent manner.	Cyclosporine	9-12	beclin 1, autophagy related	Mus musculus	63-71
22814107-1	2012	Cyclophilin A (CyPA) is a peptidyl-prolyl cis/trans isomerase originally identified as the target of the immunosuppressive drug cyclosporine A.	Cyclosporine	128-142	peptidylprolyl isomerase A	Homo sapiens	0-13
22814107-1	2012	Cyclophilin A (CyPA) is a peptidyl-prolyl cis/trans isomerase originally identified as the target of the immunosuppressive drug cyclosporine A.	Cyclosporine	128-142	peptidylprolyl isomerase A	Homo sapiens	15-19
21631587-7	2012	Cyclosporine and TAC led to a comparable and significant decrease in the efflux ratio of ImTORs, suggesting inhibition of a P-gp-mediated efflux transport.	Cyclosporine	0-12	phosphoglycolate phosphatase	Homo sapiens	124-128
22788126-7	2012	IL-2 levels in the SIN-only and CsA-only groups were lower than those in the control group (p &lt; 0.05) and higher than those in the cotreated group (p &lt; 0.05); however, the results for IL-10 were different.	Cyclosporine	32-35	interleukin 2	Rattus norvegicus	0-4
22788126-7	2012	IL-2 levels in the SIN-only and CsA-only groups were lower than those in the control group (p &lt; 0.05) and higher than those in the cotreated group (p &lt; 0.05); however, the results for IL-10 were different.	Cyclosporine	32-35	interleukin 10	Rattus norvegicus	190-195
22279052-5	2012	Six of these compounds were evaluated additionally in the presence of the P-gp inhibitor cyclosporine A.	Cyclosporine	89-103	PGP	Canis lupus familiaris	74-78
22812226-7	2012	CsA inhibited the expression of VEGF and the complement inhibitor DAF and increased the expression of CRP of vascular endothelial cells.	Cyclosporine	0-3	vascular endothelial growth factor A	Rattus norvegicus	32-36
22812226-10	2012	CONCLUSION: CsA can damage vascular endothelium of hyperlipidemic rats by activating the complement system induced by VEGF/DAF and ROS/CRP pathway.	Cyclosporine	12-15	vascular endothelial growth factor A	Rattus norvegicus	118-122
22564602-11	2012	CsA produced a dose-dependent induction of p27 and reduction of procasapase-3.	Cyclosporine	0-3	interferon alpha inducible protein 27	Homo sapiens	43-46
22564603-8	2012	CsA induced p27 and p53, as well as degradation of 116-kd PARP into an 89-kd fragment.	Cyclosporine	0-3	interferon alpha inducible protein 27	Homo sapiens	12-15
22564605-7	2012	RESULTS: MMP-1, MMP-3, MMP-8, MMP-9, and MMP-13 activities were increased after CsA treatment; MMP-1 = 121; MMP-3 = 164; MMP-8 = 133; MMP-9 = 124; and MMP-13 = 121.	Cyclosporine	80-83	matrix metallopeptidase 1	Homo sapiens	9-14
22564605-7	2012	RESULTS: MMP-1, MMP-3, MMP-8, MMP-9, and MMP-13 activities were increased after CsA treatment; MMP-1 = 121; MMP-3 = 164; MMP-8 = 133; MMP-9 = 124; and MMP-13 = 121.	Cyclosporine	80-83	matrix metallopeptidase 8	Homo sapiens	23-28
22564605-9	2012	CONCLUSIONS: This study showed CsA to activate most MMPs (except MMP-2) in endothelial cells.	Cyclosporine	31-34	matrix metallopeptidase 1	Homo sapiens	52-56
22334041-10	2012	In single-SNP adjusted analysis, nine SNPs in the XPC, CYP2C9, PAX4, MTRR, and GAN genes were associated with cyclosporine nephrotoxicity.	Cyclosporine	110-122	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	55-61
21918035-7	2011	However, vectorial transport across LLC-OCT1/MDR1 cells was identified, which was inhibited by the MDR1 inhibitor cyclosporine A, clearly indicating that YM155 is in fact a substrate of MDR1.	Cyclosporine	114-128	ATP-binding cassette, sub-family B (MDR/TAP), member 1	Sus scrofa	99-103
21918035-7	2011	However, vectorial transport across LLC-OCT1/MDR1 cells was identified, which was inhibited by the MDR1 inhibitor cyclosporine A, clearly indicating that YM155 is in fact a substrate of MDR1.	Cyclosporine	114-128	ATP-binding cassette, sub-family B (MDR/TAP), member 1	Sus scrofa	99-103
21728990-1	2011	Cyclophilin A (CyPA) is a cytosolic receptor of immunosuppressive drug cyclosporin A (CsA) which possesses peptidyl-prodyl cis/trans isomerase (PPIase) activity.	Cyclosporine	71-84	peptidylprolyl isomerase A	Homo sapiens	0-13
21728990-1	2011	Cyclophilin A (CyPA) is a cytosolic receptor of immunosuppressive drug cyclosporin A (CsA) which possesses peptidyl-prodyl cis/trans isomerase (PPIase) activity.	Cyclosporine	71-84	peptidylprolyl isomerase A	Homo sapiens	15-19
21728990-1	2011	Cyclophilin A (CyPA) is a cytosolic receptor of immunosuppressive drug cyclosporin A (CsA) which possesses peptidyl-prodyl cis/trans isomerase (PPIase) activity.	Cyclosporine	71-84	peptidylprolyl isomerase like 6	Homo sapiens	107-142
21728990-1	2011	Cyclophilin A (CyPA) is a cytosolic receptor of immunosuppressive drug cyclosporin A (CsA) which possesses peptidyl-prodyl cis/trans isomerase (PPIase) activity.	Cyclosporine	71-84	peptidylprolyl isomerase like 6	Homo sapiens	144-150
21728990-1	2011	Cyclophilin A (CyPA) is a cytosolic receptor of immunosuppressive drug cyclosporin A (CsA) which possesses peptidyl-prodyl cis/trans isomerase (PPIase) activity.	Cyclosporine	86-89	peptidylprolyl isomerase A	Homo sapiens	0-13
21728990-1	2011	Cyclophilin A (CyPA) is a cytosolic receptor of immunosuppressive drug cyclosporin A (CsA) which possesses peptidyl-prodyl cis/trans isomerase (PPIase) activity.	Cyclosporine	86-89	peptidylprolyl isomerase A	Homo sapiens	15-19
21728990-1	2011	Cyclophilin A (CyPA) is a cytosolic receptor of immunosuppressive drug cyclosporin A (CsA) which possesses peptidyl-prodyl cis/trans isomerase (PPIase) activity.	Cyclosporine	86-89	peptidylprolyl isomerase like 6	Homo sapiens	107-142
21728990-1	2011	Cyclophilin A (CyPA) is a cytosolic receptor of immunosuppressive drug cyclosporin A (CsA) which possesses peptidyl-prodyl cis/trans isomerase (PPIase) activity.	Cyclosporine	86-89	peptidylprolyl isomerase like 6	Homo sapiens	144-150
21757611-4	2011	Two P-glycoprotein (P-gp) inhibitors, verapamil and cyclosporine A, substantially decreased the efflux ratio of Rh2s from 28.5 to 1.0 and 1.2, respectively, in Caco-2 cells.	Cyclosporine	52-66	Rh associated glycoprotein	Homo sapiens	112-115
21844115-10	2011	Although the use of cyclosporine A (CyA) was associated with hypertension (p &lt; 0.05), those who received a lower cumulative dose of CyA had thicker CIMT (r (s) = -0.33, p =0.01) and CyA use remained an independent predictor of CIMT during linear regression analysis.	Cyclosporine	135-138	CIMT	Homo sapiens	230-234
22128262-1	2011	The effect of cyclosporin A (CsA), an immunosuppressant, on human ether-a-go-go-related gene (HERG) channel as it is expressed in human embryonic kidney cells was studied using a whole-cell, patch-clamp technique.	Cyclosporine	29-32	potassium voltage-gated channel subfamily H member 2	Homo sapiens	94-98
22128262-2	2011	CsA inhibited the HERG channel in a concentration-dependent manner, with an IC(50) value and a Hill coefficient of 3.17 microM and 0.89, respectively.	Cyclosporine	0-3	potassium voltage-gated channel subfamily H member 2	Homo sapiens	18-22
22128262-4	2011	The CsA-induced inhibition of HERG channels was voltage-dependent, with a steep increase over the voltage range of the channel opening.	Cyclosporine	4-7	potassium voltage-gated channel subfamily H member 2	Homo sapiens	30-34
22128262-6	2011	CsA blocked the HERG channels predominantly in the open and inactivated states rather than in the closed state.	Cyclosporine	0-3	potassium voltage-gated channel subfamily H member 2	Homo sapiens	16-20
22128262-7	2011	Results of the present study suggest that CsA acts directly on the HERG channel as an open-channel blocker, and it acts independently of its effect on calcineurin activity.	Cyclosporine	42-45	potassium voltage-gated channel subfamily H member 2	Homo sapiens	67-71
21773745-0	2011	Different effects of CsA and FK506 on aquaporin-2 abundance in rat primary cultured collecting duct cells.	Cyclosporine	21-24	aquaporin 2	Rattus norvegicus	38-49
21773745-3	2011	CsA (0.5-5 muM) but not FK 506 (0.01-1 muM) decreased expression of AQP2 protein and messenger RNA (mRNA) in a concentration and time dependent manner, without affecting mRNA stability.	Cyclosporine	0-3	aquaporin 2	Rattus norvegicus	68-72
21773745-4	2011	This effect was observed despite similar inhibition of Cn activity by both CnI, thereby suggesting that the CsA-dependent decrease in AQP2 expression was Cn independent.	Cyclosporine	108-111	aquaporin 2	Rattus norvegicus	134-138
21773745-8	2011	Phosphorylation of CREB at an activating phosphorylation site (S133) was decreased by CsA, but not by FK506.	Cyclosporine	86-89	cAMP responsive element binding protein 1	Rattus norvegicus	19-23
21773745-10	2011	We show that CsA decreases transcription of AQP2, a process that is in part independent of Cn or cyclophilin A and suggests dependence on decreased activity of CREB.	Cyclosporine	13-16	aquaporin 2	Rattus norvegicus	44-48
21773745-10	2011	We show that CsA decreases transcription of AQP2, a process that is in part independent of Cn or cyclophilin A and suggests dependence on decreased activity of CREB.	Cyclosporine	13-16	cAMP responsive element binding protein 1	Rattus norvegicus	160-164
21725799-5	2011	The inhibitory potencies of known P-gp inhibitors viz verapamil, ketoconazole, tacrolimus and cyclosporine A, determined over a wide concentration range, showed low apparent IC(50) values.	Cyclosporine	94-108	phosphoglycolate phosphatase	Homo sapiens	34-38
21341336-6	2011	Moreover, pretreatment of CsA, a cyclophilin D ligand that inhibits mitochondria potential uncoupling, prevented the activation of caspase-9 and caspase-3, but not caspase-8, and the apoptosis of MG-63 cells, triggered by corosolic acid.	Cyclosporine	26-29	caspase 9	Homo sapiens	131-140
21781066-0	2011	CD26/dipeptidyl-peptidase IV and adenosine deaminase serum levels in psoriatic patients treated with cyclosporine, etanercept, and psoralen plus ultraviolet A phototherapy.	Cyclosporine	101-113	dipeptidyl peptidase 4	Homo sapiens	0-28
21622902-0	2011	Nrf-2 regulates cyclosporine-stimulated HO-1 expression in gingiva.	Cyclosporine	16-28	heme oxygenase 1	Homo sapiens	40-44
21622902-1	2011	Cyclosporine-A (CsA) stimulates heme oxygenase-1 (HO-1) expression in the gingiva, but the regulation and the role of HO-1 in gingival overgrowth are not well-understood.	Cyclosporine	0-14	heme oxygenase 1	Homo sapiens	32-48
21622902-1	2011	Cyclosporine-A (CsA) stimulates heme oxygenase-1 (HO-1) expression in the gingiva, but the regulation and the role of HO-1 in gingival overgrowth are not well-understood.	Cyclosporine	0-14	heme oxygenase 1	Homo sapiens	50-54
21622902-1	2011	Cyclosporine-A (CsA) stimulates heme oxygenase-1 (HO-1) expression in the gingiva, but the regulation and the role of HO-1 in gingival overgrowth are not well-understood.	Cyclosporine	16-19	heme oxygenase 1	Homo sapiens	32-48
21622902-1	2011	Cyclosporine-A (CsA) stimulates heme oxygenase-1 (HO-1) expression in the gingiva, but the regulation and the role of HO-1 in gingival overgrowth are not well-understood.	Cyclosporine	16-19	heme oxygenase 1	Homo sapiens	50-54
21622902-3	2011	The aim of this study was to examine the role of Nrf-2 in the regulation of CsA-stimulated HO-1 expression in human gingival fibroblasts.	Cyclosporine	76-79	heme oxygenase 1	Homo sapiens	91-95
21622902-5	2011	Treatment with siNrf-2, but not with an NF-kappaB inhibitor, reduced CsA-stimulated HO-1 mRNA expression.	Cyclosporine	69-72	heme oxygenase 1	Homo sapiens	84-88
21596928-12	2011	Accordingly, PAR-3 expression was suppressed by the NFAT inhibitor cyclosporine A or NFAT2 siRNA.	Cyclosporine	67-81	coagulation factor II thrombin receptor like 2	Homo sapiens	13-18
21421070-1	2011	This retrospective study was performed to compare results with tacrolimus versus cyclosporine in combination with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation (HCT) with granulocyte colony-stimulating factor-mobilized blood cells.	Cyclosporine	81-93	colony stimulating factor 3	Homo sapiens	212-249
21474569-11	2011	CsA induced expression of p53, the degree of which was attenuated by fasudil in association with decreases of proapoptotic markers such as Bad, Bax, and total/cleaved caspase-3.	Cyclosporine	0-3	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	26-29
21474569-11	2011	CsA induced expression of p53, the degree of which was attenuated by fasudil in association with decreases of proapoptotic markers such as Bad, Bax, and total/cleaved caspase-3.	Cyclosporine	0-3	BCL2 associated X, apoptosis regulator	Rattus norvegicus	144-147
21297316-3	2011	Among these drugs, cyclosporin A markedly increases the plasma concentrations of OATP1B1 substrates.	Cyclosporine	19-32	solute carrier organic anion transporter family member 1B1	Homo sapiens	81-88
21430235-5	2011	Finally, budesonide, cyclosporine, and rifampin were identified as inhibitors of OATP1B1-, OATP1B3-, and OATP2B1-meditated mesalazine uptake.	Cyclosporine	21-33	solute carrier organic anion transporter family member 1B1	Homo sapiens	81-88
21430235-5	2011	Finally, budesonide, cyclosporine, and rifampin were identified as inhibitors of OATP1B1-, OATP1B3-, and OATP2B1-meditated mesalazine uptake.	Cyclosporine	21-33	solute carrier organic anion transporter family member 2B1	Homo sapiens	105-112
21396746-2	2011	After testing these three synthetic peptides, we found that the peptide Trp-Gly-Pro (WGP) showed comparable inhibitory ability as positive control cyclosporine A (CsA) on CypA-mediated PPIase activity with IC50 values of 33.11 nM and 10.25 nM, respectively.	Cyclosporine	147-161	peptidylprolyl isomerase A	Homo sapiens	171-175
21396746-2	2011	After testing these three synthetic peptides, we found that the peptide Trp-Gly-Pro (WGP) showed comparable inhibitory ability as positive control cyclosporine A (CsA) on CypA-mediated PPIase activity with IC50 values of 33.11 nM and 10.25 nM, respectively.	Cyclosporine	163-166	peptidylprolyl isomerase A	Homo sapiens	171-175
21426898-8	2011	In vitro studies further showed that cyclosporine A, a widely used immunosuppressive drug in transplant patients, attenuated induction of hTERT and telomerase activation in T cells treated with the mitogenic agent concanavalin A.	Cyclosporine	37-51	telomerase reverse transcriptase	Homo sapiens	138-143
24900335-1	2011	Cyclosporine A (CsA) and its chemical analogues EthVal4Cs, MeVal4Cs, and Me(d-Ala)3EthVal4Cs (Alisporivir) all interact with cyclophilin A (CypA).	Cyclosporine	0-14	peptidylprolyl isomerase A	Homo sapiens	125-138
24900335-1	2011	Cyclosporine A (CsA) and its chemical analogues EthVal4Cs, MeVal4Cs, and Me(d-Ala)3EthVal4Cs (Alisporivir) all interact with cyclophilin A (CypA).	Cyclosporine	0-14	peptidylprolyl isomerase A	Homo sapiens	140-144
24900335-1	2011	Cyclosporine A (CsA) and its chemical analogues EthVal4Cs, MeVal4Cs, and Me(d-Ala)3EthVal4Cs (Alisporivir) all interact with cyclophilin A (CypA).	Cyclosporine	16-19	peptidylprolyl isomerase A	Homo sapiens	125-138
24900335-1	2011	Cyclosporine A (CsA) and its chemical analogues EthVal4Cs, MeVal4Cs, and Me(d-Ala)3EthVal4Cs (Alisporivir) all interact with cyclophilin A (CypA).	Cyclosporine	16-19	peptidylprolyl isomerase A	Homo sapiens	140-144
21443601-8	2011	The CYP3A4 +- PgP substrates of simvastatin and ciclosporin A did not affect the single or repeated dose PK of alitretinoin.	Cyclosporine	48-61	phosphoglycolate phosphatase	Homo sapiens	14-17
21430707-7	2011	We first reported that metformin and cyclosporin A (CsA) prevented Ca2+-induced PTP opening in permeabilized and intact INS-1 cells.	Cyclosporine	37-50	insulin 1	Rattus norvegicus	120-125
21430707-7	2011	We first reported that metformin and cyclosporin A (CsA) prevented Ca2+-induced PTP opening in permeabilized and intact INS-1 cells.	Cyclosporine	52-55	insulin 1	Rattus norvegicus	120-125
21199863-10	2011	In summary, the evidence provided here argues for a previously unanticipated role of calcineurin in CBM complex formation as a molecular basis of the inhibitory function of CsA or FK506 on TCR-induced NF-kappaB activity.	Cyclosporine	173-176	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	189-192
21310770-7	2011	RESULTS: Compared with the control group, acidic buffer or plus cyclosporine A post-conditioning significantly improved myocardial performance, decreased cytochrome C release into the cytosol, increased Bcl-2 expression and decreased Bax expression, decreased sensitivity of mPTP-opening to [Ca2+] and the rate of apoptosis after reperfusion.	Cyclosporine	64-78	BCL2 associated X, apoptosis regulator	Rattus norvegicus	234-237
21078360-0	2011	Human adipose tissue-derived mesenchymal stem cells facilitate the immunosuppressive effect of cyclosporin A on T lymphocytes through Jagged-1-mediated inhibition of NF-kappaB signaling.	Cyclosporine	95-108	jagged canonical Notch ligand 1	Homo sapiens	134-142
21078360-11	2011	CONCLUSIONS: Human AMSCs facilitate the immunosuppressive effect of CsA on T lymphocytes through Jagged-1/Notch-related inhibition of NF-kappaB signaling.	Cyclosporine	68-71	jagged canonical Notch ligand 1	Homo sapiens	97-105
21148296-7	2011	In addition, pretreatment with CsA blocked NaBT-mediated induction of intestinal alkaline phosphatase (IAP) activity and villin and p27(kip1) expression; knockdown of either NFATc1 or NFATc4 attenuated NaBT-induced IAP activity.	Cyclosporine	31-34	interferon alpha inducible protein 27	Homo sapiens	132-135
21148296-7	2011	In addition, pretreatment with CsA blocked NaBT-mediated induction of intestinal alkaline phosphatase (IAP) activity and villin and p27(kip1) expression; knockdown of either NFATc1 or NFATc4 attenuated NaBT-induced IAP activity.	Cyclosporine	31-34	cyclin dependent kinase inhibitor 1B	Homo sapiens	136-140
21094139-6	2011	Dephosphorylation and nuclear translocation of NFAT1 caused by ILY were prevented by [Ca(2+)]i calcium chelator, BAPTA/AM, and calcineurin inhibitors, cyclosporine A and tacrolimus.	Cyclosporine	151-165	nuclear factor of activated T cells 2	Homo sapiens	47-52
21057045-4	2011	On the other hand, SERCA2 expression is reduced by CN inhibition with cyclosporine.	Cyclosporine	70-82	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2	Rattus norvegicus	19-25
21168749-0	2010	Effects of a cGMP-specific phosphodiesterase inhibitor on expression of endothelial nitric oxide synthase and vascular endothelial growth factor in rats with cyclosporine-induced nephrotoxicity.	Cyclosporine	158-170	vascular endothelial growth factor A	Rattus norvegicus	110-144
21168749-1	2010	BACKGROUND: The mechanism of cyclosporine (CsA)-induced nephrotoxicity has been suggested to be vasoconstriction due to reduced nitric oxide (NO), providing tissue fibrosis by elevation of transforming growth factor beta and vascular endothelial growth factor (VEGF).	Cyclosporine	29-41	vascular endothelial growth factor A	Rattus norvegicus	225-259
21168749-1	2010	BACKGROUND: The mechanism of cyclosporine (CsA)-induced nephrotoxicity has been suggested to be vasoconstriction due to reduced nitric oxide (NO), providing tissue fibrosis by elevation of transforming growth factor beta and vascular endothelial growth factor (VEGF).	Cyclosporine	29-41	vascular endothelial growth factor A	Rattus norvegicus	261-265
21168749-1	2010	BACKGROUND: The mechanism of cyclosporine (CsA)-induced nephrotoxicity has been suggested to be vasoconstriction due to reduced nitric oxide (NO), providing tissue fibrosis by elevation of transforming growth factor beta and vascular endothelial growth factor (VEGF).	Cyclosporine	43-46	vascular endothelial growth factor A	Rattus norvegicus	225-259
21168749-1	2010	BACKGROUND: The mechanism of cyclosporine (CsA)-induced nephrotoxicity has been suggested to be vasoconstriction due to reduced nitric oxide (NO), providing tissue fibrosis by elevation of transforming growth factor beta and vascular endothelial growth factor (VEGF).	Cyclosporine	43-46	vascular endothelial growth factor A	Rattus norvegicus	261-265
21168749-2	2010	In this study using a rat model of CsA-induced nephrotoxicity, we administered a phosphodiesterase-5 inhibitor to ameliorate the renal injury and alter the expression of endothelial No synthase (eNOS) and VEGF.	Cyclosporine	35-38	vascular endothelial growth factor A	Rattus norvegicus	205-209
21168749-12	2010	Western blots for VEGF revealed reduced expression only in the CsA plus udenafil group.	Cyclosporine	63-66	vascular endothelial growth factor A	Rattus norvegicus	18-22
21168749-14	2010	VEGF mRNA which was decreased in the CsA group (2.026 +- 1.109), showed greater tendency after administration of udenafil (0.440 +- 0.449) (P = .003).	Cyclosporine	37-40	vascular endothelial growth factor A	Rattus norvegicus	0-4
21168749-15	2010	CONCLUSION: The phosphodiesterase inhibitor ameliorated renal injury in a rat model of CsA-induced nephrotoxicity, possibly related to increased eNOS and reduced VEGF expression.	Cyclosporine	87-90	vascular endothelial growth factor A	Rattus norvegicus	162-166
20709092-10	2010	Thus, the MPT induced by 10 and 50 muM troglitazone are regulated by different mechanism; the MPT induced by 10 muM troglitazone is regulated by the activation of iPLA2 and caused by the opening of CsA-regulating MPT pores followed by accumulation of Ca2+ in mitochondria, while that induced by 50 muM troglitazone is partly regulated by reactive oxygen species and mainly caused by the opening of CsA-insensitive MPT pores.	Cyclosporine	398-401	phospholipase A2 group VI	Rattus norvegicus	163-168
20840389-3	2010	The P-gp substrates quinidine, loperamide, nelfinavir, cyclosporin and the control (non P-gp substrate) drug diazepam were individually administered intravenously and per os to ABCB1-1Delta dogs, which have a P-gp null phenotype and ABCB1 wildtype dogs.	Cyclosporine	55-66	PGP	Canis lupus familiaris	4-8
21129263-0	2010	[Impact of cyclosporine A on the expression of T-bet, GATA-3, relevant signal transduction molecules, cytokine and Th1/Th2 balance in patients with chronic aplastic anemia].	Cyclosporine	11-25	T-box transcription factor 21	Homo sapiens	47-52
21129263-5	2010	After treating with CsA for 6 months of CsA treatment, expression of T-bet, STAT4, T-bet/GATA-3 ratio, Th1 proportion, IFN-gamma and IL-12 levels were lower than before, however, the expression of T-bet, STAT4, T-bet/GATA-3 ratio, Th1 proportion and IFN-gamma had not been reduced to normal state.	Cyclosporine	20-23	T-box transcription factor 21	Homo sapiens	69-74
21129263-5	2010	After treating with CsA for 6 months of CsA treatment, expression of T-bet, STAT4, T-bet/GATA-3 ratio, Th1 proportion, IFN-gamma and IL-12 levels were lower than before, however, the expression of T-bet, STAT4, T-bet/GATA-3 ratio, Th1 proportion and IFN-gamma had not been reduced to normal state.	Cyclosporine	20-23	T-box transcription factor 21	Homo sapiens	83-88
21129263-5	2010	After treating with CsA for 6 months of CsA treatment, expression of T-bet, STAT4, T-bet/GATA-3 ratio, Th1 proportion, IFN-gamma and IL-12 levels were lower than before, however, the expression of T-bet, STAT4, T-bet/GATA-3 ratio, Th1 proportion and IFN-gamma had not been reduced to normal state.	Cyclosporine	20-23	T-box transcription factor 21	Homo sapiens	83-88
21129263-5	2010	After treating with CsA for 6 months of CsA treatment, expression of T-bet, STAT4, T-bet/GATA-3 ratio, Th1 proportion, IFN-gamma and IL-12 levels were lower than before, however, the expression of T-bet, STAT4, T-bet/GATA-3 ratio, Th1 proportion and IFN-gamma had not been reduced to normal state.	Cyclosporine	20-23	T-box transcription factor 21	Homo sapiens	83-88
20519340-1	2010	The aim of this study was to investigate the potential of calcineurin inhibitors [cyclosporine A (CsA) and tacrolimus (Tac)] to inhibit cellular uptake of atorvastatin mediated by the liver-specific organic anion-transporting polypeptide 1B1 (OATP1B1) in vitro.	Cyclosporine	82-96	solute carrier organic anion transporter family member 1B1	Homo sapiens	243-250
20505666-0	2010	Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up.	Cyclosporine	120-132	phosphoglycolate phosphatase	Homo sapiens	6-10
20505666-1	2010	Cyclosporin A (CsA) is a substrate for cytochrome P450 3A and the efflux transporter P-glycoprotein (P-gp; ABCB1), both abundantly expressed in the kidney.	Cyclosporine	0-13	phosphoglycolate phosphatase	Homo sapiens	101-105
20505666-1	2010	Cyclosporin A (CsA) is a substrate for cytochrome P450 3A and the efflux transporter P-glycoprotein (P-gp; ABCB1), both abundantly expressed in the kidney.	Cyclosporine	15-18	phosphoglycolate phosphatase	Homo sapiens	101-105
20451281-1	2010	BACKGROUND &amp; AIMS: The cyclophilin (Cyp) inhibitors - cyclosporine A (CsA), NIM811, Debio 025, and SCY 635 - block HCV replication both in vitro and in vivo, and represent a novel class of potent anti-HCV agents.	Cyclosporine	58-72	peptidylprolyl isomerase G	Homo sapiens	27-38
20451281-1	2010	BACKGROUND &amp; AIMS: The cyclophilin (Cyp) inhibitors - cyclosporine A (CsA), NIM811, Debio 025, and SCY 635 - block HCV replication both in vitro and in vivo, and represent a novel class of potent anti-HCV agents.	Cyclosporine	58-72	peptidylprolyl isomerase G	Homo sapiens	40-43
20451281-8	2010	Remarkably, CsA prevents the CypA-NS5A interaction in a dose-dependent manner.	Cyclosporine	12-15	peptidylprolyl isomerase A	Homo sapiens	29-33
20451281-9	2010	Importantly, the CypA-NS5A interaction is conserved among genotypes and is interrupted by CsA.	Cyclosporine	90-93	peptidylprolyl isomerase A	Homo sapiens	17-21
20451281-10	2010	Surprisingly, the NS5A mutant protein, which arose in CsA-resistant HCV variants, behaves similarly to wild-type NS5A in terms of both CypA binding and CsA-mediated release from CypA.	Cyclosporine	152-155	peptidylprolyl isomerase A	Homo sapiens	178-182
20620543-5	2010	But the expression of AQP2 mRNA and protein in the syngeneic grafts (sTX) versus the immunosuppression group (aTX+CsA) showed no difference compared with a control group (P &gt; 0.05).	Cyclosporine	114-117	aquaporin 2	Rattus norvegicus	22-26
20132841-7	2010	Importantly, the NS5A-CypA interactions were sensitive to CsA in a dose-responsive manner and an isomerase mutant of CypA interacted with NS5A less efficiently than wild-type CypA.	Cyclosporine	58-61	peptidylprolyl isomerase A	Homo sapiens	22-26
20132841-7	2010	Importantly, the NS5A-CypA interactions were sensitive to CsA in a dose-responsive manner and an isomerase mutant of CypA interacted with NS5A less efficiently than wild-type CypA.	Cyclosporine	58-61	peptidylprolyl isomerase A	Homo sapiens	117-121
20132841-7	2010	Importantly, the NS5A-CypA interactions were sensitive to CsA in a dose-responsive manner and an isomerase mutant of CypA interacted with NS5A less efficiently than wild-type CypA.	Cyclosporine	58-61	peptidylprolyl isomerase A	Homo sapiens	117-121
20132841-8	2010	These findings correlate the anti-HCV properties of CsA with an ability of the compound to disrupt NS5A-CypA interactions in vitro and in vivo, whilst providing the basis for development of assay platforms suitable to screen compound libraries for novel inhibitors of the NS5A-CypA interaction.	Cyclosporine	52-55	peptidylprolyl isomerase A	Homo sapiens	104-108
20132841-8	2010	These findings correlate the anti-HCV properties of CsA with an ability of the compound to disrupt NS5A-CypA interactions in vitro and in vivo, whilst providing the basis for development of assay platforms suitable to screen compound libraries for novel inhibitors of the NS5A-CypA interaction.	Cyclosporine	52-55	peptidylprolyl isomerase A	Homo sapiens	277-281
20364129-2	2010	CypA suppresses T-cell activation through cyclosporine complexation and is required for effective HIV-1 replication in host cells.	Cyclosporine	42-54	peptidylprolyl isomerase A	Homo sapiens	0-4
20364129-4	2010	We determined atomic-resolution structures of acetylated CypA and its complexes with cyclosporine and HIV-1 capsid.	Cyclosporine	85-97	peptidylprolyl isomerase A	Homo sapiens	57-61
20364129-6	2010	Furthermore, CypA acetylation antagonized the immunosuppressive effects of cyclosporine by inhibiting the sequential steps of cyclosporine binding and calcineurin inhibition.	Cyclosporine	75-87	peptidylprolyl isomerase A	Homo sapiens	13-17
20364129-6	2010	Furthermore, CypA acetylation antagonized the immunosuppressive effects of cyclosporine by inhibiting the sequential steps of cyclosporine binding and calcineurin inhibition.	Cyclosporine	126-138	peptidylprolyl isomerase A	Homo sapiens	13-17
20305583-7	2010	CONCLUSION: These results demonstrate that inhibition of CD40-CD40L interaction or treatment with rapamycin could be successfully combined with in vitro-expanded Treg cell therapy, but the concomitant use of mycophenolate mofetil or cyclosporine A in this type of Treg cell therapy should be carefully considered.	Cyclosporine	233-247	CD40 ligand	Mus musculus	62-67
20402674-5	2010	In addition, the proliferation of cyclosporin A (CsA)-treated spleen lymphocytes was also significantly promoted in the same pattern (p&lt;0.001); the production of IL-2 was elevated and the effect appeared as early as 24 h after PGP-SL treatment.	Cyclosporine	34-47	interleukin 2	Mus musculus	165-169
20402674-5	2010	In addition, the proliferation of cyclosporin A (CsA)-treated spleen lymphocytes was also significantly promoted in the same pattern (p&lt;0.001); the production of IL-2 was elevated and the effect appeared as early as 24 h after PGP-SL treatment.	Cyclosporine	49-52	interleukin 2	Mus musculus	165-169
20194728-3	2010	Liver mitochondria isolated from ArKO mice displayed increased activity of the mitochondrial respiratory complex IV compared with wild-type mice and were less prone to undergo cyclosporin A-sensitive mitochondrial permeability transition (MPT) induced by calcium loading.	Cyclosporine	176-189	cytochrome P450, family 19, subfamily a, polypeptide 1	Mus musculus	33-37
20236315-8	2010	Furthermore, cell damage induced by the silencing of TRAP1 was prevented by the mitochondrial permeability transition pore inhibitor, cyclosporin A.	Cyclosporine	134-147	TNF receptor-associated protein 1	Rattus norvegicus	53-58
20089806-6	2010	We show that the VSMC differentiation marker genes smooth muscle alpha-actin (ACTA2), transgelin (TAGLN), smoothelin (SMTN), and myocardin (MYOCD) are all down-regulated by CSA in VSMC monoculture, whereas cyclin-dependent kinase inhibitor-1A (CDKN1A) and matrix metalloproteinase-3 (MMP3) are up-regulated.	Cyclosporine	173-176	actin alpha 2, smooth muscle	Rattus norvegicus	78-83
20089806-6	2010	We show that the VSMC differentiation marker genes smooth muscle alpha-actin (ACTA2), transgelin (TAGLN), smoothelin (SMTN), and myocardin (MYOCD) are all down-regulated by CSA in VSMC monoculture, whereas cyclin-dependent kinase inhibitor-1A (CDKN1A) and matrix metalloproteinase-3 (MMP3) are up-regulated.	Cyclosporine	173-176	myocardin	Rattus norvegicus	129-138
20089806-6	2010	We show that the VSMC differentiation marker genes smooth muscle alpha-actin (ACTA2), transgelin (TAGLN), smoothelin (SMTN), and myocardin (MYOCD) are all down-regulated by CSA in VSMC monoculture, whereas cyclin-dependent kinase inhibitor-1A (CDKN1A) and matrix metalloproteinase-3 (MMP3) are up-regulated.	Cyclosporine	173-176	myocardin	Rattus norvegicus	140-145
20089806-8	2010	Administration of CSA to rat carotid artery in vivo resulted in acute and transient suppression of ACTA2, TAGLN, SMTN, MYOCD, and smooth muscle myosin heavy chain (MYH11) mRNA levels.	Cyclosporine	18-21	actin alpha 2, smooth muscle	Rattus norvegicus	99-104
20089806-8	2010	Administration of CSA to rat carotid artery in vivo resulted in acute and transient suppression of ACTA2, TAGLN, SMTN, MYOCD, and smooth muscle myosin heavy chain (MYH11) mRNA levels.	Cyclosporine	18-21	myocardin	Rattus norvegicus	119-124
20089806-8	2010	Administration of CSA to rat carotid artery in vivo resulted in acute and transient suppression of ACTA2, TAGLN, SMTN, MYOCD, and smooth muscle myosin heavy chain (MYH11) mRNA levels.	Cyclosporine	18-21	myosin heavy chain 11	Rattus norvegicus	130-162
20089806-8	2010	Administration of CSA to rat carotid artery in vivo resulted in acute and transient suppression of ACTA2, TAGLN, SMTN, MYOCD, and smooth muscle myosin heavy chain (MYH11) mRNA levels.	Cyclosporine	18-21	myosin heavy chain 11	Rattus norvegicus	164-169
20204291-3	2010	Cyclophilin A (CypA), a target of immunosuppressive drugs cyclosporin A (CsA) and sanglifehrin A (SFA), is an intracellular protein that has peptidyl-prolyl cis-trans isomerase (PPIase) enzymatic activity.	Cyclosporine	58-71	peptidylprolyl isomerase A	Homo sapiens	0-13
20204291-3	2010	Cyclophilin A (CypA), a target of immunosuppressive drugs cyclosporin A (CsA) and sanglifehrin A (SFA), is an intracellular protein that has peptidyl-prolyl cis-trans isomerase (PPIase) enzymatic activity.	Cyclosporine	58-71	peptidylprolyl isomerase A	Homo sapiens	15-19
20204291-3	2010	Cyclophilin A (CypA), a target of immunosuppressive drugs cyclosporin A (CsA) and sanglifehrin A (SFA), is an intracellular protein that has peptidyl-prolyl cis-trans isomerase (PPIase) enzymatic activity.	Cyclosporine	73-76	peptidylprolyl isomerase A	Homo sapiens	0-13
20204291-3	2010	Cyclophilin A (CypA), a target of immunosuppressive drugs cyclosporin A (CsA) and sanglifehrin A (SFA), is an intracellular protein that has peptidyl-prolyl cis-trans isomerase (PPIase) enzymatic activity.	Cyclosporine	73-76	peptidylprolyl isomerase A	Homo sapiens	15-19
20204291-10	2010	In conclusion, CsA or SFA in combination with cisplatin synergistically enhances cisplatin-induced apoptosis in C6 glioma cells via inhibition of PPIase activity of CypA, indicating that development of new drugs that selectively inhibit the CypA PPIase activity without immune suppression may facilitate alleviation of chemoresistance in treatment of high-grade glioma.	Cyclosporine	15-18	peptidylprolyl isomerase A	Homo sapiens	165-169
20204291-10	2010	In conclusion, CsA or SFA in combination with cisplatin synergistically enhances cisplatin-induced apoptosis in C6 glioma cells via inhibition of PPIase activity of CypA, indicating that development of new drugs that selectively inhibit the CypA PPIase activity without immune suppression may facilitate alleviation of chemoresistance in treatment of high-grade glioma.	Cyclosporine	15-18	peptidylprolyl isomerase A	Homo sapiens	241-245
20371885-15	2010	Statistical analysis of morphometric data showed significant increase in the optical density of GST immunoreactivity in the cells of renal tubules and glomeruli of CsA-treated group when compared with the control or prophylactic groups.	Cyclosporine	164-167	hematopoietic prostaglandin D synthase	Rattus norvegicus	96-99
20371885-16	2010	However, a significant decrease in the area of GST immunoreactivity in sections from prophylactic group was observed when compared with control or CsA-treated groups.	Cyclosporine	147-150	hematopoietic prostaglandin D synthase	Rattus norvegicus	47-50
20371885-17	2010	In conclusion, protective effect of curcumin against cyclosporine-induced nephrotoxicity in rats was proven based on the study of histological changes and GST immunoexpression.	Cyclosporine	53-65	hematopoietic prostaglandin D synthase	Rattus norvegicus	155-158
19856205-1	2010	In the present study, we observed the effects of cyclosporine A (CsA), an efficient immunosuppressant, on cell proliferation and neuroblast differentiation in the subgranular zone of the dentate gyrus (SZDG) in normal C57BL/6 mice using Ki67 and doublecortin (DCX) immunohistochemical staining, respectively.	Cyclosporine	65-68	doublecortin	Mus musculus	260-263
19856205-8	2010	Numbers of DCX(+) neuroblasts with well-developed processes (tertiary dendrites) were much lower in the CsA-treated group than those in the vehicle-treated group; however, numbers of DCX(+) neuroblasts with secondary dendrites were similar in both the groups.	Cyclosporine	104-107	doublecortin	Mus musculus	11-14
20055798-6	2010	Cardiac grafts from hTBM mice to rats treated with cyclosporine in a model of AVR have prolonged survival compared to controls.	Cyclosporine	51-63	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	20-24
20109345-15	2010	After the cells were exposed to 10 mug/mL DDP for 24 h, the cell apoptosis rate of SK-Hep1/DDP was decreased in comparison with SK-Hep1, but it was increased in those with pretreatment of MDR1 inhibitor CsA as compared with those without pretreatment.	Cyclosporine	203-206	translocase of inner mitochondrial membrane 8A	Homo sapiens	42-45
20109345-15	2010	After the cells were exposed to 10 mug/mL DDP for 24 h, the cell apoptosis rate of SK-Hep1/DDP was decreased in comparison with SK-Hep1, but it was increased in those with pretreatment of MDR1 inhibitor CsA as compared with those without pretreatment.	Cyclosporine	203-206	translocase of inner mitochondrial membrane 8A	Homo sapiens	91-94
19914243-4	2010	Down Syndrome critical region 1 (DSCR1) and heparin-binding EGF-like growth factor (HB-EGF) are two genes identified by DNA microarray as being up-regulated by VEGF-A in a cyclosporine-A-sensitive manner.	Cyclosporine	172-186	regulator of calcineurin 1	Homo sapiens	33-38
19914243-4	2010	Down Syndrome critical region 1 (DSCR1) and heparin-binding EGF-like growth factor (HB-EGF) are two genes identified by DNA microarray as being up-regulated by VEGF-A in a cyclosporine-A-sensitive manner.	Cyclosporine	172-186	heparin binding EGF like growth factor	Homo sapiens	44-82
19914243-4	2010	Down Syndrome critical region 1 (DSCR1) and heparin-binding EGF-like growth factor (HB-EGF) are two genes identified by DNA microarray as being up-regulated by VEGF-A in a cyclosporine-A-sensitive manner.	Cyclosporine	172-186	heparin binding EGF like growth factor	Homo sapiens	84-90
20851384-2	2010	DTH paw swelling, along with the cytokines IL-2, IFNgamma, MCP-1 and TNFalpha, were inhibited in Balb/c mice by cyclosporine A (CsA).	Cyclosporine	112-126	interleukin 2	Mus musculus	43-47
20851384-2	2010	DTH paw swelling, along with the cytokines IL-2, IFNgamma, MCP-1 and TNFalpha, were inhibited in Balb/c mice by cyclosporine A (CsA).	Cyclosporine	128-131	interleukin 2	Mus musculus	43-47
20851384-7	2010	Co-administration of temsirolimus and CsA also reduced DTH and IL-2 levels in B6D2F1 mice, demonstrating involvement of the mTORC1 pathway.	Cyclosporine	38-41	interleukin 2	Mus musculus	63-67
20357482-8	2010	The inhibitory effect became saturated (50-70% reduction) at concentrations higher than 10(-10)M. Cyclosporin A inhibited the release of TSLP by 50-60% at 10(-5) and 10(-4)M. FK506 had no effect at 10(-5)M or less, but almost completely inhibited the release of TSLP at 10(-4)M. No synergistic effect was obtained with a glucocorticoid plus either of the calcineurin inhibitors.	Cyclosporine	98-111	thymic stromal lymphopoietin	Homo sapiens	137-141
20357482-8	2010	The inhibitory effect became saturated (50-70% reduction) at concentrations higher than 10(-10)M. Cyclosporin A inhibited the release of TSLP by 50-60% at 10(-5) and 10(-4)M. FK506 had no effect at 10(-5)M or less, but almost completely inhibited the release of TSLP at 10(-4)M. No synergistic effect was obtained with a glucocorticoid plus either of the calcineurin inhibitors.	Cyclosporine	98-111	thymic stromal lymphopoietin	Homo sapiens	262-266
19866449-11	2010	Cyclosporine or tacrolimus alone had no impact on rPBC, but cyclosporine with azathioprine was protective for rPBC in comparison with tacrolimus/azathioprine (0/18 versus 7/25, respectively; P &lt; 0.001).	Cyclosporine	60-72	dihydrolipoamide S-acetyltransferase	Rattus norvegicus	110-114
19866449-14	2010	Tacrolimus or cyclosporine individually had no effect, but cyclosporine and azathioprine in combination resulted in the least rPBC.	Cyclosporine	59-71	dihydrolipoamide S-acetyltransferase	Rattus norvegicus	126-130
19923468-5	2009	Histone acetylation and T-bet expression were strongly inhibited by cyclosporine A, and we detected binding of NF-AT to a HS in vivo.	Cyclosporine	68-82	T-box transcription factor 21	Homo sapiens	24-29
19801635-3	2009	The ATP synthase-CyPD interactions have functional consequences on enzyme catalysis and are modulated by phosphate (increased CyPD binding and decreased enzyme activity) and cyclosporin (Cs) A (decreased CyPD binding and increased enzyme activity).	Cyclosporine	174-185	peptidylprolyl isomerase F	Bos taurus	17-21
19801635-3	2009	The ATP synthase-CyPD interactions have functional consequences on enzyme catalysis and are modulated by phosphate (increased CyPD binding and decreased enzyme activity) and cyclosporin (Cs) A (decreased CyPD binding and increased enzyme activity).	Cyclosporine	174-185	peptidylprolyl isomerase F	Bos taurus	126-130
19801635-3	2009	The ATP synthase-CyPD interactions have functional consequences on enzyme catalysis and are modulated by phosphate (increased CyPD binding and decreased enzyme activity) and cyclosporin (Cs) A (decreased CyPD binding and increased enzyme activity).	Cyclosporine	174-185	peptidylprolyl isomerase F	Bos taurus	126-130
19801635-3	2009	The ATP synthase-CyPD interactions have functional consequences on enzyme catalysis and are modulated by phosphate (increased CyPD binding and decreased enzyme activity) and cyclosporin (Cs) A (decreased CyPD binding and increased enzyme activity).	Cyclosporine	187-189	peptidylprolyl isomerase F	Bos taurus	17-21
19801635-3	2009	The ATP synthase-CyPD interactions have functional consequences on enzyme catalysis and are modulated by phosphate (increased CyPD binding and decreased enzyme activity) and cyclosporin (Cs) A (decreased CyPD binding and increased enzyme activity).	Cyclosporine	187-189	peptidylprolyl isomerase F	Bos taurus	126-130
19801635-3	2009	The ATP synthase-CyPD interactions have functional consequences on enzyme catalysis and are modulated by phosphate (increased CyPD binding and decreased enzyme activity) and cyclosporin (Cs) A (decreased CyPD binding and increased enzyme activity).	Cyclosporine	187-189	peptidylprolyl isomerase F	Bos taurus	126-130
19801635-4	2009	Treatment of MgATP submitochondrial particles or intact mitochondria with CsA displaced CyPD from membranes and activated both hydrolysis and synthesis of ATP sustained by the enzyme.	Cyclosporine	74-77	peptidylprolyl isomerase F	Bos taurus	88-92
19481339-0	2009	Cyclosporine A inhibits colorectal cancer proliferation probably by regulating expression levels of c-Myc, p21(WAF1/CIP1) and proliferating cell nuclear antigen.	Cyclosporine	0-14	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	100-105
19481339-0	2009	Cyclosporine A inhibits colorectal cancer proliferation probably by regulating expression levels of c-Myc, p21(WAF1/CIP1) and proliferating cell nuclear antigen.	Cyclosporine	0-14	proliferating cell nuclear antigen	Homo sapiens	126-160
19481339-5	2009	CsA decreased the expressions of c-Myc and the proliferating cell nuclear antigen (PCNA) but also increased p21(WAF1/CIP1) expression.	Cyclosporine	0-3	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	33-38
19481339-5	2009	CsA decreased the expressions of c-Myc and the proliferating cell nuclear antigen (PCNA) but also increased p21(WAF1/CIP1) expression.	Cyclosporine	0-3	proliferating cell nuclear antigen	Homo sapiens	47-81
19481339-5	2009	CsA decreased the expressions of c-Myc and the proliferating cell nuclear antigen (PCNA) but also increased p21(WAF1/CIP1) expression.	Cyclosporine	0-3	proliferating cell nuclear antigen	Homo sapiens	83-87
19692655-1	2009	Evidence for a modulatory effect of cyclosporin A (CsA) on calcium signaling and cell survival in dystrophin-deficient cells is presented.	Cyclosporine	51-54	dystrophin	Homo sapiens	98-108
19692655-4	2009	In the present work, we demonstrate that CsA exposure displayed a dual-modulator effect on calcium signaling in dystrophin-deficient cells.	Cyclosporine	41-44	dystrophin	Homo sapiens	112-122
19656870-2	2009	In Jurkat T lymphocytes, disrupting CypA-CA interaction either by cyclosporine (Cs) treatment or by alteration (e.g., P90A) of the CA inhibits HIV-1 infection.	Cyclosporine	66-78	peptidylprolyl isomerase A	Homo sapiens	36-40
19656870-2	2009	In Jurkat T lymphocytes, disrupting CypA-CA interaction either by cyclosporine (Cs) treatment or by alteration (e.g., P90A) of the CA inhibits HIV-1 infection.	Cyclosporine	80-82	peptidylprolyl isomerase A	Homo sapiens	36-40
19656870-6	2009	Reducing the binding of CypA to the A92E mutant capsid, either by Cs treatment or by an additional P90A change in the CA protein, increased the amount of particulate capsids and viral infectivity in HeLa cells.	Cyclosporine	66-68	peptidylprolyl isomerase A	Homo sapiens	24-28
19865066-1	2009	Cyclophilin A (CypA) is a cytosolic binding protein of the immunosuppressive drug cyclosporin A.	Cyclosporine	82-95	peptidylprolyl isomerase A	Homo sapiens	0-13
19865066-1	2009	Cyclophilin A (CypA) is a cytosolic binding protein of the immunosuppressive drug cyclosporin A.	Cyclosporine	82-95	peptidylprolyl isomerase A	Homo sapiens	15-19
19605734-2	2009	The PKC-induced internalization of EAAC1 is negatively regulated by the calcineurin inhibitor cyclosporine A and by the expression of a dominant-negative mutant of the endocytic protein dynamin 1, a well-known target of the phosphatase activity of calcineurin.	Cyclosporine	94-108	solute carrier family 1 member 1	Canis lupus familiaris	35-40
19659609-1	2009	We have so far reported that an immunosuppressant cyclosporin A (CsA), a well-known cyclophilin (CyP) inhibitor (CPI), strongly suppressed hepatitis C virus (HCV) replication in cell culture, and that CyPB was a cellular cofactor for viral replication.	Cyclosporine	50-63	peptidylprolyl isomerase G	Homo sapiens	84-95
19659609-1	2009	We have so far reported that an immunosuppressant cyclosporin A (CsA), a well-known cyclophilin (CyP) inhibitor (CPI), strongly suppressed hepatitis C virus (HCV) replication in cell culture, and that CyPB was a cellular cofactor for viral replication.	Cyclosporine	50-63	peptidylprolyl isomerase G	Homo sapiens	97-100
19659609-1	2009	We have so far reported that an immunosuppressant cyclosporin A (CsA), a well-known cyclophilin (CyP) inhibitor (CPI), strongly suppressed hepatitis C virus (HCV) replication in cell culture, and that CyPB was a cellular cofactor for viral replication.	Cyclosporine	65-68	peptidylprolyl isomerase G	Homo sapiens	84-95
19659609-1	2009	We have so far reported that an immunosuppressant cyclosporin A (CsA), a well-known cyclophilin (CyP) inhibitor (CPI), strongly suppressed hepatitis C virus (HCV) replication in cell culture, and that CyPB was a cellular cofactor for viral replication.	Cyclosporine	65-68	peptidylprolyl isomerase G	Homo sapiens	97-100
19659609-6	2009	Knockdown of individual CyP subtypes revealed CyP40, in addition to CyPA and CyPB, contributed to viral replication, and CsA-resistant replicons acquired independence from CyPA for efficient replication.	Cyclosporine	121-124	peptidylprolyl isomerase G	Homo sapiens	24-27
19589390-4	2009	The effect of CsA on CJX1-stimulated and Ver-stimulated P-gp ATPase activity was non-competitive and competitive inhibition, respectively.	Cyclosporine	14-17	phosphoglycolate phosphatase	Homo sapiens	56-60
19589390-5	2009	These findings implying that CJX1 and Tet can bind P-gp either on overlapping sites or distinct but interacting sites, while CJX1 and Ver as well as CsA can bind P-gp on separated sites in K562/DOX cells.	Cyclosporine	149-152	phosphoglycolate phosphatase	Homo sapiens	162-166
19523970-6	2009	CsA opened the permeability transition pores, caused Bax migration to mitochondria, and decreased mitochondrial membrane potential and cardiolipin content.	Cyclosporine	0-3	apoptosis regulator BAX	Sus scrofa	53-56
19691347-2	2009	The activities of the two most potent CypA inhibitors (3h and 3i) are 2.59 and 1.52 nM, respectively, which are about 16 and 27 times more potent than that of cyclosporin A.	Cyclosporine	159-172	peptidylprolyl isomerase A	Homo sapiens	38-42
19666510-3	2009	Th2 cells that have upregulated T1ST2 produce IL-13, but not IL-4, in response to IL-33 plus a STAT5 activator in an antigen-independent, NF-kappaB-dependent, cyclosporin A (CsA)-resistant manner.	Cyclosporine	159-172	signal transducer and activator of transcription 5A	Homo sapiens	95-100
19503092-7	2009	The Cyp inhibitor cyclosporine A (CsA) caused similar effects.	Cyclosporine	18-32	peptidylprolyl isomerase G	Homo sapiens	4-7
19503092-7	2009	The Cyp inhibitor cyclosporine A (CsA) caused similar effects.	Cyclosporine	34-37	peptidylprolyl isomerase G	Homo sapiens	4-7
19451286-0	2009	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.	Cyclosporine	0-12	peptidylprolyl isomerase A	Homo sapiens	91-103
19451286-7	2009	Furthermore, antiviral experiments demonstrated that cyclosporine (Cs; an 11-amino-acid cyclic peptide known to block the PPIase activity of CyPA) inhibits flavivirus replication in cell culture at nontoxic concentrations.	Cyclosporine	53-65	peptidylprolyl isomerase A	Homo sapiens	141-145
19480458-5	2009	CypA binding of this inhibitor has been characterized by fluorescence anisotropy- and isothermal titration calorimetry-based cyclosporin competition assays.	Cyclosporine	125-136	peptidylprolyl isomerase A	Homo sapiens	0-4
19542435-6	2009	Col(V) plus CsA was associated with alloantigen-induced expression of IL-10 in mediastinal lymph node or splenic T cells, intragraft expression of IL-10 and Foxp3 in perivascular and peribronchiolar mononuclear cells, and constitutive production of IL-10 from allograft alveolar macrophages.	Cyclosporine	12-15	interleukin 10	Rattus norvegicus	70-75
19542435-6	2009	Col(V) plus CsA was associated with alloantigen-induced expression of IL-10 in mediastinal lymph node or splenic T cells, intragraft expression of IL-10 and Foxp3 in perivascular and peribronchiolar mononuclear cells, and constitutive production of IL-10 from allograft alveolar macrophages.	Cyclosporine	12-15	interleukin 10	Rattus norvegicus	147-152
19542435-6	2009	Col(V) plus CsA was associated with alloantigen-induced expression of IL-10 in mediastinal lymph node or splenic T cells, intragraft expression of IL-10 and Foxp3 in perivascular and peribronchiolar mononuclear cells, and constitutive production of IL-10 from allograft alveolar macrophages.	Cyclosporine	12-15	interleukin 10	Rattus norvegicus	147-152
19288164-8	2009	Pre-treatment of SD rats with Cys-A result in significant increase in the kidney and liver uptake of Tc-99m-N-MPO.	Cyclosporine	30-35	myeloperoxidase	Rattus norvegicus	110-113
19423340-3	2009	The last two cell lines were selected through chronic exposure of A2780wt to paclitaxel and Pgp blocker cyclosporine.	Cyclosporine	104-116	phosphoglycolate phosphatase	Homo sapiens	92-95
19454717-0	2009	Suppression of NF-kappaB by cyclosporin a and tacrolimus (FK506) via induction of the C/EBP family: implication for unfolded protein response.	Cyclosporine	28-41	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	86-91
19454717-9	2009	CsA and FK506, as well as other UPR inducers, caused up-regulation of C/EBP family members, especially C/EBPbeta and CHOP (C/EBP homologous protein), and overexpression of either C/EBPbeta or CHOP significantly attenuated TNF-alpha-triggered NF-kappaB activation.	Cyclosporine	0-3	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	70-75
19454717-9	2009	CsA and FK506, as well as other UPR inducers, caused up-regulation of C/EBP family members, especially C/EBPbeta and CHOP (C/EBP homologous protein), and overexpression of either C/EBPbeta or CHOP significantly attenuated TNF-alpha-triggered NF-kappaB activation.	Cyclosporine	0-3	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	103-112
19454717-9	2009	CsA and FK506, as well as other UPR inducers, caused up-regulation of C/EBP family members, especially C/EBPbeta and CHOP (C/EBP homologous protein), and overexpression of either C/EBPbeta or CHOP significantly attenuated TNF-alpha-triggered NF-kappaB activation.	Cyclosporine	0-3	DNA-damage inducible transcript 3	Mus musculus	117-121
19454717-9	2009	CsA and FK506, as well as other UPR inducers, caused up-regulation of C/EBP family members, especially C/EBPbeta and CHOP (C/EBP homologous protein), and overexpression of either C/EBPbeta or CHOP significantly attenuated TNF-alpha-triggered NF-kappaB activation.	Cyclosporine	0-3	DNA-damage inducible transcript 3	Mus musculus	123-147
19454717-9	2009	CsA and FK506, as well as other UPR inducers, caused up-regulation of C/EBP family members, especially C/EBPbeta and CHOP (C/EBP homologous protein), and overexpression of either C/EBPbeta or CHOP significantly attenuated TNF-alpha-triggered NF-kappaB activation.	Cyclosporine	0-3	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	179-188
19454717-9	2009	CsA and FK506, as well as other UPR inducers, caused up-regulation of C/EBP family members, especially C/EBPbeta and CHOP (C/EBP homologous protein), and overexpression of either C/EBPbeta or CHOP significantly attenuated TNF-alpha-triggered NF-kappaB activation.	Cyclosporine	0-3	DNA-damage inducible transcript 3	Mus musculus	192-196
19454717-10	2009	Furthermore, down-regulation of C/EBPbeta by small interfering RNA substantially reversed the suppressive effect of CsA on TNF-alpha-induced MCP-1 expression.	Cyclosporine	116-119	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	32-41
19454717-11	2009	These results suggested that CsA and FK506 confer insensitiveness to TNF-alpha on resident cells through UPR-dependent induction of the C/EBP family members.	Cyclosporine	29-32	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	136-141
19545743-8	2009	Allografts of As(2)O(3)-treated and As(2)O(3) plus CsA-treated mice showed a changing pattern of Th1/Th2 cytokine mRNA expression.	Cyclosporine	51-54	heart and neural crest derivatives expressed 2	Mus musculus	101-104
19539558-8	2009	However, combined therapy with low-dose CsA (5 mg/kg) or tacrolimus (1 mg/kg) reduced significantly the expression of Foxp3 and failed to prolong the allograft survival.	Cyclosporine	40-43	forkhead box P3	Mus musculus	118-123
19418307-8	2009	With respect to these untreated allografts, CsA lowered mRNA levels of MMP-7, TIMP-1/-3 (TIMP-2/-4 remained relatively low) and ADAM17, but augmented mRNA levels of MMP-11/-16/-23 and of many ECM genes.	Cyclosporine	44-47	TIMP metallopeptidase inhibitor 2	Rattus norvegicus	89-95
18997826-7	2009	The regimen of MTX-CsA vs CsA alone (four trials) yielded no statistically significant difference in ACM (RR=0.84 (0.61-1.14)), but a significant decrease in aGVHD (RR=0.52 (0.39-0.7)).	Cyclosporine	19-22	metaxin 1	Homo sapiens	15-18
19276353-3	2009	GD3-induced apoptosis of activated T cells was dose dependent and inhibitable by pretreating the lymphocytes with N-acetylcysteine, cyclosporin A, or bongkrekic acid, emphasizing the essential role of ROS and mitochondrial permeability to the process.	Cyclosporine	132-145	GRDX	Homo sapiens	0-3
19166511-9	2009	Co-expression of both mutant Pink1 and alpha-syn led to alterations in mitochondrial structure and neurite outgrowth that were partially ameliorated by treatment with cyclosporine A, and completely restored by treatment with the mitochondrial calcium influx blocker Ruthenium Red, but not with other cellular calcium flux blockers.	Cyclosporine	167-181	synuclein alpha	Homo sapiens	39-48
18973526-3	2009	The roles of the endothelin receptors A and B (ET(A) and ET(B)) in CsA-enhanced expression of PCNA and iNOS were examined in cultured human gingival fibroblasts pretreated with receptor antagonists, by immunocytochemistry and RT-PCR, respectively.	Cyclosporine	67-70	proliferating cell nuclear antigen	Homo sapiens	94-98
18962896-7	2009	Cyclosporine A treatment on wild type Th2 cells or Th2 cells derived from NFAT1 knockout (NFAT1(-/-)) mice showed significantly reduced trans-activity of CNS-9.	Cyclosporine	0-14	heart and neural crest derivatives expressed 2	Mus musculus	38-41
18962896-7	2009	Cyclosporine A treatment on wild type Th2 cells or Th2 cells derived from NFAT1 knockout (NFAT1(-/-)) mice showed significantly reduced trans-activity of CNS-9.	Cyclosporine	0-14	heart and neural crest derivatives expressed 2	Mus musculus	51-54
19067665-9	2009	Patients receiving combined cyclosporine-A and everolimus had the lowest serum MMP-1 concentrations.	Cyclosporine	28-42	matrix metallopeptidase 1	Homo sapiens	79-84
18727660-2	2009	Mycophenolate mofetil and CSA (MMF-CSA) combination has been successfully used for GVHD prophylaxis after non-reduced intensity conditioning (non-RIC) allo-SCT with peripheral blood or non-G-CSF stimulated bone marrow as stem cell source.	Cyclosporine	26-29	colony stimulating factor 3	Homo sapiens	189-194
18727660-2	2009	Mycophenolate mofetil and CSA (MMF-CSA) combination has been successfully used for GVHD prophylaxis after non-reduced intensity conditioning (non-RIC) allo-SCT with peripheral blood or non-G-CSF stimulated bone marrow as stem cell source.	Cyclosporine	35-38	colony stimulating factor 3	Homo sapiens	189-194
18818682-0	2009	Inhibition of JAK2 protects renal endothelial and epithelial cells from oxidative stress and cyclosporin A toxicity.	Cyclosporine	93-106	Janus kinase 2	Mus musculus	14-18
18818682-3	2009	The AG490 JAK2 inhibitor and overexpression of a dominant negative JAK2 protein protected endothelial and renal epithelial cells in culture against peroxide, superoxide anion and cyclosporin A induced cell death while reducing intracellular oxidation in cells challenged with peroxide and cyclosporin A.	Cyclosporine	179-192	Janus kinase 2	Mus musculus	10-14
18818682-3	2009	The AG490 JAK2 inhibitor and overexpression of a dominant negative JAK2 protein protected endothelial and renal epithelial cells in culture against peroxide, superoxide anion and cyclosporin A induced cell death while reducing intracellular oxidation in cells challenged with peroxide and cyclosporin A.	Cyclosporine	179-192	Janus kinase 2	Mus musculus	67-71
18818682-3	2009	The AG490 JAK2 inhibitor and overexpression of a dominant negative JAK2 protein protected endothelial and renal epithelial cells in culture against peroxide, superoxide anion and cyclosporin A induced cell death while reducing intracellular oxidation in cells challenged with peroxide and cyclosporin A.	Cyclosporine	289-302	Janus kinase 2	Mus musculus	67-71
18818682-6	2009	Our study shows that JAK2 inhibition is a promising renoprotective strategy defending endothelial and tubular cells from cyclosporin A- and oxidative stress-induced death.	Cyclosporine	121-134	Janus kinase 2	Mus musculus	21-25
18656999-8	2009	Moreover, CsA induced renal alterations and the translocation of Bax and cytochrome c from cytoplasm to mitochondria and vice versa.	Cyclosporine	10-13	BCL2 associated X, apoptosis regulator	Rattus norvegicus	65-68
19925294-7	2009	RESULTS: The administration of CsA alone resulted in higher myeloperoxidase (MPO) activity, lipid peroxidation, superoxide dismutase (SOD), and catalase (CAT) than in the control.	Cyclosporine	31-34	myeloperoxidase	Rattus norvegicus	60-75
19925294-7	2009	RESULTS: The administration of CsA alone resulted in higher myeloperoxidase (MPO) activity, lipid peroxidation, superoxide dismutase (SOD), and catalase (CAT) than in the control.	Cyclosporine	31-34	myeloperoxidase	Rattus norvegicus	77-80
18821711-0	2008	Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura.	Cyclosporine	23-35	ADAM metallopeptidase with thrombospondin type 1 motif 13	Homo sapiens	47-55
19100473-10	2008	RESULTS: Protosappanin A or cyclosporine significantly prolonged heart allograft survival (P &lt; .01), alleviated myocardial pathologic damages (P &lt; .01), decreased the CD4+/CD8+ ratio (P &lt; .05), and inhibited perforin and granzyme B mRNA expressions in the graft (P &lt; .05).	Cyclosporine	28-40	granzyme B	Rattus norvegicus	230-240
18845086-9	2008	FK506 can not only inhibit the expression of positive co-stimulatory molecules CD28 and ICOS but also promote the expression of negative co-stimulatory molecule CD152, while CsA can exert its immunosuppressive effect mainly through promoting the expression of CD152.	Cyclosporine	174-177	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	260-265
18582853-6	2008	Application to rats of two inhibitors of calcineurin (tacrolimus-FK506 and cyclosporin A) demonstrated that the mRNA levels of both the AChE catalytic subunit and ColQ in the extrajunctional regions of the soleus muscle are regulated by the calcineurin signaling pathway, but in a reciprocal way.	Cyclosporine	75-88	acetylcholinesterase	Rattus norvegicus	136-140
18653356-7	2008	Although novel ligands for cyclophilin A were not discovered, cyclosporin A, a known ligand to CypA and a blind control in the library, was identified as a hit.	Cyclosporine	62-75	peptidylprolyl isomerase A	Homo sapiens	95-99
18567920-7	2008	CSA and HAb18G/CD147 antagonistic peptide AP-9 against CD147, respectively, dramatically decreased MMP-2 and MMP-9 expression, both in the absence or presence of CypA.	Cyclosporine	0-3	basigin (Ok blood group)	Homo sapiens	55-60
18567920-7	2008	CSA and HAb18G/CD147 antagonistic peptide AP-9 against CD147, respectively, dramatically decreased MMP-2 and MMP-9 expression, both in the absence or presence of CypA.	Cyclosporine	0-3	peptidylprolyl isomerase A	Homo sapiens	162-166
19048951-0	2008	[Anti-MuSK antibody positive myasthenia gravis with HIV infection successfully treated with cyclosporin: a case report].	Cyclosporine	92-103	muscle associated receptor tyrosine kinase	Homo sapiens	6-10
18684975-2	2008	Herein we demonstrate that the CNI cyclosporin A and tacrolimus (FK506), independent of TGFbeta synthesis, rapidly activate TGFbeta/Smad signaling in cultured mesangial cells and in whole kidney samples from CNI-treated rats.	Cyclosporine	35-48	SMAD family member 4	Rattus norvegicus	132-136
18594053-5	2008	DATA SYNTHESIS: Corticosteroids share common metabolic and transporter pathways, the cytochrome P450 and P-glycoprotein (P-gp/ABCB1) systems, respectively, with cyclosporine, tacrolimus, and sirolimus.	Cyclosporine	161-173	phosphoglycolate phosphatase	Homo sapiens	121-125
18353617-10	2008	The mRNA expression levels of NFAT1, NFAT2, BPAG1, and involucrin were downregulated by CsA treatment in NHEK.	Cyclosporine	88-91	nuclear factor of activated T cells 2	Homo sapiens	30-35
18448283-9	2008	LPL activity in post-heparin normal human plasma was suppressed following the co-incubation with CsA, RAPA, FK-506 or MMF whereas HL activity remained unaffected.	Cyclosporine	97-100	lipoprotein lipase	Homo sapiens	0-3
18369646-11	2008	At 7 days, we observed many mononuclear cells possessing both MEF2C and myogenin protein in mice treated with CsA, but not the placebo.	Cyclosporine	110-113	myogenin	Mus musculus	72-80
18278071-5	2008	We found human pre-B lymphocytes, a key target population for BMT conditioning, when deficient for DNA ligase IV, unexpectedly exhibit significant sensitivity to CsA the principal prophylaxis for GVHD.	Cyclosporine	162-165	DNA ligase 4	Homo sapiens	99-112
18412220-6	2008	Neurons treated with cyclosporin, an inhibitor of the Ca(2+)-dependent phosphatase calcineurin, also showed increased levels of phosphorylated NF-M.	Cyclosporine	21-32	neurofilament, medium polypeptide	Mus musculus	143-147
18703392-3	2008	Cyclosporine A-induced nephrotoxicity is particularly due to the activation of pro-apoptotic genes leading to tubular atrophy with tubular cell apoptosis and to hemodynamic changes inducing interstitial fibrosis by the activation of factors stimulating the fibroblast proliferation (TGFbeta, Endothelin-A and Plasminogen activator inhibitor-1).	Cyclosporine	0-14	serpin family E member 1	Homo sapiens	292-342
18953738-12	2008	RESULTS: The difference of 45Ca accumulation (measured by relative optical density) in the CsA group was greater by 30-70% in the following structures compared to vehicle treated traumatized animals: temporal cortex, CA1, anteromedial and posteromedial thalamus (p &lt; 0.05).	Cyclosporine	91-94	carbonic anhydrase 1	Rattus norvegicus	217-220
18490522-9	2008	In GSK3beta-S9A mice, only CsA, but not postconditioning or SB21, reduced infarct size.	Cyclosporine	27-30	glycogen synthase kinase 3 beta	Mus musculus	3-11
18490522-10	2008	Postconditioning, CsA, and SB21 all improved the resistance of the mPTP in wild-type mice, but only CsA did so in GSK3beta-S9A mice.	Cyclosporine	100-103	glycogen synthase kinase 3 beta	Mus musculus	114-122
17919644-7	2008	Pretreatment of CyPA with cyclosporine A prevented its effect on THP-1 cell migration; similarly, PPIase-deficient mutant CyPA protein did not induce migration of these cells.	Cyclosporine	26-40	peptidylprolyl isomerase A	Homo sapiens	16-20
18157160-7	2008	These apoptotic effects were inhibited by cyclosporine A (CsA), indicating that mutant TRX1 targeted to mPTP.	Cyclosporine	42-56	thioredoxin	Homo sapiens	87-91
18157160-7	2008	These apoptotic effects were inhibited by cyclosporine A (CsA), indicating that mutant TRX1 targeted to mPTP.	Cyclosporine	58-61	thioredoxin	Homo sapiens	87-91
19356075-1	2008	The calcineurin inhibitor cyclosporine is removed from lymphocytes by the drug efflux transporter P-glycoprotein (P-gp) encoded by the ABCB1 gene for which several single nucleotide polymorphisms (SNPs) have been identified.	Cyclosporine	26-38	phosphoglycolate phosphatase	Homo sapiens	114-118
19356075-7	2008	Similarly, a negative correlation was detected in the GG-CC group between P-gp activity in CD4(+) and cyclosporine PBMC AUC(0-24) (r(S)=-0.69, p=0.03), as well as PBMC to whole blood AUC(0-24) ratio (r(S)=-0.60, p=0.07).	Cyclosporine	102-114	phosphoglycolate phosphatase	Homo sapiens	74-78
19356075-10	2008	In conclusion, cyclosporine PBMC pharmacokinetics was influenced by P-gp activity and cyclosporine whole blood concentrations did not predict PBMC drug levels, suggesting that despite values in the therapeutic range, some subjects could have inadequate intracellular drug levels.	Cyclosporine	15-27	phosphoglycolate phosphatase	Homo sapiens	68-72
18387391-0	2008	Urinary epidermal growth factor and interleukin-6 levels in patients with painful bladder syndrome/interstitial cystitis treated with cyclosporine or pentosan polysulfate sodium.	Cyclosporine	134-146	epidermal growth factor	Homo sapiens	8-31
18094068-0	2008	Cyclosporine increases ischemia-induced endothelial progenitor cell mobilization through manipulation of the CD26 system.	Cyclosporine	0-12	dipeptidylpeptidase 4	Mus musculus	109-113
18094068-3	2008	This study investigated whether CsA manipulates CD26/DPP IV activity and increases EPC mobilization.	Cyclosporine	32-35	dipeptidylpeptidase 4	Mus musculus	48-52
18094068-3	2008	This study investigated whether CsA manipulates CD26/DPP IV activity and increases EPC mobilization.	Cyclosporine	32-35	dipeptidylpeptidase 4	Mus musculus	53-59
18094068-9	2008	In the peripheral blood, CsA significantly decreased CD26+ cell numbers and attenuated the plasma CD26/DPP IV activity (P &lt; 0.001).	Cyclosporine	25-28	dipeptidylpeptidase 4	Mus musculus	53-57
18094068-9	2008	In the peripheral blood, CsA significantly decreased CD26+ cell numbers and attenuated the plasma CD26/DPP IV activity (P &lt; 0.001).	Cyclosporine	25-28	dipeptidylpeptidase 4	Mus musculus	98-102
18094068-9	2008	In the peripheral blood, CsA significantly decreased CD26+ cell numbers and attenuated the plasma CD26/DPP IV activity (P &lt; 0.001).	Cyclosporine	25-28	dipeptidylpeptidase 4	Mus musculus	103-109
18094068-11	2008	In summary, CsA manipulates the mobilization of EPCs into the circulation via the CD26/DPP IV system.	Cyclosporine	12-15	dipeptidylpeptidase 4	Mus musculus	82-86
18094068-11	2008	In summary, CsA manipulates the mobilization of EPCs into the circulation via the CD26/DPP IV system.	Cyclosporine	12-15	dipeptidylpeptidase 4	Mus musculus	87-93
17592478-14	2008	The MAOA-LPR low activity allele appears to confer increased vulnerability to the adverse psychosocial consequences of CSA.	Cyclosporine	119-122	monoamine oxidase A	Homo sapiens	4-8
18054347-9	2008	Cyclosporin A (CyA) restored the sensitivity, intracellular accumulation and transport activity for both drugs in L-MDR1 cells.	Cyclosporine	0-13	ATP-binding cassette, sub-family B (MDR/TAP), member 1	Sus scrofa	116-120
18230104-0	2008	Expression of p21 and p53 in rat gingival and human oral epithelial cells after cyclosporine A treatment.	Cyclosporine	80-94	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	22-25
18230104-6	2008	RESULTS: The mRNA expression of p21 was significantly higher in the cyclosporine A group than in the control group.	Cyclosporine	68-82	H3 histone pseudogene 16	Homo sapiens	32-35
18230104-7	2008	A greater number of positive anti-p21-stained cells were observed in the gingival epithelium of the cyclosporine A group than in the control group.	Cyclosporine	100-114	H3 histone pseudogene 16	Homo sapiens	34-37
18230104-8	2008	Significantly higher levels of p21 protein and activity were observed in OECM1 cells after cyclosporine A treatment than in cells without treatment.	Cyclosporine	91-105	H3 histone pseudogene 16	Homo sapiens	31-34
18230104-10	2008	CONCLUSION: In the present study, higher p21 mRNA and protein expressions were observed after cyclosporine A treatment.	Cyclosporine	94-108	H3 histone pseudogene 16	Homo sapiens	41-44
18230104-11	2008	Thus, an up-regulation of p21 expression, via a p53-independent pathway, by cyclosporine A in gingival and oral epithelial cells was suggested.	Cyclosporine	76-90	H3 histone pseudogene 16	Homo sapiens	26-29
18192894-1	2008	OBJECTIVE: To evaluate whether variations in the ABCB1, ABCC2, SLCO1B1, CYP3A4, CYP3A5, or NR1I2 genes are associated with the pharmacokinetics of cyclosporine in pediatric renal transplant candidates, and whether the effects of these variants are related to age.	Cyclosporine	147-159	solute carrier organic anion transporter family member 1B1	Homo sapiens	63-70
18365668-0	2008	[Efficacy of therapeutic monitoring of cyclosporine through C2 and AUC(0-4) during the first 24 months following kidney transplantation].	Cyclosporine	39-51	complement C2	Homo sapiens	60-74
18365668-22	2008	CONCLUSION: In the patients with CyA TDM through with the C2 and AUC(0-4), AR frequency was considerably lower, and AR episodes had a milder flow than in those with CyA TDM through the CO.	Cyclosporine	33-36	complement C2	Homo sapiens	58-72
18365668-22	2008	CONCLUSION: In the patients with CyA TDM through with the C2 and AUC(0-4), AR frequency was considerably lower, and AR episodes had a milder flow than in those with CyA TDM through the CO.	Cyclosporine	165-168	complement C2	Homo sapiens	58-72
18365668-26	2008	CyA dose determination through C2 and AUC(0-4) is efficient TDM method, relatively simple for use in day to day clinical practice.	Cyclosporine	0-3	complement C2	Homo sapiens	31-45
18566557-0	2008	Human leukocyte antigen (HLA) B-27 and older age are associated with augmented cyclosporine blood bioavailability in renal allograft recipients: an attempt toward individualization of immunosuppression.	Cyclosporine	79-91	major histocompatibility complex, class I, B	Homo sapiens	6-34
18354729-0	2008	Methotrexate and cyclosporine treatments modify the activities of dipeptidyl peptidase IV and prolyl oligopeptidase in murine macrophages.	Cyclosporine	17-29	dipeptidylpeptidase 4	Mus musculus	66-89
18354729-7	2008	The opposite effects of methotrexate and cyclosporine on POP activity might influence the availability of the nociceptive mediators bradykinin and substance P in proinflammatory Mphis.	Cyclosporine	41-53	tachykinin 1	Mus musculus	147-158
18261580-0	2008	Do MMP-1 levels of gingival fibroblasts have a role in the gingival overgrowth of cyclosporine-treated patients?	Cyclosporine	82-94	matrix metallopeptidase 1	Homo sapiens	3-8
18261580-1	2008	The aim of this study was to compare the matrix metalloproteinase-1 (MMP-1) levels in gingival fibroblast cultures derived from two groups of renal transplant patients receiving cyclosporine (CsA) who exhibit gingival overgrowth and who have healthy periodontium.	Cyclosporine	178-190	matrix metallopeptidase 1	Homo sapiens	69-74
18261580-1	2008	The aim of this study was to compare the matrix metalloproteinase-1 (MMP-1) levels in gingival fibroblast cultures derived from two groups of renal transplant patients receiving cyclosporine (CsA) who exhibit gingival overgrowth and who have healthy periodontium.	Cyclosporine	192-195	matrix metallopeptidase 1	Homo sapiens	69-74
18261580-5	2008	As the CsA concentration and the duration in the cell media increased, the CsA-GO showed that fibroblasts displayed significantly suppressed MMP-1 levels with respect to the baseline, at which fibroblasts from CsA patients with healthy periodontium exhibited the same result as at the highest CsA concentration.	Cyclosporine	7-10	matrix metallopeptidase 1	Homo sapiens	141-146
18261580-5	2008	As the CsA concentration and the duration in the cell media increased, the CsA-GO showed that fibroblasts displayed significantly suppressed MMP-1 levels with respect to the baseline, at which fibroblasts from CsA patients with healthy periodontium exhibited the same result as at the highest CsA concentration.	Cyclosporine	75-78	matrix metallopeptidase 1	Homo sapiens	141-146
18031601-0	2007	Electrophysiological actions of cyclosporin A and tacrolimus on rat hippocampal CA1 pyramidal neurons.	Cyclosporine	32-45	carbonic anhydrase 1	Rattus norvegicus	80-83
17935163-9	2007	Cyclosporin A also reduced the nuclear expression of two Tax-related transfer factors, ATF-1 and ATF-2 on Western blot.	Cyclosporine	0-13	activating transcription factor 1	Homo sapiens	87-92
17927958-2	2007	We used the database-mining program LIDAEUS and in silico screening to discover the dimedone family of inhibitors which show a conserved "ball and socket" binding mode with a dimethyl group in the hydrophobic binding pocket of human cyclophilin A (CypA) mimicking a key interaction of the natural inhibitor cyclosporin A (CsA).	Cyclosporine	307-320	peptidylprolyl isomerase A	Homo sapiens	233-246
17927958-2	2007	We used the database-mining program LIDAEUS and in silico screening to discover the dimedone family of inhibitors which show a conserved "ball and socket" binding mode with a dimethyl group in the hydrophobic binding pocket of human cyclophilin A (CypA) mimicking a key interaction of the natural inhibitor cyclosporin A (CsA).	Cyclosporine	322-325	peptidylprolyl isomerase A	Homo sapiens	233-246
17927958-3	2007	The most potent derivative binds CypA with a K(d) of 11.2+/-9.2 microM and an IC50 for activity against Caenorhabditis elegans (C. elegans) of 190 microM compared to 28 microM for CsA.	Cyclosporine	180-183	peptidylprolyl isomerase A	Homo sapiens	33-37
17827263-8	2007	These CsA-induced, PLB-mediated effects were associated with an augmentation in cardiomyocyte peak Ca(2+) and a reduced rate (time constant of isovolumic pressure relaxation, tau) and magnitude of diastolic Ca(2+) during beta-AR stimulation.	Cyclosporine	6-9	phospholamban	Rattus norvegicus	19-22
17910638-1	2007	We hypothesized that cyclosporin (CSA) as adjunct to plasma exchange (PE) improves the efficacy of PE in idiopathic thrombotic thrombocytopenic purpura (TTP) via suppression of the antibody inhibitor of ADAMTS13.	Cyclosporine	21-32	ADAM metallopeptidase with thrombospondin type 1 motif 13	Homo sapiens	203-211
17910638-1	2007	We hypothesized that cyclosporin (CSA) as adjunct to plasma exchange (PE) improves the efficacy of PE in idiopathic thrombotic thrombocytopenic purpura (TTP) via suppression of the antibody inhibitor of ADAMTS13.	Cyclosporine	34-37	ADAM metallopeptidase with thrombospondin type 1 motif 13	Homo sapiens	203-211
17910638-6	2007	These data suggest that the efficacy of CSA is at least in part related to its suppression of the antibody inhibitor of ADAMTS13 and a subsequent improvement in ADAMTS13 activity and antigen.	Cyclosporine	40-43	ADAM metallopeptidase with thrombospondin type 1 motif 13	Homo sapiens	120-128
17910638-6	2007	These data suggest that the efficacy of CSA is at least in part related to its suppression of the antibody inhibitor of ADAMTS13 and a subsequent improvement in ADAMTS13 activity and antigen.	Cyclosporine	40-43	ADAM metallopeptidase with thrombospondin type 1 motif 13	Homo sapiens	161-169
18021981-0	2007	Possible association of CTLA-4 gene polymorphism with cyclosporine-induced gingival overgrowth in kidney transplant recipients.	Cyclosporine	54-66	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	24-30
18021981-11	2007	The results suggested that appearance of an adenosine allele(A) in position +49 of the CTLA-4 gene may be a permissive element for CsA-induced GO.	Cyclosporine	131-134	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	87-93
17707777-8	2007	Most of the single substitution mutations also decreased Cyp-CsA inhibition.	Cyclosporine	61-64	peptidylprolyl isomerase G	Homo sapiens	57-60
17916018-5	2007	RESULTS: Known P-gp substrate drugs ivermectin and cyclosporin A altered rhodamine efflux by 90% and 95%, respectively.	Cyclosporine	51-64	PGP	Canis lupus familiaris	15-19
17882219-4	2007	Calcineurin is transiently activated after adding Ca2+ to egg extracts, and inhibitors of calcineurin such as cyclosporin A (ref.	Cyclosporine	110-123	protein phosphatase 3, catalytic subunit, alpha isozyme L homeolog	Xenopus laevis	0-11
17882219-4	2007	Calcineurin is transiently activated after adding Ca2+ to egg extracts, and inhibitors of calcineurin such as cyclosporin A (ref.	Cyclosporine	110-123	protein phosphatase 3, catalytic subunit, alpha isozyme L homeolog	Xenopus laevis	90-101
17496208-0	2007	Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.	Cyclosporine	132-145	solute carrier organic anion transporter family member 1B1	Homo sapiens	33-40
17559898-7	2007	While the DAS-mediated apoptosis and activation of caspase-9 and caspase-3 were slightly suppressed by the mitochondrial permeability transition pore inhibitor (CsA), both caspase-8 activation and Bid cleavage were not affected by CsA.	Cyclosporine	161-164	caspase 9	Homo sapiens	51-60
17229932-6	2007	CsA administration enhanced Th2 and reduced Th1 cytokine production at the materno-fetal interface, and it expanded peripheral CD4(+)CD25(+) FOXP3(+) regulatory T cells in abortion-prone matings, implying development of Th2 bias and regulatory T cells.	Cyclosporine	0-3	heart and neural crest derivatives expressed 2	Mus musculus	28-31
17229932-6	2007	CsA administration enhanced Th2 and reduced Th1 cytokine production at the materno-fetal interface, and it expanded peripheral CD4(+)CD25(+) FOXP3(+) regulatory T cells in abortion-prone matings, implying development of Th2 bias and regulatory T cells.	Cyclosporine	0-3	forkhead box P3	Mus musculus	141-146
17229932-6	2007	CsA administration enhanced Th2 and reduced Th1 cytokine production at the materno-fetal interface, and it expanded peripheral CD4(+)CD25(+) FOXP3(+) regulatory T cells in abortion-prone matings, implying development of Th2 bias and regulatory T cells.	Cyclosporine	0-3	heart and neural crest derivatives expressed 2	Mus musculus	220-223
17351648-3	2007	Cyclosporine and rapamycin reduce the expansion of effector T cells by blocking interleukin (IL)-2, but signaling by IL-2 is pivotal for T(REG) homeostasis.	Cyclosporine	0-12	interleukin 2	Mus musculus	80-98
17351648-6	2007	Here we demonstrate in a mouse model that in contrast to rapamycin, cyclosporine compromises not only the thymic generation of CD4(+)CD25(+)FoxP3(+) T cells but also their homeostatic behavior in peripheral immune compartments.	Cyclosporine	68-80	forkhead box P3	Mus musculus	140-145
17351648-7	2007	Treatment with cyclosporine resulted in a sharp reduction of peripheral CD25(+)FoxP3(+) T cells in all immune compartments studied.	Cyclosporine	15-27	forkhead box P3	Mus musculus	79-84
17351648-9	2007	In conclusion, cyclosporine and rapamycin differentially affect homeostasis of CD4(+)FoxP3(+) T(REG) in vivo.	Cyclosporine	15-27	forkhead box P3	Mus musculus	85-90
17571306-7	2007	Pretreatment with Cs A prevented mouse liver from injury by Con A and partly inhibited the mGST2 gene expression upregulation.	Cyclosporine	18-22	microsomal glutathione S-transferase 2	Mus musculus	91-96
17371972-5	2007	Treatment with the immunosuppressive drug cyclosporine abolished H60-specific T cell expansion and rescued animals from fatal pancytopenia.	Cyclosporine	42-54	histocompatibility 60a	Mus musculus	65-68
17267487-2	2007	The immunosuppressive drug cyclosporine A (CsA) and its nonimmunosuppressive analogs bind with high affinity to CypA and inhibit HIV-1 replication.	Cyclosporine	27-41	peptidylprolyl isomerase A	Homo sapiens	112-116
17267487-2	2007	The immunosuppressive drug cyclosporine A (CsA) and its nonimmunosuppressive analogs bind with high affinity to CypA and inhibit HIV-1 replication.	Cyclosporine	43-46	peptidylprolyl isomerase A	Homo sapiens	112-116
17267487-3	2007	Previous studies have identified two mutations, A92E and G94D, in the CypA-binding loop of CA that confer the ability of HIV-1 to replicate in the presence of CsA.	Cyclosporine	159-162	peptidylprolyl isomerase A	Homo sapiens	70-74
17598423-5	2007	We start from the assumption that the concomitant use of cyclosporin with mycophenolate mofetil and lamivudine, despite normal concentrations of cyclosporin, might cause the accumulation of toxic metabolites and lead to neurotoxicity that mimics PML in a chronic viral environment.	Cyclosporine	57-68	PML nuclear body scaffold	Homo sapiens	246-249
17133350-7	2007	CsA administration totally inhibited the exercise-induced increase in MCIP-1 mRNA (P &lt; 0.01), blunted the IL-6 gene transcription related to muscle activity, and suppressed the changes in IL-6 protein in plasma.	Cyclosporine	0-3	regulator of calcineurin 1	Rattus norvegicus	70-76
17227295-5	2007	RESULTS: In group I, at time points C0 and C2, increased CsA-PK significantly inhibited expression of IL-2, IFN-gamma, PCNA and CD25 (P &lt; 0.05).	Cyclosporine	57-60	proliferating cell nuclear antigen	Homo sapiens	119-123
17267565-8	2007	Treatment by tacrolimus and cyclosporin A, two inhibitors of calcineurin (but not by a related substance rapamycin, which does not inhibit calcineurin), increased the levels of AChE transcripts in the control soleus muscles and in tonically electrically stimulated soleus and EDL muscles, even to reach those in the control EDL muscles.	Cyclosporine	28-41	acetylcholinesterase	Rattus norvegicus	177-181
17264507-7	2007	The specific inhibitor of calcineurin, cyclosporin A, inhibited the stretch-induced increase in calcineurin activity, MCIP1 gene expression and hypertrophy.	Cyclosporine	39-52	regulator of calcineurin 1	Homo sapiens	118-123
17072859-11	2007	In contrast, CsA-treated Cux-1 transgenic kidney cultures were not growth inhibited, but showed high levels of cell proliferation in the nephrogenic zone.	Cyclosporine	13-16	cut-like homeobox 1	Mus musculus	25-30
17072859-12	2007	Moreover, in CsA-treated Cux-1 transgenic kidney cultures, p27 was not expressed in the nephrogenic zone, but only up-regulated in maturing glomeruli and tubules.	Cyclosporine	13-16	cut-like homeobox 1	Mus musculus	25-30
17072859-13	2007	Taken together, our results demonstrate that ectopic expression of Cux-1 can rescue the effects of CsA inhibition of CnA and suggest that Cux-1 may be regulated by calcineurin A.	Cyclosporine	99-102	cut-like homeobox 1	Mus musculus	67-72
17603247-0	2007	Successful treatment of refractory thrombotic thrombocytopenic purpura with cyclosporine and corticosteroids in a patient with systemic lupus erythematosus and antibodies to ADAMTS13.	Cyclosporine	76-88	ADAM metallopeptidase with thrombospondin type 1 motif 13	Homo sapiens	174-182
17684442-8	2007	Further, p22phox positive area ratio in DCA specimens was also correlated with vessel CSA and plaque CSA (r = 0.47, p = 0.0095; r = 0.47, p = 0.0103, respectively).	Cyclosporine	86-89	cytochrome b-245 alpha chain	Homo sapiens	9-16
17684442-8	2007	Further, p22phox positive area ratio in DCA specimens was also correlated with vessel CSA and plaque CSA (r = 0.47, p = 0.0095; r = 0.47, p = 0.0103, respectively).	Cyclosporine	101-104	cytochrome b-245 alpha chain	Homo sapiens	9-16
17198268-7	2006	PD-L1.Ig gene transfer combined with a subtherapeutic regimen of cyclosporin A (CsA) was superior to CsA alone: MST, 25 (15-42) vs. 15 (13-19) days (P &lt; 0.05).	Cyclosporine	80-83	CD274 molecule	Homo sapiens	0-5
17030615-3	2006	Secretion of DEK is modulated by casein kinase 2, stimulated by interleukin-8, and inhibited by dexamethasone and cyclosporine A, consistent with a role as a proinflammatory molecule.	Cyclosporine	114-128	DEK proto-oncogene	Homo sapiens	13-16
17082615-2	2006	Previous studies have shown that the immunosuppressants cyclosporin A or FK506, which interact with the peptidyl-propyl isomerases cyclophilin A and FK506-binding protein (FKBP12), respectively, block cytokine expression.	Cyclosporine	56-69	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	172-178
16965524-3	2006	This study aimed to investigate IL-1A gene polymorphism in Cyclosporin A (CsA)-treated renal transplant patients and investigate the association between this polymorphism and gingival crevicular fluid (GCF) levels of several cytokines.	Cyclosporine	74-77	interleukin 1 alpha	Homo sapiens	32-37
16965524-8	2006	IL-1alpha, IL-1beta and IL-8, but not IL-6, were detected in GCF of CsA-treated patients, but none of them was significantly associated with gingival overgrowth.	Cyclosporine	68-71	interleukin 1 alpha	Homo sapiens	0-9
16965524-9	2006	CONCLUSIONS: This study is the first to associate a gene polymorphism as a risk factor for CsA-induced gingival overgrowth in renal transplant patients, demonstrating that IL-1A polymorphism might alter individual susceptibility to CsA.	Cyclosporine	91-94	interleukin 1 alpha	Homo sapiens	172-177
16799071-8	2006	MAIN RESULTS: Acute exposure to hypoxia led to a marked increase in mRNA levels of serotonin transporter, modulatory calcineurin-interacting protein-1, and HIF-1 target genes, which was blunted by CsA treatment.	Cyclosporine	197-200	regulator of calcineurin 1	Rattus norvegicus	106-150
23105616-0	2006	Serum alpha-2-macroglobulin, antitrypsin and antichymotrypsin activities in patients receiving treatment with cyclosporine.	Cyclosporine	110-122	alpha-2-macroglobulin	Homo sapiens	6-27
23105616-11	2006	Serum antiproteinase activities of serum alpha 2 macroglobulin (AMG), alpha 1-antitrypsin (AT) and alpha 1-antichymotrypsin (ACT) were found to be altered in renal transplant patients receiving cyclosporine.	Cyclosporine	194-206	alpha-2-macroglobulin	Homo sapiens	41-62
23105616-11	2006	Serum antiproteinase activities of serum alpha 2 macroglobulin (AMG), alpha 1-antitrypsin (AT) and alpha 1-antichymotrypsin (ACT) were found to be altered in renal transplant patients receiving cyclosporine.	Cyclosporine	194-206	alpha-2-macroglobulin	Homo sapiens	64-67
16980052-6	2006	Western blot analysis showed enhanced processing of caspase-8, Bax, and p53 after CsA treatment.	Cyclosporine	82-85	BCL2 associated X, apoptosis regulator	Rattus norvegicus	63-66
16980052-6	2006	Western blot analysis showed enhanced processing of caspase-8, Bax, and p53 after CsA treatment.	Cyclosporine	82-85	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	72-75
16980052-7	2006	Expression of cleaved poly (ADP-ribose) polymerase (PARP) was elevated by CsA treatment.	Cyclosporine	74-77	poly (ADP-ribose) polymerase 1	Rattus norvegicus	22-50
16980055-10	2006	CsA produced dose-dependent induction of p53, caspase-6, and Bax protein expression.	Cyclosporine	0-3	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	41-44
16980055-10	2006	CsA produced dose-dependent induction of p53, caspase-6, and Bax protein expression.	Cyclosporine	0-3	BCL2 associated X, apoptosis regulator	Rattus norvegicus	61-64
16980055-13	2006	CONCLUSIONS: In this study, CsA induced apoptosis by up-regulating proapoptotic factors, caspase-3 and -6, p53, Bax, cleaving PARP, and down-regulating antiapoptotic factor, Bcl-2, and cIAP.	Cyclosporine	28-31	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	107-110
16980055-13	2006	CONCLUSIONS: In this study, CsA induced apoptosis by up-regulating proapoptotic factors, caspase-3 and -6, p53, Bax, cleaving PARP, and down-regulating antiapoptotic factor, Bcl-2, and cIAP.	Cyclosporine	28-31	BCL2 associated X, apoptosis regulator	Rattus norvegicus	112-115
16980076-7	2006	RESULTS: The CsA group exhibited higher TC (P = .001), LDL-C (P = .004), non-HDL-C (P = .009), HDL-C (P = .03), apoB (P = .008), and apoCIII (P = .002) levels than the FK group.	Cyclosporine	13-16	apolipoprotein C3	Homo sapiens	133-140
16226372-3	2006	Using SEM and RS4;11 lines with the t(4;11) translocation, the B-ALL line REH, and the T-ALL line Jurkat, we show that pre-treatment with CsA or PK11195 significantly enhances resveratrol-mediated apoptosis and mitochondrial membrane depolarization in these cells, as measured by annexin V and JC-1 staining, respectively.	Cyclosporine	138-141	annexin A5	Homo sapiens	280-289
16643975-6	2006	Inhibition of Cyp A function by cyclosporine significantly decreased the efficiency of TRIM5alpha-mediated restriction only when the restricted virus capsid interacted with Cyp A.	Cyclosporine	32-44	peptidylprolyl isomerase A	Homo sapiens	14-19
16729976-9	2006	Sensitivity to inhibition by transport-substrate vinblastine and competitive modulator cyclosporin A suggests that the elevated level of [125I]IAAP binding to the fragment represents a functionally relevant interaction with the substrate site of Pgp.	Cyclosporine	87-100	phosphoglycolate phosphatase	Homo sapiens	246-249
16913847-8	2006	Injection of CsA led to enhanced phosphorylation of tau at Ser-262 (12E8 site), Ser-198, Ser-199, and/or Ser-202 (Tau-1 site) and Ser-396 and/or Ser-404 (PHF-1 site), as well as to impaired spatial memory, which are two characteristic features of Alzheimer"s disease.	Cyclosporine	13-16	PHD finger protein 1	Mus musculus	154-159
16547932-3	2006	CsA administration decreased by eightfold the level of transcription of MCIP-1, a well-known calcineurin-induced gene, in intact as well as in regenerated muscles (P &lt; 0.001).	Cyclosporine	0-3	regulator of calcineurin 1	Rattus norvegicus	72-78
16645967-11	2006	Addition of cyclosporine improved the ACR20 and ACR-N responses, whereas the ACR50 and ACR70 responses, remission rates, and radiographic changes did not differ between the 2 study groups.	Cyclosporine	12-24	acrosin	Homo sapiens	38-41
16724420-3	2006	Here we show that the MDR1 inhibitor, cyclosporin A (CsA) can deplete Gaucher lymphoid cell lines of accumulated glucosyl ceramide and Fabry cell lines of globotriaosyl ceramide (Gb3), by preventing de novo synthesis.	Cyclosporine	53-56	alpha 1,4-galactosyltransferase (P blood group)	Homo sapiens	179-182
16724420-9	2006	Serum Gb3 recovered to lower levels after CsA treatment.	Cyclosporine	42-45	alpha 1,4-galactosyltransferase (P blood group)	Homo sapiens	6-9
16724420-10	2006	Gb3 was undetected in wild-type liver, and the levels of Gb3 (but not gangliosides) in Fabry mouse liver were significantly depleted by CsA treatment.	Cyclosporine	136-139	alpha 1,4-galactosyltransferase (P blood group)	Homo sapiens	0-3
16724420-10	2006	Gb3 was undetected in wild-type liver, and the levels of Gb3 (but not gangliosides) in Fabry mouse liver were significantly depleted by CsA treatment.	Cyclosporine	136-139	alpha 1,4-galactosyltransferase (P blood group)	Homo sapiens	57-60
16612258-9	2006	CsA induced the expression of fibrogenic connective tissue growth factor both in the heart and kidneys.	Cyclosporine	0-3	cellular communication network factor 2	Rattus norvegicus	41-72
16612258-13	2006	CsA-induced myocardial ANP and connective tissue growth factor (CTGF) mRNA overexpression, RAS activation, NADPH oxidase induction, and NRF2 overexpression were prevented by LA.	Cyclosporine	0-3	cellular communication network factor 2	Rattus norvegicus	31-62
16612258-13	2006	CsA-induced myocardial ANP and connective tissue growth factor (CTGF) mRNA overexpression, RAS activation, NADPH oxidase induction, and NRF2 overexpression were prevented by LA.	Cyclosporine	0-3	cellular communication network factor 2	Rattus norvegicus	64-68
16696922-8	2006	The expression levels of RANKL and M-CSF mRNAs and the RANKL mRNA/OPG mRNA ratio in the untreated group, KFSG-treated group and CsA-treated group were all significantly higher than those in the normal control group, while the expression levels of OPG mRNA in those three groups were significantly lower than that in the normal control group.	Cyclosporine	128-131	TNF receptor superfamily member 11B	Rattus norvegicus	66-69
16307882-1	2006	Cyclophilin A (CypA) is a member of cyclophilins, a family of the highly homologous peptidyl prolyl cis-trans isomerases (PPIases), which can bind to cyclosporin A (CsA).	Cyclosporine	150-163	peptidylprolyl isomerase A	Homo sapiens	0-13
16307882-1	2006	Cyclophilin A (CypA) is a member of cyclophilins, a family of the highly homologous peptidyl prolyl cis-trans isomerases (PPIases), which can bind to cyclosporin A (CsA).	Cyclosporine	150-163	peptidylprolyl isomerase A	Homo sapiens	15-19
16307882-1	2006	Cyclophilin A (CypA) is a member of cyclophilins, a family of the highly homologous peptidyl prolyl cis-trans isomerases (PPIases), which can bind to cyclosporin A (CsA).	Cyclosporine	150-163	peptidylprolyl isomerase A	Homo sapiens	36-48
16307882-1	2006	Cyclophilin A (CypA) is a member of cyclophilins, a family of the highly homologous peptidyl prolyl cis-trans isomerases (PPIases), which can bind to cyclosporin A (CsA).	Cyclosporine	165-168	peptidylprolyl isomerase A	Homo sapiens	0-13
16307882-1	2006	Cyclophilin A (CypA) is a member of cyclophilins, a family of the highly homologous peptidyl prolyl cis-trans isomerases (PPIases), which can bind to cyclosporin A (CsA).	Cyclosporine	165-168	peptidylprolyl isomerase A	Homo sapiens	15-19
16307882-1	2006	Cyclophilin A (CypA) is a member of cyclophilins, a family of the highly homologous peptidyl prolyl cis-trans isomerases (PPIases), which can bind to cyclosporin A (CsA).	Cyclosporine	165-168	peptidylprolyl isomerase A	Homo sapiens	36-48
16408196-8	2006	In all cyclosporin-A treated groups, there was a significant reduction in NFATc1 expression (P&lt;0.001).	Cyclosporine	7-20	nuclear factor of activated T-cells 1	Rattus norvegicus	74-80
16571786-4	2006	We find that Vpr coimmunoprecipitates with CypA and that this interaction is disrupted by substitution of proline-35 of Vpr as well as incubation with the CypA inhibitor cyclosporine A (CsA).	Cyclosporine	170-184	peptidylprolyl isomerase A	Homo sapiens	43-47
16571786-4	2006	We find that Vpr coimmunoprecipitates with CypA and that this interaction is disrupted by substitution of proline-35 of Vpr as well as incubation with the CypA inhibitor cyclosporine A (CsA).	Cyclosporine	170-184	peptidylprolyl isomerase A	Homo sapiens	155-159
16571786-4	2006	We find that Vpr coimmunoprecipitates with CypA and that this interaction is disrupted by substitution of proline-35 of Vpr as well as incubation with the CypA inhibitor cyclosporine A (CsA).	Cyclosporine	186-189	peptidylprolyl isomerase A	Homo sapiens	43-47
16476567-2	2006	CsA is reported to competitively inhibit the transport of the substrates of the bile salt export pump (Bsep), multidrug resistance protein 2 (Mrp2) and P-glycoprotein (P-gp) in the canalicular membrane vesicles.	Cyclosporine	0-3	ATP binding cassette subfamily B member 4	Rattus norvegicus	110-140
16476567-2	2006	CsA is reported to competitively inhibit the transport of the substrates of the bile salt export pump (Bsep), multidrug resistance protein 2 (Mrp2) and P-glycoprotein (P-gp) in the canalicular membrane vesicles.	Cyclosporine	0-3	ATP binding cassette subfamily B member 4	Rattus norvegicus	142-146
16476567-4	2006	Therefore, in the present study, the acute effect of CsA on the biliary excretion of the substrates of Bsep, Mrp2 and P-gp was examined under the same condition.	Cyclosporine	53-56	ATP binding cassette subfamily B member 4	Rattus norvegicus	109-113
16476567-8	2006	In conclusion, CsA may competitively inhibit biliary excretion of substrates of Bsep, Mrp2 and P-gp also in vivo, and CsA is considered to inhibit bile acid-dependent bile flow by the competitive inhibition of the canalicular transport of bile acids by Bsep.	Cyclosporine	15-18	ATP binding cassette subfamily B member 4	Rattus norvegicus	86-90
16458014-7	2006	In mechanistic studies related to the loss of viability, treating cells with 10 microM CsA for 24 h resulted in both DNA fragmentation and an increase of annexin-V-positive cells.	Cyclosporine	87-90	annexin A5	Homo sapiens	154-163
16456021-9	2006	The calcineurin phosphatase inhibitor cyclosporine A, which blocks KC terminal differentiation, also blocked CD1d gene expression by cultured KC.	Cyclosporine	38-52	CD1d molecule	Homo sapiens	109-113
16522547-7	2006	Flow cytometric analysis of P-gp/170 surface expression was performed using UIC-2 MoAb together with the functional assay using Rhodamine 123 (Rh 123) and Cyclosporin A as a modulator.P-gp/170 was expressed on the leukemic cells of 37.5% of relapsed patients (40.0% of AML and 33.3% of ALL cases), whereas 27.2% of de novo patients expressed P-gp/170 (33.3% of AML cases and 0% of ALL cases).	Cyclosporine	155-168	phosphoglycolate phosphatase	Homo sapiens	184-188
16522547-7	2006	Flow cytometric analysis of P-gp/170 surface expression was performed using UIC-2 MoAb together with the functional assay using Rhodamine 123 (Rh 123) and Cyclosporin A as a modulator.P-gp/170 was expressed on the leukemic cells of 37.5% of relapsed patients (40.0% of AML and 33.3% of ALL cases), whereas 27.2% of de novo patients expressed P-gp/170 (33.3% of AML cases and 0% of ALL cases).	Cyclosporine	155-168	phosphoglycolate phosphatase	Homo sapiens	184-188
16471698-1	2006	The structure of the complex of cyclophilin A (CypA) with cyclosporin A (CsA, 1) shows a cluster of four water molecules buried at the binding interface, which is rearranged when CsA is replaced by (5-hydroxynorvaline)-2-cyclosporin (2).	Cyclosporine	73-76	peptidylprolyl isomerase A	Homo sapiens	32-45
16471698-1	2006	The structure of the complex of cyclophilin A (CypA) with cyclosporin A (CsA, 1) shows a cluster of four water molecules buried at the binding interface, which is rearranged when CsA is replaced by (5-hydroxynorvaline)-2-cyclosporin (2).	Cyclosporine	73-76	peptidylprolyl isomerase A	Homo sapiens	47-51
16471698-1	2006	The structure of the complex of cyclophilin A (CypA) with cyclosporin A (CsA, 1) shows a cluster of four water molecules buried at the binding interface, which is rearranged when CsA is replaced by (5-hydroxynorvaline)-2-cyclosporin (2).	Cyclosporine	179-182	peptidylprolyl isomerase A	Homo sapiens	32-45
16471698-1	2006	The structure of the complex of cyclophilin A (CypA) with cyclosporin A (CsA, 1) shows a cluster of four water molecules buried at the binding interface, which is rearranged when CsA is replaced by (5-hydroxynorvaline)-2-cyclosporin (2).	Cyclosporine	179-182	peptidylprolyl isomerase A	Homo sapiens	47-51
16622732-10	2006	Northern blot analysis revealed that the CsA-treated group showed an increase in the expression of OCN, OPN, and cathepsin K mRNAs on day 8 compared with the controls.	Cyclosporine	41-44	cathepsin K	Rattus norvegicus	113-124
16332239-7	2005	The mRNA expressions of TGF-beta1, IGF-1, and VEGF were higher in the gingivae of the CsA group than in the control group.	Cyclosporine	86-89	insulin-like growth factor 1	Rattus norvegicus	35-40
16332239-7	2005	The mRNA expressions of TGF-beta1, IGF-1, and VEGF were higher in the gingivae of the CsA group than in the control group.	Cyclosporine	86-89	vascular endothelial growth factor A	Rattus norvegicus	46-50
16332239-8	2005	In addition, a greater mRNA expression (7.21-fold) of VEGF was demonstrated in the CsA group than in the control group by real-time polymerase chain reaction (PCR).	Cyclosporine	83-86	vascular endothelial growth factor A	Rattus norvegicus	54-58
16332239-10	2005	CONCLUSIONS: Greater mRNA expression and positive staining for TGF-beta1 and VEGF were observed in the edentulous gingivae of rats that received CsA.	Cyclosporine	145-148	vascular endothelial growth factor A	Rattus norvegicus	77-81
16332239-11	2005	Therefore, CsA may upregulate TGF-beta1 and VEGF gene expression and protein secretion in CsA-induced gingival overgrowth.	Cyclosporine	11-14	vascular endothelial growth factor A	Rattus norvegicus	44-48
16311095-4	2005	The aim of the study was to evaluate the LDL receptor uptake of CsA-transported LDL (CsA-LDL) compared with normal LDL in normal and CsA-treated lymphocytes.	Cyclosporine	64-67	low density lipoprotein receptor	Homo sapiens	41-53
16412961-8	2005	TF staining of the brush border of renal transplants undergoing acute cyclosporin A (CsA) nephrotoxicity (n=18) was significantly higher than in normal kidneys (p=0.0003), as well as in transplants undergoing various degrees of acute rejection (ARI, p=0.027; ARII, p=0.0012; and ARIII, p=0.0001).	Cyclosporine	70-83	coagulation factor III, tissue factor	Homo sapiens	0-2
16412961-8	2005	TF staining of the brush border of renal transplants undergoing acute cyclosporin A (CsA) nephrotoxicity (n=18) was significantly higher than in normal kidneys (p=0.0003), as well as in transplants undergoing various degrees of acute rejection (ARI, p=0.027; ARII, p=0.0012; and ARIII, p=0.0001).	Cyclosporine	85-88	coagulation factor III, tissue factor	Homo sapiens	0-2
16412961-9	2005	Tubular brush border-expressed TF was also evident in 10 of 15 allografts suffering from chronic CsA nephrotoxicity, compared to 4 out of 13 cases with chronic allograft vasculopathy (CAV), but the increase was not statistically significant relative to normal kidneys.	Cyclosporine	97-100	coagulation factor III, tissue factor	Homo sapiens	31-33
16412961-12	2005	Furthermore, TF immunoreactivity in the tubular brush border may be specific to acute CsA nephrotoxicity and might be used as a biomarker for this condition.	Cyclosporine	86-89	coagulation factor III, tissue factor	Homo sapiens	13-15
16412961-13	2005	Further studies are required to evaluate the possible role of brush border-expressed TF in the pathogenesis of CsA nephrotoxicity.	Cyclosporine	111-114	coagulation factor III, tissue factor	Homo sapiens	85-87
16321613-8	2005	RESULTS: At visit 1, cyclosporine-treated patients had significantly enhanced CD62P and PAC1 expression and platelet-leukocyte aggregate formation, as well as elevated sCD40L concentrations, compared with tacrolimus-treated patients (all P &lt; .03).	Cyclosporine	21-33	selectin P	Homo sapiens	78-83
16198658-13	2005	The effect of cyclosporine on repaglinide AUC0-infinity was 42% lower in subjects with the SLCO1B1 521TC genotype than in subjects with the 521TT (reference) genotype (P=.047).	Cyclosporine	14-26	solute carrier organic anion transporter family member 1B1	Homo sapiens	91-98
16198658-15	2005	CONCLUSIONS: Cyclosporine raised the plasma concentrations of repaglinide, probably by inhibiting its CYP3A4-catalyzed biotransformation and OATP1B1-mediated hepatic uptake.	Cyclosporine	13-25	solute carrier organic anion transporter family member 1B1	Homo sapiens	141-148
16030052-11	2005	RESULTS: CsA induced striking morphological changes in epithelial cells, including changes in cellular morphology, F-actin stress fibre formation, delocalization of the adherens junction protein beta-catenin and increased levels of collagen IV and fibronectin.	Cyclosporine	9-12	catenin beta 1	Homo sapiens	195-207
16116173-5	2005	However, we demonstrate that a brief course of cyclosporine A to rat renal allograft recipients promotes progressive accumulation of CD103+CD8+ cells within the graft, concomitant with the development of tubular atrophy and interstitial fibrosis.	Cyclosporine	47-61	integrin subunit alpha E	Homo sapiens	133-138
15963461-1	2005	Cyclophilins (CyPs) are a widespreading protein family in living organisms and possess the activity of peptidyl-prolyl cis-trans isomerase (PPIase), which is inhibited by cyclosporin A (CsA).	Cyclosporine	186-189	peptidylprolyl isomerase A	Homo sapiens	0-12
15963461-5	2005	Superposition of the structure of the C domain of hCyP33 with the structure of CypA suggests that the C domain contains PPIase active site which binds to CsA.	Cyclosporine	154-157	peptidylprolyl isomerase A	Homo sapiens	79-83
15829415-8	2005	It is worth noting that TNFR-Ig or prednisolone, which is effective for treatment of patients with severe-fulminant Crohn"s disease, markedly attenuated pathological clinical indices in this colitis model, whereas the immunosuppressive agents, azathioprine, tacrolimus, and cyclosporine A produced no significant effect.	Cyclosporine	274-288	TNF receptor superfamily member 1A	Homo sapiens	24-28
15687239-5	2005	Major risk factors for the development of SCC were long duration of chronic GVHD therapy (P &lt; .001); use of azathioprine, particularly when combined with cyclosporine and steroids (P &lt; .001); and severe chronic GVHD (P = .004).	Cyclosporine	157-169	serpin family B member 3	Homo sapiens	42-45
15879096-3	2005	Immunosuppression by cyclosporine is thought to result from the formation of a drug-cyclophilin complex that binds to and inhibits calcineurin, a serine/threonine phosphatase that is activated by TCR engagement.	Cyclosporine	21-33	T cell receptor alpha variable 6-3	Mus musculus	196-199
15879096-7	2005	TCR-induced proliferation and signal transduction by Ppia(-/-) CD4(+) T cells were resistant to cyclosporine, an effect that was attributable to diminished calcineurin inhibition.	Cyclosporine	96-108	T cell receptor alpha variable 6-3	Mus musculus	0-3
15919519-8	2005	CsA, MMF, and AS-ODNs inhibited MD-1 expression and lymphocyte proliferation, as well as decreased serum level of IL-2 and increased that of IL-10; FK506, treatment showed all the effects mentioned above but up-regulated the IL-10 level; SRL had no significant influence on either MD-1 expression or IL-2 and IL-10 level, although it equally suppressed the proliferation (P &lt; .05 vs controls).	Cyclosporine	0-3	interleukin 2	Mus musculus	114-118
15919519-8	2005	CsA, MMF, and AS-ODNs inhibited MD-1 expression and lymphocyte proliferation, as well as decreased serum level of IL-2 and increased that of IL-10; FK506, treatment showed all the effects mentioned above but up-regulated the IL-10 level; SRL had no significant influence on either MD-1 expression or IL-2 and IL-10 level, although it equally suppressed the proliferation (P &lt; .05 vs controls).	Cyclosporine	0-3	interleukin 2	Mus musculus	300-304
15722361-9	2005	When RANKL signaling through NFATc1 was blocked with cyclosporin A, both MCP-1 and RANTES expression was down-regulated.	Cyclosporine	53-66	C-C motif chemokine ligand 2	Homo sapiens	73-78
15722361-10	2005	Furthermore, addition of MCP-1 and RANTES reversed the effects of cyclosporin A and recovered the TRAP-positive multinuclear cell phenotype.	Cyclosporine	66-79	C-C motif chemokine ligand 2	Homo sapiens	25-30
15706440-1	2005	Cyclophilins are originally identified as cellular binding proteins for the immunosuppressive drug cyclosporin A.	Cyclosporine	99-112	peptidylprolyl isomerase A	Homo sapiens	0-12
15661399-11	2005	P-gp inhibitors GF120918 and cyclosporin A enhanced ceramide-induced apoptosis in the p-gp expressing cells.	Cyclosporine	29-42	phosphoglycolate phosphatase	Homo sapiens	0-4
16541750-5	2005	Furthemore, recent mechanistic studies have shown organic anion transporting peptides (OATP) C to mediate the uptake of some statins and cyclosporine has been shown to inhibit the uptake via OATP-C in cultured cells.	Cyclosporine	137-149	solute carrier organic anion transporter family member 1B1	Homo sapiens	191-197
15767220-10	2005	All patients in the preprandial administration group showed a high-absorption pattern and reached the peak cyclosporine concentration at C 1 .	Cyclosporine	107-119	heterogeneous nuclear ribonucleoprotein C	Homo sapiens	137-140
15767220-13	2005	From the correlation with AUC 0-4 , we concluded that C 2 , and not C 0 , is a reliable marker for monitoring cyclosporine exposure.	Cyclosporine	110-122	complement C2	Homo sapiens	54-57
15808628-6	2005	A direct in situ polymerase chain reaction (ISPCR) for the SRY gene showed SRY-marked endothelial and smooth muscle-like cells in neointima at 2 weeks in the PCI group, at 4 weeks in the control group, and rarely at 3 months in the CyA group.	Cyclosporine	232-235	sex determining region Y	Rattus norvegicus	59-62
15542632-5	2004	Disruption of the CA-CypA interaction, either by the competitive inhibitor cyclosporine (CsA) or by mutation of CA residue G89 or P90, suggested that producer cell CypA was required for full virion infectivity.	Cyclosporine	75-87	peptidylprolyl isomerase A	Homo sapiens	21-25
15542632-5	2004	Disruption of the CA-CypA interaction, either by the competitive inhibitor cyclosporine (CsA) or by mutation of CA residue G89 or P90, suggested that producer cell CypA was required for full virion infectivity.	Cyclosporine	75-87	peptidylprolyl isomerase A	Homo sapiens	164-168
15542632-5	2004	Disruption of the CA-CypA interaction, either by the competitive inhibitor cyclosporine (CsA) or by mutation of CA residue G89 or P90, suggested that producer cell CypA was required for full virion infectivity.	Cyclosporine	89-92	peptidylprolyl isomerase A	Homo sapiens	21-25
15347678-6	2004	The effects of IL-15 and IL-2 on both CX3CR1 reporter activity and endogenous CX3CR1 transcription in PBMCs were abolished by the NFAT inhibitors cyclosporin A and VIVIT.	Cyclosporine	146-159	interleukin 2	Mus musculus	25-29
15383526-8	2004	However, CsA treatment decreased cholesterol content in caveolae and displaced eNOS from caveolae, which may be caused by CsA disrupting the association of caveolin-1 and cyclophilin A.	Cyclosporine	9-12	caveolin 1	Bos taurus	156-166
15383526-8	2004	However, CsA treatment decreased cholesterol content in caveolae and displaced eNOS from caveolae, which may be caused by CsA disrupting the association of caveolin-1 and cyclophilin A.	Cyclosporine	122-125	caveolin 1	Bos taurus	156-166
15355478-0	2004	Cyclosporine treatment decreases the percentage of cutaneous lymphocyte antigen (CLA)(+)CD4(+) T cells in children with severe atopic dermatitis.	Cyclosporine	0-12	selectin P ligand	Homo sapiens	81-84
15353287-1	2004	Cyclophilin (CyP) is a cytosolic receptor of immunosuppressive drug cyclosporin A (CsA).	Cyclosporine	68-81	peptidylprolyl isomerase G	Homo sapiens	0-11
15353287-1	2004	Cyclophilin (CyP) is a cytosolic receptor of immunosuppressive drug cyclosporin A (CsA).	Cyclosporine	68-81	peptidylprolyl isomerase G	Homo sapiens	13-16
15497749-2	2004	The lipophilic model drug cyclosporin A was incorporated into SLN to study encapsulation efficiency, zeta potential (charge) and drug delivery.	Cyclosporine	26-39	sarcolipin	Homo sapiens	62-65
15497749-3	2004	Stearylamine and cyclosporin A were dissolved in ethanol and acetone and the resultant organic solution was dropped into water at 60 degrees C. The drug-loaded SLN suspension quickly formed with an azury color.	Cyclosporine	17-30	sarcolipin	Homo sapiens	160-163
15221438-0	2004	The immunosuppressant and hyperplasia-inducing drug cyclosporin A regulates the cell cycle and cyclin B1 gene expression in gingival fibroblasts in vitro.	Cyclosporine	52-65	cyclin B1	Homo sapiens	95-104
15221438-3	2004	In the present study, flow cytometry analysis of the effects of the immunosuppressant drug cyclosporin A showed that it enhanced cell-cycle progression of gingival fibroblasts in vitro and also up-regulated the expression of cyclin B1.	Cyclosporine	91-104	cyclin B1	Homo sapiens	225-234
15455731-10	2004	MMP-1 secretion was inhibited significantly by phenytoin, nifedipine, and cyclosporin A and the depressed MMP-1 recovered to the control level with tranilast.	Cyclosporine	74-87	matrix metallopeptidase 1	Homo sapiens	0-5
15130913-1	2004	OBJECTIVE: Cyclophilin A (CyPA) is an abundant intracellular protein that is considered to be the main target of the immunosuppressive drug cyclosporine A.	Cyclosporine	140-154	peptidylprolyl isomerase A	Homo sapiens	11-24
15130913-1	2004	OBJECTIVE: Cyclophilin A (CyPA) is an abundant intracellular protein that is considered to be the main target of the immunosuppressive drug cyclosporine A.	Cyclosporine	140-154	peptidylprolyl isomerase A	Homo sapiens	26-30
15063741-5	2004	Moreover, the apoptosis produced by ANT3 was inhibited by bongkrekic acid and by cyclosporin A.	Cyclosporine	81-94	solute carrier family 25 member 6	Homo sapiens	36-40
15066193-4	2004	In the present study, we demonstrate that calcineurin inhibitors (cyclosporine A, FK506, and FK520), but not non-calcineurin inhibitors (rapamycin and GPI1046) that bind the same intracellular receptor as that for FK506, induce edema and gut coiling disruption and exhibit teratogenesis in the kidney, heart, gut, liver, and somitic tissue during Xenopus development.	Cyclosporine	66-80	protein phosphatase 3, catalytic subunit, alpha isozyme L homeolog	Xenopus laevis	42-53
15009516-8	2004	Western blot analyses showed that the expression of TSP2 protein was dose-dependently reduced by the CsA treatments in human cultured gingival fibroblasts.	Cyclosporine	101-104	thrombospondin 2	Homo sapiens	52-56
15009516-9	2004	CONCLUSIONS: These results indicate that the decrease in angiostatic TSP2 expression may be attributed to the CsA-induced gingival vascularization rather than to the increased expression of angiogenic genes.	Cyclosporine	110-113	thrombospondin 2	Homo sapiens	69-73
15009516-10	2004	It suggests that TSP2 is involved in the development of CsA-induced gingival overgrowth with the gingival vascularization.	Cyclosporine	56-59	thrombospondin 2	Homo sapiens	17-21
17642761-0	2004	C-2 monitoring for cyclosporin: considerations for implementation.	Cyclosporine	19-30	complement C2	Homo sapiens	0-3
15021830-9	2004	In CsA-treated rats, RWI was also associated with an increase in inflammatory infiltrates, elevated immunostain for ED1 (indicating extensive macrophage influx), and elevated immunostain for alpha-smooth muscle actin (indicating myofibroblast activation).	Cyclosporine	3-6	actin gamma 2, smooth muscle	Rattus norvegicus	191-216
14758529-1	2004	The aim of this study was to evaluate the role of osteopontin (OPN) in cyclosporine (CsA) nephrotoxicity of the human kidney.	Cyclosporine	71-83	secreted phosphoprotein 1	Homo sapiens	50-61
14758529-1	2004	The aim of this study was to evaluate the role of osteopontin (OPN) in cyclosporine (CsA) nephrotoxicity of the human kidney.	Cyclosporine	71-83	secreted phosphoprotein 1	Homo sapiens	63-66
14758529-1	2004	The aim of this study was to evaluate the role of osteopontin (OPN) in cyclosporine (CsA) nephrotoxicity of the human kidney.	Cyclosporine	85-88	secreted phosphoprotein 1	Homo sapiens	50-61
14758529-1	2004	The aim of this study was to evaluate the role of osteopontin (OPN) in cyclosporine (CsA) nephrotoxicity of the human kidney.	Cyclosporine	85-88	secreted phosphoprotein 1	Homo sapiens	63-66
14758529-7	2004	OPN expression was significantly increased in the glomerular mesangium (P=0.001) and tubules (P=0.025) after CsA treatment, whereas the number of CD34-positive peritubular capillaries decreased (P=0.022).	Cyclosporine	109-112	secreted phosphoprotein 1	Homo sapiens	0-3
14758529-10	2004	This study indicates that increased OPN expression may be related to microvascular injury in human CsA nephrotoxicity.	Cyclosporine	99-102	secreted phosphoprotein 1	Homo sapiens	36-39
14758529-11	2004	It also shows that OPN expression may be used as an early but non-specific marker of CsA toxicity before the manifestation of interstitial fibrosis.	Cyclosporine	85-88	secreted phosphoprotein 1	Homo sapiens	19-22
14603530-5	2004	Cyclosporine A, which prevented the loss of psim, also inhibited HMG-induced DNA fragmentation in cells expressing an activated p21Ras.	Cyclosporine	0-14	HRas proto-oncogene, GTPase	Homo sapiens	128-134
15147634-4	2004	In cyclosporine-A-treated rats, we found changes in Bax staining of neurons: type A neurons and type B neurons were weakly stained, whereas type C neurons were moderately stained.	Cyclosporine	3-17	BCL2 associated X, apoptosis regulator	Rattus norvegicus	52-55
15147634-10	2004	We conclude that (1) in normal conditions, Bax and Bcl-2 were differently expressed in neurons and satellite cells; (2) cyclosporine-A treatment rapidly enhanced Bax expression in satellite cells only, whereas Bcl-2 expression increased moderately in type A neurons and was strongly expressed in type B and C neurons; (3) cyclosporine-A has a protective role in neurons but not in satellite cells; and (4) the neuroprotective role of cyclosporine-A is dose dependent.	Cyclosporine	120-134	BCL2 associated X, apoptosis regulator	Rattus norvegicus	43-46
15147634-10	2004	We conclude that (1) in normal conditions, Bax and Bcl-2 were differently expressed in neurons and satellite cells; (2) cyclosporine-A treatment rapidly enhanced Bax expression in satellite cells only, whereas Bcl-2 expression increased moderately in type A neurons and was strongly expressed in type B and C neurons; (3) cyclosporine-A has a protective role in neurons but not in satellite cells; and (4) the neuroprotective role of cyclosporine-A is dose dependent.	Cyclosporine	120-134	BCL2 associated X, apoptosis regulator	Rattus norvegicus	162-165
15147634-10	2004	We conclude that (1) in normal conditions, Bax and Bcl-2 were differently expressed in neurons and satellite cells; (2) cyclosporine-A treatment rapidly enhanced Bax expression in satellite cells only, whereas Bcl-2 expression increased moderately in type A neurons and was strongly expressed in type B and C neurons; (3) cyclosporine-A has a protective role in neurons but not in satellite cells; and (4) the neuroprotective role of cyclosporine-A is dose dependent.	Cyclosporine	322-336	BCL2 associated X, apoptosis regulator	Rattus norvegicus	43-46
15147634-10	2004	We conclude that (1) in normal conditions, Bax and Bcl-2 were differently expressed in neurons and satellite cells; (2) cyclosporine-A treatment rapidly enhanced Bax expression in satellite cells only, whereas Bcl-2 expression increased moderately in type A neurons and was strongly expressed in type B and C neurons; (3) cyclosporine-A has a protective role in neurons but not in satellite cells; and (4) the neuroprotective role of cyclosporine-A is dose dependent.	Cyclosporine	322-336	BCL2 associated X, apoptosis regulator	Rattus norvegicus	43-46
15061651-6	2004	The presence of cyclosporin A, trifluoperazine, or SOD inhibited the Ca(2+)-induced increase of L-012 CHL and decrease in the free thiols of ANT.	Cyclosporine	16-29	solute carrier family 25 member 6	Homo sapiens	141-144
15047987-6	2004	Moreover, significant decrease in IL-2 secretion at 0.25, 0.5, 1 and 50 microM CsA and FK506 at concentrations of 100 and 1000 nM were observed.	Cyclosporine	79-82	interleukin 2	Rattus norvegicus	34-38
17670108-8	2003	In allografts treated with cyclosporine and 1A29 histologically a lower grade of rejection was seen and less MPO were detected compared to groups A, B and D. Anti-ICAM-1 monoclonal antibodies alone as well as a subtherapeutic dose of cyclosporine are not effective to prevent acute allograft rejection after lung transplantation.	Cyclosporine	27-39	myeloperoxidase	Rattus norvegicus	109-112
14642132-0	2003	CsA downregulates IFN-gamma gene transcription after liver transplantation by inhibiting NF-kappa B activity.	Cyclosporine	0-3	interferon gamma	Rattus norvegicus	18-27
14642132-12	2003	CsA appears to downregulate NF-kappa B activity, thus inhibiting IFN-gamma gene transcription.	Cyclosporine	0-3	interferon gamma	Rattus norvegicus	65-74
14611999-0	2003	Cyclosporine preconditions dendritic cells during differentiation and reduces IL-2 and IL-12 production following activation: a potential tolerogenic effect.	Cyclosporine	0-12	interleukin 2	Mus musculus	78-82
14611999-1	2003	The mode of action of cyclosporine (CsA) has been ascribed to its capacity to inhibit IL-2 and IFNgamma production by T cells, two cytokines implicated in allograft rejection.	Cyclosporine	22-34	interleukin 2	Mus musculus	86-90
14611999-1	2003	The mode of action of cyclosporine (CsA) has been ascribed to its capacity to inhibit IL-2 and IFNgamma production by T cells, two cytokines implicated in allograft rejection.	Cyclosporine	36-39	interleukin 2	Mus musculus	86-90
14611999-7	2003	Our results show that when CsA is added during the differentiation period following activation with LPS, IL-2 and IL-12 secretion are significantly reduced without affecting the evolution of the DC.	Cyclosporine	27-30	interleukin 2	Mus musculus	105-109
12881522-5	2003	The CypA inhibitor cyclosporin A and non-immunosuppressive PPIase inhibitors such as NIM811 and sanglifehrin A block expression of Vpr without affecting pre- or post-translational events such as transcription, intracellular transport, or virus incorporation of Vpr.	Cyclosporine	19-32	peptidylprolyl isomerase A	Homo sapiens	4-8
14576824-2	2003	We found that cyclosporin A (CsA) induces apoptosis of C6 glioma cells, which is associated with transcriptional activation of fasL.	Cyclosporine	14-27	Fas ligand	Homo sapiens	127-131
14576824-2	2003	We found that cyclosporin A (CsA) induces apoptosis of C6 glioma cells, which is associated with transcriptional activation of fasL.	Cyclosporine	29-32	Fas ligand	Homo sapiens	127-131
14576824-3	2003	In the present paper, we investigated an involvement of Akt signalling in the regulation of FasL expression in CsA-induced apoptosis.	Cyclosporine	111-114	Fas ligand	Homo sapiens	92-96
14521916-6	2003	Intracellular protein levels of the cyclin-dependent kinase inhibitor p27(Kip1)decreased from the G0 to G2/M phase and from the cycling to the activation state, but remained unchanged during the induction of apoptosis by CsA and lactacystin, suggesting a role of p27(Kip1)in the regulation of susceptibility to apoptosis during cell cycle progression and activation.	Cyclosporine	221-224	interferon alpha inducible protein 27	Homo sapiens	70-73
14521916-6	2003	Intracellular protein levels of the cyclin-dependent kinase inhibitor p27(Kip1)decreased from the G0 to G2/M phase and from the cycling to the activation state, but remained unchanged during the induction of apoptosis by CsA and lactacystin, suggesting a role of p27(Kip1)in the regulation of susceptibility to apoptosis during cell cycle progression and activation.	Cyclosporine	221-224	cyclin dependent kinase inhibitor 1B	Homo sapiens	74-78
14521916-7	2003	Inhibition of CsA- but not lactacytin-induced apoptosis by overexpression of Bcl-2 in Jurkat T cells revealed that CsA and proteasome inhibitors activate different apoptotic pathways, while both CsA- and lactacystin-induced apoptosis were found to be dependent on caspase activation and independent of the FasL/Fas system.	Cyclosporine	115-118	Fas ligand	Homo sapiens	306-310
14521916-7	2003	Inhibition of CsA- but not lactacytin-induced apoptosis by overexpression of Bcl-2 in Jurkat T cells revealed that CsA and proteasome inhibitors activate different apoptotic pathways, while both CsA- and lactacystin-induced apoptosis were found to be dependent on caspase activation and independent of the FasL/Fas system.	Cyclosporine	115-118	Fas ligand	Homo sapiens	306-310
12909621-5	2003	TMEA is a cross-linker substrate of P-gp that allowed us to test for stimulation of cross-linking by a second substrate such as calcein-acetoxymethyl ester, colchicine, demecolcine, cyclosporin A, rhodamine B, progesterone, and verapamil.	Cyclosporine	182-195	phosphoglycolate phosphatase	Homo sapiens	36-40
12796489-0	2003	Cloning and characterization of N4WBP5A, an inducible, cyclosporine-sensitive, Nedd4-binding protein in human T lymphocytes.	Cyclosporine	55-67	NEDD4 E3 ubiquitin protein ligase	Homo sapiens	79-84
14677627-7	2003	CYP3A and CYP2C11 protein expression was suppressed by 27% and 39%, respectively, in the HDL-CSA treatment group and by 38% and 40% in the Plasma-CSA treated group as compared with CSA controls.	Cyclosporine	93-96	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	10-17
14677627-7	2003	CYP3A and CYP2C11 protein expression was suppressed by 27% and 39%, respectively, in the HDL-CSA treatment group and by 38% and 40% in the Plasma-CSA treated group as compared with CSA controls.	Cyclosporine	146-149	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	10-17
12885921-5	2003	CypA relocation to viral factories required the synthesis of viral postreplicative proteins, and treatment of infected cells with cyclosporine (CsA) prevented CypA relocation, clearly excluding the virosomes from CypA staining.	Cyclosporine	130-142	peptidylprolyl isomerase A	Homo sapiens	159-163
12885921-5	2003	CypA relocation to viral factories required the synthesis of viral postreplicative proteins, and treatment of infected cells with cyclosporine (CsA) prevented CypA relocation, clearly excluding the virosomes from CypA staining.	Cyclosporine	130-142	peptidylprolyl isomerase A	Homo sapiens	159-163
12885921-5	2003	CypA relocation to viral factories required the synthesis of viral postreplicative proteins, and treatment of infected cells with cyclosporine (CsA) prevented CypA relocation, clearly excluding the virosomes from CypA staining.	Cyclosporine	144-147	peptidylprolyl isomerase A	Homo sapiens	159-163
12885921-5	2003	CypA relocation to viral factories required the synthesis of viral postreplicative proteins, and treatment of infected cells with cyclosporine (CsA) prevented CypA relocation, clearly excluding the virosomes from CypA staining.	Cyclosporine	144-147	peptidylprolyl isomerase A	Homo sapiens	159-163
12708624-5	2003	RESULTS: Serum TRX levels (mean +/- standard deviation ng/ml) were significantly higher in CSA (64 +/- 44) than in iCSA (28 +/- 26), in Control (34 +/- 15), and in SEA (36 +/- 16).	Cyclosporine	91-94	thioredoxin	Homo sapiens	15-18
12708624-9	2003	In nine patients with CSA, the serum TRX level decreased (93 +/- 41 --&gt; 41 +/- 35 ng/ml) and the alpha-tocopherol level increased (2.7 +/- 0.6 --&gt; 3.2 +/- 0.7 mg/g lipids) significantly under medication with calcium entry blockers after an at least 3-month angina-free period.	Cyclosporine	22-25	thioredoxin	Homo sapiens	37-40
12644839-6	2003	Cyclosporin A combined with Taxol treatment augments caspase-9, -3 activation and loss of mitochondrial membrane potential in HepG2 cells.	Cyclosporine	0-13	caspase 9	Homo sapiens	53-62
11546652-8	2001	On the other hand, W-7, a calmodulin inhibitor, and cyclosporin A, a calcineurin inhibitor, prevented JNK activation by stretch.	Cyclosporine	52-65	mitogen-activated protein kinase 8	Rattus norvegicus	102-105
11607878-0	2001	Cyclosporin a treatment is able to revert the decrease in circulating GH and IGF-I and the increase in IGFBPs induced by adjuvant arthritis.	Cyclosporine	0-13	insulin-like growth factor 1	Rattus norvegicus	77-82
11607878-1	2001	The aim of this study was to find out whether cyclosporin A administration is able to revert the decrease in circulating growth hormone (GH) and insulin-like growth factor-I (IGF-I) and the increase in IGF-binding proteins (IGFBPs) levels caused by adjuvant-induced arthritis in rats.	Cyclosporine	46-59	insulin-like growth factor 1	Rattus norvegicus	145-173
11607878-1	2001	The aim of this study was to find out whether cyclosporin A administration is able to revert the decrease in circulating growth hormone (GH) and insulin-like growth factor-I (IGF-I) and the increase in IGF-binding proteins (IGFBPs) levels caused by adjuvant-induced arthritis in rats.	Cyclosporine	46-59	insulin-like growth factor 1	Rattus norvegicus	175-180
11607878-7	2001	Cyclosporin administration increased circulating IGF-I, and there was a negative correlation between circulating IGF-I and arthritis index scores in arthritic rats injected with cyclosporin (p &lt; 0.05).	Cyclosporine	0-11	insulin-like growth factor 1	Rattus norvegicus	49-54
11607878-7	2001	Cyclosporin administration increased circulating IGF-I, and there was a negative correlation between circulating IGF-I and arthritis index scores in arthritic rats injected with cyclosporin (p &lt; 0.05).	Cyclosporine	178-189	insulin-like growth factor 1	Rattus norvegicus	113-118
11641530-5	2001	CsA induced apoptosis in cultured tubular epithelial cells demonstrated by increased number of TUNEL positive cells and it was accompanied by a significant increase in Fas mRNA and Fas ligand protein expressions.	Cyclosporine	0-3	Fas ligand	Homo sapiens	181-191
11570623-7	2001	Both cyclosporine and Cremophor EL induced considerable activation of the basophils from our study patient, with an upregulation of CD63 expression from 1% to 39% and 55%, respectively.	Cyclosporine	5-17	CD63 molecule	Homo sapiens	132-136
11564081-6	2001	Levels of intracellular FasL in patients examined 1 month after immunosuppression with antilymphocyte globulin and cyclosporin A were lower than prior to treatment.	Cyclosporine	115-128	Fas ligand	Homo sapiens	24-28
11688669-12	2001	There was a statistically significant reduction in the number of CD4+, CD8+ as well as CD45+ cells in both the RAD- and the CSA-treated animals compared with the allogeneic control.	Cyclosporine	124-127	protein tyrosine phosphatase, receptor type, C	Rattus norvegicus	87-91
11573696-17	2001	The decreases in mRNA levels of Kv4.2 and Kv4.3 and I(to) density in the LV of the post-MI + cyclosporin A group were significantly less compared with the post-MI group.	Cyclosporine	93-106	potassium voltage-gated channel subfamily D member 2	Rattus norvegicus	32-37
11463358-7	2001	Its translocation across the apical membrane was greatly stimulated by the expression of MDR1 Pgp, and inhibited by the MDR1 inhibitors PSC833 and cyclosporin A.	Cyclosporine	147-160	ATP-binding cassette, sub-family B (MDR/TAP), member 1	Sus scrofa	89-93
11463358-7	2001	Its translocation across the apical membrane was greatly stimulated by the expression of MDR1 Pgp, and inhibited by the MDR1 inhibitors PSC833 and cyclosporin A.	Cyclosporine	147-160	ATP-binding cassette, sub-family B (MDR/TAP), member 1	Sus scrofa	120-124
11468554-0	2001	Expression of vascular endothelial growth factor and its receptors Flt-1 and KDR/Flk-1 in chronic cyclosporine nephrotoxicity.	Cyclosporine	98-110	vascular endothelial growth factor A	Rattus norvegicus	14-48
11468554-0	2001	Expression of vascular endothelial growth factor and its receptors Flt-1 and KDR/Flk-1 in chronic cyclosporine nephrotoxicity.	Cyclosporine	98-110	kinase insert domain receptor	Rattus norvegicus	77-80
11468554-0	2001	Expression of vascular endothelial growth factor and its receptors Flt-1 and KDR/Flk-1 in chronic cyclosporine nephrotoxicity.	Cyclosporine	98-110	kinase insert domain receptor	Rattus norvegicus	81-86
11468554-4	2001	RESULTS: CsA induced VEGF mRNA and protein expressions at 7 and 28 days in LSD rats.	Cyclosporine	9-12	vascular endothelial growth factor A	Rattus norvegicus	21-25
11468554-5	2001	At 7 days, CsA up-regulated the expression of Flt-1 and KDR/Flk-1 receptors; however, at 28 days, Flt-1 remained unchanged whereas KDR/Flk-1 expression declined.	Cyclosporine	11-14	kinase insert domain receptor	Rattus norvegicus	56-59
11468554-5	2001	At 7 days, CsA up-regulated the expression of Flt-1 and KDR/Flk-1 receptors; however, at 28 days, Flt-1 remained unchanged whereas KDR/Flk-1 expression declined.	Cyclosporine	11-14	kinase insert domain receptor	Rattus norvegicus	60-65
11468554-5	2001	At 7 days, CsA up-regulated the expression of Flt-1 and KDR/Flk-1 receptors; however, at 28 days, Flt-1 remained unchanged whereas KDR/Flk-1 expression declined.	Cyclosporine	11-14	kinase insert domain receptor	Rattus norvegicus	135-140
11521968-8	2001	Their production was ablated with cyclosporin A, a sterol 27-hydroxylase inhibitor.	Cyclosporine	34-47	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	51-72
11389609-9	2001	Phospholipid flipping was inhibited in a concentration-dependent, saturable fashion by various substrates and modulators, including vinblastine, verapamil, and cyclosporin A, and the efficiency of inhibition correlated well with the affinity of binding to Pgp.	Cyclosporine	160-173	phosphoglycolate phosphatase	Homo sapiens	256-259
11395030-8	2001	CYP27 is upregulated by dexamethasone and downregulated by cyclosporin A and cholic acid.	Cyclosporine	59-72	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	0-5
11395030-10	2001	Cyclosporin A affects bile acid metabolism by repressing CYP27 at the transcriptional level.	Cyclosporine	0-13	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	57-62
2138899-0	1990	The beneficial effect of atrial natriuretic peptide on cyclosporine nephrotoxicity.	Cyclosporine	55-67	natriuretic peptide A	Rattus norvegicus	25-51
2138899-8	1990	Similar effects on renal hemodynamics and electrolyte excretion rates were detected after ANP administration in chronic CyA treatment.	Cyclosporine	120-123	natriuretic peptide A	Rattus norvegicus	90-93
2316699-0	1990	Altered pressor responses to NE and ANG II during cyclosporin A administration to conscious rats.	Cyclosporine	50-63	angiogenin	Rattus norvegicus	36-39
2338629-1	1990	Cyclosporine (CsA), commercially available as iv or oral Sandimmune, is a potent immunosuppressant which can induce dose-related nephrotoxocity.	Cyclosporine	0-12	chorionic somatomammotropin hormone 1	Homo sapiens	14-17
1689353-5	1990	RAP potentiated the effect of CsA on proliferation and IL-2R expression in T cells stimulated with ionomycin + PMA.	Cyclosporine	30-33	interleukin 2 receptor, alpha chain	Mus musculus	55-60
2106180-2	1990	Using a rat model, we have shown that accelerated (24 hr) rejection of LBN cardiac Tx in LEW rats sensitized with BN skin grafts 7 days earlier, could be prevented by treatment with cyclosporine (15 mg/kg/day x7 days, Tx survival about 42 days) or ART-18, an anti-IL-2R mAb (300 micrograms/kg/day x10 days i.v., Tx survival about 16 days).	Cyclosporine	182-194	interleukin 2 receptor, alpha chain	Mus musculus	264-269
2104905-5	1990	We found that T cell activation was associated with the up-regulation of these src family genes and that the expression of these genes was specifically blocked in the presence of cyclosporine indicating that these activation-related genes were coordinately regulated.	Cyclosporine	179-191	Fyn proto-oncogene	Mus musculus	79-82
2136804-12	1990	CSA from tumor cell supernatants was neutralized by antiserum to GM-CSF but not with anti-M-CSF or anti-granulocyte colony-stimulating factor (G-CSF).	Cyclosporine	0-3	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	65-71
2136804-12	1990	CSA from tumor cell supernatants was neutralized by antiserum to GM-CSF but not with anti-M-CSF or anti-granulocyte colony-stimulating factor (G-CSF).	Cyclosporine	0-3	colony stimulating factor 1 (macrophage)	Mus musculus	66-71
2294993-7	1990	Furthermore, it is conceivable that cyclosporine facilitates recipient-derived antibody synthesis after major ABO-incompatible BMT.	Cyclosporine	36-48	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	110-113
2262069-8	1990	Simultaneous treatment with CsA resulted in a significant inhibition of camostate-induced increases in ODC, SAM-DC as well as putrescine and spermidine and furthermore caused a nearly complete inhibition of the increase of all trophic parameters, while CCK plasma levels were not altered.	Cyclosporine	28-31	cholecystokinin	Rattus norvegicus	253-256
2262069-10	1990	Therefore we conclude that CsA does not directly interact with the polyamine metabolism, but rather with the second messenger system or any other intracellular mechanism, that is activated after stimulation with CCK before the polyamine metabolism is induced.	Cyclosporine	27-30	cholecystokinin	Rattus norvegicus	212-215
2295296-0	1990	Effect of cyclosporine on hepatic cytosolic estrogen and androgen receptor levels before and after partial hepatectomy.	Cyclosporine	10-22	androgen receptor	Rattus norvegicus	57-74
2295296-7	1990	In contrast, preoperative levels of androgen receptor activity in the cyclosporine-treated and vehicle-treated animals were similar.	Cyclosporine	70-82	androgen receptor	Rattus norvegicus	36-53
1968392-6	1990	Similarly, pretreatment of a CD8 clone with actinomycin D or CsA inhibited lymphokine production without affecting cytolytic activity.	Cyclosporine	61-64	CD8a molecule	Homo sapiens	29-32
1970683-1	1990	The effects of a prolonged (30-day) treatment with daily therapeutical doses of cyclosporin A (CAS) (20 mg/kg) on testicular Leydig cells were studied in adult rats.	Cyclosporine	80-93	BCAR1 scaffold protein, Cas family member	Rattus norvegicus	95-98
33236407-11	2021	The molecular docking simulation indicated that the compound II-1 and CSA could compete with diketonitrile (DKN) at the active site of HPPD, which is a hydrolyzed product of IXF in plant, causing the herbicide to be ineffective.	Cyclosporine	70-73	4-hydroxyphenylpyruvate dioxygenase 1	Zea mays	135-139
34559341-0	2022	Cyclosporine A C1.5 monitoring reflects the area under the curve in children with nephrotic syndrome: a single-center experience.	Cyclosporine	0-14	placenta associated 8	Homo sapiens	15-19
34800717-13	2022	The immunosuppressant CsA inhibited LEC proliferation through the autophagy-mediated cell death pathway.	Cyclosporine	22-25	C-C motif chemokine ligand 16	Homo sapiens	36-39
34398459-3	2021	We present a 14-year-old girl of Chinese heritage who was diagnosed with SPTCL in the context of homozygous HAVCR2 status for c.245A>G p. (Tyr82Cys) and achieved complete remission after treatment with cyclosporin and steroids.	Cyclosporine	202-213	hepatitis A virus cellular receptor 2	Homo sapiens	108-114
34740104-9	2021	Fourthly, cyclosporine A and EDTA facilitate corneal epithelial wound healing in Cisd2 knockout mice.	Cyclosporine	10-24	CDGSH iron sulfur domain 2	Mus musculus	81-86
34478761-8	2021	CsA effectively alleviated Cd-induced mitochondrial dysfunction, blocked mitochondrial membrane potential collapse, and suppressed PINK1/Parkin-mediated mitophagy.	Cyclosporine	0-3	PTEN induced putative kinase 1	Gallus gallus	131-136
34445576-8	2021	Moreover, CD40-CD40L interaction induced a cytoskeleton reorganization and increased the expression of integrin beta1 on RCC cell lines, and this effect was reversed by cyclosporine A and NFAT inhibition.	Cyclosporine	169-183	integrin subunit beta 1	Homo sapiens	103-117
34392151-6	2021	Moreover, treatments with NAC could significantly alleviate the changes of the above factors co-induced by Mo and Cd, and CsA intensify the changes of the above factors.	Cyclosporine	122-125	NLR family, pyrin domain containing 1A	Mus musculus	26-29
34381450-7	2021	p70 S6 kinase and mTOR were reduced by CsA with/without CHBP at 2 weeks, so were S6 ribosomal protein and GSK-3beta at 8 weeks, with reduced CASP-3 at both time points.	Cyclosporine	39-42	caspase 3	Mus musculus	141-147
34381450-9	2021	Furthermore, in TCMK-1 cells CsA induced apoptosis was decreased by CHBP and/or CASP-3siRNA treatment.	Cyclosporine	29-32	caspase 3	Mus musculus	80-86
34381450-12	2021	CsA divergently affects apoptosis in kidneys and cultured kidney epithelial cells, in which CHBP and/or CASP-3siRNA reduces inflammation and apoptosis.	Cyclosporine	0-3	caspase 3	Mus musculus	104-110
34350189-7	2021	Finally, chromatin immunoprecipitation (ChIP) assays showed that NFATc1 potentially binds the promoter region of H-Ras and the binding efficiency was significantly enhanced by the overexpression of H-Ras G12V , which was abolished by treatment with the calcineurin/NFAT pathway inhibitors cyclosporine A (CsA) or VIVIT.	Cyclosporine	289-303	nuclear factor of activated T cells 1	Homo sapiens	65-71
34350189-7	2021	Finally, chromatin immunoprecipitation (ChIP) assays showed that NFATc1 potentially binds the promoter region of H-Ras and the binding efficiency was significantly enhanced by the overexpression of H-Ras G12V , which was abolished by treatment with the calcineurin/NFAT pathway inhibitors cyclosporine A (CsA) or VIVIT.	Cyclosporine	305-308	nuclear factor of activated T cells 1	Homo sapiens	65-71
34089287-8	2021	Through screening and molecular docking, PRKDC, CUL7, CUL1, HSPA8, HSPA4 and SIRT7 were the most likely multi-target mechanism of Cyclosporin A in the treatment of vitiligo.	Cyclosporine	130-143	cullin 7	Homo sapiens	48-52
34089287-8	2021	Through screening and molecular docking, PRKDC, CUL7, CUL1, HSPA8, HSPA4 and SIRT7 were the most likely multi-target mechanism of Cyclosporin A in the treatment of vitiligo.	Cyclosporine	130-143	heat shock protein family A (Hsp70) member 8	Homo sapiens	60-65
34089287-8	2021	Through screening and molecular docking, PRKDC, CUL7, CUL1, HSPA8, HSPA4 and SIRT7 were the most likely multi-target mechanism of Cyclosporin A in the treatment of vitiligo.	Cyclosporine	130-143	heat shock protein family A (Hsp70) member 4	Homo sapiens	67-72
34089287-8	2021	Through screening and molecular docking, PRKDC, CUL7, CUL1, HSPA8, HSPA4 and SIRT7 were the most likely multi-target mechanism of Cyclosporin A in the treatment of vitiligo.	Cyclosporine	130-143	sirtuin 7	Homo sapiens	77-82
34089287-9	2021	CONCLUSIONS: In our study, Cyclosporin A might not only affect the repair of DNA strands by targeting PRKDC, but also affected the innate and adaptive immune function of vitiligo patients by the targets of CUL1, CUL7 and HSP70.	Cyclosporine	27-40	cullin 7	Homo sapiens	212-216
34089287-9	2021	CONCLUSIONS: In our study, Cyclosporin A might not only affect the repair of DNA strands by targeting PRKDC, but also affected the innate and adaptive immune function of vitiligo patients by the targets of CUL1, CUL7 and HSP70.	Cyclosporine	27-40	heat shock protein family A (Hsp70) member 4	Homo sapiens	221-226
34089287-10	2021	In addition, Cyclosporin A might promote the repigmentation of vitiligo by adjusting the expression of SIRT7.	Cyclosporine	13-26	sirtuin 7	Homo sapiens	103-108
35212420-0	2022	Quercetin boosts nitric oxide levels and modulates the activities of arginase, acetylcholinesterase and adenosine deaminase in the corpus cavernosum of cyclosporine-treated rats.	Cyclosporine	152-164	adenosine deaminase	Rattus norvegicus	104-123
35536669-8	2022	CSA treatment was associated with significant reductions in serum cytokines and chemokines important in COVID-19 hyper-inflammation, including CXCL10.	Cyclosporine	0-3	C-X-C motif chemokine ligand 10	Homo sapiens	143-149
35397430-8	2022	However, pretreatment with unlabelled Seltorexant and P-gp competitor CsA observed significantly increased brain uptake of (18F)Seltorexant, indicating (18F)Seltorexant could interact P-gp at the blood-brain barrier.	Cyclosporine	70-73	phosphoglycolate phosphatase	Mus musculus	54-58
35397430-8	2022	However, pretreatment with unlabelled Seltorexant and P-gp competitor CsA observed significantly increased brain uptake of (18F)Seltorexant, indicating (18F)Seltorexant could interact P-gp at the blood-brain barrier.	Cyclosporine	70-73	phosphoglycolate phosphatase	Mus musculus	184-188
35553638-10	2022	Cyclosporine A and prednisolone synergistically increased GCR expression and inhibited pro-inflammatory cytokine production by CD28null CD8- T and NKT-like cells.	Cyclosporine	0-14	CD8a molecule	Homo sapiens	136-139
35369435-9	2022	Interestingly, when we blunted antiviral immune responses using clodronate liposomes (which depletes antigen-presenting cells) or cyclosporin (which inhibits cytokine production that regulates T-cell proliferation), significantly lower IFN-gamma producing CD8+ T cells infiltrated into tendon tissues, resulting in reduced tendon tissues apoptosis and milder disease manifestations.	Cyclosporine	130-141	CD8a molecule	Homo sapiens	256-259
35280715-7	2022	We initiated a combination therapy with prednisolone and cyclosporine as a calcineurin inhibitor.	Cyclosporine	57-69	calcineurin binding protein 1	Homo sapiens	75-96
35342744-12	2022	Univariate analyses revealed that patients with lower platelet count and higher interleukin 10 level predict an active response to CsA while higher level of fetal hemoglobin (HbF) tended to be a negative factor.	Cyclosporine	131-134	interleukin 10	Homo sapiens	80-94
35342744-19	2022	Patients with lower platelet count and higher interleukin 10 level predicted an active response to CsA.	Cyclosporine	99-102	interleukin 10	Homo sapiens	46-60
2514685-1	1989	Cyclosporin A, immunosuppressive agent, reversibly blocks the mitogenic effect of prolactin in rat lymphoma Nb-2 cells and removal from the medium leads to a rapid and transient induction of c-fos mRNA.	Cyclosporine	0-13	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	191-196
2531848-3	1989	The biochemical basis of CsA action is not known: its primary cellular target has been suggested to be calmodulin, the prolactin receptor or cyclophilin, a CsA-binding protein originally isolated from the cytosol of bovine thymocytes.	Cyclosporine	25-28	prolactin receptor	Bos taurus	119-137
2531775-5	1989	A suboptimal dose of CsA was synergistic with an anti-CD4 mAb but not with an anti-CD8 antibody for whole MHC-mismatched grafts.	Cyclosporine	21-24	CD4 antigen	Mus musculus	54-57
2667211-9	1989	Cyclosporine treatment of blood-transfused recipients reduced the leukocyte infiltration and MHC induction to levels seen in untreated controls--i.e., the accelerated MHC induction caused by the transfusion was partially reversible by cyclosporine.	Cyclosporine	0-12	major histocompatibility complex, class I, C	Homo sapiens	93-96
2667211-9	1989	Cyclosporine treatment of blood-transfused recipients reduced the leukocyte infiltration and MHC induction to levels seen in untreated controls--i.e., the accelerated MHC induction caused by the transfusion was partially reversible by cyclosporine.	Cyclosporine	0-12	major histocompatibility complex, class I, C	Homo sapiens	167-170
2667211-9	1989	Cyclosporine treatment of blood-transfused recipients reduced the leukocyte infiltration and MHC induction to levels seen in untreated controls--i.e., the accelerated MHC induction caused by the transfusion was partially reversible by cyclosporine.	Cyclosporine	235-247	major histocompatibility complex, class I, C	Homo sapiens	167-170
2664782-2	1989	Isolation of the ninaA gene by chromosomal walking revealed that it is expressed only in the eye and encodes a 237-amino acid polypeptide that shows strong sequence similarity to cyclophilin, a putative molecular target for cyclosporine A, a potent immunosuppressant used in human organ transplantations.	Cyclosporine	224-238	neither inactivation nor afterpotential A	Drosophila melanogaster	17-22
2656339-3	1989	Insulin secretion in response to intravenous glucose and glucagon was significantly inhibited during the administration of CsA (areas under insulin-response curves, pmol.min-1.L-1; IVGTT, pre-CsA, 11,127 +/- 1285; during CsA, 5954 +/- 1147, P less than .05; glucagon tolerance test, pre-CsA, 18,617 +/- 2807; during CsA, 4401 +/- 486, P less than .05 vs. pretreatment levels).	Cyclosporine	123-126	insulin	Canis lupus familiaris	0-7
2656339-3	1989	Insulin secretion in response to intravenous glucose and glucagon was significantly inhibited during the administration of CsA (areas under insulin-response curves, pmol.min-1.L-1; IVGTT, pre-CsA, 11,127 +/- 1285; during CsA, 5954 +/- 1147, P less than .05; glucagon tolerance test, pre-CsA, 18,617 +/- 2807; during CsA, 4401 +/- 486, P less than .05 vs. pretreatment levels).	Cyclosporine	123-126	insulin	Canis lupus familiaris	140-147
2568932-2	1989	Defective thymic education of CD4 T helper cell function in cyclosporin A-treated mice.	Cyclosporine	60-73	CD4 antigen	Mus musculus	30-33
2795127-5	1989	We found that the W3/25/MRCOX-8 ratio increased to 3.2 +/- 0.3 in the PAN rats but significantly decreased to 2.8 +/- 0.3 with CY treatment.	Cyclosporine	127-129	Cd4 molecule	Rattus norvegicus	18-23
2660341-3	1989	A 10-day course of cyclosporine treatment inhibits the capacity of DA rats to reject PVG heart grafts and leads to the development of specific unresponsiveness and indefinite graft survival, which is mediated by a W3/25+ (CD4+) suppressor cell.	Cyclosporine	19-31	CD4 antigen	Mus musculus	222-225
2651520-3	1989	In this report, we investigate the effect of cyclosporin A (CsA) on lymphopoiesis, and demonstrate that CsA selectively abrogates the development of CD4+CD8- and CD4-CD8+ T cells (single positive cells) in the thymus.	Cyclosporine	104-107	CD4 antigen	Mus musculus	149-152
2651520-3	1989	In this report, we investigate the effect of cyclosporin A (CsA) on lymphopoiesis, and demonstrate that CsA selectively abrogates the development of CD4+CD8- and CD4-CD8+ T cells (single positive cells) in the thymus.	Cyclosporine	104-107	CD4 antigen	Mus musculus	162-165
2651520-6	1989	In the thymus, the generation of CD4+CD8+ thymocytes was not affected by CsA treatment, and CD4-CD8- thymocytes of CsA-treated mice expressed surface markers characteristic of normal CD4-CD8- thymocytes, and exhibited normal functional activity when stimulated with anti-CD3 antibody.	Cyclosporine	115-118	CD4 antigen	Mus musculus	92-95
2651520-6	1989	In the thymus, the generation of CD4+CD8+ thymocytes was not affected by CsA treatment, and CD4-CD8- thymocytes of CsA-treated mice expressed surface markers characteristic of normal CD4-CD8- thymocytes, and exhibited normal functional activity when stimulated with anti-CD3 antibody.	Cyclosporine	115-118	CD4 antigen	Mus musculus	92-95
2492638-8	1989	The catalysis of prolyl isomerization in oligopeptides and of protein folding by PPIase are strongly inhibited in the presence of low levels of CsA.	Cyclosporine	144-147	peptidylprolyl isomerase like 1	Homo sapiens	81-87
2644542-3	1989	We purified PPIase from pig kidney and found that its amino-acid sequence is identical to that reported for bovine cyclophilin, a protein known to bind the immunosuppressive drug, cyclosporin A (ref.	Cyclosporine	180-193	peptidylprolyl isomerase like 1	Bos taurus	12-18
2644542-5	1989	To investigate the functional relationship between PPIase and cyclophilin we examined the effect of cyclosporin A on PPIase activity and found that it was inhibitory.	Cyclosporine	100-113	peptidylprolyl isomerase like 1	Bos taurus	51-57
2644542-5	1989	To investigate the functional relationship between PPIase and cyclophilin we examined the effect of cyclosporin A on PPIase activity and found that it was inhibitory.	Cyclosporine	100-113	peptidylprolyl isomerase like 1	Bos taurus	117-123
2644542-6	1989	Thus we propose that the peptidyl-prolyl cis-trans isomerizing activity of PPIase may be involved in events, such as those occurring early in T-cell activation, that are suppressed by cyclosporin A.	Cyclosporine	184-197	peptidylprolyl isomerase like 1	Bos taurus	75-81
2627977-1	1989	Ciclosporin (CsA) was administered subcutaneously at a dose of 3 mg/kg body weight/day from the day of operation to 14 days of liver allotransplantation in ACI rat (RT1a) to LEW rat (RT1(l) strain combination.	Cyclosporine	0-11	RT1 class I, locus A	Rattus norvegicus	165-169
2576219-7	1989	The data suggest that Ca2(+)-independent (CsA-resistant) T cell activation induces synthesis of GM-CSF and IFN-gamma but is a poor stimulus for IL-3 production.	Cyclosporine	42-45	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	96-102
2647926-3	1989	Our hypothesis was that changes in histocompatibility (MHC) expression induced by immunosuppressive therapy with cyclosporine plays an important role in directing an immune response to the arterial bed.	Cyclosporine	113-125	major histocompatibility complex, class I, C	Homo sapiens	55-58
2647928-0	1989	Effect of ABO blood type on survival of heart transplant patients treated with cyclosporine.	Cyclosporine	79-91	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	10-13
2671930-1	1989	UNLABELLED: This report summarizes results of the treatment of SAA with ciclosporin A (CSA) or antithymocyte globulin (ATG) in 82 patients (pts) randomized since January 1986 from 28 centers.	Cyclosporine	72-85	serum amyloid A1 cluster	Homo sapiens	63-66
2671930-1	1989	UNLABELLED: This report summarizes results of the treatment of SAA with ciclosporin A (CSA) or antithymocyte globulin (ATG) in 82 patients (pts) randomized since January 1986 from 28 centers.	Cyclosporine	87-90	serum amyloid A1 cluster	Homo sapiens	63-66
2516375-4	1989	During Cy-A administration CD4(+)-cell regeneration was almost completely suppressed, but within 3 weeks after withdrawal of the drug such cells reappeared in blood and reached pre-irradiation levels about 6 weeks later.	Cyclosporine	7-11	Cd4 molecule	Rattus norvegicus	27-30
3136564-9	1988	Also, when we eliminate CD4 T cells from the diseased animals and graft islet tissue prior to the administration of cyclosporine, we are unable to maintain a graft with low-dose cyclosporine therapy.	Cyclosporine	116-128	CD4 antigen	Mus musculus	24-27
3130696-9	1988	This is believed to be the first report of delayed immune hemolysis due to non-ABO antibodies in a liver transplant patient treated with cyclosporine.	Cyclosporine	137-149	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	79-82
3314021-0	1987	Hemolytic anemia in cyclosporine-treated recipients of kidney or heart grafts from donors with minor incompatibility for ABO antigens.	Cyclosporine	20-32	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	121-124
3498003-5	1987	Inhibitors of T cell activation, cyclosporin A and anti-LFA-1 antibody, blocked the induction of c-fos and c-ets-1 mRNAs without reducing the levels of c-myc and c-ets-2.	Cyclosporine	33-46	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	97-102
3620471-1	1987	This study examined the effects of the mitogen, prolactin and the cell cycle inhibitors, cyclosporin A and neomycin sulfate, on expression of the proto-oncogenes c-fos and c-myc in the rat lymphoma Nb-2 cell line.	Cyclosporine	89-102	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	162-167
3620471-5	1987	However, the release of Nb-2 cells from a cyclosporin A or a neomycin sulfate block resulted in a rapid transient induction of c-fos which peaked at 0.5-1 h and declined rapidly thereafter.	Cyclosporine	42-55	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	127-132
3494996-1	1987	Although cyclosporin A (CsA), an immunosuppressive drug, has been shown to inhibit the production of certain lymphokines, including interleukin 2 (IL-2), interleukin 3 (IL-3), and gamma-interferon, its effect on the production of granulocyte/macrophage colony-stimulating factor (GM-CSF) has not been evaluated.	Cyclosporine	24-27	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	230-278
3494996-1	1987	Although cyclosporin A (CsA), an immunosuppressive drug, has been shown to inhibit the production of certain lymphokines, including interleukin 2 (IL-2), interleukin 3 (IL-3), and gamma-interferon, its effect on the production of granulocyte/macrophage colony-stimulating factor (GM-CSF) has not been evaluated.	Cyclosporine	24-27	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	280-286
3494996-3	1987	In contrast, significant activity was detected when the CsA-treated culture supernatants were assayed on a cell line that is dependent on GM-CSF and/or IL-3.	Cyclosporine	56-59	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	138-144
3494996-5	1987	The activity resistant to CsA was identified as GM-CSF by the ability of specific antibodies against murine recombinant GM-CSF to neutralize its activity.	Cyclosporine	26-29	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	48-54
3494996-8	1987	Expression of the GM-CSF gene in EL-4 cells was detected independent of CsA, whereas CsA inhibited the expression of the IL-2 gene.	Cyclosporine	72-75	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	18-24
3527006-5	1986	The increase in the number of Lyt-1 positive T cells was abrogated by Cy A treatment.	Cyclosporine	70-74	CD5 antigen	Mus musculus	30-35
3871377-3	1985	CsA treatment at the time of primary immunization suppressed the antibody responses to AChR virtually completely.	Cyclosporine	0-3	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	87-91
3871377-4	1985	Following 12 weeks of CsA, the AChR-immunized rats responded like naive controls to a further challenge of AChR.	Cyclosporine	22-25	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	31-35
3871377-4	1985	Following 12 weeks of CsA, the AChR-immunized rats responded like naive controls to a further challenge of AChR.	Cyclosporine	22-25	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	107-111
3871377-6	1985	The secondary response to a challenge of AChR was prevented by CsA treatment, but a very large challenge dose in adjuvant partially overwhelmed the effect of CsA.	Cyclosporine	63-66	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	41-45
3871377-8	1985	The efficacy of CsA in suppressing ongoing and secondary hetero- and autoimmune responses against AChR in EAMG encourages its ultimate application in autoimmune diseases of man, such as MG. Its usefulness will depend on the ability to determine effective doses of CsA that are well tolerated.	Cyclosporine	16-19	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	98-102
3871377-8	1985	The efficacy of CsA in suppressing ongoing and secondary hetero- and autoimmune responses against AChR in EAMG encourages its ultimate application in autoimmune diseases of man, such as MG. Its usefulness will depend on the ability to determine effective doses of CsA that are well tolerated.	Cyclosporine	264-267	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	98-102
6982917-2	1982	CY A suppressed T cell activation by the mitogen, concanavalin A, by blocking IL 2 production and not by blocking the induction of IL 2 receptors.	Cyclosporine	0-4	interleukin-2	Cavia porcellus	78-82
6982917-6	1982	CY A completely blocked the primary allogeneic MLR but this inhibitory effect could be reversed when exogenous IL 2 was added to the cultures.	Cyclosporine	0-4	interleukin-2	Cavia porcellus	111-115
6982917-9	1982	Thus, in the guinea pig, CY A inhibits Ti cell activation both by blocking IL 2 production as well as by inhibiting the induction of IL 2 responsiveness.	Cyclosporine	25-29	interleukin-2	Cavia porcellus	75-79
6982917-9	1982	Thus, in the guinea pig, CY A inhibits Ti cell activation both by blocking IL 2 production as well as by inhibiting the induction of IL 2 responsiveness.	Cyclosporine	25-29	interleukin-2	Cavia porcellus	133-137
25291644-1	1982	Cyclosporin A (CS-A) is a fungal metabolite, one of many cyclosporins with a narrow spectrum of antibiotic activity, but one with profound immunosuppressive effects on cell-mediated cytolysis in vitro, graft v. host reactions and delayed-type hypersensitivity.	Cyclosporine	0-13	chorionic somatomammotropin hormone 1	Homo sapiens	15-19
33631201-6	2021	Although BLECs were still undergoing transcriptional changes over time, a targeted transcriptome analysis (TempO-Seq) indicated a time and concentration dependent activation of ATF4, XBP1, Nrf2 and p53 stress response pathways under CsA treatment.	Cyclosporine	233-236	activating transcription factor 4	Homo sapiens	177-181
34041859-7	2021	In cultured H9C2 cells, adenovirus vector-mediated MD1 overexpression decreased angiotensin II-induced mRNA expression of brain natriuretic peptide (BNP) and beta-MHC and cell CSA (P < 0.002), whereas knockdown of MD1 by shRNA exhibited opposite effects (P < 0.04).	Cyclosporine	176-179	lymphocyte antigen 86	Mus musculus	51-54
33974505-0	2021	Association of polymorphism of CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR with the concentration of cyclosporin a in allogeneic hematopoietic stem cell transplantation recipients.	Cyclosporine	106-119	ATP binding cassette subfamily C member 2	Homo sapiens	46-51
33974505-2	2021	In this study, we aimed to identify the association of CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms with CsA concentrations in patients with allogeneic hematopoietic cell transplantation (allo-HSCT) based on the route of administration.A total of 40 allo-HSCT recipients receiving CsA were genotyped for CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR polymorphisms.	Cyclosporine	123-126	ATP binding cassette subfamily C member 2	Homo sapiens	70-75
32794232-2	2021	The result revealed that CsA-stressed rats treated with captopril and extracts (ALE and ABE) had lowered ACE, arginase, AChE, PDE-5, ADA activities, and TBARS level, coupled with improved SOD and catalase activities compared with untreated CsA-stressed rats, which had reversed these biochemicals compared to normal rats.	Cyclosporine	25-28	adenosine deaminase	Rattus norvegicus	133-136
33716932-9	2021	The CSA variability of median nerves was significantly higher in CIDP than in TTR-FAP and HC groups, with high sensitivity (0.692) and specificity (0.833) to differentiate CIDP from TTR-FAP.	Cyclosporine	4-7	transthyretin	Homo sapiens	78-81
33716932-9	2021	The CSA variability of median nerves was significantly higher in CIDP than in TTR-FAP and HC groups, with high sensitivity (0.692) and specificity (0.833) to differentiate CIDP from TTR-FAP.	Cyclosporine	4-7	transthyretin	Homo sapiens	182-185
33626603-0	2021	Gum Hypertrophy from Cyclosporine.	Cyclosporine	21-33	OTU deubiquitinase with linear linkage specificity	Homo sapiens	0-3
33637323-7	2021	We also found the higher frequency of Eomes+dCD4+T cells from miscarriage in response to cyclosporine, tacrolimus, Trophoblasts, and HTR8/SVneo cell line, might provide new strategy for therapy to promote maternal-fetal tolerance and prevent pregnancy loss.	Cyclosporine	89-101	eomesodermin	Homo sapiens	38-43
32860837-13	2020	In addition, cyclosporine A prevented EMT induced by PMCA4 inhibition by suppressing the NFATc1-ZEB1 pathway.	Cyclosporine	13-27	nuclear factor of activated T cells 1	Homo sapiens	89-95
32860837-13	2020	In addition, cyclosporine A prevented EMT induced by PMCA4 inhibition by suppressing the NFATc1-ZEB1 pathway.	Cyclosporine	13-27	zinc finger E-box binding homeobox 1	Homo sapiens	96-100
32905741-3	2020	RESULTS: A significant increase was observed in CD2AP, ACTN4, podocin and also MMP9 and 2, cystatin C levels in the cyclosporine A group following treatment for four weeks, whereas a decrease was found in nephrin gene expression than the control group.	Cyclosporine	116-130	matrix metallopeptidase 9	Rattus norvegicus	79-89
33272156-11	2021	Area under the curve for receiver operating characteristic showed that accuracy of serum creatinine (0.267; 95% CI, 0.11-0.43) at day 0 of cyclosporine treatment was significantly lower (P = .017) than the accuracy of urine creatinine (0.477; 95% CI, 0.28-0.67) and urine levels of the KIM-1 kidney injury molecule (0.594; 95% CI, 0.41-0.78).	Cyclosporine	139-151	hepatitis A virus cellular receptor 1	Homo sapiens	286-291
32653591-9	2020	Moreover, the decreased Clop-AM level in T2DM rats was eliminated by the pretreatment of cyclosporin A, a P-gp inhibitor.	Cyclosporine	89-102	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	106-110
32739890-1	2020	This drug-drug interaction (DDI) study determined the effect of cyclosporine, an inhibitor of OATP1B3 and P-gp, on the pharmacokinetics (PK) of fevipiprant, an oral, highly selective, competitive antagonist of the prostaglandin D2 receptor 2 and a substrate of the two transporters.	Cyclosporine	64-76	prostaglandin D2 receptor 2	Homo sapiens	214-241
32449990-10	2020	CONCLUSION: Taken together, these results reveal for the first time Gal-8 as a fibrogenic stimulus exerted through beta1-integrin/FAK pathways in human gingival fibroblasts, which can be triggered by cyclosporine.	Cyclosporine	200-212	integrin subunit beta 1	Homo sapiens	115-129
33067978-6	2020	After the mitochondrial was protected by CsA, the shedding of GPIbalpha was inhibited significantly.	Cyclosporine	41-44	glycoprotein Ib platelet subunit alpha	Homo sapiens	62-71
32569592-7	2020	The molecular analysis demonstrated that CsA exposure increased 8-OHdg and Nox4 protein contents in the testis tissue.	Cyclosporine	41-44	NADPH oxidase 4	Rattus norvegicus	75-79
32601168-6	2020	The potential role of efflux pumps (MDR/MRP) in the development of resistance was assessed by co-incubation of aminopyrazoles with specific efflux pump inhibitors (verapamil, cyclosporine A and probenecid).Results: Repeated drug exposure of amastigotes did not result in the emergence of drug resistance, either in vitro or in vivo Selection on the promastigote stage, however, was able to select for parasites with reduced susceptibility (resistance index: 5-24).	Cyclosporine	175-189	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	40-43
32942816-17	2020	There was one case of progression to SAA in the CsA + rhTPO treated group but none in the CsA alone group.	Cyclosporine	48-51	serum amyloid A1 cluster	Homo sapiens	37-40
32787951-11	2020	DHMEQ treatment also had an inhibitory effect on the increased expression of chemokines, monocyte chemoattractant protein-1, and chemokine (c-c motif) ligand 5 due to repeated CsA administration, which inhibited the infiltration of macrophages and neutrophils into the renal tissue.	Cyclosporine	176-179	C-C motif chemokine ligand 5	Rattus norvegicus	129-159
32641627-0	2020	[A case of neurofascin-155 antibody-positive chronic inflammatory demyelinating polyradiculoneuropathy successfully treated with Cyclosporine A].	Cyclosporine	129-143	neurofascin	Homo sapiens	11-22
30805796-10	2020	CONCLUSIONS: Although DM causes swelling of the median nerve at the wrist level, patients with CTS have a larger CSA regardless of preexisting DM.	Cyclosporine	113-116	transthyretin	Homo sapiens	95-98
31680236-11	2020	CONCLUSION: CsA enhanced the osteogenic differentiation and reduced angiogenesis by blocking the ERK and p38/c-fos pathway in hPDLSCs.	Cyclosporine	12-15	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	109-114
32298299-13	2020	Treatment of CsA rats with apocynin, catalase, and their combination prevented hypertension and restored renal functional parameters and tissue Nox4 expression in this model.	Cyclosporine	13-16	NADPH oxidase 4	Rattus norvegicus	144-148
31900967-3	2020	In addition, there was a paucity of studies investigating the difference of therapeutic effects between Cyclophosphamide and Cyclosporin A in PLA2R-associated IMN.	Cyclosporine	125-138	phospholipase A2 receptor 1	Homo sapiens	142-147
31900967-6	2020	The difference of therapeutic effects between cyclophosphamide and cyclosporin A were also investigated in PLA2R-associated IMN.	Cyclosporine	67-80	phospholipase A2 receptor 1	Homo sapiens	107-112
31887874-1	2020	Chondroitin sulfate A-deoxycholic acid-polyethylene glycol-maleimide (CSA-DOCA-PEG-MAL; CDPM) nanostructures were designed for the transient binding of MAL with thiol in blood components and cell membranes, in addition to the CD44 receptor targeting, for the therapy of breast cancer.	Cyclosporine	70-82	CD44 molecule (Indian blood group)	Homo sapiens	226-230
32027281-1	2020	OBJECTIVE: To analyze the clinical efficacy and side effects of reduced-dose of cyclophosphamide combined cyclosporine A for severe aplastic anemia(SAA) children.	Cyclosporine	106-120	serum amyloid A1 cluster	Homo sapiens	148-151
31980477-1	2020	Rituximab (375 mg/m2) achieved remission of the first episode and six relapses of nephrotic syndrome (NS) in a young male patient with podocyte phospholipase A2 receptor (PLA2R)-related membranous nephropathy (MN) refractory to steroids and cyclosporine.	Cyclosporine	241-253	phospholipase A2 receptor 1	Homo sapiens	144-169
31980477-1	2020	Rituximab (375 mg/m2) achieved remission of the first episode and six relapses of nephrotic syndrome (NS) in a young male patient with podocyte phospholipase A2 receptor (PLA2R)-related membranous nephropathy (MN) refractory to steroids and cyclosporine.	Cyclosporine	241-253	phospholipase A2 receptor 1	Homo sapiens	171-176
31963361-9	2020	The administration of cyclosporine A was followed by down-regulation of other genes: COL7A1, the transmembrane receptors ITGB2 and ITGB4, and the basement membrane constituents LAMA2 and LAMB1.	Cyclosporine	22-36	collagen type VII alpha 1 chain	Homo sapiens	85-91
31606265-5	2020	RESULTS: Compared with cyclosporine and methotrexate, anti-IL-17A treatment resulted in a greater increase in GLS at 4 and 12 months after treatment (10% and 14% with anti-IL-17A vs 2% and 2% with cyclosporine vs 4% and 4% with methotrexate, respectively), GLSR, GLSR at early diastole (45% and 41% vs 5% and 4% vs 7% and 9%, respectively), and LV twisting (32% and 28% vs 6% and 8% vs 7% and 6%, respectively) (P &lt; 0.05).	Cyclosporine	197-209	interleukin 17A	Homo sapiens	59-65
31606265-10	2020	CONCLUSIONS: In psoriasis, inhibition of IL-17A results in a greater improvement of vascular and myocardial function compared with cyclosporine or methotrexate treatment, indicating a beneficial effect on overall cardiovascular function.	Cyclosporine	131-143	interleukin 17A	Homo sapiens	41-47
31325587-6	2019	Specifically, compared with cyclosporine/MMF as GVHD prophylaxis, the odds ratio (OR) for calcineurin inhibitor/methotrexate was .8 and for cyclosporine/prednisone .6.	Cyclosporine	28-40	calcineurin binding protein 1	Homo sapiens	90-111
31631469-6	2019	The expression of TNF-alpha was downregulated during therapy, IL23A was upregulated during CsA treatment, while the expression of IFN-gamma and IL17 were higher after 42 days and lower after 84 days compared to 0 days of CsA treatment.	Cyclosporine	221-224	interleukin 17A	Homo sapiens	144-148
31427432-3	2019	Following a 30 minute preincubation with an inhibitor, approximately 50-fold higher inhibition potency was observed for Cyclosporine (CsA) against OCT1-mediated uptake of metformin as compared to coincubation, with IC50 values of 0.43 +- 0.12 and 21.6 +- 4.5 muM, respectively.	Cyclosporine	120-132	chorionic somatomammotropin hormone 1	Homo sapiens	134-137
30943799-0	2019	Omega-3 fatty acid decreases oleic acid by decreasing SCD-1 expression in the liver and kidney of a cyclosporine-induced nephropathy rat model.	Cyclosporine	100-112	stearoyl-CoA desaturase	Rattus norvegicus	54-59
30943799-6	2019	Compared to the control group, CsA-induced rats showed elevated SCD-1 expression in the kidney and liver, which omega-3 FA treatment reversed.	Cyclosporine	31-34	stearoyl-CoA desaturase	Rattus norvegicus	64-69
30943799-8	2019	CONCLUSIONS: Omega-3 FA supplementation decreased erythrocyte membrane oleic acid content by modulating SCD-1 and Elovl-6 expression in the kidney and liver of CsA-induced rats.	Cyclosporine	160-163	stearoyl-CoA desaturase	Rattus norvegicus	104-109
31305009-11	2019	A combination of cyclosporine A with DNR prolonged survival of NSG mice inoculated with P-gp-positive t(17;19)-ALL cell line.	Cyclosporine	17-31	phosphoglycolate phosphatase	Mus musculus	88-92
31319381-10	2019	Of note, RANKL treatment inhibited Homer proteins interaction with NFATc1, but it was restored by cyclosporine A treatment to inhibit calcineurin.	Cyclosporine	98-112	TNF superfamily member 11	Homo sapiens	9-14
31085229-9	2019	In hippocampal homogenates from Ts65Dn mice, we found that CSA normalized the excessive levels of p21, a key determinant of proliferation impairment.	Cyclosporine	59-62	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	98-101
31269364-10	2019	Among patients in remission who tested positive for anti-phospholipase A2 receptor (PLA2R) antibodies, the decline in autoantibodies to anti-PLA2R was faster and of greater magnitude and duration in the rituximab group than in the cyclosporine group.	Cyclosporine	231-243	phospholipase A2 receptor 1	Homo sapiens	52-82
31269364-10	2019	Among patients in remission who tested positive for anti-phospholipase A2 receptor (PLA2R) antibodies, the decline in autoantibodies to anti-PLA2R was faster and of greater magnitude and duration in the rituximab group than in the cyclosporine group.	Cyclosporine	231-243	phospholipase A2 receptor 1	Homo sapiens	84-89
31269364-10	2019	Among patients in remission who tested positive for anti-phospholipase A2 receptor (PLA2R) antibodies, the decline in autoantibodies to anti-PLA2R was faster and of greater magnitude and duration in the rituximab group than in the cyclosporine group.	Cyclosporine	231-243	phospholipase A2 receptor 1	Homo sapiens	141-146
31109455-1	2019	We have previously shown that blockade of ATP-binding cassette transporter A1 (ABCA1) with cyclosporine A (CsA) stimulates the epithelial sodium channel (ENaC) in cultured distal nephron cells.	Cyclosporine	91-105	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	42-77
31109455-1	2019	We have previously shown that blockade of ATP-binding cassette transporter A1 (ABCA1) with cyclosporine A (CsA) stimulates the epithelial sodium channel (ENaC) in cultured distal nephron cells.	Cyclosporine	91-105	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	79-84
31109455-1	2019	We have previously shown that blockade of ATP-binding cassette transporter A1 (ABCA1) with cyclosporine A (CsA) stimulates the epithelial sodium channel (ENaC) in cultured distal nephron cells.	Cyclosporine	107-110	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	42-77
31109455-1	2019	We have previously shown that blockade of ATP-binding cassette transporter A1 (ABCA1) with cyclosporine A (CsA) stimulates the epithelial sodium channel (ENaC) in cultured distal nephron cells.	Cyclosporine	107-110	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	79-84
31109455-9	2019	These data suggest that elevation of intracellular Cho due to blockade of ABCA1 stimulates ENaC, which may contribute to CsA-induced hypertension.	Cyclosporine	121-124	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	74-79
30653687-8	2019	Moreover, ER stress induced by mGPDH depletion could be abrogated by the intracellular Ca2+ chelator 1,2-bis (2-aminophenoxy) ethane N,N,N ,N -tetraacetic acid acetoxymethyl ester, mitochondrial permeability transition pore (mPTP) inhibitor cyclosporine A, or cyclophilin-D (Cyp-D) knockdown.	Cyclosporine	241-255	glycerol phosphate dehydrogenase 2, mitochondrial	Mus musculus	31-36
31063938-3	2019	Cyclophilin A is the target for the cyclosporine A, a drug with schistosomicide activity, and its orthologue from Schistosoma japonicum induces a protective immune response in mice.	Cyclosporine	36-50	peptidylprolyl isomerase A	Mus musculus	0-13
31293389-11	2019	CsA attenuated IL-1beta and Iba1 expressions in BV-2 microglia exposed to OGD/R.	Cyclosporine	0-3	allograft inflammatory factor 1	Mus musculus	28-32
30378503-14	2019	We also demonstrated that CsA could inhibit the expression of NFATc1 and its downstream genes COX-2, c-Myc, MMP-9, and MMP-2 in OSCC cells.	Cyclosporine	26-29	nuclear factor of activated T cells 1	Homo sapiens	62-68
30378503-14	2019	We also demonstrated that CsA could inhibit the expression of NFATc1 and its downstream genes COX-2, c-Myc, MMP-9, and MMP-2 in OSCC cells.	Cyclosporine	26-29	matrix metallopeptidase 9	Homo sapiens	108-113
30378503-17	2019	CONCLUSION: The present study initially demonstrated that CsA could inhibit the progression of OSCC cells and can mediate the signal molecules of NFATc1 signaling pathway, which has strong relationship with cancer development.	Cyclosporine	58-61	nuclear factor of activated T cells 1	Homo sapiens	146-152
30415182-1	2019	Calcineurin-inhibitor induced pain syndrome (CIPS) is a condition characterized by lower extremity pain in patients receiving tacrolimus or cyclosporine therapy following organ transplantation.	Cyclosporine	140-152	calcineurin binding protein 1	Homo sapiens	0-21
30577261-10	2018	CONCLUSIONS: Using advanced modeling methodologies of longitudinal data we identified that the factors associated with acute cellular rejection during the first year after the transplant are related to the therapeutic levels of the calcineurin inhibitor (cyclosporin) during the first 6 months of follow-up and the age of the receptor.	Cyclosporine	255-266	calcineurin binding protein 1	Homo sapiens	232-253
30464243-7	2018	Accordingly, addition of BAPTA-AM and cyclosporine-A, fully and partially inhibited IL-10 and TNF-alpha respectively.	Cyclosporine	38-52	interleukin 10	Homo sapiens	84-89
30483129-11	2018	Moreover, the present study reveals that combination of radicicol, VER-155008, cyclosporine A, and FK506, which are specific pharmacological inhibitors of Hsp90, Hsp70, Cyps, and FKBPs, respectively, resulted in a stronger inhibition of intoxication of cells with C2 toxin compared to application of the single inhibitors.	Cyclosporine	79-93	heat shock protein family A (Hsp70) member 4	Homo sapiens	162-167
30142334-7	2018	Cyclosporin also prevented the running-induced changes in expression of genes involved in excitability (Scn4a and Cacna1s) and slower contractile phenotype (Myh2 and Tnni1) in TA muscle.	Cyclosporine	0-11	sodium channel, voltage-gated, type IV, alpha	Mus musculus	104-109
30142334-7	2018	Cyclosporin also prevented the running-induced changes in expression of genes involved in excitability (Scn4a and Cacna1s) and slower contractile phenotype (Myh2 and Tnni1) in TA muscle.	Cyclosporine	0-11	calcium channel, voltage-dependent, L type, alpha 1S subunit	Mus musculus	114-121
30142334-7	2018	Cyclosporin also prevented the running-induced changes in expression of genes involved in excitability (Scn4a and Cacna1s) and slower contractile phenotype (Myh2 and Tnni1) in TA muscle.	Cyclosporine	0-11	myosin, heavy polypeptide 2, skeletal muscle, adult	Mus musculus	157-161
30142334-7	2018	Cyclosporin also prevented the running-induced changes in expression of genes involved in excitability (Scn4a and Cacna1s) and slower contractile phenotype (Myh2 and Tnni1) in TA muscle.	Cyclosporine	0-11	troponin I, skeletal, slow 1	Mus musculus	166-171
30007437-0	2018	Differential expression of cyclosporine A-Induced calcineurin isoform-specific matrix metalloproteinase 9 (MMP-9) in renal fibroblasts.	Cyclosporine	27-41	matrix metallopeptidase 9	Homo sapiens	107-112
30007437-5	2018	This study evaluates whether the expressions of matrix metalloproteinases (MMP-2 and MMP-9) induced by CsA are calcineurin isoform specific.	Cyclosporine	103-106	matrix metallopeptidase 9	Homo sapiens	85-90
30007437-8	2018	These results indicate that MMP-9 secretion is CnA-isoform specific, i.e. the CnAbeta isoform contributes to the CsA-induced upregulation of MMP-9 while the CnAalpha does not.	Cyclosporine	113-116	matrix metallopeptidase 9	Homo sapiens	28-33
30007437-8	2018	These results indicate that MMP-9 secretion is CnA-isoform specific, i.e. the CnAbeta isoform contributes to the CsA-induced upregulation of MMP-9 while the CnAalpha does not.	Cyclosporine	113-116	matrix metallopeptidase 9	Homo sapiens	141-146
30185657-3	2018	We have shown increased risk for catastrophic SCC in OTRs via CSA-mediated induction of IL-22.	Cyclosporine	62-65	interleukin 22	Homo sapiens	88-93
30185657-4	2018	Herein, we found that CSA drives SCC proliferation and tumor growth through IL-22 and JAK/STAT pathway induction.	Cyclosporine	22-25	interleukin 22	Homo sapiens	76-81
30185657-4	2018	Herein, we found that CSA drives SCC proliferation and tumor growth through IL-22 and JAK/STAT pathway induction.	Cyclosporine	22-25	signal transducer and activator of transcription 1	Homo sapiens	90-94
30185657-8	2018	JAK/STAT pathway genes were highly expressed in tumors from a cohort of CSA-exposed OTRs and in SCC with high risk for metastasis.	Cyclosporine	72-75	signal transducer and activator of transcription 1	Homo sapiens	4-8
30185657-10	2018	In nude mice engrafted with human A431 cells, IL-22 and CSA treatment increased tumor growth and upregulated IL-22 receptor, JAK1, and STAT1/3 expression.	Cyclosporine	56-59	signal transducer and activator of transcription 1	Homo sapiens	135-142
29968377-9	2018	This interaction was up-regulated by H2 O2 but restricted by cyclosporin A, an inhibitor of cyclophilin D.	Cyclosporine	61-74	peptidylprolyl isomerase D	Rattus norvegicus	92-105
28707509-9	2018	The P-gp inhibitors cyclosporine significantly enhanced Pallidifloside D absorption in all four intestinal segments (duodenum, jejunum, ileum and colon) and the fold change ranged from 5.5 to 15.3.	Cyclosporine	20-32	phosphoglycolate phosphatase	Mus musculus	4-8
29643244-7	2018	Treatment of SUN1-expressing cells with cyclosporine (CsA) significantly reduced the sensitivity of the virus to SUN1, and an HIV-1 mutant containing CA-G89A, which does not interact with cyclophilin A (CypA), was resistant to SUN1 overexpression.	Cyclosporine	40-52	Sad1 and UNC84 domain containing 1	Homo sapiens	13-17
29643244-7	2018	Treatment of SUN1-expressing cells with cyclosporine (CsA) significantly reduced the sensitivity of the virus to SUN1, and an HIV-1 mutant containing CA-G89A, which does not interact with cyclophilin A (CypA), was resistant to SUN1 overexpression.	Cyclosporine	40-52	Sad1 and UNC84 domain containing 1	Homo sapiens	113-117
29643244-7	2018	Treatment of SUN1-expressing cells with cyclosporine (CsA) significantly reduced the sensitivity of the virus to SUN1, and an HIV-1 mutant containing CA-G89A, which does not interact with cyclophilin A (CypA), was resistant to SUN1 overexpression.	Cyclosporine	40-52	Sad1 and UNC84 domain containing 1	Homo sapiens	113-117
29643244-7	2018	Treatment of SUN1-expressing cells with cyclosporine (CsA) significantly reduced the sensitivity of the virus to SUN1, and an HIV-1 mutant containing CA-G89A, which does not interact with cyclophilin A (CypA), was resistant to SUN1 overexpression.	Cyclosporine	54-57	Sad1 and UNC84 domain containing 1	Homo sapiens	13-17
29643244-7	2018	Treatment of SUN1-expressing cells with cyclosporine (CsA) significantly reduced the sensitivity of the virus to SUN1, and an HIV-1 mutant containing CA-G89A, which does not interact with cyclophilin A (CypA), was resistant to SUN1 overexpression.	Cyclosporine	54-57	Sad1 and UNC84 domain containing 1	Homo sapiens	113-117
29643244-7	2018	Treatment of SUN1-expressing cells with cyclosporine (CsA) significantly reduced the sensitivity of the virus to SUN1, and an HIV-1 mutant containing CA-G89A, which does not interact with cyclophilin A (CypA), was resistant to SUN1 overexpression.	Cyclosporine	54-57	Sad1 and UNC84 domain containing 1	Homo sapiens	113-117
29866118-14	2018	Furthermore, p62 knockdown-enhanced adipogenesis in hADSCs was abolished by inhibiting mitophagy with cyclosporine A.	Cyclosporine	102-116	nucleoporin 62	Homo sapiens	13-16
31950652-2	2018	The first step of the reaction involves the colloidal synthesis of spherical PbX2 seed NCs, which are subsequently converted to Cs4 PbX6 and CsPbX3 NCs through hot injection of a Cs precursor at the desired reaction temperatures.	Cyclosporine	128-131	PBX homeobox 2	Homo sapiens	77-81
29942927-5	2018	NCX1 inhibition by small interfering RNA or small molecules activates the calcineurin/nuclear factor of activated T cells (NFAT) pathway and inhibits apoptosis induced by the immunosuppressors cyclosporine A (CsA) and tacrolimus in insulin-producing cell.	Cyclosporine	193-207	solute carrier family 8 (sodium/calcium exchanger), member 1	Mus musculus	0-4
29942927-5	2018	NCX1 inhibition by small interfering RNA or small molecules activates the calcineurin/nuclear factor of activated T cells (NFAT) pathway and inhibits apoptosis induced by the immunosuppressors cyclosporine A (CsA) and tacrolimus in insulin-producing cell.	Cyclosporine	209-212	solute carrier family 8 (sodium/calcium exchanger), member 1	Mus musculus	0-4
29540150-0	2018	Expression of brain-derived neurotrophic factor in kidneys from normal and cyclosporine-treated rats.	Cyclosporine	75-87	brain-derived neurotrophic factor	Rattus norvegicus	14-47
29540150-3	2018	The present study examined the expression of BDNF and tropomyosin-related kinase (Trk) receptors in an experimental model of chronic cyclosporine A (CsA) nephropathy.	Cyclosporine	133-147	brain-derived neurotrophic factor	Rattus norvegicus	45-49
29540150-3	2018	The present study examined the expression of BDNF and tropomyosin-related kinase (Trk) receptors in an experimental model of chronic cyclosporine A (CsA) nephropathy.	Cyclosporine	133-147	neurotrophic receptor tyrosine kinase 1	Rattus norvegicus	82-85
29540150-3	2018	The present study examined the expression of BDNF and tropomyosin-related kinase (Trk) receptors in an experimental model of chronic cyclosporine A (CsA) nephropathy.	Cyclosporine	149-152	brain-derived neurotrophic factor	Rattus norvegicus	45-49
29540150-3	2018	The present study examined the expression of BDNF and tropomyosin-related kinase (Trk) receptors in an experimental model of chronic cyclosporine A (CsA) nephropathy.	Cyclosporine	149-152	neurotrophic receptor tyrosine kinase 1	Rattus norvegicus	82-85
29540150-10	2018	By contrast, the expression of these factors decreased in kidneys from CsA-treated rats (BDNF: 51.1 +- 19.5% vs. 102.0 +- 30.3%, p &lt; 0.01).	Cyclosporine	71-74	brain-derived neurotrophic factor	Rattus norvegicus	89-93
29540150-13	2018	CONCLUSIONS: BDNF is expressed in the collecting duct of the kidney and may be associated with urine-concentrating ability in an experimental model of chronic CsA-induced nephropathy.	Cyclosporine	159-162	brain-derived neurotrophic factor	Rattus norvegicus	13-17
29341918-2	2018	Here, a size-based separation and characterization method for globule size distribution using an asymmetric flow field flow fractionation (AF4) is reported for comparative assessment of cyclosporine ophthalmic emulsion drug products (model formulation) with a wide size span and poly-dispersity.	Cyclosporine	186-198	AF4/FMR2 family member 1	Homo sapiens	139-142
29133357-5	2018	Daily interleukin-33 treatment, which increased MDSC levels, completely prevented CsA-induced hypertension and vascular and renal toxicity.	Cyclosporine	82-85	interleukin 33	Mus musculus	6-20
32188225-6	2017	Compared with the BMF group, the CSA and flavone groups had significantly higher and expressions of caspase family proteins (all P<0.05) whereas the levels of Cyt C, PS, Ca2+, and expressions of Bak and Bax were reduced (all P<0.05).	Cyclosporine	33-36	BCL2-associated X protein	Mus musculus	203-206
28472720-9	2017	RESULTS: The mRNA and protein levels of TGF-beta1, ZEB1, and ZEB2 in gingivae were significantly upregulated after 40 and 60days of CsA administration.	Cyclosporine	132-135	zinc finger E-box binding homeobox 1	Rattus norvegicus	51-55
28472720-13	2017	Three members of miR-200s (miR-200a, miR-200b and miR-200c) were significantly downregulated in CsA-treated rats at 40 and 60days, while miR-9, miR-23a and miR-155 were significantly upregulated when compared with those of the control group.	Cyclosporine	96-99	microRNA 200b	Rattus norvegicus	37-45
28472720-13	2017	Three members of miR-200s (miR-200a, miR-200b and miR-200c) were significantly downregulated in CsA-treated rats at 40 and 60days, while miR-9, miR-23a and miR-155 were significantly upregulated when compared with those of the control group.	Cyclosporine	96-99	microRNA 155	Rattus norvegicus	156-163
28472720-14	2017	CONCLUSIONS: The process of EMT in CsA-induced rat gingival overgrowth is associated with increased expression of TGF-beta1, ZEB1, and ZEB2, and decreased expression of E-cadherin.	Cyclosporine	35-38	zinc finger E-box binding homeobox 1	Rattus norvegicus	125-129
28624888-1	2017	PURPOSE: The study aims to evaluate the impact of recipients" and donors" polymorphisms in multidrug resistance-associated protein 2 (MRP2) gene ABCC2 -24C&gt;T and 1249G&gt;A on disposition of mycophenolic acid (MPA) and their interaction with cyclosporine (CsA) (compared to tacrolimus, TAC) in stable de novo adult renal transplant patients of Croatian origin.	Cyclosporine	245-257	ATP binding cassette subfamily C member 2	Homo sapiens	91-132
28624888-1	2017	PURPOSE: The study aims to evaluate the impact of recipients" and donors" polymorphisms in multidrug resistance-associated protein 2 (MRP2) gene ABCC2 -24C&gt;T and 1249G&gt;A on disposition of mycophenolic acid (MPA) and their interaction with cyclosporine (CsA) (compared to tacrolimus, TAC) in stable de novo adult renal transplant patients of Croatian origin.	Cyclosporine	245-257	ATP binding cassette subfamily C member 2	Homo sapiens	134-138
28624888-1	2017	PURPOSE: The study aims to evaluate the impact of recipients" and donors" polymorphisms in multidrug resistance-associated protein 2 (MRP2) gene ABCC2 -24C&gt;T and 1249G&gt;A on disposition of mycophenolic acid (MPA) and their interaction with cyclosporine (CsA) (compared to tacrolimus, TAC) in stable de novo adult renal transplant patients of Croatian origin.	Cyclosporine	245-257	ATP binding cassette subfamily C member 2	Homo sapiens	145-150
28624888-1	2017	PURPOSE: The study aims to evaluate the impact of recipients" and donors" polymorphisms in multidrug resistance-associated protein 2 (MRP2) gene ABCC2 -24C&gt;T and 1249G&gt;A on disposition of mycophenolic acid (MPA) and their interaction with cyclosporine (CsA) (compared to tacrolimus, TAC) in stable de novo adult renal transplant patients of Croatian origin.	Cyclosporine	259-262	ATP binding cassette subfamily C member 2	Homo sapiens	91-132
28624888-1	2017	PURPOSE: The study aims to evaluate the impact of recipients" and donors" polymorphisms in multidrug resistance-associated protein 2 (MRP2) gene ABCC2 -24C&gt;T and 1249G&gt;A on disposition of mycophenolic acid (MPA) and their interaction with cyclosporine (CsA) (compared to tacrolimus, TAC) in stable de novo adult renal transplant patients of Croatian origin.	Cyclosporine	259-262	ATP binding cassette subfamily C member 2	Homo sapiens	134-138
28624888-1	2017	PURPOSE: The study aims to evaluate the impact of recipients" and donors" polymorphisms in multidrug resistance-associated protein 2 (MRP2) gene ABCC2 -24C&gt;T and 1249G&gt;A on disposition of mycophenolic acid (MPA) and their interaction with cyclosporine (CsA) (compared to tacrolimus, TAC) in stable de novo adult renal transplant patients of Croatian origin.	Cyclosporine	259-262	ATP binding cassette subfamily C member 2	Homo sapiens	145-150
28863192-7	2017	Furthermore, by testing with the calcineurin inhibitor (CsA), it was confirmed that calcineurin acted as a key mediator for the anti-hypertrophic effect of E2/ERbeta.	Cyclosporine	56-59	cystatin 12, pseudogene	Homo sapiens	156-165
28903485-7	2017	T0901317 and cyclosporin A increased fatty acid uptake, decreased lipid efflux (inferred from apolipoprotein B100 levels), and increased fatty acid synthase protein levels.	Cyclosporine	13-26	fatty acid synthase	Homo sapiens	137-156
28583569-15	2017	CONCLUSIONS: A high-dose MZ regimen including calcineurin inhibitor (CsA or Tac), Bas, Rit, and steroids was effective and safe in reducing the frequency of CMV-related events in ABO-i LKT.	Cyclosporine	69-72	calcineurin binding protein 1	Homo sapiens	46-67
28569216-8	2017	However, prevention of cyclophilin A (CypA) binding to the HIV-1 capsid via use of either a CypA inhibitor (cyclosporine A) or CypA-independent capsid mutants improved transduction.	Cyclosporine	108-122	peptidylprolyl isomerase A	Mus musculus	38-42
28373092-5	2017	In addition, Collagen IV, ZO-1, Occludin and Claudin 5 expressions in ipsilateral/left hemisphere were downregulated after SAH, but increased after CsA treatment.	Cyclosporine	148-151	claudin 5	Mus musculus	45-54
27982677-2	2017	The long-term outcomes of solid organ transplant recipients have improved considerably since the introduction of the first calcineurin inhibitor (CNI) - cyclosporine.	Cyclosporine	153-165	calcineurin binding protein 1	Homo sapiens	123-144
27916761-3	2017	In our previous study, a potent P-gp and MRP1 modulator, Cyclosporine A, potentiated MTX concentration in rat brain.	Cyclosporine	57-71	ATP binding cassette subfamily C member 1	Rattus norvegicus	41-45
28881606-6	2017	Reversely, mPTP blockers (sanglifehrin A, cyclosporin A and bongkrekic acid) or cyclophilin-D shRNA dramatically alleviated GSK1059615-induced SCC-9 cell death.	Cyclosporine	42-55	colon tumor susceptibility 9	Mus musculus	143-148
28881606-8	2017	injection suppressed SCC-9 tumor growth in nude mice, which was compromised with co-administration with cyclosporin A.	Cyclosporine	104-117	colon tumor susceptibility 9	Mus musculus	21-26
27643869-2	2017	We previously showed that rTM increased levels of antiapoptotic protein Mcl-1 and protected endothelial cells from calcineurin inhibitor cyclosporine A (CsA)-induced apoptosis.	Cyclosporine	153-156	calcineurin binding protein 1	Homo sapiens	115-136
26961540-8	2017	From the further evaluation with the typical inhibitors of each transporter, it was confirmed that BPS is a substrate for P-gp, BCRP, OAT3, OATP1B1, OATP1B3 and MRP2, because the typical inhibitor, cyclosporine, had no effects on BPS transport by BSEP.	Cyclosporine	198-210	ATP binding cassette subfamily C member 2	Homo sapiens	161-165
27720433-15	2017	While CsA inhibits both calcineurin and NFATc1, autumnalamide did not produce any effect.	Cyclosporine	6-9	nuclear factor of activated T cells 1	Homo sapiens	40-46
27451286-0	2017	Stress Response Gene Nupr1 Alleviates Cyclosporin A Nephrotoxicity In Vivo.	Cyclosporine	38-51	nuclear protein transcription regulator 1	Mus musculus	21-26
27451286-7	2017	Compared with controls, mouse models of ischemia-reperfusion injury, urinary obstruction, and hypertension exhibited upregulated expression of renal NUPR1, and cyclosporin A induced Nupr1 expression in cultured human tubular epithelial cells.	Cyclosporine	160-173	nuclear protein transcription regulator 1	Mus musculus	182-187
28094770-6	2017	In contrast, treating activated rCD4s with the immunosuppressant cyclosporin, a calcineurin inhibitor, robustly inhibited HIV-1 reactivation.	Cyclosporine	65-76	Cd4 molecule	Rattus norvegicus	32-36
27941787-4	2017	Notably, CsA inhibited integrin-LFA-1-dependent and NFAT-independent adhesion of T cells to the intercellular adhesion molecule ICAM-1, with little effect on cells expressing mutant Lck.	Cyclosporine	9-12	intercellular adhesion molecule 1	Homo sapiens	128-134
28102966-9	2017	Treatment with 10 mg/L theophylline + 1 micromol/L prednisolone or 2.5 ng/mL cyclosporine A synergistically upregulated HDAC2 and inhibited IFN-gamma and TNF-alpha production by CD8+ T and NKT-like lymphocytes.	Cyclosporine	77-91	CD8a molecule	Homo sapiens	178-181
27664163-3	2017	We showed that while cerebral I/R injury is accompanied by loss of MMP, mitochondrial swelling and programmed cell death, pretreatment with cyclosporine-A (CsA) as a potent inhibitor of CypD, led to partial but significant reduction in necroptosis markers, RIP1 and RIP3 as well as activity of glutamate-ammonia ligase (GLUL) and glutamate dehydrogenase 1 (GLUD1), downstream enzymes of RIP3.	Cyclosporine	140-154	receptor interacting serine/threonine kinase 3	Homo sapiens	266-270
27664163-3	2017	We showed that while cerebral I/R injury is accompanied by loss of MMP, mitochondrial swelling and programmed cell death, pretreatment with cyclosporine-A (CsA) as a potent inhibitor of CypD, led to partial but significant reduction in necroptosis markers, RIP1 and RIP3 as well as activity of glutamate-ammonia ligase (GLUL) and glutamate dehydrogenase 1 (GLUD1), downstream enzymes of RIP3.	Cyclosporine	140-154	receptor interacting serine/threonine kinase 3	Homo sapiens	387-391
27664163-3	2017	We showed that while cerebral I/R injury is accompanied by loss of MMP, mitochondrial swelling and programmed cell death, pretreatment with cyclosporine-A (CsA) as a potent inhibitor of CypD, led to partial but significant reduction in necroptosis markers, RIP1 and RIP3 as well as activity of glutamate-ammonia ligase (GLUL) and glutamate dehydrogenase 1 (GLUD1), downstream enzymes of RIP3.	Cyclosporine	156-159	receptor interacting serine/threonine kinase 3	Homo sapiens	266-270
27664163-3	2017	We showed that while cerebral I/R injury is accompanied by loss of MMP, mitochondrial swelling and programmed cell death, pretreatment with cyclosporine-A (CsA) as a potent inhibitor of CypD, led to partial but significant reduction in necroptosis markers, RIP1 and RIP3 as well as activity of glutamate-ammonia ligase (GLUL) and glutamate dehydrogenase 1 (GLUD1), downstream enzymes of RIP3.	Cyclosporine	156-159	receptor interacting serine/threonine kinase 3	Homo sapiens	387-391
28439573-7	2017	Interleukin-1A, interleukin-10, transforming growth factor-beta1 and androgen receptor gene polymorphisms may have a significant effect on an individual susceptibility to cyclosporin A-induced gingival overgrowth in renal transplant patients.	Cyclosporine	171-184	interleukin 10	Homo sapiens	16-64
28736029-0	2017	Protective Role of Apelin Against Cyclosporine-Induced Renal Tubular Injury in Rats.	Cyclosporine	34-46	apelin	Rattus norvegicus	19-25
28736029-8	2017	Conversely, apelin attenuated CsA-induced tubular injury and had no effect on urinary NGAL excretion.	Cyclosporine	30-33	apelin	Rattus norvegicus	12-18
28736029-9	2017	In histopathologic examination, the apelin-treated group had lower tubulo-interstitial injury scores compared with those in the CsA group.	Cyclosporine	128-131	apelin	Rattus norvegicus	36-42
28736029-10	2017	Regarding the effects of apelin, our results indicate that apelin provides protection against CsA-induced tubular injury by activating nitric oxide and/or the NFATc1 pathway.	Cyclosporine	94-97	apelin	Rattus norvegicus	59-65
28736029-11	2017	Notably, we also found that CsA inhibits renal glucose reabsorption by reducing Na+-K+ ATPase expression and that apelin reverses reduced renal glucose reabsorption by CsA in tubular cells.	Cyclosporine	168-171	apelin	Rattus norvegicus	114-120
28736029-12	2017	CONCLUSIONS: Our study demonstrates the renoprotective effect of apelin against CsA-induced renal tubular toxicity and provides novel insights into the effects of CsA and apelin on renal tubular cells.	Cyclosporine	80-83	apelin	Rattus norvegicus	65-71
27755569-0	2016	1,25(OH)2D3 and VDR Signaling Pathways Regulate the Inhibition of Dectin-1 Caused by Cyclosporine A in Response to Aspergillus Fumigatus in Human Corneal Epithelial Cells.	Cyclosporine	85-99	vitamin D receptor	Homo sapiens	16-19
27755569-5	2016	Dectin-1 and proinflammatory cytokine expression levels were higher when HCECs were pretreated with VDR inhibitor and CsA compared to pretreatment with CsA alone, while dectin-1 and proinflammatory cytokine levels were lower when HCECs were pretreated with 1,25(OH)2D3 and CsA compared to pretreatment with CsA alone.	Cyclosporine	152-155	vitamin D receptor	Homo sapiens	100-103
27755569-5	2016	Dectin-1 and proinflammatory cytokine expression levels were higher when HCECs were pretreated with VDR inhibitor and CsA compared to pretreatment with CsA alone, while dectin-1 and proinflammatory cytokine levels were lower when HCECs were pretreated with 1,25(OH)2D3 and CsA compared to pretreatment with CsA alone.	Cyclosporine	152-155	vitamin D receptor	Homo sapiens	100-103
27755569-5	2016	Dectin-1 and proinflammatory cytokine expression levels were higher when HCECs were pretreated with VDR inhibitor and CsA compared to pretreatment with CsA alone, while dectin-1 and proinflammatory cytokine levels were lower when HCECs were pretreated with 1,25(OH)2D3 and CsA compared to pretreatment with CsA alone.	Cyclosporine	152-155	vitamin D receptor	Homo sapiens	100-103
27441470-9	2016	Comparison demonstrated that the CSA-CHF group had significantly higher TT genotype and T allele frequencies in the rs1739843 single nucleotide polymorphism (SNP) of the HSPB7 gene.	Cyclosporine	33-36	heat shock protein family B (small) member 7	Homo sapiens	170-175
27101736-5	2016	CsA treatment significantly decreased the percentages of CD4+ and CD8+ T lymphocytes in the thymus (P&lt;0.01).	Cyclosporine	0-3	CD8a molecule	Homo sapiens	66-69
27101736-7	2016	CsA treatment significantly depleted the peripheral blood CD3+, CD4+ and CD8+ T lymphocytes (P&lt;0.01).	Cyclosporine	0-3	CD8a molecule	Homo sapiens	73-76
26948033-8	2016	Our data suggested that CsA induced cardiomyocyte apoptosis through the miR-377-XIAP/NRP2 axis.	Cyclosporine	24-27	X-linked inhibitor of apoptosis	Homo sapiens	80-84
26948033-8	2016	Our data suggested that CsA induced cardiomyocyte apoptosis through the miR-377-XIAP/NRP2 axis.	Cyclosporine	24-27	neuropilin 2	Homo sapiens	85-89
26547660-10	2016	In the cyclosporine A-treated rats, the expression of TGF-beta1 and TIMP-1 was significantly upregulated, whereas expression of the MMP-1 was downregulated, along with thicker and denser collagen fibers.	Cyclosporine	7-21	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	68-74
26547660-12	2016	CONCLUSIONS: Cyclosporine A enhanced gingival fibrous overgrowth via upregulation of the TGF-beta1 and TIMP-1 expression, and downregulation of MMP-1 expression.	Cyclosporine	13-27	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	103-109
26547660-13	2016	Tan IIA can effectively prevent cyclosporine A-induced gingival fibrous overgrowth in rats by downregulating TGF-beta1 and TIMP-1 expression, and upregulating MMP-1 expression.	Cyclosporine	32-46	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	123-129
27569281-4	2016	Cyclophilin B (CypB) is an endoplasmic reticulum protein that binds to cyclosporine A as a cyclophilin family member.	Cyclosporine	71-85	peptidylprolyl isomerase B	Homo sapiens	0-13
27569281-4	2016	Cyclophilin B (CypB) is an endoplasmic reticulum protein that binds to cyclosporine A as a cyclophilin family member.	Cyclosporine	71-85	peptidylprolyl isomerase B	Homo sapiens	15-19
27569281-4	2016	Cyclophilin B (CypB) is an endoplasmic reticulum protein that binds to cyclosporine A as a cyclophilin family member.	Cyclosporine	71-85	peptidylprolyl isomerase B	Homo sapiens	91-102
27147271-12	2016	However, GM-CSF + CsA-induced MDSCs express higher iNOS than control MDSCs.	Cyclosporine	18-21	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	9-15
27147271-13	2016	Blocking iNOS activity by inhibitor or gene deletion significantly reversed the inhibitory effects of GM-CSF + CsA-induced MDSCs on T cell proliferation.	Cyclosporine	111-114	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	102-108
27580845-4	2016	Our results showed that CsA and FK506 treatment decreased proteinuria via a mechanism associated to a reduction in the foot-process fusion and desmin, and a recovery of synaptopodin and podocin.	Cyclosporine	24-27	nephrosis 2, podocin	Mus musculus	186-193
27580845-5	2016	In PAN-treated mouse podocytes, pre-incubation with CsA and FK506 restored the distribution of the actin cytoskeleton, increased the expression of synaptopodin and podocin, improved podocyte viability, and reduced the migrating activities of podocytes.	Cyclosporine	52-55	nephrosis 2, podocin	Mus musculus	164-171
27580845-6	2016	Treatment with CsA and FK506 also inhibited PAN-induced podocytes apoptosis, which was associated with the induction of Bcl-xL and inhibition of Bax, cleaved caspase 3, and cleaved PARP expression.	Cyclosporine	15-18	BCL2-associated X protein	Mus musculus	145-148
27580845-6	2016	Treatment with CsA and FK506 also inhibited PAN-induced podocytes apoptosis, which was associated with the induction of Bcl-xL and inhibition of Bax, cleaved caspase 3, and cleaved PARP expression.	Cyclosporine	15-18	poly (ADP-ribose) polymerase family, member 1	Mus musculus	181-185
27580845-7	2016	Further studies revealed that CsA and FK506 inhibited PAN-induced p38 and JNK signaling, thereby protecting podocytes from PAN-induced injury.	Cyclosporine	30-33	mitogen-activated protein kinase 8	Mus musculus	74-77
27000539-5	2016	The transport activity was inhibited by the bile salt export pump (BSEP) inhibitors ketoconazole, saquinavir, cyclosporine, and troglitazone.	Cyclosporine	110-122	ATP binding cassette subfamily B member 11	Homo sapiens	44-65
27000539-5	2016	The transport activity was inhibited by the bile salt export pump (BSEP) inhibitors ketoconazole, saquinavir, cyclosporine, and troglitazone.	Cyclosporine	110-122	ATP binding cassette subfamily B member 11	Homo sapiens	67-71
27470424-8	2016	The levels of c-Fos, NF-kappaB, IL-6, and TNF-alpha were upregulated in LPS- and PGN-treated eyes and downregulated by CSA treatment.	Cyclosporine	119-122	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	14-19
29949699-3	2016	Immunosuppression caused by cyclosporin (daily dose 5 mg/kg, p.o., for 13 days) worsened brain ischemia outcome, as manifested by increased mortality, more severe neurological marker score, increased levels of brain damage markers (NSE and MBP) in the blood serum, decrease in muscle strength and locomotor activity, and impairment of orientation and research activity as compared to animals with brain ischemia and intact immunity.	Cyclosporine	28-39	myelin basic protein	Rattus norvegicus	240-243
27287534-3	2016	The aim of this study is to investigate the role of epithelial-mesenchymal transition marker Slug in the pathogenesis of CsA-induced gingival overgrowth.	Cyclosporine	121-124	snail family transcriptional repressor 2	Homo sapiens	93-97
27287534-5	2016	The effect of CsA on normal human gingival fibroblasts (HGFs) was used to elucidate whether Slug expression could be affected by CsA by real-time reverse transcription-polymerase chain reaction and western blot.	Cyclosporine	129-132	snail family transcriptional repressor 2	Homo sapiens	92-96
27287534-6	2016	Cell proliferation in CsA-treated HGFs with Slug lentiviral-mediated shRNAi knockdown was evaluated by tetrazolium bromide reduction assay.	Cyclosporine	22-25	snail family transcriptional repressor 2	Homo sapiens	44-48
27287534-7	2016	RESULTS: Slug expression was higher in CsA-induced gingival overgrowth specimens than in clinical healthy gingiva (p &lt; 0.05).	Cyclosporine	39-42	snail family transcriptional repressor 2	Homo sapiens	9-13
27287534-8	2016	Slug expression was significantly higher in CsA-induced gingival overgrowth specimens with higher levels of inflammatory infiltrates (p &lt; 0.05).	Cyclosporine	44-47	snail family transcriptional repressor 2	Homo sapiens	0-4
27287534-9	2016	CsA was found to increase Slug transcript and protein expression in HGFs in a dose-dependent manner (p &lt; 0.05).	Cyclosporine	0-3	snail family transcriptional repressor 2	Homo sapiens	26-30
27287534-10	2016	In addition, knockdown of Slug significantly suppressed CsA-induced cell proliferation in HGFs (p &lt; 0.05).	Cyclosporine	56-59	snail family transcriptional repressor 2	Homo sapiens	26-30
27287534-11	2016	CONCLUSION: Taken together, upregulation of Slug in HGFs stimulated by CsA may play an important role in the pathogenesis of CsA-induced gingival overgrowth.	Cyclosporine	71-74	snail family transcriptional repressor 2	Homo sapiens	44-48
27279606-7	2016	Interestingly, the infectivity of wild-type or P90A virus could be rescued from the MX2-independent IFN-alpha-induced blocks in THP-1 cells by treatment with cyclosporine (Cs) or its nonimmunosuppressive analogue SDZ-NIM811, indicating that Cs-sensitive host cell cyclophilins other than CypA contribute to the activity of IFN-alpha-induced blocks.	Cyclosporine	158-170	MX dynamin like GTPase 2	Homo sapiens	84-87
27279606-7	2016	Interestingly, the infectivity of wild-type or P90A virus could be rescued from the MX2-independent IFN-alpha-induced blocks in THP-1 cells by treatment with cyclosporine (Cs) or its nonimmunosuppressive analogue SDZ-NIM811, indicating that Cs-sensitive host cell cyclophilins other than CypA contribute to the activity of IFN-alpha-induced blocks.	Cyclosporine	172-174	MX dynamin like GTPase 2	Homo sapiens	84-87
27446786-8	2016	CONCLUSION: The results of our study suggest that the symptoms of CTS in patients with diabetes are related to CSA of the median nerve, which is consistent with swelling of the nerve.	Cyclosporine	111-114	transthyretin	Homo sapiens	66-69
26950727-4	2016	RESULTS: We observed that chemical and genetic inhibition of Nox2 in rats and mice resulted in the prevention of CsA-induced hypoxia independent of regional perfusion (blood oxygen level-dependent magnetic resonance imaging and dynamic contrast-enhanced magnetic resonance imaging, pimonidazole, HIF-1alpha).	Cyclosporine	113-116	cytochrome b-245 beta chain	Rattus norvegicus	61-65
26255732-9	2016	Co-treatment of DL-CE with cyclosporine A, an immunosuppressant or telaprevir, an NS3 protease inhibitor, resulted in additive and synergistic antiviral effects, respectively.	Cyclosporine	27-41	KRAS proto-oncogene, GTPase	Homo sapiens	82-85
27000241-4	2016	Tetrandrine (0.1, 0.3, 1 muM) or cyclosporine A (0.1, 0.3, 1 muM) had non-competitively inhibitory manner on Z-guggulsterone-stimulated P-glycoprotein ATPase activity, suggesting that Z-guggulsterone might have unique binding site or regulating site on P-glycoprotein.	Cyclosporine	33-47	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	136-150
27000241-4	2016	Tetrandrine (0.1, 0.3, 1 muM) or cyclosporine A (0.1, 0.3, 1 muM) had non-competitively inhibitory manner on Z-guggulsterone-stimulated P-glycoprotein ATPase activity, suggesting that Z-guggulsterone might have unique binding site or regulating site on P-glycoprotein.	Cyclosporine	33-47	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	253-267
27627555-0	2016	The Effect of P-Glycoprotein Inhibition and Activation on the Absorption and Serum Levels of Cyclosporine and Tacrolimus in Rats.	Cyclosporine	93-105	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	14-28
27627555-1	2016	BACKGROUND: Permeability glycoprotein (P-glycoprotein or P-gp) plays an important role in the intestinal absorption of the immunosuppressive agents: cyclosporine and tacrolimus.	Cyclosporine	149-161	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	39-53
26954314-4	2016	Cyclosporine, a potent calcineurin inhibitor that acts selectively on T-cells, revolutionized the world of immunosuppression upon its discovery in 1970.	Cyclosporine	0-12	calcineurin binding protein 1	Homo sapiens	23-44
26031900-3	2016	As only a high intestinal first-pass effect of VR was found, that is, there existed a low bioavailability of VR (2.40%), inhibitors of P-glycoprotein (P-gp) and cytochrome P450 3A (CYP3A), including verapamil, cyclosporin A and midazolam, and absorption enhancers, including bile salts and borneol, combined with VR, were instilled into duodenum to evaluate the effects on bioavailability of VR.	Cyclosporine	210-223	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	135-149
26559821-11	2016	However, a distinction from CMT1, which also showed enlarged CSA values at entrapment sites, was only possible by calculating the entrapment ratios and entrapment score.	Cyclosporine	61-64	myelin protein zero	Homo sapiens	28-32
26496921-6	2016	Furthermore, we show that inhibition of the interaction with calcineurin inhibitor, cyclosporin A (CsA), leads to the retention of ATOH8 to the cytoplasm, suggesting that the interaction renders nuclear localization of ATOH8 which may be critical to control its activity as transcription factor.	Cyclosporine	84-97	calcineurin binding protein 1	Homo sapiens	61-82
26496921-6	2016	Furthermore, we show that inhibition of the interaction with calcineurin inhibitor, cyclosporin A (CsA), leads to the retention of ATOH8 to the cytoplasm, suggesting that the interaction renders nuclear localization of ATOH8 which may be critical to control its activity as transcription factor.	Cyclosporine	99-102	calcineurin binding protein 1	Homo sapiens	61-82
26915843-7	2016	Cyclosporine-based ISx was associated with more common erythropoiesis-stimulating agent use, including after estimated glomerular filtration rate adjustment (aOR 1.61, 95% CI 1.24-2.10).	Cyclosporine	0-12	intestine specific homeobox	Homo sapiens	19-22
26634693-0	2015	Cyclosporine A protects podocytes by regulating WAVE1 phosphorylation.	Cyclosporine	0-14	WASP family, member 1	Mus musculus	48-53
26634693-7	2015	CsA restored WAVE1 expression and also partially rescued the disordered F-actin arrangement after PAN injury.	Cyclosporine	0-3	WASP family, member 1	Mus musculus	13-18
25370934-0	2015	Cyclosporine A and MnTMPyP Alleviate alpha-Synuclein Expression and Aggregation in Cypermethrin-Induced Parkinsonism.	Cyclosporine	0-14	synuclein alpha	Rattus norvegicus	37-52
25370934-6	2015	Cyclosporine A or MnTMPyP alleviated the expression and aggregation of alpha-synuclein along with indicators of the mitochondrial dysfunction, oxidative damage and dopaminergic neurodegeneration.	Cyclosporine	0-14	synuclein alpha	Rattus norvegicus	71-86
25370934-7	2015	The results demonstrate that cypermethrin induces alpha-synuclein expression and aggregation while cyclosporine A or MnTMPyP rescues from alpha-synuclein over-expression and aggregation along with the mitochondrial dysfunction and oxidative damage leading to Parkinsonism in rats.	Cyclosporine	99-113	synuclein alpha	Rattus norvegicus	138-153
26489621-4	2015	In this study, we aimed to explore whether and how the important inflammatory cytokine IL-17 is associated with MPTP opening in platelets activation by using MPTP inhibitor cyclosporine-A (CsA).	Cyclosporine	173-187	interleukin 17A	Homo sapiens	87-92
26489621-4	2015	In this study, we aimed to explore whether and how the important inflammatory cytokine IL-17 is associated with MPTP opening in platelets activation by using MPTP inhibitor cyclosporine-A (CsA).	Cyclosporine	189-192	interleukin 17A	Homo sapiens	87-92
26489621-9	2015	However, CsA attenuated these effects triggered by IL-17.	Cyclosporine	9-12	interleukin 17A	Homo sapiens	51-56
26017975-11	2015	The effects of TNF on NFATc1 and TRPC6 expression were blocked by cyclosporine A but were not blocked by the pan-TRP inhibitor SKF-96365.	Cyclosporine	66-80	nuclear factor of activated T cells 1	Homo sapiens	22-28
26361868-10	2015	Inhibition of the calcineurin/NFATc1 pathway by cyclosporin A and FK506, attenuated Tbeta4-induced osteoblastic differentiation and activation of Wnt-related genes, as well as nuclear beta-catenin in hPDLCs.	Cyclosporine	48-61	nuclear factor of activated T cells 1	Homo sapiens	30-36
26071337-6	2015	RESULTS: CSA occurred in 44% (69/157) of patients and was associated with SLC28A2 rs11854484 [CC/CT genotypes: 33% (26/78) vs. TT genotype: 56% (36/64); p=0.006].	Cyclosporine	9-12	solute carrier family 28 member 2	Homo sapiens	74-81
26071337-11	2015	CONCLUSIONS: In patients receiving first generation protease inhibitors, genotype SLC28A2 rs11854484 predicts CSA, and helps to identify a subgroup of patients with better tolerance of triple therapy.	Cyclosporine	110-113	solute carrier family 28 member 2	Homo sapiens	82-89
26106294-8	2015	Finally, we find that blocking the opening of the mitochondrial permeability transition pore with cyclosporine A, or inhibiting mitochondrial calcium uptake with Ru360, reduces ROS production and c-Abl activation.	Cyclosporine	98-112	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	196-201
26448755-0	2015	Regulatory T Cells Resist Cyclosporine-Induced Cell Death via CD44-Mediated Signaling Pathways.	Cyclosporine	26-38	CD44 molecule (Indian blood group)	Homo sapiens	62-66
26448755-3	2015	Here, we asked whether CD44 signaling also promotes Treg resistance to CSA.	Cyclosporine	71-74	CD44 molecule (Indian blood group)	Homo sapiens	23-27
25119556-11	2015	The CsA-induced attenuation of periodontal bone loss was strongly correlated positively with the expressions of MMP-2, MMP-9, and EMMPRIN in gingiva.	Cyclosporine	4-7	matrix metallopeptidase 9	Rattus norvegicus	119-124
25645789-2	2015	The objective of this study is to compare the incidence of development of obesity after HT, according to the calcineurin inhibitor (CNI) used (cyclosporine [CsA] vs tacrolimus [Tac]).	Cyclosporine	143-155	calcineurin binding protein 1	Homo sapiens	109-130
26329549-4	2015	The first finding is that the oral bioavailability of cyclosporine A (CsA), which is an immunosuppressant, was decreased by increased first-pass metabolism due to elevated CYP3A and P-glycoprotein (P-gp) specifically in the upper small intestine after liver I/R.	Cyclosporine	54-68	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	182-196
26329549-4	2015	The first finding is that the oral bioavailability of cyclosporine A (CsA), which is an immunosuppressant, was decreased by increased first-pass metabolism due to elevated CYP3A and P-glycoprotein (P-gp) specifically in the upper small intestine after liver I/R.	Cyclosporine	54-68	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	198-202
26329549-4	2015	The first finding is that the oral bioavailability of cyclosporine A (CsA), which is an immunosuppressant, was decreased by increased first-pass metabolism due to elevated CYP3A and P-glycoprotein (P-gp) specifically in the upper small intestine after liver I/R.	Cyclosporine	70-73	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	182-196
26329549-4	2015	The first finding is that the oral bioavailability of cyclosporine A (CsA), which is an immunosuppressant, was decreased by increased first-pass metabolism due to elevated CYP3A and P-glycoprotein (P-gp) specifically in the upper small intestine after liver I/R.	Cyclosporine	70-73	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	198-202
25310383-2	2014	However, alisporivir, cyclosporin A, and most other cyclosporins are potent inhibitors of OATP1B1, MRP2, MDR1, and other important drug transporters.	Cyclosporine	22-35	ATP binding cassette subfamily C member 2	Rattus norvegicus	99-103
25310383-2	2014	However, alisporivir, cyclosporin A, and most other cyclosporins are potent inhibitors of OATP1B1, MRP2, MDR1, and other important drug transporters.	Cyclosporine	22-35	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	105-109
25299210-11	2014	Manganese superoxide dismutase (Mn-SOD) showed a similar dose-dependent reduction in cells undergoing apoptosis, while levels of the intracellular calcium ion exchange maker calbindin-D9k were decreased in apoptosis (1.0 to 5 microM CsA), but unchanged in autophagy.	Cyclosporine	233-236	superoxide dismutase 2	Rattus norvegicus	0-30
25299210-11	2014	Manganese superoxide dismutase (Mn-SOD) showed a similar dose-dependent reduction in cells undergoing apoptosis, while levels of the intracellular calcium ion exchange maker calbindin-D9k were decreased in apoptosis (1.0 to 5 microM CsA), but unchanged in autophagy.	Cyclosporine	233-236	superoxide dismutase 2	Rattus norvegicus	32-38
25299210-12	2014	In conclusion, these results suggest that CsA induction of apoptotic or autophagic cell death in rat pituitary GH3 cells depends on the relative expression of factors and correlates with Bcl-2 and Mn-SOD levels.	Cyclosporine	42-45	superoxide dismutase 2	Rattus norvegicus	197-203
24853130-5	2014	In the short-term, creatinine and blood urea nitrogen (BUN) levels increased and clearances decreased, accompanied by glomerular filtration rate (GFR) reduction, but without kidney lesions; at that stage, CsA exposure induced proliferating cell nuclear antigen (PCNA), transforming growth factor beta 1 (TGF-beta1), factor nuclear kappa B (NF-kappabeta) and Tumor Protein P53 (TP53) kidney mRNA up-regulation.	Cyclosporine	205-208	proliferating cell nuclear antigen	Rattus norvegicus	226-260
24853130-5	2014	In the short-term, creatinine and blood urea nitrogen (BUN) levels increased and clearances decreased, accompanied by glomerular filtration rate (GFR) reduction, but without kidney lesions; at that stage, CsA exposure induced proliferating cell nuclear antigen (PCNA), transforming growth factor beta 1 (TGF-beta1), factor nuclear kappa B (NF-kappabeta) and Tumor Protein P53 (TP53) kidney mRNA up-regulation.	Cyclosporine	205-208	proliferating cell nuclear antigen	Rattus norvegicus	262-266
24853130-5	2014	In the short-term, creatinine and blood urea nitrogen (BUN) levels increased and clearances decreased, accompanied by glomerular filtration rate (GFR) reduction, but without kidney lesions; at that stage, CsA exposure induced proliferating cell nuclear antigen (PCNA), transforming growth factor beta 1 (TGF-beta1), factor nuclear kappa B (NF-kappabeta) and Tumor Protein P53 (TP53) kidney mRNA up-regulation.	Cyclosporine	205-208	tumor protein p53	Rattus norvegicus	358-375
24853130-5	2014	In the short-term, creatinine and blood urea nitrogen (BUN) levels increased and clearances decreased, accompanied by glomerular filtration rate (GFR) reduction, but without kidney lesions; at that stage, CsA exposure induced proliferating cell nuclear antigen (PCNA), transforming growth factor beta 1 (TGF-beta1), factor nuclear kappa B (NF-kappabeta) and Tumor Protein P53 (TP53) kidney mRNA up-regulation.	Cyclosporine	205-208	tumor protein p53	Rattus norvegicus	377-381
24853130-7	2014	Transition from CsA-induced renal dysfunction to nephrotoxicity is accompanied by modification of molecular mechanisms and biomarkers, being mTOR one of the key players for kidney lesion evolution, thus suggesting, by mean of molecular evidences, that early CsA replacement by mTOR inhibitors is indeed the better therapeutic choice to prevent chronic allograft nephropathy.	Cyclosporine	16-19	mechanistic target of rapamycin kinase	Rattus norvegicus	141-145
24806754-10	2014	Cyclosporin-A improved plasma membrane localization of both ABCB4(S320F) and ABCB4(A953D), but inhibited floppase activity.	Cyclosporine	0-13	ATP binding cassette subfamily B member 4	Homo sapiens	60-65
24806754-10	2014	Cyclosporin-A improved plasma membrane localization of both ABCB4(S320F) and ABCB4(A953D), but inhibited floppase activity.	Cyclosporine	0-13	ATP binding cassette subfamily B member 4	Homo sapiens	77-82
24806754-13	2014	Cyclosporin-A increased expression of ABCB4(S320F) and ABCB4(A953D), suggesting that chemical chaperones could be exploited for therapeutic benefit to usher in a new era of personalized medicine for patients with ABCB4-dependent cholestatic disease.	Cyclosporine	0-13	ATP binding cassette subfamily B member 4	Homo sapiens	38-43
24806754-13	2014	Cyclosporin-A increased expression of ABCB4(S320F) and ABCB4(A953D), suggesting that chemical chaperones could be exploited for therapeutic benefit to usher in a new era of personalized medicine for patients with ABCB4-dependent cholestatic disease.	Cyclosporine	0-13	ATP binding cassette subfamily B member 4	Homo sapiens	55-60
24806754-13	2014	Cyclosporin-A increased expression of ABCB4(S320F) and ABCB4(A953D), suggesting that chemical chaperones could be exploited for therapeutic benefit to usher in a new era of personalized medicine for patients with ABCB4-dependent cholestatic disease.	Cyclosporine	0-13	ATP binding cassette subfamily B member 4	Homo sapiens	55-60
23907422-9	2014	CsA reduced Eln level, whereas PhT increased it.	Cyclosporine	0-3	elastin	Homo sapiens	12-15
24941805-8	2014	RESULTS: Compared with other groups, CsA+Talpha1 group had significant lower IL-1alpha, IL-2, IL-6, IL-17, and significant higher IL-10 at 1 d, 7 d, 14 d, 21 d after the treatments (P &lt; 0.05).	Cyclosporine	37-40	interleukin 17A	Mus musculus	100-105
24280122-3	2014	The aim of the current study was to investigate if similar effects occur with another P-gp inhibitor, cyclosporin A (CsA).	Cyclosporine	117-120	phosphoglycolate phosphatase	Mus musculus	86-90
24280122-5	2014	P-gp inhibition by CsA enhanced the brain distribution of escitalopram by 70-80%.	Cyclosporine	19-22	phosphoglycolate phosphatase	Mus musculus	0-4
23624721-9	2014	Using cyclosporin A as an inhibitor, we revealed that NF-ATc1 directly regulates OC-STAMP and P2X7 receptor expression during LPA-stimulated osteoclast fusion.	Cyclosporine	6-19	nuclear factor of activated T cells 1	Homo sapiens	54-61
24415751-9	2014	The calcineurin-NFATc mediated up-regulation of the Itpr2 promoter was attenuated by cyclosporine-A.	Cyclosporine	85-99	nuclear factor of activated T cells 1	Homo sapiens	16-21
24291231-7	2014	Disruption of the interaction between cyclophilin-D and F1F0-ATP synthase by cyclosporin A attenuated the mitochondrial protection induced by hypoxic preconditioning in both NARP cybrids and wild-type 143B cells.	Cyclosporine	77-90	neuronal pentraxin 2	Homo sapiens	174-178
24284479-10	2014	We also demonstrated that NFATc1-mediated resistance can be overcome by cyclosporin A (CsA), an NFAT inhibitor, and that the combination of P-S and CsA synergistically inhibited pancreatic cancer cell growth.	Cyclosporine	72-85	nuclear factor of activated T cells 1	Homo sapiens	26-32
24284479-10	2014	We also demonstrated that NFATc1-mediated resistance can be overcome by cyclosporin A (CsA), an NFAT inhibitor, and that the combination of P-S and CsA synergistically inhibited pancreatic cancer cell growth.	Cyclosporine	87-90	nuclear factor of activated T cells 1	Homo sapiens	26-32
24284479-10	2014	We also demonstrated that NFATc1-mediated resistance can be overcome by cyclosporin A (CsA), an NFAT inhibitor, and that the combination of P-S and CsA synergistically inhibited pancreatic cancer cell growth.	Cyclosporine	148-151	nuclear factor of activated T cells 1	Homo sapiens	26-32
24163074-8	2014	Caspase-3 activity and terminal deoxynucleotidyl transferase dUTP-mediated nick-end labeling in distal nonnecrotic LV both increased after MI but were lower in CsA-treated mice compared with vehicle (P &lt; 0.05).	Cyclosporine	160-163	caspase 3	Mus musculus	0-9
24971338-8	2014	Prolonged CsA exposure aggravated renal damage, without clear changes on the traditional markers, but with changes in serums TGF- beta and IL-7, TBARs clearance, and kidney TGF-beta and mTOR.	Cyclosporine	10-13	interleukin 7	Rattus norvegicus	139-143
24971338-8	2014	Prolonged CsA exposure aggravated renal damage, without clear changes on the traditional markers, but with changes in serums TGF- beta and IL-7, TBARs clearance, and kidney TGF-beta and mTOR.	Cyclosporine	10-13	mechanistic target of rapamycin kinase	Rattus norvegicus	186-190
24391506-8	2014	In primary murine B cells, addition of cyclosporine (CsA) resulted in a significant decrease in M2-induced IL-10 levels as well as IRF4 expression, emphasizing the importance of the NFAT pathway in M2- -mediated induction of IL-10.	Cyclosporine	39-51	interferon regulatory factor 4	Mus musculus	131-135
24391506-8	2014	In primary murine B cells, addition of cyclosporine (CsA) resulted in a significant decrease in M2-induced IL-10 levels as well as IRF4 expression, emphasizing the importance of the NFAT pathway in M2- -mediated induction of IL-10.	Cyclosporine	53-56	interferon regulatory factor 4	Mus musculus	131-135
24090809-4	2013	Kinetic studies on ATPase activity showed the effects of Tetrandrine (Tet) on CJY-stimulated, CsA on CJY-stimulated, and CsA on Tet-stimulated P-gp ATPase activity were all non-competitive inhibition, indicating that these substrates can simultaneously but independently bind to diverse sites on P-gp.	Cyclosporine	121-124	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	143-147
24090809-4	2013	Kinetic studies on ATPase activity showed the effects of Tetrandrine (Tet) on CJY-stimulated, CsA on CJY-stimulated, and CsA on Tet-stimulated P-gp ATPase activity were all non-competitive inhibition, indicating that these substrates can simultaneously but independently bind to diverse sites on P-gp.	Cyclosporine	121-124	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	296-300
23851154-9	2013	(5) Cyclosporine A did not effectively reduce the rapid infiltration of CD4(+) or CD8(+) infiltration in 3d, but significantly reduced the degree of CD4(+) T cell infiltration in cardiac tissues between 3 and 7d.	Cyclosporine	4-18	Cd4 molecule	Rattus norvegicus	149-152
24064216-7	2013	The intracellularly trapped misprocessed protein associates more with chaperone Hsp70, and the treatment with cyclosporine A reduces the association of mutant P-gp, thus allowing it to be trafficked to the cell surface.	Cyclosporine	110-124	heat shock protein family A (Hsp70) member 4	Homo sapiens	80-85
23953030-3	2013	The canalicular transport of irinotecan and SN-38G is mediated by ABCC2 (MRP2) and ABCB1 (MDR1) which are both inhibited by ciclosporin.	Cyclosporine	124-135	ATP binding cassette subfamily C member 2	Homo sapiens	66-71
23953030-3	2013	The canalicular transport of irinotecan and SN-38G is mediated by ABCC2 (MRP2) and ABCB1 (MDR1) which are both inhibited by ciclosporin.	Cyclosporine	124-135	ATP binding cassette subfamily C member 2	Homo sapiens	73-77
24011632-5	2013	RESULTS: The result showed that RE of gefitinib at the concentrations of 1 muM and 10 muM was 4.12 and 4.05, respectively, but significantly decreased to 1 and 1.35 after adding a P-glycoprotein (P-gp) inhibitor, cyclosporine A.	Cyclosporine	213-227	phosphoglycolate phosphatase	Mus musculus	180-194
23732701-1	2013	Cyclosporine A and FK506 produce immunosuppression by blocking calcineurin phosphatase activity and consequently activation of cytosolic Nuclear Factor of Activated T-cell (NFATc) transcription factor.	Cyclosporine	0-14	nuclear factor of activated T cells 1	Homo sapiens	173-178
23643609-0	2013	Interleukin-10 gene promoter polymorphisms are associated with cyclosporin A-induced gingival overgrowth in renal transplant patients.	Cyclosporine	63-76	interleukin 10	Homo sapiens	0-14
23643609-2	2013	The aim of this study was to investigate the possible association of IL-10 single nucleotide polymorphisms (SNPs) and cyclosporin A (CsA)-induced gingival overgrowth (GO) in renal transplant patients in a Chinese population, taking into account subgingival microbiota as additional variables.	Cyclosporine	118-131	interleukin 10	Homo sapiens	69-74
23643609-2	2013	The aim of this study was to investigate the possible association of IL-10 single nucleotide polymorphisms (SNPs) and cyclosporin A (CsA)-induced gingival overgrowth (GO) in renal transplant patients in a Chinese population, taking into account subgingival microbiota as additional variables.	Cyclosporine	133-136	interleukin 10	Homo sapiens	69-74
23643609-10	2013	CONCLUSIONS: Our results show that IL-10-819TT (-592AA) genotype and ATA halpotype are associated with susceptibility to CsA-induced GO.	Cyclosporine	121-124	interleukin 10	Homo sapiens	35-40
23846495-11	2013	Finally, cyclosporine A and CyPA-peptidyl-prolyl cis-trans isomerase mutant, R55A, inhibited AngII-stimulated CyPA and p47phox association in VSMC, suggesting that peptidyl-prolyl cis-trans isomerase activity was required for their interaction.	Cyclosporine	9-23	neutrophil cytosolic factor 1	Homo sapiens	119-126
23470307-13	2013	Similarly, the CSA increase at 12 h was abolished by inhibitors of the PI3K/Akt pathway as well as by AR inhibition.	Cyclosporine	15-18	androgen receptor	Rattus norvegicus	102-104
24028719-9	2013	Compared with control group, the expression of TNF-beta was significantly higher in IL-2 group (73.36% +- 16.73% vs 66.61% +- 16.20%, P &lt; 0.05), significantly lower in FK506 and FK506 plus CsA groups (P &lt; 0.05).	Cyclosporine	192-195	lymphotoxin alpha	Homo sapiens	47-55
23724161-10	2013	CONCLUSIONS: Alloantigen induced lymphocytes to release IL-2R and P59 and stimulated the induction of the CD4 gene" transcription for 6 h. Cyclosporin A stimulated the release of IL-2R for 2 h. These results provide an in vitro basis for describing the time phases of rejection inhibited by cyclosporin A.	Cyclosporine	139-152	Cd4 molecule	Rattus norvegicus	106-109
23724161-10	2013	CONCLUSIONS: Alloantigen induced lymphocytes to release IL-2R and P59 and stimulated the induction of the CD4 gene" transcription for 6 h. Cyclosporin A stimulated the release of IL-2R for 2 h. These results provide an in vitro basis for describing the time phases of rejection inhibited by cyclosporin A.	Cyclosporine	291-304	Cd4 molecule	Rattus norvegicus	106-109
23499865-5	2013	CsA treatment down-regulates expression of gluconeogenic gene including Pepck, G6Pase and Pgc1alpha, leading to a decrease in blood glucose level and an improvement of glucose tolerance in the obese animals.	Cyclosporine	0-3	phosphoenolpyruvate carboxykinase 1, cytosolic	Mus musculus	72-77
23499865-6	2013	RT-PCR analysis of genes involved in adipocyte differentiation and lipid metabolism in white adipose tissue reveal that CsA application reduces expression of Ppargamma, Fas and Scd 1.	Cyclosporine	120-123	stearoyl-Coenzyme A desaturase 1	Mus musculus	177-182
23332985-1	2013	OBJECTIVE: By binding to cyclophilin D, cyclosporine A (CsA) inhibits mitochondrial permeability transition pore (mPTP) opening and prevents mitochondrial dysfunction and ultimately cell death after ischemia-reperfusion (IR) injury in cardiac muscle.	Cyclosporine	40-54	peptidylprolyl isomerase D	Rattus norvegicus	25-38
23622648-11	2013	CsA-induced nephrotoxicity was accompanied by kidney overexpression of inflammatory and proliferative mRNA markers (IL-1beta, mTOR and PCNA), which were absent among SRL group.	Cyclosporine	0-3	mechanistic target of rapamycin kinase	Rattus norvegicus	126-130
23622648-11	2013	CsA-induced nephrotoxicity was accompanied by kidney overexpression of inflammatory and proliferative mRNA markers (IL-1beta, mTOR and PCNA), which were absent among SRL group.	Cyclosporine	0-3	proliferating cell nuclear antigen	Rattus norvegicus	135-139
23622648-13	2013	Renal over expression of mTOR in the CsA-treated group, associated with renal dysfunction and structural damage, reinforces the potential beneft of SRL as a strategy to reduce CsA-evoked nephrotoxicity.	Cyclosporine	37-40	mechanistic target of rapamycin kinase	Rattus norvegicus	25-29
22673852-6	2013	The presence of elevated MMP-9 on the ocular surface will identify those patients who should receive antiinflammatory therapy, such as cyclosporine, and may predict those patients who will respond to this therapy.	Cyclosporine	135-147	matrix metallopeptidase 9	Homo sapiens	25-30
22217400-6	2013	Our experiments revealed that a single peripheral administration of CsA increases neuronal activity in the insular cortex and the amygdala as evident from increased electric activity, c-Fos expression and amygdaloid noradrenaline release.	Cyclosporine	68-71	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	184-189
23594788-9	2013	Consistent with these results, in vitro studies showed that addition of KRG protected against CsA-induced morphological changes, cytotoxicity, inflammation, and apoptotic cell death as demonstrated by annexin V binding.	Cyclosporine	94-97	annexin A5	Mus musculus	201-210
23796541-0	2013	Cyclosporine attenuates arginine transport, in human endothelial cells, through modulation of cationic amino acid transporter-1.	Cyclosporine	0-12	solute carrier family 7 member 1	Homo sapiens	94-127
23796541-6	2013	We hypothesize that CsA inhibits eNOS activity through modulation of its selective arginine supplier CAT-1.	Cyclosporine	20-23	solute carrier family 7 member 1	Homo sapiens	101-106
23796541-11	2013	CsA significantly decreased the abundance of CAT-1 protein, an effect that was attenuated by L-arginine.	Cyclosporine	0-3	solute carrier family 7 member 1	Homo sapiens	45-50
23796541-13	2013	CONCLUSION: CsA inhibits arginine transport and induces protein nitration in HUVEC through modulation of CAT-1.	Cyclosporine	12-15	solute carrier family 7 member 1	Homo sapiens	105-110
22722879-9	2012	The regulation of calcineurin activity by ionomycin or cyclosporin A caused rapid nuclear import or export of NFATc1 in HepG2 cells.	Cyclosporine	55-68	nuclear factor of activated T cells 1	Homo sapiens	110-116
23057591-8	2012	Here, CsA increased phospho-JAK2 and phospho-STAT3 levels and reduced the phospho-IKKgamma and p65 proteins, thus activating NF-kappaB signaling.	Cyclosporine	6-9	Janus kinase 2	Rattus norvegicus	28-32
23057591-8	2012	Here, CsA increased phospho-JAK2 and phospho-STAT3 levels and reduced the phospho-IKKgamma and p65 proteins, thus activating NF-kappaB signaling.	Cyclosporine	6-9	inhibitor of nuclear factor kappa B kinase regulatory subunit gamma	Rattus norvegicus	82-90
22822477-6	2012	Immunosuppressive drugs, such as tacrolimus (FK506) and cyclosporine A (CsA), were used to inhibit T cell interactions under the physiologic model of T cell migration at a ratio of 5 : 4.3 : 3.9 (E-selectin : ICAM-1 : VCAM-1).	Cyclosporine	72-75	intercellular adhesion molecule 1	Homo sapiens	209-215
23554774-5	2012	In addition, cyclosporine A caused an increase in the expression of vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and nerve growth factor (NGF), and inhibited follistatin expression.	Cyclosporine	13-27	vascular endothelial growth factor A	Mus musculus	68-102
23554774-5	2012	In addition, cyclosporine A caused an increase in the expression of vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and nerve growth factor (NGF), and inhibited follistatin expression.	Cyclosporine	13-27	vascular endothelial growth factor A	Mus musculus	104-108
23554774-5	2012	In addition, cyclosporine A caused an increase in the expression of vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and nerve growth factor (NGF), and inhibited follistatin expression.	Cyclosporine	13-27	hepatocyte growth factor	Mus musculus	111-135
23554774-5	2012	In addition, cyclosporine A caused an increase in the expression of vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and nerve growth factor (NGF), and inhibited follistatin expression.	Cyclosporine	13-27	hepatocyte growth factor	Mus musculus	137-140
23554774-5	2012	In addition, cyclosporine A caused an increase in the expression of vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and nerve growth factor (NGF), and inhibited follistatin expression.	Cyclosporine	13-27	nerve growth factor	Mus musculus	147-166
23554774-5	2012	In addition, cyclosporine A caused an increase in the expression of vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and nerve growth factor (NGF), and inhibited follistatin expression.	Cyclosporine	13-27	nerve growth factor	Mus musculus	168-171
22484354-6	2012	Analysis of T-cell phenotype by flow cytometry in 2 subjects showed a decrease in circulating activated CD8(+) and CD4(+) T effector memory cells after treatment with CSA.	Cyclosporine	167-170	CD8a molecule	Homo sapiens	104-107
22790389-9	2012	The number of p62-positive cells was also significantly increased in a CsA dose-dependent manner.	Cyclosporine	71-74	nucleoporin 62	Mus musculus	14-17
22790389-11	2012	Expression of active caspase-3 was increased in a CsA dose-dependent manner and was colocalized with LC3-II in the injured area of CsA-treated kidneys.	Cyclosporine	50-53	caspase 3	Mus musculus	21-30
22790389-11	2012	Expression of active caspase-3 was increased in a CsA dose-dependent manner and was colocalized with LC3-II in the injured area of CsA-treated kidneys.	Cyclosporine	131-134	caspase 3	Mus musculus	21-30
22669715-12	2012	Treatment with corticosteroids and cyclosporine A (CsA) resolved the intraocular inflammation in association with an upregulation of IL-27 and a downregulation of IL-17.	Cyclosporine	35-49	interleukin 17A	Homo sapiens	163-168
22669715-12	2012	Treatment with corticosteroids and cyclosporine A (CsA) resolved the intraocular inflammation in association with an upregulation of IL-27 and a downregulation of IL-17.	Cyclosporine	51-54	interleukin 17A	Homo sapiens	163-168
23018254-1	2012	BACKGROUND: Calcineurin inhibitor (cyclosporine, CsA) and mTOR inhibitors (sirolimus, SRL) - immunosuppressants used to prevent allograft rejection after renal transplantation - have a narrow therapeutic index and show considerable inter-individual pharmacokinetic differences.	Cyclosporine	35-47	calcineurin binding protein 1	Homo sapiens	12-33
22495096-8	2012	RESULTS: CsA up-regulated CXCL12 and CXCR4 expression in human first-trimester cytotrophoblast cells, but not in DSCs.	Cyclosporine	9-12	C-X-C motif chemokine receptor 4	Homo sapiens	37-42
22495096-9	2012	Blocking the mitogen-activated proteinkinase/extracellular signal-regulated kinase (MAPK/ERK1/2) signaling by U0126 abrogated the CsA-induced increase in CXCL12 and CXCR4 expression and neutralizing antibodies to CXCL12 or CXCR4 completely inhibited the CsA-induced increase in cell number, invasion and MMP-9 and MMP-2 activity of cytotrophoblast.	Cyclosporine	130-133	C-X-C motif chemokine receptor 4	Homo sapiens	165-170
22495096-9	2012	Blocking the mitogen-activated proteinkinase/extracellular signal-regulated kinase (MAPK/ERK1/2) signaling by U0126 abrogated the CsA-induced increase in CXCL12 and CXCR4 expression and neutralizing antibodies to CXCL12 or CXCR4 completely inhibited the CsA-induced increase in cell number, invasion and MMP-9 and MMP-2 activity of cytotrophoblast.	Cyclosporine	130-133	C-X-C motif chemokine receptor 4	Homo sapiens	223-228
22495096-9	2012	Blocking the mitogen-activated proteinkinase/extracellular signal-regulated kinase (MAPK/ERK1/2) signaling by U0126 abrogated the CsA-induced increase in CXCL12 and CXCR4 expression and neutralizing antibodies to CXCL12 or CXCR4 completely inhibited the CsA-induced increase in cell number, invasion and MMP-9 and MMP-2 activity of cytotrophoblast.	Cyclosporine	130-133	matrix metallopeptidase 9	Homo sapiens	304-309
22495096-10	2012	CsA also significantly promoted the activity of MMP-9 and MMP-2 in DSCs, but this was unaffected by CXCL12 or CXCR4 neutralizing antibody.	Cyclosporine	0-3	matrix metallopeptidase 9	Homo sapiens	48-53
22211698-0	2012	Interleukin-17- and protease-activated receptor 2-mediated production of CXCL1 and CXCL8 modulated by cyclosporine A, vitamin D3 and glucocorticoids in human keratinocytes.	Cyclosporine	102-116	C-X-C motif chemokine ligand 1	Homo sapiens	73-78
22211698-4	2012	The SLIGKV-NH(2) -induced production of both CXCL1 and CXCL8 was markedly reduced by cyclosporine A.	Cyclosporine	85-99	C-X-C motif chemokine ligand 1	Homo sapiens	45-50
22211698-7	2012	These results suggest that the IL-17-induced pro-inflammatory reaction is enhanced by the activation of PAR2 in keratinocytes, and that the effect of PAR2 is differentially modulated by cyclosporine A, the active form of vitamin D(3)  and glucocorticoids.	Cyclosporine	186-200	interleukin 17A	Homo sapiens	31-36
22852277-1	2012	Immunosuppressive therapy designed to prevent kidney graft rejection usually consists of a triple-drug combination including a corticosteroid, a calcineurin inhibitor (ciclosporin or tacrolimus) and a drug that inhibits cell proliferation (azathioprine or mycophenolate mofetil).	Cyclosporine	168-179	calcineurin binding protein 1	Homo sapiens	145-166
22841242-12	2012	Anti-GSTT1 antibody was observed more frequently albeit not significantly, among the cyclosporine versus tacrolimus patient group (P = .16).	Cyclosporine	85-97	glutathione S-transferase theta 1	Homo sapiens	5-10
22620865-4	2012	In this study, we report the backbone amide-(15)N CSA tensors for a 16.7-kDa membrane-bound and paramagnetic-heme containing protein, rabbit Cytochrome b(5) (cytb(5)), determined using the (15)N CSA/(15)N-(1)H dipolar transverse cross-correlation rates.	Cyclosporine	50-53	cytochrome b5	Oryctolagus cuniculus	141-156
22620865-4	2012	In this study, we report the backbone amide-(15)N CSA tensors for a 16.7-kDa membrane-bound and paramagnetic-heme containing protein, rabbit Cytochrome b(5) (cytb(5)), determined using the (15)N CSA/(15)N-(1)H dipolar transverse cross-correlation rates.	Cyclosporine	50-53	cytochrome b5	Oryctolagus cuniculus	158-165
22476221-6	2012	Both protease inhibitors can modify the levels of drugs metabolized by the CYP3A/4 pathway, and in posttransplant patients, the protease inhibitors increase the levels of cyclosporine and tacrolimus, with the magnitude of the drug-drug interactions varying with protease inhibitor and type of calcineurin inhibitor (CNI).	Cyclosporine	171-183	calcineurin binding protein 1	Homo sapiens	293-314
22476221-6	2012	Both protease inhibitors can modify the levels of drugs metabolized by the CYP3A/4 pathway, and in posttransplant patients, the protease inhibitors increase the levels of cyclosporine and tacrolimus, with the magnitude of the drug-drug interactions varying with protease inhibitor and type of calcineurin inhibitor (CNI).	Cyclosporine	171-183	calcineurin binding protein 1	Homo sapiens	316-319
22788126-6	2012	Compared with the SIN and CsA groups, levels of CD4(+)CD25(+)FoxP3(+) lymphocytes in the control group were decreased (p &lt; 0.05) and were increased in the cotreated group (p &lt; 0.05).	Cyclosporine	26-29	Cd4 molecule	Rattus norvegicus	48-51
21869731-1	2012	OBJECTIVE: Multidrug resistance-related protein 2 (Mrp2) is expressed in apical membranes of renal proximal tubular cells and contributes to the renal secretion of cyclosporine A (CsA).	Cyclosporine	164-178	ATP binding cassette subfamily C member 2	Rattus norvegicus	11-49
21869731-1	2012	OBJECTIVE: Multidrug resistance-related protein 2 (Mrp2) is expressed in apical membranes of renal proximal tubular cells and contributes to the renal secretion of cyclosporine A (CsA).	Cyclosporine	164-178	ATP binding cassette subfamily C member 2	Rattus norvegicus	51-55
21869731-1	2012	OBJECTIVE: Multidrug resistance-related protein 2 (Mrp2) is expressed in apical membranes of renal proximal tubular cells and contributes to the renal secretion of cyclosporine A (CsA).	Cyclosporine	180-183	ATP binding cassette subfamily C member 2	Rattus norvegicus	11-49
21869731-1	2012	OBJECTIVE: Multidrug resistance-related protein 2 (Mrp2) is expressed in apical membranes of renal proximal tubular cells and contributes to the renal secretion of cyclosporine A (CsA).	Cyclosporine	180-183	ATP binding cassette subfamily C member 2	Rattus norvegicus	51-55
21869731-2	2012	Mrp2-/- deficiency may lead to local renal CsA accumulation.	Cyclosporine	43-46	ATP binding cassette subfamily C member 2	Rattus norvegicus	0-4
22471287-0	2012	Cyclosporin but not everolimus inhibits chemokine receptor expression on CD4+ T cell subsets circulating in the peripheral blood of renal transplant recipients.	Cyclosporine	0-11	C-X-C motif chemokine receptor 4	Homo sapiens	40-58
22471287-9	2012	CsA, but not everolimus, inhibits both T(reg) development and expression of CXCR3 and CCR5 on CD4(+) T cell subsets.	Cyclosporine	0-3	C-C motif chemokine receptor 5	Homo sapiens	86-90
22361031-1	2012	Co-administration of P-glycoprotein (P-gp) inhibitors such as cyclosporine A (CyA) and its analogue valspodar with doxorubicin (DOX) can result in diminished clearance of DOX, leading to accentuated toxicity.	Cyclosporine	62-76	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	21-35
22361031-1	2012	Co-administration of P-glycoprotein (P-gp) inhibitors such as cyclosporine A (CyA) and its analogue valspodar with doxorubicin (DOX) can result in diminished clearance of DOX, leading to accentuated toxicity.	Cyclosporine	62-76	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	37-41
22034230-8	2012	In contrast, S(SEC1) was lower in men (p &lt; 0.001) and remained so after normalization to CSA(TS) .	Cyclosporine	92-95	secretory blood group 1, pseudogene	Homo sapiens	15-19
22307172-10	2012	Rho123 (a mitochondrial fluorescent probe)             accumulation was largely reduced and efflux was strongly increased in the mitochondria             of MCF-7/ADM cells compared to those of MCF-7 cells (P&lt;0.01), and these were             completely reversed in the presence of the P-gp inhibitor CsA (P&lt;0.01).	Cyclosporine	304-307	adrenomedullin	Homo sapiens	163-166
22564605-7	2012	RESULTS: MMP-1, MMP-3, MMP-8, MMP-9, and MMP-13 activities were increased after CsA treatment; MMP-1 = 121; MMP-3 = 164; MMP-8 = 133; MMP-9 = 124; and MMP-13 = 121.	Cyclosporine	80-83	matrix metallopeptidase 9	Homo sapiens	30-35
22564605-7	2012	RESULTS: MMP-1, MMP-3, MMP-8, MMP-9, and MMP-13 activities were increased after CsA treatment; MMP-1 = 121; MMP-3 = 164; MMP-8 = 133; MMP-9 = 124; and MMP-13 = 121.	Cyclosporine	80-83	matrix metallopeptidase 9	Homo sapiens	121-139
22394628-14	2012	Alveolar epithelial cells,  bronchiolar epithelial cells,  mononuclear macrophages,  neutrophils and lymphocytes were demonstrated to express CD147,  there was higher CD147 expression in BLM model group than those in CsA treatment groups.	Cyclosporine	217-220	basigin	Mus musculus	142-147
22394628-15	2012	CONCLUSION: CsA may heal BLM induced interstitial pulmonary disease by blocking CD147-CypA interaction,  then decreasing chemotaxis for the immunocyte,  and reducing migration of immunocytes to the lung and collagen deposition in the lung.	Cyclosporine	12-15	basigin	Mus musculus	80-85
22394628-15	2012	CONCLUSION: CsA may heal BLM induced interstitial pulmonary disease by blocking CD147-CypA interaction,  then decreasing chemotaxis for the immunocyte,  and reducing migration of immunocytes to the lung and collagen deposition in the lung.	Cyclosporine	12-15	peptidylprolyl isomerase A	Mus musculus	86-90
22267156-0	2012	Drug interaction between cyclosporine and mTOR inhibitors in experimental model of chronic cyclosporine nephrotoxicity and pancreatic islet dysfunction.	Cyclosporine	91-103	mechanistic target of rapamycin kinase	Rattus norvegicus	42-46
22170067-0	2012	Mechanisms of rapid induction of interleukin-22 in activated T cells and its modulation by cyclosporin a.	Cyclosporine	91-104	interleukin 22	Homo sapiens	33-47
22170067-5	2012	We report that IL-22 induction by TPA/A23187 (T/A) or alphaCD3 is inhibited by CsA or related FK506.	Cyclosporine	79-82	interleukin 22	Homo sapiens	15-20
22170067-13	2012	In particular the crucial role of NF-AT detected herein may form the basis of direct action of CsA on IL-22 expression by T cells, which may contribute to therapeutic efficacy of the drug in autoimmunity.	Cyclosporine	95-98	interleukin 22	Homo sapiens	102-107
21876558-3	2012	The K-RAS protein is associated with mitochondria, and induces a rapid suppression of respiratory chain complex-I and a decrease in mitochondrial transmembrane potential by affecting the cyclosporin-sensitive permeability transition pore.	Cyclosporine	187-198	KRAS proto-oncogene, GTPase	Homo sapiens	4-9
22236010-7	2012	Senescent cells and CD4(+) /IL-17A(+) cells were increased among graft biopsies in subjects receiving cyclosporin A (CsA) compared to those under belatacept treatment.	Cyclosporine	102-115	interleukin 17A	Homo sapiens	28-34
22236010-7	2012	Senescent cells and CD4(+) /IL-17A(+) cells were increased among graft biopsies in subjects receiving cyclosporin A (CsA) compared to those under belatacept treatment.	Cyclosporine	117-120	interleukin 17A	Homo sapiens	28-34
22236010-8	2012	Meanwhile, CD16(+) /IDO(+) and FoxP3(+) -expressing cells were lower in biopsies from CsA treatment compared to patients treated with Belatacept.	Cyclosporine	86-89	Fc gamma receptor IIIa	Homo sapiens	11-15
21246373-1	2012	The IGF-IR density on CD4+T-lymphocytes was studied using flow cytometry in 40 early steroid- and DMARD-naive rheumatoid arthritis (RA) patients before and after 52 weeks of treatment with methotrexate+placebo or methotrexate+cyclosporine A and in 15 controls.	Cyclosporine	226-240	insulin like growth factor 1 receptor	Homo sapiens	4-10
22151386-2	2012	Cyclosporin A, a calcineurin inhibitor, is used as a standard immunosuppressant and clearly increases the skin cancer risk.	Cyclosporine	0-13	calcineurin binding protein 1	Homo sapiens	17-38
22062948-7	2012	Expression of the exchange factor GEF-H1/lfc was elevated in cells treated with CsA and CsA/SRL.	Cyclosporine	80-83	Rho/Rac guanine nucleotide exchange factor 2	Homo sapiens	34-40
22062948-7	2012	Expression of the exchange factor GEF-H1/lfc was elevated in cells treated with CsA and CsA/SRL.	Cyclosporine	88-91	Rho/Rac guanine nucleotide exchange factor 2	Homo sapiens	34-40
22062948-8	2012	GEF-H1 silencing inhibited RhoA activation by  50%, and potently reduced cofilin phosphorylation and stress fiber formation induced by CsA and CsA/SRL.	Cyclosporine	135-138	Rho/Rac guanine nucleotide exchange factor 2	Homo sapiens	0-6
22974789-11	2012	CONCLUSIONS: Our data indicate that small molecules immunosuppressants, especially CsA, inhibit Pgp activity and T-cell function being the CD8+ T cells more susceptible to this effect.	Cyclosporine	83-86	CD8a molecule	Homo sapiens	139-142
23428559-0	2012	Cyclosporine-induced tubular vacuolization: the role of Bip/Grp78.	Cyclosporine	0-12	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	56-59
23428559-0	2012	Cyclosporine-induced tubular vacuolization: the role of Bip/Grp78.	Cyclosporine	0-12	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	60-65
22848341-0	2012	CXCL12/CXCR4 axis triggers the activation of EGF receptor and ERK signaling pathway in CsA-induced proliferation of human trophoblast cells.	Cyclosporine	87-90	C-X-C motif chemokine receptor 4	Homo sapiens	7-12
22848341-7	2012	The inhibition of CXCL12 or CXCR4 by either neutralizing antibodies or small interfering RNA (siRNA) could completely block the CsA-induced EGFR phosphorylation.	Cyclosporine	128-131	C-X-C motif chemokine receptor 4	Homo sapiens	28-33
22848341-9	2012	CsA promoted the activation of ERK in JEG-3 cells, which was markedly abrogated in the presence of CXCL12 siRNA, or CXCR4 siRNA, or AG1478.	Cyclosporine	0-3	C-X-C motif chemokine receptor 4	Homo sapiens	116-121
22848341-10	2012	CONCLUSIONS: CsA may promote EGFR activation via CXCL12/CXCR4 axis, and EGFR downstream ERK signaling pathway may be involved in the CsA-induced proliferation of human trophoblast cells.	Cyclosporine	13-16	C-X-C motif chemokine receptor 4	Homo sapiens	56-61
22312704-1	2011	In this study, we sought to determine whether the calcium-sensing receptor (CaSR) is involved in Cyclosporin A (CsA)-induced cardiomyocyte apoptosis and identify its signal transduction pathway.	Cyclosporine	97-110	calcium-sensing receptor	Rattus norvegicus	76-80
22312704-1	2011	In this study, we sought to determine whether the calcium-sensing receptor (CaSR) is involved in Cyclosporin A (CsA)-induced cardiomyocyte apoptosis and identify its signal transduction pathway.	Cyclosporine	112-115	calcium-sensing receptor	Rattus norvegicus	76-80
22312704-10	2011	CsA increased the expression of CaSR mRNA and protein and enhanced cardiomyocyte apoptosis.	Cyclosporine	0-3	calcium-sensing receptor	Rattus norvegicus	32-36
22312704-13	2011	We determined for the first time that CaSR is involved in CsA-induced cardiomyocyte apoptosis in the rat through the activation of downstream cytochrome c-caspase-3 pathways.	Cyclosporine	58-61	calcium-sensing receptor	Rattus norvegicus	38-42
22008303-9	2011	Significantly increased TRAP-5b serum level was noted in the CsA group when compared with the control group.	Cyclosporine	61-64	acid phosphatase 5, tartrate resistant	Rattus norvegicus	24-28
21782974-6	2011	Conditioned media from GPx1(+/-) SMCs caused increased NF-kappaB activation of quiescent WT SMCs, and this was inhibited by the antioxidant N-acetyl-l-cysteine or by cyclosporine A (CsA).	Cyclosporine	166-180	glutathione peroxidase 1	Homo sapiens	23-27
21782974-6	2011	Conditioned media from GPx1(+/-) SMCs caused increased NF-kappaB activation of quiescent WT SMCs, and this was inhibited by the antioxidant N-acetyl-l-cysteine or by cyclosporine A (CsA).	Cyclosporine	182-185	glutathione peroxidase 1	Homo sapiens	23-27
21782974-7	2011	In co-culture experiments, SMCs derived from GPx1(+/-) aorta caused increased proliferation of WT SMCs, which was also inhibited by CsA.	Cyclosporine	132-135	glutathione peroxidase 1	Homo sapiens	45-49
22339914-8	2011	The third month CsA concentrations was the most important for the response and maintaining CsA levels with C(0) &gt;= 200 microg/L and C(2) &gt;= 700 microg/L may improve the response to IST in SAA/VSAA.	Cyclosporine	16-19	serum amyloid A1 cluster	Homo sapiens	194-197
21816902-8	2011	The central role of calcineurin in mediating V1aR-dependent myogenesis was also demonstrated by using its specific inhibitor, cyclosporine A.	Cyclosporine	126-140	arginine vasopressin receptor 1A	Mus musculus	45-49
21871105-11	2011	Likewise, inhibition of CypA peptidyl-prolyl cis-trans isomerase (PPIase) activity using cyclosporin A (CsA) decreased cell proliferation.	Cyclosporine	89-102	peptidylprolyl isomerase A	Mus musculus	24-28
21871105-11	2011	Likewise, inhibition of CypA peptidyl-prolyl cis-trans isomerase (PPIase) activity using cyclosporin A (CsA) decreased cell proliferation.	Cyclosporine	104-107	peptidylprolyl isomerase A	Mus musculus	24-28
21646357-5	2011	Cell surface expression of G50C and G50A was rescued upon MG132 treatment as well as cyclosporine A, but not by FK506 or bile acids, suggesting that Gly(50) is involved in hASBT folding.	Cyclosporine	85-99	solute carrier family 10 member 2	Homo sapiens	172-177
21514407-7	2011	Cyclosporin A and FK506, inhibitors of calcineurin phosphatase, blocked high [Ca(2+)](o)-induced expression of NFAT and RANKL.	Cyclosporine	0-13	TNF superfamily member 11	Homo sapiens	120-125
21781066-0	2011	CD26/dipeptidyl-peptidase IV and adenosine deaminase serum levels in psoriatic patients treated with cyclosporine, etanercept, and psoralen plus ultraviolet A phototherapy.	Cyclosporine	101-113	adenosine deaminase	Homo sapiens	33-52
21558877-0	2011	PPARgamma dependence of cyclosporine-isoprenaline renovascular interaction: roles of nitric oxide synthase and heme oxygenase.	Cyclosporine	24-36	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	0-9
21558877-6	2011	Also, supplementation with the PPARgamma agonist pioglitazone or with l-arginine or hemin, substrates for NOS and HO, respectively, eliminated the unfavorable effect of CSA on isoprenaline vasodilations.	Cyclosporine	169-172	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	31-40
21558877-8	2011	In conclusion, the activation of the HO/CO/PPARgamma cascade is probably the cellular mechanism that underlies the beneficial effect of pioglitazone on the CSA-isoprenaline interaction.	Cyclosporine	156-159	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	43-52
21677130-0	2011	Cyclosporine-resistant, Rab27a-independent mobilization of intracellular preformed CD40 ligand mediates antigen-specific T cell help in vitro.	Cyclosporine	0-12	RAB27A, member RAS oncogene family	Homo sapiens	24-30
21447388-8	2011	Ischemia for 30min activated calcineurin, and pre-treatment with a calcineurin inhibitor, cyclosporine A (CsA), inhibited PKC-alpha translocation, I-1 phosphorylation at Ser(67), and PLB dephosphorylation in ischemia.	Cyclosporine	90-104	protein kinase C, alpha	Rattus norvegicus	122-131
21447388-8	2011	Ischemia for 30min activated calcineurin, and pre-treatment with a calcineurin inhibitor, cyclosporine A (CsA), inhibited PKC-alpha translocation, I-1 phosphorylation at Ser(67), and PLB dephosphorylation in ischemia.	Cyclosporine	90-104	protein phosphatase 1, regulatory (inhibitor) subunit 1A	Rattus norvegicus	147-150
21447388-8	2011	Ischemia for 30min activated calcineurin, and pre-treatment with a calcineurin inhibitor, cyclosporine A (CsA), inhibited PKC-alpha translocation, I-1 phosphorylation at Ser(67), and PLB dephosphorylation in ischemia.	Cyclosporine	106-109	protein kinase C, alpha	Rattus norvegicus	122-131
21447388-8	2011	Ischemia for 30min activated calcineurin, and pre-treatment with a calcineurin inhibitor, cyclosporine A (CsA), inhibited PKC-alpha translocation, I-1 phosphorylation at Ser(67), and PLB dephosphorylation in ischemia.	Cyclosporine	106-109	protein phosphatase 1, regulatory (inhibitor) subunit 1A	Rattus norvegicus	147-150
20633034-1	2011	INTRODUCTION: Although cyclosporine A (CSA) is considered to be an efficient immunosuppressive compound in transplantation, vascular side effects like arterial hypertension, neurologic complications and other adverse reactions occur.	Cyclosporine	23-37	chorionic somatomammotropin hormone 1	Homo sapiens	39-42
21606250-2	2011	In this study, we report that the cold-shock protein Y-box binding protein-1 (YB-1) is a TGF-beta independent downstream effector in CsA- as well as in tacrolimus- but not in rapamycin-mediated activation of rat mesangial cells (rMCs).	Cyclosporine	133-136	Y box binding protein 1	Rattus norvegicus	53-76
21606250-2	2011	In this study, we report that the cold-shock protein Y-box binding protein-1 (YB-1) is a TGF-beta independent downstream effector in CsA- as well as in tacrolimus- but not in rapamycin-mediated activation of rat mesangial cells (rMCs).	Cyclosporine	133-136	Y box binding protein 1	Rattus norvegicus	78-82
21606250-9	2011	CsA-induced YB-1 accumulation results in mRNA stabilization and subsequent generation of collagen.	Cyclosporine	0-3	Y box binding protein 1	Rattus norvegicus	12-16
21738288-1	2011	The observation that cyclosporine inhibits HCV replication in vitro has led some programs to use cyclosporine as the calcineurin inhibitor (CNI) of choice after orthotopic liver transplantation (OLT).	Cyclosporine	21-33	calcineurin binding protein 1	Homo sapiens	117-138
21738288-1	2011	The observation that cyclosporine inhibits HCV replication in vitro has led some programs to use cyclosporine as the calcineurin inhibitor (CNI) of choice after orthotopic liver transplantation (OLT).	Cyclosporine	97-109	calcineurin binding protein 1	Homo sapiens	117-138
21693287-1	2011	The calcineurin inhibitor cyclosporine (CSA) displays nephrotoxic side effects.	Cyclosporine	26-38	calcineurin binding protein 1	Homo sapiens	4-25
21693311-4	2011	RESULTS: HO-1 expression in both the kidney transplantation model group and the hemin-induced groups were higher compared with the CsA group (P &lt; .05-.01).	Cyclosporine	131-134	heme oxygenase 1	Rattus norvegicus	9-13
21292993-7	2011	This study demonstrates that, during the 21 days of immunosuppressive therapy, functional mechanisms are in place that result in increased homing of CD4(+) T effector cells to colons of CsA-treated mice.	Cyclosporine	186-189	CD4 antigen	Mus musculus	149-152
21396746-2	2011	After testing these three synthetic peptides, we found that the peptide Trp-Gly-Pro (WGP) showed comparable inhibitory ability as positive control cyclosporine A (CsA) on CypA-mediated PPIase activity with IC50 values of 33.11 nM and 10.25 nM, respectively.	Cyclosporine	163-166	peptidylprolyl isomerase like 1	Homo sapiens	185-191
21566860-0	2011	[Expression of TGF-beta1 and PCNA in cyclosporin A-induced gingival overgrowth].	Cyclosporine	37-50	proliferating cell nuclear antigen	Rattus norvegicus	29-33
21566860-1	2011	PURPOSE: To investigate the expression of transforming growth factor-beta1(TGF-beta1) and proliferating cell nuclear of antigen (PCNA) in cyclosporin A(CsA)-induced gingival overgrowth (GO) tissues.	Cyclosporine	138-151	proliferating cell nuclear antigen	Rattus norvegicus	129-133
21566860-1	2011	PURPOSE: To investigate the expression of transforming growth factor-beta1(TGF-beta1) and proliferating cell nuclear of antigen (PCNA) in cyclosporin A(CsA)-induced gingival overgrowth (GO) tissues.	Cyclosporine	152-155	proliferating cell nuclear antigen	Rattus norvegicus	129-133
21307294-4	2011	These in vivo results in the MVC/CsA group correlated with delayed alloantibody response and markedly decreased graft infiltration by CCR5(+), CD4(+), CD8(+), and CD68(+) cells (p &lt; 0.05), as compared with other groups.	Cyclosporine	33-36	C-C motif chemokine receptor 5	Homo sapiens	134-138
21307294-4	2011	These in vivo results in the MVC/CsA group correlated with delayed alloantibody response and markedly decreased graft infiltration by CCR5(+), CD4(+), CD8(+), and CD68(+) cells (p &lt; 0.05), as compared with other groups.	Cyclosporine	33-36	CD68 molecule	Homo sapiens	163-167
20813770-11	2011	CONCLUSIONS: Angiotensin II may play a pivotal role in regulating Klotho expression in CsA-induced renal injury.	Cyclosporine	87-90	klotho	Mus musculus	66-72
21148296-7	2011	In addition, pretreatment with CsA blocked NaBT-mediated induction of intestinal alkaline phosphatase (IAP) activity and villin and p27(kip1) expression; knockdown of either NFATc1 or NFATc4 attenuated NaBT-induced IAP activity.	Cyclosporine	31-34	nuclear factor of activated T cells 1	Homo sapiens	174-180
21148038-6	2011	After terminating TCR stimulation or adding cyclosporin A to the culture, Ccr9 gene transcription was induced, accompanied by inactivation of NFATc1 and sustained activation of NFATc2.	Cyclosporine	44-57	chemokine (C-C motif) receptor 9	Mus musculus	74-78
21691056-6	2011	CsA and tacrolimus reduced mRNA abundance in TRPV5 (CsA: 64 +- 3% of control; tacrolimus: 50 +- 3%) calbindin-D28k (CsA: 62 +- 4%; tacrolimus: 43 +- 3%), and vitamin D receptor (CsA: 52 +- 3%; tacrolimus: 58 +- 2%, all p &lt; 0.05).	Cyclosporine	0-3	vitamin D receptor	Homo sapiens	158-176
21191769-6	2010	However, cyclosporine A (5 mg/kg, an inhibitor of Mrp2) significantly decreased the AUC and biliary clearance of PSP.	Cyclosporine	9-23	ATP binding cassette subfamily C member 2	Rattus norvegicus	50-54
20553921-0	2010	Cyclosporin A induces hyperpermeability of the blood-brain barrier by inhibiting autocrine adrenomedullin-mediated up-regulation of endothelial barrier function.	Cyclosporine	0-13	adrenomedullin	Homo sapiens	91-105
20553921-4	2010	Here, we show that in rodent brain endothelial cells, cyclosporin A decreased transendothelial electrical resistance (TEER) by inhibiting intracellular signal transduction downstream of adrenomedullin, an autocrine regulator of BBB function.	Cyclosporine	54-67	adrenomedullin	Homo sapiens	186-200
20553921-5	2010	Cyclosporin A stimulated adrenomedullin release from brain endothelial cells, but did not affect binding of adrenomedullin to its receptors.	Cyclosporine	0-13	adrenomedullin	Homo sapiens	25-39
20553921-6	2010	This cyclosporin A-induced decrease in TEER was attenuated by exogenous addition of adrenomedullin.	Cyclosporine	5-18	adrenomedullin	Homo sapiens	84-98
20553921-9	2010	Thus, these data suggest that cyclosporin A inhibits the adenylyl cyclase/cyclic AMP/PKA signaling pathway activated by adrenomedullin, leading to impairment of brain endothelial barrier function.	Cyclosporine	30-43	adrenomedullin	Homo sapiens	120-134
20726688-5	2010	Amongst the last is the calcineurin inhibitor (CNI) (cyclosporine A (CsA) and tacrolimus)-related nephrotoxicity.	Cyclosporine	53-67	calcineurin binding protein 1	Homo sapiens	24-45
21129263-0	2010	[Impact of cyclosporine A on the expression of T-bet, GATA-3, relevant signal transduction molecules, cytokine and Th1/Th2 balance in patients with chronic aplastic anemia].	Cyclosporine	11-25	GATA binding protein 3	Homo sapiens	54-60
21129263-0	2010	[Impact of cyclosporine A on the expression of T-bet, GATA-3, relevant signal transduction molecules, cytokine and Th1/Th2 balance in patients with chronic aplastic anemia].	Cyclosporine	11-25	negative elongation factor complex member C/D	Homo sapiens	115-118
21129263-5	2010	After treating with CsA for 6 months of CsA treatment, expression of T-bet, STAT4, T-bet/GATA-3 ratio, Th1 proportion, IFN-gamma and IL-12 levels were lower than before, however, the expression of T-bet, STAT4, T-bet/GATA-3 ratio, Th1 proportion and IFN-gamma had not been reduced to normal state.	Cyclosporine	20-23	signal transducer and activator of transcription 4	Homo sapiens	76-81
21129263-5	2010	After treating with CsA for 6 months of CsA treatment, expression of T-bet, STAT4, T-bet/GATA-3 ratio, Th1 proportion, IFN-gamma and IL-12 levels were lower than before, however, the expression of T-bet, STAT4, T-bet/GATA-3 ratio, Th1 proportion and IFN-gamma had not been reduced to normal state.	Cyclosporine	20-23	GATA binding protein 3	Homo sapiens	89-95
21129263-5	2010	After treating with CsA for 6 months of CsA treatment, expression of T-bet, STAT4, T-bet/GATA-3 ratio, Th1 proportion, IFN-gamma and IL-12 levels were lower than before, however, the expression of T-bet, STAT4, T-bet/GATA-3 ratio, Th1 proportion and IFN-gamma had not been reduced to normal state.	Cyclosporine	20-23	negative elongation factor complex member C/D	Homo sapiens	103-106
21129263-5	2010	After treating with CsA for 6 months of CsA treatment, expression of T-bet, STAT4, T-bet/GATA-3 ratio, Th1 proportion, IFN-gamma and IL-12 levels were lower than before, however, the expression of T-bet, STAT4, T-bet/GATA-3 ratio, Th1 proportion and IFN-gamma had not been reduced to normal state.	Cyclosporine	20-23	signal transducer and activator of transcription 4	Homo sapiens	204-209
21129263-5	2010	After treating with CsA for 6 months of CsA treatment, expression of T-bet, STAT4, T-bet/GATA-3 ratio, Th1 proportion, IFN-gamma and IL-12 levels were lower than before, however, the expression of T-bet, STAT4, T-bet/GATA-3 ratio, Th1 proportion and IFN-gamma had not been reduced to normal state.	Cyclosporine	20-23	GATA binding protein 3	Homo sapiens	217-223
21129263-5	2010	After treating with CsA for 6 months of CsA treatment, expression of T-bet, STAT4, T-bet/GATA-3 ratio, Th1 proportion, IFN-gamma and IL-12 levels were lower than before, however, the expression of T-bet, STAT4, T-bet/GATA-3 ratio, Th1 proportion and IFN-gamma had not been reduced to normal state.	Cyclosporine	20-23	negative elongation factor complex member C/D	Homo sapiens	231-234
20927389-0	2010	Cyclosporine A-sensitive, cyclophilin B-dependent endoplasmic reticulum-associated degradation.	Cyclosporine	0-14	peptidylprolyl isomerase B	Homo sapiens	26-39
20927389-5	2010	We identify cyclophilin B (CyPB) as the ER-resident target of CsA that catalytically enhances disposal from the ER of ERAD-L(S) substrates containing cis proline residues.	Cyclosporine	62-65	peptidylprolyl isomerase B	Homo sapiens	12-25
20927389-5	2010	We identify cyclophilin B (CyPB) as the ER-resident target of CsA that catalytically enhances disposal from the ER of ERAD-L(S) substrates containing cis proline residues.	Cyclosporine	62-65	peptidylprolyl isomerase B	Homo sapiens	27-31
20634434-1	2010	The murine model of cyclosporine A (CsA)-induced syngeneic graft-versus-host disease (SGVHD) is a bone marrow (BM) transplantation model that develops chronic colon inflammation identical to other murine models of CD4(+) T cell-mediated colitis.	Cyclosporine	20-34	CD4 antigen	Mus musculus	214-217
20634434-1	2010	The murine model of cyclosporine A (CsA)-induced syngeneic graft-versus-host disease (SGVHD) is a bone marrow (BM) transplantation model that develops chronic colon inflammation identical to other murine models of CD4(+) T cell-mediated colitis.	Cyclosporine	36-39	CD4 antigen	Mus musculus	214-217
21179729-9	2010	SXM and CsA could lower the aforesaid abnormal activation and correct Th1 hyper-polarization, so as to alleviate the over-activated cell-mediated immunity to eliminate hematopoietic depression in CAA patients.	Cyclosporine	8-11	negative elongation factor complex member C/D	Homo sapiens	70-73
20505521-8	2010	Pioglitazone (PPAR gamma agonist, 10 microM) abolished the CSA-induced attenuation of carbachol responses, an effect that was not manifest in presence of GW9662 or l-NAME.	Cyclosporine	59-62	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	14-24
20505521-10	2010	More importantly, NOS signaling downstream of PPAR gamma mediates, at least partly, the inhibitory effect of CSA on carbachol vasodilations.	Cyclosporine	109-112	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	46-56
20221751-12	2010	However, using the SAPS 3 for CSA resulted in more precise estimations of the probability of death [SMR = 1.02 (95% confidence interval = 0.87-1.19)].	Cyclosporine	30-33	protein phosphatase 6 regulatory subunit 3	Homo sapiens	19-25
20361354-0	2010	Chronic administration of cyclosporine A changes expression of BDNF and TrkB in rat hippocampus and midbrain.	Cyclosporine	26-40	brain-derived neurotrophic factor	Rattus norvegicus	63-67
20565459-5	2010	When patients were divided according to the immunosuppressive co-treatment, a significant effect of UGT1A8 2 was found in those co-treated with CsA (HR = 2.414; 95%CI (1.089, 5.354); P = 0.0301) but not TAC or SIR (P = 0.4331).	Cyclosporine	144-147	UDP glucuronosyltransferase family 1 member A8	Homo sapiens	100-106
20460505-5	2010	Pretreatment with topical cyclosporin A (CsA), verapamil, or XR9576, modulators of P-glycoprotein (P-gp), prevented Ing3A-induced hemorrhage but not neutrophil infiltration.	Cyclosporine	26-39	phosphoglycolate phosphatase	Mus musculus	83-97
20460505-5	2010	Pretreatment with topical cyclosporin A (CsA), verapamil, or XR9576, modulators of P-glycoprotein (P-gp), prevented Ing3A-induced hemorrhage but not neutrophil infiltration.	Cyclosporine	26-39	phosphoglycolate phosphatase	Mus musculus	99-103
20460505-5	2010	Pretreatment with topical cyclosporin A (CsA), verapamil, or XR9576, modulators of P-glycoprotein (P-gp), prevented Ing3A-induced hemorrhage but not neutrophil infiltration.	Cyclosporine	41-44	phosphoglycolate phosphatase	Mus musculus	83-97
20460505-5	2010	Pretreatment with topical cyclosporin A (CsA), verapamil, or XR9576, modulators of P-glycoprotein (P-gp), prevented Ing3A-induced hemorrhage but not neutrophil infiltration.	Cyclosporine	41-44	phosphoglycolate phosphatase	Mus musculus	99-103
19909402-0	2010	The upregulation of heat shock protein 47 in human gingival fibroblasts stimulated with cyclosporine A.	Cyclosporine	88-102	serpin family H member 1	Homo sapiens	20-41
19909402-3	2010	The aim of this study was to compare Hsp47 expression in normal gingival tissues and cyclosporine A-induced gingival overgrowth specimens and further explore the potential mechanisms that may lead to induction of Hsp47 expression.	Cyclosporine	85-99	serpin family H member 1	Homo sapiens	37-42
19909402-5	2010	Western blot was used to investigate the effects of cyclosporine A on the expression of Hsp47 in human gingival fibroblasts.	Cyclosporine	52-66	serpin family H member 1	Homo sapiens	88-93
19909402-7	2010	RESULTS: A significantly higher percentage of cells positively stained for Hsp47 was noted in the cyclosporine A-induced gingival overgrowth group than in the normal gingival group (p &lt; 0.05).	Cyclosporine	98-112	serpin family H member 1	Homo sapiens	75-80
19909402-9	2010	Expression of Hsp47 was significantly higher in cyclosporine A-induced gingival overgrowth specimens with higher levels of inflammatory infiltrates (p &lt; 0.05).	Cyclosporine	48-62	serpin family H member 1	Homo sapiens	14-19
19909402-10	2010	Cyclosporine A upregulated Hsp47 expression in human gingival fibroblasts in a dose-dependent manner (p &lt; 0.05).	Cyclosporine	0-14	serpin family H member 1	Homo sapiens	27-32
19909402-11	2010	The addition of A. actinomycetemcomitans or interleukin-1 alpha significantly increased Hsp47 expression compared with cyclosporine A alone (p &lt; 0.05).	Cyclosporine	119-133	serpin family H member 1	Homo sapiens	88-93
19909402-12	2010	The MEK inhibitor U0126 was found to inhibit cyclosporine A-induced Hsp47 expression (p &lt; 0.05).	Cyclosporine	45-59	serpin family H member 1	Homo sapiens	68-73
19909402-13	2010	CONCLUSION: Expression of Hsp47 is significantly upregulated in cyclosporine A-induced gingival overgrowth specimens, and Hsp47 expression induced by cyclosporine A in fibroblasts may be mediated by the MEK signal transduction pathway.	Cyclosporine	64-78	serpin family H member 1	Homo sapiens	26-31
19909402-13	2010	CONCLUSION: Expression of Hsp47 is significantly upregulated in cyclosporine A-induced gingival overgrowth specimens, and Hsp47 expression induced by cyclosporine A in fibroblasts may be mediated by the MEK signal transduction pathway.	Cyclosporine	150-164	serpin family H member 1	Homo sapiens	26-31
19909402-13	2010	CONCLUSION: Expression of Hsp47 is significantly upregulated in cyclosporine A-induced gingival overgrowth specimens, and Hsp47 expression induced by cyclosporine A in fibroblasts may be mediated by the MEK signal transduction pathway.	Cyclosporine	150-164	serpin family H member 1	Homo sapiens	122-127
19878094-8	2010	High cyclosporine levels were only found to be associated with lower estimated GFR (p &lt; 0.009).	Cyclosporine	5-17	Rap guanine nucleotide exchange factor 5	Homo sapiens	79-82
20620516-6	2010	Conversely, the percentage of CD4(+)Foxp3(+) Tregs in the liver graft and blood decreased in the cyclosporine group.	Cyclosporine	97-109	Cd4 molecule	Rattus norvegicus	30-33
20620545-7	2010	The CsA+ATRA group showed a marked reduction in PCNA- and CD68-positive cells: namely, 33.96 +/- 8.65% versus 60.17 +/- 17.74% (P &lt; .01) and 17.63 +/- 4.24% versus 32.13 +/- 9.26 (P &lt; .01), respectively.	Cyclosporine	4-7	proliferating cell nuclear antigen	Rattus norvegicus	48-52
20416375-9	2010	CONCLUSION: PXR activation is anti-inflammatory in the liver and the effects of cyclosporin A in PBC disease recurrence may be mediated in part via the PXR.	Cyclosporine	80-93	nuclear receptor subfamily 1, group I, member 2	Mus musculus	152-155
20508866-11	2010	In vitro, CsA significantly inhibited the production of IL-17 and IFN-gamma by PBMCs activated with anti-CD3 and anti-CD28 antibodies or phorbol 12-myristate,13-acetate and ionomycin in BD patients with active uveitis.	Cyclosporine	10-13	interleukin 17A	Homo sapiens	56-61
20508866-13	2010	CONCLUSIONS: Our findings showed that CsA can significantly inhibit the intraocular inflammation of BD patients and the expression of IL-17 and IFN-gamma in vivo and in vitro.	Cyclosporine	38-41	interleukin 17A	Homo sapiens	134-139
20508866-14	2010	The results suggested that the inhibitory effect of CsA on uveitis in BD patients may be partially mediated through inhibiting the production of IL-17 and IFN-gamma.	Cyclosporine	52-55	interleukin 17A	Homo sapiens	145-150
20207814-8	2010	Cyclosporine A, a CaN inhibitor, markedly suppressed MEF2c nuclear translocation and inhibited TG-induced hypertrophy.	Cyclosporine	0-14	myocyte enhancer factor 2C	Rattus norvegicus	53-58
20447559-6	2010	RESULTS: Modulation of P-gp with CsA (50 mg/kg) as well as mdr1a gene depletion resulted in significant increase in cerebral uptake of [(123)I]-FMIP with only minor effect on blood activity.	Cyclosporine	33-36	phosphoglycolate phosphatase	Mus musculus	23-27
20072790-0	2010	Neutrophil gelatinase-associated lipocalin (NGAL): a new  marker of cyclosporine nephrotoxicity?	Cyclosporine	68-80	lipocalin 2	Homo sapiens	0-42
20072790-0	2010	Neutrophil gelatinase-associated lipocalin (NGAL): a new  marker of cyclosporine nephrotoxicity?	Cyclosporine	68-80	lipocalin 2	Homo sapiens	44-48
20072790-1	2010	The aim of work was to investigate whether serum and urinary neutrophil gelatinase-associated lipocalin(sNGAL and uNGAL, respectively) are potential biomarkers of early cyclosporine A (CsA) nephrotoxicity in steroid-dependent nephrotic children (SDNS).	Cyclosporine	169-183	lipocalin 2	Homo sapiens	61-103
20072790-1	2010	The aim of work was to investigate whether serum and urinary neutrophil gelatinase-associated lipocalin(sNGAL and uNGAL, respectively) are potential biomarkers of early cyclosporine A (CsA) nephrotoxicity in steroid-dependent nephrotic children (SDNS).	Cyclosporine	185-188	lipocalin 2	Homo sapiens	61-103
20230790-4	2010	In vitro, the P-gp antagonist PSC833, a non-calcineurin-inhibitory cyclosporine A analogue, specifically inhibited cellular efflux of the P-gp substrate rhodamine-123 in wild-type CD3(+) T cells and MHC class II(+) APCs but not their P-gp knockout counterparts that lacked rhodamine-123 efflux capacity.	Cyclosporine	67-81	phosphoglycolate phosphatase	Mus musculus	14-18
20230790-4	2010	In vitro, the P-gp antagonist PSC833, a non-calcineurin-inhibitory cyclosporine A analogue, specifically inhibited cellular efflux of the P-gp substrate rhodamine-123 in wild-type CD3(+) T cells and MHC class II(+) APCs but not their P-gp knockout counterparts that lacked rhodamine-123 efflux capacity.	Cyclosporine	67-81	phosphoglycolate phosphatase	Mus musculus	138-142
20230790-4	2010	In vitro, the P-gp antagonist PSC833, a non-calcineurin-inhibitory cyclosporine A analogue, specifically inhibited cellular efflux of the P-gp substrate rhodamine-123 in wild-type CD3(+) T cells and MHC class II(+) APCs but not their P-gp knockout counterparts that lacked rhodamine-123 efflux capacity.	Cyclosporine	67-81	phosphoglycolate phosphatase	Mus musculus	138-142
20368803-0	2010	The crystal structure of PPIL1 bound to cyclosporine A suggests a binding mode for a linear epitope of the SKIP protein.	Cyclosporine	40-54	peptidylprolyl isomerase like 1	Homo sapiens	25-30
20368803-6	2010	The crystal structure of PPIL1 in complex with the inhibitor cyclosporine A (CsA) was obtained at a resolution of 1.15 A and exhibited two bound Cd(2+) ions that enabled SAD phasing.	Cyclosporine	61-75	peptidylprolyl isomerase like 1	Homo sapiens	25-30
20368803-6	2010	The crystal structure of PPIL1 in complex with the inhibitor cyclosporine A (CsA) was obtained at a resolution of 1.15 A and exhibited two bound Cd(2+) ions that enabled SAD phasing.	Cyclosporine	77-80	peptidylprolyl isomerase like 1	Homo sapiens	25-30
20060322-6	2010	RESULTS: Compared with recipients treated with control Ab plus PBS, allografts treated with anti-CCR5 Ab and cyclosporine showed significantly prolonged survival (p &lt; 0.001), markedly decreased CD4+ and CD8+ T cells (p &lt; 0.005), and increased frequency of CD4+CD25+Foxp3+ regulatory cells (23.98% +/- 1.55% vs 6.30% +/- 0.57%, p &lt; 0.005).	Cyclosporine	109-121	CD4 antigen	Mus musculus	197-200
20060322-6	2010	RESULTS: Compared with recipients treated with control Ab plus PBS, allografts treated with anti-CCR5 Ab and cyclosporine showed significantly prolonged survival (p &lt; 0.001), markedly decreased CD4+ and CD8+ T cells (p &lt; 0.005), and increased frequency of CD4+CD25+Foxp3+ regulatory cells (23.98% +/- 1.55% vs 6.30% +/- 0.57%, p &lt; 0.005).	Cyclosporine	109-121	CD4 antigen	Mus musculus	262-265
20060322-6	2010	RESULTS: Compared with recipients treated with control Ab plus PBS, allografts treated with anti-CCR5 Ab and cyclosporine showed significantly prolonged survival (p &lt; 0.001), markedly decreased CD4+ and CD8+ T cells (p &lt; 0.005), and increased frequency of CD4+CD25+Foxp3+ regulatory cells (23.98% +/- 1.55% vs 6.30% +/- 0.57%, p &lt; 0.005).	Cyclosporine	109-121	interleukin 2 receptor, alpha chain	Mus musculus	266-270
20060322-7	2010	Adoptive transfer of CD4+CD25+ splenocytes from anti-CCR5 Ab plus cyclosporine-treated recipients induced significantly prolonged survival in secondary recipients (p &lt; 0.01 vs adoptive transfer from naive mice and recipients depleted of CD25+ cells).	Cyclosporine	66-78	interleukin 2 receptor, alpha chain	Mus musculus	25-29
20060322-7	2010	Adoptive transfer of CD4+CD25+ splenocytes from anti-CCR5 Ab plus cyclosporine-treated recipients induced significantly prolonged survival in secondary recipients (p &lt; 0.01 vs adoptive transfer from naive mice and recipients depleted of CD25+ cells).	Cyclosporine	66-78	interleukin 2 receptor, alpha chain	Mus musculus	240-244
20089806-6	2010	We show that the VSMC differentiation marker genes smooth muscle alpha-actin (ACTA2), transgelin (TAGLN), smoothelin (SMTN), and myocardin (MYOCD) are all down-regulated by CSA in VSMC monoculture, whereas cyclin-dependent kinase inhibitor-1A (CDKN1A) and matrix metalloproteinase-3 (MMP3) are up-regulated.	Cyclosporine	173-176	transgelin	Rattus norvegicus	86-96
20089806-6	2010	We show that the VSMC differentiation marker genes smooth muscle alpha-actin (ACTA2), transgelin (TAGLN), smoothelin (SMTN), and myocardin (MYOCD) are all down-regulated by CSA in VSMC monoculture, whereas cyclin-dependent kinase inhibitor-1A (CDKN1A) and matrix metalloproteinase-3 (MMP3) are up-regulated.	Cyclosporine	173-176	transgelin	Rattus norvegicus	98-103
20089806-6	2010	We show that the VSMC differentiation marker genes smooth muscle alpha-actin (ACTA2), transgelin (TAGLN), smoothelin (SMTN), and myocardin (MYOCD) are all down-regulated by CSA in VSMC monoculture, whereas cyclin-dependent kinase inhibitor-1A (CDKN1A) and matrix metalloproteinase-3 (MMP3) are up-regulated.	Cyclosporine	173-176	smoothelin	Rattus norvegicus	106-116
20089806-6	2010	We show that the VSMC differentiation marker genes smooth muscle alpha-actin (ACTA2), transgelin (TAGLN), smoothelin (SMTN), and myocardin (MYOCD) are all down-regulated by CSA in VSMC monoculture, whereas cyclin-dependent kinase inhibitor-1A (CDKN1A) and matrix metalloproteinase-3 (MMP3) are up-regulated.	Cyclosporine	173-176	smoothelin	Rattus norvegicus	118-122
20089806-6	2010	We show that the VSMC differentiation marker genes smooth muscle alpha-actin (ACTA2), transgelin (TAGLN), smoothelin (SMTN), and myocardin (MYOCD) are all down-regulated by CSA in VSMC monoculture, whereas cyclin-dependent kinase inhibitor-1A (CDKN1A) and matrix metalloproteinase-3 (MMP3) are up-regulated.	Cyclosporine	173-176	matrix metallopeptidase 3	Rattus norvegicus	256-282
20089806-6	2010	We show that the VSMC differentiation marker genes smooth muscle alpha-actin (ACTA2), transgelin (TAGLN), smoothelin (SMTN), and myocardin (MYOCD) are all down-regulated by CSA in VSMC monoculture, whereas cyclin-dependent kinase inhibitor-1A (CDKN1A) and matrix metalloproteinase-3 (MMP3) are up-regulated.	Cyclosporine	173-176	matrix metallopeptidase 3	Rattus norvegicus	284-288
20089806-8	2010	Administration of CSA to rat carotid artery in vivo resulted in acute and transient suppression of ACTA2, TAGLN, SMTN, MYOCD, and smooth muscle myosin heavy chain (MYH11) mRNA levels.	Cyclosporine	18-21	transgelin	Rattus norvegicus	106-111
20089806-8	2010	Administration of CSA to rat carotid artery in vivo resulted in acute and transient suppression of ACTA2, TAGLN, SMTN, MYOCD, and smooth muscle myosin heavy chain (MYH11) mRNA levels.	Cyclosporine	18-21	smoothelin	Rattus norvegicus	113-117
20204291-3	2010	Cyclophilin A (CypA), a target of immunosuppressive drugs cyclosporin A (CsA) and sanglifehrin A (SFA), is an intracellular protein that has peptidyl-prolyl cis-trans isomerase (PPIase) enzymatic activity.	Cyclosporine	58-71	peptidylprolyl isomerase like 1	Homo sapiens	141-176
20204291-3	2010	Cyclophilin A (CypA), a target of immunosuppressive drugs cyclosporin A (CsA) and sanglifehrin A (SFA), is an intracellular protein that has peptidyl-prolyl cis-trans isomerase (PPIase) enzymatic activity.	Cyclosporine	58-71	peptidylprolyl isomerase like 1	Homo sapiens	178-184
20204291-3	2010	Cyclophilin A (CypA), a target of immunosuppressive drugs cyclosporin A (CsA) and sanglifehrin A (SFA), is an intracellular protein that has peptidyl-prolyl cis-trans isomerase (PPIase) enzymatic activity.	Cyclosporine	73-76	peptidylprolyl isomerase like 1	Homo sapiens	141-176
20204291-3	2010	Cyclophilin A (CypA), a target of immunosuppressive drugs cyclosporin A (CsA) and sanglifehrin A (SFA), is an intracellular protein that has peptidyl-prolyl cis-trans isomerase (PPIase) enzymatic activity.	Cyclosporine	73-76	peptidylprolyl isomerase like 1	Homo sapiens	178-184
20204291-10	2010	In conclusion, CsA or SFA in combination with cisplatin synergistically enhances cisplatin-induced apoptosis in C6 glioma cells via inhibition of PPIase activity of CypA, indicating that development of new drugs that selectively inhibit the CypA PPIase activity without immune suppression may facilitate alleviation of chemoresistance in treatment of high-grade glioma.	Cyclosporine	15-18	peptidylprolyl isomerase like 1	Homo sapiens	146-152
20204291-10	2010	In conclusion, CsA or SFA in combination with cisplatin synergistically enhances cisplatin-induced apoptosis in C6 glioma cells via inhibition of PPIase activity of CypA, indicating that development of new drugs that selectively inhibit the CypA PPIase activity without immune suppression may facilitate alleviation of chemoresistance in treatment of high-grade glioma.	Cyclosporine	15-18	peptidylprolyl isomerase like 1	Homo sapiens	246-252
19955189-0	2010	Sirolimus and cyclosporine A alter barrier function in renal proximal tubular cells through stimulation of ERK1/2 signaling and claudin-1 expression.	Cyclosporine	14-28	claudin 1	Canis lupus familiaris	128-137
19955189-7	2010	CsA treatment increased total cellular expression and membrane localization of the tight junction protein claudin-1 and this further increased with the combination of SRL/CsA.	Cyclosporine	0-3	claudin 1	Canis lupus familiaris	106-115
19955189-7	2010	CsA treatment increased total cellular expression and membrane localization of the tight junction protein claudin-1 and this further increased with the combination of SRL/CsA.	Cyclosporine	171-174	claudin 1	Canis lupus familiaris	106-115
19955189-10	2010	U0126 also reduced the CsA and CsA/SRL-induced increase in the membrane localization of claudin-1.	Cyclosporine	23-26	claudin 1	Canis lupus familiaris	88-97
19955189-10	2010	U0126 also reduced the CsA and CsA/SRL-induced increase in the membrane localization of claudin-1.	Cyclosporine	31-34	claudin 1	Canis lupus familiaris	88-97
19955189-12	2010	However, the results suggest that the modulation in expression and localization of claudin-1 appears to be pivotal in the SRL- and CsA-induced modulation of the epithelial barrier function and that modulation is regulated by ERK1/2 signaling pathway.	Cyclosporine	131-134	claudin 1	Canis lupus familiaris	83-92
19856205-1	2010	In the present study, we observed the effects of cyclosporine A (CsA), an efficient immunosuppressant, on cell proliferation and neuroblast differentiation in the subgranular zone of the dentate gyrus (SZDG) in normal C57BL/6 mice using Ki67 and doublecortin (DCX) immunohistochemical staining, respectively.	Cyclosporine	65-68	antigen identified by monoclonal antibody Ki 67	Mus musculus	237-241
19856205-7	2010	In the vehicle-treated group, Ki67 immunoreactive (+) nuclei were clustered in the SZDG, whereas in the CsA-treated group Ki67(+) nuclei were scattered in the SZDG, showing no difference in cell numbers.	Cyclosporine	104-107	antigen identified by monoclonal antibody Ki 67	Mus musculus	122-126
20109345-15	2010	After the cells were exposed to 10 mug/mL DDP for 24 h, the cell apoptosis rate of SK-Hep1/DDP was decreased in comparison with SK-Hep1, but it was increased in those with pretreatment of MDR1 inhibitor CsA as compared with those without pretreatment.	Cyclosporine	203-206	DNL-type zinc finger	Homo sapiens	86-90
19901022-4	2010	Recombinant SOUL protein facilitated mitochondrial permeability transition and collapse of mitochondrial membrane potential (MMP) and facilitated the release of proapoptotic mitochondrial intermembrane proteins (PMIP) at low calcium and phosphate concentrations in a cyclosporine A-dependent manner in vitro in isolated mitochondria.	Cyclosporine	267-281	heme binding protein 2	Homo sapiens	12-16
20573295-9	2010	Among the observed immunosuppressive agents, corticosteroids, prednisolone, 6alpha-methylprednisolone, dexamethasone, and beclomethasone inhibited PS-PLA(1) expression with half-maximal inhibitory concentrations less than 3.0 nM, while methotrexate, cyclosporine A, tacrolimus, 6-mercaptopurine, and mycophenoic acid showed either a weak or moderate inhibition.	Cyclosporine	250-264	phospholipase A1 member A	Homo sapiens	147-156
20003325-14	2009	Hypoxia-induced PASMC proliferation and TRPC1 up-regulation were inhibited by SKF and NFAT blocker (VIVIT and Cyclosporin A).	Cyclosporine	110-123	transient receptor potential cation channel subfamily C member 1	Homo sapiens	40-45
19930311-3	2009	Calcineurin inhibitor such as ciclosporin A inhibits T-cell activation by interfering with the cytosolic protein cyclophilin (immunophilin).	Cyclosporine	30-43	calcineurin binding protein 1	Homo sapiens	0-21
19602127-1	2009	BACKGROUND AND OBJECTIVE: We reported previously that cyclosporine A induces a high level of expression of p21 in rat gingival keratinocytes and in OECM1 cells.	Cyclosporine	54-68	KRAS proto-oncogene, GTPase	Rattus norvegicus	107-110
19819100-1	2009	Nifedipine (NFP) is an anti-hypersensitive drug and a well-known substrate of cytochrome P450 3A4 (CYP3A4), while cyclosporine (CSP) is a potent p-glycoprotein (P-gp) inhibitor.	Cyclosporine	114-126	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	145-159
19819100-1	2009	Nifedipine (NFP) is an anti-hypersensitive drug and a well-known substrate of cytochrome P450 3A4 (CYP3A4), while cyclosporine (CSP) is a potent p-glycoprotein (P-gp) inhibitor.	Cyclosporine	114-126	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	161-165
19819100-1	2009	Nifedipine (NFP) is an anti-hypersensitive drug and a well-known substrate of cytochrome P450 3A4 (CYP3A4), while cyclosporine (CSP) is a potent p-glycoprotein (P-gp) inhibitor.	Cyclosporine	128-131	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	145-159
19819100-1	2009	Nifedipine (NFP) is an anti-hypersensitive drug and a well-known substrate of cytochrome P450 3A4 (CYP3A4), while cyclosporine (CSP) is a potent p-glycoprotein (P-gp) inhibitor.	Cyclosporine	128-131	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	161-165
19563436-3	2009	Pre-incubation with phosphatase inhibitors (okadaic acid and cyclosporine A) resulted in a modest inhibition of the TaALMT1-mediated currents.	Cyclosporine	61-75	aluminum-activated malate transporter 1	Triticum aestivum	116-123
19659609-1	2009	We have so far reported that an immunosuppressant cyclosporin A (CsA), a well-known cyclophilin (CyP) inhibitor (CPI), strongly suppressed hepatitis C virus (HCV) replication in cell culture, and that CyPB was a cellular cofactor for viral replication.	Cyclosporine	50-63	peptidylprolyl isomerase B	Homo sapiens	201-205
19659609-1	2009	We have so far reported that an immunosuppressant cyclosporin A (CsA), a well-known cyclophilin (CyP) inhibitor (CPI), strongly suppressed hepatitis C virus (HCV) replication in cell culture, and that CyPB was a cellular cofactor for viral replication.	Cyclosporine	65-68	peptidylprolyl isomerase B	Homo sapiens	201-205
19758695-7	2009	Cyclosporin A (5 microM) and ascomycin (5 microM), inhibitors of the Ca(2+)/calmodulin-dependent protein phosphatase, calcineurin, fully restored the inhibitory effect of PMA and TMX on channel activity.	Cyclosporine	0-13	thioredoxin related transmembrane protein 1	Homo sapiens	179-182
19523970-7	2009	Also CsA released cytochrome c into cytosol and provoked cellular apoptosis.	Cyclosporine	5-8	cytochrome c	Sus scrofa	18-30
19721377-7	2009	Cyclosporine A decreased TRPM6 expression and Mg(2+) influx, suggesting that the decrease in TRPM6 expression may cause hypomagnesemia.	Cyclosporine	0-14	transient receptor potential cation channel subfamily M member 6	Homo sapiens	25-30
19721377-7	2009	Cyclosporine A decreased TRPM6 expression and Mg(2+) influx, suggesting that the decrease in TRPM6 expression may cause hypomagnesemia.	Cyclosporine	0-14	transient receptor potential cation channel subfamily M member 6	Homo sapiens	93-98
19464389-5	2009	Immunosuppressants (dexamethasone and cyclosporin A) inhibited the TNF-alpha-elicited formation of IL-8, prostaglandin E(2) and CCL27, but did not affect formation of reactive species.	Cyclosporine	38-51	C-C motif chemokine ligand 27	Homo sapiens	128-133
19293339-3	2009	Treatment with cyclosporin (Cs) A, a drug that desensitizes the PTP by binding to cyclophilin (Cyp)-D, was shown to rescue myofiber alterations in Col6a1(-/-) mice and in UCMD patients, suggesting a correlation between PTP opening and pathogenesis of ColVI muscular dystrophies.	Cyclosporine	15-26	collagen, type VI, alpha 1	Mus musculus	147-153
19293339-3	2009	Treatment with cyclosporin (Cs) A, a drug that desensitizes the PTP by binding to cyclophilin (Cyp)-D, was shown to rescue myofiber alterations in Col6a1(-/-) mice and in UCMD patients, suggesting a correlation between PTP opening and pathogenesis of ColVI muscular dystrophies.	Cyclosporine	28-30	collagen, type VI, alpha 1	Mus musculus	147-153
18855917-3	2009	The activities of P-gp in these models were characterized using a known substrate (quinidine) and known inhibitors [cyclosporine A (CyA), GF-120918, PSC-833] of P-gp.	Cyclosporine	116-130	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	18-22
18855917-3	2009	The activities of P-gp in these models were characterized using a known substrate (quinidine) and known inhibitors [cyclosporine A (CyA), GF-120918, PSC-833] of P-gp.	Cyclosporine	116-130	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	161-165
19545746-0	2009	Effect of cyclosporine and sirolimus on fatty acid desaturase activities in cultured HEPG2 cells.	Cyclosporine	10-22	stearoyl-CoA desaturase	Homo sapiens	40-61
19545746-7	2009	The distribution of radioactive metabolic products after incubation of these cells with [1-(14)C]palmitic acid revealed a decrease in Delta9 desaturase activity in the presence of each immunosuppressive drug: CsA = 0.61 +/- 0.01; SRL = 0.59 +/- 0.04 versus control = 0.79 +/- 0.05 (P &lt; .01).	Cyclosporine	209-212	stearoyl-CoA desaturase	Homo sapiens	134-151
19545746-9	2009	In conclusion, CsA and SRL modulated the biosynthesis of polyunsaturated FAs, decreasing Delta9 desaturase and increasing Delta6 and Delta5 desaturase activities.	Cyclosporine	15-18	stearoyl-CoA desaturase	Homo sapiens	95-106
19349967-15	2009	CsA decreased the PE-induced NFATc1 level in the nucleus.	Cyclosporine	0-3	nuclear factor of activated T cells 1	Homo sapiens	29-35
19349967-18	2009	CONCLUSION: CsA partially suppresses PE-induced VSMC proliferation by inhibiting calcineurin activity and NFATc1 nuclear translocation.	Cyclosporine	12-15	nuclear factor of activated T cells 1	Homo sapiens	106-112
19200788-7	2009	In vitro experiments showed that CsA and dexamethasone could decrease the frequencies of Th1 and Th17 cells and inhibit IL-17 and IFN-gamma production.	Cyclosporine	33-36	negative elongation factor complex member C/D	Homo sapiens	89-92
19200788-7	2009	In vitro experiments showed that CsA and dexamethasone could decrease the frequencies of Th1 and Th17 cells and inhibit IL-17 and IFN-gamma production.	Cyclosporine	33-36	interleukin 17A	Homo sapiens	120-125
19200788-9	2009	CsA and corticosteroids may exert their immunosuppressive role by downregulating Th1 and Th17 cells.	Cyclosporine	0-3	negative elongation factor complex member C/D	Homo sapiens	81-84
19233271-11	2009	On the other hand, in vitro assays showed that cyclosporine (5.0 ug/mL) and tacrolimus (100 ng/mL) diminished the percentages of CD8+CD28- cells, with no significant effect on natural T regulatory cells.	Cyclosporine	47-59	CD8a molecule	Homo sapiens	129-132
19418307-8	2009	With respect to these untreated allografts, CsA lowered mRNA levels of MMP-7, TIMP-1/-3 (TIMP-2/-4 remained relatively low) and ADAM17, but augmented mRNA levels of MMP-11/-16/-23 and of many ECM genes.	Cyclosporine	44-47	matrix metallopeptidase 7	Rattus norvegicus	71-76
19418307-8	2009	With respect to these untreated allografts, CsA lowered mRNA levels of MMP-7, TIMP-1/-3 (TIMP-2/-4 remained relatively low) and ADAM17, but augmented mRNA levels of MMP-11/-16/-23 and of many ECM genes.	Cyclosporine	44-47	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	78-87
19418307-8	2009	With respect to these untreated allografts, CsA lowered mRNA levels of MMP-7, TIMP-1/-3 (TIMP-2/-4 remained relatively low) and ADAM17, but augmented mRNA levels of MMP-11/-16/-23 and of many ECM genes.	Cyclosporine	44-47	matrix metallopeptidase 11	Rattus norvegicus	165-171
19174155-2	2009	Cyclophilin B (CypB) is a target of cyclosporin A (CsA), an immunosuppressive drug recently shown to suppress HCV replication in cell culture.	Cyclosporine	36-49	peptidylprolyl isomerase B	Homo sapiens	15-19
19174155-2	2009	Cyclophilin B (CypB) is a target of cyclosporin A (CsA), an immunosuppressive drug recently shown to suppress HCV replication in cell culture.	Cyclosporine	51-54	peptidylprolyl isomerase B	Homo sapiens	15-19
19174155-4	2009	recently demonstrated that CypB is important for efficient HCV replication, and proposed that it mediates the anti-HCV effects of CsA through an interaction with NS5B [Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, et al.	Cyclosporine	130-133	peptidylprolyl isomerase B	Homo sapiens	27-31
19193795-9	2009	In BCG-immune mice the resistance to VV infection and VV-induced CD4 T-cell IFN-gamma production were ablated by cyclosporine A, which inhibits signaling through the T-cell receptor.	Cyclosporine	113-127	CD4 antigen	Mus musculus	65-68
18985346-3	2009	The function of Pgp can be blocked with cyclosporin A.	Cyclosporine	40-53	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	16-19
19166511-9	2009	Co-expression of both mutant Pink1 and alpha-syn led to alterations in mitochondrial structure and neurite outgrowth that were partially ameliorated by treatment with cyclosporine A, and completely restored by treatment with the mitochondrial calcium influx blocker Ruthenium Red, but not with other cellular calcium flux blockers.	Cyclosporine	167-181	PTEN induced kinase 1	Homo sapiens	29-34
19091785-9	2009	Since enhanced ENaC activity is known to cause hypertension, these data together suggest that CsA may cause hypertension by stimulating ENaC through a pathway associated with inhibition of ABCA1 and consequent elevation of cholesterol in the cells.	Cyclosporine	94-97	ATP binding cassette subfamily A member 1	Homo sapiens	189-194
18973526-4	2009	RESULTS: The mRNA expression of ET-1, ET(A) and ET(B), as well as of PCNA and iNOS, was significantly greater in edentulous gingiva that received CsA compared with control gingiva.	Cyclosporine	146-149	proliferating cell nuclear antigen	Rattus norvegicus	69-73
18973526-7	2009	Cyclosporine A-enhanced PCNA expression was somewhat reduced by blockade of ET(A), but not ET(B), whereas iNOS expression was somewhat reduced by blockade of ET(B).	Cyclosporine	0-14	proliferating cell nuclear antigen	Rattus norvegicus	24-28
18842703-8	2009	Our study clearly demonstrates for the first time that liver I/R decreases the oral bioavailability of CsA and that this is attributable principally to increased first-pass metabolism mediated by CYP3A and P-gp in the upper small intestine.	Cyclosporine	103-106	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	206-210
18836818-4	2009	It was found that while D7 inhibited the proliferation of tumor cells, the associated apoptosis induced by D7 was prevented by treating the cells with N-acetyl-L-cysteine (NAC), an antioxidant, and cyclosporine A (CsA), an inhibitor of mitochondrial permeability transition (MPT).	Cyclosporine	214-217	X-linked Kx blood group	Homo sapiens	172-175
19252740-2	2009	To better understand the molecular events associated with PTDM we investigated the effect of cyclosporine on expression and activity of hepatic nuclear factor (HNF)1alpha and 4alpha and on genes coding for glucose metabolism in cultures of the rat insulinoma cell line INS-1E, the human epithelial cell line Caco-2 and with Zucker diabetic fatty (ZDF) rats.	Cyclosporine	93-105	HNF1 homeobox A	Rattus norvegicus	136-181
19252740-4	2009	Furthermore, cyclosporine treatment of the insulinoma-1E cell line resulted in remarkable reduction in HNF4alpha protein and INS1 as well as INS2 gene expression, while transcript expression of HNF4alpha, apolipoprotein C2, glycerolkinase, pyruvatekinase and aldolase B was repressed in treated Caco-2 cells.	Cyclosporine	13-25	forkhead box M1	Homo sapiens	125-129
19227897-15	2009	This case suggests possible beneficial effects of cyclosporin in preventing attacks of myelitis with anti-AQP4 seropositivity.	Cyclosporine	50-61	aquaporin 4	Homo sapiens	106-110
19008001-6	2008	In addition, the presence of Pgp1-, BSEP- and MRP-like transport activities were indicated using putative specific fluorescent substrates (rhodamine 123, calcein-AM, bodipy-verapamil and dihydrofluorescein diacetat), model inhibitors (verapamil, cyclosporine A, MK571, reversine 205, taurocholate and taurochenodeoxycholate) and their combinations.	Cyclosporine	246-260	CD44 molecule (Indian blood group)	Homo sapiens	29-33
19008001-6	2008	In addition, the presence of Pgp1-, BSEP- and MRP-like transport activities were indicated using putative specific fluorescent substrates (rhodamine 123, calcein-AM, bodipy-verapamil and dihydrofluorescein diacetat), model inhibitors (verapamil, cyclosporine A, MK571, reversine 205, taurocholate and taurochenodeoxycholate) and their combinations.	Cyclosporine	246-260	ATP binding cassette subfamily B member 11	Homo sapiens	36-40
18604533-0	2008	Cyclosporine, a P-glycoprotein modulator, increases [18F]MPPF uptake in rat brain and peripheral tissues: microPET and ex vivo studies.	Cyclosporine	0-12	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	16-30
18604533-1	2008	PURPOSE: Pretreatment with cyclosporine, a P-glycoprotein (P-gp) modulator increases brain uptake of 4-(2"-methoxyphenyl)-1-[2"-(N-2"-pyridinyl)-p-[(18)F]fluorobenzamido]ethylpiperazine ([(18)F]MPPF) for binding to hydroxytryptamine(1A) (5-HT(1A)) receptors.	Cyclosporine	27-39	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	43-57
18604533-1	2008	PURPOSE: Pretreatment with cyclosporine, a P-glycoprotein (P-gp) modulator increases brain uptake of 4-(2"-methoxyphenyl)-1-[2"-(N-2"-pyridinyl)-p-[(18)F]fluorobenzamido]ethylpiperazine ([(18)F]MPPF) for binding to hydroxytryptamine(1A) (5-HT(1A)) receptors.	Cyclosporine	27-39	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	59-63
18708588-5	2008	UVR also evoked NFAT2 nuclear translocation in a parallel wavelength-dependent fashion and both transcriptional activation and nuclear translocation were inhibited by the calcineurin inhibitor cyclosporin A.	Cyclosporine	193-206	nuclear factor of activated T cells 1	Homo sapiens	16-21
19100473-10	2008	RESULTS: Protosappanin A or cyclosporine significantly prolonged heart allograft survival (P &lt; .01), alleviated myocardial pathologic damages (P &lt; .01), decreased the CD4+/CD8+ ratio (P &lt; .05), and inhibited perforin and granzyme B mRNA expressions in the graft (P &lt; .05).	Cyclosporine	28-40	Cd4 molecule	Rattus norvegicus	173-176
19019314-5	2008	Treatment of Col6a1(-/-) mice with cyclosporin A (CsA) rescued the mitochondrial dysfunction and decreased apoptosis.	Cyclosporine	35-48	collagen, type VI, alpha 1	Mus musculus	13-19
19019314-5	2008	Treatment of Col6a1(-/-) mice with cyclosporin A (CsA) rescued the mitochondrial dysfunction and decreased apoptosis.	Cyclosporine	50-53	collagen, type VI, alpha 1	Mus musculus	13-19
18594870-9	2008	Urinary MMP2/Cr was similar, and urinary TIMP2/Cr was significantly higher in children treated with CyA (p &lt; 0.01).	Cyclosporine	100-103	TIMP metallopeptidase inhibitor 2	Homo sapiens	41-46
18594870-10	2008	The MMP2/TIMP2 ratio in NS children treated with CyA was significantly lower in comparison with healthy controls (p &lt; 0.01).	Cyclosporine	49-52	TIMP metallopeptidase inhibitor 2	Homo sapiens	9-14
18929835-13	2008	CONCLUSIONS: Our data suggested that among several cytokines elevated levels of the LIX, MCP-1, beta-NGF, and TIMP-1 are the contributing factors to CsA-induced nephropathy.	Cyclosporine	149-152	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	110-116
18845086-0	2008	[Regulatory function of tacrolimus and CsA on CD4/CD8 T lymphocyte subgroups and costimulators on them in allo-liver recipients].	Cyclosporine	39-42	CD8a molecule	Homo sapiens	50-53
18845086-1	2008	AIM: To explore the regulatory function of FK506 and CsA on CD4/CD8 T lymphocyte subgroups and co-stimulators on them.	Cyclosporine	53-56	CD8a molecule	Homo sapiens	64-67
18845086-6	2008	Between two treatment group, the expression of CD4(+)T cells and the expression of CD28 and ICOS on CD8(+)T cells in CsA-treated group were much higher than those in FK506-treated group (P&lt;0.05), and there was no significant difference between two treatment groups in other indexes.	Cyclosporine	117-120	inducible T cell costimulator	Homo sapiens	92-96
18845086-6	2008	Between two treatment group, the expression of CD4(+)T cells and the expression of CD28 and ICOS on CD8(+)T cells in CsA-treated group were much higher than those in FK506-treated group (P&lt;0.05), and there was no significant difference between two treatment groups in other indexes.	Cyclosporine	117-120	CD8a molecule	Homo sapiens	100-103
18582853-6	2008	Application to rats of two inhibitors of calcineurin (tacrolimus-FK506 and cyclosporin A) demonstrated that the mRNA levels of both the AChE catalytic subunit and ColQ in the extrajunctional regions of the soleus muscle are regulated by the calcineurin signaling pathway, but in a reciprocal way.	Cyclosporine	75-88	collagen like tail subunit of asymmetric acetylcholinesterase	Rattus norvegicus	163-167
18567920-7	2008	CSA and HAb18G/CD147 antagonistic peptide AP-9 against CD147, respectively, dramatically decreased MMP-2 and MMP-9 expression, both in the absence or presence of CypA.	Cyclosporine	0-3	matrix metallopeptidase 9	Homo sapiens	109-114
18485890-2	2008	P-gp overexpression in MDCK-MDR cells was correlated with enhanced cell migration whereas treatment with P-gp inhibitors CsA or PSC833 reduced it.	Cyclosporine	121-124	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	105-109
19356088-1	2008	Cyclosporin A (CsA) is a P-glycoprotein (P-gp) inhibitor clinically used as an immunosuppressant.	Cyclosporine	0-13	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	25-39
18562569-7	2008	Acid-base status, 17beta estradiol, and the immunosuppressive agents FK506 and cyclosporine affect plasma Mg(2+) levels by altering TRPM6 expression.	Cyclosporine	79-91	transient receptor potential cation channel subfamily M member 6	Homo sapiens	132-137
18766961-1	2008	The Class II human leukocyte antigen (HLA) DRB1 antigen DR4 is associated with autoimmune disorders and response to cyclosporine immunosuppression in T-lymphoproliferative disorders.	Cyclosporine	116-128	major histocompatibility complex, class II, DR beta 4	Homo sapiens	56-59
18632621-5	2008	Using a full-length VEGF promoter-luciferase construct, we found that CsA markedly induced VEGF transcriptional activation through the protein kinase C (PKC) signaling pathway, specifically involving PKC zeta and PKC delta isoforms.	Cyclosporine	70-73	vascular endothelial growth factor A	Mus musculus	20-24
18632621-5	2008	Using a full-length VEGF promoter-luciferase construct, we found that CsA markedly induced VEGF transcriptional activation through the protein kinase C (PKC) signaling pathway, specifically involving PKC zeta and PKC delta isoforms.	Cyclosporine	70-73	vascular endothelial growth factor A	Mus musculus	91-95
18632621-5	2008	Using a full-length VEGF promoter-luciferase construct, we found that CsA markedly induced VEGF transcriptional activation through the protein kinase C (PKC) signaling pathway, specifically involving PKC zeta and PKC delta isoforms.	Cyclosporine	70-73	protein kinase C, delta	Mus musculus	153-156
18632621-5	2008	Using a full-length VEGF promoter-luciferase construct, we found that CsA markedly induced VEGF transcriptional activation through the protein kinase C (PKC) signaling pathway, specifically involving PKC zeta and PKC delta isoforms.	Cyclosporine	70-73	protein kinase C, delta	Mus musculus	213-222
18632621-6	2008	Moreover, CsA promoted the association of PKC zeta and PKC delta with the transcription factor Sp1 as observed by immunoprecipitation assays.	Cyclosporine	10-13	protein kinase C, delta	Mus musculus	55-64
18632621-8	2008	Furthermore, CsA-induced and PKC-Sp1-mediated VEGF transcriptional activation was partially inhibited by von Hippel-Lindau protein.	Cyclosporine	13-16	vascular endothelial growth factor A	Mus musculus	46-50
18632621-10	2008	Finally, to evaluate the in vivo significance of CsA-induced VEGF overexpression in terms of post-transplantation tumor development, we injected CT26 murine carcinoma cells (known to form angiogenic tumors) into mice with fully MHC mismatched cardiac transplants.	Cyclosporine	49-52	vascular endothelial growth factor A	Mus musculus	61-65
18632621-13	2008	Collectively, these findings define PKC-mediated VEGF transcriptional activation as a key component in the progression of CsA-induced post-transplantation cancer.	Cyclosporine	122-125	protein kinase C, delta	Mus musculus	36-39
18632621-13	2008	Collectively, these findings define PKC-mediated VEGF transcriptional activation as a key component in the progression of CsA-induced post-transplantation cancer.	Cyclosporine	122-125	vascular endothelial growth factor A	Mus musculus	49-53
18353617-10	2008	The mRNA expression levels of NFAT1, NFAT2, BPAG1, and involucrin were downregulated by CsA treatment in NHEK.	Cyclosporine	88-91	nuclear factor of activated T cells 1	Homo sapiens	37-42
18353617-10	2008	The mRNA expression levels of NFAT1, NFAT2, BPAG1, and involucrin were downregulated by CsA treatment in NHEK.	Cyclosporine	88-91	dystonin	Homo sapiens	44-49
18353617-14	2008	In addition, the data suggest that CsA can downregulate the BPAG1 gene expression perhaps via the NFAT consensus cis-elements in the BPAG1 promoter region.	Cyclosporine	35-38	dystonin	Homo sapiens	60-65
18353617-14	2008	In addition, the data suggest that CsA can downregulate the BPAG1 gene expression perhaps via the NFAT consensus cis-elements in the BPAG1 promoter region.	Cyclosporine	35-38	dystonin	Homo sapiens	133-138
18293408-3	2008	NFATs are activated by calcium-mobilizing agents in astrocytes, and this activation is blocked by the calcineurin inhibitor cyclosporine A.	Cyclosporine	124-138	calcineurin binding protein 1	Homo sapiens	102-123
18482683-5	2008	METHODS: In control rats and in rats treated with the Pgp modulator cyclosporin A (CsA), cerebral accumulation of radiolabeled [(11)C]celecoxib was investigated by ex vivo biodistribution and micro-positron emission tomography imaging.	Cyclosporine	68-81	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	54-57
18482683-5	2008	METHODS: In control rats and in rats treated with the Pgp modulator cyclosporin A (CsA), cerebral accumulation of radiolabeled [(11)C]celecoxib was investigated by ex vivo biodistribution and micro-positron emission tomography imaging.	Cyclosporine	83-86	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	54-57
18482683-6	2008	In addition, the effect of unlabeled celecoxib and CsA (positive control) on the cerebral uptake of the Pgp substrate [(11)C]verapamil was studied.	Cyclosporine	51-54	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	104-107
18276028-3	2008	Cyclosporin A (CsA) treatment led to suppression of cell-mediated immunity such as CD8+ T-cells and reduced expression of IFN-gamma mRNA.	Cyclosporine	0-13	interferon gamma	Gallus gallus	122-131
18276028-3	2008	Cyclosporin A (CsA) treatment led to suppression of cell-mediated immunity such as CD8+ T-cells and reduced expression of IFN-gamma mRNA.	Cyclosporine	15-18	interferon gamma	Gallus gallus	122-131
19356075-1	2008	The calcineurin inhibitor cyclosporine is removed from lymphocytes by the drug efflux transporter P-glycoprotein (P-gp) encoded by the ABCB1 gene for which several single nucleotide polymorphisms (SNPs) have been identified.	Cyclosporine	26-38	calcineurin binding protein 1	Homo sapiens	4-25
18094068-7	2008	The CsA group displayed a significant increase in the number of circulating EPCs (sca-1+KDR+ and c-kit+CD31+ EPCs, both P &lt; 0.05).	Cyclosporine	4-7	ataxin 1	Mus musculus	82-87
18230104-0	2008	Expression of p21 and p53 in rat gingival and human oral epithelial cells after cyclosporine A treatment.	Cyclosporine	80-94	KRAS proto-oncogene, GTPase	Rattus norvegicus	14-17
18230104-1	2008	BACKGROUND AND OBJECTIVE: Expression of p21 and p53 were examined, at gene and protein levels, in edentulous gingival epithelial cells from rats and from a human oral epidermoid carcinoma cell line, OECM1, after cyclosporine A therapy.	Cyclosporine	212-226	KRAS proto-oncogene, GTPase	Rattus norvegicus	40-43
18540481-1	2008	The primary endpoint of this study was to determine the intestinal permeability of ciclosporin (cyclosporine A, CsA, CAS 59865-13-3) using the single-pass intestinal perfusion technique (SPIP) and a range of concentrations in rats.	Cyclosporine	83-94	BCAR1 scaffold protein, Cas family member	Rattus norvegicus	117-120
18540481-2	2008	The second objective was to assess the quantitative contribution of P-glycoprotein (P-gp)-mediated efflux in limiting the oral bioavailability of CsA using erythromycin (Ery, CAS 114-07-8) as an inhibitor of P-gp efflux transporter.	Cyclosporine	146-149	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	68-82
18540481-2	2008	The second objective was to assess the quantitative contribution of P-glycoprotein (P-gp)-mediated efflux in limiting the oral bioavailability of CsA using erythromycin (Ery, CAS 114-07-8) as an inhibitor of P-gp efflux transporter.	Cyclosporine	146-149	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	84-88
18445990-5	2008	The uptake of olopatadine in LLC-GA5-COL150 was increased in the same level as that in LLC-PK1 in the presence of cyclosporine A, a P-gp inhibitor.	Cyclosporine	114-128	pyruvate kinase liver and red blood cell	Mus musculus	91-94
18445990-5	2008	The uptake of olopatadine in LLC-GA5-COL150 was increased in the same level as that in LLC-PK1 in the presence of cyclosporine A, a P-gp inhibitor.	Cyclosporine	114-128	phosphoglycolate phosphatase	Mus musculus	132-136
18776723-0	2008	Expression of ammonia transporters, Rhbg and Rhcg, in chronic cyclosporine nephropathy in rats.	Cyclosporine	62-74	Rh family, C glycoprotein	Rattus norvegicus	45-49
18776723-7	2008	Rhcg mRNA expression was unchanged in both the cortex and outer medulla, but Rhcg protein expression in the CsA group was significantly reduced in the cortex and outer medulla.	Cyclosporine	108-111	Rh family, C glycoprotein	Rattus norvegicus	77-81
18776723-9	2008	CONCLUSION: Long-term treatment with CsA in rats results in decreased urinary ammonia excretion accompanied by decreased expression of Rhcg; these changes are likely to mediate the CsA-induced defect in ammonium excretion in the collecting duct.	Cyclosporine	37-40	Rh family, C glycoprotein	Rattus norvegicus	135-139
18776723-9	2008	CONCLUSION: Long-term treatment with CsA in rats results in decreased urinary ammonia excretion accompanied by decreased expression of Rhcg; these changes are likely to mediate the CsA-induced defect in ammonium excretion in the collecting duct.	Cyclosporine	181-184	Rh family, C glycoprotein	Rattus norvegicus	135-139
18261605-1	2008	BACKGROUND: Cyclosporine (CsA)-associated nephrotoxicity is a long-term complication in transplant patients.	Cyclosporine	12-24	chorionic somatomammotropin hormone 1	Homo sapiens	26-29
17996694-2	2007	Using MACS-purified CD4 cells, we found that rapamycin and cyclosporine A (CsA) potently inhibited the TGFbeta and IL-6-induced generation of IL-17-producing cells.	Cyclosporine	59-73	interleukin 17A	Homo sapiens	142-147
17996694-2	2007	Using MACS-purified CD4 cells, we found that rapamycin and cyclosporine A (CsA) potently inhibited the TGFbeta and IL-6-induced generation of IL-17-producing cells.	Cyclosporine	75-78	interleukin 17A	Homo sapiens	142-147
17935163-9	2007	Cyclosporin A also reduced the nuclear expression of two Tax-related transfer factors, ATF-1 and ATF-2 on Western blot.	Cyclosporine	0-13	activating transcription factor 2	Homo sapiens	97-102
17935163-10	2007	Cyclosporin A alone did not show any cytotoxicity by itself, but sensitized cells to VP-16 when combined with VP-16.	Cyclosporine	0-13	host cell factor C1	Homo sapiens	85-90
17935163-10	2007	Cyclosporin A alone did not show any cytotoxicity by itself, but sensitized cells to VP-16 when combined with VP-16.	Cyclosporine	0-13	host cell factor C1	Homo sapiens	110-115
17980495-9	2007	In BNIP3+ cells, cyclosporin-A, an inhibitor of mitochondrial pore transition, blocked the cyanide-induced reduction of delta psim and decreased the apoptotic death.	Cyclosporine	17-30	BCL2 interacting protein 3	Rattus norvegicus	3-8
17686907-4	2007	Considering that cyclosporin A and rifampicin inhibit multiple uptake/efflux transporters, the interactions of CP-671,305 with major human hepatic drug transporters, multidrug resistance protein 1 (MDR1), multidrug resistance-associated protein 2 (MRP2), breast cancer resistant protein (BCRP), and organic anion-transporting polypeptide (OATPs) were evaluated in vitro.	Cyclosporine	17-30	ATP binding cassette subfamily C member 2	Homo sapiens	205-246
17686907-4	2007	Considering that cyclosporin A and rifampicin inhibit multiple uptake/efflux transporters, the interactions of CP-671,305 with major human hepatic drug transporters, multidrug resistance protein 1 (MDR1), multidrug resistance-associated protein 2 (MRP2), breast cancer resistant protein (BCRP), and organic anion-transporting polypeptide (OATPs) were evaluated in vitro.	Cyclosporine	17-30	ATP binding cassette subfamily C member 2	Homo sapiens	248-252
17537281-7	2007	CSA was of relevance in both women (OR 1.2, 95% CI 1.1-1.4) and persistent ideators (OR 1.3, 95% CI 1.1-1.5).	Cyclosporine	0-3	olfactory receptor family 10 subfamily T member 2	Homo sapiens	85-91
17987881-7	2007	RESULTS: Gingival overgrowth was higher in the group that was administered the higher cyclosporine dosage (CsA2) than in the group that received the therapeutic dosage, showing a positive relation between dosage and severity of gingival overgrowth.	Cyclosporine	86-98	IK cytokine	Rattus norvegicus	107-111
17760825-7	2007	RESULTS: The results indicate that cyclosporine A treatment was associated with bone resorption, represented by a decrease in the bone volume, alveolar bone surface and the number of osteoblasts per bone surface and by an increase in the number of osteoclasts per bone surface and TRAP-5b.	Cyclosporine	35-49	acid phosphatase 5, tartrate resistant	Rattus norvegicus	281-285
18082675-3	2007	Cyclophilin A isolated from the supernatant of the cortisone-resistant thymoma EL-4 shows its characteristic functional features as it demonstrates isomerase activity and binds with cyclosporine A.	Cyclosporine	182-196	peptidylprolyl isomerase A	Mus musculus	0-13
18082675-3	2007	Cyclophilin A isolated from the supernatant of the cortisone-resistant thymoma EL-4 shows its characteristic functional features as it demonstrates isomerase activity and binds with cyclosporine A.	Cyclosporine	182-196	epilepsy 4	Mus musculus	79-83
19093450-5	2007	Cyclosporine, a P-glycoprotein/MRP2 inhibitor, significantly suppressed the efflux transport of andrographolide in distal region of intestine, whereas probenecid, an MRP inhibitor, showed no significant effect in both proximal and distal regions of intestine.	Cyclosporine	0-12	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	16-30
19093450-5	2007	Cyclosporine, a P-glycoprotein/MRP2 inhibitor, significantly suppressed the efflux transport of andrographolide in distal region of intestine, whereas probenecid, an MRP inhibitor, showed no significant effect in both proximal and distal regions of intestine.	Cyclosporine	0-12	ATP binding cassette subfamily C member 2	Rattus norvegicus	31-35
19093450-5	2007	Cyclosporine, a P-glycoprotein/MRP2 inhibitor, significantly suppressed the efflux transport of andrographolide in distal region of intestine, whereas probenecid, an MRP inhibitor, showed no significant effect in both proximal and distal regions of intestine.	Cyclosporine	0-12	ATP binding cassette subfamily C member 2	Rattus norvegicus	31-34
17565322-5	2007	Interestingly, induction of IL-21 was highly dependent on IL-2 (as in the presence of anti-IL-2, anti-IL-2R alpha-chain, and the immunosuppressive drugs cyclosporine A, tacrolimus, and rapamycin) the transcription of IL-21 was almost completely inhibited, whereas in the presence of exogenous IL-2 the mRNA expression of IL-21 was even more upregulated.	Cyclosporine	153-167	interleukin 21	Homo sapiens	28-33
17482516-6	2007	However, the calcineurin inhibitors, tacrolimus and cyclosporine A (CsA), inhibited the IL-18-enhanced cytokine production and lymphocyte proliferation without any effect on the adhesion molecule expression.	Cyclosporine	52-66	interleukin 18	Homo sapiens	88-93
17482516-6	2007	However, the calcineurin inhibitors, tacrolimus and cyclosporine A (CsA), inhibited the IL-18-enhanced cytokine production and lymphocyte proliferation without any effect on the adhesion molecule expression.	Cyclosporine	68-71	interleukin 18	Homo sapiens	88-93
17347151-0	2007	Cyclosporin A and FK506 inhibit IL-12p40 production through the calmodulin/calmodulin-dependent protein kinase-activated phosphoinositide 3-kinase in lipopolysaccharide-stimulated human monocytic cells.	Cyclosporine	0-13	interleukin 12b	Mus musculus	32-40
17229932-6	2007	CsA administration enhanced Th2 and reduced Th1 cytokine production at the materno-fetal interface, and it expanded peripheral CD4(+)CD25(+) FOXP3(+) regulatory T cells in abortion-prone matings, implying development of Th2 bias and regulatory T cells.	Cyclosporine	0-3	CD4 antigen	Mus musculus	127-130
17351648-6	2007	Here we demonstrate in a mouse model that in contrast to rapamycin, cyclosporine compromises not only the thymic generation of CD4(+)CD25(+)FoxP3(+) T cells but also their homeostatic behavior in peripheral immune compartments.	Cyclosporine	68-80	CD4 antigen	Mus musculus	127-130
17351648-6	2007	Here we demonstrate in a mouse model that in contrast to rapamycin, cyclosporine compromises not only the thymic generation of CD4(+)CD25(+)FoxP3(+) T cells but also their homeostatic behavior in peripheral immune compartments.	Cyclosporine	68-80	interleukin 2 receptor, alpha chain	Mus musculus	133-137
17351648-7	2007	Treatment with cyclosporine resulted in a sharp reduction of peripheral CD25(+)FoxP3(+) T cells in all immune compartments studied.	Cyclosporine	15-27	interleukin 2 receptor, alpha chain	Mus musculus	72-76
17351648-9	2007	In conclusion, cyclosporine and rapamycin differentially affect homeostasis of CD4(+)FoxP3(+) T(REG) in vivo.	Cyclosporine	15-27	CD4 antigen	Mus musculus	79-82
17571306-1	2007	OBJECTIVE: To explore the gene expressions of LTC4 synthase homologs in concanavalin A (Con A)-induced mouse hepatitis and regulation role of cyclosporine A (Cs A) treatment.	Cyclosporine	142-156	leukotriene C4 synthase	Mus musculus	46-59
17571306-1	2007	OBJECTIVE: To explore the gene expressions of LTC4 synthase homologs in concanavalin A (Con A)-induced mouse hepatitis and regulation role of cyclosporine A (Cs A) treatment.	Cyclosporine	158-162	leukotriene C4 synthase	Mus musculus	46-59
17196174-6	2007	The calcineurin inhibitors, tacrolimus (FK506) and cyclosporin A, had no effect on cell migration but completely blocked both cytokine production and the nuclear translocation of NFATc1 suggesting that Ca2+/calcineurin/NFAT is involved in CRTH2-dependent cytokine production but not chemotaxis.	Cyclosporine	51-64	nuclear factor of activated T cells 1	Homo sapiens	179-185
17196174-6	2007	The calcineurin inhibitors, tacrolimus (FK506) and cyclosporin A, had no effect on cell migration but completely blocked both cytokine production and the nuclear translocation of NFATc1 suggesting that Ca2+/calcineurin/NFAT is involved in CRTH2-dependent cytokine production but not chemotaxis.	Cyclosporine	51-64	prostaglandin D2 receptor 2	Homo sapiens	239-244
17357450-0	2007	[Modulation of cyclosporin a on the expression of MMP-9 AND MMP-2 of the first-trimester human trophoblast cells].	Cyclosporine	15-28	matrix metallopeptidase 9	Homo sapiens	50-55
17357450-1	2007	The aim of this study was to explore whether cyclosporine A (CsA) can modulate expression of MMP-9 and MMP-2 and invasion of the first-trimester human trophoblast cells.	Cyclosporine	45-59	matrix metallopeptidase 9	Homo sapiens	93-98
17357450-1	2007	The aim of this study was to explore whether cyclosporine A (CsA) can modulate expression of MMP-9 and MMP-2 and invasion of the first-trimester human trophoblast cells.	Cyclosporine	61-64	matrix metallopeptidase 9	Homo sapiens	93-98
17357450-3	2007	The effect of CsA on the transcription and translation of MMP-9 and MMP-2 was determined by Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and Gelatin Zymography.	Cyclosporine	14-17	matrix metallopeptidase 9	Homo sapiens	58-63
17357450-6	2007	These results above indicate that CsA can induce the expression of MMP-9 and MMP-2 through activating MAPK/ERK1/2, which contributes to the improved invasion of the first-trimester human trophoblast cells.	Cyclosporine	34-37	matrix metallopeptidase 9	Homo sapiens	67-72
17117422-0	2007	Effect of a P-glycoprotein inhibitor, Cyclosporin A, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [11C](R)-(-)-RWAY.	Cyclosporine	38-51	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	12-26
17072859-12	2007	Moreover, in CsA-treated Cux-1 transgenic kidney cultures, p27 was not expressed in the nephrogenic zone, but only up-regulated in maturing glomeruli and tubules.	Cyclosporine	13-16	cyclin-dependent kinase inhibitor 1B	Mus musculus	59-62
17072859-13	2007	Taken together, our results demonstrate that ectopic expression of Cux-1 can rescue the effects of CsA inhibition of CnA and suggest that Cux-1 may be regulated by calcineurin A.	Cyclosporine	99-102	protein phosphatase 3, catalytic subunit, alpha isoform	Mus musculus	117-120
17072859-13	2007	Taken together, our results demonstrate that ectopic expression of Cux-1 can rescue the effects of CsA inhibition of CnA and suggest that Cux-1 may be regulated by calcineurin A.	Cyclosporine	99-102	protein phosphatase 3, catalytic subunit, alpha isoform	Mus musculus	164-177
17204702-3	2007	METHODS: Modulation of 8 radioligands by P-gp was assayed in mice by evaluating the effect of treatment with cyclosporine A (CsA) on uptake into the brain (assay 1) and the effect of treatment with a cold ligand of the corresponding radioligand on uptake of (11)C-verapamil, a representative radioligand for P-gp (assay 2).	Cyclosporine	109-123	phosphoglycolate phosphatase	Mus musculus	41-45
17204702-3	2007	METHODS: Modulation of 8 radioligands by P-gp was assayed in mice by evaluating the effect of treatment with cyclosporine A (CsA) on uptake into the brain (assay 1) and the effect of treatment with a cold ligand of the corresponding radioligand on uptake of (11)C-verapamil, a representative radioligand for P-gp (assay 2).	Cyclosporine	125-128	phosphoglycolate phosphatase	Mus musculus	41-45
17199961-7	2006	RESULTS: Combined medication of 10(-9) mol/L calcitriol and 100 ng/ml CsA inhibited human peripheral mononuclear cells" proliferation to alloantigen and the production of IL-2 and IFN-gamma but promoted that of IL-4 and IL-10.	Cyclosporine	70-73	interleukin 10	Homo sapiens	220-225
17015956-5	2006	In in vitro monolayer efflux assays, compound 3 was found to be a substrate for the P-glycoprotein (P-gp) efflux pump, but pretreatment of rats with the potent P-gp inhibitor, cyclosporine A, did not have any significant influence on the cerebral uptake of [11C]3.	Cyclosporine	176-190	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	84-98
17015956-5	2006	In in vitro monolayer efflux assays, compound 3 was found to be a substrate for the P-glycoprotein (P-gp) efflux pump, but pretreatment of rats with the potent P-gp inhibitor, cyclosporine A, did not have any significant influence on the cerebral uptake of [11C]3.	Cyclosporine	176-190	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	100-104
17015956-5	2006	In in vitro monolayer efflux assays, compound 3 was found to be a substrate for the P-glycoprotein (P-gp) efflux pump, but pretreatment of rats with the potent P-gp inhibitor, cyclosporine A, did not have any significant influence on the cerebral uptake of [11C]3.	Cyclosporine	176-190	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	160-164
16799071-2	2006	Cyclosporin A (CsA) inhibits calcium-induced calcineurin activation and blocks the stabilization of HIF-1alpha in cultured cells.	Cyclosporine	0-13	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	100-110
16799071-2	2006	Cyclosporin A (CsA) inhibits calcium-induced calcineurin activation and blocks the stabilization of HIF-1alpha in cultured cells.	Cyclosporine	15-18	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	100-110
23105616-11	2006	Serum antiproteinase activities of serum alpha 2 macroglobulin (AMG), alpha 1-antitrypsin (AT) and alpha 1-antichymotrypsin (ACT) were found to be altered in renal transplant patients receiving cyclosporine.	Cyclosporine	194-206	serpin family A member 3	Homo sapiens	99-123
16857389-0	2006	Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET.	Cyclosporine	23-34	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	43-57
16857389-5	2006	The P-gp modulator cyclosporin A (CsA) (3, 10 and 25 mg/kg) was administered as a short bolus injection 30 min after the start of the [(11)C]verapamil infusion.	Cyclosporine	19-32	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	4-8
16857389-7	2006	The CsA blood concentrations were used as input to model P-gp inhibition.	Cyclosporine	4-7	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	57-61
16857389-10	2006	A model in which CsA inhibited P-gp by decreasing the transport of [(11)C]verapamil out from the brain resulted in the best fit.	Cyclosporine	17-20	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	31-35
16857389-11	2006	Our data suggest that it is not the CsA concentration in blood, but rather the CsA concentration in an effect compartment, probably the endothelial cells of the blood-brain barrier that is responsible for the inhibition of P-gp.	Cyclosporine	79-82	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	223-227
16980052-6	2006	Western blot analysis showed enhanced processing of caspase-8, Bax, and p53 after CsA treatment.	Cyclosporine	82-85	caspase 8	Rattus norvegicus	52-61
16825605-8	2006	Caspase 8 activities induced by ANG II were attenuated by U-0126, SP-600125, and CsA.	Cyclosporine	81-84	caspase 8	Rattus norvegicus	0-9
16829796-4	2006	Glucocorticoids and the calcineurin inhibitor cyclosporine induce endothelial dysfunction, and although tacrolimus may not have the same disruptive effects on endothelial function as cyclosporine, its endothelial activity is still being established.	Cyclosporine	46-58	calcineurin binding protein 1	Homo sapiens	24-45
16545584-12	2006	The cells demonstrated P-glycoprotein-mediated function by directional transport of dexamethasone, ritonavir, and vinblastine in a transwell assay that was inhibited in the presence of cyclosporin A, verapamil, or quinidine.	Cyclosporine	185-198	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	23-37
16805961-4	2006	Because both drugs are transported via P-glycoprotein and breast cancer resistance protein and metabolized by cytochrome P450 3A2, the interaction of imatinib mesilate with these proteins may be responsible for the increased intestinal absorption of ciclosporin in rats.	Cyclosporine	250-261	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	39-53
16756642-3	2006	The aim of the present study was to evaluate P-gp expression on the surface of CD4(+), CD8(+), CD19(+) and CD56(+) cells in kidney transplant patients treated with cyclosporine A as a main immunosuppressant, using flow cytometry.	Cyclosporine	164-178	CD8a molecule	Homo sapiens	87-90
16601147-9	2006	Further studies show that ruthenium red, an inhibitor of the mitochondrial Ca(2+) uniporter, blocks PUFA-induced Ca(2+) efflux from mitochondria, whereas inhibitors of the mitochondrial permeability transition pore cyclosporin A and bongkrekic acid have no effect.	Cyclosporine	215-228	pumilio RNA binding family member 3	Homo sapiens	100-104
16457995-3	2006	Intestinal absorption of tacrolimus itself was as extensive as other P-gp modulators such as cyclosporine and verapamil.	Cyclosporine	93-105	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	69-73
16457995-4	2006	While cyclosporine and verapamil significantly increased the absorption of methylprednisolone and vinblastine through potent inhibition of intestinal P-gp, tacrolimus failed to achieve this.	Cyclosporine	6-18	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	150-154
16457995-8	2006	It was considered that the extensive absorption of cyclosporine and verapamil was closely associated with their potent ability to inhibit intestinal P-gp.	Cyclosporine	51-63	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	149-153
16612258-10	2006	The detrimental effects of CsA were associated with upregulation of myocardial atrial natriuretic peptide (ANP) mRNA expression, paradoxical activation of the renin-angiotensin system (RAS), induction of renal reduced nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase, and overexpression of oxidative stress-induced transcription factor NRF2.	Cyclosporine	27-30	natriuretic peptide A	Rattus norvegicus	79-105
16415090-11	2006	This is the first time that an in vivo CsA EC(50) of P-gp inhibition at the rat BBB has been determined and the magnitude of such inhibition was compared between the rat and the human BBB at the same blood CsA concentration.	Cyclosporine	39-42	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	53-57
16476567-2	2006	CsA is reported to competitively inhibit the transport of the substrates of the bile salt export pump (Bsep), multidrug resistance protein 2 (Mrp2) and P-glycoprotein (P-gp) in the canalicular membrane vesicles.	Cyclosporine	0-3	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	152-166
16476567-2	2006	CsA is reported to competitively inhibit the transport of the substrates of the bile salt export pump (Bsep), multidrug resistance protein 2 (Mrp2) and P-glycoprotein (P-gp) in the canalicular membrane vesicles.	Cyclosporine	0-3	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	168-172
16476567-4	2006	Therefore, in the present study, the acute effect of CsA on the biliary excretion of the substrates of Bsep, Mrp2 and P-gp was examined under the same condition.	Cyclosporine	53-56	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	118-122
16476567-8	2006	In conclusion, CsA may competitively inhibit biliary excretion of substrates of Bsep, Mrp2 and P-gp also in vivo, and CsA is considered to inhibit bile acid-dependent bile flow by the competitive inhibition of the canalicular transport of bile acids by Bsep.	Cyclosporine	15-18	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	95-99
16467444-1	2006	The calcineurin inhibitor cyclosporine (CsA) induces a fibrogenic response that may lead to scarring of the renal allograft.	Cyclosporine	40-43	calcineurin binding protein 1	Homo sapiens	4-25
16384676-0	2006	Contributions of intestinal P-glycoprotein and CYP3A to oral bioavailability of cyclosporin A in mice treated with or without dexamethasone.	Cyclosporine	80-93	phosphoglycolate phosphatase	Mus musculus	28-42
16384676-0	2006	Contributions of intestinal P-glycoprotein and CYP3A to oral bioavailability of cyclosporin A in mice treated with or without dexamethasone.	Cyclosporine	80-93	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	47-52
16671447-2	2006	We show that neuroprotection by 2 types of immunosuppressants, cyclosporin A (CsA) and tacrolimus (FK506), in a cryogenic brain injury model results from inhibition of calcineurin and protection from mitochondrial damage caused by formation of a mitochondrial permeability transition pore induced by cyclophilin D (CyPD), one of the prolyl cis/trans isomerase family members.	Cyclosporine	63-76	peptidylprolyl isomerase D	Rattus norvegicus	300-313
16671447-2	2006	We show that neuroprotection by 2 types of immunosuppressants, cyclosporin A (CsA) and tacrolimus (FK506), in a cryogenic brain injury model results from inhibition of calcineurin and protection from mitochondrial damage caused by formation of a mitochondrial permeability transition pore induced by cyclophilin D (CyPD), one of the prolyl cis/trans isomerase family members.	Cyclosporine	63-76	peptidylprolyl isomerase D	Rattus norvegicus	315-319
16671447-2	2006	We show that neuroprotection by 2 types of immunosuppressants, cyclosporin A (CsA) and tacrolimus (FK506), in a cryogenic brain injury model results from inhibition of calcineurin and protection from mitochondrial damage caused by formation of a mitochondrial permeability transition pore induced by cyclophilin D (CyPD), one of the prolyl cis/trans isomerase family members.	Cyclosporine	78-81	peptidylprolyl isomerase D	Rattus norvegicus	300-313
16671447-2	2006	We show that neuroprotection by 2 types of immunosuppressants, cyclosporin A (CsA) and tacrolimus (FK506), in a cryogenic brain injury model results from inhibition of calcineurin and protection from mitochondrial damage caused by formation of a mitochondrial permeability transition pore induced by cyclophilin D (CyPD), one of the prolyl cis/trans isomerase family members.	Cyclosporine	78-81	peptidylprolyl isomerase D	Rattus norvegicus	315-319
16377671-5	2006	Hepatobiliary excretion experiments revealed that cyclosporine almost completely inhibited the biliary clearance of telithromycin, suggesting that telithromycin is a substrate of P glycoprotein and a potential substrate of Mrp2.	Cyclosporine	50-62	ATP binding cassette subfamily C member 2	Homo sapiens	223-227
17033176-0	2006	Aggressive CD30 large cell lymphoma after cyclosporine given for putative atopic dermatitis.	Cyclosporine	42-54	TNF receptor superfamily member 8	Homo sapiens	11-15
16275896-8	2006	Dexamethasone and cyclosporine A inhibit PGE2-induced MCP-1 secretion by approximately 60%.	Cyclosporine	18-32	chemokine (C-C motif) ligand 2	Mus musculus	54-59
16410675-6	2006	In the CsA-treated animals C-FOS expression was found to increase, but the expression level reduced to a statistically insignificant level within 48 h after the ischemia.	Cyclosporine	7-10	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	27-32
16517475-9	2006	The increased staining intensity of tumor necrosis factor-alpha and intercellular adhesion molecule-1 on epidermal keratinocytes and endothelial cells was reduced after cyclosporin A therapy.	Cyclosporine	169-182	intercellular adhesion molecule 1	Homo sapiens	68-101
16517475-10	2006	Cyclosporin A treatment results in total normalization of the electron microscopic picture of psoriasis and its beneficial effect depends on the direct inhibition of tumor necrosis factor-alpha and consequently intercellular adhesion molecule-1.	Cyclosporine	0-13	intercellular adhesion molecule 1	Homo sapiens	211-244
16006549-8	2005	CsA treatment significantly reduced caspase 3 activity in control and lpr hearts.	Cyclosporine	0-3	caspase 3	Mus musculus	36-45
16321613-12	2005	MMP-9 decreased from 88 ng/mL (range, 49-135 ng/mL) to 57 ng/mL (range, 38-73 ng/mL) (P &lt; .05) in tacrolimus-treated patients and from 79 ng/mL (range, 54-148 ng/mL) to 66 ng/mL (range, 41-97 ng/mL) (P &lt; .01) in cyclosporine-treated patients.	Cyclosporine	218-230	matrix metallopeptidase 9	Homo sapiens	0-5
16162182-4	2005	IgM or IgG reactive with vimentin was elaborated within 30 days with unmodified acute rejection (3/4) or in CsA-treated animals (5/6).	Cyclosporine	108-111	vimentin	Macaca fascicularis	25-33
16162182-8	2005	Acute and chronic alloimmunity disrupt modulation of autoreactivity to vimentin through pathways, which are resistant to CsA, but may be partially regulated by CD154.	Cyclosporine	121-124	vimentin	Macaca fascicularis	71-79
16223671-4	2005	Using CD4(-/-) and CD8(-/-) mice, we established that CyA immunosuppression at this dose was only effective at preventing allograft vasculopathy in mice lacking CD8(+) T cells.	Cyclosporine	54-57	CD4 antigen	Mus musculus	6-9
16223671-11	2005	We interpret these data to suggest that in the face of CyA immunosuppression CD4(+) T cell effector function is ablated while CD8(+) T cell function remains partially intact.	Cyclosporine	55-58	CD4 antigen	Mus musculus	77-80
16116173-5	2005	However, we demonstrate that a brief course of cyclosporine A to rat renal allograft recipients promotes progressive accumulation of CD103+CD8+ cells within the graft, concomitant with the development of tubular atrophy and interstitial fibrosis.	Cyclosporine	47-61	CD8a molecule	Homo sapiens	139-142
15890444-5	2005	Using an immediate early gene product Fos as a reporter of inducible gene expression, cyclosporin A was found to upregulate Fos expression in the dorsal striatum.	Cyclosporine	86-99	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	38-41
15890444-5	2005	Using an immediate early gene product Fos as a reporter of inducible gene expression, cyclosporin A was found to upregulate Fos expression in the dorsal striatum.	Cyclosporine	86-99	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	124-127
15963461-1	2005	Cyclophilins (CyPs) are a widespreading protein family in living organisms and possess the activity of peptidyl-prolyl cis-trans isomerase (PPIase), which is inhibited by cyclosporin A (CsA).	Cyclosporine	186-189	peptidylprolyl isomerase like 1	Homo sapiens	103-138
15963461-1	2005	Cyclophilins (CyPs) are a widespreading protein family in living organisms and possess the activity of peptidyl-prolyl cis-trans isomerase (PPIase), which is inhibited by cyclosporin A (CsA).	Cyclosporine	186-189	peptidylprolyl isomerase like 1	Homo sapiens	140-146
15963461-5	2005	Superposition of the structure of the C domain of hCyP33 with the structure of CypA suggests that the C domain contains PPIase active site which binds to CsA.	Cyclosporine	154-157	peptidylprolyl isomerase like 1	Homo sapiens	120-126
16085598-8	2005	To demonstrate the influence of P-glycoprotein on cerebral uptake of (11)C-GR218231, the efflux pump was modulated with 50 mg/kg cyclosporine A.	Cyclosporine	129-143	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	32-46
16085598-13	2005	Modulation of P-glycoprotein with cyclosporine A caused a 12-fold higher (11)C-GR218231 uptake in the brain, indicating that the low cerebral tracer uptake was caused by the P-glycoprotein efflux pump in the blood-brain barrier.	Cyclosporine	34-48	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	14-28
16085598-13	2005	Modulation of P-glycoprotein with cyclosporine A caused a 12-fold higher (11)C-GR218231 uptake in the brain, indicating that the low cerebral tracer uptake was caused by the P-glycoprotein efflux pump in the blood-brain barrier.	Cyclosporine	34-48	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	174-188
15855205-10	2005	Both hydroxytyrosol and resveratrol strengthened the CsA induction of HO-1 expression.	Cyclosporine	53-56	heme oxygenase 1	Rattus norvegicus	70-74
15788440-7	2005	It is surprising that the increased proliferation of CD4(+) T cells with a suppressive dose of Con A on blocking CTLA4-CD80/CD86 interactions is largely interleukin (IL)-2-independent but is cyclosporine A-sensitive.	Cyclosporine	191-205	CD4 antigen	Mus musculus	53-56
15788440-7	2005	It is surprising that the increased proliferation of CD4(+) T cells with a suppressive dose of Con A on blocking CTLA4-CD80/CD86 interactions is largely interleukin (IL)-2-independent but is cyclosporine A-sensitive.	Cyclosporine	191-205	cytotoxic T-lymphocyte-associated protein 4	Mus musculus	113-118
16182764-2	2005	Standard primary immunosuppressive therapy after orthotopic liver transplantation (OLT) is based on a calcineurin-inhibitor (CNI): cyclosporine or tacrolimus.	Cyclosporine	131-143	calcineurin binding protein 1	Homo sapiens	102-123
16182764-2	2005	Standard primary immunosuppressive therapy after orthotopic liver transplantation (OLT) is based on a calcineurin-inhibitor (CNI): cyclosporine or tacrolimus.	Cyclosporine	131-143	calcineurin binding protein 1	Homo sapiens	125-128
15910387-1	2005	We encountered two cases of pediatric living-related liver transplant recipients who showed increases in blood concentration of cyclosporine or tacrolimus, a dual substrate for cytochrome P450 (CYP) 3A and P-glycoprotein (P-gp), during a diarrheal episode.	Cyclosporine	128-140	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	206-220
15910387-1	2005	We encountered two cases of pediatric living-related liver transplant recipients who showed increases in blood concentration of cyclosporine or tacrolimus, a dual substrate for cytochrome P450 (CYP) 3A and P-glycoprotein (P-gp), during a diarrheal episode.	Cyclosporine	128-140	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	222-226
15910387-8	2005	These findings suggest that the suppression of CYP3A and P-gp activities may be involved in the mechanism of elevated blood concentrations of cyclosporine and tacrolimus during enteritis-induced diarrhea.	Cyclosporine	142-154	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	57-61
15879096-7	2005	TCR-induced proliferation and signal transduction by Ppia(-/-) CD4(+) T cells were resistant to cyclosporine, an effect that was attributable to diminished calcineurin inhibition.	Cyclosporine	96-108	peptidylprolyl isomerase A	Mus musculus	53-57
15879096-10	2005	Thus, among multiple potential ligands, CypA is the primary mediator of immunosuppression by cyclosporine.	Cyclosporine	93-105	peptidylprolyl isomerase A	Mus musculus	40-44
15809053-4	2005	Using a simple binding assay, where membranes were incubated with either purified adaptors or cytosols, we observed an inhibitory effect of tyrphostin, a tyrosine kinase inhibitor, on the binding of AP-2 to membranes, but also an unexpected decrease induced by the phosphatase inhibitor cyclosporine.	Cyclosporine	287-299	transcription factor AP-2 alpha	Homo sapiens	199-203
15909533-12	2005	In addition, the AUC of ranitidine in bile decreased in the treatment of cyclosporine or quinidine, which suggests that the hepatobiliary excretion of ranitidine was partially regulated by P-glycoprotein or organic cation transporter.	Cyclosporine	73-85	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	189-203
15816878-0	2005	Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2.	Cyclosporine	0-12	ATP binding cassette subfamily C member 2	Rattus norvegicus	64-105
15816878-8	2005	This finding suggests that CsA-mediated inhibition of the biliary excretion of MPAG by the Mrp2 transporter is the mechanism responsible for the interaction between CsA and MMF.	Cyclosporine	27-30	ATP binding cassette subfamily C member 2	Rattus norvegicus	91-95
15816878-8	2005	This finding suggests that CsA-mediated inhibition of the biliary excretion of MPAG by the Mrp2 transporter is the mechanism responsible for the interaction between CsA and MMF.	Cyclosporine	165-168	ATP binding cassette subfamily C member 2	Rattus norvegicus	91-95
15722361-9	2005	When RANKL signaling through NFATc1 was blocked with cyclosporin A, both MCP-1 and RANTES expression was down-regulated.	Cyclosporine	53-66	TNF superfamily member 11	Homo sapiens	5-10
15722361-9	2005	When RANKL signaling through NFATc1 was blocked with cyclosporin A, both MCP-1 and RANTES expression was down-regulated.	Cyclosporine	53-66	nuclear factor of activated T cells 1	Homo sapiens	29-35
15722361-9	2005	When RANKL signaling through NFATc1 was blocked with cyclosporin A, both MCP-1 and RANTES expression was down-regulated.	Cyclosporine	53-66	C-C motif chemokine ligand 5	Homo sapiens	83-89
15722361-10	2005	Furthermore, addition of MCP-1 and RANTES reversed the effects of cyclosporin A and recovered the TRAP-positive multinuclear cell phenotype.	Cyclosporine	66-79	C-C motif chemokine ligand 5	Homo sapiens	35-41
15711594-3	2005	Cyclosporin A and tacrolimus also inhibit other calcineurin-dependent transcription factors including the ubiquitously expressed cAMP response element-binding protein (CREB).	Cyclosporine	0-13	cAMP responsive element binding protein 1	Homo sapiens	129-166
15711594-3	2005	Cyclosporin A and tacrolimus also inhibit other calcineurin-dependent transcription factors including the ubiquitously expressed cAMP response element-binding protein (CREB).	Cyclosporine	0-13	cAMP responsive element binding protein 1	Homo sapiens	168-172
15711594-5	2005	It was unknown at what step in CREB-mediated transcription cyclosporin A and tacrolimus interfere.	Cyclosporine	59-72	cAMP responsive element binding protein 1	Homo sapiens	31-35
15711594-6	2005	In transient transfection experiments, using GAL4-CREB fusion proteins and a pancreatic islet beta-cell line, cyclosporin A inhibited depolarization-induced activation of CREB proteins which carried various deletions or mutations throughout their sequence providing no evidence for the existence of a distinct CREB domain conferring cyclosporin A sensitivity.	Cyclosporine	110-123	galectin 4	Homo sapiens	45-49
15711594-6	2005	In transient transfection experiments, using GAL4-CREB fusion proteins and a pancreatic islet beta-cell line, cyclosporin A inhibited depolarization-induced activation of CREB proteins which carried various deletions or mutations throughout their sequence providing no evidence for the existence of a distinct CREB domain conferring cyclosporin A sensitivity.	Cyclosporine	110-123	cAMP responsive element binding protein 1	Homo sapiens	50-54
15711594-6	2005	In transient transfection experiments, using GAL4-CREB fusion proteins and a pancreatic islet beta-cell line, cyclosporin A inhibited depolarization-induced activation of CREB proteins which carried various deletions or mutations throughout their sequence providing no evidence for the existence of a distinct CREB domain conferring cyclosporin A sensitivity.	Cyclosporine	110-123	cAMP responsive element binding protein 1	Homo sapiens	171-175
15711594-6	2005	In transient transfection experiments, using GAL4-CREB fusion proteins and a pancreatic islet beta-cell line, cyclosporin A inhibited depolarization-induced activation of CREB proteins which carried various deletions or mutations throughout their sequence providing no evidence for the existence of a distinct CREB domain conferring cyclosporin A sensitivity.	Cyclosporine	110-123	cAMP responsive element binding protein 1	Homo sapiens	171-175
15711594-6	2005	In transient transfection experiments, using GAL4-CREB fusion proteins and a pancreatic islet beta-cell line, cyclosporin A inhibited depolarization-induced activation of CREB proteins which carried various deletions or mutations throughout their sequence providing no evidence for the existence of a distinct CREB domain conferring cyclosporin A sensitivity.	Cyclosporine	333-346	cAMP responsive element binding protein 1	Homo sapiens	171-175
15711594-6	2005	In transient transfection experiments, using GAL4-CREB fusion proteins and a pancreatic islet beta-cell line, cyclosporin A inhibited depolarization-induced activation of CREB proteins which carried various deletions or mutations throughout their sequence providing no evidence for the existence of a distinct CREB domain conferring cyclosporin A sensitivity.	Cyclosporine	333-346	cAMP responsive element binding protein 1	Homo sapiens	171-175
15711594-8	2005	Using GAL4-CBP fusion proteins, cyclosporin A inhibited depolarization-induced CBP activity, with cyclosporin A-sensitive domains mapped to both the N- (aa 1-451) and C-terminal (aa 2040-2305) ends of CBP.	Cyclosporine	32-45	galectin 4	Homo sapiens	6-10
15711594-10	2005	These data suggest that, in contrast to NFAT, cyclosporin A and tacrolimus inhibit CREB transcriptional activity at the coactivator level.	Cyclosporine	46-59	cAMP responsive element binding protein 1	Homo sapiens	83-87
15728482-3	2005	Consistent with the microarray reports, pro-IL-16 mRNA levels fell within 4 h of activation, and this response is inhibited by cyclosporin A.	Cyclosporine	127-140	interleukin 16	Mus musculus	44-49
15709044-1	2005	We have previously shown that human immunodeficiency virus type 1 (HIV-1) virions which have their own nef gene deleted and are trans complemented to contain HIV-2 or simian immunodeficiency virus (SIV) Nef become resistant to treatment with cyclosporin A.	Cyclosporine	242-255	Nef	Human immunodeficiency virus 1	103-106
15684491-1	2005	In this study, the in vivo effects of cyclosporin A (CsA) and ketoconazole (KCZ), which are used as inhibitors of P-glycoprotein (Pgp) and cytochrome P450 (CYP) 3A, respectively, on the pharmacokinetics of rhodamine 123 (Rho123), nelfinavir (NFV) and erythromycin (EM) were evaluated in rats.	Cyclosporine	53-56	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	114-128
15684491-1	2005	In this study, the in vivo effects of cyclosporin A (CsA) and ketoconazole (KCZ), which are used as inhibitors of P-glycoprotein (Pgp) and cytochrome P450 (CYP) 3A, respectively, on the pharmacokinetics of rhodamine 123 (Rho123), nelfinavir (NFV) and erythromycin (EM) were evaluated in rats.	Cyclosporine	53-56	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	130-133
15837449-3	2005	Evidence from large-scale analyses of registry databases has shown that the calcineurin inhibitor, tacrolimus, is associated with approximately a 50% increase in the risk of NODM compared to the microemulsion formulation of cyclosporine (CsA); but to date, little robust evidence is available from clinical trials.	Cyclosporine	224-236	calcineurin binding protein 1	Homo sapiens	76-97
15514034-6	2005	Cyclosporine A, the calcineurin inhibitor, regulated AUF1 posttranslationally, and this correlated with an increase in the stability of GH-PTH 63-nt mRNA but not of the control GH mRNA.	Cyclosporine	0-14	heterogeneous nuclear ribonucleoprotein D	Homo sapiens	53-57
15895828-6	2005	Results showed an increase in the activity of constitutive NOS (cNOS) after lesion, inhibited by CsA (2.5 mg/kg i.p.).	Cyclosporine	97-100	nitric oxide synthase 1	Rattus norvegicus	46-62
15895828-6	2005	Results showed an increase in the activity of constitutive NOS (cNOS) after lesion, inhibited by CsA (2.5 mg/kg i.p.).	Cyclosporine	97-100	nitric oxide synthase 1	Rattus norvegicus	64-68
15895828-7	2005	Western blot assays showed an increased expression of both nNOS and eNOS after trauma, also antagonized by CsA administration.	Cyclosporine	107-110	nitric oxide synthase 1	Rattus norvegicus	59-63
15642145-7	2005	Such an increase in MMP-9 production was partially blocked by treatment with cyclosporin A.	Cyclosporine	77-90	matrix metallopeptidase 9	Homo sapiens	20-25
15654983-3	2005	We report here that treatment of cesium-137-irradiated Ptch1+/- mice with immunosuppressive doses of cyclosporine A plus prednisolone for 4-1/2 mo increased basal cell carcinoma burden by 2.5-fold.	Cyclosporine	101-115	patched 1	Mus musculus	55-60
15702787-1	2005	OBJECTIVE: To investigate the effect of cyclosporine A (CsA) on the trophoblast cell secretion of interleukin-10 (IL-10) and interferon-gamma (IFN-gamma) in early pregnancy.	Cyclosporine	56-59	interleukin 10	Homo sapiens	98-112
15702787-1	2005	OBJECTIVE: To investigate the effect of cyclosporine A (CsA) on the trophoblast cell secretion of interleukin-10 (IL-10) and interferon-gamma (IFN-gamma) in early pregnancy.	Cyclosporine	56-59	interleukin 10	Homo sapiens	114-119
15702787-5	2005	RESULTS: CsA at 0.1 and 1 micromol/L obviously increased the secretion of protein IL-10 in trophoblast cell (P&lt;0.05).	Cyclosporine	9-12	interleukin 10	Homo sapiens	82-87
15499375-5	2004	This was inhibited by cyclosporin A (5 microM) and Ruthenium Red (1 microg/ml), indicating the involvement of mitochondrial Ca2+ transport mechanisms.	Cyclosporine	22-35	carbonic anhydrase 2	Homo sapiens	124-127
15638085-2	2004	The results showed that CsA combined with Ver or Tet synergistically inhibited P-gp mediated efflux of Rh123 from rat BMEC, suggesting that the combined application of P-gp inhibitors would possibly be a useful approach to increase drug concentration in brain tissues, enhance the therapeutic effect and reduce the toxicity of drugs.	Cyclosporine	24-27	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	79-83
15638085-2	2004	The results showed that CsA combined with Ver or Tet synergistically inhibited P-gp mediated efflux of Rh123 from rat BMEC, suggesting that the combined application of P-gp inhibitors would possibly be a useful approach to increase drug concentration in brain tissues, enhance the therapeutic effect and reduce the toxicity of drugs.	Cyclosporine	24-27	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	168-172
15347678-6	2004	The effects of IL-15 and IL-2 on both CX3CR1 reporter activity and endogenous CX3CR1 transcription in PBMCs were abolished by the NFAT inhibitors cyclosporin A and VIVIT.	Cyclosporine	146-159	interleukin 15	Mus musculus	15-20
15347678-6	2004	The effects of IL-15 and IL-2 on both CX3CR1 reporter activity and endogenous CX3CR1 transcription in PBMCs were abolished by the NFAT inhibitors cyclosporin A and VIVIT.	Cyclosporine	146-159	chemokine (C-X3-C motif) receptor 1	Mus musculus	38-44
15347678-6	2004	The effects of IL-15 and IL-2 on both CX3CR1 reporter activity and endogenous CX3CR1 transcription in PBMCs were abolished by the NFAT inhibitors cyclosporin A and VIVIT.	Cyclosporine	146-159	chemokine (C-X3-C motif) receptor 1	Mus musculus	78-84
15358601-0	2004	Cyclosporin A traps ABCA1 at the plasma membrane and inhibits ABCA1-mediated lipid efflux to apolipoprotein A-I.	Cyclosporine	0-13	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	20-25
15358601-0	2004	Cyclosporin A traps ABCA1 at the plasma membrane and inhibits ABCA1-mediated lipid efflux to apolipoprotein A-I.	Cyclosporine	0-13	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	62-67
15358601-0	2004	Cyclosporin A traps ABCA1 at the plasma membrane and inhibits ABCA1-mediated lipid efflux to apolipoprotein A-I.	Cyclosporine	0-13	apolipoprotein A-I	Mus musculus	93-111
15358601-2	2004	In this study, we analyzed the effect of the immunosuppressant cyclosporin A on the ABCA1-mediated lipid effluxes reactions.	Cyclosporine	63-76	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	84-89
15358601-3	2004	METHODS AND RESULTS: Cyclosporin A acted as a potent inhibitor of ABCA1 activity in several cell lines.	Cyclosporine	21-34	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	66-71
15358601-4	2004	Using the RAW264.7 mouse macrophage cell line, in which ABCA1 and its associated cholesterol efflux activity are inducible by cAMP analogues, cyclosporin A inhibition of cholesterol efflux to apolipoprotein A-I was rapidly reversible after its removal from the culture media, implying that ABCA1 levels were not drastically reduced by cyclosporin A.	Cyclosporine	142-155	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	56-61
15358601-4	2004	Using the RAW264.7 mouse macrophage cell line, in which ABCA1 and its associated cholesterol efflux activity are inducible by cAMP analogues, cyclosporin A inhibition of cholesterol efflux to apolipoprotein A-I was rapidly reversible after its removal from the culture media, implying that ABCA1 levels were not drastically reduced by cyclosporin A.	Cyclosporine	142-155	apolipoprotein A-I	Mus musculus	192-210
15358601-4	2004	Using the RAW264.7 mouse macrophage cell line, in which ABCA1 and its associated cholesterol efflux activity are inducible by cAMP analogues, cyclosporin A inhibition of cholesterol efflux to apolipoprotein A-I was rapidly reversible after its removal from the culture media, implying that ABCA1 levels were not drastically reduced by cyclosporin A.	Cyclosporine	142-155	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	290-295
15358601-5	2004	In fact, cyclosporin A treatment decreased ABCA1 turnover and yielded a 2-fold increase in cell-surface ABCA1.	Cyclosporine	9-22	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	43-48
15358601-7	2004	Finally, consistent with the inhibition of ABCA1 in vitro, cyclosporin A treatment induced a 33% reduction of high-density lipoprotein (HDL) levels in mice.	Cyclosporine	59-72	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	43-48
15358601-8	2004	CONCLUSIONS: ABCA1 inhibition by cyclosporin A supports a role for ABCA1 endocytic trafficking in ABCA1-mediated lipid efflux and could explain in part the low HDL levels observed in some patients with transplants.	Cyclosporine	33-46	ATP binding cassette subfamily A member 1	Homo sapiens	13-18
15358601-8	2004	CONCLUSIONS: ABCA1 inhibition by cyclosporin A supports a role for ABCA1 endocytic trafficking in ABCA1-mediated lipid efflux and could explain in part the low HDL levels observed in some patients with transplants.	Cyclosporine	33-46	ATP binding cassette subfamily A member 1	Homo sapiens	67-72
15358601-8	2004	CONCLUSIONS: ABCA1 inhibition by cyclosporin A supports a role for ABCA1 endocytic trafficking in ABCA1-mediated lipid efflux and could explain in part the low HDL levels observed in some patients with transplants.	Cyclosporine	33-46	ATP binding cassette subfamily A member 1	Homo sapiens	67-72
15567778-0	2004	[Effects of cyclosporine A on NIT-1 beta cell proliferation and pol alpha1 gene expression in vitro].	Cyclosporine	12-26	nitrilase 1	Mus musculus	30-35
15567778-1	2004	OBJECTIVE: To investigate the effects of cyclosporine A on the proliferation and pol alpha1 mRNA expression of cultured NIT-1 beta cells.	Cyclosporine	41-55	nitrilase 1	Mus musculus	120-125
15567778-2	2004	METHODS: After exposure to cyclosporine A at various concentrations (0.05 to 10 micromol/L) for 48 h and 72 h, NIT-1 cell proliferation was analyzed by MTT assay and the gene expression determined by reverse transcriptional PCR (RT-PCR).	Cyclosporine	27-41	nitrilase 1	Mus musculus	111-116
15567778-4	2004	CONCLUSION: Cyclosporine A can effectively inhibit the proliferation of NIT-1 cells possibly through down-regulating the expression of pol alpha1 mRNA.	Cyclosporine	12-26	nitrilase 1	Mus musculus	72-77
15382121-5	2004	DCA activated the ERK1/2 pathway in HuH7 human hepatoma cells that was blocked by the incubation of cells with an ERBB1 inhibitor, NAC, TX, CsA, or BKA.	Cyclosporine	140-143	MIR7-3 host gene	Homo sapiens	36-40
15382121-7	2004	In HuH7 cells and primary hepatocytes, DCA enhanced the production of ROS, an effect that was abolished in Rho 0 cells and by prior incubation of cells with CsA or BKA.	Cyclosporine	157-160	MIR7-3 host gene	Homo sapiens	3-7
15284224-10	2004	The widely used immunosuppressive drug cyclosporin A (CsA) inhibited DAF induction by VEGF in a dose-dependent manner.	Cyclosporine	39-52	CD55 molecule (Cromer blood group)	Homo sapiens	69-72
15284224-10	2004	The widely used immunosuppressive drug cyclosporin A (CsA) inhibited DAF induction by VEGF in a dose-dependent manner.	Cyclosporine	54-57	CD55 molecule (Cromer blood group)	Homo sapiens	69-72
15284224-11	2004	The VEGF-induced DAF expression was functionally effective, significantly reducing complement-mediated EC lysis, and this cytoprotective effect was reversed by CsA.	Cyclosporine	160-163	CD55 molecule (Cromer blood group)	Homo sapiens	17-20
15114410-1	2004	PURPOSE: Cyclosporine A (CyA) is able to inhibit P-glycoprotein (P-gp) and to increase cytotoxicity of some anticancer drugs, including etoposide.	Cyclosporine	9-23	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	49-63
15114410-1	2004	PURPOSE: Cyclosporine A (CyA) is able to inhibit P-glycoprotein (P-gp) and to increase cytotoxicity of some anticancer drugs, including etoposide.	Cyclosporine	9-23	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	65-69
15114410-1	2004	PURPOSE: Cyclosporine A (CyA) is able to inhibit P-glycoprotein (P-gp) and to increase cytotoxicity of some anticancer drugs, including etoposide.	Cyclosporine	25-28	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	49-63
15114410-1	2004	PURPOSE: Cyclosporine A (CyA) is able to inhibit P-glycoprotein (P-gp) and to increase cytotoxicity of some anticancer drugs, including etoposide.	Cyclosporine	25-28	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	65-69
15308100-1	2004	Cyclophilin A (CypA/Ppia) is a peptidyl-prolyl isomerase (PPIase) that binds the immunosuppressive drug cyclosporine.	Cyclosporine	104-116	peptidylprolyl isomerase A	Mus musculus	0-13
15308100-1	2004	Cyclophilin A (CypA/Ppia) is a peptidyl-prolyl isomerase (PPIase) that binds the immunosuppressive drug cyclosporine.	Cyclosporine	104-116	peptidylprolyl isomerase A	Mus musculus	15-19
15308100-1	2004	Cyclophilin A (CypA/Ppia) is a peptidyl-prolyl isomerase (PPIase) that binds the immunosuppressive drug cyclosporine.	Cyclosporine	104-116	peptidylprolyl isomerase A	Mus musculus	20-24
15207740-9	2004	The apoptosis inhibitor z-VAD partially prevented the inhibitory effects of CsA and FK506 on the survival of TRAP+ multinucleated cells in the cultures and also preserved the normal osteoclast morphology.	Cyclosporine	76-79	acid phosphatase 5, tartrate resistant	Mus musculus	109-113
15056263-3	2004	RESULTS: Cyclosporin exposure increases c-fos and c-jun mRNA in the rat kidney but not in the liver.	Cyclosporine	9-20	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	40-45
15056263-4	2004	Furthermore, chronic CsA exposure causes a further increase in c-fos and c-jun mRNA and increases the renal expression of transforming growth factor-beta (TGF-beta) mRNA.	Cyclosporine	21-24	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	63-68
15056263-6	2004	The combined insult of ischaemia and CsA resulted in synergistic increases in c-fos, suggesting that CsA recruited a pathway for c-fos activation different from ischaemia.	Cyclosporine	37-40	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	78-83
15056263-6	2004	The combined insult of ischaemia and CsA resulted in synergistic increases in c-fos, suggesting that CsA recruited a pathway for c-fos activation different from ischaemia.	Cyclosporine	37-40	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	129-134
15056263-6	2004	The combined insult of ischaemia and CsA resulted in synergistic increases in c-fos, suggesting that CsA recruited a pathway for c-fos activation different from ischaemia.	Cyclosporine	101-104	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	78-83
15056263-6	2004	The combined insult of ischaemia and CsA resulted in synergistic increases in c-fos, suggesting that CsA recruited a pathway for c-fos activation different from ischaemia.	Cyclosporine	101-104	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	129-134
15056263-7	2004	The calcium channel blocker, verapamil, blocked CsA-induced expression of c-fos and c-jun mRNA, and reduced the amount of TGF-beta expression.	Cyclosporine	48-51	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	74-79
15001192-1	2004	BACKGROUND: Calcineurin inhibitor drugs (cyclosporine and tacrolimus) given to renal transplant recipients to prevent rejection are associated with an increased incidence of hypertension.	Cyclosporine	41-53	calcineurin binding protein 1	Homo sapiens	12-33
14982769-4	2004	When rats received an infusion of azithromycin, cyclosporine and probenecid, a validated Mrp2 inhibitor, significantly decreased the steady-state biliary clearance of azithromycin to 5 and 40% of the corresponding control values, respectively.	Cyclosporine	48-60	ATP binding cassette subfamily C member 2	Rattus norvegicus	89-93
14993881-4	2004	Quantitative real-time polymerase chain reaction analysis revealed that perforin/granzyme B, TNF-alpha, and interleukin-18 messenger RNA (mRNA) levels in peripheral blood mononuclear cells from patients in whom autoGVHD developed were markedly higher (and temporally associated with the onset of autoaggression) compared with the levels detected in healthy individuals and in control, non-CsA-treated SCT patients.	Cyclosporine	389-392	interleukin 18	Homo sapiens	108-122
15084930-10	2004	The release of interleukin-10 was strikingly augmented with CsA or Tac therapy (P &lt;0.01), but transforming growth factor-beta secretion was similar.	Cyclosporine	60-63	interleukin 10	Homo sapiens	15-29
15191166-9	2004	CD4+ helper cells were almost nondetectable in transplanted rats that received CsA, but also only minimally elevated in transplanted rats that received vehicle.	Cyclosporine	79-82	Cd4 molecule	Rattus norvegicus	0-3
15641687-6	2004	Administration of cyclosporine A, an inhibitor of mitochondria permeability transition pore only partly inhibited caspase3 activity and reduced DNA damage.	Cyclosporine	18-32	caspase 3	Mus musculus	114-122
17670108-8	2003	In allografts treated with cyclosporine and 1A29 histologically a lower grade of rejection was seen and less MPO were detected compared to groups A, B and D. Anti-ICAM-1 monoclonal antibodies alone as well as a subtherapeutic dose of cyclosporine are not effective to prevent acute allograft rejection after lung transplantation.	Cyclosporine	27-39	intercellular adhesion molecule 1	Rattus norvegicus	163-169
14638906-9	2003	Apoptosis induced by CsA is associated with the translocation of Bax to the mitochondria and Bax antisense oligodeoxynucleotides protected from CsA-induced apoptosis.	Cyclosporine	21-24	BCL2-associated X protein	Mus musculus	65-68
14638906-9	2003	Apoptosis induced by CsA is associated with the translocation of Bax to the mitochondria and Bax antisense oligodeoxynucleotides protected from CsA-induced apoptosis.	Cyclosporine	21-24	BCL2-associated X protein	Mus musculus	93-96
14675174-0	2003	Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol.	Cyclosporine	117-131	interleukin 19	Homo sapiens	28-50
14675174-2	2003	Using in situ hybridization we have studied mRNA expression of IL-19, 20, and 24 and their related receptor chains in skin from psoriatic patients before and during short-term treatment with either oral cyclosporine A or topical calcipotriol.	Cyclosporine	203-217	interleukin 19	Homo sapiens	63-107
14675174-6	2003	Treatment with cyclosporine A and calcipotriol resulted in disappearance of the IL-19 and 20 mRNA.	Cyclosporine	15-29	interleukin 19	Homo sapiens	80-85
14761114-7	2003	Immunohistochemistry showed that i) integrin alpha2 expression is restricted to the gingival epithelium of cyclosporin A-treated patients, ii) the reduction of alpha6 integrin expression in cyclosporin A-treated gingiva is due to loss of expression at focal contacts and iii) beta1 integrin is evenly distributed in the three populations with an intensity decrease in periodontitis and cyclosporin A-treated gingiva.	Cyclosporine	190-203	integrin subunit beta 1	Homo sapiens	276-290
14761114-7	2003	Immunohistochemistry showed that i) integrin alpha2 expression is restricted to the gingival epithelium of cyclosporin A-treated patients, ii) the reduction of alpha6 integrin expression in cyclosporin A-treated gingiva is due to loss of expression at focal contacts and iii) beta1 integrin is evenly distributed in the three populations with an intensity decrease in periodontitis and cyclosporin A-treated gingiva.	Cyclosporine	190-203	integrin subunit beta 1	Homo sapiens	276-290
12857937-7	2003	Cyclosporin A, an inhibitor of the mitochondrial permeability pore, partially decreased mitochondrial depolarization, caspase 3 activation, and caspase 9 activation, suggesting a role for mitochondrial dysfunction in these events.	Cyclosporine	0-13	caspase 3	Mus musculus	118-127
14743973-6	2003	The results indicated that P-gp inhibitors Ery and CsA may increase concentration in rat brain by inhibiting elimination of NMD from brain.	Cyclosporine	51-54	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	27-31
14550820-7	2003	RESULTS: CsA and FK 506 reduced the presence graft-infiltrating leukocytes (CD4, CD8, CD11a, CD18) in the PVS of intra- and epicardial arteries when compared with control animals.	Cyclosporine	9-12	Cd4 molecule	Rattus norvegicus	76-79
14550820-7	2003	RESULTS: CsA and FK 506 reduced the presence graft-infiltrating leukocytes (CD4, CD8, CD11a, CD18) in the PVS of intra- and epicardial arteries when compared with control animals.	Cyclosporine	9-12	CD8a molecule	Homo sapiens	81-84
12950728-5	2003	Melanocytes incubated with 10 microM CsA for 6 days showed decreased pigmentation and tyrosinase activity.	Cyclosporine	37-40	tyrosinase	Homo sapiens	86-96
12950728-6	2003	Western blot analysis using an anti-tyrosinase antibody revealed that CsA (0.1-10 microM) decreased tyrosinase protein levels in a dose-dependent manner.	Cyclosporine	70-73	tyrosinase	Homo sapiens	36-46
12950728-6	2003	Western blot analysis using an anti-tyrosinase antibody revealed that CsA (0.1-10 microM) decreased tyrosinase protein levels in a dose-dependent manner.	Cyclosporine	70-73	tyrosinase	Homo sapiens	100-110
14554103-2	2003	In particular, EGTA, ADP, and cyclosporin A (potent mitochondrial permeability transition antagonists) affected mainly Cd2+-induced changes in resting state respiration, eliminating its stimulation in KCl medium, while dithiothreitol (DTT, a dithiol reductant) produced its effect both on Cd2+ activation of the basal respiration and Cd2+ depression of uncoupler-stimulated respiration, evoking its restoration.	Cyclosporine	30-43	Cd2 molecule	Rattus norvegicus	119-122
14554103-2	2003	In particular, EGTA, ADP, and cyclosporin A (potent mitochondrial permeability transition antagonists) affected mainly Cd2+-induced changes in resting state respiration, eliminating its stimulation in KCl medium, while dithiothreitol (DTT, a dithiol reductant) produced its effect both on Cd2+ activation of the basal respiration and Cd2+ depression of uncoupler-stimulated respiration, evoking its restoration.	Cyclosporine	30-43	Cd2 molecule	Rattus norvegicus	289-292
14554103-2	2003	In particular, EGTA, ADP, and cyclosporin A (potent mitochondrial permeability transition antagonists) affected mainly Cd2+-induced changes in resting state respiration, eliminating its stimulation in KCl medium, while dithiothreitol (DTT, a dithiol reductant) produced its effect both on Cd2+ activation of the basal respiration and Cd2+ depression of uncoupler-stimulated respiration, evoking its restoration.	Cyclosporine	30-43	Cd2 molecule	Rattus norvegicus	289-292
14507967-7	2003	When cultured oligodendrocytes were exposed to staurosporine or cyclosporin A, drugs known to stimulate apoptosis in oligodendrocytes, those from Bax-/- mice but not from Bax+/+ or Bax+/- mice were resistant to the apoptotic death.	Cyclosporine	64-77	BCL2-associated X protein	Mus musculus	146-149
12919912-3	2003	RESULTS: Cyclosporin A reduced insulin release in the cell culture after 24 and 48 h exposure and decreased Nuox23, Cox7c and Atp5K mRNA expressions.	Cyclosporine	9-22	cytochrome c oxidase subunit 7C	Mus musculus	116-121
12820149-2	2003	Evaluation was made by measuring the effects of a potent P-gp inhibitor (verapamil, cyclosporin A) on in vitro efflux transport of these compounds across the everted small intestine, on in situ absorption from the small intestine, and on in vivo total plasma clearance (CL(total)) as well as biliary and urinary excretions after intravenous administration.	Cyclosporine	84-97	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	57-61
12795679-0	2003	Maintenance triple immunosuppression with cyclosporin A, mycophenolate sodium and steroids allows prolonged survival of primate recipients of hDAF porcine renal xenografts.	Cyclosporine	42-55	CD55 molecule (Cromer blood group)	Homo sapiens	142-146
12639710-3	2003	NF-kappaB activation by CnA was associated with elevated phospho-IkappaBalpha, and could be repressed by specific genetic (porZAKI-4 and porDSCR1) and chemical (cyclosporin A) inhibitors of CnA, but tumour necrosis factor-alpha (TNF-alpha) appeared not to be a key component in the cross-talk.	Cyclosporine	161-174	protein phosphatase 3, catalytic subunit, alpha isoform	Mus musculus	24-27
12639710-3	2003	NF-kappaB activation by CnA was associated with elevated phospho-IkappaBalpha, and could be repressed by specific genetic (porZAKI-4 and porDSCR1) and chemical (cyclosporin A) inhibitors of CnA, but tumour necrosis factor-alpha (TNF-alpha) appeared not to be a key component in the cross-talk.	Cyclosporine	161-174	protein phosphatase 3, catalytic subunit, alpha isoform	Mus musculus	190-193
12644894-0	2003	Regulation of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus at concentrations that inhibit calcineurin activity and involving the transcription factor CREB.	Cyclosporine	78-91	cAMP responsive element binding protein 1	Homo sapiens	198-202
11813632-0	2001	[Quantitative changes in CD4+ and CD8+ T-lymphocytes in the skin of patients with psoriasis treated with cyclosporin A].	Cyclosporine	105-118	CD8a molecule	Homo sapiens	34-37
11722644-3	2001	Cyclosporin A (CsA), which interferes with NFAT1 activation, has been shown to be an effective inhibitor of TCR-triggered CD154/CD40L expression by resting T cells.	Cyclosporine	0-13	nuclear factor of activated T cells 1	Homo sapiens	43-48
11722644-3	2001	Cyclosporin A (CsA), which interferes with NFAT1 activation, has been shown to be an effective inhibitor of TCR-triggered CD154/CD40L expression by resting T cells.	Cyclosporine	15-18	nuclear factor of activated T cells 1	Homo sapiens	43-48
11557129-3	2001	Inhibitors of mdr1-dependent transport such as verapamil or cyclosporin A have been found to decrease Rh123 efflux from mdr1-expressing cells.	Cyclosporine	60-73	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	14-18
11557129-3	2001	Inhibitors of mdr1-dependent transport such as verapamil or cyclosporin A have been found to decrease Rh123 efflux from mdr1-expressing cells.	Cyclosporine	60-73	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	120-124
11696858-4	2001	The MDR1 inhibitors cyclosporine A (10 microm) and verapramil (10 microm) inhibited ATP release by 69% and 62%, respectively (p &lt; 0.001).	Cyclosporine	20-34	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	4-8
11768242-6	2001	Substantial increases in ANF and betaMHC gene expression were detected in the AngII treated animals, which were either attenuated or blocked with CsA treatment.	Cyclosporine	146-149	natriuretic peptide A	Rattus norvegicus	25-28
11571455-16	2001	Our results support the possible involvement of renal IL-15 in graft rejection and suggest that resistance to CsA treatment is related to its failure to decrease IL-15 activity.	Cyclosporine	110-113	interleukin 15	Homo sapiens	162-167
11688669-12	2001	There was a statistically significant reduction in the number of CD4+, CD8+ as well as CD45+ cells in both the RAD- and the CSA-treated animals compared with the allogeneic control.	Cyclosporine	124-127	Cd4 molecule	Rattus norvegicus	65-68
11573696-16	2001	In the post-MI + cyclosporin A group, the increase in protein phosphatase 1 activity was much less (18% vs 36%; P &lt; 0.05), and the decrease in basal level of p16-phospholamban was markedly ameliorated (20% vs 79%; P &lt; 0.01).	Cyclosporine	17-30	cyclin-dependent kinase inhibitor 2A	Rattus norvegicus	161-164
11586066-9	2001	Ciclosporin, in contrast, was found to inhibit perforin-granule release significantly and dose dependently: whereas release from CD8(+) lymphocytes was almost maximal for the untreated control after 60 min (41% of CD8(+) perforin(+) cells at time zero), ciclosporin at 20, 4 and 2 microg/ml elevated the aforementioned parameter up to 73, 65 and 53%, respectively.	Cyclosporine	0-11	CD8a molecule	Homo sapiens	129-132
11586066-9	2001	Ciclosporin, in contrast, was found to inhibit perforin-granule release significantly and dose dependently: whereas release from CD8(+) lymphocytes was almost maximal for the untreated control after 60 min (41% of CD8(+) perforin(+) cells at time zero), ciclosporin at 20, 4 and 2 microg/ml elevated the aforementioned parameter up to 73, 65 and 53%, respectively.	Cyclosporine	0-11	CD8a molecule	Homo sapiens	214-217
11489261-7	2001	In mice treated with MPTP and a P-GP inhibitor (quinidine, trans-flupentixol or cyclosporine A), the elimination of MPP(+) from the striatum was significantly delayed.	Cyclosporine	80-94	phosphoglycolate phosphatase	Mus musculus	32-36
11493684-3	2001	Treatment of primary mouse keratinocytes with cyclosporin A, an inhibitor of calcineurin activity, suppresses the expression of terminal differentiation markers and of p21(WAF1/Cip1) and p27(KIP1), two cyclin-dependent kinase inhibitors that are usually induced with differentiation.	Cyclosporine	46-59	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	168-171
11493684-3	2001	Treatment of primary mouse keratinocytes with cyclosporin A, an inhibitor of calcineurin activity, suppresses the expression of terminal differentiation markers and of p21(WAF1/Cip1) and p27(KIP1), two cyclin-dependent kinase inhibitors that are usually induced with differentiation.	Cyclosporine	46-59	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	172-176
11493684-3	2001	Treatment of primary mouse keratinocytes with cyclosporin A, an inhibitor of calcineurin activity, suppresses the expression of terminal differentiation markers and of p21(WAF1/Cip1) and p27(KIP1), two cyclin-dependent kinase inhibitors that are usually induced with differentiation.	Cyclosporine	46-59	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	177-181
11493684-3	2001	Treatment of primary mouse keratinocytes with cyclosporin A, an inhibitor of calcineurin activity, suppresses the expression of terminal differentiation markers and of p21(WAF1/Cip1) and p27(KIP1), two cyclin-dependent kinase inhibitors that are usually induced with differentiation.	Cyclosporine	46-59	cyclin-dependent kinase inhibitor 1B	Mus musculus	187-190
11493684-3	2001	Treatment of primary mouse keratinocytes with cyclosporin A, an inhibitor of calcineurin activity, suppresses the expression of terminal differentiation markers and of p21(WAF1/Cip1) and p27(KIP1), two cyclin-dependent kinase inhibitors that are usually induced with differentiation.	Cyclosporine	46-59	cyclin-dependent kinase inhibitor 1B	Mus musculus	191-195
11438213-1	2001	OBJECTIVE: Cyclosporin A (CsA), effective in prophylaxis and treatment of graft-vs-host disease (GVHD) after human allogeneic transplantation, blunts T-cell responses by inhibiting nuclear factor of activated T cells-1 (NFAT1) activation.	Cyclosporine	26-29	nuclear factor of activated T cells 1	Homo sapiens	220-225
11368976-1	2001	Cyclosporin A (CsA) inhibits the membrane transport protein p-glycoprotein (p-gp) and can enhance the accumulation of vinblastine (VBL) and doxorubicin (Dx) in the inner ear of mice.	Cyclosporine	15-18	phosphoglycolate phosphatase	Mus musculus	60-74
11368976-1	2001	Cyclosporin A (CsA) inhibits the membrane transport protein p-glycoprotein (p-gp) and can enhance the accumulation of vinblastine (VBL) and doxorubicin (Dx) in the inner ear of mice.	Cyclosporine	15-18	phosphoglycolate phosphatase	Mus musculus	76-80
11279073-8	2001	Inhibition of endogenous calcineurin with cyclosporin A decreased MKP-1 protein levels and increased p38 activation in response to agonist stimulation.	Cyclosporine	42-55	dual specificity phosphatase 1	Mus musculus	66-71
9647434-10	1998	Survival of BN rat small bowel allografts was increased in Lewis (LEW; RTl1) rat recipients treated with RAPA, CsA, and unfractionated BN hepatocytes from 10.2 +/- 1.9 to 21.2 +/- 1.5 days.	Cyclosporine	111-114	retrotransposon-like 1	Rattus norvegicus	71-75
9647435-11	1998	With cyclosporine, EGF-, TGF-alpha- and HGF-dependent DNA synthesis in fetal hepatocyte cultures decreased by 36-46%, whereas in adult hepatocytes by 19-27 %.	Cyclosporine	5-17	transforming growth factor alpha	Rattus norvegicus	25-34
9647435-11	1998	With cyclosporine, EGF-, TGF-alpha- and HGF-dependent DNA synthesis in fetal hepatocyte cultures decreased by 36-46%, whereas in adult hepatocytes by 19-27 %.	Cyclosporine	5-17	hepatocyte growth factor	Rattus norvegicus	40-43
9603452-7	1998	Inhibition of IL-10 production, and to a lesser degree of IL-4 production, by CD4+ cells was responsible for the enhancement of IFN-gamma production in the presence of CsA.	Cyclosporine	168-171	interleukin 10	Homo sapiens	14-19
9603452-8	1998	In conclusion, IFN-gamma production by CD28-co-stimulated CD4+ T cells is resistant to inhibition by CsA and can even be facilitated by CsA as a result of removing a negative regulatory signal which is mainly IL-10 mediated.	Cyclosporine	136-139	interleukin 10	Homo sapiens	209-214
9583869-0	1998	Enhancing the effect of secreted cyclophilin B on immunosuppressive activity of cyclosporine.	Cyclosporine	80-92	peptidylprolyl isomerase B	Homo sapiens	33-46
9583869-1	1998	BACKGROUND: Cyclophilin B (CyPB) is a cyclosporine (CsA)-binding protein, located within intracellular vesicles and secreted in biological fluids.	Cyclosporine	38-50	peptidylprolyl isomerase B	Homo sapiens	12-25
9583869-1	1998	BACKGROUND: Cyclophilin B (CyPB) is a cyclosporine (CsA)-binding protein, located within intracellular vesicles and secreted in biological fluids.	Cyclosporine	38-50	peptidylprolyl isomerase B	Homo sapiens	27-31
9566798-4	1998	In fact, rapamycin and FK-506 block both alphabeta+, CD4+ and gammadelta+ T lymphocytes, while CsA inhibits only the alphabeta+, CD4+ T lymphocyte.	Cyclosporine	95-98	CD4 antigen	Mus musculus	129-132
9580169-3	1998	Herein, we have examined whether the renal expression of PTHrP and its PTH/PTHrP receptor is affected by chronic CsA nephrotoxicity.	Cyclosporine	113-116	parathyroid hormone-like hormone	Rattus norvegicus	57-62
9580169-7	1998	We found that PTH/PTHrP receptor mRNA was unchanged, but PTHrP mRNA, and also transforming growth factor-beta1 mRNA expression as positive control, was about twofold increased in the kidney of CsA-treated rats.	Cyclosporine	193-196	parathyroid hormone-like hormone	Rattus norvegicus	57-62
9580169-9	1998	CONCLUSION: This study demonstrates an up-regulation of PTHrP, associated with chronic CsA-induced nephrotoxicity.	Cyclosporine	87-90	parathyroid hormone-like hormone	Rattus norvegicus	56-61
9525837-0	1998	Modulation of doxorubicin concentration by cyclosporin A in brain and testicular barrier tissues expressing P-glycoprotein in rats.	Cyclosporine	43-56	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	108-122
9530528-5	1998	CsA inhibited cNOS activity of rat ventricles and failed to bring about changes in their iNOS activity.	Cyclosporine	0-3	nitric oxide synthase 3	Rattus norvegicus	14-18
9519776-5	1998	Vbeta7.1/CD8/CD3 triple immunofluorescence stainings appeared to be valuable for titrating the cyclosporin A dosage by monitoring the T-LGL cells during treatment.	Cyclosporine	95-108	CD8a molecule	Homo sapiens	9-12
9973645-0	1998	Pure red cell aplasia associated to clonal CD8+ T-cell large granular lymphocytosis: dependence on cyclosporin A therapy.	Cyclosporine	99-112	CD8a molecule	Homo sapiens	43-46
9458727-4	1998	However, the development of fluorescence was accelerated two- to threefold by substrates and/or inhibitors of MDR1, such as verapamil, tamoxifen, and cyclosporin A, and by addition of the transport-blocking antibody to MDR1, UIC2.	Cyclosporine	150-163	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	110-114
9486927-0	1998	Red cell aplasia and megakaryocytic hypoplasia with elevated counts of CD8-positive lymphocytes after resection of a thymoma responding to cyclosporine.	Cyclosporine	139-151	CD8a molecule	Homo sapiens	71-74
10474025-1	1998	In the present study, the effect of in vitro cyclosporin A (CsA) treatment on IL-2R expression and the metastatic behavior of B16F10 melanoma cells has been reported.	Cyclosporine	45-58	interleukin 2 receptor, alpha chain	Mus musculus	78-83
10474025-1	1998	In the present study, the effect of in vitro cyclosporin A (CsA) treatment on IL-2R expression and the metastatic behavior of B16F10 melanoma cells has been reported.	Cyclosporine	60-63	interleukin 2 receptor, alpha chain	Mus musculus	78-83
10474025-2	1998	CsA treatment was found to increase the percentage of B16F10 cells expressing the alpha-subunit of IL-2R on the cell surface and also at the mRNA level.	Cyclosporine	0-3	interleukin 2 receptor, alpha chain	Mus musculus	99-104
9422352-8	1998	A selective inhibitor of calmodulin kinases (KN-62) and cyclosporin, an inhibitor of calcineurin, also antagonized the depolarization-induced increase in DOR mRNA levels, which indicates that both calcium/calmodulin-dependent enzymes are involved in the activity-dependent induction of DOR gene expression.	Cyclosporine	56-67	opioid receptor, delta 1	Mus musculus	154-157
9403721-1	1997	P-glycoprotein (P-gp) expels hydrophobic substances from the cell, including chemotherapeutic agents and immunosuppressants such as cyclosporin A (CsA) and FK506.	Cyclosporine	132-145	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	0-14
9403721-1	1997	P-glycoprotein (P-gp) expels hydrophobic substances from the cell, including chemotherapeutic agents and immunosuppressants such as cyclosporin A (CsA) and FK506.	Cyclosporine	132-145	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	16-20
9403721-1	1997	P-glycoprotein (P-gp) expels hydrophobic substances from the cell, including chemotherapeutic agents and immunosuppressants such as cyclosporin A (CsA) and FK506.	Cyclosporine	147-150	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	0-14
9403721-1	1997	P-glycoprotein (P-gp) expels hydrophobic substances from the cell, including chemotherapeutic agents and immunosuppressants such as cyclosporin A (CsA) and FK506.	Cyclosporine	147-150	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	16-20
9403721-2	1997	Exposure of cultured renal tubular cells to CsA induces P-gp overexpression in cell membranes.	Cyclosporine	44-47	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	56-60
9403721-7	1997	Treatment with CsA induced overexpression of P-gp in tubular cells of the kidney that increased with time.	Cyclosporine	15-18	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	45-49
9403721-12	1997	These results support the hypothesis that the role of P-gp as a detoxicant in renal cells may be related to mechanisms that control the cytoplasmic removal of both toxic metabolites from CsA and those originating from the catabolism of signal transduction proteins (methylcysteine esters), which are produced as a result of ras activation in presence of angiotensin II.	Cyclosporine	187-190	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	54-58
9414111-0	1997	Cyclosporin A-sensitive release of Ca2+ from mitochondria in intact thymocytes.	Cyclosporine	0-13	carbonic anhydrase 2	Homo sapiens	35-38
9414111-2	1997	It was shown that the release of Ca2+ induced by the dithiol cross-linking agent phenylarsine oxide or by uncoupler was strongly inhibited by cyclosporin A, a specific inhibitor of the permeability transition pore (PTP) in mitochondria.	Cyclosporine	142-155	carbonic anhydrase 2	Homo sapiens	33-36
9414111-3	1997	Oxidative stress sensitized the pore so even partial uncoupling caused rapid cyclosporin A-sensitive release of Ca2+.	Cyclosporine	77-90	carbonic anhydrase 2	Homo sapiens	112-115
9374872-0	1997	P-glycoprotein is a dimer in the kidney and brain capillary membranes: effect of cyclosporin A and SDZ-PSC 833.	Cyclosporine	81-94	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	0-14
9374872-9	1997	P-gp expressed in renal BBMs isolated from rats which had been treated daily with cyclosporin A (CsA) or PSC also migrated as a 264 kDa protein.	Cyclosporine	82-95	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	0-4
9374872-9	1997	P-gp expressed in renal BBMs isolated from rats which had been treated daily with cyclosporin A (CsA) or PSC also migrated as a 264 kDa protein.	Cyclosporine	97-100	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	0-4
9430427-6	1997	The increase in apoptosis elicited by cyclosporin A and cyclosporin H took place also in the presence of 10 U/ml GM-CSF but to a lesser extent.	Cyclosporine	38-51	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	113-119
9344552-1	1997	The immunosuppressant drugs FK506 and cyclosporin A inhibit T-cell proliferation via a common mechanism: calcineurin inhibition following binding to their respective binding proteins, the peptidyl prolyl isomerases FKBP-12 and cyclophilin A.	Cyclosporine	38-51	FKBP prolyl isomerase 1A	Rattus norvegicus	215-222
9349628-3	1997	Previous studies in pancreatic islet cell lines have shown that cyclosporin A and FK506 through inhibition of calcineurin interfere also with the function of the transcription factor cAMP response element binding protein (CREB) that is activated by cAMP and calcium signals and binds to cAMP/calcium response elements (CRE).	Cyclosporine	64-77	cAMP responsive element binding protein 1	Homo sapiens	222-226
9349628-4	1997	By transient expression of CRE-reporter genes or GAL4-CREB fusion proteins, the present study shows that inhibition of CREB/CRE-directed transcription by cyclosporin A and FK506 occurs in a great variety of cell types including in cell lines derived from tissues in which adverse effects of the immunosuppressants develop.	Cyclosporine	154-167	galectin 4	Homo sapiens	49-53
9349628-4	1997	By transient expression of CRE-reporter genes or GAL4-CREB fusion proteins, the present study shows that inhibition of CREB/CRE-directed transcription by cyclosporin A and FK506 occurs in a great variety of cell types including in cell lines derived from tissues in which adverse effects of the immunosuppressants develop.	Cyclosporine	154-167	cAMP responsive element binding protein 1	Homo sapiens	54-58
9349628-4	1997	By transient expression of CRE-reporter genes or GAL4-CREB fusion proteins, the present study shows that inhibition of CREB/CRE-directed transcription by cyclosporin A and FK506 occurs in a great variety of cell types including in cell lines derived from tissues in which adverse effects of the immunosuppressants develop.	Cyclosporine	154-167	cAMP responsive element binding protein 1	Homo sapiens	119-123
9349628-6	1997	When taken together with recent evidence for an essential role of CREB in T-cell activation and proliferation, the present results suggest that inhibition of CREB/CRE-directed transcription may be a molecular mechanism of the immunosuppressive effect of cyclosporin A and FK506.	Cyclosporine	254-267	cAMP responsive element binding protein 1	Homo sapiens	66-70
9349628-6	1997	When taken together with recent evidence for an essential role of CREB in T-cell activation and proliferation, the present results suggest that inhibition of CREB/CRE-directed transcription may be a molecular mechanism of the immunosuppressive effect of cyclosporin A and FK506.	Cyclosporine	254-267	cAMP responsive element binding protein 1	Homo sapiens	158-162
9351063-1	1997	The greatest change in GFR in response to treatment with cyclosporin occurs in the first 3-6 months and the magnitude of the decrement in the first year (or perhaps the first few months) appears to be a vital indicator of future problems.	Cyclosporine	57-68	Rap guanine nucleotide exchange factor 5	Homo sapiens	23-26
9342876-4	1997	The subcellular distribution of ADL1 is affected by various agents such as Ca2+, cyclosporin A, GTP, and ATP.	Cyclosporine	81-94	dynamin-like protein	Arabidopsis thaliana	32-36
9295299-10	1997	The immunosuppressants cyclosporin A and FK506 abolish calcineurin-mediated induction of CTF-1 activity.	Cyclosporine	23-36	cardiotrophin 1	Mus musculus	89-94
9223476-11	1997	The findings also support the hypothesis that Nef and CyPA enhance HIV-1 infectivity through independent processes and demonstrate a mechanistic difference between reduction of HIV-1 infectivity by cyclosporin A and gag mutations that decrease HIV-1 incorporation of CyPA.	Cyclosporine	198-211	Nef	Human immunodeficiency virus 1	46-49
9247148-2	1997	gp120-apoptosis of the Th1 clone 103 was inhibited by Cyclosporin A, the PTK inhibitors Genistein and PNU152518, as well as the anti-oxidants Ascorbic Acid and Glutathione.	Cyclosporine	54-67	negative elongation factor complex member C/D	Homo sapiens	23-26
9214404-14	1997	Most of the changes in the immunofluorescence deposition of the glycoproteins tenascin and fibronectin EDA+ were in the tubulointerstitium and vessels of the kidneys of rats on a LSD and were mostly significant at 28 days, in accordance with the characteristic histology of chronic CsA nephropathy.	Cyclosporine	282-285	tenascin C	Rattus norvegicus	78-86
9264327-5	1997	The colchicine and vinblastine uptake rate was increased by cyclosporin A, an inhibitor of the drug efflux pump P-glycoprotein, which is expressed at the blood-brain barrier.	Cyclosporine	60-73	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	112-126
9203180-6	1997	AUC correlated with C12 h for SIM (r2 = 0.833) and NEO (r2 = 0.699) and also C1.5 h for NEO (r2 = 0.775).	Cyclosporine	88-91	placenta associated 8	Homo sapiens	77-81
9166283-7	1997	Specimens with cyclosporine A toxicity (n = 7) or acute tubular necrosis (n = 13) showed fewer GMP-17+ cells in the interstitium (22 +/- 46/mm2 and 62 +/- 50/mm2, respectively) and tubules (2 +/- 6/mm2 and 10 +/- 10/mm2, respectively) (all p &lt; 0.01 versus rejection).	Cyclosporine	15-29	natural killer cell granule protein 7	Homo sapiens	95-101
9166283-7	1997	Specimens with cyclosporine A toxicity (n = 7) or acute tubular necrosis (n = 13) showed fewer GMP-17+ cells in the interstitium (22 +/- 46/mm2 and 62 +/- 50/mm2, respectively) and tubules (2 +/- 6/mm2 and 10 +/- 10/mm2, respectively) (all p &lt; 0.01 versus rejection).	Cyclosporine	15-29	PNMA family member 2	Homo sapiens	140-150
9166283-7	1997	Specimens with cyclosporine A toxicity (n = 7) or acute tubular necrosis (n = 13) showed fewer GMP-17+ cells in the interstitium (22 +/- 46/mm2 and 62 +/- 50/mm2, respectively) and tubules (2 +/- 6/mm2 and 10 +/- 10/mm2, respectively) (all p &lt; 0.01 versus rejection).	Cyclosporine	15-29	PNMA family member 2	Homo sapiens	198-208
9106655-0	1997	Nuclear localization of NF-ATc by a calcineurin-dependent, cyclosporin-sensitive intramolecular interaction.	Cyclosporine	59-70	nuclear factor of activated T cells 1	Homo sapiens	24-30
9159527-4	1997	Although enzyme activity of these cyclophilins was inhibited by CsA, pretreatment of L. major parasites with CsA did not result in reduction of a subsequent macrophage infection, arguing against a role of L. major cyclophilins as infectivity potentiators.	Cyclosporine	64-67	peptidylprolyl isomerase A	Mus musculus	34-46
9034151-8	1997	In contrast, the calcineurin inhibitor cyclosporin A, which inhibits DPK cell differentiation as well as positive selection, inhibits expression of Egr-2 and Egr-3, but not Egr-1.	Cyclosporine	39-52	early growth response 3	Mus musculus	158-163
9045922-6	1997	Conversely, rIL-7 and recombinant interferon-gamma restored proliferation of peripheral blood lymphocytes stimulated by PHA in the presence of cyclosporin A but did not restore sensitivity to class I-mediated apoptosis.	Cyclosporine	143-156	interleukin 7	Rattus norvegicus	12-17
9013979-0	1997	Lymphotactin gene expression in mast cells following Fc(epsilon) receptor I aggregation: modulation by TGF-beta, IL-4, dexamethasone, and cyclosporin A.	Cyclosporine	138-151	X-C motif chemokine ligand 1	Homo sapiens	0-12
9013979-6	1997	Fc(epsilon)RI aggregation-dependent Ltn mRNA expression was detected by 1 to 2 h, maximal at 6 h, independent of de novo protein synthesis, and was inhibited by cyclosporin A and dexamethasone.	Cyclosporine	161-174	X-C motif chemokine ligand 1	Homo sapiens	36-39
9043669-1	1997	Cyclosporin A (CsA) is a tight-binding inhibitor of the peptidyl-prolyl cis/trans isomerase (PPIase) activity of human cytosolic cyclophilin (Cyp18), the putative receptor for immunosuppressive effects of the drug.	Cyclosporine	15-18	peptidylprolyl isomerase like 1	Homo sapiens	56-91
9043669-1	1997	Cyclosporin A (CsA) is a tight-binding inhibitor of the peptidyl-prolyl cis/trans isomerase (PPIase) activity of human cytosolic cyclophilin (Cyp18), the putative receptor for immunosuppressive effects of the drug.	Cyclosporine	15-18	peptidylprolyl isomerase like 1	Homo sapiens	93-99
9043669-3	1997	Stock solutions of CsA in CEL administered into aqueous PPIase assays led to inhibition kinetics reminiscent to those of CsA dissolved in tetrahydrofurane, but caused an increase in the final Ki value of about sevenfold at 0.33% (v/v) CEL.	Cyclosporine	19-22	peptidylprolyl isomerase like 1	Homo sapiens	56-62
9186042-4	1997	The immunosuppressant cyclosporin A (CsA), which inhibits mitochondrial PT, protects against delayed neuronal necrosis of the hippocampal CA1 sector following transient forebrain/global ischemia.	Cyclosporine	22-35	carbonic anhydrase 1	Homo sapiens	138-141
9186042-4	1997	The immunosuppressant cyclosporin A (CsA), which inhibits mitochondrial PT, protects against delayed neuronal necrosis of the hippocampal CA1 sector following transient forebrain/global ischemia.	Cyclosporine	37-40	carbonic anhydrase 1	Homo sapiens	138-141
9156650-5	1997	The lysosomotropic amines, at low concentrations, in combination with the T cell-specific agent, cyclosporin A, synergistically suppresses the T cell response to MiHC and MHC in mouse and in human.	Cyclosporine	97-110	major histocompatibility complex, class I, C	Homo sapiens	171-174
8980113-6	1996	The resistance to aureobasidin A conferred by the MDR2/Pgp as well as by the MDR1/Pgp was overcome by vinblastine, verapamil, and cyclosporin A, depending on their concentrations, but not by colchicine.	Cyclosporine	130-143	ATP binding cassette subfamily B member 4	Homo sapiens	50-54
8973621-9	1996	PAN caused an augmentation in IP-10, MCP-1 and cyclophilin B mRNA levels (12-, 9.5, and two-fold, respectively), while CsA increased only cyclophilin B mRNA in a dose-dependent manner.	Cyclosporine	119-122	peptidylprolyl isomerase B	Rattus norvegicus	138-151
8895755-9	1996	Infusion of cyclosporine (6 microM), an inhibitor of both P-gp and MOAT, significantly blocked both E(2)17G cholestasis and biliary excretion, such that 16 micromol E(2)17G decreased the bile flow only 15-20%.	Cyclosporine	12-24	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	58-62
8914013-0	1996	Effects of cyclosporine A on Na,K-ATPase expression in the renal epithelial cell line NBL-1.	Cyclosporine	11-25	NBL1, DAN family BMP antagonist	Bos taurus	86-91
8914013-1	1996	The bovine renal epithelial cell line NBL-1 has been used to monitor the effects of cyclosporine A (CsA) on Na+,K(+)-ATPase activity and expression.	Cyclosporine	84-98	NBL1, DAN family BMP antagonist	Bos taurus	38-43
8914013-1	1996	The bovine renal epithelial cell line NBL-1 has been used to monitor the effects of cyclosporine A (CsA) on Na+,K(+)-ATPase activity and expression.	Cyclosporine	100-103	NBL1, DAN family BMP antagonist	Bos taurus	38-43
8915851-3	1996	Several studies have focused on ICAM-1 changes on keratinocytes and endothelial cells after cyclosporin treatment in psoriatic patients but their results have been somewhat contradictory.	Cyclosporine	92-103	intercellular adhesion molecule 1	Homo sapiens	32-38
8915851-11	1996	Although slightly reduced, endothelial ICAM-1 expression persisted after cyclosporin therapy.	Cyclosporine	73-84	intercellular adhesion molecule 1	Homo sapiens	39-45
8953513-8	1996	When in-vivo intestinal absorption was evaluated by the rat jejunal loop method, with simultaneous intravenous administration of a P-glycoprotein inhibitor, cyclosporin, intestinal absorption of both acebutolol and vinblastine increased 2.6- and 2.2-fold, respectively, but no such enhancement was observed in the absorption of acetamide.	Cyclosporine	157-168	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	131-145
8949985-3	1996	The sequels were suggestive of CsA- or ivermectin-induced central nervous system dysfunction; they were interpreted as caused by the neutralization of the Pgp at the blood-brain barrier level, implying that CsA and ivermectin were Pgp substrates.	Cyclosporine	31-34	phosphoglycolate phosphatase	Mus musculus	155-158
8949985-3	1996	The sequels were suggestive of CsA- or ivermectin-induced central nervous system dysfunction; they were interpreted as caused by the neutralization of the Pgp at the blood-brain barrier level, implying that CsA and ivermectin were Pgp substrates.	Cyclosporine	31-34	phosphoglycolate phosphatase	Mus musculus	231-234
8949985-3	1996	The sequels were suggestive of CsA- or ivermectin-induced central nervous system dysfunction; they were interpreted as caused by the neutralization of the Pgp at the blood-brain barrier level, implying that CsA and ivermectin were Pgp substrates.	Cyclosporine	207-210	phosphoglycolate phosphatase	Mus musculus	155-158
8949985-4	1996	CsA was already known to display both Pgp substrate and Pgp inhibitor properties.	Cyclosporine	0-3	phosphoglycolate phosphatase	Mus musculus	38-41
8949985-4	1996	CsA was already known to display both Pgp substrate and Pgp inhibitor properties.	Cyclosporine	0-3	phosphoglycolate phosphatase	Mus musculus	56-59
8702849-8	1996	Transient expression of NFATc.beta was capable of activating an interleukin-2 NFAT-driven reporter gene in stimulated Jurkat cells in a CsA-sensitive manner.	Cyclosporine	136-139	nuclear factor of activated T cells 1	Homo sapiens	24-29
8633380-7	1996	In addition, Impaired renal function and morphologic lesions in rats (CsA 2.5 mg/kg) receiving L-NAME or CsA alone demonstrated CsA blood levels within the therapeutic range of human renal transplant patients.	Cyclosporine	105-108	IK cytokine	Rattus norvegicus	70-75
8803575-10	1996	Significantly enhanced decreases in levels of CD 4+ lymphocytes were observed following treatment with CsA, LF, and, particularly, therapy with RIB 5/2 and a subtherapeutic dose of CsA.	Cyclosporine	103-106	Cd4 molecule	Rattus norvegicus	46-50
8803575-10	1996	Significantly enhanced decreases in levels of CD 4+ lymphocytes were observed following treatment with CsA, LF, and, particularly, therapy with RIB 5/2 and a subtherapeutic dose of CsA.	Cyclosporine	181-184	Cd4 molecule	Rattus norvegicus	46-50
8803575-12	1996	In contrast, the combination of RIB 5/2 and CsA (1.5 mg/kg) resulted in a reactive increase in levels of CD 8+ lymphocytes as well as an increased expression of RT 1b by the remaining CD 4+ lymphocytes.	Cyclosporine	44-47	Cd4 molecule	Rattus norvegicus	184-188
8618953-3	1996	We have extended those findings by showing that cyclosporin A (CS) can inhibit the BCNU-mediated rejection of EL-4 or L1210 tumors in mice.	Cyclosporine	48-61	epilepsy 4	Mus musculus	110-114
8618953-3	1996	We have extended those findings by showing that cyclosporin A (CS) can inhibit the BCNU-mediated rejection of EL-4 or L1210 tumors in mice.	Cyclosporine	63-65	epilepsy 4	Mus musculus	110-114
8618953-5	1996	When CS, an inhibitor of the activation of T lymphocytes, was administered to mice that had received either EL-4 or L1210 tumor and were treated with BCNU, nearly all the mice died by Day 60.	Cyclosporine	5-7	epilepsy 4	Mus musculus	108-112
8620476-2	1996	The function of P-gp was analyzed by the accumulation and efflux of rhodamine 123 (Rh123) in the presence or absence of cyclosporin A (CSA) and a non-immunosuppressive analog of CSA (CSA-1).	Cyclosporine	120-133	phosphoglycolate phosphatase	Mus musculus	16-20
8708959-0	1996	PDGF-B producing cells and PDGF-B gene expression in normal gingival and cyclosporine A-induced gingival overgrowth.	Cyclosporine	73-87	platelet derived growth factor subunit B	Homo sapiens	0-6
8708959-0	1996	PDGF-B producing cells and PDGF-B gene expression in normal gingival and cyclosporine A-induced gingival overgrowth.	Cyclosporine	73-87	platelet derived growth factor subunit B	Homo sapiens	27-33
8708960-0	1996	Cyclosporine A upregulates platelet-derived growth factor B chain in hyperplastic human gingiva.	Cyclosporine	0-14	platelet derived growth factor subunit B	Homo sapiens	27-59
8708960-1	1996	Cyclosporine A (CSA) is a widely used immunosuppressant for transplant patients and is also used for the treatment of a wide variety of systemic diseases with immunologic components.	Cyclosporine	0-14	chorionic somatomammotropin hormone 1	Homo sapiens	16-19
8762014-0	1996	CD45RA+ and CD45RO+ T cells differ in susceptibility to cyclosporin A mediated inhibition of interleukin-2 production.	Cyclosporine	56-69	protein tyrosine phosphatase receptor type C	Homo sapiens	0-4
8599928-2	1996	Cyclophilins are also known as the intracellular receptors for the immunosuppressive drug cyclosporin A (CsA).	Cyclosporine	90-103	peptidylprolyl isomerase B	Homo sapiens	0-12
8599928-2	1996	Cyclophilins are also known as the intracellular receptors for the immunosuppressive drug cyclosporin A (CsA).	Cyclosporine	105-108	peptidylprolyl isomerase B	Homo sapiens	0-12
8845051-9	1996	GAD67 expression was also reduced (P &lt; 0.03) in a CsA dose-dependent manner.	Cyclosporine	53-56	glutamate decarboxylase 1	Homo sapiens	0-5
8978786-1	1996	We isolated a human cDNA clone encoding a novel protein homologous to cyclophilins, specific cellular targets of cyclosporin A, which are conserved in species ranging from human to prokaryotes.	Cyclosporine	113-126	peptidylprolyl isomerase like 1	Homo sapiens	70-82
8732432-1	1996	Our objective was to study the re-expression of CD4 and CD8 on activated human T-lymphocytes in the presence of dexamethasone and cyclosporine A at physiologically relevant concentrations.	Cyclosporine	130-144	CD8a molecule	Homo sapiens	56-59
8732432-9	1996	We concluded that activation of T-lymphocytes results in rapid down-modulation of surface CD3, CD4 and CD8 followed by re-expression which is inhibited in the case of CD4, but not CD8, by dexamethasone and cyclosporine A.	Cyclosporine	206-220	CD8a molecule	Homo sapiens	103-106
8890933-2	1996	Rhodamine 123 accumulation was increased significantly in BBMEC monolayers treated with the P-gp modifying agent, cyclosporin A (CSA).	Cyclosporine	114-127	phosphoglycolate phosphatase	Bos taurus	92-96
8890933-2	1996	Rhodamine 123 accumulation was increased significantly in BBMEC monolayers treated with the P-gp modifying agent, cyclosporin A (CSA).	Cyclosporine	129-132	phosphoglycolate phosphatase	Bos taurus	92-96
8845485-5	1995	Cyclosporin A (CsA) is a widely used immunosuppressant which has been demonstrated to be a potent inhibitor of Pgp in vitro at concentrations which are clinically achievable.	Cyclosporine	15-18	phosphoglycolate phosphatase	Mus musculus	111-114
7565718-9	1995	We have previously shown that growth of fks1 null mutants is highly sensitive to the calcineurin inhibitors FK506 and cyclosporin A.	Cyclosporine	118-131	1,3-beta-D-glucan synthase	Saccharomyces cerevisiae S288C	40-44
7588713-6	1995	Another of the lumenal proteins was suggested to be a lumenal cyclophilin-type peptidyl prolyl cis-trans isomerase by the effect of cyclosporin A.	Cyclosporine	132-145	peptidylprolyl isomerase like 4	Homo sapiens	62-114
7657645-3	1995	Here we report that CsA treatment of Raji B and Jurkat T cell lines yields a phosphorylated form of NFATp that is inhibited in DNA-binding and in its ability to form an NFAT complex with Fos and Jun.	Cyclosporine	20-23	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	187-190
7650486-2	1995	We report here that the nuclear factor of activated T cells (NFATp), a cyclosporin A (CsA)-sensitive factor that regulates the transcription of several cytokines, mediates CD16-induced activation of cytokine genes in human NK cells.	Cyclosporine	71-84	Fc gamma receptor IIIa	Homo sapiens	172-176
7650486-2	1995	We report here that the nuclear factor of activated T cells (NFATp), a cyclosporin A (CsA)-sensitive factor that regulates the transcription of several cytokines, mediates CD16-induced activation of cytokine genes in human NK cells.	Cyclosporine	86-89	Fc gamma receptor IIIa	Homo sapiens	172-176
7650486-3	1995	CD16 (Fc gamma RIIIA)-induced expression of cytokine mRNA in NK cells occurs via a CsA-sensitive and Ca(2+)-dependent mechanism.	Cyclosporine	83-86	Fc gamma receptor IIIa	Homo sapiens	0-4
7650486-3	1995	CD16 (Fc gamma RIIIA)-induced expression of cytokine mRNA in NK cells occurs via a CsA-sensitive and Ca(2+)-dependent mechanism.	Cyclosporine	83-86	Fc gamma receptor IIIa	Homo sapiens	6-20
7629154-12	1995	Treatment of cells with cyclosporin A diminished the levels of CyPB bound to procollagen and diminished the rate of Hsp47 released from procollagen and the rate of procollagen secretion, suggesting that Hsp47 release from procollagen may be driven by helix formation.	Cyclosporine	24-37	peptidylprolyl isomerase B	Homo sapiens	63-67
7629154-12	1995	Treatment of cells with cyclosporin A diminished the levels of CyPB bound to procollagen and diminished the rate of Hsp47 released from procollagen and the rate of procollagen secretion, suggesting that Hsp47 release from procollagen may be driven by helix formation.	Cyclosporine	24-37	serpin family H member 1	Homo sapiens	116-121
7629154-12	1995	Treatment of cells with cyclosporin A diminished the levels of CyPB bound to procollagen and diminished the rate of Hsp47 released from procollagen and the rate of procollagen secretion, suggesting that Hsp47 release from procollagen may be driven by helix formation.	Cyclosporine	24-37	serpin family H member 1	Homo sapiens	203-208
7583777-0	1995	Cyclosporin A promotes nuclear transfer of a cytoplasmic progesterone receptor mutant.	Cyclosporine	0-13	progesterone receptor	Mus musculus	57-78
7542741-6	1995	CND1 is identical to the gene identified previously as FKS1, ETG1, and CWH53, cnd1 mutants are sensitive to FK506 and cyclosporin A and exhibit slow growth that is improved by the addition of osmotic stabilizing agents.	Cyclosporine	118-131	1,3-beta-D-glucan synthase	Saccharomyces cerevisiae S288C	0-4
7542741-6	1995	CND1 is identical to the gene identified previously as FKS1, ETG1, and CWH53, cnd1 mutants are sensitive to FK506 and cyclosporin A and exhibit slow growth that is improved by the addition of osmotic stabilizing agents.	Cyclosporine	118-131	1,3-beta-D-glucan synthase	Saccharomyces cerevisiae S288C	55-59
7542741-6	1995	CND1 is identical to the gene identified previously as FKS1, ETG1, and CWH53, cnd1 mutants are sensitive to FK506 and cyclosporin A and exhibit slow growth that is improved by the addition of osmotic stabilizing agents.	Cyclosporine	118-131	1,3-beta-D-glucan synthase	Saccharomyces cerevisiae S288C	61-65
7542741-6	1995	CND1 is identical to the gene identified previously as FKS1, ETG1, and CWH53, cnd1 mutants are sensitive to FK506 and cyclosporin A and exhibit slow growth that is improved by the addition of osmotic stabilizing agents.	Cyclosporine	118-131	1,3-beta-D-glucan synthase	Saccharomyces cerevisiae S288C	71-76
7542741-6	1995	CND1 is identical to the gene identified previously as FKS1, ETG1, and CWH53, cnd1 mutants are sensitive to FK506 and cyclosporin A and exhibit slow growth that is improved by the addition of osmotic stabilizing agents.	Cyclosporine	118-131	1,3-beta-D-glucan synthase	Saccharomyces cerevisiae S288C	78-82
7598941-8	1995	An additive effect of IL-10 to cyclosporine was found for all three parameters studied.	Cyclosporine	31-43	interleukin 10	Homo sapiens	22-27
7601249-7	1995	Expression of the IL-5, IL-6, and IL-10 genes was resistant to cyclosporine A (CsA), whereas IL-3 and IL-4 gene expression was completely inhibited, indicating the involvement of different signalling pathways in the regulation of these genes.	Cyclosporine	63-77	interleukin 10	Homo sapiens	34-39
7601249-7	1995	Expression of the IL-5, IL-6, and IL-10 genes was resistant to cyclosporine A (CsA), whereas IL-3 and IL-4 gene expression was completely inhibited, indicating the involvement of different signalling pathways in the regulation of these genes.	Cyclosporine	79-82	interleukin 10	Homo sapiens	34-39
7602099-4	1995	Like the human GM-CSF enhancer, this element formed a cyclosporin A-inhibitable DNase I-hypersensitive site in the murine T cell line EL4 upon activation with phorbol ester and calcium ionophore.	Cyclosporine	54-67	epilepsy 4	Mus musculus	134-137
7541577-0	1995	Implication of cyclosporine in up-regulation of Bcl-2 expression and maintenance of CD8 lymphocytosis in cytomegalovirus-infected allograft recipients.	Cyclosporine	15-27	CD8a molecule	Homo sapiens	84-87
7541577-11	1995	Combination of CMV latent infection and cyclosporine therapy appears therefore critical to shift the homeostatic maintenance of the peripheral lymphocyte compartment toward persistingly high numbers of CD8+ T cells.	Cyclosporine	40-52	CD8a molecule	Homo sapiens	202-205
7722292-8	1995	Of note, cyclosporin A prevented the IL-10-mediated promotion of the apoptosis of SA-activated B cells, thus resulting in the marked enhancement of IgM production of B cells stimulated with SA + IL-10.	Cyclosporine	9-22	interleukin 10	Homo sapiens	37-42
7722292-8	1995	Of note, cyclosporin A prevented the IL-10-mediated promotion of the apoptosis of SA-activated B cells, thus resulting in the marked enhancement of IgM production of B cells stimulated with SA + IL-10.	Cyclosporine	9-22	interleukin 10	Homo sapiens	195-200
7722312-9	1995	However, we demonstrate that the constitutive nuclear ARE-associated factors react with Abs, raised to NF-ATp and NF-ATc, preferentially bind to the ARE but not to the NF-AT binding site and are cyclosporin A sensitive.	Cyclosporine	195-208	nuclear factor of activated T cells 1	Homo sapiens	114-120
7537264-2	1995	We report here that the immunosuppressants FK506 and cyclosporin A cause general growth inhibition of the vma3 mutant.	Cyclosporine	53-66	H(+)-transporting V0 sector ATPase subunit c	Saccharomyces cerevisiae S288C	106-110
7643135-5	1995	Immunosuppression with Cyclosporin A prevented invasion of T-lymphocytes and allowed differentiation of implanted myoblasts into myofibres as well as down-regulation of MHC expression.	Cyclosporine	23-36	major histocompatibility complex, class I, C	Homo sapiens	169-172
7643135-13	1995	It is suggested that the start of immune reaction following Cyclosporin A withdrawal is initiated by remaining small amounts of donor MHC molecules, possibly related to the continuous proliferation of the cell-lined-derived donor myoblasts.	Cyclosporine	60-73	major histocompatibility complex, class I, C	Homo sapiens	134-137
7541915-7	1995	Cyclosporin A diminished CCK-8-stimulated secretion by 35%, whereas secretion in response to cAMP-mediated secretagogues was not affected.	Cyclosporine	0-13	cholecystokinin	Rattus norvegicus	25-28
7708727-4	1995	To investigate the possible immunomodulatory role of IL-10, its expression during the induction of tolerance to kidney allografts by cyclosporin A in miniature swine was also investigated.	Cyclosporine	133-146	interleukin 10	Sus scrofa	53-58
7708727-6	1995	Since tolerance is achieved by a short course of cyclosporin A, we have also studied the in vitro effect of this drug on IL-10 gene transcription in blood mononuclear cells and have found that cyclosporin A inhibits IL-10 gene activation in T cells but does not interfere with IL-10 transcription in lipopolysaccharide-activated cells.	Cyclosporine	193-206	interleukin 10	Sus scrofa	121-126
7708727-6	1995	Since tolerance is achieved by a short course of cyclosporin A, we have also studied the in vitro effect of this drug on IL-10 gene transcription in blood mononuclear cells and have found that cyclosporin A inhibits IL-10 gene activation in T cells but does not interfere with IL-10 transcription in lipopolysaccharide-activated cells.	Cyclosporine	193-206	interleukin 10	Sus scrofa	216-221
7708727-6	1995	Since tolerance is achieved by a short course of cyclosporin A, we have also studied the in vitro effect of this drug on IL-10 gene transcription in blood mononuclear cells and have found that cyclosporin A inhibits IL-10 gene activation in T cells but does not interfere with IL-10 transcription in lipopolysaccharide-activated cells.	Cyclosporine	193-206	interleukin 10	Sus scrofa	216-221
7532665-3	1995	In this report, we investigated the effects of dexamethasone, cyclosporin A, FK506, and pyrrolidine dithiocarbamate (PDTC) on the induction of the ICAM-1 gene by cytokines in fibroblasts.	Cyclosporine	62-75	intercellular adhesion molecule 1	Homo sapiens	147-153
7829860-1	1995	Cyclophilins A and B (CyPA and CyPB) are known to be the main binding proteins for cyclosporin A (CsA), a potent immunosuppressive drug.	Cyclosporine	83-96	peptidylprolyl isomerase B	Homo sapiens	31-35
7829860-1	1995	Cyclophilins A and B (CyPA and CyPB) are known to be the main binding proteins for cyclosporin A (CsA), a potent immunosuppressive drug.	Cyclosporine	98-101	peptidylprolyl isomerase B	Homo sapiens	31-35
7628053-12	1995	The mechanism responsible for this enhanced toxicity has not yet been elucidated but is likely to be related to an increased tissue retention of Dx due to inhibition of the P-glycoprotein (Pgp) pump by PSC 833, as has recently been proposed for cyclosporin A.	Cyclosporine	245-258	phosphoglycolate phosphatase	Mus musculus	189-192
7718516-12	1995	The activation of CD4+ T cells by anti-CD52 antibodies was inhibited by cyclosporin A, suggesting a role for the calcineurin-dependent signal transduction pathways.	Cyclosporine	72-85	CD52 molecule	Homo sapiens	39-43
7499064-6	1995	CsA enhanced the MDP-Lys(L18)-induced changes in these populations and caused additional decreases in the number of CD5+ cells.	Cyclosporine	0-3	Cd5 molecule	Rattus norvegicus	116-119
7499064-7	1995	Only the CD4+ cell population was increased on day 15 in AIA, and this increase was inhibited by CsA.	Cyclosporine	97-100	Cd4 molecule	Rattus norvegicus	9-12
7753267-1	1995	Ciclosporin (CS-A) has recently been considered a separate risk factor for the development of hyperlipidemia in transplant patients.	Cyclosporine	0-11	chorionic somatomammotropin hormone 1	Homo sapiens	13-17
7700025-13	1994	Dot blot analysis and in situ hybridization showed significantly decreased mRNA levels for alpha 1(I) and alpha 1(IV) collagen in kidneys of CsA-treated mice as compared to those of untreated mice 12 weeks after induction of the disease, if the highest dose of CsA was administered before the onset of proteinuria.	Cyclosporine	141-144	collagen, type IV, alpha 1	Mus musculus	106-126
7700025-13	1994	Dot blot analysis and in situ hybridization showed significantly decreased mRNA levels for alpha 1(I) and alpha 1(IV) collagen in kidneys of CsA-treated mice as compared to those of untreated mice 12 weeks after induction of the disease, if the highest dose of CsA was administered before the onset of proteinuria.	Cyclosporine	261-264	collagen, type IV, alpha 1	Mus musculus	106-126
7986214-0	1994	In vivo evidence for ATP-dependent and P-glycoprotein-mediated transport of cyclosporin A at the blood-brain barrier.	Cyclosporine	76-89	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	39-53
7986214-1	1994	To evaluate the significance of P-glycoprotein (P-gp)-mediated active efflux on the blood-brain barrier (BBB) permeability of cyclosporin A (CsA) in vivo, we investigated the effects of ATP depletion in the brain and of a multidrug-resistant (MDR) reversing agent on the transport of CsA across the BBB.	Cyclosporine	126-139	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	48-52
7986214-1	1994	To evaluate the significance of P-glycoprotein (P-gp)-mediated active efflux on the blood-brain barrier (BBB) permeability of cyclosporin A (CsA) in vivo, we investigated the effects of ATP depletion in the brain and of a multidrug-resistant (MDR) reversing agent on the transport of CsA across the BBB.	Cyclosporine	141-144	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	48-52
7986214-5	1994	The ATP-dependent and QND-sensitive efflux of CsA from the brain strongly indicates that P-gp in the brain capillary endothelial cells functions as an efflux pump under the physiological state, and that P-gp-mediated efflux of CsA is a major mechanism of the restricted transfer from blood into the brain.	Cyclosporine	46-49	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	89-93
7926302-0	1994	Glutamic acid decarboxylase (GAD65) autoantibodies in prediction of beta-cell function and remission in recent-onset IDDM after cyclosporin treatment.	Cyclosporine	128-139	glutamate decarboxylase 1	Homo sapiens	0-27
7926302-2	1994	We have investigated whether glutamic acid decarboxylase (GAD) autoantibodies (GAD65 Ab) were affected by cyclosporin therapy and were related to subsequent non-insulin-requiring remission and loss of glucagon-stimulated C-peptide response in 132 recent-onset insulin-dependent diabetes mellitus (IDDM) patients treated with cyclosporin or placebo for 12 months.	Cyclosporine	106-117	glutamate decarboxylase 1	Homo sapiens	29-56
7926302-2	1994	We have investigated whether glutamic acid decarboxylase (GAD) autoantibodies (GAD65 Ab) were affected by cyclosporin therapy and were related to subsequent non-insulin-requiring remission and loss of glucagon-stimulated C-peptide response in 132 recent-onset insulin-dependent diabetes mellitus (IDDM) patients treated with cyclosporin or placebo for 12 months.	Cyclosporine	106-117	glutamate decarboxylase 1	Homo sapiens	58-61
7926302-2	1994	We have investigated whether glutamic acid decarboxylase (GAD) autoantibodies (GAD65 Ab) were affected by cyclosporin therapy and were related to subsequent non-insulin-requiring remission and loss of glucagon-stimulated C-peptide response in 132 recent-onset insulin-dependent diabetes mellitus (IDDM) patients treated with cyclosporin or placebo for 12 months.	Cyclosporine	325-336	glutamate decarboxylase 1	Homo sapiens	29-56
7926302-2	1994	We have investigated whether glutamic acid decarboxylase (GAD) autoantibodies (GAD65 Ab) were affected by cyclosporin therapy and were related to subsequent non-insulin-requiring remission and loss of glucagon-stimulated C-peptide response in 132 recent-onset insulin-dependent diabetes mellitus (IDDM) patients treated with cyclosporin or placebo for 12 months.	Cyclosporine	325-336	glutamate decarboxylase 1	Homo sapiens	58-61
7826608-0	1994	Anti-CD4 monoclonal antibody treatment in combination with total lymphoid irradiation and cyclosporin A in hamster-to-rat cardiac transplantation.	Cyclosporine	90-103	Cd4 molecule	Rattus norvegicus	5-8
7925567-9	1994	More strikingly, deletion of CD4+8+ thymocytes from BM3.3-Tg increased, whilst activation was partially inhibited by CsA.	Cyclosporine	117-120	CD4 antigen	Mus musculus	29-32
7826950-7	1994	Induction of the unresponsive state, as well as the subsequent IL-10 production in sTC3 cells, could be prevented by the addition of cyclosporin A to the primary co-culture of sTC3 and the autologous melanoma.	Cyclosporine	133-146	interleukin 10	Homo sapiens	63-68
8082307-6	1994	A statistically significant correlation was calculated between the levels of soluble CD8 and whole blood cyclosporin A level.	Cyclosporine	105-118	CD8a molecule	Homo sapiens	85-88
7837047-6	1994	This was evidenced by the lower CSF phenobarbitone concentration, at the onset of the hypnotic effect, in the cyclosporin-treated group vs control values (115 +/- 4 vs 93 +/- 7 mg L-1, P = 0.01).	Cyclosporine	110-121	colony stimulating factor 2	Rattus norvegicus	32-35
7837047-6	1994	This was evidenced by the lower CSF phenobarbitone concentration, at the onset of the hypnotic effect, in the cyclosporin-treated group vs control values (115 +/- 4 vs 93 +/- 7 mg L-1, P = 0.01).	Cyclosporine	110-121	ribosomal protein L4	Rattus norvegicus	180-183
7996799-4	1994	In the CsA group, NAME also increased MAP, but renal vasoconstriction was more intense; a greater rise of AR lowered PGC (P &lt; 0.05 vs. V) further decreasing SNGFR by 38.9%.	Cyclosporine	7-10	progastricsin	Rattus norvegicus	117-120
7520433-5	1994	Preincubation with the calcineurin inhibitors FK-506 or cyclosporin A strongly enhanced expression of NGFI-A and blocked transcription of NGFI-B, but it had no significant effect on Ca(2+)-stimulated transcription of c-fos.	Cyclosporine	56-69	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	217-222
8033411-6	1994	After administration of CsA to newborn NOD mice, there was a reduction (P &lt; 0.01) of both CD4+CD8- and CD4-CD8+ thymocytes, whereas the number of double positive CD4+CD8+ thymocytes was increased.	Cyclosporine	24-27	CD4 antigen	Mus musculus	93-96
8033411-6	1994	After administration of CsA to newborn NOD mice, there was a reduction (P &lt; 0.01) of both CD4+CD8- and CD4-CD8+ thymocytes, whereas the number of double positive CD4+CD8+ thymocytes was increased.	Cyclosporine	24-27	CD4 antigen	Mus musculus	106-109
8033411-6	1994	After administration of CsA to newborn NOD mice, there was a reduction (P &lt; 0.01) of both CD4+CD8- and CD4-CD8+ thymocytes, whereas the number of double positive CD4+CD8+ thymocytes was increased.	Cyclosporine	24-27	CD4 antigen	Mus musculus	106-109
7953197-0	1994	Effects of cyclosporin-A and D-penicillamine on the development of hepatitis and the production of antibody to protein disulfide isomerase in LEC rats.	Cyclosporine	11-24	prolyl 4-hydroxylase subunit beta	Rattus norvegicus	111-138
8029023-0	1994	Cyclosporin A sensitivity of the NF-kappa B site of the IL2R alpha promoter in untransformed murine T cells.	Cyclosporine	0-13	interleukin 2 receptor, alpha chain	Mus musculus	56-66
8029023-4	1994	The CsA sensitivity of IL2R alpha mRNA induction represented a direct effect on the TCR/CD3 response, and was not due to CsA-sensitive release of the lymphokines IL2 or tumour necrosis factor alpha (TNF alpha) and consequent lymphokine-mediated induction of IL2R alpha mRNA.	Cyclosporine	4-7	interleukin 2 receptor, alpha chain	Mus musculus	23-33
8029023-4	1994	The CsA sensitivity of IL2R alpha mRNA induction represented a direct effect on the TCR/CD3 response, and was not due to CsA-sensitive release of the lymphokines IL2 or tumour necrosis factor alpha (TNF alpha) and consequent lymphokine-mediated induction of IL2R alpha mRNA.	Cyclosporine	4-7	interleukin 2 receptor, alpha chain	Mus musculus	258-268
8029023-9	1994	Based on these results, we propose that the NF-kappa B site of the IL2R alpha promoter mediates at least part of the CsA sensitivity of IL2R alpha gene induction in untransformed T cells, possibly because de novo synthesis of p105 NF-kappa B is required for sustained IL2R alpha expression.	Cyclosporine	117-120	interleukin 2 receptor, alpha chain	Mus musculus	67-77
8029023-9	1994	Based on these results, we propose that the NF-kappa B site of the IL2R alpha promoter mediates at least part of the CsA sensitivity of IL2R alpha gene induction in untransformed T cells, possibly because de novo synthesis of p105 NF-kappa B is required for sustained IL2R alpha expression.	Cyclosporine	117-120	interleukin 2 receptor, alpha chain	Mus musculus	136-146
8029023-9	1994	Based on these results, we propose that the NF-kappa B site of the IL2R alpha promoter mediates at least part of the CsA sensitivity of IL2R alpha gene induction in untransformed T cells, possibly because de novo synthesis of p105 NF-kappa B is required for sustained IL2R alpha expression.	Cyclosporine	117-120	interleukin 2 receptor, alpha chain	Mus musculus	136-146
7921781-3	1994	Various processes could be responsible for the CsA-induced nephrotoxicity including an interaction with glutathione metabolism, a lipoperoxidative process, or an interaction with platelet-activating factor (PAF).	Cyclosporine	47-50	PCNA clamp associated factor	Rattus norvegicus	207-210
7921781-4	1994	Therefore, the aim of this study was to assess the potential role of PAF in CsA-induced nephrotoxicity using a new PAF antagonist, BN50726.	Cyclosporine	76-79	PCNA clamp associated factor	Rattus norvegicus	69-72
7921781-9	1994	These data indicate the potential therapeutic capacity of a PAF antagonist, BN50726, in reducing CsA nephrotoxicity and suggest interactions between PAF and CsA in the mechanism of renal injury.	Cyclosporine	97-100	PCNA clamp associated factor	Rattus norvegicus	60-63
8072258-6	1994	Repeat biopsy (RB2) was done after 19.6 +/- 15.2 months (6 to 78) of CsA treatment.	Cyclosporine	69-72	RB transcriptional corepressor like 2	Homo sapiens	15-18
8072258-8	1994	In patients with FSGS on RB1 and RB2, serum creatinine at the end of CsA treatment was 130.6 +/- 60.1 mumol/liter, significantly greater (P = 0.022) than the corresponding levels in the subset with MCD (87.3 +/- 24.8).	Cyclosporine	69-72	RB transcriptional corepressor like 2	Homo sapiens	33-36
7913684-6	1994	Labeling of the immunoprecipitated P-glycoprotein was inhibited by acridine orange, verapamil, and by cyclosporin A.	Cyclosporine	102-115	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	35-49
8169829-1	1994	Cyclosporin A (CsA) inhibits the membrane transport protein Pgp and can thus restore sensitivity to doxorubicin (Dx) and other antineoplastic agents in multidrug resistant cancer cells.	Cyclosporine	0-13	phosphoglycolate phosphatase	Mus musculus	60-63
8169829-1	1994	Cyclosporin A (CsA) inhibits the membrane transport protein Pgp and can thus restore sensitivity to doxorubicin (Dx) and other antineoplastic agents in multidrug resistant cancer cells.	Cyclosporine	15-18	phosphoglycolate phosphatase	Mus musculus	60-63
8169829-2	1994	Because Pgp is not expressed only in resistant tumor cells but also in normal tissues, CsA may modify the distribution of a concomitantly given antitumor agent which is a substrate for Pgp-mediated transport.	Cyclosporine	87-90	phosphoglycolate phosphatase	Mus musculus	8-11
8169829-2	1994	Because Pgp is not expressed only in resistant tumor cells but also in normal tissues, CsA may modify the distribution of a concomitantly given antitumor agent which is a substrate for Pgp-mediated transport.	Cyclosporine	87-90	phosphoglycolate phosphatase	Mus musculus	185-188
8137549-6	1994	Cyclosporine inhibited IL-2 receptor expression to a significantly greater degree in cord CD4 and CD8 cells (49.7% and 70.1%) than in adults (17.9% and 30.0%).	Cyclosporine	0-12	CD8a molecule	Homo sapiens	98-101
8196271-6	1994	CsA induced a dramatic decrease in GFR, 0.14 in CsA versus 0.67 ml/min/100 g in control, P &lt; 0.001, and increased urinary excretion of N-acetyl beta-D-glucosaminidase (NAG), 21 in CsA versus 13 IU/gCr in control rats, P &lt; 0.001.	Cyclosporine	0-3	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	200-203
8139144-0	1994	[Effect of recombinant atrial natriuretic peptide (r-ANP) on ischemic and cyclosporine-induced kidney damage in rats].	Cyclosporine	74-86	natriuretic peptide A	Rattus norvegicus	23-49
7905714-0	1994	Interaction of rat kidney P-glycoprotein with a urinary component and various drugs including cyclosporin A.	Cyclosporine	94-107	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	26-40
7905714-7	1994	Of the drugs tested, the immunosuppressant drug, cyclosporin A, interacted with kidney P-glycoprotein with the highest affinity (K0.5 = 50 nM).	Cyclosporine	49-62	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	87-101
7905714-11	1994	A hypothesis of drug-induced nephrotoxicity based on the interaction of various compounds like cyclosporin A with P-glycoprotein is presented.	Cyclosporine	95-108	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	114-128
7831928-0	1994	CD4+ and CD8+ cells in mice infected with Trichinella spiralis and treated with cyclosporine A.	Cyclosporine	80-94	CD4 antigen	Mus musculus	0-3
7831928-5	1994	It was found that the number of CD4+ cells in the control and in the CyA-treated mice was similar but in the animals receiving the drug the reaction was less intensive.	Cyclosporine	69-72	CD4 antigen	Mus musculus	32-35
8242902-6	1993	We also demonstrated that in T cells a Na+/K+ ATPase inhibitor, ouabain, could induce a late (16 h poststimulation) c-jun expression, which was sensitive to cyclosporin A (CsA) but not to RAPA.	Cyclosporine	157-170	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	116-121
8242902-6	1993	We also demonstrated that in T cells a Na+/K+ ATPase inhibitor, ouabain, could induce a late (16 h poststimulation) c-jun expression, which was sensitive to cyclosporin A (CsA) but not to RAPA.	Cyclosporine	172-175	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	116-121
8304053-3	1993	Untreated cells constitutively secreted CSA, which increased with PTH and PTHrP treatment.	Cyclosporine	40-43	parathyroid hormone-like hormone	Rattus norvegicus	74-79
8304053-4	1993	The colonies formed were principally comprised of macrophages, and preincubation of CM with antiserum to murine macrophage colony-stimulating factor (M-CSF) neutralized most of the CSA, suggesting that the osteoblast-derived CSA was predominantly due to M-CSF.	Cyclosporine	181-184	colony stimulating factor 1 (macrophage)	Mus musculus	112-148
8304053-4	1993	The colonies formed were principally comprised of macrophages, and preincubation of CM with antiserum to murine macrophage colony-stimulating factor (M-CSF) neutralized most of the CSA, suggesting that the osteoblast-derived CSA was predominantly due to M-CSF.	Cyclosporine	181-184	colony stimulating factor 1 (macrophage)	Mus musculus	150-155
8304053-7	1993	We conclude that M-CSF is responsible for the majority of the CSA released by PTH- and PTHrP-treated rat osteoblasts.	Cyclosporine	62-65	parathyroid hormone-like hormone	Rattus norvegicus	87-92
7694584-0	1993	Effect of dexamethasone, 6-mercaptopurine and cyclosporine A on intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression.	Cyclosporine	46-60	intercellular adhesion molecule 1	Homo sapiens	64-97
8262697-0	1993	IL-4 receptor expression by SAC-activated B-lymphocytes: its role in B-cell proliferation and the effect of cyclosporine (CsA), prednisolone and verapamil.	Cyclosporine	108-120	interleukin 4 receptor	Homo sapiens	0-13
8262697-0	1993	IL-4 receptor expression by SAC-activated B-lymphocytes: its role in B-cell proliferation and the effect of cyclosporine (CsA), prednisolone and verapamil.	Cyclosporine	122-125	interleukin 4 receptor	Homo sapiens	0-13
7689606-9	1993	Treatment of T cells with cyclosporin A or a protein tyrosine kinase inhibitor herbimycin A inhibited ICAM-1 or VCAM-1-promoted activation-induced T cell death.	Cyclosporine	26-39	intercellular adhesion molecule 1	Homo sapiens	102-108
8372681-4	1993	The damage induced by CyA was demonstrated by cell detachment from the culture plate and cell lysis as characterized by the increase in lactate dehydrogenase (LDH) at the same time after CyA treatment.	Cyclosporine	22-25	LDH	Bos taurus	136-157
8372681-4	1993	The damage induced by CyA was demonstrated by cell detachment from the culture plate and cell lysis as characterized by the increase in lactate dehydrogenase (LDH) at the same time after CyA treatment.	Cyclosporine	22-25	LDH	Bos taurus	159-162
7684344-12	1993	Cyclosporin use was associated with a significant decrease in CD45RA antigen density on both CD4+ and CD8+ T-cells.	Cyclosporine	0-11	protein tyrosine phosphatase receptor type C	Homo sapiens	62-66
7684344-12	1993	Cyclosporin use was associated with a significant decrease in CD45RA antigen density on both CD4+ and CD8+ T-cells.	Cyclosporine	0-11	CD8a molecule	Homo sapiens	102-105
7679116-7	1993	This work identifies NF-ATp as a DNA-binding phosphoprotein and a target for the drug/immunophilin/calcineurin complexes thought to mediate the inhibition of interleukin-2 gene induction by cyclosporin A and FK506.	Cyclosporine	190-203	interleukin 2	Bos taurus	158-171
7680201-0	1993	Sensitivity of mitochondrial peptidyl-prolyl cis-trans isomerase, pyridine nucleotide hydrolysis and Ca2+ release to cyclosporine A and related compounds.	Cyclosporine	117-131	peptidylprolyl isomerase like 1	Homo sapiens	29-64
7680201-2	1993	Here we investigate the inhibitory potency of cyclosporine A and six related compounds with respect to peptidyl-prolyl cis-trans isomerase (PPIase), pyridine nucleotide hydrolysis and Ca2+ release.	Cyclosporine	46-60	peptidylprolyl isomerase like 1	Homo sapiens	103-138
7680201-2	1993	Here we investigate the inhibitory potency of cyclosporine A and six related compounds with respect to peptidyl-prolyl cis-trans isomerase (PPIase), pyridine nucleotide hydrolysis and Ca2+ release.	Cyclosporine	46-60	peptidylprolyl isomerase like 1	Homo sapiens	140-146
8492414-0	1993	[Cyclosporin for pure red cell aplasia caused rapid improvement of anemia and increase of CD4/8 ratio].	Cyclosporine	1-12	CD48 molecule	Homo sapiens	90-95
8434390-2	1993	CD4+ cells from CsA-treated DA rats with long-surviving PVG heart allografts specifically suppress the capacity of naive CD4+ cells to restore allograft rejection in irradiated DA rats, but have normal donor-specific alloreactivity in MLC.	Cyclosporine	16-19	Cd4 molecule	Rattus norvegicus	0-3
8434390-2	1993	CD4+ cells from CsA-treated DA rats with long-surviving PVG heart allografts specifically suppress the capacity of naive CD4+ cells to restore allograft rejection in irradiated DA rats, but have normal donor-specific alloreactivity in MLC.	Cyclosporine	16-19	Cd4 molecule	Rattus norvegicus	121-124
8434390-3	1993	CD4+ suppressor cells from CsA-treated DA rats cultured for 3 days against either PVG or DA spleen cells lost the capacity to transfer suppression into irradiated DA rats grafted with PVG hearts and regained the ability to mediate rejection.	Cyclosporine	27-30	Cd4 molecule	Rattus norvegicus	0-3
8434390-5	1993	CD4+ cells from CsA-treated rats cultured against either third-party stimulator cells or syngeneic cells expressing anti-PVG idiotype in media supplemented with Con A supernatant failed to maintain suppressor cell function.	Cyclosporine	16-19	Cd4 molecule	Rattus norvegicus	0-3
8434390-6	1993	CD4+ cells from CsA-treated rats cultured in media supplemented with Con A supernatant alone also failed to maintain suppressor function.	Cyclosporine	16-19	Cd4 molecule	Rattus norvegicus	0-3
8434390-10	1993	These studies demonstrate that the CD4+ suppressor cell from CsA-treated rats with long-surviving grafts is short-lived; its survival is dependent upon contact with specific alloantigens and cytokines, one of which is IL-2.	Cyclosporine	61-64	Cd4 molecule	Rattus norvegicus	35-38
8438399-0	1993	Cyclosporine preferentially inhibits clonal deletion of CD8-positive T cells with an MHC class II restricted autoreactive T-cell receptor.	Cyclosporine	0-12	CD8a molecule	Homo sapiens	56-59
8104444-8	1993	In the EMT6 parent line, which expresses very low levels of Pgp, 10-30-fold sensitisation to doxorubicin may be achieved using 0.1-5 microgram/ml of CsA.	Cyclosporine	149-152	phosphoglycolate phosphatase	Mus musculus	60-63
7692621-8	1993	The analysis of lymphocyte subsets proved the decrease of W3/25: OX8 ratio in both FK506- and cyclosporin-treated groups.	Cyclosporine	94-105	Cd4 molecule	Rattus norvegicus	58-63
7915954-0	1993	Anti-CD4 monoclonal antibody treatment combined with total lymphoid irradiation and cyclosporin A in hamster-to-rat cardiac transplantation.	Cyclosporine	84-97	Cd4 molecule	Rattus norvegicus	5-8
1282000-3	1992	Using this and immunohistochemical staining, we found that the immunosuppressants cyclosporin A and FK506 decreased CD4 expression in cultured murine microglia without causing any significant decrease in cell viability.	Cyclosporine	82-95	CD4 antigen	Mus musculus	116-119
1336994-6	1992	Treatment of mice with drugs stimulating the release of endogenous PRL, or with exogenous ovine PRL, was found to antagonize the suppression of lymphocyte proliferative responses to mitogens induced in mice by glucocorticoid or cyclosporin treatment.	Cyclosporine	228-239	prolactin	Mus musculus	67-70
1336994-6	1992	Treatment of mice with drugs stimulating the release of endogenous PRL, or with exogenous ovine PRL, was found to antagonize the suppression of lymphocyte proliferative responses to mitogens induced in mice by glucocorticoid or cyclosporin treatment.	Cyclosporine	228-239	prolactin	Mus musculus	96-99
1334967-3	1992	In control animals, CsA reduced basal anterior pituitary POMC and IL-6 mRNA and decreased plasma levels of ACTH and B. Adjuvant-injected animals that were treated with CsA showed no clinical signs of AA.	Cyclosporine	20-23	proopiomelanocortin	Rattus norvegicus	57-61
1284133-6	1992	After the 6 months of CsA therapy we observed a significant increase of CD3+, HLA-DR+, CD3+, CD16+ and/or CD56+, total B, and CD20+, CD5+ cells in the 11 patients with PsA compared to pretreatment values.	Cyclosporine	22-25	Fc gamma receptor IIIa	Homo sapiens	93-97
1449518-6	1992	Measurement of the intracellular Ca2+ pools showed an early depletion of the mitochondrial Ca2+ pool in hepatocytes exposed to 3,5-Me2-NAPQI, tBH or cumene hydroperoxide; this loss was prevented by CsA.	Cyclosporine	198-201	carbonic anhydrase 2	Homo sapiens	33-36
1449518-6	1992	Measurement of the intracellular Ca2+ pools showed an early depletion of the mitochondrial Ca2+ pool in hepatocytes exposed to 3,5-Me2-NAPQI, tBH or cumene hydroperoxide; this loss was prevented by CsA.	Cyclosporine	198-201	carbonic anhydrase 2	Homo sapiens	91-94
1449518-7	1992	In conclusion, these results show that CsA protected hepatocytes from prooxidant injury by preventing mitochondrial Ca2+ cycling and subsequent mitochondrial dysfunction.	Cyclosporine	39-42	carbonic anhydrase 2	Homo sapiens	116-119
1400439-4	1992	Cyclosporin A-sensitive PPIase detected in the chloroplast was mostly localized to the thylakoids, which is suggestive of its function in the folding of membranal proteins.	Cyclosporine	0-13	peptidylprolyl isomerase like 1	Homo sapiens	24-30
1468539-6	1992	Even though the myelotoxicity of VP-16 was increased by the addition of CsA, this effect was nonspecific as shown by a similar chemosensitization in sensitive P388 as well as in P388/VP 2.5 cells, an atypical MDR variant lacking P-glycoprotein.	Cyclosporine	72-75	host cell factor C1	Homo sapiens	33-38
1454879-7	1992	Ultraviolet-B or UV-B plus cyclosporin A exposure caused increased immunohistochemical staining for Ia and F4/80 antigens in the upper dermis of tissue from Skh-1 mice, as compared to controls.	Cyclosporine	27-40	adhesion G protein-coupled receptor E1	Mus musculus	107-112
1384191-2	1992	The objective of this study was to determine whether cyclosporine and L-683,590 (FK520) could modify the adhesion and emigration of leukocytes in postcapillary venules that are exposed to inflammatory mediators such as platelet activating factor (PAF) and leukotriene B4 (LTB4).	Cyclosporine	53-65	PCNA clamp associated factor	Rattus norvegicus	247-250
1384191-9	1992	Cyclosporine prevented all of the adhesive and hemodynamic alterations induced by PAF, but not LTB4.	Cyclosporine	0-12	PCNA clamp associated factor	Rattus norvegicus	82-85
1497650-0	1992	Correlation between up-regulation of lymphokine mRNA and down-regulation of TcR, CD4, CD8 and lck mRNA as shown by the effect of CsA on activated T lymphocytes.	Cyclosporine	129-132	CD8a molecule	Homo sapiens	86-89
1499163-1	1992	Cyclosporine (CSA)-associated arteriolopathy (CAA) is the second most frequent morphological diagnosis in renal allografts and its final outcome remains unclear.	Cyclosporine	0-12	teashirt zinc finger homeobox 1	Homo sapiens	46-49
1499163-1	1992	Cyclosporine (CSA)-associated arteriolopathy (CAA) is the second most frequent morphological diagnosis in renal allografts and its final outcome remains unclear.	Cyclosporine	14-17	teashirt zinc finger homeobox 1	Homo sapiens	46-49
1499163-2	1992	The present study was performed to clarify the morphological outcome of CAA by follow-up histological analysis after stopping CSA.	Cyclosporine	126-129	teashirt zinc finger homeobox 1	Homo sapiens	72-75
1499163-7	1992	Improvement of CAA was noted a few months after stopping CSA or after lower dose CSA therapy.	Cyclosporine	57-60	teashirt zinc finger homeobox 1	Homo sapiens	15-18
1499163-7	1992	Improvement of CAA was noted a few months after stopping CSA or after lower dose CSA therapy.	Cyclosporine	81-84	teashirt zinc finger homeobox 1	Homo sapiens	15-18
1499163-13	1992	The complete regression of CAA and the remodelling of arterioles showing well preserved vascular patency were frequently found after stopping or reducing the dose of CSA.	Cyclosporine	166-169	teashirt zinc finger homeobox 1	Homo sapiens	27-30
1398338-7	1992	OB-5 and cyclosporine A, a positive control drug, prevented the increase in the number of OX-1, CD8 and ED-1 positive cells in the glomeruli.	Cyclosporine	9-23	NAD(P)H dehydrogenase, quinone 1	Mus musculus	90-94
1604471-0	1992	Recovery and hypersecretion of insulin and reversal of insulin resistance after withdrawal of short-term cyclosporine treatment.	Cyclosporine	105-117	insulin	Canis lupus familiaris	31-38
1604471-0	1992	Recovery and hypersecretion of insulin and reversal of insulin resistance after withdrawal of short-term cyclosporine treatment.	Cyclosporine	105-117	insulin	Canis lupus familiaris	55-62
1604471-1	1992	We have previously demonstrated decreased insulin release and insulin resistance in dogs treated with cyclosporine (20 mg/kg/day).	Cyclosporine	102-114	insulin	Canis lupus familiaris	42-49
1349278-11	1992	Further, incubation of astrocytes with 1 nM PRL in the presence of 100 nM cyclosporine, an immunosuppressive agent that specifically displaces PRL from its receptor, decreased the percentage of nuclei stained for PCNA to that observed in non-PRL-stimulated controls.	Cyclosporine	74-86	proliferating cell nuclear antigen	Rattus norvegicus	213-217
1591884-3	1992	PPIase, which catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides, has recently been found to be identical to cyclophilin, a specific binding protein of a potent immunosuppressant, cyclosporin A.	Cyclosporine	216-229	peptidylprolyl isomerase like 1	Homo sapiens	0-6
1591884-3	1992	PPIase, which catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides, has recently been found to be identical to cyclophilin, a specific binding protein of a potent immunosuppressant, cyclosporin A.	Cyclosporine	216-229	peptidylprolyl isomerase like 1	Homo sapiens	145-156
1529801-3	1992	The immunosuppressants, cyclophosphamide and cyclosporine A, and the glucocorticoids (e.g., dexamethasone, hydrocortisone, and corticosterone) were all able to suppress the GVH response.	Cyclosporine	45-59	graft versus host regulation	Mus musculus	173-176
1379812-4	1992	Microsomal NADPH-cytochrome c reductase activities were decreased up to 67% of the control with the increasing dose of FK506 and to 62% in a group treated orally with cyclosporin A (25 mg/kg/d for 7 days), although another microsomal electron-transport component, cytochrome b5, was rather increased in all the treated groups.	Cyclosporine	167-180	cytochrome b5 type A	Rattus norvegicus	264-277
1545136-0	1992	Cyclosporin increases granulocyte/macrophage colony-stimulating factor (GM-CSF) activity and gene expression in murine keratinocytes.	Cyclosporine	0-11	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	22-70
1545136-0	1992	Cyclosporin increases granulocyte/macrophage colony-stimulating factor (GM-CSF) activity and gene expression in murine keratinocytes.	Cyclosporine	0-11	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	72-78
1545136-4	1992	This investigation examined the direct effect of cyclosporin on the production of GM-CSF by murine keratinocytes and the keratinocyte cell line PAM 212.	Cyclosporine	49-60	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	82-88
1545136-5	1992	GM-CSF bioactivity increased in cell supernatants from keratinocytes exposed in vitro to 1 microgram/ml cyclosporin for up to 24 h. GM-CSF and IL-1 mRNA levels in keratinocytes cultured under similar conditions or in the presence of lipopolysaccharide also increased.	Cyclosporine	104-115	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	0-6
1545136-5	1992	GM-CSF bioactivity increased in cell supernatants from keratinocytes exposed in vitro to 1 microgram/ml cyclosporin for up to 24 h. GM-CSF and IL-1 mRNA levels in keratinocytes cultured under similar conditions or in the presence of lipopolysaccharide also increased.	Cyclosporine	104-115	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	132-138
1571830-2	1992	The immunosuppressive cyclosporins A (CsA) and G (CsG) inhibited thyroid hormone (T4 + T3)-stimulated resorption and beta-glucuronidase release into the culture medium, whereas the weak or nonimmunosuppressive cyclosporins D (CsD) and H (CsH) did not show this effect.	Cyclosporine	22-36	glucuronidase, beta	Rattus norvegicus	117-135
1571830-2	1992	The immunosuppressive cyclosporins A (CsA) and G (CsG) inhibited thyroid hormone (T4 + T3)-stimulated resorption and beta-glucuronidase release into the culture medium, whereas the weak or nonimmunosuppressive cyclosporins D (CsD) and H (CsH) did not show this effect.	Cyclosporine	38-41	glucuronidase, beta	Rattus norvegicus	117-135
1349161-4	1992	The in vitro expression of ICAM-1 was examined in cultured human tubular cells after stimulation with gamma-interferon and interleukin-1, treatment with cyclosporin and/or verapamil and coculture with allogenic mononuclear cells.	Cyclosporine	153-164	intercellular adhesion molecule 1	Homo sapiens	27-33
1363723-2	1992	This T-cell proliferative response displays a much higher DOX sensitivity in the presence of novel potent inhibitors of P-glycoprotein (Pgp)-mediated multidrug resistance (MDR), the cyclosporin (Cs) derivative, SDZ PSC 833, and the semi-synthetic cyclopeptolide, SDZ 280-446.	Cyclosporine	195-197	phosphoglycolate phosphatase	Mus musculus	120-134
1363723-2	1992	This T-cell proliferative response displays a much higher DOX sensitivity in the presence of novel potent inhibitors of P-glycoprotein (Pgp)-mediated multidrug resistance (MDR), the cyclosporin (Cs) derivative, SDZ PSC 833, and the semi-synthetic cyclopeptolide, SDZ 280-446.	Cyclosporine	195-197	phosphoglycolate phosphatase	Mus musculus	136-139
1363723-6	1992	Our results may open the way to a novel form of immunomodulation combining classical antineoplastic agents with Pgp-blocking Cs analogs (even non-immunosuppressive ones), which may be particularly useful when treating acute graft rejection.	Cyclosporine	125-127	phosphoglycolate phosphatase	Mus musculus	112-115
1372739-6	1992	The release of amylase in response to CCK was reduced by FK506 in a dose-related manner (p less than 0.01) and by CS at 25 mg/kg (p less than 0.01).	Cyclosporine	114-116	cholecystokinin	Rattus norvegicus	38-41
1756174-1	1991	Fractionation of differentiating murine teratocarcinoma F9 cells and extraction of the nuclear/microsomal pellets with ethidium bromide led to the purification and microsequencing of the protein mCyP-S1, a novel cyclosporin A-sensitive peptidyl-prolyl cis-trans isomerase (PPIase).	Cyclosporine	212-225	peptidylprolyl isomerase B	Mus musculus	195-202
1717576-8	1991	CD7 up-regulation by ionomycin was transient (24 to 72 h) and inhibitable by cyclosporin A, whereas CD7 up-regulation by PHA was sustained over 5 to 7 days and was significantly less inhibitable by cyclosporin A.	Cyclosporine	77-90	CD7 molecule	Homo sapiens	0-3
1717576-8	1991	CD7 up-regulation by ionomycin was transient (24 to 72 h) and inhibitable by cyclosporin A, whereas CD7 up-regulation by PHA was sustained over 5 to 7 days and was significantly less inhibitable by cyclosporin A.	Cyclosporine	198-211	CD7 molecule	Homo sapiens	100-103
2040592-4	1991	The cyclophilin-like protein has also peptidyl-prolyl cis/trans-isomerase activity, although less efficient, that is inhibited by cyclosporin A.	Cyclosporine	130-143	peptidylprolyl isomerase B	Homo sapiens	4-28
1903221-4	1991	Thymuses from the day-18 embryos exposed to CsA were partially depleted of CD4+CD8- single positive cells.	Cyclosporine	44-47	CD4 antigen	Mus musculus	75-78
1652970-4	1991	Notably, CyA-treated syngeneic bone marrow chimeras (SBMC) had transiently increased numbers of peripheral CD4+ CD8+ T-cells, expressing a marker normally limited to thymocytes.	Cyclosporine	9-12	Cd4 molecule	Rattus norvegicus	107-110
1672545-4	1991	The mechanism(s) by which NKSF induces IFN-gamma production results in accumulation of IFN-gamma mRNA, is insensitive to cyclosporin A, and synergizes with those mediated by phytohemagglutinin, phorbol diesters, anti-CD3 antibodies, and allogeneic antigens, but not by Ca2+ ionophores.	Cyclosporine	121-132	interleukin 12B	Homo sapiens	26-30
1706397-9	1991	Interestingly, pretreatment of basophils with drugs that either inhibited or enhanced histamine release (isobutylmethylxanthine and cyclosporin A vs cytochalasin B, respectively) significantly decreased the magnitude of anti-IgE-induced CD11b up-regulation; down-regulation of Leu 8 expression was also partially inhibited by treatment with isobutylmethylaxanthine.	Cyclosporine	132-145	integrin subunit alpha M	Homo sapiens	237-242
1997649-3	1991	Second, we ask whether the nephrotoxicity observed with CsA is related to inhibition of PPIase-dependent pathways in cells other than lymphocytes.	Cyclosporine	56-59	peptidylprolyl isomerase (cyclophilin)-like 6	Mus musculus	88-94
1672137-4	1991	In CsA-treated patients there was a dramatic reduction in the ICAM-1 expression by papillary endothelial cells, but density, pattern, and phenotype of infiltrating inflammatory cells remained essentially unchanged.	Cyclosporine	3-6	intercellular adhesion molecule 1	Homo sapiens	62-68
1672137-6	1991	These results favor, but do not prove, the assumption that the CsA regimen chosen in this study exerts its anti-psoriatic effect primarily at the level of the keratinocyte, i.e., by inhibiting events leading to keratinocyte proliferation as well as by interfering with the secretion of mediators responsible for ICAM-1 expression by papillary endothelial cells.	Cyclosporine	63-66	intercellular adhesion molecule 1	Homo sapiens	312-318